﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Barrado, LG
   Burzykowski, T
   Legrand, C
   Buyse, M
AF Barrado, Leandro Garcia
   Burzykowski, Tomasz
   Legrand, Catherine
   Buyse, Marc
TI Using an interim analysis based exclusively on an early outcome in a
   randomized clinical trial with a long-term clinical endpoint
SO PHARMACEUTICAL STATISTICS
LA English
DT Article
DE efficacy stopping; group-sequential design; interim analysis; randomized
   clinical trial; surrogate endpoint
ID SURROGATE; SURVIVAL
AB In RCTs with an interest in a long-term efficacy endpoint, the follow-up time necessary to observe the endpoint may be substantial. In order to reduce the expected duration of such trials, early-outcome data may be collected to enrich an interim analysis aimed at stopping the trial early for efficacy. We propose to extend such a design with an additional interim analysis using solely early-outcome data in order to expedite the evaluation of treatment's efficacy. We evaluate the potential gain in operating characteristics (power, expected trial duration, and expected sample size) when introducing such an early interim analysis, in function of the properties of the early outcome as a surrogate for the long-term endpoint. In the context of a longitudinal age-related macular degeneration (ARMD) ophthalmology trial, results show potentially substantial gains in both the expected trial duration and the expected sample size. A prerequisite, though, is that the treatment effect on the early outcome has to be strongly correlated with the treatment effect on the long-term endpoint, that is, that the early outcome is a validated surrogate for the long-term endpoint.
C1 [Barrado, Leandro Garcia; Burzykowski, Tomasz; Buyse, Marc] Int Drug Dev Inst IDDI, Ave Prov 30, B-1340 Louvain, Belgium.
   [Barrado, Leandro Garcia; Legrand, Catherine] Louvain Inst Data Anal & Modeling, Inst Stat Biostat & Actuarial Sci ISBA, Louvain, Belgium.
   [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Data Sci Inst, I BioStat, Hasselt, Belgium.
C3 International Drug Development Institute; Hasselt University
RP Barrado, LG (通讯作者)，Int Drug Dev Inst IDDI, Ave Prov 30, B-1340 Louvain, Belgium.
EM leandro.garciabarrado@iddi.be
FU Service Public de Wallonie [8162]; International Drug Development
   Institute (IDDI) SA; Universite Catholique de Louvain (UCLouvain)
FX Service Public de Wallonie, Grant/Award Number: First Entreprice Docteur
   nr. 8162, jointly awarded to International Drug Development Institute
   (IDDI) SA and the Universite Catholique de Louvain (UCLouvain)
CR Beaver JA, 2018, JAMA ONCOL, V4, P849, DOI 10.1001/jamaoncol.2017.5618
   Branchoux S, 2019, CRIT REV ONCOL HEMAT, V137, P35, DOI 10.1016/j.critrevonc.2019.02.013
   Burzykowski T, 2017, JAMA ONCOL, V3, P416, DOI 10.1001/jamaoncol.2016.3941
   Burzykowski T, 2011, PHARM STAT, V10, P115, DOI 10.1002/pst.419
   Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49
   Chen XT, 2020, CONT CLIN TRIAL COMM, V18, DOI 10.1016/j.conctc.2020.100562
   Eisenstein EL, 2008, CLIN TRIALS, V5, P75, DOI 10.1177/1740774507087551
   Friede T, 2011, Stat Med, V30, P1528, DOI 10.1002/sim.4202
   Galbraith S, 2003, STAT MED, V22, P1787, DOI 10.1002/sim.1311
   Jenkins M, 2011, PHARM STAT, V10, P347, DOI 10.1002/pst.472
   Jennison C., 1999, GROUP SEQUENTIAL MET
   Li Y, 2010, STAT MED, V29, P1875, DOI 10.1002/sim.3931
   Marschner IC, 2001, STAT MED, V20, P177, DOI 10.1002/1097-0258(20010130)20:2<177::AID-SIM653>3.0.CO;2-K
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pryseley A, 2010, COMPUT STAT DATA AN, V54, P1342, DOI 10.1016/j.csda.2009.11.024
   Royston P, 2003, STAT MED, V22, P2239, DOI 10.1002/sim.1430
   Whitehead J., 1997, DESIGN ANAL SEQUENTI
NR 17
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1539-1604
EI 1539-1612
J9 PHARM STAT
JI Pharm. Stat.
PD JAN
PY 2022
VL 21
IS 1
BP 209
EP 219
DI 10.1002/pst.2165
EA SEP 2021
PG 11
WC Pharmacology & Pharmacy; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Mathematics
GA YJ5DN
UT WOS:000694628500001
PM 34505395
DA 2022-11-30
ER

PT J
AU Gupta, A
   Sharma, R
   Kuche, K
   Jain, S
AF Gupta, Aditya
   Sharma, Reena
   Kuche, Kaushik
   Jain, Sanyog
TI Exploring the therapeutic potential of the bioinspired reconstituted
   high density lipoprotein nanostructures
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Review
DE Reconstituted high-density lipoprotein; Bioinspired nanocarrier; Drug
   delivery; Targeted delivery; Imaging and therapy
AB Lipoproteins are endogenously present nanocarriers and are the primary commuters of cholesterol within the body. Among lipoproteins, HDL inherits size in nm range with anti-oxidant potential and receptor affinity which makes them an attractive candidate for drug delivery. Hence, in this review, we glance across the biosynthesis, architecture, and methods to prepare rHDL which acts as an endogenously present delivery vehicle. The review critically describes the range of applications possible for targeted delivery in multiple ailments (cancer, atherosclerosis, Alzheimer, age-related macular degeneration and psoriasis) using rHDL. Moreover, the review also expounds on to the case reports where, drug delivery aspect of rHDL is augmented through stimuli sensitivity (ultrasounds, magnetic field, photodynamic therapy) and pH dependent approaches. Further, the role of rHDL in combating the blood brain barrier for efficient delivery of peptides into the brain is also been highlighted. Additionally, the manuscript also expounds on rHDL based formulations which are under clinical review with elaboration on challenges and future prospects pertaining to their clinical translation. Overall, the present article showcases several aspects of rHDL, which are or can be explored for present and future investigations.
C1 [Gupta, Aditya; Sharma, Reena; Kuche, Kaushik; Jain, Sanyog] Natl Inst Pharmaceut Educ & Res NIPER, Ctr Pharmaceut Nanotechnol, Dept Pharmaceut, Sect 67, Mohali, Punjab, India.
C3 National Institute of Pharmaceutical Education & Research (NIPER);
   National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali)
RP Jain, S (通讯作者)，Natl Inst Pharmaceut Educ & Res NIPER, Ctr Pharmaceut Nanotechnol, Dept Pharmaceut, Sect 67, Mohali, Punjab, India.
EM sanyogjain@niper.ac.in
CR Aboumsallem JP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061273
   Ackermann R., 2012, GOOGLE PATENTS
   Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518
   Aguilar JC, 2007, VACCINE, V25, P3752, DOI 10.1016/j.vaccine.2007.01.111
   Ahn J, 2018, ADV DRUG DELIVER REV, V128, P29, DOI 10.1016/j.addr.2018.04.001
   Amin A., 2018, MOJ DRUG DESIGN DEV, V2, P24
   ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248
   Andrews J, 2017, CARDIOVASC DIAGN THE, V7, P45, DOI 10.21037/cdt.2017.01.01
   Auton M, 2013, BIOCHEMISTRY-US, V52, P4324, DOI 10.1021/bi4006732
   Balazs Z, 2004, J NEUROCHEM, V89, P939, DOI 10.1111/j.1471-4159.2004.02373.x
   Barter PJ, 2003, ARTERIOSCL THROM VAS, V23, P160, DOI 10.1161/01.ATV.0000054658.91146.64
   Bavelloni A, 2017, ANTICANCER RES, V37, P6511, DOI 10.21873/anticanres.12107
   Ben-Aicha S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030732
   BENAZET F, 1980, EXPERIENTIA, V36, P414, DOI 10.1007/BF01975121
   Bhattacharya P, 2010, J VIROL, V84, P361, DOI 10.1128/JVI.01355-09
   Bolanos-Garcia VM, 2003, PROG BIOPHYS MOL BIO, V83, P47, DOI 10.1016/S0079-6107(03)00028-2
   Bricarello DA, 2011, ACS NANO, V5, P42, DOI 10.1021/nn103098m
   BROWN MS, 1985, ANN NY ACAD SCI, V454, P178, DOI 10.1111/j.1749-6632.1985.tb11856.x
   Cai Qin-sheng, 2005, Yaoxue Xuebao, V40, P462
   Cao WG, 2009, BIOCONJUGATE CHEM, V20, P2023, DOI 10.1021/bc900404y
   Capodanno D, 2018, EXPERT OPIN INV DRUG, V27, P997, DOI 10.1080/13543784.2018.1543399
   CASAS AT, 1995, J SURG RES, V59, P544, DOI 10.1006/jsre.1995.1204
   Chakraborty M, 2011, APPL BIOCHEM BIOTECH, V165, P1178, DOI 10.1007/s12010-011-9336-6
   CHAPMAN MJ, 1980, J LIPID RES, V21, P789
   Chekman I S, 2011, Lik Sprava, P3
   Chen J, 2020, NANO CONVERG, V7, DOI 10.1186/s40580-019-0214-1
   Chen KR, 2019, THERANOSTICS, V9, P2984, DOI 10.7150/thno.31157
   Chen R, 2013, BIOMATERIALS, V34, P8314, DOI 10.1016/j.biomaterials.2013.07.034
   Chen T, 2008, J PHYS CHEM B, V112, P16357, DOI 10.1021/jp805826a
   Chen W, 2010, FASEB J, V24, P1689, DOI 10.1096/fj.09-139865
   Cho K.-H, 2019, HDL THERAPEUTIC TOOL, P77
   Cho KH, 2011, J GERONTOL A-BIOL, V66, P1274, DOI 10.1093/gerona/glr169
   Corbin IR, 2013, NANOMEDICINE-UK, V8, P875, DOI [10.2217/NNM.12.137, 10.2217/nnm.12.137]
   Cormode DP, 2008, NANO LETT, V8, P3715, DOI 10.1021/nl801958b
   Cormode DP, 2008, SMALL, V4, P1437, DOI 10.1002/smll.200701285
   Cruz PMR, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00119
   Csaky KG, 2015, OPHTHALMOLOGY, V122, P579, DOI 10.1016/j.ophtha.2014.09.036
   Cui LY, 2015, ACS NANO, V9, P4484, DOI 10.1021/acsnano.5b01077
   Damiano MG, 2013, ADV DRUG DELIVER REV, V65, P649, DOI 10.1016/j.addr.2012.07.013
   Darabi M, 2016, PHARMACOL THERAPEUT, V157, P28, DOI 10.1016/j.pharmthera.2015.10.010
   De Jong WH, 2008, INT J NANOMED, V3, P133, DOI 10.2147/ijn.s596
   Diditchenko S, 2013, ARTERIOSCL THROM VAS, V33, P2202, DOI 10.1161/ATVBAHA.113.301981
   Ding Y, 2015, BIOMATERIALS, V72, P90, DOI 10.1016/j.biomaterials.2015.08.051
   Ding Y, 2014, BIOMATERIALS, V35, P7214, DOI 10.1016/j.biomaterials.2014.05.009
   Duivenvoorden R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4065
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   Easton R, 2014, J CLIN PHARMACOL, V54, P301, DOI 10.1002/jcph.194
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Feng H, 2020, J DERMATOL, V47, P147, DOI 10.1111/1346-8138.15149
   Feng MQ, 2008, J DRUG TARGET, V16, P502, DOI [10.1080/10611860802200938, 10.1080/10611860802200938 ]
   Fernandez-de-Retana S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15215-w
   Fischer NO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093342
   Fischer NO, 2013, J AM CHEM SOC, V135, P2044, DOI 10.1021/ja3063293
   Frias MA, 2010, CARDIOVASC RES, V85, P118, DOI 10.1093/cvr/cvp289
   Fukuda R, 2020, BIOCHEMISTRY-US, V59, P1455, DOI 10.1021/acs.biochem.0c00075
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gao ZB, 2013, NANOMED-NANOTECHNOL, V9, P174, DOI 10.1016/j.nano.2012.06.003
   Garg S, 2016, J DRUG TARGET, V24, P821, DOI 10.1080/1061186X.2016.1198354
   GOLDSTEIN JL, 1979, ANNU REV GENET, V13, P259, DOI 10.1146/annurev.ge.13.120179.001355
   Harisa GI, 2014, SAUDI PHARM J, V22, P504, DOI 10.1016/j.jsps.2013.12.015
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182
   He HL, 2014, PHARM RES-DORDR, V31, P1689, DOI 10.1007/s11095-013-1273-3
   He JH, 2020, J MATER CHEM B, V8, P1496, DOI 10.1039/c9tb02101a
   Henrich SE, 2019, J AM CHEM SOC, V141, P9753, DOI 10.1021/jacs.9b00651
   Hong JS, 2010, LANGMUIR, V26, P11581, DOI 10.1021/la100879p
   Huang C, 2013, ACS NANO, V7, P5791, DOI 10.1021/nn400683s
   Huang GL, 2018, J CONTROL RELEASE, V278, P122, DOI 10.1016/j.jconrel.2018.04.015
   Huang GL, 2017, DRUG DELIV, V24, P108, DOI 10.1080/10717544.2017.1399305
   Huang JS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030739
   Huang M, 2015, ACS NANO, V9, P10801, DOI 10.1021/acsnano.5b03124
   Ibanez B, 2012, ATHEROSCLEROSIS, V220, P72, DOI 10.1016/j.atherosclerosis.2011.10.006
   Isaac-Olive K, 2019, NANOSCALE, V11, P541, DOI 10.1039/c8nr07484d
   Jeong Yohan, 2018, Biomater Res, V22, P20, DOI 10.1186/s40824-018-0130-1
   Jiang CP, 2019, J CONTROL RELEASE, V308, P71, DOI 10.1016/j.jconrel.2019.07.007
   Jiang TY, 2012, BIOMATERIALS, V33, P9246, DOI 10.1016/j.biomaterials.2012.09.027
   JONAS A, 1986, METHOD ENZYMOL, V128, P553
   Kadiyala P, 2019, ACS NANO, V13, P1365, DOI 10.1021/acsnano.8b06842
   Kallend DG, 2016, EUR HEART J-CARD PHA, V2, P23, DOI 10.1093/ehjcvp/pvv041
   Kaminskas LM, 2011, ADV DRUG DELIVER REV, V63, P890, DOI 10.1016/j.addr.2011.05.016
   Karnik R, 2008, NANO LETT, V8, P2906, DOI 10.1021/nl801736q
   Khumsupan P, 2011, BBA-BIOMEMBRANES, V1808, P352, DOI 10.1016/j.bbamem.2010.09.007
   Kim SY, 2020, ARTHRITIS RHEUMATOL, V72, P20, DOI 10.1002/art.41059
   Kim Y, 2013, ACS NANO, V7, P9975, DOI 10.1021/nn4039063
   Kingwell BA, 2014, NAT REV DRUG DISCOV, V13, P445, DOI 10.1038/nrd4279
   Kontush A, 2006, PHARMACOL REV, V58, P342, DOI 10.1124/pr.58.3.1
   Kornmueller K, 2019, MOLECULES, V24, DOI 10.3390/molecules24152829
   Krause BR, 2013, CURR OPIN LIPIDOL, V24, P480, DOI 10.1097/MOL.0000000000000020
   Kuai R, 2017, NAT MATER, V16, P489, DOI [10.1038/NMAT4822, 10.1038/nmat4822]
   Kuai R, 2016, ACS NANO, V10, P3015, DOI 10.1021/acsnano.5b07522
   Lacko AG, 2007, EXPERT OPIN DRUG DEL, V4, P665, DOI 10.1517/17425247.4.6.665
   Lacko AG, 2006, CHEMOTHERAPY, V52, P171, DOI 10.1159/000093268
   Lacko AG, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00247
   Leon CG, 2010, PROSTATE, V70, P390, DOI 10.1002/pros.21072
   Levkau B, 2004, CIRCULATION, V110, P3355, DOI 10.1161/01.CIR.0000147827.43912.AE
   Lewis DR, 2011, WIRES NANOMED NANOBI, V3, P400, DOI 10.1002/wnan.145
   Liu C, 2018, J MICROENCAPSUL, V35, P115, DOI 10.1080/02652048.2017.1413146
   Liu LS, 2014, BIOMATERIALS, V35, P8002, DOI 10.1016/j.biomaterials.2014.05.081
   Lobatto ME, 2011, NAT REV DRUG DISCOV, V10, P835, DOI 10.1038/nrd3578
   Lou B, 2005, WORLD J GASTROENTERO, V11, P954, DOI 10.3748/wjg.v11.i7.954
   Luthi AJ, 2010, TRENDS MOL MED, V16, P553, DOI 10.1016/j.molmed.2010.10.006
   Ma PK, 2018, ACS APPL MATER INTER, V10, P12351, DOI 10.1021/acsami.7b18437
   Mahmoudian M, 2018, CANCER CHEMOTH PHARM, V82, P371, DOI 10.1007/s00280-018-3626-4
   Marrache S, 2013, P NATL ACAD SCI USA, V110, P9445, DOI 10.1073/pnas.1301929110
   McConathy WJ, 2008, ANTI-CANCER DRUG, V19, P183, DOI 10.1097/CAD.0b013e3282f1da86
   McDonald MC, 2003, SHOCK, V20, P551, DOI 10.1097/01.shk.0000097249.97298.a3
   McMahon KM, 2011, NANO LETT, V11, P1208, DOI 10.1021/nl1041947
   McMahon KM, 2014, EXPERT OPIN DRUG DEL, V11, P231, DOI 10.1517/17425247.2014.866089
   Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024
   Mieszawska AJ, 2013, BIOCONJUGATE CHEM, V24, P1429, DOI 10.1021/bc400166j
   Mo ZC, 2016, ADV DRUG DELIVER REV, V106, P132, DOI 10.1016/j.addr.2016.04.030
   Mooberry LK, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00466
   Mooberry LK, 2010, J DRUG TARGET, V18, P53, DOI 10.3109/10611860903156419
   Mulya A, 2007, ARTERIOSCL THROM VAS, V27, P1828, DOI 10.1161/ATVBAHA.107.142455
   Mura S, 2013, NAT MATER, V12, P991, DOI [10.1038/nmat3776, 10.1038/NMAT3776]
   Murakami T, 2010, NANOMEDICINE-UK, V5, P867, DOI 10.2217/NNM.10.66
   Murray SC, 2016, BIOPHYS J, V110, P810, DOI 10.1016/j.bpj.2015.10.028
   Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1325, DOI 10.1161/01.ATV.0000165694.39518.95
   Neubi GMN, 2018, BIOMATER SCI-UK, V6, P958, DOI [10.1039/C8BM00175H, 10.1039/c8bm00175h]
   Ng KK, 2011, ACCOUNTS CHEM RES, V44, P1105, DOI 10.1021/ar200017e
   Nicholls SJ, 2011, EXPERT OPIN BIOL TH, V11, P387, DOI 10.1517/14712598.2011.557061
   Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292
   Oda MN, 2006, J LIPID RES, V47, P260, DOI 10.1194/jlr.D500033-JLR200
   Oram JF, 2005, PHYSIOL REV, V85, P1343, DOI 10.1152/physrev.00005.2005
   Oram JF, 2002, TRENDS CARDIOVAS MED, V12, P170, DOI 10.1016/S1050-1738(02)00159-7
   Pajkrt D, 1997, THROMB HAEMOSTASIS, V77, P303
   Patel S, 2009, J AM COLL CARDIOL, V53, P962, DOI 10.1016/j.jacc.2008.12.008
   Pedersbaek D, 2019, BIOCONJUGATE CHEM, V30, P2634, DOI 10.1021/acs.bioconjchem.9b00552
   Pei Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072492
   Perez-Medina C, 2015, J NUCL MED, V56, P1272, DOI 10.2967/jnumed.115.158956
   Petkar KC, 2011, CRIT REV THER DRUG, V28, P101, DOI 10.1615/CritRevTherDrugCarrierSyst.v28.i2.10
   Plebanek MP, 2018, MOL CANCER THER, V17, P686, DOI 10.1158/1535-7163.MCT-17-0981
   Poteryaeva O. N., 2018, Biomeditsinskaya Khimiya, V64, P463, DOI 10.18097/PBMC20186406463
   Pownall Henry J, 2016, Methodist Debakey Cardiovasc J, V12, P146
   Pysz MA, 2010, CLIN RADIOL, V65, P500, DOI 10.1016/j.crad.2010.03.011
   Raut S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01154
   Raut S, 2018, THER DELIV, V9, P257, DOI 10.4155/tde-2017-0122
   Raut SG, 2020, J PHARMACOL EXP THER, V373, P113, DOI 10.1124/jpet.119.262899
   Redmond KA, 2007, INT J PHARM, V339, P246, DOI 10.1016/j.ijpharm.2007.02.033
   Regazzi R, 2012, CURR OPIN LIPIDOL, V23, P165, DOI 10.1097/MOL.0b013e32835135aa
   Reijers JAA, 2017, CARDIOVASC DRUG THER, V31, P381, DOI 10.1007/s10557-017-6746-x
   Rensen PCN, 2001, ADV DRUG DELIVER REV, V47, P251, DOI 10.1016/S0169-409X(01)00109-0
   Rhee KJ, 2015, INT J MOL SCI, V16, P30015, DOI 10.3390/ijms161226215
   Richart A, 2015, CIRCULATION, V132
   Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037
   Rocco AG, 2010, J MOL GRAPH MODEL, V29, P406, DOI 10.1016/j.jmgm.2010.08.002
   Rothblat GH, 2010, CURR OPIN LIPIDOL, V21, P229, DOI 10.1097/MOL.0b013e328338472d
   Rui MJ, 2017, MOL PHARMACEUT, V14, P107, DOI 10.1021/acs.molpharmaceut.6b00732
   Ryan RO, 2008, EXPERT OPIN DRUG DEL, V5, P343, DOI [10.1517/17425247.5.3.343, 10.1517/17425247.5.3.343 ]
   Ryan Robert O., 2010, Journal of Nanobiotechnology, V8, P28, DOI 10.1186/1477-3155-8-28
   Sabnis N, 2012, THER DELIV, V3, P599, DOI 10.4155/TDE.12.41
   Sabnis N, 2012, INT J NANOMED, V7, P975, DOI 10.2147/IJN.S28029
   Sabnis S, 2017, INT J NANOMED, V12, P1453, DOI 10.2147/IJN.S122036
   Sanchez-Gaytan BL, 2015, BIOCONJUGATE CHEM, V26, P443, DOI 10.1021/bc500517k
   Schultz ML, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1423-5
   SEGREST JP, 1992, J LIPID RES, V33, P141
   Sheng Y, 2019, BIOMATER SCI-UK, V7, P3425, DOI 10.1039/c9bm00588a
   Simonsen JB, 2016, NANOMED-NANOTECHNOL, V12, P2161, DOI 10.1016/j.nano.2016.05.009
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Skajaa T, 2011, BIOMATERIALS, V32, P206, DOI 10.1016/j.biomaterials.2010.08.078
   Song QX, 2016, MOL PHARMACEUT, V13, P3976, DOI 10.1021/acs.molpharmaceut.6b00781
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   Szeto GL, 2016, J MATER CHEM B, V4, P1610, DOI 10.1039/c5tb01825k
   Tabet F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4292
   Tanaka S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02860-3
   Tardif JC, 2014, EUR HEART J, V35, P3277, DOI 10.1093/eurheartj/ehu171
   Tardy C, 2014, ATHEROSCLEROSIS, V232, P110, DOI 10.1016/j.atherosclerosis.2013.10.018
   Thaxton CS, 2016, ADV DRUG DELIVER REV, V106, P116, DOI 10.1016/j.addr.2016.04.020
   Thaxton CS, 2009, J AM CHEM SOC, V131, P1384, DOI 10.1021/ja808856z
   Tsujita M, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0759-1
   Valencia PM, 2012, NAT NANOTECHNOL, V7, P623, DOI 10.1038/nnano.2012.168
   Vance DE, 2008, N COMP BIOC, P1
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Wang FH, 2014, J CONTROL RELEASE, V174, P126, DOI 10.1016/j.jconrel.2013.11.020
   Wang GY, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-020-01382-9
   Wang J, 2013, DRUG DELIV, V20, P356, DOI 10.3109/10717544.2013.834418
   Wang JJ, 2011, INT J NANOMED, V6, P765, DOI 10.2147/IJN.S17296
   Wang TT, 2016, ACS NANO, V10, P3496, DOI 10.1021/acsnano.5b07706
   Wang YZ, 2016, COLLOID SURFACE B, V148, P533, DOI 10.1016/j.colsurfb.2016.09.037
   Wolfrum C, 2007, NAT BIOTECHNOL, V25, P1149, DOI 10.1038/nbt1339
   Woo JMP, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3020
   Xiong Fangyuan, 2017, Nanotheranostics, V1, P440, DOI 10.7150/ntno.21905
   Xu ZH, 2013, J CONTROL RELEASE, V172, P259, DOI 10.1016/j.jconrel.2013.08.021
   Yamamoto H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00685-9
   Yang M, 2011, NANOMEDICINE-UK, V6, P631, DOI [10.2217/NNM.11.10, 10.2217/nnm.11.10]
   Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986
   Zannis VI, 2006, J MOL MED, V84, P276, DOI 10.1007/s00109-005-0030-4
   Zhang B, 2013, BIOMATERIALS, V34, P9171, DOI 10.1016/j.biomaterials.2013.08.039
   Zhang FR, 2016, MAT SCI ENG C-MATER, V64, P208, DOI 10.1016/j.msec.2016.03.083
   Zhang MY, 2013, ASIAN J PHARM SCI, V8, P11, DOI 10.1016/j.ajps.2013.07.002
   Zhang XB, 2010, CANCER LETT, V298, P26, DOI 10.1016/j.canlet.2010.05.023
   Zhang XQ, 2018, DRUG DELIV, V25, P1840, DOI 10.1080/10717544.2018.1519001
   Zhang XQ, 2017, DRUG DELIV, V24, P16, DOI 10.1080/10717544.2017.1384518
   Zhang ZH, 2010, SMALL, V6, P430, DOI 10.1002/smll.200901515
   Zheng G, 2005, P NATL ACAD SCI USA, V102, P17757, DOI 10.1073/pnas.0508677102
   Zheng Y, 2013, THERANOSTICS, V3, P477, DOI 10.7150/thno.6617
NR 197
TC 6
Z9 6
U1 6
U2 29
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD MAR 1
PY 2021
VL 596
AR 120272
DI 10.1016/j.ijpharm.2021.120272
EA JAN 2021
PG 22
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA QK9QA
UT WOS:000620711800040
PM 33486038
DA 2022-11-30
ER

PT J
AU Li, XY
   Xie, L
   Qu, XL
   Zhao, BY
   Fu, W
   Wu, BL
   Wu, J
AF Li, Xinyi
   Xie, Li
   Qu, Xiangli
   Zhao, Bangyi
   Fu, Wei
   Wu, Beili
   Wu, Jian
TI GPR91, a critical signaling mechanism in modulating pathophysiologic
   processes in chronic illnesses
SO FASEB JOURNAL
LA English
DT Review
DE G protein-coupled receptor; innate immunity; metabolic regulation;
   succinate; SUCNR1
ID SUCCINATE RECEPTOR GPR91; PROTEIN-COUPLED RECEPTORS; CELLS; ACTIVATION;
   DISCOVERY; LEADS; GPCRS; DYSFUNCTION; NANOBODIES; FUMARATE
AB Succinate receptor GPR91 is one of G protein-coupled receptors (GPCRs), and is expressed in a variety of cell types and tissues. Succinate is its natural ligand, and its activation represents that an intrinsic metabolic intermediate exerts a regulatory role on many critical life processes involving pathophysiologic mechanisms, such as innate immunity, inflammation, tissue repair, and oncogenesis. With the illustration of 3-dimensional crystal structure of the receptor and discovery of its antagonists, it is possible to dissect the succinate-GPR91-G protein signaling pathways in different cell types under pathophysiological conditions. Deep understanding of the GPR91-ligand binding mode with various agonists and antagonists would aid in elucidating the molecular basis of a spectrum of chronic illnesses, such as hypertension, diabetes, and their renal and retina complications, metabolic-associated fatty liver diseases, such as nonalcoholic steatohepatitis and its fibrotic progression, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), age-related macular degeneration, rheumatoid arthritis, and progressive behaviors of malignancies. With better delineation of critical regulatory role of the succinate-GPR91 axis in these illnesses, therapeutic intervention may be developed by specifically targeting this signaling pathway with small molecular antagonists or other strategies.
C1 [Li, Xinyi; Xie, Li; Wu, Jian] Fudan Univ, Sch Basic Med Sci, MOE NHC CAMS Key Lab Med Mol Virol, Dept Med Microbiol, Shanghai, Peoples R China.
   [Qu, Xiangli; Wu, Beili] Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zhuchongzhi Rd, Shanghai 201203, Peoples R China.
   [Zhao, Bangyi; Fu, Wei] Fudan Univ, Sch Pharm, Dept Med Chem, Shanghai, Peoples R China.
   [Wu, Jian] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol & Hepatol, Shanghai, Peoples R China.
   [Wu, Jian] Fudan Univ, Shanghai Med Coll, Shanghai Inst Liver Dis, Shanghai, Peoples R China.
   [Qu, Xiangli; Wu, Beili] Univ Chinese Acad Sci, Beijing, Peoples R China.
C3 Fudan University; Chinese Academy of Sciences; Shanghai Institute of
   Materia Medica, CAS; Fudan University; Fudan University; Fudan
   University; Chinese Academy of Sciences; University of Chinese Academy
   of Sciences, CAS
RP Wu, BL (通讯作者)，Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, 555 Zhuchongzhi Rd, Shanghai 201203, Peoples R China.; Wu, J (通讯作者)，Fudan Univ, Sch Basic Med Sci, Key Lab Mol Virol, Dept Med Microbiol, 138 Yixue Yuan Rd,POB 228, Shanghai 200032, Peoples R China.
EM beiliwu@simm.ac.cn; jian.wu@fudan.edu.cn
RI Wu, Jian/AAU-5221-2020; li, xinyi/GWZ-8941-2022
OI Wu, Jian/0000-0001-9933-7364; 
FU National Natural Science Foundation of China [81572356, 81871997,
   31825010]; National Key R&D Program of China [2016YFE0107400]; Shanghai
   Commission of Science and Technology [16140903700]
FX The National Natural Science Foundation of China, Grant/Award Number:
   81572356, 81871997 and 31825010; National Key R&D Program of China,
   Grant/Award Number: 2016YFE0107400; Shanghai Commission of Science and
   Technology, Grant/Award Number: 16140903700
CR Aguiar CJ, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0078-2
   Audet M, 2012, CELL, V151, P14, DOI 10.1016/j.cell.2012.09.003
   Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI 10.1016/S1043-9471(05)80049-7
   Cho EH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00455
   Correa PRAV, 2007, J HEPATOL, V47, P262, DOI 10.1016/j.jhep.2007.03.016
   de Alwis NMW, 2008, J HEPATOL, V48, pS104, DOI 10.1016/j.jhep.2008.01.009
   Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519
   Favret S, 2013, AGING-US, V5, P427, DOI 10.18632/aging.100563
   Geubelle P, 2017, BRIT J PHARMACOL, V174, P796, DOI 10.1111/bph.13738
   Gilissen J, 2016, PHARMACOL THERAPEUT, V159, P56, DOI 10.1016/j.pharmthera.2016.01.008
   Gilissen J, 2015, BIOCHEM PHARMACOL, V98, P381, DOI 10.1016/j.bcp.2015.09.010
   Gurevich VV, 2019, CELL MOL LIFE SCI, V76, P4413, DOI 10.1007/s00018-019-03272-5
   Gutkind JS, 2018, NAT REV MOL CELL BIO, V19, P615, DOI 10.1038/s41580-018-0041-y
   Haffke M, 2019, NATURE, V574, P581, DOI 10.1038/s41586-019-1663-8
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488
   Heineke J, 2006, NAT REV MOL CELL BIO, V7, P589, DOI 10.1038/nrm1983
   Hodge RJ, 2013, CLIN PHARM DRUG DEV, V2, P213, DOI 10.1002/cpdd.34
   Hogberg C, 2011, J THROMB HAEMOST, V9, P361, DOI 10.1111/j.1538-7836.2010.04158.x
   HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x
   Hsu CC, 2016, EXP BIOL MED, V241, P1281, DOI 10.1177/1535370216641787
   Hu JY, 2013, EXP EYE RES, V109, P31, DOI 10.1016/j.exer.2013.01.011
   Huang YH, 2017, CURR OPIN PHARMACOL, V32, P96, DOI 10.1016/j.coph.2017.02.001
   Jakowiecki J, 2020, GPCRS: STRUCTURE, FUNCTION, AND DRUG DISCOVERY, P43, DOI 10.1016/B978-0-12-816228-6.00003-9
   Kahsai AW, 2018, CELL RES, V28, P783, DOI 10.1038/s41422-018-0067-x
   Kamal FA, 2017, J AM SOC NEPHROL, V28, P197, DOI 10.1681/ASN.2015080852
   Keiran N, 2019, NAT IMMUNOL, V20, P581, DOI 10.1038/s41590-019-0372-7
   KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706
   Laukka T, 2016, J BIOL CHEM, V291, P4256, DOI 10.1074/jbc.M115.688762
   Lei WW, 2018, P NATL ACAD SCI USA, V115, P5552, DOI 10.1073/pnas.1720758115
   Li M, 2017, BBA-MOL BASIS DIS, V1863, P3202, DOI 10.1016/j.bbadis.2017.09.008
   Li Y, 2018, FREE RADICAL BIO MED, V126, P1, DOI 10.1016/j.freeradbiomed.2018.07.009
   Li YH, 2016, J BIOL CHEM, V291, P10277, DOI 10.1074/jbc.M115.692244
   Littlewood-Evans A, 2016, J EXP MED, V213, P1655, DOI 10.1084/jem.20160061
   Liu XJ, 2020, LIVER INT, V40, P830, DOI 10.1111/liv.14370
   Luo J, 2019, BONE RES, V7, DOI 10.1038/s41413-019-0059-6
   Macias-Ceja DC, 2019, MUCOSAL IMMUNOL, V12, P178, DOI 10.1038/s41385-018-0087-3
   McCreath KJ, 2015, DIABETES, V64, P1154, DOI 10.2337/db14-0346
   Mu XM, 2017, ONCOTARGET, V8, P13174, DOI 10.18632/oncotarget.14485
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   Nadjsombati MS, 2018, IMMUNITY, V49, P33, DOI 10.1016/j.immuni.2018.06.016
   Pardon E, 2014, NAT PROTOC, V9, P674, DOI 10.1038/nprot.2014.039
   Pellicciari R, 2009, J MED CHEM, V52, P7958, DOI 10.1021/jm901390p
   Raval Z, 2011, J AM COLL CARDIOL, V58, P223, DOI 10.1016/j.jacc.2011.03.026
   Regard JB, 2008, CELL, V135, P561, DOI 10.1016/j.cell.2008.08.040
   Riddy DM, 2018, PHARMACOL REV, V70, P39, DOI 10.1124/pr.117.014373
   Robben JH, 2009, KIDNEY INT, V76, P1258, DOI 10.1038/ki.2009.360
   Rubic T, 2008, NAT IMMUNOL, V9, P1261, DOI 10.1038/ni.1657
   Sanchack K, 2018, AM FAM PHYSICIAN, V97, P573
   Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Saraiva AL, 2018, FASEB J, V32, P6550, DOI 10.1096/fj.201800285
   Schioth HB, 2005, GEN COMP ENDOCR, V142, P94, DOI 10.1016/j.ygcen.2004.12.018
   Schmitt J, 2015, LIVER INT, V35, P1133, DOI 10.1111/liv.12456
   SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986
   Sum CS, 2009, J BIOL CHEM, V284, P3529, DOI 10.1074/jbc.M806987200
   Sundstrom L, 2013, FEBS LETT, V587, P2399, DOI 10.1016/j.febslet.2013.05.067
   Sushma, 2019, MOL CELL NEUROSCI, V101, DOI 10.1016/j.mcn.2019.103414
   Tang XL, 2012, ACTA PHARMACOL SIN, V33, P363, DOI 10.1038/aps.2011.210
   Toma I, 2008, J CLIN INVEST, V118, P2526, DOI 10.1172/JCI33293
   Trauelsen M, 2017, MOL METAB, V6, P1585, DOI 10.1016/j.molmet.2017.09.005
   Tseng PL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21361-6
   Vargas SL, 2009, J AM SOC NEPHROL, V20, P1002, DOI 10.1681/ASN.2008070740
   Vass M, 2018, TRENDS PHARMACOL SCI, V39, P494, DOI 10.1016/j.tips.2018.02.004
   Venkatakrishnan AJ, 2013, NATURE, V494, P185, DOI 10.1038/nature11896
   Wentzel JF, 2017, BIOCHIMIE, V135, P28, DOI 10.1016/j.biochi.2017.01.004
   Wettschureck N, 2005, PHYSIOL REV, V85, P1159, DOI 10.1152/physrev.00003.2005
   Wittenberger T, 2001, J MOL BIOL, V307, P799, DOI 10.1006/jmbi.2001.4520
   Wu J, 2016, ONCOTARGET, V7, P42762, DOI 10.18632/oncotarget.8641
   Yang JW, 2018, DIABETES OBES METAB, V20, P257, DOI 10.1111/dom.13062
   Yu XN, 2019, BBA-REV CANCER, V1871, P379, DOI 10.1016/j.bbcan.2019.03.001
   Zhang DD, 2015, NATURE, V520, P317, DOI 10.1038/nature14287
   Zhao J, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00058
   Zhao T, 2017, ONCOTARGET, V8, P53819, DOI 10.18632/oncotarget.17734
NR 75
TC 9
Z9 9
U1 5
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2020
VL 34
IS 10
BP 13091
EP 13105
DI 10.1096/fj.202001037R
EA AUG 2020
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA NY3XM
UT WOS:000567542800001
PM 32812686
OA Bronze
DA 2022-11-30
ER

PT J
AU Chen, X
   Sun, RX
   Yang, DD
   Jiang, C
   Liu, QH
AF Chen, Xue
   Sun, Ruxu
   Yang, Daidi
   Jiang, Chao
   Liu, Qinghuai
TI LINC00167 Regulates RPE Differentiation by Targeting the
   miR-203a-3p/SOCS3 Axis
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; LONG NONCODING RNAS; MACULAR DEGENERATION;
   STEM-CELLS; ACTIVATION; DEDIFFERENTIATION; PROLIFERATION; DYSFUNCTION;
   PREVALENCE; MIGRATION
AB Increasing evidence has indicated that long non-coding RNAs (lncRNAs) play significant roles in various diseases; however, their roles in age-related macular degeneration (AMD) remain unclear. Dedifferentiation and dysfunction of retinal pigment epithelium (RPE) cells have been shown to contribute to AMD etiology in several studies. Herein, we found that 1ncRNA LINC00167 was downregulated in RPE-choroid samples of AMD patients and dysfunctional RPE cells, and it was consistently upregulated along with RPE differentiation. In vitro study indicated that reduced endogenous LINC00167 expression resulted in RPE dedifferentiation, which was typified by attenuated expression of RPE markers, reduced vascular endothelial growth factor A secretion, accumulation of mitochondrial reactive oxygen species, and interrupted phagocytic ability. Mechanistically, LINC00167 functioned as a sponge for microRNA miR-203a-3p to restore the expression of the suppressor of cytokine signaling 3 (SOCS3), which further inhibited the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. Taken together, our study demonstrated that LINC00167 showed a protective role in AMD by maintaining RPE differentiation through the LINC00167/miR-203a-3p/SOCS3 axis and might be a potential therapeutic target for AMD.
C1 [Chen, Xue; Sun, Ruxu; Yang, Daidi; Jiang, Chao; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Peoples R China.
C3 Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing 210029, Peoples R China.
EM liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964; Chen, Xue/0000-0003-0370-6909
FU National Natural Science Foundation of China [81770973, 81700877];
   National Key Research and Development Program of China [2017YFA0104100];
   Natural Science Foundation of Jiangsu Province [BK20171087]; Six Talent
   Peaks Project in Jiangsu Province [WSW-004]; Priority Academic Program
   Development (PAPD) of Jiangsu Higher Education Institutions
FX This study was supported by the National Natural Science Foundation of
   China (81770973 to Q.L and 81700877 to X.C); the National Key Research
   and Development Program of China (2017YFA0104100 to Q.L); the Natural
   Science Foundation of Jiangsu Province (BK20171087 to X.C); the Six
   Talent Peaks Project in Jiangsu Province (WSW-004 to X.C); and a project
   funded by the Priority Academic Program Development (PAPD) of Jiangsu
   Higher Education Institutions.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Ballantyne MD, 2016, CLIN PHARMACOL THER, V99, P494, DOI 10.1002/cpt.355
   Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cascella R, 2018, PROG RETIN EYE RES, V63, P132, DOI 10.1016/j.preteyeres.2017.11.004
   Cascella Raffaella, 2018, Oncotarget, V9, P7812, DOI 10.18632/oncotarget.23241
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chen L, 2018, AM J CANCER RES, V8, P2387
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Chen M, 2018, AM J PATHOL, V188, P1007, DOI 10.1016/j.ajpath.2017.12.021
   Chen XY, 2017, MICROMACHINES-BASEL, V8, DOI 10.3390/mi8030064
   Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Eid RA, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0671-4
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghanbari M, 2017, HUM MUTAT, V38, P827, DOI 10.1002/humu.23226
   Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398
   Han N, 2020, CLIN EXP PHARMACOL P, V47, P85, DOI 10.1111/1440-1681.13163
   Jiang C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0481-5
   Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965
   Li F, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040478
   Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006
   Li XL, 2014, MUTAT RES-REV MUTAT, V762, P1, DOI 10.1016/j.mrrev.2014.04.002
   Liu KK, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108913
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Muhammad N, 2016, ONCOTARGET, V7, P58595, DOI 10.18632/oncotarget.11193
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Paraskevopoulou MD, 2016, METHODS MOL BIOL, V1402, P271, DOI 10.1007/978-1-4939-3378-5_21
   Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Sen R., 2014, SCIENTIFICWORLDJOURN, V2014
   Shen Y, 2016, J CELL MOL MED, V20, P537, DOI 10.1111/jcmm.12755
   Sheng XR, 2009, CELL STEM CELL, V5, P191, DOI 10.1016/j.stem.2009.05.024
   Steyn PJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215273
   Strafella C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071578
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wonganan O, 2017, TOXICOL APPL PHARM, V336, P31, DOI 10.1016/j.taap.2017.10.004
   Xu CH, 2019, J CELL PHYSIOL, V234, P22272, DOI 10.1002/jcp.28794
   Xu JZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1382-y
   Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510
   Zhang JJ, 2017, MECH AGEING DEV, V164, P8, DOI 10.1016/j.mad.2017.03.009
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 55
TC 10
Z9 10
U1 2
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD MAR 6
PY 2020
VL 19
BP 1015
EP 1026
DI 10.1016/j.omtn.2019.12.040
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA KU2SH
UT WOS:000519557700121
PM 32044724
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Parisi, L
   Fuhrer, R
   Zinkernagel, M
   Enzmann, V
AF Parisi, Lorenzo
   Fuhrer, Reto
   Zinkernagel, Martin
   Enzmann, Volker
TI Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of
   Primary Human Retinal Pigment Epithelium in vitro
SO OPHTHALMOLOGICA
LA English
DT Article
DE Primary human RPE in vitro; Scleral fibroblasts; Viability; Ranibizumab;
   Bevacizumab; Aflibercept; Proliferation
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CELLS; TOXICITY;
   ATROPHY; VEGF
AB Aim: Treatment of exudative age-related macular degeneration by using vascular endothelial growth factor (VEGF) antagonists is the gold standard today. So far, several bioactive molecules have been approved for therapeutic use. In this study, we investigate the effects of ranibizumab (Lucentis (R)), bevacizumab (Avastin (R)), and aflibercept (Eylea (R)) on primary human retinal pigment epithelial (hRPE) cells in vitro. Methods: hRPE cells were prepared from donor eyes and cultured under standard culture conditions. Scleral fibroblasts also prepared from donor tissue served as physiological controls. The impact of the anti-VEGF molecules on cell viability was investigated with the trypan blue exclusion assay, whereas proliferation was measured using the MTT assay. Biological activity of the molecules was quantified in a VEGF-enzyme-linked immunosorbent assay (ELISA). Results: All tested substances were biologically active in vitro. They displayed no cytotoxicity on RPE cells or scleral fibroblasts. However, proliferation of RPE cells was significantly decreased after treatment with ranibizumab or bevacizumab but not with aflibercept. Conclusions: The humanized anti-bodies (fragments) interfered specifically with the RPE cells. The thereby measured inhibition of cell proliferation may indicate possible side effects on the physiology of RPE cells. (c) 2018 S. Karger AG, Basel
C1 [Parisi, Lorenzo; Fuhrer, Reto; Zinkernagel, Martin; Enzmann, Volker] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Zinkernagel, Martin; Enzmann, Volker] Univ Bern, Dept Biomed Res, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern; University of Bern
RP Enzmann, V (通讯作者)，Univ Bern, Inselspital, Dept Ophthalmol, Freiburgstr 14, CH-3010 Bern, Switzerland.
EM volker.enzmann@insel.ch
OI Enzmann, Volker/0000-0003-4384-4855
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Brar VS, 2009, J OCUL PHARMACOL TH, V25, P507, DOI 10.1089/jop.2009.0028
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2013, EUR J OPHTHALMOL, V23, P690, DOI 10.5301/ejo.5000248
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Puddu A, 2016, EUR J OPHTHALMOL, V26, P425, DOI 10.5301/ejo.5000786
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Takashima A, 2001, Curr Protoc Cell Biol, VChapter 2, DOI 10.1002/0471143030.cb0201s00
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
NR 23
TC 4
Z9 4
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2019
VL 241
IS 3
BP 137
EP 142
DI 10.1159/000490430
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HR0NA
UT WOS:000462824100003
PM 30001546
DA 2022-11-30
ER

PT J
AU Rohowetz, LJ
   Kraus, JG
   Koulen, P
AF Rohowetz, Landon J.
   Kraus, Jacob G.
   Koulen, Peter
TI Reactive Oxygen Species-Mediated Damage of Retinal Neurons: Drug
   Development Targets for Therapies of Chronic Neurodegeneration of the
   Retina
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE reactive oxygen species; oxidative stress; glaucoma; diabetic
   retinopathy; age-related macular degeneration; biologicals; small
   molecules; therapy; retina
ID GLYCATION END-PRODUCTS; PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL
   GROWTH-FACTOR; P38 MAPK INHIBITION; ROD OUTER SEGMENTS; OXIDATIVE
   STRESS; DIABETIC-RETINOPATHY; NADPH OXIDASE; TRABECULAR MESHWORK;
   HIGH-GLUCOSE
AB The significance of oxidative stress in the development of chronic neurodegenerative diseases of the retina has become increasingly apparent in recent years. Reactive oxygen species (ROS) are free radicals produced at low levels as a result of normal cellular metabolism that are ultimately metabolized and detoxified by endogenous and exogenous mechanisms. In the presence of oxidative cellular stress, ROS are produced in excess, resulting in cellular injury and death and ultimately leading to tissue and organ dysfunction. Recent studies have investigated the role of excess ROS in the pathogenesis and development of chronic neurodegenerative diseases of the retina including glaucoma, diabetic retinopathy, and age-related macular degeneration. Findings from these studies are promising insofar as they provide clear rationales for innovative treatment and prevention strategies of these prevalent and disabling diseases where currently therapeutic options are limited. Here, we briefly outline recent developments that have contributed to our understanding of the role of ROS in the pathogenesis of chronic neurodegenerative diseases of the retina. We then examine and analyze the peer-reviewed evidence in support of ROS as targets for therapy development in the area of chronic neurodegeneration of the retina.
C1 [Rohowetz, Landon J.; Kraus, Jacob G.; Koulen, Peter] Univ Missouri, Sch Med, Dept Ophthalmol, Vis Res Ctr, 2411 Holmes St, Kansas City, MO 64108 USA.
   [Koulen, Peter] Univ Missouri, Sch Med, Dept Biomed Sci, 2411 Holmes St, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City
RP Koulen, P (通讯作者)，Univ Missouri, Sch Med, Dept Ophthalmol, Vis Res Ctr, 2411 Holmes St, Kansas City, MO 64108 USA.; Koulen, P (通讯作者)，Univ Missouri, Sch Med, Dept Biomed Sci, 2411 Holmes St, Kansas City, MO 64108 USA.
EM ljrvx8@mail.umkc.edu; jgkppb@umkc.edu; koulenp@umkc.edu
RI Rohowetz, Landon/M-1167-2019; Rohowetz, Landon/AIC-4846-2022
OI Rohowetz, Landon/0000-0002-5403-421X; Rohowetz,
   Landon/0000-0002-5403-421X
FU National Eye Institute of the National Institutes of Health [EY022774,
   EY027005]; Felix and Carmen Sabates Missouri Endowed Chair in Vision
   Research; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [R01EY027005] Funding Source: NIH RePORTER
FX This publication was supported in part by grants from the National Eye
   Institute (EY022774 and EY027005) of the National Institutes of Health
   (P.K.). The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Institutes
   of Health. Additional support by the Felix and Carmen Sabates Missouri
   Endowed Chair in Vision Research and a Challenge Grant from Research to
   Prevent Blindness (P.K.) is gratefully acknowledged.
CR Abu El-Asrar AM, 2015, INVEST OPHTH VIS SCI, V56, P1956, DOI 10.1167/iovs.14-16144
   Adachi T, 2011, BIOL PHARM BULL, V34, P1297, DOI 10.1248/bpb.34.1297
   Ahn HR, 2014, J AGR FOOD CHEM, V62, P1310, DOI 10.1021/jf4046232
   Aiello LP, 2011, RETINA-J RET VIT DIS, V31, P2084, DOI 10.1097/IAE.0b013e3182111669
   Aiello LP, 2005, DIABETES, V54, P2188
   Aimjongjun S, 2013, J PHOTOCH PHOTOBIO B, V124, P34, DOI 10.1016/j.jphotobiol.2013.04.003
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Amano S, 2002, BIOCHEM BIOPH RES CO, V299, P183, DOI 10.1016/S0006-291X(02)02584-6
   Antonenko YN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1273, DOI 10.1134/S0006297908120018
   Beazley-Long N, 2013, AM J PATHOL, V183, P918, DOI 10.1016/j.ajpath.2013.05.031
   Boveris A, 2008, IUBMB LIFE, V60, P308, DOI 10.1002/iub.46
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Caldwell R.B., 2009, INVEST OPHTH VIS SCI, V50, P32
   Calzia D, 2016, BIOCHIMIE, V125, P171, DOI 10.1016/j.biochi.2016.03.016
   Calzia D, 2015, BRIT J PHARMACOL, V172, P3890, DOI 10.1111/bph.13173
   Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646
   Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t
   Castilho AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042428
   Cervellati F, 2014, FREE RADICAL RES, V48, P303, DOI 10.3109/10715762.2013.867484
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Charkoudian LK, 2008, J INORG BIOCHEM, V102, P2130, DOI 10.1016/j.jinorgbio.2008.08.001
   Chen Y, 2013, J CLIN INVEST, V123, P5119, DOI 10.1172/JCI69076
   Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002
   Choudhuri S, 2013, MOL VIS, V19, P100
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   CROOKS J, 1992, J COMP NEUROL, V315, P287, DOI 10.1002/cne.903150305
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Dong ZY, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00191
   Donnelly R, 2004, BRIT J OPHTHALMOL, V88, P145, DOI 10.1136/bjo.88.1.145
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Du YP, 2010, INVEST OPHTH VIS SCI, V51, P2158, DOI 10.1167/iovs.09-3674
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Fu DX, 2014, J LIPID RES, V55, P860, DOI 10.1194/jlr.M045401
   Gawad AE, 2009, EYE, V23, P2245, DOI 10.1038/eye.2008.398
   Gil J, 2003, FREE RADICAL BIO MED, V35, P1500, DOI 10.1016/j.freeradbiomed.2003.08.022
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Groeger G, 2012, INVEST OPHTH VIS SCI, V53, P6645, DOI 10.1167/iovs.12-10525
   Groeger G, 2009, J NEUROCHEM, V109, P1544, DOI 10.1111/j.1471-4159.2009.06081.x
   Guo DD, 2013, INT J BIOCHEM CELL B, V45, P1849, DOI 10.1016/j.biocel.2013.06.002
   Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140
   Hamada Y, 2009, BONE, V45, pS35, DOI 10.1016/j.bone.2009.02.004
   Hao M, 2015, GRAEF ARCH CLIN EXP, V253, P83, DOI 10.1007/s00417-014-2771-7
   Harada C, 2006, AM J PATHOL, V168, P261, DOI 10.2353/ajpath.2006.050765
   Harada C, 2010, CELL DEATH DIFFER, V17, P1751, DOI 10.1038/cdd.2010.62
   He Y, 2016, INT J MOL MED, V37, P631, DOI 10.3892/ijmm.2016.2478
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P1447, DOI 10.1167/iovs.07-1361
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Himori N, 2013, J NEUROCHEM, V127, P669, DOI 10.1111/jnc.12325
   Inagaki Y, 2003, DIABETOLOGIA, V46, P284, DOI 10.1007/s00125-002-1013-4
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Iomdina EN, 2015, FRONT BIOSCI-LANDMRK, V20, P892, DOI 10.2741/4343
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Izzotti A, 2009, INVEST OPHTH VIS SCI, V50, P5251, DOI 10.1167/iovs.09-3871
   Jain SK, 2001, FREE RADICAL BIO MED, V30, P232, DOI 10.1016/S0891-5849(00)00462-7
   Jitsanong T, 2011, TOXICOL IN VITRO, V25, P167, DOI 10.1016/j.tiv.2010.10.014
   Jung HA, 2008, FOOD CHEM TOXICOL, V46, P3818, DOI 10.1016/j.fct.2008.10.004
   KAHN MG, 1983, INVEST OPHTH VIS SCI, V24, P1283
   Karlsson M, 2016, ACTA OPHTHALMOL, V94, P556, DOI 10.1111/aos.13076
   Katome T, 2013, CELL DEATH DIFFER, V20, P270, DOI 10.1038/cdd.2012.122
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kida T, 2015, INVEST OPHTH VIS SCI, V56, P6754, DOI 10.1167/iovs.15-17534
   Kim Sukjin, 2015, Korean J Ophthalmol, V29, P424, DOI 10.3341/kjo.2015.29.6.424
   Kimura A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2817252
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kowluru RA, 2006, INVEST OPHTH VIS SCI, V47, P1594, DOI 10.1167/iovs.05-1276
   Kowluru RA, 2004, DIABETES, V53, P3233, DOI 10.2337/diabetes.53.12.3233
   Kowluru RA, 2014, DIABETOLOGIA, V57, P1047, DOI 10.1007/s00125-014-3194-z
   Kowluru RA, 2009, FREE RADICAL BIO MED, V46, P1677, DOI 10.1016/j.freeradbiomed.2009.03.024
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kumar B, 2015, INVEST OPHTH VIS SCI, V56, P2985, DOI 10.1167/iovs.15-16466
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Lacy F, 1998, FREE RADICAL BIO MED, V25, P720, DOI 10.1016/S0891-5849(98)00154-3
   LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0
   Lee HS, 2014, MOLECULES, V19, P12150, DOI 10.3390/molecules190812150
   Lee KH, 2008, J PHOTOCH PHOTOBIO B, V92, P175, DOI 10.1016/j.jphotobiol.2008.06.008
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Li CP, 2016, NEUROL SCI, V37, P755, DOI 10.1007/s10072-016-2491-3
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Li GR, 2007, MOL VIS, V13, P2282
   Li JM, 2010, DIABETES, V59, P1528, DOI 10.2337/db09-1057
   Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047600
   Li XY, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-19
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Li ZR, 2013, MOL VIS, V19, P1656
   Linsenmeier RA, 1998, INVEST OPHTH VIS SCI, V39, P1647
   Liton P, 2006, MOL VIS, V12, P774
   Liu HT, 2015, J BIOL CHEM, V290, P21568, DOI 10.1074/jbc.M115.655555
   Liu HT, 2015, INVEST OPHTH VIS SCI, V56, P647, DOI 10.1167/iovs.14-15220
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lv BC, 2016, INT J MOL MED, V37, P225, DOI 10.3892/ijmm.2015.2418
   Maciulaitiene R, 2017, MED SCI MONITOR, V23, P1173, DOI 10.12659/MSM.899699
   Mackey AM, 2008, CELL DEATH DIFFER, V15, P1291, DOI 10.1038/cdd.2008.43
   Martinez T, 2014, MOL THER, V22, P81, DOI 10.1038/mt.2013.216
   Meng D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048393
   Mian MF, 2008, CHEM-BIOL INTERACT, V171, P57, DOI 10.1016/j.cbi.2007.08.009
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mitra RN, 2016, ADV EXP MED BIOL, V854, P463, DOI 10.1007/978-3-319-17121-0_62
   Mittag TW, 2000, INVEST OPHTH VIS SCI, V41, P3451
   Mohammad G, 2010, LAB INVEST, V90, P1365, DOI 10.1038/labinvest.2010.89
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Nagai H, 2007, J BIOCHEM MOL BIOL, V40, P1
   Nagaoka T, 2008, INVEST OPHTH VIS SCI, V49, P2053, DOI 10.1167/iovs.07-1387
   Nahomi RB, 2014, BBA-MOL BASIS DIS, V1842, P164, DOI 10.1016/j.bbadis.2013.11.011
   Nakamura S, 2011, CURR NEUROVASC RES, V8, P25, DOI 10.2174/156720211794520224
   Namekata K, 2013, CELL DEATH DIFFER, V20, P1250, DOI 10.1038/cdd.2013.91
   Nanou A, 2013, MOL THER, V21, P1486, DOI 10.1038/mt.2013.115
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Nezhad ZK, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5561-9
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Noro T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.93
   Noro T, 2015, INVEST OPHTH VIS SCI, V56, P5012, DOI 10.1167/iovs.15-17142
   Nowotny K, 2015, BIOMOLECULES, V5, P194, DOI 10.3390/biom5010194
   Obrosova IG, 2006, DIABETOLOGIA, V49, P2525, DOI 10.1007/s00125-006-0356-7
   Osborne NN, 2014, DRUG DISCOV TODAY, V19, P1613, DOI 10.1016/j.drudis.2014.05.010
   Panfoli I, 2013, CELL BIOCHEM FUNCT, V31, P532, DOI 10.1002/cbf.2943
   Payne AJ, 2014, INT J MOL SCI, V15, P1865, DOI 10.3390/ijms15021865
   Payne Andrew J, 2013, Mo Med, V110, P429
   Pizzolla A, 2012, J IMMUNOL, V188, P5003, DOI 10.4049/jimmunol.1103430
   Prokai-Tatrai K, 2013, MOL PHARMACEUT, V10, P3253, DOI 10.1021/mp400313u
   Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P5360, DOI 10.1167/iovs.07-0254
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Qu JF, 2009, INVEST OPHTH VIS SCI, V50, P1814, DOI 10.1167/iovs.08-2656
   Quinlan CL, 2013, REDOX BIOL, V1, P304, DOI 10.1016/j.redox.2013.04.005
   Ranjbar M, 2016, CELL PHYSIOL BIOCHEM, V38, P737, DOI 10.1159/000443030
   Ray K, 2009, J GENET, V88, P451, DOI 10.1007/s12041-009-0065-3
   Reyes RC, 2012, J NEUROSCI, V32, P12973, DOI 10.1523/JNEUROSCI.1597-12.2012
   Rider JE, 2007, AMINO ACIDS, V33, P231, DOI 10.1007/s00726-007-0513-4
   Roddy GW, 2012, MOL THER, V20, P788, DOI 10.1038/mt.2011.308
   Roehlecke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071570
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596
   Santos JM, 2011, INVEST OPHTH VIS SCI, V52, P8791, DOI 10.1167/iovs.11-8203
   Santos JM, 2011, CURR PHARM BIOTECHNO, V12, P352
   Schlieve CR, 2006, INVEST OPHTH VIS SCI, V47, P3878, DOI 10.1167/iovs.05-1010
   Schwechter BR, 2007, INVEST OPHTH VIS SCI, V48, P2845, DOI 10.1167/iovs.06-1364
   Semba K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.296
   Semba K, 2014, NEUROSCI LETT, V581, P89, DOI 10.1016/j.neulet.2014.08.034
   Sheikpranbabu S, 2010, BIOCHIMIE, V92, P1040, DOI 10.1016/j.biochi.2010.05.004
   Sheu SJ, 2015, ACTA OPHTHALMOL, V93, pE631, DOI 10.1111/aos.12745
   Shibagaki K, 2015, EXP EYE RES, V139, P64, DOI 10.1016/j.exer.2015.07.007
   Siemianowicz K, 2004, INT J MOL MED, V14, P433
   Simpkins JW, 2005, CNS NEUROL DISORD-DR, V4, P69, DOI 10.2174/1568007053005073
   Skulachev VP, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1385, DOI 10.1134/S0006297907120139
   Skulachev VP, 2009, BBA-BIOENERGETICS, V1787, P437, DOI 10.1016/j.bbabio.2008.12.008
   Sozmen EY, 2001, ARCH MED RES, V32, P283, DOI 10.1016/S0188-4409(01)00285-5
   Sugano E, 2013, CELL STRUCT FUNCT, V38, P81, DOI 10.1247/csf.12025
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Sun JZ, 2010, MOL CELL BIOCHEM, V343, P27, DOI 10.1007/s11010-010-0495-5
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tanito M, 2005, J NEUROSCI, V25, P2396, DOI 10.1523/JNEUROSCI.4866-04.2005
   Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P1201, DOI 10.1167/iovs.06-0737
   Veluthakal R, 2015, CELL PHYSIOL BIOCHEM, V36, P208, DOI 10.1159/000374065
   Voeikov V, 2001, RIV BIOL-BIOL FORUM, V94, P237
   Wagenfeld L, 2014, INVEST OPHTH VIS SCI, V55, P5531, DOI 10.1167/iovs.14-14032
   Wanek J, 2014, INVEST OPHTH VIS SCI, V55, P1588, DOI 10.1167/iovs.13-13537
   Wang DD, 2016, J AGR FOOD CHEM, V64, P1528, DOI 10.1021/acs.jafc.5b05864
   Wang HB, 2014, MOL VIS, V20, P231
   Wang HT, 2015, J MOL NEUROSCI, V55, P931, DOI 10.1007/s12031-014-0448-7
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Whiteside CL, 2005, CURR HYPERTENS REP, V7, P148, DOI 10.1007/s11906-005-0090-4
   Wilding C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090737
   Wood JPM, 2008, MOL VIS, V14, P334
   Wu Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/752387
   Xing Y, 2013, NEURAL REGEN RES, V8, P909, DOI 10.3969/j.issn.1673-5374.2013.10.005
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Yamagishi S, 2002, MOL MED, V8, P179, DOI 10.1007/BF03402010
   Yamagishi SI, 2008, OPHTHAL RES, V40, P10, DOI 10.1159/000111152
   Yamagishi SI, 2007, OPHTHAL RES, V39, P92, DOI 10.1159/000099244
   Yamagishi S, 2006, MICROVASC RES, V72, P86, DOI 10.1016/j.mvr.2006.04.002
   Yamagishi S, 2006, J BIOL CHEM, V281, P20213, DOI 10.1074/jbc.M602110200
   Yamagishi SI, 2009, DIABETES-METAB RES, V25, P266, DOI 10.1002/dmrr.906
   Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007
   Yamamoto K, 2014, INVEST OPHTH VIS SCI, V55, P7126, DOI 10.1167/iovs.13-13842
   Yang IH, 2015, INVEST OPHTH VIS SCI, V56, P761, DOI 10.1167/iovs.14-15299
   Yang J, 2010, HYPERTENSION, V55, P468, DOI 10.1161/HYPERTENSIONAHA.109.145714
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Yang PM, 2016, LIFE SCI, V155, P94, DOI 10.1016/j.lfs.2016.05.006
   Yao J, 2014, CELL PHYSIOL BIOCHEM, V33, P107, DOI 10.1159/000356654
   Ye L, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/413024
   Yin JG, 2011, J CELL PHYSIOL, V226, P2025, DOI 10.1002/jcp.22532
   Ying ZK, 2011, INFLAMM RES, V60, P219, DOI 10.1007/s00011-010-0256-7
   Yokota T, 2015, CLIN EXP OPHTHALMOL, V43, P568, DOI 10.1111/ceo.12525
   Yoshida Y., 2007, INVESTIG OPHTHALMOL, V48, P4967
   Yoshida Y, 2009, DIABETES-METAB RES, V25, P678, DOI 10.1002/dmrr.1007
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
   Zaidi A, 1999, FREE RADICAL BIO MED, V27, P810, DOI 10.1016/S0891-5849(99)00128-8
   Zeitz O, 2006, BRIT J OPHTHALMOL, V90, P1245, DOI 10.1136/bjo.2006.093633
   Zetterqvist AV, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/428473
   Zhang B, 2009, INVEST OPHTH VIS SCI, V50, P3943, DOI 10.1167/iovs.08-2954
   Zhang ZZ, 2012, CURR EYE RES, V37, P429, DOI 10.3109/02713683.2011.653616
   Zhao L, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/425705
   Zhong Q, 2013, DIABETES, V62, P2559, DOI 10.2337/db12-1141
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zhou P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043173
   Zhou T, 2011, DIABETOLOGIA, V54, P459, DOI 10.1007/s00125-010-1943-1
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
   Zhu X, 2015, INT J MOL SCI, V16, P21775, DOI 10.3390/ijms160921775
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 207
TC 39
Z9 41
U1 3
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2018
VL 19
IS 11
AR 3362
DI 10.3390/ijms19113362
PG 30
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HC0ZM
UT WOS:000451528500078
PM 30373222
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Ma, WX
   Zhang, YK
   Gao, C
   Fariss, RN
   Tam, J
   Wong, WT
AF Ma, Wenxin
   Zhang, Yikui
   Gao, Chun
   Fariss, Robert N.
   Tam, Johnny
   Wong, Wai T.
TI Monocyte infiltration and proliferation reestablish myeloid cell
   homeostasis in the mouse retina following retinal pigment epithelial
   cell injury
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; MACULAR DEGENERATION; BONE-MARROW; GEOGRAPHIC
   ATROPHY; RESIDENT MICROGLIA; SUBRETINAL MICROGLIA; FRACTALKINE RECEPTOR;
   STEM-CELLS; AGE; MICE
AB Age-related macular degeneration (AMD), a leading contributor of vision loss, currently lacks comprehensive treatment. While AMD histopathology involves retinal pigment epithelium (RPE) injury associated with immune cell infiltration, the nature of immune cell responses to RPE injury remains undefined. We induced RPE injury pharmacologically and genetically in transgenic mouse models in which microglia and systemic monocytes were separately tagged, enabling a spatial and temporal dissection of the relative contributions of microglia vs. monocytes to post-injury changes. We found that myeloid cell responses to RPE injury occur in stages: (1) an early mobilization of endogenous microglia from the inner retina to the RPE layer, followed by (2) subsequent monocyte infiltration from the retinal vasculature into the inner retina that replenishes the local myeloid cell population in a CCR2-regulated manner. These altered distributions of myeloid cells post-injury were long-lived, with recruited monocytes acquiring the distribution, markers, and morphologies of neighboring endogenous microglia in a durable manner. These findings indicate the role played by infiltrating monocytes in maintaining myeloid cell homeostasis in the retina following AMD-relevant RPE injury and provide a foundation for understanding and therapeutically modulating immune aspects in retinal disease.
C1 [Ma, Wenxin; Zhang, Yikui; Wong, Wai T.] NIH, Unit Neuron Glia Interact Retinal Dis, Bethesda, MD 20892 USA.
   [Gao, Chun; Fariss, Robert N.] NEI, Biol Imaging Core, NIH, Bethesda, MD 20892 USA.
   [Tam, Johnny] NEI, Ophthalm Genet & Visual Funct Branch, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Wong, WT (通讯作者)，NIH, Unit Neuron Glia Interact Retinal Dis, Bethesda, MD 20892 USA.
EM wongw@nei.nih.gov
RI Fariss, Robert/ABI-1771-2020; Tam, Johnny/AHD-6065-2022; Wong,
   Wai/B-6118-2017
OI Tam, Johnny/0000-0003-2300-0567; Wong, Wai/0000-0003-0681-4016; Fariss,
   Robert/0000-0003-3227-7170; Ma, Wenxin/0000-0001-8396-6625
FU National Eye Institute Intramural Research Program; NATIONAL EYE
   INSTITUTE [ZIAEY000541, ZICEY000459, ZIAEY000544] Funding Source: NIH
   RePORTER
FX The study is supported by the National Eye Institute Intramural Research
   Program.
CR Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014
   Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ashhurst TM, 2014, CELL IMMUNOL, V291, P49, DOI 10.1016/j.cellimm.2014.07.002
   Beamer E, 2016, NEUROPHARMACOLOGY, V104, P94, DOI 10.1016/j.neuropharm.2015.09.019
   Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113
   Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012
   Buttgereit A, 2016, NAT IMMUNOL, V17, P1397, DOI 10.1038/ni.3585
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040
   Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujimura N, 2015, SCI REP-UK, V5, DOI 10.1038/srep11664
   Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249
   Grigsby JG, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/705783
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin N, 2017, MOL NEUROBIOL, V54, P4094, DOI 10.1007/s12035-016-9960-9
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kokovay E, 2005, NEUROBIOL DIS, V19, P471, DOI 10.1016/j.nbd.2005.01.023
   Lad EM, 2016, GRAEF ARCH CLIN EXP, V254, P1239, DOI 10.1007/s00417-015-3249-y
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   LAWSON LJ, 1992, NEUROSCIENCE, V48, P405, DOI 10.1016/0306-4522(92)90500-2
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Liu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072935
   Ma WX, 2012, ADV EXP MED BIOL, V723, P37, DOI 10.1007/978-1-4614-0631-0_6
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mitchell CH, 2008, PURINERG SIGNAL, V4, P101, DOI 10.1007/s11302-007-9054-2
   Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421
   Mones J, 2016, INVEST OPHTH VIS SCI, V57, P3974, DOI 10.1167/iovs.16-19355
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693
   Schwartz M, 2014, EMBO J, V33, P7, DOI 10.1002/embj.201386609
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Simard AR, 2004, FASEB J, V18, P998, DOI 10.1096/fj.04-1517fje
   Tabor-Godwin JM, 2010, J NEUROSCI, V30, P8676, DOI 10.1523/JNEUROSCI.1860-10.2010
   Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919
   Tay TL, 2017, J PHYSIOL-LONDON, V595, P1929, DOI 10.1113/JP272134
   Varvel NH, 2016, P NATL ACAD SCI USA, V113, pE5665, DOI 10.1073/pnas.1604263113
   Wang JW, 2016, J GLAUCOMA, V25, P459, DOI 10.1097/IJG.0000000000000200
   Wang X, 2016, J NEUROSCI, V36, P2827, DOI 10.1523/JNEUROSCI.3575-15.2016
   Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zieger M, 2016, ONCOTARGET, V7, P9620, DOI 10.18632/oncotarget.7330
NR 69
TC 45
Z9 46
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 16
PY 2017
VL 7
AR 8433
DI 10.1038/s41598-017-08702-7
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FD6ZV
UT WOS:000407677300008
PM 28814744
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yu, GP
   Wu, XM
   Ayat, N
   Maeda, A
   Gao, SQ
   Golczak, M
   Palczewski, K
   Lu, ZR
AF Yu, Guanping
   Wu, Xueming
   Ayat, Nadia
   Maeda, Akiko
   Gao, Song-Qi
   Golczak, Marcin
   Palczewski, Krzysztof
   Lu, Zheng-Rong
TI Multifunctional PEG Retinylamine Conjugate Provides Prolonged Protection
   against Retinal Degeneration in Mice
SO BIOMACROMOLECULES
LA English
DT Article
ID DRUG-DELIVERY SYSTEMS; VISUAL CYCLE MODULATOR; BRUSH-BORDER ENZYMES;
   N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMERS; CLEAVAGE; DISEASES;
   ACU-4429
AB A polyethylene glycol (PEG) retinylamine (Ret-NH2) conjugate PEG-GFL-NH-Ret with a glycine-phenylalanine-leucine (GFL) spacer was synthesized for controlled oral delivery of Ret-NH2 to treat retinal degenerative diseases, including Stargardt disease (STGD) and age-related macular degeneration (AMD). The peptide spacer was introduced for sustained release of the drug by digestive enzymes in the gastrointestinal tract. The pharmacokinetics experiments showed that the PEG conjugate could control the sustained drug release after oral administration and had much lower nonspecific liver drug accumulation than the free drug in wild-type female C57BL mice. In the mean time, the conjugate maintained the same concentration of Ret-NH2 in the eye as the free drug. Also, PEG-GFL-NH-Ret at a Ret-NH2 equivalent dose of 25 mg/kg produced complete protection of Abca4(-/-)Rdh8(-/-) mouse retinas against light-induced retinal degeneration for 3 days after oral administration, as revealed by OCT retina imaging, whereas free Ret-NH2 did not provide any protection under identical conditions. The polymer conjugate PEG-GFL-NH-Ret has great potential for controlled delivery of Ret-NH2 to the eye for effective protection against retinal degenerative diseases.
C1 [Yu, Guanping; Wu, Xueming; Ayat, Nadia; Lu, Zheng-Rong] Case Western Reserve Univ, Sch Engn, Dept Biomed Engn, Cleveland, OH 44140 USA.
   [Maeda, Akiko; Gao, Song-Qi; Golczak, Marcin; Palczewski, Krzysztof] Case Western Reserve Univ, Sch Med, Cleveland Ctr Membrane & Struct Biol, Dept Pharmacol, Cleveland, OH 44140 USA.
   [Maeda, Akiko] Case Western Reserve Univ, Sch Med, Dept Ophthalmol, Cleveland, OH 44140 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University
RP Lu, ZR (通讯作者)，Case Western Reserve Univ, Sch Engn, Dept Biomed Engn, Cleveland, OH 44140 USA.
FU National Eye Institute of the National Institutes of Health
   [R24EY0211260]; Knights Templar Eye Foundation pediatric ophthalmology
   career-starter research grant; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER
FX The authors thank Dr. Zhuxian Zhou for valuable advice on data
   preparation. This work was supported in part by funding from the
   National Eye Institute of the National Institutes of Health (Grant
   R24EY0211260). G.Y. is also supported in part by a Knights Templar Eye
   Foundation pediatric ophthalmology career-starter research grant. K.P.
   is John H. Hord Professor of Pharmacology. Z.-R.L. is M. Frank Rudy and
   Margaret Domiter Rudy Professor of Biomedical Engineering.
CR Achouri D, 2013, DRUG DEV IND PHARM, V39, P1599, DOI 10.3109/03639045.2012.736515
   [Anonymous], 2006, Genta Salus LLC, Patent No. [07060498, US7060498, 7060498]
   Barbu E, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/22/225108
   Coin I, 2007, NAT PROTOC, V2, P3247, DOI 10.1038/nprot.2007.454
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Eljarrat-Binstock E., 2010, J PHARM RES, V27, P530
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Golczak M, 2005, J BIOL CHEM, V280, P42263, DOI 10.1074/jbc.M509351200
   Hacker MC, 2009, J BIOMED MATER RES A, V88A, P976, DOI 10.1002/jbm.a.31942
   Heizmann J, 1996, PEPTIDES, V17, P1083, DOI 10.1016/S0196-9781(96)00178-7
   Kaur IP, 2004, INT J PHARMACEUT, V269, P1, DOI 10.1016/j.ijpharm.2003.09.016
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   KOPECKOVA P, 1992, MAKROMOL CHEM, V193, P2605
   KOPECKOVA P, 1991, MAKROMOL CHEM-RAPID, V12, P101
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Shirasaki Y, 2008, J PHARM SCI-US, V97, P2462, DOI 10.1002/jps.21200
   Vandamme TF, 2002, PROG RETIN EYE RES, V21, P15, DOI 10.1016/S1350-9462(01)00017-9
   Wu XM, 2014, ACS NANO, V8, P153, DOI 10.1021/nn4054107
NR 27
TC 8
Z9 8
U1 0
U2 27
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
EI 1526-4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD DEC
PY 2014
VL 15
IS 12
BP 4570
EP 4578
DI 10.1021/bm501352s
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA AW2JR
UT WOS:000346114400021
PM 25390360
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Hyttinen, JMT
   Amadio, M
   Viiri, J
   Pascale, A
   Salminen, A
   Kaarniranta, K
AF Hyttinen, Juha M. T.
   Amadio, Marialaura
   Viiri, Johanna
   Pascale, Alessia
   Salminen, Antero
   Kaarniranta, Kai
TI Clearance of misfolded and aggregated proteins by aggrephagy and
   implications for aggregation diseases
SO AGEING RESEARCH REVIEWS
LA English
DT Review
DE Age-related macular degeneration; Aggrephagy; Aggresome; Alzheimer's
   disease; Autophagy; Protein folding
ID FRONTOTEMPORAL LOBAR DEGENERATION; REGULATES AGGRESOME FORMATION;
   UBIQUITIN-PROTEASOME SYSTEM; TRANSCRIPTION FACTOR NRF2; INCLUSION-BODY
   FORMATION; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; SEQUESTOSOME
   1/P62; OXIDATIVE STRESS; QUALITY-CONTROL
AB Processing of misfolded proteins is important in order for the cell to maintain its normal functioning and homeostasis. Three systems control the quality of proteins: chaperone-mediated refolding, proteasomal degradation of ubiquitinated proteins, and finally, when the two others fail, aggrephagy, as selective form of autophagy, degrades ubiquitin-labelled aggregated cargos. In this route misfolded proteins gradually form larger aggregates, aggresomes and they eventually become double membrane-wrapped organelles called autophagosomes, which become degraded when they fuse to lysosomes, for reuse by the cell. The stages, the main molecules participating in the process, and the regulation of aggrephagy are discussed here, as is the role of protein aggregation in protein accumulation diseases. In particular, we emphasize that both Alzheimer's disease and age-related macular degeneration, two of the most common pathologies in the aged, are characterized by altered protein clearance and deposits. Based on the hypothesis that manipulations of autophagy may be potentially useful in these and other aggregation-related diseases, we will discuss some promising therapeutic strategies to counteract protein aggregates-induced cellular toxicity. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Hyttinen, Juha M. T.; Viiri, Johanna; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, FI-70211 Kuopio, Finland.
   [Amadio, Marialaura; Pascale, Alessia] Univ Pavia, Pharmacol Sect, Dept Drug Sci, I-27100 Pavia, Italy.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, FI-70211 Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Pavia; University of
   Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Hyttinen, JMT (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, POB 1627, FI-70211 Kuopio, Finland.
EM Juha.Hyttinen@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Kaarniranta, Kai/0000-0003-2600-8679
CR Aguzzi A, 2010, NAT REV DRUG DISCOV, V9, P237, DOI 10.1038/nrd3050
   Babu JR, 2008, J NEUROCHEM, V106, P107, DOI 10.1111/j.1471-4159.2008.05340.x
   Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x
   Bang Y, 2014, NEUROSCI LETT, V566, P263, DOI 10.1016/j.neulet.2014.02.056
   Barnett A, 2011, J ALZHEIMERS DIS, V25, P385, DOI 10.3233/JAD-2011-101989
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Biswas N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021153
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008
   Bonanomi M, 2014, INT J BIOCHEM CELL B, V51, P58, DOI 10.1016/j.biocel.2014.03.015
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Boyault C, 2006, EMBO J, V25, P3357, DOI 10.1038/sj.emboj.7601210
   Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a
   Bucciantini M, 2010, METHODS MOL BIOL, V648, P231, DOI 10.1007/978-1-60761-756-3_15
   Burnett BG, 2005, P NATL ACAD SCI USA, V102, P4330, DOI 10.1073/pnas.0407252102
   Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v
   Caccamo A, 2013, AGING CELL, V12, P370, DOI 10.1111/acel.12057
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Cecconi F, 2007, AUTOPHAGY, V3, P506
   Chin LS, 2010, BIOCHEM SOC T, V38, P144, DOI 10.1042/BST0380144
   Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239
   Chung KKK, 2001, TRENDS NEUROSCI, V24, pS7, DOI 10.1016/S0166-2236(00)01998-6
   Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q
   Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226
   Congdon EE, 2012, AUTOPHAGY, V8, P609, DOI 10.4161/auto.19048
   Corboy Michael J., 2005, V301, P305
   Ding HP, 2008, J NEUROCHEM, V106, P2119, DOI 10.1111/j.1471-4159.2008.05564.x
   Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261
   Du YF, 2009, NEUROBIOL DIS, V35, P302, DOI 10.1016/j.nbd.2009.05.015
   Du YF, 2009, FREE RADICAL BIO MED, V46, P492, DOI 10.1016/j.freeradbiomed.2008.11.003
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fecto F, 2011, ARCH NEUROL-CHICAGO, V68, P1440, DOI 10.1001/archneurol.2011.250
   Fengsrud M, 2004, AUTOPHAGY, P11
   Filimonenko M, 2010, MOL CELL, V38, P265, DOI 10.1016/j.molcel.2010.04.007
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Furuta N, 2010, MOL BIOL CELL, V21, P1001, DOI 10.1091/mbc.E09-08-0693
   Fusco C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040440
   Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024
   Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x
   Geetha T, 2012, BIOMARKERS, V17, P99, DOI 10.3109/1354750X.2011.653986
   Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Guthrie CR, 2011, J MOL NEUROSCI, V45, P32, DOI 10.1007/s12031-011-9502-x
   Halawani D, 2010, J NEUROSCI, V30, P6132, DOI 10.1523/JNEUROSCI.5874-09.2010
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317
   Heir R, 2006, EMBO REP, V7, P1252, DOI 10.1038/sj.embor.7400823
   Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Isakson P, 2013, CELL DEATH DIFFER, V20, P12, DOI 10.1038/cdd.2012.66
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067
   Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102
   Jaeger PA, 2010, ARCH NEUROL-CHICAGO, V67, P1181, DOI 10.1001/archneurol.2010.258
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Ju JS, 2008, J BIOL CHEM, V283, P30289, DOI 10.1074/jbc.M805517200
   Jung HJ, 2013, EXP NEUROL, V248, P441, DOI 10.1016/j.expneurol.2013.07.013
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaganovich D, 2008, NATURE, V454, P1088, DOI 10.1038/nature07195
   Kalia SK, 2010, CNS NEUROL DISORD-DR, V9, P741
   Kardon JR, 2009, NAT REV MOL CELL BIO, V10, P854, DOI 10.1038/nrm2804
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kinnunen PKJ, 2012, BBA-BIOMEMBRANES, V1818, P2446, DOI 10.1016/j.bbamem.2012.04.008
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3
   Koronyo Y, 2012, NEURODEGENER DIS, V10, P285, DOI 10.1159/000335154
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008
   Leger F, 2011, J NEUROPATH EXP NEUR, V70, P63, DOI 10.1097/NEN.0b013e31820376cc
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Lin AL, 2013, J CEREBR BLOOD F MET, V33, P1412, DOI 10.1038/jcbfm.2013.82
   Liu QS, 2012, J BIOL CHEM, V287, P9742, DOI 10.1074/jbc.M111.304485
   Lu Q, 2013, BIOCHEM J, V452, P381, DOI 10.1042/BJ20121721
   Lucin KM, 2013, NEURON, V79, P873, DOI 10.1016/j.neuron.2013.06.046
   Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X
   Lynch-Day MA, 2010, FEBS LETT, V584, P1359, DOI 10.1016/j.febslet.2010.02.013
   Ma QY, 2011, EXP GERONTOL, V46, P533, DOI 10.1016/j.exger.2011.02.006
   Pareja MEM, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00054
   Marx FP, 2007, FASEB J, V21, P1759, DOI 10.1096/fj.06-6734com
   Matthias P, 2008, CELL CYCLE, V7, P7, DOI 10.4161/cc.7.1.5186
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nair U, 2011, CELL, V146, P290, DOI 10.1016/j.cell.2011.06.022
   Nakaso K, 2006, BIOCHEM BIOPH RES CO, V339, P915, DOI 10.1016/j.bbrc.2005.11.095
   Ohno-Matsui K., 2009, ACTA OPHTHALMOL    S, V87, ps244
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olzmann JA, 2008, CURR MED CHEM, V15, P47
   Olzmann JA, 2007, J CELL BIOL, V178, P1025, DOI 10.1083/jcb.200611128
   Ouyang H, 2012, J BIOL CHEM, V287, P2317, DOI 10.1074/jbc.M111.273730
   Overbye A, 2007, AUTOPHAGY, V3, P300, DOI 10.4161/auto.3910
   Pai MT, 2007, J MOL BIOL, V370, P290, DOI 10.1016/j.jmb.2007.04.015
   Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Paul S, 2014, MOL CELL BIOCHEM, V386, P45, DOI 10.1007/s11010-013-1844-y
   Perez M, 2009, J NEUROCHEM, V109, P1756, DOI 10.1111/j.1471-4159.2009.06102.x
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Ravikumar B, 2004, NEUROREPORT, V15, P2443, DOI 10.1097/00001756-200411150-00001
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Reggiori Fulvio, 2012, Int J Cell Biol, V2012, P219625, DOI 10.1155/2012/219625
   Richter-Landsberg C, 2013, ACTA NEUROPATHOL, V126, P793, DOI 10.1007/s00401-013-1158-x
   Ross CA, 2005, NAT REV MOL CELL BIO, V6, P891, DOI 10.1038/nrm1742
   Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066
   Rubino E, 2012, NEUROLOGY, V79, P1556, DOI 10.1212/WNL.0b013e31826e25df
   Ryhanen T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/798052
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002
   Salminen A, 2012, PROG NEUROBIOL, V96, P87, DOI 10.1016/j.pneurobio.2011.11.005
   Santos AN, 2012, J ALZHEIMERS DIS, V29, P171, DOI 10.3233/JAD-2012-111361
   Sarkar S, 2013, BIOCHEM SOC T, V41, P1103, DOI 10.1042/BST20130134
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096
   Seibenhener ML, 2013, BBA-MOL CELL RES, V1833, P452, DOI 10.1016/j.bbamcr.2012.11.004
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004
   Sha YB, 2009, MOL CELL BIOL, V29, P116, DOI 10.1128/MCB.00829-08
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shiarli AM, 2006, NEUROPATH APPL NEURO, V32, P374, DOI 10.1111/j.1365-2990.2006.00736.x
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Simoes-Pires C, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-7
   Simonsen A, 2004, J CELL SCI, V117, P4239, DOI 10.1242/jcs.01287
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200
   Son JH, 2012, EXP MOL MED, V44, P89, DOI 10.3858/emm.2012.44.2.031
   Spilman P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009979
   Su M, 2011, J NEUROCHEM, V117, P112, DOI 10.1111/j.1471-4159.2011.07180.x
   Takats S, 2013, J CELL BIOL, V201, P531, DOI 10.1083/jcb.201211160
   Tan CC, 2014, NEUROBIOL AGING, V35, P941, DOI 10.1016/j.neurobiolaging.2013.11.019
   Tanji K, 2013, J NEUROPATH EXP NEUR, V72, P18, DOI 10.1097/NEN.0b013e31827b5713
   Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85
   Tomkinson B, 2005, INT J BIOCHEM CELL B, V37, P1933, DOI 10.1016/j.biocel.2005.02.009
   Uchiyama Y, 2008, AUTOPHAGY, V4, P404, DOI 10.4161/auto.5598
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang HF, 2012, J BIOL CHEM, V287, P28576, DOI 10.1074/jbc.M111.299990
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573
   Watabe M, 2011, J CELL SCI, V124, P1519, DOI 10.1242/jcs.081778
   Watanabe Y, 2011, J CELL SCI, V124, P2692, DOI 10.1242/jcs.081232
   Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003
   Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888
   Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Wooten MW, 2008, J BIOL CHEM, V283, P6783, DOI 10.1074/jbc.M709496200
   Xu Z, 2013, J CELL SCI, V126, P4173, DOI 10.1242/jcs.126102
   Yamada Y, 2007, J BIOL CHEM, V282, P8036, DOI 10.1074/jbc.M611473200
   Yamamoto A, 2011, NEUROBIOL DIS, V43, P17, DOI 10.1016/j.nbd.2010.08.015
   Yan J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076016
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082
   Zaarur N, 2008, J BIOL CHEM, V283, P27575, DOI 10.1074/jbc.M802216200
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
   Zhang L, 2013, J ALZHEIMERS DIS, V33, P283, DOI 10.3233/JAD-2012-120727
   Zhu XC, 2013, MOL NEUROBIOL, V48, P702, DOI 10.1007/s12035-013-8457-z
   Zucchi PC, 2011, MOL BIOL CELL, V22, P4635, DOI 10.1091/mbc.E11-08-0680
NR 185
TC 110
Z9 111
U1 4
U2 42
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1568-1637
EI 1872-9649
J9 AGEING RES REV
JI Ageing Res. Rev.
PD NOV
PY 2014
VL 18
BP 16
EP 28
DI 10.1016/j.arr.2014.07.002
PG 13
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA AY7XK
UT WOS:000347769000002
PM 25062811
DA 2022-11-30
ER

PT J
AU Mallet, JD
   Rochette, PJ
AF Mallet, Justin D.
   Rochette, Patrick J.
TI Ultraviolet Light-Induced Cyclobutane Pyrimidine Dimers in Rabbit Eyes
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID LENS EPITHELIAL-CELLS; INDUCED DNA-DAMAGE; BIOMECHANICAL PROPERTIES; UV
   DAMAGE; RADIATION; REPAIR; CORNEA; PHOTOPRODUCTS; SPECIFICITY;
   MECHANISMS
AB Sunlight exposure of the eye leads to pathologies including photokeratitis, cortical cataracts, pterygium, actinic conjunctivitis and age-related macular degeneration. It is well established that exposure to ultraviolet (UV) radiations leads to DNA damage, mainly cyclobutane pyrimidine dimers (CPDs). CPD formation is the principal factor involved in skin cancer. However, the exact mechanism by which sunlight induces ocular pathologies is not well understood. To shed light on this issue, we quantified the CPD formation onto DNA of rabbit ocular cells following UVB exposure. We found that CPDs were induced only in the structures of the ocular anterior chamber (cornea, iris and lens) and were more concentrated in the corneal epithelium. Residual UVB that pass through the cornea are completely absorbed by the anterior layers of the iris. CPDs were also detected in the central portion of the lens that is not protected by the iris (pupil). By determining the UV-induced DNA damage formation in eyes, we showed that anterior ocular structures are a reliable physical barrier that protects the subjacent structures from the toxic effects of UV. Although the corneal epithelium is the structure where most of the CPDs were detected, no cancer is related to solar exposure.
C1 [Rochette, Patrick J.] Univ Laval, LOEX CUO Rech, Ctr Rech CHA, Quebec City, PQ, Canada.
   Univ Laval, Dept Ophthalmol, Quebec City, PQ, Canada.
C3 Laval University; Laval University
RP Rochette, PJ (通讯作者)，Univ Laval, LOEX CUO Rech, Ctr Rech CHA, Quebec City, PQ, Canada.
EM patrick.rochette@orlo.ulaval.ca
OI Rochette, Patrick/0000-0002-0678-8869
FU Fondation des maladies de l'oeil; Reseau de recherche en sante de la
   vision du FRSQ
FX The authors are grateful to the laboratories of Dr. Lucie Germain and
   Dr. Marc Hebert (Laval University, Quebec, Canada) for technical
   support. This work was supported by grants from the "Fondation des
   maladies de l'oeil" and the "Reseau de recherche en sante de la vision
   du FRSQ."
CR ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x
   BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59
   Brubaker RF, 2000, INVEST OPHTH VIS SCI, V41, P1681
   Cai CX, 1998, MOL BIOL CELL, V9, P1037, DOI 10.1091/mbc.9.5.1037
   Elsheikh A, 2007, CURR EYE RES, V32, P11, DOI 10.1080/02713680601077145
   Faragher RGA, 1997, BRIT J OPHTHALMOL, V81, P814, DOI 10.1136/bjo.81.10.814
   Friedberg EC, 1995, DNA REPAIR MUTAGENES
   KANAI A, 1973, Annals of Ophthalmology, V5, P178
   KINSEY VE, 1948, ARCH OPHTHALMOL-CHIC, V39, P508
   KLEIMAN NJ, 1990, CURR EYE RES, V9, P1185, DOI 10.3109/02713689009003475
   Kotecha A, 2006, INVEST OPHTH VIS SCI, V47, P5337, DOI 10.1167/iovs.06-0557
   LEBKOWSKI JS, 1985, P NATL ACAD SCI USA, V82, P8606, DOI 10.1073/pnas.82.24.8606
   Lerman S., 1980, RADIANT ENERGY EYE, P73
   Lytle C D, 1992, Photodermatol Photoimmunol Photomed, V9, P268
   MALIK NS, 1992, BIOCHIM BIOPHYS ACTA, V1138, P222, DOI 10.1016/0925-4439(92)90041-K
   Marrot L, 2008, J AM ACAD DERMATOL, V58, pS139, DOI 10.1016/j.jaad.2007.12.007
   MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927
   MILLER JH, 1983, ANNU REV GENET, V17, P215, DOI 10.1146/annurev.ge.17.120183.001243
   MITCHELL J, 1995, CORNEA, V14, P266, DOI 10.1097/00003226-199505000-00007
   MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x
   NORREN DV, 1974, VISION RES, V14, P1237, DOI 10.1016/0042-6989(74)90222-3
   Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x
   Reddy VN, 1998, INVEST OPHTH VIS SCI, V39, P344
   Rochette PJ, 2006, PHOTOCHEM PHOTOBIOL, V82, P1370, DOI 10.1562/2004-12-01-RA-390
   Rochette PJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000926
   Rochette PJ, 2003, NUCLEIC ACIDS RES, V31, P2786, DOI 10.1093/nar/gkg402
   Sasaki H, 2003, INVEST OPHTH VIS SCI, V44, P4210, DOI 10.1167/iovs.01-1221
   SIDJANIN D, 1993, CURR EYE RES, V12, P773, DOI 10.3109/02713689309020382
   SUTHERLAND JC, 1981, RADIAT RES, V86, P399, DOI 10.2307/3575456
   TAYLOR HR, 1989, PHOTOCHEM PHOTOBIOL, V50, P489, DOI 10.1111/j.1751-1097.1989.tb05553.x
   TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201
   Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   Wielgus AR, 2008, PHOTOCHEM PHOTOBIOL, V84, P683, DOI 10.1111/j.1751-1097.2008.00341.x
   YOUNG RW, 1994, OPTOMETRY VISION SCI, V71, P125, DOI 10.1097/00006324-199402000-00013
   ZIGLER JS, 1981, PHOTOCHEM PHOTOBIOL, V33, P869
   ZIGMAN S, 1991, INVEST OPHTH VIS SCI, V32, P1723
   ZIGMAN S, 1993, PHOTOCHEM PHOTOBIOL, V57, P1060, DOI 10.1111/j.1751-1097.1993.tb02972.x
NR 38
TC 21
Z9 21
U1 1
U2 16
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0031-8655
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD NOV-DEC
PY 2011
VL 87
IS 6
BP 1363
EP 1368
DI 10.1111/j.1751-1097.2011.00977.x
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 839EO
UT WOS:000296348400015
PM 21770949
DA 2022-11-30
ER

PT J
AU Caramoy, A
   Fauser, S
   Kirchhof, B
AF Caramoy, Albert
   Fauser, Sascha
   Kirchhof, Bernd
TI Retinal stimuli can be restored after autologous transplant of retinal
   pigment epithelium and choroid in pigment epithelium tears
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE autologous transplantation; exudative age-related macular degeneration;
   microperimetry; retinal pigment epithelium rip; Retinal pigment
   epithelium tear; vitreoretinal surgery
ID MACULAR DEGENERATION; BRUCHS MEMBRANE; SILICONE OIL; TRANSLOCATION
AB Purpose: To evaluate the functional and anatomical outcome of patients undergoing autologous transplant of retinal pigment epithelium (RPE) and choroid after RPE tear secondary to age-related macular degeneration (AMD).
   Methods: Data from nine eyes of nine patients were analysed retrospectively. Examinations included fluorescein and indocyanine green angiography, fundus autofluorescence imaging, optical coherence tomography, microperimetry and determination of visual acuity (far and reading ability). Data regarding intraoperative and postoperative complications were recorded. Mean follow-up time was 18 months (range 4 months to 5 years).
   Results: After surgery, far visual acuity improved or remained stable (+/- 3 lines) in three of nine eyes and for the near visual acuity in three of nine eyes. Visual acuity decreased postoperatively at the last follow-up in four eyes mainly because of postoperative complications, i.e. retinal detachment due to proliferative vitreoretinopathy, retinal artery occlusion, pucker and fibrosis of the graft. In one case, retinal stimuli were restored over the scotoma as seen in microperimetry.
   Conclusion: Autologous transplant of RPE and choroid is a therapy option for RPE tears. Retinal stimuli can be restored in selected cases. Numerous intra- and postoperative complications compromise the functional prognosis and outcome.
C1 [Caramoy, Albert; Fauser, Sascha; Kirchhof, Bernd] Univ Cologne, Dept Vitreo Retinal Surg, Ctr Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Caramoy, A (通讯作者)，Univ Cologne, Dept Vitreo Retinal Surg, Ctr Ophthalmol, Kerpener St 62, D-50924 Cologne, Germany.
EM acaramoy@yahoo.co.uk
FU Forschung fur das Sehen e.V.
FX Financial disclosures: supported in part by Forschung fur das Sehen e.V.
CR CARAMOY A, 2011, ARCH OPHTHA IN PRESS
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Herbert EN, 2006, GRAEF ARCH CLIN EXP, V244, P248, DOI 10.1007/s00417-005-0076-6
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   la Cour M, 2010, KLIN MONATSBL AUGENH, V227, P181, DOI 10.1055/s-0029-1245295
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Ma ZZ, 2009, INVEST OPHTH VIS SCI, V50, P2975, DOI 10.1167/iovs.08-2573
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 16
TC 11
Z9 11
U1 0
U2 3
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2011
VL 89
IS 6
BP E490
EP E495
DI 10.1111/j.1755-3768.2011.02143.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812BE
UT WOS:000294261900003
PM 21410906
OA Bronze
DA 2022-11-30
ER

PT J
AU Querques, G
   Coscas, G
   Soubrane, G
   Souied, EH
AF Querques, Giuseppe
   Coscas, Gabriel
   Soubrane, Gisele
   Souied, Eric H.
TI Type II idiopathic macular telangiectasia and soft confluent drusen
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Drusen; Fluorescein angiography;
   Idiopathic macular telangiectasia; Spectral domain optical coherence
   tomography; Type 2a acquired idiopathic juxtafoveal retinal
   telangiectasis
ID JUXTAFOVEOLAR RETINAL TELANGIECTASIS; OPTICAL COHERENCE TOMOGRAPHY;
   THICKNESS
AB PURPOSE. To describe the simultaneous presentation of soft confluent drusen and type 2 idiopathic macular telangiectasia (IMT) in both eyes of one patient.
   METHODS. A 79-year-old man with bilateral metamorphopsia and gradual reduction of central vision underwent a complete ophthalmologic examination.
   RESULTS. In this patient, fundus biomicroscopy revealed soft confluent drusen and a cystic appearance within the fovea, and fluorescein angiography (FA) showed late dye leakage. Interestingly, indocyanine green angiography (ICGA) showed absence of late hypercyanescence, and spectral domain optical coherence tomography (Spectralis SD-OCT) clearly revealed the presence of bilateral foveal cysts with thinning and loss of the normal architecture of the outer retina, as well as absence of retinal thickening within the parafoveolar area showing discrete late dye leakage on FA. Based on these findings, the patient was diagnosed with nonexudative age-related macular degeneration with foveal soft confluent drusen, and coincident nonproliferative type 2 IMT.
   CONCLUSIONS. To our knowledge, there is no previously reported case of simultaneous presentation of soft confluent drusen and type 2 IMT. This report highlights the importance of ICGA and OCT in the correct diagnosis of such cases. (Eur J Ophthalmol 2010; 20: 466-8)
C1 [Querques, Giuseppe; Coscas, Gabriel; Soubrane, Gisele; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   GASS JD, 1982, ARCH OPHTHALMOL-CHIC, V100, P769
   Gass JD, 1997, STEREOSCOPIC ATLAS M, P505
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Gaudric A, 2006, ARCH OPHTHALMOL-CHIC, V124, P1410, DOI 10.1001/archopht.124.10.1410
   Issa PC, 2008, AM J OPHTHALMOL, V145, P169, DOI 10.1016/j.ajo.2007.08.028
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
NR 7
TC 6
Z9 6
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR-APR
PY 2010
VL 20
IS 2
BP 466
EP 468
DI 10.1177/112067211002000234
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 611ED
UT WOS:000278793200034
PM 19967665
DA 2022-11-30
ER

PT J
AU Chien, J
   He, XP
   Shridhar, V
AF Chien, Jeremy
   He, Xiaoping
   Shridhar, Viji
TI Identification of Tubulins as Substrates of Serine Protease HtrA1 by
   Mixture-Based Oriented Peptide Library Screening
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE SERINE PROTEASE; HtrA1; TUBULINS; PEPTIDE LIBRARY
ID ESCHERICHIA-COLI; PDZ DOMAINS; FAMILY; GENE; SPECIFICITY; CALPAIN;
   TARGETS; MOTIFS; SWITCH
AB Serine protease HtrA1 belongs to a family of chymotrypsin-like proteases that were first identified in bacteria and later in mammalian systems. These proteases were identified as components of protein quality control in prokaryotic systems and as regulators of diverse signaling pathways in mammalian systems. In particular, HtrA1 is implicated in trophoblast cell migration and invasion, tumor progression, chemotherapy-induced cytotoxicity, osteoarthritis, age-related macular degeneration, and pathogenesis of Alzheimer's disease. However, systematic analysis of its potential substrates in biological system is still lacking. Therefore, we performed a mixture-based oriented peptide library screening to identify putative substrates of HtrA1. We identified [AEGR]-[LAGR]-[IAMLR]-[TVIAL] as consensus residues for P1 to P4 sites. We identified several putative substrates of HtrA1 involved in the pathogenesis of various diseases. In this study, we report on the identification of tubulins as potential substrates of HtrA1, and validated tubulins as in vitro and intracellular substrates of HtrA1. These results provide initial insights into substrate identification and functional characterization of HtrA1 in pathogenesis of various diseases. J. Cell. Biochem. 107: 253-263, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Chien, Jeremy; He, Xiaoping; Shridhar, Viji] Mayo Clin, Coll Med, Dept Expt Pathol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Chien, J (通讯作者)，200 1st St SW,Stabile 2-47, Rochester, MN 55905 USA.
EM chien.jeremy@mayo.edu; shridhar.vijaylakshmi@mayo.edu
RI Seal, Sudipta/A-7698-2012; Chien, Jeremy/AID-8939-2022
OI Chien, Jeremy/0000-0003-4744-8374
FU National Cancer Institute [1R01CA123249]; Mayo Clinic Bernard and Edith
   Waterman Center for Cancer Genetics; Mayo Foundation; Ovarian Cancer
   Research Fund; NATIONAL CANCER INSTITUTE [R01CA123249] Funding Source:
   NIH RePORTER
FX Grant sponsor: National Cancer Institute; Grant number: 1R01CA123249;
   Grant sponsor: Mayo Clinic Bernard and Edith Waterman Center for Cancer
   Genetics; Grant sponsor: Mayo Foundation; Grant sponsor: Ovarian Cancer
   Research Fund.
CR Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200
   Ajayi F, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.046
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Bovenschen N, 2008, J IMMUNOL, V180, P8184, DOI 10.4049/jimmunol.180.12.8184
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5
   Clawson GA, 2008, J CELL BIOCHEM, V105, P81, DOI 10.1002/jcb.21804
   Cuerrier D, 2005, J BIOL CHEM, V280, P40632, DOI 10.1074/jbc.M506870200
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   GONG ZY, 1988, DEVELOPMENT, V102, P31
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795
   Lingle WL, 2001, METHOD CELL BIOL, V67, P325
   LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053
   Martins LM, 2003, J BIOL CHEM, V278, P49417, DOI 10.1074/jbc.M308659200
   Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435
   Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x
   Runyon ST, 2007, PROTEIN SCI, V16, P2454, DOI 10.1110/ps.073049407
   Schlieker C, 2004, CELL, V117, P417, DOI 10.1016/S0092-8674(04)00453-2
   Sohn J, 2007, CELL, V131, P572, DOI 10.1016/j.cell.2007.08.044
   Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6
   Stiffler MA, 2007, SCIENCE, V317, P364, DOI 10.1126/science.1144592
   STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576
   Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0
   Tonami K, 2007, MOL CELL BIOL, V27, P2548, DOI 10.1128/MCB.00992-06
   Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015
   Turk BE, 2004, METHODS, V32, P398, DOI 10.1016/j.ymeth.2003.10.003
   Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 38
TC 34
Z9 34
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY 15
PY 2009
VL 107
IS 2
BP 253
EP 263
DI 10.1002/jcb.22121
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 442SG
UT WOS:000265860300008
PM 19301262
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhan, PF
   Cui, YQ
   Cao, YJ
   Bao, X
   Wu, ML
   Yang, Q
   Yang, JH
   Zheng, HH
   Zou, J
   Xie, TH
   Cai, JP
   Yao, Y
   Wang, XL
AF Zhan, Pengfei
   Cui, Yuqing
   Cao, Yujuan
   Bao, Xun
   Wu, Meili
   Yang, Qian
   Yang, Jiahui
   Zheng, Haohan
   Zou, Jian
   Xie, Tianhua
   Cai, Jiping
   Yao, Yong
   Wang, Xiaolu
TI PGE(2) promotes macrophage recruitment and neovascularization in murine
   wet-type AMD models
SO CELL COMMUNICATION AND SIGNALING
LA English
DT Article
DE PGE2; Neovascularization; Macrophage; AMD
ID FACTOR-KAPPA-B; EXPRESSION; THERAPY
AB Age-related macular degeneration (AMD), a progressive chronic disease of the central retina, is a leading cause of blindness worldwide. Activated macrophages recruited to the injured eyes greatly contribute to the pathogenesis of choroidal neovascularization (CNV) in exudative AMD (wet AMD). This study describes the effects of cyclooxygenase-2 (COX2)/prostaglandin E-2 (PGE(2)) signalling on the macrophage activation and CNV formation of wet AMD. In a mouse model of laser-induced wet AMD, the mice received an intravitreal injection of celecoxib (a selective COX2 inhibitor). Optical coherence tomography (OCT), fundus fluorescein angiography (FFA), choroidal histology of the CNV lesions, and biochemical markers were assessed. The level of PGE(2) expression was high in the laser-induced CNV lesions. Macrophage recruitment and CNV development were significantly less after celecoxib treatment. E-prostanoid1 receptor (EP1R)/protein kinase C (PKC) signalling was involved in M2 macrophage activation and interleukin-10 (IL-10) production of bone marrow-derived macrophages (BMDMs) in vitro. In addition, IL-10 was found to induce the proliferation and migration of human choroidal microvascular endothelial cells (HCECs). Thus, the PGE(2)/EP1R signalling network serves as a potential therapeutic target for CNV of the wet-type AMD.
C1 [Zhan, Pengfei; Cui, Yuqing; Cao, Yujuan; Bao, Xun; Yang, Qian; Yang, Jiahui; Zheng, Haohan; Xie, Tianhua; Cai, Jiping; Yao, Yong] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Ophthalmol, 299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China.
   [Cao, Yujuan; Wu, Meili; Zou, Jian; Wang, Xiaolu] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Ctr Clin Res, 299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China.
   [Cao, Yujuan; Yao, Yong] Nanjing Med Univ, Affiliated Wuxi 2 Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Yao, Y (通讯作者)，Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Dept Ophthalmol, 299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China.; Wang, XL (通讯作者)，Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Ctr Clin Res, 299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China.; Yao, Y (通讯作者)，Nanjing Med Univ, Affiliated Wuxi 2 Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Jiangsu, Peoples R China.
EM yongyao@njmu.edu.cn; xlwang@njmu.edu.cn
FU National Natural Science Foundation of China [81800845, 81770941];
   Technology Development Fund [CSE12N1701]; Wuxi Taihu Lake Talent Plan,
   Supports for Leading Talents in Medical and Health Profession
   [2020-THRCTD-1, THRC-DJ-1]; Top Talent Support Program for young and
   middle-aged people of Wuxi Health Committee [HB2020004, HB2020022];
   Natural Science Foundation of Jiangsu Province [BK20190150]; Wuxi
   translational medicine research project [ZH201902]
FX Supported by the National Natural Science Foundation of China (81800845,
   81770941), Technology Development Fund (CSE12N1701), Wuxi Taihu Lake
   Talent Plan, Supports for Leading Talents in Medical and Health
   Profession (2020-THRCTD-1, THRC-DJ-1), Top Talent Support Program for
   young and middle-aged people of Wuxi Health Committee (HB2020004,
   HB2020022), the Natural Science Foundation of Jiangsu Province
   (BK20190150) and Wuxi translational medicine research project
   (ZH201902).
CR Akaogi Jun, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P383
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Berthou F, 2015, MOL ENDOCRINOL, V29, P1025, DOI 10.1210/me.2015-1027
   Blatteis CM, 2005, PROSTAG OTH LIPID M, V76, P1, DOI 10.1016/j.prostaglandins.2005.01.001
   Cen B, 2020, GASTROENTEROLOGY, V158, P971, DOI 10.1053/j.gastro.2019.11.013
   Chen YN, 2020, EUR J PHARMACOL, V877, DOI 10.1016/j.ejphar.2020.173090
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Jo N, 2002, CURR EYE RES, V24, P465, DOI 10.1076/ceyr.24.6.465.8600
   Joo KM, 2019, TOXICOL IN VITRO, V60, P412, DOI 10.1016/j.tiv.2019.06.017
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kiriakidis S, 2003, J CELL SCI, V116, P665, DOI 10.1242/jcs.00286
   Liu XJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03222-1
   Liu YQ, 2021, EXP EYE RES, V207, DOI 10.1016/j.exer.2021.108568
   Luan B, 2015, P NATL ACAD SCI USA, V112, P15642, DOI 10.1073/pnas.1519644112
   Lurier EB, 2017, IMMUNOBIOLOGY, V222, P847, DOI 10.1016/j.imbio.2017.02.006
   Machado-Carvalho L, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0100-7
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   NeuschaferRube F, 1997, FEBS LETT, V401, P185, DOI 10.1016/S0014-5793(96)01468-8
   Sasaki F, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96902
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Toda Gotaro, 2021, STAR Protoc, V2, P100246, DOI 10.1016/j.xpro.2020.100246
   Tsuge K, 2019, INT IMMUNOL, V31, P597, DOI 10.1093/intimm/dxz021
   Wang CX, 2020, MOL IMMUNOL, V121, P72, DOI 10.1016/j.molimm.2020.03.002
   Wang M, 2019, DIABETOLOGIA, V62, P335, DOI 10.1007/s00125-018-4755-3
   Xie TH, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108507
   Zhang B, 2017, ONCOTARGET, V8, P17347, DOI 10.18632/oncotarget.14468
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
NR 32
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1478-811X
J9 CELL COMMUN SIGNAL
JI Cell Commun. Signal.
PD OCT 13
PY 2022
VL 20
IS 1
AR 155
DI 10.1186/s12964-022-00973-6
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 5H7NN
UT WOS:000867861700001
PM 36229856
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kao, YW
   Hsu, SK
   Chen, JYF
   Lin, IL
   Chen, KJ
   Lee, PY
   Ng, HS
   Chiu, CC
   Cheng, KC
AF Kao, Yu-Wen
   Hsu, Sheng-Kai
   Chen, Jeff Yi-Fu
   Lin, I-Ling
   Chen, Kuo-Jen
   Lee, Po-Yen
   Ng, Hui-Suan
   Chiu, Chien-Chih
   Cheng, Kai-Chun
TI Curcumin Metabolite Tetrahydrocurcumin in the Treatment of Eye Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE curcumin; COX; SIRT1; tetrahydrocurcumin (THC); ophthalmic diseases;
   VEGF
ID ENDOTHELIAL GROWTH-FACTOR; OPEN-ANGLE GLAUCOMA; DIABETIC-RETINOPATHY;
   OXIDATIVE STRESS; GLOBAL PREVALENCE; VISION IMPAIRMENT; RISK-FACTORS;
   VEGF EXPRESSION; TEMPORAL-TRENDS; AGE
AB Curcumin is one of the most valuable natural products due to its pharmacological activities. However, the low bioavailability of curcumin has long been a problem for its medicinal use. Large studies have been conducted to improve the use of curcumin; among these studies, curcumin metabolites have become a relatively new research focus over the past few years. Additionally, accumulating evidence suggests that curcumin or curcuminoid metabolites have similar or better biological activity than the precursor of curcumin. Recent studies focus on the protective role of plasma tetrahydrocurcumin (THC), a main metabolite of curcumin, against tumors and chronic inflammatory diseases. Nevertheless, studies of THC in eye diseases have not yet been conducted. Since ophthalmic conditions play a crucial role in worldwide public health, the prevention and treatment of ophthalmic diseases are of great concern. Therefore, the present study investigated the antioxidative, anti-inflammatory, antiangiogenic, and neuroprotective effects of THC on four major ocular diseases: age-related cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy (DR). While this study aimed to show curcumin as a promising potential solution for eye conditions and discusses the involved mechanistic pathways, further work is required for the clinical application of curcumin.
C1 [Kao, Yu-Wen] Kaohsiung Med Univ, Dept Med, Kaohsiung 807, Taiwan.
   [Hsu, Sheng-Kai; Chen, Jeff Yi-Fu; Chiu, Chien-Chih] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung 807, Taiwan.
   [Hsu, Sheng-Kai; Lin, I-Ling] Kaohsiung Med Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung 807, Taiwan.
   [Chen, Kuo-Jen; Cheng, Kai-Chun] Kaohsiung Municipal Siaogang Hosp, Dept Ophthalmol, Kaohsiung 812, Taiwan.
   [Lee, Po-Yen; Cheng, Kai-Chun] Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 807, Taiwan.
   [Ng, Hui-Suan] UCSI Univ, Fac Appl Sci, UCSI Hts, Kuala Lumpur 56000, Malaysia.
   [Chiu, Chien-Chih] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 804, Taiwan.
   [Chiu, Chien-Chih] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 807, Taiwan.
   [Chiu, Chien-Chih] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.
   [Chiu, Chien-Chih] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Cheng, Kai-Chun] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Ophthalmol, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Municipal
   Siao-Gang Hospital; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital; UCSI University; National Sun Yat Sen University;
   Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Medical University
RP Chiu, CC (通讯作者)，Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung 807, Taiwan.; Cheng, KC (通讯作者)，Kaohsiung Municipal Siaogang Hosp, Dept Ophthalmol, Kaohsiung 812, Taiwan.; Cheng, KC (通讯作者)，Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 807, Taiwan.; Chiu, CC (通讯作者)，Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 804, Taiwan.; Chiu, CC (通讯作者)，Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 807, Taiwan.; Chiu, CC (通讯作者)，Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.; Chiu, CC (通讯作者)，Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan.; Cheng, KC (通讯作者)，Kaohsiung Med Univ, Coll Med, Sch Med, Dept Ophthalmol, Kaohsiung 807, Taiwan.
EM u106001068@kmu.edu.tw; b043100050@gmail.com; yifuc@kmu.edu.tw;
   linili@kmu.edu.tw; 0870649@kmhk.org.tw; maco69@gmail.com;
   GrraceNg@ucsiuniversity.edu.my; cchiu@kmu.edu.tw; pington64@gmail.com
RI Ng, Hui Suan/F-7399-2015; Ng, Hui Suan/AAW-6282-2020; Chiu,
   Chien-Chih/AAW-9861-2020
OI Ng, Hui Suan/0000-0002-1990-614X; Ng, Hui Suan/0000-0002-1990-614X;
   Chiu, Chien-Chih/0000-0001-7307-2468; LIN, I-LING/0000-0001-7022-4315;
   Lee, Po Yen/0000-0002-1825-0003; Cheng, Kai-Chun/0000-0002-1240-4219
FU Ministry of Science and Technology, Taiwan [MOST 108-2314-B-037-088,
   MOST108-2314-B-037-051, MOST 109-2313-B-037-001,
   109-2314-B-037-069-MY3]; Kaohsiung Municipal Siaogang Hospital, Taiwan
   [KMHK-106-022, KMHK-107-008, KMHK-108-032]
FX We thank the following institutions for providing financial support:
   Ministry of Science and Technology, Taiwan (grants MOST
   108-2314-B-037-088, MOST108-2314-B-037-051, MOST 109-2313-B-037-001 and
   109-2314-B-037-069-MY3); and the Kaohsiung Municipal Siaogang Hospital,
   Taiwan (grants KMHK-106-022, KMHK-107-008 and KMHK-108-032).
CR Ackland Peter, 2017, Community Eye Health, V30, P71
   Aggarwal BB, 2015, MOLECULES, V20, P185, DOI 10.3390/molecules20010185
   Allegri P, 2010, CLIN OPHTHALMOL, V4, P1201, DOI 10.2147/OPTH.S13271
   Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Antony B, 2008, INDIAN J PHARM SCI, V70, P445, DOI 10.4103/0250-474X.44591
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   BABIZHAYEV MA, 1988, MECH AGEING DEV, V44, P69, DOI 10.1016/0047-6374(88)90080-2
   Barchitta M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051119
   Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   Berthoud VM, 2016, J BIOL CHEM, V291, P17569, DOI 10.1074/jbc.M115.707950
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   BORSEY DQ, 1984, J CLIN PATHOL, V37, P659, DOI 10.1136/jcp.37.6.659
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cao K, 2018, J CLIN PATHOL, V71, P1090, DOI 10.1136/jclinpath-2018-205320
   CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L
   Celebioglu A, 2020, FOOD CHEM, V317, DOI 10.1016/j.foodchem.2020.126397
   Chan TCW, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108255
   Chapman K, 2019, THROMB RES, V179, P28, DOI 10.1016/j.thromres.2019.04.029
   Claesson-Welsh L, 2015, UPSALA J MED SCI, V120, P135, DOI 10.3109/03009734.2015.1064501
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   Doozandeh Azadeh, 2016, J Ophthalmic Vis Res, V11, P209, DOI 10.4103/2008-322X.183923
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Du YP, 2010, INVEST OPHTH VIS SCI, V51, P2158, DOI 10.1167/iovs.09-3674
   Du ZY, 2013, ARCH PHARM RES, V36, P1204, DOI 10.1007/s12272-013-0216-1
   Ellwein LB, 1995, B WORLD HEALTH ORGAN, V73, P681
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Forman HJ, 2009, MOL ASPECTS MED, V30, P1, DOI 10.1016/j.mam.2008.08.006
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gabelt BT, 2005, PROG RETIN EYE RES, V24, P612, DOI 10.1016/j.preteyeres.2004.10.003
   Gangwar RK, 2013, J AGR FOOD CHEM, V61, P9632, DOI 10.1021/jf402894x
   Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014
   Geraldes P, 2010, CIRC RES, V106, P1319, DOI 10.1161/CIRCRESAHA.110.217117
   Grzybowski A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030761
   Gupta N, 2013, OPEN OPHTHALMOL J, V7, P4, DOI 10.2174/1874364101307010004
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4
   HOLDER GM, 1978, XENOBIOTICA, V8, P761, DOI 10.3109/00498257809069589
   Hussain Z, 2017, MAT SCI ENG C-MATER, V77, P1316, DOI 10.1016/j.msec.2017.03.226
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Isaacs Robert, 2004, J Agromedicine, V9, P207
   Jansirani, 2004, Indian J Clin Biochem, V19, P110, DOI 10.1007/BF02872403
   Jiang BH, 1997, CANCER RES, V57, P5328
   Khalil NM, 2013, COLLOID SURFACE B, V101, P353, DOI 10.1016/j.colsurfb.2012.06.024
   Kowluru RA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/635284
   Krizaj D, 2014, CURR EYE RES, V39, P105, DOI 10.3109/02713683.2013.836541
   Le A, 2003, INVEST OPHTH VIS SCI, V44, P3783, DOI 10.1167/iovs.03-0077
   Li KF, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6746907
   Lin CC, 2010, FREE RADICAL BIO MED, V48, P240, DOI 10.1016/j.freeradbiomed.2009.10.047
   Lin CZ, 2004, J ORTHOP RES, V22, P1175, DOI 10.1016/j.orthres.2004.03.002
   Liu R, 2016, PHARM DEV TECHNOL, V21, P576, DOI 10.3109/10837450.2015.1026607
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Lou J, 2014, INT J NANOMED, V9, P2517, DOI 10.2147/IJN.S60270
   Luo DD, 2019, FOOD CHEM TOXICOL, V123, P349, DOI 10.1016/j.fct.2018.11.012
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Maugeri A, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5407482
   McMonnies Charles W, 2017, J Optom, V10, P71, DOI 10.1016/j.optom.2016.02.003
   Miglior S, 2007, OPHTHALMOLOGY, V114, P3, DOI 10.1016/j.ophtha.2006.05.075
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Munemasa Y, 2015, PROG RETIN EYE RES, V47, P1, DOI 10.1016/j.preteyeres.2015.03.002
   Nangia V, 2019, BRIT J OPHTHALMOL, V103, P871, DOI 10.1136/bjophthalmol-2018-312292
   Nickells RW, 1996, J GLAUCOMA, V5, P345
   Nowak MS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000505
   Pan MH, 1999, DRUG METAB DISPOS, V27, P486
   Park HYL, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.26
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pradhan N, 2015, J MOL MED, V93, P1095, DOI 10.1007/s00109-015-1277-z
   Quigley HA, 2012, CURR OPIN OPHTHALMOL, V23, P144, DOI 10.1097/ICU.0b013e32834ff490
   Rachmawati H, 2013, J PHARM SCI-US, V102, P204, DOI 10.1002/jps.23335
   Rahimi HR, 2016, AVICENNA J PHYTOMEDI, V6, P383
   Rao PNP, 2008, J PHARM PHARM SCI, V11, P81, DOI 10.18433/J3T886
   Reddy GB, 2006, IUBMB LIFE, V58, P632, DOI 10.1080/15216540601010096
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9
   SRIVASTAVA KC, 1995, PROSTAG LEUKOTR ESS, V52, P223, DOI 10.1016/0952-3278(95)90040-3
   Stefan Cornel, 2016, Rom J Ophthalmol, V60, P209
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Stohs SJ, 2020, MOLECULES, V25, DOI 10.3390/molecules25061397
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Suryanarayana P, 2003, MOL VIS, V9, P223
   Thapa R, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0175-z
   Thiagarajan R, 2013, FREE RADICAL RES, V47, P337, DOI 10.3109/10715762.2013.777155
   Huynh TP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/549174
   Tyagi N, 2012, J MOL NEUROSCI, V47, P128, DOI 10.1007/s12031-011-9695-z
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Wat N, 2016, HONG KONG MED J, V22, P589, DOI 10.12809/hkmj164869
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Yarmohammadi A, 2016, OPHTHALMOLOGY, V123, P2498, DOI 10.1016/j.ophtha.2016.08.041
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yeung AWK, 2019, MOLECULES, V24, DOI 10.3390/molecules24071393
   Yoysungnoen B, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/391748
   Zhang ZB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01181
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P244, DOI 10.1167/iovs.12-10854
   Zhou MW, 2018, INT J MOL MED, V42, P13, DOI 10.3892/ijmm.2018.3623
   Zuo L, 2013, INVEST OPHTH VIS SCI, V54, P5097, DOI 10.1167/iovs.13-12157
NR 100
TC 11
Z9 12
U1 6
U2 18
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2021
VL 22
IS 1
AR 212
DI 10.3390/ijms22010212
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PP7LW
UT WOS:000606040800001
PM 33379248
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yamanari, M
   Mase, M
   Obata, R
   Matsuzaki, M
   Minami, T
   Takagi, S
   Yamamoto, M
   Miyamoto, N
   Ueda, K
   Koide, N
   Maeda, T
   Totani, K
   Aoki, N
   Hirami, Y
   Sugiyama, S
   Mandai, M
   Aihara, M
   Takahashi, M
   Kato, S
   Kurimoto, Y
AF Yamanari, Masahiro
   Mase, Mutsuki
   Obata, Ryo
   Matsuzaki, Mitsuhiro
   Minami, Takahiro
   Takagi, Seiji
   Yamamoto, Motoshi
   Miyamoto, Noriko
   Ueda, Koji
   Koide, Naoshi
   Maeda, Tadao
   Totani, Kota
   Aoki, Nobuyori
   Hirami, Yasuhiko
   Sugiyama, Satoshi
   Mandai, Michiko
   Aihara, Makoto
   Takahashi, Masayo
   Kato, Satoshi
   Kurimoto, Yasuo
TI Melanin concentration and depolarization metrics measurement by
   polarization-sensitive optical coherence tomography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; TARGET DECOMPOSITION-THEOREMS; JONES-MATRIX;
   HUMAN MACULA; BIREFRINGENCE; UNIFORMITY; LIPOFUSCIN; CONTRAST; SWEPT;
   OCT
AB Imaging of melanin in the eye is important as the melanin is structurally associated with some ocular diseases, such as age-related macular degeneration. Although optical coherence tomography (OCT) cannot distinguish tissues containing the melanin from other tissues intrinsically, polarization-sensitive OCT (PS-OCT) can detect the melanin through spatial depolarization of the backscattered light from the melanin granules. Entropy is one of the depolarization metrics that can be used to detect malanin granules in PS-OCT and valuable quantitative information on ocular tissue abnormalities can be retrived by correlating entropy with the melanin concentration. In this study, we investigate a relationship between the melanin concentration and some depolarization metrics including the entropy, and show that the entropy is linearly proportional to the melanin concentration in double logarithmic scale when noise bias is corrected for the entropy. In addition, we also confirm that the entropy does not depend on the incident state of polarization using the experimental data, which is one of important attributes that depolarization metrics should have. The dependence on the incident state of polarization is also analyzed for other depolarization metrics.
C1 [Yamanari, Masahiro; Mase, Mutsuki; Totani, Kota; Aoki, Nobuyori; Sugiyama, Satoshi] Tomey Corp, Engn Dept, Nagoya, Aichi, Japan.
   [Obata, Ryo; Minami, Takahiro; Yamamoto, Motoshi; Ueda, Koji; Aihara, Makoto; Kato, Satoshi] Univ Tokyo, Dept Ophthalmol, Grad Sch Med, Tokyo, Japan.
   [Obata, Ryo; Minami, Takahiro; Yamamoto, Motoshi; Ueda, Koji; Aihara, Makoto; Kato, Satoshi] Univ Tokyo, Fac Med, Tokyo, Japan.
   [Matsuzaki, Mitsuhiro; Takagi, Seiji; Miyamoto, Noriko; Maeda, Tadao; Hirami, Yasuhiko; Mandai, Michiko; Takahashi, Masayo; Kurimoto, Yasuo] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Matsuzaki, Mitsuhiro; Takagi, Seiji; Miyamoto, Noriko; Maeda, Tadao; Hirami, Yasuhiko; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
   [Koide, Naoshi; Maeda, Tadao; Hirami, Yasuhiko; Mandai, Michiko; Takahashi, Masayo; Kurimoto, Yasuo] Riken Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo, Japan.
   [Takahashi, Masayo] Vis Care Inc, Kobe, Hyogo, Japan.
C3 University of Tokyo; University of Tokyo; Kobe City Medical Center
   General Hospital; RIKEN
RP Yamanari, M (通讯作者)，Tomey Corp, Engn Dept, Nagoya, Aichi, Japan.
EM m-yamanari@tomey.co.jp
OI Yamanari, Masahiro/0000-0001-9873-2151; Minami,
   Takahiro/0000-0003-2289-8811
FU Japan Agency for Medical Research and Development (AMED) [JP19he1302011]
FX We acknowledge Danielle Harper and Bernhard Baumann for their kind
   comments on how to make the melanin suspension, Susumu Oshima for his
   support to the project. This study was supported in part by Japan Agency
   for Medical Research and Development (AMED) under Grant Number
   JP19he1302011.
CR Baumann B, 2017, APPL SCI-BASEL, V7, DOI 10.3390/app7050474
   Baumann B, 2015, J MOD OPTIC, V62, P1758, DOI 10.1080/09500340.2014.945501
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2009, J BIOPHOTONICS, V2, P426, DOI 10.1002/jbio.200910031
   Cloude S., 2009, POLARISATION APPL RE
   CLOUDE SR, 1986, OPTIK, V75, P26
   Cloude SR, 1996, IEEE T GEOSCI REMOTE, V34, P498, DOI 10.1109/36.485127
   de Boer JF, 2017, BIOMED OPT EXPRESS, V8, P1838, DOI 10.1364/BOE.8.001838
   DREHER AW, 1992, APPL OPTICS, V31, P3730, DOI 10.1364/AO.31.003730
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Gil J. J., 2016, POLARIZED LIGHT MUEL
   GIL JJ, 1986, OPT ACTA, V33, P185, DOI 10.1080/713821924
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Gotzinger E, 2005, OPT EXPRESS, V13, P10217, DOI 10.1364/OPEX.13.010217
   Gouras P, 2011, EXP EYE RES, V93, P937, DOI 10.1016/j.exer.2011.10.011
   Grulkowski I, 2012, BIOMED OPT EXPRESS, V3, P2733, DOI 10.1364/BOE.3.002733
   Harper DJ, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201900153
   Jayaraman V, 2012, ELECTRON LETT, V48, P1331, DOI 10.1049/el.2012.3180
   Knighton RW, 2002, INVEST OPHTH VIS SCI, V43, P82
   Lammer J, 2014, INVEST OPHTH VIS SCI, V55, P1564, DOI 10.1167/iovs.13-13539
   Lapierre-Landry M, 2018, J BIOL ENG, V12, DOI 10.1186/s13036-018-0124-5
   Lee JS, 2009, OPT SCI ENG-CRC, P1
   Lee JS, 2001, IEEE T GEOSCI REMOTE, V39, P2343, DOI 10.1109/36.964970
   Lippok N, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800156
   Lippok N, 2017, NAT PHOTONICS, V11, DOI 10.1038/nphoton.2017.128
   Lippok N, 2015, OPT LETT, V40, P3954, DOI 10.1364/OL.40.003954
   Lopez-Martinez C, 2005, IEEE T GEOSCI REMOTE, V43, P2058, DOI 10.1109/TGRS.2005.853934
   Lu SY, 1996, J OPT SOC AM A, V13, P1106, DOI 10.1364/JOSAA.13.001106
   Makita S, 2014, OPT LETT, V39, P6783, DOI 10.1364/OL.39.006783
   Matsuzaki M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64601-4
   Mishchenko MI, 2009, J QUANT SPECTROSC RA, V110, P808, DOI 10.1016/j.jqsrt.2008.12.005
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Nielsen Michael A, 2002, QUANTUM COMPUTATION, DOI DOI 10.1017/CBO9780511976667
   Oldenburg AL, 2007, IEEE J SEL TOP QUANT, V13, P1629, DOI 10.1109/JSTQE.2007.910292
   Ossikovski R, 2010, J OPT SOC AM A, V27, P808, DOI 10.1364/JOSAA.27.000808
   Pelkonen L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160352
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Yamanari M, 2019, BIOMED OPT EXPRESS, V10, P2318, DOI 10.1364/BOE.10.002318
   Yamanari M, 2019, PROC SPIE, V10867, DOI 10.1117/12.2511467
   Yamanari M, 2016, BIOMED OPT EXPRESS, V7, P3551, DOI 10.1364/BOE.7.003551
   Yamanari M, 2015, BIOMED OPT EXPRESS, V6, P369, DOI 10.1364/BOE.6.000369
NR 45
TC 10
Z9 10
U1 0
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 11
PY 2020
VL 10
IS 1
AR 19513
DI 10.1038/s41598-020-76397-4
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OZ3GM
UT WOS:000594818600020
PM 33177585
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tezuka-Kagajo, M
   Maekawa, M
   Ogawa, A
   Hatta, Y
   Ishii, E
   Eguchi, M
   Higashiyama, S
AF Tezuka-Kagajo, Mari
   Maekawa, Masashi
   Ogawa, Atsushi
   Hatta, Yoshiko
   Ishii, Eiichi
   Eguchi, Mariko
   Higashiyama, Shigeki
TI Development of Human CBF1-Targeting Single-Stranded DNA Aptamers with
   Antiangiogenic ActivityIn Vitro
SO NUCLEIC ACID THERAPEUTICS
LA English
DT Article
DE angiogenesis; Notch; CBF1; DNA aptamer
ID NOTCH PATHWAY; CELLS; RESISTANCE; INHIBITORS; RECEPTORS; SELECTION;
   COMPLEX; SYSTEM; CANCER; VEGFR
AB C promoter binding factor 1 (CBF1) (alias RBPJ) is a critical transcription factor involved in Notch signaling. The activation of Notch signaling through CBF1 maintains the angiostatic state of endothelial cells suppressing angiogenesis, that is, the formation of new blood vessels. Vascular endothelial growth factor (VEGF) induces angiogenesis by promoting the proteasomal degradation of CBF1, in addition to endothelial cell proliferation. To date, angiogenic inhibitors targeting VEGF have been successfully used in clinics for cancer and age-related macular degeneration. Most antiangiogenic drugs, however, only target VEGF or VEGF receptors. In this study, to expand the repertoire of antiangiogenic therapeutics, we developed 15 single-stranded deoxyribonucleic acid (ssDNA) aptamers capable of binding to CBF1 with high affinity (K-d; 10-300 nM). To this end, systematic evolution of ligands by the exponential enrichment (SELEX) method was applied. One of the CBF1-binding ssDNA aptamers, Apt-3, inhibited angiogenesis through the activation of Notch signalingin vitro. We found that Apt-3 directly interacted with the LAG1 domain of CBF1. We suggest that the Apt-3 ssDNA aptamer may contribute to the development of a novel angiogenic inhibitor, which does not target VEGF.
C1 [Tezuka-Kagajo, Mari; Maekawa, Masashi; Higashiyama, Shigeki] Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Japan.
   [Tezuka-Kagajo, Mari; Ishii, Eiichi; Eguchi, Mariko] Ehime Univ, Grad Sch Med, Dept Pediat, Toon, Japan.
   [Maekawa, Masashi; Higashiyama, Shigeki] Ehime Univ, Proteosci Ctr, Div Cell Growth & Tumor Regulat, Toon 7910295, Japan.
   [Ogawa, Atsushi; Hatta, Yoshiko] Ehime Univ, Proteosci Ctr, Div Biomol Engn, Matsuyama, Ehime 7908577, Japan.
C3 Ehime University; Ehime University; Ehime University; Ehime University
RP Maekawa, M; Higashiyama, S (通讯作者)，Ehime Univ, Proteosci Ctr, Div Cell Growth & Tumor Regulat, Toon 7910295, Japan.; Ogawa, A (通讯作者)，Ehime Univ, Proteosci Ctr, Div Biomol Engn, Matsuyama, Ehime 7908577, Japan.
EM masashim@m.ehime-u.ac.jp; ogawa.atsushi.mf@ehime-u.ac.jp;
   shigeki@m.ehime-u.ac.jp
OI Ogawa, Atsushi/0000-0001-5240-3395; Maekawa, Masashi/0000-0002-9574-1906
FU JSPS KAKENHI [19K22564, 18K15718, 18K15244]; Takeda Science Foundation
FX This work was supported by JSPS KAKENHI grant no. 18K15718 to M.T-.K.,
   JSPS KAKENHI grant no. 18K15244 to M.M., Takeda Science Foundation to
   Proteo-Science Center, and JSPS KAKENHI grant no. 19K22564 to A.O. and
   S.H.
CR Alva JA, 2004, CURR OPIN HEMATOL, V11, P278, DOI 10.1097/01.moh.0000130309.44976.ad
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Aryan Z, 2015, CURR OPIN ALLERGY CL, V15, P568, DOI 10.1097/ACI.0000000000000212
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Clarke JM, 2013, J GASTROINTEST ONCOL, V4, P253, DOI 10.3978/j.issn.2078-6891.2013.036
   Dou GR, 2008, FASEB J, V22, P1606, DOI 10.1096/fj.07-9998com
   El Kebir D, 2009, J IMMUNOL, V182, P4386, DOI 10.4049/jimmunol.0803044
   El-Gebali S, 2019, NUCLEIC ACIDS RES, V47, pD427, DOI 10.1093/nar/gky995
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Eskens FALM, 2006, EUR J CANCER, V42, P3127, DOI 10.1016/j.ejca.2006.09.015
   Friedmann DR, 2008, J BIOL CHEM, V283, P14781, DOI 10.1074/jbc.M709501200
   Hurtado C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46948-5
   Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476
   Kovall RA, 2004, EMBO J, V23, P3441, DOI 10.1038/sj.emboj.7600349
   Lan GH, 2019, ONCOTARGETS THER, V12, P2869, DOI 10.2147/OTT.S199046
   LATO SM, 1995, CHEM BIOL, V2, P291, DOI 10.1016/1074-5521(95)90048-9
   Li JL, 2005, CANCER CELL, V8, P1, DOI 10.1016/j.ccr.2005.06.013
   Lupo G, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00519
   Maekawa M, 2017, BIOL OPEN, V6, P1707, DOI 10.1242/bio.029579
   Mathews David H, 2006, Curr Protoc Bioinformatics, VChapter 12, DOI 10.1002/0471250953.bi1206s13
   Mukai K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11932
   Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037
   Nam Y, 2002, CURR OPIN CHEM BIOL, V6, P501, DOI 10.1016/S1367-5931(02)00346-0
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Ohnuki H, 2012, BLOOD, V119, P2688, DOI 10.1182/blood-2011-03-345306
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Sakaue T, 2017, J BIOCHEM, V162, P237, DOI 10.1093/jb/mvx051
   Sawasaki T, 2002, P NATL ACAD SCI USA, V99, P14652, DOI 10.1073/pnas.232580399
   Shawber CJ, 2004, BIOESSAYS, V26, P225, DOI 10.1002/bies.20004
   Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001
   Tabaja N, 2017, J BIOL CHEM, V292, P10549, DOI 10.1074/jbc.M117.791707
   Takahashi H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156718
   Tanigawa K, 2019, J CELL PHYSIOL, V234, P17280, DOI 10.1002/jcp.28346
   Torella R, 2014, NUCLEIC ACIDS RES, V42, P10550, DOI 10.1093/nar/gku730
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Uematsu A, 2019, J BIOL CHEM, V294, P14135, DOI 10.1074/jbc.RA119.010119
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   VanderWielen BD, 2011, J BIOL CHEM, V286, P14892, DOI 10.1074/jbc.M110.181156
   Watanabe R, 2020, MOL BIOL CELL, V31, P478, DOI 10.1091/mbc.E19-08-0456
   Yuan ZY, 2019, CELL REP, V26, P845, DOI 10.1016/j.celrep.2018.12.097
   Zhang Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24050941
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
NR 43
TC 5
Z9 5
U1 3
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2159-3337
EI 2159-3345
J9 NUCLEIC ACID THER
JI Nucl. Acid Ther.
PD DEC 1
PY 2020
VL 30
IS 6
BP 365
EP 378
DI 10.1089/nat.2020.0875
EA SEP 2020
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Research &
   Experimental Medicine
GA PB9GF
UT WOS:000566827000001
PM 32881630
DA 2022-11-30
ER

PT J
AU Takeda, A
   Yanai, R
   Murakami, Y
   Arima, M
   Sonoda, KH
AF Takeda, Atsunobu
   Yanai, Ryoji
   Murakami, Yusuke
   Arima, Mitsuru
   Sonoda, Koh-Hei
TI New Insights Into Immunological Therapy for Retinal Disorders
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE immune privilege; non-infectious uveitis; diabetic retinopathy;
   retinopathy of prematurity; retinitis pigmentosa; vitreoretinal lymphoma
ID CENTRAL-NERVOUS-SYSTEM; PRIMARY CNS LYMPHOMA; DIABETIC MACULAR EDEMA;
   T-REGULATORY CELLS; C-REACTIVE PROTEIN; CHRONIC INFLAMMATORY REACTION;
   OCULAR IMMUNE PRIVILEGE; RECURRENT PRIMARY CNS; DENDRITIC CELLS; MOUSE
   MODEL
AB In the twentieth century, a conspicuous lack of effective treatment strategies existed for managing several retinal disorders, including age-related macular degeneration; diabetic retinopathy (DR); retinopathy of prematurity (ROP); retinitis pigmentosa (RP); uveitis, including Behcet's disease; and vitreoretinal lymphoma (VRL). However, in the first decade of this century, advances in biomedicine have provided new treatment strategies in the field of ophthalmology, particularly biologics that target vascular endothelial growth factor or tumor necrosis factor (TNF)-alpha. Furthermore, clinical trials on gene therapy specifically for patients with autosomal recessive or X-linked RP have commenced. The overall survival rates of patients with VRL have improved, owing to earlier diagnoses and better treatment strategies. However, some unresolved problems remain such as primary or secondary non-response to biologics or chemotherapy, and the lack of adequate strategies for treating most RP patients. In this review, we provide an overview of the immunological mechanisms of the eye under normal conditions and in several retinal disorders, including uveitis, DR, ROP, RP, and VRL. In addition, we discuss recent studies that describe the inflammatory responses that occur during the course of these retinal disorders to provide new insights into their diagnosis and treatment.
C1 [Takeda, Atsunobu; Murakami, Yusuke; Arima, Mitsuru; Sonoda, Koh-Hei] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Takeda, Atsunobu] Natl Hosp Org, Kyushu Med Ctr, Clin Res Inst, Dept Ophthalmol, Fukuoka, Japan.
   [Yanai, Ryoji] Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, Yamaguchi, Japan.
C3 Kyushu University; Yamaguchi University
RP Takeda, A (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.; Takeda, A (通讯作者)，Natl Hosp Org, Kyushu Med Ctr, Clin Res Inst, Dept Ophthalmol, Fukuoka, Japan.
EM atakeda417@yahoo.co.jp
FU Japan Society for the Promotion of Science (JSPS) KAKENHI [18K09471,
   18K09449, 19K09952, 18H02956]; Ministry of Education, Science, Sports
   and Culture, Japan; Novartis Pharma Research Grants (Tokyo, Japan);
   Alcon Pharma Research Grants (Tokyo, Japan)
FX This work were supported by grants from Japan Society for the Promotion
   of Science (JSPS) KAKENHI Grant no. 18K09471 to AT, 18K09449 to RY,
   19K09952 to YM, and 18H02956 to K-HS from the Ministry of Education,
   Science, Sports and Culture, Japan, and grants from Novartis Pharma
   Research Grants (AT; Tokyo, Japan) and Alcon Pharma Research Grants (AT;
   Tokyo, Japan).
CR Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Akiyama H, 2016, CANCER SCI, V107, P1458, DOI 10.1111/cas.13012
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Arida A, 2014, CLIN EXP RHEUMATOL, V32, pS149
   Baehring JM, 2005, CANCER-AM CANCER SOC, V104, P591, DOI 10.1002/cncr.21191
   Bardenstein, 1998, Cancer Control, V5, P317
   Barisani-Asenbauer T, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-57
   Bartelds GM, 2011, JAMA-J AM MED ASSOC, V305, P1460, DOI 10.1001/jama.2011.406
   Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296
   Blencowe H, 2013, PEDIATR RES, V74, P35, DOI 10.1038/pr.2013.205
   Bonzheim I, 2015, BLOOD, V126, P76, DOI 10.1182/blood-2015-01-620518
   Bressler SB, 2016, JAMA OPHTHALMOL, V134, P278, DOI 10.1001/jamaophthalmol.2015.5346
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Cani AK, 2017, ONCOTARGET, V8, P7989, DOI 10.18632/oncotarget.14008
   Cao XG, 2011, ACTA OPHTHALMOL, V89, pE149, DOI 10.1111/j.1755-3768.2009.01797.x
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Chan CC, 2003, OPHTHALMOLOGY, V110, P421, DOI 10.1016/S0161-6420(02)01737-2
   Chan Chi-Chao, 2003, Trans Am Ophthalmol Soc, V101, P275
   Chan CC, 2013, DISCOV MED, V15, P93
   Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236
   Chen M, 2018, AM J PATHOL, V188, P1007, DOI 10.1016/j.ajpath.2017.12.021
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chibber R, 2007, CURR DIABETES REV, V3, P3, DOI 10.2174/157339907779802139
   Chong WP, 2015, J EXP MED, V212, P1739, DOI 10.1084/jem.20141678
   Correa DD, 2012, NEURO-ONCOLOGY, V14, P101, DOI 10.1093/neuonc/nor186
   Crombie JL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00109
   Czarneski J, 2004, LEUKEMIA, V18, P597, DOI 10.1038/sj.leu.2403244
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   Davis Janet L, 2012, Trans Am Ophthalmol Soc, V110, P117
   Davis JL, 2005, AM J OPHTHALMOL, V140, P822, DOI 10.1016/j.ajo.2005.05.032
   Davis JL, 1997, AM J OPHTHALMOL, V124, P362, DOI 10.1016/S0002-9394(14)70828-1
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Dick AD, 2018, OPHTHALMOLOGY, V125, P757, DOI 10.1016/j.ophtha.2017.11.017
   Diedrichs-Mohring M, 2018, PROG RETIN EYE RES, V65, P107, DOI 10.1016/j.preteyeres.2018.02.003
   Douglas RS, 1997, BLOOD, V89, P941, DOI 10.1182/blood.V89.3.941
   ESSER P, 1993, BRIT J OPHTHALMOL, V77, P731, DOI 10.1136/bjo.77.11.731
   Felfeli T, 2019, AM J OPHTHALMOL, V206, P176, DOI 10.1016/j.ajo.2019.04.002
   Fend F, 2016, BRIT J HAEMATOL, V173, P680, DOI 10.1111/bjh.14025
   Foster CS, 2016, SURV OPHTHALMOL, V61, P1, DOI 10.1016/j.survophthal.2015.07.001
   Fowler NH, 2016, HAEMATOLOGICA, V101, P531, DOI 10.3324/haematol.2015.139493
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847
   Fu Q, 2019, J CELL MOL MED, V23, P1827, DOI 10.1111/jcmm.14081
   Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037
   Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019
   Gale JD, 2018, INVEST OPHTH VIS SCI, V59, P2659, DOI 10.1167/iovs.17-22731
   Garafalo AV, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100827
   Ghesquieres H, 2019, ANN ONCOL, V30, P621, DOI 10.1093/annonc/mdz032
   Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Goldschneider I, 2003, TRENDS IMMUNOL, V24, P77, DOI 10.1016/S1471-4906(02)00038-8
   Good William V, 2004, Trans Am Ophthalmol Soc, V102, P233
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Grommes C, 2019, NEURO-ONCOLOGY, V21, P306, DOI 10.1093/neuonc/noy193
   Guariguata L, 2014, DIABETES RES CLIN PR, V103, P137, DOI 10.1016/j.diabres.2013.11.002
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hasegawa E, 2019, IMMUNOL MED, V42, P79, DOI 10.1080/25785826.2019.1642080
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323
   Heuss ND, 2012, J IMMUNOL, V188, P1191, DOI 10.4049/jimmunol.1101621
   Hillier RJ, 2018, JAMA OPHTHALMOL, V136, P382, DOI 10.1001/jamaophthalmol.2018.0179
   Hori J, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.002
   Houillier C, 2015, NEUROLOGY, V84, P325, DOI 10.1212/WNL.0000000000001158
   Intzedy L, 2008, EYE, V22, P289, DOI 10.1038/sj.eye.6702965
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Ishikawa K, 2012, LAB INVEST, V92, P91, DOI 10.1038/labinvest.2011.141
   Ito T, 2019, GRAEF ARCH CLIN EXP, V257, P1029, DOI 10.1007/s00417-019-04266-6
   Kaburaki T, 2017, BRIT J HAEMATOL, V179, P246, DOI 10.1111/bjh.14848
   Kase S, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0479-1
   Kasenda B, 2016, BLOOD, V128, P32, DOI 10.1182/blood-2016-01-650101
   Kimura K, 2012, JPN J OPHTHALMOL, V56, P383, DOI 10.1007/s10384-012-0150-7
   Kitaichi N, 2005, J LEUKOCYTE BIOL, V77, P496, DOI 10.1189/jlb.0204114
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Kobayashi Y, 2015, BRIT J OPHTHALMOL, V99, P451, DOI 10.1136/bjophthalmol-2014-305321
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kreher S, 2015, ANN HEMATOL, V94, P409, DOI 10.1007/s00277-014-2212-z
   Kuroyanagi K, 2015, JPN J OPHTHALMOL, V59, P401, DOI 10.1007/s10384-015-0404-2
   Laursen JVN, 2013, CURR EYE RES, V38, P174, DOI 10.3109/02713683.2012.713153
   Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Lin W, 2019, IMMUNOL LETT, V209, P4, DOI 10.1016/j.imlet.2019.03.016
   Lin W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13412-1
   Liu Y, 2009, CANCER IMMUNOL IMMUN, V58, P687, DOI 10.1007/s00262-008-0591-5
   Lu B, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154943
   Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258
   Lyu J, 2018, GRAEF ARCH CLIN EXP, V256, P1469, DOI 10.1007/s00417-018-4034-5
   MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K
   Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017
   Matsuda K, 2017, J CLIN INVEST, V127, P3987, DOI 10.1172/JCI89893
   McMurtrey JJ, 2018, SURV OPHTHALMOL, V63, P769, DOI 10.1016/j.survophthal.2018.03.002
   Merida S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/671417
   Mesquida M, 2014, INT OPHTHALMOL, V34, P365, DOI 10.1007/s10792-013-9788-5
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mishra A, 2017, BIOL OPEN, V6, P449, DOI 10.1242/bio.021618
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   Mochizuki M, 2009, OCUL IMMUNOL INFLAMM, V17, P69, DOI 10.1080/09273940902957305
   Muhammad F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53297-w
   Murakami Y, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100778
   Murakami Y, 2018, ACTA OPHTHALMOL, V96, pe174, DOI 10.1111/aos.13502
   Murakami Y, 2015, AM J OPHTHALMOL, V159, P958, DOI 10.1016/j.ajo.2015.02.001
   Nagasaka Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep33921
   Nakao S, 2012, INVEST OPHTH VIS SCI, V53, P4323, DOI 10.1167/iovs.11-9119
   Nakatake S, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87781
   Nayak L, 2017, BLOOD, V129, P3071, DOI 10.1182/blood-2017-01-764209
   NEWSOME DA, 1988, AM J OPHTHALMOL, V105, P596, DOI 10.1016/0002-9394(88)90050-5
   Nishiguchi KM, 2019, BRIT J OPHTHALMOL, V103, P475, DOI 10.1136/bjophthalmol-2018-312225
   Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005
   Noda K, 2014, FASEB J, V28, P2038, DOI 10.1096/fj.12-215715
   O'Connor T, 2019, CANCER CELL, V36, P250, DOI 10.1016/j.ccell.2019.08.001
   Oh Keunhee, 2011, Immune Netw, V11, P399, DOI 10.4110/in.2011.11.6.399
   Okada AA, 2012, ARCH OPHTHALMOL-CHIC, V130, P592, DOI 10.1001/archophthalmol.2011.2698
   Okunuki Y, 2019, P NATL ACAD SCI USA, V116, P9989, DOI 10.1073/pnas.1820387116
   Mackern-Oberti JP, 2015, AUTOIMMUN REV, V14, P127, DOI 10.1016/j.autrev.2014.10.010
   Paschalis EI, 2018, P NATL ACAD SCI USA, V115, pE11359, DOI 10.1073/pnas.1807123115
   Pasqualucci L, 2015, SEMIN HEMATOL, V52, P67, DOI 10.1053/j.seminhematol.2015.01.005
   Peng YT, 2014, CURR STEM CELL RES T, V9, P124, DOI 10.2174/1574888X09666131219115125
   Petit L, 2018, CELL REP, V23, P2629, DOI 10.1016/j.celrep.2018.04.111
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Qiao H, 2005, BRIT J OPHTHALMOL, V89, P513, DOI 10.1136/bjo.2004.050658
   Quinn GE, 2016, OPHTHALMOLOGY, V123, P1595, DOI 10.1016/j.ophtha.2016.03.026
   Rakoczy EP, 2010, AM J PATHOL, V177, P2659, DOI 10.2353/ajpath.2010.090883
   Ramos-Casals M, 2007, MEDICINE, V86, P242, DOI 10.1097/MD.0b013e3181441a68
   Riemersma SA, 2000, BLOOD, V96, P3569, DOI 10.1182/blood.V96.10.3569.h8003569_3569_3577
   Roh MI, 2011, INVEST OPHTH VIS SCI, V52, P3825, DOI 10.1167/iovs.10-6797
   Rohrer B, 2007, EXP EYE RES, V84, P82, DOI 10.1016/j.exer.2006.08.017
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy S, 2017, AM J PATHOL, V187, P9, DOI 10.1016/j.ajpath.2016.08.022
   Rutgeerts P, 2004, GASTROENTEROLOGY, V126, P402, DOI 10.1053/j.gastro.2003.11.014
   Sagoo MS, 2014, SURV OPHTHALMOL, V59, P503, DOI 10.1016/j.survophthal.2013.12.001
   Sakamoto T, 2011, RETINA-J RET VIT DIS, V31, P222, DOI 10.1097/IAE.0b013e3181facfa9
   Sato T, 2009, OPHTHALMOLOGY, V116, P2165, DOI 10.1016/j.ophtha.2009.04.026
   Satoh M, 2016, EXP EYE RES, V153, P79, DOI 10.1016/j.exer.2016.10.003
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sfikakis PP, 2005, DIABETES CARE, V28, P445, DOI 10.2337/diacare.28.2.445
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Shimura M, 2017, BRIT J OPHTHALMOL, V101, P1518, DOI 10.1136/bjophthalmol-2016-309953
   Shoda H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138241
   Siemerink MJ, 2010, DEV OPHTHALMOL, V46, P4, DOI 10.1159/000320006
   Silver P, 2015, J IMMUNOL, V194, P3011, DOI 10.4049/jimmunol.1402650
   Silverman LI, 2020, SPINE J, V20, P138, DOI 10.1016/j.spinee.2019.08.006
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Sonoda KH, 2005, IMMUNOLOGY, V116, P390, DOI 10.1111/j.1365-2567.2005.02239.x
   Sonoda KH, 2001, J IMMUNOL, V166, P42, DOI 10.4049/jimmunol.166.1.42
   Soussain C, 2019, EUR J CANCER, V117, P121, DOI 10.1016/j.ejca.2019.05.024
   Soussain C, 2008, J CLIN ONCOL, V26, P2512, DOI 10.1200/JCO.2007.13.5533
   Stahl A, 2019, LANCET, V394, P1551, DOI 10.1016/S0140-6736(19)31344-3
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Steinman RM, 2007, NAT MED, V13, P1155, DOI 10.1038/nm1643
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   Stoll BJ, 2015, JAMA-J AM MED ASSOC, V314, P1039, DOI 10.1001/jama.2015.10244
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sugita S, 2006, J IMMUNOL, V176, P118, DOI 10.4049/jimmunol.176.1.118
   Sugita S, 2003, J EXP MED, V198, P161, DOI 10.1084/jem.20030097
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P263, DOI 10.1167/iovs.08-2536
   Sugita S, 2009, J IMMUNOL, V183, P5013, DOI 10.4049/jimmunol.0901623
   Sugita S, 2009, JPN J OPHTHALMOL, V53, P209, DOI 10.1007/s10384-009-0662-y
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Suzuki J, 2012, INVEST OPHTH VIS SCI, V53, P4158, DOI 10.1167/iovs.11-9323
   Takeda A., 2013, INFLAMM REGEN, V33, P261, DOI [10.2492/inflammregen.33.261, DOI 10.2492/INFLAMMREGEN.33.261]
   Takeda A, 2018, JPN J OPHTHALMOL, V62, P398, DOI 10.1007/s10384-018-0587-4
   Takeda A, 2015, INVEST OPHTH VIS SCI, V56, P7516, DOI 10.1167/iovs.15-17465
   Takeuchi M, 2014, OPHTHALMOLOGY, V121, P1877, DOI 10.1016/j.ophtha.2014.04.042
   Tan WJ, 2019, BLOOD, V134, P709, DOI 10.1182/blood.2019000022
   Taylor AW, 2018, J LEUKOCYTE BIOL, V103, P1179, DOI 10.1002/JLB.3MIR0817-337R
   Taylor AW, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00037
   Taylor AW, 2010, OCUL IMMUNOL INFLAMM, V18, P488, DOI 10.3109/09273948.2010.525730
   Toscano MA, 2006, J IMMUNOL, V176, P6323, DOI 10.4049/jimmunol.176.10.6323
   Uchi SH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219405
   Usui Y, 2012, INVEST OPHTH VIS SCI, V53, P5395, DOI 10.1167/iovs.11-8719
   Usui Y, 2009, ARCH OPHTHALMOL-CHIC, V127, P514, DOI 10.1001/archophthalmol.2009.34
   Van Brussel I, 2014, AUTOIMMUN REV, V13, P138, DOI 10.1016/j.autrev.2013.09.008
   van der Laken CJ, 2007, ANN RHEUM DIS, V66, P253, DOI 10.1136/ard.2006.057406
   van Hecke MV, 2005, DIABETOLOGIA, V48, P1300, DOI 10.1007/s00125-005-1799-y
   van Rhijn-Brouwer FCC, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-015-0555-7
   Vendomele J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01686
   Venkatesh R, 2019, CLIN OPHTHALMOL, V13, P353, DOI 10.2147/OPTH.S159014
   Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343
   Whitcup SM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1157, DOI 10.1001/archopht.1997.01100160327010
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Yonese I, 2019, EUR J HAEMATOL, V102, P191, DOI 10.1111/ejh.13191
   Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yoshimura T, 2008, INT IMMUNOL, V20, P209, DOI 10.1093/intimm/dxm135
   Zabel MK, 2016, GLIA, V64, P1479, DOI 10.1002/glia.23016
   Zhang YK, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aap8492
   Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298
   Zhou R, 2011, J IMMUNOL, V187, P4170, DOI 10.4049/jimmunol.1101634
   Zhou YD, 2015, INVEST OPHTH VIS SCI, V56, P4767, DOI 10.1167/iovs.14-16012
NR 194
TC 8
Z9 8
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 3
PY 2020
VL 11
AR 1431
DI 10.3389/fimmu.2020.01431
PG 19
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA MR8BT
UT WOS:000553816700001
PM 32719682
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gunther, F
   Brandl, C
   Heid, IM
   Kuchenhoff, H
AF Guenther, Felix
   Brandl, Caroline
   Heid, Iris M.
   Kuechenhoff, Helmut
TI Response misclassification in studies on bilateral diseases
SO BIOMETRICAL JOURNAL
LA English
DT Article
DE age-related macular degeneration; bilateral diseases; maximum
   likelihood; measurement error; response misclassification
AB Misclassification in binary outcomes can severely bias effect estimates of regression models when the models are naively applied to error-prone data. Here, we discuss response misclassification in studies on the special class of bilateral diseases. Such diseases can affect neither, one, or both entities of a paired organ, for example, the eyes or ears. If measurements are available on both organ entities, disease occurrence in a person is often defined as disease occurrence in at least one entity. In this setting, there are two reasons for response misclassification: (a) ignorance of missing disease assessment in one of the two entities and (b) error-prone disease assessment in the single entities. We investigate the consequences of ignoring both types of response misclassification and present an approach to adjust the bias from misclassification by optimizing an adequate likelihood function. The inherent modelling assumptions and problems in case of entity-specific misclassification are discussed. This work was motivated by studies on age-related macular degeneration (AMD), a disease that can occur separately in each eye of a person. We illustrate and discuss the proposed analysis approach based on real-world data of a study on AMD and simulated data.
C1 [Guenther, Felix; Kuechenhoff, Helmut] Ludwig Maximilians Univ Munchen, Dept Stat, Stat Consulting Unit, StaBLab, Ludwigstr 33, D-80539 Munich, Germany.
   [Guenther, Felix; Brandl, Caroline; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
   [Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
C3 University of Munich; University of Regensburg; University of Regensburg
RP Gunther, F (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Stat, Stat Consulting Unit, StaBLab, Ludwigstr 33, D-80539 Munich, Germany.; Gunther, F (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM felix.guenther@stat.uni-muenchen.de
OI Brandl, Caroline/0000-0001-8223-6137; Kuchenhoff,
   Helmut/0000-0002-6372-2487; Guenther, Felix/0000-0001-6582-1174
FU Foundation for the National Institutes of Health [NIH-2017 R01 EY
   RES511967]; Bundesministerium fur Bildung und Forschung [BMBF01ER1206,
   BMBF 01ER1507]; Deutsche Forschungsgemeinschaft [DFG HE3690/5-1]
FX Foundation for the National Institutes of Health, Grant/Award Number:
   NIH-2017 R01 EY RES511967; Bundesministerium fur Bildung und Forschung,
   Grant/Award Numbers: BMBF01ER1206, BMBF 01ER1507; Deutsche
   Forschungsgemeinschaft, Grant/Award Number: DFG HE3690/5-1
CR Agresti A, 2002, CATEGORICAL DATA ANA, V2
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Carroll R. J., 2006, MEASUREMENT ERROR NO, DOI DOI 10.1201/9781420010138
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lyles RH, 2011, EPIDEMIOLOGY, V22, P589, DOI 10.1097/EDE.0b013e3182117c85
   Neuhaus JM, 1999, BIOMETRIKA, V86, P843, DOI 10.1093/biomet/86.4.843
   R Core Team, 2018, R LANG ENV STAT COMP
   Stark K, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0122-0
NR 10
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0323-3847
EI 1521-4036
J9 BIOMETRICAL J
JI Biom. J.
PD JUL
PY 2019
VL 61
IS 4
BP 1033
EP 1048
DI 10.1002/bimj.201900039
PG 16
WC Mathematical & Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology; Mathematics
GA IH4VY
UT WOS:000474491400017
PM 31087360
DA 2022-11-30
ER

PT J
AU Lei, D
   Jin, X
   Wen, L
   Dai, H
   Ye, Z
   Wang, G
AF Lei, D.
   Jin, X.
   Wen, L.
   Dai, H.
   Ye, Z.
   Wang, G.
TI bmp3 is Required for Integrity of Blood Brain Barrier by Promoting
   Pericyte Coverage in Zebrafish Embryos
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Blood brain barrier (BBB); bmp3; pericyte; permeability; hemorrhage;
   zebrafish
ID SMALL-VESSEL DISEASE; BETA BINDING-PROTEIN; HEREDITARY HEMORRHAGIC
   TELANGIECTASIA; TGF-BETA; PULMONARY-HYPERTENSION; MICE; DIFFERENTIATION;
   MUTATIONS; RECEPTOR; CELLS
AB Background: The compromise of blood brain barrier (BBB) integrity is often associated with human hemorrhage stroke and neurodegeneration diseases, including retina diseases, such as age-related macular degeneration and diabetic retinopathy. Brain pericytes play pivotal roles in regulation and maintenance of BBB integrity. However, the mechanisms underlying brain pericyte development to establish BBB integrity remain unclear.
   Methods: Zebrafish transgenic lines Tg(flk1: GFP; gata1: dsRed), Tg(flk1: GFP), Tg(fli1: GFP) and Tg(BRE: GFP) were used in this work. The functional studies of bmp3 were performed by mopholino oligonucleotide (MO) injection, dye-based permeability assay, RT-PCR, in vivo imaging, immunofluorescence staining and statics analysis.
   Results: Here we report that bmp3 regulates BBB integrity in zebrafish brain by promoting pericyte development. Knockdown of bmp3 with injection of bmp3-MO causes intracerebral hemorrhage in zebrafish embryos. Meanwhile, disruption of bmp3 function by bmp3-MO injection impairs cerebral pericyte coverage in zebrafish embryos. Mechanistically, knockdown of bmp3 disrupts the pattern and activities of BMP signaling in zebrafish brain, thus probably disrupting the balance of TGF beta/BMP signaling in zebrafish embryos.
   Conclusion: In summary, our data shows that bmp3 regulates BBB integrity potentially by promoting pericyte development.
C1 [Lei, D.; Jin, X.; Wen, L.; Dai, H.; Ye, Z.; Wang, G.] Chongqing Univ, Key Lab Biorheol Sci & Technol, State & Local Joint Engn Lab Vasc Implants, Bioengn Coll,Minist Educ, Chongqing 400030, Peoples R China.
C3 Chongqing University
RP Wang, G (通讯作者)，Chongqing Univ, Key Lab Biorheol Sci & Technol, State & Local Joint Engn Lab Vasc Implants, Bioengn Coll,Minist Educ, Chongqing 400030, Peoples R China.
EM wanggx@cqu.edu.cn
FU National Natural Science Foundation of China [111572064, 31370949];
   National Key Technology R&D Program of China [2016YFC1102305,
   2016YFC1101101]; Chongqing Engineering Laboratory in Vascular Implants;
   Public Experiment Center of State Bioindustrial Base (Chongqing)
FX This study was partially supported by grants from the National Natural
   Science Foundation of China (111572064, 31370949), the National Key
   Technology R&D Program of China (2016YFC1102305, 2016YFC1101101) as well
   as the Chongqing Engineering Laboratory in Vascular Implants and the
   Public Experiment Center of State Bioindustrial Base (Chongqing).
CR Beaufort N, 2014, P NATL ACAD SCI USA, V111, P16496, DOI 10.1073/pnas.1418087111
   Beppu H, 2004, AM J PHYSIOL-LUNG C, V287, pL1241, DOI 10.1152/ajplung.00239.2004
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Carvalho RLC, 2004, DEVELOPMENT, V131, P6237, DOI 10.1242/dev.01529
   Daluiski A, 2001, NAT GENET, V27, P84, DOI 10.1038/83810
   Faucheux C, 1997, BIOCHEM BIOPH RES CO, V241, P787, DOI 10.1006/bbrc.1997.7792
   French CR, 2014, J CLIN INVEST, V124, P4877, DOI 10.1172/JCI75109
   Gould DB, 2006, NEW ENGL J MED, V354, P1489, DOI 10.1056/NEJMoa053727
   Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326
   Guo Xia, 2012, World J Biol Chem, V3, P41, DOI 10.4331/wjbc.v3.i3.41
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kast J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0096-8
   Kokabu S, 2012, MOL ENDOCRINOL, V26, P87, DOI 10.1210/me.2011-1168
   Lane KB, 2000, NAT GENET, V26, P81, DOI 10.1038/79226
   Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663
   Loeys BL, 2009, NEW ENGL J MED, V355, P788
   Maddaluno L, 2013, NATURE, V498, P492, DOI 10.1038/nature12207
   MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345
   Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116
   Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407
   Onodera Osamu, 2011, Rinsho Shinkeigaku, V51, P943
   Palmer AM, 2010, NEUROBIOL DIS, V37, P3, DOI 10.1016/j.nbd.2009.07.029
   Schoenebeck JJ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002849
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262
   Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634
   Whitesell TR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090590
   Xiao L, 2017, J PATHOL, V241, P25, DOI 10.1002/path.4814
   Zhang X. H., 2016, GPS SOLUT, V20, P1
   Zhou XP, 2015, INT J MOL SCI, V16, P20344, DOI 10.3390/ijms160920344
NR 31
TC 6
Z9 7
U1 1
U2 12
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2017
VL 17
IS 4
BP 298
EP 303
DI 10.2174/1566524017666171106114234
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FP4XR
UT WOS:000417620800007
PM 29110609
DA 2022-11-30
ER

PT J
AU Klassen, H
AF Klassen, Henry
TI Stem cells in clinical trials for treatment of retinal degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE age-related macular degeneration; cell-based; intravitreal;
   photoreceptor; progenitor; retinal pigment epithelial; retinitis
   pigmentosa; Stargardt; subretinal; transplantation
ID RETINITIS-PIGMENTOSA PATIENTS; PROGENITOR CELLS; MACULAR DEGENERATION;
   INTRAVITREAL USE; VISUAL FUNCTION; RCS RAT; TRANSPLANTATION; EPITHELIUM;
   RPE; RESCUE
AB Introduction: After decades of basic science research involving the testing of regenerative strategies in animal models of retinal degenerative diseases, a number of clinical trials are now underway, with additional trials set to begin shortly. These efforts will evaluate the safety and preliminary efficacy of cell-based products in the eyes of patients with a number of retinal conditions, notably including age-related macular degeneration, retinitis pigmentosa and Stargardt's disease.Areas covered: This review considers the scientific work and early trials with fetal cells and tissues that set the stage for the current clinical investigatory work, as well the trials themselves, specifically those either now completed, underway or close to initiation. The cells of interest include retinal pigment epithelial cells derived from embryonic stem or induced pluripotent stem cells, undifferentiated neural or retinal progenitors or cells from the vascular/bone marrow compartment or umbilical cord tissue.Expert opinion: Degenerative diseases of the retina represent a popular target for emerging cell-based therapeutics and initial data from early stage clinical trials suggest that short-term safety objectives can be met in at least some cases. The question of efficacy will require additional time and testing to be adequately resolved.
C1 [Klassen, Henry] Univ Calif Irvine, Gavin Herbert Eye Inst, Sue & Bill Gross Hall,Room 2006,845 Hlth Sci Rd, Irvine, CA 92697 USA.
   [Klassen, Henry] Univ Calif Irvine, Stem Cell Res Ctr, Sue & Bill Gross Hall,Room 2006,845 Hlth Sci Rd, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Klassen, H (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Sue & Bill Gross Hall,Room 2006,845 Hlth Sci Rd, Irvine, CA 92697 USA.
EM hklassen@uci.edu
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   [Anonymous], 2014, NEWS NATURE
   ARAMANT R, 1990, RESTOR NEUROL NEUROS, V2, P9, DOI 10.3233/RNN-1990-2102
   BioTime's Subsidiary Cell Cure Neurosciences Ltd, 2015, AW 1 6 MILL GRANT IS
   BJORKLUND A, 1981, NATURE, V289, P497, DOI 10.1038/289497a0
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   ClinicalTrials, 2015, STUD HUM CENTR NERV
   ClinicalTrials. gov A service of the National Institutes of Health, 2015, STUD HUCNS SC SUBR T
   ClinicalTrials. gov A service of the National Institutes of Health, 2015, SAF TOL SUBR TRANSPL
   ClinicalTrials. gov A service of the National Institutes of Health, 2015, STUD EV SAF CNTO 247
   ClinicalTrials. gov A service of the National Institutes of Health, 2015, SAF STUD CNTO 2476 P
   ClinicalTrials. gov A service of the National Institutes of Health, 2015, CLIN TRIAL AUT INTR
   ClinicalTrials. gov A service of the National Institutes of Health, 2015, SUBR TRANSPL HESC DE
   ClinicalTrials. gov A service of the National Institutes of Health, 2015, SAF SINGL INTR INJ H
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   ECT Pipeline. Neurotech, 2005, ECT TREATM RET DIS
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Humayun MS, 2000, INVEST OPHTH VIS SCI, V41, P3100
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kaplan HJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1168, DOI 10.1001/archopht.1997.01100160338012
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Klassen H, 2004, J NEUROSCI RES, V77, P334, DOI 10.1002/jnr.20183
   KLASSEN H, 1987, P NATL ACAD SCI USA, V84, P6958, DOI 10.1073/pnas.84.19.6958
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Park SS, 2012, INVEST OPHTH VIS SCI, V53, P986, DOI 10.1167/iovs.11-8833
   Radtke ND, 1999, AM J OPHTHALMOL, V128, P384, DOI 10.1016/S0002-9394(99)00250-0
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   ReNeuron, 2015, PHAS 1 2 CLIN TRIAL
   Sass T.R, 2015, 125 AM I RES CTR AN
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SHEEDLO HJ, 1989, EXP EYE RES, V48, P841, DOI 10.1016/0014-4835(89)90067-5
   SILVERMAN MS, 1990, CURR EYE RES, V9, P183, DOI 10.3109/02713689008995205
   Siqueira RC, 2013, BONE MARROW TRANSPL, V48, P612, DOI 10.1038/bmt.2012.185
   Siqueira RC, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0020-6
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   StemCells Inc CNN Money, 2015, TRANSPL 1 PAT PHAS 2
   Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
NR 53
TC 51
Z9 52
U1 0
U2 34
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JAN 2
PY 2016
VL 16
IS 1
BP 7
EP 14
DI 10.1517/14712598.2016.1093110
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DB6SJ
UT WOS:000368645000001
PM 26414165
DA 2022-11-30
ER

PT J
AU Kam, JH
   Lynch, A
   Begum, R
   Cunea, A
   Jeffery, G
AF Kam, Jaimie Hoh
   Lynch, Aisling
   Begum, Rana
   Cunea, Alex
   Jeffery, Glen
TI Topical cyclodextrin reduces amyloid beta and inflammation improving
   retinal function in ageing mice
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Retinal ageing; Cyclodextrin; RPE65; Retinal inflammation; Retinal
   amyloid beta; Lipid
ID AGE-RELATED MACULOPATHY; BASAL DEPOSITS; CHOLESTEROL; DRUSEN; MODEL;
   EYES; RPE; PHOTORECEPTORS; COMPONENT; DELIVERY
AB Retinal ageing results in chronic inflammation, extracellular deposition, including that of amyloid beta (A beta) and declining visual function. In humans this can progress into age-related macular degeneration (AMD), which is without cure. Therapeutic approaches have focused on systemic immunotherapies without clinical resolution. Here, we show using aged mice that 2-Hydroxypropyl-beta-cyclodextrin, a sugar molecule given as eye drops over 3 months results in significant reductions in A beta by 65% and inflammation by 75% in the aged mouse retina. It also elevates retinal pigment epithelium specific protein 65 (RPE65), a key molecule in the visual cycle, in aged retina. These changes are accompanied by a significant improvement in retinal function measured physiologically. 2-Hydroxypropyl-beta-cyclodextrin is as effective in reducing A beta and inflammation in the complement factor H knockout (Cfh(-/-)) mouse that shows advanced ageing and has been proposed as an AMD model. beta-cyclodextrin is economic, safe and may provide an efficient route to reducing the impact of retinal ageing. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Kam, Jaimie Hoh; Lynch, Aisling; Begum, Rana; Cunea, Alex; Jeffery, Glen] UCL, Inst Ophthalmol, London WC1E 6BT, England.
C3 University of London; University College London
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM g.jeffery@ucl.ac.uk
FU Rose Trees Trust
FX We thank Dr. Paul Ocin-Renegew for his constructive comments on the
   manuscript and Chris Hogg for his help in interpreting the ERG. This
   research was supported by the Rose Trees Trust.
CR Arden G.B., 2006, PRINCIPLES PRACTICE
   Atger VM, 1997, J CLIN INVEST, V99, P773, DOI 10.1172/JCI119223
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   Cunea A, 2014, NEUROBIOL AGING, V35, P2584, DOI 10.1016/j.neurobiolaging.2014.05.012
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Grimm MO, 2007, TRENDS MOL MED, V13, P337, DOI 10.1016/j.molmed.2007.06.004
   Haddley K., 2011, DRUGS FUTURE, V36, P7, DOI DOI 10.1358/D0F.2011.036.07.1673558
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hirsch-Reinshagen V, 2005, J BIOL CHEM, V280, P43243, DOI 10.1074/jbc.M508781200
   IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson D, 2010, J OCUL PHARMACOL TH, V26, P245, DOI 10.1089/jop.2010.0020
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Loftsson T, 2008, PHARMAZIE, V63, P171, DOI 10.1691/ph.2008.7322
   Loftsson T, 2007, INT J PHARMACEUT, V329, P1, DOI 10.1016/j.ijpharm.2006.10.044
   McCauliff LA, 2011, BIOCHEMISTRY-US, V50, P7341, DOI 10.1021/bi200574f
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nociari MM, 2014, P NATL ACAD SCI USA, V111, pE1402, DOI 10.1073/pnas.1400530111
   OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Ruseckaite R, 2011, J VISION, V11, DOI 10.1167/11.8.2
   Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sigurdsson HH, 2007, ACTA OPHTHALMOL SCAN, V85, P598, DOI 10.1111/j.1600-0420.2007.00885.x
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Stella VJ, 2008, TOXICOL PATHOL, V36, P30, DOI 10.1177/0192623307310945
   Suzuki M, 2007, MOL VIS, V13, P772
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Yao JQ, 2012, J EXP MED, V209, P2501, DOI 10.1084/jem.20121239
NR 50
TC 12
Z9 20
U1 0
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2015
VL 135
BP 59
EP 66
DI 10.1016/j.exer.2015.03.023
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ8RC
UT WOS:000355770200006
PM 25921262
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Pinazo-Duran, MD
   Gallego-Pinazo, R
   Garcia-Medina, JJ
   Zanon-Moreno, I
   Nucci, C
   Dolz-Marco, R
   Martinez-Castillo, S
   Galbis-Estrada, C
   Marco-Ramirez, C
   Lopez-Galvez, MI
   Galarreta, DJ
   Diaz-Llopis, M
AF Dolores Pinazo-Duran, Maria
   Gallego-Pinazo, Roberto
   Garcia-Medina, Jose Javier
   Zanon-Moreno, Icente
   Nucci, Carlo
   Dolz-Marco, Rosa
   Martinez-Castillo, Sebastian
   Galbis-Estrada, Carmen
   Marco-Ramirez, Carla
   Lopez-Galvez, Maria Isabel
   Galarreta, David J.
   Diaz-Llopis, Manuel
TI Oxidative stress and its downstream signaling in aging eyes
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Review
DE oxidative stress; eyes; aging; ophthalmic diseases; antioxidants;
   epidemiology
ID PIGMENT EPITHELIAL-CELLS; AGE-RELATED MACULOPATHY; GINKGO-BILOBA
   EXTRACT; 3RD NATIONAL-HEALTH; LONG-TERM INCIDENCE; MACULAR DEGENERATION;
   DRY EYE; LIPID-PEROXIDATION; FREE-RADICALS; FATTY-ACIDS
AB Background: Oxidative stress (OS) and its biomarkers are the biochemical end point of the imbalance between reactive oxygen species (ROS) production and the ability of the antioxidant (AOX) biological systems to fight against oxidative injury.
   Objective: We reviewed the role of OS and its downstream signaling in aging eyes.
   Methods: A search of the literature and current knowledge on the physiological and pathological mechanisms of OS were revisited in relation to the eyes and the aging process. Most prevalent ocular diseases have been analyzed herein in relation to OS and nutraceutic supplements, such as dry-eye disorders, glaucoma, age-related macular degeneration, and diabetic retinopathy.
   Results: Clinical, biochemical, and molecular data from anterior and posterior eye segment diseases point to OS as the common pathogenic mechanism in the majority of these ocular disorders, many of which are pathologies causing visual impairment, blindness, and subsequent loss of life quality. Studies with nutraceutic supplements in aging eye-related pathologies have also been reviewed.
   Conclusion: OS, nutritional status, and nutraceutic supplements have to be considered within the standards of care of older ophthalmologic patients. OS biomarkers and surrogate end points may help in managing the aging population with ocular diseases.
C1 [Dolores Pinazo-Duran, Maria; Garcia-Medina, Jose Javier; Zanon-Moreno, Icente; Galbis-Estrada, Carmen; Marco-Ramirez, Carla] Ophthalm Res Unit Santiago Grisolia, Valencia, Spain.
   [Gallego-Pinazo, Roberto; Dolz-Marco, Rosa; Martinez-Castillo, Sebastian] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Macula Sect, Valencia, Spain.
   [Garcia-Medina, Jose Javier] Univ Hosp Reina Sofia, Dept Ophthalmol, Murcia, Spain.
   [Zanon-Moreno, Icente; Diaz-Llopis, Manuel] Univ Valencia, Fac Med, E-46003 Valencia, Spain.
   [Nucci, Carlo] Univ Roma Tor Vergata, Rome, Italy.
   [Lopez-Galvez, Maria Isabel; Galarreta, David J.] Inst Oftalmobiol Aplicada IOBA, Valladolid, Spain.
C3 University of Valencia; University of Rome Tor Vergata
RP Pinazo-Duran, MD (通讯作者)，Univ Hosp Doctor Peset, Santiago Grisolia Ophthalm Res Unit FISABIO, Ave Gaspar Aguilar 90, Valencia 46017, Spain.
EM dolores.pinazo@uv.es
RI Galarreta, David J/ABH-2141-2020; Zanon-Moreno, Vicente/B-8348-2009
OI Zanon-Moreno, Vicente/0000-0003-1179-1592; Galarreta, David
   J/0000-0001-5649-6971; Pinazo-Duran, Maria Dolores/0000-0002-0118-7837;
   Garcia-Medina, Jose Javier/0000-0002-6245-7271; Dolz-Marco,
   Rosa/0000-0002-2963-2541
CR Agil A, 2006, J NEUROL SCI, V240, P31, DOI 10.1016/j.jns.2005.08.016
   Alaluf S, 2000, DIFFERENTIATION, V66, P147, DOI 10.1046/j.1432-0436.2000.660209.x
   Alexandrova M, 2004, J CLIN NEUROSCI, V11, P501, DOI 10.1016/j.jocn.2003.10.015
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   [Anonymous], 1987, GEORGE WASH LAW REV, VI, P1
   Arden GB, 2011, CURR DIABETES REV, V7, P291, DOI 10.2174/157339911797415620
   Baudouin C, 1997, INVEST OPHTH VIS SCI, V38, P1458
   Bazan NG, 2006, ADV EXP MED BIOL, V572, P531
   Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Block KI, 2008, INT J CANCER, V123, P1227, DOI 10.1002/ijc.23754
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calandria JM, 2012, J BIOL CHEM, V287, P23726, DOI 10.1074/jbc.M111.287078
   Carocho M, 2013, FOOD CHEM TOXICOL, V51, P15, DOI 10.1016/j.fct.2012.09.021
   Castilho AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042428
   CHEESEMAN KH, 1993, BRIT MED BULL, V49, P481, DOI 10.1093/oxfordjournals.bmb.a072625
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choi J, 2006, J BIOL CHEM, V281, P10816, DOI 10.1074/jbc.M509079200
   Coleman AL, 2008, AM J OPHTHALMOL, V145, P1081, DOI 10.1016/j.ajo.2008.01.022
   Conner EM, 1996, NUTRITION, V12, P274, DOI 10.1016/S0899-9007(96)00000-8
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Doly M, 1992, EXS, V62, P299
   Enriquez-de-Salamanca A, 2010, MOL VIS, V16, P862
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Fenton H.J.H., 1894, J CHEM SOC, V65, P899, DOI DOI 10.1039/CT8946500899
   *FOOD NUTR BOARD I, 2001, COPP DIET REF INT VI, P224
   FOSMIRE GJ, 1990, AM J CLIN NUTR, V51, P225, DOI 10.1093/ajcn/51.2.225
   Galbis-Estrada C, 2012, FREE RADICAL RES, V46, P77, DOI 10.3109/10715762.2011.640324
   Galbis-Estrada C, 2013, CLIN INTERV AGING, V8, P711, DOI 10.2147/CIA.S43191
   GERSCHMAN R, 1954, P SOC EXP BIOL MED, V86, P27
   Gerschman R, 1954, AM J PHYSIOL, V179, P639
   Gerschman R, 1952, AM J PHYSIOL, V176, P6
   Gipson IK, 2003, INVEST OPHTH VIS SCI, V44, P2496, DOI 10.1167/iovs.02-0851
   GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T
   Gupta Madhur M, 2005, Indian J Physiol Pharmacol, V49, P187
   Haber F, 1932, NATURWISSENSCHAFTEN, V20, P948, DOI 10.1007/BF01504715
   Halliwell B, 2012, NUTR REV, V70, P257, DOI 10.1111/j.1753-4887.2012.00476.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Higuchi A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009911
   Huang W, 2005, AM J PATHOL, V167, P673, DOI 10.1016/S0002-9440(10)62042-1
   Garcia-Medina JJ, 2011, EUR J OPHTHALMOL, V21, P637, DOI 10.5301/EJO.2010.6212
   Kang JH, 2004, AM J CLIN NUTR, V79, P755
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   KEYS A, 1995, AM J CLIN NUTR, V61, p1321S, DOI 10.1093/ajcn/61.6.1321S
   KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Koenekoop Robert K, 2003, Ophthalmic Genet, V24, P75, DOI 10.1076/opge.24.2.75.13996
   Krebs H A, 1972, Adv Enzyme Regul, V10, P397, DOI 10.1016/0065-2571(72)90025-8
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Labbe A, 2007, J FR OPHTALMOL, V30, P76, DOI 10.1016/S0181-5512(07)89557-X
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Maleki S, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.1.016004
   Malet F, ACTA OPHTHALMOL
   Mancino R, 2011, MOL VIS, V17, P1298
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Martin-Gallan P, 2003, FREE RADICAL BIO MED, V34, P1563, DOI 10.1016/S0891-5849(03)00185-0
   Mayer-Davis EJ, 1998, OPHTHALMOLOGY, V105, P2264, DOI 10.1016/S0161-6420(98)91227-1
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   Melo P, 2010, NEUROCHEM INT, V56, P431, DOI 10.1016/j.neuint.2009.11.017
   Millen AE, 2003, AM J EPIDEMIOL, V158, P225, DOI 10.1093/aje/kwg116
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moss SE, 2008, OPTOMETRY VISION SCI, V85, P668, DOI 10.1097/OPX.0b013e318181a947
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nakamura S, 2007, INVEST OPHTH VIS SCI, V48, P1552, DOI 10.1167/iovs.06-1027
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Osborne NN, 1999, BRIT J OPHTHALMOL, V83, P980, DOI 10.1136/bjo.83.8.980
   Pacal Lukas, 2011, Archives of Physiology and Biochemistry, V117, P222, DOI 10.3109/13813455.2010.551135
   Perry Henry D, 2008, Am J Manag Care, V14, pS79
   Pinazo-Duran MD, 2013, CLIN INTERV AGING, V8, P139, DOI 10.2147/CIA.S40640
   Pinazo-Duran MD, 2013, CURR OPIN PHARMACOL, V13, P98, DOI 10.1016/j.coph.2012.10.007
   Pinazo-Duran MD, 2000, OPHTHALMIC RES, V32, P61, DOI 10.1159/000055591
   Pinazo-Duran MD, 1998, ALCOHOL CLIN EXP RES, V22, pA84
   Pinazo-Duran MD, 2011, GLAUCOMA BASIC CLIN, P207
   PRASHAR S, 1993, ACTA OPHTHALMOL, V71, P214
   Quaranta L, 2003, OPHTHALMOLOGY, V110, P359, DOI 10.1016/S0161-6420(02)01745-1
   Rahman K, 2007, CLIN INTERV AGING, V2, P219
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Ritch R, 2000, MED HYPOTHESES, V54, P221, DOI 10.1054/mehy.1999.0025
   Robison WG, 2000, J OCUL PHARMACOL TH, V16, P109, DOI 10.1089/jop.2000.16.109
   Rodriguez-Castilla V, 2005, CLIN INVEST ARTERIOS, V17, P101, DOI 10.1016/S0214-9168(05)73325-8
   Rogers BS, 2007, INVEST OPHTH VIS SCI, V48, P438, DOI 10.1167/iovs.06-0528
   Roy S, 2002, FREE RADICAL RES, V36, P1023, DOI 10.1080/1071576021000006662
   Sacca SC, 2008, PROG BRAIN RES, V173, P385, DOI 10.1016/S0079-6123(08)01127-8
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6
   Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5
   Schweigert FJ, 2011, KLIN MONATSBL AUGENH, V228, P537, DOI 10.1055/s-0029-1245527
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Selman Colin, 2013, Biology Letters, V9, P1
   Semba RD, 2003, MED HYPOTHESES, V61, P465, DOI 10.1016/S0306-9877(03)00198-1
   Serra-Majem L, 2006, NUTR REV, V64, pS27, DOI [10.1111/j.1753-4887.2006.tb00232.x, 10.1301/nr.2006.feb.S27-S47]
   Sies H., 1985, OXIDATIVE STRESS, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3
   Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344
   Son SM, 2007, DIABETES RES CLIN PR, V77, pS65, DOI 10.1016/j.diabres.2007.01.036
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tavares FD, 2010, SEMIN OPHTHALMOL, V25, P84, DOI 10.3109/08820538.2010.488568
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Tsubota K, 2011, CORNEA, V30, pS1, DOI 10.1097/ICO.0b013e3182284b69
   Uchino Yuichi, 2012, Cornea, V31 Suppl 1, pS63, DOI 10.1097/ICO.0b013e31826a5de1
   USDA, 2020, DIET GUID AM 2020 20
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VanDerMeid KR, 2011, MOL VIS, V17, P1056
   Verdejo C, 1999, EYE, V13, P183, DOI 10.1038/eye.1999.48
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Yadav UCS, 2011, CURR MED CHEM, V18, P931
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
   Zanon-Moreno V, 2013, MOL VIS, V19, P231
   Zanon-Moreno V, 2011, MOL VIS, V17, P2997
   Zhuo YH, 2012, P NATL ACAD SCI USA, V109, P19882, DOI 10.1073/pnas.1218953109
   ZUCLICH JA, 1976, INVEST OPHTH VISUAL, V15, P760
NR 135
TC 77
Z9 83
U1 2
U2 31
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2014
VL 9
BP 637
EP 652
DI 10.2147/CIA.S52662
PG 16
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA AE6QU
UT WOS:000334119400002
PM 24748782
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Rosca, EV
   Koskimaki, JE
   Pandey, NB
   Tamiz, AP
   Popel, AS
AF Rosca, Elena V.
   Koskimaki, Jacob E.
   Pandey, Niranjan B.
   Tamiz, Amir P.
   Popel, Aleksander S.
TI Structure-Activity Relationship Study of Collagen-Derived
   Anti-Angiogenic Biomimetic Peptides
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE age-related macular degeneration; angiogenesis; cancer; endothelial
   cell; lymphangiogenesis; peptidomimetics
ID TUMOR-GROWTH; IV COLLAGEN; IDENTIFICATION; GLIOBLASTOMA; TRIAL
AB Structureactivity relationship (SAR) studies are essential in the generation of peptides with enhanced activity and efficacy as therapeutic agents. In this study, we report a Structureactivity relationship study for a family of mimetic peptides derived from type IV collagen with potent anti-angiogenic properties. The Structureactivity relationship study was conducted using a number of validated in vitro assays including cell proliferation, adhesion, migration, and tubule formation. We report a critical sequence (NINNV) within this peptide series, which is required for the potent anti-angiogenic activity. Detailed amino acid substitutions resulted in peptides with superior efficacy. Specifically, substitutions with isoleucine at positions 12 and 18 along with the substitution of the methionine at position 10 with the non-natural amino acid d-alanine led to an increase in potency by two orders of magnitude over the parent peptide. Several mimetic peptides in this series exhibit a significant improvement of activity over the parent peptide. This improved in vitro activity is expected to correlate with an increase in in vivo activity leading to effective peptides for anti-angiogenic therapy for different disease applications including cancer and age-related macular degeneration.
C1 [Rosca, Elena V.; Koskimaki, Jacob E.; Pandey, Niranjan B.; Tamiz, Amir P.; Popel, Aleksander S.] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
   [Popel, Aleksander S.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
   [Popel, Aleksander S.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins Medicine
RP Rosca, EV (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
EM e.v.rosca@gmail.com
RI Popel, Aleksander S/A-6724-2009
OI Popel, Aleksander/0000-0002-6706-9235
FU National Institutes of Health [R21 CA131931, R21 CA152473, R01
   CA138264]; Safeway Foundation; Edward N. and Della L. Thome Memorial
   Foundation; NATIONAL CANCER INSTITUTE [R21CA152473, R21CA131931,
   R01CA138264] Funding Source: NIH RePORTER
FX The authors thank all members of the laboratory for insightful
   discussions and review of the manuscript. We are grateful to ACEA
   Biosciences for the use of the Personal RT-CIS system, which allowed us
   to perform migration and adhesion experiments and in particular to Dr
   Yama Abassi for detailed technical discussions. Dr Popel serves as the
   Chief Scientific Officer of AsclepiX Therapeutics, LLC. The terms of
   this arrangement are being managed by the Johns Hopkins University in
   accordance with its conflict of interest policies. This work was
   supported by the National Institutes of Health grants R21 CA131931, R21
   CA152473, and R01 CA138264, the Safeway Foundation, and the Edward N.
   and Della L. Thome Memorial Foundation.
CR Abraham S, 2007, P NATL ACAD SCI USA, V104, P5584, DOI 10.1073/pnas.0700223104
   Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456-009-9146-4
   Bhutia SK, 2008, TRENDS BIOTECHNOL, V26, P210, DOI 10.1016/j.tibtech.2008.01.002
   Bradley DA, 2011, INVEST NEW DRUG, V29, P1432, DOI 10.1007/s10637-010-9420-8
   Eikesdal HP, 2008, P NATL ACAD SCI USA, V105, P15040, DOI 10.1073/pnas.0807055105
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Gautier B, 2010, J MED CHEM, V53, P4428, DOI 10.1021/jm1002167
   Gentilucci L, 2010, CURR PHARM DESIGN, V16, P3185, DOI 10.2174/138161210793292555
   Haviv F, 2005, J MED CHEM, V48, P2838, DOI 10.1021/jm0401560
   HRUBY VJ, 1993, ANN NY ACAD SCI, V680, P51, DOI 10.1111/j.1749-6632.1993.tb19674.x
   Karagiannis ED, 2008, P NATL ACAD SCI USA, V105, P13775, DOI 10.1073/pnas.0803241105
   Karagiannis ED, 2007, BIOCHEM BIOPH RES CO, V354, P434, DOI 10.1016/j.bbrc.2006.12.231
   Kenny LM, 2008, J NUCL MED, V49, P879, DOI 10.2967/jnumed.107.049452
   Koskimaki JE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-29
   Koskimaki JE, 2009, NEOPLASIA, V11, P1285, DOI 10.1593/neo.09620
   Lee E, 2011, INT J BIOCHEM CELL B, V43, P1812, DOI 10.1016/j.biocel.2011.08.020
   Li M, 2008, BIOORG MED CHEM LETT, V18, P4584, DOI 10.1016/j.bmcl.2008.07.028
   Mirochnik Y, 2009, CLIN CANCER RES, V15, P1655, DOI 10.1158/1078-0432.CCR-08-2113
   Nabors LB, 2010, ARCH NEUROL-CHICAGO, V67, P313, DOI 10.1001/archneurol.2010.16
   Pernot M, 2011, EXPERT OPIN DRUG MET, V7, P793, DOI 10.1517/17425255.2011.574126
   Reardon DA, 2008, J CLIN ONCOL, V26, P5610, DOI 10.1200/JCO.2008.16.7510
   Rivera CG, 2011, J MED CHEM, V54, P6492, DOI 10.1021/jm200114f
   Rosca EV, 2011, CANCER BIOL THER, V12, P808, DOI 10.4161/cbt.12.9.17677
   Rosca EV, 2011, CURR PHARM BIOTECHNO, V12, P1101
   Saladin PM, 2009, IDRUGS, V12, P779
NR 26
TC 12
Z9 12
U1 2
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD JUL
PY 2012
VL 80
IS 1
BP 27
EP 37
DI 10.1111/j.1747-0285.2012.01376.x
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 955AT
UT WOS:000304990200004
PM 22405100
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Al-Latayfeh, M
   Silva, PS
   Sun, JK
   Aiello, LP
AF Al-Latayfeh, Motasem
   Silva, Paolo S.
   Sun, Jennifer K.
   Aiello, Lloyd Paul
TI Antiangiogenic Therapy for Ischemic Retinopathies
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-VEIN-OCCLUSION; INTRAVITREAL
   BEVACIZUMAB AVASTIN; PROLIFERATIVE DIABETIC-RETINOPATHY; MACULAR EDEMA
   SECONDARY; FACTOR TRAP-EYE; VASCULAR-PERMEABILITY FACTOR;
   EPITHELIUM-DERIVED FACTOR; PPAR-GAMMA LIGANDS; PROTEIN-KINASE-C
AB Neovascularization is a common pathological process in various retinal vascular disorders including diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinal vein occlusion (RVO). The development of neovascular vessels may lead to complications such as vitreous hemorrhage, fibrovascular tissue formation, and traction retinal detachments. Ultimately, irreversible vision loss may result. Various proangiogenic factors are involved in these complex processes. Different antiangiogenic drugs have been formulated in an attempt treat these vascular disorders. One factor that plays a major role in the development of retinal neovascularization is vascular endothelial growth factor (VEGF). Anti-VEGF agents are currently FDA approved for the treatment of AMD and RVO. They are also extensively used as an off-label treatment for diabetic macular edema (DME), proliferative DR, and neovascular glaucoma. However, at this time, the long-term safety of chronic VEGF inhibition has not been extensively evaluated. A large and rapidly expanding body of research on angiogenesis is being conducted at multiple centers across the globe to determine the exact contributions and interactions among a variety of angiogenic factors in an effort to determine the therapeutic potential of antiangiogenic agent in the treatment of a variety of retinal diseases.
C1 [Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA.
C3 Harvard University; Joslin Diabetes Center, Inc.; Harvard University;
   Harvard Medical School
RP Aiello, LP (通讯作者)，Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
EM lpaiello@joslin.harvard.edu
RI Sun, Jennifer K/AAP-2734-2020; Al-latayfeh, Motasem/AAM-1895-2021
OI Sun, Jennifer K/0000-0003-0915-6303; Al-latayfeh,
   Motasem/0000-0003-2107-8213
CR Abhary S, 2010, ARCH OPHTHALMOL-CHIC, V128, P102, DOI 10.1001/archophthalmol.2009.355
   Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   Ahmadieh H, 2009, OPHTHALMOLOGY, V116, P1943, DOI 10.1016/j.ophtha.2009.07.001
   Aiello LP, 2007, ARCH OPHTHALMOL-CHIC, V125, P318
   Aiello LP, 2002, SURV OPHTHALMOL, V47, pS263, DOI 10.1016/S0039-6257(02)00391-0
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Aiello LP, 2005, DIABETES, V54, P2188
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aljada A, 2008, ANGIOGENESIS, V11, P361, DOI 10.1007/s10456-008-9118-0
   Altinsoy Halil Ibrahim, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-03
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Avery RL, 2006, RETINA-J RET VIT DIS, V26, P352, DOI 10.1097/00006982-200603000-00016
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beutel Julia, 2010, International Ophthalmology, V30, P15, DOI 10.1007/s10792-008-9282-7
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyd SR, 2002, ARCH OPHTHALMOL-CHIC, V120, P1644
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brouzas D, 2009, CLIN OPHTHALMOL, V3, P685
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cai J, 2008, INVEST OPHTH VIS SCI, V49, P2163, DOI 10.1167/iovs.07-1206
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113
   Chen J, 2009, INVEST OPHTH VIS SCI, V50, P1329, DOI 10.1167/iovs.08-2521
   Chew EY, 2003, OPHTHALMOLOGY, V110, P1683, DOI 10.1016/S0161-6420(03)00579-7
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2006, ARCH OPHTHALMOL-CHIC, V124, P726, DOI 10.1001/archopht.124.5.726
   Davidorf FH, 2006, RETINA-J RET VIT DIS, V26, P354, DOI 10.1097/00006982-200603000-00017
   Davis MD, 2009, INVEST OPHTH VIS SCI, V50, P1, DOI 10.1167/iovs.08-2473
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Erdol H, 2010, RETINA-J RET VIT DIS, V30, P570, DOI 10.1097/IAE.0b013e3181bf5ff0
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907
   Fong DS, 1999, AM J OPHTHALMOL, V127, P137, DOI 10.1016/S0002-9394(98)00309-2
   Gao BB, 2007, NAT MED, V13, P181, DOI 10.1038/nm1534
   Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052
   Gharbiya M, 2010, AM J OPHTHALMOL, V149, P458, DOI 10.1016/j.ajo.2009.10.010
   Girach A, 2009, EYE, V23, P209, DOI 10.1038/eye.2008.324
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gregori NZ, 2008, RETINA-J RET VIT DIS, V28, P1325, DOI 10.1097/IAE.0b013e318188501f
   Gupta A, 2008, RETINA-J RET VIT DIS, V28, P964, DOI 10.1097/IAE.0b013e3181706302
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Hayashi K, 2009, AM J OPHTHALMOL, V148, P396, DOI 10.1016/j.ajo.2009.03.026
   HAYREH SS, 1994, AM J OPHTHALMOL, V117, P429, DOI 10.1016/S0002-9394(14)70001-7
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   HENKIND P, 1974, BRIT J OPHTHALMOL, V58, P413, DOI 10.1136/bjo.58.4.413
   Hernandez-Da Mota SE, 2010, EUR J OPHTHALMOL, V20, P1047, DOI 10.1177/112067211002000604
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   Ikuno Y, 2009, AM J OPHTHALMOL, V147, P94, DOI 10.1016/j.ajo.2008.07.017
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Law JC, 2010, J AAPOS, V14, P6, DOI 10.1016/j.jaapos.2009.10.011
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Mansour AM, 2009, AM J OPHTHALMOL, V148, P310, DOI 10.1016/j.ajo.2009.03.023
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P683, DOI 10.1111/j.1755-3768.2008.01391.x
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mirshahi A, 2008, EUR J OPHTHALMOL, V18, P263, DOI 10.1177/112067210801800215
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Modarres M, 2009, EUR J OPHTHALMOL, V19, P848, DOI 10.1177/112067210901900526
   MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ogata N, 2001, AM J OPHTHALMOL, V132, P378, DOI 10.1016/S0002-9394(01)01008-X
   Oshima Y, 2009, OPHTHALMOLOGY, V116, P927, DOI 10.1016/j.ophtha.2008.11.005
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634
   Pe'er J, 1998, OPHTHALMOLOGY, V105, P412, DOI 10.1016/S0161-6420(98)93020-2
   Phipps JA, 2009, HYPERTENSION, V53, P175, DOI 10.1161/HYPERTENSIONAHA.108.117663
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Prager F, 2009, BRIT J OPHTHALMOL, V93, P452, DOI 10.1136/bjo.2008.141085
   Praidou A, 2010, CURR DIABETES REV, V6, P304, DOI 10.2174/157339910793360815
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rogers SL, 2010, OPHTHALMOLOGY, V117, P1094, DOI 10.1016/j.ophtha.2010.01.058
   Rojas M, 2010, INVEST OPHTH VIS SCI, V51, P1709, DOI 10.1167/iovs.09-3375
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233
   Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418
   Shen LQ, 2008, ARCH OPHTHALMOL-CHIC, V126, P793, DOI 10.1001/archopht.126.6.793
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Siqueira RC, 2006, ACTA OPHTHALMOL SCAN, V84, P834, DOI 10.1111/j.1600-0420.2006.00779.x
   Stefansson E, 2006, SURV OPHTHALMOL, V51, P364, DOI 10.1016/j.survophthal.2006.04.005
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Sultan MB, 2011, OPHTHALMOLOGY, V118, P1107, DOI 10.1016/j.ophtha.2011.02.045
   Sun JK, 2008, PRINCIPLES PRACTICE, P1807
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Takagi H, 2003, INVEST OPHTH VIS SCI, V44, P393, DOI 10.1167/iovs.02-0276
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tonello M, 2008, ACTA OPHTHALMOL, V86, P385, DOI 10.1111/j.1600-0420.2007.01056.x
   Tong ZZ, 2008, P NATL ACAD SCI USA, V105, P6998, DOI 10.1073/pnas.0800454105
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Wakabayashi T, 2008, OPHTHALMOLOGY, V115, P1571, DOI 10.1016/j.ophtha.2008.02.026
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Wiegand TW, 2009, BRIT J OPHTHALMOL, V93, P47, DOI 10.1136/bjo.2008.143461
   Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006
   Xiong SQ, 2009, OPHTHALMOLOGICA, V223, P306, DOI 10.1159/000215825
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
NR 136
TC 44
Z9 48
U1 0
U2 4
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD JUN
PY 2012
VL 2
IS 6
AR a006411
DI 10.1101/cshperspect.a006411
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 080XW
UT WOS:000314278600008
PM 22675660
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Dahlmann-Noor, A
   Vijay, S
   Jayaram, H
   Limb, A
   Khaw, PT
AF Dahlmann-Noor, Annegret
   Vijay, Sauparnika
   Jayaram, Hari
   Limb, Astrid
   Khaw, Peng Tee
TI Current approaches and future prospects for stem cell rescue and
   regeneration of the retina and optic nerve
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Review
CT Next Generation Eye Surgery, Device and Drug Delivery Symposium
CY OCT 17, 2009
CL Toronto, CANADA
DE stem cell; retina; optic nerve; regeneration; repair; glaucoma; macular
   degeneration; retinal dystrophy; diabetic retinopathy
ID OLFACTORY ENSHEATHING CELLS; CILIARY NEUROTROPHIC FACTOR; NEURAL
   PROGENITOR CELLS; ADENOVIRUS-MEDIATED EXPRESSION; IN-VITRO
   DIFFERENTIATION; LONG-TERM SURVIVAL; GANGLION-CELLS; RAT MODEL; MULLER
   GLIA; MORPHOLOGICAL INTEGRATION
AB The 3 most common causes of visual impairment and legal blindness in developed countries (age-related macular degeneration, glaucoma, and diabetic retinopathy) share I end point: the loss of neural cells of the eye. Although recent treatment advances can slow down the progression of these conditions, many individuals still suffer irreversible loss of vision. Research is aimed at developing new treatment strategies to rescue damaged photoreceptors and retinal ganglion cells (RGC) and to replace lost cells by transplant. The neuroprotective and regenerative potential of stem and progenitor cells from a variety of sources has been explored in models of retinal disease and ganglion cell loss. Continuous intraocular delivery of neurotrophic factors via stem cells (SC) slows down photoreceptor cells and RGC loss in experimental models. Following intraocular transplantation, SC are capable of expressing proteins and of developing a morphology characteristic of photoreceptors or RGC. Recently, recovery of vision has been achieved for the first time in a rodent model of retinal dystrophy, using embryonic SC differentiated into photoreceptors prior to transplant. This indicates that clinically significant synapse formation and acquisition of the functional properties of retinal neurons, and restoration of vision, are distinct future possibilities.
C1 [Khaw, Peng Tee] UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Khaw, Peng Tee] UCL Partners AHSC, London, England.
   [Khaw, Peng Tee] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Khaw, PT (通讯作者)，Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM p.khaw@ucl.ac.uk
RI Khaw, Peng T/C-1881-2008; Jayaram, Hari/H-7016-2019; Dahlmann-Noor,
   Annegret/A-2967-2017
OI Jayaram, Hari/0000-0003-1998-0670; Limb, Gloria
   Astrid/0000-0001-7014-8922; Dahlmann-Noor, Annegret/0000-0002-7402-4350;
   Khaw, Sir Peng Tee/0000-0002-8087-2268
FU Fight for Sight; Helen Hamlyn Trust; NIHR Biomedical Research Centre at
   Moorfields Eye Hospital; UCL Institute of Ophthalmology, London, United
   Kingdom; Moorfields Trustees; Hobson Foundation; Freemasons' Grand
   Charity; Ron and Liora Moskovitz; Jules Thorn Trust; Engineering and
   Physical Sciences Research Council; Medical Research Council; Michael
   and Ilsa Katz Foundation; MRC [G0701341, G0900002, G0300259] Funding
   Source: UKRI; Medical Research Council [G0701341] Funding Source:
   researchfish
FX This work was supported by Fight for Sight, the Helen Hamlyn Trust in
   memory of Paul Hamlyn, the NIHR Biomedical Research Centre at Moorfields
   Eye Hospital, and the UCL Institute of Ophthalmology, London, United
   Kingdom. Our stem-cell research, human stem cell facility, and
   antiscarring and clinical research are also supported by Moorfields
   Trustees, the Hobson Foundation, the Freemasons' Grand Charity, Ron and
   Liora Moskovitz, the Jules Thorn Trust, the Engineering and Physical
   Sciences Research Council, the Medical Research Council, and the Michael
   and Ilsa Katz Foundation. This article is dedicated to Michael Katz for
   making possible much of our early research into stem cells and for
   giving hope to many of our patients. The authors have no proprietary or
   commercial interest in any materials discussed in this article.
CR Ahmed Z, 2006, BRAIN, V129, P1517, DOI 10.1093/brain/awl080
   Akagi T, 2003, NEUROSCI LETT, V341, P213, DOI 10.1016/S0304-3940(03)00177-0
   Aoki H, 2008, GRAEF ARCH CLIN EXP, V246, P255, DOI 10.1007/s00417-007-0710-6
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Bhatia B, 2009, EXP EYE RES, V89, P373, DOI 10.1016/j.exer.2009.04.005
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Bull ND, 2008, INVEST OPHTH VIS SCI, V49, P3449, DOI 10.1167/iovs.08-1770
   Bull ND, 2009, INVEST OPHTH VIS SCI, V50, P4244, DOI 10.1167/iovs.08-3239
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Canola K, 2007, INVEST OPHTH VIS SCI, V48, P446, DOI 10.1167/iovs.06-0190
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chacko DM, 2003, VISION RES, V43, P937, DOI 10.1016/S0042-6989(02)00688-0
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chaudhry GR, 2009, STEM CELLS DEV, V18, P247, DOI 10.1089/scd.2008.0057
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   DANCE A, CELL MIGHT SAVE SIGH
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fischer AJ, 2003, GLIA, V43, P70, DOI 10.1002/glia.10218
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Gregory-Evans K, 2009, MOL VIS, V15, P962
   Grozdanic SD, 2006, EXP EYE RES, V82, P597, DOI 10.1016/j.exer.2005.08.020
   Guo Y, 2003, INVEST OPHTH VIS SCI, V44, P3194, DOI 10.1167/iovs.02-0875
   Halme DG, 2006, NEW ENGL J MED, V355, P1730, DOI 10.1056/NEJMhpr063086
   Hara A, 2006, BRAIN RES, V1085, P33, DOI 10.1016/j.brainres.2006.02.079
   Hentze H, 2007, TRENDS BIOTECHNOL, V25, P24, DOI 10.1016/j.tibtech.2006.10.010
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jagatha B, 2009, BIOCHEM BIOPH RES CO, V380, P230, DOI 10.1016/j.bbrc.2009.01.038
   Jalving M, 2009, CURR OPIN MOL THER, V11, P383
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Jonas JB, 2008, ACTA OPHTHALMOL, V86, P225, DOI 10.1111/j.1600-0420.2007.00987.x
   Koike-Kiriyama N, 2007, ACTA NEUROBIOL EXP, V67, P359
   Kolonin MG, 2009, NAT BIOTECHNOL, V27, P252, DOI 10.1038/nbt0309-252
   Kurimoto Y, 2001, NEUROSCI LETT, V306, P57, DOI 10.1016/S0304-3940(01)01857-2
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lawrence JM, 2007, STEM CELLS, V25, P2033, DOI 10.1634/stemcells.2006-0724
   Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791
   Leaver SG, 2006, EUR J NEUROSCI, V24, P3323, DOI 10.1111/j.1460-9568.2006.05230.x
   Lefort N, 2008, NAT BIOTECHNOL, V26, P1364, DOI 10.1038/nbt.1509
   Li Y, 2008, NEUROSCI LETT, V440, P251, DOI 10.1016/j.neulet.2008.05.085
   Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000
   Li Y, 2003, J NEUROSCI, V23, P7783
   Li Y, 2007, GLIA, V55, P312, DOI 10.1002/glia.20458
   Limb GA, 2002, INVEST OPHTH VIS SCI, V43, P864
   Logan A, 2006, BRAIN, V129, P490, DOI 10.1093/brain/awh706
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014
   MacDonald IM, 2007, CAN J OPHTHALMOL, V42, P399, DOI 10.3129/i07-039
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   MacNeil A, 2007, STEM CELLS, V25, P2430, DOI 10.1634/stemcells.2007-0035
   Maier PC, 2005, BMJ-BRIT MED J, V331, P134, DOI 10.1136/bmj.38506.594977.E0
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   Martinez-Navarrete GC, 2008, J COMP NEUROL, V511, P557, DOI 10.1002/cne.21860
   Mellough CB, 2007, RESTOR NEUROL NEUROS, V25, P177
   Mellough CB, 2004, EXP NEUROL, V186, P6, DOI 10.1016/j.expneurol.2003.10.021
   Moe MC, 2009, EXP EYE RES, V88, P30, DOI 10.1016/j.exer.2008.09.020
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Moreno-Flores MT, 2006, MOL THER, V13, P598, DOI 10.1016/j.ymthe.2005.11.014
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nathan DM, 2009, ARCH INTERN MED, V169, P1307, DOI 10.1001/archinternmed.2009.193
   Nishida A, 2000, INVEST OPHTH VIS SCI, V41, P4268
   O'Doherty M, 2008, BRIT J OPHTHALMOL, V92, P1581, DOI 10.1136/bjo.2008.144550
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Parravano M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub2
   Parrilla-Reverter G, 2009, EXP EYE RES, V89, P32, DOI 10.1016/j.exer.2009.02.015
   Pease ME, 2009, INVEST OPHTH VIS SCI, V50, P2194, DOI 10.1167/iovs.08-3013
   Pitchford SC, 2009, CELL STEM CELL, V4, P62, DOI 10.1016/j.stem.2008.10.017
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Rosenbeck LL, 2010, ANN PHARMACOTHER, V44, P107, DOI 10.1345/aph.1M289
   Schmeer C, 2002, EUR J NEUROSCI, V15, P637, DOI 10.1046/j.1460-9568.2002.01893.x
   Selles-Navarro I, 2001, EXP NEUROL, V167, P282, DOI 10.1006/exnr.2000.7573
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Singhal S, 2010, EXP EYE RES, V90, P308, DOI 10.1016/j.exer.2009.11.008
   Singhal S, 2008, STEM CELLS, V26, P1074, DOI 10.1634/stemcells.2007-0898
   Spits C, 2008, NAT BIOTECHNOL, V26, P1361, DOI 10.1038/nbt.1510
   Suzuki T, 2007, CELL TRANSPLANT, V16, P493, DOI 10.3727/000000007783464966
   Suzuki T, 2006, STEM CELLS, V24, P2406, DOI 10.1634/stemcells.2005-0587
   Swijnenburg RJ, 2005, CIRCULATION, V112, pI166, DOI 10.1161/CIRCULATIONAHA.104.525824
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TEMPLETON SK, BLIND BE CURED STEM
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Uteza Y, 1999, P NATL ACAD SCI USA, V96, P3126, DOI 10.1073/pnas.96.6.3126
   Van Adel BA, 2003, HUM GENE THER, V14, P103, DOI 10.1089/104303403321070801
   Verdu E, 2001, NEUROREPORT, V12, P2303, DOI 10.1097/00001756-200108080-00005
   Wan J, 2008, VISION RES, V48, P223, DOI 10.1016/j.visres.2007.11.002
   Wang NL, 2002, CHINESE MED J-PEKING, V115, P1394
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   Wu MM, 2010, CELL TRANSPLANT, V19, P159, DOI 10.3727/096368910X492625
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu S, 2006, BIOCHEM BIOPH RES CO, V344, P1071, DOI 10.1016/j.bbrc.2006.03.231
   Zwart I, 2009, EXP NEUROL, V216, P439, DOI 10.1016/j.expneurol.2008.12.028
NR 103
TC 50
Z9 55
U1 0
U2 20
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2010
VL 45
IS 4
BP 333
EP 341
DI 10.3129/i10-077
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Ophthalmology
GA 645MI
UT WOS:000281463000004
PM 20648090
DA 2022-11-30
ER

PT J
AU Detrick, B
   Hooks, JJ
AF Detrick, Barbara
   Hooks, John J.
TI Immune regulation in the retina
SO IMMUNOLOGIC RESEARCH
LA English
DT Article
DE RPE; IFN-beta; AMD; Retina; ECOR
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; CYTOMEGALOVIRUS
   REPLICATION; RECEPTOR POLYMORPHISMS; MICROSOMAL PROTEIN;
   INTERFERON-GAMMA; EXPRESSION; GENE; BETA; AUTOANTIBODIES
AB Immune reactivity in the retina can be critically important in inflammation and infections, but regulation of this response is essential. The retinal pigment epithelial (RPE), a unique retinal cell, displays a number of essential functions to support the health of the retina. In this review, we highlight how the RPE cell plays a pivotal role in immune defense. The RPE cell orchestrates both innate and adaptive immunity since it expresses TLRs, complement components, MHC class I and II molecules, and serves as an antigen presenting cell. Moreover, both of these immune responses result in the production of a plethora of cytokines, mainly proinflammatory. In order to counteract these inflammatory factors and silence unwanted immune reactivity, the RPE cell also generates suppressive molecules. Recently, chronic immune reactivity has been implicated in a number of retinal diseases, such as age-related macular degeneration (AMD). Current evidence suggests that the generation of excessive retinal inflammation may be the consequence of a loss of RPE immunosuppressive factors. Herein, we summarize the varied interactions of the RPE cell with the immune response and highlight how the RPE cell survives and participates in this dynamic environment.
C1 [Detrick, Barbara] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Hooks, John J.] NEI, Immunol & Virol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Detrick, B (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
EM bdetrick@jhmi.edu; HooksJ@NEI.NIH.gov
FU NIDA NIH HHS [R01 DA012777, R01 DA025524] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [ZIAEY000233] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DRUG ABUSE [R01DA025524, R01DA012777] Funding
   Source: NIH RePORTER
CR Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   BOK D, 1993, J CELL SCI, P189
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CHAN CC, 1986, ARCH OPHTHALMOL-CHIC, V104, P725
   Chin MS, 2006, J AUTOIMMUN, V27, P17, DOI 10.1016/j.jaut.2006.04.002
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Detrick B, 2001, INVEST OPHTH VIS SCI, V42, P163
   Detrick B, 1996, INVEST OPHTH VIS SCI, V37, P814
   DETRICK B, 1986, AM J OPHTHALMOL, V101, P584, DOI 10.1016/0002-9394(86)90949-9
   Detrick B, 2008, J NEUROIMMUNOL, V193, P28, DOI 10.1016/j.jneuroim.2007.09.032
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Forrester JV, 2008, MUCOSAL IMMUNOL, V1, P372, DOI 10.1038/mi.2008.27
   Gurfein BT, 2009, J IMMUNOL, V183, P4229, DOI 10.4049/jimmunol.0900622
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406
   HAMEL CP, 1990, EXP EYE RES, V50, P173, DOI 10.1016/0014-4835(90)90228-M
   HOOKS JJ, 1979, NEW ENGL J MED, V301, P5, DOI 10.1056/NEJM197907053010102
   Hooks JJ, 2003, INVEST OPHTH VIS SCI, V44, P3402, DOI 10.1167/iovs.02-1106
   HOOKS JJ, 1993, J IMMUNOL, V151, P3381
   HOOKS JJ, 1988, INVEST OPHTH VIS SCI, V29, P1444
   HOOKS JJ, 1989, INVEST OPHTH VIS SCI, V30, P2106
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Hooks JJ, 2006, MICROBES INFECT, V8, P2236, DOI 10.1016/j.micinf.2006.04.010
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Komurasaki Y, 1996, VIROLOGY, V222, P446, DOI 10.1006/viro.1996.0442
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lee MT, 2007, CLIN EXP IMMUNOL, V147, P71, DOI 10.1111/j.1365-2249.2006.03253.x
   Lutty G, 1999, MOL VIS, V5
   MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58
   Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088
   Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839
   Nagineni CN, 2010, BIOCHEM BIOPH RES CO, V391, P287, DOI 10.1016/j.bbrc.2009.11.051
   Nagineni CN, 2000, INFECT IMMUN, V68, P407, DOI 10.1128/IAI.68.1.407-410.2000
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   PERCOPO CM, 1990, J IMMUNOL, V145, P4101
   ROBBINS SG, 1992, INVEST OPHTH VIS SCI, V33, P60
   ROBBINS SG, 1991, INVEST OPHTH VIS SCI, V32, P1883
   ROBBINS SG, 1990, LAB INVEST, V62, P417
   Sabroe I, 2008, J PATHOL, V214, P126, DOI 10.1002/path.2264
   Stanley AV, 2001, J NEUROIMMUNOL, V119, P175, DOI 10.1016/S0165-5728(01)00374-5
   Sugita S, 2009, ARCH IMMUNOL THER EX, V57, P263, DOI 10.1007/s00005-009-0030-0
   Wang Y, 1996, INVEST OPHTH VIS SCI, V37, P250
   Wang Y, 2000, INVEST OPHTH VIS SCI, V41, P3011
   WANG Y, 1993, VIROLOGY, V193, P124, DOI 10.1006/viro.1993.1109
   WETZIG R, 1988, CURR EYE RES, V7, P809, DOI 10.3109/02713688809033212
NR 49
TC 79
Z9 81
U1 0
U2 7
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0257-277X
EI 1559-0755
J9 IMMUNOL RES
JI Immunol. Res.
PD JUL
PY 2010
VL 47
IS 1-3
SI SI
BP 153
EP 161
DI 10.1007/s12026-009-8146-1
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 614UB
UT WOS:000279084200014
PM 20082152
OA Green Published
DA 2022-11-30
ER

PT J
AU Knupp, C
   Pinali, C
   Munro, PM
   Gruber, HE
   Sherratt, MJ
   Baldock, C
   Squire, JM
AF Knupp, Carlo
   Pinali, Christian
   Munro, Peter M.
   Gruber, Helen E.
   Sherratt, Michael J.
   Baldock, Clair
   Squire, John M.
TI Structural correlation between collagen VI microfibrils and collagen VI
   banded aggregates
SO JOURNAL OF STRUCTURAL BIOLOGY
LA English
DT Article
DE type VI collagen; beaded filaments; network-forming collagen; long
   spacing collagen; Luse bodies; age-related macular degeneration;
   Sorsby's fundus dystrophy; intervertebral disc
ID SORSBYS-FUNDUS-DYSTROPHY; TISSUE INHIBITOR; METALLOPROTEINASES-3 TIMP3;
   ASSEMBLIES; ATTACHMENT; MUTATION
AB Collagen VI is a component of the extracellular matrix that is able to form structural links with cells. Collagen VI monomers cross-link into tetramers that come together to form long molecular chains known as microfibrils. Collagen VI tetramers are also the most likely candidates for the formation of banded aggregates with an axial periodicity of about 105 nm that are seen in the retinas of people suffering from age-related macular degeneration and Sorsby's fundus dystrophy, in the vitreous of patients with full thickness macular holes and in the intervertebral discs of normal individuals. Here, a protocol is developed to carry out a structural comparison between the microfibrils, which are known to be made of collagen VI tetramers, and the banded aggregates. The comparison shows that the banded aggregates are easily explained as being a lateral assembly of microfibrils, thus supporting the hypothesis that they too are made of collagen VI. Understanding the role played by the collagen VI aggregates in normal and pathological conditions will help to throw light on the pathologies with which they are associated. (c) 2006 Published by Elsevier Inc.
C1 Cardiff Univ, Sch Optometry & Vis Sci, Struct Biophys Grp, Cardiff CF10 3NB, S Glam, Wales.
   Univ London Imperial Coll Sci Technol & Med, Biol Struct & Funct Sect, Biomed Sci Div, London SW7 2AZ, England.
   UCL, Inst Ophthalmol, Imaging Unit, London EC1V 9EL, England.
   Carolinas Med Ctr, Dept Orthoped Surg, Charlotte, NC 28203 USA.
   Univ Manchester, Fac Med & Human Sci, Div Lab & Regenerat Med, Manchester M13 9PT, Lancs, England.
   Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
C3 Cardiff University; Imperial College London; University of London;
   University College London; Carolinas Medical Center; University of
   Manchester; University of Manchester
RP Knupp, C (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Struct Biophys Grp, Redwood Bldg, Cardiff CF10 3NB, S Glam, Wales.
EM c.knupp@ic.ac.uk
RI Sherratt, Michael J/A-1175-2015
OI Sherratt, Michael J/0000-0003-4759-6617; Baldock,
   Clair/0000-0003-3497-1959; Squire, John/0000-0001-5731-253X; Squire,
   John/0000-0001-6656-7390; Pinali, Christian/0000-0001-9815-6940
FU Wellcome Trust [14480, 0389048] Funding Source: Medline
CR Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100
   AUMAILLEY M, 1989, EXP CELL RES, V181, P463, DOI 10.1016/0014-4827(89)90103-1
   Ayad S, 1994, EXTRACELLULAR MATRIX
   Baldock C, 2003, J MOL BIOL, V330, P297, DOI 10.1016/S0022-2836(03)00585-0
   Bertini Enrico, 2002, Eur J Paediatr Neurol, V6, P193, DOI 10.1053/ejpn.2002.0593
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303
   Gruber HE, 2002, SPINE, V27, P798, DOI 10.1097/00007632-200204150-00004
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979
   Kielty CM, 1997, MICROSC RES TECHNIQ, V38, P413, DOI 10.1002/(SICI)1097-0029(19970815)38:4<413::AID-JEMT9>3.0.CO;2-J
   KIELTY CM, 1992, J CELL SCI, V103, P445
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   Knupp C, 2001, EMBO J, V20, P372, DOI 10.1093/emboj/20.3.372
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   KNUPP C, 2005, REV COILED COILS COL
   KOCSIS E, 1991, J STRUCT BIOL, V107, P6, DOI 10.1016/1047-8477(91)90025-R
   KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x
   Lampe AK, 2005, J MED GENET, V42, P673, DOI 10.1136/jmg.2002.002311
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   LUTHER PK, 1988, ULTRAMICROSCOPY, V24, P7, DOI 10.1016/0304-3991(88)90322-1
   Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3
   Schneider SW, 1998, PFLUG ARCH EUR J PHY, V435, P362, DOI 10.1007/s004240050524
   Sherratt MJ, 2004, BIOPHYS J, V86, P3211, DOI 10.1016/S0006-3495(04)74369-6
   Ueda J, 2003, INVEST OPHTH VIS SCI, V44, P4772, DOI 10.1167/iovs.02-1002
   VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200
NR 30
TC 24
Z9 25
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1047-8477
EI 1095-8657
J9 J STRUCT BIOL
JI J. Struct. Biol.
PD JUN
PY 2006
VL 154
IS 3
BP 312
EP 326
DI 10.1016/j.jsb.2006.03.023
PG 15
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 050RF
UT WOS:000238104900011
PM 16713302
DA 2022-11-30
ER

PT J
AU Phillips, JD
   Hwang, ES
   Morgan, DJ
   Creveling, CJ
   Coats, B
AF Phillips, Joseph D.
   Hwang, Eileen S.
   Morgan, Denise J.
   Creveling, Christopher J.
   Coats, Brittany
TI Structure and mechanics of the vitreoretinal interface
SO JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS
LA English
DT Article
DE Vitreous; Retina; Vitreoretinal adhesion; Vitreoretinal mechanics;
   Posterior vitreous detachment
ID AGE-RELATED-CHANGES; ENDOTHELIAL GROWTH-FACTOR; RETINAL ADHESIVE FORCE;
   COLLAGEN TYPE-II; VITREOUS BODY; BASEMENT-MEMBRANE; VITREOMACULAR
   ADHESION; MACULAR DEGENERATION; EPITHELIAL ADHESION; LIMITING MEMBRANE
AB Vitreoretinal mechanics plays an important role in retinal trauma and many sight-threatening diseases. In age -related pathologies, such as posterior vitreous detachment and vitreomacular traction, lingering vitreoretinal adhesions can lead to macular holes, epiretinal membranes, retinal tears and detachment. In age-related macular degeneration, vitreoretinal traction has been implicated in the acceleration of the disease due to the stimulation of vascular growth factors. Despite this strong mechanobiological influence on trauma and disease in the eye, fundamental understanding of the mechanics at the vitreoretinal interface is limited. Clarification of adhesion mechanisms and the role of vitreoretinal mechanics in healthy eyes and disease is necessary to develop inno-vative treatments for these pathologies. In this review, we evaluate the existing literature on the structure and function of the vitreoretinal interface to gain insight into age-and region-dependent mechanisms of vitreoretinal adhesion. We explore the role of vitreoretinal adhesion in ocular pathologies to identify knowledge gaps and future research areas. Finally, we recommend future mechanics-based studies to address the critical needs in the field, increase fundamental understanding of vitreoretinal mechanisms and disease, and inform disease treatments.
C1 [Phillips, Joseph D.; Creveling, Christopher J.; Coats, Brittany] Univ Utah, Dept Mech Engn, Salt Lake City, UT USA.
   [Hwang, Eileen S.; Morgan, Denise J.] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Coats, Brittany] Univ Utah, Dept Mech Engn, 1495 100 S, Salt Lake City, UT 84112 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah
RP Coats, B (通讯作者)，Univ Utah, Dept Mech Engn, 1495 100 S, Salt Lake City, UT 84112 USA.
EM brittany.coats@utah.edu
OI Phillips, Joseph/0000-0001-6900-5246
FU National Eye Institute of the US National Institutes of Health
   [EY025813]; National Institutes of Health Core Grant [EY014800];
   Research to Prevent Blindness; Alsam Foundation; Knights Templar Eye
   Foundation
FX Research reported in this review was supported by the National Eye
   Institute of the US National Institutes of Health under award number
   EY025813. The authors would like to acknowledge the Utah Lions Eye Bank
   for human tissue donation and the Dr. Kurt Albertine Lab for sheep eye
   donation. Electron microscopy was performed by C.J. Creveling at the
   University of Utah Electron Microscopy Core Laboratory. Financial
   support for authors E. Hwang and D. Morgan during generation of this
   review article include the National Institutes of Health Core Grant
   (EY014800) , an unrestricted grant from Research to Prevent Blindness,
   the Alsam Foundation, and the Knights Templar Eye Foundation. The
   content is solely the responsibility of the authors and does not
   neces-sarily represent the official views of these supporting
   organizations.
CR Aermes C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70428-w
   BALAZS E A, 1973, International Ophthalmology Clinics, V13, P169, DOI 10.1097/00004397-197301330-00014
   Balazs E.A., 1982, AGING HUMAN VISUAL F, P45
   Balazs E.A., 1984, EYE, P533
   BALAZS EA, 1959, J BIOL CHEM, V234, P422
   Bhardwaj R, 2014, BIOMECH MODEL MECHAN, V13, P123, DOI 10.1007/s10237-013-0490-3
   Bishop P, 1996, EYE, V10, P664, DOI 10.1038/eye.1996.159
   Bishop PN, 1999, INVEST OPHTH VIS SCI, V40, P2173
   BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497
   Bishop PN, 2004, INVEST OPHTH VIS SCI, V45, P1041, DOI 10.1167/iovs.03-1017
   BISHOP PN, 1994, BIOCHEM BIOPH RES CO, V203, P289, DOI 10.1006/bbrc.1994.2180
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Bonfiglio A, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0020-8
   Bottega WJ, 2013, MATH MED BIOL, V30, P287, DOI 10.1093/imammb/dqs024
   Bottos Juliana, 2012, J Ophthalmic Vis Res, V7, P148
   Bottos JM, 2012, CURR OPIN OPHTHALMOL, V23, P195, DOI 10.1097/ICU.0b013e328352404c
   Bu SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134325
   Candiello J, 2007, FEBS J, V274, P2897, DOI 10.1111/j.1742-4658.2007.05823.x
   Candiello J, 2010, MATRIX BIOL, V29, P402, DOI 10.1016/j.matbio.2010.03.004
   CHAN FL, 1993, CELL TISSUE RES, V273, P41, DOI 10.1007/BF00304610
   Chi C, 2013, J CELL PHYSIOL, V228, P925, DOI 10.1002/jcp.24268
   Colter J, 2015, J MECH BEHAV BIOMED, V41, P315, DOI 10.1016/j.jmbbm.2014.09.004
   COMPER WD, 1978, PHYSIOL REV, V58, P255, DOI 10.1152/physrev.1978.58.1.255
   Creveling CJ, 2022, EXP EYE RES, V223, DOI 10.1016/j.exer.2022.109189
   Creveling C.J., 2021, THESIS U UTAH SALT L
   Creveling CJ, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00153
   David T, 1998, PHYS MED BIOL, V43, P1385, DOI 10.1088/0031-9155/43/6/001
   Di Michele F, 2020, BIOMECH MODEL MECHAN, V19, P2627, DOI 10.1007/s10237-020-01360-1
   Durbeej M, 2010, CELL TISSUE RES, V339, P259, DOI 10.1007/s00441-009-0838-2
   Eagle Jr R.C., 2016, EYE PATHOLOGY ATLAS, VThird
   Elner SG, 1996, INVEST OPHTH VIS SCI, V37, P696
   ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584
   Errera MH, 2018, OPHTHALMOLOGY, V125, P701, DOI 10.1016/j.ophtha.2017.10.035
   Escoffery R F, 1976, Int Ophthalmol Clin, V16, P45, DOI 10.1097/00004397-197601610-00007
   Filas BA, 2014, INVEST OPHTH VIS SCI, V55, P55, DOI 10.1167/iovs.13-13026
   Foos R Y, 1973, Trans Am Acad Ophthalmol Otolaryngol, V77, pOP171
   FOOS RY, 1972, INVEST OPHTH VISUAL, V11, P801
   Furashova O, 2020, CLIN OPHTHALMOL, V14, P389, DOI 10.2147/OPTH.S240480
   Gandorfer A, 2005, CURR EYE RES, V30, P977, DOI 10.1080/02713680500320745
   Gandorfer A, 2002, BRIT J OPHTHALMOL, V86, P902, DOI 10.1136/bjo.86.8.902
   Gandorfer A, 2002, AM J OPHTHALMOL, V133, P156, DOI 10.1016/S0002-9394(01)01252-1
   Gandorfer A, 2001, BRIT J OPHTHALMOL, V85, P6, DOI 10.1136/bjo.85.1.6
   GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3
   GIPSON IK, 1992, ACTA OPHTHALMOL, V70, P13
   GLOOR BP, 1975, T OPHTHAL SOC UK, V95, P387
   GOLDBERG M, 1986, EUR J CELL BIOL, V42, P365
   GRIGNOLO A, 1952, AMA ARCH OPHTHALMOL, V47, P760
   Guidry C, 2003, INVEST OPHTH VIS SCI, V44, P1355, DOI 10.1167/iovs.02-0046
   Halfter W, 2008, EYE, V22, P1207, DOI 10.1038/eye.2008.19
   Halfter W, 2000, DEV BIOL, V220, P111, DOI 10.1006/dbio.2000.9649
   Harocopos GJ, 2004, INVEST OPHTH VIS SCI, V45, P77, DOI 10.1167/iovs.03-0820
   Heegaard S, 1997, ACTA OPHTHALMOL SCAN, V75, P7
   Herath SCB, 2017, SLAS TECHNOL, V22, P413, DOI 10.1177/2211068216680078
   HOGAN MJ, 1975, T OPHTHAL SOC UK, V95, P378
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Itakura H, 2013, JAMA OPHTHALMOL, V131, P1348, DOI 10.1001/jamaophthalmol.2013.4578
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   JERDAN JA, 1989, OPHTHALMOLOGY, V96, P801
   KITA M, 1992, INVEST OPHTH VIS SCI, V33, P1879
   KITA M, 1990, INVEST OPHTH VIS SCI, V31, P624
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506
   Koller EC, 2021, RETINA-J RET VIT DIS, V41, P1396, DOI 10.1097/IAE.0000000000003039
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krishnan R, 2015, RETINA-J RET VIT DIS, V35, P1750, DOI 10.1097/IAE.0000000000000714
   Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522
   Lakawicz JM, 2015, MATH MED BIOL, V32, P137, DOI 10.1093/imammb/dqt023
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   LEE B, 1992, BIORHEOLOGY, V29, P521
   LEE B, 1994, BIORHEOLOGY, V31, P339
   LEE B, 1994, BIORHEOLOGY, V31, P327
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindqvist N, 2010, INVEST OPHTH VIS SCI, V51, P1683, DOI 10.1167/iovs.09-4159
   Los LI, 2003, INVEST OPHTH VIS SCI, V44, P2828, DOI 10.1167/iovs.02-0588
   Ma J, 2005, MOL VIS, V11, P744
   MacDonald RB, 2015, J CELL BIOL, V210, P1075, DOI 10.1083/jcb.201503115
   MADIGAN MC, 1992, INVEST OPHTH VIS SCI, V33, P314
   MATSUMOTO B, 1984, INVEST OPHTH VIS SCI, V25, P71
   MAUMENEE AE, 1967, ARCH OPHTHALMOL-CHIC, V78, P151
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Nickerson CS, 2008, J BIOMECH, V41, P1840, DOI 10.1016/j.jbiomech.2008.04.015
   Noulas AV, 2002, BIOCHIMIE, V84, P295, DOI 10.1016/S0300-9084(02)01389-5
   Ockleford CD, 2013, PLACENTA, V34, P727, DOI 10.1016/j.placenta.2013.06.002
   Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059
   Patronas Marena, 2009, Int Ophthalmol Clin, V49, P133, DOI 10.1097/IIO.0b013e3181924b3e
   Ponsioen TL, 2008, INVEST OPHTH VIS SCI, V49, P4089, DOI 10.1167/iovs.07-1456
   Ponsioen TL, 2005, EXP EYE RES, V80, P643, DOI 10.1016/j.exer.2004.11.014
   Rangarajan N, 2009, J AAPOS, V13, P364, DOI 10.1016/j.jaapos.2008.11.006
   Repetto R, 2004, J FLUID MECH, V503, P1, DOI 10.1017/S0022112003007389
   Rossi T, 2011, INVEST OPHTH VIS SCI, V52, P3994, DOI 10.1167/iovs.10-6477
   RUOSLAHTI E, 1982, J INVEST DERMATOL, V79, pS65, DOI 10.1111/1523-1747.ep12545783
   RUSSELL SR, 1991, INVEST OPHTH VIS SCI, V32, P1986
   Sarthy V., 2001, PERSP VIS R
   Schulz A, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.56
   SEBAG J, 1989, INVEST OPHTH VIS SCI, V30, P1867
   SEBAG J, 1991, ARCH OPHTHALMOL-CHIC, V109, P966, DOI 10.1001/archopht.1991.01080070078039
   Sebag J, 1998, PROG POLYM SCI, V23, P415, DOI 10.1016/S0079-6700(97)00035-X
   SEBAG J, 1987, GRAEF ARCH CLIN EXP, V225, P89, DOI 10.1007/BF02160337
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   Shawky JH, 2015, DEV BIOL, V401, P152, DOI 10.1016/j.ydbio.2014.12.005
   Smith SM, 2012, EXP EYE RES, V98, P105, DOI 10.1016/j.exer.2010.08.003
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P226, DOI 10.1016/S0002-9394(01)01377-0
   Stirpe M, 1996, Eur J Ophthalmol, V6, P50
   Strasser S, 2007, BIOCHEM BIOPH RES CO, V354, P27, DOI 10.1016/j.bbrc.2006.12.114
   Sun YL, 2004, J BIOMECH, V37, P1665, DOI 10.1016/j.jbiomech.2004.02.028
   TERRANOVA VP, 1980, CELL, V22, P719, DOI 10.1016/0092-8674(80)90548-6
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Tolentino F.I., 1987, VITREOUS VITREORETIN
   Tram NK, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00199
   Tsukahara M, 2018, OPHTHALMOLOGY, V125, P1372, DOI 10.1016/j.ophtha.2018.02.039
   van der Rijt JAJ, 2006, MACROMOL BIOSCI, V6, P697, DOI 10.1002/mabi.200600063
   Wang J, 2003, INVEST OPHTH VIS SCI, V44, P1793, DOI 10.1167/iovs.02-0802
   Wenstrup RJ, 2004, J CELL BIOCHEM, V92, P113, DOI 10.1002/jcb.20024
   Wenstrup RJ, 2004, J BIOL CHEM, V279, P53331, DOI 10.1074/jbc.M409622200
   Yoshida M, 2014, J BIOMECH, V47, P3454, DOI 10.1016/j.jbiomech.2014.09.014
   Zagon IS, 2001, BRAIN RES, V900, P205, DOI 10.1016/S0006-8993(01)02296-X
   ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486
NR 118
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1751-6161
EI 1878-0180
J9 J MECH BEHAV BIOMED
JI J. Mech. Behav. Biomed. Mater.
PD OCT
PY 2022
VL 134
AR 105399
DI 10.1016/j.jmbbm.2022.105399
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 6A2UK
UT WOS:000880513800004
PM 35963021
DA 2022-11-30
ER

PT J
AU Mahmud, NM
   Paraoan, L
   Khaliddin, N
   Kamalden, TA
AF Mahmud, Nur Musfirah
   Paraoan, Luminita
   Khaliddin, Nurliza
   Kamalden, Tengku Ain
TI Thymoquinone in Ocular Neurodegeneration: Modulation of Pathological
   Mechanisms via Multiple Pathways
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE thymoquinone; neuroprotection; retinal pigment epithelium; oxidative
   stress; age-related macular degeneration
ID GLYCATION END-PRODUCTS; NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS;
   INDUCED ALZHEIMERS-DISEASE; PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS;
   RAT MODEL; NIGELLA-SATIVA; MACULAR DEGENERATION; ANTIINFLAMMATORY
   PROPERTIES
AB Thymoquinone is a naturally occurring compound and is the major component of Nigella sativa, also known as black seed or black cumin. For centuries thymoquinone has been used especially in the Middle East traditionally to treat wounds, asthma, allergies, fever, headache, cough, hypertension, and diabetes. Studies have suggested beneficial effects of thymoquinone to be attributed to its antioxidant, antibacterial, anti-oxidative stress, anti-inflammatory, and neuroprotective properties. Recently, there has been a surge of interest in thymoquinone as a treatment for neurodegeneration in the brain, such as that seen in Alzheimer's (AD) and Parkinson's diseases (PD). In vitro and in vivo studies on animal models of AD and PD suggest the main neuroprotective mechanisms are based on the anti-inflammatory and anti-oxidative properties of thymoquinone. Neurodegenerative conditions of the eye, such as Age-related Macular Degeneration (AMD) and glaucoma share at least in part similar mechanisms of neuronal cell death with those occurring in AD and PD. This review aims to summarize and critically analyze the evidence to date of the effects and potential neuroprotective actions of thymoquinone in the eye and ocular neurodegenerations.
C1 [Mahmud, Nur Musfirah; Khaliddin, Nurliza; Kamalden, Tengku Ain] Univ Malaya, UM Eye Res Ctr, Dept Ophthalmol, Kuala Lumpur, Malaysia.
   [Mahmud, Nur Musfirah; Paraoan, Luminita] Univ Liverpool, Inst Life Course & Med Sci, Dept Eye & Vis Sci, Liverpool, Merseyside, England.
C3 Universiti Malaya; University of Liverpool
RP Kamalden, TA (通讯作者)，Univ Malaya, UM Eye Res Ctr, Dept Ophthalmol, Kuala Lumpur, Malaysia.
EM taftkamalden@um.edu.my
RI KAMALDEN, TENGKU AIN FATHLUN TENGKU/B-9941-2010; KHALIDDIN,
   NURLIZA/AHE-2379-2022; MAHMUD, NUR MUSFIRAH/AFN-9157-2022
OI KAMALDEN, TENGKU AIN FATHLUN TENGKU/0000-0001-9810-5334; KHALIDDIN,
   NURLIZA/0000-0003-1167-5313; 
FU University of Malaya Research Grant (UMRG Program) - HTM (Wellness)
   [RP033-14HTM]; Alcon Research Institute Grant [IF011-2020]; High Impact
   Research Grant, Ministry of Higher Education, Malaysia
   [H-20001-00-E000059]; UMSC
FX This research was supported by University of Malaya Research Grant (UMRG
   Program) -HTM (Wellness) (Grant Number: RP033-14HTM), Alcon Research
   Institute Grant (IF011-2020), High Impact Research Grant, Ministry of
   Higher Education, Malaysia (Grant Number: H-20001-00-E000059), and UMSC
   CareFund 2021.
CR Abd El-Ghany RM, 2009, DRUG DISCOV THER, V3, P296
   Abulfadl YS, 2018, HUM EXP TOXICOL, V37, P1092, DOI 10.1177/0960327118755256
   Abulfadl YS, 2018, NEUROL RES, V40, P324, DOI 10.1080/01616412.2018.1441776
   Ahmad A, 2020, EXP LUNG RES, V46, P53, DOI 10.1080/01902148.2020.1726529
   Ahuja S, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0179-6
   Al Fayi M, 2020, J DRUG TARGET, V28, P913, DOI 10.1080/1061186X.2020.1722136
   Al-Majed AA, 2006, EUR J PHARMACOL, V543, P40, DOI 10.1016/j.ejphar.2006.05.046
   Alghamdi R.M., 2020, EUR J CELL SCI, V2, P20, DOI [10.34154/2020-EJCS-0201-20-26/euraass, DOI 10.34154/2020-EJCS-0201-20-26/EURAASS]
   Alhebshi AH, 2014, NEUROSCI LETT, V570, P126, DOI 10.1016/j.neulet.2013.09.049
   Alhebshi AH, 2013, BIOCHEM BIOPH RES CO, V433, P362, DOI 10.1016/j.bbrc.2012.11.139
   Alhibshi AH, 2019, BIOCHEM BIOPHYS REP, V17, P122, DOI 10.1016/j.bbrep.2018.12.005
   Ammar ESM, 2011, INT IMMUNOPHARMACOL, V11, P2232, DOI 10.1016/j.intimp.2011.10.013
   Angeles DC, 2016, ANN CLIN TRANSL NEUR, V3, P288, DOI 10.1002/acn3.282
   Ansar FHZ, 2020, INT J NANOMED, V15, P7703, DOI 10.2147/IJN.S262395
   Anwar S, 2014, INT J BIOL MACROMOL, V69, P476, DOI 10.1016/j.ijbiomac.2014.06.003
   Aoyama K, 2015, MOLECULES, V20, P8742, DOI 10.3390/molecules20058742
   ARAKI N, 1992, J BIOL CHEM, V267, P10211
   Ardah MT, 2019, NEUROCHEM INT, V128, P115, DOI 10.1016/j.neuint.2019.04.014
   Armutcu F., 2018, ELECT J GEN MED, V15, P1
   Ascaso FJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/432685
   Atteya M, 2019, FOLIA MORPHOL, V78, P773, DOI 10.5603/FM.a2019.0027
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Badary OA, 2003, DRUG CHEM TOXICOL, V26, P87, DOI 10.1081/DCT-120020404
   Baugh JM, 2009, J MOL BIOL, V386, P814, DOI 10.1016/j.jmb.2008.12.081
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benvidi A, 2018, INT J BIOL MACROMOL, V107, P2465, DOI 10.1016/j.ijbiomac.2017.10.135
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Bonfili L, 2008, FEBS J, V275, P5512, DOI 10.1111/j.1742-4658.2008.06696.x
   Boudiaf K, 2016, BIOCHEM PHARMACOL, V104, P62, DOI 10.1016/j.bcp.2016.01.006
   Bouhlel A, 2018, CLIN EXP PHARMACOL P, V45, P943, DOI 10.1111/1440-1681.12961
   Bouhlel A, 2017, BIOMED PHARMACOTHER, V94, P964, DOI 10.1016/j.biopha.2017.08.018
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Bourne RRA, 2020, INVEST OPHTH VIS SCI, V61
   Bradshaw PC, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030504
   Braidy N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019194
   Burton GJ, 2011, BEST PRACT RES CL OB, V25, P287, DOI 10.1016/j.bpobgyn.2010.10.016
   Calabrese V, 2006, ANTIOXID REDOX SIGN, V8, P1975, DOI 10.1089/ars.2006.8.1975
   Catanzaro M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00844
   Cecarini V, 2010, FEBS J, V277, P2128, DOI 10.1111/j.1742-4658.2010.07629.x
   CHAKRAVARTY N, 1993, ANN ALLERGY, V70, P237
   Charakidas A, 2005, EUR J OPHTHALMOL, V15, P213, DOI 10.1177/112067210501500206
   Chen YM, 2018, EXP THER MED, V15, P4987, DOI 10.3892/etm.2018.6072
   Cobourne-Duval MK, 2018, J NEUROIMMUNOL, V320, P87, DOI 10.1016/j.jneuroim.2018.04.018
   Cobourne-Duval MK, 2016, NEUROCHEM RES, V41, P3227, DOI 10.1007/s11064-016-2047-1
   Coenraads P J, 1975, Contact Dermatitis, V1, P377, DOI 10.1111/j.1600-0536.1975.tb05478.x
   Comitato A, 2014, INVEST OPHTH VIS SCI, V55, P3555, DOI 10.1167/iovs.14-13917
   Costello MJ, 2013, EXP EYE RES, V116, P141, DOI 10.1016/j.exer.2013.08.017
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Dalli T, 2018, BIOMED PHARMACOTHER, V99, P391, DOI 10.1016/j.biopha.2018.01.047
   Das UN, 2016, ARCH MED SCI, V12, P1142, DOI 10.5114/aoms.2016.61918
   Dera A, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13216
   Dera AA, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13366
   Dera AA, 2020, BIOFACTORS, V46, P292, DOI 10.1002/biof.1590
   Desai, 2015, J PHARM SCI RES, V7
   Dong JJ, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.615598
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ebrahimi SS, 2017, TOXICOL LETT, V276, P108, DOI 10.1016/j.toxlet.2017.05.018
   Eilken HM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01738-3
   El Gazzar MA, 2007, BBA-GEN SUBJECTS, V1770, P556, DOI 10.1016/j.bbagen.2007.01.002
   El-Shemi AG, 2018, PHARMACOLOGY, V101, P9, DOI 10.1159/000480018
   Elibol B, 2020, PHYTOMEDICINE, V79, DOI 10.1016/j.phymed.2020.153324
   Elibol B, 2019, PSYCHIAT CLIN PSYCH, V29, P379, DOI 10.1080/24750573.2019.1673945
   Fahmy HM, 2018, INT J PHARMACEUT, V548, P597, DOI 10.1016/j.ijpharm.2018.07.012
   Fattahl LIA, 2016, INT J STEM CELLS, V9, P230, DOI 10.15283/ijsc16021
   Feenstra Derrick J, 2013, J Clin Exp Ophthalmol, V4, P298
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Firdaus F, 2018, BIOMED PHARMACOTHER, V102, P1152, DOI 10.1016/j.biopha.2018.03.159
   Forrester JV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583687
   Fouad AA, 2015, ENVIRON TOXICOL PHAR, V40, P960, DOI 10.1016/j.etap.2015.09.010
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Goyal SN, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00656
   Gray JP, 2016, AM J PHYSIOL-ENDOC M, V310, pE394, DOI 10.1152/ajpendo.00250.2015
   Gurung RL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012124
   Hamdan AM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43568-x
   Hayat K, 2011, CURR EYE RES, V36, P591, DOI 10.3109/02713683.2011.573898
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P1447, DOI 10.1167/iovs.07-1361
   Ho MC, 2010, J CLIN GERONTOL GERI, V1, P17, DOI 10.1016/j.jcgg.2010.10.006
   Homayouni Mansour, 2009, J Ophthalmic Vis Res, V4, P105
   Hosseinian S, 2017, PHARMACOL REP, V69, P648, DOI 10.1016/j.pharep.2017.03.002
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hu X, 2019, J CELL BIOCHEM, V120, P4514, DOI 10.1002/jcb.27739
   Hussain Tarique, 2016, Oxid Med Cell Longev, V2016, P7432797
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Ismail N, 2017, BIOMED PHARMACOTHER, V95, P780, DOI 10.1016/j.biopha.2017.08.074
   Ismail N, 2017, CHEM-BIOL INTERACT, V275, P61, DOI 10.1016/j.cbi.2017.07.014
   Ismail N, 2013, CELL MOL NEUROBIOL, V33, P1159, DOI 10.1007/s10571-013-9982-z
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jadeja, 2021, OXIDATIVE STRESS INF
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalemci S, 2013, CLIN TER, V164, pE155, DOI 10.7417/CT.2013.1559
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Kassab R.B., 2017, J BASIC APPL SCI, V4, P160, DOI [10.1016/j.ejbas.2017.07.002, DOI 10.1016/J.EJBAS.2017.07.002]
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keyhanmanesh R, 2014, BIOIMPACTS, V4, P75, DOI 10.5681/bi.2014.006
   Khalfaoui T, 2010, J MOL HISTOL, V41, P143, DOI 10.1007/s10735-010-9271-9
   Khalife KH, 2007, FREE RADICAL RES, V41, P153, DOI 10.1080/10715760600978815
   Khan A, 2012, MOL CELL BIOCHEM, V369, P55, DOI 10.1007/s11010-012-1368-x
   Kim KY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.180
   Kocaturk T, 2018, TURK OFTALMOL DERG, V48, P281, DOI 10.4274/tjo.50146
   Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353
   Lingappan Krithika, 2018, Current Opinion in Toxicology, V7, P81, DOI 10.1016/j.cotox.2017.11.002
   Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812
   Losso JN, 2011, FOOD CHEM, V128, P55, DOI 10.1016/j.foodchem.2011.02.076
   Luevano-Contreras C, 2010, NUTRIENTS, V2, P1247, DOI 10.3390/nu2121247
   Mabrouk A, 2017, ACTA BIOL HUNG, V68, P248, DOI 10.1556/018.68.2017.3.2
   Mahmood, 2013, INT J SCI RES, V2, P25
   Mandrekar-Colucci S, 2010, CNS NEUROL DISORD-DR, V9, P156, DOI 10.2174/187152710791012071
   Mao MQ, 2020, EXP LUNG RES, V46, P297, DOI 10.1080/01902148.2020.1801895
   Michael J Morgan, 2011, Cell Research, V21, P103
   Mischley LK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9409363
   Nagi MN, 1999, BIOCHEM MOL BIOL INT, V47, P153
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Nickells RW, 1996, OPHTHALMIC GENET, V17, P145, DOI 10.3109/13816819609057889
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Ono Y, 1998, DIABETES RES CLIN PR, V41, P131, DOI 10.1016/S0168-8227(98)00074-6
   Osnes-Ringen O, 2016, ACTA OPHTHALMOL, V94, P514, DOI 10.1111/aos.13009
   Pan WW, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01765-3
   Pandey R., 2018, CURR PERSPECT MED AR, V1, P1
   Parlar A, 2020, TURK J SURG, V36, P96, DOI 10.5578/turkjsurg.4583
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Payne AJ, 2014, INT J MOL SCI, V15, P1865, DOI 10.3390/ijms15021865
   Picone P, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/780179
   Poorgholam P, 2018, AVICENNA J PHYTOMEDI, V8, P188
   Pop RM, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100921
   Qian L, 2008, IMMUNOL RES, V41, P155, DOI 10.1007/s12026-008-8018-0
   Radad K, 2009, PHYTOTHER RES, V23, P696, DOI 10.1002/ptr.2708
   Rani R, 2018, CHEM-BIOL INTERACT, V295, P119, DOI 10.1016/j.cbi.2018.02.006
   Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468
   Saez I, 2014, CURR GENOMICS, V15, P38, DOI 10.2174/138920291501140306113344
   Sahu I, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26427-0
   Sankaranarayanan C, 2011, CHEM-BIOL INTERACT, V190, P148, DOI 10.1016/j.cbi.2011.02.029
   Savran M, 2020, ANDROLOGIA, V52, DOI 10.1111/and.13623
   Sayed AAR, 2007, PHYTOTHER RES, V21, P898, DOI 10.1002/ptr.2177
   Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180
   Sedaghat R, 2014, IRAN J PHARM RES, V13, P227
   Selcuk CT, 2013, J BURN CARE RES, V34, pE274, DOI 10.1097/BCR.0b013e31827a2be1
   Sener U, 2016, RENAL FAILURE, V38, P117, DOI 10.3109/0886022X.2015.1103601
   Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158/1541-7786.MCR-07-2088
   Sharif U, 2019, J CELL MOL MED, V23, P405, DOI 10.1111/jcmm.13944
   Silachev DN, 2015, MOLECULES, V20, P14487, DOI 10.3390/molecules200814487
   Siriwattanasatorn M, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/6795383
   Stitt AW, 1997, AM J PATHOL, V150, P523
   Sun LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14015-6
   Tabeshpour J, 2020, NEUROCHEM RES, V45, P254, DOI 10.1007/s11064-019-02908-z
   Taka E, 2015, J NEUROIMMUNOL, V286, P5, DOI 10.1016/j.jneuroim.2015.06.011
   Takihara Y, 2015, P NATL ACAD SCI USA, V112, P10515, DOI 10.1073/pnas.1509879112
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Taysi S, 2015, CUTAN OCUL TOXICOL, V34, P101, DOI 10.3109/15569527.2014.910802
   Tian F, 2020, METABOLITES, V10, DOI 10.3390/metabo10010027
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Turkoz D, 2021, TURK J MED SCI, V51, P375, DOI 10.3906/sag-2006-147
   Ursini F, 2016, REDOX BIOL, V8, P205, DOI 10.1016/j.redox.2016.01.010
   Velagapudi R, 2017, MOL CELL BIOCHEM, V435, P149, DOI 10.1007/s11010-017-3064-3
   Velagapudi R, 2017, INT IMMUNOPHARMACOL, V48, P17, DOI 10.1016/j.intimp.2017.04.018
   VLASSARA H, 1994, LAB INVEST, V70, P138
   Vomund S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122772
   Wang AL, 2008, MOL VIS, V14, P644
   Wang DY, 2015, INFLAMMATION, V38, P2235, DOI 10.1007/s10753-015-0206-1
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang YN, 2015, INT IMMUNOPHARMACOL, V26, P169, DOI 10.1016/j.intimp.2015.03.013
   Woo CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075356
   Wu TH, 2002, INVEST OPHTH VIS SCI, V43, P2834
   Xiao WS, 2018, ANTIOXID REDOX SIGN, V28, P251, DOI 10.1089/ars.2017.7216
   Xiao XiaoYu, 2016, BioMed Research International, V2016, P2571060
   Xu JY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0829-y
   Yang LP, 2007, INVEST OPHTH VIS SCI, V48, P4766, DOI 10.1167/iovs.06-0871
   Yu MZ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070842
   Zafar H., 2013, ASIAN J AGR BIOL, V1, P187
   Zafrilla P, 2013, J NUTR HEALTH AGING, V17, P219, DOI 10.1007/s12603-012-0095-z
   Zaher MF, 2019, J PHARM RES INT, V31, DOI 10.9734/JPRI/2019/v31i630358
   Zalewska Renata, 2004, Klin Oczna, V106, P155
   Zeinvand-Lorestani H, 2018, PESTIC BIOCHEM PHYS, V148, P16, DOI 10.1016/j.pestbp.2018.03.006
   Zeng HY, 2008, MOL VIS, V14, P1075
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhang MZ, 2018, CHEM-BIOL INTERACT, V292, P65, DOI 10.1016/j.cbi.2018.06.013
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 183
TC 1
Z9 1
U1 6
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD MAR 2
PY 2022
VL 16
AR 786926
DI 10.3389/fncel.2022.786926
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA ZZ1BS
UT WOS:000773011400001
PM 35308121
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hoy, SM
AF Hoy, Sheridan M.
TI Pegcetacoplan: First Approval
SO DRUGS
LA English
DT Article
AB Pegcetacoplan (Empaveli (TM)) is a PEGylated pentadecapeptide developed by Apellis Pharmaceuticals for the treatment of complement-mediated diseases. It binds to complement component 3 (C3) and its activation fragment C3b, controlling the cleavage of C3 and the generation of the downstream effectors of complement activation and thus both C3b-mediated extravascular haemolysis and terminal complement-mediated intravascular haemolysis. Pegcetacoplan is the first C3-targeted paroxysmal nocturnal haemoglobinuria (PNH) therapy to be approved (in May 2021) in the USA, where it is indicated for the treatment of adults with PNH, including those switching from C5 inhibitor therapy with eculizumab and ravulizumab. A regulatory assessment of pegcetacoplan for the treatment of PNH is currently underway in the EU and Australia. Pegcetacoplan is also being investigated as a therapeutic option in other complement-mediated diseases, including age-related macular degeneration, C3 glomerulopathy and autoimmune haemolytic anaemia. The recommended dosage regimen of pegcetacoplan is 1080 mg twice weekly, administered as a subcutaneous infusion via an infusion pump with a >= 20 mL reservoir. This article summarizes the milestones in the development of pegcetacoplan leading to this first approval for the treatment of adults with PNH.
C1 [Hoy, Sheridan M.] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
RP Hoy, SM (通讯作者)，Springer Nat, Private Bag 65901, Auckland 0754, New Zealand.
EM dru@adis.com
CR Apellis Pharmaceuticals, SECURITIES EXCHANGE
   Apellis Pharmaceuticals, EMPAVELI PEGC INJ SU, P2021
   El Mehdi D, 2019, J AM SOC NEPHROL, V30, P918
   European Medicines Agency, 2019, PUBL SUMM OP ORPH DE
   Gertz M, 2019, BRIT J HAEMATOL, V185, P24
   Hill A, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.28
   Hillmen P, 2021, NEW ENGL J MED, V384, P1028, DOI 10.1056/NEJMoa2029073
   Huang L., 2020, J AM SOC NEPHROL, V31, P577
   Inoue N, 2006, BLOOD, V108, P4232, DOI 10.1182/blood-2006-05-025148
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Risitano AM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01157
   US Library of Medicine, GENETICS HOME REFERE, P2021
   Wykoff CC, 2021, OPHTHALMOLOGY, V128, P1325, DOI 10.1016/j.ophtha.2021.02.025
NR 13
TC 11
Z9 11
U1 3
U2 9
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD AUG
PY 2021
VL 81
IS 12
BP 1423
EP 1430
DI 10.1007/s40265-021-01560-8
EA AUG 2021
PG 8
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA TX8HL
UT WOS:000680823000001
PM 34342834
DA 2022-11-30
ER

PT J
AU Bernstein, PS
   Arunkumar, R
AF Bernstein, Paul S.
   Arunkumar, Ranganathan
TI The emerging roles of the macular pigment carotenoids throughout the
   lifespan and in prenatal supplementation
SO JOURNAL OF LIPID RESEARCH
LA English
DT Review
DE age-related macular degeneration; antioxidant; lutein; meso-zeaxanthin;
   nutrition; ocular health; zeaxanthin; ocular development; retina
ID MESO-ZEAXANTHIN; OPTICAL-DENSITY; BINDING PROTEIN; VITAMIN-C; LUTEIN;
   DEGENERATION; IDENTIFICATION; DISEASE
AB Since the publication of the Age-Related Eye Disease Study 2 (AREDS2) in 2013, the macular pigment carotenoids lutein (L) and zeaxanthin (Z) have become well known to both the eye care community and the public. It is a fascinating aspect of evolution that primates have repurposed photo-protective pigments and binding proteins from plants and insects to protect and enhance visual acuity. Moreover, utilization of these plant-derived nutrients has been widely embraced for preventing vision loss from age-related macular degeneration. More recently, there has been growing awareness that these nutrients can also play a role in improving visual performance in adults. On the other hand, the potential benefits of L and Z supplementation at very young ages have been underappreciated. In this review, we examine the biochemical mechanisms and supportive data for L and Z supplementation throughout the lifespan, with particular emphasis on prenatal supplementation. We propose that prenatal nutritional recommendations may aim at improving maternal and infant carotenoid status. Prenatal supplementation with L and Z might enhance infant visual development and performance and may even prevent retinopathy of prematurity, possibilities that should be examined in future clinical studies.
C1 [Bernstein, Paul S.; Arunkumar, Ranganathan] Univ Utah, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Sch Med, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Sch Med, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
OI Bernstein, Paul/0000-0002-4228-7666
FU National Institutes of Health [EY29857, EY11600, EY14800]; Research to
   Prevent Blindness
FX This work was supported by National Institutes of Health Grants EY29857,
   EY11600, and EY14800 and an unrestricted departmental grant from
   Research to Prevent Blindness. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Institutes of Health.
CR ABADI RV, 1992, INVEST OPHTH VIS SCI, V33, P494
   Akuffo KO, 2017, BRIT J OPHTHALMOL, V101, P190, DOI 10.1136/bjophthalmol-2016-308418
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Arunkumar R, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158617
   Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 2013, INVEST OPHTH VIS SCI, V54, P4034, DOI 10.1167/iovs.13-11891
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2007, BIOCHEMISTRY-US, V46, P9050, DOI 10.1021/bi700558f
   Bohn T, 2008, CURR NUTR FOOD SCI, V4, P240, DOI 10.2174/157340108786263685
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Buscemi S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091321
   Chan GM, 2013, J PEDIATR GASTR NUTR, V56, P556, DOI 10.1097/MPG.0b013e318282a8fe
   Chew EY, 2019, OPHTHALMOLOGY, V126, P540, DOI 10.1016/j.ophtha.2018.09.041
   Chew EY, 2015, AM J OPHTHALMOL, V159, P659, DOI 10.1016/j.ajo.2014.12.013
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choi RY, 2017, RETINA-J RET VIT DIS, V37, P2238, DOI 10.1097/IAE.0000000000001450
   Choi RY, 2016, JAMA OPHTHALMOL, V134, P1445, DOI 10.1001/jamaophthalmol.2016.4117
   Connor SL, 2008, FASEB J, V22
   Cota F, 2022, J MATERN-FETAL NEO M, V35, P175, DOI 10.1080/14767058.2020.1712700
   Crosby-Nwaobi R, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S102798
   Gantner ML, 2019, NEW ENGL J MED, V381, P1422, DOI 10.1056/NEJMoa1815111
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Giordano E, 2018, ARCH BIOCHEM BIOPHYS, V647, P33, DOI 10.1016/j.abb.2018.04.008
   Gorusupudi A, 2016, INVEST OPHTH VIS SCI, V57, P1853, DOI 10.1167/iovs.16-19111
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Harvey PS, 2006, J AAPOS, V10, P237, DOI 10.1016/j.jaapos.2006.01.008
   Helb HM, 2008, RETINA-J RET VIT DIS, V28, P808, DOI 10.1097/IAE.0b013e31816d81aa
   Henriksen BS, 2013, INVEST OPHTH VIS SCI, V54, P5568, DOI 10.1167/iovs.13-12331
   Holz FG, 2010, ESSENT OPHTHALMOL, P1, DOI 10.1007/978-3-540-85540-8
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Li BX, 2018, ARCH BIOCHEM BIOPHYS, V649, P22, DOI 10.1016/j.abb.2018.05.003
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   McCorkle SM, 2015, FOODS, V4, P594, DOI 10.3390/foods4040594
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Muller S, 2018, AM J OPHTHALMOL, V194, P163, DOI 10.1016/j.ajo.2018.07.017
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Ronquillo CC, 2018, JAMA OPHTHALMOL, V136, P1158, DOI 10.1001/jamaophthalmol.2018.3283
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sasano H, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.3
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Shyam R, 2017, ARCH BIOCHEM BIOPHYS, V634, P21, DOI 10.1016/j.abb.2017.09.013
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Stringham JM, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0060-8
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Vachali PP, 2013, ARCH BIOCHEM BIOPHYS, V539, P181, DOI 10.1016/j.abb.2013.07.008
   Widomska J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051333
   Wolfson Y, 2016, EXP EYE RES, V145, P468, DOI 10.1016/j.exer.2015.10.006
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Zeimer MB, 2010, RETINA-J RET VIT DIS, V30, P1282, DOI 10.1097/IAE.0b013e3181e096dd
NR 66
TC 11
Z9 11
U1 3
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PY 2021
VL 62
AR 100038
DI 10.1194/jlr.TR120000956
EA FEB 2021
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SD5OP
UT WOS:000651423500001
PM 32709621
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Fleissig, E
   Apenbrinck, E
   Zhang, X
   Barr, CC
AF Fleissig, Efrat
   Apenbrinck, Eddie
   Zhang, Xiang
   Barr, Charles C.
TI Vitamin Analysis Comparison Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION
AB PURPOSE: We compared and analyzed the concentra-tions of vitamin C, vitamin E, zinc, and copper in both na-tional and regional brands of dietary supplements recommended for patients who are at risk for macular degeneration.
   DESIGN: Prospective cross-sectional study.
   METHODS: National brand name and generic multivi-tamin formulations for age-related macular degeneration were obtained. Comparative analysis of the vitamin C and vitamin E content was performed by gas chromatography-mass spectrometry and the zinc and copper content was analyzed by atomic absorption spectros-copy in an institutional chemistry laboratory.
   RESULTS: All national brand name vitamins, both tablet and gel capsule formulations, and generic brands in tablet form were relatively accurate in their product labeling. For most of the samples tested, the measured quantities of vitamin C, vitamin E, zinc, and copper were slightly higher than labeled but not to an amount that would cause any systemic toxicity if taken at the recommended dosages.
   CONCLUSIONS: Physicians may recommend national brand name vitamins and generic brands in tablet form to their patients with some confidence; however, the content may have some inaccuracies regarding labeling. (Am J Ophthalmol 2021;222:202-205. (c) 2020 Elsevier Inc. All rights reserved.)
C1 [Fleissig, Efrat; Apenbrinck, Eddie; Barr, Charles C.] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA.
   [Fleissig, Efrat] Tel Aviv Univ, Dept Ophthalmol, Tel Aviv Med Ctr, Sackler Fac Med, Tel Aviv, Israel.
   [Zhang, Xiang] Univ Louisville, Dept Chem, Louisville, KY 40202 USA.
C3 University of Louisville; Tel Aviv University; Sackler Faculty of
   Medicine; University of Louisville
RP Barr, CC (通讯作者)，Univ Louisville, Dept Ophthalmol & Visual Sci, Sch Med, 301 E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM ccbarr01@louisville.edu
FU Research to Prevent Blindness
FX Supported by an unrestricted grant from Research to Prevent Blindness.
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P279, DOI 10.1081/CLT-100102426
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Harel Z, 2013, JAMA INTERN MED, V173, P926, DOI 10.1001/jamainternmed.2013.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Miller RK, 2008, FOOD DRUG LAW J, V63, P929
   Paolo MS, 2018, HARRISONS PRINCIPLES, V20th, P2309
   United States Government Accountability Office, DIETARY SUPPLEMENTS
NR 10
TC 1
Z9 1
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2021
VL 222
BP 202
EP 205
DI 10.1016/j.ajo.2020.08.028
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QR8QU
UT WOS:000625478500023
PM 32828875
DA 2022-11-30
ER

PT J
AU Klipfel, L
   Cordonnier, M
   Thiebault, L
   Clerin, E
   Blond, F
   Millet-Puel, G
   Mohand-Said, S
   Goureau, O
   Sahel, JA
   Nandrot, EF
   Leveillard, T
AF Klipfel, Laurence
   Cordonnier, Marie
   Thiebault, Lea
   Clerin, Emmanuelle
   Blond, Frederic
   Millet-Puel, Geraldine
   Mohand-Said, Saddek
   Goureau, Olivier
   Sahel, Jose-Alain
   Nandrot, Emeline F.
   Leveillard, Thierry
TI A Splice Variant in SLC16A8 Gene Leads to Lactate Transport Deficit in
   Human iPS Cell-Derived Retinal Pigment Epithelial Cells
SO CELLS
LA English
DT Article
DE retinal pigment epithelium; lactate transport; induced pluripotent stem
   cells; splicing; MCT3; age-related macular degeneration
ID COMPLEMENT FACTOR-H; FOVEOMACULAR VITELLIFORM DYSTROPHY; MACULAR
   DEGENERATION; MONOCARBOXYLATE TRANSPORTERS; SUSCEPTIBILITY;
   POLYMORPHISM; METABOLISM; INCREASES; RISK
AB Age-related macular degeneration (AMD) is a blinding disease for which most of the patients remain untreatable. Since the disease affects the macula at the center of the retina, a structure specific to the primate lineage, rodent models to study the pathophysiology of AMD and to develop therapies are very limited. Consequently, our understanding relies mostly on genetic studies highlighting risk alleles at many loci. We are studying the possible implication of a metabolic imbalance associated with risk alleles within the SLC16A8 gene that encodes for a retinal pigment epithelium (RPE)-specific lactate transporter MCT3 and its consequences for vision. As a first approach, we report here the deficit in transepithelial lactate transport of a rare SLC16A8 allele identified during a genome-wide association study. We produced induced pluripotent stem cells (iPSCs) from the unique patient in our cohort that carries two copies of this allele. After in vitro differentiation of the iPSCs into RPE cells and their characterization, we demonstrate that the rare allele results in the retention of intron 2 of the SLC16A8 gene leading to the absence of MCT3 protein. We show using a biochemical assay that these cells have a deficit in transepithelial lactate transport.
C1 [Klipfel, Laurence; Cordonnier, Marie; Thiebault, Lea; Clerin, Emmanuelle; Blond, Frederic; Millet-Puel, Geraldine; Goureau, Olivier; Sahel, Jose-Alain; Nandrot, Emeline F.; Leveillard, Thierry] Sorbonne Univ, Inst Vis, INSERM, CNRS, 17 Rue Moreau, F-75012 Paris, France.
   [Mohand-Said, Saddek; Sahel, Jose-Alain] CHNO Quinze Vingts, INSERM, DGOS, CIC 1423, 28 Rue Charenton, F-75012 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite
RP Leveillard, T (通讯作者)，Sorbonne Univ, Inst Vis, INSERM, CNRS, 17 Rue Moreau, F-75012 Paris, France.
EM laurence.klipfel@inserm.fr; marie.cordonnier@hotmail.fr;
   lea.thiebault@inserm.fr; emmanuelle.clerin@inserm.fr;
   frederic.blond@inserm.fr; geraldine.millet-puel@inserm.fr;
   saddekms@gmail.com; olivier.goureau@inserm.fr; j.sahel@gmail.com;
   emeline.nandrot@inserm.fr; thierry.leveillard@inserm.fr
RI GOUREAU, Olivier/F-2752-2017; GOUREAU, Olivier/ABH-9547-2020;
   Léveillard, Thierry/AAR-1804-2020; Sahel, Jose-Alain/F-3172-2017
OI GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU,
   Olivier/0000-0001-7730-9143; Léveillard, Thierry/0000-0001-5692-8770;
   Sahel, Jose-Alain/0000-0002-4831-1153; Puel,
   Geraldine/0000-0003-2387-538X; Blond, Frederic/0000-0002-2314-0570;
   Nandrot, Emeline/0000-0003-3087-078X
FU SATT-LUTECH Convention de maturation [J15S568]; Inserm; Sorbonne
   Universite; Agence Nationale pour la Recherche (ANR, Labex Lifesenses);
   Foundation Fighting Blindness (USA); IHU FOReSIGHT by French state funds
   [ANR-18-IAHU-0001]
FX This research was funded by SATT-LUTECH Convention de maturation
   J15S568. This work was also supported by Inserm, Sorbonne Universite,
   the Agence Nationale pour la Recherche (ANR, Labex Lifesenses),
   Foundation Fighting Blindness (USA) and IHU FOReSIGHT [ANR-18-IAHU-0001]
   supported by French state funds managed by the ANR within the
   Investissements d'Avenir program.
CR Abramowicz A, 2019, J APPL GENET, V60, P231, DOI 10.1007/s13353-019-00493-z
   Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Adijanto J, 2012, CURR TOP MEMBR, V70, P275, DOI 10.1016/B978-0-12-394316-3.00009-0
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Baker KE, 2004, CURR OPIN CELL BIOL, V16, P293, DOI 10.1016/j.ceb.2004.03.003
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Blond F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194922
   Castorino JJ, 2011, TRAFFIC, V12, P483, DOI 10.1111/j.1600-0854.2010.01155.x
   Chowers I, 2015, PROG RETIN EYE RES, V47, P64, DOI 10.1016/j.preteyeres.2015.02.001
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Daniele LL, 2008, AM J PHYSIOL-CELL PH, V295, pC451, DOI 10.1152/ajpcell.00124.2008
   De Jong PTVM, 2018, EYE, V32, P904, DOI 10.1038/eye.2017.298
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572
   Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573
   Hyacinthe JN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62319-x
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Leveillard T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030762
   Leveillard T, 2017, CELL MOL LIFE SCI, V74, P3649, DOI 10.1007/s00018-016-2318-7
   Leveillard T, 2015, ONCOTARGET, V6, P32285, DOI 10.18632/oncotarget.5963
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Payen VL, 2020, MOL METAB, V33, P48, DOI 10.1016/j.molmet.2019.07.006
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   Philp NJ, 1998, AM J PHYSIOL-REG I, V274, pR1824, DOI 10.1152/ajpregu.1998.274.6.R1824
   Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Slembrouck-Brec A, 2018, JOVE-J VIS EXP, DOI 10.3791/57795
   Smith EN, 2019, STEM CELL REP, V12, P1342, DOI 10.1016/j.stemcr.2019.04.012
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Terray A, 2017, STEM CELL RES, V25, P26, DOI 10.1016/j.scr.2017.10.007
   Tiosano L, 2016, BRIT J OPHTHALMOL, V100, P1476, DOI 10.1136/bjophthalmol-2015-307658
   Warburg O., 1925, J CANC RES, V9, P148, DOI [10.1158/jcr.1925.148, DOI 10.1158/JCR.1925.148]
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 40
TC 4
Z9 4
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JAN
PY 2021
VL 10
IS 1
AR 179
DI 10.3390/cells10010179
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PV4VL
UT WOS:000609987100001
PM 33477551
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Puertas-Neyra, K
   Usategui-Martin, R
   Coco, RM
   Fernandez-Bueno, I
AF Puertas-Neyra, Kevin
   Usategui-Martin, Ricardo
   Coco, Rosa M.
   Fernandez-Bueno, Ivan
TI Intravitreal stem cell paracrine properties as a potential
   neuroprotective therapy for retinal photoreceptor neurodegenerative
   diseases
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE clinical trials; growth factors; intraocular injection; intravitreal
   injection; neuroprotection; paracrine properties; photoreceptors;
   preclinical models; retinal diseases; stem cells
ID OPTIC-NERVE DISEASES; OPHTHALMOLOGY TREATMENT; NEUROTROPHIC FACTORS;
   COCULTURE MODEL; RPE CELLS; TRANSPLANTATION; SCOTS; IMPROVEMENT;
   DEGENERATION; NEURORETINA
AB Retinal degenerations are the leading causes of irreversible visual loss worldwide. Many pathologies included under this umbrella involve progressive degeneration and ultimate loss of the photoreceptor cells, with age-related macular degeneration and inherited and ischemic retinal diseases the most relevant. These diseases greatly impact patients' daily lives, with accompanying marked social and economic consequences. However, the currently available treatments only delay the onset or slow progression of visual impairment, and there are no cures for these photoreceptor diseases. Therefore, new therapeutic strategies are being investigated, such as gene therapy, optogenetics, cell replacement, or cell-based neuroprotection. Specifically, stem cells can secrete neurotrophic, immunomodulatory, and anti-angiogenic factors that potentially protect and preserve retinal cells from neurodegeneration. Further, neuroprotection can be used in different types of retinal degenerative diseases and at different disease stages, unlike other potential therapies. This review summarizes stem cell-based paracrine neuroprotective strategies for photoreceptor degeneration, which are under study in clinical trials, and the latest preclinical studies. Effective retinal neuroprotection could be the next frontier in photoreceptor diseases, and the development of novel neuroprotective strategies will address the unmet therapeutic needs.
C1 [Puertas-Neyra, Kevin; Usategui-Martin, Ricardo; Coco, Rosa M.; Fernandez-Bueno, Ivan] Univ Valladolid, Inst Univ Oftalmobiol Aplicada, Valladolid, Spain.
   [Coco, Rosa M.; Fernandez-Bueno, Ivan] Ctr Red Med Regenerat & Terapia Celular Castilla, Valladolid, Spain.
   [Coco, Rosa M.; Fernandez-Bueno, Ivan] Inst Salud Carlos III, Red Temat Invest Cooperat Salud, Oftared, Valladolid, Spain.
C3 Universidad de Valladolid; Instituto de Salud Carlos III
RP Fernandez-Bueno, I (通讯作者)，Univ Valladolid, Inst Univ Oftalmobiol Aplicada, Valladolid, Spain.; Fernandez-Bueno, I (通讯作者)，Ctr Red Med Regenerat & Terapia Celular Castilla, Valladolid, Spain.; Fernandez-Bueno, I (通讯作者)，Inst Salud Carlos III, Red Temat Invest Cooperat Salud, Oftared, Valladolid, Spain.
EM ifernandezb@ioba.med.uva.es
RI Martin, Rosa Maria Coco/H-4511-2015; Neyra, Kevin Louis
   Puertas/AAS-3495-2021
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; Puertas Neyra, Kevin
   Louis/0000-0002-9641-4042
FU Fundacion Carolina, Madrid, Spain; Fondo Europeo de Desarrollo Regional;
   Fondo Social Europeo; Consejeria de Educacion, Junta de Castilla y Leon,
   Spain [VA077P17]; Centro en Red de Medicina Regenerativa y Terapia
   Celular, Junta de Castilla y Leon, Spain
FX KPN, RUM, and IFB were supported by Fundacion Carolina, Madrid, Spain;
   Fondo Europeo de Desarrollo Regional, Fondo Social Europeo, and
   Consejeria de Educacion (Grant VA077P17), Junta de Castilla y Leon,
   Spain; and Centro en Red de Medicina Regenerativa y Terapia Celular,
   Junta de Castilla y Leon, Spain, respectively.
CR Alonso-Alonso ML, 2015, WORLD J STEM CELLS, V7, P641, DOI 10.4252/wjsc.v7.i3.641
   Bachmann-Gagescu R, 2019, CURR OPIN GENET DEV, V56, P22, DOI 10.1016/j.gde.2019.05.004
   Berglund AK, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0742-8
   Birch DG, 2013, AM J OPHTHALMOL, V156, P283, DOI 10.1016/j.ajo.2013.03.021
   Carr AJ, 2009, MOL VIS, V15, P283
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cotrim CC, 2017, CLIN OPHTHALMOL, V11, P931, DOI 10.2147/OPTH.S133502
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Di Lauro S, 2016, MOL VIS, V22, P243
   Emre E, 2015, CYTOTHERAPY, V17, P543, DOI 10.1016/j.jcyt.2014.12.005
   Fernandez-Bueno I, 2012, EXP EYE RES, V104, P26, DOI 10.1016/j.exer.2012.08.012
   Gagliardi G, 2019, PROG RETIN EYE RES, V71, P1, DOI 10.1016/j.preteyeres.2019.03.001
   Gasparini SJ, 2019, PROG RETIN EYE RES, V69, P1, DOI 10.1016/j.preteyeres.2018.11.001
   Hill AJ, 2009, STEM CELLS DEV, V18, P399, DOI 10.1089/scd.2008.0084
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Johnson TV, 2009, EYE, V23, P1980, DOI 10.1038/eye.2008.376
   Johnson TV, 2011, EXPERT REV OPHTHALMO, V6, P165, DOI 10.1586/EOP.11.3
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Jones BW, 2012, SOURCEWEBVISION ORG
   Jones MK, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800213
   Kadlubowska J, 2016, CURR NEUROPHARMACOL, V14, P831, DOI 10.2174/1570159X14666160614095559
   Kolomeyer AM, 2014, SURV OPHTHALMOL, V59, P134, DOI 10.1016/j.survophthal.2013.09.004
   Kurokawa T, 1999, INVEST OPHTH VIS SCI, V40, P3006
   Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X
   Velandia SL, 2018, GRAEF ARCH CLIN EXP, V256, P125, DOI 10.1007/s00417-017-3842-3
   Labrador-Velandia S, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.05.011
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lejkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030777
   Levkovitch-Verbin H, 2010, INVEST OPHTH VIS SCI, V51, P6394, DOI 10.1167/iovs.09-4310
   Li JQ, 2019, OPHTHALMOLOGICA, V241, P183, DOI 10.1159/000494224
   Li N, 2009, GRAEF ARCH CLIN EXP, V247, P503, DOI 10.1007/s00417-008-1009-y
   Lin N, 2009, LIFE SCI, V85, P291, DOI 10.1016/j.lfs.2009.06.007
   Lo B, 2009, ENDOCR REV, V30, P204, DOI 10.1210/er.2008-0031
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Mellough CB, 2007, RESTOR NEUROL NEUROS, V25, P177
   Mollick T, 2016, BRAIN RES, V1646, P522, DOI 10.1016/j.brainres.2016.06.039
   Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Rodriguez-Crespo D, 2014, CELL TISSUE RES, V358, P705, DOI 10.1007/s00441-014-1987-5
   Sanchez I, 2011, GRAEF ARCH CLIN EXP, V249, P475, DOI 10.1007/s00417-011-1617-9
   Seo JH, 2012, YONSEI MED J, V53, P1059, DOI 10.3349/ymj.2012.53.6.1059
   Simunovic MP, 2019, EXP EYE RES, V178, P15, DOI 10.1016/j.exer.2018.09.003
   Siqueira RC, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0020-6
   Siqueira RC, 2015, ACTA OPHTHALMOL, V93, pE174, DOI 10.1111/aos.12473
   Takahata K, 2003, INVEST OPHTH VIS SCI, V44, P1760, DOI 10.1167/iovs.02-0471
   Terrell D, 2019, SEMIN OPHTHALMOL, V34, P287, DOI 10.1080/08820538.2019.1620808
   Trapani I, 2018, TRENDS MOL MED, V24, P669, DOI 10.1016/j.molmed.2018.06.006
   Vidal-Sanz M, 2001, EUR J OPHTHALMOL, V11, pS36, DOI 10.5301/EJO.2008.4056
   Vugler AA, 2010, RETINA-J RET VIT DIS, V30, P983, DOI 10.1097/IAE.0b013e3181e2a680
   Waldron PV, 2018, STEM CELL REP, V10, P406, DOI 10.1016/j.stemcr.2017.12.008
   Wang HC, 2010, VISION RES, V50, P665, DOI 10.1016/j.visres.2009.09.003
   Weiss Jeffrey N, 2019, Stem Cell Investig, V6, P31, DOI 10.21037/sci.2019.08.07
   Weiss Jeffrey N, 2019, Stem Cell Investig, V6, P8, DOI 10.21037/sci.2019.03.01
   Weiss Jeffrey N, 2018, Stem Cell Investig, V5, P18, DOI 10.21037/sci.2018.04.02
   Weiss Jeffrey N, 2017, Stem Cell Investig, V4, P94, DOI 10.21037/sci.2017.11.05
   Weiss JN, 2016, NEURAL REGEN RES, V11, P1685, DOI 10.4103/1673-5374.193251
   Weiss JN, 2016, NEURAL REGEN RES, V11, P1512, DOI 10.4103/1673-5374.191229
   Weiss JN, 2015, NEURAL REGEN RES, V10, P1507, DOI 10.4103/1673-5374.165525
   Weiss JN, 2015, NEURAL REGEN RES, V10, P982, DOI 10.4103/1673-5374.158365
   Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147
   Xu W, 2011, INT J OPHTHALMOL-CHI, V4, P413, DOI 10.3980/j.issn.2222-3959.2011.04.19
   Zhang Y, 2007, J NEUROSCI, V27, P4499, DOI 10.1523/JNEUROSCI.0200-07.2007
NR 67
TC 7
Z9 8
U1 2
U2 110
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD SEP
PY 2020
VL 15
IS 9
BP 1631
EP 1638
DI 10.4103/1673-5374.276324
PG 8
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA KT6HN
UT WOS:000519115200007
PM 32209762
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Brodszki, N
   Frazer-Abel, A
   Grumach, AS
   Kirschfink, M
   Litzman, J
   Perez, E
   Seppanen, MRJ
   Sullivan, KE
   Jolles, S
AF Brodszki, Nicholas
   Frazer-Abel, Ashley
   Grumach, Anete S.
   Kirschfink, Michael
   Litzman, Jiri
   Perez, Elena
   Seppanen, Mikko R. J.
   Sullivan, Kathleen E.
   Jolles, Stephen
TI European Society for Immunodeficiencies (ESID) and European Reference
   Network on Rare Primary Immunodeficiency, Autoinflammatory and
   Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies,
   Diagnosis, and Management
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article
DE Complement; complement deficiencies; classical pathway; alternative
   pathway; mannan-binding lectin
ID MANNOSE-BINDING LECTIN; STEM-CELL TRANSPLANTATION; HEMOLYTIC-UREMIC
   SYNDROME; HUMAN C1Q DEFICIENCY; GENE POLYMORPHISM; HEREDITARY
   ANGIOEDEMA; PROPERDIN DEFICIENCY; MACULAR DEGENERATION; FACTOR-H;
   CLINICAL PRESENTATION
AB This guideline aims to describe the complement system and the functions of the constituent pathways, with particular focus on primary immunodeficiencies (PIDs) and their diagnosis and management. The complement system is a crucial part of the innate immune system, with multiple membrane-bound and soluble components. There are three distinct enzymatic cascade pathways within the complement system, the classical, alternative and lectin pathways, which converge with the cleavage of central C3. Complement deficiencies account for similar to 5% of PIDs. The clinical consequences of inherited defects in the complement system are protean and include increased susceptibility to infection, autoimmune diseases (e.g., systemic lupus erythematosus), age-related macular degeneration, renal disorders (e.g., atypical hemolytic uremic syndrome) and angioedema. Modern complement analysis allows an in-depth insight into the functional and molecular basis of nearly all complement deficiencies. However, therapeutic options remain relatively limited for the majority of complement deficiencies with the exception of hereditary angioedema and inhibition of an overactivated complement system in regulation defects. Current management strategies for complement disorders associated with infection include education, family testing, vaccinations, antibiotics and emergency planning.
C1 [Brodszki, Nicholas] Skane Univ Hosp, Childrens Hosp, Dept Pediat, Lund, Sweden.
   [Frazer-Abel, Ashley] Univ Colorado, Div Rheumatol, Dept Med, Sch Med, Aurora, CO USA.
   [Grumach, Anete S.] Univ Ctr Hlth ABC, Reference Ctr Rare Dis, Clin Immunol, Santo Andre, SP, Brazil.
   [Kirschfink, Michael] Heidelberg Univ, Inst Immunol, Heidelberg, Germany.
   [Litzman, Jiri] Masaryk Univ, St Annes Univ Hosp, Dept Clin Immunol & Allergol, Brno, Czech Republic.
   [Litzman, Jiri] Masaryk Univ, Fac Med, Brno, Czech Republic.
   [Perez, Elena] Allergy Associates Palm Beaches, North Palm Beach, FL USA.
   [Seppanen, Mikko R. J.] Univ Helsinki, Childrens Hosp, Rare Dis Ctr, Helsinki, Finland.
   [Seppanen, Mikko R. J.] Univ Helsinki, Adult Primary Immunodeficiency Outpatient Clin, Inflammat Ctr, Helsinki, Finland.
   [Seppanen, Mikko R. J.] Helsinki Univ Hosp, Helsinki, Finland.
   [Sullivan, Kathleen E.] Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA.
   [Jolles, Stephen] Cardiff Univ, Immunodeficiency Ctr Wales, Cardiff, Wales.
   [Jolles, Stephen] Univ Hosp Wales, Cardiff, Wales.
C3 Lund University; Skane University Hospital; University of Colorado
   System; University of Colorado Anschutz Medical Campus; Ruprecht Karls
   University Heidelberg; Masaryk University Brno; St Anne's University
   Hospital Brno (FNUSA-ICRC); Masaryk University Brno; University of
   Helsinki; University of Helsinki; University of Helsinki; Helsinki
   University Central Hospital; University of Pennsylvania; Pennsylvania
   Medicine; Childrens Hospital of Philadelphia; Cardiff University;
   Cardiff University
RP Jolles, S (通讯作者)，Cardiff Univ, Immunodeficiency Ctr Wales, Cardiff, Wales.; Jolles, S (通讯作者)，Univ Hosp Wales, Cardiff, Wales.
EM jollessr@cardiff.ac.uk
RI Grumach, Anete S/I-3430-2014
OI Jolles, Stephen/0000-0002-7394-6804; Seppanen,
   Mikko/0000-0001-9733-3650; Litzman, Jiri/0000-0002-1926-5426
CR Al-Herz W, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00162
   Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P72
   [Anonymous], 2014, TRAV HLTH UPD
   Ardicli D, 2017, NEUROPEDIATRICS, V48, P477, DOI 10.1055/s-0037-1604483
   Arkwright PD, 2014, J ALLERGY CLIN IMMUN, V133, P265, DOI 10.1016/j.jaci.2013.07.035
   Aygoren-Pursun E, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0815-5
   Baines AC, 2017, BLOOD REV, V31, P213, DOI 10.1016/j.blre.2017.02.003
   Baiu DC, 1999, J IMMUNOL, V162, P3125
   Barnum SR, 2017, PHARMACOL THERAPEUT, V172, P63, DOI 10.1016/j.pharmthera.2016.11.014
   Bjarnadottir H, 2016, IMMUNOGENETICS, V68, P315, DOI 10.1007/s00251-016-0903-4
   Blazina S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00500
   Bonilla FA, 2018, J ALLERGY CLIN IMMUN, V141, P474, DOI 10.1016/j.jaci.2017.12.980
   Bork K, 2015, ALLERGY, V70, P1004, DOI 10.1111/all.12648
   Botto M, 2009, MOL IMMUNOL, V46, P2774, DOI 10.1016/j.molimm.2009.04.029
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884
   Brodsky RA, 2014, BLOOD, V124, P2804, DOI 10.1182/blood-2014-02-522128
   Bryan AR, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0448-2
   Caccia S, 2014, PEDIAT ALLER IMM PUL, V27, P159, DOI 10.1089/ped.2014.0425
   Coppo R, 2016, PEDIATR NEPHROL, V31, P759, DOI 10.1007/s00467-015-3278-0
   Costa-Carvalho BT, 2014, J CLIN IMMUNOL, V34, P10, DOI 10.1007/s10875-013-9954-6
   Csuka D, 2017, MOL IMMUNOL, V89, P59, DOI 10.1016/j.molimm.2017.05.020
   Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001
   Dahl M, 2004, J EXP MED, V199, P1391, DOI 10.1084/jem.20040111
   de Rooij BJF, 2010, HEPATOLOGY, V52, P1100, DOI 10.1002/hep.23782
   Degn SE, 2011, AM J HUM GENET, V88, P689, DOI 10.1016/j.ajhg.2011.05.011
   Dobo J, 2016, IMMUNOL REV, V274, P98, DOI 10.1111/imr.12460
   Dobo J, 2014, MOL IMMUNOL, V61, P69, DOI 10.1016/j.molimm.2014.05.013
   Eibl MM, 2015, IMMUNOTHERAPY-UK, V7, P1273, DOI 10.2217/IMT.15.74
   Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324
   Ejstrud P, 2000, SCAND J INFECT DIS, V32, P521, DOI 10.1080/003655400458811
   EKDAHL K, 1995, SCAND J INFECT DIS, V27, P111, DOI 10.3109/00365549509018989
   Engelberts PJ, 2016, J IMMUNOL, V197, P4829, DOI 10.4049/jimmunol.1600811
   Erdei A, 2016, IMMUNOL REV, V274, P127, DOI 10.1111/imr.12498
   ESID registry, 2018, ESID REG ESID DAT ST
   FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991
   Fijen CAP, 1999, MOL IMMUNOL, V36, P863, DOI 10.1016/S0161-5890(99)00107-8
   Fijen CAP, 1996, CLIN EXP IMMUNOL, V105, P511, DOI 10.1046/j.1365-2249.1996.d01-777.x
   Frazer-Abel A, 2016, ADV CLIN CHEM, V77, P1, DOI 10.1016/bs.acc.2016.06.001
   Fu J, 2016, MICROB PATHOGENESIS, V100, P221, DOI 10.1016/j.micpath.2016.10.004
   Garcia-Laorden MI, 2008, J ALLERGY CLIN IMMUN, V122, P368, DOI 10.1016/j.jaci.2008.05.037
   Garred P, 2016, IMMUNOL REV, V274, P74, DOI 10.1111/imr.12468
   Geerlings MJ, 2018, CLIN GENET, V94, P330, DOI 10.1111/cge.13392
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Genetic Disorders UK, 2017, GOING HOL TRAV TIPS
   Genetic testing registry, 2018, GENETIC TESTING REGI
   Germenis AE, 2020, J ALLER CL IMM-PRACT, V8, P901, DOI 10.1016/j.jaip.2019.10.004
   Ghebrehiwet Berhane, 2016, F1000Res, V5, P2840
   Gomes A, 2018, PEDIAT CANC GENETICS, P47, DOI DOI 10.1016/B978-0-323-48555-5.00005-3
   Grumach AS, 2014, MOL IMMUNOL, V61, P110, DOI 10.1016/j.molimm.2014.06.030
   Grumach AS, 2006, CLIN EXP IMMUNOL, V143, P297, DOI 10.1111/j.1365-2249.2005.02988.x
   Guy's and St Thomas' NHS, WHOL EX SEQ CLIN GEN
   Hamblin A, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002230
   Hamilton AJ, 2013, NEPHRON EXTRA, V3, P86, DOI 10.1159/000354667
   Helminen M, 2012, SCAND J IMMUNOL, V75, P445, DOI 10.1111/j.1365-3083.2012.02674.x
   Heurich M, 2016, THROMB RES, V145, P84, DOI 10.1016/j.thromres.2016.07.017
   HIEMSTRA PS, 1989, J CLIN INVEST, V84, P1957, DOI 10.1172/JCI114384
   Hill A, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.28
   Holmes LV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060352
   Hourcade DE, 2006, J BIOL CHEM, V281, P2128, DOI 10.1074/jbc.M508928200
   Hovingh ES, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02004
   Janeway Jr C.A., 2001, IMMUNOBIOLOGY IMMUNE, V5th
   Johnson Nathan M, 2018, Skin Therapy Lett, V23, P6
   Jonsson G, 2005, MEDICINE, V84, P23, DOI 10.1097/01.md.0000152371.22747.1e
   Karpman D, 2013, HAMOSTASEOLOGIE, V33, P96, DOI 10.5482/HAMO-12-12-0025
   Kasperkiewicz K, 2017, IMMUNOL CELL BIOL, V95, P666, DOI 10.1038/icb.2017.31
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kavanagh D, 2013, SEMIN NEPHROL, V33, P508, DOI 10.1016/j.semnephrol.2013.08.003
   Kerr H, 2012, IMMUNOBIOLOGY, V217, P195, DOI 10.1016/j.imbio.2011.07.028
   Kiss TL, 2005, BONE MARROW TRANSPL, V35, P213, DOI 10.1038/sj.bmt.1704748
   Kjaer TR, 2015, STRUCTURE, V23, P342, DOI 10.1016/j.str.2014.10.024
   Klausegger A, 2012, BONE MARROW TRANSPL, V47, P1259, DOI 10.1038/bmt.2012.7
   Kleinstein SE, 2019, GENES IMMUN, V20, P112, DOI 10.1038/s41435-018-0013-4
   Lee JXW, 2014, ANN ALLERG ASTHMA IM, V112, P557, DOI 10.1016/j.anai.2014.04.003
   Legendre CM, 2013, NEW ENGL J MED, V368, P2169, DOI 10.1056/NEJMoa1208981
   Lewis LA, 2014, VIRULENCE, V5, P98, DOI 10.4161/viru.26515
   Liesmaa I, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199305
   Liszewski MK, 2015, J INTERN MED, V277, P294, DOI 10.1111/joim.12338
   Liszewski MK, 2017, MOL IMMUNOL, V84, P2, DOI 10.1016/j.molimm.2017.01.004
   Loirat C, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-60
   Lundbo LF, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv127
   Macedo ACL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00055
   Marcelino-Rodriguez I, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00900
   Mathern DR, 2015, CLIN J AM SOC NEPHRO, V10, P1636, DOI 10.2215/CJN.06230614
   Maurer M, 2018, ALLERGY, V73, P1575, DOI 10.1111/all.13384
   Mayilyan KR, 2012, PROTEIN CELL, V3, P487, DOI 10.1007/s13238-012-2924-6
   McKeage K, 2019, DRUGS, V79, P347, DOI 10.1007/s40265-019-01068-2
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Michalski M, 2012, IMMUNOBIOLOGY, V217, P730, DOI 10.1016/j.imbio.2011.12.004
   Michels MAHM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00612
   MOLLNES TE, 1988, CLIN EXP IMMUNOL, V73, P484
   Mollnes TE, 2007, MOL IMMUNOL, V44, P3838, DOI 10.1016/j.molimm.2007.06.150
   Mortensen SA, 2017, P NATL ACAD SCI USA, V114, P986, DOI 10.1073/pnas.1616998114
   Nakar CHB, 2018, RARE COAGULATION DIS
   National Hemophilia Foundation, 2018, FACT 12 HAG FACT DEF
   Nesargikar PN, 2012, EUR J MICROBIOL IMMU, V2, P103, DOI 10.1556/EuJMI.2.2012.2.2
   Nester CM, 2015, MOL IMMUNOL, V67, P31, DOI 10.1016/j.molimm.2015.03.246
   NICE, 2019, LAN PREV REC ATT HER
   Nilsson B, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/962702
   Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001
   Noris M, 2012, NAT REV NEPHROL, V8, P622, DOI 10.1038/nrneph.2012.195
   Olsson RF, 2016, TRANSPLANTATION, V100, P1356, DOI 10.1097/TP.0000000000000975
   Overturf GD, 2003, CLIN INFECT DIS, V36, P189, DOI 10.1086/345527
   Ozen A, 2017, NEW ENGL J MED, V377, P52, DOI 10.1056/NEJMoa1615887
   Paakkanen R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038813
   Palarasah Y, 2011, CLIN EXP IMMUNOL, V164, P388, DOI 10.1111/j.1365-2249.2011.04322.x
   Patel RR, 2015, THER CLIN RISK MANAG, V11, P217, DOI 10.2147/TCRM.S52008
   Pawaskar D, 2018, CLIN EXP ALLERGY, V48, P1325, DOI 10.1111/cea.13220
   Pettigrew HD, 2009, ANN NY ACAD SCI, V1173, P108, DOI 10.1111/j.1749-6632.2009.04633.x
   Prohaszka Z, 2016, IMMUNOBIOLOGY, V221, P1247, DOI 10.1016/j.imbio.2016.06.008
   Qiao F, 2010, AM J PATHOL, V177, P3061, DOI 10.2353/ajpath.2010.100158
   Qiu T, 2018, ALLERGY
   Ram S, 2010, CLIN MICROBIOL REV, V23, P740, DOI 10.1128/CMR.00048-09
   Reddy YNV, 2017, CURR OPIN NEPHROL HY, V26, P123, DOI 10.1097/MNH.0000000000000305
   Regal JF, 2015, MOL IMMUNOL, V67, P56, DOI 10.1016/j.molimm.2015.02.030
   Rooryck C, 2011, NAT GENET, V43, P197, DOI 10.1038/ng.757
   Rosain J, 2014, ANN BIOL CLIN-PARIS, V72, P271, DOI 10.1684/abc.2014.0961
   Salmon JE, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001013
   Sanghera P, 2017, AM J MED SCI, V354, P533, DOI 10.1016/j.amjms.2017.03.024
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Schein, 2017, COMPLEMENT FACTSBOOK
   Schlapbach LJ, 2007, PEDIATR INFECT DIS J, V26, P989, DOI 10.1097/INF.0b013e31811ffe6a
   Schlapbach LJ, 2009, PEDIAT ALLERG IMM-UK, V20, P219, DOI 10.1111/j.1399-3038.2008.00782.x
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seelen MA, 2005, J IMMUNOL METHODS, V296, P187, DOI 10.1016/j.jim.2004.11.016
   Seppanen M, 2009, HUM IMMUNOL, V70, P218, DOI 10.1016/j.humimm.2009.01.022
   Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P961, DOI 10.1016/j.jaci.2013.11.043
   SHIANG R, 1989, GENOMICS, V4, P82, DOI 10.1016/0888-7543(89)90318-2
   Shih AR, 2015, AM J HEMATOL, V90, P1180, DOI 10.1002/ajh.24209
   Shire, 2018, TAKHZ NOW APPR
   Skattum L, 2011, MOL IMMUNOL, V48, P1643, DOI 10.1016/j.molimm.2011.05.001
   Slade C, 2013, NEW ENGL J MED, V369, P1667, DOI 10.1056/NEJMc1306326
   Smith LC, 2001, IMMUNOL REV, V180, P16, DOI 10.1034/j.1600-065X.2001.1800102.x
   Sng CCT, 2018, J ALLERGY CLIN IMMUN, V142, P311, DOI 10.1016/j.jaci.2018.01.048
   Sobh A, 2016, J ALLER CL IMM-PRACT, V4, P1066, DOI 10.1016/j.jaip.2016.09.012
   Stegert M, 2015, MOL IMMUNOL, V67, P3, DOI 10.1016/j.molimm.2015.03.007
   Stengaard-Pedersen K, 2003, NEW ENGL J MED, V349, P554, DOI 10.1056/NEJMoa022836
   Swierzko AS, 2016, IMMUNOBIOLOGY, V221, P657, DOI 10.1016/j.imbio.2016.01.003
   Takahashi R, 2005, ANN RHEUM DIS, V64, P311, DOI 10.1136/ard.2003.020172
   Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Turley AJ, 2015, J CLIN IMMUNOL, V35, P199, DOI 10.1007/s10875-015-0137-5
   van Schaarenburg RA, 2015, J AUTOIMMUN, V62, P39, DOI 10.1016/j.jaut.2015.06.002
   Varela JC, 2015, HEMATOL ONCOL CLIN N, V29, P409, DOI 10.1016/j.hoc.2015.02.001
   Vaught AJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99128
   Vekemans M, 2007, CLIN INFECT DIS, V44, P1593, DOI 10.1086/518171
   Vyse TJ, 1996, J CLIN INVEST, V97, P925, DOI 10.1172/JCI118515
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Weckerle CE, 2011, CLIN REV ALLERG IMMU, V40, P42, DOI 10.1007/s12016-009-8192-4
   Wehling C, 2017, CLIN EXP IMMUNOL, V187, P304, DOI 10.1111/cei.12890
   West EE, 2018, ANNU REV IMMUNOL, V36, P309, DOI 10.1146/annurev-immunol-042617-053245
   Zegers IHA, 2015, NETH J MED, V73, P383
   Zhang KX, 2017, HEMATOL REP, V9, P62, DOI 10.4081/hr.2017.7053
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zuraw BL, 2018, J ALLERGY CLIN IMMUN, V141, P884, DOI 10.1016/j.jaci.2018.01.015
NR 157
TC 24
Z9 25
U1 2
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271-9142
EI 1573-2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD MAY
PY 2020
VL 40
IS 4
BP 576
EP 591
DI 10.1007/s10875-020-00754-1
EA FEB 2020
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA LR9MX
UT WOS:000516182000001
PM 32064578
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Sun, JK
   Jampol, LM
AF Sun, Jennifer K.
   Jampol, Lee M.
TI The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its
   Contributions to the Treatment of Diabetic Retinopathy
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE Diabetic Retinopathy Clinical Research Network; Proliferative diabetic
   retinopathy; Panretinal photocoagulation; Diabetic macular edema
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR EDEMA; RANIBIZUMAB; TRIAL
AB Over the past two decades, the Diabetic Retinopathy Clinical Research Network (now known as the DRCR Retina Network) has contributed to multiple and substantial advances in the clinical care of diabetic eye disease. Network studies helped establish anti-vascular endothelial growth factor (VEGF) agents as an effective alternative to panretinal photocoagulation for eyes with proliferative diabetic retinopathy (PDR) and as first-line therapy for eyes with visual impairment for diabetic macular edema (DME), defined treatment algorithms for the use of intravitreal medications in these conditions, and provided critical data to understand how to better evaluate the diabetic eye using optical coherence tomography and other imaging modalities. Ongoing DRCR.net studies will address whether anti-VEGF therapy is effective at preventing vision-threatening complications in eyes with severe non-proliferative diabetic retinopathy, if photobiomodulation has a beneficial effect in eyes with DME, and whether initiation of DME treatment with bevacizumab and rescue with aflibercept can provide visual outcomes as good as those achieved with aflibercept alone. Future plans for the Network also include the expansion into non-diabetic eye disease in areas such as age-related macular degeneration.
C1 [Sun, Jennifer K.] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
   [Sun, Jennifer K.] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA.
   [Jampol, Lee M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
C3 Harvard University; Joslin Diabetes Center, Inc.; Harvard University;
   Harvard Medical School; Northwestern University; Feinberg School of
   Medicine
RP Sun, JK (通讯作者)，Beetham Eye Inst, 1 Joslin Pl, Boston, MA 02115 USA.
EM Jennifer.Sun@joslin.harvard.edu
RI Sun, Jennifer K/AAP-2734-2020
OI Sun, Jennifer K/0000-0003-0915-6303
CR Aiello LP, 2019, JAMA OPHTHALMOL, V137, P65, DOI 10.1001/jamaophthalmol.2018.4982
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   [Anonymous], 10 ETDRS
   Baker CW, 2019, JAMA-J AM MED ASSOC, V321, P1880, DOI 10.1001/jama.2019.5790
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   COGAN DG, 1964, NEW ENGL J MED, V270, P787, DOI 10.1056/NEJM196404092701508
   Diabetic Retinopathy Clinical Research Network, 2010, OPHTHALMOLOGY, V117, P1064
   Elman MJ, 2015, OPHTHALMOLOGY, V122, P375, DOI 10.1016/j.ophtha.2014.08.047
   Gangaputra S, 2011, INVEST OPHTH VIS SCI, V52, P6168, DOI 10.1167/iovs.11-7321
   Gross JG, 2018, JAMA OPHTHALMOL, V136, P1138, DOI 10.1001/jamaophthalmol.2018.3255
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Maturi RK, 2018, JAMA OPHTHALMOL, V136, P29, DOI 10.1001/jamaophthalmol.2017.4914
   Michaelides M, 2010, OPHTHALMOLOGY, V117, P1078, DOI 10.1016/j.ophtha.2010.03.045
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
NR 20
TC 20
Z9 22
U1 2
U2 7
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2019
VL 62
IS 4
BP 225
EP 230
DI 10.1159/000502779
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JU4CC
UT WOS:000501624000007
PM 31554001
OA Bronze
DA 2022-11-30
ER

PT J
AU Wang, C
   Seo, SJ
   Kim, JS
   Lee, SH
   Jeon, JK
   Kim, JW
   Kim, KH
   Kim, JK
   Park, J
AF Wang, Cong
   Seo, Seung-Jun
   Kim, Jin-Seong
   Lee, Se-Hee
   Jeon, Jae-Kun
   Kim, Jae-Woo
   Kim, Ki-Hong
   Kim, Jong-Ki
   Park, Jungyul
TI Intravitreal implantable magnetic micropump for on-demand VEGFR-targeted
   drug delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Drug delivery; On-demand; Magnetic micropump; VEGFR; Gold nanoparticle
ID MACULAR DEGENERATION; DISEASES; RELEASE; DEVICE; FOCUS
AB In this paper, we propose an intravitreal implantable magnetic micropump integrated with micro check valve capable of on-demand vascular endothelial growth factor receptor (VEGFR)-targeted drug delivery for the treatment of age-related macular degeneration, diabetic retinopathy and other eye pathologies characterized by ocular neoangiogenesis. Precise on-demand drug release is realized by the deflection of the magnetic membrane assembly according to the external magnetic field, and the membrane assembly consists of a thin elastic polydimethylsiloxane (PDMS) membrane and a cylindrical magnetic nanoparticle-PDMS composite block. Additionally, a micro check valve composed of two PDMS layers was integrated into the micropump to realize a diode-like one-directional drug delivery and prevent undesired drug diffusion. For specifically targeting VEGFR and suppression of VEGF-induced proliferation of microvascular endothelial cells, anti-Flt1 gold nanocomplexes are synthesized. In vitro and in vivo experiments and quantitative analysis are carried out in order to verify our proposed concept: precise drug release control according to the external magnetic field, targeting to microvascular endothelial cells, and efficient and on-demand drug delivery from the proposed micropump to the macular area of rabbit's eye.
C1 [Wang, Cong; Kim, Jin-Seong; Park, Jungyul] Sogang Univ, Dept Mech Engn, 35 Baekbeom Ro Sinsu Dong, Seoul 04107, South Korea.
   [Park, Jungyul] Sogang Univ, Interdisciplinary Program Integrated Biotechnol, 35 Baekbeom Ro Sinsu Dong, Seoul 04107, South Korea.
   [Seo, Seung-Jun; Lee, Se-Hee; Jeon, Jae-Kun; Kim, Jong-Ki] Catholic Univ Daegu, Sch Med, Biomed Engn, 33 Duryugongwonro 17 Gil, Daegu 42472, South Korea.
   [Jeon, Jae-Kun] Catholic Univ Daegu, Sch Med, Ophthalmol, 33 Duryugongwonro 17 Gil, Daegu 42472, South Korea.
   [Kim, Ki-Hong] Catholic Univ Daegu, Coll Med Sci, Optometry & Vis Sci, 13-13 Hayang Ro, Gyongsan 38430, South Korea.
C3 Sogang University; Sogang University; Catholic University of Daegu;
   Catholic University of Daegu; Catholic University of Daegu
RP Park, J (通讯作者)，Sogang Univ, Dept Mech Engn, 35 Baekbeom Ro Sinsu Dong, Seoul 04107, South Korea.; Kim, JK (通讯作者)，Catholic Univ Daegu, Sch Med, Biomed Engn, 33 Duryugongwonro 17 Gil, Daegu 42472, South Korea.
EM jkkim@cu.ac.kr; sortpark@sogang.ac.kr
RI Park, Jungyul/AAI-8690-2020; Wang, Cong/E-6162-2016
OI Park, Jungyul/0000-0002-6885-9466; Wang, Cong/0000-0001-7245-5109
FU National Research Foundation of Korea (NRF) - Korean government (MSIP)
   [NRF-2017R1A4A1015564]; Industrial Materials Fundamental Technology
   Development Program - Ministry of Trade, Industry and Energy (MOTIE) of
   Korea [10052981, 10062194]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MSIP) (NRF-2017R1A4A1015564) and
   by the Industrial Materials Fundamental Technology Development Program
   (10052981, 10062194) funded by the Ministry of Trade, Industry and
   Energy (MOTIE) of Korea.
CR Al-Shabrawey M, 2013, EXPERT REV OPHTHALMO, V8, P267, DOI 10.1586/EOP.13.17
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Hou HY, 2014, J CONTROL RELEASE, V178, P46, DOI 10.1016/j.jconrel.2014.01.003
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   Kaji H., 2017, ADV DRUG DELIV REV
   Lee SH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15032
   Lee SS, 2009, OPHTHALMIC RES, V41, P124, DOI 10.1159/000209665
   Mosadegh B, 2010, NAT PHYS, V6, P433, DOI [10.1038/NPHYS1637, 10.1038/nphys1637]
   Nicholson BP, 2010, GRAEF ARCH CLIN EXP, V248, P915, DOI 10.1007/s00417-010-1315-z
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oh EJ, 2011, BIOMATERIALS, V32, P3115, DOI 10.1016/j.biomaterials.2011.01.003
   Pirmoradi FN, 2011, LAB CHIP, V11, P3072, DOI 10.1039/c1lc20438f
   Pirmoradi FN, 2011, LAB CHIP, V11, P2744, DOI 10.1039/c1lc20134d
   Pirmoradi F, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/1/015032
   Sassa Y, 2010, CLIN OPHTHALMOL, V4, P275
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
NR 21
TC 23
Z9 23
U1 2
U2 44
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG 10
PY 2018
VL 283
BP 105
EP 112
DI 10.1016/j.jconrel.2018.05.030
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA GM4HZ
UT WOS:000438079900009
PM 29852193
DA 2022-11-30
ER

PT J
AU Liefers, B
   Venhuizen, FG
   Schreur, V
   van Ginneken, B
   Hoyng, C
   Fauser, S
   Theelen, T
   Sanchez, CI
AF Liefers, Bart
   Venhuizen, Freerk G.
   Schreur, Vivian
   van Ginneken, Bram
   Hoyng, Carel
   Fauser, Sascha
   Theelen, Thomas
   Sanchez, Clara I.
TI Automatic detection of the foveal center in optical coherence tomography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID VISUAL-ACUITY; RETINAL LAYER; MACULAR DEGENERATION; FLUID SEGMENTATION;
   OCT IMAGES; THICKNESS; EYES; CLASSIFICATION; HEALTHY; EDEMA
AB We propose a method for automatic detection of the foveal center in optical coherence tomography (OCT). The method is based on a pixel-wise classification of all pixels in an OCT volume using a fully convolutional neural network (CNN) with dilated convolution filters. The CNN-architecture contains anisotropic dilated filters and a shortcut connection and has been trained using a dynamic training procedure where the network identifies its own relevant training samples. The performance of the proposed method is evaluated on a data set of 400 OCT scans of patients affected by age-related macular degeneration (AMD) at different severity levels. For 391 scans (97 : 75%) the method identified the foveal center with a distance to a human reference less than 750 mu m, with a mean (+/- SD) distance of 71 mu m +/- 107 mu m. Two independent observers also annotated the foveal center, with a mean distance to the reference of 57 mu m +/- 84 mu m and 56 mu m +/- 80 mu m, respectively. Furthermore, we evaluate variations to the proposed network architecture and training procedure, providing insight in the characteristics that led to the demonstrated performance of the proposed method. (C) 2017 Optical Society of America.
C1 [Liefers, Bart; Venhuizen, Freerk G.; van Ginneken, Bram; Theelen, Thomas; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, Nijmegen, Netherlands.
   [Liefers, Bart; Venhuizen, Freerk G.; Schreur, Vivian; Hoyng, Carel; Theelen, Thomas; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Fauser, Sascha] F Hollmann La Roche Ltd, Roche Pharma Res & Early Dev, Basel, Switzerland.
   [Fauser, Sascha] Cologne Univ, Eye Clin, Cologne, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Roche Holding;
   University of Cologne
RP Liefers, B (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, Nijmegen, Netherlands.; Liefers, B (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
EM Bart.Liefers@radboudumc.nl
RI Liefers, Bart/C-1364-2018; Venhuizen, Freerk/P-5736-2015
FU Radboud University; Fraunhofer-Gesellschaft as an ICON project; Radboud
   University Medical Center
FX This work is funded by Radboud University, Radboud University Medical
   Center and the Fraunhofer-Gesellschaft as an ICON project.
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Balaratnasingam C, 2016, OPHTHALMOLOGY, V123, P2352, DOI 10.1016/j.ophtha.2016.07.008
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Chen Liang-Chieh, 2016, ARXIV160600915
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fang LY, 2017, IEEE T MED IMAGING, V36, P407, DOI 10.1109/TMI.2016.2611503
   Fang LY, 2013, IEEE T MED IMAGING, V32, P2034, DOI 10.1109/TMI.2013.2271904
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fauser S, 2011, INVEST OPHTH VIS SCI, V52, P5525, DOI 10.1167/iovs.10-6827
   Geitzenauer W., 2010, BR J OPHTHALMOL
   Gerendas B., 2012, INVEST OPHTHALMOL, V53, P4114
   Govetto A, 2017, AM J OPHTHALMOL, V175, P99, DOI 10.1016/j.ajo.2016.12.006
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Holschneider M, 1990, WAVELETS, P286
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Kafieh R, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/259123
   Karri SPK, 2017, BIOMED OPT EXPRESS, V8, P579, DOI 10.1364/BOE.8.000579
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   Liefers B., 2017, P SPIE
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Long J, 2015, PROC CVPR IEEE, P3431, DOI 10.1109/CVPR.2015.7298965
   Maas A. L., 2013, P INT MACHINE LEARNI, V30
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Massin P, 2002, EUR J OPHTHALMOL, V12, P102, DOI 10.1177/112067210201200205
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Niemeijer M, 2009, MED IMAGE ANAL, V13, P859, DOI 10.1016/j.media.2009.08.003
   Otani T, 2010, RETINA-J RET VIT DIS, V30, P774, DOI 10.1097/IAE.0b013e3181c2e0d6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Theano Development Team, 2016, P CORR
   Tick S, 2011, INVEST OPHTH VIS SCI, V52, P5105, DOI 10.1167/iovs.10-7005
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van Grinsven MJJP, 2016, IEEE T MED IMAGING, V35, P1273, DOI 10.1109/TMI.2016.2526689
   Venhuizen FG, 2017, BIOMED OPT EXPRESS, V8, P3292, DOI 10.1364/BOE.8.003292
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wang Fenghua, 2012, Ophthalmic Surg Lasers Imaging, V43, pS32, DOI 10.3928/15428877-20121001-06
   Wu J, 2016, INT J BIOMED IMAGING, V2016, DOI 10.1155/2016/7468953
   Yu F., 2015, INT C LEARN REPR ICL
NR 48
TC 23
Z9 23
U1 0
U2 8
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD NOV 1
PY 2017
VL 8
IS 11
BP 5160
EP 5178
PG 19
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA FL4SE
UT WOS:000414220600030
PM 29188111
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Berra, S
   Clivio, A
AF Berra, Silvia
   Clivio, Alberto
TI Rapid isolation of pure Complement Factor H from serum for functional
   studies by the use of a monoclonal antibody that discriminates FH from
   all the other isoforms
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Complement Factor H; Functional assays; Purification; Affinity
   chromatography; Immunoassays
ID HEMOLYTIC-UREMIC SYNDROME; CONTROL PROTEIN MODULE; SIALIC-ACID;
   ALTERNATIVE PATHWAY; BINDING; VARIANTS; BETA-1H; CELLS; GENE; SITE
AB Several mutations have been identified in the gene coding for Complement Factor H (FH) from patients with atypical Hemolytic Uraemic Syndrome (aHUS), Age-related Macular Degeneration (AMD) and Membranoproliferative Glomerulonephritis (MPGN). These data allow for a precise description of the structural changes affecting FH, but a simple test for specifically assessing FH function routinely is not yet of common use. We have produced and characterised a monoclonal antibody (5H5) which discriminates between FH and the smaller FH-like 1 and FH-related proteins and show here that it specifically binds to FH without detecting the smaller isoforms. We therefore used this mAb for a quick, one-step micro purification of FH directly from control sera and showed that this affinity chromatography procedure is not disruptive of its cofactor function. We also developed a modified sheep erythrocytes haemolysis test using our antibody and affinity-purified FH. These tests can be used in conjunction for assessing the function of FH purified from patients affected by FH-related diseases. Moreover we used this mAb to develop a FH-specific ELISA test. (c) 2016 Elsevier Ltd. All rights reserved.
C1 [Berra, Silvia; Clivio, Alberto] Univ Milan, L Sacco Dept Biomed & Clin Sci DIBIC, Via GB Grassi 74, I-20157 Milan, Italy.
C3 University of Milan
RP Berra, S (通讯作者)，Univ Milan, L Sacco Dept Biomed & Clin Sci DIBIC, Via GB Grassi 74, I-20157 Milan, Italy.
EM silvia.berra@unimi.it
RI Berra, Silvia/E-2863-2015
OI Berra, Silvia/0000-0003-1151-7040
FU Kedrion S.p.A., Castelvecchio Pascoli, Barga (Lucca), Italy; University
   of Milan, Italy
FX This work was partially supported by a grant of Kedrion S.p.A.,
   Castelvecchio Pascoli, Barga (Lucca), Italy. S.B. is the recipient of a
   fellowship in the PhD program in Molecular Medicine, University of
   Milan, Italy. We acknowledge Dott. G. Ardissino and the Center for HUS
   Control, Prevention and Management, Fondazione IRCCS Ca'Granda, Ospedale
   Maggiore Policlinico of Milan for providing aHUS patients serum samples
   and Prof. P. Zipfel (Department of Infection Biology, Leibniz Institute
   for Natural Product Research and Infection Biology, Jena, Germany) for
   providing FHR-3 antibody. Finally we would like to thank Mrs. Alessandra
   Rebay for her voluntary support to S.B.
CR ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389
   BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016
   Bernabeu-Herrero ME, 2015, MOL IMMUNOL, V67, P276, DOI 10.1016/j.molimm.2015.06.021
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   BROOIMANS RA, 1990, J IMMUNOL, V144, P3835
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   CONRAD DH, 1978, J EXP MED, V147, P1792, DOI 10.1084/jem.147.6.1792
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Fulop TG, 2015, EUR J NANOMED, V7, P7, DOI 10.1515/ejnm-2015-0004
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   HONG K, 1982, J IMMUNOL, V129, P647
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75
   Kemper C, 2014, MOL IMMUNOL, V61, P56, DOI 10.1016/j.molimm.2014.07.004
   KOISTINEN V, 1992, BIOCHEM J, V283, P317, DOI 10.1042/bj2830317
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   Licht C, 2009, BLOOD, V114, P4538, DOI 10.1182/blood-2009-03-205096
   Moreno-Indias I, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-91
   NILSSON UR, 1965, J EXP MED, V122, P277, DOI 10.1084/jem.122.2.277
   NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T
   Nozal P, 2014, MOL IMMUNOL, V58, P194, DOI 10.1016/j.molimm.2013.11.021
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   PANGBURN MK, 1983, J IMMUNOL, V131, P1930
   PANGBURN MK, 1983, ANN NY ACAD SCI, V421, P291, DOI 10.1111/j.1749-6632.1983.tb18116.x
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   PINTER C, 1995, AIDS RES HUM RETROV, V11, P971, DOI 10.1089/aid.1995.11.971
   PINTER C, 1995, AIDS RES HUM RETROV, V11, P577, DOI 10.1089/aid.1995.11.577
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205
   Skerka C, 2013, MOL IMMUNOL, V56, P170, DOI 10.1016/j.molimm.2013.06.001
   Tu ZD, 2010, STEM CELLS DEV, V19, P1803, DOI 10.1089/scd.2009.0418
   VANDENDOBBELSTEEN MEA, 1994, CLIN EXP IMMUNOL, V95, P173
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   Yu BB, 2014, METHODS MOL BIOL, V1100, P207, DOI 10.1007/978-1-62703-724-2_17
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 45
TC 4
Z9 4
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD APR
PY 2016
VL 72
BP 65
EP 73
DI 10.1016/j.molimm.2016.03.001
PG 9
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA DK3FI
UT WOS:000374802100008
PM 26972487
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Veritti, D
   Macor, S
   Menchini, F
   Lanzetta, P
AF Veritti, Daniele
   Macor, Sara
   Menchini, Francesca
   Lanzetta, Paolo
TI EFFECTS OF VEGF INHIBITION ON RETINAL MORPHOLOGY, NEOVASCULAR NETWORK
   SIZE, AND VISUAL ACUITY IN PATIENTS WITH VASCULARIZED PIGMENT EPITHELIUM
   DETACHMENT BECAUSE OF OCCULT CHOROIDAL NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; occult choroidal
   neovascularization; pigment epithelium detachment; ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; ANGIOMATOUS
   PROLIFERATION; RANIBIZUMAB; TEARS; THERAPY; EYES
AB Purpose: To report the results of vascular endothelial growth factor inhibition for vascularized pigment epithelium detachment associated with choroidal neovascularization secondary to age-related macular degeneration.
   Methods: We performed a retrospective analysis of patients affected by vascularized pigment epithelium detachment treated with intravitreal anti-vascular endothelial growth factor (0.5 mg of ranibizumab or 1 mg of bevacizumab) and a follow-up of 12 months. Retinal angiomatous proliferations were excluded. Treatment was conducted with an initial loading phase followed by a pro re nata phase. Fluorescein angiography and indocyanine green angiography were performed at baseline and every 3 months.
   Results: Forty eyes were included in this study. After a follow-up of 12 months and 5.5 treatments on average, best-corrected visual acuity did not vary significantly. Central retinal thickness and pigment epithelium detachment height were significantly reduced, whereas the choroidal neovascularization area remained constant.
   Conclusion: In vascularized pigment epithelium detachment, anti-vascular endothelial growth factor therapy shows visual stabilization but not best-corrected visual acuity gain. However, it is associated with significant morphologic improvements, and it may offer a benefit over the natural course of the disease. RETINA 33: 982-989, 2013
C1 [Veritti, Daniele; Macor, Sara; Menchini, Francesca; Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
C3 University of Udine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazza Santa Maria della Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
OI VERITTI, Daniele/0000-0003-0148-5348; Macor, Sara/0000-0001-6855-7866
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gharbiya M, 2009, RETINA-J RET VIT DIS, V29, P740, DOI 10.1097/IAE.0b013e3181a0be1d
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2007, INVEST OPHTH VIS SCI, V48, P1751, DOI 10.1167/iovs.06-0686
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 28
TC 10
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 982
EP 989
DI 10.1097/IAE.0b013e31826d8ff4
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131QY
UT WOS:000318011100014
PM 23296046
DA 2022-11-30
ER

PT J
AU Anderson, C
   Blaha, GR
   Marx, JL
AF Anderson, C.
   Blaha, G. R.
   Marx, J. L.
TI Humphrey visual field findings in hydroxychloroquine toxicity
SO EYE
LA English
DT Article
DE hydroxychloroquine toxicity; Plaquenil; toxic maculopathy; Humphrey
   visual field; retinal toxicity; automated perimetry
ID RETINAL TOXICITY; CHLOROQUINE; RETINOPATHY; THERAPY
AB Purpose To analyze Humphrey visual field (HVF) findings in hydroxychloroquine (HCQ) retinal toxicity.
   Methods HVF tests were interpreted retrospectively in this observational case series of 15 patients with HCQ toxicity. Patients seen at Lahey Clinic were identified by diagnosis coding search. Patients with age-related macular degeneration or glaucoma with visual field loss were excluded. HVFs done before the diagnosis were analyzed to see if earlier diagnosis could have been possible.
   Results A total of 66 HVFs were reviewed and categorized. Some abnormalities were subtle. Paracentral defects were seen on 10-2 tests whereas 24-2 tests, due to their compressed scale, showed central changes. The abnormalities were often more obvious on pattern deviation rather than the gray scale. Of those patients with prior HVFs available for review, 50% showed HVF abnormalities typical of HCQ toxicity present several months or years before diagnosis. HVF changes preceded fundus changes in nine patients.
   Conclusion HVF abnormalities indicating HCQ toxicity vary depending on the specific HVF test performed. Clinicians need to be aware of the subtle nature of HVF changes in early toxicity. Eye (2011) 25, 1535-1545; doi:10.1038/eye.2011.245; published online 18 November 2011
C1 [Anderson, C.; Blaha, G. R.; Marx, J. L.] Lahey Clin Fdn, Dept Ophthalmol, Peabody, MA 01960 USA.
C3 Lahey Hospital & Medical Center
RP Anderson, C (通讯作者)，Lahey Clin Fdn, Dept Ophthalmol, 1 Essex Ctr Dr, Peabody, MA 01960 USA.
EM Carolyn.Anderson@Lahey.org
CR BERNSTEIN HN, 1991, ANN OPHTHALMOL, V23, P292
   Easterbrook E, 1988, AM J MED, V85, P23
   Elder M, 2006, ARCH OPHTHALMOL-CHIC, V124, P1729, DOI 10.1001/archopht.124.12.1729
   HART WM, 1984, ARCH OPHTHALMOL-CHIC, V102, P377, DOI 10.1001/archopht.1984.01040030295022
   JOHNSON MW, 1987, AM J OPHTHALMOL, V104, P139, DOI 10.1016/0002-9394(87)90005-5
   Marmor MF, 2011, OPHTHALMOLOGY, V118, P415, DOI 10.1016/j.ophtha.2010.11.017
   Michaelides M, 2011, ARCH OPHTHALMOL-CHIC, V129, P30, DOI 10.1001/archophthalmol.2010.321
   Wolfe F, 2010, ARTHRIT CARE RES, V62, P775, DOI 10.1002/acr.20133
NR 8
TC 28
Z9 30
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD DEC
PY 2011
VL 25
IS 12
BP 1535
EP 1545
DI 10.1038/eye.2011.245
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 863HG
UT WOS:000298152800003
PM 22094300
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Babizhayev, MA
AF Babizhayev, Mark A.
TI Designation of imidazole-containing dipeptides as pharmacological
   chaperones
SO HUMAN & EXPERIMENTAL TOXICOLOGY
LA English
DT Article
DE skin care; cosmetic science; ophthalmic treatment; human cataractous
   lenses; age-related cataract; macular degeneration
ID GLYCATION END-PRODUCTS; CARCININE BETA-ALANYLHISTAMINE;
   HISTIDINE-CONTAINING DIPEPTIDE; HEAT-SHOCK PROTEINS; N-ACETYLCARNOSINE;
   ALPHA-CRYSTALLIN; L-CARNOSINE; TRANSDERMAL DELIVERY; CHEMICAL
   CHAPERONES; OXIDATIVE STRESS
AB We review the dichotomous regulatory roles of natural imidazole-containing peptidomimetics (N-acetylcarnosine [NAC], carcinine, non-hydrolized carnosine) in maintaining skin homeostasis that determines whether keratinocytes survive or undergo apoptosis in response to various insults and in the development of skin diseases. General strategies addressing common ground techniques to improve absorption of usually active chaperone proteins or their dipeptide inducer (usually poorly absorbed) compounds include encapsulation into hydrophobic carriers, combination with penetration enhancers, active electrical transport or chemical modification to increase hydrophobicity. A growing evidence is presented that demonstrates the ability of NAC (lubricant eye drops) or carcinine to act as pharmacological chaperones, or being synergistically coupled in patented formulations with another imidazole-containing peptidomimetic (such as, Leucyl-histidylhydrazide), to decrease oxidative stress and ameliorate oxidative and excessive glycation stress-related eye disease phenotypes, suggesting that the field of chaperone therapy might hold novel treatments for age-related cataracts, glaucoma, age-related macular degeneration (AMD), and ocular complications of diabetes (OCD). Current efforts are being directed towards exploring therapeutic approaches of pharmacological targeting and human drug delivery for chaperone molecules based on innovative patented strategies.
C1 [Babizhayev, Mark A.] Innovat Vis Prod Inc, Cty New Castle, Delaware, OH USA.
   [Babizhayev, Mark A.] Moscow Helmholtz Res Inst Eye Dis, Moscow, Russia.
C3 Helmholtz National Medical Research Center of Eye Diseases
RP Babizhayev, MA (通讯作者)，Innovat Vis Prod Inc, Moscow Div, Ivanovskaya 20,Suite 74, Moscow 127434, Russia.
EM markbabizhayev@mail.ru
FU Innovative Vision Products, Inc. (IVP)
FX This work was planned, organized, and supported by Innovative Vision
   Products, Inc. (IVP). Dr. Mark A. Babizhayev is thankful to Exsymol SAM
   (Principaute de Monaco) for the provided cooperation in this study. The
   biologicallysignificant applications of carnosine mimetics were patented
   by Dr. Babizhayev and the alliance Groups (WO 2004/028536 A1; WO
   94/19325; WO 95/12581; WO 2004/064866 A1). IVP Inc. is a Pharmaceutical
   and Nanotechnology Development Company with a focus on innovative
   chemical entities, drug delivery systems, and unique medical devices to
   target specific biomedical applications. Over the last decade, IVP has
   developed a track record in developing these technologies to effectively
   address the unmet needs of specific diseased populations.
CR Ahmad MF, 2008, J MOL BIOL, V382, P812, DOI 10.1016/j.jmb.2008.07.068
   ANDLEY UP, 1989, INVEST OPHTH VIS SCI, V30, P706
   ARNOULD JM, 1977, ARCH INT PHYSIOL BIO, V85, P339, DOI 10.3109/13813457709058766
   Attanasio F, 2009, BIOCHEMISTRY-US, V48, P6522, DOI 10.1021/bi900343n
   BABIZHAEV MA, 1986, BIOFIZIKA+, V31, P109
   Babizhayev MA, 2006, LIFE SCI, V78, P2343, DOI 10.1016/j.lfs.2005.09.054
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P363, DOI 10.1016/0005-2760(89)90085-4
   BABIZHAYEV MA, 1994, BBA-MOL BASIS DIS, V1225, P326, DOI 10.1016/0925-4439(94)90014-0
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P124, DOI 10.1016/0005-2760(89)90222-1
   Babizhayev MA, 2004, REJUV RES, V7, P186, DOI 10.1089/rej.2004.7.186
   Babizhayev MA, 2001, PEPTIDES, V22, P979, DOI 10.1016/S0196-9781(01)00407-7
   BABIZHAYEV MA, 1994, BIOCHEM J, V304, P509, DOI 10.1042/bj3040509
   Babizhayev MA, 2000, J ANTI-AGING MED, V3, P43, DOI 10.1089/rej.1.2000.3.43
   BABIZHAYEV MA, 2006, J PHARM TOXICOL, V1, P201
   Babizhayev MA, 1998, US Patent, Patent No. [5,792,784, 5792784]
   BABIZHAYEV MA, 2004, Patent No. 2004000351
   BABIZHAYEV MA, 2009, EXPERT REV OPHTHALMO, V4, P581
   BABIZHAYEV MA, 2004, Patent No. 2004028536
   Babizhayev MA, 2004, Patent No. [2004064866, WO 2004/064866 PCT/JP2004/000351]
   Babizhayev MA, 2006, CURR DRUG THER, V1, P91, DOI 10.2174/157488506775268425
   Babizhayev MA, 2008, DRUG DEV IND PHARM, V34, P1071, DOI [10.1080/03639040801958413, 10.1080/03639040801958413 ]
   Babizhayev Mark A, 2004, Drugs R D, V5, P125, DOI 10.2165/00126839-200405030-00001
   Babizhayev Mark A, 2002, Drugs R D, V3, P87, DOI 10.2165/00126839-200203020-00004
   Babizhayev MA, 2009, AM J THER, V16, P517, DOI 10.1097/MJT.0b013e318195e327
   Babizhayev MA, 2009, J DRUG TARGET, V17, P36, DOI [10.1080/10611860802438736, 10.1080/10611860802438736 ]
   Bai CX, 1998, J PHARMACOL TOX MET, V40, P39, DOI 10.1016/S1056-8719(98)00034-3
   BARRY BW, 1988, INT J COSMETIC SCI, V10, P281, DOI 10.1111/j.1467-2494.1988.tb00028.x
   Baynes JW, 2001, EXP GERONTOL, V36, P1527, DOI 10.1016/S0531-5565(01)00138-3
   Biswas A, 2008, BIOCHEMISTRY-US, V47, P804, DOI 10.1021/bi7011965
   Bloemendal H, 2004, PROG BIOPHYS MOL BIO, V86, P407, DOI 10.1016/j.pbiomolbio.2003.11.012
   BOLDYREV AA, 1987, BIOCHEM INT, V15, P1105
   BOLDYREV AA, 1990, ADV ENZYME REGUL, V30, P175
   Bonnefont-Rousselot D, 2000, DIABETES METAB, V26, P163
   BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19
   Calabrese V, 1999, DRUG EXP CLIN RES, V25, P43
   Calabrese V, 2001, INT J TISSUE REACT, V23, P127
   Calabrese V, 2008, NEUROCHEM RES, V16
   Cevc G, 1998, BBA-BIOMEMBRANES, V1368, P201, DOI 10.1016/S0005-2736(97)00177-6
   CHOI HK, 1990, PHARMACEUT RES, V7, P1099, DOI 10.1023/A:1015915922363
   Conner JR, 2005, ANN NY ACAD SCI, V1043, P824, DOI 10.1196/annals.1333.095
   Diamant S, 2001, J BIOL CHEM, V276, P39586, DOI 10.1074/jbc.M103081200
   EGBARIA K, 1990, ANTIMICROB AGENTS CH, V34, P107, DOI 10.1128/AAC.34.1.107
   Fenton WA, 1997, PROTEIN SCI, V6, P743
   Foldvari M, 1999, BIOTECHNOL APPL BIOC, V30, P129
   Gavin BA, 2007, PLOS GENET, V3, P2358, DOI 10.1371/journal.pgen.0030206
   GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0
   GREEN PG, 1991, PHARMACEUT RES, V8, P1121, DOI 10.1023/A:1015846100305
   Guiotto A, 2007, BIOORGAN MED CHEM, V15, P6158, DOI 10.1016/j.bmc.2007.06.029
   Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0
   HEIT MC, 1994, PHARM RES-DORDR, V11, P1000, DOI 10.1023/A:1018983303842
   Hipkiss AR, 2006, EXP GERONTOL, V41, P464, DOI 10.1016/j.exger.2006.03.004
   Hipkiss AR, 2009, BIOGERONTOLOGY, V10, P523, DOI 10.1007/s10522-008-9188-9
   Hipkiss AR, 2002, ANN NY ACAD SCI, V959, P285, DOI 10.1111/j.1749-6632.2002.tb02100.x
   Hipkiss AR, 1998, BIOCHEM BIOPH RES CO, V248, P28, DOI 10.1006/bbrc.1998.8806
   Hobart LJ, 2004, LIFE SCI, V75, P1379, DOI 10.1016/j.lfs.2004.05.002
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   HUNT JV, 1993, BIOCHEM J, V291, P529, DOI 10.1042/bj2910529
   Jonak C., 2006, International Journal of Cosmetic Science, V28, P233, DOI 10.1111/j.1467-2494.2006.00327.x
   Kang JH, 2002, BBA-GEN SUBJECTS, V1570, P89, DOI 10.1016/S0304-4165(02)00158-7
   Kang JH, 2007, B KOREAN CHEM SOC, V28, P1881
   Kosmaoglou M, 2001, TRENDS MOL MED, V7, P414
   Lohwasser C, 2006, J INVEST DERMATOL, V126, P291, DOI 10.1038/sj.jid.5700070
   LORAND L, 1988, ADV POSTTRANSLATIONA, P79
   LU MYF, 1992, PHARMACEUT RES, V9, P1575, DOI 10.1023/A:1015860324161
   MCDERMOTT M, 1991, BIOCHEMISTRY-US, V30, P8653, DOI 10.1021/bi00099a023
   Mehta AD, 2005, J ENZYM INHIB MED CH, V20, P199, DOI 10.1080/14756360400020538
   Mikami KI, 2006, J GASTROEN HEPATOL, V21, P1669, DOI 10.1111/j.1440-1746.2006.04328.x
   MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603
   MIYACHI Y, 1987, J INVEST DERMATOL, V89, P111, DOI 10.1111/1523-1747.ep12580453
   Muranov K O, 2008, Vestn Oftalmol, V124, P3
   NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257
   NIEMIEC SM, 1995, PHARMACEUT RES, V12, P1184, DOI 10.1023/A:1016268027854
   Ohkawara T, 2006, WORLD J GASTROENTERO, V12, P6178, DOI 10.3748/wjg.v12.i38.6178
   Pegova A, 2000, COMP BIOCHEM PHYS B, V127, P443, DOI 10.1016/S0305-0491(00)00279-0
   Perlmutter DH, 2002, PEDIATR RES, V52, P832, DOI 10.1203/01.PDR.0000036878.28942.14
   Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200
   Santosa S, 2005, CAN MED ASSOC J, V173, P861, DOI 10.1503/cmaj.1031425
   Schoneich C, 2006, EXP GERONTOL, V41, P807, DOI 10.1016/j.exger.2006.07.002
   Seidler NW, 2004, ARCH BIOCHEM BIOPHYS, V427, P110, DOI 10.1016/j.abb.2004.04.024
   SEVERIN SE, 1964, P PLEN SESS 7 INT BI, P45
   SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130
   SPECTOR A, 1973, INVEST OPHTH VISUAL, V12, P225
   Srivastava K, 2008, EXP EYE RES, V87, P356, DOI 10.1016/j.exer.2008.07.001
   Stitt AW, 2005, PHARMACOL REP, V57, P156
   Stitt AW, 2005, DIABETES, V54, P785, DOI 10.2337/diabetes.54.3.785
   Szwergold BS, 2005, BIOCHEM BIOPH RES CO, V336, P36, DOI 10.1016/j.bbrc.2005.08.033
   TACHIBANA K, 1991, J PHARM PHARMACOL, V43, P270, DOI 10.1111/j.2042-7158.1991.tb06681.x
   Takemoto L, 2000, MOL VIS, V6, P164
   Trouba KJ, 2002, ANTIOXID REDOX SIGN, V4, P665, DOI 10.1089/15230860260220175
   Ukeda H, 2002, BIOSCI BIOTECH BIOCH, V66, P36, DOI 10.1271/bbb.66.36
   Vlassara H, 1996, ANN MED, V28, P419, DOI 10.3109/07853899608999102
   Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2
   Yamagishi S, 2005, CURR DIABETES REV, V1, P93, DOI 10.2174/1573399052952631
   Yan H, 2006, MOL VIS, V12, P205
   Yan H, 2005, BBA-MOL BASIS DIS, V1741, P120, DOI 10.1016/j.bbadis.2004.11.008
   Zhang C, 2003, CURR OPIN CHEM BIOL, V7, P28, DOI 10.1016/S1367-5931(02)00015-7
NR 96
TC 6
Z9 7
U1 1
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0960-3271
EI 1477-0903
J9 HUM EXP TOXICOL
JI Hum. Exp. Toxicol.
PD JUL
PY 2011
VL 30
IS 7
BP 736
EP 761
DI 10.1177/0960327110377526
PG 26
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 780WV
UT WOS:000291891200022
PM 20656726
DA 2022-11-30
ER

PT J
AU Tanito, M
   Anderson, RE
AF Tanito, Masaki
   Anderson, Robert E.
TI Dual roles of polyunsaturated fatty acids in retinal physiology and
   pathophysiology associated with retinal degeneration
SO CLINICAL LIPIDOLOGY
LA English
DT Review
DE 4-hydroxyhexenal; 4-hydroxynonenal; age-related macular degeneration;
   docosahexaenoic acid; glutathione; light-induced retinal degeneration;
   nuclear factor E2-related factor 2; polyunsaturated fatty acid;
   thioredoxin
ID DOMINANT RETINITIS-PIGMENTOSA; LIGHT-DAMAGE SUSCEPTIBILITY; ROD OUTER
   SEGMENTS; MACULAR DEGENERATION; DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS;
   RAT RETINA; LIPID-PEROXIDATION; EPITHELIAL-CELLS; DIETARY-FAT
AB Retinas are highly enriched with long-chain polyunsaturated fatty acids (PUFAs). The reduction of docosahexenoic acid in the photoreceptor outer segment membrane leads to a reduction in the electroretinographic response, suggesting crucial roles for PUFAs in normal retinal physiology. Epidemiological studies suggest a correlation between environmental light exposure and the development/progression of human retinal degenerations such as age-related macular degeneration and retinitis pigmentosa. The double bonds in PUFAs could be target substrates to propagate photooxidative stress in photoreceptors. Light exposure to animals results in selective losses of photoreceptor and retinal pigment epithelial cells and post-translational modifications of retinal proteins by 4-hydroxynonenal and 4-hydroxyhexenal. These end products of nonezymatic oxidation of n-6 and n-3 PUFAs, respectively, are likely to be involved in the light-induced retinal degeneration. Low levels of 4-HNE generated by low levels of environmental light exposure upregulate endogenous redox molecules such as thioreodoxin and thioreodoxin reductase via the nuclear-factor E2-related factor 2/antioxidant-responsive element pathway in the retina, and confer retinal neuroprotection. This paper highlights the dual roles of retinal PUFAs in cellular physiology and pathology.
C1 [Tanito, Masaki] Shimane Univ, Dept Ophthalmol, Fac Med, Izumo, Shimane 6938501, Japan.
   [Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Norman, OK 73019 USA.
   [Anderson, Robert E.] Dean A McGee Eye Inst, Norman, OK USA.
C3 Shimane University; University of Oklahoma System; University of
   Oklahoma Health Sciences Center; University of Oklahoma - Norman
RP Tanito, M (通讯作者)，Shimane Univ, Dept Ophthalmol, Fac Med, Enya 89-81, Izumo, Shimane 6938501, Japan.
EM tanito-oph@umin.ac.jp
FU NIH [EY00871, EY04149, EY12190, RR17703]; Foundation Fighting Blindness;
   Research to Prevent Blindness
FX This work was supported by grants from the NIH (EY00871, EY04149,
   EY12190 and RR17703) and the Foundation Fighting Blindness to REA, and
   an unrestricted grant from Research to Prevent Blindness. The authors
   have no other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Anderson RE, 2004, LIPIDS, V39, P1121, DOI 10.1007/s11745-004-1338-8
   Anderson RE, 2002, MOL VIS, V8, P351
   Anderson RE, 2001, INVEST OPHTH VIS SCI, V42, P1715
   ANDERSON RE, 1987, EXP EYE RES, V44, P155, DOI 10.1016/S0014-4835(87)80034-9
   ANDERSON RE, 1972, ARCH BIOCHEM BIOPHYS, V151, P270, DOI 10.1016/0003-9861(72)90497-3
   Awasthi YC, 2004, FREE RADICAL BIO MED, V37, P607, DOI 10.1016/j.freeradbiomed.2004.05.033
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENOLKEN RM, 1973, SCIENCE, V182, P1253, DOI 10.1126/science.182.4118.1253
   Bicknell IR, 2002, MOL VIS, V8, P333
   BIRCH DG, 1992, INVEST OPHTH VIS SCI, V33, P2365
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P7103, DOI 10.1073/pnas.95.12.7103
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   ESTERBAUER H, 1993, AM J CLIN NUTR, V57, P779, DOI 10.1093/ajcn/57.5.779S
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   HOFFMAN DR, 1995, EXP EYE RES, V60, P279, DOI 10.1016/S0014-4835(05)80110-1
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Iles KE, 2005, FREE RADICAL BIO MED, V39, P355, DOI 10.1016/j.freeradbiomed.2005.03.026
   Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45
   Kaldi I, 2003, MOL VIS, V9, P337
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Lecomte M, 1996, J NEUROCHEM, V66, P2160
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   NEURINGER M, 1991, RETINAL DEGENERATION, P1
   Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200
   Organisciak DT, 1999, PHOTOCHEM PHOTOBIOL, V70, P261, DOI 10.1111/j.1751-1097.1999.tb07998.x
   PENN JS, 1987, EXP EYE RES, V44, P779, DOI 10.1016/S0014-4835(87)80041-6
   PENN JS, 1986, EXP EYE RES, V43, P915, DOI 10.1016/0014-4835(86)90070-9
   PENN JS, 1987, EXP EYE RES, V44, P767, DOI 10.1016/S0014-4835(87)80040-4
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   Rex TS, 2004, HUM GENE THER, V15, P960, DOI 10.1089/hum.2004.15.960
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Sunadai S, 2006, FREE RADICAL RES, V40, P837, DOI 10.1080/10715760600719557
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   Tanito M, 2005, J NEUROSCI, V25, P2396, DOI 10.1523/JNEUROSCI.4866-04.2005
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tanito M, 2009, J LIPID RES, V50, P807, DOI 10.1194/jlr.M800170-JLR200
   Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x
   Tytell M, 1989, Prog Clin Biol Res, V314, P523
   UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   van Reyk DM, 2003, REDOX REP, V8, P187, DOI 10.1179/135100003225002673
   VANKUIJK FJGM, 1990, BIOCHIM BIOPHYS ACTA, V1043, P116, DOI 10.1016/0005-2760(90)90118-H
   Weisinger HS, 1996, ANN NUTR METAB, V40, P91, DOI 10.1159/000177900
   WHEELER TG, 1975, SCIENCE, V188, P1312, DOI 10.1126/science.1145197
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   WIEGAND RD, 1995, EXP EYE RES, V60, P291, DOI 10.1016/S0014-4835(05)80111-3
   Winkler BS, 1999, MOL VIS, V5
NR 59
TC 13
Z9 13
U1 0
U2 5
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1758-4299
EI 1758-4302
J9 CLIN LIPIDOL
JI Clin. Lipidol.
PD DEC
PY 2009
VL 4
IS 6
BP 821
EP 827
DI 10.2217/CLP.09.65
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 532XA
UT WOS:000272782500018
DA 2022-11-30
ER

PT J
AU Boekhoorn, SS
   Vingerling, JR
   Hofman, A
   de Jong, PTVM
AF Boekhoorn, Sharmila S.
   Vingerling, Johannes R.
   Hofman, Albert
   de Jong, Paulus T. V. M.
TI Alcohol consumption and risk of aging macula disorder in a general
   population - The Rotterdam Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; CORONARY-HEART-DISEASE; BEAVER DAM EYE; VISUAL
   IMPAIRMENT; DEGENERATION; PREVALENCE; MORTALITY; BLINDNESS; DRINKING;
   SMOKING
AB Objective: To investigate the possible relationship between overall or specific alcohol consumption and risk of aging macula disorder (AMD), a synonym for age-related macular degeneration, in a general population.
   Methods: Alcohol consumption and risk of early or late incident AMD (iAMD) were examined among all participants in the prospective population-based Rotterdam Study, with complete data on alcohol consumption among 4229 subjects at risk of AMD. Aging macula disorder was graded according to the International Classification and Grading System for AMD by 2 trained professionals who were masked for all other determinants. We used Cox proportional hazards regression models to estimate hazard ratios and corresponding 95% confidence intervals.
   Results: During a mean follow-up period of 8.0 years, 600 cases of iAMD were identified, of which 519 were early iAMD and 81 were late iAMD. After correction for age, sex, smoking, complement factor H genotype status, and other potential confounders, we did not find an association between overall or specific alcohol consumption and development of early iAMD or dry or wet late iAMD.
   Conclusion: Our findings suggest that overall or specific alcohol consumption is not a risk factor for AMD.
C1 [de Jong, Paulus T. V. M.] Netherlands Royal Acad Arts & Sci, Netherlands Inst Neurosci, NL-1105 BA Amsterdam, Netherlands.
   [Boekhoorn, Sharmila S.; Vingerling, Johannes R.; Hofman, Albert; de Jong, Paulus T. V. M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Boekhoorn, Sharmila S.; Vingerling, Johannes R.; Hofman, Albert; de Jong, Paulus T. V. M.] Erasmus MC, Dept Biostat, Rotterdam, Netherlands.
   [Vingerling, Johannes R.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [de Jong, Paulus T. V. M.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Netherlands Royal Acad Arts & Sci, Netherlands Inst Neurosci, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM p.dejong@nin.knaw.nl
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911
   Feunekes GIJ, 1999, AM J EPIDEMIOL, V150, P105
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731
   RITTER LL, 1995, AM J OPHTHALMOL, V120, P190, DOI 10.1016/S0002-9394(14)72607-8
   Shaper AG, 1998, NOVART FDN SYMP, V216, P173
   SHAPER AG, 1990, BRIT J ADDICT, V85, P837
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vliegenthart R, 2002, AM J EPIDEMIOL, V155, P332, DOI 10.1093/aje/155.4.332
   Wu DF, 2003, ALCOHOL RES HEALTH, V27, P277
NR 28
TC 12
Z9 13
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUN
PY 2008
VL 126
IS 6
BP 834
EP 839
DI 10.1001/archopht.126.6.834
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 310RX
UT WOS:000256548900011
PM 18541849
DA 2022-11-30
ER

PT J
AU Lifshitz, T
   Levy, J
AF Lifshitz, T
   Levy, J
TI Posterior assisted levitation: Long-term follow-up data
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID RETAINED LENS FRAGMENTS; CATARACT-SURGERY; PHACOEMULSIFICATION;
   VITRECTOMY; MANAGEMENT; NUCLEUS
AB Purpose: To report the long-term outcome of posterior assisted levitation (PAL) in cases of a sinking dropped nucleus. Setting: Department of Ophthalmology, Soroka University Medical Center, Beer-Sheva, Israel.
   Methods: The medical records of all the patients having cataract surgery at Soroka University Medical Center from January 1999 to December 2002 were retrospectively reviewed. The PAL technique was used in 7 eyes, 3 of which had mini-nuc cataract surgery and 4 of which had phacoemulsification. Posterior assisted levitation was done because of an intraciperative posterior capsule tear with vitreous loss and a sinking dropped nucleus. A spatula was inserted via the pars plana, and the nucleus was lifted to and removed from the anterior chamber.
   Results: The follow-up ranged from 16 to 28 months. The postoperative visual acuity was 20/40 or better in all but 2 eyes, which had 20/50 acuity because of age-related macular degeneration and diabetic macular edema, respectively. No postoperative complications were observed.
   Conclusions: The PAL technique was successfully performed during cataract surgery in 7 eyes with a posterior capsule tear, vitreous loss, and a sinking dropped nucleus. There were no complications over the long-term follow-up.
C1 Ben Gurion Univ Negev, Dept Ophthalmol, Soroka Univ Med Ctr, IL-84101 Beer Sheva, Israel.
C3 Ben Gurion University; Soroka Medical Center
RP Levy, J (通讯作者)，Ben Gurion Univ Negev, Dept Ophthalmol, Soroka Univ Med Ctr, POB 151, IL-84101 Beer Sheva, Israel.
EM ljaime@bgu.ac.il
CR BLODI BA, 1992, OPHTHALMOLOGY, V99, P41
   Borne MJ, 1996, OPHTHALMOLOGY, V103, P971, DOI 10.1016/S0161-6420(96)30577-0
   BROWNING DJ, 1985, OPHTHALMOLOGY, V92, P1647
   Chang DF, 2003, J CATARACT REFR SURG, V29, P1860, DOI 10.1016/S0886-3350(03)00216-5
   GILLILAND GD, 1992, OPHTHALMOLOGY, V99, P1263
   GUZEK JP, 1987, OPHTHALMOLOGY, V94, P461, DOI 10.1016/S0161-6420(87)33424-4
   Kageyama T, 2001, BRIT J OPHTHALMOL, V85, P1038, DOI 10.1136/bjo.85.9.1038
   KIM JE, 1994, OPHTHALMOLOGY, V101, P1827
   LAMBROU FH, 1992, OPHTHALMOLOGY, V99, P1260
   Margherio RR, 1997, OPHTHALMOLOGY, V104, P1426, DOI 10.1016/S0161-6420(97)30120-1
   Packard RBS, 1991, MANUAL CATARACT INTR, P47
   Rao SK, 1999, J CATARACT REFR SURG, V25, P1311
   Stefaniotou M, 2003, J CATARACT REFR SURG, V29, P1985, DOI 10.1016/S0886-3350(03)00245-1
   Teichmann KD, 2002, SURV OPHTHALMOL, V47, P78, DOI 10.1016/S0039-6257(01)00284-3
   Vajpayee RB, 2001, SURV OPHTHALMOL, V45, P473, DOI 10.1016/S0039-6257(01)00195-3
NR 15
TC 15
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD MAR
PY 2005
VL 31
IS 3
BP 499
EP 502
DI 10.1016/j.jcrs.2004.07.021
PG 4
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 917VD
UT WOS:000228496400015
PM 15811737
DA 2022-11-30
ER

PT J
AU Ferrara, N
AF Ferrara, N
TI Vascular endothelial growth factor: Basic science and clinical progress
SO ENDOCRINE REVIEWS
LA English
DT Review
ID LINDAU TUMOR-SUPPRESSOR; FACTOR GENE-EXPRESSION; RECEPTOR TYROSINE
   KINASE; FACTOR-INDUCED ANGIOGENESIS; MESSENGER-RIBONUCLEIC-ACID;
   IMMUNOGLOBULIN-LIKE DOMAIN; RABBIT ISCHEMIC HINDLIMB; PIGMENT
   EPITHELIAL-CELLS; HUMAN PROSTATE CARCINOMA; MIDDLE CEREBRAL-ARTERY
AB Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models. Hypoxia has been shown to be a major inducer of VEGF gene transcription. The tyrosine kinases Flt-1 (VEGFR-1) and Flk-1/KDR (VEGFR-2) are high-affinity VEGF receptors. The role of VEGF in developmental angiogenesis is emphasized by the finding that loss of a single VEGF allele results in defective vascularization and early embryonic lethality. VEGF is critical also for reproductive and bone angiogenesis. Substantial evidence also implicates VEGF as a mediator of pathological angiogenesis. In situ hybridization studies demonstrate expression of VEGF mRNA in the majority of human tumors. Anti-VEGF monoclonal antibodies and other VEGF inhibitors block the growth of several tumor cell lines in nude mice. Clinical trials with various VEGF inhibitors in a variety of malignancies are ongoing. Very recently, an anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the Food and Drug Administration as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. Furthermore, VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.
C1 Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
RI CLIHON, Residencia Medica/K-4896-2013
OI CLIHON, Residencia Medica/0000-0001-6734-2513
CR ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435
   Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Adini A, 2002, CANCER RES, V62, P2749
   Afuwape AO, 2003, GENE THER, V10, P1950, DOI 10.1038/sj.gt.3302104
   Agrawal R, 1998, HUM REPROD, V13, P651, DOI 10.1093/humrep/13.3.651
   Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Amano H, 2003, J EXP MED, V197, P221, DOI 10.1084/jem.20021408
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   ASANO M, 1995, CANCER RES, V55, P5296
   Autiero M, 2003, J THROMB HAEMOST, V1, P1356, DOI 10.1046/j.1538-7836.2003.00263.x
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Bagri A, 2002, ADV EXP MED BIOL, V515, P13
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Barleon B, 1997, J BIOL CHEM, V272, P10382
   Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206
   Bates DO, 1996, AM J PHYSIOL-HEART C, V271, pH2520, DOI 10.1152/ajpheart.1996.271.6.H2520
   Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Bates DO, 2002, CANCER RES, V62, P4123
   Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114
   BAUTERS C, 1995, CIRCULATION, V91, P2802, DOI 10.1161/01.CIR.91.11.2802
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165
   Borgstrom P, 1998, PROSTATE, V35, P1
   Borgstrom P, 1999, ANTICANCER RES, V19, P4203
   Borgstrom P, 1996, CANCER RES, V56, P4032
   Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534-200206000-00033
   BROWN LF, 1993, AM J PATHOL, V143, P1255
   BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1
   BROWN LF, 1993, CANCER RES, V53, P4727
   Broxmeyer HE, 1995, INT J HEMATOL, V62, P203
   Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6
   Campochiaro PA, 2003, ONCOGENE, V22, P6537, DOI 10.1038/sj.onc.1206773
   Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359-6446(03)02866-6
   Carlevaro MF, 2000, J CELL SCI, V113, P59
   Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   CARR BR, 1982, FERTIL STERIL, V38, P303
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cho NK, 2002, CELL, V108, P865, DOI 10.1016/S0092-8674(02)00676-1
   Christenson LK, 1997, J CLIN ENDOCR METAB, V82, P2135, DOI 10.1210/jc.82.7.2135
   Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5
   Davis-Smyth T, 1998, J BIOL CHEM, V273, P3216, DOI 10.1074/jbc.273.6.3216
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871
   Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545
   DENNIS PA, 1990, J CELL PHYSIOL, V144, P84, DOI 10.1002/jcp.1041440112
   DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542
   Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DEWAILLY D, 1994, CLIN ENDOCRINOL, V41, P557, DOI 10.1111/j.1365-2265.1994.tb01818.x
   Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978
   Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213
   Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939
   Dor Y, 2001, AM J PHYSIOL-CELL PH, V280, pC1367, DOI 10.1152/ajpcell.2001.280.6.C1367
   Dunaif A, 2001, ANNU REV MED, V52, P401, DOI 10.1146/annurev.med.52.1.401
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   DVORAK HF, 1987, LAB INVEST, V57, P673
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   EHRMANN RL, 1968, J NATL CANCER I, V41, P1329
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Ellis LM, 1998, EUR J CANCER, V34, P337, DOI 10.1016/S0959-8049(97)10068-5
   Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273
   ENGEL T, 1972, AM J OBSTET GYNECOL, V112, P1052, DOI 10.1016/0002-9378(72)90180-9
   Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Ergun S, 2000, MOL CELL, V5, P311, DOI 10.1016/S1097-2765(00)80426-8
   ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   FERRARA N, 1995, LAB INVEST, V72, P615
   Ferrara N, 2003, AM J PATHOL, V162, P1881, DOI 10.1016/S0002-9440(10)64322-2
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Fong GH, 1999, DEVELOPMENT, V126, P3015
   FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607
   Fraser HM, 2000, ENDOCRINOLOGY, V141, P995, DOI 10.1210/en.141.3.995
   Fraser HM, 2000, BRIT MED BULL, V56, P787, DOI 10.1258/0007142001903364
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Fuh G, 2000, J BIOL CHEM, V275, P26690
   Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349
   Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198
   Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6
   Fulghesu AM, 2001, FERTIL STERIL, V76, P326, DOI 10.1016/S0015-0282(01)01919-7
   Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096
   Garber K, 2002, NAT BIOTECHNOL, V20, P1067, DOI 10.1038/nbt1102-1067
   Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504
   Garner Alec, 1994, P1625
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064
   Goede V, 1998, LAB INVEST, V78, P1385
   GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355
   Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795
   GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325
   GOSPODAROWICZ D, 1978, P NATL ACAD SCI USA, V75, P847, DOI 10.1073/pnas.75.2.847
   GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95
   GRAOR RA, 1991, INTERVENTIONAL TREAT
   Gratton JP, 2003, CANCER CELL, V4, P31, DOI 10.1016/S1535-6108(03)00168-5
   GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111
   GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915
   Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   Guidi AJ, 1996, CANCER-AM CANCER SOC, V78, P454
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Haigh JJ, 2003, DEV BIOL, V262, P225, DOI 10.1016/S0012-1606(03)00356-7
   Haigh JJ, 2000, DEVELOPMENT, V127, P1445
   Hamilton W.J., 1962, HUMAN EMBRYOLOGY
   HANING RV, 1985, OBSTET GYNECOL, V66, P220
   Harada K, 1996, AM J PHYSIOL-HEART C, V270, pH1791, DOI 10.1152/ajpheart.1996.270.5.H1791
   Harrigan MR, 2003, ACTA NEUROCHIR, V145, P49, DOI 10.1007/s00701-002-1035-1
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005
   Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039
   Hazzard TM, 2002, BIOL REPROD, V67, P1305, DOI 10.1095/biolreprod67.4.1305
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8
   Hiratsuka S, 2001, CANCER RES, V61, P1207
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Hull ML, 2003, J CLIN ENDOCR METAB, V88, P2889, DOI 10.1210/jc.2002-021912
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4
   Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
   JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568
   JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848
   JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756
   Joukov V, 1996, EMBO J, V15, P290
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kabrun N, 1997, DEVELOPMENT, V124, P2039
   KAMAT BR, 1995, AM J PATHOL, V146, P157
   Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2
   Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013
   Kaser A, 2003, EMBO REP, V4, P469, DOI 10.1038/sj.embor.embor830
   Kawasaki T, 1999, DEVELOPMENT, V126, P4895
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   KEMMANN E, 1981, AM J OBSTET GYNECOL, V141, P58, DOI 10.1016/0002-9378(81)90675-X
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kishimoto J, 2000, AM J PATHOL, V157, P103, DOI 10.1016/S0002-9440(10)64522-1
   Kitamoto Y, 1997, J CLIN INVEST, V99, P2351, DOI 10.1172/JCI119416
   KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217
   Klein M, 2001, J CLIN ENDOCR METAB, V86, P656, DOI 10.1210/jc.86.2.656
   Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829
   Kobayashi H, 1998, J MOL ENDOCRINOL, V20, P363, DOI 10.1677/jme.0.0200363
   KOCH AE, 1994, J IMMUNOL, V152, P4149
   Kong HL, 1998, HUM GENE THER, V9, P823, DOI 10.1089/hum.1998.9.6-823
   Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865
   Kozin SV, 2001, CANCER RES, V61, P39
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586
   Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344
   Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6
   Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545
   Lange T, 2003, J BIOL CHEM, V278, P17164, DOI 10.1074/jbc.M212224200
   LASLEY B, 1994, J SOC GYNECOL INVEST, V1, P247, DOI 10.1177/107155769400100402
   LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562
   LeCouter J, 2003, ENDOCRINOLOGY, V144, P2606, DOI 10.1210/en.2002-0146
   LeCouter J, 2002, NAT MED, V8, P913, DOI 10.1038/nm0902-913
   LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000
   Lee CG, 2000, CANCER RES, V60, P5565
   Lee EW, 2003, J CLIN INVEST, V111, P1853, DOI 10.1172/JCI200316929
   Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988
   Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299
   Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Levin ER, 1998, J CLIN INVEST, V102, P1978, DOI 10.1172/JCI4814
   Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884
   LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Liu JJ, 1999, INVEST OPHTH VIS SCI, V40, P752
   LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638
   Lloyd RV, 1999, ENDOCR PATHOL, V10, P229, DOI 10.1007/BF02738884
   Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732
   Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800
   LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994
   Mack CA, 1998, J THORAC CARDIOV SUR, V115, P168, DOI 10.1016/S0022-5223(98)70455-6
   Mack CA, 1998, J VASC SURG, V27, P699, DOI 10.1016/S0741-5214(98)70236-8
   MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   MAGLIONE D, 1993, ONCOGENE, V8, P925
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Maru Y, 1998, ONCOGENE, V16, P2585, DOI 10.1038/sj.onc.1201786
   Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889
   Matsumoto T., 2001, SCI STKE, V112, P1
   Matsumoto Y, 2002, J IMMUNOL, V168, P5824, DOI 10.4049/jimmunol.168.11.5824
   MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911
   MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026
   Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1
   MCCLURE N, 1994, LANCET, V344, P235, DOI 10.1016/S0140-6736(94)93001-5
   McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815
   Melnyk O, 1996, CANCER RES, V56, P921
   Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6
   MESRI EA, 1995, CIRC RES, V76, P161, DOI 10.1161/01.RES.76.2.161
   Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   Miller DL, 2000, MOL CELL BIOL, V20, P2260, DOI 10.1128/MCB.20.6.2260-2268.2000
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Miotla J, 2000, LAB INVEST, V80, P1195, DOI 10.1038/labinvest.3780127
   Miquerol L, 2000, DEVELOPMENT, V127, P3941
   Mole DR, 2001, IUBMB LIFE, V52, P43
   MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995
   Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892
   Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411
   Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097
   Mueller MD, 2003, FERTIL STERIL, V79, P386, DOI 10.1016/S0015-0282(02)04577-6
   Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192
   Munier AI, 2002, EMBO REP, V3, P1195, DOI 10.1093/embo-reports/kvf242
   MURATA T, 1992, GRAEF ARCH CLIN EXP, V230, P428, DOI 10.1007/BF00175927
   Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244
   Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Nicol D, 1997, J UROLOGY, V157, P1482, DOI 10.1016/S0022-5347(01)65028-6
   NICOSIA RF, 1994, AM J PATHOL, V145, P1023
   ObergWelsh C, 1997, MOL CELL ENDOCRINOL, V126, P125, DOI 10.1016/S0303-7207(96)03977-9
   Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273
   Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9
   Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609
   Oku T, 1998, CANCER RES, V58, P4185
   OLK RJ, 1993, DIABETIC RETINOPATHY
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   OLSON TA, 1994, CANCER RES, V54, P276
   Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675
   Ortega Nathalie, 1999, Frontiers in Bioscience, V4, pD141, DOI 10.2741/Ortega
   Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740
   Oura H, 2003, BLOOD, V101, P560, DOI 10.1182/blood-2002-05-1516
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   PAJUSOLA K, 1992, CANCER RES, V52, P5738
   PALADE GE, 1979, ACTA PHYSIOL SCAND, P11
   Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19
   PATZ A, 1980, INVEST OPHTH VIS SCI, V19, P1133
   Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675
   PEPPER MS, 1994, EXP CELL RES, V210, P298, DOI 10.1006/excr.1994.1042
   Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346
   PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5
   PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271
   Pham CD, 1998, CANCER INVEST, V16, P225, DOI 10.3109/07357909809039771
   Phillips G D, 1994, In Vivo, V8, P961
   PHILLIPS HS, 1993, INT J ONCOL, V2, P913
   PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   Pipp F, 2003, CIRC RES, V92, P378, DOI 10.1161/01.RES.0000057997.77714.72
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   PLOUET J, 1990, J BIOL CHEM, V265, P22071
   Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390
   PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x
   Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151
   POOLE AR, 1991, CARTILAGE MOL ASPECT, P179
   Presta LG, 1997, CANCER RES, V57, P4593
   Prewett M, 1999, CANCER RES, V59, P5209
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Raab S, 2004, THROMB HAEMOSTASIS, V91, P595, DOI 10.1160/TH03-09-0582
   Rafii S, 2002, SEMIN CELL DEV BIOL, V13, P61, DOI 10.1006/scdb.2001.0285
   RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254
   Reinders MEJ, 2003, J CLIN INVEST, V112, P1655, DOI 10.1172/JCI17712
   Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Rowe AJ, 2002, BIOL REPROD, V67, P1180, DOI 10.1095/biolreprod67.4.1180
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   Ruzinova MB, 2003, CANCER CELL, V4, P277, DOI 10.1016/S1535-6108(03)00240-X
   Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115
   SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Saleh M, 1996, CANCER RES, V56, P393
   Schoenberger J, 2004, ENDOCRINOLOGY, V145, P1031, DOI 10.1210/en.2003-1228
   Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664
   Schwarzenbach H, 2004, J ANDROL, V25, P128
   Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423
   Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SENGER DR, 1990, CANCER RES, V50, P1774
   Seno H, 2002, CANCER RES, V62, P506
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   SHEN H, 1993, BLOOD, V81, P2767
   Shi YP, 1999, BIOCHEM BIOPH RES CO, V254, P480, DOI 10.1006/bbrc.1998.9966
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shifren JL, 1998, J CLIN ENDOCR METAB, V83, P1342, DOI 10.1210/jc.83.4.1342
   Shifren JL, 1996, J CLIN ENDOCR METAB, V81, P3112, DOI 10.1210/jc.81.8.3112
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450
   Siemeister G, 1996, CANCER RES, V56, P2299
   Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413
   Soh EY, 2000, SURGERY, V128, P1059, DOI 10.1067/msy.2000.110430
   Soh EY, 1996, SURGERY, V120, P944, DOI 10.1016/S0039-6060(96)80038-9
   Soh EY, 1997, J CLIN ENDOCR METAB, V82, P3741, DOI 10.1210/jc.82.11.3741
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Sone H, 2001, BIOCHEM BIOPH RES CO, V281, P562, DOI 10.1006/bbrc.2001.4395
   Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048
   Sowter HM, 1997, LAB INVEST, V77, P607
   Stacker SA, 2002, NAT REV CANCER, V2, P573, DOI 10.1038/nrc863
   Stewart RJ, 2001, J UROLOGY, V165, P688, DOI 10.1097/00005392-200102000-00095
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Strawn LM, 1996, CANCER RES, V56, P3540
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Sugimoto H, 2003, J BIOL CHEM, V278, P12605, DOI 10.1074/jbc.C300012200
   Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977
   Suzuki K, 1996, CANCER RES, V56, P3004
   Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   Takeshita S, 1996, LAB INVEST, V75, P487
   Takeshita S, 1996, BIOCHEM BIOPH RES CO, V227, P628, DOI 10.1006/bbrc.1996.1556
   TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018
   Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X
   Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200
   Tarkka T, 2003, J GENE MED, V5, P560, DOI 10.1002/jgm.392
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   TERMAN BI, 1991, ONCOGENE, V6, P1677
   THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tomisawa M, 1999, EUR J CANCER, V35, P133, DOI 10.1016/S0959-8049(98)00278-0
   Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399
   Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589
   Tsuzuki Y, 2000, CANCER RES, V60, P6248
   Tulandi T, 2000, FERTIL STERIL, V74, P585, DOI 10.1016/S0015-0282(00)00684-1
   Turner HE, 2003, ENDOCR REV, V24, P600, DOI 10.1210/er.2002-0008
   Uchida S, 1998, BRIT J CANCER, V77, P1704, DOI 10.1038/bjc.1998.281
   VAISMAN N, 1990, J BIOL CHEM, V265, P19461
   van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292
   Volm M, 1997, INT J CANCER, V74, P64, DOI 10.1002/(SICI)1097-0215(19970220)74:1<64::AID-IJC11>3.0.CO;2-I
   Volm M, 1997, ANTICANCER RES, V17, P99
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483
   WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857
   Wedge SR, 2000, CANCER RES, V60, P970
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621
   Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071
   WIZIGMANN VS, 1995, CANCER RES, V155, P1358
   Wood JM, 2000, CANCER RES, V60, P2178
   Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096
   Yamamoto S, 1997, BRIT J CANCER, V76, P1221, DOI 10.1038/bjc.1997.537
   Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yang RH, 1996, J CARDIOVASC PHARM, V27, P838, DOI 10.1097/00005344-199606000-00011
   YEN SSC, 1996, REPROD ENDOCRINOLOGY, P1117
   Yoshiji H, 1996, CANCER RES, V56, P2013
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
   Yuan L, 2002, DEVELOPMENT, V129, P4797
   ZELEZNIK AJ, 1981, ENDOCRINOLOGY, V109, P356, DOI 10.1210/endo-109-2-356
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200
   ZETTER BR, 1988, CHEST S, V93, P159
   Zhang XB, 2001, CANCER RES, V61, P6050
   Zheng M, 2001, J VIROL, V75, P9828, DOI 10.1128/JVI.75.20.9828-9835.2001
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
   Zimmermann RC, 2001, MICROVASC RES, V62, P15, DOI 10.1006/mvre.2001.2312
   Zimmermann RC, 2001, J CLIN ENDOCR METAB, V86, P768, DOI 10.1210/jc.86.2.768
   Zundel W, 2000, GENE DEV, V14, P391
NR 435
TC 2644
Z9 2890
U1 14
U2 522
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0163-769X
EI 1945-7189
J9 ENDOCR REV
JI Endocr. Rev.
PD AUG
PY 2004
VL 25
IS 4
BP 581
EP 611
DI 10.1210/er.2003-0027
PG 31
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 843RA
UT WOS:000223101000004
PM 15294883
OA Bronze
DA 2022-11-30
ER

PT J
AU Li, X
   Holt, RR
   Keen, CL
   Morse, LS
   Yiu, G
   Hackman, RM
AF Li, Xiang
   Holt, Roberta R.
   Keen, Carl L.
   Morse, Lawrence S.
   Yiu, Glenn
   Hackman, Robert M.
TI Goji Berry Intake Increases Macular Pigment Optical Density in Healthy
   Adults: A Randomized Pilot Trial
SO NUTRIENTS
LA English
DT Article
DE goji berry; zeaxanthin; lutein; carotenoids; age-related macular
   degeneration; macular pigment optical density
ID LYCIUM-BARBARUM; EYE DISEASE; AGE; ZEAXANTHIN; LUTEIN; DEGENERATION;
   CAROTENOIDS; BENEFITS; ZINC; HPLC
AB Age-related macular degeneration (AMD) is the third leading cause of blindness worldwide. Macular pigment optical density (MPOD), a biomarker for AMD, is a non-invasive measure to assess risk. The macula xanthophyll pigments lutein (L) and zeaxanthin (Z) protect against blue light and provide oxidant defense, which can be indexed by MPOD. This study examined the effects of Z-rich goji berry intake on MPOD and skin carotenoids in healthy individuals. A randomized, unmasked, parallel-arm study was conducted with 27 participants, aged 45-65, who consumed either 28 g of goji berries or a supplement containing 6 mg L and 4 mg Z (LZ), five times weekly for 90 days. After 90 days, MPOD was significantly increased in the goji berry group at 0.25 and 1.75 retinal eccentricities (p = 0.029 and p = 0.044, respectively), while no changes were noted in the LZ group. Skin carotenoids were significantly increased in the goji berry group at day 45 (p = 0.025) and day 90 (p = 0.006), but not in the LZ group. Regular intake of goji berries in a healthy middle-aged population increases MPOD may help prevent or delay the development of AMD.
C1 [Li, Xiang; Holt, Roberta R.; Keen, Carl L.; Hackman, Robert M.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.
   [Keen, Carl L.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA.
   [Morse, Lawrence S.; Yiu, Glenn] Univ Calif Davis, Med Ctr, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis;
   University of California System; University of California Davis
RP Hackman, RM (通讯作者)，Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.
EM xxlli@ucdavis.edu; rrholt@ucdavis.edu; clkeen@ucdavis.edu;
   lsmorse@ucdavis.edu; gyiu@ucdavis.edu; rmhackman@ucdavis.edu
OI Hackman, Robert/0000-0003-3505-6461; Li, Xiang/0000-0003-3417-8475
FU College of Agricultural and Environmental Sciences; Department of
   Nutrition, University of California, Davis
FX This research was supported by graduate student awards to XL from the
   College of Agricultural and Environmental Sciences and the Department of
   Nutrition, University of California, Davis.
CR Amagase H, 2011, FOOD RES INT, V44, P1702, DOI 10.1016/j.foodres.2011.03.027
   Arunkumar R, 2018, EYE, V32, P992, DOI 10.1038/s41433-018-0044-0
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bovier ER, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108178
   Breithaupt DE, 2004, BRIT J NUTR, V91, P707, DOI 10.1079/BJN20041105
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Bungau S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9783429
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Conrady CD, 2017, INVEST OPHTH VIS SCI, V58, P3616, DOI 10.1167/iovs.17-21818
   Edwards CG, 2020, INT J PSYCHOPHYSIOL, V148, P13, DOI 10.1016/j.ijpsycho.2019.12.006
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Howells O, 2011, GRAEF ARCH CLIN EXP, V249, P315, DOI 10.1007/s00417-010-1577-5
   Iannaccone A, 2016, FOODS, V5, DOI 10.3390/foods5020032
   Jahns L, 2019, NUTR J, V18, DOI 10.1186/s12937-019-0500-0
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Karioti A, 2014, J AGR FOOD CHEM, V62, P12529, DOI 10.1021/jf503769s
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Li S, 2018, INT J OPHTHALMOL-CHI, V11, P970, DOI 10.18240/ijo.2018.06.12
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Maret W, 2006, J TRACE ELEM MED BIO, V20, P3, DOI 10.1016/j.jtemb.2006.01.006
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Neelam K, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010246
   Nzeuwa IBY, 2019, J FOOD QUALITY, DOI 10.1155/2019/4396027
   Obana A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66962-2
   Phelan D, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101133
   Pitts SBJ, 2018, PUBLIC HEALTH NUTR, V21, P1664, DOI 10.1017/S136898001700430X
   Potterat O, 2010, PLANTA MED, V76, P7, DOI 10.1055/s-0029-1186218
   Ranard KM, 2017, EUR J NUTR, V56, P537, DOI 10.1007/s00394-017-1580-2
   Rodriguez-Concepcion M, 2018, PROG LIPID RES, V70, P62, DOI 10.1016/j.plipres.2018.04.004
   Rush E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010113
   Scott TM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090919
   Song MK, 2011, BIOCHEM PHARMACOL, V82, P1209, DOI 10.1016/j.bcp.2011.07.089
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   USDA What We Eat in America, NHANES 2017 2018 IND
   van der Made SM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/9035745
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   Wang CC, 2010, FOOD CHEM, V120, P184, DOI 10.1016/j.foodchem.2009.10.005
   Widomska J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051333
   World Health Organization, BLINDN VIS IMP
   Zhao LQ, 2013, IND CROP PROD, V47, P51, DOI 10.1016/j.indcrop.2013.02.008
NR 48
TC 4
Z9 4
U1 4
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD DEC
PY 2021
VL 13
IS 12
AR 4409
DI 10.3390/nu13124409
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA XY3TA
UT WOS:000736897900001
PM 34959963
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Pietras-Baczewska, A
   Jasinska, E
   Toro, MD
   Bonfiglio, V
   Reibaldi, M
   Avitabile, T
   Nowomiejska, K
   Rejdak, R
AF Pietras-Baczewska, Agata
   Jasinska, Ewa
   Toro, Mario Damiano
   Bonfiglio, Vincenza
   Reibaldi, Michele
   Avitabile, Teresio
   Nowomiejska, Katarzyna
   Rejdak, Robert
TI Urgent Vitrectomy with Vancomycin Infusion, Silicone Oil Endotamponade,
   and General Antibiotic Treatment in Multiple Cases of Endophthalmitis
   from a Single Day of Intravitreal Injections-Case Series
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE post-injection endophthalmitis; bacterial endophthalmitis; Streptococcus
   mitis; oralis; endophthalmitis treatment
AB The aim of this study was to report on the anatomical and functional results of surgical management of seven cases of endophthalmitis related to a single day of intravitreal aflibercept injections. Patients with signs of endophthalmitis who underwent aflibercept injections (seven eyes) performed on the same day were retrospectively evaluated. The data of visual acuity and optical coherence tomography (OCT) within nine months of the follow-up and the treatment and results of microbiological cultures are reported. Four of the total seven cases had a positive bacterial culture outcome (Streptococcus mitis). All patients underwent vitrectomy combined with phacoemulsification when the eyes were not pseudophakic, vancomycin infusion, and silicone oil tamponade within 24 h; additionally, systemic antibiotics were administered intravenously. The final best-corrected visual acuity (BCVA) after the treatment was finger counting or light perception in all cases, and all eyes were saved with disruption of the inner retinal layers and stabilization of the retina in regard to changes related to the wet age-related macular degeneration (AMD). Although the retinal anatomy was mostly preserved, most of the patients affected by Streptococcus mitis-induced endophthalmitis did not regain baseline vision after the therapy.
C1 [Pietras-Baczewska, Agata; Jasinska, Ewa; Toro, Mario Damiano; Nowomiejska, Katarzyna; Rejdak, Robert] Med Univ Lublin, Dept Gen Ophthalmol, PL-20059 Lublin, Poland.
   [Toro, Mario Damiano] Cardinal Stefan Wyszynski Univ, Coll Med, Fac Med, PL-01815 Warsaw, Poland.
   [Bonfiglio, Vincenza] Univ Palermo, Ophthalmol Sect, Dept Expt Biomed & Clin Neurosci, I-90133 Palermo, Italy.
   [Reibaldi, Michele] Univ Turin, Eye Clin Sect, Dept Surg Sci, I-10124 Turin, Italy.
   [Avitabile, Teresio] Univ Catania, Dept Ophthalmol, I-95124 Catania, Italy.
C3 Medical University of Lublin; Cardinal Stefan Wyszynski University in
   Warsaw; University of Palermo; University of Turin; University of
   Catania
RP Pietras-Baczewska, A (通讯作者)，Med Univ Lublin, Dept Gen Ophthalmol, PL-20059 Lublin, Poland.
EM agatapie@gmail.com; Ewjasisnka@gmail.com; toro.mario@email.it;
   enzabonfiglio@gmail.com; mreibaldi@libero.it; t.avitabile@unict.it;
   katarzyna.nowomiejska@umlub.pl; robert.rejdak@umlub.pl
RI Reibaldi, Michele/AAL-1113-2021; Avitabile, Teresio/AAC-6076-2022
OI Nowomiejska, Katarzyna/0000-0002-5805-8761; BONFIGLIO,
   VINCENZA/0000-0001-5468-0978; Reibaldi, Michele/0000-0003-1368-6729;
   Rejdak, Robert/0000-0003-3321-2723
CR Adebayo A, 2011, GRAEF ARCH CLIN EXP, V249, P111, DOI 10.1007/s00417-010-1426-6
   Azad R, 2003, GRAEF ARCH CLIN EXP, V241, P478, DOI 10.1007/s00417-003-0670-4
   Bali E, 2003, Bull Soc Belge Ophtalmol, P9
   Barry P, 2007, J CATARACT REFR SURG, V33, P978, DOI 10.1016/j.jcrs.2007.02.032
   Bek-Thomsen M, 2008, INFECT IMMUN, V76, P1889, DOI 10.1128/IAI.01511-07
   d'Azy CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156431
   Dave VP, 2019, J OPHTHALMIC INFLAMM, V9, DOI 10.1186/s12348-019-0187-6
   Durand ML, 2017, CLIN MICROBIOL REV, V30, P597, DOI 10.1128/CMR.00113-16
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Garg SJ, 2015, OSLI RETINA, V46, P1028, DOI 10.3928/23258160-20151027-07
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Kurniawan ED, 2018, CLIN EXP OPHTHALMOL, V46, P424, DOI 10.1111/ceo.13077
   Kutlu SS, 2008, INT J INFECT DIS, V12, pE107, DOI 10.1016/j.ijid.2008.01.003
   Lalwani GA, 2008, OPHTHALMOLOGY, V115, P473, DOI 10.1016/j.ophtha.2007.06.006
   Li AL, 2016, RETINA-J RET VIT DIS, V36, P1349, DOI 10.1097/IAE.0000000000000901
   Lu X, 2017, EYE, V31, P1488, DOI 10.1038/eye.2017.100
   Marquart ME, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209849
   Marsot A, 2012, CLIN PHARMACOKINET, V51, P1, DOI 10.2165/11596390-000000000-00000
   Matthews JL, 2014, OPHTHALMOLOGY, V121, P702, DOI 10.1016/j.ophtha.2013.10.015
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Ornek Nurgul, 2014, Indian J Ophthalmol, V62, P388, DOI 10.4103/0301-4738.126994
   Ozdamar A, 1999, RETINA-J RET VIT DIS, V19, P122
   Reibaldi M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8071031
   Rejdak R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1830-6
   Relhan N, 2018, AM J OPHTHALMOL, V187, pXX, DOI 10.1016/j.ajo.2017.11.021
   Sachdeva MM, 2016, J OPHTHALMIC INFLAMM, V6, DOI 10.1186/s12348-015-0069-5
   Shivaramaiah Hegde Sharat, 2018, Am J Ophthalmol Case Rep, V10, P211, DOI 10.1016/j.ajoc.2018.02.030
   Uhr JH, 2021, RETINA-J RET VIT DIS, V41, P1470, DOI 10.1097/IAE.0000000000003050
   Whatmore AM, 2000, INFECT IMMUN, V68, P1374, DOI 10.1128/IAI.68.3.1374-1382.2000
   Yospaiboon Y, 2018, CLIN OPHTHALMOL, V12, DOI 10.2147/OPTH.S161217
NR 30
TC 5
Z9 5
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2021
VL 10
IS 5
AR 1059
DI 10.3390/jcm10051059
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QV9KM
UT WOS:000628281100001
PM 33806541
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tang, WY
   Guo, JL
   Liu, W
   Ma, J
   Xu, GZ
AF Tang, Wenyi
   Guo, Jingli
   Liu, Wei
   Ma, Jun
   Xu, Gezhi
TI Ferrostatin-1 attenuates ferroptosis and protects the retina against
   light-induced retinal degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Retinal degeneration; Ferroptosis; Photoreceptor; Ferrostatin-1; Lipid
   peroxidation
ID LIPID-PEROXIDATION; CELL-DEATH; DAMAGE; ILLUMINATION; INFLAMMATION; IRON
AB Degenerative retinal diseases, including age-related macular degeneration, are serious diseases that may lead to irreversible retinal neuron damage and permanent vision impairment. There are currently no effective treatments for these diseases due to our incomplete understanding of the underlying pathological mechanisms. Ferroptosis, a newly identified iron-dependent mode of cell death, is implicated in various diseases. However, it is unknown whether ferroptosis is involved in light-induced retinal degeneration. In this study, we found that light exposure significantly reduced the viability of photoreceptor cells in vitro and induced pro-ferroptotic changes, including iron accumulation, mitochondrial shrinkage, glutathione depletion, increased malondialdehyde (MDA), and decreased protein expression of SLC7A11 and GPX4. The effects of light exposure on ferroptosis were attenuated by ferrostatin-1. Consistently, the results of in vivo studies demonstrated that ferrostatin-1 protected against light induced ferroptosis. And it exerted therapeutic effects by inhibiting neuroinflammation and prevented the effects of light exposure on the structure and function of the retina. The findings reveal an important role of ferroptosis in the pathogenesis of light-induced retinal degeneration and suggest that ferroptosis may be a novel treatment target for preventing retinal degeneration.
   (c) 2021 Elsevier Inc. All rights reserved.
C1 [Tang, Wenyi; Guo, Jingli; Liu, Wei; Ma, Jun; Xu, Gezhi] Fudan Univ, Eye Inst, Eye & ENT Hosp, Shanghai, Peoples R China.
   [Tang, Wenyi; Guo, Jingli; Liu, Wei; Ma, Jun; Xu, Gezhi] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai, Peoples R China.
   [Tang, Wenyi; Guo, Jingli; Liu, Wei; Ma, Jun; Xu, Gezhi] Fudan Univ, Key Lab Visual Impairment & Restorat, Shanghai, Peoples R China.
   [Tang, Wenyi; Guo, Jingli; Liu, Wei; Ma, Jun; Xu, Gezhi] Fudan Univ, Chinese Acad Med Sci, Natl Hlth Commiss, Key Lab Myopia, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Fudan University
RP Ma, J; Xu, GZ (通讯作者)，Fudan Univ, Eye & ENT Hosp, 83 Fenyang Rd, Shanghai 200031, Peoples R China.
EM ma886615@126.com; xugezhi@sohu.com
FU National Natural Science Foundation of China [81700863, 81770944,
   81800846]
FX This work was supported by the National Natural Science Foundation of
   China [grant numbers 81700863, 81770944, 81800846] .
CR Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Bai T, 2020, FREE RADICAL BIO MED, V160, P92, DOI 10.1016/j.freeradbiomed.2020.07.026
   Berkowitz BA, 1998, INVEST OPHTH VIS SCI, V39, P391
   Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020
   Conrad M, 2019, NAT CHEM BIOL, V15, P1137, DOI 10.1038/s41589-019-0408-1
   Contin MA, 2016, EYE, V30, P255, DOI 10.1038/eye.2015.221
   Daher B, 2019, CANCER RES, V79, P3877, DOI 10.1158/0008-5472.CAN-18-3855
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Forcina GC, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800311
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Gu RP, 2019, CLIN EXP OPHTHALMOL, V47, P646, DOI 10.1111/ceo.13452
   Guo CX, 2016, INVEST OPHTH VIS SCI, V57, P3961, DOI 10.1167/iovs.15-16643
   Hambright WS, 2017, REDOX BIOL, V12, P8, DOI 10.1016/j.redox.2017.01.021
   Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002
   Jaadane I, 2015, FREE RADICAL BIO MED, V84, P373, DOI 10.1016/j.freeradbiomed.2015.03.034
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Koppula P, 2021, PROTEIN CELL, V12, P599, DOI 10.1007/s13238-020-00789-5
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   Mao HM, 2020, PROG BIOPHYS MOL BIO, V155, P20, DOI 10.1016/j.pbiomolbio.2020.04.001
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Miotto G, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101328
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Peng JJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107922
   Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455
   Tang WY, 2018, INVEST OPHTH VIS SCI, V59, P6014, DOI 10.1167/iovs.18-25213
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Viringipurampeer IA, 2014, CELL DEATH DIFFER, V21, P665, DOI 10.1038/cdd.2013.191
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Yoshizawa K, 2002, GRAEF ARCH CLIN EXP, V240, P214, DOI 10.1007/s00417-002-0427-5
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
NR 31
TC 9
Z9 9
U1 2
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 9
PY 2021
VL 548
BP 27
EP 34
DI 10.1016/j.bbrc.2021.02.055
EA FEB 2021
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA RB1JH
UT WOS:000631872200004
PM 33631670
DA 2022-11-30
ER

PT J
AU Karakus, MM
   Caliskan, UK
AF Karakus, Methiye M.
   Caliskan, Ufuk K.
TI Phytotherapeutic and Natural Compound Applications for Age-Related,
   Inflammatory and Serious Eye Ailments
SO CURRENT MOLECULAR PHARMACOLOGY
LA English
DT Review
DE Eye disease; phytotherapeutic; natural compounds; macular degeneration;
   cataracts; glaucoma; herbal treatment
ID ACID PHENETHYL ESTER; ENDOTHELIAL GROWTH-FACTOR; PIGMENT
   OPTICAL-DENSITY; GINKGO-BILOBA EXTRACT; POLYUNSATURATED FATTY-ACIDS;
   HELIOTROPIUM-INDICUM LINN; ENDOTOXIN-INDUCED UVEITIS; OCULAR BLOOD-FLOW;
   OXIDATIVE STRESS; MACULAR DEGENERATION
AB Tissue cells of the eye are sensitive to oxidative stress, leading to oxidative damage and inflammation, which have crucial roles in the pathogenesis of most of the eye diseases. Moreover, factors such as age, angiogenesis, ischemia, genetic predisposition, diabetes, obesity, and smoking affect the onset and progression of ocular anomalies. Major eye diseases are either age-related such as age-related macular degeneration, cataracts, diabetic retinopathy, glaucoma, dry eye, or inflammatory eye diseases such as blepharitis, conjunctivitis, uveitis and other retinal pathologies, which can cause ocular damage and visual problems through oxidative stress, inflammation pathways. Although there are conventional chemical or surgical treatments, due to their mainly antiapoptotic, anti-inflammatory and antioxidant properties, phytotherapeutic preparations and their natural compounds can be applied to prevent or treat eye disease as follows: oral, topical or both. Thus, this study aims to comprehensively evaluate the pre-clinical and clinical studies of the phytotherapeutics and natural compounds used in the prevention and treatment of common serious and painful eye diseases. Moreover, for the first time, nature-derived preparations/supplements commonly used for eye problems also included in this review to present applications of the extracts/compounds in the pharmaceutical field.
C1 [Karakus, Methiye M.; Caliskan, Ufuk K.] Gazi Univ, Dept Pharmacognosy & Pharmaceut Bot, Fac Pharm, TR-06330 Ankara, Turkey.
C3 Gazi University
RP Karakus, MM; Caliskan, UK (通讯作者)，Gazi Univ, Dept Pharmacognosy & Pharmaceut Bot, Fac Pharm, TR-06330 Ankara, Turkey.
EM methiyemancak@gazi.edu.tr; ukoca@gazi.edu.tr
OI MANCAK KARAKUS, METHIYE/0000-0002-0085-7552
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Akpek EK, 2011, OPHTHALMOLOGY, V118, P1242, DOI 10.1016/j.ophtha.2010.12.016
   Akyol S, 2014, J OCUL PHARMACOL TH, V30, P700, DOI 10.1089/jop.2014.0046
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Alex AF, 2010, CURR EYE RES, V35, P1021, DOI 10.3109/02713683.2010.506970
   Anonymous, 2005, International Ophthalmology Clinics, V45, P1, DOI 10.1097/01.iio.0000155938.83083.94
   [Anonymous], 2014, TAIWAN J OPHTHALMOL, DOI DOI 10.1016/J.TJO.2014.03.005
   Aoki A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20723
   Arrua M, 2015, Arch Soc Esp Oftalmol, V90, P112, DOI 10.1016/j.oftal.2013.09.003
   Asbell PA, 2005, LANCET, V365, P599
   Auran J., 2019, COLUMBIA GUIDE BASIC, V9, P97, DOI [10.1007/978-3-030-10886-1_9, DOI 10.1007/978-3-030-10886-1_9]
   Barabino S, 2014, EUR J OPHTHALMOL, V24, P173, DOI 10.5301/ejo.5000355
   Beilin M, 2000, J OCUL PHARMACOL TH, V16, P217, DOI 10.1089/jop.2000.16.217
   Belda JI, 1999, MECH AGEING DEV, V107, P159, DOI 10.1016/S0047-6374(98)00144-4
   Biswas NR, 2001, PHYTOTHER RES, V15, P618, DOI 10.1002/ptr.896
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Bonyadi MHJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-399
   BRAVETTI G O, 1989, Annali di Ottalmologia e Clinica Oculistica, V115, P109
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Calkins DJ, 2012, PROG RETIN EYE RES, V31, P702, DOI 10.1016/j.preteyeres.2012.07.001
   Cekic O, 1998, BRIT J OPHTHALMOL, V82, P186, DOI 10.1136/bjo.82.2.186
   Cekic O, 1999, OPHTHALMIC RES, V31, P332, DOI 10.1159/000055555
   Chan CM, 2010, MOL VIS, V16, P586
   Chan HHL, 2019, J ETHNOPHARMACOL, V236, P336, DOI 10.1016/j.jep.2019.03.023
   Chen L, 2015, OPHTHALMIC RES, V54, P157, DOI 10.1159/000439026
   Chen M, 2010, EXP EYE RES, V90, P437, DOI 10.1016/j.exer.2009.12.004
   Chen Y, 2008, GRAEF ARCH CLIN EXP, V246, P373, DOI 10.1007/s00417-007-0728-9
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho JY, 2001, PLANTA MED, V67, P213, DOI 10.1055/s-2001-12005
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chung SH, 2012, MOL VIS, V18, P1966
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cordova C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091282
   Corso L, 2016, PURINERG SIGNAL, V12, P161, DOI 10.1007/s11302-015-9490-3
   Davies NP, 2002, INVEST OPHTH VIS SCI, V43, P281
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Deschenes J, 2008, OCUL IMMUNOL INFLAMM, V16, P1, DOI 10.1080/09273940801899822
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Dias MF, 2018, PROG RETIN EYE RES, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Doganay S, 2006, CURR EYE RES, V31, P147, DOI 10.1080/02713680500514685
   Duarte DA, 2015, J NUTR BIOCHEM, V26, P64, DOI 10.1016/j.jnutbio.2014.09.003
   Dulull NK, 2018, CURR MOL PHARMACOL, V11, P237, DOI 10.2174/1874467211666180125163009
   Duncan G, 2003, LIFE SCI, V72, P2013, DOI 10.1016/S0024-3205(03)00064-X
   Erdurmus M, 2014, HANDBOOK OF NUTRITION, DIET, AND THE EYE, P21, DOI 10.1016/B978-0-12-401717-7.00003-4
   Evans J.R., 2000, COCHRANE DB SYST REV, V2
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Falsini B, 2009, GRAEF ARCH CLIN EXP, V247, P1223, DOI 10.1007/s00417-009-1064-z
   Fernandez-Albarral JA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174110
   Fernandez-Sanchez L, 2015, MOLECULES, V20, P13875, DOI 10.3390/molecules200813875
   Fernandez-Sanchez L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043074
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fong DS, 2003, DIABETES CARE, V26, P226, DOI 10.2337/diacare.26.1.226
   Gao YY, 2007, CORNEA, V26, P136, DOI 10.1097/01.ico.0000244870.62384.79
   Gao YY, 2012, CORNEA, V31, P14, DOI 10.1097/ICO.0b013e31820ce56c
   Gao YY, 2005, INVEST OPHTH VIS SCI, V46, P3089, DOI 10.1167/iovs.05-0275
   Giannaccare G, 2019, CORNEA, V38, P565, DOI 10.1097/ICO.0000000000001884
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Gorusupudi A., 2016, CAROTENOIDS NUTR ANA, V5, P59
   Gupta SK, 2002, OPHTHALMIC RES, V34, P258, DOI 10.1159/000063881
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Gurib-Fakim Ameenah, 2006, Molecular Aspects of Medicine, V27, P1, DOI 10.1016/j.mam.2005.07.008
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Head K A, 2001, Altern Med Rev, V6, P141
   Head K A, 1999, Altern Med Rev, V4, P342
   HEPLER RS, 1971, J AMER MED ASSOC, V217, P1392, DOI 10.1001/jama.1971.03190100074024
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hong TY, 2016, VASC PHARMACOL, V76, P18, DOI 10.1016/j.vph.2015.08.015
   Hu BJ, 2011, INT J OPHTHALMOL-CHI, V4, P303, DOI 10.3980/j.issn.2222-3959.2011.03.19
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Huang Qing-shan, 2002, Zhongguo Zhong Xi Yi Jie He Za Zhi, V22, P432
   Huang SY, 2004, CLIN NUTR, V23, P615, DOI 10.1016/j.clnu.2003.10.010
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Ishizuka F, 2013, EUR J PHARMACOL, V703, P1, DOI [10.1016/j.ephar.2013.02.007, 10.1016/j.ejphar.2013.02.007]
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Jarvinen T, 2002, PHARMACOL THERAPEUT, V95, P203, DOI 10.1016/S0163-7258(02)00259-0
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jayakody SA, 2015, PROG RETIN EYE RES, V46, P31, DOI 10.1016/j.preteyeres.2015.01.003
   Jia LY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1700, DOI 10.1001/archophthalmol.2008.512
   KAHN HA, 1974, AM J OPHTHALMOL, V78, P58, DOI 10.1016/0002-9394(74)90010-5
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P29
   Kim J, 2015, INT J FOOD SCI NUTR, V66, P236, DOI 10.3109/09637486.2014.979319
   Kim NR, 2010, J GINSENG RES, V34, P237, DOI 10.5142/jgr.2010.34.3.237
   Kim YH, 2012, ACTA OPHTHALMOL, V90, pE31, DOI 10.1111/j.1755-3768.2011.02243.x
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Koo H, 2012, J KOREAN MED SCI, V27, P1574, DOI 10.3346/jkms.2012.27.12.1574
   Kowluru RA, 2003, FREE RADICAL RES, V37, P1169, DOI 10.1080/10715760310001604189
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kronschlager M, 2013, EXP EYE RES, V113, P26, DOI 10.1016/j.exer.2013.04.015
   Kumar B, 2014, EXP EYE RES, V125, P193, DOI 10.1016/j.exer.2014.06.009
   Kumar PA, 2005, MOL VIS, V11, P561
   Kyei S., 2015, J ALLERGY CAIRO, V2015
   Kyei S, 2017, CURR EYE RES, V42, P394, DOI 10.1080/02713683.2016.1198486
   Kyei S, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0027-1
   Kyei S, 2016, INT J OPHTHALMOL-CHI, V9, P528, DOI 10.18240/ijo.2016.04.08
   Kyrou I., 2018, ENDOTEXT
   Kyselova Z, 2012, J FOOD NUTR RES-SLOV, V51, P185
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lashay Alireza, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P32
   Lee Sung Min, 2010, Korean J Ophthalmol, V24, P101, DOI 10.3341/kjo.2010.24.2.101
   Li CZ, 2012, INVEST OPHTH VIS SCI, V53, P3241, DOI 10.1167/iovs.11-8406
   Lima VC, 2010, INVEST OPHTH VIS SCI, V51, P5840, DOI 10.1167/iovs.09-4695
   Lindsey JD, 2015, NEUROBIOL AGING, V36, P1969, DOI 10.1016/j.neurobiolaging.2014.12.021
   Losada M, 1997, DOC OPHTHALMOL, V93, P223, DOI 10.1007/BF02569062
   Lou MF, 2000, J OCUL PHARMACOL TH, V16, P137, DOI 10.1089/jop.2000.16.137
   Ma QH, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/231570
   Macsai Marian S, 2008, Trans Am Ophthalmol Soc, V106, P336
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Makri O.E., 2012, ACTA OPHTHALMOL, V90, P1
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Manikandan R, 2010, CURR EYE RES, V35, P122, DOI 10.3109/02713680903447884
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Mi XS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045469
   Milbury Paul E., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P254, DOI 10.1080/21551197.2012.698221
   Mitra RN, 2016, ADV EXP MED BIOL, V854, P463, DOI 10.1007/978-3-319-17121-0_62
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moreau KL, 2012, TRENDS MOL MED, V18, P273, DOI 10.1016/j.molmed.2012.03.005
   Mrudula T, 2007, BIOCHEM BIOPH RES CO, V361, P528, DOI 10.1016/j.bbrc.2007.07.059
   Nagaki Y, 2001, JPN J OPHTHALMOL, V45, P216, DOI 10.1016/S0021-5155(01)00330-6
   Nejabat M, 2017, J CLIN DIAGN RES, V11, pNC5, DOI 10.7860/JCDR/2017/23336.9426
   Nelson JD, 2011, INVEST OPHTH VIS SCI, V52, P1930, DOI 10.1167/iovs.10-6997b
   Nemesure B, 2007, OPHTHALMOLOGY, V114, P1810, DOI 10.1016/j.ophtha.2007.04.003
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Ohgami K, 2005, INVEST OPHTH VIS SCI, V46, P275, DOI 10.1167/iovs.04-0715
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Paeng SH, 2015, INT J MOL MED, V35, P1419, DOI 10.3892/ijmm.2015.2116
   Pan J, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-013-0409-1
   Panahi Y, 2017, BIOMED PHARMACOTHER, V86, P620, DOI 10.1016/j.biopha.2016.11.106
   Pandya U, 2000, TOXICOL LETT, V115, P195, DOI 10.1016/S0378-4274(00)00191-0
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Peng W, 2013, J ETHNOPHARMACOL, V148, P729, DOI 10.1016/j.jep.2013.05.007
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Pinheiro Jr. Manuel Neuzimar, 2007, Arq. Bras. Oftalmol., V70, P649, DOI 10.1590/S0004-27492007000400016
   Pinho BR, 2013, J PHARM PHARMACOL, V65, P1681, DOI 10.1111/jphp.12081
   Pinna A, 2007, CORNEA, V26, P260, DOI 10.1097/ICO.0b013e318033d79b
   Pirhan D, 2016, CURR EYE RES, V41, P59, DOI 10.3109/02713683.2015.1004719
   Porcella A, 2001, EUR J NEUROSCI, V13, P409, DOI 10.1046/j.0953-816X.2000.01401.x
   Qi Y, 2013, EXP EYE RES, V107, P44, DOI 10.1016/j.exer.2012.11.011
   Quaranta L, 2003, OPHTHALMOLOGY, V110, P359, DOI 10.1016/S0161-6420(02)01745-1
   Raju T. N., 2006, Indian Journal of Experimental Biology, V44, P733
   RAO GN, 1983, OPHTHALMIC RES, V15, P173, DOI 10.1159/000265254
   Rauf A, 2017, FOOD FUNCT, V8, P4284, DOI [10.1039/c7fo01300k, 10.1039/C7FO01300K]
   Riazi A, 2017, ITAL J MED, V11, P196, DOI 10.4081/itjm.2016.758
   Richards A, 2010, PEDIATR REV, V31, P196, DOI 10.1542/pir.31-5-196
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Ritch R, 2007, CAN J OPHTHALMOL, V42, P425, DOI 10.3129/i07-044
   Riva A, 2017, EUR REV MED PHARMACO, V21, P2518
   ROBISON WG, 1982, RETINA-J RET VIT DIS, V2, P263, DOI 10.1097/00006982-198202040-00012
   Rohini S., 2018, DRUG INVENT TODAY, V10
   Rolando Maurizio, 2007, BMC Ophthalmol, V7, P5, DOI 10.1186/1471-2415-7-5
   Rosenbaum JT, 2019, SEMIN ARTHRITIS RHEU, V49, P438, DOI 10.1016/j.semarthrit.2019.06.004
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Rx Media Pharma, 2020, INTERACTIVE PHARM IN
   Sahdev AK., 2018, ASIAN J PHARM PHARM, V4, P421
   Saif A.T, 2017, DELTA J OPHTHALMOL, V18, P51
   Salib GM, 2006, J CATARACT REFR SURG, V32, P772, DOI 10.1016/j.jcrs.2005.10.034
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   Sandhu P., 2011, J PHARM SCI RES, V3, P1127
   Sangeetha J., 2018, INT J PHARM DRUG ANA, V6, P191
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Scanlon G, 2015, RETINA-J RET VIT DIS, V35, P1808, DOI 10.1097/IAE.0000000000000551
   Sen S, 2013, PHYTOTHER RES, V27, P290, DOI 10.1002/ptr.4719
   Sepahi S, 2018, AM J OPHTHALMOL, V190, P89, DOI 10.1016/j.ajo.2018.03.007
   Sheppard JD, 2013, CORNEA, V32, P1297, DOI 10.1097/ICO.0b013e318299549c
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohn E, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030140
   Solomon A, 2001, INVEST OPHTH VIS SCI, V42, P2283
   Song E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112054
   Song Y, 2016, J NEUROIMMUNOL, V301, P1, DOI 10.1016/j.jneuroim.2016.11.001
   Sun Xiaoshen, 2015, Yale Journal of Biology and Medicine, V88, P265
   Sunkireddy P, 2013, COLLOID SURFACE B, V112, P554, DOI 10.1016/j.colsurfb.2013.07.068
   Suryanarayana P, 2005, INVEST OPHTH VIS SCI, V46, P2092, DOI 10.1167/iovs.04-1304
   Szumny D, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/939402
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P396, DOI 10.1167/iovs.06-0872
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tighe S, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.7.2
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Huynh TP, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/549174
   Turner K, 2000, CORNEA, V19, P492, DOI 10.1097/00003226-200007000-00018
   Tzeng TF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8090572
   Tzeng Thing-Fong, 2013, Evid Based Complement Alternat Med, V2013, P340645, DOI 10.1155/2013/340645
   Upadhyay S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/504253
   VARMA SD, 1984, CURR EYE RES, V3, P35, DOI 10.3109/02713688408997186
   Varma SD, 2008, J OCUL PHARMACOL TH, V24, P439, DOI 10.1089/jop.2008.0035
   Varma SD, 2010, MOL VIS, V16, P2626
   Velpandian T., 2016, PHARM OCULAR THERAPE, V20, P517
   Velpandian T, 2016, PHARM OCULAR THERAPE, P269
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   WU ZZ, 1983, CHINESE MED J-PEKING, V96, P445
   Xuan B, 1999, J OCUL PHARMACOL TH, V15, P143, DOI 10.1089/jop.1999.15.143
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yang XG, 2017, J MOL NEUROSCI, V61, P581, DOI 10.1007/s12031-017-0899-8
   Yao N, 2010, J AGR FOOD CHEM, V58, P4731, DOI 10.1021/jf904572a
   Yar AS, 2012, J MED FOOD, V15, P391, DOI 10.1089/jmf.2011.0135
   Yildirim O, 2007, CELL BIOCHEM FUNCT, V25, P693, DOI 10.1002/cbf.1377
   Yilmaz A, 2005, CURR EYE RES, V30, P755, DOI 10.1080/02713680590967962
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhang B, 2007, BRAIN RES, V1159, P40, DOI 10.1016/j.brainres.2007.05.029
   Zhang L, 2013, ASIAN PAC J TROP MED, V6, P145, DOI 10.1016/S1995-7645(13)60011-5
   Zhao YE, 2012, OPHTHAL EPIDEMIOL, V19, P95, DOI 10.3109/09286586.2011.642052
   Zhu W, 2014, NUTR REV, V72, P662, DOI 10.1111/nure.12145
NR 212
TC 0
Z9 0
U1 3
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1874-4672
EI 1874-4702
J9 CURR MOL PHARMACOL
JI Curr. Molec. Pharmacol.
PY 2021
VL 14
IS 5
BP 689
EP 713
DI 10.2174/1874467213666201221163210
PG 25
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA WX9AM
UT WOS:000718880600003
PM 33349225
DA 2022-11-30
ER

PT J
AU Froger, N
   Matonti, F
   Roubeix, C
   Forster, V
   Ivkovic, I
   Brunel, N
   Baudouin, C
   Sahel, JA
   Picaud, S
AF Froger, Nicolas
   Matonti, Frederic
   Roubeix, Christophe
   Forster, Valerie
   Ivkovic, Ivana
   Brunel, Nadege
   Baudouin, Christophe
   Sahel, Jose-Alain
   Picaud, Serge
TI VEGF is an autocrine/paracrine neuroprotective factor for injured
   retinal ganglion neurons
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; NERVE-FIBER LAYER; HIPPOCAMPAL-NEURONS;
   VITREOUS LEVELS; AQUEOUS-HUMOR; ANTI-VEGF; CELLS; EXPRESSION; PROTEIN;
   RANIBIZUMAB
AB Vascular endothelial growth factor-A (VEGF) is the angiogenic factor promoting the pathological neovascularization in age-related macular degeneration (AMD) or diabetic macular edema (DME). Evidences have suggested a neurotrophic and neuroprotective role of VEGF, albeit in retina, cellular mechanisms underlying the VEGF neuroprotection remain elusive. Using purified adult retinal ganglion cells (RGCs) in culture, we demonstrated here that VEGF is released by RGCs themselves to promote their own survival, while VEGF neutralization by specific antibodies or traps drastically reduced the RGC survival. These results indicate an autocrine VEGF neuroprotection on RGCs. In parallel, VEGF produced by mixed retinal cells or by mesenchymal stem cells exerted a paracrine neuroprotection on RGCs. Such neuroprotective effect was obtained using the recombinant VEGF-B, suggesting the involvement of VEGF-R1 pathway in VEGF-elicited RGC survival. Finally, glaucomatous patients injected with VEGF traps (ranibizumab or aflibercept) due to either AMD or DME comorbidity, showed a significant reduction of RGC axon fiber layer thickness, consistent with the plausible reduction of the VEGF autocrine stimulation of RGCs. Our results provide evidence of the autocrine neuroprotective function of VEGF on RGCs is crucially involved to preserve injured RGCs such as in glaucomatous patients.
C1 [Froger, Nicolas; Matonti, Frederic; Roubeix, Christophe; Forster, Valerie; Ivkovic, Ivana; Baudouin, Christophe; Sahel, Jose-Alain; Picaud, Serge] Sorbonne Univ, Inst La Vis, CNRS, INSERM, 17 Rue Moreau, F-75012 Paris, France.
   [Brunel, Nadege] UMS 29 INSERM Plateforme FluExGen UPMC, F-75012 Paris, France.
   [Baudouin, Christophe; Sahel, Jose-Alain] CHNO Quinze Vingts, DHU Sight Restore, INSERM DGOS CIC 1423, F-75012 Paris, France.
   [Sahel, Jose-Alain; Picaud, Serge] Fdn Ophtalmol Adolphe de Rothschild, F-75020 Paris, France.
   [Sahel, Jose-Alain] Univ Pittsburgh, Dept Ophthalmol, Sch Med, Pittsburgh, PA 15213 USA.
   [Matonti, Frederic] Ctr Monticelli Paradis, 433 Bis Rue Paradis, F-13008 Marseille, France.
   [Matonti, Frederic] Aix Marseille Univ, Inst Neurosci Timone, INT, CNRS, F-13005 Marseille, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; CHNO des
   Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Centre National de la Recherche Scientifique (CNRS);
   UDICE-French Research Universities; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille
RP Froger, N; Picaud, S (通讯作者)，Sorbonne Univ, Inst La Vis, CNRS, INSERM, 17 Rue Moreau, F-75012 Paris, France.; Picaud, S (通讯作者)，Fdn Ophtalmol Adolphe de Rothschild, F-75020 Paris, France.
EM nifroger@yahoo.fr; serge.picaud@inserm.fr
RI Picaud, Serge/H-4012-2014
OI Picaud, Serge/0000-0002-0548-5145; BRUNEL, Nadege/0000-0001-8433-3811
FU LabEx LIFESENSES as part of the first Investissements d'Avenir program
   by French state funds by the Agence Nationale de la Recherche within the
   Investissements d'Avenir program [ANR-10-LABX-65, ANR-11-IDEX-0004-02];
   IHU FOReSIGHT by French state funds by the Agence Nationale de la
   Recherche within the Investissements d'Avenir program
   [ANR-18-IAHU-0001]; INSERM; Universite Pierre et Marie Curie (Paris VI);
   Fondation Ophtalmologique A. de Rothschild (Paris); Agence Nationale
   pour la Recherche (ANR: GLAUCOME); Federation des Aveugles de France;
   IRRP; city of Paris; Regional Council of Ile-de-France; Fondation pour
   la Recherche Medicale; Fondation Bailly
FX This work was supported by LabEx LIFESENSES (ANR-10-LABX-65) as part of
   the first Investissements d'Avenir program (ANR-11-IDEX-0004-02) and IHU
   FOReSIGHT [ANR-18-IAHU-0001] both supported by French state funds
   managed by the Agence Nationale de la Recherche within the
   Investissements d'Avenir program. This work was supported by INSERM, the
   Universite Pierre et Marie Curie (Paris VI), the Fondation
   Ophtalmologique A. de Rothschild (Paris), the Agence Nationale pour la
   Recherche (ANR: GLAUCOME), the Federation des Aveugles de France, IRRP,
   the city of Paris, and the Regional Council of Ile-de-France. NF
   received postdoctoral fellowships from the Fondation pour la Recherche
   Medicale and Fondation Bailly.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Carmeliet P, 2013, CELL MOL LIFE SCI, V70, P1763, DOI 10.1007/s00018-013-1283-7
   De Almodovar CR, 2009, PHYSIOL REV, V89, P607, DOI 10.1152/physrev.00031.2008
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Deng J, 1999, Yan Ke Xue Bao, V15, P17
   Eichler W, 2000, NEUROREPORT, V11, P3533, DOI 10.1097/00001756-200011090-00026
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Flammer J, 2013, EUR HEART J, V34, P1270, DOI 10.1093/eurheartj/eht023
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Froger N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042017
   Fuchs C, 2005, INVEST OPHTH VIS SCI, V46, P2983, DOI 10.1167/iovs.04-1177
   Hernandez C, 2001, DIABETES CARE, V24, P516, DOI 10.2337/diacare.24.3.516
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Lee JJ, 2012, MOL VIS, V18, P838
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li Y, 2008, J CLIN INVEST, V118, P913, DOI 10.1172/JCI33673
   Marie M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223839
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Rao S, 2013, NATURE, V494, P243, DOI 10.1038/nature11823
   Robbins SG, 1997, GROWTH FACTORS, V14, P229, DOI 10.3109/08977199709021522
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roubeix C, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0168-0
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Sawada O, 2007, ARCH OPHTHALMOL-CHIC, V125, P1363, DOI 10.1001/archopht.125.10.1363
   Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Sun C, 2020, INT OPHTHALMOL, V40, P467, DOI 10.1007/s10792-019-01207-4
   Suzuki M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-176
   Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170, DOI 10.1097/01.wcb.0000037988.07114.98
   Van Den Bosch L, 2004, NEUROBIOL DIS, V17, P21, DOI 10.1016/j.nbd.2004.06.004
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   Whittles CE, 2002, MICROCIRCULATION, V9, P513, DOI 10.1038/sj.mn.7800164
   Zhao TT, 2011, GRAEF ARCH CLIN EXP, V249, P1021, DOI 10.1007/s00417-011-1635-7
NR 45
TC 27
Z9 28
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 24
PY 2020
VL 10
IS 1
AR 12409
DI 10.1038/s41598-020-68488-z
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MU1VB
UT WOS:000555459900003
PM 32710087
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Widomska, J
   SanGiovanni, JP
   Subczynski, WK
AF Widomska, Justyna
   SanGiovanni, John Paul
   Subczynski, Witold K.
TI Why Is Zeaxanthin the Most Concentrated Xanthophyll in the Central
   Fovea?
SO NUTRIENTS
LA English
DT Review
DE lutein; zeaxanthin; macular xanthophyll; lipid bilayer; macula; AMD
ID FATTY-ACID INTAKE; MACULAR PIGMENT; VITAMIN-E; BETA-CAROTENE; SINGLET
   OXYGEN; ALL-TRANS; SERUM CONCENTRATIONS; ANTIOXIDANT ENZYMES;
   OPTICAL-DENSITY; HUMAN RETINA
AB Diet-based xanthophylls (zeaxanthin and lutein) are conditionally essential polar carotenoids preferentially accreted in high concentrations (1 mM) to the central retina, where they have the capacity to impart unique physiologically significant biophysical biochemical properties implicated in cell function, rescue, and survival. Macular xanthophylls interact with membrane-bound proteins and lipids to absorb/attenuate light energy, modulate oxidative stress and redox balance, and influence signal transduction cascades implicated in the pathophysiology of age-related macular degeneration. There is exclusive transport, sequestration, and appreciable bioamplification of macular xanthophylls from the circulating carotenoid pool to the retina and within the retina to regions required for high-resolution sensory processing. The distribution of diet-based macular xanthophylls and the lutein metabolite meso-zeaxanthin varies considerably by retinal eccentricity. Zeaxanthin concentrations are 2.5-fold higher than lutein in the cone-dense central fovea. This is an similar to 20-fold increase in the molar ratio relative to eccentric retinal regions with biochemically detectable macular xanthophylls. In this review, we discuss how the differences in the specific properties of lutein and zeaxanthin could help explain the preferential accumulation of zeaxanthin in the most vulnerable region of the macula.
C1 [Widomska, Justyna] Med Univ Lublin, Dept Biophys, Jaczewskiego 4, PL-20090 Lublin, Poland.
   [SanGiovanni, John Paul] Univ Arizona, Dept Nutr Sci, 1657 East Helen St, Tucson, AZ 85721 USA.
   [Subczynski, Witold K.] Med Coll Wisconsin, Dept Biophys, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.
C3 Medical University of Lublin; University of Arizona; Medical College of
   Wisconsin
RP Widomska, J (通讯作者)，Med Univ Lublin, Dept Biophys, Jaczewskiego 4, PL-20090 Lublin, Poland.; SanGiovanni, JP (通讯作者)，Univ Arizona, Dept Nutr Sci, 1657 East Helen St, Tucson, AZ 85721 USA.
EM justynawidomska@umlub.pl; jpsangio@post.harvard.edu; subczyn@mcw.edu
RI SanGiovanni, John Paul/AAU-3895-2020
OI Widomska, Justyna/0000-0003-2358-4099
FU National Institutes of Health, USA [R01 EY015526]
FX The research reported in this publication was supported by grant R01
   EY015526 from the National Institutes of Health, USA. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Agardh CD, 2006, METABOLISM, V55, P892, DOI 10.1016/j.metabol.2006.02.016
   Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Agbaga MP, 2010, J LIPID RES, V51, P1624, DOI 10.1194/jlr.R005025
   Alcantara S, 1999, J IND MICROBIOL BIOT, V23, P697, DOI 10.1038/sj.jim.2900688
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   [Anonymous], JAMA
   [Anonymous], J NUTR
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2008, INVEST OPHTH VIS SCI, V49, P843, DOI 10.1167/iovs.07-1276
   BenAmotz A, 1996, AM J CLIN NUTR, V63, P729, DOI 10.1093/ajcn/63.5.729
   Benzie IFF, 2006, BRIT J NUTR, V96, P154, DOI 10.1079/BJN20061796
   Berdeaux O, 2011, OCL OILS FAT CROP LI, V18, P284, DOI 10.1051/ocl.2011.0406
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2005, ANAL BIOCHEM, V345, P296, DOI 10.1016/j.ab.2005.07.006
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bilgihan A, 2003, ACTA OPHTHALMOL SCAN, V81, P177, DOI 10.1034/j.1600-0420.2003.00042.x
   Boileau TWM, 2002, EXP BIOL MED, V227, P914, DOI 10.1177/153537020222701012
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Borel P, 1996, J LIPID RES, V37, P250
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   Breithaupt DE, 2004, BRIT J NUTR, V91, P707, DOI 10.1079/BJN20041105
   Breithaupt DE, 2003, BRIT J NUTR, V90, P795, DOI 10.1079/BJN2003962
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Choi RY, 2017, RETINA-J RET VIT DIS, V37, P2238, DOI 10.1097/IAE.0000000000001450
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Chung HY, 2009, AM J CLIN NUTR, V90, P533, DOI 10.3945/ajcn.2009.27712
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   CONN PF, 1991, J PHOTOCH PHOTOBIO B, V11, P41, DOI 10.1016/1011-1344(91)80266-K
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Craft N E, 2004, J Nutr Health Aging, V8, P156
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dall'Osto L, 2012, J BIOL CHEM, V287, P41820, DOI 10.1074/jbc.M112.405498
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Delgado-Vargas F., 2002, NATURAL COLORANTS FO
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Distler C, 1996, VISION RES, V36, P2381, DOI 10.1016/0042-6989(96)00005-3
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Edge R, 1997, J PHOTOCH PHOTOBIO B, V41, P189, DOI 10.1016/S1011-1344(97)00092-4
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   ENGLERT G, 1991, HELV CHIM ACTA, V74, P969, DOI 10.1002/hlca.19910740507
   Ernst H, 2002, PURE APPL CHEM, V74, P2213, DOI 10.1351/pac200274112213
   FARNSWORTH CC, 1979, BIOCHIM BIOPHYS ACTA, V552, P281, DOI 10.1016/0005-2736(79)90283-9
   Fernandez-Sevilla JM, 2010, APPL MICROBIOL BIOT, V86, P27, DOI 10.1007/s00253-009-2420-y
   Fiedor J, 2005, BBA-BIOENERGETICS, V1709, P1, DOI 10.1016/j.bbabio.2005.05.008
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Fukuzawa K, 1998, LIPIDS, V33, P751, DOI 10.1007/s11745-998-0266-y
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Gorusupudi A, 2016, INVEST OPHTH VIS SCI, V57, P1853, DOI 10.1167/iovs.16-19111
   Gosbell AD, 2006, INVEST OPHTH VIS SCI, V47, P2613, DOI 10.1167/iovs.05-0962
   Grudzinski W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10183-7
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   Harrison EH, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801046
   Havaux M, 1999, P NATL ACAD SCI USA, V96, P8762, DOI 10.1073/pnas.96.15.8762
   Havaux M, 2007, PLANT PHYSIOL, V145, P1506, DOI 10.1104/pp.107.108480
   Hempel J, 2017, BRIT J NUTR, V118, P698, DOI 10.1017/S0007114517002653
   Horvath MP, 2016, ACTA CRYSTALLOGR F, V72, P609, DOI 10.1107/S2053230X16010694
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   INFANTE JP, 1986, MOL CELL BIOCHEM, V69, P93
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson Elizabeth J, 2013, J Aging Res, V2013, P951786, DOI 10.1155/2013/951786
   Johnson MP, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702831200
   KANNAN R, 1993, EXP EYE RES, V56, P45, DOI 10.1006/exer.1993.1007
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P29
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P205
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Koo E, 2014, AM J CLIN NUTR, V100, p336S, DOI 10.3945/ajcn.113.071563
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Li S, 2018, INT J OPHTHALMOL-CHI, V11, P970, DOI 10.18240/ijo.2018.06.12
   LIEBLER DC, 1993, ANN NY ACAD SCI, V691, P20, DOI 10.1111/j.1749-6632.1993.tb26154.x
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Madhavan J, 2018, PHARMACOGN MAG, V14, P268, DOI 10.4103/pm.pm_340_17
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   Makuch K, 2019, COMPUT STRUCT BIOTEC, V17, P516, DOI 10.1016/j.csbj.2019.04.001
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Masetto A, 2001, J BIOSCI BIOENG, V92, P55, DOI 10.1263/jbb.92.55
   MICOZZI MS, 1992, AM J CLIN NUTR, V55, P1120, DOI 10.1093/ajcn/55.6.1120
   Milanowska J, 2005, J PHOTOCH PHOTOBIO B, V80, P178, DOI 10.1016/j.jphotobiol.2005.05.004
   Mitchell D., 2008, COMPLETE BOOK NUTR H
   Mozzo M, 2008, J BIOL CHEM, V283, P6184, DOI 10.1074/jbc.M708961200
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   Nimalaratne C, 2012, J AGR FOOD CHEM, V60, P12547, DOI 10.1021/jf303828n
   Nishino A, 2017, J OLEO SCI, V66, P77, DOI 10.5650/jos.ess16107
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   O'Connell OF, 2007, NUTR RES, V27, P258, DOI 10.1016/j.nutres.2007.04.002
   Olmedilla B, 2001, BRIT J NUTR, V85, P227, DOI 10.1079/BJN2000248
   Olmedilla-Alonso B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-52
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   Peng Y, 2005, PLANT FOOD HUM NUTR, V60, P161, DOI 10.1007/s11130-005-9550-5
   PENN JS, 1992, INVEST OPHTH VIS SCI, V33, P1836
   Perera CO, 2007, INT J FOOD PROP, V10, P201, DOI 10.1080/10942910601045271
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Pop RM, 2014, FOOD CHEM, V147, P1, DOI 10.1016/j.foodchem.2013.09.083
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Ramel F, 2012, PLANT PHYSIOL, V158, P1267, DOI 10.1104/pp.111.182394
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Reboul E, 2006, J AGR FOOD CHEM, V54, P8749, DOI 10.1021/jf061818s
   Reboul E, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040838
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1362, DOI 10.1111/j.1751-1097.2012.01161.x
   Sajilata MG, 2008, COMPR REV FOOD SCI F, V7, P29, DOI 10.1111/j.1541-4337.2007.00028.x
   Sajilata MG, 2010, SEP PURIF TECHNOL, V71, P173, DOI 10.1016/j.seppur.2009.11.017
   Sanabria JC, 2020, JOVE-J VIS EXP, DOI 10.3791/60429
   SanGiovanni J.P., ENCY DIETARY SUPPLEM
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2014, CAROTENOIDS AND RETINAL DISEASE, P93
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, P3094, DOI 10.1167/iovs.18-23886
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P270, DOI 10.1007/s003470100533
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sharifzadeh M, 2008, J OPT SOC AM A, V25, P947, DOI 10.1364/JOSAA.25.000947
   Sharifzadeh M, 2006, J OPT SOC AM A, V23, P2373, DOI 10.1364/JOSAA.23.002373
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Shyam R, 2017, ARCH BIOCHEM BIOPHYS, V634, P21, DOI 10.1016/j.abb.2017.09.013
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Sommerburg Olaf, 2000, Biofactors, V11, P3
   SOUKUP M, 1990, HELV CHIM ACTA, V73, P868, DOI 10.1002/hlca.19900730412
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Stringham JM, 2016, EXP EYE RES, V151, P1, DOI 10.1016/j.exer.2016.07.005
   Subczynski WK, 2012, ACTA BIOCHIM POL, V59, P109
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   SUBCZYNSKI WK, 1993, BIOCHIM BIOPHYS ACTA, V1150, P173, DOI 10.1016/0005-2736(93)90087-G
   SUBCZYNSKI WK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P97, DOI 10.1016/0005-2736(92)90167-K
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P396, DOI 10.1167/iovs.06-0872
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Torregrosa F, 2005, J AGR FOOD CHEM, V53, P9519, DOI 10.1021/jf051171w
   Trevithick JR, 2005, INVEST OPHTHALMOL, V46, P3855
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Tudor C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010076
   Tyssandier V, 2001, BBA-MOL CELL BIOL L, V1533, P285, DOI 10.1016/S1388-1981(01)00163-9
   Updike AA, 2003, J AGR FOOD CHEM, V51, P6184, DOI 10.1021/jf030350f
   van den Berg H, 1999, NUTR REV, V57, P1, DOI 10.1111/j.1753-4887.1999.tb01769.x
   Vishwanathan R, 2014, J PEDIATR GASTR NUTR, V59, P659, DOI 10.1097/MPG.0000000000000389
   Vu HTV, 2006, BRIT J OPHTHALMOL, V90, P389, DOI 10.1136/bjo.2005.078055
   Wang YM, 2010, EUR J NUTR, V49, P327, DOI 10.1007/s00394-009-0089-8
   Weller P, 2003, J AGR FOOD CHEM, V51, P7044, DOI 10.1021/jf034803s
   Wen X, 2017, J AGR FOOD CHEM, V65, P6140, DOI 10.1021/acs.jafc.7b02514
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Widomska J, 2016, FOODS, V5, DOI 10.3390/foods5010007
   Wingerath T, 1995, ARCH BIOCHEM BIOPHYS, V324, P385, DOI 10.1006/abbi.1995.0052
   Wisniewska A, 2006, ACTA BIOCHIM POL, V53, P475
   Wisniewska A, 2006, FREE RADICAL BIO MED, V41, P1257, DOI 10.1016/j.freeradbiomed.2006.07.003
   Wisniewska A, 2006, FREE RADICAL BIO MED, V40, P1820, DOI 10.1016/j.freeradbiomed.2006.01.016
   Zeimer MB, 2010, RETINA-J RET VIT DIS, V30, P1282, DOI 10.1097/IAE.0b013e3181e096dd
NR 202
TC 11
Z9 11
U1 2
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD MAY
PY 2020
VL 12
IS 5
AR 1333
DI 10.3390/nu12051333
PG 25
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA MB0AV
UT WOS:000542272700298
PM 32392888
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yang, C
   Shani, S
   Tahiri, H
   Ortiz, C
   Gu, MQ
   Lavoie, JC
   Croteau, S
   Hardy, P
AF Yang, Chun
   Shani, Saeideh
   Tahiri, Houda
   Ortiz, Christina
   Gu, Muqing
   Lavoie, Jean-Claude
   Croteau, Stephane
   Hardy, Pierre
TI Extracellular microparticles exacerbate oxidative damage to retinal
   pigment epithelial cells
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Oxidative stress; Retinal pigment epithelial cell (RPE); RPE
   cell-Derived microparticles (RMPs); RPE cell Dysfunction; Senescence;
   Phagocytosis; Extracellular vesicles
ID NONLETHAL OXIDANT INJURY; SUB-RPE DEPOSITS; CELLULAR SENESCENCE;
   ENDOTHELIAL-CELLS; MACULAR DEGENERATION; PREMATURE SENESCENCE; AGE;
   STRESS; ACTIVATION; MECHANISMS
AB Oxidative stress-induced retinal pigment epithelial cell (RPE) dysfunction is a primary contributing factor to early dry age-related macular degeneration (AMD). Oxidative injury to the retina may promote extracellular vesicles (EVs) released from RPE. In this study, we investigated the effects of oxidative-induced RPE cell-derived microparticles (RMPs) on RPE cell functions. The oxidative stress induced more RMPs released from RPE cells in vitro and in vivo, and significant more RMPs were released from aged RPE cells than that from younger RPE cells. RMPs were taken up by RPE cells in a time-dependent manner; however, blockage of CD36 attenuated the uptake process. Furthermore, the decrease of RPE cell viability by RMPs treatment was associated with an increased expression of cyclin-dependent kinase inhibitors p15 and p21. RMPs enhanced senescence and interrupted phagocytic activity of RPE cells as well. The present study demonstrated that RMPs produce a strong effect of inducing RPE cell degeneration. This finding further supports the postulate that RMPs exacerbate oxidative stress damage to RPE cells, which may uncover a potentially relevant process in the genesis of dry AMD.
C1 [Yang, Chun; Shani, Saeideh; Tahiri, Houda; Ortiz, Christina; Hardy, Pierre] Univ Montreal, Dept Pediat Pharmacol & Physiol, Montreal, PQ H3T 1C5, Canada.
   [Gu, Muqing] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Dept Gynecol Endocrinol, Beijing, Peoples R China.
   [Lavoie, Jean-Claude] Dept Pediat & Nutr, Montreal, PQ H3T 1C5, Canada.
   [Croteau, Stephane] Univ Montreal, Dept Med, Montreal, PQ H3T 1C5, Canada.
C3 Universite de Montreal; Capital Medical University; Universite de
   Montreal
RP Hardy, P (通讯作者)，CHU St Justine, Res Ctr, 3175 Cote St Catherine,Room 2714, Montreal, PQ H3T 105, Canada.
EM pierre.hardy@recherche-ste-justine.qc.ca
FU Canadian Institutes of Health Research [362383]
FX This work was supported by the Canadian Institutes of Health Research
   under an operating grant [362383].
CR Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   Atienzar-Aroca S, 2018, J CELL MOL MED, V22, P5244, DOI 10.1111/jcmm.13730
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Iloki-Assanga SB, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0765-6
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Carver KA, 2016, INVEST OPHTH VIS SCI, V57, P360, DOI 10.1167/iovs.15-17117
   Chen J, 2006, AM J PHYSIOL-HEART C, V290, pH1729, DOI 10.1152/ajpheart.01103.2005
   Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   Dragovic RA, 2011, NANOMED-NANOTECHNOL, V7, P780, DOI 10.1016/j.nano.2011.04.003
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Green RW, 1999, MOL VIS, V5
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446
   Hristov M, 2004, BLOOD, V104, P2761, DOI 10.1182/blood-2003-10-3614
   Hugel B, 2005, PHYSIOLOGY, V20, P22, DOI 10.1152/physiol.00029.2004
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Jackson SJ, 2017, LAB ANIM-UK, V51, P160, DOI 10.1177/0023677216653984
   Jeyapalan JC, 2008, MECH AGEING DEV, V129, P467, DOI 10.1016/j.mad.2008.04.001
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Mao YY, 2012, MOL BIOL CELL, V23, P1104, DOI 10.1091/mbc.E11-10-0840
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   MARMOR M F, 1975, International Ophthalmology Clinics, V15, P115, DOI 10.1097/00004397-197501510-00010
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Morel O, 2004, CURR OPIN HEMATOL, V11, P156, DOI 10.1097/01.moh.0000131441.10020.87
   Narayan S, 2003, INVEST OPHTH VIS SCI, V44, P4885, DOI 10.1167/iovs.03-0387
   Naylor RM, 2013, CLIN PHARMACOL THER, V93, P105, DOI 10.1038/clpt.2012.193
   Perez-Gonzalez R, 2012, J BIOL CHEM, V287, P43108, DOI 10.1074/jbc.M112.404467
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shet AS, 2003, BLOOD, V102, P2678, DOI 10.1182/blood-2003-03-0693
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun K, 2007, MOL VIS, V13, P2310
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tahiri H, 2013, INVEST OPHTH VIS SCI, V54, P6084, DOI 10.1167/iovs.13-11896
   Tetta C, 2013, ENDOCRINE, V44, P11, DOI 10.1007/s12020-012-9839-0
   Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7
   van Kuijk Frederik J G M, 2017, Trans Am Ophthalmol Soc, V115, pT3
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Yang C, 2008, AM J PHYSIOL-REG I, V294, pR467, DOI 10.1152/ajpregu.00432.2007
   Yang C, 2015, JOVE-J VIS EXP, DOI 10.3791/52651
   Yang C, 2012, AM J PHYSIOL-REG I, V302, pR941, DOI 10.1152/ajpregu.00527.2011
   Yang C, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12533
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
NR 64
TC 6
Z9 7
U1 2
U2 6
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD MAY 1
PY 2020
VL 390
IS 1
AR 111957
DI 10.1016/j.yexcr.2020.111957
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA LC5YD
UT WOS:000525406700010
PM 32173468
DA 2022-11-30
ER

PT J
AU Oltra, M
   Vidal-Gil, L
   Maisto, R
   Oltra, SS
   Romero, FJ
   Sancho-Pelluz, J
   Barcia, JM
AF Oltra, Maria
   Vidal-Gil, Lorena
   Maisto, Rosa
   Oltra, Sara S.
   Javier Romero, Francisco
   Sancho-Pelluz, Javier
   Miguel Barcia, Jorge
TI miR302a and 122 are deregulated in small extracellular vesicles from
   ARPE-19 cells cultured with H2O2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; MACULAR DEGENERATION;
   HEPATOCELLULAR-CARCINOMA; POTENTIAL BIOMARKERS; MICRORNA EXPRESSION;
   CIRCULATING MIRNAS; PROLIFERATION; MIR-122; INFLAMMATION
AB Age related macular degeneration (AMD) is a common retina-related disease leading to blindness. Little is known on the origin of the disease, but it is well documented that oxidative stress generated in the retinal pigment epithelium and choroid neovascularization are closely involved. The study of circulating miRNAs is opening new possibilities in terms of diagnosis and therapeutics. miRNAs can travel associated to lipoproteins or inside small Extracellular Vesicles (sEVs). A number of reports indicate a significant deregulation of circulating miRNAs in AMD and experimental approaches, but it is unclear whether sEVs present a significant miRNA cargo. The present work studies miRNA expression changes in sEVs released from ARPE-19 cells under oxidative conditions (i.e. hydrogen peroxide, H2O2). H2O2 increased sEVs release from ARPE-19 cells. Moreover, 218 miRNAs could be detected in control and H2O2 induced-sEVs. Interestingly, only two of them (hsa-miR-302a and hsa-miR-122) were significantly under-expressed in H2O2-induced sEVs. Results herein suggest that the down regulation of miRNAs 302a and 122 might be related with previous studies showing sEVs-induced neovascularization after oxidative challenge in ARPE-19 cells.
C1 [Oltra, Maria; Vidal-Gil, Lorena] Univ Catolica Valencia San Vicente Martir, Escuela Doctorado, Valencia, Spain.
   [Oltra, Maria; Vidal-Gil, Lorena; Sancho-Pelluz, Javier; Miguel Barcia, Jorge] Univ Catolica Valencia San Vicente Martir, Fac Med & Ciencias Salud, Neurobiol & Neurofisiol, Valencia, Spain.
   [Oltra, Maria; Vidal-Gil, Lorena; Sancho-Pelluz, Javier; Miguel Barcia, Jorge] Univ Catolica Valencia San Vicente Martir, Ctr Invest Traslac San Alberto Magno, Valencia, Spain.
   [Maisto, Rosa] Univ Campania Luigi Vanvitelli, Naples, Italy.
   [Oltra, Sara S.] Univ Valencia, Hosp Clin Univ Valencia, INCLIVA Biomed Res Inst, Valencia, Spain.
   [Javier Romero, Francisco] Hosp Gen Requena, Valencia, Spain.
C3 Universidad Catolica de Valencia San Vicente Martir; Universidad
   Catolica de Valencia San Vicente Martir; Universidad Catolica de
   Valencia San Vicente Martir; Universita della Campania Vanvitelli;
   University of Valencia
RP Sancho-Pelluz, J (通讯作者)，Univ Catolica Valencia San Vicente Martir, Fac Med & Ciencias Salud, Neurobiol & Neurofisiol, Valencia, Spain.; Sancho-Pelluz, J (通讯作者)，Univ Catolica Valencia San Vicente Martir, Ctr Invest Traslac San Alberto Magno, Valencia, Spain.
EM fj.sancho@ucv.es
RI Sancho-Pelluz, Javier/ABG-8588-2020; Vidal Gil, Lorena/AAZ-8342-2021;
   JM, Barcia/ABH-2932-2020; Sanchis, Maria Oltra/G-5543-2017
OI Sanchis, Maria Oltra/0000-0001-6397-2702; S Oltra,
   Sara/0000-0002-0128-6106; Barcia, Jorge M./0000-0002-3660-7977; Sancho
   Pelluz, Francisco Javier/0000-0001-5409-5760
FU Universidad Catolica de Valencia San Vicente Martir [2018-128-001];
   Centro de Investigacion Traslacional San Alberto Magno de la UCV
   [2019-128-001]; Conselleria de Educacion, Investigacion, Cultura y
   Deporte; Generalitat Valenciana [PROMETEO/2016/094]; Oltra M and
   Vidal-Gil L, PhD training program fellowship UCV [EDUCV-PRE-2016-005,
   EDUCV-PRE-2015-006]
FX The present project was supported by internal funds from Universidad
   Catolica de Valencia San Vicente Martir (2018-128-001), Centro de
   Investigacion Traslacional San Alberto Magno de la UCV (2019-128-001),
   and Conselleria de Educacion, Investigacion, Cultura y Deporte;
   Generalitat Valenciana (PROMETEO/2016/094). Oltra M and Vidal-Gil L, PhD
   training program fellowship UCV (EDUCV-PRE-2016-005 and
   EDUCV-PRE-2015-006 Personal Investigador en Formacion UCV,
   respectively).
CR Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Ayaz L, 2018, CUTAN OCUL TOXICOL, V37, P121, DOI 10.1080/15569527.2017.1355314
   Bai J., 2019, OXID MED CELL LONGEV, V2019, P1
   Baker JR, 2016, SCI REP-UK, V6, DOI 10.1038/srep35871
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhaskaran M, 2014, VET PATHOL, V51, P759, DOI 10.1177/0300985813502820
   Biasutto L, 2013, EXP CELL RES, V319, P2113, DOI 10.1016/j.yexcr.2013.05.005
   Bukong TN, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004424
   Chen W, 2019, AM J TRANSL RES, V11, P4348
   Creemers EE, 2012, CIRC RES, V110, P483, DOI 10.1161/CIRCRESAHA.111.247452
   Desjarlais M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218282
   Dinc E., 2018, J OCUL PHARMACOL TH, V34, P1
   Drewry MD, 2018, HUM MOL GENET, V27, P1263, DOI 10.1093/hmg/ddy040
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   Ertekin S, 2014, MOL VIS, V20, P1057
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fevrier B, 2004, CURR OPIN CELL BIOL, V16, P415, DOI 10.1016/j.ceb.2004.06.003
   Gao ZQ, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150138
   Genini S, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-172
   Grasmeijer F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087825
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Howell JC, 2013, MOL VIS, V19, P544
   Jesus ABD, 2009, CELL CYCLE, V8, P394
   Jiao XY, 2017, J MED VIROL, V89, P1597, DOI 10.1002/jmv.24829
   Karali M, 2016, NUCLEIC ACIDS RES, V44, P1525, DOI 10.1093/nar/gkw039
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Kumar S, 2017, PROG MOL BIOL TRANSL, V146, P47, DOI 10.1016/bs.pmbts.2016.12.013
   Kuo CH, 2012, BIOCHEM BIOPH RES CO, V417, P11, DOI 10.1016/j.bbrc.2011.11.058
   Li CF, 2016, ONCOTARGET, V7, P17021, DOI 10.18632/oncotarget.7740
   Li DD, 2016, MOL BIOL REP, V43, P1079, DOI 10.1007/s11033-016-4041-8
   Li KJ, 2014, MED SCI MONITOR, V20, P639, DOI 10.12659/MSM.890686
   Li WB, 2012, INVEST OPHTH VIS SCI, V53, P5334, DOI 10.1167/iovs.12-8303
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Lipchina I, 2012, CELL CYCLE, V11, P1517, DOI 10.4161/cc.19846
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Magenta A, 2013, INT J MOL SCI, V14, P17319, DOI 10.3390/ijms140917319
   Maisto R, 2019, CELL CYCLE, V18, P413, DOI 10.1080/15384101.2019.1568745
   Mazzeo A, 2019, EXP EYE RES, V184, P56, DOI 10.1016/j.exer.2019.04.015
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Pastukh N, 2019, CLIN EXP MED, V19, P255, DOI 10.1007/s10238-019-00546-x
   Qin CL, 2017, MOL MED REP, V16, P6360, DOI 10.3892/mmr.2017.7312
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   SanGiovanni JP, 2017, CLIN CHEM LAB MED, V55, P763, DOI 10.1515/cclm-2016-0898
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Song L, 2015, GENET MOL RES, V14, P13258, DOI 10.4238/2015.October.26.22
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Tian B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160887
   Turturici G, 2014, AM J PHYSIOL-CELL PH, V306, pC621, DOI 10.1152/ajpcell.00228.2013
   van Balkom BWM, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26760
   Walz JM, 2019, EXP EYE RES, V181, P98, DOI 10.1016/j.exer.2019.01.006
   Wang HC, 2014, CANCER INFORM, V13, P25, DOI 10.4137/CIN.S14074
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wang Y, 2016, AM J TRANSL RES, V8, P3056
   Wu JC, 2015, BIOCHEM BIOPH RES CO, V466, P155, DOI 10.1016/j.bbrc.2015.08.121
   Xiang L, 2017, P NATL ACAD SCI USA, V114, P6376, DOI 10.1073/pnas.1618757114
   Yang X, 2014, TOXICOL LETT, V225, P401, DOI 10.1016/j.toxlet.2014.01.013
   Yoon C, 2016, TUMOR BIOL, V37, P313, DOI 10.1007/s13277-015-3769-4
   Zhang J, 2017, CURR MOL MED, V17, P359, DOI 10.2174/1566524018666171205122540
   Zhang Y., 2017, FORTSCHR MINERAL, V7, P1, DOI [DOI 10.3969/J.-, DOI 10.1038/s41598-016-0028-x]
   Zhang Y, 2017, ONCOTARGET, V8, P31993, DOI 10.18632/oncotarget.16669
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 65
TC 11
Z9 11
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 29
PY 2019
VL 9
AR 17954
DI 10.1038/s41598-019-54373-x
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA JR8SG
UT WOS:000499887500001
PM 31784665
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mohlin, C
   Delbro, D
   Kvanta, A
   Johansson, K
AF Mohlin, Camilla
   Delbro, Dick
   Kvanta, Anders
   Johansson, Kjell
TI Evaluation of Congo Red Staining in Degenerating Porcine Photoreceptors
   In Vitro: Protective Effects by Structural and Trophic Support
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE Congo red; electron microscopy; fluorescence microscopy; photoreceptor;
   retina
ID AGING HUMAN RETINA; MACULAR DEGENERATION; AMYLOID-BETA;
   NEURODEGENERATIVE DISEASES; PROTEIN AGGREGATION; ALZHEIMERS-DISEASE;
   ER-STRESS; CELLS; EYE; RHODOPSIN
AB Congo red (CR) is a histological stain used for the detection of extracellular amyloids mediating various neurodegenerative diseases. Given that damaged photoreceptors appear to degenerate similarly to other nerve cells, CR staining was evaluated in experimentally injured porcine retina. CR staining appeared mostly as discrete cytosolic deposits with no obvious plaque formation during the investigated time period. Increases of CR labeling coincided temporally with the known accumulation of mislocalized opsins and increases of cell death. Coculture, either with human retinal pigment epithelium (ARPE) or human neural progenitor (ReN) cells, was accompanied by a significant reduction of CR labeling. Of particular interest was the reduction of CR labeling in cone photoreceptors, which are important for the perception of color and fine details and afflicted in age-related macular degeneration (AMD). Electron microscopy revealed inclusions in the inner segment, cell body, and occasionally synaptic terminals of photoreceptor cells in cultured specimens. Closer examinations indicated the presence of different types of inclusions resembling protein aggregates as well as inclusion bodies. The current results indicate that injury-related response resulted in accumulation of CR deposits in photoreceptor cells, and that trophic and/or structural support attenuated this response.
C1 [Mohlin, Camilla] Linnaeus Univ, Dept Chem & Biomed, Kalmar, Sweden.
   [Delbro, Dick] Orebro Univ, Sch Med Sci, Orebro, Sweden.
   [Kvanta, Anders] Karolinska Inst, Dept Clin Neurosci, Sect Ophthalmol & Vis, St Erik Eye Hosp, Stockholm, Sweden.
   [Johansson, Kjell] Kristianstad Univ, Dept Sci, Elmetorpsvagen 15, SE-29188 Kristianstad, Sweden.
C3 Linnaeus University; Orebro University; Karolinska Institutet;
   Kristianstad University
RP Johansson, K (通讯作者)，Kristianstad Univ, Dept Sci, Elmetorpsvagen 15, SE-29188 Kristianstad, Sweden.
EM kjell.johansson@hkr.se
RI mohlin, camilla/AAP-2726-2020
OI mohlin, camilla/0000-0002-9301-1977
FU faculty of Medical Sciences at Orebro University; Olle Engkvist
   Foundation; Ogonfonden; Crown Princess Margaretas Committee for the
   Blind; Edwin Jordan Foundation; Sven and Dagmar Salen Foundation
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: Support
   was provided by the faculty of Medical Sciences at Orebro University,
   Olle Engkvist Foundation, Ogonfonden, the Crown Princess Margaretas
   Committee for the Blind, Edwin Jordan and Sven and Dagmar Salen
   Foundations.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Bales KL, 2016, EXP EYE RES, V150, P71, DOI 10.1016/j.exer.2015.11.007
   Bayer TA, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00008
   Butler MR, 2017, J BIOL CHEM, V292, P11189, DOI 10.1074/jbc.M117.782326
   Clement CG, 2014, HUM PATHOL, V45, P1766, DOI 10.1016/j.humpath.2014.04.016
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dentchev T, 2003, MOL VIS, V9, P184
   Desai S, 2018, EXP BIOL MED, V243, P554, DOI 10.1177/1535370217752351
   Du LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135499
   Englund-Johansson U, 2010, EXP EYE RES, V90, P292, DOI 10.1016/j.exer.2009.11.005
   Frid P, 2007, BRAIN RES REV, V53, P135, DOI 10.1016/j.brainresrev.2006.08.001
   Gregory-Evans K, 1998, OPHTHALMOLOGY, V105, P2306, DOI 10.1016/S0161-6420(98)91233-7
   Ho T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029892
   Illing ME, 2002, J BIOL CHEM, V277, P34150, DOI 10.1074/jbc.M204955200
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3
   Koffie RM, 2009, P NATL ACAD SCI USA, V106, P4012, DOI 10.1073/pnas.0811698106
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Lefevere E, 2017, MITOCHONDRION, V36, P66, DOI 10.1016/j.mito.2017.03.006
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Mohlin C, 2014, BRAIN RES, V1585, P167, DOI 10.1016/j.brainres.2014.08.055
   Mohlin C, 2011, J NEUROSCI METH, V197, P56, DOI 10.1016/j.jneumeth.2011.01.030
   Mollick T, 2016, BRAIN RES, V1646, P522, DOI 10.1016/j.brainres.2016.06.039
   Nag TC, 2006, BRAIN RES BULL, V71, P224, DOI 10.1016/j.brainresbull.2006.09.007
   Ortin-Martinez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113798
   Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saliba RS, 2002, J CELL SCI, V115, P2907
   Shah TM, 2017, MOL PSYCHIATR, V22, P353, DOI 10.1038/mp.2016.251
   Sharma Rajesh K, 2005, BMC Ophthalmol, V5, P25, DOI 10.1186/1471-2415-5-25
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Sipe JD, 2014, AMYLOID, V21, P221, DOI 10.3109/13506129.2014.964858
   Sjolander D, 2016, AMYLOID, V23, P98, DOI 10.3109/13506129.2016.1158159
   Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X
   Taylor-Walker G, 2016, EXP EYE RES, V153, P110, DOI 10.1016/j.exer.2016.10.013
   TUCKER GS, 1986, INVEST OPHTH VIS SCI, V27, P708
   Tzekov R, 2013, COLD SPRING HARB PER, V3
   Zhang T, 2011, P NATL ACAD SCI USA, V108, P8879, DOI 10.1073/pnas.1017127108
NR 42
TC 2
Z9 2
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
EI 1551-5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD SEP
PY 2018
VL 66
IS 9
DI 10.1369/0022155418768222
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GS2BT
UT WOS:000443345700002
PM 29624116
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU West, SD
   Turnbull, C
AF West, Sophie D.
   Turnbull, Chris
TI Eye disorders associated with obstructive sleep apnoea
SO CURRENT OPINION IN PULMONARY MEDICINE
LA English
DT Review
DE glaucoma; keratoconus; NAION; obstructive sleep apnoea; retinopathy
ID POSITIVE AIRWAY PRESSURE; ISCHEMIC OPTIC NEUROPATHY; BLOOD-PRESSURE;
   METAANALYSIS; PREVALENCE; HYPERTENSION; GLAUCOMA; ADULTS; RISK
AB Purpose of review
   Obstructive sleep apnoea (OSA) is increasing in prevalence due to rising obesity. Public awareness is also growing. Although OSA is a disorder primarily of the upper airway during sleep, its physiological impact on other parts of the body is now well recognized. There is increasing interest in the association of OSA with various eye disorders. Work in this field has been directed predominantly to OSA prevalence and association studies, but some authors have tried to elucidate the effect of OSA therapies on eye diseases, including continuous positive airway pressure, upper airway surgery or bariatric surgery. This review discusses the publications in this area from the past year.
   Recent findings
   The key ocular disorders featured in the studies and meta-analayses include glaucoma, floppy eyelid syndrome, nonarteritic ischaemic optic neuropathy, keratoconus, age-related macular degeneration and diabetic retinopathy. Associations with OSA were found with all these conditions, but aspects of the studies still leave gaps in our knowledge.
   Summary
   This review highlights the need for ophthalmologists to consider OSA in their patients and also makes recommendations for future research studies, especially whether therapies for OSA can be effective for ocular disorders also.
C1 [West, Sophie D.] Newcastle Upon Tyne Hosp NHS Trust, Newcastle Reg Sleep Serv, Newcastle Upon Tyne, Tyne & Wear, England.
   [Turnbull, Chris] Oxford Univ Hosp, Oxford Ctr Resp Med, Oxford, England.
   [Turnbull, Chris] Univ Oxford, NIHR Biomed Res Ctr Oxford, Churchill Campus, Oxford, England.
C3 Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Oxford
RP West, SD (通讯作者)，Newcastle Upon Tyne Hosp NHS Trust, Newcastle Reg Sleep Serv, Freeman Hosp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
EM Sophie.west@nuth.nhs.uk
OI Turnbull, Christopher/0000-0001-8942-5424
FU NIHR Oxford Biomedical Research Centre
FX C.T. was supported/funded by the NIHR Oxford Biomedical Research Centre.
CR Acar M, 2016, LARYNGOSCOPE
   Amin AM, 2016, SURG OBES RELAT DIS, V12, P606, DOI 10.1016/j.soard.2015.08.508
   Aptel F, 2015, JAMA OPHTHALMOL, V133, P797, DOI 10.1001/jamaophthalmol.2015.0893
   Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175
   Hu XY, 2015, J CLIN HYPERTENS, V17, P215, DOI 10.1111/jch.12472
   Kohler M, 2015, THORAX, V70, P817, DOI 10.1136/thoraxjnl-2015-207247
   Kohler M, 2010, NAT REV CARDIOL, V7, P677, DOI 10.1038/nrcardio.2010.145
   Leong WB, 2016, DIABETIC MED, V33, P158, DOI 10.1111/dme.12817
   Naderan M, 2015, BRIT J OPHTHALMOL, V99, P1675, DOI 10.1136/bjophthalmol-2015-306665
   Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002
   Peppard PE, 2013, AM J EPIDEMIOL, V177, P1006, DOI 10.1093/aje/kws342
   Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901
   Randerath WJ, 2011, EUR RESPIR J, V37, P1000, DOI 10.1183/09031936.00099710
   Schaal S, 2016, RETINA-J RET VIT DIS, V36, P791, DOI 10.1097/IAE.0000000000000981
   Shi YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115625
   Stansbury RC, 2015, J THORAC DIS, V7, pE298, DOI 10.3978/j.issn.2072-1439.2015.09.13
   Ulusoy S, 2015, MED SCI MONITOR, V21, P3415, DOI 10.12659/MSM.895897
   West SD, 2006, THORAX, V61, P945, DOI 10.1136/thx.2005.057745
   West SD, 2016, AM THOR SOC 2016 INT, pP1071
   Wu XH, 2015, INT J CLIN EXP MED, V8, P297
   Wu Y, 2016, CURR EYE RES, V41, P987, DOI 10.3109/02713683.2015.1075221
   YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704
   Zhang R, 2016, DIABETES TECHNOL THE, V18, P415, DOI 10.1089/dia.2015.0433
NR 23
TC 14
Z9 14
U1 1
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-5287
EI 1531-6971
J9 CURR OPIN PULM MED
JI Curr. Opin. Pulm. Med.
PD NOV
PY 2016
VL 22
IS 6
BP 595
EP 601
DI 10.1097/MCP.0000000000000322
PG 7
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA DY1FC
UT WOS:000384839300011
PM 27635626
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Walsh, RP
   Bartlett, H
   Eperjesi, F
AF Walsh, Rachel P.
   Bartlett, Hannah
   Eperjesi, Frank
TI Variation in Carotenoid Content of Kale and Other Vegetables: A Review
   of Pre- and Post-harvest Effects
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Review
DE AMD; lutein; zeaxanthin; xanthophylls; composition
ID PIGMENT OPTICAL-DENSITY; HEALTH-PROMOTING COMPOUNDS; COOKED GREEN
   VEGETABLES; MACULAR PIGMENT; BRASSICA-OLERACEA; COOKING METHODS; DIETARY
   SUPPLEMENTATION; LUTEIN SUPPLEMENTATION; ANTIOXIDANT ACTIVITY; LEAFY
   VEGETABLES
AB Lutein and zeaxanthin are carotenoids that are selectively taken up into the macula of the eye, where they are thought to protect against the development of age-related macular degeneration. They are obtained from dietary sources, with the highest concentrations found in dark green leafy vegetables, such as kale and spinach. In this Review, compositional variations due to variety/cultivar, stage of maturity, climate or season, farming practice, storage, and processing effects are highlighted. Only data from studies which report on lutein and zeaxanthin content in foods are reported. The main focus is kale; however, other predominantly xanthophyll containing vegetables such as spinach and broccoli are included. A small amount of data about exotic fruits is also referenced for comparison. The qualitative and quantitative composition of carotenoids in fruits and vegetables is known to vary with multiple factors. In kale, lutein and zeaxanthin levels are affected by pre-harvest effects such as maturity, climate, and farming practice. Further research is needed to determine the post-harvest processing and storage effects of lutein and zeaxanthin in kale; this will enable precise suggestions for increasing retinal levels of these nutrients.
C1 [Walsh, Rachel P.; Bartlett, Hannah; Eperjesi, Frank] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Walsh, RP (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
EM walshr1@aston.ac.uk; h.e.bartlett@aston.ac.uk; f.eperjesi@aston.ac.uk
OI Bartlett Eperjesi, Hannah E/0000-0002-7531-6902
CR AKPAPUNAM MA, 1984, QUAL PLANT, V34, P177, DOI 10.1007/BF01091466
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bone RA, 2003, INVEST OPHTH VIS SCI, V44, pU79
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P1199
   Bunea A, 2008, FOOD CHEM, V108, P649, DOI 10.1016/j.foodchem.2007.11.056
   Bunea A, 2012, CHEM PAP, V66, P935, DOI 10.2478/s11696-012-0162-2
   Cano A, 2011, J SCI FOOD AGR, V91, P1702, DOI 10.1002/jsfa.4375
   CHANDLER LA, 1988, J AGR FOOD CHEM, V36, P129, DOI 10.1021/jf00079a033
   Cinar I, 2004, LEBENSM-WISS TECHNOL, V37, P363, DOI 10.1016/j.lwt.2003.10.006
   de Azevedo CH, 2005, J SCI FOOD AGR, V85, P591, DOI 10.1002/jsfa.1993
   de Azevedo-Meleiro CH, 2005, J FOOD COMPOS ANAL, V18, P845, DOI 10.1016/j.jfca.2004.10.006
   de Sa MC, 2003, FOOD CHEM, V83, P595, DOI 10.1016/S0308-8146(03)00227-9
   de Sa MC, 2004, J FOOD COMPOS ANAL, V17, P37, DOI 10.1016/S0889-1575(03)00100-5
   FRASER PD, 1994, PLANT PHYSIOL, V105, P405, DOI 10.1104/pp.105.1.405
   Gliszczynska-Swiglo A, 2006, FOOD ADDIT CONTAM A, V23, P1088, DOI 10.1080/02652030600887594
   GRANADO F, 1992, J AGR FOOD CHEM, V40, P2135, DOI 10.1021/jf00023a019
   Gruissem W., 1987, PLASTID NUCL GENE EX, P239
   HAM WT, 1983, J OCCUP ENVIRON MED, V25, P101
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hegedus A, 2010, J FOOD SCI, V75, pC722, DOI 10.1111/j.1750-3841.2010.01826.x
   HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011
   Jimenez-Monreal AM, 2009, J FOOD SCI, V74, pH97, DOI 10.1111/j.1750-3841.2009.01091.x
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kao FJ, 2012, LWT-FOOD SCI TECHNOL, V46, P485, DOI 10.1016/j.lwt.2011.11.019
   KHACHIK F, 1992, J AGR FOOD CHEM, V40, P390, DOI 10.1021/jf00015a006
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1992, METHOD ENZYMOL, V213, P347
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   Kimura M, 2003, J AGR FOOD CHEM, V51, P2603, DOI 10.1021/jf020539b
   KIMURA M, 1991, FOOD SCI TECHNOL-LEB, V24, P415
   Kopsell DA, 2004, HORTSCIENCE, V39, P361, DOI 10.21273/HORTSCI.39.2.361
   Kopsell DA, 2006, J AGR FOOD CHEM, V54, P7998, DOI 10.1021/jf0614802
   Korus A, 2011, INT J FOOD PROP, V14, P1069, DOI 10.1080/10942910903580926
   Kurilich AC, 1999, J AGR FOOD CHEM, V47, P1576, DOI 10.1021/jf9810158
   Landrum J, 2012, ACTA BIOCHIM POL, V59, P167
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lefsrud M, 2007, SCI HORTIC-AMSTERDAM, V112, P136, DOI 10.1016/j.scienta.2006.12.026
   Lessin WJ, 1997, J AGR FOOD CHEM, V45, P3728, DOI 10.1021/jf960803z
   Mamatha BS, 2012, FOOD BIOPROCESS TECH, V5, P1355, DOI 10.1007/s11947-010-0403-8
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Mazzeo T, 2011, FOOD CHEM, V128, P627, DOI 10.1016/j.foodchem.2011.03.070
   MERCADANTE AZ, 1991, J AGR FOOD CHEM, V39, P1094, DOI 10.1021/jf00006a018
   Miglio C, 2008, J AGR FOOD CHEM, V56, P139, DOI 10.1021/jf072304b
   Milella L, 2011, J AGR FOOD CHEM, V59, P5293, DOI 10.1021/jf104991z
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nonaka K, 2012, J AM SOC HORTIC SCI, V137, P243, DOI 10.21273/JASHS.137.4.243
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Porrini M, 1998, BRIT J NUTR, V80, P353, DOI 10.1079/096582198388300
   RAMOS DMR, 1987, J MICRONUTR ANAL, V3, P147
   Rodriguez-Amaya DB, 1999, ARCH LATINOAM NUTR, V49, p38S
   Rodriguez-Amaya DB, 2008, J FOOD COMPOS ANAL, V21, P445, DOI 10.1016/j.jfca.2008.04.001
   Rodriguez-Amaya Delia B, 2003, Forum Nutr, V56, P35
   Schonhof I, 1996, GARTENBAUWISSENSCHAF, V61, P281
   Singh J, 2007, J FOOD COMPOS ANAL, V20, P106, DOI 10.1016/j.jfca.2006.08.002
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   STAHL W, 1992, J NUTR, V122, P2161, DOI 10.1093/jn/122.11.2161
   STEWART I, 1977, J AGR FOOD CHEM, V25, P1132, DOI 10.1021/jf60213a048
   van den Berg H, 2000, J SCI FOOD AGR, V80, P880, DOI 10.1002/(SICI)1097-0010(20000515)80:7&lt;880::AID-JSFA646&gt;3.0.CO;2-1
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
NR 65
TC 23
Z9 23
U1 4
U2 117
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV 11
PY 2015
VL 63
IS 44
BP 9677
EP 9682
DI 10.1021/acs.jafc.5b03691
PG 6
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA CW1CO
UT WOS:000364727400001
PM 26477753
DA 2022-11-30
ER

PT J
AU Hirsch, L
   Nazari, H
   Sreekumar, PG
   Kannan, R
   Dustin, L
   Zhu, DH
   Barron, E
   Hinton, DR
AF Hirsch, Louis
   Nazari, Hossein
   Sreekumar, Parameswaran G.
   Kannan, Ram
   Dustin, Laurie
   Zhu, Danhong
   Barron, Ernesto
   Hinton, David R.
TI TGF-beta 2 secretion from RPE decreases with polarization and becomes
   apically oriented
SO CYTOKINE
LA English
DT Article
DE Retinal pigment epithelium; TGF-beta; Embryonic stem cell; Proliferative
   vitreoretinopathy; Polarity
ID PIGMENT EPITHELIAL-CELLS; GROWTH-FACTOR-BETA; CONTRACTION; EYE
AB Retinal pigmented epithelium (RPE) secretes transforming growth factor beta 1 and 2 (TGF-beta 1 and -beta 2) cytokines involved in fibrosis, immune privilege, and proliferative vitreoretinopathy (PVR). Since RPE cell polarity may be altered in various disease conditions including PVR and age-related macular degeneration, we determined levels of TGF-beta from polarized human RPE (hRPE) and human stem cell derived RPE (hESC-RPE) as compared to nonpolarized cells. TGF-beta 2 was the predominant isoform in all cell culture conditions. Nonpolarized cells secreted significantly more TGF-beta 2 supporting the contention that loss of polarity of RPE in PVR leads to rise of intravitreal TGF-beta 2. Active TGF-beta 2, secreted mainly from apical side of polarized RPE, represented 6-10% of total TGF-beta 2. In conclusion, polarity is an important determinant of TGF-beta 2 secretion in RPE. Low levels of apically secreted active TGF-beta 2 may play a role in the normal physiology of the subretinal space. Comparable secretion of TGF-beta from polarized hESC-RPE and hRPE supports the potential for hESC-RPE in RPE replacement therapies. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Hirsch, Louis; Nazari, Hossein; Zhu, Danhong; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.
   [Zhu, Danhong; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA.
   [Dustin, Laurie] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [Sreekumar, Parameswaran G.; Kannan, Ram; Barron, Ernesto] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; Doheny Eye Institute
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch, Dept Pathol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90089 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020; Nazari, Hossein/GOK-8161-2022
OI kannan, ram/0000-0002-1583-3414; Nazari, Hossein/0000-0002-8945-9680;
   /0000-0002-9425-3986
FU NIH [EYO1545]; Core Grant Research to Prevent Blindness, New York
   [EY03040]; Keck School of Medicine Dean's Research Scholars Program;
   Arnold and Mabel Beckman Foundation; NATIONAL CANCER INSTITUTE
   [P30CA014089] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY001545, P30EY003040] Funding Source: NIH RePORTER
FX The California Institute for Regenerative Medicine DR1-01444 and
   TG2-01161; NIH Grant EYO1545 and Core Grant EY03040, Research to Prevent
   Blindness, New York; The Arnold and Mabel Beckman Foundation; The Keck
   School of Medicine Dean's Research Scholars Program. The authors thank
   Christine Spee for maintenance of RPE cultures.
CR Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Carrington L, 2000, INVEST OPHTH VIS SCI, V41, P1210
   CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065
   Cordeiro MF, 2000, INVEST OPHTH VIS SCI, V41, P756
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Kannan R, 2011, INVEST OPHTH VIS SCI, V52, P9047, DOI 10.1167/iovs.11-8737
   KVANTA A, 1994, OPHTHALMIC RES, V26, P361, DOI 10.1159/000267502
   Li R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023148
   Parapuram SK, 2009, INVEST OPHTH VIS SCI, V50, P5965, DOI 10.1167/iovs.09-3621
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Saika Shizuya, 2009, Front Biosci (Schol Ed), V1, P376, DOI 10.2741/e32
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sugita S, 2006, EXP EYE RES, V83, P1459, DOI 10.1016/j.exer.2006.08.005
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
NR 15
TC 21
Z9 21
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD FEB
PY 2015
VL 71
IS 2
BP 394
EP 396
DI 10.1016/j.cyto.2014.11.014
PG 3
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA CA6YJ
UT WOS:000349063500037
PM 25496702
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kanan, Y
   Siefert, JC
   Kinter, M
   Al-Ubaidi, MR
AF Kanan, Yogita
   Siefert, Joseph C.
   Kinter, Michael
   Al-Ubaidi, Muayyad R.
TI Complement Factor H, Vitronectin, and Opticin Are Tyrosine-Sulfated
   Proteins of the Retinal Pigment Epithelium
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; O-SULFATION; TYROSYLPROTEIN SULFOTRANSFERASE-2;
   P-SELECTIN; S-PROTEIN; BINDING; GENE; IDENTIFICATION; CELLS; SITE
AB Lack of tyrosine sulfation of ocular proteins results in disorganized photoreceptor structure and drastically reduced visual function, demonstrating the importance of this post-translational modification to vision. To understand the role that tyrosine sulfation plays in the function of ocular proteins, we identified some tyrosine-sulfated proteins in the retinal pigment epithelium using two independent methods, immuno-affinity column purification with an anti-sulfotyrosine specific antibody and computer-based sequence analysis of retinal pigment epithelium secretome by means of the prediction program Sulfinator. Radioactive labeling followed by thin layer electrophoresis revealed that three proteins, vitronectin, opticin, and complement factor H (CFH), were post-translationally modified by tyrosine sulfation. The identification of vitronectin and CFH as tyrosine-sulfated proteins is significant, since both are deposited in drusen in the eyes of patients with age-related macular degeneration (AMD). Furthermore, mutations in CFH have been determined to be a major risk factor in the development of AMD. Future studies that seek to understand the role of CFH in the development of AMD should take into account the role that tyrosine sulfation plays in the interaction of this protein with its partners, and examine whether modulating sulfation provides a potential therapeutic target.
C1 [Kanan, Yogita; Siefert, Joseph C.; Al-Ubaidi, Muayyad R.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73106 USA.
   [Kinter, Michael] Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Oklahoma City, OK USA.
   [Kinter, Michael] Oklahoma Med Res Fdn, Free Rad Biol & Aging Res Program, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; Oklahoma Medical Research Foundation
RP Kanan, Y (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73106 USA.
EM ykanan@ouhsc.edu; muayyad-al-ubaidi@ouhsc.edu
OI Siefert, Joseph/0000-0001-5584-8672; Kinter, Michael/0000-0001-7409-8918
FU National Eye Institute; Oklahoma Center for the Advancement of Science
   and Technology; Foundation Fighting Blindness
FX This study was supported by the National Eye Institute to MRA, Oklahoma
   Center for the Advancement of Science and Technology to YK, and
   Foundation Fighting Blindness to MRA. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   NIH or any of its institutes.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Annunen S, 1999, AM J HUM GENET, V65, P974, DOI 10.1086/302585
   BAEUERLE PA, 1988, J BIOL CHEM, V263, P14925
   BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655
   Bhattacharjee A, 2010, MOL IMMUNOL, V47, P1686, DOI 10.1016/j.molimm.2010.03.007
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Borghei A, 2006, J BIOL CHEM, V281, P9423, DOI 10.1074/jbc.M513768200
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   BUDARF ML, 1982, J BIOL CHEM, V257, P128
   Caraci F, 2008, NEUROCHEM RES, V33, P2401, DOI 10.1007/s11064-008-9710-0
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Choe H, 2009, METHOD ENZYMOL, V461, P147, DOI 10.1016/S0076-6879(09)05407-X
   Choi Y, 2010, PROTEOMICS, V10, P72, DOI 10.1002/pmic.200900146
   Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004
   Fenaille F, 2007, GLYCOBIOLOGY, V17, P932, DOI 10.1093/glycob/cwm060
   Fernando AN, 2007, J MOL BIOL, V368, P564, DOI 10.1016/j.jmb.2007.02.038
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HINTNER H, 1991, J INVEST DERMATOL, V96, P747, DOI 10.1111/1523-1747.ep12470980
   HIROSE S, 1988, J BIOL CHEM, V263, P7426
   Hoffhines AJ, 2006, J BIOL CHEM, V281, P37877, DOI 10.1074/jbc.M609398200
   Hoffhines AJ, 2009, J BIOL CHEM, V284, P3096, DOI 10.1074/jbc.M808434200
   HORTIN G, 1986, J BIOL CHEM, V261, P1786
   HORTIN G, 1986, J BIOL CHEM, V261, P5827
   HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200
   HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051
   JENNE D, 1989, EUR J BIOCHEM, V185, P391, DOI 10.1111/j.1432-1033.1989.tb15127.x
   Kanan Y., 2014, J BIOL CHEM IN PRESS
   Kanan Y, 2012, ADV EXP MED BIOL, V723, P835, DOI 10.1007/978-1-4614-0631-0_107
   Kanan Y, 2010, J NEUROCHEM, V113, P477, DOI 10.1111/j.1471-4159.2010.06609.x
   Kanan Y, 2009, EXP EYE RES, V89, P559, DOI 10.1016/j.exer.2009.05.010
   Karagianni N, 2010, ADV EXP MED BIOL, V703, P1, DOI 10.1007/978-1-4419-5635-4_1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRAJEWSKI T, 1968, ACTA CHEM SCAND, V22, P1339, DOI 10.3891/acta.chem.scand.22-1339
   Le Goff MM, 2012, J BIOL CHEM, V287, P28027, DOI 10.1074/jbc.M111.331157
   Le Goff MM, 2012, INVEST OPHTH VIS SCI, V53, P228, DOI 10.1167/iovs.11-8514
   Le Goff MM, 2003, J BIOL CHEM, V278, P45280, DOI 10.1074/jbc.M303117200
   Liu ZJ, 2011, ACTA PHARMACOL SIN, V32, P1038, DOI 10.1038/aps.2011.53
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Ma J, 2012, CYTOKINE, V59, P100, DOI 10.1016/j.cyto.2012.03.025
   Monfort J, 2008, OSTEOARTHR CARTILAGE, V16, P749, DOI 10.1016/j.joca.2007.11.007
   Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769
   Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200
   MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687
   Morse E E, 1971, Ann Clin Lab Sci, V1, P155
   Muthana SM, 2012, ACS CHEM BIOL, V7, P31, DOI 10.1021/cb2004466
   Nicholas HB, 1999, ENDOCRINE, V11, P285, DOI 10.1385/ENDO:11:3:285
   Nishimura Y, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001174
   Okemefuna AI, 2008, J MOL BIOL, V375, P80, DOI 10.1016/j.jmb.2007.09.026
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200
   Ouyang YB, 2002, J BIOL CHEM, V277, P23781, DOI 10.1074/jbc.M202420200
   Pauleikhoff D, 1992, Ophthalmologe, V89, P39
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609
   Perkins SJ, 2010, BIOCHEM SOC T, V38, P894, DOI 10.1042/BST0380894
   PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294
   PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89
   POHL WR, 1991, AM REV RESPIR DIS, V143, P1369, DOI 10.1164/ajrccm/143.6.1369
   Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771
   Ramesh S, 2004, BRIT J OPHTHALMOL, V88, P697, DOI 10.1136/bjo.2003.031989
   Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339
   Rodgers SD, 2001, BIOPHYS J, V81, P2001, DOI 10.1016/S0006-3495(01)75850-X
   ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Sanders EJ, 2003, INVEST OPHTH VIS SCI, V44, P5404, DOI 10.1167/iovs.03-0500
   Schmidt C, 2008, REV ECON POLIT, V118, P3
   SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015
   Seger D, 2000, FEBS LETT, V480, P169, DOI 10.1016/S0014-5793(00)01917-7
   Sherry DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039702
   Sherry DM, 2010, EUR J NEUROSCI, V32, P1461, DOI 10.1111/j.1460-9568.2010.07431.x
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Stone MJ, 2009, NEW BIOTECHNOL, V25, P299, DOI 10.1016/j.nbt.2009.03.011
   VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Westmuckett AD, 2008, GEN COMP ENDOCR, V156, P145, DOI 10.1016/j.ygcen.2007.12.006
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yu YH, 2007, NAT METHODS, V4, P583, DOI 10.1038/NMETH1056
   Zhu JZ, 2011, BIOCHEMISTRY-US, V50, P1524, DOI 10.1021/bi101240v
NR 82
TC 18
Z9 18
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2014
VL 9
IS 8
AR e105409
DI 10.1371/journal.pone.0105409
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AN6XM
UT WOS:000340742100091
PM 25136834
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Morera, Y
   Gonzalez, R
   Lamdan, H
   Perez, L
   Gonzalez, Y
   Agilero, J
   Castro, J
   Romero, JC
   Etchegoyen, AY
   Ayala, M
   Gavilondo, JV
AF Morera, Yanelys
   Gonzalez, Rafael
   Lamdan, Humberto
   Perez, Lincidio
   Gonzalez, Yorlandis
   Agilero, Judith
   Castro, Jorge
   Romero, Juan C.
   Etchegoyen, Ana Yansy
   Ayala, Marta
   Gavilondo, Jorge V.
TI Vaccination with a mutated variant of human Vascular Endothelial Growth
   Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit
   experimental model
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE CIGB-247-V; VEGF; vaccine; retinal neovascularization; angiogenesis
ID INTRAVITREAL SUSTAINED-RELEASE; MACULAR DEGENERATION; BEVACIZUMAB
   AVASTIN; ACTIVE IMMUNOTHERAPY; BARRIER; RANIBIZUMAB; OUTCOMES; ANTIGEN;
   AGENTS
AB Vascular Endothelial Growth Factor (VEGF) is a key driver of the neovascularization and vascular permeability that leads to the loss of visual acuity of eye diseases like wet age-related macular degeneration, diabetic macular edema, and retinopathy of premature. Among the several anti-VEGF therapies under investigation for the treatment of neovascular eye diseases, our group has developed the vaccine candidate CIGB-247-V that uses a mutated form of human VEGF as antigen. In this work we evaluated if the vaccine could prevent or attenuate VEGF-induced retinal neovascularization in the course of a rabbit eye neovascularization model, based on direct intravitreal injection of human VEGF. Our experimental findings have shown that anti-VEGF IgG antibodies induced by the vaccine were available in the retina blood circulation, and could neutralize in situ the neovascularization effect of VEGF. CIGB-247-V vaccination proved to effectively reduce retinal neovascularization caused by intravitreal VEGF injection. Altogether, these results open the way for human studies of the vaccine in neovascular eye syndromes, and inform on the potential mechanisms involved in its effect. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Morera, Yanelys; Lamdan, Humberto; Perez, Lincidio; Etchegoyen, Ana Yansy; Ayala, Marta; Gavilondo, Jorge V.] Ctr Genet Engn & Biotechnol, Dept Pharmaceut, Canc Immunotherapy Lab, Havana 10600, Cuba.
   [Gonzalez, Rafael; Gonzalez, Yorlandis; Agilero, Judith] Cuban Inst Ophthalmol Ramon Pando Ferrer, Havana 10600, Cuba.
   [Castro, Jorge; Romero, Juan C.] Ctr Genet Engn & Biotechnol, Anim Facil, Havana 10600, Cuba.
C3 Centro de Ingenieria Genetica y Biotecnologia; Centro de Ingenieria
   Genetica y Biotecnologia
RP Morera, Y (通讯作者)，Ctr Genet Engn & Biotechnol, Dept Pharmaceut, Canc Immunotherapy Lab, POB 6162,Ave 31-158 & 190, Havana 10600, Cuba.
EM yanelys.morera@cigb.edu.cu
RI Morera, Yanelys/GQP-2646-2022
OI Morera, Yanelys/0000-0001-6051-5514
FU Center for Genetic Engineering and Biotechnology; Center for Genetic
   Engineering and Biorec
FX This work was supported by the Center for Genetic Engineering and
   Biotechnology, and Biorec.
CR Alikacem N, 2000, INVEST OPHTH VIS SCI, V41, P1561
   Ameri H, 2007, INVEST OPHTH VIS SCI, V48, P5708, DOI 10.1167/iovs.07-0731
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bock F, 2008, GRAEF ARCH CLIN EXP, V246, P281, DOI 10.1007/s00417-007-0684-4
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1393, DOI 10.1016/j.ophtha.2009.11.024
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849
   Estevez F, 1999, VACCINE, V18, P190, DOI 10.1016/S0264-410X(99)00219-4
   Evoy KE, 2013, ANN PHARMACOTHER, V47, P819, DOI 10.1345/aph.1R705
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Gavilondo JV, 2014, VACCINE, V32, P2241, DOI 10.1016/j.vaccine.2013.11.102
   Giansanti F, 2009, INVEST OPHTH VIS SCI, V50, P5328, DOI 10.1167/iovs.09-3569
   Heckmann M, 2008, OPHTHALMOLOGE, V105, P1101, DOI 10.1007/s00347-008-1789-9
   Honda M, 2013, INT J NANOMED, V8, P495, DOI 10.2147/IJN.S30725
   HURWITZ H, 2004, BEVACIZUMAB PLUS IRI
   Jansen RM, 2013, MED LAW, V32, P65
   Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   MILLER K, 2007, PACLITAXEL PLUS BEVA
   Morera Y, 2006, BIOTECHNOL APPL BIOC, V44, P45, DOI 10.1042/BA20050169
   Morera Y, 2012, VACCINE, V30, P368, DOI 10.1016/j.vaccine.2011.10.082
   Morera Y, 2010, VACCINE, V28, P3453, DOI 10.1016/j.vaccine.2010.02.069
   Morera Y, 2008, ANGIOGENESIS, V11, P381, DOI 10.1007/s10456-008-9121-5
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   NUZZI R, 2013, SEMIN OPHTHALMOL
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   PEIFFER RL, 1980, LAB ANIM, V14, P331, DOI 10.1258/002367780781071094
   PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   SCHMIDTERFURTH U, 2013, OPHTHALMOLOGY, V10
   Takahashi H, 2008, INVEST OPHTH VIS SCI, V49, P2143, DOI 10.1167/iovs.07-0523
   Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309
   Wong CG, 2001, CURR EYE RES, V22, P140, DOI 10.1076/ceyr.22.2.140.5528
NR 37
TC 8
Z9 11
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2014
VL 122
BP 102
EP 109
DI 10.1016/j.exer.2014.03.006
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH3FQ
UT WOS:000336009500013
PM 24675387
DA 2022-11-30
ER

PT J
AU Sarao, V
   Veritti, D
   Boscia, F
   Lanzetta, P
AF Sarao, Valentina
   Veritti, Daniele
   Boscia, Francesco
   Lanzetta, Paolo
TI Intravitreal Steroids for the Treatment of Retinal Diseases
SO SCIENTIFIC WORLD JOURNAL
LA English
DT Review
ID DIABETIC MACULAR EDEMA; RANDOMIZED CLINICAL-TRIAL; DRUG-DELIVERY SYSTEM;
   TRIAMCINOLONE ACETONIDE INJECTION; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; FLUOCINOLONE ACETONIDE; PHOTODYNAMIC THERAPY;
   PANRETINAL PHOTOCOAGULATION; TRIPLE THERAPY
AB Diabetic macular edema (DME), pseudophakic cystoid macular edema (CME), age-related macular degeneration (AMD), retinal vascular occlusion (RVO), and uveitis are ocular conditions related to severe visual impairment worldwide. Corticosteroids have been widely used in the treatment of these retinal diseases, due to their well-known antiangiogenic, antiedematous, and anti-inflammatory properties. Intravitreal steroids have emerged as novel and essential tools in the ophthalmologist's armamentarium, allowing for maximization of drug efficacy and limited risk of systemic side effects. Recent advances in ocular drug delivery methods led to the development of intraocular implants, which help to provide prolonged treatment with controlled drug release. Moreover, they may add some potential advantages over traditional intraocular injections by delivering certain rates of drug directly to the site of action, amplifying the drug's half-life, contributing in the minimization of peak plasma levels of the drug, and avoiding the side effects associated with repeated intravitreal injections. The purpose of this review is to provide an update on the use of intravitreal steroids as a treatment option for a variety of retinal diseases and to review the current literature considering their properties, safety, and adverse events.
C1 [Sarao, Valentina; Veritti, Daniele; Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Boscia, Francesco] Univ Sassari, Dept Ophthalmol, I-07100 Sassari, Italy.
C3 University of Udine; University of Sassari
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazza Santa Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
RI Boscia, Francesco/AAC-7729-2022
OI Lanzetta, Paolo/0000-0003-3746-141X; Boscia,
   Francesco/0000-0002-5478-060X; VERITTI, Daniele/0000-0003-0148-5348
CR Abelson M. B., 1994, PRINCIPLES PRACTICE
   Alldredge CD, 2003, RETINA-J RET VIT DIS, V23, P113, DOI 10.1097/00006982-200302000-00022
   Audren F, 2004, INVEST OPHTH VIS SCI, V45, P3435, DOI 10.1167/iovs.03-1110
   Audren F, 2006, ACTA OPHTHALMOL SCAN, V84, P624, DOI 10.1111/j.1600-0420.2006.00700.x
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avitabile T, 2005, AM J OPHTHALMOL, V140, P695, DOI 10.1016/j.ajo.2005.05.021
   Bakri SJ, 2003, OPHTHALMIC SUR LA IM, V34, P386
   Bakri SJ, 2005, AM J OPHTHALMOL, V139, P290, DOI 10.1016/j.ajo.2004.09.038
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Bandello F, 2006, ARCH OPHTHALMOL-CHIC, V124, P643, DOI 10.1001/archopht.124.5.643
   Bandello F, 2004, GRAEF ARCH CLIN EXP, V242, P1024, DOI 10.1007/s00417-004-0911-1
   Bandi N, 2001, EUR J PHARMACOL, V425, P109, DOI 10.1016/S0014-2999(01)01192-X
   Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   BHATTACHERJEE P, 1983, INVEST OPHTH VIS SCI, V24, P1143
   Bonini MA, 2005, INVEST OPHTH VIS SCI, V46, P3845, DOI 10.1167/iovs.05-0297
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Cardillo JA, 2005, OPHTHALMOLOGY, V112, P1557, DOI 10.1016/j.ophtha.2005.03.023
   Cekic O, 2005, AM J OPHTHALMOL, V139, P993, DOI 10.1016/j.ajo.2005.01.022
   Cellini M., 2008, BMC OPHTHALMOLOGY, V8
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Chen WQ, 2011, RETINA-J RET VIT DIS, V31, P1137, DOI 10.1097/IAE.0b013e3181fe5427
   Choi Kyung Seek, 2007, Korean J Ophthalmol, V21, P11, DOI 10.3341/kjo.2007.21.1.11
   Choi Young Jae, 2006, Korean J Ophthalmol, V20, P205
   Couch SM, 2009, CLIN OPHTHALMOL, V3, P41
   Detry-Morel M, 2004, Bull Soc Belge Ophtalmol, P45
   Driot JY, 2004, J OCUL PHARMACOL TH, V20, P269, DOI 10.1089/1080768041223611
   Ehmann D, 2010, CAN J OPHTHALMOL, V45, P36, DOI 10.3129/i09-243
   Eisenstadt W. S., 1965, ANN ALLERGY, V13, P252
   ELIOTT D, 2008, ANN M ASS RES VIS OP
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Enaida H, 2003, RETINA-J RET VIT DIS, V23, P764, DOI 10.1097/00006982-200312000-00003
   Fischer S, 2001, EUR J PHARMACOL, V411, P231, DOI 10.1016/S0014-2999(00)00915-8
   FLOMAN N, 1977, INVEST OPHTH VIS SCI, V16, P69
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Gillies MC, 2007, BRIT J OPHTHALMOL, V91, P1323, DOI 10.1136/bjo.2006.113167
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Gillies MC, 2009, OPHTHALMOLOGY, V116, P2182, DOI 10.1016/j.ophtha.2009.04.049
   Gilman A.G., 2001, GOODMAN GILMANS PHAR
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21
   Haller JA, 2009, RETINA-J RET VIT DIS, V29, P46, DOI 10.1097/IAE.0b013e318188c814
   Hauser D, 2008, RETINA-J RET VIT DIS, V28, P825, DOI 10.1097/IAE.0b013e318165767e
   HEFFERNAN JT, 1978, INVEST OPHTH VIS SCI, V17, P565
   Hyung Woo Kwak H. W. K., 1992, ARCH OPHTHALMOL-CHIC, V110, P259
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Ip MS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1101, DOI 10.1001/archophthalmol.2009.234
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jonas JB, 2006, AM J OPHTHALMOL, V141, P579, DOI 10.1016/j.ajo.2005.10.007
   Jonas JB, 2006, CORNEA, V25, P240, DOI 10.1097/01.ico.0000176614.73332.58
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Jonas JB, 2005, EYE, V19, P65, DOI 10.1038/sj.eye.6701395
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P1054, DOI 10.1016/j.ajo.2004.06.041
   Jonas JB, 2004, ACTA OPHTHALMOL SCAN, V82, P637, DOI 10.1111/j.1600-0420.2004.00319.x
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P587, DOI 10.1136/bjo.2003.028688
   Jonas JB, 2004, AM J OPHTHALMOL, V137, P367, DOI 10.1016/S0002-9394(03)00899-7
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2003, ACTA OPHTHALMOL SCAN, V81, P540, DOI 10.1034/j.1600-0420.2003.00130.x
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2003, EUR J OPHTHALMOL, V13, P575, DOI 10.1177/112067210301300611
   Jonas J, 2010, DEV OPHTHALMOL, V47, P111, DOI 10.1159/000320076
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P200, DOI 10.1089/jop.2006.22.200
   Kaderli Berkant, 2005, International Ophthalmology, V26, P207, DOI 10.1007/s10792-007-9042-0
   Kang BS, 2001, BIOL PHARM BULL, V24, P701, DOI 10.1248/bpb.24.701
   Karacorlu M, 2006, EUR J OPHTHALMOL, V16, P481, DOI 10.1177/112067210601600322
   Kim JE, 2008, RETINA-J RET VIT DIS, V28, P735, DOI 10.1097/IAE.0b013e318163194c
   Kivilcim M, 2000, OPHTHALMIC SURG LAS, V31, P474
   Kupperman B., 2010, P 33 ANN MAC SOC M T
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   Lam DSC, 2007, BRIT J OPHTHALMOL, V91, P199, DOI 10.1136/bjo.2006.102848
   Lang YR, 2007, RETINA-J RET VIT DIS, V27, P778, DOI 10.1097/IAE.0b013e318030c517
   Lanzetta P., 2011, RET SOC ROM IT
   LEE CM, 1991, OPHTHALMOLOGY, V98, P1594
   LEWIS GD, 1986, ENDOCRINOLOGY, V119, P62, DOI 10.1210/endo-119-1-62
   Lim JI, 2011, OPHTHALMOLOGY, V118, P1416, DOI 10.1016/j.ophtha.2010.12.029
   LIVANOU T, 1967, LANCET, V2, P856
   Loewenstein A., 2010, ASS RES VIS OPHTH MA
   Carrero JL, 2008, ARCH OPHTHALMOL-CHIC, V126, P142, DOI 10.1001/archophthalmol.2007.20
   Lowder C, 2011, ARCH OPHTHALMOL-CHIC, V129, P545, DOI 10.1001/archophthalmol.2010.339
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Maia OO, 2009, AM J OPHTHALMOL, V147, P291, DOI 10.1016/j.ajo.2008.08.024
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   NACHOD G R, 1951, J Am Med Womens Assoc, V6, P453
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   NAVEH N, 1991, PROSTAG LEUKOTR ESS, V42, P101, DOI 10.1016/0952-3278(91)90075-G
   Ozdek S, 2006, J DIABETES COMPLICAT, V20, P246, DOI 10.1016/j.jdiacomp.2005.06.015
   Ozdemir H, 2005, ACTA OPHTHALMOL SCAN, V83, P248, DOI 10.1111/j.1600-0420.2005.00395.x
   Park Hye Young, 2005, Korean J Ophthalmol, V19, P122
   QLT, 2012, QLT ANN FIN RES ITS
   Rechtman E, 2003, AM J OPHTHALMOL, V136, P739, DOI 10.1016/S0002-9394(03)00389-1
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Scott IU, 2009, ARCH OPHTHALMOL-CHIC, V127, P1115, DOI 10.1001/archophthalmol.2009.233
   Singer M., 2011, RET SOC ANN M ROM IT
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Sutter FKP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1491, DOI 10.1001/archopht.121.10.1491
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   Tamura H, 2005, INVEST OPHTH VIS SCI, V46, P1440, DOI 10.1167/iovs.04-0905
   Tokuda K, 2004, ACTA OPHTHALMOL SCAN, V82, P189, DOI 10.1111/j.1600-0420.2004.00224.x
   Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1
   Veritti D, 2011, EUR J OPHTHALMOL, V21, pS75, DOI 10.5301/EJO.2010.6060
   Veritti D, 2009, INVEST OPHTH VIS SCI, V50, P2391, DOI 10.1167/iovs.08-2518
   Williams G, 2009, TLS-TIMES LIT SUPPL, P6
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
   Yilmaz T, 2009, OPHTHALMOLOGY, V116, P902, DOI 10.1016/j.ophtha.2009.02.002
   Zacks DN, 2005, RETINA-J RET VIT DIS, V25, P135, DOI 10.1097/00006982-200502000-00003
   Zein WM, 2006, RETINA-J RET VIT DIS, V26, P137, DOI 10.1097/00006982-200602000-00002
NR 113
TC 58
Z9 59
U1 0
U2 11
PU HINDAWI PUBLISHING CORPORATION
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1537-744X
J9 SCI WORLD J
JI Sci. World J.
PY 2014
AR 989501
DI 10.1155/2014/989501
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 299XT
UT WOS:000330429700001
PM 24526927
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Edwards, KH
   Gibson, GA
AF Edwards, Keith H.
   Gibson, G. Anthony
TI Intraocular lens short wavelength light filtering
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE age-related macular degeneration; cataract; intraocular lenses; retina;
   ultraviolet
ID AGE-RELATED MACULOPATHY; BLUE-LIGHT; MACULAR DEGENERATION; BEAVER DAM;
   DARK-ADAPTATION; CONTRAST SENSITIVITY; VISUAL IMPAIRMENT;
   CATARACT-SURGERY; RISK-FACTORS; RPE CELLS
AB There is increasing interest in the effects of reactive oxygen species ('free radicals') in ageing, both in the body overall and specifically in the eye. Cataract and age-related macular degeneration (AMD) are two major causes of blindness, with cataract accounting for 48 per cent of world blindness and AMD accounting for 8.7 per cent. Both cataract and AMD affect an older population (over 50 years of age) and while cataract is largely treatable provided resources are available, AMD is a common cause of untreatable, progressive visual loss. There is evidence that AMD is linked to exposure to short wavelength electromagnetic radiation, which includes ultraviolet, blue and violet wavelengths. The ageing crystalline lens provides some protection to the posterior pole because, as it yellows with age, its spectral absorption increasingly blocks the shorter wavelengths of light. Ultraviolet blocking intraocular lenses (IOLs) have been the standard of care for many years but a more recent trend is to include blue-blocking filters based on theoretical benefits. As these filters absorb part of the visible spectrum, they may affect visual function. This review looks at the risks and the benefits of filtering out short wavelength light in pseudophakic patients.
C1 [Gibson, G. Anthony] Darlington Mem Hosp, Dept Ophthalmol, Darlington, Durham, England.
   [Edwards, Keith H.] LensAR Inc, Winter Pk, FL USA.
RP Edwards, KH (通讯作者)，210 N Pk Ave, Winter Pk, FL 32789 USA.
EM keith.edwards@lensar.com
CR AARNISALO EA, 1988, AM J OPHTHALMOL, V105, P408, DOI 10.1016/0002-9394(88)90307-8
   ABRAHAM FA, 1988, OPHTHALMIC RES, V20, P117, DOI 10.1159/000266261
   ANDERSON RE, 1994, ADV EXP MED BIOL, V366, P73
   BABU V, 1995, BIOCHEM BIOPH RES CO, V210, P417, DOI 10.1006/bbrc.1995.1677
   Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bennett L W, 1994, J Am Optom Assoc, V65, P273
   Bergmanson Jan P. G., 1997, CLAO Journal, V23, P196
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   BORGES J, 1990, ARCH OPHTHALMOL-CHIC, V108, P727, DOI 10.1001/archopht.1990.01070070113047
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Brabyn JA, 2005, OPTOMETRY VISION SCI, V82, P755, DOI 10.1097/01.opx.0000174723.64798.2b
   Burkle A, 2001, EYE, V15, P371, DOI 10.1038/eye.2001.139
   Cionni RJ, 2006, J CATARACT REFR SURG, V32, P236, DOI 10.1016/j.jcrs.2005.12.129
   CLARKE SM, 1990, ACTA OPHTHALMOL, V68, P639
   COILE DC, 1992, VISUAL NEUROSCI, V8, P27, DOI 10.1017/S0952523800006465
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   CULLEN AP, 1984, AM J OPTOM PHYS OPT, V61, P473
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   DE FES, 2002, Optom Vis Sci, V79, P590
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V28, P357, DOI 10.1111/j.1751-1097.1978.tb07718.x
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   DOMEY RG, 1960, J GERONTOL, V15, P267, DOI 10.1093/geronj/15.3.267
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Feigl B, 2007, CLIN OPHTHALMOL, V1, P167
   Foster RG, 2007, CURR BIOL, V17, pR746, DOI 10.1016/j.cub.2007.07.007
   FOWLER MS, 1992, LANCET, V339, P1230, DOI 10.1016/0140-6736(92)91168-8
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GLADSTONE GJ, 1978, ARCH OPHTHALMOL-CHIC, V96, P1368
   GORGELS T, 1995, INVEST OPHTH VIS SCI, V36, pS517
   GOTTSCH JD, 1990, INVEST OPHTH VIS SCI, V31, P1674
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREENSTEIN VC, 1993, OPTOMETRY VISION SCI, V70, P18, DOI 10.1097/00006324-199301000-00005
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Gurrey R.K., 1985, CLIN OPHTHALMOLOGY, P1
   HAMMER HM, 1986, T OPHTHAL SOC UK, V105, P441
   HAMWT JR, 1980, VISION RES, V20, P1105
   HAMWT JR, 1976, NATURE, V260, P153
   Hankins MW, 2008, TRENDS NEUROSCI, V31, P27, DOI 10.1016/j.tins.2007.11.002
   Hawkins BS, 1999, MOL VIS, V5
   HECHT S, 1948, AM J OPHTHALMOL, V31, P1573, DOI 10.1016/S0002-9394(48)91296-3
   HILLER R, 1977, AM J EPIDEMIOL, V105, P450, DOI 10.1093/oxfordjournals.aje.a112404
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Ishida Misako, 1994, Nippon Ganka Gakkai Zasshi, V98, P192
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   Jin Chenjin, 2004, Yan Ke Xue Bao, V20, P158
   KAMEL ID, 1973, CAN J OPHTHALMOL, V8, P563
   Kara N, 2006, J CATARACT REFR SURG, V32, P1328, DOI 10.1016/j.jcrs.2006.03.033
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katoh N, 2001, ACTA OPHTHALMOL SCAN, V79, P154, DOI 10.1034/j.1600-0420.2001.079002154.x
   KELLY SA, 1984, AM J OPTOM PHYS OPT, V61, P657
   KEUNEN JEE, 1987, INVEST OPHTH VIS SCI, V28, P985
   Kim YY, 2001, AM J OPHTHALMOL, V132, P217, DOI 10.1016/S0002-9394(01)00969-2
   KINNEY JAS, 1983, AM J OPTOM PHYS OPT, V60, P132
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   KLINE DW, 1991, SUSCEPTIBLE VISUAL A, P150
   KREMERS JJM, 1989, INVEST OPHTH VIS SCI, V30, P1032
   KUYK TK, 1990, OPTOMETRY VISION SCI, V67, P522, DOI 10.1097/00006324-199007000-00010
   Lawwill T, 1982, Trans Am Ophthalmol Soc, V80, P517
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mainster M A, 1978, J Am Intraocul Implant Soc, V4, P84
   MAINSTER MA, 1987, EYE-T OPHTH SOC UK, V1, P304, DOI 10.1038/eye.1987.49
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   MAINSTER MA, 1983, OPHTHALMOLOGY, V90, P927
   MAINSTER MA, 1986, AM J OPHTHALMOL, V102, P727, DOI 10.1016/0002-9394(86)90400-9
   MAINSTER MA, 2001, RETINA, V2, P1797
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Makous W, 2004, VISUAL NEUROSCIENCES, P838
   Mandel Y, 2004, INVEST OPHTH VIS SCI, V45, pU657
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Mayer S, 2006, KLIN MONATSBL AUGENH, V223, P142, DOI 10.1055/s-2005-858867
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCMURDO MET, 1991, GERONTOLOGY, V37, P221
   MELLERIO J, 1987, VISION RES, V27, P1581, DOI 10.1016/0042-6989(87)90166-0
   MELLERIO J, 1994, PRINCIPLES PRACTICE, V1, P1326
   Miyake K, 1999, J CATARACT REFR SURG, V25, P891, DOI 10.1016/S0886-3350(99)00069-3
   Munoz B, 1999, ANN EPIDEMIOL, V9, P53, DOI 10.1016/S1047-2797(98)00026-X
   NAARENDORP F, 1988, VISION RES, V28, P67, DOI 10.1016/S0042-6989(88)80007-5
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Niwa K, 1996, OPHTHAL PHYSL OPT, V16, P297, DOI 10.1046/j.1475-1313.1996.95001182.x
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1980, VISION RES, V20, P1163, DOI 10.1016/0042-6989(80)90055-3
   Organization WH, 2010, PREV BLINDN VIS IMP
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 1999, SURV OPHTHALMOL, V43, P535, DOI 10.1016/S0039-6257(99)00035-1
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   PAUTLER EL, 1990, PHOTOCHEM PHOTOBIOL, V51, P599, DOI 10.1111/j.1751-1097.1990.tb01972.x
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   PITTS DG, 1977, INVEST OPHTH VIS SCI, V16, P932
   PLANTNER JJ, 1988, CURR EYE RES, V7, P1125, DOI 10.3109/02713688809001883
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   PULOS E, 1989, INVEST OPHTH VIS SCI, V30, P1738
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Reszka K, 1995, PHOTOCHEM PHOTOBIOL, V62, P1005
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Rubin RM, 2007, INVEST OPHTHALMOL, V48, P6011
   RUSHTON WAH, 1972, PHOTOCHEMISTRY VISIO, P364
   Schefrin BE, 1999, VISION RES, V39, P3728, DOI 10.1016/S0042-6989(99)00072-3
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Sliney DH, 2001, J PHOTOCH PHOTOBIO B, V64, P166, DOI 10.1016/S1011-1344(01)00229-9
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, pS145
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Sturr JF, 1997, VISION RES, V37, P475, DOI 10.1016/S0042-6989(96)00196-4
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1994, DOC OPHTHALMOL, V88, P285
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   THOMAS SR, 1988, AM J OPTOM PHYS OPT, V65, P697
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, pU353
   VANDERHOEVE J, 1918, GRAEFES ARCH CLIN EX, V98, P1
   VANNORREN D, 1990, ARCH OPHTHALMOL-CHIC, V108, P1670, DOI 10.1001/archopht.1990.01070140024009
   VANNORREN D, 1995, LIGHTING AGING VISIO, P11
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WEALE RA, 1988, J PHYSIOL-LONDON, V395, P577, DOI 10.1113/jphysiol.1988.sp016935
   WEALE RA, 1982, BRIT J OPHTHALMOL, V66, P31, DOI 10.1136/bjo.66.1.31
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
   WERNER JS, 1989, GRAEF ARCH CLIN EXP, V227, P248, DOI 10.1007/BF02172758
   WERNER JS, 1989, OPHTHALMOLOGY, V96, P1552
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   WOLF E, 1960, ARCH OPHTHALMOL-CHIC, V64, P502
   WOLF E, 1946, P NATL ACAD SCI USA, V32, P219, DOI 10.1073/pnas.32.8.219
   Wolffsohn JS, 2000, OPTOMETRY VISION SCI, V77, P73, DOI 10.1097/00006324-200002000-00011
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   Wong D, 2004, BRIT J OPHTHALMOL, V88, P598
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YAP M, 1984, OPHTHAL PHYSL OPT, V4, P227, DOI 10.1111/j.1475-1313.1984.tb00360.x
   Yuan ZX, 2004, AM J OPHTHALMOL, V138, P138, DOI 10.1016/j.ajo.2004.02.024
   ZIGMAN S, 1982, ARCH OPHTHALMOL-CHIC, V100, P998
   ZIGMAN S, 1992, OPTOMETRY VISION SCI, V69, P325, DOI 10.1097/00006324-199204000-00012
NR 163
TC 9
Z9 9
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV
PY 2010
VL 93
IS 6
SI SI
BP 390
EP 399
DI 10.1111/j.1444-0938.2010.00538.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 673UJ
UT WOS:000283688700004
PM 20950366
DA 2022-11-30
ER

PT J
AU Ekinci, D
   Beydemir, S
AF Ekinci, Deniz
   Beydemir, Suekrue
TI Evaluation of the impacts of antibiotic drugs on PON 1; a major
   bioscavenger against cardiovascular diseases
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Paraoxonase; Inhibition; Antibiotic; Atherosclerosis; Organophosphate
ID LOW-DENSITY-LIPOPROTEIN; SERUM PARAOXONASE; IN-VITRO;
   BIOLOGICAL-ACTIVITY; OXIDATIVE STRESS; HDL; ATHEROSCLEROSIS; PROTEIN;
   PLASMA; ENZYME
AB Paroxonase 1(PON1) is an antiatherogenic enzyme which is also an organophosphate hydrolyzer. It has crucial roles in detoxification of highly toxic substances and protecting LDL against oxidation. Decrease in the levels of this enzyme is a great risk for the patients with cardiovascular diseases, diabetes mellitus, chronic renal failure, rheumatoid arthritis, hyperthyroidism, and age-related macular degeneration. Therefore, inhibitors and activators of PON1 must be well-characterized, and drug studies would be a good starting point in this regard. Moreover, purification of PON1 has been a challenge for scientists due to its tight association with HDL. Here we report the purification of human serum PON1 using very simple methods and investigation of the interactions between the enzyme and some commonly used antibiotics. We purified PON1 from human serum with a high specific activity and used the pure enzyme for inhibition studies. We observed that some antibiotics inhibit the enzyme at very low doses while some are efficient at higher doses. The antibiotics exhibited different inhibition mechanisms. We concluded that usage of these antibiotics would be very dangerous in some cases. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Ekinci, Deniz; Beydemir, Suekrue] Ataturk Univ, Fac Sci, Dept Chem, Div Biochem, TR-25240 Erzurum, Turkey.
   [Beydemir, Suekrue] Ataturk Univ, Biotechnol Applicat & Res Ctr, TR-25240 Erzurum, Turkey.
C3 Ataturk University; Ataturk University
RP Beydemir, S (通讯作者)，Ataturk Univ, Fac Sci, Dept Chem, Div Biochem, TR-25240 Erzurum, Turkey.
EM beydemir@atauni.edu.tr
RI Ekinci, Deniz/E-2396-2011
CR ABBOTT CA, 1995, ARTERIOSCL THROM VAS, V15, P1812, DOI 10.1161/01.ATV.15.11.1812
   Alici HA, 2008, CLIN BIOCHEM, V41, P1384, DOI 10.1016/j.clinbiochem.2008.06.017
   Ashani Y, 2004, TOXICOL SCI, V77, P358, DOI 10.1093/toxsci/kfh012
   Aviram M, 2004, FREE RADICAL BIO MED, V37, P1304, DOI 10.1016/j.freeradbiomed.2004.06.030
   Aviram M, 1998, J CLIN INVEST, V101, P1581, DOI 10.1172/JCI1649
   Bergmeier C, 2004, CLIN CHEM, V50, P2309, DOI 10.1373/clinchem.2004.034439
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chait A, 2005, J LIPID RES, V46, P389, DOI 10.1194/jlr.R400017-JLR200
   Ciftci M, 2008, ASIAN J CHEM, V20, P2189
   Coban TA, 2007, BIOL PHARM BULL, V30, P2257, DOI 10.1248/bpb.30.2257
   Deakin SP, 2004, CLIN SCI, V107, P435, DOI 10.1042/CS20040187
   Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473
   EKINCI D, 2009, EFFECT SOME ANALGESI, V21, P1034
   Ekinci D, 2007, PHARMACOL REP, V59, P580
   FORTMANN SP, 1986, AM J EPIDEMIOL, V124, P706, DOI 10.1093/oxfordjournals.aje.a114445
   Gaidukov L, 2005, BIOCHEMISTRY-US, V44, P11843, DOI 10.1021/bi050862i
   GAN KN, 1991, DRUG METAB DISPOS, V19, P100
   Getz GS, 2004, CURR OPIN LIPIDOL, V15, P261, DOI 10.1097/00041433-200406000-00005
   Gulcin I, 2008, FRESEN ENVIRON BULL, V17, P1283
   James RW, 2004, FREE RADICAL BIO MED, V37, P1986, DOI 10.1016/j.freeradbiomed.2004.08.012
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Laplaud PM, 1998, CLIN CHEM LAB MED, V36, P431, DOI 10.1515/CCLM.1998.073
   LI WF, 1993, J TOXICOL ENV HEALTH, V40, P337, DOI 10.1080/15287399309531798
   Li WF, 2000, PHARMACOGENETICS, V10, P767, DOI 10.1097/00008571-200012000-00002
   Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036
   Mackness B, 2008, PARAOXONASES THEIR R
   Mackness M, 2004, CURR OPIN LIPIDOL, V15, P399, DOI 10.1097/01.mol.0000137227.54278.29
   MACKNESS MI, 1991, FEBS LETT, V286, P152, DOI 10.1016/0014-5793(91)80962-3
   Ng CJ, 2005, FREE RADICAL BIO MED, V38, P153, DOI 10.1016/j.freeradbiomed.2004.09.035
   Ng CJ, 2001, J BIOL CHEM, V276, P44444, DOI 10.1074/jbc.M105660200
   Nishio E, 1997, BIOCHEM BIOPH RES CO, V236, P289, DOI 10.1006/bbrc.1997.6961
   Pla A, 2007, CHEM-BIOL INTERACT, V167, P63, DOI 10.1016/j.cbi.2007.01.006
   Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542
   Renault F, 2006, J CHROMATOGR B, V836, P15, DOI 10.1016/j.jchromb.2006.03.029
   Rosenblat M, 2006, ATHEROSCLEROSIS, V187, P74, DOI 10.1016/j.athersclerosis.2005.08.026
   Rozenberg O, 2005, ATHEROSCLEROSIS, V181, P9, DOI 10.1016/j.atherosclerosis.2004.12.030
   SCHEFFLER E, 1990, ATHEROSCLEROSIS, V82, P261, DOI 10.1016/0021-9150(90)90048-N
   Shadnia S, 2005, HUM EXP TOXICOL, V24, P439, DOI 10.1191/0960327105ht549oa
   Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406
   Sinan S, 2006, BIOCHIMIE, V88, P565, DOI 10.1016/j.biochi.2005.12.004
   Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359
NR 41
TC 49
Z9 53
U1 0
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 1
PY 2009
VL 617
IS 1-3
BP 84
EP 89
DI 10.1016/j.ejphar.2009.06.048
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 495CO
UT WOS:000269867400014
PM 19577563
DA 2022-11-30
ER

PT J
AU Wang, SQ
   Wang, JJ
   Wong, TY
AF Wang, Shiqi
   Wang, Jie Jin
   Wong, Tien Yin
TI Alcohol and Eye Diseases
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; alcohol; cataract; eye disease;
   glaucoma; retinopathy
ID AGE-RELATED MACULOPATHY; OPEN-ANGLE GLAUCOMA; BEAVER DAM EYE;
   DENSITY-LIPOPROTEIN CHOLESTEROL; ELDERLY CHINESE POPULATION;
   RISK-FACTORS; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   INTRAOCULAR-PRESSURE; OCULAR HYPERTENSION
AB Alcohol consumption is a modifiable lifestyle factor, but there is uncertainty regarding its assocation with eye diseases in adults. A relationship between alcohol consumption and an increased risk of cataract has been reported from cross-sectional studies, but several prospective cohort studies have not found this association. Prospective population-based study findings suggest that heavy alcohol consumption is weakly related to an increased risk of age-related macular degeneration. Reports of an association of alcohol consumption and diabetic retinopathy have been limited mainly to cross-sectional data. There is little evidence of an association between alcohol consumption and glaucoma, and findings of association between alcohol consumption and increased intraocular pressure have been inconsistent. This review shows there is no consistent evidence supporting a major role of moderate alcohol. This review shows there is no consistent evidence supporting a major role of moderate alcohol consumption in the development or progression of common eye diseases. The effect of heavy alcohol consumption on different ocular conditions needs to be clarified, although heavy consumption of alcohol has significant detrimental social, mental, and medical consequences. (Surv Ophthalmol 53:512-525, 2008. (C) 2008 Elsevier Inc. All rights reserved.)
C1 [Wang, Shiqi; Wang, Jie Jin; Wong, Tien Yin] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   [Wang, Jie Jin] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Sydney; National University of Singapore; Singapore National Eye
   Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 52 Gisborne St, Melbourne, Vic 3002, Australia.
RI Wong, Tien Yin/AAC-9724-2020; wang, jie/GRS-0942-2022; Wang, Jie
   Jin/P-1499-2014
OI Wong, Tien Yin/0000-0002-8448-1264; Wang, Jie Jin/0000-0001-9491-4898
CR Ajani UA, 1999, ANN EPIDEMIOL, V9, P172, DOI 10.1016/S1047-2797(98)00053-2
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Beilin LJ, 2006, HYPERTENSION, V47, P1035, DOI 10.1161/01.HYP.0000218586.21932.3c
   Bengtsson B, 2005, J GLAUCOMA, V14, P135, DOI 10.1097/01.ijg.0000151683.04410.f3
   Bergheim I, 2003, EUR J CLIN NUTR, V57, P431, DOI 10.1038/sj.ejcn.1601557
   BJORNEBOE GEA, 1988, ANN NUTR METAB, V32, P56, DOI 10.1159/000177408
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   CASTELLI WP, 1977, LANCET, V2, P153
   Chasan-Taber L, 2000, ANN EPIDEMIOL, V10, P347, DOI 10.1016/S1047-2797(00)00054-5
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331
   Corrao G, 2000, ADDICTION, V95, P1505, DOI 10.1046/j.1360-0443.2000.951015056.x
   Cumming RG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1296, DOI 10.1001/archopht.1997.01100160466015
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Durant JS, 2006, EYE, V20, P1254, DOI 10.1038/sj.eye.6702087
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, AM J OPHTHALMOL, V138, pS19, DOI 10.1016/j.ajo.2004.04.058
   Galan P, 2005, EUR J CLIN NUTR, V59, P1181, DOI 10.1038/sj.ejcn.1602230
   GERSTER H, 1989, Z ERNAHRUNGSWISS, V28, P56, DOI 10.1007/BF02025566
   Giuffre G, 2004, GRAEF ARCH CLIN EXP, V242, P535, DOI 10.1007/s00417-004-0880-4
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   GORDON T, 1981, CIRCULATION, V64, P63
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Howard AA, 2004, ANN INTERN MED, V140, P211, DOI 10.7326/0003-4819-140-6-200403160-00011
   JAKUBOWSKI JA, 1988, ARTERIOSCLEROSIS, V8, P436, DOI 10.1161/01.ATV.8.4.436
   KAHN HA, 1980, ARCH OPHTHALMOL-CHIC, V98, P2172, DOI 10.1001/archopht.1980.01020041024003
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Klein B E, 1999, Ophthalmic Epidemiol, V6, P247
   KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261
   Klein BEK, 2003, AM J OPHTHALMOL, V136, P506, DOI 10.1016/S0002-9394(03)00290-3
   KLEIN BEK, 1993, OPHTHALMOLOGY, V100, P1609
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   KOSTRABA JN, 1991, AM J EPIDEMIOL, V133, P381, DOI 10.1093/oxfordjournals.aje.a115892
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Leske M C, 1996, Ophthalmic Epidemiol, V3, P85, DOI 10.3109/09286589609080113
   Lin HY, 2005, ARCH OPHTHALMOL-CHIC, V123, P381, DOI 10.1001/archopht.123.3.381
   Lindblad BE, 2007, OPHTHALMOLOGY, V114, P680, DOI 10.1016/j.ophtha.2006.07.046
   Manari AP, 2003, ADDICT BIOL, V8, P201, DOI 10.1080/1355621031000117437
   MANSON JE, 1994, AM J PREV MED, V10, P156, DOI 10.1016/S0749-3797(18)30612-3
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   McKay R, 2000, BRIT J OPHTHALMOL, V84, P865, DOI 10.1136/bjo.84.8.865
   MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153
   MIROUZE J, 1990, ARCH OPHTHALMOL-CHIC, V108, P1577
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Morris MS, 2004, OPHTHAL EPIDEMIOL, V11, P53, DOI 10.1076/opep.11.1.53.26439
   Moss SE, 2001, AM J OPHTHALMOL, V132, P70, DOI 10.1016/S0002-9394(01)00936-9
   MOSS SE, 1992, OPHTHALMOLOGY, V99, P926
   MOSS SE, 1994, OPHTHALMOLOGY, V101, P1962
   MUNOZ B, 1993, ARCH OPHTHALMOL-CHIC, V111, P110, DOI 10.1001/archopht.1993.01090010114036
   Nemesure B, 2003, ARCH OPHTHALMOL-CHIC, V121, P856, DOI 10.1001/archopht.121.6.856
   Nirmalan PK, 2006, INVEST OPHTH VIS SCI, V47, P2324, DOI 10.1167/iovs.05-1192
   Obisesan TO, 1998, J AM GERIATR SOC, V46, P1
   Phillips CI, 1996, OPHTHALMIC RES, V28, P237, DOI 10.1159/000267909
   PIETINEN P, 1987, AM HEART J, V113, P620, DOI 10.1016/0002-8703(87)90643-0
   PONTE F, 1994, DOC OPHTHALMOL, V85, P203, DOI 10.1007/BF01664928
   Rehm J, 2003, EUR ADDICT RES, V9, P157, DOI 10.1159/000072222
   RIKANS LE, 1990, ALCOHOL CLIN EXP RES, V14, P872, DOI 10.1111/j.1530-0277.1990.tb01830.x
   Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2
   ROSENBLUM ER, 1989, FREE RADICAL BIO MED, V7, P569, DOI 10.1016/0891-5849(89)90034-8
   SEDDON JM, 1983, ARCH OPHTHALMOL-CHIC, V101, P891
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Single E, 1999, AM J PUBLIC HEALTH, V89, P385, DOI 10.2105/AJPH.89.3.385
   Sjogren H, 2000, ALCOHOL ALCOHOLISM, V35, P601, DOI 10.1093/alcalc/35.6.601
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026
   SPARROW JM, 1986, INT OPHTHALMOL, V9, P207, DOI 10.1007/BF00137534
   Sperduto RD, 1998, OPHTHALMOLOGY, V105, P765, DOI 10.1016/S0161-6420(98)95012-6
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Suzuki Y, 2006, OPHTHALMOLOGY, V113, P1613, DOI 10.1016/j.ophtha.2006.03.059
   Tavani A, 1996, ANN EPIDEMIOL, V6, P41, DOI 10.1016/1047-2797(95)00099-2
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   *USDA, 1990, PROM NUTR DAT SET US
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Weih LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P875
   Wu SY, 1997, ARCH OPHTHALMOL-CHIC, V115, P1572, DOI 10.1001/archopht.1997.01100160742012
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yoshida M, 2003, JPN J OPHTHALMOL, V47, P191, DOI 10.1016/S0021-5155(02)00666-4
   YOUNG RJ, 1984, BRIT MED J, V288, P1035, DOI 10.1136/bmj.288.6423.1035
   Zeng JW, 1998, ALCOHOL, V16, P189, DOI 10.1016/S0741-8329(97)00172-9
   Zima T, 2001, J BIOMED SCI, V8, P59, DOI 10.1007/BF02255972
NR 97
TC 55
Z9 55
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD SEP-OCT
PY 2008
VL 53
IS 5
BP 512
EP 525
DI 10.1016/j.survophthal.2008.06.003
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366KQ
UT WOS:000260480100006
PM 18929762
DA 2022-11-30
ER

PT J
AU Garkal, A
   Bangar, P
   Rajput, A
   Pingale, P
   Dhas, N
   Sami, A
   Mathur, K
   Joshi, S
   Dhuri, S
   Parikh, D
   Mutalik, S
   Mehta, T
AF Garkal, Atul
   Bangar, Priyanka
   Rajput, Amarjitsing
   Pingale, Prashant
   Dhas, Namdev
   Sami, Anam
   Mathur, Khushboo
   Joshi, Shubham
   Dhuri, Sonika
   Parikh, Dhaivat
   Mutalik, Srinivas
   Mehta, Tejal
TI Long-acting formulation strategies for protein and peptide delivery in
   the treatment of PSED
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Posterior Segment; Long -acting injectables; Ocular delivery; Protein
   and Peptide delivery; Anti-VEGF; Port delivery system
ID OPHTHALMIC DRUG-DELIVERY; ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR
   EDEMA; CONTROL-CARDIOVASCULAR-RISK; BLOCK-COPOLYMER HYDROGELS;
   DEACETYLATED GELLAN GUM; POSTERIOR SEGMENT; IN-VITRO; SUSTAINED-RELEASE;
   OCULAR DELIVERY
AB The invigoration of protein and peptides in serious eye disease includes age-related macular degeneration, choroidal neovascularization, retinal neovascularization, and diabetic retinopathy. The transportation of mac-romolecules like aptamers, recombinant proteins, and monoclonal antibodies to the posterior segment of the eye is challenging due to their high molecular weight, rapid degradation, and low solubility. Moreover, it requires frequent administration for prolonged therapy. The long-acting novel formulation strategies are helpful to overcome these issues and provide superior therapy. It avoids frequent administration, improves stability, high retention time, and avoids burst release. This review briefly enlightens posterior segments of eye diseases with their diagnosis techniques and treatments. This article mainly focuses on recent advanced approaches like intravitreal implants and injectables, electrospun injectables, 3D printed drug-loaded implants, nanostructure thin-film polymer devices encapsulated cell technology-based intravitreal implants, injectable and depots, microneedles, PDS with ranibizumab, polymer nanoparticles, inorganic nanoparticles, hydrogels and micro -particles for delivering macromolecules in the eye for intended therapy. Furthermore, novel techniques like aptamer, small Interference RNA, and stem cell therapy were also discussed. It is predicted that these systems will make revolutionary changes in treating posterior segment eye diseases in future.
C1 [Garkal, Atul; Bangar, Priyanka; Sami, Anam; Mathur, Khushboo; Joshi, Shubham; Dhuri, Sonika; Parikh, Dhaivat; Mehta, Tejal] Nirma Univ, Inst Pharm, Dept Pharmaceut, Ahmadabad 382481, Gujarat, India.
   [Rajput, Amarjitsing] Bharti Vidyapeeth Deemed Univ, Poona Coll Pharm, Dept Pharmaceut, Pune 411038, Maharashtra, India.
   [Pingale, Prashant] GESs Sir Dr MS Gosavi Coll Pharmaceut Educ & Res, Dept Pharmaceut, Nasik 422005, Maharashtra, India.
   [Dhas, Namdev; Mutalik, Srinivas] Manipal Acad Higher Educ MAHE, Manipal Coll Pharmaceut Sci, Dept Pharmaceut, Manipal 576104, Karnataka, India.
   [Mehta, Tejal] Nirma Univ, Inst Pharm, Dept Pharmaceut, SG Highway, Ahmadabad 382481, Gujarat, India.
C3 Nirma University; Bharati Vidyapeeth Deemed University; Poona College of
   Pharmacy; Manipal Academy of Higher Education (MAHE); Nirma University
RP Mehta, T (通讯作者)，Nirma Univ, Inst Pharm, Dept Pharmaceut, SG Highway, Ahmadabad 382481, Gujarat, India.
EM tjshah3@gmail.com
RI Parikh, Dhaivat/HCH-0829-2022
FU Nirma University;  [NU/ Ph.D./IP/GAD/19-20/1496]
FX The authors would like to thank Nirma University for providing financial
   assistance in the form of Nirma University fellowship-SRF to Atul Garkal
   (NU/ Ph.D./IP/GAD/19-20/1496) . The authors would like to thank Manipal
   College of Pharmaceutical Sciences, Manipal Academy of Higher Education,
   Manipal, Karnataka, for providing the necessary facilities.
CR Agarwal P, 2018, PHARM NANOTECHNO, P137, DOI 10.1016/B978-0-12-813667-6.00004-8
   Agrahari V, 2016, MOL PHARMACEUT, V13, P2912, DOI 10.1021/acs.molpharmaceut.5b00828
   Agrawal AK, 2012, EXPERT OPIN DRUG DEL, V9, P383, DOI 10.1517/17425247.2012.665367
   Akgonullu S, 2021, MICROMACHINES-BASEL, V12, DOI 10.3390/mi12111349
   Al Khateb K, 2016, INT J PHARMACEUT, V502, P70, DOI 10.1016/j.ijpharm.2016.02.027
   Allam A, 2021, INT J PHARMACEUT, V598, DOI 10.1016/j.ijpharm.2021.120380
   Alm A, 2009, EXP EYE RES, V88, P760, DOI 10.1016/j.exer.2008.12.012
   Alonso MJ, 2003, J PHARM PHARMACOL, V55, P1451, DOI 10.1211/0022357022476
   Alsaykhan H, 2020, REGEN BIOMATER, V7, P413, DOI 10.1093/rb/rbaa018
   Amrite AC, 2008, INVEST OPHTH VIS SCI, V49, P320, DOI 10.1167/iovs.07-0593
   Andres-Guerrero V, 2015, J CONTROL RELEASE, V211, P105, DOI 10.1016/j.jconrel.2015.05.279
   Angkawinitwong U, 2017, ACTA BIOMATER, V64, P126, DOI 10.1016/j.actbio.2017.10.015
   Arcadu F, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0172-3
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Ayuso JM, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30384-7
   Azab A.E., 2017, SAUDI J BIOMEDICAL R, V4, P96, DOI [10.21276/sjbr, DOI 10.15406/JABB.2017.04.00096, 10.15406/jabb.2017.04.00096, DOI 10.21276/SJBR]
   Bachu RD, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010028
   Badiee P, 2018, J BIOMED MATER RES A, V106, P2261, DOI 10.1002/jbm.a.36424
   Baker PS, 2009, CURR OPIN OPHTHALMOL, V20, P175, DOI 10.1097/ICU.0b013e328329b5f2
   Balasubramaniam Jagdish, 2003, Acta Pharmaceutica (Zagreb), V53, P251
   Bargahi N, 2022, BIOL PROCED ONLINE, V24, DOI 10.1186/s12575-022-00166-y
   Belhaj M, 2020, JOVE-J VIS EXP, DOI 10.3791/60162
   Bernards DA, 2013, J OCUL PHARMACOL TH, V29, P249, DOI 10.1089/jop.2012.0152
   Bernards DA, 2012, NANO LETT, V12, P5355, DOI 10.1021/nl302747y
   Bhandari P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20363-8
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Billheimer J, 2019, SCREEN CLASSIC, P59
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blizzard C, 2016, J OCUL PHARMACOL TH, V32, P595, DOI 10.1089/jop.2016.0025
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Boffito M, 2015, J BIOMED MATER RES A, V103, P1276, DOI 10.1002/jbm.a.35253
   Bonilla L, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14010090
   Booth BA, 2007, DRUG AGING, V24, P581, DOI 10.2165/00002512-200724070-00006
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Bourges X, 2002, ADV COLLOID INTERFAC, V99, P215, DOI 10.1016/S0001-8686(02)00035-0
   Bradbeer JF, 2015, FOOD HYDROCOLLOID, V43, P501, DOI 10.1016/j.foodhyd.2014.07.006
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Brown HDH, 2016, OPHTHAL PHYSL OPT, V36, P240, DOI 10.1111/opo.12293
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Bruce BB, 2013, NEURO-OPHTHALMOLOGY, V37, P51, DOI 10.3109/01658107.2013.773451
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Buwalda SJ, 2017, BIOMACROMOLECULES, V18, P316, DOI 10.1021/acs.biomac.6b01604
   Cabrera FJ, 2019, DRUG DISCOV TODAY, V24, P1679, DOI 10.1016/j.drudis.2019.05.035
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Canavan KS, 2003, BRIT J ANAESTH, V90, P787, DOI 10.1093/bja/aeg105
   Canto-Soler V, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.16-19127
   Cao YQ, 2019, DRUG DISCOV TODAY, V24, P1694, DOI 10.1016/j.drudis.2019.05.031
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chakravarthy U, 2020, OPHTHALMOL RETINA, V4, P662, DOI 10.1016/j.oret.2020.01.012
   Chan A, 2013, ADV DRUG DELIVER REV, V65, P497, DOI 10.1016/j.addr.2012.07.007
   Chang D, 2019, DRUG DISCOV TODAY, V24, P1470, DOI 10.1016/j.drudis.2019.05.037
   Chen ER, 2020, CLIN OPHTHALMOL, V14, P1349, DOI 10.2147/OPTH.S194234
   Chen H, 2018, COLLOID INTERFAC SCI, V24, P54, DOI 10.1016/j.colcom.2018.03.008
   Cheng YH, 2016, CARBOHYD POLYM, V144, P390, DOI 10.1016/j.carbpol.2016.02.080
   Chew EY, 2016, DIABETES CARE, V39, P1089, DOI 10.2337/dc16-0024
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2443, DOI 10.1016/j.ophtha.2014.07.019
   Chivate A., 2021, PDA J PHARM SCI TECH, DOI [10.5731/pdajpst.2019.011403pdajpst.2019.011403, DOI 10.5731/PDAJPST.2019.011403PDAJPST.2019.011403]
   Chivate A, 2020, INT J PHARM INVESTIG, V10, P233, DOI 10.5330/ijpi.2020.3.43
   Cholkar K, 2013, J OCUL PHARMACOL TH, V29, P106, DOI 10.1089/jop.2012.0200
   Conley SM, 2010, PROG RETIN EYE RES, V29, P376, DOI 10.1016/j.preteyeres.2010.04.004
   Cornel Stefan, 2015, Rom J Ophthalmol, V59, P235
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Dasari BC, 2017, MOL THER-NUCL ACIDS, V8, P77, DOI 10.1016/j.omtn.2017.06.004
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   de Cogan F, 2017, INVEST OPHTH VIS SCI, V58, P2578, DOI 10.1167/iovs.16-20072
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Delplace V, 2019, J CONTROL RELEASE, V293, P10, DOI 10.1016/j.jconrel.2018.11.012
   Deng Y, 2014, GENE, V538, P217, DOI 10.1016/j.gene.2013.12.019
   Desai SD, 1998, J PHARM SCI, V87, P226, DOI 10.1021/js970090e
   Dhas N, 2021, J CONTROL RELEASE, V333, P188, DOI 10.1016/j.jconrel.2021.03.021
   Dhas N, 2021, J CONTROL RELEASE, V330, P257, DOI 10.1016/j.jconrel.2020.12.015
   Dhiman N, 2019, BIOSENS BIOELECTRON, V137, P236, DOI 10.1016/j.bios.2019.02.070
   Di Colo G, 2001, INT J PHARM, V215, P101, DOI 10.1016/S0378-5173(00)00671-2
   Dias MS, 2019, GENE THER, V26, P479, DOI 10.1038/s41434-019-0100-9
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.21, 10.1038/natrevmats.2016.71]
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4
   Edman P, 1989, BYE RES, V8, P563
   Ehara K, 2002, CELLULOSE, V9, P301, DOI 10.1023/A:1021192711007
   Ejaz S, 2008, DIABETES OBES METAB, V10, P53, DOI 10.1111/j.1463-1326.2007.00795.x
   El Zaoui I, 2015, J OCUL PHARMACOL TH, V31, P17, DOI 10.1089/jop.2014.0019
   El-Kamel AH, 2002, INT J PHARMACEUT, V241, P47, DOI 10.1016/S0378-5173(02)00234-X
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   EMI K, 1989, INVEST OPHTH VIS SCI, V30, P233
   Endo M, 2001, HORM METAB RES, V33, P317, DOI 10.1055/s-2001-15122
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   Ewaldz E, 2022, ACS POLYM AU, V2, P108, DOI 10.1021/acspolymersau.1c00041
   Eymann J, 2019, J COMP NEUROL, V527, P2356, DOI 10.1002/cne.24677
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Falavarjani KG, 2016, J CURR OPHTHALMOL, V28, P57, DOI 10.1016/j.joco.2016.04.001
   Famili A, 2017, MOL PHARMACEUT, V14, P1961, DOI 10.1021/acs.molpharmaceut.7b00067
   Fathalla ZMA, 2017, EUR J PHARM BIOPHARM, V114, P119, DOI 10.1016/j.ejpb.2017.01.008
   Ferreira NN, 2018, EUR POLYM J, V99, P117, DOI 10.1016/j.eurpolymj.2017.12.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine D, 2010, LAB CHIP, V10, P3074, DOI [10.1039/c0lc00013b, 10.1039/c01c00013b]
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Furino C, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/6654168
   Gao JM, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001404
   Gao Y, 2019, OCUL SURF, V17, P635, DOI 10.1016/j.jtos.2019.08.001
   Garcia-Cordero JL, 2020, CURR OPIN BIOTECH, V65, P37, DOI 10.1016/j.copbio.2019.11.022
   Garkal A, 2022, J DRUG DELIV SCI TEC, V67, DOI 10.1016/j.jddst.2021.102938
   Garkal A, 2021, NEW J CHEM, V45, P21508, DOI 10.1039/d1nj04159b
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gavini E, 2004, EUR J PHARM BIOPHARM, V57, P207, DOI 10.1016/j.ejpb.2003.10.018
   Gebreel RM, 2021, DRUG DES DEV THER, V15, P399, DOI 10.2147/DDDT.S293127
   Genta I, 1997, J PHARM PHARMACOL, V49, P737, DOI 10.1111/j.2042-7158.1997.tb06103.x
   Ghate D, 2008, J GLAUCOMA, V17, P147, DOI 10.1097/IJG.0b013e31814b990d
   Giannaccini M, 2017, SCI REP-UK, V7, DOI 10.1038/srep43092
   Goh James Kang Hao, 2016, J Diabetes Sci Technol, V10, P282, DOI 10.1177/1932296816629491
   Gong C, 2013, CURR MED CHEM, V20, P79
   Gote V, 2019, J PHARMACOL EXP THER, V370, P602, DOI 10.1124/jpet.119.256933
   Gracitelli CPB, 2020, J GLAUCOMA, V29, P622, DOI 10.1097/IJG.0000000000001558
   Grover VPB, 2015, J CLIN EXP HEPATOL, V5, P246, DOI 10.1016/j.jceh.2015.08.001
   Guidotti G, 2017, TRENDS PHARMACOL SCI, V38, P406, DOI 10.1016/j.tips.2017.01.003
   Guidry C., 2010, PROLIFERATIVE VITREO, VSecond, DOI [10.1016/B978-0-7020-2983-7.00078-4, DOI 10.1016/B978-0-7020-2983-7.00078-4]
   Guise P, 2012, LOCAL REG ANESTH, V5, P35, DOI 10.2147/LRA.S16314
   Gulsen D, 2004, INVEST OPHTH VIS SCI, V45, P2342, DOI 10.1167/iovs.03-0959
   Gupta P, 2019, LIFE SCI, V237, DOI 10.1016/j.lfs.2019.116907
   Gupta V, 2014, SAUDI J OPHTHALMOL, V28, P95, DOI 10.1016/j.sjopt.2014.02.008
   Hayashi K, 2009, EYE, V23, P389, DOI 10.1038/sj.eye.6703022
   He CL, 2008, J CONTROL RELEASE, V127, P189, DOI 10.1016/j.jconrel.2008.01.005
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hegarty SV, 2014, NEURAL REGEN RES, V9, P1708, DOI 10.4103/1673-5374.143410
   HILTON G, 1983, OPHTHALMOLOGY, V90, P121, DOI 10.1016/s0161-6420(83)34588-7
   Ho W, 2016, ADV HEALTHC MATER, V5, P2715, DOI 10.1002/adhm.201600418
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Huang D., 2003, LASERS IMAGING RETIN, V34, P78, DOI [10.3928/1542-8877-20030101-19, DOI 10.3928/1542-8877-20030101-19]
   Huang QT, 2017, CHEM SOC REV, V46, P6255, DOI 10.1039/c6cs00052e
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Hunter AC, 2002, DRUG DISCOV TODAY, V7, P998, DOI 10.1016/S1359-6446(02)02444-3
   Ibrahim HM, 2020, POLYM TEST, V90, DOI 10.1016/j.polymertesting.2020.106647
   Idrees Sana, 2019, Int Ophthalmol Clin, V59, P221, DOI 10.1097/IIO.0000000000000258
   Ilochonwu BC, 2020, J CONTROL RELEASE, V326, P419, DOI 10.1016/j.jconrel.2020.07.031
   Iqbal U, 2021, INT J RETINA VITR, V77, DOI 10.1186/s40942-021-00313-9
   Iyer S, 2019, J CONTROL RELEASE, V296, P140, DOI 10.1016/j.jconrel.2019.01.007
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jandorf S, 2019, ACTA OPHTHALMOL, V97, pE670, DOI 10.1111/aos.14014
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Jeon EY, 2020, ACTA BIOMATER, V114, P244, DOI 10.1016/j.actbio.2020.07.033
   Jiang PF, 2020, J CONTROL RELEASE, V320, P442, DOI 10.1016/j.jconrel.2020.01.036
   Joglekar M, 2013, BIOTECHNOL J, V8, P931, DOI 10.1002/biot.201300073
   Johnson KA, 2020, ACTA BIOMATER, V112, P101, DOI 10.1016/j.actbio.2020.06.006
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Jung JH, 2019, DRUG DISCOV TODAY, V24, P1654, DOI 10.1016/j.drudis.2019.03.027
   Jung JH, 2018, INVEST OPHTH VIS SCI, V59, P2069, DOI 10.1167/iovs.17-23758
   Jung JH, 2018, J CONTROL RELEASE, V277, P14, DOI 10.1016/j.jconrel.2018.03.001
   Kakar S, 2013, J ACUTE DIS, V2, P1, DOI 10.1016/S2221-6189(13)60087-6
   Kakehashi A, 2008, DIABETES RES CLIN PR, V79, P438, DOI 10.1016/j.diabres.2007.10.018
   Kanamori A, 2003, AM J OPHTHALMOL, V135, P513, DOI 10.1016/S0002-9394(02)02003-2
   KANG KS, 1982, APPL ENVIRON MICROB, V43, P1086, DOI 10.1128/AEM.43.5.1086-1091.1982
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kannan B., 2016, NANO SIZE POLYM, P309, DOI [DOI 10.1007/978-3-319-39715-3_11, 10.1007/978-3-319-39715-3_11]
   Karki S, 2016, ASIAN J PHARM SCI, V11, P559, DOI 10.1016/j.ajps.2016.05.004
   Karp CL, 2001, OPHTHALMOLOGY, V108, P1704, DOI 10.1016/S0161-6420(01)00793-X
   Karumanchi DK, 2018, J DRUG DELIV SCI TEC, V47, P275, DOI 10.1016/j.jddst.2018.07.003
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   Khadka DB, 2012, NANOMED-NANOTECHNOL, V8, P1242, DOI 10.1016/j.nano.2012.02.013
   Khalil M, 2020, INT J BIOL MACROMOL, V143, P483, DOI 10.1016/j.ijbiomac.2019.10.256
   Khanani AM, 2021, EXPERT OPIN DRUG DEL, V18, P1571, DOI 10.1080/17425247.2021.1968826
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Kim J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031095
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kimura H., 2002, SOURCE SCI NEW SER, V297, P803
   Kompella UB, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100901
   Kontturi LS, 2015, EUR J PHARM BIOPHARM, V95, P387, DOI 10.1016/j.ejpb.2014.10.005
   Kornblau IS, 2019, SURV OPHTHALMOL, V64, P679, DOI 10.1016/j.survophthal.2019.02.004
   Krauland AH, 2003, J PHARM SCI, V92, P1234, DOI 10.1002/jps.10371
   Krishnaswami V, 2018, INT J BIOL MACROMOL, V110, P7, DOI 10.1016/j.ijbiomac.2018.01.120
   Kristinsson JK, 1997, BRIT J OPHTHALMOL, V81, P274, DOI 10.1136/bjo.81.4.274
   Krohn J, 1997, ACTA OPHTHALMOL SCAN, V75, P28
   Kumar Sunil, 2017, Indian J Occup Environ Med, V21, P9, DOI 10.4103/ijoem.IJOEM_155_16
   Kushwaha SKS, 2012, INT J PHARM INVESTIG, V2, P54, DOI 10.4103/2230-973X.100036
   Lance KD, 2016, DRUG DELIV TRANSL RE, V6, P771, DOI 10.1007/s13346-016-0298-7
   Lanchares E, 2008, J BIOMECH, V41, P797, DOI 10.1016/j.jbiomech.2007.11.010
   LEAN JS, 1989, OPHTHALMOLOGY, V96, P765
   Lee TWY, 2001, J OCUL PHARMACOL TH, V17, P565, DOI 10.1089/10807680152729257
   Li D, 2004, ADV MATER, V16, P1151, DOI 10.1002/adma.200400719
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li JW, 2019, REGEN BIOMATER, V6, P129, DOI 10.1093/rb/rbz022
   Li XY, 2013, INT J PHARMACEUT, V448, P96, DOI 10.1016/j.ijpharm.2013.03.024
   Liang SYW, 2011, J CATARACT REFR SURG, V37, P960, DOI 10.1016/j.jcrs.2011.03.005
   Liaskoni A, 2021, INT J PHARMACEUT, V597, DOI 10.1016/j.ijpharm.2021.120330
   Lieberman H., 2007, THEORY PRACTICE IND
   Lin DQ, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201900001
   Littlewood R, 2019, NEURO-OPHTHALMOLOGY, V43, P217, DOI 10.1080/01658107.2019.1604764
   Liu C, 2016, ACS APPL MATER INTER, V8, P19256, DOI 10.1021/acsami.6b04551
   Liu CJ, 2019, ACTA BIOMATER, V96, P281, DOI 10.1016/j.actbio.2019.07.024
   Liu H, 2016, ACTA BIOMATER, V35, P228, DOI 10.1016/j.actbio.2016.02.028
   Liu Y., 2000, CHIN OPHTHALMIC RES, V18, P305
   Lorenzo-Veiga B, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10040709
   Lu JJ, 2019, REGEN BIOMATER, V6, P325, DOI 10.1093/rb/rbz027
   de Redin IL, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.107697
   de Redin IL, 2018, INT J PHARMACEUT, V541, P214, DOI 10.1016/j.ijpharm.2018.02.003
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   MAGUIRE AM, 1988, ARCH OPHTHALMOL-CHIC, V106, P718
   Mahlumba P, 2016, MOLECULES, V21, DOI 10.3390/molecules21081002
   Majeed A., 2019, J DRUG DELIVERY THER, V9, P337, DOI DOI 10.22270/JDDT.V9I1.2231
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Mandal S, 2012, INT J PHARM INVESTIG, V2, P78, DOI 10.4103/2230-973X.100042
   Martens TF, 2015, J CONTROL RELEASE, V202, P83, DOI 10.1016/j.jconrel.2015.01.030
   Masteikova Ruta, 2003, Medicina (Kaunas), V39 Suppl 2, P19
   Miller K, 2018, ASIA-PAC J OPHTHALMO, V7, P28, DOI 10.22608/APO.2017529
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mohammadian F, 2017, ARTIF CELL NANOMED B, V45, P881, DOI 10.1080/21691401.2016.1185726
   Moisseiev E, 2017, DEV OPHTHALMOL, V58, P87, DOI 10.1159/000455276
   MORITERA T, 1994, CURR EYE RES, V13, P171, DOI 10.3109/02713689408995774
   Mudhar HS, 2020, EYE, V34, P246, DOI 10.1038/s41433-019-0724-4
   Mura S, 2013, NAT MATER, V12, P991, DOI [10.1038/nmat3776, 10.1038/NMAT3776]
   Nabili M, 2013, ULTRASOUND MED BIOL, V39, P638, DOI 10.1016/j.ultrasmedbio.2012.11.010
   Nadagouda MN, 2007, BIOMACROMOLECULES, V8, P2762, DOI 10.1021/bm700446p
   Nagasaki H, 1998, PROG RETIN EYE RES, V17, P77, DOI 10.1016/S1350-9462(97)00007-4
   Naguib MJ, 2021, INT J PHARMACEUT, V607, DOI 10.1016/j.ijpharm.2021.121010
   Nair AB, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248857
   Naruse K, 2000, EXP EYE RES, V71, P309, DOI 10.1006/exer.2000.0882
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   Ni P, 2014, BIOMATERIALS, V35, P236, DOI 10.1016/j.biomaterials.2013.10.016
   Ni SJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081683
   Nikkhah H, 2018, J OPHTHAL VIS RES, V13, P158, DOI 10.4103/jovr.jovr_50_18
   Nimjee SM, 2017, ANNU REV PHARMACOL, V57, P61, DOI 10.1146/annurev-pharmtox-010716-104558
   O'Donnell LJ, 2011, NEUROSURG CLIN N AM, V22, P185, DOI 10.1016/j.nec.2010.12.004
   Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291
   Omer S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101637
   Orive G, 2002, TRENDS BIOTECHNOL, V20, P382, DOI 10.1016/S0167-7799(02)02037-1
   Osmalek T, 2014, INT J PHARMACEUT, V466, P328, DOI 10.1016/j.ijpharm.2014.03.038
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Ozawa R, 2020, ACTA BIOMATER, V110, P82, DOI 10.1016/j.actbio.2020.04.003
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Park SM, 2019, MAT SCI ENG C-MATER, V104, DOI 10.1016/j.msec.2019.109964
   Park SH, 2020, ACTA BIOMATER, V117, P108, DOI 10.1016/j.actbio.2020.09.013
   Pastor JC, 2002, PROG RETIN EYE RES, V21, P127, DOI 10.1016/S1350-9462(01)00023-4
   Patel J.K., 2018, SPRINGER INT PUBL, P1, DOI [10.1007/978-3-319-95807-1, DOI 10.1007/978-3-319-95807-1]
   Patel M, 2018, TISSUE ENG REGEN MED, V15, P521, DOI 10.1007/s13770-018-0148-4
   Patel M, 2018, BIOMATERIALS, V159, P91, DOI 10.1016/j.biomaterials.2018.01.001
   Paulsson M, 1999, EUR J PHARM SCI, V9, P99, DOI 10.1016/S0928-0987(99)00051-2
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Perez MA, 2012, NEUROLOGIST, V18, P350, DOI 10.1097/NRL.0b013e318272f7d7
   Pescina S, 2018, J CONTROL RELEASE, V284, P84, DOI 10.1016/j.jconrel.2018.06.023
   Peters T, 2017, BIOMATERIALS, V124, P157, DOI 10.1016/j.biomaterials.2017.02.006
   Petit A, 2014, BIOMATERIALS, V35, P7919, DOI 10.1016/j.biomaterials.2014.05.064
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Porta M, 2002, DIABETOLOGIA, V45, P1617, DOI 10.1007/s00125-002-0990-7
   Prakash G, 2008, AM J OPHTHALMOL, V146, P56, DOI 10.1016/j.ajo.2008.02.023
   Prezotti FG, 2014, CARBOHYD POLYM, V113, P286, DOI 10.1016/j.carbpol.2014.07.021
   Pszczola D.E., 1993, FOOD TECHNOL-CHICAGO, V47, P94
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Qu J, 2018, BIOMATERIALS, V183, P185, DOI 10.1016/j.biomaterials.2018.08.044
   Rabinovich-Guilatt L, 2004, J DRUG TARGET, V12, P623, DOI 10.1080/10611860400015910
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P803, DOI 10.2147/OPTH.S133637
   Rajalakshmi R, 2021, EYE, V35, P162, DOI 10.1038/s41433-020-01262-7
   Rajput A, 2021, DRUG DEV IND PHARM, V47, P1713, DOI 10.1080/03639045.2022.2058531
   Raju B, 2015, INDIAN J OPHTHALMOL, V63, P170, DOI 10.4103/0301-4738.154407
   Rebibo L, 2021, J CONTROL RELEASE, V333, P283, DOI 10.1016/j.jconrel.2021.03.035
   Reissmann S, 2014, J PEPT SCI, V20, P760, DOI 10.1002/psc.2672
   Richard G., 1998, FLUORESCEIN ICG ANGI
   Rimpela AK, 2018, ADV DRUG DELIVER REV, V126, P23, DOI 10.1016/j.addr.2017.12.008
   ROZIER A, 1989, INT J PHARM, V57, P163, DOI 10.1016/0378-5173(89)90305-0
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Ruia S., 2021, FLUORESCEIN ANGIOGRA
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sabanayagam C, 2019, LANCET DIABETES ENDO, V7, P140, DOI 10.1016/S2213-8587(18)30128-1
   Sahle FF, 2019, ADV DRUG DELIVER REV, V148, P290, DOI 10.1016/j.addr.2019.10.006
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Salz DA, 2015, MIDDLE EAST AFR J OP, V22, P145, DOI 10.4103/0974-9233.151887
   Santonocito M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094404
   Sarao V, 2018, EXPERT OPIN PHARMACO, V19, P1551, DOI 10.1080/14656566.2018.1516206
   Satarian Leila, 2017, J Ophthalmic Vis Res, V12, P58, DOI 10.4103/2008-322X.200164
   Schlesinger EB, 2019, BIOENG TRANSL MED, V4, P152, DOI 10.1002/btm2.10121
   Shah Hiral J., 2014, J BIOMOL RES THER, V03, DOI [10.4172/2167-7956.1000116, DOI 10.4172/2167-7956.1000116]
   Shaikh R, 2011, J PHARM BIOALLIED SC, V3, P89, DOI 10.4103/0975-7406.76478
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Sharma A, 2020, BIOADHESIVES IN DRUG DELIVERY, P173
   Sharma N, 2011, BRIT J OPHTHALMOL, V95, P1735, DOI 10.1136/bjo.2010.192815
   Shi H, 2019, INT J PHARMACEUT, V570, DOI 10.1016/j.ijpharm.2019.118688
   Shi JY, 2021, ACTA BIOMATER, V128, P42, DOI 10.1016/j.actbio.2021.04.009
   Shikari H, 2014, SEMIN OPHTHALMOL, V29, P276, DOI 10.3109/08820538.2014.962167
   Shoughy SS, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0058-2
   Shukr MH, 2021, J DRUG DELIV SCI TEC, V61, DOI 10.1016/j.jddst.2021.102333
   Silva MRT, 2021, ADV DRUG DELIVER REV, V173, P439, DOI 10.1016/j.addr.2021.04.007
   Singh MN, 2010, RES PHARM SCI, V5, P65
   Singh RRT, 2017, EXPERT OPIN DRUG DEL, V14, P525, DOI 10.1080/17425247.2016.1218460
   Soh YQ, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.28
   Song YH, 2018, MAT SCI ENG C-MATER, V88, P1, DOI 10.1016/j.msec.2018.02.022
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Street J, 1978, OPHTHALMOLOGY, V3347, P33
   Streets J, 2020, SCI PHARM, V88, DOI 10.3390/scipharm88030030
   STROMAN GA, 1995, ARCH OPHTHALMOL-CHIC, V113, P168, DOI 10.1001/archopht.1995.01100020050027
   Sun JF, 2018, DRUG DES DEV THER, V12, P383, DOI 10.2147/DDDT.S153405
   Suri R, 2020, MED HYPOTHESES, V136, DOI 10.1016/j.mehy.2019.109518
   Tahara K, 2017, ASIAN J PHARM SCI, V12, P394, DOI 10.1016/j.ajps.2017.03.002
   Takashima Y, 2012, YAKUGAKU ZASSHI, V132, P1365, DOI 10.1248/yakushi.12-00234-3
   Tao W., RETIN DEGENER, P401, DOI [10.1007/978-1-59745-186-4_21, DOI 10.1007/978-1-59745-186-4_21]
   Tao Weng, 2006, Expert Opin Biol Ther, V6, P717, DOI 10.1517/14712598.6.7.717
   Thakkar S, 2017, EUR J PHARM SCI, V107, P148, DOI 10.1016/j.ejps.2017.07.001
   Than A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06981-w
   Toffoletto N, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010036
   Tonade D, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100919
   Trenfield SJ, 2019, EXPERT OPIN DRUG DEL, V16, P1081, DOI 10.1080/17425247.2019.1660318
   Tu EY, 2014, CORNEA, V33, P990, DOI 10.1097/ICO.0000000000000192
   Tuekprakhon A, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02122-7
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8
   Tyagi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048188
   Urias EA, 2017, VISION RES, V139, P221, DOI 10.1016/j.visres.2017.06.015
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Urtti A, 2019, SMALL, V15, DOI 10.1002/smll.201805199
   Utech S, 2016, J MATER SCI, V51, P271, DOI 10.1007/s10853-015-9382-5
   Vaishya RD, 2015, INT J PHARMACEUT, V489, P237, DOI 10.1016/j.ijpharm.2015.04.075
   Van Vlierberghe S, 2011, BIOMACROMOLECULES, V12, P1387, DOI 10.1021/bm200083n
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Vasir JK, 2003, INT J PHARMACEUT, V255, P13, DOI 10.1016/S0378-5173(03)00087-5
   Vermonden T, 2012, CHEM REV, V112, P2853, DOI 10.1021/cr200157d
   Vieira-Potter VJ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3801570
   Vyas S., 2006, CONTROLLED DRUG DELI
   Wadhwa S, 2009, MINI-REV MED CHEM, V9, P1639, DOI 10.2174/138955709791012292
   Waite D, 2017, THER DELIV, V8, P685, DOI 10.4155/tde-2017-0097
   Wang B, 2020, ACTA BIOMATER, V116, P259, DOI 10.1016/j.actbio.2020.09.018
   Wang CY, 2012, DYES PIGMENTS, V94, P40, DOI 10.1016/j.dyepig.2011.11.002
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Williams GA, 2004, OPHTHALMOLOGY, V111, P1055, DOI 10.1016/j.ophtha.2004.02.004
   Wischke C, 2008, INT J PHARMACEUT, V364, P298, DOI 10.1016/j.ijpharm.2008.04.042
   WOLF S, 1989, GRAEF ARCH CLIN EXP, V227, P145, DOI 10.1007/BF02169788
   Won JY, 2020, ACTA BIOMATER, V116, P174, DOI 10.1016/j.actbio.2020.09.015
   Wozniak JR, 2006, NEUROSCI BIOBEHAV R, V30, P762, DOI 10.1016/j.neubiorev.2006.06.003
   Wu Y, 2021, EUR J PHARM BIOPHARM, V165, P306, DOI 10.1016/j.ejpb.2021.05.022
   Wylegala A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004907
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Xu YW, 2020, ACTA BIOMATER, V108, P87, DOI 10.1016/j.actbio.2020.03.039
   Yan J, 2018, J PHOTOCH PHOTOBIO B, V183, P133, DOI 10.1016/j.jphotobiol.2018.04.033
   Yan WQ, 2020, REGEN BIOMATER, V7, P77, DOI 10.1093/rb/rbz039
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   Ye ML, 2010, J CONTROL RELEASE, V146, P241, DOI 10.1016/j.jconrel.2010.05.011
   Ye Z, 2015, INT J OPHTHALMOL-CHI, V8, P653, DOI 10.3980/j.issn.2222-3959.2015.04.02
   Yellepeddi VK, 2016, J OCUL PHARMACOL TH, V32, P67, DOI 10.1089/jop.2015.0047
   Yoo MK, 2005, DRUG DEV IND PHARM, V31, P455, DOI 10.1080/03639040500214688
   Yorston David, 2014, Community Eye Health, V27, P44
   Yu L, 2008, CHEM SOC REV, V37, P1473, DOI 10.1039/b713009k
   Zadeh MA, 2019, DRUG DISCOV TODAY, V24, P1669, DOI 10.1016/j.drudis.2019.04.009
   Zambito Y, 2006, EUR J PHARM BIOPHARM, V64, P16, DOI 10.1016/j.ejpb.2006.01.004
   Zhang LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135608
   Zhang XP, 2018, BIOMED PHARMACOTHER, V107, P1056, DOI 10.1016/j.biopha.2018.08.092
   Zhao C, 2020, PROC 2019 9 INT WORK, P99
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
   Zhu LN, 2015, DRUG DES DEV THER, V9, P3943, DOI 10.2147/DDDT.S87368
NR 355
TC 0
Z9 0
U1 11
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT
PY 2022
VL 350
BP 538
EP 568
DI 10.1016/j.jconrel.2022.08.040
PG 31
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 5A4QO
UT WOS:000862873800001
PM 36030993
DA 2022-11-30
ER

PT J
AU Xing, G
   Chen, L
   Wang, HL
   Zhang, J
   Sun, DK
   Xu, F
   Lei, JQ
   Xu, XY
AF Xing, Gang
   Chen, Li
   Wang, Hualin
   Zhang, Jiong
   Sun, Dongke
   Xu, Feng
   Lei, Jianqin
   Xu, Xiayu
TI Multi-Scale Pathological Fluid Segmentation in OCT With a Novel
   Curvature Loss in Convolutional Neural Network
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Fluids; Lesions; Retina; Image segmentation; Shape; Loss measurement;
   Pathology; Image segmentation; loss function; optical coherence
   tomography; pathological fluid
ID RETINAL-DETACHMENT SEGMENTATION; SD-OCT; IMAGES; BENCHMARK; LAYER
AB The segmentation of pathological fluid lesions in optical coherence tomography (OCT), including intraretinal fluid, subretinal fluid, and pigment epithelial detachment, is of great importance for the diagnosis and treatment of various eye diseases such as neovascular age-related macular degeneration and diabetic macular edema. Although significant progress has been achieved with the rapid development of fully convolutional neural networks (FCN) in recent years, some important issues remain unsolved. First, pathological fluid lesions in OCT show large variations in location, size, and shape, imposing challenges on the design of FCN architecture. Second, fluid lesions should be continuous regions without holes inside. But the current architectures lack the capability to preserve the shape prior information. In this study, we introduce an FCN architecture for the simultaneous segmentation of three types of pathological fluid lesions in OCT. First, attention gate and spatial pyramid pooling modules are employed to improve the ability of the network to extract multi-scale objects. Then, we introduce a novel curvature regularization term in the loss function to incorporate shape prior information. The proposed method was extensively evaluated on public and clinical datasets with significantly improved performance compared with the state-of-the-art methods.
C1 [Xing, Gang; Wang, Hualin; Xu, Feng; Xu, Xiayu] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
   [Chen, Li; Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian 710049, Peoples R China.
   [Zhang, Jiong] Chinese Acad Sci, Ningbo Inst Mat Technol & Engn, Cixi Inst Biomed Engn, Ningbo 315300, Peoples R China.
   [Sun, Dongke] Southeast Univ, Jiangsu Key Lab Design & Manufacture Micronano Bi, Nanjing 211189, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Chinese Academy of
   Sciences; Ningbo Institute of Materials Technology and Engineering, CAS;
   Southeast University - China
RP Xu, XY (通讯作者)，Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.; Lei, JQ (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian 710049, Peoples R China.
EM 1533483380@qq.com; chenli7792@163.com; 1517764786@qq.com;
   jiong.zhang@loni.usc.edu; dksun@seu.edu.cn; fengxu@xjtu.edu.cn;
   drleijq@163.com; xiayuxu@xjtu.edu.cn
OI Xing, Gang/0000-0003-1820-5445
FU Shaanxi National Science Foundation [2020JQ-071 2021KW-50]; Open
   Research Fund of the Jiangsu Key Laboratory for Design and Manufacture
   of Micro-Nano Biomedical Instruments [KF202005]
FX This work was supported in part by the Shaanxi National Science
   Foundation under Grant 2020JQ-071 2021KW-50 and in part by the Open
   Research Fund of the Jiangsu Key Laboratory for Design and Manufacture
   of Micro-Nano Biomedical Instruments under Grant KF202005.
CR Abraham N, 2019, I S BIOMED IMAGING, P683, DOI 10.1109/ISBI.2019.8759329
   Alsaih K, 2020, COMPUT METH PROG BIO, V195, DOI 10.1016/j.cmpb.2020.105566
   [Anonymous], 2015, OPTIMA CYST SEGMENTA
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Chen L, 2018, PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON COMPUTER SCIENCE AND APPLICATION ENGINEERING (CSAE2018), DOI 10.1145/3207677.3278067
   Chen Q., 2017, P MICCAI RET OCT FLU, P15
   Chen X, 2019, PROC CVPR IEEE, P11624, DOI 10.1109/CVPR.2019.01190
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Ganjee R, 2020, MED PHYS, V47, P4872, DOI 10.1002/mp.14361
   Gao K, 2019, COMPUT METH PROG BIO, V176, P69, DOI 10.1016/j.cmpb.2019.04.027
   Girish GN, 2019, IEEE J BIOMED HEALTH, V23, P296, DOI 10.1109/JBHI.2018.2810379
   Girish GN, 2018, COMPUT METH PROG BIO, V153, P105, DOI 10.1016/j.cmpb.2017.10.010
   Gong YH, 2017, IEEE T IMAGE PROCESS, V26, P1786, DOI 10.1109/TIP.2017.2658954
   Gopinath K, 2019, IEEE J BIOMED HEALTH, V23, P273, DOI 10.1109/JBHI.2018.2793534
   Hassan T, 2019, COMPUT BIOL MED, V105, P112, DOI 10.1016/j.compbiomed.2018.12.015
   Karimi D, 2020, IEEE T MED IMAGING, V39, P499, DOI 10.1109/TMI.2019.2930068
   Kepp T, 2019, I S BIOMED IMAGING, P1437, DOI 10.1109/ISBI.2019.8759261
   Kermany Daniel, 2018, Mendeley Data, V2, DOI 10.17632/rscbjbr9sj.2
   Kervadec H, 2021, MED IMAGE ANAL, V67, DOI 10.1016/j.media.2020.101851
   Lu DH, 2019, MED IMAGE ANAL, V54, P100, DOI 10.1016/j.media.2019.02.011
   Mirikharaji Z, 2018, LECT NOTES COMPUT SC, V11073, P737, DOI 10.1007/978-3-030-00937-3_84
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Morley D., 2017, P MICCAI RET OCT FLU, P46
   Rashno A., 2017, P MICCAI RET OCT FLU, P54
   Rashno A, 2018, IEEE T BIO-MED ENG, V65, P989, DOI 10.1109/TBME.2017.2734058
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Teja RV, 2019, IEEE ENG MED BIO, P48, DOI 10.1109/EMBC.2019.8857075
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Wang T, 2016, INFORM SCIENCES, V358, P92, DOI 10.1016/j.ins.2016.04.017
   Wei H, 2020, IEEE ACCESS, V8, P60929, DOI 10.1109/ACCESS.2020.2983818
   Wu ML, 2018, IEEE T BIO-MED ENG, V65, P87, DOI 10.1109/TBME.2017.2695461
   Wu ML, 2017, BIOMED OPT EXPRESS, V8, P4257, DOI 10.1364/BOE.8.004257
   Xing RW, 2021, BIOMED OPT EXPRESS, V12, P2312, DOI 10.1364/BOE.416167
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yadav S., 2017, P MICCAI RET OCT FLU
   Zhao HS, 2017, PROC CVPR IEEE, P6230, DOI 10.1109/CVPR.2017.660
   Zhou ZW, 2018, LECT NOTES COMPUT SC, V11045, P3, DOI 10.1007/978-3-030-00889-5_1
   Zhu WF, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.7.076014
NR 43
TC 2
Z9 2
U1 12
U2 19
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD JUN
PY 2022
VL 41
IS 6
BP 1547
EP 1559
DI 10.1109/TMI.2022.3142048
PG 13
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 1T4GX
UT WOS:000804690300021
PM 35015634
DA 2022-11-30
ER

PT J
AU Cremers, FPM
   Lee, W
   Collin, RWJ
   Allikmets, R
AF Cremers, Frans P. M.
   Lee, Winston
   Collin, Rob W. J.
   Allikmets, Rando
TI Clinical spectrum, genetic complexity and therapeutic approaches for
   retinal disease caused by ABCA4 mutations
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Stargardt disease; ABCA4-associated retinopathy; Allelic heterogeneity;
   Autofluorescence; Phenocopies; Hypomorphic variant; Penetrance; Splice
   defects; Pseudoexon; Structural variant; Therapy
ID OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE FUNDUS AUTOFLUORESCENCE;
   RECESSIVE STARGARDT DISEASE; CONE-ROD DYSTROPHY; SHORT-WAVELENGTH
   AUTOFLUORESCENCE; NEAR-INFRARED AUTOFLUORESCENCE; CASSETTE TRANSPORTER
   ABCA4; EXTERNAL LIMITING MEMBRANE; DEEP-INTRONIC VARIANTS; VISUAL-ACUITY
   LOSS
AB The ABCA4 protein (then called a "rim protein") was first identified in 1978 in the rims and incisures of rod photoreceptors. The corresponding gene, ABCA4, was cloned in 1997, and variants were identified as the cause of autosomal recessive Stargardt disease (STGD1). Over the next two decades, variation in ABCA4 has been attributed to phenotypes other than the classically defined STGD1 or fundus flavimaculatus, ranging from early onset and fast progressing cone-rod dystrophy and retinitis pigmentosa-like phenotypes to very late onset cases of mostly mild disease sometimes resembling, and confused with, age-related macular degeneration. Similarly, analysis of the ABCA4 locus uncovered a trove of genetic information, including >1200 disease-causing mutations of varying severity, and of all types - missense, nonsense, small deletions/insertions, and splicing affecting variants, of which many are located deep-intronic. Altogether, this has greatly expanded our understanding of complexity not only of the diseases caused by ABCA4 mutations, but of all Mendelian diseases in general. This review provides an in depth assessment of the cumulative knowledge of ABCA4-associated retinopathy - clinical manifestations, genetic complexity, pathophysiology as well as current and proposed therapeutic approaches.
C1 [Cremers, Frans P. M.; Collin, Rob W. J.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, POB 9101, NL-6500 HB Nijmegen, Netherlands.
   [Cremers, Frans P. M.; Collin, Rob W. J.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, POB 9104, NL-6500 HE Nijmegen, Netherlands.
   [Lee, Winston; Allikmets, Rando] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Lee, Winston] Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Columbia
   University; Columbia University; Columbia University
RP Cremers, FPM (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, POB 9101, NL-6500 HB Nijmegen, Netherlands.; Allikmets, R (通讯作者)，Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
EM frans.cremers@radboudumc.nl; rla22@cumc.columbia.edu
RI Allikmets, Rando/ABD-4533-2021; Lee, Winston/CAA-0102-2022; Cremers,
   Frans/A-5625-2014
OI Lee, Winston/0000-0002-1777-8519; Cremers, Frans/0000-0002-4954-5592
FU Retina UK [GR591, GR596]; Fighting Blindness Ireland [FB18CRE]; Horizon
   2020, Marie Sklodowska-Curie Innovative Training Network entitled
   European Training Network to Diagnose, Understand and Treat Stargardt
   Disease, a Frequent Inherited Blinding Disorder-StarT [813490];
   Foundation Fighting Blindness USA [PPA-1218-0751-COLU,
   PPA-0517-0717-RAD, BR-GE-1018-0738-RAD]; Rotterdamse Stichting
   Blindenbelangen; Stichting Blindenhulp; Stichting tot Verbetering van
   het Lot der Blinden; Landelijke Stichting voor Blinden en Slechtzienden;
   Macula Degeneratie fonds; Stichting Blinden-Penning [2016-12]; National
   Eye Institute, NIH [R01 EY028203, R01 EY028954, R01 EY029315, R01
   EY024091, P30 19007]; Research to Prevent Blindness
FX FPMC and RWJC wish to acknowledge long-standing collaborations with Drs.
   Carel B. Hoyng and L. Ingeborgh van den Born and the contributions of
   Drs. Claire-Marie Dhaenens, Alex Garanto, Riccardo Sangermano and Irene
   Vazquez-Dominguez, and of Ms. Mubeen Khan, and Ms. Esmee H. Runhart. RA
   and WL wish to acknowledge the patients and their families,
   long-standing collaborations with Drs. Stephen H. Tsang, Janet R.
   Sparrow and Gerald A. Fishman and, especially, Dr. Jana Zernant for
   almost 20 years of work in ABCA4 genetics and help with data analysis
   for this manuscript. This work was supported in part by the Retina UK
   grants no. GR591 (to FPMC), and GR596 (to RWJC and FPMC), a Fighting
   Blindness Ireland grant no. FB18CRE (to FPMC), a Horizon 2020, Marie
   Sklodowska-Curie Innovative Training Network entitled European Training
   Network to Diagnose, Understand and Treat Stargardt Disease, a Frequent
   Inherited Blinding Disorder-StarT (813490) (to FPMC, RWJC), the
   Foundation Fighting Blindness USA, grant no. PPA-0517-0717-RAD (to FPMC
   and RWJC), the Foundation Fighting Blindness USA, grant no.
   BR-GE-1018-0738-RAD (to FPMC), the Rotterdamse Stichting
   Blindenbelangen, the Stichting Blindenhulp, and the Stichting tot
   Verbetering van het Lot der Blinden (to FPMC), and by the Landelijke
   Stichting voor Blinden en Slechtzienden, Macula Degeneratie fonds and
   the Stichting Blinden-Penning that contributed through Uitzicht 2016-12
   (to FPMC). This work was supported, in part, by the National Eye
   Institute, NIH grants R01 EY028203, R01 EY028954, R01 EY029315, R01
   EY024091, P30 19007 (Core Grant for Vision Research), the Foundation
   Fighting Blindness USA, grant no. PPA-1218-0751-COLU, and the
   unrestricted grant to the Department of Ophthalmology, Columbia
   University, from Research to Prevent Blindness (to RA and WL).
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Acton JH, 2013, CAN J OPHTHALMOL, V48, P358, DOI 10.1016/j.jcjo.2013.03.021
   Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Aguirre-Lamban J, 2011, INVEST OPHTH VIS SCI, V52, P6206, DOI 10.1167/iovs.10-5743
   Ahn J, 2000, METHOD ENZYMOL, V315, P864
   Alabduljalil T, 2019, AM J OPHTHALMOL, V202, P79, DOI 10.1016/j.ajo.2019.02.007
   Albert S, 2018, AM J HUM GENET, V102, P517, DOI 10.1016/j.ajhg.2018.02.008
   Aldahmesh MA, 2011, AM J HUM GENET, V89, P745, DOI 10.1016/j.ajhg.2011.10.011
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R., 2007, RETINAL DEGENERATION, P105
   Allikmets R, 2018, INVEST OPHTH VIS SCI, V59, P5564, DOI 10.1167/iovs.18-25579
   ANDERSON KL, 1995, AM J HUM GENET, V57, P1351
   ANMARKRUD N, 1979, ACTA OPHTHALMOL, V57, P172
   Arepalli S, 2018, RETINA-J RET VIT DIS, V38, P1427, DOI 10.1097/IAE.0000000000001716
   Bauwens M, 2019, GENET MED, V21, P1761, DOI 10.1038/s41436-018-0420-y
   Bauwens M, 2015, HUM MUTAT, V36, P39, DOI 10.1002/humu.22716
   Bax NM, 2019, INVEST OPHTH VIS SCI, V60, P3456, DOI 10.1167/iovs.18-26533
   Bax NM, 2019, GRAEF ARCH CLIN EXP, V257, P1147, DOI 10.1007/s00417-019-04280-8
   Bax NM, 2015, HUM MUTAT, V36, P43, DOI 10.1002/humu.22717
   Beharry S, 2004, J BIOL CHEM, V279, P53972, DOI 10.1074/jbc.M405216200
   Beit-Ya'acov A, 2007, INVEST OPHTH VIS SCI, V48, P4308, DOI 10.1167/iovs.07-0244
   Bernstein A, 2016, RETINA-J RET VIT DIS, V36, P1741, DOI 10.1097/IAE.0000000000001003
   Bertelsen M, 2014, INVEST OPHTH VIS SCI, V55, P2766, DOI 10.1167/iovs.13-13391
   Bethlehem RAI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100171
   Billon P, 2017, MOL CELL, V67, P1068, DOI 10.1016/j.molcel.2017.08.008
   Birch DG, 2001, EXP EYE RES, V73, P877, DOI 10.1006/exer.2001.1093
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Birtel J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22096-0
   Blacharski P., 1988, RETINAL DYSTROPHIES
   Bok Dean, 2005, Retina, V25, pS18, DOI 10.1097/00006982-200512001-00007
   Braun TA, 2013, HUM MOL GENET, V22, P5136, DOI 10.1093/hmg/ddt367
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Burke TR, 2013, OPHTHALMIC GENET, V34, P75, DOI 10.3109/13816810.2012.707271
   Burke TR, 2012, INVEST OPHTH VIS SCI, V53, P4458, DOI 10.1167/iovs.11-9166
   Cai CX, 2018, AM J OPHTHALMOL, V186, P1, DOI 10.1016/j.ajo.2017.10.032
   Carss KJ, 2017, AM J HUM GENET, V100, P75, DOI 10.1016/j.ajhg.2016.12.003
   Cella W, 2009, EXP EYE RES, V89, P16, DOI 10.1016/j.exer.2009.02.001
   Chacon-Camacho OF, 2013, EXP EYE RES, V109, P77, DOI 10.1016/j.exer.2013.02.006
   Chapi M, 2019, OPHTHALMIC GENET, V40, P259, DOI 10.1080/13816810.2019.1622023
   Chen B, 2010, EXP EYE RES, V91, P143, DOI 10.1016/j.exer.2010.03.021
   Chen L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42772-z
   Cherry TJ, 2020, P NATL ACAD SCI USA, V117, P9001, DOI 10.1073/pnas.1922501117
   Cideciyan AV, 2007, J OPT SOC AM A, V24, P1457, DOI 10.1364/JOSAA.24.001457
   Cideciyan AV, 2019, NAT MED, V25, P225, DOI 10.1038/s41591-018-0295-0
   Cideciyan AV, 2015, INVEST OPHTH VIS SCI, V56, P5946, DOI 10.1167/iovs.15-17698
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Cideciyan AV, 2005, INVEST OPHTH VIS SCI, V46, P4739, DOI 10.1167/iovs.05-0805
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Collin RWJ, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.3
   Collison FT, 2018, RETINA-J RET VIT DIS, V38, P2387, DOI 10.1097/IAE.0000000000001903
   Collison FT, 2019, RETINA-J RET VIT DIS, V39, P2311, DOI 10.1097/IAE.0000000000002316
   Collison FT, 2014, RETINA-J RET VIT DIS, V34, P1888, DOI 10.1097/IAE.0000000000000144
   Cornelis SS, 2017, HUM MUTAT, V38, P400, DOI 10.1002/humu.23165
   Cremers F P M, 2004, Novartis Found Symp, V255, P68
   Cremers FP, 2004, NOVART FDN SYMP, V255, P177
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Cremers FPM, 2004, NOVART FDN SYMP, V255, P79
   Cremers FPM, 2018, INVEST OPHTH VIS SCI, V59, P5566, DOI 10.1167/iovs.18-25944
   Cukras CA, 2012, ARCH OPHTHALMOL-CHIC, V130, P171, DOI 10.1001/archophthalmol.2011.332
   Dahl SG, 2004, J PHARMACOL EXP THER, V309, P853, DOI 10.1124/jpet.103.059972
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   Derwent JJK, 2004, INVEST OPHTH VIS SCI, V45, P2447, DOI 10.1167/iovs.03-1178
   Deutman A.F., 1971, HEREDITARY DYSTROPHI
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   Ducroq D, 2006, EUR J HUM GENET, V14, P1269, DOI 10.1038/sj.ejhg.5201691
   Dugel PU, 2015, RETINA-J RET VIT DIS, V35, P1173, DOI 10.1097/IAE.0000000000000606
   Dulla K, 2018, MOL THER-NUCL ACIDS, V12, P730, DOI 10.1016/j.omtn.2018.07.010
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P7274, DOI 10.1167/iovs.15-17371
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P3159, DOI 10.1167/iovs.14-16343
   Duncker T, 2015, OPHTHALMOLOGY, V122, P345, DOI 10.1016/j.ophtha.2014.08.017
   Duncker T, 2014, INVEST OPHTH VIS SCI, V55, P8134, DOI 10.1167/iovs.14-14848
   Duncker T, 2013, INVEST OPHTH VIS SCI, V54, P6820, DOI 10.1167/iovs.13-12895
   Dyka FM, 2019, HUM GENE THER, V30, P1361, DOI 10.1089/hum.2019.132
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   Ergun E, 2005, INVEST OPHTH VIS SCI, V46, P310, DOI 10.1167/iovs.04-0212
   ERNEST JT, 1966, AM J OPHTHALMOL, V62, P1
   Fadaie Z, 2019, HUM MUTAT, V40, P2365, DOI 10.1002/humu.23890
   Falfoul Y, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1030184
   FISH G, 1981, BRIT J OPHTHALMOL, V65, P359, DOI 10.1136/bjo.65.5.359
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   FISHMAN GA, 1976, ARCH OPHTHALMOL-CHIC, V94, P2061, DOI 10.1001/archopht.1976.03910040721003
   Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Franceschetti A, 1965, Arch Ophtalmol Rev Gen Ophtalmol, V25, P505
   Franceschetti A, 1965, Trans Am Acad Ophthalmol Otolaryngol, V69, P1048
   FRANCOIS P, 1975, ARCH OPHTALMOL-PARIS, V35, P817
   Fujinami K, 2019, BRIT J OPHTHALMOL, V103, P390, DOI 10.1136/bjophthalmol-2018-312064
   Fujinami K, 2015, OPHTHALMOLOGY, V122, P326, DOI 10.1016/j.ophtha.2014.08.012
   Fujinami K, 2013, INVEST OPHTH VIS SCI, V54, P8181, DOI 10.1167/iovs.13-12104
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Fukui T, 2002, INVEST OPHTH VIS SCI, V43, P2819
   Garanto A., 2019, ANTISENSE OLIGONUCLE, P10
   Garanto A, 2016, HUM MOL GENET, V25, P2552, DOI 10.1093/hmg/ddw118
   Garg A, 2017, OPHTHALMIC GENET, V38, P575, DOI 10.1080/13816810.2017.1323339
   Gerard X, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.21
   GERBER S, 1995, AM J HUM GENET, V56, P396
   GIROUX JM, 1972, ARCH DERMATOL, V106, P183, DOI 10.1001/archderm.106.2.183
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Greenstein VC, 2017, INVEST OPHTH VIS SCI, V58, P5227, DOI 10.1167/iovs.17-22532
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Han ZC, 2012, J CLIN INVEST, V122, P3221, DOI 10.1172/JCI64833
   Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010
   Hu FY, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00773
   Huckfeldt RM, 2016, JAMA OPHTHALMOL, V134, P580, DOI 10.1001/jamaophthalmol.2015.5471
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Jacobson SG, 2009, INVEST OPHTH VIS SCI, V50, P2368, DOI 10.1167/iovs.08-2696
   Jacobson SG, 2005, P NATL ACAD SCI USA, V102, P6177, DOI 10.1073/pnas.0500646102
   Jespersgaard C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38007-2
   Jiang F, 2016, INVEST OPHTH VIS SCI, V57, P145, DOI 10.1167/iovs.15-18190
   John HF, 2006, ARCH OPHTHALMOL-CHIC, V124, P744, DOI 10.1001/archopht.124.5.744
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Jurgensmeier C, 2007, CURR EYE RES, V32, P911, DOI 10.1080/02713680701616156
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kellner S, 2009, AM J OPHTHALMOL, V147, P895, DOI 10.1016/j.ajo.2008.12.023
   Khan KN, 2018, OPHTHALMOLOGY, V125, P735, DOI 10.1016/j.ophtha.2017.11.020
   Khan M, 2020, GENET MED, V22, P1235, DOI 10.1038/s41436-020-0787-4
   Khan M, 2019, HUM MUTAT, V40, P1749, DOI 10.1002/humu.23787
   Kim HJ, 2018, J LIPID RES, V59, P1620, DOI 10.1194/jlr.M084459
   Kjellstrom U, 2015, MOL VIS, V21, P767
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klevering BJ, 2002, INVEST OPHTH VIS SCI, V43, P1980
   KLIEN BA, 1967, AM J OPHTHALMOL, V64, P3, DOI 10.1016/0002-9394(67)93339-9
   Kniazeva M, 1999, AM J HUM GENET, V64, P1394, DOI 10.1086/302377
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Kong XR, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.46
   Kong X, 2016, OPHTHALMOLOGY, V123, P1887, DOI 10.1016/j.ophtha.2016.05.027
   Krishnan AK, 2018, GRAEF ARCH CLIN EXP, V256, P29, DOI 10.1007/s00417-017-3818-3
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kuniyoshi K, 2014, OPHTHALMOLOGICA, V232, P118, DOI 10.1159/000361056
   Lambertus S, 2016, INVEST OPHTH VIS SCI, V57, P5186, DOI 10.1167/iovs.16-19833
   Lambertus S, 2015, OPHTHALMOLOGY, V122, P335, DOI 10.1016/j.ophtha.2014.08.032
   Lang W., 1885, T OPHTHAL SOC UK, V5, P140
   Lee W, 2019, OPHTHALMIC GENET, V40, P369, DOI 10.1080/13816810.2019.1660382
   Lee W, 2018, AM J OPHTHALMOL, V195, P16, DOI 10.1016/j.ajo.2018.07.018
   Lee W, 2017, EUR J HUM GENET, V25, P735, DOI 10.1038/ejhg.2017.13
   Lee W, 2016, HUM GENET, V135, P9, DOI 10.1007/s00439-015-1605-y
   Lee W, 2014, INVEST OPHTH VIS SCI, V55, P6139, DOI 10.1167/iovs.14-15126
   Lenis TL, 2018, P NATL ACAD SCI USA, V115, pE11120, DOI 10.1073/pnas.1802519115
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20980
   Liu Qiangni, 2019, Cell Physiol Biochem, V53, P400, DOI 10.33594/000000146
   Lois N, 2004, AM J OPHTHALMOL, V138, P55, DOI 10.1016/j.ajo.2004.02.056
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   Lopez-Rubio S, 2018, MOL VIS, V24, P105
   Ma C.J., 2019, COLD SPRING HARB MOL
   MacDonald IM, 2018, OPHTHALMIC GENET, V39, P477, DOI 10.1080/13816810.2018.1484931
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017
   Maia-Lopes S, 2008, INVEST OPHTH VIS SCI, V49, P1191, DOI 10.1167/iovs.07-1051
   Makelainen S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007873
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Maugeri A, 2002, EUR J HUM GENET, V10, P197, DOI 10.1038/sj.ejhg.5200784
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27
   McBain VA, 2012, AM J OPHTHALMOL, V154, P146, DOI 10.1016/j.ajo.2012.01.019
   McClements ME, 2019, HUM GENE THER, V30, P590, DOI 10.1089/hum.2018.156
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Melillo P, 2016, INVEST OPHTH VIS SCI, V57, pOCT247, DOI 10.1167/iovs.15-18751
   Michaelides M, 2005, OPHTHALMOLOGY, V112, P1592, DOI 10.1016/j.ophtha.2005.04.004
   Molday L.L., 2016, LOCALIZATION FUNCTIO
   Molday LL, 2018, HUM MOL GENET, V27, P295, DOI 10.1093/hmg/ddx400
   Molday RS, 2015, PROG MOL BIOL TRANSL, V134, P415, DOI 10.1016/bs.pmbts.2015.06.008
   Muller PL, 2017, RETINA-J RET VIT DIS, V37, P359, DOI 10.1097/IAE.0000000000001169
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Nakao T, 2012, JPN J OPHTHALMOL, V56, P584, DOI 10.1007/s10384-012-0172-1
   Nassisi M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205053
   Noupuu K, 2016, GRAEF ARCH CLIN EXP, V254, P865, DOI 10.1007/s00417-015-3142-8
   Noupuu K, 2014, INVEST OPHTH VIS SCI, V55, P7217, DOI 10.1167/iovs.14-14674
   Oner A, 2018, CELL REPROGRAM, V20, P329, DOI 10.1089/cell.2018.0045
   Paavo M, 2018, INVEST OPHTH VIS SCI, V59, P2459, DOI 10.1167/iovs.18-24213
   Paavo M, 2019, J NEUROSCI RES, V97, P98, DOI 10.1002/jnr.24252
   Pang CE, 2015, OSLI RETINA, V46, P257, DOI 10.3928/23258160-20150213-09
   PAPERMASTER DS, 1976, EXP EYE RES, V23, P105, DOI 10.1016/0014-4835(76)90194-9
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park JC, 2015, INVEST OPHTH VIS SCI, V56, P4662, DOI 10.1167/iovs.15-16955
   Parker MA, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.5.10
   Parodi MB, 2015, BRIT J OPHTHALMOL, V99, P1354, DOI 10.1136/bjophthalmol-2014-306237
   Passerini I, 2010, EYE, V24, P158, DOI 10.1038/eye.2009.35
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Piccardi M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102461
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Quazi F, 2013, J BIOL CHEM, V288, P34414, DOI 10.1074/jbc.M113.508812
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Querques G, 2008, EUR J OPHTHALMOL, V18, P239, DOI 10.1177/112067210801800212
   Querques G, 2006, BRIT J OPHTHALMOL, V90, P1157, DOI 10.1136/bjo.2006.094136
   Racz B, 2018, J BIOL CHEM, V293, P11574, DOI 10.1074/jbc.RA118.002062
   Rees HA, 2018, NAT REV GENET, V19, P770, DOI 10.1038/s41576-018-0059-1
   Riveiro-Alvarez R, 2007, MOL VIS, V13, P96
   Riveiro-Alvarez R, 2013, OPHTHALMOLOGY, V120, P2332, DOI 10.1016/j.ophtha.2013.04.002
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rosenberg T, 2007, MOL VIS, V13, P1962
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Rozet JM, 1999, J MED GENET, V36, P447
   Runhart EH, 2019, INVEST OPHTH VIS SCI, V60, P4249, DOI 10.1167/iovs.19-27524
   Runhart EH, 2018, INVEST OPHTH VIS SCI, V59, P3220, DOI 10.1167/iovs.18-23881
   Sabirzhanova I, 2015, J BIOL CHEM, V290, P19743, DOI 10.1074/jbc.M115.647685
   Sachdeva MM, 2016, SEMIN OPHTHALMOL, V31, P25, DOI 10.3109/08820538.2015.1115253
   Salvatore S, 2014, RETINA-J RET VIT DIS, V34, P989, DOI 10.1097/IAE.0000000000000022
   Sangermano R, 2019, GENET MED, V21, P1751, DOI 10.1038/s41436-018-0414-9
   Sangermano R, 2018, GENOME RES, V28, P100, DOI 10.1101/gr.226621.117
   Sangermano R, 2016, OPHTHALMOLOGY, V123, P1375, DOI 10.1016/j.ophtha.2016.01.053
   Scholl HPN, 2002, INVEST OPHTH VIS SCI, V43, P1248
   Schonbach EM, 2018, AM J OPHTHALMOL, V193, P54, DOI 10.1016/j.ajo.2018.06.003
   Schonbach EM, 2017, JAMA OPHTHALMOL, V135, P696, DOI 10.1001/jamaophthalmol.2017.1162
   Schonbach EM, 2017, OPHTHALMOL RETINA, V1, P68, DOI 10.1016/j.oret.2016.08.009
   Schorderet DF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/198089
   Schulz HL, 2017, INVEST OPHTH VIS SCI, V58, P394, DOI 10.1167/iovs.16-19936
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sciezynska A, 2016, EXP EYE RES, V145, P93, DOI 10.1016/j.exer.2015.11.011
   Shankar SP, 2016, INVEST OPHTH VIS SCI, V57, P349, DOI 10.1167/iovs.15-16965
   Sharon D, 2020, HUM MUTAT, V41, P140, DOI 10.1002/humu.23903
   Shroyer NF, 2000, HUM GENET, V106, P244, DOI 10.1007/s004390051034
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   Shroyer NF, 2001, AM J OPHTHALMOL, V131, P761, DOI 10.1016/S0002-9394(01)00838-8
   Simon WA, 2007, J PHARMACOL EXP THER, V321, P866, DOI 10.1124/jpet.107.120428
   Sisk RA, 2014, RETINA-J RET VIT DIS, V34, P1567, DOI 10.1097/IAE.0000000000000136
   Sodi A, 2016, GRAEF ARCH CLIN EXP, V254, P1669, DOI 10.1007/s00417-015-3254-1
   Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101
   Song HX, 2015, JAMA OPHTHALMOL, V133, P1198, DOI 10.1001/jamaophthalmol.2015.2443
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2
   Sparrow JR, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100774
   Sparrow JR, 2015, INVEST OPHTH VIS SCI, V56, P5029, DOI 10.1167/iovs.15-16763
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P2812, DOI 10.1167/iovs.12-11490
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2012, ADV EXP MED BIOL, V723, P761, DOI 10.1007/978-1-4614-0631-0_97
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   Stenirri S, 2006, CLIN CHEM LAB MED, V44, P533, DOI 10.1515/CCLM.2006.116
   STONE EM, 1994, ARCH OPHTHALMOL-CHIC, V112, P765, DOI 10.1001/archopht.1994.01090180063036
   Strauss RW, 2017, JAMA OPHTHALMOL, V135, P1232, DOI 10.1001/jamaophthalmol.2017.4152
   Strauss RW, 2017, JAMA OPHTHALMOL, V135, P687, DOI 10.1001/jamaophthalmol.2017.1121
   Strauss RW, 2016, OPHTHALMOLOGY, V123, P817, DOI 10.1016/j.ophtha.2015.12.009
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sunness JS, 2008, RETINA-J RET VIT DIS, V28, P794, DOI 10.1097/IAE.0b013e31816690bd
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Tanaka K, 2018, OPHTHALMOLOGY, V125, P89, DOI 10.1016/j.ophtha.2017.07.019
   Tanna P, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.2.1
   Testa F, 2014, OPHTHALMOLOGY, V121, P2399, DOI 10.1016/j.ophtha.2014.06.032
   Testa F, 2012, INVEST OPHTH VIS SCI, V53, P4409, DOI 10.1167/iovs.11-8201
   Teussink MM, 2015, AM J OPHTHALMOL, V159, P964, DOI 10.1016/j.ajo.2015.02.004
   Tosha C, 2010, CURR EYE RES, V35, P63, DOI 10.3109/02713680903374224
   Tracewska AM, 2019, GENES-BASEL, V10, DOI 10.3390/genes10120959
   Trapani I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040287
   Trapani I, 2015, HUM MOL GENET, V24, P6811, DOI 10.1093/hmg/ddv386
   Trapani I, 2014, EMBO MOL MED, V6, P194, DOI 10.1002/emmm.201302948
   Tsybovsky Y, 2014, PROTEIN EXPRES PURIF, V97, P50, DOI 10.1016/j.pep.2014.02.010
   Tsybovsky Y, 2013, STRUCTURE, V21, P854, DOI 10.1016/j.str.2013.03.001
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   Turcotte Gauthier M.T., 2010, ETUDE CLIN GENETIQUE
   Valverde D, 2006, MOL VIS, V12, P902
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   van Huet RAC, 2014, INVEST OPHTH VIS SCI, V55, P7467, DOI 10.1167/iovs.13-13825
   Vandenbroucke T, 2015, OPHTHALMIC RES, V54, P181, DOI 10.1159/000438906
   VazquezDominguez I., 2019, OPPORTUNITIES CHALLE
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Verdina T., 2012, J CLIN EXP OPHTHALMO, V3
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Wolock CJ, 2019, GENET MED, V21, P2336, DOI 10.1038/s41436-019-0495-0
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
   Yanik M, 2017, PROG RETIN EYE RES, V56, P1, DOI 10.1016/j.preteyeres.2016.09.001
   Yatsenko AN, 2003, HUM MUTAT, V21, P636, DOI 10.1002/humu.10219
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zernant J, 2018, CSH MOL CASE STUD, V4, DOI 10.1101/mcs.a002733
   Zernant J, 2017, J MED GENET, V54, P404, DOI 10.1136/jmedgenet-2017-104540
   Zernant J, 2014, HUM MOL GENET, V23, P6797, DOI 10.1093/hmg/ddu396
   Zernant J, 2014, HUM MUTAT, V35, P1187, DOI 10.1002/humu.22626
   Zhang N, 2015, HUM MOL GENET, V24, P3220, DOI 10.1093/hmg/ddv073
   Zhang QJ, 2007, HUM GENET, V122, P293, DOI 10.1007/s00439-007-0395-2
   Zolnikova IV, 2017, EUR J MED GENET, V60, P140, DOI 10.1016/j.ejmg.2016.12.002
NR 292
TC 76
Z9 76
U1 2
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2020
VL 79
AR 100861
DI 10.1016/j.preteyeres.2020.100861
PG 33
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH4OZ
UT WOS:000600395400001
PM 32278709
OA Green Accepted, hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Issa, PC
   Tysoe, C
   Caswell, R
AF Issa, Peter Charbel
   Tysoe, Carolyn
   Caswell, Richard
TI Late-onset Pseudoxanthoma Elasticum Associated with a Hypomorphic ABCC6
   Variant
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; GENE; PATHOLOGY; MEMBRANE; SPECTRUM
AB PURPOSE: To describe patients with late-onset pseudoxanthoma elasticum (PXE) associated with a likely hypomorphic ABCC6 variant.
   DESIGN: Retrospective observational case series.
   METHODS: Clinical evaluation, multimodal retinal imaging, genetic testing, and molecular modeling.
   RESULTS: Three patients, in whom vision symptoms first arose at 80 years of age or later, showed age-related macular degeneration (AMD)-like fundus changes. However, features characteristic of PXE, including discrete angioid streaks and reduced fluorescence on late-phase indocyanine green angiography, prompted genetic testing which revealed the c.1171A > G variant in combination with a large deletion in the ABCC6 gene in each case. None of the patients had obvious skin changes or cardiovascular disease atypical for their age. Comparative molecular modeling supported the hypothesis that the c.1171A > G(ABCC6) variant acted as a hypomorphic variant.
   CONCLUSIONS: Late-onset PXE extends the spectrum of ectopic calcification disorders caused by mutations in ABCC6 and may clinically be limited to the eye, mimicking AMD. Patients may be identified based on specific ocular changes, whereas skin and cardiovascular changes may remain ambiguous. The study provides evidence for a role for hypomorphic ABCC6 variants in the pathogenesis of PXE. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Issa, Peter Charbel] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
   [Issa, Peter Charbel] Univ Oxford, Nuffield Lab Ophthalmol, Dept Clin Neurosci, Oxford, England.
   [Tysoe, Carolyn; Caswell, Richard] Royal Devon & Exeter NHS Fdn Trust, Genom Lab, Exeter, Devon, England.
   [Caswell, Richard] Univ Exeter, Sch Med, Inst Biomed & Clin Sci, Exeter, Devon, England.
C3 Oxford University Hospitals NHS Foundation Trust; University of Oxford;
   University of Exeter; University of Exeter
RP Issa, PC (通讯作者)，Oxford Eye Hosp, John Radcliffe Hosp, Oxford OX3 9DU, England.
EM study-enquiry@outlook.com
RI Charbel Issa, Peter/E-8935-2018
OI Charbel Issa, Peter/0000-0002-0351-6673; Caswell,
   Richard/0000-0003-0713-4602
FU National Institute for Health Research (NIHR) Oxford Biomedical Research
   Centre (BRC), Oxford, United Kingdom
FX Supported by the National Institute for Health Research (NIHR) Oxford
   Biomedical Research Centre (BRC), Oxford, United Kingdom. The views
   expressed are those of the authors and not necessarily those of the NHS,
   the NIHR or the Department of Health. The sponsor and funding
   organization had no role in the design or conduct of this research.
CR Barteselli G, 2014, OPHTHALMOLOGY, V121, P709, DOI 10.1016/j.ophtha.2013.10.016
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Germain DP, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0639-8
   Gliem M, 2020, BRIT J OPHTHALMOL, V104, P1089, DOI 10.1136/bjophthalmol-2018-313448
   Gliem M, 2016, INVEST OPHTH VIS SCI, V57, P3323, DOI 10.1167/iovs.16-19388
   Gliem M, 2015, JAMA OPHTHALMOL, V133, P581, DOI 10.1001/jamaophthalmol.2015.117
   Gliem Martin, 2013, Frontiers in Genetics, V4, P14, DOI 10.3389/fgene.2013.00014
   Issa PC, 2010, OPHTHALMOLOGY, V117, P1406, DOI 10.1016/j.ophtha.2009.11.008
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Johnson ZL, 2018, CELL, V172, P81, DOI 10.1016/j.cell.2017.12.005
   Johnson ZL, 2017, CELL, V168, P1075, DOI 10.1016/j.cell.2017.01.041
   Legrand A, 2017, GENET MED, V19, P909, DOI 10.1038/gim.2016.213
   Li QL, 2019, AM J PATHOL, V189, P216, DOI 10.1016/j.ajpath.2018.09.014
   Medical Research Council NHRA, IS MY STUD RES
   Nitschke Y, 2012, AM J HUM GENET, V90, P25, DOI 10.1016/j.ajhg.2011.11.020
   Pfendner EG, 2007, J MED GENET, V44, P621, DOI 10.1136/jmg.2007.051094
   Plomp AS, 2010, AM J MED GENET A, V152A, P1049, DOI 10.1002/ajmg.a.33329
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Stenson PD, 2017, HUM GENET, V136, P665, DOI 10.1007/s00439-017-1779-6
NR 21
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2020
VL 218
BP 255
EP 260
DI 10.1016/j.ajo.2020.05.009
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NW3OQ
UT WOS:000574920300003
PM 32442430
DA 2022-11-30
ER

PT J
AU Karumanchi, DK
   Skrypai, Y
   Thomas, A
   Gaillard, ER
AF Karumanchi, Devi Kalyan
   Skrypai, Yana
   Thomas, Alexander
   Gaillard, Elizabeth R.
TI Rational design of liposomes for sustained release drug delivery of
   bevacizumab to treat ocular angiogenesis
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Liposomes; Drug delivery; Stability; Anti-oxidants; Antibodies; Thermal
   analysis
ID FREEZE-DRIED LIPOSOMES; INTRACELLULAR DELIVERY; LIPID-BILAYERS;
   PHARMACOKINETICS; CHOLESTEROL; STABILITY; TREHALOSE; PERMEABILITY;
   RANIBIZUMAB; DEHYDRATION
AB Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD) are the most common ocular diseases and a leading cause of blindness in American adults. Laser treatments and drug intervention with Ranibizumab, Aflibercept and Bevacizumab are available for controlling angiogenesis by inhibiting the growth of new blood vessels. These antibody injections are given monthly into the eye which are inconvenient as well as very expensive. Our research focuses on encapsulating the protein drugs within the liposomes to obtain drug release over a longer period, thereby decreasing the frequency and cost of the injections. We used calorimetric, spectroscopic and light scattering methods to identify the variations in the liposomes in terms of particle size, encapsulation efficiency, time of release and thermal stabilities to screen and downsize our ideal formulations to three with the DPPC: DOPE: DPPG: cholesterol compositions of 60:10:0:30, 65:5:5:25 and 60:5:5:30. Overall, his paper focuses on developing Bevacizumab loaded liposomes for extended released drug delivery to treat ocular angiogenesis. In vitro biological activity and RPE cell cytotoxicity were also tested to determine the efficacy of the drug delivery system for potential human use.
C1 [Karumanchi, Devi Kalyan; Skrypai, Yana; Gaillard, Elizabeth R.] Northern Illinois Univ, Dept Chem & Biochem, De Kalb, IL USA.
   [Karumanchi, Devi Kalyan; Thomas, Alexander; Gaillard, Elizabeth R.] Northern Illinois Univ, Dept Biol Sci, De Kalb, IL USA.
C3 Northern Illinois University; Northern Illinois University
RP Gaillard, ER (通讯作者)，1425 W Lincoln Hwy, De Kalb, IL 60115 USA.
EM gaillard@nin.edu
RI Gaillard, Elizabeth/M-2627-2019
OI Karumanchi, Devi Kalyan/0000-0001-8392-5997
CR ALLEN TM, 1983, J PHARMACOL EXP THER, V226, P539
   ALONSOROMANOWSKI S, 1989, J MEMBRANE BIOL, V108, P1, DOI 10.1007/BF01870420
   Amstad E, 2011, NANO LETT, V11, P1664, DOI 10.1021/nl2001499
   Bachu R. D., 2018, PHARMACEUTICS, P10
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brown Larry R, 2005, Expert Opin Drug Deliv, V2, P29, DOI 10.1517/17425247.2.1.29
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x
   CROWE JH, 1988, BIOCHIM BIOPHYS ACTA, V947, P367, DOI 10.1016/0304-4157(88)90015-9
   Crowe LM, 1996, BIOPHYS J, V71, P2087, DOI 10.1016/S0006-3495(96)79407-9
   CROWE LM, 1985, ARCH BIOCHEM BIOPHYS, V242, P240, DOI 10.1016/0003-9861(85)90498-9
   CROWE LM, 1986, BIOCHIM BIOPHYS ACTA, V861, P131, DOI 10.1016/0005-2736(86)90411-6
   Date PV, 2010, AAPS PHARMSCITECH, V11, P304, DOI 10.1208/s12249-010-9382-3
   Demetzos C, 2008, J LIPOSOME RES, V18, P159, DOI 10.1080/08982100802310261 
   Forooghian F, 2017, CAN J OPHTHALMOL, V52, P616, DOI 10.1016/j.jcjo.2017.04.016
   Fu AL, 2014, BIOCONJUGATE CHEM, V25, P1602, DOI 10.1021/bc500320j
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gurny R., 2015, GOOGLE PATENTS
   Hashizaki K, 2003, CHEM PHARM BULL, V51, P815
   Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026
   Janoff AS, 1998, LIPOSOMES RATIONAL D
   MADDEN TD, 1985, BIOCHIM BIOPHYS ACTA, V817, P67, DOI 10.1016/0005-2736(85)90069-0
   Melnikova I, 2005, NAT REV DRUG DISCOV, V4, P711, DOI 10.1038/nrd1827
   Miao L, 2002, BIOPHYS J, V82, P1429, DOI 10.1016/S0006-3495(02)75497-0
   Nicholas AR, 2000, BBA-BIOMEMBRANES, V1463, P167, DOI 10.1016/S0005-2736(99)00192-3
   Oselkin M, 2017, THER DELIV, V8, P747, DOI 10.4155/tde-2017-0036
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Pisal DS, 2010, J PHARM SCI-US, V99, P2557, DOI 10.1002/jps.22054
   Pouton CW, 1997, ADV DRUG DELIVER REV, V25, P47, DOI 10.1016/S0169-409X(96)00490-5
   Prokop A, 2008, J PHARM SCI-US, V97, P3518, DOI 10.1002/jps.21270
   Reis A, 2012, BBA-BIOMEMBRANES, V1818, P2374, DOI 10.1016/j.bbamem.2012.02.002
   Rudolphi-Skorska E, 2017, J MEMBRANE BIOL, V250, P493, DOI 10.1007/s00232-017-9976-8
   Samuni AM, 2000, CHEM PHYS LIPIDS, V105, P121, DOI 10.1016/S0009-3084(99)00136-X
   Sawant RR, 2012, PHARM RES-DORDR, V29, P375, DOI 10.1007/s11095-011-0557-8
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Suzuki T, 1996, BBA-BIOMEMBRANES, V1278, P176
   WEIS RM, 1985, J PHYS CHEM-US, V89, P4453, DOI 10.1021/j100267a011
   Wujcik D., 2014, SEMINARS ONCOLOGY NU
   Yacout SM, 2017, PHOTOCHEM PHOTOBIOL, V93, P590, DOI 10.1111/php.12683
NR 39
TC 20
Z9 20
U1 2
U2 26
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD OCT
PY 2018
VL 47
BP 275
EP 282
DI 10.1016/j.jddst.2018.07.003
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GU3FV
UT WOS:000445162500032
DA 2022-11-30
ER

PT J
AU Katschke, KJ
   Xi, HK
   Cox, C
   Truong, T
   Malato, Y
   Lee, WP
   McKenzie, B
   Arceo, R
   Tao, JH
   Rangell, L
   Reichelt, M
   Diehl, L
   Elstrott, J
   Weimer, RM
   Campagne, MV
AF Katschke, Kenneth J., Jr.
   Xi, Hongkang
   Cox, Christian
   Truong, Tom
   Malato, Yann
   Lee, Wyne P.
   McKenzie, Brent
   Arceo, Rommel
   Tao, Jianhua
   Rangell, Linda
   Reichelt, Mike
   Diehl, Lauri
   Elstrott, Justin
   Weimer, Robby M.
   Campagne, Menno van Lookeren
TI Classical and alternative complement activation on photoreceptor outer
   segments drives monocyte-dependent retinal atrophy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; PIGMENT EPITHELIUM; FACTOR-H;
   CHOROIDAL NEOVASCULARIZATION; GRADING SYSTEM; DEFICIENT MICE; AGE; RISK;
   RARE
AB Geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD), is characterized by progressive loss of retinal pigment epithelium cells and photoreceptors in the setting of characteristic extracellular deposits and remains a serious unmet medical need. While genetic predisposition to AMD is dominated by polymorphisms in complement genes, it remains unclear how complement activation contributes to retinal atrophy. Here we demonstrate that complement is activated on photoreceptor outer segments (POS) in the retina peripheral to atrophic lesions associated with GA. When exposed to human serum following outer blood-retinal barrier breakdown, POS act as potent activators of the classical and alternative complement pathway. In mouse models of retinal degeneration, classical and alternative pathway complement activation on photoreceptors contributed to the loss of photoreceptor function. This was dependent on C5a-mediated recruitment of peripheral blood monocytes but independent of resident microglia. Genetic or pharmacologic inhibition of both classical and alternative complement C3 and C5 convertases was required to reduce progressive degeneration of photoreceptor rods and cones. Our study implicates systemic classical and alternative complement proteins and peripheral blood monocytes as critical effectors of localized retinal degeneration with potential relevance for the contribution of complement activation to GA.
C1 [Katschke, Kenneth J., Jr.; Xi, Hongkang; Cox, Christian; Campagne, Menno van Lookeren] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
   [Truong, Tom; Malato, Yann; Lee, Wyne P.; McKenzie, Brent] Genentech Inc, Dept Translat Immunol, San Francisco, CA 94080 USA.
   [Arceo, Rommel; Tao, Jianhua; Rangell, Linda; Reichelt, Mike; Diehl, Lauri] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Elstrott, Justin; Weimer, Robby M.] Genentech Inc, Dept Biomed Imaging, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech
RP Campagne, MV (通讯作者)，Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA.
EM menno@gene.com
OI Elstrott, Justin/0000-0001-6694-5929
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   BOESZEBATTAGLIA K, 1992, EXP EYE RES, V54, P821, DOI 10.1016/0014-4835(92)90040-Y
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1
   Coburn PS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154560
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Dolgin E, 2017, NAT BIOTECHNOL, V35, P1000, DOI 10.1038/nbt1117-1000
   Eandi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.16490
   Fischer MB, 1996, J IMMUNOL, V157, P549
   FREI Y, 1987, MOL CELL PROBE, V1, P141, DOI 10.1016/0890-8508(87)90022-3
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hadders MA, 2012, CELL REP, V1, P200, DOI 10.1016/j.celrep.2012.02.003
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hariri S, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.026017
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373
   Hume DA, 2006, CURR OPIN IMMUNOL, V18, P49, DOI 10.1016/j.coi.2005.11.008
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Lyzogubov VV, 2016, AM J PATHOL, V186, P2088, DOI 10.1016/j.ajpath.2016.03.021
   Machalinska A, 2010, NEUROCHEM RES, V35, P1819, DOI 10.1007/s11064-010-0248-6
   Martin M, 2012, J BIOL CHEM, V287, P33733, DOI 10.1074/jbc.M112.341339
   Mones J, 2016, INVEST OPHTH VIS SCI, V57, P3974, DOI 10.1167/iovs.16-19355
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   OLSEN KJ, 1979, ACTA PHARMACOL TOX, V44, P241
   Paidassi H, 2008, J IMMUNOL, V180, P2329, DOI 10.4049/jimmunol.180.4.2329
   Paidassi H, 2011, J MOL BIOL, V408, P277, DOI 10.1016/j.jmb.2011.02.029
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030
   PERLMAN I, 1983, BRIT J OPHTHALMOL, V67, P443, DOI 10.1136/bjo.67.7.443
   Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Ruggiero L, 2012, P NATL ACAD SCI USA, V109, P8145, DOI 10.1073/pnas.1121101109
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Sekar A, 2016, NATURE, V530, P177, DOI 10.1038/nature16549
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070
   Sikorav A, 2017, BRIT J OPHTHALMOL, V101, P438, DOI 10.1136/bjophthalmol-2015-308065
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Sweigard JH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1482
   Tan X, 2015, SCI REP-UK, V5, DOI 10.1038/srep15702
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   WILLERSON D, 1978, BRIT J OPHTHALMOL, V62, P551, DOI 10.1136/bjo.62.8.551
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
NR 70
TC 32
Z9 32
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 9
PY 2018
VL 8
AR 7348
DI 10.1038/s41598-018-25557-8
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GF1ZX
UT WOS:000431737300034
PM 29743491
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Feng, TT
   Liang, ZY
   Chen, S
AF Feng, Ting-Ting
   Liang, Ze-Yu
   Chen, Song
TI Squamosamide derivative FLZ inhibits TNF-alpha-induced ICAM-1 expression
   via down-regulation of the NF-kappa B signaling pathway in ARPE-19 cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Squamosamide derivative FLZ; age-related macular degeneration (AMD);
   retinal pigment epithelium (RPE); tumor necrosis factor-alpha
   (TNF-alpha); intercellular adhesion molecule-1 (ICAM-1)
ID NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE-1; COMPOUND FLZ; MONOCYTE
   ADHESION; TIGHT JUNCTIONS; ACTIVATION; LIPOPOLYSACCHARIDE; ADHESIVENESS;
   TRANSDUCTION; INFLAMMATION
AB Dysfunction of the retinal pigment epithelium (RPE) resulting from chronic inflammation is implicated in the pathogenesis of age-related macular degeneration (AMD). It has been reported that tumor necrosis factor-a (TNF-alpha) could induce intercellular adhesion molecule-1 (ICAM-1) expression in RPE cells. FLZ, a novel synthetic squamosamide derivative from a Chinese herb, Annona glabra, has displayed significant anti-inflammatory activity. However, the effects of FLZ on TNF-alpha-induced ICAM-1 expression in RPE cells remain unknown. Therefore, in the present study, we evaluated the effects of FLZ on TNF-alpha-induced ICAM-1 expression in RPE cells. We found that FLZ prevented TNF-alpha-induced ICAM-1 expression and the ability of monocytes to adhere to ARPE-19 cells induced by TNF-alpha. Furthermore, FLZ inhibited TNF-alpha-induced NF-kappa B p65 expression, as well as phosphorylation of I kappa B alpha in ARPE-19 cells. Taken together, these results suggest that FLZ inhibited TNF-alpha-induced ICAM-1 expression through blocking NF-kappa B signaling pathway in ARPE-19 cells. Thus, FLZ could be used for designing novel therapeutic agents against AMD.
C1 [Feng, Ting-Ting; Liang, Ze-Yu; Chen, Song] Tianjin Med Univ, Tianjin Eye Inst, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin Eye Hosp, Tianjin 300020, Peoples R China.
C3 Tianjin Medical University
RP Chen, S (通讯作者)，Tianjin Med Univ, Tianjin Eye Inst, Tianjin Key Lab Ophthalmol & Visual Sci, Tianjin Eye Hosp, Tianjin 300020, Peoples R China.
EM chen_song022@126.com
FU Tianjin Science and Technology Committee, China [14JCYBJC27400]
FX This study was supported by a grant from Tianjin Science and Technology
   Committee, China (No. 14JCYBJC27400).
CR Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867
   Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen JT, 2006, INVEST OPHTH VIS SCI, V47, P664, DOI 10.1167/iovs.05-1008
   Cheng LB, 2014, INT J MOL SCI, V15, P18762, DOI 10.3390/ijms151018762
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Feghali Carol A., 1997, Frontiers in Bioscience (online), V2, pD12
   Feng WH, 2005, MOL NEUROBIOL, V31, P295, DOI 10.1385/MN:31:1-3:295
   Jayaraman T, 2005, NEUROSURGERY, V57, P558, DOI 10.1227/01.NEU.0000170439.89041.D6
   Jersmann HPA, 2001, INFECT IMMUN, V69, P1273, DOI 10.1128/IAI.69.3.1273-1279.2001
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Lee IT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117911
   Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mezzano S, 2004, NEPHROL DIAL TRANSPL, V19, P2505, DOI 10.1093/ndt/gfh207
   Pang HY, 2009, ACTA PHARMACOL SIN, V30, P209, DOI 10.1038/aps.2008.29
   Peng SM, 2012, INVEST OPHTH VIS SCI, V53, P5016, DOI 10.1167/iovs.11-8311
   SCHLEIMER RP, 1986, J IMMUNOL, V136, P649
   Seo WY, 2010, BIOCHEM BIOPH RES CO, V398, P140, DOI 10.1016/j.bbrc.2010.06.053
   Thichanpiang P, 2015, AM J CHINESE MED, V43, P103, DOI 10.1142/S0192415X1550007X
   Thichanpiang P, 2014, MOL VIS, V20, P781
   Wornle M, 2011, INVEST OPHTH VIS SCI, V52, P6536, DOI 10.1167/iovs.10-6993
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Yamawaki H, 2011, BIOCHEM BIOPH RES CO, V408, P339, DOI 10.1016/j.bbrc.2011.04.039
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Zech JC, 1998, INVEST OPHTH VIS SCI, V39, P1600
   Zhang D, 2007, EUR J PHARMACOL, V561, P1, DOI 10.1016/j.ejphar.2006.11.015
   Zhang D, 2007, NEUROPHARMACOLOGY, V52, P423, DOI 10.1016/j.neuropharm.2006.08.020
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 32
TC 3
Z9 3
U1 0
U2 0
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 8
BP 9126
EP 9132
PG 7
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CW1TV
UT WOS:000364775400043
PM 26464656
DA 2022-11-30
ER

PT J
AU Vaishya, RD
   Khurana, V
   Patel, S
   Mitra, AK
AF Vaishya, Ravi D.
   Khurana, Varun
   Patel, Sulabh
   Mitra, Ashim K.
TI Controlled ocular drug delivery with nanomicelles
SO WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY
LA English
DT Review
ID POLYION COMPLEX MICELLES; IN-VIVO EVALUATION; GLYCOL)-POLY(L-LYSINE)
   BLOCK-COPOLYMER; CYCLOSPORINE-A; POLYMERIC MICELLES; PHOTODYNAMIC
   THERAPY; SUSTAINED-RELEASE; RABBIT EYE; SYSTEM; NEOVASCULARIZATION
AB Many vision threatening ocular diseases such as age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, and proliferative vitreoretinopathy may result in blindness. Ocular drug delivery specifically to the intraocular tissues remains a challenging task due to the presence of various physiological barriers. Nonetheless, recent advancements in the field of nanomicelle-based novel drug delivery system could fulfil these unmet needs. Nanomicelles consists of amphiphilic molecules that self-assemble in aqueous media to form organized supramolecular structures. Micelles can be prepared in various sizes (10-1000 nm) and shapes depending on the molecular weights of the core and corona forming blocks. Nanomicelles have been an attractive carrier for their potential to solubilize hydrophobic molecules in aqueous solution. In addition, small size in nanometer range and highly modifiable surface properties have been reported to be advantageous in ocular drug delivery. In this review, various factors influencing rationale design of nanomicelles formulation and disposition are discussed along with case studies. Despite the progress in the field, influence of various properties of nanomicelles such as size, shape, surface charge, rigidity of structure on ocular disposition need to be studied in further details to develop an efficient nanocarrier system. (C) 2014 Wiley Periodicals, Inc.
C1 [Vaishya, Ravi D.; Khurana, Varun; Patel, Sulabh; Mitra, Ashim K.] Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64108 USA.
   [Khurana, Varun] INSYS Therapeut Inc, Chandler, AZ 85224 USA.
C3 University of Missouri System; University of Missouri Kansas City
RP Mitra, AK (通讯作者)，Univ Missouri, Sch Pharm, Div Pharmaceut Sci, Kansas City, MO 64108 USA.
EM mitraa@umkc.edu
RI Vaishya, Ravi/F-6498-2016; VAISHYA, RAJU/I-3726-2015
OI Vaishya, Ravi/0000-0002-7909-5019; VAISHYA, RAJU/0000-0002-9577-9533;
   KHURANA, VARUN/0000-0003-4971-2597
FU NEI NIH HHS [R01 EY010659, R01 EY009171] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R01EY010659, R01EY009171] Funding Source: NIH
   RePORTER
CR Adams ML, 2003, J PHARM SCI-US, V92, P1343, DOI 10.1002/jps.10397
   Aliabadi Hamidreza Montazeri, 2006, Expert Opin Drug Deliv, V3, P139
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Anand BS, 2003, CURR EYE RES, V26, P151, DOI 10.1076/ceyr.26.3.151.14893
   Ananthula H.K., 2009, BIOAVAILABILITY
   BARSOTTI MF, 1992, INVEST OPHTH VIS SCI, V33, P581
   Castro E, 2005, J PHYS CHEM B, V109, P5592, DOI 10.1021/jp044766n
   Chi SC, 2003, ARCH PHARM RES, V26, P173
   CHIEN YW, 1982, NOVEL DRUG DELIVERY
   Chopra P, 2012, J CONTROL RELEASE, V160, P96, DOI 10.1016/j.jconrel.2012.01.032
   Civiale C, 2009, INT J PHARMACEUT, V378, P177, DOI 10.1016/j.ijpharm.2009.05.028
   Cunha-Vaz JG, 1997, DOC OPHTHALMOL, V93, P149, DOI 10.1007/BF02569055
   Di Tommaso C, 2012, EUR J PHARM BIOPHARM, V81, P257, DOI 10.1016/j.ejpb.2012.02.014
   Di Tommaso C, 2012, INVEST OPHTH VIS SCI, V53, P2292, DOI 10.1167/iovs.11-8829
   Di Tommaso C, 2011, INT J PHARMACEUT, V416, P515, DOI 10.1016/j.ijpharm.2011.01.004
   Di Tommaso C, 2010, EUR J PHARM SCI, V40, P38, DOI 10.1016/j.ejps.2010.02.006
   Dursun D, 2000, OPHTHALMOLOGY, V107, P1754, DOI 10.1016/S0161-6420(00)00273-6
   ELTAYAR N, 1993, J MED CHEM, V36, P3757, DOI 10.1021/jm00076a002
   Gong CY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/21/215103
   Gupta AK, 2000, INT J PHARM, V209, P1, DOI 10.1016/S0378-5173(00)00508-1
   Harada A, 1998, MACROMOLECULES, V31, P288, DOI 10.1021/ma971277v
   HARADA A, 1995, MACROMOLECULES, V28, P5294, DOI 10.1021/ma00119a019
   Harada A, 2005, OPHTHALMIC DRUG DELI
   Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Ideta R, 2004, FEBS LETT, V557, P21, DOI 10.1016/S0014-5793(03)01315-2
   Itaka K, 2003, BIOMATERIALS, V24, P4495, DOI 10.1016/S0142-9612(03)00347-8
   KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P639, DOI 10.1021/bc00036a001
   Kataoka K, 1996, MACROMOLECULES, V29, P8556, DOI 10.1021/ma961217+
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1
   Katayose S, 1997, BIOCONJUGATE CHEM, V8, P702, DOI 10.1021/bc9701306
   Kim H, 2012, ACTA BIOMATER, V8, P3932, DOI 10.1016/j.actbio.2012.07.016
   Kim S, 2010, POLYM MICELLES DRUG
   Kuwano M, 2002, PHARMACEUT RES, V19, P108, DOI 10.1023/A:1013671819604
   Lens A., 1999, OCULAR ANATOMY PHYSL
   Liaw J, 2001, GENE THER, V8, P999, DOI 10.1038/sj.gt.3301485
   Lin HR, 2013, J BIOMED MATER RES B, V101B, P689, DOI 10.1002/jbm.b.32871
   Luschmann C, 2013, INT J PHARMACEUT, V455, P331, DOI 10.1016/j.ijpharm.2013.07.002
   Luschmann C, 2014, CORNEA, V33, P77, DOI 10.1097/ICO.0b013e3182a7f3bf
   MISHIMA S., 1966, INVEST OPHTHALMOL, V5, P264
   Mitra AK, 2011, OPHTHALMIC COMPOSITI
   Pepic I, 2004, INT J PHARMACEUT, V272, P57, DOI 10.1016/j.ijpharm.2003.11.032
   Pepic I, 2012, CHEM BIOCHEM ENG Q, V26, P365
   Pepic I, 2010, J PHARM SCI-US, V99, P4317, DOI 10.1002/jps.22137
   Qu XZ, 2006, BIOMACROMOLECULES, V7, P3452, DOI 10.1021/bm0604000
   Rafie F, 2010, CURR EYE RES, V35, P1081, DOI 10.3109/02713683.2010.508867
   Ribeiro A, 2013, COLLOID SURFACE B, V103, P550, DOI 10.1016/j.colsurfb.2012.10.055
   Ribeiro A, 2012, J R SOC INTERFACE, V9, P2059, DOI 10.1098/rsif.2012.0102
   Schlingemann RO, 1998, EXP EYE RES, V66, P747, DOI 10.1006/exer.1998.0483
   Shintaro Nakao AH-M, 2012, J OPHTHALMOL, V2012, P13
   Srirangam R, 2012, ADV OCULAR DRUG DELI
   STEWART PA, 1994, J COMP NEUROL, V340, P566, DOI 10.1002/cne.903400409
   Sugisaki K, 2008, INVEST OPHTH VIS SCI, V49, P894, DOI 10.1167/iovs.07-0389
   Tu JS, 2007, DRUG DEV IND PHARM, V33, P1142, DOI 10.1080/03639040701397381
   Vadlapudi AD, 2013, J OCUL PHARM THER
   Vaishya R, 2014, AAPS PHARMSCITECH
   Velagaleti PR., 2010, DRUG DELIV TECHNOL, V10, P42
   Xu L, 2013, COLLOID SURFACE B, V112, P30, DOI 10.1016/j.colsurfb.2013.06.047
   Zhang GD, 2003, J CONTROL RELEASE, V93, P141, DOI 10.1016/j.jconrel.2003.05.002
NR 59
TC 85
Z9 89
U1 1
U2 92
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5116
EI 1939-0041
J9 WIRES NANOMED NANOBI
JI Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol.
PD SEP-OCT
PY 2014
VL 6
IS 5
BP 422
EP 437
DI 10.1002/wnan.1272
PG 16
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Research & Experimental Medicine
GA AN2CI
UT WOS:000340390600002
PM 24888969
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Michalewski, J
   Nawrocki, J
   Trebinska, M
   Michalewska, Z
AF Michalewski, Janusz
   Nawrocki, Jerzy
   Trebinska, Magdalena
   Michalewska, Zofia
TI Spectral-domain optical coherence tomography features preceding
   new-onset neovascular membrane formation
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID LINE VISUAL-ACUITY; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   RANIBIZUMAB; BEVACIZUMAB
AB Objective: To determine the frequency and characteristic spectral-domain optical coherence tomography (SD-OCT) features preceding new-onset choroidal neovascularization (CNV) in the fellow eye of neovascular age-related macular degeneration (AMD) with SD-OCT.
   Design: A prospective, observational study.
   Participants: Sixty-eight fellow eyes of patients with unilateral CNV.
   Methods: SD-OCT was performed at baseline and then monthly. The main outcome measure is the description of retinal morphology 1 month before new onset of neovascularization.
   Results: During the 48-month observation period, new-onset CNV was observed in 27 fellow eyes. Several morphologic features characterized SD-OCT images >= 1 months before new onset of CNV. These included new retinal pigment epithelium defects (2 eyes), new photoreceptor defects (7 eyes), drusen touching the photoreceptor layer and the external limiting membrane (13 eyes), and new drusen (4 eyes) hyperreflective spots probably representing new growing vessels (5 eyes).
   Conclusions: Monthly SD-OCT screening of fellow eyes of patients treated with anti vascular endothelial growth factor enables identification of morphologic changes that may predispose or precede CNV formation. Rapid identification of CNV formation enhances treatment immediacy.
C1 [Michalewski, Janusz; Nawrocki, Jerzy; Michalewska, Zofia] Klin Okulistyczna Jasne Blonia, PL-91162 Lodz, Poland.
   [Trebinska, Magdalena] III Municipal Hosp, Lodz, Poland.
RP Michalewska, Z (通讯作者)，Klin Okulistyczna Jasne Blonia, Ul Rojna 90, PL-91162 Lodz, Poland.
EM zosia_n@yahoo.com
OI Nawrocka, Zofia Anna/0000-0001-8376-9218; Michalewski,
   Janusz/0000-0002-1516-6703
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   McCarthy LC, 2012, AM J OPHTHALMOL, V154, P568, DOI 10.1016/j.ajo.2012.03.021
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Takahashi M, 2010, JPN J OPHTHALMOL, V54, P565, DOI 10.1007/s10384-010-0864-3
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 14
TC 6
Z9 6
U1 0
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2014
VL 49
IS 4
BP 339
EP 344
DI 10.1016/j.jcjo.2014.04.018
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR2GI
UT WOS:000343401400015
PM 25103650
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Nicod, E
   Simpson, A
   Angelis, A
   Grimaccia, F
   Kanavos, P
AF Jackson, Timothy L.
   Nicod, Elena
   Simpson, Andrew
   Angelis, Aris
   Grimaccia, Federico
   Kanavos, Panos
TI SYMPTOMATIC VITREOMACULAR ADHESION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; diabetic macular edema; macular hole;
   posterior vitreous detachment; retinal vein occlusion; vitreomacular
   adhesion; vitreomacular traction
ID POSTERIOR VITREOUS DETACHMENT; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   HOLE FORMATION; SURGICAL-MANAGEMENT; AUTOLOGOUS-PLASMIN; TRACTION
   SYNDROME; VITRECTOMY; INJECTION; TRIAMCINOLONE; GAS
AB Background: Symptomatic vitreomacular adhesion describes symptomatic loss of visual function as a result of vitreous traction at the macula.
   Methods: Literature review.
   Results: Symptomatic vitreomacular adhesion can occur in isolation as vitreomacular traction, which may lead to the development of a macular hole, or it may occur alongside epiretinal membrane. It is likely to be associated with age-related macular degeneration and possibly diabetic maculopathy, although this is less certain. The treatment depends largely on the cause, but options include observation, vitrectomy, and pharmacologic vitreolysis. Small uncontrolled trials have also explored the use of an intravitreal gas bubble as a means of releasing VMA. If all cases of sVMA are considered together, then the burden of illness is substantial, with a prevalence of similar to 0.35 per 100 population (excluding epiretinal membrane). Furthermore, there may be many more cases of undiagnosed sVMA.
   Conclusion: The recent introduction of ocriplasmin is likely to increase interest in sVMA. Clinical trials suggest that it has a role in the treatment of vitreomacular traction and Stages 1 to 3 macular holes but not primarily as a treatment of epiretinal membrane. Its role in other diseases associated with VMA remains to be determined.
C1 [Jackson, Timothy L.; Simpson, Andrew] Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
   [Jackson, Timothy L.; Simpson, Andrew] Kings Coll London, Sch Med, London WC2R 2LS, England.
   [Nicod, Elena; Angelis, Aris; Grimaccia, Federico; Kanavos, Panos] London Sch Econ, London WC2A 2AE, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London; University of London;
   London School Economics & Political Science
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM t.jackson1@nhs.net
RI Angelis, Aris/AAH-1532-2021
OI Angelis, Aris/0000-0002-0261-4634; Nicod, Elena/0000-0001-6798-9923;
   Jackson, Timothy/0000-0001-7618-1555
FU Thrombogenics
FX This project was supported by an unrestricted grant from Thrombogenics.
CR Abdelkader E, 2008, SURV OPHTHALMOL, V53, P368, DOI 10.1016/j.survophthal.2008.04.006
   APPIAH AP, 1988, AM J OPHTHALMOL, V106, P533, DOI 10.1016/0002-9394(88)90581-8
   Benz MS, 2010, OPHTHALMOLOGY, V117, P791, DOI 10.1016/j.ophtha.2009.11.005
   CHAN CK, 1995, OPHTHALMOLOGY, V102, P757, DOI 10.1016/S0161-6420(95)30958-X
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P4605, DOI 10.1167/iovs.10-6387
   Chauhan DS, 2000, ARCH OPHTHALMOL-CHIC, V118, P32
   de Smet MD, 2009, OPHTHALMOLOGY, V116, P1349, DOI 10.1016/j.ophtha.2009.03.051
   Ezra E, 2001, BRIT J OPHTHALMOL, V85, P102, DOI 10.1136/bjo.85.1.102
   FOOS RY, 1982, OPHTHALMOLOGY, V89, P1502
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   Garay-Aramburu G, 2005, Arch Soc Esp Oftalmol, V80, P741
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   HIKICHI T, 1995, BRIT J OPHTHALMOL, V79, P517, DOI 10.1136/bjo.79.6.517
   HIROKAWA H, 1986, AM J OPHTHALMOL, V101, P166, DOI 10.1016/0002-9394(86)90589-1
   Jackson TL, 2005, BRIT J OPHTHALMOL, V89, P395, DOI 10.1136/bjo.2004.055558
   Jackson TL, 2004, INVEST OPHTH VIS SCI, V45, P993, DOI 10.1167/iovs.03-0791
   Jackson TL, RETINA
   Jaycock PD, 2005, EYE, V19, P879, DOI 10.1038/sj.eye.6701679
   Johnson MW, 2010, AM J OPHTHALMOL, V149, P371, DOI 10.1016/j.ajo.2009.11.022
   Jorge R, 2006, AM J OPHTHALMOL, V142, P869, DOI 10.1016/j.ajo.2006.05.062
   LIOTTA LA, 1981, CANCER RES, V41, P4629
   Margherio AR, 1998, OPHTHALMOLOGY, V105, P1617, DOI 10.1016/S0161-6420(98)99027-3
   McHugh D, 2011, CLIN OPHTHALMOL, V5, P1543, DOI 10.2147/OPTH.S25348
   MELBERG NS, 1995, RETINA-J RET VIT DIS, V15, P192, DOI 10.1097/00006982-199515030-00002
   Meyer CH, 2004, GRAEF ARCH CLIN EXP, V242, P977, DOI 10.1007/s00417-004-0934-7
   Mori K, 2007, OPHTHALMOLOGY, V114, P127, DOI 10.1016/j.ophtha.2006.07.001
   Nordmann J, 1968, BIOL CHIRURGIE CORPS
   Ochoa-Contreras D, 2000, ACTA OPHTHALMOL SCAN, V78, P687, DOI 10.1034/j.1600-0420.2000.078006687.x
   Oono Y, 2011, CASE REP OPHTHALM, V2, P55, DOI 10.1159/000324462
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   Rodrigues IA, AM J OPHTHALMOL
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   RUSSELL SR, 1991, INVEST OPHTH VIS SCI, V32, P1986
   Sakamoto T, 2002, GRAEF ARCH CLIN EXP, V240, P423, DOI 10.1007/s00417-002-0454-2
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Sakuma T, 2006, EUR J OPHTHALMOL, V16, P138, DOI 10.1177/112067210601600122
   Schneider EW, 2011, CLIN OPHTHALMOL, V5, P1151, DOI 10.2147/OPTH.S14840
   Sebag J, 1992, ADDLERS PHYSL EYE, P271
   Simpson A, 2012, RETINA UNPUB
   Simpson A, SURV OPTHALMOL
   Simpson ARH, 2012, DIS VITREO MACULAR I
   Sonmez K, 2008, RETINA-J RET VIT DIS, V28, P1207, DOI 10.1097/IAE.0b013e31817b6b0f
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Stalmans P, 2010, RETINA-J RET VIT DIS, V30, P1122, DOI 10.1097/IAE.0b013e3181e0970a
   Tanner V, 2001, BRIT J OPHTHALMOL, V85, P1092, DOI 10.1136/bjo.85.9.1092
   Williams JG, 2001, OPHTHALMOLOGY, V108, P1902, DOI 10.1016/S0161-6420(01)00720-5
   Yamakiri K, 2008, GRAEF ARCH CLIN EXP, V246, P959, DOI 10.1007/s00417-008-0829-0
   Yanoff M, 1996, OCULAR PATHOLOGY, P419
NR 49
TC 62
Z9 63
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1503
EP 1511
DI 10.1097/IAE.0b013e31829232fd
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200003
PM 23714857
DA 2022-11-30
ER

PT J
AU Gamulescu, MA
   Panagakis, G
   Theek, C
   Helbig, H
AF Gamulescu, Maria-Andreea
   Panagakis, Georgios
   Theek, Carmen
   Helbig, Horst
TI Predictive Factors in OCT Analysis for Visual Outcome in Exudative AMD
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC MACULAR EDEMA; TRIAMCINOLONE ACETONIDE; RESOLUTION; INJECTION;
   INTEGRITY; ACUITY
AB Background. Reliable predictive factors for therapy outcome may enable treating physicians to counsel their patients more efficiently concerning probability of improvement or time point of discontinuation of a certain therapy. Methods. This is a retrospective analysis of 87 patients with exudative age-related macular degeneration who received three monthly intravitreal ranibizumab injections. Visual acuity before initiation of intravitreal therapy and 4-6 weeks after last intravitreal injection was compared and related to the preoperative visualisation of continuity of the outer retinal layers as assessed by OCT: external limiting membrane (ELM), inner photoreceptor segments (IPS), junction between inner and outer segments (IS/OS), and outer photoreceptor segments (OPS). Results. Visual acuity increased in 40 of 87 (46.0%) patients, it remained stable in 25 (28.7%), and 22 (25.3%) patients had decreased visual acuity four to six weeks after triple intravitreal ranibizumab injections. No statistically significant predictive value could be demonstrated for grade of continuity of outer retinal layers concerning visual acuity development. Conclusions. In our series of AMD patients, grade of continuity of outer retinal layers was not a significant predictive value for visual acuity development after triple ranibizumab injections.
C1 [Gamulescu, Maria-Andreea; Panagakis, Georgios; Helbig, Horst] Univ Eye Clin, D-93051 Regensburg, Germany.
   [Theek, Carmen] IFE Europe GmbH, D-45307 Essen, Germany.
C3 University of Regensburg
RP Gamulescu, MA (通讯作者)，Univ Eye Clin, Franz Josef Strauss Allee 11, D-93051 Regensburg, Germany.
EM agamulescu@web.de
CR Ahlers C, 2009, ACTA OPHTHALMOL, V87, P511, DOI 10.1111/j.1755-3768.2008.01468.x
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Brasil OFM, 2007, BRIT J OPHTHALMOL, V91, P761, DOI 10.1136/bjo.2006.105783
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oishi A, 2009, EYE, V23, P1411, DOI 10.1038/eye.2008.266
   Ota M, 2008, RETINA-J RET VIT DIS, V28, P1502, DOI 10.1097/IAE.0b013e3181840b3c
   Sakamoto A, 2009, GRAEF ARCH CLIN EXP, V247, P1325, DOI 10.1007/s00417-009-1107-5
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Srinivasan VJ, 2008, INVEST OPHTH VIS SCI, V49, P1571, DOI 10.1167/iovs.07-0838
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
   Wakabayashi T, 2009, OPHTHALMOLOGY, V116, P519, DOI 10.1016/j.ophtha.2008.10.001
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P3334, DOI 10.1167/iovs.10-6097
   YAMADA E, 1969, ARCH OPHTHALMOL-CHIC, V82, P151
NR 17
TC 12
Z9 12
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2012
VL 2012
AR 851648
DI 10.1155/2012/851648
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 979FK
UT WOS:000306801200001
PM 22523654
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cao, GF
   Liu, Y
   Yang, W
   Wan, J
   Yao, J
   Wan, YS
   Jiang, Q
AF Cao, Guo-Fan
   Liu, Yuan
   Yang, Wen
   Wan, Jerry
   Yao, Jin
   Wan, Yinsheng
   Jiang, Qin
TI Rapamycin sensitive mTOR activation mediates nerve growth factor (NGF)
   induced cell migration and pro-survival effects against hydrogen
   peroxide in retinal pigment epithelial cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Nerve growth factor; Hydrogen peroxide; mTOR; Cell survival; Cell
   migration; Retinal pigment epithelial cells
ID MACULAR DEGENERATION; OXIDATIVE STRESS; PROTEIN-KINASE;
   (-)-EPIGALLOCATECHIN GALLATE; POLY(ADP-RIBOSE) POLYMERASE;
   DOWN-REGULATION; RPE; DEATH; APOPTOSIS; SYSTEM
AB Patients with age related macular degeneration (AMD) have a loss of vision in the center of the visual field. Oxidative stress plays an important role in this progress. Nerve growth factor (NGF) is important for the survival and maintenance of sympathetic and sensory neurons and NGF eye drops improve visual acuity and electro-functional activity in patients with AMD. However, the molecular mechanisms and signaling events involved in this have not been fully investigated. Using cultured human retinal pigment epithelial (RPE) cells, we demonstrate here that NGF protects RPE cells against hydrogen peroxide (H(2)O(2))-induced cell apoptosis. NGF also induces RPE cell migration, the latter is important for retinal regeneration and the recovery from AMD. H(2)O(2) decreases S6 phosphorylation and cell viability, which is restored by NGF. Rapamycin, the pharmacologic inhibitor of mammalian target of rapamycin (mTOR), diminished NGF-induced S6 phosphorylation, cell migration and protective effects against oxidative stress. Collectively, we conclude that activation of rapamycin sensitive mTOR signaling mediates NGF induced cell migration and pro-survival effects in H(2)O(2) treated RPE cells. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Cao, Guo-Fan; Liu, Yuan; Yang, Wen; Yao, Jin; Jiang, Qin] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing 210029, Jiangsu, Peoples R China.
   [Wan, Jerry; Wan, Yinsheng] Providence Coll, Dept Biol, Providence, RI 02918 USA.
C3 Nanjing Medical University; Providence College
RP Jiang, Q (通讯作者)，Nanjing Med Univ, Affiliated Eye Hosp, 138 HanZhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM Jqin710@vip.sina.com
RI liu, yuan/L-9239-2018
OI liu, yuan/0000-0003-4887-907X
FU National Natural Science Foundation of China [ky1040511101 111116]
FX This work was generously supported by Grants from the National Natural
   Science Foundation of China (Nos. ky1040511101 111116).
CR ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5
   Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005
   Chan CM, 2010, MOL VIS, V16, P586
   Chan CM, 2008, MOL VIS, V14, P2528
   Chen L, 2010, LAB INVEST, V90, P762, DOI 10.1038/labinvest.2010.36
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544
   Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043
   Defoe DM, 2004, EXP EYE RES, V79, P51, DOI 10.1016/j.exer.2004.02.017
   Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jaswal J.S., 2006, AM J PHYSL HEART CIR
   Jiang Q, 2009, INT J MOL MED, V23, P771, DOI 10.3892/ijmm_00000191
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Lambiase A, 2005, INVEST OPHTH VIS SCI, V46, P3800, DOI 10.1167/iovs.05-0301
   Lambiase A, 1997, GRAEF ARCH CLIN EXP, V235, P780, DOI 10.1007/BF02332863
   Lambiase A, 2007, BRAIN RES, V1127, P45, DOI 10.1016/j.brainres.2006.09.102
   Lanni C, 2010, CURR PHARM DESIGN, V16, P698, DOI 10.2174/138161210790883741
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Micera A, 2004, CYTOKINE GROWTH F R, V15, P411, DOI 10.1016/j.cytogfr.2004.09.003
   Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak Michal, 2005, Klin Oczna, V107, P715
   PACIFICI RE, 1991, GERONTOLOGY, V37, P166
   Peng XH, 2007, MOL PHARMACOL, V71, P101, DOI 10.1124/mol.106.027367
   Schutt F, 2007, KLIN MONATSBL AUGENH, V224, P580, DOI 10.1055/s-2007-963339
   SILIPRANDI R, 1993, INVEST OPHTH VIS SCI, V34, P3232
   SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5
   TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3
NR 35
TC 40
Z9 42
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 28
PY 2011
VL 414
IS 3
BP 499
EP 505
DI 10.1016/j.bbrc.2011.09.094
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 868JL
UT WOS:000298519500010
PM 21968016
DA 2022-11-30
ER

PT J
AU Ku, CS
   Loy, EY
   Pawitan, Y
   Chia, KS
AF Ku, Chee Seng
   Loy, En Yun
   Pawitan, Yudi
   Chia, Kee Seng
TI The pursuit of genome-wide association studies: where are we now?
SO JOURNAL OF HUMAN GENETICS
LA English
DT Review
DE cancer; complex diseases; copy number variants; genome-wide association
   studies; indels; rare variants; resequencing; 1000 Genomes Project
ID CANCER SUSCEPTIBILITY LOCUS; COPY NUMBER VARIATION; SINGLE-NUCLEOTIDE
   POLYMORPHISMS; COMMON SEQUENCE VARIANTS; QT INTERVAL DURATION;
   COLORECTAL-CANCER; GENETIC-VARIATION; LUNG-CANCER; RISK LOCI; CONFER
   SUSCEPTIBILITY
AB It is now 5 years since the first genome-wide association studies (GWAS), published in 2005, identified a common risk allele with large effect size for age-related macular degeneration in a small sample set. Following this exciting finding, researchers have become optimistic about the prospect of the genome-wide association approach. However, most of the risk alleles identified in the subsequent GWAS for various complex diseases are common with small effect sizes ( odds ratio <1.5). So far, more than 450 GWAS have been published and the associations of greater than 2000 single nucleotide polymorphisms ( SNPs) or genetic loci were reported. The aim of this review paper is to give an overview of the evolving field of GWAS, discuss the progress that has been made by GWAS and some of the interesting findings, and summarize what we have learned over the past 5 years about the genetic basis of human complex diseases. This review will focus on GWAS of SNPs association for complex diseases but not studies of copy number variations. Journal of Human Genetics ( 2010) 55, 195-206; doi:10.1038/jhg.2010.19; published online 19 March 2010
C1 [Ku, Chee Seng; Loy, En Yun; Chia, Kee Seng] Natl Univ Singapore, Ctr Mol Epidemiol, Dept Epidemiol & Publ Hlth, Yong Loo Lin Sch Med, Singapore 117597, Singapore.
   [Pawitan, Yudi; Chia, Kee Seng] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
C3 National University of Singapore; Karolinska Institutet
RP Ku, CS (通讯作者)，Natl Univ Singapore, Ctr Mol Epidemiol, Dept Epidemiol & Publ Hlth, Yong Loo Lin Sch Med, 16 Med Dr, Singapore 117597, Singapore.
EM cmekcs@nus.edu.sg; ephcks@nus.edu.sg
RI CHIA, Kee Seng/C-5790-2011
CR Adeyemo A, 2010, PUBLIC HEALTH GENOMI, V13, P72, DOI 10.1159/000218711
   Ahn SM, 2009, GENOME RES, V19, P1622, DOI 10.1101/gr.092197.109
   Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409
   Amos CI, 2008, NAT GENET, V40, P616, DOI 10.1038/ng.109
   Arking DE, 2006, NAT GENET, V38, P644, DOI 10.1038/ng1790
   Asano K, 2009, NAT GENET, V41, P1325, DOI 10.1038/ng.482
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801
   Barrett JC, 2009, NAT GENET, V41, P1330, DOI 10.1038/ng.483
   Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381
   Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517
   Bishop DT, 2009, NAT GENET, V41, P920, DOI 10.1038/ng.411
   Broderick P, 2007, NAT GENET, V39, P1315, DOI 10.1038/ng.2007.18
   Budarf ML, 2009, TRENDS GENET, V25, P137, DOI 10.1016/j.tig.2009.01.001
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cahan P, 2009, NAT GENET, V41, P430, DOI 10.1038/ng.350
   Chanock SJ, 2008, NATURE, V452, P537, DOI 10.1038/452537a
   Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a
   Chen W, 2009, EXP EYE RES, V89, P292, DOI 10.1016/j.exer.2008.10.017
   Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Conrad S, 2009, NATURE, V460, DOI 10.1038/nature08353
   Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537
   Coon KD, 2007, J CLIN PSYCHIAT, V68, P613, DOI 10.4088/JCP.v68n0419
   Cooper JD, 2008, NAT GENET, V40, P1399, DOI 10.1038/ng.249
   de Bakker PIW, 2008, HUM MOL GENET, V17, pR122, DOI 10.1093/hmg/ddn288
   De Jager PL, 2009, NAT GENET, V41, P776, DOI 10.1038/ng.401
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887
   Easton DF, 2008, HUM MOL GENET, V17, pR109, DOI 10.1093/hmg/ddn287
   Eberle MA, 2007, PLOS GENET, V3, P1827, DOI 10.1371/journal.pgen.0030170
   Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90
   Eeles RA, 2009, NAT GENET, V41, P1116, DOI 10.1038/ng.450
   Elbaz A, 2006, LANCET NEUROL, V5, P917, DOI 10.1016/S1474-4422(06)70579-8
   Florez JC, 2008, J CLIN ENDOCR METAB, V93, P4633, DOI 10.1210/jc.2008-1345
   Franke A, 2008, NAT GENET, V40, P1319, DOI 10.1038/ng.221
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554
   Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6
   Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284
   Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160
   Graham RR, 2009, J INTERN MED, V265, P680, DOI 10.1111/j.1365-2796.2009.02096.x
   Gudmundsson J, 2008, NAT GENET, V40, P281, DOI 10.1038/ng.89
   Gudmundsson J, 2007, NAT GENET, V39, P977, DOI 10.1038/ng2062
   Gudmundsson J, 2007, NAT GENET, V39, P631, DOI 10.1038/ng1999
   Gudmundsson J, 2009, NAT GENET, V41, P1122, DOI 10.1038/ng.448
   Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092
   Han JW, 2009, NAT GENET, V41, P1234, DOI 10.1038/ng.472
   Hannan AJ, 2010, TRENDS GENET, V26, P59, DOI 10.1016/j.tig.2009.11.008
   Harold D, 2009, NAT GENET, V41, P1088, DOI 10.1038/ng.440
   He CY, 2009, NAT GENET, V41, P724, DOI 10.1038/ng.385
   Heap GA, 2009, HUM MOL GENET, V18, pR101, DOI [10.1093/hmg/ddp001, 10.1093/hmg/ddp473]
   Heid IM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000694
   Helgadottir A, 2008, NAT GENET, V40, P217, DOI 10.1038/ng.72
   Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842
   Henrichsen CN, 2009, NAT GENET, V41, P424, DOI 10.1038/ng.345
   Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695
   Hirakawa M, 2002, NUCLEIC ACIDS RES, V30, P158, DOI 10.1093/nar/30.1.158
   Hirschhorn JN, 2009, NEW ENGL J MED, V360, P1699, DOI 10.1056/NEJMp0808934
   Hollox EJ, 2008, NAT GENET, V40, P23, DOI 10.1038/ng.2007.48
   Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262
   Hung RJ, 2008, NATURE, V452, P633, DOI 10.1038/nature06885
   Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075
   Imielinski M, 2009, NAT GENET, V41, P1335, DOI 10.1038/ng.489
   Ioannidis JPA, 2009, NAT REV GENET, V10, P318, DOI 10.1038/nrg2544
   Kanetsky PA, 2009, NAT GENET, V41, P811, DOI 10.1038/ng.393
   Kim JI, 2009, NATURE, V460, P1011, DOI 10.1038/nature08211
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kraft P, 2009, NEW ENGL J MED, V360, P1701, DOI 10.1056/NEJMp0810107
   Kuehn BM, 2008, JAMA-J AM MED ASSOC, V300, P2715, DOI 10.1001/jama.2008.823
   Kugathasan S, 2008, NAT GENET, V40, P1211, DOI 10.1038/ng.203
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lettre G, 2008, HUM MOL GENET, V17, pR116, DOI 10.1093/hmg/ddn246
   Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254
   Li H, 2008, ARCH NEUROL-CHICAGO, V65, P45, DOI 10.1001/archneurol.2007.3
   Li MY, 2008, EUR J HUM GENET, V16, P635, DOI 10.1038/sj.ejhg.5202007
   Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242
   Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058
   Lyon HN, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030061
   Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a
   Manolio TA, 2007, NAT GENET, V39, P1045, DOI 10.1038/ng2127
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902
   Mathew CG, 2008, NAT REV GENET, V9, P9, DOI 10.1038/nrg2203
   McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696
   McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   McKay JD, 2008, NAT GENET, V40, P1404, DOI 10.1038/ng.254
   McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447
   Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014
   Mototani H, 2005, HUM MOL GENET, V14, P1009, DOI 10.1093/hmg/ddi093
   Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311
   Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728
   Newton-Cheh C, 2009, NAT GENET, V41, P399, DOI 10.1038/ng.364
   Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250
   Obara W, 2003, J HUM GENET, V48, P293, DOI 10.1007/s10038-003-0027-1
   Ohnishi Y, 2001, J HUM GENET, V46, P471, DOI 10.1007/s100380170047
   Oksenberg JR, 2008, NAT REV GENET, V9, P516, DOI 10.1038/nrg2395
   Ong KK, 2009, NAT GENET, V41, P729, DOI 10.1038/ng.382
   Owen MJ, 2009, CURR OPIN GENET DEV, V19, P266, DOI 10.1016/j.gde.2009.02.008
   Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Pennisi E, 2007, SCIENCE, V318, P1842, DOI 10.1126/science.318.5858.1842
   Perry JRB, 2009, NAT GENET, V41, P648, DOI 10.1038/ng.386
   Pfeufer A, 2009, NAT GENET, V41, P407, DOI 10.1038/ng.362
   Pharoah PDP, 2008, NEW ENGL J MED, V358, P2796, DOI 10.1056/NEJMsa0708739
   Plenge RM, 2009, CURR OPIN RHEUMATOL, V21, P262, DOI 10.1097/BOR.0b013e32832a2e2d
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Prokopenko I, 2008, TRENDS GENET, V24, P613, DOI 10.1016/j.tig.2008.09.004
   Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185
   Pushkarev D, 2009, NAT BIOTECHNOL, V27, P847, DOI 10.1038/nbt.1561
   Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296
   Ragoussis J, 2009, ANNU REV GENOM HUM G, V10, P117, DOI 10.1146/annurev-genom-082908-150116
   Rapley EA, 2009, NAT GENET, V41, P807, DOI 10.1038/ng.394
   Raychaudhuri S, 2008, NAT GENET, V40, P1216, DOI 10.1038/ng.233
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Romeo S, 2007, NAT GENET, V39, P513, DOI 10.1038/ng1984
   Sakamoto H, 2008, NAT GENET, V40, P730, DOI 10.1038/ng.152
   Satake W, 2009, NAT GENET, V41, P1303, DOI 10.1038/ng.485
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Schork NJ, 2009, CURR OPIN GENET DEV, V19, P212, DOI 10.1016/j.gde.2009.04.010
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   Sebat J, 2007, SCIENCE, V316, P445, DOI 10.1126/science.1138659
   Shete S, 2009, NAT GENET, V41, P899, DOI 10.1038/ng.407
   Shi JX, 2009, NATURE, V460, P753, DOI 10.1038/nature08192
   Shimazaki A, 2005, DIABETES, V54, P1171, DOI 10.2337/diabetes.54.4.1171
   Silverberg MS, 2009, NAT GENET, V41, P216, DOI 10.1038/ng.275
   Simon-Sanchez J, 2009, NAT GENET, V41, P1308, DOI 10.1038/ng.487
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Stacey SN, 2009, NAT GENET, V41, P909, DOI 10.1038/ng.412
   Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186
   Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043
   Stolk L, 2009, NAT GENET, V41, P645, DOI 10.1038/ng.387
   Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239
   Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678
   Sulem P, 2009, NAT GENET, V41, P734, DOI 10.1038/ng.383
   Tanaka N, 2003, DIABETES, V52, P2848, DOI 10.2337/diabetes.52.11.2848
   Tenesa A, 2008, NAT GENET, V40, P631, DOI 10.1038/ng.133
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thomas G, 2008, NAT GENET, V40, P310, DOI 10.1038/ng.91
   Thomas G, 2009, NAT GENET, V41, P579, DOI 10.1038/ng.353
   Thorgeirsson TE, 2008, NATURE, V452, P638, DOI 10.1038/nature06846
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   Tomlinson I, 2007, NAT GENET, V39, P984, DOI 10.1038/ng2085
   Tomlinson IPM, 2008, NAT GENET, V40, P623, DOI 10.1038/ng.111
   Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406
   Unoki H, 2008, NAT GENET, V40, P1098, DOI 10.1038/ng.208
   Wain LV, 2009, LANCET, V374, P340, DOI 10.1016/S0140-6736(09)60249-X
   Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174
   Wang J, 2008, NATURE, V456, P60, DOI 10.1038/nature07484
   Wang YF, 2008, NAT GENET, V40, P1407, DOI 10.1038/ng.273
   Webster JA, 2008, NEURODEGENER DIS, V5, P60, DOI 10.1159/000110789
   Wheeler DA, 2008, NATURE, V452, P872, DOI 10.1038/nature06884
   Winckler W, 2007, DIABETES, V56, P685, DOI 10.2337/db06-0202
   Wu XF, 2009, NAT GENET, V41, P991, DOI 10.1038/ng.421
   Yamazaki K, 2005, HUM MOL GENET, V14, P3499, DOI 10.1093/hmg/ddi379
   Yasuda K, 2008, NAT GENET, V40, P1092, DOI 10.1038/ng.207
   Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022
   Zanke BW, 2007, NAT GENET, V39, P989, DOI 10.1038/ng2089
   Zeggini E, 2009, PHARMACOGENOMICS, V10, P191, DOI 10.2217/14622416.10.2.191
   Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120
   Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364
   Zhang XJ, 2009, NAT GENET, V41, P205, DOI 10.1038/ng.310
   Zheng SL, 2008, NEW ENGL J MED, V358, P910, DOI 10.1056/NEJMoa075819
   Zheng W, 2009, NAT GENET, V41, P324, DOI 10.1038/ng.318
   Zhernakova A, 2009, NAT REV GENET, V10, P43, DOI 10.1038/nrg2489
NR 171
TC 131
Z9 142
U1 1
U2 37
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD APR
PY 2010
VL 55
IS 4
BP 195
EP 206
DI 10.1038/jhg.2010.19
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 587UD
UT WOS:000277017900001
PM 20300123
OA Bronze
DA 2022-11-30
ER

PT J
AU Noda, K
   She, H
   Nakazawa, T
   Hisatomi, T
   Nakao, S
   Almulki, L
   Zandi, S
   Miyahara, S
   Ito, Y
   Thomas, KL
   Garland, RC
   Miller, JW
   Gragoudas, ES
   Mashima, Y
   Hafezi-Moghadam, A
AF Noda, Kousuke
   She, Haicheng
   Nakazawa, Toru
   Hisatomi, Toshio
   Nakao, Shintaro
   Almulki, Lama
   Zandi, Souska
   Miyahara, Shinsuke
   Ito, Yasuhiro
   Thomas, Kennard L.
   Garland, Rebecca C.
   Miller, Joan W.
   Gragoudas, Evangelos S.
   Mashima, Yukihiko
   Hafezi-Moghadam, Ali
TI Vascular adhesion protein-1 blockade suppresses choroidal
   neovascularization
SO FASEB JOURNAL
LA English
DT Article
DE age-related macular degeneration; leukocyte recruitment; macrophage;
   angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; GENE-EXPRESSION; BRUCHS
   MEMBRANE; INFLAMMATION; MACROPHAGES; ANGIOGENESIS; PATHOGENESIS;
   INDUCTION; MOLECULES
AB Vascular adhesion protein-1 (VAP-1) is an endothelial cell adhesion molecule involved in leukocyte recruitment. Leukocytes and, in particular, macrophages play an important role in the development of choroidal neovascularization (CNV), an integral component of age-related macular degeneration (AMD). Previously, we showed a role for VAP-1 in ocular inflammation. Here, we investigate the expression of VAP-1 in the choroid and its role in CNV development. VAP-1 was expressed in the choroid, exclusively in the vessels, and colocalized in the vessels of the CNV lesions. VAP-1 blockade with a novel and specific inhibitor significantly decreased CNV size, fluorescent angiographic leakage, and the accumulation of macrophages in the CNV lesions. Furthermore, VAP-1 blockade significantly reduced the expression of inflammation-associated molecules such as tumor necrosis factor (TNF)-alpha, monocyte chemoattractant protein (MCP)-1, and intercellular adhesion molecule (ICAM) - 1. This work provides evidence for an important role of VAP-1 in the recruitment of macrophages to CNV lesions, establishing a novel link between VAP-1 and angiogenesis. Inhibition of VAP-1 may become a new therapeutic strategy in the treatment of AMD.
C1 [Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA.
   [Noda, Kousuke; She, Haicheng; Nakazawa, Toru; Hisatomi, Toshio; Nakao, Shintaro; Almulki, Lama; Zandi, Souska; Miyahara, Shinsuke; Ito, Yasuhiro; Thomas, Kennard L.; Garland, Rebecca C.; Miller, Joan W.; Gragoudas, Evangelos S.; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Mashima, Yukihiko] R Tech Ueno Ltd, Tokyo, Japan.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School
RP Hafezi-Moghadam, A (通讯作者)，Massachusetts Eye & Ear Infirm, Angiogenesis Lab, 325 Cambridge St,3rd Floor, Boston, MA 02114 USA.
EM Ali_Hafezi-Moghadam@meei.harvard.edu
OI Zandi, Souska/0000-0001-9351-4278; Miller, Joan/0000-0003-2046-3996;
   Hisatomi, Toshio/0000-0003-2552-9595; Hafezi-Moghadam,
   Ali/0000-0002-5336-0697
FU NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086933] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
   [K08AI050775] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY014104,
   EY14104] Funding Source: Medline; NHLBI NIH HHS [HL086933, R01 HL086933]
   Funding Source: Medline; NIAID NIH HHS [AI050775, K08 AI050775] Funding
   Source: Medline
CR Akin E, 2001, INFECT IMMUN, V69, P1774, DOI 10.1128/IAI.69.3.1774-1780.2001
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Eckhart L, 2000, BIOCHEM BIOPH RES CO, V271, P726, DOI 10.1006/bbrc.2000.2716
   ELNER SG, 1991, LAB INVEST, V64, P819
   ELNER VM, 1990, AM J PATHOL, V136, P745
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Jaakkola K, 2000, J AM COLL CARDIOL, V36, P122, DOI 10.1016/S0735-1097(00)00706-3
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Koskinen K, 2004, BLOOD, V103, P3388, DOI 10.1182/blood-2003-09-3275
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lehr HA, 1999, J HISTOCHEM CYTOCHEM, V47, P119, DOI 10.1177/002215549904700113
   Lehr HA, 1997, J HISTOCHEM CYTOCHEM, V45, P1559, DOI 10.1177/002215549704501112
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martelius T, 2000, AM J PATHOL, V157, P1229, DOI 10.1016/S0002-9440(10)64638-X
   Matyus P, 2004, CURR MED CHEM, V11, P1285, DOI 10.2174/0929867043365305
   Merinen M, 2005, AM J PATHOL, V166, P793, DOI 10.1016/S0002-9440(10)62300-0
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Noda K, 2008, FASEB J, V22, P1094, DOI 10.1096/fj.07-9377com
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341
   SALMI M, 1993, J EXP MED, V178, P2255, DOI 10.1084/jem.178.6.2255
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   She HC, 2007, INVEST OPHTH VIS SCI, V48, P2268, DOI 10.1167/iovs.06-0979
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Singh B, 2003, VIRCHOWS ARCH, V442, P491, DOI 10.1007/s00428-003-0802-6
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Yamashiro K, 2001, INVEST OPHTH VIS SCI, V42, P1553
   Zambarakji HJ, 2006, INVEST OPHTH VIS SCI, V47, P2623, DOI 10.1167/iovs.05-0855
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 45
TC 53
Z9 59
U1 0
U2 2
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2008
VL 22
IS 8
BP 2928
EP 2935
DI 10.1096/fj.07-105346
PG 8
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 332NI
UT WOS:000258089300033
PM 18436961
OA Green Published
DA 2022-11-30
ER

PT J
AU Kroyer, K
   la Cour, M
   Larsen, M
AF Kroyer, Kristian
   la Cour, Morten
   Larsen, Michael
TI Dissociation of rod and cone sensitivity by acute localized retinal
   pigment epithelium loss
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE perimetry; retinal pigment epithelium rip; retinal pigment epithelium
   tear; scotopic and photopic sensitivity
ID TEARS
AB Purpose: To assess the impact of acute retinal pigment epithelium (RPE) loss on photopic and scotopic sensitivity.
   Methods: A 68-year-old woman who had been followed for drusenoid RPE detachment in age-related macular degeneration presented with an acute spontaneous retinal pigment epithelium tear. Three months later, she was seen for routine follow-up and was examined by manual photopic and scotopic threshold perimetry (a static 0.46-degree-diameter 660 nm stimulus under photopic conditions; then, following 25 min of dark adaptation, a static 0.46-degree-diameter 532 nm stimulus under scotopic conditions). The stimuli were applied over the RPE defect and at reference points of similar eccentricity in the opposite vertical haemifield of the same eye where the RPE remained present.
   Results: Acute RPE loss was associated with only a marginal reduction of photopic sensitivity (-1.5 dB) but a pronounced loss of scotopic sensitivity (-19.5 dB).
   Conclusion: Our observations show that RPE is essential for scotopic but not for photopic retinal function, supporting the theory that cone photopigment regeneration occurs within the human neurosensory retina independently of the RPE.
C1 [Kroyer, Kristian; la Cour, Morten; Larsen, Michael] Univ Copenhagen, Glostrup Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
C3 University of Copenhagen
RP Kroyer, K (通讯作者)，Univ Copenhagen, Glostrup Hosp, Dept Ophthalmol, Ndr Ringvej 57, DK-2600 Glostrup, Denmark.
EM kroyer@dadlnet.dk
RI la Cour, Morten/L-1600-2013; Larsen, Michael/E-9620-2010
OI Larsen, Michael/0000-0002-5172-5891; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
CR BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   MARMOR MF, 1978, SURV OPHTHALMOL, V22, P279, DOI 10.1016/0039-6257(78)90074-7
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 7
TC 6
Z9 6
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2008
VL 86
IS 3
BP 338
EP 340
DI 10.1111/j.1600-0420.2007.00993.x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 317LB
UT WOS:000257020600017
PM 17662094
OA Bronze
DA 2022-11-30
ER

PT J
AU Goodrow, EF
   Wilson, TA
   Houde, SC
   Vishwanathan, R
   Scollin, PA
   Handelman, G
   Nicolosi, RJ
AF Goodrow, Elizabeth F.
   Wilson, Thomas A.
   Houde, Susan Crocker
   Vishwanathan, Rohini
   Scollin, Patrick A.
   Handelman, Garry
   Nicolosi, Robert J.
TI Consumption of one egg per day increases serum lutein and zeaxanthin
   concentrations in older adults without altering serum lipid and
   lipoprotein cholesterol concentrations
SO JOURNAL OF NUTRITION
LA English
DT Article
ID PIGMENT OPTICAL-DENSITY; MACULAR PIGMENT; DIETARY-CHOLESTEROL; PLASMA;
   AGE; MEN; CAROTENOIDS; SUPPLEMENTS; RATIO; LDL
AB Lutein and zeaxanthin accumulate in the macular pigment of the retina, and area reported to be associated with a reduced incidence of age-related macular degeneration. A rich source of lutein and zeaxanthin in the American diet is the yolk of chicken eggs. Thus, the objective of the study was to investigate the effect of consuming 1 egg/d for 5 wk on the serum concentrations of lutein, zeaxanthin, lipids, and lipoprotein cholesterol in individuals > 60 y of age. In a randomized crossover design, 33 men and women participated in the 18-wk study, which included one run-in and one washout period of no eggs prior to and between two 5-wk interventions of either consuming 1 egg or egg substitute/d. Serum lutein 26% (P < 0.001) and zeaxanthin 38% (P < 0.001) concentrations increased after 5-wk of I egg/d compared with the phase prior to consuming eggs. Serum concentrations of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides were not affected. These findings indicate that in older adults, 5 wk of consuming 1 egg/d significantly increases serum lutein and zeaxanthin concentrations without elevating serum lipids and lipoprotein cholesterol concentrations.
C1 Univ Massachusetts, Ctr Hlth & Dis Res, Dept Clin Lab & Nutr Sci, Lowell, MA 01854 USA.
   Univ Massachusetts, Dept Nursing, Lowell, MA 01854 USA.
   Univ Massachusetts, Dept Community Hlth & Sustainabil, Lowell, MA 01854 USA.
C3 University of Massachusetts System; University of Massachusetts Lowell;
   University of Massachusetts System; University of Massachusetts Lowell;
   University of Massachusetts System; University of Massachusetts Lowell
RP Nicolosi, RJ (通讯作者)，Univ Massachusetts, Ctr Hlth & Dis Res, Dept Clin Lab & Nutr Sci, Lowell, MA 01854 USA.
EM robert_nicolosi@uml.edu
OI Wilson, Thomas/0000-0001-8363-4356
CR ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BUCOLO G, 1973, CLIN CHEM, V19, P476
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Clark RM, 2006, J NUTR, V136, P601, DOI 10.1093/jn/136.3.601
   Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   ERDMAN JW, 1993, CAROTENOIDS HUMAN HL
   ETTINGER WH, 1992, CIRCULATION, V86, P858, DOI 10.1161/01.CIR.86.3.858
   Ferrara A, 1997, CIRCULATION, V96, P37
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   GARRY PJ, 1992, AM J CLIN NUTR, V55, P682, DOI 10.1093/ajcn/55.3.682
   Greene CM, 2005, J NUTR, V135, P2793, DOI 10.1093/jn/135.12.2793
   Gruber M, 2004, J NUTR, V134, P2387, DOI 10.1093/jn/134.9.2387
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P336
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Houde S, 2007, VISION LOSS OLDER AD
   Howell WH, 1997, AM J CLIN NUTR, V65, P1747, DOI 10.1093/ajcn/65.6.1747
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LICHTENSTEIN AH, 1994, ARTERIOSCLER THROMB, V14, P168, DOI 10.1161/01.ATV.14.1.168
   *NAT EYE I, 1993, NIH PUB
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SPERLING HG, 1980, VISION RES, V20, P1117, DOI 10.1016/0042-6989(80)90049-8
   Surai PF, 2000, EUR J CLIN NUTR, V54, P298, DOI 10.1038/sj.ejcn.1600939
   Thurmann PA, 2005, AM J CLIN NUTR, V82, P88
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Weggemans RM, 2001, AM J CLIN NUTR, V73, P885
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
   ZORGE I, 1999, INVEST OPHTH VIS SCI, V40, pS679
NR 38
TC 90
Z9 96
U1 1
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD OCT
PY 2006
VL 136
IS 10
BP 2519
EP 2524
DI 10.1093/jn/136.10.2519
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 089OH
UT WOS:000240889600012
PM 16988120
OA Bronze
DA 2022-11-30
ER

PT J
AU Constable, I
   Shen, WY
   Rakoczy, E
AF Constable, I
   Shen, WY
   Rakoczy, E
TI Emerging biological therapies for age-related macula degeneration
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE age-related macular degeneration; anti-VEGF antibody fragment; anti-VEGF
   pegylated RNA aptamer; cortisene; triamcinolone
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; MEDIATED GENE-TRANSFER; FACTOR-H
   POLYMORPHISM; OCULAR NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE;
   PHOTODYNAMIC THERAPY; STARGARDT-DISEASE; BETA-CAROTENE
AB Age-related macular degeneration (AMD) has emerged as the dominant cause of irretrievable visual loss in most developed countries achieving increasing longevity. The major cause of rapid and severe visual loss is the development of choroidal neovascularisation under the macula (exudative or wet AMD). Physical treatments, especially thermal laser and photodynamic therapy following intravenous verteporfin, have made statistically significant but modest progress in limiting visual loss, whereas surgical translocation of the macula and even light or electrically sensitive retinal implants are spectacular, but likely to only ever benefit a few. Intravitreal fine needle injections and slow release implants of steroid derivatives have opened new areas for investigation. The blocking of endothelial receptors for vascular endothelial growth factor by RNA-based aptamer or immune-protected antibody fragments has been the subject of intensive scientific development and large scale clinical trials. This approach may expand the range of AMD patients amenable to treatment. Additional therapeutic gains await measures to modify photoreceptor cell loss and subretinal fibrosis involving the retinal pigment epithelium as well as prevention or treatment for pigment epithelial detachment. Epidemiological associations with smoking and diet, and antioxidant dietary supplements offer important strategies for prevention.
C1 Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Nedlands, WA 6009, Australia.
C3 Lions Eye Institute; University of Western Australia
RP Constable, I (通讯作者)，Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM ijc@cyllene.uwa.edu.au
OI constable, ian/0000-0002-2140-6478
CR Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Adamus G, 2003, J AUTOIMMUN, V21, P121, DOI 10.1016/S0896-8411(03)00092-1
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Ali RR, 2000, NAT GENET, V25, P306, DOI 10.1038/77068
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Bainbridge JWB, 2003, CLIN SCI, V104, P561, DOI 10.1042/CS20020314
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Burger C, 2004, MOL THER, V10, P302, DOI 10.1016/j.ymthe.2004.05.024
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chakravarthy U, 2000, EYE, V14, P151, DOI 10.1038/eye.2000.45
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Comer Grant M, 2005, Expert Opin Emerg Drugs, V10, P119, DOI 10.1517/14728214.10.2.441
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   Das A, 2004, ARCH OPHTHALMOL-CHIC, V122, P1844, DOI 10.1001/archopht.122.12.1844
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2005, NAT REV DRUG DISCOV, V4, P187, DOI 10.1038/nrd1677
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   Fujii GY, 2002, AM J OPHTHALMOL, V134, P69, DOI 10.1016/S0002-9394(02)01511-8
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795
   GOTTLIEB JL, 2002, JAMA-J AM MED ASSOC, V28, P2233
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdi HK, 2003, FRONT BIOSCI-LANDMRK, V8, pE305, DOI 10.2741/1019
   Hauswirth WW, 2000, PROG RETIN EYE RES, V19, P689, DOI 10.1016/S1350-9462(00)00007-0
   Hennig AK, 2004, MOL THER, V10, P106, DOI 10.1016/j.ymthe.2004.03.018
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Joseph DP, 2003, RETINA-J RET VIT DIS, V23, P463, DOI 10.1097/00006982-200308000-00003
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lau D, 2000, INVEST OPHTH VIS SCI, V41, P3622
   Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Marano RJ, 2004, J BIOL CHEM, V279, P37808, DOI 10.1074/jbc.M400047200
   Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Petersen SV, 2003, BIOCHEM J, V374, P199, DOI 10.1042/BJ20030313
   Provost N, 2005, MOL THER, V11, P275, DOI 10.1016/j.ymthe.2004.09.022
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rakoczy PE, 1999, EXP EYE RES, V69, P367, DOI 10.1006/exer.1999.0700
   Rolling F, 2004, GENE THER, V11, pS26, DOI 10.1038/sj.gt.3302366
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schlichtenbrede FC, 2003, J GENE MED, V5, P757, DOI 10.1002/jgm.401
   Schuettauf F, 2004, CURR EYE RES, V29, P379, DOI 10.1080/02713680490517872
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Semba RD, 2003, MED HYPOTHESES, V61, P465, DOI 10.1016/S0306-9877(03)00198-1
   Shen WY, 2002, LAB INVEST, V82, P167, DOI 10.1038/labinvest.3780409
   Shen WY, 2003, J GENE MED, V5, P576, DOI 10.1002/jgm.375
   SIES H, 1992, ANN NY ACAD SCI, V669, P7
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Stringham JM, 2005, NUTR REV, V63, P59, DOI 10.1111/j.1753-4887.2005.tb00122.x
   Sugano E, 2003, EXP EYE RES, V77, P203, DOI 10.1016/S0014-4835(03)00115-5
   Takaya K, 2004, RETINA-J RET VIT DIS, V24, P23, DOI 10.1097/00006982-200402000-00004
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang D, 2002, BIOGERONTOLOGY, V3, P61, DOI 10.1023/A:1015259413857
   Ziche M, 2004, CURR DRUG TARGETS, V5, P485, DOI 10.2174/1389450043345371
NR 108
TC 5
Z9 5
U1 2
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD OCT
PY 2005
VL 5
IS 10
BP 1373
EP 1385
DI 10.1517/14712598.5.10.1373
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 977IV
UT WOS:000232797700009
PM 16197342
DA 2022-11-30
ER

PT J
AU Hattenbach, LO
   Falk, B
   Nurnberger, F
   Koch, FHJ
   Ohrloff, C
AF Hattenbach, LO
   Falk, B
   Nurnberger, F
   Koch, FHJ
   Ohrloff, C
TI Detection of inducible nitric oxide synthase and vascular endothelial
   growth factor in choroidal neovascular membranes
SO OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; nitric
   oxide; vascular endothelial growth factor
ID PROLIFERATIVE DIABETIC-RETINOPATHY; PIGMENTED EPITHELIAL-CELLS; MACULAR
   DEGENERATION; TUMOR-GROWTH; EXPRESSION; ANGIOGENESIS; DISEASE; BETA
AB Vascular endothelial growth factor (VEGF) is among the cytokines which have been implicated in the pathogenesis of choroidal neovascularization secondary to age-related macular degeneration (ARMD). There is, however, evidence that intercellular signaling molecules, such as nitric oxide (NO), are involved in this process. NO is synthesized via the inducible isoform of NO synthase iNOS), which is expressed after induction by cytokines. In the current study, we investigated whether VEGF and iNOS are coexpressed in choroidal neovascular membranes (n = 7) from patients with ARMD. Immunohistochemistry was performed on cryosections with anti-iNOS and anti-VEGF. Moderate to intense immunostaining for iNOS and VEGF was observed in retinal pigment epithelial cells, macrophages, and in spatial relation to vessel walls. As scored by light microscopy, we found a significant correlation between immunoreactivity for VEGF and iNOS (p < 0.0341) in vascular endothelial cells. Our study supports a significant role for iNOS in the pathogenesis of neovascularization and membrane growth in ARMD. Moreover, our findings suggest a possible relationship between NO and VEGF in the regulation of pathologic angiogenesis in this disease. Copyright (C) 2002 S. Karger AG, Basel.
C1 Univ Frankfurt Klinikum, Klin Augenheilkunde, D-60590 Frankfurt, Germany.
C3 Goethe University Frankfurt; Goethe University Frankfurt Hospital
RP Hattenbach, LO (通讯作者)，Univ Frankfurt Klinikum, Klin Augenheilkunde, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
RI Hattenbach, Lars-Olof/AAC-5621-2020
OI Hattenbach, Lars-Olof/0000-0002-5275-8118
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Armstrong D, 1998, OPHTHALMOLOGICA, V212, P410, DOI 10.1159/000027378
   Channon KM, 1997, ARTERIOSCL THROM VAS, V17, P1313, DOI 10.1161/01.ATV.17.7.1313
   CHAUDHURY AR, 1996, J CELL BIOCHEM, V63, P125
   COBBS CS, 1995, CANCER RES, V55, P727
   Doi K, 1996, CANCER-AM CANCER SOC, V77, P1598, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1598::AID-CNCR3>3.0.CO;2-A
   Farrell AJ, 1996, ANN RHEUM DIS, V55, P7, DOI 10.1136/ard.55.1.7
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   GOUREAU O, 1994, BIOCHEM BIOPH RES CO, V198, P120, DOI 10.1006/bbrc.1994.1017
   GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hattenbach LO, 1999, RETINA-J RET VIT DIS, V19, P383, DOI 10.1097/00006982-199909000-00003
   Hattenbach LO, 2000, INVEST OPHTH VIS SCI, V41, P213
   Hirase K, 1998, ARCH OPHTHALMOL-CHIC, V116, P738, DOI 10.1001/archopht.116.6.738
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   LUTTY GA, 1994, CURR EYE RES, V13, P125, DOI 10.3109/02713689409042407
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   Miller JW, 1997, AM J PATHOL, V151, P13
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Nitsch DD, 1997, AM J PATHOL, V150, P889
   Orucevic A, 1996, BRIT J CANCER, V73, P189, DOI 10.1038/bjc.1996.34
   SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444
   SHIMA D, 1995, MOL MED, V2, P182
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   TILTON RG, 1993, DIABETES, V42, P221, DOI 10.2337/diabetes.42.2.221
   Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451
NR 34
TC 31
Z9 38
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD MAY-JUN
PY 2002
VL 216
IS 3
BP 209
EP 214
DI 10.1159/000059634
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 568YD
UT WOS:000176571700011
PM 12065859
DA 2022-11-30
ER

PT J
AU Tariq, A
   Mahroo, OA
   Williams, KM
   Liew, SHM
   Beatty, S
   Gilbert, CE
   Van Kuijk, FJ
   Hammond, CJ
AF Tariq, Ambreen
   Mahroo, Omar A.
   Williams, Katie M.
   Liew, S. H. Melissa
   Beatty, Stephen
   Gilbert, Clare E.
   Van Kuijk, Frederik J.
   Hammond, Christopher J.
TI The Heritability of the Ring-Like Distribution of Macular Pigment
   Assessed in a Twin Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular pigment; heritability; lutein
ID AGE-RELATED MACULOPATHY; SPATIAL-DISTRIBUTION; SUPPLEMENTAL LUTEIN;
   OXIDATIVE STRESS; OPTICAL-DENSITY; PROTECTIVE ROLE; ZEAXANTHIN;
   DEGENERATION; PROFILE
AB PURPOSE. It has been suggested that ring-like patterns of macular pigment, as measured with dual wavelength autofluorescence, are observed less frequently in subjects with age-related maculopathy. We explored relative contributions of genetic and environmental factors in macular pigment optical density (MPOD) distributions using a classic twin study.
   METHODS. As part of a previous nutritional study, 322 healthy Caucasian female twins, aged 16 to 50 (mean 40) years, underwent measurement of MPOD optical density by two-wavelength fundus autofluorescence. In the present study, the right eye MPOD profile was assessed for the presence of a ring-like pattern by two graders independently, using common criteria, with a third grader arbitrating in cases of disagreement. Concordance was calculated as 2C/(2C + D), where C is the number of twin pairs concordant, and D the number discordant, for the ring-like pattern. Also, heritability was calculated using maximum-likelihood structural equation modeling.
   RESULTS. Images and zygosity data were available for 314 twins (88 monozygotic [MZ] and 69 dizygotic [DZ] pairs). The overall prevalence of the ring pattern was 25.8%. Respective concordances for MZ and DZ twins were 0.75 and 0.22. Additive genetic factors were estimated to contribute to 84.0% of the total variance (95% confidence intervals, 63.7%-94.6%).
   CONCLUSIONS. Concordance for MZ twins was over three times that for DZ twins, with heritability estimated at 84%, indicating that genetic factors contribute to the development of the ring structure. Studies have suggested that ring-like patterns of macular pigment can affect risk for age-related maculopathy. In a classic twin study, we found that the presence of such a pattern was highly heritable.
C1 [Tariq, Ambreen; Mahroo, Omar A.; Williams, Katie M.; Hammond, Christopher J.] Kings Coll London, Dept Ophthalmol, London SE1 7EH, England.
   [Liew, S. H. Melissa; Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London SE1 7EH, England.
   [Beatty, Stephen] Waterford Inst Technol, Macular Pigment Res Grp, Waterford, Ireland.
   [Gilbert, Clare E.] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London, England.
   [Van Kuijk, Frederik J.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
C3 University of London; King's College London; University of London;
   King's College London; South East Technological University (SETU);
   University of London; London School of Hygiene & Tropical Medicine;
   University of Minnesota System; University of Minnesota Twin Cities
RP Mahroo, OA (通讯作者)，Kings Coll London, Dept Ophthalmol, St Thomas Hosp Campus,Westminster Bridge Rd, London SE1 7EH, England.
EM omar.mahroo@kcl.ac.uk
OI Mahroo, Omar/0000-0003-1254-0832; Hammond,
   Christopher/0000-0002-3227-2620; Williams, Katie M/0000-0003-4596-3938
FU Wellcome Trust; Fight for Sight UK; Medical Research Center; Research to
   Prevent Blindness (University of Minnesota); National Institute for
   Health Research (NIHR) BioResource Clinical Research Facility and
   Biomedical Research Centre; St. Thomas' National Heath Service
   Foundation Trust and King's College London; MRC [MR/K023721/1] Funding
   Source: UKRI; Medical Research Council [MR/K023721/1] Funding Source:
   researchfish; National Institute for Health Research [CL-2011-17-501,
   SRF/01/010] Funding Source: researchfish
FX Supported by grants from Wellcome Trust (CJH), Fight for Sight UK (OAM),
   Medical Research Center (KMW), and Research to Prevent Blindness
   (University of Minnesota). TwinsUK also receives support from the
   National Institute for Health Research (NIHR) BioResource Clinical
   Research Facility and Biomedical Research Centre based at Guy's and St.
   Thomas' National Heath Service Foundation Trust and King's College
   London.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P8016, DOI 10.1167/iovs.11-7610
   Hammond BR, 2013, INVEST OPHTH VIS SCI, V54, P476, DOI 10.1167/iovs.12-10411
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Hogg RE, 2012, EYE, V26, P1217, DOI 10.1038/eye.2012.98
   Kernt M, 2012, CLIN EXP OPHTHALMOL, V40, pE87, DOI 10.1111/j.1442-9071.2011.02620.x
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Sanfilippo PG, 2011, INVEST OPHTH VIS SCI, V52, P5565, DOI 10.1167/iovs.11-7258
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Zeimer M, 2012, INVEST OPHTH VIS SCI, V53, P4852, DOI 10.1167/iovs.12-9713
NR 23
TC 7
Z9 7
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2014
VL 55
IS 4
BP 2214
EP 2219
DI 10.1167/iovs.13-13829
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH1WS
UT WOS:000335913100026
PM 24609627
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Shahandeh, A
   Bui, BV
   Finkelstein, DI
   Nguyen, CTO
AF Shahandeh, Ali
   Bui, Bang V.
   Finkelstein, David I.
   Nguyen, Christine T. O.
TI Effects of Excess Iron on the Retina: Insights From Clinical Cases and
   Animal Models of Iron Disorders
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE retina; iron; hemochromatosis; iron overload; retinal disorder
ID CHELATOR DEFERIPRONE PROTECTS; TRANSFERRIN RECEPTOR 2; HEREDITARY
   HEMOCHROMATOSIS; MITOCHONDRIAL DYSFUNCTION; TYROSINE-HYDROXYLASE;
   PIGMENT EPITHELIUM; MEDICAL PROGRESS; RPE65 MUTATIONS; MOUSE RETINA;
   HEPCIDIN
AB Iron plays an important role in a wide range of metabolic pathways that are important for neuronal health. Excessive levels of iron, however, can promote toxicity and cell death. An example of an iron overload disorder is hemochromatosis (HH) which is a genetic disorder of iron metabolism in which the body's ability to regulate iron absorption is altered, resulting in iron build-up and injury in several organs. The retina was traditionally assumed to be protected from high levels of systemic iron overload by the blood-retina barrier. However, recent data shows that expression of genes that are associated with HH can disrupt retinal iron metabolism. Thus, the effects of iron overload on the retina have become an area of research interest, as excessively high levels of iron are implicated in several retinal disorders, most notably age-related macular degeneration. This review is an effort to highlight risk factors for excessive levels of systemic iron build-up in the retina and its potential impact on the eye health. Information is integrated across clinical and preclinical animal studies to provide insights into the effects of systemic iron loading on the retina.
C1 [Shahandeh, Ali; Bui, Bang V.; Nguyen, Christine T. O.] Univ Melbourne, Dept Optometry & Vis Sci, Fac Med Dent & Hlth Sci, Parkville, Vic, Australia.
   [Finkelstein, David I.] Univ Melbourne, Florey Dept Neurosci & Mental Hlth, Parkville, Vic, Australia.
C3 University of Melbourne; University of Melbourne
RP Nguyen, CTO (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Fac Med Dent & Hlth Sci, Parkville, Vic, Australia.
EM christine.nguyen@unimelb.edu.au
RI Bui, Bang/AAD-2679-2021; Finkelstein, David/B-9617-2009
OI Bui, Bang/0000-0001-7298-1352; Finkelstein, David/0000-0002-8167-4917;
   Shahandeh, Ali/0000-0002-0434-0593
FU Australian Research Council [LP160100126]
FX Funding This research was supported by the Australian Research Council
   Linkage grant LP160100126 (CN and BB).
CR Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Abreu R, 2018, BLOOD ADV, V2, P1089, DOI 10.1182/bloodadvances.2017015255
   Adams PC, 2005, LANCET, V366, P269, DOI 10.1016/S0140-6736(05)66384-2
   Allen KJ, 2008, MED J AUSTRALIA, V189, P300, DOI 10.5694/j.1326-5377.2008.tb02043.x
   Andrews NC, 2008, BLOOD, V112, P219, DOI 10.1182/blood-2007-12-077388
   Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607
   Arosio P, 2009, BBA-GEN SUBJECTS, V1790, P589, DOI 10.1016/j.bbagen.2008.09.004
   Ayton S, 2013, ANN NEUROL, V73, P554, DOI 10.1002/ana.23817
   Babitt JL, 2006, NAT GENET, V38, P531, DOI 10.1038/ng1777
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Battaglia AM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061505
   Baumann BH, 2019, AM J PATHOL, V189, P1814, DOI [10.1016/j.ajpath.2019.0.5.022, 10.1016/j.ajpath.2019.05.022]
   Bellsmith Kellyn N, 2020, Am J Ophthalmol Case Rep, V18, P100674, DOI 10.1016/j.ajoc.2020.100674
   Bereta G, 2008, BIOCHEMISTRY-US, V47, P9856, DOI 10.1021/bi800905v
   Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0
   Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027
   Bhoiwala DL, 2015, INVEST OPHTH VIS SCI, V56, P5344, DOI 10.1167/iovs.15-17026
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Billings JL, 2016, ACS CHEM NEUROSCI, V7, P360, DOI 10.1021/acschemneuro.5b00305
   BJORNRASMUSSEN E, 1974, J CLIN INVEST, V53, P247, DOI 10.1172/JCI107545
   Brissot Pierre, 2006, Hematology Am Soc Hematol Educ Program, P36
   Brissot P, 2019, TRANSFUS CLIN BIOL, V26, P80, DOI 10.1016/j.tracli.2018.08.006
   Callebaut I, 2014, HUM MOL GENET, V23, P4479, DOI 10.1093/hmg/ddu160
   Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534
   CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485
   Chen H, 2009, INVEST OPHTH VIS SCI, V50, P1895, DOI 10.1167/iovs.08-2850
   Chen L, 2003, MOL VIS, V9, P151
   Chua ACG, 2007, CRIT REV CL LAB SCI, V44, P413, DOI 10.1080/10408360701428257
   Chuang JZ, 2007, CELL, V130, P535, DOI 10.1016/j.cell.2007.06.030
   Coffman LG, 2009, P NATL ACAD SCI USA, V106, P570, DOI 10.1073/pnas.0812010106
   Colak E, 2018, CURR EYE RES, V43, P659, DOI 10.1080/02713683.2018.1437452
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Crichton RR, 2011, J NEURAL TRANSM, V118, P301, DOI 10.1007/s00702-010-0470-z
   Cullen LM, 1998, AM J HUM GENET, V62, P1403, DOI 10.1086/301878
   Cunningham MJ, 2004, BLOOD, V104, P34, DOI 10.1182/blood-2003-09-3167
   D'Mello SR, 2020, EXP BIOL MED, V245, P1444, DOI 10.1177/1535370220953065
   Daglas M, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00981
   DAVIES G, 1972, BRIT J OPHTHALMOL, V56, P338, DOI 10.1136/bjo.56.4.338
   DECLERCQ SS, 1977, ARCH OPHTHALMOL-CHIC, V95, P1051, DOI 10.1001/archopht.1977.04450060138014
   Dekker MCJ, 2003, NEUROSCI LETT, V348, P117, DOI 10.1016/S0304-3940(03)00713-4
   Rueda AD, 2011, REV ESP ENFERM DIG, V103, P379, DOI 10.4321/S1130-01082011000700010
   del-Castillo-Rueda A, 2012, GENE, V508, P15, DOI 10.1016/j.gene.2012.07.069
   Desmond MA, 2021, AM J CLIN NUTR, V113, P1565, DOI 10.1093/ajcn/nqaa445
   Detivaud L, 2013, HUM MUTAT, V34, P1529, DOI 10.1002/humu.22396
   DICKINSON TK, 1995, J COMP NEUROL, V355, P67, DOI 10.1002/cne.903550109
   DICKMAN SR, 1950, ARCH BIOCHEM, V25, P229
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   DOLY M, 1984, OPHTHALMIC RES, V16, P292, DOI 10.1159/000265332
   Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Dwork AJ, 1995, J NEUROL SCI, V134, P45, DOI 10.1016/0022-510X(95)00207-I
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   Fix O K, 2008, Minerva Med, V99, P605
   Fuqua BK, 2012, J TRACE ELEM MED BIO, V26, P115, DOI 10.1016/j.jtemb.2012.03.015
   Ganz T, 2005, BEST PRACT RES CL HA, V18, P171, DOI 10.1016/j.beha.2004.08.020
   Gao XS, 2009, J BIOL CHEM, V284, P4767, DOI 10.1074/jbc.M806235200
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Gnana-Prakasam JP, 2012, BIOCHEM J, V441, P599, DOI 10.1042/BJ20111148
   Gnana-Prakasam JP, 2009, BIOCHEM J, V424, P243, DOI 10.1042/BJ20090424
   Gnana-Prakasam JP, 2009, BIOCHEM J, V419, P533, DOI 10.1042/BJ20082240
   Gochee PA, 2002, GASTROENTEROLOGY, V122, P646, DOI 10.1016/S0016-5085(02)80116-0
   Goswami T, 2006, J BIOL CHEM, V281, P28494, DOI 10.1074/jbc.C600197200
   GOTTSCHALL DW, 1982, J BIOL CHEM, V257, P845
   Guerreiro RJ, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-24
   Guiney SJ, 2017, NEUROCHEM INT, V104, P34, DOI 10.1016/j.neuint.2017.01.004
   Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Hahn P, 2009, EXP GERONTOL, V44, P594, DOI 10.1016/j.exger.2009.06.006
   Haider LM, 2018, CRIT REV FOOD SCI, V58, P1359, DOI 10.1080/10408398.2016.1259210
   Hare DJ, 2017, NPJ PARKINSONS DIS, V3, DOI 10.1038/s41531-016-0004-y
   Hare DJ, 2015, NAT REV NEUROL, V11, P536, DOI 10.1038/nrneurol.2015.100
   Harmatz P, 2000, BLOOD, V96, P76, DOI 10.1182/blood.V96.1.76.013k22_76_79
   Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812
   Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   HUDSON JR, 1953, BRIT J OPHTHALMOL, V37, P242, DOI 10.1136/bjo.37.4.242
   Ingrassia R, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00575
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200
   Jiang B, 2016, SCI REP-UK, V6, DOI 10.1038/srep39470
   Joitihan HA, 2008, MOL MED, V14, P98, DOI 10.2119/2007-00114.Jouihan
   Jouanolle AM, 1997, HUM GENET, V100, P544, DOI 10.1007/s004390050549
   Kaur D, 2007, NEUROBIOL AGING, V28, P907, DOI 10.1016/j.neurobiolaging.2006.04.003
   Kaushik P, 2007, J COMPUT NEUROSCI, V22, P147, DOI 10.1007/s10827-006-0004-8
   Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826
   Kohgo Y, 2008, INT J HEMATOL, V88, P7, DOI 10.1007/s12185-008-0120-5
   Koorts A. M., 2007, Archives of Physiology and Biochemistry, V113, P30, DOI 10.1080/13813450701318583
   KUHN DM, 1980, J BIOL CHEM, V255, P4137
   Lacovelli J, 2009, BRAIN RES, V1289, P85, DOI 10.1016/j.brainres.2009.06.098
   Lane DJR, 2018, J ALZHEIMERS DIS, V64, pS379, DOI 10.3233/JAD-179944
   Latour C, 2014, HEPATOLOGY, V59, P683, DOI 10.1002/hep.26648
   Lederman M, 2012, INVEST OPHTH VIS SCI, V53, P605, DOI 10.1167/iovs.11-7436
   Ledolter AA, 2015, DOC OPHTHALMOL, V130, P197, DOI 10.1007/s10633-015-9482-1
   Lee JH, 2009, BIOCHEM BIOPH RES CO, V389, P399, DOI 10.1016/j.bbrc.2009.08.125
   Li N, 2020, FREE RADICAL BIO MED, V160, P303, DOI 10.1016/j.freeradbiomed.2020.08.009
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Liu YR, 2021, AGING CELL, V20, DOI 10.1111/acel.13490
   Lloyd RV, 1997, FREE RADICAL BIO MED, V22, P885, DOI 10.1016/S0891-5849(96)00432-7
   LOHMANN W, 1964, EXPERIENTIA, V20, P399, DOI 10.1007/BF02147991
   Lozoff B, 2003, PEDIATRICS, V112, P846
   Maddox K, 1933, BRIT J OPHTHALMOL, V17, P392, DOI [10.1136/bjo.17.7.392, DOI 10.1136/BJO.17.7.392]
   Martin PM, 2006, INVEST OPHTH VIS SCI, V47, P4238, DOI 10.1167/iovs.06-0026
   Masaldan S, 2019, FREE RADICAL BIO MED, V133, P221, DOI 10.1016/j.freeradbiomed.2018.09.033
   McCarthy RC, 2013, J BIOL CHEM, V288, P17932, DOI 10.1074/jbc.M113.455428
   Menghini M, 2018, RETINA-J RET VIT DIS, V38, P594, DOI 10.1097/IAE.0000000000001577
   MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275
   Meynard D, 2014, BLOOD, V123, P168, DOI 10.1182/blood-2013-06-427757
   Miret S, 2003, ANNU REV NUTR, V23, P283, DOI 10.1146/annurev.nutr.23.011702.073139
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468
   Moreau C, 2018, MOVEMENT DISORD, V33, P568, DOI 10.1002/mds.27275
   Mura C, 1999, BLOOD, V93, P2502, DOI 10.1182/blood.V93.8.2502.408k27_2502_2505
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498
   Niederkofler V, 2005, J CLIN INVEST, V115, P2180, DOI 10.1172/JCI25683
   Olynyk JK, 2008, HEPATOLOGY, V48, P991, DOI 10.1002/hep.22507
   Pamphlett R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241054
   Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274
   Patel BN, 2002, J NEUROSCI, V22, P6578
   Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573
   Pietrangelo A, 2005, GASTROENTEROLOGY, V128, P470, DOI 10.1053/j.gastro.2004.11.057
   Pietrangelo A, 2003, GUT, V52, pII23, DOI 10.1136/gut.52.suppl_2.ii23
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Piperno A, 2020, TRANSL GASTROENT HEP, V5, DOI 10.21037/tgh.2019.11.15
   Powell LW, 2016, LANCET, V388, P706, DOI 10.1016/S0140-6736(15)01315-X
   Ramsey AJ, 1996, J BIOL CHEM, V271, P24395, DOI 10.1074/jbc.271.40.24395
   REDFEARN ER, 1964, NATURE, V202, P1313, DOI 10.1038/2021313a0
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Rogers BS, 2007, INVEST OPHTH VIS SCI, V48, P438, DOI 10.1167/iovs.06-0528
   ROTH AM, 1972, ARCH OPHTHALMOL-CHIC, V87, P507
   Schmidt PJ, 2008, CELL METAB, V7, P205, DOI 10.1016/j.cmet.2007.11.016
   SHICHI H, 1969, EXP EYE RES, V8, P60, DOI 10.1016/S0014-4835(69)80081-3
   Shu WT, 2019, INVEST OPHTH VIS SCI, V60, P4378, DOI 10.1167/iovs.19-28250
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Simovich M J, 2001, Hum Mutat, V18, P164, DOI 10.1002/humu.1168
   SLATER EC, 1949, BIOCHEM J, V44, P305, DOI 10.1042/bj0440305
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Song DL, 2014, INVEST OPHTH VIS SCI, V55, P4525, DOI 10.1167/iovs.14-14568
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Sterling J, 2017, EXP EYE RES, V155, P15, DOI 10.1016/j.exer.2016.12.008
   Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293
   Trenor CC, 2000, BLOOD, V96, P1113, DOI 10.1182/blood.V96.3.1113.015k03_1113_1118
   Ugarte M, 2012, METALLOMICS, V4, P1245, DOI 10.1039/c2mt20157g
   Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979
   Wallace DF, 2009, HEPATOLOGY, V50, P1992, DOI 10.1002/hep.23198
   Ward R, 2014, LANCET NEUROL, V13, P1045, DOI 10.1016/S1474-4422(14)70117-6
   Wessling-Resnick M, 2017, AM J CLIN NUTR, V106, p1600S, DOI 10.3945/ajcn.117.155879
   Widdowson EM, 1937, BIOCHEM J, V31, P2029, DOI 10.1042/bj0312029
   Wolkow N, 2012, AM J PATHOL, V180, P1614, DOI 10.1016/j.ajpath.2011.12.041
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
   Zerbib Jennyfer, 2015, Retin Cases Brief Rep, V9, P190, DOI 10.1097/ICB.0000000000000135
   Zhao LL, 2014, AM J PATHOL, V184, P2862, DOI 10.1016/j.ajpath.2014.07.008
NR 165
TC 2
Z9 2
U1 2
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD FEB 3
PY 2022
VL 15
AR 794809
DI 10.3389/fnins.2021.794809
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA ZF8FW
UT WOS:000759806700001
PM 35185447
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Heljak, MK
   Swieszkowski, W
AF Heljak, Marcin K.
   Swieszkowski, Wojciech
TI In silico model of bevacizumab sustained release from intravitreal
   administrated PLGA drug-loaded microspheres
SO MATERIALS LETTERS
LA English
DT Article
DE AMD; Bevacizumab; Controlled release; PLGA microspheres
ID INJECTION; TRANSPORT; RABBIT
AB This paper demonstrates a computational model of the bevacizumab release from intravitreal administrated microspheres made of biodegradable poly(lactic-co-glycolic acid) PLGA. Intravitreal administrated bevacizumab is known to be an efficient antibody directed against VEGF expression supplied in the age-related macular degeneration (AMD) therapy. The developed diffusion-convection model of the ocular drug transport considering bevacizumab controlled release from intravitreal injected degradable PLGA microspheres and the drug clearance caused by the aqueous humor drainage. The applied model of the drug release from biodegradable microspheres was based on the Koizumi empirical approach. The aqueous humor drainage was predicted by computer fluid dynamics (CFD). The developed model enables for prediction of the time-drug concentration profiles separately for the vitreous and the aqueous body. It was validated against the experimental rabbit models data on the bevacizumab controlled release from intravitreal injected PLGA nano- and microspheres. One can see that the numerical results are in good agreement with the experimental results obtained for PLGA drug-loaded spheres having micrometer size. It is expected that the developed model of drug sustained release and ocular transport will allow for reliable evaluation of planned anti-VEGF therapies.
C1 [Heljak, Marcin K.; Swieszkowski, Wojciech] Warsaw Univ Technol, Fac Mat Sci & Engn, Ul Woloska 141, PL-02507 Warsaw, Poland.
C3 Warsaw University of Technology
RP Heljak, MK (通讯作者)，Warsaw Univ Technol, Fac Mat Sci & Engn, Ul Woloska 141, PL-02507 Warsaw, Poland.
EM marcin.heljak@pw.edu.pl
OI Heljak, Marcin/0000-0002-2006-9211
FU National Science Centre (NCN) [UMO-2016/23/Z/ST8/04375, 4246]
FX This work was supported by the National Science Centre (NCN) under the
   Grant No.: UMO-2016/23/Z/ST8/04375 (BIOMEMBRANE project (M-ERA.NET2
   project 4246) ) .
CR Causin P, 2016, J MATH IND, V6, DOI 10.1186/s13362-016-0031-7
   Faisant N, 2002, EUR J PHARM SCI, V15, P355, DOI 10.1016/S0928-0987(02)00023-4
   Heljak MK, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40280
   Lamminsalo M, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-020-02946-1
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Missel PJ, 2010, PHARM RES-DORDR, V27, P1530, DOI 10.1007/s11095-010-0163-1
   Park J, 2005, J CONTROL RELEASE, V105, P279, DOI 10.1016/j.jconrel.2005.03.010
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Ye Z, 2015, INT J OPHTHALMOL-CHI, V8, P653, DOI 10.3980/j.issn.2222-3959.2015.04.02
   Zhang Y, 2018, INVEST OPHTH VIS SCI, V59, P5266, DOI 10.1167/iovs.17-23632
NR 10
TC 0
Z9 0
U1 4
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-577X
EI 1873-4979
J9 MATER LETT
JI Mater. Lett.
PD JAN 15
PY 2022
VL 307
AR 131080
DI 10.1016/j.matlet.2021.131080
EA OCT 2021
PG 4
WC Materials Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science; Physics
GA WM6TF
UT WOS:000711215100010
DA 2022-11-30
ER

PT J
AU Xin, H
   Biswas, N
   Li, P
   Zhong, CL
   Chan, TMC
   Nudleman, E
   Ferrara, N
AF Xin, Hong
   Biswas, Nilima
   Li, Pin
   Zhong, Cuiling
   Chan, Tamara C.
   Nudleman, Eric
   Ferrara, Napoleone
TI Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for
   treatment of intraocular neovascular disorders
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE angiogenesis; VEGF; age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; EXTRACELLULAR DOMAIN; TUMOR
   ANGIOGENESIS; CRYSTAL-STRUCTURE; CHOROIDAL NEOVASCULARIZATION;
   MONOCLONAL-ANTIBODY; LIGAND-BINDING; IN-VITRO; RECEPTOR
AB Neovascularization is a key feature of ischemic retinal diseases and the wet form of age-related macular degeneration (AMD), all leading causes of severe vision loss. Vascular endothelial growth factor (VEGF) inhibitors have transformed the treatment of these disorders. Millions of patients have been treated with these drugs worldwide. However, in real-life clinical settings, many patients do not experience the same degree of benefit observed in clinical trials, in part because they receive fewer anti-VEGF injections. Therefore, there is an urgent need to discover and identify novel long-acting VEGF inhibitors. We hypothesized that binding to heparan-sulfate proteoglycans (HSPG) in the vitreous, and possibly other ocular structures, may be a strategy to promote intraocular retention, ultimately leading to a reduced burden of intravitreal injections. We designed a series of VEGF receptor 1 variants and identified some with strong heparin-binding characteristics and ability to bind to vitreous matrix. Our data indicate that some of our variants have longer duration and greater efficacy in animal models of intraocular neovascularization than current standard of care. Our study represents a systematic attempt to exploit the functional diversity associated with heparin affinity of a VEGF receptor.
C1 [Xin, Hong; Biswas, Nilima; Li, Pin; Zhong, Cuiling; Ferrara, Napoleone] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
   [Chan, Tamara C.; Nudleman, Eric; Ferrara, Napoleone] Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Ferrara, N (通讯作者)，Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.; Ferrara, N (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
EM nferrara@ucsd.edu
OI Chan, Tamara/0000-0002-1630-395X
FU NIH [EY031345]
FX We thank Dr. Leonard G. Presta for modeling the differential interaction
   of VEGF-A with Iglike domain 3 of VEGFR1 versus VEGFR2. We thank Dr.
   Karen Messer for help and advice in statistical analyses. This work was
   supported by NIH grant EY031345.
CR Alitalo K, 2005, NATURE, V438, P946, DOI 10.1038/nature04480
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024
   Barleon B, 1997, J BIOL CHEM, V272, P10382
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bogdanovich S, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.1
   Brozzo MS, 2012, BLOOD, V119, P1781, DOI 10.1182/blood-2011-11-390922
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chamow S. M., 2014, THERAPEUTIC FC FUSIO
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Ferrara N, 2010, MOL BIOL CELL, V21, P687, DOI 10.1091/mbc.E09-07-0590
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Gerber HP, 2007, P NATL ACAD SCI USA, V104, P3478, DOI 10.1073/pnas.0611492104
   Gerber HP, 2000, CANCER RES, V60, P6253
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806
   HOUCK KA, 1992, J BIOL CHEM, V267, P26031
   Ichiyama Y, 2021, FASEB J, V35, DOI 10.1096/fj.202002414R
   Joukov V, 1996, EMBO J, V15, P290
   Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399
   KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   Lee JE, 2015, MOL CANCER THER, V14, P470, DOI 10.1158/1535-7163.MCT-14-0968-T
   Silva RLE, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8030
   Lissbrant IF, 2004, PROSTATE, V58, P57, DOI 10.1002/pros.10312
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malyala P, 2008, J PHARM SCI-US, V97, P2041, DOI 10.1002/jps.21152
   Markovic-Mueller S, 2017, STRUCTURE, V25, P341, DOI 10.1016/j.str.2016.12.012
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Morin J, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3218
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Park M, 1999, BIOCHEM BIOPH RES CO, V264, P730, DOI 10.1006/bbrc.1999.1580
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Presta LG, 1997, CANCER RES, V57, P4593
   QUHONG, 1995, J HISTOCHEM CYTOCHEM, V43, P381, DOI 10.1177/43.4.7534783
   Ratanji KD, 2014, J IMMUNOTOXICOL, V11, P99, DOI 10.3109/1547691X.2013.821564
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   Roberts CJ, 2014, TRENDS BIOTECHNOL, V32, P372, DOI 10.1016/j.tibtech.2014.05.005
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sankar MJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009734.pub3
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shibuya M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009092
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Vorum H, 2016, CURR MED RES OPIN, V32, P1943, DOI 10.1080/03007995.2016.1221803
   Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0
   Xiao S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.97585
   Xin H, 2016, CELL, V167, P275, DOI 10.1016/j.cell.2016.08.054
   Yang DL, 2016, ANAL BIOCHEM, V508, P78, DOI 10.1016/j.ab.2016.06.024
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07-1175
   Zheng M, 2001, J VIROL, V75, P9828, DOI 10.1128/JVI.75.20.9828-9835.2001
   Zhong CL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20108-0
NR 72
TC 2
Z9 2
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 25
PY 2021
VL 118
IS 21
AR e1921252118
DI 10.1073/pnas.1921252118
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SP1MW
UT WOS:000659437300015
PM 34006633
OA Green Published
DA 2022-11-30
ER

PT J
AU Wu, QW
   Liu, BY
   Yuan, L
   Peng, QS
   Cheng, L
   Zhong, PT
   Yang, XH
   Yu, HH
AF Wu, Qiaowei
   Liu, Baoyi
   Yuan, Ling
   Peng, Qingsheng
   Cheng, Lin
   Zhong, Pingting
   Yang, Xiaohong
   Yu, Honghua
TI Dysregulations of follicular helper T cells through IL-21 pathway in
   age-Check forelated macular degeneration
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Age-related macular degeneration; IL-21; PD-1; Follicular helper T cell
ID FACTOR-H POLYMORPHISM; TFH CELLS; ICOS; INDUCTION; DIFFERENTIATION;
   NLRP3; CD56
AB Age-related macular degeneration (AMD) is the most common cause of vision loss in the aged population. Aging and inflammation are thought to promote AMD pathogenesis in people with genetic predisposition. Follicular helper T (Tfh) cells play critical roles in inflammatory responses. Here, we investigated circulating Tfh cells in AMD patients. Circulating Tfh cells were defined as CXCR5(+) CD4 T cells. Data showed that patients with the wet-type AMD presented significantly higher levels of Tfh cells than non-AMD controls. Interestingly, the Tfh cells from dry and wet AMD patients also presented significantly higher ICOS and PD-1 expression, together with higher IL-17 and IL-21 expression directly ex vivo and following PMA/ionomycin stimulation. The expression of IFNg and IL-10, on the other hand, was not different between Tfh cells from AMD patients and their counterparts in non-AMD controls. Functional analysis revealed that Tfh cells from AMD patients were better at inducing the production of IgG and IgA, and this effect was in an IL-21-dependent manner. Together, we demonstrated that the circulating Tfh cell responses were dysregulated in AMD patients.
C1 [Wu, Qiaowei; Liu, Baoyi; Peng, Qingsheng; Zhong, Pingting; Yang, Xiaohong; Yu, Honghua] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangdong Eye Inst, Guangzhou, Guangdong, Peoples R China.
   [Wu, Qiaowei; Yu, Honghua] PLA, Guangzhou Mil Command, Gen Hosp, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China.
   [Wu, Qiaowei; Liu, Baoyi] Southern Med Univ, Guangzhou, Guangdong, Peoples R China.
   [Yuan, Ling] Kunming Med Coll, Affiliated Hosp 1, Dept Ophthalmol, Kunming, Yunnan, Peoples R China.
   [Peng, Qingsheng; Zhong, Pingting] Shantou Univ, Coll Med, Shantou, Peoples R China.
   [Cheng, Lin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Guangdong Academy of Medical Sciences & Guangdong General Hospital;
   Southern Theater Command General Hospital; Southern Medical University -
   China; Kunming Medical University; Shantou University; Sun Yat Sen
   University
RP Yang, XH; Yu, HH (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangdong Eye Inst, Guangzhou, Guangdong, Peoples R China.
EM 13922278789@126.com; yhhgtm1@gmail.com
OI Yu, Honghua/0000-0002-0782-346X; Cheng, Lin/0000-0002-4960-8186; Wu,
   Qiaowei/0000-0002-3054-2682; peng, qing cheng/0000-0002-4259-3102
FU National Natural Science Foundation of China [81870663, 81760175];
   Talent Introduction Fund of Guangdong General hospital [Y012018145];
   Applied Basic Research Foundation of the Department of Science and
   Technology of Yunnan Province, Yunnan, China [2016FB126]; Department of
   Science and Technology of Yunnan Province, Yunnan, China [2014RA009]
FX This work was supported by Grant 81870663 from the National Natural
   Science Foundation of China (H.Y.), the Talent Introduction Fund of
   Guangdong General hospital (Y012018145) (H.Y.), Grant 81760175 from the
   National Natural Science Foundation of China (L. Y.), Grant 2016FB126
   from the Applied Basic Research Foundation of the Department of Science
   and Technology of Yunnan Province, Yunnan, China (L. Y.), Grant
   2014RA009 from the Department of Science and Technology of Yunnan
   Province, Yunnan, China (L. Y.).
CR Akiba H, 2005, J IMMUNOL, V175, P2340, DOI 10.4049/jimmunol.175.4.2340
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023
   Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Faber C, 2013, OPHTHALMOLOGY, V120, P2310, DOI 10.1016/j.ophtha.2013.04.014
   Gaddis DE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03493-5
   Hector SM, 2017, CLIN OPHTHALMOL, V11, P179, DOI 10.2147/OPTH.S121332
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kim Y, 2014, P NATL ACAD SCI USA, V111, P16082, DOI 10.1073/pnas.1403814111
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Lemster BH, 2008, J IMMUNOL, V180, P1979, DOI 10.4049/jimmunol.180.3.1979
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031
   Ma CS, 2014, IMMUNOL CELL BIOL, V92, P64, DOI 10.1038/icb.2013.55
   Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994
   Ma J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/827480
   McDermott DF, 2013, CANCER MED-US, V2, P662, DOI 10.1002/cam4.106
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Odegard JM, 2008, J EXP MED, V205, P2873, DOI 10.1084/jem.20080840
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Pittet MJ, 2000, J IMMUNOL, V164, P1148, DOI 10.4049/jimmunol.164.3.1148
   Rasheed AU, 2006, EUR J IMMUNOL, V36, P1892, DOI 10.1002/eji.200636136
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Tangye SG, 2013, NAT REV IMMUNOL, V13, P412, DOI 10.1038/nri3447
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Viisanen T, 2017, DIABETES, V66, P437, DOI 10.2337/db16-0714
   Vinuesa CG, 2011, IMMUNITY, V34, P10, DOI 10.1016/j.immuni.2011.01.006
   Warnatz K, 2006, BLOOD, V107, P3045, DOI 10.1182/blood-2005-07-2955
   Wikenheiser DJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00304
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhou JJ, 2018, MOL IMMUNOL, V97, P27, DOI 10.1016/j.molimm.2018.03.008
   Zhu YY, 2016, INT IMMUNOL, V28, P173, DOI 10.1093/intimm/dxv079
NR 40
TC 6
Z9 6
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD OCT
PY 2019
VL 114
BP 243
EP 250
DI 10.1016/j.molimm.2019.07.028
PG 8
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA JE3WN
UT WOS:000490625600028
PM 31394381
DA 2022-11-30
ER

PT J
AU Avila-Robinson, A
   Islam, N
   Sengoku, S
AF Avila-Robinson, Alfonso
   Islam, Nazrul
   Sengoku, Shintaro
TI Co-evolutionary and systemic study on the evolution of emerging stem
   cell-based therapies
SO TECHNOLOGICAL FORECASTING AND SOCIAL CHANGE
LA English
DT Article
DE Knowledge dynamics; Emerging technologies; Stem cell therapies; Cell
   transplantations; Knowledge structures; Clinical practices
ID MEDICAL KNOW-HOW; TECHNOLOGICAL-INNOVATION SYSTEMS; MULTILEVEL
   PERSPECTIVE; KNOWLEDGE; STRATEGIES; COMMERCIALIZATION; TRANSLATION;
   UNCERTAINTY; CHALLENGES; EMERGENCE
AB Newly emerging therapeutic technologies have the potential to reconfigure the understanding, diagnosis, and treatment of diseases, and, consequently, to impact human health. This study integrates co-evolutionary and system-oriented perspectives to investigate factors influencing the way emerging therapies evolve in their attempt to become established medical practices. We examined the case of the use of induced pluripotent stem (iPS) cell-based therapies for age-related macular degeneration (AMD) disease. Cell therapy evolution is explored by considering their constitutive components, namely disease, biomedical technologies, and clinical practices, and observing the changes experienced by their underlying knowledge structures. We adopted a mixed methods approach that simultaneously uses publication, patent, and clinical trial data. Our results highlight the significance of the diversity of technological possibilities, the role of subjective issues in the selection of directions of search, the complementary nature between established and emerging therapies, and the tight product-process interdependencies. This study contributes to an understanding of the difficulties encountered during the emergence of new cell therapies, and the ways in which such difficulties can be circumvented to establish effective and safe cell-based clinical practices.
C1 [Avila-Robinson, Alfonso] Kyoto Univ, Grad Sch Management, Kyoto, Japan.
   [Islam, Nazrul] Univ Exeter, Business Sch, Exeter, Devon, England.
   [Sengoku, Shintaro] Tokyo Inst Technol, Sch Environm & Soc, Dept Innovat Sci, Tokyo, Japan.
C3 Kyoto University; University of Exeter; Tokyo Institute of Technology
RP Avila-Robinson, A (通讯作者)，Kyoto Univ, Grad Sch Management, Kyoto, Japan.; Islam, N (通讯作者)，Univ Exeter, Business Sch, Exeter, Devon, England.
EM avilarobinson.alfonso@gmail.com; n.islam@exeter.ac.uk
RI Sengoku, Shintaro/AAZ-8605-2020; Sengoku, Shintaro/S-6190-2019
OI Sengoku, Shintaro/0000-0001-8008-3667; Sengoku,
   Shintaro/0000-0001-8008-3667; Islam, Nazrul/0000-0003-0515-1134;
   Avila-Robinson, Alfonso/0000-0002-0994-0918
FU MEXT/JSPS World Premier International Research Center (WPI) Initiative;
   MEXT/JSPS Kakenhi [26301022, 16K17165]; Organisation in Transition
   Research Cluster, University of Exeter Business School, University of
   Exeter, UK [1-SC-C-N68-242-USC01-SSC31-A355-PZSC177]
FX We thank the Editor and three anonymous reviewers for their helpful
   comments. This work was financially supported by MEXT/JSPS World Premier
   International Research Center (WPI) Initiative [AAR] and by MEXT/JSPS
   Kakenhi Grant No. 26301022 [SS] and MEXT/JSPS Kakenhi Grant No. 16K17165
   [AAR]. Funding is also provided by Organisation in Transition Research
   Cluster, University of Exeter Business School, University of Exeter, UK
   (No. 1-SC-C-N68-242-USC01-SSC31-A355-PZSC177). The authors appreciate
   the helpful discussions with researchers in Kyoto University's Center
   for iPS Cell Research and Application (CiRA), the Center for Stem Cell
   Biology and Engineering and the Center for the Study of Macular
   Degeneration at the University of California Santa Barbara, and the
   Roski Eye Institute at the University of Southern California. All
   remaining errors are our own.
CR Amir-Aslani A, 2010, TECHNOL FORECAST SOC, V77, P203, DOI 10.1016/j.techfore.2009.09.005
   Andrews PW, 2014, NAT BIOTECHNOL, V32, P724, DOI 10.1038/nbt.2973
   Arthur W., 2009, NATURE TECHNOLOGY WH
   Avila-Robinson A., 2013, THESIS
   Avila-Robinson A, 2013, TECHNOL FORECAST SOC, V80, P1071, DOI 10.1016/j.techfore.2012.07.012
   Azuma K, 2016, REGEN THER, V4, P36, DOI 10.1016/j.reth.2016.01.009
   Barbera-Tomas D, 2012, TECHNOL FORECAST SOC, V79, P932, DOI 10.1016/j.techfore.2011.12.009
   Barfoot J. K., 2013, STEM CELL RES TRENDS
   Batagelj V., 2014, WILEY SER COMPU QUAN
   Bergek A, 2008, TECHNOL ANAL STRATEG, V20, P575, DOI 10.1080/09537320802292768
   Bergek A, 2015, ENVIRON INNOV SOC TR, V16, P51, DOI 10.1016/j.eist.2015.07.003
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Boon WPC, 2014, RES POLICY, V43, P792, DOI 10.1016/j.respol.2014.01.005
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   CALLON M, 1983, SOC SCI INFORM, V22, P191, DOI 10.1177/053901883022002003
   Coccia M, 2015, TECHNOL FORECAST SOC, V94, P155, DOI 10.1016/j.techfore.2014.09.007
   Consoli D., 2016, MED INNOVATION SCI T
   Consoli D, 2008, J EVOL ECON, V18, P31, DOI 10.1007/s00191-007-0074-4
   Consoli D, 2012, IND CORP CHANGE, V21, P315, DOI 10.1093/icc/dtr043
   Davis AP, 2012, DATABASE-OXFORD, DOI 10.1093/database/bar065
   De Nooy W., 2011, EXPLORATORY SOCIAL N
   Dobbs David, 2016, National Geographic, V230, P30
   Dodson BP, 2015, BMC BIOTECHNOL, V15, DOI 10.1186/s12896-015-0190-4
   Epicoco M, 2013, RES POLICY, V42, P180, DOI 10.1016/j.respol.2012.06.009
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Geels FW, 2002, RES POLICY, V31, P1257, DOI 10.1016/S0048-7333(02)00062-8
   Gelijns AC, 2001, J HEALTH POLIT POLIC, V26, P913, DOI 10.1215/03616878-26-5-913
   Gittelman M, 2016, RES POLICY, V45, P82, DOI 10.1016/j.respol.2016.01.007
   Grinin LE, 2017, TECHNOL FORECAST SOC, V115, P52, DOI 10.1016/j.techfore.2016.09.017
   Hekkert MP, 2009, TECHNOL FORECAST SOC, V76, P584, DOI 10.1016/j.techfore.2008.04.013
   Horlings E, 2013, SCIENTOMETRICS, V94, P1137, DOI 10.1007/s11192-012-0789-3
   Huenteler J, 2016, RES POLICY, V45, P1195, DOI 10.1016/j.respol.2016.03.014
   Inoue H, 2014, EMBO J, V33, P409, DOI 10.1002/embj.201387098
   Islam N, 2010, TECHNOVATION, V30, P229, DOI 10.1016/j.technovation.2009.10.002
   Jacobsson S, 2008, ENERG POLICY, V36, P1491, DOI 10.1016/j.enpol.2007.12.013
   Judson HF, 2006, TECHNOL REV, V109, P40
   Kauffman S., 1995, Complexity, V1, P26
   Kimbrel EA, 2015, NAT REV DRUG DISCOV, V14, P681, DOI 10.1038/nrd4738
   Kukk P, 2015, TECHNOL FORECAST SOC, V98, P47, DOI 10.1016/j.techfore.2015.05.019
   Kukk P, 2016, RES POLICY, V45, P70, DOI 10.1016/j.respol.2016.01.016
   Laredo P., 2015, ANR10ORA007 IFRIS
   Leydesdorff L, 2012, J AM SOC INF SCI TEC, V63, P2239, DOI 10.1002/asi.22715
   Linton JD, 2008, TECHNOL FORECAST SOC, V75, P583, DOI 10.1016/j.techfore.2007.02.005
   Lipsey R.G., 2005, EC TRANSFORMATIONS G
   Loasby BJ, 2002, RES POLICY, V31, P1227, DOI 10.1016/S0048-7333(02)00060-4
   Lopolito A, 2013, RES POLICY, V42, P1225, DOI 10.1016/j.respol.2013.03.002
   Lopolito A, 2011, FUTURES, V43, P27, DOI 10.1016/j.futures.2010.03.002
   Markard J, 2008, RES POLICY, V37, P596, DOI 10.1016/j.respol.2008.01.004
   Mason C, 2011, REGEN MED, V6, P265, DOI [10.2217/RME.11.28, 10.2217/rme.11.28]
   Metcalfe JS, 2005, RES POLICY, V34, P1283, DOI 10.1016/j.respol.2005.01.015
   Mina A, 2007, RES POLICY, V36, P789, DOI 10.1016/j.respol.2006.12.007
   Morlacchi P, 2011, RES POLICY, V40, P511, DOI 10.1016/j.respol.2011.01.001
   Musiolik J, 2012, TECHNOL FORECAST SOC, V79, P1032, DOI 10.1016/j.techfore.2012.01.003
   Musiolik J, 2011, ENERG POLICY, V39, P1909, DOI 10.1016/j.enpol.2010.12.052
   NASEM, 2017, EXPL STAT SCI FIELD, DOI [10.17226/24671, DOI 10.17226/24671]
   NEI, 2017, AG REL MAC DEG AMD
   Nelson R., 1982, EVOL THEOR
   Nelson RR, 2011, RES POLICY, V40, P1339, DOI 10.1016/j.respol.2011.06.014
   Nelson RR, 2003, RES POLICY, V32, P909, DOI 10.1016/S0048-7333(02)00093-8
   Neofytou E, 2015, J CLIN INVEST, V125, P2551, DOI 10.1172/JCI80575
   NRC, 2014, CONV FAC TRANSD INT
   Perez C, 2010, CAMB J ECON, V34, P185, DOI 10.1093/cje/bep051
   Perkel J. M., 2014, SCIENTIST, V28
   Petersen AM, 2016, RES POLICY, V45, P666, DOI 10.1016/j.respol.2015.12.004
   Prescott C, 2011, PHILOS T R SOC B, V366, P2323, DOI 10.1098/rstb.2011.0047
   Propp T, 2009, SCI PUBL POLICY, V36, P199, DOI 10.3152/030234209X430884
   Ramsden CM, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18643
   Rao M, 2015, REGEN MED, V10, P181, DOI [10.2217/rme.14.80, 10.2217/RME.14.80]
   Ravven W., 2017, NY TIMES
   Robinson DKR, 2013, TECHNOL FORECAST SOC, V80, P267, DOI 10.1016/j.techfore.2011.06.004
   Rotolo D, 2015, RES POLICY, V44, P1827, DOI 10.1016/j.respol.2015.06.006
   Schachter B, 2014, NAT BIOTECHNOL, V32, P736, DOI 10.1038/nbt.2984
   Schmidt J.C., 2008, POIESIS PRAXIS, V5, P53, DOI DOI 10.1007/S10202-007-0037-8
   Sengoku S., 2015, CELL GENE THER INSIG, V1, P83, DOI [10.18609/cgti.2015.008, DOI 10.18609/CGTI.2015.008]
   Sengoku S, 2011, STEM CELL REV REP, V7, P221, DOI 10.1007/s12015-010-9204-8
   Sharp PA, 2011, SCIENCE, V333, P527, DOI 10.1126/science.1205008
   Silva M, 2015, CELL STEM CELL, V16, P13, DOI 10.1016/j.stem.2014.12.013
   Smith D, 2010, REGEN MED, V5, P593, DOI 10.2217/RME.10.50
   Stephan A, 2017, RES POLICY, V46, P709, DOI 10.1016/j.respol.2017.01.009
   Styhre A, 2015, FINANCING LIFE SCI I
   Trainor N, 2014, NAT BIOTECHNOL, V32, P729, DOI 10.1038/nbt.2970
   Trounson A, 2016, NAT REV MOL CELL BIO, V17, P194, DOI 10.1038/nrm.2016.10
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   van Merkerk RO, 2008, TECHNOL FORECAST SOC, V75, P312, DOI 10.1016/j.techfore.2007.01.003
   Wagner CS, 2011, J INFORMETR, V5, P14, DOI 10.1016/j.joi.2010.06.004
   Wallace ML, 2018, RES POLICY, V47, P1975, DOI 10.1016/j.respol.2018.07.005
   Watatani K, 2013, REGEN MED, V8, P659, DOI 10.2217/rme.13.51
   Wiley LA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017160
   Wirth S, 2011, TECHNOL FORECAST SOC, V78, P635, DOI 10.1016/j.techfore.2011.01.001
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamanaka S, 2013, ANGEW CHEM INT EDIT, V52, P13900, DOI 10.1002/anie.201306721
   Yamanaka S, 2009, NAT MED, V15, P1145, DOI 10.1038/nm1009-1145
   Yaqub O, 2012, SOC SCI MED, V75, P2143, DOI 10.1016/j.socscimed.2012.07.023
   Yuan F, 2017, INT J INNOV TECHNOL, V14, DOI 10.1142/S0219877017400065
NR 94
TC 3
Z9 3
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0040-1625
EI 1873-5509
J9 TECHNOL FORECAST SOC
JI Technol. Forecast. Soc. Chang.
PD JAN
PY 2019
VL 138
BP 324
EP 339
DI 10.1016/j.techfore.2018.10.012
PG 16
WC Business; Regional & Urban Planning
WE Social Science Citation Index (SSCI)
SC Business & Economics; Public Administration
GA HF8BK
UT WOS:000454465700026
DA 2022-11-30
ER

PT J
AU Thao, MT
   Karumanchi, DK
   Yacout, SM
   Gaillard, ER
AF Thao, Mai T.
   Karumanchi, Devi Kalyan
   Yacout, Sally M.
   Gaillard, Elizabeth R.
TI Nitrite ion modifies tyrosine and lysine residues of extracellular
   matrix proteins
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Article
DE AMD; Inflammation; Bruch's membrane; Nitrite; 3-Nitrotyrosine;
   Extracellular matrix; Lysine deamination
ID RETINAL-PIGMENT EPITHELIUM; COMPLEMENT FACTOR-H; MACULAR DEGENERATION;
   BRUCHS MEMBRANE; IN-VIVO; SYNOVIAL-FLUID; NITROTYROSINE; NITRATION;
   MARKER; DAMAGE
AB Age-related macular degeneration (AMD) is a disease characterized by degenerative changes in the retinal pigment epithelium and Bruch's membrane. Inflammation is considered a major risk factor for the development and progression of AMD. Nitrite is a potent byproduct of inflammation and has been detected at elevated concentrations in AMD donor tissue. We hypothesize that nitrite chemically modifies the extracellular matrix (ECM) of Bruch's membrane as an initial step to degenerative changes observed in AMD. Non-enzymatically nitrated synthetic ECM peptides, fibronectin and laminin, were used as model systems for inflammation. Using LC/MS, we identified that nitration preferentially occurred on tyrosine and deamination of lysine under the studied conditions. At tyrosine residues, 3-nitrotyrosine was produced and shifted the total mass by the addition of 45 amu. Deamination of lysine occurred and resulted in the formation of either an alkene or alcohol group. The alkene group was observed with a loss of 17 amu. An addition of 1 amu was observed with alcohol formation. We hypothesize that these initial chemical modifications to the structure of ECM proteins may be the responsible for altering the structure and consequent function of Bruch's membrane.
C1 [Thao, Mai T.; Karumanchi, Devi Kalyan; Yacout, Sally M.; Gaillard, Elizabeth R.] Northern Illinois Univ, Dept Chem & Biochem, De Kalb, IL USA.
   [Gaillard, Elizabeth R.] Northern Illinois Univ, Dept Biol Sci, De Kalb, IL USA.
C3 Northern Illinois University; Northern Illinois University
RP Gaillard, ER (通讯作者)，1425 W Lincoln Hwy, De Kalb, IL 60115 USA.
EM gaillard@niu.edu
RI Gaillard, Elizabeth/M-2627-2019
OI Yacout, Sally/0000-0002-7675-041X; Karumanchi, Devi
   Kalyan/0000-0001-8392-5997
CR Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077
   Crow JP, 1996, METHOD ENZYMOL, V269, P185
   Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017
   Deng HT, 2006, RAPID COMMUN MASS SP, V20, P3634, DOI 10.1002/rcm.2776
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Fields MA, 2015, INVEST OPHTH VIS SCI, V56, P4231, DOI 10.1167/iovs.15-16438
   Gaillard E. R., 2016, GOOGLE PATENTS
   Ghosh T, 2003, BIOPHYS J, V85, P3187, DOI 10.1016/S0006-3495(03)74736-5
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   KATO T, 1992, FOOD CHEM TOXICOL, V30, P617, DOI 10.1016/0278-6915(92)90196-R
   KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5
   Keil B, 1987, Protein Seq Data Anal, V1, P13
   Khan F, 2006, SCAND J IMMUNOL, V64, P507, DOI 10.1111/j.1365-3083.2006.01794.x
   Kim IK, 2008, MOL VIS, V14, P1487
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li R, 2009, INVEST OPHTH VIS SCI, V50, P5988, DOI 10.1167/iovs.09-3591
   MALIN EL, 1989, J AGR FOOD CHEM, V37, P1071, DOI 10.1021/jf00088a056
   MARTIN BL, 1990, J BIOL CHEM, V265, P7108
   Moreira EF, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.10
   Mu H, 2008, BBA-MOL CELL RES, V1783, P1576, DOI 10.1016/j.bbamcr.2008.04.004
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OHSHIMA H, 1990, FOOD CHEM TOXICOL, V28, P647, DOI 10.1016/0278-6915(90)90173-K
   Paik DC, 1997, CONNECT TISSUE RES, V36, P241, DOI 10.3109/03008209709160224
   Paik DC, 2000, EXP EYE RES, V70, P73, DOI 10.1006/exer.1999.0761
   Paik DC, 2001, CONNECT TISSUE RES, V42, P111, DOI 10.3109/03008200109014253
   Pham VV, 2009, NITRIC OXIDE-BIOL CH, V21, P210, DOI 10.1016/j.niox.2009.09.001
   Radi R, 2013, ACCOUNTS CHEM RES, V46, P550, DOI 10.1021/ar300234c
   Sun K, 2007, MOL VIS, V13, P2310
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Wang Z, 2007, EXP MOL MED, V39, P74, DOI 10.1038/emm.2007.9
NR 39
TC 7
Z9 7
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
EI 1089-8611
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD SEP 1
PY 2018
VL 79
BP 51
EP 56
DI 10.1016/j.niox.2018.07.006
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GR7BU
UT WOS:000442843000008
PM 30055286
DA 2022-11-30
ER

PT J
AU Olivares, AM
   Jelcick, AS
   Reinecke, J
   Leehy, B
   Haider, A
   Morrison, MA
   Cheng, L
   Chen, DF
   DeAngelis, MM
   Haider, NB
AF Olivares, A. M.
   Jelcick, A. S.
   Reinecke, J.
   Leehy, B.
   Haider, A.
   Morrison, M. A.
   Cheng, L.
   Chen, D. F.
   DeAngelis, M. M.
   Haider, N. B.
TI Multimodal Regulation Orchestrates Normal and Complex Disease States in
   the Retina
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RECEPTOR ROR-ALPHA; NUCLEAR RECEPTOR; TRANSCRIPTION FACTOR; MICRORNA
   EXPRESSION; PIGMENT EPITHELIUM; NEOVASCULAR AMD; GENE-EXPRESSION; MOUSE
   RETINA; CONE GENES; STEM-CELLS
AB Regulation of biological processes occurs through complex, synergistic mechanisms. In this study, we discovered the synergistic orchestration of multiple mechanisms regulating the normal and diseased state (age related macular degeneration, AMD) in the retina. We uncovered gene networks with overlapping feedback loops that are modulated by nuclear hormone receptors (NHR), miRNAs, and epigenetic factors. We utilized a comprehensive filtering and pathway analysis strategy comparing miRNA and microarray data between three mouse models and human donor eyes (normal and AMD). The mouse models lack key NHRS (Nr2e3, RORA) or epigenetic (Ezh2) factors. Fifty-four total miRNAs were differentially expressed, potentially targeting over 150 genes in 18 major representative networks including angiogenesis, metabolism, and immunity. We identified sixty-eight genes and 5 miRNAS directly regulated by NR2E3 and/or RORA. After a comprehensive analysis, we discovered multimodal regulation by miRNA, NHRs, and epigenetic factors of three miRNAs (miR-466, miR1187, and miR-710) and two genes (Ell2 and Entpd1) that are also associated with AMD. These studies provide insight into the complex, dynamic modulation of gene networks as well as their impact on human disease, and provide novel data for the development of innovative and more effective therapeutics.
C1 [Olivares, A. M.; Haider, A.; Cheng, L.; Chen, D. F.; Haider, N. B.] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02115 USA.
   [Jelcick, A. S.; Reinecke, J.; Leehy, B.] Univ Nebraska, Med Ctr, Genet Cell Biol & Anat, Omaha, NE USA.
   [Morrison, M. A.; DeAngelis, M. M.] Univ Utah, Sch Med, Ophthalmol & Visual Sci, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Schepens Eye Research Institute; University of Nebraska
   System; University of Nebraska Medical Center; Utah System of Higher
   Education; University of Utah
RP Haider, NB (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02115 USA.
EM neena_haider@meei.harvard.edu
RI Chen, Dong/AAJ-2444-2020
OI Chen, Dong/0000-0001-6283-8843; Cheng, Lin/0000-0002-4960-8186
FU Research to Prevent Blindness, Inc., New York, NY; Harvard Medical
   School; Hope for Vision; Massachusetts Lions Eye Research Fund; American
   Macular Degeneration Foundation; Webster Foundation; Edward N. & Della
   L. Thome Memorial Foundation; NIH/NEI [EY014800]; University of Utah;
   The Skaggs Foundation for Research; The Carl Marshall Reeves & Mildred
   Almen Reeves Foundation, Inc.; Macular Degeneration Foundation, Inc.; 
   [NIH-NCRRP20-RRO18788-03];  [NIH-NEI RO1EY017653];  [NIH-NEI
   RO1EY017653-01A2S1];  [NIH/NEI R41 EY025913];  [NIH/NEI R01EY025259];
   NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018788] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [P30EY014800, R41EY025913, R01EY025259,
   R01EY017653] Funding Source: NIH RePORTER
FX This work was supported by the following funding agencies:
   NIH-NCRRP20-RRO18788-03 (NBH), NIH-NEI RO1EY017653 (NBH), NIH-NEI
   RO1EY017653-01A2S1 (NBH), an unrestricted grant from Research to Prevent
   Blindness, Inc., New York, NY to Department of Ophthalmology, Harvard
   Medical School (NBH), Hope for Vision (NBH), Massachusetts Lions Eye
   Research Fund (NBH), American Macular Degeneration Foundation (NBH),
   Webster Foundation (NBH), Edward N. & Della L. Thome Memorial Foundation
   (NBH, MMD), NIH/NEI EY014800 (MMD), an unrestricted grant from Research
   to Prevent Blindness, Inc., New York, NY to the Department of
   Ophthalmology & Visual Sciences, University of Utah (MMD), The Skaggs
   Foundation for Research (MMD), The Carl Marshall Reeves & Mildred Almen
   Reeves Foundation, Inc., (MMD), and the Macular Degeneration Foundation,
   Inc. (MMD), NIH/NEI R41 EY025913 (DFC), and NIH/NEI R01EY025259 (DFC).
   We wish to thank Gloria Chen for assistance with R and generating the
   heat map.
CR Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Aronin N, 2006, GENE THER, V13, P509, DOI 10.1038/sj.gt.3302726
   Arora A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-1
   Bao ZZ, 1997, J NEUROSCI, V17, P1425
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777
   Cheng H, 2011, HUM MOL GENET, V20, P4102, DOI 10.1093/hmg/ddr334
   Choi SW, 2015, STEM CELL REV REP, V11, P376, DOI 10.1007/s12015-014-9568-2
   Chow L, 1998, MECH DEVELOP, V77, P149, DOI 10.1016/S0925-4773(98)00135-X
   Chung SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28993
   Chung SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118949
   Conte I, 2015, P NATL ACAD SCI USA, V112, pE3236, DOI 10.1073/pnas.1401464112
   Corbo JC, 2005, PLOS GENET, V1, P140, DOI 10.1371/journal.pgen.0010011
   Ding JD, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-216
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Forrest D, 2012, MOL ENDOCRINOL, V26, P905, DOI 10.1210/me.2012-1010
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujieda H, 2009, J NEUROCHEM, V108, P91, DOI 10.1111/j.1471-4159.2008.05739.x
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Genini S, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-172
   Georgi SA, 2011, DEV NEUROBIOL, V71, P1153, DOI 10.1002/dneu.20899
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Hackler L, 2010, INVEST OPHTH VIS SCI, V51, P1823, DOI 10.1167/iovs.09-4657
   Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619
   Haider NB, 2006, VISUAL NEUROSCI, V23, P917, DOI 10.1017/S095252380623027X
   Haider NB, 2009, EXP EYE RES, V89, P365, DOI 10.1016/j.exer.2009.04.006
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200
   Hill JM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00232
   Hu WQ, 2012, CELL RES, V22, P1322, DOI 10.1038/cr.2012.80
   Human M. R. C., 1995, NOVEL HUMAN PHOSPHOG, V353, P350
   Ino H, 2004, J HISTOCHEM CYTOCHEM, V52, P311, DOI 10.1177/002215540405200302
   Ishida W, 2011, INVEST OPHTH VIS SCI, V52, P611, DOI 10.1167/iovs.10-6115
   Jelcick AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021858
   Jetten Anton M, 2009, Nucl Recept Signal, V7, pe003, DOI 10.1621/nrs.07003
   Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566
   Jin ZB, 2009, MOL VIS, V15, P523
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   KAS K, 1995, GENOMICS, V30, P403
   Kloeckener-Gruissem B, 2008, AM J HUM GENET, V82, P772, DOI 10.1016/j.ajhg.2007.12.013
   Kovacs B, 2011, INVEST OPHTH VIS SCI, V52, P4402, DOI 10.1167/iovs.10-6879
   Krol J, 2010, CELL, V141, P618, DOI 10.1016/j.cell.2010.03.039
   Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998
   Kutty RK, 2013, MOL VIS, V19, P737
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   La Torre A, 2013, P NATL ACAD SCI USA, V110, pE2362, DOI 10.1073/pnas.1301837110
   Levin TG, 2010, GASTROENTEROLOGY, V139, P2072, DOI 10.1053/j.gastro.2010.08.053
   Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4
   Li YC, 2012, CELL SIGNAL, V24, P685, DOI 10.1016/j.cellsig.2011.10.017
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Lumayag S, 2013, P NATL ACAD SCI USA, V110, pE507, DOI 10.1073/pnas.1212655110
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   McGregor L, 2003, NAT GENET, V34, P203, DOI 10.1038/ng1142
   Mollema N, 2010, EXP EYE RES, V91, P116, DOI 10.1016/j.exer.2010.04.013
   Mollema NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017494
   Morgan DJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017210
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nakagawa S, 1997, NEUROSCI RES, V28, P177, DOI 10.1016/S0168-0102(97)00042-4
   Nogueira T, 2000, CURR OPIN MICROBIOL, V3, P154, DOI 10.1016/S1369-5274(00)00068-0
   Nothnick WB, 2010, ENDOCRINE, V37, P265, DOI 10.1007/s12020-009-9293-9
   Ohana R, 2015, DEVELOPMENT, V142, P2487, DOI 10.1242/dev.121533
   Olivares AM, 2015, J EXP NEUROSCI, V9, P93, DOI 10.4137/JEN.S25480
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Owen LA, 2014, INVEST OPHTH VIS SCI, V55, P3543, DOI 10.1167/iovs.14-14047
   Palfi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31431
   Pandi SPS, 2013, INVEST OPHTH VIS SCI, V54, P8140, DOI 10.1167/iovs.13-12631
   Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187
   Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070
   Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Sanuki R, 2011, NAT NEUROSCI, V14, P1125, DOI 10.1038/nn.2897
   Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002
   Saxena K, 2015, INVEST OPHTH VIS SCI, V56, P1820, DOI 10.1167/iovs.14-15449
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schorderet DF, 2009, HUM MUTAT, V30, P1475, DOI 10.1002/humu.21096
   Selcuklu SD, 2012, BIOCHEM BIOPH RES CO, V423, P234, DOI 10.1016/j.bbrc.2012.05.074
   Seo M, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-014-0104-0
   Sevigny J, 1997, BBA-GEN SUBJECTS, V1334, P73, DOI 10.1016/S0304-4165(96)00079-7
   Shalgi R, 2007, PLOS COMPUT BIOL, V3, P1291, DOI 10.1371/journal.pcbi.0030131
   Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639
   Silveira AC, 2010, VISION RES, V50, P698, DOI 10.1016/j.visres.2009.09.016
   Starlard-Davenport Athena, 2013, J Carcinog, V12, P15, DOI 10.4103/1477-3163.115720
   Steinmayr M, 1998, P NATL ACAD SCI USA, V95, P3960, DOI 10.1073/pnas.95.7.3960
   Sun H, 2001, SCI AM, V285, P69, DOI 10.1038/scientificamerican1001-68
   Sundermeier TR, 2012, CELL MOL LIFE SCI, V69, P2739, DOI 10.1007/s00018-012-0976-7
   Surface LE, 2010, CELL STEM CELL, V7, P288, DOI 10.1016/j.stem.2010.08.004
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tang Y, 2015, METAB BRAIN DIS, V30, P943, DOI 10.1007/s11011-015-9653-5
   Tian B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160887
   Trimarchi JM, 2009, DEV DYNAM, V238, P2327, DOI 10.1002/dvdy.21973
   Tsang J, 2007, MOL CELL, V26, P753, DOI 10.1016/j.molcel.2007.05.018
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Walker JC, 2009, GENE DEV, V23, P1046, DOI 10.1101/gad.1777709
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961
   Wang JW, 2017, ACTA OPHTHALMOL, V95, pE10, DOI 10.1111/aos.13227
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Weiner JA, 2004, MOL CELL NEUROSCI, V27, P59, DOI 10.1016/j.mcn.2004.06.005
   Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200
   Xu SB, 2015, P NATL ACAD SCI USA, V112, P8805, DOI 10.1073/pnas.1511019112
   Yan NH, 2016, SCI REP-UK, V6, DOI 10.1038/srep33887
   Yanagi Y, 2002, INVEST OPHTH VIS SCI, V43, P3489
   Yang ZH, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-31
   Yu DS, 2012, INT J MOL MED, V29, P663, DOI 10.3892/ijmm.2012.888
   Yu XP, 2008, NUCLEIC ACIDS RES, V36, P6494, DOI 10.1093/nar/gkn712
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhao Z, 2015, ONCOGENE, V34, P1596, DOI 10.1038/onc.2014.53
   Zhao ZG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0061814, 10.1371/journal.pone.0052044, 10.1371/journal.pone.0080574]
   Zhou QB, 2016, MOL THER, V24, P1823, DOI 10.1038/mt.2016.108
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 123
TC 8
Z9 8
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 6
PY 2017
VL 7
AR 690
DI 10.1038/s41598-017-00788-3
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ER1JI
UT WOS:000398545900009
PM 28386079
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Casalino, G
   Upendran, M
   Bandello, F
   Chakravarthy, U
AF Casalino, G.
   Upendran, M.
   Bandello, F.
   Chakravarthy, U.
TI Stellate nonhereditary idiopathic foveomacular retinoschisis concomitant
   to exudative maculopathies
SO EYE
LA English
DT Article
AB Purpose To report the clinical course of patients presenting with stellate nonhereditary idiopathic foveomacular retinoschisis (SNIFR) concomitant with exudative maculopathies.
   Methods Retrospective case series. Multimodal imaging findings, including spectral-domain optical coherence tomography (SD-OCT) were reviewed. Genetic testing for the RS1 gene was performed in one patient.
   Results We identified two female patients who fit the definition of SNIFR and presented with concomitant neovascular age-related macular degeneration (n-AMD). In both the patients, SD-OCT showed exudative macular features and splitting (bilateral in patient 1, unilateral in patient 2) of the outer plexiform layer (OPL) in the macula with no other evidence of hereditary or an acquired predisposing condition. Genetic testing excluded mutation of RS1 gene in patient 1. The fundi of both the patients showed characteristic signs of active choroidal neovascularization (CNV) and following anti-VEGF treatment, visual acuity improved and CNV-related exudative changes resolved. However, the split along the OPL remained unaltered.
   Conclusions SNIFR may be associated with n-AMD. It is important to recognise the presence of retinoschisis when there is other exudative pathology as the former may be misinterpreted as intraretinal fluid, prompting unnecessary treatment.
C1 [Casalino, G.; Upendran, M.; Chakravarthy, U.] Queens Univ Belfast, Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Casalino, G.; Upendran, M.; Chakravarthy, U.] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Casalino, G.; Bandello, F.] Univ Vita Salute San Raffaele, Sci Inst San Raffaele, Milan, Italy.
C3 Queens University Belfast; Queens University Belfast; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele
RP Casalino, G (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Belfast Hlth & Social Care Trust, Block A Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.; Casalino, G (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Ctr Med Expt, Block A Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM peppecasalino@gmail.com
RI bandello, francesco/AAH-2405-2019; Casalino, Giuseppe/I-1729-2019
OI bandello, francesco/0000-0003-3238-9682; Casalino,
   Giuseppe/0000-0002-0208-0740; Chakravarthy, Usha/0000-0002-2606-3734
CR Molday RS, 2012, PROG RETIN EYE RES, V31, P195, DOI 10.1016/j.preteyeres.2011.12.002
   Ober MD, 2014, OPHTHALMOLOGY, V121, P1406, DOI 10.1016/j.ophtha.2014.02.002
NR 2
TC 3
Z9 3
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAY
PY 2016
VL 30
IS 5
BP 754
EP 757
DI 10.1038/eye.2016.17
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL5UL
UT WOS:000375702400016
PM 26915743
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Weaver, TRE
   Beaumont, PE
AF Weaver, Travers R. E.
   Beaumont, Paul E.
TI The Effect of Intensive Education on Concordance with the Age-Related
   Eye Disease Study (AREDS) Recommendations in a Tertiary Referral
   Practice
SO OPHTHALMOLOGICA
LA English
DT Article
DE Concordance; Age-Related Eye Disease Study (AREDS); Age-related macular
   degeneration; Retina
ID MODEL; CARE
AB Background/Aims: The Age-Related Eye Disease Study (AREDS) showed that supplementation with their formula led to a significant decrease in progression of age-related macular degeneration (AMD). This study aims to assess the effect of different education protocols on concordance with the trial recommendations in two retinal clinics. Methods: A prospective controlled survey of concordance with the AREDS recommendations in two retinal clinics was administered to 330 patients with AREDS category 3 or 4 AMD. The results were evaluated to assess the effect of differing levels of patient education. In clinic 1, there was a formal policy of giving the patient both verbal and written instructions and verbal repetition of these instructions from each staff member on each patient visit; in clinic 2, there was no specific education policy. Results: Clinic 1 had a concordance rate of 81.6% and clinic 2 of 44.1%. There were no significant differences in the patient demographics between the two clinics. Conclusion: A high concordance rate can be achieved in clinical practice with rigorous patient education that includes a policy of having continual repetition of instructions. (C) 2014 S. Karger AG, Basel
C1 [Weaver, Travers R. E.; Beaumont, Paul E.] Eye & Vis Res Inst, Sydney, NSW, Australia.
   [Weaver, Travers R. E.] Griffith Univ, Sch Med, Gold Coast, Qld, Australia.
C3 Griffith University
RP Weaver, TRE (通讯作者)，169 Dugandan St, Nerang, Qld 4211, Australia.
EM trav.weaver@gmail.com
FU Blackmores, Balgowlah, N.S.W., Australia; Travers R.E. Weaver
FX We thank Blackmores, Balgowlah, N.S.W., Australia for providing funding.
   Travers R.E. Weaver received support from a grant to the Eye and Vision
   Research Institute by Blackmores which manufactures an AREDS formulation
   minus the beta-carotene. The funding organization had no role in the
   design, patient selection, conduct, analysis or any other aspect of this
   research.
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Arroll B, 2003, BMJ-BRIT MED J, V327, P1144, DOI 10.1136/bmj.327.7424.1144
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Health Minister's Advisory Council, 1997, STAND UN SCHED DRUGS
   Bissell P, 2004, SOC SCI MED, V58, P851, DOI 10.1016/S0277-9536(03)00259-4
   Briesacher BA, 2007, J GEN INTERN MED, V22, P864, DOI 10.1007/s11606-007-0180-x
   Campbell RJ, 2005, NEW ENGL J MED, V353, P1972
   Chang CW, 2003, CAN J OPHTHALMOL, V38, P27, DOI 10.1016/S0008-4182(03)80005-4
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Evans JR, 2006, COCHRANE DB SYST REV, V2
   GREENBERG RN, 1984, CLIN THER, V6, P592
   Hochstetler BS, 2010, RETINA-J RET VIT DIS, V30, P1166, DOI 10.1097/IAE.0b013e3181cea5c6
   Jampol LM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1634, DOI 10.1001/archopht.121.11.1634
   Jin Jing, 2008, Ther Clin Risk Manag, V4, P269
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Thistlethwaite J E, 2003, Educ Health (Abingdon), V16, P307
   Treharne GJ, 2006, RHEUMATOLOGY, V45, P1, DOI 10.1093/rheumatology/kei223
   Trevithick JR, 2004, OPHTHAL EPIDEMIOL, V11, P337, DOI 10.1080/09286580490888780
NR 21
TC 0
Z9 0
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 2
BP 61
EP 65
DI 10.1159/000366456
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC8AX
UT WOS:000350591400001
PM 25503414
DA 2022-11-30
ER

PT J
AU Lee, MY
   Ham, DI
AF Lee, Mee Yon
   Ham, Don-Il
TI SUBRETINAL DRUSENOID DEPOSITS WITH INCREASED AUTOFLUORESCENCE IN EYES
   WITH RETICULAR PSEUDODRUSEN
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE reticular pseudodrusen; age-related macular degeneration;
   autofluorescence; subretinal drusenoid deposit
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; VITELLIFORM
   MACULAR DYSTROPHY; AGE-RELATED MACULOPATHY; CUTICULAR DRUSEN;
   DEGENERATION; LIPOFUSCIN; DISEASE; FLUORESCENCE; PREVALENCE
AB Purpose: To characterize a variant type of drusenoid deposit with different imaging features in comparison to reticular pseudodrusen.
   Methods: Retrospective observational consecutive case series. Eyes showing atypical drusenoid lesions were sorted out from 257 eyes of 133 patients previously diagnosed as reticular pseudodrusen. Eyes were evaluated using color fundus photography, confocal scanning laser ophthalmoscopy, and spectral domain optical coherence tomography.
   Results: A variant type of drusenoid deposits showing different imaging features from reticular pseudodrusen was found in 17 eyes of 12 patients (6.6%). The mean age of patients was 62.7 +/- 11.6 years, and all patients were women. These deposits were observed as yellowish white, round to oval lesions on color photographs, located under the sensory retina and above the retinal pigment epithelium on spectral domain optical coherence tomography similar to reticular pseudodrusen. However, they were present in a smaller number as discrete lesions and showed increased autofluorescence. None of them were accompanied by late age-related macular degeneration.
   Conclusion: Subretinal drusenoid deposits are not homogeneous and can be classified into two types according to the fundus autofluorescence. Multimodal imaging tests are needed for the differential diagnosis of subretinal drusenoid deposits.
C1 [Lee, Mee Yon] Chung Ang Univ, Coll Med, Dept Ophthalmol, Seoul 156756, South Korea.
   [Ham, Don-Il] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
C3 Chung Ang University; Chung Ang University Hospital; Sungkyunkwan
   University (SKKU); Samsung Medical Center
RP Ham, DI (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM oculus@naver.com
CR Arnold JJ, 2003, EYE, V17, P717, DOI 10.1038/sj.eye.6700460
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Ferrara DC, 2010, GRAEF ARCH CLIN EXP, V248, P1377, DOI 10.1007/s00417-010-1381-2
   Finger RP, 2010, RETINA-J RET VIT DIS, V30, P1455, DOI 10.1097/IAE.0b013e3181e09829
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   KITAGAWA K, 1989, OPHTHALMOLOGICA, V199, P116, DOI 10.1159/000310027
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Leng T, 2009, RETINA-J RET VIT DIS, V29, P988, DOI 10.1097/IAE.0b013e3181ae7113
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, GRAEF ARCH CLIN EXP, V249, P1617, DOI 10.1007/s00417-011-1702-0
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 27
TC 25
Z9 25
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2014
VL 34
IS 1
BP 69
EP 76
DI 10.1097/IAE.0b013e318295f701
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI6CZ
UT WOS:000336958700012
PM 23743636
DA 2022-11-30
ER

PT J
AU Ozel, AB
   Moroi, SE
   Reed, DM
   Nika, M
   Schmidt, CM
   Akbari, S
   Scott, K
   Rozsa, F
   Pawar, H
   Musch, DC
   Lichter, PR
   Gaasterland, D
   Branham, K
   Gilbert, J
   Garnai, SJ
   Chen, W
   Othman, M
   Heckenlively, J
   Swaroop, A
   Abecasis, G
   Friedman, DS
   Zack, D
   Ashley-Koch, A
   Ulmer, M
   Kang, JH
   Liu, YT
   Yaspan, BL
   Haines, J
   Allingham, RR
   Hauser, MA
   Pasquale, L
   Wiggs, J
   Richards, JE
   Li, JZ
AF Ozel, A. Bilge
   Moroi, Sayoko E.
   Reed, David M.
   Nika, Melisa
   Schmidt, Caroline M.
   Akbari, Sara
   Scott, Kathleen
   Rozsa, Frank
   Pawar, Hemant
   Musch, David C.
   Lichter, Paul R.
   Gaasterland, Doug
   Branham, Kari
   Gilbert, Jesse
   Garnai, Sarah J.
   Chen, Wei
   Othman, Mohammad
   Heckenlively, John
   Swaroop, Anand
   Abecasis, Goncalo
   Friedman, David S.
   Zack, Don
   Ashley-Koch, Allison
   Ulmer, Megan
   Kang, Jae H.
   Liu, Yutao
   Yaspan, Brian L.
   Haines, Jonathan
   Allingham, R. Rand
   Hauser, Michael A.
   Pasquale, Louis
   Wiggs, Janey
   Richards, Julia E.
   Li, Jun Z.
CA NEIGHBOR Consortium
TI Genome-wide association study and meta-analysis of intraocular pressure
SO HUMAN GENETICS
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; CENTRAL CORNEAL THICKNESS; TO-DISC RATIO; MACULAR
   DEGENERATION; MOLECULAR-BIOLOGY; GENETIC-VARIANTS; RISK-FACTORS;
   HERITABILITY; EYE; POPULATION
AB Elevated intraocular pressure (IOP) is a major risk factor for glaucoma and is influenced by genetic and environmental factors. Recent genome-wide association studies (GWAS) reported associations with IOP at TMCO1 and GAS7, and with primary open-angle glaucoma (POAG) at CDKN2B-AS1, CAV1/CAV2, and SIX1/SIX6. To identify novel genetic variants and replicate the published findings, we performed GWAS and meta-analysis of IOP in > 6,000 subjects of European ancestry collected in three datasets: the NEI Glaucoma Human genetics collaBORation, GLAUcoma Genes and ENvironment study, and a subset of the Age-related Macular Degeneration-Michigan, Mayo, AREDS and Pennsylvania study. While no signal achieved genome-wide significance in individual datasets, a meta-analysis identified significant associations with IOP at TMCO1 (rs7518099-G, p = 8.0 x 10(-8)). Focused analyses of five loci previously reported for IOP and/or POAG, i.e., TMCO1, CDKN2B-AS1, GAS7, CAV1/CAV2, and SIX1/SIX6, revealed associations with IOP that were largely consistent across our three datasets, and replicated the previously reported associations in both effect size and direction. These results confirm the involvement of common variants in multiple genomic regions in regulating IOP and/or glaucoma risk.
C1 [Ozel, A. Bilge; Li, Jun Z.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
   [Moroi, Sayoko E.; Reed, David M.; Nika, Melisa; Schmidt, Caroline M.; Akbari, Sara; Scott, Kathleen; Rozsa, Frank; Pawar, Hemant; Musch, David C.; Lichter, Paul R.; Branham, Kari; Gilbert, Jesse; Garnai, Sarah J.; Othman, Mohammad; Heckenlively, John; Richards, Julia E.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Musch, David C.; Richards, Julia E.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Gaasterland, Doug] Eye Doctors Washington DC, Washington, DC USA.
   [Chen, Wei] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Div Pulm Med Allergy & Immunol, Pittsburgh, PA USA.
   [Chen, Wei] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Chen, Wei] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA.
   [Swaroop, Anand] NEI, NIH, Bethesda, MD 20892 USA.
   [Abecasis, Goncalo] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Friedman, David S.; Zack, Don] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Ashley-Koch, Allison; Ulmer, Megan; Liu, Yutao; Allingham, R. Rand; Hauser, Michael A.] Duke Univ, Sch Med, Ctr Human Genet, Durham, NC USA.
   [Kang, Jae H.; Pasquale, Louis] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
   [Yaspan, Brian L.; Haines, Jonathan] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Pasquale, Louis; Wiggs, Janey] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); University of Michigan System; University of
   Michigan; Johns Hopkins University; Duke University; Harvard University;
   Brigham & Women's Hospital; Vanderbilt University; Harvard University;
   Harvard Medical School; Massachusetts Eye & Ear Infirmary
RP Li, JZ (通讯作者)，Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
EM smoroi@med.umich.edu; junzli@med.umich.edu
RI Reed, David Millard/AFQ-5520-2022; Chen, Wei/AAX-5994-2020; Reed, David
   M/S-7063-2019; Branham, Kari/AAA-8336-2022; Haines, Jonathan/C-3374-2012
OI Chen, Wei/0000-0001-7196-8703; Reed, David M/0000-0002-4772-6138;
   Haines, Jonathan/0000-0002-4351-4728; Swaroop,
   Anand/0000-0002-1975-1141; Yaspan, Brian/0000-0002-3787-2510; Ozel, Ayse
   Bilge/0000-0002-1112-4258; Branham, Kari/0000-0002-2492-254X; Moroi,
   Sayoko E/0000-0002-0418-0657; Carnes, Megan/0000-0002-7270-132X; Li,
   Jun/0000-0001-6727-0812; Friedman, David/0000-0002-2055-5797; Musch,
   David/0000-0002-4164-3841; Lichter, Paul/0000-0001-8394-4813; Zack,
   Don/0000-0002-7966-1973; Rozsa, Frank/0000-0002-1378-7020; Ashley-Koch,
   Allison/0000-0001-5409-9155
FU University of Michigan Glaucoma Research Center; Ellison Medical
   Foundation; Harvard Glaucoma Center for Excellence; Margolis Fund;
   Research to Prevent Blindness; Glaucoma Research Foundation; Glaucoma
   Foundation; American Health Assistance Foundation; Elmer and Silvia
   Sramek Foundation; Foundation Fighting Blindness; Macula Vision Research
   Foundation; Pew Charitable Trusts; Casey Macular Degeneration Center
   Fund; Marion W. and Edward F. Knight AMD Fund; Harold and Pauline Price
   Foundation; National Genotyping Centre of Spain; NATIONAL CANCER
   INSTITUTE [P01CA087969, R01CA049449, U01CA049449] Funding Source: NIH
   RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015574] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY016862, T32EY021453,
   R01EY012118, R01EY011008, R01EY013315, U10EY012118, ZIAEY000475,
   U10EY009149, R01EY013178, R01EY008208, R01EY010886, P30EY014104,
   R01EY022124, R01EY018660, R01EY009847, R03EY015682, R01EY019126,
   R01EY015543, R01EY009580, R01EY011671, R01EY015872, R01EY015473,
   U10EY006827, R56EY011671, R01EY007758, R01EY009611, R01EY022305,
   R29EY009847] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [U01HL084729, R01HL112642, R01HL039693, R01HL073389]
   Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE
   [U01HG004608, U01HG004728, U54HG004570, R01HG002651, U01HG006389,
   RC1HG005334, U01HG004424] Funding Source: NIH RePORTER
FX Other supports included funding from University of Michigan Glaucoma
   Research Center (S. E. M., J.E.R., J.Z.L.); Ellison Medical Foundation
   (J.Z.L.); Harvard Glaucoma Center for Excellence, and the Margolis Fund
   (J.W. and L. P.); Research to Prevent Blindness (A. S., D. C. M., J.W.,
   L. P., J.R.H., and J.E.R.); the Glaucoma Research Foundation (S. E. M.,
   Y.L.); the Glaucoma Foundation (Y.L.); American Health Assistance
   Foundation (Y.L., J.E.R., J.R.H., A. S.); Elmer and Silvia Sramek
   Foundation (J.R.H., A. S.); Foundation Fighting Blindness (J.R.H., A.
   S.); the Macula Vision Research Foundation (J.R.H., A. S.); the Pew
   Charitable Trusts (J.R.H., A. S.); the Casey Macular Degeneration Center
   Fund (J.R.H., A. S.); the Marion W. and Edward F. Knight AMD Fund
   (J.R.H., A. S.); the Harold and Pauline Price Foundation, National
   Genotyping Centre of Spain (J.R.H., A.S.).
CR Anderson Douglas R, 2003, Curr Opin Ophthalmol, V14, P86
   Anderson DR, 2003, AM J OPHTHALMOL, V136, P820, DOI 10.1016/S0002-9394(03)00478-1
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Brubaker RF, 2004, EXP EYE RES, V78, P633, DOI 10.1016/j.exer.2003.07.002
   Burdon KP, 2011, NAT GENET, V43, P574, DOI 10.1038/ng.824
   Carbonaro F, 2008, BRIT J OPHTHALMOL, V92, P1125, DOI 10.1136/bjo.2007.133272
   Chang TC, 2005, OPHTHALMOLOGY, V112, P1186, DOI 10.1016/j.ophtha.2005.03.006
   Charlesworth J, 2010, INVEST OPHTH VIS SCI, V51, P3509, DOI 10.1167/iovs.09-4786
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cornelis MC, 2010, GENET EPIDEMIOL, V34, P364, DOI 10.1002/gepi.20492
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Freeman EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055573
   Fukuoka S, 2008, ACTA OPHTHALMOL, V86, P434, DOI 10.1111/j.1600-0420.2007.01068.x
   GIUFFRE G, 1995, ACTA OPHTHALMOL SCAN, V73, P222
   Hashemi H, 2005, BRIT J OPHTHALMOL, V89, P652, DOI 10.1136/bjo.2004.058057
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Klein BEK, 2004, INVEST OPHTH VIS SCI, V45, P59, DOI 10.1167/iovs.03-0516
   Kohlhaas M, 2006, ARCH OPHTHALMOL-CHIC, V124, P471, DOI 10.1001/archopht.124.4.471
   Lee MK, 2012, OPHTHALMOLOGY, V119, P450, DOI 10.1016/j.ophtha.2011.09.016
   Leske MC, 2007, OPHTHALMOLOGY, V114, P1965, DOI 10.1016/j.ophtha.2007.03.016
   Leske MC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1051, DOI 10.1001/archopht.1997.01100160221012
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Li X, 2012, INVEST OPHTH VIS SCI, V53, P3082, DOI 10.1167/iovs.12-9967
   Liton P, 2006, MOL VIS, V12, P774
   Liu JHK, 2011, OPHTHALMOLOGY, V118, P1995, DOI 10.1016/j.ophtha.2011.03.015
   Miglior S, 2007, AM J OPHTHALMOL, V144, P266, DOI 10.1016/j.ajo.2007.04.040
   Moroi SE, 2009, EXPERT REV OPHTHALMO, V4, P145, DOI 10.1586/EOP.09.6
   Musch DC, 2011, OPHTHALMOLOGY, V118, P1766, DOI 10.1016/j.ophtha.2011.01.047
   Nickells RW, 2012, INVEST OPHTH VIS SCI, V53, P2476, DOI 10.1167/iovs.12-9483h
   Parssinen O, 2007, OPHTHALMOLOGY, V114, P2227, DOI 10.1016/j.ophtha.2007.03.011
   Pekmezci M, 2011, ARCH OPHTHALMOL-CHIC, V129, P276, DOI 10.1001/archophthalmol.2011.33
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Qureshi I A, 1996, Chin J Physiol, V39, P183
   Sharma S, 2012, INVEST OPHTH VIS SCI, V53, P4917, DOI 10.1167/iovs.11-9047
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Thorleifsson G, 2010, NAT GENET, V42, P906, DOI 10.1038/ng.661
   van der Valk R, 2005, OPHTHALMOLOGY, V112, P1177, DOI 10.1016/j.ophtha.2005.01.042
   van Koolwijk LME, 2007, INVEST OPHTH VIS SCI, V48, P3669, DOI 10.1167/iovs.06-1519
   van Koolwijk LME, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002611
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   Wiggs JL, 2012, PLOS GENET, V8, P413, DOI 10.1371/journal.pgen.1002654
   Wiggs JL, 2012, INVEST OPHTH VIS SCI, V53, P2467, DOI 10.1167/iovs.12-9483e
   Wiggs JL, 2012, J GLAUCOMA
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Wong TT, 2009, INVEST OPHTH VIS SCI, V50, P4097, DOI 10.1167/iovs.08-2822
   Xin BZ, 2010, P NATL ACAD SCI USA, V107, P258, DOI 10.1073/pnas.0908457107
   Zhang ZS, 2010, MOL BIOL REP, V37, P1611, DOI 10.1007/s11033-009-9573-8
   Zheng YF, 2009, INVEST OPHTH VIS SCI, V50, P2040, DOI 10.1167/iovs.08-3082
NR 50
TC 77
Z9 77
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD JAN
PY 2014
VL 133
IS 1
BP 41
EP 57
DI 10.1007/s00439-013-1349-5
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 283KH
UT WOS:000329244500004
PM 24002674
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chiu, K
   Chan, TF
   Wu, A
   Leung, IYP
   So, KF
   Chang, RCC
AF Chiu, Kin
   Chan, Tin-Fung
   Wu, Andrew
   Leung, Irene Yan-Pui
   So, Kwok-Fai
   Chang, Raymond Chuen-Chung
TI Neurodegeneration of the retina in mouse models of Alzheimer's disease:
   what can we learn from the retina?
SO AGE
LA English
DT Article
DE Age-related macular degeneration; Alzheimer's disease; Glaucoma; Inner
   nuclear layer; Neurodegeneration; Retina; Retinal ganglion cells
ID AMYLOID PRECURSOR PROTEIN; EUKARYOTIC INITIATION FACTOR-2-ALPHA;
   LONG-TERM POTENTIATION; A-BETA-PEPTIDE; GANGLION-CELLS; IN-VIVO; OCULAR
   HYPERTENSION; LYCIUM-BARBARUM; MITOCHONDRIAL DYSFUNCTION; COGNITIVE
   PERFORMANCE
AB Alzheimer's disease (AD) is an age-related progressive neurodegenerative disease commonly found among elderly. In addition to cognitive and behavioral deficits, vision abnormalities are prevalent in AD patients. Recent studies investigating retinal changes in AD double-transgenic mice have shown altered processing of amyloid precursor protein and accumulation of beta-amyloid peptides in neurons of retinal ganglion cell layer (RGCL) and inner nuclear layer (INL). Apoptotic cells were also detected in the RGCL. Thus, the pathophysiological changes of retinas in AD patients are possibly resembled by AD transgenic models. The retina is a simple model of the brain in the sense that some pathological changes and therapeutic strategies from the retina may be observed or applicable to the brain. Furthermore, it is also possible to advance our understanding of pathological mechanisms in other retinal degenerative diseases. Therefore, studying AD-related retinal degeneration is a promising way for the investigation on (1) AD pathologies and therapies that would eventually benefit the brain and (2) cellular mechanisms in other retinal degenerations such as glaucoma and age-related macular degeneration. This review will highlight the efforts on retinal degenerative research using AD transgenic mouse models.
C1 [So, Kwok-Fai; Chang, Raymond Chuen-Chung] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Pokfulam, Hong Kong, Peoples R China.
   [So, Kwok-Fai; Chang, Raymond Chuen-Chung] Univ Hong Kong, Res Ctr Heart Brain Hormone & Healthy Aging, Pokfulam, Hong Kong, Peoples R China.
   [Chiu, Kin; Chan, Tin-Fung; Wu, Andrew; Leung, Irene Yan-Pui; So, Kwok-Fai; Chang, Raymond Chuen-Chung] Univ Hong Kong, Dept Anat, Lab Neurodegenerat Dis, Pokfulam, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong; University of Hong
   Kong
RP Chang, RCC (通讯作者)，Univ Hong Kong, State Key Lab Brain & Cognit Sci, Rm L1-49,Lab Block,Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.
EM rccchang@hku.hk
RI Chang, Raymond Chuen-Chung/C-1107-2009; Chiu, Kin/ABI-7938-2020
OI Chang, Raymond Chuen-Chung/0000-0001-8538-7993; Chiu,
   Kin/0000-0001-6581-9007; So, Kwok-Fai/0000-0003-4039-4246
FU HKU Alzheimer's Disease Research Network under Strategic Research Theme
   on Healthy Aging; Strategic Research Theme on Drug Discovery; Azalea;
   HKU [20097176185]
FX Research in this laboratory is partly supported by HKU Alzheimer's
   Disease Research Network under Strategic Research Theme on Healthy
   Aging, Strategic Research Theme on Drug Discovery, Azalea (1972)
   Endowment Fund, and HKU Small Project Fund (20097176185).
CR Allen B, 2002, J NEUROSCI, V22, P9340
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Arendash GW, 2004, BRAIN RES, V1012, P29, DOI 10.1016/j.brainres.2004.02.081
   Bakalash S, 2002, INVEST OPHTH VIS SCI, V43, P2648
   Baum L, 2008, J CLIN PSYCHOPHARM, V28, P110, DOI 10.1097/jcp.0b013e318160862c
   Bayer AU, 2002, EUR NEUROL, V47, P165, DOI 10.1159/000047976
   Bayer TA, 2008, GENES BRAIN BEHAV, V7, P6, DOI 10.1111/j.1601-183X.2007.00372.x
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   Blanks JC, 1996, NEUROBIOL AGING, V17, P377, DOI 10.1016/0197-4580(96)00010-3
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Caroni P, 1997, J NEUROSCI METH, V71, P3, DOI 10.1016/S0165-0270(96)00121-5
   Casas C, 2004, AM J PATHOL, V165, P1289, DOI 10.1016/S0002-9440(10)63388-3
   Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031
   Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011
   Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x
   Chiu K, 2005, BRAIN RES, V1046, P207, DOI 10.1016/j.brainres.2005.04.016
   Chiu Kin, 2007, J Vis Exp, P313, DOI 10.3791/313
   Chiu Kin, 2009, J Ocul Biol Dis Infor, V2, P127
   Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539
   Cordeiro MF, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.3
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Duyckaerts C, 2008, ACTA NEUROPATHOL, V115, P5, DOI 10.1007/s00401-007-0312-8
   Eriksen JL, 2007, BEHAV GENET, V37, P79, DOI 10.1007/s10519-006-9118-z
   Frank S, 2008, ACTA NEUROPATHOL, V115, P39, DOI 10.1007/s00401-007-0291-9
   Garcia MF, 2004, NEUROREPORT, V15, P73, DOI 10.1097/00001756-200401190-00015
   Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x
   Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017
   Gasparini L, 2011, NEUROBIOL AGING, V32, P419, DOI 10.1016/j.neurobiolaging.2009.03.002
   Gau JT, 2002, AM J PATHOL, V160, P731, DOI 10.1016/S0002-9440(10)64893-6
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gruart A, 2008, NEUROBIOL DIS, V30, P439, DOI 10.1016/j.nbd.2008.03.001
   GRUNDKEIQBAL I, 1989, P NATL ACAD SCI USA, V86, P2853, DOI 10.1073/pnas.86.8.2853
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hedges TR, 1996, ACTA OPHTHALMOL SCAN, V74, P271
   Hintersteiner M, 2005, NAT BIOTECHNOL, V23, P577, DOI 10.1038/nbt1085
   Ho YS, 2010, AGEING RES REV, V9, P354, DOI 10.1016/j.arr.2009.10.001
   Ho YS, 2010, J ALZHEIMERS DIS, V19, P813, DOI 10.3233/JAD-2010-1280
   Ho YS, 2009, CELL MOL NEUROBIOL, V29, P1233, DOI 10.1007/s10571-009-9419-x
   Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99
   Hung CHL, 2010, AGEING RES REV, V9, P447, DOI 10.1016/j.arr.2010.05.003
   Ji JZ, 2004, EUR J NEUROSCI, V19, P265, DOI 10.1111/j.0953-816X.2003.03107.x
   Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Ju WK, 2007, INVEST OPHTH VIS SCI, V48, P2145, DOI 10.1167/iovs.06-0573
   Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001
   King DL, 1999, BEHAV BRAIN RES, V103, P145, DOI 10.1016/S0166-4328(99)00037-6
   Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Le Cudennec C, 2008, GENES BRAIN BEHAV, V7, P83, DOI 10.1111/j.1601-183X.2007.00374.x
   Li M, 2007, PROG NEUROBIOL, V83, P131, DOI 10.1016/j.pneurobio.2007.08.002
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   Liu XG, 2009, INT J BIOCHEM CELL B, V41, P1972, DOI 10.1016/j.biocel.2009.05.013
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malamas MS, 2010, BIOORG MED CHEM LETT, V20, P6597, DOI 10.1016/j.bmcl.2010.09.029
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   McKinnon SJ, 2003, FRONT BIOSCI-LANDMRK, V8, pS1140, DOI 10.2741/1172
   McKinnon SJ, 2002, INVEST OPHTH VIS SCI, V43, P1077
   MENDEZ MF, 1990, NEUROLOGY, V40, P439, DOI 10.1212/WNL.40.3_Part_1.439
   MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J
   Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483
   Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116
   MORIN PJ, 1993, J NEUROCHEM, V61, P464
   Muyllaert D, 2008, GENES BRAIN BEHAV, V7, P57, DOI 10.1111/j.1601-183X.2007.00376.x
   Nakada T, 2008, J NEUROIMAGING, V18, P125, DOI 10.1111/j.1552-6569.2007.00179.x
   Nimmrich V, 2008, J NEUROSCI, V28, P788, DOI 10.1523/JNEUROSCI.4771-07.2008
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047
   Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3
   Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Pezzini A, 2009, CURR MED CHEM, V16, P2498, DOI 10.2174/092986709788682047
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461
   Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079
   Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479
   Rizzo M, 2000, NEUROPSYCHOLOGIA, V38, P1157, DOI 10.1016/S0028-3932(00)00023-3
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   ROQUE RS, 1990, GLIA, V3, P464, DOI 10.1002/glia.440030605
   Santos RX, 2010, J ALZHEIMERS DIS, V20, pS401, DOI 10.3233/JAD-2010-100666
   Saotome M, 2008, P NATL ACAD SCI USA, V105, P20728, DOI 10.1073/pnas.0808953105
   Scattoni ML, 2010, BEHAV BRAIN RES, V208, P250, DOI 10.1016/j.bbr.2009.12.002
   Seo AY, 2010, J CELL SCI, V123, P2533, DOI 10.1242/jcs.070490
   Shimazawa M, 2007, INVEST OPHTH VIS SCI, V48, P3729, DOI 10.1167/iovs.06-1122
   Spires Tara L, 2005, NeuroRx, V2, P423, DOI 10.1602/neurorx.2.3.423
   Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057
   Suen KC, 2003, J BIOL CHEM, V278, P49819, DOI 10.1074/jbc.M306503200
   Suo Z, 2007, NEUROBIOL AGING, V28, P1873, DOI 10.1016/j.neurobiolaging.2006.08.013
   Tamura H, 2006, J NEUROL SCI, V246, P79, DOI 10.1016/j.jns.2006.02.009
   Tanghe An, 2010, Int J Alzheimers Dis, V2010, DOI 10.4061/2010/417314
   Terwel D, 2005, J BIOL CHEM, V280, P3963, DOI 10.1074/jbc.M409876200
   Valenti DA, 2010, OPTOMETRY, V81, P12, DOI 10.1016/j.optm.2009.04.101
   Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a
   Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485
   Wan J, 2010, J NEUROSCI, V30, P6873, DOI 10.1523/JNEUROSCI.0519-10.2010
   Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X
   Wang XL, 2009, J NEUROSCI, V29, P9090, DOI 10.1523/JNEUROSCI.1357-09.2009
   Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002
   Wostyn P, 2008, CLIN NEUROL NEUROSUR, V110, P101, DOI 10.1016/j.clineuro.2007.10.011
   Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200
   Yin HB, 2008, MED HYPOTHESES, V71, P77, DOI 10.1016/j.mehy.2008.01.030
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yu MS, 2007, INT J MOL MED, V20, P261
   Yu MS, 2006, INT J MOL MED, V17, P1157
   Zahs KR, 2010, TRENDS NEUROSCI, V33, P381, DOI 10.1016/j.tins.2010.05.004
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 114
TC 68
Z9 71
U1 2
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD JUN
PY 2012
VL 34
IS 3
BP 633
EP 649
DI 10.1007/s11357-011-9260-2
PG 17
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 935GP
UT WOS:000303507400010
PM 21559868
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Jing, GJ
   Wang, JJ
   Zhang, SX
AF Jing, Guangjun
   Wang, Joshua J.
   Zhang, Sarah X.
TI ER Stress and Apoptosis: A New Mechanism for Retinal Cell Death
SO EXPERIMENTAL DIABETES RESEARCH
LA English
DT Review
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; EXPERIMENTAL
   AUTOIMMUNE UVEORETINITIS; DIABETIC-RETINOPATHY; RETINITIS-PIGMENTOSA;
   TRANSCRIPTION FACTOR; MESSENGER-RNA; OXIDATIVE STRESS; TRANSMEMBRANE
   PROTEIN; MAMMALIAN-CELLS
AB The endoplasmic reticulum (ER) is the primary subcellular organelle where proteins are synthesized and folded. When the homeostasis of the ER is disturbed, unfolded or misfolded proteins accumulate in the ER lumen, resulting in ER stress. In response to ER stress, cells activate a set of tightly controlled regulatory programs, known as the unfolded protein response (UPR), to restore the normal function of the ER. However, if ER stress is sustained and the adaptive UPR fails to eliminate unfolded/misfolded proteins, apoptosis will occur to remove the stressed cells. In recent years, a large body of studies has shown that ER stress-induced apoptosis is implicated in numerous human diseases, such as diabetes and neurogenerative diseases. Moreover, emerging evidence supports a role of ER stress in retinal apoptosis and cell death in blinding disorders such as age-related macular degeneration and diabetic retinopathy. In the present review, we summarize recent progress on ER stress and apoptosis in retinal diseases, focusing on various proapoptotic and antiapoptotic pathways that are activated by the UPR, and discuss how these pathways contribute to ER stress-induced apoptosis in retinal cells.
C1 [Jing, Guangjun; Wang, Joshua J.; Zhang, Sarah X.] Univ Oklahoma, Hlth Sci Ctr, Dept Med Endocrinol & Diabet, Oklahoma City, OK 73104 USA.
   [Jing, Guangjun; Wang, Joshua J.; Zhang, Sarah X.] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK 73104 USA.
   [Zhang, Sarah X.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; University of Oklahoma System; University of Oklahoma
   Health Sciences Center
RP Zhang, SX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Med Endocrinol & Diabet, 941 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.
EM xin-zhang@ouhsc.edu
FU National Institutes of Health [EY019949]; American Diabetes Association;
   Juvenile Diabetes Research Foundation; Oklahoma Center for the
   Advancement of Science and Technology; American Health Assistance
   Foundation; Harold Hamm Diabetes Center; NATIONAL EYE INSTITUTE
   [R01EY019949] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health Grant
   EY019949 and research awards from the American Diabetes Association,
   Juvenile Diabetes Research Foundation, Oklahoma Center for the
   Advancement of Science and Technology, American Health Assistance
   Foundation, and Harold Hamm Diabetes Center (all to S. X. Zhang).
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Amano S, 2005, MICROVASC RES, V69, P45, DOI 10.1016/j.mvr.2004.11.001
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Arita R, 2009, DIABETES, V58, P215, DOI 10.2337/db08-0762
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Behl Y, 2008, AM J PATHOL, V172, P1411, DOI 10.2353/ajpath.2008.071070
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014
   Bouman L, 2011, CELL DEATH DIFFER, V18, P769, DOI 10.1038/cdd.2010.142
   Bromati CR, 2011, AM J PHYSIOL-REG I, V300, pR92, DOI 10.1152/ajpregu.00169.2010
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646
   Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Dasmahapatra G, 2009, CANCER BIOL THER, V8, P808, DOI 10.4161/cbt.8.9.8131
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Doh SH, 2010, BRAIN RES, V1308, P158, DOI 10.1016/j.brainres.2009.10.025
   Eymin B, 1997, CANCER RES, V57, P686
   Friedman AD, 1996, CANCER RES, V56, P3250
   Galehdar Z, 2010, J NEUROSCI, V30, P16938, DOI 10.1523/JNEUROSCI.1598-10.2010
   GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5
   Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391
   Gorbatyuk MS, 2010, P NATL ACAD SCI USA, V107, P5961, DOI 10.1073/pnas.0911991107
   Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.0.CO;2-5
   Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787
   Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019
   Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480
   HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2
   Inokuchi Y, 2009, INVEST OPHTH VIS SCI, V50, P334, DOI 10.1167/iovs.08-2123
   Iwawaki T, 2009, P NATL ACAD SCI USA, V106, P16657, DOI 10.1073/pnas.0903775106
   Jousse C, 2007, J BIOL CHEM, V282, P15851, DOI 10.1074/jbc.M611723200
   Joussen AM, 2002, FASEB J, V16, P76, DOI 10.1096/fj.02-0157fje
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Joussen AM, 2002, AM J PATHOL, V160, P1683, DOI 10.1016/S0002-9440(10)61115-7
   Ju KR, 2006, BRAIN RES, V1122, P209, DOI 10.1016/j.brainres.2006.09.022
   Kang MJ, 2009, P NATL ACAD SCI USA, V106, P17043, DOI 10.1073/pnas.0905566106
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205
   Kowluru RA, 2005, ANTIOXID REDOX SIGN, V7, P1581, DOI 10.1089/ars.2005.7.1581
   Kusner LL, 2004, INVEST OPHTH VIS SCI, V45, P1553, DOI 10.1167/iovs.03-1294
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807
   Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003
   Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702
   Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173
   Li B, 2008, MOL VIS, V14, P1122
   Li JM, 2011, J BIOL CHEM, V286, P4912, DOI 10.1074/jbc.M110.199729
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200
   Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778
   Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004
   Liu Y, 2009, CELL DEATH DIFFER, V16, P847, DOI 10.1038/cdd.2009.14
   Martin PM, 2004, INVEST OPHTH VIS SCI, V45, P3330, DOI 10.1167/iovs.04-0247
   Matsuguchi T, 2009, J BONE MINER RES, V24, P398, DOI 10.1359/JBMR.081107
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Mendes CS, 2009, EMBO J, V28, P1296, DOI 10.1038/emboj.2009.76
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   MORI K, 1993, CELL, V74, P743
   Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200
   Naidoo N, 2008, J NEUROSCI, V28, P6539, DOI 10.1523/JNEUROSCI.5685-07.2008
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550
   Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Poulaki V, 2001, EXP EYE RES, V72, P623, DOI 10.1006/exer.2001.0992
   Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027
   Rajan SS, 2007, INDIAN J MED RES, V125, P411
   Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378
   Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200
   Rebello G, 2004, P NATL ACAD SCI USA, V101, P6617, DOI 10.1073/pnas.0401529101
   Reimold AM, 2000, GENE DEV, V14, P152
   Reme CE, 2000, NEWS PHYSIOL SCI, V15, P120, DOI 10.1152/physiologyonline.2000.15.3.120
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477
   Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Shimazawa M, 2007, MOL VIS, V13, P578
   Shinohara T, 2008, MED HYPOTHESES, V70, P378, DOI 10.1016/j.mehy.2007.04.041
   Sittler A, 2001, HUM MOL GENET, V10, P1307, DOI 10.1093/hmg/10.12.1307
   Sueda J, 2000, INVEST OPHTH VIS SCI, V41, P799
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Szegezdi E, 2006, BIOCHEM BIOPH RES CO, V349, P1406, DOI 10.1016/j.bbrc.2006.09.009
   Tam BM, 2006, INVEST OPHTH VIS SCI, V47, P3234, DOI 10.1167/iovs.06-0213
   Tam LCS, 2010, HUM MOL GENET, V19, P4421, DOI 10.1093/hmg/ddq369
   Tarrant TK, 1999, J EXP MED, V189, P219, DOI 10.1084/jem.189.2.219
   Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857
   Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812
   Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359
   Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101
   Verma G, 2010, APOPTOSIS, V15, P864, DOI 10.1007/s10495-010-0498-4
   Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200
   Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347
   Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   WOLTER JR, 1961, AM J OPHTHALMOL, V51, P1123
   Yang LP, 2008, J NEUROSCI RES, V86, P910, DOI 10.1002/jnr.21535
   Yang PZ, 2000, CHINESE MED J-PEKING, V113, P643
   Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
   Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000
   Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4
   Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x
   Zhong Y., ADV EXPT ME IN PRESS
NR 117
TC 135
Z9 142
U1 0
U2 24
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-5214
EI 1687-5303
J9 EXP DIABETES RES
JI Exp. Diabetes Res.
PY 2012
AR 589589
DI 10.1155/2012/589589
PG 11
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 870YA
UT WOS:000298703600001
PM 22216020
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lee, E
   MacLaren, RE
AF Lee, E.
   MacLaren, R. E.
TI Sources of retinal pigment epithelium (RPE) for replacement therapy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID PLURIPOTENT STEM-CELLS; MACULAR DEGENERATION; BRUCHS MEMBRANE;
   AUTOLOGOUS TRANSLOCATION; TERM SURVIVAL; TRANSPLANTATION; ADHESION;
   FETAL; NEOVASCULARIZATION; IMPLANTATION
AB Stem cells, with their capacity to regenerate and replace diseased tissues, have recently been proposed as having great potential in the treatment of age-related macular degeneration (AMD). A stem cell therapeutic approach could operate to replace either the retinal pigment epithelium (RPE), the neurosensory retina or a combination of both. From the scientific perspective, RPE replacement alone is likely to be far more straightforward than rebuilding the complex circuitry of the neurosensory retina. Furthermore, recent advances with induced pluripotent stem cells have raised the real possibility of transplanting healthy 'young' autologous RPE into patients with early signs of AMD. At this stage, however, it is useful to reconsider some of the earlier clinical studies that used suspensions of autologous RPE cells harvested from the peripheral retina. These showed that isolated RPE cell suspensions had little capacity to recreate a monolayer on the diseased Bruch's membrane of AMD. To counter this problem, researchers from Southampton in the UK report the use of a synthetic polymer alternative to Bruch's membrane, which could provide a scaffold for future RPE derived from stem cells or possibly reopen opportunities for autologous RPE cells harvested from the peripheral retina.
C1 [MacLaren, R. E.] Univ Oxford, John Radcliffe Hosp, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
   [Lee, E.; MacLaren, R. E.] UCL Inst Ophthalmol, London, England.
   [Lee, E.; MacLaren, R. E.] Fdn Trust NIHR Ophthalmol Biomed Res Ctr, Moorfields Eye Hosp, London, England.
   [MacLaren, R. E.] John Radcliffe Hosp, Oxford Eye Hosp, Oxford OX3 9DU, England.
C3 University of Oxford; University of London; University College London;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Oxford
RP MacLaren, RE (通讯作者)，Univ Oxford, John Radcliffe Hosp, Nuffield Lab Ophthalmol, Level 6,Headley Way, Oxford OX3 9DU, England.
EM enquiries@eye.ox.ac.uk
OI MacLaren, Robert/0000-0002-3096-4682
FU Medical Research Council; Royal College of Surgeons of Edinburgh; Fight
   for Sight; Oxford University Press; Special Trustees of Moorfields Eye
   Hospital; NIHR Ophthalmology Biomedical Research Centre; Wellcome Trust;
   MRC; Health Foundation; NIHR; MRC [G0601588] Funding Source: UKRI;
   Medical Research Council [G0601588] Funding Source: researchfish
FX EL is a Wellcome Trust Clinical Training Fellow; REM is a Health
   Foundation Clinician Scientist Fellow. This research is also supported
   by the Medical Research Council, the Royal College of Surgeons of
   Edinburgh, Fight for Sight, the John Fell Fund of Oxford University
   Press, the Special Trustees of Moorfields Eye Hospital and the NIHR
   Ophthalmology Biomedical Research Centre. Other Funders: Wellcome Trust;
   MRC, Health Foundation, NIHR.
CR Afshari FT, 2009, EYE, V23, P1890, DOI 10.1038/eye.2008.411
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Byrne JA, 2007, NATURE, V450, P497, DOI 10.1038/nature06357
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Crafoord S, 1999, ACTA OPHTHALMOL SCAN, V77, P247, DOI 10.1034/j.1600-0420.1999.770301.x
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Ebert AD, 2009, NATURE, V457, P277, DOI 10.1038/nature07677
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Economopoulou M, 2009, INVEST OPHTH VIS SCI, V50, P1454, DOI 10.1167/iovs.08-2129
   Enzmann V, 1998, ACTA ANAT, V162, P178
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Franzco FKC, 2009, CLIN EXP OPHTHALMOL, V37, P275, DOI 10.1111/j.1442-9071.2009.01915.x
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Grisanti S, 2002, JPN J OPHTHALMOL, V46, P36, DOI 10.1016/S0021-5155(01)00464-6
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   Jorgensen A, 1998, INVEST OPHTH VIS SCI, V39, P1590
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Lu LC, 1998, J BIOMAT SCI-POLYM E, V9, P1187
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   LUND RD, 1989, TRANSPLANT P, V21, P3159
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P380, DOI 10.1001/archopht.1964.00970020380016
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   TAKEI Y, 1975, INVEST OPHTH VISUAL, V14, P903
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thomson HAJ, 2011, BRIT J OPHTHALMOL, V95, P563, DOI 10.1136/bjo.2009.166728
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2008, AM J OPHTHALMOL, V146, P151, DOI 10.1016/j.ajo.2008.05.027
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 59
TC 27
Z9 29
U1 2
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2011
VL 95
IS 4
BP 445
EP 449
DI 10.1136/bjo.2009.171918
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 736NZ
UT WOS:000288502700003
PM 20601659
DA 2022-11-30
ER

PT J
AU Clausen, M
   Huang, SY
   Emek, SC
   Sjoholm, I
   Akerlund, HE
AF Clausen, Maria
   Huang, Siyu
   Emek, Sinan C.
   Sjoholm, Ingegerd
   Akerlund, Hans-Erik
TI Post harvest improvement of zeaxanthin content of vegetables
SO JOURNAL OF FOOD ENGINEERING
LA English
DT Article
DE Carotenoid; Lutein; Violaxanthin; AMD; Violaxanthin de-epoxidase;
   Age-related macular degeneration; Antioxidant
ID VIOLAXANTHIN DE-EPOXIDASE; MACULAR PIGMENT; XANTHOPHYLL CYCLE; PRIMATE
   RETINAS; NUTRITIONAL MANIPULATION; LUTEIN; AGE; DEGENERATION;
   PHOTOSYNTHESIS; TEMPERATURE
AB Zeaxanthin is a carotenoid produced by plants and has been associated with protection of the photosynthetic machinery under light stress and, together with lutein, in protection of the central retina of the eye. Zeaxanthin levels in blood plasma have been negatively correlated to the development of AMD (age-related macular degeneration) (Gale et al, 2003). Under normal conditions, plants have a low content of zeaxanthin. The aim of this study was to increase the zeaxanthin content in green vegetables by post harvest treatments. Efficient conditions for activation of the endogenous enzyme system generating zeaxanthin was established and included incubation at low pH (2.5-5.5), with the membrane permeable acetic acid/acetate buffer at room temperature or above for 30 min or more. Typically more than 20-fold increase in zeaxanthin content was obtained for spinach, corn salad, parsley, basil, lemon balm and peas. For spinach up to 4 mg/100 g fresh weight of leaves were obtained. In consequence less amount of vegetables would be needed in the diet to provide the same amount of zeaxanthin for the eye. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Clausen, Maria; Huang, Siyu; Emek, Sinan C.; Akerlund, Hans-Erik] Lund Univ, Dept Biochem, Ctr Mol Prot Sci, SE-22100 Lund, Sweden.
   [Sjoholm, Ingegerd] Lund Univ, Dept Food Technol, Ctr Chem & Chem Engn, SE-22100 Lund, Sweden.
C3 Lund University; Lund University
RP Akerlund, HE (通讯作者)，Lund Univ, Dept Biochem, Ctr Mol Prot Sci, POB 124, SE-22100 Lund, Sweden.
EM Hans-Erik.Akerlund@biochemistry.lu.se
OI Akerlund, Hans-Erik/0000-0003-2104-2077
FU Carl Trygger Foundation; Magnus Bergvall Foundation; Sven & Lilly Lawski
   Foundation
FX This work has been financially supported by Carl Trygger Foundation and
   Magnus Bergvall Foundation and individually to MC from Sven & Lilly
   Lawski Foundation.
CR Arvidsson PO, 1997, PHOTOSYNTH RES, V52, P39, DOI 10.1023/A:1005868026374
   Barua AB, 2001, J NUTR, V131, P3212, DOI 10.1093/jn/131.12.3212
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhosale P, 2007, ARCH BIOCHEM BIOPHYS, V458, P121, DOI 10.1016/j.abb.2006.10.005
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BRATT CE, 1995, PHOTOSYNTH RES, V45, P169, DOI 10.1007/BF00032588
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557
   DemmigAdams B, 1996, TRENDS PLANT SCI, V1, P21, DOI 10.1016/S1360-1385(96)80019-7
   Emek SC, 2010, PREP BIOCHEM BIOTECH, V40, P13, DOI 10.1080/10826060903413057
   Eskling M, 1998, PHOTOSYNTH RES, V57, P41, DOI 10.1023/A:1006015630167
   Eskling M, 1997, PHYSIOL PLANTARUM, V100, P806, DOI 10.1034/j.1399-3054.1997.1000407.x
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   HAGER A, 1969, PLANTA, V89, P224, DOI 10.1007/BF00385028
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   *JOINT FAO WHO EXP, 2004, WHO TECH REP SER, V928
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Nagy V, 2009, PHYTOCHEM ANALYSIS, V20, P143, DOI 10.1002/pca.1109
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Szilagyi A, 2008, BBA-BIOMEMBRANES, V1778, P348, DOI 10.1016/j.bbamem.2007.10.006
   Szilagyi A, 2007, BBA-BIOMEMBRANES, V1768, P2310, DOI 10.1016/j.bbamem.2007.06.001
   THYER SS, 1990, PHOTOSYNTH RES, V23, P331
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Young AJ, 1997, PURE APPL CHEM, V69, P2125, DOI 10.1351/pac199769102125
NR 26
TC 4
Z9 5
U1 1
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0260-8774
EI 1873-5770
J9 J FOOD ENG
JI J. Food Eng.
PD MAY
PY 2010
VL 98
IS 2
BP 192
EP 197
DI 10.1016/j.jfoodeng.2009.12.025
PG 6
WC Engineering, Chemical; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Food Science & Technology
GA 569AU
UT WOS:000275569100006
DA 2022-11-30
ER

PT J
AU Salahuddin, A
AF Salahuddin, Ahmad
TI Inverse horse-shoe technique for the phacoemulsification of posterior
   polar cataract
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE phacoemulsification; posterior polar cataract; posterior capsular
   rupture
ID SURGERY; MANAGEMENT
AB Objective: To study a new technique of controlled hydrodelineation followed by viscodelineation and viscodissection during phacoemulsification in eyes with posterior polar cataracts and to report its effectiveness in preserving the posterior capsule.
   Design: Prospective interventional study.
   Participants: Twenty-eight eyes of 22 patients with posterior polar cataracts.
   Methods: All patients underwent phacoemulsification under topical anaesthesia with controlled hydrodelineation, viscodelineation, and viscodissection with minimal stress on the posterior capsule. Hydrodissection was not done. The preoperative complications and visual outcome were recorded.
   Results: The mean follow-up time was 8 months (range 2-24 months). Posterior capsule rupture occurred only in 2 eyes (7.1%); neither of the 2 had any vitreous prolapse, so anterior vitrectomy was not required. Mean visual acuity improved significantly after surgery (p = 0.0001, paired t test). The causes of the low postoperative visual acuity were amblyopia in 3 eyes (10.7%) and age-related macular degeneration in 1 (3.6%).
   Conclusions: This inverse horse-shoe technique of controlled viscodelineation and viscodissection markedly reduced the risk of posterior capsule rupture. Moreover, if it occurred, the anterior vitreous face remained intact, so the IOL could be implanted in the sulcus without resorting to anterior vitrectomy.
C1 [Salahuddin, Ahmad] Combined Mil Hosp, Eye Dept, Rawalpindi, Pakistan.
RP Salahuddin, A (通讯作者)，Combined Mil Hosp, Eye Dept, Tamizuddin Rd, Rawalpindi Cantt 44000, Punjab, Pakistan.
EM muzains7@hotmail.com
CR Allen D, 2002, J CATARACT REFR SURG, V28, P742, DOI 10.1016/S0886-3350(02)01244-0
   Chee SP, 2007, J CATARACT REFR SURG, V33, P1509, DOI 10.1016/j.jcrs.2007.05.027
   DAS S, 2003, BR J OPHTHALMOL, V92, P1476
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Duke-Elder S., 1964, SYSTEM OPHTHALMOLO 2, V3, P723
   Fine IH, 2003, J CATARACT REFR SURG, V29, P16, DOI 10.1016/S0886-3350(02)01616-4
   Gavris Monica, 2004, Oftalmologia, V48, P36
   Haripriya A, 2006, J CATARACT REFR SURG, V32, P914, DOI 10.1016/j.jcrs.2006.02.049
   Hayashi K, 2003, J CATARACT REFR SURG, V29, P45, DOI 10.1016/S0886-3350(02)01692-9
   HEJTMANCIK JF, 2001, DUANES CLIN OPHTHALM, V1, pCH74
   Ionides ACW, 1997, HUM MOL GENET, V6, P47, DOI 10.1093/hmg/6.1.47
   Jaycock P, 2009, EYE, V23, P38, DOI 10.1038/sj.eye.6703015
   Lee MW, 2003, BRIT J OPHTHALMOL, V87, P1426, DOI 10.1136/bjo.87.11.1426-a
   Luntz MH., 2006, DUANES OPHTHALMOLOGY
   Moghimi S, 2007, EYE, V21, P675, DOI 10.1038/sj.eye.6702685
   OSHER RH, 1990, J CATARACT REFR SURG, V16, P157, DOI 10.1016/S0886-3350(13)80724-9
   TULLOH C G, 1955, Br J Ophthalmol, V39, P374, DOI 10.1136/bjo.39.6.374
   Vajpayee RB, 2008, EYE, V22, P1008, DOI 10.1038/sj.eye.6702795
   Vasavada A, 1999, J CATARACT REFR SURG, V25, P238, DOI 10.1016/S0886-3350(99)80133-3
   Yamada K, 2000, AM J OPHTHALMOL, V129, P159, DOI 10.1016/S0002-9394(99)00313-X
NR 20
TC 5
Z9 5
U1 0
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD APR
PY 2010
VL 45
IS 2
BP 154
EP 156
DI 10.3129/i09-231
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 581TB
UT WOS:000276546400011
PM 20379301
DA 2022-11-30
ER

PT J
AU Smith, BT
   Kraus, CL
   Apte, RS
AF Smith, Bradley T.
   Kraus, Courtney L.
   Apte, Rajendra S.
TI RETINAL PIGMENT EPITHELIAL TEARS IN RANIBIZUMAB-TREATED EYES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retina; ranibizumab; lucentis; retinal pigment epithelium; retinal
   pigment epithelial detachment; rip; tear; neovascular; age-related
   macular degeneration; vascular endothelial growth factor
ID INTRAVITREAL BEVACIZUMAB INJECTION; CHOROIDAL NEOVASCULARIZATION
   SECONDARY; GOOD VISUAL-ACUITY; MACULAR DEGENERATION; PHOTODYNAMIC
   THERAPY; LASER PHOTOCOAGULATION; AMD; PATHOGENESIS; VERTEPORFIN; AVASTIN
AB Purpose: To report the incidence of retinal pigment epithelial (RPE) tears in patients treated with ranibizumab therapy for choroidal neovascularization due to age-related macular degeneration.
   Design: Interventional case series.
   Methods: One hundred sixty-four eyes from a large clinical practice were retrospectively reviewed for number of injections and the presence or absence of a fibrovascular retinal pigment epithelial detachment. Main outcome measures were occurrence of RPE tears, and timing of tears following the last injection.
   Results: Patients were observed for an average of 11 months. A single patient (0.61 %) experienced an RPE tear and this occurred after the first injection. In eyes with a fibrovascular retinal pigment epithelial detachment the incidence was 5%. Lesions containing a fibrovascular retinal pigment epithelial detachment tended to be larger (4.5 versus 3.8 Macular Photocoagulation Study Disc Areas), but this was not statistically significant. (P 0.63). However, these lesions required more injections on average (P = 0.05).
   Conclusion: The incidence of RPE tears associated with ranibizumab therapy is low and may result from a predisposition rather than an effect of treatment. Even so, patients undergoing ranibizumab therapy should be counseled regarding this possible complication.
C1 [Smith, Bradley T.; Kraus, Courtney L.; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Smith, Bradley T.; Apte, Rajendra S.] Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Apte, RS (通讯作者)，660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.
EM apte@vision.wustl.edu
RI Smith, Bradley/ABB-2596-2021
OI Smith, Bradley/0000-0002-9456-5429
CR Amselem L, 2007, EYE, V21, P846, DOI 10.1038/sj.eye.6702702
   Apte Rajendra S., 2007, International Ophthalmology, V27, P59, DOI 10.1007/s10792-007-9066-5
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   BARONDES MJ, 1992, BRIT J OPHTHALMOL, V76, P5, DOI 10.1136/bjo.76.1.5
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   CASWELL AG, 1985, BR J OPHTHALMOL, V69, P397
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Fasolino G, 2007, ACTA OPHTHALMOL SCAN, V85, P575, DOI 10.1111/j.1600-0420.2007.00897.x
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Hannan SR, 2007, BRIT J OPHTHALMOL, V91, P977, DOI 10.1136/bjo.2006.101899
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kiss C, 2007, ACTA OPHTHALMOL SCAN, V85, P902, DOI 10.1111/j.1600-0420.2007.00928.x
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   KRISHAN NR, 1985, AM J OPHTHALMOL, V100, P698, DOI 10.1016/0002-9394(85)90626-9
   Lee GKY, 2007, GRAEF ARCH CLIN EXP, V245, P1225, DOI 10.1007/s00417-007-0536-2
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P689, DOI 10.1111/j.1600-0420.2007.00926.x
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Nicolo M, 2006, EUR J OPHTHALMOL, V16, P770, DOI 10.1177/112067210601600521
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P218
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shaikh Saad, 2007, Indian Journal of Ophthalmology, V55, P470
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 33
TC 47
Z9 50
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2009
VL 29
IS 3
BP 335
EP 339
DI 10.1097/IAE.0b013e318195cad5
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 420RK
UT WOS:000264306700009
PM 19174716
DA 2022-11-30
ER

PT J
AU Althin, R
   Lundstrom, M
   Roos, P
AF Althin, R
   Lundstrom, M
   Roos, P
TI A new index approach to measure lost benefits from progression to
   blindness
SO INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
LA English
DT Article
DE blindness; cataract; linear programming; outcome measures
ID BEAVER DAM EYE; AGE-RELATED MACULOPATHY; CATARACT-SURGERY CARE;
   OPEN-ANGLE GLAUCOMA; BLUE MOUNTAINS EYE; CATQUEST QUESTIONNAIRE;
   PREVALENCE; AUSTRALIA
AB Objectives: An index approach for measuring the reduction in daily activities of patients suffering from an eye disease associated with progressive visual loss is proposed. The approach is illustrated using data collected from patients with cataract.
   Method: The approach uses recently developed methods based on index theory together with measurements of daily activities. In a simulation based on observations of visual acuity and daily activities in patients with cataract, indexes. of changes in benefits were estimated for varying levels of visual acuity.
   Results: Results show the development of loss in benefits resulting from a progressive deterioration in visual acuity. The results indicate a 40% loss in benefits at low levels of visual acuity, equivalent to a potential increase in benefits of 75% for these individuals following successful treatment.
   Conclusions: The proposed index approach may prove useful for measuring reductions in daily activities resulting from the progressive loss of vision in eye disease. The approach has successfully measured the reduction in daily activities in patients with cataract and may be applicable in patients with other eye diseases, including age-related macular degeneration and open-angle glaucoma.
C1 Pharmacia Corp, Global Outcomes Res, High Wycombe, Bucks, England.
   Blekinge Hosp, Dept Ophthalmol, Karlskrona, Sweden.
   RR Inst Appl Econ, S-20074 Malmo, Sweden.
C3 Pfizer
RP Althin, R (通讯作者)，Pharmacia Corp, Global Outcomes Res, High Wycombe, Bucks, England.
CR [Anonymous], 1996, J OPER RES SOC
   Ekstrom C, 1996, ACTA OPHTHALMOL SCAN, V74, P107
   Fre R, 1998, INDEX NUMBERS ESSAYS
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GLOOR P, 1989, Investigative Ophthalmology and Visual Science, V30, P500
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lundstrom M, 1998, J CATARACT REFR SURG, V24, P968, DOI 10.1016/S0886-3350(98)80053-9
   Lundstrom M, 1997, J CATARACT REFR SURG, V23, P1226, DOI 10.1016/S0886-3350(97)80321-5
   Malmquist S., 1953, TRABAJOS ESTADISTICA, V4, P209, DOI [10.1007/BF03006863, DOI 10.1007/BF03006863]
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nussbaum M.C., 1993, QUALITY LIFE
   Roos P, 1998, INFOR, V36, P120
   Sen A., 1999, COMMODITIES CAPABILI
   Shephard Ronald W, 1953, COST PRODUCTION FUNC
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   [No title captured]
NR 21
TC 3
Z9 3
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA
SN 0266-4623
J9 INT J TECHNOL ASSESS
JI Int. J. Technol. Assess. Health Care
PD SUM
PY 2002
VL 18
IS 3
BP 635
EP 644
PG 10
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Medical Informatics
GA 602YN
UT WOS:000178532200017
PM 12391956
DA 2022-11-30
ER

PT J
AU Huang, S
   Liu, CH
   Wang, ZX
   Fu, ZJ
   Britton, WR
   Blomfield, AK
   Kamenecka, TM
   Dunaief, JL
   Solt, LA
   Chen, J
AF Huang, Shuo
   Liu, Chi-Hsiu
   Wang, Zhongxiao
   Fu, Zhongjie
   Britton, William R.
   Blomfield, Alexandra K.
   Kamenecka, Theodore M.
   Dunaief, Joshua L.
   Solt, Laura A.
   Chen, Jing
TI REV-ERBa regulates age-related and oxidative stress-induced degeneration
   in retinal pigment epithelium via NRF2
SO REDOX BIOLOGY
LA English
DT Article
DE Retinal pigment epithelium; Aging; Age-related macular degeneration;
   REV-ERB alpha; Oxidative damage; NRF2
ID MACULAR DEGENERATION; NUCLEAR RECEPTORS; CIRCADIAN BEHAVIOR; ALPHA;
   GENE; DRUSEN; TRANSCRIPTION; PHAGOCYTOSIS; INFLAMMATION; METABOLISM
AB Retinal pigment epithelium (RPE) dysfunction and atrophy occur in dry age-related macular degeneration (AMD), often leading to photoreceptor degeneration and vision loss. Accumulated oxidative stress during aging contributes to RPE dysfunction and degeneration. Here we show that the nuclear receptor REV-ERB alpha, a redox sensitive transcription factor, protects RPE from age-related degeneration and oxidative stress-induced damage. Genetic deficiency of REV-ERB alpha leads to accumulated oxidative stress, dysfunction and degeneration of RPE, and AMD-like ocular pathologies in aging mice. Loss of REV-ERB alpha exacerbates chemical-induced RPE damage, and pharmacological activation of REV-ERB alpha protects RPE from oxidative damage both in vivo and in vitro. REV-ERB alpha directly regulates transcription of nuclear factor erythroid 2-related factor 2 (NRF2) and its downstream antioxidant enzymes superoxide dismutase 1 (SOD1) and catalase to counter oxidative damage. Moreover, aged mice with RPE specific knockout of REV-ERB alpha also exhibit accumulated oxidative stress and fundus and RPE pathologies. Together, our results suggest that REV-ERB alpha is a novel intrinsic protector of the RPE against age dependent oxidative stress and a new molecular target for developing potential therapies to treat age-related retinal degeneration.
C1 [Huang, Shuo; Liu, Chi-Hsiu; Wang, Zhongxiao; Fu, Zhongjie; Britton, William R.; Blomfield, Alexandra K.; Chen, Jing] Harvard Med Sch, Dept Ophthalmol, Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
   [Kamenecka, Theodore M.; Solt, Laura A.] Scripps Res Inst, Dept Mol Med, 130 Scripps Way, Jupiter, FL 33458 USA.
   [Dunaief, Joshua L.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Perelman Sch Med, Scheie Eye Inst, 305 Stellar Chance Lab, Philadelphia, PA 19104 USA.
   [Solt, Laura A.] Scripps Res Inst, Dept Immunol & Microbiol, 130 Scripps Way, Jupiter, FL 33458 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Scripps Research Institute; University of Pennsylvania; Pennsylvania
   Medicine; Scripps Research Institute
RP Chen, J (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Boston Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
EM jing.chen@childrens.harvard.edu
OI Blomfield, Alexandra/0000-0002-2550-477X; FU,
   ZHONGJIE/0000-0002-8182-2983
FU NIH/NEI [EY031765, EY028100, EY024963]; BrightFocus Foundation; Research
   to Prevent Blindness Dolly Green Special Scholar Award; Boston Childrens
   Hospital Ophthalmology Foundation; Mass Lions Eye Research Fund Inc.;
   Knights Templar Eye Foundation Career Starter Grants
FX This work was supported by NIH/NEI R01 grants (EY031765, EY028100, and
   EY024963) , BrightFocus Foundation, Research to Pre-vent Blindness Dolly
   Green Special Scholar Award, Boston Childrens Hospital Ophthalmology
   Foundation, and Mass Lions Eye Research Fund Inc. (to J.C.) . C.-H.L.
   and Z.W. acknowledge support by Knights Templar Eye Foundation Career
   Starter Grants.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amir M, 2018, CELL REP, V25, P3733, DOI 10.1016/j.celrep.2018.11.101
   Aryan Nona, 2016, Open Neurol J, V10, P83, DOI 10.2174/1874205X01610010083
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Bugge A, 2012, GENE DEV, V26, P657, DOI 10.1101/gad.186858.112
   Butler AA, 2015, CELL METAB, V22, P197, DOI 10.1016/j.cmet.2015.07.014
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Caratti G, 2018, J CLIN INVEST, V128, P4454, DOI 10.1172/JCI96138
   CHAWLA A, 1993, J BIOL CHEM, V268, P16265
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173
   Cho H, 2012, NATURE, V485, P123, DOI 10.1038/nature11048
   Cocheme HM, 2008, J BIOL CHEM, V283, P1786, DOI 10.1074/jbc.M708597200
   Crumbley C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017290
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dierickx P, 2019, P NATL ACAD SCI USA, V116, P12147, DOI 10.1073/pnas.1904226116
   Duez H, 2008, GASTROENTEROLOGY, V135, P689, DOI 10.1053/j.gastro.2008.05.035
   Duez H, 2009, J APPL PHYSIOL, V107, P1972, DOI 10.1152/japplphysiol.00570.2009
   DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Feng D, 2011, SCIENCE, V331, P1315, DOI 10.1126/science.1198125
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Guillaumond F, 2005, J BIOL RHYTHM, V20, P391, DOI 10.1177/0748730405277232
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113
   HARDING HP, 1995, MOL CELL BIOL, V15, P4791
   He LZ, 2014, AM J PATHOL, V184, P1660, DOI 10.1016/j.ajpath.2014.02.007
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JOHNSON LV, 1986, INVEST OPHTH VIS SCI, V27, P129
   Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100
   Kumar N, 2010, ENDOCRINOLOGY, V151, P3015, DOI 10.1210/en.2009-0800
   Lam MTY, 2013, NATURE, V498, P511, DOI 10.1038/nature12209
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li T, 2014, HEPATOLOGY, V59, P2383, DOI 10.1002/hep.27049
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Malek G, 2014, ADV EXP MED BIOL, V801, P317, DOI 10.1007/978-1-4614-3209-8_40
   Matsuoka H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137955
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Migita H, 2004, FEBS LETT, V561, P69, DOI 10.1016/S0014-5793(04)00118-8
   Mollema NJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017494
   Mrowicka M, 2017, ACTA OPHTHALMOL, V95, P530, DOI 10.1111/aos.13289
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Olchawa MM, 2013, INVEST OPHTH VIS SCI, V54, P2276, DOI 10.1167/iovs.12-11154
   Pardee KI, 2009, PLOS BIOL, V7, P384, DOI 10.1371/journal.pbio.1000043
   Pariollaud M, 2018, J CLIN INVEST, V128, P2281, DOI 10.1172/JCI93910
   Raghuram S, 2007, NAT STRUCT MOL BIOL, V14, P1207, DOI 10.1038/nsmb1344
   Ramakrishnan Sathiya N, 2006, Nucl Recept Signal, V4, pe009
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sengupta S, 2016, FREE RADICAL BIO MED, V93, P177, DOI 10.1016/j.freeradbiomed.2016.02.004
   Solt LA, 2012, NATURE, V485, P62, DOI 10.1038/nature11030
   Surjit M, 2011, CELL, V145, P224, DOI 10.1016/j.cell.2011.03.027
   Teboul M, 2003, M S-MED SCI, V19, P411, DOI 10.1051/medsci/2003194411
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Vasu VT, 2009, INTEGR CANCER THER, V8, P321, DOI 10.1177/1534735409352027
   Wakabayashi N, 2010, ANTIOXID REDOX SIGN, V13, P1649, DOI 10.1089/ars.2010.3216
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Woldt E, 2013, NAT MED, V19, P1039, DOI 10.1038/nm.3213
   Yang G, 2014, ANTIOXID REDOX SIGN, V21, P17, DOI 10.1089/ars.2013.5539
   Yang ZH, 2016, AM J PATHOL, V186, P2909, DOI 10.1016/j.ajpath.2016.07.014
   Yin L, 2005, MOL ENDOCRINOL, V19, P1452, DOI 10.1210/me.2005-0057
   Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179
   Zhang HQ, 2015, FREE RADICAL BIO MED, V88, P314, DOI 10.1016/j.freeradbiomed.2015.05.036
   Zhang YX, 2015, SCIENCE, V348, P1488, DOI 10.1126/science.aab3021
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 77
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD MAY
PY 2022
VL 51
AR 102261
DI 10.1016/j.redox.2022.102261
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 1C1IP
UT WOS:000792881800002
PM 35176707
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Carlson, M
   Kim, S
   Aparicio-Domingo, S
   Li, KV
   Puig, B
   Batabyal, S
   Canto-Soler, MV
   Mohanty, S
AF Carlson, Michael
   Kim, Sanghoon
   Aparicio-Domingo, Silvia
   Li, Kang V.
   Puig, Ben
   Batabyal, Subrata
   Canto-Soler, M. Valeria
   Mohanty, Samarendra
TI OCT guided micro-focal ERG system with multiple stimulation wavelengths
   for characterization of ocular health
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MINIATURE SWINE; RETINITIS-PIGMENTOSA; STARGARDT-DISEASE; GENE;
   FEASIBILITY; SENSITIVITY; EPITHELIUM; VISION; SAFETY; MODEL
AB Inherited retinal disorders and dry age-related macular degeneration are characterized by the degeneration and death of different types of photoreceptors at different rate and locations. Advancement of new therapeutic interventions such as optogenetics gene therapy and cell replacement therapies are dependent on electrophysiological measurements at cellular resolution. Here, we report the development of an optical coherence tomography (OCT) guided micro-focal multi-color laser stimulation and electroretinogram (ERG) platform for highly localized monitoring of retina function. Functional evaluation of wild type and transgenic pigs affected by retinal degeneration was carried out using OCT guided micro-focal ERG (mu fERG) with selected stimulation wavelengths for S, M and L cones as well as rod photoreceptors. In wild type pigs, mu fERG allowed functional recording from rods and each type of cone photoreceptor cells separately. Furthermore, functional deficits in P23H transgenic pigs consistent with their retinal degeneration phenotype were observed, including decrease in the S and M cone function and lack of rod photoreceptor function. OCT guided mu fERG based monitoring of physiological function will enable characterization of animal models of retinal degenerative diseases and evaluation of therapeutic interventions at the cellular level.
C1 [Carlson, Michael; Kim, Sanghoon; Puig, Ben; Mohanty, Samarendra] Nanoscope Instruments Inc, 1312 Brown Trail, Bedford, TX 76022 USA.
   [Aparicio-Domingo, Silvia; Li, Kang V.; Canto-Soler, M. Valeria] Univ Colorado, Dept Ophthalmol, CellSight Ocular Stem Cell & Regenerat Res Progra, Sue Anschutz Rodgers Eye Ctr,Sch Med, 12800 East 19th Ave, Aurora, CO 80045 USA.
   [Batabyal, Subrata; Mohanty, Samarendra] Nanoscope Technol LLC, 1624 New York Ave, Arlington, TX 76010 USA.
   [Canto-Soler, M. Valeria] Univ Colorado, Charles C Gates Ctr Regenerat Med, Sch Med, Anschutz Med Campus, Aurora, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus
RP Mohanty, S (通讯作者)，Nanoscope Instruments Inc, 1312 Brown Trail, Bedford, TX 76022 USA.; Mohanty, S (通讯作者)，Nanoscope Technol LLC, 1624 New York Ave, Arlington, TX 76010 USA.
EM smohanty@nanoscopetech.com
FU National Institute of Health [1R01EY025717-01A1, 1R01 EY028216-01A1];
   Department of Defense [VR190095]; Gates Grubstake Award [GGF012-18-01];
   Gates Frontiers Fund; Solich Fund; CellSight Fund; University of
   Colorado from Research to Prevent Blindness
FX National Institute of Health (1R01EY025717-01A1, 1R01 EY028216-01A1)
   funding to SM, and funding to V.C.S. including Department of Defense
   (VR190095), The Gates Grubstake Award (GGF012-18-01), Gates Frontiers
   Fund, The Solich Fund, CellSight Fund, and an Unrestricted Research
   Award to the Department of Ophthalmology at the University of Colorado
   from Research to Prevent Blindness.
CR Batabyal S, 2021, GENE THER, V28, P162, DOI 10.1038/s41434-020-00200-2
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Chandler Matthew J., 1999, Veterinary Ophthalmology, V2, P179
   Cheng J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.6.18
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   du Sert NP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000411
   Fernandes RAB, 2016, OSLI RETINA, V47, P342, DOI 10.3928/23258160-20160324-07
   Han ZC, 2014, ADV EXP MED BIOL, V801, P719, DOI 10.1007/978-1-4614-3209-8_90
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hendrickson A, 2002, EXP EYE RES, V74, P435, DOI 10.1006/exer.2002.1181
   Hoffmann MB, 2021, DOC OPHTHALMOL, V142, P5, DOI 10.1007/s10633-020-09812-w
   Hood DC, 1997, VISUAL NEUROSCI, V14, P533, DOI 10.1017/S0952523800012190
   Hood DC, 1998, VISION RES, V38, P163, DOI 10.1016/S0042-6989(97)00143-0
   JACOBS GH, 1994, BEHAV NEUROSCI, V108, P993, DOI 10.1037/0735-7044.108.5.993
   Kalatzis V, 2013, AM J OPHTHALMOL, V156, P433, DOI 10.1016/j.ajo.2013.05.009
   Korenbrot JI, 2012, PROG RETIN EYE RES, V31, P442, DOI 10.1016/j.preteyeres.2012.05.002
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Kostic C, 2016, J PATHOL, V238, P300, DOI 10.1002/path.4641
   Labin AM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5319
   Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mahato B, 2020, NATURE, V581, P83, DOI 10.1038/s41586-020-2201-4
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   MERBS SL, 1992, NATURE, V356, P433, DOI 10.1038/356433a0
   Oh KT, 2004, RETINA-J RET VIT DIS, V24, P920, DOI 10.1097/00006982-200412000-00013
   Perrault I, 1999, MOL GENET METAB, V68, P200, DOI 10.1006/mgme.1999.2906
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   SANDBERG MA, 1979, AM J OPHTHALMOL, V88, P702, DOI 10.1016/0002-9394(79)90669-X
   Schomberg DT, 2016, TOXICOL PATHOL, V44, P299, DOI 10.1177/0192623315618292
   Schwahn HN, 2001, GRAEF ARCH CLIN EXP, V239, P961, DOI 10.1007/s004170100368
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Stricker-Krongrad A, 2016, TOXICOL PATHOL, V44, P612, DOI 10.1177/0192623316641784
   Stricker-Krongrad A, 2016, TOXICOL PATHOL, V44, P421, DOI 10.1177/0192623315613337
   Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7
NR 37
TC 1
Z9 1
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 7
PY 2022
VL 12
IS 1
AR 4009
DI 10.1038/s41598-022-07622-5
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZO7QV
UT WOS:000765922600009
PM 35256656
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sharma, PK
   Sharma, HP
   Chakole, CM
   Pandey, J
   Chauhan, MK
AF Sharma, Pankaj Kumar
   Sharma, Hanuman Prasad
   Chakole, Chandrashekhar Mahadeo
   Pandey, Jaya
   Chauhan, Meenakshi Kanwar
TI Application of Vitamin E TPGS in ocular therapeutics - Attributes beyond
   excipient
SO JOURNAL OF THE INDIAN CHEMICAL SOCIETY
LA English
DT Article
DE Vitamin E; TPGS; Ocular disorders; Drug delivery; Ophthalmological
   diseases; Permeation enhancer
ID CHRONIC CHILDHOOD CHOLESTASIS; IN-SITU GEL; DRUG-DELIVERY; MACULAR
   DEGENERATION; CROSS-LINKING; E-DEFICIENCY; MULTIDRUG-RESISTANCE;
   TRABECULAR MESHWORK; OXIDATIVE STRESS; PRODRUG MICELLES
AB Diseases affecting the anterior segment and the external surface of the eye are usually treated by drugs applied topically. The formulations designed for this purpose are developed to deliver active pharmaceutical agents to the eye optimally. These formulations are prepared by adding various agents (excipients) that help to maintain stability of the formulation, prevent microbial contamination, and allow easy administration with adequate drug bioavailability with the minimum ocular irritation and toxic effects at the administration site. The excipients do not have their own pharmacological actions, but Vitamin E TPGS (D-alpha-Tocopheryl polyethylene glycol 1000 succinate) seems to break this notion. Besides having drug formulation enhancement properties, it also possesses antioxidant properties, which have been found to have a beneficial effect on various ophthalmological diseases such as age-related macular degeneration, uveitis, glaucoma, and cataract. In this review, we primarily focus on the properties and applications of Vitamin E TPGS in ocular drug delivery and the benefits of Vitamin E (Vit E) in numerous sight-threatening ailments of the rear and front segment of the eye. Additionally, p-glycoprotein inhibition and the anti-cancer potential of vitamin E TPGS have also been summarized.
C1 [Sharma, Pankaj Kumar; Chakole, Chandrashekhar Mahadeo; Chauhan, Meenakshi Kanwar] DPSR Univ, Delhi Inst Pharmaceut Sci & Res, Dept Pharmaceut, NDDS Res Lab, Sec 3, New Delhi 110017, India.
   [Sharma, Hanuman Prasad] AIIMS, Dept Ocular Pharmacol, Dr RP Ctr, New Delhi 110023, India.
   [Pandey, Jaya] Amity Univ, Amity Sch Appl Sci Lucknow, Noida 226028, Uttar Pradesh, India.
C3 Meenakshi Academy of Higher Education & Research (MAHER); Delhi
   Pharmaceutical Sciences & Research University (DPSRU); Delhi Institute
   of Pharmaceutical Sciences & Research; All India Institute of Medical
   Sciences (AIIMS) New Delhi; Amity University Noida
RP Chauhan, MK (通讯作者)，DPSR Univ, Delhi Inst Pharmaceut Sci & Res, Dept Pharmaceut, Sec 3, New Delhi 110017, India.
EM meenakshindds@gmail.com
RI CHAKOLE, CHANDRASHEKHAR mahadeo/AEQ-4915-2022
OI CHAKOLE, CHANDRASHEKHAR mahadeo/0000-0002-3090-1366; Chauhan, Meenakshi
   Kanwar/0000-0002-7477-9761
CR Agarwal R, 2013, EXP EYE RES, V110, P35, DOI 10.1016/j.exer.2013.02.011
   Aggarwal N, 2012, AAPS PHARMSCITECH, V13, P67, DOI 10.1208/s12249-011-9722-y
   Ali M, 2008, EXPERT REV CLIN PHAR, V1, P145, DOI 10.1586/17512433.1.1.145
   Alkholief M, 2019, SAUDI PHARM J, V27, P293, DOI 10.1016/j.jsps.2018.11.011
   Anand BS, 2003, CURR EYE RES, V26, P151, DOI 10.1076/ceyr.26.3.151.14893
   Arbelaez Maria Clara, 2009, Oman J Ophthalmol, V2, P33, DOI 10.4103/0974-620X.48420
   AUGUSTIN AJ, 1994, INVEST OPHTH VIS SCI, V35, P3897
   Bao YL, 2014, MOL PHARMACEUT, V11, P3196, DOI 10.1021/mp500384d
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bogman K, 2005, CLIN PHARMACOL THER, V77, P24, DOI 10.1016/j.clpt.2004.09.001
   Bogman K, 2003, J PHARM SCI, V92, P1250, DOI 10.1002/jps.10395
   Butt GF, 2014, INVEST OPHTH VIS SCI, V55
   Chakole C.M., 2020, EUR J MOL CLIN, P2064
   Chakole MC., 2021, DRUG DELIV LETT, V11, P203, DOI [10.2174/2210303111666210212143011, DOI 10.2174/2210303111666210212143011]
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Christen WG, 2010, OPHTHALMOLOGY, V117, P1163, DOI 10.1016/j.ophtha.2009.10.043
   CID L, 1992, INT OPHTHALMOL, V16, P27, DOI 10.1007/BF00917069
   Collnot EM, 2007, MOL PHARM, V4, P465, DOI 10.1021/mp060121r
   Condic-Jurkic K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191882
   Constantinou C, 2012, NUTR CANCER, V64, P136, DOI 10.1080/01635581.2012.630167
   DellaPenna D, 2005, J PLANT PHYSIOL, V162, P729, DOI 10.1016/j.jplph.2005.04.004
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Duan YW, 2015, COLLOID SURFACE B, V128, P322, DOI 10.1016/j.colsurfb.2015.02.007
   Durairaj C, 2017, HANDB EXP PHARMACOL, V242, P31, DOI 10.1007/164_2016_32
   El-Raggal TM, 2009, MIDDLE EAST AFR J OP, V16, P256, DOI 10.4103/0974-9233.58418
   Fritsche S, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040099
   Fuchshofer R, 2011, EXP EYE RES, V93, P165, DOI 10.1016/j.exer.2010.07.014
   Grimaudo MA, 2018, MOL PHARMACEUT, V15, P571, DOI 10.1021/acs.molpharmaceut.7b00939
   Guo YY, 2013, EUR J PHARM SCI, V49, P175, DOI 10.1016/j.ejps.2013.02.006
   Hao TN, 2015, ACS APPL MATER INTER, V7, P18064, DOI 10.1021/acsami.5b04995
   Hollander D., 1975, GASTROENTEROLOGY, V68
   Hsu KH, 2015, EUR J PHARM BIOPHARM, V94, P312, DOI 10.1016/j.ejpb.2015.06.001
   JACQUES PF, 1995, AM J CLIN NUTR, V62, P1228, DOI 10.1093/ajcn/62.6.1228
   Jansook P, 2010, EUR J PHARM BIOPHARM, V76, P208, DOI 10.1016/j.ejpb.2010.07.005
   Jin QS, 2018, INT J PHARMACEUT, V553, P21, DOI 10.1016/j.ijpharm.2018.10.033
   Jones MN, 1999, INT J PHARM, V177, P137, DOI 10.1016/S0378-5173(98)00345-7
   Kang JH, 2003, AM J EPIDEMIOL, V158, P337, DOI 10.1093/aje/kwg167
   Khare V, 2016, RSC ADV, V6, P60126, DOI 10.1039/c6ra09347g
   Khiev D, 2021, NANOMATERIALS-BASEL, V11, DOI 10.3390/nano11010173
   Ko ML, 2010, CURR EYE RES, V35, P842, DOI 10.3109/02713683.2010.489728
   Ko ML, 2005, FREE RADICAL BIO MED, V39, P365, DOI 10.1016/j.freeradbiomed.2005.03.025
   Koch FHJ, 1996, GER J OPHTHALMOL, V5, P185
   Koppen C, 2009, J REFRACT SURG, V25, pS819, DOI 10.3928/1081597X-20090813-11
   Lakhani P, 2018, J DRUG DELIV SCI TEC, V47, P159, DOI 10.1016/j.jddst.2018.07.010
   Lawler T, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051002
   Li XF, 2021, DRUG DELIV TRANSL RE, V11, P1119, DOI 10.1007/s13346-020-00834-0
   Lim YH, 2015, ACS NANO, V9, P1995, DOI 10.1021/nn507046h
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu XF, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00066
   Loftsson T, 2012, ACTA OPHTHALMOL, V90, P603, DOI 10.1111/j.1755-3768.2011.02299.x
   Mandal A, 2017, J CONTROL RELEASE, V248, P96, DOI 10.1016/j.jconrel.2017.01.012
   Meng X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03123-y
   Mi Y, 2013, J CONTROL RELEASE, V169, P185, DOI 10.1016/j.jconrel.2013.01.035
   Mi Y, 2012, INT J PHARMACEUT, V438, P98, DOI 10.1016/j.ijpharm.2012.08.038
   Murakami T, 2016, J PHARM SCI-US, V105, P2515, DOI 10.1016/j.xphs.2016.05.012
   MURALIDHARA KS, 1977, J LAB CLIN MED, V90, P85
   Nasir NAA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174542
   Nasir NAA, 2014, MOL VIS, V20, P822
   Neophytou CM, 2014, BIOCHEM PHARMACOL, V89, P31, DOI 10.1016/j.bcp.2014.02.003
   Nissman SA, 2008, AM J OPHTHALMOL, V145, P623, DOI 10.1016/j.ajo.2007.11.012
   O'Brart DPS, 2016, DRUG TODAY, V52, P331, DOI 10.1358/dot.2016.52.6.2494140
   Ostacolo C, 2013, INT J PHARMACEUT, V440, P148, DOI 10.1016/j.ijpharm.2012.09.051
   Parkinson EI, 2011, CHEMMEDCHEM, V6, P1957, DOI 10.1002/cmdc.201100381
   Pastor-Valero M, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-52
   Peng CC, 2012, LANGMUIR, V28, P1478, DOI 10.1021/la203606z
   Periman LM, 2020, CLIN OPHTHALMOL, V14, P4187, DOI 10.2147/OPTH.S279051
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Radomska-Lesniewska DM, 2019, CENT EUR J IMMUNOL, V44, P181, DOI 10.5114/ceji.2019.87070
   Ramdas WD, 2018, NUTRIENTS, V10, DOI 10.3390/nu10030359
   Rao N A, 1990, Trans Am Ophthalmol Soc, V88, P797
   Rao NA, 2000, PROG RETIN EYE RES, V19, P41, DOI 10.1016/S1350-9462(99)00003-8
   Read Russell W, 2006, Curr Rheumatol Rep, V8, P260, DOI 10.1007/s11926-006-0006-6
   Reboul E, 2019, IUBMB LIFE, V71, P416, DOI 10.1002/iub.1955
   Reboul E, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040095
   Rigotti A, 2007, MOL ASPECTS MED, V28, P423, DOI 10.1016/j.mam.2007.01.002
   Ruiz-Moreno C, 2016, APOPTOSIS, V21, P1019, DOI 10.1007/s10495-016-1266-x
   Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schultz C, 2014, OPHTHALMOL EYE DIS, V6, P37, DOI 10.4137/OED.S16067
   Sen CK, 2007, MOL ASPECTS MED, V28, P692, DOI 10.1016/j.mam.2007.03.001
   Sen CK, 2006, LIFE SCI, V78, P2088, DOI 10.1016/j.lfs.2005.12.001
   Shah M, 2017, INVEST OPHTH VIS SCI, V58, P372, DOI 10.1167/iovs.16-19159
   Shahab MS, 2022, J DRUG DELIV SCI TEC, V68, DOI 10.1016/j.jddst.2021.103062
   Sharma HP, 2018, EUR J PHARM SCI, V114, P364, DOI 10.1016/j.ejps.2017.12.027
   Sharma PK, 2021, CURR EYE RES, V46, P1703, DOI 10.1080/02713683.2021.1916037
   Sharma PK, 2021, INORG NANO-MET CHEM, V51, P701, DOI 10.1080/24701556.2020.1802756
   SOKOL RJ, 1993, GASTROENTEROLOGY, V104, P1727, DOI 10.1016/0016-5085(93)90652-S
   SOKOL RJ, 1987, J PEDIATR-US, V111, P830, DOI 10.1016/S0022-3476(87)80196-8
   SOKOL RJ, 1987, GASTROENTEROLOGY, V93, P975, DOI 10.1016/0016-5085(87)90559-2
   Song GP, 2015, BIOORG MED CHEM LETT, V25, P4610, DOI 10.1016/j.bmcl.2015.08.043
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tataru C P, 2012, J Med Life, V5, P247
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vadlapudi AD, 2014, J OCUL PHARMACOL TH, V30, P49, DOI 10.1089/jop.2013.0157
   Vadlapudi AD, 2013, PHARM RES-DORDR, V30, P2063, DOI 10.1007/s11095-013-1059-7
   van Rooij J, 1999, BRIT J OPHTHALMOL, V83, P1277, DOI 10.1136/bjo.83.11.1277
   Warsi MH, 2014, COLLOID SURFACE B, V122, P423, DOI 10.1016/j.colsurfb.2014.07.004
   Warsi MH, 2021, J DRUG DELIV SCI TEC, V61, DOI 10.1016/j.jddst.2020.102121
   Wordinger RJ, 2007, INVEST OPHTH VIS SCI, V48, P1191, DOI 10.1167/iovs.06-0296
   Woreta FA, 2013, SURV OPHTHALMOL, V58, P529, DOI 10.1016/j.survophthal.2012.11.004
   Yang CM, 2013, J BIOMED NANOTECHNOL, V9, P1617, DOI 10.1166/jbn.2013.1646
   Yang CL, 2018, THERANOSTICS, V8, P464, DOI 10.7150/thno.22711
   Youk HJ, 2005, J CONTROL RELEASE, V107, P43, DOI 10.1016/j.jconrel.2005.05.014
   Yu AL, 2013, CURR EYE RES, V38, P952, DOI 10.3109/02713683.2013.793360
   Yu AL, 2013, ACTA OPHTHALMOL, V91, pe92, DOI 10.1111/aos.12013
   Zanon-Moreno V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112302
   Zanon-Moreno V, 2013, MOL VIS, V19, P231
   Zhang ZJ, 2012, ADV MATER, V24, P1418, DOI 10.1002/adma.201104714
NR 110
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0019-4522
J9 J INDIAN CHEM SOC
JI J. Indian Chem. Soc.
PD MAR
PY 2022
VL 99
IS 3
AR 100387
DI 10.1016/j.jics.2022.100387
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 2P7LQ
UT WOS:000819918000017
DA 2022-11-30
ER

PT J
AU Cen, LP
   Ji, J
   Lin, JW
   Ju, ST
   Lin, HJ
   Li, TP
   Wang, Y
   Yang, JF
   Liu, YF
   Tan, SY
   Tan, L
   Li, DJ
   Wang, YF
   Zheng, DZ
   Xiong, YQ
   Wu, HF
   Jiang, JJ
   Wu, ZG
   Huang, DG
   Shi, TK
   Chen, BY
   Yang, JL
   Zhang, XL
   Luo, L
   Huang, CK
   Zhang, GH
   Huang, YQ
   Ng, TK
   Chen, HY
   Chen, WQ
   Pang, CP
   Zhang, MZ
AF Cen, Ling-Ping
   Ji, Jie
   Lin, Jian-Wei
   Ju, Si-Tong
   Lin, Hong-Jie
   Li, Tai-Ping
   Wang, Yun
   Yang, Jian-Feng
   Liu, Yu-Fen
   Tan, Shaoying
   Tan, Li
   Li, Dongjie
   Wang, Yifan
   Zheng, Dezhi
   Xiong, Yongqun
   Wu, Hanfu
   Jiang, Jingjing
   Wu, Zhenggen
   Huang, Dingguo
   Shi, Tingkun
   Chen, Binyao
   Yang, Jianling
   Zhang, Xiaoling
   Luo, Li
   Huang, Chukai
   Zhang, Guihua
   Huang, Yuqiang
   Ng, Tsz Kin
   Chen, Haoyu
   Chen, Weiqi
   Pang, Chi Pui
   Zhang, Mingzhi
TI Automatic detection of 39 fundus diseases and conditions in retinal
   photographs using deep neural networks
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DIABETIC-RETINOPATHY; MACULAR DEGENERATION; ARTIFICIAL-INTELLIGENCE;
   GLOBAL PREVALENCE; RISK-FACTORS; IMAGES; CLASSIFICATION; VALIDATION
AB Retinal fundus diseases can lead to irreversible visual impairment without timely diagnoses and appropriate treatments. Single disease-based deep learning algorithms had been developed for the detection of diabetic retinopathy, age-related macular degeneration, and glaucoma. Here, we developed a deep learning platform (DLP) capable of detecting multiple common referable fundus diseases and conditions (39 classes) by using 249,620 fundus images marked with 275,543 labels from heterogenous sources. Our DLP achieved a frequency-weighted average F1 score of 0.923, sensitivity of 0.978, specificity of 0.996 and area under the receiver operating characteristic curve (AUC) of 0.9984 for multi-label classification in the primary test dataset and reached the average level of retina specialists. External multihospital test, public data test and tele-reading application also showed high efficiency for multiple retinal diseases and conditions detection. These results indicate that our DLP can be applied for retinal fundus disease triage, especially in remote areas around the world.
   Systems for automatic detection of a single disease may miss other important conditions. Here, the authors show a deep learning platform can detect 39 common retinal diseases and conditions.
C1 [Cen, Ling-Ping; Lin, Jian-Wei; Ju, Si-Tong; Lin, Hong-Jie; Li, Tai-Ping; Wang, Yun; Yang, Jian-Feng; Liu, Yu-Fen; Tan, Shaoying; Tan, Li; Li, Dongjie; Wang, Yifan; Zheng, Dezhi; Xiong, Yongqun; Wu, Hanfu; Jiang, Jingjing; Wu, Zhenggen; Huang, Dingguo; Shi, Tingkun; Chen, Binyao; Yang, Jianling; Zhang, Xiaoling; Luo, Li; Huang, Chukai; Zhang, Guihua; Huang, Yuqiang; Ng, Tsz Kin; Chen, Haoyu; Chen, Weiqi; Pang, Chi Pui; Zhang, Mingzhi] Joint Shantou Int Eye Ctr Shantou Univ & Chinese, Shantou, Guangdong, Peoples R China.
   [Ji, Jie] Shantou Univ, Network & Informat Ctr, Shantou, Guangdong, Peoples R China.
   [Ji, Jie; Ng, Tsz Kin] Shantou Univ Med Coll, Shantou, Guangdong, Peoples R China.
   [Ji, Jie] XuanShi Med Tech Shanghai Co Ltd, Shanghai, Peoples R China.
   [Ng, Tsz Kin; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Shatin, Hong Kong, Peoples R China.
C3 Shantou University; Chinese University of Hong Kong
RP Zhang, MZ (通讯作者)，Joint Shantou Int Eye Ctr Shantou Univ & Chinese, Shantou, Guangdong, Peoples R China.
EM zmz@jsiec.org
RI Ng, Tsz Kin/I-8061-2014; Cen Ling-Ping, Cen Lingping/O-4216-2015; zhang,
   guihua/GVU-4494-2022; Chen, Haoyu/A-7432-2013
OI Ng, Tsz Kin/0000-0001-7863-7229; Cen Ling-Ping, Cen
   Lingping/0000-0003-3876-0606; Chen, Haoyu/0000-0003-0676-4610; Lin,
   Jian-Wei/0000-0001-5712-1581; Tan, Shaoying/0000-0001-9997-7396; Ji,
   Jie/0000-0002-8864-2352
FU National Natural Science Foundation of China (NSFC) [81570849,
   81800822]; Natural Science Foundation of Guangdong Province, China
   (NSFG) [2020A1515010415]; Key Disciplinary Project of Clinical Medicine
   under the Guangdong High-level University Development Program
   [002-18119101]; Joint Shantou International Eye Center of The Shantou
   University; Chinese University of Hong Kong [17-003];  [2020LKSFG16B]
FX This study was supported by the National Natural Science Foundation of
   China (NSFC, 81570849 to L.-P.C., 81800822 to S.T.), Natural Science
   Foundation of Guangdong Province, China (NSFG, 2020A1515010415 to
   L.-P.C.), Grant for Key Disciplinary Project of Clinical Medicine under
   the Guangdong High-level University Development Program (002-18119101),
   LKSF cross-disciplinary research grants (2020LKSFG16B to L.-P.C. and
   M.Z.), and an internal grant from the Joint Shantou International Eye
   Center of The Shantou University and The Chinese University of Hong Kong
   (17-003 to L.-P.C.).
CR Andreoli MT, 2017, CAN J OPHTHALMOL, V52, P592, DOI 10.1016/j.jcjo.2017.05.012
   Ardila D, 2019, NAT MED, V25, P954, DOI 10.1038/s41591-019-0447-x
   Balyen L, 2019, ASIA-PAC J OPHTHALMO, V8, P264, DOI 10.22608/APO.2018479
   Baskaran M, 2015, JAMA OPHTHALMOL, V133, P874, DOI 10.1001/jamaophthalmol.2015.1110
   Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585
   Bowling B., 2015, CORNEA CLIN OPHTHALM, V8th
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cen L. P., AUTOMATIC DETECTION, DOI [10.5281/zenodo.4946799, DOI 10.5281/ZENODO.4946799]
   Chang J, 2021, OPHTHALMOLOGY, V128, P78, DOI [10.1016/j.ophtha.2020.06.036, 10.1016/j.opatha.2020.06.036]
   Chilamkurthy S, 2018, LANCET, V392, P2388, DOI 10.1016/S0140-6736(18)31645-3
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Courtiol P, 2019, NAT MED, V25, P1519, DOI 10.1038/s41591-019-0583-3
   Cuadros Jorge, 2009, J Diabetes Sci Technol, V3, P509
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   EyeWiki, EYE ENC WRITT EYE PH EYE ENC WRITT EYE PH
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Giancardo L, 2012, MED IMAGE ANAL, V16, P216, DOI 10.1016/j.media.2011.07.004
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hannun AY, 2019, NAT MED, V25, P65, DOI 10.1038/s41591-018-0268-3
   Hollon TC, 2020, NAT MED, V26, P52, DOI 10.1038/s41591-019-0715-9
   Japkowicz N. A. R. H, 2000, LEARNING IMBALANCED
   Jocelyn Desbiens S. G., 2018, DEEP ANNOTATED LEARN
   Kanski J. J, 2010, SIGNS OPHTHALMOLOGY
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Milea D, 2020, NEW ENGL J MED, V382, P1687, DOI 10.1056/NEJMoa1917130
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Duc NT, 2020, NEUROINFORMATICS, V18, P71, DOI 10.1007/s12021-019-09419-w
   Orlando JI, 2020, MED IMAGE ANAL, V59, DOI 10.1016/j.media.2019.101570
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Saito T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118432
   Sayres R, 2019, OPHTHALMOLOGY, V126, P552, DOI 10.1016/j.ophtha.2018.11.016
   Son J, 2020, OPHTHALMOLOGY, V127, P85, DOI 10.1016/j.ophtha.2019.05.029
   Song PG, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010427
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7
   Verbraak FD, 2019, DIABETES CARE, V42, P651, DOI 10.2337/dc18-0148
   Wang J, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.8758
   Wang LZZ, 2017, BRIT J OPHTHALMOL, V101, P1352, DOI 10.1136/bjophthalmol-2016-310002
   Wong TY, 2016, JAMA-J AM MED ASSOC, V316, P2366, DOI 10.1001/jama.2016.17563
   Wong TY, 2017, ICO GUIDELINES DIABE
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang GH, 2017, BRIT J OPHTHALMOL, V101, P1591, DOI 10.1136/bjophthalmol-2017-310316
   Zhang ML, 2014, IEEE T KNOWL DATA EN, V26, P1819, DOI 10.1109/TKDE.2013.39
   Zhou DJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16777-6
   Zhu HL, 2020, LANCET DIGIT HEALTH, V2, pE348, DOI 10.1016/S2589-7500(20)30107-2
NR 50
TC 17
Z9 19
U1 9
U2 19
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 10
PY 2021
VL 12
IS 1
AR 4828
DI 10.1038/s41467-021-25138-w
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TY6RM
UT WOS:000683910200036
PM 34376678
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Armento, A
   Honisch, S
   Panagiotakopoulou, V
   Sonntag, I
   Jacob, A
   Bolz, S
   Kilger, E
   Deleidi, M
   Clark, S
   Ueffing, M
AF Armento, Angela
   Honisch, Sabina
   Panagiotakopoulou, Vasiliki
   Sonntag, Inga
   Jacob, Anke
   Bolz, Sylvia
   Kilger, Ellen
   Deleidi, Michela
   Clark, Simon
   Ueffing, Marius
TI Loss of Complement Factor H impairs antioxidant capacity and energy
   metabolism of human RPE cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE IMPLICATIONS; MACULAR
   DEGENERATION; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; ACTIVATION;
   EXPRESSION; PHOSPHORYLATION; MITOCHONDRIA; POLYMORPHISM
AB Polymorphisms in the Complement Factor H (CFH) gene, coding for the Factor H protein (FH), can increase the risk for age-related macular degeneration (AMD). AMD-associated CFH risk variants, Y402H in particular, impair FH function leading to complement overactivation. Whether this alone suffices to trigger AMD pathogenesis remains unclear. In AMD, retinal homeostasis is compromised due to the dysfunction of retinal pigment epithelium (RPE) cells. To investigate the impact of endogenous FH loss on RPE cell balance, we silenced CFH in human hTERT-RPE1 cells. FH reduction led to accumulation of C3, at both RNA and protein level and increased RPE vulnerability toward oxidative stress. Mild hydrogen-peroxide exposure in combination with CFH knock-down led to a reduction of glycolysis and mitochondrial respiration, paralleled by an increase in lipid peroxidation, which is a key aspect of AMD pathogenesis. In parallel, cell viability was decreased. The perturbations of energy metabolism were accompanied by transcriptional deregulation of several glucose metabolism genes as well as genes modulating mitochondrial stability. Our data suggest that endogenously produced FH contributes to transcriptional and metabolic homeostasis and protects RPE cells from oxidative stress, highlighting a novel role of FH in AMD pathogenesis.
C1 [Armento, Angela; Honisch, Sabina; Sonntag, Inga; Jacob, Anke; Bolz, Sylvia; Kilger, Ellen; Clark, Simon; Ueffing, Marius] Inst Ophthalm Res, Dept Ophthalmol, Tubingen, Germany.
   [Panagiotakopoulou, Vasiliki; Deleidi, Michela] German Ctr Neurodegenerat Dis DZNE, Tubingen, Germany.
   [Panagiotakopoulou, Vasiliki; Deleidi, Michela] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Helmholtz Association; German Center for
   Neurodegenerative Diseases (DZNE); Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Ueffing, M (通讯作者)，Inst Ophthalm Res, Dept Ophthalmol, Tubingen, Germany.
EM marius.ueffing@uni-tuebingen.de
RI Panagiotakopoulou, Vasiliki/AAU-8041-2021
OI Deleidi, Michela/0000-0003-0357-0124; Panagiotakopoulou,
   Vasiliki/0000-0002-8006-552X
FU Kerstan Foundation; Helmut Ecker Foundation; European consortium
   EYE-RISK (European Union's Horizon 2020 research and innovation
   programme) [634479]
FX This work was supported by the Kerstan Foundation, the Helmut Ecker
   Foundation and the European consortium EYE-RISK (European Union's
   Horizon 2020 research and innovation programme under grant agreement No
   634479). EYE-RISK members are listed in supplementary material. S.C. is
   funded by the Helmut Ecker Foundation.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Armstrong Richard A, 2015, J Stem Cells, V10, P171
   Bajic G, 2015, EMBO J, V34, P2735, DOI 10.15252/embj.201591881
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brinkmann CR, 2013, J BIOL CHEM, V288, P8016, DOI 10.1074/jbc.M112.430249
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Castellanos E, 2019, YALE J BIOL MED, V92, P523
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Eamegdool SS, 2020, FREE RADICAL BIO MED, V146, P357, DOI 10.1016/j.freeradbiomed.2019.11.018
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Feoktistova Maria, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087379
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Kaarniranta K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082317
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Keeling E, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800951
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kolev M, 2015, IMMUNITY, V42, P1033, DOI 10.1016/j.immuni.2015.05.024
   Krilis M, 2018, FREE RADICAL BIO MED, V129, P237, DOI 10.1016/j.freeradbiomed.2018.09.034
   KRISTENSEN SR, 1994, MOL CELL BIOCHEM, V140, P81, DOI 10.1007/BF00928369
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lee H, 2014, J BIOL CHEM, V289, P11862, DOI 10.1074/jbc.M113.533299
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   Manczak M, 2004, NEUROMOL MED, V5, P147, DOI 10.1385/NMM:5:2:147
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martin M, 2016, CELL DEATH DIFFER, V23, P903, DOI 10.1038/cdd.2015.164
   McCarty WJ, 2008, J APPL PHYSIOL, V105, P621, DOI 10.1152/japplphysiol.01245.2007
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Mopert K, 2009, EXP CELL RES, V315, P2165, DOI 10.1016/j.yexcr.2009.04.016
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Nesargikar PN, 2012, EUR J MICROBIOL IMMU, V2, P103, DOI 10.1556/EuJMI.2.2012.2.2
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007
   Quillen DA, 1999, AM FAM PHYSICIAN, V60, P99
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Seaman MNJ, 2012, J CELL SCI, V125, P4693, DOI 10.1242/jcs.103440
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugiura A, 2014, EMBO J, V33, P2142, DOI 10.15252/embj.201488104
   Swarup A, 2019, AM J PHYSIOL-CELL PH, V316, pC121, DOI 10.1152/ajpcell.00410.2018
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Tsubone TM, 2019, BIOPHYS CHEM, V254, DOI 10.1016/j.bpc.2019.106263
   Valvona CJ, 2016, BRAIN PATHOL, V26, P3, DOI 10.1111/bpa.12299
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vilarino-Guell C, 2011, AM J HUM GENET, V89, P162, DOI 10.1016/j.ajhg.2011.06.001
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wen L, 2011, J CELL BIOL, V195, P765, DOI 10.1083/jcb.201105109
   Yang YF, 2008, P NATL ACAD SCI USA, V105, P7070, DOI 10.1073/pnas.0711845105
NR 76
TC 24
Z9 24
U1 1
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 25
PY 2020
VL 10
IS 1
AR 10320
DI 10.1038/s41598-020-67292-z
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MH2OO
UT WOS:000546571200011
PM 32587311
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Pelaez, R
   Pariente, A
   Perez-Sala, A
   Larrayoz, IM
AF Pelaez, Rafael
   Pariente, Ana
   Perez-Sala, Alvaro
   Larrayoz, Ignacio M.
TI Sterculic Acid: The Mechanisms of Action beyond Stearoyl-CoA Desaturase
   Inhibition and Therapeutic Opportunities in Human Diseases
SO CELLS
LA English
DT Review
DE sterculic acid; inflammation; cell death; macular degeneration;
   metabolism
ID CONJUGATED LINOLEIC-ACID; ABERRANT LIPID-METABOLISM; CYCLOPROPENE
   FATTY-ACIDS; DE-NOVO LIPOGENESIS; GENE-EXPRESSION; ENDOGENOUS SYNTHESIS;
   AMYLOID-BETA; CANCER-CELLS; STEM-CELLS; DAIRY-COWS
AB In many tissues, stearoyl-CoA desaturase 1 (SCD1) catalyzes the biosynthesis of monounsaturated fatty acids (MUFAS), (i.e., palmitoleate and oleate) from their saturated fatty acid (SFA) precursors (i.e., palmitate and stearate), influencing cellular membrane physiology and signaling, leading to broad effects on human physiology. In addition to its predominant role in lipid metabolism and body weight control, SCD1 has emerged recently as a potential new target for the treatment for various diseases, such as nonalcoholic steatohepatitis, Alzheimer's disease, cancer, and skin disorders. Sterculic acid (SA) is a cyclopropene fatty acid originally found in the seeds of the plant Sterculia foetida with numerous biological activities. On the one hand, its ability to inhibit stearoyl-CoA desaturase (SCD) allows its use as a coadjuvant of several pathologies where this enzyme has been associated. On the other hand, additional effects independently of its SCD inhibitory properties, involve anti-inflammatory and protective roles in retinal diseases such as age-related macular degeneration (AMD). This review aims to summarize the mechanisms by which SA exerts its actions and to highlight the emerging areas where this natural compound may be of help for the development of new therapies for human diseases.
C1 [Pelaez, Rafael; Pariente, Ana; Perez-Sala, Alvaro; Larrayoz, Ignacio M.] Ctr Biomed Res La Rioja CIBIR, Neurodegenerat Area, Biomarkers & Mol Signaling Grp, Piqueras 98, Logrono 26006, Spain.
RP Larrayoz, IM (通讯作者)，Ctr Biomed Res La Rioja CIBIR, Neurodegenerat Area, Biomarkers & Mol Signaling Grp, Piqueras 98, Logrono 26006, Spain.
EM rpelaez@riojasalud.es; apariente@riojasalud.es; aperez@riojasalud.es;
   ilarrayoz@riojasalud.es
RI Larrayoz, Ignacio M/I-5613-2012
OI Larrayoz, Ignacio M/0000-0003-1629-152X; Perez Sala,
   Alvaro/0000-0002-7310-6792; Pariente Delgado, Ana/0000-0001-9046-6629;
   Pelaez, Rafael/0000-0002-4047-6017
FU Fundacion Rioja Salud; Instituto de Salud Carlos III-FEDER (Fondo
   Europeo de Desarrollo Regional) [CP15/00198]
FX This research was funded by the Fundacion Rioja Salud. I.M.L. is
   supported by a Miguel Servet contract (CP15/00198) from the Instituto de
   Salud Carlos III-FEDER (Fondo Europeo de Desarrollo Regional, a way to
   build Europe).
CR Aarsland A, 1997, AM J CLIN NUTR, V65, P1774, DOI 10.1093/ajcn/65.6.1774
   ALLEN E, 1967, LIPIDS, V2, P419, DOI 10.1007/BF02531857
   Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80
   Astarita G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024777
   Bao XM, 2003, J BIOL CHEM, V278, P12846, DOI 10.1074/jbc.M212464200
   Bellenghi M, 2015, J PATHOL, V236, P315, DOI 10.1002/path.4535
   Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015
   Bichi E, 2012, J DAIRY SCI, V95, P5242, DOI 10.3168/jds.2012-5349
   Brown JM, 2008, CIRCULATION, V118, P1467, DOI 10.1161/CIRCULATIONAHA.108.793182
   Brown JM, 2010, CURR OPIN LIPIDOL, V21, P192, DOI 10.1097/MOL.0b013e32833854ac
   Bruschini S, 2020, J CELL PHYSIOL, V235, P1877, DOI 10.1002/jcp.29121
   Busch AK, 2005, DIABETES, V54, P2917, DOI 10.2337/diabetes.54.10.2917
   Buttari B, 2013, BIOCHEM PHARMACOL, V86, P130, DOI 10.1016/j.bcp.2013.04.008
   Byagowi S, 2015, CAN J DIABETES, V39, P123, DOI 10.1016/j.jcjd.2014.09.006
   CAO JM, 1993, BIOCHIM BIOPHYS ACTA, V1210, P27, DOI 10.1016/0005-2760(93)90045-B
   Cheng D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017299
   Chu K, 2006, MOL CELL BIOL, V26, P6786, DOI 10.1128/MCB.00077-06
   Corl BA, 2001, J NUTR BIOCHEM, V12, P622, DOI 10.1016/S0955-2863(01)00180-2
   Dalla Valle A, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00726
   Dallaire MP, 2014, J DAIRY SCI, V97, P6411, DOI 10.3168/jds.2013-7853
   ENOCH HG, 1976, J BIOL CHEM, V251, P5095
   Ferrero H, 2018, MOL NEUROBIOL, V55, P5177, DOI 10.1007/s12035-017-0700-6
   Flowers MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019734
   Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064
   Galbraith L, 2018, PHARMACOL RES, V131, P177, DOI 10.1016/j.phrs.2018.02.022
   Gomez FE, 2003, BIOCHEM BIOPH RES CO, V300, P316
   Gratraud P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006889
   Griinari JM, 2000, J NUTR, V130, P2285, DOI 10.1093/jn/130.9.2285
   Hao P, 2016, KOREAN J PARASITOL, V54, P139, DOI 10.3347/kjp.2016.54.2.139
   Hayden JM, 2002, J LIPID RES, V43, P26
   Herrera-Meza MS, 2013, INT J FOOD SCI NUTR, V64, P575, DOI 10.3109/09637486.2013.763908
   Herrera-Meza S, 2017, J MED FOOD, V20, P1133, DOI 10.1089/jmf.2017.0006
   Hess D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011394
   Holder AM, 2013, BREAST CANCER RES TR, V137, P319, DOI 10.1007/s10549-012-2354-4
   Huang GM, 2015, CANCER LETT, V358, P180, DOI 10.1016/j.canlet.2014.12.036
   Huang JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100985
   Huang JD, 2012, BBA-MOL CELL BIOL L, V1821, P637, DOI 10.1016/j.bbalip.2012.01.013
   Igal RA, 2016, BBA-MOL CELL BIOL L, V1861, P1865, DOI 10.1016/j.bbalip.2016.09.009
   Jalil A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153787
   JEFFCOAT R, 1977, LIPIDS, V12, P480, DOI 10.1007/BF02535446
   Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200
   Kadegowda AKG, 2013, LIPIDS, V48, P967, DOI 10.1007/s11745-013-3823-1
   Kay JK, 2004, J DAIRY SCI, V87, P369, DOI 10.3168/jds.S0022-0302(04)73176-8
   Kim HJ, 2002, J LIPID RES, V43, P1750, DOI 10.1194/jlr.M100433-JLR200
   Kim SJ, 2011, MOL CELLS, V31, P371, DOI 10.1007/s10059-011-0043-5
   Kovalic AJ, 2018, J CLIN EXP HEPATOL, V8, P390, DOI 10.1016/j.jceh.2018.04.001
   Larrayoz IM, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00384
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   LEE DJ, 1971, CANCER RES, V31, P960
   LEGROS JE, 1987, IMMUNOL CELL BIOL, V65, P57, DOI 10.1038/icb.1987.7
   Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004
   Liu G, 2007, J MED CHEM, V50, P3086, DOI 10.1021/jm070219p
   Liu XQ, 2011, ADV NUTR, V2, P15, DOI 10.3945/an.110.000125
   Lock AL, 2004, J NUTR, V134, P2698, DOI 10.1093/jn/134.10.2698
   Lyn RK, 2014, SCI REP-UK, V4, DOI 10.1038/srep04549
   MacDonald MLE, 2009, ARTERIOSCL THROM VAS, V29, P341, DOI 10.1161/ATVBAHA.108.181099
   MACFARLANE JJ, 1957, NATURE, V179, P830, DOI 10.1038/179830a0
   Major CA, 2008, J LIPID RES, V49, P1456, DOI 10.1194/jlr.M700596-JLR200
   Mancini R, 2018, ONCOGENE, V37, P2367, DOI 10.1038/s41388-018-0141-3
   Mason P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033823
   Mauvoisin D, 2010, MOL CELL ENDOCRINOL, V319, P116, DOI 10.1016/j.mce.2010.01.027
   Mauvoisin D, 2007, J CELL COMMUN SIGNAL, V1, P113, DOI 10.1007/s12079-007-0011-1
   Meingassner JG, 2013, J INVEST DERMATOL, V133, P2091, DOI 10.1038/jid.2013.89
   Miyazaki M, 2004, J BIOL CHEM, V279, P25164, DOI 10.1074/jbc.M402781200
   Miyazaki M, 2001, J NUTR, V131, P2260, DOI 10.1093/jn/131.9.2260
   Miyazaki M, 2001, J LIPID RES, V42, P1018
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mosley EE, 2007, LIPIDS, V42, P939, DOI 10.1007/s11745-007-3085-x
   Nagao K, 2019, CHEM PHARM BULL, V67, P327, DOI 10.1248/cpb.c18-01001
   Nakaya K, 2013, BBA-MOL CELL BIOL L, V1831, P1402, DOI 10.1016/j.bbalip.2013.05.009
   Noto A, 2017, ONCOGENE, V36, P4573, DOI [10.1038/onc.2017.75, 10.1038/onc.2017.212]
   Noto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.444
   Noureddin Mazen, 2018, Curr Hepatol Rep, V17, P350, DOI 10.1007/s11901-018-0425-7
   Oballa RM, 2011, J MED CHEM, V54, P5082, DOI 10.1021/jm200319u
   Olivier E, 2016, BIOCHIMIE, V127, P70, DOI 10.1016/j.biochi.2016.04.014
   Ortinau LC, 2013, OBESITY, V21, P344, DOI 10.1002/oby.20040
   Ortinau Laura C, 2012, ISRN Endocrinol, V2012, P947323, DOI 10.5402/2012/947323
   Pariente A, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107746
   Paton CM, 2009, AM J PHYSIOL-ENDOC M, V297, pE28, DOI 10.1152/ajpendo.90897.2008
   Peck B, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0146-8
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Phan HTT, 2013, BBA-BIOMEMBRANES, V1828, P2487, DOI 10.1016/j.bbamem.2013.06.021
   Phetsuksiri B, 2003, J BIOL CHEM, V278, P53123, DOI 10.1074/jbc.M311209200
   Pi HF, 2019, J CELL MOL MED, V23, P5259, DOI 10.1111/jcmm.14401
   Piccinin E, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102283
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Pisanu ME, 2017, CANCER LETT, V406, P93, DOI 10.1016/j.canlet.2017.07.027
   Poudyal Hemant, 2011, Endocrine Metabolic & Immune Disorders-Drug Targets, V11, P217
   Puglisi Rossella, 2018, Oncotarget, V9, P7567, DOI 10.18632/oncotarget.24085
   RAJU PK, 1967, J BIOL CHEM, V242, P379
   Ray U, 2018, FEBS J, V285, P432, DOI 10.1111/febs.14281
   Rey-Funes M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07294-6
   Rey-Funes M, 2016, AM J PHYSIOL-REG I, V310, pR1011, DOI 10.1152/ajpregu.00266.2015
   Rini BI, 2008, CLIN CANCER RES, V14, P1286, DOI 10.1158/1078-0432.CCR-07-4719
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126
   Samuel W, 2014, J CELL PHYSIOL, V229, P1028, DOI 10.1002/jcp.24527
   Savransky V, 2008, CIRC RES, V103, P1173, DOI 10.1161/CIRCRESAHA.108.178533
   Scaglia N, 2008, INT J ONCOL, V33, P839, DOI 10.3892/ijo_00000072
   Seibert JT, 2018, J ANIM SCI, V96, P510, DOI 10.1093/jas/skx067
   Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002
   Sherling DH, 2017, J CARDIOVASC PHARM T, V22, P365, DOI 10.1177/1074248416686187
   Sinner DI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039787
   SLAYDEN OV, 1990, ENDOCRINOLOGY, V127, P3166, DOI 10.1210/endo-127-6-3166
   Smith U, 2016, J INTERN MED, V280, P465, DOI 10.1111/joim.12540
   Song ZY, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101383
   Tesfay L, 2019, CANCER RES, V79, P5355, DOI 10.1158/0008-5472.CAN-19-0369
   Testa G, 2016, REDOX BIOL, V10, P24, DOI 10.1016/j.redox.2016.09.001
   Tracz-Gaszewska Z, 2019, CANCERS, V11, DOI 10.3390/cancers11070948
   Uto Y, 2016, CHEM PHYS LIPIDS, V197, P3, DOI 10.1016/j.chemphyslip.2015.08.018
   Vejux A, 2009, MOL ASPECTS MED, V30, P153, DOI 10.1016/j.mam.2009.02.006
   von Roemeling CA, 2015, J CLIN ENDOCR METAB, V100, pE697, DOI 10.1210/jc.2014-2764
   Vriens K, 2019, NATURE, V566, P403, DOI 10.1038/s41586-019-0904-1
   Wang H, 2015, NAT STRUCT MOL BIOL, V22, P581, DOI 10.1038/nsmb.3049
   Wang J, 2005, BIOCHEM BIOPH RES CO, V332, P735, DOI 10.1016/j.bbrc.2005.05.013
   Xu TL, 2016, BMC MOL BIOL, V17, DOI 10.1186/s12867-016-0069-5
   Zhang L, 1999, BIOCHEM J, V340, P255, DOI 10.1042/0264-6021:3400255
   Zhang ZH, 2014, J MED CHEM, V57, P5039, DOI 10.1021/jm401516c
   Zhao GY, 2019, CANCERS, V11, DOI 10.3390/cancers11121870
   Zhu XP, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0762-0
   ZOELLER RA, 1984, LIPIDS, V19, P529, DOI 10.1007/BF02534486
NR 121
TC 22
Z9 22
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JAN
PY 2020
VL 9
IS 1
AR 140
DI 10.3390/cells9010140
PG 20
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KO2RZ
UT WOS:000515398200140
PM 31936134
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ji, WW
   Yu, DA
   Yang, P
   Fang, P
   Cao, YX
   Li, H
   Xie, N
   Yan, SS
AF Ji, Wan-Wan
   Yu, Dong-An
   Yang, Peng
   Fang, Peng
   Cao, Yu-Xia
   Li, Hu
   Xie, Ning
   Yan, Shou-Sheng
TI Recombinant humanized anti-vascular endothelial growth factor monoclonal
   antibody efficiently suppresses laser-induced choroidal
   neovascularization in rhesus monkeys
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE VEGF; Monoclonal antibody; RabMAb; CNV; Wet AMD
ID MACULAR DEGENERATION; VEGF TRAP; ANGIOGENESIS; EYE
AB Neovascular age-related macular degeneration, characterized by abnormal choroidal neovascularization (CNV), is a major cause of blindness worldwide. Anti-vascular endothelial growth factor (VEGF) antibodies have demonstrated significant efficacy in improving visual acuity. TMAB001 is a new recombinant humanized rabbit anti-VEGF monoclonal antibody. It presents high activities in vitro studies. In the binding affinity assay, TMAB001 exhibited a high binding capability to VEGF with an affinity constant of 10(-11) M. In the receptor antagonist activity assay, IC50 of TMAB001 was 0.15 mu g/ml. In a cell-based assay, TMAB001 inhibited wVEGF(165)-induced HUVEC cells proliferation in a dose-dependent manner. Furthermore, in the rhesus monkey model of laser-induced CNV, results showed the growth and leakage of experimental CNV were significantly decreased with a single bilateral intravitreal injection of TMAB001, and the grade 4 lesions were complete absence in TMAB001 groups. The efficacy of TMAB001 was maintained for at least 28 days. In a mice model of oxygen-induced retinopathy, the retina fluorescence leakage was reduced and the vascular morphology in retina was normalized by TMAB001 intraperitoneal administration. In conclusion, those results indicate that TMAB001 might be a potential drug candidate for wet AMD.
C1 [Ji, Wan-Wan; Yu, Dong-An; Yang, Peng; Fang, Peng; Cao, Yu-Xia; Li, Hu; Xie, Ning; Yan, Shou-Sheng] Jiangsu T Mab BioPharma Co Ltd, G03,1 Yao Cheng Ave, Taizhou, Jiangsu, Peoples R China.
RP Yan, SS (通讯作者)，Jiangsu T Mab BioPharma Co Ltd, G03,1 Yao Cheng Ave, Taizhou, Jiangsu, Peoples R China.
EM shoushengyan@t-mab.com
FU Ministry of Science and Technology of P.R. China [2012ZX09401008];
   department of finance of Jiangsu Province & department of science and
   technology of Jiangsu province [BE2015016]
FX This work was supported by Ministry of Science and Technology of P.R.
   China [grant number 2012ZX09401008] and department of finance of Jiangsu
   Province & department of science and technology of Jiangsu province
   [grant number BE2015016]. These funding sources did not have any
   influence on study design, data analyses and interpretation, writing of
   the manuscript and decision on publishing. All of the authors have
   nothing to declare.
CR Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Cavallaro G, 2014, ACTA OPHTHALMOL, V92, P2, DOI 10.1111/aos.12049
   FDA, 2016, LABL EYLEA AFL INJ
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0071808, 10.1371/journal.pone.0076982]
   Huang H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021411
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Nork TM, 2011, ARCH OPHTHALMOL-CHIC, V129, P1042, DOI 10.1001/archophthalmol.2011.210
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Shankar G, 2008, J PHARMACEUT BIOMED, V48, P1267, DOI 10.1016/j.jpba.2008.09.020
   Takeda H, 2015, SCI REP-UK, V5, DOI 10.1038/srep11333
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yano T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156716
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yu Y., 2010, HUMANIZED ANTI VEGF, V5
   Yu YL, 2013, BIOCHEM BIOPH RES CO, V436, P543, DOI 10.1016/j.bbrc.2013.06.007
   Zhang J.S., 2017, CEDILANID INHIBITS R, P346
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 21
TC 4
Z9 4
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD NOV 15
PY 2017
VL 109
BP 624
EP 630
DI 10.1016/j.ejps.2017.09.021
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FK2PV
UT WOS:000413325000063
PM 28916483
DA 2022-11-30
ER

PT J
AU Song, DL
   Sulewski, ME
   Wang, CG
   Song, JT
   Bhuyan, R
   Sterling, J
   Clark, E
   Song, WC
   Dunaief, JL
AF Song, Delu
   Sulewski, Michael E., Jr.
   Wang, Chenguang
   Song, Jiantao
   Bhuyan, Rupak
   Sterling, Jacob
   Clark, Esther
   Song, Wen-Chao
   Dunaief, Joshua L.
TI Complement C5a receptor knockout has diminished light-induced
   microglia/macrophage retinal migration
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MICROGLIA; RISK; DEGENERATION; ACTIVATION;
   PROTECTS; DRUSEN; C3A; MACROPHAGES; DEPOSITION
AB Purpose: The complement system is involved in the pathogenesis of age-related macular degeneration (AMD). Because activated microglia are also associated with AMD, we studied the relationship between complement anaphylatoxin receptors and microglial recruitment.
   Methods: We assessed the effect of anaphylatoxin C3a receptor (C3aR) and C5a receptor (C5aR) knockout (KO) on light damage-induced migration of microglia/macrophages into the mouse outer retina via immunofluorescence and real-time quantitative PCR.
   Results: We found that the mRNA levels of C3, C5, C3aR, C5aR, and two activators of the complement alternative pathway, Cfb and Cfd, were all upregulated after light exposure. Retinal Iba1-positive microglia/macrophages express receptors for C3a and C5a. Light damage increased the number of retinal Iba1-positive cells and the mRNA levels of Iba1. Compared with the wild-type (WT) mice, these increases were attenuated in the C5aR KO mice but not in the C3aR KO mice.
   Conclusions: C5aR but not C3aR promoted the recruitment of microglia/macrophages. These divergent properties of complement anaphylatoxins in the light damage model provide a rationale for testing the differential effects of these receptors in additional retinal and neurodegeneration models.
C1 [Song, Delu; Sulewski, Michael E., Jr.; Wang, Chenguang; Song, Jiantao; Bhuyan, Rupak; Sterling, Jacob; Clark, Esther; Dunaief, Joshua L.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Perelman Sch Med, Scheie Eye Inst, 305 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
   [Wang, Chenguang] Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun, Jilin, Peoples R China.
   [Song, Jiantao] China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.
   [Song, Wen-Chao] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Jilin University;
   China Academy of Chinese Medical Sciences; Eye Hospital, CACMS;
   University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Univ Penn, FM Kirby Ctr Mol Ophthalmol, Perelman Sch Med, Scheie Eye Inst, 305 Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
OI Sterling, Jacob/0000-0001-7535-1073
FU NIH CTSA [KL2TR000139]; Research to Prevent Blindness; FM Kirby
   Foundation; Paul and Evanina Bell Mackall Foundation Trust; 
   [R01EY015240];  [R01EY023709]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [KL2TR001879, KL2TR000139] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY015240, R01EY023709, P30EY001583]
   Funding Source: NIH RePORTER
FX This work was supported by R01EY015240, R01EY023709, NIH CTSA
   KL2TR000139, Research to Prevent Blindness, the FM Kirby Foundation, the
   Paul and Evanina Bell Mackall Foundation Trust, a gift in memory of Dr.
   Lee F. Mauger.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eter N, 2008, INVEST OPHTH VIS SCI, V49, P3649, DOI 10.1167/iovs.07-1322
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grassmann F, 2014, ADV EXP MED BIOL, V801, P291, DOI 10.1007/978-1-4614-3209-8_37
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Klein R, 1960, ARCH OPHTHALMOL-CHIC, V2011, P75
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOHNO T, 1982, JPN J OPHTHALMOL, V26, P53
   Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Schraufstatter IU, 2009, J IMMUNOL, V182, P3827, DOI 10.4049/jimmunol.0803055
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Wohl SG, 2010, INVEST OPHTH VIS SCI, V51, P2686, DOI 10.1167/iovs.09-4537
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
   Zhang C, 2005, MOL VIS, V11, P887
   Zhang L, 2015, J LEUKOC BIOL
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
NR 34
TC 18
Z9 18
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 10
PY 2017
VL 23
BP 210
EP 218
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA ER5FU
UT WOS:000398827800001
PM 28442885
DA 2022-11-30
ER

PT J
AU Hennig, R
   Goepferich, A
AF Hennig, Robert
   Goepferich, Achim
TI Nanoparticles for the treatment of ocular neovascularizations
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Nanoparticles; Age-related macular degeneration; Proliferative diabetic
   retinopathy; Retinopathy of prematurity; Drug delivery; Gene delivery;
   EPR effect; RGD peptide
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION AMD; TARGETED
   DRUG-DELIVERY; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   INTRAVITREAL BEVACIZUMAB; GENE-THERAPY; BLOOD-FLOW; RETINAL
   NEOVASCULARIZATION; SUPRAMOLECULAR NANOCARRIER
AB Neovascular diseases of the posterior eye like age-related macular degeneration, proliferative diabetic retinopathy or retinopathy of prematurity carry a tremendous burden for patient and health care system alike. Although intravitreal injections of anti-VEGF based therapeutics have significantly improved the visual outcome for many patients, current therapeutic options still show significant drawbacks such as the injection-related risk of contracting an infection. Due to their ability to encapsulate drugs with otherwise poor bioavailability, accumulate in areas of increased vascular permeability and control the release of active ingredients over time, nanoparticle systems have been widely researched to enhance current therapeutic strategies and expand the therapeutic arsenal. In this review, emphasis is placed both on the possibilities and drawbacks that a systemic nanoparticle-based therapy could have in the context of neovascular posterior eye diseases. Recent investigations into intravenous and intravitreal administration of nanomaterials and their potential to deliver potent drugs and genes to pathologic lesions will also be presented. Furthermore, we will focus on the exceptional anti-oxidative and anti-angiogenic properties of selected nanoscale systems that carve out new paths for the treatment of these severe posterior eye diseases. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Hennig, Robert; Goepferich, Achim] Univ Regensburg, Dept Pharmaceut Technol, D-93053 Regensburg, Germany.
C3 University of Regensburg
RP Goepferich, A (通讯作者)，Univ Regensburg, Dept Pharmaceut Technol, Univ Str 31, D-93053 Regensburg, Germany.
EM achim.goepferich@chemie.uni-regensburg.de
RI Goepferich, Achim/G-1151-2016
OI Goepferich, Achim/0000-0002-7646-0252
FU Deutsche Forschungsgemeinschaft: DFG Grant [GO565/17-1]
FX This work was supported by the Deutsche Forschungsgemeinschaft: DFG
   Grant No. GO565/17-1. We thank Paul Bisso and Andreas Ohlmann for
   carefully revising the manuscript. Furthermore, we would like to express
   our gratitude to Thomas Stuebner for designing the graphical abstract.
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arden GB, 2012, DOC OPHTHALMOL, V124, P15, DOI 10.1007/s10633-011-9305-y
   Austeng D, 2009, ARCH OPHTHALMOL-CHIC, V127, P1315, DOI 10.1001/archophthalmol.2009.244
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   babAmmar D.A., 2013, J NANOMATER MOL NANO, V02
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Bainbridge JWB, 2006, GENE THER, V13, P1191, DOI 10.1038/sj.gt.3302812
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P147, DOI 10.1097/IAE.0b013e3180dc9360
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Bejjani R, 2005, MOL VIS, V11, P124
   Bennett J, 2003, GENE THER, V10, P977, DOI 10.1038/sj.gt.3302030
   Benny O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012515
   Berger L., 2010, ME LASER APPL, V25, P235
   Bhattacharya R, 2004, NANO LETT, V4, P2479, DOI 10.1021/nl0483789
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   BREM RB, 1994, INVEST OPHTH VIS SCI, V35, P3466
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   CASLEYSMITH JR, 1978, J PATHOL, V124, P13, DOI 10.1002/path.1711240104
   Chang YG, 2007, J CELL SCI, V120, P3053, DOI 10.1242/jcs.006361
   Chauhan VP, 2013, NAT MATER, V12, P958, DOI 10.1038/nmat3792
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340
   Chowdhary RK, 2003, J PHARM PHARM SCI, V6, P13
   COMPER WD, 1995, KIDNEY INT, V47, P1242, DOI 10.1038/ki.1995.178
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Danis RP, 2008, DIABETIC RETINOPATHY
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   del Pozo-Rodriguez A, 2008, INT J PHARM, V360, P177, DOI 10.1016/j.ijpharm.2008.04.023
   Diebold Y, 2010, PROG RETIN EYE RES, V29, P596, DOI 10.1016/j.preteyeres.2010.08.002
   Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gross N, 2013, MOL VIS, V19, P54
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Hawkins BS, 1999, MOL VIS, V5
   Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365
   Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Hennig R, 2014, J CONTROL RELEASE, V194, P20, DOI 10.1016/j.jconrel.2014.07.062
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hua J, 2012, MOL VIS, V18, P1045
   Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d
   Iriyama A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028560
   ISchmetterer L., 2007, RETINAL VASCULAR DIS
   Iwase T, 2013, J CONTROL RELEASE, V172, P625, DOI 10.1016/j.jconrel.2013.10.008
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang WD, 2005, ANGEW CHEM INT EDIT, V44, P419, DOI 10.1002/anie.200461603
   Jo DH, 2014, NANOMED-NANOTECHNOL, V10, P1109, DOI 10.1016/j.nano.2014.02.007
   Jo DH, 2012, NANOMED-NANOTECHNOL, V8, P784, DOI 10.1016/j.nano.2011.09.003
   Kadam RS, 2012, INT J PHARMACEUT, V434, P140, DOI 10.1016/j.ijpharm.2012.05.025
   Kalishwaralal K, 2009, COLLOID SURFACE B, V73, P51, DOI 10.1016/j.colsurfb.2009.04.025
   Kamizuru H, 2001, INVEST OPHTH VIS SCI, V42, P2664
   KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688
   Karakoti AS, 2008, JOM-US, V60, P33, DOI 10.1007/s11837-008-0029-8
   Karthikeyan B, 2010, EXP EYE RES, V91, P769, DOI 10.1016/j.exer.2010.09.003
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Kim H, 2012, ACTA BIOMATER, V8, P3932, DOI 10.1016/j.actbio.2012.07.016
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim JH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/50/505101
   Kim JH, 2011, BIOMATERIALS, V32, P1865, DOI 10.1016/j.biomaterials.2010.11.030
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kobayashi H, 2014, THERANOSTICS, V4, P81, DOI 10.7150/thno.7193
   Kohno RI, 2010, AM J OPHTHALMOL, V150, P223, DOI 10.1016/j.ajo.2010.03.016
   Koirala A, 2011, BIOMATERIALS, V32, P9483, DOI 10.1016/j.biomaterials.2011.08.062
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Kotoh K, 2004, INT J MOL MED, V14, P1049
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063
   LANGHAM ME, 1991, EXP EYE RES, V52, P167, DOI 10.1016/0014-4835(91)90256-E
   Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Ma L, 2009, J OCUL PHARMACOL TH, V25, P195, DOI 10.1089/jop.2008.0119
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mas-Moruno C, 2010, ANTI-CANCER AGENT ME, V10, P753, DOI 10.2174/187152010794728639
   MASSIA SP, 1993, J BIOL CHEM, V268, P8053
   Mastorakos P., 2014, NANOSCALE
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   MELAMED S, 1980, BRIT J OPHTHALMOL, V64, P537, DOI 10.1136/bjo.64.7.537
   Millard M, 2011, THERANOSTICS, V1, P154, DOI 10.7150/thno/v01p0154
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P204
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mitra RN, 2014, CHEMMEDCHEM, V9, P189, DOI 10.1002/cmdc.201300371
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oh EJ, 2011, BIOMATERIALS, V32, P3115, DOI 10.1016/j.biomaterials.2011.01.003
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Park K, 2009, DIABETES, V58, P1902, DOI 10.2337/db08-1327
   Parveen S, 2012, NANOMED-NANOTECHNOL, V8, P147, DOI 10.1016/j.nano.2011.05.016
   PARVER L M, 1991, Eye (London), V5, P181
   Patil S, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2210795
   Penha FM, 2011, AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT, P79, DOI 10.1007/978-1-4614-0125-4_6
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pincus T, 2002, RHEUMATOLOGY, V41, P1346, DOI 10.1093/rheumatology/41.12.1346
   Pollinger K, 2013, P NATL ACAD SCI USA, V110, P6115, DOI 10.1073/pnas.1220281110
   Prow TW, 2008, NANOMED-NANOTECHNOL, V4, P340, DOI 10.1016/j.nano.2008.06.003
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Ran S, 2002, CANCER RES, V62, P6132
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   RENNKE HG, 1975, J CELL BIOL, V67, P638, DOI 10.1083/jcb.67.3.638
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Salehi-Had H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018864
   Saugstad OD, 2006, J PERINATOL, V26, pS46, DOI 10.1038/sj.jp.7211475
   Saugstad OD, 2006, J PERINATOL S1, V26, pS63
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Shibuya M, 2013, J BIOCHEM, V153, P13, DOI 10.1093/jb/mvs136
   Singh N, 2005, INVEST OPHTH VIS SCI, V46, P1647, DOI 10.1167/iovs.04-1172
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Skupin-Mrugalska P, 2013, DRUG DISCOV TODAY, V18, P776, DOI 10.1016/j.drudis.2013.04.003
   Soderstjerna E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105359
   Song HY, 2014, NANOSCALE, V6, P3206, DOI 10.1039/c3nr04363k
   Stitt AW, 2013, CLIN SCI, V125, P1, DOI 10.1042/CS20120588
   Stupack DG, 2004, CURR TOP DEV BIOL, V64, P207, DOI 10.1016/S0070-2153(04)64009-9
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Torosean S, 2013, NANOMED-NANOTECHNOL, V9, P151, DOI 10.1016/j.nano.2012.07.002
   Torres-Soriano Mitzy E, 2009, Retin Cases Brief Rep, V3, P70, DOI 10.1097/ICB.0b013e3181578dd8
   Vavvas D.G., 2013, INVEST OPHTHALMOL VI, V54
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Wang JL, 2013, INVEST OPHTH VIS SCI, V54, P7983, DOI 10.1167/iovs.13-13068
   Weis SM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006478
   Winkler BS, 1999, MOL VIS, V5
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Xu JF, 2007, J OCUL PHARMACOL TH, V23, P527, DOI 10.1089/jop.2007.0002
   Yasukawa T, 1999, INVEST OPHTH VIS SCI, V40, P2690
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhang C, 2010, GENE THER, V17, P338, DOI 10.1038/gt.2009.158
   Zhou XH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0016733, 10.1371/journal.pone.0017812]
NR 171
TC 21
Z9 21
U1 1
U2 48
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2015
VL 95
BP 294
EP 306
DI 10.1016/j.ejpb.2015.02.027
PN B
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CU8WH
UT WOS:000363824300014
PM 25758124
DA 2022-11-30
ER

PT J
AU Kester, EM
AF Kester, Elizabeth M.
TI Charles Bonnet syndrome: Case presentation and Literature review
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Review
DE Charles Bonnet syndrome; Visual hallucinations; Legal blindness;
   Deafferentation; Macular degeneration
AB BACKGROUND: Charles Bonnet syndrome (CBS) is an under-recognized and under-reported disorder that involves visual hallucinations in visually impaired individuals. These patients have intact cognition, do not have hallucinations in any other sensory modalities, and retain insight into the unreal nature of their hallucinations.
   CASE REPORTS: Two case reports are presented. Case 1 is a 79-year-old man who presented with a 6-month history of hallucinations. Case 2 is an 86-year-old man who presented with a 2-month history of hallucinations. Both patients are legally blind from age-related macular degeneration. In both cases, the ocular examinations were otherwise unremarkable. A workup for other pathological causes of visual hallucinations was negative for both patients. They were given the diagnoses of CBS and were counseled. No other intervention was indicated at that time.
   CONCLUSION: Optometrists should be aware of the potential for visual hallucinations in patients with visual impairment. Early recognition by clinicians of the symptoms of CBS, and sharing proper information, treatment, and advice, can alleviate distress or suffering experienced by patients with CBS. Optometry 2009;80:360-366
C1 William Chappell Vet Affairs Outpatient Clin, Daytona Beach, FL 32114 USA.
RP Kester, EM (通讯作者)，William Chappell Vet Affairs Outpatient Clin, 551 Natl Healthcare Dr, Daytona Beach, FL 32114 USA.
EM Elizabeth.kester@va.gov
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   Adachi N, 2000, PSYCHIAT CLIN NEUROS, V54, P157, DOI 10.1046/j.1440-1819.2000.00652.x
   Bassuk SS, 2003, J CLIN EPIDEMIOL, V56, P622, DOI 10.1016/S0895-4356(03)00111-2
   Batra A, 1997, ACTA PSYCHIAT SCAND, V96, P129, DOI 10.1111/j.1600-0447.1997.tb09917.x
   BERRIOS GE, 1982, AGE AGEING, V11, P17, DOI 10.1093/ageing/11.1.17
   Bonnet C., 1760, ESSAI ANALYTIQUE FAC, P426
   Burke W, 2002, J NEUROL NEUROSUR PS, V73, P535, DOI 10.1136/jnnp.73.5.535
   Chen JP, 1996, GEN HOSP PSYCHIAT, V18, P453, DOI 10.1016/S0163-8343(96)00060-6
   COGAN DG, 1973, A GRAEF ARCH KLIN EX, V188, P139, DOI 10.1007/BF00407835
   Contardi S, 2007, EPILEPTIC DISORD, V9, P271, DOI 10.1684/epd.2007.0110
   CUMMINGS JL, 1987, WESTERN J MED, V146, P46
   DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584
   DEMORSIER G, 1967, ANN MED-PSYCHOL, V125, P677
   Eperjesi Frank, 2004, Clin Exp Optom, V87, P149
   Fernandez A, 1997, J NERV MENT DIS, V185, P195, DOI 10.1097/00005053-199703000-00009
   Ffytche DH, 1998, NAT NEUROSCI, V1, P738, DOI 10.1038/3738
   Ffytche Dominic H, 2007, Dialogues Clin Neurosci, V9, P173
   Ffytche Dominic H, 2005, Curr Psychiatry Rep, V7, P168, DOI 10.1007/s11920-005-0050-3
   Freiman TM, 2004, J NEUROSURG, V101, P846, DOI 10.3171/jns.2004.101.5.0846
   Guptha SH, 2007, LANCET, V370, P1588, DOI 10.1016/S0140-6736(07)61663-8
   Hedges TR, 2007, SURV OPHTHALMOL, V52, P111, DOI 10.1016/j.survophthal.2006.10.007
   Hori H, 2000, INT CLIN PSYCHOPHARM, V15, P117, DOI 10.1097/00004850-200015020-00009
   Lang UE, 2007, J PSYCHOPHARMACOL, V21, P553, DOI 10.1177/0269881106075275
   Lorberboym M, 2002, CLIN NUCL MED, V27, P87, DOI 10.1097/00003072-200202000-00002
   Manford M, 1998, BRAIN, V121, P1819, DOI 10.1093/brain/121.10.1819
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Merabet LB, 2004, J NEURO-OPHTHALMOL, V24, P109, DOI 10.1097/00041327-200406000-00003
   Mewasingh LD, 2002, PEDIATR NEUROL, V26, P143, DOI 10.1016/S0887-8994(01)00358-7
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Mocellin R, 2006, AUST NZ J PSYCHIAT, V40, P742
   Moja MC, 2005, NEUROL SCI, V26, P168, DOI 10.1007/s10072-005-0455-0
   OLBRICH HM, 1987, GRAEF ARCH CLIN EXP, V225, P217, DOI 10.1007/BF02175452
   Pankow L, 1996, J NEUROPSYCH CLIN N, V8, P88
   Paulig M, 2001, J NEUROL NEUROSUR PS, V70, P813, DOI 10.1136/jnnp.70.6.813
   Plummer C, 2007, J CLIN NEUROSCI, V14, P709, DOI 10.1016/j.jocn.2006.08.006
   Poggel DA, 2007, NEUROPSYCHOLOGIA, V45, P2598, DOI 10.1016/j.neuropsychologia.2007.03.005
   ROSENBAUM F, 1987, J AM GERIATR SOC, V35, P66, DOI 10.1111/j.1532-5415.1987.tb01321.x
   Ross J, 2005, EYE, V19, P811, DOI 10.1038/sj.eye.6701647
   Santhouse AM, 2000, BRAIN, V123, P2055, DOI 10.1093/brain/123.10.2055
   SCHULTZ G, 1991, PERCEPTION, V20, P809, DOI 10.1068/p200809
   Shiraishi Y, 2004, EUR ARCH PSY CLIN N, V254, P362, DOI 10.1007/S00406-004-0515-0
   SIATKOWSKI RM, 1990, J CLIN NEURO-OPHTHAL, V10, P215
   Tan CSH, 2006, ARCH NEUROL-CHICAGO, V63, P598, DOI 10.1001/archneur.63.4.598
   Tan CSH, 2006, EUR ARCH PSY CLIN N, V256, P62, DOI 10.1007/s00406-005-0594-6
   Tan CSH, 2004, BRIT J OPHTHALMOL, V88, P1325, DOI 10.1136/bjo.2004.041947
   Tan CSH, 2005, ARCH NEUROL-CHICAGO, V62, P1479, DOI 10.1001/archneur.62.9.1479-a
   Tan CSH, 2005, J NEUROSURG, V103, P193
   Teunisse RJ, 1999, COMPR PSYCHIAT, V40, P315, DOI 10.1016/S0010-440X(99)90133-5
   Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7
   TEUTH MJ, 1995, J GERIATR PSYCH NEUR, V8, P1
NR 50
TC 33
Z9 34
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1529-1839
J9 OPTOMETRY
JI Optometry
PD JUL
PY 2009
VL 80
IS 7
BP 360
EP 366
DI 10.1016/j.optm.2008.10.017
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V18QH
UT WOS:000208018800006
PM 19545849
DA 2022-11-30
ER

PT J
AU Halili, MA
   Andrews, MR
   Sweet, MJ
   Fairlie, DP
AF Halili, Maria A.
   Andrews, Melanie R.
   Sweet, Matthew J.
   Fairlie, David P.
TI Histone Deacetylase Inhibitors In Inflammatory Disease
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Histone deacetylase inhibitor; inflammation; cytokines; arthritis;
   cancer
ID PROINFLAMMATORY GENE-EXPRESSION; AMYOTROPHIC-LATERAL-SCLEROSIS;
   OBSTRUCTIVE PULMONARY-DISEASE; VERSUS-HOST-DISEASE; KAPPA-B ACTIVATION;
   REGULATORY T-CELLS; TRICHOSTATIN-A; HYDROXAMIC ACID; IN-VIVO; VALPROIC
   ACID
AB Lysine acetylation is becoming increasingly appreciated as a key post-translational modification in the endogenous regulation of protein function. The so-called histone acetyl transferases (HATs) and histone deacetylases (HDACs), best known for their roles in controlling chromatin remodeling via histone acetylation/deacetylation, are now known to modify a large number of non-histone proteins to control diverse cell processes. In relation to inflammation, acetylation modulates the activity or function of cytokine receptors, nuclear hormone receptors, intracellular signaling molecules and transcription factors. Small molecule inhibitors of HDACs have been found to trigger both pro and anti-inflammatory effects in a range of inflammation-relevant cell types. Although their inflammatory profiles have only just begun to be elucidated, some HDAC inhibitors are already showing therapeutic promise in animal models of inflammatory diseases such as arthritis, inflammatory bowel diseases, septic shock, ischemia-reperfusion injury, airways inflammation and asthma, diabetes, age-related macular degeneration, cardiovascular diseases, multiple sclerosis and other CNS and neurodegenerative diseases. This article describes those HDAC inhibitors which have been most examined to date for their potentially beneficial effects on inflammatory cells or in animal models of inflammatory disease.
C1 [Halili, Maria A.; Andrews, Melanie R.; Sweet, Matthew J.; Fairlie, David P.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
C3 University of Queensland
RP Fairlie, DP (通讯作者)，Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
EM d.fairlie@imb.uq.edu.au
RI Fairlie, David P/F-8865-2014; Halili, Maria A/J-8362-2014; Shakespear,
   Melanie/G-4867-2014; Sweet, Matthew J/F-2229-2011
OI Fairlie, David P/0000-0002-7856-8566; Halili, Maria
   A/0000-0003-4407-5269; Shakespear, Melanie/0000-0002-9517-0699; Sweet,
   Matthew J/0000-0002-0406-8139
FU National Health and Medical Research Council of Australia; The Cancer
   Council Queensland; Australian Research Council
FX We thank the National Health and Medical Research Council of Australia
   The Cancer Council Queensland and the Australian Research Council for
   research support and for a Federation Fellowship (to DPF) from the
   latter.
CR Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166
   Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016
   ADENUGA D, 2008, AM J RESP CELL MOL B
   Alenghat T, 2008, NATURE, V456, P997, DOI 10.1038/nature07541
   Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200
   Aung HT, 2006, FASEB J, V20, P1315, DOI 10.1096/fj.05-5360com
   Barnes PJ, 2006, CHEST, V129, P151, DOI 10.1378/chest.129.1.151
   Barnes PJ, 2005, EXPERT OPIN THER TAR, V9, P1111, DOI 10.1517/14728222.9.6.1111
   Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243
   Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156
   Blair HC, 2006, REV ENDOCR METAB DIS, V7, P23, DOI 10.1007/s11154-006-9010-4
   Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4
   Bode KA, 2007, IMMUNOLOGY, V122, P596, DOI 10.1111/j.1365-2567.2007.02678.x
   Bosisio D, 2008, J LEUKOCYTE BIOL, V84, P1540, DOI 10.1189/jlb.0708401
   Bottomley MJ, 2008, J BIOL CHEM, V283, P26694, DOI 10.1074/jbc.M803514200
   Brogdon JL, 2007, BLOOD, V109, P1123, DOI 10.1182/blood-2006-04-019711
   BROWN L, 2009, J IMMUNOLOGY
   Butzner JD, 1996, GUT, V38, P568, DOI 10.1136/gut.38.4.568
   Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022
   Cantley MD, 2009, BONE, V44, pS133, DOI 10.1016/j.bone.2009.01.292
   Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC
   Chahrour M, 2007, NEURON, V56, P422, DOI 10.1016/j.neuron.2007.10.001
   Chang SR, 2006, CELL, V126, P321, DOI 10.1016/j.cell.2006.05.040
   Chen PS, 2007, NEUROSCIENCE, V149, P203, DOI 10.1016/j.neuroscience.2007.06.053
   Choi JH, 2005, CLIN EXP ALLERGY, V35, P89, DOI 10.1111/j.1365-2222.2004.02006.x
   Choi JH, 2005, ARTERIOSCL THROM VAS, V25, P2404, DOI 10.1161/01.ATV.0000184758.07257.88
   Choo QY, 2008, CURR PHARM DESIGN, V14, P803, DOI 10.2174/138161208784007699
   Chung YL, 2003, MOL THER, V8, P707, DOI 10.1016/S1525-0016(03)00235-1
   Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC
   Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Denu JM, 2005, CURR OPIN CHEM BIOL, V9, P431, DOI 10.1016/j.cbpa.2005.08.010
   Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Duvic M, 2007, EXPERT OPIN INV DRUG, V16, P1111, DOI 10.1517/13543784.16.7.1111
   Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Gibson PR, 2000, GUT, V46, P447, DOI 10.1136/gut.46.4.447
   Glauben R, 2008, GUT, V57, P613, DOI 10.1136/gut.2007.134650
   Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015
   Gray SG, 2006, EPIGENETICS-US, V1, P67, DOI 10.4161/epi.1.2.2678
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Hamalainen M, 2008, PULM PHARMACOL THER, V21, P331, DOI 10.1016/j.pupt.2007.08.003
   Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC
   Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541
   Huang LL, 2006, J CELL PHYSIOL, V209, P611, DOI 10.1002/jcp.20781
   Huang N, 1997, CYTOKINE, V9, P27, DOI 10.1006/cyto.1996.0132
   Hume DA, 2005, CURR MED CHEM, V12, P2925, DOI 10.2174/092986705774462923
   Inoue K, 2006, ARTERIOSCL THROM VAS, V26, P2652, DOI 10.1161/01.ATV.0000247247.89787.e7
   Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466
   Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892
   Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046
   Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060
   Ito K, 2007, PHARMACOL THERAPEUT, V116, P249, DOI 10.1016/j.pharmthera.2007.06.009
   Kee HJ, 2006, CIRCULATION, V113, P51, DOI 10.1161/CIRCULATIONAHA.105.559724
   Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188
   Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   Larsen L, 2007, DIABETOLOGIA, V50, P779, DOI 10.1007/s00125-006-0562-3
   Leng C, 2006, EXP HEMATOL, V34, P776, DOI 10.1016/j.exphem.2006.02.014
   Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006-00005.Dinarello
   Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999
   Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630
   Lin HS, 2007, BRIT J PHARMACOL, V150, P862, DOI 10.1038/sj.bjp.0707165
   Lin T, 2006, SURGERY, V139, P365, DOI 10.1016/j.surg.2005.08.022
   Luhrs H, 2002, SCAND J GASTROENTERO, V37, P458, DOI 10.1080/003655202317316105
   Malo MS, 2006, DNA CELL BIOL, V25, P684, DOI 10.1089/dna.2006.25.684
   Manabe H, 2008, INFLAMM RES, V57, P4, DOI 10.1007/s00011-007-7036-z
   Marks PA, 2007, NAT BIOTECHNOL, V25, P84, DOI 10.1038/nbt1272
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Nakamura T, 2005, J IMMUNOL, V175, P5809, DOI 10.4049/jimmunol.175.9.5809
   Nasu Y, 2008, OSTEOARTHR CARTILAGE, V16, P723, DOI 10.1016/j.joca.2007.10.014
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Nencioni A, 2007, CLIN CANCER RES, V13, P3933, DOI 10.1158/1078-0432.CCR-06-2903
   Nishida K, 2004, ARTHRITIS RHEUM-US, V50, P3365, DOI 10.1002/art.20709
   Park JH, 2004, CLIN CANCER RES, V10, P5271, DOI 10.1158/1078-0432.CCR-03-0709
   Peng GS, 2005, MOL BRAIN RES, V134, P162, DOI 10.1016/j.molbrainres.2004.10.021
   Petri S, 2006, NEUROBIOL DIS, V22, P40, DOI 10.1016/j.nbd.2005.09.013
   PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0
   Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood-2002-08-2622
   Reddy P, 2008, J CLIN INVEST, V118, P2562, DOI 10.1172/JCI34712
   Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x
   ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M
   Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x
   Sailhamer EA, 2008, SURGERY, V144, P204, DOI 10.1016/j.surg.2008.03.034
   Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039
   Schroeder TM, 2005, J BONE MINER RES, V20, P2254, DOI 10.1359/JBMR.050813
   Schuetz A, 2008, J BIOL CHEM, V283, P11355, DOI 10.1074/jbc.M707362200
   Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006
   Skov S, 2003, BLOOD, V101, P1430, DOI 10.1182/blood-2002-07-2073
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Suzuki T, 2006, J MED CHEM, V49, P4809, DOI 10.1021/jm060554y
   Takada Y, 2006, J BIOL CHEM, V281, P5612, DOI 10.1074/jbc.M507213200
   Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652
   Vannini A, 2004, P NATL ACAD SCI USA, V101, P15064, DOI 10.1073/pnas.0404603101
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   VERDIN E, 2004, NOVART FDN SYMP, V129, P163
   Verdin Eric, 2004, Novartis Found Symp, V259, P115
   VILLAGRA A, 2008, NAT IMMUNOL
   Wang B, 2008, CELL IMMUNOL, V253, P54, DOI 10.1016/j.cellimm.2008.04.016
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Yi T, 2007, EXP MOL MED, V39, P213, DOI 10.1038/emm.2007.24
   Young DA, 2005, ARTHRITIS RES THER, V7, pR503, DOI 10.1186/ar1702
   Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9
   Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06
NR 111
TC 148
Z9 154
U1 0
U2 32
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-5294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PD FEB
PY 2009
VL 9
IS 3
BP 309
EP 319
DI 10.2174/156802609788085250
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 441VJ
UT WOS:000265798300008
PM 19355993
DA 2022-11-30
ER

PT J
AU Li, QH
   Dinculescu, A
   Shan, ZY
   Miller, R
   Pang, JJ
   Lewin, AS
   Raizada, MK
   Hauswirth, WW
AF Li, Qiuhong
   Dinculescu, Astra
   Shan, Zhiying
   Miller, Rehae
   Pang, Jijing
   Lewin, Alfred S.
   Raizada, Mohan K.
   Hauswirth, William W.
TI Downregulation of p22phox in retinal pigment epithelial cells inhibits
   choroidal neovascularization in mice
SO MOLECULAR THERAPY
LA English
DT Article
ID CHRONIC GRANULOMATOUS-DISEASE; ANGIOGENIC GROWTH-FACTORS; NADPH OXIDASE;
   NAD(P)H OXIDASE; REACTIVE OXYGEN; MACULAR DEGENERATION; CHORIORETINAL
   LESIONS; ENDOTHELIAL-CELLS; ANGIOTENSIN-II; EXPRESSION
AB Choroidal neovascularization (CNV) occurs in a variety of chorioretinal diseases including age-related macular degeneration (AMD), and is the major cause of severe visual loss in patients with AMD. Oxidative stress has been thought to play an important role in the development of CNV. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is one of the major intracellular sources of reactive oxygen species (ROS) in the vascular system. In this study, we examined the expression of p22phox, an integral subunit in the NADPH oxidase complex, in the mouse eye. We determined that p22phox is expressed in the retinal pigment epithelial (RPE) cells and inner retinal neurons. A small-interfering RNA (siRNA) designed against p22phox efficiently reduced the expression of the protein in the eye when delivered by means of recombinant adeno-associated virus (AAV) vector. Vector treatment inhibited CNV in the mouse when delivered into the subretinal space where RPE cells were transduced. These results suggest that NADPH oxidase-mediated ROS production in RPE cells may play an important role in the pathogenesis of neovascular AMD, and that this pathway may represent a new target for therapeutic intervention in AMD.
C1 [Li, Qiuhong] Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
   [Shan, Zhiying; Raizada, Mohan K.] Univ Florida, Dept Phys & Funct Genom, Gainesville, FL 32610 USA.
   [Lewin, Alfred S.; Hauswirth, William W.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida
RP Li, QH (通讯作者)，Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA.
EM qli@ufl.edu
OI Lewin, Alfred/0000-0002-4192-9727
FU National Institutes of Health [EY13729, EY11123, NS36302, EY08571,
   EY016073, HL56921]; Macular Vision Research Foundation; Foundation
   Fighting Blindness; Juvenile Diabetes Research Foundation; Research to
   Prevent Blindness, Inc.; University of Florida; NATIONAL EYE INSTITUTE
   [R01EY011123, U10EY013729, R01EY018335, R01EY016073, P30EY008571]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL056921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKE [P01NS036302] Funding Source: NIH
   RePORTER
FX We acknowledge the National Institutes of Health grants EY13729,
   EY11123, NS36302, EY08571, EY016073, HL56921 and grants from the Macular
   Vision Research Foundation, Foundation Fighting Blindness, Juvenile
   Diabetes Research Foundation, and Research to Prevent Blindness, Inc.
   for partial support of this work. W. W. H. and the University of Florida
   have a financial interest in the use of adeno-associated virus (AAV)
   therapies, and own equity in a company ( AGTC Inc.) that might, in the
   future, commercialize some aspects of this work. We thank Mike Daniel
   for help with statistical analysis, and Clay Smith for help with western
   blot analysis.
CR Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001
   Babior BM, 2000, IUBMB LIFE, V50, P267, DOI 10.1080/15216540051080976
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   BOK D, 1993, J CELL SCI, P189
   Cacicedo JM, 2005, DIABETES, V54, P1838, DOI 10.2337/diabetes.54.6.1838
   Cross AR, 2004, BBA-BIOENERGETICS, V1657, P1, DOI 10.1016/j.bbabio.2004.03.008
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Ellis EA, 1998, FREE RADICAL BIO MED, V24, P111, DOI 10.1016/S0891-5849(97)00202-5
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Goldblatt D, 1999, J PEDIATR-US, V134, P780, DOI 10.1016/S0022-3476(99)70299-4
   Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26
   Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494
   Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2
   Infanger DW, 2006, ANTIOXID REDOX SIGN, V8, P1583, DOI 10.1089/ars.2006.8.1583
   ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U
   Kamsler A, 2004, MOL NEUROBIOL, V29, P167, DOI 10.1385/MN:29:2:167
   Kawahara T, 2007, BMC EVOL BIOL, V7, DOI 10.1186/147-2148-7-109
   Kent D, 2003, MOL VIS, V9, P747
   Kim SJ, 2003, RETINA-J RET VIT DIS, V23, P360, DOI 10.1097/00006982-200306000-00012
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   Li JM, 2004, AM J PHYSIOL-REG I, V287, pR1014, DOI 10.1152/ajpregu.00124.2004
   Manea A, 2005, BIOL CELL, V97, P723, DOI 10.1042/BC20040107
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Saito Y, 2007, MOL VIS, V13, P840
   Schrader M, 2004, HISTOCHEM CELL BIOL, V122, P383, DOI 10.1007/s00418-004-0673-1
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Ushio-Fukai M, 2006, CARDIOVASC RES, V71, P226, DOI 10.1016/j.cardiores.2006.04.015
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zimmerman MC, 2002, CIRC RES, V91, P1038, DOI 10.1161/01.RES.0000043501.47934.FA
NR 50
TC 33
Z9 33
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD OCT
PY 2008
VL 16
IS 10
BP 1688
EP 1694
DI 10.1038/mt.2008.164
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 356RW
UT WOS:000259796300007
PM 18665154
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Leeson, S
   Caston, L
   Namkung, H
AF Leeson, S.
   Caston, L.
   Namkung, H.
TI Effect of dietary lutein and flax on performance, egg composition and
   liver status of laying hens
SO CANADIAN JOURNAL OF ANIMAL SCIENCE
LA English
DT Article
DE egg composition; flaxseed; lutein; layers
ID MACULAR PIGMENT; CAROTENOIDS; SUPPLEMENT; ZEAXANTHIN; QUALITY; PLASMA;
   ACID; MEN
AB Lutein is considered a protective nutrient against age-related macular degeneration in humans. An experiment was designed to study the long-term effect of feeding lutein in combination with flaxseed on layer performance, egg parameters, and lutein deposition in eggs and tissues. Laying hens were fed diets with 0 or 10% flax supplemented with 0, 125 or 250 ppm lutein for 11 consecutive 28-d periods beginning at 18 wk of age. Early production was reduced (P < 0.01) by feeding diets with 10% flax and when supplemented with 250 ppm lutein. Diet treatments had no effect on feed intake, egg weight or eggshell deformation. Addition of lutein to the diets significantly (P < 0.01) increased yolk color, and lutein content in the egg, liver, and the preen gland. Egg lutein content increased (P < 0.0 1) from a basal level of 0. 10 mg to 1.60 mg 60g(-1) egg by addition of lutein to the diet. Liver fat was lower (P < 0.05) in hens fed 10% flaxseed. Liver hemorrhage score was dramatically reduced (P < 0.01) in birds fed lutein.
C1 Univ Guelph, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada.
C3 University of Guelph
RP Leeson, S (通讯作者)，Univ Guelph, Dept Anim & Poultry Sci, Guelph, ON N1G 2W1, Canada.
EM sleeson@uoguelph.ca
CR CASTON LJ, 1994, CAN J ANIM SCI, V74, P347, DOI 10.4141/cjas94-047
   CHAN JK, 1991, AM J CLIN NUTR, V53, P1230, DOI 10.1093/ajcn/53.5.1230
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   GONZALEZ R, 2001, CAN J ANIM SCI, V81, P291
   Gonzalez-Esquerra R, 2000, POULTRY SCI, V79, P1603, DOI 10.1093/ps/79.11.1603
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   KRINSKY NI, 1993, ANNU REV NUTR, V13, P561, DOI [10.1146/annurev.nu.13.070193.003021, 10.1146/annurev.nutr.13.1.561]
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Landrum JT, 1999, PURE APPL CHEM, V71, P2237, DOI 10.1351/pac199971122237
   Leeson S, 2004, POULTRY SCI, V83, P1709, DOI 10.1093/ps/83.10.1709
   Leeson S., 1997, COMMERCIAL POULTRY N, P205
   LESSON S, 2004, MERCK VET MANUAL, P2226
   Novak C, 2001, POULTRY SCI, V80, P1480, DOI 10.1093/ps/80.10.1480
   *SAS I INC, 1995, SAS US GUID
   Scheideler SE, 1996, POULTRY SCI, V75, P1221, DOI 10.3382/ps.0751221
   Schumann BE, 2000, BRIT POULTRY SCI, V41, P465, DOI 10.1080/713654970
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SUMMERS JD, 1976, POULTRY SCI, V55, P402, DOI 10.3382/ps.0550402
   Wang Z, 2004, CAN J ANIM SCI, V84, P1, DOI 10.4141/A03-123
   Wolfinger R., 1998, COMP SAS GLM MIXED P
NR 23
TC 20
Z9 21
U1 0
U2 7
PU AGRICULTURAL INST CANADA
PI OTTAWA
PA 280 ALBERT ST, SUITE 900, OTTAWA, ONTARIO K1P 5G8, CANADA
SN 0008-3984
J9 CAN J ANIM SCI
JI Can. J. Anim. Sci.
PD SEP
PY 2007
VL 87
IS 3
BP 365
EP 372
DI 10.4141/A06-043
PG 8
WC Agriculture, Dairy & Animal Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture
GA 230CX
UT WOS:000250854500010
DA 2022-11-30
ER

PT J
AU Stenirri, S
   Battistella, S
   Fermo, I
   Manitto, MP
   Martina, E
   Brancato, R
   Ferrari, M
   Cremonesi, L
AF Stenirri, Stefania
   Battistella, Stefania
   Fermo, Isabella
   Manitto, Maria Pia
   Martina, Elisabetta
   Brancato, Rosario
   Ferrari, Maurizio
   Cremonesi, Laura
TI De novo deletion removes a conserved motif in the C-terminus of ABCA4
   and results in cone-rod dystrophy
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE ABCA4; cone-rod dystrophy; denaturing HPLC (DHPLC); de novo mutation
ID STARGARDT-DISEASE; MACULAR DEGENERATION; TRANSPORTER GENE;
   TANGIER-DISEASE; MUTATIONS; PHENOTYPE; PROTEIN
AB Background: Mutations in the retina-specific ABC transporter (ABCA4) gene are associated with different types of macular degeneration, including Star-gardt disease, cone-rod dystrophy, Fundus flavimaculatus, Retinitis pigmentosa and probably age-related macular degeneration.
   Methods: Screening for mutations in the ABCA4 gene was performed using denaturing high-performance liquid chromatography and direct sequencing.
   Results: We describe the identification of a new de novo 44-bp deletion in an Italian patient affected by cone-rod dystrophy. The mutation, located in intron 48 of the ABCA4 gene, is predicted to cause exon 49 skipping, resulting in loss of the C-terminus of the ABCA4 protein. Interestingly, exon 49 also codes for a highly conserved VFVNFA motif, which has been demonstrated to be essential for the activity of ABCA1, another gene of the ABC transporter family. The presence of CT repeats at the breakpoints might have facilitated the generation of the deletion through a slippage mispairing mechanism.
   Conclusions: The new 6730-16del44 deletion is the first de novo mutation associated with cone-rod dystrophy and may contribute to a better understanding of the role of ABCA4 mutations in macular dystrophies.
C1 San Raffaele Sci Inst, Unit Genom Diag Human Pathol, I-20132 Milan, Italy.
   San Raffaele Sci Inst, Unit Separat Techniques, I-20132 Milan, Italy.
   San Raffaele Sci Inst, Dept Ophthalmol & Visual Sci, I-20132 Milan, Italy.
   Diagnost & Ric San Raffaele SpA, Milan, Italy.
   Univ Vita Salute San Raffaele, Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita-Salute San Raffaele University
RP Cremonesi, L (通讯作者)，San Raffaele Sci Inst, Unit Genom Diag Human Pathol, Via Olgettina 58, I-20132 Milan, Italy.
EM cremonesi.laura@hsr.it
RI fermo, isabella/AAN-3999-2020
OI fermo, isabella/0000-0003-2947-1933
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Briggs CE, 2001, INVEST OPHTH VIS SCI, V42, P2229
   Brousseau ME, 2000, J LIPID RES, V41, P433
   Cremonesi L, 2003, HUM MUTAT, V22, P98, DOI 10.1002/humu.10234
   EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8
   Fitzgerald ML, 2004, J BIOL CHEM, V279, P48477, DOI 10.1074/jbc.M409848200
   Fumagalli A, 2001, HUM GENET, V109, P326, DOI 10.1007/s004390100583
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Lovett ST, 2004, MOL MICROBIOL, V52, P1243, DOI 10.1111/j.1365-2958.2004.04076.x
   Magnani C, 1996, HUM GENET, V98, P102, DOI 10.1007/s004390050167
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Molday, 2000, Am J Ophthalmol, V130, P689, DOI 10.1016/S0002-9394(00)00756-X
   Oram JF, 2000, BBA-MOL CELL BIOL L, V1529, P321, DOI 10.1016/S1388-1981(00)00157-8
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Simonelli F, 2000, INVEST OPHTH VIS SCI, V41, P892
   Stenirri S, 2004, CLIN CHEM, V50, P1336, DOI 10.1373/clinchem.2004.033241
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
NR 22
TC 11
Z9 11
U1 0
U2 1
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD MAY
PY 2006
VL 44
IS 5
BP 533
EP 537
DI 10.1515/CCLM.2006.116
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 050YB
UT WOS:000238125300004
PM 16681420
DA 2022-11-30
ER

PT J
AU Oner, A
   Karakucuk, S
   Mirza, E
   Erkilic, K
AF Oner, A
   Karakucuk, S
   Mirza, E
   Erkilic, K
TI Electrooculography after photodynamic therapy
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE electrooculography; photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION;
   VERTEPORFIN; STANDARD
AB Purpose: To evaluate the changes in electrooculography (EOG) after photodynamic therapy (PDT). Methods: Thirty-eight eyes of 38 patients (21 males, 17 females) with choroidal neovascularization secondary to age related macular degeneration were included in this study. Standart PDT with verteporfin was performed on each patient. Serial EOG recordings were performed before, 1 week, and 1 month after PDT. Results: Mean age of the patients was 69.8 +/- 9.7 years (range 56 and 90 years). Seven days after PDT the visual acuity improved in 17 eyes, remained unchanged in 16 eyes and deteriorated in 5 eyes. One month after PDT the visual acuity findings were the same as the first week. New hemorrhages were seen in three eyes in the first week after PDT and visual acuity was decreased in those patients. No other patient complained of ocular and systemic adverse events. There was a statistically significant reduction in the Arden ratio of the EOG 1 week after PDT and the reduction persisted in the first month recordings. Conclusions: The reduction in Arden ratio of EOG findings may indicate that retina pigment epithelium function could be affected after PDT.
C1 Erciyes Univ, Fac Med, Dept Ophthalmol, TR-38039 Kayseri, Turkey.
C3 Erciyes University
RP Oner, A (通讯作者)，Erciyes Univ, Fac Med, Dept Ophthalmol, TR-38039 Kayseri, Turkey.
EM aoner@erciyes.edu.tr
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FISHMAN GA, 1975, OPHTHALMOLOGY MONOGR, V2, P96
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   KOLDER HE, 1991, PRINCIPLES PRACTICE, P301
   Lai TYY, 2004, AM J OPHTHALMOL, V137, P826, DOI 10.1016/j.ajo.2003.11.079
   Marmor MF, 1998, DOC OPHTHALMOL, V95, P91, DOI 10.1023/A:1001788731171
   MARMOR MF, 1993, DOC OPHTHALMOL, V85, P115, DOI 10.1007/BF01371127
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Parodi MB, 2003, RETINA-J RET VIT DIS, V23, P171, DOI 10.1097/00006982-200304000-00006
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
NR 15
TC 10
Z9 10
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD SEP
PY 2005
VL 111
IS 2
BP 83
EP 86
DI 10.1007/s10633-005-4410-4
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 032HN
UT WOS:000236765600003
PM 16514489
DA 2022-11-30
ER

PT J
AU Clare, AJ
   Liu, J
   Copland, DA
   Theodoropoulou, S
   Dick, AD
AF Clare, Alison J.
   Liu, Jian
   Copland, David A.
   Theodoropoulou, Sofia
   Dick, Andrew D.
TI Unravelling the therapeutic potential of IL-33 for atrophic AMD
SO EYE
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; MACULAR DEGENERATION; OXIDATIVE STRESS;
   IMMUNE-RESPONSE; MAST-CELLS; T-CELLS; INFLAMMATION; EXPRESSION; RISK;
   POLYMORPHISMS
AB Age-related macular degeneration (AMD), a degenerative disease affecting the retinal pigment epithelium (RPE) and photoreceptors in the macula, is the leading cause of central blindness in the elderly. AMD progresses to advanced stages of the disease, atrophic AMD (aAMD), or in 15% of cases "wet" or neovascular AMD (nAMD), associated with substantial vision loss. Whilst there has been advancement in therapies treating nAMD, to date, there are no licenced effective treatments for the 85% affected by aAMD, with disease managed by changes to diet, vitamin supplements, and regular monitoring. AMD has a complex pathogenesis, involving highly integrated and common age-related disease pathways, including dysregulated complement/inflammation, impaired autophagy, and oxidative stress. The intricacy of AMD pathogenesis makes therapeutic development challenging and identifying a target that combats the converging disease pathways is essential to provide a globally effective treatment. Interleukin-33 is a cytokine, classically known for the proinflammatory role it plays in allergic disease. Recent evidence across degenerative and inflammatory disease conditions reveals a diverse immune-modulatory role for IL-33, with promising therapeutic potential. Here, we will review IL-33 function in disease and discuss the future potential for this homeostatic cytokine in treating AMD.
C1 [Clare, Alison J.; Liu, Jian; Copland, David A.; Theodoropoulou, Sofia; Dick, Andrew D.] Univ Bristol, Acad Unit Ophthalmol, Translat Hlth Sci, Bristol, Avon, England.
   [Dick, Andrew D.] Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.
   [Dick, Andrew D.] Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Dick, Andrew D.] UCL Inst Ophthalmol, London, England.
C3 University of Bristol; University of Bristol; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Dick, AD (通讯作者)，Univ Bristol, Acad Unit Ophthalmol, Translat Hlth Sci, Bristol, Avon, England.; Dick, AD (通讯作者)，Univ Bristol, Sch Cellular & Mol Med, Bristol, Avon, England.; Dick, AD (通讯作者)，Moorfields Eye Hosp, NIHR Biomed Res Ctr Ophthalmol, London, England.; Dick, AD (通讯作者)，UCL Inst Ophthalmol, London, England.
EM a.dick@bristol.ac.uk
FU Academy of Medical Sciences; GOAP Bayer award; Elizabeth Blackwell
   Institute Wellcome Trust
FX Data included in this review paper were supported by grants from the
   Academy of Medical Sciences (ST and ADD), GOAP Bayer award (ST) and
   Elizabeth Blackwell Institute Wellcome Trust (ADD).
CR Augustine J, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1625-y
   Bandara G, 2015, EUR J IMMUNOL, V45, P3034, DOI 10.1002/eji.201545501
   Barbour M, 2014, EUR J IMMUNOL, V44, P3320, DOI 10.1002/eji.201444671
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Brestoff JR, 2015, CELL, V161, P146, DOI 10.1016/j.cell.2015.02.022
   Brown CN, 2019, METABOLITES, V9, DOI 10.3390/metabo9010004
   CARLOCK C, 2017, TRANSL PSYCHIAT, V7
   Caslin HL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03026
   Cayrol C, 2018, IMMUNOL REV, V281, P154, DOI 10.1111/imr.12619
   Chan BCL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00364
   Chapuis J, 2009, MOL PSYCHIATR, V14, P1004, DOI 10.1038/mp.2009.10
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Chou MY, 2008, J INTERN MED, V263, P479, DOI 10.1111/j.1365-2796.2008.01968.x
   Clare AJ, 2020, J CELL MOL MED, V24, P13546, DOI 10.1111/jcmm.16000
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DEGUIMARAES TAC, BRIT J OPHTHALMOL, V2021
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ding W, 2018, MOLECULES, V23, DOI 10.3390/molecules23071665
   Dreismann AK, 2021, GENE THER, V28, P265, DOI 10.1038/s41434-021-00239-9
   Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383
   Finlay CM, 2020, J IMMUNOL, V205, P1909, DOI 10.4049/jimmunol.1901321
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu AKY, 2016, P NATL ACAD SCI USA, V113, pE2705, DOI 10.1073/pnas.1604032113
   Gadani SP, 2015, NEURON, V85, P703, DOI 10.1016/j.neuron.2015.01.013
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Han JM, 2015, J IMMUNOL, V194, P4777, DOI 10.4049/jimmunol.1500020
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hristova M, 2016, J ALLERGY CLIN IMMUN, V137, P1545, DOI 10.1016/j.jaci.2015.10.003
   Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535
   Jia JY, 2020, MOL CELL, V77, P951, DOI 10.1016/j.molcel.2019.12.028
   Jiang HR, 2012, EUR J IMMUNOL, V42, P1804, DOI 10.1002/eji.201141947
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kijlstra A, 2015, OPHTHALMIC RES, V54, P64, DOI 10.1159/000432401
   Kim EJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21104-7
   Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020
   Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780
   Lau SF, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107530
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Leonardo TR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082966
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu JZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19711
   Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868
   Miller AM, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-22
   Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104
   Molofsky AB, 2015, IMMUNITY, V42, P1005, DOI 10.1016/j.immuni.2015.06.006
   Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021
   Nguyen PT, 2020, CELL, V182, P388, DOI 10.1016/j.cell.2020.05.050
   Nilsson AMZ, 2018, AM J PHYSIOL-LUNG C, V314, pL484, DOI 10.1152/ajplung.00270.2017
   O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570
   Ogura S, 2020, FASEB J, V34, P10117, DOI 10.1096/fj.202000807R
   Patel CH, 2019, NAT REV DRUG DISCOV, V18, P669, DOI 10.1038/s41573-019-0032-5
   Petit L, 2018, CELL REP, V23, P2629, DOI 10.1016/j.celrep.2018.04.111
   Pool FM, 2020, NPJ AGING MECH DIS, V6, DOI 10.1038/s41514-019-0039-5
   Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080
   Schroder PC, 2016, PEDIAT ALLERG IMM-UK, V27, P687, DOI 10.1111/pai.12597
   Scott LM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.129429
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Uchida M, 2017, ALLERGY, V72, P1521, DOI 10.1111/all.13158
   Wang X, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-1304-1
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J, 2015, J IMMUNOL, V194, P2140, DOI 10.4049/jimmunol.1402503
   Wu WK, 2015, AM J PATHOL, V185, P2324, DOI 10.1016/j.ajpath.2015.04.013
   Xi HK, 2016, J EXP MED, V213, P189, DOI 10.1084/jem.20150894
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu HD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00127
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zhang HF, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-120
NR 91
TC 1
Z9 1
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2022
VL 36
IS 2
BP 266
EP 272
DI 10.1038/s41433-021-01725-5
EA SEP 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ7VR
UT WOS:000696437400005
PM 34531552
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Suarez-Barrio, C
   del Olmo-Aguado, S
   Garcia-Perez, E
   Fernandez-Vega-Cueto, L
   Cueto, AFV
   Baamonde-Arbaiza, B
   Fernandez-Vega, L
   Merayo-Lloves, J
AF Suarez-Barrio, Carlota
   del Olmo-Aguado, Susana
   Garcia-Perez, Eva
   Fernandez-Vega-Cueto, Luis
   Fernandez-Vega Cueto, Andres
   Baamonde-Arbaiza, Begona
   Fernandez-Vega, Luis
   Merayo-Lloves, Jesus
TI Plasma Rich in Growth Factors Promotes Autophagy in ARPE19 Cells in
   Response to Oxidative Stress Induced by Blue Light
SO BIOMOLECULES
LA English
DT Article
DE PRGF; AMD; ARPE19; oxidative stress; autophagy; antioxidant;
   neuroprotection
ID PIGMENT EPITHELIAL-CELLS; FACTORS PRGF; EYE DROPS; MITOCHONDRIA;
   APOPTOSIS; DEGENERATION; SURVIVAL; ARPE-19; PROLIFERATION; INFLAMMATION
AB Age-related macular degeneration (AMD) causes the degeneration of photoreceptors and retinal cells leading to vision loss in older subjects. Among possible exogenous risk factors, it has been recently proposed that long-term exposure to blue light could aggravate the course of AMD. In the search for therapeutic options, plasma rich in growth factors (PRGF) has been shown to enhance cell antioxidant pathways and protect photoreceptors against the harm produced by blue light, although its mechanism of action remains unknown. One possible mechanism, autophagy, is one of the most conservative cell renewal systems used in eukaryotes to destroy cellular components that have been damaged by some kind of insult. The oxidative stress of exposure to blue light is known to induce cell autophagy. In this study, we examined the combined effects on autophagy of blue light and PRGF in a retinal cell line, ARPE19. In response to treatment with both PRGF and blue light, we detected the modulated expression of autophagy markers such as NF-kB, p62/sqstm1, Atg5, LC3 and Beclin1, and inflammatory markers such as IL1B and IL18. Our findings suggest that PRGF promotes cell autophagy in response to exposure to blue light.
C1 [Suarez-Barrio, Carlota; del Olmo-Aguado, Susana; Garcia-Perez, Eva; Fernandez-Vega-Cueto, Luis; Fernandez-Vega Cueto, Andres; Baamonde-Arbaiza, Begona; Fernandez-Vega, Luis; Merayo-Lloves, Jesus] Inst Univ Fernandez Vega, Fdn Invest Oftalmol, Oviedo 33012, Spain.
   [Suarez-Barrio, Carlota; del Olmo-Aguado, Susana; Garcia-Perez, Eva; Fernandez-Vega-Cueto, Luis; Fernandez-Vega Cueto, Andres; Baamonde-Arbaiza, Begona; Fernandez-Vega, Luis; Merayo-Lloves, Jesus] Univ Oviedo, Oviedo 33012, Spain.
   [del Olmo-Aguado, Susana; Fernandez-Vega-Cueto, Luis; Fernandez-Vega Cueto, Andres; Baamonde-Arbaiza, Begona; Fernandez-Vega, Luis; Merayo-Lloves, Jesus] Inst Invest Sanitaria Principado Asturias, Ave Roma S-N, Oviedo 33011, Spain.
C3 University of Oviedo; Instituto de Investigacion Sanitaria del
   Principado de Asturias (ISPA)
RP del Olmo-Aguado, S (通讯作者)，Inst Univ Fernandez Vega, Fdn Invest Oftalmol, Oviedo 33012, Spain.; del Olmo-Aguado, S (通讯作者)，Univ Oviedo, Oviedo 33012, Spain.
EM carlotasb.8@gmail.com; solmo@fio.as; evagp2002@gmail.com;
   lfvc@fernandez-vega.com; afvc@fernandez-vega.com; bbaamonde@yahoo.es;
   prof.luis@fernandez-vega.com; merayo@fio.as
RI del Olmo Aguado, Susana/AAY-3497-2021; Garcia, Eva/M-2382-2017
OI del Olmo Aguado, Susana/0000-0002-2867-7254; Fernandez-Vega Cueto
   Felgueroso, Luis/0000-0001-9197-5847; Fernandez-Vega Cueto,
   Andres/0000-0001-7320-3368; Suarez Barrio, Carlota/0000-0003-0171-1851;
   Garcia, Eva/0000-0002-3594-9318
FU "Accion Estrategica en Salud (AES)"-Instituto de Salud Carlos III-of the
   Spanish Ministry of Economy and Competitiveness [PI17/01549]; European
   Union through the "Fondo Europeo de Desarrollo Regional (FEDER)"
FX This research was supported by the grant PI17/01549 from the "Accion
   Estrategica en Salud (AES)"-Instituto de Salud Carlos III-of the Spanish
   Ministry of Economy and Competitiveness, and the European Union through
   the "Fondo Europeo de Desarrollo Regional (FEDER)".
CR Abcouwer SF, 2008, INVEST OPHTH VIS SCI, V49, P5581, DOI 10.1167/iovs.07-1032
   Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867
   Anitua E, 2015, EXP EYE RES, V135, P118, DOI 10.1016/j.exer.2015.02.016
   Anitua E, 2012, KNEE SURG SPORT TR A, V20, P1657, DOI 10.1007/s00167-011-1697-4
   Anitua E, 2008, TRENDS PHARMACOL SCI, V29, P37, DOI 10.1016/j.tips.2007.10.010
   Anitua E, 2007, BIOMATERIALS, V28, P4551, DOI 10.1016/j.biomaterials.2007.06.037
   Anitua E, 2020, CLIN EXP OPHTHALMOL, V48, P830, DOI 10.1111/ceo.13767
   Anitua E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121713
   Anitua E, 2013, EXPERT OPIN BIOL TH, V13, P1161, DOI 10.1517/14712598.2013.801450
   Anitua E, 2011, INVEST OPHTH VIS SCI, V52, P6066, DOI 10.1167/iovs.11-7302
   Arias Juan D, 2022, Retin Cases Brief Rep, V16, P155, DOI 10.1097/ICB.0000000000000957
   Benedetto MM, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00139
   Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Chang JY, 2008, PPAR RES, V2008, DOI 10.1155/2008/720163
   Chen Y, 2016, EXP EYE RES, V144, P64, DOI 10.1016/j.exer.2015.08.021
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Chen YH, 2019, CURR MOL MED, V19, P395, DOI 10.2174/1566524019666190509105502
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de la Sen-Corcuera B, 2020, CLIN OPHTHALMOL, V14, P1619, DOI 10.2147/OPTH.S252253
   De Maranon AM, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101563
   del Olmo-Aguado S, 2012, PHOTOCHEM PHOTOBIOL, V88, P1346, DOI 10.1111/j.1751-1097.2012.01120.x
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dohan Ehrenfest David M, 2014, Muscles Ligaments Tendons J, V4, P3
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Ehrenfest DMD, 2009, TRENDS BIOTECHNOL, V27, P158, DOI 10.1016/j.tibtech.2008.11.009
   Etxebarria J, 2017, ACTA OPHTHALMOL, V95, pe693, DOI 10.1111/aos.13371
   Freire V, 2012, INVEST OPHTH VIS SCI, V53, P5571, DOI 10.1167/iovs.11-7340
   Frudd K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02352-z
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Graf MR, 2009, J STEROID BIOCHEM, V115, P137, DOI 10.1016/j.jsbmb.2009.03.013
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Harris J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00083
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255
   Howell JC, 2013, MOL VIS, V19, P544
   Hu ZY, 2011, AUTOPHAGY, V7, P1514, DOI 10.4161/auto.7.12.18040
   Ichimura Y, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00210
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Katsuragi Yoshinori, 2016, Current Opinion in Toxicology, V1, P54, DOI 10.1016/j.cotox.2016.09.005
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182
   Knels L, 2011, EUR J NEUROSCI, V34, P548, DOI 10.1111/j.1460-9568.2011.07790.x
   Krigel A, 2016, NEUROSCIENCE, V339, P296, DOI 10.1016/j.neuroscience.2016.10.015
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Li GY, 2008, BRAIN RES, V1188, P35, DOI 10.1016/j.brainres.2007.10.073
   Lin CH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071799
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Lockwood DB, 2005, DENT MATER, V21, P683, DOI 10.1016/j.dental.2004.07.022
   Lopez-Plandolit S, 2010, CORNEA, V29, P843, DOI 10.1097/ICO.0b013e3181a81820
   Ma D, 2012, TRENDS ENDOCRIN MET, V23, P319, DOI 10.1016/j.tem.2012.03.004
   Ma D, 2011, EMBO J, V30, P4642, DOI 10.1038/emboj.2011.322
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Marchesi N, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4956080
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Molina-Minano F, 2009, INT WOUND J, V6, P145, DOI 10.1111/j.1742-481X.2009.00592.x
   Natoli R, 2016, EXP EYE RES, V147, P114, DOI 10.1016/j.exer.2016.04.015
   Nunez-Alvarez C, 2019, ACTA OPHTHALMOL, V97, pE103, DOI 10.1111/aos.13812
   Okamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146517
   Ornatowski W, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101679
   Osborne NN, 2008, J NEUROCHEM, V105, P2013, DOI 10.1111/j.1471-4159.2008.05320.x
   Osborne NN, 2017, MITOCHONDRION, V36, P29, DOI 10.1016/j.mito.2016.11.009
   Osborne NN, 2014, EXP EYE RES, V128, P8, DOI 10.1016/j.exer.2014.08.012
   Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2
   Ozawa Y, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101779
   Paknejad M, 2012, J Dent (Tehran), V9, P59
   Qian MJ, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0154-5
   Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278
   Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49
   Ryzhikov M, 2019, CELL REP, V26, P1880, DOI 10.1016/j.celrep.2019.01.072
   Sanchez-Avila RM, 2019, INT MED CASE REP J, V12, P229, DOI 10.2147/IMCRJ.S170329
   Sanchez-Avila RM, 2018, INT MED CASE REP J, V11, P97, DOI 10.2147/IMCRJ.S153918
   Schaeffer V, 2012, AUTOPHAGY, V8, P1686, DOI 10.4161/auto.21488
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Su J, 2015, ONCOL REP, V34, P235, DOI 10.3892/or.2015.3944
   Suarez-Barrio C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207442
   Suarez-Barrio C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031021
   Suarez-Barrio C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071655
   Takayama K, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8694641
   Tang JY, 2013, ANTICANCER RES, V33, P5611
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Trachsel-Moncho L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0855-8
   Ursu ON, 2014, CELL PHYSIOL BIOCHEM, V33, P52, DOI 10.1159/000356649
   Vazquez S, 2002, J BIOL CHEM, V277, P4867, DOI 10.1074/jbc.M107529200
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Wei QQ, 2018, DRUG DES DEV THER, V12, P2715, DOI 10.2147/DDDT.S176349
   Xia HK, 2019, SCI CHINA LIFE SCI, V62, P244, DOI 10.1007/s11427-018-9357-y
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Yu T, 2017, INT J OPHTHALMOL-CHI, V10, P524, DOI [10.18240/ijo.2017.04.04, 10.18240/1jo.2017.04.04]
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
NR 104
TC 2
Z9 2
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD JUL
PY 2021
VL 11
IS 7
AR 954
DI 10.3390/biom11070954
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA TO2SF
UT WOS:000676767600001
PM 34203504
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Hong, T
   Bahrami, B
   Flood, V
   Liew, G
   Chang, AA
AF Broadhead, Geoffrey K.
   Hong, Thomas
   Bahrami, Bobak
   Flood, Victoria
   Liew, Gerald
   Chang, Andrew A.
TI Diet and risk of visual impairment: a review of dietary factors and risk
   of common causes of visual impairment
SO NUTRITION REVIEWS
LA English
DT Review
DE age-related macular degeneration; cataract; diabetic retinopathy; diet;
   glaucoma
ID AGE-RELATED CATARACT; OPEN-ANGLE GLAUCOMA; BODY-MASS INDEX; RETINAL
   OXIDATIVE STRESS; LUTEIN PLUS ZEAXANTHIN; LONG-TERM INCIDENCE; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; GLYCEMIC INDEX; EYE DISEASE
AB Age-related macular degeneration, diabetic retinopathy, cataract, and glaucoma remain the leading causes of visual impairment in developed nations, resulting in a substantial treatment burden on sufferers and health care systems. Despite significant advances in diagnostic testing and therapeutics, population-based strategies to reduce the burden of these diseases remain limited. However, there is some evidence that these diseases may share overlapping risk factors, particularly in regard to dietary intake and antioxidant status, and it is thus possible that dietary modification may reduce both the prevalence and severity of these conditions. In particular, dietary intake of green leafy vegetables, hyperglycemia/glycemia index, and omega-3 fatty acid intake, as well as overall dietary patterns, may affect risk of one or more of these conditions. In this review, we analyse the evidence for dietary intake and the association with these conditions, and provide insights into possible modifications that may thus simultaneously reduce the risk of visual impairment from multiple causes, including improving dietary intake of green leafy vegetables and reducing dietary glycemic index, both of which have been associated with a decreased risk of multiple causes of visual impairment.
C1 [Broadhead, Geoffrey K.; Bahrami, Bobak; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Hong, Thomas; Bahrami, Bobak; Chang, Andrew A.] Sydney Inst Vis Sci, Level 7,187 Macquarie St, Sydney, NSW 2000, Australia.
   [Flood, Victoria] Univ Sydney, Fac Med & Hlth, Sydney Sch Hlth Sci, Sydney, NSW, Australia.
   [Flood, Victoria] Western Sydney Local Hlth Dist, Sydney, NSW, Australia.
   [Flood, Victoria] Westmead Hosp, Western Sydney Local Hlth Dist, Westmead, NSW, Australia.
   [Liew, Gerald] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney; University of Sydney;
   University of Sydney; Westmead Institute for Medical Research
RP Chang, AA (通讯作者)，Sydney Inst Vis Sci, Level 7,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
RI Flood, Victoria M/A-8732-2016; Liew, Gerald/AAB-6870-2022
OI Flood, Victoria M/0000-0001-5310-7221; 
CR Aiello LP, 2001, AM J OPHTHALMOL, V132, P760, DOI 10.1016/S0002-9394(01)01124-2
   Alcubierre N, 2016, NUTR METAB, V13, DOI 10.1186/s12986-016-0099-5
   Alqawlaq Samih, 2019, Exp Eye Res, V183, P88, DOI 10.1016/j.exer.2018.11.005
   Alswailmi FK, 2018, PAK J MED SCI, V34, P751, DOI 10.12669/pjms.343.14510
   Ansari R, 2014, J CLIN NEUROL, V10, P281, DOI 10.3988/jcn.2014.10.4.281
   Bae JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136218
   Bahrami B, 2016, DIABETOLOGIA, V59, P1594, DOI 10.1007/s00125-016-3974-8
   Bandello F, 2013, ACTA DIABETOL, V50, P1, DOI 10.1007/s00592-012-0449-3
   Barclay AW, 2008, AM J CLIN NUTR, V87, P627, DOI 10.1093/ajcn/87.3.627
   Bazan NG, 2011, ANNU REV NUTR, V31, P321, DOI 10.1146/annurev.nutr.012809.104635
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Brand-Miller J, 2003, DIABETES CARE, V26, P2261, DOI 10.2337/diacare.26.8.2261
   Brazionis L, 2009, BRIT J NUTR, V101, P270, DOI 10.1017/S0007114508006545
   Bunce C, 2015, PUBLIC HEALTH, V129, P138, DOI 10.1016/j.puhe.2014.12.018
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P1177, DOI 10.1093/ajcn/83.5.1177
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cumming RG, 2000, OPHTHALMOLOGY, V107, P450, DOI 10.1016/S0161-6420(99)00024-X
   Cundiff David K, 2005, MedGenMed, V7, P3
   Das R, 2015, OPHTHALMOLOGY, V122, P1820, DOI 10.1016/j.ophtha.2015.05.011
   de Jager J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2181
   Di Benedetto A, 1999, J DIABETES COMPLICAT, V13, P159, DOI 10.1016/S1056-8727(98)00023-3
   Diaz-Lopez A, 2015, DIABETES CARE, V38, P2134, DOI 10.2337/dc15-1117
   Eisenhauer B, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020120
   Fan JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052182
   Foster PJ, 2003, BRIT J OPHTHALMOL, V87, P1112, DOI 10.1136/bjo.87.9.1112
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Ganesan S, 2012, CLIN EXP OPHTHALMOL, V40, P288, DOI 10.1111/j.1442-9071.2011.02594.x
   Giaconi JA, 2012, AM J OPHTHALMOL, V154, P635, DOI 10.1016/j.ajo.2012.03.048
   Glaser TS, 2015, OPHTHALMOLOGY, V122, P1471, DOI 10.1016/j.ophtha.2015.04.007
   GLYNN RJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P1131, DOI 10.1001/archopht.1995.01100090057023
   Gomez-Ambrosi J, 2004, AM J CLIN NUTR, V79, P888
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Gritz DC, 2006, BRIT J OPHTHALMOL, V90, P847, DOI 10.1136/bjo.2005.088104
   Hashemi H, 2018, J CURR OPHTHALMOL, V30, P161, DOI 10.1016/j.joco.2017.01.003
   He K, 2006, CIRCULATION, V113, P1675, DOI 10.1161/CIRCULATIONAHA.105.588327
   Hiller R, 1998, OPHTHALMOLOGY, V105, P1244, DOI 10.1016/S0161-6420(98)97029-4
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Hoogeveen EK, 1998, ARTERIOSCL THROM VAS, V18, P133, DOI 10.1161/01.ATV.18.1.133
   HOWARDWILLIAMS J, 1985, BRIT J OPHTHALMOL, V69, P15, DOI 10.1136/bjo.69.1.15
   Jacques PF, 2001, ARCH OPHTHALMOL-CHIC, V119, P1009, DOI 10.1001/archopht.119.7.1009
   Joe B, 2004, CRIT REV FOOD SCI, V44, P97, DOI 10.1080/10408690490424702
   Kang JH, 2016, JAMA OPHTHALMOL, V134, P294, DOI 10.1001/jamaophthalmol.2015.5601
   Kang JH, 2014, JAMA OPHTHALMOL, V132, P549, DOI 10.1001/jamaophthalmol.2014.100
   Kang JH, 2004, AM J CLIN NUTR, V79, P755
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kato S, 2001, AM J OPHTHALMOL, V131, P301, DOI 10.1016/S0002-9394(00)00804-7
   Kaulmann A, 2014, NUTR RES, V34, P907, DOI 10.1016/j.nutres.2014.07.010
   Khairallah M, 2015, INVEST OPHTH VIS SCI, V56, P6762, DOI 10.1167/iovs.15-17201
   Khan SA, 2016, J CURR OPHTHALMOL, V28, P123, DOI 10.1016/j.joco.2016.05.001
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173
   Klein BEK, 2003, AM J OPHTHALMOL, V136, P506, DOI 10.1016/S0002-9394(03)00290-3
   KLEIN BEK, 1993, OPHTHALMOLOGY, V100, P1609
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Ko F, 2016, INVEST OPHTH VIS SCI, V57, P2152, DOI 10.1167/iovs.15-18373
   KOSKELA TK, 1989, INVEST OPHTH VIS SCI, V30, P2265
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Kowluru RA, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-8
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Kuang TM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1109, DOI 10.1001/archopht.123.8.1109
   Kumar B, 2012, OPHTHALMIC RES, V47, P103, DOI 10.1159/000330051
   Kuzniarz M, 2001, AM J OPHTHALMOL, V132, P19, DOI 10.1016/S0002-9394(01)00922-9
   Lachin JM, 2015, DIABETES, V64, P631, DOI 10.2337/db14-0930
   Lee CTC, 2010, OPHTHALMOLOGY, V117, P71, DOI 10.1016/j.ophtha.2009.06.040
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   Leske MC, 1998, OPHTHALMOLOGY, V105, P831, DOI 10.1016/S0161-6420(98)95021-7
   Li JQ, 2020, EUR J EPIDEMIOL, V35, P11, DOI 10.1007/s10654-019-00560-z
   Liew G, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004015
   Ma QH, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/231570
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Mahoney SE, 2014, J DIABETES COMPLICAT, V28, P767, DOI 10.1016/j.jdiacomp.2014.06.011
   Malhotra S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018894
   Mares JA, 2004, NUTR REV, V62, P28, DOI 10.1301/nr.2004.jan.28-32
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mares-Perlman JA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1556, DOI 10.1001/archopht.118.11.1556
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Michael R, 2011, PHILOS T R SOC B, V366, P1278, DOI 10.1098/rstb.2010.0300
   Mirsamadi Mansour, 2004, Int J Med Sci, V1, P165
   Mrudula T, 2007, BIOCHEM BIOPH RES CO, V361, P528, DOI 10.1016/j.bbrc.2007.07.059
   Nelen WLDM, 2000, FERTIL STERIL, V74, P1196, DOI 10.1016/S0015-0282(00)01595-8
   Nourmohammadi I, 2006, ANN NUTR METAB, V50, P51, DOI 10.1159/000089565
   Nowak MS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000505
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pasquale LR, 2012, INVEST OPHTH VIS SCI, V53, P6427, DOI 10.1167/iovs.12-10085
   de Arcelus MP, 2014, CLIN NUTR, V33, P1041, DOI 10.1016/j.clnu.2013.11.005
   Premanand C, 2006, INVEST OPHTH VIS SCI, V47, P2179, DOI 10.1167/iovs.05-0580
   Radd-Vagenas S, 2017, ASIA PAC J CLIN NUTR, V26, P749, DOI 10.6133/apjcn.082016.06
   Ravindran RD, 2011, OPHTHALMOLOGY, V118, P1958, DOI 10.1016/j.ophtha.2011.03.016
   Renard JP, 2013, ACTA OPHTHALMOL, V91, P505, DOI 10.1111/j.1755-3768.2011.02356.x
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   RODRIGUEZSARGENT C, 1987, HYPERTENSION, V9, P304, DOI 10.1161/01.HYP.9.3.304
   Ryskulova A, 2008, AM J PUBLIC HEALTH, V98, P454, DOI 10.2105/AJPH.2006.098202
   Sacks FM, 2014, CIRCULATION, V129, P999, DOI 10.1161/CIRCULATIONAHA.113.002529
   Sahli MW, 2016, OPHTHAL EPIDEMIOL, V23, P99, DOI 10.3109/09286586.2015.1129426
   Salas-Salvado J, 2014, ANN INTERN MED, V160, P1, DOI 10.7326/M13-1725
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sargeant LA, 2000, DIABETES CARE, V23, P726, DOI 10.2337/diacare.23.6.726
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shane B, 2008, FOOD NUTR BULL, V29, pS5, DOI 10.1177/15648265080292S103
   Shen JH, 2013, ARCH MED RES, V44, P514, DOI 10.1016/j.arcmed.2013.09.010
   Shen L, 2016, OPHTHALMOLOGY, V123, P92, DOI 10.1016/j.ophtha.2015.07.002
   Silva KC, 2013, INVEST OPHTH VIS SCI, V54, P1325, DOI 10.1167/iovs.12-10647
   Smolek MK, 2013, CLIN OPHTHALMOL, V7, P1451, DOI 10.2147/OPTH.S46718
   Spencer BG, 2020, INFLAMMOPHARMACOLOGY, V28, P697, DOI 10.1007/s10787-019-00647-9
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Stahl W, 2002, BIOL CHEM, V383, P553, DOI 10.1515/BC.2002.056
   Steigerwalt R., 2012, PANMINERVA MED, V54, P11
   Tan AG, 2008, AM J CLIN NUTR, V87, P1899, DOI 10.1093/ajcn/87.6.1899
   Tan AG, 2016, JAMA OPHTHALMOL, V134, P522, DOI 10.1001/jamaophthalmol.2016.0167
   Tan AG, 2015, INVEST OPHTH VIS SCI, V56, P216, DOI 10.1167/iovs.14-15531
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tanaka S, 2013, EPIDEMIOLOGY, V24, P204, DOI 10.1097/EDE.0b013e318281725e
   Taylor A, 2002, AM J CLIN NUTR, V75, P540, DOI 10.1093/ajcn/75.3.540
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tsuneki Hiroshi, 2004, BMC Pharmacology, V4, P18, DOI 10.1186/1471-2210-4-18
   Turati F, 2015, EUR J NUTR, V54, P475, DOI 10.1007/s00394-014-0731-y
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Weintraub JM, 2002, INT J OBESITY, V26, P1588, DOI 10.1038/sj.ijo.0802158
   Wiemer NGM, 2008, OPHTHALMOLOGY, V115, P2017, DOI 10.1016/j.ophtha.2008.06.032
   Wong TY, 2003, OPHTHALMOLOGY, V110, P211, DOI 10.1016/S0161-6420(02)01260-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu H, 2014, INVEST OPHTH VIS SCI, V55, P3660, DOI 10.1167/iovs.13-13695
   Xu C, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0167-y
   Yamagishi SI, 2003, MICROVASC RES, V65, P186, DOI 10.1016/S0026-2862(03)00005-0
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yildiz P, 2016, EXP CLIN ENDOCR DIAB, V124, P385, DOI 10.1055/s-0035-1569379
   Yoshida M, 2007, EUR J NUTR, V46, P118, DOI 10.1007/s00394-006-0641-8
   Younan C, 2003, OPHTHALMIC EPIDEMIOL, V10, P227, DOI 10.1076/opep.10.4.227.15905
   Yu N, 2015, NUTRIENTS, V7, P9309, DOI 10.3390/nu7115463
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zhao D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146057
   Zhao D, 2015, OPHTHALMOLOGY, V122, P72, DOI 10.1016/j.ophtha.2014.07.051
   Zhou Y, 2016, PUBLIC HEALTH, V140, P84, DOI 10.1016/j.puhe.2016.04.016
NR 160
TC 5
Z9 5
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD JUN
PY 2021
VL 79
IS 6
BP 636
EP 650
DI 10.1093/nutrit/nuaa100
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA SS1WS
UT WOS:000661533900002
PM 33051676
DA 2022-11-30
ER

PT J
AU Dreismann, AK
   McClements, ME
   Barnard, AR
   Orhan, E
   Hughes, JP
   Lachmann, PJ
   MacLaren, RE
AF Dreismann, Anna K.
   McClements, Michelle E.
   Barnard, Alun R.
   Orhan, Elise
   Hughes, Jane P.
   Lachmann, Peter J.
   MacLaren, Robert E.
TI Functional expression of complement factor I following AAV-mediated gene
   delivery in the retina of mice and human cells
SO GENE THERAPY
LA English
DT Article
ID POSTTRANSCRIPTIONAL REGULATORY ELEMENT; MACULAR DEGENERATION;
   ACTIVATION; RARE; VARIANTS; PATHWAY; CONVERTASE; PROPERDIN; SURFACES;
   THERAPY
AB Dry age-related macular degeneration (AMD) is characterised by loss of central vision and currently has no approved medical treatment. Dysregulation of the complement system is thought to play an important role in disease pathology and supplementation of Complement Factor I (CFI), a key regulator of the complement system, has the potential to provide a treatment option for AMD. In this study, we demonstrate the generation of AAV constructs carrying the human CFI sequence and expression of CFI in cell lines and in the retina of C57BL/6 J mice. Four codon optimised constructs were compared to the most common human CFI sequence. All constructs expressed CFI protein; however, most codon optimised sequences resulted in significantly reduced CFI secretion compared to the non-optimised CFI sequence. In vivo expression analysis showed that CFI was predominantly expressed in the RPE and photoreceptors. Secreted protein in vitreous humour was demonstrated to be functionally active. The findings presented here have led to the formulation of an AAV-vectored gene therapy product currently being tested in a first-in-human clinical trial in subjects with geographic atrophy secondary to dry AMD (NCT03846193).
C1 [Dreismann, Anna K.; Orhan, Elise; Hughes, Jane P.] Gyroscope Therapeut Ltd, Stevenage Biosci Catalyst, Stevenage, Herts, England.
   [McClements, Michelle E.; Barnard, Alun R.; MacLaren, Robert E.] Univ Oxford, Nuffield Lab Ophthalmol, Oxford, England.
   [Lachmann, Peter J.] Univ Cambridge, Dept Vet Med, Cambridge, England.
   [MacLaren, Robert E.] Oxford Eye Hosp, NIHR Biomed Res Ctr, Oxford, England.
C3 University of Oxford; University of Cambridge; University of Oxford
RP MacLaren, RE (通讯作者)，Univ Oxford, Nuffield Lab Ophthalmol, Oxford, England.; MacLaren, RE (通讯作者)，Oxford Eye Hosp, NIHR Biomed Res Ctr, Oxford, England.
EM maclaren@eye.ox.ac.uk
OI MacLaren, Robert/0000-0002-3096-4682; Orhan, Elise/0000-0002-8306-5250
FU Gyroscope Therapeutics Limited; NIHR Oxford Biomedical Research Centre
FX This research project was funded by Gyroscope Therapeutics Limited with
   additional support for vector production from the NIHR Oxford Biomedical
   Research Centre.
CR Boyer DS., 2019, RETINAL PHYS, V16, P25
   Dittmar KA, 2006, PLOS GENET, V2, P2107, DOI 10.1371/journal.pgen.0020221
   Ekdahl KN, 2019, MOL IMMUNOL, V114, P353, DOI 10.1016/j.molimm.2019.07.032
   FEARON DT, 1977, P NATL ACAD SCI USA, V74, P1683, DOI 10.1073/pnas.74.4.1683
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Harboe M, 2017, P NATL ACAD SCI USA, V114, pE534, DOI 10.1073/pnas.1612385114
   Harboe M, 2009, MOL IMMUNOL, V47, P373, DOI 10.1016/j.molimm.2009.09.005
   Harrison RA, 2018, SEMIN IMMUNOPATHOL, V40, P15, DOI 10.1007/s00281-017-0661-x
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Lachmann PJ, 2016, CLIN EXP IMMUNOL, V183, P150, DOI 10.1111/cei.12714
   Lachmann PJ, 2009, ADV IMMUNOL, V104, P115, DOI 10.1016/S0065-2776(08)04004-2
   LACHMANN PJ, 1975, CLIN EXP IMMUNOL, V21, P109
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   LeWitt PA, 2011, LANCET NEUROL, V10, P309, DOI 10.1016/S1474-4422(11)70039-4
   Liao DS., 2019, RETINAL PHYS, V16, P34
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loeb JE, 1999, HUM GENE THER, V10, P2295, DOI 10.1089/10430349950016942
   Mauro VP, 2014, TRENDS MOL MED, V20, P604, DOI 10.1016/j.molmed.2014.09.003
   Paterna JC, 2000, GENE THER, V7, P1304, DOI 10.1038/sj.gt.3301221
   Patircio MI, 2017, MOL THER-NUCL ACIDS, V6, P198, DOI 10.1016/j.omtn.2016.12.006
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sohn JH, 2000, INVEST OPHTH VIS SCI, V41, P3492
   Spitzer D, 2007, J IMMUNOL, V179, P2600, DOI 10.4049/jimmunol.179.4.2600
   WONG MJ, 1995, MOL IMMUNOL, V32, P379, DOI 10.1016/0161-5890(94)00151-P
   Xue KM, 2018, NAT MED, V24, P1507, DOI 10.1038/s41591-018-0185-5
NR 33
TC 13
Z9 13
U1 2
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD MAY
PY 2021
VL 28
IS 5
BP 265
EP 276
DI 10.1038/s41434-021-00239-9
EA MAR 2021
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA SH6LB
UT WOS:000626803800001
PM 33750925
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wubben, TJ
   Zacks, DN
   Besirli, CG
AF Wubben, Thomas J.
   Zacks, David N.
   Besirli, Cagri G.
TI Retinal neuroprotection: current strategies and future directions
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE complement; gene therapy; metabolism; neuroprotection; photoreceptor
ID SMALL PEPTIDE INHIBITOR; INDUCED APOPTOSIS; GENE-THERAPY;
   PHOTORECEPTORS; VISION; VIVO; FAS
AB Purpose of review
   Photoreceptor cell death is the ultimate cause of vision loss in many retinal disorders. Currently, there are no commercially available treatments to prevent photoreceptor cell loss and preserve vision, and there is a critical unmet need for neuroprotective modalities to improve photoreceptor survival in a multitude of retinal disorders. This review summarizes the literature published on this topic in the last 18 months.
   Recent findings
   A plethora of novel therapeutic modalities for photoreceptor neuroprotection have recently been examined in clinical trials for age-related macular degeneration, inherited retinal dystrophies, and macular telangiectasia type 2. These modalities include agents that target the complement pathway, stem cells, gene therapies, and neurotrophic factors. Additionally, improved understanding in the metabolic signals that regulate photoreceptor survival and function may ultimately identify targets for developing novel neuroprotective agents in a multitude of retinal disorders.
   Summary
   Retinal neuroprotection is the next frontier in ophthalmic disease, and the discovery of novel neuroprotective strategies will fill a critical unmet need. Although the clinical utility of existing neuroprotective therapies is still quite limited, we are cautiously optimistic in light of the recent successes described in this review as well as other promising developments.
C1 [Wubben, Thomas J.; Zacks, David N.; Besirli, Cagri G.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan
RP Besirli, CG (通讯作者)，Univ Michigan, Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM cbesirli@med.umich.edu
OI Wubben, Thomas/0000-0002-5183-3817; Besirli, Cagri/0000-0001-7154-2024;
   Zacks, David/0000-0001-8592-5165
CR Aleman TS, 2017, OPHTHALMOLOGY, V124, P359, DOI 10.1016/j.ophtha.2016.10.022
   Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Besirli CG, 2010, INVEST OPHTH VIS SCI, V51, P2177, DOI 10.1167/iovs.09-4439
   Birch DG, 2018, JAMA OPHTHALMOL, V136, P849, DOI 10.1001/jamaophthalmol.2018.1171
   Brown D., 2018, RET SOC ANN M 13 SEP
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Chen M, 2017, MOL MED REP, V15, P2179, DOI 10.3892/mmr.2017.6271
   Chew E. Y., 2018, OPHTHALMOLOGY
   Cousins SW, 2015, ASS RES VIS OPHTH AN
   Cousins SW, 2018, RET SOC ANN M SEP 20
   Cukras C, 2018, MOL THER, V26, P2282, DOI 10.1016/j.ymthe.2018.05.025
   Cukras CA, 2018, INVEST OPHTH VIS SCI, V59, P2841, DOI 10.1167/iovs.17-23297
   Danesh-Meyer HV, 2011, CURR OPIN OPHTHALMOL, V22, P78, DOI 10.1097/ICU.0b013e32834372ec
   Dimopoulos IS, 2018, AM J OPHTHALMOL, V193, P130, DOI 10.1016/j.ajo.2018.06.011
   Du JH, 2015, METHOD ENZYMOL, V561, P149, DOI 10.1016/bs.mie.2015.04.002
   Fischer MD, 2018, RETINA PHILADELPHIA
   Freeman WR, 2018, AAO ANN M RET SUBSP
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hussain RM, 2018, EXPERT OPIN BIOL TH, V18, P1049, DOI 10.1080/14712598.2018.1513486
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kooragayala K, 2015, INVEST OPHTH VIS SCI, V56, P8428, DOI 10.1167/iovs.15-17901
   Lam BL, 2019, AM J OPHTHALMOL, V197, P65, DOI 10.1016/j.ajo.2018.09.012
   Len ACL, 2012, J PROTEOME RES, V11, P537, DOI 10.1021/pr200889t
   Lin JB, 2016, CELL REP, V17, P69, DOI 10.1016/j.celrep.2016.08.073
   Ma W, 2015, MOL MED REP, V12, P5026, DOI 10.3892/mmr.2015.4055
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Ortin-Martinez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113798
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Santiago CP, 2018, MOL THER, V26, P2407, DOI 10.1016/j.ymthe.2018.07.016
   Saylor M, 2009, ARCH OPHTHALMOL-CHIC, V127, P402, DOI 10.1001/archophthalmol.2009.9
   Scerri TS, 2017, NAT GENET, V49, P559, DOI 10.1038/ng.3799
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI DOI 10.1167/I0VS.15-18681
   Singh MS, 2018, INVEST OPHTH VIS SCI, V59, P78
   Singh R, 2018, MAC SOC ANN M 22 FEB
   Szeto HH, 2018, PROTEIN PEPTIDE LETT, V25, P1108, DOI 10.2174/0929866525666181101105209
   Takahashi VKL, 2018, OPHTHALMIC GENET, V39, P560, DOI 10.1080/13816810.2018.1495745
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Wen R, 1996, J NEUROSCI, V16, P5986
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wubben TJ, 2018, AM J OPHTHALMOL, V192, pXV, DOI 10.1016/j.ajo.2018.04.012
   Wubben TJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18098-z
   Xiao JH, 2017, INVEST OPHTH VIS SCI, V58, P1801, DOI 10.1167/iovs.16-21392
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Xue KM, 2018, NAT MED, V24, P1507, DOI 10.1038/s41591-018-0185-5
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zarbin M, 2019, METHODS MOL BIOL, V1834, P367, DOI 10.1007/978-1-4939-8669-9_23
NR 48
TC 17
Z9 18
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2019
VL 30
IS 3
BP 199
EP 205
DI 10.1097/ICU.0000000000000558
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF0ZH
UT WOS:000472806400009
PM 30844942
DA 2022-11-30
ER

PT J
AU Nag, TC
   Kathpalia, P
   Gorla, S
   Wadhwa, S
AF Nag, Tapas C.
   Kathpalia, Poorti
   Gorla, Shilpa
   Wadhwa, Shashi
TI Localization of nitro-tyrosine immunoreactivity in human retina
SO ANNALS OF ANATOMY-ANATOMISCHER ANZEIGER
LA English
DT Article
DE Oxidative stress; Nitroro-tyrosine; Photoreceptor cells; Fibers of
   Henle; Neurodegeneration
ID AGING HUMAN RETINA; CONE CELL-DEATH; OXIDATIVE STRESS; MACULAR
   DEGENERATION; OXIDE SYNTHASE; GROWTH-FACTOR; AGE; PEROXYNITRITE;
   GLUTATHIONE; NITRATION
AB Oxidative stress (OS) is associated with retinal aging and age-related macular degeneration (AMD). In both cases there are reports for the presence of markers of lipid peroxidation in retinal cells. We investigated if nitrosative stress also occurs in the human retina with aging. We examined the cellular localization of nitro-tyrosine, a biomarker of protein tyrosine nitration, in human donor retina (17-91 years; N= 15) by immunohistochemistry. Immunoreactivity (IR) to nitro-tyrosine was present in ten retinas and absent in five retinas. It was predominant in photoreceptor inner segments, cell bodies and axons. In six retinas, IR was present in abnormal, swollen axons of macular and peripheral cones. In the inner retina, weak immunoreactivity was detected in the outer and inner plexiform layer. Transmission electron microscopy revealed a variable degree of microtubule disorganization, abnormal outgrowth from the swollen macular axons (as the fibers of Henle) and few dead axons. The present study adds further evidence to the presence of aberrant photoreceptor axonal changes in the human retina and that nitro-tyrosine immunoreactivity is associated with the photoreceptor cells in select human retina. (C) 2019 Elsevier GmbH. All rights reserved.
C1 [Nag, Tapas C.; Kathpalia, Poorti; Gorla, Shilpa; Wadhwa, Shashi] All India Inst Med Sci, Dept Anat, Neurobiol Lab, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi
RP Nag, TC (通讯作者)，All India Inst Med Sci, Dept Anat, Neurobiol Lab, New Delhi 110029, India.
EM tapas_nag@aiims.edu
RI NAG, TAPAS CHANDRA/R-6285-2019
OI NAG, TAPAS CHANDRA/0000-0002-6962-0844
FU Department of Biotechnology, Govt. of India [BT/PR10195/BRB/10/589/2007]
FX The work was supported by funds from Department of Biotechnology, Govt.
   of India (BT/PR10195/BRB/10/589/2007) to TCN. We thank The
   Officer-In-Charge, National Eye Bank, Dr. Rajendra Prasad center for
   Ophthalmic Sciences, for providing the eyeballs. We sincerely thank Dr
   ICA Jha, University of Tennessee Health Science Center, Memphis, USA,
   for kindly donating the nitro-tyrosine control. The TEM work was carried
   out at the SAIF (DST)-New Delhi, AIIMS, India.
CR Abu El-Asrar AM, 2004, EYE, V18, P306, DOI 10.1038/sj.eye.6700642
   Ali TK, 2008, DIABETES, V57, P889, DOI 10.2337/db07-1669
   Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Ceriello A, 2002, INT J CLIN PRACT, P51
   CURCIO CA, 1994, INVEST OPHTH VIS SCI, V35, P783
   Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a
   DAVIDSON PC, 1994, INVEST OPHTH VIS SCI, V35, P2843
   DELAPAZ M, 1992, INVEST OPHTH VIS SCI, V33, P3497
   DeLaPaz MA, 1996, CURR EYE RES, V15, P273, DOI 10.3109/02713689609007621
   Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x
   Eliasieh K, 2007, INVEST OPHTH VIS SCI, V48, P2824, DOI 10.1167/iovs.06-1228
   Ethen CM, 2007, INVEST OPHTH VIS SCI, V48, P3469, DOI 10.1167/iovs.06-1058
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Liu QP, 2013, ANTIOXID REDOX SIGN, V18, P1141, DOI 10.1089/ars.2012.4583
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Malone PE, 2007, EXP EYE RES, V84, P444, DOI 10.1016/j.exer.2006.10.020
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   Nag TC, 2017, EXP EYE RES, V165, P125, DOI 10.1016/j.exer.2017.09.014
   Nag TC, 2006, BRAIN RES BULL, V71, P224, DOI 10.1016/j.brainresbull.2006.09.007
   Nag TC, 2011, ANN ANAT, V193, P205, DOI 10.1016/j.aanat.2011.02.004
   Nag TC, 2016, MITOCHONDRION, V31, P20, DOI 10.1016/j.mito.2016.08.016
   Nag TC, 2012, MICRON, V43, P759, DOI 10.1016/j.micron.2012.01.011
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   PUERTAS FJ, 1993, FREE RADICAL BIO MED, V14, P549, DOI 10.1016/0891-5849(93)90112-8
   Rogers BS, 2007, INVEST OPHTH VIS SCI, V48, P438, DOI 10.1167/iovs.06-0528
   Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199
   Sekhar RV, 2011, AM J CLIN NUTR, V94, P847, DOI 10.3945/ajcn.110.003483
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   TUCKER GS, 1986, INVEST OPHTH VIS SCI, V27, P708
   Usui S, 2009, J NEUROCHEM, V110, P1028, DOI 10.1111/j.1471-4159.2009.06195.x
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   Wilkins HM, 2013, J BIOL CHEM, V288, P5091, DOI 10.1074/jbc.M112.405738
   Winkler BS, 1999, MOL VIS, V5
   Wu GS, 2005, INVEST OPHTH VIS SCI, V46, P2271, DOI 10.1167/iovs.04-1525
NR 54
TC 10
Z9 10
U1 0
U2 2
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0940-9602
EI 1618-0402
J9 ANN ANAT
JI Ann. Anat.-Anat. Anz.
PY 2019
VL 223
BP 8
EP 18
DI 10.1016/j.aanat.2019.01.006
PG 11
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology
GA IA1GM
UT WOS:000469307300002
PM 30716468
DA 2022-11-30
ER

PT J
AU Tan, BY
   Chua, J
   Barathi, VA
   Baskaran, M
   Chan, A
   Lin, E
   Ang, M
   Klose, G
   Schmetterer, L
AF Tan, Bingyao
   Chua, Jacqueline
   Barathi, Veluchamy Amutha
   Baskaran, Mani
   Chan, Anita
   Lin, Emily
   Ang, Marcus
   Klose, Gerd
   Schmetterer, Leopold
TI Quantitative analysis of choriocapillaris in non-human primates using
   swept-source optical coherence tomography angiography (SS-OCTA)
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID CHOROIDAL BLOOD-FLOW; MORPHOMETRIC-ANALYSIS; MACULAR DEGENERATION;
   ULTRAHIGH-SPEED; CIRCULATION; THICKNESS; EYES
AB The choriocapillaris is a unique vascular plexus located posterior to the retinal pigment epithelium. In recent years, there is an increasing interest in the examination of the interrelationship between the choriocapillaris and eye diseases. We used several techniques to study choroidal perfusion, including laser Doppler flowmetry, laser speckle flowgraphy, and optical coherence tomography angiography (OCTA), but with the latter no standardized algorithm for quantitative analysis has been provided. We analyzed different algorithms to quantify flow voids in non-human primates that can be easily implemented into clinical research. In-vivo, high-resolution images of the non-human primate choriocapillaris were acquired with a sweet-source OCTA (SS-OCTA) system with 100kHz A-scan/s rate, over regions of 3 x 3 mm(2) - and 12 x 12 mm(2). The areas of non-perfusion, also called flow voids, were segmented with a structural, intensity adjusted, uneven illuminance-compensated algorithm and the new technique was compared to previously published methods. The new algorithm shows improved reproducibility and may have applications in a wide array of eye diseases including age-related macular degeneration (AMD). (C) 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Tan, Bingyao; Chua, Jacqueline; Barathi, Veluchamy Amutha; Baskaran, Mani; Chan, Anita; Lin, Emily; Ang, Marcus; Schmetterer, Leopold] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Chua, Jacqueline; Barathi, Veluchamy Amutha; Baskaran, Mani; Chan, Anita; Ang, Marcus; Schmetterer, Leopold] Duke NUS Med Sch, Acad Clin Program, Singapore, Singapore.
   [Barathi, Veluchamy Amutha] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Ang, Marcus] Moorfield Hosp, London, England.
   [Klose, Gerd] Carl Zeiss Meditec Inc, Tokyo, Japan.
   [Schmetterer, Leopold] Nanyang Technol Univ, Lee Kong Chian Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore; Carl
   Zeiss AG; Nanyang Technological University & National Institute of
   Education (NIE) Singapore; Nanyang Technological University; Medical
   University of Vienna; Medical University of Vienna
RP Schmetterer, L (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.; Schmetterer, L (通讯作者)，Duke NUS Med Sch, Acad Clin Program, Singapore, Singapore.; Schmetterer, L (通讯作者)，Nanyang Technol Univ, Lee Kong Chian Sch Med, Dept Ophthalmol, Singapore, Singapore.; Schmetterer, L (通讯作者)，Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.; Schmetterer, L (通讯作者)，Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
EM leopold.schmetterer@seri.com.sg
RI Mani, Baskaran/GWZ-8299-2022
OI Tan, Bingyao/0000-0002-6532-9603; Schmetterer,
   Leopold/0000-0002-7189-1707
FU National Medical Research Council [NMRC/CG/C010A/2017, OFIRG/0048/2017,
   NMRC/TA/0026/2014]; A*STAR (BMRC-AStar MedTech) Singapore [1619077002]
FX National Medical Research Council (NMRC/CG/C010A/2017, OFIRG/0048/2017,
   NMRC/TA/0026/2014); A*STAR (BMRC-AStar MedTech, 1619077002) Singapore.
CR Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Al-Sheikh M, 2017, INVEST OPHTH VIS SCI, V58, P2063, DOI 10.1167/iovs.16-21289
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   An L, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3642638
   Ang M, 2018, GRAEF ARCH CLIN EXP, V256, P237, DOI 10.1007/s00417-017-3896-2
   [Anonymous], 2012, OCULAR BLOOD FLOW
   Blank JLT, 2000, PUBLIC PROVISION AND PERFORMANCE, P3
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Calzetti G, 2018, BRIT J OPHTHALMOL, V102, P1679, DOI 10.1136/bjophthalmol-2017-311750
   Chen CL, 2017, BIOMED OPT EXPRESS, V8, P1056, DOI 10.1364/BOE.8.001056
   Chen YL, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3119103
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Goverdhan S., 2013, DRUG DISCOV TODAY DI, V10, pe181
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kirby MA, 2018, PROC SPIE, V10474, DOI 10.1117/12.2291057
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Montesano G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185256
   Nesper PL, 2017, INVEST OPHTH VIS SCI, V58, P307, DOI 10.1167/iovs.17-21787
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nicolo M, 2017, INVEST OPHTH VIS SCI, V58, P2002, DOI 10.1167/iovs.17-21417
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Ruiz-Moreno JM, 2013, INVEST OPHTH VIS SCI, V54, P353, DOI 10.1167/iovs.12-10863
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Stalmans I, 2011, ACTA OPHTHALMOL, V89, pe609, DOI 10.1111/j.1755-3768.2011.02178.x
   Sugiyama T, 2010, ACTA OPHTHALMOL, V88, P723, DOI 10.1111/j.1755-3768.2009.01586.x
   Tan ACS, 2018, EYE, V32, P262, DOI 10.1038/eye.2017.181
   Tan BY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193592
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zouache MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep35754
NR 46
TC 16
Z9 17
U1 0
U2 6
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD JAN 1
PY 2019
VL 10
IS 1
BP 356
EP 371
DI 10.1364/BOE.10.000356
PG 16
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA HF3ZQ
UT WOS:000454173400027
PM 30775105
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jo, DH
   Kim, JH
AF Jo, Dong Hyun
   Kim, Jeong Hun
TI Application of genome engineering for treatment of retinal diseases
SO BMB REPORTS
LA English
DT Article
DE Clustered regularly interspaced short palindromic repeats; Genome
   engineering; Intraocular injection; Retinal diseases; Ribonucleoprotein
AB Genome engineering with clustered regularly interspaced short palindromic repeats (CRISPR) system can be used as a tool to correct pathological mutations or modulate gene expression levels associated with pathogenesis of human diseases. Owing to well-established local administration methods including intravitreal and subretinal injection, it is relatively easy to administer therapeutic genome engineering machinery to ocular tissues for treating retinal diseases. In this context, we have investigated the potential of in vivo genome engineering as a therapeutic approach in the form of ribonucleoprotein or CRISPR packaged in viral vectors. Major issues in therapeutic application of genome engineering include specificity and efficacy according to types of CRISPR system. In addition to previous platfoims based on ribonucleoprotein and CRISPR-associated protein 9 derived from Carnpylobacter jejuni, we evaluated the therapeutic effects of a CRISPR RNA-guided endonuclease derived from Lachnospiraceae bacterium ND2006 (LbCpf1) in regulating pathological angiogenesis in an animal model of wet-type age-related macular degeneration. LbCpf1 targeting Vegfa or Hifla effectively disrupted the expression of genes in ocular tissues, resulting in suppression of choroidal neovascularization. It was also notable that there were no significant off-target effects in vivo.
C1 [Jo, Dong Hyun; Kim, Jeong Hun] Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul 03080, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 03080, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU)
RP Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul 03080, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 03080, South Korea.; Kim, JH (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 03080, South Korea.
EM steph25@snu.ac.kr
RI Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU National Research Foundation - Korean government, MSIP
   [NRF-2015M3A9E6028949]; Development of Platform Technology for
   Innovative Medical Measurements - Korea Research Institute of Standards
   and Science [KRISS - 2018 - GP2018-0018]; National Research Foundation
   of Korea (NRF) - Ministry of Education [2017R1A6A3A04004741]
FX This work was supported by the Bio & Medical Technology Development
   Program of the National Research Foundation funded by the Korean
   government, MSIP (NRF-2015M3A9E6028949 to J.H.K.), Development of
   Platform Technology for Innovative Medical Measurements funded by Korea
   Research Institute of Standards and Science (KRISS - 2018 - GP2018-0018
   to J.H.K.), and the Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (2017R1A6A3A04004741 to D.H.J.).
NR 0
TC 0
Z9 0
U1 3
U2 3
PU KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
PI SEOUL
PA KOREA SCIENCE & TECHNOLOGY CENTER, # 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA
SN 1976-6696
EI 1976-670X
J9 BMB REP
JI BMB Rep.
PY 2018
VL 51
IS 7
BP 315
EP 316
DI 10.5483/BMBRep.2018.51.7.130
PG 2
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GP9AO
UT WOS:000441209400001
PM 29921414
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Chung, SH
   Gillies, M
   Yam, M
   Wang, Y
   Shen, WY
AF Chung, Sook Hyun
   Gillies, Mark
   Yam, Michelle
   Wang, Ying
   Shen, Weiyong
TI Differential expression of microRNAs in retinal vasculopathy caused by
   selective Muller cell disruption
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; DIABETIC MACULAR EDEMA; MIR-200
   FAMILY; CHOROIDAL NEOVASCULARIZATION; TRANSGENIC MODEL; REPRESSORS ZEB1;
   FEEDBACK LOOP; ANGIOGENESIS; RETINOPATHY; VEGF
AB Vascular changes and photoreceptor degeneration are features of age-related macular degeneration, diabetic retinopathy and macular telangiectasis. We have profiled the differential expression of microRNAs and analysed their target genes in transgenic mice in which induced Muller cell disruption results in photoreceptor degeneration, vascular leak and deep retinal neovascularisation. We identified 9 miRNAs which were differentially expressed during the development of retinal neovascularization and chose miR-200b and its target genes for further study. Using qRT-PCR and western blot analysis, we found that downregulation of miR-200b was negatively correlated with its target genes, including zinc finger E-box binding homeobox (ZEB) 1 and 2 and vascular endothelial growth factor receptor 1. Double immunofluorescence labelling revealed that the newly formed vessels in the outer retina were positive for ZEB2. Furthermore, intravitreal injections of a miR-200b-mimic and anti-miR-200b confirmed the negative correlation of miR-200b and its target gene expression. We also found that the miR-200b-mimic inhibited vascular leak in the established mild vascular lesions, whereas anti-miR-200b promoted it. Taken together, these data suggest that miR-200b may play a role in the development of intraretinal neovascularisation.
C1 [Chung, Sook Hyun; Gillies, Mark; Yam, Michelle; Wang, Ying; Shen, Weiyong] Univ Sydney, Save Sight Inst, Macula Res Grp, Clin Ophthalmol & Eye Hlth, Sydney, NSW, Australia.
C3 University of Sydney
RP Chung, SH; Shen, WY (通讯作者)，Univ Sydney, Save Sight Inst, Macula Res Grp, Clin Ophthalmol & Eye Hlth, Sydney, NSW, Australia.
EM sook.chung@sydney.edu.au; weiyong.shen@sydney.edu.au
OI Yam, Michelle/0000-0001-5250-994X
FU Lowy Medical Research Institute; National Health and Medical Research
   Council (NHMRC, Australia) [APP1028393]; Ophthalmic Research Institute
   of Australia; NHMRC Practitioner Fellowship
FX This study was supported by grants from Lowy Medical Research Institute,
   National Health and Medical Research Council (NHMRC, Australia;
   APP1028393) and Ophthalmic Research Institute of Australia. Mark Gillies
   is a fellow of Sydney Medical School Foundation and supported by a NHMRC
   Practitioner Fellowship.
CR Ahn J, 2013, EMBO MOL MED, V5, P1602, DOI 10.1002/emmm.201302647
   Arora A, 2007, INVEST OPHTH VIS SCI, V48, P3962, DOI 10.1167/iovs.06-1221
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Cai JJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-88
   Campochiaro PA, 2007, J CELL PHYSIOL, V213, P348, DOI 10.1002/jcp.21213
   Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790
   Chang SH, 2013, J BIOL CHEM, V288, P4908, DOI 10.1074/jbc.M112.423871
   Choi YC, 2011, MOL CELLS, V32, P77, DOI 10.1007/s10059-011-1042-2
   Chung S. H, 2013, INVESTIGATIVE OPHTHA
   Chung SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118949
   Chung SH, 2013, INVEST OPHTH VIS SCI, V54, P6578, DOI 10.1167/iovs.13-12311
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   Dang LTH, 2013, ARTERIOSCL THROM VAS, V33, P193, DOI 10.1161/ATVBAHA.112.300142
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Feng Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.462
   FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290
   Fichtlscherer S, 2010, CIRC RES, V107, P677, DOI 10.1161/CIRCRESAHA.109.215566
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Gillies MC, 2006, ARCH OPHTHALMOL-CHIC, V124, P1478, DOI 10.1001/archopht.124.10.1478
   Harraz MM, 2012, P NATL ACAD SCI USA, V109, P18962, DOI 10.1073/pnas.1121288109
   Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936
   Huszar J., 2013, METABOLOMICS, V3
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Li Q, 2002, INVEST OPHTH VIS SCI, V43, P3109
   Li YX, 2011, IUBMB LIFE, V63, P553, DOI 10.1002/iub.486
   Lu H, 2010, CARDIOVASC RES, V86, P410, DOI 10.1093/cvr/cvq010
   McArthur K, 2011, DIABETES, V60, P1314, DOI 10.2337/db10-1557
   MICHELS RG, 1978, ARCH OPHTHALMOL-CHIC, V96, P237
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Quaggin SE, 2012, J CLIN INVEST, V122, P3849, DOI 10.1172/JCI65509
   Renthal NE, 2010, P NATL ACAD SCI USA, V107, P20828, DOI 10.1073/pnas.1008301107
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Shen WY, 2014, GLIA, V62, P1110, DOI 10.1002/glia.22666
   Shen WY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-137
   Shen WY, 2012, J NEUROSCI, V32, P15715, DOI 10.1523/JNEUROSCI.2841-12.2012
   Sun ZW, 2014, MOL CELL BIOCHEM, V397, P277, DOI 10.1007/s11010-014-2195-z
   Takahashi Y, 2015, FEBS LETT, V589, P1143, DOI 10.1016/j.febslet.2015.03.010
   Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156
   Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965
   Wainwright EN, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.110155
   Wang B, 2010, DIABETES, V59, P1794, DOI 10.2337/db09-1736
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Weidemann A, 2010, GLIA, V58, P1177, DOI 10.1002/glia.20997
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Xu SB, 2009, PROG RETIN EYE RES, V28, P87, DOI 10.1016/j.preteyeres.2008.11.003
   Xue XF, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0062-x
   Yin H, 2013, CELL METAB, V17, P210, DOI 10.1016/j.cmet.2013.01.004
   Zhao RB, 2014, BIOCHEM BIOPH RES CO, V452, P428, DOI 10.1016/j.bbrc.2014.08.096
   Zhao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069756
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 62
TC 15
Z9 15
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 4
PY 2016
VL 6
AR 28993
DI 10.1038/srep28993
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DQ2CZ
UT WOS:000379010200001
PM 27373709
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU de Hoz, R
   Rojas, B
   Ramirez, AI
   Salazar, JJ
   Gallego, BI
   Trivino, A
   Ramirez, JM
AF de Hoz, Rosa
   Rojas, Blanca
   Ramirez, Ana I.
   Salazar, Juan J.
   Gallego, Beatriz I.
   Trivino, Alberto
   Ramirez, Jose M.
TI Retinal Macroglial Responses in Health and Disease
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Review
ID TUMOR-NECROSIS-FACTOR; MULLER GLIAL-CELLS; FIBRILLARY ACIDIC PROTEIN;
   ENDOTHELIAL GROWTH-FACTOR; OPTIC-NERVE HEAD; CILIARY NEUROTROPHIC
   FACTOR; NITRIC-OXIDE; UP-REGULATION; FACTOR-ALPHA; MOUSE MODEL
AB Due to their permanent and close proximity to neurons, glial cells perform essential tasks for the normal physiology of the retina. Astrocytes and Muller cells (retinal macroglia) provide physical support to neurons and supplement them with several metabolites and growth factors. Macroglia are involved in maintaining the homeostasis of extracellular ions and neurotransmitters, are essential for information processing in neural circuits, participate in retinal glucose metabolism and in removing metabolic waste products, regulate local blood flow, induce the blood-retinal barrier (BRB), play fundamental roles in local immune response, and protect neurons from oxidative damage. In response to polyetiological insults, glia cells react with a process called reactive gliosis, seeking to maintain retinal homeostasis. When malfunctioning, macroglial cells can become primary pathogenic elements. A reactive gliosis has been described in different retinal pathologies, including age-related macular degeneration (AMD), diabetes, glaucoma, retinal detachment, or retinitis pigmentosa. A better understanding of the dual, neuroprotective, or cytotoxic effect of macroglial involvement in retinal pathologies would help in treating the physiopathology of these diseases. The extensive participation of the macroglia in retinal diseases points to these cells as innovative targets for new drug therapies.
C1 [de Hoz, Rosa; Rojas, Blanca; Ramirez, Ana I.; Salazar, Juan J.; Gallego, Beatriz I.; Trivino, Alberto; Ramirez, Jose M.] Univ Complutense Madrid, Inst Invest Oftalmol Ramon Castroviejo, E-28040 Madrid, Spain.
   [de Hoz, Rosa; Ramirez, Ana I.; Salazar, Juan J.] Univ Complutense Madrid, Dept Oftalmol & ORL, Fac Opt & Optometria, E-28040 Madrid, Spain.
   [Rojas, Blanca; Trivino, Alberto; Ramirez, Jose M.] Univ Complutense Madrid, Fac Med, Dept Oftalmol & ORL, E-28040 Madrid, Spain.
C3 Complutense University of Madrid; Complutense University of Madrid;
   Complutense University of Madrid
RP Ramirez, JM (通讯作者)，Univ Complutense Madrid, Inst Invest Oftalmol Ramon Castroviejo, E-28040 Madrid, Spain.; Ramirez, JM (通讯作者)，Univ Complutense Madrid, Fac Med, Dept Oftalmol & ORL, E-28040 Madrid, Spain.
EM ramirezs@med.ucm.es
RI De Hoz, Rosa/ABF-9295-2020; Salazar, Juan J/L-6887-2014; ROJAS,
   BLANCA/V-8292-2017; Ramírez, Ana I/ABF-4789-2021; Alberto,
   Trivino/ABG-2416-2020
OI De Hoz, Rosa/0000-0002-1581-087X; Salazar, Juan J/0000-0001-5480-5902;
   Ramírez, Ana I/0000-0002-2656-4723; 
FU Ophthalmological Network OFTARED [RD12-0034/0002]; Institute of Health
   of Carlos III of the Spanish Ministry of Economy; PN I+D+i;
   ISCIII-Subdireccion General de Redes y Centros de Investigacion
   Cooperativa; European Programme FEDER; Neuroinflammation in Glaucoma:
   Sequencing of Glial and Blood-Retinal Barrier Damage (Spanish Ministry
   of Economy and Competitiveness) [SAF2014-53779-R]
FX This work was supported by the Ophthalmological Network OFTARED
   (RD12-0034/0002: Prevencion, Deteccion Precoz y Tratamiento de la
   Patologia Ocular Prevalente Degenerativa y Cronica), the Institute of
   Health of Carlos III of the Spanish Ministry of Economy. This work has
   been funded by the PN I+D+i 2008-2011, by the ISCIII-Subdireccion
   General de Redes y Centros de Investigacion Cooperativa, by the European
   Programme FEDER, and by the SAF2014-53779-R: Neuroinflammation in
   Glaucoma: Sequencing of Glial and Blood-Retinal Barrier Damage (Spanish
   Ministry of Economy and Competitiveness). The authors thank David
   Nesbitt for correcting the English version of this work.
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106
   Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2
   Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6
   Barateiro A, 2016, CURR PHARM DESIGN, V22, P656, DOI 10.2174/1381612822666151204000636
   Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561
   Barcia C, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.17
   Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013
   Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490
   Biernacki K, 2001, J NEUROPATH EXP NEUR, V60, P1127, DOI 10.1093/jnen/60.12.1127
   Bolz S, 2008, GRAEF ARCH CLIN EXP, V246, P1249, DOI 10.1007/s00417-008-0872-x
   Bringmann A, 2000, GLIA, V29, P35, DOI 10.1002/(SICI)1098-1136(20000101)29:1<35::AID-GLIA4>3.0.CO;2-A
   Bringmann A, 2001, Front Biosci, V6, pE72
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Bringmann A, 2009, GRAEF ARCH CLIN EXP, V247, P865, DOI 10.1007/s00417-009-1082-x
   Bringmann A, 2009, NEUROCHEM INT, V54, P143, DOI 10.1016/j.neuint.2008.10.014
   Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034
   BURKE JM, 1981, INVEST OPHTH VIS SCI, V20, P582
   CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U
   Chauhan BC, 2008, CAN J OPHTHALMOL, V43, P356, DOI 10.3129/i08-060
   Chen SD, 2013, CHINESE MED J-PEKING, V126, P1567, DOI 10.3760/cma.j.issn.0366-6999.20123565
   Chong RS, 2015, CURR OPIN OPHTHALMOL, V26, P73, DOI 10.1097/ICU.0000000000000125
   Chu Y, 1999, AUST NZ J OPHTHALMOL, V27, P117, DOI 10.1046/j.1440-1606.1999.00164.x
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852
   Cotinet A, 1997, OCUL IMMUNOL INFLAMM, V5, P111, DOI 10.3109/09273949709085059
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Dalloz C, 2003, HUM MOL GENET, V12, P1543, DOI 10.1093/hmg/ddg170
   DEKOZAK Y, 1994, J NEUROIMMUNOL, V55, P1, DOI 10.1016/0165-5728(94)90141-4
   Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107
   Drescher KM, 1996, J NEUROIMMUNOL, V64, P71, DOI 10.1016/0165-5728(95)00156-5
   Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774
   Ergorul C, 2010, J MOL NEUROSCI, V42, P183, DOI 10.1007/s12031-010-9343-z
   Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005
   Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6
   Fernandez-Sanchez L, 2010, INVEST OPHTH VIS SCI, V51
   Francke M, 2003, OPHTHALMIC RES, V35, P30, DOI 10.1159/000068192
   Francke M, 2001, J NEUROCYTOL, V30, P131, DOI 10.1023/A:1011987107034
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Ganesh BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018305
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Gonzalez H, 2014, J NEUROIMMUNOL, V274, P1, DOI 10.1016/j.jneuroim.2014.07.012
   Gordon GRJ, 2007, GLIA, V55, P1214, DOI 10.1002/glia.20543
   Goureau O, 1999, J NEUROCHEM, V72, P2506, DOI 10.1046/j.1471-4159.1999.0722506.x
   Halassa MM, 2007, TRENDS MOL MED, V13, P54, DOI 10.1016/j.molmed.2006.12.005
   Heneka MT, 2010, BRAIN RES REV, V63, P189, DOI 10.1016/j.brainresrev.2009.11.004
   Hernandez MR, 2008, PROG BRAIN RES, V173, P353, DOI 10.1016/S0079-6123(08)01125-4
   Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8
   Honjo M, 2000, INVEST OPHTH VIS SCI, V41, P552
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Iadecola C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003
   Iandiev I, 2008, INVEST OPHTH VIS SCI, V49, P3559, DOI 10.1167/iovs.08-1723
   Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516
   Ji-Yeon Lee, 2014, [Applied Microscopy, 한국현미경학회지], V44, P21
   Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431
   Johnson EC, 2011, INVEST OPHTH VIS SCI, V52, P504, DOI 10.1167/iovs.10-5317
   Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6
   Kanamori A, 2005, EXP EYE RES, V81, P48, DOI 10.1016/j.exer.2005.01.012
   Kandel E. R., 2001, PRINCIPIOS NEUROCIEN, P19
   Kashii S, 1996, BRAIN RES, V711, P93, DOI 10.1016/0006-8993(95)01330-X
   Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010
   Kettenmann H, 2008, TRENDS NEUROSCI, V31, P653, DOI 10.1016/j.tins.2008.09.003
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kimelberg HK, 2010, NEUROTHERAPEUTICS, V7, P338, DOI 10.1016/j.nurt.2010.07.006
   Kirsch M, 2010, GLIA, V58, P768, DOI 10.1002/glia.20961
   Koeberle PD, 1999, EXP NEUROL, V158, P366, DOI 10.1006/exnr.1999.7113
   Koehler RC, 2009, TRENDS NEUROSCI, V32, P160, DOI 10.1016/j.tins.2008.11.005
   Kraft AW, 2013, FASEB J, V27, P187, DOI 10.1096/fj.12-208660
   Kuno R, 2006, BRAIN RES, V1116, P12, DOI 10.1016/j.brainres.2006.07.120
   Lam D, 2009, MOL VIS, V15, P2217
   Lee HJ, 2010, J BIOL CHEM, V285, P9262, DOI 10.1074/jbc.M109.081125
   Lewis GP, 2010, MOL VIS, V16, P1361
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   Lieth E, 2000, CLIN EXP OPHTHALMOL, V28, P3, DOI 10.1046/j.1442-9071.2000.00222.x
   Lieth E, 1998, DIABETES, V47, P815, DOI 10.2337/diabetes.47.5.815
   Luna G, 2010, MOL VIS, V16, P2511
   Matteucci A, 2014, EXP EYE RES, V125, P20, DOI 10.1016/j.exer.2014.05.011
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Minton AZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043199
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   Nakazawa T, 2007, INVEST OPHTH VIS SCI, V48, P2760, DOI 10.1167/iovs.06-1398
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Naskar R, 2000, INVEST OPHTH VIS SCI, V41, P1940
   Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008
   Nikcevich KM, 1997, J IMMUNOL, V158, P614
   Oberheim NA, 2009, J NEUROSCI, V29, P3276, DOI 10.1523/JNEUROSCI.4707-08.2009
   Oku H, 2002, OPHTHALMIC RES, V34, P38, DOI 10.1159/000048323
   Pannicke T, 2006, DIABETES, V55, P633, DOI 10.2337/diabetes.55.03.06.db05-1349
   Pannicke T, 2005, J NEUROIMMUNOL, V161, P145, DOI 10.1016/j.jneuroim.2005.01.003
   Pannicke T, 2004, MOL CELL NEUROSCI, V26, P493, DOI 10.1016/j.mcn.2004.04.005
   Pease ME, 2009, INVEST OPHTH VIS SCI, V50, P2194, DOI 10.1167/iovs.08-3013
   Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1
   Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013
   Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071
   Pena JDO, 1999, BRIT J OPHTHALMOL, V83, P209, DOI 10.1136/bjo.83.2.209
   Pena JDO, 2001, INVEST OPHTH VIS SCI, V42, P2303
   Peng L, 2014, CURR NEUROPHARMACOL, V12, P303, DOI 10.2174/1570159X12999140829152550
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001
   Perez-Alvarez A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00051
   Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5
   Pfrieger FW, 2002, CURR OPIN NEUROBIOL, V12, P486, DOI 10.1016/S0959-4388(02)00358-6
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179
   Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460
   Ramirez AI, 2006, EXP EYE RES, V83, P1423, DOI 10.1016/j.exer.2006.07.023
   Ramirez AI, 2010, INVEST OPHTH VIS SCI, V51, P5690, DOI 10.1167/iovs.10-5248
   Ramirez J. M., 2014, CARDIOVASCULAR DIS, VII, P123
   Ramirez J. M., 1988, UNDERSTANDING GLIAL, P47
   Ramirez JM, 1996, VISION RES, V36, P2029, DOI 10.1016/0042-6989(95)00322-3
   RAMIREZ JM, 1994, VISION RES, V34, P1935, DOI 10.1016/0042-6989(94)90024-8
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Reichenbach A, 1995, PROG RETIN EYE RES, V15, P139, DOI 10.1016/1350-9462(95)00008-9
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Reichenbach Andreas, 1995, P58
   Rieck J, 2013, INVEST OPHTH VIS SCI, V54, P2393, DOI 10.1167/iovs.12-9781
   Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978
   Roth S, 1997, CLIN NEUROSCI, V4, P216
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Sarthy V., 2001, PERSP VIS R
   Sarup V, 2004, BRAIN RES, V1013, P152, DOI 10.1016/j.brainres.2004.03.030
   Schnitzer J., 1988, Progress in Retinal Research, V7, P209, DOI 10.1016/0278-4327(88)90009-0
   Schutte M, 1998, NEUROSCI LETT, V246, P53, DOI 10.1016/S0304-3940(98)00229-8
   Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870
   Seitz R, 2013, CELL TISSUE RES, V353, P339, DOI 10.1007/s00441-013-1666-y
   Shen WY, 2010, J NEUROSCI RES, V88, P1485, DOI 10.1002/jnr.22317
   Shin ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103148
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Stolp HB, 2009, NEUROPATH APPL NEURO, V35, P132, DOI 10.1111/j.1365-2990.2008.01005.x
   Takeda M, 2008, INVEST OPHTH VIS SCI, V49, P1142, DOI 10.1167/iovs.07-0434
   Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Tezel G, 2003, INVEST OPHTH VIS SCI, V44, P3025, DOI 10.1167/iovs.02-1136
   Tezel Gulgun, 2007, Chem Immunol Allergy, V92, P221, DOI 10.1159/000099273
   TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S
   Trivino A, 2005, HISTOL HISTOPATHOL, V20, P393, DOI 10.14670/HH-20.393
   TRIVINO A, 1992, VISION RES, V32, P1601, DOI 10.1016/0042-6989(92)90153-A
   Trivino A, 1997, VISION RES, V37, P1707, DOI 10.1016/S0042-6989(97)00021-7
   Trivino A., 2005, FOCUS EYE RES, P1
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Tsacopoulos M, 1996, J NEUROSCI, V16, P877
   Verkhratsky A, 2014, BIOCHEM SOC T, V42, P1291, DOI 10.1042/BST20140107
   Vorwerk CK, 1999, SURV OPHTHALMOL, V43, pS142, DOI 10.1016/S0039-6257(99)00017-X
   Wang JJ, 2015, WORLD J DIABETES, V6, P726, DOI 10.4239/wjd.v6.i5.726
   Wang MH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-173
   Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360
   Wang X, 2009, EXP EYE RES, V88, P378, DOI 10.1016/j.exer.2008.09.009
   Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Yan XM, 2000, ARCH OPHTHALMOL-CHIC, V118, P666, DOI 10.1001/archopht.118.5.666
   Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3
   Zhang SD, 2009, BRAIN RES, V1303, P131, DOI 10.1016/j.brainres.2009.09.029
NR 154
TC 98
Z9 99
U1 1
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
VL 2016
AR 2954721
DI 10.1155/2016/2954721
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA DN2TD
UT WOS:000376915000001
PM 27294114
OA gold, Green Published, Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Caramoy, A
   Fauser, S
   Kirchhof, B
AF Caramoy, Albert
   Fauser, Sascha
   Kirchhof, Bernd
TI Fundus autofluorescence and spectral-domain optical coherence tomography
   findings suggesting tissue remodelling in retinal pigment epithelium
   tear
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; 360-DEGREES RETINOTOMY; MIGRATION; TRANSLOCATION;
   REPOPULATION; CELLS
AB Aim To study tissue remodelling and wound healing after retinal pigment epithelium (RPE) tears due to age-related macular degeneration.
   Methods Retrospective longitudinal study of 36 eyes (33 patients) with RPE tears. Imaging was performed using fundus autofluorescence (FAF) (lambda-488 nm) and spectral-domain optical coherence tomography (SD-OCT). Presence of intraretinal hyper-reflective dots in SD-OCT, which correlated with hyperfluorescent dots in FAF, indicating RPE migration was studied. Morphology of subretinal mass and RPE layer integrity in the RPE denuded area over time were examined.
   Results 7 of 36 eyes (19.4%) showed patchy or hazy hyperfluorescent areas in FAF, and the majority of eyes (83.3%) showed hyper-reflective dots, which possibly represent intraretinal RPE migration and hard exudates. Homogenous subretinal mass was encountered in about half of all cases. In one case (2.8%), the RPE layer proliferated and covered the defect.
   Conclusions SD-OCT and FAF showed a considerable amount of RPE proliferation, migration and repopulation. Intraretinal RPE migration did not form a functional RPE layer. A small defect might be repaired by cell proliferation. But this RPE proliferation is not sufficient to cover large defects.
C1 [Caramoy, Albert; Fauser, Sascha; Kirchhof, Bernd] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50924 Cologne, Germany.
C3 University of Cologne
RP Caramoy, A (通讯作者)，Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Kerpenerstr 62, D-50924 Cologne, Germany.
EM acaramoy@yahoo.co.uk
CR Binder S, 2011, BRIT J OPHTHALMOL, V95, P441, DOI 10.1136/bjo.2009.171926
   Caramoy A, 2012, ACTA OPHTHALMOL, V90, pE328, DOI 10.1111/j.1755-3768.2011.02284.x
   Caramoy A, 2011, ACTA OPHTHALMOL, V89, pE490, DOI 10.1111/j.1755-3768.2011.02143.x
   Caramoy A, 2011, ARCH OPHTHALMOL-CHIC, V129, P575, DOI 10.1001/archophthalmol.2011.105
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gelisken F, 2005, GRAEF ARCH CLIN EXP, V243, P619, DOI 10.1007/s00417-004-1098-1
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Han QH, 2001, GRAEF ARCH CLIN EXP, V239, P531, DOI 10.1007/s004170000212
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hogg PA, 2002, INVEST OPHTH VIS SCI, V43, P2749
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   Maaijwee K, 2008, BRIT J OPHTHALMOL, V92, P526, DOI 10.1136/bjo.2007.131383
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   Ota M, 2010, OPHTHALMOLOGY, V117, P1996, DOI 10.1016/j.ophtha.2010.06.019
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Schneider S, 1998, DOC OPHTH P, V62, P69
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanzel BV, 2012, GRAEF ARCH CLIN EXP, V250, P313, DOI 10.1007/s00417-011-1624-x
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
NR 28
TC 28
Z9 31
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2012
VL 96
IS 9
BP 1211
EP 1216
DI 10.1136/bjophthalmol-2012-301750
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004IH
UT WOS:000308674500012
PM 22826551
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, KS
   Lee, WK
AF Kim, Kyu Seop
   Lee, Won Ki
TI PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR AVASCULAR SEROUS PIGMENT
   EPITHELIAL DETACHMENT IN ELDERLY KOREANS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE avascular serous pigment epithelial detachment; central serous
   chorioretinopathy; drusen; exudative age-related macular degeneration;
   photodynamic therapy
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; DISCIFORM MACULAR DEGENERATION;
   NATURAL-HISTORY; CHOROIDAL NEOVASCULARIZATION; 2ND EYE;
   CHORIORETINOPATHY; CLASSIFICATION; ANGIOGRAPHY; DISEASE
AB Purpose: To evaluate the efficacy of photodynamic therapy (PDT) with verteporfin for avascular serous pigment epithelial detachment (PED) in elderly Korean patients.
   Methods: We retrospectively analyzed the medical records of 5 consecutive patients (7 eyes) who presented with a single large (>1 disk diameter) serous PED without clinical signs of soft drusen. Evident or faint choroidal hyperfluorescence was observed around the PED on indocyanine green angiogram (ICGA). Standard PDT was performed with laser spot covering the PED area.
   Results: The mean follow-up period was 17 months (range, 12-31 months). Five eyes (71%) of 4 patients showed complete resolution of the PED with visual improvement 1 month post-PDT, and these results were sustained during the follow-up period. In the remaining 2 eyes (29%) of 1 patient, there was no change in PED with stable or decreased vision. Vision-threatening adverse events did not occur.
   Conclusion: In elderly Asians, it is uncertain whether large serous PED without soft drusen is associated with age-related macular degeneration. Most of these PEDs may represent a variant of central serous chorioretinopathy in the elderly and PDT for these lesions showed encouraging results. RETINA 30:93-99,2010
C1 [Kim, Kyu Seop; Lee, Won Ki] Catholic Univ Korea, Dept Ophthalmol, Kangnam St Marys Hosp, Seoul 137701, South Korea.
C3 Catholic University of Korea; Catholic University Korea Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol, Kangnam St Marys Hosp, 505 Banpo Dong, Seoul 137701, South Korea.
EM wklee@catholic.ac.kr
CR [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   BIRD AC, 1991, EYE, V5, P1
   BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   ELMAN MJ, 1986, OPHTHALMOLOGY, V93, P224
   Flower RW, 1998, RETINA-J RET VIT DIS, V18, P260, DOI 10.1097/00006982-199803000-00012
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, V1, P79
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hirami Y, 2007, CLIN EXP OPHTHALMOL, V35, P225, DOI 10.1111/j.1442-9071.2006.01447.x
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   KLEIN ML, 1980, BRIT J OPHTHALMOL, V64, P412, DOI 10.1136/bjo.64.6.412
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   Lee PY, 2009, JPN J OPHTHALMOL, V53, P52, DOI 10.1007/s10384-008-0613-z
   LEWIS ML, 1978, ARCH OPHTHALMOL-CHIC, V96, P620
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sivaprasad S, 2006, EYE, V20, P923, DOI 10.1038/sj.eye.6702056
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   TEETERS VW, 1973, AM J OPHTHALMOL, V76, P1
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 33
TC 8
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2010
VL 30
IS 1
BP 93
EP 99
DI 10.1097/IAE.0b013e3181b094a1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 607ZX
UT WOS:000278547300012
PM 19696702
DA 2022-11-30
ER

PT J
AU Schwarz, F
   Christie, D
AF Schwarz, F.
   Christie, D.
TI Use of 'sham' radiotherapy in randomized clinical trials
SO JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY
LA English
DT Review
DE irradiation; placebo; plantar fasciitis; radiotherapy; randomized
   controlled trial; sham
ID TOTAL LYMPHOID IRRADIATION; PROPHYLACTIC BREAST IRRADIATION;
   DOUBLE-BLIND; MACULAR DEGENERATION; ORBITAL RADIOTHERAPY; COMPARING
   PLACEBO; BETA-RADIATION; PTERYGIUM; POWERLESS; QUALITY
AB The objective of this systematic review was to identify quality trials that use sham radiotherapy in their design and review them to determine its potential value. The Cochrane Library, Pubmed and a Reference Search served as data sources. Trials were included if they met a minimum quality score of 3 on a validated assessment instrument (which assesses randomization, control and blinding) and if they compared sham radiotherapy to active treatment. External beam therapy and brachytherapy trials were considered. Twenty-six trials were identified, collectively including 2663 participants in the period of 1970-2004. All the trials studied the value of radiotherapy for treatment or prevention of benign diseases, including multiple sclerosis, coronary artery restenosis, age-related macular degeneration and Graves' ophthalmopathy. There were no trials relating to the use of radiotherapy in the treatment of malignancy. This review showed that it is possible to carry out sham radiotherapy with due regard for ethical concerns, with effective blinding and high levels of patient acceptance. Large sample sizes with multicentre trial designs were achievable. Although the statistical philosophy for using sham radiotherapy in trials is legitimate, it is no longer routinely used.
C1 [Schwarz, F.] Univ Queensland, Sch Med, Rural Clin Div Queensland, Rockhampton, Qld, Australia.
   [Christie, D.] Bond Univ, Fac Med & Hlth Sci, Gold Coast, Qld, Australia.
C3 University of Queensland; Bond University
RP Christie, D (通讯作者)，E Coast Canc Ctr, Inland Dr, Tugun, Qld 4224, Australia.
EM dchristie@wesley.com.au
OI Christie, David/0000-0001-5494-8751
CR Beers M.H., 1999, MERCK MANUAL DIAGNOS
   Bhargava B, 2002, LANCET, V359, P543, DOI 10.1016/S0140-6736(02)07720-6
   CHANTELAU E, 1997, PRACT DIABETES INT, V14, P154
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   COMI G, 1996, EUR J NEUROL, V3, P35
   COOK SD, 1986, LANCET, V1, P1405
   Cook SD, 1997, J NEUROL SCI, V152, P172, DOI 10.1016/S0022-510X(97)00189-5
   DEVEREUX CK, 1988, INT J RADIAT ONCOL, V14, P197, DOI 10.1016/0360-3016(88)90068-5
   DRACHMAN DB, 1994, ANN NEUROL, V35, P142, DOI 10.1002/ana.410350205
   ERNST E, 1995, BMJ-BRIT MED J, V311, P551, DOI 10.1136/bmj.311.7004.551
   Fritz P, 2004, INT J RADIAT ONCOL, V59, P815, DOI 10.1016/j.ijrobp.2003.11.036
   Fukushima S, 1999, INT J RADIAT ONCOL, V43, P597, DOI 10.1016/S0360-3016(98)00431-3
   GALLO C, 1995, LANCET, V346, P1060, DOI 10.1016/S0140-6736(95)91741-1
   GOLDIE I, 1970, ACTA RADIOL THER PHY, V9, P311, DOI 10.3109/02841867009129108
   Gorman CA, 2002, THYROID, V12, P251, DOI 10.1089/105072502753600232
   Gorman CA, 2001, OPHTHALMOLOGY, V108, P1523, DOI 10.1016/S0161-6420(01)00632-7
   HANSRANI M, 2002, COCHRANE DB SYST REV, V2
   HOLBROOK A, 2004, CAN J CLIN PHARM, V11, P39
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Horng S, 2003, CRIT CARE MED, V31, pS126, DOI 10.1097/01.CCM.0000054906.49187.67
   Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106
   Hrobjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jurgenliemk-Schulz IM, 2004, INT J RADIAT ONCOL, V59, P1138, DOI 10.1016/j.ijrobp.2003.12.021
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 1999, RETINA-J RET VIT DIS, V19, P525, DOI 10.1097/00006982-199911000-00008
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Mourits MP, 2000, LANCET, V355, P1505, DOI 10.1016/S0140-6736(00)02165-6
   NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16
   Papakostas YG, 2001, EPILEPSIA, V42, P1614, DOI 10.1046/j.1528-1157.2001.41601.x
   PILEPICH MV, 1983, TRANSPLANTATION, V35, P208, DOI 10.1097/00007890-198303000-00004
   Popma JJ, 2002, CIRCULATION, V106, P1090, DOI 10.1161/01.CIR.0000027814.96651.72
   Prummel MF, 2004, J CLIN ENDOCR METAB, V89, P15, DOI 10.1210/jc.2003-030809
   PRUMMEL MF, 1993, LANCET, V342, P949, DOI 10.1016/0140-6736(93)92001-A
   Raizner AE, 2000, CIRCULATION, V102, P951, DOI 10.1161/01.CIR.102.9.951
   Scheinert D, 2002, CIRCULATION, V105, P1420, DOI 10.1161/01.CIR.0000012525.73993.C9
   Schwarz Fabian, 2004, Australas Radiol, V48, P162, DOI 10.1111/j.1440-1673.2004.01292.x
   Shakespeare TP, 2005, CANCER-AM CANCER SOC, V103, P1976, DOI 10.1002/cncr.20993
   Teirstein P S, 1999, Cardiovasc Radiat Med, V1, P3, DOI 10.1016/S1522-1865(98)00002-X
   Tyrrell CJ, 2004, INT J RADIAT ONCOL, V60, P476, DOI 10.1016/j.ijrobp.2004.03.022
   VALTONEN EJ, 1975, SCAND J RHEUMATOL, V4, P247, DOI 10.3109/03009747509165265
   Waksman R, 2002, LANCET, V359, P551, DOI 10.1016/S0140-6736(02)07741-3
   Widmark A, 2003, UROLOGY, V61, P145, DOI 10.1016/S0090-4295(02)02107-6
   WILES CM, 1994, J NEUROL NEUROSUR PS, V57, P154, DOI 10.1136/jnnp.57.2.154
   YU RCH, 1992, ACTA DERM-VENEREOL, V72, P134
   2004, HLTH NEWS, V10, P12
NR 46
TC 5
Z9 5
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1754-9477
EI 1754-9485
J9 J MED IMAG RADIAT ON
JI J. Med. Imag. Radiat. Oncol.
PD JUN
PY 2008
VL 52
IS 3
BP 269
EP 277
DI 10.1111/j.1440-1673.2008.01936.x
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 309CK
UT WOS:000256438100011
PM 18477122
DA 2022-11-30
ER

PT J
AU Rakic, JM
   Lambert, V
   Munaut, C
   Bajou, K
   Peyrollier, K
   Alvarez-Gonzalez, ML
   Carmeliet, P
   Foidart, JM
   Noel, A
AF Rakic, JM
   Lambert, V
   Munaut, C
   Bajou, K
   Peyrollier, K
   Alvarez-Gonzalez, ML
   Carmeliet, P
   Foidart, JM
   Noel, A
TI Mice without uPA, tPA, or plasminogen genes are resistant to
   experimental choroidal neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MATRIX-METALLOPROTEINASE; ACTIVATOR INHIBITOR-1; ENDOTHELIAL-CELLS;
   UROKINASE; ANGIOGENESIS; MEMBRANES; VASCULARIZATION; PROTEOLYSIS;
   MODULATION; INVASION
AB PURPOSE. To evaluate the presence and potential involvement of members of the plasminogen/plasminogen activator (Plg/PA) system in the exudative form of age-related macular degeneration (AMD).
   METHODS. The expression of PA members mRNA was evaluated in human and experimental choroidal neovascularization (CNV) by RT-PCR. The presence and activity of PA was studied by immunofluorescence and in situ zymography. The influence of endogenous plasminogen (Plg), urokinase (uPA), tissue type plasminogen activator (tPA), and uPA receptor (uPAR) was explored in single-gene-deficient mice in a model of laser-induced CNV.
   RESULTS. Members of the Plg/PA system were present both in human and murine CNV. The absence of Pig, uPA, or tPA significantly decreased the development of experimental CNV compared with wild-type or uPAR-deficient mice. This effect could be attributable, partly to a modulation of matrix metalloproteinase activity, but also to an accumulation of fibrinogen-fibrin in the laser-induced wounds.
   CONCLUSIONS. Together with previous work done by the authors, this study indicates that choroidal neovascularization is extremely sensitive to the modulation of Plg/PA system activity. This may provide a new strategy for the treatment of exudative AMD.
C1 Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium.
   Univ Liege, Lab Tumor & Dev Biol, Liege, Belgium.
   Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium.
C3 University of Liege; University of Liege; Flanders Institute for
   Biotechnology (VIB); KU Leuven
RP Rakic, JM (通讯作者)，Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium.
EM jmrakic@chu.ulg.ac.be
RI Carmeliet, Peter/AAQ-5140-2020; Munaut, Carine/K-8138-2019
OI Carmeliet, Peter/0000-0001-7961-1821; Noel, Agnes/0000-0002-7670-6179;
   Bajou, Khalid/0000-0002-5529-9228
CR Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z
   Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777
   Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   BERMAN M, 1982, INVEST OPHTH VIS SCI, V22, P191
   Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298
   Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4
   CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0
   Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233
   Carmeliet P, 1997, TRENDS CARDIOVAS MED, V7, P271, DOI 10.1016/S1050-1738(97)00093-5
   Cavallaro U, 2001, J CELL BIOCHEM, V82, P619, DOI 10.1002/jcb.1190
   Das A, 1999, INVEST OPHTH VIS SCI, V40, P809
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com
   Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   GRANT MB, 1991, INVEST OPHTH VIS SCI, V32, P53
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   HACKETT SF, 1993, INVEST OPHTH VIS SCI, V34, P2055
   Hattenbach LO, 1999, RETINA-J RET VIT DIS, V19, P383, DOI 10.1097/00006982-199909000-00003
   Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459
   Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Munaut C, 1995, INVAS METAST, V15, P169
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009
   Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870
   WANG YF, 1995, INVEST OPHTH VIS SCI, V36, P1625
NR 35
TC 44
Z9 50
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2003
VL 44
IS 4
BP 1732
EP 1739
DI 10.1167/iovs.02-0809
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 660TG
UT WOS:000181848900048
PM 12657615
DA 2022-11-30
ER

PT J
AU Igarashi, T
   Miyake, K
   Kato, K
   Watanabe, A
   Ishizaki, M
   Ohara, K
   Shimada, T
AF Igarashi, T
   Miyake, K
   Kato, K
   Watanabe, A
   Ishizaki, M
   Ohara, K
   Shimada, T
TI Lentivirus-mediated expression of angiostatin efficiently inhibits
   neovascularization in a murine proliferative retinopathy model
SO GENE THERAPY
LA English
DT Article
DE retinal neovascularization; retinopathy of prematurity; diabetic
   retinopathy; gene therapy; lentivirus vector; angiostatin
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; GENE-TRANSFER;
   CHOROIDAL NEOVASCULARIZATION; ANGIOGENESIS INHIBITOR;
   DIABETIC-RETINOPATHY; LEUKEMIA-VIRUS; CELLS; RELEASE; DEGENERATION
AB Ischemic retinal diseases, such as diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration, are a major cause of blindness worldwide. Angiostatin is an internal peptide fragment of plasminogen that inhibits endothelial proliferation in vitro and tumor growth in vivo. We now demonstrate that HIV vector encoding angiostatin (HIV-angiostatin) can inhibit retinal neovascularization in a mouse model of proliferative retinopathy. Intravitreal injections of HIV-angiostatin led to stable expression of the angiostatin gene in retinal tissue. Retinal neovascularization was histologically quantitated by a masked protocol. Retinal neovascularization in the eye injected with HIV-angiostatin was reduced in 90% (9/10; P=0.025) of animals, compared with the eye injected with phosphate-buffered saline. Reduction of histologically evident neovascular nuclei per 6-mum section averaged 68%, with maximal inhibitory effects of 87%. Neovascularization was not reduced in the eyes injected with HIV vector encoding enhanced green fluorescent protein. This is the first report that HIV-angiostatin can reduce neovascular cell nuclei in a murine proliferative retinopathy model. These data suggest that the anti-angiogenic activity of angiostatin has therapeutic potential for the treatment of retinal neovascularization.
C1 Nippon Med Coll, Dept Biochem & Mol Biol, Div Gene Therapy, Res Ctr Adv Med Technol,Bunkyo Ku, Tokyo 1138602, Japan.
   Nippon Med Coll, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138602, Japan.
   Nippon Med Coll, Dept Joint Dis & Rheumatism, Bunkyo Ku, Tokyo 1138602, Japan.
   Nippon Med Coll, Dept Pathol, Bunkyo Ku, Tokyo 1138602, Japan.
C3 Nippon Medical School; Nippon Medical School; Nippon Medical School;
   Nippon Medical School
RP Shimada, T (通讯作者)，Nippon Med Coll, Dept Biochem & Mol Biol, Div Gene Therapy, Res Ctr Adv Med Technol,Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.
RI WATANABE, Atsushi/F-5687-2019
OI WATANABE, Atsushi/0000-0001-9143-3079; Igarashi,
   Tsutomu/0000-0002-7467-6746
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 1976, Am J Ophthalmol, V81, P383
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Berger AS, 1996, INVEST OPHTH VIS SCI, V37, P2318
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   EMI N, 1991, J VIROL, V65, P1202, DOI 10.1128/JVI.65.3.1202-1207.1991
   Ferrari FK, 1996, J VIROL, V70, P3227, DOI 10.1128/JVI.70.5.3227-3234.1996
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gyorffy S, 2001, AM J PATHOL, V159, P1137, DOI 10.1016/S0002-9440(10)61790-7
   Igarashi T, 2002, CURR EYE RES, V24, P46, DOI 10.1076/ceyr.24.1.46.5436
   Indraccolo S, 2001, CANCER RES, V61, P5441
   KLEIN R, 1995, DIABETES AM, P305
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1
   LI TS, 1994, INVEST OPHTH VIS SCI, V35, P2543
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lucas R, 1998, BLOOD, V92, P4730
   MCDONALD HR, 1985, RETINA-J RET VIT DIS, V5, P5, DOI 10.1097/00006982-198500510-00002
   Miyake K, 2001, HUM GENE THER, V12, P227, DOI 10.1089/10430340150218378
   Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998
   Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Murata T, 1998, DIABETOLOGIA, V41, P500, DOI 10.1007/s001250050938
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D
   OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   Orimo H, 2000, J HUM GENET, V45, P228, DOI 10.1007/s100380070031
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Sambrook J, 1989, MOL CLONING LAB MANU, P1860
   SHIMADA T, 1991, J CLIN INVEST, V88, P1043, DOI 10.1172/JCI115365
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Spranger J, 2000, DIABETOLOGIA, V43, P1404, DOI 10.1007/s001250051546
   Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999
   Tanaka K, 2002, CLIN CANCER RES, V8, P1125
   Tanaka T, 1998, CANCER RES, V58, P3362
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247
   Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 45
TC 64
Z9 65
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD FEB
PY 2003
VL 10
IS 3
BP 219
EP 226
DI 10.1038/sj.gt.3301878
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 638TX
UT WOS:000180588000004
PM 12571629
DA 2022-11-30
ER

PT J
AU Peli, E
AF Peli, E
TI The optical functional advantages of an intraocular low-vision telescope
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE macular degeneration; adaptation; rehabilitation; binocular vision
ID ONE EYE; VESTIBULOOCULAR REFLEX; MACULAR DEGENERATION; ADAPTATION; LENS;
   SPECTACLES; SYSTEM
AB An implantable miniaturized telescope (IMT) for low vision has recently been developed. Surgically inserted into only one eye of patients with bilateral central visual loss, the IMT provides a nominal magnification of 3.0x and a field-of-view of 6.6 (9.2degrees for the 2.2x magnification version). Theoretical concerns have been raised regarding the ability of patients to function with a large interocular magnification difference, the impact of the monocular restriction of the field-of-view, and the impact of this design on depth perception. This article addresses these concerns regarding the design of the IMT in comparison with spectacle-mounted telescopes and combined intraocular lens/spectacle (or combined contact lens/spectacle) telescopic systems. The effective field-of-view (as determined by the combination of both the field-of-view and the field-of-fixation), the effects of head motion and the vestibular reflex, and the disruption of stereo depth perception with a monocular device are considered here. Physiological optics considerations of these issues show that the IMT may have important advantages over other designs of magnification devices for patients with age-related macular degeneration.
C1 Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Schepens Eye Research
   Institute
RP Peli, E (通讯作者)，Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02115 USA.
EM eli@vision.eri.harvard.edu
OI Peli, Eli/0000-0002-1340-9257
FU NEI NIH HHS [EY05957, EY12890] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R24EY012890, R01EY012890] Funding Source: NIH RePORTER
CR Bailey I L, 1987, CLAO J, V13, P217
   BERG RV, 1983, UNDERSTANDING LOW VI, P277
   Choyce P, 1964, INTRAOCULAR LENSES I, P156
   COOPER J, 1979, J AM OPTOM ASSOC, V50, P807
   Dallos J, 1936, ARCH OPHTHALMOL-CHIC, V15, P617
   DEMER JL, 1989, INVEST OPHTH VIS SCI, V30, P159
   DOESSCHATE JT, 1948, OPHTHALMOLOGICA, V127, P65
   DONN A, 1986, CLAO Journal, V12, P81
   DRASDO N, 1970, BRIT J PHYSIOL OPT, V25, P14
   Fasce F, 2000, VISION REHABILITATIO, P177
   FILDERMAN I P, 1959, Am J Optom Arch Am Acad Optom, V36, P135
   FILDERMAN IP, 1959, CONTACTO, V3, P94
   FONDA G, 1983, ARCH OPHTHALMOL-CHIC, V101, P1907
   GAUTHIER GM, 1975, BRAIN RES, V92, P331, DOI 10.1016/0006-8993(75)90279-6
   Isen A., 1963, ENCY CONTACT LENS 13, V3, P53
   JOSE RT, 1976, OPTICAL J REV OP DEC, P33
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KOZIOL JE, 1994, OPHTHALMIC SURG LAS, V25, P675
   Lipshitz I, 1997, OPHTHALMIC SURG LAS, V28, P513
   LUDLAM W M, 1960, Am J Optom Arch Am Acad Optom, V37, P363
   MANDELL RB, 1977, LOW VISION CONTACT L, P633
   MAROTTA JJ, 1995, EXP BRAIN RES, V104, P107
   Mehr EB, 1975, LOW VISION CARE
   MIDLER B, 1991, FINE ART PRESCRIBING
   MILES FA, 1991, PERSP VIS R, P113
   MOORE L, 1964, Br J Physiol Opt, V21, P203
   Nguyen A., 1993, J VIS REHAB, V7, P5
   Peli E, 2001, OPTOMETRY VISION SCI, V78, P304, DOI 10.1097/00006324-200105000-00014
   PELI E, 1986, AM J OPTOM PHYS OPT, V63, P981
   PELI E, 2000, 6 INT M AM AC OPT MA, P22
   PELI E, 1998, SID 98 SAN JOS SOC I, P1033
   Peli E., 2000, VISION REHABILITATIO, P200
   PELI E, 2002, DRIVING CONFIDENCE P, P122
   *PREV BLINDN AM, 1994, PREV BLINDN AM VIS P, P1
   ROGERS B, 1979, PERCEPTION, V8, P125, DOI 10.1068/p080125
   RUSHTON D, 1987, J NEUROL NEUROSUR PS, V50, P411, DOI 10.1136/jnnp.50.4.411
   Siegel M, 2000, IEEE T CIRC SYST VID, V10, P387, DOI 10.1109/76.836283
   SNOW R, 1985, INVEST OPHTH VIS SCI, V26, P924
   SPITZBERG LA, 1989, OPTOMETRY VISION SCI, V66, P616, DOI 10.1097/00006324-198909000-00008
   Srinivasan MV, 1999, NATURE, V399, P305, DOI 10.1038/20550
   STONE J, 1989, CONTACT LENSES TXB P, P870
   VIIRRE E, 1987, J NEUROPHYSIOL, V57, P92, DOI 10.1152/jn.1987.57.1.92
   WESTHEIMER G, 1957, Am J Optom Arch Am Acad Optom, V34, P430
   Westheimer G., 1994, P ROY SOC LOND B BIO, V257, P205, DOI DOI 10.1098/RSPB.1994.0117)
   WILLIS TR, 1989, EUR J IMPLANT REFRAC, V1, P271
NR 45
TC 28
Z9 29
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD APR
PY 2002
VL 79
IS 4
BP 225
EP 233
DI 10.1097/00006324-200204000-00009
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 541CW
UT WOS:000174968500003
PM 11999148
DA 2022-11-30
ER

PT J
AU Schurer-Waldheim, S
   Seebock, P
   Bogunovic, H
   Gerendas, BS
   Schmidt-Erfurth, U
AF Schurer-Waldheim, Simon
   Seebock, Philipp
   Bogunovic, Hrvoje
   Gerendas, Bianca S.
   Schmidt-Erfurth, Ursula
TI Robust Fovea Detection in Retinal OCT Imaging Using Deep Learning
SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
LA English
DT Article
DE Retina; Diseases; Task analysis; Location awareness; Training;
   Three-dimensional displays; Solid modeling; Age-related macular
   degeneration; deep learning; diabetic macula edema; fovea detection;
   landmark detection; optical coherence tomography; retinal vein occlusion
ID AORTIC-VALVE
AB The fovea centralis is an essential landmark in the retina where the photoreceptor layer is entirely composed of cones responsible for sharp, central vision. The localization of this anatomical landmark in optical coherence tomography (OCT) volumes is important for assessing visual function correlates and treatment guidance in macular disease. In this study, the "PRE U-net" is introduced as a novel approach for a fully automated fovea centralis detection, addressing the localization as a pixel-wise regression task. 2D B-scans are sampled from each image volume and are concatenated with spatial location information to train the deep network. A total of 5586 OCT volumes from 1,541 eyes were used to train, validate and test the deep learning method. The test data is comprised of healthy subjects and patients affected by neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME) and macular edema from retinal vein occlusion (RVO), covering the three major retinal diseases responsible for blindness. Our experiments demonstrate that the PRE U-net significantly outperforms state-of-the-art methods and improves the robustness of automated localization, which is of value for clinical practice.
C1 [Schurer-Waldheim, Simon; Seebock, Philipp; Bogunovic, Hrvoje; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Seebock, P (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, A-1090 Vienna, Austria.
EM schuerer-waldheim@meduniwien.ac.at; philipp.seeboeck@meduniwien.ac.at;
   hrvoje.bogunovic@meduniwien.ac.at; bianca.gerendas@meduni-wien.ac.at;
   ursula.schmidt-erfurth@meduniwien.ac.at
RI Bogunovic, Hrvoje/J-3445-2014
OI Bogunovic, Hrvoje/0000-0002-9168-0894; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
CR Al WA, 2020, IEEE T MED IMAGING, V39, P1245, DOI 10.1109/TMI.2019.2946345
   Al WA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200317
   Alansary A, 2019, MED IMAGE ANAL, V53, P156, DOI 10.1016/j.media.2019.02.007
   [Anonymous], 2013, P ICML
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Bhende M, 2018, INDIAN J OPHTHALMOL, V66, P20, DOI 10.4103/ijo.IJO_902_17
   Chen LCE, 2018, LECT NOTES COMPUT SC, V11211, P833, DOI 10.1007/978-3-030-01234-2_49
   Cootes T. F, 2015, P IEEE INT S BIOM IM
   Cuenca N, 2018, OPHTHALMOLOGY, V125, P407, DOI 10.1016/j.ophtha.2017.09.016
   Dabbah MA, 2014, PROC SPIE, V9034, DOI 10.1117/12.2039157
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Gao YZ, 2015, PHYS MED BIOL, V60, P9377, DOI 10.1088/0031-9155/60/24/9377
   Garcia-Melendo E., 1988, 8829 TREE PURD U SCH
   Han D, 2014, LECT NOTES COMPUT SC, V8673, P186, DOI 10.1007/978-3-319-10404-1_24
   He KM, 2015, IEEE I CONF COMP VIS, P1026, DOI 10.1109/ICCV.2015.123
   Hildebrand GD, 2011, PEDIATRIC RETINA, P39, DOI 10.1007/978-3-642-12041-1_2
   Ibragimov B., 2015, PROC IEEE INT S BIOM, P1
   Ioffe S, 2015, PR MACH LEARN RES, V37, P448
   Ionasec RI, 2008, LECT NOTES COMPUT SC, V5241, P686, DOI 10.1007/978-3-540-85988-8_82
   Karia N, 2010, CLIN OPHTHALMOL, V4, P809
   Kingma D.P., 2015, INT C LEARN REPR
   Kolb Helga, 1995, SIMPLE ANATOMY RETIN, P1
   Lee H, 2017, PROC SPIE, V10134, DOI 10.1117/12.2255870
   Li MC, 2020, OSA CONTINUUM, V3, P528, DOI 10.1364/OSAC.381120
   Liefers B, 2017, BIOMED OPT EXPRESS, V8, P5160, DOI 10.1364/BOE.8.005160
   Liefers B, 2017, PROC SPIE, V10133, DOI 10.1117/12.2254301
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mahapatra Dwarikanath, 2013, Statistical Atlases and Computational Models of the Heart. Imaging and Modelling Challenges. Third International Workshop, STACOM 2012. Held in Conjunction with MICCAI 2012. Revised Selected Papers, P115, DOI 10.1007/978-3-642-36961-2_14
   Meyer MI, 2018, LECT NOTES COMPUT SC, V11071, P39, DOI 10.1007/978-3-030-00934-2_5
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   O'Neil AQ, 2019, LECT NOTES COMPUT SC, V11131, P470, DOI 10.1007/978-3-030-11015-4_34
   Odell D, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/692574
   Oktay O, 2017, IEEE T MED IMAGING, V36, P332, DOI 10.1109/TMI.2016.2597270
   Paszke A, 2019, ADV NEUR IN, V32
   Payer C, 2019, MED IMAGE ANAL, V54, P207, DOI 10.1016/j.media.2019.03.007
   Ronneberger O., 2015, P INT C MED IM COMP, P234, DOI DOI 10.1007/978-3-319-24574-4_28
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Seebock P, 2019, IEEE T MED IMAGING, V38, P1037, DOI 10.1109/TMI.2018.2877080
   Simader C., 2012, INVEST OPHTH VIS SCI, V53, P4067
   Stern Darko, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P221, DOI 10.1007/978-3-319-46723-8_26
   Swanson E., 2011, RETINAL PHYS, V8, P58
   Urschler M, 2018, MED IMAGE ANAL, V43, P23, DOI 10.1016/j.media.2017.09.003
   Vujosevic S, 2020, ACTA DIABETOL, V57, P287, DOI 10.1007/s00592-019-01424-4
   Waechter I, 2010, LECT NOTES COMPUT SC, V6361, P526
   Wang Fenghua, 2012, Ophthalmic Surg Lasers Imaging, V43, pS32, DOI 10.3928/15428877-20121001-06
   WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269
   Wolterink JM, 2019, MED IMAGE ANAL, V51, P46, DOI 10.1016/j.media.2018.10.005
   Wu J, 2016, INT J BIOMED IMAGING, V2016, DOI 10.1155/2016/7468953
   Xu B, 2015, ARXIV150500853
   Zhang DQ, 2020, MED IMAGE ANAL, V61, DOI 10.1016/j.media.2020.101659
   Zhang J, 2017, IEEE T IMAGE PROCESS, V26, P4753, DOI 10.1109/TIP.2017.2721106
NR 51
TC 0
Z9 0
U1 1
U2 2
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2168-2194
EI 2168-2208
J9 IEEE J BIOMED HEALTH
JI IEEE J. Biomed. Health Inform.
PD AUG
PY 2022
VL 26
IS 8
BP 3927
EP 3937
DI 10.1109/JBHI.2022.3166068
PG 11
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Mathematical & Computational Biology;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematical & Computational Biology; Medical
   Informatics
GA 3V7PB
UT WOS:000841851000034
PM 35394920
OA hybrid
DA 2022-11-30
ER

PT J
AU Roblain, Q
   Louis, T
   Yip, C
   Baudin, L
   Struman, I
   Caolo, V
   Lambert, V
   Lecomte, J
   Noel, A
   Heymans, S
AF Roblain, Quentin
   Louis, Thomas
   Yip, Cassandre
   Baudin, Louis
   Struman, Ingrid
   Caolo, Vincenza
   Lambert, Vincent
   Lecomte, Julie
   Noel, Agnes
   Heymans, Stephane
TI Intravitreal injection of anti-miRs against miR-142-3p reduces
   angiogenesis and microglia activation in a mouse model of laser-induced
   choroidal neovascularization
SO AGING-US
LA English
DT Article
DE miR-142-3p; age-related macular degeneration; angiogenesis;
   inflammation; microglia
ID MACULAR DEGENERATION; MICRORNA-142; EXPRESSION
AB Age-related macular degeneration (AMD) is a worldwide leading cause of blindness affecting individuals over 50 years old. The most aggressive form, wet AMD, is characterized by choroidal neovascularization (CNV) and inflammation involving microglia recruitment. By using a laser-induced CNV mouse model, we provide evidence for a key role played by miR-142-3p during CNV formation. MiR-142-3p was overexpressed in murine CNV lesions and its pharmacological inhibition decreased vascular and microglia densities by 46% and 30%, respectively. Consistently, miR-142-3p overexpression with mimics resulted in an increase of 136% and 126% of blood vessels and microglia recruitment. Interestingly, miR-142-3p expression was linked to the activation state of mouse microglia cells as determined by morphological analysis (cell solidity) through a computational method. In vitro, miR-142-3p overexpression in human microglia cells (HMC3) modulated microglia activation, as shown by CD68 levels. Interestingly, miR142-3p modulation also regulated the production of VEGF-A, the main pro-angiogenic factor. Together, these data strongly support the unprecedented importance of miR-142-3p-dependent vascular-inflammation axis during CNV progression, through microglia activation.
C1 [Roblain, Quentin; Louis, Thomas; Yip, Cassandre; Baudin, Louis; Lambert, Vincent; Lecomte, Julie; Noel, Agnes] Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, Liege, Belgium.
   [Roblain, Quentin; Heymans, Stephane] Maastricht Univ, Fac Hlth Med & Life Sci, CARIM Sch Cardiovasc Dis, Dept Cardiol, Maastricht, Netherlands.
   [Struman, Ingrid] Univ Liege, Mol Angiogenesis Lab, GIGA Canc, Liege, Belgium.
   [Lambert, Vincent] Univ Hosp Liege, Dept Ophthalmol, Ophthalm Tissue Bank, Sart Tilman Par Liege, Belgium.
   [Caolo, Vincenza; Heymans, Stephane] Katholieke Univ Leuven, Dept Cardiovasc Sci, Ctr Mol & Vasc Biol, Leuven, Belgium.
C3 University of Liege; Maastricht University; University of Liege;
   University of Liege; KU Leuven
RP Noel, A (通讯作者)，Univ Liege, Lab Tumor & Dev Biol, GIGA Canc, Liege, Belgium.
EM Agnes.Noel@uliege.be
OI Heymans, Stephane/0000-0001-9477-7803; struman,
   ingrid/0000-0003-2550-3707
FU University of Liege; Maastricht University; Fondation Leon Fredericq,
   FEDER; FNRS-PDR [T.1080.15]; Fonds Speciaux de l'Universite de Liege;
   ERA-Net-CVD project MacroERA [01KL1706]; Netherlands Cardiovascular
   Research Initiative; Dutch Heart Foundation; CVON2016-Early HFPEF
   [2015-10]; CVON ShePREDICTS; CVON Arena-PRIME
FX This study was financially supported by a joined PhD funding program in
   the framework of the cooperation between the University of Liege and
   Maastricht University named "Towards a joint imaging valley". Financial
   supports from Fondation Leon Fredericq, FEDER (BIOMED HUB -DMLA-AB),
   FNRS-PDR (grant number: T.1080.15) and "Fonds Speciaux de l'Universite
   de Liege" are gratefully acknowledged. This study has also been possible
   thanks to the support of the ERA-Net-CVD project MacroERA, 01KL1706. The
   authors acknowledge the support from the Netherlands Cardiovascular
   Research Initiative, an initiative with support of the Dutch Heart
   Foundation, CVON2016-Early HFPEF, 2015-10, CVON ShePREDICTS, grant
   2017-21, CVON Arena-PRIME, 2017-18.
CR Adelman RA, 2011, US OPHTHALMIC REV, V04, DOI [10.17925/USOR.2011.04.02.119, DOI 10.17925/USOR.2011.04.02.119]
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bao H, 2018, FASEB J, V32, P3912, DOI 10.1096/fj.201701073R
   Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006
   Cappoli N, 2019, EXCLI J, V18, P779, DOI 10.17179/excli2019-1715
   Carofino Brandi L, 2019, Oncotarget, V10, P7251, DOI 10.18632/oncotarget.27387
   Chaudhuri AD, 2013, FASEB J, V27, P3720, DOI 10.1096/fj.13-232678
   Costa N, 2020, 2020 IEEE 7TH INTERNATIONAL CONFERENCE ON INDUSTRIAL ENGINEERING AND APPLICATIONS (ICIEA 2020), P1, DOI [10.1145/3463858.3463898, 10.1109/ICIEA49774.2020.9102023]
   Crespo-Garcia S, 2015, EXP EYE RES, V139, P13, DOI 10.1016/j.exer.2015.07.012
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Du XL, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2015-z
   Fan B, 2020, INT J ONCOL, V56, P178, DOI 10.3892/ijo.2019.4928
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guiot J, 2020, THORAX, V75, P870, DOI 10.1136/thoraxjnl-2019-214077
   Gupta N, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00132
   Hernandez S, 2006, ULTRASTRUCT PATHOL, V30, P221, DOI 10.1080/01913120500521018
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huang PR, 2017, INVEST OPHTH VIS SCI, V58, P1726, DOI 10.1167/iovs.16-20043
   Kiel C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082689
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Liu CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020649
   Marques-Rocha JL, 2015, FASEB J, V29, P3595, DOI 10.1096/fj.14-260323
   Leo EEM, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13207
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Park YG, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/637316
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Raghunath A, 2015, OPHTHALMIC RES, V53, P169, DOI 10.1159/000371853
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shrestha A, 2017, DEV DYNAM, V246, P285, DOI 10.1002/dvdy.24477
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Stankov Aleksandar, 2015, Pril (Makedon Akad Nauk Umet Odd Med Nauki), V36, P141, DOI 10.1515/prilozi-2015-0062
   Storey P, 2014, HANDBOOK OF NUTRITION, DIET, AND THE EYE, P11, DOI 10.1016/B978-0-12-401717-7.00002-2
   Tiwari A, 2018, CURR CANCER DRUG TAR, V18, P266, DOI 10.2174/1568009617666170630142725
   Tong NT, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00137
   Walz JM, 2019, EXP EYE RES, V181, P98, DOI 10.1016/j.exer.2019.01.006
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2019, WORLD REP VIS
   Xu SB, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7090359
   Young K, 2018, JOVE-J VIS EXP, DOI 10.3791/57648
   Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0
   Zhang LW, 2019, CURR EYE RES, V44, P1226, DOI 10.1080/02713683.2019.1625407
   Zuber-Laskawiec K, 2019, J PHYSIOL PHARMACOL, V70, P779, DOI 10.26402/jpp.2019.5.13
NR 49
TC 2
Z9 2
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAY 15
PY 2021
VL 13
IS 9
BP 12359
EP 12377
PG 19
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA SD4NQ
UT WOS:000651350800007
PM 33952723
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU McGuinness, MB
   Kasza, J
   Wu, ZC
   Guymer, RH
AF McGuinness, Myra B.
   Kasza, Jessica
   Wu, Zhichao
   Guymer, Robyn H.
TI Focus on Survival Analysis for Eye Research
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE survival analysis; time-to-event; age-related macular degeneration;
   biostatistics
ID TUTORIAL; MODEL; EXPLANATION
AB Analysis of time-to-event data, otherwise known as survival analysis, is a common investigative tool in ophthalmic research. For example, time-to-event data is useful when researchers are interested in investigating how long it takes for an ocular condition to worsen or whether treatment can delay the development of a potentially vision-threatening complication. Its implementation requires a different set of statistical tools compared to those required for analyses of other continuous and categorial outcomes. In this installment of the Focus on Data series, we present an overview of selected concepts relating to analysis of time-to-event data in eye research. We introduce censoring, model selection, consideration of model assumptions, and best practice for reporting. We also consider challenges that commonly arise when analyzing time-to-event data in ophthalmic research, including collection of data from two eyes per person and the presence of multiple outcomes of interest. The concepts are illustrated using data from the Laser Intervention in Early Stages of Age-Related Macular Degeneration study and statistical computing code for Stata is provided to demonstrate the application of the statistical methods to illustrative data.
C1 [McGuinness, Myra B.; Wu, Zhichao; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [McGuinness, Myra B.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.
   [Kasza, Jessica] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
   [Wu, Zhichao; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Monash University; University of Melbourne
RP McGuinness, MB (通讯作者)，Level 7,Peter Howson Wing,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM myra.mcguinness@unimelb.edu.au
OI McGuinness, Myra/0000-0002-5422-040X
FU Victorian Government; National Health & Medical Research Council of
   Australia [APP1027624, GNT1103013, APP1104985]; Bupa Health Foundation,
   Australia; Ellex R&D Pty Ltd, Adelaide, Australia
FX Supported by the Victorian Government, the National Health & Medical
   Research Council of Australia (project grant no.: APP1027624 [RHG, CDL];
   and fellowship grant nos.: GNT1103013 [RHG], APP1104985 [ZW]); and Bupa
   Health Foundation, Australia (RHG). Ellex R&D Pty Ltd, Adelaide,
   Australia, provided partial funding of the central coordinating center.
CR Austin PC, 2017, STAT MED, V36, P4391, DOI 10.1002/sim.7501
   Austin PC, 2017, INT STAT REV, V85, P185, DOI 10.1111/insr.12214
   Clark TG, 2003, BRIT J CANCER, V89, P781, DOI 10.1038/sj.bjc.6601117
   Committee for Medicinal Products for Human Use, 2015, GUID ADJ BAS COV CLI
   Dekker FW, 2008, KIDNEY INT, V74, P994, DOI 10.1038/ki.2008.328
   du Sert NP, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000411
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Goel Manish Kumar, 2010, Int J Ayurveda Res, V1, P274, DOI 10.4103/0974-7788.76794
   Gomez G, 2009, STAT MODEL, V9, P259, DOI 10.1177/1471082X0900900402
   Grand MK, 2019, STAT MED, V38, P1802, DOI 10.1002/sim.8069
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510
   Ibrahim JG, 2010, J CLIN ONCOL, V28, P2796, DOI 10.1200/JCO.2009.25.0654
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   McGuinness MB, 2020, JAMA OPHTHALMOL, V138, P477, DOI 10.1001/jamaophthalmol.2020.0262
   Moher David, 2010, J Clin Epidemiol, V63, pe1, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   Pencina MJ, 2007, STAT MED, V26, P1343, DOI 10.1002/sim.2699
   Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712
   Quartilho A, 2020, EYE, V34, P657, DOI 10.1038/s41433-019-0554-4
   Templeton AJ, 2020, NAT REV CLIN ONCOL, V17, P327, DOI 10.1038/s41571-020-0368-0
   von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]
   Witzel C, 2015, NEURAL REGEN RES, V10, P976, DOI 10.4103/1673-5374.150744
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2021
VL 62
IS 6
AR 7
DI 10.1167/iovs.62.6.7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UA5IZ
UT WOS:000685196300026
PM 33950248
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, HC
   Ichikawa, O
   Glicksberg, BS
   Divaraniya, AA
   Becker, CE
   Agarwal, P
   Dudley, JT
AF Lee, Hao-Chih
   Ichikawa, Osamu
   Glicksberg, Benjamin S.
   Divaraniya, Aparna A.
   Becker, Christine E.
   Agarwal, Pankaj
   Dudley, Joel T.
TI Identification of therapeutic targets from genetic association studies
   using hierarchical component analysis
SO BIODATA MINING
LA English
DT Article
DE Genome-wide association study; Network biology; Gene candidate discovery
ID INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY
   LOCI; COMPLEX DISEASES; NETWORK; TRAITS; ARCHITECTURE; METAANALYSIS;
   MACROPHAGES; EXPRESSION
AB Background Mapping disease-associated genetic variants to complex disease pathophysiology is a major challenge in translating findings from genome-wide association studies into novel therapeutic opportunities. The difficulty lies in our limited understanding of how phenotypic traits arise from non-coding genetic variants in highly organized biological systems with heterogeneous gene expression across cells and tissues. Results We present a novel strategy, called GWAS component analysis, for transferring disease associations from single-nucleotide polymorphisms to co-expression modules by stacking models trained using reference genome and tissue-specific gene expression data. Application of this method to genome-wide association studies of blood cell counts confirmed that it could detect gene sets enriched in expected cell types. In addition, coupling of our method with Bayesian networks enables GWAS components to be used to discover drug targets. Conclusions We tested genome-wide associations of four disease phenotypes, including age-related macular degeneration, Crohn's disease, ulcerative colitis and rheumatoid arthritis, and demonstrated the proposed method could select more functional genes than S-PrediXcan, the previous single-step model for predicting gene-level associations from SNP-level associations.
C1 [Lee, Hao-Chih; Ichikawa, Osamu; Glicksberg, Benjamin S.; Divaraniya, Aparna A.; Becker, Christine E.; Dudley, Joel T.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Lee, Hao-Chih; Ichikawa, Osamu; Glicksberg, Benjamin S.; Divaraniya, Aparna A.; Becker, Christine E.; Dudley, Joel T.] Icahn Sch Med Mt Sinai, Inst Next Generat Healthcare, New York, NY 10029 USA.
   [Ichikawa, Osamu] Sumitomo Dainippon Pharma Co Ltd, Drug Res Div, Konohana Ku, 3-1-98 Kasugade Naka, Osaka 5540022, Japan.
   [Glicksberg, Benjamin S.] Icahn Sch Med Mt Sinai, Hasso Plattner Inst Digital Hlth Mt Sinai, New York, NY 10032 USA.
   [Agarwal, Pankaj] BioInfi, 1150 First Ave,Ste 501, King Of Prussia, PA 19406 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Dainippon Sumitomo Pharmaceutical Company; Icahn School of
   Medicine at Mount Sinai
RP Dudley, JT (通讯作者)，Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.; Dudley, JT (通讯作者)，Icahn Sch Med Mt Sinai, Inst Next Generat Healthcare, New York, NY 10029 USA.
EM joel.dudley@gmail.com
OI Glicksberg, Benjamin/0000-0003-4515-8090
FU GlaxoSmithKline
FX This work was supported by a Postdoctoral Fellowship from
   GlaxoSmithKline.
CR Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042
   Barbeira AN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03621-1
   Battle A, 2014, GENOME RES, V24, P14, DOI 10.1101/gr.155192.113
   Blake JA, 2003, NUCLEIC ACIDS RES, V31, P193, DOI 10.1093/nar/gkg047
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Califano A, 2012, NAT GENET, V44, P841, DOI 10.1038/ng.2355
   Charbonneau M, 2016, J IMMUNOL, V196, P3264, DOI 10.4049/jimmunol.1500502
   Clark NR, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-79
   Cohain A, 2017, BIOCOMPUT-PAC SYM, P120, DOI 10.1142/9789813207813_0013
   Cuzzocrea S, 2005, LAB INVEST, V85, P808, DOI 10.1038/labinvest.3700276
   Demenais F, 2003, HUM MOL GENET, V12, P1865, DOI 10.1093/hmg/ddg195
   Divaraniya AA, 2017, MAPPING SHARED MOL A
   Duan QN, 2016, NPJ SYST BIOL APPL, V2, DOI 10.1038/npjsba.2016.15
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Guan WH, 2008, HUM HERED, V66, P35, DOI 10.1159/000114164
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hill SM, 2016, NAT METHODS, V13, P310, DOI [10.1038/nmeth.3773, 10.1038/NMETH.3773]
   Jiao HH, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0278-0
   Jin Lv, 2014, Genomics Proteomics & Bioinformatics, V12, P210, DOI 10.1016/j.gpb.2014.10.002
   Josephs EB, 2017, GENOME BIOL EVOL, V9, P1099, DOI 10.1093/gbe/evx068
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Lamparter D, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004714
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359
   Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009
   Loh PR, 2015, NAT GENET, V47, P1385, DOI 10.1038/ng.3431
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Mahler N, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006402
   Mattiola I, 2019, NAT IMMUNOL, V20, P1012, DOI 10.1038/s41590-019-0417-y
   Miyabe Y, 2013, ARTHRITIS RHEUM-US, V65, P2037, DOI 10.1002/art.37991
   Pierson E, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004220
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Sandler C, 2006, BIOCHEM BIOPH RES CO, V347, P31, DOI 10.1016/j.bbrc.2006.06.052
   Sanyal R, 2017, IMMUNOL CELL BIOL, V95, P611, DOI 10.1038/icb.2017.18
   Shi H, 2016, AM J HUM GENET, V99, P139, DOI 10.1016/j.ajhg.2016.05.013
   Shoemaker JE, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-460
   Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447
   Timpson NJ, 2018, NAT REV GENET, V19, P110, DOI 10.1038/nrg.2017.101
   Van Limbergen J, 2009, ANNU REV GENOM HUM G, V10, P89, DOI 10.1146/annurev-genom-082908-150013
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Wang ZC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12846
   Yugi K, 2016, TRENDS BIOTECHNOL, V34, P276, DOI 10.1016/j.tibtech.2015.12.013
   Zhu J, 2004, CYTOGENET GENOME RES, V105, P363, DOI 10.1159/000078209
   Zhu J, 2008, NAT GENET, V40, P854, DOI 10.1038/ng.167
   Zhu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06805-x
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 52
TC 0
Z9 0
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-0381
J9 BIODATA MIN
JI BioData Min.
PD JUN 17
PY 2020
VL 13
IS 1
AR 6
DI 10.1186/s13040-020-00216-9
PG 15
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA MB7GR
UT WOS:000542768500001
PM 32565911
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Doguizi, S
   Sekeroglu, MA
   Inanc, M
   Anayol, MA
   Yilmazbas, P
AF Doguizi, Sibel
   Sekeroglu, Mehmet A.
   Inanc, Merve
   Anayol, Mustafa A.
   Yilmazbas, Pelin
TI Evaluation of pain during intravitreal aflibercept injections
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Intravitreal injection; Ocular pain; Visual analog scale
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; OCULAR PAIN;
   RANIBIZUMAB; DEGENERATION; BEVACIZUMAB; INFLAMMATION; ANESTHESIA;
   INTENSITY; TRIAL
AB Purpose: To evaluate the pain associated with intravitreal aflibercept injections.
   Methods: The study included 119 patients who received intravitreal aflibercept injection at a single institution. Pain was evaluated by visual analog scale (VAS) immediately after the injection of 2 mg/0.05 mL aflibercept into the vitreous cavity using a 27-G needle. Additional variables including age, sex, indication for the injection, injection site by quadrant (superotemporal or inferotemporal), position during injection (sitting or supine), number of previous intravitreal injections in the study eye, presence of diabetes mellitus or hypertension, and lens status (phakic or pseudophakic) were recorded and assessed with self-reported pain scores.
   Results: Pain scores on the VAS ranged from 9 to 70, with a median of 18. Indications for injection included diabetic macular edema (21.0%), macular edema secondary to central retinal vein occlusion (12.6%), and neovascular age-related macular degeneration (66.38%). Pain did not significantly correlate with any of the recorded variables.
   Conclusions: This is the first series evaluating the pain associated with intravitreal aflibercept injections. We demonstrated that pain associated with intravitreal aflibercept injection is generally mild with low pain scores.
C1 [Doguizi, Sibel; Sekeroglu, Mehmet A.; Inanc, Merve; Anayol, Mustafa A.; Yilmazbas, Pelin] Ulucanlar Eye Training & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
C3 Ankara Ulucanlar Eye Training & Research Hospital
RP Doguizi, S (通讯作者)，Ulucanlar Eye Training & Res Hosp, TR-O6230 Altindag Ankara, Turkey.
EM eryigits@yahoo.com
CR AMOAKU W, 2009, GUIDELINES INTRAVITR
   Balaratnasingam C, 2015, CLIN OPHTHALMOL, V9, P2355, DOI 10.2147/OPTH.S80040
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, DOI DOI 10.1016/J.OPHTHA.2010.02.021
   Cintra LP, 2009, OPHTHAL SURG LAS IM, V40, P13, DOI 10.3928/15428877-20090101-05
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Gambrell J, 2012, EXPERT OPIN DRUG DEL, V9, P731, DOI 10.1517/17425247.2012.685156
   Goldberg RA, 2014, AM J OPHTHALMOL, V158, P733, DOI 10.1016/j.ajo.2014.06.019
   Guler Mete, 2015, Korean J Ophthalmol, V29, P190, DOI 10.3341/kjo.2015.29.3.190
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Haas P, 2016, ACTA OPHTHALMOL, V94, P198, DOI 10.1111/aos.12901
   Kim Ju Young, 2015, Korean J Ophthalmol, V29, P325, DOI 10.3341/kjo.2015.29.5.325
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   Massamba N, 2015, ACTA OPHTHALMOL, V93, pe231, DOI 10.1111/aos.12531
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Moisseiev E, 2012, CURR EYE RES, V37, P813, DOI 10.3109/02713683.2012.681335
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Prenner JL, 2011, RETINA-J RET VIT DIS, V31, P433, DOI 10.1097/IAE.0b013e31820a686a
   Rifkin L, 2012, RETINA-J RET VIT DIS, V32, P696, DOI 10.1097/IAE.0b013e3182252ad3
   Sanabria MR, 2013, CURR EYE RES, V38, P278, DOI 10.3109/02713683.2012.758290
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Segal O, 2016, ACTA OPHTHALMOL, V94, P203, DOI 10.1111/aos.12802
   Souied EH, 2016, OPHTHAL EPIDEMIOL, V23, P71, DOI 10.3109/09286586.2015.1090004
   Van Asten F, 2015, RETINA-J RET VIT DIS, V35, P1778, DOI 10.1097/IAE.0000000000000550
   Yau GL, 2011, AM J OPHTHALMOL, V151, P333, DOI 10.1016/j.ajo.2010.08.031
NR 30
TC 6
Z9 6
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2018
VL 28
IS 1
BP 63
EP 67
DI 10.5301/ejo.5001001
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC5BJ
UT WOS:000429800100012
PM 28665474
DA 2022-11-30
ER

PT J
AU Abdelmoula, WM
   Shah, SM
   Fahmy, AS
AF Abdelmoula, Walid M.
   Shah, Syed M.
   Fahmy, Ahmed S.
TI Segmentation of Choroidal Neovascularization in Fundus Fluorescein
   Angiograms
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Choroidal neovascularization; fluorescein angiograms; modeling;
   segmentation; temporal intensity variation
ID MACULAR DEGENERATION; MEMBRANES
AB Choroidal neovascularization (CNV) is a common manifestation of age-related macular degeneration (AMD). It is characterized by the growth of abnormal blood vessels in the choroidal layer causing blurring and deterioration of the vision. In late stages, these abnormal vessels can rupture the retinal layers causing complete loss of vision at the affected regions. Determining the CNV size and type in fluorescein angiograms is required for proper treatment and prognosis of the disease. Computer-aided methods for CNV segmentation is needed not only to reduce the burden of manual segmentation but also to reduce inter- and intraobserver variability. In this paper, we present a framework for segmenting CNV lesions based on parametric modeling of the intensity variation in fundus fluorescein angiograms. First, a novel model is proposed to describe the temporal intensity variation at each pixel in image sequences acquired by fluorescein angiography. The set of model parameters at each pixel are used to segment the image into regions of homogeneous parameters. Preliminary results on datasets from 21 patients with Wet-AMD show the potential of the method to segment CNV lesions in close agreement with the manual segmentation.
C1 [Abdelmoula, Walid M.; Fahmy, Ahmed S.] Nile Univ, Ctr Informat Sci, Cairo 12677, Egypt.
   [Shah, Syed M.] Univ Rochester, Flaum Eye Inst, New York, NY 14611 USA.
   [Fahmy, Ahmed S.] Cairo Univ, Dept Syst & Biomed Engn, Cairo 11559, Egypt.
C3 Egyptian Knowledge Bank (EKB); Nile University; University of Rochester;
   Egyptian Knowledge Bank (EKB); Cairo University
RP Fahmy, AS (通讯作者)，Nile Univ, Ctr Informat Sci, Cairo 12677, Egypt.
EM walid.abdelmoula@nileu.edu.eg; mahmood@abbottabad.net;
   asfahmy@nileuniversity.edu.eg
RI Abdelmoula, Walid/S-7328-2019; Fahmy, Ahmed S/K-5314-2019; Fahmy, Ahmed
   S/R-1361-2017
OI Abdelmoula, Walid/0000-0003-3117-7389
CR ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552
   Berger JW, 2000, INVEST OPHTH VIS SCI, V41, P2286
   Brankin E, 2008, 2008 INTERNATIONAL MACHINE VISION AND IMAGE PROCESSING CONFERENCE, PROCEEDINGS, P165, DOI 10.1109/IMVIP.2008.30
   Brankin E, 2006, COMP MED SY, P430, DOI 10.1109/CBMS.2006.157
   Campochiaro B., 2008, PROGR REPORT GENETIC
   DAVENPORT R, 1983, J NUCL MED, V24, P945
   Duda R.O., 1973, PATTERN CLASSIFICATI, VXVII, P482
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Hipwell JH, 1998, PHYSIOL MEAS, V19, P165, DOI 10.1088/0967-3334/19/2/004
   Holz F. G., 2004, MED RETINA
   Masters T., 1993, PRACTICAL NN RECIPES
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shah SM, 2006, INVEST OPHTH VIS SCI, V47, P5460, DOI 10.1167/iovs.06-0012
   Takerkart S, 2008, I S BIOMED IMAGING, P1457, DOI 10.1109/ISBI.2008.4541282
   Tsai CL, 2011, INVEST OPHTH VIS SCI, V52, P2767, DOI 10.1167/iovs.10-6048
   Tsai CL, 2010, IEEE T MED IMAGING, V29, P636, DOI 10.1109/TMI.2009.2030324
   VANSTOKKUM IHM, 1995, GRAEF ARCH CLIN EXP, V233, P123, DOI 10.1007/BF00166603
NR 17
TC 12
Z9 12
U1 0
U2 8
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
EI 1558-2531
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD MAY
PY 2013
VL 60
IS 5
BP 1439
EP 1445
DI 10.1109/TBME.2013.2237906
PG 7
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 133SP
UT WOS:000318160500031
PM 23314765
DA 2022-11-30
ER

PT J
AU Luo, L
   Zhang, XH
   Hirano, Y
   Tyagi, P
   Barabas, P
   Uehara, H
   Miya, TR
   Singh, N
   Archer, B
   Qazi, Y
   Jackman, K
   Das, SK
   Olsen, T
   Chennamaneni, SR
   Stagg, BC
   Ahmed, F
   Emerson, L
   Zygmunt, K
   Whitaker, R
   Mamalis, C
   Huang, W
   Gao, GP
   Srinivas, SP
   Krizaj, D
   Baffi, J
   Ambati, J
   Kompella, UB
   Ambati, BK
AF Luo, Ling
   Zhang, Xiaohui
   Hirano, Yoshio
   Tyagi, Puneet
   Barabas, Peter
   Uehara, Hironori
   Miya, Tadashi R.
   Singh, Nirbhai
   Archer, Bonnie
   Qazi, Yureeda
   Jackman, Kyle
   Das, Subrata K.
   Olsen, Thomas
   Chennamaneni, Srinivas R.
   Stagg, Brian C.
   Ahmed, Faisal
   Emerson, Lyska
   Zygmunt, Kristen
   Whitaker, Ross
   Mamalis, Christina
   Huang, Wei
   Gao, Guangping
   Srinivas, Sangly P.
   Krizaj, David
   Baffi, Judit
   Ambati, Jayakrishna
   Kompella, Uday B.
   Ambati, Balamurali K.
TI Targeted Intraceptor Nanoparticle Therapy Reduces Angiogenesis and
   Fibrosis in Primate and Murine Macular Degeneration
SO ACS NANO
LA English
DT Article
DE nanoparticles; gene delivery; choroidal neovascularization models;
   anti-VEGF therapy; angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; SURVIVAL
   FACTOR; RGD PEPTIDE; RANIBIZUMAB; INHIBITION; EXPRESSION; DELIVERY;
   CELLS; VEGF
AB Monthly intraocular injections are widely used to deliver protein-based drugs that cannot cross the blood-retina barrier for the treatment of leading blinding diseases such as age-related macular degeneration (AMD). This invasive treatment carries significant risks, including bleeding, pain, infection, and retinal detachment. Further, current therapies are associated with a rate of retinal fibrosis and geographic atrophy significantly higher than that which occurs in the described natural history of AMD. A novel therapeutic strategy which improves outcomes in a less invasive manner, reduces risk, and provides long-term inhibition of angiogenesis and fibrosis is a felt medical need. Here we show that a single intravenous Injection of targeted, biodegradable nanoparticles delivering a recombinant Flt23k intraceptor plasmid homes to neovascular lesions in the retina and regresses (NV in primate and murine AMD models. Moreover, this treatment suppressed subretinal fibrosis, which is currently not addressed by clinical therapies. Murine vision, as tested by OptoMotry, significantly improved with nearly 40% restoration of visual loss induced by (NV. We found no evidence of ocular or systemic toxicity from nanopartide treatment These findings offer a nanoparticle-based platform for targeted, vitreous-sparing, extended-release, nonviral gene therapy.
C1 [Luo, Ling; Zhang, Xiaohui; Barabas, Peter; Uehara, Hironori; Miya, Tadashi R.; Singh, Nirbhai; Archer, Bonnie; Qazi, Yureeda; Jackman, Kyle; Das, Subrata K.; Olsen, Thomas; Chennamaneni, Srinivas R.; Stagg, Brian C.; Ahmed, Faisal; Mamalis, Christina; Huang, Wei; Krizaj, David; Ambati, Balamurali K.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Luo, Ling] 306th Hosp PLA, Dept Ophthalmol, Beijing 100101, Peoples R China.
   [Hirano, Yoshio; Baffi, Judit; Ambati, Jayakrishna] Univ Kentucky, Dept Ophthalmol & Visual Sci, Lexington, KY 40536 USA.
   [Tyagi, Puneet; Kompella, Uday B.] Univ Colorado Denver, Skaggs Sch Pharm, Aurora, CO 80262 USA.
   [Emerson, Lyska] Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA.
   [Zygmunt, Kristen; Whitaker, Ross] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT 84132 USA.
   [Gao, Guangping] Univ Massachusetts, Gene Therapy Ctr, Worcester, MA 01605 USA.
   [Srinivas, Sangly P.] Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
C3 Utah System of Higher Education; University of Utah; University of
   Kentucky; Children's Hospital Colorado; University of Colorado System;
   University of Colorado Anschutz Medical Campus; Utah System of Higher
   Education; University of Utah; Utah System of Higher Education;
   University of Utah; University of Massachusetts System; University of
   Massachusetts Worcester; Indiana University System; Indiana University
   Bloomington
RP Ambati, BK (通讯作者)，Univ Utah, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
EM bala.ambati@utah.edu
RI srinivas, sangly/M-1223-2019; Krrr, Daa/ABG-2688-2020; Barabas,
   Peter/AAL-5650-2020
OI Krrr, Daa/0000-0003-4468-3029; Barabas, Peter/0000-0002-8166-3476; DAS,
   SUBRATA/0000-0001-8608-3270; Stagg, Brian/0000-0003-4023-1885; Ahmed,
   Faisal/0000-0003-1294-5274; Hirano, Yoshio/0000-0002-9173-0839
FU National Institutes for Health [NEI 5R01EY017182-04, ER01EY017950-03,
   P20 RR024215]; VAMerit Award; Foundation Fighting Blindness; NIH/NCRR
   Center for Integrative Biomedical Computing [2P41 RR0112553-12]; 
   [EY13870]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024215] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY022238, R01EY022076,
   P30EY014800, R01EY017182, R01EY013870, R01EY017950] Funding Source: NIH
   RePORTER
FX We thank Dr. W. Baehr for thoughtful discussions and critical reading of
   the manuscript. We also thank Dr. R. Marc, J. Ahmed and J. Anderson for
   technical support. This work was made possible by funding from the
   National Institutes for Health (NEI 5R01EY017182-04, ER01EY017950-03,
   P20 RR024215), VAMerit Award. This work is also made in part by EY13870
   and The Foundation Fighting Blindness; and software from the NIH/NCRR
   Center for Integrative Biomedical Computing (2P41 RR0112553-12).
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Amrite AC, 2008, MOL VIS, V14, P150
   Bellerive C, 2012, CAN J OPHTHALMOL, V47, P165, DOI 10.1016/j.jcjo.2012.01.011
   Bhisitkul R., 2011, 2011 UCSF OPHTHALMOL
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Cho YK, 2012, INVEST OPHTH VIS SCI, V53, P2328, DOI 10.1167/iovs.11-8393
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Furino C, 2009, J CATARACT REFR SURG, V35, P1518, DOI 10.1016/j.jcrs.2009.04.032
   Gailit J, 1997, EXP CELL RES, V232, P118, DOI 10.1006/excr.1997.3512
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Halbert CL, 2006, HUM GENE THER, V17, P440, DOI 10.1089/hum.2006.17.440
   Hsieh WJ, 2012, INT J NANOMED, V7, P2833, DOI 10.2147/IJN.S32154
   Jackson TL, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5058
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jani PD, 2007, INVEST OPHTH VIS SCI, V48, P2030, DOI 10.1167/iovs.06-0853
   Kotoh K, 2004, INT J MOL MED, V14, P1049
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   NOMURA M, 1995, J BIOL CHEM, V270, P28316
   Pascolini D, 2002, OPHTHAL EPIDEMIOL, V2004, P67
   Qazi Y, 2012, INVEST OPHTH VIS SCI, V53, P2837, DOI 10.1167/iovs.11-9139
   Quaggin SE, 2012, J CLIN INVEST, V122, P3849, DOI 10.1172/JCI65509
   Redfern WS, 2011, J PHARMACOL TOXICOL, V63, P102, DOI 10.1016/j.vascn.2010.06.008
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ruggeri M, 2009, OPT EXPRESS, V17, P4074, DOI 10.1364/OE.17.004074
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD-2003-05-1634
   Schmucker C, 2004, VISION RES, V44, P1857, DOI 10.1016/j.visres.2004.03.011
   Singh N, 2005, INVEST OPHTH VIS SCI, V46, P1647, DOI 10.1167/iovs.04-1172
   Singh N, 2006, INVEST OPHTH VIS SCI, V47, P4787, DOI 10.1167/iovs.06-0419
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066
   Tweden K S, 1995, J Heart Valve Dis, V4 Suppl 1, pS90
   Vasir JK, 2008, BIOMATERIALS, V29, P4244, DOI 10.1016/j.biomaterials.2008.07.020
   Wang LS, 2006, WORLD J GASTROENTERO, V12, P1303, DOI 10.3748/wjg.v12.i8.1303
   Xu XD, 2010, ACS APPL MATER INTER, V2, P2663, DOI 10.1021/am100484c
   Zahn G, 2009, ARCH OPHTHALMOL-CHIC, V127, P1329, DOI 10.1001/archophthalmol.2009.265
NR 50
TC 62
Z9 64
U1 2
U2 81
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD APR
PY 2013
VL 7
IS 4
BP 3264
EP 3275
DI 10.1021/nn305958y
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 133MU
UT WOS:000318143300041
PM 23464925
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Benhar, I
   London, A
   Schwartz, M
AF Benhar, Inbal
   London, Anat
   Schwartz, Michal
TI The privileged immunity of immune privileged organs: the case of the eye
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE immune privilege; visual system; immunomodulation; neuroprotection and
   neuronal repair; inflammation
AB Understanding of ocular diseases and the search for their cure have been based on the common assumption that the eye is an immune privileged site, and the consequent conclusion that entry of immune cells to this organ is forbidden. Accordingly, it was assumed that when immune cell entry does occur, this reflects an undesired outcome of breached barriers. However, studies spanning more than a decade have demonstrated that acute insults to the retina, or chronic conditions resulting in retinal ganglion cell loss, such as in glaucoma, result in an inferior outcome in immunocompromised mice; likewise, steroidal treatment was found to be detrimental under these conditions. Moreover, even conditions that are associated with inflammation, such as age-related macular degeneration, are not currently believed to require immune suppression for treatment, but rather, are thought to benefit from immune modulation. Here, we propose that the immune privilege of the eye is its ability to enable, upon need, the entry of selected immune cells for its repair and healing, rather than to altogether prevent immune cell entry. The implications for acute and chronic degenerative diseases, as well as for infection and inflammatory diseases, are discussed.
C1 [Benhar, Inbal; London, Anat; Schwartz, Michal] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.
C3 Weizmann Institute of Science
RP Schwartz, M (通讯作者)，Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.
EM michal.schwartz@weizmann.ac.il
FU Glaucoma Foundation; European Research Council (ERG) Advanced Grant
FX We thank Dr. Shelley Schwarzbaum for editing the manuscript. This work
   was funded in part by The Glaucoma Foundation and the European Research
   Council (ERG) Advanced Grant given to Michal Schwartz.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075
   Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557
   Bakalash S, 2003, INVEST OPHTH VIS SCI, V44, P3374, DOI 10.1167/iovs.03-0080
   Bakalash S, 2002, INVEST OPHTH VIS SCI, V43, P2648
   Butovsky O, 2007, EUR J NEUROSCI, V26, P413, DOI 10.1111/j.1460-9568.2007.05652.x
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785
   Caspi R, 2011, J IMMUNOL, V186
   CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097
   Cui Q, 2009, NEUROSCIENCE, V158, P1039, DOI 10.1016/j.neuroscience.2008.07.036
   DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T
   Dimitriu C, 2008, INVEST OPHTH VIS SCI, V49, P5003, DOI 10.1167/iovs.08-1869
   DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001
   Fitch MT, 1999, J NEUROSCI, V19, P8182
   Frank M, 1996, GLIA, V16, P227, DOI 10.1002/(SICI)1098-1136(199603)16:3<227::AID-GLIA5>3.0.CO;2-Z
   Gee JM, 2008, STROKE, V39, P1575, DOI 10.1161/STROKEAHA.107.501486
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Ghirnikar RS, 2001, J NEUROSCI RES, V64, P582, DOI 10.1002/jnr.1110
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Gronert K, 2010, EXP EYE RES, V91, P478, DOI 10.1016/j.exer.2010.07.004
   KAPLAN HJ, 1975, J IMMUNOL, V115, P805
   Kerr EC, 2008, J AUTOIMMUN, V31, P354, DOI 10.1016/j.jaut.2008.08.006
   Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009
   Kipnis J, 2004, J NEUROSCI, V24, P6133, DOI 10.1523/JNEUROSCI.0600-04.2004
   Kipnis J, 2002, P NATL ACAD SCI USA, V99, P15620, DOI 10.1073/pnas.232565399
   Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564
   LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043
   Levin LA, 1999, OPHTHALMOLOGY, V106, P1268, DOI 10.1016/S0161-6420(99)00707-1
   Li XY, 1997, OCUL IMMUNOL INFLAMM, V5, P245, DOI 10.3109/09273949709085065
   London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202
   MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58
   Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734
   MORRISON RP, 1989, J EXP MED, V169, P663, DOI 10.1084/jem.169.3.663
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   NIEDERKORN J Y, 1991, Eye (London), V5, P186
   Niederkorn JY, 2010, OCUL IMMUNOL INFLAMM, V18, P19, DOI 10.3109/09273940903564766
   Niederkorn JY, 2006, NAT IMMUNOL, V7, P354, DOI 10.1038/ni1328
   O'Shea John J, 2008, Nat Immunol, V9, P450, DOI 10.1038/ni0508-450
   Ohlsson M, 2004, J NEURO-OPHTHALMOL, V24, P11, DOI 10.1097/00041327-200403000-00003
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118
   Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923
   Robertson MJ, 2002, INVEST OPHTH VIS SCI, V43, P2250
   Rolls A, 2009, NAT REV NEUROSCI, V10, P235, DOI 10.1038/nrn2591
   Saint Andre AV, 2002, SCIENCE, V295, P1892, DOI 10.1126/science.1068732
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schewitz-Bowers LP, 2010, EXPERT REV OPHTHALMO, V5, P43, DOI 10.1586/EOP.09.68
   Schori H, 2001, J NEUROIMMUNOL, V119, P199, DOI 10.1016/S0165-5728(01)00358-7
   Schwartz M, 2009, NEUROSCIENCE, V158, P1133, DOI 10.1016/j.neuroscience.2008.12.013
   Schwartz M, 2010, NAT REV NEUROL, V6, P405, DOI 10.1038/nrneurol.2010.71
   Serpe CJ, 1999, J NEUROSCI, V19
   Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113
   Solberg Y, 1999, SURV OPHTHALMOL, V44, pS85, DOI 10.1016/S0039-6257(99)00093-4
   Stirling DP, 2009, J NEUROSCI, V29, P753, DOI 10.1523/JNEUROSCI.4918-08.2009
   Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6
   Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701
   Yin YQ, 2009, P NATL ACAD SCI USA, V106, P19587, DOI 10.1073/pnas.0907085106
   Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001
   Zhou R, 2012, J IMMUNOL, V188, P1742, DOI 10.4049/jimmunol.1102415
   Zhu B, 2011, J IMMUNOL, V187, P2418, DOI 10.4049/jimmunol.1100403
NR 68
TC 73
Z9 74
U1 1
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PY 2012
VL 3
AR 296
DI 10.3389/fimmu.2012.00296
PG 6
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA V40TQ
UT WOS:000209501300291
PM 23049533
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Johnson, M
   Rudolf, M
   Huang, JD
AF Curcio, Christine A.
   Johnson, Mark
   Rudolf, Martin
   Huang, Jiahn-Dar
TI The oil spill in ageing Bruch membrane
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; TRIGLYCERIDE TRANSFER PROTEIN; OPTICAL
   COHERENCE TOMOGRAPHY; LIPOPROTEIN-LIKE PARTICLES;
   LOW-DENSITY-LIPOPROTEIN; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; CHOLESTERYL ESTERS; APOLIPOPROTEIN-B; HYDRAULIC
   CONDUCTIVITY
AB Ageing is the largest risk factor for age-related macular degeneration (AMD), and soft drusen and basal linear deposits are lipid-rich extracellular lesions specific to AMD. Oil red O binding neutral lipid represents a major age-related deposition in the Bruch membrane (BrM) and the first identified druse component. Decades after these seminal observations, a natural history of neutral lipid deposition has been articulated and a biochemical model proposed. Results obtained with multiple biochemical, histochemical, and ultrastructural methods, and supported indirectly by epidemiology, suggest that the RPE secretes apolipoprotein B (apoB)-lipoprotein particles of unusual composition into BrM, where they accumulate with age eventually forming a lipid wall, a precursor of basal linear deposit. The authors propose that constituents of these lesions interact with reactive oxygen species to form pro-inflammatory peroxidised lipids that elicit neovascularisation. Here, the authors summarise key evidence supporting both accumulation of BrM lipoproteins leading to lesion formation and lipoprotein production by the RPE. The authors update their model with genetic associations between AMD and genes historically associated with plasma HDL metabolism, and suggest future directions for research and therapeutic strategies based on an oil-spill analogy.
C1 [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, EyeSight Fdn Alabama Vis Sci Labs, Sch Med, Birmingham, AL 35294 USA.
   [Johnson, Mark] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Rudolf, Martin] Univ Klinikum Schleswig Holstein, Dept Ophthalmol, D-23538 Lubeck, Germany.
   [Rudolf, Martin] Univ Eye Hosp Lubeck, Lubeck, Germany.
   [Huang, Jiahn-Dar] NEI, NIH, Bethesda, MD 20892 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   Northwestern University; University of Kiel; Schleswig Holstein
   University Hospital; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol, EyeSight Fdn Alabama Vis Sci Labs, Sch Med, Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Johnson, Mark/B-6921-2009
FU NIH [EY06109, EY014662]; International Retinal Research Foundation;
   American Health Assistance Foundation; EyeSight Foundation of Alabama;
   Research to Prevent Blindness, Inc.; Macula Vision Research Foundation;
   Roger Johnson Prize in Macular Degeneration Research; Deutsche
   Forschungsgemeinschaft; NATIONAL EYE INSTITUTE [R01EY006109,
   R01EY014662] Funding Source: NIH RePORTER
FX NIH grants EY06109 and EY014662, International Retinal Research
   Foundation, American Health Assistance Foundation, EyeSight Foundation
   of Alabama, Research to Prevent Blindness, Inc., Macula Vision Research
   Foundation, Roger Johnson Prize in Macular Degeneration Research, and
   Deutsche Forschungsgemeinschaft.
CR Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Brown JM, 2010, CURR OPIN LIPIDOL, V21, P192, DOI 10.1097/MOL.0b013e32833854ac
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chowers I, 2001, EYE, V15, P525, DOI 10.1038/eye.2001.167
   Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013
   Contois JH, 2009, CLIN CHEM, V55, P407, DOI 10.1373/clinchem.2008.118356
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Funatsu T, 2001, ATHEROSCLEROSIS, V157, P107, DOI 10.1016/S0021-9150(00)00714-0
   Garcia-Garcia HM, 2009, HEART, V95, P1362, DOI 10.1136/hrt.2008.151159
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Hodge AM, 2005, EFFECTS OMEGA 3 FATT
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Koh AS, 2010, ANN ACAD MED SINGAP, V39, P203
   Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Matter CM, 2009, EUR HEART J, V30, P2566, DOI 10.1093/eurheartj/ehp419
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Miller YI, 2003, CURR OPIN LIPIDOL, V14, P437, DOI 10.1097/00041433-200310000-00004
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Peponis V, 2010, CLIN OPHTHALMOL, V4, P865
   Provost AC, 2009, INVEST OPHTH VIS SCI, V50, P3931, DOI 10.1167/iovs.08-2527
   Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679
   Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576
   Ruberg FL, 2006, J LIPID RES, V47, P310, DOI 10.1194/jlr.M500431-JLR200
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2010, INVEST OPHTH VIS SCI, V51
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Samuel W, 2001, J BIOL CHEM, V276, P28744, DOI 10.1074/jbc.M103587200
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Shoulders CC, 2005, CURR TOP MED CHEM, V5, P283, DOI 10.2174/1568026053544560
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Thomas T, 2010, CURR ATHEROSCLER REP, V12, P58, DOI 10.1007/s11883-009-0078-7
   Tomoda H, 2007, PHARMACOL THERAPEUT, V115, P375, DOI 10.1016/j.pharmthera.2007.05.008
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Upston JM, 2002, AM J PATHOL, V160, P701, DOI 10.1016/S0002-9440(10)64890-0
   Van Lenten BJ, 2009, CURR ATHEROSCLER REP, V11, P52, DOI 10.1007/s11883-009-0008-8
   Vance DE, 2002, BIOCH LIPIDS LIPOPRO
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wierzbicki AS, 2009, CURR VASC PHARMACOL, V7, P277, DOI 10.2174/157016109788340703
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Zarbin MA, 2010, AM J OPHTHALMOL, V150, P144, DOI 10.1016/j.ajo.2010.03.019
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 107
TC 232
Z9 238
U1 0
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2011
VL 95
IS 12
BP 1638
EP 1645
DI 10.1136/bjophthalmol-2011-300344
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 851IM
UT WOS:000297261700005
PM 21890786
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lyzogubov, VV
   Tytarenko, RG
   Liu, J
   Bora, NS
   Bora, PS
AF Lyzogubov, Valeriy V.
   Tytarenko, Ruslana G.
   Liu, Juan
   Bora, Nalini S.
   Bora, Puran S.
TI Polyethylene Glycol (PEG)-induced Mouse Model of Choroidal
   Neovascularization
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID COMPLEMENT MEMBRANE ATTACK; GROWTH-FACTOR SECRETION; MACULAR
   DEGENERATION; ALTERNATIVE PATHWAY; FACTOR-H; TARGETED INHIBITOR;
   ACTIVATION; VEGF; CELLS; RPE
AB In this study, we describe a new method for inducing choroidal neovascularization (CNV) in C57BL/6 mice, an animal model of wet age-related macular degeneration (AMD). AMD is a disease that causes central blindness in humans. We injected PEG-8 subretinally in different doses (0.125-2 mg) to induce CNV. After PEG-8 injection, we examined CNV at several time points (days 3-42). We also used Western blotting, immunohistochemistry, and ELISA to examine the complement component C3 split products, C9, VEGF, TGF-beta 2, and basic FGF. As early as day 1 after treatment, we found that a single subretinal injection of 1 mg of PEG-8 increased the C3 split products and the C9, TGF-beta 2, and basic FGF levels in the retinal pigment epithelium-choroid tissue. By day 3 after PEG-8 injection, the intraocular activation of the complement system caused induction and progression of CNV, including new vessels penetrating the Bruch's membrane. At day 5 after PEG-8 injection, we observed a fully developed CNV and retinal degeneration. Thus, in this study, we present a new, inexpensive, and accelerated mouse model of CNV that may be useful to study AMD.
C1 [Lyzogubov, Valeriy V.; Tytarenko, Ruslana G.; Liu, Juan; Bora, Nalini S.; Bora, Puran S.] Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Pat & Willard Walker Eye Res Ctr, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Bora, PS (通讯作者)，Univ Arkansas Med Sci, Dept Ophthalmol, Jones Eye Inst, Pat & Willard Walker Eye Res Ctr, 4301 W Markham St,Slot 523-7, Little Rock, AR 72205 USA.
EM pbora@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU University of Arkansas for Medical Sciences; Pat and Willard Walker Eye
   Research Center
FX This work was supported in part by grants from the University of
   Arkansas for Medical Sciences and the Pat and Willard Walker Eye
   Research Center.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2006, INT J TOXICOL, V25, P121, DOI 10.1080/10915810600964642
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   ELIZABETH RP, 2006, EXP EYE RES, V82, P741, DOI DOI 10.1016/J.EXER.2005.10.012
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   Hamada I, 2008, MOL IMMUNOL, V46, P225, DOI 10.1016/j.molimm.2008.08.276
   Huang YX, 2008, J IMMUNOL, V181, P8068, DOI 10.4049/jimmunol.181.11.8068
   Itaya M, 2007, INVEST OPHTH VIS SCI, V48, P5677, DOI 10.1167/iovs.07-0156
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Li WB, 2010, MED SCI MONITOR, V16, pBR17
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Moghimi SM, 2006, J LIPOSOME RES, V16, P167, DOI 10.1080/08982100600848801
   Montezuma SR, 2009, SEMIN OPHTHALMOL, V24, P52, DOI 10.1080/08820530902800017
   MORGAN BP, 1989, BIOCHEM J, V264, P1
   Palarasah Y, 2010, J IMMUNOL METHODS, V362, P142, DOI 10.1016/j.jim.2010.09.024
   Pawliuk R., 2001, WIPO Patent Application, Patent No. [WO/2001/087312, 2001087312]
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Shen WY, 2001, ANTISENSE NUCLEIC A, V11, P257, DOI 10.1089/108729001317022250
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0
   YAMAOKA T, 1995, J PHARM SCI, V84, P349, DOI 10.1002/jps.2600840316
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao L, 2007, MOL VIS, V13, P873
NR 39
TC 39
Z9 41
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 6
PY 2011
VL 286
IS 18
DI 10.1074/jbc.M110.204701
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 756ON
UT WOS:000290022800062
PM 21454496
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Krohne, TU
   Eter, N
   Holz, FG
   Meyer, CH
AF Krohne, Tim U.
   Eter, Nicole
   Holz, Frank G.
   Meyer, Carsten H.
TI Intraocular pharmacokinetics of bevacizumab after a single intravitreal
   injection in humans
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC MACULAR EDEMA; ENDOTHELIAL GROWTH-FACTOR; RETINAL VEIN
   OCCLUSION; TRIAMCINOLONE ACETONIDE; AVASTIN THERAPY; DEGENERATION;
   TRIAL; EYES
AB PURPOSE: To investigate intraocular concentrations and pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
   DESIGN: Prospective, noncomparative, interventional case series.
   METHODS: We included 30 nonvitrectomized eyes of 30 patients (age range, 43 to 93 years) diagnosed with clinically significant cataract and concurrent macular edema secondary to neovascular age-related macular degeneration, diabetic retinopathy, or retinal venous occlusion in the same eye. All patients received an intravitreal injection of 1.5 mg bevacizumab. Between one and 53 days after injection, an aqueous humor sample was obtained during elective cataract surgery. Concentrations of unbound bevacizumab in these samples were quantified by enzyme-linked immunosorbent assay.
   RESULTS: Concentration of bevacizumab in aqueous humor peaked on the first day after injection with a mean concentration (c(max)) of 33.3 mu g/ml (range, 16.6 to 42.5 mu g/ml) and subsequently declined in a monoexponential fashion. Nonlinear regression analysis determined an elimination half-time (t(1/2)) of 9.82 days (R-2 = 0.81). No significant differences between diagnosis subgroups were noted.
   CONCLUSIONS: In human nonvitrectomized eyes, the aqueous half-life of 1.5 mg intravitreally injected bevacizumab is 9.82 days.
C1 [Krohne, Tim U.; Eter, Nicole; Holz, Frank G.; Meyer, Carsten H.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
C3 University of Bonn
RP Meyer, CH (通讯作者)，Univ Eye Hosp, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM carsten_h.meyer@ukb.uni-bonn.de
RI Krohne, Tim/D-1497-2013; Krohne, Tim/AAG-4412-2020; Meyer,
   Carsten/A-3981-2017
OI Krohne, Tim/0000-0003-2280-925X; Meyer, Carsten/0000-0002-0530-5298
FU GERMAN RESEARCH COUNCIL (DFG) PRIORITY PROGRAMME [1926/2-2]; Bonn
   University BONFOR Program
FX THIS STUDY WAS SUPPORTED BY GERMAN RESEARCH COUNCIL (DFG) PRIORITY
   PROGRAMME "AGE-RELATED MACULAR Degeneration," (SPP 1088), Grant Ho
   1926/2-2; and Bonn University BONFOR Program, Gerok Fellowship (Dr
   Krohne). The authors indicate no financial conflict of interest.
   Involved in design and conduct of study (T.U.K., C.H.M.); selection,
   treatment, and sampling of patients (ICE., F.G.H., C.H.M.); analysis of
   samples and statistical evaluation of the data (T.U.K., C.H.M.);
   interpretation of the data (T.U.K., N.E., F.G.H., C.H.M.); and
   preparation, review, and approval of the manuscript (T.U.K., N.E.,
   F.G.H., C.H.M.). The study and data accumulation were carried out with
   approval from the Institutional Review Board of the University of Bonn.
   Informed consent was obtained from the patients. The authors thank
   Claudine Strack for expert technical assistance. The article will he
   presented at the Gonin Club 2008 in St Moritz, Switzerland.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   *EMEA, AV BEV SCI DISC
   *EMEA, LUC RAN SUMM PROD CH
   European Medicines Agency (EMEA), LUC RAN SCI DISC
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jaissle GB, 2006, OPHTHALMOLOGE, V103, P471, DOI 10.1007/s00347-006-1355-2
   Jaissle GB, 2005, KLIN MONATSBL AUGENH, V222, P390, DOI 10.1055/s-2005-858231
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Priglinger SG, 2007, RETINA-J RET VIT DIS, V27, P1004, DOI 10.1097/IAE.0b013e3180ed458d
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
NR 20
TC 265
Z9 274
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2008
VL 146
IS 4
BP 508
EP 512
DI 10.1016/j.ajo.2008.05.036
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 355XH
UT WOS:000259742200006
PM 18635152
DA 2022-11-30
ER

PT J
AU Wang, Z
   Dillon, J
   Gaillard, ER
AF Wang, Z
   Dillon, J
   Gaillard, ER
TI Antioxidant properties of melanin in retinal pigment epithelial cells
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID LIGHT-INDUCED DAMAGE; AGE-RELATED-CHANGES; LIPOFUSCIN FLUOROPHORE;
   MACULAR DEGENERATION; HUMAN RPE; A2E; OXIDATION; COMPONENT;
   ACCUMULATION; FLUORESCENCE
AB The retinal pigment epithelium (RPE) is a monolayer of highly pigmented cells lining the inner aspect of Bruch's membrane. This pigmentation is due to eumelanin and a possible antioxidant role of melanin is reported here. The photo-oxidation of A2E, a constituent of RPE lipofuscin, leads to the sequential addition of up to nine oxygen atoms and/or the addition or loss of two hydrogen atoms. These photo-oxidations were investigated in the presence and absence of either calf or human RPE melanin in A2E-laden RPE cells. It was found that calf melanin was protective against the photo-oxidation of A2E, with an inhibition of oxidation of up to 50% in the case of the addition of two oxygen atoms. Calf melanin was also protective against blue light-induced damage to RPE cells. In addition this ability appears to decrease in humans as they grow older. With aging, a melanin-lipofuscin complex called melanolipofuscin forms. It is suggested that the oxidation or photo-oxidation of A2E in vivo may contribute to the age-related deterioration of the anti-oxidant role of RPE melanin and lead to various retinal disorders, such as age-related macular degeneration.
C1 No Illinois Univ, De Kalb, IL 60115 USA.
   Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Northern Illinois University; Columbia University
RP Gaillard, ER (通讯作者)，No Illinois Univ, De Kalb, IL 60115 USA.
EM gaillard@niu.edu
RI Gaillard, Elizabeth/M-2627-2019
FU NATIONAL EYE INSTITUTE [R01EY012344] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY12344] Funding Source: Medline
CR Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Carr RE, 1979, RETINAL PIGMENT EPIT, P413
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   DUNFORD R, 1995, FREE RADICAL BIO MED, V19, P735, DOI 10.1016/0891-5849(95)00059-7
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1982, METHOD ENZYMOL, V81, P95
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gaillard ER, 2004, EXP EYE RES, V79, P313, DOI 10.1016/j.exer.2004.05.005
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Green W R, 1999, Mol Vis, V5, P27
   HAYASAKA S, 1989, JPN J OPHTHALMOL, V33, P36
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   KATZ ML, 1978, INVEST OPHTH VIS SCI, V17, P1049
   KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   KOLLIAS N, 1991, J PHOTOCH PHOTOBIO B, V9, P135, DOI 10.1016/1011-1344(91)80147-A
   KORYTOWSKI W, 1995, ARCH BIOCHEM BIOPHYS, V319, P142, DOI 10.1006/abbi.1995.1276
   LAVAIL MM, 1975, J HERED, V66, P242, DOI 10.1093/oxfordjournals.jhered.a108621
   MASON HS, 1960, ARCH BIOCHEM BIOPHYS, V86, P225, DOI 10.1016/0003-9861(60)90409-4
   MCGINNESS J, 1974, SCIENCE, V183, P853, DOI 10.1126/science.183.4127.853
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   PARISH EJ, 1998, RRD ORG CHEM 1, V2, P95
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   SARNA T, 1985, PHOTOCHEM PHOTOBIOL, V42, P529, DOI 10.1111/j.1751-1097.1985.tb01605.x
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   SCHRAERMEYER U, 1994, CELL TISSUE RES, V276, P273, DOI 10.1007/BF00306113
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STROVSKY MA, 1987, VISION RES, V27, P893
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Winkler BS, 1999, MOL VIS, V5
NR 49
TC 90
Z9 101
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD MAR-APR
PY 2006
VL 82
IS 2
BP 474
EP 479
DI 10.1562/2005-10-21-RA-725
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 036CK
UT WOS:000237048300020
PM 16613501
DA 2022-11-30
ER

PT J
AU Klenotic, PA
   Munier, FL
   Marmorstein, LY
   Anand-Apte, B
AF Klenotic, PA
   Munier, FL
   Marmorstein, LY
   Anand-Apte, B
TI Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner
   of epithelial growth factor-containing fibulin-like extracellular matrix
   protein 1 (EFEMP1) - Implications for macular degenerations
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SORSBYS-FUNDUS-DYSTROPHY; MUTATION; EXPRESSION; LOCALIZATION;
   ANGIOGENESIS; ACCUMULATION; PHENOTYPE; GENE
AB Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a matrix-bound inhibitor of matrix metalloproteinases. Mutations in the Timp-3 gene cause Sorsby fundus dystrophy (SFD), a hereditary macular degenerative disease. The pathogenic mechanisms responsible for the disease phenotype are unknown. In an in vivo quest for binding partners of the TIMP-3 protein in the subretina, we identified epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1, also known as fibulin 3) as a strong interacting protein. The COOH-terminal end of TIMP-3 was involved in the interaction. Interestingly, a missense mutation in EFEMP1 is responsible for another hereditary macular degenerative disease, Malattia Leventinese (ML). Both SFD and ML have strong similarities to age-related macular degeneration (AMD), a major cause of blindness in the elderly population of the Western hemisphere. Our results were supported by significant accumulation and expression overlap of both TIMP-3 and EFEMP1 between the retinal pigment epithelia and Bruch membrane in the eyes of ML and AMD patients. These results provide the first link between two different macular degenerative disease genes and imply the possibility of a common pathogenic mechanism behind different forms of macular degeneration.
C1 Univ Arizona, Dept Ophthalmol & Cell Biol, Tucson, AZ 85711 USA.
   Cleveland Clin Fdn, Dept Ophthalm Res, Cole Eye Inst, Cleveland, OH 44195 USA.
   Jules Gonin Eye Hosp, Oculognet Unit, CH-1004 Lausanne, Switzerland.
   Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA.
C3 University of Arizona; Cleveland Clinic Foundation; Cleveland Clinic
   Foundation
RP Marmorstein, LY (通讯作者)，Univ Arizona, Dept Ophthalmol & Cell Biol, Tucson, AZ 85711 USA.
EM lmarmorstein@oacs01.eyes.arizona.edu; anandab@ccf.org
FU NATIONAL EYE INSTITUTE [R01EY016490, R01EY013847, R29EY012109] Funding
   Source: NIH RePORTER; NEI NIH HHS [R01 EY016490, R29 EY012109, 1 R29
   EY12109-01, R01EY13847] Funding Source: Medline
CR Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3
   Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X
   Bergers G, 2000, CURR OPIN GENET DEV, V10, P120, DOI 10.1016/S0959-437X(99)00043-X
   Blackburn J, 2003, INVEST OPHTH VIS SCI, V44, P4613, DOI 10.1167/iovs.03-0112
   BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770
   Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811
   Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985
   Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Soboleva G, 2003, J CELL PHYSIOL, V197, P149, DOI 10.1002/jcp.10361
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/s004390050803
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709
   Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200
NR 30
TC 125
Z9 131
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 16
PY 2004
VL 279
IS 29
BP 30469
EP 30473
DI 10.1074/jbc.M403026200
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 836CD
UT WOS:000222531900074
PM 15123717
OA hybrid
DA 2022-11-30
ER

PT J
AU Goncalves, A
   Antonetti, DA
AF Goncalves, Andreia
   Antonetti, David A.
TI Transgenic animal models to explore and modulate the blood brain and
   blood retinal barriers of the CNS
SO FLUIDS AND BARRIERS OF THE CNS
LA English
DT Review
DE Blood-brain barrier; Blood-retinal barrier; Transgenic animal models;
   Neurovascular unit; Central nervous system disorders; Tight junctions
ID JUNCTIONAL-ADHESION-MOLECULE; CAPILLARY ENDOTHELIAL-CELLS;
   PROTEIN-COUPLED RECEPTOR; TIGHT-JUNCTION; VASCULAR DEVELOPMENT;
   TRICELLULAR CONTACTS; ALZHEIMERS-DISEASE; OCCLUDIN PHOSPHORYLATION;
   DIFFERENTIAL EXPRESSION; ZONULA OCCLUDENS
AB The unique environment of the brain and retina is tightly regulated by blood-brain barrier and the blood-retinal barrier, respectively, to ensure proper neuronal function. Endothelial cells within these tissues possess distinct properties that allow for controlled passage of solutes and fluids. Pericytes, glia cells and neurons signal to endothelial cells (ECs) to form and maintain the barriers and control blood flow, helping to create the neurovascular unit. This barrier is lost in a wide range of diseases affecting the central nervous system (CNS) and retina such as brain tumors, stroke, dementia, and in the eye, diabetic retinopathy, retinal vein occlusions and age-related macular degeneration to name prominent examples. Recent studies directly link barrier changes to promotion of disease pathology and degradation of neuronal function. Understanding how these barriers form and how to restore these barriers in disease provides an important point for therapeutic intervention. This review aims to describe the fundamentals of the blood-tissue barriers of the CNS and how the use of transgenic animal models led to our current understanding of the molecular framework of these barriers. The review also highlights examples of targeting barrier properties to protect neuronal function in disease states.
C1 [Goncalves, Andreia; Antonetti, David A.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St Rm, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan
RP Antonetti, DA (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St Rm, Ann Arbor, MI 48109 USA.
EM dantonet@med.umich.edu
FU National Institutes of Health [HL055374, EY012021]; Research to Prevent
   Blindness Stein Innovation Award (DAA)
FX This research was supported by Grants from the National Institutes of
   Health, HL055374 (DAA), EY012021 (DAA); and Research to Prevent
   Blindness Stein Innovation Award (DAA).
CR Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008
   Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575
   Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936
   Anderson KD, 2011, P NATL ACAD SCI USA, V108, P2807, DOI 10.1073/pnas.1019761108
   Andreone BJ, 2017, NEURON, V94, P581, DOI 10.1016/j.neuron.2017.03.043
   Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4
   Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522
   Arrate MP, 2001, J BIOL CHEM, V276, P45826, DOI 10.1074/jbc.M105972200
   Ashraf M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.53
   Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699
   Balda MS, 2009, BBA-BIOMEMBRANES, V1788, P761, DOI 10.1016/j.bbamem.2008.11.024
   Bauer H, 2016, CNS NEUROL DISORD-DR, V15, P1016, DOI 10.2174/1871527315666160915142244
   Bazzoni G, 2000, J BIOL CHEM, V275, P20520, DOI 10.1074/jbc.M905251199
   Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043
   Ben-Zvi A, 2014, NATURE, V509, P507, DOI 10.1038/nature13324
   Bendriem RM, 2019, ELIFE, V8, DOI 10.7554/eLife.49376
   Benz F, 2019, ELIFE, V8, DOI 10.7554/eLife.43818
   Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109
   Campbell M, 2018, PROG RETIN EYE RES, V62, P120, DOI 10.1016/j.preteyeres.2017.09.003
   Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852
   Chen ZL, 2013, J CELL BIOL, V202, P381, DOI 10.1083/jcb.201212032
   Cho C, 2017, NEURON, V95, P1056, DOI 10.1016/j.neuron.2017.07.031
   Chow BW, 2017, NEURON, V93, P1325, DOI 10.1016/j.neuron.2017.02.043
   Coelho-Santos V, 2020, WIRES DEV BIOL, V9, DOI 10.1002/wdev.363
   Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002
   Corada M, 2019, CIRC RES, V124, P511, DOI 10.1161/CIRCRESAHA.118.313316
   Corada M, 2010, DEV CELL, V18, P938, DOI 10.1016/j.devcel.2010.05.006
   Cullen M, 2011, P NATL ACAD SCI USA, V108, P5759, DOI 10.1073/pnas.1017192108
   Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513
   Daneman R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013741
   Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106
   Daniele LL, 2007, J COMP NEUROL, V505, P166, DOI 10.1002/cne.21489
   DERMIETZEL R, 1992, DEV DYNAM, V193, P152, DOI 10.1002/aja.1001930207
   Dias MC, 2021, J CELL SCI, V134, DOI 10.1242/jcs.253880
   Dias MC, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0150-9
   Dias MC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36731-3
   Diaz-Coranguez M, 2017, VISION RES, V139, P123, DOI 10.1016/j.visres.2017.05.009
   Dorfel MJ, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-40
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   Ebnet K, 2000, J BIOL CHEM, V275, P27979
   Economopoulou M, 2015, THROMB HAEMOSTASIS, V114, P1241, DOI 10.1160/TH15-01-0051
   Elias BC, 2009, J BIOL CHEM, V284, P1559, DOI 10.1074/jbc.M804783200
   Eubelen M, 2018, SCIENCE, V361, P663, DOI 10.1126/science.aat1178
   Fanning AS, 2009, ANN NY ACAD SCI, V1165, P113, DOI 10.1111/j.1749-6632.2009.04440.x
   FRANK RN, 1990, INVEST OPHTH VIS SCI, V31, P999
   Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391
   FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777
   Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006
   FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617
   Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122
   Goncalves A, 2022, BLOOD
   Goncalves A, 2021, DIABETES, V70, P1549, DOI 10.2337/db20-1220
   Goncalves A, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.24782
   Greene C, 2018, MOL PSYCHIATR, V23, P2156, DOI 10.1038/mp.2017.156
   Greene C, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29657-y
   Greene C, 2019, FLUIDS BARRIERS CNS, V16, DOI 10.1186/s12987-019-0123-z
   Gu XW, 2014, AM J PATHOL, V184, P541, DOI 10.1016/j.ajpath.2013.10.022
   Guemez-Gamboa A, 2015, NAT GENET, V47, P809, DOI 10.1038/ng.3311
   Gunzel D, 2012, COMPR PHYSIOL, V2, P1819, DOI 10.1002/cphy.c110045
   Guerit S, 2021, PROG NEUROBIOL, V199, DOI 10.1016/j.pneurobio.2020.101937
   GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460
   Gurnik S, 2016, ACTA NEUROPATHOL, V131, P753, DOI 10.1007/s00401-016-1551-3
   Hartz AMS, 2010, MOL PHARMACOL, V77, P715, DOI 10.1124/mol.109.061754
   Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199
   Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543
   Hirase T, 1997, J CELL SCI, V110, P1603
   Hori S, 2004, J NEUROCHEM, V89, P503, DOI 10.1111/j.1471-4159.2004.02343.x
   Hosoya K, 2013, ADV EXP MED BIOL, V763, P85
   Ikenouchi J, 2005, J CELL BIOL, V171, P939, DOI 10.1083/jcb.200510043
   Inoko A, 2003, GENES CELLS, V8, P837, DOI 10.1046/j.1365-2443.2003.00681.x
   Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351
   Iwamoto N, 2014, CELL STRUCT FUNCT, V39, P1
   Jaeger LB, 2009, J ALZHEIMERS DIS, V17, P553, DOI 10.3233/JAD-2009-1074
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   Junge HJ, 2009, CELL, V139, P299, DOI 10.1016/j.cell.2009.07.048
   Kamitani T, 2015, SCI REP-UK, V5, DOI 10.1038/srep18402
   Katsuno T, 2008, MOL BIOL CELL, V19, P2465, DOI 10.1091/mbc.E07-12-1215
   Keaney J, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500472
   Keuschnigg J, 2009, BLOOD, V114, P478, DOI 10.1182/blood-2008-11-188763
   Kim NKD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116931
   Kitajiri S, 2014, BIOL OPEN, V3, P759, DOI 10.1242/bio.20147799
   Krause G, 2008, BBA-BIOMEMBRANES, V1778, P631, DOI 10.1016/j.bbamem.2007.10.018
   Kuhnert F, 2010, SCIENCE, V330, P985, DOI 10.1126/science.1196554
   Kummer D, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7040025
   Lendahl U, 2019, EMBO REP, V20, DOI 10.15252/embr.201948070
   Susan WSL, 2022, ACTA PHARMACOL SIN, V43, P251, DOI 10.1038/s41401-021-00647-y
   Li FF, 2011, DEV CELL, V20, P291, DOI 10.1016/j.devcel.2011.01.011
   Liebner S, 2000, EUR J CELL BIOL, V79, P707, DOI 10.1078/0171-9335-00101
   Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Lobanova ES, 2019, J NEUROSCI, V39, P9689, DOI 10.1523/JNEUROSCI.1142-19.2019
   Luo Y, 2011, INVEST OPHTH VIS SCI, V52, P7556, DOI 10.1167/iovs.11-7185
   Ma FF, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay5686
   Mae MA, 2021, CIRC RES, V128, pE46, DOI 10.1161/CIRCRESAHA.120.317473
   Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117
   Masuda S, 2011, J CELL SCI, V124, P548, DOI 10.1242/jcs.072058
   Menard C, 2017, NAT NEUROSCI, V20, P1752, DOI 10.1038/s41593-017-0010-3
   Mesli S, 2004, EUR J BIOCHEM, V271, P3103, DOI 10.1111/j.1432-1033.2004.04223.x
   MILSTED A, 1990, P NATL ACAD SCI USA, V87, P5720, DOI 10.1073/pnas.87.15.5720
   Mineta K, 2011, FEBS LETT, V585, P606, DOI 10.1016/j.febslet.2011.01.028
   Monteiro AC, 2014, MOL BIOL CELL, V25, P1574, DOI 10.1091/mbc.E14-01-0018
   Moon Randall T, 2005, Sci STKE, V2005, pcm1
   Murakami T, 2012, DIABETES, V61, P1573, DOI 10.2337/db11-1367
   Murakami T, 2009, J BIOL CHEM, V284, P21036, DOI 10.1074/jbc.M109.016766
   Muthusamy A, 2014, J CEREBR BLOOD F MET, V34, P522, DOI 10.1038/jcbfm.2013.230
   Nagase T, 2008, ANGIOGENESIS, V11, P71, DOI 10.1007/s10456-008-9105-5
   Nakatsu D, 2014, GENES CELLS, V19, P565, DOI 10.1111/gtc.12158
   Nehra G, 2022, PHARMACOL THERAPEUT, V234, DOI 10.1016/j.pharmthera.2022.108119
   Nguyen LN, 2014, NATURE, V509, P503, DOI 10.1038/nature13241
   Nikopoulos K, 2010, HUM MUTAT, V31, P656, DOI 10.1002/humu.21250
   Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070
   O'Leary F, 2021, FEBS J, DOI 10.1111/febs.16330
   O'Sullivan ML, 2017, GLIA, V65, P1697, DOI 10.1002/glia.23189
   Ohtsuki S, 2008, J NEUROCHEM, V104, P147, DOI 10.1111/j.1471-4159.2007.05008.x
   Ohtsuki S, 2007, J CELL PHYSIOL, V210, P81, DOI 10.1002/jcp.20823
   Ooshio T, 2010, J BIOL CHEM, V285, P5003, DOI 10.1074/jbc.M109.043760
   Ornelas S, 2021, J CEREBR BLOOD F MET, V41, P2185, DOI 10.1177/0271678X211012836
   Osterlund T, 2006, TRENDS CELL BIOL, V16, P176, DOI 10.1016/j.tcb.2006.02.004
   Paes KT, 2011, INVEST OPHTH VIS SCI, V52, P6452, DOI 10.1167/iovs.10-7146
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512
   Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193
   Pfister F, 2010, ACTA DIABETOL, V47, P59, DOI 10.1007/s00592-009-0099-2
   Piontek J, 2008, FASEB J, V22, P146, DOI 10.1096/fj.07-8319com
   Piontek J, 2011, CELL MOL LIFE SCI, V68, P3903, DOI 10.1007/s00018-011-0680-z
   Posokhova E, 2015, CELL REP, V10, P123, DOI 10.1016/j.celrep.2014.12.020
   Profaci CP, 2020, J EXP MED, V217, DOI 10.1084/jem.20190062
   Pulgar VM, 2019, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.01019
   Pulido RS, 2020, NEURON, V108, DOI 10.1016/j.neuron.2020.09.002
   Raleigh DR, 2011, J CELL BIOL, V193, P565, DOI 10.1083/jcb.201010065
   Rangasamy S, 2011, INVEST OPHTH VIS SCI, V52, P3784, DOI 10.1167/iovs.10-6386
   Riazuddin S, 2006, AM J HUM GENET, V79, P1040, DOI 10.1086/510022
   Saito AC, 2021, MOL BIOL CELL, V32, P722, DOI 10.1091/mbc.E20-07-0464
   Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131
   Schlingemann RO, 1997, OPHTHALMIC RES, V29, P130, DOI 10.1159/000268007
   Schulzke JD, 2005, BBA-BIOMEMBRANES, V1669, P34, DOI 10.1016/j.bbamem.2005.01.008
   Severson EA, 2008, MOL BIOL CELL, V19, P1862, DOI 10.1091/mbc.E07-09-0869
   Shi QN, 2021, TRENDS BIOCHEM SCI, V46, P1003, DOI 10.1016/j.tibs.2021.07.008
   Shi YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10523
   Shi YJ, 2017, P NATL ACAD SCI USA, V114, pE1243, DOI 10.1073/pnas.1621174114
   Shue EH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-29
   Sladojevic N, 2019, J NEUROSCI, V39, P743, DOI 10.1523/JNEUROSCI.1432-18.2018
   Smallwood PM, 2007, J BIOL CHEM, V282, P4057, DOI 10.1074/jbc.M609618200
   Sohet F, 2015, J CELL BIOL, V208, P703, DOI 10.1083/jcb.201410131
   Solar P, 2020, FLUIDS BARRIERS CNS, V17, DOI 10.1186/s12987-020-00196-2
   Steed E, 2014, J CELL BIOL, V204, P821, DOI 10.1083/jcb.201304115
   Steed E, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-95
   Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594
   STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755
   STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1
   Storck SE, 2016, J CLIN INVEST, V126, P123, DOI 10.1172/JCI81108
   Sundstrom JM, 2009, J PROTEOME RES, V8, P808, DOI 10.1021/pr7007913
   Suzuki T, 2009, P NATL ACAD SCI USA, V106, P61, DOI 10.1073/pnas.0802741106
   Takano K, 2014, EXCLI J, V13, P1145
   Tash BR, 2012, P NATL ACAD SCI USA, V109, P10855, DOI 10.1073/pnas.1121390109
   Tomi M, 2004, J NEUROCHEM, V91, P1244, DOI 10.1111/j.1471-4159.2004.02842.x
   Tornavaca O, 2015, J CELL BIOL, V208, P821, DOI 10.1083/jcb.201404140
   TOUT S, 1993, J COMP NEUROL, V332, P433, DOI 10.1002/cne.903320405
   Toyama K, 2018, ARTERIOSCL THROM VAS, V38, P1392, DOI 10.1161/ATVBAHA.118.310822
   Tran KA, 2016, CIRCULATION, V133, P177, DOI 10.1161/CIRCULATIONAHA.115.015982
   Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0
   Umans RA, 2017, DEV BIOL, V425, P101, DOI 10.1016/j.ydbio.2017.03.017
   Umeda K, 2006, CELL, V126, P741, DOI 10.1016/j.cell.2006.06.043
   Vacca B, 2016, BIOL OPEN, V5, P1631, DOI 10.1242/bio.018945
   Van Itallie CM, 2017, MOL BIOL CELL, V28, P524, DOI 10.1091/mbc.E16-10-0698
   Vanhollebeke B, 2015, ELIFE, V4, DOI 10.7554/eLife.06489
   Vanlandewijck M, 2018, NATURE, V554, P475, DOI 10.1038/nature25739
   Wang D, 2006, HUM MOL GENET, V15, P1169, DOI 10.1093/hmg/ddl032
   Wang YS, 2012, CELL, V151, P1332, DOI 10.1016/j.cell.2012.10.042
   Wang ZX, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba7457
   Winkler EA, 2015, NAT NEUROSCI, V18, P521, DOI 10.1038/nn.3966
   Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946
   Winkler L, 2021, J CEREBR BLOOD F MET, V41, P132, DOI 10.1177/0271678X20904687
   Wisniewska-Kruk J, 2016, AM J PATHOL, V186, P1044, DOI 10.1016/j.ajpath.2015.11.019
   Wong BH, 2016, J BIOL CHEM, V291, P10501, DOI 10.1074/jbc.M116.721340
   Woodfin A, 2007, BLOOD, V110, P1848, DOI 10.1182/blood-2006-09-047431
   Wosik K, 2007, J NEUROSCI, V27, P9032, DOI 10.1523/JNEUROSCI.2088-07.2007
   Xu JL, 2008, MOL CELL BIOL, V28, P1669, DOI 10.1128/MCB.00891-07
   Xu Q, 2004, CELL, V116, P883, DOI 10.1016/S0092-8674(04)00216-8
   Yao Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4413
   Ye X, 2009, CELL, V139, P285, DOI 10.1016/j.cell.2009.07.047
   Zhou YL, 2014, DEV CELL, V31, P248, DOI 10.1016/j.devcel.2014.08.018
   Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431
   Zhu XJ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139869
   Zihni C, 2016, NAT REV MOL CELL BIO, V17, P564, DOI 10.1038/nrm.2016.80
NR 187
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-8118
J9 FLUIDS BARRIERS CNS
JI Fluids Barriers CNS
PD NOV 1
PY 2022
VL 19
IS 1
AR 86
DI 10.1186/s12987-022-00386-0
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 5W1VY
UT WOS:000877710600003
PM 36320068
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fuentes-Broto, L
   Perdices, L
   Segura, F
   Orduna-Hospital, E
   Insa-Sanchez, G
   Sanchez-Cano, AI
   Cuenca, N
   Pinilla, I
AF Fuentes-Broto, Lorena
   Perdices, Lorena
   Segura, Francisco
   Orduna-Hospital, Elvira
   Insa-Sanchez, Gema
   Sanchez-Cano, Ana, I
   Cuenca, Nicolas
   Pinilla, Isabel
TI Effects of Daily Melatonin Supplementation on Visual Loss, Circadian
   Rhythms, and Hepatic Oxidative Damage in a Rodent Model of Retinitis
   Pigmentosa
SO ANTIOXIDANTS
LA English
DT Article
DE retinitis pigmentosa; antioxidant; melatonin; oxidative stress;
   neurodegeneration; circadian rhythms; vision; retina
ID LIPID-PEROXIDATION; RETINAL DEGENERATION; NITROSATIVE STRESS;
   GLUTATHIONE; PATHWAY; AUTOPHAGY; PROTEIN; CELLS; SLEEP; PHARMACOLOGY
AB Retinitis pigmentosa (RP) is a group of inherited neurodegenerative diseases characterized by a progressive loss of visual function that primarily affect photoreceptors, resulting in the complete disorganization and remodeling of the retina. Progression of the disease is enhanced by increased oxidative stress in the retina, aqueous humor, plasma, and liver of RP animal models and patients. Melatonin has beneficial effects against age-related macular degeneration, glaucoma, and diabetic retinopathy, in which oxidative stress plays a key role. In the present study, we used the P23HxLE rat as an animal model of RP. Melatonin treatment (10 mg/kg b.w. daily in drinking water for 6 months) improved the parameters of visual function and decreased the rate of desynchronization of the circadian rhythm, both in P23HxLE and wild-type rats. Melatonin reduced oxidative stress and increased antioxidant defenses in P23HxLE animals. In wild-type animals, melatonin did not modify any of the oxidative stress markers analyzed and reduced the levels of total antioxidant defenses. Treatment with melatonin improved visual function, circadian synchronization, and hepatic oxidative stress in P23HxLE rats, an RP model, and had beneficial effects against age-related visual damage in wild-type rats.
C1 [Fuentes-Broto, Lorena; Insa-Sanchez, Gema] Univ Zaragoza, Dept Pharmacol Physiol & Legal & Forens Med, Zaragoza 50009, Spain.
   [Perdices, Lorena; Segura, Francisco; Orduna-Hospital, Elvira; Insa-Sanchez, Gema; Sanchez-Cano, Ana, I; Pinilla, Isabel] Aragon Inst Hlth Res IIS Aragon, Zaragoza 50009, Spain.
   [Segura, Francisco; Pinilla, Isabel] Univ Zaragoza, Dept Surg, Zaragoza 50009, Spain.
   [Orduna-Hospital, Elvira; Sanchez-Cano, Ana, I] Univ Zaragoza, Dept Appl Phys, Zaragoza 50009, Spain.
   [Cuenca, Nicolas] Univ Alicante, Dept Physiol Genet & Microbiol, San Vicente Del Raspeig 03690, Spain.
   [Pinilla, Isabel] Lozano Blesa Univ Hosp, Dept Ophthalmol, Zaragoza 50009, Spain.
C3 University of Zaragoza; University of Zaragoza; University of Zaragoza;
   Universitat d'Alacant; Lozano Blesa University Clinical Hospital
RP Pinilla, I (通讯作者)，Aragon Inst Hlth Res IIS Aragon, Zaragoza 50009, Spain.; Pinilla, I (通讯作者)，Univ Zaragoza, Dept Surg, Zaragoza 50009, Spain.; Pinilla, I (通讯作者)，Lozano Blesa Univ Hosp, Dept Ophthalmol, Zaragoza 50009, Spain.
EM lfuentes@unizar.es; lperdices@gmail.com; psegura@unizar.es;
   eordunahospital@unizar.es; gis@unizar.es; anaisa@unizar.es;
   cuenca@ua.es; ipinilla@unizar.es
RI Cuenca, Nicolas/I-2007-2015; ORDUNA HOSPITAL, ELVIRA/AGE-2130-2022;
   Sanchez-Cano, Ana/J-4612-2012; Fuentes-Broto, Lorena/D-2773-2009
OI Cuenca, Nicolas/0000-0002-6767-5710; ORDUNA HOSPITAL,
   ELVIRA/0000-0003-2710-1875; Sanchez-Cano, Ana/0000-0002-5621-1937;
   Fuentes-Broto, Lorena/0000-0003-2656-6750
FU Instituto de Salud Carlos III Ocular Pathology National Net
   RETICS-Oftared [RD16/0008, PI13/01124]; Government of Aragon [B08_17R,
   C060/2014]; Fondo Europeo de Desarrollo Regional (FEDER)
FX This research was funded by the Instituto de Salud Carlos III Ocular
   Pathology National Net RETICS-Oftared (RD16/0008) and project
   PI13/01124; the Government of Aragon (Group B08_17R and a predoctoral
   grant to L. Perdices, C060/2014); and Fondo Europeo de Desarrollo
   Regional (FEDER) funds: "Una manera de hacer Europa".
CR Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Agathokleous E, 2019, CHEM-BIOL INTERACT, V299, P163, DOI 10.1016/j.cbi.2018.12.008
   Amstrup AK, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0093-1
   Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434
   Aubin S, 2016, SLEEP MED, V23, P100, DOI 10.1016/j.sleep.2016.07.021
   Baba K, 2009, P NATL ACAD SCI USA, V106, P15043, DOI 10.1073/pnas.0904400106
   BARCHAS J, 1967, NATURE, V214, P919, DOI 10.1038/214919a0
   Belforte NA, 2010, J PINEAL RES, V48, P353, DOI 10.1111/j.1600-079X.2010.00762.x
   Blanco S, 2017, NITRIC OXIDE-BIOL CH, V62, P32, DOI 10.1016/j.niox.2016.12.001
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cheng G, 2021, FOOD FUNCT, V12, DOI [10.1039/d0fo03213a, 10.1039/D0FO03213A]
   Crooke A, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12430
   Cuenca N, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00151
   Cuesta M, 2009, HORM BEHAV, V55, P338, DOI 10.1016/j.yhbeh.2008.10.015
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   Deng Y, 2015, NEUROTOX RES, V27, P156, DOI 10.1007/s12640-014-9489-5
   do Amaral FG, 2018, ARCH ENDOCRIN METAB, V62, P472, DOI 10.20945/2359-3997000000066
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Fernandez-Sanchez L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177998
   Fu Y, 2012, FRONT BIOSCI-LANDMRK, V17, P1461, DOI 10.2741/3997
   Gagne Anne-Marie, 2009, J Circadian Rhythms, V7, P14, DOI 10.1186/1740-3391-7-14
   Ghorbaninejad P, 2020, HORM MOL BIOL CLIN I, V41, DOI 10.1515/hmbci-2020-0030
   GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764
   GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6
   Guo YC, 2010, J HUAZHONG U SCI-MED, V30, P1, DOI 10.1007/s11596-010-0101-9
   Hanif AM, 2016, EXP EYE RES, V149, P75, DOI 10.1016/j.exer.2016.06.010
   Hardeland R, 2021, MOLECULES, V26, DOI 10.3390/molecules26134105
   Hardeland R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051223
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Huang CC, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0199-6
   Huang H, 2013, PROG RETIN EYE RES, V32, P64, DOI 10.1016/j.preteyeres.2012.07.003
   Jagannath A, 2017, HUM MOL GENET, V26, pR128, DOI 10.1093/hmg/ddx240
   JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2
   Kim SJ, 2000, NEUROENDOCRINOL LETT, V21, P269
   Kimball SR, 2008, J PINEAL RES, V44, P379, DOI 10.1111/j.1600-079X.2007.00539.x
   Kolli VK, 2013, CANCER CHEMOTH PHARM, V71, P1209, DOI 10.1007/s00280-013-2115-z
   Kruk J, 2016, MINI-REV MED CHEM, V16, P241, DOI 10.2174/1389557516666151120114605
   Kurhaluk N, 2018, CAN J PHYSIOL PHARM, V96, P1153, DOI 10.1139/cjpp-2018-0011
   Lax P, 2016, CHRONOBIOL INT, V33, P374, DOI 10.3109/07420528.2016.1151025
   Lax P, 2011, J PINEAL RES, V50, P183, DOI 10.1111/j.1600-079X.2010.00827.x
   LEVINE RL, 1990, METHOD ENZYMOL, V186, P464
   Liu Y, 2014, INT J MOL SCI, V15, P18437, DOI 10.3390/ijms151018437
   Manikonda PK, 2012, BIOGERONTOLOGY, V13, P511, DOI 10.1007/s10522-012-9396-1
   de la Camara CMF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074223
   Meng X, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040367
   MILLER NJ, 1995, FEBS LETT, V365, P164, DOI 10.1016/0014-5793(95)00448-I
   Moniruzzaman M, 2018, BIOL RES, V51, DOI 10.1186/s40659-018-0168-5
   Ortiz-Tudela E, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000996
   Osborne NN, 1998, INVEST OPHTH VIS SCI, V39, P2374
   Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4
   Patschan D, 2012, AM J PHYSIOL-RENAL, V302, pF1305, DOI 10.1152/ajprenal.00445.2011
   Perdices L, 2022, NEURAL REGEN RES, V17, P625, DOI 10.4103/1673-5374.320990
   Perdices L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080718
   Perdices L, 2018, FREE RADICAL BIO MED, V124, P550, DOI 10.1016/j.freeradbiomed.2018.07.005
   Pevet P, 2017, BEST PRACT RES CL EN, V31, P547, DOI 10.1016/j.beem.2017.10.010
   Pinilla I, 2004, VISION RES, V44, P2467, DOI 10.1016/j.visres.2004.05.020
   Pinilla I, 2016, EXP EYE RES, V150, P122, DOI 10.1016/j.exer.2015.10.012
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Rayapudi S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008428.pub2
   Reiter RJ, 2011, NEUROENDOCRINOL LETT, V32, P575
   Segura F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28394-x
   Segura F, 2015, INVEST OPHTH VIS SCI, V56, P6275, DOI 10.1167/iovs.15-17257
   Siew-Keah L, 2014, J PHYSIOL BIOCHEM, V70, P73, DOI 10.1007/s13105-013-0282-3
   TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5
   Tordjman S, 2017, CURR NEUROPHARMACOL, V15, P434, DOI 10.2174/1570159X14666161228122115
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Vega-Naredo I, 2012, J PINEAL RES, V52, P80, DOI 10.1111/j.1600-079X.2011.00922.x
   Vriend J, 2015, MOL CELL ENDOCRINOL, V401, P213, DOI 10.1016/j.mce.2014.12.013
   Wasdell MB, 2008, J PINEAL RES, V44, P57, DOI 10.1111/j.1600-079X.2007.00528.x
   Wiechmann AF, 2013, INT REV CEL MOL BIO, V300, P211, DOI 10.1016/B978-0-12-405210-9.00006-0
   Xu Guo-Xing, 2009, Zhonghua Yan Ke Za Zhi, V45, P528
   Yamazaki H, 2015, PATHOL INT, V65, P210, DOI 10.1111/pin.12261
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Zhao ZW, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12521
NR 75
TC 2
Z9 2
U1 5
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD NOV
PY 2021
VL 10
IS 11
AR 1853
DI 10.3390/antiox10111853
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA XG9SL
UT WOS:000725085500001
PM 34829724
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Choi, S
   Moon, SW
   Lee, SH
   Kim, W
   Kim, S
   Kim, SK
   Shin, JH
   Park, YG
   Jin, KH
   Kim, TG
AF Choi, Samjin
   Moon, Sang Woong
   Lee, Seung Ho
   Kim, Wansun
   Kim, Soogeun
   Kim, Su Kang
   Shin, Jae-Ho
   Park, Young-Guk
   Jin, Kyung-Hyun
   Kim, Tae Gi
TI A recyclable CNC-milled microfluidic platform for colorimetric assays
   and label-free aged-related macular degeneration detection
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article
DE Microfluidic platform; CNC; Colorimetry; SERS; Human aqueous humors
ID PAPER PLATFORM; LOW-COST; CELLULOSE; FABRICATION; NANOPARTICLES; ARRAYS;
   CELLS
AB We report the development of a simple, low-cost, and eco-friendly stand-alone 3D microfluidic chemical sensing platform capable of colorimetric and biochemical analyses at the same time. The microfluidic cellulose micro-fiber (mu CM) chip was prototyped by injecting 10% CM mixtures on computer numeric control (CNC)-milled substrates. We show that the mu CM chip has a 3-fold faster flow rate than conventional microfluidic paper-based analytical devices and is a recyclable platform that could perform basic microfluidic experiments. The colorimetric assays of the mu CM chip can successfully detect clinically relevant concentrations of albumin (R-2=0.9994) and glucose (R-2=0.9464). The gold nanoparticle-induced surface-enhanced Raman scattering (SERS) label-free bioassay of mu CM chips can enhance the Raman signal by 5.15x10(8) and a sensitivity of 0.94 (10 pM-1 mM for CV molecules) with an excellent stability of <5%. We can detect the presence of exudative age-related macular degeneration (AMD) from human aqueous humors with > 96% clinical sensitivity and > 78% clinical specificity (87% accuracy) from principal component linear discriminant analysis (PC-LDA) model-based multivariate statistical analysis methods.
C1 [Choi, Samjin; Lee, Seung Ho; Kim, Wansun; Kim, Soogeun] Kyung Hee Univ, Coll Med, Dept Biomed Engn, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Moon, Sang Woong; Shin, Jae-Ho; Jin, Kyung-Hyun; Kim, Tae Gi] Kyung Hee Univ, Coll Med, Dept Ophthalmol, 23 Kyungheedae Ro, Seoul 02447, South Korea.
   [Kim, Su Kang] Catholic Kwandong Univ, Dept Biomed Lab Sci, Kangnung 25601, South Korea.
   [Park, Young-Guk] Kyung Hee Univ, Coll Dent, Dept Orthodont, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University; Catholic Kwandong
   University; Kyung Hee University
RP Choi, S (通讯作者)，Kyung Hee Univ, Coll Med, Dept Biomed Engn, 26 Kyungheedae Ro, Seoul 02447, South Korea.; Kim, TG (通讯作者)，Kyung Hee Univ, Coll Med, Dept Ophthalmol, 23 Kyungheedae Ro, Seoul 02447, South Korea.
EM medchoi@khu.ac.kr; tk1213@hanmail.net
RI Kim, Tae Gi/ABC-9304-2020; Park, Young Guk/AAI-8483-2020
OI Kim, Soogeun/0000-0001-5483-6661; Choi, Samjin/0000-0003-3498-0652; KIM,
   Wansun/0000-0001-9186-6448
FU National Research Foundation of Korea (NRF) [2017R1A2B4002765,
   2017R1D1A1B03035912, 2018M3A9E8078812]; Korean Health Technology
   Research & Development Project [HI14C2241]
FX This research was supported by the National Research Foundation of Korea
   (NRF) funded by 2017R1A2B4002765, 2017R1D1A1B03035912, and
   2018M3A9E8078812 and the Korean Health Technology Research & Development
   Project (HI14C2241).
CR Anciaux SK, 2016, ANAL CHEM, V88, P7675, DOI 10.1021/acs.analchem.6b01573
   Choi S, 2015, SENSOR ACTUAT B-CHEM, V219, P245, DOI 10.1016/j.snb.2015.05.035
   Dhar P, 2015, CELLULOSE, V22, P3755, DOI 10.1007/s10570-015-0759-z
   Gao BB, 2014, LANGMUIR, V30, P15041, DOI 10.1021/la503720b
   Gautam R, 2015, EPJ TECH INSTRUM, V2, DOI 10.1140/epjti/s40485-015-0018-6
   Glavan AC, 2013, LAB CHIP, V13, P2922, DOI 10.1039/c3lc50371b
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   Hong B, 2016, BIOMED MICRODEVICES, V18, DOI 10.1007/s10544-016-0054-2
   Huang Y, 2015, J MANUF SCI E-T ASME, V137, DOI 10.1115/1.4028725
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Kim WS, 2016, SENSOR ACTUAT B-CHEM, V222, P1112, DOI 10.1016/j.snb.2015.08.030
   Kim W, 2018, ACS NANO, V12, P7100, DOI 10.1021/acsnano.8b02917
   Kim W, 2018, BIOSENS BIOELECTRON, V111, P59, DOI 10.1016/j.bios.2018.04.003
   Kim W, 2017, ANAL CHEM, V89, P6448, DOI 10.1021/acs.analchem.7b00300
   Kim W, 2017, ACS APPL MATER INTER, V9, P5891, DOI 10.1021/acsami.6b16130
   Kim W, 2015, ACS APPL MATER INTER, V7, P27910, DOI 10.1021/acsami.5b09982
   Kulicke WM, 1996, POLYMER, V37, P2723, DOI 10.1016/0032-3861(96)87634-8
   Le Ru EC, 2007, J PHYS CHEM C, V111, P13794, DOI 10.1021/jp0687908
   Lee SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28588
   Ling DD, 2017, ACS NANO, V11, P1478, DOI 10.1021/acsnano.6b06778
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Moon SW, 2016, MICROSC RES TECHNIQ, V79, P1050, DOI 10.1002/jemt.22743
   Ni HB, 2015, ACS NANO, V9, P1913, DOI 10.1021/nn506834r
   Osborn JL, 2010, LAB CHIP, V10, P2659, DOI 10.1039/c004821f
   Renault C, 2014, J AM CHEM SOC, V136, P4616, DOI 10.1021/ja4118544
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sescousse R, 2010, J PHYS CHEM B, V114, P7222, DOI 10.1021/jp1024203
   Shin JH, 2016, SENSOR ACTUAT B-CHEM, V230, P380, DOI 10.1016/j.snb.2016.02.085
   Su X, 2017, SPECTROCHIM ACTA A, V177, P15, DOI 10.1016/j.saa.2017.01.021
   Wang C, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/9/092001
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Yang PP, 2016, ADV MATER, V28, P10508, DOI 10.1002/adma.201601739
   Yasar F, 2007, J FOOD ENG, V81, P187, DOI 10.1016/j.jfoodeng.2006.10.022
   Zhang D, 2018, SENSOR ACTUAT B-CHEM, V256, P721, DOI 10.1016/j.snb.2017.09.209
   Zhu ZC, 2014, INT J ADV MANUF TECH, V74, P1115, DOI 10.1007/s00170-014-6053-7
NR 35
TC 5
Z9 5
U1 11
U2 84
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD JUL 1
PY 2019
VL 290
BP 484
EP 492
DI 10.1016/j.snb.2019.04.025
PG 9
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA HU6YJ
UT WOS:000465427900062
DA 2022-11-30
ER

PT J
AU Baakdhah, T
   van der Kooy, D
AF Baakdhah, Tahani
   van der Kooy, Derek
TI Expansion of retinal stem cells and their progeny using cell
   microcarriers in a bioreactor
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
DE bioreactor; hypoxia; microcarriers; retina; stem cells
ID TO-BEAD TRANSFER; SCALE-UP; OPTIMIZATION; DIFFERENTIATION; MAINTAIN;
   GROWTH
AB Blindness as a consequence of degenerative eye diseases (e.g., age-related macular degeneration and retinitis pigmentosa) is a major health problem and numbers are expected to increase by up to 50% by 2020. Unfortunately, adult mouse and human retinal stem cells (RSCs), unlike fish and amphibians, are quiescent in vivo and do not regenerate following disease or injury. To replace lost cells, we used microcarriers (MCs) in a suspension stirring bioreactor to help achieve numbers suitable for differentiation and transplantation. We achieved a significant 10-fold enrichment of RSC yield compared to conventional static culture techniques using a combination of FACTIII MCs and relative hypoxia (5%) inside the bioreactor. We found that hypoxia (5% O-2) was associated with better RSC expansion across all platforms; and this can be attributed to hypoxia-induced increases in survival and/or symmetric division of stem cells. In the future, we will target the differentiation of RSCs and their progeny toward rod and cone photoreceptor phenotypes using FACTIII MCs inside bioreactors to expand their populations in order to produce the large numbers of cells needed for transplantation.
C1 [Baakdhah, Tahani; van der Kooy, Derek] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada.
   [van der Kooy, Derek] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto
RP Baakdhah, T (通讯作者)，Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada.
EM tahani.baakdhah@mail.utoronto.ca
RI Baakdhah, Tahani/AAZ-3238-2021
OI Baakdhah, Tahani/0000-0002-2918-1103
FU Canadian Institutes of Health Research [FDN-148407]; Krembil Foundation
   [410005024]
FX Canadian Institutes of Health Research, Grant/Award Number: FDN-148407;
   Krembil Foundation, Grant/Award Number: 410005024
CR Abdouh M, 2006, EXP EYE RES, V83, P153, DOI 10.1016/j.exer.2005.11.016
   Abranches E, 2007, BIOTECHNOL BIOENG, V96, P1211, DOI 10.1002/bit.21191
   Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Alfred R, 2011, BIOTECHNOL PROGR, V27, P811, DOI 10.1002/btpr.591
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Bae D, 2012, STEM CELLS DEV, V21, P1344, DOI 10.1089/scd.2011.0225
   Balenci L, 2013, STEM CELLS, V31, P2218, DOI 10.1002/stem.1470
   Ballios BG, 2012, BIOL OPEN, V1, P237, DOI 10.1242/bio.2012027
   Chen HY, 2016, MOL VIS, V22, P1077
   Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591
   Choi YS, 2010, BIOTECHNOL LETT, V32, P1969, DOI 10.1007/s10529-010-0355-0
   Cicero SA, 2009, P NATL ACAD SCI USA, V106, P6685, DOI 10.1073/pnas.0901596106
   Clarke L, 2012, EUR J NEUROSCI, V36, P1951, DOI 10.1111/j.1460-9568.2012.08123.x
   Coles BLK, 2006, EUR J NEUROSCI, V23, P75, DOI 10.1111/j.1460-9568.2005.04537.x
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   Coles-Takabe BLK, 2008, STEM CELLS, V26, P2938, DOI 10.1634/stemcells.2008-0558
   Cormier JT, 2006, TISSUE ENG, V12, P3233, DOI 10.1089/ten.2006.12.3233
   Cowan PJ, 2016, CURR OPIN ORGAN TRAN, V21, P461, DOI 10.1097/MOT.0000000000000347
   Del Debbio CB, 2013, BMC NEUROSCI, P14
   Demontis GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033338
   DiStefano T, 2018, STEM CELL REP, V10, P300, DOI 10.1016/j.stemcr.2017.11.001
   Fang Y, 2013, STEM CELLS, V31, P349, DOI 10.1002/stem.1283
   Fernandes AM, 2009, BRAZ J MED BIOL RES, V42, P515, DOI 10.1590/S0100-879X2009000600007
   FORESTELL SP, 1992, BIOTECHNOL BIOENG, V39, P305, DOI 10.1002/bit.260390308
   Frauenschuh S, 2007, BIOTECHNOL PROGR, V23, P187, DOI 10.1021/bp060155w
   Garita-Hernandez M, 2013, STEM CELLS, V31, P966, DOI 10.1002/stem.1339
   Geng ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173575
   Gilbertson JA, 2006, BIOTECHNOL BIOENG, V94, P783, DOI 10.1002/bit.20900
   Gualdoni S, 2010, STEM CELLS, V28, P1048, DOI 10.1002/stem.423
   Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010
   Inoue T, 2010, STEM CELLS, V28, P489, DOI 10.1002/stem.279
   Irshad K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118201
   Jadhav AP, 2006, P NATL ACAD SCI USA, V103, P18998, DOI 10.1073/pnas.0608155103
   Kallos MS, 2003, MED BIOL ENG COMPUT, V41, P271, DOI 10.1007/BF02348431
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   King JA, 2007, CURR OPIN CHEM BIOL, V11, P394, DOI 10.1016/j.cbpa.2007.05.034
   Liu Meimei, 2013, World J Stem Cells, V5, P124, DOI 10.4252/wjsc.v5.i4.124
   Luo F, 2008, BIOTECHNOL LETT, V30, P645, DOI 10.1007/s10529-007-9604-2
   Merten OW, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0040
   Ng YC, 1996, BIOTECHNOL BIOENG, V50, P627, DOI 10.1002/(SICI)1097-0290(19960620)50:6<627::AID-BIT3>3.0.CO;2-M
   OHLSON S, 1994, CYTOTECHNOLOGY, V14, P67, DOI 10.1007/BF00772197
   Otteson DC, 2003, VISION RES, V43, P927, DOI 10.1016/S0042-6989(02)00400-5
   Panchision DM, 2009, J CELL PHYSIOL, V220, P562, DOI 10.1002/jcp.21812
   Pearson RA, 2014, BIOTECHNOL ADV, V32, P485, DOI 10.1016/j.biotechadv.2014.01.001
   Phillips BW, 2008, J BIOTECHNOL, V138, P24, DOI 10.1016/j.jbiotec.2008.07.1997
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rourou S, 2007, VACCINE, V25, P3879, DOI 10.1016/j.vaccine.2007.01.086
   Saito K, 2003, DEV GROWTH DIFFER, V45, P219
   Schop D, 2008, J TISSUE ENG REGEN M, V2, P126, DOI 10.1002/term.73
   Schop D, 2010, J TISSUE ENG REGEN M, V4, P131, DOI 10.1002/term.224
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Sen A, 2001, IND ENG CHEM RES, V40, P5350, DOI 10.1021/ie001107y
   Sowden JC, 2014, CELL STEM CELL, V15, P537, DOI 10.1016/j.stem.2014.10.008
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Uygun Basak E., 2009, Critical Reviews in Biomedical Engineering, V37, P355
   Wu N, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2361763
   Youn BS, 2006, BIOTECHNOL PROGR, V22, P801, DOI 10.1021/bp050430z
   Youn BS, 2005, BIOTECHNOL PROGR, V21, P984, DOI 10.1021/bp050059f
   Yuan YF, 2014, J TISSUE ENG REGEN M, V8, P210, DOI 10.1002/term.1515
   Yue FM, 2010, BIOCHEM BIOPH RES CO, V394, P877, DOI 10.1016/j.bbrc.2010.03.008
NR 60
TC 8
Z9 8
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8756-7938
EI 1520-6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD MAY
PY 2019
VL 35
IS 3
AR e2800
DI 10.1002/btpr.2800
PG 11
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA IC9PA
UT WOS:000471314600007
PM 30840351
DA 2022-11-30
ER

PT J
AU Gioelli, N
   Maione, F
   Camillo, C
   Ghitti, M
   Valdembri, D
   Morello, N
   Darche, M
   Zentilin, L
   Cagnoni, G
   Qiu, YQ
   Giacca, M
   Giustetto, M
   Paques, M
   Cascone, I
   Musco, G
   Tamagnone, L
   Giraudo, E
   Serini, G
AF Gioelli, Noemi
   Maione, Federica
   Camillo, Chiara
   Ghitti, Michela
   Valdembri, Donatella
   Morello, Noemi
   Darche, Marie
   Zentilin, Lorena
   Cagnoni, Gabriella
   Qiu, Yaqi
   Giacca, Mauro
   Giustetto, Maurizio
   Paques, Michel
   Cascone, Ilaria
   Musco, Giovanna
   Tamagnone, Luca
   Giraudo, Enrico
   Serini, Guido
TI A rationally designed NRP1-independent superagonist SEMA3A mutant is an
   effective anticancer agent
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID LOCAL PROTEIN-SYNTHESIS; SEMAPHORIN 3A; VASCULAR-PERMEABILITY; SECRETED
   SEMAPHORINS; MOLECULAR-DYNAMICS; CHROMOSOME 3P21.3; PANCREATIC-CANCER;
   STRUCTURAL BASIS; BREAST-CANCER; CELL
AB Vascular normalizing strategies, aimed at ameliorating blood vessel perfusion and lessening tissue hypoxia, are treatments that may improve the outcome of cancer patients. Secreted class 3 semaphorins (SEMA3), which are thought to directly bind neuropilin (NRP) co-receptors that, in turn, associate with and elicit plexin (PLXN) receptor signaling, are effective normalizing agents of the cancer vasculature. Yet, SEMA3A was also reported to trigger adverse side effects via NRP1. We rationally designed and generated a safe, parenterally deliverable, and NRP1-independent SEMA3A point mutant isoform that, unlike its wild-type counterpart, binds PLXNA4 with nanomolar affinity and has much greater biochemical and biological activities in cultured endothelial cells. In vivo, when parenterally administered in mouse models of pancreatic cancer, the NRP1-independent SEMA3A point mutant successfully normalized the vasculature, inhibited tumor growth, curbed metastatic dissemination, and effectively improved the supply and anticancer activity of chemotherapy. Mutant SEMA3A also inhibited retinal neovascularization in a mouse model of age-related macular degeneration. In summary, mutant SEMA3A is a vascular normalizing agent that can be exploited to treat cancer and, potentially, other diseases characterized by pathological angiogenesis.
C1 [Gioelli, Noemi; Camillo, Chiara; Valdembri, Donatella; Cagnoni, Gabriella; Tamagnone, Luca; Serini, Guido] Univ Turin, Sch Med, Dept Oncol, I-10060 Turin, Italy.
   [Gioelli, Noemi; Maione, Federica; Camillo, Chiara; Valdembri, Donatella; Cagnoni, Gabriella; Qiu, Yaqi; Tamagnone, Luca; Giraudo, Enrico; Serini, Guido] IRCCS, FPO, Candiolo Canc Inst, I-10060 Turin, Italy.
   [Maione, Federica; Qiu, Yaqi; Giraudo, Enrico] Univ Turin, Dept Sci & Drug Technol, I-10125 Turin, Italy.
   [Ghitti, Michela; Musco, Giovanna] IRCCS, Osped San Raffaele, Biomol NMR Unit, I-20132 Milan, Italy.
   [Morello, Noemi; Giustetto, Maurizio] Univ Turin, Sch Med, Dept Neurosci, I-10126 Turin, Italy.
   [Darche, Marie; Cascone, Ilaria] Univ Paris Est, ERL CNRS 9215, Growth Reparat & Tissue Regenerat Lab, F-94000 Creteil, France.
   [Zentilin, Lorena; Giacca, Mauro] Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34149 Trieste, Italy.
   [Giustetto, Maurizio] Nat Inst Neurosci Italy, I-10126 Turin, Italy.
   [Paques, Michel] UPMC Univ Paris 06, Sorbonne Univ, INSERM, CNRS,Vis Inst, F-75012 Paris, France.
   [Paques, Michel] Ctr Hosp Natl Ophtalmol Quinze Vingts, INSERM, DHOS, CIC 503, F-75012 Paris, France.
C3 University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia;
   University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale
   San Raffaele; University of Turin; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); International Center for Genetic
   Engineering & Biotechnology (ICGEB); Centre National de la Recherche
   Scientifique (CNRS); Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite; CHNO des Quinze-Vingts; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite
RP Serini, G (通讯作者)，Univ Turin, Sch Med, Dept Oncol, I-10060 Turin, Italy.; Giraudo, E; Serini, G (通讯作者)，IRCCS, FPO, Candiolo Canc Inst, I-10060 Turin, Italy.; Giraudo, E (通讯作者)，Univ Turin, Dept Sci & Drug Technol, I-10125 Turin, Italy.
EM enrico.giraudo@ircc.it; guido.serini@ircc.it
RI Ghitti, Michela/J-6038-2016; musco, giovanna/I-7122-2012; giustetto,
   maurizio/D-6606-2011; ghitti, michela/ABA-7693-2021; Maione,
   Federica/K-6679-2016; Cascone, Ilaria/Q-7844-2018; Giraudo,
   Enrico/K-3192-2016; Giraudo, Enrico/K-6441-2019; Musco,
   Giovanna/Q-2756-2019; Serini, Guido/AAF-2873-2021; GIACCA,
   MAURO/J-9287-2016
OI Ghitti, Michela/0000-0003-4059-0095; musco,
   giovanna/0000-0002-0469-2994; giustetto, maurizio/0000-0003-1323-4060;
   ghitti, michela/0000-0003-4059-0095; Maione,
   Federica/0000-0003-2789-799X; Cascone, Ilaria/0000-0003-4903-8926;
   Giraudo, Enrico/0000-0003-4128-4786; Giraudo,
   Enrico/0000-0003-4128-4786; Serini, Guido/0000-0002-3502-8367; GIACCA,
   MAURO/0000-0003-2927-7225; Camillo, Chiara/0000-0001-8000-3188; Morello,
   Noemi/0000-0001-8988-1665; Cagnoni, Gabriella/0000-0002-9718-0321;
   Gioelli, Noemi/0000-0002-4982-8410; Valdembri,
   Donatella/0000-0003-4590-417X
FU Italian Association for Cancer Research (AIRC-IG) [13016, 16702, 15645,
   15179]; Fondazione Piemontese per la Ricerca sul Cancro (FPRC)-ONLUS;
   Associazione "Augusto per la Vita"; Swiss National Science Foundation
   [CRSII3 160742/1]; Ministero della Salute [RF-2011-02350836]; Agence
   National de la Recherche grant "Normather"; Fondazione Telethon
   [GGP15098]; Albero di Greta ONLUS; International Foundation for CDKL5
   Research; Giulio Dalbesio Memorial Cancer Research Fellowship;
   Associazione Augusto per la Vita
FX This study was supported by Italian Association for Cancer Research
   (AIRC-IG grant nos. 13016 and 16702 to G.S., 15645 to E.G., and 15179 to
   L.T.), Fondazione Piemontese per la Ricerca sul Cancro (FPRC)-ONLUS
   grant "MIUR 2010 Vaschetto-5 per mille 2010 MIUR" and "FPRC-5 per mille
   2014 Ministero Salute" (to G.S., E.G., and L.T.), Associazione "Augusto
   per la Vita" (to G.S.), Swiss National Science Foundation (Sinergia
   grant no. CRSII3 160742/1 to E.G.), Ministero della Salute (grant no.
   RF-2011-02350836 to G.M.), Agence National de la Recherche grant
   "Normather" (to I.C.), Fondazione Telethon (grant no. GGP15098 to M.
   Giustetto), Albero di Greta ONLUS (to M. Giustetto), and International
   Foundation for CDKL5 Research (to M. Giustetto). C.C. was supported, in
   part, by the Giulio Dalbesio Memorial Cancer Research Fellowship, in
   partnership with Associazione Augusto per la Vita. N.M. was supported by
   a fellowship from Fondazione Telethon (grant no. GGP15098).
CR Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205
   Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077
   Antipenko A, 2003, NEURON, V39, P589, DOI 10.1016/S0896-6273(03)00502-6
   Atwal JK, 2003, J NEUROSCI, V23, P7602
   Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Barresi V, 2009, VIRCHOWS ARCH, V454, P563, DOI 10.1007/s00428-009-0757-3
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Camillo C, 2017, METHODS MOL BIOL, V1493, P195, DOI 10.1007/978-1-4939-6448-2_14
   Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7
   Casazza A, 2014, ONCOGENE, V33, P1743, DOI 10.1038/onc.2013.121
   Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007
   Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101
   Cerani A, 2013, CELL METAB, V18, P505, DOI 10.1016/j.cmet.2013.09.003
   Cheng AL, 1996, J PHYS CHEM-US, V100, P1927, DOI 10.1021/jp951968y
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Winter F, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/3679545
   Fournier AE, 2000, J CELL BIOL, V149, P411, DOI 10.1083/jcb.149.2.411
   Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53
   Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726
   Gilles ME, 2016, CANCER RES, V76, P7181, DOI 10.1158/0008-5472.CAN-16-0300
   Greaves M, 2015, CANCER DISCOV, V5, P806, DOI 10.1158/2159-8290.CD-15-0439
   Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6
   Guo HF, 2015, J BIOL CHEM, V290, P29120, DOI 10.1074/jbc.R115.687327
   Guttmann-Raviv N, 2007, J BIOL CHEM, V282, P26294, DOI 10.1074/jbc.M609711200
   Hanchate NK, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002896
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006
   Janssen BJC, 2012, NAT STRUCT MOL BIOL, V19, P1293, DOI 10.1038/nsmb.2416
   Janssen BJC, 2010, NATURE, V467, P1118, DOI 10.1038/nature09468
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Jung HS, 2012, NAT REV NEUROSCI, V13, P308, DOI 10.1038/nrn3210
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kigel B, 2011, BLOOD, V118, P4285, DOI 10.1182/blood-2011-03-341388
   Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8
   Koppel AM, 1998, J BIOL CHEM, V273, P15708, DOI 10.1074/jbc.273.25.15708
   Kruger RR, 2005, NAT REV MOL CELL BIO, V6, P789, DOI 10.1038/nrm1740
   Kumanogoh A, 2013, NAT REV IMMUNOL, V13, P802, DOI 10.1038/nri3545
   Kuroki T, 2003, CANCER RES, V63, P3352
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Le Jan S, 2012, ARTERIOSCL THROM VAS, V32, P1255, DOI 10.1161/ATVBAHA.111.240622
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Maione F, 2012, J CLIN INVEST, V122, P1832, DOI 10.1172/JCI58976
   Maione F, 2009, J CLIN INVEST, V119, P3356, DOI 10.1172/JCI36308
   Montassar F, 2017, FASEB J, V31, P1107, DOI 10.1096/fj.201600351R
   Moreira IS, 2007, PROTEINS, V68, P803, DOI 10.1002/prot.21396
   Nogi T, 2010, NATURE, V467, P1123, DOI 10.1038/nature09473
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Pall S, 2013, COMPUT PHYS COMMUN, V184, P2641, DOI 10.1016/j.cpc.2013.06.003
   Pang HB, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500821
   Pang HB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5904
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Piper M, 2005, NAT NEUROSCI, V8, P179, DOI 10.1038/nn1380
   Potiron VA, 2007, CANCER RES, V67, P8708, DOI 10.1158/0008-5472.CAN-06-3612
   Qin QY, 2010, P NATL ACAD SCI USA, V107, P13883, DOI 10.1073/pnas.1008652107
   Radu M, 2013, JOVE-J VIS EXP, DOI 10.3791/50062
   Sabag AD, 2014, J CELL SCI, V127, P5240, DOI 10.1242/jcs.155960
   Sakai T, 1999, J BIOL CHEM, V274, P29666, DOI 10.1074/jbc.274.42.29666
   Sakurai A, 2010, MOL CELL BIOL, V30, P3086, DOI 10.1128/MCB.01652-09
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Semenza GL, 2016, MOL ASPECTS MED, V47-48, P15, DOI 10.1016/j.mam.2015.09.004
   Serini G, 2013, J INTERN MED, V273, P138, DOI 10.1111/joim.12017
   Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784
   Shahi P, 2017, ONCOGENE, V36, P5567, DOI 10.1038/onc.2017.165
   Siebold C, 2013, SEMIN CELL DEV BIOL, V24, P139, DOI 10.1016/j.semcdb.2012.11.003
   Song X, 2012, MED ORAL PATOL ORAL, V17, pE962, DOI 10.4317/medoral.18168
   Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X
   Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031
   Tang C, 2014, INT J CLIN EXP PATHO, V7, P4782
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Tse C, 2002, CANCER RES, V62, P542
   Valdembri D, 2009, PLOS BIOL, V7, P115, DOI 10.1371/journal.pbio.1000025
   Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408
   Wang YX, 2013, ELIFE, V2, DOI 10.7554/eLife.01279
   WANG YX, 2012, SCI SIGNAL, V5
   Welford SM, 2011, MOL CANCER RES, V9, P538, DOI 10.1158/1541-7786.MCR-11-0065
   Worzfeld T, 2014, NAT REV DRUG DISCOV, V13, P603, DOI 10.1038/nrd4337
   Yacoub M, 2009, HISTOPATHOLOGY, V55, P392, DOI 10.1111/j.1365-2559.2009.03406.x
   Yan-Chun L., 2015, APPL IMMUNOHISTO M M, V25, P251
   Yaron A, 2005, NEURON, V45, P513, DOI 10.1016/j.neuron.2005.01.013
   Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211
   Zylbersztejn K, 2012, J CELL BIOL, V196, P37, DOI 10.1083/jcb.201106113
NR 89
TC 37
Z9 37
U1 0
U2 13
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 23
PY 2018
VL 10
IS 442
AR eaah4807
DI 10.1126/scitranslmed.aah4807
PG 15
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GG9YG
UT WOS:000433056400001
PM 29794061
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Liang, KJ
   Woodard, KT
   Weaver, MA
   Gaylor, JP
   Weiss, ER
   Samulski, RJ
AF Liang, Katharine J.
   Woodard, Kenton T.
   Weaver, Mark A.
   Gaylor, John Paul
   Weiss, Ellen R.
   Samulski, R. Jude
TI AAV-Nrf2 Promotes Protection and Recovery in Animal Models of Oxidative
   Stressle
SO MOLECULAR THERAPY
LA English
DT Article
ID INDUCED PHOTORECEPTOR APOPTOSIS; LEBER CONGENITAL AMAUROSIS;
   GENE-THERAPY; SULFORAPHANE PROTECTS; KEAP1-NRF2 SYSTEM; UP-REGULATION;
   HEMOPHILIA-B; LIGHT DAMAGE; MOUSE MODEL; NRF2
AB NRF2 is a transcription factor that drives antioxidant gene expression in multiple organ systems. We hypothesized that Nrf2 overexpression could be therapeutically applied toward diseases in which redox homeostasis is disrupted. In this study, adeno-associated virus (AAV)-Nrf2 was tested in a mouse model of acute acetaminophen-induced liver toxicity and successfully conferred protection from hepatotoxicity, validating the vector design and early onset of NRF2-mediated protection. Furthermore, therapeutic potential of AAV-Nrf2 in chronic disease also was tested in a light -induced mouse model of age-related macular degeneration. Adult BALB/c mice were intravitreally injected with AAV-Nrf2 and subject to light damage following injection. Retinal thickness and function were monitored following light damage using optical coherence tomography and electroretinography, respectively. By 3 months post-damage, injected eyes had greater retinal thickness compared to uninjected controls. At 1 month post-damage, AAV-Nrf2 injection facilitated full functional recovery from light damage. Our results suggest a therapeutic potential for Nrf2 overexpression in acute and long-term capacities in multiple organ systems, opening up doors for combination gene therapy where replacement gene therapy requires additional therapeutic support to prevent further degeneration.
C1 [Liang, Katharine J.; Woodard, Kenton T.; Gaylor, John Paul; Samulski, R. Jude] Univ North Carolina Chapel Hill, Gene Therapy Ctr, 7119 Thurston Bowles Bldg,104 Manning Dr, Chapel Hill, NC 27599 USA.
   [Weaver, Mark A.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC 27599 USA.
   [Weaver, Mark A.] Univ North Carolina Chapel Hill, Dept Biostat, Chapel Hill, NC 27599 USA.
   [Weiss, Ellen R.] Univ North Carolina Chapel Hill, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill; University of North Carolina School of Medicine
RP Samulski, RJ (通讯作者)，Univ North Carolina Chapel Hill, Gene Therapy Ctr, 7119 Thurston Bowles Bldg,104 Manning Dr, Chapel Hill, NC 27599 USA.
EM rjs@med.unc.edu
RI , Animal Studies Core/ADK-4234-2022; , Histology Research Core
   Facility/ABF-6317-2021; Ariel, Pablo/AGJ-4118-2022; Weiss,
   Ellen/AAK-9868-2020; , Animal Studies Core/AAF-4432-2022
FU NCI Center Core Support Grant [CA16086]; UNC Lineberger Comprehensive
   Cancer Center; NIH through NIA [F30AG044100]; NEI [R01EY012224]; NIDDK
   [R0IDK084033]; NHLBI [P01HL112761]; NIAID [R01A1117408, R01AI072176];
   NINDS [5T32NS007431]; NCATS [UL1TR001111]; NATIONAL CANCER INSTITUTE
   [P30CA016086] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR001111] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY012224] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL112761]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [R01AI072176, R01AI117408] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK084033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007431] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [F30AG044100] Funding Source: NIH
   RePORTER
FX The authors thank C. Li for his assistance with liver experiments and
   valuable discussion; M. Ross for his assistance with animal perfusions;
   B. Sullivan and H. Jivanji for their contributions to OCT measurements;
   A. Travis for her contribution of the MATLAB program used for ERG
   analysis; R. Heineman for her work on statistical analysis for the
   luciferase assay; and T. Lentz, M.B. Major, and S. Houck for valuable
   discussion. The authors also thank the following core facilities at the
   University of North Carolina at Chapel Hill for their work on multiple
   aspects of this project the Vector Core, the Center for Gastrointestinal
   Biology and Disease Histology Core, Histology Research Core Facility in
   the Department of Cell Biology and Physiology, the Michael Hooker
   Microscopy Core, the Microscopy Services Laboratory, and the LCCC Animal
   Studies Core Facility. The LCCC Animal Studies Core is supported in part
   by an NCI Center Core Support Grant (CA16086) to the UNC Lineberger
   Comprehensive Cancer Center. The project described was supported by the
   NIH through NIA grant F30AG044100 to K.J.L.; NEI grant R01EY012224 to
   E.R.W.; NIDDK grant R0IDK084033, NHLBI grant P01HL112761, and NIAID
   grants R01A1117408 and R01AI072176 to R.J.S.; NINDS grant 5T32NS007431;
   and NCATS grant UL1TR001111. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   NIH.
CR Ashtari M, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8791
   Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bowles DE, 2012, MOL THER, V20, P443, DOI 10.1038/mt.2011.237
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Calkins MJ, 2010, TOXICOL SCI, V115, P557, DOI 10.1093/toxsci/kfq072
   Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731
   Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098
   Chen PC, 2009, P NATL ACAD SCI USA, V106, P2933, DOI 10.1073/pnas.0813361106
   Chen X, 2013, BRIT J PHARMACOL, V169, P437, DOI 10.1111/bph.12133
   Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   Dreger H, 2009, CARDIOVASC RES, V83, P354, DOI 10.1093/cvr/cvp107
   Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gray SJ, 2011, HUM GENE THER, V22, P1143, DOI 10.1089/hum.2010.245
   Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Hast BE, 2013, CANCER RES, V73, P2199, DOI 10.1158/0008-5472.CAN-12-4400
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Herrmann R, 2010, J NEUROSCI, V30, P3239, DOI 10.1523/JNEUROSCI.4775-09.2010
   Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372
   Kanninen K, 2009, P NATL ACAD SCI USA, V106, P16505, DOI 10.1073/pnas.0908397106
   Kanninen KM, 2015, FREE RADICAL BIO MED, V88, P350, DOI 10.1016/j.freeradbiomed.2015.06.037
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004
   Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200
   Leiser SF, 2010, MOL CELL BIOL, V30, P871, DOI 10.1128/MCB.01145-09
   Li CW, 2011, P NATL ACAD SCI USA, V108, P14258, DOI 10.1073/pnas.1109522108
   Luo C, 2011, MED HYPOTHESES, V77, P174, DOI 10.1016/j.mehy.2011.04.002
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Marc RE, 2008, MOL VIS, V14, P782
   Mazzuferi M, 2013, ANN NEUROL, V74, P560, DOI 10.1002/ana.23940
   Monahan PE, 2015, HUM GENE THER, V26, P69, DOI 10.1089/hum.2014.106
   Mukherjee S, 2008, J AGR FOOD CHEM, V56, P609, DOI 10.1021/jf0728146
   Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012
   Pomeshchik Y, 2014, ANTIOXID REDOX SIGN, V20, P1313, DOI 10.1089/ars.2013.5453
   Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146
   Reid AB, 2005, J PHARMACOL EXP THER, V312, P509, DOI 10.1124/jpet.104.075945
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164
   Uno K, 2010, EXP EYE RES, V90, P493, DOI 10.1016/j.exer.2009.12.012
   Usui S, 2011, FREE RADICAL BIO MED, V51, P1347, DOI 10.1016/j.freeradbiomed.2011.06.010
   Wang CY, 2014, ANTIOXID REDOX SIGN, V21, P2208, DOI 10.1089/ars.2014.5845
   Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Woodard KT, 2016, J VIROL, V90, P9878, DOI 10.1128/JVI.01568-16
   Wu Z, 2008, MOL THER, V16, P280, DOI 10.1038/sj.mt.6300355
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008
NR 60
TC 17
Z9 17
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD MAR 1
PY 2017
VL 25
IS 3
BP 765
EP 779
DI 10.1016/j.ymthe.2016.12.016
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA EO4AF
UT WOS:000396635500019
PM 28253482
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Marneros, AG
AF Marneros, Alexander G.
TI Increased VEGF-A promotes multiple distinct aging diseases of the eye
   through shared pathomechanisms
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; aging; cataract; NLRP3 inflammasome;
   VEGF-A
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; MEMBRANE ATTACK
   COMPLEX; AGE-RELATED CATARACT; SUPEROXIDE-DISMUTASE;
   MACULAR-DEGENERATION; NLRP3 INFLAMMASOME; OXIDATIVE-STRESS; CHOROIDAL
   NEOVASCULARIZATION; RECEPTOR 2
AB While increased VEGF-A has been associated with neovascular age-related macular degeneration (AMD), it is not known whether VEGF-A may also promote other age-related eye diseases. Here, we show that an increase in VEGF-A is sufficient to cause multiple distinct common aging diseases of the eye, including cataracts and both neovascular and non-exudative AMD-like pathologies. In the lens, increased VEGF-A induces age-related opacifications that are associated with ERK hyperactivation, increased oxidative damage, and higher expression of the NLRP3 inflammasome effector cytokine IL-1. Similarly, increased VEGF-A induces oxidative stress and IL-1 expression also in the retinal pigment epithelium (RPE). Targeting NLRP3 inflammasome components or Il1r1 strongly inhibited not only VEGF-A-induced cataract formation, but also both neovascular and non-exudative AMD-like pathologies. Moreover, increased VEGF-A expression specifically in the RPE was sufficient to cause choroidal neovascularization (CNV) as in neovascular AMD, which could be inhibited by RPE-specific inactivation of Flk1, while Tlr2 inactivation strongly reduced CNV. These findings suggest a shared pathogenic role of VEGF-A-induced andNLRP3 inflammasome-mediated IL-1 activation for multiple distinct ocular aging diseases.
C1 [Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.
   [Marneros, Alexander G.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School
RP Marneros, AG (通讯作者)，Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.; Marneros, AG (通讯作者)，Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
EM amarneros@mgh.harvard.edu
OI Marneros, Alexander/0000-0003-3866-020X
FU NEI [R01-EY019297]; BrightFocus Foundation; NATIONAL EYE INSTITUTE
   [R01EY019297] Funding Source: NIH RePORTER
FX For some technical assistance, I would like to thank Oscar Morales and
   Karin Strittmatter. This work was supported by grants to A.G.M. from the
   NEI (R01-EY019297) and from the BrightFocus Foundation.
CR Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje
   Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X
   Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119
   Brydges SD, 2009, IMMUNITY, V30, P875, DOI 10.1016/j.immuni.2009.05.005
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Damert A, 2002, DEVELOPMENT, V129, P1881
   Dhimolea E, 2011, APPL CLIN GENET, V4, P21, DOI 10.2147/TACG.S8146
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Glaccum MB, 1997, J IMMUNOL, V159, P3364
   Gong XH, 2001, INVEST OPHTH VIS SCI, V42, P539
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   He LZ, 2014, AM J PATHOL, V184, P1660, DOI 10.1016/j.ajpath.2014.02.007
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Into T, 2010, J BIOL CHEM, V285, P35759, DOI 10.1074/jbc.M110.126904
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Klein AP, 2005, AM J EPIDEMIOL, V161, P707, DOI 10.1093/aje/kwi102
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Lalor SJ, 2011, J IMMUNOL, V186, P5738, DOI 10.4049/jimmunol.1003597
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Li JY, 2007, NAT CELL BIOL, V9, P276, DOI 10.1038/ncb1541
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   Lin DB, 2005, MOL VIS, V11, P853
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miquerol L, 1999, DEV BIOL, V212, P307, DOI 10.1006/dbio.1999.9355
   Miura K, 2013, HEPATOLOGY, V57, P577, DOI 10.1002/hep.26081
   Monaghan-Benson E, 2009, J BIOL CHEM, V284, P25602, DOI 10.1074/jbc.M109.009894
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Neelam S, 2013, MOL VIS, V19, P1
   Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720
   Olofsson EM, 2012, CLIN EXP OPHTHALMOL, V40, P813, DOI 10.1111/j.1442-9071.2012.02794.x
   Olofsson EM, 2009, INVEST OPHTH VIS SCI, V50, P2913, DOI 10.1167/iovs.09-3510
   Petrash JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12940
   Rajkumar S, 2013, INVEST OPHTH VIS SCI, V54, P6224, DOI 10.1167/iovs.13-11935
   Rao GN, 2011, CURR OPIN OPHTHALMOL, V22, P4, DOI 10.1097/ICU.0b013e3283414fc8
   Rautiainen S, 2014, JAMA OPHTHALMOL, V132, P247, DOI 10.1001/jamaophthalmol.2013.6241
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Semkova I, 2011, INVEST OPHTH VIS SCI, V52, P6101, DOI 10.1167/iovs.10-5996
   Shaikh M R, 1997, J Pak Med Assoc, V47, P141
   Shi YY, 2011, GRAEF ARCH CLIN EXP, V249, P1667, DOI 10.1007/s00417-011-1699-4
   Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Wang L, 2014, CARDIOVASC RES, V101, P383, DOI 10.1093/cvr/cvt258
   Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zatechka DS, 2002, EXP EYE RES, V74, P703, DOI 10.1006/exer.2002.1168
   Zhang L, 2010, THESIS 4 MILITARY ME
NR 65
TC 29
Z9 32
U1 1
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD MAR
PY 2016
VL 8
IS 3
BP 208
EP 231
DI 10.15252/emmm.201505613
PG 24
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DG5WT
UT WOS:000372151100004
PM 26912740
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU De Falco, S
AF De Falco, Sandro
TI Antiangiogenesis therapy: an update after the first decade
SO KOREAN JOURNAL OF INTERNAL MEDICINE
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; MACULAR DEGENERATION;
   MOLECULAR-MECHANISMS; FACTOR RECEPTOR-1; DOUBLE-BLIND; CELL; ANTIBODY;
   RANIBIZUMAB; COMBINATION
AB Angiogenesis is a complex biological phenomenon that forms new blood vessels from the pre-existing vasculature. Aberrant angiogenesis has been implicated in a variety of diseases such as cancer, atherosclerosis, arthritis, obesity, pulmonary hypertension, diabetic retinopathy, and age-related macular degeneration. These conditions collectively affect nearly io% of the global population. Much effort has focused on identifying new therapeutic agents that inhibit pathological angiogenesis since 1971, when Judah Folkman published the hypothesis that tumor growth is angiogenesis-dependent and that its inhibition may be therapeutic. In 2004, the U.S. Food and Drug Administration approved the first antiangiogenic drug for the treatment of metastatic colon cancer, bevacizumab (Avastin, Genen-tech). This drug is a humanized monoclonal antibody that neutralizes the vascular endothelial growth factor. It is used in combination with chemotherapy, and its use began the era of antiangiogenesis therapy. Several new therapeutic agents have been added to the list of approved drugs, and clinical trials of new therapeutic options and antiangiogenic agents are ongoing. This review describes the progress made in the first decade of antiangiogenesis therapy, and addresses both validated and possible targets for future drug development.
C1 Inst Genet & Biophys Adriano Buzzati Trayerso, Angiogenesis LAB, I-80131 Naples, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e
   Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)
RP De Falco, S (通讯作者)，Inst Genet & Biophys Adriano Buzzati Trayerso, Angiogenesis LAB, Via Pietro Castellino 111, I-80131 Naples, Italy.
EM sandro.defalco@igh.cnr.it
RI De Falco, Sandro/P-6724-2015
OI De Falco, Sandro/0000-0002-6501-1697
FU Associazione Italiana Ricerca sul Cancro (AIRC) [IG 11420]
FX The author would like to thank Anna Maria Aliperti for editing the
   manuscript. S.D.F. was supported by the Associazione Italiana Ricerca
   sul Cancro (AIRC grant no. IG 11420).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andre T, 2013, B CANCER, V100, P1027, DOI 10.1684/bdc.2013.1808
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Besse B, 2013, ANN ONCOL, V24, P90, DOI 10.1093/annonc/mds281
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bry M, 2010, CIRCULATION, V122, P1725, DOI 10.1161/CIRCULATIONAHA.110.957332
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Ciombor KK, 2013, CLIN CANCER RES, V19, P1920, DOI 10.1158/1078-0432.CCR-12-2911
   Clarke JM, 2013, EXPERT OPIN BIOL TH, V13, P1187, DOI 10.1517/14712598.2013.810717
   Crawford Y, 2009, CELL TISSUE RES, V335, P261, DOI 10.1007/s00441-008-0675-8
   De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8
   De Falco S, 2012, EXP MOL MED, V44, P1, DOI 10.3858/emm.2012.44.1.025
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123
   Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034
   Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21
   Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Garnock-Jones KP, 2011, DRUGS, V71, P455, DOI 10.2165/11206900-000000000-00000
   Gigante B, 2006, FASEB J, V20, P970, DOI 10.1096/fj.05-4481fje
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Gu CH, 2013, EXP CELL RES, V319, P1306, DOI 10.1016/j.yexcr.2013.02.003
   Hagberg CE, 2010, NATURE, V464, P917, DOI 10.1038/nature08945
   Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7
   Ho TH, 2011, FUTURE ONCOL, V7, P1247, DOI [10.2217/FON.11.107, 10.2217/fon.11.107]
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369
   Kimoto K, 2011, J OPHTHALMOL, V2012
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Lyseng-Williamson KA, 2013, BIODRUGS, V27, P525, DOI 10.1007/s40259-013-0061-2
   MacDonald TJ, 2013, NEURO-ONCOLOGY, V15, P1438, DOI 10.1093/neuonc/not058
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mosch B, 2010, J ONCOL, V2010, DOI 10.1155/2010/135285
   Motzer RJ, 2006, J CLIN ONCOL, V24, P16, DOI 10.1200/JCO.2005.02.2574
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298
   O'Connor R, 2007, EXPERT OPIN DRUG MET, V3, P805, DOI 10.1517/17425255.3.6.805
   Peeters M, 2013, BRIT J CANCER, V108, P503, DOI 10.1038/bjc.2012.594
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Presta LG, 1997, CANCER RES, V57, P4593
   Ribatti Domenico, 2010, J Angiogenes Res, V2, P27, DOI 10.1186/2040-2384-2-27
   Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102
   Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Schmidt-Erfurth U, 2013, OPHTHALMOLOGY
   Schoffski P, 2012, EXPERT REV ANTICANC, V12, P711, DOI [10.1586/ERA.12.41, 10.1586/era.12.41]
   Schwartz JD, 2010, CANCER-AM CANCER SOC, V116, P1027, DOI 10.1002/cncr.24789
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445
   Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045
   Tarallo V, 2010, CANCER RES, V70, P1804, DOI 10.1158/0008-5472.CAN-09-2609
   Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130
   Tugues S, 2011, MOL ASPECTS MED, V32, P88, DOI 10.1016/j.mam.2011.04.004
   Tvorogov D, 2010, CANCER CELL, V18, P630, DOI 10.1016/j.ccr.2010.11.001
   Verma S, 2011, ONCOLOGIST, V16, P25, DOI 10.1634/theoncologist.2010-0278
   Ward JE, 2010, CLIN CANCER RES, V16, P5923, DOI 10.1158/1078-0432.CCR-10-0728
   Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040
   Wu Y, 2006, CLIN CANCER RES, V12, P6573, DOI 10.1158/1078-0432.CCR-06-0831
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yodoi Y, 2009, AM J OPHTHALMOL, V147, P816, DOI 10.1016/j.ajo.2008.11.020
NR 87
TC 43
Z9 44
U1 0
U2 7
PU KOREAN ASSOC INTERNAL MEDICINE
PI SEOUL
PA 101-2501 LOTTE CASTLE PRESIDENT, 109 MAPO-DAERO, MAPO-GU, SEOUL,
   121-916, SOUTH KOREA
SN 1226-3303
EI 2005-6648
J9 KOREAN J INTERN MED
JI Korean J. Intern. Med.
PD JAN
PY 2014
VL 29
IS 1
BP 1
EP 11
DI 10.3904/kjim.2014.29.1.1
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AY7NK
UT WOS:000347746500001
PM 24574826
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Georgiadis, A
   Tschernutter, M
   Bainbridge, JWB
   Balaggan, KS
   Mowat, F
   West, EL
   Munro, PMG
   Thrasher, AJ
   Matter, K
   Balda, MS
   Ali, RR
AF Georgiadis, Anastasios
   Tschernutter, Marion
   Bainbridge, James W. B.
   Balaggan, Kamaljit S.
   Mowat, Freya
   West, Emma L.
   Munro, Peter M. G.
   Thrasher, Adrian J.
   Matter, Karl
   Balda, Maria S.
   Ali, Robin R.
TI The Tight Junction Associated Signalling Proteins ZO-1 and ZONAB
   Regulate Retinal Pigment Epithelium Homeostasis in Mice
SO PLOS ONE
LA English
DT Article
ID BOX-BINDING PROTEIN; MESENCHYMAL TRANSITION; PROLIFERATIVE
   VITREORETINOPATHY; DIABETIC-RETINOPATHY; CELL-PROLIFERATION;
   GENE-EXPRESSION; E-CADHERIN; TRANSCRIPTION; BARRIER; DIFFERENTIATION
AB Cell-cell adhesion regulates the development and function of epithelia by providing mechanical support and by guiding cell proliferation and differentiation. The tight junction (TJ) protein zonula occludens (ZO)-1 regulates cell proliferation and gene expression by inhibiting the activity of the Y-box transcription factor ZONAB in cultured epithelial cells. We investigated the role of this TJ-associated signalling pathway in the retinal pigment epithelium (RPE) in vivo by lentivirally-mediated overexpression of ZONAB, and knockdown of its cellular inhibitor ZO-1. Both overexpression of ZONAB or knockdown of ZO-1 resulted in increased RPE proliferation, and induced ultrastructural changes of an epithelial-mesenchymal transition (EMT)-like phenotype. Electron microscopy analysis revealed that transduced RPE monolayers were disorganised with increased pyknosis and monolayer breaks, correlating with increased expression of several EMT markers. Moreover, fluorescein angiography analysis demonstrated that the increased proliferation and EMT-like phenotype induced by overexpression of ZONAB or downregulation of ZO-1 resulted in RPE dysfunction. These findings demonstrate that ZO-1 and ZONAB are critical for differentiation and homeostasis of the RPE monolayer and may be involved in RPE disorders such as proliferative vitroretinopathy and atrophic age-related macular degeneration.
C1 [Georgiadis, Anastasios; Tschernutter, Marion; Bainbridge, James W. B.; Balaggan, Kamaljit S.; Mowat, Freya; West, Emma L.; Ali, Robin R.] UCL, Dept Genet, UCL Inst Ophthalmol, London, England.
   [Matter, Karl; Balda, Maria S.] UCL, Dept Cell Biol, UCL Inst Ophthalmol, London, England.
   [Munro, Peter M. G.] UCL, Electron Microscopy Unit, UCL Inst Ophthalmol, London, England.
   [Thrasher, Adrian J.; Ali, Robin R.] UCL, Mol Immunol Unit, UCL Inst Child Hlth, London, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; University of London; University College London
RP Georgiadis, A (通讯作者)，UCL, Dept Genet, UCL Inst Ophthalmol, London, England.
EM m.balda@ucl.ac.uk; r.ali@ucl.ac.uk
RI Georgiadis, Anastasios/G-8777-2012; West, Emma L/C-5252-2013; Matter,
   Karl/C-4880-2008; MOWAT, FREYA/AAD-5102-2021
OI Georgiadis, Anastasios/0000-0001-5079-3588; Matter,
   Karl/0000-0001-8026-7220; Thrasher, Adrian/0000-0002-6097-6115; Mowat,
   Freya/0000-0002-8726-8768; West, Emma/0000-0002-7006-3686;
   /0000-0002-8427-6746; Ali, Robin/0000-0003-3126-6517; Bainbridge,
   James/0000-0003-1318-8201
FU European Union [LSHG-CT-2005-512036]; Medical Research Council; National
   Institute for Health Research Biomedical Centre for Ophthalmology; BBSRC
   [BB/H002294/1] Funding Source: UKRI; MRC [G0400678, G0700743, G0900098]
   Funding Source: UKRI; Biotechnology and Biological Sciences Research
   Council [BB/H002294/1] Funding Source: researchfish; Medical Research
   Council [G0400678, G0900098, G0700743] Funding Source: researchfish;
   Great Ormond Street Hospital Childrens Charity [V1223] Funding Source:
   researchfish
FX This project was supported by the European Union (Integrated Project
   EVI-GENORET: LSHG-CT-2005-512036), Medical Research Council and the
   National Institute for Health Research Biomedical Centre for
   Ophthalmology. JWBB is a Wellcome Trust Advanced Fellow. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Ali RR, 1996, HUM MOL GENET, V5, P591, DOI 10.1093/hmg/5.5.591
   Anderson JM, 2004, CURR OPIN CELL BIOL, V16, P140, DOI 10.1016/j.ceb.2004.01.005
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Arakawa Y, 2004, BIOCHEM BIOPH RES CO, V322, P297, DOI 10.1016/j.bbrc.2004.04.208
   Bainbridge JWB, 2006, GENE THER, V13, P1191, DOI 10.1038/sj.gt.3302812
   Bainbridge JWB, 2001, GENE THER, V8, P1665, DOI 10.1038/sj.gt.3301574
   Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024
   Balda MS, 2003, TRENDS CELL BIOL, V13, P310, DOI 10.1016/S0962-8924(03)00105-3
   Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020
   Buchert M, 2009, GASTROENTEROLOGY, V137, P156, DOI 10.1053/j.gastro.2009.03.037
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349
   Defoe DM, 2007, MOL VIS, V13, P273
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675
   Katsuno T, 2008, MOL BIOL CELL, V19, P2465, DOI 10.1091/mbc.E07-12-1215
   Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300
   Kroll P, 2007, OPHTHALMOLOGICA, V221, P78, DOI 10.1159/000098253
   Leal EC, 2007, INVEST OPHTH VIS SCI, V48, P5257, DOI 10.1167/iovs.07-0112
   Lee H, 2007, INVEST OPHTH VIS SCI, V48, P4291, DOI 10.1167/iovs.07-0086
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Lima WR, 2010, J AM SOC NEPHROL, V21, P478, DOI 10.1681/ASN.2009070698
   Lopes VS, 2007, MOL BIOL CELL, V18, P3914, DOI 10.1091/mbc.E07-03-0268
   Matter K, 2007, J CELL SCI, V120, P1505, DOI 10.1242/jcs.005975
   Moiseyev G, 2006, J BIOL CHEM, V281, P2835, DOI 10.1074/jbc.M508903200
   Pannequin J, 2007, MOL CANCER RES, V5, P1147, DOI 10.1158/1541-7786.MCR-07-0198
   Paris L, 2008, BBA-BIOMEMBRANES, V1778, P646, DOI 10.1016/j.bbamem.2007.08.004
   Pastor JC, 1998, SURV OPHTHALMOL, V43, P3, DOI 10.1016/S0039-6257(98)00023-X
   Pena C, 2006, INT J CANCER, V119, P2098, DOI 10.1002/ijc.22083
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102
   Sourisseau T, 2006, MOL CELL BIOL, V26, P2387, DOI 10.1128/MCB.26.6.2387-2398.2006
   STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tsapara A, 2006, MOL BIOL CELL, V17, P1322, DOI 10.1091/mbc.E05-06-0507
   Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
NR 40
TC 79
Z9 82
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2010
VL 5
IS 12
AR e15730
DI 10.1371/journal.pone.0015730
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 701DD
UT WOS:000285793600031
PM 21209887
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Gupta, D
   Goldsmith, C
   Burton, RL
AF Gupta, D.
   Goldsmith, C.
   Burton, R. L.
TI Surgery for bilateral macular holes
SO EYE
LA English
DT Article
DE bilateral macular hole surgery
ID SURGICAL-MANAGEMENT; COMPLICATION; OUTCOMES
AB Objective To report on bilateral sequential macular hole repair.
   Design Retrospective case series report.
   Participants Sixteen eyes of eight patients with reduced visual acuity (VA) and metamorphopsia due to bilateral macular hole.
   Intervention Patients underwent vitrectomy surgery for bilateral macular hole. Seven patients had both eyes operated on consecutively at the same operating session. One patient had surgery to the fellow eye the next day. Strict facedown posturing was undertaken for 1 week by all patients.
   Main Outcome Measures Closure of macular hole; final VA; complications.
   Results In 15 (94%) eyes the macular holes closed with resolution of symptoms; the mean VA at discharge was 6/15; two patients had reduced VA due to age-related macular degeneration (6/36, 6/18); five eyes had entry site tears; there was one case of lens touch with elevated intraocular pressure (IOP); in one (6%) patient the macular hole reopened after later cataract surgery (VA 6/24).
   Conclusions Surgical closure of bilateral macular holes at the same operating session has distinct advantages but also considerable disadvantages. Case selection is paramount-patients require careful preoperative counselling and postoperative support, especially during the posturing week.
C1 [Gupta, D.; Goldsmith, C.] James Paget Univ Teaching Hosp, Dept Ophthalmol, Gorleston NR31 6LA, England.
   [Burton, R. L.] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England.
C3 Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk &
   Norwich University Hospital
RP Gupta, D (通讯作者)，James Paget Univ Teaching Hosp, Dept Ophthalmol, Gorleston NR31 6LA, England.
EM dgupta_01@yahoo.com
CR Benson WE, 2001, OPHTHALMOLOGY, V108, P1328, DOI 10.1016/S0161-6420(01)00731-X
   CHARLES S, 2002, VITREOUS MICROSURGER, P2
   Ho AC, 1998, SURV OPHTHALMOL, V42, P393, DOI 10.1016/S0039-6257(97)00132-X
   Holekamp NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1607
   Jaycock PD, 2005, EYE, V19, P879, DOI 10.1038/sj.eye.6701679
   Lewis ML, 1996, GRAEF ARCH CLIN EXP, V234, P241, DOI 10.1007/BF00430416
   Mann D F, 1996, Optom Clin, V5, P95
   MCDONNELL PJ, 1982, AM J OPHTHALMOL, V93, P777, DOI 10.1016/0002-9394(82)90474-3
   Merkur AB, 2007, RETINA-J RET VIT DIS, V27, P365, DOI 10.1097/01.iae.0000242856.72514.5a
   Mester U, 1998, OPHTHALMOLOGE, V95, P158, DOI 10.1007/s003470050255
   Niwa H, 2005, AM J OPHTHALMOL, V140, P370, DOI 10.1016/j.ajo.2005.03.070
   Oz O, 2004, OPHTHAL SURG LAS IM, V35, P207, DOI 10.3928/1542-8877-20040501-07
   Rubinstein A, 2007, CLIN EXP OPHTHALMOL, V35, P458, DOI 10.1111/j.1442-9071.2007.01532.x
   Simcock PR, 2001, BRIT J OPHTHALMOL, V85, P1316, DOI 10.1136/bjo.85.11.1316
   Szijarto Z, 2006, ANN OPHTHALMOL, V38, P149, DOI 10.1385/AO:38:2:149
   Szurman P, 2000, KLIN MONATSBL AUGENH, V217, P351, DOI 10.1055/s-2000-9574
   Tabandeh H, 2002, OPHTHALMIC SURG LAS, V33, P9
   Tornambe PE, 1997, RETINA-J RET VIT DIS, V17, P179, DOI 10.1097/00006982-199705000-00001
   Tranos PG, 2007, EYE, V21, P802, DOI 10.1038/sj.eye.6702339
   Vincent JM, 2003, OPHTHAL SURG LAS IM, V34, P485
   YANOFF M, 1999, OPHTHALMOLOGY MOSBY, pCH8
NR 21
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2009
VL 23
IS 3
BP 556
EP 558
DI 10.1038/eye.2008.75
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 418AL
UT WOS:000264119500009
PM 18388963
OA Bronze
DA 2022-11-30
ER

PT J
AU Ye, JH
   Ryu, SB
   Kim, KH
   Goo, YS
AF Ye, Jang Hee
   Ryu, Sang Baek
   Kim, Kyung Hwan
   Goo, Yong Sook
TI Functional Connectivity Map of Retinal Ganglion Cells for Retinal
   Prosthesis
SO KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
LA English
DT Article
DE Retinal prosthesis; Retinal ganglion cell; Multielectrode array; Narrow
   correlation; Functional connectivity map
ID RABBIT; MORPHOLOGIES; STIMULATION; MECHANISMS
AB Retinal prostheses are being developed to restore vision for the blind with retinal diseases such as retinitis pigmentosa (RP) or age-related macular degeneration (AMD). Among the many issues for prosthesis development, stimulation encoding strategy is one of the most essential electrophysiological issues. The more we understand the retinal circuitry how it encodes and processes visual information, the greater it could help decide stimulation encoding strategy for retinal prosthesis. Therefore, we examined how retinal ganglion cells (RGCs) in in-vitro retinal preparation act together to encode a visual scene with multielectrode array (MEA). Simultaneous recording of many RGCs with MEA showed that nearby neurons often fired synchronously, with spike delays mostly within 1 ms range. This synchronized firing - narrow correlation - was blocked by gap junction blocker, heptanol, but not by glutamatergic synapse blocker, kynurenic acid. By tracking down all the RGC pairs which showed narrow correlation, we could harvest 40 functional connectivity maps of RGCs which showed the cell cluster firing together. We suggest that finding functional connectivity map would be useful in stimulation encoding strategy for the retinal prosthesis since stimulating the cluster of RGCs would be more efficient than separately stimulating each individual RGC.
C1 [Ye, Jang Hee; Goo, Yong Sook] Chungbuk Natl Univ, Dept Physiol, Sch Med, Cheongju 361763, South Korea.
   [Ryu, Sang Baek; Kim, Kyung Hwan] Yonsei Univ, Coll Hlth Sci, Dept Biomed Engn, Wonju 220710, South Korea.
   [Ye, Jang Hee; Ryu, Sang Baek; Kim, Kyung Hwan; Goo, Yong Sook] Seoul Natl Univ Hosp, Nano Artificial Vis Res Ctr, Seoul 110744, South Korea.
C3 Chungbuk National University; Yonsei University; Seoul National
   University (SNU); Seoul National University Hospital
RP Goo, YS (通讯作者)，Chungbuk Natl Univ, Dept Physiol, Sch Med, 410 Sungbong Ro, Cheongju 361763, South Korea.
EM ysgoo@chungbuk.ac.kr
RI Abrams, William R/A-5782-2008
OI Kim, Kyung Hwan/0000-0001-9044-0437
FU Ministry of Health Welfare [A050251]; ERC Program of MEST/KOSEF
   [R11-2000-075-01002-0]
FX This work was supported by grants of Ministry of Health & Welfare
   (A050251), ERC Program of MEST/KOSEF (R11-2000-075-01002-0).
CR AMTHOR FR, 1989, J COMP NEUROL, V280, P72, DOI 10.1002/cne.902800107
   AMTHOR FR, 1989, J COMP NEUROL, V280, P97, DOI 10.1002/cne.902800108
   ARNETT D, 1981, J PHYSIOL-LONDON, V317, P29, DOI 10.1113/jphysiol.1981.sp013812
   Brivanlou IH, 1998, NEURON, V20, P527, DOI 10.1016/S0896-6273(00)80992-7
   Brown SP, 2000, NEURON, V27, P371, DOI 10.1016/S0896-6273(00)00044-1
   CALDWELL JH, 1978, J PHYSIOL-LONDON, V276, P257, DOI 10.1113/jphysiol.1978.sp012232
   DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048
   DeVries SH, 1999, J NEUROPHYSIOL, V81, P908, DOI 10.1152/jn.1999.81.2.908
   Egert U, 1998, BRAIN RES PROTOC, V2, P229, DOI 10.1016/S1385-299X(98)00013-0
   GUENTHER E, 2006, ADV NETWORK ELECTROP, P321
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Loewenstein JI, 2004, ARCH OPHTHALMOL-CHIC, V122, P587, DOI 10.1001/archopht.122.4.587
   Margolis DJ, 2007, J NEUROSCI, V27, P5994, DOI 10.1523/JNEUROSCI.0130-07.2007
   MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P350, DOI 10.1152/jn.1983.49.2.350
   Meister M, 1999, NEURON, V22, P435, DOI 10.1016/S0896-6273(00)80700-X
   MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2
   MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207
   Meister M, 1996, P NATL ACAD SCI USA, V93, P609, DOI 10.1073/pnas.93.2.609
   NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   SEO J, 2007, VISUAL PROSTHESIS OP, P107
   Stett A, 2000, VISION RES, V40, P1785, DOI 10.1016/S0042-6989(00)00005-5
   ZRENNER E, 2006, INVEST OPHTHALMOL VI, V47
NR 23
TC 6
Z9 6
U1 0
U2 1
PU KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY
PI SEOUL
PA C/O EDITORIAL OFFICE, 448-13 SEOKYO-DONG, SEOUL, SOUTH KOREA
SN 1226-4512
EI 2093-3827
J9 KOREAN J PHYSIOL PHA
JI KOREAN J. PHYSIOL. PHARMACOL.
PD DEC
PY 2008
VL 12
IS 6
BP 307
EP 314
DI 10.4196/kjpp.2008.12.6.307
PG 8
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA 395LK
UT WOS:000262525400004
PM 19967072
OA Green Published
DA 2022-11-30
ER

PT J
AU Shonat, RD
   Kight, AC
AF Shonat, RD
   Kight, AC
TI Oxygen tension imaging in the mouse retina
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE phosphorescence lifetime; phosphorescence quenching; phase-sensitive
   detection; palladium-porphyrin compound
ID BLOOD-FLOW; IN-VIVO; DIABETIC-RETINOPATHY; INITIAL DIP; PHOSPHORESCENCE;
   CAT; CALIBRATION; PATHOGENESIS; SATURATION; DISRUPTION
AB A newly developed microscope-based imaging system was used to measure the oxygen tension (PO2) inside the retinal and choroidal vessels of mice and to generate in vivo maps of retinal PO2. These maps were generated from the phosphorescence lifetimes of an injected palladium-porphyrin compound using a frequency-domain measurement. The system was fully calibrated and used to produce retinal PO2 maps at different inspiratory oxygen fractions. PO2 rose accordingly and predictably as inspiratory O-2 was stepped from hypoxic to hyperoxic conditions. Important experimental and acquisition parameters necessary for applying phosphorescence lifetime imaging to the mouse eye were investigated, including camera exposure and intensifier gain settings. Because of a need to limit light exposure to the retina, PO2 map quality as measured by the coefficient of determination was investigated as a function of signal-to-noise and accumulated excitation energy deposition. With the development of this technology for use in mice, the potential for investigating the oxygen dynamics in genetically engineered mouse models of retinal disease, including diabetic retinopathy, glaucoma, and age-related macular degeneration, is advanced. (C) 2003 Biomedical Engineering Society.
C1 Worcester Polytech Inst, Dept Biomed Engn, Worcester, MA 01609 USA.
C3 Worcester Polytechnic Institute
RP Shonat, RD (通讯作者)，Worcester Polytech Inst, Dept Biomed Engn, 100 Inst Rd, Worcester, MA 01609 USA.
FU NIDDK NIH HHS [DK32520] Funding Source: Medline; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source:
   NIH RePORTER
CR Alder VA, 1997, CLIN EXP PHARMACOL P, V24, P785, DOI 10.1111/j.1440-1681.1997.tb02133.x
   ALDER VA, 1983, INVEST OPHTH VIS SCI, V24, P30
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P261, DOI 10.1111/j.1748-1716.1972.tb05177.x
   AMIN RH, 1997, INVEST OPHTH VIS SCI, V38, P2729
   Beach JM, 1999, J APPL PHYSIOL, V86, P748, DOI 10.1152/jappl.1999.86.2.748
   BERKOWITZ BA, 1995, MAGNET RESON MED, V33, P579, DOI 10.1002/mrm.1910330419
   BERKOWITZ BA, 1991, INVEST OPHTH VIS SCI, V32, P2382
   Bonhoeffer Tobias, 1996, P55
   BUERK DG, 1993, MICROVASC RES, V45, P134, DOI 10.1006/mvre.1993.1013
   Buxton RB, 2001, NEUROIMAGE, V13, P953, DOI 10.1006/nimg.2001.0814
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Crittin M, 2002, KLIN MONATSBL AUGENH, V219, P289, DOI 10.1055/s-2002-30648
   Duong TQ, 2002, INVEST OPHTH VIS SCI, V43, P1176
   Golub AS, 2002, COMP BIOCHEM PHYS A, V132, P169, DOI 10.1016/S1095-6433(01)00544-X
   Golub AS, 1999, PHOTOCHEM PHOTOBIOL, V69, P624, DOI 10.1111/j.1751-1097.1999.tb03338.x
   HAYREH SS, 1976, T AM ACAD OPHTHALMOL, V81, P197
   Kim DS, 2000, NAT NEUROSCI, V3, P164, DOI 10.1038/72109
   LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K
   LAKOWICZ JR, 1991, REV SCI INSTRUM, V62, P1727, DOI 10.1063/1.1142413
   LANNI F, 2000, IMAGING NEURONS LAB
   Linsenmeier RA, 1998, INVEST OPHTH VIS SCI, V39, P1647
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   PATZ A, 1984, CURR EYE RES, V3, P159, DOI 10.3109/02713688408997197
   RIVA CE, 1986, J APPL PHYSIOL, V61, P592, DOI 10.1152/jappl.1986.61.2.592
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P608
   RIVA CE, 1979, APPL OPTICS, V18, P2302
   RUMSEY WL, 1994, AM J PHYSIOL, V266, pH1676, DOI 10.1152/ajpheart.1994.266.4.H1676
   SAKAUE H, 1989, JPN J OPHTHALMOL, V33, P199
   SCHWARTZ B, 1977, ARCH OPHTHALMOL-CHIC, V95, P1961
   Shonat RD, 1997, BIOPHYS J, V73, P1223, DOI 10.1016/S0006-3495(97)78155-4
   SHONAT RD, 1992, INVEST OPHTH VIS SCI, V33, P3174
   SHONAT RD, 1992, APPL OPTICS, V31, P3711, DOI 10.1364/AO.31.003711
   Shonat RD, 1997, AM J PHYSIOL-HEART C, V272, pH2233, DOI 10.1152/ajpheart.1997.272.5.H2233
   Silva AC, 2000, J CEREBR BLOOD F MET, V20, P201, DOI 10.1097/00004647-200001000-00025
   Sinaasappel M, 1996, J APPL PHYSIOL, V81, P2297, DOI 10.1152/jappl.1996.81.5.2297
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   STEFANSSON E, 1992, AM J OPHTHALMOL, V113, P36, DOI 10.1016/S0002-9394(14)75750-2
   STEFANSSON E, 1990, GRAEF ARCH CLIN EXP, V228, P120, DOI 10.1007/BF00935719
   Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253
   VANDERKOOI JM, 1987, J BIOL CHEM, V262, P5476
   Vanzetta I, 2001, NEUROIMAGE, V13, P959, DOI 10.1006/nimg.2001.0843
   Vinogradov SA, 1996, BIOPHYS J, V70, P1609, DOI 10.1016/S0006-3495(96)79764-3
   WILSON DF, 1991, J APPL PHYSIOL, V70, P2691, DOI 10.1152/jappl.1991.70.6.2691
   Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116
   Yu DY, 1999, INVEST OPHTH VIS SCI, V40, P2082
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 48
TC 91
Z9 92
U1 0
U2 3
PU BIOMEDICAL ENGINEERING SOC AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0090-6964
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD OCT
PY 2003
VL 31
IS 9
BP 1084
EP 1096
DI 10.1114/1.1603256
PG 13
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 731WE
UT WOS:000185908800007
PM 14582611
DA 2022-11-30
ER

PT J
AU Patel, A
   Rova, U
   Christakopoulos, P
   Matsakas, L
AF Patel, Alok
   Rova, Ulrika
   Christakopoulos, Paul
   Matsakas, Leonidas
TI Microalgal lutein biosynthesis: Recent trends and challenges to enhance
   the lutein content in microalgal cell factories
SO FRONTIERS IN MARINE SCIENCE
LA English
DT Review
DE microalgae; carotenoids; lutein; genetic engineering; fermentation
ID CHLAMYDOMONAS-REINHARDTII; MIXOTROPHIC CULTIVATION; CAROTENOID
   PRODUCTION; PHYTOENE SYNTHASE; BETA-CAROTENE; CHLORELLA; CULTURE;
   TRANSFORMATION; INHIBITORS; ZEAXANTHIN
AB Photosynthetic organisms such as eukaryotic microalgae and prokaryotic cyanobacteria synthesize a wide range of valuable chemicals. They are predicted to become efficient and renewable sources for valuable products in the future due to their high biomass synthesis using CO2 and solar energy. Microalgae are producers of several carotenoids including lutein, which is a xanthophyll carotenoid with several health advantages, including the prevention of age-related macular degeneration. Currently, it is extracted on commercial scale from marigold flower petals, however, production from plant sources is highly affected by seasonal variations, requires arable land, and has high production cost. Microalgae, on the other hand, are an ideal alternative for lutein synthesis due to their rapid growth and high biomass and lutein yield. It is, however, necessary to further improve lutein productivity, for a successful transition to commercial production. This article describes lutein biosynthesis in microalgae by using their native biochemical pathways, as well as possible target genes for genetic engineering to enhance lutein production. Understanding the processes behind lipid droplet synthesis in chloroplasts, as well as carotenoid transport across chloroplast membranes and carotenoid esterification, might lead to novel ways to boost lutein levels in microalgae.
C1 [Patel, Alok; Rova, Ulrika; Christakopoulos, Paul; Matsakas, Leonidas] Lulea Univ Technol, Dept Civil Environm & Nat Resources Engn, Div Chem Engn, Biochem Proc Engn, Lulea, Sweden.
C3 Lulea University of Technology
RP Patel, A (通讯作者)，Lulea Univ Technol, Dept Civil Environm & Nat Resources Engn, Div Chem Engn, Biochem Proc Engn, Lulea, Sweden.
EM alok.kumar.patel@ltu.se
FU Swedish Research Council (FORMAS) Sweden [2020-01028]
FX Authors would like to thank the Swedish Research Council (FORMAS) Sweden
   for supporting this work as part of the projects `Green and sustainable
   approach to valorise high saline and oily fish processing effluents for
   the production of nutraceuticals' (INVENTION; 2020-01028).
CR [Anonymous], 2018, LUTEIN MARKET GLOBAL
   Asker D, 2019, FOOD RES INT, V116, P660, DOI 10.1016/j.foodres.2018.08.093
   Baek K, 2018, BIOTECHNOL BIOENG, V115, P719, DOI 10.1002/bit.26499
   Begum H, 2016, CRIT REV FOOD SCI, V56, P2209, DOI 10.1080/10408398.2013.764841
   Bian Q, 2021, METAB ENG, V67, P19, DOI 10.1016/j.ymben.2021.05.008
   Chen CY, 2021, BIORESOURCE TECHNOL, V326, DOI 10.1016/j.biortech.2021.124773
   Chen CY, 2018, BIORESOURCE TECHNOL, V262, P74, DOI 10.1016/j.biortech.2018.04.024
   Chen CY, 2016, BIORESOURCE TECHNOL, V200, P500, DOI 10.1016/j.biortech.2015.10.071
   Chen JH, 2019, BIORESOURCE TECHNOL, V278, P17, DOI 10.1016/j.biortech.2019.01.041
   Cordero BF, 2011, MAR DRUGS, V9, P1607, DOI 10.3390/md9091607
   Cordero BF, 2011, APPL MICROBIOL BIOT, V91, P341, DOI 10.1007/s00253-011-3262-y
   Couso I, 2011, BIOTECHNOL PROGR, V27, P54, DOI 10.1002/btpr.527
   Garcia-Canedo JC, 2016, ALGAL RES, V13, P41, DOI 10.1016/j.algal.2015.11.013
   Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557
   Doddaiah KM, 2013, J FOOD SCI TECH MYS, V50, P1130, DOI 10.1007/s13197-011-0429-6
   Eggersdorfer M, 2018, ARCH BIOCHEM BIOPHYS, V652, P18, DOI 10.1016/j.abb.2018.06.001
   El-Mekkawi S.A., 2019, B NATL RES CENT, V43, p:130, DOI [10.1186/s42269-019-0169-8, DOI 10.1186/S42269-019-0169-8]
   Fernandez-Sevilla JM, 2010, APPL MICROBIOL BIOT, V86, P27, DOI 10.1007/s00253-009-2420-y
   Fitzpatrick E, 2014, J PEDIATR GASTR NUTR, V59, P551, DOI 10.1097/MPG.0000000000000522
   Florez-Miranda L, 2017, J BIOTECHNOL, V262, P67, DOI 10.1016/j.jbiotec.2017.09.002
   Fraser PD, 2000, PLANTA, V211, P361, DOI 10.1007/s004250050008
   Garbayo I, 2008, PROCESS BIOCHEM, V43, P1158, DOI 10.1016/j.procbio.2008.06.012
   Gong MY, 2017, APPL BIOCHEM BIOTECH, V183, P652, DOI 10.1007/s12010-017-2537-x
   Guardini Z, 2021, PLANTS-BASEL, V10, DOI 10.3390/plants10050911
   Ho SH, 2014, BIORESOURCE TECHNOL, V152, P275, DOI 10.1016/j.biortech.2013.11.031
   Huang JJH, 2017, BIOTECHNOL ADV, V35, P597, DOI 10.1016/j.biotechadv.2017.05.001
   Huang PW, 2021, APPL MICROBIOL BIOT, V105, P4919, DOI 10.1007/s00253-021-11368-x
   Huang WP, 2018, J AGR FOOD CHEM, V66, P891, DOI 10.1021/acs.jafc.7b05400
   Kato Y, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01976-8
   Khoo KS, 2019, BIORESOURCE TECHNOL, V288, DOI 10.1016/j.biortech.2019.121606
   Liang MH, 2019, ENZYME MICROB TECH, V131, DOI 10.1016/j.enzmictec.2019.109426
   Lin JY, 2022, BIORESOURCE TECHNOL, V351, DOI 10.1016/j.biortech.2022.127009
   Lin JH, 2015, BIORESOURCE TECHNOL, V184, P421, DOI 10.1016/j.biortech.2014.09.099
   Lou SL, 2021, ALGAL RES, V55, DOI 10.1016/j.algal.2021.102246
   Ma CAT, 2021, CURR OPIN BIOTECH, V69, P281, DOI 10.1016/j.copbio.2021.02.008
   Ma RJ, 2020, ALGAL RES, V47, DOI 10.1016/j.algal.2020.101821
   McClure DD, 2019, ALGAL RES, V44, DOI 10.1016/j.algal.2019.101707
   Molina-Marquez A, 2019, METABOLITES, V9, DOI 10.3390/metabo9030049
   Mussagy CU, 2021, CRIT REV FOOD SCI, V62, P6932, DOI 10.1080/10408398.2021.1908222
   Narang PK, 2022, WORLD J MICROB BIOT, V38, DOI 10.1007/s11274-021-03188-y
   Patel A, 2022, TRENDS BIOTECHNOL, V40, P1261, DOI 10.1016/j.tibtech.2022.03.008
   Patel VK, 2019, MOL BIOTECHNOL, V61, P541, DOI 10.1007/s12033-019-00185-3
   Piccaglia R, 1998, IND CROP PROD, V8, P45, DOI 10.1016/S0926-6690(97)10005-X
   Pourkarimi S, 2020, BIOCATAL AGR BIOTECH, V29, DOI 10.1016/j.bcab.2020.101771
   Praveen A., 2022, OCTA J BIOSCI, V10, P6
   Quinlan RF, 2012, PLANT PHYSIOL, V160, P204, DOI 10.1104/pp.112.198556
   Rajendran L, 2020, BIOCHEM ENG J, V161, DOI 10.1016/j.bej.2020.107684
   Rathod JP, 2020, APPL BIOCHEM BIOTECH, V190, P1457, DOI 10.1007/s12010-019-03194-9
   Ren YY, 2021, MAR DRUGS, V19, DOI 10.3390/md19120713
   Roberts RL, 2009, CLIN DERMATOL, V27, P195, DOI 10.1016/j.clindermatol.2008.01.011
   Rohmer M, 1999, NAT PROD REP, V16, P565, DOI 10.1039/a709175c
   Saini DK, 2020, CRIT REV FOOD SCI, V60, P391, DOI 10.1080/10408398.2018.1533518
   Sampathkumar SJ, 2019, BIOCATAL AGR BIOTECH, V22, DOI 10.1016/j.bcab.2019.101406
   Shah MMR, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00531
   Shaker Saeedeh, 2021, Recent Pat Biotechnol, V15, P216, DOI [10.2174/187220831566621071212195, 10.2174/1872208315666210712121951]
   Song I, 2022, MICROB CELL FACT, V21, DOI 10.1186/s12934-021-01736-7
   Steinbrenner J, 2006, APPL ENVIRON MICROB, V72, P7477, DOI 10.1128/AEM.01461-06
   Takemura M, 2021, SYN BIOL, V6, DOI 10.1093/synbio/ysab012
   Tokunaga S, 2021, APPL BIOCHEM BIOTECH, V193, P1967, DOI 10.1007/s12010-021-03524-w
   Velmurugan A, 2022, CURR RES BIOTECHNOL, V4, P221, DOI 10.1016/j.crbiot.2022.03.005
   Vishwanathan R, 2014, J PEDIATR GASTR NUTR, V59, P659, DOI 10.1097/MPG.0000000000000389
   Vuppaladadiyam AK, 2018, BIOFUEL BIOPROD BIOR, V12, P304, DOI 10.1002/bbb.1864
   Wolf L, 2021, ENG LIFE SCI, V21, P115, DOI 10.1002/elsc.202000044
   Xie YP, 2020, BIORESOURCE TECHNOL, V314, DOI 10.1016/j.biortech.2020.123767
   Xie YX, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9051068
   Yildirim A, 2017, TURK J BIOL, V41, P213, DOI 10.3906/biy-1606-10
   Zhao Z., 2021, ACS AGR SCI TECHNOL, V2, P258, DOI [10.1021/acsagscitech.1c00284, DOI 10.1021/ACSAGSCITECH.1C00284]
   Zheng HS, 2022, RENEW SUST ENERG REV, V153, DOI 10.1016/j.rser.2021.111795
NR 68
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-7745
J9 FRONT MAR SCI
JI Front. Mar. Sci.
PD OCT 7
PY 2022
VL 9
AR 1015419
DI 10.3389/fmars.2022.1015419
PG 9
WC Environmental Sciences; Marine & Freshwater Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Marine & Freshwater Biology
GA 5Q4DQ
UT WOS:000873784700001
OA gold
DA 2022-11-30
ER

PT J
AU Zou, M
   Gong, LL
   Ke, Q
   Qi, RL
   Zhu, XF
   Liu, W
   Sun, Q
   Tang, XC
   Luo, ZW
   Gong, XD
   Liu, YZ
   Li, DWC
AF Zou, Ming
   Gong, Lili
   Ke, Qin
   Qi, Ruili
   Zhu, Xingfei
   Liu, Wei
   Sun, Qian
   Tang, Xiangcheng
   Luo, Zhongwen
   Gong, Xiaodong
   Liu, Yizhi
   Li, David Wan-Cheng
TI Heterochromatin inhibits cGAS and STING during oxidative stress-induced
   retinal pigment epithelium and retina degeneration
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Heterochromatin; Inflammation;
   Methotrexate; cGAS; STING
ID CYCLIC GMP-AMP; HISTONE H3; MACULAR DEGENERATION; SODIUM IODATE;
   METHOTREXATE; INFLAMMATION; DAMAGE; METHYLATION; DISEASE
AB Age-related macular degeneration (AMD) is a leading cause of blindness characterized by degeneration of retina pigment epithelium (RPE) and photoreceptors in the macular region. Activation of the innate immune cGASSTING signaling has been detected in RPE of dry AMD patients, but the regulatory basis is largely unexplored. Heterochromatin is a highly compact, transcription inert chromatin status. We have recently shown that heterochromatin is required for RPE survival through epigenetically silencing p53-mediated apoptosis signaling. Here, we found that cGAS and STING were dose-dependently upregulated in mouse RPE and retina during oxidative injury, correlated with decreased chromatin compaction in their gene loci. Genetic or pharmaceutical disruption of heterochromatin leads to elevated cGAS and STING expression and enhanced inflammatory response in oxidative stress-induced RPE and retina degeneration. In contrast, application of methotrexate (MTX), a recently identified heterochromatin-promoting drug, inhibits cGAS and STING in both RPE and retina, attenuates RPE/retina degeneration and inflammation. Further, we show that intact heterochromatin is required for MTX to repress cGAS and STING. Together, we demonstrated an unrevealed regulatory function of heterochromatin on cGAS and STING expression and provide potential new therapeutic strategy for AMD treatment.
C1 [Zou, Ming; Gong, Lili; Ke, Qin; Qi, Ruili; Zhu, Xingfei; Liu, Wei; Sun, Qian; Tang, Xiangcheng; Luo, Zhongwen; Gong, Xiaodong; Liu, Yizhi; Li, David Wan-Cheng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Li, DWC (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 7 Jinsui Rd,Res Bldg,Room 602-5, Guangzhou 510230, Guangdong, Peoples R China.; Gong, LL (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 7 Jinsui Rd,Room 602-7, Guangzhou 510230, Guangdong, Peoples R China.
EM gonglili@gzzoc.com; liwancheng@gzzoc.com
RI liu, yi/GXE-9662-2022
OI Gong, Lili/0000-0002-3129-3868
FU National Natural Science Foundation of China [82070969, 81770910,
   81970910]; Natural Science Foundation of Guangdong province Guangzhou
   City [2019B1515120014]; Guangdong Natural Science Foundation
   [2021A1515011793]; Fundamental Research Funds of the State Key
   Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yatsen
   University [3030901010111, 3030901010110]
FX We would like to thank all members from Dr. David Li labs. This work is
   supported by the National Natural Science Foundation of China (Grants
   82070969, 81770910 and 81970910), the joint key project grant from the
   Natural Science Foundation of Guangdong provinceGuangzhou City
   (2019B1515120014), Guangdong Natural Science Foundation
   (2021A1515011793) as well as the Fundamental Research Funds of the State
   Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
   Yat-sen University (3030901010111 and 3030901010110). in China.
CR Allan RS, 2012, NATURE, V487, P249, DOI 10.1038/nature11173
   Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138
   Bosch-Presegue L, 2017, CELL REP, V21, P2048, DOI 10.1016/j.celrep.2017.10.092
   Canzio D, 2014, TRENDS CELL BIOL, V24, P377, DOI 10.1016/j.tcb.2014.01.002
   Carey M., 2007, CSH PROTOC, V2007
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Gong LL, 2018, P NATL ACAD SCI USA, V115, pE3987, DOI 10.1073/pnas.1715237115
   Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721
   Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Higashijima Y, 2020, EMBO J, V39, DOI 10.15252/embj.2019103949
   Huang LS, 2020, IMMUNITY, V52, P475, DOI 10.1016/j.immuni.2020.02.002
   Illner D, 2010, EXP CELL RES, V316, P1662, DOI 10.1016/j.yexcr.2010.03.008
   Janssen A, 2018, ANNU REV CELL DEV BI, V34, P265, DOI 10.1146/annurev-cellbio-100617-062653
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Kurup SK, 2010, ACTA OPHTHALMOL, V88, pe145, DOI 10.1111/j.1755-3768.2009.01560.x
   Li P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00460
   Li Q, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911002
   Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139
   Loyola AC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48137-w
   Maekawa H, 2019, CELL REP, V29, P1261, DOI 10.1016/j.celrep.2019.09.050
   Maksakova IA, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-12
   Montesinos MC, 2007, ARTHRITIS RHEUM-US, V56, P1440, DOI 10.1002/art.22643
   Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   NEWTON I, 1994, PESTIC SCI, V41, P187, DOI 10.1002/ps.2780410304
   Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502
   Soheilian M, 2011, EUR J OPHTHALMOL, V21, P77, DOI 10.5301/EJO.2010.5696
   Sorsby A, 1941, Br J Ophthalmol, V25, P58, DOI 10.1136/bjo.25.2.58
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Sun Q, 2020, FREE RADICAL BIO MED, V147, P271, DOI 10.1016/j.freeradbiomed.2019.12.029
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
   Yang YT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1514-4
   Yelamos O, 2015, EXPERT REV CLIN IMMU, V11, P553, DOI 10.1586/1744666X.2015.1026894
NR 46
TC 2
Z9 2
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD JAN
PY 2022
VL 178
BP 147
EP 160
DI 10.1016/j.freeradbiomed.2021.11.040
EA DEC 2021
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA XV3VO
UT WOS:000734873800004
PM 34875339
DA 2022-11-30
ER

PT J
AU Courtaut, F
   Aires, V
   Acar, N
   Bretillon, L
   Guerrera, IC
   Chhuon, C
   De Barros, JPP
   Olmiere, C
   Delmas, D
AF Courtaut, Flavie
   Aires, Virginie
   Acar, Niyazi
   Bretillon, Lionel
   Guerrera, Ida Chiara
   Chhuon, Cerina
   De Barros, Jean-Paul Pais
   Olmiere, Celine
   Delmas, Dominique
TI RESVEGA, a Nutraceutical Omega-3/Resveratrol Supplementation, Reduces
   Angiogenesis in a Preclinical Mouse Model of Choroidal
   Neovascularization
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AMD; angiogenesis; ocular diseases; proteomic; omega-3 fatty acids;
   resveratrol
ID NUTRITIONAL SUPPLEMENT; MACULAR DEGENERATION; TRANS-RESVERATROL;
   METABOLITES; POLYPHENOLS; PREVENTION
AB Age-related macular degeneration (AMD) is an eye disease that is characterized by damage to the central part of the retina, the macula, and that affects millions of people worldwide. At an advanced stage, a blind spot grows in the center of vision, severely handicapping patients with this degenerative condition. Despite therapeutic advances thanks to the use of anti-VEGF, many resistance mechanisms have been found to accentuate the visual deficit. In the present study, we explored whether supplementation with Resvega(R), a nutraceutical formulation composed of omega-3 fatty acids and resveratrol, a well-known polyphenol in grapes, was able to counteract laser-induced choroidal neovascularization (CNV) in mice. We highlight that Resvega(R) significantly reduced CNV in mice compared with supplementations containing omega-3 or resveratrol alone. Moreover, a proteomic approach confirmed that Resvega(R) could counteract the progression of AMD through a pleiotropic effect targeting key regulators of neoangiogenesis in retina cells in vivo. These events were associated with an accumulation of resveratrol metabolites within the retina. Therefore, a supplementation of omega-3/resveratrol could improve the management or slow the progression of AMD in patients with this condition.
C1 [Courtaut, Flavie; Aires, Virginie; Acar, Niyazi; Bretillon, Lionel; De Barros, Jean-Paul Pais; Delmas, Dominique] Univ Bourgogne Franche Comte, F-21000 Dijon, France.
   [Courtaut, Flavie; Aires, Virginie; De Barros, Jean-Paul Pais; Delmas, Dominique] INSERM Res Ctr, U1231, Canc & Adapt Immune Response Team, Bioact Mol & Hlth Res Grp, F-21000 Dijon, France.
   [Acar, Niyazi; Bretillon, Lionel] AgroSup Dijon, Eye & Nutr Res Grp, INRAE, CNRS,Ctr Sci Gait & Alimentat, F-21000 Dijon, France.
   [Guerrera, Ida Chiara; Chhuon, Cerina] Univ Paris Struct Federat Rech Necker, INSERM US24 CNRS UMS3633, Prote Platform Necker, F-75015 Paris, France.
   [De Barros, Jean-Paul Pais] INSERM Res Ctr U1231 Lipid Analyt Platform, F-21000 Dijon, France.
   [Olmiere, Celine] Labs Thea, 12 Rue Louis Bleriot, F-63000 Clermont Ferrand, France.
   [Delmas, Dominique] Ctr Anticanc Georges Francois Leclerc, F-21000 Dijon, France.
C3 Institut Agro; AgroSup Dijon; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de
   la Recherche Scientifique (CNRS); INRAE; Institut Agro; AgroSup Dijon;
   Universite de Bourgogne; UDICE-French Research Universities; Universite
   Paris Cite; Institut Agro; AgroSup Dijon; Universite de Bourgogne;
   UNICANCER; Centre Georges-Francois Leclerc
RP Delmas, D (通讯作者)，Univ Bourgogne Franche Comte, F-21000 Dijon, France.; Delmas, D (通讯作者)，INSERM Res Ctr, U1231, Canc & Adapt Immune Response Team, Bioact Mol & Hlth Res Grp, F-21000 Dijon, France.; Delmas, D (通讯作者)，Ctr Anticanc Georges Francois Leclerc, F-21000 Dijon, France.
EM flavie.courtaut@gmail.com; virginie.aires02@u-bourgogne.fr;
   niyazi.acar@inrae.fr; Lionel.Bretillon@u-bourgogne.fr;
   chiara.guerrera@inserm.fr; cerina.chhuon@inserm.fr;
   jppais@u-bourgogne.fr; celine.olmiere@theaopeninnovation.com;
   dominique.delmas@u-bourgogne.fr
RI GUERRERA, Ida Chiara/GOJ-9151-2022
OI GUERRERA, Ida Chiara/0000-0002-4832-6793; ACAR,
   Niyazi/0000-0002-3401-8079; PAIS DE BARROS,
   Jean-Paul/0000-0002-5124-2283; Delmas, Dominique/0000-0002-8911-8499
FU ANRT by a French Government [2016/0003]; French National Research Agency
   under the program Investissements dAvenir [ANR-11-LABX-0021]; Conseil
   Regional Bourgogne, Franche-Comte (PARI grant); FEDER (European Funding
   for Regional Economic Development)
FX This work was supported by grants from the ANRT No2016/0003, by a French
   Government grant managed by the French National Research Agency under
   the program Investissements dAvenir, reference ANR-11-LABX-0021, the
   Conseil Regional Bourgogne, Franche-Comte (PARI grant) and the FEDER
   (European Funding for Regional Economic Development).
CR Aires V, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-79
   Aires V, 2013, MOL NUTR FOOD RES, V57, P1170, DOI 10.1002/mnfr.201200766
   Bhattarai N, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010067
   Bhattarai N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062066
   Boocock DJ, 2007, J CHROMATOGR B, V848, P182, DOI 10.1016/j.jchromb.2006.10.017
   Cao YH, 2002, J NUTR BIOCHEM, V13, P380, DOI 10.1016/S0955-2863(02)00204-8
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Delmas D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031295
   Dot C, 2007, EXP EYE RES, V84, P1081, DOI 10.1016/j.exer.2007.01.024
   Ghiringhelli F, 2012, ANTI-CANCER AGENT ME, V12, P852, DOI 10.2174/187152012802650048
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin CT, 2016, RENAL FAILURE, V38, P214, DOI 10.3109/0886022X.2015.1128236
   Marshall Leisa L, 2013, Consult Pharm, V28, P723, DOI 10.4140/TCP.n.2013.723
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Patel KR, 2011, ANN NY ACAD SCI, V1215, P161, DOI 10.1111/j.1749-6632.2010.05853.x
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Seeliger MW, 2005, VISION RES, V45, P3512, DOI 10.1016/j.visres.2005.08.014
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Thierry M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112450
   Wang SS, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4052094
   Wang SS, 2016, CURR EYE RES, V41, P1339, DOI 10.3109/02713683.2015.1119282
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
NR 32
TC 2
Z9 2
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2021
VL 22
IS 20
AR 11023
DI 10.3390/ijms222011023
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WT8ZA
UT WOS:000716146000001
PM 34681683
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, L
   Kaya, KD
   Kim, S
   Brooks, MJ
   Wang, J
   Xin, Y
   Qian, J
   Swaroop, A
   Handa, JT
AF Wang, Lei
   Kaya, Koray D.
   Kim, Sujung
   Brooks, Matthew J.
   Wang, Jie
   Xin, Ying
   Qian, Jiang
   Swaroop, Anand
   Handa, James T.
TI Retinal pigment epithelium transcriptome analysis in chronic smoking
   reveals a suppressed innate immune response and activation of
   differentiation pathways
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Aging; Age-related macular degeneration; Differentiation; Innate
   immunity; RNA sequencing; Smoking
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; OXIDATIVE STRESS; MATRIX
   METALLOPROTEINASES; BRUCHS MEMBRANE; RPE CELLS; EXPRESSION; STAT3;
   DRUSEN; RANIBIZUMAB
AB Cigarette smoking, a powerful mixture of chemical oxidants, is the strongest environmental risk factor for developing age-related macular degeneration (AMD), the most common cause of blindness among the elderly in western societies. Despite intensive study, the full impact of smoking on the retinal pigment epithelium (RPE), a central cell type involved in AMD pathobiology, remains unknown. The relative contribution of the known dysfunctional pathways to AMD, at what stage they are most pathogenic, or whether other processes are relevant, is poorly understood, and furthermore, whether smoking activates them, is unknown. We performed global RNA-sequencing of the RPE from C57BL/6J mice exposed to chronic cigarette smoke for 6 months to identify potential pathogenic and cytoprotective pathways. The RPE transcriptome induced by chronic cigarette smoking exhibited a mixed response of marked suppression of the innate immune response including type I and II interferons and upregulation of cell differentiation and morphogenic gene clusters, suggesting an attempt by the RPE to maintain its differentiated state despite smoke-induced injury. Given that mice exposed to chronic smoke develop early features of AMD, these novel findings are potentially relevant to the transition from aging to AMD.
C1 [Wang, Lei; Kim, Sujung; Wang, Jie; Xin, Ying; Qian, Jiang; Handa, James T.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Kaya, Koray D.; Brooks, Matthew J.; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Handa, JT (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Johns Hopkins Sch Med, Smith Bldg,Room 3015,400 N Broadway, Baltimore, MD 21218 USA.
EM lwang9@jhmi.edu; koraydogan.kaya@nih.gov; sjun6@jhmi.edu;
   brooksma@nei.nih.gov; lwang9@jhmi.edu; yingxinac@gmail.com;
   jiang.qian@jhmi.edu; swaroopa@nei.nih.gov; jthanda@jhmi.edu
FU National Institutes of Health [NIH NEI] [R01 EY027691]; NEI Core grant
   [EY001765]; Macular Degeneration Foundation; NEIIntramural Research
   Program [ZIAEY000450, ZIAEY000546]
FX This work was supported by the National Institutes of Health [NIH NEI
   R01 EY027691 to JTH], NEI Core grant [EY001765], Macular Degeneration
   Foundation to JTH, RPB (Wilmer Eye Institute), NEIIntramural Research
   Program [ZIAEY000450 and ZIAEY000546 to AS].JTH is the Robert Bond Welch
   Professor. We thank Kathleen BoeszeBattaglia, PhD for providing the RPE
   cell template for the Graphic Abstract.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2014, HLTH CONSMOK 50 YE
   Brooks MJ, 2019, STEM CELL REP, V13, P891, DOI 10.1016/j.stemcr.2019.09.009
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055
   Chaudhary V, 2015, J GEN VIROL, V96, P3204, DOI 10.1099/jgv.0.000280
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Chiba T, 2009, MOL PSYCHIATR, V14, P206, DOI 10.1038/mp.2008.105
   Collin GB, 2015, HUM MOL GENET, V24, P6958, DOI 10.1093/hmg/ddv399
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dhillon NK, 2009, TOXICOL APPL PHARM, V237, P22, DOI 10.1016/j.taap.2009.02.021
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   DRUEKE T, 1990, KIDNEY INT, V37, P1438, DOI 10.1038/ki.1990.134
   Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ebrahimi KB, 2018, ANTIOXID REDOX SIGN, V29, P389, DOI 10.1089/ars.2017.7084
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Geraghty P, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00267
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Handa JT, 2015, T AM OPHTHALMOL SOC, V113, pT51
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hsu WL, 2014, NEUROPSYCHOPHARMACOL, V39, P746, DOI 10.1038/npp.2013.263
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Iba MM, 1998, XENOBIOTICA, V28, P827, DOI 10.1080/004982598239083
   Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760
   Jia ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183622
   Joo A, 2004, ONCOGENE, V23, P726, DOI 10.1038/sj.onc.1207174
   Joshi-Barve S, 2009, FREE RADICAL BIO MED, V47, P47, DOI 10.1016/j.freeradbiomed.2009.03.021
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kaya KD, 2019, MOL VIS, V25, P663
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Little JP, 2014, MOL CELL NEUROSCI, V60, P88, DOI 10.1016/j.mcn.2014.04.003
   Liu K, 2020, CYTOKINE, V128, DOI 10.1016/j.cyto.2020.155001
   Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147
   Mian MF, 2009, MOL IMMUNOL, V46, P821, DOI 10.1016/j.molimm.2008.09.007
   Miller YI, 2011, CIRC RES, V108, P235, DOI 10.1161/CIRCRESAHA.110.223875
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moschen AR, 2017, TRENDS ENDOCRIN MET, V28, P388, DOI 10.1016/j.tem.2017.01.003
   Nickel AG, 2015, CELL METAB, V22, P472, DOI 10.1016/j.cmet.2015.07.008
   OLSEN S, 1989, MEDICINE, V68, P173, DOI 10.1097/00005792-198905000-00005
   OLSEN TS, 1986, ULTRASTRUCT PATHOL, V10, P1
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Ratnapriya R, 2019, NAT GENET, V51, P1067, DOI 10.1038/s41588-019-0430-y
   Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369
   Regis G, 2008, SEMIN CELL DEV BIOL, V19, P351, DOI 10.1016/j.semcdb.2008.06.004
   Ren PP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12248-z
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Saxena AR, 2017, FREE RADICAL BIO MED, V104, P371, DOI 10.1016/j.freeradbiomed.2017.02.009
   Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sonnenblick A, 2004, MOL CELL BIOL, V24, P10584, DOI 10.1128/MCB.24.24.10584-10592.2004
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Starnes AC, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523815000310
   Stejskalova L, 2011, CURR PHARM BIOTECHNO, V12, P715, DOI 10.2174/138920111795470994
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sundman L, 2010, NEUROGASTROENT MOTIL, V22, P79, DOI 10.1111/j.1365-2982.2009.01366.x
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takagi Y, 2002, J CEREBR BLOOD F MET, V22, P1311, DOI 10.1097/01.WCB.0000034148.72481.F4
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383
   Yang K., 2019, CANC GENE THER
   Yu GC, 2015, BIOINFORMATICS, V31, P608, DOI 10.1093/bioinformatics/btu684
NR 95
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD AUG 20
PY 2020
VL 156
BP 176
EP 189
DI 10.1016/j.freeradbiomed.2020.06.004
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA NA9KN
UT WOS:000560135700011
PM 32634473
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kumar-Singh, R
AF Kumar-Singh, Rajendra
TI The role of complement membrane attack complex in dry and wet AMD - From
   hypothesis to clinical trials
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Membrane attack complex; age-related macular degeneration; Geographic
   atrophy; Adeno-associated virus; Complement; CD59; gene therapy
ID PIGMENT EPITHELIAL-CELLS; GLOMERULAR MESANGIAL CELLS;
   MACULAR-DEGENERATION; FACTOR-H; GROWTH-FACTOR; NLRP3 INFLAMMASOME;
   CIGARETTE-SMOKE; GENE-THERAPY; BLOOD-FLOW; SUBLYTIC COMPLEMENT
AB Data from human dry and wet age-related macular degeneration (AMD) eyes support the hypothesis that constant 'tickover' of the alternative complement pathway results in chronic deposition of the complement membrane attack complex (MAC) on the choriocapillaris and the retinal pigment epithelium (RPE). Sub-lytic levels of MAC lead to cell signaling associated with tissue remodeling and the production of cytokines and inflammatory molecules. Lytic levels of MAC lead to cell death. CD59 is a naturally occurring inhibitor of the assembly of MAC. CD59 may thus be therapeutically efficacious against the pathophysiology of dry and wet AMD. The first gene therapy clinical trial for geographic atrophy - the advanced form of dry AMD has recently completed recruitment. This trial is studying the safety and tolerability of expressing CD59 from an adeno-associated virus (AAV) vector injected once into the vitreous. A second clinical trial assessing the efficacy of CD59 in wet AMD patients is also under way. Herein, the evidence for the role of MAC in the pathophysiology of dry as well as wet AMD and the scientific rationale underlying the use of AAV- delivered CD59 for the treatment of dry and wet AMD is discussed.
C1 [Kumar-Singh, Rajendra] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA.
C3 Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA.
EM Rajendra.Kumar-Singh@tufts.edu
OI Kumar-Singh, Rajendra/0000-0002-7754-0713
FU Department of Defense/US Army [W81XWH-16-1-0650]; Brightfocus Foundation
   [M2017175]; Ellison Foundation of Boston, MA, USA
FX I would like to thank Dr. Siobhan Cashman for helpful comments during
   the preparation of this review. Research in my laboratory is currently
   funded by The Department of Defense/US Army (W81XWH-16-1-0650), The
   Brightfocus Foundation (M2017175) and The Ellison Foundation of Boston,
   MA, USA.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Bayly-Jones C, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0221
   Bennett J, 2017, MOL THER, V25, P1076, DOI 10.1016/j.ymthe.2017.03.008
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Berends ETM, 2015, MOL IMMUNOL, V65, P328, DOI 10.1016/j.molimm.2015.01.020
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   Birke MT, 2014, GENE THER, V21, P507, DOI 10.1038/gt.2014.24
   BJORK J, 1985, J IMMUNOL, V134, P1115
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P1783, DOI 10.1016/j.ophtha.2014.03.021
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cashman SM, 2015, J GENE MED, V17, P229, DOI 10.1002/jgm.2865
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Farkas I, 2002, J PHYSIOL-LONDON, V539, P537, DOI 10.1113/jphysiol.2001.013381
   FLOWER RW, 1995, INVEST OPHTH VIS SCI, V36, P1247
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gandhi J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021621
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guy J, 2017, OPHTHALMOLOGY, V124, P1621, DOI 10.1016/j.ophtha.2017.05.016
   HAKULINEN J, 1995, IMMUNOLOGY, V85, P495
   HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418
   HAMILTON KK, 1990, J BIOL CHEM, V265, P3809
   HANSCH GM, 1987, INT ARCH ALLER A IMM, V82, P317, DOI 10.1159/000234216
   Happonen KE, 2012, J BIOL CHEM, V287, P8092, DOI 10.1074/jbc.M111.291476
   Harris CL, 2018, MOL IMMUNOL, V102, P89, DOI 10.1016/j.molimm.2018.06.008
   Hayat MJ, 2007, ONCOLOGIST, V12, P20, DOI 10.1634/theoncologist.12-1-20
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hila S, 2001, GLIA, V36, P58, DOI 10.1002/glia.1095
   HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172
   Huang Y, 2006, J BIOL CHEM, V281, P27398, DOI 10.1074/jbc.M603690200
   Huang YX, 2005, J BIOL CHEM, V280, P34073, DOI 10.1074/jbc.M504922200
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Kassab ES, 2019, ENLIGHTENMENT ON THE EVE OF REVOLUTION, P1
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   KILGORE KS, 1995, J IMMUNOL, V155, P1434
   KIM SH, 1989, MOL IMMUNOL, V26, P323
   KIM SH, 1987, J IMMUNOL, V138, P1530
   Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027
   Kodjikian L, 2017, RETINA
   KOSKI CL, 1983, P NATL ACAD SCI-BIOL, V80, P3816, DOI 10.1073/pnas.80.12.3816
   Kosmidou C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17634-1
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   LABARBERA M, 1990, SCIENCE, V249, P992, DOI 10.1126/science.2396104
   Leaderer D, 2015, J GENE MED, V17, P101, DOI 10.1002/jgm.2829
   LI CKN, 1975, IMMUNOCHEMISTRY, V12, P89, DOI 10.1016/0019-2791(75)90054-3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu LS, 2012, J BIOL CHEM, V287, P16410, DOI 10.1074/jbc.M111.319566
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MERI S, 1990, IMMUNOLOGY, V71, P1
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Miyama K, 2002, BIOL PHARM BULL, V25, P648, DOI 10.1248/bpb.25.648
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   MORGAN BP, 1987, J IMMUNOL, V138, P246
   MORGAN BP, 1989, BIOCHEM J, V264, P1
   Moskovich O, 2007, J BIOL CHEM, V282, P29977, DOI 10.1074/jbc.M703742200
   Moskovich O, 2012, J BIOL CHEM, V287, P19904, DOI 10.1074/jbc.M111.333039
   Mukai R, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00015
   Muller S, 2017, GRAEFES ARCH CLIN EX
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nauta AJ, 2002, EUR J IMMUNOL, V32, P783, DOI 10.1002/1521-4141(200203)32:3<783::AID-IMMU783>3.0.CO;2-Q
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   NINOMIYA H, 1992, J BIOL CHEM, V267, P13675
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okada N, 1989, Int Immunol, V1, P205, DOI 10.1093/intimm/1.2.205
   PHILBRICK WM, 1990, EUR J IMMUNOL, V20, P87, DOI 10.1002/eji.1830200113
   Ramo K, 2008, INVEST OPHTH VIS SCI, V49, P4126, DOI 10.1167/iovs.08-2025
   Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x
   Ricklin D, 2016, IMMUNOBIOLOGY, V221, P740, DOI 10.1016/j.imbio.2015.06.012
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rus HG, 1996, J IMMUNOL, V156, P4892
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schraufstatter IU, 2002, J IMMUNOL, V169, P2102, DOI 10.4049/jimmunol.169.4.2102
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   SUGITA Y, 1993, J BIOCHEM-TOKYO, V114, P473, DOI 10.1093/oxfordjournals.jbchem.a124202
   SUGITA Y, 1994, IMMUNOLOGY, V82, P34
   SUGITA Y, 1989, J BIOCHEM-TOKYO, V106, P555, DOI 10.1093/oxfordjournals.jbchem.a122893
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tian Y, 2015, ACTA OPHTHALMOL, V93, P141, DOI 10.1111/aos.12535
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Toomey CB, 2018, INVEST OPHTH VIS SCI, V59, P662, DOI 10.1167/iovs.17-23134
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   WAGNER C, 1994, EXP NEPHROL, V2, P51
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   WEITER JJ, 1973, INVEST OPHTH VISUAL, V12, P327
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
   Zaiss AK, 2008, J VIROL, V82, P2727, DOI 10.1128/JVI.01990-07
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 135
TC 31
Z9 32
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2019
VL 184
BP 266
EP 277
DI 10.1016/j.exer.2019.05.006
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF3ND
UT WOS:000472986600030
PM 31082363
DA 2022-11-30
ER

PT J
AU Bales, KL
   Gross, AK
AF Bales, Katie L.
   Gross, Alecia K.
TI Aberrant protein trafficking in retinal degenerations: The initial phase
   of retinal remodeling
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Protein trafficking; Retinal remodeling; Rhodopsin; Transition zone
   cilia; Retinitis pigmentosa; Glaucoma
ID BARDET-BIEDL-SYNDROME; LEBER CONGENITAL AMAUROSIS; LINKED
   RETINITIS-PIGMENTOSA; PHOTORECEPTOR OUTER SEGMENT; REGULATOR
   (RPGR)-INTERACTING PROTEIN; NUCLEOTIDE-EXCHANGE FACTOR; CONE-ROD
   DYSTROPHY; PRIMARY CILIUM; MYOSIN VIIA; GTPASE REGULATOR
AB Retinal trafficking proteins are involved in molecular assemblies that govern protein transport, orchestrate cellular events involved in cilia formation, regulate signal transduction, autophagy and endocytic trafficking, all of which if not properly controlled initiate retinal degeneration. Improper function and or trafficking of these proteins and molecular networks they are involved in cause a detrimental cascade of neural retinal remodeling due to cell death, resulting as devastating blinding diseases. A universal finding in retinal degenerative diseases is the profound detection of retinal remodeling, occurring as a phased modification of neural retinal function and structure, which begins at the molecular level. Retinal remodeling instigated by aberrant trafficking of proteins encompasses many forms of retinal degenerations, such as the diverse forms of retinitis pigmentosa (RP) and disorders that resemble RP through mutations in the rhodopsin gene, retinal ciliopathies, and some forms of glaucoma and age related macular degeneration (AMD). As a large majority of genes associated with these different retinopathies are overlapping, it is imperative to understand their underlying molecular mechanisms. This review will discuss some of the most recent discoveries in vertebrate retinal remodeling and retinal degenerations caused by protein mistrafficking. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Bales, Katie L.; Gross, Alecia K.] Univ Alabama Birmingham, Birmingham, AL 35233 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Gross, AK (通讯作者)，Univ Alabama Birmingham, Birmingham, AL 35233 USA.
EM agross@uab.edu
RI Gross, Alecia K./AAJ-1792-2021
OI Gross, Alecia K./0000-0003-1857-6633
FU E. Matilda Ziegler Foundation; EyeSight Foundation of Alabama; Karl
   Kirchgessner Foundation; National Eye Institute [EY019311]; NATIONAL EYE
   INSTITUTE [R01EY019311] Funding Source: NIH RePORTER
FX Retinal research in the Gross laboratory has been supported by The E.
   Matilda Ziegler Foundation, The EyeSight Foundation of Alabama, The Karl
   Kirchgessner Foundation and from the National Eye Institute EY019311. We
   thank Itia C. Dowdell, Evan R. Boitet and Sam R. LaMagna for critical
   review of this manuscript.
CR Abd-El-Barr MM, 2007, VISION RES, V47, P3394, DOI 10.1016/j.visres.2007.09.016
   Adams NA, 2007, OPHTHALMIC GENET, V28, P113, DOI 10.1080/13816810701537424
   Baye LM, 2011, HUM MOL GENET, V20, P1467, DOI 10.1093/hmg/ddr025
   Beales PL, 1999, J MED GENET, V36, P437
   Berbari NF, 2008, MOL BIOL CELL, V19, P1540, DOI 10.1091/mbc.E07-09-0942
   Berbari NF, 2009, CURR BIOL, V19, pR526, DOI 10.1016/j.cub.2009.05.025
   Bessant D A, 1999, Hum Mutat, V13, P83, DOI 10.1002/(SICI)1098-1004(1999)13:1<83::AID-HUMU12>3.0.CO;2-5
   Bielas SL, 2009, NAT GENET, V41, P1032, DOI 10.1038/ng.423
   Birch DG, 2015, OPHTHALMOLOGY, V122, P833, DOI 10.1016/j.ophtha.2014.11.005
   Booij JC, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.035121
   Boylan JP, 2000, HUM MOL GENET, V9, P2085, DOI 10.1093/hmg/9.14.2085
   Brancati F, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-20
   Breuer DK, 2002, AM J HUM GENET, V70, P1545, DOI 10.1086/340848
   Chan F, 2004, P NATL ACAD SCI USA, V101, P9109, DOI 10.1073/pnas.0403149101
   Chang B, 2006, HUM MOL GENET, V15, P1847, DOI 10.1093/hmg/ddl107
   Christensen ST, 2007, TRAFFIC, V8, P97, DOI 10.1111/j.1600-0854.2006.00516.x
   Chuang Jen-Zen, 2015, Cilia, V4, P4, DOI 10.1186/s13630-015-0013-1
   Chuang JZ, 2004, J CLIN INVEST, V114, P131, DOI 10.1172/JCI200421136
   Collin GB, 2012, INVEST OPHTH VIS SCI, V53, P967, DOI 10.1167/iovs.11-8766
   Concepcion F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010904
   Cook SA, 2009, J AM SOC NEPHROL, V20, P753, DOI 10.1681/ASN.2008040412
   Coppieters F, 2010, HUM MUTAT, V31, P1097, DOI 10.1002/humu.21337
   Dawe HR, 2007, HUM MOL GENET, V16, P173, DOI 10.1093/hmg/ddl459
   Deretic D, 1998, P NATL ACAD SCI USA, V95, P10620, DOI 10.1073/pnas.95.18.10620
   Deretic D, 1996, J BIOL CHEM, V271, P2279, DOI 10.1074/jbc.271.4.2279
   Deretic D, 2004, MOL BIOL CELL, V15, P359, DOI 10.1091/mbc.e03-04-0203
   Deretic D, 2006, VISION RES, V46, P4427, DOI 10.1016/j.visres.2006.07.028
   DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419
   Dryja TP, 2001, AM J HUM GENET, V68, P1295, DOI 10.1086/320113
   Eichers ER, 2006, HUM GENET, V120, P211, DOI 10.1007/s00439-006-0197-y
   Emmer BT, 2010, J CELL SCI, V123, P529, DOI 10.1242/jcs.062968
   Ernest S, 2000, HUM MOL GENET, V9, P2189, DOI 10.1093/hmg/9.14.2189
   Fernandez-Martinez L, 2011, EUR J HUM GENET, V19, P445, DOI 10.1038/ejhg.2010.217
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Forsythe E, 2013, EUR J HUM GENET, V21, P8, DOI 10.1038/ejhg.2012.115
   Futter CE, 2004, MOL BIOL CELL, V15, P2264, DOI 10.1091/mbc.E03-10-0772
   Galvin JA, 2005, RETINA-J RET VIT DIS, V25, P919, DOI 10.1097/00006982-200510000-00016
   Gao JG, 2002, P NATL ACAD SCI USA, V99, P5698, DOI 10.1073/pnas.042122399
   Garcia-Gonzalo FR, 2011, NAT GENET, V43, P776, DOI 10.1038/ng.891
   Gerber S, 2001, EUR J HUM GENET, V9, P561, DOI 10.1038/sj.ejhg.5200689
   Gerdes JM, 2009, CELL, V137, P32, DOI 10.1016/j.cell.2009.03.023
   Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580
   Gross A.K., 2008, REGULATION PHOTORESP
   Gross AK, 2006, VISION RES, V46, P4510, DOI 10.1016/j.visres.2006.07.012
   GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863
   Hakim S, 2012, CURR TOP MICROBIOL, V362, P246, DOI 10.1007/978-94-007-5025-8_12
   Hamann S, 2002, INT REV CYTOL, V215, P395
   Hameed A, 2003, J MED GENET, V40, P616, DOI 10.1136/jmg.40.8.616
   Hampshire DJ, 2006, EUR J HUM GENET, V14, P543, DOI 10.1038/sj.ejhg.5201577
   Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010
   HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815
   Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597
   Hollingsworth TJ, 2013, J BIOL CHEM, V288, P29047, DOI 10.1074/jbc.M113.495184
   Hollingsworth TJ, 2012, INT REV CEL MOL BIO, V293, P1, DOI 10.1016/B978-0-12-394304-0.00006-3
   Hong DH, 2001, J BIOL CHEM, V276, P12091, DOI 10.1074/jbc.M009351200
   HORST CJ, 1990, CELL MOTIL CYTOSKEL, V17, P329, DOI 10.1002/cm.970170408
   Hosch J, 2011, OPHTHALMIC GENET, V32, P1, DOI 10.3109/13816810.2010.535889
   Insinna C, 2008, DEV DYNAM, V237, P1982, DOI 10.1002/dvdy.21554
   Jacobson SG, 2013, CLIN GENET, V84, P175, DOI 10.1111/cge.12165
   JACOBSON SG, 1994, INVEST OPHTH VIS SCI, V35, P2521
   Jacoby M, 2009, NAT GENET, V41, P1027, DOI 10.1038/ng.427
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Karmous-Benailly H, 2005, AM J HUM GENET, V76, P493, DOI 10.1086/428679
   Kremer H, 2006, HUM MOL GENET, V15, pR262, DOI 10.1093/hmg/ddl205
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Leitch CC, 2008, NAT GENET, V40, P443, DOI 10.1038/ng.97
   Leroux MR, 2007, CELL, V129, P1041, DOI 10.1016/j.cell.2007.05.049
   Lheriteau E, 2009, MOL VIS, V15, P349
   LI ZY, 1995, J NEUROSCI, V15, P5429
   Liu Q, 2004, J NEUROSCI, V24, P6427, DOI 10.1523/JNEUROSCI.1335-04.2004
   Liu Q, 2003, INVEST OPHTH VIS SCI, V44, P4171, DOI 10.1167/iovs.03-0410
   Liu QP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048295
   Liu XR, 1999, J NEUROSCI, V19, P6267
   Lodowski Kerrie H, 2015, Methods Mol Biol, V1271, P293, DOI 10.1007/978-1-4939-2330-4_19
   Lodowski KH, 2013, J NEUROSCI, V33, P13621, DOI 10.1523/JNEUROSCI.1520-13.2013
   Lorenz Birgit, 2003, Ophthalmic Genet, V24, P89, DOI 10.1076/opge.24.2.89.14001
   Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Mazelova J, 2009, EMBO J, V28, P183, DOI 10.1038/emboj.2008.267
   Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35
   Mellersh CS, 2006, GENOMICS, V88, P293, DOI 10.1016/j.ygeno.2006.05.004
   Mizuno-Yamasaki E, 2012, ANNU REV BIOCHEM, V81, P637, DOI 10.1146/annurev-biochem-052810-093700
   Murga-Zamalloa CA, 2011, J BIOL CHEM, V286, P28276, DOI 10.1074/jbc.M111.237560
   Murga-Zamalloa CA, 2009, J GENET, V88, P399, DOI 10.1007/s12041-009-0061-7
   Mykytyn K, 2004, P NATL ACAD SCI USA, V101, P8664, DOI 10.1073/pnas.0402354101
   Nachury MV, 2007, CELL, V129, P1201, DOI 10.1016/j.cell.2007.03.053
   Narfstrom K, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/906943
   Nemet I, 2014, CHANNELS, V8, P528, DOI 10.4161/19336950.2014.973776
   Nishimura DY, 2004, P NATL ACAD SCI USA, V101, P16588, DOI 10.1073/pnas.0405496101
   Patil H, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.96
   Rana T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.539
   Reish NJ, 2014, J NEUROSCI, V34, P14854, DOI 10.1523/JNEUROSCI.1943-14.2014
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Roberson EC, 2015, J CELL BIOL, V209, P129, DOI 10.1083/jcb.201411087
   Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035
   Roepman R, 2000, METHOD ENZYMOL, V316, P688
   Roepman R, 2005, P NATL ACAD SCI USA, V102, P18520, DOI 10.1073/pnas.0505774102
   Roepman Ronald, 2007, V43, P209, DOI 10.1007/978-1-4020-5943-8_10
   Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644
   Sammons JD, 2013, VISION RES, V93, P43, DOI 10.1016/j.visres.2013.10.008
   Sandoval IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108135
   Seo S, 2010, P NATL ACAD SCI USA, V107, P1488, DOI 10.1073/pnas.0910268107
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   SUNG CH, 1994, J NEUROSCI, V14, P5818
   Tam BM, 2006, J NEUROSCI, V26, P203, DOI 10.1523/JNEUROSCI.3849-05.2006
   Tammachote R, 2009, HUM MOL GENET, V18, P3311, DOI 10.1093/hmg/ddp272
   Tian GL, 2014, J COMP NEUROL, V522, P3577, DOI 10.1002/cne.23630
   Valente EM, 2010, NAT GENET, V42, P619, DOI 10.1038/ng.594
   Vervoort R, 2002, HUM MUTAT, V19, P486, DOI 10.1002/humu.10057
   Walia S, 2008, ARCH OPHTHALMOL-CHIC, V126, P379, DOI 10.1001/archophthalmol.2007.72
   Wang J, 2014, PROG RETIN EYE RES, V38, P1, DOI 10.1016/j.preteyeres.2013.08.004
   Wang J, 2012, EMBO J, V31, P4057, DOI 10.1038/emboj.2012.253
   Wasfy MM, 2014, EXP EYE RES, V122, P65, DOI 10.1016/j.exer.2014.03.007
   Weleber R.G., 1993, LEBER CONGENITAL AMA
   WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0
   Wensel TG, 2005, VISION RES, V45, P3445, DOI 10.1016/j.visres.2005.07.016
   Williams CL, 2011, J CELL BIOL, V192, P1023, DOI 10.1083/jcb.201012116
   Williams CL, 2010, J AM SOC NEPHROL, V21, P782, DOI 10.1681/ASN.2009060597
   Williams DS, 2011, BIOCHEM SOC T, V39, P1207, DOI 10.1042/BST0391207
   Won JY, 2009, HUM MOL GENET, V18, P4329, DOI 10.1093/hmg/ddp385
   Wu ZJ, 2015, HUM MOL GENET, V24, P3956, DOI 10.1093/hmg/ddv134
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   Zhao CT, 2011, EMBO J, V30, P2532, DOI 10.1038/emboj.2011.165
   Zhao Y, 2003, P NATL ACAD SCI USA, V100, P3965, DOI 10.1073/pnas.0637349100
NR 128
TC 18
Z9 18
U1 1
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2016
VL 150
SI SI
BP 71
EP 80
DI 10.1016/j.exer.2015.11.007
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DX5BR
UT WOS:000384395300007
PM 26632497
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wang, L
   Yang, ZK
   Yu, Y
   Cui, C
   Guan, HJ
   Chen, H
AF Wang, Li
   Yang, Zhongkai
   Yu, Ying
   Cui, Chen
   Guan, Huaijin
   Chen, Hui
TI Blockage of tissue factor ameliorates the lesion of laser-induced
   choroidal neovascularization in mice
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE tissue factor; choroidal neovascularization; anti-TF monoclonal
   antibody; mouse
ID FACTOR CYTOPLASMIC DOMAIN; MACULAR DEGENERATION; GROWTH-FACTOR; TUMOR
   PROGRESSION; CANCER CELLS; ANGIOGENESIS; EXPRESSION; INFLAMMATION;
   MODEL; BEVACIZUMAB
AB Choroidal neovascularization (CNV) occurs as a result of age-related macular degeneration (AMD) and causes severe vision loss among elderly patients. High expression of tissue factor (TF) was found in the retinas of AMD patients. In this study, we used anti-TF monoclonal antibody to test the effect of the TF blockage on experimental CNV induced by laser photocoagulation of retina in mice. Anti-TF monoclonal antibody or vehicle was administered intravitreally at day 1, 2 or 3 after laser application. We found that TF expression increased, and reached the peak at the 3rd week after the after laser application. Anti-TF monoclonal antibody can predominantly decrease the expression of TF, VEGF and F4/80, and reduced the area of CNV. Anti-TF monoclonal antibody also decreased incidence of CNV and leakage area. There were no pathological changes in the liver, heart, brain or kidney tissue. We conclude that TF plays an important role in CNV and anti-TF monoclonal antibody significantly decreases CNV in mouse model and anti-TF monoclonal antibody may have therapeutic potential in AMD. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Wang, Li; Yu, Ying; Cui, Chen; Guan, Huaijin; Chen, Hui] Nantong Univ, Affiliated Hosp, Inst Eye, Nantong 226001, Jiangsu, Peoples R China.
   [Yang, Zhongkai] Xinhua Hosp, Dept Ophthalmol, Yili, Peoples R China.
C3 Nantong University
RP Chen, H (通讯作者)，Nantong Univ, Affiliated Hosp, Inst Eye, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
EM chenhuieye@126.com
FU National Natural Science Foundation of China [81200680]
FX The study was supported by National Natural Science Foundation of China
   (81200680).
CR Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663
   Ahamed J, 2004, J BIOL CHEM, V279, P23038, DOI 10.1074/jbc.M401376200
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Belting M, 2005, ARTERIOSCL THROM VAS, V25, P1545, DOI 10.1161/01.ATV.0000171155.05809.bf
   Belting M, 2004, NAT MED, V10, P502, DOI 10.1038/nm1037
   Bluff JE, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1871
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cho YG, 2011, LAB INVEST, V91, P519, DOI 10.1038/labinvest.2010.184
   Chu AJ, 2006, CELL BIOCHEM FUNCT, V24, P173, DOI 10.1002/cbf.1200
   Croce K, 2007, CURR OPIN HEMATOL, V14, P55, DOI 10.1097/00062752-200701000-00011
   Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hembrough TA, 2003, CANCER RES, V63, P2997
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Lu F, 2009, INVEST OPHTH VIS SCI, V50, P3890, DOI 10.1167/iovs.08-2833
   MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Ngo CV, 2007, INT J CANCER, V120, P1261, DOI 10.1002/ijc.22426
   Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632
   Peng WY, 2013, MOL VIS, V19, P1296
   Rak J, 2006, SEMIN THROMB HEMOST, V32, P54, DOI 10.1055/s-2006-933341
   Rong Y, 2006, CANCER RES, V66, P7067, DOI 10.1158/0008-5472.CAN-06-0346
   Ruf W, 2011, J THROMB HAEMOST, V9, P306, DOI 10.1111/j.1538-7836.2011.04318.x
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takehana Y, 1999, INVEST OPHTH VIS SCI, V40, P459
   Tezel TH, 2007, OCUL IMMUNOL INFLAMM, V15, P3, DOI 10.1080/09273940601147760
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Uusitalo-Jarvinen H, 2007, ARTERIOSCL THROM VAS, V27, P1456, DOI 10.1161/ATVBAHA.107.142539
   Valmaggia C, 2008, KLIN MONATSBL AUGENH, V225, P380, DOI 10.1055/s-2008-1027266
   Wang GF, 2012, INT J OPHTHALMOL-CHI, V5, P609, DOI 10.3980/j.issn.2222-3959.2012.05.13
   Wickremasinghe SS, 2011, INVEST OPHTH VIS SCI, V52, P4072, DOI 10.1167/iovs.10-6550
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
   Zhang J, 2005, CANCER BIOL THER, V4, P769, DOI 10.4161/cbt.4.7.1871
   Zhang W., 2012, PLOS ONE, V7
NR 48
TC 9
Z9 10
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2014
VL 127
BP 117
EP 123
DI 10.1016/j.exer.2014.07.006
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ1KI
UT WOS:000342539900014
PM 25063201
DA 2022-11-30
ER

PT J
AU Ablonczy, Z
   Smith, N
   Anderson, DM
   Grey, AC
   Spraggins, J
   Koutalos, Y
   Schey, KL
   Crouch, RK
AF Ablonczy, Zsolt
   Smith, Noah
   Anderson, David M.
   Grey, Angus C.
   Spraggins, Jeffrey
   Koutalos, Yiannis
   Schey, Kevin L.
   Crouch, Rosalie K.
TI The utilization of fluorescence to identify the components of lipofuscin
   by imaging mass spectrometry
SO PROTEOMICS
LA English
DT Article
DE A2E; Biomedicine; Lipofuscin; MALDI imaging; Mouse; RPE
ID RETINAL-PIGMENT EPITHELIUM; A2E; FLUOROPHORE; BIOSYNTHESIS;
   DEGENERATION; PRECURSOR; NEURONS; BRAIN
AB Lipofuscin, an aging marker in the retinal pigment epithelium (RPE) associated with the development of age-related macular degeneration, is primarily characterized by its fluorescence. The most abundant component of RPE lipofuscin is N-retinylidene-N-retinylethanolamine (A2E) but its exact composition is not known due to the complexity of the RPE extract. In this study, we utilized MALDI imaging to find potential molecules responsible for lipofuscin fluorescence in RPE tissue from Abca4(-/-), Sv129, and C57Bl6/J mice aged 2 and 6 months. To assert relationships, the individual images in the MALDI imaging datasets were correlated with lipofuscin fluorescence recorded from the same tissues following proper registration. Spatial correlation information, which is usually lost in bioanalytics, pinpointed a relatively small number of potential lipofuscin components. The comparison of four samples in each condition further limited the possibility of false positives and provided various new, age- and strain-specific targets. Validating the usefulness of the fluorescence-enhanced imaging strategy, many known adducts of A2E were identified in the short list of lipofuscin components. These results provided evidence that mass spectrometric imaging can be utilized as a tool to begin to identify the molecular substructure of clinically-relevant diagnostic information.
C1 [Ablonczy, Zsolt; Koutalos, Yiannis; Crouch, Rosalie K.] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   [Smith, Noah] Clemson Univ, Clemson, SC USA.
   [Anderson, David M.; Spraggins, Jeffrey; Schey, Kevin L.] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA.
   [Grey, Angus C.] Univ Auckland, Dept Physiol, Auckland, New Zealand.
C3 Medical University of South Carolina; Clemson University; Vanderbilt
   University; University of Auckland
RP Ablonczy, Z (通讯作者)，Med Univ S Carolina, Inst Eye, Rm 518E,167 Ashley Ave, Charleston, SC 29425 USA.
EM ablonczy@musc.edu
RI Grey, Gus/J-7024-2015; Grey, Angus/O-3473-2019
OI Grey, Gus/0000-0002-1540-1080; Grey, Angus/0000-0002-1540-1080;
   Spraggins, Jeffrey/0000-0001-9198-5498
FU NIH [R21 EY020661, R01 EY004939, R01 EY014850, R01 EY019728, R01
   EY19065]; Research to Prevent Blindness (RPB; New York); NATIONAL EYE
   INSTITUTE [R01EY014850, R21EY020661, R21EY019728, R01EY019065,
   R01EY004939] Funding Source: NIH RePORTER
FX This study is compliant with the recommendations for "Minimum
   Information About a Proteomics Experiment." The study was supported in
   part by NIH grants R21 EY020661 (ZA/RKC), R01 EY004939 (RKC), R01
   EY014850 (YK), R01 EY019728 (KS) and R01 EY19065 (ZA); and an
   unrestricted grant to the Department of Ophthalmology at MUSC from
   Research to Prevent Blindness (RPB; New York); RKC is an RPB Senior
   Scientific Investigator. The work has in part been conducted in the MUSC
   Mass Spectrometry Institutional Research Resource Facility and in the
   Vanderbilt Mass Spectrometry Research Center.
CR Ablonczy Z., 2013, ARCH BIOCH BIOPHYS
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Bajaj NPS, 1998, NEUROSCI LETT, V245, P45, DOI 10.1016/S0304-3940(98)00176-1
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Chiou G. C. Y., 2012, AGE RELATED MACULAR, P283
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Gutierrez DB, 2010, PHOTOCH PHOTOBIO SCI, V9, P1513, DOI 10.1039/c0pp00230e
   Hashemzadeh-Bonehi L, 2006, EXP NEUROL, V199, P328, DOI 10.1016/j.expneurol.2005.12.030
   Herrmann KA, 2005, ANAL CHEM, V77, P7626, DOI 10.1021/ac050828+
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Nakanishi H, 1997, J NEUROCHEM, V68, P739
   Nakano M, 1995, GERONTOLOGY, V41, P69
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Tang PH, 2013, PROG RETIN EYE RES, V32, P48, DOI 10.1016/j.preteyeres.2012.09.002
   ULFIG N, 1989, NEUROSCI RES, V6, P456, DOI 10.1016/0168-0102(89)90007-2
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler BS, 1999, MOL VIS, V5
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
NR 33
TC 19
Z9 21
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD APR
PY 2014
VL 14
IS 7-8
SI SI
BP 936
EP 944
DI 10.1002/pmic.201300406
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AE0YE
UT WOS:000333691400014
PM 24453194
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jo, DH
   Kim, JH
   Kim, KW
   Suh, YG
   Kim, JH
AF Jo, Dong Hyun
   Kim, Jin Hyoung
   Kim, Kyu-Won
   Suh, Young-Ger
   Kim, Jeong Hun
TI Allosteric regulation of pathologic angiogenesis: potential application
   for angiogenesis-related blindness
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Review
DE Allosteric regulation; Pathologic angiogenesis; Age-related macular
   degeneration; Diabetic retinopathy; Retinopathy of prematurity
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; POSITIVE
   COOPERATIVE INTERACTIONS; PROTEIN-COUPLED RECEPTORS; BLOOD-RETINAL
   BARRIER; MACULAR DEGENERATION; DRUG DISCOVERY; MUSCARINIC RECEPTORS;
   TUMOR VASCULATURE; TYROSINE KINASES
AB Angiogenesis-related blindness (ARB) includes age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity, all of which are based on pathologic angiogenesis. Current treatment options such as surgery, laser photocoagulation, and steroid have shown limitations because they do not directly resolve the pathologic events in the retina. Furthermore, recently approved and developed therapeutic drugs only focus on direct inhibition of growth factors and suppression of downstream signaling molecules of activated receptor proteins by orthosteric ligands. In this regard, allosteric regulation of receptors and ligands can be a valuable mechanism in the development of novel drugs for ARB. In this review, we briefly address the clinical significance of ARB for further discussion on allosteric regulation of pathologic angiogenesis for ARB. Interestingly, key molecules in the pathogenesis of ARB can be targets for allosteric regulation, sharing characteristics as allosteric proteins. With investigation of allostery by introducing well-established models for allosteric proteins and currently published novel allosteric modulators, we discuss the potential of allosteric regulation for ARB. In conclusion, we hope that allosteric regulation of pathologic angiogenesis in ARB can open new opportunities for drug development.
C1 [Jo, Dong Hyun; Kim, Jin Hyoung; Kim, Jeong Hun] Seoul Natl Univ Hosp, Clin Res Inst, FARB Lab, Seoul 110744, South Korea.
   [Jo, Dong Hyun; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul 110799, South Korea.
   [Kim, Kyu-Won; Suh, Young-Ger] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
   [Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Kim, JH (通讯作者)，Seoul Natl Univ Hosp, Clin Res Inst, FARB Lab, Seoul 110744, South Korea.
EM steph25@snu.ac.kr
RI Kim, Kyu Won/AAJ-7213-2020; Jo, Dong Hyun/D-5962-2012
OI Jo, Dong Hyun/0000-0002-6320-6829; Kim, Jeong Hun/0000-0003-2957-1766
FU National Research Foundation (NRF); Korea government (MEST)
   [2012-0006019]; Seoul National University [800-20130338]; Pioneer
   Research Program of NRF/MEST [2012-0009544]; Bio-Signal Analysis
   Technology Innovation Program of NRF/MEST [2009-0090895]
FX This study was supported by National Research Foundation (NRF) grant
   funded by the Korea government (MEST) (2012-0006019), the Seoul National
   University Research Grant (800-20130338), the Pioneer Research Program
   of NRF/MEST (2012-0009544), and the Bio-Signal Analysis Technology
   Innovation Program of NRF/MEST (2009-0090895).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217
   Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200
   Birdsall NJM, 1999, MOL PHARMACOL, V55, P778
   Booth B, 2004, NAT REV DRUG DISCOV, V3, P451, DOI 10.1038/nrd1384
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Buttner A, 2010, BIOORGAN MED CHEM, V18, P3387, DOI 10.1016/j.bmc.2010.04.001
   Byeon SH, 2012, RETINA-J RET VIT DIS, V32, P1087, DOI 10.1097/IAE.0b013e3182349686
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Changeux JP, 2012, ANNU REV BIOPHYS, V41, P103, DOI 10.1146/annurev-biophys-050511-102222
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Chen J, 2011, CURR OPIN PEDIATR, V23, P173, DOI 10.1097/MOP.0b013e3283423f35
   Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760
   COOPER A, 1984, EUR BIOPHYS J BIOPHY, V11, P103, DOI 10.1007/BF00276625
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   del Sol A, 2009, STRUCTURE, V17, P1042, DOI 10.1016/j.str.2009.06.008
   Fens MHAM, 2010, EXPERT OPIN INV DRUG, V19, P1321, DOI 10.1517/13543784.2010.524204
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Fiedler LR, 2008, J BIOL CHEM, V283, P17406, DOI 10.1074/jbc.M710025200
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   George B, 2009, CURR EYE RES, V34, P134, DOI 10.1080/02713680802585946
   Good WV, 2005, PEDIATRICS, V116, P15, DOI 10.1542/peds.2004-1413
   Goodey NM, 2008, NAT CHEM BIOL, V4, P474, DOI 10.1038/nchembio.98
   Gregory KJ, 2011, NEUROPHARMACOLOGY, V60, P66, DOI 10.1016/j.neuropharm.2010.07.007
   Hauske P, 2008, CHEMBIOCHEM, V9, P2920, DOI 10.1002/cbic.200800528
   Heo JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033456
   Hilser VJ, 2012, ANNU REV BIOPHYS, V41, P585, DOI 10.1146/annurev-biophys-050511-102319
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hoogerwerf A, 2010, NEONATOLOGY, V98, P137, DOI 10.1159/000280386
   Huang ZM, 2011, NUCLEIC ACIDS RES, V39, pD663, DOI 10.1093/nar/gkq1022
   Hyde CAC, 2012, MOL CELL BIOL, V32, P3802, DOI 10.1128/MCB.06787-11
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jo Dong Hyun, 2012, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V12, P110
   Jo DH, 2010, ARCH PHARM RES, V33, P1557, DOI 10.1007/s12272-010-1007-6
   Jonas JB, 2007, OPHTHAL RES, V39, P139, DOI 10.1159/000102935
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kenakin T, 2005, NAT REV DRUG DISCOV, V4, P919, DOI 10.1038/nrd1875
   Keov P, 2011, NEUROPHARMACOLOGY, V60, P24, DOI 10.1016/j.neuropharm.2010.07.010
   Khan Zia A., 2005, Angiogenesis, V8, P183, DOI 10.1007/s10456-005-9017-6
   Kim JH, 2009, J CEREBR BLOOD F MET, V29, P1559, DOI 10.1038/jcbfm.2009.78
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98
   KOSHLAND DE, 1959, J CELL COMPAR PHYSL, V54, P245, DOI 10.1002/jcp.1030540420
   Lad EM, 2009, AM J OPHTHALMOL, V148, P451, DOI 10.1016/j.ajo.2009.04.018
   Lazareno S, 2004, MOL PHARMACOL, V65, P257, DOI 10.1124/mol.65.1.257
   Lazareno S, 1998, MOL PHARMACOL, V53, P573, DOI 10.1124/mol.53.3.573
   Lee BJ, 2012, EYE, V26, P903, DOI 10.1038/eye.2012.111
   Liekens S, 2012, MOL CANCER THER, V11, P817, DOI 10.1158/1535-7163.MCT-11-0738
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim YM, 2012, DIABETES, V61, P1599, DOI 10.2337/db11-1541
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Manousaridis K, 2012, BRIT J OPHTHALMOL, V96, P179, DOI 10.1136/bjophthalmol-2011-301087
   May LT, 2007, ANNU REV PHARMACOL, V47, P1, DOI 10.1146/annurev.pharmtox.47.120505.105159
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008
   MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6
   MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1
   Murakami M, 2008, J CLIN INVEST, V118, P3355, DOI 10.1172/JCI35298
   Murakami M, 2011, J CLIN INVEST, V121, P2668, DOI 10.1172/JCI44762
   Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925
   Nathan DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1707, DOI 10.1001/archopht.126.12.1707
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Nilsson I, 2010, EMBO J, V29, P1377, DOI 10.1038/emboj.2010.30
   Ning A, 2008, CAN J OPHTHALMOL, V43, P683, DOI 10.3129/i08-145
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240
   PALMER EA, 1991, OPHTHALMOLOGY, V98, P1628
   Patel RD, 2012, ARCH OPHTHALMOL-CHIC, V130, P801, DOI 10.1001/archophthalmol.2011.1802
   Peracchi A, 2011, BBA-PROTEINS PROTEOM, V1814, P922, DOI 10.1016/j.bbapap.2010.10.008
   Popovych N, 2006, NAT STRUCT MOL BIOL, V13, P831, DOI 10.1038/nsmb1132
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   Sato T, 2009, OPHTHALMOLOGY, V116, P1599, DOI 10.1016/j.ophtha.2008.12.023
   Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Silva R, 2008, ARTERIOSCL THROM VAS, V28, P1703, DOI 10.1161/ATVBAHA.108.172015
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Tewari S, 2012, INVEST OPHTH VIS SCI, V53, P4881, DOI 10.1167/iovs.12-9732
   Tsai CJ, 2008, J MOL BIOL, V378, P1, DOI 10.1016/j.jmb.2008.02.034
   Udugamasooriya DG, 2008, J AM CHEM SOC, V130, P5744, DOI 10.1021/ja711193x
   Udugamasooriya DG, 2008, BIOORGAN MED CHEM, V16, P6338, DOI 10.1016/j.bmc.2008.05.015
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Weikl TR, 2009, PROTEINS, V75, P104, DOI 10.1002/prot.22223
   Yin H, 2006, BIOORG MED CHEM LETT, V16, P3380, DOI 10.1016/j.bmcl.2006.04.037
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhong Q, 2011, DIABETES, V60, P1304, DOI 10.2337/db10-0133
NR 108
TC 7
Z9 7
U1 0
U2 12
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD MAR
PY 2014
VL 37
IS 3
BP 285
EP 298
DI 10.1007/s12272-013-0324-y
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AC4HB
UT WOS:000332480600001
PM 24395531
DA 2022-11-30
ER

PT J
AU Chavali, VRM
   Khan, NW
   Cukras, CA
   Bartsch, DU
   Jablonski, MM
   Ayyagari, R
AF Chavali, Venkata R. M.
   Khan, Naheed W.
   Cukras, Catherine A.
   Bartsch, Dirk-Uwe
   Jablonski, Monica M.
   Ayyagari, Radha
TI A CTRP5 gene S163R mutation knock-in mouse model for late-onset retinal
   degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PIGMENT-EPITHELIUM DEPOSITS; SORSBYS-FUNDUS-DYSTROPHY; FRIZZLED-RELATED
   PROTEIN; AGE-RELATED MACULOPATHY; ANTERIOR LENS ZONULES; CHEMOKINE
   RECEPTOR 2; MACULAR DEGENERATION; PHOTORECEPTOR DEGENERATION;
   DARK-ADAPTATION; ACCELERATED ACCUMULATION
AB Late-onset retinal macular degeneration (L-ORD) is an autosomal dominant inherited disorder caused by a single missense mutation (S163R) in the CTRP5/C1QTNF5 protein. Early phenotypic features of L-ORD include: dark adaptation abnormalities, nyctalopia, and drusen deposits in the peripheral macular region. Apart from posterior segment abnormalities, these patients also develop abnormally long anterior lens zonules. In the sixth decade of life the rod and cone function declines, accompanied by electroretinogram (ERG) abnormalities. Some patients also develop choroidal neovascularization and glaucoma. In order to understand the disease pathology and mechanisms involved in retinal dystrophy, we generated a knock-in (Ctrp5(+/-)) mouse model carrying the disease-associated mutation in the mouse Ctrp5/C1QTNF5 gene. These mice develop slower rod-b wave recovery consistent with early dark adaptation abnormalities, accumulation of hyperautofluorescence spots, retinal pigment epithelium abnormalities, drusen, Bruch's membrane abnormalities, loss of photoreceptors, and retinal vascular leakage. The Ctrp5(+/-) mice, which have most of the pathological features of age-related macular degeneration, are unique and may serve as a valuable model both to understand the molecular pathology of late-onset retinal degeneration and to evaluate therapies.
C1 [Chavali, Venkata R. M.; Bartsch, Dirk-Uwe; Ayyagari, Radha] Univ Calif San Diego, La Jolla, CA 92037 USA.
   [Khan, Naheed W.] Univ Michigan, Ann Arbor, MI 48105 USA.
   [Jablonski, Monica M.] Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, Memphis, TN 38163 USA.
   [Cukras, Catherine A.] NEI, NIH, Bethesda, MD 20892 USA.
C3 University of California System; University of California San Diego;
   University of Michigan System; University of Michigan; University of
   Tennessee System; University of Tennessee Health Science Center;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Ayyagari, R (通讯作者)，Univ Calif San Diego, La Jolla, CA 92037 USA.
EM rayyagari@ucsd.edu
FU National Institute of Health [RO1 EY016323, P30EY007003, R01EY013198];
   Foundation Fighting Blindness Centre; Research to Prevent Blindness, New
   York, NY; UCSD Neuroscience Microscopy Shared Facility [P30 NS047101];
   NATIONAL EYE INSTITUTE [P30EY007003, R01EY013198, R01EY016323] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKE [P30NS047101] Funding Source: NIH RePORTER
FX This work is supported by National Institute of Health grants (RO1
   EY016323 to D.-U.B., P30EY007003 to M.M.J. and R01EY013198 to R.A.); a
   Foundation Fighting Blindness Centre grant to R.A.; an unrestricted
   grant from Research to Prevent Blindness, New York, NY (to M.M.J.); and
   the UCSD Neuroscience Microscopy Shared Facility grant (P30 NS047101).
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Applebury ML, 2000, NEURON, V27, P513, DOI 10.1016/S0896-6273(00)00062-3
   Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Ayyagari R, 2000, ARCH OPHTHALMOL-CHIC, V118, P85
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Borooah S, 2009, BRIT J OPHTHALMOL, V93, P284, DOI 10.1136/bjo.2008.150151
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BROSNAHAN DM, 1994, OPHTHALMOLOGY, V101, P38
   Brunk UT, 1995, GERONTOLOGY, V41, P201
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DUVALL J, 1986, GRAEF ARCH CLIN EXP, V224, P299, DOI 10.1007/BF02143075
   ELIZABETH RP, 2006, EXP EYE RES, V82, P741, DOI DOI 10.1016/J.EXER.2005.10.012
   Farris AB, 2009, AM J SURG PATHOL, V33, P1485, DOI 10.1097/PAS.0b013e3181adbaf9
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Gresh J, 2003, VISUAL NEUROSCI, V20, P211, DOI 10.1017/S0952523803202108
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Haimovici R, 2002, EYE, V16, P7, DOI 10.1038/sj.eye.6700018
   Hammer M, 2006, MOL VIS, V12, P1348
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Jimenez AJ, 1996, CELL TISSUE RES, V284, P193, DOI 10.1007/s004410050579
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LILLARDWETHEREL.K, 2008, APERIO SUPPORT DOCUM, P1
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Machida S, 2000, INVEST OPHTH VIS SCI, V41, P3200
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5505, DOI 10.1167/iovs.06-0312
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5514, DOI 10.1167/iovs.06-0449
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Moroi SE, 2003, AM J OPHTHALMOL, V136, P1176, DOI 10.1016/S0002-9394(03)00657-3
   Oh ECT, 2008, BRAIN RES, V1236, P16, DOI 10.1016/j.brainres.2008.01.028
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Park SY, 2009, J BIOL CHEM, V284, P27780, DOI 10.1074/jbc.M109.005611
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seeliger MW, 2005, VISION RES, V45, P3512, DOI 10.1016/j.visres.2005.08.014
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Staniszewski W, 2009, FOLIA HISTOCHEM CYTO, V47, P699, DOI 10.2478/v10042-009-0115-y
   STEINMETZ RL, 1992, INVEST OPHTH VIS SCI, V33, P1633
   Subrayan V, 2005, AM J OPHTHALMOL, V140, P1127, DOI 10.1016/j.ajo.2005.06.023
   Sundin OH, 2005, P NATL ACAD SCI USA, V102, P9553, DOI 10.1073/pnas.0501451102
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WALI N, 1991, DOC OPHTHALMOL, V76, P367, DOI 10.1007/BF00142675
   Wang NK, 2009, BRIT J OPHTHALMOL, V93, P1234, DOI 10.1136/bjo.2008.153577
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 67
TC 46
Z9 47
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2011
VL 20
IS 10
BP 2000
EP 2014
DI 10.1093/hmg/ddr080
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 754EU
UT WOS:000289837400012
PM 21349921
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jarrett, SG
   Lewin, AS
   Boulton, ME
AF Jarrett, Stuart G.
   Lewin, Alfred S.
   Boulton, Michael E.
TI The Importance of Mitochondria in Age-Related and Inherited Eye
   Disorders
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Mitochondria; Ocular function; Reactive oxygen species
ID RETINAL-PIGMENT EPITHELIUM; DNA-POLYMERASE-GAMMA; HEREDITARY OPTIC
   NEUROPATHY; BASE EXCISION-REPAIR; OXIDATIVE STRESS;
   SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; NUCLEAR-DNA; MACULAR
   DEGENERATION; PROGRESSIVE STAGES
AB Mitochondria are critical for ocular function as they represent the major source of a cell's supply of energy and play an important role in cell differentiation and survival. Mitochondrial dysfunction can occur as a result of inherited mitochondrial mutations (e.g. Leber's hereditary optic neuropathy and chronic progressive external ophthalmoplegia) or stochastic oxidative damage which leads to cumulative mitochondrial damage and is an important factor in age-related disorders (e.g. age-related macular degeneration, cataract and diabetic retinopathy). Mitochondrial DNA (mtDNA) instability is an important factor in mitochondrial impairment culminating in age-related changes and pathology, and in all regions of the eye mtDNA damage is increased as a consequence of aging and age-related disease. It is now apparent that the mitochondrial genome is a weak link in the defenses of ocular cells since it is susceptible to oxidative damage and it lacks some of the systems that protect the nuclear genome, such as nucleotide excision repair. Accumulation of mitochondrial mutations leads to cellular dysfunction and increased susceptibility to adverse events which contribute to the pathogenesis of numerous sporadic and chronic disorders in the eye. Copyright (C) 2010 S. Karger AG, Basel
C1 [Boulton, Michael E.] Univ Florida, Dept Anat & Cell Biol, Coll Med, Gainesville, FL 32610 USA.
   [Jarrett, Stuart G.] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA.
   [Lewin, Alfred S.] Univ Florida, Dept Mol Genet, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; University of
   Kentucky; State University System of Florida; University of Florida
RP Boulton, ME (通讯作者)，Univ Florida, Dept Anat & Cell Biol, Coll Med, POB 100235, Gainesville, FL 32610 USA.
EM meboulton@ufl.edu
OI Lewin, Alfred/0000-0002-4192-9727; Jarrett, Stuart/0000-0001-8029-1554
FU NIH [EY019688]; NATIONAL EYE INSTITUTE [R01EY019688] Funding Source: NIH
   RePORTER
FX This work was supported by NIH grant EY019688.
CR Abner CW, 2004, DNA REPAIR, V3, P1141, DOI 10.1016/j.dnarep.2004.03.009
   Abu-Amero KK, 2006, INVEST OPHTH VIS SCI, V47, P2533, DOI 10.1167/iovs.05-1639
   Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x
   Bedlack RS, 2004, MUSCLE NERVE, V29, P364, DOI 10.1002/mus.10546
   Besch D, 2000, OPHTHALMOLOGE, V97, P27, DOI 10.1007/PL00007105
   Bohr VA, 2007, NEUROSCIENCE, V145, P1183, DOI 10.1016/j.neuroscience.2007.03.015
   Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6
   Bosch-Morell F, 2002, FREE RADICAL BIO MED, V33, P669, DOI 10.1016/S0891-5849(02)00954-1
   Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034
   BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Burkhalter MD, 2009, DNA REPAIR, V8, P1258, DOI 10.1016/j.dnarep.2009.07.009
   Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Carelli V, 2001, J NEUROL NEUROSUR PS, V71, P813, DOI 10.1136/jnnp.71.6.813
   Carelli V, 2001, OPHTHALMOLOGY, V108, P1172, DOI 10.1016/S0161-6420(01)00618-2
   Carelli V, 2007, BIOSCIENCE REP, V27, P173, DOI 10.1007/s10540-007-9045-0
   Cavelier L, 2000, EXP CELL RES, V259, P79, DOI 10.1006/excr.2000.4949
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   CHEN EP, 1992, CURR EYE RES, V11, P825, DOI 10.3109/02713689209033480
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Di Fonzo A, 2009, AM J HUM GENET, V84, P594, DOI 10.1016/j.ajhg.2009.04.004
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Ellis EA, 2000, FREE RADICAL BIO MED, V28, P91, DOI 10.1016/S0891-5849(99)00216-6
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   ESTABROOK RW, 1962, BIOCHIM BIOPHYS ACTA, V60, P249, DOI 10.1016/0006-3002(62)90400-6
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   GERSCHMAN R, 1954, P SOC EXP BIOL MED, V86, P27
   GERSCHMAN R, 1954, SCIENCE, V119, P623, DOI 10.1126/science.119.3097.623
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Godley BF, 2008, INVEST OPHTHALMOL VI, V49
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   GREEN K, 1995, OPHTHALMIC RES, V27, P143, DOI 10.1159/000267860
   Grishko VI, 2005, J BIOL CHEM, V280, P8901, DOI 10.1074/jbc.M413022200
   Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007
   Gusdon AM, 2008, J BIOL CHEM, V283, P10690, DOI 10.1074/jbc.M708801200
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harrison JF, 2005, NUCLEIC ACIDS RES, V33, P4660, DOI 10.1093/nar/gki759
   Hightower KR, 1999, PHOTOCHEM PHOTOBIOL, V69, P595, DOI 10.1111/j.1751-1097.1999.tb03333.x
   Holt IJ, 2007, MITOCHONDRION, V7, P311, DOI 10.1016/j.mito.2007.06.004
   HOWELL N, 1991, AM J HUM GENET, V49, P939
   HOWELL N, 1993, AM J HUM GENET, V53, P959
   Huang L, 2006, FREE RADICAL BIO MED, V41, P926, DOI 10.1016/j.freeradbiomed.2006.05.023
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Johns D R, 1995, Semin Ophthalmol, V10, P295, DOI 10.3109/08820539509063800
   Jones M, 2004, AM J OPHTHALMOL, V138, P1051, DOI 10.1016/j.ajo.2004.06.026
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   KERRISON JB, 1995, OPHTHALMOLOGY, V102, P1509
   Khurana RN, 2008, INVEST OPHTH VIS SCI, V49, P3299, DOI 10.1167/iovs.07-1607
   Kokotas H, 2007, CLIN GENET, V71, P379, DOI 10.1111/j.1399-0004.2007.00800.x
   Kong GYX, 2009, J GLAUCOMA, V18, P93, DOI 10.1097/IJG.0b013e318181284f
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Kowluru RA, 2006, INVEST OPHTH VIS SCI, V47, P1594, DOI 10.1167/iovs.05-1276
   Kowluru RA, 2005, ANTIOXID REDOX SIGN, V7, P1581, DOI 10.1089/ars.2005.7.1581
   Kowluru RA, 2003, INVEST OPHTH VIS SCI, V44, P5327, DOI 10.1167/iovs.03-0353
   Kowluru RA, 2003, DIABETES, V52, P818, DOI 10.2337/diabetes.52.3.818
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kowluru RA, 2006, FREE RADICAL BIO MED, V41, P1191, DOI 10.1016/j.freeradbiomed.2006.01.012
   Kowluru RA, 2010, BRAIN RES BULL, V81, P297, DOI 10.1016/j.brainresbull.2009.05.006
   Laloi-Michelin M, 2009, J CLIN ENDOCR METAB, V94, P3025, DOI 10.1210/jc.2008-2680
   Lascaratos G, 2007, VISION RES, V47, P1191, DOI 10.1016/j.visres.2006.12.014
   LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967
   Lee HC, 2007, EXP BIOL MED, V232, P592
   Liang FQ, 2005, EXP EYE RES, V80, P113, DOI 10.1016/j.exer.2004.08.017
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liang LP, 2004, J NEUROCHEM, V90, P1076, DOI 10.1111/j.1471-4159.2004.02567.x
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200
   Liu ZR, 2008, MOL VIS, V14, P1995
   Lou MF, 2003, PROG RETIN EYE RES, V22, P657, DOI 10.1016/S1350-9462(03)00050-8
   Mackey DA, 1996, AM J HUM GENET, V59, P481
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mannella CA, 2006, BBA-MOL BASIS DIS, V1762, P140, DOI 10.1016/j.bbadis.2005.07.001
   Mason PA, 2003, NUCLEIC ACIDS RES, V31, P1052, DOI 10.1093/nar/gkg167
   Mathews CE, 2005, DIABETOLOGIA, V48, P261, DOI 10.1007/s00125-004-1644-8
   MCCORD JM, 1969, J BIOL CHEM, V244, P6056
   MCCORD JM, 1969, J BIOL CHEM, V244, P6049
   Min D B, 2002, Compr Rev Food Sci Food Saf, V1, P58, DOI 10.1111/j.1541-4337.2002.tb00007.x
   Mittag TW, 2000, INVEST OPHTH VIS SCI, V41, P3451
   Monsalve M, 2007, FRONT BIOSCI-LANDMRK, V12, P1131, DOI 10.2741/2132
   Newsholme P, 2007, J PHYSIOL-LONDON, V583, P9, DOI 10.1113/jphysiol.2007.135871
   Nishikawa T, 2007, DIABETES RES CLIN PR, V77, pS41, DOI 10.1016/j.diabres.2007.01.031
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   OCONNOR GR, 1983, AM J OPHTHALMOL, V96, P577, DOI 10.1016/S0002-9394(14)73415-4
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Osborne NN, 2006, BRIT J OPHTHALMOL, V90, P237, DOI 10.1136/bjo.2005.082230
   Panahi MSS, 2006, ARCH MED RES, V37, P1028, DOI 10.1016/j.arcmed.2006.04.009
   Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5
   Puomila A, 2002, J NEUROL SCI, V205, P41, DOI 10.1016/S0022-510X(02)00276-9
   Rajendram R, 2007, BRIT J OPHTHALMOL, V91, P531, DOI 10.1136/bjo.2006.101576
   Reddan JR, 1999, EXP EYE RES, V68, P117, DOI 10.1006/exer.1998.0606
   Reeve AK, 2008, ANN NY ACAD SCI, V1147, P21, DOI 10.1196/annals.1427.016
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Santos DL, 2003, MOL CELL BIOCHEM, V246, P163, DOI 10.1023/A:1023475022025
   Santosa S, 2005, CAN MED ASSOC J, V173, P861, DOI 10.1503/cmaj.1031425
   Saraswathy S, 2009, INVEST OPHTH VIS SCI, V50, P5559, DOI 10.1167/iovs.08-2842
   SATOH M, 1991, EXP CELL RES, V196, P137, DOI 10.1016/0014-4827(91)90467-9
   Simpkins JW, 2005, CNS NEUROL DISORD-DR, V4, P69, DOI 10.2174/1568007053005073
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Stitt AW, 2005, PHARMACOL REP, V57, P156
   Stuart JA, 2005, NUCLEIC ACIDS RES, V33, P3722, DOI 10.1093/nar/gki683
   Tatton W, 2001, SURV OPHTHALMOL, V45, pS295
   Tatton WG, 2001, SURV OPHTHALMOL, V45, pS277, DOI 10.1016/S0039-6257(01)00207-7
   Terman A, 2006, ANTIOXID REDOX SIGN, V8, P197, DOI 10.1089/ars.2006.8.197
   Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TOMKINSON AE, 1990, NUCLEIC ACIDS RES, V18, P929, DOI 10.1093/nar/18.4.929
   TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0
   Uchigata Y, 2002, DIABETES CARE, V25, P2106, DOI 10.2337/diacare.25.11.2106
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Wang AL, 2008, MOL VIS, V14, P644
   Whiteside CL, 2005, CURR HYPERTENS REP, V7, P148, DOI 10.1007/s11906-005-0090-4
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yao K, 2009, AM J CHINESE MED, V37, P785, DOI 10.1142/S0192415X09007247
   Yorek MA, 2003, FREE RADICAL RES, V37, P471, DOI 10.1080/1071576031000083161
NR 147
TC 77
Z9 82
U1 0
U2 15
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2010
VL 44
IS 3
BP 179
EP 190
DI 10.1159/000316480
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 652AN
UT WOS:000281972300006
PM 20829642
OA Green Published
DA 2022-11-30
ER

PT J
AU Schadlu, AP
   Schadlu, R
   Shepherd, JB
AF Schadlu, Anita P.
   Schadlu, Ramin
   Shepherd, J. Banks, III
TI Charles Bonnet syndrome: a review
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE Charles Bonnet syndrome; low vision; visual hallucinations
ID COMPLEX VISUAL HALLUCINATIONS; MACULAR DEGENERATION; PREVALENCE; THERAPY
AB Purpose of review The aging of the population and the resultant increase in the number of patients with low vision due to age-related macular degeneration and other ocular diseases necessitate an increase in awareness of the Charles Bonnet syndrome among ophthalmic care providers.
   Recent findings The clinical features of Charles Bonnet syndrome have been described by several different authors as formed visual hallucinations due to disturbances of the visual system in patients who are otherwise mentally normal. Theories regarding the causes underlying the Charles Bonnet syndrome are multifaceted and offer insight into the function of the visual system. The incidence of the Charles Bonnet syndrome varies among different population groups, but is underdiagnosed in most settings. Recent case reports of treatment options involve varied pharmacologic interventions, but visual improvement and patient reassurance remain the mainstays of treatment.
   Summary As Charles Bonnet syndrome becomes more prevalent as the population ages, all physicians who care for low vision or elderly patients should be aware of its clinical characteristics and treatment options. Understanding of this syndrome by caregivers will lead to decreased anxiety among the patients who experience it. Further exploration of treatment options will be necessary in the future.
C1 [Schadlu, Anita P.] Wills Eye Hosp & Res Inst, Philadelphia, PA USA.
   [Schadlu, Ramin] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
   [Shepherd, J. Banks, III] Washington Univ, Dept Ophthalmol, St Louis, MO USA.
C3 Jefferson University; University of Pennsylvania; Washington University
   (WUSTL)
RP Schadlu, AP (通讯作者)，840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM anita.g.prasad@gmail.com
CR Abbou EJ, 2007, INVEST OPHTH VIS SCI, V48, P1416, DOI 10.1167/iovs.06-0942
   Ashwin PT, 2007, J NEUROL SCI, V263, P184, DOI 10.1016/j.jns.2007.05.027
   Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   Crumbliss Kara E, 2008, Semin Ophthalmol, V23, P121, DOI 10.1080/08820530801888170
   de Morsier G, 1967, Ann Med Psychol (Paris), V2, P678
   Eng Jeffrey G, 2008, Retin Cases Brief Rep, V2, P130, DOI 10.1097/ICB.0b013e31804d1d9d
   Eperjesi Frank, 2004, Clin Exp Optom, V87, P149
   Hedges TR, 2007, SURV OPHTHALMOL, V52, P111, DOI 10.1016/j.survophthal.2006.10.007
   HOLROYD S, 1992, AM J PSYCHIAT, V149, P1701
   Hori H, 2001, PSYCHOPATHOLOGY, V34, P164, DOI 10.1159/000049301
   Khan JC, 2008, OPHTHAL EPIDEMIOL, V15, P202, DOI 10.1080/09286580801939320
   Lang UE, 2007, J PSYCHOPHARMACOL, V21, P553, DOI 10.1177/0269881106075275
   Menon GJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P349, DOI 10.1001/archopht.123.3.349
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Moja MC, 2005, NEUROL SCI, V26, P168, DOI 10.1007/s10072-005-0455-0
   Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x
   Tan CSH, 2006, ARCH NEUROL-CHICAGO, V63, P598, DOI 10.1001/archneur.63.4.598
   TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254
   TEUNISSE RJ, 1994, COMPR PSYCHIAT, V35, P70, DOI 10.1016/0010-440X(94)90172-4
   Ukai S, 2004, INT CLIN PSYCHOPHARM, V19, P355, DOI 10.1097/00004850-200411000-00008
   Vukicevic M, 2008, CLIN EXP OPHTHALMOL, V36, P659, DOI [10.1111/j.1442-9071.2008.01814.x, 10.1111/j.1442-9071.2008.01864.x]
   Walker Jonathan D, 2008, Retin Cases Brief Rep, V2, P27, DOI 10.1097/01.iae.0000243039.22011.5f
NR 23
TC 74
Z9 78
U1 2
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2009
VL 20
IS 3
BP 219
EP 222
DI 10.1097/ICU.0b013e328329b643
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 446TN
UT WOS:000266144200012
PM 19349864
DA 2022-11-30
ER

PT J
AU Stieger, K
   Lheriteau, E
   Moullier, P
   Rolling, F
AF Stieger, Knut
   Lheriteau, Elsa
   Moullier, Philippe
   Rolling, Fabienne
TI AAV-Mediated Gene Therapy for Retinal Disorders in Large Animal Models
SO ILAR JOURNAL
LA English
DT Review
DE adeno-associated virus (AAV); dog model; gene therapy; nonhuman primate;
   retinal disorders
ID ENDOTHELIAL GROWTH-FACTOR; LEBER CONGENITAL AMAUROSIS;
   EPITHELIUM-DERIVED FACTOR; AGE-RELATED MACULOPATHY; CONE-ROD DYSTROPHY;
   INHIBITS CHOROIDAL NEOVASCULARIZATION; REGULATOR (RPGR)-INTERACTING
   PROTEIN; ADENOASSOCIATED VIRAL VECTORS; LINKED RETINITIS-PIGMENTOSA;
   CALCIUM-CHANNEL BLOCKER
AB Retinal gene therapy holds great promise for the treatment of inherited and noninherited blinding diseases such as retinitis pigmentosa and age-related macular degeneration. The most widely used vectors for ocular gene delivery are based on adeno-associated virus (AAV) because they elicit minimal immune responses and mediated long-term transgene expression in a variety of retinal cell types. Extensive preclinical evaluation of new strategies in large animal models is key to the development of successful gene-based therapies for the retina. Because of differences in the retinal structures among species and unique structures such as the macula and fovea in the primate retina, nonhuman primates are widely used as preclinical animal models. But the observation of inherited retinal degenerations in dogs, which share a number of clinical and pathologic similarities with humans, has led to the characterization of several canine models for retinal diseases, one of which has already responded successfully to AAV-mediated gene therapy. This article presents a review and detailed discussion of the various large animal models available for the study of AAV-mediated gene-based therapies in the retina.
C1 [Lheriteau, Elsa; Moullier, Philippe; Rolling, Fabienne] INSERM, Lab Nantes, U649, F-75654 Paris 13, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Rolling, F (通讯作者)，CHU Hotel Dieu, Lab Therapie Gen, INSERM, U649, Batiment J Monnet,30 Ave J Monnet, F-44035 Nantes 01, France.
EM fabienne.rolling@univ-nantes.fr
RI Stieger, Knut/A-1600-2012
OI Stieger, Knut/0000-0002-8298-5629
CR Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6
   Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aguirre G D, 1998, Mol Vis, V4, P23
   AGUIRRE GD, 1974, INVEST OPHTH VISUAL, V13, P231
   AGUIRRE GD, 1975, INVEST OPHTH VISUAL, V14, P840
   Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   ATCHISON RW, 1965, SCIENCE, V149, P754, DOI 10.1126/science.149.3685.754
   Auricchio A, 2005, CURR GENE THER, V5, P339, DOI 10.2174/1566523054065020
   Auricchio A, 2002, MOL THER, V6, P238, DOI 10.1006/mthe.2002.0660
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bainbridge JWB, 2003, GENE THER, V10, P1336, DOI 10.1038/sj.gt.3301990
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beltran WA, 2006, INVEST OPHTH VIS SCI, V47, P1669, DOI 10.1167/iovs.05-0845
   Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920
   BENNICELLI J, 2008, MOL THER, V22, P22
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boylan JP, 2000, HUM MOL GENET, V9, P2085, DOI 10.1093/hmg/9.14.2085
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch PK, 2008, GENE THER, V15, P849, DOI 10.1038/gt.2008.66
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2007, J CELL PHYSIOL, V210, P575, DOI 10.1002/jcp.20893
   Castagnet P, 2003, HUM MOL GENET, V12, P1847, DOI 10.1093/hmg/ddg202
   Chamberlain M, 2006, SURV OPHTHALMOL, V51, P576, DOI 10.1016/j.survophthal.2006.08.003
   Chong H, 2002, MOL THER, V5, P195, DOI 10.1006/mthe.2002.0531
   Chong NHV, 1998, BRIT J OPHTHALMOL, V82, P1441, DOI 10.1136/bjo.82.12.1441
   Cideciyan AV, 2005, P NATL ACAD SCI USA, V102, P5233, DOI 10.1073/pnas.0408892102
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dryja TP, 2001, AM J HUM GENET, V68, P1295, DOI 10.1086/320113
   Dryja TP, 1999, INVEST OPHTH VIS SCI, V40, P1859
   Dudus L, 1999, VISION RES, V39, P2545, DOI 10.1016/S0042-6989(98)00308-3
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   FARBER DB, 1992, NEURON, V9, P349, DOI 10.1016/0896-6273(92)90173-B
   Favre D, 2001, MOL THER, V4, P559, DOI 10.1006/mthe.2001.0494
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Flotte TR, 2004, GENE THER, V11, P805, DOI 10.1038/sj.gt.3302233
   Folliot S, 2003, J GENE MED, V5, P493, DOI 10.1002/jgm.367
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerber S, 2001, EUR J HUM GENET, V9, P561, DOI 10.1038/sj.ejhg.5200689
   GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547
   GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603
   Grahn B. H., 1998, Veterinary Ophthalmology, V1, P211
   Grahn BH, 2001, VET OPHTHALMOL, V4, P191, DOI 10.1046/j.1463-5216.2001.00154.x
   Grahn BH, 2008, VET OPHTHALMOL, V11, P242, DOI 10.1111/j.1463-5224.2008.00632.x
   Grahn BH, 2006, CAN VET J, V47, P929
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Griffey M, 2005, MOL THER, V12, P413, DOI 10.1016/j.ymthe.2005.04.018
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Gu D, 2007, INVEST OPHTH VIS SCI, V48, P4907, DOI 10.1167/iovs.07-0428
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Guy J, 1999, ARCH OPHTHALMOL-CHIC, V117, P929
   Guyon R, 2007, MOL VIS, V13, P1094
   Guziewicz KE, 2007, INVEST OPHTH VIS SCI, V48, P1959, DOI 10.1167/iovs.06-1374
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanein S, 2004, HUM MUTAT, V23, P306, DOI 10.1002/humu.20010
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   He S, 2008, VISION RES, V48, P366, DOI 10.1016/j.visres.2007.08.005
   Hennig AK, 2003, J NEUROSCI, V23, P3302
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hong DH, 2001, J BIOL CHEM, V276, P12091, DOI 10.1074/jbc.M009351200
   Hong DH, 2002, INVEST OPHTH VIS SCI, V43, P3373
   Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   KAPLAN J, 1990, HUM GENET, V85, P635
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kent D, 2000, BRIT J OPHTHALMOL, V84, P542, DOI 10.1136/bjo.84.5.542
   Khan NW, 2007, INVEST OPHTH VIS SCI, V48, P3864, DOI 10.1167/iovs.06-1521
   Khanna H, 2005, J BIOL CHEM, V280, P33580, DOI 10.1074/jbc.M505827200
   Kijas JW, 2002, P NATL ACAD SCI USA, V99, P6328, DOI 10.1073/pnas.082714499
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koenekoop RK, 2004, SURV OPHTHALMOL, V49, P379, DOI 10.1016/j.survophthal.2004.04.003
   Kohl S, 2005, EUR J HUM GENET, V13, P302, DOI 10.1038/sj.ejhg.5201269
   Komaromy AM, 2008, GENE THER, V15, P1073, DOI 10.1038/gt.2008.107
   KOMAROMY AM, 2008, ARVO PRES ASS RES VI
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Le Meur G, 2007, GENE THER, V14, P292, DOI 10.1038/sj.gt.3302861
   Le Meur G, 2005, ARCH OPHTHALMOL-CHIC, V123, P500, DOI 10.1001/archopht.123.4.500
   Lebherz C, 2005, HUM GENE THER, V16, P178, DOI 10.1089/hum.2005.16.178
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lotery AJ, 2003, HUM GENE THER, V14, P1663, DOI 10.1089/104303403322542301
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Marigo V, 2007, CELL CYCLE, V6, P652, DOI 10.4161/cc.6.6.4029
   Mavlyutov TA, 2002, HUM MOL GENET, V11, P1899, DOI 10.1093/hmg/11.16.1899
   MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35
   Mellersh CS, 2006, GENOMICS, V88, P293, DOI 10.1016/j.ygeno.2006.05.004
   Michaelides M, 2006, SURV OPHTHALMOL, V51, P232, DOI 10.1016/j.survophthal.2006.02.007
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895
   Narfstrom K, 2005, DOC OPHTHALMOL, V111, P39, DOI [10.1007/s10633-005-3159-0, 10.1007/S10633-005-3159-0]
   Narfstrom K, 1999, J Feline Med Surg, V1, P135, DOI 10.1016/S1098-612X(99)90202-4
   Narfstrom K, 2003, J HERED, V94, P31, DOI 10.1093/jhered/esg015
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Orth P, 1998, J MOL BIOL, V279, P439, DOI 10.1006/jmbi.1998.1775
   Pang JJ, 2005, MOL VIS, V11, P152
   Pearce-Kelling SE, 2001, MOL VIS, V7, P42
   Petersen-Jones S, 2005, J SMALL ANIM PRACT, V46, P371, DOI 10.1111/j.1748-5827.2005.tb00333.x
   Petters RM, 1997, NAT BIOTECHNOL, V15, P965, DOI 10.1038/nbt1097-965
   Pollock R, 2002, NAT BIOTECHNOL, V20, P729, DOI 10.1038/nbt0702-729
   Provost N, 2005, MOL THER, V11, P275, DOI 10.1016/j.ymthe.2004.09.022
   PUECH B, 1991, J FR OPHTALMOL, V14, P153
   RABB MF, 1986, OPHTHALMOLOGY, V93, P1443
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood-2004-06-2501
   Rivera VM, 1996, NAT MED, V2, P1028, DOI 10.1038/nm0996-1028
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Sanftner LHM, 2001, MOL THER, V3, P688, DOI 10.1006/mthe.2001.0308
   Seddon JM, 2006, ANIM GENET, V37, P407, DOI 10.1111/j.1365-2052.2006.01484.x
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Shen WY, 2004, ARCH OPHTHALMOL-CHIC, V122, P353, DOI 10.1001/archopht.122.3.353
   Sidjanin DJ, 2002, HUM MOL GENET, V11, P1823, DOI 10.1093/hmg/11.16.1823
   SIEGL G, 1985, INTERVIROLOGY, V23, P61, DOI 10.1159/000149587
   SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983
   Stieger K, 2007, GENE THER, V14, P1668, DOI 10.1038/sj.gt.3303034
   Stieger K, 2008, MOL THER, V16, P916, DOI 10.1038/mt.2008.41
   Stieger K, 2006, MOL THER, V13, P967, DOI 10.1016/j.ymthe.2005.12.001
   Stohr H, 2005, OPHTHALMOLOGE, V102, P116, DOI 10.1007/s00347-004-1159-1
   Strauss O, 2005, OPHTHALMOLOGE, V102, P122, DOI 10.1007/s00347-004-1157-3
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968
   Ting JHY, 2006, CURR GENE THER, V6, P193, DOI 10.2174/156652306776359487
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Turney C, 2007, INVEST OPHTH VIS SCI, V48, P4240, DOI 10.1167/iovs.04-0737
   Vervoort R, 2000, NAT GENET, V25, P462, DOI 10.1038/78182
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Warrington KH, 2006, HUM GENET, V119, P571, DOI 10.1007/s00439-006-0165-6
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   WISSMANN A, 1986, NUCLEIC ACIDS RES, V14, P4253, DOI 10.1093/nar/14.10.4253
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   ZANGERL B, 2008, ARVO PRES ASS RES VI
   Zeiss GJ, 1999, INVEST OPHTH VIS SCI, V40, P3292
   Zhang Q, 2002, HUM MOL GENET, V11, P993, DOI 10.1093/hmg/11.9.993
   Zhao YG, 2003, P NATL ACAD SCI USA, V100, P9005, DOI 10.1073/pnas.1537759100
NR 168
TC 28
Z9 35
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1084-2020
EI 1930-6180
J9 ILAR J
JI ILAR J.
PY 2009
VL 50
IS 2
BP 206
EP 224
DI 10.1093/ilar.50.2.206
PG 19
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA 448ZW
UT WOS:000266301500009
PM 19293463
OA Bronze
DA 2022-11-30
ER

PT J
AU Dou, GR
   Wang, YC
   Hu, XB
   Hou, LH
   Wang, CM
   Xu, JF
   Wang, YS
   Liang, YM
   Yao, LB
   Yang, AG
   Han, H
AF Dou, Guo-Rui
   Wang, Yao-Chun
   Hu, Xing-Bin
   Hou, Li-Hong
   Wang, Chun-Mei
   Xu, Jian-Feng
   Wang, Yu-Sheng
   Liang, Ying-Min
   Yao, Li-Bo
   Yang, An-Gang
   Han, Hua
TI RBPJ, the transcription factor downstream of Notch receptors, is
   essential for the maintenance of vascular homeostasis in adult mice
SO FASEB JOURNAL
LA English
DT Article
DE angiogenesis; Notch signaling; endothelial cells; choroidal
   neovascularization
ID ARTERIOVENOUS-MALFORMATIONS; ACTIVATED NOTCH4; PROGENITOR CELLS;
   TUMOR-GROWTH; EXPRESSION; PATHWAY; ANGIOGENESIS; INHIBITION; TARGET;
   GENES
AB In adults, angiogenic abnormalities are involved in not only tumor growth but several human inherited diseases as well. It is unclear, however, concerning how the normal vascular structure is maintained and how angiogenesis is initiated in normal adults. Using the Cre-LoxP-mediated conditional gene deletion, we show in the present study that in adult mice disruption of the transcription factor recombination signal-binding protein J kappa (RBP-J) in endothelial cells strikingly induced spontaneous angiogenesis in multiple tissues, including retina and cornea, as well as in internal organs, such as liver and lung. In a choroidal neovascularization model, which mimics the angiogenic process in tumor growth and age-related macular degeneration, RBP-J deficiency induced a more intensive angiogenic response to injury. This could be transmitted by bone marrow, indicating that RBP-J could modulate bone marrow-derived endothelial progenitor cells in adult angiogenesis. In addition, in the absence of RBP-J, proliferation of endothelial cells increased significantly, leading to accumulative vessel outgrowth. These findings suggest that in adults RBP-J-mediated Notch signaling may play an essential role in the maintenance of vascular homeostasis by repressing endothelial cell proliferation.
C1 [Dou, Guo-Rui; Wang, Yao-Chun; Hu, Xing-Bin; Hou, Li-Hong; Wang, Chun-Mei; Liang, Ying-Min; Yao, Li-Bo; Yang, An-Gang; Han, Hua] Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China.
   [Dou, Guo-Rui; Xu, Jian-Feng; Wang, Yu-Sheng; Liang, Ying-Min] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Han, Hua] Fourth Mil Med Univ, Tangdu Hosp, Dept Hematol, Xian 710032, Peoples R China.
C3 Air Force Military Medical University; Air Force Military Medical
   University; Air Force Military Medical University
RP Han, H (通讯作者)，Fourth Mil Med Univ, Dept Med Genet & Dev Biol, State Key Lab Canc Biol, Chang Le Xi St 17, Xian 710032, Peoples R China.
EM wangys@fmmu.edu.cn
RI Hu, XB/U-8501-2019
CR Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Carey KA, 2007, J GERONTOL A-BIOL, V62, P9, DOI 10.1093/gerona/62.1.9
   Carlson TR, 2005, P NATL ACAD SCI USA, V102, P9884, DOI 10.1073/pnas.0504391102
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0
   Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Gridley T, 2001, P NATL ACAD SCI USA, V98, P5377, DOI 10.1073/pnas.101138098
   Gridley T, 2007, DEVELOPMENT, V134, P2709, DOI 10.1242/dev.004184
   Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030
   HANS EG, 2004, AM J OPHTHALMOL, V137, P496
   HARRINGTON LS, 2007, MICROVASC RES
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Henderson AM, 2001, J BIOL CHEM, V276, P6169, DOI 10.1074/jbc.M008506200
   Hou HY, 2006, CURR EYE RES, V31, P1051, DOI 10.1080/02713680601100459
   Iso T, 2002, J BIOL CHEM, V277, P6598, DOI 10.1074/jbc.M110495200
   Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Karsan A, 2005, CAN J PHYSIOL PHARM, V83, P14, DOI 10.1139/Y04-125
   Kato H, 1997, DEVELOPMENT, V124, P4133
   Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880
   Krebs LT, 2000, GENE DEV, V14, P1343
   Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204
   Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb
   Lawson ND, 2002, DEV CELL, V3, P127, DOI 10.1016/S1534-5807(02)00198-3
   Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002
   Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244
   Liu ZJ, 2006, FASEB J, V20, P1009, DOI 10.1096/fj.05-4880fje
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Nakajima M, 2003, MECH DEVELOP, V120, P657, DOI 10.1016/S0925-4773(03)00064-9
   Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Noseda M, 2004, MOL CELL BIOL, V24, P8813, DOI 10.1128/MCB.24.20.8813-8822.2004
   Noseda M, 2006, CIRC RES, V98, P1468, DOI 10.1161/01.RES.0000229683.81357.26
   Paris D, 2005, EUR J PHARMACOL, V514, P1, DOI 10.1016/j.ejphar.2005.02.050
   Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427
   Rao PK, 2000, EXP CELL RES, V260, P379, DOI 10.1006/excr.2000.5034
   Rehman AO, 2006, TRENDS CELL BIOL, V16, P293, DOI 10.1016/j.tcb.2006.04.003
   Roberts N, 2005, J CELL MOL MED, V9, P583, DOI 10.1111/j.1582-4934.2005.tb00490.x
   Roy M, 2007, CURR OPIN GENET DEV, V17, P52, DOI 10.1016/j.gde.2006.12.001
   Sainson RCA, 2005, FASEB J, V19, P1027, DOI 10.1096/fj.04-3172fje
   Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577
   SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707
   Takahashi H, 2004, BIOCHEM BIOPH RES CO, V325, P461, DOI 10.1016/j.bbrc.2004.10.054
   Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443
   Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598
   Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925-4773(01)00469-5
   Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood-2005-03-1000
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
NR 54
TC 85
Z9 94
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD MAY
PY 2008
VL 22
IS 5
BP 1606
EP 1617
DI 10.1096/fj.07-9998com
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 301LW
UT WOS:000255898700032
PM 18096813
DA 2022-11-30
ER

PT J
AU Yamada, Y
   Tian, J
   Yang, Y
   Cutler, RG
   Wu, T
   Telljohann, RS
   Mattson, MP
   Handa, JT
AF Yamada, Yuko
   Tian, Jane
   Yang, Yanqin
   Cutler, Roy G.
   Wu, Tinghuai
   Telljohann, Richard S.
   Mattson, Mark P.
   Handa, James T.
TI Oxidized low density lipoproteins induce a pathologic response by
   retinal pigmented epithelial cells
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE age-related macular degeneration; apoptosis; ceramides; cholesterol;
   oxidized low density lipoproteins; retinal pigmented epithelium
ID RECOGNITION RECEPTOR PTX3; AGE-RELATED MACULOPATHY; HUMAN BRUCHS
   MEMBRANE; SMOOTH-MUSCLE-CELLS; MACULAR DEGENERATION; CHOLESTEROL
   ACYLTRANSFERASE; DENDRITIC CELLS; BASAL DEPOSITS; ACYL-COENZYME;
   ACCUMULATION
AB The accumulation of apolipoprotein B100 lipoproteins in Bruch membrane is an early event thought to promote age-related macular degeneration (AMD). Immunohistochemistry using an anti-oxidized low density lipoprotein antibody on 10 AMD specimens showed staining in Bruch membrane including basal deposits, a marker of AMD. To determine whether retinal pigmented epithelial cells develop a pathologic phenotype after interaction with lipoproteins, ARPE-19 cells were exposed to low density lipoproteins (LDL) or oxidized LDLs (oxLDL). Analysis using the Affymetrix U133 Plus 2.0 (Affymetrix, Inc., Santa Clara, CA, USA) gene chip showed physiological and pathological transcriptional responses after LDL and oxLDL treatment, respectively. LDL induced a down-regulation of cholesterol biosynthesis genes while oxLDL induced transcriptional alterations in genes related to lipid metabolism, oxidative stress, inflammation and apoptosis. Electrospray mass spectrometry showed that oxLDL, but not LDL induced large cellular increases of sphingomyelin, ceramides, and cholesteryl esters. With TUNEL labeling, oxLDL caused 14.6% apoptosis compared to < 1% after LDL. Addition of an inhibitor of sphingomyelin synthase inhibited this apoptosis by 41%. These data support the hypothesis that oxidized lipoproteins are one trigger for initiating early events in the pathogenesis of AMD.
C1 [Yamada, Yuko; Tian, Jane; Yang, Yanqin; Wu, Tinghuai; Handa, James T.] Johns Hopkins Med Inst, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Cutler, Roy G.; Telljohann, Richard S.; Mattson, Mark P.] NIA, Intramural Res Program, Neurosci Lab, Baltimore, MD 21224 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; National Institutes of
   Health (NIH) - USA; NIH National Institute on Aging (NIA)
RP Handa, JT (通讯作者)，Johns Hopkins Med Inst, Wilmer Eye Inst, 1550 Orleans St,Room 144, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
RI Mattson, Mark P/F-6038-2012; Cutler, Roy G./L-5572-2013
FU NATIONAL EYE INSTITUTE [P30EY001765, R01EY014005] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY 14055, 5P30EY001765] Funding Source: Medline
CR Akiba S, 2003, J LIPID RES, V44, P1676, DOI 10.1194/jlr.M300012-JLR200
   Baruah P, 2006, BLOOD, V107, P151, DOI 10.1182/blood-2005-03-1112
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255
   Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Doni A, 2003, EUR J IMMUNOL, V33, P2886, DOI 10.1002/eji.200324390
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gesquiere L, 1999, FREE RADICAL BIO MED, V27, P134, DOI 10.1016/S0891-5849(99)00055-6
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Gouaze V, 2001, MOL PHARMACOL, V60, P488
   Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HAMMER A, 1995, ARTERIOSCL THROM VAS, V15, P704, DOI 10.1161/01.ATV.15.5.704
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Irizarry R. A., 2003, ANAL GENE EXPRESSION, P102
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Klouche M, 2004, ATHEROSCLEROSIS, V175, P221, DOI 10.1016/j.atherosclerosis.2004.03.020
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li XP, 2003, BIOCHEMISTRY-US, V42, P10406, DOI 10.1021/bi027093c
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   STEIN O, 1992, BIOCHIM BIOPHYS ACTA, V1165, P153, DOI 10.1016/0005-2760(92)90181-T
   STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603
   SUZUKAWA M, 1994, ATHEROSCLEROSIS, V110, P77, DOI 10.1016/0021-9150(94)90070-1
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Virella G, 2000, CLIN IMMUNOL, V95, P135, DOI 10.1006/clim.2000.4857
   Wang HB, 2000, AM J PHYSIOL-CELL PH, V279, pC1345, DOI 10.1152/ajpcell.2000.279.5.C1345
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271
   Yuan XM, 2004, FREE RADICAL RES, V38, P1133, DOI 10.1080/10715760400011692
NR 47
TC 78
Z9 79
U1 0
U2 5
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD MAY
PY 2008
VL 105
IS 4
BP 1187
EP 1197
DI 10.1111/j.1471-4159.2008.05211.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 292SO
UT WOS:000255286600011
PM 18182060
DA 2022-11-30
ER

PT J
AU Yang, HT
   Yang, QW
   Zheng, LF
AF Yang, Haitao
   Yang, Qingwu
   Zheng, Linfei
TI Inhibition of hypoxia-inducible factor-1 by salidroside in an in vitro
   model of choroidal neovascularization
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Salidroside; choroidal neovascularization; RF; 6A cells; tube formation;
   hypoxia-inducible factor-1
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; FACTOR EXPRESSION;
   ANGIOGENESIS; RANIBIZUMAB; INJURY; CELLS
AB Purpose As a characteristic of age-related macular degeneration (AMD), choroidal neovascularization (CNV) causes severe vision loss. The current treatment has limited efficacy. This study was to investigate effects of Salidroside against CNV and explore its underlying mechanisms. Methods RF/6A cells were treated with 200 mM cobalt chloride (CoCl2) for 6 hr to mimic hypoxic condition. Cells were then treated with Salidroside at 10, 30, and 100 mu M for 24 hr. Cells treated with DMSO were used as negative control. The cell proliferation was assessed using 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium-bromid assay. The tube formation was investigated on Matrigel. The cell migration was measured by a Transwell assay. RT-qPCR was used to detect the gene expression. Immuohistochemistry and western blot were used to detect the expression of proteins. Results Salidroside significantly inhibited the cell migration and tube formation activity of RF/6A cells under hypoxia. Moreover, Salidroside reduced the expression levels of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1 (HIF-1) in RF/6A cells. Conclusions Our data suggested that Salidroside could be a potential novel therapeutic agent against CNV.
C1 [Yang, Haitao; Yang, Qingwu; Zheng, Linfei] Xiamen Univ, Dept Neurosurg, Fuzhou Hosp 2, Fuzhou, Peoples R China.
C3 Xiamen University
RP Zheng, LF (通讯作者)，Xiamen Univ, Dept Neurosurg, Fuzhou Hosp 2, Fuzhou, Peoples R China.
EM zhenglinfei11@yeah.net
FU Key Clinical Specialty Discipline Construction Program of Fuzhou
   [201912006]
FX This research was supported by Key Clinical Specialty Discipline
   Construction Program of Fuzhou [No. 201912006].
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chen XP, 2020, J CELL BIOCHEM, V121, P165, DOI 10.1002/jcb.29000
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Flynn KM, 2013, ANGIOGENESIS, V16, P689, DOI 10.1007/s10456-013-9346-9
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gunda Venugopal, 2013, J Cancer Sci Ther, V5, P417
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Li L, 2016, SCI REP-UK, V6, DOI 10.1038/srep32131
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Marelli-Berg FM, 2013, J CELL SCI, V126, P2343, DOI 10.1242/jcs.124099
   Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649
   Oladipupo SS, 2014, P NATL ACAD SCI USA, V111, P13379, DOI 10.1073/pnas.1324235111
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Shao J, 2016, DEV OPHTHALMOL, V55, P125, DOI 10.1159/000438969
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Xing SS, 2015, VASC PHARMACOL, V72, P141, DOI 10.1016/j.vph.2015.07.004
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zhao T, 2015, J OCUL PHARMACOL TH, V31, P611, DOI 10.1089/jop.2014.0148
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhu LP, 2015, NEUROSCI LETT, V606, P1, DOI 10.1016/j.neulet.2015.08.025
   Zhu LP, 2015, APOPTOSIS, V20, P1433, DOI 10.1007/s10495-015-1174-5
   Zhuang XY, 2017, EXP THER MED, V14, P515, DOI 10.3892/etm.2017.4541
NR 35
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD JUL 3
PY 2022
VL 41
IS 3
BP 203
EP 209
DI 10.1080/15569527.2021.1973023
EA JUL 2022
PG 7
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA 4L5MR
UT WOS:000826029800001
PM 34428999
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Alcalde, I
   Sanchez-Fernandez, C
   Martin, C
   De Pablo, N
   Jemni-Damer, N
   Guinea, GV
   Merayo-Lloves, J
   Del Olmo-Aguado, S
AF Alcalde, Ignacio
   Sanchez-Fernandez, Cristina
   Martin, Carla
   De Pablo, Nagore
   Jemni-Damer, Nahla
   Guinea, Gustavo V.
   Merayo-Lloves, Jesus
   Del Olmo-Aguado, Susana
TI Human Stem Cell Transplantation for Retinal Degenerative Diseases: Where
   Are We Now?
SO MEDICINA-LITHUANIA
LA English
DT Article
DE retina; stem cells; transplantation; clinical trial
ID MACULAR DEGENERATION; PIGMENT EPITHELIUM; VISUAL FUNCTION;
   PHOTORECEPTORS; GENERATION; RESTORES; VISION
AB Background and Objectives: Irreversible visual impairment is mainly caused by retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa. Stem cell research has experienced rapid progress in recent years, and researchers and clinical ophthalmologists are trying to implement this promising technology to treat retinal degeneration. The objective of this systematic review is to analyze currently available data from clinical trials applying stem cells to treat human retinal diseases. Materials and Methods: We performed a systematic literature search in PubMed to identify articles related with stem cell therapies to retinal diseases published prior to September 2021. Furthermore, a systematic search in ClinicalTrials (NIH U.S. National Library of Medicine) was performed to identify clinical trials using stem cells to treat retinal diseases. A descriptive analysis of status, conditions, phases, interventions, and outcomes is presented here. Conclusions: To date, no available therapy based on stem cell transplantation is approved for use with patients. However, numerous clinical trials are currently finishing their initial phases and, in general, the outcomes related to implantation techniques and their long-term safety seem promising. In the next few years, we expect to see quantifiable results pertaining to visual function improvement.
C1 [Alcalde, Ignacio; Sanchez-Fernandez, Cristina; Martin, Carla; De Pablo, Nagore; Merayo-Lloves, Jesus; Del Olmo-Aguado, Susana] Univ Oviedo, Inst Univ Fernandez Vega, Fdn Invest Oftalmol, Oviedo 33012, Spain.
   [Alcalde, Ignacio; Sanchez-Fernandez, Cristina; Martin, Carla; De Pablo, Nagore; Merayo-Lloves, Jesus; Del Olmo-Aguado, Susana] Inst Invest Sanitaria Principado Asturias ISPA, Oviedo 33011, Spain.
   [Martin, Carla] Univ Oviedo, Dept Funct Biol, Oviedo 33006, Spain.
   [Jemni-Damer, Nahla] Univ Complutense Madrid, Neurocomp & Neurorobot Res Grp, Madrid 28040, Spain.
   [Jemni-Damer, Nahla] San Carlos Clin Hosp IdISSC, Innovat Grp, Inst Hlth Res, Madrid 28040, Spain.
   [Jemni-Damer, Nahla; Guinea, Gustavo V.] Univ Politecn Madrid, Ctr Biomed Technol CTB, Madrid 28223, Spain.
   [Guinea, Gustavo V.] Univ Politecn Madrid, Dept Ciencia Mat, ETSI Caminos Canales & Puertos, Madrid 28040, Spain.
   [Guinea, Gustavo V.] Biomed Res Networking Ctr Bioengn, Biomat & Nanomed CIBER BBN, Madrid 28040, Spain.
   [Guinea, Gustavo V.] Hosp Clin San Carlos IdISSC, Biomat & Regenerat Med Grp, Inst Invest Sanitaria, Madrid 28040, Spain.
C3 University of Oviedo; Instituto de Investigacion Sanitaria del
   Principado de Asturias (ISPA); University of Oviedo; Complutense
   University of Madrid; Universidad Politecnica de Madrid; Centro de
   Tecnologia Biomedica (CTB); Universidad Politecnica de Madrid; CIBER -
   Centro de Investigacion Biomedica en Red; CIBERBBN; Hospital Clinico San
   Carlos
RP Alcalde, I (通讯作者)，Univ Oviedo, Inst Univ Fernandez Vega, Fdn Invest Oftalmol, Oviedo 33012, Spain.; Alcalde, I (通讯作者)，Inst Invest Sanitaria Principado Asturias ISPA, Oviedo 33011, Spain.
EM nacho.alcalde@fio.as; criis.san.fer.94@gmail.com;
   cmartincueto@gmail.com; nagore.depablo@fio.as; nahlajem@ucm.es;
   gustavovictor.guinea@ctb.upm.es; merayo@fio.as; solmo@fio.as
RI De Pablo, Nagore/AFV-1794-2022; del Olmo Aguado, Susana/AAY-3497-2021;
   Alcalde, Ignacio/L-2005-2014; GUINEA TORTUERO, GUSTAVO
   VICTOR/N-1241-2014
OI De Pablo, Nagore/0000-0001-9675-7689; del Olmo Aguado,
   Susana/0000-0002-2867-7254; Alcalde, Ignacio/0000-0001-6051-9240;
   Sanchez, Cristina/0000-0001-6658-2590; GUINEA TORTUERO, GUSTAVO
   VICTOR/0000-0002-4326-3746
CR Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Decembrini S, 2014, STEM CELL REP, V2, P853, DOI 10.1016/j.stemcr.2014.04.010
   DELCERRO M, 1991, NEUROREPORT, V2, P529, DOI 10.1097/00001756-199109000-00008
   Dias MF, 2018, PROG RETIN EYE RES, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Gasparini SJ, 2019, PROG RETIN EYE RES, V69, P1, DOI 10.1016/j.preteyeres.2018.11.001
   Gonzalez-Cordero A, 2017, STEM CELL REP, V9, P820, DOI 10.1016/j.stemcr.2017.07.022
   GOURAS P, 1991, INVEST OPHTH VIS SCI, V32, P3167
   GOURAS P, 1991, Journal of Neural Transplantation and Plasticity, V2, P91
   Jemni-Damer N, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.588014
   Jemni-Damer N, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.549089
   Jha BS, 2015, CURR STEM CELL REP, V1, P79, DOI 10.1007/s40778-015-0014-4
   Jin ZB, 2012, PROG BRAIN RES, V201, P171, DOI 10.1016/B978-0-444-59544-7.00008-1
   Jin ZB, 2009, J GENET, V88, P417, DOI 10.1007/s12041-009-0063-5
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Li SY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13100
   Liu Y, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0661-8
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Oner A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0432-y
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Roberts JM, 2018, CELL REP, V22, P2519, DOI 10.1016/j.celrep.2018.02.078
   Romito A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9451492
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sung Y, 2021, BRIT J OPHTHALMOL, V105, P829, DOI 10.1136/bjophthalmol-2020-316225
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhu J, 2018, STEM CELL TRANSL MED, V7, P210, DOI 10.1002/sctm.17-0205
NR 39
TC 1
Z9 1
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PD JAN
PY 2022
VL 58
IS 1
AR 102
DI 10.3390/medicina58010102
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YN1XQ
UT WOS:000747058500001
PM 35056410
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Braovic, M
   Stipanicev, D
   Seric, L
AF Braovic, Maja
   Stipanicev, Darko
   Seric, Ljiljana
TI Retinal Blood Vessel Segmentation Based on Heuristic Image Analysis
SO COMPUTER SCIENCE AND INFORMATION SYSTEMS
LA English
DT Article
DE Retinal blood vessels; fundus images; heuristic analysis; image
   segmentation
ID MATCHED-FILTER; EXTRACTION; ALGORITHM
AB Automatic analysis of retinal fundus images is becoming increasingly present today, and diseases such as diabetic retinopathy and age-related macular degeneration are getting a higher chance of being discovered in the early stages of their development. In order to focus on discovering those diseases, researchers commonly preprocess retinal fundus images in order to detect the retinal landmarks - blood vessels, fovea and the optic disk. A large number of methods for the automatic detection of retinal blood vessels from retinal fundus images already exists, but many of them are using unnecessarily complicated approaches. In this paper we demonstrate that a reliable retinal blood vessel segmentation can be achieved with a cascade of very simple image processing methods. The proposed method puts higher emphasis on high specificity (i.e. high probability that the segmented pixels actually belong to retinal blood vessels and are not false positive detections) rather than on high sensitivity. The proposed method is based on heuristically determined parametric edge detection and shape analysis, and is evaluated on the publicly available DRIVE and STARE datasets on which it achieved the average accuracy of 96.33% and 96.10%, respectively.
C1 [Braovic, Maja; Stipanicev, Darko; Seric, Ljiljana] Fac Elect Engn Mech Engn & Naval Architecture, Rudera Boskovica 32, Split 21000, Croatia.
C3 University of Split
RP Braovic, M (通讯作者)，Fac Elect Engn Mech Engn & Naval Architecture, Rudera Boskovica 32, Split 21000, Croatia.
EM maja.braovic@fesb.hr
RI Seric, Ljiljana/E-4885-2017
OI Seric, Ljiljana/0000-0002-6390-1899; Braovic, Maja/0000-0002-3655-3534
FU Ministry of Science, Education and Sport of the Republic of Croatia
FX This work was partly supported by the Ministry of Science, Education and
   Sport of the Republic of Croatia under grant "ViO - Vision Based
   Intelligent Observers" (in Croatian: "ViO - Vidom temeljeni inteligentni
   opserveri"). This work is part of activities of ACROSS - Centre of
   Research Excellence for Advanced Cooperative Systems
   (http://across.fer.hr).The authors would like to thank Dr. Ljubo Znaor
   from the Clinical Hospital Center in Split for all the help he provided
   during their research on this project. The authors would also like to
   thank Dr. Stephen M. Smith from the University of Oxford for letting
   them know that the SUSAN edge detector was always free to use for
   non-commercial purposes.
CR Akram MU, 2013, ENG COMPUT-GERMANY, V29, P165, DOI 10.1007/s00366-011-0253-7
   Al-Rawi M, 2007, COMPUT BIOL MED, V37, P262, DOI 10.1016/j.compbiomed.2006.03.003
   Barkhoda W., 2011, EURASIP J ADV SIGNAL, V113
   Chakraborti T, 2015, MACH VISION APPL, V26, P55, DOI 10.1007/s00138-014-0636-z
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Datta NS, 2013, PROC TECH, V10, P731, DOI 10.1016/j.protcy.2013.12.416
   Fatima J., 2013, IEEE WORKSH BIOM MEA
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   Fukuta K., 2008, P OF SPIE, V6914
   Gosciewska K, 2013, J THEOR APPL COMPUT, V7, P35
   Hatanaka Y, 2011, PROC SPIE, V7963, DOI 10.1117/12.877232
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Hoover A., STRUCTURED ANAL RETI
   Hoover A., 2000, STARE IMAGE DATASET
   Iivarinen J., 1997, P 8 BRIT MACH VIS C, P430
   Kande GB, 2010, J MED SYST, V34, P849, DOI 10.1007/s10916-009-9299-0
   Marin D, 2011, IEEE T MED IMAGING, V30, P146, DOI 10.1109/TMI.2010.2064333
   Martinez-Perez ME, 2007, MED IMAGE ANAL, V11, P47, DOI 10.1016/j.media.2006.11.004
   Melinscak Martina, 2015, 10th International Conference on Computer Vision Theory and Applications (VISAPP 2015). Proceedings, P577
   Mendonca AM, 2006, IEEE T MED IMAGING, V25, P1200, DOI 10.1109/TMI.2006.879955
   Miri M. S., 2011, IEEE T BIOMEDICAL EN, V58
   Nguyen UTV, 2013, PATTERN RECOGN, V46, P703, DOI 10.1016/j.patcog.2012.08.009
   Niemeijer M., 2004, P SPIE INT SOC OPTIC, V5370
   OpenCV team, OPENCV OP SOURC COMP
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Panchal P, 2016, PROCEDIA COMPUT SCI, V79, P61, DOI 10.1016/j.procs.2016.03.009
   Petrou M., 2006, IMAGE PROCESSING DEA
   ROSENFELD A, 1970, J ACM, V17, P146, DOI 10.1145/321556.321570
   Rosin PL, 2003, MACH VISION APPL, V14, P172, DOI 10.1007/s00138-002-0118-6
   Russ J.C., 2016, IMAGE PROCESSING HDB
   Salazar-Gonzalez A, 2014, IEEE J BIOMED HEALTH, V18, P1874, DOI 10.1109/JBHI.2014.2302749
   Santhi N, 2012, PROCEDIA ENGINEER, V38, P3880, DOI 10.1016/j.proeng.2012.06.446
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Smith SM, 1997, INT J COMPUT VISION, V23, P45, DOI 10.1023/A:1007963824710
   SMITH SM, 1995, TR95SMS1C DEF RES AG
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Sreejini KS, 2015, EGYPT INFORM J, V16, P253, DOI 10.1016/j.eij.2015.06.004
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Arenas-Cavalli JT, 2015, PROCEDIA COMPUT SCI, V60, P557, DOI 10.1016/j.procs.2015.08.179
   World Health Organization, PREV BLINDN VIS IMP
   Xu LL, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-14
   Yin Y., 2013, COMP MATH MATH PHYS, V2013
   Zhang B, 2010, COMPUT BIOL MED, V40, P438, DOI 10.1016/j.compbiomed.2010.02.008
   Zhao YT, 2015, IEEE T MED IMAGING, V34, P1797, DOI 10.1109/TMI.2015.2409024
NR 45
TC 7
Z9 7
U1 1
U2 9
PU COMSIS CONSORTIUM
PI NOVI SAD
PA UNIV NOVI SAD, FAC TECH SCI, TRG DOSITEJA OBRADOVICA 6, NOVI SAD, 21000,
   SERBIA
SN 1820-0214
J9 COMPUT SCI INF SYST
JI Comput. Sci. Inf. Syst.
PD JAN
PY 2019
VL 16
IS 1
BP 227
EP 245
DI 10.2298/CSIS180220014B
PG 19
WC Computer Science, Information Systems; Computer Science, Software
   Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA HJ7MB
UT WOS:000457380600009
OA gold
DA 2022-11-30
ER

PT J
AU Lane, M
   Lane, V
   Abbott, J
   Braithwaite, T
   Shah, P
   Denniston, AK
AF Lane, Mark
   Lane, Victoria
   Abbott, Joseph
   Braithwaite, Tasanee
   Shah, Peter
   Denniston, Alastair K.
TI Multiple deprivation, vision loss, and ophthalmic disease in adults:
   global perspectives
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE socioeconomic factors; education; income
ID EYE-CARE SERVICES; NUTRITION EXAMINATION SURVEY; OPEN-ANGLE GLAUCOMA;
   PAKISTAN NATIONAL BLINDNESS; CATARACT SURGICAL SERVICES; SELF-REPORTED
   GLAUCOMA; AGE-RELATED CATARACT; WILLINGNESS-TO-PAY; LIFE-STYLE FACTORS;
   RURAL SOUTH-INDIA
AB The association between socioeconomic position and morbidity and mortality has long been recognized. We evaluate the evidence for an association between multiple aspects of deprivation and ocular health in a global context. This is a systematic review of studies that evaluated deprivation in the adult population in the context of the major acquired causes of visual loss such as cataract, diabetic eye disease, glaucoma, age-related macular degeneration, and ocular trauma. The search strategy identified relevant studies reported between 1946 and August 2016, with randomized control trials, case-control, cohort, and cross-sectional study designs being selected for inclusion. The studies identified in this review from across the world demonstrate the extent to which the common themes such as low educational attainment and low income may be associated with increased incidence of various sight-threatening conditions and may adversely affect access to specialist assessment and delivery of treatment. Health inequality may always persist, but an increased recognition of the importance of the various impacts of deprivation may empower policy makers to target limited resources to the most vulnerable groups in order to deliver the greatest benefit. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Lane, Mark; Shah, Peter; Denniston, Alastair K.] Univ Hosp Birmingham NHS Fdn Trust, Dept Ophthalmol, Birmingham, W Midlands, England.
   [Lane, Victoria] Birmingham & Solihull Mental Hlth Fdn Trust, Birmingham, W Midlands, England.
   [Abbott, Joseph] Birmingham Childrens Hosp NHS Fdn Trust, Dept Ophthalmol, Birmingham, W Midlands, England.
   [Braithwaite, Tasanee] Moorfields Eye Hosp, London, England.
   [Shah, Peter] Inst Translat Med, Birmingham Inst Glaucoma Res, Birmingham, W Midlands, England.
   [Shah, Peter] UCL, London, England.
   [Shah, Peter] Univ Wolverhampton, Sch Hlth & Wellbeing, Ctr Hlth & Social Care Improvement, Wolverhampton, England.
   [Denniston, Alastair K.] Inst Translat Med, Ctr Rare Dis, Birmingham, W Midlands, England.
   [Denniston, Alastair K.] Univ Birmingham, Inst Inflammat & Ageing, Birmingham B15 2WB, W Midlands, England.
   [Denniston, Alastair K.] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London, England.
   [Denniston, Alastair K.] UCL Inst Ophthalmol, London, England.
C3 University of Birmingham; University of Birmingham; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of Birmingham; University of London;
   University College London; University of Wolverhampton; University of
   Birmingham; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust; University of London; University
   College London
RP Denniston, AK (通讯作者)，Univ Hosp Birmingham NHS Fdn Trust, Dept Ophthalmol, Birmingham, W Midlands, England.; Denniston, AK (通讯作者)，Univ Birmingham, Inst Inflammat & Ageing, Birmingham B15 2WB, W Midlands, England.
EM a.denniston@bham.ac.uk
RI Braithwaite, Tasanee/AAZ-1118-2020; Denniston, Alastair/ABD-1238-2020
OI Braithwaite, Tasanee/0000-0002-3025-4066; Denniston,
   Alastair/0000-0001-7849-0087
FU Birdshot Uveitis Service/Fight for Sight (UK) [24BU151]; Department of
   Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields
   Eye Hospital; UCL Institute of Ophthalmology; Medical Research Council
   [G0600416] Funding Source: researchfish; National Institute for Health
   Research [CL-2009-09-002] Funding Source: researchfish; Fight for Sight
   [24BU151] Funding Source: researchfish; MRC [G0600416] Funding Source:
   UKRI
FX M. L. was supported by a grant from Birdshot Uveitis Service/Fight for
   Sight (UK) (24BU151). A. K. D receives a proportion of his funding from
   the Department of Health's NIHR Biomedical Research Centre for
   Ophthalmology at Moorfields Eye Hospital and UCL Institute of
   Ophthalmology. The views expressed in the publication are those of the
   author and not necessarily those of the Department of Health.
CR Aagaard-Hansen J, 2010, EQUITY, SOCIAL DETERMINANTS AND PUBLIC HEALTH PROGRAMMES, P135
   Abdull MM, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0097-9
   Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   Ackuaku-Dogbe E M, 2015, Ghana Med J, V49, P84, DOI 10.4314/gmj.v49i2.4
   Action for Development (ACFODE), 1995, ARISE MAGAZINE
   Adriono G, 2011, ARCH OPHTHALMOL-CHIC, V129, P930, DOI 10.1001/archophthalmol.2011.147
   al Arab GE, 2001, BRIT J OPHTHALMOL, V85, P1406, DOI 10.1136/bjo.85.12.1406
   Alkire S, 2010, ACUTE MULTIDIMENSION
   Alkire SRJ, 2011, MULTIDIMENSIONAL POV
   Baker RS, 2005, OPHTHAL EPIDEMIOL, V12, P1, DOI 10.1080/09286580590921330
   Baker RS, 1998, OPHTHALMOLOGY, V105, P1373, DOI 10.1016/S0161-6420(98)98015-0
   Bertelsen M, 2015, ACTA OPHTHALMOL, V93, P134, DOI 10.1111/aos.12467
   BIDDYR S, PUBLIC HEALTH
   Bihan H, 2012, DIABETES METAB, V38, P82, DOI 10.1016/j.diabet.2011.10.004
   Bijlsma WR, 2011, BRIT J OPHTHALMOL, V95, P360, DOI 10.1136/bjo.2009.175190
   Blumberg DM, 2016, JAMA OPHTHALMOL, V134, P212, DOI 10.1001/jamaophthalmol.2015.5090
   Blumberg DM, 2015, JAMA OPHTHALMOL, V133, P985, DOI 10.1001/jamaophthalmol.2015.1671
   Bourne RRA, 2007, LANCET GLOB HEALTH, P30393
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714
   Brezin AP, 2005, ARCH OPHTHALMOL-CHIC, V123, P1117, DOI 10.1001/archopht.123.8.1117
   Brian G, 2012, OPHTHAL EPIDEMIOL, V19, P43, DOI 10.3109/09286586.2011.628135
   Broman AT, 2005, ARCH OPHTHALMOL-CHIC, V123, P1231, DOI 10.1001/archopht.123.9.1231
   Buys YM, 2013, CAN J OPHTHALMOL, V48, P83, DOI 10.1016/j.jcjo.2012.10.003
   Byun SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062991
   CACKETT P, BR J OPHTHALMOL
   Castel OC, 2014, FAM PRACT, V31, P453, DOI 10.1093/fampra/cmu031
   Chan CH, 2014, INVEST OPHTH VIS SCI, V55, P8544, DOI 10.1167/iovs.14-15361
   Chandrashekhar TS, 2007, PUBLIC HEALTH, V121, P130, DOI 10.1016/j.puhe.2006.07.027
   CHATTERJEE A, 1982, BRIT J OPHTHALMOL, V66, P35, DOI 10.1136/bjo.66.1.35
   Chaturvedi N, 1996, DIABETES CARE, V19, P423, DOI 10.2337/diacare.19.5.423
   CHATURVEDI N, 1995, BRIT J GEN PRACT, V45, P127
   Chaveepojnkamjorn W, 2015, SE ASIAN J TROP MED, V46, P322
   CHEN MS, 1992, AM J OPHTHALMOL, V114, P723, DOI 10.1016/S0002-9394(14)74051-6
   Chew H, 2005, CAN J OPHTHALMOL, V40, P384, DOI 10.1016/S0008-4182(05)80081-X
   Chiu-Fang C, 2015, AM J PUBLIC HLTH, V105, P1262
   CHONG EW, ARCH OPHTHALMOL
   CHOU CF, 2012, AM J OPHTHALMOL, V41, P154
   Chou CF, 2014, DIABETES CARE, V37, P180, DOI 10.2337/dc13-1507
   Chua D, 2011, OPHTHAL EPIDEMIOL, V18, P281, DOI 10.3109/09286586.2011.628775
   Chua J, 2015, OPHTHALMOLOGY, V122, P2169, DOI 10.1016/j.ophtha.2015.06.052
   Chua PY, 2013, EUR J OPHTHALMOL, V23, P831, DOI 10.5301/ejo.5000302
   Chua PY, 2013, OPHTHALMOLOGY, V120, P2436, DOI 10.1016/j.ophtha.2013.07.050
   Courtright P, 1994, TROP GEOGR MED, V47, P15
   Cumberland PM, 2015, J CATARACT REFR SURG, V41, P2466, DOI 10.1016/j.jcrs.2015.05.040
   Dandona L, 1997, BRIT J OPHTHALMOL, V81, P726, DOI 10.1136/bjo.81.9.726
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Dandona L, 2000, OPHTHALMOLOGY, V107, P1702, DOI 10.1016/S0161-6420(00)00275-X
   DANDONA L, 2000, CLIN EXP OPHTHALMOL, P28
   Dandona R, 2003, BRIT J OPHTHALMOL, V87, P133, DOI 10.1136/bjo.87.2.133
   Dandona R, 2002, BRIT J OPHTHALMOL, V86, P373, DOI 10.1136/bjo.86.4.373
   Dandona R, 2002, OPHTHALMOLOGY, V109, P1871, DOI 10.1016/S0161-6420(02)01183-1
   Danquah L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094140
   Dhaliwal Upreet, 2007, Indian Journal of Ophthalmology, V55, P133
   Dickey H, 2012, HEALTH POLICY, V108, P286, DOI 10.1016/j.healthpol.2012.09.006
   Djafari F, 2009, J GLAUCOMA, V18, P238, DOI 10.1097/IJG.0b013e3181815421
   Do AT, 2016, AM J OPHTHALMOL, V163, P180, DOI 10.1016/j.ajo.2015.12.009
   Doshi V, 2008, OPHTHALMOLOGY, V115, P639, DOI 10.1016/j.ophtha.2007.05.032
   Edwards T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001585
   Emamian MH, 2011, AM J EPIDEMIOL, V173, P1463, DOI 10.1093/aje/kwr050
   Essue BM, 2014, OPHTHALMOLOGY, V121, P2138, DOI 10.1016/j.ophtha.2014.05.014
   Finger RP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044268
   FONG LP, 1995, MED J AUSTRALIA, V162, P64, DOI 10.5694/j.1326-5377.1995.tb138434.x
   Forouzanfar MH, 2016, LANCET, V388, P1659, DOI 10.1016/S0140-6736(16)31679-8
   Forrest KYZ, 2008, OPHTHAL EPIDEMIOL, V15, P37, DOI 10.1080/09286580701609247
   Forrest KYZ, 2009, OPHTHAL EPIDEMIOL, V16, P156, DOI 10.1080/09286580902738175
   Foster PJ, 2014, EYE, V28, P202, DOI 10.1038/eye.2013.280
   Foster PJ, 2003, BRIT J OPHTHALMOL, V87, P1112, DOI 10.1136/bjo.87.9.1112
   Fotouhi Akbar, 2006, BMC Ophthalmol, V6, P4, DOI 10.1186/1471-2415-6-4
   FOUAD D, 2004, BR J OPHTHALMOL, P88
   Fraser S, 2001, BMJ-BRIT MED J, V322, P639, DOI 10.1136/bmj.322.7287.639
   Fraser-Bell S, 2005, AM J OPHTHALMOL, V139, P30, DOI 10.1016/j.ajo.2004.08.029
   Freeman EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063315
   Fricke TR, 2012, B WORLD HEALTH ORGAN, V90, P728, DOI 10.2471/BLT.12.104034
   Frost A, 2001, EYE, V15, P739, DOI 10.1038/eye.2001.241
   Garap JN, 2006, CLIN EXP OPHTHALMOL, V34, P335, DOI 10.1111/j.1442-9071.2006.01219.x
   Gasch AT, 2000, OPHTHALMOLOGY, V107, P303, DOI 10.1016/S0161-6420(99)00076-7
   Gerente VM, 2008, ARQ BRAS OFTALMOL, V71, P149, DOI 10.1590/S0004-27492008000200004
   Gibson DM, 2014, JAMA OPHTHALMOL, V132, P471, DOI 10.1001/jamaophthalmol.2013.7682
   Gilbert CE, 2008, BMJ-BRIT MED J, V336, P29, DOI 10.1136/bmj.39395.500046.AE
   GNYAWALI S, NEPAL J OPHTHALMOL
   Gogate P, 2011, INDIAN J OPHTHALMOL, V59, P29, DOI 10.4103/0301-4738.73720
   Goverdhan S, 2011, OPHTHAL EPIDEMIOL, V18, P44, DOI 10.3109/09286586.2010.528853
   Gulliford MC, 2010, DIABETIC MED, V27, P282, DOI 10.1111/j.1464-5491.2010.02946.x
   Gupta V, 2013, OPHTHAL EPIDEMIOL, V20, P40, DOI 10.3109/09286586.2012.741278
   Gwira JA, 2006, OPHTHALMOLOGY, V113, P1315, DOI 10.1016/j.ophtha.2006.04.017
   Habtamu E, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-480
   HAFFNER SM, 1989, DIABETES CARE, V12, P128, DOI 10.2337/diacare.12.2.128
   Hashemi H, 2015, OPTOMETRY VISION SCI, V92, P707, DOI 10.1097/OPX.0000000000000590
   Hashemi H, 2012, OPHTHAL EPIDEMIOL, V19, P242, DOI 10.3109/09286586.2012.691600
   Haymes SA, 2009, OPHTHAL EPIDEMIOL, V16, P163, DOI 10.1080/09286580902738167
   He MG, 2007, OPHTHALMOLOGY, V114, P411, DOI 10.1016/j.ophtha.2006.09.012
   Hirsch E.D., 1988, CULTURAL LITERACY WH
   Ho CK, 2008, KAOHSIUNG J MED SCI, V24, P10, DOI 10.1016/S1607-551X(08)70067-6
   Ho VH, 2001, BRIT J OPHTHALMOL, V85, P653, DOI 10.1136/bjo.85.6.653
   Hoevenaars JGMM, 2006, ACTA OPHTHALMOL SCAN, V84, P84, DOI 10.1111/j.1600-0420.2005.00587.x
   Hoffelt Z, 2011, OPHTHALMOLOGY, V118, P1327, DOI 10.1016/j.ophtha.2010.12.013
   Holden BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1731, DOI 10.1001/archopht.126.12.1731
   Hoskin AK, 2015, CLIN EXP OPTOM, V98, P203, DOI 10.1111/cxo.12283
   HTTP, DSF
   HTTP, 2006, DF, V220, P101
   HTTP, 2014, DS, V2, pE106
   HTTP, DF
   HTTP, 2015, DSF, P23
   HTTP, 2013, SD, V131, P1198
   Huang OS, 2013, OPHTHAL EPIDEMIOL, V20, P52, DOI 10.3109/09286586.2012.751429
   Husain R, 2005, OPHTHALMOLOGY, V112, P1255, DOI 10.1016/j.ophtha.2005.02.015
   Hwang J, 2015, CAN J OPHTHALMOL, V50, P119, DOI 10.1016/j.jcjo.2014.11.014
   Iliffe S, 2005, FAM PRACT, V22, P585, DOI 10.1093/fampra/cmi067
   Islam FM, 2015, PLOS ONE, V10
   Jadoon Z, 2007, BRIT J OPHTHALMOL, V91, P1269, DOI 10.1136/bjo.2006.106914
   Jahan S, 2015, HUMAN DEVELOPMENT RE
   JAVITT JC, 1995, MED CARE, V33, P90, DOI 10.1097/00005650-199501000-00008
   Jimenez-Corona A, 2015, OPHTHAL EPIDEMIOL, V22, P342, DOI 10.3109/09286586.2014.949009
   Jin YP, 2013, CAN J OPHTHALMOL, V48, P167, DOI 10.1016/j.jcjo.2013.01.002
   Jin YP, 2011, CAN J OPHTHALMOL, V46, P133, DOI 10.3129/i10-120
   Jonas JB, 2011, J GLAUCOMA, V20, P405, DOI 10.1097/IJG.0b013e3181f7af9b
   KAISERMAN I, AM J OPHTHALMOL
   Kandel RP, 2010, OPHTHAL EPIDEMIOL, V17, P276, DOI 10.3109/09286586.2010.508355
   Kasi PM, 2004, PLOS MED, V1, P105, DOI 10.1371/journal.pmed.0010044
   KEENAN T, BR J OPHTHALMOL
   Keskimaki I, 1996, HEALTH POLICY, V36, P245, DOI 10.1016/0168-8510(96)00816-0
   Kessy JP, 2007, BRIT J OPHTHALMOL, V91, P1114, DOI 10.1136/bjo.2006.112474
   KHATRY S, BR J OPHTHALMOL
   Khokhar S, 2014, INT OPHTHALMOL, V34, P197, DOI 10.1007/s10792-013-9813-8
   Kiely PM, 2011, CLIN EXP OPTOM, V94, P468, DOI 10.1111/j.1444-0938.2011.00590.x
   Kim YK, 2014, J RURAL HLTH, V9
   KIM YK, 2014, PLOS ONE, P9
   Klein BEK, 2003, AM J OPHTHALMOL, V136, P506, DOI 10.1016/S0002-9394(03)00290-3
   Klein R, 2001, AM J OPHTHALMOL, V132, P128, DOI 10.1016/S0002-9394(00)00931-4
   KLEIN R, 1994, OPHTHALMOLOGY, V101, P1969
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kliner M, 2012, EYE, V26, P671, DOI 10.1038/eye.2012.3
   Ko F, 2016, INVEST OPHTH VIS SCI, V57, P2152, DOI 10.1167/iovs.15-18373
   Ko F, 2012, JAMA-J AM MED ASSOC, V308, P2361, DOI 10.1001/jama.2012.85685
   KO YC, 2016, PLOS ONE, P11
   KOK PW, 1983, SOC SCI MED, V17, P1709, DOI 10.1016/0277-9536(83)90381-7
   KOVAI V, OPHTHALMIC EPIDEMIOL
   Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341
   KRISHNAIAH S, OPHTHALMOLOGY
   Kuper H, 2008, PLOS MED, V5, P1716, DOI 10.1371/journal.pmed.0050244
   Kyari F, 2016, PLOS ONE, V16, P78
   Kyari F, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0264-7
   LAD M, 2010, ENGLISH INDICES OF D
   Lane M, 2015, CLIN OPHTHALMOL, V9, P347, DOI 10.2147/OPTH.S73272
   Latalska M, 2013, ANN AGR ENV MED, V20, P726
   LE Q, 2012, BMC PUBLIC HEALTH, V409, P12
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Lee BW, 2008, ARCH OPHTHALMOL-CHIC, V126, P1448, DOI 10.1001/archopht.126.10.1448
   LEESE GP, 2008, DIABETES CARE, P31
   Leske MC, 1997, INT J EPIDEMIOL, V26, P1314, DOI 10.1093/ije/26.6.1314
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Leske MC, 2002, OPHTHALMOLOGY, V109, P1303, DOI 10.1016/S0161-6420(02)01094-1
   Leung VC, 2015, J GLAUCOMA, V24, P69, DOI 10.1097/IJG.0000000000000081
   LEWALLEN S, 2006, BR J OPHTHALMOL, P90
   Lian JX, 2013, OPHTHALMOLOGY, V120, P1247, DOI 10.1016/j.ophtha.2012.11.024
   Liesegang TJ, 1997, CORNEA, V16, P125
   Lim A, 2008, OPHTHAL EPIDEMIOL, V15, P402, DOI 10.1080/09286580802435179
   Lim SS, 2016, LANCET, V388, P1813, DOI 10.1016/S0140-6736(16)31467-2
   LIN H, 2016, BMJ OPEN, P6
   Lindfield R, 2009, BRIT J OPHTHALMOL, V93, P875, DOI 10.1136/bjo.2008.152744
   Lipton BJ, 2016, SOC SCI MED, V150, P258, DOI 10.1016/j.socscimed.2015.10.055
   Liu DP, 2002, DIABETES RES CLIN PR, V56, P125, DOI 10.1016/S0168-8227(01)00349-7
   LIU JH, OPHTHALMIC EPIDEMIOL
   LIVINGSTON PM, BR J OPHTHALMOL
   LOW L, 2015, BMJ OPEN, V7290, P5
   LUCCHINI M, SOC INDIC RES
   Luo HB, 2012, OPHTHAL EPIDEMIOL, V19, P103, DOI 10.3109/09286586.2011.639977
   MABASO RG, 2014, AFR J PRIM HEALTH CA, V623, P6
   Mahande M, 2007, BRIT J OPHTHALMOL, V91, P139, DOI 10.1136/bjo.2006.103374
   MANSOURI K, 2005, OPHTHALMOLOGICA
   Mariotti SP, 2009, BRIT J OPHTHALMOL, V93, P563, DOI 10.1136/bjo.2008.148494
   McCarty CA, 2000, CLIN EXP OPHTHALMOL, V28, P77, DOI 10.1046/j.1442-9071.2000.00276.x
   Meddings DR, 1998, SOC SCI MED, V46, P1451, DOI 10.1016/S0277-9536(97)10138-1
   Mehari ZA, 2013, GRAEFES ARCH AM EXP, V20, P229
   Mehari Zelalem Addisu, 2013, Middle East Afr J Ophthalmol, V20, P229, DOI 10.4103/0974-9233.114798
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Minassian DC, 2002, BRIT J OPHTHALMOL, V86, P548, DOI 10.1136/bjo.86.5.548
   Mitry D, 2010, INVEST OPHTH VIS SCI, V51, P4963, DOI 10.1167/iovs.10-5400
   Moss S E, 1995, Arch Fam Med, V4, P529, DOI 10.1001/archfami.4.6.529
   MTUYA C, 2016, BMC OPHTHALMOL, V115, P16
   Muhlhauser I, 1998, DIABETOLOGIA, V41, P1139, DOI 10.1007/s001250051043
   Muir KW, 2006, AM J OPHTHALMOL, V142, P223, DOI 10.1016/j.ajo.2006.03.018
   Muir KW, 2012, PATIENT EDUC COUNS, V87, P160, DOI 10.1016/j.pec.2011.09.009
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   Nam GE, 2015, EYE, V29, P913, DOI 10.1038/eye.2015.66
   NANGIA V, 2011, PLOS ONE, P6
   Nayak B, 2015, INDIAN J OPHTHALMOL, V63, P20, DOI 10.4103/0301-4738.151458
   Negrel A D, 1998, Ophthalmic Epidemiol, V5, P143, DOI 10.1076/opep.5.3.143.8364
   Nessim M, 2010, BRIT J OPHTHALMOL, V94, P1304, DOI 10.1136/bjo.2009.160721
   Ng JQ, 2006, CLIN EXP OPHTHALMOL, V34, P317, DOI 10.1111/j.1442-9071.2006.01214.x
   Ng WS, 2010, BRIT J OPHTHALMOL, V94, P85, DOI 10.1136/bjo.2008.153312
   Nicolucci A, 1998, DIABETES CARE, V21, P1439, DOI 10.2337/diacare.21.9.1439
   Nirmalan PK, 2004, OPHTHALMOLOGY, V111, P1778, DOI 10.1016/j.ophtha.2004.02.012
   Nirmalan PK, 2003, BRIT J OPHTHALMOL, V87, P847, DOI 10.1136/bjo.87.7.847
   Nirmalan PK, 2002, BRIT J OPHTHALMOL, V86, P505, DOI 10.1136/bjo.86.5.505
   NORRIS KL, J WOMENS HEALTH
   Nowak MS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000505
   Paksin-Hall A, 2013, OPHTHAL EPIDEMIOL, V20, P281, DOI 10.3109/09286586.2013.789531
   Park SJ, 2016, J KOREAN MED SCI, V31, P963, DOI 10.3346/jkms.2016.31.6.963
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Park SH, 2015, INVEST OPHTH VIS SCI, V56, P484, DOI 10.1167/iovs.14-14909
   PERRUCCIO AV, CAN J OPHTHALMOL
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Pisati M, 2010, SOC SCI RES, V39, P405, DOI 10.1016/j.ssresearch.2009.11.004
   Ploubidis GB, 2013, INT J PUBLIC HEALTH, V58, P133, DOI 10.1007/s00038-012-0389-2
   PUBLIC H, 2014, SCREENING, P3
   PUNNONEN E, 1989, ACTA OPHTHALMOL, V67, P492
   PUODZIUVIENE E, 2006, MED LITH, V43, P637
   Quintana JM, 2013, EYE, V27, P698, DOI 10.1038/eye.2013.85
   Ramachandran A, 2002, DIABETIC MED, V19, P130, DOI 10.1046/j.1464-5491.2002.00656.x
   RAMAN R, 2001, EYE LOND
   Raman R, 2010, INVEST OPHTH VIS SCI, V51, P6253, DOI 10.1167/iovs.10-5414
   Ramdas WD, 2011, ARCH OPHTHALMOL-CHIC, V129, P767, DOI 10.1001/archophthalmol.2010.373
   Ramke J, 2007, BRIT J OPHTHALMOL, V91, P1117, DOI 10.1136/bjo.2006.106559
   Rani PK, 2008, RURAL REMOTE HEALTH, V8
   Ravindran RD, 2009, J CATARACT REFR SURG, V35, P629, DOI 10.1016/j.jcrs.2009.01.002
   REINSTEIN DZ, 1993, BRIT J OPHTHALMOL, V77, P293, DOI 10.1136/bjo.77.5.293
   Ribadu D Y, 2010, Niger Postgrad Med J, V17, P308
   Richter GM, 2009, OPHTHALMOLOGY, V116, P2327, DOI 10.1016/j.ophtha.2009.05.040
   Rim THT, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-4
   Roy MS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1297, DOI 10.1001/archopht.124.9.1297
   Sachs J, 2008, EUR J DENT EDUC, V12, P17, DOI 10.1111/j.1600-0579.2007.00476.x
   Salomao SR, 2008, OPHTHAL EPIDEMIOL, V15, P167, DOI 10.1080/09286580701843812
   Sandhu S, 2013, CLIN EXP OPHTHALMOL, V41, P56, DOI 10.1111/j.1442-9071.2012.02820.x
   Sapkota YD, 2006, BRIT J OPHTHALMOL, V90, P411, DOI 10.1136/bjo.2005.082503
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P446, DOI 10.1136/bjo.87.4.446
   Scanlon PH, 2008, J MED SCREEN, V15, P118, DOI 10.1258/jms.2008.008013
   Schein OD, 2012, OPHTHAL EPIDEMIOL, V19, P257, DOI 10.3109/09286586.2012.698692
   Schneider J, 2010, SURV OPHTHALMOL, V55, P539, DOI 10.1016/j.survophthal.2010.02.004
   SDTP, SD
   Sharma HE, 2014, BRIT J OPHTHALMOL, V98, P1625, DOI 10.1136/bjophthalmol-2014-304959
   Sheng XL, 2014, INT J OPHTHALMOL-CHI, V7, P557, DOI 10.3980/j.issn.2222-3959.2014.03.30
   Shrestha MK, 2004, BRIT J OPHTHALMOL, V88, P319, DOI 10.1136/bjo.2003.026260
   Shweikh Y, 2015, EYE, V29, P1360, DOI 10.1038/eye.2015.157
   Siddiqui MAR, 2010, ACTA OPHTHALMOL, V88, pe352, DOI 10.1111/j.1755-3768.2009.01771.x
   SINGH MC, J INDIAN MED ASS
   SINGH MC, 1994, J INDIAN MED ASSOC, V365, P361
   SINGH N, 2014, PLOS ONE, P9
   Singh N, 2014, BR J OPHTHALMOL, V9
   Sinha R, 2005, EYE, V19, P451, DOI 10.1038/sj.eye.6701534
   Sit AJ, 2004, OPHTHAL EPIDEMIOL, V11, P199, DOI 10.1080/09286580490514504
   Sloan FA, 2014, OPHTHALMOLOGY, V121, P2452, DOI 10.1016/j.ophtha.2014.07.020
   Smirthwaite G, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0302-3
   Smith TST, 2009, B WORLD HEALTH ORGAN, V87, P431, DOI 10.2471/BLT.08.055673
   SNELLINGEN T, BR J OPHTHALMOL
   SONG X, 2014, PLOS ONE, P9
   SRIVASTAVA RN, 1978, J EPIDEMIOL COMMUN H, V32, P131, DOI 10.1136/jech.32.2.131
   STANG A, 1998, EUR J PUBLIC HEALTH, P6962
   Stapleton Fiona, 1993, CLAO (Contact Lens Association of Ophthalmologists) Journal, V19, P204
   Su Z, 2014, BRIT J OPHTHALMOL, V98, P1009, DOI 10.1136/bjophthalmol-2013-304504
   Sukumar S, 2009, EYE, V23, P1038, DOI 10.1038/eye.2008.245
   Syed A, 2013, DISABIL REHABIL, V35, P1660, DOI 10.3109/09638288.2012.748843
   Tabbara K F, 1997, Ophthalmic Epidemiol, V4, P127
   Tao XM, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0376-7
   Tarwadi K, 2004, NUTRITION, V20, P261, DOI 10.1016/j.nut.2003.11.020
   Tarwadi KV, 2008, CLIN NUTR, V27, P464, DOI 10.1016/j.clnu.2008.01.014
   Tarwadi KV, 2011, NUTRITION, V27, P40, DOI 10.1016/j.nut.2009.11.015
   Thapa SS, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-2
   THOMAS R, 2009, J TRAUMA SUPPL, P66
   Thompson AGH, 2007, SOC SCI MED, V64, P1297, DOI 10.1016/j.socscimed.2006.11.002
   TIELSCH JM, 1990, OPHTHALMOLOGY, V97, P231
   TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027
   Townsend P., 1979, POVERTY UK SURVEY HO
   *UN ED SCIENT, 2017, POVERTY, V2017, P17
   UNITED N, 2017, THE REAL WEALTH OF N, V2010, P24
   United Nations Development Program, 1995, THE COPENHAGEN DECLA
   United Nations Development Program, 2010, PRESS
   United Nations Educational Scientific and Cultural Organization, 2017, HUMAN DEV REPORT 201
   Vaidyanathan K, 1999, B WORLD HEALTH ORGAN, V77, P104
   Varma R, 2008, MED CARE, V46, P497, DOI 10.1097/MLR.0b013e31816080fe
   Vats S, 2008, INDIAN J OPHTHALMOL, V56, P313
   Venkata G, 2005, BRIT J OPHTHALMOL, V89, P257, DOI 10.1136/bjo.2004.056937
   VENKATASWAMY PG, 1981, J VISUAL IMPAIR BLIN, V75, P405
   Verhaeghe PP, 2016, DISABIL HEALTH J, V9, P234, DOI 10.1016/j.dhjo.2015.10.002
   VIJAYA L, INDIAN J OPHTHALMOL
   WAH W, 2015, PLOS ONE, P10
   Walker EA, 2008, AM J PREV MED, V34, P185, DOI 10.1016/j.amepre.2007.11.020
   Wang JD, 2012, ACTA OPHTHALMOL, V90, pE61, DOI 10.1111/j.1755-3768.2011.02230.x
   Wang JJ, 1999, AUST NZ J OPHTHALMOL, V27, P294, DOI 10.1046/j.1440-1606.1999.00227.x
   WANG M, 2015, PLOS ONE, P10
   WAQAR S, DIABETES METAB SYNDR
   Weng C, 2000, DIABETIC MED, V17, P612, DOI 10.1046/j.1464-5491.2000.00352.x
   Wesolosky JD, 2015, CAN J OPHTHALMOL, V50, pS16, DOI 10.1016/j.jcjo.2015.04.004
   WEST SK, AM J OPHTHALMOL
   *WHO, 2016, VISION 2020 CONTROL, V214, P2
   WILSON MR, 1991, J NATL MED ASSOC, V83, P697
   WOODWARD EG, 1981, BRIT J OPHTHALMOL, V65, P104, DOI 10.1136/bjo.65.2.104
   World Bank and Lending Groups, 2017, LANCET GLOB HLTH
   *WORLD BANK LEND G, 2017, HISTORICAL CLASSIFIC, V1
   World Health Organisation, 1940, SA
   Wright HR, 2007, CLIN EXP OPTOM, V90, P422, DOI 10.1111/j.1444-0938.2007.00218.x
   Wu RY, 2010, ARCH OPHTHALMOL-CHIC, V128, P1029, DOI 10.1001/archophthalmol.2010.147
   Xu J, 2002, BRIT J OPHTHALMOL, V86, P723, DOI 10.1136/bjo.86.7.723
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Xu L, 2011, ACTA OPHTHALMOL, V89, P442, DOI 10.1111/j.1755-3768.2009.01734.x
   YAWSON AE, BMC PUBLIC HEALTH
   Yin QX, 2009, INVEST OPHTH VIS SCI, V50, P1069, DOI 10.1167/iovs.08-2783
   Yip JLY, 2007, BRIT J OPHTHALMOL, V91, P56, DOI 10.1136/bjo.2006.099549
   Yip JLY, 2014, J EPIDEMIOL COMMUN H, V68, P204, DOI 10.1136/jech-2013-203265
   Yip JLY, 2011, OPHTHAL EPIDEMIOL, V18, P217, DOI 10.3109/09286586.2011.602507
   YONEKAWA Y, OPHTHALMOLOGY
   Younan C, 2002, CLIN EXP OPHTHALMOL, V30, P163, DOI 10.1046/j.1442-9071.2002.00523.x
   ZHANG X, AM J OPHTHALMOL
   ZHANG X, 2002, JAMA OPHTHALMOL
   ZHANG X, 2007, ARCH OPHTHALMOL-CHIC, P125
   Zhang XZ, 2008, ARCH OPHTHALMOL-CHIC, V126, P1421, DOI 10.1001/archopht.126.10.1421
   Zhang Y, 2013, OPHTHAL EPIDEMIOL, V20, P248, DOI 10.3109/09286586.2013.809126
   ZHENG Y, INVEST OPHTHALMOL VI
   ZHENG Y, 2012, INDIAN J OPHTHALMOL, P60
   Zheng YF, 2012, OPHTHALMOLOGY, V119, P2119, DOI 10.1016/j.ophtha.2012.04.027
NR 311
TC 21
Z9 21
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2018
VL 63
IS 3
BP 406
EP 436
DI 10.1016/j.survophthal.2017.10.009
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GF3HJ
UT WOS:000431835900010
PM 29100897
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Dubail, J
   Vasudevan, D
   Wang, LW
   Earp, SE
   Jenkins, MW
   Haltiwanger, RS
   Apte, SS
AF Dubail, Johanne
   Vasudevan, Deepika
   Wang, Lauren W.
   Earp, Sarah E.
   Jenkins, Michael W.
   Haltiwanger, Robert S.
   Apte, Suneel S.
TI Impaired ADAMTS9 secretion: A potential mechanism for eye defects in
   Peters Plus Syndrome
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ANTERIOR SEGMENT DYSGENESIS; O-FUCOSYLATION; EXTRACELLULAR-MATRIX; LENS
   DEVELOPMENT; HOMEOBOX GENE; MUTATIONS; HAPLOINSUFFICIENCY;
   METALLOPROTEASES; ABNORMALITIES; PEROXIDASIN
AB Peters Plus syndrome (PPS), a congenital disorder of glycosylation, results from recessive mutations affecting the glucosyltransferase B3GLCT, leading to congenital corneal opacity and diverse extraocular manifestations. Together with the fucosyltransferase POFUT2, B3GLCT adds Glucose beta 1-3Fucose disaccharide to a consensus sequence in thrombospondin type 1 repeats (TSRs) of several proteins. Which of these target proteins is functionally compromised in PPS is unknown. We report here that haploinsufficiency of murine Adamts9, encoding a secreted metalloproteinase with 15 TSRs, leads to congenital corneal opacity and Peters anomaly (persistent lens-cornea adhesion), which is a hallmark of PPS. Mass spectrometry of recombinant ADAMTS9 showed that 9 of 12 TSRs with the O-fucosylation consensus sequence carried the Glucose beta 1-3Fucose disaccharide and B3GLCT knockdown reduced ADAMTS9 secretion in HEK293F cells. Together, the genetic and biochemical findings imply a dosage-dependent role for ADAMTS9 in ocular morphogenesis. Reduced secretion of ADAMTS9 in the absence of B3GLCT is proposed as a mechanism of Peters anomaly in PPS. The functional link between ADAMTS9 and B3GLCT established here also provides credence to their recently reported association with age-related macular degeneration.
C1 [Dubail, Johanne; Wang, Lauren W.; Earp, Sarah E.; Apte, Suneel S.] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Vasudevan, Deepika; Haltiwanger, Robert S.] SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.
   [Jenkins, Michael W.] Case Western Reserve Univ, Dept Pediat & Biomed Engn, 11000 Euclid Ave, Cleveland, OH 44106 USA.
   [Dubail, Johanne] Paris Descartes Univ, Sorbonne Paris Cite,Imagine Inst, Necker Enfants Malades Hosp,Dept Genet,INSERM UMR, Lab Mol & Physiopathol Bases Osteochondrodysplasi, Paris, France.
   [Vasudevan, Deepika] NYU, Langone Med Ctr, Dept Cell Biol, New York, NY USA.
   [Haltiwanger, Robert S.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.
C3 Cleveland Clinic Foundation; State University of New York (SUNY) System;
   SUNY Community College; State University of New York (SUNY) Stony Brook;
   Case Western Reserve University; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite Paris Cite; New York University; NYU
   Langone Medical Center; University System of Georgia; University of
   Georgia
RP Apte, SS (通讯作者)，Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM aptes@ccf.org
RI Dubail, Johanne/AAB-1980-2021
OI Dubail, Johanne/0000-0001-9124-9765; Vasudevan,
   Deepika/0000-0003-1930-3549; Apte, Suneel/0000-0001-8441-1226; Jenkins,
   Michael/0000-0002-8908-5383
FU Pediatric Ophthalmology Career-Starter Research and Competitive renewal
   grants from the Knight Templar Eye Foundation; National Eye Institute
   [EY024943]; National Institute of General Medical Sciences [GM061126];
   NIH [T32EY024236]; NATIONAL EYE INSTITUTE [R01EY024943, T32EY024236]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [R01GM061126] Funding Source: NIH RePORTER
FX We are grateful to Elias Traboulsi for helpful discussion and Timothy
   Mead for valuable comments on the manuscript. We thank Andrew Rollins
   for the OCT system, and Megumi Takeuchi, Joshua Kantharia, and Beth
   Harvey for assistance in the mass spectral analysis of ADAMTS9 protein.
   This work was supported by Pediatric Ophthalmology Career-Starter
   Research and Competitive renewal grants from the Knight Templar Eye
   Foundation (to J.D.), and awards from the National Eye Institute
   (EY024943 to S.A.) and the National Institute of General Medical
   Sciences (GM061126 to R.H.). S.E. was funded by NIH award T32EY024236.
CR Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014
   Benz BA, 2016, DEV BIOL, V416, P111, DOI 10.1016/j.ydbio.2016.05.038
   Collinson JM, 2001, P NATL ACAD SCI USA, V98, P9688, DOI 10.1073/pnas.161144098
   Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231
   Danysh BP, 2009, EXP EYE RES, V88, P151, DOI 10.1016/j.exer.2008.08.002
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Du JG, 2010, DEV BIOL, V346, P25, DOI 10.1016/j.ydbio.2010.07.008
   Dubail J., 2015, MATRIX BIOL, DOI [10.1016/j.matbio.2015.03.001, DOI 10.1016/J.MATBIO.2015.03.0]
   Dubail J, 2014, GENESIS, V52, P702, DOI 10.1002/dvg.22784
   Enomoto H, 2010, DEVELOPMENT, V137, P4029, DOI 10.1242/dev.050591
   Evans AL, 2005, HUM MOL GENET, V14, P3347, DOI 10.1093/hmg/ddi365
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gould DB, 2002, HUM MOL GENET, V11, P1185, DOI 10.1093/hmg/11.10.1185
   Gould DB, 2007, HUM MOL GENET, V16, P798, DOI 10.1093/hmg/ddm024
   Heinonen TYK, 2009, ANN MED, V41, P2, DOI 10.1080/07853890802301975
   Helisalmi S, 2014, ACTA OPHTHALMOL, V92, pE410, DOI 10.1111/aos.12341
   Hu Z, 2007, OPT LETT, V32, P3525, DOI 10.1364/OL.32.003525
   Ito YA, 2014, CLIN EXP OPHTHALMOL, V42, P13, DOI 10.1111/ceo.12152
   Karunamuni G, 2014, AM J PHYSIOL-HEART C, V306, pH414, DOI 10.1152/ajpheart.00600.2013
   Kern CB, 2010, MATRIX BIOL, V29, P304, DOI 10.1016/j.matbio.2010.01.005
   Kidson SH, 1999, DEV BIOL, V211, P306, DOI 10.1006/dbio.1999.9314
   Koo BH, 2006, J BIOL CHEM, V281, P12485, DOI 10.1074/jbc.M511083200
   Koo BH, 2010, AM J PATHOL, V176, P1494, DOI 10.2353/ajpath.2010.090655
   Kozma K, 2006, J BIOL CHEM, V281, P36742, DOI 10.1074/jbc.M605912200
   Kurilec JM, 2014, CORNEA, V33, P848, DOI 10.1097/ICO.0000000000000182
   Lazar E, 2015, FREE RADICAL BIO MED, V83, P273, DOI 10.1016/j.freeradbiomed.2015.02.015
   Le Goff C, 2008, NAT GENET, V40, P1119, DOI 10.1038/ng.199
   Leonhard-Melief C, 2010, METHOD ENZYMOL, V480, P401, DOI 10.1016/S0076-6879(10)80018-7
   Lesnik Oberstein S.A.J, 1993, GENEREVIEWS
   Libby RT, 2003, SCIENCE, V299, P1578, DOI 10.1126/science.1080095
   Luo Y, 2006, J BIOL CHEM, V281, P9385, DOI 10.1074/jbc.M511974200
   Luo Y, 2006, J BIOL CHEM, V281, P9393, DOI 10.1074/jbc.M511975200
   Mataftsi A, 2011, MOL VIS, V17, P1624
   McCulloch DR, 2009, DEV CELL, V17, P687, DOI 10.1016/j.devcel.2009.09.008
   Morales J, 2009, AM J HUM GENET, V85, P558, DOI 10.1016/j.ajhg.2009.09.011
   Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335
   Nandadasa S, 2015, CELL REP, V11, P1519, DOI 10.1016/j.celrep.2015.05.005
   Oberstein SAJL, 2006, AM J HUM GENET, V79, P562, DOI 10.1086/507567
   Ormestad M, 2002, INVEST OPHTH VIS SCI, V43, P1350
   Pathania M, 2014, SCI WORLD J, DOI 10.1155/2014/524929
   Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668
   Reis LM, 2011, CURR OPIN OPHTHALMOL, V22, P314, DOI 10.1097/ICU.0b013e328349412b
   Ricketts LM, 2007, J BIOL CHEM, V282, P17014, DOI 10.1074/jbc.M700317200
   Rossi M, 2003, EMBO J, V22, P236, DOI 10.1093/emboj/cdg019
   Sato T, 2006, GLYCOBIOLOGY, V16, P1194, DOI 10.1093/glycob/cwl035
   Semina EV, 2000, HUM MOL GENET, V9, P1575, DOI 10.1093/hmg/9.11.1575
   Shigeyasu C, 2012, CORNEA, V31, P293, DOI 10.1097/ICO.0b013e31820cd2ab
   Silver DL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000003
   Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200
   Sowden JC, 2007, EYE, V21, P1310, DOI 10.1038/sj.eye.6702852
   Teo ZL, 2014, EXP EYE RES, V121, P130, DOI 10.1016/j.exer.2014.01.013
   Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200
   Van Agtmael T, 2005, HUM MOL GENET, V14, P3161, DOI 10.1093/hmg/ddi348
   Vasudevan D, 2015, CURR BIOL, V25, P286, DOI 10.1016/j.cub.2014.11.049
   Vasudevan D, 2014, GLYCOCONJUGATE J, V31, P417, DOI 10.1007/s10719-014-9556-4
   Walker J, 2009, EXP EYE RES, V88, P216, DOI 10.1016/j.exer.2008.06.020
   Wang LW, 2007, J BIOL CHEM, V282, P17024, DOI 10.1074/jbc.M701065200
   Wederell ED, 2006, SEMIN CELL DEV BIOL, V17, P759, DOI 10.1016/j.semcdb.2006.10.006
   Weh E, 2014, CLIN GENET, V86, P142, DOI 10.1111/cge.12241
   Weh E, 2014, HUM GENET, V133, P1497, DOI 10.1007/s00439-014-1481-x
   Wenniger-Prick LJJMMD, 2002, ANN GENET-PARIS, V45, P97
   Yan XH, 2014, HUM MOL GENET, V23, P5597, DOI 10.1093/hmg/ddu274
NR 62
TC 21
Z9 21
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 30
PY 2016
VL 6
AR 33974
DI 10.1038/srep33974
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DX4GG
UT WOS:000384338600001
PM 27687499
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Szemraj, M
   Bielecka-Kowalska, A
   Oszajca, K
   Krajewska, M
   Gos, R
   Jurowski, P
   Kowalski, M
   Szemraj, J
AF Szemraj, Maciej
   Bielecka-Kowalska, Anna
   Oszajca, Katarzyna
   Krajewska, Marta
   Gos, Roman
   Jurowski, Piotr
   Kowalski, Michal
   Szemraj, Janusz
TI Serum MicroRNAs as Potential Biomarkers of AMD
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Gene Expression Profiling; MicroRNAs; Serum
ID MACULAR DEGENERATION AMD; CIRCULATING MICRORNAS; MIRNAS; IDENTIFICATION;
   POLYMORPHISMS; EXPRESSION; CANCER
AB Background: Age-related macular degeneration (AMD) is a major cause of blindness worldwide. Circulating microRNAs (miRNAs) in serum have emerged as novel candidate biomarkers for many diseases. The aim of the present study was to identify a serum microRNA (miRNA) expression profile specific for dry and wet forms of AMD.
   Material/Methods: Serum miRNA expression was first screened using TaqMan (R) Human MicroRNA Array A (Applied Biosystems). An extensive, self-validated, individual, quantitative RT-PCR (qRT-PCR) study was then performed on a cohort of 300 AMD patients (150 wet form and 150 dry form) and 200 controls. The Mann-Whitney U test and non-parametric Spearman's rank correlation coefficient were used for statistical analysis.
   Results: miRNA expression analysis revealed increased expression of miR661 and miR3121 in serum of patients with dry AMD and miR4258, miR889, and Let7 in patients with wet form. Expression of analyzed miRNA was not observed or remained at low level in controls.
   Conclusions: Differences in miRNA serum profile exist between patients with wet and dry form of AMD, which indicates miRNAs as potential biomarkers of AMD. Further studies should be performed to confirm its significance in clinical practice.
C1 [Szemraj, Maciej; Krajewska, Marta; Gos, Roman; Jurowski, Piotr] Med Univ Lodz, Dept Eye Dis, Lodz, Poland.
   [Bielecka-Kowalska, Anna; Kowalski, Michal] Med Ctr Sal Med, Lodz, Poland.
   [Oszajca, Katarzyna; Szemraj, Janusz] Med Univ Lodz, Dept Med Biochem, Lodz, Poland.
C3 Medical University Lodz; Medical University Lodz
RP Szemraj, M (通讯作者)，Med Univ Lodz, Dept Eye Dis, Lodz, Poland.
EM janusz.szemraj@umed.lodz.pl
RI Oszajca, Katarzyna Anna/S-9288-2016
OI Oszajca, Katarzyna Anna/0000-0002-7070-8720; Jurowski,
   Piotr/0000-0003-1471-8577
FU National Center of Science [NN 402 591340]
FX This work was supported by grant NN 402 591340 from the National Center
   of Science
CR Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Chen Z, 2013, J CLIN INVEST, V123, P1057, DOI 10.1172/JCI65344
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Dhoot DS, 2012, EXPERT OPIN BIOL TH, V12, P371, DOI 10.1517/14712598.2012.660523
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Galecki P, 2013, PROG NEURO-PSYCHOPH, V45, P117, DOI 10.1016/j.pnpbp.2013.04.011
   Galecki P, 2013, J AFFECT DISORDERS, V147, P144, DOI 10.1016/j.jad.2012.10.025
   Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148
   Gommans Willemijn M, 2012, Methods Mol Biol, V822, P1, DOI 10.1007/978-1-61779-427-8_1
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Karali M, 2007, INVEST OPHTH VIS SCI, V48, P509, DOI 10.1167/iovs.06-0866
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Li KJ, 2014, MED SCI MONITOR, V20, P639, DOI 10.12659/MSM.890686
   Li X, 2005, CELL, V123, P1267, DOI 10.1016/j.cell.2005.10.040
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lodes MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006229
   Loscher CJ, 2008, EXP EYE RES, V87, P529, DOI 10.1016/j.exer.2008.08.016
   Loscher CJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r248
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Meister G, 2007, CELL, V131, P25, DOI 10.1016/j.cell.2007.09.021
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Pitlick JM, 2012, ANN PHARMACOTHER, V46, P290, DOI 10.1345/aph.1Q471
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Weiland M, 2012, RNA BIOL, V9, P850, DOI 10.4161/rna.20378
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Zhao JJ, 2009, CHILD NERV SYST, V25, P13, DOI 10.1007/s00381-008-0701-x
NR 37
TC 54
Z9 55
U1 0
U2 9
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD SEP 14
PY 2015
VL 21
BP 2734
EP 2742
DI 10.12659/MSM.893697
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CR6FO
UT WOS:000361440200002
PM 26366973
OA Green Published
DA 2022-11-30
ER

PT J
AU Nittala, MG
   Hariri, A
   Wong, WT
   Chew, EY
   Ferris, FL
   Sadda, SR
AF Nittala, Muneeswar G.
   Hariri, Amirhossein
   Wong, Wai T.
   Chew, Emily Y.
   Ferris, Frederick L.
   Sadda, Srinivas R.
TI Image Scaling Difference Between a Confocal Scanning Laser
   Ophthalmoscope and a Flash Fundus Camera
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID GEOGRAPHIC ATROPHY; MACULAR DEGENERATION; AUTOFLUORESCENCE
AB BACKGROUND AND OBJECTIVE: To evaluate scaling and measurement differences between flash and scanning laser fundus images.
   PATIENTS AND METHODS: The authors analyzed fundus autofluorescence images of patients with geographic atrophy secondary to age-related macular degeneration imaged with both 30(sic) confocal scanning laser ophthalmoscope (cSLO) and 50(sic) flash fundus camera (FFC). Multiple vessel-crossing points served as landmarks.
   RESULTS: The mean (+/- SD; range) scaling factor between cSLO and FFC images (by GRADOR) for the horizontal dimension was 1.217 (+/- 0.0487; 1.0474-1.272) versus 1.138 (+/- 0.0311; 1.0841-1.193) for the vertical dimension. The mean percentage difference between horizontal and vertical scaling factors was 7.48 (+/- 2.29; 2.30-10.70). Refractive error (focus) and aperture size (or field of view of the image) were positively correlated and aspect ratio was negatively correlated with landmark pair measurements.
   CONCLUSION: Inherent image-scaling differences between fundus autofluorescence imaging systems are not restricted to simple pixel-to-millimeter calibration variances, but appear to vary depending on measurement orientation. Differences should be considered when comparing measurements obtained using different imaging systems, particularly for clinical trials.
C1 [Nittala, Muneeswar G.; Hariri, Amirhossein; Sadda, Srinivas R.] Doheny Eye Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Wong, Wai T.; Chew, Emily Y.; Ferris, Frederick L.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Wong, Wai T.] NEI, Off Sci Director, NIH, Bethesda, MD 20892 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020; Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Ferris, Frederick/0000-0002-4933-0639
FU NEI [R01 EY014375]; NIH [EY0304]; Research to Prevent Blindness; DFG [He
   6094/1-1]; Optos plc; Carl Zeiss Meditec; NATIONAL EYE INSTITUTE
   [R01EY014375, ZIAEY000489] Funding Source: NIH RePORTER
FX Supported in part by NEI Grant R01 EY014375, NIH Grant EY0304, an
   unrestricted grant from Research to Prevent Blindness, and DFG Grant He
   6094/1-1.; Dr. Sadda is a consultant for and receives research support
   from Optos plc and Carl Zeiss Meditec. The remaining authors report no
   relevant financial disclosures.
CR Bellmann C, 2003, BRIT J OPHTHALMOL, V87, P1381, DOI 10.1136/bjo.87.11.1381
   Fleckenstein M, 2010, OPHTHALMOLOGE, V107, P1007, DOI 10.1007/s00347-010-2159-y
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Hariri A, 2013, INVEST OPHTH VIS SCI, V54, P8020, DOI 10.1167/iovs.13-12302
   Lee N, 2007, P ANN INT IEEE EMBS, P4965, DOI 10.1109/IEMBS.2007.4353455
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 1999, BRIT J OPHTHALMOL, V83, P276, DOI 10.1136/bjo.83.3.276
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2008, AM J OPHTHALMOL, V146, P183, DOI 10.1016/j.ajo.2008.04.006
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yamamoto Manabu, 2009, Osaka City Med J, V55, P19
NR 15
TC 4
Z9 6
U1 0
U2 5
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2015
VL 46
IS 8
BP 872
EP 879
DI 10.3928/23258160-20150909-13
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UD
UT WOS:000378842000014
PM 26431304
DA 2022-11-30
ER

PT J
AU Nakama, T
   Yoshida, S
   Ishikawa, K
   Kobayashi, Y
   Zhou, Y
   Nakao, S
   Sassa, Y
   Oshima, Y
   Takao, K
   Shimahara, A
   Yoshikawa, K
   Hamasaki, T
   Ohgi, T
   Hayashi, H
   Matsuda, A
   Kudo, A
   Nozaki, M
   Ogura, Y
   Kuroda, M
   Ishibashi, T
AF Nakama, T.
   Yoshida, S.
   Ishikawa, K.
   Kobayashi, Y.
   Zhou, Y.
   Nakao, S.
   Sassa, Y.
   Oshima, Y.
   Takao, K.
   Shimahara, A.
   Yoshikawa, K.
   Hamasaki, T.
   Ohgi, T.
   Hayashi, H.
   Matsuda, A.
   Kudo, A.
   Nozaki, M.
   Ogura, Y.
   Kuroda, M.
   Ishibashi, T.
TI Inhibition of choroidal fibrovascular membrane formation by new class of
   RNA interference therapeutic agent targeting periostin
SO GENE THERAPY
LA English
DT Article
ID PROLIFERATIVE DIABETIC-RETINOPATHY; SUBRETINAL NEOVASCULAR MEMBRANES;
   DEGENERATION TREATMENTS TRIALS; OXYGEN-INDUCED RETINOPATHY; PIGMENT
   EPITHELIAL-CELLS; TOLL-LIKE RECEPTOR-3; MACULAR DEGENERATION;
   GROWTH-FACTOR; GEOGRAPHIC ATROPHY; MOUSE MODEL
AB Age-related macular degeneration (AMD) is a vision-threatening disease characterized by choroidal fibrovascular membrane (FVM) formation, choroidal neovascularization (CNV) and choroidal fibrosis. No safe and effective therapeutic method has been developed for the choroidal fibrosis, although anti-vascular endothelial growth factor therapy can partially shrink the CNV. We recently reported that periostin (POSTN), which is produced by retinal pigment epithelial cells, has an important role in the formation of preretinal FVMs, but its role in choroidal FVMs has not been determined. In this study, we used Postn knockout mice to investigate the role played by POSTN in choroidal FVM formation. In addition, we used a new class of RNA interference (RNAi) agent (NK0144) that targets POSTN and determined its effect on choroidal FVM development. Genetic ablation of Postn had an inhibitory effect not only on CNV formation but also on choroidal fibrosis in a mouse CNV model. NK0144 also had a greater inhibitory effect on both the CNV and choroidal fibrosis than control RNAi with no apparent adverse effects. These findings suggest a causal relationship between POSTN and choroidal FVM formation, and also a potential therapeutic role of intravitreal NK0144 for AMD.
C1 [Nakama, T.; Yoshida, S.; Ishikawa, K.; Kobayashi, Y.; Zhou, Y.; Nakao, S.; Sassa, Y.; Oshima, Y.; Ishibashi, T.] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan.
   [Sassa, Y.] Fukuoka Univ, Chikushi Hosp, Dept Ophthalmol, Fukuoka 81401, Japan.
   [Takao, K.; Shimahara, A.; Yoshikawa, K.] AQUA Therapeut Co Ltd, Kobe, Hyogo, Japan.
   [Hamasaki, T.; Ohgi, T.; Hayashi, H.] BIO Factory, BONAC Corp, Strateg Headquarters Res & Dev, Fukuoka, Japan.
   [Matsuda, A.] Juntendo Univ, Sch Med, Dept Ophthalmol, Tokyo 113, Japan.
   [Kudo, A.] Tokyo Inst Technol, Dept Biol Informat, Yokohama, Kanagawa 227, Japan.
   [Nozaki, M.; Ogura, Y.] Nagoya City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med Sci, Nagoya, Aichi, Japan.
   [Kuroda, M.] Tokyo Med Univ, Dept Mol Pathol, Tokyo 1608402, Japan.
C3 Kyushu University; Fukuoka University; Juntendo University; Tokyo
   Institute of Technology; Nagoya City University; Tokyo Medical
   University
RP Yoshida, S (通讯作者)，Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan.
EM yosida@eye.med.kyushu-u.ac.jp
RI Matsuda, Akira/A-9981-2010; Kudo, Akira/C-7340-2015
OI Matsuda, Akira/0000-0002-0792-3663; Kudo, Akira/0000-0001-6289-3391;
   Zhou, Yedi/0000-0002-8948-1108; Yoshida, Shigeo/0000-0003-1049-8909;
   Sassa, Yukio/0000-0002-3782-5351; Nakama, Takahito/0000-0001-8999-3667
FU JSPS KAKENHI grant [24249083, 23592574, 26293374, 26670757]; Takeda
   Science Foundation; Adaptable and Seamless Technology Transfer Program
   through Target-driven R&D from the Japan Science and Technology Agency;
   Japan Society for the Promotion of Science
FX We thank the staff of the Research Support Center (Graduate School of
   Medical Sciences, Kyushu University) for technical support and Masayo
   Eto, Kinuko Sasada and Hiroko Miura for their excellent technical
   assistance. This work was supported in part by JSPS KAKENHI grant
   numbers 24249083, 23592574, 26293374, 26670757, Takeda Science
   Foundation, and Adaptable and Seamless Technology Transfer Program
   through Target-driven R&D from the Japan Science and Technology Agency.
   T Nakama is supported by a fellowship from the Japan Society for the
   Promotion of Science for Young Scientists.
CR Arima M, 2012, INVEST OPHTH VIS SCI, V53, P6495, DOI 10.1167/iovs.12-9684
   Asato R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054191
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   CHANDRA SR, 1974, AM J OPHTHALMOL, V78, P579, DOI 10.1016/S0002-9394(14)76293-2
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Conway SJ, 2014, CELL MOL LIFE SCI, V71, P1279, DOI 10.1007/s00018-013-1494-y
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujita Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03325
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hamasaki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042655
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Ishikawa K, 2012, LAB INVEST, V92, P91, DOI 10.1038/labinvest.2011.141
   Ishikawa K, 2010, INVEST OPHTH VIS SCI, V51, P4307, DOI 10.1167/iovs.09-4605
   Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kudo A, 2011, CELL MOL LIFE SCI, V68, P3201, DOI 10.1007/s00018-011-0784-5
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Ontsuka K, 2012, EXP DERMATOL, V21, P331, DOI 10.1111/j.1600-0625.2012.01454.x
   Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Recalde S, 2011, INVEST OPHTH VIS SCI, V52, P7090, DOI 10.1167/iovs.11-7300
   Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Shimazaki M, 2008, J EXP MED, V205, P295, DOI 10.1084/jem.20071297
   Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tanimoto N, 2009, FRONT BIOSCI-LANDMRK, V14, P2730, DOI 10.2741/3409
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Yamaji Y, 2008, INVEST OPHTH VIS SCI, V49, P3151, DOI 10.1167/iovs.07-1249
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yoshida S, 2011, INVEST OPHTH VIS SCI, V52, P5670, DOI 10.1167/iovs.10-6625
   Yoshida S, 2010, BRIT J OPHTHALMOL, V94, P795, DOI 10.1136/bjo.2009.167072
NR 50
TC 32
Z9 34
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD FEB
PY 2015
VL 22
IS 2
BP 127
EP 137
DI 10.1038/gt.2014.112
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA CB2CK
UT WOS:000349434100003
PM 25503692
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ugarte, M
   Osborne, NN
AF Ugarte, Marta
   Osborne, Neville N.
TI Recent advances in the understanding of the role of zinc in ocular
   tissues
SO METALLOMICS
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; ERG B-WAVE; NIGHT BLINDNESS; BIOLOGICAL
   SAMPLES; ENDOGENOUS ZINC; AGE-GROUPS; INDUCED PHOTORECEPTOR; CADMIUM
   ACCUMULATION; RETINITIS-PIGMENTOSA; TRANSCRIPTION FACTOR
AB Zinc levels are high in ocular tissues and the distribution is non-uniform. Zinc is particularly concentrated in the corneal epithelium and posterior stroma. Zinc is the most abundant trace metal in the retina. Bound-zinc is particularly located in the inner nuclear layer, (e. g. forming part of the structure of zinc finger transcription factors), while loosely-bound zinc is prominent in the retinal pigment epithelium and photoreceptor layers. Loosely-bound zinc ions in the photoreceptors might play a role in the phototransduction cascade and rhodopsin regeneration. Loosely-bound zinc is also found in presynaptic vesicles of photoreceptor cells in the outer plexiform and inner plexiform layers and can be synaptically released to affect both ionotropic and metabotropic receptors and also ion channels to modulate neurotransmission. The correct amount of loosely-bound zinc ions is maintained by regulating the function of zinc transporters, sensors and trafficking/storage proteins (i.e. metallothionein). The retinal homeostasis of zinc is dysregulated in systemic zinc depletion, aging and diseases such as age-related macular degeneration. Manipulation of retinal zinc metabolism in these situations might improve visual function.
C1 [Ugarte, Marta] Moorfields Eye Hosp, London EC1V 2PD, England.
   [Osborne, Neville N.] Inst Oftalmol Fernandez Vega, Fdn Invest Oftalmol, Oviedo 33012, Asturias, Spain.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Ugarte, M (通讯作者)，Moorfields Eye Hosp, City Rd, London EC1V 2PD, England.
EM mugarte@doctors.org.uk
OI Ugarte, Marta/0000-0002-8132-5004
FU Catedra en Biomedicina, Fundacion BBVA
FX Support by Catedra en Biomedicina, Fundacion BBVA is greatly
   appreciated.
CR Afridi HI, 2012, CLIN LAB, V58, P705, DOI 10.7754/Clin.Lab.2011.110525
   Afridi HI, 2011, BIOL TRACE ELEM RES, V143, P20, DOI 10.1007/s12011-010-8834-7
   Afridi HI, 2011, BIOL TRACE ELEM RES, V142, P323, DOI 10.1007/s12011-010-8789-8
   Akagi T, 2001, J HISTOCHEM CYTOCHEM, V49, P87, DOI 10.1177/002215540104900109
   Allington C, 2001, CELL DEATH DIFFER, V8, P451, DOI 10.1038/sj.cdd.4400831
   Alvarez L, 2012, J BIOL CHEM, V287, P28456, DOI 10.1074/jbc.M112.365015
   Anastassov I, 2013, EXP EYE RES, V112, P37, DOI 10.1016/j.exer.2013.04.011
   Andreini C, 2006, J PROTEOME RES, V5, P3173, DOI 10.1021/pr0603699
   Andrews GK, 2001, BIOMETALS, V14, P223, DOI 10.1023/A:1012932712483
   Arranz V, 2001, J BIOL CHEM, V276, P11963, DOI 10.1074/jbc.M011036200
   ATMACA LS, 1989, BRIT J OPHTHALMOL, V73, P29, DOI 10.1136/bjo.73.1.29
   Bernard M, 2008, J NEUROCHEM, V105, P595, DOI 10.1111/j.1471-4159.2007.05150.x
   Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548
   Biesemeier A, 2012, METALLOMICS, V4, P323, DOI 10.1039/c2mt00187j
   Bonilha VL, 2008, EXP EYE RES, V86, P150, DOI 10.1016/j.exer.2007.10.006
   BOWNESS JM, 1952, BIOCHEM J, V51, P521, DOI 10.1042/bj0510521
   Bozym RA, 2010, EXP BIOL MED, V235, P741, DOI 10.1258/ebm.2010.009258
   BRAND IA, 1986, J BIOL CHEM, V261, P5892
   Brown AM, 2000, J BIOL CHEM, V275, P13441, DOI 10.1074/jbc.275.18.13441
   Capdor J, 2013, J TRACE ELEM MED BIO, V27, P137, DOI 10.1016/j.jtemb.2012.08.001
   Chappell RL, 2008, EXP EYE RES, V87, P394, DOI 10.1016/j.exer.2008.06.013
   Chappell RL, 2001, BIOL BULL, V201, P265, DOI 10.2307/1543357
   Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   Choi JS, 2006, VISION RES, V46, P2721, DOI 10.1016/j.visres.2006.02.014
   Clegg MS, 2005, IUBMB LIFE, V57, P661, DOI 10.1080/15216540500264554
   Collin RWJ, 2013, P NATL ACAD SCI USA, V110, P9856, DOI 10.1073/pnas.1220864110
   Colvin RA, 2010, METALLOMICS, V2, P306, DOI 10.1039/b926662c
   Costello LC, 1998, PROSTATE, V35, P285, DOI 10.1002/(SICI)1097-0045(19980601)35:4<285::AID-PROS8>3.0.CO;2-F
   Cousins RJ, 2006, J BIOL CHEM, V281, P24085, DOI 10.1074/jbc.R600011200
   Croci C, 2003, J BIOL CHEM, V278, P6128, DOI 10.1074/jbc.M205162200
   CROUCH RK, 1982, BRIT J OPHTHALMOL, V66, P417, DOI 10.1136/bjo.66.7.417
   de Benoist B., 2007, FOOD NUTR B S, V28
   de Melo J, 2011, DEVELOPMENT, V138, P2325, DOI 10.1242/dev.061846
   del Valle LJ, 2003, J BIOL CHEM, V278, P4719, DOI 10.1074/jbc.M210760200
   DeNiro M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050360
   Doherty K, 2011, BRIT DENT J, V210, P523, DOI 10.1038/sj.bdj.2011.428
   DOREA JG, 1986, J NUTR, V116, P121, DOI 10.1093/jn/116.1.121
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   EVANS GW, 1986, CLIN PHYSIOL BIOCH, V4, P94
   Evans J. R., 2002, COCHRANE DB SYST REV, V11
   Evans JR, 2006, COCHRANE DB SYST REV, V19
   Evans JR, 2006, COCHRANE DB SYST REV, V2
   Fabe JS, 2000, BIOL TRACE ELEM RES, V75, P43, DOI 10.1385/BTER:75:1-3:43
   Faure P, 2003, CLIN CHEM LAB MED, V41, P995, DOI 10.1515/CCLM.2003.152
   Feigenspan A, 2000, J NEUROPHYSIOL, V84, P1697, DOI 10.1152/jn.2000.84.4.1697
   Frazzini V, 2006, BIOGERONTOLOGY, V7, P307, DOI 10.1007/s10522-006-9045-7
   Frederickson CJ, 2006, J NEUROSCI METH, V154, P19, DOI 10.1016/j.jneumeth.2005.11.014
   Fukada T, 2011, METALLOMICS, V3, P662, DOI 10.1039/c1mt00011j
   Gao HL, 2009, HISTOL HISTOPATHOL, V24, P567, DOI 10.14670/HH-24.567
   Gleim S, 2009, BIOCHEMISTRY-US, V48, P1793, DOI 10.1021/bi800968w
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Greenberg SA, 2004, J NEUROL, V251, P111, DOI 10.1007/s00415-004-0263-0
   Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453
   He F, 2000, J BIOL CHEM, V275, P20572, DOI 10.1074/jbc.M000440200
   Hedera P, 2003, ARCH NEUROL-CHICAGO, V60, P1303, DOI 10.1001/archneur.60.9.1303
   HENDERSON LM, 1988, BIOCHEM J, V255, P285
   Herrera E, 2003, CELL, V114, P545, DOI 10.1016/S0092-8674(03)00684-6
   Ho Y, 2008, MOL PHARMACOL, V74, P1141, DOI 10.1124/mol.108.049064
   HUBER AM, 1975, J NUTR, V105, P1486, DOI 10.1093/jn/105.11.1486
   Hyun HJ, 2000, BRAIN RES, V869, P39, DOI 10.1016/S0006-8993(00)02340-4
   Jansen J, 2009, J NUTR BIOCHEM, V20, P399, DOI 10.1016/j.jnutbio.2009.01.009
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Kaneda M, 2005, J MOL HISTOL, V36, P179, DOI 10.1007/s10735-005-1693-4
   Kaneda M, 2000, VISUAL NEUROSCI, V17, P273, DOI 10.1017/S0952523800172098
   KARCIOGLU ZA, 1984, CURR EYE RES, V3, P1043, DOI 10.3109/02713688409011750
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200
   Kokkinou D, 2005, GRAEF ARCH CLIN EXP, V243, P1050, DOI 10.1007/s00417-005-1197-7
   Komatsu K, 2005, J AM CHEM SOC, V127, P10197, DOI 10.1021/ja050301e
   Krebs NF, 2003, J NUTR, V133, p1498S, DOI 10.1093/jn/133.5.1498S
   Kreitzer MA, 2009, VISUAL NEUROSCI, V26, P375, DOI 10.1017/S0952523809990149
   Kubalska J, 1984, Pediatr Pol, V59, P209
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Lee DW, 2011, BIOCHEMISTRY-US, V50, P4263, DOI 10.1021/bi200230e
   Lee JM, 2002, NEUROSCIENCE, V115, P871, DOI 10.1016/S0306-4522(02)00513-4
   Lee SC, 2008, SYNAPSE, V62, P352, DOI 10.1002/syn.20501
   Lemire J, 2008, J APPL TOXICOL, V28, P175, DOI 10.1002/jat.1263
   Lengyel D, 2006, KLIN MONATSBL AUGENH, V223, P453, DOI 10.1055/s-2006-926632
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Leung KW, 2008, INVEST OPHTH VIS SCI, V49, P1221, DOI 10.1167/iovs.07-0781
   Leung KW, 2012, J MOL NEUROSCI, V46, P122, DOI 10.1007/s12031-011-9536-0
   LEUREDUPREE AE, 1982, INVEST OPHTH VIS SCI, V23, P425
   Lima L, 2004, NEUROCHEM RES, V29, P247, DOI 10.1023/B:NERE.0000010453.96832.97
   Luo DG, 2002, BRAIN RES, V958, P222, DOI 10.1016/S0006-8993(02)03598-9
   Luo DG, 2002, BRAIN RES BULL, V58, P461, DOI 10.1016/S0361-9230(02)00818-3
   Luo DG, 2001, BRAIN RES, V900, P95, DOI 10.1016/S0006-8993(01)02268-5
   Lynch S, 2011, AM J CLIN NUTR, V94, p673S, DOI 10.3945/ajcn.110.005959
   Malaiyandi LM, 2005, J NEUROSCI, V25, P9507, DOI 10.1523/JNEUROSCI.0868-05.2005
   Maret W., 2013, ADV NUTR, V85, P379
   Maret W, 2008, EXP GERONTOL, V43, P363, DOI 10.1016/j.exger.2007.11.005
   Maret W, 2006, J TRACE ELEM MED BIO, V20, P3, DOI 10.1016/j.jtemb.2006.01.006
   Maret W, 2011, BIOMETALS, V24, P411, DOI 10.1007/s10534-010-9406-1
   Maret W, 2009, BIOMETALS, V22, P149, DOI 10.1007/s10534-008-9186-z
   McBee Wendy L, 2003, Curr Opin Ophthalmol, V14, P159, DOI 10.1097/00055735-200306000-00009
   Miao X, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/425854
   Miceli MV, 1999, INVEST OPHTH VIS SCI, V40, P1238
   Mocchegiani E, 2006, REJUV RES, V9, P351, DOI 10.1089/rej.2006.9.351
   Mochizuki K, 2006, JPN J OPHTHALMOL, V50, P532, DOI 10.1007/s10384-006-0376-3
   MORRISON SA, 1978, AM J CLIN NUTR, V31, P276, DOI 10.1093/ajcn/31.2.276
   Moustafa SA, 2004, TOXICOL APPL PHARM, V201, P149, DOI 10.1016/j.taap.2004.05.014
   Musset Boris, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P605
   Nakamichi H, 2007, PHOTOCHEM PHOTOBIOL, V83, P232, DOI 10.1562/2006-13-RA-920
   Nakamichi N, 2003, NEUROPHARMACOLOGY, V45, P637, DOI 10.1016/S0028-3908(03)00206-5
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   NISHIMURA H, 1991, HISTOCHEMISTRY, V95, P535, DOI 10.1007/BF00266738
   Nusetti S, 2005, NEUROCHEM RES, V30, P1483, DOI 10.1007/s11064-005-8825-9
   Nusetti S, 2009, ADV EXP MED BIOL, V643, P233, DOI 10.1007/978-0-387-75681-3_24
   Obolensky A, 2011, FREE RADICAL BIO MED, V51, P1482, DOI 10.1016/j.freeradbiomed.2011.07.014
   Organisciak D, 2012, PHOTOCHEM PHOTOBIOL, V88, P1396, DOI 10.1111/j.1751-1097.2012.01134.x
   Osborne NN, 2006, INVEST OPHTH VIS SCI, V47, P3178, DOI 10.1167/iovs.05-1370
   Otteson DC, 2004, INVEST OPHTH VIS SCI, V45, P2522, DOI 10.1167/iovs.04-0072
   Overbeck S, 2008, ARCH IMMUNOL THER EX, V56, P15, DOI 10.1007/s00005-008-0003-8
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x
   Park PSH, 2007, J BIOL CHEM, V282, P11377, DOI 10.1074/jbc.M610341200
   Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750
   Permyakov SE, 2003, J PROTEOME RES, V2, P51, DOI 10.1021/pr025553i
   Prasad AS, 2009, J AM COLL NUTR, V28, P257, DOI 10.1080/07315724.2009.10719780
   Qian J, 2005, J PHYSIOL-LONDON, V566, P747, DOI 10.1113/jphysiol.2005.089276
   Redenti S, 2005, VISION RES, V45, P3520, DOI 10.1016/j.visres.2005.07.039
   Redenti S, 2003, BIOL BULL-US, V205, P213, DOI 10.2307/1543258
   Redenti S, 2002, BIOL BULL, V203, P200, DOI 10.2307/1543396
   Redenti S, 2007, MOL MED, V13, P376, DOI 10.2119/2007-00041.Redenti
   Redenti S, 2007, EXP EYE RES, V85, P580, DOI 10.1016/j.exer.2007.07.017
   Ricchelli F., 2011, BIOCH BIOPHYS ACTA, V1807, P482
   Rosenstein FJ, 2003, NEUROSCI LETT, V345, P81, DOI 10.1016/S0304-3940(03)00472-5
   Saghizadeh M, 2009, INVEST OPHTH VIS SCI, V50, P3580, DOI 10.1167/iovs.08-2751
   SAMUELSON DA, 1993, EXP EYE RES, V56, P63, DOI 10.1006/exer.1993.1009
   Satarug S, 2008, EXP EYE RES, V87, P587, DOI 10.1016/j.exer.2008.09.014
   Schippert R, 2007, INVEST OPHTH VIS SCI, V48, P11, DOI 10.1167/iovs.06-0851
   Schmitt S, 2009, HUM MUTAT, V30, P926, DOI 10.1002/humu.20988
   Sekler I, 2012, GLIA, V60, P843, DOI 10.1002/glia.22286
   Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100
   Sharif R, 2012, MUTAT RES-FUND MOL M, V733, P111, DOI 10.1016/j.mrfmmm.2011.08.009
   Sheline CT, 2010, MOL VIS, V16, P2639
   Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000
   Shi Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002084
   Shindler KS, 2000, NEUROREPORT, V11, P2299, DOI 10.1097/00001756-200007140-00046
   Shukolyukov SA, 2013, BIOCHEMISTRY-MOSCOW+, V78, P660, DOI 10.1134/S0006297913060114
   Siapich SA, 2010, CURR EYE RES, V35, P322, DOI 10.3109/02713680903509410
   Smidt K, 2012, BIOMETALS, V25, P1, DOI 10.1007/s10534-011-9490-x
   Sobieszczanska M, 2012, ADV CLIN EXP MED, V21, P245
   Suemori S, 2006, INVEST OPHTH VIS SCI, V47, P3975, DOI 10.1167/iovs.06-0275
   Suh SW, 2009, J CEREBR BLOOD F MET, V29, P1579, DOI 10.1038/jcbfm.2009.80
   Sun Y, 2010, BRAIN RES, V1345, P103, DOI 10.1016/j.brainres.2010.05.033
   Sun Z, 2009, J NEUROPHYSIOL, V101, P1774, DOI 10.1152/jn.90581.2008
   Tamada Y, 2007, CURR EYE RES, V32, P565, DOI 10.1080/02713680701359633
   Tate DJ, 2006, CURR EYE RES, V31, P675, DOI 10.1080/02713680600801024
   Tate DJ, 1999, FREE RADICAL BIO MED, V26, P704, DOI 10.1016/S0891-5849(98)00253-6
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Ugarte M, 2014, METALLOMICS, V6, P274, DOI 10.1039/c3mt00271c
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Ugarte M, 2012, METALLOMICS, V4, P1245, DOI 10.1039/c2mt20157g
   Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6
   Wang X, 2006, BRAIN RES BULL, V71, P91, DOI 10.1016/j.brainresbull.2006.08.002
   Watabe Y, 2011, BIOCHEM BIOPH RES CO, V415, P42, DOI 10.1016/j.bbrc.2011.10.007
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wilson David J, 2002, Trans Am Ophthalmol Soc, V100, P353
   Wilson M, 2012, J BIOL CHEM, V287, P9322, DOI 10.1074/jbc.C111.320796
   Wong CP, 2013, J NUTR BIOCHEM, V24, P353, DOI 10.1016/j.jnutbio.2012.07.005
   Wong CP, 2012, MOL NUTR FOOD RES, V56, P77, DOI 10.1002/mnfr.201100511
   Wood JPM, 2001, ARCH OPHTHALMOL-CHIC, V119, P81
   Xu HB, 2001, BIOL TRACE ELEM RES, V79, P39, DOI 10.1385/BTER:79:1:39
   Yin SJ, 2003, CHEM-BIOL INTERACT, V143, P219, DOI 10.1016/S0009-2797(02)00167-9
   Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhang DQ, 2006, VISUAL NEUROSCI, V23, P825, DOI 10.1017/S0952523806239993
   Zhang DQ, 2002, J NEUROPHYSIOL, V88, P1245, DOI 10.1152/jn.2002.88.3.1245
   Zhang JH, 2004, DEVELOPMENT, V131, P1553, DOI 10.1242/dev.01041
NR 177
TC 33
Z9 33
U1 1
U2 17
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1756-5901
EI 1756-591X
J9 METALLOMICS
JI Metallomics
PY 2014
VL 6
IS 2
BP 189
EP 200
DI 10.1039/c3mt00291h
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AA0PA
UT WOS:000330796100002
PM 24253309
DA 2022-11-30
ER

PT J
AU Forward, H
   Hewitt, AW
   Mackey, DA
AF Forward, Hannah
   Hewitt, Alex W.
   Mackey, David A.
TI Missing X and Y: a review of participant ages in population-based eye
   studies
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE adolescent; blindness; low vision; visual impairment; young adult
ID PAKISTAN NATIONAL BLINDNESS; HEREDITARY OPTIC NEUROPATHY; AMERICAN
   URBAN-POPULATION; CAUSE-SPECIFIC PREVALENCE; VISUAL IMPAIRMENT SURVEY;
   SINGAPORE MALAY EYE; SOUTH-WEST PROVINCE; LOW-VISION; RISK-FACTORS;
   REFRACTIVE ERRORS
AB Ophthalmic population-based studies have been used to establish the frequency of eye disease and the associated environmental and genetic factors that cause vision impairment and blindness. Most of these studies have concentrated on the diseases of ageing: cataract, age-related macular degeneration, glaucoma and diabetic retinopathy. Other studies have identified eye diseases in children but few studies of young adult eye disease exist. We conducted a systematic review of the ophthalmic literature to identify potential population-based eye studies and then note the age of participants in the studies. We then summarized the disease specific to young adults to show there is a need for further research to identify eye disease in this important and often-neglected group in the community. Eighty-four large population-based studies have been conducted worldwide: 9 in North America, 2 in South America, 17 in Africa, 35 in Asia, 11 in Australia and the Pacific, 6 in Europe, 4 in the Middle East and 1 that covered 3 continents. No studies specifically examined young adults. Twenty-six per cent of studies included young adults as part of all ages examined but none of these examined a large number of young adults.
C1 [Forward, Hannah; Mackey, David A.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 Lions Eye Institute; University of Western Australia; Centre for Eye
   Research Australia; Royal Victorian Eye & Ear Hospital; University of
   Melbourne
RP Mackey, DA (通讯作者)，Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, 2 Verdun St, Nedlands, WA 6009, Australia.
EM david.mackey@lei.org.au
RI Hewitt, Alex W/D-1936-2013; Mackey, David A/H-5340-2014
OI Hewitt, Alex W/0000-0002-5123-5999; Mackey, David A/0000-0001-7914-4709
CR Abdull MM, 2009, INVEST OPHTH VIS SCI, V50, P4114, DOI 10.1167/iovs.09-3507
   ABIOSE A, 1994, BRIT J OPHTHALMOL, V78, P8, DOI 10.1136/bjo.78.1.8
   Abraham D I, 1999, Ophthalmic Epidemiol, V6, P85, DOI 10.1076/opep.6.2.85.1560
   Ahmad K, 2005, OPHTHAL EPIDEMIOL, V12, P19, DOI 10.1080/09286580490921304
   Ajaiyeoba A. I., 2005, International Ophthalmology, V26, P121, DOI 10.1007/s10792-005-4836-4
   ALFARAN MF, 1993, INT OPHTHALMOL, V17, P161
   Attebo K, 1999, OPHTHALMOLOGY, V106, P1066, DOI 10.1016/S0161-6420(99)90251-8
   BAASANHU J, 1994, B WORLD HEALTH ORGAN, V72, P771
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   Bourne R, 2005, OPHTHAL EPIDEMIOL, V12, P321, DOI 10.1080/09286580500230948
   Bourne RRA, 2002, OPHTHAL EPIDEMIOL, V9, P119, DOI 10.1076/opep.9.2.119.1520
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6
   Cajucom-Uy H, 2010, BRIT J OPHTHALMOL, V94, P977, DOI 10.1136/bjo.2008.150847
   Casson RJ, 2002, CLIN EXP OPHTHALMOL, V30, P15, DOI 10.1046/j.1442-9071.2002.00484.x
   Casson RJ, 2007, OPHTHALMOLOGY, V114, P2302, DOI 10.1016/j.ophtha.2007.02.004
   CHOW Y C, 1990, SMJ Singapore Medical Journal, V31, P472
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   Dandona L, 2000, CLIN EXP OPHTHALMOL, V28, P350, DOI 10.1046/j.1442-9071.2000.00334.x
   Dandona L, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-6
   Dandona Lalit, 1997, Indian Journal of Ophthalmology, V45, P163
   Dandona R, 1999, INVEST OPHTH VIS SCI, V40, P2810
   Dandona Rakhi, 2001, Indian Journal of Ophthalmology, V49, P215
   Dandona Rakhi, 1997, Indian Journal of Ophthalmology, V45, P251
   DANNENBERG AL, 1992, ARCH OPHTHALMOL-CHIC, V110, P849, DOI 10.1001/archopht.1992.01080180121039
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P592, DOI 10.1136/bjo.80.7.592
   DICKINSON P, 1989, AUST NZ J OPHTHALMOL, V17, P247, DOI 10.1111/j.1442-9071.1989.tb00528.x
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Dineen B, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-17
   Dirani M, 2008, INVEST OPHTH VIS SCI, V49, P3324, DOI 10.1167/iovs.07-1498
   Dunzhu S, 2003, BRIT J OPHTHALMOL, V87, P1443, DOI 10.1136/bjo.87.12.1443
   Durkin SR, 2008, BRIT J OPHTHALMOL, V92, P25, DOI 10.1136/bjo.2007.119842
   Edussuriya K, 2009, OPHTHALMOLOGY, V116, P52, DOI 10.1016/j.ophtha.2008.08.034
   FLEDELIUS HC, 1995, ACTA OPHTHALMOL SCAN, V73, P394
   FONG LP, 1995, MED J AUSTRALIA, V162, P64, DOI 10.5694/j.1326-5377.1995.tb138434.x
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Fotouhi A, 2004, BRIT J OPHTHALMOL, V88, P740, DOI 10.1136/bjo.2003.031153
   Fotouhi A, 2009, EYE, V23, P1125, DOI 10.1038/eye.2008.200
   Fox S, 2010, AUST NZ J PUBL HEAL, V34, P554, DOI 10.1111/j.1753-6405.2010.00635.x
   Friedman DS, 2008, OPHTHALMOLOGY, V115, P1786, DOI 10.1016/j.ophtha.2008.04.006
   Garap JN, 2006, CLIN EXP OPHTHALMOL, V34, P335, DOI 10.1111/j.1442-9071.2006.01219.x
   Gilbert CE, 2008, INVEST OPHTH VIS SCI, V49, P877, DOI 10.1167/iovs.07-0973
   Hammond CJ, 2001, INVEST OPHTH VIS SCI, V42, P1232
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   He MG, 2006, INVEST OPHTH VIS SCI, V47, P2782, DOI 10.1167/iovs.06-0051
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Huang TL, 2010, JPN J OPHTHALMOL, V54, P266, DOI 10.1007/s10384-010-0817-x
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Jacobsen N, 2007, ACTA OPHTHALMOL SCAN, V85, P165, DOI 10.1111/j.1600-0420.2006.00789.x
   Jadoon MZ, 2006, INVEST OPHTH VIS SCI, V47, P4749, DOI 10.1167/iovs.06-0374
   Jonas JB, 2009, AM J OPHTHALMOL, V148, P760, DOI 10.1016/j.ajo.2009.06.024
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Jovanovic M, 2010, VOJNOSANIT PREGL, V67, P983, DOI 10.2298/VSP1012983J
   Kalikivayi Venkataramana, 1997, Indian Journal of Ophthalmology, V45, P129
   Katz J, 1997, INVEST OPHTH VIS SCI, V38, P334
   Khandekar R, 2007, OPHTHAL EPIDEMIOL, V14, P9, DOI 10.1080/09286580600864802
   Kjer B, 1996, ACTA OPHTHALMOL SCAN, V74, P3
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   KLOPFER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P838, DOI 10.1001/archopht.1992.01080180110037
   Kortlang C, 1996, TROP MED INT HEALTH, V1, P314, DOI 10.1046/j.1365-3156.1996.d01-44.x
   Krishnaiah S, 2006, OPHTHALMOLOGY, V113, P1159, DOI 10.1016/j.ophtha.2006.02.020
   Kuhn F, 2006, OPHTHAL EPIDEMIOL, V13, P209, DOI 10.1080/09286580600665886
   Landers J, 2010, CLIN EXP OPHTHALMOL, V38, P375, DOI 10.1111/j.1442-9071.2010.02255.x
   LAWLESS M, 1989, AUST NZ J OPHTHALMOL, V17, P33
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Lewallen S, 2001, BRIT J OPHTHALMOL, V85, P897, DOI 10.1136/bjo.85.8.897
   Li ZJ, 2008, OPHTHAL EPIDEMIOL, V15, P334, DOI 10.1080/09286580802227386
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   Lu P, 2008, CAN J OPHTHALMOL, V43, P95, DOI 10.3129/i07-194
   Lu Q, 2009, AM J OPHTHALMOL, V147, P1075, DOI 10.1016/j.ajo.2008.11.021
   Luthra R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1827, DOI 10.1001/archopht.119.12.1827
   Ma K, 2007, CORNEA, V26, P1184, DOI 10.1097/ICO.0b013e318151f9c6
   MACKEY DA, 1992, AUST NZ J OPHTHALMOL, V20, P177, DOI 10.1111/j.1442-9071.1992.tb00937.x
   Mackey DA, 2009, TWIN RES HUM GENET, V12, P441, DOI 10.1375/twin.12.5.441
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Mansouri MR, 2010, EUR J OPHTHALMOL, V20, P770, DOI 10.1177/112067211002000420
   May DR, 2000, GRAEF ARCH CLIN EXP, V238, P153, DOI 10.1007/PL00007884
   McCarty CA, 2000, BRIT J OPHTHALMOL, V84, P289, DOI 10.1136/bjo.84.3.289
   McGwin G, 2005, ARCH OPHTHALMOL-CHIC, V123, P662, DOI 10.1001/archopht.123.5.662
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moran DJ, 1982, BR J OPHTHALMOL, V68, P343
   Morgan I, 2005, PROG RETIN EYE RES, V24, P1, DOI 10.1016/j.preteyeres.2004.06.004
   Moser CL, 2002, BRIT J OPHTHALMOL, V86, P257, DOI 10.1136/bjo.86.3.257
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P679, DOI 10.1016/S0161-6420(00)00579-0
   Nakamura Y, 2010, OPHTHALMOLOGY, V117, P2315, DOI 10.1016/j.ophtha.2010.03.043
   Nash EA, 1998, ARCH OPHTHALMOL-CHIC, V116, P1222, DOI 10.1001/archopht.116.9.1222
   Ndegwa L K, 2006, East Afr Med J, V83, P69
   Negrel AD, 2000, AM J OPHTHALMOL, V129, P421, DOI 10.1016/S0002-9394(99)00455-9
   NEWLAND HS, 1992, B WORLD HEALTH ORGAN, V70, P369
   NEWLAND HS, 1994, BRIT J OPHTHALMOL, V78, P344, DOI 10.1136/bjo.78.5.344
   Nielsen K, 2007, ACTA OPHTHALMOL SCAN, V85, P890, DOI 10.1111/j.1600-0420.2007.00981.x
   Nirmalan PK, 2003, AM J OPHTHALMOL, V136, P703, DOI 10.1016/S0002-9394(03)00421-5
   Nirmalan PK, 2002, BRIT J OPHTHALMOL, V86, P505, DOI 10.1136/bjo.86.5.505
   Ojaimi E, 2005, OPHTHAL EPIDEMIOL, V12, P59, DOI 10.1080/09286580490921296
   Onakpoya O H, 2007, Tanzan Health Res Bull, V9, P126
   Oye JE, 2006, BRIT J OPHTHALMOL, V90, P538, DOI 10.1136/bjo.2005.082271
   Oye JE, 2007, BRIT J OPHTHALMOL, V91, P1435, DOI 10.1136/bjo.2007.115840
   Panchapakesan J, 1998, AUST NZ J OPHTHALMOL, V26, pS2, DOI 10.1111/j.1442-9071.1998.tb01362.x
   Pokharel GP, 1998, BRIT J OPHTHALMOL, V82, P600, DOI 10.1136/bjo.82.6.600
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   Rabinowitz YS, 1998, SURV OPHTHALMOL, V42, P297, DOI 10.1016/S0039-6257(97)00119-7
   Rabiu M Mansur, 2008, West Afr J Med, V27, P238
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Ramke J, 2007, BRIT J OPHTHALMOL, V91, P1117, DOI 10.1136/bjo.2006.106559
   Reeves SW, 2009, CORNEA, V28, P40, DOI 10.1097/ICO.0b013e3181839b06
   Reeves SW, 2005, AM J OPHTHALMOL, V140, P607, DOI 10.1016/j.ajo.2005.05.029
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   Robaei D, 2005, OPHTHALMOLOGY, V112, P1275, DOI 10.1016/j.ophtha.2005.01.052
   Rose KA, 2008, OPHTHALMOLOGY, V115, P1279, DOI 10.1016/j.ophtha.2007.12.019
   Rutzen AR, 2007, OPHTHAL EPIDEMIOL, V14, P360, DOI 10.1080/01658100701436033
   Salomao SR, 2008, OPHTHAL EPIDEMIOL, V15, P167, DOI 10.1080/09286580701843812
   Sapkota YD, 2006, BRIT J OPHTHALMOL, V90, P411, DOI 10.1136/bjo.2005.082503
   Schellini SA, 2009, OPHTHAL EPIDEMIOL, V16, P90, DOI 10.1080/09286580902737524
   Schemann JF, 2006, OPHTHAL EPIDEMIOL, V13, P219, DOI 10.1080/09286580600681347
   Schwartz EC, 1997, BRIT J OPHTHALMOL, V81, P443, DOI 10.1136/bjo.81.6.443
   Seet B, 2001, BRIT J OPHTHALMOL, V85, P521, DOI 10.1136/bjo.85.5.521
   Shahriari HA, 2007, BRIT J OPHTHALMOL, V91, P579, DOI 10.1136/bjo.2006.105734
   Tarczy-Hornoch K, 2009, OPHTHALMOLOGY, V116, p[e1, 1990]
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1481, DOI 10.1001/archopht.1989.01070020555039
   TAYLOR HR, 1981, AM J EPIDEMIOL, V113, P62, DOI 10.1093/oxfordjournals.aje.a113067
   Taylor HR, 2003, T AM OPHTHAL SOC, V101, P10
   Taylor Hugh R, 2003, Trans Am Ophthalmol Soc, V101, P107
   Taylor HR, 2010, MED J AUSTRALIA, V192, P312, DOI 10.5694/j.1326-5377.2010.tb03529.x
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   Thulasiraj RD, 2002, OPHTHALMIC EPIDEMIOL, V9, P299, DOI 10.1076/opep.9.5.299.10334
   THYLEFORS B, 1992, AUST NZ J OPHTHALMOL, V20, P95, DOI 10.1111/j.1442-9071.1992.tb00718.x
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Turacli M E, 1995, Eur J Ophthalmol, V5, P181
   US Census Bureau, WORLD POP AG SEX
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2006, OPHTHAL EPIDEMIOL, V13, P253, DOI 10.1080/09286580600719055
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
   Wedner SH, 2000, BRIT J OPHTHALMOL, V84, P1291, DOI 10.1136/bjo.84.11.1291
   Wensor M, 1999, ARCH OPHTHALMOL-CHIC, V117, P658
   WHITFIELD R, 1990, BRIT J OPHTHALMOL, V74, P333, DOI 10.1136/bjo.74.6.333
   Wilson M R, 1996, Ophthalmic Epidemiol, V3, P23, DOI 10.3109/09286589609071598
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P73
   Wu HM, 2001, OPTOMETRY VISION SCI, V78, P234, DOI 10.1097/00006324-200104000-00012
   Wu SY, 1999, INVEST OPHTH VIS SCI, V40, P2179
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   Yu-Wai-Man P, 2010, OPHTHALMOLOGY, V117, P1538, DOI 10.1016/j.ophtha.2009.12.038
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
   Zerihun N, 1997, Ophthalmic Epidemiol, V4, P19
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
NR 155
TC 8
Z9 8
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD APR
PY 2012
VL 40
IS 3
BP 305
EP 319
DI 10.1111/j.1442-9071.2011.02626.x
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 923HD
UT WOS:000302609400012
PM 21668774
DA 2022-11-30
ER

PT J
AU Oettl, K
   Reibnegger, G
   Schmut, O
AF Oettl, Karl
   Reibnegger, Gilbert
   Schmut, Otto
TI The redox state of human serum albumin in eye diseases with and without
   complications
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE cataract; diabetes mellitus; mercaptalbumin; oxidative stress;
   retinopathy; thiol groups
ID OPEN-ANGLE GLAUCOMA; OXIDATIVE STRESS; MACULAR DEGENERATION;
   LIPID-PEROXIDATION; DIABETES-MELLITUS; SULFENIC ACID; HUMAN PLASMA;
   PROTEIN; DAMAGE; GLUTATHIONE
AB Purpose: To investigate the redox state of human serum albumin concerning cysteine-34 as a possible systemic redox marker in patients with different eye diseases with and without complications and with consideration of possible effects of age.
   Methods: Cataract (CAT), glaucoma, age-related macular degeneration (AMD), diabetes mellitus (DM), diabetic retinopathy and hypertension were the pathologies investigated. Albumin redox state concerning cysteine-34 was measured by high-performance liquid chromatography with fluorescence detection. The separation gives three fractions: the fully reduced form containing a thiol group, the disulphide form and a higher oxidized form. Statistical analysis was done by Student's t-test, analysis of variance and stepwise regression analysis.
   Results: Albumin as a systemic marker for oxidative stress was shifted to a more oxidized state by DM. An even stronger shift to the oxidized form was observed in patients with proliferative diabetic retinopathy. Notably, these effects were independent from age. In contrast, CAT and AMD had no influence on serum albumin redox state.
   Conclusion: Serum albumin is not shifted to more oxidized forms by localized oxidative stress, but it is in systemic diseases like DM.
C1 [Oettl, Karl; Reibnegger, Gilbert] Med Univ Graz, Inst Physiol Chem, Ctr Physiol Med, A-8010 Graz, Austria.
   [Schmut, Otto] Med Univ Graz, Univ Eye Hosp, A-8010 Graz, Austria.
C3 Medical University of Graz; Medical University of Graz
RP Oettl, K (通讯作者)，Med Univ Graz, Inst Physiol Chem, Ctr Physiol Med, Harrachgasse 21-2, A-8010 Graz, Austria.
EM karl.oettl@meduni-graz.at
RI Reibnegger, Gilbert/H-5742-2012
OI Reibnegger, Gilbert/0000-0001-7202-2426; Oettl, Karl/0000-0001-9792-5760
FU Franz-Lanyar-Stiftung [314]
FX The excellent technical assistance of Martina Brtnik, Martin Puhl,
   Susanne Neuhold, Gabriele Trummer and Christa Wachswender is highly
   appreciated. This work was financially supported by the
   Franz-Lanyar-Stiftung (Project # 314).
CR Altomare E, 1997, EUR J CLIN INVEST, V27, P141, DOI 10.1046/j.1365-2362.1997.780629.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carballal S, 2007, AMINO ACIDS, V32, P543, DOI 10.1007/s00726-006-0430-y
   Carballal S, 2003, BIOCHEMISTRY-US, V42, P9906, DOI 10.1021/bi027434m
   Delles C, 2008, ANTIOXID REDOX SIGN, V10, P1061, DOI 10.1089/ars.2007.2008
   ERA S, 1995, BBA-PROTEIN STRUCT M, V1247, P12, DOI 10.1016/0167-4838(94)00166-E
   ERA S, 1988, INT J PEPT PROT RES, V31, P435
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Giustarini D, 2006, J GERONTOL A-BIOL, V61, P1030, DOI 10.1093/gerona/61.10.1030
   Grattagliano I, 1998, FREE RADICAL BIO MED, V25, P369, DOI 10.1016/S0891-5849(98)00059-8
   Gupta Madhur M, 2005, Indian J Physiol Pharmacol, V49, P187
   Hartnett ME, 2000, DIABETES CARE, V23, P234, DOI 10.2337/diacare.23.2.234
   Hayashi T., 2000, PATHOPHYSIOLOGY, V6, P237, DOI [10.1016/S0928-4680(99)00022-X, DOI 10.1016/S0928-4680(99)00022-X]
   Hortin GL, 2006, CLIN CHEM, V52, P2258, DOI 10.1373/clinchem.2006.074302
   Imai H, 2002, JPN J PHYSIOL, V52, P135, DOI 10.2170/jjphysiol.52.135
   JENNINGS PE, 1991, DIABETIC MED, V8, P860, DOI 10.1111/j.1464-5491.1991.tb02125.x
   Jones DP, 2006, REJUV RES, V9, P169, DOI 10.1089/rej.2006.9.169
   Kawai K, 2001, Tokai J Exp Clin Med, V26, P93
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kumar DM, 2007, J GLAUCOMA, V16, P334
   Lamprecht M, 2008, J APPL PHYSIOL, V104, P1611, DOI 10.1152/japplphysiol.01325.2007
   Lou MF, 2003, PROG RETIN EYE RES, V22, P657, DOI 10.1016/S1350-9462(03)00050-8
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Oettl K, 2008, BBA-MOL BASIS DIS, V1782, P469, DOI 10.1016/j.bbadis.2008.04.002
   Peters T., 1995, ALL ALBUMIN BIOCH GE, P9, DOI [10.1016/B978-012552110-9/50004-0, DOI 10.1016/B978-012552110-9/50004-0]
   Rasheed Z, 2006, LIFE SCI, V79, P2320, DOI 10.1016/j.lfs.2006.07.041
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   SIES H, 1991, AM J MED, V91, pS31, DOI 10.1016/0002-9343(91)90281-2
   SUZUKI E, 1992, DIABETES RES CLIN PR, V18, P153, DOI 10.1016/0168-8227(92)90140-M
   THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   Yanai H, 2008, NUTR J, V7, DOI 10.1186/1475-2891-7-10
   Yildirim O, 2005, EYE, V19, P580, DOI 10.1038/sj.eye.6701565
NR 36
TC 26
Z9 27
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2011
VL 89
IS 2
BP E174
EP E179
DI 10.1111/j.1755-3768.2009.01824.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 725RV
UT WOS:000287664700012
PM 20064117
OA Bronze
DA 2022-11-30
ER

PT J
AU Cumurcu, T
   Kilic, R
   Yologlu, S
AF Cumurcu, Tongabay
   Kilic, Rasit
   Yologlu, Saim
TI The frequency of pseudoexfoliation syndrome in the middle Black Sea
   region of Turkey
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Cataract; Glaucoma; Phacodenesis; Pseudoexfoliation
ID POPULATION-BASED SURVEY; EXFOLIATION SYNDROME; INTRAOCULAR-PRESSURE;
   MACULAR DEGENERATION; PSEUDO-EXFOLIATION; CRETE GREECE; PREVALENCE; EYE;
   LENS; GLAUCOMA
AB PURPOSE. To assess the frequency of pseudoexfoliation syndrome (PEX) and evaluate its association with specific ocular diseases in patients attending the Department of Ophthalmology at Gaziosmanpasa University Hospital.
   METHODS. A prospective study was conducted at the Gaziosmanpasa University Hospital between December 2007 and December 2008. A total of 831 subjects aged 45 or above attending the general ophthalmic clinics were recruited for this study. Each patient underwent complete ophthalmic assessment, including ocular history, visual acuity testing, slit-lamp examination, applanation tonometry, gonioscopy, and fundus examination.
   RESULTS. Of the 831 subjects, 12.2% had PEX. Pseudoexfoliation was bilateral in 74.2% of cases, significantly associated with cataract, glaucoma, age-related macular degeneration (AMD), and phacodenesis. Of the patients with PEX, 43.6% had cataract, 6.9% had glaucoma, 7.9% had AMD, and 0.9% had phacodenesis. In addition, 9.8% had cataract + glaucoma, 13.7% had cataract + phacodenesis, and 17.8% had all of them. The prevalence of PEX had a tendency to increase with age but had no sex predilection.
   CONCLUSIONS. The study findings enhance our knowledge of PEX in Anatolia, particularly in the Middle Black Sea region.
C1 [Cumurcu, Tongabay] Inonu Univ, Sch Med, Dept Ophthalmol, Malatya, Turkey.
   [Kilic, Rasit] Gaziosmanpasa Univ, Sch Med, Dept Ophthalmol, Tokat, Turkey.
   [Yologlu, Saim] Inonu Univ, Sch Med, Dept Biostat, Malatya, Turkey.
C3 Inonu University; Gaziosmanpasa University; Inonu University
RP Cumurcu, T (通讯作者)，Inonu Univ, Sch Med, Dept Ophthalmol, Malatya, Turkey.
EM tongabay@superonline.com
RI Kılıç, Raşit/AAP-6844-2021; Yologlu, Saim/ABI-8014-2020
OI Yologlu, Saim/0000-0002-9619-3462; Kilic, Rasit/0000-0001-6671-9067
CR Al-Bdour MD, 2008, ACTA OPHTHALMOL, V86, P755, DOI 10.1111/j.1755-3768.2008.01258.x
   Arnarsson A, 2007, ACTA OPHTHALMOL SCAN, V85, P822, DOI 10.1111/j.1600-0420.2007.01051.x
   Arvind H, 2003, BRIT J OPHTHALMOL, V87, P1321, DOI 10.1136/bjo.87.11.1321
   FAULKNER HW, 1971, AM J OPHTHALMOL, V72, P206, DOI 10.1016/0002-9394(71)91616-3
   FORSIUS H, 1979, T OPHTHAL SOC UK, V99, P296
   Forsius H, 1988, Acta Ophthalmol Suppl, V184, P71
   Forsman E, 2007, ACTA OPHTHALMOL SCAN, V85, P500, DOI 10.1111/j.1600-0420.2007.00978.x
   HILLER R, 1982, ARCH OPHTHALMOL-CHIC, V100, P1080
   Kling F, 2001, J FR OPHTALMOL, V24, P7
   KOZART DM, 1982, OPHTHALMOLOGY, V89, P214
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Kozobolis VP, 1997, ACTA OPHTHALMOL SCAN, V75, P726
   Kuchle M, 1997, BRIT J OPHTHALMOL, V81, P862, DOI 10.1136/bjo.81.10.862
   Lamba P A, 1984, Indian J Ophthalmol, V32, P169
   Mitchell P, 1999, ARCH OPHTHALMOL-CHIC, V117, P1319, DOI 10.1001/archopht.117.10.1319
   Naumann GOH, 1998, OPHTHALMOLOGY, V105, P951, DOI 10.1016/S0161-6420(98)96020-1
   Nouri-Mahdavi K, 1999, ACTA OPHTHALMOL SCAN, V77, P581, DOI 10.1034/j.1600-0420.1999.770521.x
   Rao Rashad Qamar, 2006, BMC Ophthalmol, V6, P27, DOI 10.1186/1471-2415-6-27
   RINGVOLD A, 1991, ACTA OPHTHALMOL, V69, P273
   Ritch R, 1994, J Glaucoma, V3, P176
   Ritch R, 2007, ACTA OPHTHALMOL SCAN, V85, P495, DOI 10.1111/j.1600-0420.2007.00961.x
   SELAND JH, 1982, T OPHTHAL SOC UK, V102, P375
   STEFANIOTOU M, 1990, ACTA OPHTHALMOL, V68, P307
   Thomas R, 2005, INVEST OPHTH VIS SCI, V46, P1170, DOI 10.1167/iovs.04-1062
   YALAZ M, 1992, ACTA OPHTHALMOL, V70, P209
   Young AL, 2004, BRIT J OPHTHALMOL, V88, P193, DOI 10.1136/bjo.2003.021816
NR 26
TC 10
Z9 10
U1 0
U2 3
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2010
VL 20
IS 6
BP 1007
EP 1011
DI 10.1177/112067211002000621
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 661UW
UT WOS:000282754900006
PM 20544680
DA 2022-11-30
ER

PT J
AU Cruciani, F
   Abdolrahimzadeh, S
   Vicari, A
   Amore, FM
   Di Pillo, S
   Mazzeo, L
AF Cruciani, F.
   Abdolrahimzadeh, S.
   Vicari, A.
   Amore, F. M.
   Di Pillo, S.
   Mazzeo, L.
TI Causes of blind certification in an Italian Province and Comparison with
   other European Countries
SO CLINICA TERAPEUTICA
LA English
DT Article
DE blindness; age related macular degeneration; glaucoma; cataract;
   diabetic retinopathy; epidemiology
ID AGE-RELATED MACULOPATHY; VISUAL IMPAIRMENT; MACULAR DEGENERATION;
   ADULT-POPULATION; LOW-VISION; PREVALENCE; REGISTRATION; GERMANY; TRENDS;
   EYE
AB Purpose. Low vision and blindness are significantly growing both industrialized and developing countries. In Italy there are epidemiological studies that provide data on this phenomenon. In paper we report the main causes of blindness and the of the subjects who obtained a disability certification due to in an Italian province.
   Materials and Methods. Disability certificates issued by the Blind Provincial Commission of the Viterbo province over a period (2002-2003) were analysed. The causes of blindness and the of occurrence were investigated and divided into 12 groups.
   Results. The four most frequent causes of blindness were related macular degeneration (19%), cataract (14%), glaucoma (15%) and diabetic retinopathy (15%). The main eye pathology which caused partial blindness was age related macular degeneration (22.3%). Glaucoma (19.6%) was the main cause of total blindness.
   Conclusions. The estimates of blindness were based on certification for visual impairment with limited characteristics as our data was exclusively administrative. However, a general appraisal of the magnitude and causes of visual impairment was determined. This is important towards planning appropriate preventive and management measures. Clin Ter 2010; 161(1):e11-e16
C1 [Cruciani, F.] Univ Roma La Sapienza, Policlin Umberto I, Dipartimento Sci Oftalmol, I-00161 Rome, Italy.
   [Vicari, A.; Amore, F. M.; Di Pillo, S.] IAPB, Italian Branch, Rome, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome
RP Cruciani, F (通讯作者)，Univ Roma La Sapienza, Policlin Umberto I, Dipartimento Sci Oftalmol, Viale Policlin 155, I-00161 Rome, Italy.
EM filippo.cruciani@tin.it
CR Bamashmus MA, 2004, EYE, V18, P257, DOI 10.1038/sj.eye.6700606
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Canavan YM, 1997, ULSTER MED J, V66, P92
   Cedrone C, 2006, EYE, V20, P661, DOI 10.1038/sj.eye.6701934
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   CEDRONE C, 1997, MINERVA OFTALMOL, V39, P67
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Farber MD, 2003, OPHTHAL EPIDEMIOL, V10, P267, DOI 10.1076/opep.10.4.267.15910
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88
   *ISTAT NAT I STAT, 1999, COND SAL FATT RISCH
   *ISTAT NAT I STAT, 2001, TRATT PENS 1999
   *ISTAT NAT I STAT, POP RES IT 2005
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415
   Kumar N, 2006, EYE, V20, P455, DOI 10.1038/sj.eye.6701908
   Lafuma A, 2006, PHARMACOECONOMICS, V24, P193, DOI 10.2165/00019053-200624020-00007
   Munier A, 1998, BRIT J OPHTHALMOL, V82, P630, DOI 10.1136/bjo.82.6.630
   NICOLOSI A, 1994, INT J EPIDEMIOL, V23, P359, DOI 10.1093/ije/23.2.359
   Nucci C, 2005, EYE, V19, P175, DOI 10.1038/sj.eye.6701444
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   PORTA M, 1995, DIABETIC MED, V12, P355, DOI 10.1111/j.1464-5491.1995.tb00492.x
   Poulsen PB, 2005, INT C SERIES, V1282, P262
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P395
   Thylefors B, 1995, Ophthalmic Epidemiol, V2, P5, DOI 10.3109/09286589509071448
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   *WHO, 199761REV2000 WHO
   ZAPELLONI A, 1993, B OCUL, V72, P993
NR 33
TC 4
Z9 4
U1 0
U2 0
PU SOC EDITRICE UNIV
PI ROME
PA VIA G B MORGAGNI 1, ROME, 10061, ITALY
SN 0009-9074
EI 1972-6007
J9 CLIN TER
JI Clin. Ter.
PD JAN-FEB
PY 2010
VL 161
IS 1
BP E11
EP E16
PG 6
WC Medicine, General & Internal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 572JW
UT WOS:000275829000020
PM 20544148
DA 2022-11-30
ER

PT J
AU Lee, H
   Lee, HY
   Chae, JB
   Park, CW
   Kim, C
   Ryu, JH
   Jang, J
   Kim, N
   Chung, H
AF Lee, Hyungwoo
   Lee, Ho-Yeon
   Chae, Jae-Byoung
   Park, Chul-Woo
   Kim, Chaekyu
   Ryu, Ja-Hyoung
   Jang, Jiwon
   Kim, Namshin
   Chung, Hyewon
TI Single-cell transcriptome of the mouse retinal pigment epithelium in
   response to a low-dose of doxorubicin
SO COMMUNICATIONS BIOLOGY
LA English
DT Article
ID RPE CELLS; SENESCENCE; AGE; HETEROGENEITY; MECHANISMS; EXPRESSION;
   APOPTOSIS; MIGRATION; TRIGGERS; DISEASE
AB Single cell transcriptomics pinpoints a cell subpopulation that could be involved in inducing cellular senescence of the retinal pigment epithelium, which in turn may construe retinal degenerative disease.
   Cellular senescence of the retinal pigment epithelium (RPE) is thought to play an important role in vision-threatening retinal degenerative diseases, such as age-related macular degeneration (AMD). However, the single-cell RNA profiles of control RPE tissue and RPE tissue exhibiting cellular senescence are not well known. We have analyzed the single-cell transcriptomes of control mice and mice with low-dose doxorubicin (Dox)-induced RPE senescence (Dox-RPE). Our results have identified 4 main subpopulations in the control RPE that exhibit heterogeneous biological activities and play roles in ATP synthesis, cell mobility/differentiation, mRNA processing, and catalytic activity. In Dox-RPE mice, cellular senescence mainly occurs in the specific cluster, which has been characterized by catalytic activity in the control RPE. Furthermore, in the Dox-RPE mice, 6 genes that have not previously been associated with senescence also show altered expression in 4 clusters. Our results might serve as a useful reference for the study of control and senescent RPE.
C1 [Lee, Hyungwoo; Chae, Jae-Byoung; Park, Chul-Woo; Chung, Hyewon] Konkuk Univ, Dept Ophthalmol, Sch Med, Seoul, South Korea.
   [Lee, Hyungwoo; Chung, Hyewon] Konkuk Univ, Dept Ophthalmol, Med Ctr, Seoul, South Korea.
   [Lee, Ho-Yeon; Kim, Namshin] Korea Res Inst Biosci & Biotechnol, Genome Editing Res Ctr, Daejeon, South Korea.
   [Lee, Ho-Yeon; Kim, Namshin] Univ Sci & Technol UST, KRIBB Sch Biosci, Dept Bioinformat, Daejeon, South Korea.
   [Kim, Chaekyu] Fus Biotechnol Inc, Ulsan 44919, South Korea.
   [Ryu, Ja-Hyoung] Ulsan Natl Inst Sci & Technol, Dept Chem, Ulsan, South Korea.
   [Jang, Jiwon] Pohang Univ Sci & Technol POSTECH, Dept Life Sci, Pohang, South Korea.
   [Jang, Jiwon] Yonsei Univ, Inst Convergence Sci, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center; Konkuk University;
   Konkuk University Medical Center; Korea Research Institute of Bioscience
   & Biotechnology (KRIBB); University of Science & Technology (UST); Ulsan
   National Institute of Science & Technology (UNIST); Pohang University of
   Science & Technology (POSTECH); Yonsei University
RP Chung, H (通讯作者)，Konkuk Univ, Dept Ophthalmol, Sch Med, Seoul, South Korea.; Chung, H (通讯作者)，Konkuk Univ, Dept Ophthalmol, Med Ctr, Seoul, South Korea.; Kim, N (通讯作者)，Korea Res Inst Biosci & Biotechnol, Genome Editing Res Ctr, Daejeon, South Korea.; Kim, N (通讯作者)，Univ Sci & Technol UST, KRIBB Sch Biosci, Dept Bioinformat, Daejeon, South Korea.
EM n@rna.kr; hchung@kuh.ac.kr
RI ; Ryu, Ja-Hyoung/B-9566-2012
OI Chung, Hyewon/0000-0003-1312-6406; Ryu, Ja-Hyoung/0000-0003-0252-0985
FU National Research Foundation of Korea; Ministry of Science and ICT
   [NRF-2020M3A9D8038188, NRF-2019M3A9H1030948, NRF-2020R1A2C2101941]
FX This study was supported by the National Research Foundation of Korea
   and funded by the Ministry of Science and ICT (NRF-2020M3A9D8038188,
   NRF-2019M3A9H1030948, and NRF-2020R1A2C2101941).
CR Altieri P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046126
   Andrews TS, 2018, MOL ASPECTS MED, V59, P114, DOI 10.1016/j.mam.2017.07.002
   Baxter LL, 2003, GENE EXPR PATTERNS, V3, P703, DOI 10.1016/j.modgep.2003.07.002
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Boles NC, 2020, STEM CELL REP, V14, P631, DOI 10.1016/j.stemcr.2020.03.009
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   BURKE JM, 1988, INVEST OPHTH VIS SCI, V29, P1784
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Chae JB, 2021, GEROSCIENCE, V43, P2809, DOI [10.1007/s11357-021-00457-4, 10.1371/journal.pone.0101072, 10.3390/ijms21228840]
   Cheng XR, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00065
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Deng Y, 2019, NAT METHODS, V16, P311, DOI 10.1038/s41592-019-0353-7
   DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Franzen O, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz046
   Frohlich E, 2001, GRAEF ARCH CLIN EXP, V239, P25, DOI 10.1007/s004170000218
   Gao N, 2017, AM J PHYSIOL-LUNG C, V312, P1669, DOI 10.1152/ajplung.00516.2016
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Guccini I, 2021, CANCER CELL, V39, P68, DOI 10.1016/j.ccell.2020.10.012
   Guidi N, 2017, EMBO J, V36, P840, DOI 10.15252/embj.201694969
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Heller JP, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00449
   Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148
   Hwang B, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0071-8
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Kondo T, 2001, EXP GERONTOL, V36, P487, DOI 10.1016/S0531-5565(00)00256-4
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Labbadia J, 2015, ANNU REV BIOCHEM, V84, P435, DOI 10.1146/annurev-biochem-060614-033955
   Lidgerwood GE, 2021, GENOM PROTEOM BIOINF, V19, P223, DOI 10.1016/j.gpb.2020.08.002
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Rea IM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00586
   Seah S, 2018, EXP CELL RES, V370, P283, DOI 10.1016/j.yexcr.2018.06.029
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Sonoi R, 2017, J BIOSCI BIOENG, V124, P227, DOI 10.1016/j.jbiosc.2017.03.008
   Soto-Gamez A, 2019, J MOL BIOL, V431, P2629, DOI 10.1016/j.jmb.2019.05.036
   Spallarossa P, 2009, AM J PHYSIOL-HEART C, V297, pH2169, DOI 10.1152/ajpheart.00068.2009
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tian LF, 2015, GENOMICS, V105, P253, DOI 10.1016/j.ygeno.2015.01.008
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Wang S, 2021, PROTEIN CELL, V12, P889, DOI 10.1007/s13238-020-00791-x
   Whitmore SS, 2014, EXP EYE RES, V129, P93, DOI 10.1016/j.exer.2014.11.001
NR 47
TC 0
Z9 0
U1 3
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2399-3642
J9 COMMUN BIOL
JI Commun. Biol.
PD JUL 20
PY 2022
VL 5
IS 1
AR 722
DI 10.1038/s42003-022-03676-3
PG 11
WC Biology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Science & Technology - Other
   Topics
GA 3B9JA
UT WOS:000828249900003
PM 35859009
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xie, XY
   Li, D
   Cui, YQ
   Xie, TH
   Cai, JP
   Yao, Y
AF Xie, Xinyi
   Li, Duo
   Cui, Yuqing
   Xie, Tianhua
   Cai, Jiping
   Yao, Yong
TI Decorin Protects Retinal Pigment Epithelium Cells from Oxidative Stress
   and Apoptosis via AMPK-mTOR-Regulated Autophagy
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID MACULAR DEGENERATION; DAMAGE; RPE; INFLAMMATION; REFORMATION;
   EXPRESSION; GROWTH
AB Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss among the elderly worldwide with unidentified pathogenesis and limited therapeutic options. Oxidative stress-induced damage to the retinal pigment epithelium (RPE) is central in the development and progression of AMD. Decorin (DCN), a small leucine-rich proteoglycan, possesses powerful antifibrotic, anti-inflammatory, and antiangiogenic properties. DCN has also been reported to serve a cytoprotective role in various cell types, but its protective effects against H2O2-induced oxidative stress and apoptosis in ARPE-19 cells remain unclear. In this study, we showed that DCN significantly attenuated the increase in cell viability loss, apoptosis rate, and reactive oxygen species (ROS) levels in ARPE-19 cells induced by H2O2. Furthermore, DCN activated the AMPK/mTOR pathway to promote autophagy while genetic inhibition of autophagy-related gene 5 (ATG5) hindered autophagic process and diminished the protective role of DCN against oxidative stress in ARPE-19 cells. Collectively, these results suggest that DCN could protect RPE cells from H2O2-induced oxidative stress and apoptosis via autophagy promotion, thus providing the therapeutic potential for AMD prevention and treatment.
C1 [Xie, Xinyi; Li, Duo; Cui, Yuqing; Xie, Tianhua; Cai, Jiping; Yao, Yong] Nanjing Med Univ, Dept Ophthalmol, Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China.
C3 Jiangnan University; Nanjing Medical University
RP Yao, Y (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China.
EM yaoyongnjmu@126.com
FU Wuxi Taihu Lake Talent Plan, Supports for Leading Talents in Medical and
   Health Profession [2020-THRCTD-1]
FX This work was supported by grants from the Wuxi Taihu Lake Talent Plan,
   Supports for Leading Talents in Medical and Health Profession (no.
   2020-THRCTD-1).
CR Ahmed Z, 2014, NEUROBIOL DIS, V64, P163, DOI 10.1016/j.nbd.2013.12.008
   Alan C, 2011, ARCH MED SCI, V7, P211, DOI 10.5114/aoms.2011.22069
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Burlacu A, 2003, J CELL MOL MED, V7, P249, DOI 10.1111/j.1582-4934.2003.tb00225.x
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x
   Di Mambro VM, 2003, J PHARMACEUT BIOMED, V32, P97, DOI 10.1016/S0731-7085(03)00055-4
   Du SS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0224251
   Du ZJ, 2019, J CELL BIOCHEM, V120, P10413, DOI 10.1002/jcb.28326
   Ferdous Z, 2007, J BIOL CHEM, V282, P35887, DOI 10.1074/jbc.M705180200
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Gawel Stefan, 2004, Wiad Lek, V57, P453
   Ge YX, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.697281
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Goyal A, 2014, MATRIX BIOL, V34, P46, DOI 10.1016/j.matbio.2013.12.011
   Gubbiotti MA, 2015, MATRIX BIOL, V48, P14, DOI 10.1016/j.matbio.2015.09.001
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hu XD, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01590-0
   Iozzo RV, 2011, BIOL EXTRACELL MATR, P197, DOI 10.1007/978-3-642-16555-9_6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Ju WB, 2015, INT J CLIN EXP MED, V8, P13347
   Kannan, 2000, Pathophysiology, V7, P153, DOI 10.1016/S0928-4680(00)00053-5
   Karimi P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082949
   Kauppinen A, 2020, CELL MOL LIFE SCI, V77, P779, DOI 10.1007/s00018-019-03418-5
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Matsushita M, 2007, J BIOL CHEM, V282, P6763, DOI 10.1074/jbc.M609876200
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Neill T, 2017, J BIOL CHEM, V292, P16211, DOI 10.1074/jbc.M116.769950
   Ozay R, 2017, WORLD NEUROSURG, V97, P407, DOI 10.1016/j.wneu.2016.09.115
   Rong YG, 2011, P NATL ACAD SCI USA, V108, P7826, DOI 10.1073/pnas.1013800108
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Tang Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.453
   Winkler BS, 1999, MOL VIS, V5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yao T, 2016, FEBS OPEN BIO, V6, P707, DOI 10.1002/2211-5463.12076
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang TW, 2021, J ORTHOP RES, V39, P1777, DOI 10.1002/jor.24882
   Zhang XF, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108599
   Zhang ZY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2896036
   Zhao X, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2524174
NR 51
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD MAR 29
PY 2022
VL 2022
AR 3955748
DI 10.1155/2022/3955748
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 2T8VH
UT WOS:000822745300005
PM 35391926
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Droho, S
   Cuda, CM
   Perlman, H
   Lavine, JA
AF Droho, Steven
   Cuda, Carla M.
   Perlman, Harris
   Lavine, Jeremy A.
TI Macrophage-derived interleukin-6 is necessary and sufficient for
   choroidal angiogenesis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NEOVASCULARIZATION; RANIBIZUMAB; INHIBITION; PROPRANOLOL; ATTENUATION
AB Neovascular age-related macular degeneration (nAMD) commonly causes vision loss from aberrant angiogenesis, termed choroidal neovascularization (CNV). Interleukin-6 (IL6) is a pro-inflammatory and pro-angiogenic cytokine that is correlated with AMD progression and nAMD activity. We hypothesize that anti-IL6 therapy is a potential nAMD therapeutic. We found that IL6 levels were increased after laser injury and expressed by macrophages. Il6-deficiency decreased laser-induced CNV area and exogenous IL6 addition increased choroidal sprouting angiogenesis. Il6-null mice demonstrated equally increased macrophage numbers as wildtype mice. At steady state, IL6R expression was detected on peripheral blood and ocular monocytes. After laser injury, the number of IL6R(+)Ly6C(+) monocytes in blood and IL6R(+) macrophages in the eye were increased. In human choroid, macrophages expressed IL6, IL6R, and IL6ST. Furthermore, IL6R(+) macrophages displayed a transcriptional profile consistent with STAT3 (signal transducer and activator of transcription 3) activation and angiogenesis. Our data show that IL6 is both necessary and sufficient for choroidal angiogenesis. Macrophage-derived IL6 may stimulate choroidal angiogenesis via classical activation of IL6R(+) macrophages, which then stimulate angiogenesis. Targeting IL6 or the IL6R could be an effective adjunctive therapy for treatment-resistant nAMD patients.
C1 [Droho, Steven; Lavine, Jeremy A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Cuda, Carla M.; Perlman, Harris] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Rheumatol, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine
RP Lavine, JA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
EM jeremy.lavine@northwestern.edu
OI Lavine, Jeremy/0000-0002-0884-1336
FU Lupus Research Alliance Novel Research Grant; Rheumatology Research
   Foundation Innovative Research Award; Northwestern University Dixon
   Translational Research Grant; NIH [AR064546, HL134375, AG049665,
   UH2AR067687, K08 EY030923]; United States-Israel Binational Science
   Foundation [2013247]; Rheumatology Research Foundation; Research to
   Prevent Blindness Sybil B. Harrington Career Development; Research to
   Prevent Blindness; CCSG [P30 CA060553]; Robert H Lurie Comprehensive
   Cancer Center; Northwestern University Research Histology and
   Phenotyping Laboratory [NCI P30-CA060553]
FX CMC was supported by a Lupus Research Alliance Novel Research Grant, a
   Rheumatology Research Foundation Innovative Research Award, and a
   Northwestern University Dixon Translational Research Grant Initiative
   Award. HP was supported by NIH grant AR064546, HL134375, AG049665,
   UH2AR067687, the United States-Israel Binational Science Foundation
   (2013247), and the Rheumatology Research Foundation (Agmt 05/06/14). HP
   was also supported by the Mabel Greene Myers Professor of Medicine and
   generous donations to the Rheumatology Precision Medicine Fund. JAL was
   supported by NIH grant K08 EY030923 and the Research to Prevent
   Blindness Sybil B. Harrington Career Development Award for Macular
   Degeneration. This study was supported by an Unrestricted Departmental
   Grant from Research to Prevent Blindness. Imaging work was performed at
   the Northwestern University Center for Advanced Microscopy generously
   supported by CCSG P30 CA060553 awarded to the Robert H Lurie
   Comprehensive Cancer Center. RNA Scope and immunohistochemistry services
   were provided by the Northwestern University Research Histology and
   Phenotyping Laboratory which is supported by NCI P30-CA060553 awarded to
   the Robert H Lurie Comprehensive Cancer Center. No funding body had any
   role in the design of the study, collection, analysis, interpretation of
   data, or in writing the manuscript.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Cabral T., 2017, INT J RETINA VITREOU, V3, P31, DOI [10.1186/s40942-017-0084-9, DOI 10.1186/S40942-017-0084-9]
   Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897
   Chiarella SE, 2014, J CLIN INVEST, V124, P2935, DOI 10.1172/JCI75157
   Droho S, 2020, OCULAR MACROPHAGE OR, P1, DOI [10.1186/s12974-020-02010-0, DOI 10.1186/S12974-020-02010-0]
   Droho S, 2020, JOVE-J VIS EXP, DOI 10.3791/61348
   Droho S, 2019, INVEST OPHTH VIS SCI, V60, P5059, DOI 10.1167/iovs.19-28165
   Eden E, 2007, PLOS COMPUT BIOL, V3, P508, DOI 10.1371/journal.pcbi.0030039
   Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48
   Gopinathan G, 2015, CANCER RES, V75, P3098, DOI 10.1158/0008-5472.CAN-15-1227
   Hsu J, 2020, J ASTHMA, P1, DOI [10.1001/jamaophthalmol.2020.0724, DOI 10.1080/02770903.2020.1804577]
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Lavalette S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03032
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lavine JA, 2017, INVEST OPHTH VIS SCI, V58, P299, DOI 10.1167/iovs.16-20204
   Lavine JA, 2013, JAMA OPHTHALMOL, V131, P376, DOI 10.1001/jamaophthalmol.2013.1476
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miao H, 2012, MOL VIS, V18, P574
   Nahavandipour A, 2020, ACTA OPHTHALMOL, V98, P434, DOI 10.1111/aos.14402
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nourinia R, 2015, INVEST OPHTH VIS SCI, V56, P8228, DOI 10.1167/iovs.15-17169
   O'Brien BJ, 2021, FASEB J, V35, DOI 10.1096/fj.202002755R
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Omri S, 2019, INVEST OPHTH VIS SCI, V60, P4632, DOI 10.1167/iovs.18-25502
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Tan X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160985
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024
NR 35
TC 5
Z9 5
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 10
PY 2021
VL 11
IS 1
AR 18084
DI 10.1038/s41598-021-97522-x
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UO7IY
UT WOS:000694868000036
PM 34508129
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mohlin, C
   Sandholm, K
   Kvanta, A
   Ekdahl, KN
   Johansson, K
AF Mohlin, Camilla
   Sandholm, Kerstin
   Kvanta, Anders
   Ekdahl, Kristina N.
   Johansson, Kjell
TI A model to study complement involvement in experimental retinal
   degeneration
SO UPSALA JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE AMD; complement system; ocular diseases; retina; RPE
ID MANNOSE-BINDING LECTIN; C-REACTIVE PROTEIN; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; FACTOR-H; PHOTORECEPTOR DEGENERATION; PIGMENT
   EPITHELIUM; SUNLIGHT EXPOSURE; RISK-FACTORS; ACTIVATION
AB Background: The complement system (CS) plays a role in the pathogenesis of a number of ocular diseases, including diabetic retinopathy (DR), glaucoma, uveitis, and age-related macular degeneration (AMD). Given that many of the complex eye-related degenerative diseases have limited treatment opportunities, we aimed to mimic the in vivo retinal degenerative process by developing a relevant co-culture system.
   Method and materials: The adult porcine retina was co-cultured with the spontaneously arising human retinal pigment epithelial cells-19 (ARPE-19).
   Results: Inflammatory activity was found after culture and included migrating microglial cells, gliosis, cell death, and CS activation (demonstrated by a minor increase in the secreted anaphylotoxin C3a in co-culture). CS components, including C1q, C3, C4, soluble C5b-9, and the C5a receptor, were expressed in the retina and/or ARPE cells after culture. C1q, C3, and CS regulators such as C4 binding protein (C4BP), factor H (CFH), and factor I (CFI) were secreted after culture.
   Discussion: Thus, our research indicates that this co-culturing system may be useful for investigations of the CS and its involvement in experimental neurodegenerative diseases.
C1 [Mohlin, Camilla; Sandholm, Kerstin; Ekdahl, Kristina N.] Linnaeus Univ, Linnaeus Ctr Biomat Chem, Fac Hlth & Life Sci, Kalmar, Sweden.
   [Kvanta, Anders] Karolinska Inst, St Erik Eye Hosp, Sect Ophthalmol & Vis, Dept Clin Neurosci, Stockholm, Sweden.
   [Ekdahl, Kristina N.] Rudbeck Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden.
   [Johansson, Kjell] Orebro Univ, Sch Med Sci, Orebro, Sweden.
C3 Linnaeus University; Karolinska Institutet; Orebro University
RP Mohlin, C (通讯作者)，Linnaeus Univ, Linnaeus Ctr Biomat Chem, S-39182 Kalmar, Sweden.
EM Camilla.mohlin@lnu.se
RI mohlin, camilla/AAP-2726-2020
OI mohlin, camilla/0000-0002-9301-1977
FU Carmen and Bertil Regners Foundation; Crown Princess Margaretas
   Committee for the Blind; Olle Engqvist Foundation; Sven and Dagmar
   Salens Foundation; Ogonfonden ('The Eye Foundation'); FORSS (Medical
   Research Council of Southeast Sweden); faculty of Medical Sciences at
   Orebro University; Linnaeus University; Swedish Medical Research Council
   (VR)
FX This study was supported by grants from the Carmen and Bertil Regners
   Foundation, Crown Princess Margaretas Committee for the Blind, Olle
   Engqvist Foundation, Sven and Dagmar Salens Foundation, Ogonfonden ('The
   Eye Foundation'), FORSS (Medical Research Council of Southeast Sweden),
   the faculty of Medical Sciences at Orebro University, faculty grants
   from the Linnaeus University, and by the Swedish Medical Research
   Council (VR) grant.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Adamus G, 2017, AUTOIMMUN REV, V16, P231, DOI 10.1016/j.autrev.2017.01.005
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   BEAUCHEMIN ML, 1974, A GRAEF ARCH KLIN EX, V190, P27, DOI 10.1007/BF00414333
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bossi F, 2014, P NATL ACAD SCI USA, V111, P4209, DOI 10.1073/pnas.1311968111
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Bulla R, 2008, MOL IMMUNOL, V45, P2629, DOI 10.1016/j.molimm.2007.12.025
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chandler Matthew J., 1999, Veterinary Ophthalmology, V2, P179
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cheng LJ, 2013, INVEST OPHTH VIS SCI, V54, P8191, DOI 10.1167/iovs.13-12428
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Carvalho JER, 2013, INVEST OPHTH VIS SCI, V54, P6489, DOI 10.1167/iovs.13-12374
   EKDAHL KN, 1992, SCAND J IMMUNOL, V35, P85, DOI 10.1111/j.1365-3083.1992.tb02837.x
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g
   Geng PL, 2015, DIABETES CARE, V38, P868, DOI 10.2337/dc14-1873
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Ghebrehiwet Berhane, 2016, F1000Res, V5, P2840
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grimm C, 2001, CELL DEATH DIFFER, V8, P859, DOI 10.1038/sj.cdd.4400871
   Guan LZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119699
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hansen TK, 2010, DIABETOLOGIA, V53, P1517, DOI 10.1007/s00125-010-1742-8
   Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P4857, DOI 10.1210/jc.2003-030742
   Hau J, 1990, SCANDINAVIAN J LABOR, V17, P3
   Hendrickson A, 2002, EXP EYE RES, V74, P435, DOI 10.1006/exer.2002.1181
   Hess K, 2012, DIABETOLOGIA, V55, P1103, DOI 10.1007/s00125-011-2301-7
   Hess K, 2014, DIABETOLOGIA, V57, P1737, DOI 10.1007/s00125-014-3267-z
   Hohn A, 2011, FREE RADICAL BIO MED, V50, P585, DOI 10.1016/j.freeradbiomed.2010.12.011
   Huang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121244
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lopes-Virella MF, 1999, CLIN IMMUNOL, V90, P165, DOI 10.1006/clim.1998.4631
   German OL, 2015, PHOTOCH PHOTOBIO SCI, V14, P1737, DOI 10.1039/c5pp00194c
   Martin M, 2016, IMMUNOL REV, V274, P218, DOI 10.1111/imr.12462
   McGeer PL, 2017, NEUROBIOL AGING, V52, P12, DOI 10.1016/j.neurobiolaging.2016.12.017
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mellbin LG, 2012, DIABETES CARE, V35, P911, DOI 10.2337/dc11-1642
   Mihlan M, 2011, FASEB J, V25, P4198, DOI 10.1096/fj.11-186460
   Mohlin C, 2011, ADV EYE RES, V2, P177
   Mohlin C, 2017, MOL IMMUNOL, V89, P84, DOI 10.1016/j.molimm.2017.05.028
   Mohlin C, 2014, BRAIN RES, V1585, P167, DOI 10.1016/j.brainres.2014.08.055
   Mollick T, 2016, BRAIN RES, V1646, P522, DOI 10.1016/j.brainres.2016.06.039
   MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x
   MONDINO BJ, 1984, INVEST OPHTH VIS SCI, V25, P483
   MONDINO BJ, 1984, INVEST OPHTH VIS SCI, V25, P871
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Muramatsu D, 2013, GRAEF ARCH CLIN EXP, V251, P15, DOI 10.1007/s00417-012-2024-6
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Peng Qi, 2009, Inflammation & Allergy Drug Targets, V8, P236
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Prete M, 2016, CLIN EXP MED, V16, P125, DOI 10.1007/s10238-015-0345-6
   Qin XB, 2004, DIABETES, V53, P2653, DOI 10.2337/diabetes.53.10.2653
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Romano C, 2007, PROG RETIN EYE RES, V26, P379, DOI 10.1016/j.preteyeres.2007.03.001
   Sanchez I, 2011, GRAEF ARCH CLIN EXP, V249, P475, DOI 10.1007/s00417-011-1617-9
   Schafer N, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00197
   Schick T, 2017, EYE, V31, P810, DOI 10.1038/eye.2016.328
   Schick T, 2016, RETINA-J RET VIT DIS, V36, P787, DOI 10.1097/IAE.0000000000000756
   Schmidt CQ, 2016, IMMUNOL REV, V274, P152, DOI 10.1111/imr.12475
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Silverman SM, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0089-0
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Smith JR, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.2
   Song DL, 2017, MOL VIS, V23, P210
   Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tezel G, 2010, INVEST OPHTH VIS SCI, V51, P5071, DOI 10.1167/iovs.10-5289
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   VERGANI S, 1986, BRIT J OPHTHALMOL, V70, P60, DOI 10.1136/bjo.70.1.60
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Wang H, 2013, EXP EYE RES, V108, P110, DOI 10.1016/j.exer.2012.11.023
   Wang L, 2002, INVEST OPHTH VIS SCI, V43, P1088
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Xu HP, 2017, VISION RES, V139, P39, DOI 10.1016/j.visres.2017.04.013
   Yang Y, 2006, INT J OBESITY, V30, P439, DOI 10.1038/sj.ijo.0803173
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang A, 2002, DIABETES, V51, P3499
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 101
TC 16
Z9 16
U1 0
U2 5
PU UPSALA MED SOC
PI UPPSALA
PA BOX 571, UPPSALA, SWEDEN
SN 0300-9734
EI 2000-1967
J9 UPSALA J MED SCI
JI Ups. J. Med. Sci.
PY 2018
VL 123
IS 1
BP 28
EP 42
DI 10.1080/03009734.2018.1431744
PG 15
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GA1FF
UT WOS:000428060300004
PM 29436895
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Murinello, S
   Moreno, SK
   Macauley, MS
   Sakimoto, S
   Westenskow, PD
   Friedlander, M
AF Murinello, Salome
   Moreno, Stacey K.
   Macauley, Matthew S.
   Sakimoto, Susumu
   Westenskow, Peter D.
   Friedlander, Martin
TI Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow
   Cytometry-based Assay
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Immunology; Issue 116; phagocytosis; microglia; macrophage; retina; in
   vivo; flow cytometry; myeloid cells
ID VIABLE NEURONS; BRAIN; LPS; LIPOPOLYSACCHARIDE; MACROPHAGES; ISOFLURANE;
   PHENOTYPE; RECEPTOR; INJURY; BETA
AB Microglia are the tissue resident macrophages of the central nervous system (CNS) and they perform a variety of functions that support CNS homeostasis, including phagocytosis of damaged synapses or cells, debris, and/or invading pathogens. Impaired phagocytic function has been implicated in the pathogenesis of diseases such as Alzheimer's and age-related macular degeneration, where amyloid-beta plaque and drusen accumulate, respectively. Despite its importance, microglial phagocytosis has been challenging to assess in vivo. Here, we describe a simple, yet robust, technique for precisely monitoring and quantifying the in vivo phagocytic potential of retinal microglia. Previous methods have relied on immunohistochemical staining and imaging techniques. Our method uses flow cytometry to measure microglial uptake of fluorescently labeled particles after intravitreal delivery to the eye in live rodents. This method replaces conventional practices that involve laborious tissue sectioning, immunostaining, and imaging, allowing for more precise quantification of microglia phagocytic function in just under six hours. This procedure can also be adapted to test how various compounds alter microglial phagocytosis in physiological settings. While this technique was developed in the eye, its use is not limited to vision research.
C1 [Murinello, Salome; Moreno, Stacey K.; Sakimoto, Susumu; Westenskow, Peter D.; Friedlander, Martin] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
   [Macauley, Matthew S.] Scripps Res Inst, Dept Chem Physiol, La Jolla, CA 92037 USA.
   [Westenskow, Peter D.] Lowy Med Res Inst, La Jolla, CA USA.
C3 Scripps Research Institute; Scripps Research Institute
RP Murinello, S (通讯作者)，Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
EM smuri@scripps.edu
FU American Diabetes Association grant [1-16-PDF-072]; National Institutes
   of Health (National Eye Institute) [EY11254, EY22025]; Lowy Medical
   Research Institute
FX Salome Murinello is supported by American Diabetes Association grant
   #1-16-PDF-072. This work was supported by grants to Martin Friedlander
   from the National Institutes of Health (National Eye Institute EY11254
   and EY22025) and the Lowy Medical Research Institute.
CR ABDELBASSET E, 1995, J NEUROSCI RES, V41, P222, DOI 10.1002/jnr.490410210
   Chan G, 2015, NAT NEUROSCI, V18, P1556, DOI 10.1038/nn.4126
   Derecki N., 2012, PROTOC EXCHANGE
   Fricker M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-196
   Fricker M, 2012, J NEUROSCI, V32, P2657, DOI 10.1523/JNEUROSCI.4837-11.2012
   Fritzenwanger M, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/429501
   Gomez-Nicola D, 2015, NEUROSCIENTIST, V21, P169, DOI 10.1177/1073858414530512
   Hughes MM, 2010, GLIA, V58, P2017, DOI 10.1002/glia.21070
   Jackson WS, 2014, DIS MODEL MECH, V7, P21, DOI 10.1242/dmm.012146
   Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005
   Kotani N, 1998, ANESTHESIOLOGY, V89, P1125, DOI 10.1097/00000542-199811000-00012
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Menon V, 2014, JOVE-J VIS EXP, DOI 10.3791/52241
   Mildner A, 2011, J NEUROSCI, V31, P11159, DOI 10.1523/JNEUROSCI.6209-10.2011
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Neher JJ, 2013, P NATL ACAD SCI USA, V110, pE4098, DOI 10.1073/pnas.1308679110
   Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174
   Preissler J, 2015, GLIA, V63, P206, DOI 10.1002/glia.22744
   RAGSDALE RL, 1989, J IMMUNOL METHODS, V123, P259, DOI 10.1016/0022-1759(89)90230-5
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026
   Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006
   Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014
   Stokes L, 2009, EUR J IMMUNOL, V39, P986, DOI 10.1002/eji.200838818
   Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527
   Usui Y, 2015, ANNU REV VIS SCI, V1, P155, DOI 10.1146/annurev-vision-082114-035439
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Xu XB, 2008, ANESTHESIOLOGY, V108, P643, DOI 10.1097/ALN.0b013e318167aeb4
NR 30
TC 2
Z9 2
U1 0
U2 2
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD OCT
PY 2016
IS 116
AR e54677
DI 10.3791/54677(2016)
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EQ1QO
UT WOS:000397844900069
DA 2022-11-30
ER

PT J
AU Zhang, LJ
   Justus, S
   Xu, Y
   Pluchenik, T
   Hsu, CW
   Yang, J
   Duong, JK
   Lin, CS
   Jia, YD
   Bassuk, AG
   Mahajan, VB
   Tsang, SH
AF Zhang, Lijuan
   Justus, Sally
   Xu, Yu
   Pluchenik, Tamara
   Hsu, Chun-Wei
   Yang, Jin
   Duong, Jimmy K.
   Lin, Chyuan-Sheng
   Jia, Yading
   Bassuk, Alexander G.
   Mahajan, Vinit B.
   Tsang, Stephen H.
TI Reprogramming towards anabolism impedes degeneration in a preclinical
   model of retinitis pigmentosa
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID RETINAL DEGENERATION; CONE SURVIVAL; MOUSE MODEL; MTOR; MUTATIONS; MICE;
   PHOTORECEPTORS; AUTOPHAGY; GENES; PREVALENCE
AB Retinitis pigmentosa (RP) is an incurable neurodegenerative condition featuring photoreceptor death that leads to blindness. Currently, there is no approved therapeutic for photoreceptor degenerative conditions like RP and atrophic age-related macular degeneration (AMD). Although there are promising results in human gene therapy, RP is a genetically diverse disorder, such that gene-specific therapies would be practical in a small fraction of patients with RP. Here, we explore a non-genespecific strategy that entails reprogramming photoreceptors towards anabolism by upregulating the mechanistic target of rapamycin (mTOR) pathway. We conditionally ablated the tuberous sclerosis complex 1 (Tsc1) gene, an mTOR inhibitor, in the rods of the Pde6b(H620Q/H620Q) preclinical RP mouse model and observed, functionally and morphologically, an improvement in the survival of rods and cones at early and late disease stages. These results elucidate the ability of reprogramming the metabolome to slow photoreceptor degeneration. This strategy may also be applicable to a wider range of neurodegenerative diseases, as enhancement of nutrient uptake is not gene-specific and is implicated in multiple pathologies. Enhancing anabolism promoted neuronal survival and function and could potentially benefit a number of photoreceptor and other degenerative conditions.
C1 [Zhang, Lijuan; Justus, Sally; Xu, Yu; Pluchenik, Tamara; Hsu, Chun-Wei; Yang, Jin; Tsang, Stephen H.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Inst Human Nutr,Dept Ophthalmol, Barbara & Donald Jonas Stem Cell & Regenerat Med, New York, NY USA.
   [Zhang, Lijuan; Justus, Sally; Xu, Yu; Pluchenik, Tamara; Hsu, Chun-Wei; Yang, Jin; Tsang, Stephen H.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Inst Human Nutr,Dept Ophthalmol, Bernard & Shirlee Brown Glaucoma Lab, New York, NY USA.
   [Zhang, Lijuan; Justus, Sally; Xu, Yu; Pluchenik, Tamara; Hsu, Chun-Wei; Yang, Jin; Tsang, Stephen H.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Inst Human Nutr, Dept Pathol & Cell Biol, New York, NY USA.
   [Zhang, Lijuan; Justus, Sally; Xu, Yu; Pluchenik, Tamara; Hsu, Chun-Wei; Tsang, Stephen H.] New York Presbyterian Hosp, Edward S Harkness Eye Inst, New York, NY USA.
   [Zhang, Lijuan; Jia, Yading] Shanxi Med Univ, Shanxi Eye Hosp, Taiyuan, Shanxi, Peoples R China.
   [Xu, Yu] Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Xinhua Hosp, Shanghai, Peoples R China.
   [Yang, Jin] Tianjin Med Univ, Hosp Eye, Tianjin, Peoples R China.
   [Duong, Jimmy K.] Columbia Univ, Med Ctr, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA.
   [Lin, Chyuan-Sheng] Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol & Cell Biol,Transgen Anim Facil, New York, NY USA.
   [Bassuk, Alexander G.] Univ Iowa, Dept Pediat & Neurol, Iowa City, IA USA.
   [Mahajan, Vinit B.] Univ Iowa, Omics Lab, Iowa City, IA USA.
   [Mahajan, Vinit B.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 Columbia University; Columbia University; Columbia University;
   NewYork-Presbyterian Hospital; Shanxi Medical University; Shanghai Jiao
   Tong University; Tianjin Medical University; Columbia University;
   Columbia University; University of Iowa; University of Iowa; University
   of Iowa
RP Tsang, SH (通讯作者)，Columbia Univ, Edward S Harkness Eye Inst, Med Ctr, New York Presbyterian Hosp, 635 West 165th St,Box 112, New York, NY 10032 USA.
EM sht2@columbia.edu
OI Bassuk, Alexander/0000-0002-4067-2157; Mahajan,
   Vinit/0000-0003-1886-1741
FU CDMRP [TSCRP:TS080017]; National Institute of Health [5P30EY019007,
   R01EY018213, R01EY024698, 1R01EY026682, R21AG050437]; National Cancer
   Institute Core [5P30CA013696]; Research to Prevent Blindness (RPB)
   Physician-Scientist Award; RPB, New York, NY, USA; Tistou and Charlotte
   Kerstan Foundation; Crowley Family Fund; Schneeweiss Stem Cell Fund;
   Foundation Fighting Blindness New York Regional Research Center Grant
   [C-NY05-0705-0312]; Gebroe Family Foundation; National Natural Science
   Funds, China [81400412]; Key Program of Tianjin Natural Science
   Foundation Tianjin, China [15JCZDJC34500]; NIH [R01EY024698,
   R21AG050437, K08EY020530, R01EY024665, R01EY025225]; RPB;  [C029572]; 
   [1R01NS098590-01]; NATIONAL CANCER INSTITUTE [P30CA013696] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY024665, R01EY024698,
   R01EY026682, R01EY025225, K08EY020530, P30EY019007, R01EY018213] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND
   STROKE [R01NS098590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON
   AGING [R21AG050437] Funding Source: NIH RePORTER
FX This work was conducted in the Barbara & Donald Jonas Laboratory of
   Regenerative Medicine and Bernard & Shirlee Brown Glaucoma Laboratory,
   which are supported by the CDMRP TSCRP:TS080017, National Institute of
   Health [5P30EY019007, R01EY018213, R01EY024698, 1R01EY026682,
   R21AG050437]; National Cancer Institute Core [5P30CA013696]; the
   Research to Prevent Blindness (RPB) Physician-Scientist Award;
   unrestricted funds from RPB, New York, NY, USA; the Tistou and Charlotte
   Kerstan Foundation; the Crowley Family Fund; the Schneeweiss Stem Cell
   Fund; New York State [C029572]; the Foundation Fighting Blindness New
   York Regional Research Center Grant [C-NY05-0705-0312]; and the Gebroe
   Family Foundation. JY is supported by National Natural Science Funds
   [81400412], China and the Key Program of Tianjin Natural Science
   Foundation [15JCZDJC34500] Tianjin, China. VBM is supported by NIH
   grants [K08EY020530, R01EY024665, R01EY025225, R01EY024698 and
   R21AG050437] and RPB. AGB is supported by 1R01NS098590-01.
CR Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090
   Byrne LC, 2015, J CLIN INVEST, V125, P105, DOI 10.1172/JCI65654
   Caron A, 2015, ANNU REV NUTR, V35, P321, DOI 10.1146/annurev-nutr-071714-034355
   Cepko C, 2015, NATURE, V522, P425, DOI 10.1038/522428a
   Daiger SP, 2008, ADV EXP MED BIOL, V613, P203, DOI 10.1007/978-0-387-74904-4_23
   Daiger SP, 2007, ARCH OPHTHALMOL-CHIC, V125, P151, DOI 10.1001/archopht.125.2.151
   Davis RJ, 2008, INVEST OPHTH VIS SCI, V49, P5067, DOI 10.1167/iovs.07-1422
   Demetrius LA, 2013, BIOGERONTOLOGY, V14, P641, DOI 10.1007/s10522-013-9479-7
   Demetrius LA, 2012, BIOGERONTOLOGY, V13, P583, DOI 10.1007/s10522-012-9403-6
   Dickinson J, 1990, Nurs Times, V86, P36
   Du JH, 2016, J BIOL CHEM, V291, P4698, DOI 10.1074/jbc.M115.698985
   Evangelisti C, 2016, BRIT J CLIN PHARMACO, V82, P1229, DOI 10.1111/bcp.12928
   Fahim A.T., 1993, GENEREVIEWS IN PRESS
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gardner TW, 2015, AM J PHYSIOL-ENDOC M, V309, pE546, DOI 10.1152/ajpendo.00180.2015
   Ghazi NG, 2016, HUM GENET, V135, P327, DOI 10.1007/s00439-016-1637-y
   Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hart AW, 2005, INVEST OPHTH VIS SCI, V46, P3443, DOI 10.1167/iovs.05-0254
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Howell JJ, 2013, BIOCHEM SOC T, V41, P906, DOI 10.1042/BST20130041
   Koch SF, 2015, J CLIN INVEST, V125, P3704, DOI 10.1172/JCI82462
   Kousal B, 2016, Cesk Slov Oftalmol, V72, P293
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   KURUMAJI Y, 1990, Journal of Dermatology (Tokyo), V17, P176
   Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525
   Liko D, 2015, J MOL MED, V93, P1061, DOI 10.1007/s00109-015-1326-7
   Lin Michael K, 2015, Retin Physician, V12, P52
   Lopes V.S., 2015, COLD SPRING HARB PER, V5
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   de Morentin PBM, 2014, CURR MOL MED, V14, P3, DOI 10.2174/1566524013666131118103706
   Mohand-Said S, 2000, ARCH OPHTHALMOL-CHIC, V118, P807, DOI 10.1001/archopht.118.6.807
   Molday RS, 2015, J CELL SCI, V128, P4039, DOI 10.1242/jcs.175687
   OLNEY JW, 1968, INVEST OPHTH VISUAL, V7, P250
   Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Sahel J A, 2001, Prog Brain Res, V131, P649
   Sullivan LS, 2006, INVEST OPHTH VIS SCI, V47, P3052, DOI 10.1167/iovs.05-1443
   Tanabe T., 1998, INVEST OPHT IN PRESS
   Tosi J, 2011, EXP BIOL MED, V236, P1211, DOI 10.1258/ebm.2011.011053
   Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117
   Tsang SH, 1997, INVEST OPHTH VIS SCI, V38, P943
   Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026
   Tsang SH, 2008, AM J OPHTHALMOL, V146, P780, DOI 10.1016/j.ajo.2008.06.017
   Tsang Stephen H, 2014, Trans Am Ophthalmol Soc, V112, P103
   Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Xue H, 2016, LIFE SCI, V153, P23, DOI 10.1016/j.lfs.2016.04.004
   Zhou Z, 2015, CELL DEATH DIFFER, V22, P488, DOI 10.1038/cdd.2014.229
   Zhou ZQ, 2015, AUTOPHAGY, V11, P1821, DOI 10.1080/15548627.2015.1084456
NR 52
TC 24
Z9 24
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 1
PY 2016
VL 25
IS 19
BP 4244
EP 4255
DI 10.1093/hmg/ddw256
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EN1YZ
UT WOS:000395807800008
PM 27516389
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Koskela, A
   Reinisalo, M
   Petrovski, G
   Sinha, D
   Olmiere, C
   Karjalainen, R
   Kaarniranta, K
AF Koskela, Ali
   Reinisalo, Mika
   Petrovski, Goran
   Sinha, Debasish
   Olmiere, Celine
   Karjalainen, Reijo
   Kaarniranta, Kai
TI Nutraceutical with Resveratrol and Omega-3 Fatty Acids Induces Autophagy
   in ARPE-19 Cells
SO NUTRIENTS
LA English
DT Article
DE autophagy; p62/SQSTM1; LC3; proteasome; resveratrol; omega-3
ID RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS; NUTRITIONAL SUPPLEMENT;
   MACULAR DEGENERATION; CYTOPROTECTION; ACTIVATION; EXPRESSION; DISEASE;
   HEALTH
AB autophagic and proteasomal cleansing have been documented in aged retinal pigment epithelial (RPE) cells and age-related macular degeneration (AMD). Omega-3 fatty acids and resveratrol have many positive homeostatic effects in RPE cells. In this work, ARPE-19 cells were treated with 288 ng of Resvega, containing 30 mg of trans resveratrol and 665 mg of omega-3 fatty acids, among other nutrients, with proteasome inhibitor MG-132 or autophagy inhibitor bafilomycin A1 up to 48 h. Autophagy markers p62/SQSTM1 (p62) and LC3 (microtubule-associated protein 1A/1B-light chain 3) were analyzed by Western blotting. Fluorescence microscopy with mCherry-GFP-LC3 plasmid was applied to study the autophagy flux, and cytoprotective effects were investigated with colorimetric MTT and LDH assays. Resvega induced autophagy by showing increased autolysosome formation and autophagy flux, and the change in the p62 and LC3 protein levels further confirmed the fluorescent microscopy results. Moreover, Resvega provided a clear cytoprotection under proteasome inhibition. These findings highlight the potential of the nutraceuticals containing resveratrol, omega-3 fatty acids and other nutrients in the prevention of ARPE-19 cell damage.
C1 [Koskela, Ali; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
   [Reinisalo, Mika] Univ Eastern Finland, Sch Pharm, Kuopio 70211, Finland.
   [Petrovski, Goran] Univ Szeged, Fac Med, Dept Ophthalmol, Stem Cells & Eye Res Lab, H-6720 Szeged, Hungary.
   [Petrovski, Goran] Univ Oslo, Oslo Univ Hosp, Dept Ophthalmol, Ctr Eye Res, N-0450 Oslo, Norway.
   [Sinha, Debasish] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Olmiere, Celine] Lab Thea, F-63000 Clermont Ferrand, France.
   [Karjalainen, Reijo] Univ Eastern Finland, Dept Biol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70029, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Szeged
   University; University of Oslo; Johns Hopkins University; Johns Hopkins
   Medicine; University of Eastern Finland; Kuopio University Hospital;
   University of Eastern Finland
RP Koskela, A (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio 70211, Finland.
EM ali.koskela@uef.fi; mika.reinisalo@uef.fi;
   goran.petrovski@medisin.uio.no; debasish@jhmi.edu;
   c.olmiere@laboratoires-thea.fr; reijo.karjalainen@uef.fi;
   kai.kaarniranta@uef.fi
OI Petrovski, Goran/0000-0003-2905-9252; Kaarniranta,
   Kai/0000-0003-2600-8679
FU University of Eastern Finland spearhead project "Changing Climate and
   Biological Interactions Related to Forests, CABI"; Finnish Cultural
   Foundation-North-Savo; Finnish Eye Foundation; Kuopio University
   Hospital VTR grant [5503743]; National Brain Research Program in Hungary
   [KTIA_NAP_13-A_III/9]
FX The authors would like to thank Anne Seppanen for technical assistance.
   This work was supported by a grant from University of Eastern Finland
   spearhead project "Changing Climate and Biological Interactions Related
   to Forests, CABI", the Finnish Cultural Foundation-North-Savo, the
   Finnish Eye Foundation and the Kuopio University Hospital VTR grant
   (5503743). Goran Petrovski and his Group are funded by the National
   Brain Research Program (KTIA_NAP_13-A_III/9) in Hungary.
CR Ivanescu AA, 2015, NUTRIENTS, V7, P5423, DOI 10.3390/nu7075229
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Choi MS, 2013, EXP DERMATOL, V22, P491, DOI 10.1111/exd.12175
   Chuang SY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/297293
   Ciechanover A, 2014, BBA-MOL CELL RES, V1843, P86, DOI 10.1016/j.bbamcr.2013.07.007
   Ferrington D., 2015, PROG RETIN EYE RES
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koskela A, 2014, MOL VIS, V20, P760
   Lan DM, 2015, MOL MED REP, V11, P1655, DOI 10.3892/mmr.2014.3011
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Lin TK, 2014, INT J MOL SCI, V15, P1625, DOI 10.3390/ijms15011625
   Liu XM, 2011, AM J PHYSIOL-HEART C, V300, pH84, DOI 10.1152/ajpheart.00749.2010
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Petrovski G, 2011, ANN NY ACAD SCI, V1215, P22, DOI 10.1111/j.1749-6632.2010.05843.x
   Reinisalo M., 2015, OXID MED CELL LONGEV, V2015
   Rhone M, 2008, NUTR REV, V66, P465, DOI 10.1111/j.1753-4887.2008.00078.x
   Richer S, 2014, NUTRIENTS, V6, P4404, DOI 10.3390/nu6104404
   Singh S, 2016, THER TARGETS NEUROL
   Spagnuolo C., NEUROPROTECTIVE ROLE
   Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Zhang YM, 2016, IEEE ACM T NETWORK, V24, P1632, DOI 10.1109/TNET.2015.2425146
NR 41
TC 29
Z9 30
U1 1
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD MAY
PY 2016
VL 8
IS 5
AR 284
DI 10.3390/nu8050284
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA DP8XI
UT WOS:000378780900045
PM 27187449
OA Green Accepted, Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Guo, LY
   Alekseev, O
   Li, YF
   Song, Y
   Dunaief, JL
AF Guo, Lucie Y.
   Alekseev, Oleg
   Li, Yafeng
   Song, Ying
   Dunaief, Joshua L.
TI Iron increases APP translation and amyloid-beta production in the retina
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Iron; Amyloid precursor protein;
   Amyloid-beta; Aceruloplasminemia
ID MACULAR DEGENERATION; PRECURSOR PROTEIN; DRUSEN; ACERULOPLASMINEMIA;
   METABOLISM; OVERLOAD; BINDING; ZINC
AB Age-related macular degeneration (AMD) is the most common cause of blindness among older adults in developed countries, and retinal iron accumulation may exacerbate the disease. Iron can upregulate the production of amyloid precursor protein (APP). Since amyloid-beta (A beta), a byproduct of APP proteolysis, is found in drusen, the histopathological hallmark of AMD, we tested the role of iron in regulating APP and A beta levels in the retinal pigment epithelial cell line ARPE-19. We found that treatment with ferric ammonium citrate (FAC) increases APP at the translational level. FAC treatment also results in increased generation of APP C-terminal fragments C83 and C99, the products of APP proteolysis by alpha- and beta-secretase, respectively, as well as levels of A beta 42, a highly aggregative amyloid species. Additionally, retinal tissue sections from a patient with aceruloplasminemia, a disease causing iron overload in the retinal pigment epithelium (RPE), showed increased A beta deposition in the RPE and drusen. Overall, our results suggest that RPE iron overload could contribute to A beta accumulation in the retina. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Guo, Lucie Y.; Alekseev, Oleg; Li, Yafeng; Song, Ying; Dunaief, Joshua L.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Alekseev, Oleg] Drexel Univ, Coll Med, Philadelphia, PA 19129 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Drexel University
RP Dunaief, JL (通讯作者)，Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, 305 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM lucieguo@mail.med.upenn.edu; oa43@drexel.edu;
   yafengli@mail.med.upenn.edu; yingsong@mail.med.upenn.edu;
   jdunaief@upenn.edu
FU Research to Prevent Blindness, NIH/NEI [R01 EY015240]; FM Kirby
   Foundation; Beckman Institute for Macular Research; Paul and Evanina
   Bell MacKall Foundation Trust; NATIONAL EYE INSTITUTE [R01EY015240,
   P30EY001583] Funding Source: NIH RePORTER
FX The authors are grateful for the support from Research to Prevent
   Blindness, NIH/NEI R01 EY015240, the FM Kirby Foundation, the Beckman
   Institute for Macular Research, the Paul and Evanina Bell MacKall
   Foundation Trust.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bernstein KE, 2014, J CLIN INVEST, V124, P1000, DOI 10.1172/JCI66541
   BODOVITZ S, 1995, J NEUROCHEM, V64, P307
   Bousejra-ElGarah F, 2011, INORG CHEM, V50, P9024, DOI 10.1021/ic201233b
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175
   Ho T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029892
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jayaraman A, 2012, ENDOCRINOLOGY, V153, P5467, DOI 10.1210/en.2012-1464
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kim CH, 2013, KOREAN J PHYSIOL PHA, V17, P189, DOI 10.4196/kjpp.2013.17.3.189
   LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168
   Li XX, 2013, NEUROSCI LETT, V548, P90, DOI 10.1016/j.neulet.2013.05.018
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nair NG, 2010, J ALZHEIMERS DIS, V20, P57, DOI 10.3233/JAD-2010-1346
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Postina R, 2008, CURR ALZHEIMER RES, V5, P179, DOI 10.2174/156720508783954668
   RAO KK, 1985, MOL CELL BIOL, V5, P595, DOI 10.1128/MCB.5.4.595
   Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200
   Sipe JC, 2002, DEV NEUROSCI-BASEL, V24, P188, DOI 10.1159/000065701
   Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851
   Thakker DR, 2009, P NATL ACAD SCI USA, V106, P4501, DOI 10.1073/pnas.0813404106
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Xiong K, 2007, EXP BRAIN RES, V181, P435, DOI 10.1007/s00221-007-0943-y
   Yoshida T., 2005, J CLIN INVESTIG, V115
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
NR 39
TC 24
Z9 24
U1 1
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2014
VL 129
BP 31
EP 37
DI 10.1016/j.exer.2014.10.012
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX4HJ
UT WOS:000346893800006
PM 25456519
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Porter, LF
   Black, GCM
AF Porter, L. F.
   Black, G. C. M.
TI Personalized ophthalmology
SO CLINICAL GENETICS
LA English
DT Review
DE gene therapy; genetics; genomics; inherited eye disease; molecular
   diagnosis; personalized medicine; personalized ophthalmology;
   next-generation sequencing; targeted therapies
ID RETINAL GENE-THERAPY; MACULAR DEGENERATION; CONGENITAL AMAUROSIS;
   TRANSLATION; DISEASE
AB Ophthalmology has been an early adopter of personalized medicine. Drawing on genomic advances to improve molecular diagnosis, such as next-generation sequencing, and basic and translational research to develop novel therapies, application of genetic technologies in ophthalmology now heralds development of gene replacement therapies for some inherited monogenic eye diseases. It also promises to alter prediction, diagnosis and management of the complex disease age-related macular degeneration. Personalized ophthalmology is underpinned by an understanding of the molecular basis of eye disease. Two important areas of focus are required for adoption of personalized approaches: disease stratification and individualization. Disease stratification relies on phenotypic and genetic assessment leading to molecular diagnosis; individualization encompasses all aspects of patient management from optimized genetic counseling and conventional therapies to trials of novel DNA-based therapies. This review discusses the clinical implications of these twin strategies. Advantages and implications of genetic testing for patients with inherited eye diseases, choice of molecular diagnostic modality, drivers for adoption of personalized ophthalmology, service planning implications, ethical considerations and future challenges are considered. Indeed, whilst many difficulties remain, personalized ophthalmology truly has the potential to revolutionize the specialty.
C1 [Porter, L. F.; Black, G. C. M.] Univ Manchester, MAHSC, Fac Med & Human Sci, Ctr Genom Med,Inst Human Dev,St Marys Hosp, Manchester M13 9WL, Lancs, England.
   [Porter, L. F.] Manchester Royal Eye Hosp, Dept Ophthalmol, Manchester M13 9WH, Lancs, England.
   [Black, G. C. M.] Cent Manchester Univ Hosp NHS Fdn Trust, St Marys Hosp, MAHSC, Ctr Genom Med, Manchester, Lancs, England.
C3 University of Manchester; Manchester Royal Eye Hospital; University of
   Manchester
RP Black, GCM (通讯作者)，Univ Manchester, MAHSC, Fac Med & Human Sci, Ctr Genom Med,Inst Human Dev, Manchester M13 9WL, Lancs, England.
EM Graeme.black@manchester.ac.uk
RI Porter, Louise/GQP-6108-2022; Black, Graeme/K-7374-2015
OI Black, Graeme/0000-0001-8727-6592; Porter, Louise/0000-0002-7406-0319
FU Manchester Academic Health Science Centre; Manchester National Institute
   for Health Research Biomedical Research Centre; National Institute for
   Health Research [BRF-2011-015, ACF-2007-06-011, NF-SI-0509-10185]
   Funding Source: researchfish; Fight for Sight [1801/02] Funding Source:
   researchfish
FX The authors would also like to acknowledge the support of the Manchester
   Academic Health Science Centre and the Manchester National Institute for
   Health Research Biomedical Research Centre. L. F. P. is a National
   Institute of Health (NIHR) research fellow.
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014
   Alkuraya FS, 2013, CLIN GENET, V84, P203, DOI 10.1111/cge.12131
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Harvey A, 2012, NEW BIOTECHNOL, V29, P625, DOI 10.1016/j.nbt.2012.03.009
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   O'Sullivan J, 2012, J MED GENET, V49, P322, DOI 10.1136/jmedgenet-2012-100847
   Smith A, 2014, HUM MUTAT, V35, P265, DOI 10.1002/humu.22480
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Sutherland JE, 2009, CURR OPIN OPHTHALMOL, V20, P343, DOI 10.1097/ICU.0b013e32832f7f0d
   Wiggs JL, 2013, JAMA OPHTHALMOL, V131, P1265, DOI 10.1001/jamaophthalmol.2013.4509
   Xuan JK, 2013, CANCER LETT, V340, P284, DOI 10.1016/j.canlet.2012.11.025
NR 15
TC 14
Z9 15
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9163
EI 1399-0004
J9 CLIN GENET
JI Clin. Genet.
PD JUL
PY 2014
VL 86
IS 1
SI SI
BP 1
EP 11
DI 10.1111/cge.12389
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AJ3BC
UT WOS:000337538900001
PM 24665880
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Rudolf, M
   Seckerdieck, K
   Grisanti, S
   Curcio, CA
AF Rudolf, Martin
   Seckerdieck, Katja
   Grisanti, Salvatore
   Curcio, Christine A.
TI Internal structure consistent with remodelling in very small drusen,
   revealed by filipin histochemistry for esterified cholesterol
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; BRUCHS MEMBRANE;
   COMPLEMENT ACTIVATION; GEOGRAPHIC ATROPHY; DENDRITIC CELLS; SOFT DRUSEN;
   AGE; PREVALENCE; MACULOPATHY
AB Background/aims Drusen, the pathognomonic lesion of age-related macular degeneration, are dynamic and undergo both growth and regression. Using histochemistry to localise esterified cholesterol (EC), we investigated small drusen to discover signs of dynamism.
   Methods Flat mounts of Bruch's membrane were prepared from peripheral retinas of six donor eyes without chorioretinal pathology that were preserved within 6 h of death. Tissues were pretreated with ethanol to extract native unesterified cholesterol, incubated with cholesterol esterase and stained with filipin to bind unesterified cholesterol that was newly released by hydrolysis. Tissues were imaged with wide-field epifluorescence microscopy. Diameters were measured and internal substructures (shells, lakes) assessed using previous descriptors.
   Results Of 676 drusen with mean diameter of 26.87 mu m, 41.6% were stained homogeneously and 45.7% had lakes of pooled EC. Clusters of 2-7 drusen with similar staining patterns accounted for 25.3% of drusen. Increased EC content near the druse rim (shells) occurred in 10.5%.
   Conclusions Over half of very small drusen at the edge of clinical detectability have evidence for internal remodelling, suggesting that both formative and removal events are present early in the druse lifecycle.
C1 [Rudolf, Martin; Seckerdieck, Katja; Grisanti, Salvatore] Med Univ Lubeck, Dept Ophthalmol, D-23538 Lubeck, Germany.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 University of Lubeck; University of Alabama System; University of
   Alabama Birmingham
RP Rudolf, M (通讯作者)，Univ Klinikum Schleswig Holstein, Univ Eye Hosp Lubeck, RatzeburgerAllee 160, D-23538 Lubeck, Germany.
EM martin.rudolf@uksh.de
FU National Institutes of Health [EY06109]; EyeSight Foundation of Alabama;
   Research to Prevent Blindness, Inc; Macula Vision Research Foundation;
   NATIONAL EYE INSTITUTE [R01EY006109] Funding Source: NIH RePORTER
FX (CAC) National Institutes of Health grant EY06109, EyeSight Foundation
   of Alabama, Research to Prevent Blindness, Inc, Macula Vision Research
   Foundation.
CR Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bobryshev YV, 2010, LAB INVEST, V90, P970, DOI 10.1038/labinvest.2010.94
   BODENSTEIN L, 1987, DEV BIOL, V121, P205, DOI 10.1016/0012-1606(87)90153-9
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Cherepanoff S, BR J OPHTHALMOL, V94, P918
   Choi JH, 2011, IMMUNITY, V35, P819, DOI 10.1016/j.immuni.2011.09.014
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2011, P NATL ACAD SCI USA, V108, P18569, DOI 10.1073/pnas.1115497108
   Curcio CA, 2009, METHODS MOL BIOL, V580, P267, DOI 10.1007/978-1-60761-325-1_15
   Frennesson CI, 2009, ACTA OPHTHALMOL, V87, P720, DOI 10.1111/j.1755-3768.2008.01396.x
   GUYTON JR, 1989, AM J PATHOL, V134, P705
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hsu J, 2005, CAN J OPHTHALMOL, V40, P320, DOI 10.1016/S0008-4182(05)80075-4
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KRUTH HS, 1984, ATHEROSCLEROSIS, V51, P281, DOI 10.1016/0021-9150(84)90175-8
   Lenassi E, 2013, AM J OPHTHALMOL, V155, P190, DOI 10.1016/j.ajo.2012.07.003
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Rudolf M, 2010, INVEST OPHTH VIS SCI, V51
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sato R, 2012, INVEST OPHTH VIS SCI, DOI [10.1167/iovs.12-10068, DOI 10.1167/I0VS.12-10068]
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Silvestri G, 2012, EYE, V26, P1357, DOI 10.1038/eye.2012.165
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   van Soest SS, 2007, MOL VIS, V13, P1608
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538
   Wedl C, 1854, GRUNDZUGE PATHOLOGIS
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Youssoufian H, 2002, NAT REV GENET, V3, P748, DOI 10.1038/nrg906
NR 50
TC 11
Z9 11
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2014
VL 98
IS 5
BP 698
EP 702
DI 10.1136/bjophthalmol-2013-304226
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF0IL
UT WOS:000334397400021
PM 24554738
DA 2022-11-30
ER

PT J
AU Borooah, S
   Collins, C
   Wright, A
   Dhillon, B
AF Borooah, S.
   Collins, C.
   Wright, A.
   Dhillon, B.
TI Late-onset retinal macular degeneration: clinical insights into an
   inherited retinal degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID COMPLEMENT FACTOR-H; SORSBY FUNDUS DYSTROPHY; ANTERIOR LENS ZONULES;
   VITAMIN-A-DEFICIENCY; RETINITIS-PIGMENTOSA; DARK-ADAPTATION; BOTHNIA
   DYSTROPHY; GENETIC MODEL; MUTATION; DISEASE
AB Aim: This study describes, in detail, the phenotype of late-onset retinal macular degeneration (L-ORMD) an inherited condition affecting both the retina and anterior segment. A staging based on clinical characteristics is proposed, and the relevance of this condition to current understanding of age-related macular degeneration is discussed.
   Methods: A systematic review of the literature regarding this condition supports a detailed description of the natural history. Clinical experiences in identifying, monitoring and managing patients are also presented.
   Results: L-ORMD is a rare fully penetrant autosomal dominant condition resulting from a mutation in the C1QTNF5 gene on chromosome 11. Affected individuals develop bilateral loss of vision, dark-adaptation abnormalities, fundus drusen-like yellow spots, midperipheral pigmentation, choroidal neovascularisation, chorioretinal atrophy and long anteriorly inserted lens zonules. Patients may benefit from treatment with high-dose vitamin A.
   Conclusions: Raised awareness of L-ORMD should lead to earlier diagnosis and improved care for patients. New antivascular endothelial growth factor treatment may provide a new possibility for management. A deeper insight into molecular and genetic mechanisms of L-ORMD may suggest avenues to explore new treatments of this disorder.
C1 [Borooah, S.; Collins, C.; Dhillon, B.] Princess Alexandra Eye Pavil, Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
   [Wright, A.] MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland.
C3 University of Edinburgh
RP Borooah, S (通讯作者)，Princess Alexandra Eye Pavil, Chalmers St, Edinburgh EH3 9HA, Midlothian, Scotland.
EM shyamanga@aol.com
RI Borooah, Shyamanga/AAM-6581-2021
FU Medical Research Council [MC_U127584475] Funding Source: Medline; MRC
   [MC_U127584475] Funding Source: UKRI
CR Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Ayyagari R, 2000, ARCH OPHTHALMOL-CHIC, V118, P85
   BORS F, 1971, BRIT J OPHTHALMOL, V55, P210, DOI 10.1136/bjo.55.3.210
   BROSNAHAN DM, 1994, OPHTHALMOLOGY, V101, P38
   Burstedt MSI, 2003, VISION RES, V43, P2559, DOI 10.1016/S0042-6989(03)00440-1
   Burstedt MSL, 2001, ARCH OPHTHALMOL-CHIC, V119, P260
   Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091
   Cideciyan AV, 1997, INVEST OPHTH VIS SCI, V38, P1786
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DOYNE RW, 1910, T OPHTHAL SOC UK, V30, P93
   DUVALL J, 1986, GRAEF ARCH CLIN EXP, V224, P299, DOI 10.1007/BF02143075
   Edwards AO, 1998, AM J OPHTHALMOL, V126, P417, DOI 10.1016/S0002-9394(98)00097-X
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans K, 1997, ARCH OPHTHALMOL-CHIC, V115, P904, DOI 10.1001/archopht.1997.01100160074012
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   FUCHS A, 1959, AM J OPHTHALMOL, V48, P101, DOI 10.1016/0002-9394(59)90294-6
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Haimovici R, 2002, EYE, V16, P7, DOI 10.1038/sj.eye.6700018
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAMILTON WK, 1989, OPHTHALMOLOGY, V96, P1755
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Jacobson SG, 2001, INVEST OPHTH VIS SCI, V42, P1882
   Kalloniatis Michael, 2004, Clin Exp Optom, V87, P65
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   MARMOR MF, 1979, ARCH OPHTHALMOL-CHIC, V97, P1300
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   Marneros AG, 2003, INVEST OPHTH VIS SCI, V44, P2367, DOI 10.1167/iovs.02-1180
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Moroi SE, 2003, AM J OPHTHALMOL, V136, P1176, DOI 10.1016/S0002-9394(03)00657-3
   Mura M, 2007, ARCH OPHTHALMOL-CHIC, V125, P1107, DOI 10.1001/archopht.125.8.1107
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2
   Shu XH, 2006, ADV EXP MED BIOL, V572, P41
   Shu XH, 2006, HUM MOL GENET, V15, P1680, DOI 10.1093/hmg/ddl091
   Sivaprasad S, 2008, AM J OPHTHALMOL, V146, P228, DOI 10.1016/j.ajo.2008.03.024
   SORSBY A, 1952, BRIT J OPHTHALMOL, V36, P547, DOI 10.1136/bjo.36.10.547
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Stephan S, 2004, J BIOL CHEM, V279, P21469, DOI 10.1074/jbc.M305805200
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Styles CJ, 2003, EYE, V17, P530, DOI 10.1038/sj.eye.6700408
   Subrayan V, 2005, AM J OPHTHALMOL, V140, P1127, DOI 10.1016/j.ajo.2005.06.023
   Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Valle D, 1982, Prog Clin Biol Res, V82, P123
   Wright A, 2003, TRENDS GENET, V19, P97, DOI 10.1016/S0168-9525(02)00033-1
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 51
TC 29
Z9 30
U1 1
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2009
VL 93
IS 3
BP 284
EP 289
DI 10.1136/bjo.2008.150151
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 411NH
UT WOS:000263655800005
PM 19098033
DA 2022-11-30
ER

PT J
AU You, QS
   Xu, L
   Jonas, JB
AF You, Qisheng
   Xu, Liang
   Jonas, Jost B.
TI Prevalence of myelinated retinal nerve fibres in urban and rural adult
   Chinese populations: the Beijing Eye Study
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE glaucoma; myelinated retinal nerve fibres; oligodendrocytes; optic
   nerve; retina
ID GLAUCOMA
AB Purpose: To determine the prevalence of myelinated retinal nerve fibres in the elderly Chinese population.
   Methods: The Beijing Eye Study, a population-based, cross-sectional cohort study, included 4439 subjects out of the 5324 invited to participate (response rate 83.4%) with an age of > 40 years. The present investigation consisted of 8663 eyes of 4378 (98.6%) subjects for whom readable fundus photographs were available.
   Results: Myelinated retinal nerve fibres were detected in 35 eyes (29 subjects) with a prevalence rate of 0.4 +/- 6.3%[95% confidence interval (CI): 0.27, 0.54] per eye and 0.7 +/- 8.1% (95% CI: 0.42, 0.90) per subject. The myelinated nerve fibres were located most often in the temporal inferior region, followed by the temporal superior region and the nasal region. Prevalence of myelinated nerve fibres was not associated statistically with age, gender, refractive error, visual acuity (VA), intraocular pressure, cataract, glaucoma and age-related macular degeneration.
   Conclusions: Myelinated retinal nerve fibres are present in about seven out of 1000 elderly Chinese in northern China, without association to VA, refractive error, glaucoma and macular degeneration.
C1 Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Hougou St,Chong Wen Men, Beijing 100005, Peoples R China.
EM jost.jonas@augen.ma.uniheidelberg.de
RI You, Qisheng/AAG-7153-2020; You, Qisheng/A-3619-2014
OI You, Qisheng/0000-0003-0743-7320; You, Qisheng/0000-0003-0743-7320
CR Brusini P, 2006, ACTA OPHTHALMOL SCAN, V84, P650, DOI 10.1111/j.1600-0420.2006.00747.x
   Dichtl A, 1999, GRAEF ARCH CLIN EXP, V237, P474, DOI 10.1007/s004170050264
   DUKEELDER S, 1964, SYSTEM OPHTHALMOLOGY, P646
   KODAMA T, 1990, OPHTHALMOLOGICA, V200, P77, DOI 10.1159/000310082
   Magacho L, 2005, ACTA OPHTHALMOL SCAN, V83, P322, DOI 10.1111/j.1600-0420.2005.00468.x
   UEHARA F, 1988, INCIDENCE RETINAL MY, V5, P1355
   Xu L, 2006, AM J OPHTHALMOL, V141, P591, DOI 10.1016/j.ajo.2005.10.018
NR 7
TC 12
Z9 12
U1 0
U2 5
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD SEP
PY 2007
VL 85
IS 6
BP 631
EP 632
DI 10.1111/j.1600-0420.2007.00909.x
PG 2
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202SD
UT WOS:000248922800009
PM 17662098
DA 2022-11-30
ER

PT J
AU Campochiaro, PA
AF Campochiaro, Peter A.
TI Targeted pharmacotherapy of retinal diseases with ranibizumab
SO DRUGS OF TODAY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; MONOCLONAL-ANTIBODY; BEVACIZUMAB AVASTIN; THERAPY;
   PHARMACOKINETICS; VERTEPORFIN; BREAKDOWN; RABBITS
AB Diseases of retinal and/or choroidal blood vessels are the most prevalent causes of moderate and severe vision loss in developed countries. Vascular endothelial growth factor (VEGF)-A plays a critical role in the pathogenesis of many of these diseases. Ranibizumab is a humanized antigen-binding fragment that binds all isoforms of VEGFA. Intraocular injections of ranibizumab cause significant visual improvement in approximately 40% of patients with choroidal neovascularization due to age-related macular degeneration (AMD). Pilot trials have indicated that intraocular injections ofranibizumab also provide benefits in patients with macular edema due to diabetic retinopathy or retinal vein occlusions. Based upon several case series, bevacizumab, a full-length humanized monoclonal antibody that binds all isoforms of VEGF-A, improves vision in patients with choroidal neovascularization due to AMD and other diseases. Case series also suggest that bevacizumab can cause regression of retinal neovascularization in patients with proliferative diabetic retinopathy. Taken together, results with ranibizumab and bevacizumab suggest that potent antagonists of VEGF will provide the foundation of treatment for a wide variety of diseases complicated by retinal or choroidal neovascularization, or by excessive vascular leakage leading to macular edema. (c) 2007 Prous Science. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CAMPOCHIARO PA, 2007, INVEST OPHTHALMOL VI
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   HAFIZ G, 2007, INVEST OPHTHALMOL VI
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Laud K, 2006, RETINA-J RET VIT DIS, V26, P960, DOI 10.1097/01.iae.0000240121.28034.c3
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Presta LG, 1997, CANCER RES, V57, P4593
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P210, DOI 10.1002/jcp.10238
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Teixeira A, 2006, ACTA OPHTHALMOL SCAN, V84, P835, DOI 10.1111/j.1600-0420.2006.00762.x
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YI X, 1997, LAB INVEST, V235, P313
NR 30
TC 32
Z9 32
U1 0
U2 3
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD AUG
PY 2007
VL 43
IS 8
BP 529
EP 537
DI 10.1358/dot.2007.43.8.1120868
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 214QU
UT WOS:000249754000002
PM 17925884
DA 2022-11-30
ER

PT J
AU Yao, ZM
   Yuan, YZ
   Shi, ZN
   Mao, WX
   Zhu, GC
   Zhang, GX
   Wang, ZG
AF Yao, Zhaomin
   Yuan, Yizhe
   Shi, Zhenning
   Mao, Wenxin
   Zhu, Gancheng
   Zhang, Guoxu
   Wang, Zhiguo
TI FunSwin: A deep learning method to analysis diabetic retinopathy grade
   and macular edema risk based on fundus images
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE fundus image; diabetic retinopathy; macular edema; disease stage
   prediction; swin; transformer
ID DEGENERATION
AB Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are forms of degenerative retinal disorders that may result in vision impairment or even permanent blindness. Early detection of these conditions is essential to maintaining a patient's quality of life. The fundus photography technique is non-invasive, safe, and rapid way of assessing the function of the retina. It is widely used as a diagnostic tool for patients who suffer from fundus-related diseases. Using fundus images to analyze these two diseases is a challenging exercise, since there are rarely obvious features in the images during the incipient stages of the disease. In order to deal with these issues, we have proposed a deep learning method called FunSwin. The Swin Transformer constitutes the main framework for this method. Additionally, due to the characteristics of medical images, such as their small number and relatively fixed structure, transfer learning strategy that are able to increase the low-level characteristics of the model as well as data enhancement strategy to balance the data are integrated. Experiments have demonstrated that the proposed method outperforms other state-of-the-art approaches in both binary and multiclass classification tasks on the benchmark dataset.
C1 [Yao, Zhaomin; Zhang, Guoxu; Wang, Zhiguo] Northeastern Univ, Coll Med & Biol Informat Engn, Shenyang, Liaoning, Peoples R China.
   [Yao, Zhaomin; Zhang, Guoxu; Wang, Zhiguo] Gen Hosp Northern Theater Command, Dept Nucl Med, Shenyang, Liaoning, Peoples R China.
   [Yuan, Yizhe; Shi, Zhenning; Mao, Wenxin; Zhu, Gancheng] Jilin Univ, Coll Comp Sci & Technol, Key Lab Symbol Computat & Knowledge Engn, Minist Educ, Changchun, Jilin, Peoples R China.
C3 Northeastern University - China; Jilin University
RP Zhang, GX; Wang, ZG (通讯作者)，Northeastern Univ, Coll Med & Biol Informat Engn, Shenyang, Liaoning, Peoples R China.; Zhang, GX; Wang, ZG (通讯作者)，Gen Hosp Northern Theater Command, Dept Nucl Med, Shenyang, Liaoning, Peoples R China.
EM zhangguoxu_502@163.com; wangzhiguo5778@163.com
FU Key Research and Development Program of Liaoning Provence
   [2019JH2/10300010]
FX Funding This work was supported by the Key Research and Development
   Program of Liaoning Provence (2019JH2/10300010).
CR Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Alqudah AM, 2018, J BIOMIM BIOMATER BI, V39, P40, DOI 10.4028/www.scientific.net/JBBBE.39.40
   Bien N, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002699
   Das S, 2021, BIOMED SIGNAL PROCES, V68, DOI 10.1016/j.bspc.2021.102600
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Dong L, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100875
   Dosovitskiy A, 2020, ARXIV
   Du JY, 2022, BIOMED SIGNAL PROCES, V74, DOI 10.1016/j.bspc.2022.103536
   Gao SH, 2021, IEEE T PATTERN ANAL, V43, P652, DOI 10.1109/TPAMI.2019.2938758
   Ghani A, 2019, ELECTRONICS-SWITZ, V8, DOI 10.3390/electronics8121522
   Grunwald JE, 2010, CLIN J AM SOC NEPHRO, V5, P867, DOI 10.2215/CJN.08271109
   Jiang Y, 2022, BRAIN SCI, V12, DOI 10.3390/brainsci12060797
   Kanimozhi J, 2021, J AMB INTEL HUM COMP, V12, P7407, DOI 10.1007/s12652-020-02417-w
   Lee LP, 2005, SCIENCE, V310, P1148, DOI 10.1126/science.1115248
   Liu Z., 2022, ARXIV, DOI DOI 10.48550/ARXIV.2201.03545
   Liu Z, 2021, 2021 IEEE/CVF INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV 2021), P9992, DOI 10.1109/ICCV48922.2021.00986
   Musadiq M, 2003, EYE, V17, P619, DOI 10.1038/sj.eye.6700418
   NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306
   Peng ZL, 2021, 2021 IEEE/CVF INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV 2021), P357, DOI 10.1109/ICCV48922.2021.00042
   Selcuk T, 2022, CONCURR COMP-PRACT E, V34, DOI 10.1002/cpe.6768
   Shahhosseini M, 2021, FRONT PLANT SCI, V12, DOI 10.3389/fpls.2021.709008
   Sikder N, 2021, SYMMETRY-BASEL, V13, DOI 10.3390/sym13040670
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Tolstikhin I. O., 2021, P ADV NEUR INF PROC, V34, P1, DOI 10.48550
   Valan M, 2019, SYST BIOL, V68, P876, DOI 10.1093/sysbio/syz014
   Wang JD, 2021, IEEE T PATTERN ANAL, V43, P3349, DOI 10.1109/TPAMI.2020.2983686
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Xu FB, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.649316
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
   Yuan L, 2021, 2021 IEEE/CVF INTERNATIONAL CONFERENCE ON COMPUTER VISION (ICCV 2021), P538, DOI 10.1109/ICCV48922.2021.00060
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhang X, 2018, PROC CVPR IEEE, P6848, DOI 10.1109/CVPR.2018.00716
   Zhang Z., 2021, INT C COMPUT INF SCI, P153, DOI [10.1109/CISAI54367.2021.00036, DOI 10.1109/CISAI54367.2021.00036, 10.1109/cisai54367.2021.00036]
NR 34
TC 0
Z9 0
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD JUL 25
PY 2022
VL 13
AR 961386
DI 10.3389/fphys.2022.961386
PG 9
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA 3Q3IX
UT WOS:000838128000001
PM 35957992
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Farhan, F
   Almarhoun, M
   Wong, A
   Findlay, AS
   Bartholomew, C
   Williams, MTS
   Hurd, TW
   Shu, XH
AF Farhan, Fahad
   Almarhoun, Mohammad
   Wong, Aileen
   Findlay, Amy S.
   Bartholomew, Chris
   Williams, Mark T. S.
   Hurd, Toby W.
   Shu, Xinhua
TI Deletion of TSPO Causes Dysregulation of Cholesterol Metabolism in Mouse
   Retina
SO CELLS
LA English
DT Article
DE TSPO; retina; cholesterol; inflammation; age-related macular
   degeneration
ID TRANSLOCATOR PROTEIN TSPO; MACULAR DEGENERATION;
   BENZODIAZEPINE-RECEPTOR; TARGET; POLYMORPHISM; MICROGLIA; RISK; FAT
AB Cholesterol dysregulation has been implicated in age-related macular degeneration (AMD), the most common cause of visual impairment in the elderly. The 18 KDa translocator protein (TSPO) is a mitochondrial outer membrane protein responsible for transporting cholesterol from the mitochondrial outer membrane to the inner membrane. TSPO is highly expressed in retinal pigment epithelial (RPE) cells, and TSPO ligands have shown therapeutic potential for the treatment of AMD. Here, we characterized retinal pathology of Tspo knockout (KO) mice using histological, immunohistochemical, biochemical and molecular biological approaches. We found that Tspo KO mice had normal retinal morphology (by light microscopy) but showed elevated levels of cholesterol, triglycerides and phospholipids with perturbed cholesterol efflux in the RPE cells of Tspo KO mice. Expression of cholesterol-associated genes (Nr1h3, Abca1, Abcg1, Cyp27a1 and Cyp46a1) was significantly downregulated, and production of pro-inflammatory cytokines was markedly increased in Tspo KO retinas. Furthermore, microglial activation was also observed in Tspo KO mouse retinas. These findings provide new insights into the function of TSPO in the retina and may aid in the design of new therapeutic strategies for the treatment of AMD.
C1 [Farhan, Fahad; Almarhoun, Mohammad; Wong, Aileen; Bartholomew, Chris; Williams, Mark T. S.; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Findlay, Amy S.; Hurd, Toby W.] Univ Edinburgh, Inst Genet & Canc, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Peoples R China.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
C3 Glasgow Caledonian University; University of Edinburgh; Shaoyang
   University; Glasgow Caledonian University
RP Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.; Shu, XH (通讯作者)，Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Peoples R China.; Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
EM fahad.farhan@gcu.ac.uk; MALMAR200@caledonian.ac.uk;
   Aileen.Wong@gcu.ac.uk; Amy.Findlay@igmm.ed.ac.uk;
   C.Bartholomew@gcu.ac.uk; Mark.Williams@gcu.ac.uk; toby.hurd@ed.ac.uk;
   Xinhua.Shu@gcu.ac.uk
OI Bartholomew, Chris/0000-0002-1153-8389; Williams,
   Mark/0000-0003-1114-1418; Shu, Xinhua/0000-0003-3760-3019
FU Rosetrees Trust; Sight Research UK; Scottish Universities Life Sciences
   Alliance; Lotus Scholarship Program of Hunan Province, China; Office of
   the Assistant Military Attache for Training Embassy of the State of
   Kuwait-London
FX This study was supported by the Rosetrees Trust, Sight Research UK,
   Scottish Universities Life Sciences Alliance, the Lotus Scholarship
   Program of Hunan Province, China (2019), and a PhD studentship from the
   Office of the Assistant Military Attache for Training Embassy of the
   State of Kuwait-London.
CR Barron AM, 2018, BIOCHEM J, V475, P75, DOI 10.1042/BCJ20170645
   Betlazar C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092707
   Biswas L, 2021, EXP EYE RES, V208, DOI 10.1016/j.exer.2021.108625
   Biswas L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123740
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   BRAESTRUP C, 1977, P NATL ACAD SCI USA, V74, P3805, DOI 10.1073/pnas.74.9.3805
   Chung JY, 2013, ENDOCRINOLOGY, V154, P2156, DOI 10.1210/en.2012-2226
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Dimitrova-Shumkovska J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040870
   Fan JJ, 2020, J ENDOCR SOC, V4, DOI 10.1210/jendso/bvaa001
   Fan JJ, 2015, P NATL ACAD SCI USA, V112, P7261, DOI 10.1073/pnas.1502670112
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307
   Hermann M, 2012, ACTA OPHTHALMOL, V90, pe500, DOI 10.1111/j.1755-3768.2011.02347.x
   Ibrahim KS, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114151
   Jaremko L, 2014, SCIENCE, V343, P1363, DOI 10.1126/science.1248725
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lee Y, 2020, BMB REP, V53, P20, DOI 10.5483/BMBRep.2020.53.1.273
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morohaku K, 2014, ENDOCRINOLOGY, V155, P89, DOI 10.1210/en.2013-1556
   Owen DR, 2017, BIOCHEM J, V474, P3985, DOI 10.1042/BCJ20170648
   Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129
   PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295
   Rupprecht R, 2009, SCIENCE, V325, P490, DOI 10.1126/science.1175055
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tu LN, 2014, J BIOL CHEM, V289, P27444, DOI 10.1074/jbc.M114.578286
   Veenman L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207586
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang SK, 2020, J CLIN INVEST, V130, P4360, DOI 10.1172/JCI136160
   Yang RL, 2008, NUTRITION, V24, P582, DOI 10.1016/j.nut.2008.02.002
   Zhang X, 2021, BRIT J PHARMACOL, V178, P3205, DOI 10.1111/bph.15391
   Zhang X, 2019, J CELL PHYSIOL, V234, P18801, DOI 10.1002/jcp.28519
NR 45
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2021
VL 10
IS 11
AR 3066
DI 10.3390/cells10113066
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XH1BV
UT WOS:000725177600001
PM 34831289
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liang, R
   Zhao, Q
   Zhu, Q
   He, X
   Gao, MJ
   Wang, YR
AF Liang, Ran
   Zhao, Qi
   Zhu, Qing
   He, Xin
   Gao, Mingjun
   Wang, Yiru
TI Lycium barbarum polysaccharide protects ARPE-19 cells against
   H2O2-induced oxidative stress via the Nrf2/HO-1 pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE age-related macular degeneration; oxidative stress; Lycium barbarum
   polysaccharide; retinal pigment epithelium; nuclear factor erythroid
   2-related factor 2; heme oxygenase-1 pathway
ID RETINAL-PIGMENT EPITHELIUM; LIPID-PEROXIDATION; EXPRESSION; CULTURES;
   DAMAGE; MODEL; NRF2
AB Age-related macular degeneration (AMD) is a global health problem. Lycium barbarum polysaccharide (LBP), a traditional Chinese herbal medicine, has been proven to be effective against several eye diseases. However, only a few studies have investigated the effectiveness of LBP for AMD. In the present study, the human retinal epithelial cell line, ARPE-19, was pretreated with LBP for 24 h before exposure to H2O2 (500 mu M). Cell viability was assessed, and a series of oxidative and antioxidant indicators were evaluated to determine the influence of LBP on H2O2-triggered oxidative stress. The present study also determined the apoptosis status, as well as the expression levels of apoptotic proteins and nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway proteins. The present study aimed to determine the protective role for LBP pretreatment and its underlying molecular mechanism. The results of the present study suggest that pretreatment of ARPE-19 cells with LBP exhibit high efficacy at reducing oxidative damage and inhibiting cell apoptosis. Furthermore, LBP may modulate the expression of proteins involved in the apoptotic pathway and activate the Nrf2 signaling pathway.
C1 [Liang, Ran; Zhao, Qi; Zhu, Qing; He, Xin; Gao, Mingjun; Wang, Yiru] Dalian Med Univ, Dept Ophthalmol, Hosp 2, Dalian 116021, Liaoning, Peoples R China.
C3 Dalian Medical University
RP Zhao, Q (通讯作者)，Dalian Med Univ, Dept Ophthalmol, Hosp 2, Dalian 116021, Liaoning, Peoples R China.
EM zhaiqidyey@163.com
CR ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cameron BD, 2018, RADIAT RES, V190, P99, DOI 10.1667/RR15059.1
   Cao SM, 2017, EXP THER MED, V14, P4919, DOI 10.3892/etm.2017.5127
   Catala A, 2006, INT J BIOCHEM CELL B, V38, P1482, DOI 10.1016/j.biocel.2006.02.010
   Chen B, 2015, J ENDOCRINOL, V225, pR83, DOI 10.1530/JOE-14-0662
   Chen L, 2018, FREE RADICAL RES, V52, P480, DOI 10.1080/10715762.2018.1447105
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Geiger RC, 2005, INVEST OPHTH VIS SCI, V46, P3435, DOI 10.1167/iovs.04-1487
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Hao YM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071515
   Hiramatsu K, 2016, NUTR RES, V36, P143, DOI 10.1016/j.nutres.2015.09.018
   Huang YY, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102-865020190010000003
   Jiang P, 2019, J PHARMACOL SCI, V139, P105, DOI 10.1016/j.jphs.2018.12.003
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Li S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061736
   Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380
   Liu W, 2016, CARBOHYD POLYM, V147, P114, DOI 10.1016/j.carbpol.2016.03.087
   Mi XS, 2012, NEURAL REGEN RES, V7, P645, DOI 10.3969/j.issn.1673-5374.2012.09.001
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Musat O, 2012, Oftalmologia, V56, P45
   Pan Hong, 2019, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V35, P55, DOI 10.12047/j.cjap.5749.2019.014
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Qi B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110275
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Sakai E, 2013, J PHARMACOL SCI, V121, P288, DOI 10.1254/jphs.12243FP
   Schoppet M, 2018, J ORG CHEM, V83, P7206, DOI 10.1021/acs.joc.8b00418
   Shelton LM, 2013, KIDNEY INT, V84, P1090, DOI 10.1038/ki.2013.248
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Varoni MV, 2017, ENVIRON SCI POLLUT R, V24, P2946, DOI 10.1007/s11356-016-8050-x
   Xiong GF, 2019, MED SCI MONITOR, V25, P3880, DOI 10.12659/MSM.913820
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134658
   Yao Q, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/7943212
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zhou JZ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20194347
NR 41
TC 5
Z9 5
U1 5
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2021
VL 24
IS 5
AR 769
DI 10.3892/mmr.2021.12409
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA UT2VJ
UT WOS:000697978400001
PM 34490478
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Droho, S
   Perlman, H
   Lavine, JA
AF Droho, Steven
   Perlman, Harris
   Lavine, Jeremy A.
TI Dendritic cells play no significant role in the laser-induced choroidal
   neovascularization model
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FACTOR-H POLYMORPHISM; COMPLEMENT; MACROPHAGES; REGULATORS; EXPRESSION
AB Age-related macular degeneration (AMD) is genetically associated with complement. Dendritic cells (DCs) play key roles during innate and adaptive immunity, and express complement components and their receptors. We investigated ocular DC heterogeneity and the role of DCs in the laser-induced choroidal neovascularization (CNV) model. In order to determine the function of DCs, we used two models of DC deficiency: the Flt3(-/-) and Flt3l(-/-) mouse. We identified three types of ocular DCs: plasmacytoid DC, classical DC-1, and classical DC-2. At steady-state, classical DCs were found in the iris and choroid but were not detectable in the retina. Plasmacytoid DCs existed at very low levels in iris, choroid, and retina. After laser injury, the number of each DC subset was up-regulated in the choroid and retina. In Flt3(-/-) mice, we found reduced numbers of classical DCs at steady-state, but each DC subset equally increased after laser injury between wildtype and Flt3(-/-) mice. In Flt3l(-/-) mice, each DC subsets was severely reduced after laser injury. Neither Flt3(-/-) or Flt3l(-/-) mice demonstrated reduced CNV area compared to wildtype mice. DCs do not play any significant role during the laser-induced CNV model of neovascular AMD.
C1 [Droho, Steven; Lavine, Jeremy A.] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Perlman, Harris] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Feinberg School of Medicine
RP Lavine, JA (通讯作者)，Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA.
EM jeremy.lavine@northwestern.edu
OI Lavine, Jeremy/0000-0002-0884-1336
FU NIH [AR064546, HL134375, AG049665, UH2AR067687, K08 EY030923]; United
   States-Israel Binational Science Foundation [2013247]; Rheumatology
   Research Foundation [Agmt 05/06/14]; Research to Prevent Blindness Sybil
   B. Harrington Career Development Award for Macular Degeneration;
   Illinois Society for the Prevention of Blindness; CCSG [P30 CA060553];
   Research to Prevent Blindness
FX We thank Kenneth M. Murphy for generously providing the
   Flt3<SUP>-/-</SUP> and Flt3l<SUP>-/-</SUP> mice. HP was supported by NIH
   Grant AR064546, HL134375, AG049665, UH2AR067687, the United
   States-Israel Binational Science Foundation (2013247), and the
   Rheumatology Research Foundation (Agmt 05/06/14). HP was also supported
   by the Mabel Greene Myers Professor of Medicine and generous donations
   to the Rheumatology Precision Medicine Fund. JAL was supported by NIH
   grant K08 EY030923, the Research to Prevent Blindness Sybil B.
   Harrington Career Development Award for Macular Degeneration, and the
   Illinois Society for the Prevention of Blindness. Imaging work was
   performed at the Northwestern University Center for Advanced Microscopy
   generously supported by CCSG P30 CA060553 awarded to the Robert H Lurie
   Comprehensive Cancer Center. This study was supported by an Unrestricted
   Departmental Grant from Research to Prevent Blindness. No funding body
   had any role in the design of the study, collection, analysis,
   interpretation of data, or in writing the manuscript.
CR Anderson DA, 2021, NAT REV IMMUNOL, V21, P101, DOI 10.1038/s41577-020-00413-x
   Brown CC, 2019, CELL, V179, P846, DOI 10.1016/j.cell.2019.09.035
   Droho S, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02010-0
   Droho S, 2020, JOVE-J VIS EXP, DOI 10.3791/61348
   Droho S, 2019, INVEST OPHTH VIS SCI, V60, P5059, DOI 10.1167/iovs.19-28165
   Durai V, 2018, J EXP MED, V215, P1417, DOI 10.1084/jem.20171784
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Gao YS, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2518568
   Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419
   Jamali Arsia, 2021, Prog Retin Eye Res, V80, P100877, DOI 10.1016/j.preteyeres.2020.100877
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li K, 2011, MOL IMMUNOL, V48, P1121, DOI 10.1016/j.molimm.2011.02.003
   MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1
   McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nakai K, 2008, INVEST OPHTH VIS SCI, V49, P3666, DOI 10.1167/iovs.07-1640
   Waskow C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615
   Yang X, 2020, ELIFE, V9, DOI 10.7554/eLife.55564
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034
   Zhou YM, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.3.37
NR 23
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 26
PY 2021
VL 11
IS 1
AR 17254
DI 10.1038/s41598-021-96704-x
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UJ0YJ
UT WOS:000691021200024
PM 34446787
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mittal, K
   Rajam, VMA
AF Mittal, Kanupriya
   Rajam, V. Mary Anita
TI Computerized retinal image analysis-a survey
SO MULTIMEDIA TOOLS AND APPLICATIONS
LA English
DT Article
DE Retinal image; Machine learning; Diabetic retinopathy
ID BLOOD-VESSEL SEGMENTATION; AUTOMATIC EXUDATE DETECTION; COLOR FUNDUS
   IMAGES; OPTIC-NERVE HEAD; DIABETIC-RETINOPATHY; MATHEMATICAL MORPHOLOGY;
   MICROANEURYSM DETECTION; NEURAL-NETWORK; BIT PLANES; MODEL
AB The speedy development of digital imaging and computer vision has extended the potential of using these technologies in ophthalmology. Image processing systems are increasingly prominent in medical diagnostic systems and especially to modern ophthalmology. The retinal images give information about the health of the visual system. Retinal diseases, such as glaucoma, diabetic retinopathy, age-related macular degeneration, and many other diseases that can lead to blindness, manifest themselves in the retina. An automated system offers standardized large-scale screening at a lower cost, reduces human errors, and provides services to remote areas. Extensive research has been done since the last two decades in developing automated methods. Due to the fast evolution of new techniques, a comprehensive review is needed on such technique and algorithms present to date. This survey paper provides the reader a comprehensive review of the existing research in automated retinal image analysis. In this paper, automated computer aided methods used to diagnose retinal diseases have been reviewed. Several state-of-the art techniques and algorithms used to localize and segment features, such as optic disc and optic cup, macula and fovea, retinal blood vessels, detection of retinal lesions (microaneurysms, haemorrhages, exudates), are discussed and presented.
C1 [Mittal, Kanupriya; Rajam, V. Mary Anita] Anna Univ, Dept CSE, CEG, Chennai, Tamil Nadu, India.
C3 Anna University; Anna University Chennai; College of Engineering Guindy
RP Mittal, K (通讯作者)，Anna Univ, Dept CSE, CEG, Chennai, Tamil Nadu, India.
EM kanu.05@gmail.com; anitav@annauniv.edu
RI Rajam, Mary Anita/AAR-5031-2021
CR Abdelazeem S, 2002, 2002 IEEE PROCEEDINGS OF THE NINETEENTH NATIONAL RADIO SCIENCE CONFERENCE, VOLS 1 AND 2, P421, DOI 10.1109/NRSC.2002.1022650
   Abramoff M. D., 2006, C P IEEE ENG MED BIO, P4432, DOI [DOI 10.1109/IEMBS.2006.259622, 10.1109/IEMBS.2006.259622]
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Acharya UR, 2009, P I MECH ENG H, V223, P545, DOI 10.1243/09544119JEIM486
   Acharya UR, 2012, J MED SYST, V36, P2011, DOI 10.1007/s10916-011-9663-8
   ADAMS R, 1994, IEEE T PATTERN ANAL, V16, P641, DOI 10.1109/34.295913
   Akram F, 2019, ARXIV190702742
   Al-Diri B, 2008, IEEE ENG MED BIO, P2262, DOI 10.1109/IEMBS.2008.4649647
   ALLEN L, 1964, AM J OPHTHALMOL, V57, P13, DOI 10.1016/0002-9394(64)92027-6
   Andreini P., 2019, ARXIV PREPRINT ARXIV
   [Anonymous], 2005, 2D 3D IMAGE REGISTRA
   Antal B, 2013, COMPUT MED IMAG GRAP, V37, P403, DOI 10.1016/j.compmedimag.2013.05.001
   Antal B, 2012, IEEE T BIO-MED ENG, V59, P1720, DOI 10.1109/TBME.2012.2193126
   Azzopardi G, 2015, MED IMAGE ANAL, V19, P46, DOI 10.1016/j.media.2014.08.002
   Bernardes R, 2011, OPHTHALMOLOGICA, V226, P161, DOI 10.1159/000329597
   Boyd K, 2018, WHAT IS GLAUCOMA
   CANNY J, 1986, IEEE T PATTERN ANAL, V8, P679, DOI 10.1109/TPAMI.1986.4767851
   Carmona EJ, 2008, ARTIF INTELL MED, V43, P243, DOI 10.1016/j.artmed.2008.04.005
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Cheng J, 2013, IEEE T MED IMAGING, V32, P1019, DOI 10.1109/TMI.2013.2247770
   Chin KS, 2013, PATTERN RECOGN LETT, V34, P1152, DOI 10.1016/j.patrec.2013.03.016
   Christodoulidis A, 2016, COMPUT MED IMAG GRAP, V52, P28, DOI 10.1016/j.compmedimag.2016.06.001
   Chutatape O, 1998, P ANN INT IEEE EMBS, V20, P3144, DOI 10.1109/IEMBS.1998.746160
   Dai PS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127748
   De J, 2016, IEEE T MED IMAGING, V35, P257, DOI 10.1109/TMI.2015.2465962
   Decenciere E, 2014, IMAGE ANAL STEREOL, V33, P231, DOI 10.5566/ias.1155
   Deepa V, 2019, IET IMAGE PROCESS, V13, P1341, DOI 10.1049/iet-ipr.2018.5672
   FLICK C S, 1947, Optician, V113, P246
   Foracchia M, 2004, IEEE T MED IMAGING, V23, P1189, DOI 10.1109/TMI.2004.829331
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Fraser CE, 2017, DIABETIC RETINOPATHY
   Fraz MM, 2013, J DIGIT IMAGING, V26, P274, DOI 10.1007/s10278-012-9513-3
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P600, DOI 10.1016/j.cmpb.2011.08.009
   Fraz MM, 2012, IEEE T BIO-MED ENG, V59, P2538, DOI 10.1109/TBME.2012.2205687
   Frucci M, 2014, 10TH INTERNATIONAL CONFERENCE ON SIGNAL-IMAGE TECHNOLOGY AND INTERNET-BASED SYSTEMS SITIS 2014, P592, DOI 10.1109/SITIS.2014.18
   Garcia M, 2009, COMPUT METH PROG BIO, V93, P9, DOI 10.1016/j.cmpb.2008.07.006
   Gardner GG, 1996, BRIT J OPHTHALMOL, V80, P940, DOI 10.1136/bjo.80.11.940
   Gerloff O., 1891, KLIN MONATSBL AUGENH, V29, P397
   Gong HM, 2015, 2015 8TH INTERNATIONAL CONGRESS ON IMAGE AND SIGNAL PROCESSING (CISP), P413, DOI 10.1109/CISP.2015.7407915
   Gonzalez R.C., 2017, DIGITAL IMAGE PROCES
   Gramatikov BI, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475-925X-13-52
   Gullstrand A., 1910, BERICHTE DTSCH OPHTH, V36, P326
   Habib M. M., 2017, Informatics in Medicine Unlocked, V9, P44, DOI 10.1016/j.imu.2017.05.006
   Haddrill M, 2018, WHAT IS AGE RELATED
   Hajdu A, 2013, IEEE T IMAGE PROCESS, V22, P4182, DOI 10.1109/TIP.2013.2271116
   Han J, 2012, MOR KAUF D, P1
   Harangi B, 2012, IEEE ENG MED BIO, P5951, DOI 10.1109/EMBC.2012.6347349
   Harangi B., 2012, COMP BAS MED SYST CB, P1
   Hatanaka Y., 2012, COMPUTER BASED MEDIC, P1, DOI DOI 10.1109/CBMS.2012.6266339
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Orlando JI, 2017, IEEE T BIO-MED ENG, V64, P16, DOI 10.1109/TBME.2016.2535311
   Jiang ZX, 2017, BIOCYBERN BIOMED ENG, V37, P412, DOI 10.1016/j.bbe.2017.04.001
   Jothi JAA, 2017, ARTIF INTELL REV, V48, P31, DOI 10.1007/s10462-016-9494-6
   KALVIAINEN H, 1995, IMAGE VISION COMPUT, V13, P239, DOI 10.1016/0262-8856(95)99713-B
   KASS M, 1987, INT J COMPUT VISION, V1, P321, DOI 10.1007/BF00133570
   Kauppi T, 2007, DIARETDB1 DIABETIC R, V2007, DOI [10.5244/C.21.15, DOI 10.5244/C.21.15]
   Keeler CR, 1997, ARCH OPHTHALMOL-CHIC, V115, P1456, DOI 10.1001/archopht.1997.01100160626017
   Khaderi K. R., 2011, RETINAL PHYS, V44, P8
   Khomri B, 2018, IET IMAGE PROCESS, V12, P2163, DOI 10.1049/iet-ipr.2018.5425
   Kohler T, 2013, COMP MED SY, P95, DOI 10.1109/CBMS.2013.6627771
   Kolb H., 2012, SIMPLE ANATOMY RETIN
   Kong F, 2015, 2015 INTERNATIONAL CONFERENCE ON ICT CONVERGENCE (ICTC), P26, DOI 10.1109/ICTC.2015.7354487
   Lay B, 1984, P SOC PHOTO-OPT INS, P165, DOI DOI 10.1117/12.936655
   Lazar I, 2013, IEEE T MED IMAGING, V32, P400, DOI 10.1109/TMI.2012.2228665
   Li HQ, 2004, IEEE T BIO-MED ENG, V51, P246, DOI 10.1109/TBME.2003.820400
   Lindeberg T., 1994, J APPL STAT, V21, P225, DOI [10.1080/757582976, DOI 10.1080/757582976]
   Liskowski P, 2016, IEEE T MED IMAGING, V35, P2369, DOI 10.1109/TMI.2016.2546227
   Liu DJ, 2009, HIS 2009: 2009 NINTH INTERNATIONAL CONFERENCE ON HYBRID INTELLIGENT SYSTEMS, VOL 1, PROCEEDINGS, P344, DOI 10.1109/HIS.2009.74
   Lowell J, 2004, IEEE T MED IMAGING, V23, P256, DOI 10.1109/TMI.2003.823261
   Lu SJ, 2011, IEEE T MED IMAGING, V30, P2126, DOI 10.1109/TMI.2011.2164261
   Lupascu CA, 2010, IEEE T INF TECHNOL B, V14, P1267, DOI 10.1109/TITB.2010.2052282
   Maintz J B, 1998, Med Image Anal, V2, P1, DOI 10.1016/S1361-8415(01)80026-8
   Maji D, 2015, IEEE ENG MED BIO, P3029, DOI 10.1109/EMBC.2015.7319030
   Maninis Kevis-Kokitsi, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P140, DOI 10.1007/978-3-319-46723-8_17
   Matsopoulos G K, 1999, IEEE Trans Inf Technol Biomed, V3, P47, DOI 10.1109/4233.748975
   Mitra, 2016, ARXIV160304833
   Mizutani A, 2009, INT SOC OPTICS PHOTO, V7260
   Moghimirad E, 2012, COMPUT BIOL MED, V42, P50, DOI 10.1016/j.compbiomed.2011.10.008
   NEKOVEI R, 1995, IEEE T NEURAL NETWOR, V6, P64, DOI 10.1109/72.363449
   Neto LC, 2017, EXPERT SYST APPL, V78, P182, DOI 10.1016/j.eswa.2017.02.015
   Nguyen UTV, 2013, PATTERN RECOGN, V46, P703, DOI 10.1016/j.patcog.2012.08.009
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Niemeijer M, 2007, IEEE T MED IMAGING, V26, P116, DOI 10.1109/TMI.2006.885336
   Niemeijer M, 2009, MED IMAGE ANAL, V13, P859, DOI 10.1016/j.media.2009.08.003
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Oliveira A, 2018, EXPERT SYST APPL, V112, P229, DOI 10.1016/j.eswa.2018.06.034
   Porwal P., 2018, INDIAN DIABETIC RETI
   Rammy SA, 2019, 2019 22 INT MULT C I, P1, DOI [10.1109/INMIC48123.2019.9022732, DOI 10.1109/INMIC48123.2019.9022732]
   Roerdink J. B. T. M., 2000, Fundamenta Informaticae, V41, P187
   Sathananthavathi V, 2018, IET IMAGE PROCESS, V12, P2075, DOI 10.1049/iet-ipr.2017.1266
   Schmitt JM, 1999, IEEE J SEL TOP QUANT, V5, P1205, DOI 10.1109/2944.796348
   Sekhar S, 2008, I S BIOMED IMAGING, P1577, DOI 10.1109/ISBI.2008.4541312
   Serra J., 1982, BIOMETRICS
   Sezgin M, 2004, J ELECTRON IMAGING, V13, P146, DOI 10.1117/1.1631315
   Shah SAA, 2019, UNSUPERVISED METHOD, V7, P167
   Sharma S, 2015, J NETWORK COMMUNICAT, V4, P1
   Sigurosson EM, 2014, PATTERN RECOGN LETT, V47, P164, DOI 10.1016/j.patrec.2014.03.006
   Singh NP, 2016, COMPUT METH PROG BIO, V129, P40, DOI 10.1016/j.cmpb.2016.03.001
   Sinthanayothin C, 2002, DIABETIC MED, V19, P105, DOI 10.1046/j.1464-5491.2002.00613.x
   Sinthanayothin C, 1999, BRIT J OPHTHALMOL, V83, P902, DOI 10.1136/bjo.83.8.902
   Smistad E, 2015, MED IMAGE ANAL, V20, P1, DOI 10.1016/j.media.2014.10.012
   Sopharak A, 2010, J MOD OPTIC, V57, P124, DOI 10.1080/09500340903118517
   Sopharak A, 2009, SENSORS-BASEL, V9, P2148, DOI 10.3390/s90302148
   Sopharak A, 2008, COMPUT MED IMAG GRAP, V32, P720, DOI 10.1016/j.compmedimag.2008.08.009
   Spencer T, 1996, COMPUT BIOMED RES, V29, P284, DOI 10.1006/cbmr.1996.0021
   Srinidhi CL, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0719-2
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   U RA, 2008, J MED SYST, V32, P481, DOI 10.1007/s10916-008-9154-8
   (US)Gonzales,(US)Woods, 2011, DIGITAL IMAGE PROCES
   Usher D, 2004, DIABETIC MED, V21, P84, DOI 10.1046/j.1464-5491.2003.01085.x
   von Helmholtz H, 1851, BESCHREIBUNG AUGENSP, P28
   Walter T, 2002, IEEE T MED IMAGING, V21, P1236, DOI 10.1109/TMI.2002.806290
   Walter T, 2007, MED IMAGE ANAL, V11, P555, DOI 10.1016/j.media.2007.05.001
   Wang SL, 2015, NEUROCOMPUTING, V149, P708, DOI 10.1016/j.neucom.2014.07.059
   Wang YF, 2013, PATTERN RECOGN, V46, P2117, DOI 10.1016/j.patcog.2012.12.014
   WebMD, 2018, DIABETIC RETINOPATHY
   Welfer D, 2011, COMPUT METH PROG BIO, V104, P397, DOI 10.1016/j.cmpb.2010.07.006
   Wisaeng K, 2019, IEEE ACCESS, V7, P11946, DOI 10.1109/ACCESS.2018.2890426
   World Health Organization, 2012, GLOB DAT VIS IMP
   Wu CH, 2007, I S BIOMED IMAGING, P604, DOI 10.1109/ISBI.2007.356924
   Xiao ZY, 2013, COMPUT MATH METHOD M, V2013, DOI 10.1155/2013/401413
   Xie SH, 2013, 2013 THIRD INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEM DESIGN AND ENGINEERING APPLICATIONS (ISDEA), P1225, DOI 10.1109/ISDEA.2012.289
   Yedidya Tamir, 2008, 2008 Digital Image Computing: Techniques and Applications, P52, DOI 10.1109/DICTA.2008.72
   Yin Y, 2012, PATTERN RECOGN, V45, P1235, DOI 10.1016/j.patcog.2011.09.019
   You XG, 2011, PATTERN RECOGN, V44, P2314, DOI 10.1016/j.patcog.2011.01.007
   Yu H, 2012, PROC SPIE, V8315, DOI 10.1117/12.911547
   Zhang J, 2014, COMPUT MED IMAG GRAP, V38, P517, DOI 10.1016/j.compmedimag.2014.05.010
   Zhang J, 2016, IEEE T MED IMAGING, V35, P2631, DOI 10.1109/TMI.2016.2587062
   Zhang SH, 2019, LECT NOTES COMPUT SC, V11764, P797, DOI 10.1007/978-3-030-32239-7_88
   Zhao YT, 2015, IEEE T MED IMAGING, V34, P1797, DOI 10.1109/TMI.2015.2409024
   Zhao YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122332
   Zhao YQ, 2014, PATTERN RECOGN, V47, P2437, DOI 10.1016/j.patcog.2014.01.006
   Zhu CZ, 2017, COMPUT MED IMAG GRAP, V55, P68, DOI 10.1016/j.compmedimag.2016.05.004
   Zolfagharnasab Hooshiar, 2014, J Med Signals Sens, V4, P1
NR 137
TC 9
Z9 9
U1 3
U2 27
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1380-7501
EI 1573-7721
J9 MULTIMED TOOLS APPL
JI Multimed. Tools Appl.
PD AUG
PY 2020
VL 79
IS 31-32
BP 22389
EP 22421
DI 10.1007/s11042-020-09041-y
EA MAY 2020
PG 33
WC Computer Science, Information Systems; Computer Science, Software
   Engineering; Computer Science, Theory & Methods; Engineering, Electrical
   & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering
GA NB5OB
UT WOS:000534982800003
DA 2022-11-30
ER

PT J
AU Mammo, DA
   Watson, D
   Armbrust, KR
AF Mammo, Danny A.
   Watson, Daniel
   Armbrust, Karen R.
TI Post-intravitreal injection endophthalmitis secondary to Turicella
   otitidis: a case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Endophthalmitis; Anti-VEGF; Aflibercept; Turicella otitidis; Case report
ID DIAGNOSIS; PROFILE
AB Background Endophthalmitis is a rare but potentially devastating complication of intravitreal injection. The causative organism plays an important role in prognosis following endophthalmitis. Here we present the first reported case of Turicella otitidis endophthalmitis, which is notable for a delayed presentation. Case presentation A 71 year old male who was receiving intravitreal aflibercept injections for neovascular age-related macular degeneration presented 4 weeks after his most recent intravitreal injection and was found to have endophthalmitis. Polymerase chain reaction (PCR) testing of aqueous fluid was positive for Turicella otitidis. The endophthalmitis responded well to treatment with intravitreal antibiotics. Conclusions Coryneform bacteria are a rare cause of endophthalmitis, and this is the first reported case of endophthalmitis caused by the corynebacterium species Turicella otitidis. As in this case, post-intravitreal injection endophthalmitis may have a bacterial etiology even with delayed presentation. The relatively indolent disease course and excellent response to intravitreal antibiotics is consistent with previous ophthalmic reports regarding other corynebacteria, as well as with otolaryngology and hematology oncology reports addressing Turicella otitidis specifically. This case supports the growing body of evidence for pathogenicity of Turicella otitidis and demonstrates the utility of PCR for diagnosis in small volume aqueous specimens.
C1 [Mammo, Danny A.; Watson, Daniel; Armbrust, Karen R.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, 420 Delaware St Southeast,MMC 493, Minneapolis, MN 55455 USA.
   [Armbrust, Karen R.] Vet Affairs Hlth Care Syst, Dept Ophthalmol, Minneapolis, MN 55417 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities; US
   Department of Veterans Affairs; Veterans Health Administration (VHA)
RP Armbrust, KR (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, 420 Delaware St Southeast,MMC 493, Minneapolis, MN 55455 USA.; Armbrust, KR (通讯作者)，Vet Affairs Hlth Care Syst, Dept Ophthalmol, Minneapolis, MN 55417 USA.
EM karen.armbrust@va.gov
RI Armbrust, Karen/AHB-4705-2022
OI Armbrust, Karen/0000-0001-9381-4756
FU University of Minnesota ophthalmology teaching and research fund
FX Funding was provided by the University of Minnesota ophthalmology
   teaching and research fund. The funding body had no role in study
   design, data analysis, data interpretation, or manuscript writing.
CR Bhattacharjee H, 2016, INDIAN J MED MICROBI, V34, P153, DOI 10.4103/0255-0857.180280
   Chiquet C, 2008, INVEST OPHTH VIS SCI, V49, P1971, DOI 10.1167/iovs.07-1377
   Dobinson HC, 2015, J CLIN MICROBIOL, V53, P2895, DOI 10.1128/JCM.00760-15
   Fileta JB, 2014, OSLI RETINA, V45, P143, DOI 10.3928/23258160-20140306-08
   Gomez-Garces JL, 2004, CLIN MICROBIOL INFEC, V10, P854, DOI 10.1111/j.1198-743X.2004.00965.x
   Han DP, 1996, AM J OPHTHALMOL, V122, P1
   Harper TW, 2009, AM J OPHTHALMOL, V147, P140, DOI 10.1016/j.ajo.2008.07.043
   Joseph J, 2016, BRIT J OPHTHALMOL, V100, P189, DOI 10.1136/bjophthalmol-2015-306910
   Kosacki J, 2020, AM J OPHTHALMOL, V212, P34, DOI 10.1016/j.ajo.2019.11.026
   Kuriyan AE, 2017, OPHTHALMOL RETINA, V1, P200, DOI 10.1016/j.oret.2016.11.007
   Loiez C, 2002, CLIN MICROBIOL INFEC, V8, P758, DOI 10.1046/j.1469-0691.2002.00474.x
   Pongsachareonnont P, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2264-5
   Sachdeva MM, 2016, J OPHTHALMIC INFLAMM, V6, DOI 10.1186/s12348-015-0069-5
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Stem MS, 2019, OPHTHALMOL RETINA, V3, P3, DOI 10.1016/j.oret.2018.09.013
   Sugita S, 2011, BRIT J OPHTHALMOL, V95, P345, DOI 10.1136/bjo.2009.171504
   Xu K, 2018, OPHTHALMOLOGY, V125, P1279, DOI 10.1016/j.ophtha.2018.01.022
   Yannuzzi NA, 2018, OSLI RETINA, V49, P313, DOI 10.3928/23258160-20180501-04
NR 18
TC 2
Z9 2
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 10
PY 2020
VL 20
IS 1
AR 142
DI 10.1186/s12886-020-01412-1
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LC9PS
UT WOS:000525666700001
PM 32276621
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Goh, JHL
   Lim, ZW
   Fang, XL
   Anees, A
   Nusinovici, S
   Rim, TH
   Cheng, CY
   Tham, YC
AF Goh, Jocelyn Hui Lin
   Lim, Zhi Wei
   Fang, Xiaoling
   Anees, Ayesha
   Nusinovici, Simon
   Rim, Tyler Hyungtaek
   Cheng, Ching-Yu
   Tham, Yih-Chung
TI Artificial Intelligence for Cataract Detection and Management
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE artificial intelligence; deep learning; cataract; visual impairment
ID INTRAOCULAR-LENS POWER; DIABETIC-RETINOPATHY; REFRACTIVE SURGERY;
   SYSTEM; FORMULA; EYES; IMPAIRMENT; PREVALENCE; VALIDATION; IMAGES
AB The rising popularity of artificial intelligence (AI) in ophthalmology is fuelled by the ever-increasing clinical "big data" that can be used for algorithm development. Cataract is one of the leading causes of visual impairment worldwide. However, compared with other major age-related eye diseases, such as diabetic retinopathy, age-related macular degeneration, and glaucoma, AI development in the domain of cataract is still relatively underexplored. In this regard, several previous studies explored algorithms for automated cataract assessment using either slit lamp of color fundus photographs. However, several other study groups proposed or derived new AI-based calculation for pre-cataract surgery intraocular lens power. Along with advancements in digitization of clinical data, data curation for future cataract-related AI developmental work is bound to undergo significant improvements in the foreseeable future. Even though most of these previous studies reported early promising performances, limitations such as lack of robust, high-quality training data, and lack of external validations remain. In the next phase of work, apart from algorithm's performance, it will also be pertinent to evaluate deployment angles, feasibility, efficiency, and cost-effectiveness of these new cataract-related AI systems.
C1 [Goh, Jocelyn Hui Lin; Lim, Zhi Wei; Fang, Xiaoling; Nusinovici, Simon; Rim, Tyler Hyungtaek; Cheng, Ching-Yu; Tham, Yih-Chung] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Goh, Jocelyn Hui Lin] Nanyang Technol Univ, Sch Chem & Biomed Engn, Div Bioengn, Singapore, Singapore.
   [Lim, Zhi Wei] Univ New South Wales, Fac Med, Sydney, NSW, Australia.
   [Fang, Xiaoling] Shanghai Eye Hosp, Shanghai Eye Dis Prevent & Treatment Ctr, Dept Ophthalmol, Shanghai, Peoples R China.
   [Anees, Ayesha] ASTAR, Inst High Performance Comp, Singapore, Singapore.
   [Rim, Tyler Hyungtaek; Cheng, Ching-Yu; Tham, Yih-Chung] Duke NUS Med Sch, Singapore, Singapore.
   [Cheng, Ching-Yu] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Cheng, Ching-Yu] Natl Univ Hlth Syst, Singapore, Singapore.
   [Goh, Jocelyn Hui Lin; Lim, Zhi Wei; Fang, Xiaoling; Nusinovici, Simon; Rim, Tyler Hyungtaek; Cheng, Ching-Yu; Tham, Yih-Chung] SERI, 20 Coll Rd,Level 6,Discovery Tower, Singapore 169856, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Nanyang
   Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; University of New South
   Wales Sydney; Agency for Science Technology & Research (A*STAR); A*STAR
   - Institute of High Performance Computing (IHPC); National University of
   Singapore; National University of Singapore; National University of
   Singapore
RP Cheng, CY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.; Cheng, CY (通讯作者)，Duke NUS Med Sch, Singapore, Singapore.; Cheng, CY (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.; Cheng, CY (通讯作者)，SERI, 20 Coll Rd,Level 6,Discovery Tower, Singapore 169856, Singapore.
EM chingyu.cheng@duke-nus.edu.sg
RI Chung, Yih/AIF-2414-2022; Cheng, Ching-Yu/Y-2229-2019
OI Chung, Yih/0000-0002-6752-797X; Cheng, Ching-Yu/0000-0003-0655-885X
FU National Medical Research Council, Singapore [NMRC/MOH-TA18-000268]
FX YCT is supported by the National Medical Research Council, Singapore
   [NMRC/MOH-TA18-000268]. The funding organization had no role in the
   design or conduct of this research.
CR Al Hajj H, 2019, MED IMAGE ANAL, V52, P24, DOI 10.1016/j.media.2018.11.008
   Alio JL, 2016, SURV OPHTHALMOL, V61, P769, DOI 10.1016/j.survophthal.2016.07.001
   Ardila D, 2019, NAT MED, V25, P954, DOI 10.1038/s41591-019-0447-x
   Aristodemou P, 2011, J CATARACT REFR SURG, V37, P63, DOI 10.1016/j.jcrs.2010.07.032
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585
   Bolster Nigel M, 2015, J Diabetes Sci Technol, V10, P318, DOI 10.1177/1932296815617969
   Chen C, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/976847
   Chen X, 2016, J CATARACT REFR SURG, V42, P163, DOI 10.1016/j.jcrs.2015.12.005
   Chua J, 2017, PLOS ONE, V12
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Connell BJ, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000251
   Dai W, 2020, BRIT J OPHTHALMOL, V104, P330, DOI 10.1136/bjophthalmol-2019-314256
   Dong YY, 2017, IEEE CONF IMAGING SY, P127, DOI 10.1109/ist.2017.8261463
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hee MR, 2015, JAMA OPHTHALMOL, V133, P1436, DOI 10.1001/jamaophthalmol.2015.3844
   Hoffer KJ, 2009, J CATARACT REFR SURG, V35, P759, DOI 10.1016/j.jcrs.2009.01.005
   Kane JX, 2016, J CATARACT REFR SURG, V42, P1490, DOI 10.1016/j.jcrs.2016.07.021
   Keel S, 2019, EYE, V33, P957, DOI 10.1038/s41433-019-0354-x
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   Ladas JG, 2015, JAMA OPHTHALMOL, V133, P1431, DOI 10.1001/jamaophthalmol.2015.3832
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Li HQ, 2003, PATTERN RECOGN, V36, P2093, DOI 10.1016/S0031-3203(03)00052-9
   Li HQ, 2009, IEEE ENG MED BIO, P3693, DOI 10.1109/IEMBS.2009.5334735
   Li JQ, 2018, IEEE SYS MAN CYBERN, P3964, DOI 10.1109/SMC.2018.00672
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Lian JX, 2016, BRIT J OPHTHALMOL, V100, P151, DOI 10.1136/bjophthalmol-2015-307382
   Liang YT, 2008, 2008 IEEE INTERNATIONAL SYMPOSIUM ON IT IN MEDICINE AND EDUCATION, VOLS 1 AND 2, PROCEEDINGS, P670, DOI 10.1109/ITME.2008.4743950
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Maamari RN, 2014, BRIT J OPHTHALMOL, V98, P438, DOI 10.1136/bjophthalmol-2013-303797
   Maier-Hein L, 2017, NAT BIOMED ENG, V1, P691, DOI 10.1038/s41551-017-0132-7
   Melles RB, 2019, OPHTHALMOLOGY, V126, P1334, DOI 10.1016/j.ophtha.2019.04.011
   Olsen T, 2007, ACTA OPHTHALMOL SCAN, V85, P472, DOI 10.1111/j.1600-0420.2007.00879.x
   Pead E, 2019, SURV OPHTHALMOL, V64, P498, DOI 10.1016/j.survophthal.2019.02.003
   Pratap T, 2019, BIOMED SIGNAL PROCES, V53, DOI 10.1016/j.bspc.2019.04.010
   Prescott G, 2014, BRIT J OPHTHALMOL, V98, P1042, DOI 10.1136/bjophthalmol-2013-304338
   Ran J, 2018, IEEE I C NETW INFRAS, P155, DOI 10.1109/ICNIDC.2018.8525852
   Resnikoff S, 2019, BR J OPHTHALMOL
   Rong XF, 2019, J CATARACT REFR SURG, V45, P732, DOI 10.1016/j.jcrs.2018.12.025
   Siddiqui AA, 2017, INDIAN J OPHTHALMOL, V65, P1289, DOI 10.4103/ijo.IJO_834_17
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Varma R, 2008, MED CARE, V46, P497, DOI 10.1097/MLR.0b013e31816080fe
   Wang L, 2015, OPHTHALMOLOGY, V122, P2443, DOI 10.1016/j.ophtha.2015.08.037
   Wang L, 2011, J CATARACT REFR SURG, V37, P2018, DOI 10.1016/j.jcrs.2011.05.042
   Wang P, 2019, GUT, V68, P1813, DOI 10.1136/gutjnl-2018-317500
   Wu XH, 2019, BRIT J OPHTHALMOL, V103, P1553, DOI 10.1136/bjophthalmol-2019-314729
   Xu YW, 2013, LECT NOTES COMPUT SC, V8150, P468, DOI 10.1007/978-3-642-40763-5_58
   Yu F, JAMA NETW OPEN
   Yu KH, 2018, NAT BIOMED ENG, V2, P719, DOI 10.1038/s41551-018-0305-z
   Zhang LL, 2017, IEEE INT C NETW SENS, P60, DOI 10.1109/ICNSC.2017.8000068
   Zhang YC, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/1917268
   Zisimopoulos O, 2018, LECT NOTES COMPUT SC, V11073, P265, DOI 10.1007/978-3-030-00937-3_31
NR 56
TC 16
Z9 16
U1 2
U2 13
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAR-APR
PY 2020
VL 9
IS 2
BP 88
EP 95
DI 10.1097/01.APO.0000656988.16221.04
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LJ4VB
UT WOS:000530163700006
PM 32349116
OA gold
DA 2022-11-30
ER

PT J
AU Zhang, C
   Han, M
   Wu, S
AF Zhang, Chao
   Han, Mei
   Wu, Shuai
TI Silencing fibroblast growth factor 7 inhibits krypton laser-induced
   choroidal neovascularization in a rat model
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE choroidal neovascularization; fibroblast growth factor 7; invasion;
   proliferation; vascular endothelial growth factor
ID VEGF; EPITHELIUM; EXPRESSION; CANCER
AB Choroidal neovascularization (CNV), a characteristic of age-related macular degeneration, is an underlying cause of severe vision loss among elderly patients. Fibroblast growth factor (FGF) is suggested to exert an important role in the pathogenesis of CNV. However, the molecular mechanisms governing this event are not fully elucidated. Herein, we identified the potential role of FGF7 in CNV. To examine the roles of FGF7 in the progression of CNV, rat CNV models were established and treated with small interfering RNA (siRNA) against FGF7 or FGF7 overexpression, followed by identification of expression of FGF7 in the CNV modeled rats. Next, proliferation and migration, and in vitro tube formation of human umbilical vein endothelial cells, as well as expression of vascular endothelial growth factor (VEGF) and transforming growth factor-beta 2 (TGF-beta 2) were evaluated. CNV led to upregulated FGF7 expression. Cells in the presence of FGF7 siRNA showed suppressed proliferation, migration, and tube formation, along with downregulated VEGF and TGF-beta 2 expression. Taken together, functional suppression of FGF7 inhibited the onset of CNV, ultimately highlighting a novel therapeutic target for suppressing CNV progression.
C1 [Zhang, Chao; Han, Mei] Jilin Univ, Hosp 2, Dept Strabismus & Pediat Ophthalmol, Changchun, Jilin, Peoples R China.
   [Wu, Shuai] Jilin Univ, Hosp 2, Dept Orbital Dis & Ocular Plast Surg, 218 Ziqiang St, Changchun 130000, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Wu, S (通讯作者)，Jilin Univ, Hosp 2, Dept Orbital Dis & Ocular Plast Surg, 218 Ziqiang St, Changchun 130000, Jilin, Peoples R China.
EM wushuai1986@yeah.net
CR Bai YJ, 2014, MOL VIS, V20, P1258
   Cui KX, 2018, BIOCHEM BIOPH RES CO, V503, P202, DOI 10.1016/j.bbrc.2018.06.003
   Feng LL, 2017, AM J PATHOL, V187, P2208, DOI 10.1016/j.ajpath.2017.06.015
   Fu ZJ, 2017, CELL REP, V18, P1606, DOI 10.1016/j.celrep.2017.01.014
   Hayashi M, 2005, MOL VIS, V11, P201
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Huang TT, 2017, INT J ONCOL, V50, P1501, DOI 10.3892/ijo.2017.3927
   Jiang H, 2017, J NEUROCHEM, V140, P307, DOI 10.1111/jnc.13900
   Jiang J, 2018, EUR J PHARM SCI, V121, P251, DOI 10.1016/j.ejps.2018.04.043
   Kao WWY, 2010, EYE CONTACT LENS, V36, P265, DOI 10.1097/ICL.0b013e3181ef0e00
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Katoh M, 2016, INT J MOL MED, V38, P3, DOI 10.3892/ijmm.2016.2620
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Li YM, 2017, J CELL MOL MED, V21, P1555, DOI 10.1111/jcmm.13086
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Nochioka K, 2016, ACTA HISTOCHEM CYTOC, V49, P67, DOI 10.1267/ahc.15036
   Peng H, 2019, CELL SIGNAL, V54, P179, DOI 10.1016/j.cellsig.2018.11.006
   Peng YT, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0481-8
   Semrad TJ, 2012, CLIN LUNG CANCER, V13, P90, DOI 10.1016/j.cllc.2011.08.001
   Shang AQ, 2019, J CELL BIOCHEM, V120, P778, DOI 10.1002/jcb.27438
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Wu Chanyuan, 2014, Zhonghua Nei Ke Za Zhi, V53, P460
   Xin Wang, 2017, Proceedings of the ACM on Measurement and Analysis of Computing Systems, V1, DOI 10.1145/3084444
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
   Zhao JF, 2018, EXP EYE RES, V174, P152, DOI 10.1016/j.exer.2018.05.030
NR 27
TC 1
Z9 1
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG
PY 2019
VL 120
IS 8
BP 13792
EP 13801
DI 10.1002/jcb.28652
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ID5LQ
UT WOS:000471718300165
PM 31017714
DA 2022-11-30
ER

PT J
AU Liu, LY
   Zhou, X
   Kuang, XL
   Long, CD
   Liu, WW
   Tang, Y
   Liu, HJ
   He, J
   Huang, ZX
   Fan, YT
   Zhang, QJ
   Shen, HX
AF Liu, Lanying
   Zhou, Xin
   Kuang, Xielan
   Long, Chongde
   Liu, Weiwei
   Tang, Yan
   Liu, Huijun
   He, Jia
   Huang, Zixin
   Fan, Yuting
   Zhang, Qingjiong
   Shen, Huangxuan
TI The inhibition of NOTCH2 reduces UVB-induced damage in retinal pigment
   epithelium cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium;
   ultraviolet B; Notch signaling
ID MACULAR DEGENERATION; INDUCED APOPTOSIS; RPE CELLS; EYE; EXPRESSION;
   PATHWAYS
AB Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly. The pathogenesis of dry AMD remains indistinct and the mechanism of retinal pigment epithelium (RPE) cells death in dry AMD is controversial. The aim of the present study was to investigate the functions of Notch signaling in ultraviolet B (UVB)-induced damage of RPE cells. It was identified that, in RPE cells, UVB increased intracellular reactive oxygen species (ROS) and induced cell apoptosis. In addition, UVB activated Notch signaling in a dose dependent manner. Surprisingly, NOTCH2, but not NOTCH1, was demonstrated to be the major Notch receptor in RPE cells. Under normal conditions, the inhibition of NOTCH2 reduced cell growth and cell migration, but had no impact on intracellular ROS and cell apoptosis. However, in the presence of UVB, the inhibition of NOTCH2, but not NOTCH1, attenuated intracellular ROS and cell apoptosis. The function of Notch signaling involved in UVB damage of RPE cells may not only be significant to understanding the pathogenesis of AMD (especially dry AMD), but also useful for designing effective therapeutic agents for dry AMD.
C1 [Liu, Lanying; Zhou, Xin; Kuang, Xielan; Long, Chongde; Liu, Weiwei; Tang, Yan; Liu, Huijun; He, Jia; Huang, Zixin; Fan, Yuting; Zhang, Qingjiong; Shen, Huangxuan] Sun Yat Sen Univ, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China.
   [Kuang, Xielan; Shen, Huangxuan] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Biobank Eye, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Shen, HX (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM shenhx@mail.sysu.edu.cn
RI Zhang, Qingjiong/AAR-6331-2021
OI Zhang, Qingjiong/0000-0001-7508-848X; Zhou, Xin/0000-0002-0480-3068
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Balaiya S, 2010, CLIN OPHTHALMOL, V4, P33
   Bao ZZ, 1997, J NEUROSCI, V17, P1425
   Biarnes M, 2011, OPTOMETRY VISION SCI, V88, P881, DOI 10.1097/OPX.0b013e31821988c1
   Bolos V, 2007, ENDOCR REV, V28, P339, DOI 10.1210/er.2006-0046
   Chen Jie, 2010, Genes Cancer, V1, P822, DOI 10.1177/1947601910383564
   Chen ZR, 2012, BIOCHEM BIOPH RES CO, V422, P522, DOI 10.1016/j.bbrc.2012.05.068
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Fukunaga-Kalabis M, 2015, J INVEST DERMATOL, V135, P1521, DOI 10.1038/jid.2015.59
   KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Kraljevic Pavelic S, 2015, BIOCHIM BIOPHYS ACTA, V1852, P1833
   Kulms D, 2002, BIOCHEM PHARMACOL, V64, P837, DOI 10.1016/S0006-2952(02)01146-2
   Lin S, 2013, ONCOGENE, V32, P4845, DOI 10.1038/onc.2012.482
   Liu WW, 2013, SCI WORLD J, DOI 10.1155/2013/178708
   Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45
   McCright B, 2001, DEVELOPMENT, V128, P491
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Park GB, 2015, INVEST OPHTH VIS SCI, V56, P5162, DOI 10.1167/iovs.14-16058
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Schouwey K, 2011, ONCOGENE, V30, P313, DOI 10.1038/onc.2010.428
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Valerie K, 2007, MOL CANCER THER, V6, P789, DOI 10.1158/1535-7163.MCT-06-0596
   Vatsyayan R, 2012, BIOCHEM BIOPH RES CO, V417, P346, DOI 10.1016/j.bbrc.2011.11.113
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou Y, 2013, P NATL ACAD SCI USA, V110, P8966, DOI 10.1073/pnas.1218145110
NR 33
TC 7
Z9 7
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2017
VL 16
IS 1
BP 730
EP 736
DI 10.3892/mmr.2017.6625
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EZ9TZ
UT WOS:000405074100096
PM 28560393
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Krigel, A
   Berdugo, M
   Picard, E
   Levy-Boukris, R
   Jaadane, I
   Jonet, L
   Dernigoghossian, M
   Andrieu-Soler, C
   Torriglia, A
   Behar-Cohen, F
AF Krigel, A.
   Berdugo, M.
   Picard, E.
   Levy-Boukris, R.
   Jaadane, I.
   Jonet, L.
   Dernigoghossian, M.
   Andrieu-Soler, C.
   Torriglia, A.
   Behar-Cohen, F.
TI LIGHT-INDUCED RETINAL DAMAGE USING DIFFERENT LIGHT SOURCES, PROTOCOLS
   AND RAT STRAINS REVEALS LED PHOTOTOXICITY
SO NEUROSCIENCE
LA English
DT Article
DE retina; Light Emitting Diodes; phototoxicity; pigmented rats; chronic
   light exposure
ID MACULAR DEGENERATION; PHOTOCHEMICAL DAMAGE; MECHANISMS; EXPOSURE;
   CONSEQUENCES
AB To save energy, the European directives from the Eco-design of Energy Using Products (2005/32/CE) have recommended the replacement of incandescent lamps by more economic devices such as Light Emitting Diodes (LEDs). However, the emission spectrum of these devices is enriched in blue radiations, known to be potentially dangerous to the retina. Recent studies showed that light exposure contributes to the onset of early stages of age-related macular degeneration (AMD). Here, we investigate, in albinos and pigmented rats, the effects of different exposure protocols. Twenty-four hours exposure at high luminance was compared to a cyclic (dark/light) exposure at domestic levels for 1 week and 1 month, using different LEDs (Cold white, blue and green), as well as fluorocompact bulbs and fluorescent tubes. The data suggest that the blue component of the white-LED may cause retinal toxicity at occupational domestic illuminance and not only in extreme experimental conditions, as previously reported. It is important to note that the current regulations and standards have been established on the basis of acute light exposure and do not take into account the effects of repeated exposure. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Krigel, A.; Berdugo, M.; Picard, E.; Levy-Boukris, R.; Jaadane, I.; Jonet, L.; Dernigoghossian, M.; Andrieu-Soler, C.; Torriglia, A.; Behar-Cohen, F.] Univ Paris 06, Univ Paris Descartes, Ctr Recherches Cordeliers, INSERM,U1138, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite
RP Torriglia, A; Behar-Cohen, F (通讯作者)，Univ Paris 06, Univ Paris Descartes, Ctr Recherches Cordeliers, INSERM,U1138, Paris, France.
EM alicia.torriglia@inserm.fr; francine.behar@gmail.com
RI picard, Emilie/A-6919-2013; Torriglia, Alicia/L-6957-2017; Torriglia,
   Alicia/Q-3509-2019
OI picard, Emilie/0000-0002-2689-0510; Torriglia,
   Alicia/0000-0003-1181-6710; Imene, Jaadane/0000-0003-1887-1659;
   Andrieu-Soler, Charlotte/0000-0002-3287-6117
FU region Ile de France; ADEME, Retinaled grant
FX This work was supported by the region Ile de France, grant to FBC and AK
   and by ADEME, Retinaled grant to IJ and AT.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Behar-Cohen F, 2011, PROG RETIN EYE RES, V30, P239, DOI 10.1016/j.preteyeres.2011.04.002
   Chahory S, 2010, NEUROCHEM INT, V57, P278, DOI 10.1016/j.neuint.2010.06.006
   Dawson W, 2001, EXP EYE RES, V73, P137, DOI 10.1006/exer.2001.1020
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jaadane I, 2015, FREE RADICAL BIO MED, V84, P373, DOI 10.1016/j.freeradbiomed.2015.03.034
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Mukai R, 2012, INVEST OPHTH VIS SCI, V53, P6035, DOI 10.1167/iovs.12-9608
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   ORTINMARTINEZ A, 2014, PLOS ONE, V9, DOI DOI 10.1371/journal.pone.0113798
   Peng ML, 2012, LIFE SCI J, V9, P477
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Shang YM, 2014, ENVIRON HEALTH PERSP, V122, P269, DOI 10.1289/ehp.1307294
   Sliney DH, 2005, PHOTOCHEM PHOTOBIOL, V81, P483, DOI 10.1562/2005-02-14-RA-439.1
   Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Ueda T, 2009, EXP EYE RES, V89, P863, DOI 10.1016/j.exer.2009.07.018
   van Norren D, 2011, PHOTOCHEM PHOTOBIOL, V87, P747, DOI 10.1111/j.1751-1097.2011.00921.x
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Ziegelberger G, 2013, HEALTH PHYS, V105, P74, DOI 10.1097/HP.0b013e318289a611
NR 26
TC 74
Z9 75
U1 1
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD DEC 17
PY 2016
VL 339
BP 296
EP 307
DI 10.1016/j.neuroscience.2016.10.015
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA ED9CT
UT WOS:000389168500026
PM 27751961
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Dibas, A
   Yorio, T
AF Dibas, Adnan
   Yorio, Thomas
TI Glucocorticoid therapy and ocular hypertension
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Glaucoma; Glucocorticoids; Steroid receptors; Trabecular meshwork
ID HUMAN TRABECULAR MESHWORK; RECEPTOR-BETA-ISOFORM; CORTICOSTEROID-BINDING
   GLOBULIN; OPEN-ANGLE GLAUCOMA; 11-BETA-HYDROXYSTEROID DEHYDROGENASE
   TYPE-2; INTRAVITREAL TRIAMCINOLONE ACETONIDE; LINKED ACTIN NETWORKS;
   NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-I; INTRAOCULAR-PRESSURE
AB The projected number of people who will develop age-related macular degeneration in estimated at 2020 is 196 million and is expected to reach 288 million in 2040. Also, the number of people with Diabetic retinopathy will grow from 126.6 million in 2010 to 191.0 million by 2030. In addition, it is estimated that there are 2.3 million people suffering from uveitis worldwide. Because of the anti-inflammatory properties of glucocorticoids (GCs), they are often used topically and/or intravitreally to treat ocular inflammation conditions or edema associated with macular degeneration and diabetic retinopathy. Unfortunately, ocular GC therapy can lead to severe side effects. Serious and sometimes irreversible eye damage can occur as a result of the development of GC-induced ocular hypertension causing secondary open-angle glaucoma. According to the world health organization, glaucoma is the second leading cause of blindness in the world and it is estimated that 80 million will suffer from glaucoma by 2020. In the current review, mechanisms of GC-induced damage in ocular tissue, GC-resistance, and enhancing GC therapy will be discussed. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Dibas, Adnan; Yorio, Thomas] UNT Hlth Sci Ctr, North Texas Eye Res Inst, Ft Worth, TX USA.
C3 University of North Texas System; University of North Texas Health
   Science Center
RP Dibas, A (通讯作者)，Univ North Texas Hlth Sci Ctr Ft Worth, North Texas Eye Res Inst, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.
EM adnan.dibas@unthsc.edu
FU National Eye Institute [EY016242]; NATIONAL EYE INSTITUTE [R01EY016242]
   Funding Source: NIH RePORTER
FX This work was supported by a grant from the National Eye Institute
   (EY016242).
CR Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091
   Adams M, 2003, MOL ENDOCRINOL, V17, P2583, DOI 10.1210/me.2002-0305
   AKINGBEHIN AO, 1983, BRIT J OPHTHALMOL, V67, P661, DOI 10.1136/bjo.67.10.661
   Al Bakir M, 2008, ANN NY ACAD SCI, V1137, P283, DOI 10.1196/annals.1448.007
   Anderson S, 2009, J OCUL PHARMACOL TH, V25, P215, DOI 10.1089/jop.2008.0120
   ARMALY MF, 1963, ARCH OPHTHALMOL-CHIC, V70, P492, DOI 10.1001/archopht.1963.00960050494011
   Avenant C, 2010, MOL CELL ENDOCRINOL, V327, P72, DOI 10.1016/j.mce.2010.06.007
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   BARTLETT JD, 1993, J OCUL PHARMACOL, V9, P35, DOI 10.1089/jop.1993.9.35
   Beck IME, 2009, ENDOCR REV, V30, P830, DOI 10.1210/er.2009-0013
   Beck IM, 2008, EMBO J, V27, P1682, DOI 10.1038/emboj.2008.95
   Beger C, 2003, BRIT J HAEMATOL, V122, P245, DOI 10.1046/j.1365-2141.2003.04426.x
   Bernstein H.N., 1977, ARCH OPHTHALMOL-CHIC, V9, P1075
   Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6
   Blind RD, 2008, J STEROID BIOCHEM, V109, P150, DOI 10.1016/j.jsbmb.2008.01.002
   Brady C.J., 2016, COCHRANE DB SYST REV, V12, P2
   Budzynski E.S.A., 2009, ARVO ANN M FORT LAUD
   Burdge GC, 2009, J NUTR, V139, P1054, DOI 10.3945/jn.109.104653
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Cameron A, 2010, J CLIN ENDOCR METAB, V95, P4689, DOI 10.1210/jc.2010-0942
   Cannarile L, 2001, CELL DEATH DIFFER, V8, P201, DOI 10.1038/sj.cdd.4400798
   Cao Y, 2013, BLOOD, V121, P1553, DOI 10.1182/blood-2012-05-432336
   Carballo-Jane E, 2004, J STEROID BIOCHEM, V88, P191, DOI 10.1016/j.jsbmb.2003.11.012
   Carrigan A, 2007, J BIOL CHEM, V282, P10963, DOI 10.1074/jbc.M602931200
   CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355
   Charmandari E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025612
   Chen WW, 2008, MOL ENDOCRINOL, V22, P1754, DOI 10.1210/me.2007-0219
   Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479
   Chrousos G.P., 2005, SCI STKE, P48
   Chrousos GP, 2012, BASIC CLIN PHARMACOL, P697
   Clark AF, 2007, SURV OPHTHALMOL, V52, pS26, DOI 10.1016/j.survophthal.2006.11.003
   CLARK AF, 1994, INVEST OPHTH VIS SCI, V35, P281
   CLARK AF, 1995, INVEST OPHTH VIS SCI, V36, P478
   Connors BW, 2012, EPILEPSY CURR, V12, P66, DOI 10.5698/1535-7511-12.2.66
   COPE CL, 1958, BMJ-BRIT MED J, V1, P1020, DOI 10.1136/bmj.1.5078.1020
   Davies L, 2008, MOL ENDOCRINOL, V22, P1331, DOI 10.1210/me.2007-0360
   DAVIES TG, 1968, BRIT J OPHTHALMOL, V52, P32, DOI 10.1136/bjo.52.1.32
   De Bosscher K, 2006, ONCOGENE, V25, P6868, DOI 10.1038/sj.onc.1209935
   De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102
   de Lange P, 2001, CANCER RES, V61, P3937
   de Rooij SR, 2012, PSYCHONEUROENDOCRINO, V37, P782, DOI 10.1016/j.psyneuen.2011.09.010
   Derijk RH, 2001, J RHEUMATOL, V28, P2383
   Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002
   Dewint P, 2008, J IMMUNOL, V180, P2608, DOI 10.4049/jimmunol.180.4.2608
   Dibas A, 2012, INVEST OPHTH VIS SCI, V53, P2938, DOI 10.1167/iovs.11-8331
   Drebert Z, 2015, J STEROID BIOCHEM, V149, P92, DOI 10.1016/j.jsbmb.2015.02.002
   DuBois DC, 2013, STEROIDS, V78, P312, DOI 10.1016/j.steroids.2012.11.014
   Echeverria PC, 2009, MOL CELL BIOL, V29, P4788, DOI 10.1128/MCB.00649-09
   ETTINGER B, 2001, J MANAGE CARE PHARM, V7, P228
   Fan BJ, 2008, INVEST OPHTH VIS SCI, V49, P1886, DOI 10.1167/iovs.07-0414
   Faralli JA, 2013, BBA-MOL CELL RES, V1833, P3306, DOI 10.1016/j.bbamcr.2013.09.020
   FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245
   Fingert JH, 1998, GENOME RES, V8, P377, DOI 10.1101/gr.8.4.377
   Fingert JH, 2001, INVEST OPHTH VIS SCI, V42, P145
   Foster C, 2002, DIAGNOSIS TREATMENT
   FREEDMAN J, 1976, BRIT J OPHTHALMOL, V60, P786, DOI 10.1136/bjo.60.11.786
   Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839
   Frijters R, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-359
   Friso S, 2008, ATHEROSCLEROSIS, V199, P323, DOI 10.1016/j.atherosclerosis.2007.11.029
   Galliher-Beckley AJ, 2011, MOL CELL BIOL, V31, P4663, DOI 10.1128/MCB.05866-11
   Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com
   Gathercole LL, 2013, ENDOCR REV, V34, P525, DOI 10.1210/er.2012-1050
   Gelatt KN, 1998, J OCUL PHARMACOL TH, V14, P57, DOI 10.1089/jop.1998.14.57
   Gerometta R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1492, DOI 10.1001/archopht.122.10.1492
   Gerometta R, 2009, INVEST OPHTH VIS SCI, V50, P669, DOI 10.1167/iovs.08-2410
   Goecke A, 2006, IMMUNOBIOLOGY, V211, P85, DOI 10.1016/j.imbio.2005.11.002
   GOULD NR, 1978, POULTRY SCI, V57, P1733, DOI 10.3382/ps.0571733
   Gramlich OW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057557
   Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014
   Haeck IM, 2011, J AM ACAD DERMATOL, V64, P275, DOI 10.1016/j.jaad.2010.01.035
   Hakim A, 2013, FASEB J, V27, P4510, DOI 10.1096/fj.12-222604
   Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131
   HAMMOND GL, 1991, J STEROID BIOCHEM, V40, P755, DOI 10.1016/0960-0760(91)90300-T
   HAMMOND GL, 1990, ENDOCR REV, V11, P65, DOI 10.1210/edrv-11-1-65
   Hauk PJ, 2002, AM J RESP CELL MOL, V27, P361, DOI 10.1165/rcmb.4861
   HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x
   Heinz C, 2009, OCUL IMMUNOL INFLAMM, V17, P243, DOI 10.1080/09273940902913035
   Henschkowski J, 2008, AM J HYPERTENS, V21, P644, DOI 10.1038/ajh.2008.152
   Herbert HM, 2004, J GLAUCOMA, V13, P96, DOI 10.1097/00061198-200404000-00003
   Hinds TD, 2010, MOL ENDOCRINOL, V24, P1715, DOI 10.1210/me.2009-0411
   Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100
   Holmstrom SR, 2008, MOL ENDOCRINOL, V22, P2061, DOI 10.1210/me.2007-0581
   Holownia A, 2009, EUR J MED RES, V14, P108, DOI 10.1186/2047-783X-14-S4-108
   Honda M, 2000, GASTROENTEROLOGY, V118, P859, DOI 10.1016/S0016-5085(00)70172-7
   Huang P, 2010, J GLAUCOMA, V19, P324, DOI 10.1097/IJG.0b013e3181b4cac7
   IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081
   Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466
   Jain A, 2012, INVEST OPHTH VIS SCI, V53, P857, DOI 10.1167/iovs.11-8497
   Jewell CM, 2012, MOL ENDOCRINOL, V26, P244, DOI 10.1210/me.2011-1116
   Johansson-Haque K, 2008, J MOL ENDOCRINOL, V41, P239, DOI 10.1677/JME-08-0015
   Johnson D, 1997, ARCH OPHTHALMOL-CHIC, V115, P375, DOI 10.1001/archopht.1997.01100150377011
   JOHNSON DH, 1990, INVEST OPHTH VIS SCI, V31, P2568
   Jones R, 2006, CURR OPIN OPHTHALMOL, V17, P163
   KASS MA, 1976, AM J OPHTHALMOL, V82, P496, DOI 10.1016/0002-9394(76)90501-8
   Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003
   Kelly A, 2008, J ALLERGY CLIN IMMUN, V121, P203, DOI 10.1016/j.jaci.2007.09.010
   Kiddee W, 2013, SURV OPHTHALMOL, V58, P291, DOI 10.1016/j.survophthal.2012.08.003
   Kino T, 2009, BIOCHEM BIOPH RES CO, V381, P671, DOI 10.1016/j.bbrc.2009.02.110
   KLEMETTI A, 1990, ACTA OPHTHALMOL, V68, P29
   Kostadinova RM, 2005, FASEB J, V19, P650, DOI 10.1096/fj.04-2820fje
   KRETT NL, 1995, CANCER RES, V55, P2727
   Kubota R, 1998, BIOCHEM BIOPH RES CO, V242, P396, DOI 10.1006/bbrc.1997.7972
   Kuo TY, 2012, P NATL ACAD SCI USA, V109, P11160, DOI 10.1073/pnas.1111334109
   Kwok AKH, 1997, OPHTHALMOLOGY, V104, P2112, DOI 10.1016/S0161-6420(97)30052-9
   Lam DSC, 2005, CLIN EXP OPHTHALMOL, V33, P252, DOI 10.1111/j.1442-9071.2005.01022.x
   LANDINWILHELMSEN K, 1994, CLIN ENDOCRINOL, V41, P351, DOI 10.1111/j.1365-2265.1994.tb02556.x
   Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135
   Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567
   Levin DS, 2002, AM J OPHTHALMOL, V133, P196, DOI 10.1016/S0002-9394(01)01372-1
   Lewis-Tuffin LJ, 2007, MOL CELL BIOL, V27, P2266, DOI 10.1128/MCB.01439-06
   Lewis-Tuffin LJ, 2006, ANN NY ACAD SCI, V1069, P1, DOI 10.1196/annals.1351.001
   Li A, 2011, INVEST OPHTH VIS SCI, V52, P7996, DOI 10.1167/iovs.11-8170
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019
   Lin HY, 2010, MOL CELL ENDOCRINOL, V316, P3, DOI 10.1016/j.mce.2009.06.015
   Lo WR, 2003, INVEST OPHTH VIS SCI, V44, P473, DOI 10.1167/iovs.02-0444
   Longui CA, 2000, HORM METAB RES, V32, P401, DOI 10.1055/s-2007-978661
   LORENZETTI OJ, 1970, J PHARMACOL EXP THER, V175, P763
   Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025
   MCCARTY GR, 1991, INVEST OPHTH VIS SCI, V32, P1600
   Melander O, 2000, J HUM HYPERTENS, V14, P819, DOI 10.1038/sj.jhh.1001116
   MEREDIG WE, 1980, A GRAEF ARCH KLIN EX, V213, P215, DOI 10.1007/BF00410991
   MEULENBERG PMM, 1990, CLIN CHEM, V36, P70
   Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919
   MOALLI PA, 1993, CANCER RES, V53, P3877
   Morin B, 2006, BIOCHEMISTRY-US, V45, P7299, DOI 10.1021/bi060314k
   Nagy Z, 2016, J STEROID BIOCHEM, V155, P76, DOI 10.1016/j.jsbmb.2015.10.006
   Nehme A, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-58
   Neri P, 2004, J GLAUCOMA, V13, P461, DOI 10.1097/01.ijg.0000146391.77618.d0
   Newnham JP, 2001, CLIN EXP PHARMACOL P, V28, P957, DOI 10.1046/j.1440-1681.2001.03559.x
   Ng JSK, 2000, OPHTHALMOLOGY, V107, P2097, DOI 10.1016/S0161-6420(00)00357-2
   Nixon M, 2013, STEROIDS, V78, P59, DOI 10.1016/j.steroids.2012.09.013
   Noble S, 1998, BIODRUGS, V10, P329, DOI 10.2165/00063030-199810040-00007
   Nusbaum DM, 2015, EXP EYE RES, V136, P38, DOI 10.1016/j.exer.2015.04.014
   Oakley RH, 1996, J BIOL CHEM, V271, P9550, DOI 10.1074/jbc.271.16.9550
   Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007
   Oakley RH, 2011, J BIOL CHEM, V286, P3177, DOI 10.1074/jbc.R110.179325
   Orii F, 2002, BIOCHEM BIOPH RES CO, V296, P1286, DOI 10.1016/S0006-291X(02)02030-2
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Paakinaho V, 2014, NUCLEIC ACIDS RES, V42, P1575, DOI 10.1093/nar/gkt1033
   PARENTE L, 1994, TRENDS PHARMACOL SCI, V15, P362, DOI 10.1016/0165-6147(94)90154-6
   Patel R, 2014, MOL ENDOCRINOL, V28, P999, DOI 10.1210/me.2014-1062
   Paterson G, 1965, Trans Ophthalmol Soc U K, V85, P295
   Payette H, 2003, J AM GERIATR SOC, V51, P1237, DOI 10.1046/j.1532-5415.2003.51407.x
   Pena CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039791
   PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x
   Presman DM, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001813
   Qiu X, 2015, CURR EYE RES, V40, P290, DOI 10.3109/02713683.2014.922191
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Raghunathan VK, 2015, INVEST OPHTH VIS SCI, V56, P4447, DOI 10.1167/iovs.15-16739
   Rauz S, 2001, INVEST OPHTH VIS SCI, V42, P2037
   Ray DW, 1996, CANCER RES, V56, P3276
   RAY S, 1977, ANN OPHTHALMOL, V9, P1151
   Reddy TE, 2009, GENOME RES, V19, P2163, DOI 10.1101/gr.097022.109
   Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6
   Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663
   Rivers C, 1999, J CLIN ENDOCR METAB, V84, P4283, DOI 10.1210/jc.84.11.4283
   Robertson S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064831
   Robertson S, 2013, STEROIDS, V78, P182, DOI 10.1016/j.steroids.2012.10.016
   Robertson S, 2010, J BIOL CHEM, V285, P8061, DOI 10.1074/jbc.M109.087866
   Robin AL, 2009, AM J OPHTHALMOL, V147, P45, DOI 10.1016/j.ajo.2008.07.039
   Ronkko S, 2007, GRAEF ARCH CLIN EXP, V245, P697, DOI 10.1007/s00417-006-0440-1
   Rosen J, 2005, ENDOCR REV, V26, P452, DOI 10.1210/er.2005-0002
   ROSENBERG S, 1974, ARCH OPHTHALMOL-CHIC, V92, P6
   Rozsa FW, 2006, MOL VIS, V12, P125
   ROZSIVAL P, 1981, CURR EYE RES, V1, P391, DOI 10.3109/02713688109019976
   Ruiz M, 2001, CLIN ENDOCRINOL, V55, P363, DOI 10.1046/j.1365-2265.2001.01323.x
   Russcher H, 2005, J CLIN ENDOCR METAB, V90, P5804, DOI 10.1210/jc.2005-0646
   Savory JGA, 1999, MOL CELL BIOL, V19, P1025
   Sawada H, 2010, INVEST OPHTH VIS SCI, V51, P903, DOI 10.1167/iovs.09-4247
   Sawaguchi K, 2005, OPHTHALMIC RES, V37, P235, DOI 10.1159/000086946
   Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696
   Schaaf MJM, 2008, ENDOCRINOLOGY, V149, P1591, DOI 10.1210/en.2007-1364
   Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8
   SCHWARTZ B, 1972, ARCH OPHTHALMOL-CHIC, V87, P369, DOI 10.1001/archopht.1972.01000020371001
   SCHWARTZ B, 1987, ARCH OPHTHALMOL-CHIC, V105, P1060
   Schwartz J.T., 1973, T AM ACAD OPHTHALMOL, V77, P126
   Selim A, 2014, TURK J MED SCI, V44, P889, DOI 10.3906/sag-1104-54
   Sen HN, 2014, OPHTHALMOLOGY, V121, P2275, DOI 10.1016/j.ophtha.2014.05.021
   Shahidi H, 1999, BIOCHEM BIOPH RES CO, V254, P559, DOI 10.1006/bbrc.1998.9980
   Sharma A, 2013, METABOLISM, V62, P1819, DOI 10.1016/j.metabol.2013.08.014
   Shepard AR, 2013, ACS CHEM BIOL, V8, P549, DOI 10.1021/cb300296m
   SIITERI PK, 1982, RECENT PROG HORM RES, V38, P457
   SILVA CM, 1994, STEROIDS, V59, P436, DOI 10.1016/0039-128X(94)90013-2
   Sinclair AJ, 2010, J CLIN ENDOCR METAB, V95, P5348, DOI 10.1210/jc.2010-0729
   Singh IP, 2004, AM J OPHTHALMOL, V138, P286, DOI 10.1016/j.ajo.2004.03.001
   Smith C L, 1966, Am J Med Sci, V252, P239, DOI 10.1097/00000441-196608000-00017
   Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486
   Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898
   Stamer WD, 2013, INVEST OPHTH VIS SCI, V54, P2100, DOI 10.1167/iovs.12-11298
   STEWART RH, 1979, ARCH OPHTHALMOL-CHIC, V97, P2139
   Stokes J, 2000, INVEST OPHTH VIS SCI, V41, P1629
   Stokes J, 2003, INVEST OPHTH VIS SCI, V44, P5163, DOI 10.1167/iovs.02-1318
   Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668
   Sundahl N, 2015, PHARMACOL THERAPEUT, V152, P28, DOI 10.1016/j.pharmthera.2015.05.001
   Surjit M, 2011, CELL, V145, P224, DOI 10.1016/j.cell.2011.03.027
   Suzuki T, 2001, MOL CELL ENDOCRINOL, V173, P121, DOI 10.1016/S0303-7207(00)00403-2
   Takai Y, 2012, INVEST OPHTH VIS SCI, V53, P241, DOI 10.1167/iovs.11-8434
   Tamm ER, 2007, SURV OPHTHALMOL, V52, pS101, DOI 10.1016/j.survophthal.2007.08.002
   Tanaka M, 2003, ENDOCRINOLOGY, V144, P4070, DOI 10.1210/en.2003-0282
   Tao T, 2006, AM J RESP CELL MOL, V35, P668, DOI 10.1165/rcmb.2006-0073OC
   Tawara A, 2008, GRAEF ARCH CLIN EXP, V246, P1021, DOI 10.1007/s00417-008-0800-0
   Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025
   Thomas-Chollier M, 2013, P NATL ACAD SCI USA, V110, P17826, DOI 10.1073/pnas.1316235110
   Torpy DJ, 2007, CLIN ENDOCRINOL, V67, P161, DOI 10.1111/j.1365-2265.2007.02890.x
   TRIPATHI RC, 1992, GASTROENTEROLOGY, V102, P1957, DOI 10.1016/0016-5085(92)90319-T
   Tyrka AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030148
   Uings IJ, 2013, BRIT J PHARMACOL, V169, P1389, DOI 10.1111/bph.12232
   VADOT E, 1992, DEV OPHTHALMOL, V23, P33
   Vakalis N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08627
   van Staa TP, 2000, QJM-MON J ASSOC PHYS, V93, P105, DOI 10.1093/qjmed/93.2.105
   VanCauter E, 1996, J CLIN ENDOCR METAB, V81, P2468, DOI 10.1210/jc.81.7.2468
   Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098
   WEINREB RN, 1985, INVEST OPHTH VIS SCI, V26, P170
   WEINSTEIN BI, 1985, INVEST OPHTH VIS SCI, V26, P890
   Westberry JM, 2006, J STEROID BIOCHEM, V100, P34, DOI 10.1016/j.jsbmb.2006.03.004
   Westphal U, 1986, Monogr Endocrinol, V27, P1
   Whitlock NA, 2010, INVEST OPHTH VIS SCI, V51, P6496, DOI 10.1167/iovs.10-5430
   Wiggs JL, 1998, AM J HUM GENET, V63, P1549, DOI 10.1086/302098
   Will CL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003707
   Wostyn P., 2015, CLIN EXP OPTOM
   Wu I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.193
   Xue W, 2007, INVEST OPHTH VIS SCI, V48, P3184, DOI 10.1167/iovs.06-1403
   Yamamoto Y, 2008, CAN J OPHTHALMOL, V43, P42, DOI 10.3129/i07-186
   Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152
   Yorio T, 2004, EXPERT OPIN THER PAT, V14, P1743, DOI 10.1517/13543776.14.12.1743
   Yuan Y, 2013, INVEST OPHTH VIS SCI, V54, P6502, DOI 10.1167/iovs.13-12447
   ZHAN GL, 1992, EXP EYE RES, V54, P211, DOI 10.1016/S0014-4835(05)80210-6
   Zhang HN, 2012, J CARDIOVASC PHARM, V60, P33, DOI 10.1097/FJC.0b013e3182567fef
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P1037, DOI 10.1167/iovs.07-1279
   Zhang XY, 2007, EXP EYE RES, V84, P275, DOI 10.1016/j.exer.2006.09.022
   Zhang XY, 2005, INVEST OPHTH VIS SCI, V46, P4607, DOI 10.1167/iovs.05-0571
   Zhang Z., 2015, ACTA OPHTHALMOL
   Zhao D, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12507
   Zheng YC, 2015, MOL ENDOCRINOL, V29, P1486, DOI 10.1210/me.2015-1128
   Zhuo YH, 2010, MOL VIS, V16, P61
NR 236
TC 32
Z9 35
U1 0
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2016
VL 787
SI SI
BP 57
EP 71
DI 10.1016/j.ejphar.2016.06.018
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DW0EX
UT WOS:000383314800008
PM 27388141
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Jee, D
   Zako, M
   La, TY
AF Jee, Donghyun
   Zako, Masahiro
   La, Tae Yoon
TI Serum D-Dimer Levels to Evaluate the Risk for Arterial Thromboembolism
   After Intravitreal Injection of Bevacizumab and Ranibizumab
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID MACULAR DEGENERATION; VENOUS THROMBOEMBOLISM; ELEVATED LEVELS; VEGF;
   PHARMACOKINETICS; DIAGNOSIS; THROMBOSIS; THERAPY
AB Purpose: There are concerns about arterial thromboembolic event after intravitreal injection of bevacizumab or ranibizumab. Motivated by the fact that D-dimer was a sensitive biomarker for thromboembolism, we evaluated serum D-dimer levels in patients with age-related macular degeneration (AMD) after intravitreal injection of bevacizumab and ranibizumab.
   Methods: In this prospective, nonrandomized, uncontrolled study, 122 patients (122 eyes) with AMD were enrolled. Sixty-two eyes received intravitreal injections of bevacizumab and 60 eyes received intravitreal injections of ranibizumab monthly for 3 months. Serum D-dimer levels were measured in patients before intravitreal injection and 1 day, 1 week, 1 month, and 3 months thereafter.
   Results: Serum D-dimer levels were not significantly altered following injection of either bevacizumab or ranibizumab. Subgroup analysis for patients at risk for thromboembolic events revealed that serum D-dimer levels showed no significant change after injection of ranibizumab. However, D-dimer levels significantly increased at 1 day (P=0.041) and 1 week (P=0.022) after injection of bevacizumab.
   Conclusions: Serum D-dimer levels were not changed after injection with either bevacizumab or ranibizumab. In subgroup analysis, bevacizumab injection in patients at risk of thromboembolism increased serum D-dimer levels.
C1 [Jee, Donghyun; La, Tae Yoon] St Vincent Hosp, Dept Ophthalmol & Visual Sci, Suwon, South Korea.
   [Jee, Donghyun; La, Tae Yoon] Catholic Univ Korea, Coll Med, Seoul 137701, South Korea.
   [Zako, Masahiro] Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi, Japan.
C3 Catholic University of Korea; Aichi Medical University
RP La, TY (通讯作者)，Catholic Univ Korea, Coll Med, Seoul 137701, South Korea.
EM laty@catholic.ac.kr
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Brill-Edwards P, 1999, THROMB HAEMOSTASIS, V82, P688
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Cosmi B, 2010, THROMB RES, V125, pS62, DOI 10.1016/S0049-3848(10)70016-5
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Hargett CW, 2008, SEMIN RESP CRIT CARE, V29, P15, DOI 10.1055/s-2008-1047559
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Kilickap S, 2003, J CLIN ONCOL, V21, P3542, DOI 10.1200/JCO.2003.99.046
   Kim H, 2009, MOL VIS, V15
   Lippi G, 2010, J THROMB THROMBOLYS, V30, P459, DOI 10.1007/s11239-010-0460-x
   Lowe GDO, 2006, BRIT J HAEMATOL, V133, P232, DOI 10.1111/j.1365-2141.2006.06021.x
   Mannucci PM, 2002, PATHOPHYSIOL HAEMO T, V32, P209, DOI 10.1159/000073567
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama W, 2000, CHEST, V118, P948, DOI 10.1378/chest.118.4.948
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2010, EXPERT OPIN DRUG SAF, V9, P149, DOI 10.1517/14740330903418422
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Thorneycroft IH, 2003, J REPROD MED, V48, P911
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Tripodi A, 2011, CLIN CHEM, V57, P1256, DOI 10.1373/clinchem.2011.166249
   Tseng CS, 2005, FEMS IMMUNOL MED MIC, V43, P99, DOI 10.1016/j.femsim.2004.10.004
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Verhovsek M, 2008, ANN INTERN MED, V149, P481, DOI 10.7326/0003-4819-149-7-200810070-00008
   Wada H, 2006, J THROMB HAEMOST, V4, P1253, DOI 10.1111/j.1538-7836.2006.01942.x
   Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 36
TC 4
Z9 4
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB 1
PY 2015
VL 31
IS 1
BP 32
EP 36
DI 10.1089/jop.2013.0234
PG 5
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA AY2AR
UT WOS:000347391500006
PM 25229129
DA 2022-11-30
ER

PT J
AU Pescosolido, N
   Barbato, A
   Pascarella, A
   Giannotti, R
   Genzano, M
   Nebbioso, M
AF Pescosolido, Nicola
   Barbato, Andrea
   Pascarella, Antonia
   Giannotti, Rossella
   Genzano, Martina
   Nebbioso, Marcella
TI Role of Protease-Inhibitors in Ocular Diseases
SO MOLECULES
LA English
DT Review
DE age-related macular degeneration; endophthalmitis; keratitis;
   keratoconus; neurodegenerative disorders; optic neuritis;
   protease-inhibitors; retinal ganglion cells; Sorsby dystrophy
ID RETINAL GANGLION-CELLS; CORNEAL ALDEHYDE DEHYDROGENASE; ACUTE OPTIC
   NEURITIS; KERATOCONUS CORNEAS; PROMOTER ACTIVITY; OXIDATIVE STRESS;
   PATHOLOGICAL CORNEAS; DIABETIC-RETINOPATHY; EXTRACELLULAR-MATRIX;
   CALPAIN INHIBITOR
AB It has been demonstrated that the balance between proteases and protease-inhibitors system plays a key role in maintaining cellular and tissue homeostasis. Indeed, its alteration has been involved in many ocular and systemic diseases. In particular, research has focused on keratoconus, corneal wounds and ulcers, keratitis, endophthalmitis, age-related macular degeneration, Sorsby fundus dystrophy, loss of nerve cells and photoreceptors during optic neuritis both in vivo and in vitro models. Protease-inhibitors have been extensively studied, rather than proteases, because they may represent a therapeutic approach for some ocular diseases. The protease-inhibitors mainly involved in the onset of the above-mentioned ocular pathologies are: alpha 2-macroglobulin, alpha 1-proteinase inhibitor (alpha 1-PI), metalloproteinase inhibitor (TIMP), maspin, SERPINA3K, SERPINB13, secretory leukocyte protease inhibitor (SLPI), and calpeptin. This review is focused on the several characteristics of dysregulation of this system and, particularly, on a possible role of proteases and protease-inhibitors in molecular remodeling that may lead to some ocular diseases. Recently, researchers have even hypothesized a possible therapeutic effect of the protease-inhibitors in the treatment of injured eye in animal models.
C1 [Pescosolido, Nicola] Univ Roma La Sapienza, Fac Med & Odontol, Dept Cardiovasc Resp Nephrol Anesthesiol & Geriat, Policlin Umberto I, I-00185 Rome, Italy.
   [Barbato, Andrea; Giannotti, Rossella; Genzano, Martina; Nebbioso, Marcella] Univ Roma La Sapienza, Fac Med & Odontol, Ocular Electrophysiol Ctr, Dept Sense Organs,Policlin Umberto I, I-00185 Rome, Italy.
   [Pascarella, Antonia] Univ Roma La Sapienza, Fac Med & Odontol, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome; Sapienza
   University Rome; University Hospital Sapienza Rome; Sapienza University
   Rome
RP Nebbioso, M (通讯作者)，Univ Roma La Sapienza, Fac Med & Odontol, Ocular Electrophysiol Ctr, Dept Sense Organs,Policlin Umberto I, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM marcella.nebbioso@uniroma1.it
RI Nebbioso, Marcella/K-6878-2018
OI Nebbioso, Marcella/0000-0002-5512-0849
FU Alfa Wassermann S.P.A., Bologna, Italy
FX This work was supported by Alfa Wassermann S.P.A., Bologna, Italy.
CR AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
   ANDO H, 1993, INVEST OPHTH VIS SCI, V34, P3541
   Behndig A, 2001, INVEST OPHTH VIS SCI, V42, P2293
   Brooks DE, 2004, VET CLIN N AM-SMALL, V34, P611, DOI 10.1016/j.cvsm.2003.12.005
   Buddi R, 2002, J HISTOCHEM CYTOCHEM, V50, P341, DOI 10.1177/002215540205000306
   Caberoy NB, 2011, MOLECULES, V16, P1739, DOI 10.3390/molecules16021739
   Chiambaretta F, 2006, INVEST OPHTH VIS SCI, V47, P582, DOI 10.1167/iovs.05-0551
   COYLE JT, 1984, AM J OPHTHALMOL, V97, P527
   Das A, 2006, BRAIN RES, V1084, P146, DOI 10.1016/j.brainres.2006.02.051
   Das A, 2013, J NEUROCHEM, V124, P133, DOI 10.1111/jnc.12064
   GONDHOWIARDJO TD, 1993, CORNEA, V12, P146, DOI 10.1097/00003226-199303000-00010
   GONDHOWIARDJO TD, 1993, CORNEA, V12, P310, DOI 10.1097/00003226-199307000-00006
   Hashimoto M, 2003, J BIOL CHEM, V278, P5044, DOI 10.1074/jbc.M210129200
   Horswill MA, 2008, EXP EYE RES, V86, P586, DOI 10.1016/j.exer.2008.01.003
   Huma Habib, 2007, Biotechnology and Molecular Biology Reviews, V2, P068
   Kenney MC, 2005, INVEST OPHTH VIS SCI, V46, P823, DOI 10.1167/iovs.04-0549
   Kermer P, 1998, J NEUROSCI, V18, P4656
   KRACHMER JH, 1984, SURV OPHTHALMOL, V28, P293, DOI 10.1016/0039-6257(84)90094-8
   Kuro M, 2011, IN VIVO, V25, P617
   Li YH, 1998, J BIOL CHEM, V273, P9959, DOI 10.1074/jbc.273.16.9959
   Liu Q, 2000, MOL BIOL REP, V27, P241, DOI 10.1023/A:1010971219806
   Liu XC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016712
   Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200
   Ma M, 2012, J NEUROTRAUM, V29, P2555, DOI 10.1089/neu.2012.2473
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   MACSAI MS, 1990, ARCH OPHTHALMOL-CHIC, V108, P534, DOI 10.1001/archopht.1990.01070060082054
   Malagola R, 2012, CLIN TER, V163, pE393
   Maruyama I, 2000, CURR EYE RES, V21, P886, DOI 10.1076/ceyr.21.5.886.5538
   Maruyama Y, 2001, INVEST OPHTH VIS SCI, V42, P1980
   Meghpara B, 2009, ARCH OPHTHALMOL-CHIC, V127, P1029, DOI 10.1001/archophthalmol.2009.184
   Narayan M, 2011, PROTEOMICS, V11, P1382, DOI 10.1002/pmic.201000362
   Narayan M, 2010, EXP EYE RES, V90, P2, DOI 10.1016/j.exer.2009.07.003
   Nebbioso M, 2013, J BIOL REG HOMEOS AG, V27, P197
   Nebbioso M, 2013, EXPERT OPIN PHARMACO, V14, P1829, DOI 10.1517/14656566.2013.813483
   Nebbioso M, 2012, DIABETES TECHNOL THE, V14, P257, DOI 10.1089/dia.2011.0172
   Ngamkitidechakul C, 2001, INVEST OPHTH VIS SCI, V42, P3135
   PERSSON H, 1993, BRAIN RES, V611, P272, DOI 10.1016/0006-8993(93)90513-M
   PRAUSE JU, 1984, ACTA OPHTHALMOL, P1
   Qi RF, 2005, ACTA BIOCH BIOPH SIN, V37, P283, DOI 10.1111/j.1745-7270.2005.00048.x
   Rabinowitz YS, 1998, SURV OPHTHALMOL, V42, P297, DOI 10.1016/S0039-6257(97)00119-7
   Reviglio VE, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/259393
   Reviglio VE, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93857
   SAWAGUCHI S, 1994, INVEST OPHTH VIS SCI, V35, P4008
   Shanab AY, 2012, NEUROBIOL DIS, V48, P556, DOI 10.1016/j.nbd.2012.07.025
   SHAPIRO MB, 1985, AM J OPHTHALMOL, V99, P659, DOI 10.1016/S0002-9394(14)76031-3
   Shellenberger TD, 2005, CANCER RES, V65, P11501, DOI 10.1158/0008-5472.CAN-05-2262
   Shen X, 2009, GENES CELLS, V14, P1133, DOI 10.1111/j.1365-2443.2009.01340.x
   Smith AW, 2011, INVEST OPHTH VIS SCI, V52, P4935, DOI 10.1167/iovs.10-7027
   TWINING SS, 1994, INVEST OPHTH VIS SCI, V35, P458
   Vigneswara V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053473
   Whitelock RB, 1997, INVEST OPHTH VIS SCI, V38, P529
   YUE BYJT, 1984, P SOC EXP BIOL MED, V175, P336
   Zhang B, 2009, INVEST OPHTH VIS SCI, V50, P3943, DOI 10.1167/iovs.08-2954
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhou LL, 1998, INVEST OPHTH VIS SCI, V39, P1117
   Zicari AM, 2013, EUR REV MED PHARMACO, V17, P1419
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 57
TC 29
Z9 30
U1 1
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1420-3049
J9 MOLECULES
JI Molecules
PD DEC
PY 2014
VL 19
IS 12
BP 20557
EP 20569
DI 10.3390/molecules191220557
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AX2SA
UT WOS:000346793200072
PM 25493637
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Grover, VK
   Cole, DEC
   Hamilton, DC
AF Grover, Vaneeta K.
   Cole, David E. C.
   Hamilton, David C.
TI Genotype-Based Association Analysis Using Discordant Pairs: A Penetrance
   Odds Ratio Approach
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE Genetic association; discordant relative pairs; penetrance; odds ratios
ID MACULAR DEGENERATION; SIBSHIP TEST; LINKAGE; DISEQUILIBRIUM; TESTS
AB Genotypic counts of paired relatives discordant for a complex late-onset disease are often used to test for genetic association. The power of the various statistical test options, when data on covariates are unavailable, has been the focus of recent research. Comparison of the Cochran-Armitage, Bhapkar, and McNemar tests indicates that none is superior to the others in all cases. Using an alternative approach, we found that the theoretical genotypic frequencies of the discordant pairs depend only on the penetrance odds ratios, after conditioning. These odds ratios can be estimated by maximizing a product binomial likelihood and provide insight into the mode of inheritance. We identified cases where exact maximum likelihood (ML) estimates can be explicitly obtained. This approach led us to two tests for association which depend on likelihood ratio (LR) or score statistics. We quantified the power of these tests analytically and examined their performance through simulation. We explored the utility of these tests with an example from the literaturethe association between complement factor H (CFH) polymorphisms and age-related macular degeneration. The LR and Score tests serve as simple and effective ways of interpreting paired case-control data sets.
C1 [Grover, Vaneeta K.; Hamilton, David C.] Dalhousie Univ, Halifax, NS B3H 4R2, Canada.
   [Cole, David E. C.] Univ Toronto, Banting Inst, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada.
C3 Dalhousie University; University of Toronto
RP Hamilton, DC (通讯作者)，Dalhousie Univ, 6316 Coburg Rd,POB 15000, Halifax, NS B3H 4R2, Canada.
EM hamilton@mathstat.dal.ca
FU NSERC; Dairy Farmers of Canada
FX This work was supported by operating grants from NSERC (DCH) and the
   Dairy Farmers of Canada (DECC). We thank Dr. M. DeAngelis (Moran Eye
   Center, The University of Utah) for providing the AMD data and Dr. H.
   Zhang (Institute of Biostatistics, Fudan University) for helpful
   discussions.
CR ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775
   BHAPKAR VP, 1966, J AM STAT ASSOC, V61, P228, DOI 10.2307/2283057
   Boehnke M, 1998, AM J HUM GENET, V62, P950, DOI 10.1086/301787
   BOWKER AH, 1948, J AM STAT ASSOC, V43, P572, DOI 10.2307/2280710
   Breslow NE, 1980, STAT METHODS CANC RE
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   Cox DR., 1974, THEORETICAL STAT
   Curtis D, 1997, ANN HUM GENET, V61, P319, DOI 10.1017/S000348009700626X
   Hamilton DC, 2009, ANN HUM GENET, V73, P176, DOI 10.1111/j.1469-1809.2008.00492.x
   Horvath S, 1998, AM J HUM GENET, V63, P1886, DOI 10.1086/302137
   Monks SA, 1998, AM J HUM GENET, V63, P1507, DOI 10.1086/302104
   Rayner JCW, 2005, AUST NZ J STAT, V47, P211, DOI 10.1111/j.1467-842X.2005.00385.x
   Sham P., 1998, STAT HUMAN GENETICS
   SPIELMAN RS, 1993, AM J HUM GENET, V52, P506
   Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Yan T, 2009, ANN HUM GENET, V73, P84, DOI 10.1111/j.1469-1809.2008.00488.x
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 18
TC 0
Z9 0
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD MAR
PY 2013
VL 77
BP 137
EP 146
DI 10.1111/ahg.12002
PN 2
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 093MW
UT WOS:000315197000005
PM 23362881
DA 2022-11-30
ER

PT J
AU Cai, J
   Qi, XP
   Kociok, N
   Skosyrski, S
   Emilio, A
   Ruan, Q
   Han, S
   Liu, L
   Chen, ZJ
   Rickman, CB
   Golde, T
   Grant, MB
   Saftig, P
   Serneels, L
   de Strooper, B
   Joussen, AM
   Boulton, ME
AF Cai, Jun
   Qi, Xiaoping
   Kociok, Norbert
   Skosyrski, Sergej
   Emilio, Alonso
   Ruan, Qing
   Han, Song
   Liu, Li
   Chen, Zhijuan
   Rickman, Catherine Bowes
   Golde, Todd
   Grant, Maria B.
   Saftig, Paul
   Serneels, Lutgarde
   de Strooper, Bart
   Joussen, Antonia M.
   Boulton, Michael E.
TI ss-Secretase (BACE1) inhibition causes retinal pathology by vascular
   dysregulation and accumulation of age pigment
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE angiogenesis; ss-secretase; lipofuscin; retina; retinal pigment
   epithelium
ID EXPERIMENTAL OPTIC NEURITIS; GROWTH-FACTOR RECEPTOR-1; CULTURED HUMAN
   RPE; BETA-SECRETASE; MACULAR DEGENERATION; ALZHEIMERS-DISEASE;
   GAMMA-SECRETASE; AMYLOID-BETA; OXIDATIVE STRESS; EPITHELIAL-CELLS
AB beta-Secretase (BACE1) is a major drug target for combating Alzheimer's disease (AD). Here we show that BACE1-/- mice develop significant retinal pathology including retinal thinning, apoptosis, reduced retinal vascular density and an increase in the age pigment, lipofuscin. BACE1 expression is highest in the neural retina while BACE2 was greatest in the retinal pigment epithelium (RPE)/choroid. Pigment epithelial-derived factor, a known regulator of ?-secretase, inhibits vascular endothelial growth factor (VEGF)-induced in vitro and in vivo angiogenesis and this is abolished by BACE1 inhibition. Moreover, intravitreal administration of BACE1 inhibitor or BACE1 small interfering RNA (siRNA) increases choroidal neovascularization in mice. BACE1 induces ectodomain shedding of vascular endothelial growth factor receptor 1 (VEGFR1) which is a prerequisite for ?-secretase release of a 100?kDa intracellular domain. The increase in lipofuscin following BACE1 inhibition and RNAI knockdown is associated with lysosomal perturbations. Taken together, our data show that BACE1 plays a critical role in retinal homeostasis and that the use of BACE inhibitors for AD should be viewed with extreme caution as they could lead to retinal pathology and exacerbate conditions such as age-related macular degeneration.
C1 [Cai, Jun; Qi, Xiaoping; Emilio, Alonso; Ruan, Qing; Chen, Zhijuan; Boulton, Michael E.] Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
   [Kociok, Norbert; Skosyrski, Sergej; Joussen, Antonia M.] Charite, Dept Ophthalmol, D-13353 Berlin, Germany.
   [Han, Song] Univ Florida, Dept Surg, Gainesville, FL USA.
   [Liu, Li; Grant, Maria B.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA.
   [Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Ophthalmol & Cell Biol, Durham, NC USA.
   [Golde, Todd] Univ Florida, Dept Neurosci, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32610 USA.
   [Saftig, Paul] Univ Kiel, Inst Biochem, D-2300 Kiel, Germany.
   [Serneels, Lutgarde; de Strooper, Bart] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium.
   [Serneels, Lutgarde; de Strooper, Bart] Katholieke Univ Leuven, Leuven Inst Neurodegenerat Dis, Louvain, Belgium.
   [Serneels, Lutgarde; de Strooper, Bart] Vlaams Inst Biotechnol, VIB Ctr Biol Dis, Louvain, Belgium.
C3 State University System of Florida; University of Florida; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; State University System of Florida;
   University of Florida; State University System of Florida; University of
   Florida; Duke University; State University System of Florida; University
   of Florida; University of Kiel; KU Leuven; KU Leuven; Flanders Institute
   for Biotechnology (VIB)
RP Boulton, ME (通讯作者)，Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.
EM meboulton@ufl.edu
RI Joussen, Antonia/AAA-6901-2022; Saftig, Paul/A-7966-2010; de+Strooper,
   Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012
OI De Strooper, Bart/0000-0001-5455-5819; Han, Song/0000-0002-6542-335X;
   Bowes Rickman, Catherine/0000-0002-8555-9596; Serneels,
   Lutgarde/0000-0002-5463-4231
FU Fund for Scientific Research, Flanders; K.U. Leuven; Flemisch
   government; Foundation for Alzheimer Research (SAO/FRMA); Deutsche
   Forschungsgemeinschaft [SFB877]; Hans and Ilse Breuer Award; NIH
   [EY019038, AG020206 AG18454]; RPB Special Scholars Award; Ruth and
   Milton Steinbach Fund; Macular Vision Research Foundation; Ellison
   Medical Foundation; NEI [EY007739, EY 012606];  [NIH EY018358];  [NIH
   EY019688];  [AHAF M2009024]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCES [UL1TR000064] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY019038, R01EY012606, R01EY019688, R29EY007739,
   R01EY007739, P30EY005722, R01EY018358, R01EY011286] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [P01AG020206, R01AG018454] Funding
   Source: NIH RePORTER
FX MEB is supported by grants NIH EY018358, NIH EY019688 and AHAF M2009024.
   BDS is supported by the Fund for Scientific Research, Flanders; the K.U.
   Leuven; a Methusalem grant from the K.U. Leuven and the Flemisch
   government, the Foundation for Alzheimer Research (SAO/FRMA). BDS is
   Arthur Bax and Anna Vanluffelen chair for AD. PS is supported through
   grants from the Deutsche Forschungsgemeinschaft SFB877 and the Hans and
   Ilse Breuer Award. CBR is funded by NIH EY019038, a RPB Special Scholars
   Award, The Ruth and Milton Steinbach Fund and the Macular Vision
   Research Foundation. TEG is supported by the NIH (AG020206 AG18454) and
   the Ellison Medical Foundation. MBG is supported by NEI EY007739 and EY
   012606.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bjorklund C, 2010, J MED CHEM, V53, P1458, DOI 10.1021/jm901168f
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   Boulton ME, 2008, J CELL MOL MED, V12, P781, DOI 10.1111/j.1582-4934.2008.00274.x
   Boulton ME, 2008, ADV EXP MED BIOL, V613, P313, DOI 10.1007/978-0-387-74904-4_36
   Brunner S, 2010, INVEST OPHTH VIS SCI, V51, P1106, DOI 10.1167/iovs.08-2742
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200
   Cai J, 2011, J BIOL CHEM, V286, P42514, DOI 10.1074/jbc.M111.296590
   Cai J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021164
   Cai J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018076
   De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Klaver DW, 2010, BIOL CHEM, V391, P849, DOI 10.1515/BC.2010.089
   May PC, 2011, J NEUROSCI, V31, P16507, DOI 10.1523/JNEUROSCI.3647-11.2011
   Pasternak SH, 2004, J ALZHEIMERS DIS, V6, P53
   Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P5360, DOI 10.1167/iovs.07-0254
   Qi XP, 2007, MOL VIS, V13, P1
   Rahimi N, 2006, FRONT BIOSCI-LANDMRK, V11, P818
   Rahimi N, 2009, CANCER RES, V69, P2607, DOI 10.1158/0008-5472.CAN-08-2905
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Sealy JM, 2009, BIOORG MED CHEM LETT, V19, P6386, DOI 10.1016/j.bmcl.2009.09.061
   Sengupta N, 2009, MOL THER, V17, P1594, DOI 10.1038/mt.2009.145
   Shaw LC, 2006, GENE THER, V13, P752, DOI 10.1038/sj.gt.3302718
   Solans A, 2000, CYTOGENET CELL GENET, V89, P177, DOI 10.1159/000015608
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g
   Tombran-Tink J, 2005, FRONT BIOSCI-LANDMRK, V10, P2131, DOI 10.2741/1686
   Vassar R, 2009, J NEUROSCI, V29, P12787, DOI 10.1523/JNEUROSCI.3657-09.2009
   Wassell J, 1998, INVEST OPHTH VIS SCI, V39, P1487
   Woo HN, 2011, BIOCHEM BIOPH RES CO, V404, P10, DOI 10.1016/j.bbrc.2010.11.132
   Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x
   Xiong K, 2007, EXP BRAIN RES, V181, P435, DOI 10.1007/s00221-007-0943-y
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
NR 36
TC 114
Z9 114
U1 0
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD SEP
PY 2012
VL 4
IS 9
BP 980
EP 991
DI 10.1002/emmm.201101084
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 999IK
UT WOS:000308302900014
PM 22903875
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU O'Brien, EE
   Greferath, U
   Vessey, KA
   Jobling, AI
   Fletcher, EL
AF O'Brien, Emily E.
   Greferath, Ursula
   Vessey, Kirstan A.
   Jobling, Andrew I.
   Fletcher, Erica L.
TI Electronic restoration of vision in those with photoreceptor
   degenerations
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Review
DE photoreceptor; retinal implant; retinal remodelling; retinitis
   pigmentosa
ID RETINAL GANGLION-CELLS; LEBER CONGENITAL AMAUROSIS; HUMAN
   RETINITIS-PIGMENTOSA; ELECTRICAL-STIMULATION; VISUAL-PERCEPTION;
   GENE-THERAPY; MICROSCOPIC OBSERVATIONS; MICROELECTRODE ARRAY; RPE65
   MUTATIONS; PROSTHESIS
AB Complete loss of vision is one of the most feared sequelae of retinal disease. Currently, there are few if any treatment options available to patients that may slow or prevent blindness in diseases caused by photoreceptor loss, such as retinitis pigmentosa and age-related macular degeneration. Electronic restoration of vision has emerged over recent years as a safe and viable option for those who have lost substantial numbers of photoreceptors and who are severely vision impaired. Indeed, there has been a dramatic increase in our understanding of what is required to restore vision using an electronic retinal prosthesis. Recent reports show that for some patients, restoration of vision to the point of reading large letters is possible. In this review, we examine the types of implants currently under investigation and the results these devices have achieved clinically. We then consider a range of engineering and biological factors that may need to be considered to improve the visual performance of newer-generation devices. With added research, it is hoped that the level of vision achieved with newer generation devices will steadily improve, resulting in enhanced quality of life for those with severe vision impairment.
C1 [O'Brien, Emily E.; Greferath, Ursula; Vessey, Kirstan A.; Jobling, Andrew I.; Fletcher, Erica L.] Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3052, Australia.
   [O'Brien, Emily E.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic 3052, Australia.
C3 University of Melbourne; University of Melbourne
RP O'Brien, EE (通讯作者)，Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3052, Australia.
EM elf@unimelb.edu.au
RI ; Jobling, Andrew/C-8221-2015; Fletcher, Erica/E-6364-2012
OI Greferath, Ursula/0000-0003-1028-648X; Jobling,
   Andrew/0000-0002-7827-3135; Vessey, Kirstan/0000-0003-1031-1964;
   Fletcher, Erica/0000-0001-9412-9523
FU National Health and Medical Research Council of Australia [566814,
   566815]; Retina Australia; Australian Research Council through its
   Special Research Initiative in Bionic Vision Science and Technology
FX This work was supported by the National Health and Medical Research
   Council of Australia (Numbers 566814 and 566815 to ELF), Retina
   Australia and the Australian Research Council, through its Special
   Research Initiative in Bionic Vision Science and Technology grant to
   Bionic Vision Australia.
CR Abramian M, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/035004
   Aguirre GK, 2007, PLOS MED, V4, P1117, DOI 10.1371/journal.pmed.0040230
   Ahuja AK, 2011, BRIT J OPHTHALMOL, V95, P539, DOI 10.1136/bjo.2010.179622
   Aleman TS, 2008, INVEST OPHTH VIS SCI, V49, P1580, DOI 10.1167/iovs.07-1110
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   BERSON EL, 1968, ARCH OPHTHALMOL-CHIC, V80, P58
   BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   BRINDLEY GS, 1964, J PHYSIOL-LONDON, V171, P514, DOI 10.1113/jphysiol.1964.sp007394
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   Chow Alan Y, 2010, Trans Am Ophthalmol Soc, V108, P120
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Chowdhury V, 2008, J CLIN NEUROSCI, V15, P900, DOI 10.1016/j.jocn.2007.08.012
   Cicione R, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/3/036009
   Cideciyan AV, 2010, PROG RETIN EYE RES, V29, P398, DOI 10.1016/j.preteyeres.2010.04.002
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Colodetti L, 2007, EXP EYE RES, V85, P23, DOI 10.1016/j.exer.2007.02.014
   Damiani D, 2012, J COMP NEUROL, V520, P1406, DOI 10.1002/cne.22802
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   DeMarco PJ, 2007, INVEST OPHTH VIS SCI, V48, P916, DOI 10.1167/iovs.06-0811
   Djilas M, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046020
   Eng JG, 2011, INVEST OPHTH VIS SCI, V52, P4610, DOI 10.1167/iovs.09-4936
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fornos AP, 2012, INVEST OPHTH VIS SCI, V53, P2720, DOI 10.1167/iovs.11-9344
   Fornos AP, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00057
   Fujikado T, 2011, INVEST OPHTH VIS SCI, V52, P4726, DOI 10.1167/iovs.10-6836
   Ganesan K, 2010, IEEE ENG MED BIO, P6757, DOI 10.1109/IEMBS.2010.5626003
   Gekeler F, 2007, GRAEF ARCH CLIN EXP, V245, P230, DOI 10.1007/s00417-006-0339-x
   Greenwald SH, 2009, INVEST OPHTH VIS SCI, V50, P5017, DOI 10.1167/iovs.08-2897
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Horsager A, 2010, INVEST OPHTH VIS SCI, V51, P1223, DOI 10.1167/iovs.09-3746
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Jensen RJ, 2007, J NEURAL ENG, V4, pS1, DOI 10.1088/1741-2560/4/1/S01
   Jensen RJ, 2005, INVEST OPHTH VIS SCI, V46, P1486, DOI 10.1167/iovs.04-1018
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Keseru M, 2012, ACTA OPHTHALMOL, V90, pE1, DOI 10.1111/j.1755-3768.2011.02288.x
   Kim ET, 2008, SENSORS-BASEL, V8, P5845, DOI 10.3390/s8095845
   Klauke S, 2011, INVEST OPHTH VIS SCI, V52, P449, DOI 10.1167/iovs.09-4410
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOLB H, 1974, INVEST OPHTH VISUAL, V13, P487
   Koo KI, 2006, SENSOR ACTUAT A-PHYS, V130, P609, DOI 10.1016/j.sna.2005.11.070
   Kusnyerik A, 2012, INVEST OPHTHALMOL VI
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Miller CA, 2003, HEARING RES, V175, P200
   O'Hearn TM, 2006, VISION RES, V46, P3198, DOI 10.1016/j.visres.2006.03.031
   PAGON RA, 1988, SURV OPHTHALMOL, V33, P137, DOI 10.1016/0039-6257(88)90085-9
   Palanker DV, 2005, INVEST OPHTH VIS SCI, V46
   Pardue MT, 2005, J NEURAL ENG, V2, pS39, DOI 10.1088/1741-2560/2/1/006
   Pardue MT, 2005, INVEST OPHTH VIS SCI, V46, P674, DOI 10.1167/iovs.04-0515
   POTTS AM, 1968, INVEST OPHTH VISUAL, V7, P269
   Rattay F, 2004, IEEE T BIO-MED ENG, V51, P1659, DOI 10.1109/TBME.2004.828044
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Ray A, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/045003
   Ray A, 2009, BRAIN RES, V1255, P89, DOI 10.1016/j.brainres.2008.11.089
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Sekirnjak C, 2008, J NEUROSCI, V28, P4446, DOI 10.1523/JNEUROSCI.5138-07.2008
   Sekirnjak C, 2006, J NEUROPHYSIOL, V95, P3311, DOI 10.1152/jn.01168.2005
   Sekirnjak C, 2011, J NEUROPHYSIOL, V105, P2560, DOI 10.1152/jn.01061.2010
   Sekirnjak C, 2009, J NEUROPHYSIOL, V102, P3260, DOI 10.1152/jn.00663.2009
   Shivdasani MN, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/3/036008
   Siu T, 2008, ACTA NEUROCHIR, V150, P477, DOI 10.1007/s00701-008-1528-7
   Snyder RL, 2008, HEARING RES, V235, P23, DOI 10.1016/j.heares.2007.09.013
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Suzuki S, 2004, JPN J OPHTHALMOL, V48, P345, DOI 10.1007/s10384-004-0084-9
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Verhoeff FH, 1931, ARCH OPHTHALMOL-CHIC, V5, P392
   Villalobos J, 2012, GRAEF ARCH CLIN EXP, V250, P399, DOI 10.1007/s00417-011-1794-6
   WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447
   Weiland JD, 2005, ANNU REV BIOMED ENG, V7, P361, DOI 10.1146/annurev.bioeng.7.060804.100435
   Weiland JD, 1999, GRAEF ARCH CLIN EXP, V237, P1007, DOI 10.1007/s004170050337
   Wilke RGH, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046016
   Wilke R, 2011, INVEST OPHTH VIS SCI, V52, P5995, DOI 10.1167/iovs.10-6946
   Yamauchi Y, 2005, J NEURAL ENG, V2, pS48, DOI 10.1088/1741-2560/2/1/007
   Ye JH, 2007, P ANN INT IEEE EMBS, P5783
   Zhou JA, 2008, J BIOMED BIOTECHNOL, DOI 10.1155/2008/547428
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 94
TC 16
Z9 16
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2012
VL 95
IS 5
BP 473
EP 483
DI 10.1111/j.1444-0938.2012.00783.x
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 993SX
UT WOS:000307881000002
PM 22823954
DA 2022-11-30
ER

PT J
AU Koo, H
   Moon, H
   Han, H
   Na, JH
   Huh, MS
   Park, JH
   Wood, SJ
   Park, KH
   Kwon, IC
   Kim, K
   Kim, H
AF Koo, Heebeom
   Moon, Hyungwon
   Han, Hyounkoo
   Na, Jin Hee
   Huh, Myung Sook
   Park, Jae Hyung
   Wood, Se Joon
   Park, Kyu Hyung
   Kwon, Ick Chan
   Kim, Kwangmeyung
   Kim, Hyuncheol
TI The movement of self-assembled amphiphilic polymeric nanoparticles in
   the vitreous and retina after intravitreal injection
SO BIOMATERIALS
LA English
DT Article
DE Ocular; Intravitreal; Nanoparticle; Drug delivery; Vitreous; Retina
ID GROWTH-FACTOR THERAPY; DRUG-DELIVERY; MACULAR DEGENERATION; TARGETED
   DELIVERY; GENE DELIVERY; ORGANIZATION; CHITOSAN; SYSTEM; SIRNA
AB The purpose of this study is to determine the correlation between the distribution of nanoparticles in the vitreous and retina and their surface properties after intravitreal injection. For this purpose, we synthesized seven kinds of nanoparticles through self-assembly of amphiphilic polymer conjugates in aqueous condition. They showed similar size but different surface properties. They were labeled with fluorescent dyes for efficient tracking. After intravitreal injection of these nanoparticles into a rodent eye, their time-dependent distribution in the vitreous and retina was determined in stacking tissue images by confocal microscopy. The results demonstrated that the surface property of nanoparticles is a key factor in determining their distribution in the vitreous and retina after intravitreal injection. In addition, immunohistochemistry and TEM images of retina tissues suggested the important mechanism related with Muffler cells for intravitreally administered nanoparticles to overcome the physical barrier of inner limiting membrane and to penetrate into the deeper retinal structures. Therefore, we expect that this study can provide valuable information for biomedical researchers to develop optimized nanoparticles as drug or gene carriers for retinal and optic nerve disorders such as glaucoma, age-related macular degeneration, and diabetic retinopathy. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Koo, Heebeom; Na, Jin Hee; Huh, Myung Sook; Kwon, Ick Chan; Kim, Kwangmeyung] Korea Inst Sci & Technol, Ctr Theragnosis, Biomed Res Inst, Seoul 136791, South Korea.
   [Moon, Hyungwon; Han, Hyounkoo; Kim, Hyuncheol] Sogang Univ, Seoul 121742, South Korea.
   [Park, Jae Hyung] Sungkyunkwan Univ, Dept Polymer Sci & Engn, Suwon 440746, South Korea.
   [Wood, Se Joon; Park, Kyu Hyung] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Seongnarn 463707, South Korea.
C3 Korea Institute of Science & Technology (KIST); Sogang University;
   Sungkyunkwan University (SKKU); Seoul National University (SNU)
RP Kim, K (通讯作者)，Korea Inst Sci & Technol, Ctr Theragnosis, Biomed Res Inst, Hwarangno 14 Gil 6, Seoul 136791, South Korea.
EM kim@kist.re.kr; hyuncheol@sogang.ac.kr
RI byun, jaehyun/G-5584-2014; Kim, Kwangmeyung/ABB-2882-2021; Woo,
   Joon/I-7357-2013; Park, Kyu Hyung/J-5481-2012; Koo,
   Heebeom/AAB-3264-2019; KWON, ICK CHAN/AAS-4776-2020; Park, Jae
   Hyung/B-5967-2018
OI Woo, Joon/0000-0003-3692-7169; KWON, ICK CHAN/0000-0003-1272-7074; Koo,
   Heebeom/0000-0002-2193-6583
FU National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology [2011-0009606]; Graduate School of Specialization
   for Biotechnology of the Ministry of Knowledge Economy (MKE); Small &
   Medium Buisiness Administration [SD122946]; MEST [2009-0081876]; KIST
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2011-0009606), the Graduate School
   of Specialization for Biotechnology Program of the Ministry of Knowledge
   Economy (MKE), Company-Researcher co-work program of Small & Medium
   Buisiness Administration (SD122946), Fusion Technology Project
   (2009-0081876) of MEST, and the Intramural Research Program
   (Theragnosis) of KIST.
CR Choi KY, 2010, BIOMATERIALS, V31, P106, DOI 10.1016/j.biomaterials.2009.09.030
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Curtis TM, 2009, EYE, V23, P1496, DOI 10.1038/eye.2009.108
   Danesh-Meyer HV, 2011, CURR OPIN OPHTHALMOL, V22, P78, DOI 10.1097/ICU.0b013e32834372ec
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Farjo KM, 2010, J ANGIOGENES RES, P2
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Godbey WT, 1999, J CONTROL RELEASE, V60, P149, DOI 10.1016/S0168-3659(99)00090-5
   Hawkins MJ, 2008, ADV DRUG DELIVER REV, V60, P876, DOI 10.1016/j.addr.2007.08.044
   Huh MS, 2010, J CONTROL RELEASE, V144, P134, DOI 10.1016/j.jconrel.2010.02.023
   Irigoyen C, GRAEFES AR IN PRESS
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim H, 2009, PHARM RES-DORDR, V26, P329, DOI 10.1007/s11095-008-9745-6
   Kim K, 2010, J CONTROL RELEASE, V146, P219, DOI 10.1016/j.jconrel.2010.04.004
   Koo H, 2011, ACCOUNTS CHEM RES, V44, P1018, DOI 10.1021/ar2000138
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Liu ZH, 2008, ADV DRUG DELIVER REV, V60, P1650, DOI 10.1016/j.addr.2008.09.001
   Los LI, 1999, EXP EYE RES, V69, P343, DOI 10.1006/exer.1999.0708
   Na JH, 2011, BIOMATERIALS, V32, P5252, DOI 10.1016/j.biomaterials.2011.03.076
   NISHIHARA H, 1989, Nippon Ganka Gakkai Zasshi, V93, P429
   NISHIHARA H, 1991, Nippon Ganka Gakkai Zasshi, V95, P951
   Park JH, 2010, ADV DRUG DELIVER REV, V62, P28, DOI 10.1016/j.addr.2009.10.003
   Petersen H, 2002, BIOCONJUGATE CHEM, V13, P845, DOI 10.1021/bc025529v
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Stern R, 2006, CHEM REV, V106, P818, DOI 10.1021/cr050247k
NR 28
TC 125
Z9 128
U1 1
U2 102
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2012
VL 33
IS 12
BP 3485
EP 3493
DI 10.1016/j.biomaterials.2012.01.030
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA 913OC
UT WOS:000301886300011
PM 22322197
DA 2022-11-30
ER

PT J
AU Rouvas, AA
   Papakostas, TD
   Ladas, ID
   Vergados, I
AF Rouvas, Alexandros A.
   Papakostas, Thanos D.
   Ladas, Ioannis D.
   Vergados, Ioannis
TI Enlargement of the hypofluorescent post photodynamic therapy treatment
   spot after a combination of photodynamic therapy with an intravitreal
   injection of bevacizumab for retinal angiomatous proliferation
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE retinal angiomatous proliferation; age-related macular degeneration;
   photodynamic therapy; bevacizumab; hypofluorescence
ID CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; PIGMENT-EPITHELIUM;
   VERTEPORFIN; EXPRESSION; ACTIVATION; RECEPTOR; VEGF
AB Background To report a case of enlargement of the post photodynamic therapy treatment (PDT) spot in a patient with retinal angiomatous proliferation (RAP) that was treated with PDT combined with an intravitreal injection of bevacizumab.
   Methods 74-year-old woman with RAP due to age-related macular degeneration was treated with one verteporfin PDT session, sequenced by a single intravitreal injection of bevacizumab (1.25 mg) after 30 minutes.
   Results The patient's visual acuity (VA) at baseline was 20/200 and is now at the 10-month follow-up visit 20/400, while the RAP has disappeared according to the indocyanine angiography (ICG) findings. The post PDT hypofluorescent treatment spot has enlarged from 1,450 mu m at the day of the treatment, to 5,360 mu m at the 6-week visit. The patient is now at the 10-month follow-up visit and the hypofluorescence is still persisting.
   Conclusions The simultaneous combination of PDT with bevacizumab in patients with RAP may enhance the photochemical stress in normal choroid with prolonged and magnified hypofluorescence in ICG, due to ischemia in normal choriocapillaries.
C1 [Rouvas, Alexandros A.; Vergados, Ioannis] Univ Athens, Sch Med, Dept Ophthalmol 2, GR-11527 Athens, Greece.
   [Papakostas, Thanos D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
   [Ladas, Ioannis D.] Univ Athens, Sch Med, Dept Ophthalmol 1, GR-11527 Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; Athens Medical School; National & Kapodistrian University of
   Athens
RP Rouvas, AA (通讯作者)，Univ Athens, Sch Med, Dept Ophthalmol 2, Ag Meletiou 85-87 Str, GR-11527 Athens, Greece.
EM rallex@hol.gr
CR Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   HOLZ FG, 2007, 4566 B247 ASS RES VI
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wick A, 2002, J NEUROSCI, V22, P6401
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 14
TC 18
Z9 20
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2008
VL 246
IS 2
BP 315
EP 318
DI 10.1007/s00417-007-0669-3
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 252SU
UT WOS:000252467700022
PM 17957379
DA 2022-11-30
ER

PT J
AU Maaijwee, KJM
   van Meurs, JC
   Kirchhof, B
   Mooij, CM
   Fischer, JH
   Mackiewicz, J
   Kobuch, K
   Joussen, AM
AF Maaijwee, Kristel J. M.
   van Meurs, Jan C.
   Kirchhof, Bernd
   Mooij, Cornelia M.
   Fischer, Jurgen H.
   Mackiewicz, Jerzy
   Kobuch, Karin
   Joussen, Antonia M.
TI Histological evidence for revascularisation of an autologous retinal
   pigment epithelium-choroid graft in the pig
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; MINIATURE PIG;
   TRANSLOCATION; NEOVASCULARIZATION; TRANSPLANTATION; RETINOTOMY;
   MANAGEMENT; CIRCULATION
AB Background: Translocation of a free autologous graft consisting of retinal pigment epithelium (RPE), Bruch's membrane, choriocapillaris and choroid in patients with exudative age-related macular degeneration is currently being evaluated in clinical practice. Angiographic studies in these patients suggest that their grafts become revascularised.
   Aim: To investigate the histological evidence of revascularisation of the graft in a porcine model.
   Methods: In 11 pigs (11 eyes), an RPE-choroid graft was translocated from the mid-periphery to an intact or an intentionally damaged RPE and Bruch's membrane at the recipient site. The eyes were enucleated 1 week or 3 months after surgery. Tissue sections were evaluated using immunohistochemistry.
   Results: Bridging vessels between recipient layer and graft were identified from 1 week to 3 months after surgery. This reconnection occurred regardless of whether the Bruch's membrane of the recipient site was left intact or intentionally damaged at the time of transplantation. The vasculature of the graft appeared open and perfused. Vessels with transcapillary pillars and conglomerates of small new vessels were present in the graft.
   Conclusions: This study showed histological evidence for revascularisation by angiogenesis of a free autologous RPE-choroid graft.
C1 Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-5000 Cologne 41, Germany.
   Rotterdam Eye Hosp, Dept Vitreoretinal Surg, Rotterdam, Netherlands.
   Erasmus MC, Dept Pathol, Rotterdam, Netherlands.
   Univ Cologne, Inst Expt Med, D-5000 Cologne 41, Germany.
   Univ Regensburg, Dept Ophthalmol, D-8400 Regensburg, Germany.
C3 University of Cologne; Rotterdam Eye Hospital; Erasmus University
   Rotterdam; Erasmus MC; University of Cologne; University of Regensburg
RP Joussen, AM (通讯作者)，Univ Dusseldorf, Dept Ophthalmol, Moorenstr 5, D-40225 Dusseldorf, Germany.
EM joussena@googlemail.com
RI Joussen, Antonia/AAA-6901-2022
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   Campochiaro P A, 1999, Mol Vis, V5, P34
   CONVERSE JM, 1956, ANN SURG, V143, P306, DOI 10.1097/00000658-195603000-00003
   DESCHAEPDRIJVER L, 1992, EXP EYE RES, V54, P975, DOI 10.1016/0014-4835(92)90162-L
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hasumura T, 2000, INVEST OPHTH VIS SCI, V41, P4300
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hirata A, 2000, AM J OPHTHALMOL, V130, P611, DOI 10.1016/S0002-9394(00)00597-3
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Maaijwee K, 2006, OPHTHALMOLOGY, V113, P1471, DOI 10.1016/j.ophtha.2006.04.011
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Pawlak D, 2004, AM J OPHTHALMOL, V137, P880, DOI 10.1016/j.ajo.2003.12.041
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   RYAN SJ, 1980, A GRAEF ARCH KLIN EX, V215, P29, DOI 10.1007/BF00413394
   SIMOENS P, 1992, EXP EYE RES, V54, P965, DOI 10.1016/0014-4835(92)90161-K
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   TAKEMURA R, 1984, AM J PHYSIOL, V246, pC1, DOI 10.1152/ajpcell.1984.246.1.C1
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2005, ESSENT OPHTHALMOL, P73
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   YOUNG CMA, 1982, PLAST RECONSTR SURG, V70, P455, DOI 10.1097/00006534-198210000-00008
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 42
TC 22
Z9 22
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2007
VL 91
IS 4
BP 546
EP 550
DI 10.1136/bjo.2006.103259
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 147XH
UT WOS:000245037700033
PM 16987900
OA Green Published
DA 2022-11-30
ER

PT J
AU Yamagata, M
   Rook, SL
   Sassa, Y
   Ma, RC
   Geraldes, P
   Goddard, L
   Clermont, A
   Gao, B
   Salti, H
   Gundel, R
   White, M
   Feener, EP
   Aiello, LP
   King, GL
AF Yamagata, Michiko
   Rook, Susan L.
   Sassa, Yukio
   Ma, Ronald C.
   Geraldes, Pedro
   Goddard, Lucy
   Clermont, Allen
   Gao, Benbo
   Salti, Haytham
   Gundel, Robert
   White, Mark
   Feener, Edward P.
   Aiello, Lloyd Paul
   King, George L.
TI Bactericidal/permeability-increasing protein's signaling pathways and
   its retinal trophic and anti-angiogenic effects
SO FASEB JOURNAL
LA English
DT Article
DE ERK; Akt; diabetic retinopathy; age-related macular degeneration;
   glypican 4
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; IN-VIVO; BPI;
   NEOVASCULARIZATION; RETINOPATHY; EXPRESSION; APOPTOSIS; FRAGMENT; CELLS
AB Bactericidal/permeability-increasing protein (BPI) was originally identified as a lipopolysaccharide (LPS) binding protein with Gram-negative bactericidal activity in the leukocytes. In this study, we characterized the previously unknown effects of BPI in the eye and the molecular mechanisms involved in its action. BPI mRNA was detected in bovine retina; retinal pigment epithelium; and primary cultures of bovine retinal pigment epithelial cells (RPE), pericytes (RPC), and endothelial cells (REC); while BPI protein was measured in human vitreous and plasma. BPI, but not control protein thaumatin, activated extracellular regulated kinase (ERK) and AKT, and increased DNA synthesis in RPE and RPC but not in REC. A human recombinant 21 kDa modified amino-terminal fragment of BPI (rBPI(21)) reduced H2O2-induced apoptosis in RPE and inhibited vascular endothelial growth factor (VEGF)-stimulated ERK phosphorylation in REC when preincubated with VEGF. Intraperitoneal (i.p.)-injected rBPI21 reduced ischemia-induced retinal neovascularization and diabetes-induced retinal permeability. Since BPI has unusual dual properties of promoting RPC and RPE growth while suppressing VEGF-induced REC growth and vascular permeability, the mechanistic understanding of BPI's action may provide novel therapeutic opportunities for diabetic retinopathy and age-related macular degeneration.
C1 Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.
   XOMA US LLC, Dept Preclin Res & Cellular, Berkeley, CA USA.
   XOMA US LLC, Dept Analyt Dev, Berkeley, CA USA.
   Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA.
C3 Harvard University; Harvard Medical School; Joslin Diabetes Center,
   Inc.; Harvard University; Harvard Medical School; Joslin Diabetes
   Center, Inc.; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School
RP King, GL (通讯作者)，Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.
EM george.king@joslin.harvard.edu
RI Sassa, Yukio/H-6339-2012; Ma, Ronald/C-2788-2009
OI Ma, Ronald/0000-0002-1227-803X
FU NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
   [P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK36836]
   Funding Source: Medline
CR Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Canny G, 2002, P NATL ACAD SCI USA, V99, P3902, DOI 10.1073/pnas.052533799
   Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Harkin DW, 2001, ANN SURG, V234, P233, DOI 10.1097/00000658-200108000-00014
   KING GL, 1987, DIABETES, V36, P1460, DOI 10.2337/diabetes.36.12.1460
   KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764
   KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013
   Levine KB, 2002, BIOCHEMISTRY-US, V41, P12629, DOI 10.1021/bi0258997
   LITTLE RG, 1994, J BIOL CHEM, V269, P1865
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8
   NAYAK RC, 1988, J EXP MED, V167, P1003, DOI 10.1084/jem.167.3.1003
   Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Rauniyar RK, 2002, INVEST OPHTH VIS SCI, V43, P503
   SHAFER WM, 1984, INFECT IMMUN, V45, P29, DOI 10.1128/IAI.45.1.29-35.1984
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566
   Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499
   Takahashi M, 2004, EXP DERMATOL, V13, P55, DOI 10.1111/j.0906-6705.2004.00116.x
   van der Schaft DWJ, 2000, BLOOD, V96, P176, DOI 10.1182/blood.V96.1.176.013k32_176_181
   Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624
   WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930
   WEISS J, 1978, J BIOL CHEM, V253, P2664
NR 32
TC 19
Z9 27
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2006
VL 20
IS 12
BP 2058
EP 2067
DI 10.1096/05-5662com
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 093GS
UT WOS:000241156900014
PM 17012258
DA 2022-11-30
ER

PT J
AU Miao, HQ
   Hu, K
   Jimenez, X
   Navarro, E
   Zhang, HF
   Lu, D
   Ludwig, DL
   Balderes, P
   Zhu, ZP
AF Miao, Hua-Quan
   Hu, Kun
   Jimenez, Xenia
   Navarro, Elizabeth
   Zhang, Haifan
   Lu, Dan
   Ludwig, Dale L.
   Balderes, Paul
   Zhu, Zhenping
TI Potent neutralization of VEGF biological activities with a fully human
   antibody Fab fragment directed against VEGF receptor 2
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE angiogenesis; anti-angiogenic therapy; endothelial cell; Fab fragment;
   human antibody; VEGF; VEGFR2/KDR
ID ENDOTHELIAL GROWTH-FACTOR; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION;
   CHOROIDAL NEOVASCULARIZATION; ANGIOGENESIS INHIBITORS; PLC-GAMMA;
   IN-VITRO; KDR; ACTIVATION; SELECTION
AB Compelling evidence suggest that vascular endothelial growth factor (VEGF) and its receptors, especially receptor 2 (VEGFR2, or kinase insert domain-containing receptor, KDR), play a critical role in angiogenesis under both physiological and pathological conditions, including cancer and angiogenic retinopathies such as age-related macular degeneration (AMD). To this end, inhibition of angiogenesis with antagonists to either VEGF or KDR has yielded significant therapeutic efficacy both in preclinical studies in animal models and in clinical trials in patients with cancer and AMD. We previously reported the identification of a high affinity, fully human anti-KDR antibody fragment, 1121B Fab, through a highly stringent affinity maturation process with a Fab originally isolated from a naive human antibody phage display library. In this study, we demonstrate that 1121B Fab is able to strongly block KDR/VEGF interaction, resulting in potent inhibition of an array of biological activities of VEGF, including activation of the receptor and its signaling pathway, intracellular calcium mobilization, and migration and proliferation of endothelial cells. Taken together, our data lend strong support to the further development of 1121B Fab fragment as an anti-angiogenesis agent in both cancer and angiogenic retinopathies. (c) 2006 Elsevier Inc. All rights reserved.
C1 ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA.
   ImClone Syst Inc, Dept Prot Sci, New York, NY 10014 USA.
   ImClone Syst Inc, Dept Cell Engn & Express, New York, NY 10014 USA.
C3 Eli Lilly; Eli Lilly; Eli Lilly
RP Miao, HQ (通讯作者)，ImClone Syst Inc, Dept Antibody Technol, New York, NY 10014 USA.
EM hua-quan.miao@imclone.com; zhenping.zhu@imclone.com
CR Barouch Fina C., 2004, International Ophthalmology Clinics, V44, P23, DOI 10.1097/00004397-200404430-00005
   Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Collins TS, 2005, SEMIN ONCOL, V32, P61, DOI 10.1053/j.seminoncol.2004.09.026
   Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176
   Doggrell SA, 2005, EXPERT OPIN PHARMACO, V6, P1421, DOI 10.1517/14656566.6.8.1421
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2005, EXP SUPPL, V94, P209
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2005, ONCOLOGY-BASEL, V69, P11, DOI 10.1159/000088479
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gliki G, 2001, BIOCHEM J, V353, P503, DOI 10.1042/0264-6021:3530503
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729
   Hicklin DJ, 2001, DRUG DISCOV TODAY, V6, P517, DOI 10.1016/S1359-6446(01)01759-7
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kinose F, 2005, MOL VIS, V11, P366
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KU DD, 1993, AM J PHYSIOL, V265, pH586, DOI 10.1152/ajpheart.1993.265.2.H586
   Lau SC, 2005, CURR OPIN MOL THER, V7, P493
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321
   Lu D, 2003, J BIOL CHEM, V278, P43496, DOI 10.1074/jbc.M307742200
   Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634
   McLaughlin AP, 2001, AM J PHYSIOL-CELL PH, V281, pC1448, DOI 10.1152/ajpcell.2001.281.5.C1448
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P474
   Paz K, 2005, FRONT BIOSCI-LANDMRK, V10, P1415, DOI 10.2741/1629
   Persaud K, 2004, J CELL SCI, V117, P2745, DOI 10.1242/jcs.01138
   Prewett M, 1999, CANCER RES, V59, P5209
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Ramakrishnan S, 1996, CANCER RES, V56, P1324
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047
   Underiner TL, 2004, CURR MED CHEM, V11, P731, DOI 10.2174/0929867043455756
   Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Weng D E, 2001, Curr Oncol Rep, V3, P141, DOI 10.1007/s11912-001-0014-7
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427
   Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200
   Zhu Z, 2003, LEUKEMIA, V17, P604, DOI 10.1038/sj.leu.2402831
   Zhu ZP, 2002, CURR CANCER DRUG TAR, V2, P135, DOI 10.2174/1568009023333881
   Zhu ZP, 1999, CANCER LETT, V136, P203, DOI 10.1016/S0304-3835(98)00324-3
   Zhu ZP, 1998, CANCER RES, V58, P3209
   Zimmermann RC, 2003, J CLIN INVEST, V112, P659, DOI 10.1172/JCI200318740
   Zimmermann RC, 2002, ENDOCRINOLOGY, V143, P2496, DOI 10.1210/en.143.7.2496
NR 48
TC 78
Z9 90
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 23
PY 2006
VL 345
IS 1
BP 438
EP 445
DI 10.1016/j.bbrc.2006.04.119
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 047KH
UT WOS:000237877700059
PM 16682007
DA 2022-11-30
ER

PT J
AU Gupta, SK
   Viswanath, K
   Thulasiraj, RD
   Murthy, GVS
   Lamping, DL
   Smith, SC
   Donoghue, M
   Fletcher, AE
AF Gupta, SK
   Viswanath, K
   Thulasiraj, RD
   Murthy, GVS
   Lamping, DL
   Smith, SC
   Donoghue, M
   Fletcher, AE
TI The development of the Indian vision function questionnaire: field
   testing and psychometric evaluation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE
AB Objective: To develop and evaluate the acceptability, reliability, validity, and responsiveness of the Indian vision function questionnaire (IND-VFQ).
   Methods: Problem statements from previous qualitative studies were reduced to a 45 item interviewer administered questionnaire representing three a priori domains (general functioning, psychosocial impact, and visual symptoms) which was evaluated in patients with cataract (n = 420), glaucoma (n = 120), diabetic retinopathy, or age related macular degeneration (n = 120) and normal controls (n = 120). Standard methods were used for item reduction and to evaluate psychometric properties.
   Results: Psychometric item reduction produced a 33 item questionnaire. Psychometric evaluation showed that two of the three scales (psychosocial impact and visual symptoms) had good acceptability, and that all three scales showed high internal consistency (alpha >0.80; item-total correlations 0.54-0.86) and test-retest reliability (>0.89). All three scales showed moderate evidence of convergent and discriminant validity. Responsiveness, assessed in cataract patients (n = 120) before and after surgery, was good for all three scales (effect sizes >1).
   Conclusions: The IND-VFQ33 is a psychometrically sound measure of vision function addressing a gap in patient defined measures of vision function developed in populations living in low income countries.
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
   Sarojini Devi Eye Hosp, Hyderabad, Andhra Pradesh, India.
   Lions Aravind Inst Community Ophthalmol, Madurai, Tamil Nadu, India.
C3 University of London; London School of Hygiene & Tropical Medicine; All
   India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Fletcher, AE (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
CR Aaronson N, 2002, QUAL LIFE RES, V11, P193
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
   Fletcher A, 1998, AM J OPHTHALMOL, V125, P26, DOI 10.1016/S0002-9394(99)80231-1
   Fletcher AE, 1997, ARCH OPHTHALMOL-CHIC, V115, P767, DOI 10.1001/archopht.1997.01100150769013
   HAYS RD, 1990, BEHAV RES METH INS C, V22, P167, DOI 10.3758/BF03203140
   Lamping DL, 2002, CHEST, V122, P920, DOI 10.1378/chest.122.3.920
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   McDowell I, 1996, J Health Serv Res Policy, V1, P238
   Murthy GVS, 2005, BRIT J OPHTHALMOL, V89, P498, DOI 10.1136/bjo.2004.047217
   Streiner DL, 1995, HLTH MEASUREMENT SCA
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   Ware J. E., 1997, MAP R WINDOWS MULTIT
NR 15
TC 47
Z9 50
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2005
VL 89
IS 5
BP 621
EP 627
DI 10.1136/bjo.2004.050732
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 917GN
UT WOS:000228444600027
PM 15834097
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Bevitt, DJ
   Mohamed, J
   Catterall, JB
   Li, Z
   Arris, CE
   Hiscott, P
   Sheridan, C
   Langton, KP
   Barker, MD
   Clarke, MP
   McKie, N
AF Bevitt, DJ
   Mohamed, J
   Catterall, JB
   Li, Z
   Arris, CE
   Hiscott, P
   Sheridan, C
   Langton, KP
   Barker, MD
   Clarke, MP
   McKie, N
TI Expression of ADAMTS metalloproteinases in the retinal pigment
   epithelium derived cell line ARPE-19: transcriptional regulation by TNF
   alpha
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION
LA English
DT Article
DE retinal pigment epithelium; metalloproteinase; cytokine; proteoglycan;
   extracellular matrix
ID INTERPHOTORECEPTOR MATRIX; THROMBOSPONDIN MOTIFS; IN-VIVO; FAMILY;
   CLONING; BINDING; PROTEINS; MEMBER; DISINTEGRIN; INHIBITOR
AB ADAMTS (A Disintegrin-like And Metalloprotease domain with ThromboSpondin type I motifs) are multidomain proteins with demonstrated metalloproteinase functionality and have potential roles in embryonic development, angiogenesis and cartilage degradation. We present here investigations of ADAMTS expression in an ocular cell type, ARPE-19, with a view to implicating them in retinal matrix turnover. Expression analysis was undertaken using a combination of reverse transcription polymerase chain reaction (RT-PCR) and Northern blotting experiments, which together detected the expression of mRNAs for several ADAMTS proteins, all of which have active site motifs characteristic of matrix metalloproteases (MMPs). These included ADAMTS1, ADAMTS2, ADAMTS3, ADAMTS5, ADAMTS6, ADAMTS7 and ADAMTS9. The expression of mRNA isoforms for ADAMTS7 and ADAMTS9 were also detected. Following stimulation with TNFalpha ADAMTS1, ADAMTS6 and both ADAMTS9 transcripts expressed in ARPE-19 cells showed a potent upregulation. The expression of ADAMTS genes in ARPE-19 cells and the transcriptional stimulation of some family members by TNFalpha may implicate them in inflammatory eye disease and the compromise of retinal matrix structure, which is evident in age-related macular degeneration (ARMD) and other retinal pathologies. (C) 2003 Elsevier Science B.V. All rights reserved.
C1 Univ Newcastle Upon Tyne, Sch Med, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Liverpool, Dept Med & Pathol, Unit Ophthalmol, Liverpool L69 3BX, Merseyside, England.
   Univ Sheffield, Sch Med, Div Genom Med, Acad Unit Div, Sheffield S10 2RX, S Yorkshire, England.
   Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; University of Liverpool; University of
   Sheffield; Newcastle University - UK
RP McKie, N (通讯作者)，Univ Newcastle Upon Tyne, Sch Med, Dept Rheumatol, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
RI Sheridan, Carl/AAH-3607-2021
OI Sheridan, Carl/0000-0003-0100-9587; Li, Zheng/0000-0002-7060-2213
CR Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443
   ALEXANDER JP, 1990, INVEST OPHTH VIS SCI, V31, P2520
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263
   Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196
   Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X
   Carpizo D, 2000, CANCER METAST REV, V19, P159, DOI 10.1023/A:1026570331022
   Cawston TE, 1998, ARTHRITIS RHEUM-US, V41, P1760, DOI 10.1002/1529-0131(199810)41:10<1760::AID-ART8>3.0.CO;2-M
   Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246
   Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374
   Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504
   Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200
   Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   HISCOTT P, 1998, RETINAL PIGMENT EPIT, P478
   Hollyfield JG, 1999, EXP EYE RES, V69, P311, DOI 10.1006/exer.1999.0707
   Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   JONES BE, 1994, EXP EYE RES, V59, P257, DOI 10.1006/exer.1994.1107
   Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200
   Kon CH, 1998, INVEST OPHTH VIS SCI, V39, P1524
   Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556
   Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Marmor M, 1998, RETINAL PIGMENT EPIT, P3
   Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199
   Padgett LC, 1997, EXP EYE RES, V64, P927, DOI 10.1006/exer.1997.0287
   PLANTNER JJ, 1994, EXP EYE RES, V59, P577, DOI 10.1006/exer.1994.1143
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200
   Salzmann J, 2000, BRIT J OPHTHALMOL, V84, P1091, DOI 10.1136/bjo.84.10.1091
   Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200
   Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231
   Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298
   Tang BL, 2001, INT J BIOCHEM CELL B, V33, P33, DOI 10.1016/S1357-2725(00)00061-3
   Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664
   Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349
   Yang CH, 1997, CURR EYE RES, V16, P1119, DOI 10.1076/ceyr.16.11.1119.5106
   Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200
NR 42
TC 38
Z9 43
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-4781
J9 BBA-GENE STRUCT EXPR
JI Biochim. Biophys. Acta-Gene Struct. Expression
PD APR 15
PY 2003
VL 1626
IS 1-3
BP 83
EP 91
DI 10.1016/S0167-4781(03)00047-2
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 670PY
UT WOS:000182418600011
PM 12697333
DA 2022-11-30
ER

PT J
AU Yang, X
   Zou, R
   Dai, XC
   Wu, XY
   Yuan, F
   Feng, YF
AF Yang, Xi
   Zou, Rong
   Dai, Xiaochan
   Wu, Xinyuan
   Yuan, Fei
   Feng, Yifan
TI YAP is critical to inflammation, endothelial-mesenchymal transition and
   subretinal fibrosis in experimental choroidal neovascularization
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Choroidal neovascularization; Endothelial-to-mesenchymal transition;
   Yes-associated protein; TGF-&beta; 2; Subretinal fibrosis; Reactive
   oxygen species
ID TRANSFORMING GROWTH-FACTOR-BETA-2; BETA; INHIBITION; EXPRESSION; GENE
AB Subretinal fibrosis causes local damage to the retina and irreversible vision loss, as the final stage of neovascular age-related macular degeneration (nAMD). More recently, the endothelial-to-mesenchymal transition (EndoMT) has been considered one of the most significant sources of myofibroblasts in subretinal fibrosis, though the underpinning molecular mechanisms remain unclear. In this study, a series of experiments were performed to test the hypothesis that Yes-associated protein (YAP) may be involved in EndoMT and subretinal fibrosis. We demonstrated that transforming growth factor (TGF)-82 stimulation induces YAP dephosphorylation (activated) and nuclear transcription in human umbilical vein endothelial cells (HUVECs) by increasing reactive oxygen species (ROS) levels. Moreover, TGF-82-mediated EndoMT and proinflammatory cytokine production in HUVECs were reduced by ROS clearance or YAP knockdown. Furthermore, the severity of subretinal fibrosis was markedly relieved by intravitreal administration of a small interfering RNA targeting YAP in the mouse laser induced choroidal neovascularization (CNV) model. Our findings provide novel insights into a previously unknown effect of YAP on the EndoMT process and reveal YAP as a potential target for suppressing CNV-related subretinal fibrosis and protect vision.
C1 [Yang, Xi; Zou, Rong; Dai, Xiaochan; Wu, Xinyuan; Yuan, Fei; Feng, Yifan] Fudan Univ, Zhongshan Hosp, Dept Ophthalmol, Shanghai 200032, Peoples R China.
   [Yuan, Fei; Feng, Yifan] Fudan Univ, Zhongshan Hosp, Dept Ophthalmol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University
RP Yuan, F; Feng, YF (通讯作者)，Fudan Univ, Zhongshan Hosp, Dept Ophthalmol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM yuanfeiyk@163.com; wzafengyifan@163.com
FU National Natural Science Foundation of China [81970817, 81873680];
   Science and Technology Program of Yichang [A2020-2-029]
FX Funding The present work was funded by the National Natural Science
   Foundation of China (nos. 81970817 and 81873680) and the Science and
   Technology Program of Yichang (no. A2020-2-029) .
CR Azad T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050407
   Bischoff J, 2019, CIRC RES, V124, P1163, DOI 10.1161/CIRCRESAHA.119.314813
   Chen JZ, 2019, EXP EYE RES, V184, P64, DOI 10.1016/j.exer.2019.03.006
   Cho JG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00294
   CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Doridot L, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2019.101122
   Feng YF, 2021, ANGIOGENESIS, V24, P489, DOI 10.1007/s10456-020-09760-8
   Feng YF, 2018, FASEB J, V32, P1626, DOI 10.1096/fj.201700640R
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Lai KB, 2021, PHYTOMEDICINE, V93, DOI 10.1016/j.phymed.2021.153747
   Li J, 2019, J DENT RES, V98, P920, DOI 10.1177/0022034519851804
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072242
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo XT, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032060
   Ma J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00260
   Mao YZ, 2021, J PHYSIOL SCI, V71, DOI 10.1186/s12576-021-00815-z
   Medici D, 2011, BIOCHEM J, V437, P515, DOI 10.1042/BJ20101500
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Pardali E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102157
   Park JA, 2018, BMB REP, V51, P157, DOI 10.5483/BMBRep.2018.51.3.016
   Perez L, 2017, CYTOKINE GROWTH F R, V33, P41, DOI 10.1016/j.cytogfr.2016.09.002
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Piera-Velazquez S, 2019, PHYSIOL REV, V99, P1281, DOI 10.1152/physrev.00021.2018
   Piersma B, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00059
   Pocaterra A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.230425
   Ramos-Tovar E, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121279
   Rao VR, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.4.4
   Ren YF, 2021, ACS PHARMACOL TRANSL, V4, P1066, DOI 10.1021/acsptsci.1c00010
   Rossato FA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092057
   Ruan Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080761
   Savorani C., 2021, J CELL SCI, P134
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stewart AG, 2018, RESPIROLOGY, V23, P1096, DOI 10.1111/resp.13415
   Tenbrock L, 2022, CELL TISSUE RES, V387, P361, DOI 10.1007/s00441-021-03514-8
   Wang YJ, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108417
   Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150
   Wu D, 2019, FASEB J, V33, P2498, DOI 10.1096/fj.201801227R
   Xiao H, 2021, BRIT J OPHTHALMOL, V105, P103, DOI 10.1136/bjophthalmol-2019-315763
   Yan ZZ, 2018, MOL VIS, V24, P83
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhang W, 2021, J CELL MOL MED, V25, P10213, DOI 10.1111/jcmm.16958
   Zhang W, 2020, J CELL MOL MED, V24, P12390, DOI 10.1111/jcmm.15739
   Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907
   Zhu MH, 2018, EXP CELL RES, V373, P155, DOI 10.1016/j.yexcr.2018.10.007
NR 56
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD AUG 15
PY 2022
VL 417
IS 2
AR 113221
DI 10.1016/j.yexcr.2022.113221
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA 2C2SU
UT WOS:000810725000003
PM 35623419
DA 2022-11-30
ER

PT J
AU Arjunan, P
   Swaminathan, R
AF Arjunan, Pachiappan
   Swaminathan, Radhika
TI Do Oral Pathogens Inhabit the Eye and Play a Role in Ocular Diseases?
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE ocular microbiome; oral microbiota; periodontal; inflammation;
   dysbiosis; homeostasis; age-related macular degeneration; glaucoma;
   diabetic retinopathy; uveitis
ID PORPHYROMONAS-GINGIVALIS; DENDRITIC CELLS; MACULAR DEGENERATION; GUT
   MICROBIOTA; PERIODONTAL-DISEASE; ALZHEIMERS-DISEASE; BACTERIAL-FLORA;
   AGE; HEALTH; INFLAMMATION
AB Fascinatingly, the immune-privileged healthy eye has a small unique population of microbiota. The human microbiome project led to continuing interest in the ocular microbiome. Typically, ocular microflorae are commensals of low diversity that colonize the external and internal sites of the eye, without instigating any disorders. Ocular commensals modulate immunity and optimally regulate host defense against pathogenic invasion, both on the ocular surface and neuroretina. Yet, any alteration in this symbiotic relationship culminates in the perturbation of ocular homeostasis and shifts the equilibrium toward local or systemic inflammation and, in turn, impaired visual function. A compositional variation in the ocular microbiota is associated with surface disorders such as keratitis, blepharitis, and conjunctivitis. Nevertheless, innovative studies now implicate non-ocular microbial dysbiosis in glaucoma, age-related macular degeneration (AMD), uveitis, and diabetic retinopathy. Accordingly, prompt identification of the extra-ocular etiology and a methodical understanding of the mechanisms of invasion and host-microbial interaction is of paramount importance for preventative and therapeutic interventions for vision-threatening conditions. This review article aims to explore the current literature evidence to better comprehend the role of oral pathogens in the etiopathogenesis of ocular diseases, specifically AMD.
C1 [Arjunan, Pachiappan; Swaminathan, Radhika] Augusta Univ, Dept Periodont, Dent Coll Georgia, Augusta, GA 30912 USA.
   [Arjunan, Pachiappan] Augusta Univ, James & Jean Culver Vision Discovery Inst, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University
RP Arjunan, P (通讯作者)，Augusta Univ, Dept Periodont, Dent Coll Georgia, Augusta, GA 30912 USA.; Arjunan, P (通讯作者)，Augusta Univ, James & Jean Culver Vision Discovery Inst, Augusta, GA 30912 USA.
EM pachiarjun@gmail.com; radhipachi2021@gmail.com
CR Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005
   Abbayya K, 2015, N AM J MED SCI, V7, P241, DOI 10.4103/1947-2714.159325
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   [Anonymous], NEI Age-Related Macular Degeneration (AMD) Data and Statistics
   Arjunan P, 2016, MOL ORAL MICROBIOL, V31, P78, DOI 10.1111/omi.12131
   Arjunan P, INVESTIGATING ENIGMA
   Arjunan P, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020309
   Arjunan P, 2021, INT REV IMMUNOL, V40, P409, DOI 10.1080/08830185.2020.1845330
   Arjunan P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64449-8
   Arjunan P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35126-8
   Astafurov K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104416
   Avila M, 2009, DNA CELL BIOL, V28, P405, DOI 10.1089/dna.2009.0874
   Azam S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01000
   Baim AD, 2019, EXP BIOL MED, V244, P419, DOI 10.1177/1535370218813616
   Barros A, 2022, OCUL SURF, V23, P40, DOI 10.1016/j.jtos.2021.10.010
   Bhat UG, 2014, J PERIODONTOL, V85, P1629, DOI 10.1902/jop.2014.140070
   Brennan CA, 2019, NAT REV MICROBIOL, V17, P156, DOI 10.1038/s41579-018-0129-6
   Bringer MA, 2022, EXP EYE RES, V214, DOI 10.1016/j.exer.2021.108867
   Bron AJ, 2004, EXP EYE RES, V78, P347, DOI 10.1016/j.exer.2003.09.019
   Brook I, 2010, ANAEROBE, V16, P183, DOI 10.1016/j.anaerobe.2009.12.001
   Brzozowska Aleksandra, 2012, Klin Oczna, V114, P29
   Burleson GR, 2017, TOXICOL PATHOL, V45, P146, DOI 10.1177/0192623316677070
   Burns R, 1922, Cal State J Med, V20, P120
   Cahill TJ, 2016, LANCET, V387, P882, DOI 10.1016/S0140-6736(15)00067-7
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491
   Carrion J, 2012, J IMMUNOL, V189, P3178, DOI 10.4049/jimmunol.1201053
   CDC-Common Eye Disorders and Diseases, US
   Celenligil H, 1998, J PERIODONTOL, V69, P571, DOI 10.1902/jop.1998.69.5.571
   Chakravarthy SK, 2018, INDIAN J MICROBIOL, V58, P457, DOI 10.1007/s12088-018-0746-9
   Chang PC, 2012, J DENT SCI, V7, P272, DOI 10.1016/j.jds.2012.02.002
   Chen YW, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.625913
   Chiu CJ, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.2.23
   Chiu CJ, 2019, INVEST OPHTH VIS SCI, V60
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cutler CW, 1999, J PERIODONTAL RES, V34, P406, DOI 10.1111/j.1600-0765.1999.tb02274.x
   D'Aiuto F, 2004, J DENT RES, V83, P156, DOI 10.1177/154405910408300214
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   DEBELIAN GJ, 1994, ENDOD DENT TRAUMATOL, V10, P57
   Detert J, 2010, Z RHEUMATOL, V69, P109, DOI 10.1007/s00393-009-0560-1
   Devine L, 1996, IMMUNOLOGY, V88, P456, DOI 10.1046/j.1365-2567.1996.d01-666.x
   Doan T, 2016, INVEST OPHTH VIS SCI, V57, P5116, DOI 10.1167/iovs.16-19803
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Dong QF, 2011, INVEST OPHTH VIS SCI, V52, P5408, DOI 10.1167/iovs.10-6939
   Duran-Pinedo AE, 2015, MICROBES INFECT, V17, P505, DOI 10.1016/j.micinf.2015.03.014
   Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520
   Entezami P, 2011, HAND CLIN, V27, P1, DOI 10.1016/j.hcl.2010.09.006
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fan XT, 2022, BMC OPHTHALMOL, V22, DOI 10.1186/s12886-022-02348-4
   Fan Y, 2021, NAT REV MICROBIOL, V19, P55, DOI 10.1038/s41579-020-0433-9
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Carrizales-Sepulveda EF, 2018, HEART LUNG CIRC, V27, P1327, DOI 10.1016/j.hlc.2018.05.102
   Gambini G, 2021, CORNEA, V40, P477, DOI 10.1097/ICO.0000000000002643
   Gendron R, 2000, MICROBES INFECT, V2, P897, DOI 10.1016/S1286-4579(00)00391-9
   Graham Joanna E, 2007, Invest Ophthalmol Vis Sci, V48, P5616
   Graves DT, 2008, FRONT BIOSCI-LANDMRK, V13, P1227, DOI 10.2741/2757
   Guncu Guliz Nigar, 2011, Eur J Dent, V5, P337
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   Hajishengallis G, 2022, PERIODONTOL 2000, V89, P9, DOI 10.1111/prd.12430
   Hajishengallis G, 2011, NAT REV IMMUNOL, V11, P187, DOI 10.1038/nri2918
   Hajishengallis G, 2009, MICROBES INFECT, V11, P637, DOI 10.1016/j.micinf.2009.03.009
   Hawrelak Jason A, 2004, Altern Med Rev, V9, P180
   Heron E, 2017, J FR OPHTALMOL, V40, P681, DOI 10.1016/j.jfo.2017.04.007
   Heuss ND, 2012, J IMMUNOL, V188, P1191, DOI 10.4049/jimmunol.1101621
   Ho EXP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201768
   Horikawa Y, 2020, EXP CLIN ENDOCR DIAB, V128, P231, DOI 10.1055/a-0879-1890
   Huang YH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.646348
   Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234
   Iacopino A M, 2001, Ann Periodontol, V6, P125, DOI 10.1902/annals.2001.6.1.125
   Igari K, 2014, ORAL BIOL DENT, V2, P1, DOI [10.7243/2053-5775-2-4, DOI 10.7243/2053-5775-2-4]
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Javed F, 2021, ACTA OPHTHALMOL, V99, P351, DOI 10.1111/aos.14629
   Jayasudha R, 2018, J BIOSCIENCES, V43, P835, DOI 10.1007/s12038-018-9798-6
   Jiao JH, 2021, J INFLAMM RES, V14, P6929, DOI 10.2147/JIR.S336148
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jotwani R, 2004, INFECT IMMUN, V72, P1725, DOI 10.1128/IAI.72.3.1725-1732.2004
   Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kingman S, 2004, B WORLD HEALTH ORGAN, V82, P887
   Kolde R, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0515-8
   Konkel JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01403
   Kozarov E, 2012, FUTUR CARDIOL, V8, P123, DOI [10.2217/fca.11.75, 10.2217/FCA.11.75]
   Kridin M, 2022, EYE, DOI 10.1038/s41433-022-02037-y
   Kwok SK, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3780
   Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579-018-0089-x
   Leccese P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01067
   Li XJ, 2000, CLIN MICROBIOL REV, V13, P547, DOI 10.1128/CMR.13.4.547-558.2000
   Liang HY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063983, 10.1371/journal.pone.0074121]
   Lima-Fontes M, 2022, SURV OPHTHALMOL, V67, P883, DOI 10.1016/j.survophthal.2021.11.009
   Lin P, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102072
   Lin P, 2019, CLIN EXP OPHTHALMOL, V47, P418, DOI 10.1111/ceo.13493
   Lin P, 2018, CURR OPIN OPHTHALMOL, V29, P261, DOI 10.1097/ICU.0000000000000465
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Lu Louise J., 2016, Yale Journal of Biology and Medicine, V89, P325
   MacNevin M.G., 1922, ABSTRACT LIT MOUTH I
   Marsh Philip D, 2006, BMC Oral Health, V6 Suppl 1, pS14, DOI 10.1186/1472-6831-6-S1-S14
   Marsh Philip D., 2000, Microbial Ecology in Health and Disease, V12, P130, DOI 10.1080/089106000750051800
   Mesquida M, 2014, CLIN EXP IMMUNOL, V176, P301, DOI 10.1111/cei.12295
   Michaud DS, 2017, EPIDEMIOL REV, V39, P49, DOI 10.1093/epirev/mxx006
   Michaud DS, 2013, CARCINOGENESIS, V34, P2193, DOI 10.1093/carcin/bgt249
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Napolitano P, 2021, ANN MED, V53, P750, DOI 10.1080/07853890.2021.1925150
   Nayar G, 2016, ANAEROBE, V38, P70, DOI 10.1016/j.anaerobe.2015.10.005
   Offenbacher S, 1996, Ann Periodontol, V1, P821, DOI 10.1902/annals.1996.1.1.821
   Ohira S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147080
   Page R C, 1998, Ann Periodontol, V3, P108, DOI 10.1902/annals.1998.3.1.108
   PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x
   Pappas G, 2008, INT J INFECT DIS, V12, P347, DOI 10.1016/j.ijid.2007.11.003
   Pasquale LR, 2016, OPHTHALMOLOGY, V123, P2318, DOI 10.1016/j.ophtha.2016.07.014
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pockpa Zocko Ange Desire, 2019, Perm J, V23, DOI 10.7812/TPP/18.260
   Polla D, 2017, J GLAUCOMA, V26, P320, DOI 10.1097/IJG.0000000000000465
   Popov I., 2022, CESK SLOV OFTALMOL, V2, P1001
   Popova C, 2013, BIOTECHNOL BIOTEC EQ, V27, P3754, DOI 10.5504/BBEQ.2013.0027
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Ramsey DT, 1996, J AM ANIM HOSP ASSOC, V32, P215, DOI 10.5326/15473317-32-3-215
   Rath H, 2017, FEMS MICROBIOL ECOL, V93, DOI 10.1093/femsec/fix010
   Horliana ACRT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098271
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Roca-Millan E, 2018, MED ORAL PATOL ORAL, V23, pE681, DOI 10.4317/medoral.22725
   Rosenow EC, 1919, J DENT RES, V1, P205, DOI [DOI 10.1177/00220345190010030101, 10.1177/00220345190010030101]
   Rullo J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60674-3
   Sampaio-Maia B, 2016, ADV APPL MICROBIOL, V97, P171, DOI 10.1016/bs.aambs.2016.08.002
   Scuderi G, 2022, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.726792
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Sen HN, 2017, INVEST OPHTH VIS SCI, V58
   Shijo T, 2020, INT OPHTHALMOL, V40, P2735, DOI 10.1007/s10792-020-01460-y
   Shimizu E, 2019, OCUL SURF, V17, P265, DOI 10.1016/j.jtos.2019.02.001
   Shin YU, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006418
   Singhrao SK, 2018, J ALZHEIMERS DIS REP, V2, P219, DOI 10.3233/ADR-180080
   Slepova O S, 2015, Vestn Oftalmol, V131, P56, DOI 10.17116/oftalma2015131456-59
   Somma F, 2011, EUR REV MED PHARMACO, V15, P35
   St Leger AJ, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800046
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sun KT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74589-6
   Sun KT, 2020, RETINA-J RET VIT DIS, V40, P2312, DOI 10.1097/IAE.0000000000002750
   Swidsinski A, 2011, GUT, V60, P34, DOI 10.1136/gut.2009.191320
   Tien PT, 2016, RETINA-J RET VIT DIS, V36, P2391, DOI 10.1097/IAE.0000000000001103
   Tlaskalova-Hogenova H, 2004, IMMUNOL LETT, V93, P97, DOI 10.1016/j.imlet.2004.02.005
   Topcuoglu N, 2015, ANAEROBE, V35, P35, DOI 10.1016/j.anaerobe.2015.01.011
   Trujillo-Vargas CM, 2020, OCUL SURF, V18, P335, DOI 10.1016/j.jtos.2019.10.006
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Ursell LK, 2012, NUTR REV, V70, pS38, DOI 10.1111/j.1753-4887.2012.00493.x
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   Wang X, 2013, DIABETES CARE, V36, P166, DOI 10.2337/dc12-0702
   Wen XF, 2017, INVEST OPHTH VIS SCI, V58, P6030, DOI 10.1167/iovs.17-22957
   Wijarnpreecha K, 2016, N AM J MED SCI, V8, P197, DOI 10.4103/1947-2714.179961
   Willcox MDP, 2020, CLIN EXP OPTOM, V103, P418, DOI 10.1111/cxo.13088
   Willcox MDP, 2013, EXP EYE RES, V117, P99, DOI 10.1016/j.exer.2013.06.003
   Winning Lewis, 2017, Curr Oral Health Rep, V4, P1, DOI 10.1007/s40496-017-0121-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu HZ, 2017, J CLIN INVEST, V127, P43, DOI [10.1172/JCI88880, 10.1172/jci88880]
   Xu JX, 2020, J PATHOL, V251, P200, DOI 10.1002/path.5447
   Xue W, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.759333
   Ye PP, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.667632
   Yoon BW, 2021, J ORAL MICROBIOL, V13, DOI 10.1080/20002297.2021.1962125
   Yucel-Lindberg T, 2013, EXPERT REV MOL MED, V15, DOI 10.1017/erm.2013.8
   Zhang YH, 2018, BIOMED PHARMACOTHER, V99, P883, DOI 10.1016/j.biopha.2018.01.146
   Zheng WN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02399-4
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 166
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2022
VL 11
IS 10
AR 2938
DI 10.3390/jcm11102938
PG 20
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1P0UU
UT WOS:000801735800001
PM 35629064
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Huang, YH
   Kuo, CH
   Peng, IC
   Chang, YS
   Tseng, SH
   Conway, EM
   Wu, HL
AF Huang, Yi-Hsun
   Kuo, Cheng-Hsiang
   Peng, I-Chen
   Chang, Yi-Sheng
   Tseng, Sung-Huei
   Conway, Edward M.
   Wu, Hua-Lin
TI Recombinant thrombomodulin domain 1 rescues pathological angiogenesis by
   inhibition of HIF-1 alpha-VEGF pathway
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Hypoxia-inducible factor-l alpha (HIF-1 alpha); Oxygen induced
   retinopathy (OIR); Pathological angiogenesis (PA); Recombinant
   thrombomodulin domain 1 (rTMD1); Vascular endothelial growth factor
   (VEGF)
ID OXYGEN-INDUCED RETINOPATHY; LECTIN-LIKE DOMAIN; SOLUBLE THROMBOMODULIN;
   INTRAVITREAL BEVACIZUMAB; DIABETIC-RETINOPATHY; AQUEOUS-HUMOR; RETINAL
   NEOVASCULARIZATION; PLASMA THROMBOMODULIN; VEGF; RANIBIZUMAB
AB Pathological angiogenesis (PA) contributes to various ocular diseases, including age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity, which are major causes of blindness over the world. Current treatments focus on anti-vascular endothelial growth factor (VEGF) therapy, but persistent avascular retina, recurrent intravitreal neovascularization, and general adverse effects are reported. We have previously found that recombinant thrombomodulin domain 1 (rTMD1) can suppress vascular inflammation. However, the function of rTMD1 in VEGF-induced PA remains unknown. In this study, we found that rTMD1 inhibited VEGF-induced angiogenesis in vitro. In an oxygen induced retinopathy (OIR) animal model, rTMD1 treatment significantly decreased retinal neovascularization but spared normal physiological vessel growth. Furthermore, loss of TMD1 significantly promoted PA in OIR. Meanwhile, hypoxia-inducible factor-1 alpha, the transcription factor that upregulates VEGF, was suppressed after rTMD1 treatment. The levels of interleukin-6, and intercellular adhesion molecule-1 were also significantly suppressed. In conclusion, our results indicate that rTMD1 not only has dual effects to suppress PA and inflammation in OIR, but also can be a potential HIF-1 alpha inhibitor for clinical use. These data bring forth the possibility of rTMD1 as a novel therapeutic agent for PA.
C1 [Huang, Yi-Hsun; Peng, I-Chen; Chang, Yi-Sheng; Tseng, Sung-Huei] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Ophthalmol, Tainan, Taiwan.
   [Kuo, Cheng-Hsiang; Wu, Hua-Lin] Natl Cheng Kung Univ, Int Ctr Wound Repair & Regenerat, Tainan, Taiwan.
   [Conway, Edward M.] Univ British Columbia, Ctr Blood Res, Vancouver, BC, Canada.
   [Wu, Hua-Lin] Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University Hospital;
   National Cheng Kung University; University of British Columbia; National
   Cheng Kung University
RP Huang, YH (通讯作者)，Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Ophthalmol, Tainan, Taiwan.; Wu, HL (通讯作者)，Natl Cheng Kung Univ, Int Ctr Wound Repair & Regenerat, Tainan, Taiwan.; Wu, HL (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol, Tainan, Taiwan.
EM jackhyh@gmail.com; halnwu@mail.ncku.edu.tw
RI Kuo, Cheng-Hsiang/GRJ-7463-2022
OI Kuo, Cheng-Hsiang/0000-0002-4885-9020; Huang,
   Yi-Hsun/0000-0002-4150-5481
FU Ministry of Science and Technology [109-2628-B-006-032,
   110-2320-B-006-051]
FX Supported by Grants Ministry of Science and Technology
   109-2628-B-006-032 to YHH and 110-2320-B-006-051 to HLW, Taiwan.
CR Abeyama K, 2005, J CLIN INVEST, V115, P1267, DOI 10.1172/JCI200522782
   Adeniran JMF, 2017, OCUL IMMUNOL INFLAMM, V25, P834, DOI 10.1080/09273948.2016.1184284
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Beharry KD, 2016, SEMIN PERINATOL, V40, P189, DOI 10.1053/j.semperi.2015.12.006
   Boulton M, 1997, BRIT J OPHTHALMOL, V81, P228, DOI 10.1136/bjo.81.3.228
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Castro-Navarro V, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-018-1022-9
   Chan SH, 2006, INT J CARDIOL, V111, P280, DOI 10.1016/j.ijcard.2005.09.015
   Chang LY, 2021, J PERIODONTOL, V92, P1622, DOI 10.1002/JPER.20-0732
   Chao TH, 2014, INT J CARDIOL, V172, P340, DOI 10.1016/j.ijcard.2014.01.009
   Cheung N, 2014, DIABETES CARE, V37, P900, DOI 10.2337/dc13-1990
   Chu SJ, 2017, INT J OPHTHALMOL-CHI, V10, P366, DOI 10.18240/ijo.2017.03.07
   Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Conway EM, 2012, SEMIN IMMUNOPATHOL, V34, P107, DOI 10.1007/s00281-011-0282-8
   Conway EM, 2002, J EXP MED, V196, P565, DOI 10.1084/jem.20020077
   Esmon C, 2005, NAT MED, V11, P475, DOI 10.1038/nm0505-475
   ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Hillier RJ, 2017, RETINA-J RET VIT DIS, V37, P761, DOI 10.1097/IAE.0000000000001210
   Huang YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122491
   IBA T, 1995, SURG TODAY, V25, P585, DOI 10.1007/BF00311430
   Ileri M, 2001, CLIN CARDIOL, V24, P377, DOI 10.1002/clc.4960240506
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kawasoe J, 2021, AM J TRANSPLANT, V21, P540, DOI 10.1111/ajt.16269
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Kuo CH, 2012, BLOOD, V119, P1302, DOI 10.1182/blood-2011-08-376038
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lai CH, 2013, ANN SURG, V258, P1103, DOI 10.1097/SLA.0b013e31827df7cb
   Lains I, 2014, RETINA-J RET VIT DIS, V34, P1199, DOI 10.1097/IAE.0000000000000053
   Lepore D, 2014, OPHTHALMOLOGY, V121, P2212, DOI 10.1016/j.ophtha.2014.05.015
   Li YH, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-34
   Lim CC, 2020, J ADV RES, V22, P1, DOI 10.1016/j.jare.2019.11.012
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Maturi RK, 2018, JAMA OPHTHALMOL, V136, P29, DOI 10.1001/jamaophthalmol.2017.4914
   Miao H, 2012, MOL VIS, V18, P574
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Miwa Y, 2019, NEUROCHEM INT, V128, P21, DOI 10.1016/j.neuint.2019.03.008
   Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200
   Morita M, 2003, EMBO J, V22, P1134, DOI 10.1093/emboj/cdg117
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Park SW, 2014, J CELL MOL MED, V18, P875, DOI 10.1111/jcmm.12235
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salomaa V, 1999, LANCET, V354, P1646, DOI 10.1016/S0140-6736(05)77134-8
   Sato T, 2012, AM J OPHTHALMOL, V153, P327, DOI 10.1016/j.ajo.2011.07.005
   Shi CS, 2008, BLOOD, V112, P3661, DOI 10.1182/blood-2008-03-142760
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stahl A, 2018, JAMA PEDIATR, V172, P278, DOI 10.1001/jamapediatrics.2017.4838
   Szade A, 2015, IUBMB LIFE, V67, P145, DOI 10.1002/iub.1358
   Thorand B, 2007, DIABETOLOGIA, V50, P545, DOI 10.1007/s00125-006-0568-x
   Tokunaga CC, 2014, INVEST OPHTH VIS SCI, V55, P1884, DOI 10.1167/iovs.13-13397
   Van de Wouwer M, 2006, J THROMB HAEMOST, V4, P1813, DOI 10.1111/j.1538-7836.2006.02033.x
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719
   Xu Y, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12473
   Yenihayat F, 2019, INT OPHTHALMOL, V39, P821, DOI 10.1007/s10792-018-0874-6
   Yonekawa Y, 2018, RETINA-J RET VIT DIS, V38, P1079, DOI 10.1097/IAE.0000000000001685
   Zhang FQ, 2016, CANCER SCI, V107, P746, DOI 10.1111/cas.12937
NR 66
TC 4
Z9 4
U1 2
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD DEC
PY 2021
VL 78
IS 23
BP 7681
EP 7692
DI 10.1007/s00018-021-03950-3
EA OCT 2021
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA XE9QL
UT WOS:000712523100002
PM 34705054
DA 2022-11-30
ER

PT J
AU Khandia, R
   Singh, C
   Mehra, R
   Dhama, K
   Munjal, A
AF Khandia, Rekha
   Singh, Chitra
   Mehra, Reena
   Dhama, Kuldeep
   Munjal, Ashok
TI Ethnomedicines' effects on the process of vascularisation in embryonated
   chicken eggs
SO INDIAN JOURNAL OF TRADITIONAL KNOWLEDGE
LA English
DT Article
DE Anti-angiogenesis; Chorioallantoic membrane (CAM) assay; Digimizer;
   Ethnomedicines; Vascularisation
ID ENDOTHELIAL-CELLS; CHORIOALLANTOIC MEMBRANE; BUTEA-MONOSPERMA;
   ANGIOGENESIS; EXTRACTS; PLANTS; TUMOR; ANTIOXIDANT; FLAVONOIDS; SAPONINS
AB Angiogenesis (vascularisation) is a vivacious progression during embryonic development, which is required for the growth, development, wound healing and maintenance. However, the process may turn into pathological conditions; excessive angiogenesis occurs in diseases such as cancer, diabetic blindness, age related macular degeneration, rheumatoid arthritis, etc., whereas insufficient angiogenesis occurs in diseases like coronary artery disease and chronic wounds. Since ancient times, the human population has been dependent on plants for deriving medicines to cure diseases. In the present study, aqueous extract of 04 ethnomedicinal plants parts, Butea monosperma (Kamarkas), Dioscorea hispida (Beychandi), Myristica fragrans (Nutmeg) and Mesua ferrea (Nagkesar), were evaluated for modulation of angiogenesis in chorioallantoic membrane (CAM) of embryonated chicken eggs. Out of these 04, B. monosperma revealed mild inhibitory effects on angiogenesis. M. fragrans and D. hispida inhibited angiogenesis, but also showed detrimental effect on growth of normal CAM with irregular outgrowths in form of projections and uneven thickness. The M. ferrea revealed its potential as antiangiogenic material by inhibiting the vascularisation by reducing the number of blood vessels without effecting normal morphology of CAM tissue. The study paves way to screen ethnomedicinal wealth for screening of plant produce for therapeutic purposes in ameliorating angiogenic disorders.
C1 [Khandia, Rekha; Singh, Chitra; Mehra, Reena; Munjal, Ashok] Barkatullah Univ, Dept Genet, Bhopal 462026, Madhya Pradesh, India.
   [Dhama, Kuldeep] Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India.
C3 Barkatullah University; Indian Council of Agricultural Research (ICAR);
   ICAR - Indian Veterinary Research Institute
RP Munjal, A (通讯作者)，Barkatullah Univ, Dept Genet, Bhopal 462026, Madhya Pradesh, India.
EM ak.munjal@bubhopal.ac.in
RI Khandia, Rekha/AAE-6122-2022
OI Khandia, Rekha/0000-0002-9961-3127
FU DBT-Builder Programme, Barkatullah University, Bhopal
   [BT/PR4479/INF/22/175/2012]
FX Assistance from DBT-Builder Programme (BT/PR4479/INF/22/175/2012),
   Barkatullah University, Bhopal is gratefully acknowledged. Special
   thanks to Dr Anil Binjade for his technical assistance. Authors of the
   manuscript thank and acknowledge their respective University and
   Institute.
CR Achilli TM, 2012, EXPERT OPIN BIOL TH, V12, P1347, DOI 10.1517/14712598.2012.707181
   Ahmad S, 2016, BIOL RES, V49, DOI 10.1186/s40659-016-0079-2
   Ahmed FA, 2015, J BIOL SCI, V4, P19
   Al-Rawi SS, 2011, PROC FOOD SCI, V1, P1946, DOI 10.1016/j.profoo.2011.09.286
   Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466
   Ariharan V. N., 2015, Journal of Chemical and Pharmaceutical Research, V7, P486
   Arnaoutova I, 2009, ANGIOGENESIS, V12, P267, DOI 10.1007/s10456-009-9146-4
   Ashvin Godghate, 2012, Rasayan Journal of Chemistry, V5, P456
   Avin B.R.V., 2014, BIOMED AGING PATHOL, V4, P343, DOI [10.1016/j.biomag.2014.07.006, DOI 10.1016/J.BIOMAG.2014.07.006]
   Ayaz M, 2016, FRONT PHARMACOL, V7, DOI [10.7789/fphar.2016.00074, 10.3389/fphar.2016.00074]
   Ayoola GA, 2008, TROP J PHARM RES, V7, P1019
   Baker M, 2012, NAT PROTOC, V7, P89, DOI 10.1038/nprot.2011.435
   Bamidele O., 2011, INT J MED MED SCI, V3, P215
   Banerjee D, 2011, PHARM RES, V25, P1601
   Chaubey S, 2014, INT J AYU ALT MED, V2, P48
   Choudhary GP, 2012, INT J ADV PHARM BIOL, VI, P369
   Dai ZJ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-150
   Das PR, 2013, ANC SCI LIFE, V32, P217, DOI 10.4103/0257-7941.131975
   Dulak J, 2005, J Physiol Pharmacol, V56 Suppl 1, P51
   Ejaz S, 2014, CENT EUR J BIOL, V9, P298, DOI 10.2478/s11535-013-0266-x
   Fan TP, 2006, TRENDS PHARMACOL SCI, V27, P297, DOI 10.1016/j.tips.2006.04.006
   Foubert K, 2012, NAT PROD COMMUN, V7, P1149
   Geetha T. S., 2014, International Journal of PharmTech Research, V6, P521
   Gibbs R.D., 1974, CHEMOTAXONOMY FLOWER, DOI [10.2307/j.ctt1w0ddx8, DOI 10.2307/J.CTT1W0DDX8]
   Glen K, 2012, J CELL PHYSIOL, V227, P2710, DOI 10.1002/jcp.23015
   Gurib-Fakim Ameenah, 2006, Molecular Aspects of Medicine, V27, P1, DOI 10.1016/j.mam.2005.07.008
   Haraguchi Y, 2012, RSC ADV, V2, P2184, DOI 10.1039/c2ra00704e
   Hong SJ, 2009, PHYTOTHER RES, V23, P677, DOI 10.1002/ptr.2705
   Hossain Mohammad Amzad, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P705, DOI 10.1016/S2221-1691(13)60142-2
   Jaiswal Preetee, 2009, ARBS Annual Review of Biomedical Sciences, V11, P21
   Jalalpure SS, 2011, J ETHNOPHARMACOL, V138, P700, DOI 10.1016/j.jep.2011.09.042
   Kelm JM, 2010, ADV DRUG DELIVER REV, V62, P753, DOI 10.1016/j.addr.2010.02.003
   Kumar S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00052
   Li K, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-86
   Li S, 2003, AM J CHINESE MED, V31, P713, DOI 10.1142/S0192415X03001430
   Logsdon EA, 2014, J CELL MOL MED, V18, P1491, DOI 10.1111/jcmm.12164
   Meena KL, 2010, INDIAN J TRADIT KNOW, V9, P169
   Melkonian G, 2002, J EXP ZOOL, V292, P241, DOI 10.1002/jez.10014
   Mishra S, 2011, PGR NEWSLETT, V56, P63
   Ngo TX, 2013, BIOTECHNOL LETT, V35, P1001, DOI 10.1007/s10529-013-1174-x
   Nicoli S, 2007, CANCER RES, V67, P2927, DOI 10.1158/0008-5472.CAN-06-4268
   Phillips Gregg D., 1995, Wound Repair and Regeneration, V3, P533, DOI 10.1046/j.1524-475X.1995.30420.x
   Piaru SP, 2012, ASIAN PAC J TROP MED, V5, P294, DOI 10.1016/S1995-7645(12)60042-X
   Rao PK, 2015, J ETHNOPHARMACOL, V171, P12, DOI 10.1016/j.jep.2015.05.028
   Rasheed Z, 2010, J PHARMACOL EXP THER, V333, P354, DOI 10.1124/jpet.109.165209
   Rekha Khandia, 2015, Advances in Animal and Veterinary Sciences, V3, P372, DOI 10.14737/journal.aavs/2015/3.7.372.376
   Ribatti D, 2010, PHARMACEUTICALS, V3, P482, DOI 10.3390/ph3030482
   Roy A., 2017, INT J COMPLEMENT ALT, V9, P291
   Sagar S M, 2006, Curr Oncol, V13, P99
   Saran U, 2014, ARCH BIOCHEM BIOPHYS, V561, P109, DOI 10.1016/j.abb.2014.07.006
   Seema Firdouse, 2011, International Journal of Phytomedicine, V3, P32
   Singh R, 2012, J INTERCULT ETHNOPHA, V1, P101, DOI 10.5455/jice.20120525014326
   Song Myoung-Chong, 2007, Journal of Applied Biological Chemistry, V50, P249
   Stuart G.U., 2010, MANUAL SOME PHILIPPI
   Sumitra M, 2005, INT J BIOCHEM CELL B, V37, P566, DOI 10.1016/j.biocel.2004.08.003
   To Dao Cuong, 2012, Natural Product Sciences, V18, P97
   van Moorst M, 2011, J PHARM PHARMACOL, V63, P1513, DOI 10.1111/j.2042-7158.2011.01352.x
   Wang XH, 2009, LIFE SCI, V84, P240, DOI 10.1016/j.lfs.2008.12.010
   Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8
NR 59
TC 2
Z9 2
U1 1
U2 2
PU NATL INST SCIENCE COMMUNICATION-NISCAIR
PI NEW DELHI
PA DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
SN 0972-5938
EI 0975-1068
J9 INDIAN J TRADIT KNOW
JI Indian J. Tradit. Knowl.
PD OCT
PY 2019
VL 18
IS 4
BP 731
EP 738
PG 8
WC Plant Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences
GA JT0SE
UT WOS:000500708800012
DA 2022-11-30
ER

PT J
AU Musa, Y
   Alime, G
   Cihangir, U
   Ozlem, YT
   Levent, T
   Ahmi, O
   Mustafa, N
AF Musa, Yigit
   Alime, Gunes
   Cihangir, Uguz
   Ozlem, Yalcin Tok
   Levent, Tok
   Ahmi, Oz
   Mustafa, Naziroglu
TI Effects of astaxanthin on antioxidant parameters in ARPE-19 cells on
   oxidative stress model
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE apoptosis; ARPE-19 cell; astaxanthin; oxidative stress
ID MACULAR DEGENERATION; EPITHELIAL-CELLS; IN-VITRO; CALCIUM; APOPTOSIS;
   SELENIUM; CAROTENOIDS; MELATONIN; LIGHT; GLUTATHIONE
AB AIM: To observe the protective effect of astaxanthin (AST) against hydroquinone (HQ) mediated cell death in the apoptotic cascade and evaluate intracellular Ca2+ release, caspase-3, and -9 activation, reactive oxygen species (ROS) production in ARPE-19 cells.
   METHODS: We cultured ARPE-19 cells in special mediums and performed MTT tests to determine protective effect of AST, before exposing the cells to HQ in an incubator. We analyzed intracellular Ca2+ release experiments, mitochondrial membrane depolarization, glutathione (GSH), glutathione peroxidase (GSH-Px) and ROS experiments, and apoptosis assay.
   RESULTS: ROS production ranges depend on the amount of cell death. We computed the correlation between ROS ranges and cell death by 20,70-dichlorofluorescein fluorescence, and Ca2+ levels by Fura-2-AM. HQ-induced cell death found out to rise ranges of caspase-3 and -9, and mitochondrial depolarization. These three steps were delayed by AST management.
   CONCLUSION: ARPE-19 cells are avoided from HQ-induced ROS production and caspase-3 and -9 activation by AST. AST may limit the range of caspase synthesis, Ca2+ release and excess production of ROS with antiapoptotic effect. This study proposes a new therapeutic approach for the treatment of age-related macular degeneration.
C1 [Musa, Yigit; Alime, Gunes; Ozlem, Yalcin Tok; Levent, Tok] Suleyman Demirel Univ, Dept Ophthalmol, Res & Educ Hosp, TR-32200 Cunur Isparta, Turkey.
   [Cihangir, Uguz; Ahmi, Oz; Mustafa, Naziroglu] Suleyman Demirel Univ, Dept Biophys, Res & Educ Hosp, Fac Med, TR-32200 Cunur Isparta, Turkey.
C3 Suleyman Demirel University; Suleyman Demirel University
RP Musa, Y (通讯作者)，Suleyman Demirel Univ, Dept Ophthalmol, Res & Educ Hosp, TR-32200 Cunur Isparta, Turkey.
EM myigit15@gmail.com
RI ÖZ, Ahmi/AGP-2521-2022; Uğuz, A. Cihangir/J-8531-2012
OI ÖZ, Ahmi/0000-0003-1881-8460; 
CR Altinkilic S, 2010, J MEMBRANE BIOL, V235, P211, DOI 10.1007/s00232-010-9267-0
   Balietti M, 2016, J SCI FOOD AGR, V96, P615, DOI 10.1002/jsfa.7131
   Bardak H, 2018, CUTAN OCUL TOXICOL, V37, P112, DOI 10.1080/15569527.2017.1354218
   Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chen CS, 2007, ORG LETT, V9, P2985, DOI 10.1021/ol0709533
   Deisinger PJ, 1996, J TOXICOL ENV HEALTH, V47, P31, DOI 10.1080/009841096161915
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Gammone MA, 2015, MAR DRUGS, V13, P6226, DOI 10.3390/md13106226
   Giblin FJ, 2000, J OCUL PHARMACOL TH, V16, P121, DOI 10.1089/jop.2000.16.121
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hajnoczky G, 2010, CURR BIOL, V20, pR888, DOI 10.1016/j.cub.2010.09.035
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Igielska-Kalwat Joanna, 2015, Postepy Hig Med Dosw (Online), V69, P418
   Ivanova TN, 2008, BRAIN RES, V1207, P111, DOI 10.1016/j.brainres.2008.02.025
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Kim Chan Joong, 2007, Korean J Ophthalmol, V21, P90, DOI 10.3341/kjo.2007.21.2.90
   Kowluru RA, 2015, PROG RETIN EYE RES, V48, P40, DOI 10.1016/j.preteyeres.2015.05.001
   LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6
   Li ZR, 2013, MOL VIS, V19, P1656
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAINSTER MA, 1987, EYE-T OPHTH SOC UK, V1, P304, DOI 10.1038/eye.1987.49
   Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k
   Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013
   Naziroglu M, 2009, NEUROCHEM RES, V34, P2181, DOI 10.1007/s11064-009-0015-8
   Otsuka T, 2013, J PHARMACOL SCI, V123, P209, DOI 10.1254/jphs.13066FP
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9
   Reijo T, 2008, J AM GERIATR SOC, V56, P1573, DOI 10.1111/j.1532-5415.2008.01774.x
   Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1
   Rimessi A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00143
   SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4
   Sharma A, 2012, INDIAN J OPHTHALMOL, V60, P189, DOI 10.4103/0301-4738.95869
   Song XD, 2014, J CELL MOL MED, V18, P2198, DOI 10.1111/jcmm.12347
   Sun G, 2005, DIABETES, V54, P3336, DOI 10.2337/diabetes.54.11.3336
   Uguz AC, 2009, J MEMBRANE BIOL, V232, P15, DOI 10.1007/s00232-009-9212-2
   Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x
   Uguz AC, 2012, NEUROCHEM RES, V37, P1631, DOI 10.1007/s11064-012-0758-5
   Wu JM, 1999, EYE, V13, P577, DOI 10.1038/eye.1999.142
   Wu J, 2015, JAMA OPHTHALMOL, V133, P1415, DOI 10.1001/jamaophthalmol.2015.3590
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
NR 43
TC 11
Z9 11
U1 1
U2 7
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2019
VL 12
IS 6
BP 930
EP 935
DI 10.18240/ijo.2019.06.08
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID8HE
UT WOS:000471923600008
PM 31236348
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kessel, L
   Erngaard, D
   Flesner, P
   Andresen, J
   Hjortdal, J
AF Kessel, Line
   Erngaard, Ditte
   Flesner, Per
   Andresen, Jens
   Hjortdal, Jesper
TI Do evidence-based guidelines change clinical practice patterns?
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE cataract surgery; evidence-based medicine; postoperative
   endophthalmitis; toric intraocular lenses
ID BILATERAL CATARACT-SURGERY; POSTOPERATIVE ENDOPHTHALMITIS; INTRACAMERAL
   CEFUROXIME; ANTIBIOTIC-PROPHYLAXIS; SIMULATION-MODEL; METAANALYSIS;
   SAFETY; RISK; OPHTHALMOLOGY; PREVENTION
AB In 2013, the Danish Health and Medicines Authorities published a National Clinical Guideline on the treatment of age-related cataracts. The guideline provided evidence-based recommendations on the indication for cataract surgery, cataract surgery in patients with age-related macular degeneration, on the use of toric intraocular lenses (IOLs) to correct preoperative corneal astigmatism, the use of intracameral and topical antibiotics to prevent endophthalmitis, choice of anti-inflammatory medication to control postoperative inflammation and prevent cystoid macular oedema, the use of immediate sequential bilateral cataract surgery and on the postoperative check-up of patients. A questionnaire was sent to all members of the Danish Ophthalmological Society before and after publication of the guideline. The responses showed that the guideline had changed practice patterns so that surgeons were more likely to prescribe non-steroidal anti-inflammatory eye drops and to not prescribe topical antibiotic eye drops after the guideline was published. Other parameters, most notably the use of toric IOLs and use of postoperative examinations were more guided by reimbursement standards than by evidence-based medicine. Thus, evidence-based guidelines do change practice patterns unless they are counteracted by the reimbursement system.
C1 [Kessel, Line] Rigshosp Glostrup, Dept Ophthalmol, Ctr Head & Orthoped, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
   [Kessel, Line] Univ Copenhagen, Fac Hlth & Med Sci, Inst Clin Med, Copenhagen, Denmark.
   [Erngaard, Ditte] Zealand Univ Hosp, Dept Ophthalmol, Naestved, Denmark.
   [Flesner, Per] Odense Eye Clin, Odense, Denmark.
   [Andresen, Jens] Skanderborg Eye Clin, Skanderborg, Denmark.
   [Hjortdal, Jesper] Aarhus Univ Hosp NBG, Dept Ophthalmol, Aarhus, Denmark.
C3 University of Copenhagen; University of Southern Denmark; Odense
   University Hospital; Aarhus University
RP Kessel, L (通讯作者)，Rigshosp Glostrup, Dept Ophthalmol, Ctr Head & Orthoped, Nordre Ringvej 57, DK-2600 Glostrup, Denmark.
EM line.kessel@dadlnet.dk
OI Kessel, Line/0000-0002-9375-1510
CR Anijeet DR, 2010, CLIN OPHTHALMOL, V4, P321
   Arshinoff SA, 2015, ISBCS GEN PRINCIPLES
   Barreau G, 2012, J CATARACT REFR SURG, V38, P1370, DOI 10.1016/j.jcrs.2012.03.024
   Barry P, 2007, J CATARACT REFR SURG, V33, P978, DOI 10.1016/j.jcrs.2007.02.032
   Baun O, 2001, RETNINGSLINIER VEDRO
   Behndig A, 2015, J CATARACT REFR SURG, V41, P2635, DOI 10.1016/j.jcrs.2015.06.031
   Behndig A, 2013, J CATARACT REFR SURG, V39, P1421, DOI 10.1016/j.jcrs.2013.06.014
   Beselga D, 2014, EUR J OPHTHALMOL, V24, P516, DOI 10.5301/ejo.5000417
   Comas M, 2008, BRIT J OPHTHALMOL, V92, P888, DOI 10.1136/bjo.2007.133603
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Friling E, 2013, J CATARACT REFR SURG, V39, P15, DOI 10.1016/j.jcrs.2012.10.037
   Galvis V, 2014, OPHTHALMOL EYE DIS, V6, P1, DOI [10.4137/OEd.s13102, 10.4137/OED.S13102]
   Garat M, 2009, J CATARACT REFR SURG, V35, P637, DOI 10.1016/j.jcrs.2008.12.023
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Henderson BA, 2012, SURV OPHTHALMOL, V57, P580, DOI 10.1016/j.survophthal.2012.05.001
   Herrinton LJ, 2016, OPHTHALMOLOGY, V123, P287, DOI 10.1016/j.ophtha.2015.08.039
   Javitt JC, 2016, OPHTHALMOLOGY, V123, P226, DOI 10.1016/j.ophtha.2015.12.011
   Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039
   Kessel L, 2016, ACTA OPHTHALMOL
   Kessel L., 2011, J CLIN EXPT OPHTHALM, V2, DOI [10.4172/2155-9570.1000174, DOI 10.4172/2155-9570.1000174]
   Kessel L, 2016, ACTA OPHTHALMOL, V94, pE164, DOI 10.1111/aos.12813
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P10, DOI 10.1111/aos.12758
   Kessel L, 2016, OPHTHALMOLOGY, V123, P275, DOI 10.1016/j.ophtha.2015.10.002
   Kessel L, 2015, J CATARACT REFR SURG, V41, P2755, DOI 10.1016/j.jcrs.2015.11.010
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Kessel L, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/912481
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P303, DOI 10.1111/aos.12684
   Kessel L, 2014, OPHTHALMOLOGY, V121, P1915, DOI 10.1016/j.ophtha.2014.04.035
   Kessel L, 2011, ACTA OPHTHALMOL, V89, pe289, DOI 10.1111/j.1755-3768.2009.01839.x
   Kim SJ, 2015, OPHTHALMOLOGY, V122, P2159, DOI 10.1016/j.ophtha.2015.05.014
   Laurendeau C, 2009, J Med Econ, V12, P230, DOI 10.3111/13696990903257439
   Leivo T, 2011, J CATARACT REFR SURG, V37, P1003, DOI 10.1016/j.jcrs.2010.12.050
   Lundstom M, 2007, OPHTHALMOLOGY, V114, P866, DOI 10.1016/j.ophtha.2006.11.025
   Lundstrom M, 2006, ACTA OPHTHALMOL SCAN, V84, P495, DOI 10.1111/j.1600-0420.2006.00707.x
   Lundstrom M, 2016, ACTA OPHTHALMOL, V94, P9, DOI 10.1111/aos.12820
   Malvankar-Mehta MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131857
   Matsuura K, 2013, J CATARACT REFR SURG, V39, P1702, DOI 10.1016/j.jcrs.2013.05.036
   Myneni J, 2013, J HOSP INFECT, V84, P326, DOI 10.1016/j.jhin.2013.05.009
   Ostri C, 2015, ACTA OPHTHALMOL, V93, pE396, DOI 10.1111/aos.12584
   Rodriguez-Caravaca G, 2013, J CATARACT REFR SURG, V39, P1399, DOI 10.1016/j.jcrs.2013.03.031
   Romero-Aroca P, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-2
   Rosen ES, 2012, J CATARACT REFR SURG, V38, P1707, DOI 10.1016/j.jcrs.2012.08.028
   Rudnisky CJ, 2014, OPHTHALMOLOGY, V121, P835, DOI 10.1016/j.ophtha.2013.08.046
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P251, DOI 10.2147/OPTH.S100429
   Shorstein NH, 2013, J CATARACT REFR SURG, V39, P8, DOI 10.1016/j.jcrs.2012.07.031
   Sundhedsstyrelsen, 2014, FAGL VIS BEH ALD GRA
   Sundhedsstyrelsen, 2013, NAT KLIN RETN BEH AL
   Tan CSH, 2012, J CATARACT REFR SURG, V38, P425, DOI 10.1016/j.jcrs.2011.09.040
   Tatham A, 2012, EYE, V26, P1033, DOI 10.1038/eye.2012.92
   Tuulonen A, 2009, ACTA OPHTHALMOL, V87, P820, DOI 10.1111/j.1755-3768.2009.01532.x
   van der Merwe J, 2012, J CATARACT REFR SURG, V38, P2054, DOI 10.1016/j.jcrs.2012.09.004
   Wejde G, 2005, ACTA OPHTHALMOL SCAN, V83, P7, DOI 10.1111/j.1600-0420.2005.00377.x
   Wilkins MR, 2009, BRIT J OPHTHALMOL, V93, P1307, DOI 10.1136/bjo.2008.151829
   Yu-Wai-Man P, 2008, J CATARACT REFR SURG, V34, P447, DOI 10.1016/j.jcrs.2007.10.041
NR 54
TC 11
Z9 11
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2017
VL 95
IS 4
BP 337
EP 343
DI 10.1111/aos.13314
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OJ
UT WOS:000403361300017
PM 27966271
OA Bronze
DA 2022-11-30
ER

PT J
AU Nebel, C
   Aslanidis, A
   Rashid, K
   Langmann, T
AF Nebel, Christopher
   Aslanidis, Alexander
   Rashid, Khalid
   Langmann, Thomas
TI Activated microglia trigger inflammasome activation and lysosomal
   destabilization in human RPE cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Inflammasome; Age-related macular degeneration; Microglia; Retinal
   pigment epithelium
ID PIGMENT EPITHELIAL-CELLS; MEDIATED PHOTOOXIDATIVE DAMAGE; NLRP3
   INFLAMMASOME; MACULAR DEGENERATION; RETINAL MICROGLIA; DISEASE; LECTURE;
   INNATE; IMMUNITY; BRAIN
AB Activation of the innate immune system plays a major role in retinal degenerative diseases including age related macular degeneration (AMD). In this study, we investigated whether reactive microglia trigger and sustain NLRP3 inflammasome activation in human retinal pigment epithelium (ARPE-19) cells. Specifically, we analyzed the potential of cell culture supernatants from lipopolysaccharide (LPS)-stimulated human microglia in combination with the lysosomal destabilization agent Leu-Leu-O-Me (LLOMe) to activate the inflammasome in ARPE-19 cells. We found disorganization of ARPE-19 cytoskeletal structure after incubation with conditioned media of LPS-stimulated microglia and LLOMe and accumulation of lipid deposits in these cells using Nile Red staining. LC3-II, the active form of the'autophagy marker microtubule-associated protein 1 light chain 3 beta (LOB), was also elevated in ARPE-19 cells after inducing inflammasome activation. Finally, a significant increase of transcripts for IL -6, IL -8, IL -1 beta, GM-CSF and CCL-2 was detected in ARPE-19 stimulated with both microglia-conditioned medium and LLOMe. Our findings highlight a potential role of microglia in RPE inflammasome activation. (C ) 2017 Elsevier Inc. All rights reserved.
C1 [Nebel, Christopher; Aslanidis, Alexander; Rashid, Khalid; Langmann, Thomas] Univ Cologne, Lab Expt Immunol Eye, Dept Ophthalmol, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.
C3 University of Cologne
RP Langmann, T (通讯作者)，Univ Cologne, Lab Expt Immunol Eye, Dept Ophthalmol, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.
EM thomas.langmann@uk-koeln.de
OI Rashid, Khalid/0000-0002-5070-8010
FU Hans and Marlies Stock-Foundation; Deutsche Forschungsgemeinschaft
   [FOR2240]; ProRetina Foundation
FX The work was supported by the Hans and Marlies Stock-Foundation, the
   Deutsche Forschungsgemeinschaft (FOR2240), and the ProRetina Foundation.
   We thank Dr. Sarah Hermann for critical reading of the manuscript and
   Prof. Harald Neumann for providing iPSdM cells.
CR Bauernfeind F, 2013, EMBO MOL MED, V5, P814, DOI 10.1002/emmm.201201771
   Beutner C, 2010, NAT PROTOC, V5, P1481, DOI 10.1038/nprot.2010.90
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   GIULIAN D, 1995, J NEUROSCI, V15, P7712
   Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997
   Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Kaarniranta K., 2016, CELL BIOL TOXICOL
   Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240
   Karlstetter M., 2016, EMBO MOL MED
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Martinon F, 2007, SEMIN IMMUNOPATHOL, V29, P213, DOI 10.1007/s00281-007-0079-y
   Miller JW, 2016, INVEST OPHTH VIS SCI, V57, P6911, DOI 10.1167/iovs.16-21201
   Mohr LKM, 2015, INVEST OPHTH VIS SCI, V56, P6404, DOI 10.1167/iovs.15-16898
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Orr CF, 2002, PROG NEUROBIOL, V68, P325, DOI 10.1016/S0301-0082(02)00127-2
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Raivich G, 2004, BRAIN RES REV, V46, P261, DOI 10.1016/j.brainresrev.2004.06.006
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 36
TC 31
Z9 33
U1 2
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 11
PY 2017
VL 484
IS 3
BP 681
EP 686
DI 10.1016/j.bbrc.2017.01.176
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EN4FR
UT WOS:000395963900033
PM 28159556
DA 2022-11-30
ER

PT J
AU Qu, YX
   Li, BB
   Zhou, Q
   Jin, L
   Liu, XY
   Yang, XX
   Xu, W
   Ye, LY
   Chen, J
AF Qu, Yixin
   Li, Binbin
   Zhou, Qing
   Jin, Ling
   Liu, Xiaoyong
   Yang, Xiaoxi
   Xu, Wei
   Ye, Longyan
   Chen, Jian
TI EGFL6 regulates hypoxia-induced angiogenic factors in retinal pigment
   epithelial cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Epidermal growth factor like domain 6; retinal pigment epithelial;
   hypoxia; angiogenic factors
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; VEGF EXPRESSION; INHIBITION; ACTIVATION; GENE
AB Epidermal growth factor like domain 6 (EGFL6), which is a member of the epidermal growth factor repeat superfamily of proteins, has been demonstrated to be important in angiogenesis. However, the expression and role of EGFL6 in the retinal pigment epithelial (RPE) cells remains to be elucidated. The aim of the present study was to investigate the role of EGFL6 in cultured human RPE cells. ARPE-19 cells were pretreated by 200 mu M CoCl2 for 24 h, then transfected with siRNA-EGFL6 or control siRNA. Cell proliferation was measured using the MTT assay. The expression protein levels of EGFL6, VEGF, pigment epithelium-derived factor (PEDF), stromal cell-derived factor (SDF)-1 and IL-1 beta were detected using western blotting. The expression of EGFL6 was significantly elevated under hypoxic conditions. EGFL6 knockdown inhibited hypoxia-induced RPE cell proliferation. In addition, knockdown of EGFL6 inhibited hypoxia-induced pro-angiogenic factor expression and the expression of inflammatory factors in RPE cells. These results suggested that the knockdown of EGFL6 suppressed pro-angiogenic factors induced by hypoxia in RPE cells. Therefore, EGFL6 may be a potential therapeutic target for the treatment of age-related macular degeneration.
C1 [Qu, Yixin; Li, Binbin; Zhou, Qing; Liu, Xiaoyong; Xu, Wei; Ye, Longyan; Chen, Jian] Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou 510630, Guangdong, Peoples R China.
   [Jin, Ling] Peoples Hosp Baoan Shenzhen, Dept Ophthalmol, Shenzhen 518101, Guangdong, Peoples R China.
   [Yang, Xiaoxi] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Ophthalmol, Guangzhou 510655, Guangdong, Peoples R China.
C3 Jinan University; Sun Yat Sen University
RP Chen, J (通讯作者)，Jinan Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou 510630, Guangdong, Peoples R China.
EM chenjian_oph@sina.com
FU Fundamental Research of Knowledge Innovation Program [20140304115407];
   Natural Science Foundation of Guangdong Province [2014A030310085];
   Medical Science and Technology Research of Guangdong Province [A2015164]
FX The present study was supported by the Fundamental Research of Knowledge
   Innovation Program (grant no. 20140304115407), the Natural Science
   Foundation of Guangdong Province (grant no. 2014A030310085) and the
   Medical Science and Technology Research of Guangdong Province (grant no.
   A2015164).
CR Buchner G, 2000, MECH DEVELOP, V98, P179, DOI 10.1016/S0925-4773(00)00462-7
   Chim SM, 2011, J BIOL CHEM, V286, P22035, DOI 10.1074/jbc.M110.187633
   DAVIS C G, 1990, New Biologist, V2, P410
   DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   Ferrara N., 1999, ADV ORG BIO, P25
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Karakousis PC, 2001, MOL VIS, V7, P154
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04-1489
   Oberauer R, 2010, MOL CELL BIOCHEM, V343, P257, DOI 10.1007/s11010-010-0521-7
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   Sengupta N, 2005, INVEST OPHTH VIS SCI, V46, P343, DOI 10.1167/iovs.04-0153
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Unoki N, 2010, INVEST OPHTH VIS SCI, V51, P3362, DOI 10.1167/iovs.09-4978
   Wang YQ, 2010, MOL BIOL REP, V37, P1203, DOI 10.1007/s11033-009-9490-x
   Watanabe K, 2009, GRAEF ARCH CLIN EXP, V247, P207, DOI 10.1007/s00417-008-0990-5
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhu J, 2009, EXP EYE RES, V88, P910, DOI 10.1016/j.exer.2008.11.034
NR 30
TC 0
Z9 0
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 9
BP 13419
EP 13425
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FL5PK
UT WOS:000414297600053
DA 2022-11-30
ER

PT J
AU Yavuz, B
   Pehlivan, SB
   Bolu, BS
   Sanyal, RN
   Vural, I
   Unlu, N
AF Yavuz, Burcin
   Pehlivan, Sibel Bozdag
   Bolu, Burcu Sumer
   Sanyal, Rana Nomak
   Vural, Imran
   Unlu, Nursen
TI Dexamethasone - PAMAM dendrimer conjugates for retinal delivery:
   preparation, characterization and in vivo evaluation
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE controlled and sustained release systems; dosage form design and
   characterization; drug delivery to specific tissues; PAMAM dendrimers;
   retinal drug delivery
ID DRUG-DELIVERY; NANOPARTICLES; CYTOTOXICITY
AB ObjectiveOcular diseases affecting retina, such as diabetic retinopathy (DR), age-related macular degeneration (AMD) and glaucoma are the major causes of blindness, and their treatment is still a challenge due to the special structure of the eye. The purpose of this study was to prepare a sustained release DEX conjugate formulation with enhanced ocular permeation using poly(amidoamine) (PAMAM) dendrimers and to evaluate the effects of conjugation on DEX release and ocular residence time.
   MethodsPAMAM G3.5 and PAMAM G4.5 dendrimers were used to prepare DEX conjugates, and conjugation was confirmed using H-1-NMR. Formulations were evaluated in terms of drug release in the presence of ocular enzymes and cytotoxicity on ARPE19 cell lines. Fluorotron analysis was performed and ocular pharmacokinetic properties of DEX-PAMAM conjugates were studied in Sprague Dawley rats following intravitreal and subconjunctival applications.
   Key FindingsThe results indicated that DEX-PAMAM conjugates were able to enhance ocular permeability and ocular tissue levels of DEX following subconjunctival injection, and results were encouraging when compared to the literature that has reported DEX getting cleared from vitreous in 3 h.
   ConclusionCurrent studies are focused on formulation improvement to enhance hydrolysis and clearance time.
C1 [Yavuz, Burcin; Pehlivan, Sibel Bozdag; Vural, Imran; Unlu, Nursen] Hacettepe Univ, Dept Pharmaceut Technol, Fac Pharm, TR-06100 Ankara, Turkey.
   [Bolu, Burcu Sumer; Sanyal, Rana Nomak] Bogazici Univ, Dept Chem, Istanbul, Turkey.
C3 Hacettepe University; Bogazici University
RP Pehlivan, SB (通讯作者)，Hacettepe Univ, Dept Pharmaceut Technol, Fac Pharm, TR-06100 Ankara, Turkey.
EM sbozdag@hacettepe.edu.tr
RI Sanyal, Rana/ABE-2211-2020; YAVUZ, Burcin/J-1044-2013
OI Sanyal, Rana/0000-0003-4803-5811; YAVUZ, Burcin/0000-0003-2352-9321;
   Vural, Imran/0000-0002-1627-3834; Sumer Bolu, Burcu/0000-0003-3606-4260
FU 'Scientific and Technological Research Council of Turkey' (TUBITAK)
FX Authors would like to thank Deva for kindly supplying Dexamethasone.
   This research was supported by 'The Scientific and Technological
   Research Council of Turkey' (TUBITAK) via 2214 scholarship. The authors
   are thankful to Drs Uday B. Kompella and Sunil Vooturi of University of
   Colorado Denver for supporting this research and LC-MS analysis,
   respectively. The authors also would like to thank Dr Puneet Tyagi for
   sharing his experiences in fluorotron analysis.
CR Bozdag S, 2004, J MICROENCAPSUL, V21, P751, DOI 10.1080/02652040400000553
   Caminade AM, 2005, ADV DRUG DELIVER REV, V57, P2130, DOI 10.1016/j.addr.2005.09.011
   Chen HT, 2004, J AM CHEM SOC, V126, P10044, DOI 10.1021/ja048548j
   Clark AF, 2003, NAT REV DRUG DISCOV, V2, P448, DOI 10.1038/nrd1106
   D'Emanuele A, 2005, ADV DRUG DELIVER REV, V57, P2147, DOI 10.1016/j.addr.2005.09.012
   Diebold Y, 2010, PROG RETIN EYE RES, V29, P596, DOI 10.1016/j.preteyeres.2010.08.002
   Duncan R, 2005, ADV DRUG DELIVER REV, V57, P2215, DOI 10.1016/j.addr.2005.09.019
   Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359-6446(01)01757-3
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gillies ER, 2005, DRUG DISCOV TODAY, V10, P35, DOI 10.1016/S1359-6446(04)03276-3
   Gomez MV, 2009, J AM CHEM SOC, V131, P341, DOI 10.1021/ja807488d
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Huang BH, 2011, TETRAHEDRON LETT, V52, P1411, DOI 10.1016/j.tetlet.2010.12.025
   Jain NK, 2008, EXPERT OPIN DRUG MET, V4, P1035, DOI 10.1517/17425255.4.8.1035 
   Jevprasesphant R, 2003, PHARM RES-DORDR, V20, P1543, DOI 10.1023/A:1026166729873
   Jiang J, 2009, PHARM RES-DORDR, V26, P395, DOI 10.1007/s11095-008-9756-3
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Kurtoglu YE, 2010, INT J PHARMACEUT, V384, P189, DOI 10.1016/j.ijpharm.2009.10.017
   Menjoge AR, 2010, DRUG DISCOV TODAY, V15, P171, DOI 10.1016/j.drudis.2010.01.009
   Najlah M, 2007, INT J PHARMACEUT, V336, P183, DOI 10.1016/j.ijpharm.2006.11.047
   Pauli GF, 2005, J NAT PROD, V68, P133, DOI 10.1021/np0497301
   RAINES MF, 1988, J ROY SOC MED, V81, P403, DOI 10.1177/014107688808100714
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Sunkara G, 2010, BRAIN RES BULL, V81, P327, DOI 10.1016/j.brainresbull.2009.09.001
   Tyagi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048188
   Weijtens O, 2002, OPHTHALMOLOGY, V109, P1887, DOI 10.1016/S0161-6420(02)01176-4
   Weijtens O, 1998, AM J OPHTHALMOL, V125, P673, DOI 10.1016/S0002-9394(98)00003-8
   Yang H, 2006, J BIOMAT SCI-POLYM E, V17, P3, DOI 10.1163/156856206774879171
   Yang H, 2005, J BIOMED MATER RES A, V72A, P107, DOI 10.1002/jbm.a.30220
   Yang H, 2007, J MATER SCI-MATER M, V18, P2061, DOI 10.1007/s10856-007-3144-0
   Yavuz B, 2015, J PHARM SCI-US, V104, P3814, DOI 10.1002/jps.24588
NR 35
TC 31
Z9 31
U1 0
U2 55
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD AUG
PY 2016
VL 68
IS 8
BP 1010
EP 1020
DI 10.1111/jphp.12587
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DR5XH
UT WOS:000379975200006
PM 27283886
DA 2022-11-30
ER

PT J
AU Szablowski, JO
   Raskatov, JA
   Dervan, PB
AF Szablowski, Jerzy O.
   Raskatov, Jevgenij A.
   Dervan, Peter B.
TI An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID INDUCIBLE FACTOR-I; ENDOTHELIAL GROWTH-FACTOR; ANTITUMOR-ACTIVITY;
   GENE-EXPRESSION; CANCER; TRANSCRIPTION; MODULATION; TOXICITY; THERAPY;
   VARIES
AB Hypoxic gene expression contributes to the pathogenesis of many diseases, including organ fibrosis, age-related macular degeneration, and cancer. Hypoxia-inducible factor-1 (HIF1), a transcription factor central to the hypoxic gene expression, mediates multiple processes including neovascularization, cancer metastasis, and cell survival. Pyrrole-imidazole polyamide 1 has been shown to inhibit HIF1-mediated gene expression in cell culture but its activity in vivo was unknown. This study reports activity of polyamide 1 in subcutaneous tumors capable of mounting a hypoxic response and showing neovascularization. We show that 1 distributes into subcutaneous tumor xenografts and normal tissues, reduces the expression of proangiogenic and prometastatic factors, inhibits the formation of new tumor blood vessels, and suppresses tumor growth. Tumors treated with 1 show no increase in HIF1 alpha and have reduced ability to adapt to the hypoxic conditions, as evidenced by increased apoptosis in HIF1 alpha-positive regions and the increased proximity of necrotic regions to vasculature. Overall, these results show that a molecule designed to block the transcriptional activity of HIF1 has potent antitumor activity in vivo, consistent with partial inhibition of the tumor hypoxic response. (C) 2015 AACR.
C1 [Szablowski, Jerzy O.; Raskatov, Jevgenij A.; Dervan, Peter B.] CALTECH, Div Chem Chem Engn, Pasadena, CA 91125 USA.
   [Raskatov, Jevgenij A.] Univ Calif Santa Cruz, Dept Chem & Biochem, 1156 High St, Santa Cruz, CA 95064 USA.
C3 California Institute of Technology; University of California System;
   University of California Santa Cruz
RP Dervan, PB (通讯作者)，CALTECH, 1200 East Calif Blvd, Pasadena, CA 91125 USA.
EM dervan@caltech.edu
OI Szablowski, Jerzy/0000-0001-7851-5408
FU NIH [GM-51747]; Alexander von Humboldt Foundation; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [R01GM027681, R01GM051747] Funding Source: NIH
   RePORTER
FX This work was supported by the NIH grant GM-51747. J.O. Szablowski was
   supported by NIH GM-51747. J.A. Raskatov received postdoctoral support
   from the Alexander von Humboldt Foundation.
CR Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Blagosklonny MV, 2004, CANCER CELL, V5, P13, DOI 10.1016/S1535-6108(03)00336-2
   Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367
   de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078
   Du W, 2015, ONCOGENE, V34, P3215, DOI 10.1038/onc.2014.291
   Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695
   Hsu CF, 2007, TETRAHEDRON, V63, P6146, DOI 10.1016/j.tet.2007.03.041
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Jacobs VL, 2011, ASN NEURO, V3, DOI 10.1042/AN20110014
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kim D, 2013, GENOME BIOL, P14
   Kung AL, 2004, CANCER CELL, V6, P33, DOI 10.1016/j.ccr.2004.06.009
   Lao BB, 2014, P NATL ACAD SCI USA, V111, P7531, DOI 10.1073/pnas.1402393111
   Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106
   Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106
   Li LJ, 2011, HEMATOL ONCOL CLIN N, V25, P667, DOI 10.1016/j.hoc.2011.04.004
   Loges Sonja, 2010, Genes Cancer, V1, P12, DOI 10.1177/1947601909356574
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   LYNG H, 1992, CANCER RES, V52, P584
   Martinez TF, 2014, NUCLEIC ACIDS RES, V42, P11546, DOI 10.1093/nar/gku866
   Mencher Simon K, 2005, BMC Clin Pharmacol, V5, P3, DOI 10.1186/1472-6904-5-3
   Mizukami Y, 2007, CLIN CANCER RES, V13, P5670, DOI 10.1158/1078-0432.CCR-07-0111
   Nickols NG, 2007, ACS CHEM BIOL, V2, P561, DOI 10.1021/cb700110z
   Nickols NG, 2007, P NATL ACAD SCI USA, V104, P10418, DOI 10.1073/pnas.0704217104
   Nickols NG, 2013, MOL CANCER THER, V12, P675, DOI 10.1158/1535-7163.MCT-12-1040
   Olenyuk BZ, 2004, P NATL ACAD SCI USA, V101, P16768, DOI 10.1073/pnas.0407617101
   Onnis B, 2009, J CELL MOL MED, V13, P2780, DOI 10.1111/j.1582-4934.2009.00876.x
   Presta LG, 1997, CANCER RES, V57, P4593
   Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274
   Raskatov JA, 2014, J MED CHEM, V57, P8471, DOI 10.1021/jm500964c
   Raskatov JA, 2014, BIOORGAN MED CHEM, V22, P4371, DOI 10.1016/j.bmc.2014.04.010
   Raskatov JA, 2012, J AM CHEM SOC, V134, P7995, DOI 10.1021/ja302588v
   Raskatov JA, 2012, P NATL ACAD SCI USA, V109, P1023, DOI 10.1073/pnas.1118506109
   Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005
   Sarkaria JN, 2006, CLIN CANCER RES, V12, P2264, DOI 10.1158/1078-0432.CCR-05-2510
   SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005
   Synold TW, 2012, CANCER CHEMOTH PHARM, V70, P617, DOI 10.1007/s00280-012-1954-3
   Tang CM, 2013, J GASTROEN HEPATOL, V28, P401, DOI 10.1111/jgh.12038
   Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61
   THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55
   Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Yang F, 2013, J MED CHEM, V56, P7449, DOI 10.1021/jm401100s
   Yang F, 2013, P NATL ACAD SCI USA, V110, P1863, DOI 10.1073/pnas.1222035110
   Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338
NR 50
TC 10
Z9 10
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD APR
PY 2016
VL 15
IS 4
BP 608
EP 617
DI 10.1158/1535-7163.MCT-15-0719
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DI6GD
UT WOS:000373596300007
PM 26719577
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, YM
   Lee, YR
   Kim, JS
   Kim, YH
   Kim, J
AF Lee, Yun Mi
   Lee, Yu Ri
   Kim, Jin Sook
   Kim, Young Ho
   Kim, Junghyun
TI Cinidium officinale and its Bioactive Compound, Butylidenephthalide,
   Inhibit Laser-Induced Choroidal Neovascularization in a Rat Model
SO MOLECULES
LA English
DT Article
DE age-related macular degeneration; butylidenephthalide; choroidal
   neovascularization; Cinidium officinale
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL INJECTION; MACULAR DEGENERATION;
   ENDOPHTHALMITIS; EXPRESSION
AB Choroidal neovascularization (CNV) is a common pathology in age-related macular degeneration. In this study, we evaluated in a rat model the effect of an extract of Cinidium officinale Makino and its bioactive compound, butylidenephthalide, on laser-induced CNV. Experimental CNV was induced in Long-Evans rats by laser photocoagulation. C. officinale extract (COE) and butylidenephthalide was intraperitoneally injected once per day for ten days after laser photocoagulation. Choroidal flat mounts were prepared to measure CNV areas and macrophage infiltration. We used a protein array to evaluate the expression levels of angiogenic factors. The CNV area and macrophage infiltration in COE-treated rats were significantly lower than in vehicle-treated rats. COE decreased the expression levels of IGFBP-1, MCP-1, PAI-1, and VEGF. Additionally, butylidenephthalide also inhibited the laser-induced CNV formation and macrophage infiltration and down-regulated the expression of IGFBP-1, MCP-1 and VEGF. These results suggest that COE exerts anti-angiogenic effects on laser-induced CNV by inhibiting the expression of IGFBP-1, MCP-1, and VEGF, indicating that anti-angiogenic activities of COE may be in part due to its bioactive compound, butylidenephthalide.
C1 [Lee, Yun Mi; Kim, Young Ho] Chungnam Natl Univ, Coll Pharm, Taejon 34134, South Korea.
   [Lee, Yun Mi; Lee, Yu Ri; Kim, Jin Sook; Kim, Junghyun] Korea Inst Oriental Med, Korean Med Convergence Res Div, Taejon 34054, South Korea.
C3 Chungnam National University; Korea Institute of Oriental Medicine
   (KIOM)
RP Kim, J (通讯作者)，Korea Inst Oriental Med, Korean Med Convergence Res Div, Taejon 34054, South Korea.
EM candykong@kiom.re.kr; yrsanta@kiom.re.kr; jskim@kiom.re.kr;
   yhk@cnu.ac.kr; dvmhyun@kiom.re.kr
OI , Young Ho/0000-0002-7441-9459; Kim, Young Ho/0000-0003-0703-1136
FU Korea Institute of Oriental Medicine [K15801]
FX This research was supported by a grant of the Korea Institute of
   Oriental Medicine (K15801).
CR Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Ehlken C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126859
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Fu RH, 2011, BIOTECHNOL LETT, V33, P903, DOI 10.1007/s10529-011-0528-5
   Funatsu H, 2005, OPHTHALMOLOGY, V112, P806, DOI 10.1016/j.ophtha.2004.11.045
   HARANAKA K, 1985, CANCER IMMUNOL IMMUN, V20, P1
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Higashi K., 1996, JPN J ORIENTAL MED, V46, P753
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim J, 2015, BIOCHEM BIOPH RES CO, V456, P53, DOI 10.1016/j.bbrc.2014.11.033
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak DH, 2002, J ETHNOPHARMACOL, V81, P373, DOI 10.1016/S0378-8741(02)00122-8
   Kwon JH, 2002, J AGR FOOD CHEM, V50, P4479, DOI 10.1021/jf020293a
   Lofqvist C, 2009, INVEST OPHTH VIS SCI, V50, P1831, DOI 10.1167/iovs.08-2903
   Muranaka K, 2005, FEBS LETT, V579, P6084, DOI 10.1016/j.febslet.2005.09.079
   Onishi Y, 1998, BIOL PHARM BULL, V21, P761, DOI 10.1248/bpb.21.761
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Takahashi K, 2003, INVEST OPHTH VIS SCI, V44, P409, DOI 10.1167/iovs.02-0346
   WANG JD, 1989, CHEM PHARM BULL, V37, P2236
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yeh JC, 2011, ANGIOGENESIS, V14, P187, DOI 10.1007/s10456-011-9202-8
NR 29
TC 3
Z9 3
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2015
VL 20
IS 11
BP 20699
EP 20708
DI 10.3390/molecules201119728
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CX8AX
UT WOS:000365925200030
PM 26610445
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Weinberger, AWA
   Eddahabi, C
   Carstesen, D
   Zipfel, PF
   Walter, P
   Skerka, C
AF Weinberger, Andreas W. A.
   Eddahabi, Cordula
   Carstesen, Doerthe
   Zipfel, Peter F.
   Walter, Peter
   Skerka, Christine
TI Human Complement Factor H and Factor H-Like Protein 1 Are Expressed in
   Human Retinal Pigment Epithelial Cells
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Factor H; Interleukin; In situ
   hybridization; Retinal cell culture; Retinal pigment epithelium
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; GENOMEWIDE-SCAN;
   SUSCEPTIBILITY LOCI; EXTENDED FAMILIES; FACTOR-I; POLYMORPHISM; VARIANT;
   Y402H; RISK
AB Background: A common haplotype in the gene for the regulator of the alternative pathway of complement activation factor H has been linked to individual predisposition to age-related macular degeneration (AMD). Methods: In this study, retinal pigment epithelial (RPE) cells, i.e. immortalized ARPE-19 as well as primary human RPE cells, were investigated for expression of factor H and FHL-1 by immunohistochemistry and in situ hybridization analysis. Results: Factor H and the alternative spliced product FHL-1 are expressed in RPE cells, i.e. in immortalized ARPE-19 and primary human RPE cells. Factor H and FHL-1 expression was induced in a dose-dependent manner in ARPE-19 cells upon treatment with the inflammatory marker interleukin-6 (IL-6). In situ hybridization experiments confirmed an elevated expression rate of the factor H gene in IL-6-treated ARPE-19 cells. AMD is characterized by complement-associated inflammatory processes in the retina. Thus, local synthesis of complement regulators affects the protection of retinal cells and may be involved in the pathogenesis at the RPE-choroid interface. (C) 2013 S. Karger AG, Basel
C1 [Weinberger, Andreas W. A.; Eddahabi, Cordula; Carstesen, Doerthe; Walter, Peter] Rhein Westfal TH Aachen, Dept Ophthalmol, DE-52074 Aachen, Germany.
   [Zipfel, Peter F.; Skerka, Christine] Hans Knoell Inst, Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Jena, Germany.
   [Zipfel, Peter F.] Univ Jena, Jena, Germany.
C3 RWTH Aachen University; Hans Knoll Institute (HKI); Friedrich Schiller
   University of Jena
RP Weinberger, AWA (通讯作者)，Rhein Westfal TH Aachen, Dept Ophthalmol, Pauwelsstr 30, DE-52074 Aachen, Germany.
EM aweinberger@ukaachen.de
RI Walter, Peter/L-5982-2018
OI Walter, Peter/0000-0001-8745-6593
FU Interdisciplinary Centre for Clinical Research 'BIOMAT' of the RWTH
   Aachen University Faculty of Medicine [TV-B109]; START program of the
   RWTH Aachen University Faculty of Medicine; Deutsche
   Forschungsgemeinschaft [DFG SK46]
FX This work was supported by a grant (TV-B109) of the Interdisciplinary
   Centre for Clinical Research 'BIOMAT' of the RWTH Aachen University
   Faculty of Medicine and a grant from the START program of the RWTH
   Aachen University Faculty of Medicine, and by the Deutsche
   Forschungsgemeinschaft (DFG SK46).
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Febbraio MA, 2005, EXERC SPORT SCI REV, V33, P114, DOI 10.1097/00003677-200507000-00003
   Friese MA, 1999, MOL IMMUNOL, V36, P809, DOI 10.1016/S0161-5890(99)00101-7
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Goodship T, 2004, Bull Mem Acad R Med Belg, V159, P195
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Huang SJ, 2003, RETINA-J RET VIT DIS, V23, P429, DOI 10.1097/00006982-200306000-00036
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jozsi M, 2004, HISTOL HISTOPATHOL, V19, P251, DOI 10.14670/HH-19.251
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Schlaf G, 2001, MOL IMMUNOL, V38, P231, DOI 10.1016/S0161-5890(01)00045-1
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seitsonen S, 2006, MOL VIS, V12, P796
   Skerka C, 2008, VACCINE, V26, pI9, DOI 10.1016/j.vaccine.2008.11.021
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Soames CJ, 1997, BIOCHEM J, V326, P553, DOI 10.1042/bj3260553
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
   Zipfel PF, 2008, VACCINE, V26, pI67, DOI 10.1016/j.vaccine.2008.11.015
   Zipfel PF, 1999, MOL IMMUNOL, V36, P241, DOI 10.1016/S0161-5890(99)00038-3
NR 41
TC 8
Z9 8
U1 0
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2014
VL 51
IS 2
BP 59
EP 66
DI 10.1159/000351624
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 293GQ
UT WOS:000329959800001
PM 24280833
DA 2022-11-30
ER

PT J
AU Guzman-Aranguez, A
   Loma, P
   Pintor, J
AF Guzman-Aranguez, A.
   Loma, P.
   Pintor, J.
TI Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Review
DE siRNAs; therapy; eye; glaucoma; retinitis pigmentosa; age-related
   macular degeneration; diabetic retinopathy; corneal neovascularization
ID TISSUE GROWTH-FACTOR; TRABECULAR MESHWORK CELLS; AQUEOUS-HUMOR DYNAMICS;
   DOUBLE-STRANDED-RNA; EXPRESSION IN-VIVO; EXTRACELLULAR-MATRIX;
   INTRAOCULAR-PRESSURE; CORNEAL NEOVASCULARIZATION; RETINITIS-PIGMENTOSA;
   RETINAL DEGENERATION
AB RNA interference (RNAi) can be used to inhibit the expression of specific genes in vitro and in vivo, thereby providing an extremely useful tool for investigating gene function. Progress in the understanding of RNAi-based mechanisms has opened up new perspectives in therapeutics for the treatment of several diseases including ocular disorders. The eye is currently considered a good target for RNAi therapy mainly because it is a confined compartment and, therefore, enables local delivery of small-interfering RNAs (siRNAs) by topical instillation or direct injection. However, delivery strategies that protect the siRNAs from degradation and are suitable for long-term treatment would be help to improve the efficacy of RNAi-based therapies for ocular pathologies. siRNAs targeting critical molecules involved in the pathogenesis of glaucoma, retinitis pigmentosa and neovascular eye diseases (age-related macular degeneration, diabetic retinopathy and corneal neovascularization) have been tested in experimental animal models, and clinical trials have been conducted with some of them. This review provides an update on the progress of RNAi in ocular therapeutics, discussing the advantages and drawbacks of RNAi-based therapeutics compared to previous treatments.
C1 [Guzman-Aranguez, A.; Loma, P.; Pintor, J.] Univ Complutense Madrid, Fac Opt & Optometry, Dept Biochem & Mol Biol 4, Madrid 28037, Spain.
C3 Complutense University of Madrid
RP Pintor, J (通讯作者)，Univ Complutense Madrid, Fac Opt & Optometry, Dept Biochem & Mol Biol 4, C Arcos de Jalon 118, Madrid 28037, Spain.
EM jpintor@ucm.es
RI guzman, ana/Y-8286-2019
OI Guzman-Aranguez, Ana/0000-0001-6722-2044; Pintor,
   Jesus/0000-0002-9191-7679
FU Universidad Complutense de Madrid [GR35/10-A-920777]; Ministry of
   Economy [SAF 2010/16024]; Institute Carlos III (Redes tematicas de
   investigacion cooperativa en salud) [RD12/0034/0003]
FX This work was supported by Universidad Complutense de Madrid (Project
   GR35/10-A-920777), the Ministry of Economy (SAF 2010/16024) and the
   Institute Carlos III (Redes tematicas de investigacion cooperativa en
   salud RD12/0034/0003).
CR Ahmed Z, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.54
   Alexander SPH, 2011, BRIT J PHARMACOL, V164, pS1, DOI 10.1111/j.1476-5381.2011.01649_1.x
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Alm A, 2009, EXP EYE RES, V88, P760, DOI 10.1016/j.exer.2008.12.012
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Ashikari M, 2010, INVEST OPHTH VIS SCI, V51, P3820, DOI 10.1167/iovs.09-5121
   Bachmann B, 2010, OPHTHALMOLOGY, V117, P1300, DOI 10.1016/j.ophtha.2010.01.039
   Berson EL, 2012, ARCH OPHTHALMOL-CHIC, V130, P707, DOI 10.1001/archophthalmol.2011.2580
   Berson EL, 2010, ARCH OPHTHALMOL-CHIC, V128, P403, DOI 10.1001/archophthalmol.2010.32
   Beverly M, 2006, J CHROMATOGR B, V835, P62, DOI 10.1016/j.jchromb.2006.03.008
   Bhattacharya SK, 2005, J BIOL CHEM, V280, P6080, DOI 10.1074/jbc.M411233200
   Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   Brar VS, 2010, MOL VIS, V16, P1848
   Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169
   Brucker A, 2006, COMB RET SOC GON SOC
   BULLER C, 1994, INVEST OPHTH VIS SCI, V35, P3841
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Cashman SM, 2005, GENE THER, V12, P1223, DOI 10.1038/sj.gt.3302512
   Castany M, 2011, EXP EYE RES, V92, P221, DOI 10.1016/j.exer.2010.12.004
   Chang JH, 2012, SURV OPHTHALMOL, V57, P415, DOI 10.1016/j.survophthal.2012.01.007
   Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002
   Chang L, 2001, INVEST OPHTH VIS SCI, V42, P1531
   Chen P, 2012, MOL VIS, V18, P864
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   ClinicalTrials, 2008, SAF EFF STUD EV COMB
   Comes N, 2007, MOL VIS, V13, P1363
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Crooke A, 2009, MOL VIS, V15, P1169
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   De Fougerolles AR, 2008, HUM GENE THER, V19, P125, DOI 10.1089/hum.2008.928
   Deshpande MC, 2004, J CONTROL RELEASE, V97, P143, DOI 10.1016/j.jconrel.2004.02.019
   Devi TS, 2012, EXP DIABETES RES, DOI 10.1155/2012/438238
   Dursun A, 2012, INT J OPHTHALMOL-CHI, V5, P448, DOI 10.3980/j.issn.2222-3959.2012.04.08
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Evans T, 2000, DIABETES, V49, P662, DOI 10.2337/diabetes.49.4.662
   Fan S, 2011, ARCH OPHTHALMOL-CHIC, V129, P1162, DOI 10.1001/archophthalmol.2011.226
   Fedorov Y, 2006, RNA, V12, P1188, DOI 10.1261/rna.28106
   Feinstein HA, 2009, INV OPHTH VIS SCI AR, V50, P5693
   Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gaglione M, 2010, MINI-REV MED CHEM, V10, P578, DOI 10.2174/138955710791384036
   Gastinger MJ, 2006, INVEST OPHTH VIS SCI, V47, P3143, DOI 10.1167/iovs.05-1376
   Goel M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034309
   Gorbatyuk M, 2007, VISION RES, V47, P1202, DOI 10.1016/j.visres.2006.11.026
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   Guo H, 2012, IMMUNOL CELL BIOL, V90, P352, DOI 10.1038/icb.2011.49
   Guo JF, 2010, MOL BIOSYST, V6, P1143, DOI 10.1039/c001050m
   Gupta D, 2011, CORNEA, V30, P927, DOI 10.1097/ICO.0b013e318201405a
   Guzman-Aranguez A, 2013, J OCUL PHARMACOL TH, V29, P189, DOI 10.1089/jop.2012.0212
   Hall AHS, 2004, NUCLEIC ACIDS RES, V32, P5991, DOI 10.1093/nar/gkh936
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hernan I, 2011, INVEST OPHTH VIS SCI, V52, P3723, DOI 10.1167/iovs.10-6933
   Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   JAMPEL HD, 1988, ARCH OPHTHALMOL-CHIC, V106, P89
   Jiang J, 2009, J CELL PHYSIOL, V218, P66, DOI 10.1002/jcp.21566
   Johnson EC, 2009, EXP EYE RES, V88, P808, DOI 10.1016/j.exer.2009.02.004
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002
   Junglas B, 2012, AM J PATHOL, V180, P2386, DOI 10.1016/j.ajpath.2012.02.030
   Junglas B, 2009, EXP EYE RES, V88, P1065, DOI 10.1016/j.exer.2009.01.008
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Kalloniatis Michael, 2004, Clin Exp Optom, V87, P65
   Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801
   Kiang AS, 2005, MOL THER, V12, P555, DOI 10.1016/j.ymthe.2005.03.028
   Kiel JW, 2011, PROG RETIN EYE RES, V30, P1, DOI 10.1016/j.preteyeres.2010.08.001
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kurz Daryl, 2002, Ophthalmol Clin North Am, V15, P405, DOI 10.1016/S0896-1549(02)00034-2
   Lacono P, 2010, DEV OPHTHALMOL, V46, P39, DOI 10.1159/000320008
   Lingor P, 2005, BRAIN, V128, P550, DOI 10.1093/brain/awh382
   Liu HB, 2008, ENDOCRINOLOGY, V149, P1666, DOI 10.1210/en.2007-1415
   Liu JHK, 2004, AM J OPHTHALMOL, V138, P389, DOI 10.1016/j.ajo.2004.04.022
   Liu JHK, 1998, INVEST OPHTH VIS SCI, V39, P2707
   Liu JHK, 1999, INVEST OPHTH VIS SCI, V40, P2912
   Liu Q, 2012, CURR MOL MED, V12, P1015
   Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519
   Macknight ADC, 2000, CLIN EXP PHARMACOL P, V27, P100, DOI 10.1046/j.1440-1681.2000.03208.x
   Mao HY, 2012, HUM GENE THER, V23, P356, DOI 10.1089/hum.2011.213
   Markovskaya A, 2008, EUR J PHARMACOL, V579, P93, DOI 10.1016/j.ejphar.2007.10.040
   Marques JT, 2006, NAT BIOTECHNOL, V24, P559, DOI 10.1038/nbt1205
   Martin-Gil A, 2012, BRIT J PHARMACOL, V165, P1163, DOI 10.1111/j.1476-5381.2011.01586.x
   Massof RW, 2010, ARCH OPHTHALMOL-CHIC, V128, P493, DOI 10.1001/archophthalmol.2010.46
   Mediero A, 2009, AUTON NEUROSCI-BASIC, V147, P14, DOI 10.1016/j.autneu.2008.12.009
   Mezentsev A, 2005, J PHARMACOL EXP THER, V315, P42, DOI 10.1124/jpet.105.088211
   Mincione F, 2008, CURR PHARM DESIGN, V14, P649, DOI 10.2174/138161208783877866
   Morris MB, 2009, INT J BIOCHEM CELL B, V41, P721, DOI 10.1016/j.biocel.2008.04.025
   Moses R.A., 1981, ADLERS PHYSL EYE CLI, P227
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   Nakamura H, 2004, MOL VIS, V10, P703
   NATHANSON JA, 1981, INVEST OPHTH VIS SCI, V21, P798
   Nguyen QD, 2012, EYE, V26, P1099, DOI 10.1038/eye.2012.106
   Nozaki RB, 2006, INVEST OPHTH VIS SCI, V47, P900
   O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025
   Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshitari T, 2006, DIABETES, V55, P86, DOI 10.2337/diabetes.55.01.06.db05-0186
   Palfi A, 2006, HUM MUTAT, V27, P260, DOI 10.1002/humu.20287
   Paneda C, 2013, AOPT 2013 SCI M, V1, P96
   Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462
   Peeters L, 2007, BIOCHEM SOC T, V35, P47, DOI 10.1042/BST0350047
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Peral A, 2009, EXP EYE RES, V89, P63, DOI 10.1016/j.exer.2009.02.010
   Perrone L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.42
   Perrone L, 2009, J CELL PHYSIOL, V221, P262, DOI 10.1002/jcp.21852
   Petrs-Silva H, 2012, ADV EXP MED BIOL, V723, P215, DOI 10.1007/978-1-4614-0631-0_29
   Phelan JK, 2000, MOL VIS, V6, P116
   Pintor J, 2012, AN REAL ACAD NAC F, V78, P230
   Pisanti S, 2011, BLOOD, V117, P5541, DOI 10.1182/blood-2010-09-307355
   Pitkanen L, 2003, PHARM RES-DORDR, V20, P576, DOI 10.1023/A:1023238530504
   Qazi Y, 2012, INVEST OPHTH VIS SCI, V53, P2837, DOI 10.1167/iovs.11-9139
   Nguyen QD, 2012, INVEST OPHTH VIS SCI, V53, P7666, DOI 10.1167/iovs.12-9961
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P1867, DOI 10.1016/j.ophtha.2012.03.043
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020
   Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101
   Reich S, 2003, MOL VIS, V9, P210
   RILEY MV, 1986, EXP EYE RES, V42, P559, DOI 10.1016/0014-4835(86)90046-1
   Robinson R, 2012, DIS MODEL MECH, V5, P444, DOI 10.1242/dmm.009597
   Roy S, 2003, DIABETES, V52, P1229, DOI 10.2337/diabetes.52.5.1229
   Roy S, 2011, MOL VIS, V17, P3166
   Saika S, 2001, GRAEF ARCH CLIN EXP, V239, P234, DOI 10.1007/s004170100275
   Sbai O, 2010, J CELL SCI, V123, P4332, DOI 10.1242/jcs.074674
   Seet LF, 2012, J CELL MOL MED, V16, P1245, DOI 10.1111/j.1582-4934.2011.01400.x
   Seigel D, 2013, JAMA OPHTHALMOL, V131, P267, DOI 10.1001/jamaophthalmol.2013.590
   Seta F, 2007, PROSTAG OTH LIPID M, V84, P116, DOI 10.1016/j.prostaglandins.2007.05.001
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shi FX, 2002, BIOCHEM J, V366, P333, DOI 10.1042/BJ20020590
   Silver LH, 1998, AM J OPHTHALMOL, V126, P400, DOI 10.1016/S0002-9394(98)00095-6
   Singh N, 2007, CORNEA, V26, P65
   Sioud M, 2005, J MOL BIOL, V348, P1079, DOI 10.1016/j.jmb.2005.03.013
   Sohn S, 2002, INVEST OPHTH VIS SCI, V43, P3680
   Song LY, 2002, BBA-BIOMEMBRANES, V1558, P1, DOI 10.1016/S0005-2736(01)00399-6
   Su Y, 2012, MOL VIS, V18, P1881
   Tamm ER, 2009, EXP EYE RES, V88, P648, DOI 10.1016/j.exer.2009.02.007
   Tessitore A, 2006, MOL THER, V14, P692, DOI 10.1016/j.ymthe.2006.07.008
   Tian BH, 2000, INVEST OPHTH VIS SCI, V41, P619
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P660, DOI 10.1097/00006982-200408000-00039
   Toris CB, 1999, AM J OPHTHALMOL, V128, P8, DOI 10.1016/S0002-9394(99)00076-8
   Tosi J, 2011, EXP BIOL MED, V236, P1211, DOI 10.1258/ebm.2011.011053
   Tovar-Vidales T, 2011, EXP EYE RES, V93, P2, DOI 10.1016/j.exer.2010.06.006
   Tshionyi M, 2012, CORNEA, V31, P74, DOI 10.1097/ICO.0b013e31821dd986
   Turchinovich A, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-25
   van Setten G, 2005, OPHTHALMIC RES, V37, P289, DOI 10.1159/000087698
   Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429
   Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Weinreb RN, 2002, SURV OPHTHALMOL, V47, pS53, DOI 10.1016/S0039-6257(02)00306-5
   Winkler JL, 2012, MOL VIS, V18, P874
   Wistrand PJ, 1997, SURV OPHTHALMOL, V41, pS129, DOI 10.1016/S0039-6257(97)80020-3
   Yang HW, 2010, INT J OPHTHALMOL-CHI, V3, P120, DOI 10.3980/j.issn.2222-3959.2010.02.06
   Yang HW, 2010, ACTA OPHTHALMOL, V88, P652, DOI 10.1111/j.1755-3768.2009.01641.x
   Ye HH, 2010, MOL VIS, V16, P2502
   Yuan C, 2007, MOL VIS, V13, P2083
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
   Zhang X, 2007, EXP EYE RES, V85, P637, DOI 10.1016/j.exer.2007.07.016
   Zuo L, 2010, CURR EYE RES, V35, P375, DOI 10.3109/02713681003597230
NR 172
TC 78
Z9 88
U1 1
U2 42
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD OCT
PY 2013
VL 170
IS 4
BP 730
EP 747
DI 10.1111/bph.12330
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 227UC
UT WOS:000325139400004
PM 23937539
OA Green Published
DA 2022-11-30
ER

PT J
AU Kaiser, PK
   Cruess, AF
   Bogaert, P
   Khunti, K
   Kelly, SP
AF Kaiser, Peter K.
   Cruess, Alan F.
   Bogaert, Peter
   Khunti, Kamlesh
   Kelly, Simon P.
TI Balancing risk in ophthalmic prescribing: assessing the safety of
   anti-VEGF therapies and the risks associated with unlicensed medicines
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Medication safety; Off-label prescribing; Ranibizumab; Bevacizumab;
   Age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; ADVERSE DRUG-REACTIONS; MACULAR DEGENERATION;
   MYOCARDIAL-INFARCTION; INTRAVITREAL INJECTION; THROMBOEMBOLIC EVENTS;
   ROSIGLITAZONE STORY; PLASMA-LEVELS; BEVACIZUMAB; RANIBIZUMAB
AB Vascular endothelial growth factor (VEGF) inhibitor medications such as ranibizumab, pegaptanib and bevacizumab are in use for the treatment of neovascular age-related macular degeneration (AMD) and other retinal conditions, although only ranibizumab and pegaptanib are approved for these conditions. In contrast, bevacizumab was developed for the intravenous systemic treatment of colorectal cancer and is not formulated for intravitreal use, but is commonly used off-label in ophthalmology. European Union legislation permits the use of drugs outside the terms of their licence ('off-label') only under certain circumstances, such as during clinical trials, compassionate/named patient use in the absence of a licensed alternative, emergency scenarios (e.g., pandemics) or at the discretion of a treating physician. In such cases, patients should be fully informed regarding their treatment and any potential risks involved. Off-label drug use can be an important tool to provide patients with treatment in cases of unmet medical need. However, the use of an unlicensed medicinal product, when a suitable licensed alternative is available, puts prescribing physicians at risk of liability if safety issues arise. Emerging clinical evidence suggests safety differences exist between ranibizumab and bevacizumab.
C1 [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44195 USA.
   [Cruess, Alan F.] Dalhousie Univ, Dept Ophthalmol & Visual Sci, Halifax, NS B3H 3J5, Canada.
   [Bogaert, Peter] Covington & Burling LLP, Brussels, Belgium.
   [Khunti, Kamlesh] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England.
   [Kelly, Simon P.] Royal Bolton Hosp NHS Fdn Trust, Bolton, England.
C3 Cleveland Clinic Foundation; Dalhousie University; University of
   Leicester; Royal Bolton Hospital
RP Kaiser, PK (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,Desk I32, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
RI /ABC-9527-2021
OI Khunti, Kamlesh/0000-0003-2343-7099; Kaiser, Peter/0000-0001-5126-045X
FU Novartis Pharma AG, Basel, Switzerland; Alcon; Allergan; Regeneron; Novo
   Nordisk; Eli Lilly; Merck Sharpe Dohme; Sanofi-Aventis; Novartis
FX We acknowledge Jennifer Green of Alpha-Plus Medical Communications Ltd,
   UK, who provided medical writing services, with funding from Novartis
   Pharma AG, Basel, Switzerland. This service encompassed the preparation
   of a first draft, editing, checking content and language, formatting,
   referencing, preparing tables and figures, and incorporating the
   authors' revisions, all carried out under our direction. At all stages,
   we had control over the content of this manuscript, for which we have
   given final approval and taken full responsibility.; PKK has acted as a
   consultant for Genentech, Regeneron, Bayer, Novartis and Kanghong
   Biotech. AC has acted as a speaker for Novartis and Bayer/Regeneron, and
   has received grants from Alcon, Allergan and Regeneron. PB provides
   legal advice to multiple pharmaceutical clients on an ongoing basis,
   including Abbott, Amgen, AstraZeneca, BiogenIdec, BMS, GSK, Johnson &
   Johnson, Merck, Novartis, Roche, Sanofi-Aventis, Vifor, ViroPharma and
   others. KK has acted as a consultant and speaker for Novartis, Novo
   Nordisk, Sanofi-Aventis, Lilly and Merck Sharp & Dohme. He has received
   funding for research from Novo Nordisk, Eli Lilly, Merck Sharpe & Dohme
   and Sanofi-Aventis. SPK has acted as a consultant and speaker for
   Novartis, and a consultant for Alimera, Allergan, Bayer and Pfizer.;
   Novartis sponsored Alpha-Plus Medical Communications Ltd (UK) to provide
   writing and editorial assistance with the production of this review,
   under the guidance of the authors.
CR [Anonymous], 2005, USP28NF23
   [Anonymous], 2005, USP28NF23
   Backstrom M, 2004, PHARMACOEPIDEM DR S, V13, P483, DOI 10.1002/pds.962
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Current opinion of the German Ophthalmological Society the Retinological Society and the Professional Association of German Ophthalmologists, 2012, ANT THER NEOV AG REL
   Current opinion of the German Ophthalmological Society the Retinological Society and the Professional Association of German Ophthalmologists, 2009, NEW ASP TREATM NEOV
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Donaldson LJ., 2000, ORG MEMORY REPORT EX
   European Medicines Agency, 2007, LUC EUR PUBL ASS REP
   Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri, 2006, COD DEONT MED
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferroni P, 2010, CURR VASC PHARMACOL, V8, P102, DOI 10.2174/157016110790226660
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Genentech, 2010, LUC PRESCR INF
   Genentech, 2011, AV PRESCR INF
   General Medical Council, 2008, CONS PAT DOCT MAK DE
   General Medical Council, 2008, GOOD PRACT PRESCR ME
   General Medical Council, 2008, GOOD PRACT PRESCR ME
   German Medical Association, 2006, PROF COD PHYS GERM
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Gower EW, 2011, ASS RES VIS OPHTH AR
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kairuz TE, 2007, CURR DRUG SAF, V2, P89
   Kelly SP, 2011, EYE, V25, P710, DOI 10.1038/eye.2011.89
   Killick J, 2009, PHARM LAW INSIGHT, V6, P4
   Kim H, 2009, MOL VIS, V15
   Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Medical Products Agency - Sweden, 2012, POS MED PROD AG REG
   Medicines and Healthcare products Regulatory Agency, 2009, DRUG SAF UPD OFF LAB
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Molyneux C, 2010, REGULATORY AFFAI NOV, P13
   *NAT AUD OFF, 2000, MAN CONTR HOSP ACQ I
   Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761
   Novartis, LUC PRESCR INF
   Ornek K, 2008, ANN PHARMACOTHER, V42, P1425, DOI 10.1345/aph.1L270
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Riley J.B., 2007, HEMATOLOGY ONCOLOGY, V6, P24, DOI DOI 10.1377/HLTHAFF.2010.1032
   Rosen CJ, 2007, NEW ENGL J MED, V357, P844, DOI 10.1056/NEJMp078167
   Rosen CJ, 2010, NEW ENGL J MED, V363, P803, DOI 10.1056/NEJMp1008233
   Shah R. R., 2001, Adverse Drug Reactions and Toxicological Reviews, V20, P199
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   Sun XD, 2011, NEW ENGL J MED, V365, P378, DOI 10.1056/NEJMc1106415
   Thanigaimani S, 2011, CURR VASC PHARMACOL, V9, P358, DOI 10.2174/157016111795495503
   The Royal College of Ophthalmologists, 2012, POT BEV STER END CAS
   The Royal College of Opthalmologists, 2011, BEV AV US MED OPHTH
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Weynants L, 2010, REGULATORY AFFAI NOV, P7
   Winkelmayer WC, 2008, ARCH INTERN MED, V168, P2368, DOI 10.1001/archinte.168.21.2368
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 67
TC 15
Z9 15
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2012
VL 250
IS 11
BP 1563
EP 1571
DI 10.1007/s00417-012-2123-4
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 032VV
UT WOS:000310748100002
PM 23011000
OA hybrid, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Bora, RS
   Gupta, D
   Mukkur, TKS
   Saini, KS
AF Bora, Roop Singh
   Gupta, Dikshi
   Mukkur, Trilochan Kanwaljit Singh
   Saini, Kulvinder Singh
TI RNA interference therapeutics for cancer: Challenges and opportunities
   (Review)
SO MOLECULAR MEDICINE REPORTS
LA English
DT Review
DE RNA interference; short interfering RNA; gene silencing; cancer; short
   interfering RNA delivery; target specificity
ID DOUBLE-STRANDED-RNA; APTAMER-SIRNA CHIMERAS; INHIBITS TUMOR-GROWTH;
   IN-VIVO; GENE-EXPRESSION; MAMMALIAN-CELLS; PROTEIN-KINASE; TARGETED
   NANOPARTICLES; NONHUMAN-PRIMATES; MESSENGER-RNA
AB RNA interference (RNAi) is a sequence-specific, post-transcriptional gene silencing mechanism in animals and plants, which is mediated by double-stranded RNA (dsRNA). There has recently been an increasing interest in harnessing the gene silencing activity of dsRNA to develop novel drugs for the treatment of various diseases, such as cancer, neuro-logical disorders, age-related macular degeneration and viral infections. Small interfering RNA (siRNA)-based drugs have distinct advantages over conventional small molecule or protein-based drugs, including high specificity, higher potency and reduced toxicity. However, there are several technical obstacles to overcome before siRNA-based drugs reach the clinic. Delivery of siRNA to the target tissues and stability in the serum remain a major challenge and are the main focus of current research and development efforts. This review focused primarily on the progress made in developing RNAi as therapeutics for cancer and the challenges associated with its clinical development. Use of ligands recognizing cell-specific receptors to achieve tumor-specific delivery of siRNA, methods for enhanced siRNA delivery, improving the bioavailability and pharmacokinetic properties of siRNA and reducing the off-target effects and non-specific gene silencing are discussed in the light of current evidence.
C1 [Bora, Roop Singh; Gupta, Dikshi; Saini, Kulvinder Singh] Ranbaxy Labs Ltd, Dept Biotechnol, Gurgaon 122015, Haryana, India.
   [Mukkur, Trilochan Kanwaljit Singh] Curtin Univ Technol, Curtin Hlth Innovat Res Inst, Sch Biomed Sci, Western Australian Biomed Res Inst, Perth, WA 6102, Australia.
C3 Ranbaxy Laboratories Limited; Curtin University
RP Bora, RS (通讯作者)，Ranbaxy Labs Ltd, Ranbaxy Biol Div, Sy 16,Siddlaghatta Rd, Bangalore 562114, Karnataka, India.
EM roop.singh@ranbaxy.com
RI Saini, Kulvinder/G-4729-2013
OI BORA, ROOP SINGH/0000-0002-5586-3829
CR Aleku M, 2008, CANCER RES, V68, P9788, DOI 10.1158/0008-5472.CAN-08-2428
   Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774
   Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9
   Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758
   Cheng K, 2006, J PHARMACOL EXP THER, V317, P797, DOI 10.1124/jpet.105.100347
   Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703
   Dassie JP, 2009, NAT BIOTECHNOL, V27, P839, DOI 10.1038/nbt.1560
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   De Paula D, 2007, RNA, V13, P431, DOI 10.1261/rna.459807
   DeVincenzo J, 2008, ANTIVIR RES, V77, P225, DOI 10.1016/j.antiviral.2007.11.009
   Diaz-Hernandez M, 2005, J NEUROSCI, V25, P9773, DOI 10.1523/JNEUROSCI.3183-05.2005
   DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104
   Dykxhoorn DM, 2006, CELL, V126, P231, DOI 10.1016/j.cell.2006.07.007
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Gao HJ, 2005, P NATL ACAD SCI USA, V102, P9469, DOI 10.1073/pnas.0503879102
   Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2
   Grunweller A, 2005, CURR MED CHEM, V12, P3143, DOI 10.2174/092986705774933489
   Grzelinski M, 2006, HUM GENE THER, V17, P751, DOI 10.1089/hum.2006.17.751
   Guo PX, 2010, ADV DRUG DELIVER REV, V62, P650, DOI 10.1016/j.addr.2010.03.008
   Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104
   Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Hutvagner G, 2005, FEBS LETT, V579, P5850, DOI 10.1016/j.febslet.2005.08.071
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831
   Jain KK, 2005, DRUG DISCOV TODAY, V10, P1435, DOI 10.1016/S1359-6446(05)03573-7
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515
   Kariko K, 2004, CELLS TISSUES ORGANS, V177, P132, DOI 10.1159/000079987
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Kim SH, 2006, J CONTROL RELEASE, V116, P123, DOI 10.1016/j.jconrel.2006.05.023
   Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530
   Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604
   Leenders F, 2004, EMBO J, V23, P3303, DOI 10.1038/sj.emboj.7600345
   Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944
   Li SD, 2008, MOL THER, V16, P163, DOI 10.1038/sj.mt.6300323
   Li YC, 2005, AVIAN DIS, V49, P562, DOI 10.1637/7365-041205R2.1
   Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513
   Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100
   MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238
   Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904
   McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a
   McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223
   Mendonca LS, 2010, BIOCONJUGATE CHEM, V21, P157, DOI 10.1021/bc9004365
   MINKS MA, 1979, J BIOL CHEM, V254, P180
   NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Peer D, 2008, SCIENCE, V319, P627, DOI 10.1126/science.1149859
   Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020
   Rose SD, 2005, NUCLEIC ACIDS RES, V33, P4140, DOI 10.1093/nar/gki732
   Santel A, 2006, GENE THER, V13, P1360, DOI 10.1038/sj.gt.3302778
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008
   Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Singh D, 2011, DRUG DISCOV TODAY, V16, P793, DOI 10.1016/j.drudis.2011.08.003
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828
   Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227
   Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003
   Thanik VD, 2007, GENE THER, V14, P1305, DOI 10.1038/sj.gt.3302986
   Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191
   Ui-Tei K, 2000, FEBS LETT, V479, P79, DOI 10.1016/S0014-5793(00)01883-4
   Vaishnaw A.K., 2010, SILENCE, V1, P1, DOI DOI 10.1186/1758-907X-1-14
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
   Wu Y, 2010, INT J NANOMED, V5, P129
   Xia HB, 2004, NAT MED, V10, P816, DOI 10.1038/nm1076
   Yagi N, 2009, CANCER RES, V69, P6531, DOI 10.1158/0008-5472.CAN-08-3945
   Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 74
TC 81
Z9 88
U1 1
U2 43
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2012
VL 6
IS 1
BP 9
EP 15
DI 10.3892/mmr.2012.871
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 956ML
UT WOS:000305093700002
PM 22576734
OA Bronze
DA 2022-11-30
ER

PT J
AU Bocci, V
   Zanardi, I
   Borrelli, E
   Travagli, V
AF Bocci, Velio
   Zanardi, Iacopo
   Borrelli, Emma
   Travagli, Valter
TI Reliable and effective oxygen-ozone therapy at a crossroads with
   ozonated saline infusion and ozone rectal insufflation
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Review
DE drug safety; oxidative stress; oxygen-ozone therapy; reactive oxygen
   species; therapeutic ozone
ID EXTRACORPOREAL BLOOD OXYGENATION; PORTAL-VEIN OXYGENATION; GENERATION;
   TRIAL; HERNIATION; EFFICACY; FAILURE; DISEASE; DAMAGE; EBOO
AB Objectives This review aims to highlight the advantages and safety of oxygen-ozone therapy (OOT) and to suggest ways to enhance its acceptance.
   Key findings The treatment of a herniated disk by injecting a gaseous oxygen-ozone mixture inside the nucleus pulposus is a great clinical success. However, the use of OOT lags for a number of reasons, including lack of standardization, the need for numerous treatments, lack of knowledge and even denial. Anecdotally, several million treatments by OOT have been performed worldwide indicating its usefulness, mainly in peripheral arterial diseases and age-related macular degeneration. The scepticism that accompanies the systemic use of ozone can only be overcome by demonstrating the validity of OOT in controlled and randomized clinical trials. Cheaper and quicker methods, such as ozonating physiological saline with successive infusion as well as ozone rectal insufflations, are becoming popular, however, such alternative procedures are erratic, unstable and liable to be toxic, with deleterious consequences, and are likely to discredit the beneficial use of ozone.
   Summary The approval of ozone in terms of both therapeutic efficacy and safety will depend on the results achieved by authoritative clinical trials.
C1 [Zanardi, Iacopo; Travagli, Valter] Univ Siena, Dip Farmaco Chim Tecnol, I-53100 Siena, Italy.
   [Bocci, Velio] Univ Siena, Dip Fisiol, I-53100 Siena, Italy.
   [Borrelli, Emma] Univ Siena, Dip Chirurg & Bioingn, I-53100 Siena, Italy.
C3 University of Siena; University of Siena; University of Siena
RP Travagli, V (通讯作者)，Univ Siena, Dip Farmaco Chim Tecnol, Viale Aldo Moro 2, I-53100 Siena, Italy.
EM valter.travagli@unisi.it
RI Borrelli, Emma/AAJ-8172-2021; Borrelli, Emma/P-1018-2017; Borrelli,
   Emma/AAE-7013-2019; Zanardi, Iacopo/E-1603-2011
OI Borrelli, Emma/0000-0002-4991-0289; Borrelli, Emma/0000-0002-4991-0289;
   Travagli, Valter/0000-0002-7574-4456; bocci, velio/0000-0002-2153-6248;
   Zanardi, Iacopo/0000-0001-7535-5322
CR Aldini G, 2006, J MASS SPECTROM, V41, P1149, DOI 10.1002/jms.1067
   Andreula CF, 2003, AM J NEURORADIOL, V24, P996
   Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0
   Artis AS, 2010, CLIN HEMORHEOL MICRO, V45, P329, DOI 10.3233/CH-2010-1316
   AUBOURG P, 1940, MEM ACAD CHIR, V65, P1183
   Awasthi YC, 2005, METHOD ENZYMOL, V401, P379, DOI 10.1016/S0076-6879(05)01024-4
   Azarpazhooh A, 2008, J DENT, V36, P104, DOI 10.1016/j.jdent.2007.11.008
   Bocci V, 1996, MED HYPOTHESES, V46, P150, DOI 10.1016/S0306-9877(96)90016-X
   Bocci V, 1998, J BIOL REG HOMEOS AG, V12, P67
   Bocci V, 2011, AM J CARDIOVASC DRUG, V11, P73, DOI 10.2165/11539890-000000000-00000
   Bocci V, 2011, OZONE: A NEW MEDICAL DRUG, SECOND EDITION, P1, DOI 10.1007/978-90-481-9234-2_1
   Bocci V, 2011, BRIT J CLIN PHARMACO, V72, P350, DOI 10.1111/j.1365-2125.2011.03974.x
   Bocci V, 2010, ATHEROSCLEROSIS, V211, P38, DOI 10.1016/j.atherosclerosis.2010.04.014
   Bocci V, 2011, DIABETES METAB SYND, V5, P45, DOI 10.1016/j.dsx.2010.05.014
   Bocci V, 2009, MED RES REV, V29, P646, DOI 10.1002/med.20150
   Bocci VA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-66
   Bond RA, 2001, TRENDS PHARMACOL SCI, V22, P273, DOI 10.1016/S0165-6147(00)01711-9
   Calabrese EJ, 2003, ANNU REV PHARMACOL, V43, P175, DOI 10.1146/annurev.pharmtox.43.100901.140223
   Calunga JL, 2009, J PHARM PHARMACOL, V61, P221, DOI 10.1211/jpp/61.02.0012
   CARPENDALE MT, 1993, J CLIN GASTROENTEROL, V17, P142, DOI 10.1097/00004836-199309000-00010
   COPPOLA L, 1992, TROMBOSI ATEROSCLERO, V3, P83
   Di Paolo N, 2005, INT J ARTIF ORGANS, V28, P1039, DOI 10.1177/039139880502801012
   Di Paolo N, 2002, INT J ARTIF ORGANS, V25, P1194, DOI 10.1177/039139880202501212
   Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001
   Foksinski M, 1999, MUTAT RES-GEN TOX EN, V438, P23, DOI 10.1016/S1383-5718(98)00155-7
   Groeger AL, 2010, MOL INTERV, V10, P39, DOI 10.1124/mi.10.1.7
   Guanche D, 2010, TOXICOL MECH METHOD, V20, P25, DOI 10.3109/15376510903503107
   Hauser-Gerspach I, 2009, CLIN ORAL INVEST, V13, P287, DOI 10.1007/s00784-008-0234-4
   Ho RL, 2008, DRUGS R&D, V9, P203, DOI 10.2165/00126839-200809040-00001
   IKONOMIDIS S, 2005, RIV ITALIANA OSSIGEN, V4, P40
   International Scientific Committee of Ozonetherapy, 2010, ISC03
   JACOBS MT, 1982, OZONACHRICHTEN, V5, P1
   Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049
   Li LJ, 2007, WORLD J GASTROENTERO, V13, P5989, DOI 10.3748/wjg.13.5989
   Li WG, 2008, BIOCHEM PHARMACOL, V76, P1485, DOI 10.1016/j.bcp.2008.07.017
   Lynch E, 2008, J ESTHET RESTOR DENT, V20, P287, DOI 10.1111/j.1708-8240.2008.00195.x
   Martinez-Sanchez G, 2005, EUR J PHARMACOL, V523, P151, DOI 10.1016/j.ejphar.2005.08.020
   Mattassi R, 1987, TERAPIA OZONO PARENT, VVIII, P109
   Mendiratta S, 1998, FREE RADICAL BIO MED, V25, P221, DOI 10.1016/S0891-5849(98)00060-4
   Motret O, 1998, OZONE-SCI ENG, V20, P51, DOI 10.1080/01919519808547290
   Paoloni M, 2009, SPINE, V34, P1337, DOI 10.1097/BRS.0b013e3181a3c18d
   Poli G, 2008, MED RES REV, V28, P569, DOI 10.1002/med.20117
   Razumovskii SD, 2010, KINET CATAL+, V51, P492, DOI 10.1134/S0023158410040051
   Re L, 2008, ARCH MED RES, V39, P17, DOI 10.1016/j.arcmed.2007.07.005
   Ripamonti CI, 2011, ORAL ONCOL, V47, P185, DOI 10.1016/j.oraloncology.2011.01.002
   Sroczynski J, 1992, Pol Tyg Lek, V47, P964
   Stone JR, 2006, ANTIOXID REDOX SIGN, V8, P243, DOI 10.1089/ars.2006.8.243
   Torre-Amione G, 2008, LANCET, V371, P228, DOI 10.1016/S0140-6736(08)60134-8
   Travagli V, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/610418
   Travagli V, 2007, INT J BIOL MACROMOL, V41, P504, DOI 10.1016/j.ijbiomac.2007.06.010
   Travagli V, 2010, INT J TOXICOL, V29, P165, DOI 10.1177/1091581809360069
   Travagli Valter, 2009, Recent Pat Antiinfect Drug Discov, V4, P130
   Turczynski B, 1991, Pol Tyg Lek, V46, P708
   Tylicki L, 2001, INT J ARTIF ORGANS, V24, P79, DOI 10.1177/039139880102400204
   Valacchi G, 2011, WOUND REPAIR REGEN, V19, P107, DOI 10.1111/j.1524-475X.2010.00649.x
   VALDES AR, 1993, ANGIOLOGIA, V45, P146
   van der Zee H, 2001, P 15 OZ WORLD C LOND, P148
   VERRAZZO G, 1995, UNDERSEA HYPERBAR M, V22, P17
   Wasser, 1981, OZONTHERAPIE BEI PER, P53
   Zaky S, 2011, BRIT J CLIN PHARMACO, V71, P411, DOI 10.1111/j.1365-2125.2010.03851.x
NR 60
TC 20
Z9 28
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD APR
PY 2012
VL 64
IS 4
BP 482
EP 489
DI 10.1111/j.2042-7158.2011.01427.x
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 908ZL
UT WOS:000301531500003
PM 22420654
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Rouvas, A
   Petrou, P
   Vergados, I
   Theodossiadis, G
   Theodossiadis, P
AF Rouvas, Alexandros
   Petrou, Petros
   Vergados, Ioannis
   Theodossiadis, Georgios
   Theodossiadis, Panagiotis
TI Extensive submacular hemorrhage following intravitreal ranibizumab for
   small occult choroidal neovascular membrane
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Complications; Intravitreal
   injections; Ranibizumab
ID MACULAR DEGENERATION; SUBRETINAL HEMORRHAGE; BEVACIZUMAB
AB Purpose. Although intravitreal ranibizumab represents an established therapeutic approach for exudative age-related macular degeneration (AMD), the possible occurrence of adverse events remains under ongoing research. The purpose of this report is to present an incidence of an extensive submacular hemorrhage after intravitreal ranibizumab administration.
   Methods. Interventional case report.
   Results. A 72-year-old woman was referred to our retinal department for sudden visual loss in the right eye (RE). She had undergone an intravitreal ranibizumab injection 48 hours prior to her presentation. She had known AMD with a confirmed occult choroidal neovascularization (CNV) for which she had been subjected to a total of 24 intravitreal injections in the RE (with monthly intervals) over the last 2 years. Clinical examination revealed an extensive submacular hemorrhage in the RE.
   Conclusions. To our knowledge, this is the first report of a submacular hemorrhage soon after ranibizumab administration in a patient with a small occult CNV. Although such a correlation cannot be established, the authors underline the possibility of such an adverse event in patients with small CNVs following a long therapeutic course involving high injection volume.
C1 [Rouvas, Alexandros; Petrou, Petros; Vergados, Ioannis; Theodossiadis, Panagiotis] Univ Athens, Attikon Hosp, Ophthalmol Dept 2, Athens, Greece.
   [Theodossiadis, Georgios] Eric Dynan Hosp, Dept Ophthalmol, Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon; Henry Dunant Hospital
RP Rouvas, A (通讯作者)，Rimini 1, Athens 1246, Greece.
EM petrospetrou4@hotmail.com
CR Baeteman C, 2009, J FR OPHTALMOL, V32, P309, DOI 10.1016/j.jfo.2009.04.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chieh JJ, 2007, ANN OPHTHALMOL, V39, P51, DOI 10.1007/BF02697326
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Iguchi Y, 2006, BRIT J OPHTHALMOL, V90, P1256, DOI 10.1136/bjo.2006.099259
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Theodossiadis GP, 2003, GRAEF ARCH CLIN EXP, V241, P13, DOI 10.1007/s00417-002-0579-3
NR 10
TC 4
Z9 4
U1 0
U2 1
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP-OCT
PY 2011
VL 21
IS 5
BP 665
EP 667
DI 10.5301/EJO.2011.6329
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 848AP
UT WOS:000297018900023
PM 21319137
DA 2022-11-30
ER

PT J
AU Ma, L
   Lin, XM
AF Ma, Le
   Lin, Xiao-Ming
TI Effects of lutein and zeaxanthin on aspects of eye health
SO JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
LA English
DT Review
DE lutein, zeaxanthin; carotenoid, macular pigment; age-related macular
   degeneration; cataract
ID AGE-RELATED MACULOPATHY; NUTRITION EXAMINATION SURVEY; ABSORBING
   INTRAOCULAR-LENS; RETINAL-PIGMENT EPITHELIUM; 3RD NATIONAL-HEALTH;
   BEAVER DAM EYE; MACULAR DEGENERATION; RETINITIS-PIGMENTOSA; PRIMATE
   RETINAS; PROTECTIVE ROLE
AB Lutein and zeaxanthin are members of the oxygenated carotenoids found particularly in egg yolks and dark-green leafy vegetables. A great deal of research has focused on their beneficial roles in eye health. The present article summarises the current literature related to the bioactivity of these carotenoids, emphasising their effects and possible mechanisms of action in relation to human eye health. Available evidence demonstrates that lutein and zeaxanthin are widely distributed in a number of body tissues and are uniquely concentrated in the retina and lens, indicating that each has a possible specific function in these two vital ocular tissues. Most of epidemiological studies and clinical trials support the notion that lutein and zeaxanthin have a potential role in the prevention and treatment of certain eye diseases such as age-related macular degeneration, cataract and retinitis pigmentosa. The biological mechanisms for the protective effects of these carotenoids may include powerful blue-light filtering activities and antioxidant properties. Although most studies point towards significant health benefits from lutein and zeaxanthin, further large-scale randomised supplementation trials are needed to define their effects on ocular function in health and disease. (c) 2009 Society of Chemical Industry
C1 [Ma, Le; Lin, Xiao-Ming] Peking Univ, Sch Publ Hlth, Dept Food Hyg & Nutr, Beijing 100191, Peoples R China.
C3 Peking University
RP Lin, XM (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Food Hyg & Nutr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
OI ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-30671758]; Chinese
   Nutrition Society [06094]
FX The authors acknowledge support received from the National Natural
   Science Foundation of China (NSFC-30671758) and the Chinese Nutrition
   Society (No. 06094). The authors declare no conflicts of interests.
CR Adackapara CA, 2008, RETINA-J RET VIT DIS, V28, P103, DOI 10.1097/IAE.0b013e31809862aa
   Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Bahrami Hossein, 2006, BMC Ophthalmol, V6, P23, DOI 10.1186/1471-2415-6-23
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2007, ARCH BIOCHEM BIOPHYS, V458, P121, DOI 10.1016/j.abb.2006.10.005
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Boscia F, 2000, INVEST OPHTH VIS SCI, V41, P2461
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   Chin CJ, 2005, AM J CLIN NUTR, V81, P1411
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Christen W, 2008, ARCH OPHTHALMOL-CHIC, V126, P1607, DOI 10.1001/archopht.126.11.1607-a
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Dagnelie G, 2000, Optometry, V71, P147
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Demmig-Adams B, 2002, SCIENCE, V298, P2149, DOI 10.1126/science.1078002
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   Dwyer JH, 2004, ARTERIOSCL THROM VAS, V24, P313, DOI 10.1161/01.ATV.0000109955.80818.8a
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gorin MB, 2007, ARCH OPHTHALMOL-CHIC, V125, P21, DOI 10.1001/archopht.125.1.21
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Greenstein VC, 2007, J CATARACT REFR SURG, V33, P667, DOI 10.1016/j.jcrs.2006.12.012
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HECKENLIVELY JR, 1988, AM J OPHTHALMOL, V105, P504, DOI 10.1016/0002-9394(88)90242-5
   Hof KHV, 2000, J NUTR, V130, P503
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson Elizabeth J, 2002, Nutr Clin Care, V5, P56, DOI 10.1046/j.1523-5408.2002.00004.x
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Kruger CL, 2002, FOOD CHEM TOXICOL, V40, P1535, DOI 10.1016/S0278-6915(02)00131-X
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Li T, 2009, BIOL TRACE ELEM RES, V128, P1, DOI 10.1007/s12011-008-8248-y
   Lin DB, 2005, MOL VIS, V11, P853
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Michaud DS, 2000, AM J CLIN NUTR, V72, P990
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   O'Neill ME, 1998, BRIT J NUTR, V79, P149, DOI 10.1079/BJN19980026
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   OJIMA F, 1993, FREE RADICAL BIO MED, V15, P377, DOI 10.1016/0891-5849(93)90037-U
   Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parker RS, 1999, P NUTR SOC, V58, P155, DOI 10.1079/PNS19990021
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Robman L, 2007, CAN J OPHTHALMOL, V42, P720, DOI 10.3129/i07-116
   Roca A, 2004, NEUROSCIENCE, V129, P779, DOI 10.1016/j.neuroscience.2004.08.021
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Sandberg MA, 2005, INVEST OPHTH VIS SCI, V46, P3349, DOI 10.1167/iovs.04-1383
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stimpson JP, 2007, J AM DIET ASSOC, V107, P1218, DOI 10.1016/j.jada.2007.04.008
   SUBCZYNSKI WK, 1991, BIOCHIM BIOPHYS ACTA, V1068, P68, DOI 10.1016/0005-2736(91)90061-C
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sujak A, 2000, J PHOTOCH PHOTOBIO B, V59, P42, DOI 10.1016/S1011-1344(00)00133-0
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tapiero H, 2004, BIOMED PHARMACOTHER, V58, P100, DOI 10.1016/j.biopha.2003.12.006
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vu HTV, 2006, INVEST OPHTH VIS SCI, V47, P3783, DOI 10.1167/iovs.05-0587
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P1449
   Woodall AA, 1997, BBA-GEN SUBJECTS, V1336, P575, DOI 10.1016/S0304-4165(97)00007-X
   Yao LH, 2000, LIPIDS, V35, P339, DOI 10.1007/s11745-000-0531-0
   Yeum K J, 1999, Asia Pac J Clin Nutr, V8, P4, DOI 10.1046/j.1440-6047.1999.00035.x
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
NR 100
TC 146
Z9 158
U1 3
U2 64
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-5142
EI 1097-0010
J9 J SCI FOOD AGR
JI J. Sci. Food Agric.
PD JAN 15
PY 2010
VL 90
IS 1
BP 2
EP 12
DI 10.1002/jsfa.3785
PG 11
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 530AJ
UT WOS:000272561000002
PM 20355006
DA 2022-11-30
ER

PT J
AU Adela, P
   Dumitrita, R
   Raluca, P
   Carmen, S
AF Adela, Pintea
   Dumitrita, Rugina
   Raluca, Parlog
   Carmen, Socaciu
TI Catechin-rich green tea extract modulates the oxidative status of human
   retinal pigment epithelial cells
SO ROMANIAN BIOTECHNOLOGICAL LETTERS
LA English
DT Article
DE RPE cells; catechins; antioxidant enzymes; reduced glutathione;
   intracellular reactive oxygen species
ID HYDROGEN-PEROXIDE; (-)-EPIGALLOCATECHIN GALLATE; ANTIOXIDANT ACTIVITY;
   IN-VITRO; STRESS; DAMAGE; PATHOGENESIS; FLAVONOIDS; GENERATION;
   QUERCETIN
AB Oxidative damages to the retinal pigment epithelium (RPE) have been suggested to play a key role in the pathogenesis of age related macular degeneration (AMD). Our purpose was to evaluate the effects of a catechin rich green tea extract Polyphenon E against induced oxidative stress in cultured human RPE cells. Cell viability (MTT assay) and level of intracellular reactive oxygen species (ROS) generated after treatments with Polyphenon E +/- hydrogen peroxide were measured. The activities of superoxid dismutase (SOD), catalase (CA 7) and glutathione peroxidase (GPx) as well as the gluthathione GSH concentration were determined. Polyphenon E has no cytotoxic effect up to concentrations of 200 microgram/ml in culture media and showed a protective effect against hydrogen peroxide induced toxicity. Administration of the catechin-rich extract induced an increase of SOD activity in normal and oxidative stress conditions and an increase of catalase only in induced oxidative stress condition. Polyphenon E determined a decrease of glutathione peroxidase activity and of glutathione level. However, the significant inhibition of intracellular ROS generation supports the hypothesis that catechin can contribute to antioxidant defense by direct scavenge of ROS in RPE cells.
C1 [Adela, Pintea; Dumitrita, Rugina; Raluca, Parlog; Carmen, Socaciu] Univ Agr Sci & Vet Med, Cluj Napoca, Romania.
C3 University of Agricultural Sciences & Veterinary Medicine Cluj Napoca
RP Adela, P (通讯作者)，Univ Agr Sci & Vet Med, Manastur St 3-5, Cluj Napoca, Romania.
EM apintea@usamvcluj.ro
RI Socaciu, Carmen/AAX-2579-2020; Socaciu, Carmen/P-8358-2014
OI Socaciu, Carmen/0000-0002-7352-5057
FU PNCD II [ID_854]
FX This work was supported by PNCD II ID_854 Research Grant. We gratefully
   acknowledge to Prof Dr. Horst A. Diehl for providing the D407 RPE cells
   and to Prof Dr. Saverio Bettuzzi for giving us the Polyphenon E extract.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Chan CM, 2008, MOL VIS, V14, P2528
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Elbling L, 2005, FASEB J, V19, P807, DOI 10.1096/fj.04-2915fje
   Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   KANDASWAMI C, 1994, ADV EXP MED BIOL, V366, P351
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Long LH, 2000, BIOCHEM BIOPH RES CO, V273, P50, DOI 10.1006/bbrc.2000.2895
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Oikawa S, 2003, FREE RADICAL RES, V37, P881, DOI 10.1080/1071576031000150751
   Qin S, 2007, DRUG DEVELOP RES, V68, P213, DOI 10.1002/ddr.20185
   Rice-Evans C, 1999, P SOC EXP BIOL MED, V220, P262, DOI 10.1046/j.1525-1373.1999.d01-45.x
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Shamsi FA, 2007, CURR EYE RES, V32, P575, DOI 10.1080/02713680701363833
   Singhal SS, 1999, INVEST OPHTH VIS SCI, V40, P2652
   Takumi-Kobayashi A, 2008, MUTAT RES-GEN TOX EN, V657, P13, DOI 10.1016/j.mrgentox.2008.08.016
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Winkler BS, 1999, MOL VIS, V5
   Yang Seong-Won, 2007, Korean J Ophthalmol, V21, P232, DOI 10.3341/kjo.2007.21.4.232
   Zhang B, 2006, BRAIN RES, V1124, P176, DOI 10.1016/j.brainres.2006.09.067
NR 36
TC 3
Z9 3
U1 1
U2 8
PU ARS DOCENDI
PI BUCHAREST
PA SOS PANDURI 90, SECT 5, BUCHAREST, RO-050663, ROMANIA
SN 1224-5984
J9 ROM BIOTECH LETT
JI Rom. Biotech. Lett.
PD JAN-FEB
PY 2010
VL 15
IS 1
BP 4964
EP 4978
PG 15
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA 565EO
UT WOS:000275272200007
DA 2022-11-30
ER

PT J
AU Majid, MA
   Smith, VA
   Newby, AC
   Dick, AD
AF Majid, Mohammed A.
   Smith, Valerie A.
   Newby, Andrew C.
   Dick, Andrew D.
TI Matrix bound SFD mutant TIMP-3 is more stable than wild type TIMP-3
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SORSBYS-FUNDUS-DYSTROPHY; PIGMENT EPITHELIAL-CELLS; HUMAN TISSUE
   INHIBITOR; METALLOPROTEINASES-3 TIMP3; MACULAR DEGENERATION;
   CLINICAL-FEATURES; BRUCHS MEMBRANE; MUTATION; GENE; FAMILY
AB Background: Sorsby's fundus dystrophy (SFD) is a degenerative retinopathy characterised by accumulation of mutant TIMP-3 protein in Bruch's membrane.
   Aim: To compare the stability of matrix bound SFD mutant TIMP-3s with wild type TIMP-3.
   Methods: COS-7 cells were transfected with plasmids containing wild type, Ser 181, Gly-167, Ser-156, and Tyr-168 TIMP-3 cDNA. The cells and their matrices were subsequently harvested and homogenised. After measuring the bound wild type and SFD mutant TIMP-3 concentrations by ELISA, aliquots of the homogenates were heated to 100 degrees C. The rates of denaturation of the TIMP proteins at this temperature were monitored by reverse zymography.
   Results: Over a period of 24 h at 100 degrees C the biological activity of both wild type and SFD mutant TIMP-3 was lost. Over a period of 6 h at this temperature the biological activity of the SFD mutant TIMP-3s was fully retained whereas that of the wild type TIMP-3 was lost.
   Conclusion: Matrix bound SFD mutant TIMP-3s are thermodynamically more stable than wild type. This may explain why SFD starts earlier in life than age related macular degeneration.
C1 Univ Bristol, Bristol Eye Hosp, Acad Unit Ophthalmol, Bristol BS1 2LX, Avon, England.
   Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS1 2LX, Avon, England.
C3 Bristol Eye Hospital; University of Bristol; Bristol Royal Infirmary;
   University of Bristol
RP Smith, VA (通讯作者)，Univ Bristol, Bristol Eye Hosp, Acad Unit Ophthalmol, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
EM Val.Smith@bristol.ac.uk
OI Dick, Andrew/0000-0002-0742-3159
CR APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016
   Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200
   CAPON MRC, 1988, EYE, V2, P114, DOI 10.1038/eye.1988.23
   CarreroValenzuela RD, 1996, ARCH OPHTHALMOL-CHIC, V114, P737, DOI 10.1001/archopht.1996.01100130729016
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Clarke M, 2001, BRIT J OPHTHALMOL, V85, P1429, DOI 10.1136/bjo.85.12.1429
   DelaPaz MA, 1997, INVEST OPHTH VIS SCI, V38, P1060
   Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Felbor U, 1996, J MED GENET, V33, P233, DOI 10.1136/jmg.33.3.233
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   Felbor U, 1997, INVEST OPHTH VIS SCI, V38, P1054
   Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192
   Majid MA, 2006, BRIT J OPHTHALMOL, V90, P1310, DOI 10.1136/bjo.2006.097246
   Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8
   Majid MA, 2002, BRIT J OPHTHALMOL, V86, P97, DOI 10.1136/bjo.86.1.97
   Peters AL, 1995, RETINA-J RET VIT DIS, V15, P480, DOI 10.1097/00006982-199515060-00004
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Smith VA, 2006, BBA-MOL BASIS DIS, V1762, P431, DOI 10.1016/j.bbadis.2006.01.010
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   STASKUS PW, 1991, J BIOL CHEM, V266, P449
   WEBER BHF, 1994, NAT GENET, V7, P158, DOI 10.1038/ng0694-158
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
NR 28
TC 1
Z9 1
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2007
VL 91
IS 8
BP 1073
EP 1076
DI 10.1136/bjo.2006.113225
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 190WD
UT WOS:000248090400022
PM 17383996
OA Green Published
DA 2022-11-30
ER

PT J
AU Lambert, V
   Wielockx, B
   Munaut, C
   Galopin, C
   Jost, M
   Itoh, T
   Werb, Z
   Baker, A
   Libert, C
   Krell, HW
   Foidart, JM
   Noel, A
   Rakic, JM
AF Lambert, V
   Wielockx, B
   Munaut, C
   Galopin, C
   Jost, M
   Itoh, T
   Werb, Z
   Baker, A
   Libert, C
   Krell, HW
   Foidart, JM
   Noel, A
   Rakic, JM
TI MMP-2 and MMP-9 synergize in promoting choroidal neovascularization
SO FASEB JOURNAL
LA English
DT Article
DE matrix metalloproteinase; CNV; age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; SORSBYS FUNDUS
   DYSTROPHY; RETINAL-PIGMENT EPITHELIUM; MATRIX METALLOPROTEINASES; TISSUE
   INHIBITORS; FIBRINOLYTIC-ACTIVITY; MACULAR DEGENERATION; ANGIOGENESIS;
   MICE
AB Matrix metalloproteinase 2 (MMP-2) and MMP-9 are increased in human choroidal neovascularization (CNV) occurring during the exudative most aggressive form of age-related macular degeneration (AMD), but their precise role and potential interactions remain unclear. To address the question of MMP-2 and MMP-9 functions, mice deficient in the expression of MMP-2 (MMP-2 KO), MMP-9 (MMP-9 KO), and both MMP-2 and MMP-9 (MMP-2,9 KO) with their corresponding wild-type mice (WT) underwent CNV induction by laser-induced rupture of the Bruch's membrane. Both the incidence and the severity of CNV were strongly attenuated in double deficient compared with single gene deficient mice or corresponding WT controls. The reduced neovascularization was accompanied by fibrinogen/fibrin accumulation. Furthermore, overexpression of the endogenous MMP inhibitors TIMP-1 or TIMP-2 (delivered by adenoviral vectors) in WT mice or daily injection of a synthetic and gelatinase selective MMP inhibitor (Ro 26-2853) significantly decreased the pathological reaction. These findings suggest that MMP-2 and MMP-9 may cooperate in the development of AMD and that their selective inhibition represents an alternative strategy for the treatment of choroidal neovascularization.
C1 Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.
   Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Ghent, Belgium.
   Univ Ghent, B-9000 Ghent, Belgium.
   Shionogi & Co Ltd, Shionogi Inst Med Sci, Osaka, Japan.
   Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.
   Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.
   Roche Diagnost GmbH, Pharma Res Penzberg, D-82372 Penzberg, Germany.
   Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium.
C3 University of Liege; Ghent University; Shionogi & Company Limited;
   University of California System; University of California San Francisco;
   Bristol Royal Infirmary; University of Bristol; Roche Holding;
   University of Liege
RP Foidart, JM (通讯作者)，Univ Liege, Lab Tumor & Dev Biol, Pathol Tower B23, B-4000 Liege, Belgium.
EM jmfoidart@ulg.ac.be
RI Wielockx, Ben/AAC-6854-2020; Munaut, Carine/K-8138-2019; Libert,
   Claude/A-6504-2010; Baker, Andy/AAO-5250-2021
OI Wielockx, Ben/0000-0002-4923-2596; Baker, Andy/0000-0003-1441-5576;
   Noel, Agnes/0000-0002-7670-6179
CR Arlt M, 2002, CANCER RES, V62, P5543
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439
   Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5
   Das A, 1999, INVEST OPHTH VIS SCI, V40, P809
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7
   Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1
   Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389
   Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643
   Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291
   Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Lein M, 2002, ONCOGENE, V21, P2089, DOI 10.1038/sj.onc.1205267
   Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793
   Lijnen HR, 2002, BIOCHEMISTRY-MOSCOW+, V67, P92, DOI 10.1023/A:1013908332232
   Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334
   Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645
   Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8
   Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Munaut C, 1995, INVAS METAST, V15, P169
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884
   Pagenstecher A, 2000, AM J PATHOL, V157, P197, DOI 10.1016/S0002-9440(10)64531-2
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87
NR 50
TC 137
Z9 152
U1 0
U2 7
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD OCT
PY 2003
VL 17
IS 13
BP 2290
EP +
DI 10.1096/fj.03-0113fje
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 739KH
UT WOS:000186343300026
PM 14563686
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Yeo, NJY
   Wazny, V
   Nguyen, NLU
   Ng, CY
   Wu, KX
   Fan, Q
   Cheung, CMG
   Cheung, C
AF Yeo, Natalie Jia Ying
   Wazny, Vanessa
   Nhi Le Uyen Nguyen
   Ng, Chun-Yi
   Wu, Kan Xing
   Fan, Qiao
   Cheung, Chui Ming Gemmy
   Cheung, Christine
TI Single-Cell Transcriptome of Wet AMD Patient-Derived Endothelial Cells
   in Angiogenic Sprouting
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; blood outgrowth endothelial cells;
   sprouting angiogenesis; single-cell transcriptome; endothelial cell
   states
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULAR DEGENERATION; GROWTH-FACTOR;
   EXTRACELLULAR-MATRIX; CULTURE MODEL; VEGF; NEOVASCULARIZATION; DRUSEN;
   MECHANISMS; ENDOSTATIN
AB Age-related macular degeneration (AMD) is a global leading cause of visual impairment in older populations. 'Wet' AMD, the most common subtype of this disease, occurs when pathological angiogenesis infiltrates the subretinal space (choroidal neovascularization), causing hemorrhage and retinal damage. Gold standard anti-vascular endothelial growth factor (VEGF) treatment is an effective therapy, but the long-term prevention of visual decline has not been as successful. This warrants the need to elucidate potential VEGF-independent pathways. We generated blood out-growth endothelial cells (BOECs) from wet AMD and normal control subjects, then induced angiogenic sprouting of BOECs using a fibrin gel bead assay. To deconvolute endothelial heterogeneity, we performed single-cell transcriptomic analysis on the sprouting BOECs, revealing a spectrum of cell states. Our wet AMD BOECs share common pathways with choroidal neovascularization such as extracellular matrix remodeling that promoted proangiogenic phenotype, and our 'activated' BOEC subpopulation demonstrated proinflammatory hallmarks, resembling the tip-like cells in vivo. We uncovered new molecular insights that pathological angiogenesis in wet AMD BOECs could also be driven by interleukin signaling and amino acid metabolism. A web-based visualization of the sprouting BOEC single-cell transcriptome has been created to facilitate further discovery research.
C1 [Yeo, Natalie Jia Ying; Wazny, Vanessa; Nhi Le Uyen Nguyen; Ng, Chun-Yi; Wu, Kan Xing; Cheung, Christine] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 636921, Singapore.
   [Fan, Qiao; Cheung, Chui Ming Gemmy] Natl Univ Singapore, Duke NUS Med Sch, Singapore 169857, Singapore.
   [Fan, Qiao] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore 169857, Singapore.
   [Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore 169856, Singapore.
   [Cheung, Christine] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore 138673, Singapore.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; National University of
   Singapore; National University of Singapore; National University of
   Singapore; Singapore National Eye Center; Agency for Science Technology
   & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology
   (IMCB)
RP Cheung, C (通讯作者)，Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 636921, Singapore.; Cheung, CMG (通讯作者)，Natl Univ Singapore, Duke NUS Med Sch, Singapore 169857, Singapore.; Cheung, CMG (通讯作者)，Singapore Eye Res Inst, Singapore 169856, Singapore.; Cheung, C (通讯作者)，Agcy Sci Technol & Res, Inst Mol & Cell Biol, Singapore 138673, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg; ccheung@ntu.edu.sg
RI ; Cheung, Christine/J-9721-2017
OI Cheung, Chui Ming Gemmy/0000-0003-3358-3516; Cheung,
   Christine/0000-0001-7127-9107; Yeo, Natalie/0000-0002-1158-1432
FU Ministry of Education, Singapore [MOE2018-T2-1-042, RG88/21]; Ministry
   of Education, Singapore; SERI-IMCB Program in Retinal Angiogenic
   Diseases (SIPRAD) from Agency for Science, Technology and Research,
   Singapore [SPF2014/002]; Nanyang President's Graduate Scholarship
FX The team from Nanyang Technological University Singapore was funded by
   the Nanyang Assistant Professorship and Academic Research Fund grants
   (MOE2018-T2-1-042 and RG88/21) from the Ministry of Education,
   Singapore. N.J.Y.Y and V.W. were supported by the Nanyang President's
   Graduate Scholarship. C.C. and C.M.G.C. were funded by the SERI-IMCB
   Program in Retinal Angiogenic Diseases (SIPRAD) grant (SPF2014/002) from
   Agency for Science, Technology and Research, Singapore.
CR Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Atkinson SP, 2012, STEM CELLS, V30, P1373, DOI 10.1002/stem.1113
   Baba T, 2020, ELIFE, V9, DOI 10.7554/eLife.54257
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bentley K, 2014, NAT CELL BIOL, V16, P309, DOI 10.1038/ncb2926
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Chappelow A.V., 2010, RETINAL PHARMACOTHER, P128
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Colombo SL, 2010, P NATL ACAD SCI USA, V107, P18868, DOI 10.1073/pnas.1012362107
   Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3
   Dumas SJ, 2020, TRENDS ENDOCRIN MET, V31, P580, DOI 10.1016/j.tem.2020.05.009
   Ecklu-Mensah G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204177
   Edgar LT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085178
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eilken HM, 2010, CURR OPIN CELL BIOL, V22, P617, DOI 10.1016/j.ceb.2010.08.010
   Elamaa H, 2005, AM J PATHOL, V166, P221, DOI 10.1016/S0002-9440(10)62246-8
   Fei P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116423
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Fu B, 2017, INT J OPHTHALMOL-CHI, V10, P535, DOI 10.18240/ijo.2017.04.06
   Fukushi J, 2000, J IMMUNOL, V165, P2818, DOI 10.4049/jimmunol.165.5.2818
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gampel A, 2006, BLOOD, V108, P2624, DOI 10.1182/blood-2005-12-007484
   Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040
   Geindreau M, 2022, CANCERS, V14, DOI 10.3390/cancers14102446
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Giacalone JC, 2019, MICROVASC RES, V123, P50, DOI 10.1016/j.mvr.2018.12.002
   Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048
   Heroult M, 2006, EXP CELL RES, V312, P642, DOI 10.1016/j.yexcr.2005.10.028
   Hneino M, 2012, J BIOL CHEM, V287, P38913, DOI 10.1074/jbc.M112.388389
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kang HJ, 2008, ACTA CRYSTALLOGR D, V64, P651, DOI 10.1107/S0907444908008561
   Kempe S, 2005, NUCLEIC ACIDS RES, V33, P5308, DOI 10.1093/nar/gki836
   Kouprina N, 2005, HUM MOL GENET, V14, P2155, DOI 10.1093/hmg/ddi220
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Labrousse-Arias D, 2016, CARDIOVASC RES, V109, P115, DOI 10.1093/cvr/cvv243
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Li ZW, 2019, EUR HEART J, V40, P2507, DOI 10.1093/eurheartj/ehz305
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Longchamp A, 2018, CELL, V173, P117, DOI 10.1016/j.cell.2018.03.001
   Lukowski SW, 2019, CELL REP, V27, P2748, DOI 10.1016/j.celrep.2019.04.102
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Marmorstein AD, 2007, TRENDS GENET, V23, P225, DOI 10.1016/j.tig.2007.03.001
   McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003
   Milbauer LC, 2008, BLOOD, V111, P3872, DOI 10.1182/blood-2007-06-097188
   Mittal B, 2014, ADV CLIN CHEM, V64, P1, DOI 10.1016/B978-0-12-800263-6.00001-X
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Nakatsu Martin N, 2007, J Vis Exp, P186, DOI 10.3791/186
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Newman DK, 2016, EYE, V30, P202, DOI 10.1038/eye.2015.251
   Ng CY, 2022, EMBO REP, V23, DOI 10.15252/embr.202255871
   Oberkersch RE, 2019, VASC PHARMACOL, V112, P17, DOI 10.1016/j.vph.2018.11.001
   Okamoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39018-3
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Ormiston ML, 2015, JOVE-J VIS EXP, DOI 10.3791/53384
   Orosz F, 2009, BBA-MOL BASIS DIS, V1792, P1168, DOI 10.1016/j.bbadis.2009.09.012
   Paschalaki KE, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00295
   Paschalaki KE, 2013, STEM CELLS, V31, P2813, DOI 10.1002/stem.1488
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7
   Rabin DM, 2013, AGING-US, V5, P51
   Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohlenova K, 2020, CELL METAB, V31, P862, DOI 10.1016/j.cmet.2020.03.009
   Rondaij MG, 2006, ARTERIOSCL THROM VAS, V26, P1002, DOI 10.1161/01.ATV.0000209501.56852.6c
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Sainson RCA, 2008, BLOOD, V111, P4997, DOI 10.1182/blood-2007-08-108597
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9
   Scimone C, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165956
   Scimone C, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00146
   Scimone C, 2019, NEUROL SCI, V40, P243, DOI 10.1007/s10072-018-3674-x
   Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5
   Seppinen L, 2011, MATRIX BIOL, V30, P83, DOI 10.1016/j.matbio.2010.11.001
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Songstad AE, 2017, STEM CELL TRANSL MED, V6, P1533, DOI 10.1002/sctm.16-0399
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Volland S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125631
   Voronov E, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00114
   Vreeken D, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165623
   Wang DY, 2005, BRAIN PATHOL, V15, P318
   Wang HB, 2016, MOL VIS, V22, P189
   Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017
   Wei P, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-2
   Wiedemann E, 2017, CELL SIGNAL, V29, P84, DOI 10.1016/j.cellsig.2016.10.003
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu GF, 2006, CARDIOVASC RES, V69, P512, DOI 10.1016/j.cardiores.2005.09.019
   Wu KX, 2022, BMC BIOL, V20, DOI 10.1186/s12915-022-01244-z
   Yamashita M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19473-0
   Yetkin-Arile B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46503-2
   Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zappia L, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy083
NR 102
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2022
VL 23
IS 20
AR 12549
DI 10.3390/ijms232012549
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 5P6KL
UT WOS:000873257800001
PM 36293401
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Palko, SI
   Saba, NJ
   Mullane, E
   Nicholas, BD
   Nagasaka, Y
   Ambati, J
   Gelfand, BD
   Ishigami, A
   Bargagna-Mohan, P
   Mohan, R
AF Palko, Sarah, I
   Saba, Nicholas J.
   Mullane, Elias
   Nicholas, Benjamin D.
   Nagasaka, Yosuke
   Ambati, Jayakrishna
   Gelfand, Bradley D.
   Ishigami, Akihito
   Bargagna-Mohan, Paola
   Mohan, Royce
TI Compartmentalized citrullination in Muller glial endfeet during retinal
   degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE Muller glial endfeet; citrullination; retinal degeneration; gliosis;
   GFAP
ID INTERMEDIATE-FILAMENTS; DEIMINATION; ACTIVATION; EXPRESSION; MODEL
AB Muller glia (MG) play a central role in reactive gliosis, a stress response associated with rare and common retinal degenerative diseases, including age-related macular degeneration (AMD). The posttranslational modification citrullination targeting glial fibrillary acidic protein (GFAP) in MG was initially discovered in a panocular chemical injury model. Here, we report in the paradigms of retinal laser injury, a genetic model of spontaneous retinal degeneration (JR5558 mice) and human wet-AMD tissues that MG citrullination is broadly conserved. After laser injury, GFAP polymers that accumulate in reactive MG are citrullinated in MG endfeet and glial cell processes. The enzyme responsible for citrullination, peptidyl arginine deiminase-4 (PAD4), localizes to endfeet and associates with GFAP polymers. Glial cell-specific PAD4 deficiency attenuates retinal hypercitrullination in injured retinas, indicating PAD4 requirement for MG citrullination. In retinas of 1-mo-old JR5558 mice, hypercitrullinated GFAP and PAD4 accumulate in MG endfeet/cell processes in a lesion-specific manner. Finally, we show that human donor maculae from patients with wet-AMD also feature the canonical endfeet localization of hypercitrullinated GFAP. Thus, we propose that endfeet are a "citrullination bunker" that initiates and sustains citrullination in retinal degeneration.
C1 [Palko, Sarah, I; Saba, Nicholas J.; Mullane, Elias; Bargagna-Mohan, Paola; Mohan, Royce] Univ Connecticut, Dept Neurosci, Hlth Ctr, Farmington, CT 06030 USA.
   [Nicholas, Benjamin D.; Nagasaka, Yosuke; Ambati, Jayakrishna; Gelfand, Bradley D.] Univ Virginia Hlth Syst, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Nagasaka, Yosuke; Ambati, Jayakrishna; Gelfand, Bradley D.] Univ Virginia Hlth Syst, Ctr Adv Vis Sci, Charlottesville, VA 22901 USA.
   [Gelfand, Bradley D.] Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA.
   [Ishigami, Akihito] Tokyo Metropolitan Inst Gerontol, Mol Regulat Aging, Tokyo 1730015, Japan.
C3 University of Connecticut; University of Virginia; University of
   Virginia; University of Virginia; Tokyo Metropolitan Institute of
   Gerontology
RP Mohan, R (通讯作者)，Univ Connecticut, Dept Neurosci, Hlth Ctr, Farmington, CT 06030 USA.
EM mohan@uchc.edu
OI Palko, Sarah/0000-0003-3862-8488; Ishigami, Akihito/0000-0001-7875-7482;
   Ambati, Jayakrishna/0000-0003-1622-6365
FU NIH [R21EY028699, R01EY028027, R01EY29799, R01EY031039]; Macular
   Degeneration gift fund; John A. and Florence Mattern Solomon endowed
   chair; BrightFocus Foundation [M2020114]; Owens Family Foundation; 
   [R01AG025493];  [R01EY032512]
FX We thank Deborah Kaback and Katie Lowther for ani-mal breeding and
   genotyping. Funding for R.M. was from NIH Grant R21EY028699, the Macular
   Degeneration gift fund, and the John A. and Florence Mattern Solomon
   endowed chair. S.I.P. was partly supported by Grant R01AG025493. J.A.
   was funded by NIH Grants R01EY028027, R01EY29799, and R01EY031039.
   B.D.G. is supported by Grants R01EY028027, R01EY031039, R01EY032512, the
   BrightFocus Foundation (Grant M2020114) , and the Owens Family
   Foundation.
CR Bonilha VL, 2013, EXP EYE RES, V111, P71, DOI 10.1016/j.exer.2013.03.017
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Chang B, 2018, INVEST OPHTH VIS SCI, V59, P5127, DOI 10.1167/iovs.18-25046
   Darrah E, 2018, CURR OPIN RHEUMATOL, V30, P72, DOI 10.1097/BOR.0000000000000452
   INAGAKI M, 1989, J BIOL CHEM, V264, P18119
   Lazarus RC, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00204
   Molnar T, 2016, J NEUROSCI, V36, P3184, DOI 10.1523/JNEUROSCI.4069-15.2016
   Sarthy V, 2007, EXP EYE RES, V84, P381, DOI 10.1016/j.exer.2005.12.014
   Tackenberg MA, 2009, MOL VIS, V15, P1886
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Terenzio M, 2017, NEURON, V96, P667, DOI 10.1016/j.neuron.2017.10.015
   Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072
   Witalison EE, 2015, CURR DRUG TARGETS, V16, P700, DOI 10.2174/1389450116666150202160954
   Wizeman JW, 2017, BIOCHEM BIOPH RES CO, V487, P134, DOI 10.1016/j.bbrc.2017.04.031
   Wizeman JW, 2016, MOL VIS, V22, P1137
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
NR 16
TC 1
Z9 1
U1 1
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 1
PY 2022
VL 119
IS 9
AR e2121875119
DI 10.1073/pnas.2121875119
PG 3
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZP8ZA
UT WOS:000766704900020
PM 35197297
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Fernandez-Albarral, JA
   de Hoz, R
   Ramirez, AI
   Lopez-Cuenca, I
   Salobrar-Garcia, E
   Pinazo-Duran, MD
   Ramirez, JM
   Salazar, JJ
AF Fernandez-Albarral, Jose A.
   de Hoz, Rosa
   Ramirez, Ana, I
   Lopez-Cuenca, Ines
   Salobrar-Garcia, Elena
   Pinazo-Duran, Maria D.
   Ramirez, Jose M.
   Salazar, Juan J.
TI Beneficial effects of saffron (Crocus sativus L.) in ocular pathologies,
   particularly neurodegenerative retinal diseases
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE AMD; crocetin; crocin; Crocus sativus L.; diabetic retinopathy;
   glaucoma; neuroprotection; ocular diseases; retinitis pigmentosa;
   saffron; safranal
ID EPITHELIAL-MESENCHYMAL TRANSITION; OXIDATIVE STRESS; MITOCHONDRIAL
   DYSFUNCTION; FLICKER SENSITIVITY; ANTIINFLAMMATORY PROPERTIES;
   PHARMACOKINETIC PROPERTIES; DIABETIC-RETINOPATHY; ACTIVE CONSTITUENTS;
   ALZHEIMERS-DISEASE; MICROGLIAL CELLS
AB Saffron (Crocus sativus L.) has been traditionally used in food preparation and as a medicinal plant. It currently has numerous therapeutic properties attributed to it, such as protection against ischemia, as well as anticonvulsant, antidepressant, anxiolytic, hypolipidemic, anti-atherogenic, anti-hypertensive, antidiabetic, and anti-cancer properties. In addition, saffron has remarkable beneficial properties, such as anti-apoptotic, anti-inflammatory and antioxidant activities, due to its main metabolites, among which crocin and crocetin stand out. Furthermore, increasing evidence underwrites the possible neuroprotective role of the main bioactive saffron constituents in neurodegenerative diseases, such as Parkinson's and Alzheimer's diseases, both in experimental models and in clinical studies in patients. Currently, saffron supplementation is being tested for ocular neurodegenerative pathologies, such as diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration and glaucoma, among others, and shows beneficial effects. The present article provides a comprehensive and up to date report of the investigations on the beneficial effects of saffron extracts on the main neurodegenerative ocular pathologies and other ocular diseases. This review showed that saffron extracts could be considered promising therapeutic agents to help in the treatment of ocular neurodegenerative diseases.
C1 [Fernandez-Albarral, Jose A.; de Hoz, Rosa; Ramirez, Ana, I; Lopez-Cuenca, Ines; Salobrar-Garcia, Elena; Ramirez, Jose M.; Salazar, Juan J.] Inst Invest Oftalmolog Ramon Castroviejo, Madrid, Spain.
   [de Hoz, Rosa; Ramirez, Ana, I; Ramirez, Jose M.; Salazar, Juan J.] Fac Opt & Optometria, Dept Inmunol Oftalmol & ORL, Madrid, Spain.
   [Pinazo-Duran, Maria D.] Univ Valencia, Unidad Invest Oftalmolog Santiago Grisolia, Valencia, Spain.
C3 University of Valencia
RP Ramirez, JM; Salazar, JJ (通讯作者)，Inst Invest Oftalmolog Ramon Castroviejo, Madrid, Spain.; Ramirez, JM; Salazar, JJ (通讯作者)，Fac Opt & Optometria, Dept Inmunol Oftalmol & ORL, Madrid, Spain.
EM ramirezs@med.ucm.es; jjsalaza@med.ucm.es
RI Salobrar-Garcia, Elena/I-6908-2019; Fernández-Albarral, Jose
   A./AAG-4357-2020; De Hoz, Rosa/ABF-9295-2020; Salazar, Juan
   J/L-6887-2014
OI Salobrar-Garcia, Elena/0000-0001-5939-5551; Fernández-Albarral, Jose
   A./0000-0003-0399-7996; De Hoz, Rosa/0000-0002-1581-087X; Salazar, Juan
   J/0000-0001-5480-5902
FU Ophthalmological Network OFTARED of the Institute of Health of Carlos
   III of the Spanish Ministry of Economy [RD16/0008/0005, RD16/0008/0022];
   PN I+D+i 2008-2011; ISCIII-Subdireccion General de Redes y Centros de
   Investigacion Cooperativa; European program FEDER; Spanish Ministry of
   Economy and Competitiveness [SAF-2014-53779-R]; UCM-Pharmactive Biotech;
   Spanish Ministry of Science, Innovation, and Universities [FPU17/01023];
   Complutense University of Madrid [CT42/18-CT43/18]
FX This work was supported by the Ophthalmological Network OFTARED
   (RD16/0008/0005, RD16/0008/0022, of the Institute of Health of Carlos
   III of the Spanish Ministry of Economy; by the PN I+D+i 2008-2011, by
   the ISCIII-Subdireccion General de Redes y Centros de Investigacion
   Cooperativa, by the European program FEDER. SAF-2014-53779-R: from the
   Spanish Ministry of Economy and Competitiveness and by Articulo 83
   118-2017 (UCM-Pharmactive Biotech). Jose A. Fernandez-Albarral is
   currently supported by a Predoctoral Fellowship (FPU17/01023) from the
   Spanish Ministry of Science, Innovation, and Universities. Ines
   Lopez-Cuenca is currently supported by a Predoctoral Fellowship
   (CT42/18-CT43/18) from the Complutense University of Madrid.
CR Ahmad AS, 2005, PHARMACOL BIOCHEM BE, V81, P805, DOI 10.1016/j.pbb.2005.06.007
   Akhondzadeh S, 2010, J CLIN PHARM THER, V35, P581, DOI 10.1111/j.1365-2710.2009.01133.x
   Almodovar P, 2018, INT J GASTRON FOOD S, V12, P1, DOI 10.1016/j.ijgfs.2018.03.001
   [Anonymous], 2007, WHO MONOGRAPHS SELEC
   Asai A, 2005, J AGR FOOD CHEM, V53, P7302, DOI 10.1021/jf0509355
   Assimopoulou AN, 2005, PHYTOTHER RES, V19, P997, DOI 10.1002/ptr.1749
   Baluchnejadmojarad T, 2019, METAB BRAIN DIS, P1
   Barber AJ, 2003, PROG NEURO-PSYCHOPH, V27, P283, DOI 10.1016/S0278-5846(03)00023-X
   BASKER D, 1983, ECON BOT, V37, P228, DOI 10.1007/BF02858789
   Bathaie SZ, 2014, BIOTECH HISTOCHEM, V89, P401, DOI 10.3109/10520295.2014.890741
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bisti S, 2014, VISUAL NEUROSCI, V31, P355, DOI 10.1017/S0952523814000108
   Bonyadi MHJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-399
   Boskabady MH, 2010, PHARMAZIE, V65, P300, DOI 10.1691/ph.2010.9760
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Brown GC, 2015, BRAIN RES, V1628, P288, DOI 10.1016/j.brainres.2015.08.031
   Bukhari SI, 2018, BIOMED PHARMACOTHER, V98, P733, DOI 10.1016/j.biopha.2017.12.090
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Campello L, 2013, MOL NEUROBIOL, V47, P790, DOI 10.1007/s12035-012-8391-5
   Chen L, 2015, OPHTHALMIC RES, V54, P157, DOI 10.1159/000439026
   Christodoulou E, 2019, J PHARM PHARMACOL, V71, P753, DOI 10.1111/jphp.13055
   Christodoulou E, 2015, J PHARM PHARMACOL, V67, P1634, DOI 10.1111/jphp.12456
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Corso L, 2016, PURINERG SIGNAL, V12, P161, DOI 10.1007/s11302-015-9490-3
   Dai QY, 2019, WEB CONFERENCE 2019: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW 2019), P329, DOI 10.1145/3308558.3313445
   de Hoz R, 2018, EXP EYE RES, V171, P12, DOI 10.1016/j.exer.2018.03.006
   de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733
   Deng LY, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22292
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Domingueti CP, 2016, J DIABETES COMPLICAT, V30, P738, DOI 10.1016/j.jdiacomp.2015.12.018
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Ernst PE, 2002, BJOG-INT J OBSTET GY, V109, P227
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Farahmand SK, 2013, BIOGERONTOLOGY, V14, P63, DOI 10.1007/s10522-012-9409-0
   Fernandez-Albarral JA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174110
   Fernandez-Sanchez L, 2015, MOLECULES, V20, P13875, DOI 10.3390/molecules200813875
   Fernandez-Sanchez L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043074
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Gazulla J, 2006, REV NEUROLOGIA, V42, P427, DOI 10.33588/rn.4207.2005223
   Geromichalos GD, 2012, J AGR FOOD CHEM, V60, P6131, DOI 10.1021/jf300589c
   Ghaffari S, 2019, BIOMED PHARMACOTHER, V109, P21, DOI 10.1016/j.biopha.2018.10.031
   Ghiso Jorge A, 2013, J Glaucoma, V22 Suppl 5, pS36, DOI 10.1097/IJG.0b013e3182934af6
   Guimares JS, 2009, REV NEUROLOGIA, V48, P304, DOI 10.33588/rn.4806.2008512
   Hashemi M, 2019, FOOD CHEM TOXICOL, V130, P44, DOI 10.1016/j.fct.2019.05.017
   Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805
   Hecht I, 2019, EUR J INTEGR MED, V25, P60, DOI 10.1016/j.eujim.2018.12.002
   Heitmar R, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030649
   Hosseini A, 2018, IRAN J BASIC MED SCI, V21, P1091, DOI 10.22038/IJBMS.2018.31243.7529
   Hosseini A, 2018, EUR J DRUG METAB PH, V43, P383, DOI 10.1007/s13318-017-0449-3
   Hosseinzadeh Hossein, 2002, BMC Pharmacol, V2, P7
   Ishizuka F, 2013, EUR J PHARMACOL, V703, P1, DOI [10.1016/j.ephar.2013.02.007, 10.1016/j.ejphar.2013.02.007]
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Bagur MJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23010030
   Karimi E, 2010, MOLECULES, V15, P6244, DOI 10.3390/molecules15096244
   Karkoula E, 2018, FITOTERAPIA, V129, P62, DOI 10.1016/j.fitote.2018.06.012
   Khalili M., 2010, Iranian Journal of Pathology, V5, P27
   Khalili Mohsen, 2010, Iran Biomed J, V14, P59
   Khazdair MR, 2015, AVICENNA J PHYTOMEDI, V5, P376
   Kianbakht S., 2011, Journal of Medicinal Plants, V10, P82
   Korani S, 2019, BIOFACTORS, V45, P835, DOI 10.1002/biof.1557
   Lascaratos G, 2012, MITOCHONDRION, V12, P202, DOI 10.1016/j.mito.2011.11.004
   Lashay Alireza, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P32
   Lautenschlager M, 2015, PHYTOMEDICINE, V22, P36, DOI 10.1016/j.phymed.2014.10.009
   Lee S, 2011, EXP EYE RES, V93, P204, DOI 10.1016/j.exer.2010.07.015
   Lv BC, 2016, NEUROCHEM RES, V41, P1949, DOI 10.1007/s11064-016-1905-1
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Maccarone R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166827
   Marangoni D, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-228
   Mashmoul M, 2013, ANTIOXIDANTS-BASEL, V2, P293, DOI 10.3390/antiox2040293
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Milajerdi A., 2014, J CLIN EXCELL, V3, P108
   Moallem SA, 2014, TOXICOL IND HEALTH, V30, P141, DOI 10.1177/0748233712452609
   Modaghegh MH, 2008, PHYTOMEDICINE, V15, P1032, DOI 10.1016/j.phymed.2008.06.003
   Mori K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081179
   Mori K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36576-w
   Moshiri M, 2015, DRUG RES, V65, P287, DOI 10.1055/s-0034-1375681
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   Natoli R, 2010, MOL VIS, V16, P1801
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Papandreou MA, 2006, J AGR FOOD CHEM, V54, P8762, DOI 10.1021/jf061932a
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Piccardi M, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429124
   Poma Anna, 2012, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V11, P37
   Purushothuman S, 2013, J PARKINSON DIS, V3, P77, DOI 10.3233/JPD-130173
   Qi Y, 2013, EXP EYE RES, V107, P44, DOI 10.1016/j.exer.2012.11.011
   Rameshrad M, 2018, EXPERT OPIN THER PAT, V28, P147, DOI 10.1080/13543776.2017.1355909
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Rios JL, 1996, PHYTOTHER RES, V10, P189, DOI 10.1002/(SICI)1099-1573(199605)10:3&lt;189::AID-PTR754&gt;3.0.CO;2-C
   Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133
   RYAN SJ, 1985, AM J OPHTHALMOL, V100, P188, DOI 10.1016/S0002-9394(14)75004-4
   Schmidt M, 2007, WIEN MED WOCHENSCHR, V157, P315, DOI 10.1007/s10354-007-0428-4
   Sepahi S, 2018, AM J OPHTHALMOL, V190, P89, DOI 10.1016/j.ajo.2018.03.007
   Serrano-Diaz J, 2012, J FOOD SCI, V77, pC1162, DOI 10.1111/j.1750-3841.2012.02926.x
   Shahidani S, 2019, METAB BRAIN DIS, V34, P459, DOI 10.1007/s11011-018-0379-z
   Soeda S, 2001, LIFE SCI, V69, P2887, DOI 10.1016/S0024-3205(01)01357-1
   Srivastava R, 2010, Pharmacogn Rev, V4, P200, DOI 10.4103/0973-7847.70919
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Tamegart L, 2019, ACTA HISTOCHEM, V121, P171, DOI 10.1016/j.acthis.2018.12.003
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823
   Verkhratsky A, 2014, BIOCHEM SOC T, V42, P1291, DOI 10.1042/BST20140107
   Vessey KA, 2012, ADV EXP MED BIOL, V723, P813, DOI 10.1007/978-1-4614-0631-0_104
   Wang HF, 2019, BIOMED PHARMACOTHER, V109, P1211, DOI 10.1016/j.biopha.2018.10.193
   Wang HF, 2017, EUR J PHARMACOL, V815, P391, DOI 10.1016/j.ejphar.2017.09.041
   Wang K, 2015, NEUROSCI LETT, V591, P53, DOI 10.1016/j.neulet.2015.02.016
   Wang K, 2014, GLIA, V62, P1943, DOI 10.1002/glia.22715
   Xi L, 2007, PHYTOMEDICINE, V14, P633, DOI 10.1016/j.phymed.2006.11.028
   Xuan B, 1999, J OCUL PHARMACOL TH, V15, P143, DOI 10.1089/jop.1999.15.143
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yang XG, 2017, J MOL NEUROSCI, V61, P581, DOI 10.1007/s12031-017-0899-8
   Yaribeygi H, 2019, J CELL PHYSIOL, V234, P8610, DOI 10.1002/jcp.27843
   Yaribeygi H, 2019, J CELL PHYSIOL, V234, P1300, DOI 10.1002/jcp.27164
   Zeinali M, 2019, IRAN J BASIC MED SCI, V22, P334, DOI 10.22038/ijbms.2019.34365.8158
   Zhang X, 2017, RESTOR NEUROL NEUROS, V35, P65, DOI 10.3233/RNN-160696
   Zhang Y, 2017, J CHROMATOGR B, V1044, P1, DOI 10.1016/j.jchromb.2016.12.003
NR 116
TC 25
Z9 25
U1 2
U2 77
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD AUG
PY 2020
VL 15
IS 8
BP 1408
EP 1416
DI 10.4103/1673-5374.274325
PG 9
WC Cell Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Neurosciences & Neurology
GA KJ2NR
UT WOS:000511895300005
PM 31997799
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Lin, WC
   Chen, JS
   Chiang, MF
   Hribar, MR
AF Lin, Wei-Chun
   Chen, Jimmy S.
   Chiang, Michael F.
   Hribar, Michelle R.
TI Applications of Artificial Intelligence to Electronic Health Record Data
   in Ophthalmology
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE artificial intelligence; electronic health record; machine learning;
   ophthalmology
ID BIG DATA; SUPPORT
AB Widespread adoption of electronic health records (EHRs) has resulted in the collection of massive amounts of clinical data. In ophthalmology in particular, the volume range of data captured in EHR systems has been growing rapidly. Yet making effective secondary use of this EHR data for improving patient care and facilitating clinical decision-making has remained challenging due to the complexity and heterogeneity of these data. Artificial intelligence (AI) techniques present a promising way to analyze these multimodal data sets. While AI techniques have been extensively applied to imaging data, there are a limited number of studies employing AI techniques with clinical data from the EHR. The objective of this review is to provide an overview of different AI methods applied to EHR data in the field of ophthalmology. This literature review highlights that the secondary use of EHR data has focused on glaucoma, diabetic retinopathy, age-related macular degeneration, and cataracts with the use of AI techniques. These techniques have been used to improve ocular disease diagnosis, risk assessment, and progression prediction. Techniques such as supervised machine learning, deep learning, and natural language processing were most commonly used in the articles reviewed.
C1 [Lin, Wei-Chun; Chiang, Michael F.; Hribar, Michelle R.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Mail Code BICC,3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.
   [Chen, Jimmy S.] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA.
   [Chiang, Michael F.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University
RP Hribar, MR (通讯作者)，Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Mail Code BICC,3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM hribarm@ohsu.edu
FU National Institutes of Health, Bethesda, MD [P30EY10572, R00LM012238,
   T15LM007088]; Research to Prevent Blindness, New York, NY; Research to
   Prevent Blindness Medical Student Fellowship
FX Supported by grants P30EY10572 (MFC), R00LM012238 (MRH), and T15LM007088
   (WL) from the National Institutes of Health, Bethesda, MD; unrestricted
   departmental funding from Research to Prevent Blindness, New York, NY
   (MFC); and Research to Prevent Blindness Medical Student Fellowship
   (JSC). The funding organizations had no role in the design or conduct of
   this research.
CR Alghamdi HF, 2016, SAUDI J OPHTHALMOL, V30, P189, DOI 10.1016/j.sjopt.2016.06.001
   [Anonymous], 2012, P 2 ACM SIGHIT INT H, DOI DOI 10.1145/2110363.2110408
   Anzai Y., 2012, PATTERN RECOGN
   Apostolova Emilia, 2017, AMIA Annu Symp Proc, V2017, P403
   Ashfaq HA, 2019, JAMA OPHTHALMOL, V137, P929, DOI 10.1001/jamaophthalmol.2019.1444
   Baxter SL, 2019, AM J OPHTHALMOL, V208, P30, DOI 10.1016/j.ajo.2019.07.005
   Berdahl CT, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.11390
   Botsis Taxiarchis, 2010, Summit Transl Bioinform, V2010, P1
   BREIMAN L, 2001, MACH LEARN, V0045
   BUCKLAND M, 1994, J AM SOC INFORM SCI, V45, P12, DOI 10.1002/(SICI)1097-4571(199401)45:1<12::AID-ASI2>3.0.CO;2-L
   Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555
   Caixinha M, 2017, CURR EYE RES, V42, P1, DOI 10.1080/02713683.2016.1175019
   Cano Isaac, 2017, Current Opinion in Systems Biology, V3, P36, DOI 10.1016/j.coisb.2017.04.012
   Chaganti S, 2017, PROC SPIE, V10138, DOI 10.1117/12.2254618
   Charles D., 2013, ONC DATA BRIEF, V9, P1
   Chawla NV., 2004, SIGKDD EXPLOR, V6, P1, DOI [DOI 10.1145/1007730.1007733, 10.1145/1007730.1007733]
   Cheng Y., 2016, P 2016 SIAM INT C DA, P432, DOI [10.1137/1.9781611974348.49, DOI 10.1137/1.9781611974348.49]
   Choi E, 2017, J AM MED INFORM ASSN, V24, P361, DOI 10.1093/jamia/ocw112
   Clark A, 2016, SURV OPHTHALMOL, V61, P443, DOI 10.1016/j.survophthal.2016.01.003
   Coleman AL, 2015, AM J OPHTHALMOL, V160, P1091, DOI 10.1016/j.ajo.2015.09.028
   Coorevits P, 2013, J INTERN MED, V274, P547, DOI 10.1111/joim.12119
   Cowie MR, 2017, CLIN RES CARDIOL, V106, P1, DOI 10.1007/s00392-016-1025-6
   Fraccaro P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10
   Friedman JH, 2002, COMPUT STAT DATA AN, V38, P367, DOI 10.1016/S0167-9473(01)00065-2
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gaskin GL, 2016, EUR J OPHTHALMOL, V26, P328, DOI 10.5301/ejo.5000706
   Goodfellow I, 2016, ADAPT COMPUT MACH LE, P1
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Hersh W.R., 2007, AM J MANAG CARE, V81, P126, DOI DOI 10.1038/sj.clpt.6100029
   Hulse J.V., 2007, P 24 INT C MACH LEAR, P935
   Jain AK, 1996, COMPUTER, V29, P31, DOI 10.1109/2.485891
   Jiang M, 2011, J AM MED INFORM ASSN, V18, P601, DOI 10.1136/amiajnl-2011-000163
   Khennou F, 2018, PROCEDIA COMPUT SCI, V127, P60, DOI 10.1016/j.procs.2018.01.098
   Kleinbaum DG, 2002, LOGISTIC REGRESSION, DOI New York
   Kononenko I, 2001, ARTIF INTELL MED, V23, P89, DOI 10.1016/S0933-3657(01)00077-X
   Kourentzes N, 2014, EXPERT SYST APPL, V41, P4235, DOI 10.1016/j.eswa.2013.12.011
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kukreja SL., 2006, P IFAC S SYS ID, V39, P814, DOI [10.3182/20060329-3-AU-2901.00128, DOI 10.3182/20060329-3-AU-2901.00128]
   Kuperman GJ, 2007, J AM MED INFORM ASSN, V14, P29, DOI 10.1197/jamia.M2170
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lewis R. J., 2000, ANN M SOC AC EM MED, P1
   Lin HT, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002674
   Meystre S M, 2017, Yearb Med Inform, V26, P38, DOI 10.15265/IY-2017-007
   Motwani M, 2017, EUR HEART J, V38, P500, DOI 10.1093/eurheartj/ehw188
   Nadkarni PM, 2011, J AM MED INFORM ASSN, V18, P544, DOI 10.1136/amiajnl-2011-000464
   Oh E, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-106
   Parke DW, 2017, OPHTHALMOLOGY, V124, P1572, DOI 10.1016/j.ophtha.2017.08.035
   Peissig PL, 2012, J AM MED INFORM ASSN, V19, P225, DOI 10.1136/amiajnl-2011-000456
   Persell SD, 2009, MED CARE, V47, P418, DOI 10.1097/MLR.0b013e31818dce21
   Ramesh AN, 2004, ANN ROY COLL SURG, V86, P334, DOI 10.1308/147870804290
   Rohm M, 2018, OPHTHALMOLOGY, V125, P1028, DOI 10.1016/j.ophtha.2017.12.034
   Safran C, 2007, J AM MED INFORM ASSN, V14, P1, DOI 10.1197/jamia.M2273
   Saleh E, 2018, ARTIF INTELL MED, V85, P50, DOI 10.1016/j.artmed.2017.09.006
   Schapire RE., 2013, EMPIRICAL INFERENCE, P37, DOI DOI 10.1007/978-3-642-41136-6_5
   Skevofilakas M, 2010, IEEE ENG MED BIO, P6713, DOI 10.1109/IEMBS.2010.5626245
   Sramka M, 2019, PEERJ, V7, DOI 10.7717/peerj.7202
   Svozil D, 1997, CHEMOMETR INTELL LAB, V39, P43, DOI 10.1016/S0169-7439(97)00061-0
   Wang W, 2016, INVEST OPHTH VIS SCI, V57, P5872, DOI 10.1167/iovs.16-19894
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   World Health Organization, 2010, GLOB DAT VIS IMP 201
NR 60
TC 27
Z9 27
U1 3
U2 20
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2020
VL 9
IS 2
AR 13
DI 10.1167/tvst.9.2.13
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA KR6WJ
UT WOS:000517757300009
PM 32704419
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Supsup, MMEE
   Shahin, M
AF Supsup, Mervat M. El-Eshmawy
   Shahin, Maha
TI Thyroid and Eye: Where They Meet in Clinical Practice
SO ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS
LA English
DT Review
DE Thyroid disorders; Graves' ophthalmopathy; diabetic retinopathy;
   age-related macular degeneration; ocular metastasis; amiodarone
ID HORMONE RECEPTOR-BETA; CONE OPSIN EXPRESSION; SUBCLINICAL
   HYPOTHYROIDISM; MACULAR DEGENERATION; INSULIN-RESISTANCE;
   DIABETIC-RETINOPATHY; ORBITAL METASTASIS; GRAVES OPHTHALMOPATHY;
   AMIODARONE KERATOPATHY; STIMULATING HORMONE
AB Objective: Thyroid Hormones (TH) are essential for normal growth, development and continued optimal function of most of the body organs including the eye. TH signaling plays a central role in the regulation of retinal development and maturation. Deficiency in TH during fetal and early postnatal development impairs growth of the eye and proliferation of all retinal cell types. The present article reviews the most important topics of the different derangements in thyroid function and structure and its relation with eye diseases.
   Methods: A literature search strategy was conducted for all English-language literature.
   Results: From a clinical practice viewpoint, it should be mentioned that both hypothyroidism and hyperthyroidism are accompanied by ocular diseases i.e. thyroid-associated ophthalmopathy, diabetic retinopathy and age-related macular degeneration. Although the orbit and globe are not common sites nor: for metastatic thyroid cancers, orbital metastasis may be the primary clinical manifestation of thyroid carcinoma. Finally, some medications as amiodarone may be accompanied by both thyroid dysfunction and adverse ocular events.
   Conclusion: Thyroid disorders and eye diseases are interrelated through several mechanisms thus, awareness of this relation has a great impact on early diagnosis and treatment.
C1 [Supsup, Mervat M. El-Eshmawy] Mansoura Univ, Fac Med, Mansoura Specialized Med Hosp, Internal Med Dept, Mansoura, Egypt.
   [Shahin, Maha] Mansoura Univ, Fac Med, Mansoura Ophthalm Ctr, Ophthalmol Dept, Mansoura, Egypt.
C3 Egyptian Knowledge Bank (EKB); Mansoura University; Egyptian Knowledge
   Bank (EKB); General Organization of Teaching Hospitals & Institutes
   (GOTHI); Research Institute of Ophthalmology (RIO); Mansoura University
RP Supsup, MMEE (通讯作者)，Mansoura Univ, Fac Med, Dept Internal Med, POB 35516, Mansoura, Egypt.
EM mervat2040@yahoo.com
RI El-Eshmawy, Mervat M./AAZ-7619-2020
OI El-Eshmawy, Mervat M./0000-0002-6019-2054
CR Acharya SH, 2008, CLIN ENDOCRINOL, V69, P943, DOI 10.1111/j.1365-2265.2008.03279.x
   Ahmed S, 2011, CLIN ENDOCRINOL, V75, P388, DOI 10.1111/j.1365-2265.2011.04087.x
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andersen SL, 2016, J CLIN ENDOCR METAB, V101, P1606, DOI 10.1210/jc.2015-4274
   Andersen SL, 2014, EUR J ENDOCRINOL, V171, pC1, DOI 10.1530/EJE-14-0524
   Andersen SL, 2013, J CLIN ENDOCR METAB, V98, P4373, DOI 10.1210/jc.2013-2831
   Aoki Y, 2007, THYROID, V17, P1211, DOI 10.1089/thy.2006.0235
   Arat YO, 2007, SURV OPHTHALMOL, V52, P523, DOI 10.1016/j.survophthal.2007.06.006
   Avram AM, 2004, J CLIN ENDOCR METAB, V89, P5303, DOI 10.1210/jc.2004-0757
   Azizi F, 2006, EXPERT OPIN DRUG SAF, V5, P107, DOI 10.1517/14740338.5.1.107
   Bahn RS, 2010, NEW ENGL J MED, V362, P726, DOI 10.1056/NEJMra0905750
   Bartley GB, 1996, OPHTHALMOLOGY, V103, P958, DOI 10.1016/S0161-6420(96)30579-4
   Basaria S, 2005, AM J MED, V118, P706, DOI 10.1016/j.amjmed.2004.11.028
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benjamens S, 2017, EUR J ENDOCRINOL, V177, P9, DOI 10.1530/EJE-17-0018
   BERNSTEINLIPSCHITZ L, 1990, GRAEF ARCH CLIN EXP, V228, P112
   BETHARIA S M, 1985, Indian Journal of Ophthalmology, V33, P191
   Bliddal S, 2011, NAT REV ENDOCRINOL, V7, P396, DOI 10.1038/nrendo.2011.34
   Bogazzi F, 2012, J ENDOCRINOL INVEST, V35, P340, DOI 10.3275/8298
   Bogazzi F, 2010, J CLIN ENDOCR METAB, V95, P2529, DOI 10.1210/jc.2010-0180
   Boughattas S, 2005, THYROID, V15, P1311, DOI 10.1089/thy.2005.15.1311
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Brent GA, 2012, J CLIN INVEST, V122, P3035, DOI 10.1172/JCI60047
   Bromfield S, 2012, CURR EYE RES, V37, P549, DOI 10.3109/02713683.2011.647223
   Bucerius J, 2008, J NATL MED ASSOC, V100, P104, DOI 10.1016/S0027-9684(15)31183-4
   BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747
   Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526
   Caraccio N, 2002, J CLIN ENDOCR METAB, V87, P1533, DOI 10.1210/jc.87.4.1533
   Chadarevian R, 1998, THROMB HAEMOSTASIS, V79, P99
   Chaker L, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0329-0
   Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G
   Chen HS, 2007, DIABETIC MED, V24, P1336, DOI 10.1111/j.1464-5491.2007.02270.x
   Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cikim AS, 2004, THYROID, V14, P605, DOI 10.1089/1050725041692891
   Clementi M, 2010, J CLIN ENDOCR METAB, V95, pE337, DOI 10.1210/jc.2010-0652
   Cooper DS, 2013, LANCET DIABETES ENDO, V1, P238, DOI 10.1016/S2213-8587(13)70086-X
   Corsello SM, 2013, J CLIN ENDOCR METAB, V98, P1361, DOI 10.1210/jc.2012-4075
   D'Avanzo A, 2004, CANCER-AM CANCER SOC, V100, P1123, DOI 10.1002/cncr.20081
   Dadu R, 2016, CANCER J, V22, P121, DOI 10.1097/PPO.0000000000000186
   DAMICO DJ, 1981, ARCH OPHTHALMOL-CHIC, V99, P257, DOI 10.1001/archopht.1981.03930010259007
   Daumerie C, 2000, THYROID, V10, P189, DOI 10.1089/thy.2000.10.189
   Davies T.F., 2000, THYROID, P518
   DEESCOBAR GM, 2004, EUR J ENDOCRINOL S3, V151, DOI DOI 10.1530/EJE.0.151U025]
   Dentice M, 2011, J ENDOCRINOL, V209, P273, DOI 10.1530/JOE-11-0002
   Devdhar M, 2007, ENDOCRIN METAB CLIN, V36, P595, DOI 10.1016/j.ecl.2007.04.008
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Douglas RS, 2011, CURR OPIN OPHTHALMOL, V22, P385, DOI 10.1097/ICU.0b013e3283499446
   Dummer R, 2012, ANN ONCOL, V23, P86, DOI 10.1093/annonc/mds229
   Duncan KG, 1999, OPHTHALMIC RES, V31, P399, DOI 10.1159/000055564
   FLACH AJ, 1983, ARCH OPHTHALMOL-CHIC, V101, P1554
   Flamant F, 2006, PHARMACOL REV, V58, P705, DOI 10.1124/pr.58.4.3
   Foulds N, 2005, AM J MED GENET A, V132A, P130, DOI 10.1002/ajmg.a.30418
   Garber JR, 2012, ENDOCR PRACT, V18, P989, DOI 10.4158/EP12280.GL
   Madariaga AG, 2014, J CLIN ENDOCR METAB, V99, P923, DOI 10.1210/jc.2013-2409
   GITTINGER JW, 1987, ARCH OPHTHALMOL-CHIC, V105, P349
   Glaschke A, 2011, J NEUROSCI, V31, P4844, DOI 10.1523/JNEUROSCI.6181-10.2011
   GOLDBERG RA, 1990, SURV OPHTHALMOL, V35, P1, DOI 10.1016/0039-6257(90)90045-W
   GOLDBERG RA, 1990, OPHTHALMOLOGY, V97, P620
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Grzesiuk Wieslaw, 2008, Pol Arch Med Wewn, V118, P318
   Hadjadj S, 2004, DIABETES CARE, V27, P2661, DOI 10.2337/diacare.27.11.2661
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hiroi Y, 2006, P NATL ACAD SCI USA, V103, P14104, DOI 10.1073/pnas.0601600103
   Hollander David A, 2004, Curr Opin Ophthalmol, V15, P541, DOI 10.1097/01.icu.0000143688.45232.15
   INGRAM DV, 1982, BRIT J OPHTHALMOL, V66, P676, DOI 10.1136/bjo.66.10.676
   ISHIKAWA T, 1989, MOL PHARMACOL, V35, P760
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jones DD, 2010, AM J MED, V123, P502, DOI 10.1016/j.amjmed.2009.12.023
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kalmann R, 2002, AM J OPHTHALMOL, V133, P727, DOI 10.1016/S0002-9394(02)01390-9
   KAPLAN LJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P601, DOI 10.1001/archopht.1982.01030030603011
   KENNERDELL JS, 1979, ARCH OPHTHALMOL-CHIC, V97, P1315, DOI 10.1001/archopht.1979.01020020057013
   Kim BY, 2011, ENDOCR J, V58, P1065, DOI 10.1507/endocrj.EJ11-0199
   Kim B, 2008, THYROID, V18, P141, DOI 10.1089/thy.2007.0266
   Kirmizibekmez H, 2014, J CLIN RES PEDIATR E, V6, P262, DOI [10.4274/jcrpe.1450, 10.4274/Jcrpe.1450]
   Klein I, 2007, CIRCULATION, V116, P1725, DOI 10.1161/CIRCULATIONAHA.106.678326
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KOLTRINGER P, 1988, J ENDOCRINOL INVEST, V11, P267
   Kurioka S, 2000, ENDOCR J, V47, P77, DOI 10.1507/endocrj.47.77
   La Vignera S, 2012, J ENDOCRINOL INVEST, V35, P96, DOI 10.3275/8190
   Laurberg P, 2014, EUR J ENDOCRINOL, V171, pR13, DOI 10.1530/EJE-14-0135
   Lee TC, 2006, INVEST OPHTH VIS SCI, V47, P5590, DOI 10.1167/iovs.06-0063
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SY, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050902
   Ma HW, 2017, FASEB J, V31, P3425, DOI 10.1096/fj.201601166RR
   Ma HW, 2014, P NATL ACAD SCI USA, V111, P3602, DOI 10.1073/pnas.1317041111
   Makhija C, 2015, THYROID, V25, P860, DOI 10.1089/thy.2014.0511
   Malhotra G, 2010, CLIN NUCL MED, V35, P362, DOI 10.1097/RLU.0b013e3181d62752
   Mandel SR, 2001, J CLIN ENDOCR METAB, V86, P2354, DOI 10.1210/jc.86.6.2354
   MANO T, 1995, J ENDOCRINOL, V145, P131, DOI 10.1677/joe.0.1450131
   Mantyjarvi M, 1998, SURV OPHTHALMOL, V42, P360, DOI 10.1016/S0039-6257(97)00118-5
   Maratou E, 2009, EUR J ENDOCRINOL, V160, P785, DOI 10.1530/EJE-08-0797
   Marcocci C, 2012, BEST PRACT RES CL EN, V26, P325, DOI 10.1016/j.beem.2011.11.005
   Martino E, 2001, ENDOCR REV, V22, P240, DOI 10.1210/er.22.2.240
   MARTINO E, 1994, ARCH INTERN MED, V154, P2722, DOI 10.1001/archinte.1994.00420230115013
   MASAKI H, 1992, J CLIN ENDOCR METAB, V75, P721, DOI 10.1210/jc.75.3.721
   McHenry CR, 2011, ONCOLOGIST, V16, P585, DOI 10.1634/theoncologist.2010-0405
   Momotani N, 1997, J CLIN ENDOCR METAB, V82, P3633, DOI 10.1210/jc.82.11.3633
   NEWELL FW, 1977, KLIN MONATSBL AUGENH, V171, P731
   Ng L, 2010, J NEUROSCI, V30, P3347, DOI 10.1523/JNEUROSCI.5267-09.2010
   Ng L, 2009, NEUROREPORT, V20, P627, DOI 10.1097/WNR.0b013e32832a2c63
   Nguyen DH, 2013, DISCOV MED, V15, P343
   Ramis JN, 2012, DIABETES RES CLIN PR, V97, pE45, DOI 10.1016/j.diabres.2012.05.015
   Pagsisihan Daveric Ablis, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2014-208870
   Park JW, 2013, AM J CANCER RES, V3, P302
   Parvanova A, 2004, J CLIN ENDOCR METAB, V89, P4371, DOI 10.1210/jc.2003-032076
   Peichl L, 2005, ANAT REC PART A, V287A, P1001, DOI 10.1002/ar.a.20262
   PERROS P, 1993, CLIN ENDOCRINOL, V38, P367, DOI 10.1111/j.1365-2265.1993.tb00516.x
   PERROS P, 1995, DIABETIC MED, V12, P622, DOI 10.1111/j.1464-5491.1995.tb00553.x
   Popescu T., 2009, J INTERN MED, V47, P235
   PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479
   Qi Q, 2017, MED SCI MONITOR, V23, P2715, DOI 10.12659/MSM.902006
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Rocha FD, 2008, ARQ BRAS ENDOCRINOL, V52, P1497, DOI 10.1590/S0004-27302008000900014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawant O, 2015, INVEST OPHTH VIS SCI, V56, P8248, DOI 10.1167/iovs.15-17743
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sevilla-Romero E, 2002, OPHTHALMIC RES, V34, P181, DOI 10.1159/000063885
   Shaha AR, 1997, AM J SURG, V174, P474
   Shyla PR, 2007, INDIAN J OTOLARYNGOL, V59, P174, DOI 10.1007/s12070-007-0052-z
   Singh Usha, 2003, Indian J Ophthalmol, V51, P81
   SKALKA HW, 1980, ARCH OPHTHALMOL-CHIC, V98, P1773
   SLAMOVITS TL, 1979, BRIT J OPHTHALMOL, V63, P169, DOI 10.1136/bjo.63.3.169
   SMITH TJ, 1989, ENDOCR REV, V10, P366, DOI 10.1210/edrv-10-3-366
   Spitzweg C, 1997, EUR J ENDOCRINOL, V136, P599, DOI 10.1530/eje.0.1360599
   Stadlmayr W, 1997, THYROID, V7, P3, DOI 10.1089/thy.1997.7.3
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   TIJL J, 1992, GRAEF ARCH CLIN EXP, V230, P527, DOI 10.1007/BF00181773
   Tran K, 2011, ASIA-PAC J CLIN ONCO, V7, P11, DOI 10.1111/j.1743-7563.2010.01332.x
   Tripathi RC, 1999, DRUG AGING, V15, P439, DOI 10.2165/00002512-199915060-00004
   Tsai CC, 2007, ARCH OPHTHALMOL-CHIC, V125, P1652, DOI 10.1001/archopht.125.12.1652
   Tsui S, 2008, J IMMUNOL, V181, P4397, DOI 10.4049/jimmunol.181.6.4397
   Ucakhan Omur O, 2005, Eye Contact Lens, V31, P148
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Uzunlulu M, 2007, ENDOCR J, V54, P71, DOI 10.1507/endocrj.K06-124
   Valyasevi RW, 1999, J CLIN ENDOCR METAB, V84, P2557, DOI 10.1210/jc.84.7.2557
   VANGHELUWE O, 1994, J FR OPHTALMOL, V17, P331
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Wagner MS, 2008, J ENDOCRINOL, V199, P351, DOI 10.1677/JOE-08-0218
   Werner S.C., 1996, THYROID FUNDAMENTAL
   Wiersinga WM, 2010, HEART FAIL REV, V15, P121, DOI 10.1007/s10741-008-9131-9
   WIERSINGA WM, 1986, POSTGRAD MED J, V62, P909, DOI 10.1136/pgmj.62.732.909
   Wu JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep12212
   Yagishita A, 2013, CIRC J, V77, P2898, DOI 10.1253/circj.CJ-13-0220
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
   Yang F, 2016, FASEB J, V30, P4313, DOI 10.1096/fj.201600715R
   Yang GR, 2010, TOHOKU J EXP MED, V222, P303, DOI 10.1620/tjem.222.303
   Yang JK, 2010, DIABETES CARE, V33, P1018, DOI 10.2337/dc09-1784
   Yudkin JS, 1999, DIABETES CARE, V22, pC25
   Zambrano A, 2014, J CELL BIOL, V204, P129, DOI 10.1083/jcb.201305084
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zhao ZG, 2012, J INT MED RES, V40, P2041, DOI 10.1177/030006051204000601
NR 155
TC 1
Z9 1
U1 1
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5303
EI 2212-3873
J9 ENDOCR METAB IMMUNE
JI Endocr. Metab. Immune Disord.-Drug Targets
PY 2020
VL 20
IS 1
BP 39
EP 49
DI 10.2174/1871530319666190618120107
PG 11
WC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Immunology; Pharmacology & Pharmacy
GA KA7UO
UT WOS:000506004000005
PM 31237221
DA 2022-11-30
ER

PT J
AU Ronquillo, CC
   Sauer, L
   Morgan, D
   Heckzo, JB
   Creel, DJ
   Mamalis, N
   Deangelis, MM
   Hagemann, GS
   Bernstein, PS
AF Ronquillo, Cecinio C.
   Sauer, Lydia
   Morgan, Denise
   Heckzo, Josh B.
   Creel, Donnell J.
   Mamalis, Nick
   Deangelis, Margaret M.
   Hagemann, Gregory S.
   Bernstein, Paul S.
TI ABSENCE OF MACULAR DEGENERATION IN A PATIENT WITH ACERULOPLASMINEMIA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE aceruloplasminemia; age-related macular degeneration; FLIO; iron
AB Purpose: To describe the clinical, histological, electrophysiologic, and multimodal imaging findings in a 76-year-old patient with aceruloplasminemia with low genetic risk of age-related macular degeneration (AMD).
   Methods: Clinical examination as well as multimodal imaging including fundus photography, optical coherence tomography, fluorescence lifetime imaging ophthalmos-copy imaging, and full-field and multifocal electroretinography were performed on one patient with aceruloplasminemia. The ceruloplasmin gene was sequenced to confirm a known mutation. Single nucleotide polymorphism genotyping of known AMD risk alleles was performed to characterize the AMD risk profile of the patient. Prussian blue staining in postmortem retinal sections was used to confirm iron accumulation.
   Results: A homozygous mutation in the ceruloplasmin gene was detected at position c. 395-1 G>A. The clinical assessment and imaging of the patient did not show any findings of AMD. Fundus examination revealed yellow flecks in the midperiphery with notable absence of macular drusen or geographic atrophy. Genotyping for AMD risk alleles revealed a low AMD risk profile. Histopathologic analysis confirms iron accumulation in retinal pigment epithelial cells.
   Conclusion: In contrast to a previous report, these findings suggest that neither aceruloplasminemia nor iron accumulation was sufficient to cause AMD in this patient.
C1 [Ronquillo, Cecinio C.; Sauer, Lydia; Morgan, Denise; Heckzo, Josh B.; Creel, Donnell J.; Mamalis, Nick; Deangelis, Margaret M.; Hagemann, Gregory S.; Bernstein, Paul S.] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol, Salt Lake City, UT USA.
   [Hagemann, Gregory S.] Univ Utah, John A Moran Eye Ctr, Steele Ctr Translat Med, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, John A Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
FU Research to Prevent Blindness; NIH core grant [EY-14800]; Achievement
   Rewards for College Scientists (ARCS) Scholar grant
FX This study was funded by an unrestricted grant from Research to Prevent
   Blindness and an NIH core grant (EY-14800). C. C. Ronquillo is a
   recipient of an Achievement Rewards for College Scientists (ARCS)
   Scholar grant. Heidelberg Engineering provided the prototype FLIO
   instrument at no cost to the University of Utah.
CR Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Gensure RH, 2018, INVEST OPHTH VIS SCI, V59
   Kono S, 2006, BIOL RES, V39, P15, DOI 10.4067/S0716-97602006000100003
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267
NR 5
TC 1
Z9 1
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2019
VL 39
IS 9
BP 1824
EP 1828
DI 10.1097/IAE.0000000000002628
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EB
UT WOS:000507473000025
PM 31356495
DA 2022-11-30
ER

PT J
AU Liu, XM
   Xu, K
   Zhou, P
   Chi, JN
AF Liu Xiaoming
   Xu Ke
   Zhou Peng
   Chi Jiannan
TI Edge detection of retinal OCT image based on complex shearlet transform
SO IET IMAGE PROCESSING
LA English
DT Article
DE optical tomography; biomedical optical imaging; image denoising; wavelet
   transforms; edge detection; image resolution; eye; vision defects;
   medical image processing; transforms; diseases; inner plexiform layer;
   ganglion cell layer; layered structures; normal retinal macula area; OCT
   images; pulse type edge; step type edge; merit value; complex
   shearlet-based method; wavelet methods; phase congruence method;
   multiscale shearlet; optimal sparse approximation singular curves; OCT
   detection method; layer structure blur; low contrast; optical coherence
   tomography images; retinal OCT image; edge detection
ID LAYER SEGMENTATION; COHERENCE
AB Aiming at the problem that optical coherence tomography (OCT) images with low contrast and layer structure blur are difficult to be automatically layered, a new OCT detection method based on complex shearlet transform is proposed. The method utilises nearly optimal sparse approximation singular curves of multi-scale shearlet transform, and the contrast invariance of the phase congruence method. Compared with the Canny edge detector and wavelet methods, the complex shearlet-based method achieved the highest Pratt figure of merit (PFOM) value. The PFOM value of a step type edge is 0.92, and that of a pulse type edge is 0.98. Three types of OCT images were tested, including normal retinal macula area, dry age-related macular degeneration, and Stargardt disease. The experimental results show that the complex shearlet-based method can detect more layered structures of OCT images, especially the boundary between the ganglion cell layer and the inner plexiform layer that is difficult to detect, and it can detect various types of OCT images. The complex shearlet-based transform method provides an effective and general way to measure retinal OCT images.
C1 [Liu Xiaoming; Zhou Peng] Univ Sci & Technol Beijing, Inst Engn Technol, Beijing 100083, Peoples R China.
   [Xu Ke] Univ Sci & Technol Beijing, Collaborat Innovat Ctr Steel Technol, Beijing 100083, Peoples R China.
   [Chi Jiannan] Univ Sci & Technol Beijing, Sch Automat, Beijing 100083, Peoples R China.
C3 University of Science & Technology Beijing; University of Science &
   Technology Beijing; University of Science & Technology Beijing
RP Xu, K (通讯作者)，Univ Sci & Technol Beijing, Collaborat Innovat Ctr Steel Technol, Beijing 100083, Peoples R China.
EM xuke@ustb.edu.cn
RI Xu, Ke/GZM-9218-2022
OI Xu, Ke/0000-0003-1809-7413
FU National Natural Science Foundation of China [51674031, 51874022]
FX `This work is sponsored by the National Natural Science Foundation of
   China (No. 51674031, No. 51874022).
CR Antony BJ, 2016, PROC SPIE, V9784, DOI 10.1117/12.2214676
   Baroni M, 2007, MED ENG PHYS, V29, P432, DOI 10.1016/j.medengphy.2006.06.003
   Chen Q, 2017, J ELECTRON INF TECHN, V39, P1101, DOI 10.11999/JEIT160663
   Chi J., 2011, VISUAL MEASUREMENT T
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Dabov K, 2007, IEEE T IMAGE PROCESS, V16, P2080, DOI 10.1109/TIP.2007.901238
   Easley G.R., 2005, WAVELETS 11, V5914, P974
   Easley G, 2008, APPL COMPUT HARMON A, V25, P25, DOI 10.1016/j.acha.2007.09.003
   Emily J.K., 2015, APPL DIGIT IMAGE PRO, VXXXVIII, P9699
   Fabritius T, 2009, OPT EXPRESS, V17, P15659, DOI 10.1364/OE.17.015659
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Hamwood J, 2018, BIOMED OPT EXPRESS, V9, P3049, DOI 10.1364/BOE.9.003049
   Hao FY, 2008, RARE METAL MAT ENG, V37, P1295
   He Q, 2016, INT J CLIMATOL, V36, P4071, DOI 10.1002/joc.4618
   Jiang Y., 2011, BEIJING BIOMED ENG, V30, P452
   Kajic V, 2010, OPT EXPRESS, V18, P14730, DOI 10.1364/OE.18.014730
   Kovesi P., 1999, VIDERE J COMPUT VIS, V1, P1
   Kutyniok G, 2016, ACM T MATH SOFTWARE, V42, DOI 10.1145/2740960
   Liu Y., 2007, MED RECAPITULATE, V13, P2014
   Ma S.F., 2010, 2010 2 INT C ADV COM
   MALLAT S, 1992, IEEE T PATTERN ANAL, V14, P710, DOI 10.1109/34.142909
   MALLAT S, 1992, IEEE T INFORM THEORY, V38, P617, DOI 10.1109/18.119727
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   MORRONE MC, 1987, PATTERN RECOGN LETT, V6, P303, DOI 10.1016/0167-8655(87)90013-4
   Rafael R., 2014, THESIS
   Reisenhofer R, 2016, EXP FLUIDS, V57, DOI 10.1007/s00348-016-2128-6
   Xiao Yi-han, 2011, Systems Engineering and Electronics, V33, P1668, DOI 10.3969/j.issn.1001-506X.2011.07.45
   XU CX, 1996, CHINA J IMAGE GRAPHI, V1, P4
   Xu Q., 2013, INF TECHNOL, V4, P136
   Yi S, 2009, IEEE T IMAGE PROCESS, V18, P929, DOI 10.1109/TIP.2009.2013082
   Yu K, 2018, BIOMED OPT EXPRESS, V9, P962, DOI 10.1364/BOE.9.000962
NR 33
TC 4
Z9 4
U1 2
U2 26
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1751-9659
EI 1751-9667
J9 IET IMAGE PROCESS
JI IET Image Process.
PD AUG 22
PY 2019
VL 13
IS 10
BP 1686
EP 1693
DI 10.1049/iet-ipr.2018.6634
PG 8
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
   Electronic; Imaging Science & Photographic Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic Technology
GA IW4UK
UT WOS:000484975000011
DA 2022-11-30
ER

PT J
AU Ghoghari, H
   Rizvi, SF
   Razzak, K
   Loya, H
AF Ghoghari, Hunain
   Rizvi, Syed Fawad
   Razzak, Kaunain
   Loya, Hina
TI Clinical application of multicolor optical coherence tomography in the
   diagnosis of retinal pathologies
SO PAKISTAN JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Multicolor OCT; Conventional color fundus photograph; vitreomacular
   interface disorder
AB Objective: To assess the clinical application of multicolor optical coherence tomography (OCT) using confocal scanning laser ophthalmoscopy (cSLO) in different retinal pathologies.
   Methods: This observational study was conducted at the Layton Rahmatullah Benevolent Trust (LRBT), Free Base Eye Hospital, Karachi, from April 2018 to June 2018. It includes 36 patients suffering from different retinal pathologies including diabetic retinopathy, age related macular degeneration, and vitreomacular interface disorders using multicolor optical coherence tomography as a screening tool.
   Results: It was found that automated eye tracking system of this new version tool enables ophthalmologists to take high-resolution cSLO reflectance images. The light scatter can be avoided with the use of confocal optics. Appearances of pigment changes and hemorrhages were some of the differences found when compared to the conventional CFP. About 20% in AMD, 37.5% with diabetes and 100% patients with vitreomacular interface disorders could have be easily missed by CFP.
   Conclusions: Multicolor OCT can provide information and figures far more authoritatively than the conventional CFP, which is highly affected by media opacities. To interpret Multicolor OCT ophthalmologists should be watchful with plenty of understanding.
C1 [Ghoghari, Hunain; Rizvi, Syed Fawad; Loya, Hina] Free Base Eye Hosp, LRBT, Korangi 2 1-2, Karachi, Pakistan.
   [Razzak, Kaunain] Observer Ship LRBT, A 80,Block 13-C,Gulshan E Iqbal, Karachi, Pakistan.
RP Ghoghari, H (通讯作者)，Free Base Eye Hosp, LRBT, Korangi 2 1-2, Karachi, Pakistan.
EM ghoghari@hotmail.com
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Ahmad MSZ, 2017, OPTOMETRY VISION SCI, V94, P1058, DOI 10.1097/OPX.0000000000001128
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Bezerra HG, 2009, JACC-CARDIOVASC INTE, V2, P1035, DOI 10.1016/j.jcin.2009.06.019
   Cavallerano JD, 2005, AM J OPHTHALMOL, V140, P667, DOI 10.1016/j.ajo.2005.03.075
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Graham KW, 2018, RETINA-J RET VIT DIS, V38, P1751, DOI 10.1097/IAE.0000000000001777
   Keane PA, 2014, OPHTHALMOLOGY, V121, P2489, DOI 10.1016/j.ophtha.2014.07.054
   Li ST, 2018, LASER MED SCI, V33, P1371, DOI 10.1007/s10103-018-2498-5
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P352, DOI 10.1097/IAE.0000000000001525
   Neubauer AS, 2008, GRAEF ARCH CLIN EXP, V246, P229, DOI 10.1007/s00417-007-0631-4
   Pang CE, 2014, AM J OPHTHALMOL, V158, P171, DOI 10.1016/j.ajo.2014.03.003
   Panwar N, 2016, TELEMED E-HEALTH, V22, P198, DOI 10.1089/tmj.2015.0068
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Reznicek L, 2014, SAUDI J OPHTHALMOL, V28, P134, DOI 10.1016/j.sjopt.2014.03.009
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Yannuzzi LA, 2004, AM J OPHTHALMOL, V137, P511, DOI 10.1016/j.ajo.2003.12.035
NR 19
TC 0
Z9 1
U1 0
U2 1
PU PROFESSIONAL MEDICAL PUBLICATIONS
PI SADDAR
PA PANORAMA CENTRE, RM 522, 5TH FLOOR, BLDG 2, RAJA GHAZANFAR ALI RD, PO
   BOX 8766, SADDAR, KARACHI 00000, PAKISTAN
SN 1682-024X
J9 PAK J MED SCI
JI Pak. J. Med. Sci.
PD NOV-DEC
PY 2018
VL 34
IS 6
BP 1555
EP 1559
DI 10.12669/pjms.346.16388
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HT2ZI
UT WOS:000464432600046
PM 30559822
OA Green Published
DA 2022-11-30
ER

PT J
AU Strzalka-Mrozik, B
   Kimsa-Furdzik, M
   Kabiesz, A
   Michalska-Malecka, K
   Nita, M
   Mazurek, U
AF Strzalka-Mrozik, Barbara
   Kimsa-Furdzik, Malgorzata
   Kabiesz, Adam
   Michalska-Malecka, Katarzyna
   Nita, Malgorzata
   Mazurek, Urszula
TI Gene expression levels of the insulin-like growth factor family in
   patients with AMD before and after ranibizumab intravitreal injections
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related macular degeneration; IGF family; ranibizumab; mRNA
ID BLOOD MONONUCLEAR-CELLS; MACULAR DEGENERATION; FACTOR-I; IGF-I;
   CHOROIDAL NEOVASCULARIZATION; VISUAL IMPAIRMENT; BINDING-PROTEINS;
   RETINOPATHY; VEGF; BEVACIZUMAB
AB Purpose: The present study focused on the assessment of the mRNA levels of the insulin-like growth factor (IGF) family in patients with the exudative form of age-related macular degeneration (AMD) before and after ranibizumab intravitreal injections.
   Patients and methods: An analysis of the expression profile of the IGF family of genes in patients with AMD was carried out using the oligonucleotide microarray and quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) methods.
   Results: In the peripheral blood mononuclear cells (PBMCs) obtained from AMD group receiving ranibizumab compared to the peripheral blood mononuclear cells from AMD group before ranibizumab treatment using oligonucleotide microarray technique, six statistically significant differentially expressed transcripts related to the IGF family were detected (unpaired t-test, p < 0.05, fold change > 1.5). Moreover, analysis using the real-time RT-qPCR technique revealed statistically significant differences in the IGF2 and IGF2R mRNA levels (Mann-Whitney U test, p < 0.05) between the two groups that were studied. Statistical analyses of both oligonucleotide microarray and real-time RT-qPCR results demonstrated a significant decreased expression only for IGF2 mRNA.
   Conclusion: Our results revealed a changed expression of IGF2 mRNA after ranibizumab treatment.
C1 [Strzalka-Mrozik, Barbara; Mazurek, Urszula] Med Univ Silesia, Sch Pharm, Div Lab Med Sosnowiec, Dept Mol Biol, Jednosci 8, PL-41200 Katowice, Poland.
   [Kimsa-Furdzik, Malgorzata] Med Univ Silesia, Sch Med Katowice, Dept Biochem, Katowice, Poland.
   [Kabiesz, Adam; Michalska-Malecka, Katarzyna] Med Univ Silesia, Univ Ctr Ophthalmol & Oncol, Independent Publ Clin Hosp, Katowice, Poland.
   [Michalska-Malecka, Katarzyna] Med Univ Silesia, Sch Med Katowice, Dept Ophthalmol, Katowice, Poland.
   [Nita, Malgorzata] Domest & Specialized Med Ctr Dilmed, Katowice, Poland.
C3 Medical University Silesia; Medical University Silesia; Medical
   University Silesia; Medical University Silesia
RP Strzalka-Mrozik, B (通讯作者)，Med Univ Silesia, Sch Pharm, Div Lab Med Sosnowiec, Dept Mol Biol, Jednosci 8, PL-41200 Katowice, Poland.
EM bstrzalka@sum.edu.pl
OI MICHALSKA-MALECKA, KATARZYNA/0000-0002-0550-8386; Mazurek,
   Urszula/0000-0003-1181-4934; STRZALKA-MROZIK,
   BARBARA/0000-0001-9854-2569; Kimsa-Furdzik,
   Malgorzata/0000-0003-1985-2038
FU PL-Grid Infrastructure
FX This research was supported in part by PL-Grid Infrastructure.
CR Bach LA, 2015, J MOL ENDOCRINOL, V54, pR1, DOI 10.1530/JME-14-0215
   Baharivand N, 2012, CLIN OPHTHALMOL, V6, P185, DOI 10.2147/OPTH.S27423
   Bergman D, 2013, GERONTOLOGY, V59, P240, DOI 10.1159/000343995
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Braczkowski R, 2016, WSPOLCZESNA ONKOL, V20, P130, DOI 10.5114/wo.2016.58720
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Burgos R, 2000, DIABETES CARE, V23, P80, DOI 10.2337/diacare.23.1.80
   Cha DM, 2013, INVEST OPHTH VIS SCI, V54, P7038, DOI 10.1167/iovs.13-12730
   Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2011, INVEST OPHTH VIS SCI, V52, P9099, DOI 10.1167/iovs.11-7782
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deissler HL, 2013, GRAEF ARCH CLIN EXP, V251, P2345, DOI 10.1007/s00417-013-2393-5
   Dong LJ, 2015, CELL TISSUE RES, V360, P233, DOI 10.1007/s00441-014-2104-5
   Dransfield DT, 2010, MOL CANCER THER, V9, P1809, DOI 10.1158/1535-7163.MCT-09-1134
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Ecker SM, 2011, MOL VIS, V17, P2856
   Falk MK, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-22
   Furstenberger G, 2002, LANCET ONCOL, V3, P298, DOI 10.1016/S1470-2045(02)00731-3
   Gharehbaghi MM, 2012, INDIAN J OPHTHALMOL, V60, P527, DOI 10.4103/0301-4738.103782
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Haurigot V, 2009, J BIOL CHEM, V284, P22961, DOI 10.1074/jbc.M109.014787
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hong YR, 2015, RETINA-J RET VIT DIS, V35, P1772, DOI 10.1097/IAE.0000000000000535
   Huang JF, 2014, CHINESE MED J-PEKING, V127, P2053, DOI 10.3760/cma.j.issn.0366-6999.20133045
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Kim JH, 2012, BIOCHIMIE, V94, P734, DOI 10.1016/j.biochi.2011.11.003
   Kong LK, 2015, INVEST OPHTH VIS SCI, V56, P956, DOI 10.1167/iovs.14-15842
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lee YM, 2015, MOLECULES, V20, P20699, DOI 10.3390/molecules201119728
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   Liu XX, 2017, J BIOMED RES, V31, P248, DOI 10.7555/JBR.31.20160096
   Lofqvist C, 2009, INVEST OPHTH VIS SCI, V50, P1831, DOI 10.1167/iovs.08-2903
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Maeng YS, 2009, BLOOD, V113, P233, DOI 10.1182/blood-2008-06-162891
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Manresa N, 2015, RETINA-J RET VIT DIS, V35, P1765, DOI 10.1097/IAE.0000000000000552
   MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877
   Michalska-Malecka K, 2016, CLIN INTERV AGING, V11, P357, DOI 10.2147/CIA.S93820
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nguyen DV, 2013, GROWTH HORM IGF RES, V23, P45, DOI 10.1016/j.ghir.2013.03.001
   Nita M, 2014, MED SCI MONITOR, V20, P875, DOI 10.12659/MSM.890031
   Pekel G, 2014, EYE, V28, P1350, DOI 10.1038/eye.2014.216
   Polat SB, 2014, PITUITARY, V17, P327, DOI 10.1007/s11102-013-0505-1
   Rajpathak SN, 2009, DIABETES-METAB RES, V25, P3, DOI 10.1002/dmrr.919
   Romaniuk D, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/986217
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Shao MH, 2012, MOL CANCER THER, V11, P1576, DOI 10.1158/1535-7163.MCT-11-0961
   Shaw LC, 2006, GENE THER, V13, P752, DOI 10.1038/sj.gt.3302718
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Spoerri PE, 1998, GROWTH HORM IGF RES, V8, P125, DOI 10.1016/S1096-6374(98)80102-0
   Spranger J, 2000, HORM METAB RES, V32, P196, DOI 10.1055/s-2007-978621
   van Beijnum JR, 2017, BIOL REV, V92, P1755, DOI 10.1111/brv.12306
   Wilkinson-Berka JL, 2006, CURR MED CHEM, V13, P3307, DOI 10.2174/092986706778773086
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wu WC, 2015, JAMA OPHTHALMOL, V133, P391, DOI 10.1001/jamaophthalmol.2014.5373
   Wu ZQ, 2008, ANN ACAD MED SINGAP, V37, P591
   Xu Y, 2014, CHINESE MED J-PEKING, V127, P2906, DOI 10.3760/cma.j.issn.0366-6999.20132990
   Yan Y, 2016, ACTA OPHTHALMOL, V94, P358, DOI 10.1111/aos.12806
   Yazgan S, 2017, INT OPHTHALMOL
   Zhang SX, 2005, AM J PATHOL, V166, P313, DOI 10.1016/S0002-9440(10)62255-9
   Zhu Y, 2013, MOL VIS, V19, P1826
NR 68
TC 1
Z9 1
U1 0
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2017
VL 12
BP 1401
EP 1408
DI 10.2147/CIA.S135030
PG 8
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA FF8NC
UT WOS:000409274100001
PM 28919726
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Regula, JT
   von Leithner, PL
   Foxton, R
   Barathi, VA
   Cheung, CMG
   Tun, SBB
   Wey, YS
   Iwata, D
   Dostalek, M
   Moelleken, J
   Stubenrauch, KG
   Nogoceke, E
   Widmer, G
   Strassburger, P
   Koss, MJ
   Klein, C
   Shima, DT
   Hartmann, G
AF Regula, Joerg T.
   von Leithner, Peter Lundh
   Foxton, Richard
   Barathi, Veluchamy A.
   Cheung, Chui Ming Gemmy
   Tun, Sai Bo Bo
   Wey, Yeo Sia
   Iwata, Daiju
   Dostalek, Miroslav
   Moelleken, Joerg
   Stubenrauch, Kay G.
   Nogoceke, Everson
   Widmer, Gabriella
   Strassburger, Pamela
   Koss, Michael J.
   Klein, Christian
   Shima, David T.
   Hartmann, Guido
TI Targeting key angiogenic pathways with a bispecific CrossMAb optimized
   for neovascular eye diseases
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; angiogenesis; angiopoietin-2; Fc
   receptor; vascular endothelial growth factor
ID ENDOTHELIAL GROWTH-FACTOR; SUPPRESSES CHOROIDAL NEOVASCULARIZATION;
   RECEPTOR TYROSINE KINASE; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   OCULAR NEOVASCULARIZATION; VITREOUS LEVELS; TIE2 RECEPTOR; VEGF-A;
   VASCULAR LEAKAGE
AB Anti-angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor-A (VEGF-A) have revolutionized treatment of retinal vascular diseases including age-related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti-VEGF-A monotherapy efficacy by targeting both VEGF-A and angiopoietin-2 (ANG-2), a factor strongly upregulated in vitreous fluids of patients with retinal vascular disease and exerting some of its activities in concert with VEGF-A. Simultaneous VEGF-A and ANG-2 inhibition was found to reduce vessel lesion number, permeability, retinal edema, and neuron loss more effectively than either agent alone in a spontaneous choroidal neovascularization (CNV) model. We describe the generation of a bispecific domain-exchanged (crossed) monoclonal antibody (CrossMAb; RG7716) capable of binding, neutralizing, and depleting VEGF-A and ANG-2. RG7716 showed greater efficacy than anti-VEGF-A alone in a non-human primate laser-induced CNV model after intravitreal delivery. Modification of RG7716's FcRn and FcR binding sites disabled the antibodies' Fc-mediated effector functions. This resulted in increased systemic, but not ocular, clearance. These properties make RG7716 a potential next-generation therapy for neovascular indications of the eye.
C1 [Regula, Joerg T.; Moelleken, Joerg; Stubenrauch, Kay G.] Roche Innovat Ctr Munchen, Roche Pharma Res & Early Dev, Penzberg, Germany.
   [von Leithner, Peter Lundh; Foxton, Richard; Iwata, Daiju; Shima, David T.] UCL London, Inst Ophthalmol, Dept Ocular Biol & Therapeut, London, England.
   [Foxton, Richard; Dostalek, Miroslav; Nogoceke, Everson; Widmer, Gabriella; Strassburger, Pamela; Hartmann, Guido] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Basel, Switzerland.
   [Barathi, Veluchamy A.; Cheung, Chui Ming Gemmy; Tun, Sai Bo Bo; Wey, Yeo Sia] Singapore Eye Res Inst, Translat Preclin Model Platform, Singapore, Singapore.
   [Barathi, Veluchamy A.] DUKE NUS Grad Med Sch, Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Koss, Michael J.] Goethe Univ, Dept Ophthalmol, Frankfurt, Germany.
   [Koss, Michael J.] Ruprecht Karls Univ Heidelberg, Dept Ophthalmol, Heidelberg, Germany.
   [Klein, Christian] F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Zurich, Zurich, Switzerland.
C3 University of London; University College London; Roche Holding; National
   University of Singapore; Singapore National Eye Center; National
   University of Singapore; Goethe University Frankfurt; Ruprecht Karls
   University Heidelberg; Roche Holding
RP Hartmann, G (通讯作者)，F Hoffmann La Roche Ltd, Roche Pharma Res & Early Dev, Roche Innovat Ctr Basel, Basel, Switzerland.
EM guido.hartmann@roche.com
RI Tun, Sai Bo Bo/GRF-2470-2022; Klein, Christian/G-1336-2010; TUN, SAI BO
   BO/O-1085-2018
OI Klein, Christian/0000-0001-7594-7280; TUN, SAI BO
   BO/0000-0002-2013-8379; Regula, Joerg Thomas/0000-0002-7343-1077;
   Cheung, Chui Ming Gemmy/0000-0003-3358-3516
FU Roche
FX The authors thank Harald Duerr, Hubert Kettenberger, Ingo Gorr, Michael
   Molhoj, Sabine Imhof-Jung, Thomas V. Hirschheydt, Ulrich Goepfert,
   Dhananjay Jere, Wolfgang Schafer, Matthias Rueth, Ulrike Reiff, and
   Markus Thomas for providing and testing of material used in this
   publication and for continuous support of this project; Yin-Shan Ng,
   Shannon Conder, and Joanna Holeniewska for assistance with the in vivo
   experiments in the sCNV model; and Greogor William Jainta for excellent
   technical support for the endothelial cell experiments. Roche provided
   funding sources for these studies to DTS and VAB.
CR Aguilar E, 2008, METHOD ENZYMOL, V444, P115, DOI 10.1016/S0076-6879(08)02806-1
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Barnett JM, 2010, DOC OPHTHALMOL, V120, P3, DOI 10.1007/s10633-009-9180-y
   Barton WA, 2006, NAT STRUCT MOL BIOL, V13, P524, DOI 10.1038/nsmb1101
   Benest AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070459
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cahoon JM, 2015, DIABETES, V64, P4247, DOI 10.2337/db14-1030
   Cai J, 2008, INVEST OPHTH VIS SCI, V49, P2163, DOI 10.1167/iovs.07-1206
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897
   Fiedler U, 2006, NAT MED, V12, P235, DOI 10.1038/nm1351
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Hammes HP, 2011, DIABETES, V60, P9, DOI 10.2337/db10-0454
   Hartnett ME, 2008, INVEST OPHTH VIS SCI, V49, P3107, DOI 10.1167/iovs.08-1780
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   KABAT EA, 1991, J IMMUNOL, V147, P1709
   Kienast Y, 2013, CLIN CANCER RES, V19, P6730, DOI 10.1158/1078-0432.CCR-13-0081
   Kim H, 2009, MOL VIS, V15
   Koss MJ, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/459251
   Koss MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096895
   Kumpers P, 2011, CRIT CARE, V15, DOI 10.1186/cc10523
   Lambert NG, 2016, EXP EYE RES, V145, P248, DOI 10.1016/j.exer.2016.01.009
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   Loukovaara S, 2013, ACTA OPHTHALMOL, V91, P531, DOI 10.1111/j.1755-3768.2012.02473.x
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Marneros AG, 2016, EMBO MOL MED, V8, P208, DOI 10.15252/emmm.201505613
   Menden H, 2015, J BIOL CHEM, V290, P5449, DOI 10.1074/jbc.M114.600692
   Meyer T, 2009, J THROMB HAEMOST, V7, P171, DOI 10.1111/j.1538-7836.2008.03212.x
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Noma H, 2010, EUR J OPHTHALMOL, V20, P402, DOI 10.1177/112067211002000222
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942
   Patsch C, 2015, NAT CELL BIOL, V17, P994, DOI 10.1038/ncb3205
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saharinen P, 2008, NAT CELL BIOL, V10, P527, DOI 10.1038/ncb1715
   Saharinen P, 2010, CURR OPIN HEMATOL, V17, P198, DOI 10.1097/MOH.0b013e3283386673
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Schaefer W, 2011, P NATL ACAD SCI USA, V108, P11187, DOI 10.1073/pnas.1019002108
   Schlothauer T, 2013, MABS-AUSTIN, V5, P576, DOI 10.4161/mabs.24981
   Stubenrauch K, 2013, J PHARMACEUT BIOMED, V72, P208, DOI 10.1016/j.jpba.2012.08.023
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Wang HB, 2016, MOL VIS, V22, P189
   Watanabe D, 2005, AM J OPHTHALMOL, V139, P476, DOI 10.1016/j.ajo.2004.10.004
   World Health Organization (WHO), 2014, VIS IMP BLINDN 2010
   Wu FTH, 2015, EMBO MOL MED, V7, P770, DOI 10.15252/emmm.201404193
   Yu XH, 2013, P NATL ACAD SCI USA, V110, P7205, DOI 10.1073/pnas.1216890110
   Ziegler T, 2013, J CLIN INVEST, V123, P3436, DOI 10.1172/JCI66549
NR 60
TC 103
Z9 108
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD NOV
PY 2016
VL 8
IS 11
BP 1265
EP 1288
DI 10.15252/emmm.201505889
PG 24
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EB1LA
UT WOS:000387111900004
PM 27742718
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Shu, X
   Liu, WZ
   Zhang, HF
AF Shu, Xiao
   Liu, Wenzhong
   Zhang, Hao F.
TI Monte Carlo investigation on quantifying the retinal pigment epithelium
   melanin concentration by photoacoustic ophthalmoscopy
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE retinal pigment epithelium; melanin; Monte Carlo simulation;
   photoacoustic imaging
ID MACULAR PIGMENT; MORPHOMETRIC-ANALYSIS; OPTICAL-PROPERTIES; HUMAN RPE;
   FUNDUS; AUTOFLUORESCENCE; REFLECTANCE; MICROSCOPY; LIPOFUSCIN;
   RESOLUTION
AB The retinal pigment epithelium (RPE) melanin plays an important role in maintaining normal visual functions. A decrease in the RPE melanin concentration with aging is believed to be associated with several blinding diseases, including age-related macular degeneration. Quantifying the RPE melanin noninvasively is therefore important in evaluating the retinal health and aging conditions. Photoacoustic ophthalmoscopy (PAOM), as an optical absorption-based imaging technology, can potentially be applied to measure variations in the RPE melanin if the relationship between the detected photoacoustic (PA) signal amplitudes and the RPE melanin concentrations can be established. In this work, we tested the feasibility of using PA signals from retinal blood vessels as references to measure RPE melanin variation using Monte Carlo (MC) simulation. The influences from PAOM axial resolution, the depth and diameter of the retinal blood vessel, and the RPE thickness were examined. We proposed a calibration scheme by relating detected PA signals to the RPE melanin concentrations, and we found that the scheme is robust to these tested parameters. This study suggests that PAOM has the capability of quantitatively measuring the RPE melanin in vivo. (C) 2015 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Shu, Xiao; Liu, Wenzhong; Zhang, Hao F.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Zhang, Hao F.] Northwestern Univ, Dept Ophthalmol, Chicago, IL 60611 USA.
C3 Northwestern University; Northwestern University
RP Zhang, HF (通讯作者)，Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
EM hfzhang@northwestern.edu
RI Zhang, Hao F/D-1695-2011; Zhang, Hao/H-6199-2012
OI Shu, Xiao/0000-0001-7998-4556
FU NIH [1R01EY019951, 1R24EY022883, 2R01EY019484]; NSF [CBET-1055379,
   DBI-1353952]; Howard Hughes Medical Institute International Research
   Fellowship; NATIONAL EYE INSTITUTE [R01EY019484, R24EY022883,
   R01EY019951] Funding Source: NIH RePORTER
FX The authors thank Siyu Chen, Dr. Ji Yi, Dr. Biqin Dong, and Christina
   Chan for insightful comments. The authors would like to acknowledge the
   generous financial support from NIH under Grant Nos. 1R01EY019951,
   1R24EY022883, and 2R01EY019484; and NSF under Grant Nos. CBET-1055379
   and DBI-1353952. Wenzhong Liu is supported by the Howard Hughes Medical
   Institute International Research Fellowship. We also acknowledge the
   computational resources and staff contributions provided by the Quest
   High-Performance Computing Facility at Northwestern University. Hao F.
   Zhang has financial interests in Opticent Health Inc., which, however,
   did not support this work.
CR ANDERSON RR, 1981, J INVEST DERMATOL, V77, P13, DOI 10.1111/1523-1747.ep12479191
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Bosschaart N, 2014, LASER MED SCI, V29, P453, DOI 10.1007/s10103-013-1446-7
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   COOK JD, 1986, BLOOD, V68, P726
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Guo Y, 2008, J OPT SOC AM A, V25, P304, DOI 10.1364/JOSAA.25.000304
   Guo ZJ, 2010, OPT LETT, V35, P2067, DOI 10.1364/OL.35.002067
   HAMMER M, 1995, PHYS MED BIOL, V40, P963, DOI 10.1088/0031-9155/40/6/001
   Hammer M, 2001, IEEE T BIO-MED ENG, V48, P592, DOI 10.1109/10.918598
   Hammer M, 2001, PHYS MED BIOL, V46, pN65, DOI 10.1088/0031-9155/46/3/402
   Hardarson SH, 2009, INVEST OPHTH VIS SCI, V50, P2308, DOI 10.1167/iovs.08-2576
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   ITO S, 1983, J INVEST DERMATOL, V80, P268, DOI 10.1111/1523-1747.ep12534616
   Jacques S., 2013, EXTINCTION COEFFICIE
   Jiao SL, 2010, OPT EXPRESS, V18, P3967, DOI 10.1364/OE.18.003967
   Kang WH, 2002, BRIT J DERMATOL, V146, P228, DOI 10.1046/j.0007-0963.2001.04556.x
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   KEIJZER M, 1989, APPL OPTICS, V28, P4286, DOI 10.1364/AO.28.004286
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Landrum J. T., 1996, ADV PHARMACOL, V38, P537
   Liu WZ, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.6.066003
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Prahl S., 2013, OPTICAL ABSORPTION H
   Preece SJ, 2002, PHYS MED BIOL, V47, P2863, DOI 10.1088/0031-9155/47/16/303
   Ritt M, 2009, HYPERTENSION, V54, P384, DOI 10.1161/HYPERTENSIONAHA.109.133025
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Song W., 2014, SCI REP, V4
   Song W, 2014, CHIN OPT LETT, V12, DOI 10.3788/COL201412.051704
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P2812, DOI 10.1167/iovs.12-11490
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje
   vandeKraats J, 1996, VISION RES, V36, P2229, DOI 10.1016/0042-6989(96)00001-6
   Viator JA, 2004, J INVEST DERMATOL, V122, P1432, DOI 10.1111/j.0022-202X.2004.22610.x
   Wang J, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3333549
   WANG LH, 1995, COMPUT METH PROG BIO, V47, P131, DOI 10.1016/0169-2607(95)01640-F
   Wang LHV, 2012, SCIENCE, V335, P1458, DOI 10.1126/science.1216210
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Yao JJ, 2014, PHOTOACOUSTICS, V2, P87, DOI 10.1016/j.pacs.2014.04.002
   Zadlo A, 2007, PIGM CELL RES, V20, P52, DOI 10.1111/j.1600-0749.2006.00350.x
   Zhang HF, 2006, NAT BIOTECHNOL, V24, P848, DOI 10.1038/nbt1220
   Zhang Hao F, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS106, DOI 10.3928/15428877-20110627-10
   Zhang XY, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3606569
NR 48
TC 15
Z9 15
U1 2
U2 8
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD OCT
PY 2015
VL 20
IS 10
AR 106005
DI 10.1117/1.JBO.20.10.106005
PG 9
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA CX9HW
UT WOS:000366017100026
PM 26469564
OA Green Published
DA 2022-11-30
ER

PT J
AU Demidenko, ZN
   Blagosklonny, MV
AF Demidenko, Zoya N.
   Blagosklonny, Mikhail V.
TI The purpose of the HIF-1/PHD feedback loop To limit mTOR-induced HIF-1
   alpha
SO CELL CYCLE
LA English
DT Article
DE hypoxia; HIF-1; PHD; mTOR; rapamycin; insulin; senescence
ID INDUCIBLE FACTOR 1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; HISTONE DEACETYLASE
   INHIBITORS; PROLYL HYDROXYLASE-ACTIVITY; IMPROVED METABOLIC-CONTROL;
   FACTOR-L-ALPHA; FACTOR-I; MAMMALIAN TARGET; PROSTATE-CANCER;
   GENE-EXPRESSION
AB Prolyl hydroxylases (PHDs) target hypoxia-inducible factor-1 alpha (HIF-1 alpha) for degradation. Hypoxia inactivates PHDs, causing accumulation of HIF-1 alpha. In turn, HIF-1 further transactivates PHDs. It is thought that the purpose of this feedback loop is to limit HIF-1 alpha accumulation caused by hypoxia. Here, we suggest that the feedback is intended to limit the induction of HIF-1 alpha by insulin, growth factors, hormones, cytokines and nutrients. These stimuli induce HIF-1 alpha by increasing its translation, not by inhibiting PHDs. As exemplified herein, in a mTOR-dependent manner, insulin transiently induced HIF-1 alpha in retinal pigment epithelial (RPE) cells. Induction of HIF-1 alpha was followed by activation of HIF-dependent transcription. Furthermore, DFX, which inactivates PHDs, potentiated the induction of HIF-1 alpha by insulin. We discuss that the most relevant function of the PHD-HIF feedback loop is to limit the induction of HIF-1 alpha by mTOR. The failure to limit mTOR-dependent induction of HIF-1 may contribute to age-related macular degeneration and diabetic retinopathy, suggesting rapamycin for prevention of these age-related diseases.
C1 [Demidenko, Zoya N.; Blagosklonny, Mikhail V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA.
C3 Roswell Park Cancer Institute
RP Blagosklonny, MV (通讯作者)，Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA.
EM blagosklonny@oncotarget.com
CR Agardh Carl-David, 1992, Journal of Diabetes and its Complications, V6, P96, DOI 10.1016/1056-8727(92)90018-G
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420
   Alam H, 2009, ENDOCRINOLOGY, V150, P915, DOI 10.1210/en.2008-0850
   Aprelikova O, 2004, J CELL BIOCHEM, V92, P491, DOI 10.1002/jcb.20067
   Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200
   Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200
   Asikainen TM, 2005, P NATL ACAD SCI USA, V102, P10212, DOI 10.1073/pnas.0504520102
   Berchner-Pfannschmidt U, 2007, J BIOL CHEM, V282, P1788, DOI 10.1074/jbc.M607065200
   Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029
   Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392
   Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042
   Blagosklonny MV, 2007, DRUG DISCOV TODAY, V12, P218, DOI 10.1016/j.drudis.2007.01.004
   Blagosklonny MV, 2006, CELL CYCLE, V5, P2087, DOI 10.4161/cc.5.18.3288
   Blagosklonny MV, 2009, AGING-US, V1, P357, DOI 10.18632/aging.100040
   Blagosklonny MV, 2003, EMBO REP, V4, P358, DOI 10.1038/sj.embor.embor806
   Blagosklonny MV, 2001, ONCOGENE, V20, P395, DOI 10.1038/sj.onc.1204055
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Chantelau E, 2005, GROWTH HORM IGF RES, V15, P130, DOI 10.1016/j.ghir.2004.12.005
   Chavez JC, 2002, J NEUROSCI, V22, P8922
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4
   Cohen JA, 1998, MUSCLE NERVE, V21, P72, DOI 10.1002/(SICI)1097-4598(199801)21:1<72::AID-MUS10>3.0.CO;2-2
   Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006
   Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200
   D'Angelo G, 2003, J BIOL CHEM, V278, P38183, DOI 10.1074/jbc.M302244200
   Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002
   del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200
   Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636
   Demidenko ZN, 2008, CELL CYCLE, V7, P3355, DOI 10.4161/cc.7.21.6919
   Demidenko ZN, 2010, P NATL ACAD SCI USA, V107, P9660, DOI 10.1073/pnas.1002298107
   Demidenko ZN, 2009, AGING-US, V1, P1008, DOI 10.18632/aging.100115
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   Deudero JJP, 2008, J BIOL CHEM, V283, P11435, DOI 10.1074/jbc.M703875200
   DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608
   Ellisen LW, 2005, CELL CYCLE, V4, P1500, DOI 10.4161/cc.4.11.2139
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   FUNATSU H, 1992, JPN J OPHTHALMOL, V36, P356
   Gibbons CH, 2010, ANN NEUROL, V67, P534, DOI 10.1002/ana.21952
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   HENRICSSON M, 1995, DIABETES CARE, V18, P1571, DOI 10.2337/diacare.18.12.1571
   Henricsson M, 1999, DIABETES CARE, V22, P1944, DOI 10.2337/diacare.22.12.1944
   Henze AT, 2010, CELL CYCLE, V9, P2749, DOI 10.4161/cc.9.14.12249
   Henze AT, 2010, CANCER RES, V70, P357, DOI 10.1158/0008-5472.CAN-09-1876
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jin HO, 2007, CELL SIGNAL, V19, P1393, DOI 10.1016/j.cellsig.2006.12.014
   Karhausen J, 2005, J CELL BIOCHEM, V95, P1264, DOI 10.1002/jcb.20489
   Kietzmann T, 2003, BLOOD, V101, P907, DOI 10.1182/blood-2002-06-1693
   Kim SH, 2006, BIOCHEM BIOPH RES CO, V340, P422, DOI 10.1016/j.bbrc.2005.12.018
   Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08
   Koh MY, 2009, CELL CYCLE, V8, P1359, DOI 10.4161/cc.8.9.8303
   Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001
   Leontieva OV, 2010, AGING-US, V2, P924, DOI 10.18632/aging.100265
   Liang DM, 2006, CELL CYCLE, V5, P2430, DOI 10.4161/cc.5.21.3409
   Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023
   Liu YV, 2007, CELL CYCLE, V6, P656, DOI 10.4161/cc.6.6.3981
   Mabjeesh NJ, 2003, CLIN CANCER RES, V9, P2416
   Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   Makino Y, 2007, J BIOL CHEM, V282, P14073, DOI 10.1074/jbc.M700732200
   Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620
   Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318
   Mi Z, 2008, CELL CYCLE, V7, P232, DOI 10.4161/cc.7.2.5193
   Minamishima YA, 2009, MOL CELL BIOL, V29, P5729, DOI 10.1128/MCB.00331-09
   Moroz E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005077
   MOSKALETS E, 1994, J DIABETES COMPLICAT, V8, P45, DOI 10.1016/1056-8727(94)90010-8
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06
   Pospelova TV, 2009, CELL CYCLE, V8, P4112, DOI 10.4161/cc.8.24.10215
   Poulaki V, 2004, AM J PATHOL, V165, P457, DOI 10.1016/S0002-9440(10)63311-1
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Qi JF, 2010, ONCOTARGET, V1, P379, DOI 10.18632/oncotarget.171
   Qutub AA, 2007, BBA-MOL CELL RES, V1773, P1511, DOI 10.1016/j.bbamcr.2007.07.004
   Regazzetti C, 2010, J BIOL CHEM, V285, P5157, DOI 10.1074/jbc.M109.047688
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680
   Slomiany MG, 2006, J PHARMACOL EXP THER, V318, P666, DOI 10.1124/jpet.106.104158
   Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565
   Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200
   Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0
   Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198
   Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497
   Tang TTL, 2003, J BIOL CHEM, V278, P30125, DOI 10.1074/jbc.M302042200
   Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298
   Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239
   Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200
   Tug S, 2009, BIOCHEM BIOPH RES CO, V384, P519, DOI 10.1016/j.bbrc.2009.05.016
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Westra J, 2007, ANN NY ACAD SCI, V1108, P340, DOI 10.1196/annals.1422.035
   Wolff NC, 2011, MOL CELL BIOL
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498
   Zhong H, 2000, CANCER RES, V60, P1541
NR 105
TC 72
Z9 79
U1 0
U2 17
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD MAY 15
PY 2011
VL 10
IS 10
BP 1557
EP 1562
DI 10.4161/cc.10.10.15789
PG 6
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 764HE
UT WOS:000290619700022
PM 21521942
OA Bronze
DA 2022-11-30
ER

PT J
AU Campbell, M
   Humphries, MM
   Kiang, AS
   Nguyen, ATH
   Gobbo, OL
   Tam, LCS
   Suzuki, M
   Hanrahan, F
   Ozaki, E
   Farrar, GJ
   Kenna, PF
   Humphries, P
AF Campbell, Matthew
   Humphries, Marian M.
   Kiang, Anna-Sophia
   Nguyen, Anh T. H.
   Gobbo, Oliviero L.
   Tam, Lawrence C. S.
   Suzuki, Mayu
   Hanrahan, Finnian
   Ozaki, Ema
   Farrar, G. -Jane
   Kenna, Paul F.
   Humphries, Peter
TI Systemic low-molecular weight drug delivery to pre-selected neuronal
   regions
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; blood-brain barrier; blood-retina
   barrier; drug delivery; RNAi/claudin-5
ID DOMINANT RETINITIS-PIGMENTOSA; BLOOD-BRAIN-BARRIER; LEBERS CONGENITAL
   AMAUROSIS; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   SUBRETINAL INJECTION; GENE-TRANSFER; MOUSE MODEL; THERAPY; GLIOBLASTOMA
AB We describe a procedure for controlled, periodic, reversible modulation of selected regions of the blood-brain barrier (BBB) or the inner-blood-retina barrier (iBRB) based on incorporation into an AAV-2/9 vector of a doxycycline-inducible gene encoding shRNA targeting claudin-5, one of 30 or so proteins constituting the BBB and iBRB. The vector may be introduced stereotaxically into pre-selected regions of the brain or into the retina, rendering these regions permeable to low-molecular weight compounds up to approximately 1kDa for the period of time during which the inducing agent, doxycycline, is administered in drinking water, but excluding potentially toxic higher molecular weight materials. We report on the use of barrier modulation in tandem with systemic drug therapy to prevent retinal degeneration and to suppress laser-induced choroidal neovascularization (CNV), the latter being the hallmark pathology associated with the exudative, or wet, form of age-related macular degeneration (AMD). These observations constitute the basis of a minimally invasive systemic therapeutic modality for retinal diseases, including retinitis pigmentosa and AMD, where, in early stage disease, the iBRB is intact and impervious to systemically administered drugs.
C1 [Campbell, Matthew; Humphries, Marian M.; Kiang, Anna-Sophia; Nguyen, Anh T. H.; Tam, Lawrence C. S.; Suzuki, Mayu; Hanrahan, Finnian; Ozaki, Ema; Farrar, G. -Jane; Kenna, Paul F.; Humphries, Peter] Trinity Coll Dublin, Dept Genet, Ocular Genet Unit, Dublin 2, Ireland.
   [Gobbo, Oliviero L.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland.
C3 Trinity College Dublin; Trinity College Dublin
RP Campbell, M (通讯作者)，Trinity Coll Dublin, Dept Genet, Ocular Genet Unit, Dublin 2, Ireland.
EM matthew.campbell@tcd.ie
RI Gobbo, Oliviero/S-2043-2019; Bateson, Jane Farrar/AAO-6147-2020; Gobbo,
   Oliviero L/R-1763-2016
OI Gobbo, Oliviero/0000-0003-4629-9485; Gobbo, Oliviero
   L/0000-0003-4629-9485
FU Science Foundation Ireland (SFI); Wellcome Trust; Irish Research Council
   for Science Engineering and Technology (IRCSET); Fighting Blindness
   Ireland (FB-Ireland); Health Research Board of Ireland (HRB); Enterprise
   Ireland (EI); US Department of Defense-Telemedicine and Advanced
   Technology Research Center (TATRC)
FX The Ocular Genetics Unit at TCD is supported by Science Foundation
   Ireland (SFI), The Wellcome Trust, Irish Research Council for Science
   Engineering and Technology (IRCSET) and Fighting Blindness Ireland
   (FB-Ireland), Health Research Board of Ireland (HRB), Enterprise Ireland
   (EI) and the US Department of Defense-Telemedicine and Advanced
   Technology Research Center (TATRC). We would like to thank Caroline
   Woods, Charles Murray, David Flynn and Rebecca Robertson for animal
   breeding and husbandry. The authors would also like to thank Dr
   Christian Kerskens for his advice with MRI experiments and the Research
   Foundation at the Royal Victoria Eye and Ear Hospital for assistance in
   the acquisition of the Index laser system.
CR Abdollahi Mohammad, 2004, J Infus Nurs, V27, P386, DOI 10.1097/00129804-200411000-00004
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Campbell M, 2008, J GENE MED, V10, P930, DOI 10.1002/jgm.1211
   Campbell M, 2009, P NATL ACAD SCI USA, V106, P17817, DOI 10.1073/pnas.0908561106
   Chadderton N, 2009, MOL THER, V17, P593, DOI 10.1038/mt.2008.301
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Foust KD, 2010, NAT BIOTECHNOL, V28, P271, DOI 10.1038/nbt.1610
   Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139
   KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   MULDOON LL, 1995, AM J PATHOL, V147, P1840
   NEUWELT EA, 1986, NEUROSURGERY, V19, P573, DOI 10.1227/00006123-198610000-00011
   O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Rizzolo LJ, 2007, MOL VIS, V13, P1259
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Sanges D, 2006, P NATL ACAD SCI USA, V103, P17366, DOI 10.1073/pnas.0606276103
   Sausville EA, 2003, CURR CANCER DRUG TAR, V3, P377, DOI 10.2174/1568009033481831
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Stieger K, 2008, MOL THER, V16, P916, DOI 10.1038/mt.2008.41
   Stieger K, 2006, MOL THER, V13, P967, DOI 10.1016/j.ymthe.2005.12.001
   Tam LCS, 2008, HUM MOL GENET, V17, P2084, DOI 10.1093/hmg/ddn107
   Tam LCS, 2010, HUM MOL GENET, V19, P4421, DOI 10.1093/hmg/ddq369
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   YANG FY, 2010, J CONTROL RELEASE
NR 31
TC 35
Z9 36
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1757-4676
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD APR
PY 2011
VL 3
IS 4
BP 235
EP 245
DI 10.1002/emmm.201100126
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 756LC
UT WOS:000290011700008
PM 21374818
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Vrabec, R
   Vatavuk, Z
   Pavlovic, D
   Sesar, A
   Cala, S
   Mandic, K
   Bucan, K
AF Vrabec, R
   Vatavuk, Z
   Pavlovic, D
   Sesar, A
   Cala, S
   Mandic, K
   Bucan, K
TI Ocular findings in patients with chronic renal failure undergoing
   haemodialysis
SO COLLEGIUM ANTROPOLOGICUM
LA English
DT Article
DE chronic renal failure; haemodialysis; ocular findings
ID INTRAOCULAR-PRESSURE; CORNEAL CALCIFICATION; CONJUNCTIVAL
AB The aim of this paper was to evaluate the ocular findings in patients with chronic renal failure (CRF) undergoing haemodialysis (HD). In 64 patients undergoing haemodialysis (30 female and 34 male), aged 24-83 years (mean 58 years) on haemodialysis 1-213 months (mean 47 months) complete ocular examination were performed: visual acuity (VA), intraocular pressure (IOP), biomicroscopic examination and fundoscopy. On right eye sixty-nine percent of patents had VA 0.6 or better, and on left eye 84% ofpatients had VA 0.6 or better. Mean IOP before dialysis was 15 mmHg and after dialysis was 14 mmHg. In 9 patients (14%) we found corneo-conjunctival calcium deposits. No correlation of ocular calcification and parathyroid hormone (PTH) level or calcium and phosphate product were observed. 39 (60%) patients had cataract. Hypertensive vascular changes were seen in 44 (68%) patients and in 6 (7%) patients age-related macular degeneration. Seven patients had diabetes mellitus and in 5 diabetic retinopathy was observed. Patients with CRF or who are receiving HD represent unique group ofpatients. Pathologic change could be found in many tissue and organs, therefore we suggest ocular examination more frequently in dialysis patients.
C1 Univ Zagreb, Dept Ophthalmol, Clin Hosp Sisters Mercy, Zagreb 10000, Croatia.
   Clin Hosp Systers Mercy, Dept Nephrol & Dialysis, Zagreb, Croatia.
   Univ Zagreb, Sch Med, Zagreb 41000, Croatia.
   Univ Hosp Split, Dept Ophthalmol, Split, Croatia.
C3 University of Zagreb; University of Zagreb, School of Dental Medicine;
   University of Zagreb; University of Zagreb, School of Dental Medicine;
   University of Split
RP Vrabec, R (通讯作者)，Univ Zagreb, Dept Ophthalmol, Clin Hosp Sisters Mercy, Vinogradsky Cesta 29, Zagreb 10000, Croatia.
EM romanourabec@hotmail.com
RI Bucan, Kajo/H-6144-2017; Pavlovic, Drasko/AAD-4566-2019; Cala,
   Svjetlana/ABG-3969-2020
OI Bucan, Kajo/0000-0003-2684-3447; Pavlovic, Drasko/0000-0002-2380-869X
CR Choong YF, 1998, BRIT J OPHTHALMOL, V82, P1342
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Diaz-Couchoud P, 2001, CORNEA, V20, P695, DOI 10.1097/00003226-200110000-00005
   Dursun D, 2000, BRIT J OPHTHALMOL, V84, P1225, DOI 10.1136/bjo.84.11.1225
   ELDER D, 1976, KIMPTON, V8, P132
   Hachache T, 1996, NEPHROLOGIE, V17, P117
   KLAASSENBROEKEMA N, 1993, BRIT J OPHTHALMOL, V77, P569, DOI 10.1136/bjo.77.9.569
   KLAASSENBROEKEMA N, 1995, GRAEF ARCH CLIN EXP, V233, P717, DOI 10.1007/BF00164676
   KLASSENBROEKEMA N, 1995, EUR J OPHTALMOL, V5, P7
   Michael Maureen, 2004, Nephrol Nurs J, V31, P185
   PAVLOVIC D, 1993, NEPHROL DIAL TRANSPL, V8, P882
   Pavlovic Drasko, 2003, Acta Medica Croatica, V57, P77
   Pelit A, 2003, CURR EYE RES, V26, P303, DOI 10.1076/ceyr.26.4.303.15425
   PORTER R, 1973, BRIT J OPHTHALMOL, V57, P339, DOI 10.1136/bjo.57.5.339
   Takeda K, 1997, CLIN NEPHROL, V48, P266
   Tawara A, 1998, CURR EYE RES, V17, P339, DOI 10.1080/02713689808951214
   TAWARA A, 2000, CURR EYE RES, V22, P33
   Tokuyama T, 1997, JPN J OPHTHALMOL, V41, P101, DOI 10.1016/S0021-5155(97)00014-2
   Tokuyama T, 2002, AM J KIDNEY DIS, V39, P291, DOI 10.1053/ajkd.2002.30548
   Tokuyama T, 1998, BRIT J OPHTHALMOL, V82, P751, DOI 10.1136/bjo.82.7.751
   Tovbin D, 2002, NEPHRON, V90, P181, DOI 10.1159/000049040
NR 21
TC 24
Z9 24
U1 1
U2 1
PU COLLEGIUM ANTROPOLOGICUM
PI ZAGREB
PA INST ANTHROPOLOGICAL RESEARCH, GAJEVA 32, PO BOX 290, HR-10000 ZAGREB,
   CROATIA
SN 0350-6134
J9 COLLEGIUM ANTROPOL
JI Coll. Anthropol.
PY 2005
VL 29
SU 1
BP 95
EP 98
PG 4
WC Anthropology
WE Social Science Citation Index (SSCI)
SC Anthropology
GA 961PH
UT WOS:000231673800022
PM 16193686
DA 2022-11-30
ER

PT J
AU Nilsson, UL
   Frennesson, C
   Nilsson, SEG
AF Nilsson, UL
   Frennesson, C
   Nilsson, SEG
TI Patients with AMD and a large absolute central scotoma can be trained
   successfully to use eccentric viewing, as demonstrated in a scanning
   laser ophthalmoscope
SO VISION RESEARCH
LA English
DT Article
DE age-related macular degeneration; central scotoma; eccentric viewing;
   reading speed; scanning laser ophthalmoscope
ID PREFERRED RETINAL LOCI; MACULAR DEGENERATION; LOW-VISION; FIXATION;
   REHABILITATION; LOCATION
AB Twenty patients with age-related macular degeneration, an absolute central scotoma and a mean visual acuity of 0.04 (20/475) were studied. A scanning laser ophthalmoscope (SLO) was used for microperimetry and determination of preferred retinal locus, often located to the left of the retinal lesion (corresponding to a location to the left of the visual field scotoma), which is considered unfavorable for reading. All 20 patients were trained to use a new and more favorable retinal locus for reading, above (or occasionally below) the retinal lesion (corresponding to a location below or above the visual field scotoma), first by reading scrolled text under simultaneous fixation monitoring and instruction in the SLO and then by reading printed text, using high magnification (mean 14.3 x). For the 18 patients who learned to use eccentric viewing, reading speed with adequate magnification prior to training was 9.0 +/- 5.8 words/min. With training (mean 5.2 hours), it increased significantly (p < 0.001) to 68.3 +/- 19.4 words per min. Training of eccentric reading has thus proved to be very successful. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Nilsson, UL (通讯作者)，Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
CR Altpeter E, 2000, VISION RES, V40, P1539, DOI 10.1016/S0042-6989(00)00059-6
   Backman O., 1979, LOW VISION TRAINING
   BRUGGEMAN H, 1997, VISION 96, P282
   CUMMINGS RW, 1992, INVEST OPHTH VIS SCI, V33, P1418
   FINE EM, 1999, VISUAL IMPAIRMENT RE, V1, P165
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Frennesson C, 1995, DOC OPHTHALMOL, V91, P9, DOI 10.1007/BF01204619
   GOODRICH GL, 1977, J VISUAL IMPAIR BLIN, V71, P377
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LOTT LA, 2002, INVEST OPHTHALMOL, P43
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P345, DOI 10.1007/BF00168266
   Nilsson UL, 2000, VISION REHABILITATIO, P59
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   ROMAYANANDA N, 1982, OPHTHALMOLOGY, V89, P937
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TrauzettelKlosinski S, 1996, NEURO-OPHTHALMOLOGY, V16, P241, DOI 10.3109/01658109609044632
NR 21
TC 158
Z9 169
U1 0
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD JUL
PY 2003
VL 43
IS 16
BP 1777
EP 1787
DI 10.1016/S0042-6989(03)00219-0
PG 11
WC Neurosciences; Ophthalmology; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology; Psychology
GA 699LV
UT WOS:000184059100009
PM 12818347
OA Bronze
DA 2022-11-30
ER

PT J
AU Chen, L
   Miyamura, N
   Ninomiya, Y
   Handa, JT
AF Chen, L
   Miyamura, N
   Ninomiya, Y
   Handa, JT
TI Distribution of the collagen IV isoforms in human Bruch's membrane
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GLOMERULAR-BASEMENT-MEMBRANE; BASAL LINEAR DEPOSIT; HUMAN MACULA;
   MONOCLONAL-ANTIBODIES; EXPRESSION; CHAINS; ORGANIZATION; NETWORK;
   MATRIX; LOCALIZATION
AB Aims: To determine the distribution of the alpha1 to alpha6 chains of type IV collagen in Bruch's membrane of the human posterior pole.
   Methods: Cryosections (10 mum) from 18 human eyes (20 months to 83 years old) were acid treated, blocked with 10% normal goat serum, incubated for 1 hour with monoclonal antibodies against type IV collagen isoform specific peptides at 1:75 dilution, and visualised with an ABC staining kit.
   Results: In Bruch's membrane, the alpha1 (IV) and alpha2(IV) chains were identified in retinal pigment epithelial (10/ 18 = 55%) and choriocapillaris basement membranes (18/18 = 100%); the alpha3(IV), alpha4(IV), and alpha5(IV) chains were also found in the retinal pigment epithelial basement membrane (13/18 = 72%). In the choroid, the alpha1 (IV) and alpha2(IV) chains were detected in the blood vessels (18/18 = 100%). The alpha(IV) chain was not identified in any sections.
   Conclusion: The heterogeneous distribution of alpha1 -2(IV) and alpha3-5(IV) in Bruch's membrane could give insights into the function of this structure in health, ageing, and diseases such as age related macular degeneration.
C1 Univ Calif Davis, Dept Ophthalmol, Davis, CA 95616 USA.
   Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 700, Japan.
   Johns Hopkins Med Inst, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 University of California System; University of California Davis; Okayama
   University; Johns Hopkins University; Johns Hopkins Medicine
RP Handa, JT (通讯作者)，Michael B Panitch Macular Degenerat Lab, 3-109 Jefferson St Bldg,600 N Wolfe St, Baltimore, MD 21287 USA.
FU NEI NIH HHS [EY14005, R01 EY014005] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [R01EY014005] Funding Source: NIH RePORTER
CR BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200
   Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Harvey SJ, 1998, KIDNEY INT, V54, P1857, DOI 10.1046/j.1523-1755.1998.00188.x
   HUDSON BG, 1993, J BIOL CHEM, V268, P26033
   ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P2680
   Kahsai TZ, 1997, J BIOL CHEM, V272, P17023, DOI 10.1074/jbc.272.27.17023
   KLEPPEL MM, 1989, AM J PATHOL, V134, P813
   KLEPPEL MM, 1990, AM J ANAT, V187, P165, DOI 10.1002/aja.1001870205
   LIN WL, 1994, CELL MOL BIOL, V40, P851
   Ljubimov AV, 1996, J HISTOCHEM CYTOCHEM, V44, P1469, DOI 10.1177/44.12.8985139
   LJUBIMOV AV, 1995, LAB INVEST, V72, P461
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455
   NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219
   Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051
   Riedle B, 1997, AM J PATHOL, V151, P215
   SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322
   Sado Y, 1998, J BIOCHEM-TOKYO, V123, P767
   Schittny JC, 1989, CURR OPIN CELL BIOL, V1, P983, DOI 10.1016/0955-0674(89)90069-0
NR 26
TC 52
Z9 52
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2003
VL 87
IS 2
BP 212
EP 215
DI 10.1136/bjo.87.2.212
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 640NR
UT WOS:000180695300020
PM 12543754
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, MJ
   Kim, DH
   Kwak, HS
   Yu, IS
   Um, MY
AF Kim, Min Jung
   Kim, Dong Hee
   Kwak, Han Sub
   Yu, In-Sun
   Um, Min Young
TI Protective Effect of Chrysanthemum boreale Flower Extracts against
   A2E-Induced Retinal Damage in ARPE-19 Cell
SO ANTIOXIDANTS
LA English
DT Article
DE Chrysanthemum boreale Makino flower; A2E; age-related macular
   degeneration; A2E accumulation; A2E-induced cell death
ID PIGMENTED EPITHELIAL-CELLS; OXIDATIVE-STRESS; RPE CELLS; LIPOFUSCIN
   FLUOROPHORE; MACULAR DEGENERATION; ESSENTIAL OIL; BLUE-LIGHT; A2E;
   INFLAMMATION; PHOTODEGRADATION
AB In age-related macular degeneration, N-retinylidene-N-retinylethanolamine (A2E) accumulates in retinal pigment epithelium (RPE) cells and generates oxidative stress, which further induces cell death. Polyphenols are well known for their antioxidant and beneficial effects on vision. Chrysanthemum boreale Makino (CB) flowers, which contain flavonoids, have antioxidant activity. We hypothesized that polyphenols in ethanolic extracts of CB (CBE) and its fractions suppressed A2E-mediated ARPE-19 cell damage, a human RPE cell line. CBE is rich in polyphenols, shows antioxidant activity, and suppresses intracellular accumulation of A2E and cell death induced by A2E. Among the five fractions, the polyphenol content and antioxidant effect were in the order of the ethyl acetate fraction (EtOAc) > butanol fraction (BuOH) > hexane fraction (Hex) > dichloromethane fraction (CH2Cl2) > water fraction (H2O). In contrast, the inhibitory ability of A2E accumulation and A2E-induced cell death was highest in H2O, followed by BuOH. In the correlation analysis, polyphenols in the H2O and BuOH fractions had a significant positive correlation with antioxidant effects, but no significant correlation with cell damage caused by A2E. Our findings suggest that substances other than polyphenols present in CBE can suppress the effects of A2E, and further research is needed.
C1 [Kim, Min Jung; Kim, Dong Hee; Yu, In-Sun; Um, Min Young] Korea Food Res Inst, Res Div Food Functional, Wonju 55365, South Korea.
   [Kwak, Han Sub] Korea Food Res Inst, Res Div Food Convergence, Wonju 55365, South Korea.
C3 Korea Food Research Institute (KFRI); Korea Food Research Institute
   (KFRI)
RP Kim, MJ (通讯作者)，Korea Food Res Inst, Res Div Food Functional, Wonju 55365, South Korea.
EM mjkim14@kfri.re.kr; donghey543@naver.com; hskwak@kfri.re.kr;
   dlslis89@gmail.com; myum@kfri.re.kr
OI Kwak, Han Sub/0000-0003-4270-6821; KIM, MIN JUNG/0000-0003-0205-016X
FU Korea Food Research Institute [E0212022-02]; Technology Innovation
   Program - Ministry of Trade, Industry & Energy (MOTIE, Korea) [20012469]
FX This work was supported by Main Research Program (E0212022-02) of the
   Korea Food Research Institute, and the Technology Innovation Program
   (20012469) funded by the Ministry of Trade, Industry & Energy (MOTIE,
   Korea).
CR Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Baba SA, 2015, J TAIBAH UNIV SCI, V9, P449, DOI 10.1016/j.jtusci.2014.11.001
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bermudez V, 2019, ADV EXP MED BIOL, V1185, P289, DOI 10.1007/978-3-030-27378-1_47
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Fontaine V, 2021, AGING-US, V13, P22040, DOI 10.18632/aging.203558
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Hapsari S, 2022, ARAB J CHEM, V15, DOI 10.1016/j.arabjc.2021.103666
   He L, 2017, CELL PHYSIOL BIOCHEM, V44, P532, DOI 10.1159/000485089
   Hohn A, 2017, REDOX BIOL, V11, P482, DOI 10.1016/j.redox.2016.12.001
   Hohn A, 2013, REDOX BIOL, V1, P140, DOI 10.1016/j.redox.2013.01.006
   Hong CU., 2002, J APPL BIOL CHEM, V45, P108
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hsueh YJ, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031255
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kang MK, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081046
   Kim DY, 2015, NAT PROD RES, V29, P562, DOI 10.1080/14786419.2014.952231
   Kim DY, 2018, CHEM BIODIVERS, V15, DOI 10.1002/cbdv.201700506
   Kim DY, 2015, PHARM BIOL, V53, P725, DOI 10.3109/13880209.2014.941882
   Kim DH, 2020, MOLECULES, V25, DOI 10.3390/molecules25071737
   Kim J, 2020, FREE RADICAL BIO MED, V152, P622, DOI 10.1016/j.freeradbiomed.2019.12.003
   Kim KJ, 2003, PLANTA MED, V69, P274, DOI 10.1055/s-2003-38479
   Kim SJ, 2014, J KOREAN SOC APPL BI, V57, P789, DOI 10.1007/s13765-014-4162-5
   Kim Yon-Suk, 2014, [Journal of the Korean Society of Food Science and Nutrition, 한국식품영양과학회지], V43, P60
   Kim Y, 2010, J ETHNOPHARMACOL, V131, P550, DOI 10.1016/j.jep.2010.07.030
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Lee BL, 2016, NUTR RES, V36, P1402, DOI 10.1016/j.nutres.2016.11.008
   Lee JR, 2003, PLANTA MED, V69, P880, DOI 10.1055/s-2003-43221
   Liu J, 2008, INVEST OPHTH VIS SCI, V49, P772, DOI 10.1167/iovs.07-0675
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Mazzoni F, 2019, METHODS MOL BIOL, V1834, P95, DOI 10.1007/978-1-4939-8669-9_7
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Nugroho A, 2013, ARCH PHARM RES, V36, P51, DOI 10.1007/s12272-013-0015-8
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Pisoschi A.M., 2011, BIOCH ANAL BIOCH, V1, P106, DOI [10.4172/2161-1009.1000106, DOI 10.4172/2161-1009.1000106]
   Porta EA, 2002, ANN NY ACAD SCI, V959, P57, DOI 10.1111/j.1749-6632.2002.tb02083.x
   Rhodahi R., 2017, INDONES FOOD NUTR PR, V14, P9
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Ryan S.J., 2012, RETINA-J RET VIT DIS, V5th, P1064
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Scimone C, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108641
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Szymanowska U, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8080299
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Wang Y, 2019, FOOD AGR IMMUNOL, V30, P829, DOI 10.1080/09540105.2019.1637825
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Yoon SM, 2016, ARCH PHARM RES, V39, P21, DOI 10.1007/s12272-015-0683-7
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   한완수, 2003, [KOREAN JOURNAL OF MEDICINAL CROP SCIENCE, 한국약용작물학회지], V11, P1
NR 55
TC 0
Z9 0
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD APR
PY 2022
VL 11
IS 4
AR 669
DI 10.3390/antiox11040669
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 0T1LK
UT WOS:000786735300001
PM 35453354
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, JR
   Tchivelekete, GM
   Zhou, XZ
   Tang, WZ
   Liu, F
   Liu, MZ
   Zhao, CX
   Shu, XH
   Zeng, ZH
AF Chen, Jianrong
   Tchivelekete, Gabriel Mbuta
   Zhou, Xinzhi
   Tang, Weizhuo
   Liu, Fang
   Liu, Minzhuo
   Zhao, Chenxi
   Shu, Xinhua
   Zeng, Zhihong
TI Anti-inflammatory activities of Gardenia jasminoides extracts in retinal
   pigment epithelial cells and zebrafish embryos
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE age-related macular degeneration; inflammation; retinal pigment
   epithelial cells; zebrafish embryos; Gardenia jasminoides
ID NF-KAPPA-B; SIGNALING PATHWAYS; INFLAMMATORY RESPONSES; MACULAR
   DEGENERATION; OXIDATIVE STRESS; GANGLION-CELLS; CROCETIN; CROCIN;
   GENIPOSIDE; DAMAGE
AB Age-related macular degeneration (AMD) is the most common cause of visual impairment in developed countries. Inflammation serves a critical role in the pathogenesis of AMD. Gardenia jasminoides is found in several regions of China and is traditionally used as an organic yellow dye but has also been widely used as a therapeutic agent in numerous diseases, including inflammation, depression, hepatic and vascular disorders, which may reflect the variability of functional compounds that are present in Gardenia jasminoides extracts (GJE). To investigate the therapeutic potential of GJE for AMD, ARPE-19 cells were treated with lipopolysaccharide (LPS) or LPS plus GJE. GJE significantly decreased LPS-induced expression of proinflammatory cytokines, including IL-1 beta, IL-6 and TNF-alpha. In the in vivo study, GJE inhibited CuSO4-induced migration of primitive macrophages to the lateral line in zebrafish embryos. GJE also attenuated expression of cytokines (IL-1 beta, IL-6 and TNF-alpha), NFKB activating protein (nkap) and TLR4 in ARPE-19 cells. The results of the present study demonstrated the anti-inflammatory potential of GJE in vitro and in vivo, and suggested GJE as a therapeutic candidate for AMD.
C1 [Chen, Jianrong; Tang, Weizhuo; Liu, Fang; Liu, Minzhuo; Zhao, Chenxi; Zeng, Zhihong] Changsha Univ, Coll Biol & Environm Engn, 98 Hongshan Rd, Changsha 410022, Hunan, Peoples R China.
   [Tchivelekete, Gabriel Mbuta; Zhou, Xinzhi; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, 70 Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Hunan, Peoples R China.
   [Zeng, Zhihong] Hunan Prov Key Lab Nutr & Qual Control Aquat Anim, Changsha 410022, Hunan, Peoples R China.
C3 Changsha University; Glasgow Caledonian University; Glasgow Caledonian
   University; Shaoyang University
RP Zeng, ZH (通讯作者)，Changsha Univ, Coll Biol & Environm Engn, 98 Hongshan Rd, Changsha 410022, Hunan, Peoples R China.; Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Biol & Biomed Sci, 70 Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.
EM Xinhua.Shu@gcu.ac.uk; Z20181201@ccsu.edu.cn
RI Zeng, Zhihong/HEV-8703-2022
FU Department of Education, Hunan, China [19A045]; Hunan Province 'Help Our
   Motherland Through Elite Intellectual Resources from Overseas' program
   [60802]; Hunan Provincial Natural Science Foundation of China
   [2020JJ4641]; Rosetrees Trust [M160, M160-F1, M160-F2]; National Eye
   Research Centre [SAC037]; Lotus Scholarship Program of Hunan Province
FX The present study was funded by the Department of Education, Hunan,
   China (grant no. 19A045); the Hunan Province `Help Our Motherland
   Through Elite Intellectual Resources from Overseas' program to ZZ (grant
   no. 60802); and a Hunan Provincial Natural Science Foundation of China
   (grant no. 2020JJ4641) to JC. The study was partially supported by the
   Rosetrees Trust (grant nos. M160, M160-F1 and M160-F2), National Eye
   Research Centre (grant no. SAC037) and the Lotus Scholarship Program of
   Hunan Province (2019) to XS.
CR Alhasani RH, 2018, FOOD CHEM TOXICOL, V112, P76, DOI 10.1016/j.fct.2017.12.037
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Chen L, 2015, OPHTHALMIC RES, V54, P157, DOI 10.1159/000439026
   Chen LP, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112829
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Duan XX, 2017, MOL IMMUNOL, V81, P160, DOI 10.1016/j.molimm.2016.12.005
   Fu YH, 2012, INT IMMUNOPHARMACOL, V14, P792, DOI 10.1016/j.intimp.2012.07.006
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Hwang SM, 2010, PHYTOTHER RES, V24, pS214, DOI 10.1002/ptr.3099
   Ishizuka F, 2013, EUR J PHARMACOL, V703, P1, DOI [10.1016/j.ephar.2013.02.007, 10.1016/j.ejphar.2013.02.007]
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kassumeh S, 2021, EUR J OPHTHALMOL, V31, P630, DOI 10.1177/1120672119895967
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011
   Laabich A, 2006, INVEST OPHTH VIS SCI, V47, P3156, DOI 10.1167/iovs.05-1621
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Li JJ, 2018, FISH SHELLFISH IMMUN, V83, P205, DOI 10.1016/j.fsi.2018.09.032
   Lin WH, 2015, IRAN J BASIC MED SCI, V18, P555
   Liu F, 2016, MOL VIS, V22, P352
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lv BC, 2016, INT J MOL MED, V37, P225, DOI 10.3892/ijmm.2015.2418
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Mantel I, 2016, THER UMSCH, V73, P79, DOI 10.1024/0040-5930/a000760
   Nam KN, 2010, EUR J PHARMACOL, V648, P110, DOI 10.1016/j.ejphar.2010.09.003
   National Commission of Pharmacopoeia, 2010, PHARMACOPOEIA PEOPLE, V1, P231
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nitta K, 2019, MOL VIS, V25, P859
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Ozal SA, 2018, CURR EYE RES, V43, P1169, DOI 10.1080/02713683.2018.1481517
   Qi Y, 2013, EXP EYE RES, V107, P44, DOI 10.1016/j.exer.2012.11.011
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sepahi S, 2018, AM J OPHTHALMOL, V190, P89, DOI 10.1016/j.ajo.2018.03.007
   Shan MQ, 2019, J ETHNOPHARMACOL, V233, P169, DOI 10.1016/j.jep.2019.01.004
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Song XJ, 2014, INFLAMMATION, V37, P1588, DOI 10.1007/s10753-014-9885-2
   Su Q, 2018, INFLAMMATION, V41, P1229, DOI 10.1007/s10753-018-0769-8
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Tao LF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0489-7
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Vaure C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00316
   Wang J, 2012, NEUROCHEM RES, V37, P2235, DOI 10.1007/s11064-012-0852-8
   Wang LP, 2019, J MOL MED, V97, P523, DOI 10.1007/s00109-019-01753-5
   Wang YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010073
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yang C, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107849
   Yorgun Mucella Arikan, 2017, Biochem Biophys Rep, V12, P245, DOI 10.1016/j.bbrep.2017.09.007
   Yuan A, 2011, SEMIN OPHTHALMOL, V26, P149, DOI 10.3109/08820538.2011.570846
   Zhang Y, 2008, J IMMUNOL, V181, P2155, DOI 10.4049/jimmunol.181.3.2155
   Zhang Y, 2019, J ETHNOPHARMACOL, V243, DOI 10.1016/j.jep.2019.112122
   Zhang Y, 2020, CHEM-BIOL INTERACT, V316, DOI 10.1016/j.cbi.2019.108928
   Zhao HL, 2019, INT J MOL MED, V43, P936, DOI 10.3892/ijmm.2018.4027
   Zhou HL, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112427
NR 55
TC 2
Z9 2
U1 10
U2 24
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUL
PY 2021
VL 22
IS 1
AR 700
DI 10.3892/etm.2021.10132
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA SD1DM
UT WOS:000651107500001
PM 34007309
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhang, R
   Engel, AL
   Wang, YK
   Li, B
   Shen, WY
   Gillies, MC
   Chao, JR
   Du, JH
AF Zhang, Rui
   Engel, Abbi L.
   Wang, Yekai
   Li, Bo
   Shen, Weiyong
   Gillies, Mark C.
   Chao, Jennifer R.
   Du, Jianhai
TI Inhibition of Mitochondrial Respiration Impairs Nutrient Consumption and
   Metabolite Transport in Human Retinal Pigment Epithelium
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE mitochondrial respiration; metabolism; retinal pigment epithelium;
   metabolites; glucose; amino acids; nucleotides; ketone bodies
ID CITRIC-ACID CYCLE; NUCLEOTIDE-METABOLISM; CELL-PROLIFERATION; CHAIN;
   PHOTORECEPTOR; DEGENERATION; NICOTINAMIDE; ANAPLEROSIS; KETOGENESIS;
   MUTATIONS
AB Mitochondrial respiration in mammalian cells not only generates ATP to meet their own energy needs but also couples with biosynthetic pathways to produce metabolites that can be exported to support neighboring cells. However, how defects in mitochondrial respiration influence these biosynthetic and exporting pathways remains poorly understood. Mitochondrial dysfunction in retinal pigment epithelium (RPE) cells is an emerging contributor to the death of their neighboring photoreceptors in degenerative retinal diseases including age-related macular degeneration. In this study, we used targeted-metabolomics and C-13 tracing to investigate how inhibition of mitochondrial respiration influences the intracellular and extracellular metabolome. We found inhibition of mitochondrial respiration strikingly influenced both the intracellular and extracellular metabolome in primary RPE cells. Intriguingly, the extracellular metabolic changes sensitively reflected the intracellular changes. These changes included substantially enhanced glucose consumption and lactate production; reduced release of pyruvate, citrate, and ketone bodies; and massive accumulation of multiple amino acids and nucleosides. In conclusion, these findings reveal a metabolic signature of nutrient consumption and release in mitochondrial dysfunction in RPE cells. Testing medium metabolites provides a sensitive and noninvasive method to assess mitochondrial function in nutrient utilization and transport.
C1 [Zhang, Rui; Wang, Yekai; Li, Bo; Du, Jianhai] West Virginia Univ, Dept Ophthalmol, Morgantown, WV 26506 USA.
   [Zhang, Rui; Wang, Yekai; Li, Bo; Du, Jianhai] West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA.
   [Zhang, Rui; Shen, Weiyong; Gillies, Mark C.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW 2000, Australia.
   [Engel, Abbi L.; Chao, Jennifer R.] Univ Washington, Dept Ophthalmol, Seattle, WA 98109 USA.
C3 West Virginia University; West Virginia University; University of
   Sydney; University of Washington; University of Washington Seattle
RP Du, JH (通讯作者)，West Virginia Univ, Dept Ophthalmol, Morgantown, WV 26506 USA.; Du, JH (通讯作者)，West Virginia Univ, Dept Biochem, Morgantown, WV 26506 USA.; Chao, JR (通讯作者)，Univ Washington, Dept Ophthalmol, Seattle, WA 98109 USA.
EM jrchao@uw.edu; jianhai.du@wvumedicine.org
OI Du, Jianhai/0000-0002-2019-8128; Chao, Jennifer/0000-0002-6859-5552
FU NIH [EY026030]; Retina Research Foundation; BrightFocus Foundation; NIH
   WV INBRE grant [P20 GM103434]; WVCTSI Grant [GM104942]; Research to
   Prevent Blindness
FX This work was supported by NIH Grants EY026030 (to J.R.C. and J.D.), the
   Retina Research Foundation (to J.D.), BrightFocus Foundation (to J.D.),
   funds for Core facilities P20 GM103434 (NIH WV INBRE grant), WVCTSI
   Grant GM104942, Research to Prevent Blindness Sybil B. Harrington
   Physician-Scientist Award for Macular Degeneration (J.R.C.), and an
   unrestricted Grant from Research to Prevent Blindness (J.R.C.). All raw
   mass spectrometry data have been deposited to MassIVE (Data set
   identifier: MSV000086157 and MSV000086159).
CR Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010
   Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085
   Barile M, 2016, J INHERIT METAB DIS, V39, P545, DOI 10.1007/s10545-016-9950-0
   Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006
   Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016
   Blancquaert L, 2016, J PHYSIOL-LONDON, V594, P4849, DOI 10.1113/JP272050
   Bowne SJ, 2002, HUM MOL GENET, V11, P559, DOI 10.1093/hmg/11.5.559
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Diebold LP, 2019, NAT METAB, V1, P158, DOI 10.1038/s42255-018-0011-x
   Du JH, 2018, ADV EXP MED BIOL, V1074, P289, DOI 10.1007/978-3-319-75402-4_35
   Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113
   Du JH, 2016, J BIOL CHEM, V291, P4698, DOI 10.1074/jbc.M115.698985
   Du JH, 2015, METHOD ENZYMOL, V561, P149, DOI 10.1016/bs.mie.2015.04.002
   Du JH, 2013, P NATL ACAD SCI USA, V110, P18501, DOI 10.1073/pnas.1311193110
   Ehebauer F, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117474
   Fasullo M, 2015, INT J MOL SCI, V16, P9431, DOI 10.3390/ijms16059431
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Gibala MJ, 2000, ACTA PHYSIOL SCAND, V168, P657, DOI 10.1046/j.1365-201x.2000.00717.x
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Grenell A, 2019, P NATL ACAD SCI USA, V116, P3530, DOI 10.1073/pnas.1812941116
   HAYAISHI O, 1961, J BIOL CHEM, V236, P781
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kraus D, 2014, NATURE, V508, P258, DOI 10.1038/nature13198
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lai YC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071502
   Lane AN, 2015, NUCLEIC ACIDS RES, V43, P2466, DOI 10.1093/nar/gkv047
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Liu L, 2018, CELL METAB, V27, P1067, DOI 10.1016/j.cmet.2018.03.018
   Millard P, 2012, BIOINFORMATICS, V28, P1294, DOI 10.1093/bioinformatics/bts127
   Olsen RKJ, 2016, AM J HUM GENET, V98, P1130, DOI 10.1016/j.ajhg.2016.04.006
   Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200
   Phang JM, 2010, ANNU REV NUTR, V30, P441, DOI 10.1146/annurev.nutr.012809.104638
   Plana-Bonamaiso A, 2020, ELIFE, V9, DOI 10.7554/eLife.56418
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   Sheline CT, 2010, MOL VIS, V16, P2639
   Shum M, 2019, J BIOL CHEM, V294, P12250, DOI 10.1074/jbc.RA119.008488
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017
   Tanianskii DA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030524
   Titov DV, 2016, SCIENCE, V352, P231, DOI 10.1126/science.aad4017
   Wang W, 2019, CELL REP, V28, P1323, DOI 10.1016/j.celrep.2019.06.093
   Wang YK, 2018, NEUROBIOL AGING, V71, P223, DOI 10.1016/j.neurobiolaging.2018.07.024
   Xu R, 2020, J BIOL CHEM, V295, P2324, DOI 10.1074/jbc.RA119.011727
   Yam M, 2019, J BIOL CHEM, V294, P10278, DOI 10.1074/jbc.RA119.007983
   Zabielska MA, 2015, PHARMACOL REP, V67, P682, DOI 10.1016/j.pharep.2015.04.007
   Zeevalk GD, 2000, J NEUROCHEM, V75, P1027, DOI 10.1046/j.1471-4159.2000.0751027.x
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 53
TC 2
Z9 2
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD JAN 1
PY 2021
VL 20
IS 1
BP 909
EP 922
DI 10.1021/acs.jproteome.0c00690
PG 14
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PO4NU
UT WOS:000605145400079
PM 32975122
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Yin, X
   Zhang, BY
   Chen, L
   Xia, W
   Liu, GQ
   Zhu, XF
   Ren, C
   Liu, WM
   Lu, PR
AF Yin, Xue
   Zhang, Bingyu
   Chen, Lei
   Xia, Wei
   Liu, Gaoqin
   Zhu, Xuefei
   Ren, Chi
   Liu, Weiming
   Lu, Peirong
TI Essential Contribution of Macrophage Tie2 Signalling in a Murine Model
   of Laser-Induced Choroidal Neovascularization
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MACULAR DEGENERATION; TUMOR ANGIOGENESIS; TIE2-EXPRESSING MONOCYTES;
   PERIPHERAL-BLOOD; EXPRESSION; INHIBITORS; PHENOTYPE; HYPOXIA; RELAPSE;
   GROWTH
AB Wet age-related macular degeneration (AMD), which can cause progressive blindness, is characterised by choroid neovascularization (CNV) in the macular area. Although close attention has been paid to AMD, and anti-vascular endothelial growth factor (VEGF) drugs are available, its complex pathogenesis is still elusive. Tie2-expressing macrophages (TEMs) have been found to promote angiogenesis in remodel tissues and tumours. This study aimed to elucidate the role of macrophage Tie2 signalling in laser-induced CNV (LCNV). We observed that TEMs were responsible for the severity of CNV. Mechanistically, TEM deletion resulted in impaired LCNV due to the suppression of inflammatory angiogenesis and the promotion of apoptosis. We also observed that TEMs prevented apoptosis of b.End3 cells, but promoted their migration, proliferation and tube formation via VEGF, extracellular signal-regulated kinase (ERK) and v-akt murine thymoma viral oncogene (AKT)-dependent signalling pathways. The flow cytometry results comparing dry AMD patients and healthy controls with wet AMD patients showed that the percentage of Tie2(+)CD14(+) cells was higher in the wet AMD patients' peripheral blood. This study demonstrates that Tie2 expression by macrophages intensifies CNV in LCNV murine models, thereby proposing an additional intervention option to inhibit CNV.
C1 [Yin, Xue; Zhang, Bingyu; Chen, Lei; Xia, Wei; Liu, Gaoqin; Zhu, Xuefei; Ren, Chi; Liu, Weiming; Lu, Peirong] Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, Suzhou, Peoples R China.
C3 Soochow University - China
RP Lu, PR (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, Suzhou, Peoples R China.
EM lupeirong@suda.edu.cn
RI Liu, Gaoqin/AAG-1684-2021
OI Liu, Weiming/0000-0002-0625-9297; Ren, Chi/0000-0003-1686-8253
FU National Natural Science Foundation in China [81671641, 30972712];
   Jiangsu Provincial Medical Innovation Team [CXTDA2017039]; Jiangsu
   Provincial Natural Science Foundation [BK20151208]; Soochow Scholar
   Project of Soochow University [R5122001]
FX The LyzCre<SUP>+/+</SUP> mice and Tie2<SUP>flox/flox</SUP> mice were a
   gift from Professor Yulong He of Soochow University. The present study
   was supported by the National Natural Science Foundation in China (Grant
   Nos. 81671641, 30972712), the Jiangsu Provincial Medical Innovation Team
   (grant no. CXTDA2017039), the Jiangsu Provincial Natural Science
   Foundation (Grant No. BK20151208) and the Soochow Scholar Project of
   Soochow University (Grant No. R5122001).
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Barben M, 2018, ADV EXP MED BIOL, V1074, P177, DOI 10.1007/978-3-319-75402-4_22
   Capobianco A, 2011, AM J PATHOL, V179, P2651, DOI 10.1016/j.ajpath.2011.07.029
   Care AS, 2013, J CLIN INVEST, V123, P3472, DOI 10.1172/JCI60561
   Chen L, 2016, CANCER RES, V76, P6828, DOI 10.1158/0008-5472.CAN-16-1114
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   De Palma M, 2003, NAT MED, V9, P789, DOI 10.1038/nm871
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Dopheide JF, 2016, ANGIOGENESIS, V19, P67, DOI 10.1007/s10456-015-9489-y
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ferraro B, 2019, J AM COLL CARDIOL, V73, P2990, DOI 10.1016/j.jacc.2019.03.503
   Garcia S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082088
   Germano Domenico, 2014, Hepatobiliary Surg Nutr, V3, P166, DOI 10.3978/j.issn.2304-3881.2014.06.04
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hangai M, 2001, HUM GENE THER, V12, P1311, DOI 10.1089/104303401750270968
   Hughes R, 2015, CANCER RES, V75, P3479, DOI 10.1158/0008-5472.CAN-14-3587
   Hume DA, 2019, TRENDS IMMUNOL, V40, P98, DOI 10.1016/j.it.2018.11.007
   Hussain Ali Aijaz, 2017, J Neurodegener Dis, V2017, P4810232, DOI 10.1155/2017/4810232
   Kabala PA, 2020, RHEUMATOLOGY, V59, P426, DOI 10.1093/rheumatology/kez315
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283
   Lederman M, 2010, INVEST OPHTH VIS SCI, V51, P53, DOI 10.1167/iovs.08-3019
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Lewis CE, 2007, CANCER RES, V67, P8429, DOI 10.1158/0008-5472.CAN-07-1684
   Liang W, 2016, CANCER IMMUNOL RES, V4, P83, DOI 10.1158/2326-6066.CIR-15-0313
   Liew G, 2007, OPHTHALMOLOGY, V114, P1793, DOI 10.1016/j.ophtha.2007.04.036
   Liu C, 2016, IMMUNITY, V44, P1162, DOI 10.1016/j.immuni.2016.03.008
   Lu PR, 2008, J IMMUNOL, V180, P4283, DOI 10.4049/jimmunol.180.6.4283
   Lu PR, 2009, INVEST OPHTH VIS SCI, V50, P4761, DOI 10.1167/iovs.08-2732
   Matsubara T, 2013, HEPATOLOGY, V57, P1416, DOI 10.1002/hep.25965
   Murdoch C, 2007, J IMMUNOL, V178, P7405, DOI 10.4049/jimmunol.178.11.7405
   Patel AS, 2013, EMBO MOL MED, V5, P858, DOI 10.1002/emmm.201302752
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003
   Premanand C, 2006, INVEST OPHTH VIS SCI, V47, P2179, DOI 10.1167/iovs.05-0580
   Rinsky B, 2017, MOL VIS, V23, P889
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Semones M, 2007, BIOORG MED CHEM LETT, V17, P4756, DOI 10.1016/j.bmcl.2007.06.068
   Spiller KL, 2014, BIOMATERIALS, V35, P4477, DOI 10.1016/j.biomaterials.2014.02.012
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504
   Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001
   Zhang BY, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107972
NR 47
TC 2
Z9 2
U1 0
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 15
PY 2020
VL 10
IS 1
AR 9613
DI 10.1038/s41598-020-66580-y
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ME8WZ
UT WOS:000544936100015
PM 32541815
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mishra, Z
   Ganegoda, A
   Selicha, J
   Wang, ZY
   Sadda, SR
   Hu, ZH
AF Mishra, Zubin
   Ganegoda, Anushika
   Selicha, Jane
   Wang, Ziyuan
   Sadda, SriniVas R.
   Hu, Zhihong
TI Automated Retinal Layer Segmentation Using Graph-based Algorithm
   Incorporating Deep-learning-derived Information
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; GEOGRAPHIC-ATROPHY; MACULAR DEGENERATION;
   VISUAL-ACUITY; PROGRESSION; IMAGES; EYES; BOUNDARIES; PATTERNS; DRUSEN
AB Regular drusen, an accumulation of material below the retinal pigment epithelium (RPE), have long been established as a hallmark early feature of nonneovascular age-related macular degeneration (AMD). Advances in imaging have expanded the phenotype of AMD to include another extracellular deposit, reticular pseudodrusen (RPD) (also termed subretinal drusenoid deposits, SDD), which are located above the RPE. We developed an approach to automatically segment retinal layers associated with regular drusen and RPD in spectral domain (SD) optical coherence tomography (OCT) images. More specifically, a shortest-path algorithm enhanced with probability maps generated through a fully convolutional neural network was used to segment drusen and RPD, as well as 11 retinal layers in SD-OCT volumes. This algorithm achieves a mean difference that is within the subpixel accuracy range drusen and RPD, alongside the other 11 retinal layers, highlighting the high robustness of this algorithm for this dataset. To the best of our knowledge, this is the first report of a validated algorithm for the automated segmentation of the retinal layers including early AMD features of RPD and regular drusen separately on SD-OCT images.
C1 [Mishra, Zubin; Ganegoda, Anushika; Selicha, Jane; Wang, Ziyuan; Sadda, SriniVas R.; Hu, Zhihong] Doheny Eye Inst, Doheny Image Anal Lab, Los Angeles, CA 90033 USA.
   [Wang, Ziyuan; Sadda, SriniVas R.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles
RP Hu, ZH (通讯作者)，Doheny Eye Inst, Doheny Image Anal Lab, Los Angeles, CA 90033 USA.
EM jhu@doheny.org
OI Hu, Zhihong/0000-0001-8307-0298
FU National Eye Institute of the National Institutes of Health
   [R21EY030619, R01EY029595]
FX Research reported in this publication was partially supported by the
   National Eye Institute of the National Institutes of Health under Award
   Number R21EY030619 and R01EY029595.
CR Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu Z., 2009, P SOC PHOTO-OPT INS, V7262
   Hu ZH, 2017, NEUROPHOTONICS, V4, DOI 10.1117/1.NPh.4.1.011012
   Hu ZH, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.7.076006
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P1722, DOI 10.1167/iovs.12-10578
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Kugelman J, 2018, BIOMED OPT EXPRESS, V9, P5759, DOI 10.1364/BOE.9.005759
   Leung CKS, 2012, OPHTHALMOLOGY, V119, P1858, DOI 10.1016/j.ophtha.2012.03.044
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Sandberg MA, 2008, INVEST OPHTH VIS SCI, V49, P4568, DOI 10.1167/iovs.08-1992
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Teng P. Y. Caserel, 2013, ZENODO
   Tian J., PLOS ONE, V10
   Wang ZY, 2019, PROC SPIE, V10950, DOI 10.1117/12.2511538
   Yazdanpanah A, 2009, LECT NOTES COMPUT SC, V5762, P649, DOI 10.1007/978-3-642-04271-3_79
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 20
Z9 20
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 12
PY 2020
VL 10
IS 1
AR 9541
DI 10.1038/s41598-020-66355-5
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MD4VH
UT WOS:000543969200022
PM 32533120
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, YT
   Wang, L
   Wise, JTF
   Shi, XL
   Chen, ZM
AF Wang, Yuting
   Wang, Lei
   Wise, James T. F.
   Shi, Xianglin
   Chen, Zhimin
TI Verteporfin inhibits lipopolysaccharide-induced inflammation by multiple
   functions in RAW 264.7 cells
SO TOXICOLOGY AND APPLIED PHARMACOLOGY
LA English
DT Article
DE Inflammation; Verteporfin; LPS; RAW 264.7
ID NF-KAPPA-B; THERAPEUTIC TARGET; IL-6; INTERLEUKIN-6; INACTIVATION;
   ACTIVATION; AUTOPHAGY
AB Inflammation is a physiologic response to damage triggered by infection, injury or chemical irritation. Chronic inflammation produces repeated damage to cells and tissues, which can induce a variety of human diseases including cancer. Verteporfin, an FDA approved drug, is used for the treatment of age-related macular degeneration. The anti-tumor effects of verteporfin have been demonstrated by a number of studies. However, fewer studies focus on the anti-inflammatory functions of this drug. In this study, we investigated the anti-inflammatory effects and potential mechanisms of verteporfin. The classic lipopolysaccharide (LPS)-induced inflammation cell model was used. RAW 264.7 cells were pre-treated with verteporfin or vehicle control, followed by LPS stimulation. Verteporfin inhibited IL-6 and TNF-alpha at mRNA and protein expression levels. This effect was mediated through inhibition of the NF-kappa B and JAK/STAT pathways. Finally, verteporfin exhibited an anti-inflammation effect by crosslinking of protein such as NF-kappa B p65, JAK1, JAK2, STAT1, or STAT3 leading to inflammation. Taken together, these results indicate that verteporfin has the potential to be an effective therapeutic agent against inflammatory diseases.
C1 [Wang, Yuting; Chen, Zhimin] Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Pulmonol,Sch Med, Hangzhou 310052, Zhejiang, Peoples R China.
   [Wang, Yuting; Wang, Lei; Wise, James T. F.; Shi, Xianglin] Univ Kentucky, Coll Med, Ctr Res Environm Dis, 1095 VA Dr, Lexington, KY 40536 USA.
   [Wise, James T. F.] Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 1095 VA Dr, Lexington, KY 40536 USA.
C3 Zhejiang University; University of Kentucky; University of Kentucky
RP Chen, ZM (通讯作者)，Zhejiang Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth, Dept Pulmonol,Sch Med, Hangzhou 310052, Zhejiang, Peoples R China.; Shi, XL (通讯作者)，Univ Kentucky, Coll Med, Ctr Res Environm Dis, 1095 VA Dr, Lexington, KY 40536 USA.
EM xianglin.shi@uky.edu; zmchen@zju.edu.cn
CR Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287
   Browning L, 2018, CANCER MANAG RES, V10, P6685, DOI 10.2147/CMAR.S179189
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dasari VR, 2017, ONCOTARGET, V8, P28628, DOI 10.18632/oncotarget.15614
   DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x
   Donohue E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114964
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Feng JT, 2016, ONCOTARGETS THER, V9, P5371, DOI 10.2147/OTT.S109979
   Gao QW, 2018, CURR DRUG TARGETS, V19, P487, DOI 10.2174/1389450117666161207163054
   GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251
   Gibault F, 2016, CURR MED CHEM, V23, P1171, DOI 10.2174/0929867323666160316125048
   Hamidzadeh K, 2017, ANNU REV PHYSIOL, V79, P567, DOI 10.1146/annurev-physiol-022516-034348
   Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Jarrot PA, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/493593
   Kim EY, 2017, CYTOKINE, V98, P87, DOI 10.1016/j.cyto.2017.04.012
   Kim SY, 2001, BIOCHIMIE, V83, P437, DOI 10.1016/S0300-9084(01)01258-5
   Kishimoto T, 2010, INT IMMUNOL, V22, P347, DOI 10.1093/intimm/dxq030
   LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327
   Lin TH, 2017, ADV PROTEIN CHEM STR, V107, P117, DOI 10.1016/bs.apcsb.2016.11.002
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Luo J, 2006, ANTIOXID REDOX SIGN, V8, P1307, DOI 10.1089/ars.2006.8.1307
   Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320
   Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006
   Popa C, 2007, J LIPID RES, V48, P751, DOI 10.1194/jlr.R600021-JLR200
   Rincon M, 2012, INT J BIOL SCI, V8, P1281, DOI 10.7150/ijbs.4874
   Ruparelia N, 2017, NAT REV CARDIOL, V14, DOI 10.1038/nrcardio.2016.185
   SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7
   Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720
   Urabe H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2536
   Wang L, 2018, PROSTATE, V78, P390, DOI 10.1002/pros.23483
   Wei HL, 2017, CANCER SCI, V108, P478, DOI 10.1111/cas.13138
   Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Yao X, 2014, PHARMACOL THERAPEUT, V141, P125, DOI 10.1016/j.pharmthera.2013.09.004
   Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418
NR 38
TC 5
Z9 5
U1 0
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0041-008X
EI 1096-0333
J9 TOXICOL APPL PHARM
JI Toxicol. Appl. Pharmacol.
PD JAN 15
PY 2020
VL 387
AR 114852
DI 10.1016/j.taap.2019.114852
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA KJ7CV
UT WOS:000512216800003
PM 31812773
DA 2022-11-30
ER

PT J
AU Cao, X
   Yu, GX
   Ren, W
   Guo, MZ
   Wang, J
AF Cao, Xia
   Yu, Guoxian
   Ren, Wei
   Guo, Maozu
   Wang, Jun
TI DualWMDR: Detecting epistatic interaction with dual screening and
   multifactor dimensionality reduction
SO HUMAN MUTATION
LA English
DT Article
DE dual screening; epistatic interaction; main effects; multifactor
   dimensionality reduction; part mutual information
ID GENOME-WIDE ASSOCIATION; BREAST-CANCER; DIFFERENTIAL EVOLUTION; SNPS;
   OPTIMIZATION; SELECTION; SEARCH; GENES
AB Detecting epistatic interaction is a typical way of identifying the genetic susceptibility of complex diseases. Multifactor dimensionality reduction (MDR) is a decent solution for epistasis detection. Existing MDR-based methods still suffer from high computational costs or poor performance. In this paper, we propose a new solution that integrates a dual screening strategy with MDR, termed as DualWMDR. Particularly, the first screening employs an adaptive clustering algorithm with part mutual information (PMI) to group single nucleotide polymorphisms (SNPs) and exclude noisy SNPs; the second screening takes into account both the single-locus effect and interaction effect to select dominant SNPs, which effectively alleviates the negative impact of main effects and provides a much smaller but accurate candidate set for MDR. After that, MDR uses the weighted classification evaluation to improve its performance in epistasis identification on the candidate set. The results on diverse simulation datasets show that DualWMDR outperforms existing competitive methods, and the results on three real genome-wide datasets: the age-related macular degeneration (AMD) dataset, breast cancer (BC), and celiac disease (CD) datasets from the Wellcome Trust Case Control Consortium, again corroborate the effectiveness of DualWMDR.
C1 [Cao, Xia; Yu, Guoxian; Ren, Wei; Wang, Jun] Southwest Univ, Coll Comp & Informat Sci, Chongqing 400715, Peoples R China.
   [Guo, Maozu] Beijing Univ Civil Engn & Architecture, Sch Elect & Informat Engn, Beijing, Peoples R China.
   [Guo, Maozu] Beijing Key Lab Intelligent Proc Bldg Big Data, Beijing, Peoples R China.
C3 Southwest University - China; Beijing University of Civil Engineering &
   Architecture
RP Wang, J (通讯作者)，Southwest Univ, Coll Comp & Informat Sci, Chongqing 400715, Peoples R China.
EM kingjun@swu.edu.cn
OI Yu, Guoxian/0000-0002-1667-6705
FU Fundamental Research Funds for the Central Universities [XDJK2019B024];
   Chongqing Graduate Student Research Innovation Project [CYS19113];
   Natural Science Foundation of CQ CSTC [cstc2018jcyjAX0228]; National Key
   Research and Development Plan Task of China [2016YFC0901902]; National
   Natural Science Foundation of China [61872300, 61873214, 61871020]
FX Fundamental Research Funds for the Central Universities, Grant/Award
   Number: XDJK2019B024; Chongqing Graduate Student Research Innovation
   Project, Grant/Award Number: CYS19113; Natural Science Foundation of CQ
   CSTC, Grant/Award Number: cstc2018jcyjAX0228; National Key Research and
   Development Plan Task of China, Grant/Award Number: 2016YFC0901902;
   National Natural Science Foundation of China, Grant/Award Numbers:
   61872300, 61873214, 61871020
CR Ackermann M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002463
   Ahn R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036926
   Bao F, 2017, IEEE T NANOBIOSCI, V16, P69, DOI 10.1109/TNB.2017.2660498
   Bateson W., 1910, Z VER ERBUNGSLEHRE, V3, P108, DOI [10.1007/bf02047719, DOI 10.1007/BF02047719]
   Ben-Gal I, 2005, DATA MINING AND KNOWLEDGE DISCOVERY HANDBOOK, P131, DOI 10.1007/0-387-25465-X_7
   Bermejo JL, 2013, INT J CANCER, V133, P362, DOI 10.1002/ijc.28040
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Bush WS, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-238
   Cai SL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1966-6
   Cao X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082267
   Chen MC, 2005, OMEGA-INT J MANAGE S, V33, P333, DOI 10.1016/j.omega.2004.05.003
   Chen SH, 2008, GENET EPIDEMIOL, V32, P152, DOI 10.1002/gepi.20272
   Coffey CS, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-49
   Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463
   Culverhouse R, 2002, AM J HUM GENET, V70, P461, DOI 10.1086/338759
   Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543
   Fisher R. A., 1919, Transactions of the Royal Society of Edinburgh, V52
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Gola D, 2016, BRIEF BIOINFORM, V17, P293, DOI 10.1093/bib/bbv038
   Guo X, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-102
   Hicklin DJ, 1999, MOL MED TODAY, V5, P178, DOI 10.1016/S1357-4310(99)01451-3
   Jing PJ, 2015, BIOINFORMATICS, V31, P634, DOI 10.1093/bioinformatics/btu702
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koboldt DC, 2006, HUM MUTAT, V27, P249, DOI 10.1002/humu.20286
   Liu J, 2017, GENES-BASEL, V8, DOI 10.3390/genes8060153
   Long N, 2007, J ANIM BREED GENET, V124, P377, DOI 10.1111/j.1439-0388.2007.00694.x
   Ma L, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002714
   Mackay TFC, 2014, GENOME MED, V6, DOI 10.1186/gm561
   Marvel S, 2012, PROCEEDINGS OF THE FOURTEENTH INTERNATIONAL CONFERENCE ON GENETIC AND EVOLUTIONARY COMPUTATION COMPANION (GECCO'12), P595
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Milne RL, 2014, HUM MOL GENET, V23, P6096, DOI 10.1093/hmg/ddu311
   Moore JH, 2010, BIOINFORMATICS, V26, P445, DOI 10.1093/bioinformatics/btp713
   Moore JH, 2005, BIOESSAYS, V27, P637, DOI 10.1002/bies.20236
   Namkung J, 2009, BIOINFORMATICS, V25, P338, DOI 10.1093/bioinformatics/btn629
   Pomares E, 2007, HUM MUTAT, V28, P511, DOI 10.1002/humu.20479
   Ritchie MD, 2011, ANN HUM GENET, V75, P172, DOI 10.1111/j.1469-1809.2010.00630.x
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Rodriguez A, 2014, SCIENCE, V344, P1492, DOI 10.1126/science.1242072
   Saeys Y, 2007, BIOINFORMATICS, V23, P2507, DOI 10.1093/bioinformatics/btm344
   Sapin E, 2015, IEEE COMPUT INTELL M, V10, P54, DOI 10.1109/MCI.2015.2471236
   Schwarz DF, 2010, BIOINFORMATICS, V26, P1752, DOI 10.1093/bioinformatics/btq257
   Selinski S., 2006, TECH REP
   Senapati S, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-016-0211-8
   Storn R, 1997, J GLOBAL OPTIM, V11, P341, DOI 10.1023/A:1008202821328
   Tang WW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000464
   Tuo SH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150669
   Turner SD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019586
   Uppu S, 2016, J SOFTWARE, V11, P965, DOI DOI 10.17706/JSW.11.10.965-975
   Urbanowicz RJ, 2012, BIODATA MIN, V5, DOI 10.1186/1756-0381-5-16
   Van Steen K, 2012, BRIEF BIOINFORM, V13, P1, DOI 10.1093/bib/bbr012
   Velez DR, 2007, GENET EPIDEMIOL, V31, P306, DOI 10.1002/gepi.20211
   Wang Yupeng, 2010, BMC Res Notes, V3, P117, DOI 10.1186/1756-0500-3-117
   Wei WH, 2014, NAT REV GENET, V15, P722, DOI 10.1038/nrg3747
   Xie MZ, 2012, BIOINFORMATICS, V28, P5, DOI 10.1093/bioinformatics/btr603
   Yang C, 2009, BIOINFORMATICS, V25, P504, DOI 10.1093/bioinformatics/btn652
   Yang CH, 2018, BIOINFORMATICS, V34, P2228, DOI 10.1093/bioinformatics/bty076
   Yang CH, 2017, BIOINFORMATICS, V33, P2354, DOI 10.1093/bioinformatics/btx163
   Yoshida M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-469
   Zhang Y, 2007, NAT GENET, V39, P1167, DOI 10.1038/ng2110
   Zhao J, 2016, P NATL ACAD SCI USA, V113, P5130, DOI 10.1073/pnas.1522586113
NR 61
TC 10
Z9 10
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD MAR
PY 2020
VL 41
IS 3
BP 719
EP 734
DI 10.1002/humu.23951
EA NOV 2019
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA KY5SL
UT WOS:000498298700001
PM 31705708
DA 2022-11-30
ER

PT J
AU Matsuda, Y
   Nonaka, Y
   Futakawa, S
   Imai, H
   Akita, K
   Nishihata, T
   Fujiwara, M
   Ali, Y
   Bhisitkul, RB
   Nakamura, Y
AF Matsuda, Yusaku
   Nonaka, Yosuke
   Futakawa, Satoshi
   Imai, Hirotaka
   Akita, Kazumasa
   Nishihata, Toshiaki
   Fujiwara, Masatoshi
   Ali, Yusuf
   Bhisitkul, Robert B.
   Nakamura, Yoshikazu
TI Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast
   Growth Factor 2 Aptamer in Animal Models of Retinal Disease
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID SMOOTH-MUSCLE-CELLS; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   MONOCLONAL-ANTIBODIES; NATURAL-HISTORY; 7-YEAR OUTCOMES; IN-VIVO;
   RANIBIZUMAB; VEGF; EYE
AB Currently approved therapies for age-related macular degeneration (AMD) are inhibitors against vascular endothelial growth factor (VEGF), which is a major contributor to the pathogenesis of neovascular AMD (nAMD). Intravitreal injections of anti-VEGF drugs have shown dramatic visual benefits for AMD patients. However, a significant portion ofAMD patients exhibit an incomplete response to therapy and, over the extended management course, can lose vision, with the formation of submacular fibrosis as one risk factor. We investigated a novel target for AMD treatments, fibroblast growth factor 2 (FGF2), which has been implicated in the pathophysiology of both angiogenesis and fibrosis in a variety of tissue and organ systems. The anti-FGF2 aptamer, RBM-007, was examined for treatment of nAMD in animal models. In in vivo studies conducted in mice and rats, RBM-007 was able to inhibit FGF2-induced angiogenesis, laser-induced choroidal neovascularization (CNV), and CNV with fibrosis. Pharmacokinetic studies of RBM-007 in the rabbit vitreous revealed high and relatively long-lasting profiles that are superior to other approved anti-VEGF drugs. The anti-angiogenic and anti-scarring dual action of RBM-007 holds promise as an additive or alternative therapy to anti-VEGF treatments for nAMD.
C1 [Matsuda, Yusaku; Nonaka, Yosuke; Futakawa, Satoshi; Imai, Hirotaka; Akita, Kazumasa; Nishihata, Toshiaki; Fujiwara, Masatoshi; Ali, Yusuf; Nakamura, Yoshikazu] RIBIC Inc, Minato Ku, 3-16-13 Shirokanedai, Tokyo 1080071, Japan.
   [Bhisitkul, Robert B.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Nakamura, Yoshikazu] Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan.
C3 University of California System; University of California San Francisco;
   University of Tokyo
RP Nakamura, Y (通讯作者)，Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan.
EM nak@ims.u-tokyo.ac.jp
FU Japan Agency for Medical Research and Development (AMED)
FX We thank Life Science Laboratories, Ltd. and Shin Nippon Biomedical
   Laboratories, Ltd. for their contributions to pharmacological and/or
   histopathological animal studies based on the contract research, Gary D.
   Novack for organizing the data package, and all members of RIBOMIC, Inc.
   for technical support and discussions. This work was supported in part
   by grants from The Japan Agency for Medical Research and Development
   (AMED).
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Belgore F, 2003, EUR J CLIN INVEST, V33, P833, DOI 10.1046/j.1365-2362.2003.01223.x
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26
   Birsner A. E., 2014, JOVE-J VIS EXP, V90
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848
   Chen J, 2014, J CELL PHYSIOL, V229, P1647, DOI 10.1002/jcp.24610
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Cordeiro MF, 2003, GENE THER, V10, P59, DOI 10.1038/sj.gt.3301865
   Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P1975
   Cuevas P, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr.02.2012.5942
   Cuevas P., 2012, BMJ CASE REP, V2012
   Cuevas P., 2012, BMJ CASE REP, V2012
   Cuevas P., 2013, J BIOMED SCI ENG, V6, P8
   Cuevas Pedro, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr-2012-007128
   Cuevas P, 2012, EUR J MED RES, V17, DOI 10.1186/2047-783X-17-22
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Drolet DW, 2016, NUCLEIC ACID THER, V26, P127, DOI 10.1089/nat.2015.0573
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Healy JM, 2004, PHARM RES-DORDR, V21, P2234, DOI 10.1007/s11095-004-7676-4
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ishikawa K, 2014, FASEB J, V28, P131, DOI 10.1096/fj.13-229740
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jin L, 2016, MOL THER, V24, P1974, DOI 10.1038/mt.2016.158
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kashani AH, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-17681
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Malabanan KP, 2008, CIRC RES, V103, P378, DOI 10.1161/CIRCRESAHA.107.168682
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911
   Nassar K, 2011, GRAEF ARCH CLIN EXP, V249, P1649, DOI 10.1007/s00417-011-1730-9
   Oladipupo SS, 2014, P NATL ACAD SCI USA, V111, P13379, DOI 10.1073/pnas.1324235111
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Rege AA, 1999, GROWTH FACTORS, V16, P161, DOI 10.3109/08977199909002126
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   SCHULTZ G S, 1991, Eye (London), V5, P170
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
   Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x
   Tomanek RJ, 2001, CIRC RES, V88, P1135, DOI 10.1161/hh1101.091191
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   U.S. Food and Drug Administration, DRUG APPR PACK EYL A
   U.S. Food and Drug Administration, DRUG APPR PACK MAC P
   US Food & Administration, DRUG APPR PACK LUC R
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   Wang LH, 2012, MOL CANCER THER, V11, P864, DOI 10.1158/1535-7163.MCT-11-0813
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamashita A, 2002, J IMMUNOL, V168, P450, DOI 10.4049/jimmunol.168.1.450
NR 57
TC 18
Z9 20
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD SEP 6
PY 2019
VL 17
BP 819
EP 828
DI 10.1016/j.omtn.2019.07.018
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA JA6XF
UT WOS:000487984400071
PM 31454678
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yacout, SM
   McIlwain, KL
   Mirza, SP
   Gaillard, ER
AF Yacout, Sally M.
   McIlwain, Kelsey L.
   Mirza, Shama P.
   Gaillard, Elizabeth R.
TI Characterization of Retinal Pigment Epithelial Melanin and Degraded
   Synthetic Melanin Using Mass Spectrometry and In Vitro Biochemical
   Diagnostics
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; ANTIOXIDANT PROPERTIES; HYDROGEN-PEROXIDE;
   OXIDATIVE STRESS; ANALYSES REVEAL; HUMAN RPE; RADICALS; PHOTOPROTECTION;
   MELANOSOMES; LIPOFUSCIN
AB With increasing age, there is an observable loss of melanin in retinal pigment epithelial (RPE) cells. It is possible that degradation of the pigment contributes to the pathogenesis of retinal disease, as the cellular antioxidant material is depleted. Functionally, intact melanin maintains protective qualities, while oxidative degradation of melanin promotes reactive oxygen species (ROS) generation and formation of metabolic byproducts, such as melanolipofuscin. Understanding the structural and functional changes to RPE melanin with increasing age may contribute to a better understanding of disease progression and risk factors for conditions such as age-related macular degeneration (AMD). In this study, human donor RPE melanin is characterized using MALDI mass spectrometry to follow melanin degradation trends. In vitro models using ARPE-19 cells are used to assess photo-reactivity in repigmented cells. Significant protection against intracellular ROS produced by blue light is observed in calf melanin-pigmented cells versus unpigmented and black latex bead controls (P < 0.0001). UV-B exposure to aged human melanin-pigmented cells results in a significant increase in nitric oxide production versus control cells (P < 0.001). Peroxide-treated synthetic melanin is characterized to elucidate degradation products that may contribute to RPE cell damage.
C1 [Yacout, Sally M.; McIlwain, Kelsey L.; Gaillard, Elizabeth R.] Northern Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA.
   [Mirza, Shama P.] Univ Wisconsin, Dept Chem & Biochem, Milwaukee, WI USA.
   [Gaillard, Elizabeth R.] Northern Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA.
C3 Northern Illinois University; University of Wisconsin System; University
   of Wisconsin Milwaukee; Northern Illinois University
RP Gaillard, ER (通讯作者)，Northern Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA.; Gaillard, ER (通讯作者)，Northern Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA.
EM gaillard@niu.edu
OI Yacout, Sally/0000-0002-7675-041X
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Burke JM, 2011, MOL VIS, V17, P2864
   Dillon J, 1999, EXP EYE RES, V68, P785, DOI 10.1006/exer.1999.0687
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Gallo RL, 2014, J INVEST DERMATOL, V134, P1508, DOI 10.1038/jid.2014.32
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hong L, 2006, PHOTOCHEM PHOTOBIOL, V82, P1265, DOI 10.1562/2006-02-23-RA-809
   Ito S, 2016, PIGM CELL MELANOMA R, V29, P340, DOI 10.1111/pcmr.12469
   Ito S, 2013, PIGM CELL MELANOMA R, V26, P357, DOI 10.1111/pcmr.12078
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kaczara P, 2012, PIGM CELL MELANOMA R, V25, P804, DOI 10.1111/pcmr.12008
   Kayatz P, 2001, INVEST OPHTH VIS SCI, V42, P241
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KORYTOWSKI W, 1990, J BIOL CHEM, V265, P12410
   KORYTOWSKI W, 1985, BIOCHEM BIOPH RES CO, V131, P659, DOI 10.1016/0006-291X(85)91288-4
   KORYTOWSKI W, 1987, PHOTOCHEM PHOTOBIOL, V45, P185, DOI 10.1111/j.1751-1097.1987.tb05362.x
   KRIPKE ML, 1992, P NATL ACAD SCI USA, V89, P7516, DOI 10.1073/pnas.89.16.7516
   Krol ES, 1998, CHEM RES TOXICOL, V11, P1434, DOI 10.1021/tx980114c
   Li YJ, 2015, ANAL CHEM, V87, P7958, DOI 10.1021/acs.analchem.5b01837
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Premi S, 2015, SCIENCE, V347, P842, DOI 10.1126/science.1256022
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   SARNA T, 1985, PHOTOCHEM PHOTOBIOL, V42, P529, DOI 10.1111/j.1751-1097.1985.tb01605.x
   SARNA T, 1986, BIOCHIM BIOPHYS ACTA, V883, P162, DOI 10.1016/0304-4165(86)90147-9
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schwarz A, 2004, J IMMUNOL, V172, P1036, DOI 10.4049/jimmunol.172.2.1036
   Schwarz A, 2011, J ALLERGY CLIN IMMUN, V128, P826, DOI 10.1016/j.jaci.2011.06.005
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Seagle BLL, 2006, P NATL ACAD SCI USA, V103, P16644, DOI 10.1073/pnas.0605986103
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sreevidya CS, 2010, J INVEST DERMATOL, V130, P1428, DOI 10.1038/jid.2009.329
   Szpoganicz B, 2002, J INORG BIOCHEM, V89, P45, DOI 10.1016/S0162-0134(01)00406-8
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Zadlo A, 2009, PHOTOCH PHOTOBIO SCI, V8, P830, DOI 10.1039/b901820d
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
NR 42
TC 6
Z9 6
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD JAN-FEB
PY 2019
VL 95
IS 1
BP 183
EP 191
DI 10.1111/php.12934
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HJ0HK
UT WOS:000456839400017
PM 29752877
DA 2022-11-30
ER

PT J
AU Kole, C
   Klipfel, L
   Yang, Y
   Ferracane, V
   Blond, F
   Reichman, S
   Millet-Puel, G
   Clerin, E
   Ait-Ali, N
   Pagan, D
   Camara, H
   Delyfer, MN
   Nandrot, EF
   Sahel, JA
   Goureau, O
   Leveillard, T
AF Kole, Christo
   Klipfel, Laurence
   Yang, Ying
   Ferracane, Vanessa
   Blond, Frederic
   Reichman, Sacha
   Millet-Puel, Geraldine
   Clerin, Emmanuelle
   Ait-Ali, Najate
   Pagan, Delphine
   Camara, Hawa
   Delyfer, Marie-Noelle
   Nandrot, Emeline F.
   Sahel, Jose-Alain
   Goureau, Olivier
   Leveillard, Thierry
TI &ITOtx2&IT-Genetically Modified Retinal Pigment Epithelial Cells Rescue
   Photoreceptors after Transplantation
SO MOLECULAR THERAPY
LA English
DT Article
ID MACULAR DEGENERATION; VISUAL FUNCTION; MESENCHYMAL TRANSITION; BEST1
   EXPRESSION; HUMAN RPE; RCS RATS; CONE; GENE; MUTATION; VISION
AB Inherited retinal degenerations are blinding diseases characterized by the loss of photoreceptors. Their extreme genetic heterogeneity complicates treatment by gene therapy. This has motivated broader strategies for transplantation of healthy retinal pigmented epithelium to protect photoreceptors independently of the gene causing the disease. The limited clinical benefit for visual function reported up to now is mainly due to dedifferentiation of the transplanted cells that undergo an epithelial-mesenchymal transition. We have studied this mechanism in vitro and revealed the role of the homeogene OTX2 in preventing dedifferentiation through the regulation of target genes. We have overexpressed OTX2 in retinal pigmented epithelial cells before their transplantation in the eye of a model of retinitis pigmentosa carrying a mutation in Mertk, a gene specifically expressed by retinal pigmented epithelial cells. OTX2 increases significantly the protection of photoreceptors as seen by histological and functional analyses. We observed that the beneficial effect of OTX2 is non-cell autonomous, and it is at least partly mediated by unidentified trophic factors. Transplantation of OTX2-genetically modified cells may be medically effective for other retinal diseases involving the retinal pigmented epithelium as age-related macular degeneration.
C1 [Kole, Christo; Klipfel, Laurence; Yang, Ying; Ferracane, Vanessa; Blond, Frederic; Reichman, Sacha; Millet-Puel, Geraldine; Clerin, Emmanuelle; Ait-Ali, Najate; Pagan, Delphine; Camara, Hawa; Delyfer, Marie-Noelle; Nandrot, Emeline F.; Sahel, Jose-Alain; Goureau, Olivier; Leveillard, Thierry] INSERM, U968, F-75012 Paris, France.
   [Kole, Christo; Klipfel, Laurence; Yang, Ying; Ferracane, Vanessa; Blond, Frederic; Reichman, Sacha; Millet-Puel, Geraldine; Clerin, Emmanuelle; Ait-Ali, Najate; Pagan, Delphine; Camara, Hawa; Delyfer, Marie-Noelle; Nandrot, Emeline F.; Sahel, Jose-Alain; Goureau, Olivier; Leveillard, Thierry] UPMC Univ Paris 06, UMR S 968, Sorbonne Univ, Inst Vis, F-75012 Paris, France.
   [Kole, Christo; Klipfel, Laurence; Yang, Ying; Ferracane, Vanessa; Blond, Frederic; Reichman, Sacha; Millet-Puel, Geraldine; Clerin, Emmanuelle; Ait-Ali, Najate; Pagan, Delphine; Camara, Hawa; Delyfer, Marie-Noelle; Nandrot, Emeline F.; Sahel, Jose-Alain; Goureau, Olivier; Leveillard, Thierry] CNRS, UMR 7210, F-75012 Paris, France.
   [Delyfer, Marie-Noelle] CHU Bordeaux, Dept Ophthalmol, Unite Retine Uveite & Neuroophtalmol, Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); CNRS - National Institute for
   Biology (INSB); UDICE-French Research Universities; Universite Paris
   Cite; CHU Bordeaux
RP Leveillard, T (通讯作者)，Univ Paris 06, Inst Vis, F-75012 Paris, France.
EM thierry.leveillard@inserm.fr
RI Léveillard, Thierry/AAR-1804-2020; Nandrot, Emeline F./AAN-3925-2020;
   GOUREAU, Olivier/ABH-9547-2020; GOUREAU, Olivier/F-2752-2017; Kole,
   Christo/ABE-5654-2020; Reichman, Sacha/R-7581-2017
OI Léveillard, Thierry/0000-0001-5692-8770; GOUREAU,
   Olivier/0000-0001-7730-9143; GOUREAU, Olivier/0000-0001-7730-9143; Kole,
   Christo/0000-0003-4695-3723; Michaelides, Michel/0000-0002-1552-7046;
   Najate, AIT-ALI/0000-0002-7626-8746; Nandrot,
   Emeline/0000-0003-3087-078X; Blond, Frederic/0000-0002-2314-0570; YANG,
   YING/0000-0002-9245-4119; Reichman, Sacha/0000-0003-1776-6339; Puel,
   Geraldine/0000-0003-2387-538X; Clerin, Emmanuelle/0000-0003-1451-6051
FU INSERM; Universite Pierre and Marie Curie; Fondation Voir Entendre
FX We thank A. Bemelmans for providing biological material. We thank D.
   Zack, J. Bennicelli, and J. Bennett for technical and scientific help.
   This work was supported by INSERM, Universite Pierre and Marie Curie,
   and Fondation Voir & Entendre.
CR ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Alexander JJ, 2007, NAT MED, V13, P685, DOI 10.1038/nm1596
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Ayton LN, 2014, INVEST OPHTH VIS SCI, V55, P1332, DOI 10.1167/iovs.13-12657
   Beby F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011673
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Bowne SJ, 2011, EUR J HUM GENET, V19, P1074, DOI 10.1038/ejhg.2011.86
   Byrne LC, 2015, J CLIN INVEST, V125, P105, DOI 10.1172/JCI65654
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Courtois V, 2003, J NEUROCHEM, V84, P840, DOI 10.1046/j.1471-4159.2003.01583.x
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Daniele LL, 2008, AM J PHYSIOL-CELL PH, V295, pC451, DOI 10.1152/ajpcell.00124.2008
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Delyfer MN., 2013, JOVE-J VIS EXP, V78
   Dorval KM, 2006, J BIOL CHEM, V281, P744, DOI 10.1074/jbc.M509470200
   Esumi N, 2009, HUM MOL GENET, V18, P128, DOI 10.1093/hmg/ddn323
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Genevois O, 2004, INVEST OPHTH VIS SCI, V45, P594, DOI 10.1167/iovs.03-0764
   Girman S, 2005, VISION RES, V45, P343, DOI 10.1016/j.visres.2004.08.023
   Hejtmancik JF, 2008, AM J HUM GENET, V82, P174, DOI 10.1016/j.ajhg.2007.08.002
   Housset M, 2013, J NEUROSCI, V33, P9890, DOI 10.1523/JNEUROSCI.1099-13.2013
   Jacobs GH, 2001, J EXP BIOL, V204, P2439
   Karali M, 2015, INT J BIOCHEM CELL B, V61, P115, DOI 10.1016/j.biocel.2015.02.007
   Ksantini M, 2012, EUR J OPHTHALMOL, V22, P647, DOI 10.5301/ejo.5000096
   Kusaka S, 2001, J PHYSIOL-LONDON, V531, P27, DOI 10.1111/j.1469-7793.2001.0027j.x
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Leveillard T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000866
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   Masuda T, 2010, J BIOL CHEM, V285, P26933, DOI 10.1074/jbc.M110.130294
   Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328
   Nandrot EF, 2006, AM J PHYSIOL-CELL PH, V290, pC1256, DOI 10.1152/ajpcell.00480.2005
   Nandrot EF, 2012, BIOL CELL, V104, P326, DOI 10.1111/boc.201100076
   Nishida A, 2003, NAT NEUROSCI, V6, P1255, DOI 10.1038/nn1155
   Paques M, 2006, VISION RES, V46, P1336, DOI 10.1016/j.visres.2005.09.037
   Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978
   Pattnaik BR, 2015, HUM MUTAT, V36, P720, DOI 10.1002/humu.22807
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pinilla I, 2004, VISION RES, V44, P2467, DOI 10.1016/j.visres.2004.05.020
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Prochiantz A, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0518
   Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541
   Reichman S, 2016, METHODS MOL BIOL, V1357, P339, DOI 10.1007/7651_2014_143
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Reichman S, 2010, HUM MOL GENET, V19, P250, DOI 10.1093/hmg/ddp484
   Ryan S. J., 2006, RETINA
   Saigo Y, 2004, INVEST OPHTH VIS SCI, V45, P1996, DOI 10.1167/iovs.03-0777
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schlichtenbrede FC, 2003, GENE THER, V10, P523, DOI 10.1038/sj.gt.3301929
   Sergouniotis PI, 2011, AM J HUM GENET, V89, P183, DOI 10.1016/j.ajhg.2011.06.002
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Wen R, 2012, ADV EXP MED BIOL, V723, P93, DOI 10.1007/978-1-4614-0631-0_13
   Yang DL, 2003, INVEST OPHTH VIS SCI, V44, P3178, DOI 10.1167/iovs.02-1189
   Yang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013469
   Yang Y, 2009, MOL THER, V17, P787, DOI 10.1038/mt.2009.28
   Zhang W, 2013, AM J PHYSIOL-CELL PH, V304, pC440, DOI 10.1152/ajpcell.00363.2012
NR 67
TC 15
Z9 16
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD JAN 3
PY 2018
VL 26
IS 1
BP 219
EP 237
DI 10.1016/j.ymthe.2017.09.007
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA FT2ZB
UT WOS:000423013500023
PM 28988713
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Otteson, DC
AF Otteson, Deborah C.
TI TALKIN' ABOUT MY (RE)GENERATION: THE WHO OF INTRINSIC RETINAL STEM CELLS
SO NEUROSCIENCE
LA English
DT Article
DE retina; neurogenesis; alpha7 nicotinic acetylcholine; receptor
   (a7-nAChR); Muller glia; mammal; teleost
ID GLOBAL PREVALENCE; TELEOST FISH; MULLER GLIA; REGENERATION; LINEAGE;
   BURDEN
AB World-wide, two degenerative retinal diseases, glaucoma and age-related macular degeneration, are estimated to affect more than 12% of individuals over the age of 40 (Tham et al., 2014; Wong et al., 2014). Current therapies can slow progression, but cannot restore lost neurons or vision. Thus, there is increasing interest in developing strategies for therapeutic retinal regeneration. Nearly 50 years of research on retinal neurogenesis and regeneration has identified Muller glia as intrinsic retinal stem cells in teleost fish. In the mammalian retina, there is no de novo neurogenesis in adults and only very limited injury-induced regeneration has been induced using exogenous growth factors. The study by (Webster et al., 2017) (Evidence of BrdU Positive Retinal Neurons after Application of an Alpha7 Nicotinic Acetylcholine Receptor Agonist, this issue) is the first to show robust, retinal neurogenesis in an adult, mammalian retina in the absence of overt injury and provides evidence that the source of the new neurons is likely to be the Muller glia. This exciting finding has the potential to be a game-changer in the field of retinal regeneration. (c) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Otteson, Deborah C.] Univ Houston, Coll Optometry, Houston, TX 77204 USA.
C3 University of Houston System; University of Houston
RP Otteson, DC (通讯作者)，Univ Houston, Coll Optometry, Houston, TX 77204 USA.
EM dotteson@central.uh.edu
FU National Institutes of Health [R01-EY021792, P30EY007551]; Glaucoma
   Foundation; University of Houston; NATIONAL EYE INSTITUTE [R01EY021792,
   P30EY007551] Funding Source: NIH RePORTER
FX This work was funded in part by research grants from National Institutes
   of Health [R01-EY021792; P30EY007551 (UH, Core)], the Glaucoma
   Foundation, and the University of Houston.
CR Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Kubota R, 2002, DEV BRAIN RES, V134, P31, DOI 10.1016/S0165-3806(01)00287-5
   Lenkowski JR, 2014, PROG RETIN EYE RES, V40, P94, DOI 10.1016/j.preteyeres.2013.12.007
   Lombardo F., 1969, Archivio Italiano di Anatomia e di Embriologia, V74, P29
   Otteson DC, 2001, DEV BIOL, V232, P62, DOI 10.1006/dbio.2001.0163
   Stenkamp DL, 2011, PROG RETIN EYE RES, V30, P395, DOI 10.1016/j.preteyeres.2011.06.004
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Wan J, 2016, CURR OPIN GENET DEV, V40, P41, DOI 10.1016/j.gde.2016.05.009
   Webster MK, 2017, NEUROSCIENCE, V346, P437, DOI 10.1016/j.neuroscience.2017.01.029
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia X, 2016, INT J STEM CELLS
NR 11
TC 4
Z9 5
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD MAR 27
PY 2017
VL 346
BP 447
EP 449
DI 10.1016/j.neuroscience.2017.01.022
PG 3
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EN1SK
UT WOS:000395790100042
PM 28131621
DA 2022-11-30
ER

PT J
AU Hu, ZZ
   Zhang, Y
   Wang, JL
   Mao, PA
   Lv, XH
   Yuan, ST
   Huang, ZR
   Ding, YZ
   Xie, P
   Liu, QH
AF Hu, Zizhong
   Zhang, Yi
   Wang, Junling
   Mao, Pingan
   Lv, Xuehua
   Yuan, Songtao
   Huang, Zhengru
   Ding, Yuzhi
   Xie, Ping
   Liu, Qinghuai
TI Knockout of Ccr2 alleviates photoreceptor cell death in rodent retina
   exposed to chronic blue light
SO CELL DEATH & DISEASE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; NLRP3 INFLAMMASOMES;
   AMYLOID-BETA; INDUCED RETINOPATHY; MICROGLIAL CELLS; DRY EYE;
   ACTIVATION; MICE; INFLAMMATION
AB Age-related macular degeneration (AMD), the leading cause of visual loss after the age of 60 years, is a degenerative retinal disease involving a variety of environmental and hereditary factors. Although it has been implicated that immune system is involved in the disease progression, the exact role that microglia has is still unclear. Here we demonstrated that knockout of Ccr2 gene could alleviate photoreceptor cell death in mice retinas exposed to chronic blue light. In Ccr2(-/-) mice, a damaged microglia recruitment was shown in retina and this could protect the visual function in electroretinogram and alleviate the photoreceptor apoptosis, which thus helped attenuate the blue light-induced retinopathy. We further found an increased co-location of NLRP3, Iba-1, and IL-1 beta in fluorescence and a concomitant increased protein expression of NLRP3, caspase-1, and IL-1 beta in western blotting in chronic blue light-induced retinopathy. Moreover, the activation of microglia and their cellular NLRP3 inflammasomes occurred as an earlier step before the structural and functional damage of the mice retinas, which collectively supported that microglial NLRP3 inflammasome might be the key to the chronic blue light-induced retinopathy.
C1 [Hu, Zizhong; Zhang, Yi; Wang, Junling; Mao, Pingan; Lv, Xuehua; Yuan, Songtao; Huang, Zhengru; Ding, Yuzhi; Xie, Ping; Liu, Qinghuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Xie, P; Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM xieping9@126.com; liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964; hu, zizhong/0000-0001-6289-1804; Xie,
   Ping/0000-0003-4257-8970
FU National Basic Research Program of China (973 Program) [2012CB066300,
   2013CB967500]; Jiangsu Provincial Special Program of Medical Science
   [BL2014089]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD) [JX10231801]
FX This study was supported by National Basic Research Program of China
   (973 Program, Nos. 2012CB066300 and 2013CB967500), Jiangsu Provincial
   Special Program of Medical Science (BL2014089), and a Project Funded by
   the Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD, JX10231801). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bai YW, 2008, IEEE T CONSUM ELECTR, V54, P1173, DOI 10.1109/TCE.2008.4637603
   Bian F, 2014, INVEST OPHTH VIS SCI, V55
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   Chen YF, 2014, AM J PATHOL, V184, P1695, DOI 10.1016/j.ajpath.2014.02.024
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep21018
   Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014
   Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Guo CR, 2012, EXP EYE RES, V104, P39, DOI 10.1016/j.exer.2012.08.013
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075
   Joly S, 2007, INVEST OPHTH VIS SCI, V48, P2311, DOI 10.1167/iovs.06-1205
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Jozwick C, 2006, EXP EYE RES, V83, P1074, DOI 10.1016/j.exer.2006.05.012
   Kaneko H, 2008, INVEST OPHTH VIS SCI, V49, P4162, DOI 10.1167/iovs.08-1738
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kezic J, 2008, J LEUKOCYTE BIOL, V84, P721, DOI 10.1189/jlb.0308166
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006
   LAVAIL MM, 1976, INVEST OPHTH VISUAL, V15, P64
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   Marc RE, 2008, MOL VIS, V14, P782
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Penn J, 1986, PROG CLIN BIOL RES, V247, P425
   PENN JS, 1986, EXP EYE RES, V43, P915, DOI 10.1016/0014-4835(86)90070-9
   Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004
   Priya RR, 2012, OPHTHALMOLOGY, V119, P2526, DOI 10.1016/j.ophtha.2012.06.042
   Qi Y, 2014, INVEST OPHTH VIS SCI, V55, P5466, DOI 10.1167/iovs.14-14380
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Roque RS, 1996, INVEST OPHTH VIS SCI, V37, P196
   Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808
   Santos AM, 2010, J COMP NEUROL, V518, P477, DOI 10.1002/cne.22227
   SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610
   Sriram S, 2011, J NEUROIMMUNOL, V239, P13, DOI 10.1016/j.jneuroim.2011.08.012
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Xie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053329
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Zheng QX, 2015, EXP EYE RES, V134, P133, DOI 10.1016/j.exer.2015.02.013
   Zheng QX, 2014, EXP EYE RES, V125, P1, DOI 10.1016/j.exer.2014.05.001
NR 61
TC 20
Z9 24
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV
PY 2016
VL 7
AR e2468
DI 10.1038/cddis.2016.363
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EH5LU
UT WOS:000391815400027
PM 27831552
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Abadia, B
   Calvo, P
   Ferreras, A
   Bartol, F
   Verdes, G
   Pablo, L
AF Abadia, Beatriz
   Calvo, Pilar
   Ferreras, Antonio
   Bartol, Fran
   Verdes, Guayente
   Pablo, Luis
TI Clinical Applications of Dexamethasone for Aged Eyes
SO DRUGS & AGING
LA English
DT Review
ID DIABETIC MACULAR EDEMA; DRUG-DELIVERY SYSTEM; INTRAVITREAL AFLIBERCEPT
   INJECTION; OCCLUSION 12-MONTH OUTCOMES; RANDOMIZED CONTROLLED-TRIAL;
   ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE; RISK-FACTORS; CHOROIDAL
   NEOVASCULARIZATION; TRIAMCINOLONE ACETONIDE
AB The risk of severe eye problems has been found to increase significantly with age, particularly between the fifth and sixth decades of life. Cataracts, dry eye, neovascular age-related macular degeneration, diabetic retinopathy and retinal vein occlusion (RVO) are very common and very different age-related ocular diseases that reduce the patient's quality of life. The rationale for using corticosteroids to treat anterior and posterior ocular segment diseases is driven by inflammation. Dexamethasone, one of the most powerful corticosteroids available, is widely used for topical or intravitreal administration. Topical dexamethasone has proven efficacy for the management of postoperative inflammation in the anterior segment after cataract surgery and symptom relief in dry-eye disease. A new sustained-release 700 A mu g dexamethasone intravitreal implant (DEX) was recently approved for the treatment of macular edema following RVO, diabetic macular edema, or non-infectious uveitis, and its use is increasing, especially when other therapeutic agents have failed. The most common side effects are increased intraocular pressure and cataract formation. The potency of DEX, alone or in combination with other agents, makes DEX a promising option for treating several retinal diseases.
C1 [Abadia, Beatriz; Calvo, Pilar; Ferreras, Antonio; Bartol, Fran; Pablo, Luis] Miguel Servet Univ Hosp, Dept Ophthalmol, IIS Aragon, Isabel la Catolica 1-3, Zaragoza 50009, Spain.
   [Calvo, Pilar; Ferreras, Antonio; Pablo, Luis] Univ Zaragoza, Zaragoza, Spain.
   [Verdes, Guayente] Obispo Polanco Hosp, Dept Endocrinol, Teruel, Spain.
C3 Miguel Servet University Hospital; University of Zaragoza
RP Calvo, P (通讯作者)，Miguel Servet Univ Hosp, Dept Ophthalmol, IIS Aragon, Isabel la Catolica 1-3, Zaragoza 50009, Spain.; Calvo, P (通讯作者)，Univ Zaragoza, Zaragoza, Spain.
EM xenatrance@yahoo.es
RI de Asís Bartol-Puyal, Francisco/AAF-8095-2020; Ferreras,
   Antonio/AAF-4220-2020
OI de Asís Bartol-Puyal, Francisco/0000-0002-4476-6003; Pablo,
   Luis/0000-0003-2389-8282; Ferreras, Antonio/0000-0002-2914-2593
CR Abdolrahimzadeh S, 2015, BIOMED RES INT, V2015
   AKINGBEHIN AO, 1983, BRIT J OPHTHALMOL, V67, P661, DOI 10.1136/bjo.67.10.661
   Albrecht E, 2011, BRIT J OPHTHALMOL, V95, P1385, DOI 10.1136/bjo.2010.187963
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   BARTLETT JD, 1993, J OCUL PHARMACOL, V9, P35, DOI 10.1089/jop.1993.9.35
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Chang DF, 2011, J CATARACT REFR SURG, V37, P675, DOI 10.1016/j.jcrs.2010.10.051
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P4605, DOI 10.1167/iovs.10-6387
   Chang-Lin JE, 2011, INVEST OPHTH VIS SCI, V52, P80, DOI 10.1167/iovs.10-5285
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Concillado M, 2016, AM J OPHTHALMOL, V165, P7, DOI 10.1016/j.ajo.2016.02.004
   Coursey TG, 2015, J CONTROL RELEASE, V213, P168, DOI 10.1016/j.jconrel.2015.07.007
   Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
   Dagnelie G, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12934
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Medeiros MD, 2013, INVEST OPHTH VIS SCI, V54, P3320, DOI 10.1167/iovs.12-11463
   El-Harazi SM, 2001, CURR OPIN OPHTHALMOL, V12, P4, DOI 10.1097/00055735-200102000-00002
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21
   Haller JA, 2009, RETINA-J RET VIT DIS, V29, P46, DOI 10.1097/IAE.0b013e318188c814
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Henderson BA, 2007, J CATARACT REFR SURG, V33, P1550, DOI 10.1016/j.jcrs.2007.05.013
   Holland EJ, 2008, CORNEA, V27, P50, DOI 10.1097/ICO.0b013e31815873c7
   Hunter RS, 2011, CLIN OPHTHALMOL, V5, P1613, DOI 10.2147/OPTH.S17419
   International Diabetes Federation, 2013, IDF DIAB ATL
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Jones R, 2006, CURR OPIN OPHTHALMOL, V17, P163
   Joussen AM, 2007, DEV OPHTHALMOL, V37, P1
   Escobar-Barranco JJ, 2015, OPHTHALMOLOGICA, V233, P176, DOI 10.1159/000371770
   Khurana RN, 2014, OPHTHALMOLOGY, V121, P67, DOI 10.1016/j.ophtha.2013.06.033
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   KUPFERMAN A, 1975, INVEST OPHTH VISUAL, V14, P252
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   Kuppermann BD, 2015, OPHTHALMOLOGICA, V234, P40, DOI 10.1159/000381865
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lazzeri S, 2015, ANGIOGENESIS, V18, P397, DOI 10.1007/s10456-015-9483-4
   Leibowitz HM, 1996, ARCH OPHTHALMOL-CHIC, V114, P933, DOI 10.1001/archopht.1996.01100140141005
   Lemp MA, 2011, AM J OPHTHALMOL, V151, P792, DOI 10.1016/j.ajo.2010.10.032
   Leung YF, 2003, MOL VIS, V9, P425
   Loewenstein A, 2010, DEV OPHTHALMOL, V47, P148, DOI 10.1159/000320078
   Loftsson T, 2002, ACTA OPHTHALMOL SCAN, V80, P144, DOI 10.1034/j.1600-0420.2002.800205.x
   Lowder C, 2011, ARCH OPHTHALMOL-CHIC, V129, P545, DOI 10.1001/archophthalmol.2010.339
   Messmer EM, 2010, DEV OPHTHALMOL, V45, P129, DOI 10.1159/000315026
   Ohira A, 2015, ACTA OPHTHALMOL, V93, P610, DOI 10.1111/aos.12803
   Oliver Alejandro, 2006, Ophthalmol Clin North Am, V19, P345
   Pleyer U, 2013, OPHTHALMOL THER, V2, P55, DOI 10.1007/s40123-013-0020-5
   Rao GN, 2011, CURR OPIN OPHTHALMOL, V22, P4, DOI 10.1097/ICU.0b013e3283414fc8
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Romero-Aroca P, 2010, DIABETES CARE, V33, P2484, DOI 10.2337/dc10-1580
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Runkle EA, 2011, METHODS MOL BIOL, V686, P133, DOI 10.1007/978-1-60761-938-3_5
   Saari KM, 2006, GRAEF ARCH CLIN EXP, V244, P620, DOI 10.1007/s00417-005-0124-2
   Sharma A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/781683
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Tanito M, 2011, INVEST OPHTH VIS SCI, V52, P7944, DOI 10.1167/iovs.11-8178
   Yonekawa Y, 2012, CURR OPIN OPHTHALMOL, V23, P26, DOI 10.1097/ICU.0b013e32834cd5f8
   Zarranz-Ventura J, 2014, AM J OPHTHALMOL, V158, P1136, DOI 10.1016/j.ajo.2014.09.003
NR 65
TC 19
Z9 19
U1 2
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-229X
EI 1179-1969
J9 DRUG AGING
JI Drugs Aging
PD SEP
PY 2016
VL 33
IS 9
BP 639
EP 646
DI 10.1007/s40266-016-0392-z
PG 8
WC Geriatrics & Gerontology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Pharmacology & Pharmacy
GA DX5PM
UT WOS:000384433400003
PM 27566619
DA 2022-11-30
ER

PT J
AU Gahlaut, N
   Suarez, S
   Uddin, MI
   Gordon, AY
   Evans, SM
   Jayagopal, A
AF Gahlaut, Nivriti
   Suarez, Sandra
   Uddin, Md. Imam
   Gordon, Andrew Y.
   Evans, Stephanie M.
   Jayagopal, Ashwath
TI Nanoengineering of therapeutics for retinal vascular disease
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Nanotechnology; Retina; Nanoparticles; Nanomedicine; Retinal vascular
   disease; AMD; Diabetic retinopathy
ID NANOPARTICLE-MEDIATED DELIVERY; CERIUM OXIDE NANOPARTICLES; ENDOTHELIAL
   GROWTH-FACTOR; ANTIGEN-PRESENTING CELLS; DIABETIC MACULAR EDEMA; VEIN
   OCCLUSION; CHOROIDAL NEOVASCULARIZATION; SUSTAINED DELIVERY;
   DRUG-DELIVERY; NANOTECHNOLOGY
AB Retinal vascular diseases, including diabetic retinopathy, neovascular age related macular degeneration, and retinal vein occlusion, are leading causes of blindness in the Western world. These diseases share several common disease mechanisms, including vascular endothelial growth factor (VEGF) signaling, hypoxia, and inflammation, which provide opportunities for common therapeutic strategies. Treatment of these diseases using laser therapy, anti-VEGF injections, and/or steroids has significantly improved clinical outcomes. However, these strategies do not address the underlying root causes of pathology, and may have deleterious side effects. Furthermore, many patients continue to progress toward legal blindness despite receiving regular therapy. Nanomedicine, the engineering of therapeutics at the 1-100 nm scale, is a promising approach for improving clinical management of retinal vascular diseases. Nanomedicine-based technologies have the potential to revolutionize the treatment of ophthalmology, through enabling sustained release of drugs over several months, reducing side effects due to specific targeting of dysfunctional cells, and interfacing with currently "undruggable" targets. We will discuss emerging nanomedicine-based applications for the treatment of complications associated with retinal vascular diseases, including angiogenesis and inflammation. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Gahlaut, Nivriti; Suarez, Sandra; Uddin, Md. Imam; Evans, Stephanie M.; Jayagopal, Ashwath] Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN USA.
   [Gordon, Andrew Y.; Jayagopal, Ashwath] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN USA.
   [Jayagopal, Ashwath] F Hoffman La Roche Ltd, Pharma Res & Early Dev, CH-4070 Basel, Switzerland.
C3 Vanderbilt University; Vanderbilt University; Roche Holding
RP Jayagopal, A (通讯作者)，F Hoffman La Roche Ltd, Pharma Res & Early Dev pRED, 124 Grenzacherstr, CH-4070 Basel, Switzerland.
EM ash.jayagopal@gmail.com
OI Uddin, MD Imam/0000-0001-5611-9666
FU American Diabetes Association; NIH [EY023397, T32EY007135, P30EY008126];
   Research to Prevent Blindness; NATIONAL EYE INSTITUTE [T32EY007135,
   R01EY023397, P30EY008126] Funding Source: NIH RePORTER
FX This work was supported by the American Diabetes Association, NIH grants
   EY023397, T32EY007135, P30EY008126, and Research to Prevent Blindness
   (Dolly Green Special Scholar Award, Unrestricted Grant to Vanderbilt Eye
   Institute).
CR Alexis F, 2008, UROL ONCOL-SEMIN ORI, V26, P74, DOI 10.1016/j.urolonc.2007.03.017
   Ali SS, 2008, NANOMED-NANOTECHNOL, V4, P283, DOI 10.1016/j.nano.2008.05.003
   Ali SS, 2004, FREE RADICAL BIO MED, V37, P1191, DOI 10.1016/j.freeradbiomed.2004.07.002
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Bucolo C, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00188
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Chan A, 2011, CLIN OPHTHALMOL, V5, P1043, DOI 10.2147/OPTH.S13775
   Chen JP, 2006, NAT NANOTECHNOL, V1, P142, DOI 10.1038/nnano.2006.91
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Dai H, 2010, NANOMEDICINE-UK, V5, P1317, DOI 10.2217/NNM.10.89
   Das S, 2013, NANOMEDICINE-UK, V8, P1483, DOI [10.2217/NNM.13.133, 10.2217/nnm.13.133]
   Ding XQ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007410
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   Evans SM, 2014, BIOCONJUGATE CHEM, V25, P2030, DOI 10.1021/bc500400z
   Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m
   Fong DS, 2003, DIABETES CARE, V26, P226, DOI 10.2337/diacare.26.1.226
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Forrest ML, 2008, ADV DRUG DELIVER REV, V60, P861, DOI 10.1016/j.addr.2008.02.013
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Gupta MK, 2014, J AM CHEM SOC, V136, P14896, DOI 10.1021/ja507626y
   Gupta MK, 2012, J CONTROL RELEASE, V162, P591, DOI 10.1016/j.jconrel.2012.07.042
   Hafezi-Moghadam A, 2012, OPHTHALMOL RES, P105, DOI 10.1007/978-1-60761-150-9_7
   Hsu J, 2014, PHARM RES-DORDR, V31, P1855, DOI 10.1007/s11095-013-1289-8
   Iezzi R, 2012, BIOMATERIALS, V33, P979, DOI 10.1016/j.biomaterials.2011.10.010
   Iwase T, 2013, J CONTROL RELEASE, V172, P625, DOI 10.1016/j.jconrel.2013.10.008
   Jayagopal A, 2008, IEEE T NANOBIOSCI, V7, P28, DOI 10.1109/TNB.2008.2000147
   Jayagopal A, 2010, CURR ATHEROSCLER REP, V12, P209, DOI 10.1007/s11883-010-0106-7
   Jin J, 2011, INVEST OPHTH VIS SCI, V52, P6230, DOI 10.1167/iovs.10-6229
   Jo DH, 2011, INT J MOL SCI, V12, P8288, DOI 10.3390/ijms12118288
   Kambhampati SP, 2013, J OCUL PHARMACOL TH, V29, P151, DOI 10.1089/jop.2012.0232
   Kannan S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003162
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Kernt M, 2012, CLIN OPHTHALMOL, V6, P289, DOI 10.2147/OPTH.S27859
   Kim H, 2010, J CONTROL RELEASE, V142, P286, DOI 10.1016/j.jconrel.2009.10.031
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kleinman ME, 2010, OPHTHALMOLOGICA, V224, P16, DOI 10.1159/000315152
   Kristjansdottir JV, 2014, INVEST OPHTH VIS SCI, V55, P3120, DOI 10.1167/iovs.13-13255
   Kyosseva SV, 2013, EXP EYE RES, V116, P63, DOI 10.1016/j.exer.2013.08.003
   Labhasetwar V, 2005, CURR OPIN BIOTECH, V16, P674, DOI 10.1016/j.copbio.2005.10.009
   Leal EC, 2010, DIABETES, V59, P2637, DOI 10.2337/db09-1421
   Liu HA, 2011, INVEST OPHTH VIS SCI, V52, P4789, DOI 10.1167/iovs.10-5891
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Martin JR, 2014, BIOMATERIALS, V35, P3766, DOI 10.1016/j.biomaterials.2014.01.026
   Mezu-Ndubuisi OJ, 2013, INVEST OPHTH VIS SCI, V54, P6968, DOI 10.1167/iovs.13-12126
   Muqit M.M., 2010, ACTA OPHTHALMOL
   Ng HI, 2012, J CONTROL RELEASE, V162, P477, DOI 10.1016/j.jconrel.2012.07.024
   Ortega R.A., 2014, NANOSCALE
   Panda JJ, 2013, J CONTROL RELEASE, V172, P1151, DOI 10.1016/j.jconrel.2013.09.016
   Park K, 2009, DIABETES, V58, P1902, DOI 10.2337/db08-1327
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Qazi Y, 2012, INVEST OPHTH VIS SCI, V53, P2837, DOI 10.1167/iovs.11-9139
   Quick KL, 2008, NEUROBIOL AGING, V29, P117, DOI 10.1016/j.neurobiolaging.2006.09.014
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryu M, 2011, J CONTROL RELEASE, V151, P65, DOI 10.1016/j.jconrel.2010.11.029
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Shahidi M, 2010, INVEST OPHTH VIS SCI, V51, P4766, DOI 10.1167/iovs.09-4710
   Simo R, 2008, DIABETOLOGIA, V51, P1574, DOI 10.1007/s00125-008-0989-9
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Song SJ, 2014, DIABETES METAB J, V38, P416, DOI 10.4093/dmj.2014.38.6.416
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   Supuran CT, 2010, BIOORG MED CHEM LETT, V20, P3467, DOI 10.1016/j.bmcl.2010.05.009
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tezel TH, 2007, OCUL IMMUNOL INFLAMM, V15, P1, DOI 10.1080/09273940701246314
   Thambi T, 2014, BIOMATERIALS, V35, P1735, DOI 10.1016/j.biomaterials.2013.11.022
   Tyagi P, 2013, MOL PHARMACEUT, V10, P2858, DOI 10.1021/mp300716t
   Valapala M, 2011, J CELL SCI, V124, P1453, DOI 10.1242/jcs.079236
   Voinea M, 2005, PHARM RES-DORDR, V22, P1906, DOI 10.1007/s11095-005-7247-3
   Wang X, 2008, J MED VIROL, V80, P11, DOI 10.1002/jmv.21029
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Wenick AS, 2012, MIDDLE EAST AFR J OP, V19, P4, DOI 10.4103/0974-9233.92110
   Wickline SA, 2006, ARTERIOSCL THROM VAS, V26, P435, DOI 10.1161/01.ATV.0000201069.47550.8b
   Wickline SA, 2003, CIRCULATION, V107, P1092, DOI 10.1161/01.CIR.0000059651.17045.77
   Wong LL, 2014, ADV EXP MED BIOL, V801, P821, DOI 10.1007/978-1-4614-3209-8_103
   Wong LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058431
   Wong TY, 2010, NEW ENGL J MED, V363, P2135, DOI 10.1056/NEJMcp1003934
   Xu Qingguo, 2013, Middle East Afr J Ophthalmol, V20, P26, DOI 10.4103/0974-9233.106384
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yau JWY, 2008, INTERN MED J, V38, P904, DOI 10.1111/j.1445-5994.2008.01720.x
   Yoshikawa T, 2008, VACCINE, V26, P1303, DOI 10.1016/j.vaccine.2007.12.037
   Yu SS, 2013, MOL PHARMACEUT, V10, P975, DOI 10.1021/mp300434e
   Yu SS, 2012, INT J NANOMED, V7, P799, DOI 10.2147/IJN.S28531
   Zarbin MA, 2012, WIRES NANOMED NANOBI, V4, P113, DOI 10.1002/wnan.167
   Zarbin MA, 2010, CAN J OPHTHALMOL, V45, P457, DOI 10.3129/i10-090
   Zhang C, 2010, GENE THER, V17, P338, DOI 10.1038/gt.2009.158
NR 103
TC 7
Z9 7
U1 0
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2015
VL 95
BP 323
EP 330
DI 10.1016/j.ejpb.2015.05.001
PN B
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CU8WH
UT WOS:000363824300016
PM 26022642
OA Green Accepted
DA 2022-11-30
ER

PT J
AU van Zeeburg, EJT
   Braaf, B
   Cereda, MG
   van Meurs, JC
   de Boer, JF
AF van Zeeburg, Elsbeth J. T.
   Braaf, Boy
   Cereda, Matteo G.
   van Meurs, Jan C.
   de Boer, Johannes F.
TI Direct Blood Flow Measurements in a Free RPE-Choroid Graft with
   Phase-Resolved Doppler OCT
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE RPE-choroid graft; phase-resolved doppler OCT; SD-OCT
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; MACULAR
   DEGENERATION; VELOCITY; BEVACIZUMAB; ANGIOGRAPHY; SPEED; SKIN; EYE; NM
AB Purpose: We directly demonstrated the revascularization in a free retinal pigment epithelium (RPE)-choroid graft with direct blood flow detection by experimental phase-resolved Doppler optical coherence tomography (PRD-OCT).
   Methods: Seven patients with age-related macular degeneration underwent an RPEchoroid graft translocation in a prospective institutional cohort study. Spectral domain optical coherence tomography (SD-OCT) was used to measure the revascularization stage. With PRD-OCT the presence of flow was imaged postoperatively.
   Results: The PRD-OCT confirmed flow in three patients when SD-OCT indicated the afferent vessel ingrowth stage, and in all seven patients when the SD-OCT indicated the efferent vessel ingrowth stage.
   Conclusions: The PRD-OCT study was able to detect the presence of blood flow in a free RPE-choroid graft. The PRD-OCT findings directly confirmed the revascularization that was otherwise based on the more circumstantial evidence provided by SD-OCT images and angiography.
   Translational Relevance: The use of both techniques to monitor the revascularization process in a free graft in patients are an interesting example of replacing more invasive by noninvasive techniques. There is potential future use of PRD-OCT for the visualization of vascularization patterns in other pathologies.
C1 [van Zeeburg, Elsbeth J. T.; Braaf, Boy; de Boer, Johannes F.] Rotterdam Ophthalm Inst, Rotterdam, Netherlands.
   [van Zeeburg, Elsbeth J. T.; Cereda, Matteo G.; van Meurs, Jan C.] Rotterdam Eye Hosp, Schiedamse Vest 180, NL-3011 BH Rotterdam, Netherlands.
   [van Meurs, Jan C.] Erasmus Univ, Dept Ophthalmol, Rotterdam, Netherlands.
   [de Boer, Johannes F.] Vrije Univ Amsterdam, Dept Phys & Astron, LaserLaB, Amsterdam, Netherlands.
C3 Rotterdam Eye Hospital; Erasmus University Rotterdam; Vrije Universiteit
   Amsterdam
RP van Zeeburg, EJT (通讯作者)，Rotterdam Eye Hosp, Schiedamse Vest 180, NL-3011 BH Rotterdam, Netherlands.
EM e.vanzeeburg@oogziekenhuis.nl
RI de Boer, Johannes F/B-7590-2012
OI de Boer, Johannes F/0000-0003-1253-4950
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Braaf B, 2012, OPT EXPRESS, V20, P20516, DOI 10.1364/OE.20.020516
   Braaf B, 2011, OPT EXPRESS, V19, P20886, DOI 10.1364/OE.19.020886
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chen YL, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3119103
   Chen ZP, 1997, OPT LETT, V22, P64, DOI 10.1364/OL.22.000064
   CONVERSE JM, 1956, ANN SURG, V143, P306, DOI 10.1097/00000658-195603000-00003
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Gelisken F, 2009, EYE, V23, P694, DOI 10.1038/sj.eye.6703098
   Grulkowski I, 2009, OPT EXPRESS, V17, P23736, DOI 10.1364/OE.17.023736
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Izatt JA, 1997, OPT LETT, V22, P1439, DOI 10.1364/OL.22.001439
   Maaijwee K, 2007, LES DLMAS, P562
   Maaijwee K, 2008, RETINA-J RET VIT DIS, V28, P498, DOI 10.1097/IAE.0b013e318159ec24
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   van Zeeburg EJT, 2011, INVEST OPHTH VIS SCI, V52, P5881, DOI 10.1167/iovs.11-7245
   Yun SH, 2004, OPT EXPRESS, V12, P5614, DOI 10.1364/OPEX.12.005614
   Yun SH, 2003, OPT EXPRESS, V11, P2953, DOI 10.1364/OE.11.002953
   Zhao YH, 2000, OPT LETT, V25, P114, DOI 10.1364/OL.25.000114
NR 26
TC 4
Z9 4
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2015
VL 4
IS 1
AR 2
DI 10.1167/tvst.4.1.2
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED0WE
UT WOS:000388562500002
PM 25599010
OA Green Published
DA 2022-11-30
ER

PT J
AU Santos-Bueso, E
   Saenz-Frances, F
   Serrador-Garcia, M
   Porta-Etessam, J
   Martinez-de-la-Casa, JM
   Garcia-Feijoo, J
   Garcia-Sanchez, J
AF Santos-Bueso, Enrique
   Saenz-Frances, Federico
   Serrador-Garcia, Mercedes
   Porta-Etessam, Jesus
   Maria Martinez-de-la-Casa, Jose
   Garcia-Feijoo, Julian
   Garcia-Sanchez, Julian
TI Prevalence and clinical characteristics of Charles Bonnet syndrome in
   Madrid, Spain
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Charles Bonnet syndrome; Glaucoma; Low
   vision; Visual hallucinations
ID VISUAL HALLUCINATIONS; GLAUCOMA
AB Purpose: Charles Bonnet syndrome (CBS) is a condition characterized by development of visual hallucinations in patients with no cognitive impairment and significant loss of vision mainly caused by age-related macular degeneration (AMD) or glaucoma.
   Methods: This was a study of prevalence and characteristics of CBS diagnosed at the Neuroophthalmic Unit within the Ophthalmology Department of Hospital Clinic San Carlos (HCSC), Madrid, Spain.
   Results: The CBS prevalence in patients from HCSC Madrid is 0.47%, rising to 15% in patients with low vision. Women over 80 years of age comprised 58.3% of the patients, who mainly had AMD (58.3%). Main characteristics of hallucinations included animals (50%), color (58.3%), moving (75%), 6- to 12-month evolution (50%), three times a day frequency (75%), and 3- to 5-minute duration (50%).
   Conclusions: Charles Bonnet syndrome is a complex process that must be treated jointly by ophthalmologists, neurologists, and psychiatrists in order to ensure accurate diagnosis and adequate management. New studies are needed in order to improve awareness of clinical manifestation of this condition, the incidence of which is underestimated due to patients' fear of being branded mentally ill, as well as physicians' lack of knowledge about CBS.
C1 [Santos-Bueso, Enrique; Saenz-Frances, Federico; Serrador-Garcia, Mercedes; Porta-Etessam, Jesus; Maria Martinez-de-la-Casa, Jose; Garcia-Feijoo, Julian; Garcia-Sanchez, Julian] Hosp Clin San Carlos, Ophthalmol Unit, Inst Invest Sanitaria, Neuroophthalmol Unit,IdISSC, Madrid 28040, Spain.
C3 Hospital Clinico San Carlos
RP Santos-Bueso, E (通讯作者)，Hosp Clin San Carlos, Serv Oftalmol, Avda Prof Martin Lagos S-N, Madrid 28040, Spain.
EM esbueso@hotmail.com
RI Porta-Etessam, Jesús/AAG-6746-2019; Santos-Bueso, Enrique/G-9870-2017;
   GARCIA FEIJOO, JULIAN/G-9762-2017; Saenz-Frances, Federico/A-3350-2012
OI Porta-Etessam, Jesús/0000-0002-7034-682X; Martinez-de-la-Casa, Jose
   Maria/0000-0001-9441-0542; Santos-Bueso, Enrique/0000-0002-0097-1726;
   GARCIA FEIJOO, JULIAN/0000-0002-7772-5718; Saenz-Frances,
   Federico/0000-0002-3196-1491
CR Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   Contardi S, 2007, EPILEPTIC DISORD, V9, P271, DOI 10.1684/epd.2007.0110
   Garcia-Catalan M R, 2013, Arch Soc Esp Oftalmol, V88, P362, DOI 10.1016/j.oftal.2012.05.007
   Gonzalez-Delgado M, 2004, NEUROLOGIA, V19, P80
   Jackson ML, 2010, EYE, V24, P1303, DOI 10.1038/eye.2010.12
   Kaeser PF, 2009, EUR J OPHTHALMOL, V19, P494, DOI 10.1177/112067210901900331
   Madill SA, 2005, BRIT J OPHTHALMOL, V89, P785, DOI 10.1136/bjo.2005.066027
   Mascaro J, 2003, AGING CLIN EXP RES, V15, P518, DOI 10.1007/BF03327376
   Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9
   Mewasingh LD, 2002, PEDIATR NEUROL, V26, P143, DOI 10.1016/S0887-8994(01)00358-7
   Meyer CH, 2007, AM J OPHTHALMOL, V143, P169, DOI 10.1016/j.ajo.2006.08.003
   Nesher R, 2001, J GLAUCOMA, V10, P396, DOI 10.1097/00061198-200110000-00006
   Sabri R, 2009, SINGAP MED J, V50, pE48
   Santos-Bueso E, 2014, Arch Soc Esp Oftalmol, V89, P43, DOI 10.1016/j.oftal.2013.09.004
   Santos-Bueso E, 2013, Arch Soc Esp Oftalmol, V88, P369, DOI 10.1016/j.oftal.2012.12.008
   Santos-Bueso E, 2013, Arch Soc Esp Oftalmol, V88, P244, DOI 10.1016/j.oftal.2012.06.014
   Schadlu AP, 2009, CURR OPIN OPHTHALMOL, V20, P219, DOI 10.1097/ICU.0b013e328329b643
   Schwartz T L, 1998, J AAPOS, V2, P310
   Serrador-Garcia M, 2012, EUR J OPHTHALMOL, V22, P836, DOI 10.5301/ejo.5000130
   Shiraishi Y, 2004, J PSYCHIATR RES, V38, P207, DOI 10.1016/S0022-3956(03)00090-6
   Terao T, 2000, AM J PSYCHIAT, V157, P2062, DOI 10.1176/appi.ajp.157.12.2062
   Teunisse RJ, 1999, COMPR PSYCHIAT, V40, P315, DOI 10.1016/S0010-440X(99)90133-5
   Unsalver BO, 2007, TURK PSIKIYATR DERG, V18, P277
NR 23
TC 13
Z9 14
U1 1
U2 14
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 960
EP 963
DI 10.5301/ejo.5000483
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX0FA
UT WOS:000346627400023
PM 24846623
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Masini, E
   Carta, F
   Scozzafava, A
   Supuran, CT
AF Masini, Emanuela
   Carta, Fabrizio
   Scozzafava, Andrea
   Supuran, Claudiu T.
TI Antiglaucoma carbonic anhydrase inhibitors: a patent review
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review
DE acetazolamide; brinzolamide; dichlorophenamide; dithiocarbamate;
   dorzolamide; glaucoma; carbonic anhydrase inhibitor; prostaglandin F2
   alpha analog; sulfamate; sulfamide; sulfonamide
ID INTRAOCULAR-PRESSURE; AROMATIC/HETEROCYCLIC SULFONAMIDES; ANION
   INHIBITION; DRUG DISCOVERY; DORZOLAMIDE; MECHANISM; BENZENESULFONAMIDES;
   DERIVATIVES; ISOENZYMES; ACTIVATORS
AB Introduction: Glaucoma is one of the major causes of blindness, affecting together with age-related macular degeneration 70 million people worldwide. One of the therapeutic options for its management is based on the inhibition of the metalloenyme carbonic anhydrase (CA, EC 4.2.1.1). CA inhibitors (CAIs) diminish intraocular pressure (IOP) by reducing the rate of bicarbonate formation and thus secretion of the aqueous humor.
   Areas covered: The main classes of clinically used antiglaucoma CAIs are the sulfonamides with systemic (acetazolamide, methazolamide, ethoxzolamide and dichlorophenamide) and topical (dorzolamide and brinzolamide) action. A patent literature review covering the period 2007 - 2013 is presented.
   Expert opinion: This review presents an overview of the patent literature in the CAI antiglaucoma drug design field during the past 6 years. Most of the patents deal with sulfonamide/sulfamide/sulfamate CAIs, sulfonamides incorporating NO-donating moieties, as well as hybrids incorporating sulfonamide and prostaglandin (PG) analogs, were also reported. There is an urgent need for new antiglaucoma CAIs/approaches to treat and diagnose this disease in the very near future, as the last drug which has been discovered in the field (latanoprost) dates back > 10 years ago.
C1 [Masini, Emanuela; Supuran, Claudiu T.] Univ Florence, NEUROFARBA Dept, Sez Farmacol, Florence, Italy.
   [Carta, Fabrizio; Scozzafava, Andrea] Univ Florence, Lab Chim Bioinorgan, I-50019 Florence, Italy.
   [Supuran, Claudiu T.] Univ Florence, NEUROFARBA Dept, Sez Sci Farmaceut, I-50019 Florence, Italy.
C3 University of Florence; University of Florence; University of Florence
RP Supuran, CT (通讯作者)，Univ Florence, NEUROFARBA Dept, Viale Pierracini 6, Florence, Italy.
EM andrea.scozzafava@unifi.it; claudiu.supuran@unifi.it
RI carta, fabrizio/Y-2333-2019
OI carta, fabrizio/0000-0002-1141-6146; Scozzafava,
   Andrea/0000-0001-5020-3322; Supuran, Claudiu/0000-0003-4262-0323
FU European Union
FX Research from the authors' laboratory was financed by several grants of
   the 6th and 7th Framework Programs of the European Union (DeZnIT,
   Metoxia and Dynano projects). The authors declare a conflict of interest
   as they are authors of many patents dealing with various classes of CA
   inhibitors (most of which are cited in the review).
CR Aalto-Korte K, 1998, CONTACT DERMATITIS, V39, P206, DOI 10.1111/j.1600-0536.1998.tb05905.x
   Abdulrazik M., 2011, Novel compounds for the treatment of glaucoma or ocular hypertension, Patent No. [US0305710, 0305710]
   Aggarwal M, 2013, J ENZYM INHIB MED CH, V28, P267, DOI 10.3109/14756366.2012.737323
   Aggarwal M, 2012, EXPERT OPIN THER PAT, V22, P903, DOI 10.1517/13543776.2012.707646
   Alp C, 2012, J ENZYM INHIB MED CH, V27, P818, DOI 10.3109/14756366.2011.617745
   Alterio V, 2012, CHEM REV, V112, P4421, DOI 10.1021/cr200176r
   Antel J., 2007, U.S. Patent, Patent No. [117,823, 117823, US 0117823, 0117823]
   Antel J, 2007, [No title captured], Patent No. [WO 054580, 054580]
   Bakhit PG, 2007, Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia, Patent No. [US0244051, 0244051]
   Baranauskiene L, 2010, J ENZYM INHIB MED CH, V25, P863, DOI 10.3109/14756360903571685
   BECKER B, 1955, AM J OPHTHALMOL, V39, P177, DOI 10.1016/0002-9394(55)90022-2
   Benedini F, 2008, Patent No. [WO 075155, 075155, WO075155]
   Bootorabi F, 2011, J ENZYM INHIB MED CH, V26, P862, DOI 10.3109/14756366.2011.588227
   Borriello M, 2013, Cyclic amide derivatives as EP4 receptor antagonists, Patent No. [WO004291, 004291]
   Burk RM, 2007, Novel sulfonamides, Patent No. [WO024611, 024611]
   Capasso C, 2012, J ENZYM INHIB MED CH, V27, P892, DOI 10.3109/14756366.2012.703185
   Carlsen J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1087
   Carta F, 2012, J MED CHEM, V55, P1721, DOI 10.1021/jm300031j
   Carta F, 2012, CHEM COMMUN, V48, P1868, DOI 10.1039/c2cc16395k
   Carta F, 2012, EXPERT OPIN THER PAT, V22, P79, DOI 10.1517/13543776.2012.649006
   Carta F, 2010, J MED CHEM, V53, P5511, DOI 10.1021/jm1003667
   Cavdar H, 2012, J ENZYM INHIB MED CH, V27, P148, DOI 10.3109/14756366.2011.629198
   Chang JN, 2011, Carbonic anhydrase inhibitor sustained release intraocular drug delivery system, Patent No. [US0034448, 0034448]
   Chiroli V, 2009, BIOORG MED CHEM LETT, V19, P2785, DOI 10.1016/j.bmcl.2009.03.111
   Chong W.K., 2008, W.O. Patent, Patent No. [075,152, 075152]
   Dantanarayana AP, 2009, Substituted furo[ 2,3-G] indazoles for the treatment of glaucoma, Patent No. [US0012291, 0012291]
   De Luca V, 2012, BIOORG MED CHEM LETT, V22, P5630, DOI 10.1016/j.bmcl.2012.06.106
   Del Prete S, 2012, J MED CHEM, V55, P10742, DOI 10.1021/jm301611m
   Dinh D.T., 2009, W.O. Patent, Patent No. [091,764, 091764]
   Ebbesen P, 2011, [No title captured], Patent No. [WO098610, 098610]
   Ekinci D, 2012, J ENZYM INHIB MED CH, V27, P845, DOI 10.3109/14756366.2011.621122
   Ekinci D, 2012, J ENZYM INHIB MED CH, V27, P744, DOI 10.3109/14756366.2011.614607
   Fabrizi F, 2012, J ENZYM INHIB MED CH, V27, P138, DOI 10.3109/14756366.2011.597749
   FRIEDENWALD JS, 1949, AM J OPHTHALMOL, V32, P9, DOI 10.1016/S0002-9394(14)78354-0
   Gant TG, 2010, Sulfonamide inhibitors of carbonic anhydrase II, Patent No. [US0125067, 0125067]
   Hellberg M.R., 2007, W.O. Patent, Patent No. [038,372, 038372]
   Hewitson KS, 2010, Carbonic anhydrase inhibitors for treating dandruff and related disorders, Patent No. [WO061185, 061185]
   Holoboski M., 2008, W.O. Patent, Patent No. [073,752, 073752]
   Huang Q, 2009, Patent No. [WO 007814, 007814, WO007814]
   Inoue J, 2011, Ophthalmic composition, Patent No. [WO140194, 140194]
   Johnson BA, 2009, Therapeutic compounds, Patent No. [US0186885, 0186885]
   Kazancioglu EA, 2012, J ENZYM INHIB MED CH, V27, P880, DOI 10.3109/14756366.2011.637202
   KINSEY VE, 1953, AMA ARCH OPHTHALMOL, V50, P401, DOI 10.1001/archopht.1953.00920030409001
   KINSEY VE, 1959, ARCH OPHTHALMOL-CHIC, V62, P78
   KINSEY VE, 1949, AM J OPHTHALMOL, V32, P189, DOI 10.1016/S0002-9394(14)78372-2
   Konowal A, 1999, AM J OPHTHALMOL, V127, P403, DOI 10.1016/S0002-9394(98)00438-3
   Kutuzova GD, 2012, ARCH BIOCHEM BIOPHYS, V518, P53, DOI 10.1016/j.abb.2011.10.022
   Liao SY, 2003, J MED GENET, V40, P257, DOI 10.1136/jmg.40.4.257
   Liu F, 2012, J ENZYM INHIB MED CH, V27, P886, DOI 10.3109/14756366.2011.638921
   Long DD, 2013, BIOORG MED CHEM LETT, V23, P939, DOI 10.1016/j.bmcl.2012.12.058
   MAREN TH, 1983, EXP EYE RES, V36, P457, DOI 10.1016/0014-4835(83)90041-6
   MAREN TH, 1967, PHYSIOL REV, V47, P595, DOI 10.1152/physrev.1967.47.4.595
   Maresca A, 2013, J ENZYM INHIB MED CH, V28, P407, DOI 10.3109/14756366.2011.641015
   Maresca A, 2010, J MED CHEM, V53, P335, DOI 10.1021/jm901287j
   Maresca A, 2009, J AM CHEM SOC, V131, P3057, DOI 10.1021/ja809683v
   Masereel B, 2012, [No title captured], Patent No. [WO175654, 175654]
   Matulis D, 2008, [No title captured], Patent No. [WO 016288, 016288]
   Maus TL, 1997, ARCH OPHTHALMOL-CHIC, V115, P45, DOI 10.1001/archopht.1997.01100150047008
   Maxey K.M., 2008, U.S. Patent, Patent No. [0,146,821, 0146821]
   McIntire GL, 2011, Complexes comprising alpha-2-adrenergic receptor agonists and methods of providing neuroprotection or treating or inhibiting progression of glaucoma, Patent No. [US0183946, 0183946]
   MILLER WH, 1950, J AM CHEM SOC, V72, P4893, DOI 10.1021/ja01167a012
   Mincione F, 2004, CRC ENZYM INHIB SER, P243
   Mincione F., 2009, DRUG DESIGN ZINC ENZ, P139
   Mincione F, 2007, CURR TOP MED CHEM, V7, P849, DOI 10.2174/156802607780636735
   Mincione F, 2011, BIOORG MED CHEM LETT, V21, P3216, DOI 10.1016/j.bmcl.2011.04.046
   Molnar F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018124
   Monti SM, 2012, BIOORG MED CHEM LETT, V22, P859, DOI 10.1016/j.bmcl.2011.12.033
   Nair SK, 2008, [No title captured], Patent No. [WO 075148, 075148]
   Old D.W., 2007, W.O. Patent, Patent No. [005,176, 005176]
   Old D.W., 2008, W.O. Patent, Patent No. [144,623, 144623]
   Patterson B, 2008, [No title captured], Patent No. [WO 120099, 120099]
   Prasanna G., 2008, W.O. Patent, Patent No. [015,517, 015517]
   Quigley HA, 2006, BR J OPHTHALMOL, V90, P151, DOI DOI 10.1136/BJ0.2005.081224
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rao T, 2010, Sulfonamide inhibitors of carbonic anhydrase, Patent No. [US0317655, 0317655]
   Reunamaki T, 2011, Method and composition for treating ocular hypertension and glaucoma, Patent No. [US0152264, 0152264]
   Ruckmick S, 2007, Novel compounds and their use related to compositions for treating glaucoma and/or ocular hypertension, Patent No. [WO050615, 050615]
   Schoen U, 2009, [No title captured], Patent No. [WO 0 50252, 050252]
   Schwartzenberg GWST, 1999, CAN J OPHTHALMOL, V34, P93
   Scozzafava A, 2002, J MED CHEM, V45, P1466, DOI 10.1021/jm0108202
   Scozzafava A, 1999, J MED CHEM, V42, P2641, DOI 10.1021/jm9900523
   Scozzafava A, 1999, J MED CHEM, V42, P3690, DOI 10.1021/jm9901879
   Scozzafava A, 2000, J MED CHEM, V43, P4542, DOI 10.1021/jm000296j
   Scozzafava A, 2006, EXPERT OPIN THER PAT, V16, P1627, DOI 10.1517/13543776.16.12.1627
   Silver LH, 2000, SURV OPHTHALMOL, V44, pS147, DOI 10.1016/S0039-6257(99)00110-1
   Singh S, 2012, J ENZYM INHIB MED CH, V27, P666, DOI 10.3109/14756366.2011.606544
   Sinha S.C., 2009, W.O. Patent, Patent No. [023,758, 023758]
   Steele RM, 2009, BIOORG MED CHEM LETT, V19, P6565, DOI 10.1016/j.bmcl.2009.10.036
   Sugrue MF, 2000, PROG RETIN EYE RES, V19, P87, DOI 10.1016/S1350-9462(99)00006-3
   Supuran C, 2012, Novel sulfonamide compounds for inhibition of metastatic tumor growth, Patent No. [W0021963, 021963, WO021963]
   Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467
   Supuran CT, 2012, J ENZYM INHIB MED CH, V27, P759, DOI 10.3109/14756366.2012.672983
   Supuran CT, 2011, FUTURE MED CHEM, V3, P1165, DOI [10.4155/FMC.11.69, 10.4155/fmc.11.69]
   Supuran CT, 2010, CURR PHARM DESIGN, V16, P3233
   Supuran CT, 2010, BIOORG MED CHEM LETT, V20, P3467, DOI 10.1016/j.bmcl.2010.05.009
   Supuran CT, 2000, EXPERT OPIN THER PAT, V10, P575, DOI 10.1517/13543776.10.5.575
   Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025
   Supuran CT, 2004, CRC ENZYM INHIB SER, P67
   Supuran CT, 2010, [No title captured], Patent No. [WO139678, 139678]
   Supuran CT, 2008, [No title captured], Patent No. [WO 071421, 071421]
   Supuran CT, 2012, [No title captured], Patent No. [WO070024, 070024]
   Temperini C, 2010, BIOORG MED CHEM LETT, V20, P474, DOI 10.1016/j.bmcl.2009.11.124
   Touisni N, 2011, J MED CHEM, V54, P8271, DOI 10.1021/jm200983e
   Vullo D, 2012, BIOORG MED CHEM LETT, V22, P7142, DOI 10.1016/j.bmcl.2012.09.065
   Vullo D, 2012, BIOORG MED CHEM LETT, V22, P6324, DOI 10.1016/j.bmcl.2012.08.088
   WISTRAND PJ, 1951, ACTA PHYSIOL SCAND, V24, P144, DOI 10.1111/j.1748-1716.1951.tb00833.x
   Woodward D.F., 2007, U.S. Patent, Patent No. [0,112,058, 0112058]
   Woodward D.F., 2007, W.O. Patent, Patent No. [027,468, 027468]
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 109
TC 233
Z9 236
U1 3
U2 49
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD JUN
PY 2013
VL 23
IS 6
BP 705
EP 716
DI 10.1517/13543776.2013.794788
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 146HB
UT WOS:000319079700004
PM 23627893
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Tobin, KW
   Chaum, E
   Govindasamy, VP
   Karnowski, TP
AF Tobin, Kenneth W.
   Chaum, Edward
   Govindasamy, V. Priya
   Karnowski, Thomas P.
TI Detection of anatomic structures in human retinal imagery
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE bayesian classifier; diabetic retinopathy; feature analysis; macula
   localization; optic nerve detection; red-free fundus imagery; vascular
   segmentation
ID DIABETIC-RETINOPATHY; OPTIC DISC; SEGMENTATION; PHOTOGRAPHY; MODEL
AB The widespread availability of electronic imaging devices throughout the medical community is leading to a growing body of research on image processing and analysis to diagnose retinal disease such as diabetic retinopathy (DR). Productive computer-based screening of large, at-risk populations at low cost requires robust, automated image analysis. In this paper we present results for the automatic detection of the optic nerve and localization of the macula using digital red-free fundus photography. Our method relies on the accurate segmentation of the vasculature of the retina followed by the determination of spatial features describing the density, average thickness, and average orientation of the vasculature in relation to the position of the optic nerve. Localization of the macula follows using knowledge of the optic nerve location to detect the horizontal raphe of the retina using a geometric model of the vasculature. We report 90.4% detection performance for the optic nerve and 92.5% localization performance for the macula for red-free fundus images representing a population of 345 images corresponding to 269 patients with 18 different pathologies associated with DR and other common retinal diseases such as age-related macular degeneration.
C1 Oak Ridge Natl Lab, Image Sci & Machine Vis Grp, Oak Ridge, TN 37831 USA.
   Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA.
C3 United States Department of Energy (DOE); Oak Ridge National Laboratory;
   University of Tennessee System; University of Tennessee Health Science
   Center
RP Tobin, KW (通讯作者)，Oak Ridge Natl Lab, Image Sci & Machine Vis Grp, Oak Ridge, TN 37831 USA.
EM tobinkwjr@ornl.gov; echaum@utmem.edu; muthusamygov@ornl.gov;
   karnowskitp@ornl.gov
RI Chaum, Edward/AAR-1512-2021
OI Chaum, Edward/0000-0003-3542-8376; Karnowski,
   Thomas/0000-0002-0376-4917; Tobin, Kenneth/0000-0003-3577-9520
FU NATIONAL EYE INSTITUTE [R01EY017065] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01-EY017065, R01 EY017065] Funding Source: Medline
CR Abramoff M. D., 2006, C P IEEE ENG MED BIO, P4432, DOI [DOI 10.1109/IEMBS.2006.259622, 10.1109/IEMBS.2006.259622]
   Abramoff MD, 2007, INVEST OPHTH VIS SCI, V48, P1665, DOI 10.1167/iovs.06-1081
   Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I
   Cavallerano AA, 2003, RETINA-J RET VIT DIS, V23, P215, DOI 10.1097/00006982-200304000-00013
   *CDCP, 2003, CDCP PREV NAT DIAB F
   Chanwimaluang T, 2006, IEEE T INF TECHNOL B, V10, P129, DOI 10.1109/TITB.2005.856859
   *CLEMS U, STARE PROJ WEBS
   Duda R.O., 2006, PATTERN CLASSIFICATI
   Fleming AD, 2007, PHYS MED BIOL, V52, P331, DOI 10.1088/0031-9155/52/2/002
   Foracchia M, 2005, MED IMAGE ANAL, V9, P179, DOI 10.1016/j.media.2004.07.001
   Foracchia M, 2004, IEEE T MED IMAGING, V23, P1189, DOI 10.1109/TMI.2004.829331
   Fransen SR, 2002, OPHTHALMOLOGY, V109, P595, DOI 10.1016/S0161-6420(01)00990-3
   FREEMAN WT, 1991, IEEE T PATTERN ANAL, V13, P891, DOI 10.1109/34.93808
   Gagnon L, 2001, PROC SPIE, V4322, P1218, DOI 10.1117/12.430999
   Hoover A, 2003, IEEE T MED IMAGING, V22, P951, DOI 10.1109/TMI.2003.815900
   JAVITT JC, 1991, OPHTHALMOLOGY, V98, P1565
   Larsen N, 2003, INVEST OPHTH VIS SCI, V44, P767, DOI 10.1167/iovs.02-0417
   Li HQ, 2004, IEEE T BIO-MED ENG, V51, P246, DOI 10.1109/TBME.2003.820400
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Lin TS, 2002, ELECTRON LETT, V38, P1090, DOI 10.1049/el:20020775
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   MARTINPEREZ ME, 1999, IEEE INT C IM PROC, P173
   MERICKEL MB, 2007, P SOC PHOTO-OPT INS
   Morris DT, 1999, IMAGE VISION COMPUT, V17, P169, DOI 10.1016/S0262-8856(98)00093-6
   Niemeijer M, 2007, IEEE T MED IMAGING, V26, P116, DOI 10.1109/TMI.2006.885336
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Pinz A, 1998, IEEE T MED IMAGING, V17, P606, DOI 10.1109/42.730405
   QING ZH, 2004, IEEE INT C AC SPEECH, P509
   Schwiegerling J., 2004, FIELD GUIDE VISUAL O
   Solouma NH, 2002, IEEE T BIO-MED ENG, V49, P1059, DOI 10.1109/TBME.2002.802059
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Stellingwerf C, 2001, DIABETES CARE, V24, P2086, DOI 10.2337/diacare.24.12.2086
   Sun H, 2001, SCI AM, V285, P69, DOI 10.1038/scientificamerican1001-68
   Teng T, 2002, MED BIOL ENG COMPUT, V40, P2, DOI 10.1007/BF02347689
   Trucco E, 2004, IEEE IMAGE PROC, P155
   WU CH, 2007, P SOC PHOTO-OPT INS
   Zana F, 2001, IEEE T IMAGE PROCESS, V10, P1010, DOI 10.1109/83.931095
NR 37
TC 155
Z9 161
U1 0
U2 18
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD DEC
PY 2007
VL 26
IS 12
BP 1729
EP 1739
DI 10.1109/TMI.2007.902801
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 237LX
UT WOS:000251376500010
PM 18092741
DA 2022-11-30
ER

PT J
AU Brancato, R
   Introini, U
   Pierro, L
   Setaccioli, M
   Forti, M
   Bolognesi, G
   Tremolada, G
AF Brancato, R
   Introini, U
   Pierro, L
   Setaccioli, M
   Forti, M
   Bolognesi, G
   Tremolada, G
TI Optical coherence tomography (OCT) in retinal angiomatous proliferation
   (RAP)
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal neovascularization;
   indocyanine green angiography (ICGA); optical coherence tomography
   (OCT); retinal angiomatous proliferation (RAP); serous retinal
   detachment (SPD)
ID MACULAR DEGENERATION; DETACHMENTS
AB PURPOSE. To verify the utility of optical coherence tomography (OCT) for diagnosing retinal angiomatous proliferations (RAP) in patients with exudative age-related macular degeneration (AMD).
   METHODS. Multiple cross-sections were taken with OCT from 41 eyes of 39 consecutive patients with AMD and RAP. The presence and the location of the angiomatous complexes had already been documented by fluorescein angiography (FA) and high-speed confocal indocyanine green videoangiography (ICGA).
   RESULTS. RAP was detectable by OCT scans in all 41 eyes, appearing as a focal hyper-reflecting area in the neuroretinal layers; it was frequently located close to the inner surface of the retinal pigment epithelium (29 eyes [70.70%]). All eyes had either no or only a low-reflecting OCT signal surrounding the RAP, caused by serous intraretinal edema. Only 13 eyes (31.7%), however, had large serous retinal detachment (SRD). OCT detected pigment epithelium detachment in 31 eyes (75.6%), but none had underlying choroidal neovascularization.
   CONCLUSIONS. OCT findings confirm the intraretinal localization of the RAP which are always associated with impressive exudative phenomena. OCT is therefore a useful diagnostic tool, adding information to FA and high-speed ICGA.
C1 San Raffaele Univ Hosp, Dept Ophthalmol & Visual Sci, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Brancato, R (通讯作者)，San Raffaele Univ Hosp, Dept Ophthalmol & Visual Sci, Via Olgettina 60, I-20132 Milan, Italy.
EM brancato.rosario@hsr.it
RI Pierro, Luisa/AAN-3900-2020
OI Setaccioli, Marco/0000-0002-0500-8728
CR HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 7
TC 28
Z9 34
U1 0
U2 0
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2002
VL 12
IS 6
BP 467
EP 472
DI 10.1177/112067210201200604
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629CL
UT WOS:000180032800004
PM 28252717
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Jiao, Y
   Li, X
   Gao, S
   Zhou, NH
   Duan, JA
   Zhang, MX
AF Zhang, Yun
   Jiao, Yan
   Li, Xun
   Gao, Sheng
   Zhou, Nenghua
   Duan, Jianan
   Zhang, Meixia
TI Pyroptosis: A New Insight Into Eye Disease Therapy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE pyroptosis; eye disease; inflammasome; NLRP3; pyroptosis inhibitors
ID NLRP3 INFLAMMASOME ACTIVATION; THIOREDOXIN-INTERACTING PROTEIN;
   ENDOTOXIN-INDUCED UVEITIS; CELL-DEATH; PATTERN-RECOGNITION; OXIDATIVE
   STRESS; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; P2X7 RECEPTOR;
   AMYLOID-BETA
AB Pyroptosis is a lytic form of programmed cell death mediated by gasdermins (GSDMs) with pore-forming activity in response to certain exogenous and endogenous stimuli. The inflammasomes are intracellular multiprotein complexes consisting of pattern recognition receptors, an adaptor protein ASC (apoptosis speck-like protein), and caspase-1 and cause autocatalytic activation of caspase-1, which cleaves gasdermin D (GSDMD), inducing pyroptosis accompanied by cytokine release. In recent years, the pathogenic roles of inflammasomes and pyroptosis in multiple eye diseases, including keratitis, dry eyes, cataracts, glaucoma, uveitis, age-related macular degeneration, and diabetic retinopathy, have been continuously confirmed. Inhibiting inflammasome activation and abnormal pyroptosis in eyes generally attenuates inflammation and benefits prognosis. Therefore, insight into the pathogenesis underlying pyroptosis and inflammasome development in various types of eye diseases may provide new therapeutic strategies for ocular disorders. Inhibitors of pyroptosis, such as NLRP3, caspase-1, and GSDMD inhibitors, have been proven to be effective in many eye diseases. The purpose of this article is to illuminate the mechanism underlying inflammasome activation and pyroptosis and emphasize its crucial role in various ocular disorders. In addition, we review the application of pyroptosis modulators in eye diseases.
C1 [Zhang, Yun; Li, Xun; Gao, Sheng; Duan, Jianan; Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
   [Zhang, Yun; Li, Xun; Gao, Sheng; Duan, Jianan; Zhang, Meixia] Sichuan Univ, West China Hosp, Res Lab Macular Dis, Chengdu, Peoples R China.
   [Jiao, Yan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.
   [Jiao, Yan] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China.
   [Zhou, Nenghua] Sichuan Univ, West China Sch Pharm, Key Lab Drug Targeting & Drug Delivery Syst, Minist Educ, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University; Sichuan University
RP Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.; Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Res Lab Macular Dis, Chengdu, Peoples R China.
EM zhangmeixia@scu.edu.cn
FU 1.3.5 project for disciplines of excellence, West China Hospital,
   Sichuan University [ZYJC21025]; Post-Doctor Research Project, West China
   Hospital, Sichuan University [2020HXBH112]; China Postdoctoral Science
   Foundation [2021M692273]
FX This work was supported by the 1.3.5 project for disciplines of
   excellence, West China Hospital, Sichuan University (ZYJC21025), the
   Post-Doctor Research Project, West China Hospital, Sichuan University
   (2020HXBH112), and the China Postdoctoral Science Foundation
   (2021M692273).
CR Adornetto A, 2019, NEURAL REGEN RES, V14, P391, DOI 10.4103/1673-5374.245465
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Baker PJ, 2015, EUR J IMMUNOL, V45, P2918, DOI 10.1002/eji.201545655
   Baudouin C, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100916
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bian F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030562
   Bordone MP, 2017, J NEUROCHEM, V142, P323, DOI 10.1111/jnc.14070
   Bosco A, 2015, DIS MODEL MECH, V8, P443, DOI 10.1242/dmm.018788
   Bose S, 2014, MBIO, V5, DOI 10.1128/mBio.02186-14
   Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240
   Camelo S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4984927
   Chavarria-Smith J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006052
   Chen H, 2020, OCUL SURF, V18, P783, DOI 10.1016/j.jtos.2020.07.001
   Chen H, 2020, MOL NEURODEGENER, V15, DOI 10.1186/s13024-020-00372-w
   Chen JQ, 2018, NATURE, V564, P71, DOI 10.1038/s41586-018-0761-3
   Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2
   Chi W, 2014, P NATL ACAD SCI USA, V111, P11181, DOI 10.1073/pnas.1402819111
   Cocco M, 2017, J MED CHEM, V60, P3656, DOI 10.1021/acs.jmedchem.6b01624
   Coll RC, 2019, NAT CHEM BIOL, V15, P556, DOI 10.1038/s41589-019-0277-7
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Craig JP, 2017, OCUL SURF, V15, P276, DOI 10.1016/j.jtos.2017.05.008
   Cui WY, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.496
   D'Osualdo A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027396
   Deguchi S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102171
   Devi TS, 2013, EXP CELL RES, V319, P1001, DOI 10.1016/j.yexcr.2013.01.012
   Di AK, 2018, IMMUNITY, V49, P56, DOI 10.1016/j.immuni.2018.04.032
   Di Virgilio F, 2013, PHARMACOL REV, V65, P872, DOI 10.1124/pr.112.006171
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Domingo-Fernandez R, 2017, J BIOL CHEM, V292, P12077, DOI 10.1074/jbc.M117.797126
   Dostert C, 2008, ADV DRUG DELIVER REV, V60, P830, DOI 10.1016/j.addr.2007.12.003
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Du JX, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108065
   Eissa LD, 2021, EUR J PHARMACOL, V901, DOI 10.1016/j.ejphar.2021.174061
   Ewald SE, 2014, INFECT IMMUN, V82, P460, DOI 10.1128/IAI.01170-13
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   Fernandez-Albarral JA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042066
   Finger JN, 2012, J BIOL CHEM, V287, P25030, DOI 10.1074/jbc.M112.378323
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Franchi L, 2009, J IMMUNOL, V183, P792, DOI 10.4049/jimmunol.0900173
   Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gan JH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4510628
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gritsenko A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565924
   Gu CF, 2019, INVEST OPHTH VIS SCI, V60, P4215, DOI 10.1167/iovs.19-27825
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Haloupek N, 2019, METHOD ENZYMOL, V625, P177, DOI 10.1016/bs.mie.2019.04.030
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hazlett LD, 2004, PROG RETIN EYE RES, V23, P1, DOI 10.1016/j.preteyeres.2003.10.002
   He Y, 2013, J IMMUNOL, V190, P334, DOI 10.4049/jimmunol.1202737
   Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725
   Hu LL, 2017, GRAEF ARCH CLIN EXP, V255, P2199, DOI 10.1007/s00417-017-3772-0
   Huang B, 2021, CELL MOL IMMUNOL, V18, P1278, DOI 10.1038/s41423-020-0444-5
   Huang PR, 2020, CELL BIOL INT, V44, P2213, DOI 10.1002/cbin.11429
   Huang Y, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708689
   Ito Y, 2010, BIOL PHARM BULL, V33, P1574, DOI 10.1248/bpb.33.1574
   Jassim AH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.699623
   Ji QS, 2021, INFLAMMATION, V44, P682, DOI 10.1007/s10753-020-01367-x
   Jin TC, 2013, J BIOL CHEM, V288, P13225, DOI 10.1074/jbc.M113.468033
   Jin TC, 2012, IMMUNITY, V36, P561, DOI 10.1016/j.immuni.2012.02.014
   Jin X, 2018, MOL MED REP, V18, P2277, DOI 10.3892/mmr.2018.9188
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johra FT, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111046
   Kanai K, 2012, CURR EYE RES, V37, P124, DOI 10.3109/02713683.2011.622853
   Kanai K, 2010, CURR EYE RES, V35, P892, DOI 10.3109/02713683.2010.495442
   Karthikeyan RS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064867
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Khan S, 2007, J LEUKOCYTE BIOL, V81, P315, DOI 10.1189/jlb.0506344
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kofoed EM, 2011, NATURE, V477, P592, DOI 10.1038/nature10394
   Kowluru RA, 2019, DIABETES, V68, P241, DOI 10.2337/dbi18-0016
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lee K, 2014, EXPERT OPIN PHARMACO, V15, P2141, DOI 10.1517/14656566.2014.948417
   Lee RW, 2014, SEMIN IMMUNOPATHOL, V36, P581, DOI 10.1007/s00281-014-0433-9
   Li LP, 2021, PART FIBRE TOXICOL, V18, DOI 10.1186/s12989-021-00403-4
   Li S, 2019, EXP ANIM TOKYO, V68, P221, DOI 10.1538/expanim.18-0146
   Li Y, 2018, BIOCHEM BIOPH RES CO, V501, P351, DOI 10.1016/j.bbrc.2018.03.148
   Lim RR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030899
   Lin J, 2018, CELL SIGNAL, V49, P39, DOI 10.1016/j.cellsig.2018.05.007
   Liu JX, 2021, EXP EYE RES, V208, DOI 10.1016/j.exer.2021.108595
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Liu Y, 2016, CURR EYE RES, V41, P1400, DOI 10.3109/02713683.2015.1127389
   Loukovaara S, 2017, ACTA OPHTHALMOL, V95, P803, DOI 10.1111/aos.13427
   Lu WN, 2019, INVEST OPHTH VIS SCI, V60, P3046, DOI 10.1167/iovs.19-27241
   Lu W, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00242
   Lyon H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010298
   Malley R, 2003, P NATL ACAD SCI USA, V100, P1966, DOI 10.1073/pnas.0435928100
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Markiewicz L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/812503
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Master SS, 2008, CELL HOST MICROBE, V3, P224, DOI 10.1016/j.chom.2008.03.003
   McKenzie BA, 2020, TRENDS NEUROSCI, V43, P55, DOI 10.1016/j.tins.2019.11.005
   Mesquida M, 2019, SEMIN IMMUNOPATHOL, V41, P427, DOI 10.1007/s00281-019-00750-7
   Mills KHG, 2013, J LEUKOCYTE BIOL, V93, P489, DOI 10.1189/jlb.1012543
   Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474
   Mohamed IN, 2014, DIABETOLOGIA, V57, P413, DOI 10.1007/s00125-013-3101-z
   Motta V, 2015, PHYSIOL REV, V95, P149, DOI 10.1152/physrev.00009.2014
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Murakami Y, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100778
   Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720
   Okada M, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.579961
   Okondo MC, 2018, CELL CHEM BIOL, V25, P262, DOI 10.1016/j.chembiol.2017.12.013
   Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818
   Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457
   Perrone L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.42
   Pflugfelder SC, 2017, OPHTHALMOLOGY, V124, pS4, DOI 10.1016/j.ophtha.2017.07.010
   Plato A, 2015, SEMIN IMMUNOPATHOL, V37, P97, DOI 10.1007/s00281-014-0462-4
   Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200
   Pronin A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00036
   Ranta-aho S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094875
   Rathkey JK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat2738
   Rose-John S, 2012, INT J BIOL SCI, V8, P1237, DOI 10.7150/ijbs.4989
   Ruhl S, 2015, EUR J IMMUNOL, V45, P2927, DOI 10.1002/eji.201545772
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Sakamoto K, 2015, EUR J PHARMACOL, V756, P52, DOI 10.1016/j.ejphar.2015.03.008
   Sandstrom A, 2019, SCIENCE, V364, P42, DOI 10.1126/science.aau1330
   Sborgi L, 2016, EMBO J, V35, P1766, DOI 10.15252/embj.201694696
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590-021-00886-5
   Sharma BR, 2019, EUR J IMMUNOL, V49, P1998, DOI 10.1002/eji.201848070
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Shome A, 2021, DRUG DISCOV TODAY, V26, P2839, DOI 10.1016/j.drudis.2021.06.017
   Sui AL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03076-7
   Sun D, 2013, GLIA, V61, P1218, DOI 10.1002/glia.22507
   Sun Y, 2020, BIOCHEM BIOPH RES CO, V532, P159, DOI 10.1016/j.bbrc.2020.07.028
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Sutterwala FS, 2007, J EXP MED, V204, P3235, DOI 10.1084/jem.20071239
   Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tang TT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00227-x
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Van Gorp H, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a028563
   Wan CK, 2016, J IMMUNOL, V196, P543, DOI 10.4049/jimmunol.1502080
   Wang XH, 2021, EXP EYE RES, V212, DOI 10.1016/j.exer.2021.108786
   Wang YM, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01565-z
   Wang YD, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108668
   Wannamaker W, 2007, J PHARMACOL EXP THER, V321, P509, DOI 10.1124/jpet.106.111344
   Wei Y, 2014, EYE CONTACT LENS, V40, P248, DOI 10.1097/ICL.0000000000000042
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Williams PA, 2017, EXP EYE RES, V157, P20, DOI 10.1016/j.exer.2017.02.014
   Wooff Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58849-z
   Xi XT, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109924
   Xie TX, 2010, ONCOL REP, V23, P725, DOI 10.3892/or_00000690
   Xu H, 2014, NATURE, V513, P237, DOI 10.1038/nature13449
   Xu S, 2021, EXP EYE RES, V211, DOI 10.1016/j.exer.2021.108750
   Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009
   Yang G, 2020, ARTHRITIS RHEUMATOL, V72, P1192, DOI 10.1002/art.41245
   Yang K, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.603689
   Yang MZ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5520644
   Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152
   Yao K, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108388
   Yu XY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108300
   Yumnamcha T, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01065
   Zeng C, 2019, INT J BIOL SCI, V15, P1345, DOI 10.7150/ijbs.33568
   Zhang J, 2021, J INFLAMM RES, V14, P2955, DOI 10.2147/JIR.S310116
   Zhang W, 2019, CURR EYE RES, V44, P67, DOI 10.1080/02713683.2018.1518458
   Zhang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.308
   Zhang YJ, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107771
   Zhao RJ, 2014, INT IMMUNOPHARMACOL, V22, P285, DOI 10.1016/j.intimp.2014.06.041
   Zhao WY, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108375
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
NR 175
TC 2
Z9 2
U1 7
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 3
PY 2021
VL 12
AR 797110
DI 10.3389/fphar.2021.797110
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XQ3GU
UT WOS:000731437500001
PM 34925047
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Muller, PL
   Pfau, M
   Schmitz-Valckenberg, S
   Fleckenstein, M
   Holz, FG
AF Mueller, Philipp L.
   Pfau, Maximilian
   Schmitz-Valckenberg, Steffen
   Fleckenstein, Monika
   Holz, Frank G.
TI Optical Coherence Tomography-Angiography in Geographic Atrophy
SO OPHTHALMOLOGICA
LA English
DT Review
DE Optical coherence tomography; Angiography; Age-related macular
   degeneration; Choroid; Choriocapillaris
AB Geographic atrophy (GA) represents the non-exudative late stage of age-related macular degeneration and constitutes a leading cause of legal blindness in the developed world. It is characterized by areas of loss of outer retinal layers including photoreceptors, degeneration of the retinal pigment epithelium, and rarefication of the choriocapillaris. As all three layers are functionally connected, the precise temporal sequence and relative contribution of these layers towards the development and progression of GA is unclear. The advent of optical coherence tomography angiography (OCT-A) has allowed for three-dimensional visualization of retinal blood flow. Using OCT-A, recent studies have demonstrated that choriocapillaris flow alterations are particularly associated with the development of GA, exceed atrophy boundaries spatially, and are a prognostic factor for future GA progression. Furthermore, OCT-A may be helpful to differentiate GA from mimicking diseases. Evidence for a potential protective effect of specific forms of choroidal neovascularization in the context of GA has been reported. This article aims to give a comprehensive review of the current literature concerning the application of OCT-A in GA, and summarizes the opportunities and limitations with regard to pathophysiologic considerations, differential diagnosis, study design, and patient assessment.
C1 [Mueller, Philipp L.; Pfau, Maximilian; Schmitz-Valckenberg, Steffen; Fleckenstein, Monika; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
   [Mueller, Philipp L.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Pfau, Maximilian] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
C3 University of Bonn; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; Stanford University; Utah
   System of Higher Education; University of Utah
RP Muller, PL (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM philipp.mueller@ukbonn.de
FU German Research Foundation (DFG) [MU4279/2-1, PF950/1-1, FL 658/4-1, FL
   658/4-2]; Research to Prevent Blindness, New York, USA
FX This work was supported by the German Research Foundation (DFG, grant
   No. MU4279/2-1 to P.L.M., PF950/1-1 to M.P., and DFG FL 658/4-1 and DFG
   FL 658/4-2 to M.F.), and the Research to Prevent Blindness, New York,
   USA (grant to S.S.-V. and M.F.). The funders had no role in the research
   design, data collection, analysis, interpretation, or the writing of the
   manuscript.
CR Alagorie AR, 2020, GRAEF ARCH CLIN EXP, V258, P995, DOI 10.1007/s00417-020-04615-w
   Arya M, 2018, EXPERT REV MED DEVIC, V15, P875, DOI 10.1080/17434440.2018.1548932
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Caixinha M, 2017, CURR EYE RES, V42, P1, DOI 10.1080/02713683.2016.1175019
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chen Katherine G, 2021, Retin Cases Brief Rep, V15, P207, DOI 10.1097/ICB.0000000000000826
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Christenbury JG, 2018, RETINA-J RET VIT DIS, V38, P1276, DOI 10.1097/IAE.0000000000001766
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gass JDM, STEREOSCOPIC ATLAS M, V4th
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Haab O, 1885, CENT F R PRAKT AUGEN, V9, P383
   Hecht A, 2020, ACTA OPHTHALMOL, V98, pE700, DOI 10.1111/aos.14352
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Khan Muhammad, 2014, ISRN Ophthalmol, V2014, P608390, DOI 10.1155/2014/608390
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Laiginhas R, 2020, OPHTHALMOL RETINA, V4, P651, DOI 10.1016/j.oret.2020.02.016
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lauermann JL, 2018, OPHTHALMOLOGICA, V239, P74, DOI 10.1159/000485261
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23203
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2020, AM J OPHTHALMOL, V214, P172, DOI 10.1016/j.ajo.2019.12.006
   Muller PL, 2018, INVEST OPHTH VIS SCI, V59, pAMD122, DOI 10.1167/iovs.18-23819
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Muller PL, 2020, AM J OPHTHALMOL, V213, P134, DOI 10.1016/j.ajo.2020.01.013
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nettleship E, 1884, T OPHTHAL SOC UK, V4, P165
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Papapostolou I, 2021, KLIN MONATSBL AUGENH, V238, P166, DOI 10.1055/a-1002-0006
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Qin J, 2018, INVEST OPHTH VIS SCI, V59, P5985, DOI 10.1167/iovs.18-25032
   Querques G., 2017, F1000RESEARCH, V6, P1
   Rabiolo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205773
   Rabiolo A, 2018, INVEST OPHTH VIS SCI, V59, P231, DOI 10.1167/iovs.17-22359
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGICA, V237, P11, DOI 10.1159/000455074
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schneider EW, 2018, CURR OPIN OPHTHALMOL, V29, P217, DOI 10.1097/ICU.0000000000000469
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Streho M, 2019, OSLI RETINA, V50, pE222, DOI 10.3928/23258160-20190905-13
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1999, MOL VIS, V5
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wintergerst MWM, 2018, AM J OPHTHALMOL, V194, P35, DOI 10.1016/j.ajo.2018.06.023
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhou H, 2020, BIOMED OPT EXPRESS, V11, P1834, DOI 10.1364/BOE.385113
NR 85
TC 2
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD FEB
PY 2021
VL 244
IS 1
BP 42
EP 50
DI 10.1159/000510727
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QR5IW
UT WOS:000625251100005
PM 32772015
DA 2022-11-30
ER

PT J
AU Afarid, M
   Sanie-Jahromi, F
AF Afarid, Mehrdad
   Sanie-Jahromi, Fatemeh
TI Potential neuroprotective biomolecules in ophthalmology
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Neuroprotection; Retinal degenerations; Glaucoma; Optic neuropathy
ID CILIARY NEUROTROPHIC FACTOR; RETINAL GANGLION-CELLS; CALCIUM-CHANNEL
   BLOCKERS; OPEN-ANGLE GLAUCOMA; OPTIC-NERVE; CYTIDINE-5'-DIPHOSPHOCHOLINE
   CITICOLINE; MULTIPLE-SCLEROSIS; OXIDATIVE STRESS; OUTER SEGMENTS; MULLER
   CELLS
AB Purposes Retinal neurodegenerative diseases are responsible for a huge number of ocular problems worldwide. It seems that the progression of these diseases can be managed by the application of neuroprotective molecules particularly in the early stages. This article focuses on the most common neuroprotective bioagents under investigation in ophthalmology. Methods We searched the web of science, PubMed and Scopus databases with these keywords: "glaucoma," "diabetic retinopathy," "age-related macular degeneration," "optic neuropathy and retinal degeneration" and/or "neuroprotection." Results The most commonly utilized neuroprotective drugs for ophthalmology diseases were introduced in this study. It seems that these agents can be divided into three categories according to their mechanism of action: (A) neurotrophins, (B) decreasing effect on intraocular pressure and (C) inhibition of retinal neuron apoptosis. Conclusion A broad range of drugs has been illustrated in the literature for treatment of neuro-ophthalmic diseases. A good classification of the most applied drugs in this field can help specialists to prescribe the best matched drug considering the stage and progression of disease. However, controlled clinical trials are needed for better evaluation of the effects of these products.
C1 [Afarid, Mehrdad; Sanie-Jahromi, Fatemeh] Shiraz Univ Med Sci, Poostchi Ophthalmol Res Ctr, Zand Blvd,Poostchi St, Shiraz, Iran.
C3 Shiraz University of Medical Science
RP Sanie-Jahromi, F (通讯作者)，Shiraz Univ Med Sci, Poostchi Ophthalmol Res Ctr, Zand Blvd,Poostchi St, Shiraz, Iran.
EM fsanie@sums.ac.ir
RI Sanie-Jahromi, Fatemeh/X-6217-2019
OI Sanie-Jahromi, Fatemeh/0000-0001-9508-2632
CR Abrishami M, 2011, J OCUL PHARMACOL TH, V27, P261, DOI 10.1089/jop.2010.0145
   Afarid M, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/1602739
   Afarid M, 2016, J NEUROL SCI, V363, P43, DOI 10.1016/j.jns.2016.02.024
   Afarid M, 2015, INT J OPHTHALMOL-CHI, V8, P991, DOI 10.3980/j.issn.2222-3959.2015.05.25
   [Anonymous], 2007, GLOB IN EL AV BLIND
   Araie M, 2011, PROG RETIN EYE RES, V30, P54, DOI 10.1016/j.preteyeres.2010.09.002
   Bakalash S, 2003, INVEST OPHTH VIS SCI, V44, P3374, DOI 10.1167/iovs.03-0080
   Beltran WA, 2005, MOL VIS, V11, P232
   Bylund DB, 1999, INVEST OPHTH VIS SCI, V40, P2299
   Dhib-Jalbut S, 2003, PHARMACOL THERAPEUT, V98, P245, DOI 10.1016/S0163-7258(03)00036-6
   Di Marco S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8070224
   Domenici L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115579
   Doonan F, 2011, J NEUROCHEM, V118, P915, DOI 10.1111/j.1471-4159.2011.07354.x
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Fuhrmann S, 1998, J COMP NEUROL, V400, P244
   Galanopoulos A, 2009, CLIN OPHTHALMOL, V3, P117
   Ganekal Sunil, 2014, J Curr Glaucoma Pract, V8, P15, DOI 10.5005/jp-journals-10008-1155
   Hosseinzadeh H, 2014, J ENDOCRINOL INVEST, V37, P783, DOI 10.1007/s40618-014-0096-3
   Iulia Chitu, 2017, Rom J Ophthalmol, V61, P152
   Jiao SS, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.186
   Jo SA, 1999, NEUROSCIENCE, V89, P579, DOI 10.1016/S0306-4522(98)00546-6
   Johnson KP, 1998, NEUROLOGY, V50, P701, DOI 10.1212/WNL.50.3.701
   JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268
   Ju WK, 1999, NEUROREPORT, V10, P419, DOI 10.1097/00001756-199902050-00038
   Kim H, 2005, PHARM RES-DORDR, V22, P1499, DOI 10.1007/s11095-005-6250-z
   Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446
   Ko ML, 2001, NEUROSCI LETT, V305, P139, DOI 10.1016/S0304-3940(01)01830-4
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009
   Li R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023148
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Liu Y, 2013, MOL MED REP, V7, P1773, DOI 10.3892/mmr.2013.1433
   Luo DW, 2012, BIOORG MED CHEM LETT, V22, P4386, DOI 10.1016/j.bmcl.2012.04.130
   Na JY, 2014, CELL MOL NEUROBIOL, V34, P1071, DOI 10.1007/s10571-014-0084-3
   Nakayama M, 2011, MOL VIS, V17, P1784
   Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944
   Ola MS, 2013, CELL MOL NEUROBIOL, V33, P359, DOI 10.1007/s10571-012-9901-8
   Ola MS, 2015, J MOL NEUROSCI, V56, P440, DOI 10.1007/s12031-015-0561-2
   Osborne A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1041-8
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Parisi V, 2005, DOC OPHTHALMOL, V110, P91, DOI 10.1007/s10633-005-7348-7
   Parisi V, 1999, OPHTHALMOLOGY, V106, P1126, DOI 10.1016/S0161-6420(99)90269-5
   Parisi V, 2008, PROG BRAIN RES, V173, P541, DOI 10.1016/S0079-6123(08)01137-0
   Park CH, 2005, EXP EYE RES, V81, P350, DOI 10.1016/j.exer.2005.02.007
   Pescosolido N, 2010, CLIN TER, V161, pE81
   POSTHUMUS RG, 1952, OPHTHALMOLOGICA, V124, P17, DOI 10.1159/000301245
   Priya KP, 2018, MATER TODAY-PROC, V5, P1929
   Rejdak R, 2002, OPHTHALMIC RES, V34, P146, DOI 10.1159/000063658
   Rejdak R, 2003, MED SCI MONITOR, V9, pP124
   Riazi A, 2017, ITAL J MED, V11, P196, DOI 10.4081/itjm.2016.758
   Rusciano D, 2017, ADV PHARMACOL SCI, V2017, DOI 10.1155/2017/4320408
   Saini R, 2011, J PHARM BIOALLIED SC, V3, P466, DOI 10.4103/0975-7406.84471
   Schmelzer C, 2008, BIOFACTORS, V32, P179, DOI 10.1002/biof.5520320121
   Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498
   Schuettauf F, 2006, EXP EYE RES, V83, P1128, DOI 10.1016/j.exer.2006.05.021
   Seki M, 2004, DIABETES, V53, P2412, DOI 10.2337/diabetes.53.9.2412
   SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139
   Seydewitz V, 2004, INVEST OPHTH VIS SCI, V45, P655, DOI 10.1167/iovs.03-0182
   Shpak AA, 2018, CURR EYE RES, V43, P224, DOI 10.1080/02713683.2017.1396617
   Shuto T, 2001, NEUROREPORT, V12, P1081, DOI 10.1097/00001756-200104170-00043
   Somayajulu M, 2005, NEUROBIOL DIS, V18, P618, DOI 10.1016/j.nbd.2004.10.021
   Spindler M, 2009, NEUROPSYCH DIS TREAT, V5, P597
   Takano Y, 2004, BIOCHEM BIOPH RES CO, V313, P1015, DOI 10.1016/j.bbrc.2003.12.034
   Thibault O, 2007, AGING CELL, V6, P307, DOI 10.1111/j.1474-9726.2007.00295.x
   Toris CB, 1999, AM J OPHTHALMOL, V128, P8, DOI 10.1016/S0002-9394(99)00076-8
   Uzel AGT, 2020, RETINA-J RET VIT DIS, V40, P121, DOI 10.1097/IAE.0000000000002355
   Valter K, 2003, BRAIN RES, V985, P169, DOI 10.1016/S0006-8993(03)03130-5
   van Adel BA, 2005, J NEUROBIOL, V63, P215, DOI 10.1002/neu.20117
   Vetrugno M, 2012, J OCUL PHARMACOL TH, V28, P536, DOI 10.1089/jop.2012.0021
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Weber AJ, 2010, INVEST OPHTH VIS SCI, V51, P327, DOI 10.1167/iovs.09-3740
   Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285
   Wen R, 2006, J NEUROSCI, V26, P13523, DOI 10.1523/JNEUROSCI.4021-06.2006
   Wheeler LA, 1999, EUR J OPHTHALMOL, V9, pS17, DOI 10.1177/112067219900901S09
   Wheeler LA, 2001, SURV OPHTHALMOL, V45, pS290, DOI 10.1016/S0039-6257(01)00206-5
   Wubben TJ, 2019, CURR OPIN OPHTHALMOL, V30, P199, DOI 10.1097/ICU.0000000000000558
   ZERBINI G, 2015, J OCUL DIS THER, V3, P1, DOI DOI 10.12974/2309-6136.2015.03.01.1
NR 77
TC 0
Z9 0
U1 1
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD MAR
PY 2021
VL 41
IS 3
BP 1103
EP 1109
DI 10.1007/s10792-020-01634-8
EA NOV 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT8ZB
UT WOS:000588861900002
PM 33180279
DA 2022-11-30
ER

PT J
AU Ogura, S
   Baldeosingh, R
   Bhutto, IA
   Kambhampati, SP
   McLeod, DS
   Edwards, MM
   Rais, R
   Schubert, W
   Lutty, GA
AF Ogura, Shuntaro
   Baldeosingh, Rajkumar
   Bhutto, Imran A.
   Kambhampati, Siva P.
   Scott McLeod, Donald
   Edwards, Malia M.
   Rais, Rana
   Schubert, William
   Lutty, Gerard A.
TI A role for mast cells in geographic atrophy
SO FASEB JOURNAL
LA English
DT Article
DE 48/80; age-related macular degeneration; choroid; degranulation;
   ketotifen fumarate; retinal pigment epithelium; tryptase
ID HUMAN EYES; TRYPTASE; KETOTIFEN; DEGENERATION; RPE; CHORIOCAPILLARIS;
   INFLAMMATION; HISTAMINE; DRUSEN; ASTHMA
AB Mast cells (MCs) are the initial responders of innate immunity and their degranulation contribute to various etiologies. While the abundance of MCs in the choroid implies their fundamental importance in the eye, little is known about the significance of MCs and their degranulation in choroid. The cause of geographic atrophy (GA), a progressive dry form of age-related macular degeneration is elusive and there is currently no therapy for this blinding disorder. Here we demonstrate in both human GA and a rat model for GA, that MC degranulation and MC-derived tryptase are central to disease progression. Retinal pigment epithelium degeneration followed by retinal and choroidal thinning, characteristic phenotypes of GA, were driven by continuous choroidal MC stimulation and activation in a slow release fashion in the rat. Genetic manipulation of MCs, pharmacological intervention targeting MC degranulation with ketotifen fumarate or inhibition of MC-derived tryptase with APC 366 prevented all of GA-like phenotypes following MC degranulation in the rat model. Our results demonstrate the fundamental role of choroidal MC involvement in GA disease etiology, and will provide new opportunities for understanding GA pathology and identifying novel therapies targeting MCs.
C1 [Ogura, Shuntaro; Baldeosingh, Rajkumar; Bhutto, Imran A.; Kambhampati, Siva P.; Scott McLeod, Donald; Edwards, Malia M.; Lutty, Gerard A.] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
   [Rais, Rana] Johns Hopkins Univ, Sch Med, Johns Hopkins Drug Discovery, Baltimore, MD USA.
   [Rais, Rana] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Schubert, William] Bayer AG Pharmaceut, Wuppertal, Germany.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins University
RP Lutty, GA (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg,400 North Broadway, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
RI Kambhampati, Siva Pramodh/AAK-6269-2020
OI Ogura, Shuntaro/0000-0002-5191-8933
FU HHS \ NIH \ National Eye Institute (NEI) [EY016151, EY01765]; Bayer;
   Arnold and Mabel Beckman Foundation; Research to Prevent Blindness (RPB)
FX HHS vertical bar NIH vertical bar National Eye Institute (NEI),
   Grant/Award Number: EY016151 and EY01765; Bayer; Arnold and Mabel
   Beckman Foundation; Research to Prevent Blindness (RPB)
CR Bhutto IA, 2018, INVEST OPHTH VIS SCI, V59, P143, DOI DOI 10.1167/I0VS.18-24245
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bousquet E, 2015, AM J PATHOL, V185, P2083, DOI 10.1016/j.ajpath.2015.04.002
   Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039
   Cairns JA, 1996, J IMMUNOL, V156, P275
   CRAPS LP, 1984, RESPIRATION, V45, P411, DOI 10.1159/000194648
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Godfrey W A, 1987, Trans Am Ophthalmol Soc, V85, P557
   GRANT SM, 1990, DRUGS, V40, P412, DOI 10.2165/00003495-199040030-00006
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863
   Hayashi A, 1999, GRAEF ARCH CLIN EXP, V237, P668, DOI 10.1007/s004170050295
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Iddamalgoda A, 2008, ARCH DERMATOL RES, V300, pS69, DOI 10.1007/s00403-007-0806-1
   Kabra SK, 2000, ANN ALLERG ASTHMA IM, V85, P46, DOI 10.1016/S1081-1206(10)62433-7
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kidd M, 2003, BRIT J OPHTHALMOL, V87, P1206, DOI 10.1136/bjo.87.10.1206
   Kinoshita M, 2005, ARTERIOSCL THROM VAS, V25, P1858, DOI 10.1161/01.ATV.0000174797.71708.97
   Krishna MT, 2001, J ALLERGY CLIN IMMUN, V107, P1039, DOI 10.1067/mai.2001.115631
   Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620
   Lu J, 2014, INT IMMUNOPHARMACOL, V20, P352, DOI 10.1016/j.intimp.2014.04.001
   Marone G, 2001, LEUKEMIA RES, V25, P583, DOI 10.1016/S0145-2126(01)00039-X
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McMenamin PG, 1997, EYE, V11, P183, DOI 10.1038/eye.1997.49
   NIWA Y, 1991, BLOOD, V78, P1936
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Pardue MT, 2014, DOC OPHTHALMOL, V128, P77, DOI 10.1007/s10633-013-9424-8
   Passante E, 2009, INFLAMM RES, V58, P737, DOI 10.1007/s00011-009-0074-y
   Payne V, 2004, ANAESTHESIA, V59, P695, DOI 10.1111/j.1365-2044.2004.03757.x
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Ponomaryov T, 2017, CIRC RES, V121, P941, DOI 10.1161/CIRCRESAHA.117.311185
   SCHWARTZ LB, 1987, ANN ALLERGY, V58, P226
   SCHWARTZ LB, 1987, J IMMUNOL, V138, P2611
   Soiberman U, 2017, BIOMATERIALS, V125, P38, DOI 10.1016/j.biomaterials.2017.02.016
   Sun J, 2007, J CLIN INVEST, V117, P3359, DOI 10.1172/JCI31311
   Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014
   Unno K, 2012, EUR J PHARMACOL, V683, P179, DOI 10.1016/j.ejphar.2012.03.017
   Valent P, 2004, J ALLERGY CLIN IMMUN, V114, P3, DOI 10.1016/j.jaci.2004.02.045
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wang Q, 2019, ELIFE, V8, DOI 10.7554/eLife.39905
   Weatherly LM, 2013, JOVE-J VIS EXP, DOI 10.3791/50671
   Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089
NR 50
TC 10
Z9 10
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2020
VL 34
IS 8
BP 10117
EP 10131
DI 10.1096/fj.202000807R
EA JUN 2020
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA NE3EW
UT WOS:000539639000001
PM 32525594
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Chen, Y
   Paluch, M
   Zorn, JA
   Rajan, S
   Leonard, B
   Estevez, A
   Brady, J
   Chiu, H
   Phung, W
   Famili, A
   Yan, MH
   Ciferri, C
   Matsumoto, ML
   Lazar, GA
   Crowell, S
   Hass, P
   Agard, NJ
AF Chen, Yvonne
   Paluch, Maciej
   Zorn, Julie A.
   Rajan, Sharmila
   Leonard, Brandon
   Estevez, Alberto
   Brady, John
   Chiu, Henry
   Phung, Wilson
   Famili, Amin
   Yan, Minhong
   Ciferri, Claudio
   Matsumoto, Marissa L.
   Lazar, Greg A.
   Crowell, Susan
   Hass, Phil
   Agard, Nicholas J.
TI Targeted IgMs agonize ocular targets with extended vitreal exposure
SO MABS
LA English
DT Article
DE IgM; antibody engineering; ocular therapeutics; agonism; long-acting
   delivery
ID DIABETIC MACULAR EDEMA; MONOCLONAL-ANTIBODY; IMMUNOGLOBULIN-M;
   CLINICAL-TRIAL; C1 BINDING; IN-VIVO; PHARMACOKINETICS; RECEPTOR;
   COMPLEMENT; ANGIOPOIETIN-2
AB Treatment of ocular disease is hindered by the presence of the blood-retinal barrier, which restricts access of systemic drugs to the eye. Intravitreal injections bypass this barrier, delivering high concentrations of drug to the targeted tissue. However, the recommended dosing interval for approved biologics is typically 6-12 weeks, and frequent travel to the physician's office poses a substantial burden for elderly patients with poor vision. Real-world data suggest that many patients are under-treated. Here, we investigate IgMs as a novel platform for treating ocular disease. We show that IgMs are well-suited to ocular administration due to moderate viscosity, long ocular exposure, and rapid systemic clearance. The complement-dependent cytotoxicity of IgMs can be readily removed with a P436G mutation, reducing safety liabilities. Furthermore, dodecavalent binding of IgM hexamers can potently activate pathways implicated in the treatment of progressive blindness, including the Tie2 receptor tyrosine kinase signaling pathway for the treatment of diabetic macular edema, or the death receptor 4 tumor necrosis family receptor pathway for the treatment of wet age-related macular degeneration. Collectively, these data demonstrate the promise of IgMs as therapeutic agonists for treating progressive blindness.
C1 [Chen, Yvonne; Leonard, Brandon; Lazar, Greg A.; Agard, Nicholas J.] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA.
   [Paluch, Maciej; Hass, Phil] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA.
   [Zorn, Julie A.; Estevez, Alberto; Ciferri, Claudio; Matsumoto, Marissa L.] Genentech Inc, Dept Struct Biol, San Francisco, CA 94080 USA.
   [Rajan, Sharmila; Crowell, Susan] Genentech Inc, Dept Preclin & Translat Pharmacokinet, San Francisco, CA 94080 USA.
   [Rajan, Sharmila; Crowell, Susan] Genentech Inc, Dept Pharmacodynam, San Francisco, CA 94080 USA.
   [Brady, John; Yan, Minhong] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.
   [Chiu, Henry] Genentech Inc, Dept Biochem & Cellular Physiol, San Francisco, CA 94080 USA.
   [Phung, Wilson] Genentech Inc, Dept Microchem Prote & Lipid, San Francisco, CA 94080 USA.
   [Famili, Amin] Genentech Inc, Dept Drug Dev, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche
   Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech;
   Roche Holding; Genentech
RP Agard, NJ (通讯作者)，Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA.
EM agardn@gene.com
OI Lazar, Greg/0000-0003-2169-8703; Agard, Nicholas/0000-0003-4916-2484;
   Matsumoto, Marissa/0000-0002-5353-1097; Estevez,
   Alberto/0000-0002-9141-5003
CR Adams C, 2008, CELL DEATH DIFFER, V15, P751, DOI 10.1038/sj.cdd.4402306
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Beutner U, 2008, ONCOL REP, V19, P761
   Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381
   Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6
   BREWER JW, 1994, J BIOL CHEM, V269, P17338
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   CHALLACOMBE SJ, 1979, IMMUNOLOGY, V36, P331
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crowell SR, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.1
   Czajkowsky DM, 2009, P NATL ACAD SCI USA, V106, P14960, DOI 10.1073/pnas.0903805106
   David S, 2011, AM J PHYSIOL-LUNG C, V300, pL851, DOI 10.1152/ajplung.00459.2010
   Dickmann LJ, 2015, INVEST OPHTH VIS SCI, V56, P6991, DOI 10.1167/iovs.15-17457
   DITZEL H, 1993, CANCER RES, V53, P5920
   Do DV, 2020, ANG EX DEG MIAM FL F
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001
   EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78
   GazzanoSantoro H, 1997, J IMMUNOL METHODS, V202, P163, DOI 10.1016/S0022-1759(97)00002-1
   GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Ho AC, 2018, ANG EX DEG MIAM FL F
   Idusogie EE, 2001, J IMMUNOL, V166, P2571, DOI 10.4049/jimmunol.166.4.2571
   Irie RF, 2004, CANCER IMMUNOL IMMUN, V53, P110, DOI 10.1007/s00262-003-0436-1
   Kelley RF, 2005, J BIOL CHEM, V280, P2205, DOI 10.1074/jbc.M410660200
   Khalaf Nervana, 2017, Electron Physician, V9, P5031, DOI 10.19082/5031
   Kim KT, 2005, J BIOL CHEM, V280, P20126, DOI 10.1074/jbc.M500292200
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Li YX, 2020, SCIENCE, V367, P1014, DOI 10.1126/science.aaz5425
   Lo M, 2017, J BIOL CHEM, V292, P3900, DOI 10.1074/jbc.M116.767749
   MACKENZIE MR, 1977, BLOOD, V49, P507
   MAIORELLA BL, 1993, BIO-TECHNOL, V11, P387, DOI 10.1038/nbt0393-387
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Marks L, 2012, MABS-AUSTIN, V4, P403, DOI 10.4161/mabs.19909
   Moh ESX, 2016, J AM SOC MASS SPECTR, V27, P1143, DOI 10.1007/s13361-016-1378-0
   Murthy KR, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-29
   Overdijk MB, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-2391
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Petrusic V, 2011, MED HYPOTHESES, V77, P959, DOI 10.1016/j.mehy.2011.08.018
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Ramamurthy V, 2015, ACTA CRYSTALLOGR F, V71, P1273, DOI 10.1107/S2053230X15016416
   Rasche L, 2015, HAEMATOLOGICA, V100, P377, DOI 10.3324/haematol.2014.117945
   Rau H, 2018, BOULD PEPT S DENV CO
   Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275
   Regula JT, 2016, EMBO MOL MED, V8, P1265, DOI 10.15252/emmm.201505889
   ROSE GE, 1990, BRIT J OPHTHALMOL, V74, P160, DOI 10.1136/bjo.74.3.160
   Ryman JT, 2017, CPT-PHARMACOMET SYST, V6, P576, DOI 10.1002/psp4.12224
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Scheres SHW, 2015, J STRUCT BIOL, V189, P114, DOI 10.1016/j.jsb.2014.11.010
   Shatz W, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218613
   Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345
   SHULMAN MJ, 1986, P NATL ACAD SCI USA, V83, P7678, DOI 10.1073/pnas.83.20.7678
   Tang G, 2007, J STRUCT BIOL, V157, P38, DOI 10.1016/j.jsb.2006.05.009
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Weiner GJ, 2010, SEMIN HEMATOL, V47, P115, DOI 10.1053/j.seminhematol.2010.01.011
   Welp A, 2016, NATL ACAD SCI ENG ME
   WRIGHT JF, 1990, J BIOL CHEM, V265, P10506
   WRIGHT JF, 1988, J BIOL CHEM, V263, P11221
   Yadav Sandeep, 2013, Biophys Rev, V5, P121, DOI 10.1007/s12551-013-0109-z
   Yang YL, 2019, MABS-AUSTIN, V11, P996, DOI 10.1080/19420862.2019.1625662
   Zarzar J, 2018, BIOPHYS CHEM, V236, P22, DOI 10.1016/j.bpc.2017.10.003
NR 70
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1942-0862
EI 1942-0870
J9 MABS-AUSTIN
JI mAbs
PD JAN 1
PY 2020
VL 12
IS 1
AR 1818436
DI 10.1080/19420862.2020.1818436
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA NP0FV
UT WOS:000569860500001
PM 32936727
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mercado, CL
   Doroslovacki, P
   Wang, JX
   Siddiqui, AA
   Kolker, AF
   Kolker, RJ
AF Mercado, Carmel L.
   Doroslovacki, Pavle
   Wang, Jiangxia
   Siddiqui, Aazim A.
   Kolker, Andrew F.
   Kolker, Richard J.
TI Comparison of distance and near visual acuity in patients with vision
   loss due to cataract
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Cataract; ARMD; Macular degeneration; Vision acuity screen
ID PINHOLE
AB The purpose of this study was to assess whether there is a disparity in distance and near best-corrected visual acuity (BCVA) in cataract eyes. 102 patients with cataract (N = 121 eyes) were seen in clinic between January and November 2013 at the Wilmer Eye Institute Comprehensive Eye Service. An age-related macular degeneration (ARMD) group (N = 27 eyes) was also identified for comparison. Distance and near BCVA were measured as part of the standard ophthalmic evaluation. Snellen measurements were converted to their LogMAR equivalents for statistical analysis. Near was better than distance BCVA with mean difference of 1.38 lines (P < 0.001) in the cataract eyes. This disparity was not seen in the ARMD eyes. Near-distance BCVA disparity is a statistically significant finding seen with cataracts. This may have further implications in patients with both cataract and ARMD as the presence of disparity may suggest a cataract etiology playing a greater role in vision loss. This comparison may be useful for surgical prognostication and as a quick triage tool in conjunction with, or in place of, a potential acuity meter and dilated near-pinhole test.
C1 [Mercado, Carmel L.; Doroslovacki, Pavle; Wang, Jiangxia; Siddiqui, Aazim A.; Kolker, Richard J.] Johns Hopkins Univ, Wilmer Eye Inst, 1800 Orleans St, Baltimore, MD 21287 USA.
   [Mercado, Carmel L.; Doroslovacki, Pavle; Wang, Jiangxia; Siddiqui, Aazim A.; Kolker, Richard J.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, 600 North Wolfe St,Maumenee 327, Baltimore, MD 21287 USA.
   [Kolker, Andrew F.] George Washington Univ, Dept Ophthalmol, Ambulatory Care Ctr 2150, Penn Ave Suite 2A, Washington, DC 20037 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; George Washington University
RP Kolker, RJ (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, 600 North Wolfe St,Maumenee 327, Baltimore, MD 21287 USA.
EM rikolker@jhmi.edu
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   McGraw PV, 1996, OPHTHAL PHYSL OPT, V16, pS26, DOI 10.1016/S0275-5408(96)90046-0
   Melki SA, 1999, OPHTHALMOLOGY, V106, P1262, DOI 10.1016/S0161-6420(99)00706-X
   MINKOWSKI JS, 1983, OPHTHALMOLOGY, V90, P1360
NR 6
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD FEB
PY 2017
VL 37
IS 1
BP 169
EP 172
DI 10.1007/s10792-016-0247-y
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK8FR
UT WOS:000394159800024
PM 27164842
DA 2022-11-30
ER

PT J
AU Hytti, M
   Piippo, N
   Korhonen, E
   Honkakoski, P
   Kaarniranta, K
   Kauppinen, A
AF Hytti, Maria
   Piippo, Niina
   Korhonen, Eveliina
   Honkakoski, Paavo
   Kaarniranta, Kai
   Kauppinen, Anu
TI Fisetin and luteolin protect human retinal pigment epithelial cells from
   oxidative stress-induced cell death and regulate inflammation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NF-KAPPA-B; ANTIINFLAMMATORY ACTIVITY; FLAVONOID LUTEOLIN; EXPRESSION;
   INHIBITION; PATHWAYS; ACTIVATION; APOPTOSIS; KINASE; MACROPHAGES
AB Degeneration of retinal pigment epithelial (RPE) cells is a clinical hallmark of age-related macular degeneration (AMD), the leading cause of blindness among aged people in the Western world. Both inflammation and oxidative stress are known to play vital roles in the development of this disease. Here, we assess the ability of fisetin and luteolin, to protect ARPE-19 cells from oxidative stressinduced cell death and to decrease intracellular inflammation. We also compare the growth and reactivity of human ARPE-19 cells in serum-free and serum-containing conditions. The absence of serum in the culture medium did not prevent ARPE-19 cells from reaching full confluency but caused an increased sensitivity to oxidative stress-induced cell death. Both fisetin and luteolin protected ARPE-19 cells from oxidative stress-induced cell death. They also significantly decreased the release of pro-inflammatory cytokines into the culture medium. The decrease in inflammation was associated with reduced activation of MAPKs and CREB, but was not linked to NF-kappa B or SIRT1. The ability of fisetin and luteolin to protect and repair stressed RPE cells even after the oxidative insult make them attractive in the search for treatments for AMD.
C1 [Hytti, Maria; Piippo, Niina; Korhonen, Eveliina; Honkakoski, Paavo; Kauppinen, Anu] Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, FI-70211 Kuopio, Finland.
   [Hytti, Maria; Piippo, Niina; Korhonen, Eveliina; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, FI-70211 Kuopio, Finland.
   [Kaarniranta, Kai; Kauppinen, Anu] Kuopio Univ Hosp, Dept Ophthalmol, FI-70029 Kys, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital
RP Kauppinen, A (通讯作者)，Univ Eastern Finland, Sch Pharm, Fac Hlth Sci, POB 1627, FI-70211 Kuopio, Finland.
EM anu.kauppinen@uef.fi
RI Hytti, Maria/AAE-4016-2019; Honkakoski, Paavo/AAJ-1278-2020
OI Hytti, Maria/0000-0003-2150-6847; Honkakoski, Paavo/0000-0002-4332-3577;
   Korhonen, Eveliina/0000-0002-5360-7258; Kaarniranta,
   Kai/0000-0003-2600-8679
FU Finnish Cultural Foundation - North-Savo and Central Foundations;
   Academy of Finland; Kuopio University Hospital; Alfred Kordelin
   Foundation; Orion-Farmos Research Foundation; Paivikki and Sakari
   Sohlberg Foundation; Emil Aaltonen Foundation; Evald and Hilda Nissi
   Foundation; Sokeain Ystavat ry; Silma- ja Kudospankkisaatio;
   Silmasaatio; CIMO
FX We would like to thank BM Ella-Noora Maatta and Dr. Kirsi Rilla for
   their technical support and Dr. Ewen MacDonald for the language
   revision. We also warmly acknowledge Res. Dir. Emeritus Antero Salminen
   for his valuable collaboration, discussions, and critical review of the
   manuscript. This work was financially supported by the Finnish Cultural
   Foundation - North-Savo and Central Foundations, the Academy of Finland,
   the Kuopio University Hospital, the Alfred Kordelin Foundation, the
   Orion-Farmos Research Foundation, the Paivikki and Sakari Sohlberg
   Foundation, the Emil Aaltonen Foundation, the Evald and Hilda Nissi
   Foundation, Sokeain Ystavat ry, Silma- ja Kudospankkisaatio,
   Silmasaatio, and CIMO.
CR Ando C, 2009, FEBS LETT, V583, P3649, DOI 10.1016/j.febslet.2009.10.045
   Bezzerri V, 2011, J IMMUNOL, V187, P6069, DOI 10.4049/jimmunol.1100821
   Bhattacharya S, 2012, INVEST OPHTH VIS SCI, V53, P8350, DOI 10.1167/iovs.12-10495
   Chen CY, 2007, LIFE SCI, V81, P1602, DOI 10.1016/j.lfs.2007.09.028
   Chen R, 2014, MOL VIS, V20, P242
   Chien CS, 2010, MOL CELL BIOCHEM, V333, P169, DOI 10.1007/s11010-009-0217-z
   Choi EY, 2011, J PERIODONTOL, V82, P1509, DOI 10.1902/jop.2011.100759
   Chou RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071983
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   De Sousa RRR, 2007, J ENZYM INHIB MED CH, V22, P439, DOI 10.1080/14756360601162063
   Donmez G, 2010, AGING CELL, V9, P285, DOI 10.1111/j.1474-9726.2010.00548.x
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Funakoshi-Tago M, 2011, INT IMMUNOPHARMACOL, V11, P1150, DOI 10.1016/j.intimp.2011.03.012
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hubbard BP, 2014, TRENDS PHARMACOL SCI, V35, P146, DOI 10.1016/j.tips.2013.12.004
   Hubbard BP, 2013, SCIENCE, V339, P1216, DOI 10.1126/science.1231097
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jang S, 2008, P NATL ACAD SCI USA, V105, P7534, DOI 10.1073/pnas.0802865105
   Jin T, 2014, J AGR FOOD CHEM, V62, P10468, DOI 10.1021/jf502849j
   Jun Eun Jung, 2007, Korean J Ophthalmol, V21, P244, DOI 10.3341/kjo.2007.21.4.244
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Kang OH, 2010, MOLECULES, V15, P385, DOI 10.3390/molecules15010385
   Kao TK, 2011, J NUTR BIOCHEM, V22, P612, DOI 10.1016/j.jnutbio.2010.01.011
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Kauppinen A, 2013, CELL SIGNAL, V25, P1939, DOI 10.1016/j.cellsig.2013.06.007
   Kim HJ, 2002, MECH AGEING DEV, V123, P1589, DOI 10.1016/S0047-6374(02)00094-5
   Kim SC, 2012, IMMUNOPHARM IMMUNOT, V34, P645, DOI 10.3109/08923973.2011.648270
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Kubota S, 2009, INVEST OPHTH VIS SCI, V50, P3512, DOI 10.1167/iovs.08-2666
   Kuo MY, 2011, FOOD CHEM TOXICOL, V49, P2660, DOI 10.1016/j.fct.2011.07.012
   Leotoing L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068388
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611
   Paimela T, 2011, PHARMACOL RES, V64, P501, DOI 10.1016/j.phrs.2011.05.027
   Pal HC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086338
   Palanisamy V, 2012, J DENT RES, V91, P651, DOI 10.1177/0022034512437372
   Rafacho BPM, 2015, HEPATOBIL SURG NUTR, V4, P124, DOI 10.3978/j.issn.2304-3881.2014.08.06
   Park CM, 2011, EUR J PHARMACOL, V660, P454, DOI 10.1016/j.ejphar.2011.04.007
   Park HH, 2007, PHARMACOL RES, V55, P31, DOI 10.1016/j.phrs.2006.10.002
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Preyat N, 2013, J LEUKOCYTE BIOL, V93, P669, DOI 10.1189/jlb.1112557
   Qiao HM, 2012, BRAIN RES, V1448, P71, DOI 10.1016/j.brainres.2012.02.003
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Ruiz PA, 2006, J NUTR, V136, P664, DOI 10.1093/jn/136.3.664
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Sinclair DA, 2014, ANNU REV PHARMACOL, V54, P363, DOI 10.1146/annurev-pharmtox-010611-134657
   Wang Q, 2012, INVEST OPHTH VIS SCI, V53, P2395, DOI 10.1167/iovs.11-8982
   Wolfle U, 2011, FREE RADICAL BIO MED, V50, P1081, DOI 10.1016/j.freeradbiomed.2011.01.027
   Wu WL, 2013, MOLECULES, V18, P8083, DOI 10.3390/molecules18078083
   Wu X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082957
   Xagorari A, 2002, BRIT J PHARMACOL, V136, P1058, DOI 10.1038/sj.bjp.0704803
   Xia F, 2014, J ATHEROSCLER THROMB, V21, P768, DOI 10.5551/jat.23697
   Xie J, 2013, PHARMACOL RES, V67, P60, DOI 10.1016/j.phrs.2012.10.010
   Zhou FT, 2011, J NEUROSCI RES, V89, P1859, DOI 10.1002/jnr.22714
NR 60
TC 55
Z9 58
U1 1
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 1
PY 2015
VL 5
AR 17645
DI 10.1038/srep17645
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CX4DU
UT WOS:000365649600001
PM 26619957
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sorensen, S
   White, K
   Mak, W
   Zanibbi, K
   Tang, W
   O'Hearn, A
   Hegel, MT
AF Soerensen, Silvia
   White, Katherine
   Mak, Wingyun
   Zanibbi, Katherine
   Tang, Wan
   O'Hearn, Amanda
   Hegel, Mark T.
TI The macular degeneration and aging study: Design and research protocol
   of a randomized trial for a psychosocial intervention with macular
   degeneration patients
SO CONTEMPORARY CLINICAL TRIALS
LA English
DT Article
DE Randomized controlled trial; Aging; Macular degeneration; Future
   planning; Preventive problem-solving
ID PROBLEM-SOLVING TREATMENT; PRIMARY-CARE PATIENTS; OLDER-ADULTS; FUTURE
   CARE; VISION LOSS; VISUAL IMPAIRMENT; SELF-MANAGEMENT; FOLLOW-UP; AGE;
   DEPRESSION
AB Background: Age-related Macular Degeneration (AMD) is the leading cause of irreversible and predictable blindness among older adults with serious physical and mental health consequences. Visual impairment is associated with negative future outlook and depression and has serious consequences for older adults' quality of life and, by way of depression, on long-term survival. Psychosocial interventions have the potential to alleviate and prevent depression symptoms among older AMD patients.
   Methods: We describe the protocol of the Macular Degeneration and Aging Study, a randomized clinical trial of a psychosocial Preventive Problem-Solving Intervention. The intervention is aimed at enhancing well-being and future planning among older adults with macular degeneration by increasing preparation for future care.
   Results: Adequate randomization and therapeutic fidelity were achieved. Current retention rates were acceptable, given the vulnerability of the population. Acceptability (adherence and satisfaction) was high.
   Conclusion: Given the high public health significance and impact on quality of life among older adults with vision loss, this protocol contributes a valid test of a promising intervention for maintaining mental and physical health in this population. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Soerensen, Silvia] Univ Rochester, Sch Med & Dent, Dept Ophthalmol, Rochester, NY 14642 USA.
   [White, Katherine] Assoc Blind & Visually Impaired, Rochester, NY 14620 USA.
   [Mak, Wingyun] Lehman Coll, Dept Psychol, Bronx, NY 10468 USA.
   [Zanibbi, Katherine; O'Hearn, Amanda] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA.
   [Tang, Wan] Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY 14642 USA.
   [Hegel, Mark T.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03766 USA.
C3 University of Rochester; City University of New York (CUNY) System;
   Lehman College (CUNY); University of Rochester; University of Rochester;
   Dartmouth College
RP Sorensen, S (通讯作者)，URMC Box 659,601 Elmwood Ave, Rochester, NY 14642 USA.
EM silvia_sorensen@urmc.rochester.edu; kwhite@abvi-goodwill.org;
   WINGYUN.MAK@lehman.cuny.edu; katherine_zanibbi@urmc.rochester.edu;
   wan_Tang@urmc.rochester.edu; Amanda_OHearn@urmc.rochester.edu;
   Mark.T.Hegel@Dartmouth.edu
RI Sörensen, Silvia/B-1070-2008; Sörensen, Silvia/AAH-7120-2019
OI Sörensen, Silvia/0000-0002-6102-1580
FU National Institute of Aging [R01 AG032032]; National Institute of Mental
   Health [R49 CE002093, T32 MH018911, T32 MH020061]; NATIONAL CENTER FOR
   INJURY PREVENTION AND CONTROL [R49CE002093] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH018911, T32MH073452,
   T32MH020061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG032032] Funding Source: NIH RePORTER
FX The authors wish to thank the National Institute of Aging (R01 AG032032,
   Sorensen) for funding the study and the National Institute of Mental
   Health (R49 CE002093, Caine) for the staff support and for student and
   postdoctoral support (T32 MH018911, Lyness; T32 MH020061, Conwell). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Alexopoulos GS, 2005, AM J PSYCHIAT, V162, P718, DOI 10.1176/appi.ajp.162.4.718
   [Anonymous], 1994, USE PSYCHOL TESTING
   AREAN PA, 1993, J CONSULT CLIN PSYCH, V61, P1003, DOI 10.1037/0022-006X.61.6.1003
   Aspinwall L. G., 1997, DEV PSYCHOL PLANNING, P285
   Aspinwall LG, 1997, PSYCHOL BULL, V121, P417, DOI 10.1037/0033-2909.121.3.417
   BARBER CE, 1995, J APPL GERONTOL, V14, P172, DOI 10.1177/073346489501400203
   Bardi A, 2007, J PERS, V75, P955, DOI 10.1111/j.1467-6494.2007.00462.x
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Biderman A, 2002, J EPIDEMIOL COMMUN H, V56, P631, DOI 10.1136/jech.56.8.631
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   D'Zurilla T. J., 1982, ADV COGNITIVE BEHAV, V1
   Dreer LE, 2005, REHABIL PSYCHOL, V50, P232, DOI 10.1037/0090-5550.50.3.232
   Erikson Erik H., 1963, CHILDHOOD SOC
   Fossati P, 2002, ENCEPHALE, V28, P97
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hegel MT, 2004, FAM MED, V36, P204
   Heyl V, 2005, SOC INDIC RES, V74, P159, DOI 10.1007/s11205-005-6522-3
   Heyl V, 2001, J VISUAL IMPAIR BLIN, V95, P739, DOI 10.1177/0145482X0109501204
   Horowitz A, 2000, J VISUAL IMPAIR BLIN, V94, P328, DOI 10.1177/0145482X0009400509
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Liu H., 1999, ASS HLTH SERV RES M, V16, P36
   Long SK, 2005, INQUIRY-J HEALTH CAR, V42, P413, DOI 10.5034/inquiryjrnl_42.4.413
   Maloney SK, 1996, HEALTH CARE FINANC R, V18, P141
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Marella M, 2010, INVEST OPHTH VIS SCI, V51, P2878, DOI 10.1167/iovs.09-4494
   Matteson MA, 1984, WORKING ELDERLY GROU, P287
   Miller SJ, 2002, PSYCHOTHERAPY, V39, P184, DOI 10.1037/0033-3204.39.2.184
   Monagle Sharon, 2002, Aust Fam Physician, V31, P1111
   MynorsWallis L, 1997, BRIT J PSYCHIAT, V170, P113, DOI 10.1192/bjp.170.2.113
   MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441
   Nezu AM, 2003, J CONSULT CLIN PSYCH, V71, P1036, DOI 10.1037/0022-006X.71.6.1036
   Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574
   Perepletchikova F, 2005, CLIN PSYCHOL-SCI PR, V12, P365, DOI 10.1093/clipsy/bpi045
   POSER W, 1992, DRUG ALCOHOL DEPEN, V30, P49, DOI 10.1016/0376-8716(92)90035-B
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702
   RYFF CD, 1995, CURR DIR PSYCHOL SCI, V4, P99, DOI 10.1111/1467-8721.ep10772395
   Ryff CD, 1996, PSYCHOTHER PSYCHOSOM, V65, P14, DOI 10.1159/000289026
   Ryff CD, 1995, FAMILY RELATIONS IND, P95
   Sbrensen S, 2013, PREFERENCE FUTURE CA
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Sorensen S, 2012, AM J GERIAT PSYCHIAT, V20, P887, DOI 10.1097/JGP.0b013e31822ccd8c
   Sorensen S, 2000, J GERONTOL B-PSYCHOL, V55, pS357, DOI 10.1093/geronb/55.6.S357
   Sorensen S, 2001, INT J AGING HUM DEV, V53, P137
   Tasman W, 2004, ARCH OPHTHALMOL-CHIC, V122, P648, DOI 10.1001/archopht.122.4.648
   Wahl HW, 1999, J GERONTOL B-PSYCHOL, V54, pP304, DOI 10.1093/geronb/54B.5.P304
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 56
TC 10
Z9 11
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1551-7144
EI 1559-2030
J9 CONTEMP CLIN TRIALS
JI Contemp. Clin. Trials
PD MAY
PY 2015
VL 42
BP 68
EP 77
DI 10.1016/j.cct.2015.03.007
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CM0DE
UT WOS:000357347800008
PM 25812482
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tian, Y
   Kijlstra, A
   van der Veen, RLP
   Makridaki, M
   Murray, IJ
   Berendschot, TTJM
AF Tian, Yuan
   Kijlstra, Aize
   van der Veen, Rob L. P.
   Makridaki, Maria
   Murray, Ian J.
   Berendschot, Tos T. J. M.
TI Lutein supplementation leads to decreased soluble complement membrane
   attack complex sC5b-9 plasma levels
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; complement system; lutein; sC5b-9
ID AGE-RELATED CATARACT; MACULAR DEGENERATION; ACTIVATION; SYSTEM;
   ATHEROSCLEROSIS; PATHOGENESIS; DRUSEN; HYPOTHESIS; PATHWAY; DISEASE
AB PurposeThe purpose of this study was to investigate the effect of lutein on systemic complement activation in elderly individuals.
   MethodsSeventy patients with signs of early age-related macular degeneration (AMD) were included in this study. All subjects were randomly assigned to receive a 10mg daily dose of lutein or a placebo for a time period of 1year. EDTA blood was collected before and at various time-points during the study (0, 4, 8 and 12months). The plasma level of the soluble complement membrane attack complex sC5b-9 was measured by ELISA.
   ResultsWe found a significant 1.1ng/ml monthly decrease in the plasma sC5b-9 concentration in the lutein group (p<0.001), resulting in a decrease from 60.3ng/ml at baseline to 46.3ng/ml at 12months. For the placebo group, we found a significant 0.6ng/ml monthly increase in plasma sC5b-9 concentration (p=0.001), resulting in an increase from 51.6ng/ml at baseline to 58.4ng/ml at 12months.
   ConclusionsLutein supplementation inhibits the systemic activation of the complement system, which provides further functional evidence for the reported beneficial effects of this carotenoid in the management of AMD.
C1 [Tian, Yuan; Kijlstra, Aize; van der Veen, Rob L. P.; Berendschot, Tos T. J. M.] Univ Eye Clin Maastricht, NL-6202 AZ Maastricht, Netherlands.
   [Makridaki, Maria; Murray, Ian J.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   University of Manchester
RP Berendschot, TTJM (通讯作者)，Univ Eye Clin Maastricht, NL-6202 AZ Maastricht, Netherlands.
EM t.berendschot@maastrichtuniversity.nl
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X; Tian, Yuan/0000-0002-9551-9061
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   HUGO F, 1987, J IMMUNOL METHODS, V99, P243, DOI 10.1016/0022-1759(87)90134-7
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Speidl WS, 2011, J THROMB HAEMOST, V9, P428, DOI 10.1111/j.1538-7836.2010.04172.x
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 36
TC 16
Z9 16
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2015
VL 93
IS 2
BP 141
EP 145
DI 10.1111/aos.12535
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CB8SC
UT WOS:000349900200031
PM 25160533
DA 2022-11-30
ER

PT J
AU Shang, JL
   Sun, Y
   Li, SJ
   Liu, JX
   Zheng, CH
   Zhang, JY
AF Shang, Junliang
   Sun, Yan
   Li, Shengjun
   Liu, Jin-Xing
   Zheng, Chun-Hou
   Zhang, Junying
TI An Improved Opposition-Based Learning Particle Swarm Optimization for
   the Detection of SNP-SNP Interactions
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ANT COLONY OPTIMIZATION; EPISTATIC INTERACTIONS; GENE-GENE; ASSOCIATION;
   INFORMATION; ALGORITHM; DISEASE; INFERENCE
AB SNP-SNP interactions have been receiving increasing attention in understanding the mechanism underlying susceptibility to complex diseases. Though many works have been done for the detection of SNP-SNP interactions, the algorithmic development is still ongoing. In this study, an improved opposition-based learning particle swarm optimization (IOBLPSO) is proposed for the detection of SNP-SNP interactions. Highlights of IOBLPSO are the introduction of three strategies, namely, opposition-based learning, dynamic inertia weight, and a postprocedure. Opposition-based learning not only enhances the global explorative ability, but also avoids premature convergence. Dynamic inertia weight allows particles to cover a wider search space when the considered SNP is likely to be a random one and converges on promising regions of the search space while capturing a highly suspected SNP. The postprocedure is used to carry out a deep search in highly suspected SNP sets. Experiments of IOBLPSO are performed on both simulation data sets and a real data set of age-related macular degeneration, results of which demonstrate that IOBLPSO is promising in detecting SNP-SNP interactions. IOBLPSO might be an alternative to existing methods for detecting SNP-SNP interactions.
C1 [Shang, Junliang; Sun, Yan; Li, Shengjun] Qufu Normal Univ, Sch Informat Sci & Engn, Rizhao 276826, Peoples R China.
   [Liu, Jin-Xing] Harbin Inst Technol, Shenzhen Grad Sch, Biocomp Res Ctr, Shenzhen 518055, Peoples R China.
   [Zheng, Chun-Hou] Anhui Univ, Coll Elect Engn & Automat, Hefei 230039, Anhui, Peoples R China.
   [Zhang, Junying] Xidian Univ, Sch Comp Sci & Technol, Xian 710071, Peoples R China.
C3 Qufu Normal University; Harbin Institute of Technology; University Town
   of Shenzhen; Anhui University; Xidian University
RP Liu, JX (通讯作者)，Qufu Normal Univ, Sch Informat Sci & Engn, Rizhao 276826, Peoples R China.
EM sdcavell@126.com
RI Liu, Jin-Xing/AAU-7257-2020
FU Scientific Research Reward Foundation for Excellent Young and Middle-age
   Scientists of Shandong Province [BS2014DX004]; Science and Technology
   Planning Project of Qufu Normal University [xkj201410]; Scientific
   Research Foundation of Qufu Normal University [BSQD20130119, XJ201226];
   Shandong Provincial Natural Science Foundation [ZR2013FL016]; China
   Postdoctoral Science Foundation [2014M560264]; Shenzhen Municipal
   Science and Technology Innovation Council [JCYJ20140417172417174]; Award
   Foundation Project of Excellent Young Scientists in Shandong Province
   [BS2014DX005]; Project of Shandong Province Higher Educational Science
   and Technology Program [J13LN31]; Innovation and Entrepreneurship
   Training Project for College Students of Qufu Normal University
   [2014A096]
FX This work was supported by the Scientific Research Reward Foundation for
   Excellent Young and Middle-age Scientists of Shandong Province
   (BS2014DX004), the Science and Technology Planning Project of Qufu
   Normal University (xkj201410), the Scientific Research Foundation of
   Qufu Normal University (BSQD20130119), the Shandong Provincial Natural
   Science Foundation (ZR2013FL016), the China Postdoctoral Science
   Foundation Funded Project (2014M560264), the Shenzhen Municipal Science
   and Technology Innovation Council (JCYJ20140417172417174), the Award
   Foundation Project of Excellent Young Scientists in Shandong Province
   (BS2014DX005), the Project of Shandong Province Higher Educational
   Science and Technology Program (J13LN31), the Scientific Research
   Foundation of Qufu Normal University (XJ201226), and the Innovation and
   Entrepreneurship Training Project for College Students of Qufu Normal
   University (2014A096).
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Aflakparast M, 2014, HEREDITY, V112, P666, DOI 10.1038/hdy.2014.4
   Bowne SJ, 2002, HUM MOL GENET, V11, P559, DOI 10.1093/hmg/11.5.559
   Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543
   Chanda P, 2008, GENETICS, V180, P1191, DOI 10.1534/genetics.108.088542
   Chanda P, 2007, AM J HUM GENET, V81, P939, DOI 10.1086/521878
   Chanda P, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-509
   Chanda P, 2009, EUR J HUM GENET, V17, P1274, DOI 10.1038/ejhg.2009.38
   Chang HW, 2009, COMPUT BIOL CHEM, V33, P114, DOI 10.1016/j.compbiolchem.2008.07.029
   Chuang LY, 2014, P ANN HICSS, P2548, DOI 10.1109/HICSS.2014.647
   Chuang LY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037018
   Chuang LY, 2012, EUR J CANCER PREV, V21, P336, DOI 10.1097/CEJ.0b013e32834e31f6
   Fontanarosa J, 2010, IEEE INT C BIO BIO W, P330, DOI 10.1109/BIBMW.2010.5703823
   Frankel WN, 1996, NAT GENET, V14, P371, DOI 10.1038/ng1296-371
   Greene CS, 2008, LECT NOTES COMPUT SC, V5217, P37, DOI 10.1007/978-3-540-87527-7_4
   Greene CS, 2009, LECT NOTES COMPUT SC, V5483, P92, DOI 10.1007/978-3-642-01184-9_9
   Guo X, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-102
   Han B., 2010, P 9 INT WORKSH DAT M
   Han B, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-S3-S14
   Han B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S12-S3
   Han B, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S3-S5
   Han B, 2009, IEEE INT C BIOINFORM, P148, DOI 10.1109/BIBM.2009.59
   Jiang R, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S1-S65
   Jiang Xia, 2010, AMIA Annu Symp Proc, V2010, P341
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/icnn.1995.488968
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kwon MS, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-S1-S6
   Kyunga Kim, 2012, Proceedings of the 2012 IEEE International Conference on Bioinformatics and Biomedicine Workshops (BIBMW), P838, DOI 10.1109/BIBMW.2012.6470249
   Lee S, 2011, IEEE INT C BIO BIO W, P691, DOI 10.1109/BIBMW.2011.6112454
   Li WT, 2000, HUM HERED, V50, P334, DOI 10.1159/000022939
   Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a
   Mei-Lee Hwang, 2014, International Journal of Machine Learning and Computing, V4, P468, DOI 10.7763/IJMLC.2014.V4.456
   Moore JH, 2010, BIOINFORMATICS, V26, P445, DOI 10.1093/bioinformatics/btp713
   Ratnaweera A, 2004, IEEE T EVOLUT COMPUT, V8, P240, DOI 10.1109/tevc.2004.826071
   Rekaya R, 2009, REV BRAS ZOOTECN, V38, P93, DOI 10.1590/S1516-35982009001300011
   Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Shang JL, 2014, DIGIT SIGNAL PROCESS, V24, P1, DOI 10.1016/j.dsp.2013.08.007
   Shang JL, 2013, GENES GENOM, V35, P305, DOI 10.1007/s13258-013-0081-9
   Shang JL, 2012, GENES GENOM, V34, P321, DOI 10.1007/s13258-012-0003-2
   Shang JL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-475
   Tang WW, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000464
   Tizhoosh HR, 2006, International Conference on Computational Intelligence for Modelling, Control & Automation Jointly with International Conference on Intelligent Agents, Web Technologies & Internet Commerce, Vol 1, Proceedings, P695, DOI 10.1109/cimca.2005.1631345
   Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433
   Wan XA, 2010, AM J HUM GENET, V87, P325, DOI 10.1016/j.ajhg.2010.07.021
   Wan X, 2010, BIOINFORMATICS, V26, P30, DOI 10.1093/bioinformatics/btp622
   Wang Yupeng, 2010, BMC Res Notes, V3, P117, DOI 10.1186/1756-0500-3-117
   Wu JX, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004237
   Wu SJ, 2013, MOL BIOL REP, V40, P4227, DOI 10.1007/s11033-013-2504-8
   Yang CH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/172049
   Yang CH, 2012, APPL MATH COMPUT, V219, P260, DOI 10.1016/j.amc.2012.06.015
   Yang CH, 2009, CANCER EPIDEMIOL, V33, P147, DOI 10.1016/j.canep.2009.07.001
   Zhang X, 2010, BIOINFORMATICS, V26, pi217, DOI 10.1093/bioinformatics/btq186
   Zhang Y, 2007, NAT GENET, V39, P1167, DOI 10.1038/ng2110
NR 54
TC 30
Z9 31
U1 4
U2 23
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 524821
DI 10.1155/2015/524821
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CN2PS
UT WOS:000358264800001
PM 26236727
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Tiosano, L
   Jaouni, T
   Averbukh, E
   Grunin, M
   Banin, E
   Chowers, I
AF Tiosano, Liran
   Jaouni, Tareq
   Averbukh, Edward
   Grunin, Michelle
   Banin, Eyal
   Chowers, Itay
TI Bevacizumab treatment for choroidal neovascularization associated with
   adult-onset foveomacular vitelliform dystrophy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Adult-onset foveomacular vitelliform dystrophy; Bevacizumab; Choroidal
   neovascularization; Pattern dystrophy
ID OPTICAL COHERENCE TOMOGRAPHY; PATTERN DYSTROPHY; INTRAVITREAL
   BEVACIZUMAB; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; RANIBIZUMAB
AB Purpose: To evaluate choroidal neovascularization (CNV) associated with adult-onset foveomacular vitelliform dystrophy (AOFVD) and its response to bevacizumab therapy.
   Methods: Demographics, clinical characteristics, response to bevacizumab therapy, and central foveal thickness (CFT) were retrospectively assessed in 11 eyes with CNV associated with AOFVD. Sixty consecutive patients with neovascular age-related macular degeneration (AMD) were compared to the patients with AOFVD for all clinical characteristics and responses evaluated.
   Results: The mean (+/- SD) initial logMAR visual acuity (0.7 +/- 0.8 vs. 1 +/- 0.75), age at onset, number of bevacizumab injections (12.4 +/- 10.4 vs 9 +/- 6.7), and final logMAR visual acuity (0.87 +/- 0.7 vs 1 +/- 0.85) were similar between AOFVD and AMD. The mean CFT in AOFVD was reduced from 418 +/- 144 mu m to 330 +/- 64 mu m following treatment (p = 0.03). At the final examination, visual acuity had improved in 3 eyes, stabilized in 1 eye, and was reduced in 7 of the AOFVD eyes examined.
   Conclusions: Bevacizumab therapy for AOFVD-associated CNV resulted in reduced foveal thickness, but a guarded visual outcome was still found, due to progression of the vitelliform lesions.
C1 [Tiosano, Liran; Jaouni, Tareq; Averbukh, Edward; Grunin, Michelle; Banin, Eyal; Chowers, Itay] Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Med Ctr, Dept Ophthalmol, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019
OI Grunin, Michelle/0000-0002-3155-2858
FU Israel Science Foundation; Hadassah Medical Center
FX Supported by an Israel Science Foundation grant and by an internal grant
   from the Hadassah Medical Center.
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Da Pozzo S, 2001, OPHTHALMOLOGICA, V215, P412, DOI 10.1159/000050899
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   Francis PJ, 2005, BRIT J OPHTHALMOL, V89, P1115, DOI 10.1136/bjo.2004.062695
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Furino C, 2008, OPHTHALMOLOGICA, V222, P240, DOI 10.1159/000130427
   Gallego-Pinazo R, 2011, GRAEF ARCH CLIN EXP, V249, P455, DOI 10.1007/s00417-010-1536-1
   Heidary Fatemeh, 2011, J Pediatr Ophthalmol Strabismus, V48 Online, pe19, DOI 10.3928/01913913-20110308-02
   Jaouni T, 2012, ARCH OPHTHALMOL-CHIC, V130, P987, DOI 10.1001/archophthalmol.2012.1483
   Kandula Sushma, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS81, DOI 10.3928/15428877-20101031-09
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KIM RY, 1995, ARCH OPHTHALMOL-CHIC, V113, P451, DOI 10.1001/archopht.1995.01100040067029
   Lee JY, 2009, OPHTHAL SURG LAS IM, V40, P319, DOI 10.3928/15428877-20090430-18
   Menchini U, 2002, ARCH OPHTHALMOL-CHIC, V120, P1761
   Mimoun G, 2013, RETINA-J RET VIT DIS, V33, P513, DOI 10.1097/IAE.0b013e3182753adb
   Montero JA, 2007, EUR J OPHTHALMOL, V17, P983, DOI 10.1177/112067210701700620
   Parodi MB, 2010, INVEST OPHTH VIS SCI, V51, P4358, DOI 10.1167/iovs.10-5237
   Parodi MB, 2003, RETINA-J RET VIT DIS, V23, P171, DOI 10.1097/00006982-200304000-00006
   Puche N, 2010, BRIT J OPHTHALMOL, V94, P1190, DOI 10.1136/bjo.2009.175075
   Querques G, 2008, ACTA OPHTHALMOL, V86, P694, DOI 10.1111/j.1600-0420.2007.01132.x
   Querques G, 2008, AM J OPHTHALMOL, V146, P135, DOI 10.1016/j.ajo.2008.02.017
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   WATZKE RC, 1982, OPHTHALMOLOGY, V89, P1400
NR 25
TC 9
Z9 11
U1 0
U2 3
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV-DEC
PY 2014
VL 24
IS 6
BP 890
EP 896
DI 10.5301/ejo.5000486
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX0FA
UT WOS:000346627400013
PM 24846624
DA 2022-11-30
ER

PT J
AU Pescosolido, N
   Giannotti, R
   Plateroti, AM
   Pascarella, A
   Nebbioso, M
AF Pescosolido, Nicola
   Giannotti, Rossella
   Plateroti, Andrea Maria
   Pascarella, Antonia
   Nebbioso, Marcella
TI Curcumin: Therapeutical Potential in Ophthalmology
SO PLANTA MEDICA
LA English
DT Article
DE anti-inflammatory drug; antioxidant drug; antitumor drug; Curcuma longa;
   Zingiberaceae; Curcumin; ocular diseases
ID ACTIVATED RECEPTOR-GAMMA; ROSIGLITAZONE TREATMENT; ENCAPSULATED
   CURCUMIN; CELL-PROLIFERATION; P-GLYCOPROTEIN; EXPRESSION; TROGLITAZONE;
   PHARMACOLOGY; PIOGLITAZONE; MANAGEMENT
AB Curcumin (diferuloylmethane) is the main curcuminoid of the popular Indian spice turmeric (Curcuma longa). In the last 50 years, in vitro and in vivo experiments supported the main role of polyphenols and curcumin for the prevention and treatment of many different inflammatory diseases and tumors. The anti-inflammatory, antioxidant, and antitumor properties of curcumin are due to different cellular mechanisms: this compound, in fact, produces different responses in different cell types. Unfortunately, because of its low solubility and oral bioavailability, the biomedical potential of curcumin is not easy to exploit; for this reason more attention has been given to nanoparticles and liposomes, which are able to improve curcumins bioavailability. Pharmacologically, curcumin does not show any dose-limiting toxicity when it is administered at doses of up to 8g/day for three months. It has been demonstrated that curcumin has beneficial effects on several ocular diseases, such as chronic anterior uveitis, diabetic retinopathy, glaucoma, age-related macular degeneration, and dry eye syndrome. The purpose of this review is to report what has so far been elucidated about curcumin properties and its potential use in ophthalmology.
C1 [Pescosolido, Nicola] Univ Roma La Sapienza, Dept Cardiovasc Resp Nephrol Geriatr & Anesthet S, I-00161 Rome, Italy.
   [Giannotti, Rossella; Plateroti, Andrea Maria; Nebbioso, Marcella] Univ Roma La Sapienza, Dept Sense Organs, I-00161 Rome, Italy.
   [Pascarella, Antonia] Univ Roma La Sapienza, Dept Biol & Biotechnol Charles Darwin, I-00161 Rome, Italy.
C3 Sapienza University Rome; Sapienza University Rome; Sapienza University
   Rome
RP Nebbioso, M (通讯作者)，Univ Roma La Sapienza, Ctr Ocular Electrophysiol, Dept Sense Organs, Viale Policlin 155, I-00161 Rome, Italy.
EM marcella.nebbioso@uniroma1.it
RI Nebbioso, Marcella/K-6878-2018
OI Nebbioso, Marcella/0000-0002-5512-0849
CR Agarwal R, 2006, AM J PHYSIOL-RENAL, V290, pF600, DOI 10.1152/ajprenal.00289.2005
   Aggarwal S, 2006, MOL PHARMACOL, V69, P195, DOI 10.1124/mol.105.017400
   Alex AF, 2010, CURR EYE RES, V35, P1021, DOI 10.3109/02713683.2010.506970
   Aljada A, 2001, J CLIN ENDOCR METAB, V86, P3250, DOI 10.1210/jc.86.7.3250
   Allegri P, 2010, CLIN OPHTHALMOL, V4, P1201, DOI 10.2147/OPTH.S13271
   AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004
   Antony B, 2008, INDIAN J PHARM SCI, V70, P445, DOI 10.4103/0250-474X.44591
   Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744
   Bisht Savita, 2007, Journal of Nanobiotechnology, V5, P3, DOI 10.1186/1477-3155-5-3
   Bonne C, 2005, J FR OPHTALMOL, V28, P326, DOI 10.1016/S0181-5512(05)81062-9
   Carmona-Ramirez I, 2013, J NUTR BIOCHEM, V24, P14, DOI 10.1016/j.jnutbio.2011.12.010
   Chen M, 2010, EXP EYE RES, V90, P437, DOI 10.1016/j.exer.2009.12.004
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Del Cano M V, 2008, PPAR RES, V2008
   Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394
   Diab A, 2004, J NEUROIMMUNOL, V148, P116, DOI 10.1016/j.jneuroim.2003.11.010
   Gong CY, 2013, BIOMATERIALS, V34, P1413, DOI 10.1016/j.biomaterials.2012.10.068
   Graber-Maier A, 2010, PLANTA MED, V76, P1866, DOI 10.1055/s-0030-1249980
   Gralinski MR, 1998, J CARDIOVASC PHARM, V31, P909, DOI 10.1097/00005344-199806000-00015
   Gregory MS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017659
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Haffner SM, 2002, CIRCULATION, V106, P679, DOI 10.1161/01.CIR.0000025403.20953.23
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Jacob A, 2007, PPAR RES, V2007, DOI 10.1155/2007/89369
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Kumar Virender, 2002, Indian Journal of Physiology and Pharmacology, V46, P209
   Lal B, 2000, PHYTOTHER RES, V14, P443, DOI 10.1002/1099-1573(200009)14:6&lt;443::AID-PTR619&gt;3.0.CO;2-V
   Lal B, 1999, PHYTOTHER RES, V13, P318, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;318::AID-PTR445&gt;3.0.CO;2-7
   Lee KJ, 2004, EXP MOL MED, V36, P534, DOI 10.1038/emm.2004.68
   Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300
   Li L, 2007, MOL CANCER THER, V6, P1276, DOI 10.1158/1535-7163.MCT-06-0556
   Libby P, 2007, AM J CARDIOL, V99, p27B, DOI 10.1016/j.amjcard.2006.11.004
   Maiti K, 2007, INT J PHARMACEUT, V330, P155, DOI 10.1016/j.ijpharm.2006.09.025
   Malchiodi-Albedi F, 2008, PPAR RES, V2008, DOI 10.1155/2008/295784
   Manikandan R, 2010, FREE RADICAL BIO MED, V48, P483, DOI 10.1016/j.freeradbiomed.2009.11.011
   Marczylo TH, 2007, CANCER CHEMOTH PHARM, V60, P171, DOI 10.1007/s00280-006-0355-x
   Marx N, 2003, CIRCULATION, V107, P1954, DOI 10.1161/01.CIR.0000069272.06194.91
   Mazzolani F, 2013, CLIN OPHTHALMOL, V7, P939, DOI 10.2147/OPTH.S45820
   Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5
   Mohanty P, 2004, J CLIN ENDOCR METAB, V89, P2728, DOI 10.1210/jc.2003-032103
   Mrudula T, 2007, BIOCHEM BIOPH RES CO, V361, P528, DOI 10.1016/j.bbrc.2007.07.059
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Passos E, 2002, INVEST OPHTHALMOL VI, V43
   Patumraj S, 2006, CLIN HEMORHEOL MICRO, V35, P481
   Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838
   Rachmawati H, 2013, J PHARM SCI-US, V102, P204, DOI 10.1002/jps.23335
   Salvatore S, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/354645
   Sarayba MA, 2005, EXP EYE RES, V80, P435, DOI 10.1016/j.exer.2004.10.009
   Sato Mayumi, 2005, Nihon Rinsho, V63, P603
   Shishodia S, 2013, BIOFACTORS, V39, P37, DOI 10.1002/biof.1041
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Steigerwalt R., 2012, PANMINERVA MED, V54, P11
   Suryanarayana P, 2003, MOL VIS, V9, P223
   Talero E, 2012, CURR PHARM DESIGN, V18, P3939, DOI 10.2174/138161212802083725
   Tamvakopoulos C, 2007, CLIN CANCER RES, V13, P1269, DOI 10.1158/1078-0432.CCR-06-1839
   Taylor Rebecca A, 2011, Altern Med Rev, V16, P152
   Toda N, 2007, PROG RETIN EYE RES, V26, P205, DOI 10.1016/j.preteyeres.2007.01.004
   Wang G, 2005, METABOLISM, V54, P590, DOI 10.1016/j.metabol.2004.11.017
   Yue GGL, 2012, J MED FOOD, V15, P242, DOI 10.1089/jmf.2011.1845
NR 59
TC 84
Z9 86
U1 0
U2 46
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD MAR
PY 2014
VL 80
IS 4
BP 249
EP 254
DI 10.1055/s-0033-1351074
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA AC3DK
UT WOS:000332395000001
PM 24323538
OA Bronze
DA 2022-11-30
ER

PT J
AU Kaja, S
   Duncan, RS
   Longoria, S
   Hilgenberg, JD
   Payne, AJ
   Desai, NM
   Parikh, RA
   Burroughs, SL
   Gregg, EV
   Goad, DL
   Koulen, P
AF Kaja, S.
   Duncan, R. S.
   Longoria, S.
   Hilgenberg, J. D.
   Payne, A. J.
   Desai, N. M.
   Parikh, R. A.
   Burroughs, S. L.
   Gregg, E. V.
   Goad, D. L.
   Koulen, P.
TI NOVEL MECHANISM OF INCREASED Ca2+ RELEASE FOLLOWING OXIDATIVE STRESS IN
   NEURONAL CELLS INVOLVES TYPE 2 INOSITOL-1,4,5-TRISPHOSPHATE RECEPTORS
SO NEUROSCIENCE
LA English
DT Article
DE calcium; central nervous system; IP3; nucleus; neurodegeneration;
   neuroprotection
ID ALZHEIMERS-DISEASE; AMYLOID-BETA; CALCIUM HOMEOSTASIS; BRAIN;
   DYSREGULATION; HYPOTHESIS; GLUTAMATE; ANTIOXIDANT; HYDROLYSIS;
   MODULATION
AB Dysregulation of Ca2+ signaling following oxidative stress is an important pathophysiological mechanism of many chronic neurodegenerative disorders, including Alzheimer's disease, age-related macular degeneration, glaucomatous and diabetic retinopathies. However, the underlying mechanisms of disturbed intracellular Ca2+ signaling remain largely unknown. We here describe a novel mechanism for increased intracellular Ca2+ release following oxidative stress in a neuronal cell line. Using an experimental approach that included quantitative polymerase chain reaction, quantitative immunoblotting, microfluorimetry and the optical imaging of intracellular Ca2+ release, we show that sub-lethal tert-butyl hydroperoxide-mediated oxidative stress result in a selective up-regulation of type-2 inositol-1,4,5,-trisphophate receptors. This oxidative stress mediated change was detected both at the transcriptional and translational level and functionally resulted in increased Ca2+ release into the nucleoplasm from the membranes of the nuclear envelope at a given receptor-specific stimulus. Our data describe a novel source of Ca2+ dysregulation induced by oxidative stress with potential relevance for differential subcellular Ca2+ signaling specifically within the nucleus and the development of novel neuroprotective strategies in neurodegenerative disorders. (c) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Kaja, S.] Univ Missouri, Vis Res Ctr, Kansas City, MO 64108 USA.
   Univ Missouri, Sch Med, Dept Ophthalmol, Kansas City, MO 64108 USA.
   Univ Missouri, Sch Med, Dept Basic Med Sci, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City
RP Kaja, S (通讯作者)，Univ Missouri, Vis Res Ctr, 2411 Holmes St, Kansas City, MO 64108 USA.
EM kajas@umkc.edu
RI Kaja, Simon/C-2267-2015; Duncan, Raymond/AAD-1969-2019
OI Kaja, Simon/0000-0001-6878-521X; Grillo, Stephanie/0000-0001-7208-300X
FU NCMHD [P20-MD001633]; NIHI NEI [EY014227]; NIHINCRR [RR022570,
   RR027093]; NIHINIA [AG010485, AG022550, AG027956]; Garvey Texas
   Foundation; Felix and Carmen Sabates Missouri Endowed Chair in Vision
   Research; National Headache Foundation; NATIONAL CENTER FOR RESEARCH
   RESOURCES [S10RR022570, S10RR027093] Funding Source: NIH RePORTER;
   NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD001633]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014227]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022550,
   P01AG027956, P01AG010485] Funding Source: NIH RePORTER
FX This study was supported in part by P20-MD001633 from NCMHD (R.S.D.),
   grants EY014227 from NIHI NEI, RR022570 and RR027093 from NIHINCRR and
   AG010485, AG022550 and AG027956 from NIHINIA (P.K.) as well as by The
   Garvey Texas Foundation (P.K.), the Felix and Carmen Sabates Missouri
   Endowed Chair in Vision Research (P. K.) and the National Headache
   Foundation (S.K.). A preliminary version of this study was presented at
   the Annual Meeting of the Society for Neuroscience 2009 in Chicago, IL
   (program # 56.26). Thanks to Dr. Robin Craig for many fruitful
   discussions on qPCR. Mr. Martin Engel and Mr. An Pham are acknowledged
   for their help with data analysis. Mr. Grant Fischer provided excellent
   technical assistance. We thank Margaret, Richard and Sara Koulen for
   generous support and encouragement.
CR Alia M, 2005, J BIOCHEM MOL TOXIC, V19, P119, DOI 10.1002/jbt.20061
   Baskys A, 2001, BRAIN RES, V907, P188, DOI 10.1016/S0006-8993(01)02517-3
   Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002
   Berridge MJ, 2010, PFLUG ARCH EUR J PHY, V459, P441, DOI 10.1007/s00424-009-0736-1
   Berridge MJ, 2009, BBA-MOL CELL RES, V1793, P933, DOI 10.1016/j.bbamcr.2008.10.005
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3
   Berry EV, 2006, NEUROTOXICOLOGY, V27, P1043, DOI 10.1016/j.neuro.2006.05.011
   Bezprozvanny I, 2008, TRENDS NEUROSCI, V31, P454, DOI 10.1016/j.tins.2008.06.005
   Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6
   Chen M, 1999, CELL CALCIUM, V26, P149, DOI 10.1054/ceca.1999.0067
   Chen Ming, 1998, Frontiers in Bioscience, V3, pA27
   Cheung KH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000818
   CREWS FT, 1994, LIFE SCI, V55, P1993, DOI 10.1016/0024-3205(94)00379-3
   Duchen MR, 2008, CELL CALCIUM, V44, P1, DOI 10.1016/j.ceca.2008.02.001
   Duncan RS, 2007, INT J BIOCHEM CELL B, V39, P1852, DOI 10.1016/j.biocel.2007.05.003
   FERRARIDILEO G, 1993, LIFE SCI, V53, pPL439, DOI 10.1016/0024-3205(93)90037-4
   Ferreiro E, 2006, NEUROBIOL DIS, V23, P669, DOI 10.1016/j.nbd.2006.05.011
   Foster TC, 2007, AGING CELL, V6, P319, DOI 10.1111/j.1474-9726.2007.00283.x
   Fu Y, 2006, NEUROTOX RES, V10, P23, DOI 10.1007/BF03033331
   GARLIND A, 1995, BRAIN RES, V681, P160, DOI 10.1016/0006-8993(95)00311-D
   Hall KE, 2001, BRAIN RES, V888, P128, DOI 10.1016/S0006-8993(00)03038-9
   Kasri NN, 2006, CELL CALCIUM, V40, P41, DOI 10.1016/j.ceca.2006.03.005
   KHACHATURIAN ZS, 1994, ANN NY ACAD SCI, V747, P1
   Kontush A, 2001, FREE RADICAL BIO MED, V31, P1120, DOI 10.1016/S0891-5849(01)00688-8
   Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754
   Koulen P, 2001, MOL NEUROBIOL, V24, P65, DOI 10.1385/MN:24:1-3:065
   Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006
   Kurumatani T, 1998, BRAIN RES, V796, P209, DOI 10.1016/S0006-8993(98)00347-3
   Kurz DJ, 2004, J CELL SCI, V117, P2417, DOI 10.1242/jcs.01097
   LANDFIELD PW, 1987, NEUROBIOL AGING, V8, P346, DOI 10.1016/0197-4580(87)90074-1
   Leissring MA, 2000, J CELL BIOL, V149, P793, DOI 10.1083/jcb.149.4.793
   Leite MF, 2003, P NATL ACAD SCI USA, V100, P2975, DOI 10.1073/pnas.0536590100
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Massheimer V, 2000, J CELL PHYSIOL, V182, P429, DOI 10.1002/(SICI)1097-4652(200003)182:3<429::AID-JCP14>3.3.CO;2-J
   Mattson M P, 1989, Prog Clin Biol Res, V317, P333
   Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4
   Mattson MP, 2001, J MOL NEUROSCI, V17, P205, DOI 10.1385/JMN:17:2:205
   Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131
   O'Neill C, 2001, BIOCHEM SOC SYMP, V67, P177
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Rhodes JD, 2009, EXP EYE RES, V88, P226, DOI 10.1016/j.exer.2008.10.025
   Rodrigues MA, 2009, BRAZ J MED BIOL RES, V42, P17, DOI 10.1590/S0100-879X2008005000050
   Rybalchenko V, 2009, J RECEPT SIG TRANSD, V29, P326, DOI 10.3109/10799890903295168
   Sagara Y, 1998, J NEUROSCI, V18, P6662
   Sagara Y, 1998, FREE RADICAL BIO MED, V24, P1375, DOI 10.1016/S0891-5849(97)00457-7
   Sayre LM, 2008, CHEM RES TOXICOL, V21, P172, DOI 10.1021/tx700210j
   Schmidt KG, 2008, CURR NEUROPHARMACOL, V6, P164, DOI 10.2174/157015908784533851
   Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier
   STOKES CE, 1987, J NEUROCHEM, V48, P1018, DOI 10.1111/j.1471-4159.1987.tb05619.x
   Stutzmann GE, 2005, NEUROSCIENTIST, V11, P110, DOI 10.1177/1073858404270899
   Stutzmann GE, 2004, J NEUROSCI, V24, P508, DOI 10.1523/JNEUROSCI.4386-03.2004
   Thibault O, 2001, J NEUROSCI, V21, P9744, DOI 10.1523/JNEUROSCI.21-24-09744.2001
   Thibault O, 1998, CELL CALCIUM, V24, P417, DOI 10.1016/S0143-4160(98)90064-1
   Tuppo E E, 2001, J Am Osteopath Assoc, V101, pS11
   Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138
   Wojda U, 2008, IUBMB LIFE, V60, P575, DOI 10.1002/iub.91
   YOUNG LT, 1988, NEUROSCI LETT, V94, P198, DOI 10.1016/0304-3940(88)90295-9
   Zitzler J, 2004, MOL CELL PROTEOMICS, V3, P834, DOI 10.1074/mcp.M400054-MCP200
NR 60
TC 33
Z9 34
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD FEB 17
PY 2011
VL 175
BP 281
EP 291
DI 10.1016/j.neuroscience.2010.11.010
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 718FK
UT WOS:000287106300027
PM 21075175
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Schneider, R
   Jensen, SA
   Whiteman, P
   McCullagh, JSO
   Redfield, C
   Handford, PA
AF Schneider, Ralf
   Jensen, Sacha A.
   Whiteman, Pat
   McCullagh, James S. O.
   Redfield, Christina
   Handford, Penny A.
TI Biophysical Characterisation of Fibulin-5 Proteins Associated with
   Disease
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE fibulin-5; protein misfolding; age-related macular degeneration; cutis
   laxa; cbEGF
ID FACTOR-LIKE DOMAIN; CALCIUM-BINDING; MARFAN-SYNDROME; CUTIS LAXA;
   MACULAR DEGENERATION; MISSENSE MUTATION; FACTOR-IX; FIBRILLIN-1;
   ELASTIN; REGION
AB FBLN5 encodes fibulin-5, an extracellular matrix calcium-binding glycoprotein that is essential for elastic fibre formation. FBLN5 mutations are associated with two distinct human diseases, age-related macular degeneration (AMD) and cutis laxa (CL), but the biochemical basis for the pathogenic effects of these mutations is poorly understood. Two missense mutations found in AMD patients (I169T and G267S) and two missense mutations found in CL patients (G202R and S227P) were analysed in a native-like context in recombinant fibulin-5 fragments. Limited proteolysis, NMR spectroscopy and chromophoric calcium chelation experiments showed that the G267S and S227P substitutions cause long-range structural effects consistent with protein misfolding. Cellular studies using fibroblast cells further demonstrated that these recombinant forms of mutant fibulin-5 were not present in the extracellular medium, consistent with retention. In contrast, no significant effects of I169T and G202R substitutions on protein fold and secretion were identified. These data establish protein misfolding as a causative basis for the effects of G267S and S227P substitutions in AMD and CL, respectively, and raise the possibility that the I169T and G202R substitutions may be polymorphisms or may increase susceptibility to disease. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Schneider, Ralf; Jensen, Sacha A.; Whiteman, Pat; Handford, Penny A.] Univ Oxford, Dept Biochem, Lab Genes & Dev, Oxford OX1 3QU, England.
   [McCullagh, James S. O.] Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England.
   [Redfield, Christina] Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England.
C3 University of Oxford; University of Oxford; University of Oxford
RP Handford, PA (通讯作者)，Univ Oxford, Dept Biochem, Lab Genes & Dev, S Parks Rd, Oxford OX1 3QU, England.
EM penny.handford@bioch.ox.ac.uk
RI Jensen, Sacha A./AAB-4034-2019; McCullagh, James/AAD-2669-2022
OI Jensen, Sacha A./0000-0002-0560-9531; McCullagh,
   James/0000-0003-4733-1205; Redfield, Christina/0000-0001-7297-7708
FU Fight for Sight [1442]; Wellcome Trust [079440]
FX We would like to thank Dr. J. Nettleship (University of Oxford) for
   routine mass spectrometry analysis. This work was supported by a Fight
   for Sight PhD Studentship (1442) awarded to P.A.H., C.R. and S.A.J. C.R.
   acknowledges support from the Wellcome Trust (grant 079440).
CR Albig AR, 2006, CANCER RES, V66, P2621, DOI 10.1158/0008-5472.CAN-04-4096
   Albig AR, 2004, DNA CELL BIOL, V23, P367, DOI 10.1089/104454904323145254
   Cardy CM, 1998, J MOL BIOL, V276, P855, DOI 10.1006/jmbi.1997.1593
   Claus S, 2008, J INVEST DERMATOL, V128, P1442, DOI 10.1038/sj.jid.5701211
   Davis JA, 2007, J BIOL CHEM, V282, P28807, DOI 10.1074/jbc.M704015200
   Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3
   El-Hallous E, 2007, J BIOL CHEM, V282, P8935, DOI 10.1074/jbc.M608204200
   Elahi E, 2006, J INVEST DERMATOL, V126, P1506, DOI 10.1038/sj.jid.5700247
   Eswar Narayanan, 2006, Curr Protoc Bioinformatics, VChapter 5, pUnit, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/cpbi.3, 10.1002/0471250953.bi0506s15]
   Freeman LJ, 2005, BIOCHEM J, V388, P1, DOI 10.1042/BJ20050368
   GADEK JE, 1984, ENVIRON HEALTH PERSP, V55, P297, DOI 10.2307/3429709
   HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x
   Hirai M, 2007, J CELL BIOL, V176, P1061, DOI 10.1083/jcb.200611026
   Hu QR, 2006, HUM MOL GENET, V15, P3379, DOI 10.1093/hmg/ddl414
   Hu QR, 2006, J INVEST DERMATOL, V126, P283, DOI 10.1038/sj.jid.5700047
   Jensen SA, 2005, J BIOL CHEM, V280, P14076, DOI 10.1074/jbc.M412832200
   Jones RPO, 2010, INVEST OPHTH VIS SCI, V51, P2356, DOI 10.1167/iovs.09-4620
   Kelleher CM, 2005, AM J RESP CELL MOL, V33, P355, DOI 10.1165/rcmb.2005-0206OC
   Kettle S, 2000, INT J BIOCHEM CELL B, V32, P201, DOI 10.1016/S1357-2725(99)00120-X
   Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003
   Kowal RC, 1999, CIRC RES, V84, P1166, DOI 10.1161/01.RES.84.10.1166
   Lee SSJ, 2004, STRUCTURE, V12, P717, DOI 10.1016/j.str.2004.02.023
   LINSE S, 1991, J BIOL CHEM, V266, P8050
   Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297
   Loeys B, 2002, HUM MOL GENET, V11, P2113, DOI 10.1093/hmg/11.18.2113
   Loeys BL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000488
   Lomas AC, 2007, BIOCHEM J, V405, P417, DOI 10.1042/BJ20070400
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Markova D, 2003, AM J HUM GENET, V72, P998, DOI 10.1086/373940
   McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987
   Megarbane H, 2009, J INVEST DERMATOL, V129, P1650, DOI 10.1038/jid.2008.450
   Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8
   Mullins RF, 2007, EXP EYE RES, V84, P378, DOI 10.1016/j.exer.2006.09.021
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Nakamura T, 1999, J BIOL CHEM, V274, P22476, DOI 10.1074/jbc.274.32.22476
   RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4
   Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339
   Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231
   Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200
   Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200
   Stenberg Y, 1997, J BIOL CHEM, V272, P23255, DOI 10.1074/jbc.272.37.23255
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Suk JY, 2004, J BIOL CHEM, V279, P51258, DOI 10.1074/jbc.M408156200
   Sullivan KM, 2007, LAB INVEST, V87, P818, DOI 10.1038/labinvest.3700594
   Whiteman P, 2003, HUM MOL GENET, V12, P727, DOI 10.1093/hmg/ddg081
   Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200
   Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807
   Whiteman P, 2007, HUM MOL GENET, V16, P907, DOI 10.1093/hmg/ddm035
   Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a
NR 49
TC 16
Z9 17
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD AUG 27
PY 2010
VL 401
IS 4
BP 605
EP 617
DI 10.1016/j.jmb.2010.06.039
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 642ZW
UT WOS:000281262400005
PM 20599547
DA 2022-11-30
ER

PT J
AU Charkoudian, LK
   Dentchev, T
   Lukinova, N
   Wolkow, N
   Dunaief, JL
   Franz, KJ
AF Charkoudian, Louise K.
   Dentchev, Tzvete
   Lukinova, Nina
   Wolkow, Natalie
   Dunaief, Joshua L.
   Franz, Katherine J.
TI Iron prochelator BSIH protects retinal pigment epithelial cells against
   cell death induced by hydrogen peroxide
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Iron; Oxidative stress; Reactive oxygen species; Fenton chemistry;
   Chelation therapy
ID SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE; MACULAR DEGENERATION; OXIDATIVE
   STRESS; PARKINSONS-DISEASE; LIPID-PEROXIDATION; SUBSTANTIA-NIGRA;
   IN-VIVO; CHELATOR; BRAIN; OVERLOAD
AB Dysregulation of localized iron homeostasis is implicated in several degenerative diseases, including Parkinson's, Alzheimer's, and age-related macular degeneration, wherein iron-mediated oxidative stress is hypothesized to contribute to cell death. Inhibiting toxic iron without altering normal metal-dependent processes presents significant challenges for standard small molecule chelating agents. We previously introduced BSIH (isonicotinic acid [2-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzylidene]hydrazide) prochelators that are converted by hydrogen peroxide into SIH (salicylaldehyde isonicotinoyl hydrazone) chelating agents that inhibit iron-catalyzed hydroxyl radical generation. Here, we show that BSIH protects a cultured cell model for retinal pigment epithelium against cell death induced by hydrogen peroxide. BSIH is more stable than SIH in cell culture medium and is more protective during long-term experiments. Repetitive exposure of cells to BSIH is nontoxic, whereas SIH and desferrioxamine induce cell death after repeated exposure. Combined, our results indicate that cell protection by BSIH involves iron sequestration that occurs only when the cells are stressed by hydrogen peroxide. These findings suggest that prochelators discriminate toxic iron from healthy iron and are promising candidates for neuro- and retinal protection. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Charkoudian, Louise K.; Franz, Katherine J.] Duke Univ, Dept Chem, Durham, NC 27708 USA.
   [Dentchev, Tzvete; Lukinova, Nina; Wolkow, Natalie; Dunaief, Joshua L.] Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
C3 Duke University; University of Pennsylvania; Pennsylvania Medicine
RP Franz, KJ (通讯作者)，Duke Univ, Dept Chem, Durham, NC 27708 USA.
EM katherine.franz@duke.edu
RI Franz, Katherine/D-3501-2011
OI Franz, Katherine/0000-0002-9015-0998; Wolkow,
   Natalie/0000-0003-1524-115X
FU Duke University's Arts and Sciences Faculty Committee on Research; NIH
   [EY018922]; Alfred P. Sloan Research Fellowship; NSF; NATIONAL EYE
   INSTITUTE [R21EY018922] Funding Source: NIH RePORTER
FX We thank Dr. Leon Charkoudian for initiating the collaboration between
   the Franz and Dunaief labs. We thank Duke University's Arts and Sciences
   Faculty Committee on Research and NIH EY018922 for funding this study.
   K. Franz is grateful for an Alfred P. Sloan Research Fellowship and an
   NSF CAREER Award.
CR Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337
   Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330
   Buss JL, 2003, BBA-GEN SUBJECTS, V1619, P177, DOI 10.1016/S0304-4165(02)00478-6
   Charkoudian LK, 2007, DALTON T, P5031, DOI 10.1039/b705199a
   Charkoudian LK, 2006, J AM CHEM SOC, V128, P12424, DOI 10.1021/ja064806w
   Chwiej J, 2007, J BIOL INORG CHEM, V12, P204, DOI 10.1007/s00775-006-0179-5
   Crichton R., 2001, INORGANIC BIOCH IRON
   DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Gotz ME, 2004, ANN NY ACAD SCI, V1012, P193, DOI 10.1196/annals.1306.017
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Hider RC, 2005, ANN NY ACAD SCI, V1054, P141, DOI 10.1196/annals.1345.017
   Horackova M, 2000, CARDIOVASC RES, V47, P529, DOI 10.1016/S0008-6363(00)00088-2
   Kovarikova P, 2005, J SEP SCI, V28, P1300, DOI 10.1002/jssc.200500077
   Kurz T, 2006, FEBS J, V273, P3106, DOI 10.1111/j.1742-4658.2006.05321.x
   LAKHANPAL V, 1984, OPHTHALMOLOGY, V91, P443
   Madsen E, 2007, ANNU REV NEUROSCI, V30, P317, DOI 10.1146/annurev.neuro.30.051606.094232
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Richardson DR, 1998, AM J HEMATOL, V58, P299, DOI 10.1002/(SICI)1096-8652(199808)58:4<299::AID-AJH9>3.3.CO;2-R
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Simunek T, 2005, J MOL CELL CARDIOL, V39, P345, DOI 10.1016/j.yjmcc.2005.05.008
   Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866
   SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x
   WALDMEIER PC, 1993, BIOCHEM PHARMACOL, V45, P2417, DOI 10.1016/0006-2952(93)90222-I
   Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537
NR 31
TC 45
Z9 45
U1 1
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD DEC
PY 2008
VL 102
IS 12
SI SI
BP 2130
EP 2135
DI 10.1016/j.jinorgbio.2008.08.001
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 379XL
UT WOS:000261429700014
PM 18835041
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lengyel, I
   Flinn, JM
   Peto, T
   Linkous, DH
   Cano, K
   Bird, AC
   Lanzirotti, A
   Frederickson, CJ
   van Kuijk, FJGM
AF Lengyel, Imre
   Flinn, Jane M.
   Peto, Tunde
   Linkous, David H.
   Cano, Katherine
   Bird, Alan C.
   Lanzirotti, Antonio
   Frederickson, Christopher J.
   van Kuijk, Frederik J. G. M.
TI High concentration of zinc in sub-retinal pigment epithelial deposits
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE zinc; drusen; sub-RPE deposit; Bruch's membrane; retinal pigment
   epithelium; age-related macular degeneration; complement factor H; trace
   element
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   X-RAY; DRUSEN FORMATION; BRUCHS MEMBRANE; GRADING SYSTEM; BASAL
   DEPOSITS; BETA; DISEASE
AB One of the hallmarks of age-related macular degeneration (AMD), the leading cause of blindness in the elderly in Western societies, is the accumulation of sub-retinal pigment epithelial deposits (sub-RPE deposits), including drusen and basal laminar deposits, in Bruch's membrane (BM). The nature and the underlying mechanisms of this deposit formation are not fully understood. Because we know that zinc contributes to deposit formation in neurodegenerative diseases, we tested the hypothesis that zinc might be involved in deposit formation in AMD. Using zinc specific fluorescent probes and microprobe synchrotron X-ray fluorescence we showed that sub-RPE deposits in post-mortem human tissues contain unexpectedly high concentrations of zinc, including abundant bio-available (ionic and/or loosely protein bound) ions. Zinc accumulation was especially high in the maculae of eyes with AMD. Internal deposit structures are especially enriched in bio-available zinc. Based on the evidence provided here we suggest that zinc plays a role in sub-RPE deposit formation in the aging human eye and possibly also in the development and/or progression of AMD. (c) 2007 Elsevier Ltd. All rights reserved.
C1 UCL, Inst Ophthalmol, Div Pathol, London EC1V 9EL, England.
   Biol Res Ctr, Dept Biochem, H-6726 Szeged, Hungary.
   George Mason Univ, Dept Psychol, Fairfax, VA USA.
   Moorfields Eye Hosp, Dept Res & Dev, London, England.
   Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL USA.
   NeuroBioTex Inc, Galveston, TX 77455 USA.
   Univ Texas, Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
C3 University of London; University College London; Hungarian Academy of
   Sciences; Hungarian Biological Research Center; George Mason University;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of Chicago; University of Texas System;
   University of Texas Medical Branch Galveston
RP Lengyel, I (通讯作者)，UCL, Inst Ophthalmol, Div Pathol, 11-43 Bath St, London EC1V 9EL, England.
EM i.lengyel@ucl.ac.uk
RI Peto, Tunde/G-8812-2018; Lengyel, Imre/B-5217-2009; Mitchell,
   Paul/P-1498-2014
OI Peto, Tunde/0000-0001-6265-0381; Lengyel, Imre/0000-0001-7467-2174;
   Lanzirotti, Antonio/0000-0002-7597-5924
CR Agte VV, 2004, BIOL TRACE ELEM RES, V99, P99, DOI 10.1385/BTER:99:1-3:099
   Akagi T, 2001, J HISTOCHEM CYTOCHEM, V49, P87, DOI 10.1177/002215540104900109
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Auld DS, 2001, BIOMETALS, V14, P271, DOI 10.1023/A:1012976615056
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Burdette SC, 2003, J AM CHEM SOC, V125, P1778, DOI 10.1021/ja0287377
   Bush AI, 2002, NEUROBIOL AGING, V23, P1031, DOI 10.1016/S0197-4580(02)00120-3
   Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Dentchev T, 2003, MOL VIS, V9, P184
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Flinn JM, 2005, PHYSIOL BEHAV, V83, P793, DOI 10.1016/j.physbeh.2004.10.009
   Frederickson Christopher, 2003, Sci STKE, V2003, ppe18, DOI 10.1126/stke.2003.182.pe18
   FREDERICKSON CJ, 1987, J HISTOCHEM CYTOCHEM, V35, P579, DOI 10.1177/35.5.2435783
   FREDERICKSON CJ, 1981, EXP NEUROL, V73, P812, DOI 10.1016/0014-4886(81)90214-4
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Levenson CW, 2003, NUTR REV, V61, P311, DOI 10.1301/nr.2003.sept.311-313
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Miller LM, 2006, J STRUCT BIOL, V155, P30, DOI 10.1016/j.jsb.2005.09.004
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   NEWSOME DA, 1992, CURR EYE RES, V11, P213, DOI 10.3109/02713689209001772
   NEWSOME DA, 1987, INVEST OPHTH VIS SCI, V28, P1795
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   PERKINS SJ, 1991, BIOCHEMISTRY-US, V30, P2847, DOI 10.1021/bi00225a017
   Powell JJ, 1999, J INORG BIOCHEM, V75, P159, DOI 10.1016/S0162-0134(99)00054-9
   Rink L, 2000, P NUTR SOC, V59, P541, DOI 10.1017/S0029665100000781
   Ritchie CW, 2004, EXPERT OPIN INV DRUG, V13, P1585, DOI 10.1517/13543784.13.12.1585
   SAMUELSON DA, 1993, EXP EYE RES, V56, P63, DOI 10.1006/exer.1993.1009
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268
   Tate DJ, 2002, CURR EYE RES, V24, P12, DOI 10.1076/ceyr.24.1.12.5426
   Turnberg D, 2003, MOL IMMUNOL, V40, P145, DOI 10.1016/S0161-5890(03)00110-X
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Ulshafer R J, 1989, Prog Clin Biol Res, V314, P131
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANKUIJK FJGM, 1991, INVEST OPHTH VIS SCI, V32, P1962
   Woodroofe CC, 2004, CHEM BIOL, V11, P1659, DOI 10.1016/j.chembiol.2004.09.013
NR 67
TC 97
Z9 104
U1 0
U2 11
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2007
VL 84
IS 4
BP 772
EP 780
DI 10.1016/j.exer.2006.12.015
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 158VC
UT WOS:000245822200019
PM 17313944
DA 2022-11-30
ER

PT J
AU Abrera-Abeleda, MA
   Nishimura, C
   Smith, JLH
   Sethi, S
   McRae, JL
   Murphy, BF
   Silvestri, G
   Skerka, C
   Jozsi, M
   Zipfel, PF
   Hageman, GS
   Smith, RJH
AF Abrera-Abeleda, M. A.
   Nishimura, C.
   Smith, J. L. H.
   Sethi, S.
   McRae, J. L.
   Murphy, B. F.
   Silvestri, G.
   Skerka, C.
   Jozsi, M.
   Zipfel, P. F.
   Hageman, G. S.
   Smith, R. J. H.
TI Variations in the complement regulatory genes factor H (CFH) and factor
   H related 5 (CFHR5) are associated with membranoproliferative
   glomerulonephritis type II (dense deposit disease)
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID MESANGIOCAPILLARY GLOMERULONEPHRITIS; LONG-TERM; ACTIVATION; DRUSEN;
   EPIDEMIOLOGY; POLYMORPHISM; EXPRESSION; MUTATIONS; SURFACE; VARIANT
AB Introduction: Membranoproliferative glomerulonephritis type II or dense deposit disease ( MPGN II/DDD) causes chronic renal dysfunction that progresses to end stage renal disease in about half of patients within 10 years of diagnosis. Deficiency of and mutations in the complement factor H ( CFH) gene are associated with the development of MPGN II/DDD, suggesting that dysregulation of the alternative pathway of the complement cascade is important in disease pathophysiology.
   Subjects: Patients with MPGN II/DDD were studied to determine whether specific allele variants of CFH and CFHR5 segregate preferentially with the MPGN II/DDD disease phenotype. The control group was compromised of 131 people in whom age related macular degeneration had been excluded.
   Results: Allele frequencies of four single nucleotide polymorphisms in CFH and three in CFHR5 were significantly different between MPGN II/DDD patients and controls.
   Conclusion: We have identified specific allele variants of CFH and CFHR5 associated with the MPGN II/ DDD disease phenotype. While our data can be interpreted to further implicate complement in the pathogenesis of MPGN II/DDD, these associations could also be unrelated to disease pathophysiology. Functional studies are required to resolve this question.
C1 Univ Iowa, Carver Coll Med, Div Nephrol, Dept Otolaryngol, Iowa City, IA USA.
   Univ Iowa, Carver Coll Med, Div Nephrol, Interdept Program Genet, Iowa City, IA USA.
   Mayo Clin Rochester, Dept Lab Med & Pathol, Rochester, MN USA.
   St Vincents Hosp, Immunol Res Ctr, Melbourne, Vic, Australia.
   Queens Univ, Dept Ophthalmol, Div Surg & Perioperat Care, Belfast, Antrim, North Ireland.
   Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Div Nephrol, Iowa City, IA USA.
   Univ Iowa, Carver Coll Med, Dept Internal Med, Div Nephrol, Iowa City, IA USA.
C3 University of Iowa; University of Iowa; Mayo Clinic; St Vincent's
   Hospital Melbourne; Queens University Belfast; Hans Knoll Institute
   (HKI); University of Iowa; University of Iowa
RP Smith, RJH (通讯作者)，Univ Iowa, Mol Otolaryngol Res Labs, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM richard-smith@uiowa.edu
RI Mohammed, Imran/J-8271-2012; Jozsi, Mihaly/I-7872-2018
OI Mohammed, Imran/0000-0002-8412-0768; Jozsi, Mihaly/0000-0002-5520-5535;
   Silvestri, Giuliana/0000-0001-5662-5374; Smith,
   Richard/0000-0003-1201-6731
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANGAKU M, 1998, KIDNEY INT, V54, P1419
   Appel GB, 2005, J AM SOC NEPHROL, V16, P1392, DOI 10.1681/ASN.2005010078
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Bao LH, 2002, KIDNEY INT, V62, P2010, DOI 10.1046/j.1523-1755.2002.t01-1-00652.x
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   CAMERON JS, 1983, AM J MED, V74, P175, DOI 10.1016/0002-9343(83)90606-X
   Colville D, 2003, AM J KIDNEY DIS, V42, DOI 10.1016/S0272-6386(03)00665-6
   DIBELGIOJOSO GB, 1977, NEPHRON, V19, P250
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   DROZ D, 1982, Nephrologie, V3, P6
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P900, DOI 10.1136/bjo.73.11.900
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   HABIB R, 1975, KIDNEY INT, V7, P204, DOI 10.1038/ki.1975.32
   HABIB R, 1987, AM J KIDNEY DIS, V10, P198, DOI 10.1016/S0272-6386(87)80175-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Jansen JH, 1998, KIDNEY INT, V53, P331, DOI 10.1046/j.1523-1755.1998.00765.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MCENERY PT, 1990, J PEDIATR-US, V116, pS109, DOI 10.1016/S0022-3476(05)82712-X
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Murphy B, 2002, AM J KIDNEY DIS, V39, P24, DOI 10.1053/ajkd.2002.29873
   Orth SR, 1998, NEW ENGL J MED, V338, P1202, DOI 10.1056/NEJM199804233381707
   PASCAUL M, 1994, J EXP MED, V79, P889
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Prasad S, 2004, AM J MED GENET A, V124A, P1, DOI 10.1002/ajmg.a.20272
   Schwertz R, 2001, PEDIAT ALLERG IMM-UK, V12, P166, DOI 10.1034/j.1399-3038.2001.012003166.x
   SWAINSON CP, 1983, J PATHOL, V141, P449, DOI 10.1002/path.1711410404
   Timmerman JJ, 1996, KIDNEY INT, V49, P730, DOI 10.1038/ki.1996.102
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VANDENDOBBELSTEEN MEA, 1994, CLIN EXP IMMUNOL, V95, P173
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Zipfel PF, 2006, PROG INFLAM RES, P199
NR 38
TC 170
Z9 181
U1 0
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD JUL
PY 2006
VL 43
IS 7
BP 582
EP 589
DI 10.1136/jmg.2005.038315
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 059DP
UT WOS:000238713800007
PM 16299065
OA Green Published
DA 2022-11-30
ER

PT J
AU Yamamoto, Y
AF Yamamoto, Y
TI Measurement of blood flow velocity in feeder vessels of choroidal
   neovascularization by a scanning laser ophthalmoscope and image analysis
   system
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; dye
   dilution curves; feeder vessel; image analysis system
ID CIRCULATION; ANGIOGRAPHY
AB Purpose: To measure the blood flow velocities in feeder vessels of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration.
   Methods: We examined the early images of indocyanine green videoangiography (v-ICGA) in 29 patients (29 eyes) with CNV, in whom feeder vessels could be identified by v-ICGA. The v-ICGA images were installed in a personal computer. With original software, optical density measurements were performed for the determination of dye-dilution curves. The flow velocity in a CNV feeder vessel was obtained by analyzing the dye-dilution curves.
   Results: The mean flow velocity in feeder vessels was 33.8 +/- 32.5 mm/s. The flow velocity in feeder vessels of CNV with a diameter of 1.5 mm or larger was significantly higher than that in feeder vessels of CNV with a diameter smaller than 1.5 mm (P < .05, unpaired t-test).
   Conclusions: The flow velocity in CNV feeder vessels can be measured with v-ICGA and a computer-based image analysis system. This system would be useful in the evaluation of choroidal circulation. Jpn J Ophthalmol 2003;47:53-58 (C) 2003 Japanese Ophthalmological Society.
C1 Okayama Univ, Dept Ophthalmol, Sch Med, Okayama 7008558, Japan.
C3 Okayama University
RP Yamamoto, Y (通讯作者)，Okayama Univ, Dept Ophthalmol, Sch Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan.
CR FIENWALD E, 1965, BIBL ANAT, V7, P129
   HATORI T, 1992, JPN J OPHTHALMOL, V46, P901
   HYVARINE.L, 1969, AM J OPHTHALMOL, V67, P653, DOI 10.1016/S0002-9394(69)90987-8
   Isono Hiroaki, 1997, Nippon Ganka Gakkai Zasshi, V101, P684
   KOYAMA T, 1990, GRAEF ARCH CLIN EXP, V228, P442, DOI 10.1007/BF00927258
   KOYAMA T, 1986, THER RES, V5, P35
   MATSUO N, 1980, Nippon Ganka Gakkai Zasshi, V84, P2147
   MIHARA K, 1996, NIHON GANKA KYO, V47, P1393
   MORI K, 1998, INVEST OPHTH VIS SCI, V39, pS586
   MYRIAN S, 2000, ARCH OPHTHALMOL-CHIC, V118, P211
   Riva CE, 1978, AM J PHYSIOL, V234, P315
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   SHIRAGA F, 1995, JPN J CLIN OPHTHAL, V49, P63
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   SUTTON DW, 1992, AM J PHYSIOL, V262, pH1646, DOI 10.1152/ajpheart.1992.262.6.H1646
   TAMAKI Y, 1995, EXP EYE RES, V60, P373, DOI 10.1016/S0014-4835(05)80094-6
   Tamaki Yasuhiro, 1993, Nippon Ganka Gakkai Zasshi, V97, P602
NR 17
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JAN-FEB
PY 2003
VL 47
IS 1
BP 53
EP 58
AR PII S0021-5155(02)00632-9
DI 10.1016/S0021-5155(02)00632-9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 646KL
UT WOS:000181034100009
PM 12586178
DA 2022-11-30
ER

PT J
AU Pantaleoni, FB
   Galante, VM
   Da Dalt, S
   Pecorella, I
AF Pantaleoni, Francesco Bozzoni
   Galante, Vittoria Magliari
   Da Dalt, Stefano
   Pecorella, Irene
TI Localizing polypoidal choroidal vasculopathy for laser treatment
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
C1 San Filippo Neri Hosp, Dept Neurosci, I-00135 Rome, Italy.
   Univ Roma La Sapienza, Dept Ophthalmol Sci, Rome, Italy.
C3 San Filippo Neri Hospital; Sapienza University Rome
RP Pantaleoni, FB (通讯作者)，San Filippo Neri Hosp, Dept Neurosci, Via Martinotti 20, I-00135 Rome, Italy.
EM f.bozzoni@iol.it
CR Gomez-Ulla F, 1998, RETINA-J RET VIT DIS, V18, P481, DOI 10.1097/00006982-199805000-00021
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Ladas ID, 2004, EUR J OPHTHALMOL, V14, P264, DOI 10.1177/112067210401400313
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1982, P MAC SOC M MIAM 5 F
NR 8
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD JUN
PY 2007
VL 85
IS 4
BP 456
EP 458
DI 10.1111/j.1600-0420.2006.00742.x
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 176UK
UT WOS:000247110200019
PM 17263781
OA Bronze
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Harding, SP
   Rogers, CA
   Downes, SM
   Lotery, AJ
   Culliford, LA
   Reeves, BC
AF Chakravarthy, Usha
   Harding, Simon P.
   Rogers, Chris A.
   Downes, Susan M.
   Lotery, Andrew J.
   Culliford, Lucy A.
   Reeves, Barnaby C.
CA IVAN Study Investigators
TI Alternative treatments to inhibit VEGF in age-related choroidal
   neovascularisation: 2-year findings of the IVAN randomised controlled
   trial
SO LANCET
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN; GROWTH-FACTOR INHIBITORS; MACULAR
   DEGENERATION; MYOCARDIAL-INFARCTION; ADVERSE EVENTS; RANIBIZUMAB;
   SAFETY; THERAPIES; EFFICACY; DESIGN
AB Background Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint.
   Methods In a multicentre, 2x2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years with active, previously untreated neovascular age-related macular degeneration and a best corrected distance visual acuity (BCVA) of at least 25 letters from 23 hospitals in the UK. Participants were randomly assigned (1: 1: 1: 1) to intravitreal injections of ranibizumab (0.5 mg) or bevacizumab (1.25 mg) in continuous (every month) or discontinuous (as needed) regimens, with monthly review. Study participants and clinical assessors were masked to drug allocation. Allocation to continuous or discontinuous treatment was masked up to 3 months, at which point investigators and participants were unmasked. The primary outcome was BCVA at 2 years, with a prespecified noninferiority limit of 3.5 letters. The primary safety outcome was arterial thrombotic event or hospital admission for heart failure. Analyses were by modified intention to treat. This trial is registered, number ISRCTN92166560.
   Findings Between March 27, 2008, and Oct 15, 2010, 628 patients underwent randomisation. 18 were withdrawn; 610 received study drugs (314 ranibizumab; 296 bevacizumab) and were included in analyses. 525 participants reached the visit at 2 years: 134 ranibizumab in continuous regimen, 137 ranibizumab in discontinuous regimen, 127 bevacizumab in continuous regimen, and 127 bevacizumab in discontinuous regimen. For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean difference -1.37 letters, 95% CI -3.75 to 1.01; p=0.26). Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1.63 letters, -4.01 to 0.75; p=0.18). Frequency of arterial thrombotic events or hospital admission for heart failure did not diff er between groups given ranibizumab (20 [6%] of 314 participants) and bevacizumab (12 [4%] of 296; odds ratio [OR] 1.69, 95% CI 0.80-3.57; p=0.16), or those given continuous (12 [4%] of 308) and discontinuous treatment (20 [7%] of 302; 0.56, 0.27-1.19; p=0.13). Mortality was lower with continuous than discontinuous treatment (OR 0.47, 95% CI 0.22-1.03; p=0.05), but did not diff er by drug group (0.96, 0.46-2.02; p=0.91).
   Interpretation Ranibizumab and bevacizumab have similar efficacy. Reduction in the frequency of retreatment resulted in a small loss of efficacy irrespective of drug. Safety was worse when treatment was administered discontinuously. These findings highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought.
C1 [Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Harding, Simon P.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
   [Rogers, Chris A.; Culliford, Lucy A.; Reeves, Barnaby C.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Downes, Susan M.] Oxford Univ Hosp NHS Trust, Oxford, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
C3 Queens University Belfast; University of Liverpool; University of
   Bristol; Oxford University Hospitals NHS Foundation Trust; University of
   Southampton
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Inst Clin Sci, RVH Site, Belfast BT12 6BA, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI ; Aslam, Tariq/A-8532-2016
OI Lotery, Andrew/0000-0001-5541-4305; Dakin, Helen/0000-0003-3255-748X;
   Foss, Alexander/0000-0001-9649-0072; Reeves,
   Barnaby/0000-0002-5101-9487; Wordsworth, Sarah/0000-0002-2361-3040;
   Harding, Simon/0000-0003-4676-1158; Aslam, Tariq/0000-0002-9739-7280;
   Maishman, Rachel/0000-0002-5052-5951; Chakravarthy,
   Usha/0000-0002-2606-3734
FU UK National Institute for Health Research Health Technology Assessment
   programme; National Institute for Health Research [NF-SI-0507-10094,
   07/36/01] Funding Source: researchfish
FX UK National Institute for Health Research Health Technology Assessment
   programme.
CR Alsheikh-Ali AA, 2008, AM J CARDIOL, V101, p9B, DOI 10.1016/j.amjcard.2008.02.027
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown H., 2015, APPL MIXED MODELS ME
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   European Medicines Agency, 2012, EYL AFL
   Fadda V, 2011, BRIT J OPHTHALMOL, V95, P1476, DOI 10.1136/bjophthalmol-2011-300316
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Green S, 2011, COCHRANE HDB SYSTEMA, P914
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mitchell J, 2008, AM J OPHTHALMOL, V146, P447, DOI 10.1016/j.ajo.2008.04.031
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P275, DOI 10.1097/00006982-200603000-00004
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   US Food and Drug Administration, VACC BLOOD BIOL BIOL
   Watson RR, 2009, HDB DIS BURDENS QUAL, P2633
   WHO Expert Committee on Specifications for Pharmaceutical Preparations, 2011, 45 WHO EXP COMM SPEC
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Williams T, 2012, ARCH OPHTHALMOL-CHIC, V130, P124, DOI 10.1001/archopht.130.1.124
NR 35
TC 537
Z9 553
U1 2
U2 53
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD OCT 12
PY 2013
VL 382
IS 9900
BP 1258
EP 1267
DI 10.1016/S0140-6736(13)61501-9
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 235XP
UT WOS:000325756400029
PM 23870813
OA Green Published, hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Jonas, JB
AF Jonas, Jost B.
TI Intravitreal triamcinolone acetonide: A change in a paradigm
SO OPHTHALMIC RESEARCH
LA English
DT Review
DE intravitreal triamcinolone acetonide; diabetic macular edema;
   age-related macular degeneration; intraocular pressure; intraocular
   steroids
ID CYSTOID MACULAR EDEMA; RETINAL VEIN OCCLUSION; PARS-PLANA VITRECTOMY;
   CENTRAL SEROUS CHORIORETINOPATHY; INTERNAL LIMITING MEMBRANE; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; GREEN-MEDIATED PHOTOTHROMBOSIS;
   INTRAOCULAR-PRESSURE ELEVATION; COMBINED PHOTODYNAMIC THERAPY;
   CRYSTALLINE CORTISONE
AB Background: Based on experimental studies and clinical observations by Robert Machemer, Gholam Peyman and others, the vitreous cavity has increasingly been used as a reservoir of drugs for the direct treatment of intraocular diseases. Methods and Results: The most widely injected drug so far has been triamcinolone acetonide for various intraocular neovascular and edematous diseases. Comparing the various diseases with respect to effect and side effects of the treatment, the best response in terms of gain in visual acuity has been achieved for intraretinal edematous diseases such as diffuse diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion, and pseudophakic cystoid macular edema. In eyes with various types of noninfectious uveitis including acute or chronic sympathetic ophthalmia and Adamantiadis-Behcet's disease, visual acuity increased and the degree of intraocular inflammation decreased. Some studies have suggested that intravitreal triamcinolone may be useful as an angiostatic agent in eyes with iris neovascularization and proliferative ischemic retinopathies. Intravitreal triamcinolone may possibly be helpful as adjunct therapy for exudative age-related macular degeneration, particularly in combination with photodynamic therapy. In eyes with chronic, therapy-resistant ocular hypotony, intravitreal triamcinolone can induce an in- crease in intraocular pressure and may stabilize the eye. The complications of intravitreal triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected; medically uncontrollable high intraocular pressure leading to antiglaucomatous surgery in about 1-2% of the eyes; posterior subcapsular cataract and nuclear cataract leading to cataract surgery in about 15-20% in elderly patients within 1 year after injection; postoperative infectious endophthalmitis with a rate of about 1:1,000; noninfectious endophthalmitis, perhaps due to a reaction to the solvent agent, and pseudoendophthalmitis with triamcinolone acetonide crystals appearing in the anterior chamber. Intravitreal triamcinolone injection can be combined with other types of intraocular surgery including cataract surgery, particularly in eyes with iris neovascularization. Cataract Surgery performed some months after the injection does not show a markedly elevated complication rate. The injection may be repeated, if vision redecreases. In nonvitrectomized eyes, the duration of the effect and side effects of a single intravitreal injection of triamcinolone is about 6-9 months for a dosage of about 20 mg, and about 2-4 months for a dosage of 4 mg. It has remained unclear so far, whether and how to remove the solvent agent. In the future, intravitreal triamcinolone may be combined with other antiangiogenic drugs for the treatment of exudative age-related macular degeneration or with neuroprotective drugs for treatment of diabetic retinopathy. Conclusions: Despite an exponentially increasing number of mostly case-series studies, the intravitreal injection of triamcinolone may still be considered an experimental procedure until randomized studies have been presented. Copyright (c) 2006 S. Karger AG, Basel.
C1 Heidelberg Univ, Fac Clin Med Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Univ Mannheim, Augenklin, Theodor Kutzer Ufer 1-3, DE-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
CR Agrawal S, 2004, AM J OPHTHALMOL, V138, P679, DOI 10.1016/j.ajo.2004.05.031
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Al-Haddad CE, 2004, AM J OPHTHALMOL, V137, P1151, DOI 10.1016/j.ajo.2004.01.032
   Alldredge CD, 2003, RETINA-J RET VIT DIS, V23, P113, DOI 10.1097/00006982-200302000-00022
   Amato JE, 2005, OCUL IMMUNOL INFLAMM, V13, P245, DOI 10.1080/09273940590928562
   Andrade RE, 2004, AM J OPHTHALMOL, V137, P572, DOI 10.1016/j.ajo.2003.08.035
   Androudi S, 2005, OCUL IMMUNOL INFLAMM, V13, P205, DOI 10.1080/09273940590933511
   Angunawela RI, 2005, ACTA OPHTHALMOL SCAN, V83, P595, DOI 10.1111/j.1600-0420.2005.00438.x
   Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arevalo JF, 2005, GRAEF ARCH CLIN EXP, V243, P1180, DOI 10.1007/s00417-005-1177-y
   Audren F, 2004, INVEST OPHTH VIS SCI, V45, P3435, DOI 10.1167/iovs.03-1110
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Avitabile T, 2005, AM J OPHTHALMOL, V140, P695, DOI 10.1016/j.ajo.2005.05.021
   Bakri SJ, 2005, EYE, V19, P686, DOI 10.1038/sj.eye.6701602
   Bakri SJ, 2004, CAN J OPHTHALMOL, V39, P755, DOI 10.1016/S0008-4182(04)80069-3
   Bakri SJ, 2003, OPHTHALMIC SUR LA IM, V34, P386
   Bakri SJ, 2005, AM J OPHTHALMOL, V139, P290, DOI 10.1016/j.ajo.2004.09.038
   Bandello F, 2004, GRAEF ARCH CLIN EXP, V242, P1024, DOI 10.1007/s00417-004-0911-1
   BARDAK Y, 2005, EYE
   Bashshur ZF, 2004, ARCH OPHTHALMOL-CHIC, V122, P1137, DOI 10.1001/archopht.122.8.1137
   BECKER B, 1966, ARCH OPHTHALMOL-CHIC, V76, P477
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   Benz MS, 2003, ARCH OPHTHALMOL-CHIC, V121, P271
   BLUMENKRANZ MS, 1984, ARCH OPHTHALMOL-CHIC, V102, P598, DOI 10.1001/archopht.1984.01040030470029
   Bonanomi Maria Teresa Brizzi Chizzotti, 2005, Clinics, V60, P347, DOI 10.1590/S1807-59322005000400014
   Boscia F, 2005, EUR J OPHTHALMOL, V15, P513, DOI 10.1177/112067210501500418
   Boscia F, 2005, EUR J OPHTHALMOL, V15, P89, DOI 10.1177/112067210501500114
   Bouzas EA, 2002, SURV OPHTHALMOL, V47, P431, DOI 10.1016/S0039-6257(02)00338-7
   Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801
   Bucher RS, 2005, RETINA-J RET VIT DIS, V25, P269, DOI 10.1097/00006982-200504000-00003
   Bucher RS, 2005, ARCH OPHTHALMOL-CHIC, V123, P649, DOI 10.1001/archopht.123.5.649
   Burk SE, 2003, J CATARACT REFR SURG, V29, P645, DOI 10.1016/S0886-3350(03)00016-6
   Bynoe LA, 2003, AM J OPHTHALMOL, V135, P382, DOI 10.1016/S0002-9394(02)02030-5
   Cardillo JA, 2005, OPHTHALMOLOGY, V112, P1557, DOI 10.1016/j.ophtha.2005.03.023
   Carroll LA, 2002, DERMATOL SURG, V28, P704, DOI 10.1046/j.1524-4725.2002.02012.x
   Cekic O, 2005, RETINA-J RET VIT DIS, V25, P851
   Cekic O, 2005, RETINA-J RET VIT DIS, V25, P846, DOI 10.1097/00006982-200510000-00005
   Cekic O, 2005, AM J OPHTHALMOL, V139, P993, DOI 10.1016/j.ajo.2005.01.022
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chan CKM, 2005, EYE, V19, P625, DOI 10.1038/sj.eye.6701585
   Chan WM, 2005, AM J OPHTHALMOL, V139, P1116, DOI 10.1016/j.ajo.2004.11.055
   CHANDLER DB, 1987, GRAEF ARCH CLIN EXP, V225, P259, DOI 10.1007/BF02150144
   Chen SDM, 2005, RETINA-J RET VIT DIS, V25, P655, DOI 10.1097/00006982-200507000-00018
   Chen SDM, 2004, BRIT J OPHTHALMOL, V88, P843, DOI 10.1136/bjo.2003.033589
   Chen SDM, 2004, BRIT J OPHTHALMOL, V88, P154, DOI 10.1136/bjo.88.1.154
   Chen TY, 2006, EYE, V20, P423, DOI 10.1038/sj.eye.6701892
   Chieh JJ, 2005, RETINA-J RET VIT DIS, V25, P828, DOI 10.1097/00006982-200510000-00002
   Chiu Yu-Te, 2005, Kaohsiung Journal of Medical Sciences, V21, P466
   Ciardella AP, 2004, BRIT J OPHTHALMOL, V88, P1131, DOI 10.1136/bjo.2004.041707
   Ciulla TA, 2003, BRIT J OPHTHALMOL, V87, P1032, DOI 10.1136/bjo.87.8.1032
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   COATS ML, 1992, RETINA-J RET VIT DIS, V12, P46, DOI 10.1097/00006982-199212010-00010
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   Dal Canto AJ, 2005, OPHTHALMOLOGY, V112, P1092, DOI 10.1016/j.ophtha.2005.01.033
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DASBHAUMIK RG, 2005, EYE
   Deckers V, 2005, Bull Soc Belge Ophtalmol, P69
   Degenring RF, 2005, ACTA OPHTHALMOL SCAN, V83, P621, DOI 10.1111/j.1600-0420.2005.00506.x
   Degenring RF, 2004, AM J OPHTHALMOL, V137, P1142, DOI 10.1016/j.ajo.2004.01.008
   Degenring RF, 2004, OPHTHALMOLOGE, V101, P251, DOI 10.1007/s00347-003-0862-7
   Degenring RF, 2003, ACTA OPHTHALMOL SCAN, V81, P399, DOI 10.1034/j.1600-0420.2003.00084.x
   Degenring RF, 2003, BRIT J OPHTHALMOL, V87, P361, DOI 10.1136/bjo.87.3.361
   Detry-Morel M, 2004, Bull Soc Belge Ophtalmol, P45
   Enaida H, 2003, AM J OPHTHALMOL, V135, P243, DOI 10.1016/S0002-9394(02)01917-7
   Er H, 2005, OPHTHALMOLOGICA, V219, P394, DOI 10.1159/000088385
   Ferrari TM, 2004, EUR J OPHTHALMOL, V14, P321, DOI 10.1177/112067210401400407
   Flynn HW, 2005, ARCH OPHTHALMOL-CHIC, V123, P258, DOI 10.1001/archopht.123.2.258
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Furino C, 2003, RETINA-J RET VIT DIS, V23, P771, DOI 10.1097/00006982-200312000-00004
   Gao H, 2004, VISION RES, V44, P349, DOI 10.1016/j.visres.2003.09.027
   Garay-Aramburu G, 2005, Arch Soc Esp Oftalmol, V80, P615
   Garcia-Arumi J, 2005, BRIT J OPHTHALMOL, V89, P1112, DOI 10.1136/bjo.2005.067744
   Gharbiya M, 2005, EYE, V19, P818, DOI 10.1038/sj.eye.6701658
   GIBRAN SK, 2005, EYE
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   Gupta R, 2005, EYE, V19, P590, DOI 10.1038/sj.eye.6701529
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Hayashi K, 2005, AM J OPHTHALMOL, V139, P972, DOI 10.1016/j.ajo.2004.12.087
   Hayreh SS, 2003, OPHTHALMOLOGICA, V217, P167, DOI 10.1159/000068980
   HAYREH SS, 1990, GRAEF ARCH CLIN EXP, V228, P281, DOI 10.1007/BF00920049
   Heras-Mulero H, 2005, Arch Soc Esp Oftalmol, V80, P417
   Hernaez-Ortega MC, 2004, OPHTHAL SURG LAS IM, V35, P350, DOI 10.3928/1542-8877-20040701-18
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   Hogan A, 2005, BRIT J OPHTHALMOL, V89, P1109, DOI 10.1136/bjo.2004.063024
   Imasawa M, 2005, ACTA OPHTHALMOL SCAN, V83, P132, DOI 10.1111/j.1600-0420.2005.00379.x
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   Inoue Makoto, 2004, Nippon Ganka Gakkai Zasshi, V108, P92
   Ip Michael, 2003, Semin Ophthalmol, V18, P67, DOI 10.1080/08820530390897873
   Ip MS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1131, DOI 10.1001/archopht.122.8.1131
   Ip MS, 2002, ARCH OPHTHALMOL-CHIC, V120, P1217
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Islam MS, 2005, EYE, V19, P1325, DOI 10.1038/sj.eye.6701766
   Jaissle GB, 2004, OPHTHALMOLOGE, V101, P121, DOI 10.1007/s00347-003-0975-z
   JARIN RR, 2005, EYE
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P729, DOI 10.1001/archopht.121.5.729
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Jonas JB, 2006, AM J OPHTHALMOL, V141, P579, DOI 10.1016/j.ajo.2005.10.007
   Jonas JB, 2006, CORNEA, V25, P240, DOI 10.1097/01.ico.0000176614.73332.58
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P751, DOI 10.1177/112067210501500615
   Jonas JB, 2005, ARCH OPHTHALMOL-CHIC, V123, P1338, DOI 10.1001/archopht.123.10.1338
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P329, DOI 10.1177/112067210501500303
   Jonas JB, 2005, BRIT J OPHTHALMOL, V89, P386, DOI 10.1136/bjo.2004.054247
   Jonas JB, 2005, BRIT J OPHTHALMOL, V89, P321, DOI 10.1136/bjo.2004.046391
   Jonas JB, 2005, BRIT J OPHTHALMOL, V89, P122, DOI 10.1136/bjo.2004.050575
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2005, EYE, V19, P65, DOI 10.1038/sj.eye.6701395
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P1054, DOI 10.1016/j.ajo.2004.06.041
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P970, DOI 10.1016/j.ajo.2004.07.007
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P158, DOI 10.1016/j.ajo.2004.02.025
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P839, DOI 10.1136/bjo.2003.034140
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P587, DOI 10.1136/bjo.2003.028688
   Jonas JB, 2004, EYE, V18, P361, DOI 10.1038/sj.eye.6700654
   Jonas JB, 2004, GRAEF ARCH CLIN EXP, V242, P184, DOI 10.1007/s00417-003-0841-3
   Jonas JB, 2004, AM J OPHTHALMOL, V137, P367, DOI 10.1016/S0002-9394(03)00899-7
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, ACTA OPHTHALMOL SCAN, V81, P663, DOI 10.1046/j.1395-3907.2003.0108.x
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1663, DOI 10.1001/archopht.121.11.1663-b
   Jonas JB, 2003, GRAEF ARCH CLIN EXP, V241, P779, DOI 10.1007/s00417-003-0719-4
   Jonas JB, 2003, ACTA OPHTHALMOL SCAN, V81, P540, DOI 10.1034/j.1600-0420.2003.00130.x
   Jonas JB, 2003, EUR J OPHTHALMOL, V13, P468, DOI 10.1177/112067210301300508
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2003, EUR J OPHTHALMOL, V13, P575, DOI 10.1177/112067210301300611
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1066, DOI 10.1136/bjo.86.9.1066
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1450, DOI 10.1136/bjo.86.12.1450-a
   Jonas JB, 2002, J CATARACT REFR SURG, V28, P2040, DOI 10.1016/S0886-3350(02)01295-6
   Jonas JB, 2002, GRAEF ARCH CLIN EXP, V240, P782, DOI 10.1007/s00417-002-0529-0
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Jonas JB, 2001, GRAEF ARCH CLIN EXP, V239, P464, DOI 10.1007/s004170100293
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   JONAS JB, 2006, ACTA OPHTHALMOL
   JONAS JB, 2006, EYE              JAN
   JONAS JB, 2006, IN PRESS INDIAN J OP
   JONAS JB, 2006, IN PRESS OPHTHALMIC
   Jonas Jost B, 2002, Graefes Arch Clin Exp Ophthalmol, V240, P873
   Kaiser PK, 2005, AM J OPHTHALMOL, V139, P1095, DOI 10.1016/j.ajo.2005.03.035
   Karacorlu M, 2005, RETINA-J RET VIT DIS, V25, P856, DOI 10.1097/00006982-200510000-00007
   Karacorlu M, 2005, GRAEF ARCH CLIN EXP, V243, P754, DOI 10.1007/s00417-005-1133-x
   Karacorlu M, 2005, EYE, V19, P382, DOI 10.1038/sj.eye.6701512
   Karacorlu M, 2004, AM J OPHTHALMOL, V138, P289, DOI 10.1016/j.ajo.2004.02.053
   Karacorlu M, 2004, RETINA-J RET VIT DIS, V24, P324, DOI 10.1097/00006982-200404000-00030
   Karacorlu M, 2003, ACTA OPHTHALMOL SCAN, V81, P648, DOI 10.1046/j.1395-3907.2003.0146.x
   Karacorlu Murat, 2004, International Ophthalmology, V25, P113, DOI 10.1023/B:INTE.0000031740.85124.78
   Kaushik S, 2004, AM J OPHTHALMOL, V137, P758, DOI 10.1016/j.ajo.2003.09.039
   Kaynak S, 2006, J CATARACT REFR SURG, V32, P56, DOI 10.1016/j.jcrs.2005.10.028
   Khairallah M, 2005, RETINA-J RET VIT DIS, V25, P835, DOI 10.1097/00006982-200510000-00003
   Kimura H, 2004, AM J OPHTHALMOL, V137, P172, DOI 10.1016/S0002-9394(03)00782-7
   Klais CM, 2004, RETINA-J RET VIT DIS, V24, P459, DOI 10.1097/00006982-200406000-00022
   Kramer M, 2004, AM J OPHTHALMOL, V138, P666, DOI 10.1016/j.ajo.2004.04.064
   Kreissig I, 2006, OPHTHALMOLOGE, V103, P30, DOI 10.1007/s00347-005-1235-1
   Krepler K, 2005, ACTA OPHTHALMOL SCAN, V83, P600, DOI 10.1111/j.1600-0420.2005.00490.x
   Krepler K, 2005, GRAEF ARCH CLIN EXP, V243, P478, DOI 10.1007/s00417-004-1059-8
   Krepler K, 2005, ACTA OPHTHALMOL SCAN, V83, P71, DOI 10.1111/j.1600-0420.2005.00400.x
   Kyto JP, 2005, ACTA OPHTHALMOL SCAN, V83, P605, DOI 10.1111/j.1600-0420.2005.00477.x
   Ladjimi A, 2005, J FR OPHTALMOL, V28, P749, DOI 10.1016/S0181-5512(05)80988-X
   Lahey JM, 2004, BRIT J OPHTHALMOL, V88, P1355
   Lam DSC, 2005, EYE, V19, P885, DOI 10.1038/sj.eye.6701686
   Lam DSC, 2004, CLIN EXP OPHTHALMOL, V32, P569, DOI 10.1111/j.1442-9071.2004.00903.x
   Larsson J, 2005, ACTA OPHTHALMOL SCAN, V83, P618, DOI 10.1111/j.1600-0420.2005.00440.x
   Larsson J, 2005, CLIN EXP OPHTHALMOL, V33, P544, DOI 10.1111/j.1442-9071.2005.01082.x
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Lee H, 2005, RETINA-J RET VIT DIS, V25, P551, DOI 10.1097/00006982-200507000-00001
   Lee WF, 2004, J FORMOS MED ASSOC, V103, P806
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Machemer R, 1996, RETINA-J RET VIT DIS, V16, P166, DOI 10.1097/00006982-199616020-00017
   MACHEMER R, 1988, INVEST OPHTH VIS SCI, V29, P1771
   Macky TA, 2002, J MED CHEM, V45, P1122, DOI 10.1021/jm010511b
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Martinez JA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1658, DOI 10.1001/archopht.121.11.1658
   Marullo M, 2004, EUR J OPHTHALMOL, V14, P581, DOI 10.1177/112067210401400624
   Mason JO, 2004, RETINA-J RET VIT DIS, V24, P900, DOI 10.1097/00006982-200412000-00009
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Matsumoto H, 2003, RETINA-J RET VIT DIS, V23, P569, DOI 10.1097/00006982-200308000-00028
   MCCUEN BW, 1981, AM J OPHTHALMOL, V91, P785, DOI 10.1016/0002-9394(81)90013-1
   Mora P, 2005, CURR EYE RES, V30, P355, DOI 10.1080/02713680590934094
   Moshfeghi AA, 2004, AM J OPHTHALMOL, V138, P489, DOI 10.1016/j.ajo.2004.03.025
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Navajas EV, 2003, EYE, V17, P563, DOI 10.1038/sj.eye.6700457
   Negi AK, 2005, EYE, V19, P747, DOI 10.1038/sj.eye.6701636
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Nicolo M, 2005, EUR J OPHTHALMOL, V15, P415, DOI 10.1177/112067210501500318
   Oishi M, 2005, JPN J OPHTHALMOL, V49, P384, DOI 10.1007/s10384-004-0226-0
   Okubo A, 2005, GRAEF ARCH CLIN EXP, V243, P837, DOI 10.1007/s00417-005-1125-x
   Ozdemir H, 2005, AM J OPHTHALMOL, V140, P251, DOI 10.1016/j.ajo.2005.03.004
   Ozdemir H, 2005, GRAEF ARCH CLIN EXP, V243, P734, DOI 10.1007/s00417-004-1064-y
   Ozdemir H, 2005, ACTA OPHTHALMOL SCAN, V83, P248, DOI 10.1111/j.1600-0420.2005.00395.x
   Ozkiris A, 2004, DOC OPHTHALMOL, V109, P139, DOI 10.1007/s10633-004-2956-1
   Ozkiris A, 2005, CAN J OPHTHALMOL, V40, P63, DOI 10.1016/S0008-4182(05)80119-X
   Ozkiris A, 2005, EUR J OPHTHALMOL, V15, P96
   Ozkiris A, 2004, EUR J OPHTHALMOL, V14, P543
   OZKIRIS A, 2005, EYE
   Palmberg P, 2001, ARCH OPHTHALMOL-CHIC, V119, P897
   Park CH, 2003, AM J OPHTHALMOL, V136, P419, DOI 10.1016/S0002-9394(03)00228-9
   Park Hye Young, 2005, Korean J Ophthalmol, V19, P122
   Parke DW, 2003, AM J OPHTHALMOL, V136, P918, DOI 10.1016/j.ajo.2003.08.051
   Patelli F, 2005, RETINA-J RET VIT DIS, V25, P840, DOI 10.1097/00006982-200510000-00004
   Pathengay A, 2005, EYE, V19, P711, DOI 10.1038/sj.eye.6701612
   Pathengay Avinash, 2005, Indian J Ophthalmol, V53, P77
   Peiretti E, 2005, RETINA-J RET VIT DIS, V25, P377, DOI 10.1097/00006982-200504000-00024
   PENFOLD L, 2002, BR J OPHTHALMOL, V86, P527
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2002, BRIT J OPHTHALMOL, V86, P600, DOI 10.1136/bjo.86.6.600
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   POTTER MJ, 2005, GRAEFES ARCH CLIN EX, P1
   Quoc EB, 2002, J FR OPHTALMOL, V25, P1048
   RAKIC JM, 2003, B SOC BELGE OPHTALMO, V288, P43
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rechtman E, 2003, AM J OPHTHALMOL, V136, P739, DOI 10.1016/S0002-9394(03)00389-1
   Reinhard T, 2002, TRANSPLANT INT, V15, P81, DOI 10.1007/s00147-002-0381-5
   Rodriguez ML, 2003, EUR J OPHTHALMOL, V13, P292, DOI 10.1177/112067210301300309
   Rodriguez-Coleman H, 2004, ARCH OPHTHALMOL-CHIC, V122, P1085, DOI 10.1001/archopht.122.7.1085
   RODRIGUEZCOLEMA.H, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Sakamoto T, 2002, GRAEF ARCH CLIN EXP, V240, P423, DOI 10.1007/s00417-002-0454-2
   Salinas-Alamán A, 2005, Arch Soc Esp Oftalmol, V80, P463
   Sallum JMF, 2003, ADV EXP MED BIOL, V533, P79
   SANCHEZ JMB, 2001, ARCH SOC ESP OFTALMO, V76, P661
   Saraiva VS, 2003, OPHTHALMIC SUR LA IM, V34, P398
   Satofuka S, 2005, RETINA-J RET VIT DIS, V25, P672, DOI 10.1097/00006982-200507000-00024
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   Scott IU, 2005, ARCH OPHTHALMOL-CHIC, V123, P581, DOI 10.1001/archopht.123.4.581
   Scott IU, 2003, AM J OPHTHALMOL, V136, P737, DOI 10.1016/S0002-9394(03)00266-6
   Shah A, 2005, CLIN EXP OPHTHALMOL, V33, P442, DOI 10.1111/j.1442-9071.2005.01048.x
   Shields CL, 2005, RETINA-J RET VIT DIS, V25, P868, DOI 10.1097/00006982-200510000-00009
   Singh IP, 2004, AM J OPHTHALMOL, V138, P286, DOI 10.1016/j.ajo.2004.03.001
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Sonoda KH, 2003, BRIT J OPHTHALMOL, V87, P1010, DOI 10.1136/bjo.87.8.1010
   Sorensen TL, 2005, ACTA OPHTHALMOL SCAN, V83, P67, DOI 10.1111/j.1600-0420.2004.00336.x
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P290, DOI 10.1097/00006982-200504000-00007
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P999, DOI 10.1136/bjo.2004.062596
   Spandau UHM, 2005, AM J OPHTHALMOL, V139, P712, DOI 10.1016/j.ajo.2004.09.059
   Sutter FKP, 2004, OPHTHALMOLOGY, V111, P2044, DOI 10.1016/j.ophtha.2004.05.025
   Sutter FKP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1491, DOI 10.1001/archopht.121.10.1491
   Sutter FKP, 2003, BRIT J OPHTHALMOL, V87, P972, DOI 10.1136/bjo.87.8.972
   Takeuchi M, 2003, AM J OPHTHALMOL, V136, P1174, DOI 10.1016/S0002-9394(03)00674-3
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Tewari HK, 2005, EUR J OPHTHALMOL, V15, P619, DOI 10.1177/112067210501500513
   Tokuda K, 2004, ACTA OPHTHALMOL SCAN, V82, P189, DOI 10.1111/j.1600-0420.2004.00224.x
   Tsujikawa A, 2005, RETINA-J RET VIT DIS, V25, P861, DOI 10.1097/00006982-200510000-00008
   Tunc M, 2005, OPHTHALMOLOGY, V112, P1086, DOI 10.1016/j.ophtha.2004.12.039
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
   Van de Moere Ann, 2005, Ophthalmology, V112, P1896, DOI 10.1016/j.ophtha.2005.06.018
   Wakabayashi T, 2004, RETINA-J RET VIT DIS, V24, P964, DOI 10.1097/00006982-200412000-00020
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   Westfall AC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1075, DOI 10.1001/archopht.123.8.1075
   Williamson TH, 2005, AM J OPHTHALMOL, V139, P860, DOI 10.1016/j.ajo.2005.01.001
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Yamakiri K, 2004, AM J OPHTHALMOL, V138, P650, DOI 10.1016/j.ajo.2004.05.033
   Yamamoto N, 2004, OPHTHALMOLOGICA, V218, P297, DOI 10.1159/000079470
   Yamamoto N, 2004, OPHTHALMOLOGICA, V218, P248, DOI 10.1159/000078615
   Yepremyan M, 2005, OPHTHAL SURG LAS IM, V36, P30
   Yeung CK, 2004, JPN J OPHTHALMOL, V48, P236, DOI 10.1007/s10384-003-0053-8
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
   Zacks DN, 2005, RETINA-J RET VIT DIS, V25, P135, DOI 10.1097/00006982-200502000-00003
NR 284
TC 111
Z9 118
U1 1
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2006
VL 38
IS 4
BP 218
EP 245
DI 10.1159/000093796
PG 28
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 073SA
UT WOS:000239761700008
PM 16763379
DA 2022-11-30
ER

PT J
AU Cupido, AJ
   Reeskamp, LF
   Hingorani, AD
   Finan, C
   Asselbergs, FW
   Hovingh, GK
   Schmidt, AF
AF Cupido, Arjen J.
   Reeskamp, Laurens F.
   Hingorani, Aroon D.
   Finan, Chris
   Asselbergs, Folkert W.
   Hovingh, G. Kees
   Schmidt, Amand F.
TI Joint Genetic Inhibition of PCSK9 and CETP and the Association With
   Coronary Artery Disease A Factorial Mendelian Randomization Study
SO JAMA CARDIOLOGY
LA English
DT Article
ID ESTER TRANSFER PROTEIN; HIGH-RISK; METAANALYSIS; CHOLESTEROL; TARGET;
   HEART
AB IMPORTANCE Cholesteryl ester transfer protein inhibition (CETP) has been shown to increase levels of high-density lipoprotein cholesterol (HDL-C) and reduce levels of low-density lipoprotein cholesterol (LDL-C). Current LDL-C target attainment is low, and novel phase 3 trials are underway to investigate whether CETP inhibitors result in reduction of cardiovascular disease risk in high-risk patients who may be treated with PCSK9-inhibiting agents.
   OBJECTIVE To explore the associations of combined reduction of CETP and PCSK9 concentrations with risk of coronary artery disease (CAD) and other clinical and safety outcomes.
   DESIGN, SETTING, AND PARTICIPANTS Two-sample 2 x 2 factorial Mendelian randomization study in a general population sample that includes data for UK Biobank participants of European ancestry.
   EXPOSURES Separate genetic scores were constructed for CETP and PCSK9 plasma protein concentrations, which were combined to determine the associations of combined genetically reduced CETP and PCSK9 concentrations with disease.
   MAIN OUTCOMES AND MEASURES Blood lipid and lipoprotein concentrations, blood pressure, CAD, age-related macular degeneration, type 2 diabetes, any stroke and ischemic stroke, Alzheimer disease, vascular dementia, heart failure, atrial fibrillation, chronic kidney disease, asthma, and multiple sclerosis.
   RESULTS Data for 425 354 UKB participants were included; the median (IQR) age was 59 years (51-64), and 229 399 (53.9%) were female. The associations of lower CETP and lower PCSK9 concentrations with CAD are similar when scaled per 10-mg/dL reduction in LDL-C concentrations (CETP: odds ratio [OR], 0.74; 95% CI, 0.67 to 0.81; PCSK9: OR, 0.75; 95% CI, 0.71to 0.79). Combined exposure to lower CETP and PCSK9 concentrations was associated with an additive magnitude with lipids and all outcomes, and we did not observe any nonadditive interactions, most notably for LDL-C (CETP: effect size, -1.11 mg/dL; 95% CI, -1.40 to -0.82; PCSK9: effect size, -2.13 mg/dL; 95% CI, -2.43 to -1.84; combined: effect size, -3.47 mg/dL; 95% CI, -3.76 to -3.18; P = .34 for interaction) and CAD (CETP: OR, 0.96; 95% CI, 0.94 to 1.00; PCSK9: OR, 0.94; 95% CI, 0.91 to 0.97; combined: OR, 0.90; 95% CI, 0.87 to 0.93; P = .83 for interaction). In addition, when corrected for multiple testing, lower CETP concentrations were associated with increased age-related macular degeneration (OR, 1.11; 95% CI, 1.04 to 1.19).
   CONCLUSIONS AND RELEVANCE Our results suggest that joint inhibition of CETP and PCSK9 has additive effects on lipid traits and disease risk, including a lower risk of CAD. Further research may explore whether a combination of CETP- and PCSK9-related therapeutics can benefit high-risk patients who are unable to reach treatment targets with existing options.
C1 [Cupido, Arjen J.; Reeskamp, Laurens F.; Hovingh, G. Kees] Univ Amsterdam, Dept Vasc Med, Amsterdam UMC Locat, Amsterdam, Netherlands.
   [Cupido, Arjen J.; Reeskamp, Laurens F.; Hovingh, G. Kees] Amsterdam Cardiovasc Sci Atherosclerosis & Ischem, Amsterdam, Netherlands.
   [Cupido, Arjen J.; Finan, Chris; Asselbergs, Folkert W.; Schmidt, Amand F.] Univ Utrecht, Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, Utrecht, Netherlands.
   [Cupido, Arjen J.] Univ Calif Los Angeles, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA.
   [Hingorani, Aroon D.; Finan, Chris; Asselbergs, Folkert W.; Schmidt, Amand F.] UCL, Fac Populat Hlth Sci, Inst Cardiovasc Sci, London, England.
   [Hingorani, Aroon D.; Finan, Chris; Asselbergs, Folkert W.; Schmidt, Amand F.] UCL, Hlth Data Res UK, London, England.
   [Hingorani, Aroon D.; Finan, Chris; Asselbergs, Folkert W.; Schmidt, Amand F.] UCL, Inst Hlth Informat, London, England.
   [Hingorani, Aroon D.; Finan, Chris; Schmidt, Amand F.] UCL British Heart Fdn Res Accelerator, London, England.
C3 University of Amsterdam; Utrecht University; Utrecht University Medical
   Center; University of California System; University of California Los
   Angeles; University of London; University College London; University of
   London; University College London; University of London; University
   College London
RP Cupido, AJ (通讯作者)，Univ Amsterdam, Med Ctr, Locat Univ Amsterdam, Room MO-118,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM a.j.cupido@amsterdamumc.nl
RI ; Schmidt, Amand Floriaan/G-6602-2017
OI Asselbergs, Folkert/0000-0002-1692-8669; Finan,
   Chris/0000-0002-3319-1937; Schmidt, Amand Floriaan/0000-0003-1327-0424;
   Hingorani, Aroon/0000-0001-8365-0081
CR ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485
   Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5
   Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117
   Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
   Black DM, 2021, J CARDIOVASC PHARM, V78, P496, DOI 10.1097/FJC.0000000000001093
   Blauw LL, 2019, EUR J HUM GENET, V27, P422, DOI 10.1038/s41431-018-0301-5
   Bruckert E, 2020, ADV THER, V37, P1724, DOI 10.1007/s12325-020-01285-2
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Chapman MJ, 2010, EUR HEART J, V31, P149, DOI 10.1093/eurheartj/ehp399
   Christen T, 2018, J CLIN LIPIDOL, V12, P137, DOI 10.1016/j.jacl.2017.10.023
   ClinicalTrials.gov, RAND STUD EV EFF OB
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Davidson M, 2013, J LIPID RES, V54, P467, DOI 10.1194/jlr.M032615
   Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601
   de Carvalho LSF, 2018, DIABETES CARE, V41, P364, DOI 10.2337/dc17-1464
   Ference BA, 2019, JAMA-J AM MED ASSOC, V322, P1381, DOI 10.1001/jama.2019.14120
   Ference BA, 2017, JAMA-J AM MED ASSOC, V318, P947, DOI 10.1001/jama.2017.11467
   Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144
   Ference BA, 2016, NEW ENGL J MED, V375, P2144, DOI 10.1056/NEJMoa1604304
   Hollstein T, 2021, AM J CARDIOVASC DRUG, V21, P83, DOI 10.1007/s40256-020-00411-3
   Holmes MV, 2019, NAT REV CARDIOL, V16, P197, DOI 10.1038/s41569-019-0157-6
   HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444
   Kettunen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11122
   Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034
   Mach F, 2019, ATHEROSCLEROSIS, V290, P140, DOI [10.1016/j.atherosclerosis.2019.08.014, 10.1093/eurheartj/ehz455]
   Menon V, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2019-000943
   National Institutes of Health, ALL US RES PROGR OV
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Nordestgaard LT, 2022, JAMA CARDIOL, V7, P55, DOI 10.1001/jamacardio.2021.3728
   Pott J, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.117.001992
   Prins BP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10812-1
   R Core Team, 2021, R LANG ENV STAT COMP
   Ray KK, 2021, EUR J PREV CARDIOL, V28, P1279, DOI 10.1093/eurjpc/zwaa047
   Rees JMB, 2020, INT J EPIDEMIOL, V49, P1147, DOI 10.1093/ije/dyz161
   Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6
   Schmidt AF, 2016, INT J EPIDEMIOL, V45, P1975, DOI 10.1093/ije/dyw123
   Schmidt AF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25703-3
   Schmidt AF, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011748.pub3
   Schmidt AF, 2017, LANCET DIABETES ENDO, V5, P97, DOI 10.1016/S2213-8587(16)30396-5
   Schwartz GG, 2020, DIABETES CARE, V43, P1077, DOI 10.2337/dc19-2204
   Swerdlow DI, 2012, LANCET, V379, P1214, DOI 10.1016/S0140-6736(12)60110-X
   Vosa U, 2021, NAT GENET, V53, P1300, DOI 10.1038/s41588-021-00913-z
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
   Zafrir B, 2021, J CLIN LIPIDOL, V15, P202, DOI 10.1016/j.jacl.2020.11.004
NR 44
TC 2
Z9 2
U1 5
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2380-6583
EI 2380-6591
J9 JAMA CARDIOL
JI JAMA Cardiol.
PD SEP
PY 2022
VL 7
IS 9
BP 955
EP 964
DI 10.1001/jamacardio.2022.2333
EA AUG 2022
PG 10
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 4N8KP
UT WOS:000836398400003
PM 35921096
DA 2022-11-30
ER

PT J
AU Kutty, RK
   Nagineni, CN
   Samuel, W
   Vijayasarathy, C
   Jaworski, C
   Duncan, T
   Cameron, JE
   Flemington, EK
   Hooks, JJ
   Redmond, TM
AF Kutty, R. Krishnan
   Nagineni, Chandrasekharam N.
   Samuel, William
   Vijayasarathy, Camasamudram
   Jaworski, Cynthia
   Duncan, Todd
   Cameron, Jennifer E.
   Flemington, Erik K.
   Hooks, John J.
   Redmond, T. Michael
TI Differential regulation of microRNA-146a and microRNA-146b-5p in human
   retinal pigment epithelial cells by interleukin-1 beta, tumor necrosis
   factor-alpha, and interferon-gamma
SO MOLECULAR VISION
LA English
DT Article
ID NF-KAPPA-B; MACULAR DEGENERATION; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION;
   INFLAMMATORY MEDIATORS; SIGNALING PROTEINS; SYNOVIAL TISSUE; RPE CELLS;
   MIR-146A; PATHWAY
AB Purpose: The inflammatory response of the retinal pigment epithelium (RPE) is implicated in the pathogenesis of age-related macular degeneration. The microRNAs miR-146a and miR-146b-5p can regulate the inflammatory process by attenuating cytokine signaling via the nuclear factor-kappa B pathway. The aim of the present study is to investigate the expression of miR-146a and miR-146b-5p in human RPE cells and their response to proinflammatory cytokines.
   Methods: Confluent cultures of RPE cells established from adult human donor eyes were treated with the proinflammatory cytokines interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-1 beta. The expression of microRNAs was analyzed by real-time PCR using total RNA fraction. The retinal pigment epithelial cell line ARPE-19 was employed to analyze the promoter activity of the genes encoding miR-146a and miR-146b-5p. STAT1-binding activity of oligonucleotides was analyzed by electrophoretic mobility shift assay. ARPE-19 cells were transiently transfected with miR-146a and miR-146b-5p mimics for the analysis of IRAK1 expression by western immunoblotting.
   Results: Real-time PCR analysis showed that miR-146a and 146b-5p are expressed in RPE cells. The cells responded to proinflammatory cytokines (IFN-gamma + TNF-alpha + IL-1 beta) by highly increasing the expression of both miR-146a and miR-146b-5p. This was associated with an increase in the expression of transcripts for CCL2, CCL5, CXCL9, CXCL10, and IL-6, and a decrease in that for HMOX1. The miR-146a induction was more dependent on IL-1 beta, since its omission from the cytokine mix resulted in a greatly reduced response. Similarly, the induction of miR-146b-5p was more dependent on IFN-gamma, since its omission from the cytokine mix minimized the effect. In addition, the increase in MIR146B promoter activity by the cytokine mix was effectively blocked by JAK inhibitor 1, a known inhibitor of the JAK/STAT signaling pathway. The expression of IRAK1 protein was decreased when ARPE-19 cells were transiently transfected with either miR-146a mimic or miR-146b-5p mimic.
   Conclusions: Our results clearly show that both miR-146a and miR-146b-5p are expressed in human RPE cells in culture and their expression is highly induced by proinflammatory cytokines (IFN-gamma + TNF-alpha + IL-1 beta). The induction of miR-146a showed a dependency on IL-1 beta, while that of miR-146b-5p on IFN-gamma. Our results show for the first time that miR-146b-5p expression is regulated by IFN-gamma, potentially via the JAK/STAT pathway. These two microRNAs could play a role in inflammatory processes underlying age-related macular degeneration or other retinal degenerative diseases through their ability to negatively regulate the nuclear factor-kappa B pathway by targeting the expression of IRAK1.
C1 [Kutty, R. Krishnan; Samuel, William; Jaworski, Cynthia; Duncan, Todd; Redmond, T. Michael] NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Nagineni, Chandrasekharam N.; Hooks, John J.] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Vijayasarathy, Camasamudram] Natl Inst Deafness & Other Commun Disorders, NIH, Bethesda, MD USA.
   [Cameron, Jennifer E.; Flemington, Erik K.] Tulane Univ, Tulane Canc Ctr, New Orleans, LA 70118 USA.
   [Cameron, Jennifer E.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA.
   [Cameron, Jennifer E.] Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Institute on Deafness & Other Communication Disorders (NIDCD); Tulane
   University; Louisiana State University System; Louisiana State
   University Health Sciences Center New Orleans; Louisiana State
   University System; Louisiana State University Health Sciences Center New
   Orleans
RP Kutty, RK (通讯作者)，NEI, Lab Retinal Cell & Mol Biol, NIH, Bldg 6,Room 112,6 Ctr Dr,MSC 0608, Bethesda, MD 20892 USA.
EM kuttyk@nei.nih.gov
OI Cameron, Jennifer/0000-0002-5785-2410; Redmond, T.
   Michael/0000-0002-1813-5291
FU Intramural Research Program of the National Eye Institute, NIH
   [Z01EY000444]; NATIONAL EYE INSTITUTE [Z01EY000444, ZIAEY000444] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASES [R01AI101046] Funding Source: NIH RePORTER
FX This study was supported by the Intramural Research Program of the
   National Eye Institute, NIH (Z01EY000444).
CR Adijanto J, 2012, J BIOL CHEM, V287, P20491, DOI 10.1074/jbc.M112.354761
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042
   Boldin MP, 2012, IMMUNOL REV, V246, P205, DOI 10.1111/j.1600-065X.2011.01089.x
   Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823
   Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07
   Cameron JE, 2008, VIROLOGY, V382, P257, DOI 10.1016/j.virol.2008.09.018
   Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200
   ELNER VM, 1990, AM J PATHOL, V136, P745
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HOOKS JJ, 1988, INVEST OPHTH VIS SCI, V29, P1444
   Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707
   Kutty RK, 2010, BIOCHEM BIOPH RES CO, V402, P390, DOI 10.1016/j.bbrc.2010.10.042
   Kutty RK, 2010, MOL VIS, V16, P1475
   Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nagineni CN, 2010, BIOCHEM BIOPH RES CO, V391, P287, DOI 10.1016/j.bbrc.2009.11.051
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Nagineni CN, 1996, CYTOKINE, V8, P622, DOI 10.1006/cyto.1996.0083
   Nakasa T, 2008, ARTHRITIS RHEUM-US, V58, P1284, DOI 10.1002/art.23429
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106
   Okada AA, 1998, OCUL IMMUNOL INFLAMM, V6, P111, DOI 10.1076/ocii.6.2.111.4046
   Pauley KM, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2493
   Perry MM, 2008, J IMMUNOL, V180, P5689, DOI 10.4049/jimmunol.180.8.5689
   Perry MM, 2009, FEBS LETT, V583, P3349, DOI 10.1016/j.febslet.2009.09.038
   Rom S, 2010, FASEB J, V24, P2292, DOI 10.1096/fj.09-143503
   Samuel W, 2006, J CELL PHYSIOL, V209, P854, DOI 10.1002/jcp.20774
   Schmid CD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011425
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Sonkoly E, 2008, CLIN EXP DERMATOL, V33, P312, DOI 10.1111/j.1365-2230.2008.02804.x
   Stanczyk J, 2008, ARTHRITIS RHEUM, V58, P1001, DOI 10.1002/art.23386
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tang YJ, 2009, ARTHRITIS RHEUM-US, V60, P1065, DOI 10.1002/art.24436
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856
   Wang XC, 1999, INVEST OPHTH VIS SCI, V40, P477
   Xu SB, 2009, PROG RETIN EYE RES, V28, P87, DOI 10.1016/j.preteyeres.2008.11.003
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
NR 48
TC 79
Z9 81
U1 0
U2 11
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 3
PY 2013
VL 19
BP 737
EP 750
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 118BM
UT WOS:000316997400001
PM 23592910
DA 2022-11-30
ER

PT J
AU Javaheri, M
   Hill, L
   Ghanekar, A
   Stoilov, I
AF Javaheri, Michael
   Hill, Lauren
   Ghanekar, Avanti
   Stoilov, Ivaylo
TI Changes in Treatment-Naive Pigment Epithelial Detachments Associated
   With the Initial Anti-Vascular Endothelial Growth Factor Injection A
   Post Hoc Analysis From the HARBOR Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID 2.0 MG RANIBIZUMAB; CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION;
   EFFICACY; SAFETY
AB IMPORTANCE: Pigment epithelial detachment (PED) is a feature commonly associated with neovascular age-related macular degeneration (nAMD) and may be perceived as being difficult to treat. Therefore, this investigation explored changes in PEDs and visual acuity outcomes following an initial anti-vascular endothelial growth factor (VEGF) injection and identified factors associated with positive response.
   OBJECTIVE: To describe changes in treatment-naive pigment epithelial detachments associated with the initial anti-VEGF injection.
   DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of patients from the Phase III, Double-masked, Multicenter, Randomized, Active Treatment-controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (HARBOR) trial (NCT00891735) with PED at baseline. The HARBOR trial was a phase 3, randomized, multicenter, double-masked, active treatment-controlled trial. Participants included treatment-naive patients with subfoveal nAMD and PEDs at baseline; intervention arms were pooled for analysis (n = 586). The HARBOR study began in July 2009 and was completed in August 2012, and the post hoc analyses were conducted between October 2016 and May 2018.
   INTERVENTIONS: Intravitreal injections of ranibizumab, 0.5 mg and 2.0 mg, administered monthly or on an as-needed basis over 24 months.
   MAIN OUTCOMES AND MEASURES: Post hoc analyses of flattened PED frequency at month 1, univariate and multivariable analysis of patient and ocular characteristics at baseline and PED status at month 1, and total number of ranibizumab injections received stratified by PED status at month 1.
   RESULTS: A total of 35.5% of patients (208 of 586) with PED at baseline achieved a flattened PED after a single ranibizumab injection. An additional 17.3% subsequently achieved a flattened PED at month 2. Univariate analysis identified an association between older age, lower PED height, and lower subretinal fluid thickness with PED flattening after a single injection. Multivariable analysis identified PED height as a factor associated with this anatomical outcome. Best-corrected visual acuity scores were not superior based on PED flattening at month 1. On average, patients in the as-needed arm who achieved a flattened PED after a single ranibizumab injection required fewer injections by month 24 vs patients whose PED remained present at month 1 (11.0 vs 14.2; difference, 3.3; 95% CI, 1.9-4.6; P < .001).
   CONCLUSIONS AND RELEVANCE: In this group of treatment-naive patients with PED from nAMD, after the initial ranibizumab injection approximately one-third and after the second injection approximately one-half had flattened PEDS, although visual outcomes were not superior among those that did vs did not have flattening. The findings suggest flattening may serve as a marker for less intensive as-needed injection frequencies.
C1 [Javaheri, Michael] Retina Specialists Beverly Hills, 9735 Wilshire Blvd,219, Beverly Hills, CA 90210 USA.
   [Hill, Lauren; Ghanekar, Avanti; Stoilov, Ivaylo] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Javaheri, M (通讯作者)，Retina Specialists Beverly Hills, 9735 Wilshire Blvd,219, Beverly Hills, CA 90210 USA.
EM mikejavaheri@gmail.com
FU Genentech Inc, South San Francisco, California
FX Funding for the study was provided by Genentech Inc, South San
   Francisco, California.
CR [Anonymous], 2019, AGE RELATED MACULAR
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Khanani AM, 2018, RETINA-J RET VIT DIS, V38, P2103, DOI 10.1097/IAE.0000000000002195
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
NR 10
TC 3
Z9 3
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2021
VL 139
IS 2
BP 219
EP 223
DI 10.1001/jamaophthalmol.2020.5130
EA DEC 2020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QJ3RS
UT WOS:000600158700006
PM 33331859
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Rofagha, S
   Bhisitkul, RB
   Boyer, DS
   Sadda, SR
   Zhang, K
AF Rofagha, Soraya
   Bhisitkul, Robert B.
   Boyer, David S.
   Sadda, SriniVas R.
   Zhang, Kang
CA SEVEN-UP Study Grp
TI Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA,
   and HORIZON
SO OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; NATURAL-HISTORY;
   EYE
AB Purpose: To assess long-term outcomes 7 to 8 years after initiation of intensive ranibizumab therapy in exudative age-related macular degeneration (AMD) patients.
   Design: Multicenter, noninterventional cohort study.
   Participants: Sixty-five AMD patients originally treated with ranibizumab in the phase 3 Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trial, Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) trial, and Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (HORIZON).
   Methods: Fourteen clinical trial sites recruited their original subjects for a return evaluation. Individual subject comparisons were obtained from the ANCHOR, MARINA, and HORIZON databases.
   Main Outcome Measures: The primary end point was percentage with best-corrected visual acuity (BCVA) of 20/70 or better; secondary outcomes included mean change in letter score compared with previous time points and anatomic results on fluorescein angiography, spectral-domain ocular coherence tomography (OCT), and fundus autofluorescence (FAF).
   Results: At a mean of 7.3 years (range, 6.3-8.5 years) after entry into ANCHOR or MARINA, 37% of study eyes met the primary end point of 20/70 or better BCVA, with 23% achieving a BCVA of 20/40 or better. Thirtyseven percent of study eyes had BCVA of 20/200 or worse. Forty-three percent of study eyes had a stable or improved letter score (>= 0-letter gain) compared with ANCHOR or MARINA baseline measurements, whereas 34% declined by 15 letters or more, with overall a mean decline of 8.6 letters (P< 0.005). Since exit from the HORIZON study, study eyes had received a mean of 6.8 anti-vascular endothelial growth factor (VEGF) injections during the mean 3.4-year interval; a subgroup of patients who received 11 or more anti-VEGF injections had a significantly better mean gain in letter score since HORIZON exit (P< 0.05). Active exudative disease was detected by spectral-domain OCT in 68% of study eyes, and 46% were receiving ongoing ocular anti-VEGF treatments. Macular atrophy was detected by FAF in 98% of eyes, with a mean area of 9.4 mm2; the area of atrophy correlated significantly with poor visual outcome (P< 0.0001).
   Conclusions: Approximately 7 years after ranibizumab therapy in the ANCHOR or MARINA trials, one third of patients demonstrated good visual outcomes, whereas another third had poor outcomes. Compared with baseline, almost half of eyes were stable, whereas one third declined by 15 letters or more. Even at this late stage in the therapeutic course, exudative AMD patients remain at risk for substantial visual decline.
C1 [Rofagha, Soraya; Bhisitkul, Robert B.] Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Boyer, David S.] Retina Vitreous Associates, Los Angeles, CA USA.
   [Sadda, SriniVas R.] Univ So Calif, Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Francisco;
   Retina Vitreous Associates Medical Group; Doheny Eye Institute;
   University of Southern California; University of California System;
   University of California San Diego
RP Bhisitkul, RB (通讯作者)，Univ Calif San Francisco, Beckman Vis Ctr, 10 Koret Way,K301, San Francisco, CA 94143 USA.
EM BhisitkulR@vision.ucsf.edu
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU Genentech, Inc.; South San Francisco, California; Research to Prevent
   Blindness, Inc., New York, New York; National Eye Institute, National
   Institutes of Health, Bethesda, Maryland [EY002162]; Man May See
   Foundation, San Francisco, CA.; NATIONAL EYE INSTITUTE [P30EY002162]
   Funding Source: NIH RePORTER
FX Supported by Genentech, Inc., South San Francisco, California; Research
   to Prevent Blindness, Inc., New York, New York; the National Eye
   Institute, National Institutes of Health, Bethesda, Maryland (core grant
   no.: EY002162); and the That Man May See Foundation, San Francisco, CA.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Ferris FL, 1996, OPHTHALMOLOGY, V103, P181, DOI 10.1016/S0161-6420(96)30742-2
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 16
TC 675
Z9 704
U1 3
U2 53
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2013
VL 120
IS 11
BP 2292
EP 2299
DI 10.1016/j.ophtha.2013.03.046
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 248FT
UT WOS:000326681700027
PM 23642856
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Nicolo, M
   Morlacchi, A
   Cappelli, F
   Desideri, LF
   Colombo, V
   Musetti, D
   Musolino, M
   Saccheggiani, M
   Bonetto, M
   Giacomini, M
   Traverso, CE
AF Nicolo, Massimo
   Morlacchi, Alessia
   Cappelli, Francesca
   Desideri, Lorenzo Ferro
   Colombo, Virginia
   Musetti, Donatella
   Musolino, Maria
   Saccheggiani, Michela
   Bonetto, Monica
   Giacomini, Mauro
   Traverso, Carlo Enrico
TI Real-Life Data in the Treatment of Neovascular Age-Related Macular
   Degeneration: Results from the Imaculaweb Registry Evaluated in a Single
   Italian Medical Retina Center
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Real-life study; Macular degeneration;
   Optical coherence tomography; Anti-VEGF; Vascular endothelial growth
   factor; Ranibizumab; Aflibercept
ID RANIBIZUMAB; OUTCOMES; BURDEN
AB Introduction: The aim of this study is to assess and compare the long-term clinical efficacy of anti-VEGF drugs using the Imaculaweb registry. Methods: In this observational study based on the Imaculaweb registry, outcome measures were the number of injections, the change in mean visual acuity (VA) and central macular thickness (CMT), and the time between diagnosis and the first injection. Results: In total, 126 eyes of 109 patients were included in the study. The mean VA was 49.4 +/- 21.4, 54.1 +/- 22.2, 51.6 +/- 24.9, and 48.3 +/- 25.7 letters at baseline and at the 1-, 2-, and 3-year follow-ups, respectively. Significant VA increases (p = 0.0002 for the first year and p = 0.045 for the second year) were documented at years 1 and 2 but not at year 3 (p = 0.8). The mean number of injections was 5.2, 2.6, and 2.3 at the 1-, 2-, and 3-year follow-ups, respectively. In the first year, 30% of the patients received at least 7 injections, while only 6.4% received <3 injections. CMT decreased significantly during the overall follow-up period, and intra- and subretinal fluid decreased (p < 0.0001). Conclusion: Imaculaweb turned out to be an effective tool to collect and share clinical data as well as to monitor patient outcome.
C1 [Nicolo, Massimo; Morlacchi, Alessia; Cappelli, Francesca; Desideri, Lorenzo Ferro; Colombo, Virginia; Musetti, Donatella; Musolino, Maria; Saccheggiani, Michela; Traverso, Carlo Enrico] Univ Genoa, Osped Policlin San Martino IRCCS, DiNOGMI, Clin Oculist, Genoa, Italy.
   [Nicolo, Massimo] Fdn Macula Onlus, Genoa, Italy.
   [Bonetto, Monica; Giacomini, Mauro] Healthropy Srl, Savona, Italy.
   [Giacomini, Mauro] Univ Genoa, DIBRIS, Genoa, Italy.
C3 University of Genoa; University of Genoa
RP Nicolo, M (通讯作者)，Osped Policlin San Martino IRCCS, Viale Benedetto 15, IT-16132 Genoa, Italy.
EM massimonicolo@gmail.com
RI Cappelli, Francesca/HDM-2955-2022
OI Bonetto, Monica/0000-0002-5317-1060
CR Bonetto A, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.101
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Desideri LF, 2020, CLIN EXP OPTOM, V103, P556, DOI 10.1111/cxo.12981
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2017, OPHTHALMIC RES, V58, P49, DOI 10.1159/000449001
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Iglicki M, 2018, ACTA DIABETOL, V55, P541, DOI 10.1007/s00592-018-1117-z
   Iglicki M, 2019, RETINA-J RET VIT DIS, V39, P44, DOI 10.1097/IAE.0000000000002196
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Li JQ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1425707
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Murdoch TB, 2013, JAMA-J AM MED ASSOC, V309, P1351, DOI 10.1001/jama.2013.393
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Waldstein SM, 2015, EYE, V29, P409, DOI 10.1038/eye.2014.319
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   ZHANG X, 2018, BIOMED RES INT, V2018, DOI DOI 10.1155/2018/9640131
   Zur D, 2019, OPHTHALMIC RES, V62, P231, DOI 10.1159/000499540
   Zur D, 2018, AM J OPHTHALMOL, V196, P129, DOI 10.1016/j.ajo.2018.08.037
NR 32
TC 16
Z9 16
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD DEC
PY 2020
VL 243
IS 6
BP 453
EP 460
DI 10.1159/000507711
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG4NP
UT WOS:000599714000008
PM 32252053
OA Green Published
DA 2022-11-30
ER

PT J
AU Erden, B
   Bolukbasi, S
   Ozkaya, A
   Karabas, L
   Alagoz, C
   Alkin, Z
   Artunay, O
   Bayramoglu, SE
   Demir, G
   Demir, M
   Demircan, A
   Erdogan, G
   Erdogan, M
   Eris, E
   Kaldirim, H
   Onur, IU
   Osmanbasoglu, OA
   Erkul, SO
   Ozturk, M
   Perente, I
   Sarici, K
   Sayin, N
   Yasa, D
   Yilmaz, I
   Yilmazabdurrahmanoglu, Z
AF Erden, Burak
   Bolukbasi, Selim
   Ozkaya, Abdullah
   Karabas, Levant
   Alagoz, Cengiz
   Alkin, Zeynep
   Artunay, Ozgur
   Bayramoglu, Sadik Etka
   Demir, Gokhan
   Demir, Mehmet
   Demircan, Ali
   Erdogan, Gurkan
   Erdogan, Mehmet
   Eris, Erdem
   Kaldirim, Havva
   Onur, Ismail Umut
   Osmanbasoglu, Ozen Ayranci
   Erkul, Sezin Ozdogan
   Ozturk, Mine
   Perente, Irfan
   Sarici, Kubra
   Sayin, Nihat
   Yasa, Dilek
   Yilmaz, Ihsan
   Yilmazabdurrahmanoglu, Zeynep
CA Bosphorus Retina Study Grp
TI Comparison of two different treatment regimens' efficacy in neovascular
   age-related macular degeneration in Turkish population-based on real
   life data-Bosphorus RWE Study Group
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE aflibercept; neovascular age-related macular degeneration; ranibizumab;
   loading dose; treatment regimen
ID INTRAVITREAL BEVACIZUMAB AVASTIN; ANTI-VEGF TREATMENT; RANIBIZUMAB
   THERAPY; OUTCOMES; VERTEPORFIN; MULTICENTER; PREVALENCE; EXPERIENCE;
   TRIALS; SAFETY
AB AIM: To compare two different anti-vascular endothelial growth factor (anti-VEGF) treatment regimens'-a priori pro re nata (PRN) and PRN regimen following the loading phaseanatomical and functional results in neovascular agerelated macular degeneration (nAMD) patients.
   METHODS: Totally 544 nAMD patients followed and treated with aflibercept (n=135) and ranibizumab (n=409) at 9 different centers between 2013 and 2015 were enrolled into this retrospective multicenter study. Patients with initial best corrected visual acuity (BCVA) interval of 1.3-0.3 (logMAR) and a minimum follow-up of 12mo were included. Patients under two different regimens-a priori pro re nata (1+PRN) or 3 consecutive intravitreal injections followed by a PRN regimen (3+PRN)-were compared in BCVA at 3th , 6th and 12th months, and in central macular thickness (CMT) at 6th and 12th months. The total study group, intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) groups were evaluated separately.
   RESULTS: The mean CMT decreased in the 1+PRN (n=101) regimen from 407 to 358 and 340 pm and in the 3+PRN (n=443) group from 398 to 318 and finally to 310 pm at months 6 and 12, respectively. Anatomically, the CMT reduction at 6th month (48.5 vs 76.4; P<0.05) was statistically significant in favor of 3+PRN group. BCVA changed in 1+PRN group from 0.77 to 0.78, 0.75 and 0.75; in 3+PRN group from 0.81 to 0.69, 0.72, and 0.76 at months 3, 6, and 12, respectively. Visual gain was statistically better in 3+PRN group at 3th month (-0.01 vs 0.12; P<0.001). In IVR group, CMT reduction was in greater in 3+PRN at 6th (44 vs 72) and 12th month (61 vs 84), but statistically insignificant. The 3+PRN group revealed statistically better visual results at 3th month (-0.02 vs 0.11, P<0.05). In IVA group, although statistically insignificant, CMT reduction (61 vs 89, 6th month; 85 vs 97, 12th month) and visual gain (0.02 vs 0.16; 0.02 vs 0.14; 0.05 vs 0.11) was found in favor of 3+PRN group at all visits.
   CONCLUSION: The loading dose of anti-VEGF treatments in nAMD leads to significantly better anatomical and functional results, regardless of the agent, specially in early follow-up interval.
C1 [Erden, Burak; Bolukbasi, Selim] Okmeydani Training & Res Hosp, Ophthalmol Clin, TR-34384 Istanbul, Turkey.
   [Ozkaya, Abdullah] Mem Sisli Hosp, Ophthalmol Clin, TR-34384 Istanbul, Turkey.
   [Karabas, Levant] Kocaeli Univ, Fac Med, Dept Ophthalmol, TR-41380 Kocaeli, Turkey.
   [Alagoz, Cengiz; Alkin, Zeynep; Artunay, Ozgur; Demir, Gokhan; Demircan, Ali; Erdogan, Gurkan; Eris, Erdem; Perente, Irfan; Yasa, Dilek; Yilmaz, Ihsan] Beyoglu Eye Training & Res Hosp, Ophthalmol Clin, TR-34421 Istanbul, Turkey.
   [Bayramoglu, Sadik Etka; Sarici, Kubra; Sayin, Nihat] Kanuni Sultan Suleyman Training & Res Hosp, Ophthalmol Clin, TR-34303 Istanbul, Turkey.
   [Demir, Mehmet; Erdogan, Mehmet] Sisli Etfal Training & Res Hosp, Ophthalmol, TR-34360 Istanbul, Turkey.
   [Kaldirim, Havva; Yilmazabdurrahmanoglu, Zeynep] Bagcilar Training & Res Hosp, Ophthalmol Clin, TR-34200 Istanbul, Turkey.
   [Onur, Ismail Umut] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Ophthalmol Clin, TR-34098 Istanbul, Turkey.
   [Osmanbasoglu, Ozen Ayranci; Erkul, Sezin Ozdogan] Istanbul Training & Res Hosp, Ophthalmol Clin, Istanbul, Turkey.
   [Ozturk, Mine] Haseki Training & Res Hosp, Ophthalmol Clin, TR-34096 Istanbul, Turkey.
C3 Istanbul Okmeydani Training & Research Hospital; Memorial Healthcare
   Group; Kocaeli University; Istanbul Kanuni Sultan Suleyman Training &
   Research Hospital; Istanbul Sisli Hamidiye Etfal Training & Research
   Hospital; Istanbul Bagcilar Training & Research Hospital; Bakirkoy Dr.
   Sadi Konuk Research & Training Hospital; Istanbul Training & Research
   Hospital; Istanbul Haseki Training & Research Hospital
RP Erden, B (通讯作者)，Selale Cad Manolya Evleri B1 Blok D 27, TR-34488 Bahcesehir Istanbul, Turkey.
EM drburakerden@gmail.com
RI bayramoğlu, sadık etka/GLS-0339-2022; demircan, ali/AAQ-3634-2020;
   Sarici, Kubra/AAT-4184-2020; Alkin, Zeynep/V-7252-2017; Erdogan,
   Gurkan/AAV-3972-2021; Sayın, Nihat/P-6732-2014; Demir,
   Mehmet/GQH-9297-2022; Onur, Ismail Umut/AAM-1423-2020; kaldırım,
   havva/ABF-9666-2020
OI bayramoğlu, sadık etka/0000-0002-9502-4368; Sarici,
   Kubra/0000-0002-9892-7554; Alkin, Zeynep/0000-0002-5363-1944; Erdogan,
   Gurkan/0000-0003-4155-0407; Onur, Ismail Umut/0000-0002-9028-2421;
   Sarici, Kubra/0000-0001-7088-4356
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cebeci Z, 2018, INT J OPHTHALMOL-CHI, V11, P267, DOI 10.18240/ijo.2018.02.15
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   El-Mollayess GM, 2012, AM J OPHTHALMOL, V153, P481, DOI 10.1016/j.ajo.2011.08.018
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2017, OPHTHALMOLOGY, V124, pE31, DOI 10.1016/j.ophtha.2016.05.054
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kucuk B, 2018, INT J OPHTHALMOL-CHI, V11, P645, DOI 10.18240/ijo.2018.04.18
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Menon G, 2013, EYE, V27, P959, DOI 10.1038/eye.2013.93
   Ozkaya A, 2018, TURK OFTALMOL DERG, V48, P232, DOI 10.4274/tjo.31697
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Vorum H, 2016, CURR MED RES OPIN, V32, P1943, DOI 10.1080/03007995.2016.1221803
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 28
TC 2
Z9 2
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2020
VL 13
IS 1
BP 104
EP 111
DI 10.18240/ijo.2020.01.15
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KA3EF
UT WOS:000505680500015
PM 31956577
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Klein, BEK
   Tomany, SC
   Wong, TY
AF Klein, R
   Klein, BEK
   Tomany, SC
   Wong, TY
TI The relation of retinal microvascular characteristics to age-related eye
   disease: The beaver dam eye study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE; LENS OPACITIES; TERM
   INCIDENCE; VISUAL-ACUITY; RISK-FACTORS; MACULOPATHY; PROGRESSION;
   HYPERTENSION; POPULATION
AB PURPOSE: To examine the relationship between microvascular characteristics (central retinal artery equivalent [CRAE], central retinal vein equivalent [CRVE], arteriole-to,venule ratio [AVR], focal retinal arteriolar nar rowing, arteriovenous [A/V] nicking, and retinopathy) associated with systemic hypertension and ocular disease (age-related maculopathy [ARM], three types of cataract, and open-angle glaucoma).
   DESIGN: Population,based cohort study.
   METHODS: Standardized grading of microvascular characteristics was performed at baseline on fundus photon graphs taken on 4,926 persons aged 43 to 86 years who participated in the Beaver Dam Eye study at the baseline examination. Age-related maculopathy, cataract, and glaucoma status were determined at baseline; ARM and cataract were again determined at 5 year and 10-year follow-up examinations using standard protocols.
   RESULTS: While controlling for age and sex, generalized retinal arteriolar narrowing (lowest quintile of CRAE) was associated with the 10,year cumulative incidence of retinal pigment epithelial (RPE) depigmentation (risk ratio [RR] 1st vs 5th quintile, 1.93; 95% confidence interval [CI], 1.11, 3.34) and, inversely, with incident nuclear cataract (RR, 0.71; 95% CI, 0.50, 0.99). Arteriovenous nicking was associated with the incidence of early ARM (RR, 2.39; 95% CI, 1.02, 5.57). Otherwise, there were no statistically significant associations of focal arteriolar narrowing or retinopathy with incident ARM or any type of age,related cataract and no relation of CRAE, focal arteriolar narrowing, A/V nicking, or retinopathy with the prevalence of glaucoma.
   CONCLUSION: These data show that retinal vascular characteristics associated with hypertension are related to the incidence of ARM and nuclear cataract but not to prevalent glaucoma. Relationships, however, were weak and inconsistent. (C) 2004 by Elsevier Inc. All rights reserved.
C1 Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, Madison, WI 53726 USA.
   Singapore Natl Eye Ctr, Singapore, Singapore.
   Natl Univ Singapore, Singapore 117548, Singapore.
C3 University of Wisconsin System; University of Wisconsin Madison;
   Singapore National Eye Center; National University of Singapore
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Cerviño, Alejandro/L-5853-2014; Wong, Tien Yin/AAC-9724-2020
OI Cerviño, Alejandro/0000-0001-8014-3279; Wong, Tien
   Yin/0000-0002-8448-1264
FU NEI NIH HHS [EY 06594] Funding Source: Medline
CR ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Angelica Moussalli M., 2001, International Ophthalmology, V23, P271, DOI 10.1023/A:1014417606396
   [Anonymous], 1991, Ophthalmology, V98, P823
   [Anonymous], 1991, Ophthalmology, V98, P786
   CALVER A, 1992, J HYPERTENS, V10, P1025
   Cohen SL, 2003, ARCH OPHTHALMOL-CHIC, V121, P33
   HENSON DB, 1985, DOC OPHTHALMOL, V59, P341, DOI 10.1007/BF00159168
   HENSON DB, 1987, 7 INT VIS FIELD S DO, P233
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   KEITH NM, 1974, AM J MED SCI, V268, P336, DOI 10.1097/00000441-197412000-00004
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173
   KLEIN BEK, 1985, OPHTHALMOLOGY, V92, P1654
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   KLENK DC, 1982, CLIN CHEM, V28, P2088
   Lam A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1494, DOI 10.1001/archopht.120.11.1494
   LANGERHORST CT, 1989, DOC OPHTHALMOL, V72, P279, DOI 10.1007/BF00153495
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882
   MAGLI YL, 1989, PROTOCOL OPTIC DISC
   Ornek K, 2003, EXP EYE RES, V76, P23, DOI 10.1016/S0014-4835(02)00268-3
   Papastathopoulos KI, 1999, BRIT J OPHTHALMOL, V83, P285, DOI 10.1136/bjo.83.3.285
   PARR JC, 1974, AM J OPHTHALMOL, V77, P472, DOI 10.1016/0002-9394(74)90457-7
   PARR JC, 1974, AM J OPHTHALMOL, V77, P478, DOI 10.1016/0002-9394(74)90458-9
   Rankin SJA, 1996, J GLAUCOMA, V5, P22
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Stein M. W., 1963, METHODS ENZYMATIC AN, P177
   WALSH JB, 1982, OPHTHALMOLOGY, V89, P1127
   WANG JJ, 2003, IN PRESS BR J OPHTHA
   WOLF S, 1993, OPHTHALMOLOGY, V100, P1561
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P1449
   WONG TY, 2003, IN PRESS OPHTHALMOLO
   1976, PREV MED, V5, P207
NR 52
TC 58
Z9 61
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2004
VL 137
IS 3
BP 435
EP 444
DI 10.1016/j.ajo.2003.10.020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 804VF
UT WOS:000220325500007
PM 15013865
DA 2022-11-30
ER

PT J
AU Zhang, C
   Owen, LA
   Lillvis, JH
   Zhang, SX
   Kim, IK
   DeAngelis, MM
AF Zhang, Charles
   Owen, Leah A.
   Lillvis, John H.
   Zhang, Sarah X.
   Kim, Ivana K.
   DeAngelis, Margaret M.
TI AMD Genomics: Non-Coding RNAs as Biomarkers and Therapeutic Targets
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; genomics; non-coding RNAs; biomarkers;
   therapeutics
ID COMPLEMENT FACTOR-H; CARDIAC RESYNCHRONIZATION THERAPY; MACULAR
   DEGENERATION; GEOGRAPHIC ATROPHY; MICRORNA SIGNATURES; HEART-FAILURE;
   CIRCULATING MICRORNAS; POTENTIAL BIOMARKERS; WIDE ASSOCIATION;
   NATURAL-HISTORY
AB Age-related macular degeneration (AMD) is a progressive neurodegenerative disease that is the world's leading cause of blindness in the aging population. Although the clinical stages and forms of AMD have been elucidated, more specific prognostic tools are required to determine when patients with early and intermediate AMD will progress into the advanced stages of AMD. Another challenge in the field has been the appropriate development of therapies for intermediate AMD and advanced atrophic AMD. After numerous negative clinical trials, an anti-C5 agent and anti-C3 agent have recently shown promising results in phase 3 clinical trials, in terms of slowing the growth of geographic atrophy, an advanced form of AMD. Interestingly, both drugs appear to be associated with an increased incidence of wet AMD, another advanced form of the disease, and will require frequent intravitreal injections. Certainly, there remains a need for other therapeutic agents with the potential to prevent progression to advanced stages of the disease. Investigation of the role and clinical utility of non-coding RNAs (ncRNAs) is a major advancement in biology that has only been minimally applied to AMD. In the following review, we discuss the clinical relevance of ncRNAs in AMD as both biomarkers and therapeutic targets.
C1 [Zhang, Charles; Owen, Leah A.; Lillvis, John H.; Zhang, Sarah X.; DeAngelis, Margaret M.] State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Ross Eye Inst, Dept Ophthalmol, Buffalo, NY 14203 USA.
   [Owen, Leah A.; DeAngelis, Margaret M.] Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Owen, Leah A.; DeAngelis, Margaret M.] Univ Utah, Sch Med, Dept Populat Hlth Sci, Salt Lake City, UT 84132 USA.
   [Owen, Leah A.] Univ Utah, Sch Med, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA.
   [Lillvis, John H.; DeAngelis, Margaret M.] Vet Adm Western New York Healthcare Syst, Buffalo, NY 14212 USA.
   [Zhang, Sarah X.; DeAngelis, Margaret M.] State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14203 USA.
   [Zhang, Sarah X.; DeAngelis, Margaret M.] State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Neurosci Grad Program, Buffalo, NY 14203 USA.
   [Kim, Ivana K.] Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [DeAngelis, Margaret M.] State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Genet Genom & Bioinformat Grad Program, Buffalo, NY 14203 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; Utah System of Higher Education; University of Utah;
   Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; State University of New York
   (SUNY) System; State University of New York (SUNY) Buffalo; State
   University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo; Harvard University; Harvard Medical School;
   Massachusetts Eye & Ear Infirmary; State University of New York (SUNY)
   System; State University of New York (SUNY) Buffalo
RP DeAngelis, MM (通讯作者)，State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Ross Eye Inst, Dept Ophthalmol, Buffalo, NY 14203 USA.; DeAngelis, MM (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.; DeAngelis, MM (通讯作者)，Univ Utah, Sch Med, Dept Populat Hlth Sci, Salt Lake City, UT 84132 USA.; DeAngelis, MM (通讯作者)，Vet Adm Western New York Healthcare Syst, Buffalo, NY 14212 USA.; DeAngelis, MM (通讯作者)，State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14203 USA.; DeAngelis, MM (通讯作者)，State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Neurosci Grad Program, Buffalo, NY 14203 USA.; Kim, IK (通讯作者)，Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear, Boston, MA 02114 USA.; DeAngelis, MM (通讯作者)，State Univ New York Univ Buffalo, Jacobs Sch Med & Biomed Sci, Genet Genom & Bioinformat Grad Program, Buffalo, NY 14203 USA.
EM czhang62@buffalo.edu; leah.owen@hsc.utah.edu; jhlillvi@buffalo.edu;
   xzhang38@buffalo.edu; ivana_kim@meei.harvard.edu; mmdeange@buffalo.edu
OI Owen, Leah/0000-0003-3802-3868; DeAngelis, Margaret/0000-0003-3731-142X
FU Macular Degeneration Foundation, Inc. (Henderson, NV, USA); Carl
   Marshall Reeves & Mildred Almen Reeves Foundation, Inc. (Fenton, MO,
   USA); NIH/NEI [1K08EY031800-01]
FX This commentary and review was funded in part by grants from The Macular
   Degeneration Foundation, Inc. (Henderson, NV, USA); The Carl Marshall
   Reeves & Mildred Almen Reeves Foundation, Inc. (Fenton, MO, USA) and
   NIH/NEI: 1K08EY031800-01.
CR Akat KM, 2014, P NATL ACAD SCI USA, V111, P11151, DOI 10.1073/pnas.1401724111
   Alexandrov PN, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00181
   Alleweldt F, 2021, EUROSURVEILLANCE, V26, P8, DOI 10.2807/1560-7917.ES.2021.26.9.1900606
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Baldassarre A, 2017, GENES-BASEL, V8, DOI 10.3390/genes8090234
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Bhattacharjee S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150211
   Bhaumik D, 2009, AGING-US, V1, P402, DOI 10.18632/aging.100042
   Binderup HG, 2016, CLIN BIOCHEM, V49, P1167, DOI 10.1016/j.clinbiochem.2016.04.017
   Blasiak J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179178
   Blasiak J, 2019, J CELL MOL MED, V23, P8464, DOI 10.1111/jcmm.14731
   Britten-Jones AC, 2022, GENET MED, V24, P521, DOI 10.1016/j.gim.2021.10.013
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Chen DL, 2012, J AM CHEM SOC, V134, P6948, DOI 10.1021/ja301621z
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chu-Tan JA, 2018, INVEST OPHTH VIS SCI, V59, P4094, DOI 10.1167/iovs.18-24623
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Crooke ST, 2000, ANTISENSE NUCLEIC A, V10, P123, DOI 10.1089/oli.1.2000.10.123
   Crooke ST, 1996, ANTISENSE NUCLEIC A, V6, P145, DOI 10.1089/oli.1.1996.6.145
   Cui XL, 2016, MED SCI MONITOR, V22, P5240, DOI 10.12659/MSM.899372
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dahlman JE, 2014, NAT NANOTECHNOL, V9, P648, DOI [10.1038/NNANO.2014.84, 10.1038/nnano.2014.84]
   Danielson KM, 2018, EBIOMEDICINE, V32, P172, DOI 10.1016/j.ebiom.2018.05.013
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Boer HC, 2013, EUR HEART J, V34, P3451, DOI 10.1093/eurheartj/eht007
   de Sousa MC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246249
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Deleavey GF, 2012, CHEM BIOL, V19, P937, DOI 10.1016/j.chembiol.2012.07.011
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dickinson BA, 2013, EUR J HEART FAIL, V15, P650, DOI 10.1093/eurjhf/hft018
   Dong YH, 2019, INT J BIOL SCI, V15, P680, DOI 10.7150/ijbs.30464
   Dong YZ, 2014, P NATL ACAD SCI USA, V111, P3955, DOI 10.1073/pnas.1322937111
   Dyrbus K, 2020, J CLIN LIPIDOL, V14, P16, DOI 10.1016/j.jacl.2019.11.001
   Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elbay A, 2019, SCAND J CLIN LAB INV, V79, P388, DOI 10.1080/00365513.2019.1637931
   Elshelmani H, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.28
   Ertekin S, 2014, MOL VIS, V20, P1057
   Farkas MH, 2021, ADV EXP MED BIOL, V1256, P221, DOI 10.1007/978-3-030-66014-7_9
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7
   Grassmann F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107461
   Guenther SPW, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.22
   Gusic M, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00095
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Heon E, 1996, ARCH OPHTHALMOL-CHIC, V114, P193, DOI 10.1001/archopht.1996.01100130187014
   Heydari E, 2020, METAB BRAIN DIS, V35, P31, DOI 10.1007/s11011-019-00485-2
   Hill JM, 2009, NEUROREPORT, V20, P1500, DOI 10.1097/WNR.0b013e3283329c05
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holoch D, 2015, NAT REV GENET, V16, P71, DOI 10.1038/nrg3863
   Hombach S, 2016, ADV EXP MED BIOL, V937, P3, DOI 10.1007/978-3-319-42059-2_1
   Hsieh CH, 2010, EXP CELL RES, V316, P1119, DOI 10.1016/j.yexcr.2009.11.013
   Iyer A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044789
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain G, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0579-2
   Jiang Y, 2015, J NEUROCHEM, V134, P173, DOI 10.1111/jnc.13097
   John M, 2007, NATURE, V449, P745, DOI 10.1038/nature06179
   Juzwik CA, 2019, PROG NEUROBIOL, V182, DOI 10.1016/j.pneurobio.2019.101664
   Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaudewitz D, 2016, CIRC RES, V118, P420, DOI 10.1161/CIRCRESAHA.114.305663
   Kauffman KJ, 2016, BIOMATERIALS, V109, P78, DOI 10.1016/j.biomaterials.2016.09.006
   Kawa M, 2014, J BIOCH PHARM RES, V2, P21
   Khaliq A, 1996, INVEST OPHTH VIS SCI, V37, P436
   Klattenhoff CA, 2013, CELL, V152, P570, DOI 10.1016/j.cell.2013.01.003
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Klinge Carolyn M., 2018, Non-Coding RNA, V4, P40, DOI 10.3390/ncrna4040040
   Kok MGM, 2016, INT J CARDIOL, V203, P262, DOI 10.1016/j.ijcard.2015.10.098
   Kotterman MA, 2014, NAT REV GENET, V15, P445, DOI 10.1038/nrg3742
   Krieg AM, 2012, NUCLEIC ACID THER, V22, P77, DOI 10.1089/nat.2012.0340
   Kuhnert F, 2008, DEVELOPMENT, V135, P3989, DOI 10.1242/dev.029736
   Kumar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069807
   Kumarswamy R, 2014, CIRC RES, V114, P1569, DOI 10.1161/CIRCRESAHA.114.303915
   Lains Ines, 2021, Ophthalmol Sci, V1, DOI 10.1016/j.xops.2021.100017
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li CM, 2021, GENET MED, V23, P451, DOI 10.1038/s41436-020-01012-w
   Li XX, 2021, INT J BIOL SCI, V17, P3413, DOI 10.7150/ijbs.62506
   Liang QN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12917-9
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Lok SI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136404
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marfella R, 2013, EUR J HEART FAIL, V15, P1277, DOI 10.1093/eurjhf/hft088
   Martin M, 2018, ELIFE, V7, DOI 10.7554/eLife.33864
   Meder B, 2011, BASIC RES CARDIOL, V106, P13, DOI 10.1007/s00395-010-0123-2
   Melman YF, 2015, CIRCULATION, V131, P2202, DOI 10.1161/CIRCULATIONAHA.114.013220
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Morley-Smith AC, 2014, EUR J HEART FAIL, V16, P871, DOI 10.1002/ejhf.116
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Myers KJ, 2000, TRENDS PHARMACOL SCI, V21, P19, DOI 10.1016/S0165-6147(99)01420-0
   Natoli R, 2018, ADV EXP MED BIOL, V1074, P37, DOI 10.1007/978-3-319-75402-4_5
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Necsulea A, 2014, NATURE, V505, P635, DOI 10.1038/nature12943
   Owen Leah A, 2019, Invest Ophthalmol Vis Sci, V60, P1204, DOI 10.1167/iovs.18-24254
   Ozcan G, 2015, ADV DRUG DELIVER REV, V87, P108, DOI 10.1016/j.addr.2015.01.007
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Patop IL, 2019, EMBO J, V38, DOI 10.15252/embj.2018100836
   Peng ZF, 2013, J NEUROSCI RES, V91, P1349, DOI 10.1002/jnr.23255
   Pogue AI, 2018, CELL MOL NEUROBIOL, V38, P1021, DOI 10.1007/s10571-017-0572-3
   Pratt AJ, 2009, J BIOL CHEM, V284, P17897, DOI 10.1074/jbc.R900012200
   Qu MJ, 2019, MOL THER-NUCL ACIDS, V16, P15, DOI 10.1016/j.omtn.2019.02.002
   Ransohoff JD, 2018, NAT REV MOL CELL BIO, V19, P143, DOI 10.1038/nrm.2017.104
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Ren CD, 2017, CELL PHYSIOL BIOCHEM, V41, P1413, DOI 10.1159/000467941
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Romano GL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00168
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sah DWY, 2011, J CLIN INVEST, V121, P500, DOI 10.1172/JCI45130
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053155
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Satoh J, 2010, J PHARMACOL SCI, V114, P269, DOI 10.1254/jphs.10R11FM
   Saugstad JA, 2010, J CEREBR BLOOD F MET, V30, P1564, DOI 10.1038/jcbfm.2010.101
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schroeder A, 2010, J INTERN MED, V267, P9, DOI 10.1111/j.1365-2796.2009.02189.x
   Schultz NM, 2021, CLIN THER, V43, P1792, DOI 10.1016/j.clinthera.2021.08.011
   Shi R, 2013, THROMB RES, V131, P508, DOI 10.1016/j.thromres.2013.02.015
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Singh G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10123374
   Sledz CA, 2004, BIOCHEM SOC T, V32, P952, DOI 10.1042/BST0320952
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smolle E, 2014, INT J MOL SCI, V15, P13494, DOI 10.3390/ijms150813494
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007
   Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9
   Stavast CJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111465
   Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI200113885
   Stein CA, 1999, NAT BIOTECHNOL, V17, P209, DOI 10.1038/6909
   Stratz C, 2012, THROMB HAEMOSTASIS, V107, P634, DOI 10.1160/TH11-10-0742
   Sun X, 2014, INT J ONCOL, V44, P1678, DOI 10.3892/ijo.2014.2321
   Svoboda P, 2007, CURR OPIN MOL THER, V9, P248
   Sweeney NM., 2021, NPJ GENOM MED, V5, P1
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tan JR, 2011, CURR MOL MED, V11, P76
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thiele S, 2021, BRIT J OPHTHALMOL, V105, P239, DOI 10.1136/bjophthalmol-2020-316004
   Tribolet L, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01197
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   van Rooij E, 2014, EMBO MOL MED, V6, P851, DOI 10.15252/emmm.201100899
   Vausort M, 2014, CIRC RES, V115, P668, DOI 10.1161/CIRCRESAHA.115.303836
   Visconti VV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186930
   Vogel B, 2013, CLIN CHEM, V59, P410, DOI 10.1373/clinchem.2011.181370
   Wang JJ, 2014, RNA BIOL, V11, P339, DOI 10.4161/rna.28300
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang SS, 2009, CURR OPIN GENET DEV, V19, P205, DOI 10.1016/j.gde.2009.04.002
   Watts JK, 2012, J PATHOL, V226, P365, DOI 10.1002/path.2993
   Willeit P, 2013, CIRC RES, V112, P595, DOI 10.1161/CIRCRESAHA.111.300539
   Wilson RC, 2013, ANNU REV BIOPHYS, V42, P217, DOI 10.1146/annurev-biophys-083012-130404
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie LL, 2019, AM J PATHOL, V189, P739, DOI 10.1016/j.ajpath.2018.12.011
   Xu XY, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8445-y
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021
   Zeller T, 2014, EUR HEART J, V35, P2106, DOI 10.1093/eurheartj/ehu151
   Zetterberg H, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0448-1
   Zhang Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07611-z
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
   Zhou LY, 2019, CURR GENE THER, V19, P172, DOI 10.2174/1566523219666190719100526
   Zhu JW, 2017, ONCOL LETT, V14, P1419, DOI 10.3892/ol.2017.6315
NR 191
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 6
AR 1484
DI 10.3390/jcm11061484
PG 21
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0C0GV
UT WOS:000775002900001
PM 35329812
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Olchawa, MM
   Herrnreiter, AM
   Skumatz, CMB
   Krzysztynska-Kuleta, OI
   Mokrzynski, KT
   Burke, JM
   Sarna, TJ
AF Olchawa, Magdalena M.
   Herrnreiter, Anja M.
   Skumatz, Christine M. B.
   Krzysztynska-Kuleta, Olga, I
   Mokrzynski, Krystian T.
   Burke, Janice M.
   Sarna, Tadeusz J.
TI The Inhibitory Effect of Blue Light on Phagocytic Activity by ARPE-19
   Cells
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MITOCHONDRIAL-DNA DAMAGE; AGE-RELATED
   MACULOPATHY; OXIDATIVE STRESS; MACULAR DEGENERATION; LIPID-PEROXIDATION;
   PHOTIC STRESS; ALPHA-V-BETA-5 INTEGRIN; PHOTOCHEMICAL DAMAGE; SUNLIGHT
   EXPOSURE
AB Chronic exposure of the retina to short wavelength visible light is a risk factor in pathogenesis of age-related macular degeneration. The proper functioning and survival of photoreceptors depends on efficient phagocytosis of photoreceptor outer segments (POS) by retinal pigment epithelium. The purpose of this study was to analyze the phagocytic activity of blue light-treated ARPE-19 cells, and to examine whether the observed effects could be related to altered levels of POS phagocytosis receptor proteins and/or to oxidation of cellular proteins and lipids. POS phagocytosis was measured by flow cytometry. Phagocytosis receptor proteins alpha v and beta 5 integrin subunits and Mer tyrosine kinase (MerTK) were quantified by western blotting. The intact functional heterodimer alpha v beta 5 was quantified by immunoprecipitation followed by immunoblotting. Cellular protein and lipid hydroperoxides were analyzed by coumarin boronic acid probe and iodometric assay, respectively. Cell irradiation induced reversible inhibition of specific phagocytosis and transient reductions in phagocytosis receptor proteins. Full recovery of functional heterodimer was apparent. Significant photooxidation of cellular proteins and lipids was observed. The results indicate that transient inhibition of specific phagocytosis by blue light could be related to the reduction in phagocytosis receptor proteins. Such changes may arise from oxidative modifications of cell phagocytic machinery components.
C1 [Olchawa, Magdalena M.; Krzysztynska-Kuleta, Olga, I; Mokrzynski, Krystian T.; Sarna, Tadeusz J.] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Biophys, Krakow, Poland.
   [Olchawa, Magdalena M.; Herrnreiter, Anja M.; Skumatz, Christine M. B.; Burke, Janice M.] Med Coll Wisconsin, Dept Ophthalmol, Eye Inst, Milwaukee, WI 53226 USA.
   [Herrnreiter, Anja M.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA.
   [Skumatz, Christine M. B.] Med Coll Wisconsin, Eye Inst, Dept Ophthalmol & Visual Sci, Milwaukee, WI 53226 USA.
C3 Jagiellonian University; Medical College of Wisconsin; Medical College
   of Wisconsin; Medical College of Wisconsin
RP Olchawa, MM (通讯作者)，Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Biophys, Krakow, Poland.; Olchawa, MM (通讯作者)，Med Coll Wisconsin, Dept Ophthalmol, Eye Inst, Milwaukee, WI 53226 USA.
EM magdalena.olchawa@uj.edu.pl
RI Mokrzyński, Krystian/AAH-1808-2022; Mokrzyński, Krystian/AFL-9677-2022
OI Mokrzyński, Krystian/0000-0001-8092-9132; Mokrzyński,
   Krystian/0000-0001-8092-9132; Sarna, Tadeusz/0000-0002-7693-5756;
   Magdalena, Olchawa/0000-0003-3276-7671
FU Poland National Science Centre [SYMFONIA1 2013/08/W/NZ3/00700]; National
   Eye Institute NIH [R01EY019664, P30EY01931, C06 RR-RR016511]; European
   Union [POIG.02.01.00-12-064/08]
FX This work was supported by Poland National Science Centre (research
   grant SYMFONIA1 2013/08/W/NZ3/00700) National Eye Institute NIH, (Grants
   R01EY019664, P30EY01931 and C06 RR-RR016511). The Faculty of
   Biochemistry, Biophysics, and Biotechnology of the Jagiellonian
   University is a beneficiary of structural funds from European Union
   Grant POIG.02.01.00-12-064/08 - 'Molecular biotechnology for health.'
   The authors thank Institute of Applied Radiation Chemistry, Lodz
   University of Technology for providing us with the CBA probe.
CR Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Behar-Cohen F, 2011, PROG RETIN EYE RES, V30, P239, DOI 10.1016/j.preteyeres.2011.04.002
   Berrougui H, 2009, REJUV RES, V12, P117, DOI 10.1089/rej.2008.0840
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Bok D., 1979, RETINAL PIGMENT EPIT, P148
   Boulton M, 2004, PHOTOCH PHOTOBIO SCI, V3, P759, DOI 10.1039/b400108g
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Burke JM, 2009, INVEST OPHTH VIS SCI, V50, P1940, DOI 10.1167/iovs.08-2671
   BURNSIDE MB, 1976, EXP EYE RES, V23, P257, DOI 10.1016/0014-4835(76)90208-6
   Catala A, 2012, BIOCHIMIE, V94, P101, DOI 10.1016/j.biochi.2011.09.025
   Catala A, 2009, CHEM PHYS LIPIDS, V157, P1, DOI 10.1016/j.chemphyslip.2008.09.004
   Coskun U, 2011, STRUCTURE, V19, P1543, DOI 10.1016/j.str.2011.10.010
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dillon J, 1996, PHOTOCHEM PHOTOBIOL, V63, P680, DOI 10.1111/j.1751-1097.1996.tb05673.x
   DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73
   Escriba PV, 2007, BBA-BIOMEMBRANES, V1768, P836, DOI 10.1016/j.bbamem.2006.09.001
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kennedy CJ, 1996, CURR EYE RES, V15, P998, DOI 10.3109/02713689609017646
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   MCLAREN MJ, 1993, INVEST OPHTH VIS SCI, V34, P317
   Michalski R, 2014, J BIOL CHEM, V289, P22536, DOI 10.1074/jbc.M114.553727
   Moutray T, 2011, THER ADV CHRONIC DIS, V2, P325, DOI 10.1177/2040622311415895
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Nakanishi-Ueda T, 2013, FREE RADICAL RES, V47, P774, DOI 10.3109/10715762.2013.829570
   Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Nandrot EF, 2008, ADV EXP MED BIOL, V613, P369, DOI 10.1007/978-0-387-74904-4_43
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nunez-Alvarez C, 2019, ACTA OPHTHALMOL, V97, pE103, DOI 10.1111/aos.13812
   Olchawa M, 2019, FREE RADICAL RES, V53, P456, DOI 10.1080/10715762.2019.1603377
   Olchawa M, 2010, PHOTOCHEM PHOTOBIOL, V86, P772, DOI 10.1111/j.1751-1097.2010.00727.x
   Olchawa MM, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111044
   Olchawa MM, 2020, PHOTOCH PHOTOBIO SCI, V19, P1022, DOI 10.1039/d0pp00165a
   Olchawa MM, 2021, PIGM CELL MELANOMA R, V34, P670, DOI 10.1111/pcmr.12914
   Olchawa MM, 2017, FREE RADICAL RES, V51, P799, DOI 10.1080/10715762.2017.1380307
   Olchawa MM, 2015, FREE RADICAL BIO MED, V89, P873, DOI 10.1016/j.freeradbiomed.2015.10.411
   Olchawa MM, 2013, INVEST OPHTH VIS SCI, V54, P2276, DOI 10.1167/iovs.12-11154
   PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48
   Pawlak A, 2003, PHOTOCHEM PHOTOBIOL, V77, P253, DOI 10.1562/0031-8655(2003)077<0253:COTAPO>2.0.CO;2
   Pawlak A, 2002, ARCH BIOCHEM BIOPHYS, V403, P59, DOI 10.1016/S0003-9861(02)00260-6
   Pollreisz A, 2018, EXP EYE RES, V166, P131, DOI 10.1016/j.exer.2017.10.018
   PUTTING BJ, 1993, GRAEF ARCH CLIN EXP, V231, P600, DOI 10.1007/BF00936526
   PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192
   Roehlecke C, 2011, MOL VIS, V17, P876
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Ruggiero L, 2012, P NATL ACAD SCI USA, V109, P8145, DOI 10.1073/pnas.1121101109
   SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tamburini I, 2004, AGING CLIN EXP RES, V16, P425, DOI 10.1007/BF03327396
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tillman TS, 2003, CELL BIOCHEM BIOPHYS, V38, P161, DOI 10.1385/CBB:38:2:161
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Wei QQ, 2018, DRUG DES DEV THER, V12, P2715, DOI 10.2147/DDDT.S176349
   WILLIAMS LL, 1993, AM J PATHOL, V142, P451
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Wu JM, 1999, EYE, V13, P577, DOI 10.1038/eye.1999.142
   Yang PM, 2020, INT J MOL MED, V46, P1096, DOI 10.3892/ijmm.2020.4656
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   YOUNG RW, 1982, T OPHTHAL SOC UK, V102, P42
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
   Zadlo A, 2009, PHOTOCH PHOTOBIO SCI, V8, P830, DOI 10.1039/b901820d
   Zou XL, 2019, INT J OPHTHALMOL-CHI, V12, P1262, DOI 10.18240/ijo.2019.08.05
NR 91
TC 0
Z9 0
U1 5
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD SEP
PY 2022
VL 98
IS 5
BP 1110
EP 1121
DI 10.1111/php.13596
EA FEB 2022
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 4O5IN
UT WOS:000750242300001
PM 35067943
DA 2022-11-30
ER

PT J
AU Khatri, A
   Pandey, A
   Joshi, K
   Singh, K
   Prasai, G
   Pradhan, E
   Agrawal, R
AF Khatri, Anadi
   Pandey, Araniko
   Joshi, Kriti
   Singh, Kinsuk
   Prasai, Gunjan
   Pradhan, Eli
   Agrawal, Rupesh
TI Redefining response in wet AMD to anti VEGF therapy based on non-OCTA
   versus OCTA evaluation
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age related macular degeneration; optical coherence tomography; OCT
   angiography
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; FLUORESCEIN
   ANGIOGRAPHY; GUIDELINES
AB Purpose Anti vascular endothelial growth factor (anti VEGF) has been the mainstay of treatment in wet age-related macular degeneration (AMD). Subsequent decision to continue anti VEGF therapy depends on the treatment response quantified by functional (visual acuity) and morphological (optical coherence tomography) parameters then categorized from good to poor. Methods This study evaluates the agreement between OCT angiography (OCTA) and non-OCTA (logMAR VA plus OCT) to decide anti-VEGF treatment's continuity. After an anti VEGF treatment, on a follow up visit, a patient underwent non-OCTA evaluation (decision A) then OCTA evaluation (decision B) to judge the necessity of future anti VEGF application. Results Out of 129 eyes, on 72 eyes (49%), there were agreements on both decision arms, but on 55 eyes (42%) there was disagreement. Particularly, disagreement on 47/55 eyes was important, where OCTA advised "continue anti VEGF" and non-OCTA advised "Stop anti VEGF" therapy. Cohen's Kappa for probability of agreement to continue anti VEGF was fair (0.33) and to stop anti VEGF therapy was none (0.1). Conclusions Based on resulting disagreements between the two modalities on deciding the continuity of anti VEGF, we conclude that OCTA must be considered in the conventional decision making algorithm in patients with wet AMD under anti VEGF therapy.
C1 [Khatri, Anadi] Birat Eye Hosp, Biratnagar, Nepal.
   [Khatri, Anadi] Birat Med Coll & Teaching Hosp, Biratnagar, Nepal.
   [Pandey, Araniko] Civil Serv Hosp Nepal, Kathmandu, Nepal.
   [Joshi, Kriti] Lumbini Eye Inst & Res Ctr, Siddharthanagar, Nepal.
   [Singh, Kinsuk] Vasan Eye Ctr, Mysuru, India.
   [Prasai, Gunjan] Kathmandu Med Coll & Teaching Hosp, Kathmandu, Nepal.
   [Pradhan, Eli] Tilganga Inst Ophthalmol, Kathmandu, Nepal.
   [Agrawal, Rupesh] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Agrawal, Rupesh] Singapore Eye Res Inst, Singapore, Singapore.
   [Agrawal, Rupesh] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Agrawal, Rupesh] Duke NUS Grad Med Sch, Ophthalmol Acad Clin Program, Singapore, Singapore.
   [Agrawal, Rupesh] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore, Singapore.
   [Agrawal, Rupesh] Lee Kong Chian Sch Med, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   National University of Singapore; Tan Tock Seng Hospital; Nanyang
   Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University
RP Khatri, A (通讯作者)，Birat Eye Hosp, Biratnagar, Nepal.; Khatri, A (通讯作者)，Birat Med Coll & Teaching Hosp, Biratnagar, Nepal.
EM anadikc@gmail.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amoaku WM, 2015, EYE, V29, P1397, DOI 10.1038/eye.2015.159
   Bae K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55871-8
   Cennamo G, 2020, OPHTHALMOL THER, V9, P77, DOI 10.1007/s40123-019-00221-0
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Faes L, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000244
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Farinha C, 2020, RETINA-J RET VIT DIS, V40, P881, DOI 10.1097/IAE.0000000000002470
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Levine ES, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00242-z
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   Rijal R., 2020, BIRAT J HLTH SCI, V5, P921
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stattin M, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/4806061
   Uchida A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218889
   Watzke RC, 2000, OPHTHALMOLOGY, V107, P1601, DOI 10.1016/S0161-6420(00)00218-9
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
NR 26
TC 1
Z9 1
U1 2
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2022
VL 32
IS 5
BP 2719
EP 2725
AR 11206721211059349
DI 10.1177/11206721211059349
EA NOV 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3S5GW
UT WOS:000721916200001
PM 34796729
DA 2022-11-30
ER

PT J
AU Wood, JM
   Black, AA
   Dingle, K
   Rutter, C
   DiStefano, M
   Koppel, S
   Charlton, JL
   Bentley, SA
AF Wood, Joanne M.
   Black, Alex A.
   Dingle, Kaeleen
   Rutter, Cameron
   DiStefano, Marilyn
   Koppel, Sjaan
   Charlton, Judith L.
   Bentley, Sharon A.
TI Impact of vision disorders and vision impairment on motor vehicle crash
   risk and on-road driving performance: A systematic review
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE driving ability; driving safety; motor vehicle crash risk; on-road
   driving performance; vision disorders; visual impairment
ID PERIPHERAL VISUAL-FIELD; OLDER DRIVERS; COLLISION INVOLVEMENT; MACULAR
   DEGENERATION; DEPRESSIVE SYMPTOMS; SENSORY IMPAIRMENTS; GLOBAL
   PREVALENCE; CATARACT-SURGERY; SELF-REPORT; AGE
AB Vision is important for safe driving, but there is limited understanding regarding the impact of vision disorders on driving ability and safety. This systematic review evaluated and summarized evidence on the impact of vision disorders and impairment on motor vehicle crash (MVC) risk and on-road driving performance across seven databases, was prospectively registered with PROSPERO (CRD42020180135), and study quality rated using a standard tool. Forty-eight studies met the inclusion criteria for MVC risk (N = 36), on-road performance (N = 9), and both MVC risk and on-road performance (N = 3). Of these studies, less than half were rated as 'good' quality. Due to the small number of studies and often conflicting findings, it was not possible to draw firm conclusions for most vision disorders. However, evidence from several 'good' and 'fair' quality studies suggested increased MVC risk with binocular visual field impairment. There was mixed evidence regarding the impact of cataract, glaucoma, age-related macular degeneration and homonymous field loss on MVC risk and no evidence of increased MVC risk with mild VA impairment. This review highlights the need for well-designed future studies to further explore the impact of vision disorders and impairment on driving outcomes to inform evidence-based policy and fitness to drive guidelines.
C1 [Wood, Joanne M.; Black, Alex A.; Bentley, Sharon A.] Queensland Univ Technol QUT, Sch Optometry & Vis Sci, Ctr Vis & Eye Res, Brisbane, Qld, Australia.
   [Dingle, Kaeleen] QUT, Sch Publ Hlth & Social Work, Brisbane, Qld, Australia.
   [Rutter, Cameron] QUT, Library, Acad Div, Brisbane, Qld, Australia.
   [DiStefano, Marilyn] Victorian State Govt, Dept Transport, Rd Safety Victoria, Melbourne, Vic, Australia.
   [Koppel, Sjaan; Charlton, Judith L.] Monash Univ, Accid Res Ctr MUARC, Clayton, Vic, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); Monash
   University
RP Wood, JM (通讯作者)，Queensland Univ Technol, Sch Optometry & Vis Sci, Ctr Vision & Eye Res, Victoria Pk Rd, Brisbane, Qld 4059, Australia.
EM j.wood@qut.edu.au
RI Dingle, Kaeleen/G-4885-2010; Black, Alex/I-9727-2012
OI Dingle, Kaeleen/0000-0001-8210-8194; Charlton,
   Judith/0000-0002-5990-2151; koppel, sjaan/0000-0003-3973-299X; Bentley,
   Sharon/0000-0003-0146-4248; , Joanne/0000-0002-0776-7736; Rutter,
   Cameron/0000-0002-7009-2575; Black, Alex/0000-0002-8671-5167
CR Abay KA, 2015, TRANSPORT RES A-POL, V71, P31, DOI 10.1016/j.tra.2014.11.002
   Adekoya BJ, 2009, CAN J OPHTHALMOL, V44, P261, DOI 10.3129/i09-049
   Adeoti C O, 2007, Niger Postgrad Med J, V14, P199
   Anstey KJ, 2011, NEUROPSYCHOLOGY, V25, P613, DOI 10.1037/a0023835
   Ball K, 1998, ACCIDENT ANAL PREV, V30, P313, DOI 10.1016/S0001-4575(97)00102-4
   Bhorade AM, 2016, AM J OPHTHALMOL, V166, P43, DOI 10.1016/j.ajo.2016.02.031
   Bro T, 2018, ACTA OPHTHALMOL, V96, P623, DOI 10.1111/aos.13741
   Chihuri S, 2016, J AM GERIATR SOC, V64, P332, DOI 10.1111/jgs.13931
   Cross JM, 2009, BRIT J OPHTHALMOL, V93, P400, DOI 10.1136/bjo.2008.144584
   Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142
   DAVISON PA, 1985, OPHTHAL PHYSL OPT, V5, P195, DOI 10.1111/j.1475-1313.1985.tb00656.x
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   DECINA LE, 1993, ACCIDENT ANAL PREV, V25, P267, DOI 10.1016/0001-4575(93)90021-N
   Devos H, 2018, TRAFFIC INJ PREV, V19, P715, DOI 10.1080/15389588.2018.1508834
   Do VQ, 2014, CLIN EXP OPTOM, V97, P356, DOI 10.1111/cxo.12142
   Elgin J, 2010, AM J OCCUP THER, V64, P268, DOI 10.5014/ajot.64.2.268
   Federal Highway Administration DoTU, 2018, HIGHW STAT 2017
   FISHMAN GA, 1981, BRIT J OPHTHALMOL, V65, P122, DOI 10.1136/bjo.65.2.122
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foreman J, 2018, JAMA OPHTHALMOL, V136, P240, DOI 10.1001/jamaophthalmol.2017.6457
   Green KA, 2013, J AM GERIATR SOC, V61, P252, DOI 10.1111/jgs.12091
   GRESSET JA, 1994, OPHTHAL PHYSL OPT, V14, P33, DOI 10.1111/j.1475-1313.1994.tb00553.x
   Haymes SA, 2008, INVEST OPHTH VIS SCI, V49, P3035, DOI 10.1167/iovs.07-1609
   Haymes SA, 2007, INVEST OPHTH VIS SCI, V48, P1149, DOI 10.1167/iovs.06-0886
   Hofstetter H W, 1976, J Am Optom Assoc, V47, P887
   Huisingh C, 2017, INVEST OPHTH VIS SCI, V58, P2959, DOI 10.1167/iovs.17-21482
   Huisingh C, 2015, INVEST OPHTH VIS SCI, V56, P132, DOI 10.1167/iovs.14-15194
   HUMPHRISS D, 1987, OPHTHAL PHYSL OPT, V7, P73
   Ihueze CC, 2018, ACCIDENT ANAL PREV, V112, P21, DOI 10.1016/j.aap.2017.12.016
   Imprialou M, 2019, ACCIDENT ANAL PREV, V130, P84, DOI 10.1016/j.aap.2017.02.022
   Ivers RQ, 1999, AM J PUBLIC HEALTH, V89, P85, DOI 10.2105/AJPH.89.1.85
   Janz NK, 2009, INVEST OPHTH VIS SCI, V50, P1718, DOI 10.1167/iovs.08-2575
   JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371
   Kasneci E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087470
   Kaye SA, 2018, J SAFETY RES, V65, P141, DOI 10.1016/j.jsr.2018.02.012
   Keay L, 2016, CLIN EXP OPTOM, V99, P449, DOI 10.1111/cxo.12414
   Keay L, 2012, OPHTHAL EPIDEMIOL, V19, P1, DOI 10.3109/09286586.2011.632704
   Keeffe JE, 2002, BRIT J OPHTHALMOL, V86, P1118, DOI 10.1136/bjo.86.10.1118
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Koppel S, 2011, TRAFFIC INJ PREV, V12, P459, DOI 10.1080/15389588.2011.580802
   Kwon M, 2016, OPHTHALMOLOGY, V123, P109, DOI 10.1016/j.ophtha.2015.08.043
   Lacherez P, 2014, J GERONTOL A-BIOL, V69, P240, DOI 10.1093/gerona/glt173
   Margolis KL, 2002, J GERONTOL A-BIOL, V57, pM186, DOI 10.1093/gerona/57.3.M186
   Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x
   MCCLOSKEY LW, 1994, AGE AGEING, V23, P267, DOI 10.1093/ageing/23.4.267
   MCGUIRE FL, 1973, J APPL PSYCHOL, V57, P300, DOI 10.1037/h0034728
   McGwin G, 2004, INVEST OPHTH VIS SCI, V45, P3934, DOI 10.1167/iovs.04-0524
   McGwin G, 1998, ACCIDENT ANAL PREV, V30, P781, DOI 10.1016/S0001-4575(98)00031-1
   McGwin Gerald Jr, 2016, Geriatrics (Basel), V1, DOI 10.3390/geriatrics1030019
   McGwin G, 2013, BRIT J OPHTHALMOL, V97, P1173, DOI 10.1136/bjophthalmol-2013-303601
   Meuleners LB, 2006, ACCIDENT ANAL PREV, V38, P1006, DOI 10.1016/j.aap.2006.04.005
   Meuleners LB, 2019, AGE AGEING, V48, P128, DOI 10.1093/ageing/afy156
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   NHLBI, 2014, QUALITY ASSESSMENT T
   Okamura K, 2019, TRANSPORT RES F-TRAF, V62, P99, DOI 10.1016/j.trf.2018.12.012
   Oladehinde M K, 2007, Indian J Occup Environ Med, V11, P71, DOI 10.4103/0019-5278.34532
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083
   Owsley C, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-1331-7
   Owsley C, 2015, SURV OPHTHALMOL, V60, P250, DOI 10.1016/j.survophthal.2015.01.005
   Owsley C, 2010, VISION RES, V50, P2348, DOI 10.1016/j.visres.2010.05.021
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rakotonirainy A, 2012, ACCIDENT ANAL PREV, V48, P423, DOI 10.1016/j.aap.2012.02.016
   Rochtchina E, 2003, CLIN EXP OPHTHALMOL, V31, P233, DOI 10.1046/j.1442-9071.2003.00635.x
   Rubin GS, 2007, INVEST OPHTH VIS SCI, V48, P1483, DOI 10.1167/iovs.06-0474
   Schlenker MB, 2018, JAMA OPHTHALMOL, V136, P998, DOI 10.1001/jamaophthalmol.2018.2510
   Sengupta S, 2014, OPHTHALMOLOGY, V121, P727, DOI 10.1016/j.ophtha.2013.09.042
   Shimada H, 2016, GERONTOLOGY, V62, P636, DOI 10.1159/000448036
   SHINAR D, 1983, ACCIDENT ANAL PREV, V15, P175, DOI 10.1016/0001-4575(83)90018-0
   Silveira S, 2007, CLIN EXP OPHTHALMOL, V35, P612, DOI 10.1111/j.1442-9071.2007.01544.x
   SZLYK JP, 1993, ARCH OPHTHALMOL-CHIC, V111, P207, DOI 10.1001/archopht.1993.01090020061024
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   SZLYK JP, 1995, HUM FACTORS, V37, P430, DOI 10.1518/001872095779064645
   Szlyk JP, 2005, J GLAUCOMA, V14, P145, DOI 10.1097/01.ijg.0000151686.89162.28
   Szlyk JP, 2002, J REHABIL RES DEV, V39, P467
   SZLYK JP, 1992, ARCH OPHTHALMOL-CHIC, V110, P1709, DOI 10.1001/archopht.1992.01080240049027
   Tanabe S, 2011, INVEST OPHTH VIS SCI, V52, P4177, DOI 10.1167/iovs.10-6264
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Windsor TD, 2007, GERONTOLOGIST, V47, P215, DOI 10.1093/geront/47.2.215
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2001, OPTOMETRY VISION SCI, V78, P343, DOI 10.1097/00006324-200105000-00018
   Wood JM, 2019, OPTOMETRY VISION SCI, V96, P626, DOI 10.1097/OPX.0000000000001421
   Wood JM, 2018, INVEST OPHTH VIS SCI, V59, P273, DOI 10.1167/iovs.17-22751
   Wood JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158318
   Wood JM, 2013, INVEST OPHTH VIS SCI, V54, P3790, DOI 10.1167/iovs.12-11485
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P577, DOI 10.1167/iovs.08-2506
   Woolnough A, 2013, ACCIDENT ANAL PREV, V61, P311, DOI 10.1016/j.aap.2013.03.020
   Yan MK, 2019, CLIN EXP OPHTHALMOL, V47, P847, DOI 10.1111/ceo.13572
NR 91
TC 4
Z9 4
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2022
VL 100
IS 2
BP E339
EP E367
DI 10.1111/aos.14908
EA JUL 2021
PG 29
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA YX9MP
UT WOS:000678843200001
PM 34309227
DA 2022-11-30
ER

PT J
AU Melinscak, M
   Radmilovic, M
   Vatavuk, Z
   Loncaric, S
AF Melinscak, Martina
   Radmilovic, Marin
   Vatavuk, Zoran
   Loncaric, Sven
TI Annotated retinal optical coherence tomography images (AROI) database
   for joint retinal layer and fluid segmentation
SO AUTOMATIKA
LA English
DT Article
DE Annotated retinal OCT images; images database; automatic image
   segmentation; deep learning; age-related macular degeneration
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY
AB Optical coherence tomography (OCT) images of the retina provide a structural representation and give an insight into the pathological changes present in age-related macular degeneration (AMD). Due to the three-dimensionality and complexity of the images, manual analysis of pathological features is difficult, time-consuming, and prone to subjectivity. Computer analysis of 3D OCT images is necessary to enable automated quantitative measuring of the features, objectively and repeatedly. As supervised and semi-supervised learning-based automatic segmentation depends on the training data and quality of annotations, we have created a new database of annotated retinal OCT images - the AROI database. It consists of 1136 images with annotations for pathological changes (fluid accumulation and related findings) and basic structures (layers) in patients with AMD. Inter- and intra-observer errors have been calculated in order to enable the validation of developed algorithms in relation to human variability. Also, we have performed the automatic segmentation with standard U-net architecture and two state-of-the-art architectures for medical image segmentation to set a baseline for further algorithm development and to get insight into challenges for automatic segmentation. To facilitate and encourage further research in the field, we have made the AROI database openly available.
C1 [Melinscak, Martina] Karlovac Univ Appl Sci, Dept Mech Engn, Karlovac, Croatia.
   [Melinscak, Martina; Loncaric, Sven] Fac Elect Engn & Comp, Dept Elect Syst & Informat Proc, Zagreb, Croatia.
   [Radmilovic, Marin; Vatavuk, Zoran] Sestre Milosrdnice Univ Hosp Ctr, Dept Ophthalmol, Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb
RP Melinscak, M (通讯作者)，Karlovac Univ Appl Sci, Karlovac 47000, Croatia.
EM martina.melinscak@gmail.com
RI Loncaric, Sven/ABE-5634-2021
OI Loncaric, Sven/0000-0002-4857-5351; Melinscak,
   Martina/0000-0001-5128-3213
CR Adamis AP, 2020, EYE, V34, P1966, DOI 10.1038/s41433-020-0895-z
   Bogunovic H, 2019, IEEE T MED IMAGING, V38, P1858, DOI 10.1109/TMI.2019.2901398
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Brown D., 2017, J VITREORETINAL DIS, V1, P294, DOI [10.1177/2474126417725946, DOI 10.1177/2474126417725946]
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Gu ZW, 2019, IEEE T MED IMAGING, V38, P2281, DOI 10.1109/TMI.2019.2903562
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Huang GL, 2017, IEEE ICC
   Ioffe S, 2015, PR MACH LEARN RES, V37, P448
   Isensee F, 2021, NAT METHODS, V18, P203, DOI 10.1038/s41592-020-01008-z
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   K. Team, KERAS DOCUMENTATION
   Kaszubski P, 2016, OPHTHALMIC RES, V55, P185, DOI 10.1159/000443209
   Khan SM, 2021, LANCET DIGIT HEALTH, V3, pE51, DOI 10.1016/S2589-7500(20)30240-5
   Kim KT, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061863
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Liu W, 2020, ALGORITHMS, V13, DOI 10.3390/a13030060
   Luo L., 2019, ARXIV190209843
   Melinscak Martina, 2021, OSF, DOI 10.17605/OSF.IO/5WYR3
   Mishra Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66355-5
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Orlando JI, 2019, I S BIOMED IMAGING, P1441, DOI 10.1109/ISBI.2019.8759581
   Patel HR, 2015, OSLI RETINA, V46, P8, DOI 10.3928/23258160-20150101-01
   Peng YF, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00317-z
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Schmidt-Erfurth U, 2020, OPHTHALMOLOGY, V127, P1211, DOI 10.1016/j.ophtha.2020.03.010
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sheyman A., 2020, RETINAL VASCULAR DIS, DOI [10.1007/978-981-15-4075-2, DOI 10.1007/978-981-15-4075-2]
   Siedlecki J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64901-9
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Waldstein SM, 2015, BRIT J OPHTHALMOL, V99, P794, DOI 10.1136/bjophthalmol-2014-305573
   Wang J., S D NET JOINT SEGMEN, P10
   Wei H, 2020, IEEE ACCESS, V8, P60929, DOI 10.1109/ACCESS.2020.2983818
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yim J, 2020, NAT MED, V26, P892, DOI 10.1038/s41591-020-0867-7
   Zhou Z., 2018, LECT NOTES COMPUT SC, DOI DOI 10.1007/978-3-030-00889-5_1
NR 46
TC 5
Z9 5
U1 2
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0005-1144
EI 1848-3380
J9 AUTOMATIKA-UK
JI Automatika
PD JUL 3
PY 2021
VL 62
IS 3
BP 375
EP 385
DI 10.1080/00051144.2021.1973298
PG 11
WC Automation & Control Systems; Engineering, Electrical & Electronic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Automation & Control Systems; Engineering
GA UL0LV
UT WOS:000692353500001
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Montorio, D
   D'Andrea, L
   Mirto, N
   Cennamo, G
AF Montorio, Daniela
   D'Andrea, Luca
   Mirto, Nicola
   Cennamo, Gilda
TI The role of optical coherence tomography angiography in reticular
   pseudodrusen
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE OCTA; Vessel density; Reticular pseudodrusen; Early age-related macular
   degeneration
ID MACULAR DEGENERATION; EYES; PREVALENCE; DRUSEN
AB Background: To investigate the changes in retinal and choriocapillaris vessel density (VD) in patients effected by early age-related macular degeneration (AMD) and reticular pseudodrusen (RPD), using Optical Coherence Tomography Angiography (OCTA).
   Methods: A total of seventy-eight eyes of 78 patients (43 male, 35 female, mean age 72.61 +/- 5.15) with nonneovascular AMD (38 eyes with early AMD and 40 eyes with RPD) was recruited in this observational prospective study. Forty eyes of 40 healthy subjects represented the control group. The VD was measured in superficial capillary plexus (SCP), deep capillary plexus (DCP) and choriocapillaris in different macular regions.
   Results: There were no significant differences in VD of the SCP and DCP among the controls and the two study groups (p > 0.05). The VD of the choriocapillaris revealed a statistically significant reduction in early AMD and RPD groups respect to controls (p < 0.001). Furthermore, the patients with RPD showed a significantly decreased VD respect to patients with early AMD in different macular regions (p < 0.001).
   Conclusions: The quantitative analysis of retinal and choriocapillaris blood flow by OCTA provided useful information regarding the vascular changes in non-neovascular AMD patients suggesting that the choriocapillaris loss is mainly involved in the pathogenesis of RPD.
C1 [Montorio, Daniela; D'Andrea, Luca; Mirto, Nicola] Univ Naples Federico II, Dept Neurosci Reprod & Dent Sci, Naples, Italy.
   [Cennamo, Gilda] Univ Naples Federico II, Dept Publ Hlth, Eye Clin, Via S Pansini 5, I-80133 Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II
RP Cennamo, G (通讯作者)，Univ Naples Federico II, Dept Publ Hlth, Eye Clin, Via S Pansini 5, I-80133 Naples, Italy.
EM xgilda@hotmail.com
RI Montorio, Daniela/AAJ-8687-2020
OI D'Andrea, Luca/0000-0002-1964-4899
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Ahn SM, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0866-3
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Chatziralli I, 2018, OPHTHALMOL THER, V7, P101, DOI 10.1007/s40123-018-0119-9
   Chatziralli I, 2018, INT OPHTHALMOL, V38, P1887, DOI 10.1007/s10792-017-0671-7
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lutty G, 1999, Mol Vis, V5, P35
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Wang JJ, 2004, BRIT J OPHTHALMOL, V88, P104, DOI 10.1136/bjo.88.1.104
   Wightman AJ, 2019, CLIN EXP OPTOM, V102, P455, DOI 10.1111/cxo.12842
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 29
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2021
VL 33
AR 102094
DI 10.1016/j.pdpdt.2020.102094
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QU9AC
UT WOS:000627570900001
PM 33188940
DA 2022-11-30
ER

PT J
AU Koller, A
   Bruckner, D
   Aigner, L
   Reitsamer, H
   Trost, A
AF Koller, Andreas
   Bruckner, Daniela
   Aigner, Ludwig
   Reitsamer, Herbert
   Trost, Andrea
TI Cysteinyl leukotriene receptor 1 modulates autophagic activity in
   retinal pigment epithelial cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OXIDATIVE STRESS; MACULAR DEGENERATION; DEATH; RPE; MECHANISMS;
   REGULATORS; INDUCTION; PATHWAY
AB The retinal pigment epithelium (RPE), which is among the tissues in the body that are exposed to the highest levels of phagocytosis and oxidative stress, is dependent on autophagy function. Impaired autophagy and continuous cellular stress are associated with various disorders, such as dry age-related macular degeneration (AMD), a disease for which effective therapies are lacking. Cysteinyl leukotriene receptor (CysLTR) 1 is a potential modulator of autophagy; thus, the aim of this study was to investigate the role of CysLTR1 in autophagy regulation in the RPE cell line ARPE-19. The polarized ARPE-19 monolayer exhibited expression of CysLTR1, which was colocalized with beta -tubulin III. In ARPE-19 cells, autophagic activity was rhythmically regulated and was increased upon CysLTR1 inhibition by Zafirlukast (ZK) treatment. H2O2 affected the proautophagic regulatory effect of ZK treatment depending on whether it was applied simultaneously with or prior to ZK treatment. Furthermore, mRNA levels of genes related to the leukotriene system, autophagy and the unfolded protein response were positively correlated. As CysLTR1 is involved in autophagy regulation under basal and oxidative stress conditions, a dysfunctional leukotriene system could negatively affect RPE functions. Therefore, CysLTR1 is a potential target for new treatment approaches for neurodegenerative disorders, such as AMD.
C1 [Koller, Andreas; Bruckner, Daniela; Reitsamer, Herbert; Trost, Andrea] Univ Hosp Paracelsus Med Univ, Dept Ophthalmol & Optometry, Res Program Expt Ophthalmol, Muellner Hauptstr 48, A-5020 Salzburg, Austria.
   [Aigner, Ludwig] Paracelsus Med Univ, Spinal Cord Injury & Tissue Regenerat Ctr, Inst Mol Regenerat Med, Salzburg, Austria.
C3 Paracelsus Private Medical University
RP Trost, A (通讯作者)，Univ Hosp Paracelsus Med Univ, Dept Ophthalmol & Optometry, Res Program Expt Ophthalmol, Muellner Hauptstr 48, A-5020 Salzburg, Austria.
EM a.koller@salk.at
OI Trost, Andrea/0000-0001-7325-6830; Koller, Andreas/0000-0001-6108-8411
FU Fuchs Foundation; PMU-FFF [R-18/01/103-ZUR]
FX This work was supported by the Fuchs Foundation and PMU-FFF
   [R-18/01/103-ZUR].
CR B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Baek A, 2017, AUTOPHAGY, V13, P248, DOI 10.1080/15548627.2016.1256932
   Bernard A, 2013, DEV CELL, V25, P116, DOI 10.1016/j.devcel.2013.04.004
   BIRKLE DL, 1989, CURR EYE RES, V8, P557, DOI 10.3109/02713688908995754
   BOK D, 1993, J CELL SCI, P189
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Bu YW, 2018, NAT CELL BIOL, V20, P104, DOI 10.1038/s41556-017-0006-y
   Cai Y, 2016, AUTOPHAGY, V12, P225, DOI 10.1080/15548627.2015.1121360
   Cheon SY, 2019, EXP NEUROBIOL, V28, P643, DOI 10.5607/en.2019.28.6.643
   Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341
   Cox KH, 2019, J MOL ENDOCRINOL, V63, pR93, DOI 10.1530/JME-19-0153
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dvash E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10112
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Gade P, 2012, P NATL ACAD SCI USA, V109, P10316, DOI 10.1073/pnas.1119273109
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Granger E, 2014, SEMIN CELL DEV BIOL, V31, P20, DOI 10.1016/j.semcdb.2014.04.011
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Holczer M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225543
   Hu CL, 2018, MOL PHARMACEUT, V15, P1996, DOI 10.1021/acs.molpharmaceut.8b00121
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Jo-Watanabe A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143580
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006
   Liang C, 2010, CELL DEATH DIFFER, V17, P1807, DOI 10.1038/cdd.2010.115
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luhr M, 2019, J BIOL CHEM, V294, P8197, DOI 10.1074/jbc.RA118.002829
   Ma D, 2011, EMBO J, V30, P4642, DOI 10.1038/emboj.2011.322
   McMahon DG, 2014, PROG RETIN EYE RES, V39, P58, DOI 10.1016/j.preteyeres.2013.12.001
   Michael J, 2019, DRUG DISCOV TODAY, V24, P505, DOI 10.1016/j.drudis.2018.09.008
   Milicevic N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48203-3
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Navarro-Yepes J, 2014, ANTIOXID REDOX SIGN, V21, P66, DOI 10.1089/ars.2014.5837
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Reynolds AL, 2016, J BIOL CHEM, V291, P7242, DOI 10.1074/jbc.M115.710665
   Roca-Agujetas V, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3809308
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Sasaki F., 2018, JCI INSIGHT, P3
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Sies H, 2017, REDOX BIOL, V11, P613, DOI 10.1016/j.redox.2016.12.035
   Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Song CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171940
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Trost A, 2018, EXP EYE RES, V173, P113, DOI 10.1016/j.exer.2018.05.001
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Yan MM, 2015, ONCOL LETT, V10, P1959, DOI 10.3892/ol.2015.3508
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
NR 59
TC 5
Z9 5
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 19
PY 2020
VL 10
IS 1
AR 17659
DI 10.1038/s41598-020-74755-w
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OL2TT
UT WOS:000585195500009
PM 33077798
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sugita, S
   Mandai, M
   Hirami, Y
   Takagi, S
   Maeda, T
   Fujihara, M
   Matsuzaki, M
   Yamamoto, M
   Iseki, K
   Hayashi, N
   Hono, A
   Fujino, S
   Koide, N
   Sakai, N
   Shibata, Y
   Terada, M
   Nishida, M
   Dohi, H
   Nomura, M
   Amano, N
   Sakaguchi, H
   Hara, C
   Maruyama, K
   Daimon, T
   Igeta, M
   Oda, T
   Shirono, U
   Tozaki, M
   Totani, K
   Sugiyama, S
   Nishida, K
   Kurimoto, Y
   Takahashi, M
AF Sugita, Sunao
   Mandai, Michiko
   Hirami, Yasuhiko
   Takagi, Seiji
   Maeda, Tadao
   Fujihara, Masashi
   Matsuzaki, Mitsuhiro
   Yamamoto, Midori
   Iseki, Kyoko
   Hayashi, Naoko
   Hono, Ayumi
   Fujino, Shoko
   Koide, Naoshi
   Sakai, Noriko
   Shibata, Yumiko
   Terada, Motoki
   Nishida, Mitsuhiro
   Dohi, Hiromi
   Nomura, Masaki
   Amano, Naoki
   Sakaguchi, Hirokazu
   Hara, Chikako
   Maruyama, Kazuichi
   Daimon, Takashi
   Igeta, Masataka
   Oda, Toshihiko
   Shirono, Utako
   Tozaki, Misato
   Totani, Kota
   Sugiyama, Satoshi
   Nishida, Kohji
   Kurimoto, Yasuo
   Takahashi, Masayo
TI HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular
   Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE HLA; immune reactions; macular degeneration; iPS cells; retina;
   transplantation
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; IMMUNE PRIVILEGE;
   PREVALENCE; INHIBITION
AB Immune attacks are key issues for cell transplantation. To assess the safety and the immune reactions after iPS cells-derived retinal pigment epithelium (iPS-RPE) transplantation, we transplanted HLA homozygote iPS-RPE cells established at an iPS bank in HLA-matched patients with exudative age-related macular degeneration. In addition, local steroids without immunosuppressive medications were administered. We monitored immune rejections by routine ocular examinations as well as by lymphocytes-graft cells immune reaction (LGIR) tests using graft RPE and the patient's blood cells. In all five of the cases that underwent iPS-RPE transplantation, the presence of graft cells was indicated by clumps or an area of increased pigmentation at 6 months, which became stable with no further abnormal growth in the graft during the 1-year observation period. Adverse events observed included corneal erosion, epiretinal membrane, retinal edema due to epiretinal membrane, elevated intraocular pressure, endophthalmitis, and mild immune rejection in the eye. In the one case exhibiting positive LGIR tests along with a slight fluid recurrence, we administrated local steroid therapy that subsequently resolved the suspected immune attacks. Although the cell delivery strategy must be further optimized, the present results suggest that it is possible to achieve stable survival and safety of iPS-RPE cell transplantation for a year.
C1 [Sugita, Sunao; Mandai, Michiko; Hirami, Yasuhiko; Takagi, Seiji; Maeda, Tadao; Fujihara, Masashi; Matsuzaki, Mitsuhiro; Yamamoto, Midori; Koide, Naoshi; Kurimoto, Yasuo; Takahashi, Masayo] Dept Ophthalmol, Kobe, Hyogo 6500047, Japan.
   [Sugita, Sunao; Mandai, Michiko; Hirami, Yasuhiko; Takagi, Seiji; Maeda, Tadao; Fujihara, Masashi; Matsuzaki, Mitsuhiro; Yamamoto, Midori; Koide, Naoshi; Kurimoto, Yasuo; Takahashi, Masayo] Kobe City Eye Hosp, Kobe, Hyogo 6500047, Japan.
   [Sugita, Sunao; Mandai, Michiko; Hirami, Yasuhiko; Takagi, Seiji; Fujihara, Masashi; Matsuzaki, Mitsuhiro; Yamamoto, Midori; Koide, Naoshi; Kurimoto, Yasuo; Takahashi, Masayo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo 6500047, Japan.
   [Sugita, Sunao; Mandai, Michiko; Maeda, Tadao; Iseki, Kyoko; Hayashi, Naoko; Hono, Ayumi; Fujino, Shoko; Koide, Naoshi; Sakai, Noriko; Shibata, Yumiko; Terada, Motoki; Nishida, Mitsuhiro; Takahashi, Masayo] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
   [Takagi, Seiji] Toho Univ, Sch Med, Dept Ophthalmol, Tokyo 1538515, Japan.
   [Dohi, Hiromi; Nomura, Masaki; Amano, Naoki] Kyoto Univ, Ctr iPS Cell Res & Applicat, Kyoto 6068567, Japan.
   [Sakaguchi, Hirokazu; Hara, Chikako] Osaka Univ, Grad Sch Med, Dept Adv Device Med, Suita, Osaka 5650871, Japan.
   [Maruyama, Kazuichi] Osaka Univ, Grad Sch Med, Dept Innovat Visual Sci, Suita, Osaka 5650871, Japan.
   [Daimon, Takashi; Igeta, Masataka] Hyogo Coll Med, Dept Biostat, Nishinomiya, Hyogo 6638501, Japan.
   [Oda, Toshihiko; Shirono, Utako; Tozaki, Misato] Kobe City Med Ctr Gen Hosp, Ctr Clin Res & Innovat, Kobe, Hyogo 6500047, Japan.
   [Totani, Kota; Sugiyama, Satoshi] Tomey Corp, Nagoya, Aichi 4510051, Japan.
   [Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Kobe City Medical Center General Hospital; RIKEN; Toho University; Kyoto
   University; Osaka University; Osaka University; Hyogo College of
   Medicine; Kobe City Medical Center General Hospital; Osaka University
RP Takahashi, M (通讯作者)，Dept Ophthalmol, Kobe, Hyogo 6500047, Japan.; Takahashi, M (通讯作者)，Kobe City Eye Hosp, Kobe, Hyogo 6500047, Japan.; Takahashi, M (通讯作者)，Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo 6500047, Japan.; Takahashi, M (通讯作者)，RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
EM sunao.sugita@riken.jp; michiko.mandai@riken.jp; yhirami@kcho.jp;
   tigerseiji@gmail.com; tadao_maeda@kcho.jp;
   masashifujihara@hotmail.co.jp; mmatsuzaki@me.com;
   midori_yamamoto@kcho.jp; kyoko.iseki@riken.jp; naoko.sp@gmail.com;
   ayumi.hono@riken.jp; shoko.fujino@riken.jp; naoshi.koide@riken.jp;
   noriko.sakai@riken.jp; yumiko.shibata@riken.jp; motoki.terada@riken.jp;
   mituhiro.nishida@riken.jp; hiromi.dohi@cira.kyoto-u.ac.jp;
   mnomura@cira.kyoto-u.ac.jp; n.amano@cira.kyoto-u.ac.jp;
   sakaguh@ophthal.med.osaka-u.ac.jp;
   chikako.ueno@ophthal.med.osaka-u.ac.jp;
   kazuichi.maruyama@ophthal.med.osaka-u.ac.jp; daimon@hyo-med.ac.jp;
   ma-igeta@hyo-med.ac.jp; t-oda@kcho.jp; ushirono@kcho.jp;
   m.tozaki.kcho@gmail.com; kt-totani@tomey.co.jp; s-sugiyama@tomey.co.jp;
   knishida@ophthal.med.osaka-u.ac.jp; ykurimoto@mac.com;
   retinalab@ml.riken.jp
RI Igeta, Masataka/AAJ-4618-2021; Maruyama, Kazuichi/GRX-8129-2022
OI Igeta, Masataka/0000-0001-8706-4231; Maruyama,
   Kazuichi/0000-0001-6283-5466; Mitsuhiro, Matsuzaki/0000-0002-4618-3696;
   Nomura, Masaki/0000-0003-1277-9122
FU AMED [JP18bm0204002, JP17bk0104002]; KAKENHI [16K21633]
FX This research was supported by AMED under Grant Number JP18bm0204002 and
   JP17bk0104002 to M.T. In addition, this study was also supported by
   grants from KAKENHI (25293357, 18H02959) to S.S. and by grants from
   KAKENHI (16K21633) to N.K.
CR Algvere PV, 1997, ACTA OPHTHALMOL SCAN, V75, P1
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205
   Ichise H, 2017, STEM CELL REP, V9, P853, DOI 10.1016/j.stemcr.2017.07.020
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Liu Y, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0053-y
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nakagawa M, 2014, SCI REP-UK, V4, DOI 10.1038/srep03594
   Niederkorn JY, 2002, CRIT REV IMMUNOL, V22, P13
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P1719, DOI 10.1167/iovs.17-22703
   Sugita S, 2017, STEM CELL REP, V9, P1501, DOI 10.1016/j.stemcr.2017.10.003
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Takagi S, 2018, JPN J OPHTHALMOL, V62, P568, DOI 10.1007/s10384-018-0611-8
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 33
TC 59
Z9 60
U1 2
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2020
VL 9
IS 7
AR 2217
DI 10.3390/jcm9072217
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA MW2FX
UT WOS:000556860700001
PM 32668747
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tarallo, V
   Iaccarino, E
   Cicatiello, V
   Sanna, R
   Ruvo, M
   De Falco, S
AF Tarallo, Valeria
   Iaccarino, Emanuela
   Cicatiello, Valeria
   Sanna, Riccardo
   Ruvo, Menotti
   De Falco, Sandro
TI Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses
   Pathological Choroid Neovascularization
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE AMD; CNV; VEGFR1; multimeric peptides; oral delivery
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; FACTOR RECEPTOR-1;
   ANGIOGENESIS; PEPTIDE; CANCER; NONRESPONDERS; RANIBIZUMAB; BEVACIZUMAB;
   INJECTION
AB Age-related macular degeneration (AMD) is the primary cause of blindness in advanced countries. Repeated intravitreal delivery of anti-vascular endothelial growth factor (VEGF) agents has represented an important advancement for the therapy of wet AMD with significative results in terms of blindness prevention and partial vision restore. Nonetheless, some patients are not responsive or do not attain significant visual improvement, intravitreal injection may cause serious complications and important side effects have been reported for the prolonged block of VEGF-A. In order to evaluate new anti-angiogenic strategies, we focused our attention on VEGF receptor 1 (VEGFR1) developing a specific VEGFR-1 antagonist, a tetrameric tripeptide named inhibitor of VEGFR 1 (iVR1). We have evaluated its anti-angiogenic activity in the preclinical model of AMD, the laser-induced choroid neovascularization (CNV). iVR1 is able to potently inhibit CNV when delivered by intravitreal injection. Surprisingly, it is able to significantly reduce CNV also when delivered by gavage. Our data show that the specific block of VEGFR1 in vivo represents a valid alternative to the block of VEGF-A and that the inhibition of the pathological neovascularization at ocular level is also possible by systemic delivery of compounds not targeting VEGF-A.
C1 [Tarallo, Valeria; Cicatiello, Valeria; De Falco, Sandro] CNR, Ist Genet & Biofis Adriano Buzzati Traverso, I-80131 Naples, Italy.
   [Iaccarino, Emanuela; Ruvo, Menotti] CNR, Ist Biostrutture & Bioimmagini, I-80134 Naples, Italy.
   [Sanna, Riccardo] BIOVIIIx Srl, Dept R&D, I-80142 Naples, Italy.
   [Ruvo, Menotti; De Falco, Sandro] ANBITION Srl, Dept R&D, I-80128 Naples, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e
   Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale
   delle Ricerche (CNR); Istituto di Biostrutture e Bioimmagini (IBB-CNR)
RP De Falco, S (通讯作者)，CNR, Ist Genet & Biofis Adriano Buzzati Traverso, I-80131 Naples, Italy.; De Falco, S (通讯作者)，ANBITION Srl, Dept R&D, I-80128 Naples, Italy.
EM valeria.tarallo@igb.cnr.it; emanuela.iaccarino@gmail.com;
   valeria.cicatiello@igb.cnr.it; riccardo.sanna@bioviiix.com;
   menotti.ruvo@unina.it; sandro.defalco@igb.cnr.it
OI Iaccarino, Emanuela/0000-0002-9073-0204; Tarallo,
   Valeria/0000-0002-6920-4402; De Falco, Sandro/0000-0002-6501-1697
FU Regione Campania; Project SATIN-POR Campania FESR 2014/2020; Project
   Campania Oncotherapies; MIUR (Italian Ministry of Instruction,
   University and Research) [PRIN 2017XJ38A4]
FX This research was funded by: Regione Campania, Project SATIN-POR
   Campania FESR 2014/2020 to M.R. and S.D.F. and Project Campania
   Oncotherapies, to M.R.; MIUR (Italian Ministry of Instruction,
   University and Research) project PRIN 2017XJ38A4, to S.D.F.
CR Apicella I, 2018, CELL REP, V23, P3635, DOI 10.1016/j.celrep.2018.05.067
   Bae DG, 2005, CLIN CANCER RES, V11, P2651, DOI 10.1158/1078-0432.CCR-04-1564
   Barth A, 2007, BBA-BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Caporale A, 2018, PEPTIDES, V102, P38, DOI 10.1016/j.peptides.2018.02.006
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Cicatiello V, 2015, ONCOTARGET, V6, P10563, DOI 10.18632/oncotarget.3384
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   De Falco S, 2014, KOREAN J INTERN MED, V29, P1, DOI 10.3904/kjim.2014.29.1.1
   Dewerchin M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011056
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hiratsuka S, 2001, CANCER RES, V61, P1207
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Meredith EL, 2015, J MED CHEM, V58, P9273, DOI 10.1021/acs.jmedchem.5b01227
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Ponticelli S, 2008, J BIOL CHEM, V283, P34250, DOI 10.1074/jbc.M806607200
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Tarallo V, 2015, INT J BIOCHEM CELL B, V64, P185, DOI 10.1016/j.biocel.2015.04.008
   Taylor AP, 2007, MOL CANCER THER, V6, P524, DOI 10.1158/1535-7163.MCT-06-0461
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   Valenti LE, 2011, ANAL BIOCHEM, V410, P118, DOI 10.1016/j.ab.2010.11.006
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wei X, 2018, EXP EYE RES, V168, P2, DOI 10.1016/j.exer.2017.12.009
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Y, 2006, CLIN CANCER RES, V12, P6573, DOI 10.1158/1078-0432.CCR-06-0831
NR 38
TC 5
Z9 5
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN 2
PY 2020
VL 21
IS 2
AR 410
DI 10.3390/ijms21020410
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KO2KZ
UT WOS:000515380000040
PM 31936463
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Pastor, M
   Johnen, S
   Harmening, N
   Quiviger, M
   Pailloux, J
   Kropp, M
   Walter, P
   Ivics, Z
   Izsvak, Z
   Thumann, G
   Scherman, D
   Marie, C
AF Pastor, Marie
   Johnen, Sandra
   Harmening, Nina
   Quiviger, Mickael
   Pailloux, Julie
   Kropp, Martina
   Walter, Peter
   Ivics, Zoltan
   Izsvak, Zsuzsanna
   Thumann, Gabriele
   Scherman, Daniel
   Marie, Corinne
TI The Antibiotic-free pFAR4 Vector Paired with the Sleeping Beauty
   Transposon System Mediates Efficient Transgene Delivery in Human Cells
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; NONVIRAL GENE DELIVERY; FREE PLASMID
   SELECTION; MACULAR DEGENERATION; INTRAVITREAL BEVACIZUMAB; DNA
   ELECTROTRANSFER; PIGGYBAC TRANSPOSON; COPY NUMBER; EXPRESSION; THERAPY
AB The anti-angiogenic and neurogenic pigment epithelium-derived factor (PEDF) demonstrated a potency to control choroidal neovascularization in age-related macular degeneration (AMD) patients. The goal of the present study was the development of an efficient and safe technique to integrate, ex vivo, the PEDF gene into retinal pigment epithelial (RPE) cells for later transplantation to the subretinal space of AMD patients to allow continuous PEDF secretion in the vicinity of the affected macula. Because successful gene therapy approaches require efficient gene delivery and stable gene expression, we used the antibiotic-free pFAR4 mini-plasmid vector to deliver the hyperactive Sleeping Beauty transposon system, which mediates transgene integration into the genome of host cells. In an initial study, lipofection-mediated co-transfection of HeLa cells with the SB100X transposase gene and a reporter marker delivered by pFAR4 showed a 2-fold higher level of genetically modified cells than when using the pT2 vectors. Similarly, with the pFAR4 constructs, electroporation-mediated transfection of primary human RPE cells led to 2.4-fold higher secretion of recombinant PEDF protein, which was still maintained 8 months after transfection. Thus, our results show that the pFAR4 plasmid is a superior vector for the delivery and integration of transgenes into eukaryotic cells.
C1 [Pastor, Marie; Quiviger, Mickael; Pailloux, Julie; Scherman, Daniel; Marie, Corinne] CNRS, Unite Technol Chim & Biol Sante UTCBS, UMR 8258, F-75006 Paris, France.
   [Pastor, Marie; Quiviger, Mickael; Pailloux, Julie; Scherman, Daniel; Marie, Corinne] PSL Res Univ, UTCBS, Chim ParisTech, F-75005 Paris, France.
   [Pastor, Marie; Quiviger, Mickael; Pailloux, Julie; Scherman, Daniel; Marie, Corinne] Univ Paris 05, UTCBS, Sorbonne Paris Cite, F-75006 Paris, France.
   [Pastor, Marie; Quiviger, Mickael; Pailloux, Julie; Scherman, Daniel; Marie, Corinne] INSERM, UTCBS U 1022, F-75006 Paris, France.
   [Johnen, Sandra; Walter, Peter] Univ Hosp RWTH Aachen, Dept Ophthalmol, D-52074 Aachen, Germany.
   [Harmening, Nina; Kropp, Martina; Thumann, Gabriele] Univ Geneva, Expt Ophthalmol, CH-1205 Geneva, Switzerland.
   [Ivics, Zoltan] Paul Ehrlich Inst, Div Med Biotechnol, D-63225 Langen, Germany.
   [Izsvak, Zsuzsanna] Max Delbruck Ctr Mol Med, Helmholtz Assoc, D-13092 Berlin, Germany.
   [Kropp, Martina; Thumann, Gabriele] Univ Hosp Geneva, Dept Ophthalmol, CH-1205 Geneva, Switzerland.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of
   Chemistry (INC); UDICE-French Research Universities; Universite Paris
   Cite; UDICE-French Research Universities; PSL Research University Paris;
   Chimie ParisTech; Universite Paris Cite; UDICE-French Research
   Universities; Universite Paris Cite; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite Paris Cite; RWTH Aachen University; RWTH Aachen University
   Hospital; University of Geneva; Paul Ehrlich Institute; Helmholtz
   Association; Max Delbruck Center for Molecular Medicine; University of
   Geneva
RP Marie, C (通讯作者)，Fac Sci Pharmaceut & Biol Paris, UTCBS, CNRS, INSERM,U1022,UMR8258, 4 Ave Observ, F-75006 Paris, France.
EM corinne.marie@parisdescartes.fr
RI Johnen, Sandra/ABA-9955-2020; Walter, Peter/L-5982-2018; Kropp,
   Martina/H-9260-2018
OI Johnen, Sandra/0000-0003-0028-2557; Walter, Peter/0000-0001-8745-6593;
   Scherman, Daniel/0000-0003-1207-1298; MARIE,
   Corinne/0000-0001-9619-5700; Kropp, Martina/0000-0001-6861-5851
FU European Union's Seventh Framework Programme for research, technological
   development and demonstration [305134]
FX The project has received funding from the European Union's Seventh
   Framework Programme for research, technological development and
   demonstration under grant agreement no. 305134. Anna Dobias, Antje
   Schiefer (Department of Ophthalmology, University Hospital RWTH Aachen),
   and Gregg Sealy (Laboratory of Ophthalmology, University of Geneva) are
   acknowledged for excellent technical support. The Aachen Cornea Bank
   (Department of Ophthalmology, University Hospital RWTH Aachen) is
   acknowledged for providing the human donor eyes. P. Hackett (University
   of Minnesota, USA) is acknowledged for the gift of pT2/BH.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Alsaggar M, 2015, ADV GENET, V89, P1, DOI 10.1016/bs.adgen.2014.10.001
   [Anonymous], 2001, NOT GUID QUAL PRECL
   BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97
   Bell JB, 2010, MOL THER, V18, P1796, DOI 10.1038/mt.2010.152
   Bloquel C, 2004, J GENE MED, V6, pS11, DOI 10.1002/jgm.508
   Byk G., 2001, US Patent, Patent No. 6171612
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2011, HUM GENE THER, V22, P523, DOI 10.1089/hum.2011.050
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chabot S, 2013, GENE THER, V20, P62, DOI 10.1038/gt.2011.215
   Chen ZY, 2005, HUM GENE THER, V16, P126, DOI 10.1089/hum.2005.16.126
   Cranenburgh RM, 2004, J MOL MICROB BIOTECH, V7, P197, DOI 10.1159/000079828
   Cranenburgh RM, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.5.e26
   Cui ZB, 2002, J MOL BIOL, V318, P1221, DOI 10.1016/S0022-2836(02)00237-1
   Feschotte C, 2007, ANNU REV GENET, V41, P331, DOI 10.1146/annurev.genet.40.110405.090448
   Fischer A, 2010, NAT IMMUNOL, V11, P457, DOI 10.1038/ni0610-457
   Food and Drug Administration, 1998, GUID HUM SOM CELL TH
   Garcia-Garcia L, 2017, MOL THER-NUCL ACIDS, V9, P1, DOI 10.1016/j.omtn.2017.08.001
   Geurts AM, 2003, MOL THER, V8, P108, DOI 10.1016/S1525-0016(03)00099-6
   Gogol-Doring A, 2016, MOL THER, V24, P592, DOI 10.1038/mt.2016.11
   Grabundzija I, 2010, MOL THER, V18, P1200, DOI 10.1038/mt.2010.47
   Hackett PB, 2007, MOL THER, V15, P10, DOI 10.1038/sj.mt.6300065
   Hackett PB, 2005, ADV GENET, V54, P189, DOI 10.1016/S0065-2660(05)54009-4
   Heller R, 2015, ADV GENET, V89, P235, DOI 10.1016/bs.adgen.2014.10.006
   Hudecek M, 2017, CRIT REV BIOCHEM MOL, V52, P355, DOI 10.1080/10409238.2017.1304354
   Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5
   Ivics Z, 2009, NAT METHODS, V6, P415, DOI [10.1038/NMETH.1332, 10.1038/nmeth.1332]
   Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047
   Izsvak Z, 2009, METHODS, V49, P287, DOI 10.1016/j.ymeth.2009.07.001
   Johnen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/863845
   Johnen S, 2012, INVEST OPHTH VIS SCI, V53, P4787, DOI 10.1167/iovs.12-9951
   Johnen S, 2011, INVEST OPHTH VIS SCI, V52, P5400, DOI 10.1167/iovs.10-6178
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5963, DOI 10.1167/iovs.10-6440
   Kreiss P, 1998, APPL MICROBIOL BIOT, V49, P560, DOI 10.1007/s002530051213
   Kreiss P, 1999, NUCLEIC ACIDS RES, V27, P3792, DOI 10.1093/nar/27.19.3792
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Kuerten D, 2015, GRAEF ARCH CLIN EXP, V253, P1061, DOI 10.1007/s00417-015-2954-x
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Luke J, 2009, VACCINE, V27, P6454, DOI 10.1016/j.vaccine.2009.06.017
   Mairhofer J, 2008, MOL BIOTECHNOL, V39, P97, DOI 10.1007/s12033-008-9046-7
   Mairhofer Jurgen, 2008, Biotechnology Journal, V3, P83, DOI 10.1002/biot.200700141
   Marie C, 2010, J GENE MED, V12, P323, DOI 10.1002/jgm.1441
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Mikkelsen JG, 2003, MOL THER, V8, P654, DOI 10.1016/S1525-0016(03)00216-8
   Monjezi R, 2017, LEUKEMIA, V31, P186, DOI 10.1038/leu.2016.180
   Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818
   Narayanavari SA, 2017, CRIT REV BIOCHEM MOL, V52, P18, DOI 10.1080/10409238.2016.1237935
   Pfaffenzeller Irene, 2006, Biotechnology Journal, V1, P675, DOI 10.1002/biot.200600017
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Quiviger M, 2014, GENE THER, V21, P1001, DOI 10.1038/gt.2014.75
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Solensky R, 2003, CLIN REV ALLERG IMMU, V24, P201, DOI 10.1385/CRIAI:24:3:201
   Soubrier F, 1999, GENE THER, V6, P1482, DOI 10.1038/sj.gt.3300968
   Soubrier F, 2005, APPL MICROBIOL BIOT, V66, P683, DOI 10.1007/s00253-004-1729-9
   Thumann G, 2010, GENE THER, V17, P181, DOI 10.1038/gt.2009.124
   Thumann G, 2017, MOL THER-NUCL ACIDS, V6, P302, DOI 10.1016/j.omtn.2017.02.002
   Vandermeulen G, 2011, MOL THER, V19, P1942, DOI 10.1038/mt.2011.182
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Williams JA, 2009, BIOTECHNOL ADV, V27, P353, DOI 10.1016/j.biotechadv.2009.02.003
   Wilson MH, 2007, MOL THER, V15, P139, DOI 10.1038/sj.mt.6300028
   Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Young JL, 2015, ADV GENET, V89, P49, DOI 10.1016/bs.adgen.2014.10.003
NR 68
TC 9
Z9 9
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD JUN 1
PY 2018
VL 11
BP 57
EP 67
DI 10.1016/j.omtn.2017.12.017
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GH5AT
UT WOS:000433428900006
PM 29858090
OA Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Park, SI
   Lee, EH
   Kim, SR
   Jang, YP
AF Park, Sang-il
   Lee, Eun Hye
   Kim, So Ra
   Jang, Young Pyo
TI Anti-apoptotic effects of Curcuma longa L. extract and its curcuminoids
   against blue light-induced cytotoxicity in A2E-laden human retinal
   pigment epithelial cells
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE A2E; age-related macular degeneration; apoptosis; blue light; curcumin
ID C-ABL; A2E; INVOLVEMENT; FLUOROPHORE; LIPOFUSCIN; RPE; MECHANISMS;
   ISO-A2E; STRESS; DAMAGE
AB Objectives The purpose of the study was to investigate the protective effect of the Curcuma longa L. extract (CLE) and its curcuminoids against blue light-induced cytotoxicity in human retinal pigment epithelial (RPE) cells laded with A2E. A2E has been concerned in age-related macular degeneration (AMD).
   Methods To perform this study, A2E-accumulated ARPE-19 cells were exposed to blue light to induce cytotoxicity. The cytotoxicity and apoptotic gene expression levels were evaluated using a lactate dehydrogenase (LDH) assay and real-time PCR analysis, respectively.
   Key findings Curcuma longa L. extract was found to exert a protective effect in a dose-dependent manner. At a concentration of 15 mu m, curcumin, demethoxycurcumin and bisdemethoxycurcumin exerted significant protective effects against blue light-induced cytotoxicity. Treatment with CLE and curcuminoids meaningfully reduced the mRNA levels of c-Abl and p53, which was known to be augmented in apoptotic RPE cells. Demethoxycurcumin and bisdemethoxycurcumin were found to inhibit p38 expression, which is increased in blue light-irradiated A2E-accumulated RPE cells.
   Conclusions Curcuma longa L. extract and its curcuminoids provided significant protection against photooxidative damage and apoptosis in the RPE cells. Our results suggest that curcuminoids may show potential in the treatment of AMD.
C1 [Park, Sang-il; Lee, Eun Hye; Jang, Young Pyo] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Grad Sch, Seoul, South Korea.
   [Kim, So Ra] Seoul Natl Univ Sci & Technol, Dept Optometry, Seoul, South Korea.
   [Jang, Young Pyo] Kyung Hee Univ, Dept Oriental Pharmaceut Sci, Coll Pharm, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Seoul National University of Science & Technology;
   Kyung Hee University
RP Jang, YP (通讯作者)，Kyung Hee Univ, Dept Oriental Pharmaceut Sci, Coll Pharm, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM ypjang@khu.ac.kr
RI Jang, Young Pyo/AAJ-8782-2020
OI Jang, Young Pyo/0000-0001-5865-9228; Kim, So Ra/0000-0001-8786-2815
CR Antony S., 2011, J EXPT SCI, V2, P21
   Apisariyakul A, 1995, J ETHNOPHARMACOL, V49, P163, DOI 10.1016/0378-8741(95)01320-2
   Araujo CAC, 2001, MEM I OSWALDO CRUZ, V96, P723, DOI 10.1590/S0074-02762001000500026
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Banerjee S, 2012, CHEM COMMUN, V48, P7702, DOI 10.1039/c2cc33576j
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Cao MH, 2013, BEHAV BRAIN RES, V237, P249, DOI 10.1016/j.bbr.2012.09.040
   DAHL TA, 1994, PHOTOCHEM PHOTOBIOL, V59, P290, DOI 10.1111/j.1751-1097.1994.tb05036.x
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Jee EH, 2012, J CHROMATOGR A, V1251, P232, DOI 10.1016/j.chroma.2012.06.046
   Jin HL, 2016, J PHARMACEUT BIOMED, V117, P560, DOI 10.1016/j.jpba.2015.10.010
   Jing GJ, 2012, EXP DIABETES RES, DOI 10.1155/2012/589589
   Kundu Subarna, 2005, Int J Low Extrem Wounds, V4, P205, DOI 10.1177/1534734605281674
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mehta S, 2015, PRIMARY CARE, V42, P377, DOI 10.1016/j.pop.2015.05.009
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   REDDY ACP, 1992, MOL CELL BIOCHEM, V111, P117
   Roth GN, 1998, J NAT PROD, V61, P542, DOI 10.1021/np970459f
   SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2
   Sionov RV, 2001, MOL CELL BIOL, V21, P5869
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Srimal R. C., 1997, Fitoterapia, V68, P483
   STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1
   Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   Woo JM, 2012, MOL VIS, V18, P901
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Zhang L, 2016, RSC ADV, V6, P12519, DOI 10.1039/c5ra23401h
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 35
TC 22
Z9 23
U1 4
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD MAR
PY 2017
VL 69
IS 3
BP 334
EP 340
DI 10.1111/jphp.12691
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EM3BJ
UT WOS:000395189200012
PM 28155996
DA 2022-11-30
ER

PT J
AU Telegina, DV
   Kozhevnikova, OS
   Bayborodin, SI
   Kolosova, NG
AF Telegina, Darya V.
   Kozhevnikova, Oyuna S.
   Bayborodin, Sergey I.
   Kolosova, Nataliya G.
TI Contributions of age-related alterations of the retinal pigment
   epithelium and of glia to the AMD-like pathology in OXYS rats
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ALPHA-B-CRYSTALLIN; MACULAR DEGENERATION; RETINOPATHY; EXPRESSION;
   MODEL; MICROGLIA; MICE; ASTROCYTES; PROTECTS; FEATURES
AB Age-related macular degeneration (AMD) is a major cause of blindness in developed countries, and the molecular pathogenesis of early events of AMD is poorly understood. It is known that age-related alterations of retinal pigment epithelium (RPE) cells and of glial reactivity are early hallmarks of AMD. Here we evaluated contributions of the age-related alterations of the RPE and of glia to the development of AMD-like retinopathy in OXYS rats. We showed that destructive alterations in RPE cells are a primary change during the development of retinopathy in OXYS rats. Furthermore, a defect of retinal maturation and decreased immune function at the preclinical stage of retinopathy were observed in OXYS rats in addition to the impairment of RPE cell proliferation and of their capacity for division. At the active stage of the disease, the atrophic alterations increased, and reactive gliosis was observed when disease progressed, but immune function stayed weakened. Unexpectedly, we did not observe migration of microglia and macrophages into the photoreceptor layer. These results and the wide spectrum of age-related retinal alterations in humans as well as individual differences in the risk of AMD may be attributed to genetic factors and to differences in the underlying molecular events.
C1 [Telegina, Darya V.; Kozhevnikova, Oyuna S.; Bayborodin, Sergey I.; Kolosova, Nataliya G.] RAS, Inst Cytol & Genet, SB, Novosibirsk 630090, Russia.
   [Kolosova, Nataliya G.] Novosibirsk State Univ, Novosibirsk 630090, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Novosibirsk State University
RP Kolosova, NG (通讯作者)，RAS, Inst Cytol & Genet, SB, Novosibirsk 630090, Russia.; Kolosova, NG (通讯作者)，Novosibirsk State Univ, Novosibirsk 630090, Russia.
EM kolosova@bionet.nsc.ru
RI Kozhevnikova, Oyuna S./H-3588-2016; Telegina, Darya/AAQ-6062-2020;
   Kolosova, Nataliya G/P-3178-2015; Kolosova, Nataliya G/AAR-7409-2020
OI Kozhevnikova, Oyuna S./0000-0001-6475-4061; Telegina,
   Darya/0000-0001-8096-0519; Kolosova, Nataliya G/0000-0003-2398-8544;
   Kolosova, Nataliya G/0000-0003-2398-8544
FU Russian Foundation for Basic Research [15-04-02195, 15-04-01938]; ICG SB
   RAS budget project [0324-2015-0003]
FX Microscopy was performed at the Microscopy Center of the Institute of
   Cytology and Genetics, SB RAS, Russia. This work was supported by the
   Russian Foundation for Basic Research (grants ##15-04-02195 and
   15-04-01938) and by the ICG SB RAS budget project #0324-2015-0003.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Fernandez-Sanchez L, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00484
   Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hippert C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120415
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339
   Kim S.-Y., 2015, MACROPHAGE, V2, pe698
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kolosova N. G., 2014, ADV GERONTOL, V4, P294, DOI DOI 10.1134/S2079057014040146
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Kozhevnikova OS, 2013, BIOGERONTOLOGY, V14, P753, DOI 10.1007/s10522-013-9439-2
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luna G, 2010, MOL VIS, V16, P2511
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Markovets AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021682
   Markovets AM, 2011, AGING-US, V3, P44
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Rickman C., 2013, INVEST OPHTH VIS SCI, V5
   Saprunova VB, 2012, BIOCHEMISTRY-MOSCOW+, V77, P648, DOI 10.1134/S0006297912060120
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   STROEVA OG, 1983, INT REV CYTOL, V83, P221, DOI 10.1016/S0074-7696(08)61689-7
   Telegina D V, 2014, Adv Gerontol, V27, P87
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhdankina AA, 2008, B EXP BIOL MED+, V146, P455, DOI 10.1007/s10517-009-0298-4
NR 45
TC 24
Z9 26
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 30
PY 2017
VL 7
AR 41533
DI 10.1038/srep41533
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EI9CO
UT WOS:000392805100001
PM 28134357
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Galveia, JNV
   Travassos, ASM
   Proenca, DMMB
   Travassos, ACT
   Proenca, RDMB
AF Vargas Galveia, Jose Nuno
   Marques Travassos, Ana Sofia
   Mateus Barreiros Proenca, Didia Maria
   Tavares Travassos, Antonio Casanova
   Mateus Barreiros Proenca, Rui Daniel
TI Asteroid hyalosis - clinical review of 58 cases
SO REVISTA BRASILEIRA DE OFTALMOLOGIA
LA English
DT Article
DE Vitreous body/pathology; Eye diseases/pathology; Vitrectomy
ID POPULATION; VITRECTOMY; HYALITIS; BODIES; EYE
AB Objective: Understand the behavior, functional repercussion and relationship with epidemiological factors of asteroid hyalosis (AH) and retrospective observational case series. Methods: Fifty-eight patients diagnosed with AH (24 women and 34 men) were studied. All patients were submitted to a thorough ophthalmological examination. Results: We observed a statistical association between the presence of AH and male sex (p=0,042). An increase in prevalence of this pathology was observed with increasing age. We determined an odds ration of 5,24 of a patient over 50 years old having AH, when compared to patients bellow this threshold. Eighty-six percent of patients had unilateral vitreous deposits. We measured a lower IOP in the affected eye, with the difference being in average 2,68 +/- 1,45 mmHg (p=0,037). We observed no statistical association between AH and age related macular degeneration, diabetes or glaucoma. Five eyes were submitted to facoemulsification combined with pars plana vitrectomy with an average gain of 7 lines (Snellen) in visual acuity (p=0,03). Conclusion: In our sample a clear association between AH, ageing and male sex was observed. The majority of patients had unilateral vitreous deposits. Vitrectomy in association with facoemulsification is a safe and effective intervention in this group of patients.
C1 [Vargas Galveia, Jose Nuno; Marques Travassos, Ana Sofia; Mateus Barreiros Proenca, Didia Maria; Tavares Travassos, Antonio Casanova; Mateus Barreiros Proenca, Rui Daniel] Ctr Cirurg Coimbra, Coimbra, Portugal.
C3 Universidade de Coimbra
RP Galveia, JNV (通讯作者)，Rua Junqueira 126, P-1349019 Lisbon, Portugal.
EM Jgalveia@gmail.com
RI Proença, Rui DMB/F-4932-2017
OI Proença, Rui DMB/0000-0003-3459-8664
CR [Anonymous], 2011, RELATORIO ANUAL OBSE
   BARD LA, 1964, AM J OPHTHALMOL, V58, P239, DOI 10.1016/0002-9394(64)91570-3
   BERGREN RL, 1991, AM J OPHTHALMOL, V111, P289, DOI 10.1016/S0002-9394(14)72311-6
   Fawzi AA, 2005, ARCH OPHTHALMOL-CHIC, V123, P486, DOI 10.1001/archopht.123.4.486
   FEIST RM, 1990, RETINA-J RET VIT DIS, V10, P173, DOI 10.1097/00006982-199001030-00003
   JERVEY ED, 1965, SOUTHERN MED J, V58, P191, DOI 10.1097/00007611-196502000-00010
   Kador PF, 2008, EYE, V22, P1278, DOI 10.1038/eye.2008.35
   LAMBROU FH, 1989, OPHTHALMIC SURG LAS, V20, P100
   LUXENBERG M, 1969, AM J OPHTHALMOL, V67, P406, DOI 10.1016/0002-9394(69)92056-X
   MILLER H, 1983, INVEST OPHTH VIS SCI, V24, P133
   Mitchell P, 2003, OPHTHAL EPIDEMIOL, V10, P331, DOI 10.1076/opep.10.5.331.17324
   Moss SE, 2001, AM J OPHTHALMOL, V132, P70, DOI 10.1016/S0002-9394(01)00936-9
   Parnes RE, 1998, AM J OPHTHALMOL, V125, P703, DOI 10.1016/S0002-9394(98)00031-2
   Vaz JC, 2006, PRINCIPAIS RECOMENDA
   Winkler J, 2001, INVEST OPHTH VIS SCI, V42, P902
NR 15
TC 0
Z9 0
U1 0
U2 3
PU SOC BRASILEIRA OFTALMOLOGIA
PI RIO DE JANEIRO
PA RUA SAO SALVADOR 107, RIO DE JANEIRO, 22231-170, BRAZIL
SN 0034-7280
J9 REV BRAS OFTALMOL
JI Rev. Bras. Oftalmol.
PD SEP-OCT
PY 2013
VL 72
IS 5
BP 312
EP 315
DI 10.1590/S0034-72802013000500006
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 296WS
UT WOS:000330216700006
OA gold
DA 2022-11-30
ER

PT J
AU Chen, N
   Huang, TL
   Tsai, RK
   Sheu, MM
AF Chen, Nancy
   Huang, Tzu-Lun
   Tsai, Rong-Kung
   Sheu, Min-Muh
TI Prevalence and causes of visual impairment in elderly Amis aborigines in
   eastern Taiwan (the Amis Eye Study)
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Amis elderly aborigines; Visual impairment; Low vision; Blindness
ID AGE-RELATED MACULOPATHY; LOW-VISION; GRADING SYSTEM; POPULATION;
   BLINDNESS; CLASSIFICATION; CATARACT
AB To investigate the prevalence and causes of visual impairment in elderly Amis aborigines in Eastern Taiwan.
   Population-based cross-sectional study of visual impairment of elderly Amis (65 years of age or older). We conducted ocular examinations on 2,316 participants, which represent 61.2 % of the elderly population. We used WHO criteria to identify visual impaired subjects, and the causes were analyzed.
   Ninety-four subjects were identified with low vision and nineteen were blind. The prevalence of low vision was 4.06 % (95 % confidence interval, 3.26, 4.56 %); that of blindness was 0.82 % (95 % confidence interval, 0.45, 1.19 %). Cataracts (47.79 %) were the main cause of visual impairment, followed by age-related macular degeneration (15.93 %), corneal opacity (7.96 %), optic neuropathy (7.96 %), diabetic retinopathy (5.31 %), and retinitis pigmentosa (2.65 %). Glaucoma was a minor cause of visual impairment. There were no significant gender differences in the prevalence and specific causes of visual impairment.
   The prevalence of treatable causes of vision impairment, for example cataracts and corneal opacity, is high among the elderly Amis aborigines. They would, therefore, benefit from a more aggressive and in-depth eye-care program as a blindness-prevention strategy.
C1 [Chen, Nancy; Huang, Tzu-Lun; Tsai, Rong-Kung; Sheu, Min-Muh] Buddhist Tzu Chi Gen Hosp, Dept Ophthalmol, Hualien 97002, Taiwan.
   [Chen, Nancy] Buddhist Tzu Chi Gen Hosp, Yuli Branch, Yuli Township 981, Hualien County, Taiwan.
   [Huang, Tzu-Lun; Tsai, Rong-Kung; Sheu, Min-Muh] Tzu Chi Univ, Dept Ophthalmol & Visual Sci, Hualien 97002, Taiwan.
C3 Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Buddhist
   Tzu Chi General Hospital; Tzu Chi University
RP Sheu, MM (通讯作者)，Buddhist Tzu Chi Gen Hosp, Dept Ophthalmol, 707,Sect 3,Chung Yang Rd, Hualien 97002, Taiwan.
EM hsuhung@tzuchi.com.tw
RI Chen, Nancy/GSD-8813-2022; huang, tzulun/G-5829-2015
OI huang, tzulun/0000-0003-0984-3525; Chen, Nancy/0000-0002-7649-2246
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   HEATH SA, 1973, AM J OPHTHALMOL, V75, P121, DOI 10.1016/0002-9394(73)90661-2
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Huang TL, 2010, JPN J OPHTHALMOL, V54, P266, DOI 10.1007/s10384-010-0817-x
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Jaross N, 2005, CLIN EXP OPHTHALMOL, V33, P26, DOI 10.1111/j.1442-9071.2005.00939.x
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Ko Ying-Chin, 1994, Kaohsiung Journal of Medical Sciences, V10, P337
   Lin M, 1998, TRANSFUS MED REV, V12, P56, DOI 10.1016/S0887-7963(98)80090-4
   MANN I, 1969, AM J OPHTHALMOL, V67, P358, DOI 10.1016/0002-9394(69)92045-5
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Nakamura Y, 2010, OPHTHALMOLOGY, V117, P2315, DOI 10.1016/j.ophtha.2010.03.043
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Taylor HR, 2010, MED J AUSTRALIA, V192, P312, DOI 10.5694/j.1326-5377.2010.tb03529.x
   Trejaut JA, 2005, PLOS BIOL, V3, P1362, DOI 10.1371/journal.pbio.0030247
   Wang JJ, 2003, CLIN EXP OPHTHALMOL, V31, P317, DOI 10.1046/j.1442-9071.2003.00659.x
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Xu L, 2011, GRAEF ARCH CLIN EXP, V249, P981, DOI 10.1007/s00417-010-1571-y
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
NR 21
TC 12
Z9 14
U1 0
U2 10
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2012
VL 56
IS 6
BP 624
EP 630
DI 10.1007/s10384-012-0178-8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 036AC
UT WOS:000310996200015
PM 22961342
DA 2022-11-30
ER

PT J
AU Dou, GR
   Sreekumar, PG
   Spee, C
   He, SK
   Ryan, SJ
   Kannan, R
   Hinton, DR
AF Dou, Guorui
   Sreekumar, Parameswaran G.
   Spee, Christine
   He, Shikun
   Ryan, Stephen J.
   Kannan, Ram
   Hinton, David R.
TI Deficiency of alpha B crystallin augments ER stress-induced apoptosis by
   enhancing mitochondrial dysfunction
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Retinal pigment epithelium (RPE); Endoplasmic reticulum (ER) stress;
   Mitochondria; alpha B Crystallin; Apoptosis
ID ENDOPLASMIC-RETICULUM-STRESS; RETINAL-PIGMENT EPITHELIUM; UNFOLDED
   PROTEIN RESPONSE; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION;
   CELL-DEATH; BAX; TRANSLOCATION; INVOLVEMENT; CASPASE-12
AB Endoplasmic reticulum (ER) stress is linked to several pathological conditions including age-related macular degeneration. Excessive ER stress initiates cell death cascades which are mediated, in part, through mitochondria] dysfunction. Here, we identify alpha B crystallin as an important regulator of ER stress-induced cell death. Retinal pigment epithelial (RPE) cells from alpha B crystallin (-/-) mice, and human RPE cells transfected with alpha B crystallin siRNA, are more vulnerable to ER stress induced by tunicamycin. ER stress-mediated cell death is associated with increased levels of reactive oxygen species, depletion of glutathione in mitochondria, decreased superoxide dismutase activity, increased release of cytochrome c, and activation of caspases 3 and 4. The ER stress signaling inhibitors, salubrinal and 4-(2-aminoethyl) benzenesulfonyl fluoride, decrease mitochondrial damage and reduce RPE apoptosis induced by ER stress. Prolonged ER stress decreases levels of alpha B crystallin, thus exacerbating mitochondrial dysfunction. Overexpression of alpha B crystallin protects RPE cells from ER stress-induced apoptosis by attenuating increases in Bax, CHOP, mitochondrial permeability transition, and cleaved caspase 3. Thus, these data collectively demonstrate that alpha B crystallin provides critical protection of mitochondrial function during ER stress-induced RPE apoptosis. (C) 2012 Elsevier Inc. All rights reserved.
C1 [He, Shikun; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Dou, Guorui; Sreekumar, Parameswaran G.; Spee, Christine; He, Shikun; Ryan, Stephen J.; Kannan, Ram; Hinton, David R.] Doheny Eye Inst, Arnold & Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Dou, Guorui] Fourth Mil Med Univ, Xijing Hosp, Dept Ophthalmol, Xian 710032, Peoples R China.
   [Spee, Christine; He, Shikun; Ryan, Stephen J.; Kannan, Ram; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 University of Southern California; Doheny Eye Institute; Air Force
   Military Medical University; University of Southern California
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90033 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU Arnold and Mabel Beckman Foundation; Research to Prevent Blindness Inc.,
   New York, NY;  [EY01545];  [EY03040]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR000130] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY001545, P30EY003040] Funding Source: NIH
   RePORTER
FX This work was supported in part by Grant EY01545 (SJR, DRH) and by core
   Grant EY03040; the Arnold and Mabel Beckman Foundation; an unrestricted
   grant to the Department of Ophthalmology from Research to Prevent
   Blindness Inc., New York, NY. We thank Jennifer Yaung, Ph.D. for
   assistance in preliminary experiments and Eric A. Barron and Ernesto
   Barron for expert technical help.
CR Bhatt K, 2008, AM J PHYSIOL-RENAL, V294, pF499, DOI 10.1152/ajprenal.00415.2007
   Bian ZM, 2009, INVEST OPHTH VIS SCI, V50, P6006, DOI 10.1167/iovs.09-3628
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bousette N, 2010, P NATL ACAD SCI USA, V107, P18481, DOI 10.1073/pnas.1013555107
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805
   Carriere A, 2004, J BIOL CHEM, V279, P40462, DOI 10.1074/jbc.M407258200
   Dasmahapatra G, 2009, CANCER BIOL THER, V8, P808, DOI 10.4161/cbt.8.9.8131
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   el Dein OS, 2009, FRONT BIOSCI-LANDMRK, V14, P3465, DOI 10.2741/3465
   Forman HJ, 2009, MOL ASPECTS MED, V30, P1, DOI 10.1016/j.mam.2008.08.006
   Fu HY, 2010, CIRCULATION, V122, P361, DOI 10.1161/CIRCULATIONAHA.109.917914
   Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369
   GUPTA S, 2010, INT J CELL BIOL
   He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2
   Hetz CA, 2007, ANTIOXID REDOX SIGN, V9, P2345, DOI 10.1089/ars.2007.1793
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Ikesugi K, 2006, EXP EYE RES, V83, P508, DOI 10.1016/j.exer.2006.01.033
   Kadono T, 2006, J MOL CELL CARDIOL, V40, P783, DOI 10.1016/j.yjmcc.2006.03.003
   Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200
   Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200
   Kannan R., 2012, PROG RET EY IN PRESS
   Kase S., 2009, BLOOD, V22, P3398
   Kim HR, 2009, J CELL SCI, V122, P1126, DOI 10.1242/jcs.038430
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kim YH, 2007, NEUROBIOL DIS, V28, P293, DOI 10.1016/j.nbd.2007.07.017
   Kowluru RA, 2006, FREE RADICAL BIO MED, V41, P1191, DOI 10.1016/j.freeradbiomed.2006.01.012
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   Kozlov AV, 2009, BBA-MOL BASIS DIS, V1792, P521, DOI 10.1016/j.bbadis.2009.03.004
   Li B, 2008, MOL VIS, V14, P1122
   Li JM, 2009, FEBS LETT, V583, P1521, DOI 10.1016/j.febslet.2009.04.007
   Lluis JM, 2003, GASTROENTEROLOGY, V124, P708, DOI 10.1053/gast.2003.50089
   Luetjens CM, 2000, J NEUROSCI, V20, P5715
   Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Mendes CS, 2009, EMBO J, V28, P1296, DOI 10.1038/emboj.2009.76
   Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200
   Momoi T, 2004, J CHEM NEUROANAT, V28, P101, DOI 10.1016/j.jchemneu.2004.05.008
   Mukhopadhyay P, 2007, BIOCHEM BIOPH RES CO, V358, P203, DOI 10.1016/j.bbrc.2007.04.106
   Muyderman H, 2007, J NEUROCHEM, V102, P1369, DOI 10.1111/j.1471-4159.2007.04641.x
   Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200
   Ouyang YB, 2011, MITOCHONDRION, V11, P279, DOI [10.1016/j.mito.2010.10.007, 10.1016/j.mito.2011.09.001]
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Rothbard JB, 2012, J BIOL CHEM, V287, P9708, DOI 10.1074/jbc.M111.337691
   Ruan Q, 2011, MOL CANCER RES, V9, P1632, DOI 10.1158/1541-7786.MCR-11-0327
   Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451
   Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2
   Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208
   Shimazawa M, 2007, MOL VIS, V13, P578
   Shin JH, 2009, NEUROSCI RES, V64, P355, DOI 10.1016/j.neures.2009.04.006
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Smith MI, 2007, CELL DEATH DIFFER, V14, P1011, DOI 10.1038/sj.cdd.4402089
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857
   Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4
   Wang J, 2000, J CELL SCI, V113, P753
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang D, 2007, CELL DEATH DIFFER, V14, P703, DOI 10.1038/sj.cdd.4402072
   Zhang DW, 2008, J BIOL CHEM, V283, P3476, DOI 10.1074/jbc.M707528200
NR 65
TC 62
Z9 65
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD SEP 1
PY 2012
VL 53
IS 5
BP 1111
EP 1122
DI 10.1016/j.freeradbiomed.2012.06.042
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 003PV
UT WOS:000308624700010
PM 22781655
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Grimm, C
   Willmann, G
AF Grimm, Christian
   Willmann, Gabriel
TI Hypoxia in the Eye: A Two-Sided Coin
SO HIGH ALTITUDE MEDICINE & BIOLOGY
LA English
DT Article
DE hypoxia inducible factor; erythropoietin; ophthalmic changes
ID ENDOTHELIAL GROWTH-FACTOR; PROLIFERATIVE DIABETIC-RETINOPATHY; CHOROIDAL
   NEOVASCULAR MEMBRANES; INDUCED RETINAL DEGENERATION; INDUCIBLE FACTOR
   1-ALPHA; OCULAR BLOOD-FLOW; OPTIC-NERVE HEAD; HIGH-ALTITUDE; MACULAR
   DEGENERATION; VEGF EXPRESSION
AB Grimm, Christian, Gabriel Willman. Hypoxia in the eye: A two-sided coin. High Alt Med Biol. 13:169-175, 2012.-Tissue oxygenation in general and hypoxia in particular are important regulators of retinal physiology and pathophysiology. Reduced oxygen tension and hypoxia-inducible transcription factors along with some of their target genes are critically involved in retinal development, and especially in the generation of a normal retinal vasculature. Well-timed hypoxia is thus vital for the young eye to establish proper retinal function and vision. However, when hypoxia is ill-timed, reduced oxygen tension may be associated with the development of retinal pathologies, including retinopathy of prematurity, diabetic retinopathy, glaucoma, age-related macular degeneration, or high altitude retinopathy. Here, reduced oxygen tension activates a hypoxic response that culminates in an increased expression of vascular endothelial growth factor. This causes pathological neovascularization of the delicate neuronal retina, a process that may ultimately lead to loss of vision. In contrast, preconditioning by well-defined and controlled short-term hypoxia is not devastating for the retina but instead induces a molecular response that provides protection to neuronal cells. Detailed investigation of hypoxic mechanisms during development and adulthood may thus reveal factors, which may be targeted by therapeutic approaches to save and preserve vision in patients.
C1 [Grimm, Christian] Univ Zurich, Lab Retinal Cell Biol, Dept Ophthalmol, Ctr Integrat Human Physiol ZIHP,USZ, CH-8952 Zurich, Switzerland.
   [Grimm, Christian] Univ Zurich, Neurosci Ctr ZNZ, CH-8952 Zurich, Switzerland.
   [Willmann, Gabriel] Univ Tubingen, Univ Eye Hosp, D-72074 Tubingen, Germany.
   [Willmann, Gabriel] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, D-72074 Tubingen, Germany.
C3 University of Zurich; Zurich Center Integrative Human Physiology (ZIHP);
   University of Zurich; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital
RP Grimm, C (通讯作者)，Univ Zurich, Lab Retinal Cell Biol, Dept Ophthalmol, Ctr Integrat Human Physiol ZIHP,USZ, Wagistr 14, CH-8952 Zurich, Switzerland.
EM cgrimm@opht.uzh.ch
OI Grimm, Christian/0000-0001-9318-4352
FU Swiss National Science Foundation (SNF)
FX Supported by a grant of the Swiss National Science Foundation (SNF).
CR Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Arden GB, 2011, CURR DIABETES REV, V7, P291, DOI 10.2174/157339911797415620
   Bandello F, 2012, EYE, V26, P485, DOI 10.1038/eye.2011.337
   Bantignies F, 2006, CURR OPIN CELL BIOL, V18, P275, DOI 10.1016/j.ceb.2006.04.003
   Barthelmes D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0011532
   Bosch MM, 2008, ARCH OPHTHALMOL-CHIC, V126, P644, DOI 10.1001/archopht.126.5.644
   Bosch MM, 2009, J APPL PHYSIOL, V106, P454, DOI 10.1152/japplphysiol.90904.2008
   Caprara C, 2012, PROG RETIN EYE RES, V31, P89, DOI 10.1016/j.preteyeres.2011.11.003
   Caprara C, 2011, INVEST OPHTH VIS SCI, V52, P2109, DOI 10.1167/iovs.10-6222
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Colombo ES, 2007, INVEST OPHTH VIS SCI, V48, P1793, DOI 10.1167/iovs.06-0923
   Ferris FL, 1999, NEW ENGL J MED, V341, P667, DOI 10.1056/NEJM199908263410907
   Fischer MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036155
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Grimm C, 2004, J NEUROSCI, V24, P5651, DOI 10.1523/JNEUROSCI.1288-04.2004
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Ho TY, 2011, RETINA-J RET VIT DIS, V31, P1650, DOI 10.1097/IAE.0b013e318207ceab
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Kuiper EJ, 2004, BRIT J OPHTHALMOL, V88, P1082, DOI 10.1136/bjo.2003.032045
   Kurihara T, 2010, DEVELOPMENT, V137, P1563, DOI 10.1242/dev.049015
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lange C, 2011, NEUROBIOL DIS, V41, P119, DOI 10.1016/j.nbd.2010.08.028
   Lara-Castillo N, 2009, AM J PATHOL, V175, P2343, DOI 10.2353/ajpath.2009.090439
   Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1
   Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667
   McNulty R, 2004, J PHYSIOL-LONDON, V559, P883, DOI 10.1113/jphysiol.2004.068619
   Mervin K, 2002, EXP EYE RES, V75, P715, DOI 10.1006/exer.2002.2064
   Mintz-Hittner HA, 2008, RETINA-J RET VIT DIS, V28, P831, DOI 10.1097/IAE.0b013e318177f934
   Mintz-Hittner HA, 2009, CURR OPIN PEDIATR, V21, P182, DOI 10.1097/MOP.0b013e32832925f9
   Morris DS, 2007, HIGH ALT MED BIOL, V8, P337, DOI 10.1089/ham.2007.1026
   Noma H, 2002, ARCH OPHTHALMOL-CHIC, V120, P1075
   Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029
   Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252
   Pavlidis M, 2005, OPHTHALMOLOGICA, V219, P404, DOI 10.1159/000088387
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Reme CE, 2000, KLIN MONATSBL AUGENH, V216, P129, DOI 10.1055/s-2000-10532
   Rex TS, 2009, EXP EYE RES, V89, P735, DOI 10.1016/j.exer.2009.06.017
   Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027
   Roth S, 1998, INVEST OPHTH VIS SCI, V39, P777
   Safvati A, 2009, CURR EYE RES, V34, P501, DOI 10.1080/02713680902919557
   Sandercoe TM, 2003, J COMP NEUROL, V462, P42, DOI 10.1002/cne.10705
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Spranger J, 1999, EXP CLIN ENDOCR DIAB, V107, P21, DOI 10.1055/s-0029-1212068
   Spranger J, 2000, DIABETOLOGIA, V43, P1404, DOI 10.1007/s001250051546
   Stahl A, 2011, OPHTHALMOLOGE, V108, P777, DOI 10.1007/s00347-011-2371-4
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Stowell Cheri, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P148
   Sullivan T, 2011, NEUROCHEM RES, V36, P613, DOI 10.1007/s11064-010-0272-6
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Thiersch M, 2009, EUR J NEUROSCI, V29, P2291, DOI 10.1111/j.1460-9568.2009.06781.x
   Thiersch M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-73
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   West H, 2005, DEVELOPMENT, V132, P1855, DOI 10.1242/dev.01732
   WIEDMAN M, 1975, ARCH OPHTHALMOL-CHIC, V93, P401
   Willmann G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027022
   Willmann G, 2010, BRIT J OPHTHALMOL, V94, P1393, DOI 10.1136/bjo.2009.178491
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wong CG, 2001, CURR EYE RES, V22, P140, DOI 10.1076/ceyr.22.2.140.5528
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Zhang C, 2010, GENE THER, V17, P338, DOI 10.1038/gt.2009.158
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
NR 75
TC 44
Z9 46
U1 0
U2 19
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1527-0297
EI 1557-8682
J9 HIGH ALT MED BIOL
JI High Alt. Med. Biol.
PD SEP
PY 2012
VL 13
IS 3
BP 169
EP 175
DI 10.1089/ham.2012.1031
PG 7
WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
GA 011JU
UT WOS:000309161700006
PM 22994516
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Matsumura, N
   Kamei, M
   Tsujikawa, M
   Suzuki, M
   Xie, P
   Nishida, K
AF Matsumura, Nagakazu
   Kamei, Motohiro
   Tsujikawa, Motokazu
   Suzuki, Mihoko
   Xie, Ping
   Nishida, Kohji
TI Low-Dose Lipopolysaccharide Pretreatment Suppresses Choroidal
   Neovascularization via IL-10 Induction
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; CHLAMYDIA-PNEUMONIAE;
   MOLECULAR MIMICRY; MURINE MODEL; INFECTION; INFLAMMATION; ENDOTOXIN;
   THERAPY; TRANSLOCATION
AB Recent studies have suggested that some kinds of microbial infection may have a crucial role in the development of many diseases such as autoimmune diseases and certain types of cancer. It has been reported that some chronic infections, such as Chlamydia pneumoniae, and immunological dysfunctions are associated with age-related macular degeneration (AMD), a leading cause of blindness. To evaluate the association between systemic low-level inflammation induced by infection and AMD pathogenesis, we investigated whether intraperitoneal injection of lipopolysaccharide (LPS) can modulate the development of laser-induced choroidal neovascularization (CNV), a key feature of AMD. Contrary to our expectations, the sizes of CNV in mice with LPS pretreatment were approximately 65% smaller than those of the control mice. After LPS pretreatment, serum IL-10 concentration and IL-10 gene expression in peritoneal macrophages and in the posterior part of the eye increased. Peritoneal injection of anti-IL10 antibody reduced CNV suppression by LPS pretreatment. Moreover, adoptive transfer of the resident peritoneal macrophages from LPS-treated mice into control littermates resulted in an approximately 26% reduction in the size of CNV compared with PBS-treated mice. We concluded that CNV formation was suppressed by low-dose LPS pretreatment via IL-10 production by macrophages.
C1 [Matsumura, Nagakazu; Kamei, Motohiro; Tsujikawa, Motokazu; Suzuki, Mihoko; Xie, Ping; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Osaka, Japan.
C3 Osaka University
RP Matsumura, N (通讯作者)，Osaka Univ, Dept Ophthalmol, Grad Sch Med, Osaka, Japan.
EM mkamei@ophthal.med.osaka-u.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610; Xie, Ping/0000-0003-4257-8970
FU Japan Society for the Promotion of Science [KAKENHI 21592231, 21592229]
FX This work was supported in part by Grant-in-Aid for Scientific Research
   from Japan Society for the Promotion of Science (KAKENHI 21592231,
   21592229). http://www.jsps.go.jp/english/index.html. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. No additional external funding
   received for this study.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Epstein SE, 2000, ARTERIOSCL THROM VAS, V20, P1417, DOI 10.1161/01.ATV.20.6.1417
   FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kamei M, 2004, AM J OPHTHALMOL, V138, P574, DOI 10.1016/j.ajo.2004.05.029
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Machemer R, 1998, AM J OPHTHALMOL, V125, P698, DOI 10.1016/S0002-9394(98)00020-8
   Mantovani A, 2007, EUR J IMMUNOL, V37, P14, DOI 10.1002/eji.200636910
   McClain MT, 2005, NAT MED, V11, P85, DOI 10.1038/nm1167
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999
   Wang JH, 2003, J IMMUNOL, V170, P14, DOI 10.4049/jimmunol.170.1.14
NR 30
TC 14
Z9 14
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 3
PY 2012
VL 7
IS 7
AR e39890
DI 10.1371/journal.pone.0039890
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 971EQ
UT WOS:000306186900021
PM 22802947
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Luke, M
   Januschowski, K
   Luke, J
   Peters, S
   Wirtz, N
   Yoruk, E
   Luke, C
   Bartz-Schmidt, KU
   Grisanti, S
   Szurman, P
AF Lueke, M.
   Januschowski, K.
   Lueke, J.
   Peters, S.
   Wirtz, N.
   Yoeruek, E.
   Lueke, C.
   Bartz-Schmidt, K. U.
   Grisanti, S.
   Szurman, P.
TI The effects of ranibizumab (Lucentis) on retinal function in isolated
   perfused vertebrate retina
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; FRAGMENT
AB Background: Intraocular ranibizumab (Lucentis, Novartis, Basel Switzerland) is the primary choice in the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor ( VEGF) is known to be a survival factor for neuronal cells. Therefore, blockage of all VEGF isoforms by ranibizumab could induce retinal dysfunction.
   Methods: Using isolated bovine retinas, the electroretinogram (ERG) was recorded as a transretinal potential using Ag/AgCl electrodes, while the retinas were perfused with an oxygen preincubated nutrient solution. For 45 min, ranibizumab was applied at a concentration of 0.2 mg/ml and alternatively the solvent carrier without the active agent. The ERG was monitored before, during and after exposure.
   Results: The concentration of 0.2 mg/ml ranibizumab induced a non-significant b-wave reduction of 22.32% after exposure (p = 0.13). For the a-wave amplitude only a reduction of 4% was detected (p = 0.18). The solvent carrier induced no significant reduction of the a- and b-wave amplitudes (p = 0.30 and p = 0.979, respectively).
   Conclusion: In the ex vivo model, the isolated perfused vertebrate retina, ranibizumab has been proven to be a safe compound at the concentrations applied. The stability of the ERG-amplitudes rules out a considerable retinal dysfunction after an injection of up to 1 mg ranibizumab.
C1 [Lueke, M.; Lueke, J.; Peters, S.; Wirtz, N.; Grisanti, S.] Med Univ Lubeck, Univ Eye Hosp, D-23538 Lubeck, Germany.
   [Januschowski, K.; Yoeruek, E.; Bartz-Schmidt, K. U.] Univ Tubingen, Ctr Ophthalmol, Univ Eye Hosp, Tubingen, Germany.
   [Lueke, C.] Univ Cologne, Ctr Ophthalmol, Cologne, Germany.
C3 University of Lubeck; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital; University of Cologne
RP Luke, M (通讯作者)，Med Univ Lubeck, Hosp Eye, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM matthias.lueke@uk-sh.de
RI Grisanti, Swaantje/AAI-1210-2020
FU Novartis (Basel, Switzerland)
FX This study has been funded by Novartis (Basel, Switzerland).
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fraser-Bell S, 2008, CURR OPIN OPHTHALMOL, V19, P185, DOI 10.1097/ICU.0b013e3282fb7c45
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   HANAWA I, 1970, EXPERIENTIA, V26, P1311, DOI 10.1007/BF02112997
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luke M, 2005, BRAIN RES PROTOC, V16, P27, DOI 10.1016/j.brainresprot.2005.09.001
   Luke M, 2005, J OCUL PHARMACOL TH, V21, P305, DOI 10.1089/jop.2005.21.305
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   SICKEL W, 1965, SCIENCE, V148, P648, DOI 10.1126/science.148.3670.648
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
NR 20
TC 13
Z9 13
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2009
VL 93
IS 10
BP 1396
EP 1400
DI 10.1136/bjo.2009.157511
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 498JN
UT WOS:000270135700027
PM 19628500
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Maaijwee, K
   Joussen, AM
   Kirchhof, B
   van Meurs, JC
AF Maaijwee, K.
   Joussen, A. M.
   Kirchhof, B.
   van Meurs, J. C.
TI Retinal pigment epithelium (RPE)-choroid graft translocation in the
   treatment of an RPE tear: Preliminary results
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CHOROID TRANSLOCATION; FOLLOW-UP; RETINOTOMY
AB Aim: To investigate whether retinal pigment epithelium ( RPE)-choroid translocation would be a suitable treatment for RPE tears, which have a poor prognosis and are encountered more often since the introduction of anti( vascular endothelial growth factor ( VEGF)) therapy for exudative age-related macular degeneration (AMD).
   Methods: Prospective interventional case series of six eyes of six patients with AMD with an RPE tear treated with an RPE-choroid translocation. The RPE tear occurred in a vascularised pigment epithelium detachment in four patients and after treatment in the other two. Preoperative and postoperative evaluation included ETDRS visual acuity (VA) and fixation testing. The follow-up period ranged from 6 months to 2 years.
   Results: The mean preoperative VA was 20/160 ( range 20/400-20/80). The mean VA at the last examination after surgery was 20/80 ( range 1/60-20/50). One of the six patients had a preoperative VA of >= 20/80, and four had a VA of 20/80 or better at their last examination. Foveal fixation on the graft was present in five of the six eyes up to the last examination.
   Conclusion: These preliminary data show that an RPE choroid translocation may be a treatment option for patients with an RPE tear.
C1 [Maaijwee, K.; van Meurs, J. C.] Rotterdam Eye Hosp, Dept Vitreoretinal Surg, NL-3011 BH Rotterdam, Netherlands.
   [Joussen, A. M.] Univ Dusseldorf, Dept Ophthalmol, Dusseldorf, Germany.
   [Kirchhof, B.] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Cologne, Germany.
   [van Meurs, J. C.] Erasmus Univ, Rotterdam, Netherlands.
C3 Rotterdam Eye Hospital; Heinrich Heine University Dusseldorf; University
   of Cologne; Erasmus University Rotterdam
RP Maaijwee, K (通讯作者)，Rotterdam Eye Hosp, Dept Vitreoretinal Surg, NL-3011 BH Rotterdam, Netherlands.
EM kmaaijwee@hotmail.com
RI Joussen, Antonia/AAA-6901-2022
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   BRESSLER NM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1694, DOI 10.1001/archopht.1990.01070140048026
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   DECKER WL, 1983, OPHTHALMOLOGY, V5, P507
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Gibran SK, 2007, BRIT J OPHTHALMOL, V91, P602, DOI 10.1136/bjo.2006.108795
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kuiper EJ, 2007, INVEST OPHTH VIS SCI, V48, P4267, DOI 10.1167/iovs.06-0804
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   MAAIJWEE K, 2008, IN PRESS RETINA
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 20
TC 29
Z9 29
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2008
VL 92
IS 4
BP 526
EP 529
DI 10.1136/bjo.2007.131383
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 279XH
UT WOS:000254388200022
PM 18369068
DA 2022-11-30
ER

PT J
AU Desideri, LF
   Traverso, CE
   Nicolo, M
AF Desideri, Lorenzo Ferro
   Traverso, Carlo Enrico
   Nicolo, Massimo
TI The emerging role of the Angiopoietin-Tie pathway as therapeutic target
   for treating retinal diseases
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE Ang; Tie; angiopoietin; Tie pathway; anti-VEGF; retina diseases; macular
   degeneration; diabetic macular edema
ID DIABETIC MACULAR EDEMA; INTRAOCULAR PHARMACOKINETICS; VEGF;
   DEGENERATION; THERAPIES; RECEPTOR; TRAP
AB Introduction Several approaches have been investigated for treating wet age-related macular degeneration (w-AMD), diabetic macular edema (DME) and retinal vein occlusions (RVOs). The first-line treatment for these exudative retinal diseases consists of anti-vascular endothelial growth factor (VEGF) agents; however, the high treatment burden and the percentage of 'non responder' patients have highlighted the need for other approaches. Increasing evidence has shown the role of angiopoietin/Tie (Ang/Tie) pathway in the pathogenesis of these exudative retinal diseases; therefore, novel drugs targeting this pathway are under evaluation in clinical trials. Areas covered We analyzed the novel, emerging drugs (ARP- 1536, the coformulation of aflibercept and nesvacumab, AXT107 and AKB-9778) that target the Ang/Tie pathway. These drugs are still in early phase clinical trials, but encouraging outcomes have emerged. We also discuss the clinical efficacy of faricimab, a bispecific monoclonal antibody that inhibits VEGF-A and Ang-2. Expert opinion The simultaneous targeting of the VEGF and Ang/Tie pathways may be more beneficial than monotherapy in patients with exudative retinal diseases. Among the investigational drugs targeting the Ang/Tie pathway, faricimab has shown promising results in phase II/III trials and in the near future may represent a viable treatment option for the management of exudative macular diseases
C1 [Desideri, Lorenzo Ferro; Traverso, Carlo Enrico; Nicolo, Massimo] IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, I-16136 Genoa, Italy.
   [Traverso, Carlo Enrico; Nicolo, Massimo] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genetics, Italy.
   [Nicolo, Massimo] Macula Onlus Fdn, Genoa, Italy.
C3 University of Genoa
RP Nicolo, M (通讯作者)，IRCCS Osped Policlin San Martino, Univ Eye Clin Genoa, I-16136 Genoa, Italy.
EM massimonicolo@gmail.com
CR Amarakoon S, 2019, ACTA OPHTHALMOL, V97, P107, DOI 10.1111/aos.13774
   [Anonymous], 2020, STUDY EVALUATE EFFIC
   [Anonymous], 2021, FAVORABLE 1 YEAR RES
   [Anonymous], 2019, TIME 2B TRIAL
   Arrigo A, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/5516981
   Batard P, 1996, BLOOD, V87, P2212, DOI 10.1182/blood.V87.6.2212.bloodjournal8762212
   Boyer DS, 2018, INVEST OPHTH VIS SCI, V59
   Cahoon JM, 2015, DIABETES, V64, P4247, DOI 10.2337/db14-1030
   Campa C, 2020, CURR DRUG TARGETS, V21, P1194, DOI 10.2174/1389450121666200428101738
   Campa C, 2016, CURR DRUG TARGETS, V17, P328, DOI 10.2174/1573399811666150615151324
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0816-5
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, P1722, DOI 10.1016/j.ophtha.2016.04.025
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P545, DOI 10.1016/j.ophtha.2014.09.023
   Chakravarthy U, 2017, OPHTHALMOL RETINA, V1, P474, DOI 10.1016/j.oret.2017.03.003
   ClinicalTrial.gov, 2022, STUDY EVALUATE LONG
   Day D, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0369-x
   Desideri LF, 2021, DRUG FUTURE, V46, P383, DOI 10.1358/dof.2021.46.5.3273779
   Desideri LF, 2020, DRUG TODAY, V56, P311, DOI 10.1358/dot.2020.56.5.3137164
   Desideri LF, 2019, DRUG FUTURE, V44, P761, DOI 10.1358/dof.2019.44.10.3058864
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Dewi NA, 2018, INT J OPHTHALMOL-CHI, V11, P375, DOI 10.18240/ijo.2018.03.05
   Desideri LF, 2020, EXPERT OPIN INV DRUG, V29, P651, DOI 10.1080/13543784.2020.1772754
   Desideri LF, 2021, EXPERT OPIN BIOL TH, V21, P553, DOI 10.1080/14712598.2021.1915278
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foxton RH, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810204
   Gavard J, 2008, DEV CELL, V14, P25, DOI 10.1016/j.devcel.2007.10.019
   Gui TS, 2021, FEBS J, DOI 10.1111/febs.16221
   Heier JS, 2021, RETINA-J RET VIT DIS, V41, P1, DOI 10.1097/IAE.0000000000003003
   Heier JS, 2014, OPHTHALMOLOGY, V121, pE5, DOI 10.1016/j.ophtha.2013.09.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894
   Hussain RM, 2019, EXPERT OPIN INV DRUG, V28, P861, DOI 10.1080/13543784.2019.1667333
   Hussain RM, 2017, EXPERT OPIN EMERG DR, V22, P235, DOI 10.1080/14728214.2017.1362390
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Kaiser Stephanie M, 2021, J Exp Pharmacol, V13, P905, DOI 10.2147/JEP.S259298
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Khayat M, 2018, SURV OPHTHALMOL, V63, P816, DOI 10.1016/j.survophthal.2018.04.005
   Kim M, 2016, J CLIN INVEST, V126, P3511, DOI 10.1172/JCI84871
   Kniggendorf V, 2020, ARQ BRAS OFTALMOL, V83, P552, DOI 10.5935/0004-2749.20200082
   Koh GY, 2013, TRENDS MOL MED, V19, P31, DOI 10.1016/j.molmed.2012.10.010
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lee J, 2014, INVEST OPHTH VIS SCI, V55, P2191, DOI 10.1167/iovs.14-13897
   Li GR, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.12
   Li ZL, 2020, J CLIN INVEST, V130, P1977, DOI 10.1172/JCI130308
   Silva RLE, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8030
   Loukovaara S, 2013, ACTA OPHTHALMOL, V91, P531, DOI 10.1111/j.1755-3768.2012.02473.x
   Ma L, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20575
   Makinde T, 2008, J CELL MOL MED, V12, P810, DOI 10.1111/j.1582-4934.2008.00254.x
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mirando AC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122043
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moore NA, 2017, EXPERT OPIN BIOL TH, V17, P1235, DOI 10.1080/14712598.2017.1356817
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Nicolo M, 2021, EXPERT OPIN INV DRUG, V30, P193, DOI 10.1080/13543784.2021.1879791
   Nicolo M, 2020, OPHTHALMOLOGICA, V243, P453, DOI 10.1159/000507711
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Parikh SM, 2006, PLOS MED, V3, P356, DOI 10.1371/journal.pmed.0030046
   Park DY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15296
   Park SJ, 2015, EYE, V29, P561, DOI 10.1038/eye.2014.329
   Park SW, 2014, DIABETES, V63, P3057, DOI 10.2337/db13-1942
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Saharinen P, 2017, NAT REV DRUG DISCOV, V16, P635, DOI 10.1038/nrd.2016.278
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schaefer W, 2011, P NATL ACAD SCI USA, V108, P11187, DOI 10.1073/pnas.1019002108
   Sharma A, 2020, EYE, V34, P802, DOI 10.1038/s41433-019-0670-1
   Sharma T, 2020, EYE, V34, P415, DOI 10.1038/s41433-019-0590-0
   Shen JK, 2014, J CLIN INVEST, V124, P4564, DOI 10.1172/JCI74527
   Striglia E, 2020, EXPERT OPIN EMERG DR, V25, P261, DOI 10.1080/14728214.2020.1801631
   TENAYA, 2021, LUCERNE TRIALS SHOW
   Virgili G, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub5
   Warmke N., 2021, ENDOCRINOLOGY, V162, DOI DOI 10.1210/ENDOCR/BQAB182
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yeung YT, 2018, CURR PHARM DESIGN, V24, P1449, DOI 10.2174/1381612824666180327165604
NR 80
TC 4
Z9 4
U1 1
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD FEB 1
PY 2022
VL 26
IS 2
BP 145
EP 154
DI 10.1080/14728222.2022.2036121
EA FEB 2022
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ZU1EC
UT WOS:000752346600001
PM 35098845
DA 2022-11-30
ER

PT J
AU Botto, C
   Rucli, M
   Tekinsoy, MD
   Pulman, J
   Sahel, JA
   Dalkara, D
AF Botto, Catherine
   Rucli, Marco
   Tekinsoy, Muge Defne
   Pulman, Juliette
   Sahel, Jose-Alain
   Dalkara, Deniz
TI Early and late stage gene therapy interventions for inherited retinal
   degenerations
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE AAV; Optogenetics; Retina; CRISPR; Cas9; Neuroprotection; Gene therapy
ID RHODOPSIN RETINITIS-PIGMENTOSA; RESTORES VISUAL RESPONSES;
   ADENOASSOCIATED VIRUS; CONE PHOTORECEPTORS; RAT MODEL;
   MORPHOMETRIC-ANALYSIS; ECTOPIC EXPRESSION; DNA NANOPARTICLES; GENOME
   SURGERY; PROTECTS CONE
AB Inherited and age-related retinal degeneration is the hallmark of a large group of heterogeneous diseases and is the main cause of untreatable blindness today. Genetic factors play a major pathogenic role in retinal degenerations for both monogenic diseases (such as retinitis pigmentosa) and complex diseases with established genetic risk factors (such as age-related macular degeneration). Progress in genotyping techniques and back of the eye imaging are completing our understanding of these diseases and their manifestations in patient populations suffering from retinal degenerations. It is clear that whatever the genetic cause, the majority of vision loss in retinal diseases results from the loss of photoreceptor function. The timing and circumstances surrounding the loss of photoreceptor function determine the adequate therapeutic approach to use for each patient. Among such approaches, gene therapy is rapidly becoming a therapeutic reality applicable in the clinic. This massive move from laboratory work towards clinical application has been propelled by the advances in our understanding of disease genetics and mechanisms, gene delivery vectors, gene editing systems, and compensatory strategies for loss of photoreceptor function. Here, we provide an overview of existing modalities of retinal gene therapy and their relevance based on the needs of patient populations suffering from inherited retinal degenerations.
C1 [Botto, Catherine; Rucli, Marco; Tekinsoy, Muge Defne; Pulman, Juliette; Sahel, Jose-Alain; Dalkara, Deniz] Sorbonne Univ, Inst Vis, INSERM, CNRS, F-75012 Paris, France.
   [Sahel, Jose-Alain] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA.
   [Sahel, Jose-Alain] CHNO Quinze Vingts, INSERM DGOS CIC 1423, F-75012 Paris, France.
   [Sahel, Jose-Alain] Fdn Ophtalmol Rothschild, F-75019 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; CHNO des Quinze-Vingts; UDICE-French Research Universities;
   Sorbonne Universite
RP Dalkara, D (通讯作者)，Sorbonne Univ, Inst Vis, INSERM, CNRS, F-75012 Paris, France.
EM deniz.dalkara@inserm.fr
RI Dalkara, Deniz/D-5057-2017; Pulman, Juliette/AAX-6060-2021
OI Dalkara, Deniz/0000-0003-4112-9321; Pulman,
   Juliette/0000-0002-8282-434X; Rucli, Marco/0000-0002-1829-7952; Botto,
   Catherine/0000-0002-2164-3852
FU LabEx LIFESENSES [ANR-10-LABX-65]; ERC StG [639888]; FRM; Paris
   Ile-de-France Region; IHU FOReSIGHT [ANR-18-IAHU-01]; AFM; Foundation
   Fighting Blindness
FX We would like to thank funding sources LabEx LIFESENSES (ANR-10-LABX-65)
   , IHU FOReSIGHT (ANR-18-IAHU-01) , Foundation Fighting Blindness, ERC
   StG (REGENETHER, 639888) , FRM, AFM. This work was supported by the
   Paris Ile-de-France Region. We are thankful to Katia Marazova for
   proofreading and comments.
CR Adijanto J, 2015, EUR J PHARM BIOPHARM, V95, P353, DOI 10.1016/j.ejpb.2014.12.028
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   [Anonymous], 2006, OPHTHALMOLOGY, V113
   Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4
   Apaolaza PS, 2016, BIOMATERIALS, V90, P40, DOI 10.1016/j.biomaterials.2016.03.004
   APOSHIAN HV, 1970, PERSPECT BIOL MED, V14, P98
   Apte RS, 2018, CELL, V173, P5, DOI 10.1016/j.cell.2018.03.021
   Astra Dinculescu, 2014, AM SOC GENE CELL THE
   Athanasiou D, 2018, PROG RETIN EYE RES, V62, P1, DOI 10.1016/j.preteyeres.2017.10.002
   Audo I, 2010, INVEST OPHTH VIS SCI, V51, P3687, DOI 10.1167/iovs.09-4766
   Bainbridge JW, 2008, GENE THER, V15, P1191, DOI 10.1038/gt.2008.117
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Bakondi B, 2016, MOL THER, V24, P556, DOI 10.1038/mt.2015.220
   Barker SE, 2009, J GENE MED, V11, P486, DOI 10.1002/jgm.1327
   Barnstable CJ, 2006, ADV EXP MED BIOL, V572, P291
   Battaglia L, 2016, EXPERT OPIN DRUG DEL, V13, P1743, DOI 10.1080/17425247.2016.1201059
   Bennett A, 2020, J STRUCT BIOL, V209, DOI 10.1016/j.jsb.2019.107433
   Bennett J, 2017, MOL THER, V25, P1076, DOI 10.1016/j.ymthe.2017.03.008
   Berry MH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09124-x
   Bi AD, 2006, NEURON, V50, P23, DOI 10.1016/j.neuron.2006.02.026
   Botta S, 2016, ELIFE, V5, DOI [10.7554/eLife/12242, 10.7554/eLife.12242]
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Byrne LC, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135112
   Byrne LC, 2015, J CLIN INVEST, V125, P105, DOI 10.1172/JCI65654
   Campochiaro PA, 2011, HUM GENE THER, V22, P523, DOI 10.1089/hum.2011.050
   Charlesworth CT, 2019, NAT MED, V25, P249, DOI 10.1038/s41591-018-0326-x
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Chew WL, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1408
   Chung SH, 2021, HUM GENE THER, V32, P682, DOI 10.1089/hum.2020.281
   Chuong AS, 2014, NAT NEUROSCI, V17, P1123, DOI 10.1038/nn.3752
   Cideciyan AV, 2018, P NATL ACAD SCI USA, V115, pE8547, DOI 10.1073/pnas.1805055115
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cottet S, 2009, CURR MOL MED, V9, P375, DOI 10.2174/156652409787847155
   Cremers FPM, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040215
   Cronin T, 2014, EMBO MOL MED, V6, P1175, DOI 10.15252/emmm.201404077
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Dalkara D, 2016, HUM GENE THER, V27, P134, DOI 10.1089/hum.2015.147
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   Dalkara D, 2011, MOL THER, V19, P1602, DOI 10.1038/mt.2011.62
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Devoldere J, 2019, J CONTROL RELEASE, V307, P315, DOI 10.1016/j.jconrel.2019.06.042
   Di Pierdomenico J, 2019, NEURAL REGEN RES, V14, P1186, DOI 10.4103/1673-5374.251204
   DiCarlo JE, 2018, J CLIN INVEST, V128, P2177, DOI 10.1172/JCI120429
   Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69
   Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038
   Farrar GJ, 2012, GENE THER, V19, P137, DOI 10.1038/gt.2011.172
   Fink TL, 2006, GENE THER, V13, P1048, DOI 10.1038/sj.gt.3302761
   Fischer A, 2010, NAT IMMUNOL, V11, P457, DOI 10.1038/ni0610-457
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Fradot M, 2011, HUM GENE THER, V22, P587, DOI 10.1089/hum.2010.157
   Frasson M, 1999, NAT MED, V5, P1183, DOI 10.1038/13508
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gagliardi G, 2019, PROG RETIN EYE RES, V71, P1, DOI 10.1016/j.preteyeres.2019.03.001
   Galvin J.A., 2005, EVALUATION GENOTYPE
   Gao GP, 2005, CURR GENE THER, V5, P285, DOI 10.2174/1566523054065057
   Gao X, 2018, NATURE, V553, P217, DOI 10.1038/nature25164
   Gaub BM, 2015, MOL THER, V23, P1562, DOI 10.1038/mt.2015.121
   Gaudelli NM, 2017, NATURE, V551, P464, DOI 10.1038/nature24644
   Gauvain G, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01594-w
   Giannelli SG, 2018, HUM MOL GENET, V27, P761, DOI 10.1093/hmg/ddx438
   Gyorgy B, 2019, NAT MED, V25, P1123, DOI 10.1038/s41591-019-0500-9
   Han ZC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052189
   Han ZC, 2012, J CLIN INVEST, V122, P3221, DOI 10.1172/JCI64833
   Hastie E, 2015, HUM GENE THER, V26, P257, DOI 10.1089/hum.2015.025
   Hickey DG, 2017, GENE THER, V24, P787, DOI 10.1038/gt.2017.85
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Jiang L, 2011, P NATL ACAD SCI USA, V108, P18476, DOI 10.1073/pnas.1112758108
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Joly S, 2007, INVEST OPHTH VIS SCI, V48, P2311, DOI 10.1167/iovs.06-1205
   Juttner J, 2019, NAT NEUROSCI, V22, P1345, DOI 10.1038/s41593-019-0431-2
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   Kalesnykas G, 2017, CURR GENE THER, V17, P235, DOI 10.2174/1566523217666171003170348
   Khabou H, 2018, HUM GENE THER, V29, P1235, DOI 10.1089/hum.2018.144
   Khabou H, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96029
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kim YB, 2017, NAT BIOTECHNOL, V35, P371, DOI 10.1038/nbt.3803
   Kolomeyer AM, 2014, SURV OPHTHALMOL, V59, P134, DOI 10.1016/j.survophthal.2013.09.004
   Komor AC, 2017, CELL, V168, P20, DOI 10.1016/j.cell.2016.10.044
   Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946
   Kotterman MA, 2015, GENE THER, V22, P116, DOI 10.1038/gt.2014.115
   Kotterman MA, 2014, NAT REV GENET, V15, P445, DOI 10.1038/nrg3742
   Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012
   Kunte MM, 2012, INVEST OPHTH VIS SCI, V53, P3792, DOI 10.1167/iovs.11-9235
   Latella MC, 2016, MOL THER-NUCL ACIDS, V5, P1, DOI 10.1038/mtna.2016.92
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Leveillard T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000866
   Levy JM, 2020, NAT BIOMED ENG, V4, P97, DOI 10.1038/s41551-019-0501-5
   Lewin AS, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017400
   Li PJ, 2018, CRISPR J, V1, P55, DOI 10.1089/crispr.2017.0009
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Lin B, 2009, EXP EYE RES, V88, P589, DOI 10.1016/j.exer.2008.11.022
   Lin JY, 2013, NAT NEUROSCI, V16, P1499, DOI 10.1038/nn.3502
   Lin JH, 2010, ADV EXP MED BIOL, V664, P115, DOI 10.1007/978-1-4419-1399-9_14
   Lombardi M, 2018, J GLAUCOMA, V27, P1017, DOI 10.1097/IJG.0000000000001066
   Luther DC, 2018, EXPERT OPIN DRUG DEL, V15, P905, DOI 10.1080/17425247.2018.1517746
   Mace E, 2015, MOL THER, V23, P7, DOI 10.1038/mt.2014.154
   Mao HY, 2012, HUM GENE THER, V23, P356, DOI 10.1089/hum.2011.213
   Mao HY, 2011, HUM GENE THER, V22, P567, DOI 10.1089/hum.2010.140
   Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139
   Maruyama T, 2015, NAT BIOTECHNOL, V33, P538, DOI 10.1038/nbt.3190
   McCullough KT, 2019, HUM GENE THER, V30, P571, DOI 10.1089/hum.2018.193
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P5756, DOI 10.1167/iovs.07-0054
   McGregor JE, 2019, ADV EXP MED BIOL, V1185, P145, DOI 10.1007/978-3-030-27378-1_24
   Mei X, 2016, ANTIOXID REDOX SIGN, V24, P909, DOI 10.1089/ars.2015.6509
   Mendes HF, 2005, TRENDS MOL MED, V11, P177, DOI 10.1016/j.molmed.2005.02.007
   Millington-Ward S, 2011, MOL THER, V19, P642, DOI 10.1038/mt.2010.293
   Mitra RN, 2014, CHEMMEDCHEM, V9, P189, DOI 10.1002/cmdc.201300371
   Mitra RN, 2018, BIOMATERIALS, V157, P26, DOI 10.1016/j.biomaterials.2017.12.004
   Moreno AM, 2018, MOL THER, V26, P1818, DOI 10.1016/j.ymthe.2018.04.017
   Mussolino C, 2011, EMBO MOL MED, V3, P118, DOI 10.1002/emmm.201000119
   O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188
   O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025
   Oh KT, 2003, AM J OPHTHALMOL, V136, P306, DOI 10.1016/S0002-9394(03)00206-X
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Orlans HO, 2020, HUM GENE THER, V31, P730, DOI 10.1089/hum.2020.008
   Patel S, 2019, J CONTROL RELEASE, V303, P91, DOI 10.1016/j.jconrel.2019.04.015
   Patrizi C, 2021, AM J HUM GENET, V108, P295, DOI 10.1016/j.ajhg.2021.01.006
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Puppo A, 2014, GENE THER, V21, P855, DOI 10.1038/gt.2014.57
   Puras G, 2013, EUR J PHARM SCI, V48, P323, DOI 10.1016/j.ejps.2012.11.009
   Ramachandran PS, 2015, J CLIN INVEST, V125, P1390, DOI 10.1172/JCI80821
   Ran FA, 2015, NATURE, V520, P186, DOI 10.1038/nature14299
   Rees HA, 2018, NAT REV GENET, V19, P770, DOI 10.1038/s41576-018-0059-1
   Rossi EA, 2011, EYE, V25, P301, DOI 10.1038/eye.2010.221
   Ryals RC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241006
   Sahel JA, 2019, NAT MED, V25, P198, DOI 10.1038/s41591-019-0346-1
   Sahel JA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax2324
   Sahel JA, 2013, ANNU REV NEUROSCI, V36, P467, DOI 10.1146/annurev-neuro-062012-170304
   Sahel JA, 2013, GRAEF ARCH CLIN EXP, V251, P1669, DOI 10.1007/s00417-013-2314-7
   Sato K, 2013, J NEUROSCI, V33, P17458, DOI 10.1523/JNEUROSCI.1380-13.2013
   Schimmer J, 2015, HUM GENE THER CL DEV, V26, P144, DOI 10.1089/humc.2015.29001.sch
   Schmidt M, 2008, J VIROL, V82, P1399, DOI 10.1128/JVI.02012-07
   Schmidt M, 2006, J VIROL, V80, P5082, DOI 10.1128/JVI.80.10.5082-5085.2006
   Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838
   Semple-Rowland SL, 2014, METHODS, V66, P466, DOI 10.1016/j.ymeth.2013.06.026
   Sengupta A, 2016, EMBO MOL MED, V8, P1248, DOI 10.15252/emmm.201505699
   Simhadri VL, 2018, MOL THER-METH CLIN D, V10, P105, DOI 10.1016/j.omtm.2018.06.006
   Simon CJ, 2020, BIOCHEM BIOPH RES CO, V527, P325, DOI 10.1016/j.bbrc.2019.12.117
   Slaymaker IM, 2016, SCIENCE, V351, P84, DOI 10.1126/science.aad5227
   Stolzenburg S, 2010, METHODS MOL BIOL, V649, P117, DOI 10.1007/978-1-60761-753-2_7
   Stone EM, 2009, CURR OPIN GENET DEV, V19, P283, DOI 10.1016/j.gde.2009.03.006
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Suh S, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-020-00632-6
   Suzuki K, 2016, NATURE, V540, P144, DOI 10.1038/nature20565
   Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293
   Thuronyi BW, 2019, NAT BIOTECHNOL, V37, P1070, DOI 10.1038/s41587-019-0193-0
   Tomita H, 2014, MOL THER, V22, P1434, DOI 10.1038/mt.2014.81
   Trapani I, 2014, PROG RETIN EYE RES, V43, P108, DOI 10.1016/j.preteyeres.2014.08.001
   Tsai YT, 2018, OPHTHALMOLOGY, V125, P1421, DOI 10.1016/j.ophtha.2018.04.001
   van Wyk M, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002143
   Venkatesh A, 2015, J CLIN INVEST, V125, P1446, DOI 10.1172/JCI79766
   Verrier JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020553
   Vignal-Clermont C, 2015, ACTA OPHTHALMOL, V93, DOI 10.1111/j.1755-3768.2015.0094
   Williams ML, 2006, PLOS MED, V3, P904, DOI 10.1371/journal.pmed.0030201
   Wright AF, 2010, NAT REV GENET, V11, P273, DOI 10.1038/nrg2717
   Wubben TJ, 2019, CURR OPIN OPHTHALMOL, V30, P199, DOI 10.1097/ICU.0000000000000558
   Xie Q, 2002, P NATL ACAD SCI USA, V99, P10405, DOI 10.1073/pnas.162250899
   Xiong WJ, 2019, P NATL ACAD SCI USA, V116, P5785, DOI 10.1073/pnas.1821000116
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Xue T, 2011, NATURE, V479, P67, DOI 10.1038/nature10567
   Yanik M, 2017, PROG RETIN EYE RES, V56, P1, DOI 10.1016/j.preteyeres.2016.09.001
   Yao K, 2018, NATURE, V560, P484, DOI 10.1038/s41586-018-0425-3
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
   Yu C, 2015, CELL STEM CELL, V16, P142, DOI 10.1016/j.stem.2015.01.003
   Yu WH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14716
   Yue L, 2016, PROG RETIN EYE RES, V53, P21, DOI 10.1016/j.preteyeres.2016.05.002
   Zeitz C, 2015, PROG RETIN EYE RES, V45, P58, DOI 10.1016/j.preteyeres.2014.09.001
   Zeng H, 2014, NEUROSCIENCE, V275, P54, DOI 10.1016/j.neuroscience.2014.05.065
   Zhang F, 2008, NAT NEUROSCI, V11, P631, DOI 10.1038/nn.2120
   Zischewski J, 2017, BIOTECHNOL ADV, V35, P95, DOI 10.1016/j.biotechadv.2016.12.003
   Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081
NR 175
TC 20
Z9 20
U1 16
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2022
VL 86
AR 100975
DI 10.1016/j.preteyeres.2021.100975
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YI7GO
UT WOS:000744013400002
PM 34058340
OA hybrid, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Ramtohul, P
   Engelbert, M
   Malcles, A
   Gigon, E
   Miserocchi, E
   Modorati, G
   De Souza, EC
   Besirli, CG
   Curcio, CA
   Freund, KB
AF Ramtohul, Prithvi
   Engelbert, Michael
   Malcles, Ariane
   Gigon, Edward
   Miserocchi, Elisabetta
   Modorati, Giulio
   De Souza, Eduardo Cunha
   Besirli, Cagri G.
   Curcio, Christine A.
   Freund, K. Bailey
TI BACILLARY LAYER DETACHMENT: MULTIMODAL IMAGING AND HISTOLOGIC EVIDENCE
   OF A NOVEL OPTICAL COHERENCE TOMOGRAPHY TERMINOLOGY Literature Review
   and Proposed Theory
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; anatomy; bacillary layer detachment;
   histology; macula; multimodal imaging; optical coherence tomography;
   photoreceptor; retina; retinal detachment; review; subretinal septa;
   Vogt-Koyanagi-Harada disease
ID KOYANAGI-HARADA DISEASE; OUTCOMES; THERAPY; RETINA; FLUID; EYES
AB Purpose: To clarify the histologic basis of bacillary layer detachment (BALAD) through a review of the current literature and an analysis of retinal imaging.
   Methods: The literature for previous reports of BALAD were reviewed. An analysis of retinal images was performed to support anatomical conclusions.
   Results: A total of 164 unique patients with BALAD on optical coherence tomography (OCT) were identified from the published literature. Twenty-two underlying etiologies, all associated with subretinal exudation, were identified. Forty-one different OCT terminologies were found. The defining OCT feature of BALAD was a split at the level of the photoreceptor inner segment myoid creating a distinctive intraretinal cavity. Resolution of BALAD was followed by a rapid restoration of the ellipsoid zone. Histology of age-related macular degeneration eyes suggests that individual photoreceptors can shed inner segments. Furthermore, detachment of the entire layer of inner segments is a common postmortem artifact. It is proposed that BALAD occurs when outwardly directed forces promoting attachment of photoreceptor outer segments to the retinal pigment epithelium exceed the tensile strength of the photoreceptor inner segment myoid.
   Conclusion: This review serves to strengthen the OCT nomenclature "bacillary layer detachment," based on specific reflectance information obtained by OCT and previously published histologic observations.
C1 [Ramtohul, Prithvi] Ctr Hosp Univ Hop Nord, Marseille, France.
   [Engelbert, Michael; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Engelbert, Michael; Freund, K. Bailey] NYU Langone Sch Med, Dept Ophthalmol, New York, NY USA.
   [Malcles, Ariane; Gigon, Edward] Geneva Univ Hosp, Dept Ophthalmol, Geneva, Switzerland.
   [Miserocchi, Elisabetta; Modorati, Giulio] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [De Souza, Eduardo Cunha] Hosp Clin FMUSP, Dept Ophthalmol, Sao Paulo, Brazil.
   [Besirli, Cagri G.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
C3 UDICE-French Research Universities; Aix-Marseille Universite; Vitreous
   Retina Macula Consultants of New York; NYU Langone Medical Center;
   University of Geneva; Vita-Salute San Raffaele University; IRCCS
   Ospedale San Raffaele; Universidade de Sao Paulo; University of Michigan
   System; University of Michigan; University of Alabama System; University
   of Alabama Birmingham
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI malcles, ariane/GVS-9056-2022; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773; Besirli,
   Cagri/0000-0001-7154-2024
FU Macula Foundation, Inc, New York, NY
FX Supported by The Macula Foundation, Inc, New York, NY.
CR Agarwal A, 2021, RETINA-J RET VIT DIS, V41, P774, DOI 10.1097/IAE.0000000000002914
   Aggarwal K, 2018, OCUL IMMUNOL INFLAMM, V26, P142, DOI 10.1080/09273948.2016.1195001
   Aggarwal K, 2017, J OPHTHALMIC INFLAMM, V7, DOI 10.1186/s12348-016-0122-z
   Anderson Erik W, 2021, Retin Cases Brief Rep, V15, P302, DOI 10.1097/ICB.0000000000000791
   [Anonymous], 1935, ACTA OPHTHALMOL, V13, P13
   Arevalo JF, 2016, OCUL IMMUNOL INFLAMM, V24, P521, DOI 10.3109/09273948.2015.1025984
   Attia S, 2012, EXPERT REV OPHTHALMO, V7, P565, DOI 10.1586/EOP.12.63
   Bae SS, 2017, OCUL IMMUNOL INFLAMM, V25, P338, DOI 10.3109/09273948.2015.1125510
   Bhende M, 2018, INDIAN J OPHTHALMOL, V66, P20, DOI 10.4103/ijo.IJO_902_17
   Chee SP, 2017, OCUL IMMUNOL INFLAMM, V25, P528, DOI 10.3109/09273948.2016.1151896
   Cicinelli MV, 2020, OPHTHALMOL RETINA, V4, P454, DOI 10.1016/j.oret.2019.12.003
   Dogan B, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2223-4
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Egawa M, 2016, BRIT J OPHTHALMOL, V100, P1646, DOI 10.1136/bjophthalmol-2015-307734
   Errera MH, 2015, ACTA OPHTHALMOL, V93, pE509, DOI 10.1111/aos.12640
   Fernandez-Avellaneda Pedro, 2022, Retin Cases Brief Rep, V16, P59, DOI 10.1097/ICB.0000000000000943
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Gill I, 2018, CAN J OPHTHALMOL, V53, pE179, DOI 10.1016/j.jcjo.2018.01.012
   Hashizume K, 2016, RETINA-J RET VIT DIS, V36, P415, DOI 10.1097/IAE.0000000000000728
   Hirooka K, 2015, GRAEF ARCH CLIN EXP, V253, P609, DOI 10.1007/s00417-014-2927-5
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hosoda Y, 2015, BRIT J OPHTHALMOL, V99, P1211, DOI 10.1136/bjophthalmol-2014-306244
   Hosoda Y, 2014, AM J OPHTHALMOL, V157, P1056, DOI 10.1016/j.ajo.2014.01.015
   Hsu YR, 2019, EYE, V33, P66, DOI 10.1038/s41433-018-0223-z
   Huang G, 2018, ACTA OPHTHALMOL, V96, P411, DOI 10.1111/aos.13606
   Ingolotti M, 2019, AM J CASE REP, V20, P300, DOI 10.12659/AJCR.914281
   Invernizzi A, 2019, CLIN EXP OPHTHALMOL, V47, P357, DOI 10.1111/ceo.13470
   Ishihara K, 2009, OPHTHALMOLOGY, V116, P1799, DOI 10.1016/j.ophtha.2009.04.002
   Kawano H, 2016, GRAEF ARCH CLIN EXP, V254, P421, DOI 10.1007/s00417-016-3283-4
   Khan KS, 2003, J ROY SOC MED, V96, P118, DOI 10.1258/jrsm.96.3.118
   Liakopoulos S, 2013, OSLI RETINA, V44, pS11, DOI 10.3928/23258160-20131101-03
   Lin DS, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-87
   Litts KM, 2018, RETINA-J RET VIT DIS, V38, P445, DOI 10.1097/IAE.0000000000001946
   Mehta Nitish, 2021, Retin Cases Brief Rep, V15, P391, DOI 10.1097/ICB.0000000000000817
   Polyak S.L., 1941, RETINA ANATOMY HISTO
   Ramtohul P, 2020, OPHTHALMOL RETINA, V4, P587, DOI 10.1016/j.oret.2020.01.017
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2016, RETINA-J RET VIT DIS, V36, P1823, DOI 10.1097/IAE.0000000000001158
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Tekin K, 2019, CLIN EXP OPTOM, V102, P343, DOI 10.1111/cxo.12876
NR 40
TC 9
Z9 9
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2021
VL 41
IS 11
BP 2193
EP 2207
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZB6BH
UT WOS:000756924700002
PM 34029276
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wassan, JT
   Zheng, HR
   Wang, HY
AF Wassan, Jyotsna Talreja
   Zheng, Huiru
   Wang, Haiying
TI Role of Deep Learning in Predicting Aging-Related Diseases: A Scoping
   Review
SO CELLS
LA English
DT Review
DE aging; deep learning; classification; prediction; PRISMA
ID NEURAL-NETWORKS; ALGORITHMS; FRAMEWORK; ERROR
AB Aging refers to progressive physiological changes in a cell, an organ, or the whole body of an individual, over time. Aging-related diseases are highly prevalent and could impact an individual's physical health. Recently, artificial intelligence (AI) methods have been used to predict aging-related diseases and issues, aiding clinical providers in decision-making based on patient's medical records. Deep learning (DL), as one of the most recent generations of AI technologies, has embraced rapid progress in the early prediction and classification of aging-related issues. In this paper, a scoping review of publications using DL approaches to predict common aging-related diseases (such as age-related macular degeneration, cardiovascular and respiratory diseases, arthritis, Alzheimer's and lifestyle patterns related to disease progression), was performed. Google Scholar, IEEE and PubMed are used to search DL papers on common aging-related issues published between January 2017 and August 2021. These papers were reviewed, evaluated, and the findings were summarized. Overall, 34 studies met the inclusion criteria. These studies indicate that DL could help clinicians in diagnosing disease at its early stages by mapping diagnostic predictions into observable clinical presentations; and achieving high predictive performance (e.g., more than 90% accurate predictions of diseases in aging).
C1 [Wassan, Jyotsna Talreja] Univ Delhi, Maitreyi Coll, New Delhi 110021, India.
   [Zheng, Huiru; Wang, Haiying] Univ Ulster, Sch Comp, Belfast BT15, North Ireland.
C3 University of Delhi; Ulster University
RP Zheng, HR (通讯作者)，Univ Ulster, Sch Comp, Belfast BT15, North Ireland.
EM jtwassan@maitreyi.du.ac.in; h.zheng@ulster.ac.uk; hy.wang@ulster.ac.uk
CR Abadi M, 2016, PROCEEDINGS OF OSDI'16: 12TH USENIX SYMPOSIUM ON OPERATING SYSTEMS DESIGN AND IMPLEMENTATION, P265
   Abiodun OI, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00938
   Agarap Abien Fred, 2018, DEEP LEARNING USING
   Ahmad J., 2019, DEEP LEARNING CONVER, P31
   Al-Shoukry S, 2020, IEEE ACCESS, V8, P77131, DOI 10.1109/ACCESS.2020.2989396
   Alom MZ, 2019, ELECTRONICS-SWITZ, V8, DOI 10.3390/electronics8030292
   Alzubaidi L, 2021, J BIG DATA-GER, V8, DOI 10.1186/s40537-021-00444-8
   Asgari E., 2015, ARXIV2015151200397
   Banerjee I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72359-y
   Basheer S, 2021, IEEE ACCESS, V9, P42449, DOI 10.1109/ACCESS.2021.3066213
   Bengio Y., 2007, ADV NEURAL INFORM PR, P153, DOI DOI 10.7551/MITPRESS/7503.003.0024
   Betancur J, 2018, JACC-CARDIOVASC IMAG, V11, P1654, DOI 10.1016/j.jcmg.2018.01.020
   Blobel B, 2018, EUR J BIOMED INFORM, V14, P10, DOI [DOI 10.24105/EJBI.2018.14.2.3, 10.24105/ejbi.2018.14.2.3]
   Bonnett LJ, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l737
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Calhoun VD, 2009, NEUROIMAGE, V45, pS163, DOI 10.1016/j.neuroimage.2008.10.057
   Cao CS, 2018, GENOM PROTEOM BIOINF, V16, P17, DOI 10.1016/j.gpb.2017.07.003
   Chase JAD, 2013, WESTERN J NURS RES, V35, P76, DOI 10.1177/0193945911416829
   Chassagnon G, 2020, RADIOL-ARTIF INTELL, V2, DOI 10.1148/ryai.2020190006
   Cheon S, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16111876
   Choi H, 2018, BEHAV BRAIN RES, V344, P103, DOI 10.1016/j.bbr.2018.02.017
   Creswell A, 2018, IEEE SIGNAL PROC MAG, V35, P53, DOI 10.1109/MSP.2017.2765202
   Ding Y, 2019, RADIOLOGY, V290, P456, DOI 10.1148/radiol.2018180958
   Dongare A.D., 2008, CERTIF INT J ENG INN, V9001, P2277
   Eddy SR, 2004, NAT BIOTECHNOL, V22, P1315, DOI 10.1038/nbt1004-1315
   Erin McNemar M., DEEP LEARNING PREDIC
   Fabris F, 2020, BIOINFORMATICS, V36, P2202, DOI 10.1093/bioinformatics/btz887
   Fernandes M, 2016, HUM MOL GENET, V25, P4804, DOI 10.1093/hmg/ddw307
   Filonenko A, 2017, C HUM SYST INTERACT, P64, DOI 10.1109/HSI.2017.8004998
   Geerts H, 2016, ALZHEIMERS DEMENT, V12, P1014, DOI 10.1016/j.jalz.2016.04.008
   Goallec AL., 2021, MEDRIXV, DOI [10.1101/2021.06.09.21258645, DOI 10.1101/2021.06.09.21258645]
   Guberman JM, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar041
   Hagan MT, 1996, NEURAL NETWORK DESIG, V20
   Hirano T, 2019, RHEUMATOL ADV PRACT, V3, DOI 10.1093/rap/rkz047
   Huang J, 2005, IEEE T KNOWL DATA EN, V17, P299, DOI 10.1109/TKDE.2005.50
   Huang YC, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00509
   Jiang F, 2017, STROKE VASC NEUROL, V2, P230, DOI 10.1136/svn-2017-000101
   Jo T, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00220
   Jonsson BA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13163-9
   Kalweit M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252289
   Kaymak S, 2018, 2018 14TH SYMPOSIUM ON NEURAL NETWORKS AND APPLICATIONS (NEUREL)
   Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kieu STH, 2020, J IMAGING, V6, DOI 10.3390/jimaging6120131
   Kusumoto D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20213-0
   Kwon SB., 2020, IEEE ACCESS, V8, P120597, DOI [10.1109/ACCESS.2020.3006335, DOI 10.1109/ACCESS.2020.3006335]
   Larochelle H, 2012, J MACH LEARN RES, V13, P643
   Larochelle H, 2009, J MACH LEARN RES, V10, P1
   LeCun Y., 1990, ADV NEURAL INFORM PR, P598, DOI DOI 10.5555/109230.109298
   Lee CS, 2021, BRAIN PATHOL, V31, DOI 10.1111/bpa.12974
   Leung K, 2020, RADIOLOGY, V296, P584, DOI 10.1148/radiol.2020192091
   Li Z, 2021, BIOGERONTOLOGY, V22, P165, DOI 10.1007/s10522-021-09910-5
   Liu T., 2015, ARXIV150601195CS
   Liu WB, 2017, NEUROCOMPUTING, V234, P11, DOI 10.1016/j.neucom.2016.12.038
   Lu B., 2021, PRACTICAL ALZHEIMER, DOI [10.1101/2020.08.18.256594, DOI 10.1101/2020.08.18.256594]
   Mishkhal Israa, 2020, IOP Conference Series: Materials Science and Engineering, V928, DOI 10.1088/1757-899X/928/3/032050
   Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873
   Nam JG, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03061-2020
   Nath RK, 2022, J SIGNAL PROCESS SYS, V94, P513, DOI 10.1007/s11265-020-01611-5
   Nguyen BP, 2019, COMPUT METH PROG BIO, V182, DOI 10.1016/j.cmpb.2019.105055
   Norgeot B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0606
   Papagiannaki A, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19040880
   Paschali M., 2019, ARXIV 2019 190403127
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Peters MDJ, 2015, INT J EVID-BASED HEA, V13, P141, DOI 10.1097/XEB.0000000000000050
   Prince John, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P3144, DOI 10.1109/EMBC.2018.8512972
   Putin E, 2016, AGING-US, V8, P1021, DOI 10.18632/aging.100968
   Qiao JP, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00417
   Quang D, 2015, BIOINFORMATICS, V31, P761, DOI 10.1093/bioinformatics/btu703
   Qureshi MNI, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00008
   Richards BA, 2019, NAT NEUROSCI, V22, P1761, DOI 10.1038/s41593-019-0520-2
   Roddick J. F., 2003, ACM SIGKDD EXPLOR NE, V5, P94, DOI 10.1145/959242.959243
   Rose MR., 2012, FRONT GENET, DOI [DOI 10.3389/fgene.2012.00134, 10.3389/fgene.2012.00134]
   RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0
   Salakhutdinov R., 2009, P 13 INT C ART INT S, V9, P448, DOI DOI 10.1109/CVPRW.2009.5206577
   Saxena V, OLD AGE DIS
   Schmidhuber J, 2015, NEURAL NETWORKS, V61, P85, DOI 10.1016/j.neunet.2014.09.003
   Schroeder JD, 2020, INT J CHRONIC OBSTR, V15, P3455, DOI 10.2147/COPD.S279850
   Shen DG, 2017, ANNU REV BIOMED ENG, V19, P221, DOI [10.1146/annurev-bioeng-071516044442, 10.1146/annurev-bioeng-071516-044442]
   Sherstinsky A, 2020, PHYSICA D, V404, DOI 10.1016/j.physd.2019.132306
   Shetty A., 2021, P 2021 4 BIENN INT C, P1
   Shi WY, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-2464
   Srivastava N, 2014, J MACH LEARN RES, V15, P1929
   Su C, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0780-3
   Summers M., 2017, DIGITCULT, V2, P9, DOI [10.4399/9788825508895, DOI 10.4399/9788825508895]
   Sundararajan K, 2018, ACM COMPUT SURV, V51, DOI 10.1145/3190618
   Suresh H., 2017, MACH LEARN HEALTHC C, P322
   Titano JJ, 2018, NAT MED, V24, P1337, DOI 10.1038/s41591-018-0147-y
   Torres-Soto J, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00320-4
   Varadarajan AV, 2018, INVEST OPHTH VIS SCI, V59, P2861, DOI 10.1167/iovs.18-23887
   Wang HY, 2021, BRIEF BIOINFORM, V22, P1543, DOI 10.1093/bib/bbaa237
   Wang JD, 2019, PATTERN RECOGN LETT, V119, P3, DOI 10.1016/j.patrec.2018.02.010
   Willmott CJ, 2005, CLIMATE RES, V30, P79, DOI 10.3354/cr030079
   Wolpert D. H., 1997, IEEE Transactions on Evolutionary Computation, V1, P67, DOI 10.1109/4235.585893
   Wu M., 2019, ONLINE J NURS INFORM, V23
   Yan Q, 2020, NAT MACH INTELL, V2, P141, DOI 10.1038/s42256-020-0154-9
   Yan Xu, 2014, 2014 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP), P1626, DOI 10.1109/ICASSP.2014.6853873
   Yeh MCH, 2021, J MED INTERNET RES, V23, DOI 10.2196/26256
   Yu-Chuan E., 2021, JMIR MED INF, V9
   Yue L, 2020, WORLD WIDE WEB, V23, P2715, DOI 10.1007/s11280-019-00764-z
   Yue T., 2018, ARXIV180200810
   Zhang PB, 2022, FOOD SCI TECH-BRAZIL, V42, DOI 10.1590/fst.42020
   Zhang TL, 2020, IEEE ACCESS, V8, P75822, DOI 10.1109/ACCESS.2020.2989143
NR 103
TC 0
Z9 0
U1 6
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD NOV
PY 2021
VL 10
IS 11
AR 2924
DI 10.3390/cells10112924
PG 34
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XL3RW
UT WOS:000728065200001
PM 34831148
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Simon, MV
   Basu, SK
   Qaladize, B
   Grambergs, R
   Rotstein, NP
   Mandal, N
AF Simon, M. Victoria
   Basu, Sandip K.
   Qaladize, Bano
   Grambergs, Richard
   Rotstein, Nora P.
   Mandal, Nawajes
TI Sphingolipids as critical players in retinal physiology and pathology
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE ceramide; sphingosine-1-phosphate; ceramide-1-phosphate; photoreceptor
   degeneration; age-related macular degeneration; retinitis pigmentosa
ID COMPLEMENT FACTOR-H; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; CERAMIDE
   TARGETS AUTOPHAGOSOMES; MACULAR TELANGIECTASIA TYPE-2; APOPTOTIC DNA
   FRAGMENTATION; STRESS-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH;
   OPTIC-NERVE DAMAGE; SPHINGOSINE 1-PHOSPHATE; GLUCOSYLCERAMIDE SYNTHASE
AB Sphingolipids have emerged as bioactive lipids involved in the regulation of many physiological and pathological processes. In the retina, they have been established to participate in numerous processes, such as neuronal survival and death, proliferation and migration of neuronal and vascular cells, inflammation, and neovascularization. Dysregulation of sphingolipids is therefore crucial in the onset and progression of retinal diseases. This review examines the involvement of sphingolipids in retinal physiology and diseases. Ceramide (Cer) has emerged as a common mediator of inflammation and death of neuronal and retinal pigment epithelium cells in animal models of retinopathies such as glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa. Sphingosine-1-phosphate (S1P) has opposite roles, preventing photoreceptor and ganglion cell degeneration but also promoting inflammation, fibrosis, and neovascularization in AMD, glaucoma, and pro-fibrotic disorders. Alterations in Cer, S1P, and ceramide 1-phosphate may also contribute to uveitis. Notably, use of inhibitors that either prevent Cer increase or modulate Si? signaling, such as Myriocin, desipramine, and Fingolimod (FTY720), preserves neuronal viability and retinal function. These findings underscore the relevance of alterations in the sphingolipid metabolic network in the etiology of multiple retinopathies and highlight the potential of modulating their metabolism for the design of novel therapeutic approaches.
C1 [Simon, M. Victoria; Rotstein, Nora P.] Univ Nacl Sur UNS, Inst Invest Bioquim Bahia Blanca INIBIBB, Argentine Natl Res Council CONICET, Dept Biol Bioquim & Farm, Bahia Blanca, Buenos Aires, Argentina.
   [Basu, Sandip K.; Qaladize, Bano; Grambergs, Richard; Mandal, Nawajes] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN 38163 USA.
   [Basu, Sandip K.; Qaladize, Bano; Grambergs, Richard; Mandal, Nawajes] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
C3 National University of the South; University of Tennessee System;
   University of Tennessee Health Science Center; University of Tennessee
   System; University of Tennessee Health Science Center
RP Rotstein, NP (通讯作者)，Univ Nacl Sur UNS, Inst Invest Bioquim Bahia Blanca INIBIBB, Argentine Natl Res Council CONICET, Dept Biol Bioquim & Farm, Bahia Blanca, Buenos Aires, Argentina.; Mandal, N (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN 38163 USA.; Mandal, N (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
EM inrotste@criba.edu.ar; nmandal@uthsc.edu
FU National Eye Institute [EY022071, EY031316]; Research to Prevent
   Blindness, Inc., USA; FonCyT (PICT 2015) [284]; Argentinean National
   Research Council (CONICET) [PIP 11220150100618]; Universidad Nacional
   del Sur, Bahia Blanca, Argentina [24/B254]
FX This work was supported by National Eye Institute Grants EY022071 and
   EY031316 and grants from Research to Prevent Blindness, Inc., USA (to
   N.M.), and by grants from FonCyT (PICT 2015-No 284), the Argentinean
   National Research Council (CONICET) (PIP 11220150100618), and the
   Secretary of Science and Technology, Universidad Nacional del Sur, Bahia
   Blanca, Argentina (24/B254) (to N.P.R.). The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Abcouwer Steven F, 2013, J Clin Cell Immunol, VSuppl 1, DOI 10.4172/2155-9899
   Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Acharya NR, 2013, JAMA OPHTHALMOL, V131, P1405, DOI 10.1001/jamaophthalmol.2013.4237
   Acharya U, 2003, SCIENCE, V299, P1740, DOI 10.1126/science.1080549
   Aerts JM, 2007, DIABETES, V56, P1341, DOI 10.2337/db06-1619
   Aiello LM, 2003, AM J OPHTHALMOL, V136, P122, DOI 10.1016/S0002-9394(03)00219-8
   Airola Michael V, 2013, Handb Exp Pharmacol, P57, DOI 10.1007/978-3-7091-1368-4_3
   Aleshin S, 2014, MOL CELL NEUROSCI, V59, P127, DOI 10.1016/j.mcn.2014.01.008
   Ali M, 2015, FEBS LETT, V589, P2213, DOI 10.1016/j.febslet.2015.06.045
   Aljohani AJ, 2013, MOL VIS, V19, P1966
   Allende ML, 2002, BBA-MOL CELL BIOL L, V1582, P222, DOI 10.1016/S1388-1981(02)00175-0
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arana L, 2013, AM J PHYSIOL-ENDOC M, V304, pE1213, DOI 10.1152/ajpendo.00480.2012
   Arana L, 2012, EXP CELL RES, V318, P350, DOI 10.1016/j.yexcr.2011.11.013
   Astudillo L, 2016, BIOCHIMIE, V125, P267, DOI 10.1016/j.biochi.2015.11.009
   Aung KZ, 2010, RETINA-J RET VIT DIS, V30, P473, DOI 10.1097/IAE.0b013e3181bd2c71
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1180
   Avila-Fernandez A, 2008, INVEST OPHTH VIS SCI, V49, P2709, DOI 10.1167/iovs.07-0865
   Awad AS, 2011, KIDNEY INT, V79, P1090, DOI 10.1038/ki.2010.544
   Azab B, 2019, CAN J OPHTHALMOL, V54, P51, DOI 10.1016/j.jcjo.2018.02.018
   BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354
   Bandhuvula P, 2007, TRENDS MOL MED, V13, P210, DOI 10.1016/j.molmed.2007.03.005
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   Baudiss K, 2016, J IMMUNOL, V196, P2319, DOI 10.4049/jimmunol.1402681
   Becker KA, 2010, AM J RESP CELL MOL, V42, P716, DOI 10.1165/rcmb.2009-0174OC
   Berwick ML, 2019, ADV EXP MED BIOL, V1159, P65, DOI 10.1007/978-3-030-21162-2_5
   Bian GL, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat1470
   Bieberich E, 2018, CHEM PHYS LIPIDS, V216, P114, DOI 10.1016/j.chemphyslip.2018.08.003
   Bionda C, 2004, BIOCHEM J, V382, P527, DOI 10.1042/BJ20031819
   Bleicher RJ, 2002, BBA-MOL CELL BIOL L, V1585, P172, DOI 10.1016/S1388-1981(02)00338-4
   Bolinches-Amoros A, 2019, STEM CELL RES, V38, DOI 10.1016/j.scr.2019.101455
   Bordone MP, 2017, J NEUROCHEM, V142, P323, DOI 10.1111/jnc.14070
   Bornancin FR, 2005, BBA-MOL CELL BIOL L, V1687, P31, DOI 10.1016/j.bbalip.2004.11.012
   BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8
   Breiden B, 2018, METHODS MOL BIOL, V1804, P97, DOI 10.1007/978-1-4939-8552-4_5
   Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200
   Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248
   Brush RS, 2010, INVEST OPHTH VIS SCI, V51, P4422, DOI 10.1167/iovs.09-5134
   Budda M. L., 2015, 12 C ASS OC PHARM TH, P127
   Burgess LG, 2015, INVEST OPHTH VIS SCI, V56, P5020, DOI 10.1167/iovs.15-16702
   Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520
   Busik JV, 2012, CLIN LIPIDOL, V7, P661, DOI 10.2217/CLP.12.68
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Cabrerizo J, 2017, J GLAUCOMA, V26, P349, DOI 10.1097/IJG.0000000000000603
   Cacicedo JM, 2005, DIABETES, V54, P1838, DOI 10.2337/diabetes.54.6.1838
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Canals D, 2018, CHEM PHYS LIPIDS, V216, P142, DOI 10.1016/j.chemphyslip.2018.09.013
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   Carrer DC, 2003, CHEM PHYS LIPIDS, V122, P147, DOI 10.1016/S0009-3084(02)00185-8
   Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440
   CASPI RR, 1988, J IMMUNOL, V140, P1490
   Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637
   Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   Chatteriee S, 2008, BBA-GEN SUBJECTS, V1780, P370, DOI 10.1016/j.bbagen.2007.08.010
   Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523
   Chatterjee S, 2012, ADV EXP MED BIOL, V749, P153, DOI 10.1007/978-1-4614-3381-1_11
   Chauhan MZ, 2019, INVEST OPHTH VIS SCI, V60, P1789, DOI 10.1167/iovs.18-25802
   Chen H, 2014, SURV OPHTHALMOL, V59, P64, DOI 10.1016/j.survophthal.2013.02.005
   Chen H, 2013, J LIPID RES, V54, P1616, DOI 10.1194/jlr.M035048
   Chen H, 2012, ADV EXP MED BIOL, V723, P553, DOI 10.1007/978-1-4614-0631-0_70
   Chen WQ, 2005, INVEST OPHTH VIS SCI, V46, P4342, DOI 10.1167/iovs.05-0601
   Chen YF, 2010, NEUROMOL MED, V12, P306, DOI 10.1007/s12017-010-8132-8
   Chew EY, 2019, OPHTHALMOLOGY, V126, P540, DOI 10.1016/j.ophtha.2018.09.041
   Coant Nicolas, 2017, Advances in Biological Regulation, V63, P122, DOI 10.1016/j.jbior.2016.10.002
   Colombini M, 2019, ADV EXP MED BIOL, V1159, P33, DOI 10.1007/978-3-030-21162-2_3
   Commodaro AG, 2010, INVEST OPHTH VIS SCI, V51, P2568, DOI 10.1167/iovs.09-4769
   Cook C, 2012, CAN J OPHTHALMOL, V47, P223, DOI 10.1016/j.jcjo.2012.02.003
   Copland DA, 2012, AM J PATHOL, V180, P672, DOI 10.1016/j.ajpath.2011.10.008
   Crousillac S, 2009, J NEUROPHYSIOL, V102, P3295, DOI 10.1152/jn.00119.2009
   Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200
   Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0
   Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0
   Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793
   Czubowicz K, 2014, MOL NEUROBIOL, V50, P26, DOI 10.1007/s12035-013-8606-4
   Dasgupta U, 2009, P NATL ACAD SCI USA, V106, P20063, DOI 10.1073/pnas.0911028106
   Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200
   Deguchi H, 2001, BLOOD, V97, P1907, DOI 10.1182/blood.V97.7.1907
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Domenici L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115579
   Dong Yunzhou, 2017, J Nat Sci, V3
   DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189
   Duan JJ, 2015, J BIOL CHEM, V290, P15380, DOI 10.1074/jbc.R115.658823
   Edwards G, 2020, J CELL MOL MED, V24, P3856, DOI 10.1111/jcmm.14975
   El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200
   Elsherbini A, 2018, ADV CANCER RES, V140, P121, DOI 10.1016/bs.acr.2018.05.004
   Fabiani C, 2017, N-S ARCH PHARMACOL, V390, P741, DOI 10.1007/s00210-017-1374-3
   Fan J, 2016, INVEST OPHTH VIS SCI, V57, P4476, DOI 10.1167/iovs.16-19717
   Fang C, 2018, FASEB J, V32, P3597, DOI 10.1096/fj.201701116R
   FECHTNER RD, 1994, SURV OPHTHALMOL, V39, P23, DOI 10.1016/S0039-6257(05)80042-6
   Fox TE, 2006, DIABETES, V55, P3573, DOI 10.2337/db06-0539
   Fujiwaki T, 2004, J CHROMATOGR B, V806, P47, DOI 10.1016/j.jchromb.2004.02.027
   Galadari S, 2015, APOPTOSIS, V20, P689, DOI 10.1007/s10495-015-1109-1
   Gallemore RP, 1997, PROG RETIN EYE RES, V16, P509, DOI 10.1016/S1350-9462(96)00037-7
   Ganesan V, 2010, APOPTOSIS, V15, P553, DOI 10.1007/s10495-009-0449-0
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Gangoiti P, 2008, CELL SIGNAL, V20, P726, DOI 10.1016/j.cellsig.2007.12.008
   Gangoiti P, 2010, FEBS LETT, V584, P517, DOI 10.1016/j.febslet.2009.11.086
   Gantner ML, 2019, NEW ENGL J MED, V381, P1422, DOI 10.1056/NEJMoa1815111
   Garanto A, 2013, EXP EYE RES, V110, P96, DOI 10.1016/j.exer.2013.03.003
   GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369
   Gargini M., 2009, INVEST OPHTHALMOL VI, V50, P4463
   Garofalo K, 2011, J CLIN INVEST, V121, P4735, DOI 10.1172/JCI57549
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056
   Geoffroy K, 2005, FEBS LETT, V579, P1249, DOI 10.1016/j.febslet.2004.12.094
   German OL, 2006, INVEST OPHTH VIS SCI, V47, P1658, DOI 10.1167/iovs.05-1310
   German OL, 2006, J NEUROCHEM, V98, P1507, DOI 10.1111/j.1471-4159.2006.04061.x
   Ghidoni R., 2009, INVEST OPHTHALMOL VI, V50, P4464
   Gomez-Munoz A, 2004, J LIPID RES, V45, P99, DOI 10.1194/jlr.M300158-JLR200
   Gomez-Munoz A, 2006, BBA-BIOMEMBRANES, V1758, P2049, DOI 10.1016/j.bbamem.2006.05.011
   Gomez-Munoz A, 2018, ADV CANCER RES, V140, P217, DOI 10.1016/bs.acr.2018.04.012
   GomezMunoz A, 1997, BIOCHEM J, V325, P435, DOI 10.1042/bj3250435
   GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883
   Graf C, 2008, BIOCHEM BIOPH RES CO, V373, P159, DOI 10.1016/j.bbrc.2008.06.002
   Grambergs R, 2019, ADV EXP MED BIOL, V1159, P139, DOI 10.1007/978-3-030-21162-2_8
   GRAMER E, 1986, KLIN MONATSBL AUGENH, V189, P190, DOI 10.1055/s-2008-1050784
   Granado MH, 2009, CELL SIGNAL, V21, P405, DOI 10.1016/j.cellsig.2008.11.003
   Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540
   Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045
   Grassme H, 2007, PROG LIPID RES, V46, P161, DOI 10.1016/j.plipres.2007.03.002
   Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154
   Hanel P, 2007, FASEB J, V21, P1202, DOI 10.1096/fj.06-7433com
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahn PY, 2003, J BIOL CHEM, V278, P2043, DOI 10.1074/jbc.M209715200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Hammad SM, 2010, J LIPID RES, V51, P3074, DOI 10.1194/jlr.D008532
   HANNUN YA, 1986, J BIOL CHEM, V261, P2604
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107
   Hannun YA, 2011, J BIOL CHEM, V286, P27855, DOI 10.1074/jbc.R111.254359
   Havulinna AS, 2016, ARTERIOSCL THROM VAS, V36, P2424, DOI 10.1161/ATVBAHA.116.307497
   Hayreh SS, 2009, OPHTHALMOLOGY, V116, P1928, DOI 10.1016/j.ophtha.2009.03.006
   Hayreh SS, 2009, OPHTHALMOLOGY, V116, P1188, DOI 10.1016/j.ophtha.2009.01.015
   Herbort CP, 2009, OCUL IMMUNOL INFLAMM, V17, P160, DOI 10.1080/09273940902818861
   Hernandez-Corbacho MJ, 2017, BBA-MOL CELL BIOL L, V1862, P56, DOI 10.1016/j.bbalip.2016.09.019
   Hernandez-Corbacho MJ, 2015, J BIOL CHEM, V290, P25356, DOI 10.1074/jbc.M115.658658
   Hinze A, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-35
   Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323
   Holland WL, 2011, NAT MED, V17, P55, DOI 10.1038/nm.2277
   Horai R, 2013, J AUTOIMMUN, V44, P21, DOI 10.1016/j.jaut.2013.06.003
   Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181
   Howell GR, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-429
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Hu XB, 2019, AUTOPHAGY, V15, P453, DOI 10.1080/15548627.2018.1520548
   Huang KP, 2014, CELL SIGNAL, V26, P629, DOI 10.1016/j.cellsig.2013.12.002
   Iwabuchi K, 2015, GLYCOBIOLOGY, V25, P655, DOI 10.1093/glycob/cwv008
   Jain A, 2017, J CELL SCI, V130, P360, DOI 10.1242/jcs.194191
   Jenkins GM, 2002, J BIOL CHEM, V277, P42572, DOI 10.1074/jbc.M207346200
   Jenkins RW, 2009, CELL SIGNAL, V21, P836, DOI 10.1016/j.cellsig.2009.01.026
   Jeon HJ, 2005, J NEUROCHEM, V95, P811, DOI 10.1111/j.1471-4159.2005.03403.x
   JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4
   Jiang WH, 2013, AUTOPHAGY, V9, P258, DOI 10.4161/auto.22739
   JIMENEZLUCHO V, 1990, INFECT IMMUN, V58, P2085, DOI 10.1128/IAI.58.7.2085-2090.1990
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Joly S, 2016, J NEUROCHEM, V138, P571, DOI 10.1111/jnc.13701
   Ju WK, 2008, INVEST OPHTH VIS SCI, V49, P4903, DOI 10.1167/iovs.07-1661
   Kaarniranta K, 2012, NEUROSCI LETT, V513, P233, DOI 10.1016/j.neulet.2012.02.050
   Kady NM, 2018, DIABETES, V67, P769, DOI 10.2337/db17-1034
   Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449
   Khawaja AP, 2016, INVEST OPHTH VIS SCI, V57, P5046, DOI 10.1167/iovs.16-20017
   Kim JW, 2016, INT J CLIN ONCOL, V21, P883, DOI 10.1007/s10147-016-0973-1
   Kim SY, 2005, DIABETES, V54, P1534, DOI 10.2337/diabetes.54.5.1534
   Kisseleva T, 2008, EXP BIOL MED, V233, P109, DOI 10.3181/0707-MR-190
   Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006
   KLEIN R, 1987, INT OPHTHALMOL CLIN, V27, P230, DOI 10.1097/00004397-198702740-00003
   Klein R, 2010, AM J OPHTHALMOL, V150, P55, DOI 10.1016/j.ajo.2010.02.013
   Knapp M, 2011, J PHYSIOL PHARMACOL, V62, P601
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759
   Kolmakova A, 2009, GLYCOCONJUGATE J, V26, P547, DOI 10.1007/s10719-008-9206-9
   Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200
   Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC
   Kuc N, 2018, BIOCHEM PHARMACOL, V156, P458, DOI 10.1016/j.bcp.2018.09.017
   Kurose S, 2000, EXP EYE RES, V70, P7, DOI 10.1006/exer.1999.0777
   Kurz J, 2019, TRENDS MOL MED, V25, P20, DOI 10.1016/j.molmed.2018.10.009
   Lahiri S, 2007, CELL MOL LIFE SCI, V64, P2270, DOI 10.1007/s00018-007-7076-0
   Lambiase A, 2009, P NATL ACAD SCI USA, V106, P13469, DOI 10.1073/pnas.0906678106
   Lavieu Gregory, 2008, V445, P159, DOI 10.1007/978-1-59745-157-4_11
   Law BA, 2018, FASEB J, V32, P1403, DOI 10.1096/fj.201700300R
   Lepine S, 2004, J IMMUNOL, V173, P3783, DOI 10.4049/jimmunol.173.6.3783
   Li C, 2014, BBA-MOL BASIS DIS, V1842, P1121, DOI 10.1016/j.bbadis.2014.04.009
   Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028
   Li GY, 2012, DIABETES, V61, P3294, DOI 10.2337/db11-1249
   Liu XH, 2011, J CELL PHYSIOL, V226, P2370, DOI 10.1002/jcp.22572
   Liu YY, 2008, FASEB J, V22, P2541, DOI 10.1096/fj.07-092981
   Luft FC, 2017, J MOL MED, V95, P1017, DOI 10.1007/s00109-017-1577-6
   Lukowski ZL, 2013, J GLAUCOMA, V22, P145, DOI 10.1097/IJG.0b013e31822e8c83
   Luo C, 2010, INVEST OPHTH VIS SCI, V51, P5697, DOI 10.1167/iovs.10-5407
   Ma YF, 2005, J BIOL CHEM, V280, P26011, DOI 10.1074/jbc.M409081200
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Maglione V, 2010, J NEUROSCI, V30, P4072, DOI 10.1523/JNEUROSCI.6348-09.2010
   Mahabadi N., 2020, RIBOFLAVIN DEFICIENC
   Mandal NA, 2013, EXP EYE RES, V106, P24, DOI 10.1016/j.exer.2012.10.014
   Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517
   Meikle PJ, 2017, NAT REV ENDOCRINOL, V13, P79, DOI 10.1038/nrendo.2016.169
   MERRILL AH, 1993, ADV LIPID RES, V25, P1
   Mesev EV, 2017, MOL PHARMACOL, V91, P373, DOI 10.1124/mol.116.107169
   Messenger W., 2015, NEUROLOGY REV, V23, P9
   Messner MC, 2010, ADV EXP MED BIOL, V688, P156
   Mietla JA, 2013, J LIPID RES, V54, P1834, DOI 10.1194/jlr.M035683
   Milara J, 2012, THORAX, V67, P147, DOI 10.1136/thoraxjnl-2011-200026
   Miranda GE, 2011, INVEST OPHTH VIS SCI, V52, P6580, DOI 10.1167/iovs.10-7065
   Miranda GE, 2009, INVEST OPHTH VIS SCI, V50, P4416, DOI 10.1167/iovs.09-3388
   Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103
   Mitra P, 2007, FEBS LETT, V581, P735, DOI 10.1016/j.febslet.2007.01.041
   Mizumura K, 2018, FASEB J, V32, P1880, DOI 10.1096/fj.201700571R
   Mohr S, 2004, EXPERT OPIN INV DRUG, V13, P189, DOI 10.1517/13543784.13.3.189
   Mondal K, 2019, ADV EXP MED BIOL, V1161, P149, DOI 10.1007/978-3-030-21735-8_14
   Mukhopadhyay A, 2009, FASEB J, V23, P751, DOI 10.1096/fj.08-120550
   Mullen TD, 2012, ANTI-CANCER AGENT ME, V12, P340, DOI 10.2174/187152012800228661
   Mullen TD, 2012, BIOCHEM J, V441, P789, DOI 10.1042/BJ20111626
   Nagata M, 2017, P NATL ACAD SCI USA, V114, pE3285, DOI 10.1073/pnas.1618133114
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Ness T, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0638-9
   Newton J, 2015, EXP CELL RES, V333, P195, DOI 10.1016/j.yexcr.2015.02.025
   Novgorodov SA, 2016, J LIPID RES, V57, P546, DOI 10.1194/jlr.M060061
   Novgorodov SA, 2014, J BIOL CHEM, V289, P13142, DOI 10.1074/jbc.M113.530311
   Novgorodov SA, 2011, J BIOL CHEM, V286, P25352, DOI 10.1074/jbc.M110.214866
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   OHTA H, 1995, CANCER RES, V55, P691
   OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0
   Olsen TG, 2017, SURV OPHTHALMOL, V62, P89, DOI 10.1016/j.survophthal.2016.07.002
   Opreanu M, 2011, DIABETES, V60, P2370, DOI 10.2337/db10-0550
   Opreanu M, 2010, INVEST OPHTH VIS SCI, V51, P3253, DOI 10.1167/iovs.09-4731
   Ordonez M, 2016, CELL SIGNAL, V28, P1066, DOI 10.1016/j.cellsig.2016.05.005
   Ouro A, 2017, EXP CELL RES, V361, P277, DOI 10.1016/j.yexcr.2017.10.027
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Panda PK, 2018, BBA-MOL CELL RES, V1865, P480, DOI 10.1016/j.bbamcr.2017.12.002
   Pannu R, 2005, J BIOL CHEM, V280, P13742, DOI 10.1074/jbc.M411959200
   Pappenhagen N, 2018, J NEUROSCI RES, V96, P1627, DOI 10.1002/jnr.24273
   Paquet-Durand F, 2007, J NEUROSCI, V27, P10311, DOI 10.1523/JNEUROSCI.1514-07.2007
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pchejetski D, 2012, EUR HEART J, V33, P2360, DOI 10.1093/eurheartj/ehr389
   Penno A, 2010, J BIOL CHEM, V285, P11178, DOI 10.1074/jbc.M109.092973
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1
   Piano I, 2013, EUR J NEUROSCI, V37, P1853, DOI 10.1111/ejn.12196
   Pike LJ, 2009, J LIPID RES, V50, pS323, DOI 10.1194/jlr.R800040-JLR200
   Platania CBM, 2019, DRUG DELIV, V26, P237, DOI 10.1080/10717544.2019.1574936
   Porter H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123885
   Presa N, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158630
   Presa N, 2016, BBA-MOL CELL BIOL L, V1861, P402, DOI 10.1016/j.bbalip.2016.02.007
   Pujol-Lereis LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200739
   Qiao YB, 2012, INVEST OPHTH VIS SCI, V53, P8200, DOI 10.1167/iovs.12-10965
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P137
   QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Ranty ML, 2009, GRAEF ARCH CLIN EXP, V247, P215, DOI 10.1007/s00417-008-0957-6
   Rathinam SR, 2013, INDIAN J OPHTHALMOL, V61, P255, DOI 10.4103/0301-4738.114092
   Raveney BJE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1390, DOI 10.1001/archopht.126.10.1390
   Rice DS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7228
   Rivera IG, 2016, BIOCHEM PHARMACOL, V102, P107, DOI 10.1016/j.bcp.2015.12.009
   Roh JL, 2015, MOL CANCER THER, V14, P1907, DOI 10.1158/1535-7163.MCT-15-0171
   Ronquillo CC, 2018, JAMA OPHTHALMOL, V136, P1158, DOI 10.1001/jamaophthalmol.2018.3283
   Rotstein NP, 2010, J LIPID RES, V51, P1247, DOI 10.1194/jlr.R003442
   Saddoughi SA, 2013, EMBO MOL MED, V5, P105, DOI 10.1002/emmm.201201283
   Sahaboglu A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181374
   Sahaboglu A, 2016, SCI REP-UK, V6, DOI 10.1038/srep39537
   Sakaguchi M, 1998, JPN J OPHTHALMOL, V42, P262, DOI 10.1016/S0021-5155(98)00016-1
   Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4
   Sanvicens N, 2006, J NEUROCHEM, V98, P1432, DOI 10.1111/j.1471-4159.2006.03977.x
   Sato K, 2007, J NEUROCHEM, V103, P2610, DOI 10.1111/j.1471-4159.2007.04958.x
   Sawai H, 2015, LEUKEMIA RES, V39, P964, DOI 10.1016/j.leukres.2015.06.002
   Scerri TS, 2017, NAT GENET, V49, P559, DOI 10.1038/ng.3799
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   Seddon JM, 2001, OPHTHALMOLOGY, V108, P2060, DOI 10.1016/S0161-6420(01)00777-1
   Seidova SF, 2009, DOC OPHTHALMOL, V118, P151, DOI 10.1007/s10633-008-9142-9
   Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Shao H, 2002, J NEUROIMMUNOL, V132, P117, DOI 10.1016/S0165-5728(02)00318-1
   Silva L, 2006, MOL MEMBR BIOL, V23, P137, DOI 10.1080/09687860500439474
   Simanshu DK, 2013, NATURE, V500, P463, DOI 10.1038/nature12332
   Simon MV, 2015, INVEST OPHTH VIS SCI, V56, P5808, DOI 10.1167/iovs.14-16195
   Siskind LJ, 2002, J BIOL CHEM, V277, P26796, DOI 10.1074/jbc.M200754200
   Skoura A, 2007, J CLIN INVEST, V117, P2506, DOI 10.1172/JCI31123
   Soulet D, 2008, CURR OPIN PHARMACOL, V8, P508, DOI 10.1016/j.coph.2008.04.002
   Spalm FHP, 2019, MOL NEUROBIOL, V56, P4760, DOI 10.1007/s12035-018-1402-4
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200
   Stamer WD, 2009, EXP EYE RES, V89, P980, DOI 10.1016/j.exer.2009.08.008
   Stefanovic M, 2016, ONCOTARGET, V7, P8253, DOI 10.18632/oncotarget.6982
   Stiban J, 2015, BBA-BIOMEMBRANES, V1848, P561, DOI 10.1016/j.bbamem.2014.11.018
   Stiles M, 2016, J LIPID RES, V57, P818, DOI 10.1194/jlr.M063719
   Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3
   Strauss O, 2012, ADV EXP MED BIOL, V723, P603, DOI 10.1007/978-1-4614-0631-0_77
   Strettoi E, 2010, P NATL ACAD SCI USA, V107, P18706, DOI 10.1073/pnas.1007644107
   Sugano E, 2019, J LIPID RES, V60, P30, DOI 10.1194/jlr.M082198
   Sullivan LS, 2017, INVEST OPHTH VIS SCI, V58, P2774, DOI 10.1167/iovs.16-21341
   Sumida GM, 2011, AM J PHYSIOL-CELL PH, V300, pC1164, DOI 10.1152/ajpcell.00437.2010
   Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101
   Swaney JS, 2008, EXP EYE RES, V87, P367, DOI 10.1016/j.exer.2008.07.005
   Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7
   Tabasinezhad M, 2013, J CANCER RES THER, V9, P556, DOI 10.4103/0973-1482.126446
   Tabuchi K, 2018, CURR MOL PHARMACOL, V11, P279, DOI 10.2174/1874467211666180516101111
   Tafesse FG, 2006, J BIOL CHEM, V281, P29421, DOI 10.1074/jbc.R600021200
   Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162
   Takuwa Y, 2013, BBA-MOL CELL BIOL L, V1831, P185, DOI 10.1016/j.bbalip.2012.06.008
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Taniguchi M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.82
   Terao R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010112
   Tettamanti G, 2003, GLYCOCONJUGATE J, V20, P301, DOI 10.1023/B:GLYC.0000033627.02765.cc
   Thompson AJ, 2018, LANCET, V391, P1622, DOI 10.1016/S0140-6736(18)30481-1
   Thundyil J, 2012, BRIT J PHARMACOL, V165, P313, DOI 10.1111/j.1476-5381.2011.01560.x
   Tikhonenko M, 2010, DIABETES, V59, P219, DOI 10.2337/db09-0728
   Toman RE, 2004, J CELL BIOL, V166, P381, DOI 10.1083/jcb.200402016
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Tripathy K, 2020, STATPEARLS
   Turpin-Nolan SM, 2019, CELL REP, V26, P1, DOI 10.1016/j.celrep.2018.12.031
   Tuson M, 2004, AM J HUM GENET, V74, P128, DOI 10.1086/381055
   Tuson M, 2009, MOL VIS, V15, P168
   Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279
   Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845
   Simon MV, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00246
   Vingolo EM, 2017, EUR REV MED PHARMACO, V21, P662
   Wang DD, 2017, CIRCULATION, V135, P2028, DOI [10.1161/CIRCULATIONAHA.116.024261, 10.1161/circulationaha.116.024261]
   Wang GH, 2005, J BIOL CHEM, V280, P26415, DOI 10.1074/jbc.M501492200
   Wang Guanghu, 2018, Advances in Biological Regulation, V70, P51, DOI 10.1016/j.jbior.2018.09.013
   Wang HY, 2018, INT J OPHTHALMOL-CHI, V11, P736, DOI 10.18240/ijo.2018.05.05
   Wang HT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/759473
   Wang P, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1014-8
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   White-Gilbertson S, 2009, ONCOGENE, V28, P1132, DOI 10.1038/onc.2008.468
   Wiggs JL, 2015, PROG MOL BIOL TRANSL, V134, P315, DOI 10.1016/bs.pmbts.2015.04.008
   Wijesinghe DS, 2005, J LIPID RES, V46, P2706, DOI 10.1194/jlr.M500313-JLR200
   Wilmott LA, 2019, J DIABETES COMPLICAT, V33, P195, DOI 10.1016/j.jdiacomp.2018.12.005
   Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574
   Wu BX, 2010, NEUROMOL MED, V12, P320, DOI 10.1007/s12017-010-8120-z
   Wu BX, 2010, J BIOL CHEM, V285, P17993, DOI 10.1074/jbc.M110.102988
   Wu GS, 2012, J NEUROSCI RES, V90, P1997, DOI 10.1002/jnr.23090
   Xiao QH, 2009, J PHYSIOL-LONDON, V587, P4379, DOI 10.1113/jphysiol.2009.176800
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Xu MC, 2016, HUM MUTAT, V37, P246, DOI 10.1002/humu.22940
   Yamane Mototeru, 2017, Biochem Biophys Rep, V11, P174, DOI 10.1016/j.bbrep.2017.02.010
   Yanagida K, 2020, DEV CELL, V52, P779, DOI 10.1016/j.devcel.2020.01.016
   Yanagida K, 2017, ANNU REV PHYSIOL, V79, P67, DOI 10.1146/annurev-physiol-021014-071635
   Yeom M, 2015, NUTR RES, V35, P241, DOI 10.1016/j.nutres.2015.01.001
   You YY, 2014, INVEST OPHTH VIS SCI, V55, P3060, DOI 10.1167/iovs.13-13262
   Young MM, 2013, J LIPID RES, V54, P5, DOI 10.1194/jlr.R031278
   Yu RK, 2011, J OLEO SCI, V60, P537, DOI 10.5650/jos.60.537
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   ZARBIN MA, 1988, ARCH OPHTHALMOL-CHIC, V106, P1163
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zeidan YH, 2010, CURR MOL MED, V10, P454, DOI 10.2174/156652410791608225
   ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155
   Zhang JL, 2016, HUM GENET, V135, P1375, DOI 10.1007/s00439-016-1730-2
   Zhao LH, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002063
   Zhu DH, 2010, VISION RES, V50, P643, DOI 10.1016/j.visres.2009.09.002
   Zitomer NC, 2009, J BIOL CHEM, V284, P4786, DOI 10.1074/jbc.M808798200
   Zuellig RA, 2014, DIABETES, V63, P1326, DOI 10.2337/db13-1042
NR 370
TC 18
Z9 18
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PY 2021
VL 62
AR 100037
DI 10.1194/jlr.TR120000972
EA MAR 2021
PG 26
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SD5OL
UT WOS:000651423000001
PM 32948663
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wan, CR
   Muya, L
   Kansara, V
   Ciulla, TA
AF Wan, Chen-rei
   Muya, Leroy
   Kansara, Viral
   Ciulla, Thomas A.
TI Suprachoroidal Delivery of Small Molecules, Nanoparticles, Gene and Cell
   Therapies for Ocular Diseases
SO PHARMACEUTICS
LA English
DT Review
DE suprachoroidal; microinjector; ocular drug delivery; suprachoroidal
   space (SCS); gene therapy; anti-VEGF; macular degeneration; glaucoma
ID DIABETIC MACULAR EDEMA; INDUCED CHOROIDAL NEOVASCULARIZATION; SYSTEMIC
   ANTIINFLAMMATORY THERAPY; GROWTH-FACTOR THERAPY; REAL-WORLD OUTCOMES;
   TRIAMCINOLONE ACETONIDE; DRUG-DELIVERY; INTRAVITREAL AFLIBERCEPT;
   INJECTABLE SUSPENSION; INTRAOCULAR-PRESSURE
AB Suprachoroidal drug delivery technology has advanced rapidly and emerged as a promising administration route for a variety of therapeutic candidates, in order to target multiple ocular diseases, ranging from neovascular age-related macular degeneration to choroidal melanoma. This review summarizes the latest preclinical and clinical progress in suprachoroidal delivery of therapeutic agents, including small molecule suspensions, polymeric entrapped small molecules, gene therapy (viral and nonviral nanoparticles), viral nanoparticle conjugates (VNCs), and cell therapy. Formulation customization is critical in achieving favorable pharmacokinetics, and sustained drug release profiles have been repeatedly observed for multiple small molecule suspensions and polymeric formulations. Novel therapeutic agents such as viral and nonviral gene therapy, as well as VNCs, have demonstrated promise in animal studies. Several of these suprachoroidally-administered therapies have been assessed in clinical trials, including small molecule suspensions of triamcinolone acetonide and axitinib, viral vector RGX-314 for gene therapy, and VNC AU-011. With continued drug delivery research and optimization, coupled with customized drug formulations, suprachoroidal drug delivery may address large unmet therapeutic needs in ophthalmology, targeting affected tissues with novel therapies for efficacy benefits, compartmentalizing therapies away from unaffected tissues for safety benefits, and achieving durability to relieve the treatment burden noted with current agents.
C1 [Wan, Chen-rei; Muya, Leroy; Kansara, Viral; Ciulla, Thomas A.] Clearside Biomed, 900 North Point Pkwy,Suite 200, Alpharetta, GA 30005 USA.
RP Ciulla, TA (通讯作者)，Clearside Biomed, 900 North Point Pkwy,Suite 200, Alpharetta, GA 30005 USA.
EM cherry.wan@clearsidebio.com; leroy.muya@clearsidebio.com;
   viral.kansara@clearsidebio.com; Thomas.Ciulla@clearsidebio.com
OI Ciulla, Thomas/0000-0001-5557-6777
CR Alhasani RH, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090367
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   [Anonymous], AURA BIOSCIENCES ANN
   [Anonymous], OTX IVT ANTI VEGF AN
   [Anonymous], REGENXBIO REP 3 QUAR
   Barakat MR, 2021, OPHTHALMOL RETINA, V5, P60, DOI 10.1016/j.oret.2020.08.007
   Bhargava P, 2011, CURR ONCOL REP, V13, P103, DOI 10.1007/s11912-011-0154-3
   Biomedical C., CLEARSIDE BIOMEDICAL
   BLOCK LH, 1973, J PHARM SCI, V62, P617, DOI 10.1002/jps.2600620416
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURNS E, 1992, AGE AGEING, V21, P168, DOI 10.1093/ageing/21.3.168
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Campochiaro PA, 2018, OPHTHALMOL RETINA, V2, P320, DOI 10.1016/j.oret.2017.07.013
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Chae JJ, 2021, ADV SCI, V8, DOI 10.1002/advs.202001908
   Chen M, 2015, J CONTROL RELEASE, V203, P109, DOI 10.1016/j.jconrel.2015.02.021
   Chiang B, 2016, J CONTROL RELEASE, V228, P48, DOI 10.1016/j.jconrel.2016.02.041
   Chiang B, 2017, INVEST OPHTH VIS SCI, V58, P545, DOI 10.1167/iovs.16-20679
   Chiang B, 2016, EXP EYE RES, V153, P101, DOI 10.1016/j.exer.2016.10.011
   Chiang B, 2016, EXP EYE RES, V145, P424, DOI 10.1016/j.exer.2016.03.008
   Cho Hee Yoon, 2012, Korean J Ophthalmol, V26, P362, DOI 10.3341/kjo.2012.26.5.362
   Ciulla TA, 2000, J OCUL PHARMACOL TH, V16, P393, DOI 10.1089/jop.2000.16.393
   Ciulla T, 2021, BRIT J OPHTHALMOL, V105, P1696, DOI 10.1136/bjophthalmol-2020-317337
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P1179, DOI 10.1016/j.oret.2018.06.004
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Das SS, 2019, CURR PHARM DESIGN, V25, P424, DOI 10.2174/1381612825666190402165845
   del Pozo-Rodriguez A, 2013, J OCUL PHARMACOL TH, V29, P173, DOI 10.1089/jop.2012.0128
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Djebli N, 2017, EUR J DRUG METAB PH, V42, P59, DOI 10.1007/s13318-016-0319-4
   Dykstra JA, 2017, STEM CELL TRANSL MED, V6, P1096, DOI 10.1002/sctm.16-0337
   Edelhauser H, 2013, INVEST OPHTH VIS SCI, V54
   Edelhauser HF, 2014, INVEST OPHTH VIS SCI, V55
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Gilger BC, 2013, INVEST OPHTH VIS SCI, V54, P2483, DOI 10.1167/iovs.13-11747
   Goldstein DA, 2020, INVEST OPHTH VIS SCI, V61
   GURWITZ JH, 1993, AM J PUBLIC HEALTH, V83, P711, DOI 10.2105/AJPH.83.5.711
   Habot-Wilner Z, 2019, ACTA OPHTHALMOL, V97, P460, DOI 10.1111/aos.14042
   Hackett SF, 2020, BIOMATERIALS, V243, DOI 10.1016/j.biomaterials.2020.119935
   Han IAC, 2020, HUM GENE THER, V31, P1288, DOI 10.1089/hum.2020.043
   Hancock SE, 2021, EXPERT OPIN DRUG DEL, V18, P777, DOI 10.1080/17425247.2021.1867532
   Hancock SE, 2020, INVEST OPHTH VIS SCI, V61
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Henry CR, 2022, BRIT J OPHTHALMOL, V106, P802, DOI 10.1136/bjophthalmol-2020-318019
   Jackson T., OPT 302 PHASE 2B WET
   James ER, 2007, J OCUL PHARMACOL TH, V23, P403, DOI 10.1089/jop.2006.0067
   Jung JH, 2018, J CONTROL RELEASE, V277, P14, DOI 10.1016/j.jconrel.2018.03.001
   Kahraman NS, 2021, EUR J OPHTHALMOL, V31, P3463, DOI 10.1177/1120672120977824
   Kang S, 2013, CURR EYE RES, V38, P119, DOI 10.3109/02713683.2012.727520
   Kansara V, 2020, J OCUL PHARMACOL TH, V36, P384, DOI 10.1089/jop.2019.0126
   Kansara V, 2019, INVEST OPHTH VIS SCI, V60
   Kansara VS, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.13.21
   Kempen JH, 2015, OPHTHALMOLOGY, V122, P1967, DOI 10.1016/j.ophtha.2015.06.042
   Kempen JH, 2011, OPHTHALMOLOGY, V118, P1916, DOI 10.1016/j.ophtha.2011.07.027
   Kim YC, 2015, EUR J PHARM BIOPHARM, V95, P398, DOI 10.1016/j.ejpb.2015.05.020
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   Kothari S, 2015, OPHTHALMOLOGY, V122, P1987, DOI 10.1016/j.ophtha.2015.06.041
   Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Limoli PG, 2020, RESTOR NEUROL NEUROS, V38, P223, DOI 10.3233/RNN-190970
   Limoli PG, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7040094
   Limoli PG, 2018, JOVE-J VIS EXP, DOI 10.3791/56469
   Limoli PG, 2016, ONCOTARGET, V7, P46913, DOI 10.18632/oncotarget.10442
   Limoli PG, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000355
   Riquelme M, 2018, CLIN EXP OPHTHALMOL, V46, P1063, DOI 10.1111/ceo.13333
   MACCUMBER MW, 1991, ARCH OPHTHALMOL-CHIC, V109, P705, DOI 10.1001/archopht.1991.01080050121041
   MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359
   Mantopoulos D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024245
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martorana G., 2012, INVEST OPHTHALMOL VI, V53, P1931
   Muya L., 2021, INVEST OPHTHALMOL VI, V61, P4925
   Muya L, 2020, INVEST OPHTH VIS SCI, V61
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   Nork TM, 2019, INVEST OPHTH VIS SCI, V60
   Noronha G, 2015, INVEST OPHTH VIS SCI, V56
   Ochakovski GA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00174
   Olsen TW, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.6.11
   Olsen TW, 2011, INVEST OPHTH VIS SCI, V52, P4749, DOI 10.1167/iovs.10-6291
   Oner A., 2017, STEM CELL RES OPEN L, V1, P1
   Oner A, 2019, INT OPHTHALMOL, V39, P2913, DOI 10.1007/s10792-019-01141-5
   Oner A, 2018, CELL REPROGRAM, V20, P329, DOI 10.1089/cell.2018.0045
   Orgul S, 1996, J GLAUCOMA, V5, P135
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel S, 2013, INVEST OPHTH VIS SCI, V54
   Patel SR, 2016, INVEST OPHTH VIS SCI, V57
   Peden MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017140
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Prieto E, 2020, BIOMED MATER, V15, DOI 10.1088/1748-605X/aba445
   Prieto E, 2018, GRAEF ARCH CLIN EXP, V256, P535, DOI 10.1007/s00417-017-3893-5
   Puliafito CA, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00221-4
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Ramakrishnan VM, 2018, TISSUE ENG PART B-RE, V24, P289, DOI [10.1089/ten.teb.2017.0061, 10.1089/ten.TEB.2017.0061]
   REGENXBIO, **NON-TRADITIONAL**
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakanaka K, 2008, BIOL PHARM BULL, V31, P1590, DOI 10.1248/bpb.31.1590
   Saliba JB, 2016, INVEST OPHTH VIS SCI, V57, P1671, DOI 10.1167/iovs.15-18127
   Savinainen A, 2020, INVEST OPHTH VIS SCI, V61
   Sen HN, 2014, OPHTHALMOLOGY, V121, P2275, DOI 10.1016/j.ophtha.2014.05.021
   Shen JK, 2016, INVEST OPHTH VIS SCI, V57
   Shen JK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba1606
   Taraborelli D., ONE WEEK STUDY EVALU
   Tavakoli S, 2020, J CONTROL RELEASE, V328, P952, DOI 10.1016/j.jconrel.2020.10.028
   Thiele S, 2013, KLIN MONATSBL AUGENH, V230, P247, DOI 10.1055/s-0032-1328161
   Tobita M, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0217-8
   Tzameret A, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-018-0438-y
   Valamanesh F., 2011, INVEST OPHTHALMOL VI, V52, P3119
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Varma R, 2012, OPHTHALMOLOGY, V119, P2108, DOI 10.1016/j.ophtha.2012.05.017
   Wang YH, 2015, J FUNCT BIOMATER, V6, P379, DOI 10.3390/jfb6020379
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Woodard KT, 2016, MOL THER, V24, pS217, DOI 10.1016/S1525-0016(16)33352-4
   Yang Y, 2015, RETINA-J RET VIT DIS, V35, P2440, DOI 10.1097/IAE.0000000000000726
   Yap YC, 2015, INT J OPHTHALMOL-CHI, V8, P835, DOI 10.3980/j.issn.2222-3959.2015.04.34
   Yeh S, 2019, RETINA-J RET VIT DIS, V39, P1880, DOI 10.1097/IAE.0000000000002279
   Yiu G., 2020, HOST IMMUNE RESPONSE, DOI [10.1101/2020.09.25.313676, DOI 10.1101/2020.09.25.313676]
   Yiu G, 2019, INVEST OPHTH VIS SCI, V60
   Yuan XY, 2015, ACS NANO, V9, P1749, DOI 10.1021/nn506599f
   Zeng MB, 2017, J MOL MED, V95, P417, DOI 10.1007/s00109-016-1498-9
NR 124
TC 13
Z9 13
U1 2
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD FEB
PY 2021
VL 13
IS 2
AR 288
DI 10.3390/pharmaceutics13020288
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA QO2ZA
UT WOS:000623013000001
PM 33671815
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhang, HY
   Zhang, QL
AF Zhang, Hengyi
   Zhang, Qinli
TI Potentiality of Risk SNPs Identification Based on GSP Theory
SO CURRENT BIOINFORMATICS
LA English
DT Article
DE GSP; SNP; joint analysis of vertex domain and frequency domain; RF;
   LASSO; Chi-square test
ID COMPLEMENT-FACTOR-H; MACULAR DEGENERATION; ASSOCIATION TEST; GENE
AB Background: A large number of studies have shown that susceptibility to diseases may be related to some Single Nucleotide Polymorphisms (SNPs). Therefore, the location of SNPs associated with diseases in genes can help us understand the genetic mechanism of disease, intervene in risk SNPs and prevent some genetic diseases. Methods: Based on Graph Signal Processing (GSP) theory, a novel method is proposed to locate the risk SNPs in this paper. The proposed method first builds the graph signal model of all SNP loci, and then realizes the location of abnormal SNPs (risk SNPs) based on the joint analysis of the vertex domain and frequency domain of the graph. Results: The experimental results on synthetic datasets show that our method outperforms many existing methods, including BOOST, SNPHarvester, SNPRule, Random Forest (RF), Chi-square Test and LASSO regression in terms of power. The experimental results on two real Genome-Wide Association Studies (GWAS) datasets, Age related Macular Degeneration (AMD) and Genetic Disease A (GDA), show that our method not only finds the risk SNPs found by several state-of-the-art methods, including RF, Chi-square Test and LASSO regression, but also discovers three potential risk SNPs. Conclusion: Our method is suitable and effective for the identification of risk SNPs in GWAS.
C1 [Zhang, Hengyi] Northwest A&F Univ, Coll Anim Sci & Technol, Yangling, Shaanxi, Peoples R China.
   [Zhang, Qinli] Yulin Normal Univ, Sch Comp Sci & Engn, Yulin 537000, Peoples R China.
C3 Northwest A&F University - China; Yulin Normal University
RP Zhang, QL (通讯作者)，Yulin Normal Univ, Sch Comp Sci & Engn, Yulin 537000, Peoples R China.
EM zqlynu@163.com
CR Chen J, 2017, MATH PRAC THEOR, V47, P78
   Chen LJ, 2007, AM J OPHTHALMOL, V143, P376, DOI [10.1016/j.ajo.2006.12.019, DOI 10.1016/J.AJO.2006.12.019]
   Chen SH, 2015, IEEE T SIGNAL PROCES, V63, P6510, DOI 10.1109/TSP.2015.2469645
   Chen ZX, 2014, STAT PROBABIL LETT, V91, P153, DOI 10.1016/j.spl.2014.04.015
   Chen ZX, 2011, GENET EPIDEMIOL, V35, P658, DOI 10.1002/gepi.20615
   Cordell HJ, 2009, NAT REV GENET, V10, P392, DOI 10.1038/nrg2579
   Ding XJ, 2015, IEEE ACM T COMPUT BI, V12, P695, DOI 10.1109/TCBB.2014.2363459
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Fang YL, 2019, J HUANGGANG NORMAL U, V39, P1
   Feng ZZ, 2012, IEEE ACM T COMPUT BI, V9, P629, DOI 10.1109/TCBB.2011.139
   Guo X, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-102
   He JW, 2006, BIOINFORMATICS, V22, P2558, DOI 10.1093/bioinformatics/btl420
   Huang K, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0914-8
   Jiang R, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S1-S65
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Lin Wan-Yu, 2010, BMC Res Notes, V3, P26, DOI 10.1186/1756-0500-3-26
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Marttinen P, 2014, BIOINFORMATICS, V30, P2026, DOI 10.1093/bioinformatics/btu140
   Milet J, 2020, MIXED LOGISTIC REGRE
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Ried JS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13357
   Sandryhaila A, 2014, IEEE T SIGNAL PROCES, V62, P3042, DOI 10.1109/TSP.2014.2321121
   Shuman DI, 2013, IEEE SIGNAL PROC MAG, V30, P83, DOI 10.1109/MSP.2012.2235192
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   Sun JL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54519-x
   Sun LY, 2019, CURR BIOINFORM, V14, P749, DOI 10.2174/1574893614666190409110843
   Wang MH, 2010, BIOINFORMATICS, V26, P831, DOI 10.1093/bioinformatics/btq038
   Wang Y, 2011, BIOINFORMATICS, V27, P2936, DOI 10.1093/bioinformatics/btr512
   Winham SJ, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-164
   Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041
   Zhou T, 2019, IEEE T BIO-MED ENG, V66, P165, DOI 10.1109/TBME.2018.2824725
NR 32
TC 0
Z9 0
U1 2
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-8936
EI 2212-392X
J9 CURR BIOINFORM
JI Curr. Bioinform.
PY 2021
VL 16
IS 4
BP 512
EP 523
DI 10.2174/1574893615999200730161941
PG 12
WC Biochemical Research Methods; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA TD6MB
UT WOS:000669437400003
DA 2022-11-30
ER

PT J
AU Narendran, S
   Pereira, F
   Yerramothu, P
   Apicella, I
   Wang, SB
   Varshney, A
   Baker, KL
   Marion, KM
   Ambati, M
   Ambati, VL
   Ambati, K
   Sadda, SR
   Gelfand, BD
   Ambati, J
AF Narendran, Siddharth
   Pereira, Felipe
   Yerramothu, Praveen
   Apicella, Ivana
   Wang, Shao-Bin
   Varshney, Akhil
   Baker, Kirstie L.
   Marion, Kenneth M.
   Ambati, Meenakshi
   Ambati, Vidya L.
   Ambati, Kameshwari
   Sadda, Srinivas R.
   Gelfand, Bradley D.
   Ambati, Jayakrishna
TI A Clinical Metabolite of Azidothymidine Inhibits Experimental Choroidal
   Neovascularization and Retinal Pigmented Epithelium Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE macular degeneration; RPE degeneration; choroidal neovascularization
ID MACULAR DEGENERATION; ZIDOVUDINE; EYES; INFLAMMASOME; MECHANISM;
   TOXICITY
AB PURPOSE. Azidothymidine (AZT), a nucleoside reverse transcriptase inhibitor, possesses anti-inflammatory and anti-angiogenic activity independent of its ability to inhibit reverse transcriptase. The aim of this study was to evaluate the efficacy of 5'-glucuronyl azidothymidine (GAZT), an antiretrovirally inert hepatic clinical metabolite of AZT, in mouse models of retinal pigment epithelium (RPE) degeneration and choroidal neovascularization (CNV), hallmark features of dry and wet age-related macular degeneration (AMD), respectively.
   METHODS. RPE degeneration was induced in wild-type (WT) C57BL/6J mice by subretinal injection of Alu RNA. RPE degeneration was assessed by fundus photography and confocal microscopy of zonula occludens-1-stained RPE flat mounts. Choroidal neovascularization was induced by laser injury in WT mice, and CNV volume was measured by confocal microscopy. AZT and GAZT were delivered by intravitreous injections. Inflammasome activation was monitored by western blotting for caspase-1 and by ELISA for IL-1 beta in Alu RNA-treated bone marrow-derived macrophages (BMDMs).
   RESULTS. GAZT inhibited Alu RNA-induced RPE degeneration and laser-induced CNV. GAZT also reduced Alu RNA-induced caspase-1 activation and IL-1 beta release in BMDMs.
   CONCLUSIONS. GAZT possesses dual anti-inflammatory and anti-angiogenic properties and could be a viable treatment option for both forms of AMD.
C1 [Narendran, Siddharth; Pereira, Felipe; Yerramothu, Praveen; Apicella, Ivana; Wang, Shao-Bin; Varshney, Akhil; Ambati, Meenakshi; Ambati, Kameshwari; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Ctr Adv Vis Sci, 415 Lane Rd, Charlottesville, VA 22908 USA.
   [Narendran, Siddharth; Pereira, Felipe; Yerramothu, Praveen; Apicella, Ivana; Wang, Shao-Bin; Varshney, Akhil; Ambati, Meenakshi; Ambati, Kameshwari; Gelfand, Bradley D.; Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Narendran, Siddharth] Aravind Eye Care Syst, Madurai, Tamil Nadu, India.
   [Baker, Kirstie L.; Marion, Kenneth M.; Sadda, Srinivas R.] Doheny Eye Inst, Los Angeles, CA USA.
   [Ambati, Meenakshi; Ambati, Vidya L.] Ctr Digital Image Evaluat, Charlottesville, VA USA.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Gelfand, Bradley D.] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Neurosci, Charlottesville, VA 22908 USA.
   [Ambati, Jayakrishna] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA.
C3 University of Virginia; University of Virginia; Doheny Eye Institute;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of Virginia; University of Virginia;
   University of Virginia; University of Virginia
RP Ambati, J (通讯作者)，Univ Virginia, Sch Med, Ctr Adv Vis Sci, 415 Lane Rd, Charlottesville, VA 22908 USA.
EM ja9qr@virginia.edu
RI WANG, SHAO-BIN/Z-1810-2018
OI WANG, SHAO-BIN/0000-0002-6699-9406; Yerramothu,
   Praveen/0000-0001-6635-6681
FU National Institutes of Health [R01EY029799, R01EY028027]; DuPont Guerry
   III Professorship; University of Virginia Strategic Investment Fund
FX Supported by National Institutes of Health grants (R01EY028027,
   R01EY029799), the DuPont Guerry III Professorship, and the University of
   Virginia Strategic Investment Fund. BDG is supported by National
   Institutes of Health grant R01EY029799. No funding agency had a role in
   study design or conduct, data collection, analysis, interpretation, or
   manuscript writing. The content of this article is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health nor does mention of
   trade names, commercial products, or organizations imply endorsement by
   the US Government.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Cooper DL, 2011, DNA REPAIR, V10, P260, DOI 10.1016/j.dnarep.2010.11.007
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   FURMAN PA, 1988, AM J MED, V85, P176
   Grossniklaus HE, 2000, ARCH OPHTHALMOL-CHIC, V118, P625
   Holec AD, 2017, CURR HIV RES, V15, P411, DOI 10.2174/1570162X15666171120110145
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Mislak AC, 2016, ANTIMICROB AGENTS CH, V60, P561, DOI 10.1128/AAC.02270-15
   Mizutani T, 2015, INVEST OPHTH VIS SCI, V56, P7122, DOI 10.1167/iovs.15-17440
   MOORE KHP, 1995, ANTIMICROB AGENTS CH, V39, P2732, DOI 10.1128/AAC.39.12.2732
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   RACHLIS A, 1993, DRUG SAFETY, V8, P312, DOI 10.2165/00002018-199308040-00005
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Veal GJ, 1995, GEN PHARMACOL, V26, P1469, DOI 10.1016/0306-3623(95)00047-X
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright CB, 2020, P NATL ACAD SCI USA, V117, P2579, DOI 10.1073/pnas.1909761117
   Zhang X, 2008, CURR PROTOC IMMUNOL, V83
NR 24
TC 4
Z9 5
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2020
VL 61
IS 10
AR 4
DI 10.1167/iovs.61.10.4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NI3HZ
UT WOS:000565248700034
PM 32749462
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kushol, R
   Kabir, MH
   Abdullah-Al-Wadud, M
   Islam, MS
AF Kushol, Rafsanjany
   Kabir, Md. Hasanul
   Abdullah-Al-Wadud, M.
   Islam, Md Saiful
TI Retinal blood vessel segmentation from fundus image using an efficient
   multiscale directional representation technique Bendlets
SO MATHEMATICAL BIOSCIENCES AND ENGINEERING
LA English
DT Article
DE Bendlets; retinal blood vessel; ensemble classifier; medical image
   segmentation; contrast enhancement; multi-resolution; multi-scale
   transform
ID MATCHED-FILTER; TRANSFORM
AB The improper circulation of blood flow inside the retinal vessel is the primary source of most of the optical disorders including partial vision loss and blindness. Accurate blood vessel segmentation of the retinal image is utilized for biometric identification, computer-assisted laser surgical procedure, automatic screening, and diagnosis of ophthalmologic diseases like Diabetic retinopathy, Age-related macular degeneration, Hypertensive retinopathy, and so on. Proper identification of retinal blood vessels at its early stage assists medical experts to take expedient treatment procedures which could mitigate potential vision loss. This paper presents an efficient retinal blood vessel segmentation approach where a 4-D feature vector is constructed by the outcome of Bendlet transform, which can capture directional information much more efficiently than the traditional wavelets. Afterward, a bunch of ensemble classifiers is applied to find out the best possible result of whether a pixel falls inside a vessel or non-vessel segment. The detailed and comprehensive experiments operated on two benchmark and publicly available retinal color image databases (DRIVE and STARE) prove the effectiveness of the proposed approach where the average accuracy for vessel segmentation accomplished approximately 95%. Furthermore, in comparison with other promising works on the aforementioned databases demonstrates the enhanced performance and robustness of the proposed method.
C1 [Kushol, Rafsanjany] Univ Alberta, Dept Comp Sci, Edmonton, AB, Canada.
   [Kushol, Rafsanjany; Kabir, Md. Hasanul] Islamic Univ Technol, Dept Comp Sci & Engn, Dhaka, Bangladesh.
   [Abdullah-Al-Wadud, M.] King Saud Univ, Dept Software Engn, Riyadh, Saudi Arabia.
   [Islam, Md Saiful] King Saud Univ, Dept Comp Sci, Riyadh, Saudi Arabia.
C3 University of Alberta; King Saud University; King Saud University
RP Kushol, R (通讯作者)，Univ Alberta, Dept Comp Sci, Edmonton, AB, Canada.; Kushol, R (通讯作者)，Islamic Univ Technol, Dept Comp Sci & Engn, Dhaka, Bangladesh.
EM kushol@ualberta.ca
RI Abdullah-Al-Wadud, M./AAI-5142-2020; Islam, Md Saiful/B-9632-2012
OI Islam, Md Saiful/0000-0002-2670-6007; Abdullah-Al-Wadud,
   M./0000-0001-6767-3574; Kabir, Md. Hasanul/0000-0002-6853-8785; Kushol,
   Rafsanjany/0000-0003-2991-9785
FU Deanship of Scientific Research at King Saud University [RG-1441-394]
FX The authors extend their appreciation to the Deanship of Scientific
   Research at King Saud University for funding this work through research
   group no (RG-1441-394).
CR Al-Rawi M, 2007, COMPUT BIOL MED, V37, P262, DOI 10.1016/j.compbiomed.2006.03.003
   Alom MZ, 2019, J MED IMAGING, V6, DOI 10.1117/1.JMI.6.1.014006
   Azzopardi G, 2015, MED IMAGE ANAL, V19, P46, DOI 10.1016/j.media.2014.08.002
   Bankhead P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032435
   Brancati N., 2017, IB C PATT REC, P119
   Candes E. J., 2000, TECHNICAL REPORT
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Do MN, 2005, IEEE T IMAGE PROCESS, V14, P2091, DOI 10.1109/TIP.2005.859376
   Fan Z., 2016, 2016 12 WORLD C INT
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P600, DOI 10.1016/j.cmpb.2011.08.009
   Fraz MM, 2012, IEEE T BIO-MED ENG, V59, P2538, DOI 10.1109/TBME.2012.2205687
   Gao J., 2020, BIOMED RES INT, V2020
   Ghadiri F., 2012, 2012 NAT C COMM NCC
   Imani E, 2015, COMPUT METH PROG BIO, V118, P263, DOI 10.1016/j.cmpb.2015.01.004
   Joussen A. M., 2007, RETINAL VASCULAR DIS
   Khomri B, 2018, IET IMAGE PROCESS, V12, P2163, DOI 10.1049/iet-ipr.2018.5425
   Kushol R., 2019, CONTRAST ENHANCEMENT
   Kushol R, 2017, LECT NOTES COMPUT SC, V10317, P533, DOI 10.1007/978-3-319-59876-5_59
   Lessig C, 2019, APPL COMPUT HARMON A, V46, P384, DOI 10.1016/j.acha.2017.06.002
   Levet F., 2016, STAG, P151
   Li LZ, 2020, IEEE WINT CONF APPL, P3645, DOI 10.1109/WACV45572.2020.9093621
   Lim WQ, 2010, IEEE T IMAGE PROCESS, V19, P1166, DOI 10.1109/TIP.2010.2041410
   Marin D, 2011, IEEE T MED IMAGING, V30, P146, DOI 10.1109/TMI.2010.2064333
   Martinez-Perez ME, 1999, LECT NOTES COMPUT SC, V1679, P90
   Mendonca AM, 2006, IEEE T MED IMAGING, V25, P1200, DOI 10.1109/TMI.2006.879955
   Miri MS, 2011, IEEE T BIO-MED ENG, V58, P1183, DOI 10.1109/TBME.2010.2097599
   Nguyen UTV, 2013, PATTERN RECOGN, V46, P703, DOI 10.1016/j.patcog.2012.08.009
   Niemeijer M., 2004, P SPIE
   Odstrcilik J, 2013, IET IMAGE PROCESS, V7, P373, DOI 10.1049/iet-ipr.2012.0455
   Ricci E, 2007, IEEE T MED IMAGING, V26, P1357, DOI 10.1109/TMI.2007.898551
   Saffarzadeh Vahid Mohammadi, 2014, J Med Signals Sens, V4, P122
   Shin SY, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101556
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Vlachos M, 2010, COMPUT MED IMAG GRAP, V34, P213, DOI 10.1016/j.compmedimag.2009.09.006
   Xu LL, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-14
   Yanli Hou, 2014, Journal of Computing Science and Engineering, V8, P119, DOI 10.5626/JCSE.2014.8.2.119
   Yue KJ, 2018, IET IMAGE PROCESS, V12, P1450, DOI 10.1049/iet-ipr.2017.1071
   Zhang B, 2010, COMPUT BIOL MED, V40, P438, DOI 10.1016/j.compbiomed.2010.02.008
NR 38
TC 4
Z9 4
U1 5
U2 7
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604, UNITED STATES
SN 1547-1063
EI 1551-0018
J9 MATH BIOSCI ENG
JI Math. Biosci. Eng.
PY 2020
VL 17
IS 6
BP 7751
EP 7771
DI 10.3934/mbe.2020394
PG 21
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA QL6KT
UT WOS:000621193300010
PM 33378918
OA gold
DA 2022-11-30
ER

PT J
AU Biswas, L
   Farhan, F
   Reilly, J
   Bartholomew, C
   Shu, XH
AF Biswas, Lincoln
   Farhan, Fahad
   Reilly, James
   Bartholomew, Chris
   Shu, Xinhua
TI TSPO Ligands Promote Cholesterol Efflux and Suppress Oxidative Stress
   and Inflammation in Choroidal Endothelial Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE TSPO; cholesterol efflux; oxidative stress; inflammation; choroidal
   endothelial cells; age-related macular degeneration
ID PERIPHERAL BENZODIAZEPINE-RECEPTOR; TRANSLOCATOR PROTEIN TSPO;
   NECROSIS-FACTOR-ALPHA; LONG RESIDENCE TIME; 18 KDA; MACULAR
   DEGENERATION; MOUSE MODEL; MITOCHONDRIAL; EXPRESSION; MICROGLIA
AB Choroidal endothelial cells supply oxygen and nutrients to retinal pigment epithelial (RPE) cells and photoreceptors, recycle metabolites, and dispose of metabolic waste through the choroidal blood circulation. Death of the endothelial cells of the choroid may cause abnormal deposits including unesterified and esterified cholesterol beneath RPE cells and within Bruch's membrane that contribute to the progression of age-related macular degeneration (AMD), the most prevalent cause of blindness in older people. Translocator protein (TSPO) is a cholesterol-binding protein that is involved in mitochondrial cholesterol transport and other cellular functions. We have investigated the role of TSPO in choroidal endothelial cells. Immunocytochemistry showed that TSPO was localized to the mitochondria of choroidal endothelial cells. Choroidal endothelial cells exposed to TSPO ligands (Etifoxine or XBD-173) had significantly increased cholesterol efflux, higher expression of cholesterol homeostasis genes (LXR, CYP27A1, CYP46A1, ABCA1 and ABCG1), and reduced biosynthesis of cholesterol and phospholipids from [C-14]acetate, when compared to untreated controls. Treatment with TSPO ligands also resulted in reduced production of reactive oxygen species (ROS), increased antioxidant capacity, and reduced release of pro-inflammatory cytokines (IL-1 beta, IL-6, TNF-alpha and VEGF) induced by oxidized LDL. These data suggest TSPO ligands may offer promise for the treatment of AMD.
C1 [Biswas, Lincoln; Farhan, Fahad; Reilly, James; Bartholomew, Chris; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
C3 Glasgow Caledonian University; Glasgow Caledonian University
RP Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.; Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
EM Lincoln.Biswas@gcu.ac.uk; Fahad.Farhan@gcu.ac.uk; J.Reilly@gcu.ac.uk;
   C.Bartholomew@gcu.ac.uk; Xinhua.Shu@gcu.ac.uk
OI Biswas, Lincoln/0000-0002-2288-341X; Shu, Xinhua/0000-0003-3760-3019
FU Rosetrees Trust [M160, M160-F1, M160-F2]; National Eye Research Centre
   [SAC037]; Office of the Assistant Military Attache for Training Embassy
   of the State of Kuwait-London
FX This work was supported by the Rosetrees Trust (M160, M160-F1, M160-F2),
   National Eye Research Centre (SAC037) and a PhD studentship from the
   Office of the Assistant Military Attache for Training Embassy of the
   State of Kuwait-London.
CR Arbo BD, 2015, J STEROID BIOCHEM, V154, P68, DOI 10.1016/j.jsbmb.2015.07.007
   Baez E, 2017, NEUROTOX RES, V32, P163, DOI 10.1007/s12640-017-9733-x
   Banati RB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6452
   Barron AM, 2018, BIOCHEM J, V475, P75, DOI 10.1042/BCJ20170645
   Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Bonsack F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061694
   BRAESTRUP C, 1977, P NATL ACAD SCI USA, V74, P3805, DOI 10.1073/pnas.74.9.3805
   Choi HB, 2002, J NEUROCHEM, V83, P546, DOI 10.1046/j.1471-4159.2002.01122.x
   Choi YM, 2015, KOREAN J PAIN, V28, P4, DOI 10.3344/kjp.2015.28.1.4
   Cosenza-Nashat M, 2009, NEUROPATH APPL NEURO, V35, P306, DOI 10.1111/j.1365-2990.2008.01006.x
   Costa B, 2017, ACS CHEM NEUROSCI, V8, P1448, DOI 10.1021/acschemneuro.7b00027
   Costa B, 2016, ACS CHEM NEUROSCI, V7, P1041, DOI 10.1021/acschemneuro.6b00149
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124
   de Tassigny AD, 2013, MITOCHONDRION, V13, P688, DOI 10.1016/j.mito.2013.10.001
   Falchi AM, 2007, NEUROPHARMACOLOGY, V53, P318, DOI 10.1016/j.neuropharm.2007.05.016
   Fan JJ, 2018, ENDOCRINOLOGY, V159, P1130, DOI 10.1210/en.2017-03065
   Fan JJ, 2015, P NATL ACAD SCI USA, V112, P7261, DOI 10.1073/pnas.1502670112
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Gatliff J, 2015, BIOCHEM SOC T, V43, P543, DOI 10.1042/BST20150037
   Girard C, 2012, J NEUROENDOCRINOL, V24, P71, DOI 10.1111/j.1365-2826.2011.02215.x
   Graham A, 2015, FREE RADICAL BIO MED, V89, P982, DOI 10.1016/j.freeradbiomed.2015.08.010
   Ji B, 2008, J NEUROSCI, V28, P12255, DOI 10.1523/JNEUROSCI.2312-08.2008
   Joo HK, 2015, MOL CELLS, V38, P1064, DOI 10.14348/molcells.2015.0165
   Joo HK, 2009, ANESTHESIOLOGY, V110, P106, DOI 10.1097/ALN.0b013e318190bc69
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kunduzova OR, 2004, J AM SOC NEPHROL, V15, P2152, DOI 10.1097/01.ASN.0000133563.41148.74
   Leducq N, 2003, J PHARMACOL EXP THER, V306, P828, DOI 10.1124/jpet.103.052068
   Leva G, 2017, BBA-MOL BASIS DIS, V1863, P3016, DOI 10.1016/j.bbadis.2017.09.007
   Li H, 1998, ENDOCRINOLOGY, V139, P4991, DOI 10.1210/en.139.12.4991
   Liao JK, 2013, J CLIN INVEST, V123, P540, DOI 10.1172/JCI66843
   MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170
   Miller YI, 2017, TRENDS ENDOCRIN MET, V28, P143, DOI 10.1016/j.tem.2016.11.002
   Mitra S, 2011, AM J MED SCI, V342, P135, DOI 10.1097/MAJ.0b013e318224a147
   Morin D, 2016, BIOCHEM PHARMACOL, V105, P1, DOI 10.1016/j.bcp.2015.12.003
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Negre-Salvayre A, 2017, FREE RADICAL BIO MED, V106, P118, DOI 10.1016/j.freeradbiomed.2017.02.006
   Paradis S, 2013, CARDIOVASC RES, V98, P420, DOI 10.1093/cvr/cvt079
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Poisbeau P, 2018, WORLD J BIOL PSYCHIA, V19, pS36, DOI 10.1080/15622975.2018.1468030
   Pol A, 2014, J CELL BIOL, V204, P635, DOI 10.1083/jcb.201311051
   Prosser HC, 2012, CURR OPIN LIPIDOL, V23, P182, DOI 10.1097/MOL.0b013e328352c4dd
   Ravikumar B, 2016, NEUROPHARMACOLOGY, V108, P229, DOI 10.1016/j.neuropharm.2016.03.053
   Rupprecht R, 2009, SCIENCE, V325, P490, DOI 10.1126/science.1175055
   Santoro A, 2016, EUR J PHARM SCI, V88, P124, DOI 10.1016/j.ejps.2016.04.006
   Schaller S, 2010, J PHARMACOL EXP THER, V333, P696, DOI 10.1124/jpet.110.167486
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   STEPHENSON DT, 1995, J NEUROSCI, V15, P5263
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Sun X, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196541
   Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793
   Taylor JMW, 2014, CLIN SCI, V127, P603, DOI 10.1042/CS20140047
   Tu LN, 2015, ENDOCRINOLOGY, V156, P1033, DOI 10.1210/en.2014-1707
   Tu LN, 2014, J BIOL CHEM, V289, P27444, DOI 10.1074/jbc.M114.578286
   Wang HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167307
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wilms H, 2003, NEUROBIOL DIS, V14, P417, DOI 10.1016/j.nbd.2003.07.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiao JJ, 2010, EXP BIOL MED, V235, P478, DOI 10.1258/ebm.2009.009291
   Yasin N, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040786
   Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101
   Zekavat SM, 2017, J LIPID RES, V58, P1325, DOI 10.1194/jlr.M074088
NR 68
TC 22
Z9 22
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2018
VL 19
IS 12
AR 3740
DI 10.3390/ijms19123740
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA HG9JM
UT WOS:000455323500042
PM 30477223
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Novosel, J
   Vermeer, KA
   de Jong, JH
   Wang, Z
   van Vliet, LJ
AF Novosel, Jelena
   Vermeer, Koenraad A.
   de Jong, Jan H.
   Wang, Ziyuan
   van Vliet, Lucas J.
TI Joint Segmentation of Retinal Layers and Focal Lesions in 3-D OCT Data
   of Topologically Disrupted Retinas
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Loosely coupled level sets; attenuation coefficients; central serous
   retinopathy; age-related macular degeneration; diabetic-macular edema
ID OPTICAL COHERENCE TOMOGRAPHY; NERVE-FIBER LAYER; DIABETIC MACULAR EDEMA;
   AUTOMATED DRUSEN SEGMENTATION; GRAPH-SEARCH; IMAGES; EYES; DEGENERATION;
   THICKNESS; CLASSIFICATION
AB Accurate quantification of retinal structures in 3-D optical coherence tomography data of eyes with pathologies provides clinically relevant information. We present an approachto jointly segment retinal layers and lesions in eyes with topology-disrupting retinal diseases by a loosely coupled level set framework. In the new approach, lesions are modeled as an additional space-variant layer delineated by auxiliary interfaces. Furthermore, the segmentation of interfaces is steered by local differences in the signal between adjacent retinal layers, thereby allowing the approach to handle local intensity variations. The accuracy of the proposed method of both layer and lesion segmentation has been evaluated on eyes affected by central serous retinopathy and age-related macular degeneration. In addition, layer segmentation of the proposed approach was evaluated on eyes without topology-disrupting retinal diseases. Good agreement between the segmentation performed manually by a medical doctor and results obtained from the automatic segmentation was found for all data types. The mean unsigned error for all interfaces varied between 2.3 and 11.9 mu m (0.6-3.1 pixels). Furthermore, lesion segmentation showed a Dice coefficient of 0.68 for drusen and 0.89 for fluid pockets. Overall, the method provides a flexible and accurate solution to jointly segment lesions and retinal layers.
C1 [Novosel, Jelena; Vermeer, Koenraad A.; de Jong, Jan H.] Rotterdam Eye Hosp, Rotterdam Ophthalm Inst, NL-3011 BH Rotterdam, Netherlands.
   [Novosel, Jelena; Wang, Ziyuan; van Vliet, Lucas J.] Delft Univ Technol, NL-2628 CD Delft, Netherlands.
C3 Rotterdam Eye Hospital; Delft University of Technology
RP Novosel, J (通讯作者)，Rotterdam Eye Hosp, Rotterdam Ophthalm Inst, NL-3011 BH Rotterdam, Netherlands.
EM j.novosel@tudelft.nl
RI Vermeer, Koen/A-9516-2009; de Jong, J.H./AAL-2888-2021; van Vliet,
   Lucas/E-1678-2012
OI Vermeer, Koen/0000-0002-4038-3945; van Vliet, Lucas/0000-0001-7018-726X;
   de Jong, J.H./0000-0002-3755-2381
FU ZonMw [91212061]; Stichting Combined Ophthalmic Research Rotterdam;
   Stichting Glaucoomfonds; Stichting voor Ooglijders
FX This work was supported in part by ZonMw under Grant 91212061, in part
   by Stichting Combined Ophthalmic Research Rotterdam, in part by
   Stichting Glaucoomfonds, and in part by Stichting voor Ooglijders.
   Asterisk indicates corresponding author.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Ahlers C, 2009, ACTA OPHTHALMOL, V87, P511, DOI 10.1111/j.1755-3768.2008.01468.x
   Antony B. J., 2016, P SOC PHOTO-OPT INS, V9784
   Antony BJ, 2013, BIOMED OPT EXPRESS, V4, P2712, DOI 10.1364/BOE.4.002712
   Bakker P., 1999, IEEE COMP SOC C COMP, V1, P540
   Bogunovic H, 2015, P OPHTH MED IM AN, P49
   Bowd C, 2000, ARCH OPHTHALMOL-CHIC, V118, P22
   Carass A, 2014, BIOMED OPT EXPRESS, V5, P1062, DOI 10.1364/BOE.5.001062
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   DeBuc DC, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3268773
   Dijkstra E.W., 1959, NUMER MATH, V1, P269, DOI [10.1007/BF01386390, DOI 10.1007/BF01386390]
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Fernandez DC, 2005, OPT EXPRESS, V13, P10200, DOI 10.1364/OPEX.13.010200
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Kafieh R, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/259123
   Kafieh R, 2013, MED IMAGE ANAL, V17, P907, DOI 10.1016/j.media.2013.05.006
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Knutsson H, 2011, LECT NOTES COMPUT SC, V6688, P545, DOI 10.1007/978-3-642-21227-7_51
   Lang A, 2015, BIOMED OPT EXPRESS, V6, P155, DOI 10.1364/BOE.6.000155
   Lang A, 2013, BIOMED OPT EXPRESS, V4, P1133, DOI 10.1364/BOE.4.001133
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7595, DOI 10.1167/iovs.13-11762
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Mujat M, 2005, OPT EXPRESS, V13, P9480, DOI 10.1364/OPEX.13.009480
   NEI, 2015, AG REL EYE DIS STUD
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Niu SJ, 2014, COMPUT BIOL MED, V54, P116, DOI 10.1016/j.compbiomed.2014.08.028
   Novosel J., 2016, P SOC PHOTO-OPT INS, V9784
   Novosel J, 2016, I S BIOMED IMAGING, P702, DOI 10.1109/ISBI.2016.7493363
   Novosel J, 2015, MED IMAGE ANAL, V26, P146, DOI 10.1016/j.media.2015.08.008
   Oguz I., 2016, P SOC PHOTO-OPT INS, V9784
   Pilch M, 2013, INVEST OPHTH VIS SCI, V54, P4385, DOI 10.1167/iovs.12-11396
   Pons ME, 2000, ARCH OPHTHALMOL-CHIC, V118, P1044, DOI 10.1001/archopht.118.8.1044
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Roychowdhury S, 2013, IEEE ENG MED BIO, P1426, DOI 10.1109/EMBC.2013.6609778
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   van der Schoot J, 2012, INVEST OPHTH VIS SCI, V53, P2424, DOI 10.1167/iovs.11-8436
   Vermeer KA, 2014, BIOMED OPT EXPRESS, V5, P322, DOI 10.1364/BOE.5.000322
   Vermeer KA, 2011, BIOMED OPT EXPRESS, V2, P1743, DOI 10.1364/BOE.2.001743
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
NR 51
TC 34
Z9 34
U1 0
U2 26
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD JUN
PY 2017
VL 36
IS 6
BP 1276
EP 1286
DI 10.1109/TMI.2017.2666045
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA EW7UM
UT WOS:000402722500006
PM 28186886
DA 2022-11-30
ER

PT J
AU Eidet, JR
   Reppe, S
   Pasovic, L
   Olstad, OK
   Lyberg, T
   Khan, AZ
   Fostad, IG
   Chen, DF
   Utheim, TP
AF Eidet, J. R.
   Reppe, S.
   Pasovic, L.
   Olstad, O. K.
   Lyberg, T.
   Khan, A. Z.
   Fostad, I. G.
   Chen, D. F.
   Utheim, T. P.
TI The Silk-protein Sericin Induces Rapid Melanization of Cultured Primary
   Human Retinal Pigment Epithelial Cells by Activating the NF-kappa B
   Pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INTERFERON-INDUCIBLE PROTEIN-10; DELAYED DARK-ADAPTATION; EMBRYONIC
   STEM-CELLS; MACULAR DEGENERATION; IN-VITRO; VISUAL CYCLE; SECRETORY
   PATHWAY; MELANOMA-CELLS; KNOCKOUT MICE; IFN-GAMMA
AB Restoration of the retinal pigment epithelial (RPE) cells to prevent further loss of vision in patients with age-related macular degeneration represents a promising novel treatment modality. Development of RPE transplants, however, requires up to 3 months of cell differentiation. We explored whether the silk protein sericin can induce maturation of primary human retinal pigment epithelial (hRPE) cells. Microarray analysis demonstrated that sericin up-regulated RPE-associated transcripts (RPE65 and CRALBP). Upstream analysis identified the NF-kappa B pathway as one of the top sericin-induced regulators. ELISA confirmed that sericin stimulates the main NF-kappa B pathway. Increased levels of RPE-associated proteins (RPE65 and the pigment melanin) in the sericin-supplemented cultures were confirmed by western blot, spectrophotometry and transmission electron microscopy. Sericin also increased cell density and reduced cell death following serum starvation in culture. Inclusion of NF-kappa B agonists and antagonists in the culture medium showed that activation of the NF-kappa B pathway appears to be necessary, but not sufficient, for sericin-induced RPE pigmentation. We conclude that sericin promotes pigmentation of cultured primary hRPE cells by activating the main NF-kappa B pathway. Sericin's potential role in culture protocols for rapid differentiation of hRPE cells derived from embryonic or induced pluripotent stem cells should be investigated.
C1 [Eidet, J. R.] Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
   [Reppe, S.; Pasovic, L.; Olstad, O. K.; Lyberg, T.; Khan, A. Z.; Utheim, T. P.] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway.
   [Pasovic, L.; Khan, A. Z.] Univ Oslo, Fac Med, Oslo, Norway.
   [Fostad, I. G.; Utheim, T. P.] Univ Oslo, Fac Dent, Dept Oral Biol, Oslo, Norway.
   [Chen, D. F.] Harvard Univ, Massachusetts Eye & Ear, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; Harvard University; Harvard Medical School; Massachusetts Eye &
   Ear Infirmary; Schepens Eye Research Institute
RP Eidet, JR (通讯作者)，Oslo Univ Hosp, Dept Ophthalmol, Oslo, Norway.
EM j.r.eidet@gmail.com
OI Pasovic, Lara/0000-0002-3871-9841; Khan, Ayyad
   Zartasht/0000-0002-2048-225X
FU Norwegian Research Council; South-Eastern Norway Regional Health
   Authority
FX The authors thank Thea Berg and Catherine Jackson, Department of Medical
   Biochemistry, Oslo University Hospital, Oslo, Norway, for their
   excellent assistance and support. This work was supported by the
   Norwegian Research Council and South-Eastern Norway Regional Health
   Authority.
CR Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155
   Aramwit P, 2012, WASTE MANAGE RES, V30, P217, DOI 10.1177/0734242X11404733
   Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Cai X, 2009, OPHTHALMIC GENET, V30, P57, DOI 10.1080/13816810802626399
   Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chlapanidas T, 2013, INT J BIOL MACROMOL, V58, P47, DOI 10.1016/j.ijbiomac.2013.03.054
   Eidet JR, 2015, CURR EYE RES, V40, P30, DOI 10.3109/02713683.2014.909497
   Eidet JR, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-92
   Farjo KM, 2009, INVEST OPHTH VIS SCI, V50, P5089, DOI 10.1167/iovs.09-3797
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   Gronskov K, 2013, AM J HUM GENET, V92, P415, DOI 10.1016/j.ajhg.2013.01.006
   Halaban R, 2002, J BIOL CHEM, V277, P14821, DOI 10.1074/jbc.M111497200
   Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004
   Heyninck K, 2005, TRENDS BIOCHEM SCI, V30, P1, DOI 10.1016/j.tibs.2004.11.001
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P645, DOI 10.1111/j.1751-1097.2007.00228.x
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kato N, 1998, BIOSCI BIOTECH BIOCH, V62, P145, DOI 10.1271/bbb.62.145
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim HJ, 2014, BIOMOL THER, V22, P207, DOI 10.4062/biomolther.2014.031
   Kim TS, 2005, J BIOL CHEM, V280, P8694, DOI 10.1074/jbc.M413172200
   Kiser PD, 2010, PROG RETIN EYE RES, V29, P428, DOI 10.1016/j.preteyeres.2010.03.002
   Kishi H, 1997, CELL BIOL INT, V21, P353, DOI 10.1006/cbir.1997.0156
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Korbolina EE, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S12-S3
   Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238
   Liu Xiao-fang, 2011, Front Biosci (Elite Ed), V3, P158, DOI 10.2741/e229
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Michaelides M, 2010, INVEST OPHTH VIS SCI, V51, P4771, DOI 10.1167/iovs.09-4561
   Natarajan VT, 2014, P NATL ACAD SCI USA, V111, P2301, DOI 10.1073/pnas.1304988111
   Ogawa A, 2004, J BIOSCI BIOENG, V98, P217
   Ohnishi K, 2012, J HEPATO-BIL-PAN SCI, V19, P354, DOI 10.1007/s00534-011-0415-4
   Parker RO, 2010, EXP EYE RES, V91, P788, DOI 10.1016/j.exer.2010.08.013
   Pasovic L, 2014, OPHTHALMOL THER, V3, P49, DOI 10.1007/s40123-014-0024-9
   Prasad AS, 2004, FREE RADICAL BIO MED, V37, P1182, DOI 10.1016/j.freeradbiomed.2004.07.007
   Raeder S, 2007, ACTA OPHTHALMOL SCAN, V85, P377, DOI 10.1111/j.1600-0420.2006.00873.x
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   Reinisalo M, 2012, MOL VIS, V18, P38
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   Sandell LL, 2007, GENE DEV, V21, P1113, DOI 10.1101/gad.1533407
   Sasaki M, 2005, BIOTECHNOL APPL BIOC, V42, P183, DOI 10.1042/BA20050019
   Schwab IR, 2006, ARCH OPHTHALMOL-CHIC, V124, P1734, DOI 10.1001/archopht.124.12.1734
   Sgadari C, 1996, P NATL ACAD SCI USA, V93, P13791, DOI 10.1073/pnas.93.24.13791
   Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi M, 2003, BIOTECHNOL LETT, V25, P1805, DOI 10.1023/A:1026284620236
   Takasu Y, 2002, BIOSCI BIOTECH BIOCH, V66, P2715, DOI 10.1271/bbb.66.2715
   Tsubouchi K, 2005, BIOSCI BIOTECH BIOCH, V69, P403, DOI 10.1271/bbb.69.403
   Verdanova M, 2014, BIOPRESERV BIOBANK, V12, P99, DOI 10.1089/bio.2013.0078
   Vessey KA, 2015, INVEST OPHTH VIS SCI, V56, P1238, DOI 10.1167/iovs.14-15334
   Wang N, 2006, PIGM CELL RES, V19, P3, DOI 10.1111/j.1600-0749.2005.00288.x
   Yang ZL, 2008, J CLIN INVEST, V118, P2908, DOI 10.1172/JCI35891
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
NR 66
TC 17
Z9 17
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 4
PY 2016
VL 6
AR 22671
DI 10.1038/srep22671
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DF7EH
UT WOS:000371520100001
PM 26940175
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Westenskow, P
   Sedillo, Z
   Barnett, A
   Friedlander, M
AF Westenskow, Peter
   Sedillo, Zack
   Barnett, Ashley
   Friedlander, Martin
TI Efficient Derivation of Retinal Pigment Epithelium Cells from Stem Cells
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Developmental Biology; Issue 97; Retinal pigment epithelium; stem cells;
   translational medicine; age-related macular degeneration; directed
   differentiation
ID LONG-TERM SAFETY; MACULAR DEGENERATION; DIRECTED DIFFERENTIATION; SMALL
   MOLECULES; RPE; TRANSPLANTATION; PHAGOCYTOSIS; PREVALENCE; GENERATION;
   MOUSE
AB No cure has been discovered for age-related macular degeneration (AMD), the leading cause of vision loss in people over the age of 55. AMD is complex multifactorial disease with an unknown etiology, although it is largely thought to occur due to death or dysfunction of the retinal pigment epithelium (RPE), a monolayer of cells that underlies the retina and provides critical support for photoreceptors. RPE cell replacement strategies may hold great promise for providing therapeutic relief for a large subset of AMD patients, and RPE cells that strongly resemble primary human cells (hRPE) have been generated in multiple independent labs, including our own. In addition, the uses for iPS-RPE are not limited to cell-based therapies, but also have been used to model RPE diseases. These types of studies may not only elucidate the molecular bases of the diseases, but also serve as invaluable tools for developing and testing novel drugs. We present here an optimized protocol for directed differentiation of RPE from stem cells. Adding nicotinamide and either Activin A or IDE-1, a small molecule that mimics its effects, at specific time points, greatly enhances the yield of RPE cells. Using this technique we can derive large numbers of low passage RPE in as early as three months.
C1 [Westenskow, Peter; Sedillo, Zack; Friedlander, Martin] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
   [Westenskow, Peter; Sedillo, Zack; Barnett, Ashley; Friedlander, Martin] Lowy Med Res Inst, La Jolla, CA USA.
C3 Scripps Research Institute
RP Westenskow, P (通讯作者)，Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
EM friedlan@scripps.edu
OI Westenskow, Peter/0000-0001-9841-6220
FU National Eye Institute (NEI) [EY11254, EY021416]; California Institute
   for Regenerative Medicine (CIRM) [TR1-01219]; Lowy Medical Research
   Institute (LMRI); NATIONAL EYE INSTITUTE [F32EY021416, R01EY011254]
   Funding Source: NIH RePORTER
FX We wish to thank the following individuals: Drs. Tim Krohne and Eyal
   Banin (along with Dr. Mandy Lehmann and David Friedlander) for generous
   help developing the differentiation protocols. Dr. Felicitas Bucher
   provided assistance differentiating the RPE cells used in this study. We
   also acknowledge the National Eye Institute (NEI grants EY11254 and
   EY021416), California Institute for Regenerative Medicine (CIRM grant
   TR1-01219), and the Lowy Medical Research Institute (LMRI) for very
   generous funding for this project.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Borowiak M, 2009, CELL STEM CELL, V4, P348, DOI 10.1016/j.stem.2009.01.014
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Gamm DM, 2013, EXPERT REV OPHTHALMO, V8, P213, DOI 10.1586/EOP.13.14
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tucker BA, 2013, STEM CELL TRANSL MED, V2, P16, DOI 10.5966/sctm.2012-0040
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Westenskow PD, 2014, NEW VISUAL NEUROSCIENCES, P1611
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Zhang K, 2013, PROTEIN CELL, V4, P432, DOI 10.1007/s13238-013-3026-9
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 43
TC 11
Z9 12
U1 0
U2 16
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD MAR
PY 2015
IS 97
AR e52214
DI 10.3791/52214
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CR7MM
UT WOS:000361534300009
PM 25867641
OA Green Published
DA 2022-11-30
ER

PT J
AU Gelman, SK
   Freund, KB
   Shah, VP
   Sarraf, D
AF Gelman, Susan K.
   Freund, K. Bailey
   Shah, Vinnie P.
   Sarraf, David
TI THE PEARL NECKLACE SIGN A Novel Spectral Domain Optical Coherence
   Tomography Finding in Exudative Macular Disease
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; Coats disease; diabetic
   macular edema; exudative maculopathy; hard exudate; lipid; retinal
   arterial macroaneurysm; spectral domain optical coherence tomography
ID RETINAL VEIN OCCLUSION; HYPERREFLECTIVE FOCI; SD-OCT; DEGENERATION;
   EDEMA; ASSOCIATION; DETACHMENT; SPACES; LAYER
AB Purpose:To report a novel spectral domain optical coherence tomography finding in exudative macular disease, called the pearl necklace sign.Methods:A retrospective case series of 21 eyes (20 patients) with chronic exudative maculopathy resulting from age-related macular degeneration, diabetic macular edema, branch retinal vein occlusion, retinal arterial macroaneurysm, and Coats disease. Spectral domain optical coherence tomography images were carefully evaluated and correlated with color fundus photography, near-infrared reflectance, and fluorescein angiography.Results:A unique spectral domain optical coherence tomography macular finding of hyperreflective dots in a contiguous ring around the inner wall of cystoid spaces in the outer plexiform layer of the retina that the authors refer to as the pearl necklace sign was seen in all patients. Visual acuity ranged from 20/30 to hand motions. The cystoid spaces and the hyperreflective dots resolved in certain cases after anti-vascular endothelial growth factor therapy and/or focal macular laser, but tended to recur.Conclusion:Because the pearl necklace configuration can be found adjacent to hard exudates in the outer plexiform layer, the authors speculate that the hyperreflective material is composed of lipoproteins or lipid-laden macrophages. This novel spectral domain optical coherence tomography sign gives further insight into the development and progression of hard lipoprotein exudates in exudative maculopathy.
C1 [Gelman, Susan K.; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA 90095 USA.
   [Gelman, Susan K.; Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA.
   [Freund, K. Bailey; Shah, Vinnie P.] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 University of California System; University of California Los Angeles;
   US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Greater Los Angeles Healthcare System; Vitreous Retina Macula
   Consultants of New York
RP Sarraf, D (通讯作者)，Univ Calif Los Angeles, Jules Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Genentech, Inc; Regeneron Pharmaceuticals, Inc; Heidelberg Engineering;
   Optos plc; Regeneron Pharmaceuticals, Inc (IST grant)
FX Financial disclosures are as follows: KBF: Genentech, Inc (advisor);
   Regeneron Pharmaceuticals, Inc (advisor); Heidelberg Engineering
   (advisor); Optos plc (advisor); DS: Heidelberg Engineering (speaker),
   Regeneron Pharmaceuticals, Inc (IST grant).
CR Barthelmes D, 2008, INVEST OPHTH VIS SCI, V49, P3529, DOI 10.1167/iovs.07-1320
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P171
   Cusick M, 2003, OPHTHALMOLOGY, V110, P2126, DOI 10.1016/j.ophtha.2003.01.001
   Framme C, 2012, INVEST OPHTH VIS SCI, V53, P5814, DOI 10.1167/iovs.12-9950
   Gass JDM, 1997, STEREOSCOPIC ATLAS M, V2, P996
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kim JT, 2013, INVEST OPHTHALMOL VI
   KOTTKE BA, 1987, J CARDIOVASC PHARM, V10, pS7
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Noma H, 2013, JAMA OPHTHALMOL, V131, P160, DOI 10.1001/2013.jamaophthalmol.228
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Ota M, 2010, OPHTHALMOLOGY, V117, P1996, DOI 10.1016/j.ophtha.2010.06.019
   PALESTINE AG, 1982, AM J OPHTHALMOL, V93, P164, DOI 10.1016/0002-9394(82)90411-1
   Panozzo Giacomo, 2003, Semin Ophthalmol, V18, P74, DOI 10.1076/soph.18.2.74.15854
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Ramasubramanian A, 2012, BRIT J OPHTHALMOL, V96, P356, DOI 10.1136/bjophthalmol-2011-300141
   Song IS, 2012, AM J OPHTHALMOL, V154, P366, DOI 10.1016/j.ajo.2012.02.031
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Taarnhoj NCBB, 2003, INVEST OPHTH VIS SCI, V44, P1680, DOI 10.1167/iovs.01-1132
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   Yamada Y, 2013, RETINA-J RET VIT DIS, V33, P726, DOI 10.1097/IAE.0b013e3182753960
   Yanoff M, 2009, OCULAR PATHOLOGY, P410
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 29
TC 19
Z9 20
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2014
VL 34
IS 10
BP 2088
EP 2095
DI 10.1097/IAE.0000000000000207
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ8BX
UT WOS:000343048200030
PM 25020214
DA 2022-11-30
ER

PT J
AU Schnichels, S
   Hagemann, U
   Januschowski, K
   Hofmann, J
   Bartz-Schmidt, KU
   Szurman, P
   Spitzer, MS
   Aisenbrey, S
AF Schnichels, Sven
   Hagemann, Ulrike
   Januschowski, Kai
   Hofmann, Johanna
   Bartz-Schmidt, Karl-Ulrich
   Szurman, Peter
   Spitzer, Martin S.
   Aisenbrey, Sabine
TI Comparative toxicity and proliferation testing of aflibercept,
   bevacizumab and ranibizumab on different ocular cells
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VEGF TRAP-EYE; MACULAR DEGENERATION;
   TRANSGENIC MICE; PEGAPTANIB; DISEASE; LINE; BINDING; TUMORS; EDEMA
AB Background/aims Vascular endothelial growth factor (VEGF) is a key factor in the pathogenesis of neovascular retinal diseases including age-related macular degeneration. VEGF inhibitors including ranibizumab, pegaptanib or bevacizumab improve retinal morphology and vision in many patients. The recently approved drug aflibercept (VEGF Trap-Eye/Eyelea, Regeneron, Tarrytown, New York, USA) offers a new therapy modality. We therefore tested for toxic and anti-proliferating effects of aflibercept.
   Methods The effects of aflibercept (0.125, 0.5, 2 mg), ranibizumab (0.125 mg) and bevacizumab (0.3125 mg) after 1, 24, 48 and 72 h on cell morphology via phase contrast pictures, cell viability via MTS assay, total cell amount via crystal violet staining, apoptosis induction via caspase 3/7 assay and proliferation via BrdU assay were investigated. Three ocular cell lines were chosen for toxicology testing: ARPE19 cells, RGC-5 cells and 661W cells.
   Results Aflibercept did not cause changes in cell morphology, induce apoptosis or cause permanent decrease in cell viability, cell density or proliferation in any cell line or concentration investigated. In general, aflibercept had fewer effects (upregulation or downregulation) compared with controls than bevacizumab or ranibizumab.
   Conclusions In our experiments, aflibercept did not lead to any negative effects on retinal cell lines and might therefore be used safely in clinical applications.
C1 [Schnichels, Sven; Hagemann, Ulrike; Januschowski, Kai; Hofmann, Johanna; Bartz-Schmidt, Karl-Ulrich; Szurman, Peter; Spitzer, Martin S.; Aisenbrey, Sabine] Univ Eye Hosp Tubingen, Ctr Ophthalmol, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Januschowski, K (通讯作者)，Univ Eye Hosp Tubingen, Ctr Ophthalmol, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM Kai.januschowski@med.uni-tuebingen.de
OI Schnichels, Sven/0000-0002-2385-5517
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681
   Ammar DA, 2013, RETINA-J RET VIT DIS, V33, P1056, DOI 10.1097/IAE.0b013e31827b646d
   Bachmann BO, 2009, BRIT J OPHTHALMOL, V93, P1075, DOI 10.1136/bjo.2008.145128
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Browning DJ, AM J OPHTHALMOL, V154, P222
   Cao J, 2011, INVEST OPHTH VIS SCI, V51, P6009
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Garbow JR, 2009, CANCER RES, V69, P7945, DOI 10.1158/0008-5472.CAN-09-1271
   Gomez-Manzano C, 2008, NEURO-ONCOLOGY, V10, P940, DOI 10.1215/15228517-2008-061
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kato A, 2007, J PLANT RES, V120, P713, DOI 10.1007/s10265-007-0117-9
   Lal D, 2010, MOL CANCER THER, V9, P2737, DOI 10.1158/1535-7163.MCT-10-0334
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schnichels S, 2012, NEUROCHEM INT, V60, P581, DOI 10.1016/j.neuint.2012.02.017
   Schultheiss M, 2012, GRAEF ARCH CLIN EXP, V250, P1221, DOI 10.1007/s00417-011-1906-3
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
NR 25
TC 43
Z9 45
U1 1
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2013
VL 97
IS 7
BP 917
EP 923
DI 10.1136/bjophthalmol-2013-303130
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 161YH
UT WOS:000320229800025
PM 23686000
DA 2022-11-30
ER

PT J
AU Kubo, MTK
   Maus, D
   Xavier, AAO
   Mercadante, AZ
   Viotto, WH
AF Kaneiwa Kubo, Mirian Tiaki
   Maus, Diogo
   Odorissi Xavier, Ana Augusta
   Mercadante, Adriana Zerlotti
   Viotto, Walkiria Hanada
TI Transference of lutein during cheese making, color stability, and
   sensory acceptance of Prato cheese
SO FOOD SCIENCE AND TECHNOLOGY
LA English
DT Article
DE lutein; Prato cheese; color
ID VITAMIN-A; CAROTENOIDS; MILK; ANTIOXIDANT; RAW
AB The consumption of lutein is associated with the prevention and reduction of age-related macular degeneration. Its incorporation into Prato cheese as a yellowish food coloring is a valid alternative to increase the daily intake of this compound. However, part of the lutein added may be lost in the whey during the cheese making, or it can be degraded by light during storage, resulting in color changes reducing the sensory acceptance of the cheese. The objectives of this study were to determine the transference of the lutein (dye), added to the milk, in the whey, and cheese, to evaluate the effect of the lutein addition, light exposure, and storage time on the cheese color, and to verify the sensory acceptance of Prato cheese with addition of lutein. The lutein recovery of cheese was 95.25%. Color saturation (chrome) increased during storage time resulting in a cheese with more intense color, but there were no changes in the hue of the cheese. Adjusting the amount of lutein added to Prato cheese may lead to greater acceptance. The high recovery of lutein in the cheese and the fact that the hue remained unchanged during storage under light showed that the incorporation of lutein into Prato cheese is feasible from a technical point of view.
C1 [Kaneiwa Kubo, Mirian Tiaki; Maus, Diogo; Odorissi Xavier, Ana Augusta; Mercadante, Adriana Zerlotti; Viotto, Walkiria Hanada] Univ Campinas UNICAMP, Fac Food Engn, Dept Food Technol, BR-13083862 Campinas, SP, Brazil.
C3 Universidade Estadual de Campinas
RP Viotto, WH (通讯作者)，Univ Campinas UNICAMP, Fac Food Engn, Dept Food Technol, Rua Monteiro Lobato 80, BR-13083862 Campinas, SP, Brazil.
EM walkiria@fea.unicamp.br
RI Mercadante, Adriana Z/C-4445-2012; Kubo, Mirian T. K./C-2465-2012;
   Xavier, Ana Augusta Odorissi/I-4532-2012; Viotto, Walkiria/N-8528-2013
OI Mercadante, Adriana Z/0000-0003-4547-6064; Kubo, Mirian T.
   K./0000-0002-3084-3960; Xavier, Ana Augusta
   Odorissi/0000-0002-3770-1658; Viotto, Walkiria/0000-0002-8580-9743
FU Brazilian foundation (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico); Brazilian foundation FAPESP (Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo)
FX The authors are grateful to the Brazilian foundations CNPq (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico) and FAPESP
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) for the financial
   support.
CR AOAC, 1995, OFFICIAL METHODS ANA
   ASSOCIACAO BRASILEIRA DAS INDUSTRIAS DE QUEIJO-ABIQ, 2010, PROD BRAS QUEIJ
   British Standards Institution, 1989, DET FAT CONT MILK MI
   BRITTON G., 1995, PFANDER CAROTENOIDS, V1B
   Buffa MN, 2001, INT DAIRY J, V11, P927, DOI 10.1016/S0958-6946(01)00141-8
   Calderon F, 2007, J DAIRY SCI, V90, P2335, DOI 10.3168/jds.2006-630
   da Silveira PR, 2003, CIENC AGROTEC, V27, P1340, DOI 10.1590/S1413-70542003000600019
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FRANCIS J. F., 1975, FOOD COLORIMETR THEO
   FURTADO M. M., 1994, TECNOLOGIA QUEIJOS M, P73
   Griffin W.C., 1949, J SOC COSMET CHEM, V1, P311
   GUIMARAES F. A., 2004, THESIS U FEDERAL VIC
   Hulshof PJM, 2006, J FOOD COMPOS ANAL, V19, P67, DOI 10.1016/j.jfca.2005.04.005
   Jones ST, 2005, J DAIRY SCI, V88, P1661, DOI 10.3168/jds.S0022-0302(05)72838-1
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Landrum JT, 1999, PURE APPL CHEM, V71, P2237, DOI 10.1351/pac199971122237
   Luruena-Martinez MA, 2010, INT J DAIRY TECHNOL, V63, P216, DOI 10.1111/j.1471-0307.2010.00565.x
   Meilgaard M.C., 2006, SENSORY EVALUATION T
   Olson JA, 1995, FASEB J, V9, P1547, DOI 10.1096/fasebj.9.15.8529833
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   RICHARDSON GH, 1985, STANDARD METHODS EXA, P340
   Rodriguez-Amaya DB, 2008, J FOOD COMPOS ANAL, V21, P445, DOI 10.1016/j.jfca.2008.04.001
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Serpeloni JM, 2010, ARCH TOXICOL, V84, P811, DOI 10.1007/s00204-010-0576-y
   Stone H, 1993, SENSORY EVALUATION P
   van den Berg H, 2000, J SCI FOOD AGR, V80, P880, DOI 10.1002/(SICI)1097-0010(20000515)80:7&lt;880::AID-JSFA646&gt;3.0.CO;2-1
   Walstra P, 1984, DAIRY CHEM PHYS
   XAVIER A. A. O., 2012, THESIS U ESTADUAL CA
   Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149
NR 29
TC 3
Z9 3
U1 0
U2 6
PU SOC BRASILEIRA CIENCIA TECNOLOGIA ALIMENTOS
PI CAMPINAS
PA AV BRASIL 2880, CAXIA POSTAL 271 CEP 13001-970, CAMPINAS, SAO PAULO
   00000, BRAZIL
SN 0101-2061
EI 1678-457X
J9 FOOD SCI TECH-BRAZIL
JI Food Sci. Technol.
PD FEB
PY 2013
VL 33
SU 1
BP 81
EP 88
PG 8
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 208TC
UT WOS:000323701400013
DA 2022-11-30
ER

PT J
AU Sharma, A
   Patil, JA
   Gramajo, AL
   Seigel, GM
   Kuppermann, BD
   Kenney, CM
AF Sharma, Ashish
   Patil, Jayaprakash A.
   Gramajo, Ana L.
   Seigel, Gail M.
   Kuppermann, Baruch D.
   Kenney, Cristina M.
TI Effects of hydroquinone on retinal and vascular cells in vitro
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Apoptosis; caspase-3/7; cigarette smoke toxicant; hydroquinone
ID AGE-RELATED MACULOPATHY; SUB-RPE DEPOSITS; CIGARETTE-SMOKE; MACULAR
   DEGENERATION; PIGMENT EPITHELIUM; INDUCED APOPTOSIS; CARCINOGENICITY;
   ACTIVATION; METABOLITE; ROTTERDAM
AB Aim: To explore the molecular pathophysiology that might explain the epidemiologic association between cigarette smoke and age-related macular degeneration (AMD) by examining the effects of hydroquinone (HQ), a toxic compound present in high concentration in cigarette smoke-related tar, on human retinal pigment epithelial cells (ARPE-19), rat retinal neurosensory cells (R-28), and human microvascular endothelial cells (HMVEC). Materials and Methods: ARPE-19, R-28, and HMVEC were treated for 24 h with four different concentrations of HQ (500 mu M, 200 mu M, 100 mu M, 50 mu M). Cell viability, caspase-3/7 activation, DNA laddering patterns, and lactate dehydrogenase (LDH) levels were analyzed. Results: At 50 mu M HQ, R-28 cells showed a significant decrease in cell viability compared with the dimethyl sulfoxide (DMSO)treated controls. At the 100-500 mu M concentrations, all three cell lines showed significant cell death (P < 0.001). In the ARPE-19, R-28, and HMVEC cultures, the caspase-3/7 activities were not increased at any of the HQ concentration. Conclusion: Our findings suggest that the mechanism of cell death in all three cell lines was through non-apoptotic pathway. In addition, neuroretinal R-28 cells were more sensitive to HQ than the ARPE-19 and HMVEC cultures.
C1 [Kenney, Cristina M.] Univ Calif Irvine, Med Ctr, Dept Ophthalmol, Gavin S Herbert Eye Inst, Orange, CA 92868 USA.
   [Sharma, Ashish] Lotus Eye Care Hosp, Coimbatore, Tamil Nadu, India.
   [Patil, Jayaprakash A.] Univ Hosp Morecambe NHS Trust, Royal Lancaster Infirm, Lancaster, England.
   [Gramajo, Ana L.] Fdn VER, Dept Oftalmol, Cordoba, Argentina.
   [Seigel, Gail M.] SUNY Buffalo, Ctr Hearing & Deafness, Buffalo, NY 14260 USA.
C3 University of California System; University of California Irvine; State
   University of New York (SUNY) System; State University of New York
   (SUNY) Buffalo
RP Kenney, CM (通讯作者)，Univ Calif Irvine, Med Ctr, Dept Ophthalmol, Gavin S Herbert Eye Inst, 101 City Dr, Orange, CA 92868 USA.
EM mkenney@uci.edu
OI Sharma, Ashish/0000-0002-8550-9791
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Chen Yi, 2004, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V22, P161
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   GOTTSCH JD, 1993, ARCH OPHTHALMOL-CHIC, V111, P126, DOI 10.1001/archopht.1993.01090010130039
   Haenen HEMG, 1996, TOXICOL IN VITRO, V10, P141, DOI 10.1016/0887-2333(95)00116-6
   Hiraku Y, 1996, CANCER RES, V56, P5172
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Kim YG, 2006, LANGMUIR, V22, P10762, DOI 10.1021/la0611920
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Lau SS, 2001, CHEM RES TOXICOL, V14, P25, DOI 10.1021/tx000161g
   Lenaz G, 1998, BBA-BIOENERGETICS, V1364, P207, DOI 10.1016/S0005-2728(98)00028-0
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Moridani MY, 2003, CHEM-BIOL INTERACT, V142, P317, DOI 10.1016/S0009-2797(02)00125-4
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Neekhra A, 2007, INVEST OPHTH VIS SCI, V48, P1362, DOI 10.1167/iovs.06-0900
   Pryor WA, 1997, ENVIRON HEALTH PERSP, V105, P875, DOI 10.2307/3433297
   Pyatt DW, 1998, TOXICOL APPL PHARM, V149, P178, DOI 10.1006/taap.1998.8369
   Seigel G M, 1996, Mol Vis, V2, P2
   Sharma A, 2008, INVEST OPHTH VIS SCI, V49, P5111, DOI 10.1167/iovs.08-2060
   Shen DX, 2003, CHEM-BIOL INTERACT, V145, P225, DOI 10.1016/S0009-2797(03)00003-6
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Sun W, 2002, NEUROREPORT, V13, P2421, DOI 10.1097/00001756-200212200-00009
   Terasaka H, 2005, ANTICANCER RES, V25, P161
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   World-Health-Orangization Geneva, 1996, IPCS INT PROGR CHEM, P22
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 31
TC 15
Z9 16
U1 0
U2 3
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD MAY-JUN
PY 2012
VL 60
IS 3
BP 189
EP 193
DI 10.4103/0301-4738.95869
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 943PN
UT WOS:000304136800006
PM 22569379
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Li, H
   Lei, N
   Zhang, M
   Li, Y
   Xiao, HB
   Hao, XF
AF Li, Hong
   Lei, Ning
   Zhang, Ming
   Li, Yue
   Xiao, Haibo
   Hao, Xiaofeng
TI Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE conbercept; pharmacokinetics; vascular endothelial growth factor;
   age-related macular degeneration; intravitreal injection
ID ENDOTHELIAL GROWTH-FACTOR; NEOVASCULARIZATION; BLOCKADE; RECEPTOR; TRAP
AB Conbercept(KH902), a recombinant fusion protein in clinical trial II/III, shows good potential to treat the neovascular age-related macular degeneration (AMD). This investigation evaluated its ocular pharmacokinetics and pharmacodynamic profile in rabbits following intravitreal administration (IVT). Rabbits (n = 120) received single bilateral conbercept IVT administration or single IV administration. Conbercept concentrations in ocular tissues and serum were measured after dosing. VEGF concentration was also measured simultaneously. The results showed that conbercept rapidly distributed from vitreous into targeted tissues and lasted over 81 days. Clearance in ocular tissues was parallel and exhibited a terminal half of 2.5-4.2 days. The drug exposure in the retina was 1/4 to 1/5 of that in vitreous. Serum conbercept concentrations after IVT dosing were low and bioavailability was approximately 44%. And single intravitreal injection induced that ocular VEGF concentration declined over 60 days and serum VEGF concentration decreased for a short time but rebounded to higher level than baseline later. All these indicated conbercept good pharmacokinetic profile in rabbits, with good ocular tropism and systemic tolerance. Combined with the efficacy data from our earlier in vitro and in vivo studies, it should have a promising clinical application for AMD treatment. (C) 2011 Published by Elsevier Ltd.
C1 [Li, Hong; Li, Yue; Hao, Xiaofeng] Chengdu Kanghong Biotechnol Co Ltd, Chengdu 610036, Sichuan Provinc, Peoples R China.
   [Li, Hong] Chengdu Med Coll, Chengdu 610083, Sichuan, Peoples R China.
   [Lei, Ning; Xiao, Haibo] Sichuan Univ, W China Hosp, Natl Chengdu Ctr Safety Evaluat Drugs, Chengdu 610041, Sichuan, Peoples R China.
   [Lei, Ning] Chengdu Univ Technol, Dept Chem & Pharmaceut Engn, Chengdu 610059, Sichuan, Peoples R China.
   [Zhang, Ming] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China.
C3 Chengdu Medical College; Sichuan University; Chengdu University of
   Technology; Sichuan University
RP Hao, XF (通讯作者)，Chengdu Kanghong Biotechnol Co Ltd, 36 Shuxi Rd, Chengdu 610036, Sichuan Provinc, Peoples R China.
EM cissi_79@163.com; hxf@cnkh.com
CR Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gerber HP, 2000, CANCER RES, V60, P6253
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100
   Ruch C, 2007, NAT STRUCT MOL BIOL, V14, P249, DOI 10.1038/nsmb1202
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Suto K, 2005, J BIOL CHEM, V280, P2126, DOI 10.1074/jbc.M411395200
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 12
TC 54
Z9 58
U1 2
U2 25
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2012
VL 97
IS 1
BP 154
EP 159
DI 10.1016/j.exer.2011.09.002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 929QU
UT WOS:000303081400018
PM 21933673
DA 2022-11-30
ER

PT J
AU Thrimawithana, TR
   Young, S
   Bunt, CR
   Green, C
   Alany, RG
AF Thrimawithana, Thilini Rasika
   Young, Simon
   Bunt, Craig Robert
   Green, Colin
   Alany, Raid Ghassan
TI Drug delivery to the posterior segment of the eye
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID RETINAL-PIGMENT-EPITHELIUM; SUB-CONJUNCTIVAL INJECTION; TRANSSCLERAL
   DELIVERY; SUSTAINED-RELEASE; CYTOMEGALOVIRUS RETINITIS;
   INTRAOCULAR-PRESSURE; PHOTODYNAMIC THERAPY; SCLERAL PERMEABILITY;
   GANCICLOVIR IMPLANT; MAGNETIC-RESONANCE
AB Delivery of drugs to the posterior eye is challenging, owing to anatomical and physiological constrains of the eye. There is an increasing need for managing rapidly progressing posterior eye diseases, such as age-related macular degeneration, diabetic retinopathy and retinitis pigmentosa. Drug delivery to the posterior segment of the eye is therefore compounded by the increasing number of new therapeutic entities (e.g. oligonucleotides, aptamers and antibodies) and the need for chronic therapy. Currently, the intravitreal route is widely used to deliver therapeutic entities to the retina. However, frequent administration of drugs via this route can lead to retinal detachment, endophthalmitis and increased intraocular pressure. Various controlled delivery systems, such as biodegradable and non-biodegradable implants, liposomes and nanoparticles, have been developed to overcome such adverse effects, with some success. The periocular route is a promising alternative, owing to the large surface area and the relatively high permeability of the sclera. Yet, the blood-retinal barrier and efflux transporters hamper the transport of therapeutic entities to the retina. As such, the efficient delivery of drugs to the posterior eye remains a major challenge facing the pharmaceutical scientist. In this review, we discuss the barriers of the posterior eye drug delivery and the various drug-delivery strategies used to overcome these barriers.
C1 [Thrimawithana, Thilini Rasika; Young, Simon; Alany, Raid Ghassan] Univ Auckland, Fac Med & Hlth Sci, Sch Pharm, Drug Delivery Res Unit, Auckland 1010, New Zealand.
   [Bunt, Craig Robert] AgResearch Ltd, Christchurch 8140, New Zealand.
   [Green, Colin] Univ Auckland, Fac Med & Hlth Sci, Dept Ophthalmol, Auckland 1010, New Zealand.
   [Alany, Raid Ghassan] Univ Auckland, Fac Med & Hlth Sci, Sch Pharm, Auckland 1010, New Zealand.
C3 University of Auckland; AgResearch - New Zealand; University of
   Auckland; University of Auckland
RP Alany, RG (通讯作者)，Kingston Univ London, Sch Pharm & Chem, Kingston upon Thames, Surrey, England.
EM t.thrimawithana@auckland.ac.nz; r.alany@auckland.ac.nz
RI Alany, Raid G./O-5956-2019; Bunt, Craig/E-7375-2011; Green, Colin
   R/B-5663-2012
OI Alany, Raid G./0000-0003-0355-7499; Bunt, Craig/0000-0001-9416-592X;
   Green, Colin R/0000-0003-3459-6298; Young, Simon/0000-0002-9245-9382
CR Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1186
   Ambati J, 2002, PROG RETIN EYE RES, V21, P145, DOI 10.1016/S1350-9462(01)00018-0
   Amrite AC, 2008, MOL VIS, V14, P150
   Ayalasomayajula SP, 2005, EUR J PHARMACOL, V511, P191, DOI 10.1016/j.ejphar.2005.02.019
   Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   Becker DL, 1999, ANTISENSE TECHNOLOGY, P149
   Bejjani R, 2005, MOL VIS, V11, P124
   BILL A, 1965, ARCH OPHTHALMOL-CHIC, V74, P248
   Boubriak OA, 2000, EXP EYE RES, V71, P503, DOI 10.1006/exer.2000.0909
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Bourges JL, 2003, INVEST OPHTH VIS SCI, V44, P3562, DOI 10.1167/iovs.02-1068
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Cheruvu N. P. S., 2003, DRUG DELIV TECHNOL, V3, P62
   Christie JG, 2008, DRUG DISCOV TODAY, V13, P124, DOI 10.1016/j.drudis.2007.12.005
   CONRAD JM, 1980, J PHARM SCI, V69, P875, DOI 10.1002/jps.2600690806
   Conway Barbara R, 2008, Recent Pat Drug Deliv Formul, V2, P1, DOI 10.2174/187221108783331410
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   Davies JB, 2003, MOL VIS, V9, P569
   de Carvalho RAP, 2006, INVEST OPHTH VIS SCI, V47, P4532, DOI 10.1167/iovs.06-0030
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Demetriades AM, 2008, J OCUL PHARMACOL TH, V24, P70, DOI 10.1089/jop.2007.0061
   dos Santos ALG, 2006, PHARM RES-DORDR, V23, P770, DOI 10.1007/s11095-006-9748-0
   Duvvuri S, 2003, EXPERT OPIN BIOL TH, V3, P45, DOI 10.1517/14712598.3.1.45
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006
   Eljarrat-Binstock E, 2006, J CONTROL RELEASE, V110, P479, DOI 10.1016/j.jconrel.2005.09.049
   Emerich DF, 2008, CURR OPIN MOL THER, V10, P506
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Ghate D, 2007, INVEST OPHTH VIS SCI, V48, P2230, DOI 10.1167/iovs.06-0954
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Gilbert JA, 2003, J CONTROL RELEASE, V89, P409, DOI 10.1016/S0168-3659(03)00151-2
   dos Santos ALG, 2006, J CONTROL RELEASE, V112, P369, DOI 10.1016/j.jconrel.2006.02.010
   Halhal M, 2004, EXP EYE RES, V78, P751, DOI 10.1016/j.exer.2003.10.017
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hsu J, 2007, CURR OPIN OPHTHALMOL, V18, P235, DOI 10.1097/ICU.0b013e3281108000
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Jiang J, 2009, PHARM RES-DORDR, V26, P395, DOI 10.1007/s11095-008-9756-3
   Jockovich ME, 2007, RETINA-J RET VIT DIS, V27, P247, DOI 10.1097/01.iae.0000242853.80913.63
   Kaiser PK, 2007, SURV OPHTHALMOL, V52, pS62, DOI 10.1016/j.survophthal.2006.10.015
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Kato A, 2004, INVEST OPHTH VIS SCI, V45, P238, DOI 10.1167/iovs.02-1258
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   Kompella UB, 2003, INVEST OPHTH VIS SCI, V44, P1192, DOI 10.1167/iovs.02-0791
   Kuno N, 2010, DRUG AGING, V27, P117, DOI 10.2165/11530970-000000000-00000
   LAM TT, 1991, GRAEF ARCH CLIN EXP, V229, P389, DOI 10.1007/BF00170699
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Lee SB, 2004, EXP EYE RES, V78, P599, DOI 10.1016/S0014-4835(03)00211-2
   Lee SS, 2009, OPHTHALMIC RES, V41, P124, DOI 10.1159/000209665
   Mainardes RM, 2005, CURR DRUG TARGETS, V6, P363, DOI 10.2174/1389450053765914
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   MARMOR MF, 1985, EXP EYE RES, V40, P687, DOI 10.1016/0014-4835(85)90138-1
   Marx JL, 1996, ARCH OPHTHALMOL-CHIC, V114, P815, DOI 10.1001/archopht.1996.01100140029003
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   MAURICE D. M., 1967, INVEST OPHTHALMOL, V6, P464
   Molokhia SA, 2009, EXP EYE RES, V88, P418, DOI 10.1016/j.exer.2008.10.010
   Montero JA, 2009, CURR DIABETES REV, V5, P26, DOI 10.2174/157339909787314211
   Moshfeghi AA, 2005, ADV DRUG DELIVER REV, V57, P2047, DOI 10.1016/j.addr.2005.09.006
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Normand N, 2005, MOL VIS, V11, P184
   Okabe J, 2003, INVEST OPHTH VIS SCI, V44, P740, DOI 10.1167/iovs.02-0375
   Olsen TW, 2006, AM J OPHTHALMOL, V142, P777, DOI 10.1016/j.ajo.2006.05.045
   Olsen TW, 1998, AM J OPHTHALMOL, V125, P237, DOI 10.1016/S0002-9394(99)80096-8
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Paasonen L, 2007, J CONTROL RELEASE, V122, P86, DOI 10.1016/j.jconrel.2007.06.009
   Parkinson TM, 2003, J OCUL PHARMACOL TH, V19, P145, DOI 10.1089/108076803321637672
   Perry CM, 1999, DRUGS, V57, P375, DOI 10.2165/00003495-199957030-00010
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Pitkanen L, 2007, PHARM RES-DORDR, V24, P2063, DOI 10.1007/s11095-007-9342-0
   PRAGER TC, 1982, ARCH OPHTHALMOL-CHIC, V100, P594
   Querques G, 2009, ACTA OPHTHALMOL, V87, P623, DOI 10.1111/j.1755-3768.2009.01580.x
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Ranta VP, 2006, ADV DRUG DELIVER REV, V58, P1164, DOI 10.1016/j.addr.2006.07.025
   Renno RZ, 2001, ADV DRUG DELIVER REV, V52, P63, DOI 10.1016/S0169-409X(01)00195-8
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rudnick DE, 1999, INVEST OPHTH VIS SCI, V40, P3054
   Russell R., 2004, PHARMA TECHNOL, V28, p18+223
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   SARRAF D, 1994, J OCUL PHARMACOL, V10, P69, DOI 10.1089/jop.1994.10.69
   SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0
   TSUJI A, 1988, OPHTHALMIC RES, V20, P31, DOI 10.1159/000266253
   Wang Y, 2004, BIOMATERIALS, V25, P4279, DOI 10.1016/j.biomaterials.2003.10.075
   Weijtens O, 1999, AM J OPHTHALMOL, V128, P192, DOI 10.1016/S0002-9394(99)00129-4
   Weijtens O, 1997, AM J OPHTHALMOL, V123, P358, DOI 10.1016/S0002-9394(14)70131-X
   Wu HJ, 2009, SEMIN OPHTHALMOL, V24, P100, DOI 10.1080/08820530902800397
   YUI N, 1993, J CONTROL RELEASE, V26, P141, DOI 10.1016/0168-3659(93)90113-J
   Zeimer R, 2001, ADV DRUG DELIVER REV, V52, P49, DOI 10.1016/S0169-409X(01)00194-6
   Zignani M, 2000, EUR J PHARM BIOPHARM, V50, P251, DOI 10.1016/S0939-6411(00)00107-7
NR 95
TC 212
Z9 223
U1 3
U2 66
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD MAR
PY 2011
VL 16
IS 5-6
BP 270
EP 277
DI 10.1016/j.drudis.2010.12.004
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 740XH
UT WOS:000288827200011
PM 21167306
DA 2022-11-30
ER

PT J
AU Jiang, SN
   Moriarty-Craige, SE
   Orr, M
   Cai, JY
   Sternberg, P
   Jones, DP
AF Jiang, SN
   Moriarty-Craige, SE
   Orr, M
   Cai, JY
   Sternberg, P
   Jones, DP
TI Oxidant-induced apoptosis in human retinal pigment epithelial cells:
   Dependence on extracellular redox state
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FORKHEAD TRANSCRIPTION FACTORS; MACULAR DEGENERATION; HUMAN PLASMA;
   OXIDATIVE STRESS; PERMEABILITY TRANSITION; CYTOCHROME-C; IN-VITRO;
   GLUTATHIONE; THIOLS; DIFFERENTIATION
AB PURPOSE. To test whether variation in extracellular cysteine (Cys) redox potential (E-h) over the physiologic range occurring in human plasma affects oxidant-induced apoptosis in cultured human retinal pigment epithelial (hRPE) cells.
   METHODS. The hRPE cells were incubated in culture medium with E-h established over the range of - 16 mV (most oxidized) to - 158 mV (most reduced) by adding different concentrations of Cys and cystine (CySS) with constant total Cys equivalents. Apoptosis was induced with tert-butylhydroperoxide (tBH).
   RESULTS. The hRPE cells were sensitized to tBH-induced apoptosis in the more oxidized extracellular conditions (E-h > - 55 mV) compared with the reduced conditions (E-h < -89 mV). Loss of mitochondrial membrane potential (Delta psi(m)), release of cytochrome c, and activation of caspase 3 after tBH treatments all increased under the more oxidized conditions. However, the extracellular redox state did not affect expression of Fas or Fast, in hRPE cells.
   CONCLUSIONS. The hRPE cells that are exposed to a more oxidized extracellular redox environment have increased susceptibility to oxidant-induced apoptosis through the intrinsic mitochondrial pathway, which could contribute to an age-related decline in cell populations in the retina and thereby provide a potential mechanism for the degenerative changes that are associated with age-related macular degeneration (ARMD).
C1 Vanderbilt Univ, Vanderbilt Eye Inst, Nashville, TN 37232 USA.
   Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
C3 Vanderbilt University; Emory University; Emory University
RP Sternberg, P (通讯作者)，Vanderbilt Univ, Vanderbilt Eye Inst, 8030 Med Ctr E, Nashville, TN 37232 USA.
EM paul.sternberg@vanderbilt.edu
FU NEI NIH HHS [EY06360, EY07892, EY08126] Funding Source: Medline; NIEHS
   NIH HHS [ES09047] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R29EY007892, R01EY007892, P30EY006360, P30EY008126] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
   [R01ES009047] Funding Source: NIH RePORTER
CR ALDER VA, 1985, CURR EYE RES, V4, P121, DOI 10.3109/02713688508999977
   Andersson A, 2000, ATHEROSCLEROSIS, V151, P535, DOI 10.1016/S0021-9150(99)00418-9
   Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292
   BUHL R, 1989, LANCET, V2, P1294
   Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629
   Cai JY, 1999, INVEST OPHTH VIS SCI, V40, P959
   Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055
   Deneke SM, 2000, CURR TOP CELL REGUL, V36, P151
   DI MASCIO P, 1991, AM J CLIN NUTR, V53, pS194, DOI 10.1093/ajcn/53.1.194S
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hall AG, 1999, EUR J CLIN INVEST, V29, P238
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Jiang S, 2002, INVEST OPHTH VIS SCI, V43, P2546
   Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645
   Jonas CR, 2002, FREE RADICAL BIO MED, V33, P1499, DOI 10.1016/S0891-5849(02)01081-X
   Jonas CR, 2000, AM J CLIN NUTR, V72, P181
   Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0
   Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7
   Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0
   Kantrow SP, 1997, BIOCHEM BIOPH RES CO, V232, P669, DOI 10.1006/bbrc.1997.6353
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1
   Moran LK, 2001, CURR MED CHEM, V8, P763, DOI 10.2174/0929867013372904
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   Naisbitt DJ, 2000, AIDS RES HUM RETROV, V16, P1929, DOI 10.1089/088922200750054657
   Nkabyo YS, 2002, AM J PHYSIOL-GASTR L, V283, pG1352, DOI 10.1152/ajpgi.00183.2002
   ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Sen CK, 2000, CURR TOP CELL REGUL, V36, P1
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Watson WH, 2003, BIOFACTORS, V17, P307, DOI 10.1002/biof.5520170130
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 45
TC 95
Z9 99
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2005
VL 46
IS 3
BP 1054
EP 1061
DI 10.1167/iovs.04-0949
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900LR
UT WOS:000227216900037
PM 15728565
DA 2022-11-30
ER

PT J
AU Paraoan, L
   Ratnayaka, A
   Spiller, DG
   Hiscott, P
   White, MRH
   Grierson, I
AF Paraoan, L
   Ratnayaka, A
   Spiller, DG
   Hiscott, P
   White, MRH
   Grierson, I
TI Unexpected intracellular localization of the AMD-associated cystatin C
   variant
SO TRAFFIC
LA English
DT Article
DE age related macular degeneration; precursor cystatin C; processing;
   retinal pigment epithelium; variant B
ID CYSTEINE PROTEINASE-INHIBITORS; SIGNAL RECOGNITION PARTICLE;
   RETINAL-PIGMENT EPITHELIUM; POST-GAMMA-GLOBULIN; AMINO-ACID-SEQUENCE;
   BIOLOGICAL-FLUIDS; CRYSTAL-STRUCTURE; CLEAVAGE SITES; TRACE;
   IDENTIFICATION
AB Cystatin C is abundantly expressed by the retinal pigment epithelium (RPE) of the eye. Targeting of cystatin C to the Golgi apparatus and processing through the secretory pathway of RPE cells are dependent upon a 26-amino acid signal sequence of precursor cystatin C. A variant with an alanine (A) to threonine (T) mutation in the penultimate amino acid of the signal sequence (A25T) was recently correlated with increased risk of developing exudative age-related macular degeneration. The biochemical consequence of the A25T mutation upon targeting of the protein is reported here. Targeting and trafficking of full-length mutant (A25T) precursor cystatin C-enhanced green fluorescent protein fusion protein were studied in living, cultured retinal pigment epithelial and HeLa cells. Confocal microscopy studies were substantiated by immunodetection. In striking contrast to wild-type precursor cystatin C fusion protein conspicuously targeted to the Golgi apparatus, the threonine variant was associated principally with mitochondria. Some diffuse fluorescence was also observed throughout the cytoplasm and nucleus (but not nucleoli). Secretion of fusion protein derived from the threonine variant was reduced by approximately 50% compared with that of the wild-type cystatin C fusion protein. Expression of the variant fusion protein did not appear to impair expression or secretion of endogenous cystatin C.
C1 Univ Liverpool, Dept Med, Unit Ophthalmol, Liverpool L69 3BX, Merseyside, England.
   Univ Liverpool, Sch Biol Sci, Ctr Cell Imaging, Liverpool L69 3BX, Merseyside, England.
C3 University of Liverpool; University of Liverpool
RP Paraoan, L (通讯作者)，Univ Liverpool, Dept Med, Unit Ophthalmol, Liverpool L69 3BX, Merseyside, England.
EM lparaoan@liv.ac.uk
RI Paraoan, Luminita/K-1066-2016; Spiller, David G/I-3645-2012
OI Paraoan, Luminita/0000-0001-7568-7116; White,
   Michael/0000-0002-3617-3232; Spiller, David
   Geoffrey/0000-0003-2502-6787; Ratnayaka, J. Arjuna/0000-0002-1027-6938
CR ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6
   ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287
   ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282
   Balija VS, 2000, J BIOL CHEM, V275, P31668, DOI 10.1074/jbc.M002963200
   BARRETT AJ, 1984, BIOCHEM BIOPH RES CO, V120, P631, DOI 10.1016/0006-291X(84)91302-0
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   BUTTLE DJ, 1990, SCAND J CLIN LAB INV, V50, P509, DOI 10.3109/00365519009089165
   CEJKA J, 1973, ARCH BIOCHEM BIOPHYS, V157, P168
   COLLE A, 1976, CLIN CHIM ACTA, V67, P93, DOI 10.1016/0009-8981(76)90221-7
   D'Agostino DM, 2002, J BIOL CHEM, V277, P34424, DOI 10.1074/jbc.M203023200
   DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0
   Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903
   Fossati G, 2003, J IMMUNOL, V170, P1964, DOI 10.4049/jimmunol.170.4.1964
   GRUBB AO, 1983, SCAND J CLIN LAB INV, V43, P421
   Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X
   Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X
   LOFBERG H, 1979, SCAND J CLIN LAB INV, V39, P619, DOI 10.3109/00365517909108866
   MARMOR MF, 1998, RETINAL PIGMENT EPIT, P23
   Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006
   Nelson G, 2002, J CELL SCI, V115, P1137
   Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863
   Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1
   Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Paraoan L, 2001, MOL MEMBR BIOL, V18, P229
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Poot M, 1999, CYTOMETRY, V35, P311, DOI 10.1002/(SICI)1097-0320(19990401)35:4<311::AID-CYTO3>3.3.CO;2-5
   ROISE D, 1988, J BIOL CHEM, V263, P4509
   Sickmann A, 2000, ELECTROPHORESIS, V21, P2721, DOI 10.1002/1522-2683(20000701)21:13<2721::AID-ELPS2721>3.3.CO;2-V
   VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17
   VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x
   VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4
   WARFEL AH, 1987, J EXP MED, V166, P1912, DOI 10.1084/jem.166.6.1912
   Zinn KM, 1979, RETINAL PIGMENT EPIT, P3
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 37
TC 37
Z9 38
U1 0
U2 13
PU BLACKWELL MUNKSGAARD
PI COPENHAGEN
PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK
SN 1398-9219
J9 TRAFFIC
JI Traffic
PD NOV
PY 2004
VL 5
IS 11
BP 884
EP 895
DI 10.1111/j.1600-0854.2004.00230.x
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 860MA
UT WOS:000224346500007
PM 15479453
DA 2022-11-30
ER

PT J
AU Rossi, GCM
   Milano, G
   Tinelli, T
AF Rossi, GCM
   Milano, G
   Tinelli, T
TI The Italian version of the 25-item National Eye Institute Visual
   Function Questionnaire: Translation, validity, and reliability
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE glaucoma; NEI-VFQ questionnaire; quality of life; validation of
   questionnaire
ID QUALITY-OF-LIFE; HEALTH SURVEY SF-36; CROSS-CULTURAL ADAPTATION;
   VALIDATION; PATIENT; SCALE; CATARACT; GLAUCOMA; TESTS; INDEX
AB Objective: To test the Italian adaptation of the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ 25) and to investigate its validity and reliability.
   Methods: This prospective observational study enrolled nonhospitalized patients with 1 of 5 chronic eye diseases, and a reference sample of subjects without eye diseases. Eligible participants had to be cognitively able to respond to a health status interview and be affected by 1 of the following eye conditions: senile cataract, age-related macular degeneration, glaucoma, diabetic retinopathy, and cytomegalovirus retinitis or low vision. A control group was composed of subjects with no evidence of underlying eye diseases. The Italian self-administered versions of Medical Outcomes Study Short Form and of the NEI-VFQ 25 were administered to all participants. Reliability and validity of the Italian translation of the NEI-VFQ 25 were tested using statistical methods.
   Results: Statistical analysis points out that the Italian version of the NEI-VFQ 25 has good validity, discriminatory power, internal consistency, and reliability.
   Conclusions: This Italian version of the NEI-VFQ 25 shows psychometric properties comparable to those of the American version, and thus can be used in clinical research as a specific measure of quality of life in patients with chronic eye diseases.
C1 Policlin San Matteo, IRCCS, Univ Eye Clin Pavia, Clin Oculist, I-27100 Pavia, Italy.
   IRCCS, Policlin San Matteo, Lab Biometria & Epidemiol Clin, Pavia, Italy.
C3 IRCCS Fondazione San Matteo; University of Pavia; IRCCS Fondazione San
   Matteo; University of Pavia
RP Rossi, GCM (通讯作者)，Policlin San Matteo, IRCCS, Univ Eye Clin Pavia, Clin Oculist, Piazzale Golgi 2, I-27100 Pavia, Italy.
EM gemma.rossi.md@inwind.it
RI rossi, gemma caterina maria/AAD-6976-2022; ROSSI, Gemma Caterina
   Maria/ABI-2573-2020
OI ROSSI, Gemma Caterina Maria/0000-0003-3519-2420; MILANO,
   GIOVANNI/0000-0002-0045-0066; Tinelli, Carmine/0000-0002-8749-1978
CR Apolone G, 1998, J CLIN EPIDEMIOL, V51, P1025, DOI 10.1016/S0895-4356(98)00094-8
   APOLONE G, 1997, QUESTIONARIO SULLO S
   Benvenuti P, 1999, J AFFECT DISORDERS, V53, P137, DOI 10.1016/S0165-0327(98)00102-5
   FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257
   Gandek B, 1998, J CLIN EPIDEMIOL, V51, P953, DOI 10.1016/S0895-4356(98)00086-9
   Groenvold M, 1997, J CLIN EPIDEMIOL, V50, P441, DOI 10.1016/S0895-4356(96)00428-3
   GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N
   Hays R D, 1992, Qual Life Res, V1, P73, DOI 10.1007/BF00435438
   HUNT SM, 1991, HEALTH POLICY, V19, P33, DOI 10.1016/0168-8510(91)90072-6
   Lee BL, 1998, ARCH OPHTHALMOL-CHIC, V116, P861, DOI 10.1001/archopht.116.7.861
   Loopez-Vivancos J, 1999, DIGESTION, V60, P274, DOI 10.1159/000007670
   LUNDSTROM M, 1994, BRIT J OPHTHALMOL, V78, P608, DOI 10.1136/bjo.78.8.608
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006
   MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004
   Parrish R K 2nd, 1996, Trans Am Ophthalmol Soc, V94, P919
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   Patrick D.L., 1995, QUALITY LIFE ASSESSM, P19
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Sherwood MB, 1998, OPHTHALMOLOGY, V105, P561, DOI 10.1016/S0161-6420(98)93043-3
   SLEVIN ML, 1988, BRIT J CANCER, V57, P109, DOI 10.1038/bjc.1988.20
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306
   Torres X, 1999, EPILEPSIA, V40, P1299, DOI 10.1111/j.1528-1157.1999.tb00861.x
   Ware J.E., 1993, LINC RI QUAL METR IN
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   WARE JE, 1997, QUALITY LIFE PHARM C, P681
NR 29
TC 64
Z9 68
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD JUN
PY 2003
VL 12
IS 3
BP 213
EP 220
DI 10.1097/00061198-200306000-00006
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 690UH
UT WOS:000183568000006
PM 12782838
DA 2022-11-30
ER

PT J
AU Fernandes, AR
   dos Santos, T
   Granja, PL
   Sanchez-Lopez, E
   Garcia, ML
   Silva, AM
   Souto, EB
AF Fernandes, Ana R.
   dos Santos, Tiago
   Granja, Pedro L.
   Sanchez-Lopez, Elena
   Garcia, Maria L.
   Silva, Amelia M.
   Souto, Eliana B.
TI Permeability, anti-inflammatory and anti-VEGF profiles of
   steroidal-loaded cationic nanoemulsions in retinal pigment epithelial
   cells under oxidative stress
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Cationic nanoemulsions; Triamcinolone acetonide; Vascular Endothelial
   Growth Factor; Tumor Necrosis Factor alpha, Choroidal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; TRIAMCINOLONE ACETONIDE; TNF-ALPHA;
   PHYSIOLOGICAL BARRIERS; MACULAR DEGENERATION; LIPID NANOPARTICLES;
   DRUG-DELIVERY; EXPRESSION; INFLAMMATION; ANGIOGENESIS
AB Age-related macular degeneration (AMD) is defined as a degenerative, progressive and multifactorial disorder that affects the macula with a complex etiology. The retinal pigment epithelium is a monolayer of cells that has the function to separate the surface of the choroid from the neural retina that is involved in the signal transduction leading to vision. The blood-aqueous barrier and the blood retinal barrier limit the permeation of drugs into the retina and thereby reducing their efficacy. Triamcinolone acetonide (TA) is widely used as antiinflammatory and immunomodulatory drug that promotes the inhibition of the inflammatory processes. The factors that stimulate or inhibit angiogenesis in AMD create a local balance that is responsible for the growth of sub-retinal neovascularization. In AMD, the main angiogenic stimulus is the vascular endothelial growth factor (VEGF). In this work, nanoemulsions with cationic surfactants (mono- and dicationic DABCO and quinuclidine) were produced to deliver TA, and were found to reduce the production of tumor necrosis factor alpha (TNF-alpha), which stimulates the choroidal neovascularization development by upregulating the VEGF production, and consequently decreased the VEGF levels. Our results support the potential use of mono- and dicationic DABCO and quinuclidine-based cationic nanoemulsions for the delivery of TA in the treatment of AMD.
C1 [Fernandes, Ana R.; dos Santos, Tiago; Granja, Pedro L.] Univ Porto, Inst Res & Innovat Hlth I3S, R Alfredo Allen 208, P-4200135 Porto, Portugal.
   [Fernandes, Ana R.; dos Santos, Tiago; Granja, Pedro L.] Univ Porto, INEB Biomed Engn Natl Inst, Alfredo Allen 208, P-4200135 Porto, Portugal.
   [Fernandes, Ana R.] Univ Porto, Fac Engn, R Dr Roberto Frias, P-4200465 Porto, Portugal.
   [Fernandes, Ana R.; Garcia, Maria L.; Silva, Amelia M.] UTAD, Ctr Res & Technol Agroenvironm & Biol Sci, CITAB, P-5001801 Vila Real, Portugal.
   [Fernandes, Ana R.; Sanchez-Lopez, Elena; Garcia, Maria L.] Univ Barcelona, Fac Pharm, Dept Pharm Pharmaceut Technol & Phys Chem, Barcelona, Spain.
   [Sanchez-Lopez, Elena] Univ Barcelona, Inst Nanosci & Nanotechnol IN2UB, Barcelona, Spain.
   [Silva, Amelia M.] Univ Tras Os Montes & Alto Douro, Dept Biol & Environm, UTAD, P-5001801 Vila Real, Portugal.
   [Souto, Eliana B.] Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
   [Souto, Eliana B.] Univ Minho, CEB Ctr Biol Engn, Campus Gualtar, P-4710057 Braga, Portugal.
   [Souto, Eliana B.] LABBELS Associate Lab, Braga, Guimaraes, Portugal.
C3 Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade do
   Porto; University of Tras-os-Montes & Alto Douro; University of
   Barcelona; University of Barcelona; University of Tras-os-Montes & Alto
   Douro; Universidade do Porto; Universidade do Minho
RP Silva, AM (通讯作者)，UTAD, Ctr Res & Technol Agroenvironm & Biol Sci, CITAB, P-5001801 Vila Real, Portugal.; Souto, EB (通讯作者)，Univ Porto, Fac Pharm, Dept Pharmaceut Technol, Rua Jorge Viterbo Ferreira 228, P-4050313 Porto, Portugal.
EM amsilva@utad.pt; ebsouto@ff.up.pt
RI Souto, Eliana/GQZ-3071-2022; Silva, Amélia M/J-7128-2013; Souto,
   Eliana/T-1645-2019
OI Silva, Amélia M/0000-0002-7524-9914; Souto, Eliana/0000-0002-9737-6017;
   Fernandes, Ana/0000-0002-8787-7854
FU Portuguese Science and Technology Foundation (FCT) from the Ministry of
   Science and Technology (MCTES) [SFRH/BD/130555/2017, UIDB/04469/2020,
   UIDB/04033/2020]; European Funds (PRODER/COMPETE); FEDER, under the
   Partnership Agreement PT2020
FX This work was funded by the Portuguese Science and Technology Foundation
   (FCT) from the Ministry of Science and Technology (MCTES) for the
   scholarship SFRH/BD/130555/2017 granted to A. R. Fernandes, and for the
   projects UIDB/04469/2020 (CEB strategic fund) and UIDB/04033/2020
   (CITAB), co-funded by European Funds (PRODER/COMPETE) and FEDER, under
   the Partnership Agreement PT2020.
CR AHMED I, 1985, INVEST OPHTH VIS SCI, V26, P584
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alaimo A, 2020, ARCH TOXICOL, V94, P553, DOI 10.1007/s00204-019-02637-w
   An EY, 2008, MOL VIS, V14, P2292
   Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029
   Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Camenisch G, 1998, EUR J PHARM SCI, V6, P313, DOI 10.1016/S0928-0987(97)10019-7
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Deissler HL, 2020, EXP EYE RES, V194, DOI 10.1016/j.exer.2020.108004
   Dello Russo C, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1288-0
   Dendoncker K, 2019, P NATL ACAD SCI USA, V116, P12942, DOI 10.1073/pnas.1821565116
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Fathollahipour S, 2018, CELLS TISSUES ORGANS, V205, P350, DOI 10.1159/000493162
   Fernandes AR, 2021, NANOMATERIALS-BASEL, V11, DOI 10.3390/nano11102758
   Fichert T, 2003, BIOORG MED CHEM LETT, V13, P719, DOI 10.1016/S0960-894X(02)01035-1
   Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5
   Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Hamalainen KM, 1997, INVEST OPHTH VIS SCI, V38, P627
   Hirani A, 2016, PHARM DEV TECHNOL, V21, P61, DOI 10.3109/10837450.2014.965326
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hosoya K, 2005, EUR J PHARM BIOPHARM, V60, P227, DOI 10.1016/j.ejpb.2004.12.007
   Islam R, 2020, MOLECULES, V25, DOI 10.3390/molecules25245809
   Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kirschke E, 2014, CELL, V157, P1685, DOI 10.1016/j.cell.2014.04.038
   Korthagen NM, 2015, BRIT J OPHTHALMOL, V99, P700, DOI 10.1136/bjophthalmol-2014-306309
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lallemand F, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/604204
   Lally DR, 2016, SURV OPHTHALMOL, V61, P759, DOI 10.1016/j.survophthal.2016.03.010
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Palop JJ, 2011, METHODS MOL BIOL, V670, P245, DOI 10.1007/978-1-60761-744-0_17
   Pashirova TN, 2019, J MOL LIQ, V296, DOI 10.1016/j.molliq.2019.112062
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Quagliariello V, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091304
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Salvati A, 2011, NANOMED-NANOTECHNOL, V7, P818, DOI 10.1016/j.nano.2011.03.005
   Samuel W, 2017, MOL VIS, V23, P60
   Sanchez-Lopez E, 2017, EUR J PHARM BIOPHARM, V110, P58, DOI 10.1016/j.ejpb.2016.10.013
   Sanchez-Lopez E, 2017, EUR J PHARM BIOPHARM, V110, P70, DOI 10.1016/j.ejpb.2016.10.009
   SATO N, 1987, J NATL CANCER I, V79, P1383
   SCHOENWALD RD, 1983, J PHARM SCI-US, V72, P1266, DOI 10.1002/jps.2600721108
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   St Johnston D, 2010, CELL, V141, P757, DOI 10.1016/j.cell.2010.05.011
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Stewart MW, 2012, CURR DIABETES REP, V12, P364, DOI 10.1007/s11892-012-0281-8
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Theodossiadis PG, 2007, RETINA-J RET VIT DIS, V27, P399, DOI 10.1097/MAJ.0b013e3180318fbc
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Trakkides TO, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110548
   Van Ooteghem M.M., 1993, BIOPHARMACEUTICS OCU, Vfirst, P27
   Vecchione R, 2016, J CONTROL RELEASE, V233, P88, DOI 10.1016/j.jconrel.2016.05.004
   Wang HB, 2016, MOL VIS, V22, P116
   Wu WS, 2006, J INVEST DERMATOL, V126, P1264, DOI 10.1038/sj.jid.5700274
   Zakharova LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225534
   Zhou HS, 2012, INT J NANOMED, V7, P4649, DOI 10.2147/IJN.S29690
   Zhu QY, 2015, J NANOSCI NANOTECHNO, V15, P9539, DOI 10.1166/jnn.2015.10880
   Zou XL, 2018, INT J OPHTHALMOL-CHI, V11, P1594, DOI 10.18240/ijo.2018.10.04
   Zur D, 2019, OPHTHALMIC RES, V62, P231, DOI 10.1159/000499540
NR 76
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD APR 5
PY 2022
VL 617
AR 121615
DI 10.1016/j.ijpharm.2022.121615
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2P6VY
UT WOS:000819877200005
PM 35217072
DA 2022-11-30
ER

PT J
AU Dammak, A
   Huete-Toral, F
   Carpena-Torres, C
   Martin-Gil, A
   Pastrana, C
   Carracedo, G
AF Dammak, Azza
   Huete-Toral, Fernando
   Carpena-Torres, Carlos
   Martin-Gil, Alba
   Pastrana, Cristina
   Carracedo, Gonzalo
TI From Oxidative Stress to Inflammation in the Posterior Ocular Diseases:
   Diagnosis and Treatment
SO PHARMACEUTICS
LA English
DT Review
DE oxidative stress; inflammation; glaucoma; retina diseases; age-related
   macular degeneration; diabetic retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; OPEN-ANGLE GLAUCOMA;
   NEURAL CELL-DEATH; NONPROLIFERATIVE DIABETIC-RETINOPATHY; MONOCYTE
   CHEMOATTRACTANT PROTEIN-1; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   INTERCELLULAR-ADHESION MOLECULE-1; RETINAL-PIGMENT EPITHELIUM; HUMAN
   TRABECULAR MESHWORK
AB Most irreversible blindness observed with glaucoma and retina-related ocular diseases, including age-related macular degeneration and diabetic retinopathy, have their origin in the posterior segment of the eye, making their physiopathology both complex and interconnected. In addition to the age factor, these diseases share the same mechanism disorder based essentially on oxidative stress. In this context, the imbalance between the production of reactive oxygen species (ROS) mainly by mitochondria and their elimination by protective mechanisms leads to chronic inflammation. Oxidative stress and inflammation share a close pathophysiological process, appearing simultaneously and suggesting a relationship between both mechanisms. The biochemical end point of these two biological alarming systems is the release of different biomarkers that can be used in the diagnosis. Furthermore, oxidative stress, initiating in the vulnerable tissue of the posterior segment, is closely related to mitochondrial dysfunction, apoptosis, autophagy dysfunction, and inflammation, which are involved in each disease progression. In this review, we have analyzed (1) the oxidative stress and inflammatory processes in the back of the eye, (2) the importance of biomarkers, detected in systemic or ocular fluids, for the diagnosis of eye diseases based on recent studies, and (3) the treatment of posterior ocular diseases, based on long-term clinical studies.
C1 [Dammak, Azza; Huete-Toral, Fernando; Carpena-Torres, Carlos; Martin-Gil, Alba; Pastrana, Cristina; Carracedo, Gonzalo] Univ Complutense Madrid, Fac Opt & Optometry, Ocupharm Grp Res, C Arcos Jalon 118, Madrid 28037, Spain.
   [Carracedo, Gonzalo] Univ Complutense Madrid, Fac Opt & Optometry, Dept Optometry & Vsi, C Arcos Jalon 118, Madrid 28037, Spain.
C3 Complutense University of Madrid; Complutense University of Madrid
RP Carracedo, G (通讯作者)，Univ Complutense Madrid, Fac Opt & Optometry, Ocupharm Grp Res, C Arcos Jalon 118, Madrid 28037, Spain.; Carracedo, G (通讯作者)，Univ Complutense Madrid, Fac Opt & Optometry, Dept Optometry & Vsi, C Arcos Jalon 118, Madrid 28037, Spain.
EM Azzadamm@ucm.es; fhueteto@ucm.es; ccarpena@ucm.es; amarting@ucm.es;
   crispast@ucm.es; jgcarrac@ucm.es
RI Martin-Gil, Alba/C-8176-2019
OI Martin-Gil, Alba/0000-0001-8641-2169; Carpena-Torres,
   Carlos/0000-0001-9077-3557; Carracedo, Gonzalo/0000-0003-0054-1731
FU European Union [Nffi 813440]
FX This work has received funding from the European Union's Horizon 2020
   research and innovation programme under theMarie Sklodowska-Curie grant
   agreement Nffi 813440 OR-BITAL-Ocular Research by Integrated Training
   and Learning.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Adamiec-Mroczek J, 2008, GRAEF ARCH CLIN EXP, V246, P1665, DOI 10.1007/s00417-008-0868-6
   Agarkov N M, 2020, Vestn Oftalmol, V136, P94, DOI 10.17116/oftalma202013604194
   Ahmad Anas, 2020, J Immunoassay Immunochem, V41, P257, DOI 10.1080/15321819.2020.1726774
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Aronson Jeffrey K, 2017, Curr Protoc Pharmacol, V76, DOI 10.1002/cpph.19
   ARSTILA AU, 1972, SCIENCE, V175, P530, DOI 10.1126/science.175.4021.530
   Domenech EB, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040347
   Bagnis A, 2012, EXP EYE RES, V103, P55, DOI 10.1016/j.exer.2012.07.011
   Bai YJ, 2014, MOL VIS, V20, P1258
   Balaiya Sankarathi, 2017, Proteomics Insights, V8, p1178641816686078, DOI 10.1177/1178641816686078
   Balaiya S, 2011, CLIN OPHTHALMOL, V5, P553, DOI 10.2147/OPTH.S19453
   Batliwala S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1703810
   Benitez-del-Castillo J, 2019, EUR J OPHTHALMOL, V29, P437, DOI 10.1177/1120672118795399
   Beranek M, 2008, MOL VIS, V14, P1114
   Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Blum A, 2018, CYTOKINE, V106, P76, DOI 10.1016/j.cyto.2017.10.014
   Bonyadi MHJ, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-399
   Boulbou MS, 2004, ACTA DIABETOL, V41, P118, DOI 10.1007/s00592-004-0154-y
   Broadhead GK, 2019, GRAEF ARCH CLIN EXP, V257, P31, DOI 10.1007/s00417-018-4163-x
   Brocker Chad, 2010, Human Genomics, V5, P30
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Burgos-Blasco B, 2020, ACTA OPHTHALMOL, V98, pE768, DOI 10.1111/aos.14374
   Busch M, 2006, AM J KIDNEY DIS, V48, P571, DOI 10.1053/j.ajkd.2006.07.009
   Capozzi ME, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107885
   Carracedo-Rodriguez G, 2020, INT OPHTHALMOL, V40, P419, DOI 10.1007/s10792-019-01199-1
   Chang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027218
   Chau KY, 2007, EYE, V21, P1511, DOI [10.1038/sj.eye.6702722, 10.1038/sj.eye.6702722x]
   Cheung CMG, 2012, MOL VIS, V18, P830
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chono I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32725-3
   Chou TH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12071910
   Chous AP, 2016, BRIT J OPHTHALMOL, V100, P227, DOI 10.1136/bjophthalmol-2014-306534
   Chrysostomou V, 2013, CURR OPIN PHARMACOL, V13, P12, DOI 10.1016/j.coph.2012.09.008
   Costagliola C, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/629529
   Couch C, 2022, ANN PHYS REHABIL MED, V65, DOI 10.1016/j.rehab.2021.101546
   Csosz E, 2019, FEBS OPEN BIO, V9, P1020, DOI 10.1002/2211-5463.12637
   Csosz E, 2012, J PROTEOMICS, V75, P2196, DOI 10.1016/j.jprot.2012.01.019
   Cui Hang, 2012, J Signal Transduct, V2012, P646354, DOI 10.1155/2012/646354
   Cvenkel B, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/939602
   Rodriguez-Carrizalez AD, 2016, REDOX REP, V21, P155, DOI 10.1179/1351000215Y.0000000040
   Davis BM, 2017, MITOCHONDRION, V36, P114, DOI 10.1016/j.mito.2017.05.010
   De Gaetano A, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050794
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z
   Dietrich M, 2021, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.601628
   Dismuke WM, 2014, EXP EYE RES, V120, P28, DOI 10.1016/j.exer.2013.12.012
   Djordjevic B, 2018, EUR J PHARMACOL, V833, P290, DOI 10.1016/j.ejphar.2018.06.011
   Doganay S, 2002, EYE, V16, P163, DOI 10.1038/sj/eye/6700095
   Domanico D, 2015, INDIAN J OPHTHALMOL, V63, P9, DOI 10.4103/0301-4738.151455
   Downie LE, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.1
   Du XL, 2003, J CLIN INVEST, V112, P1049, DOI 10.1172/JCI200318127
   Duarte JN, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/4581909
   Dulull NK, 2017, DRUG DISCOV TODAY, V22, P440, DOI 10.1016/j.drudis.2016.11.012
   Duvesh R, 2017, CURR EYE RES, V42, P1608, DOI 10.1080/02713683.2017.1362003
   Ecker SM, 2012, MOL VIS, V18, P1658
   Ejaz S, 2008, DIABETES OBES METAB, V10, P53, DOI 10.1111/j.1463-1326.2007.00795.x
   Elner SG, 1998, ARCH OPHTHALMOL-CHIC, V116, P1597, DOI 10.1001/archopht.116.12.1597
   Endo M, 2001, HORM METAB RES, V33, P317, DOI 10.1055/s-2001-15122
   Engin KN, 2010, MOL VIS, V16, P1260
   Erdurmus M, 2011, CURR EYE RES, V36, P713, DOI 10.3109/02713683.2011.584370
   Escudero C, 2021, EUR J NEUROL, V28, P1759, DOI 10.1111/ene.14641
   Evangelho K, 2019, INT OPHTHALMOL, V39, P259, DOI 10.1007/s10792-017-0795-9
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Falsini B, 2009, GRAEF ARCH CLIN EXP, V247, P1223, DOI 10.1007/s00417-009-1064-z
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Feng SF, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/8546423
   Fernandez-Albarral JA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174110
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44
   Fletcher EL, 2007, CURR PHARM DESIGN, V13, P2699, DOI 10.2174/138161207781662920
   Forte R, 2013, J OCUL PHARMACOL TH, V29, P733, DOI 10.1089/jop.2013.0010
   Fosmark DS, 2006, METABOLISM, V55, P232, DOI 10.1016/j.metabol.2005.08.017
   Friedman DS, 2004, AM J OPHTHALMOL, V138, pS19, DOI 10.1016/j.ajo.2004.04.058
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Gericke A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9736047
   Ghanei M, 2011, INHAL TOXICOL, V23, P363, DOI 10.3109/08958378.2011.576278
   Ghanem AA, 2010, CURR EYE RES, V35, P295, DOI 10.3109/02713680903548970
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   Gonzalez-Flores D, 2014, MOL CELL BIOCHEM, V390, P281, DOI 10.1007/s11010-014-1979-5
   Gorbatyuk MS, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100860
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Griffith B, 2009, ANTIOXID REDOX SIGN, V11, P2505, DOI [10.1089/ars.2009.2599, 10.1089/ARS.2009.2599]
   Gubin D, 2021, J PINEAL RES, V70, DOI 10.1111/jpi.12730
   Gupta D, 2016, AM FAM PHYSICIAN, V93, P668
   Haefliger IO, 1999, SURV OPHTHALMOL, V43, pS51, DOI 10.1016/S0039-6257(99)00026-0
   Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017
   Harada C, 2010, CELL DEATH DIFFER, V17, P1751, DOI 10.1038/cdd.2010.62
   Harasymowycz P, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6509809
   Haritoglou C, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329470
   Harris A, 2018, ACTA OPHTHALMOL, V96, pe237, DOI 10.1111/aos.13530
   Hecht I, 2019, EUR J INTEGR MED, V25, P60, DOI 10.1016/j.eujim.2018.12.002
   Heng LZ, 2013, DIABETIC MED, V30, P640, DOI 10.1111/dme.12089
   Hondur G, 2017, INVEST OPHTH VIS SCI, V58, P4078, DOI 10.1167/iovs.17-22242
   Hu DN, 2002, J GLAUCOMA, V11, P406, DOI 10.1097/00061198-200210000-00006
   Huete-Toral F, 2015, J PHARMACOL EXP THER, V352, P119, DOI 10.1124/jpet.114.218263
   Hui FR, 2020, CLIN EXP OPHTHALMOL, V48, P903, DOI 10.1111/ceo.13818
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Inman DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065389
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Jacqueminet S, 2006, CLIN CHIM ACTA, V367, P103, DOI 10.1016/j.cca.2005.11.029
   Janssen SF, 2013, PROG RETIN EYE RES, V37, P31, DOI 10.1016/j.preteyeres.2013.09.001
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Garcia-Medina JJ, 2015, ACTA OPHTHALMOL, V93, P546, DOI 10.1111/aos.12629
   Garcia-Medina JJ, 2011, EUR J OPHTHALMOL, V21, P637, DOI 10.5301/EJO.2010.6212
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Jin M, 2001, RETINA-J RET VIT DIS, V21, P28, DOI 10.1097/00006982-200102000-00005
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kakehashi A, 2008, DIABETES RES CLIN PR, V79, P438, DOI 10.1016/j.diabres.2007.10.018
   Kalogerou M, 2018, EXP EYE RES, V167, P128, DOI 10.1016/j.exer.2017.12.005
   Kang GY, 2014, J PROTEOME RES, V13, P581, DOI 10.1021/pr400751k
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katome T, 2013, CELL DEATH DIFFER, V20, P270, DOI 10.1038/cdd.2012.122
   Katome Takashi, 2014, Nippon Ganka Gakkai Zasshi, V118, P907
   Khalef Nervana, 2017, Electron Physician, V9, P3833, DOI 10.19082/3833
   Kim HJ, 2012, CLIN BIOCHEM, V45, P60, DOI 10.1016/j.clinbiochem.2011.10.006
   Kim YS, 2018, BIOCHEM BIOPH RES CO, V503, P1307, DOI 10.1016/j.bbrc.2018.07.041
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Ko ML, 2010, CURR EYE RES, V35, P842, DOI 10.3109/02713683.2010.489728
   Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007
   Kokubun T, 2018, OCUL IMMUNOL INFLAMM, V26, P1177, DOI 10.1080/09273948.2017.1327605
   Kolko M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132048
   Kondkar AA, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/6571413
   Kondkar AA, 2018, CLIN OPHTHALMOL, V12, P701, DOI 10.2147/OPTH.S162999
   Kondkar AA, 2018, CLIN OPHTHALMOL, V12, P153, DOI 10.2147/OPTH.S155168
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kumar DM, 2007, J GLAUCOMA, V16, P334
   Lafuente M, 2019, RETINA-J RET VIT DIS, V39, P1083, DOI 10.1097/IAE.0000000000002114
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lau LI, 2010, INVEST OPHTH VIS SCI, V51, P5486, DOI 10.1167/iovs.10-5663
   Lee D, 2014, INVEST OPHTH VIS SCI, V55, P993, DOI 10.1167/iovs.13-12564
   Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139
   Leite MT, 2009, CLIN EXP OPHTHALMOL, V37, P402, DOI 10.1111/j.1442-9071.2009.02046.x
   Li AF, 2004, MOL VIS, V10, P750
   Li GY, 2008, BRAIN RES, V1188, P35, DOI 10.1016/j.brainres.2007.10.073
   Li GR, 2007, MOL VIS, V13, P2282
   Li SJ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2701539
   Likhvantseva V G, 2018, Vestn Oftalmol, V134, P35, DOI 10.17116/oftalma2018134335
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lulli M, 2012, INVEST OPHTH VIS SCI, V53, P8295, DOI 10.1167/iovs.12-10374
   Luthra A, 2005, EXP EYE RES, V80, P43, DOI 10.1016/j.exer.2004.08.016
   Ma K, 2009, EYE, V23, P1598, DOI 10.1038/eye.2008.286
   Ma ZX, 2022, OCUL IMMUNOL INFLAMM, V30, P630, DOI 10.1080/09273948.2020.1828488
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Marino PF, 2020, MOLECULES, V25, DOI 10.3390/molecules25235614
   Markiewicz L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/812503
   Martinez-Aguila A, 2016, J PHARMACOL EXP THER, V357, P293, DOI 10.1124/jpet.115.231456
   Martinez-Aguila A, 2013, EUR J PHARMACOL, V701, P213, DOI 10.1016/j.ejphar.2012.12.009
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   McMonnies C, 2018, J OPTOM, V11, P3, DOI 10.1016/j.optom.2017.06.002
   Meeus M, 2013, EXPERT OPIN THER TAR, V17, P1081, DOI 10.1517/14728222.2013.818657
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   Moghadam ZM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.628991
   Mohanty K, 2017, OPHTHALMIC GENET, V38, P446, DOI 10.1080/13816810.2016.1261904
   Mokini Z, 2010, DIABETES RES CLIN PR, V87, P313, DOI 10.1016/j.diabres.2009.11.018
   Moon SW, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015515
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Mouronte-Roibas C, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1155-2
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Murugeswari P, 2008, RETINA-J RET VIT DIS, V28, P817, DOI 10.1097/IAE.0b013e31816576d5
   Mutolo MG, 2016, J OCUL PHARMACOL TH, V32, P178, DOI 10.1089/jop.2015.0121
   Naghii MR, 2002, MIL MED, V167, P573
   NATHANSON JA, 1995, NEURON, V14, P781, DOI 10.1016/0896-6273(95)90222-8
   Nebbioso M, 2022, SURV OPHTHALMOL, V67, P168, DOI 10.1016/j.survophthal.2021.04.003
   Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7
   Nguyen CTO, 2007, INVEST OPHTH VIS SCI, V48, P756, DOI 10.1167/iovs.06-0585
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nucci C, 2013, MOL VIS, V19, P1841
   Oh IK, 2010, CURR EYE RES, V35, P1116, DOI 10.3109/02713683.2010.510257
   Oharazawa H, 2010, INVEST OPHTH VIS SCI, V51, P487, DOI 10.1167/iovs.09-4089
   Ohguro H, 2013, J OCUL PHARMACOL TH, V29, P61, DOI 10.1089/jop.2012.0071
   Ojino K, 2014, BIOL PHARM BULL, V37, P424, DOI 10.1248/bpb.b13-00778
   Ozates S, 2019, EUR J OPHTHALMOL, V29, P196, DOI 10.1177/1120672118779486
   Parisi V, 2014, J GLAUCOMA, V23, P391, DOI 10.1097/IJG.0b013e318279b836
   Pendyala S, 2010, RESP PHYSIOL NEUROBI, V174, P265, DOI 10.1016/j.resp.2010.09.016
   Pfeiffer A, 1996, DIABETES CARE, V19, P1113, DOI 10.2337/diacare.19.10.1113
   Pham-Huy Lien Ai, 2008, Int J Biomed Sci, V4, P89
   Pharm TBM, 2017, CAN J DIABETES, V41, P241, DOI 10.1016/j.jcjd.2016.08.228
   Prokopiou E, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000326
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rodriguez ML, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4940825
   Rokicki W, 2016, CLIN HEMORHEOL MICRO, V62, P369, DOI 10.3233/CH-152029
   Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380
   Sabanayagam C, 2017, INVEST OPHTH VIS SCI, V58, P2538, DOI 10.1167/iovs.16-21263
   Sabaner MC, 2021, INT OPHTHALMOL, V41, P1053, DOI 10.1007/s10792-020-01663-3
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sahay P, 2017, INVEST OPHTH VIS SCI, V58, pBIO106, DOI 10.1167/iovs.17-21723
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Salt T, 2006, EYE, V20, P730, DOI 10.1038/sj.eye.6701967
   Sanganahalli BG, 2005, BRAIN RES, V1037, P200, DOI 10.1016/j.brainres.2005.01.013
   Sanz-Gonzalez S M, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P120, DOI 10.1016/j.oftal.2019.11.009
   Sanz-Gonzalez SM, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111101
   Sasongko MB, 2015, DIABETIC MED, V32, P686, DOI 10.1111/dme.12640
   Sawada H, 2010, INVEST OPHTH VIS SCI, V51, P903, DOI 10.1167/iovs.09-4247
   Schnebelen C, 2009, GRAEF ARCH CLIN EXP, V247, P1191, DOI 10.1007/s00417-009-1094-6
   Semeraro F, 2019, DIABETES METAB, V45, P517, DOI 10.1016/j.diabet.2019.04.002
   Sepahi S, 2018, AM J OPHTHALMOL, V190, P89, DOI 10.1016/j.ajo.2018.03.007
   Sharma S, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/279393
   Shirakami T, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080755
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Singh A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.561366
   Sorkhabi R, 2011, MOL VIS, V17, P41
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tamm ER, 1996, INVEST OPHTH VIS SCI, V37, P2402
   Tan SM, 2013, INVEST OPHTH VIS SCI, V54, P555, DOI 10.1167/iovs.12-10685
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Tezel G, 2005, INVEST OPHTH VIS SCI, V46, P3177, DOI 10.1167/iovs.05-0208
   Tezel G, 2004, INVEST OPHTH VIS SCI, V45, P4049, DOI 10.1167/iovs.04-0490
   Tezel G, 2000, J NEUROSCI, V20, P8693
   Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787
   Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X
   Tezel G, 2009, INVEST OPHTH VIS SCI, V50, P1001, DOI 10.1167/iovs.08-2717
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P705, DOI 10.1167/iovs.06-0810
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Thomas RL, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107840
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tokuda K, 2007, EXP EYE RES, V84, P537, DOI 10.1016/j.exer.2006.11.005
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Tsutsui H, 2006, INTERNAL MED, V45, P809, DOI 10.2169/internalmedicine.45.1765
   Ugurlu N, 2013, INTERNAL MED, V52, P2173, DOI 10.2169/internalmedicine.52.8572
   Verma RP, 2007, BIOORGAN MED CHEM, V15, P2223, DOI 10.1016/j.bmc.2007.01.011
   Vomund S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122772
   Wang AL, 2008, MOL VIS, V14, P644
   Wang HW, 2019, INT J MOL MED, V43, P671, DOI 10.3892/ijmm.2018.3992
   Wang ZG, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0921-0
   Watanabe K, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/128726
   Weinberger B, 2011, PULM PHARMACOL THER, V24, P92, DOI 10.1016/j.pupt.2010.09.004
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Whitehead M, 2018, EXPERT OPIN BIOL TH, V18, P1257, DOI 10.1080/14712598.2018.1545836
   Widjaja-Adhi MAK, 2018, FASEB J, V32, P6305, DOI 10.1096/fj.201800467R
   Wilkinson-Berka JL, 2013, CLIN SCI, V124, P597, DOI 10.1042/CS20120212
   Williams Pete A, 2018, Commun Integr Biol, V11, pe1356956, DOI 10.1080/19420889.2017.1356956
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Winiarczyk M, 2018, GRAEF ARCH CLIN EXP, V256, P1127, DOI 10.1007/s00417-018-3984-y
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wong TY, 2010, STROKE, V41, P575, DOI 10.1161/STROKEAHA.109.574475
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu F, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.26
   Wu HL, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/9402198
   Wu MY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3420187
   Xie ZG, 2007, CURR EYE RES, V32, P471, DOI 10.1080/02713680701257621
   Xu P, 2014, J OCUL PHARMACOL TH, V30, P246, DOI 10.1089/jop.2013.0183
   Yang YP, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8407206
   Yang YP, 2016, SCI REP-UK, V6, DOI 10.1038/srep29546
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Yoshizawa M, 1998, DIABETES RES CLIN PR, V42, P65, DOI 10.1016/S0168-8227(98)00091-6
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Yuan CJ, 2021, CANCER INVEST, V39, P489, DOI 10.1080/07357907.2020.1858852
   Yuki K, 2010, ACTA OPHTHALMOL, V88, pe259, DOI 10.1111/j.1755-3768.2010.01997.x
   Yulek F, 2007, ARCH MED RES, V38, P503, DOI 10.1016/j.arcmed.2007.02.006
   Zadeh JK, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5181429
   Zanón-Moreno V., 2008, Arch Soc Esp Oftalmol, V83, P365
   Zeng KH, 2017, MOL NEUROBIOL, V54, P4000, DOI 10.1007/s12035-016-9972-5
   Zhang PC, 2017, ASIA PAC J CLIN NUTR, V26, P406, DOI 10.6133/apjcn.032016.13
   Zhang X, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.47
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
   Zhong Q, 2013, INVEST OPHTH VIS SCI, V54, P3941, DOI 10.1167/iovs.13-11598
   Zhou HY, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1278-8
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
NR 290
TC 12
Z9 12
U1 8
U2 18
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD SEP
PY 2021
VL 13
IS 9
AR 1376
DI 10.3390/pharmaceutics13091376
PG 29
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UW0KA
UT WOS:000699855000001
PM 34575451
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, ZR
   Lim, G
   Ng, WY
   Keane, PA
   Campbell, JP
   Tan, GSW
   Schmetterer, L
   Wong, TY
   Liu, Y
   Ting, DSW
AF Wang, Zhaoran
   Lim, Gilbert
   Ng, Wei Yan
   Keane, Pearse A.
   Campbell, J. Peter
   Tan, Gavin Siew Wei
   Schmetterer, Leopold
   Wong, Tien Yin
   Liu, Yong
   Ting, Daniel Shu Wei
TI Generative adversarial networks in ophthalmology: what are these and how
   can they be used?
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE artificial intelligence; deep learning; generative adversarial networks;
   medical image synthesis; ophthalmology
ID COHERENCE TOMOGRAPHY IMAGES; DEEP LEARNING-SYSTEM; DIABETIC-RETINOPATHY;
   NOISE-REDUCTION; VALIDATION; MODEL
AB Purpose of review The development of deep learning (DL) systems requires a large amount of data, which may be limited by costs, protection of patient information and low prevalence of some conditions. Recent developments in artificial intelligence techniques have provided an innovative alternative to this challenge via the synthesis of biomedical images within a DL framework known as generative adversarial networks (GANs). This paper aims to introduce how GANs can be deployed for image synthesis in ophthalmology and to discuss the potential applications of GANs-produced images. Recent findings Image synthesis is the most relevant function of GANs to the medical field, and it has been widely used for generating 'new' medical images of various modalities. In ophthalmology, GANs have mainly been utilized for augmenting classification and predictive tasks, by synthesizing fundus images and optical coherence tomography images with and without pathologies such as age-related macular degeneration and diabetic retinopathy. Despite their ability to generate high-resolution images, the development of GANs remains data intensive, and there is a lack of consensus on how best to evaluate the outputs produced by GANs. Although the problem of artificial biomedical data generation is of great interest, image synthesis by GANs represents an innovation with yet unclear relevance for ophthalmology.
C1 [Wang, Zhaoran; Lim, Gilbert; Ng, Wei Yan; Tan, Gavin Siew Wei; Schmetterer, Leopold; Wong, Tien Yin; Ting, Daniel Shu Wei] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Lim, Gilbert; Ng, Wei Yan; Tan, Gavin Siew Wei; Schmetterer, Leopold; Wong, Tien Yin; Ting, Daniel Shu Wei] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Keane, Pearse A.; Liu, Yong] ASTAR, Inst High Performance Comp, Singapore, Singapore.
   [Campbell, J. Peter] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97201 USA.
   [Schmetterer, Leopold] SERI NTU Adv Ocular Engn STANCE, Singapore, Singapore.
   [Schmetterer, Leopold] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore, Singapore.
   [Schmetterer, Leopold] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
C3 National University of Singapore; National University of Singapore;
   Singapore National Eye Center; Agency for Science Technology & Research
   (A*STAR); A*STAR - Institute of High Performance Computing (IHPC);
   Oregon Health & Science University; Nanyang Technological University &
   National Institute of Education (NIE) Singapore; Nanyang Technological
   University; Medical University of Vienna; Medical University of Vienna
RP Ting, DSW (通讯作者)，Singapore Natl Eye Ctr, Surg Retina Dept, 11 Third Hosp Ave, Singapore 168751, Singapore.; Ting, DSW (通讯作者)，Duke Natl Univ Singapore, Med Sch, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM daniel.ting.s.w@singhealth.com.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Bidwai, Pooja
   Vishal/0000-0002-3077-4395; Schmetterer, Leopold/0000-0002-7189-1707;
   Keane, Pearse/0000-0002-9239-745X
FU National Institutes of Health (Bethesda, MD) [R01EY19474, R01 EY031331,
   R21 EY031883, P30 EY10572]; Research to Prevent Blindness (New York, NY)
FX This work was supported by grants R01EY19474, R01 EY031331, R21
   EY031883, and P30 EY10572 from the National Institutes of Health
   (Bethesda, MD), and by unrestricted departmental funding and a Career
   Development Award (JPC) from Research to Prevent Blindness (New York,
   NY).
CR Abdal R, 2019, IEEE I CONF COMP VIS, P4431, DOI 10.1109/ICCV.2019.00453
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Alex V, 2017, PROC SPIE, V10133, DOI 10.1117/12.2254487
   [Anonymous], 2006, LANCET, V367, P275
   Arjovsky M, 2017, PR MACH LEARN RES, V70
   Barratt S, 2018, 180101973 ARXIV
   Baydoun A, 2021, IEEE ACCESS, V9, P17208, DOI [10.1109/access.2021.3049781, 10.1109/ACCESS.2021.3049781]
   Beers A., 2018, 180503144 ARXIV 180503144 ARXIV
   Bellemo V., 2019, GENERATIVE ADVERSARI
   Bermudez C, 2018, PROC SPIE, V10574, DOI 10.1117/12.2293515
   Bhuiyan A, 2020, DIABETES CARE, V43, pE147, DOI 10.2337/dc19-2133
   Borji A, 2019, COMPUT VIS IMAGE UND, V179, P41, DOI 10.1016/j.cviu.2018.10.009
   Brock A., 2019, INT C LEARN REPR ICL, DOI DOI 10.1145/3205873.3205877
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina PM, 2019, JAMA OPHTHALMOL, V137, P258, DOI 10.1001/jamaophthalmol.2018.6156
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Costa P, 2018, IEEE T MED IMAGING, V37, P781, DOI 10.1109/TMI.2017.2759102
   Diaz-Pinto A, 2019, IEEE T MED IMAGING, V38, P2211, DOI 10.1109/TMI.2019.2903434
   Fujioka T, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9040176
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Goodfellow I, 2020, COMMUN ACM, V63, P139, DOI 10.1145/3422622
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Guan SY, 2019, J MED IMAGING, V6, DOI 10.1117/1.JMI.6.3.031411
   Gui J., 2020, ABS200106937 ARXIV ABS200106937 ARXIV
   Guibas JT., 2017, ABS170901872 ARXIV ABS170901872 ARXIV
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Heusel M., 2017, 31 C NEUR INF PROC S, P6626
   Hood DC, 2018, OPHTHALMOLOGY, V125, P1207, DOI 10.1016/j.ophtha.2018.04.020
   Informed consent for medical photographs, 2000, GENET MED, V2, P353
   Jiang Yifan, 2021, IEEE J Biomed Health Inform, V25, P441, DOI 10.1109/JBHI.2020.3042523
   Jiao JB, 2020, IEEE T MED IMAGING, V39, P4413, DOI 10.1109/TMI.2020.3018560
   Jin CB, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19102361
   Kande NA, 2021, IEEE T MED IMAGING, V40, P180, DOI 10.1109/TMI.2020.3024097
   Karras T., 2018, ABS171010196 ARXIV
   Karras T, 2019, PROC CVPR IEEE, P4396, DOI 10.1109/CVPR.2019.00453
   Keel S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22612-2
   Lee H, 2021, RETINA-J RET VIT DIS, V41, P572, DOI 10.1097/IAE.0000000000002898
   Lee JH, 2020, J KOREAN NEUROSURG S, V63, P386, DOI 10.3340/jkns.2019.0084
   Levine AB, 2020, J PATHOL, V252, P178, DOI 10.1002/path.5509
   Li C, 2016, LECT NOTES COMPUT SC, V9907, P702, DOI 10.1007/978-3-319-46487-9_43
   Lim G, 2020, EYE VISION, V7, DOI 10.1186/s40662-020-00182-7
   Liu Y, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/6675259
   Liu YT, 2020, BRIT J OPHTHALMOL, V104, P1735, DOI 10.1136/bjophthalmol-2019-315338
   Lucic M, 2018, ADV NEUR IN, V31
   Ma YH, 2018, BIOMED OPT EXPRESS, V9, P5129, DOI 10.1364/BOE.9.005129
   Madani A, 2018, I S BIOMED IMAGING, P1038, DOI 10.1109/ISBI.2018.8363749
   Mao XD, 2017, IEEE I CONF COMP VIS, P2813, DOI 10.1109/ICCV.2017.304
   Mirza M., 2014, ARXIV
   Office for Civil Rights (OCR), HIPAA PROF HIPAA PROF
   Office for Civil Rights (OCR), YOUR RIGHTS HIPAA
   Qasim A.B, 2020, MED IMAGING DEEP LEA, P655
   Rezaei M., 2018, BILDVERARBEITUNG MED, P353, DOI DOI 10.1007/978-3-662-56537-7_89
   Salimans T., 2016, IMPROVED TECHNIQUES, P2234
   Tavakkoli A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78696-2
   Ting DSW, 2019, OPHTHALMOLOGY, V126, P1475, DOI 10.1016/j.ophtha.2019.09.014
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Toda R, 2021, INT J COMPUT ASS RAD, V16, P241, DOI 10.1007/s11548-021-02308-1
   Wang Z, 2004, IEEE T IMAGE PROCESS, V13, P600, DOI 10.1109/TIP.2003.819861
   Wolterink JM, 2017, IEEE T MED IMAGING, V36, P2536, DOI 10.1109/TMI.2017.2708987
   Xu CC, 2020, MED IMAGE ANAL, V62, DOI 10.1016/j.media.2020.101668
   Yan P., 2018, 180411024 ARXIV 180411024 ARXIV
   Yi X, 2019, MED IMAGE ANAL, V58, DOI 10.1016/j.media.2019.101552
   Yu ZK, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938-019-0682-x
   Zhao H, 2018, MED IMAGE ANAL, V49, P14, DOI 10.1016/j.media.2018.07.001
   Zheng C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.29
   Zhou Yi, 2022, IEEE J Biomed Health Inform, V26, P56, DOI 10.1109/JBHI.2020.3045475
NR 66
TC 5
Z9 6
U1 7
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD SEP
PY 2021
VL 32
IS 5
BP 459
EP 467
DI 10.1097/ICU.0000000000000794
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TT8AN
UT WOS:000680565900011
PM 34324454
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Ahn, J
   Jang, K
   Sohn, J
   Park, JI
   Hwang, DDJ
AF Ahn, Jayoung
   Jang, Kyuhwan
   Sohn, Joonhong
   Park, Ji In
   Hwang, Daniel Duck-Jin
TI Effect of intravitreal ranibizumab and aflibercept injections on retinal
   nerve fiber layer thickness
SO SCIENTIFIC REPORTS
LA English
DT Article
AB The purpose is to evaluate the effects of multiple intravitreal ranibizumab (IVR) and aflibercept (IVA) injections on peripapillary retinal nerve fiber layer (RNFL) thickness in patients with exudative age-related macular degeneration (AMD). This retrospective, observational, consecutive case series study enrolled patients newly diagnosed with monocular exudative AMD from January 2014 to October 2019 who were administered IVR or IVA injections. Normal fellow eyes were included as controls. Medical records and spectral domain optical coherence tomography results were reviewed at baseline and at 3, 6, and 12 months after injection. No statistically significant differences in peripapillary RNFL thickness and intraocular pressure were observed between the treated and fellow eyes in the two groups. The global RNFL thicknesses for the treated eyes decreased significantly after 12 months compared with baseline, but no significant difference was observed in any of the six examined sectors (temporal, superior temporal, superior nasal, nasal, inferior nasal, and inferior temporal). At 12 months, the central macular thickness of the treated eyes decreased significantly. Multiple IVR and IVA injections are apparently safe considering peripapillary RNFL damage in patients with exudative AMD. The decreased RNFL thickness of the global sector was presumably due to anatomical improvement of macular lesions.
C1 [Ahn, Jayoung; Jang, Kyuhwan; Sohn, Joonhong; Hwang, Daniel Duck-Jin] Hangil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.
   [Park, Ji In] Kangwon Natl Univ, Sch Med, Kangwon Natl Univ Hosp, Dept Med, Chunchon, Gangwon Do, South Korea.
   [Hwang, Daniel Duck-Jin] Catholic Kwandong Univ, Dept Ophthalmol, Coll Med, Incheon, South Korea.
C3 Kangwon National University; Kangwon National University Hospital;
   Catholic Kwandong University
RP Hwang, DDJ (通讯作者)，Hangil Eye Hosp, Dept Ophthalmol, 35 Bupyeong Daero, Incheon 21388, South Korea.
EM daniel.dj.hwang@gmail.com
OI Hwang, Daniel Duck-Jin/0000-0003-1808-3169
CR Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Caprioli J, 2007, ARCH OPHTHALMOL-CHIC, V125, P1124, DOI 10.1001/archopht.125.8.1124
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Hwang DJ, 2014, INVEST OPHTH VIS SCI, V55, P4213, DOI 10.1167/iovs.13-13776
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Jee D, 2012, CURR EYE RES, V37, P408, DOI 10.3109/02713683.2011.632108
   Jo Young-Joon, 2016, Korean J Ophthalmol, V30, P114, DOI 10.3341/kjo.2016.30.2.114
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sengul EA, 2016, J OCUL PHARMACOL TH, V32, P665, DOI 10.1089/jop.2016.0014
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Valverde-Megias A, 2019, GRAEF ARCH CLIN EXP, V257, P1459, DOI 10.1007/s00417-019-04325-y
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
NR 29
TC 4
Z9 4
U1 3
U2 7
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 3
PY 2021
VL 11
IS 1
AR 5010
DI 10.1038/s41598-021-84648-1
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA QS8JB
UT WOS:000626138700005
PM 33658584
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Darche, M
   Cossutta, M
   Caruana, L
   Houppe, C
   Gilles, ME
   Habert, D
   Guilloneau, X
   Vignaud, L
   Paques, M
   Courty, J
   Cascone, I
AF Darche, Marie
   Cossutta, Melissande
   Caruana, Laure
   Houppe, Claire
   Gilles, Maud-Emmanuelle
   Habert, Damien
   Guilloneau, Xavier
   Vignaud, Lucile
   Paques, Michel
   Courty, Jose
   Cascone, Ilaria
TI Antagonist of nucleolin, N6L, inhibits neovascularization in mouse
   models of retinopathies
SO FASEB JOURNAL
LA English
DT Article
DE angiogenesis; choroidal neovascularization (CNV); oxygen-induced
   retinopathy (OIR); vascular endothelial growth factor (VEGF); nucleolin
ID OXYGEN-INDUCED RETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; CELL-SURFACE;
   MULTIVALENT PSEUDOPEPTIDES; CANCER; BINDING; NEUTRALIZATION;
   PLEIOTROPHIN; PROGRESSION; DELIVERY
AB Retinal vascular diseases (RVD) have been identified as a major cause of blindness worldwide. These pathologies, including the wet form of age-related macular degeneration, retinopathy of prematurity, and diabetic retinopathy are currently treated by intravitreal delivery of anti-vascular endothelial growth factor (VEGF) agents. However, repeated intravitreal injections can lead to ocular complications and resistance to these treatments. Thus, there is a need to find new targeted therapies. Nucleolin regulates the endothelial cell (EC) activation and angiogenesis. In previous studies, we designed a pseudopeptide, N6L, that binds the nucleolin and blocks the tumor angiogenesis. In this study, the effect of N6L was investigated in two experimental models of retinopathies including oxygen-induced retinopathy (OIR) and choroidal neovascularization (CNV). We found that in mouse OIR, intraperitoneal injection of N6L is delivered to activated ECs and induced a 50% reduction of pathological neovascularization. The anti-angiogenic effect of N6L has been tested in CNV model in which the systemic injection of N6L induced a 33% reduction of angiogenesis. This effect is comparable to those obtained with VEGF-trap, a standard of care drug for RVD. Interestingly, with preventive and curative treatments, neoangiogenesis is inhibited by 59%. Our results have potential interest in the development of new therapies targeting other molecules than VEGF for RVD.
C1 [Darche, Marie; Cossutta, Melissande; Caruana, Laure; Houppe, Claire; Gilles, Maud-Emmanuelle; Habert, Damien; Courty, Jose; Cascone, Ilaria] Univ Paris Est Creteil, CNRS, CRRET Lab, ERL 9215, 61 Ave Gen Gaulle, F-94010 Creteil, France.
   [Darche, Marie; Paques, Michel] Sorbonne Univ, Inst Hosp Univ ForeSight, Ctr Hosp Natl Quinze Vingts, Clin Invest Ctr 1423, Paris, France.
   [Guilloneau, Xavier; Vignaud, Lucile] Sorbonne Univ, Inst Vis, CNRS, INSERM, Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Universite Gustave-Eiffel; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHNO des Quinze-Vingts;
   UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite
RP Cascone, I (通讯作者)，Univ Paris Est Creteil, CNRS, CRRET Lab, ERL 9215, 61 Ave Gen Gaulle, F-94010 Creteil, France.
EM ilaria.cascone@u-pec.fr
RI Guillonneau, xavier/E-3995-2017; guillonneau, xavier/AAF-9495-2021
OI Guillonneau, xavier/0000-0001-7379-3935; guillonneau,
   xavier/0000-0001-7379-3935; COSSUTTA, Melissande/0000-0001-5460-8386
CR Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Berger CM, 2015, BIOCHIMIE, V113, P78, DOI 10.1016/j.biochi.2015.03.023
   Birmpas C, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-32
   Bishop P, 1996, EYE, V10, P664, DOI 10.1038/eye.1996.159
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P1783, DOI 10.1016/j.ophtha.2014.03.021
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Cossutta M, 2019, ARTERIOSCL THROM VAS, V39, P1843, DOI 10.1161/ATVBAHA.119.313021
   De Cola A, 2018, CANCER LETT, V412, P272, DOI 10.1016/j.canlet.2017.10.038
   Destouches D, 2012, J BIOL CHEM, V287, P43685, DOI 10.1074/jbc.M112.380402
   Destouches D, 2011, CANCER RES, V71, P3296, DOI 10.1158/0008-5472.CAN-10-3459
   Destouches D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002518
   Dhez AC, 2018, J CELL PHYSIOL, V233, P4091, DOI 10.1002/jcp.26205
   Diamantopoulou Z, 2017, ONCOTARGET, V8, P90108, DOI 10.18632/oncotarget.21441
   Fuma S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43509
   Gilles ME, 2016, CANCER RES, V76, P7181, DOI 10.1158/0008-5472.CAN-16-0300
   Gioelli N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aah4807
   Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071
   Hovanessian AG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015787
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Koutsioumpa M, 2013, J BIOL CHEM, V288, P343, DOI 10.1074/jbc.M112.387076
   Leaderer D, 2016, EXP EYE RES, V145, P380, DOI 10.1016/j.exer.2016.02.009
   Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x
   Montassar F, 2017, FASEB J, V31, P1107, DOI 10.1096/fj.201600351R
   Ng DS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45081
   Olsen TW, 2017, OPHTHALMOLOGY, V124, pE68, DOI 10.1016/j.ophtha.2017.03.066
   Peters S, 2007, CYTOKINE, V40, P144, DOI 10.1016/j.cyto.2007.09.001
   Presta M, 2009, EUR CYTOKINE NETW, V20, P39, DOI 10.1684/ecn.2009.0155
   Quiroz-Mercado J, 2016, GRAEF ARCH CLIN EXP, V254, P1753, DOI 10.1007/s00417-016-3409-8
   Sader M., 2015, J NANOMEDICINE NANOT, V6, P310
   Said EA, 2005, FEBS J, V272, P4646, DOI 10.1111/j.1742-4658.2005.04870.x
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Sato T, 2015, OSLI RETINA, V46, P87, DOI 10.3928/23258160-20150101-16
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Shi HB, 2007, BLOOD, V110, P2899, DOI 10.1182/blood-2007-01-064428
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628
   Tate A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-197
   Turck N, 2006, J CELL PHYSIOL, V206, P545, DOI 10.1002/jcp.20501
   Van Bergen T, 2017, EXP EYE RES, V165, P136, DOI 10.1016/j.exer.2017.09.012
   Wang WW, 2017, ANGIOGENESIS, V20, P479, DOI 10.1007/s10456-017-9557-6
   Zhu XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115523
NR 47
TC 8
Z9 8
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2020
VL 34
IS 4
BP 5851
EP 5862
DI 10.1096/fj.201901876R
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA LJ5ZA
UT WOS:000530242100069
PM 32141122
OA Bronze
DA 2022-11-30
ER

PT J
AU Zheng, C
   Ferrari, D
   Zhang, M
   Baird, P
AF Zheng, Chao
   Ferrari, Davide
   Zhang, Michael
   Baird, Paul
TI Ranking the importance of genetic factors by variable-selection
   confidence sets
SO JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS
LA English
DT Article
DE Age-related macular degeneration; Case-control genotype data; Likelihood
   ratio test; Predictor ranking; Variable-selection confidence set
ID GENOME-WIDE; PENALIZED REGRESSION; ASSOCIATION ANALYSIS; LIKELIHOOD;
   ALGORITHM
AB The widespread use of generalized linear models in case-control genetic studies has helped to identify many disease-associated risk factors typically defined as DNA variants, or single-nucleotide polymorphisms (SNPs). Up to now, most literature has focused on selecting a unique best subset of SNPs based on some statistical perspective. When the noise is large compared with the signal, however, multiple biological paths are often found to be supported by a given data set. We address the ambiguity related to SNP selection by constructing a list of models-called a variable-selection confidence set (VSCS)-which contains the collection of all well-supported SNP combinations at a user-specified confidence level. The VSCS extends the familiar notion of confidence intervals in the variable-selection setting and provides the practitioner with new tools aiding the variable-selection activity beyond trusting a single model. On the basis of the VSCS, we consider natural graphical and numerical statistics measuring the inclusion importance of an SNP based on its frequency in the most parsimonious VSCS models. This work is motivated by available case-control genetic data on age-related macular degeneration, which is a widespread disease and leading cause of loss of vision.
C1 [Zheng, Chao] Univ Lancaster, Lancaster, England.
   [Ferrari, Davide] Univ Bozen Bolzano, Bolzano, Italy.
   [Ferrari, Davide; Zhang, Michael; Baird, Paul] Univ Melbourne, Melbourne, Vic, Australia.
   [Zhang, Michael; Baird, Paul] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia.
C3 Lancaster University; Free University of Bozen-Bolzano; University of
   Melbourne; Royal Victorian Eye & Ear Hospital
RP Ferrari, D (通讯作者)，Univ Bozen Bolzano, Dept Econ & Management, Piazza Univ 1, I-39100 Bolzano, Italy.
EM davferrari@unibz.it
RI Zheng, Chao/S-1788-2019
OI Zheng, Chao/0000-0001-7943-6349; Baird, Paul/0000-0002-1305-3502
CR Ayers KL, 2010, GENET EPIDEMIOL, V34, P879, DOI 10.1002/gepi.20543
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bondell HD, 2012, J AM STAT ASSOC, V107, P1610, DOI 10.1080/01621459.2012.716344
   Breheny P, 2011, ANN APPL STAT, V5, P232, DOI 10.1214/10-AOAS388
   Claeskens G, 2008, MODEL SELECTION MODE
   Fan JQ, 2010, ANN STAT, V38, P3567, DOI 10.1214/10-AOS798
   Fan JQ, 2001, J AM STAT ASSOC, V96, P1348, DOI 10.1198/016214501753382273
   Ferrari D, 2015, STAT SINICA, V25, P1637, DOI 10.5705/ss.2014.110
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Frommlet F, 2012, COMPUT STAT DATA AN, V56, P1038, DOI 10.1016/j.csda.2011.05.005
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Han F, 2012, BIOMETRICS, V68, P307, DOI 10.1111/j.1541-0420.2011.01649.x
   Hansen PR, 2011, ECONOMETRICA, V79, P453, DOI 10.3982/ECTA5771
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Lehmann E.L., 2006, SPRINGER TEXTS STAT
   Li JH, 2014, ANN APPL STAT, V8, P2292, DOI 10.1214/14-AOAS771
   Pan W, 2009, GENET EPIDEMIOL, V33, P497, DOI 10.1002/gepi.20402
   Park MY, 2008, BIOSTATISTICS, V9, P30, DOI 10.1093/biostatistics/kxm010
   Park MY, 2007, J ROY STAT SOC B, V69, P659, DOI 10.1111/j.1467-9868.2007.00607.x
   Qian G, 2002, MONTE CARLO AND QUASI-MONTE CARLO METHODS 2000, P460
   Raftery A., 2005, R NEWS, V5, P2, DOI DOI 10.1159/000323281
   Wen XQ, 2015, BIOSTATISTICS, V16, P701, DOI 10.1093/biostatistics/kxv009
   Wu T., 2016, THESIS
   Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041
   Xie HL, 2009, ANN STAT, V37, P673, DOI 10.1214/07-AOS580
   Zhang CH, 2010, ANN STAT, V38, P894, DOI 10.1214/09-AOS729
   Zheng C., 2019, STAT SIN, V29
NR 27
TC 3
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0035-9254
EI 1467-9876
J9 J R STAT SOC C-APPL
JI J. R. Stat. Soc. Ser. C-Appl. Stat.
PD APR
PY 2019
VL 68
IS 3
BP 727
EP 749
DI 10.1111/rssc.12337
PG 23
WC Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematics
GA HM9SK
UT WOS:000459825100012
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Lazzarini, R
   Nicolai, M
   Pirani, V
   Mariotti, C
   Di Primio, R
AF Lazzarini, Raffaella
   Nicolai, Michele
   Pirani, Vittorio
   Mariotti, Cesare
   Di Primio, Roberto
TI Effects of senescent secretory phenotype acquisition on human retinal
   pigment epithelial stem cells
SO AGING-US
LA English
DT Article
DE AMD; RPESCs; age-related diseases; senescence; inflammation
ID MACULAR DEGENERATION AMD; CELLULAR SENESCENCE; DISEASE; RPE;
   MACROPHAGES; INFLAMMATION; EXPRESSION; MONOCYTES; AUTOPHAGY; CCR2(+)
AB Regenerative medicine approaches based on mesenchymal stem cells (MSCs) are being investigated to treat several aging-associated diseases, including age-related macular degeneration (AMD). Loss of retinal pigment epithelium (RPE) cells occurs early in AMD, and their transplant has the potential to slow disease progression.
   The human RPE contains a subpopulation of cells - adult RPE stem cells (RPESCs) - that are capable of self-renewal and of differentiating into RPE cells in vitro. However, age-related MSC changes involve loss of function and acquisition of a senescence-associated secretory phenotype (SASP), which can contribute to the maintenance of a chronic state of low-grade inflammation in tissues and organs.
   In a previous study we isolated, characterized, and differentiated RPESCs. Here, we induced replicative senescence in RPESCs and tested their acquisition of the senescence phenotype and the SASP as well as the differentiation ability of young and senescent RPESCs.
   Senescent RPESCs showed a significantly reduced proliferation ability, high senescence-associated beta-galactosidase activity, and SASP acquisition. RPE-specific genes were downregulated and p21 and p53 protein expression was upregulated.
   These findings document the effects of senescence and SASP acquisition on RPESC differentiation ability and highlight the need for a greater understanding of their role in AMD pathogenesis.
C1 [Lazzarini, Raffaella; Di Primio, Roberto] Univ Politecn Marche, Dept Clin & Mol Sci Histol, I-60020 Ancona, Italy.
   [Nicolai, Michele; Pirani, Vittorio; Mariotti, Cesare] Univ Politecn Marche, Ophthalmol Clin, I-60020 Ancona, Italy.
C3 Marche Polytechnic University; Marche Polytechnic University
RP Mariotti, C (通讯作者)，Univ Politecn Marche, Ophthalmol Clin, I-60020 Ancona, Italy.
EM mariottiocul@gmail.com
RI Pirani, Vittorio/AAA-3782-2019
OI Nicolai, Michele/0000-0001-8302-6107
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Amatori S, 2010, BRIT J CANCER, V103, P239, DOI 10.1038/sj.bjc.6605745
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Camelo S, 2015, MOL VIS, V21, P1051
   Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47
   Cevenini E, 2013, CURR OPIN CLIN NUTR, V16, P14, DOI 10.1097/MCO.0b013e32835ada13
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen JJ, 2017, CELL PHYSIOL BIOCHEM, V44, P357, DOI 10.1159/000484907
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Denu RA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2989076
   Elzi DJ, 2012, P NATL ACAD SCI USA, V109, P12052, DOI 10.1073/pnas.1120437109
   Fuchshofer R, 2009, EXP EYE RES, V88, P889, DOI 10.1016/j.exer.2008.11.036
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kim J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0032-5
   Krenning L, 2014, MOL CELL, V55, P59, DOI 10.1016/j.molcel.2014.05.007
   Leung S, 2010, CELL MOL IMMUNOL, V7, P182, DOI 10.1038/cmi.2010.22
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lunyak VV, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00220
   Luo C, 2018, AGING-US, V10, P1380, DOI 10.18632/aging.101474
   Mariotti C, 2015, CELL TISSUE RES, V362, P21, DOI 10.1007/s00441-015-2185-9
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Naylor RM, 2013, CLIN PHARMACOL THER, V93, P105, DOI 10.1038/clpt.2012.193
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Olivieri F, 2013, AGE, V35, P1157, DOI 10.1007/s11357-012-9440-8
   Rajapakse D, 2017, AGING-US, V9, P2051, DOI 10.18632/aging.101299
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Rodier Francis, 2013, Methods Mol Biol, V965, P165, DOI 10.1007/978-1-62703-239-1_10
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Subhi Y, 2018, CLIN EXP OPHTHALMOL, V46, P661, DOI 10.1111/ceo.13152
   Subhi Y, 2017, AGING-US, V9, P2436, DOI 10.18632/aging.101329
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
   Zon LI, 2008, NATURE, V453, P306, DOI 10.1038/nature07038
NR 58
TC 7
Z9 7
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD NOV
PY 2018
VL 10
IS 11
BP 3173
EP 3184
DI 10.18632/aging.101624
PG 12
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA HC5OW
UT WOS:000451853300021
PM 30444724
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Xu, HP
   Chen, M
AF Xu, Heping
   Chen, Mei
TI Targeting the complement system for the management of retinal
   inflammatory and degenerative diseases
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Age-related macular degeneration; Diabetic retinopathy; Glaucoma;
   Uveoretinitis; Inflammation; Complement; Treatment
ID EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; PIGMENT EPITHELIAL-CELLS;
   MEMBRANE ATTACK COMPLEX; MACULAR DEGENERATION; IMMUNE PRIVILEGE;
   DIABETIC-RETINOPATHY; FACTOR-H; CHOROIDAL NEOVASCULARIZATION; ANTERIOR
   UVEITIS; GENE-EXPRESSION
AB The retina, an immune privileged tissue, has specialized immune defense mechanisms against noxious insults that may exist in diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), uveoretinitis and glaucoma. The defense system consists of retinal innate immune cells (including microglia, perivascular macrophages, and a small population of dendritic cells) and the complement system. Under normal aging conditions, retinal innate immune cells and the complement system undergo a low-grade activation (parainflammation) which is important for retinal homeostasis. In disease states such as AMD and DR, the parainflammatory response is dysregulated and develops into detrimental chronic inflammation. Complement activation in the retina is an important part of chronic inflammation and may contribute to retinal pathology in these disease states. Here, we review the evidence that supports the role of uncontrolled or dysregulated complement activation in various retinal degenerative and angiogenic conditions. We also discuss current strategies that are used to develop complement-based therapies for retinal diseases such as AMD. The potential benefits of complement inhibition in DR, uveoretinitis and glaucoma are also discussed, as well as the need for further research to better understand the mechanisms of complement-mediated retinal damage in these disease states. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [Xu, Heping; Chen, Mei] Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk; m.chen@qub.ac.uk
RI Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X
FU Fight for Sight [1361/1362, 1425/1426]; Diabetes UK [11/0004230,
   13/0004729]; Dunhill Medical Trust [R188/0211]; National Eye Research
   Center [SCIAD 061]; The Dunhill Medical Trust [R188/0211] Funding
   Source: researchfish; Fight for Sight [1361/62] Funding Source:
   researchfish
FX Funding support is provided by Fight for Sight (1361/1362; 1425/1426),
   Diabetes UK (11/0004230; 13/0004729), Dunhill Medical Trust (R188/0211),
   and National Eye Research Center (SCIAD 061). The authors acknowledge
   the researchers who have greatly contributed to this field, but whose
   work was not cited as a result of space limitations. The authors thank
   Daniel C. Xu (Oxford University) for critically reading the manuscript
   and for helping with English expression.
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143
   Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801
   An FQ, 2009, INVEST OPHTH VIS SCI, V50, P3778, DOI 10.1167/iovs.08-3264
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Avichezer D, 2003, J EXP MED, V198, P1665, DOI 10.1084/jem.20030413
   Bora NS, 2015, MOL IMMUNOL, V63, P176, DOI 10.1016/j.molimm.2014.07.012
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   CASPI RR, 1990, CURR EYE RES, V9, P169, DOI 10.3109/02713689008999438
   CASPI RR, 1994, J IMMUNOL, V152, P890
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2013, CURR MED CHEM, V20, P3234, DOI 10.2174/09298673113209990025
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen M, 2010, EUR J IMMUNOL, V40, P2870, DOI 10.1002/eji.201040323
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen XT, 2013, J NEUROPATH EXP NEUR, V72, P782, DOI 10.1097/NEN.0b013e31829e8375
   Cheng LJ, 2013, INVEST OPHTH VIS SCI, V54, P8191, DOI 10.1167/iovs.13-12428
   Chi ZL, 2010, ADV EXP MED BIOL, V703, P127, DOI 10.1007/978-1-4419-5635-4_9
   Chirco KR., 2015, EXP EYE RES S, V50014-4835, P30024
   Chovatiya R, 2014, MOL CELL, V54, P281, DOI 10.1016/j.molcel.2014.03.030
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2010, CLIN EXP IMMUNOL, V159, P303, DOI 10.1111/j.1365-2249.2009.04070.x
   DICK AD, 1995, BRIT J OPHTHALMOL, V79, P834, DOI 10.1136/bjo.79.9.834
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Du Y, 2013, P NATL ACAD SCI USA, V110, P16586, DOI 10.1073/pnas.1314575110
   Edwards AO, 2008, ADV EXP MED BIOL, V613, P211, DOI 10.1007/978-0-387-74904-4_24
   Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x
   Ferguson Thomas A, 2007, Chem Immunol Allergy, V92, P140, DOI 10.1159/000099265
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717
   Forrester JV, 2008, MUCOSAL IMMUNOL, V1, P372, DOI 10.1038/mi.2008.27
   Forrester JV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00338
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   FORRESTER JV, 1992, CURR EYE RES, V11, P33, DOI 10.3109/02713689208999509
   Fukuoka Y, 2001, CURR EYE RES, V23, P320, DOI 10.1076/ceyr.23.5.320.5437
   Garcia Filho C.A., 2014, RETINA, V45, P18
   GASQUE P, 1995, J IMMUNOL, V155, P4882
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Gorham RD, 2013, EXP EYE RES, V116, P96, DOI 10.1016/j.exer.2013.07.023
   Gregerson DS, 1998, OCUL IMMUNOL INFLAMM, V6, P257, DOI 10.1076/ocii.6.4.257.4029
   Gregerson DS, 2003, INVEST OPHTH VIS SCI, V44, P3083, DOI 10.1167/iovs.02-1014
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heuss ND, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0143-1
   Hillebrandt S, 2005, NAT GENET, V37, P835, DOI 10.1038/ng1599
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Horie S, 2010, CLIN IMMUNOL, V136, P83, DOI 10.1016/j.clim.2010.03.001
   Howell GR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-76
   Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Jha P, 2011, MOL IMMUNOL, V48, P2151, DOI 10.1016/j.molimm.2011.07.012
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kawazoe Y, 2012, EXP EYE RES, V94, P32, DOI 10.1016/j.exer.2011.11.002
   Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Lakkaraju A, 2014, ADV EXP MED BIOL, V801, P267, DOI 10.1007/978-1-4614-3209-8_34
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lau LI, 2011, INVEST OPHTH VIS SCI, V52, P6832, DOI 10.1167/iovs.11-7815
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Lehmann U, 2010, NEUROBIOL DIS, V40, P177, DOI 10.1016/j.nbd.2010.05.022
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Liszewski MK, 2013, IMMUNITY, V39, P1143, DOI 10.1016/j.immuni.2013.10.018
   LIVERSIDGE J, 1988, CURR EYE RES, V7, P1231, DOI 10.3109/02713688809033227
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Luo C, 2011, MOL VIS, V17, P1588
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mochizuki M, 2013, PROG RETIN EYE RES, V33, P10, DOI 10.1016/j.preteyeres.2012.10.002
   MONDINO BJ, 1984, INVEST OPHTH VIS SCI, V25, P871
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Muramatsu D, 2013, GRAEF ARCH CLIN EXP, V251, P15, DOI 10.1007/s00417-012-2024-6
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Read RW, 2006, EXP EYE RES, V82, P389, DOI 10.1016/j.exer.2005.07.011
   Reis ES, 2015, CLIN IMMUNOL, V161, P225, DOI 10.1016/j.clim.2015.08.009
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Romero-Aroca P, 2010, CLIN OPHTHALMOL, V4, P1481, DOI 10.2147/OPTH.S14521
   Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344
   Sacks SH, 2010, EUR J IMMUNOL, V40, P668, DOI 10.1002/eji.201040355
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Simo R, 2012, BRIT J OPHTHALMOL, V96, P1285, DOI 10.1136/bjophthalmol-2012-302005
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Streilein JW, 1999, PROG RETIN EYE RES, V18, P357, DOI 10.1016/S1350-9462(98)00022-6
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374
   Su HR, 1996, INT ARCH ALLERGY IMM, V110, P314, DOI 10.1159/000237322
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P2862, DOI 10.1167/iovs.08-2846
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tavazzi E, 2014, CURR HIV RES, V12, P97, DOI 10.2174/1570162X12666140526114956
   Taylor AW, 2010, ADV EXP MED BIOL, V681, P143, DOI 10.1007/978-1-4419-6354-3_12
   Taylor AW, 1996, NEUROIMMUNOMODULAT, V3, P195, DOI 10.1159/000097271
   Tezel G, 2010, INVEST OPHTH VIS SCI, V51, P5071, DOI 10.1167/iovs.10-5289
   Thompson IA, 2013, AM J OPHTHALMOL, V155, P1068, DOI 10.1016/j.ajo.2013.01.019
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Weaver DJ, 2010, EUR J IMMUNOL, V40, P710, DOI 10.1002/eji.200939333
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu DF, 2015, INVEST OPHTH VIS SCI, V56, P4954, DOI 10.1167/iovs.15-16645
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2011, INVEST OPHTH VIS SCI, V52, P249, DOI 10.1167/iovs.10-6001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Xu RN, 2010, EUR J IMMUNOL, V40, P1079, DOI 10.1002/eji.200940015
   Yang MM, 2013, BRIT J OPHTHALMOL, V97, P1475, DOI 10.1136/bjophthalmol-2013-303679
   Yang MM, 2011, MOL VIS, V17, P2655
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zhang A, 2002, DIABETES, V51, P3499
   Zhang J, 1997, INVEST OPHTH VIS SCI, V38, P1848
   Zhang L, 2015, J LEUKOC BIOL
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 126
TC 88
Z9 103
U1 2
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2016
VL 787
SI SI
BP 94
EP 104
DI 10.1016/j.ejphar.2016.03.001
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DW0EX
UT WOS:000383314800012
PM 26948311
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Lim, JI
   Niec, M
   Wong, V
AF Lim, Jennifer I.
   Niec, Marcia
   Wong, Vernon
TI One year results of a phase 1 study of the safety and tolerability of
   combination therapy using sustained release intravitreal triamcinolone
   acetonide and ranibizumab for subfoveal neovascular AMD
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; BEVACIZUMAB; CLEARANCE; EFFICACY
AB Purpose To investigate safety and evidence of efficacy of IBI-20089, an intravitreal, liquid, sustained drug delivery system formulated with triamcinolone acetonide (TA) in combination with ranibizumab (Lucentis) for neovascular age related macular degeneration.
   Methods Patients received a single intravitreal injection of IBI-20089 containing either 6.9 mg (25 mu L) TA or 13.8 mg (50 mu L) TA followed a week later by intravitreal injection of 0.5 mg ranibizumab. Patients were followed monthly and underwent best corrected visual acuity testing, slit lamp biomicroscopy, dilated ophthalmoscopy, fundus photos and optical coherence tomography. Patients received pro re nata dosing of ranibizumab.
   Results Patients ranged in age from 59 years to 81 years (mean 73.4 years) and all completed 1 year follow-up. No serious related adverse events occurred. Ocular adverse events included mild, transient, elevated intraocular pressure in eight patients and cataract progression in three of the five phakic patients. At 1 year, 30 of a total 120 (25%) possible pro re nata re-Rx's had been given. Combination therapy resulted in a median number of 3.5 re-treatments at and including month 12.
   Conclusions Combination therapy IBI-20089 and ranibizumab was well-tolerated and resulted in fewer ranibizumab retreatments. Transient intraocular pressure elevation and cataract progression occurred.
C1 [Lim, Jennifer I.; Niec, Marcia] Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Marion Schenk Esq Chair, Chicago, IL USA.
   [Wong, Vernon] Icon Biosci, Sunnyvale, CA USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; ICON plc
RP Lim, JI (通讯作者)，1855 W Taylor St,Mail Code 648, Chicago, IL 60612 USA.
EM jennylim@uic.edu
FU ICON Bioscience; NIH [Ey01972]; Research to Prevent Blindness; Marion
   Schenk Chair; NATIONAL EYE INSTITUTE [P30EY001792] Funding Source: NIH
   RePORTER
FX ICON Bioscience, NIH Core Grant Ey01972, Research to Prevent Blindness,
   Marion Schenk Chair (JIL).
CR Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lim JI, 2011, OPHTHALMOLOGY, V118, P1416, DOI 10.1016/j.ophtha.2010.12.029
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   Veritti D, 2013, J OCUL PHARMACOL TH, V29, P437, DOI 10.1089/jop.2012.0173
NR 10
TC 16
Z9 20
U1 1
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2015
VL 99
IS 5
BP 618
EP 623
DI 10.1136/bjophthalmol-2014-306002
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG5BR
UT WOS:000353305800010
PM 25376617
DA 2022-11-30
ER

PT J
AU Kanan, Y
   Al-Ubaidi, MR
AF Kanan, Y.
   Al-Ubaidi, M. R.
TI Role of tyrosine-sulfated proteins in retinal structure and function
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE tyrosine sulfation; retina; extracellular matrix; retinal diseases
ID FACTOR-H POLYMORPHISM; POSTTRANSLATIONAL MODIFICATIONS; CRE RECOMBINASE;
   O-SULFATION; MALATTIA LEVENTINESE; COMPLEMENT; BINDING; MATRIX;
   COLLAGEN; GENE
AB The extracellular matrix (ECM) plays a significant role in cellular and retinal health. The study of retinal tyrosine-sulfated proteins is an important first step toward understanding the role of ECM in retinal health and diseases. These secreted proteins are members of the retinal ECM. Tyrosine sulfation was shown to be necessary for the development of proper retinal structure and function. The importance of tyrosine sulfation is further demonstrated by the evolutionary presence of tyrosylprotein sulfotransferases, enzymes that catalyze proteins' tyrosine sulfation, and the compensatory abilities of these enzymes. Research has identified four tyrosine-sulfated retinal proteins: fibulin 2, vitronectin, complement factor H (CFH), and opticin. Vitronectin and CFH regulate the activation of the complement system and are involved in the etiology of some cases of age-related macular degeneration. Analysis of the role of tyrosine sulfation in fibulin function showed that sulfation influences the protein's ability to regulate growth and migration. Although opticin was recently shown to exhibit anti-angiogenic properties, it is not yet determined what role sulfation plays in that function. Future studies focusing on identifying all of the tyrosine-sulfated retinal proteins would be instrumental in determining the impact of sulfation on retinal protein function in retinal homeostasis and diseases. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Kanan, Y.; Al-Ubaidi, M. R.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73106 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Kanan, Y (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, 940 Stanton L Young Blvd,BMSB 781, Oklahoma City, OK 73106 USA.
EM ykanan@yahoo.com; muayyad-al-ubaidi@ouhsc.edu
FU NATIONAL EYE INSTITUTE [R01EY018137] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY018137] Funding Source: Medline
CR ANTONSSON P, 1991, J BIOL CHEM, V266, P16859
   Arruda VR, 2001, BLOOD, V97, P130, DOI 10.1182/blood.V97.1.130
   Bannert N, 2001, J EXP MED, V194, P1661, DOI 10.1084/jem.194.11.1661
   Boehncke WH, 2003, TRENDS PHARMACOL SCI, V24, P49, DOI 10.1016/S0165-6147(02)00039-1
   Bonomi M, 2006, MOL ENDOCRINOL, V20, P3351, DOI 10.1210/me.2005-0521
   Borghei A, 2006, J BIOL CHEM, V281, P9423, DOI 10.1074/jbc.M513768200
   Brower ET, 2009, BIOCHEMISTRY-US, V48, P779, DOI 10.1021/bi8021476
   Buddi R, 2002, J HISTOCHEM CYTOCHEM, V50, P341, DOI 10.1177/002215540205000306
   CHANDRASEKHAR S, 1983, P NATL ACAD SCI-BIOL, V80, P4747, DOI 10.1073/pnas.80.15.4747
   Clarke AW, 2004, EUR J BIOCHEM, V271, P3085, DOI 10.1111/j.1432-1033.2004.04246.x
   Colvin RA, 2006, MOL CELL BIOL, V26, P5838, DOI 10.1128/MCB.00556-06
   Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504
   de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6
   Dorfman T, 2006, J BIOL CHEM, V281, P28529, DOI 10.1074/jbc.M602732200
   DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fang M, 2012, PROTEIN CELL, V3, P419, DOI 10.1007/s13238-012-2917-5
   FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   FESSLER LI, 1986, J BIOL CHEM, V261, P5034
   Fu SH, 2014, MOL VIS, V20, P480
   Gu YC, 2000, BRIT J HAEMATOL, V109, P305, DOI 10.1046/j.1365-2141.2000.02011.x
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HIROSE S, 1988, J BIOL CHEM, V263, P7426
   HORTIN GL, 1990, BLOOD, V76, P946
   JUKKOLA A, 1986, EUR J BIOCHEM, V154, P219, DOI 10.1111/j.1432-1033.1986.tb09382.x
   Kanan Y., 2014, J BIOL CHEM IN PRESS
   Kanan Y., 2014, PLOS ONE IN PRESS
   Kanan Y, 2012, ADV EXP MED BIOL, V723, P835, DOI 10.1007/978-1-4614-0631-0_107
   Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kraemer S, 2013, CURR MED CHEM, V20, P2524, DOI 10.2174/09298673113209990117
   Le Goff MM, 2012, J BIOL CHEM, V287, P28027, DOI 10.1074/jbc.M111.331157
   Le Goff MM, 2012, INVEST OPHTH VIS SCI, V53, P228, DOI 10.1167/iovs.11-8514
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Le YZ, 2006, ADV EXP MED BIOL, V572, P173
   Le YZ, 2006, MOL VIS, V12, P389
   LEYTE A, 1991, J BIOL CHEM, V266, P740
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   Meh DA, 2001, THROMB HAEMOSTASIS, V85, P470
   Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769
   Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200
   Morin R, 2006, BIOMACROMOLECULES, V7, P131, DOI 10.1021/bm050461i
   Nibbs RJB, 2013, NAT REV IMMUNOL, V13, P815, DOI 10.1038/nri3544
   NIEHRS C, 1992, EUR J CELL BIOL, V58, P35
   NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x
   Nishimura Y, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001174
   Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255
   Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200
   Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200
   Ouyang YB, 2002, J BIOL CHEM, V277, P23781, DOI 10.1074/jbc.M202420200
   Pacher P, 2005, CURR MED CHEM, V12, P267, DOI 10.2174/0929867053363207
   Pauleikhoff D, 1992, Ophthalmologe, V89, P39
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89
   Rapp C, 2013, PROTEIN SCI, V22, P1025, DOI 10.1002/pro.2288
   Rodgers SD, 2001, BIOPHYS J, V81, P2001, DOI 10.1016/S0006-3495(01)75850-X
   Sasaki T, 1999, FEBS LETT, V460, P280, DOI 10.1016/S0014-5793(99)01362-9
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Schuppan D, 1998, GASTROENTEROLOGY, V114, P139, DOI 10.1016/S0016-5085(98)70642-0
   Sherry DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039702
   Sherry DM, 2010, EUR J NEUROSCI, V32, P1461, DOI 10.1111/j.1460-9568.2010.07431.x
   Simpson LS, 2009, CHEM BIOL, V16, P153, DOI 10.1016/j.chembiol.2008.12.007
   SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Stone MJ, 2009, NEW BIOTECHNOL, V25, P299, DOI 10.1016/j.nbt.2009.03.011
   Suiko M, 1992, Nucleic Acids Symp Ser, P183
   Tan JHY, 2013, J BIOL CHEM, V288, P10024, DOI 10.1074/jbc.M112.447359
   Trask BC, 2001, BIOCHEMISTRY-US, V40, P4372, DOI 10.1021/bi002738z
   Ueki Y, 2009, VISION RES, V49, P615, DOI 10.1016/j.visres.2009.01.012
   Utomo ARH, 1999, NAT BIOTECHNOL, V17, P1091, DOI 10.1038/15073
   Veldkamp CT, 2006, J MOL BIOL, V359, P1400, DOI 10.1016/j.jmb.2006.04.052
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Weigell-Weber M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1184, DOI 10.1001/archopht.121.8.1184
   Werneck CC, 2004, J BIOL CHEM, V279, P23045, DOI 10.1074/jbc.M402656200
   Westmuckett AD, 2008, GEN COMP ENDOCR, V156, P145, DOI 10.1016/j.ygcen.2007.12.006
   Westmuckett AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020406
   Wolfender JL, 1999, J MASS SPECTROM, V34, P447, DOI 10.1002/(SICI)1096-9888(199904)34:4<447::AID-JMS801>3.0.CO;2-1
   Woods AS, 2007, J PROTEOME RES, V6, P1176, DOI 10.1021/pr060529g
   Zhu JZ, 2011, BIOCHEMISTRY-US, V50, P1524, DOI 10.1021/bi101240v
   Zhu L, 2013, CURR OPIN STRUC BIOL, V23, P539, DOI 10.1016/j.sbi.2013.05.003
NR 85
TC 2
Z9 4
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2015
VL 133
SI SI
BP 126
EP 131
DI 10.1016/j.exer.2014.07.007
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CF8PO
UT WOS:000352824600012
PM 25819460
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Klettner, A
   Tahmaz, N
   Dithmer, M
   Richert, E
   Roider, J
AF Klettner, Alexa
   Tahmaz, Nihat
   Dithmer, Michaela
   Richert, Elisabeth
   Roider, Johann
TI Effects of aflibercept on primary RPE cells: toxicity, wound healing,
   uptake and phagocytosis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; VEGF TRAP; IN-VITRO;
   RANIBIZUMAB; BEVACIZUMAB; THERAPY; MODEL
AB Background/aim Anti-VEGF treatment is the therapy of choice in age-related macular degeneration, and is also applied in diabetic macular oedema or retinal vein occlusion. Recently, the fusion protein, aflibercept, has been approved for therapeutic use. In this study, we investigate the effects of aflibercept on primary RPE cells.
   Methods Primary RPE cells were prepared from freshly slaughtered pigs' eyes. The impact of aflibercept on cell viability was investigated with MTT and trypan blue exclusion assay. The influence of aflibercept on wound healing was assessed with a scratch assay. Intracellular uptake of aflibercept was investigated in immunohistochemistry and its influence on phagocytosis with a phagocytosis assay using opsonised latex beads.
   Results Aflibercept displays no cytotoxicity on RPE cells but impairs its wound healing ability. It is taken up into RPE cells and can be intracellularly detected for at least 7 days. Intracellular aflibercept impairs the phagocytic capacity of RPE cells.
   Conclusions Aflibercept interferes with the physiology of RPE cells, as it is taken up into RPE cells, which is accompanied by a reduction of the phagocytic ability. Additionally, it impairs the wound healing capacity of RPE cells. These effects on the physiology of RPE cells may indicate possible side effects.
C1 [Klettner, Alexa; Tahmaz, Nihat; Dithmer, Michaela; Richert, Elisabeth; Roider, Johann] Univ Kiel, Dept Ophthalmol, Univ Med Ctr, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Kiel, Dept Ophthalmol, Univ Med Ctr, Arnold Heller Str 3, D-24105 Kiel, Germany.
EM aklettner@auge.uni-kiel.de
RI Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059
FU Novartis
FX This research was financially supported by a Novartis research grant.
CR Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Ammar DA, 2013, RETINA-J RET VIT DIS, V33, P1056, DOI 10.1097/IAE.0b013e31827b646d
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cox D, 2001, SEMIN IMMUNOL, V13, P339, DOI 10.1006/smim.2001.0330
   Deissler HL, 2012, BRIT J OPHTHALMOL, V96, P1023, DOI 10.1136/bjophthalmol-2012-301677
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hillenkamp J, 2010, RETINA-J RET VIT DIS, V30, P1685, DOI 10.1097/IAE.0b013e3181d87eb4
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2011, OPHTHALMIC RES, V46, P88, DOI 10.1159/000323271
   Klettner A, 2010, CUTAN OCUL TOXICOL, V29, P122, DOI 10.3109/15569521003745685
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Lassoued W, 2010, CANCER BIOL THER, V10, P1326, DOI 10.4161/cbt.10.12.14009
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mustafi D, 2011, FASEB J, V25, P3157, DOI 10.1096/fj.11-186767
   Nandrot EF, 2010, ADV EXP MED BIOL, V664, P133, DOI 10.1007/978-1-4419-1399-9_16
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
NR 27
TC 38
Z9 38
U1 0
U2 9
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2014
VL 98
IS 10
BP 1448
EP 1452
DI 10.1136/bjophthalmol-2014-305105
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ3HF
UT WOS:000342681400030
PM 25034050
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Liu, ZP
   Yu, N
   Holz, FG
   Yang, F
   Stanzel, BV
AF Liu, Zengping
   Yu, Na
   Holz, Frank G.
   Yang, Fang
   Stanzel, Boris V.
TI Enhancement of retinal pigment epithelial culture characteristics and
   subretinal space tolerance of scaffolds with 200 nm fiber topography
SO BIOMATERIALS
LA English
DT Article
DE Biocompatibility; Cell culture; Epithelium cell; Scaffold; Surface
   topography; Retina
ID HUMAN BRUCHS MEMBRANE; TISSUE ENGINEERING APPLICATIONS; ANTERIOR LENS
   CAPSULE; STEM-CELL; MACULAR DEGENERATION; POLYMERIC NANOFIBERS; RPE
   TRANSPLANTATION; IN-VITRO; DETACHMENT; ADHESION
AB Tissue engineered retinal pigment epithelial (RPE) transplantation is a promising cell-based therapy for age-related macular degeneration. The aim of this work is to develop a supportive scaffold with a favorable topography to aid functional RPE monolayer maintenance while being tolerated underneath the retina. To this end, films and electrospun substrates with fiber diameters ranging from 200 to 1000 nm were made of polyethylene terephthalate or poly(L-lactide-co-epsilon-caprolactone), and then tested using human fetal RPE cells in vitro and transplanted subretinally in rabbits. The results indicated that RPE on both 200 nm fiber variants showed the highest cell densities, adherent monolayers achieved deeper pigmentation, and more uniform hexagonal tight junctions. Facile subretinal implantation of flat 200 nm fiber membranes was achieved by electrospinning them onto a porous rigid-elastic carrier. Spectral-domain optical coherence tomography showed a reattached, slightly thinned retina overlying the implants over 2 weeks observation. Histology demonstrated native RPE variably migrated onto the nanofibers, and a reactive gliosis with some photoreceptor degeneration. In conclusion, scaffolds with 200 nm fiber topography enhanced RPE culture, showed subretinal biocompatibility, and should thus be considered for future cell-based therapies in blinding retinal diseases. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Liu, Zengping; Holz, Frank G.; Stanzel, Boris V.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Yu, Na; Yang, Fang] Radboud Univ Nijmegen, Med Ctr, Dept Biomat, NL-6525 ED Nijmegen, Netherlands.
C3 University of Bonn; Radboud University Nijmegen
RP Stanzel, BV (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM stanzel@uni-bonn.de
RI Liu, Zengping/GQO-9030-2022; Stanzel, Boris/AAG-7010-2022; Stanzel,
   Boris/ADP-9221-2022; Yang, Fang/E-1937-2011
OI Stanzel, Boris/0000-0002-4316-1539; Stanzel, Boris/0000-0002-4316-1539;
   Yang, Fang/0000-0002-4022-7643; Liu, Zengping/0000-0002-2578-293X
FU Dr. Ruediger Foundation, Frankfurt/Germany; Gerok/BONFOR funds of the
   University of Bonn/Germany [O-137.0015]; Chinese Scholarship Council
   [2008627116, 2008627114]
FX This study was funded by Dr. Ruediger Foundation, Frankfurt/Germany and
   Gerok/BONFOR funds of the University of Bonn/Germany (O-137.0015) to
   BVS. ZL and NY received funding by the Chinese Scholarship Council (No.
   2008627116 and 2008627114). This study was presented in parts at XX.
   Biennial Meeting of the International Society for Eye Research (ISER),
   Berlin, Germany, 22-27 July 2012; 3rd TERNS World Congress 2012 "Tissue
   Engineering and Regenerative Medicine", Vienna, Austria, 5-8 September
   2012; the Annual Meeting of the Association for Research in Vision and
   Ophthalmology (ARVO), Seattle, WA, USA, 5-9 May 2013 and the 18th
   Congress of Chinese Ophthalmological Society (CCOS), Xiamen, China,
   13-17 September 2013. The authors are grateful to Claudine Strack for
   her technical assistance and J. Bedorf at the Institute of Pathology,
   University of Bonn was very helpful in obtaining transmission electron
   micrographs. We thank Prof. B. Fleischmann, Dept. of Physiology,
   University of Bonn for kindly enabling access to the Zeiss Apotome
   Fluorescence microscope.
CR ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   Babaeijandaghi F, 2010, TISSUE ENG PT A, V16, P3527, DOI [10.1089/ten.tea.2009.0829, 10.1089/ten.TEA.2009.0829]
   Berglin L, 1997, GRAEF ARCH CLIN EXP, V235, P306, DOI 10.1007/BF01739640
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Buttafoco L, 2006, BIOMATERIALS, V27, P724, DOI 10.1016/j.biomaterials.2005.06.024
   Butterwick A, 2009, EXP EYE RES, V88, P22, DOI 10.1016/j.exer.2008.09.018
   Cereda MG, 2010, GRAEF ARCH CLIN EXP, V248, P37, DOI 10.1007/s00417-009-1201-8
   Chen M, 2007, TISSUE ENG, V13, P579, DOI 10.1089/ten.2006.0205
   Christopherson GT, 2009, BIOMATERIALS, V30, P556, DOI 10.1016/j.biomaterials.2008.10.004
   Cranford SW, 2013, ADV MATER, V25, P802, DOI 10.1002/adma.201202553
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Ediriwickrema LS, 2012, INVEST OPHTHALMOL VI, V53
   Engelmann K, 2004, GRAEF ARCH CLIN EXP, V242, P65, DOI 10.1007/s00417-003-0811-9
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Herrmann P, 2013, OPHTHALMOLOGE, V110, P377, DOI 10.1007/s00347-012-2779-5
   Hu J, 2001, MOL VIS, V7, P14
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Kearns V, 2012, J MATER SCI-MATER M, V23, P2013, DOI 10.1007/s10856-012-4675-6
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   Kumbar SG, 2006, J NANOSCI NANOTECHNO, V6, P2591, DOI 10.1166/jnn.2006.462
   Lewis GP, 2010, MOL VIS, V16, P1361
   Li Yunping, 2012, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V37, P433, DOI 10.3969/j.issn.1672-7347.2012.05.001
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lim JM, 2004, INVEST OPHTH VIS SCI, V45, P4210, DOI 10.1167/iovs.03-1036
   Lim JY, 2007, TISSUE ENG, V13, P1879, DOI 10.1089/ten.2006.0154
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Ma ZW, 2005, BIOMATERIALS, V26, P2527, DOI 10.1016/j.biomaterials.2004.07.026
   McHugh KJ, 2013, J BIOMED MATER RES B, DOI DOI 10.1002/JBM.B.32968.AVAILABLE
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Okuda T, 2009, J GLAUCOMA, V18, P220, DOI 10.1097/IJG.0b013e31817eee32
   Pham QP, 2006, TISSUE ENG, V12, P1197, DOI 10.1089/ten.2006.12.1197
   Pritchard CD, 2010, BIOMATERIALS, V31, P2153, DOI 10.1016/j.biomaterials.2009.11.074
   Quester R, 2003, BIOMATERIALS, V24, P711, DOI 10.1016/S0142-9612(02)00320-4
   Rak DJ, 2006, EXP EYE RES, V82, P648, DOI 10.1016/j.exer.2005.09.002
   Regatieri CV, 2012, INVEST OPHTHALMOL VI, V53
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Schindler M, 2005, BIOMATERIALS, V26, P5624, DOI 10.1016/j.biomaterials.2005.02.014
   Schwahn HN, 2001, GRAEF ARCH CLIN EXP, V239, P961, DOI 10.1007/s004170100368
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seiler MJ, 1998, INVEST OPHTH VIS SCI, V39, P2121
   Shang SH, 2010, EUR CELLS MATER, V19, P180, DOI 10.22203/eCM.v019a18
   Sharma S, 2011, MOL VIS, V17, P2898
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Stanzel BV, 2007, SPEKTRUM AUGENHEILKD, V21, P212, DOI 10.1007/s00717-007-0213-1
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Szurman P, 2006, INVEST OPHTH VIS SCI, V47, P4983, DOI 10.1167/iovs.06-0491
   Tezcaner A, 2003, BIOMATERIALS, V24, P4573, DOI 10.1016/S0142-9612(03)00302-8
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Thieltges F, 2011, OPHTHALMIC RES, V46, P133, DOI 10.1159/000324045
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   Treharne AJ, 2011, BRIT J OPHTHALMOL, V95, P768, DOI 10.1136/bjo.2010.184002
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Xie J, 2010, J BIOMED MATER RES B, V94B, P80, DOI 10.1002/jbm.b.31627
   Yang F, 2005, BIOMATERIALS, V26, P2603, DOI 10.1016/j.biomaterials.2004.06.051
   Yang F, 2009, ACTA BIOMATER, V5, P3295, DOI 10.1016/j.actbio.2009.05.023
   Zajicova A, 2010, CELL TRANSPLANT, V19, P1281, DOI 10.3727/096368910X509040
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 71
TC 64
Z9 67
U1 3
U2 55
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2014
VL 35
IS 9
BP 2837
EP 2850
DI 10.1016/j.biomaterials.2013.12.069
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA AC0MH
UT WOS:000332188900027
PM 24439407
DA 2022-11-30
ER

PT J
AU Kawa, MP
   Machalinska, A
   Roginska, D
   Machalinski, B
AF Kawa, Milosz P.
   Machalinska, Anna
   Roginska, Dorota
   Machalinski, Boguslaw
TI Complement System in Pathogenesis of AMD: Dual Player in Degeneration
   and Protection of Retinal Tissue
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Review
ID PIGMENT EPITHELIAL-CELLS; AGE-RELATED MACULOPATHY; ANAPHYLATOXIN C5A
   NEUROPROTECTS; COMPONENT 2 C2; FACTOR-B BF; MACULAR DEGENERATION;
   FACTOR-H; CHOROIDAL NEOVASCULARIZATION; DRUSEN FORMATION; BRUCHS
   MEMBRANE
AB Age-related macular degeneration (AMD) is the most common cause of blindness among the elderly, especially in Western countries. Although the prevalence, risk factors, and clinical course of the disease are well described, its pathogenesis is not entirely elucidated. AMD is associated with a variety of biochemical abnormalities, including complement components deposition in the retinal pigment epithelium-Bruch's membrane-choriocapillaris complex. Although the complement system (CS) is increasingly recognized as mediating important roles in retinal biology, its particular role in AMD pathogenesis has not been precisely defined. Unrestricted activation of the CS following injury may directly damage retinal tissue and recruit immune cells to the vicinity of active complement cascades, therefore detrimentally causing bystander damage to surrounding cells and tissues. On the other hand, recent evidence supports the notion that an active complement pathway is a necessity for the normal maintenance of the neurosensory retina. In this scenario, complement activation appears to have beneficial effect as it promotes cell survival and tissue remodeling by facilitating the rapid removal of dying cells and resulting cellular debris, thus demonstrating anti-inflammatory and neuroprotective activities. In this review, we discuss both the beneficial and detrimental roles of CS in degenerative retina, focusing on the diverse aspects of CS functions that may promote or inhibit macular disease.
C1 [Kawa, Milosz P.; Roginska, Dorota; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna] Pomeranian Med Univ, Dept Ophthalmol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna] Pomeranian Med Univ, Dept Histol & Embryol, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University
RP Machalinski, B (通讯作者)，Pomeranian Med Univ, Dept Gen Pathol, Al Powstancow Wlkp 72, PL-70111 Szczecin, Poland.
EM machalin@pum.edu.pl
RI Kawa, Milosz/O-7715-2014; Machaliński, Bogusław/P-3025-2014; Rogińska,
   Dorota/B-4424-2016; Machalinska, Anna/P-6701-2014
OI Rogińska, Dorota/0000-0001-8884-837X; Machalinski,
   Boguslaw/0000-0002-6013-0419
FU National Science Center [2012/06/M/NZ4/00133]
FX This work was supported by the National Science Center Grant no.
   2012/06/M/NZ4/00133 (to B. Machalinski).
CR An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Benoit ME, 2011, J NEUROSCI, V31, P3459, DOI 10.1523/JNEUROSCI.3932-10.2011
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Cashman SM, 2011, INVEST OPHTH VIS SCI, V52, P3436, DOI 10.1167/iovs.10-6002
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dinu V, 2007, GENET EPIDEMIOL, V31, P224, DOI 10.1002/gepi.20204
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2008, OPHTHALMOLOGY, V115, P1786, DOI 10.1016/j.ophtha.2008.04.006
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heese K, 1998, J NEUROCHEM, V70, P699
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hila S, 2001, GLIA, V36, P58, DOI 10.1002/glia.1095
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Ingersoll SA, 2010, MOL IMMUNOL, V48, P219, DOI 10.1016/j.molimm.2010.08.007
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Janeway Jr C.A., 2001, IMMUNOBIOLOGY IMMUNE, V5th
   Jauneau AC, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-8
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kastl SP, 2006, J THROMB HAEMOST, V4, P1790, DOI 10.1111/j.1538-7836.2006.02046.x
   Kaur I, 2010, INVEST OPHTH VIS SCI, V51, P59, DOI 10.1167/iovs.09-4135
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kociok N, 2010, GRAEF ARCH CLIN EXP, V248, P1145, DOI 10.1007/s00417-010-1371-4
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Liu JB, 2008, J IMMUNOL, V180, P5882, DOI 10.4049/jimmunol.180.9.5882
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martin CB, 2007, MOL IMMUNOL, V44, P703, DOI 10.1016/j.molimm.2006.04.017
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x
   Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1
   Mukherjee P, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-5
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Narendra U, 2009, MOL VIS, V15, P731
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okamoto H, 2006, MOL VIS, V12, P156
   Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.3.CO;2-U
   Peng Q, 2009, J IMMUNOL, V183, P6058, DOI 10.4049/jimmunol.0804186
   Peter I, 2011, AM J OPHTHALMOL, V152, P1005, DOI 10.1016/j.ajo.2011.05.016
   Pisalyaput K, 2008, J NEUROCHEM, V104, P696, DOI 10.1111/j.1471-4159.2007.05012.x
   Rahpeymai Y, 2006, EMBO J, V25, P1364, DOI 10.1038/sj.emboj.7601004
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Rus HG, 1996, J IMMUNOL, V156, P4892
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Shinjyo N, 2009, STEM CELLS, V27, P2824, DOI 10.1002/stem.225
   Soane L, 1999, J IMMUNOL, V163, P6132
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Strainic MG, 2008, IMMUNITY, V28, P425, DOI 10.1016/j.immuni.2008.02.001
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takabayashi T, 1998, J INFECT DIS, V177, P1622, DOI 10.1086/515316
   Takabayashi T, 1996, J IMMUNOL, V156, P3455
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thurman JM, 2007, J IMMUNOL, V178, P1819, DOI 10.4049/jimmunol.178.3.1819
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Van Beek J, 2003, ANN NY ACAD SCI, V992, P56
   van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Ward PA, 2009, J MOL MED, V87, P375, DOI 10.1007/s00109-009-0442-7
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 112
TC 38
Z9 46
U1 0
U2 11
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2014
VL 2014
AR 483960
DI 10.1155/2014/483960
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA AS2HA
UT WOS:000344099200001
PM 25276841
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Dong, ZY
   Noda, K
   Kanda, A
   Fukuhara, J
   Ando, R
   Murata, M
   Saito, W
   Hagiwara, M
   Ishida, S
AF Dong, Zhenyu
   Noda, Kousuke
   Kanda, Atsuhiro
   Fukuhara, Junichi
   Ando, Ryo
   Murata, Miyuki
   Saito, Wataru
   Hagiwara, Masatoshi
   Ishida, Susumu
TI Specific inhibition of serine/arginine-rich protein kinase attenuates
   choroidal neovascularization
SO MOLECULAR VISION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL TEARS; MACULAR
   DEGENERATION; BEVACIZUMAB TREATMENT; ANGIOGENIC ISOFORMS; NUCLEAR
   SPECKLES; FACTOR VEGF; RANIBIZUMAB; INJECTION; REPLICATION
AB Purpose: To investigate the applicability of serine/arginine-rich protein kinase (SRPK)-specific inhibitor, SRPIN340, for attenuation of choroidal neovascularization (CNV) formation using a mouse model.
   Methods: Laser photocoagulation was performed to induce CNV in C57BL/'6J mice, followed by intravitreal injection of SRPIN340 or vehicle. Seven days after the treatment, the CNV size was evaluated using a flatmount technique. Protein levels of vascular endothelial growth factor (VEGF) and inflammation-associated molecules, such as monocyte chemoattractant protein (MCP)-1 and intercellular adhesion molecule (ICAM)-1, in the retinal pigment epithelium-choroid complex were measured with enzyme-linked immunosorbent assay. Expression levels of total Vegf, exon 8a-containing Vegf isoforms, and F4/80 (a specific marker for macrophage) were assessed using real-time PCR.
   Results: SRPIN340 inhibited CNV formation in a dose-dependent manner. Compared with the vehicle, SRPIN340 significantly decreased the protein levels of VEGF, MCP-1, ICAM-1, and consequently inhibited macrophage infiltration. Furthermore, SRPIN340 suppressed the gene expression levels of total Vegf and exon 8a-containing Vegf isoforms.
   Conclusions: SRPIN340, a specific inhibitor of SRPK, suppressed Vegf expression and attenuated CNV formation. Our data suggest the possibility that SRPIN340 is applicable for neovascular age-related macular degeneration as a novel chemical therapeutics.
C1 [Dong, Zhenyu; Noda, Kousuke; Kanda, Atsuhiro; Fukuhara, Junichi; Ando, Ryo; Murata, Miyuki; Saito, Wataru; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Sapporo, Hokkaido 0608638, Japan.
   [Dong, Zhenyu; Noda, Kousuke; Kanda, Atsuhiro; Fukuhara, Junichi; Ando, Ryo; Murata, Miyuki; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Lab Ocular Cell Biol & Visual Sci, Sapporo, Hokkaido 0608638, Japan.
   [Hagiwara, Masatoshi] Kyoto Univ, Grad Sch Med, Dept Anat & Dev Biol, Kyoto, Japan.
C3 Hokkaido University; Hokkaido University; Kyoto University
RP Noda, K (通讯作者)，Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Kita Ku, N7,W15, Sapporo, Hokkaido 0608638, Japan.
EM nodako@med.hokudai.ac.jp
OI Saito, Wataru/0000-0001-8181-6252
FU Advanced research for medical products Mining Programme of the National
   Institute of Biomedical Innovation (NIBIO); Japan Society for the
   Promotion of Science [23, 592, 547]
FX The authors thank Ikuyo Hirose and Shiho Namba for their skillful
   technical assistance. This study was supported by the Advanced research
   for medical products Mining Programme of the National Institute of
   Biomedical Innovation (NIBIO) and Grant-in-Aid for Scientific Research
   (C; 23,592,547) of the Japan Society for the Promotion of Science.
CR Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016
   AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013
   Bakkour N, 2007, PLOS PATHOG, V3, P1530, DOI 10.1371/journal.ppat.0030159
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9
   Cunningham ET, 2011, OPHTHALMOLOGY, V118, P2447, DOI 10.1016/j.ophtha.2011.05.026
   Fukuhara T, 2006, P NATL ACAD SCI USA, V103, P11329, DOI 10.1073/pnas.0604616103
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Ishida S, 2003, NAT MED, V9, P781, DOI 10.1038/nm877
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Karakama Y, 2010, ANTIMICROB AGENTS CH, V54, P3179, DOI 10.1128/AAC.00113-10
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410
   Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40
   Schumacher VA, 2007, J AM SOC NEPHROL, V18, P719, DOI 10.1681/ASN.2006020124
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tripathi V, 2012, MOL BIOL CELL, V23, P3694, DOI 10.1091/mbc.E12-03-0206
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308
   Verheul HMW, 2007, NAT REV CANCER, V7, P475, DOI 10.1038/nrc2152
   Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117
   Zhong XY, 2009, GENE DEV, V23, P482, DOI 10.1101/gad.1752109
NR 37
TC 12
Z9 13
U1 0
U2 8
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 5
PY 2013
VL 19
BP 536
EP 543
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 110BD
UT WOS:000316416100001
PM 23559848
DA 2022-11-30
ER

PT J
AU Gao, BX
   Zhu, L
   Pan, YZ
   Yang, SW
   Zhang, LX
   Wang, HY
AF Gao, Bixia
   Zhu, Ling
   Pan, Yingzi
   Yang, Shuwen
   Zhang, Luxia
   Wang, Haiyan
TI Ocular fundus pathology and chronic kidney disease in a Chinese
   population
SO BMC NEPHROLOGY
LA English
DT Article
ID RETINAL MICROVASCULAR ABNORMALITIES; GLOMERULAR-FILTRATION-RATE; MACULAR
   DEGENERATION; VISUAL IMPAIRMENT; ADULTS; RISK; ASSOCIATIONS; STROKE; EYE
AB Background: Previous study indicated a high prevalence of ocular fundus pathology among patients with chronic kidney disease (CKD), while the relationship between them has never been explored in a Chinese Population.
   Methods: This cross-sectional study included 9 670 participants enrolled in a medical screening program. Ocular fundus examination was performed by ophthalmologists using ophthalmoscopes. The presence of eGFR less than 60 mL/min/1.73 m(2) and/or proteinuria was defined as CKD.
   Results: Compared to participants without CKD, participants with CKD had higher prevalence of retinopathy (28.5% vs. 16.3%, P < 0.001), glaucoma suspect (3.1% vs. 1.8%, P = 0.004), age-related macular degeneration (1.7% vs. 0.9%, P = 0.01) and overall eye pathology (32.0% vs. 19.4%, P < 0.001). After adjusting for potential confounders, the odds ratio of proteinuria for overall eye pathology and retinopathy was 1.29 (95% confidence interval [CI] 1.07-1.55) and 1.37 (95% CI 1.12-1.67), respectively. The results were robust after excluding participants with hypertension or with diabetes.
   Conclusions: Ocular fundus pathology is common among Chinese patients with CKD. Regular eye exam among persons with proteinuria is warranted.
C1 [Gao, Bixia; Zhang, Luxia; Wang, Haiyan] Peking Univ, Hosp 1, Dept Med, Div Renal, Beijing, Peoples R China.
   [Gao, Bixia; Zhang, Luxia; Wang, Haiyan] Peking Univ, Inst Nephrol, Key Lab Renal Dis, Minist Hlth China, Beijing, Peoples R China.
   [Gao, Bixia; Zhang, Luxia; Wang, Haiyan] Peking Univ, Minist Educ, Key Lab Chron Kidney Dis Prevent & Treatment, Beijing, Peoples R China.
   [Zhu, Ling; Yang, Shuwen] Beijing Hosp, Phys Examinat Ctr, Beijing, Peoples R China.
   [Pan, Yingzi] Peking Univ, Hosp 1, Div Ophthalmol, Beijing 100871, Peoples R China.
C3 Peking University; Peking University; Peking University; Beijing
   Hospital; Peking University
RP Zhang, LX (通讯作者)，Peking Univ, Hosp 1, Dept Med, Div Renal, Beijing, Peoples R China.
EM zhanglx@bjmu.edu.cn
FU China Health and Medical Development Foundation; Ministry of Education
   of the People's Republic of China [BMU2009131]; Beijing Municipal
   Science and Technology Commission [2006B05]
FX This study was funded by the China Health and Medical Development
   Foundation, the Program for New Century Excellent Talents in University
   (BMU2009131) from the Ministry of Education of the People's Republic of
   China, and the Beijing NOVA program (2006B05) from the Beijing Municipal
   Science and Technology Commission.
CR ALDINGTON SJ, 1995, DIABETOLOGIA, V38, P437, DOI 10.1007/BF00410281
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards MS, 2005, AM J KIDNEY DIS, V46, P214, DOI 10.1053/j.ajkd.2005.05.005
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Grunwald JE, 2010, CLIN J AM SOC NEPHRO, V5, P867, DOI 10.2215/CJN.08271109
   KEITH NM, 1974, AM J MED SCI, V268, P336, DOI 10.1097/00000441-197412000-00004
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Liew G, 2008, J AM SOC NEPHROL, V19, P806, DOI 10.1681/ASN.2007080844
   Matsushita K, 2010, LANCET, V375, P2073, DOI 10.1016/S0140-6736(10)60674-5
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Nongpiur ME, 2010, OPHTHALMOLOGY, V117, P477, DOI 10.1016/j.ophtha.2009.07.029
   Sabanayagam C, 2009, AM J EPIDEMIOL, V169, P625, DOI 10.1093/aje/kwn367
   Tamura MK, 2008, AM J KIDNEY DIS, V52, P227, DOI 10.1053/j.ajkd.2008.05.004
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong TY, 2004, J AM SOC NEPHROL, V15, P2469, DOI 10.1097/01.ASN.0000136133.28194.E4
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
NR 18
TC 20
Z9 20
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD NOV 17
PY 2011
VL 12
AR 62
DI 10.1186/1471-2369-12-62
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 946QU
UT WOS:000304369500001
PM 22093232
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pakneshan, P
   Birsner, AE
   Adini, I
   Becker, CM
   D'Amato, RJ
AF Pakneshan, Pouya
   Birsner, Amy E.
   Adini, Irit
   Becker, Christian M.
   D'Amato, Robert J.
TI Differential suppression of vascular permeability and corneal
   angiogenesis by nonsteroidal anti-inflammatory drugs
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR EXPRESSION; TUMOR-GROWTH;
   PROSTAGLANDIN E-2; CANCER; CYCLOOXYGENASE-2; INHIBITION; INDUCTION;
   THALIDOMIDE; MECHANISMS
AB PURPOSE. Angiogenesis, the formation of new capillary blood vessels, is an essential biological process under physiological conditions, including embryonic development, reproduction, and wound repair. Under pathologic conditions, this process plays a critical role in a variety of diseases such as cancer, rheumatoid arthritis, atherosclerosis, endometriosis, diabetic retinopathy, and age-related macular degeneration. The purpose of this study was to examine the effects of cyclooxygenase inhibitors on basic fibroblast growth factor (bFGF)- and vascular endothelial growth factor (VEGF) - mediated ocular neovascularization and permeability.
   METHODS. A modified Miles vascular permeability assay was used to examine VEGF-induced vascular hyperpermeability, and the mouse corneal model of angiogenesis was used to compare the efficacy of systemic treatment with different nonsteroidal anti-inflammatory drugs ( NSAIDs) on bFGF- and VEGF-induced angiogenesis.
   RESULTS. The authors demonstrated that systemic application of most NSAIDs, but not acetaminophen, blocked VEGF-induced permeability in mice. However, systemic treatment of mice with NSAIDs resulted in the differential inhibition of bFGF-induced (5%-57%) and VEGF-induced (3%-66%) corneal angiogenesis. The selective COX-2 inhibitors were more effective at suppressing bFGF- induced angiogenesis than VEGF-induced angiogenesis.
   CONCLUSIONS. Though most NSAIDS are effective at suppressing vascular leak, there exists a differential efficacy at suppressing the angiogenic response of specific cytokines such as bFGF and VEGF.
C1 [Pakneshan, Pouya; Adini, Irit; Becker, Christian M.; D'Amato, Robert J.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
   [D'Amato, Robert J.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   [Birsner, Amy E.] Childrens Hosp Boston, Vasc Biol Program, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University; Harvard
   Medical School; Harvard University; Boston Children's Hospital
RP D'Amato, RJ (通讯作者)，Childrens Hosp Boston, Karp Family Res Labs, 1 Blackfan Circle, Boston, MA 02115 USA.
EM robert.damato@childrens.harvard.edu
FU Sidney A. Swensrud Foundation; National Institutes of Health
   [R01-EY12726]; Canadian Institute of Health Research; Max Kade
   Foundation; MRC [G0601458] Funding Source: UKRI; Medical Research
   Council [G0601458] Funding Source: researchfish
FX Supported by grants from the Sidney A. Swensrud Foundation and by
   National Institutes of Health Grant R01-EY12726 (RJD). PP was supported
   by fellowship award from the Canadian Institute of Health Research. CMB
   was supported by a postdoctoral research exchange grant from the Max
   Kade Foundation.
CR Applebaum H, 2005, J PEDIATR SURG, V40, P999, DOI 10.1016/j.jpedsurg.2005.03.016
   Ayalasomayajula SP, 2003, EUR J PHARMACOL, V458, P283, DOI 10.1016/S0014-2999(02)02793-0
   Carmeliet P, 1999, NATURE, V401, P657, DOI 10.1038/44304
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Claffey KP, 1996, CANCER RES, V56, P172
   COLLINS PD, 1993, BRIT J PHARMACOL, V109, P195, DOI 10.1111/j.1476-5381.1993.tb13553.x
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225
   DiBiasie A, 2006, NEONATAL NETW, V25, P393, DOI 10.1891/0730-0832.25.6.393
   Efstathiou JA, 2005, FERTIL STERIL, V83, P171, DOI 10.1016/j.fertnstert.2004.06.058
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   FORM DM, 1983, P SOC EXP BIOL MED, V172, P214
   Fosslien E, 2001, ANN CLIN LAB SCI, V31, P325
   FULTON AM, 1984, CANCER RES, V44, P2416
   Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jones MK, 1999, NAT MED, V5, P1418
   Jubb AM, 2006, NAT REV CANCER, V6, P626, DOI 10.1038/nrc1946
   Karim S, 1997, BIOCHEM J, V326, P593, DOI 10.1042/bj3260593
   KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140
   Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625
   Klauber N, 1996, CIRCULATION, V94, P2566, DOI 10.1161/01.CIR.94.10.2566
   Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298
   Liu XH, 1999, CLIN EXP METASTAS, V17, P687, DOI 10.1023/A:1006728119549
   LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237
   Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200
   MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789
   Ozawa Y, 2006, FERTIL STERIL, V86, P1146, DOI 10.1016/j.fertnstert.2006.01.057
   Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494
   Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368
   SANGEM M, PEDIAT CARD IN PRESS
   Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007
   Seed MP, 1997, CANCER RES, V57, P1625
   Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x
   Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272
   TEICHER BA, 1994, CANCER CHEMOTH PHARM, V33, P515, DOI 10.1007/BF00686511
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6
   Verheul HMW, 1999, BRIT J CANCER, V79, P114, DOI 10.1038/sj.bjc.6690020
   Wei DY, 2004, CANCER RES, V64, P2030, DOI 10.1158/0008-5472.CAN-03-1945
   Weinberger B, 2002, TOXICOL APPL PHARM, V181, P60, DOI 10.1006/taap.2002.9387
NR 47
TC 33
Z9 37
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2008
VL 49
IS 9
BP 3909
EP 3913
DI 10.1167/iovs.07-1527
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 344AB
UT WOS:000258896500023
PM 18487370
DA 2022-11-30
ER

PT J
AU Ferguson, TA
   Apte, RS
AF Ferguson, Thomas A.
   Apte, Rajendra S.
TI Angiogenesis in eye disease: immunity gained or immunity lost?
SO SEMINARS IN IMMUNOPATHOLOGY
LA English
DT Review
DE AMD; CNV; macrophage; inflammation; immunity FasL; immune privilege;
   IL-10
ID COMPLEMENT FACTOR-H; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; LIGAND-DEFICIENT
   MICE; MACULAR DEGENERATION; FAS LIGAND; CELL-DEATH; RETINAL
   NEOVASCULARIZATION; INDUCED APOPTOSIS
AB The anti-inflammatory nature of the intraocular environment is critical to the immune privilege of the eye. An important part of immune privilege is the induction of apoptosis by two death-inducing ligands (FasL and TRAIL) that can limit the spread of inflammation and control tumor growth. While initial studies focused on control of inflammation and the impact of these molecules on the systemic immune response, more recent studies have extended this concept to pathogenic neovascularization. This process is an important component of several blinding eye disorders including age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, and corneal disease. These studies showed that the mediators of immune privilege also regulate the extent of angiogenesis. In this article, we will develop the idea that constitutive expression of FasL in the eye, as well as inducible FasL on cells of the immune system, modulates neovascularization in ocular disease. Further, we will present the idea that macrophage participation in this process and their function during disease depends on the microenvironment and the cytokine milieu. These concepts challenge the idea that neovascular eye disease is simply an inflammatory process and support the idea that these diseases may result from the loss or dysfunction of important components of the cellular immune system.
C1 [Ferguson, Thomas A.; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
C3 Washington University (WUSTL)
RP Ferguson, TA (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid,POB 8096, St Louis, MO 63110 USA.
EM ferguson@vision.wustl.edu
CR Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   BALCIUNIENE J, 1995, GENOMICS, V30, P281, DOI 10.1006/geno.1995.9876
   Barreiro R, 2003, INVEST OPHTH VIS SCI, V44, P1282, DOI 10.1167/iovs.02-0478
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bonfoco E, 1998, IMMUNITY, V9, P711, DOI 10.1016/S1074-7613(00)80668-8
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Brunner T, 1996, Behring Inst Mitt, P161
   Capoccia BJ, 2006, BLOOD, V108, P2438, DOI 10.1182/blood-2006-04-013755
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Davies MH, 2003, INVEST OPHTH VIS SCI, V44, P3202, DOI 10.1167/iovs.03-0050
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Doll JA, 2003, NAT MED, V9, P774, DOI 10.1038/nm870
   Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Ferguson TA, 1997, IMMUNOL REV, V156, P167, DOI 10.1111/j.1600-065X.1997.tb00967.x
   Ferguson TA, 1997, J CLIN IMMUNOL, V17, P1, DOI 10.1023/A:1027343210080
   Ferguson TA, 2006, IMMUNOL REV, V213, P228, DOI 10.1111/j.1600-065X.2006.00430.x
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghassabeh GH, 2006, BLOOD, V108, P575, DOI 10.1182/blood-2005-04-1485
   Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krasnici S, 2003, INT J CANCER, V105, P561, DOI 10.1002/ijc.11108
   Kuo IC, 2000, INT OPHTHALMOL CLIN, V40, P111, DOI 10.1097/00004397-200004000-00009
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lee HO, 2003, CYTOKINE GROWTH F R, V14, P325, DOI 10.1016/S1359-6101(03)00028-5
   Lee HO, 2002, J IMMUNOL, V169, P4739, DOI 10.4049/jimmunol.169.9.4739
   Liu XP, 1998, OPHTHALMIC RES, V30, P302, DOI 10.1159/000055489
   Lloberas J, 2002, EXP GERONTOL, V37, P1325, DOI 10.1016/S0531-5565(02)00125-0
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Luna J, 1996, LAB INVEST, V75, P563
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   Nagata S, 1996, ADV EXP MED BIOL, V406, P119
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Niederkorn J Y, 1989, Reg Immunol, V2, P83
   O'Connell J, 1999, IMMUNOL TODAY, V20, P46, DOI 10.1016/S0167-5699(98)01382-6
   Papadimitriou E, 2000, J DRUG TARGET, V8, P335, DOI 10.3109/10611860008997910
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Quigg RJ, 2004, CURR DIRECT AUTOIMMU, V7, P165
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342
   Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3
   Stuart PM, 2003, INVEST OPHTH VIS SCI, V44, P93, DOI 10.1167/iovs.02-0299
   Stuart PM, 1997, J CLIN INVEST, V99, P396, DOI 10.1172/JCI119173
   Tacke F, 2007, J CLIN INVEST, V117, P185, DOI 10.1172/JCI28549
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang HG, 2000, J CLIN INVEST, V105, P813, DOI 10.1172/JCI8236
NR 80
TC 35
Z9 36
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1863-2297
J9 SEMIN IMMUNOPATHOL
JI Semin. Immunopathol.
PD APR
PY 2008
VL 30
IS 2
BP 111
EP 119
DI 10.1007/s00281-008-0113-8
PG 9
WC Immunology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pathology
GA 296CA
UT WOS:000255519900005
PM 18297288
DA 2022-11-30
ER

PT J
AU Rein, DB
   Zhang, P
   Wirth, KE
   Lee, PP
   Hoerger, TJ
   McCall, N
   Klein, R
   Tielsch, JM
   Vijan, S
   Saaddine, J
AF Rein, David B.
   Zhang, Ping
   Wirth, Kathleen E.
   Lee, Paul P.
   Hoerger, Thomas J.
   McCall, Nancy
   Klein, Ronald
   Tielsch, James M.
   Vijan, Sandeep
   Saaddine, Jinan
TI The economic burden of major adult visual disorders in the United States
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID EYE DISEASES; COST CONSIDERATIONS; REFRACTIVE ERRORS; MEDICAL THERAPY;
   IMPAIRMENT; PREVALENCE; POPULATION; GLAUCOMA; BALTIMORE; BLINDNESS
AB Objective: To estimate the societal economic burden and the governmental budgetary impact of the following visual disorders among US adults aged 40 years and older: visual impairment, blindness, refractive error, age-related macular degeneration, cataracts, diabetic retinopathy, and primary open-angle glaucoma.
   Design: We estimated 3 components of economic burden: direct medical costs, other direct costs, and productivity losses. We used private insurance and Medicare claims data to estimate direct medical costs; epidemiologic evidence from multiple published sources to estimate other direct costs, such as nursing home costs; and data from the Survey of Income and Program Participation to estimate productivity losses. We used budgetary documents and our direct medical and other direct cost estimates to approximate the governmental budgetary impact.
   Results: We estimated that the annual total financial burden of major adult visual disorders is $35.4 billion ($16.2 billion in direct medical costs, $11.1 billion in other direct costs, and $8 billion in productivity losses) and that the annual governmental budgetary impact is $13.7 billion.
   Conclusions: Major visual disorders among Americans older than 40 years result in substantial economic costs for the US economy. Well-designed public health programs may have the ability to reduce this burden in the future.
C1 RTI Int, Res Triangle Pk, NC USA.
   Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA.
   Duke Univ, Ctr Hlth Policy Law & Management, Durham, NC 27706 USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21218 USA.
   Univ Michigan, Vet Affairs Hlth Serv Res, Dev Ctr Practice Management & Outcomes Res, Ann Arbor, MI 48109 USA.
C3 Research Triangle Institute; Centers for Disease Control & Prevention -
   USA; Duke University; University of Wisconsin System; University of
   Wisconsin Madison; Johns Hopkins University; University of Michigan
   System; University of Michigan
RP Rein, DB (通讯作者)，RTI Int, 2951 Flowers Rd,Suite 119, Atlanta, GA 30306 USA.
EM drein@rti.org
OI Lee, Paul/0000-0002-3338-136X; Rein, David/0000-0002-1271-5789; Hoerger,
   Thomas/0000-0003-4154-7806; Tielsch, James/0000-0002-1151-060X; Wirth,
   Kathleen/0000-0002-7468-851X
FU PHS HHS [200-2002-00776] Funding Source: Medline
CR *AG HEALTHC RES QU, 2004, EST US CIV NON POP A
   [Anonymous], 1999, METHODS EC EVALUATIO
   [Anonymous], CHARACTERISTICS ELDE
   [Anonymous], 1996, INT CLASS DIS 9 REV
   Attebo K, 1999, OPHTHALMOLOGY, V106, P1066, DOI 10.1016/S0161-6420(99)90251-8
   *CCH INC, 2003, US MAST TAX GUID
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   COONEY J, 2004, COMP ASSESSMENT COST
   *CTR MED MED SERV, DUR MED EQ PROSTH OR
   *CTR MED MED SERV, 1980, OV US HLTH CAR SYST
   *DEP AGR FOOD NUTR, 2004, FOOD STAMP PROGR AV
   Doyle JW, 2002, OPTOMETRY VISION SCI, V79, P489, DOI 10.1097/00006324-200208000-00010
   Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804
   Fiscella RG, 2003, AM J OPHTHALMOL, V136, P18, DOI 10.1016/S0002-9394(03)00102-8
   Fiscella RG, 1999, AM J OPHTHALMOL, V128, P426, DOI 10.1016/S0002-9394(99)00235-4
   FLEMING T, 2004, 2004 RED BOOK PHARM
   HU TW, 1982, EC COSTS VISUAL DISO
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Lee PP, 2003, OPHTHALMOLOGY, V110, P1952, DOI 10.1016/S0161-6420(03)00817-0
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   *MARKETSC, 2002, MARKETSC COMM CLAIMS
   MCNEIL J, 2001, AM DISABILITIES 1997
   National Center for Health Statistics, 2002, NAT HOSP AMB MED CAR
   National Center for Health Statistics, 2002, NAT AMB MED CAR SURV
   National Center for Health Statistics, 1997, NAT HLTH NUTR EX SUR
   Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207
   Sloan FA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1462, DOI 10.1001/archopht.121.10.1462
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   *US CENS BUR, 2003, SOC INS HUM SERV STA
   *US CENS BUR, 2002, STAT ABSTR US RES PO
   *US DEP ED DOE, GUID ED PROGR
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
NR 35
TC 402
Z9 416
U1 0
U2 32
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2006
VL 124
IS 12
BP 1754
EP 1760
DI 10.1001/archopht.124.12.1754
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115LE
UT WOS:000242735000011
PM 17159036
OA Bronze
DA 2022-11-30
ER

PT J
AU Pian, D
   Ferrucci, S
   Anderson, SF
   Wu, C
AF Pian, D
   Ferrucci, S
   Anderson, SF
   Wu, C
TI Paramacular coloboma
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE albinitic nevus; coloboma; congenital; embryology; macula; paramacular
   coloboma; torpedo maculopathy
ID RETINAL-PIGMENT EPITHELIUM; EYE DEVELOPMENT; HUMAN FOVEA; MACULOPATHY
AB Background. Paramacular coloboma (plural: colobomata) is a solitary oval football or torpedo-shaped chorioretinal lesion located temporal to the fovea in one or both eyes. Previous case reports have speculated varying etiology, but few have justified its pathognomonic shape and location. We believe it to be congenital in nature and caused by incomplete differentiation of the arcuate bundles along the horizontal raphe in development of the macular architecture. Associated ocular findings may include blepharophimosis, situs inversus, or other anomalous retinal vascular patterns. Case Reports. Three cases of asymptomatic unilateral paramacular colobomata are presented. In each case, a single oval chorioretinal lesion temporal to the macula was found during routine examination. Visual acuity and Humphrey threshold visual field testing were normal with no other associated congenital, systemic, or ocular abnormalities. Because the lesion is nonprogressive, these patients can be followed on an annual basis. Conclusion. Due to their anatomical origin, paramacular colobomata are always located temporal to the macula and have an oval football-shaped appearance. Visual acuity and visual field testing are usually normal, although highly observant patients may be aware of a mild scotoma. Differential diagnosis is important because the clinical appearance can be similar to acquired conditions, most notably age-related macular degeneration and presumed ocular histoplasmosis syndrome.
C1 Sepulveda VA Ambulatory Care Ctr, VA Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA.
   Santa Barbara Community Based Outpatient Clin, VA Greater Los Angeles Healthcare Syst, Santa Barbara, CA USA.
   Nursing Home, Sepulveda, CA USA.
   So Calif Coll Optometry, Fullerton, CA USA.
   Baltimore VA Med Ctr, VA Maryland Healthcare Syst, Baltimore, MD USA.
   SUNY Coll Optometry, New York, NY 10010 USA.
   Kaiser Permanente, Thousand Oaks, CA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Greater Los Angeles Healthcare System; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles
   Healthcare System; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Baltimore VA Medical Center; State University of
   New York (SUNY) System; SUNY Optometry; Kaiser Permanente
RP Ferrucci, S (通讯作者)，Sepulveda VA Ambulatory Care Ctr, VA Greater Los Angeles Healthcare Syst, 16111 Plummer St,112E, Sepulveda, CA 91343 USA.
CR ABRAMOV I, 1982, SCIENCE, V217, P265, DOI 10.1126/science.6178160
   ALEXANDER LJ, 1994, PRIMARY CARE POSTERI, P310
   Angioi-Duprez K, 2000, J FR OPHTALMOL, V23, P200
   BARBER AN, 1955, EMBRYOLOGY HUMAN EYE, P13
   BARTLETT JD, 1995, CLIN OCULAR PHARM, P981
   Bhatt Nitul S., 1997, Indian Journal of Ophthalmology, V45, P115
   Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255
   Cohen AI, 1992, ADLERS PHYSL EYE, P579
   Daily MJ., 1993, NEW DIMENSIONS RETIN, P7
   Dimanlig PV, 2001, DEVELOPMENT, V128, P4415
   DUKEELDER S, 1963, SYSTEM OPHTHALMOLOGY, V3, P19
   GASS JDM, 1989, EYE, V3, P1, DOI 10.1038/eye.1989.2
   GASS JDM, 1977, STEREOSCOPIC ATLAS M, P809
   HENDRICKSON A, 1992, BEHAV BRAIN RES, V49, P21, DOI 10.1016/S0166-4328(05)80191-3
   HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603
   Hrynchak P, 2000, OPTOMETRY VISION SCI, V77, P347, DOI 10.1097/00006324-200007000-00009
   JACOBSON AG, 1988, DEVELOPMENT, V104, P341
   Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8
   Jennings B J, 1994, J Am Optom Assoc, V65, P465
   KLEIN BA, 1959, AM J OPHTHALMOL, V48, P597
   LANGMAN J, 1995, LANGMANS MED ENBRYOL, P358
   LINBERG KA, 1990, VISUAL NEUROSCI, V5, P43, DOI 10.1017/S0952523800000067
   MANN I, 1958, DEV HUMAN EYE, P110
   MANN I, 1957, DEV ABNORMALITIES EY, P124
   MOORE KL, 1998, DEV HUMAN CLIN ORIEN, P491
   NEWMAN WA, 2000, DORLANDS MED DICT, P219
   Onwochei BC, 2000, SURV OPHTHALMOL, V45, P175, DOI 10.1016/S0039-6257(00)00151-X
   Primo S A, 1990, J Am Optom Assoc, V61, P373
   RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7
   Rigotti M, 2002, OPHTHALMOLOGICA, V216, P226, DOI 10.1159/000059639
   ROSEMAN RL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1358
   SANTOS A, 1998, RETINAL PIGMENT EPIT, P312
   SCHLERNITZAUER DA, 1971, AM J OPHTHALMOL, V72, P729, DOI 10.1016/0002-9394(71)90010-9
   Sharma S, 1996, CAN J OPHTHALMOL, V31, P27
   Sigelman J, 1982, OCULAR ANATOMY EMBRY, P456
   Teitelbaum B A, 1997, J Am Optom Assoc, V68, P373
   TOWNSEND J, 1991, VISUAL FIELDS CLIN C, P13
   Wang YP, 2002, NAT NEUROSCI, V5, P831, DOI 10.1038/nn911
   YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4
   Zhao SL, 2001, MOL VIS, V7, P277
NR 40
TC 26
Z9 31
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2003
VL 80
IS 8
BP 556
EP 563
DI 10.1097/00006324-200308000-00008
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 714CA
UT WOS:000184893700003
PM 12917574
DA 2022-11-30
ER

PT J
AU Majid, MA
   Smith, VA
   Easty, DL
   Baker, AH
   Newby, AC
AF Majid, MA
   Smith, VA
   Easty, DL
   Baker, AH
   Newby, AC
TI Adenovirus mediated gene delivery of tissue inhibitor of
   metalloproteinases-3 induces death in retinal pigment epithelial cells
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SORSBYS-FUNDUS-DYSTROPHY; MACULAR DEGENERATION; IN-VITRO; TIMP-3;
   EXPRESSION; LOCALIZATION; INVASION; OVEREXPRESSION; APOPTOSIS; CULTURE
AB Background: Sorsby's fundus dystrophy (SFD) and age related macular degeneration (ARMD) are retinal diseases associated with a high level of accumulation of mutant and wild type TIMP-3, respectively, in Bruch's membrane. The pathogenic role of TIMP-3 in these diseases is uncertain, but causative mutations have been identified in the TIMP-3 gene of patients with SFD. Recent reports that TIMP-3 causes apoptosis in certain cell types and not in others prompted the authors to investigate whether causes apoptosis in cultured retinal pigment epithelium (RPE) cells.
   Methods: RPE and MCF-7 cells (as a positive control) were initially infected with replication deficient adenovirus, to overexpress beta-golactosidose (RAdLacZ) or TIMP-3 (RAdTIMP-3). TIMP-3 was detected by blotting and ELISA. Cell viability was defined by cell counts. ISEL was used to investigate the mechanism of cell death.
   Results: Cultured RPE cells produced small quantities of endogenous TIMP-3 and remained viable. However, overexpression of TIMP-3 caused a dose related death of RPE cells. The mechanism of cell death was apoptosis.
   Conclusion: The previously unreported finding of TIMP-3 induced apoptosis of RPE cells may account some of the early features seen in SFD and ARMD.
C1 Univ Bristol, Inst Ophthalmol, Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
   Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.
C3 Bristol Eye Hospital; University of Bristol; Bristol Royal Infirmary;
   University of Bristol
RP Majid, MA (通讯作者)，Univ Bristol, Inst Ophthalmol, Bristol Eye Hosp, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
RI Baker, Andy/AAO-5250-2021
OI Baker, Andy/0000-0003-1441-5576
FU Wellcome Trust Funding Source: Medline
CR Ahonen M, 1998, CANCER RES, V58, P2310
   ALBERT DM, 1972, ARCH OPHTHALMOL-CHIC, V88, P63
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   Burke JM, 1996, EXP EYE RES, V62, P63, DOI 10.1006/exer.1996.0008
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   DELMONTE MA, 1981, VISION RES, V21, P137, DOI 10.1016/0042-6989(81)90147-4
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   FARISS RN, 1997, AM J PATHOL, V16, P102
   Jomary C, 1997, NEUROREPORT, V8, P2169, DOI 10.1097/00001756-199707070-00015
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   KAMEI M, 1997, DEGENERATIVE DIS RET
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   MCKHENIE NM, 1988, J CELL SCI, V91, P303
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Ruiz A, 1996, BIOCHEM BIOPH RES CO, V226, P467, DOI 10.1006/bbrc.1996.1379
   Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
NR 25
TC 22
Z9 25
U1 0
U2 1
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2002
VL 86
IS 1
BP 97
EP 101
DI 10.1136/bjo.86.1.97
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 509ZM
UT WOS:000173184300024
PM 11801512
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Wu, XJ
   Yao, FW
   Xu, JY
   Chen, J
   Lu, Y
   Li, W
   Deng, J
   Mou, LS
   Zhang, QL
   Pu, ZH
AF Wu, Xiaojun
   Yao, Fuwen
   Xu, Jing-Ying
   Chen, Jiao
   Lu, Ying
   Li, Wei
   Deng, Jing
   Mou, Lisha
   Zhang, Qingling
   Pu, Zuihui
TI The transcriptome profile of RPE cells by the fullerenol against
   hydrogen peroxide stress
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE fullerenol; nanomaterial; RNA sequencing; oxidative stress; senescence;
   RPE; AMD
ID PIGMENT EPITHELIAL-CELLS; INDUCED PREMATURE SENESCENCE; OXIDATIVE
   STRESS; DEGENERATION; NETWORK; DAMAGE
AB Age-related macular degeneration (AMD) causes central vision impairment with increased incidence. In the pathogenesis of AMD, reactive oxygen species (ROS) are associated with RPE cell apoptosis. H2O2 is an oxidative toxicant and is used to establish the AMD in vitro model. However, the mechanisms of ROS in H2O2-induced AMD are still unclear. Fullerenol, a promising antioxidant of nanomaterials, protects RPE cells from ROS attack. In addition to working as a scavenger, little is known about the antioxidant mechanism of fullerenol in RPE cells. In this study, transcriptome sequencing was performed to examine the global changes in mRNA transcripts induced by H2O2 in human ARPE-19 cells. Moreover, we comprehensively investigated the protective effects of fullerenol against H2O2-induced oxidative injury by RNA sequencing. Gene Ontology enrichment analysis showed that those pathways related to the release of positive regulation of DNA-templated transcription and negative regulation of apoptotic process were affected. Finally, we found that 12 hub genes were related to the oxidative-protection function of fullerenol. In summary, H2O2 affected these hub genes and signaling pathways to regulate the senescence of RPE cells. Moreover, fullerenol is a potent nanomaterial that protects the RPE and would be a promising approach for AMD prevention.
C1 [Wu, Xiaojun; Zhang, Qingling] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.
   [Wu, Xiaojun; Zhang, Qingling] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Peoples R China.
   [Wu, Xiaojun] Shenzhen Nanshan Peoples Hosp, Dept Ophthalmol, Shenzhen, Peoples R China.
   [Wu, Xiaojun] Shenzhen Univ, Affiliated Hosp 6, Hlth Sci Ctr, Shenzhen, Peoples R China.
   [Yao, Fuwen; Chen, Jiao; Lu, Ying; Deng, Jing; Mou, Lisha] Shenzhen Univ, Shenzhen Univ Sch Med, Affiliated Hosp 1, Shenzhen Peoples Hosp 2,Shenzhen Univ Hlth Sci Ctr, Shenzhen, Peoples R China.
   [Xu, Jing-Ying] Tongji Univ, Sch Med, Dept Pathol & Pathophysiol, Shanghai, Peoples R China.
   [Li, Wei] Northeastern Univ, Coll Sci, Dept Biochem, Boston, MA USA.
   [Pu, Zuihui] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Univ Sch Med, Shenzhen Peoples Hosp 2,Shenzhen Univ Hlth Sci Ctr, Shenzhen, Peoples R China.
C3 Southern Medical University - China; Guangdong Academy of Medical
   Sciences & Guangdong General Hospital; Shenzhen University; Shenzhen
   University; Tongji University; Northeastern University; Shenzhen
   University
RP Zhang, QL (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.; Zhang, QL (通讯作者)，Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Pathol, Guangzhou, Peoples R China.; Mou, LS (通讯作者)，Shenzhen Univ, Shenzhen Univ Sch Med, Affiliated Hosp 1, Shenzhen Peoples Hosp 2,Shenzhen Univ Hlth Sci Ctr, Shenzhen, Peoples R China.; Pu, ZH (通讯作者)，Shenzhen Univ, Affiliated Hosp 1, Shenzhen Univ Sch Med, Shenzhen Peoples Hosp 2,Shenzhen Univ Hlth Sci Ctr, Shenzhen, Peoples R China.
EM lishamou@gmail.com; zqllc8@126.com; pupeter190@163.com
CR Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Chen X, 2022, REDOX BIOL, V54, DOI 10.1016/j.redox.2022.102360
   Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cong WS, 2015, BIOMATERIALS, V42, P78, DOI 10.1016/j.biomaterials.2014.11.048
   Datta S, 2022, AUTOPHAGY, DOI 10.1080/15548627.2022.2109286
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Du YY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2684672
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311
   Grebowski J, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010119
   Grebowski J, 2020, FREE RADICAL BIO MED, V160, P734, DOI 10.1016/j.freeradbiomed.2020.08.017
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Hao T, 2017, ACS NANO, V11, P5474, DOI 10.1021/acsnano.7b00221
   Hwang N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236028
   Kang KH, 2009, TRENDS MOL MED, V15, P191, DOI 10.1016/j.molmed.2009.03.005
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Liang GH, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-21-7043
   Ma N, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8847844
   Macchioni L, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010025
   Mantha AK, 2014, MITOCHONDRION, V16, P38, DOI 10.1016/j.mito.2013.10.007
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nahle S, 2019, J APPL TOXICOL, V39, P764, DOI 10.1002/jat.3765
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Pang XC, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5806602
   Qingnuan L., 2002, NUCL MED BIOL, V29, P707, DOI [10.1016/S0969-8051(02)00313-X, DOI 10.1016/S0969-8051(02)00313-X]
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tanaka M, 2021, AM J PATHOL, V191, P652, DOI 10.1016/j.ajpath.2020.12.012
   Viplav A, 2019, J CELL SCI, V132, DOI 10.1242/jcs.226530
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Ye SF, 2014, INT J NANOMED, V9, P2073, DOI 10.2147/IJN.S56973
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 39
TC 0
Z9 0
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 14
PY 2022
VL 9
AR 996280
DI 10.3389/fmed.2022.996280
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4Z1PI
UT WOS:000861988700001
PM 36186803
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Biasella, F
   Strunz, T
   Kiel, C
   Weber, BHF
   Friedrich, U
AF Biasella, Fabiola
   Strunz, Tobias
   Kiel, Christina
   Weber, Bernhard H. F.
   Friedrich, Ulrike
CA Int AMD Genomics Consortium IAMDGC
TI Vitronectin and Its Interaction with PAI-1 Suggests a Functional Link to
   Vascular Changes in AMD Pathobiology
SO CELLS
LA English
DT Article
DE AMD; age-related macular degeneration; vitronectin; VTN; rs704;
   SERPINE1; PAI-1; neovascularization
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; GENOME-WIDE ASSOCIATION; MACULAR
   DEGENERATION; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GENE-EXPRESSION;
   BINDING-SITE; HUMAN-PLASMA; RPE CELLS; PROTEIN
AB The pathogenesis of age-related macular degeneration (AMD), a frequent disorder of the central retina, is incompletely understood. Genome-wide association studies (GWAS) suggest a strong contribution of genomic variation in AMD susceptibility. Nevertheless, little is known about biological mechanisms of the disease. We reported previously that the AMD-associated polymorphism rs704C > T in the vitronectin (VTN) gene influences protein expression and functional aspects of encoded vitronectin, a human blood and extracellular matrix (ECM) protein. Here, we refined the association of rs704 with AMD in 16,144 cases and 17,832 controls and noted that rs704 is carried exclusively by the neovascular AMD subtype. Interaction studies demonstrate that rs704 affects the ability of vitronectin to bind the angiogenic regulator plasminogen activator inhibitor 1 (PAI-1) but has no influence on stabilizing its active state. Western blot analysis and confocal imaging reveal a strong enrichment of PAI-1 in the ECM of cultured endothelial cells and RPE cell line ARPE-19 exposed to vitronectin. Large-scale gene expression of VTN and PAI-1 showed positive correlations and a statistically significant increase in human retinal and blood tissues aged 60 years and older. Our results suggest a mechanism by which the AMD-associated rs704 variant in combination with ageing may contribute to the vascular complications in AMD.
C1 [Biasella, Fabiola; Strunz, Tobias; Kiel, Christina; Weber, Bernhard H. F.; Friedrich, Ulrike] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Int AMD Genomics Consortium IAMDGC] Univ Miami, John P Hussman Inst Human Genom, Miami, FL 33136 USA.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Miami; University of Regensburg
RP Weber, BHF; Friedrich, U (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.; Weber, BHF (通讯作者)，Univ Hosp Regensburg, Inst Clin Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM fabiola.biasella@klinik.uni-regensburg.de;
   tobias.strunz@klinik.uni-regensburg.de;
   christina.kiel@klinik.uni-regensburg.de; bweb@klinik.uni-regensburg.de;
   friedrich@klinik.uni-regensburg.de
OI Strunz, Tobias/0000-0002-3744-9595; Kiel, Christina/0000-0003-3154-4847
FU Pro Retina Foundation, Aachen, Germany; Deutsche Forschungsgemeinschaft
   (DFG) [INST 89/506-1 FUGG]; Common Fund of the Office of the Director of
   the National Institutes of Health; NCI; NHGRI; NHLBI; NIDA; NIMH; NINDS
FX This work was supported in part by a grant from the Pro Retina
   Foundation, Aachen, Germany for FB. The FV3000 confocal microscope was
   funded by a grant (INST 89/506-1 FUGG, 91b GG) from the Deutsche
   Forschungsgemeinschaft (DFG). The Genotype-Tissue Expression (GTEx)
   Project was supported by the Common Fund of the Office of the Director
   of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA,
   NIMH, and NINDS.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644
   [Anonymous], GTEX PORTAL DATASETS
   Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143
   BARNES DW, 1983, J BIOL CHEM, V258, P2548
   BARTHA K, 1991, J BIOL CHEM, V266, P792
   Basu A, 2009, INVEST OPHTH VIS SCI, V50, P4974, DOI 10.1167/iovs.09-3619
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Biasella F, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.2
   Bird A.C., 2013, RETINA-J RET VIT DIS, V5th, P1145, DOI [10.1016/C2010-1-69566-1, DOI 10.1016/C2010-1-69566-1]
   Booth LN, 2016, MOL CELL, V62, P728, DOI 10.1016/j.molcel.2016.05.013
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Brazionis L, 2010, DIABETES RES CLIN PR, V87, P192, DOI 10.1016/j.diabres.2009.11.007
   Campisi J, 2019, NATURE, V571, P183, DOI 10.1038/s41586-019-1365-2
   CANFIELD AE, 1989, BIOCHEM J, V259, P529, DOI 10.1042/bj2590529
   CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L
   CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03788-5
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cheng L, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.547436
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Constantine NA, 2012, PERSPECT SEX REPRO H, V44, P134, DOI 10.1363/4413412
   Curcio C.A., 2012, STRUCTURE FUNCTION P, V1, P17
   Czekay RP, 2009, J CELL PHYSIOL, V220, P655, DOI 10.1002/jcp.21806
   Daniel AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145684
   DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454
   Dejana E., 1989, VASCULAR ENDOTHELIUM, P141
   Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com
   Dickey SW, 2013, CELL, V155, P1270, DOI 10.1016/j.cell.2013.10.053
   Dufourcq P, 2002, CARDIOVASC RES, V53, P952, DOI 10.1016/S0008-6363(01)00547-8
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   ESSER P, 1994, GRAEF ARCH CLIN EXP, V232, P477, DOI 10.1007/BF00195357
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gettins PGW, 2016, J BIOL CHEM, V291, P800, DOI 10.1074/jbc.M115.688820
   Gibson AD, 2001, BBA-PROTEIN STRUCT M, V1545, P289, DOI 10.1016/S0167-4838(00)00290-9
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   Grant MB, 2000, INVEST OPHTH VIS SCI, V41, P2296
   GRULICHHENN J, 1992, FIBRINOLYSIS, V6, P131
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003
   Huang JS, 2009, J MOL MED, V87, P613, DOI 10.1007/s00109-009-0456-1
   Isogai C, 2001, CANCER RES, V61, P5587
   Jang YC, 2000, SURGERY, V127, P696, DOI 10.1067/msy.2000.105858
   Kiel C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102257
   Kingston R E, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1013s31
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com
   Latifi-Navid H, 2021, J CELL MOL MED, V25, P8285, DOI 10.1111/jcmm.16778
   Le Magueresse-Battistoni B, 1998, BIOL REPROD, V59, P591, DOI 10.1095/biolreprod59.3.591
   Lee MJ, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a005918
   Li R, 2014, J VASC RES, V51, P110, DOI 10.1159/000360085
   Lin ZH, 2011, J BIOL CHEM, V286, P7027, DOI 10.1074/jbc.M110.204537
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOU DA, 1987, IN VITRO CELL DEV B, V23, P75, DOI 10.1007/BF02623586
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Madsen CD, 2007, J CELL BIOL, V177, P927, DOI 10.1083/jcb.200612058
   Mahabeleshwar GH, 2007, CIRC RES, V101, P570, DOI 10.1161/CIRCRESAHA.107.155655
   Mahmoud A., 2008, B EGYPT SOC PHYSL SC, V28, P253, DOI [10.21608/besps.2008.36961, DOI 10.21608/BESPS.2008.36961]
   McLenachan Samuel, 2017, Biochem Biophys Rep, V10, P178, DOI 10.1016/j.bbrep.2017.03.008
   Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200
   Morrow GB, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.653655
   My.LocusZoom.org, US
   Nebbioso M, 2022, DRUG AGING, V39, P107, DOI 10.1007/s40266-021-00914-x
   OLSON D, 1992, J BIOL CHEM, V267, P9129
   PHILIPS M, 1984, BIOCHIM BIOPHYS ACTA, V802, P99, DOI 10.1016/0304-4165(84)90039-4
   Plossl K, 2017, J CELL MOL MED, V21, P768, DOI 10.1111/jcmm.13019
   Pollard K. S., 2005, BIOINFORMATICS COMPU, P251, DOI DOI 10.1007/0-387-29362-0_15
   Preissner KT, 2011, SEMIN THROMB HEMOST, V37, P408, DOI 10.1055/s-0031-1276590
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SEIFFERT D, 1990, CELL DIFFER DEV, V32, P287, DOI 10.1016/0922-3371(90)90041-T
   Seiffert D, 1996, J BIOL CHEM, V271, P29644, DOI 10.1074/jbc.271.47.29644
   Sen A., 2021, BIORXIV, DOI [10.1101/2021.11.18.468035, DOI 10.1101/2021.11.18.468035]
   Shin K, 2020, P NATL ACAD SCI USA, V117, P18504, DOI 10.1073/pnas.2007699117
   Sillen M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052721
   Sillen M, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.622473
   SIMON DI, 1995, BBA-MOL CELL RES, V1268, P143, DOI 10.1016/0167-4889(95)00063-X
   SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139
   Smith JR, 2018, AM J OPHTHALMOL, V193, P197, DOI 10.1016/j.ajo.2018.03.020
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stegeman R, 2017, J MOL BIOL, V429, P2427, DOI 10.1016/j.jmb.2017.06.019
   Strunz T, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092395
   Strunz T, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008934
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Team RC. R, 2013, R CORE TEAM R LANGUA, DOI DOI 10.1890/0012-9658(2002)083[3097:CFHIWS]2.0.CO;2
   TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778
   Tomasini-Johansson BR, 1998, BRIT J RHEUMATOL, V37, P620
   Underwood P. Anne, 1996, Cells and Materials, V6, P193
   VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914
   Vaughan DE, 2017, ARTERIOSCL THROM VAS, V37, P1446, DOI 10.1161/ATVBAHA.117.309451
   Vial D, 2008, J CELL SCI, V121, P1661, DOI 10.1242/jcs.020149
   Vogel C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.59
   VOLKER W, 1993, J HISTOCHEM CYTOCHEM, V41, P1823, DOI 10.1177/41.12.7504009
   Wang HB, 2016, MOL VIS, V22, P189
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2
   Wu JB, 2015, ARTERIOSCL THROM VAS, V35, P111, DOI 10.1161/ATVBAHA.114.304554
   Yang RF, 2018, ARCH MED SCI, V14, P725, DOI 10.5114/aoms.2017.70340
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   ZEHEB R, 1987, THROMB HAEMOSTASIS, V58, P1017
   Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943
   Zuchtriegel G, 2021, HAEMATOLOGICA, V106, P2641, DOI 10.3324/haematol.2019.226241
NR 113
TC 1
Z9 1
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUN
PY 2022
VL 11
IS 11
AR 1766
DI 10.3390/cells11111766
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 1Z4GU
UT WOS:000808786000001
PM 35681461
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pan, HY
   Valapala, M
AF Pan, Hsuan-Yeh
   Valapala, Mallika
TI Regulation of Autophagy by the Glycogen Synthase Kinase-3 (GSK-3)
   Signaling Pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mTORC1; TFEB; GSK-3; GSK-3 beta; autophagy; lysosome; AKT; PKC; ULK1
ID CANCER-CELLS; PHOSPHORYLATION; MTORC1; ACTIVATION; PROTEIN; COMPLEX;
   STRESS; TFEB; DEGRADATION; CALCINEURIN
AB Autophagy is a vital cellular mechanism that benefits cellular maintenance and survival during cell stress. It can eliminate damaged or long-lived organelles and improperly folded proteins to maintain cellular homeostasis, development, and differentiation. Impaired autophagy is associated with several diseases such as cancer, neurodegenerative diseases, and age-related macular degeneration (AMD). Several signaling pathways are associated with the regulation of the autophagy pathway. The glycogen synthase kinase-3 signaling pathway was reported to regulate the autophagy pathway. In this review, we will discuss the mechanisms by which the GSK-3 signaling pathway regulates autophagy. Autophagy and lysosomal function are regulated by transcription factor EB (TFEB). GSK-3 was shown to be involved in the regulation of TFEB nuclear expression in an mTORC1-dependent manner. In addition to mTORC1, GSK-3 beta also regulates TFEB via the protein kinase C (PKC) and the eukaryotic translation initiation factor 4A-3 (eIF4A3) signaling pathways. In addition to TFEB, we will also discuss the mechanisms by which the GSK-3 signaling pathway regulates autophagy by modulating other signaling molecules and autophagy inducers including, mTORC1, AKT and ULK1. In summary, this review provides a comprehensive understanding of the role of the GSK-3 signaling pathway in the regulation of autophagy.
C1 [Pan, Hsuan-Yeh; Valapala, Mallika] Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
C3 Indiana University System; Indiana University Bloomington
RP Valapala, M (通讯作者)，Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
EM hsupan@iu.edu; mvalapal@iu.edu
FU Macular Degeneration Research (MDR) program of the BrightFocus
   Foundation [M2021019N]; Indiana University School of Optometry New
   Faculty Development award [MVSE 2335512]
FX The authors would like to acknowledge the donors of the Macular
   Degeneration Research (MDR) program of the BrightFocus Foundation
   (M2021019N) and Indiana University School of Optometry New Faculty
   Development award (MVSE 2335512), for support of this research.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5296341
   Agarwal P, 2021, NAT BIOMED ENG, V5, P1472, DOI 10.1038/s41551-021-00691-3
   Al-Bari MAA, 2020, ANN NY ACAD SCI, V1467, P3, DOI 10.1111/nyas.14305
   Ardestani A, 2018, CELL METAB, V27, P314, DOI 10.1016/j.cmet.2017.11.004
   Avrahami L, 2020, CELL SIGNAL, V71, DOI 10.1016/j.cellsig.2020.109597
   Bar-Peled L, 2014, TRENDS CELL BIOL, V24, P400, DOI 10.1016/j.tcb.2014.03.003
   Bautista SJ, 2018, J BIOL CHEM, V293, P14723, DOI 10.1074/jbc.RA118.002800
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016
   Bowman CJ, 2014, NAT CELL BIOL, V16, P1202, DOI 10.1038/ncb3062
   Bozulic L, 2009, CURR OPIN CELL BIOL, V21, P256, DOI 10.1016/j.ceb.2009.02.002
   Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006
   Buller CL, 2008, AM J PHYSIOL-CELL PH, V295, pC836, DOI 10.1152/ajpcell.00554.2007
   Chen MY, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020333
   Choi HJ, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10100675
   Creamer TP, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00636-4
   Lopez KGDC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01373
   Deb TB, 2004, J BIOL CHEM, V279, P38903, DOI 10.1074/jbc.M405314200
   Di Malta C, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00114
   Dossou AS, 2019, CANCERS, V11, DOI 10.3390/cancers11101422
   Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105
   Fu SC, 2018, MOL BIOL CELL, V29, P2037, DOI 10.1091/mbc.E18-02-0096
   Go YM, 2020, FASEB J, V34, P12502, DOI 10.1096/fj.202000612R
   Goc A, 2014, ONCOTARGET, V5, P775, DOI 10.18632/oncotarget.1770
   Goni-Oliver P, 2007, J BIOL CHEM, V282, P22406, DOI 10.1074/jbc.M702793200
   Gorostieta-Salas E, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6682336
   Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200
   Guo W, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102730
   He L, 2019, P NATL ACAD SCI USA, V116, P19523, DOI 10.1073/pnas.1902397116
   He L, 2018, MOL CELL, V70, P949, DOI 10.1016/j.molcel.2018.04.024
   Hoffmeister L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040820
   Huang JC, 2019, THERANOSTICS, V9, P1170, DOI 10.7150/thno.26281
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5
   Jung S, 2020, EXP MOL MED, V52, P921, DOI 10.1038/s12276-020-0455-4
   Karim MR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231212
   Khan NA, 2017, CELL METAB, V26, P419, DOI 10.1016/j.cmet.2017.07.007
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kofoed RH, 2020, NEUROBIOL DIS, V136, DOI 10.1016/j.nbd.2019.104720
   Krishnankutty A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09239-5
   Kumar M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71527-4
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04849-7
   Li MQ, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.560891
   Li Y, 2016, NAT CELL BIOL, V18, P1065, DOI 10.1038/ncb3407
   Li Yueyong, 2021, Bioengineered, DOI 10.1080/21655979.2021.1997564
   Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y
   Liu L, 2015, SCI REP-UK, V5, DOI 10.1038/srep14474
   Lorincz P, 2020, J MOL BIOL, V432, P2462, DOI 10.1016/j.jmb.2019.10.028
   Lu ML, 2021, BIOCHEM BIOPH RES CO, V583, P71, DOI 10.1016/j.bbrc.2021.10.014
   Manifava M, 2016, ELIFE, V5, DOI 10.7554/eLife.19960
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Markby GR, 2020, AM J PHYSIOL-ENDOC M, V319, pE763, DOI 10.1152/ajpendo.00339.2020
   Martin KR, 2018, ISCIENCE, V8, P74, DOI 10.1016/j.isci.2018.09.012
   Matoba K, 2020, NAT STRUCT MOL BIOL, V27, P1185, DOI [10.1038/s41594-020-00538-6, 10.1038/s41594-020-00518-w]
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Melick CH, 2020, GENES-BASEL, V11, DOI 10.3390/genes11090989
   Menon MB, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00137
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morgan-Smith M, 2014, ELIFE, V3, DOI 10.7554/eLife.02663
   Napolitano G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05862-6
   Nie TJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.423
   Onyenwoke RU, 2015, BIOCHEM J, V470, P331, DOI 10.1042/BJ20150219
   Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338
   Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306
   Puertollano R, 2018, EMBO J, V37, DOI 10.15252/embj.201798804
   Qi ZH, 2019, ADV EXP MED BIOL, V1206, P167, DOI 10.1007/978-981-15-0602-4_8
   Qin XY, 2016, CELL CYCLE, V15, P781, DOI 10.1080/15384101.2016.1151581
   Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/BJ20031797
   Russi S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011147
   Ryu HY, 2021, EXP MOL MED, V53, P369, DOI 10.1038/s12276-021-00570-6
   Sagredo AI, 2018, MOL ONCOL, V12, P151, DOI 10.1002/1878-0261.12100
   Sakaguchi M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09418-0
   Sakellariou D, 2021, CELL DEATH DIFFER, V28, P3344, DOI 10.1038/s41418-021-00822-y
   Sethna S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24056-1
   Shimobayashi M, 2016, CELL RES, V26, P7, DOI 10.1038/cr.2015.146
   Silvestrini MJ, 2018, CELL REP, V23, P1915, DOI 10.1016/j.celrep.2018.04.063
   Sridharan S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041199
   Stretton C, 2015, BIOCHEM J, V470, P207, DOI 10.1042/BJ20150404
   Sun X, 2018, AUTOPHAGY, V14, P38, DOI 10.1080/15548627.2017.1389822
   Szwed A, 2021, PHYSIOL REV, V101, P1371, DOI 10.1152/physrev.00026.2020
   Szymanska P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116550
   Takahara T, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00679-2
   Dang TT, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222112083
   Tian WH, 2020, NAT METHODS, V17, P232, DOI 10.1038/s41592-019-0661-y
   Tong YJ, 2015, AUTOPHAGY, V11, P1192, DOI 10.1080/15548627.2015.1054594
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   Trivedi PC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051131
   Walker SA, 2020, J MOL BIOL, V432, P2449, DOI 10.1016/j.jmb.2019.10.027
   Wang CY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05449-1
   Wang HZ, 2011, J IMMUNOL, V186, P5217, DOI 10.4049/jimmunol.1002513
   Wang L., 2021, MED RES REV, P1, DOI [10.1002/med.21867, DOI 10.1002/med.21867]
   Wang YX, 2020, AGING-US, V12, P6129, DOI 10.18632/aging.103013
   Weikel KA, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160174
   Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111
   Xu Y, 2010, ONCOGENE, V29, P3124, DOI 10.1038/onc.2010.77
   Yang LY, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00073
   Ye JZ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.712045
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yuan T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25145-x
   Yuan YH, 2015, TOXICOL LETT, V233, P163, DOI 10.1016/j.toxlet.2014.11.029
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019
   Zhang J, 2013, BBA-MOL BASIS DIS, V1832, P1980, DOI 10.1016/j.bbadis.2013.06.013
   Zhang SZ, 2021, ANIM NUTR, V7, P1009, DOI 10.1016/j.aninu.2021.05.003
   Zhu LL, 2020, THERANOSTICS, V10, P5829, DOI 10.7150/thno.44051
   Zhu YH, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12619
   Zou ZL, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00396-1
NR 111
TC 2
Z9 2
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2022
VL 23
IS 3
AR 1709
DI 10.3390/ijms23031709
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YY9DP
UT WOS:000755085800001
PM 35163631
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shen, HT
   Li, J
   Heisler-Taylor, T
   Makin, R
   Yang, H
   Mavlyutov, TA
   Gelfand, B
   Cebulla, CM
   Guo, LW
AF Shen, Hongtao
   Li, Jing
   Heisler-Taylor, Tyler
   Makin, Ryan
   Yang, Huan
   Mavlyutov, Timur A.
   Gelfand, Bradley
   Cebulla, Colleen M.
   Guo, Lian-Wang
TI TMEM97 ablation aggravates oxidant-induced retinal degeneration
SO CELLULAR SIGNALLING
LA English
DT Article
DE TMEM97; Retina; RPE; Photoreceptor; Oxidative stress; Mitochondria;
   Lysosome
ID OXIDATIVE STRESS; SODIUM IODATE; PROTEIN; IDENTIFICATION; RECEPTOR;
   AFFINITY; POLDIP2; SYSTEM; GENES; CELLS
AB The retinal pigment epithelium (RPE) is critical to the survival of the overlying photoreceptors. Subject to light exposure and active metabolism, the RPE and photoreceptors are particularly susceptible to oxidative damage that plays an important part in age-related macular degeneration (AMD). Recent meta-analyses identified TMEM97 as a new putative AMD risk locus, though it is yet to be functionally verified. The role of TMEM97 in the retina and RPE is not known. Here we investigated TMEM97 function using the sodium iodate model of oxidant-induced retinal degeneration in TMEM97 knockout (KO) mice. We found markedly increased reactive oxygen species (ROS) and loss of photoreceptos in TMEM97 KO mouse retinas relative to wild type (WT) controls. In vitro, sodium iodate treatment of CRISPR-mediated TMEM97 KO RPE cells resulted in diminished abundance of the master antioxidant transcription factor NRF2 and its target gene product SOD2, the mitochondrial superoxide dismutase, as well as elevated ROS and apoptosis markers. Moreover, TMEM97 KO affected proteins key to mitochondrial and lysosomal stability and impeded autophagy flux. These findings suggest that the absence of TMEM97 in RPE cells disturbs redox-balancing systems, thereby heightening oxidative stress. As TMEM97 is a druggable target, this study may inspire interest in basic and translational research in the context of retinal degeneration.
C1 [Shen, Hongtao; Li, Jing; Guo, Lian-Wang] Univ Virginia, Sch Med, Dept Surg, 409 Lane Rd, Charlottesville, VA 22908 USA.
   [Heisler-Taylor, Tyler; Cebulla, Colleen M.] Ohio State Univ, Dept Ophthalmol & Visual Sci, Columbus, OH 43212 USA.
   [Makin, Ryan; Gelfand, Bradley] Univ Virginia, Sch Med, Ctr Adv Vis Sci, Charlottesville, VA 22908 USA.
   [Makin, Ryan; Gelfand, Bradley; Guo, Lian-Wang] Univ Virginia, Sch Med, Dept Ophthalmol, Charlottesville, VA 22908 USA.
   [Yang, Huan; Mavlyutov, Timur A.] Univ Wisconsin, Dept Surg, Madison, WI 53705 USA.
   [Gelfand, Bradley] Univ Virginia, Sch Med, Dept Biomed Engn, Charlottesville, VA 22908 USA.
C3 University of Virginia; University System of Ohio; Ohio State
   University; University of Virginia; University of Virginia; University
   of Wisconsin System; University of Wisconsin Madison; University of
   Virginia
RP Guo, LW (通讯作者)，Univ Virginia, Sch Med, Dept Surg, 409 Lane Rd, Charlottesville, VA 22908 USA.; Cebulla, CM (通讯作者)，Ohio State Univ, Dept Ophthalmol & Visual Sci, Columbus, OH 43212 USA.
EM colleen.cebulla@osumc.edu; lg8zr@virginia.edu
FU NIH R01 grant [EY029809]; NIH [R01EY028027, R01EY031039]; BrightFocus
   Foundation; Owens Family Foundation; Ohio Lions Eye Research Foundation
FX Dr. Guo has received support from NIH R01 grant EY029809. Dr. Gelfand
   has received support from NIH grants (R01EY028027 and R01EY031039) ,
   BrightFocus Foundation, and the Owens Family Foun-dation. Dr. Cebulla
   holds the Torrence A. Makley Research Professorship and receives support
   from the Ohio Lions Eye Research Foundation. We thank Dr. Arnold E Ruoho
   for his support with the photoaffinity labeling reagents and equipment.
CR Abate C, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.589810
   Alon A, 2017, P NATL ACAD SCI USA, V114, P7160, DOI 10.1073/pnas.1705154114
   Aydar E, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.590519
   Bartz F, 2009, CELL METAB, V10, P63, DOI 10.1016/j.cmet.2009.05.009
   BERENCSI K, 1985, ACTA VIROL, V29, P61
   Blass BE, 2018, EXPERT OPIN THER PAT, V28, P655, DOI 10.1080/13543776.2018.1519024
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Chu UB, 2015, EBIOMEDICINE, V2, P1806, DOI 10.1016/j.ebiom.2015.10.017
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davidson M, 2017, AM J PSYCHIAT, V174, P1195, DOI 10.1176/appi.ajp.2017.17010122
   Elbatreek MH, 2021, HANDB EXP PHARMACOL, V264, P145, DOI 10.1007/164_2020_387
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grundman M, 2019, ALZH DEMENT-TRCI, V5, P20, DOI 10.1016/j.trci.2018.11.001
   Haileselassie B, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-019-1689-8
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   HELLEWELL SB, 1990, BRAIN RES, V527, P244, DOI 10.1016/0006-8993(90)91143-5
   Kim H, 2020, JOVE-J VIS EXP, DOI 10.3791/60682
   Leeman DS, 2018, SCIENCE, V359, P1277, DOI 10.1126/science.aag3048
   Li LL, 2018, HYPERTENSION, V72, P1208, DOI 10.1161/HYPERTENSIONAHA.118.11354
   Liu XY, 2017, ONCOTARGET, V8, P59345, DOI 10.18632/oncotarget.19581
   Lyle AN, 2009, CIRC RES, V105, P249, DOI 10.1161/CIRCRESAHA.109.193722
   Matsumoto RR, 2014, ADV PHARMACOL, V69, P323, DOI 10.1016/B978-0-12-420118-7.00009-3
   Miles AL, 2017, ELIFE, V6, DOI 10.7554/eLife.22693
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nicholson H, 2016, J PHARMACOL EXP THER, V356, P232, DOI 10.1124/jpet.115.228387
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Paredes F, 2018, P NATL ACAD SCI USA, V115, P1789, DOI 10.1073/pnas.1720693115
   Plotegher N, 2017, TRENDS MOL MED, V23, P116, DOI 10.1016/j.molmed.2016.12.003
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Riad A, 2020, MOL NEUROBIOL, V57, P3803, DOI 10.1007/s12035-020-01988-1
   Sabouny R, 2017, ANTIOXID REDOX SIGN, V27, P1447, DOI 10.1089/ars.2016.6855
   Sanchez-Blazquez P, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-00676-4
   Sano H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1365-z
   Shen HT, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.201900540
   Sivandzade F, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3128
   Sreekumar PG, 2018, J CONTROL RELEASE, V283, P94, DOI 10.1016/j.jconrel.2018.05.014
   Tanida I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110600
   Upadhyay M, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101623
   Wang FJ, 2018, TRAFFIC, V19, P918, DOI 10.1111/tra.12613
   Wang J, 2015, FREE RADICAL BIO MED, V86, P25, DOI 10.1016/j.freeradbiomed.2015.04.009
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Yang H, 2019, AUTOPHAGY, V15, P1539, DOI 10.1080/15548627.2019.1586248
   Yang H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0202-z
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zeng C, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0141-2
   Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604
NR 51
TC 2
Z9 2
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD OCT
PY 2021
VL 86
AR 110078
DI 10.1016/j.cellsig.2021.110078
EA JUL 2021
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA UH1QS
UT WOS:000689714700006
PM 34245862
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Richard, AJ
   Duker, JS
   Reichel, E
AF Richard, Alyse J.
   Duker, Jacob S.
   Reichel, Elias
TI Geographic atrophy: where we are now and where we are going
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE geographic atrophy; macular degeneration
AB Purpose of review Age-related macular degeneration (AMD) affects a significant percentage of the elderly population and end-stage disease classified by either geographic atrophy (GA) or neovascular AMD (nvAMD) is one of the leading causes of vision loss worldwide. Despite the fact that there are currently treatments for nvAMD, there are no treatments in practice to prevent disease onset or progression of GA. This topic is at the forefront of ophthalmic research demonstrated by the recent advances in disease characterization, genetic and environmental risk factor classification, biomarker discovery and mechanism of pathogenesis categorization. There are also numerous clinical treatment trials underway, targeting proposed pathways and biomarkers associated with GA that are promising. Recent findings With several clinical trials of potential treatments underway and numerous recent publications on disease diagnosis and classification, the understanding of GA pathogenesis has increased substantially. Although the exact mechanism of pathology is still elusive, recent literature has highlighted the utilization of current and new ophthalmic imaging modalities and discovery of objective and functional markers that can lead to earlier diagnosis and treatment. Herein, we will provide an overview and discussion of the current status of GA including advances in mechanism of pathogenesis, diagnosis, classification and current treatment modalities.
C1 [Richard, Alyse J.; Duker, Jacob S.; Reichel, Elias] Tufts Univ, Sch Med, New England Eye Ctr, Vitreoretinal Serv Dept, Boston, MA 02111 USA.
C3 Tufts University
RP Reichel, E (通讯作者)，New England Eye Ctr, 800 Washington St,Box 450, Boston, MA 02111 USA.
EM reichelconsulting@gmail.com
FU RPB Challenge grant
FX This research was supported in part by an RPB Challenge grant made to
   the Department of Ophthalmology, Tufts Medical Center. The authors do
   not have any proprietary interests in the materials described in the
   article. The authors have no other financial interests to disclose. This
   manuscript has not been previously presented at a meeting.
CR Ahluwalia A, 2021, GRAEF ARCH CLIN EXP, V259, P307, DOI 10.1007/s00417-020-04892-5
   Biarnes M, 2020, OPHTHALMOL RETINA, V4, P1129, DOI 10.1016/j.oret.2020.04.014
   Bonilha V., 2020, INVESTIG OPHTHALMOL, V61, P1
   Brown EE., 2018, RETIN DEGENER DIS ME, V1074, P1
   Corradetti G, 2021, BRIT J OPHTHALMOL, V105, P1584, DOI 10.1136/bjophthalmol-2020-316893
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Hou XW., 2020, INVEST OPHTHALMOL VI, V61, P1
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Kolomeyer AM, 2021, RETINA-J RET VIT DIS, V41, P125, DOI 10.1097/IAE.0000000000002825
   Kunzel SH., 2020, INVESTIG OPHTHALMOL, V61, P1
   Lashkari K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236283
   Liutkeviciene R, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1357
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Muller PL., 2020, OPHTHALMOLOGICA, V244, P42
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Rim TH, 2020, OPHTHALMOLOGY, V127, P1371, DOI 10.1016/j.ophtha.2020.04.019
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0
   Shen LL., 2020, INVESTIG OPHTHALMOL, V61, P1
   WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
NR 26
TC 5
Z9 5
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2021
VL 32
IS 3
BP 247
EP 252
DI 10.1097/ICU.0000000000000763
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SS7CW
UT WOS:000661913000011
PM 33741759
DA 2022-11-30
ER

PT J
AU Telegina, DV
   Kulikova, EA
   Kozhevnikova, OS
   Kulikov, AV
   Khomenko, TM
   Volcho, KP
   Salakhutdinov, NF
   Kolosova, NG
AF Telegina, Darya, V
   Kulikova, Elizabeth A.
   Kozhevnikova, Oyuna S.
   Kulikov, Alexander, V
   Khomenko, Tatyana M.
   Volcho, Konstantin P.
   Salakhutdinov, Nariman F.
   Kolosova, Nataliya G.
TI Alterations of STEP46 and STEP61 Expression in the Rat Retina with Age
   and AMD-Like Retinopathy Development
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; striatal-enriched protein tyrosine
   phosphatase; Ptpn5; STEP46; STEP61; TC-2153; OXYS rats
ID PROTEIN-TYROSINE-PHOSPHATASE;
   8-(TRIFLUOROMETHYL)-1,2,3,4,5-BENZOPENTATHIEPIN-6-AMINE HYDROCHLORIDE
   TC-2153; ALZHEIMERS-DISEASE; GENE-EXPRESSION; NMDA RECEPTORS;
   CELL-DEATH; MEMORY; INHIBITION; PLASTICITY; PATHWAY
AB Tyrosine phosphatase STEP (striatal-enriched tyrosine protein phosphatase) is a brain-specific protein phosphatase and is involved in the pathogenesis of many neurodegenerative diseases. Here, we examined the impact of STEP on the development of age-related macular degeneration (AMD)-like pathology in senescence-accelerated OXYS rats. Using OXYS and Wistar rats (control), we for the first time demonstrated age-dependent changes inPtpn5mRNA expression, STEP46 and STEP61 protein levels, and their phosphatase activity in the retina. The increases in STEP protein levels and the decrease of total and STEP phosphatase activities in the retina (as compared with Wistar rats) preceded the manifestation of clinical signs of AMD in OXYS rats (age 20 days). There were no differences in these retinal parameters between 13-month-old Wistar rats and OXYS rats with pronounced signs of AMD. Inhibition of STEP with TC-2153 during progressive AMD-like retinopathy (from 9 to 13 months of age) reduced the thickness of the retinal inner nuclear layer, as evidenced by a decreased amount of parvalbumin-positive amacrine neurons. Prolonged treatment with TC-2153 had no effect onPtpn5mRNA expression, STEP46 and STEP61 protein levels, and their phosphatase activity in the OXYS retina. Thus, TC-2153 may negatively affect the retina through mechanisms unrelated to STEP.
C1 [Telegina, Darya, V; Kulikova, Elizabeth A.; Kozhevnikova, Oyuna S.; Kulikov, Alexander, V; Kolosova, Nataliya G.] Russian Acad Sci SB RAS, Siberian Branch, Inst Cytol & Genet, Pr Lavrentyeva 10, Novosibirsk 630090, Russia.
   [Khomenko, Tatyana M.; Volcho, Konstantin P.; Salakhutdinov, Nariman F.; Kolosova, Nataliya G.] SB RAS, NN Vorozhtsov Inst Organ Chem, 9 Lavrentieva Ave, Novosibirsk 630090, Russia.
C3 Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Russian Academy of Sciences; Vorozhtsov Novosibirsk Institute of
   Organic Chemistry
RP Telegina, DV (通讯作者)，Russian Acad Sci SB RAS, Siberian Branch, Inst Cytol & Genet, Pr Lavrentyeva 10, Novosibirsk 630090, Russia.
EM telegina@bionet.nsc.ru; kulikova@bionet.nsc.ru; oidopova@bionet.nsc.ru;
   v_kulikov@bionet.nsc.ru; chomenko@nioch.nsc.ru; volcho@nioch.nsc.ru;
   anvar@nioch.nsc.ru; kolosova@bionet.nsc.ru
RI Kozhevnikova, Oyuna S./H-3588-2016; Telegina, Darya/AAQ-6062-2020;
   Volcho, Konstantin/Q-9188-2016; Kolosova, Nataliya G/P-3178-2015
OI Kozhevnikova, Oyuna S./0000-0001-6475-4061; Telegina,
   Darya/0000-0001-8096-0519; Volcho, Konstantin/0000-0002-4083-9324;
   Kolosova, Nataliya G/0000-0003-2398-8544; Salakhutdinov,
   Nariman/0000-0001-8512-4309
FU Russian Ministry of Science and Higher Education [14.W03.31.0034]; Basic
   Research Project for a Young Researcher [0259-2019-0002-c-01]
FX Animals: their maintenance and treatment with TC-2153,
   immunohistochemical examination, and the APC were funded by the Russian
   Ministry of Science and Higher Education within grant number
   14.W03.31.0034 (megagrant). The assays of gene expression and
   phosphatase activities, and western blotting were funded by a Basic
   Research Project for a Young Researcher, grant number
   0259-2019-0002-c-01.
CR BOULANGER LM, 1995, J NEUROSCI, V15, P1532
   Bowie D, 2012, J PHYSIOL-LONDON, V590, P49, DOI 10.1113/jphysiol.2011.221689
   Braithwaite SP, 2006, TRENDS NEUROSCI, V29, P452, DOI 10.1016/j.tins.2006.06.007
   Cases S, 2018, MOL CELL NEUROSCI, V86, P41, DOI 10.1016/j.mcn.2017.11.003
   Castonguay D, 2018, CURR BIOL, V28, P1079, DOI 10.1016/j.cub.2018.02.047
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gojon G, 2020, ANTIOXID REDOX SIGN, V33, P1010, DOI 10.1089/ars.2020.8060
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kamceva M, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8136925
   Karasawa T, 2014, NEUROSCI RES, V89, P1, DOI 10.1016/j.neures.2014.08.018
   Khomenko TM, 2009, LETT DRUG DES DISCOV, V6, P464, DOI 10.2174/157018009789057544
   Kolosova N. G., 2014, ADV GERONTOL, V4, P294, DOI DOI 10.1134/S2079057014040146
   Kolosova NG, 2018, AGING-US, V10, P2136, DOI 10.18632/aging.101537
   Kothmann WW, 2012, J NEUROSCI, V32, P6747, DOI 10.1523/JNEUROSCI.5087-11.2012
   Kozhevnikova OS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194804
   Kozhevnikova OS, 2018, BIOGERONTOLOGY, V19, P223, DOI 10.1007/s10522-018-9751-y
   Kozhevnikova OS, 2013, BIOGERONTOLOGY, V14, P753, DOI 10.1007/s10522-013-9439-2
   Kozhevnikova OS, 2013, CELL CYCLE, V12, P1745, DOI 10.4161/cc.24825
   Kulikov AV, 2014, LETT DRUG DES DISCOV, V11, P169
   Kulikov AV, 2012, PSYCHOPHARMACOLOGY, V221, P469, DOI 10.1007/s00213-011-2594-8
   Kulikov AV, 2005, J NEUROSCI METH, V141, P97, DOI 10.1016/j.jneumeth.2004.06.005
   Kulikova EA, 2020, MOL BIOL+, V54, P274, DOI 10.1134/S0026893320020090
   Kulikova EA, 2018, NEUROSCIENCE, V394, P220, DOI 10.1016/j.neuroscience.2018.10.031
   Kulikova E, 2017, CURR PROTEIN PEPT SC, V18, P1152, DOI 10.2174/1389203718666170710121532
   Kurup P, 2010, CHANNELS, V4, P347, DOI [10.1523/JNEUROSCI.0157-10.2010, 10.4161/chan.4.5.12910]
   Li L, 2015, ANESTHESIOLOGY, V122, P686, DOI 10.1097/ALN.0000000000000532
   Lombroso Paul J, 2016, F1000Res, V5, DOI 10.12688/f1000research.8571.1
   Lorber B, 2004, MOL CELL NEUROSCI, V27, P404, DOI 10.1016/j.mcn.2004.06.012
   Mota SI, 2014, NEUROPHARMACOLOGY, V76, P16, DOI 10.1016/j.neuropharm.2013.08.013
   Naumenko VS, 2008, J NEUROSCI METH, V170, P197, DOI 10.1016/j.jneumeth.2008.01.008
   Olausson P, 2012, NEUROSCIENCE, V225, P1, DOI 10.1016/j.neuroscience.2012.07.069
   Paul S, 2007, BIOL PSYCHIAT, V61, P1049, DOI 10.1016/j.biopsych.2006.08.005
   Rajagopal S, 2016, NEUROBIOL AGING, V41, P25, DOI 10.1016/j.neurobiolaging.2016.02.004
   Rudnitskaya EA, 2017, BIOCHEMISTRY-MOSCOW+, V82, P318, DOI 10.1134/S0006297917030105
   Rudnitskaya EA, 2019, EXP GERONTOL, V115, P32, DOI 10.1016/j.exger.2018.11.008
   Stenkamp DL, 2015, PROG MOL BIOL TRANSL, V134, P397, DOI 10.1016/bs.pmbts.2015.06.006
   Szabo K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09068-6
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Telegina DV, 2017, ADV GERONTOL, V7, P17, DOI 10.1134/S2079057017010155
   Telegina DV, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225632
   Telegina DV, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0493-8
   Telegina DV, 2017, SCI REP-UK, V7, DOI 10.1038/srep41533
   Telegina DV, 2015, CELL CYCLE, V14, P3544, DOI 10.1080/15384101.2015.1080399
   Veruki ML, 2019, J NEUROSCI, V39, P627, DOI 10.1523/JNEUROSCI.2267-18.2018
   Wang Z, 2017, J ALZHEIMERS DIS, V56, P415, DOI 10.3233/JAD-160724
   Xu J, 2018, MOL NEUROBIOL, V55, P3096, DOI 10.1007/s12035-017-0555-x
   Xu J, 2016, CELL MOL LIFE SCI, V73, P1503, DOI 10.1007/s00018-015-2057-1
   Xu J, 2015, J NEUROCHEM, V134, P629, DOI 10.1111/jnc.13160
   Xu J, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001923
   Xu J, 2012, ADV PHARMACOL, V64, P303, DOI 10.1016/B978-0-12-394816-8.00009-X
   Xu J, 2012, J BIOL CHEM, V287, P20942, DOI 10.1074/jbc.M112.368654
   Zhang L, 2013, J NEUROSCI RES, V91, P1581, DOI 10.1002/jnr.23263
NR 53
TC 3
Z9 3
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2020
VL 21
IS 15
AR 5182
DI 10.3390/ijms21155182
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NA0OJ
UT WOS:000559519200001
PM 32707818
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kawashima, H
   Ozawa, Y
   Toda, E
   Homma, K
   Osada, H
   Narimatsu, T
   Nagai, N
   Tsubota, K
AF Kawashima, Hirohiko
   Ozawa, Yoko
   Toda, Eriko
   Homma, Kohei
   Osada, Hideto
   Narimatsu, Toshio
   Nagai, Norihiro
   Tsubota, Kazuo
TI Neuroprotective and vision-protective effect of preserving ATP levels by
   AMPK activator
SO FASEB JOURNAL
LA English
DT Article
DE AMPK; ATP; Neurodegeneration; photostress; retina
ID RETINAL-PIGMENT EPITHELIUM; STRAND BREAK REPAIR; OXIDATIVE-METABOLISM;
   PROTEIN-KINASE; LIGHT; RHODOPSIN; DNA; OVEREXPRESSION; DEGENERATION;
   RETINOPATHY
AB Progression of blinding diseases, such as age-related macular degeneration, is accelerated by light exposure. However, no particular intervention is applied to the photostress. Here, we report neuroprotective effects of the adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator, 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR), on light-induced visual function impairment, photoreceptor disorders and death in mice. Increase in retinal ATP levels in response to photostress was transient, because oxygen consumption rate (OCR) and cytochrome c oxidase (CcO) activity were reduced under photostress. However, AICAR treatment preserved OCR, CcO activity, and high levels of retinal ATP after light exposure. AMPK knockdown in the photoreceptor-derived cell line revealed that AMPK targeted CcO activity. Further, our data indicated that photostress reduced mitochondrial respiratory function and ATP levels, while AICAR treatment promoted neuronal survival and retained visual function, stabilizing ATP levels through preserved CcO activity. The current study has provided proof of concept for providing cells with sufficient energy to promote cell survival in the presence of cellular stress. This is in contrast to the previous reports which primarily investigated therapeutic approaches to suppress stress signals. Hence, stabilization of the ATP supply may serve as a novel therapeutic approach to support tissue survival under stress and prevent neurodegeneration.
C1 [Kawashima, Hirohiko; Ozawa, Yoko; Toda, Eriko; Homma, Kohei; Osada, Hideto; Narimatsu, Toshio; Nagai, Norihiro] Keio Univ, Lab Retinal Cell Biol, Sch Med, Tokyo, Japan.
   [Kawashima, Hirohiko; Ozawa, Yoko; Narimatsu, Toshio; Nagai, Norihiro; Tsubota, Kazuo] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
C3 Keio University; Keio University
RP Ozawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ozawa@a5.keio.jp
RI Homma, Kohei/AAF-6716-2021; Ozawa, Yoko/AAH-9888-2020; Tsubota,
   Kazuo/M-1915-2013
OI Homma, Kohei/0000-0002-6253-8047; Ozawa, Yoko/0000-0003-4797-5705;
   Osada, Hideto/0000-0001-9971-8992; Tsubota, Kazuo/0000-0002-8874-7111
FU Japan Society of the Promotion of Science [18K09422]; Keio | School of
   Medicine, Keio University (School of Medicine, Keio University)
FX Japan Society of the Promotion of Science, Grant/Award Number: 18K09422;
   Keio | School of Medicine, Keio University (School of Medicine, Keio
   University)
CR Ban N, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0017-8
   Braakman I, 2011, ANNU REV BIOCHEM, V80, P71, DOI 10.1146/annurev-biochem-062209-093836
   Cai ZY, 2012, NEUROMOL MED, V14, P1, DOI 10.1007/s12017-012-8173-2
   Canto C, 2010, CELL MOL LIFE SCI, V67, P3407, DOI 10.1007/s00018-010-0454-z
   Carling D, 2017, CURR OPIN CELL BIOL, V45, P31, DOI 10.1016/j.ceb.2017.01.005
   Choi SU, 2019, EYE, V33, P1540, DOI 10.1038/s41433-019-0439-6
   CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x
   Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879
   Hopfner KP, 2014, BIOESSAYS, V36, P1170, DOI 10.1002/bies.201400102
   Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.16
   Kooragayala K, 2015, INVEST OPHTH VIS SCI, V56, P8428, DOI 10.1167/iovs.15-17901
   Kubota S, 2010, AM J PATHOL, V177, P1725, DOI 10.2353/ajpath.2010.100098
   Maeda A, 2009, J BIOL CHEM, V284, P15173, DOI 10.1074/jbc.M900322200
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Narimatsu T, 2014, CLIN EXP OPHTHALMOL, V42, P555, DOI 10.1111/ceo.12253
   Narimatsu T, 2014, FREE RADICAL BIO MED, V71, P176, DOI 10.1016/j.freeradbiomed.2014.03.020
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Okamoto T, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.20
   Okamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146517
   Osada H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178627
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Ozawa Y, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/506137
   Ozawa Y, 2008, J BIOL CHEM, V283, P24561, DOI 10.1074/jbc.M802238200
   Pobre KFR, 2019, J BIOL CHEM, V294, P2098, DOI 10.1074/jbc.REV118.002804
   Rak M, 2016, CLIN SCI, V130, P393, DOI 10.1042/CS20150707
   Reme CE, 1999, INVEST OPHTH VIS SCI, V40, P2398
   Reme CE, 1998, PROG RETIN EYE RES, V17, P443, DOI 10.1016/S1350-9462(98)00009-3
   Rojowska A, 2014, EMBO J, V33, P2847, DOI 10.15252/embj.201488889
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Saydah S, 2019, MMWR-MORBID MORTAL W, V68, P453, DOI 10.15585/mmwr.mm6820a2
   SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4
   Sung CH, 2010, J CELL BIOL, V190, P953, DOI 10.1083/jcb.201006020
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tan E, 2001, INVEST OPHTH VIS SCI, V42, P589
   Wen XH, 2009, BIOPHYS J, V96, P939, DOI 10.1016/j.bpj.2008.10.016
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667
   Xiao B, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms4017
   Xu L, 2018, P NATL ACAD SCI USA, V115, P10475, DOI 10.1073/pnas.1802724115
   Zhang C, 2015, J ALZHEIMERS DIS, V44, P375, DOI 10.3233/JAD-141890
NR 49
TC 9
Z9 9
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD APR
PY 2020
VL 34
IS 4
BP 5016
EP 5026
DI 10.1096/fj.201902387RR
EA FEB 2020
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA LJ5ZA
UT WOS:000515260900001
PM 32090372
OA hybrid
DA 2022-11-30
ER

PT J
AU Ben M'Barek, K
   Bertin, S
   Brazhnikova, E
   Jaillard, C
   Habeler, W
   Plancheron, A
   Fovet, CM
   Demilly, J
   Jarraya, M
   Bejanariu, A
   Sahel, JA
   Peschanski, M
   Goureau, O
   Monville, C
AF Ben M'Barek, Karim
   Bertin, Stephane
   Brazhnikova, Elena
   Jaillard, Celine
   Habeler, Walter
   Plancheron, Alexandra
   Fovet, Claire-Maelle
   Demilly, Joanna
   Jarraya, Mohamed
   Bejanariu, Ana
   Sahel, Jose-Alain
   Peschanski, Marc
   Goureau, Olivier
   Monville, Christelle
TI Clinical-grade production and safe delivery of human ESC derived RPE
   sheets in primates and rodents
SO BIOMATERIALS
LA English
DT Article
DE Cell therapy; Human pluripotent stem cells; Retinitis pigmentosa;
   Age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; EMBRYONIC STEM-CELLS; MACULAR DEGENERATION;
   TRANSPLANTATION; BANKING; DONOR
AB Age-related macular degeneration as well as some forms of Retinitis Pigmentosa (RP) are characterized by a retinal degeneration involving the retinal pigment epithelium (RPE). Various strategies were proposed to cure these disorders including the replacement of RPE cells using human pluripotent stem cells (hPSCs), an unlimited source material to generate in vitro RPE cells. The formulation strategy of the cell therapy (either a reconstructed sheet or a cell suspension) is crucial to achieve an efficient and long lasting therapeutic effect. We previously developed a hPSC-RPE sheet disposed on human amniotic membrane that sustained the vision of rodents with retinal degeneration compared to the same cells injected as a suspension. However, the transplantation strategy was difficult to implement in large animals. Herein we developed two medical devices for the preparation, conservation and implantation of the hPSC-RPE sheet in nonhuman primates. The surgery was safe and well tolerated during the 7-week follow up. The graft integrity was preserved in primates. Moreover, the hPSC-RPE sheet did not induce teratoma or grafted cell dispersion to other organs in rodent models. This work clears the way for the first cell therapy for RP patients carrying RPE gene mutations (LRAT, RPE65 and MERTK).
C1 [Ben M'Barek, Karim; Habeler, Walter; Plancheron, Alexandra; Peschanski, Marc; Monville, Christelle] INSERM, Inst Stem Cell Therapy & Explorat Monogen Dis, U861, I Stem,AFM, F-91100 Corbeil Essonnes, France.
   [Ben M'Barek, Karim; Habeler, Walter; Plancheron, Alexandra; Peschanski, Marc; Monville, Christelle] UEVE, Inst Stem Cell Therapy & Explorat Monogen Dis, U861, I Stem,AFM, F-91100 Corbeil Essonnes, France.
   [Ben M'Barek, Karim; Habeler, Walter; Plancheron, Alexandra; Bejanariu, Ana; Peschanski, Marc] CECS, Inst Stem Cell Therapy & Explorat Monogen Dis, AFM, I Stem, F-91100 Corbeil Essonnes, France.
   [Bertin, Stephane; Sahel, Jose-Alain] INSERM, DHU Sight Restore, CHNO Quinze Vingts, DGOS, CIC 1423, Paris, France.
   [Brazhnikova, Elena; Jaillard, Celine; Sahel, Jose-Alain; Goureau, Olivier] Sorbonne Univ, INSERM, CNRS, Inst Vis, F-75012 Paris, France.
   [Fovet, Claire-Maelle; Demilly, Joanna] CEA, MIRCen, F-92260 Far, France.
   [Jarraya, Mohamed] Hop St Louis, AP HP, Banque Tissus Humain, Paris, France.
   [Sahel, Jose-Alain] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15213 USA.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Saclay;
   UDICE-French Research Universities; Universite Paris Saclay;
   UDICE-French Research Universities; Universite Paris Saclay; CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; CEA;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris
   Cite; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh
RP Monville, C (通讯作者)，INSERM, Inst Stem Cell Therapy & Explorat Monogen Dis, U861, I Stem,AFM, F-91100 Corbeil Essonnes, France.; Monville, C (通讯作者)，UEVE, Inst Stem Cell Therapy & Explorat Monogen Dis, U861, I Stem,AFM, F-91100 Corbeil Essonnes, France.; Goureau, O (通讯作者)，Sorbonne Univ, INSERM, CNRS, Inst Vis, F-75012 Paris, France.
EM olivier.goureau@inserm.fr; cmonville@istem.fr
RI GOUREAU, Olivier/ABH-9547-2020; GOUREAU, Olivier/F-2752-2017; M'BAREK,
   Karim BEN/K-1389-2019
OI GOUREAU, Olivier/0000-0001-7730-9143; GOUREAU,
   Olivier/0000-0001-7730-9143; M'BAREK, Karim BEN/0000-0002-2556-0325;
   Demilly, Joanna/0000-0002-8345-9567
FU ANR [SightREPAIR] [ANR-16-CE17-008-02]; Fondation pour la Recherche
   Medicale [Bio-engineering program] [DBS20140930777]; LABEX REVIVE
   [ANR-10-LABX-73]; Fondation Maladies Rares (Preclinical Research); ANR
   within the Investissements d'Avenir (IA) program [ANR-10-LABX-65,
   ANR-11-IDEX-0004-02]; NeurATRIS, a translational research infrastructure
   (IA) for biotherapies in Neurosciences [ANR-11-INBS-0011]; INGESTEM, the
   national infrastructure (IA) engineering for pluripotent and
   differentiated stem cells [ANR-11-INBS-000]; Association Francaise
   contre les Myopathies (AFM)-Telethon
FX We thank EFS-ABG (Sophie Derenne, Thomas Zuliani, Pauline Souetre,
   Anne-Gaelle Chartois) for the production and the quality control of
   hESC-RPE sheets. We thank Cyrille Marechal and Nadege Morand from
   Medical Device Engineering (63160 Billom, France) for the valuable
   assistance in the development of medical devices. We thank CERB (18800
   Baugy, France) for rodent GLP safety studies, Genosafe (Evry, France)
   for the GLP biodistribution analysis and the animal facilities staff
   from CEA-MIRCen and Institut de la Vision. The authors would like to
   thank facilities from I-Stem for their support and Dr J. Larghero and Dr
   V. Vanneaux (Hopital Saint Louis, Paris, France) for their input during
   the setting-up of the strategy with human amniotic membrane. This work
   was supported by grants from the ANR [SightREPAIR: ANR-16-CE17-008-02],
   the Fondation pour la Recherche Medicale [Bio-engineering program
   -DBS20140930777] and from LABEX REVIVE [ANR-10-LABX-73] to CM and OG and
   by a grant from Fondation Maladies Rares (Preclinical Research) to OG.
   It was also performed in the frame of the LABEX LIFESENSES
   [ANR-10-LABX-65] supported by the ANR within the Investissements
   d'Avenir (IA) program [ANR-11-IDEX-0004-02] to OG and was supported by
   NeurATRIS, a translational research infrastructure (IA) for biotherapies
   in Neurosciences [ANR-11-INBS-0011] and INGESTEM, the national
   infrastructure (IA) engineering for pluripotent and differentiated stem
   cells [ANR-11-INBS-000] to CM. I-Stem is part of the Biotherapies
   Institute for Rare Diseases supported by the Association Francaise
   contre les Myopathies (AFM)-Telethon.
CR Andrews PW, 2015, REGEN MED, V10, P1, DOI [10.2217/RME.14.93, 10.2217/rme.14.93]
   Ben M'Barek K., 2018, J VIS EXP, V139
   Ben M'Barek K, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4568979
   Ben M'Barek K, 2018, ADV EXP MED BIOL, V1074, P625, DOI 10.1007/978-3-319-75402-4_76
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bendali A, 2015, BIOMATERIALS, V67, P73, DOI 10.1016/j.biomaterials.2015.07.018
   Berger W, 2010, PROG RETIN EYE RES, V29, P335, DOI 10.1016/j.preteyeres.2010.03.004
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   De Sousa PA, 2016, STEM CELL RES, V17, P1, DOI 10.1016/j.scr.2016.04.019
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gagliardi G, 2019, PROG RETIN EYE RES, V71, P1, DOI 10.1016/j.preteyeres.2019.03.001
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   He H, 2014, INVEST OPHTH VIS SCI, V55, P1647, DOI 10.1167/iovs.13-13094
   Hsiung J, 2015, STEM CELL TRANSL MED, V4, P10, DOI 10.5966/sctm.2014-0205
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kawamata S, 2015, J CLIN MED, V4, P159, DOI 10.3390/jcm4010159
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kiilgaard JF, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/716968
   Lorach H, 2015, INVEST OPHTH VIS SCI, V56, P7444, DOI 10.1167/iovs.15-17521
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Paolin A, 2016, CELL TISSUE BANK, V17, P51, DOI 10.1007/s10561-015-9520-y
   Roska B, 2018, NATURE, V557, P359, DOI 10.1038/s41586-018-0076-4
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Taylor CJ, 2005, LANCET, V366, P2019, DOI 10.1016/S0140-6736(05)67813-0
   Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Wilmut I, 2015, REGEN MED, V10, P235, DOI [10.2217/rme.15.1, 10.2217/RME.15.1]
   Zarbin M, 2019, STEM CELL TRANSL MED, V8, P466, DOI 10.1002/sctm.18-0282
NR 46
TC 13
Z9 13
U1 2
U2 24
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2020
VL 230
AR 119603
DI 10.1016/j.biomaterials.2019.119603
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA KE7QQ
UT WOS:000508746600018
PM 31732225
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kim, JW
   Kim, CG
   Lee, DW
AF Kim, Jae Hui
   Kim, Jong Woo
   Kim, Chul Gu
   Lee, Dong Won
TI Characteristics of Perifoveal Exudative Vascular Anomalous Complex in
   Korean Patients
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Perifoveal exudative vascular anomalous complex; macular telangiectasia;
   type 3 neovascularization; age-related macular degeneration; Korean
ID RETINAL ANGIOMATOUS PROLIFERATION; INTRAVITREAL BEVACIZUMAB; TYPE-3
   NEOVASCULARIZATION; EXPANDED SPECTRUM; FELLOW-EYE
AB Purpose: To investigate the clinical characteristics of perifoveal exudative vascular anomalous complex (PEVAC) in Korean patients. Methods: This retrospective study included 8 eyes (8 patients) diagnosed with PEVAC. Demographic characteristics of the patients, fundus photography, optical coherence tomography (OCT), fluorescein angiography, and indocyanine-green angiography (ICGA) findings were analyzed. Available follow-up data were also reviewed. Results: The mean +/- standard deviation age was 61.0 +/- 11.0 years and mean logarithm of minimal angle of resolution (logMAR) best-corrected visual acuity was 0.15 +/- 0.14. PEVAC was noted in 2 eyes with coincident age-related macular degeneration (AMD) and in the fellow eye of 1 eye with unilateral type 3 neovascularization. On fundus photography, PEVAC presented as a perifoveal isolated aneurysm associated with retinal exudation and hemorrhage. Well-defined hyperfluorescent lesions with leakage were noted on fluorescein angiography, but no leakage was observed on ICGA. Anti-vascular endothelial growth factor (VEGF) therapy was performed for 2 patients. However, there was no notable improvement after treatment. Conclusions: The clinical characteristics of PEVAC in Korean patients were similar to those reported in patients of other ethnicities. Further studies are needed to better understand the nature of this newly described clinical entity.
C1 [Kim, Jae Hui; Kim, Jong Woo; Kim, Chul Gu; Lee, Dong Won] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, Seoul, South Korea.
C3 Konyang University; Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center
FX This study was supported by Kim's Eye Hospital Research Center.
CR Ayachit AG, 2018, OSLI RETINA, V49, P974, DOI 10.3928/23258160-20181203-11
   Chang YS, 2016, ACTA OPHTHALMOL, V94, pE49, DOI 10.1111/aos.12748
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Issa PC, 2007, OPHTHALMOLOGY, V114, P1736, DOI 10.1016/j.ophtha.2007.03.079
   Mrejen S, 2020, RETINA-J RET VIT DIS, V40, P80, DOI 10.1097/IAE.0000000000002435
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   Querques G, 2011, J FR OPHTALMOL, V34, DOI 10.1016/j.jfo.2011.03.002
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sacconi R, 2017, AM J OPHTHALMOL, V184, P137, DOI 10.1016/j.ajo.2017.10.009
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 14
TC 7
Z9 8
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PD JUL 4
PY 2019
VL 34
IS 5
BP 353
EP 358
DI 10.1080/08820538.2019.1626450
EA JUN 2019
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ2ZF
UT WOS:000471398400001
PM 31165650
DA 2022-11-30
ER

PT J
AU Strunz, T
   Grassmann, F
   Gayan, J
   Nahkuri, S
   Souza-Costa, D
   Maugeais, C
   Fauser, S
   Nogoceke, E
   Weber, BHF
AF Strunz, Tobias
   Grassmann, Felix
   Gayan, Javier
   Nahkuri, Satu
   Souza-Costa, Debora
   Maugeais, Cyrille
   Fauser, Sascha
   Nogoceke, Everson
   Weber, Bernhard H. F.
TI A mega-analysis of expression quantitative trait loci (eQTL) provides
   insight into the regulatory architecture of gene expression variation in
   liver
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ESTER TRANSFER PROTEIN; MACULAR DEGENERATION;
   HDL-CHOLESTEROL; COMPLEMENT; VARIANTS; DATABASE; POLYMORPHISM; SEQUENCE;
   DISEASE
AB Genome-wide association studies (GWAS) have identified numerous genetic variants in the human genome associated with diseases and traits. Nevertheless, for most loci the causative variant is still unknown. Expression quantitative trait loci (eQTL) in disease relevant tissues is an excellent approach to correlate genetic association with gene expression. While liver is the primary site of gene transcription for two pathways relevant to age-related macular degeneration (AMD), namely the complement system and cholesterol metabolism, we explored the contribution of AMD associated variants to modulate liver gene expression. We extracted publicly available data and computed the largest eQTL data set for liver tissue to date. Genotypes and expression data from all studies underwent rigorous quality control. Subsequently, Matrix eQTL was used to identify significant local eQTL. In total, liver samples from 588 individuals revealed 202,489 significant eQTL variants affecting 1,959 genes (Q-Value < 0.001). In addition, a further 101 independent eQTL signals were identified in 93 of the 1,959 eQTL genes. Importantly, our results independently reinforce the notion that high density lipoprotein metabolism plays a role in AMD pathogenesis. Taken together, our study generated a first comprehensive map reflecting the genetic regulatory landscape of gene expression in liver.
C1 [Strunz, Tobias; Gayan, Javier; Nahkuri, Satu; Souza-Costa, Debora; Maugeais, Cyrille; Fauser, Sascha; Nogoceke, Everson] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Basel, Switzerland.
   [Strunz, Tobias; Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
C3 Roche Holding; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Strunz, Tobias/ABB-6300-2020; Strunz, Tobias/ABD-9798-2021
OI Strunz, Tobias/0000-0002-3744-9595; Grassmann, Felix/0000-0003-1390-7528
FU Institute of Human Genetics Regensburg [TG77]; Helmut Ecker Foundation
   (Ingolstadt, Germany) [05/17]; Roche Internships for Scientific Exchange
   (RiSE) Programme
FX TS was an awardee of the Roche Internships for Scientific Exchange
   (RiSE) Programme. The work has been supported in part by institutional
   funds (TG77) of the Institute of Human Genetics Regensburg and by a
   grant from the Helmut Ecker Foundation (Ingolstadt, Germany) to BHFW
   (No. 05/17).
CR Adams MKM, 2012, AM J EPIDEMIOL, V176, P289, DOI 10.1093/aje/kws004
   Aguet F, 2016, BIORXIV
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Arloth J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139516
   BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Benjamini Y, 2000, J EDUC BEHAV STAT, V25, P60, DOI 10.2307/1165312
   Bolstad Benjamin Milo, 2016, PREPROCESSCORE COLLE
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Clarke TK, 2017, MOL PSYCHIATR, V22, P1376, DOI 10.1038/mp.2017.153
   Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330
   Crowder M., 2011, INT STAT REV, V79, P134
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Dunning M., 2015, ILLUMINAHUMANV2 DB I
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Grassmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037979
   Gutierrez-Arcelus M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004958
   Hastie T, 1999, STATISTICS AND NEURAL NETWORKS, P1
   Hastie T., 2016, IMPUTE IMPUTATION MI
   Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198
   Hughes AE, 2016, INVEST OPHTH VIS SCI, V57, P2763, DOI 10.1167/iovs.15-18744
   Innocenti F, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002078
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kim Y, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.96
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Lin DY, 2010, GENET EPIDEMIOL, V34, P60, DOI 10.1002/gepi.20435
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Mabuchi H, 2014, MOL CELLS, V37, P777, DOI 10.14348/molcells.2014.0265
   Maller JB, 2012, NAT GENET, V44, P1294, DOI 10.1038/ng.2435
   McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330
   Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467
   Narahara M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100924
   Nguyen P, 2008, J ANIM PHYSIOL AN N, V92, P272, DOI 10.1111/j.1439-0396.2007.00752.x
   Nong ZX, 2003, J CLIN INVEST, V112, P367, DOI 10.1172/JCI200316484
   O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pouw RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152164
   R Core Team, 2015, R LANG ENV STAT COMP
   Ramasamy A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt069
   Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177
   Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107
   Schafer N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00542
   Schramm K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093844
   Schroder A, 2013, PHARMACOGENOMICS J, V13, P12, DOI 10.1038/tpj.2011.44
   Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163
   SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591
   Shrier I, 2007, CONTEMP CLIN TRIALS, V28, P324, DOI 10.1016/j.cct.2006.11.007
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142
   Stranger BE, 2012, PLOS GENET, V8, P272, DOI 10.1371/journal.pgen.1002639
   Tryka KA, 2014, NUCLEIC ACIDS RES, V42, pD975, DOI 10.1093/nar/gkt1211
   van Acker BAC, 2008, ATHEROSCLEROSIS, V200, P161, DOI 10.1016/j.atherosclerosis.2007.11.019
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Welter Danielle, 2014, Nucleic Acids Res, V42, pD1001, DOI 10.1093/nar/gkt1229
   Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864
   Wiliams AL, 2012, AM J HUM GENET, V91, P238, DOI 10.1016/j.ajhg.2012.06.013
   Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797
   Wright FA, 2014, NAT GENET, V46, P430, DOI 10.1038/ng.2951
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Zhang P, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600237
   Zhao SP, 2006, CLIN CHIM ACTA, V365, P149, DOI 10.1016/j.cca.2005.08.013
   Zheng HF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116487
   Zheng XW, 2012, BIOINFORMATICS, V28, P3326, DOI 10.1093/bioinformatics/bts606
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
NR 78
TC 38
Z9 38
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 12
PY 2018
VL 8
AR 5865
DI 10.1038/s41598-018-24219-z
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GC4WO
UT WOS:000429785900005
PM 29650998
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gonzalez-Salinas, R
   Hernandez-Zimbron, LF
   Gulias-Canizo, R
   Sanchez-Vela, MA
   Ochoa-De La Paz, L
   Zamora, R
   Quiroz-Mercado, H
AF Gonzalez-Salinas, Roberto
   Hernandez-Zimbron, Luis F.
   Gulias-Canizo, Rosario
   Alberto Sanchez-Vela, Mario
   Ochoa-De La Paz, Lenin
   Zamora, Ruben
   Quiroz-Mercado, Hugo
TI Current Anti-Integrin Therapy for Ocular Disease
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Al beta 2; alpha v beta 3; alpha 4 beta 1; integrin; LFA-1
ID DRY EYE DISEASE; OPHTHALMIC SOLUTION 5.0-PERCENT; STRUCTURAL BASIS;
   CELL-MIGRATION; RGD PEPTIDE; SAR 1118; LIFITEGRAST; ANTAGONIST;
   INFLAMMATION; LYMPHOCYTES
AB The integrin family of cell adhesion molecules mediates homeostasis, signal transduction, and various other interactions between the cell and the extracellular matrix. Integrins are type-1 transmembrane glycoproteins located on the cell surface, widely expressed in leukocytes, which play an important role in the inflammatory pathway. The purpose of this review is to summarize the current state of anti-integrin therapy and to assess ongoing clinical trials in ocular disease. We performed a search on PubMed, CINAHL, and Embase for the published literature available using the MeSH terms: "integrin therapy" and "alpha L beta 2," "alpha 4 beta 1" and "alpha 4 beta 7," "alpha v beta 3," "alpha v beta 5," and "alpha v beta 1" and/or "ophthalmology," and "clinical trials." We used no language restrictions. We generated searches to account for synonyms of these keywords and MESH headings as follows: (1) "integrin," "therapy," or "treatment"; (2) "clinical trials," "ophthalmology," or "ocular." In addition, the analysis included phase 2 and phase 3 clinical trials with a minimal follow-up of six months. Integrin antagonists have shown their capacity to improve signs and symptoms of patients with dry eye disease, age-related macular degeneration, diabetic macular edema, and vitreomacular traction.
C1 [Gonzalez-Salinas, Roberto; Hernandez-Zimbron, Luis F.; Gulias-Canizo, Rosario; Ochoa-De La Paz, Lenin; Zamora, Ruben; Quiroz-Mercado, Hugo] Asociac Evitar Ceguera Mexico IAP, Res Dept, Vicente Garcia Torres 46, Mexico City 04030, DF, Mexico.
   [Ochoa-De La Paz, Lenin] Univ Nacl Autonoma Mexico, Biochem Dept, Sch Med, Mexico City, DF, Mexico.
   [Gulias-Canizo, Rosario] IPN, Adv Res Ctr, Cell Biol Dept, CINVESTAV, Mexico City, DF, Mexico.
   [Alberto Sanchez-Vela, Mario] Inst Tecnol Estudios Super Monterrey, Sch Med, Mexico City, DF, Mexico.
   [Quiroz-Mercado, Hugo] Univ Colorado, Dept Ophthalmol, Denver, CO 80202 USA.
C3 Universidad Nacional Autonoma de Mexico; CINVESTAV - Centro de
   Investigacion y de Estudios Avanzados del Instituto Politecnico
   Nacional; Instituto Politecnico Nacional - Mexico; Tecnologico de
   Monterrey; University of Colorado System; University of Colorado Denver
RP Gonzalez-Salinas, R (通讯作者)，Asociac Evitar Ceguera Mexico IAP, Res Dept, Vicente Garcia Torres 46, Mexico City 04030, DF, Mexico.
EM dr.gonzalezsalinas@apec.com.mx.com
RI Gonzalez-Salinas, Roberto/I-3127-2016; Gulias-Cañizo,
   Rosario/AAN-1417-2020
OI Gonzalez-Salinas, Roberto/0000-0001-6654-5191; Gulias-Cañizo,
   Rosario/0000-0001-5732-9913; HERNANDEZ ZIMBRON, LUIS
   FERNANDO/0000-0002-5098-367X; Ochoa-de la Paz, Lenin/0000-0002-7561-0853
CR Abitorabi MA, 1996, J IMMUNOL, V156, P3111
   Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037
   Anderson ME, 2003, PEPTIDES, V24, P487, DOI 10.1016/S0196-9781(03)00083-4
   Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217
   Campbell DJ, 2002, J EXP MED, V195, P135, DOI 10.1084/jem.20011502
   Chauss D, 2015, J BIOL CHEM, V290, P30253, DOI 10.1074/jbc.M115.688390
   Chen C, 2014, J BIOL CHEM, V289, P28478, DOI 10.1074/jbc.M114.567446
   CURTIS TM, 1995, AM J PHYSIOL-LUNG C, V269, pL248, DOI 10.1152/ajplung.1995.269.2.L248
   Donnenfeld ED, 2016, CORNEA, V35, P741, DOI 10.1097/ICO.0000000000000803
   Ecoiffier T, 2008, ARCH OPHTHALMOL-CHIC, V126, P1695, DOI 10.1001/archopht.126.12.1695
   Evans R, 2009, J CELL SCI, V122, P215, DOI 10.1242/jcs.019117
   FDA, XIIDR LIF OPHTH SOL
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Frolikova M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33714
   Gomes JAP, 2004, BRIT J OPHTHALMOL, V88, P280, DOI 10.1136/bjo.2003.017731
   GREENWOOD J, 1995, IMMUNOLOGY, V86, P408
   Guerrero-Narranjo J.L., SAFETY EFFICACY STUD
   Hartman NC, 2009, P NATL ACAD SCI USA, V106, P12729, DOI 10.1073/pnas.0902621106
   HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x
   Hogg N, 2003, J CELL SCI, V116, P4695, DOI 10.1242/jcs.00876
   Holland EJ, 2016, CURR MED RES OPIN, V32, P1759, DOI 10.1080/03007995.2016.1210107
   Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200
   Jackson DY, 2002, CURR PHARM DESIGN, V8, P1229, DOI 10.2174/1381612023394737
   Johnson LA, 2006, J EXP MED, V203, P2763, DOI 10.1084/jem.20051759
   Karageozian V., PHASE A 2 RANDOMIZED
   Karageozian V., SAFETY EFFICACY STUD
   Karageozian V., ALLEGRO OPHTHALMICS
   Kinashi T, 2005, NAT REV IMMUNOL, V5, P546, DOI 10.1038/nri1646
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506
   Krauss AH, 2015, INVEST OPHTH VIS SCI, V56, P5888, DOI 10.1167/iovs.15-17249
   Kuppermann B.D., RETINA TODAY
   Kuppermann BD, 2016, ARVO S MAY 2 SEATTL
   Kuppermann BD., BREAKING BRIDGES INT
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Li YJ, 2014, EXP EYE RES, V129, P119, DOI 10.1016/j.exer.2014.11.004
   Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408
   Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618
   Milloud R, 2017, BIOL CELL, V109, P127, DOI 10.1111/boc.201600041
   Murphy CJ, 2011, INVEST OPHTH VIS SCI, V52, P3174, DOI 10.1167/iovs.09-5078
   Oliveira LB, 2002, CURR EYE RES, V25, P333, DOI 10.1076/ceyr.25.6.333.14234
   Pan L, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2502-0
   Park EJ, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0159-6
   Perez VL, 2016, OCUL SURF, V14, P207, DOI 10.1016/j.jtos.2016.01.001
   Pflugfelder SC, 2017, J OCUL PHARMACOL TH, V33, P5, DOI 10.1089/jop.2016.0105
   Pribila JT, 2004, ANNU REV IMMUNOL, V22, P157, DOI 10.1146/annurev.immunol.22.012703.104649
   Ravensberg AJ, 2006, ALLERGY, V61, P1097, DOI 10.1111/j.1398-9995.2006.01146.x
   Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876
   Rose DM, 2002, IMMUNOL REV, V186, P118, DOI 10.1034/j.1600-065X.2002.18611.x
   Rouzaut A, 2010, EUR J IMMUNOL, V40, P3054, DOI 10.1002/eji.201040523
   Schmidt S, 2010, CELL TISSUE RES, V339, P83, DOI 10.1007/s00441-009-0892-9
   Schwartz MA, 2011, ANNU REV CELL DEV BI, V11, P549
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Semba C., SAFETY STUDY LIFITEG
   Semba C., SAFETY EFFICACY STUD
   Semba CP, 2016, CLIN OPHTHALMOL, V10, P1083, DOI 10.2147/OPTH.S110557
   Semba CP, 2012, AM J OPHTHALMOL, V153, P1050, DOI 10.1016/j.ajo.2011.11.003
   Sheppard JD, 2014, OPHTHALMOLOGY, V121, P475, DOI 10.1016/j.ophtha.2013.09.015
   Smith A, 2003, J CELL SCI, V116, P3123, DOI 10.1242/jcs.00606
   Stern ME, 2002, INVEST OPHTH VIS SCI, V43, P2609
   Sun Y, 2013, J OCUL PHARMACOL TH, V29, P395, DOI 10.1089/jop.2012.0102
   Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215
   Tauber J., STUDY EVALUATE EFFIC
   Tauber J, 2015, OPHTHALMOLOGY, V122, P2423, DOI 10.1016/j.ophtha.2015.08.001
   Worthylake RA, 2003, J BIOL CHEM, V289, P28478
   Yonekawa K, 2005, J LEUKOCYTE BIOL, V77, P129, DOI 10.1189/jlb.0804460
   Zhang YB, 2012, IMMUNOLOGY, V135, P268, DOI 10.1111/j.1365-2567.2011.03549.x
NR 66
TC 9
Z9 10
U1 1
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2018
VL 33
IS 5
BP 634
EP 642
DI 10.1080/08820538.2017.1388411
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GM5CX
UT WOS:000438148800008
PM 29087767
DA 2022-11-30
ER

PT J
AU Tahiri, H
   Omri, S
   Yang, C
   Duhamel, F
   Samarani, S
   Ahmad, A
   Vezina, M
   Bussieres, M
   Vaucher, E
   Sapieha, P
   Hickson, G
   Hammamji, K
   Lapointe, R
   Rodier, F
   Tremblay, S
   Royal, I
   Cailhier, JF
   Chemtob, S
   Hardy, P
AF Tahiri, Houda
   Omri, Samy
   Yang, Chun
   Duhamel, Francois
   Samarani, Suzanne
   Ahmad, Ali
   Vezina, Mark
   Bussieres, Martin
   Vaucher, Elvire
   Sapieha, Przemyslaw
   Hickson, Gilles
   Hammamji, Karim
   Lapointe, Rejean
   Rodier, Francis
   Tremblay, Sophie
   Royal, Isabelle
   Cailhier, Jean-Francois
   Chemtob, Sylvain
   Hardy, Pierre
TI Lymphocytic Microparticles Modulate Angiogenic Properties of Macrophages
   in Laser-induced Choroidal Neovascularization
SO SCIENTIFIC REPORTS
LA English
DT Article
ID A SCAVENGER RECEPTORS; INFILTRATING MACROPHAGES; EPITHELIAL-CELLS; IL-12
   PRODUCTION; CD36; ACTIVATION; EXPRESSION; ATHEROSCLEROSIS; INFLAMMATION;
   APOPTOSIS
AB Pathological choroidal neovascularization (CNV) is the common cause of vision loss in patients with age-related macular degeneration (AMD). Macrophages possess potential angiogenic function in CNV. We have demonstrated that human T lymphocyte-derived microparticles (LMPs) exert a potent antiangiogenic effect in several pathological neovascularization models. In this study, we investigated the alteration of proangiogenic properties of macrophages by LMPs treatment in vitro and in vivo models. LMPs regulated the expression of several angiogenesis-related factors in macrophages and consequently stimulated their antiangiogenic effects evidenced by the suppression of the proliferation of human retinal endothelial cells in co-culture experiments. The involvement of CD36 receptor in LMPs uptake by macrophages was demonstrated by in vitro assays and by immunostaining of choroidal flat mounts. In addition, ex vivo experiments showed that CD36 mediates the antiangiogenic effect of LMPs in murine and human choroidal explants. Furthermore, intravitreal injection of LMPs in the mouse model of laser-induced CNV significantly suppressed CNV in CD36 dependent manner. The results of this study suggested an ability of LMPs to alter the gene expression pattern of angiogenesis-related factors in macrophages, which provide important information for a new therapeutic approach for efficiently interfering with both vascular and extravascular components of CNV.
C1 [Tahiri, Houda; Duhamel, Francois; Chemtob, Sylvain; Hardy, Pierre] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada.
   [Tahiri, Houda; Yang, Chun; Chemtob, Sylvain; Hardy, Pierre] Univ Montreal, CHU St Justine, Res Ctr, Montreal, PQ, Canada.
   [Omri, Samy; Sapieha, Przemyslaw; Chemtob, Sylvain] Univ Montreal, Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ, Canada.
   [Samarani, Suzanne; Ahmad, Ali] Univ Montreal, Dept Microbiol, Montreal, PQ, Canada.
   [Samarani, Suzanne; Ahmad, Ali] Univ Montreal, Dept Immunol, Montreal, PQ, Canada.
   [Vezina, Mark] Charles River Labs, Montreal, PQ, Canada.
   [Bussieres, Martin] V&O Serv, St Lazare, PQ, Canada.
   [Vaucher, Elvire] Univ Montreal, Sch Optometry, Montreal, PQ, Canada.
   [Sapieha, Przemyslaw; Hammamji, Karim; Chemtob, Sylvain] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Hickson, Gilles] Univ Montreal, Dept Pathol & Cell Biol, Montreal, PQ, Canada.
   [Lapointe, Rejean; Rodier, Francis; Royal, Isabelle; Cailhier, Jean-Francois] Univ Montreal, CRCHUM, Inst Canc Montreal, Montreal, PQ, Canada.
   [Lapointe, Rejean; Rodier, Francis; Royal, Isabelle; Cailhier, Jean-Francois] Univ Montreal, Dept Med, Montreal, PQ, Canada.
   [Rodier, Francis] Univ Montreal, Dept Radiol Radiooncol & Nucl Med, Montreal, PQ, Canada.
   [Tremblay, Sophie] Univ British Columbia, Vancouver, BC, Canada.
   [Tremblay, Sophie] Ctr Mol Med & Therapeut, Vancouver, BC, Canada.
   [Chemtob, Sylvain; Hardy, Pierre] Univ Montreal, Dept Pediat, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Centre Hospitalier
   Universitaire Sainte-Justine; Universite de Montreal; Universite de
   Montreal; Universite de Montreal; Universite de Montreal; Universite de
   Montreal; Universite de Montreal; Universite de Montreal; Universite de
   Montreal; Universite de Montreal; University of British Columbia;
   Universite de Montreal
RP Hardy, P (通讯作者)，Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada.; Hardy, P (通讯作者)，Univ Montreal, CHU St Justine, Res Ctr, Montreal, PQ, Canada.; Hardy, P (通讯作者)，Univ Montreal, Dept Pediat, Montreal, PQ, Canada.
EM pierre.hardy@recherche-ste-justine.qc.ca
OI Hickson, Gilles/0000-0001-7670-9815; Omri, Samy/0000-0002-2054-8298;
   Rodier, Francis/0000-0003-2523-309X; Vaucher, Elvire/0000-0001-7075-5263
FU Fonds de Recherche du Quebec en Sante (FRQS)-Vision Health Research
   Network and Antoine-Turmel Foundation [32645]; Canadian Institutes of
   Health Research [362383]; Fonds de Recherche du Quebec en Sante (FRQS);
   Canadian Institute of Health Research Frederick Banting and Charles Best
   Canada Graduate Scholarship; FRQS PhD Scholarship for Health
   Professional; Stars Foundation & CHU Sainte-Justine's Foundation
   Scholarship for Excellence (PhD); Hydro-Quebec Scholarship for
   Excellence; Canada Research Chair (Vision Science); Leopoldine Wolfe
   Chair in Translational Research
FX The authors thank Carmen Gagnon and Isabelle Lahaie for technical
   assistance. This work was supported by operating grants to P. Hardy from
   the Fonds de Recherche du Quebec en Sante (FRQS)-Vision Health Research
   Network and Antoine-Turmel Foundation (32645) and the Canadian
   Institutes of Health Research (362383). H. Tahiri and S. Omri were
   recipients of a fellowship from the Fonds de Recherche du Quebec en
   Sante (FRQS). F. Duhamel was recipient of a Canadian Institute of Health
   Research Frederick Banting and Charles Best Canada Graduate Scholarship
   (PhD), a FRQS PhD Scholarship for Health Professional, a Stars
   Foundation & CHU Sainte-Justine's Foundation Scholarship for Excellence
   (PhD) and the Hydro-Quebec Scholarship for Excellence (PhD). S. Chemtob
   holds a Canada Research Chair (Vision Science) and the Leopoldine Wolfe
   Chair in Translational Research in age-related macular degeneration.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Barbera-Guillem E, 2002, CANCER RES, V62, P7042
   Benameur T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012688
   Buckhaults P, 2001, CANCER RES, V61, P6996
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Carpintero R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011869
   Chabrat A, 2015, JOVE-J VIS EXP, DOI 10.3791/52510
   Chen K, 2008, CIRC RES, V102, P1512, DOI 10.1161/CIRCRESAHA.108.172064
   Cho SH, 2012, CURR PHARM DESIGN, V18, P3721, DOI 10.2174/138161212802002760
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707
   Fadok VA, 1998, J IMMUNOL, V161, P6250
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI14006
   Freilich RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079416
   Grassmann F, 2015, EUR J PHARM BIOPHARM, V95, P194, DOI 10.1016/j.ejpb.2015.04.039
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Huber LC, 2007, APOPTOSIS, V12, P363, DOI 10.1007/s10495-006-0622-7
   Hume DA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00370
   Jawad S, 2013, INVEST OPHTH VIS SCI, V54, P5959, DOI 10.1167/iovs.12-11380
   Jimenez VC, 2014, GENOM DATA, V2, P181, DOI 10.1016/j.gdata.2014.06.019
   Kennedy DJ, 2011, CARDIOVASC RES, V89, P604, DOI 10.1093/cvr/cvq360
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Mwaikambo BR, 2008, CORNEA, V27, P1037, DOI 10.1097/ICO.0b013e31817780b6
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Omri S, 2011, AM J PATHOL, V179, P942, DOI 10.1016/j.ajpath.2011.04.018
   Park JE, 2004, AM J SURG, V187, p11S, DOI 10.1016/S0002-9610(03)00296-4
   Qiu Q, 2014, APOPTOSIS, V19, P1113, DOI 10.1007/s10495-014-0993-0
   Qiu Q, 2013, MOL IMMUNOL, V55, P220, DOI 10.1016/j.molimm.2013.01.017
   Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007
   Ren B, 2011, BLOOD, V117, P6036, DOI 10.1182/blood-2010-12-326017
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   Silverstein Roy L, 2010, Trans Am Clin Climatol Assoc, V121, P206
   Silverstein RL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.272re3
   STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287
   Tahiri H, 2013, INVEST OPHTH VIS SCI, V54, P6084, DOI 10.1167/iovs.13-11896
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Utsugi M, 2010, CYTOKINE, V51, P127, DOI 10.1016/j.cyto.2010.04.002
   Utsugi M, 2009, J IMMUNOL, V182, P5225, DOI 10.4049/jimmunol.0801352
   Vasina EM, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.94
   Waetzig V, 2005, GLIA, V50, P235, DOI 10.1002/glia.20173
   Whitman SC, 2002, J LIPID RES, V43, P1201, DOI 10.1194/jlr.M200116-JLR200
   Wilkinson K., 2012, INT J ALZHEIMERS DIS, V2012, P489456, DOI [10.1155/2012/489456, DOI 10.1155/2012/489456]
   Yang C, 2008, AM J PHYSIOL-REG I, V294, pR467, DOI 10.1152/ajpregu.00432.2007
   Yang C, 2015, JOVE-J VIS EXP, DOI 10.3791/52651
   Yang C, 2012, AM J PHYSIOL-REG I, V302, pR941, DOI 10.1152/ajpregu.00527.2011
   Yang C, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12533
   Zhang Y, 2013, CELL RES, V23, P898, DOI 10.1038/cr.2013.75
   Zhang YY, 2013, INT J MOL MED, V31, P797, DOI 10.3892/ijmm.2013.1260
NR 59
TC 16
Z9 18
U1 2
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 22
PY 2016
VL 6
AR 37391
DI 10.1038/srep37391
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EC6NE
UT WOS:000388252400001
PM 27874077
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dharmarajan, TS
AF Dharmarajan, Thiruvinvamalai S.
TI Is vitamin supplementation appropriate in the healthy old?
SO CURRENT OPINION IN GASTROENTEROLOGY
LA English
DT Review
DE healthy diet versus vitamins; multivitamin use in older adults; vascular
   disease and mortality; vitamin benefits for cancer; vitamin use in
   subgroups with deficiency; vitamins and adverse effects
ID Y GASTRIC BYPASS; CARDIOVASCULAR-DISEASE; PHYSICIANS HEALTH; PRIMARY
   PREVENTION; B-VITAMINS; MULTIVITAMIN/MINERAL SUPPLEMENTS;
   MYOCARDIAL-INFARCTION; MINERAL SUPPLEMENTS; SLEEVE GASTRECTOMY;
   ALZHEIMERS-DISEASE
AB Purpose of review
   Vitamin supplements are used by large numbers of older adults. Although vitamins serve several functions in the body, the benefits or harm of routine supplementation are far from clear. Data from studies over the last decade are reviewed to enable an understanding.
   Recent findings
   Summarized data from studies conducted over the last few years, pertinent to the use of vitamins, as multivitamin combinations and as individual vitamins specifically A, D, E, C, and the B group, are presented. This review targets the benefits and harm of multivitamins when used to lower the risk of cancer, cardiovascular and cerebrovascular disease, visual disorders (e.g., cataracts and age-related macular degeneration), and bone disease. The effects of vitamins on total mortality are discussed. In addition, isolated or multiple vitamin deficiencies, their predisposing settings and manifestations from mild-to-life-threatening illness are discussed.
   Summary
   Data from studies demonstrate considerable variations, most confirming little to no benefit following supplementation in healthy adults. However, clear roles exist for vitamin supplementation in states of deficiency and in subgroups of older adults at high risk for deficiency of specific or multiple vitamins. In these settings, vitamin supplements help prevent or correct deficiency and related manifestations.
C1 [Dharmarajan, Thiruvinvamalai S.] Albert Einstein Coll Med, Univ Hosp, Dept Med, Montefiore Med Ctr, Bronx, NY 10467 USA.
C3 Montefiore Medical Center; State University of New York (SUNY) System;
   Yeshiva University; Albert Einstein College of Medicine
RP Dharmarajan, TS (通讯作者)，31 Pheasant Run, Scarsdale, NY 10583 USA.
EM dharmarajants@yahoo.com
CR Alexandrou A, 2014, SURG OBES RELAT DIS, V10, P262, DOI 10.1016/j.soard.2013.07.014
   Avenell A, 2014, COCHRANE DB SYST REV, V4
   Bailey RL, 2013, JAMA INTERN MED, V173, P355, DOI 10.1001/jamainternmed.2013.2299
   Beitz R, 2004, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, V47, P1057, DOI 10.1007/s00103-004-0924-2
   BJELAKOVIC G, 2014, COCHRANE DB SYST REV, P7469, DOI [10.1002/14651858.cd007470.pub3, DOI 10.1002/14651858.CD007470.PUB3]
   Bjelakovic G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007469.pub2
   Bjelakovic G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074558
   Broeska Valerie E., 2013, Journal of Nutrition in Gerontology and Geriatrics, V32, P317, DOI 10.1080/21551197.2013.840256
   Calton EK, 2014, NUTR RES, V34, P559, DOI 10.1016/j.nutres.2014.06.012
   Carmel R, 2008, BLOOD, V112, P2214, DOI 10.1182/blood-2008-03-040253
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Clarke R, 2014, AM J CLIN NUTR, V100, P657, DOI 10.3945/ajcn.113.076349
   Dawsey SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088774
   Debreceni B, 2014, CARDIOVASC THER, V32, P130, DOI 10.1111/1755-5922.12064
   Dhamiarajan TS, 2008, J AM MED DIR ASSOC, V9, P162, DOI 10.1016/j.jamda.2007.10.004
   Dharmarajan TS, 2008, NAT CLIN PRACT GASTR, V5, P604, DOI 10.1038/ncpgasthep1263
   Dharmarajan T. S., 2005, Journal of Nutrition for the Elderly, V25, P7, DOI 10.1300/J052v25n01_03
   Dharmarajan T S, 2000, J Am Med Dir Assoc, V1, P21
   Dharmarajan TS, 1999, ROY S MED S, P49
   Dharmarajan TS, 2012, GERIATRIC GASTROENTE, P161
   Dharmarajan TS, 2012, GERIATRIC GASTROENTE, P457
   Douaud G, 2013, P NATL ACAD SCI USA, V110, P9523, DOI 10.1073/pnas.1301816110
   Droz N, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-24
   Dysken MW, 2014, JAMA-J AM MED ASSOC, V311, P33, DOI 10.1001/jama.2013.282834
   Eilat-Adar S, 2013, NUTRIENTS, V5, P3646, DOI 10.3390/nu5093646
   Ervin R Bethene, 2008, Adv Data, P1
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2006, COCHRANE DB SYST REV, V2
   Fortmann SP, 2013, ANN INTERN MED, V159, P824, DOI 10.7326/0003-4819-159-12-201312170-00729
   Furlong VE, 2004, ASIA PAC J CLIN NUTR, V13, P222
   Gahche Jamie, 2011, NCHS Data Brief, P1
   Gaziano JM, 2012, JAMA-J AM MED ASSOC, V308, P1871, DOI 10.1001/jama.2012.14641
   Gordon NP, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-104
   Granado-Lorencio F, 2012, FOOD CHEM TOXICOL, V50, P2106, DOI 10.1016/j.fct.2012.03.001
   Grodstein F, 2013, ANN INTERN MED, V159, P806, DOI 10.7326/0003-4819-159-12-201312170-00006
   Gunturu SG, 2012, GERIATRIC GASTROENTE, P89
   Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812
   Helard L, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/428479
   Hirayama F, 2008, ASIA PAC J CLIN NUTR, V17, P280
   Holick MF, 2008, AM J CLIN NUTR, V87, p1080S
   Ji Y, 2013, NEUROLOGY, V81, P1298, DOI 10.1212/WNL.0b013e3182a823cc
   Kang JH, 2008, AM J CLIN NUTR, V88, P1602, DOI 10.3945/ajcn.2008.26404
   Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x
   Lainscak M, 2014, EUR J CLIN INVEST, V44, P813, DOI 10.1111/eci.12300
   Lam JR, 2013, JAMA-J AM MED ASSOC, V310, P2435, DOI 10.1001/jama.2013.280490
   Lamas GA, 2013, ANN INTERN MED, V159, P797, DOI 10.7326/0003-4819-159-12-201312170-00004
   Li KR, 2012, EUR J NUTR, V51, P407, DOI 10.1007/s00394-011-0224-1
   Majumder S, 2013, SURG OBES RELAT DIS, V9, P1013, DOI 10.1016/j.soard.2013.04.017
   Marques-Vidal P, 2009, EUR J CLIN NUTR, V63, P273, DOI 10.1038/sj.ejcn.1602932
   Marti-Carvajal AJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006612.pub3
   Massa J, 2014, BRIT J CANCER, V110, P249, DOI 10.1038/bjc.2013.664
   Massey LK, 2005, J NUTR, V135, P1673, DOI 10.1093/jn/135.7.1673
   Moize V, 2013, J ACAD NUTR DIET, V113, P400, DOI 10.1016/j.jand.2012.11.013
   Morris MS, 2012, ADV NUTR, V3, P801, DOI 10.3945/an.112.002535
   Moyer VA, 2014, ANN INTERN MED, V160, P558, DOI 10.7326/M14-0198
   Moyer VA, 2012, ANN INTERN MED, V157, P197, DOI 10.7326/0003-4819-157-3-201208070-00462
   Mullie P, 2011, INT J PUBLIC HEALTH, V56, P289, DOI 10.1007/s00038-010-0210-z
   Mursu J, 2011, ARCH INTERN MED, V171, P1625, DOI 10.1001/archinternmed.2011.445
   Park SY, 2008, J AM DIET ASSOC, V108, P529, DOI 10.1016/j.jada.2007.12.011
   Pastori D, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000364
   Penniston KL, 2006, AM J CLIN NUTR, V83, P191
   Pitchumoni CS, 2012, GERIATRIC GASTROENTE, P501
   Quraishi SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081120
   Rafeq Z, 2013, NUTR METAB CARDIOVAS, V23, P836, DOI 10.1016/j.numecd.2012.07.002
   Rautiainen S, 2010, AM J CLIN NUTR, V92, P1251, DOI 10.3945/ajcn.2010.29371
   Rees K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009825.pub2
   Rosen CJ, 2011, NEW ENGL J MED, V364, P248, DOI 10.1056/NEJMcp1009570
   Saarela RKT, 2014, J NUTR HEALTH AGING, V18, P34, DOI 10.1007/s12603-013-0358-3
   Saltzman E, 2013, ANNU REV NUTR, V33, P183, DOI 10.1146/annurev-nutr-071812-161225
   Sanders KM, 2010, JAMA-J AM MED ASSOC, V303, P1815, DOI 10.1001/jama.2010.594
   Saulle R, 2013, NUTRIENTS, V5, P4566, DOI 10.3390/nu5114566
   Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600
   Sesso HD, 2012, JAMA-J AM MED ASSOC, V308, P1751, DOI 10.1001/jama.2012.14805
   Snow CF, 1999, ARCH INTERN MED, V159, P1289, DOI 10.1001/archinte.159.12.1289
   Stover PJ, 2010, CURR OPIN CLIN NUTR, V13, P24, DOI 10.1097/MCO.0b013e328333d157
   Sun Y, 2007, CLIN THER, V29, P2204, DOI 10.1016/j.clinthera.2007.10.012
   Troesch B, 2012, INT J VITAM NUTR RES, V82, P355, DOI 10.1024/0300-9831/a000131
   Viveky N, 2012, APPL PHYSIOL NUTR ME, V37, P100, DOI [10.1139/h11-141, 10.1139/H11-141]
   Wallace TC, 2014, J AM COLL NUTR, V33, P94, DOI 10.1080/07315724.2013.846806
   Wang L, 2014, AM J CLIN NUTR, V100, P915, DOI 10.3945/ajcn.114.085480
   Wang SM, 2014, J BONE MINER METAB
   Zhao LQ, 2014, NUTRIENTS, V6, P931, DOI 10.3390/nu6030931
NR 82
TC 4
Z9 4
U1 0
U2 35
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0267-1379
EI 1531-7056
J9 CURR OPIN GASTROEN
JI Curr. Opin. Gastroenterol.
PD MAR
PY 2015
VL 31
IS 2
BP 143
EP 152
DI 10.1097/MOG.0000000000000150
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA CB2RC
UT WOS:000349474600010
PM 25635666
DA 2022-11-30
ER

PT J
AU Cheng, LB
   Chen, CM
   Zhong, H
   Zhu, LJ
AF Cheng, Li-Bo
   Chen, Chun-Ming
   Zhong, Hong
   Zhu, Li-Juan
TI Squamosamide Derivative FLZ Protects Retinal Pigment Epithelium Cells
   from Oxidative Stress through Activation of Epidermal Growth Factor
   Receptor (EGFR)-AKT Signaling
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration (AMD); retinal pigment epithelium
   (RPE); squamosamide derivative FLZ; apoptosis; AKT signaling and EGFR
   (epidermal growth factor receptor) trans-activation
ID PARKINSONS-DISEASE MODELS; UV-INDUCED APOPTOSIS; HYDROGEN-PEROXIDE;
   MACULAR DEGENERATION; SH-SY5Y CELLS; DOPAMINERGIC NEURON; PATHWAY;
   CANCER; EGFR; EXPRESSION
AB Reactive oxygen species (ROS)-mediated retinal pigment epithelium (RPE) cell apoptosis is attributed to age-related macular degeneration (AMD) pathogenesis. FLZ, a novel synthetic squamosamide derivative from a Chinese herb, Annona glabra, has displayed significant cyto-protective activity. In the current study, we explored the pro-survival effect of FLZ in oxidative stressed-RPE cells and studied the underlying signaling mechanisms. Our results showed that FLZ attenuated hydrogen peroxide (H2O2)-induced viability decrease and apoptosis in the RPE cell line (ARPE-19 cells) and in primary mouse RPE cells. Western blotting results showed that FLZ activated AKT signaling in RPE cells. The AKT-specific inhibitor, MK-2206, the phosphoinositide 3-kinase (PI3K)/AKT pan inhibitor, wortmannin, and AKT1-shRNA (short hairpin RNA) depletion almost abolished FLZ-mediated pro-survival/anti-apoptosis activity. We discovered that epidermal growth factor receptor (EGFR) trans-activation mediated FLZ-induced AKT activation and the pro-survival effect in RPE cells, and the anti-apoptosis effect of FLZ against H2O2 was inhibited by the EGFR inhibitor, PD153035, or by EGFR shRNA-knockdown. In conclusion, FLZ protects RPE cells from oxidative stress through activation of EGFR-AKT signaling, and our results suggest that FLZ might have therapeutic values for AMD.
C1 [Cheng, Li-Bo; Chen, Chun-Ming; Zhong, Hong; Zhu, Li-Juan] Li Yang City Hosp Tradit Chinese Med, Eye Dept, Li Yang City 213300, Peoples R China.
RP Cheng, LB (通讯作者)，Li Yang City Hosp Tradit Chinese Med, Eye Dept, Li Yang City 213300, Peoples R China.
EM dryaojin@yahoo.com; chunmingchenapp@163.com; hongapple126@126.com;
   caocong1111@hotmail.com
FU National Natural Science Foundation of China
FX This work was generously supported by grants from the National Natural
   Science Foundation of China.
CR Bao XQ, 2012, NEUROSCIENCE, V202, P396, DOI 10.1016/j.neuroscience.2011.11.036
   Bao XQ, 2014, BRAIN RES, V1547, P49, DOI 10.1016/j.brainres.2013.12.026
   Bao XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078033
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x
   Cao C, 2008, CELL SIGNAL, V20, P1830, DOI 10.1016/j.cellsig.2008.06.010
   Cao C, 2006, BIOCHEM J, V400, P225, DOI 10.1042/BJ20060816
   Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118
   Cao GF, 2011, BIOCHEM BIOPH RES CO, V414, P499, DOI 10.1016/j.bbrc.2011.09.094
   Chen K, 2004, J BIOL CHEM, V279, P35079, DOI 10.1074/jbc.M404859200
   Chen SH, 2014, BIOCHIMIE, V103, P71, DOI 10.1016/j.biochi.2014.04.004
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Cheng LB, 2014, BIOCHEM BIOPH RES CO, V443, P447, DOI 10.1016/j.bbrc.2013.11.113
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Fang F, 2008, ACTA PHARMACOL SIN, V29, P152, DOI 10.1111/j.1745-7254.2008.00714.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Ji DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085116
   Kang RX, 2012, BIOCHEM BIOPH RES CO, V417, P1176, DOI 10.1016/j.bbrc.2011.12.094
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kong XC, 2011, BRAIN RES, V1383, P99, DOI 10.1016/j.brainres.2011.01.093
   Li K, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0084171, 10.1371/journal.pone.0067018, 10.1371/journal.pone.0058057, 10.1371/journal.pone.0063139, 10.1371/journal.pone.0068157]
   Liang Y, 2000, CURR EYE RES, V20, P25, DOI 10.1076/0271-3683(200001)2011-HFT025
   Maretzky T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1232
   McElroy SJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038373
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Niwa K, 2003, ANTIOXID REDOX SIGN, V5, P713, DOI 10.1089/152308603770380016
   Nowak Michal, 2005, Klin Oczna, V107, P715
   Oganesian A, 2011, P NATL ACAD SCI USA, V108, P19796, DOI 10.1073/pnas.1116271108
   PACIFICI RE, 1991, GERONTOLOGY, V37, P166
   Qiu LH, 2006, ONCOL REP, V16, P907
   Radisavljevic ZM, 2004, J CELL BIOCHEM, V91, P1293, DOI 10.1002/jcb.20037
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x
   Sur S, 2014, CURR VASC PHARMACOL, V12, P190, DOI 10.2174/1570161112666140226123745
   Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P2242, DOI 10.1167/iovs.06-0560
   Yan F, 2007, OPHTHALMOLOGICA, V221, P244, DOI 10.1159/000101926
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zhang D, 2007, EUR J PHARMACOL, V561, P1, DOI 10.1016/j.ejphar.2006.11.015
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang Lei, 2013, Front Biosci (Schol Ed), V5, P661
NR 48
TC 12
Z9 14
U1 1
U2 4
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2014
VL 15
IS 10
BP 18762
EP 18775
DI 10.3390/ijms151018762
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AS7TI
UT WOS:000344457200068
PM 25329617
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Cui, W
   Zang, H
   Liu, ZL
AF Cui, Wei
   Zang, Han
   Liu, Zhe-Li
TI Interleukin-6 receptor blockade suppresses subretinal fibrosis in a
   mouse model
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE interleukin-6; subretinal fibrosis; age-related macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; IL-6; RANIBIZUMAB;
   BEVACIZUMAB; CELLS
AB AIM: To determine the involvement of the interleukin (IL)-6 with the development of experimental subretinal fibrosis in a mouse model.
   METHODS: Subretinal fibrosis was induced by subretinal injection of macrophage -rich peritoneal exudate cells and the local expression of IL -6 was assessed by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) at various time points. In addition, we investigated the effect of IL-6 receptor (IL-6R) monoclonal antibody (MR16-1) on subretinal fibrosis development. "
   RESULTS: IL-6 mRNA level was significantly elevated at 1d after subretinal fibrosis induction and increased further to about 12-fold at 2d, reaching the peak. The result of ELISA showed that IL -6 protein was not detected in naive. mice. At 2d after subretinal fibrosis induction, IL -6 protein level was upregulated to 67.33 +/- 14.96 pg/mg in subretinal fibrosis mice. MR16 -1 treatment resulted in a reduced subretinal fibrosis area by 48% compared to animals from control group at 7d.
   CONCLUSION: Our results indicated that IL-6 signaling may contribute to the pathogenesis of subretinal fibrogenesis and IL -6R inhibition may provide an effective, novel treatment of advanced and late -stage neovascular age-related macular degeneration.
C1 [Cui, Wei; Zang, Han; Liu, Zhe-Li] China Med Univ, Hosp 1, Dept Ophthalmol, Shenyang 110001, Liaoning Provin, Peoples R China.
C3 China Medical University
RP Liu, ZL (通讯作者)，China Med Univ, Hosp 1, Dept Ophthalmol, Shenyang 110001, Liaoning Provin, Peoples R China.
EM zheli_liu@163.com
OI Zhang, Han/0000-0002-9338-0051
FU Liaoning Science and Technology Project [2013225303]
FX Foundation: Supported by Liaoning Science and Technology Project
   (No.2013225303)
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Barnes TC, 2011, INT J RHEUMATOL, V2011, DOI DOI 10.1155/2011/721608
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630
   Dayer JM, 2010, RHEUMATOLOGY, V49, P15, DOI 10.1093/rheumatology/kep329
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Funatsu H, 2005, OPHTHALMOLOGY, V112, P806, DOI 10.1016/j.ophtha.2004.11.045
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kent D, 2003, MOL VIS, V9, P747
   KUPPNER MC, 1995, IMMUNOLOGY, V84, P265
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Liton PB, 2009, MOL VIS, V15, P326
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shima Y, 2010, RHEUMATOLOGY, V49, P2408, DOI 10.1093/rheumatology/keq275
   Symeonidis C, 2012, CYTOKINE, V59, P184, DOI 10.1016/j.cyto.2012.04.019
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tojo N, 2010, ACTA OPHTHALMOL, V88, P564, DOI 10.1111/j.1755-3768.2008.01466.x
NR 26
TC 15
Z9 20
U1 0
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2014
VL 7
IS 2
BP 194
EP 197
DI 10.3980/j.issn.2222-3959.2014.02.02
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF4BI
UT WOS:000334656000002
PM 24790857
DA 2022-11-30
ER

PT J
AU Mansoor, S
   Gupta, N
   Falatoonzadeh, P
   Kuppermann, BD
   Kenney, MC
AF Mansoor, S.
   Gupta, N.
   Falatoonzadeh, P.
   Kuppermann, B. D.
   Kenney, M. C.
TI 2-ethylpyridine, a cigarette smoke component, causes mitochondrial
   damage in human retinal pigment epithelial cells in vitro
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE 2-ethylpyridine; apoptosis; ARPE-19 cells; cigarette smoke toxicant;
   mitochondrial membrane potential; reactive oxygen/nitrogen species
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; OXIDATIVE STRESS; DNA
   DAMAGE; APOPTOSIS; ASSOCIATION; GROWTH; DYSFUNCTION; PROTECTION;
   PYRIDINES
AB Purpose: Our goal was to identify the cellular and molecular effects of 2-ethylpyridine (2-EP, a component of cigarette smoke) on human retinal pigment epithelial cells (ARPE-19) in vitro. Materials and Methods: ARPE-19 cells were exposed to varying concentrations of 2-EP. Cell viability (CV) was measured by a trypan blue dye exclusion assay. Caspase-3/7 and caspase-9 activities were measured by fluorochrome assays. The production of reactive oxygen/nitrogen species (ROS/RNS) was detected with a 2',7'-dichlorodihydrofl uorescein diacetate dye assay. The JC-1 assay was used to measure mitochondrial membrane potential (Delta Psi m). Mitochondrial redox potential was measured using a RedoxSensor Red kit and mitochondria were evaluated with Mitotracker dye. Results: Aft er 2-EP exposure, ARPE-19 cells showed significantly decreased CV, increased caspase-3/7 and caspase-9 activities, elevated ROS/RNS levels, decreased Delta Psi m value and decreased redox fluorescence when compared with control samples. Conclusions: These results show that 2-EP treatment induced cell death by caspase-dependent apoptosis associated with an oxidative stress and mitochondrial dysfunction. These data represent a possible mechanism by which smoking contributes to age-related macular degeneration and other retinal diseases and identify mitochondria as a target for future therapeutic interventions.
C1 [Mansoor, S.; Gupta, N.; Falatoonzadeh, P.; Kuppermann, B. D.; Kenney, M. C.] Univ Calif Irvine, Sch Med, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Mansoor, S.] Georgia Inst Technol, Dept Chem & Biomol Engn, Atlanta, GA 30332 USA.
   [Gupta, N.] Lotus Eye Care Hosp, Dept Ophthalmol, Coimbatore, Tamil Nadu, India.
   [Falatoonzadeh, P.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.
   [Kenney, M. C.] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University System of Georgia; Georgia Institute of Technology; Drexel
   University; University of California System; University of California
   Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Ophthalmol Res Lab, Hewitt Hall,Room 2028,843 Hlth Sci Rd, Irvine, CA 92697 USA.
EM mkenney@uci.edu
CR Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chen SR, 2000, FREE RADICAL BIO MED, V28, P1266, DOI 10.1016/S0891-5849(00)00265-3
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christoph R, 1998, RESTOR NEUROL NEUROS, V12, P59
   Chwa M, 2006, INVEST OPHTH VIS SCI, V47, P1902, DOI 10.1167/iovs.05-0828
   DAM H, 1949, ANN NY ACAD SCI, V52, P195, DOI 10.1111/j.1749-6632.1949.tb53882.x
   Delhalle S, 2003, ANN NY ACAD SCI, V1010, P1, DOI 10.1196/annals.1299.001
   Dempsey DA, 2001, DRUG SAFETY, V24, P277, DOI 10.2165/00002018-200124040-00005
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hawkins BS, 1999, MOL VIS, V5
   HOVE EL, 1951, P SOC EXP BIOL MED, V77, P502, DOI 10.3181/00379727-77-18828
   HOVE EL, 1953, J NUTR, V50, P361, DOI 10.1093/jn/50.3.361
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Ji L, 2002, TOXICOL SCI, V69, P217, DOI 10.1093/toxsci/69.1.217
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4
   Kulshreshtha NP, 2003, J CHROMATOGR A, V985, P303, DOI 10.1016/S0021-9673(02)01472-3
   Mansoor S, 2010, TOXICOLOGY, V271, P107, DOI 10.1016/j.tox.2010.03.013
   Melkonian G, 2003, TOXICOL SCI, V75, P393, DOI 10.1093/toxsci/kfg123
   Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2
   Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Ozgen U, 2000, CYTOMETRY, V42, P74, DOI 10.1002/(SICI)1097-0320(20000215)42:1<74::AID-CYTO11>3.0.CO;2-6
   Patil AJ, 2009, CURR EYE RES, V34, P672, DOI 10.1080/02713680903015892
   Pesonen M, 2012, TOXICOL LETT, V211, P239, DOI 10.1016/j.toxlet.2012.04.002
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Rao P, 2006, BIOCHEM BIOPH RES CO, V342, P1279, DOI 10.1016/j.bbrc.2006.02.074
   Riveles K, 2003, REPROD TOXICOL, V17, P191, DOI 10.1016/S0890-6238(02)00150-8
   Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Sharma A, 2008, INVEST OPHTH VIS SCI, V49, P5111, DOI 10.1167/iovs.08-2060
   Sharma A, 2012, INDIAN J OPHTHALMOL, V60, P189, DOI 10.4103/0301-4738.95869
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   TRITSCHLER HJ, 1994, BIOCHEM MOL BIOL INT, V34, P169
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wu SC, 2012, BIOL RES, V45, P101, DOI 10.4067/S0716-97602012000200001
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048501
   Yu R, 2006, TOXICOL SCI, V93, P82, DOI 10.1093/toxsci/kfl047
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 54
TC 6
Z9 8
U1 0
U2 10
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JAN
PY 2014
VL 62
IS 1
BP 16
EP 22
DI 10.4103/0301-4738.126168
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA4RP
UT WOS:000331084100004
PM 24492497
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Perepechaeva, ML
   Grishanova, AY
   Rudnitskaya, EA
   Kolosova, NG
AF Perepechaeva, M. L.
   Grishanova, A. Yu.
   Rudnitskaya, E. A.
   Kolosova, N. G.
TI The Mitochondria-Targeted Antioxidant SkQ1 Downregulates Aryl
   Hydrocarbon Receptor-Dependent Genes in the Retina of OXYS Rats with
   AMD-Like Retinopathy
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ARACHIDONIC-ACID METABOLISM; PLASTOQUINONE DERIVATIVES; INTERRUPT
   EXECUTION; CANCER CHEMOPREVENTION; TOOLS; NRF2; TRANSCRIPTION;
   SENESCENCE; EXPRESSION; INDUCTION
AB The mitochondria-targeted antioxidant SkQ1 is a novel drug thought to retard development of age-related diseases. It has been shown that SkQ1 reduces clinical signs of retinopathy in senescence-accelerated OXYS rats, which are a known animal model of human age-related macular degeneration (AMD). The aim of this work was to test whether SkQ1 affects transcriptional activity of AhR (aryl hydrocarbon receptor) and Nrf2 (nuclear factor erythroid 2-related factor 2), which are considered as AMD-associated genes in the retina of OXYS and Wistar rats. Our results showed that only AhR and AhR-dependent genes were sensitive to SkQ1. Dietary supplementation with SkQ1 decreased the AhR mRNA level in both OXYS and Wistar rats. At baseline, the retinal Cyp1a1 mRNA level was lower in OXYS rats. SkQ1 supplementation decreased the Cyp1a1 mRNA level in Wistar rats, but this level remained unchanged in OXYS rats. Baseline Cyp1a2 and Cyp1b1 mRNA expression was stronger in OXYS than in Wistar rats. In the OXYS strain, Cyp1a2 and Cyp1b1 mRNA levels decreased as a result of SkQ1 supplementation. These data suggest that the Cyp1a2 and Cyp1b1 enzymes are involved in the pathogenesis of AMD-like retinopathy of OXYS rats and are possible therapeutic targets of SkQ1.
C1 [Perepechaeva, M. L.; Grishanova, A. Yu.; Kolosova, N. G.] RAMS, Siberian Branch, Inst Mol Biol & Biophys, Novosibirsk 630117, Russia.
   [Rudnitskaya, E. A.; Kolosova, N. G.] Prospekt Acad, Inst Cytol & Genet, Novosibirsk 630090, Russia.
   [Kolosova, N. G.] Novosibirsk State Univ, Novosibirsk 630090, Russia.
C3 Russian Academy of Medical Sciences; Russian Academy of Sciences;
   Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB
   RAS; Novosibirsk State University
RP Perepechaeva, ML (通讯作者)，RAMS, Siberian Branch, Inst Mol Biol & Biophys, Timakova St 2, Novosibirsk 630117, Russia.
EM perepech@niimbb.ru
RI Kolosova, Nataliya G/P-3178-2015; Perepechaeva, Maria/AAG-1840-2020;
   Grishanova, Alevtina/C-1759-2014; Kolosova, Nataliya G/AAR-7409-2020;
   Rudnitskaya, Ekaterina/AAZ-8619-2020
OI Kolosova, Nataliya G/0000-0003-2398-8544; Perepechaeva,
   Maria/0000-0001-5791-3714; Grishanova, Alevtina/0000-0002-5894-1159;
   Kolosova, Nataliya G/0000-0003-2398-8544; Rudnitskaya,
   Ekaterina/0000-0003-3181-5934
FU Russian Foundation for Basic Research [12-04-01352-a]
FX This work was supported by the Russian Foundation for Basic Research
   (Project no. 12-04-01352-a).
CR Al-Shabrawey M, 2011, DIABETES, V60, P614, DOI 10.2337/db10-0008
   Antonenko YN, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1273, DOI 10.1134/S0006297908120018
   Bakeeva LE, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1288, DOI 10.1134/S000629790812002X
   Barnett JM, 2010, INVEST OPHTH VIS SCI, V51, P1136, DOI 10.1167/iovs.09-3691
   Choudhary D, 2004, DRUG METAB DISPOS, V32, P840, DOI 10.1124/dmd.32.8.840
   El-Sherbeni AA, 2014, BIOCHEM PHARMACOL, V87, P456, DOI 10.1016/j.bcp.2013.11.015
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Hayes JD, 2009, TOXICOL SCI, V111, P199, DOI 10.1093/toxsci/kfp168
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Jeong WS, 2006, ANTIOXID REDOX SIGN, V8, P99, DOI 10.1089/ars.2006.8.99
   Kato K, 2010, RADIAT RES, V174, P177, DOI 10.1667/RR2146.1
   Ma Q, 2001, CURR DRUG METAB, V2, P149, DOI 10.2174/1389200013338603
   Markovets AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021682
   Markovets AM, 2011, AGING-US, V3, P44
   Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481
   Nebert DW, 2006, NAT REV CANCER, V6, P947, DOI 10.1038/nrc2015
   Neroev VV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1317, DOI 10.1134/S0006297908120043
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Nowak Michal, 2005, Klin Oczna, V107, P715
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Rifkind AB, 2006, DRUG METAB REV, V38, P291, DOI 10.1080/03602530600570107
   Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001
   Saprunova VB, 2012, BIOCHEMISTRY-MOSCOW+, V77, P648, DOI 10.1134/S0006297912060120
   Saprunova VB, 2010, BIOCHEMISTRY-MOSCOW+, V75, P130, DOI 10.1134/S0006297910020021
   Schwarz D, 2004, BIOCHEM PHARMACOL, V67, P1445, DOI 10.1016/j.bcp.2003.12.023
   Skulachev MV, 2011, CURR DRUG TARGETS, V12, P800
   Skulachev VP, 2013, BIOCHEM BIOPH RES CO, V441, P275, DOI 10.1016/j.bbrc.2013.10.063
   Skulachev VP, 2009, BBA-BIOENERGETICS, V1787, P437, DOI 10.1016/j.bbabio.2008.12.008
   Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103
   Yeager RL, 2009, TOXICOL SCI, V111, P238, DOI 10.1093/toxsci/kfp115
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 31
TC 8
Z9 8
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 530943
DI 10.1155/2014/530943
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM3HC
UT WOS:000339742400001
PM 25132985
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Nilsson, OR
   Lannergard, J
   Morgan, BP
   Lindahl, G
   Gustafsson, MCU
AF Nilsson, O. Rickard
   Lannergard, Jonas
   Morgan, B. Paul
   Lindahl, Gunnar
   Gustafsson, Mattias C. U.
TI Affinity Purification of Human Factor H on Polypeptides Derived from
   Streptococcal M Protein: Enrichment of the Y402 Variant
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; HEMOLYTIC-UREMIC SYNDROME; MACULAR DEGENERATION;
   ANTIGENIC VARIATION; SURFACE PROTEIN; PEPTIDE; SYSTEM; IMMUNE
AB Recent studies indicate that defective activity of complement factor H (FH) is associated with several human diseases, suggesting that pure FH may be used for therapy. Here, we describe a simple method to isolate human FH, based on the specific interaction between FH and the hypervariable region (HVR) of certain Streptococcus pyogenes M proteins. Special interest was focused on the FH polymorphism Y402H, which is associated with the common eye disease age-related macular degeneration (AMD) and has also been implicated in the binding to M protein. Using a fusion protein containing two copies of the M5-HVR, we found that the Y402 and H402 variants of FH could be efficiently purified by single-step affinity chromatography from human serum containing the corresponding protein. Different M proteins vary in their binding properties, and the M6 and M5 proteins, but not the M18 protein, showed selective binding of the FH Y402 variant. Accordingly, chromatography on a fusion protein derived from the M6-HVR allowed enrichment of the Y402 protein from serum containing both variants. Thus, the exquisite binding specificity of a bacterial protein can be exploited to develop a simple and robust procedure to purify FH and to enrich for the FH variant that protects against AMD.
C1 [Nilsson, O. Rickard; Lannergard, Jonas; Lindahl, Gunnar; Gustafsson, Mattias C. U.] Lund Univ, Dept Lab Med, Lund, Sweden.
   [Nilsson, O. Rickard; Lindahl, Gunnar; Gustafsson, Mattias C. U.] Univ Copenhagen, Dept Vet Dis Biol, Copenhagen, Denmark.
   [Morgan, B. Paul] Cardiff Univ, Inst Infect & Immun, Cardiff CF10 3AX, S Glam, Wales.
C3 Lund University; University of Copenhagen; Cardiff University
RP Lindahl, G (通讯作者)，Lund Univ, Dept Lab Med, Lund, Sweden.
EM gunnar.lindahl@med.lu.se
RI Gustafsson, Mattias C. U./A-7451-2010; Lannergård, Jonas/L-6513-2013
OI Gustafsson, Mattias C. U./0000-0003-3260-0724; Morgan,
   Paul/0000-0003-4075-7676; Lannergard, Jonas/0000-0001-9072-6486
FU Swedish Research Council [K2011-56X-09490-21-6]; Danish Strategic
   Research Council (Center for Nano-Vaccines); Foundation Olle Engkvist
   Byggmastare; trust of Osterlund; Swedish Government Support for Clinical
   Research (ALF); Royal Physiographic Society in Lund; trust of Golje
FX This work was supported by the Swedish Research Council (Project
   K2011-56X-09490-21-6), the Danish Strategic Research Council (Center for
   Nano-Vaccines), and the Foundation Olle Engkvist Byggmastare, the trust
   of Osterlund (all to GL), the Swedish Government Support for Clinical
   Research (ALF) (to GL, MCUG and JL), and by the Royal Physiographic
   Society in Lund and the trust of Golje (to MCUG and JL). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Blom AM, 2009, MOL IMMUNOL, V46, P2808, DOI 10.1016/j.molimm.2009.04.025
   Brandstatter H, 2012, VOX SANG, V103, P201, DOI 10.1111/j.1423-0410.2012.01610.x
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Farkas H, 2012, BIOL THER, V2, P1, DOI [10.1007/s13554-012-0001-6, DOI 10.1007/S13554-012-0001-6]
   FORSGREN A, 1966, J IMMUNOL, V97, P822
   Gustafsson MCU, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003323
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Hakobyan S, 2010, KIDNEY INT, V78, P782, DOI 10.1038/ki.2010.275
   Harris CL, 2000, COMPLEMENT METHODS P, P83
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jozsi M, 2008, TRENDS IMMUNOL, V29, P380, DOI 10.1016/j.it.2008.04.008
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Kotarsky H, 1998, J IMMUNOL, V160, P3349
   Lannergard J, 2011, CELL HOST MICROBE, V10, P147, DOI 10.1016/j.chom.2011.06.011
   Loirat C, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-60
   Makou E, 2013, BIOCHEMISTRY-US, V52, P3949, DOI 10.1021/bi4003452
   Morfeldt E, 2001, J IMMUNOL, V167, P3870, DOI 10.4049/jimmunol.167.7.3870
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Persson J, 2005, J IMMUNOL METHODS, V297, P83, DOI 10.1016/j.jim.2004.11.024
   Ricklin D, 2013, J IMMUNOL, V190, P3839, DOI 10.4049/jimmunol.1203200
   Sandin C, 2002, J IMMUNOL, V169, P1357, DOI 10.4049/jimmunol.169.3.1357
   Schmidt CQ, 2011, PROTEIN EXPRES PURIF, V76, P254, DOI 10.1016/j.pep.2010.12.002
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Sofat R, 2013, J IMMUNOL METHODS, V390, P63, DOI 10.1016/j.jim.2013.01.009
   STALHAMMARCARLEMALM M, 1993, J EXP MED, V177, P1593, DOI 10.1084/jem.177.6.1593
   Steer AC, 2009, LANCET INFECT DIS, V9, P611, DOI 10.1016/S1473-3099(09)70178-1
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zuraw BL, 2010, NEW ENGL J MED, V363, P513, DOI 10.1056/NEJMoa0805538
NR 31
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 21
PY 2013
VL 8
IS 11
AR e81303
DI 10.1371/journal.pone.0081303
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 259PW
UT WOS:000327539800119
PM 24278416
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Moisseiev, E
   Regenbogen, M
   Bartfeld, Y
   Barak, A
AF Moisseiev, Elad
   Regenbogen, Michael
   Bartfeld, Yael
   Barak, Adiel
TI Evaluation of Pain in Intravitreal Bevacizumab Injections
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Bevacizumab; Intravitreal injection; Pain; Quadrant; Visual Analog Score
ID MACULAR DEGENERATION; CORNEAL SENSITIVITY; CATARACT-SURGERY; ANESTHESIA;
   RANIBIZUMAB; DICLOFENAC; LIDOCAINE; SCALES; LASER
AB Purpose: To evaluate the correlation between pain associated with intravitreal bevacizumab injection and the location of the injection.
   Methods: The study included 218 eyes of 218 patients, who received an intravitreal bevacizumab injection at our institution. Pain was measured by the Visual Analog Scale (VAS). Additional parameters recorded included age, sex, indication for the injection, injection site by quadrant, number injections in the study eye, presence of diabetes mellitus, and lens status.
   Results: Indications for injection included age-related macular degeneration (69.7%), diabetic macular edema (13.3%), neovascularization due to proliferative diabetic retinopathy (6.9%), and cystoid macular edema secondary to retinal vascular occlusions (10.1%). Pain scores on the VAS ranged from 0 to 84, with a mean of 17.4 +/- 17.1. Pain did not correlate significantly with any of the recorded parameters, but a trend was found toward less pain associated with injection in the lower-left quadrant (p = 0.067).
   Conclusions: This is the largest series studying the pain associated with intravitreal injections and provides a thorough description of the pain associated with this procedure. Since there is no anatomical difference between quadrants, we assume the demonstrated trend indicates that less pain is associated with the location in which it is most convenient for the ophthalmologist to perform the injection.
C1 [Moisseiev, Elad; Regenbogen, Michael; Bartfeld, Yael; Barak, Adiel] Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, IL-64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky
   Medical Center
RP Moisseiev, E (通讯作者)，Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Weitzman 6 St, IL-64239 Tel Aviv, Israel.
EM elad_moi@netvision.net.il
RI Yiu, Glenn/AAF-2858-2020
CR Blaha GR, 2011, RETINA-J RET VIT DIS, V31, P535, DOI 10.1097/IAE.0b013e3181eac724
   Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chiambaretta F, 2004, J FR OPHTALMOL, V27, P739, DOI 10.1016/S0181-5512(04)96208-0
   Cintra LP, 2009, OPHTHAL SURG LAS IM, V40, P13, DOI 10.3928/15428877-20090101-05
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Cousen P, 2007, J DIABETES COMPLICAT, V21, P371, DOI 10.1016/j.jdiacomp.2006.05.008
   Crandall AS, 1999, OPHTHALMOLOGY, V106, P60, DOI 10.1016/S0161-6420(99)90007-6
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   He JC, 2010, EXP EYE RES, V91, P513, DOI 10.1016/j.exer.2010.07.007
   Heimann H, 2007, MED RETINA ESSENTIAL, P67
   Jacobi PC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1037, DOI 10.1001/archopht.118.8.1037
   Johnson C, 2005, J CHIROPR MED, V4, P43, DOI 10.1016/S0899-3467(07)60112-8
   Kaderli B, 2006, EUR J OPHTHALMOL, V16, P718, DOI 10.1177/112067210601600509
   Knecht PB, 2009, RETINA-J RET VIT DIS, V29, P1175, DOI 10.1097/IAE.0b013e3181aade74
   Kozak I, 2005, RETINA-J RET VIT DIS, V25, P994, DOI 10.1097/00006982-200512000-00007
   LaHood BR, 2011, CLIN EXP OPHTHALMOL, V39, P184, DOI 10.1111/j.1442-9071.2010.02432.x
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Moisseiev E, 2011, J OCUL PHARMACOL TH, V27, P333, DOI 10.1089/jop.2011.0001
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Prenner JL, 2011, RETINA-J RET VIT DIS, V31, P433, DOI 10.1097/IAE.0b013e31820a686a
   Rodrigues EB, 2011, J OCUL PHARMACOL TH, V27, P197, DOI 10.1089/jop.2010.0082
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salo D, 2003, AM J EMERG MED, V21, P515, DOI 10.1016/S0735-6757(03)00210-9
   Tavakoli M, 2007, DIABETES CARE, V30, P1895, DOI 10.2337/dc07-0175
   Woods CA, 2009, EYE CONTACT LENS, V35, P6, DOI 10.1097/ICL.0b013e3181909b03
   Yau GL, 2011, AM J OPHTHALMOL, V151, P333, DOI 10.1016/j.ajo.2010.08.031
NR 30
TC 30
Z9 30
U1 1
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP
PY 2012
VL 37
IS 9
BP 813
EP 817
DI 10.3109/02713683.2012.681335
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 983HQ
UT WOS:000307110800008
PM 22667326
DA 2022-11-30
ER

PT J
AU Rifkin, L
   Schaal, S
AF Rifkin, Lana
   Schaal, Shlomit
TI FACTORS AFFECTING PATIENTS' PAIN INTENSITY DURING IN OFFICE INTRAVITREAL
   INJECTION PROCEDURE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intravitreal injection; pain; topical anesthesia
ID TRIAMCINOLONE; RETINOPATHY; PERCEPTION; TOXICITY
AB Purpose: To determine factors associated with patients' comfort during routine in-office intravitreal injection.
   Methods: Sixty patients receiving intravitreal injections over 15 months for macular edema because of diabetes, age-related macular degeneration, or retinal vein occlusion who were randomized into 3 groups to receive 1 of 3 commonly used forms of anesthesia-TetraVisc, proparacaine HCl, or tetracaine HCl-before receiving intravitreal injection were studied. Fifteen minutes after injection, patients were asked to rate their pain from 0 (no pain/no distress) to 10 (agonizing pain/unbearable distress) using a Visual Analog Pain score survey. Self-reported pain scores were stratified by age, gender, diagnosis, injection number, substance injected, needle gauge, and visual acuity improvement.
   Results: Intravitreal injection was associated with low pain scores. Patients receiving tetracaine reported a statistically significant lower pain score (3.05 +/- 2.01) than patients receiving proparacaine (3.17 +/- 2.18) or TetraVisc (3.3 9 +/- 2.26; P < 0.01). Other important factors influencing pain score significantly (P < 0.01) included improved vision from previous injection, female sex, and age >65 years. Pain scores decreased with each consecutive injection.
   Conclusion: Pain associated with intravitreal injection is generally mild, and may be associated with epidemiologic and environmental factors. RETINA 32: 696-700, 2012
C1 [Rifkin, Lana; Schaal, Shlomit] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
C3 University of Louisville
RP Schaal, S (通讯作者)，301E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM s.schaal@louisville.edu
FU Research to Prevent Blindness, Inc, New York, N.Y.
FX Supported in part by an unrestricted grant from Research to Prevent
   Blindness, Inc, New York, N.Y.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   [Anonymous], 2006, INTR INJ SURV ANT PR
   Bartfield J M, 1994, Acad Emerg Med, V1, P364
   BELLVILL.JW, 1971, J AMER MED ASSOC, V217, P1835, DOI 10.1001/jama.217.13.1835
   CHAWLA HB, 1973, BRIT J OPHTHALMOL, V57, P58, DOI 10.1136/bjo.57.1.58
   Corcoran K, 2004, INTRAVITREAL INJECTI
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   DAILY MJ, 1973, AM J OPHTHALMOL, V76, P343, DOI 10.1016/0002-9394(73)90489-3
   DELANEY WV, 1972, AM J OPHTHALMOL, V74, P241, DOI 10.1016/0002-9394(72)90539-9
   DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817
   Fields HL, 2000, PROG BRAIN RES, V122, P245
   GRANT RL, 1994, EXP EYE RES, V58, P469, DOI 10.1006/exer.1994.1040
   Hubschman JP, 2010, RETINA-J RET VIT DIS, V30, P167, DOI 10.1097/IAE.0b013e3181b094cf
   HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8
   Jain I S, 1972, Indian J Ophthalmol, V20, P95
   Judge AJ, 1997, OPHTHALMOLOGY, V104, P1373, DOI 10.1016/S0161-6420(97)30128-6
   KANSKI JJ, 1973, BRIT J OPHTHALMOL, V57, P542, DOI 10.1136/bjo.57.8.542
   Keogh E, 2002, PAIN, V97, P195, DOI 10.1016/S0304-3959(01)00427-4
   Kok H, 2005, OPHTHALMOLOGY, V112, P1916, DOI 10.1016/j.ophtha.2005.06.009
   Paller CJ, 2009, PAIN MED, V10, P289, DOI 10.1111/j.1526-4637.2008.00558.x
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Ploghaus A, 2001, J NEUROSCI, V21, P9896, DOI 10.1523/JNEUROSCI.21-24-09896.2001
   PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4
   Stahl A, 2007, GRAEF ARCH CLIN EXP, V245, P1429, DOI 10.1007/s00417-007-0569-6
   THORNBURY JM, 1981, J GERONTOL, V36, P34, DOI 10.1093/geronj/36.1.34
NR 26
TC 45
Z9 46
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2012
VL 32
IS 4
BP 696
EP 700
DI 10.1097/IAE.0b013e3182252ad3
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 918ET
UT WOS:000302232800008
PM 22082694
DA 2022-11-30
ER

PT J
AU Blaha, M
   Rencova, E
   Blaha, V
   Maly, R
   Blazek, M
   Studnicka, J
   Andrys, C
   Fatorova, I
   Filip, S
   Kasparova, M
   Prochazkova, R
   Maly, J
   Zimova, R
   Langrova, H
AF Blaha, M.
   Rencova, E.
   Blaha, V.
   Maly, R.
   Blazek, M.
   Studnicka, J.
   Andrys, C.
   Fatorova, I.
   Filip, S.
   Kasparova, M.
   Prochazkova, R.
   Maly, J.
   Zimova, R.
   Langrova, H.
TI The importance of rheological parameters in the therapy of
   microcirculatory disorders
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE Haemorheology; microcirculation; age related macular degeneration;
   diabetic foot; acute hearing loss
ID SUDDEN HEARING-LOSS; LDL-APHERESIS; MACULAR DEGENERATION; PLASMA
   VISCOSITY; HELP APHERESIS; RHEOPHERESIS; FIBRINOGEN; DISEASES; TRIAL
AB Rheological conditions basically influence tissue perfusion, oxygen and nutrient supply, tissue regeneration and in its consequence the course of pathological processes, especially in microcirculation and partially even in macrocirculation. Haemorheotherapy has shown to be successful in several indications (critical disorders in microcirculation) when other methods of therapy have failed. In this study we describe the changes of effectivity indicators in haemorheopheresis treatment and their clinical importance in cases of eye microcirculation, statoacoustic apparatus and disorders of the lower extremities. We treated with haemorheopheresis (separator Cobe. Spetra + Evaflux filter) 24 patients (16 patients with age related macular degeneration, 5 with critical peripheral arterial foot disease, and 3 with acute hearing loss). After the procedures alpha(2)-macroglobulin decreases by about 58%, fibrinogen by about 69%, IgM by about 61%, LDL-cholesterol by about 77%, apolipoprotein B by about 76% and lipoprotein(a) by about 63%. It corresponds with a decrease in blood and plasma viscosity and clinical improvement in the observed patients, i.e. visual improvement, acceleration of tissue defect healing and improvement in hearing. We noticed 7.1% clinically insignificant side-effects. The method of haemorheopheresis was safe. It led to improvement in patients' clinical condition in the above mentioned indications when other methods of treatment failed.
C1 [Blaha, V.; Kasparova, M.] Charles Univ Prague, Fac Med, Dept Geriatry & Metabolismus, Hradec Kralove, Czech Republic.
   [Blaha, M.; Blazek, M.; Fatorova, I.; Prochazkova, R.; Maly, J.; Zimova, R.] Charles Univ Prague, Fac Med, Dept Internal Med 2, Hradec Kralove, Czech Republic.
   [Rencova, E.; Studnicka, J.; Langrova, H.] Charles Univ Prague, Fac Med, Dept Ophthalmol, Hradec Kralove, Czech Republic.
   [Maly, R.] Charles Univ Prague, Fac Med, Dept Internal Med 1, Hradec Kralove, Czech Republic.
   [Andrys, C.] Charles Univ Prague, Fac Med, Inst Immunol & Allergol, Hradec Kralove, Czech Republic.
   [Filip, S.] Charles Univ Prague, Fac Med, Dept Radiotherapy & Oncol, Hradec Kralove, Czech Republic.
C3 Charles University Prague; Charles University Prague; Charles University
   Prague; Charles University Prague; Charles University Prague; Charles
   University Prague
RP Blaha, V (通讯作者)，Charles Univ Prague, Fac Med, Dept Geriatry & Metabolismus, Hradec Kralove, Czech Republic.
EM blaham@email.cz
RI Studnicka, Jan/K-2875-2017; Studnička, Jan/AAC-4127-2022; Maly,
   Radovan/AAH-7032-2021; Filip, Stanislav/AAU-9160-2020; Blaha,
   Milan/H-8955-2016; Blaha, Vladimir/C-1151-2016; Maly,
   Jaroslav/P-6660-2017; Filip, Stanislav/D-4908-2017
OI Studnicka, Jan/0000-0002-9911-4379; Blaha, Milan/0000-0003-2330-5838;
   Blaha, Vladimir/0000-0001-8088-9919; Maly, Jaroslav/0000-0003-4889-5504;
   Filip, Stanislav/0000-0002-8567-0745; Andrys,
   Ctirad/0000-0001-6489-8786; Prochazkova, Renata/0000-0002-8649-996X;
   Langrova, Hana/0000-0001-8488-7208
FU Internal Grant Agency, Ministry of Health, CZ [NR/9103-4]
FX The work was supported by the grant of Internal Grant Agency, Ministry
   of Health, CZ, NR/9103-4.
CR Afenyi-Annan A, 2007, TRANSFUS APHER SCI, V36, P5, DOI 10.1016/j.transci.2006.10.007
   Blaha M, 2007, THER APHER DIAL, V11, P9, DOI 10.1111/j.1744-9987.2007.00450.x
   Blaha Milan, 2003, Acta Medica (Hradec Kralove), V46, P3
   Blazek M, 2007, HEMATOLOGY, V12, P571, DOI 10.1080/10245330701448370
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   BORBERG H, 2007, SEM 25 JAHR LDL APH
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Donaldson MJ, 2006, CURR OPIN OPHTHALMOL, V17, P267, DOI 10.1097/01.icu.0000193101.13551.e5
   Ferrannini M, 2007, INT J ARTIF ORGANS, V30, P923, DOI 10.1177/039139880703001010
   Finger RP, 2006, J CLIN APHERESIS, V21, P241, DOI 10.1002/jca.20081
   HARRIS JP, 1990, LARYNGOSCOPE, V100, P516
   JUNG F, 1992, CLIN HEMORHEOL, V12, P557
   Klingel R, 2005, THER APHER DIAL, V9, P473, DOI 10.1111/j.1744-9987.2005.00276.x
   Klingel R, 2005, J CLIN APHERESIS, V20, P169, DOI 10.1002/jca.20067
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   Kobayashi S, 2005, J CLIN APHERESIS, V20, P239, DOI 10.1002/jca.20033
   Matschke K, 2008, CLIN HEMORHEOL MICRO, V39, P265, DOI 10.3233/CH-2008-1093
   Matschke K, 2004, CLIN HEMORHEOL MICRO, V30, P263
   Megighian D, 2000, GERONTOLOGY, V46, P199, DOI 10.1159/000022160
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Michalska-Malecka K, 2008, CLIN HEMORHEOL MICRO, V38, P209
   Norgren L, 2007, INT ANGIOL, V26, P81
   Park JW, 2000, ACP-APPL CARDIOPUL P, V9, P19
   Prophet H, 2007, INT J ARTIF ORGANS, V30, P689
   Pulido J.S., 2006, T AM OPHTHAL SOC, V104, P1
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Ramping MW, 2008, CLIN HEMORHEOL MICRO, V39, P9, DOI 10.3233/CH-2008-1063
   Ramunni A, 2006, THER APHER DIAL, V10, P282, DOI 10.1111/j.1744-9987.2006.00380.x
   SOUDAVAR F, 1998, INVEST OPHTH VIS SCI, V39, P386
   Suckfull M, 2002, LANCET, V360, P1811, DOI 10.1016/S0140-6736(02)11768-5
   Ullrich H, 2004, J CLIN APHERESIS, V19, P71, DOI 10.1002/jca.20001
   Valbonesi M, 2004, INT J ARTIF ORGANS, V27, P806, DOI 10.1177/039139880402700911
   WOLF S, 1992, CLIN HEMORHEOL, V12, P725
   OCCULOGICS REPORTS P
NR 36
TC 24
Z9 27
U1 0
U2 20
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2009
VL 42
IS 1
BP 37
EP 46
DI 10.3233/CH-2009-1184
PG 10
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA 444RH
UT WOS:000265997600005
PM 19363239
DA 2022-11-30
ER

PT J
AU Salm, M
   Belsky, D
   Sloan, FA
AF Salm, Martin
   Belsky, Daniel
   Sloan, Frank A.
TI Trends in cost of major eye diseases to medicare, 1991 to 2000
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID HEALTH-CARE EXPENDITURE; CATARACT-SURGERY; OCULAR HYPERTENSION;
   GLAUCOMA; BLINDNESS; PATIENT; VISION; PEOPLE
AB center dot PURPOSE: To estimate impacts of physician,diagnosed eye diseases (age,related macular degeneration (AMD), cataract, diabetic retinopathy, and glaucoma) on Medicare payments in the periods 1991 to 1995 and 1996 to 2000.
   center dot DESIGN: A retrospective cohort study to estimate program payments per capita and in total for each of the major eye diseases and the four eye diseases in total.
   center dot METHODS: Data from the 1994 and 1999 National Long,Term Care Survey (NLTCS) and medical claims to Medicare from 1991 to 2000 were merged with the NLTCS. Medicare payments for eye,related procedures on persons with and without major eye diseases as reported on Medicare claims and self,reported data from NLTCS.
   center dot RESULTS: Overall, the burden of major eye diseases was to increase Medicare spending by $4.8 billion (1999 USD) in 1991 to 1995 and by $4.5 billion in 1996 to 2000. The most expensive eye disease was cataract, costing Medicare $3.8 billion in 1991 to 1995 and $3 billion in 1996 to 2000.
   center dot CONCLUSIONS: Prevalence of major eye diseases in, creased over time, but the effect of major eye diseases on Medicare payments decreased, mainly as a result of lower payments for cataract surgery in the later years.
C1 Duke Univ, Ctr Hlth Policy, Durham, NC 27708 USA.
   Univ Mannheim, Inst Econ Aging, Mannheim, Germany.
C3 Duke University; University of Mannheim
RP Sloan, FA (通讯作者)，Duke Univ, Ctr Hlth Policy, Box 90253,114 Rubenstein Hall, Durham, NC 27708 USA.
EM fsloan@hpolicy.duke.edu
RI Belsky, Daniel W/I-7035-2013; Belsky, Daniel/AAB-4785-2021; Belsky,
   Daniel/HDN-5118-2022
OI Belsky, Daniel W/0000-0001-5463-2212; Belsky,
   Daniel/0000-0001-5463-2212; 
FU NATIONAL INSTITUTE ON AGING [R01AG017473] Funding Source: NIH RePORTER;
   NIA NIH HHS [1R01-AG-17473-01A1] Funding Source: Medline
CR *AM MED AS S, 1994, CURR PROC TERM 1995
   *AM MED ASS, 1994, MED RBRVS PHYS GUID
   *AM MED ASS, 1998, INT CLASS DIS
   *AM MED ASS, 1982, INT CLASS DIS
   *AM MED ASS, 1998, MED RBRVS PHYS GUID
   *AM MED ASS, 1996, CURR PROC TERM PROF
   *AM MED ASS, 1997, CURR PROC TERM PROF
   *AM MED ASS, 1990, CURR PROC TERM 1991
   *AM MED ASS, 1998, CURR PROC TERM PROF
   *AM MED ASS, 1995, CURR PROC TERM 1996
   BERNTHPETERSEN P, 1982, ACTA OPHTHALMOL, V60, P461
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714
   Calissendorff BM, 2001, ACTA OPHTHALMOL SCAN, V79, P286, DOI 10.1034/j.1600-0420.2001.790315.x
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   Chou SL, 2003, CLIN EXP OPHTHALMOL, V31, P336, DOI 10.1046/j.1442-9071.2003.00667.x
   Ellis RP, 1996, HEALTH CARE FINANC R, V17, P101
   *FED HOSP INS BOAR, 2005, ANN REP BOARDS TRUST
   FRENKEL M, 1989, ARCH OPHTHALMOL-CHIC, V107, P1132, DOI 10.1001/archopht.1989.01070020198024
   Iskedjian M, 2003, J GLAUCOMA, V12, P456, DOI 10.1097/00061198-200312000-00002
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1034, DOI 10.1001/archopht.1993.01090080030012
   JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255
   JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909
   Kobelt G, 1999, INT J TECHNOL ASSESS, V15, P207, DOI 10.1017/S0266462399015299
   Kobelt-Nguyen G, 1998, J GLAUCOMA, V7, P95
   MARTIN TL, 1995, DIABETES CARE, V18, P1124, DOI 10.2337/diacare.18.8.1124
   Matz H, 1996, OPHTHALMOLOGICA, V210, P348, DOI 10.1159/000310742
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Muralikrishnan R, 2004, OPHTHAL EPIDEMIOL, V11, P369, DOI 10.1080/09286580490888762
   Oostenbrink JB, 2001, J GLAUCOMA, V10, P184, DOI 10.1097/00061198-200106000-00007
   Raghunathan TE., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186
   Raghunathan TE., 2002, IVEWARE IMPUTATION V
   Seshamani Meena, 2003, Appl Health Econ Health Policy, V2, P9
   Shapiro I, 2001, STUD INCOME, V62, P411
   Sloan FA, 2005, AM J OPHTHALMOL, V140, P618, DOI 10.1016/j.ajo.2005.01.019
   Smith A F, 2001, Ophthalmic Epidemiol, V8, P13, DOI 10.1076/opep.8.1.13.1542
   Stearns SC, 2004, HEALTH ECON, V13, P315, DOI 10.1002/hec.831
   STEINBERG EP, 1990, HEALTH SERV RES, V25, P727
   STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016
   STEINMAN L, 2005, 0510 U ZUR SOC I
   Wang JC, 2004, CLIN EXP OPHTHALMOL, V32, P578, DOI 10.1111/j.1442-9071.2004.00906.x
   WYLIEROSETT J, 1995, J DIABETES COMPLICAT, V9, P49, DOI 10.1016/1056-8727(94)00005-9
   Zweifel P, 1999, HEALTH ECON, V8, P485, DOI 10.1002/(SICI)1099-1050(199909)8:6<485::AID-HEC461>3.0.CO;2-4
NR 43
TC 59
Z9 59
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2006
VL 142
IS 6
BP 976
EP 982
DI 10.1016/j.ajo.2006.07.057
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 114MU
UT WOS:000242671100011
PM 17157582
DA 2022-11-30
ER

PT J
AU Bernstein, PS
   Leppert, M
   Singh, N
   Dean, M
   Lewis, RA
   Lupski, JR
   Allikmets, R
   Seddon, JM
AF Bernstein, PS
   Leppert, M
   Singh, N
   Dean, M
   Lewis, RA
   Lupski, JR
   Allikmets, R
   Seddon, JM
TI Genotype-phenotype analysis of ABCR variants in macular degeneration
   probands and siblings
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID STARGARDT-DISEASE GENE; CASSETTE TRANSPORTER GENE; MOLECULAR-GENETICS;
   ALLELIC VARIATION; MUTATIONS; AUTOFLUORESCENCE; DYSTROPHY; PROTEIN;
   FAMILY; CANCER
AB PURPOSE. Single-copy variants of the autosomal recessive Stargardt disease (STGD1) gene ABCR (ABCA4) have been shown to confer enhanced susceptibility to age-related macular degeneration (AMD), To investigate the role of ABCR alleles in AMD further, genotype-phenotype analysis was performed on siblings of patients with AMD who had known ABCR variants. This genetically related population provides a cohort of subjects with similar age and ethnic background for genotype-phenotype comparison to the original probands.
   METHODS. All available siblings of 26 probands carrying probable disease-associated ABCR variants were examined clinically. Blood samples were collected from these siblings for genotype analysis to search for the ABCR variant alleles corresponding to the isofamilial proband.
   RESULTS. Nineteen of 33 siblings from 15 families carried the respective proband's variant ABCR allele. Some families exhibited concordance of ABCR alleles with macular degeneration phenotype, but others did not. Exudative AMD was uncommon among both probands and siblings.
   CONCLUSIONS. Although population Studies have indicated that some ABCR variant alleles may enhance susceptibility to AMD, investigation of the extent of ABCR involvement by kindred analysis is complicated by a plethora of environmental and other hereditary factors not investigated in the current study that may also play important roles.
C1 Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
   Columbia Univ, Dept Pathol, New York, NY USA.
   Columbia Univ, Dept Ophthalmol, New York, NY USA.
   Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
   NCI, Frederick Canc Res & Dev Ctr, Lab Genomic Divers, Frederick, MD USA.
   Univ Utah, Dept Human Genet, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah; Harvard University;
   Harvard Medical School; Massachusetts Eye & Ear Infirmary; Columbia
   University; Columbia University; Baylor College of Medicine; Baylor
   College of Medicine; Baylor College of Medicine; Baylor College of
   Medicine; Baylor College of Medicine; National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications
   International Corporation (SAIC); SAIC-Frederick; Utah System of Higher
   Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, 50 N Med Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
RI Allikmets, Rando/ABD-4533-2021; Dean, Michael C/G-8172-2012; Dean,
   Michael/R-7501-2019
OI Dean, Michael C/0000-0003-2234-0631; 
FU NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R29EY011600, R01EY011600] Funding
   Source: NIH RePORTER; NCI NIH HHS [5P30CA42014] Funding Source: Medline;
   NCRR NIH HHS [M01-RR00064] Funding Source: Medline; NEI NIH HHS [R01
   EY011309, EY11309, EY11600] Funding Source: Medline
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DelaPaz MA, 1997, AM J OPHTHALMOL, V124, P331, DOI 10.1016/S0002-9394(14)70825-6
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739
   Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Gorin MB, 1999, MOL VIS, V5, pU31
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Lewis RA, 2000, HOSP PRACT, V35, P41
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   LEWIS RA, 2001, METABOLIC MOL BASES, P6077
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310
   Nathanson KL, 2001, HUM MOL GENET, V10, P715, DOI 10.1093/hmg/10.7.715
   Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221
   Rozet JM, 1999, MOL GENET METAB, V68, P310, DOI 10.1006/mgme.1999.2925
   Seddon J. M., 1997, Investigative Ophthalmology and Visual Science, V38, pS676
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 1999, PRINCIPLES PRACTICE, V1, P521
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   Simonelli F, 2000, INVEST OPHTH VIS SCI, V41, P892
   Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Sun H, 2000, METHOD ENZYMOL, V315, P879
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
NR 47
TC 30
Z9 36
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2002
VL 43
IS 2
BP 466
EP 473
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 518PK
UT WOS:000173676900024
PM 11818392
DA 2022-11-30
ER

PT J
AU Zhang, NZ
   He, XJ
   Xing, YQ
   Yang, N
AF Zhang, Ningzhi
   He, Xuejun
   Xing, Yiqiao
   Yang, Ning
TI Impact of the COVID-19 pandemic on patients receiving intravitreal
   injections
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article
DE anti-vascular endothelial growth factor; COVID-19; intravitreal
   injection; post-injection endophthalmitis; vial splitting
ID ENDOPHTHALMITIS; BEVACIZUMAB; EFFICACY
AB We analyzed the economic benefits versus safety risks of sharing anti-vascular endothelial growth factor (VEGF) vials during the coronavirus disease (COVID-19) pandemic. This single-center retrospective study analyzed the data of patients with neovascular age-related macular degeneration (nAMD), proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO) who received anti-VEGF between January 2016 and July 2021 at Renmin Hospital, Wuhan University, China. Costs were compared of the two protocols of intravitreal injections (IVIs) of ranibizumab, aflibercept and conbercept after (i) splitting the vial content for use in two patients and after (ii) disposal of the remaining vial content after use in a single patient, with the COVID-19 outbreak considered as the demarcation point. The incidence rates of post-injection endophthalmitis (PIE) pre- and post-outbreak were analyzed. The mean cost of a single IVI increased by 33.3%, from 3917.67 +/- 71.69 to 5222.67 +/- 84.98 Chinese Yuan during the pandemic. The incidences of IVI-related culture-positive PIE were 0.0134% (3 in 22448) and 0.0223% (1 in 4479), respectively, before and after the pandemic (P=0.6532). We conclude that vial sharing of IVIs in a large clinical institution is not associated with increased PIE risk and can significantly reduce the cost of therapy.
C1 [Zhang, Ningzhi; He, Xuejun; Xing, Yiqiao; Yang, Ning] Wuhan Univ, Renmin Hosp, Dept Ophthalmol, Wuhan, Peoples R China.
C3 Wuhan University
RP Yang, N (通讯作者)，Wuhan Univ, Renmin Hosp, Dept Ophthalmol, Wuhan, Peoples R China.
EM rootyangning@whu.edu.cn
CR Bavinger JC, 2019, RETINA-J RET VIT DIS, V39, P2004, DOI 10.1097/IAE.0000000000002351
   Blom K, 2022, OCUL IMMUNOL INFLAMM, V30, P713, DOI 10.1080/09273948.2020.1820530
   Borkar DS, 2018, AM J OPHTHALMOL, V194, P1, DOI 10.1016/j.ajo.2018.06.022
   Cai SW, 2018, DRUG DES DEV THER, V12, P3471, DOI 10.2147/DDDT.S177192
   Chen L, 2020, J CANCER, V11, P7291, DOI 10.7150/jca.46429
   Chen Y, 2019, AM J TRANSL RES, V11, P2969
   Cheng Chunxia, 2020, ECOLOGY, VVolume 12, P13241, DOI [10.1128/MCB.00434-12, DOI 10.1890/14-1853.1, 10.2147/CMAR.S285367]
   Cruz-Guzman Oriana del Rocio, BIOMED RES INT, V2015, P1, DOI [10.1155/2015/891972, DOI 10.1155/2015/891972, 10.7860/jcdr/2015/13038.6268, DOI 10.1787/9789264234246-EN]
   Du Q, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4864
   Durand ML, 2013, CLIN MICROBIOL INFEC, V19, P227, DOI 10.1111/1469-0691.12118
   Durand ML, 2017, CLIN MICROBIOL REV, V30, P597, DOI 10.1128/CMR.00113-16
   Fawzy Ashraf, 2019, RESP RES, V20, DOI [10.1186/s12885-019-5462-2, DOI https://doi.org/10.1186/s43008-019-0021-7, 10.1186/s12931-019-1059-1, DOI 10.1186/S12931-019-1059-1]
   Feng J, 2017, OPHTHALMOLOGY, V124, P408, DOI 10.1016/j.ophtha.2016.10.032
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Gomi F, 2021, J CLIN MED, V10, DOI 10.3390/jcm10143106
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   Jayaweera M, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109819
   Lee Tsung-Ming, CELL, V104, P298, DOI [10.1016/j.freeradbiomed.2017.01.035, DOI 10.1016/J.CELL.2017.09.021]
   Li WN, 2020, P NATL ACAD SCI USA, V117, P25859, DOI 10.1073/pnas.1920037117
   Li YZ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m997
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ling SK, 2021, NAT BIOMED ENG, V5, DOI 10.1038/s41551-020-00656-y
   Liu K, 2019, AM J OPHTHALMOL, V197, P156, DOI 10.1016/j.ajo.2018.08.026
   Lode HE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54226-7
   Lode Heidrun Elisabeth, 2019, SCI REP-UK, V9, DOI [10.1038/s41598-019-54226-7, DOI 10.1038/S41598-019-54226-7, DOI 10.1038/S41598-019-55616-7]
   Mitry D, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009510.pub2
   Ng DSC, 2020, EXPERT OPIN BIOL TH, V20, P1385, DOI 10.1080/14712598.2021.1830969
   Rayess N, 2016, BRIT J OPHTHALMOL, V100, P1058, DOI 10.1136/bjophthalmol-2015-307707
   Sassalos TM, 2019, CLIN OPHTHALMOL, V13, P701, DOI 10.2147/OPTH.S169044
   Serra Tiziano, 2014, ORGANOGENESIS, V9, P239, DOI [10.1128/CMR.00113-16, DOI 10.1787/FIN_SME_ENT-2018-16-EN, 10.4161/org.26048, DOI 10.4161/ORG.26048]
   Sivertsen MS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20525-8
   Sodre SL, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7562-y
   Song PG, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.020703
   Stem MS, 2019, OPHTHALMOL RETINA, V3, P3, DOI 10.1016/j.oret.2018.09.013
   Storey PP, 2019, AM J OPHTHALMOL, V199, P200, DOI 10.1016/j.ajo.2018.11.023
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Wang HB, 2020, ANGIOGENESIS, V23, P685, DOI 10.1007/s10456-020-09740-y
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Xu TL, 2020, LANCET PUBLIC HEALTH, V5, pE682, DOI 10.1016/S2468-2667(20)30254-1
   Xu Tingling, LANCET PUBLIC HEALTH, V5, pe682, DOI [10.1016/S2468-2667(20)30254-1, DOI 10.1016/S2468-2667(19)30241-5, DOI 10.1016/S2468-2667(20)30254-1]
NR 41
TC 0
Z9 0
U1 0
U2 0
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2022
VL 74
IS 1
BP 49
EP 55
DI 10.2298/ABS220116003Z
PG 7
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA 5N7OB
UT WOS:000871976700005
OA gold
DA 2022-11-30
ER

PT J
AU Rohiwal, SS
   Ellederova, Z
   Ardan, T
   Klima, J
AF Rohiwal, Sonali Suresh
   Ellederova, Zdenka
   Ardan, Taras
   Klima, Jiri
TI Advancement in Nanostructure-Based Tissue-Engineered Biomaterials for
   Retinal Degenerative Diseases
SO BIOMEDICINES
LA English
DT Review
DE nanostructures; cell transplantation; retinal degenerative disease;
   biomaterial; implants; scaffolds
ID PIGMENT EPITHELIAL-CELLS; MESENCHYMAL STEM-CELLS; ARTIFICIAL BRUCHS
   MEMBRANE; ANTERIOR LENS CAPSULE; FOREIGN-BODY REACTION; EMBRYONIC STEM;
   AMNIOTIC MEMBRANE; IN-VITRO; NANOFIBROUS SCAFFOLDS; MACULAR DEGENERATION
AB The review intends to overview a wide range of nanostructured natural, synthetic and biological membrane implants for tissue engineering to help in retinal degenerative diseases. Herein, we discuss the transplantation strategies and the new development of material in combination with cells such as induced pluripotent stem cells (iPSC), mature retinal cells, adult stem cells, retinal progenitors, fetal retinal cells, or retinal pigment epithelial (RPE) sheets, etc. to be delivered into the subretinal space. Retinitis pigmentosa and age-related macular degeneration (AMD) are the most common retinal diseases resulting in vision impairment or blindness by permanent loss in photoreceptor cells. Currently, there are no therapies that can repair permanent vision loss, and the available treatments can only delay the advancement of retinal degeneration. The delivery of cell-based nanostructure scaffolds has been presented to enrich cell survival and direct cell differentiation in a range of retinal degenerative models. In this review, we sum up the research findings on different types of nanostructure scaffolds/substrate or material-based implants, with or without cells, used to deliver into the subretinal space for retinal diseases. Though, clinical and pre-clinical trials are still needed for these transplants to be used as a clinical treatment method for retinal degeneration.
C1 [Rohiwal, Sonali Suresh; Ellederova, Zdenka; Ardan, Taras; Klima, Jiri] Czech Acad Sci, Inst Anim Physiol & Genet, Lab Cell Regenerat & Plast, Vvi, Rumburska 89, Libechov 27721, Czech Republic.
C3 Czech Academy of Sciences; Institute of Animal Physiology & Genetics of
   the Czech Academy of Sciences
RP Rohiwal, SS (通讯作者)，Czech Acad Sci, Inst Anim Physiol & Genet, Lab Cell Regenerat & Plast, Vvi, Rumburska 89, Libechov 27721, Czech Republic.
EM rohiwalsonali@gmail.com; ellederova@iapg.cas.cz; Ardan@iapg.cas.cz;
   klima@iapg.cas.cz
FU Czech Science Foundation [18-04393S, 19-09628J]; Technology Agency of
   the Czech Republic [KAPPA-TO01000107]
FX This work was financially supported by the Czech Science Foundation,
   project numbers 18-04393S and 19-09628J, as well as The Technology
   Agency of the Czech Republic, program KAPPATO01000107.
CR Ahmed TAE, 2015, FRONT BIOENG BIOTECH, V2, DOI 10.3389/fbioe.2014.00085
   Ahmed TAE, 2011, TISSUE ENG PT A, V17, P323, DOI 10.1089/ten.TEA.2009.0773
   Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   [Anonymous], 2016, RENEURON GROUP 1 PAT
   Aramant RB, 2004, PROG RETIN EYE RES, V23, P475, DOI 10.1016/j.preteyeres.2004.05.003
   Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, P1557
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Ben M'Barek K, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4568979
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bongso A, 2008, J CELL BIOCHEM, V105, P1352, DOI 10.1002/jcb.21957
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Capeans C, 2003, ACTA OPHTHALMOL SCAN, V81, P271, DOI 10.1034/j.1600-0420.2003.00076.x
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chen HL, 2011, INT J NANOMED, V6, P453, DOI 10.2147/IJN.S17057
   Chen K, 2010, J BIOMED MATER RES A, V93A, P634, DOI 10.1002/jbm.a.32571
   Christiansen AT, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/454295
   Christiansen AT, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/263264
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   da Silva GR, 2011, INT J ARTIF ORGANS, V34, P198, DOI 10.5301/IJAO.2011.6398
   Da Silva GR, 2013, J MATER SCI-MATER M, V24, P1309, DOI 10.1007/s10856-013-4885-6
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   DELPRIORE LV, 1993, EUR J IMPLANT REF SU, V5, P128, DOI DOI 10.1016/S0955-3681(13)80263-8
   Djojosubroto MW, 2008, CELL TISSUE RES, V331, P347, DOI 10.1007/s00441-007-0501-8
   Farrokh-Siar L, 1999, CURR EYE RES, V19, P89, DOI 10.1076/ceyr.19.2.89.5331
   Fitzpatrick SD, 2010, BIOMACROMOLECULES, V11, P2261, DOI 10.1021/bm100299j
   Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433
   Garcia-Bermudez MY, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.624983
   Garg K, 2013, BIOMATERIALS, V34, P4439, DOI 10.1016/j.biomaterials.2013.02.065
   Gater R., 2016, INT J STEM CELL RES, V3, P32, DOI [10.23937/2469-570X/1410032, DOI 10.23937/2469-570X/1410032]
   Ghosh F, 1999, EXP EYE RES, V68, P67, DOI 10.1006/exer.1998.0582
   Ghosh MK, 1996, POLYIMIDES FUNDAMENT
   Gir P, 2012, PLAST RECONSTR SURG, V129, P1277, DOI 10.1097/PRS.0b013e31824ecae6
   Glowacki J, 2008, BIOPOLYMERS, V89, P338, DOI 10.1002/bip.20871
   Grayson ACR, 2004, J BIOMAT SCI-POLYM E, V15, P1281, DOI 10.1163/1568562041959991
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Grueterich M, 2002, ARCH OPHTHALMOL-CHIC, V120, P783
   Guenther E, 1999, VISION RES, V39, P3988, DOI 10.1016/S0042-6989(99)00128-5
   Haddad-Mashadrizeh A, 2013, XENOTRANSPLANTATION, V20, P165, DOI 10.1111/xen.12033
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   Ho TC, 1996, CURR EYE RES, V15, P991, DOI 10.3109/02713689609017645
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   HOW TV, 1987, J BIOMED MATER RES, V21, P1093, DOI 10.1002/jbm.820210904
   Hsiue GH, 2002, J BIOMED MATER RES, V61, P19, DOI 10.1002/jbm.2000
   Hynes SR, 2010, GRAEF ARCH CLIN EXP, V248, P763, DOI 10.1007/s00417-009-1263-7
   Ikeya M, 2021, DEV GROWTH DIFFER, V63, P3, DOI 10.1111/dgd.12712
   Imai H, 2007, CURR EYE RES, V32, P903, DOI 10.1080/02713680701604749
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   Kazemi M., 2004, P 26 ANN INT C IEEE
   Khodair MA, 2003, INVEST OPHTH VIS SCI, V44, P4976, DOI 10.1167/iovs.03-0036
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kiilgaard JF, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/716968
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Klassen H, 2004, PROG RETIN EYE RES, V23, P149, DOI 10.1016/j.preteyeres.2004.01.002
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krishna Y, 2007, J BIOMED MATER RES A, V80A, P669, DOI 10.1002/jbm.a.30953
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lavik E, 2004, APPL MICROBIOL BIOT, V65, P1, DOI 10.1007/s00253-004-1580-z
   Lavik EB, 2003, INVEST OPHTH VIS SCI, V44, pU101
   Lawley E, 2015, J BIOMATER APPL, V29, P894, DOI 10.1177/0885328214547751
   Lee CJ, 2007, BIOMATERIALS, V28, P2192, DOI 10.1016/j.biomaterials.2007.01.018
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   Lim JM, 2004, INVEST OPHTH VIS SCI, V45, P4210, DOI 10.1167/iovs.03-1036
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lotters JC, 1997, J MICROMECH MICROENG, V7, P145, DOI 10.1088/0960-1317/7/3/017
   Lu JT, 2007, BIOMATERIALS, V28, P1486, DOI 10.1016/j.biomaterials.2006.11.023
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   Machalinska A, 2013, INVEST OPHTH VIS SCI, V54, P8292, DOI 10.1167/iovs.13-12221
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Malafaya PB, 2007, ADV DRUG DELIVER REV, V59, P207, DOI 10.1016/j.addr.2007.03.012
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Martin DJ, 2001, BIOMATERIALS, V22, P973, DOI 10.1016/S0142-9612(00)00262-3
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   Mizumoto H, 2003, VISION RES, V43, P1699, DOI 10.1016/S0042-6989(03)00235-9
   Montezuma SR, 2006, INVEST OPHTH VIS SCI, V47, P3514, DOI 10.1167/iovs.06-0106
   Moreira EF, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.10
   Nazemroaya F, 2017, J CELL BIOCHEM, V118, P3080, DOI 10.1002/jcb.26014
   Nicoara SD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1236721
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489
   Noorani B, 2018, INT J POLYM MATER PO, V67, P754, DOI 10.1080/00914037.2017.1362639
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   Okamoto F, 2012, INVEST OPHTH VIS SCI, V53, P6770, DOI 10.1167/iovs.12-9683
   Patel BB, 2019, MICRO NANO TECHNOL, P215, DOI 10.1016/B978-0-12-813355-2.00010-7
   Peng YJ, 2013, J BIOMED MATER RES A, V101, P167, DOI 10.1002/jbm.a.34315
   Pera MF, 2000, J CELL SCI, V113, P5
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Popelka S, 2015, BIOMED MATER, V10, DOI 10.1088/1748-6041/10/4/045022
   Pritchard CD, 2010, BIOMATERIALS, V31, P7978, DOI 10.1016/j.biomaterials.2010.07.026
   Pritchard CD, 2010, BIOMATERIALS, V31, P2153, DOI 10.1016/j.biomaterials.2009.11.074
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Redenti Stephen, 2008, J Ocul Biol Dis Infor, V1, P19, DOI 10.1007/s12177-008-9005-3
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Reynolds J, 2014, EXP EYE RES, V123, P151, DOI 10.1016/j.exer.2013.07.010
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P48, DOI 10.1007/BF01007837
   Scholz C, 2007, J BIOACT COMPAT POL, V22, P539, DOI 10.1177/0883911507082160
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shahmoradi S, 2017, MAT SCI ENG C-MATER, V73, P300, DOI 10.1016/j.msec.2016.11.076
   Shakibaie M, 2018, J BIOACT COMPAT POL, V33, P371, DOI 10.1177/0883911518776337
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Shimazaki J, 2002, OPHTHALMOLOGY, V109, P1285, DOI 10.1016/S0161-6420(02)01089-8
   SILVERMAN MS, 1989, INVEST OPHTH VIS SCI, V30, P1684
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Singh S, 2001, BIOMATERIALS, V22, P3337, DOI 10.1016/S0142-9612(01)00171-5
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Stern JH, 2011, NEUROTHERAPEUTICS, V8, P736, DOI 10.1007/s13311-011-0077-6
   Sugino IK, 2014, DEV OPHTHALMOL, V53, P133, DOI 10.1159/000358531
   TANSLEY KATHARINE, 1933, BRIT JOUR OPHTHALMOL, V17, P321, DOI 10.1136/bjo.17.6.321
   Tao S, 2007, LAB CHIP, V7, P695, DOI 10.1039/b618583e
   Tao SL, 2007, NANO LETT, V7, P1463, DOI 10.1021/nl0700346
   Teotia P, 2015, INVEST OPHTH VIS SCI, V56
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thumann G, 2006, CURR EYE RES, V31, P241, DOI 10.1080/02713680600556966
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472
   von Recum H, 1998, J BIOMAT SCI-POLYM E, V9, P1241, DOI 10.1163/156856298X00758
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wang K, 2016, BIOMATERIALS, V102, P249, DOI 10.1016/j.biomaterials.2016.06.028
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wang YD, 2003, J BIOMED MATER RES A, V66A, P192, DOI 10.1002/jbm.a.10534
   Warnke PH, 2013, ACTA BIOMATER, V9, P9414, DOI 10.1016/j.actbio.2013.07.029
   Weiland JD, 2014, IEEE T BIO-MED ENG, V61, P1412, DOI 10.1109/TBME.2014.2314733
   Wollensak G, 2004, RETINA-J RET VIT DIS, V24, P967, DOI 10.1097/00006982-200412000-00021
   Wu HJ, 2007, GRAEF ARCH CLIN EXP, V245, P135, DOI 10.1007/s00417-006-0296-4
   Xiang P, 2014, BIOMATERIALS, V35, P9777, DOI 10.1016/j.biomaterials.2014.08.040
   Xu W, 2011, INT J OPHTHALMOL-CHI, V4, P413, DOI 10.3980/j.issn.2222-3959.2011.04.19
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006
   Zarbin M., 2012, DRUG DISCOV TODAY TH, V10, pE25, DOI [10.1016/j.ddstr.2012.08.001, DOI 10.1016/J.DDSTR.2012.08.001]
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
   Zdrahala RJ, 1996, J BIOMATER APPL, V11, P37, DOI 10.1177/088532829601100102
   Zhu S, 2019, ADV SCI, V6, DOI 10.1002/advs.201802289
NR 142
TC 2
Z9 2
U1 3
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD AUG
PY 2021
VL 9
IS 8
AR 1005
DI 10.3390/biomedicines9081005
PG 26
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA UF8KN
UT WOS:000688817500001
PM 34440209
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Liu, XJ
   Guo, AS
   Tu, YY
   Li, WD
   Li, LL
   Liu, WR
   Ju, YY
   Zhou, YM
   Sang, AM
   Zhu, MH
AF Liu, Xiaojuan
   Guo, Aisong
   Tu, Yuanyuan
   Li, Wendie
   Li, Lele
   Liu, Wangrui
   Ju, Yuanyuan
   Zhou, Yamei
   Sang, Aimin
   Zhu, Manhui
TI Fruquintinib inhibits VEGF/VEGFR2 axis of choroidal endothelial cells
   and M1-type macrophages to protect against mouse laser-induced choroidal
   neovascularization
SO CELL DEATH & DISEASE
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; FACTOR RECEPTOR 2; MACULAR
   DEGENERATION; OCULAR NEOVASCULARIZATION; KAPPA-B; ANGIOGENESIS; GROWTH;
   RESVERATROL; VEGF; M2
AB Wet age-related macular degeneration, which is characterized by choroidal neovascularization (CNV) and induces obvious vision loss. Vascular endothelial growth factor (VEGF) family member VEGF-A (also named as VEGF) and its receptor VEGFR2 contribute to the pathogenesis of CNV. Choroidal endothelial cells (CECs) secret C-C motif chemokine ligand 2 (CCL2), which attracts macrophages to CNV lesion and promotes macrophage M1 polarization. Accordingly, infiltrating macrophages secret inflammatory cytokines to promote CNV. In vivo, intravitreal injection of fruquintinib (HMPL-013), an antitumor neovascularization drug, alleviated mouse CNV formation without obvious ocular toxicity. Meanwhile, HMPL-013 inhibited VEGF/VEGFR2 binding in CECs and macrophages, as well as macrophage M1 polarization. In vitro, noncontact coculture of human choroidal vascular endothelial cells (HCVECs) and macrophages under hypoxia conditions was established. HMPL-013 downregulated VEGF/VEGFR2/phosphoinositide-3-kinase/protein kinase B (AKT)/nuclear factor kappa B pathway and CCL2 secretion in HCVECs, as well as VEGF/VEGFR2-induced macrophage M1 polarization under hypoxia condition. In addition, HMPL-013 inhibited HCEVC derived CCL2-induced macrophage migration and M1 polarization, along with macrophage M1 polarization-induced HCVECs proliferation, migration, and tube formation. Altogether, HMPL-013 alleviated CNV formation might via breaking detrimental cross talk between CECs and macrophages.
C1 [Liu, Xiaojuan] Nantong Univ, Coll Med, Dept Pathogen Biol, Nantong, Jiangsu, Peoples R China.
   [Guo, Aisong] Nantong Univ, Affiliated Hosp, Dept Tradit Chinese Med, Nantong, Jiangsu, Peoples R China.
   [Tu, Yuanyuan; Zhu, Manhui] Soochow Univ, Lixiang Eye Hosp, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.
   [Li, Wendie] Ningbo Eye Hosp, Dept Ophthalmol, Ningbo, Zhejiang, Peoples R China.
   [Li, Lele; Sang, Aimin] Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong, Jiangsu, Peoples R China.
   [Liu, Wangrui] Youjiang Med Coll Nat Baise, Affiliated Hosp, Dept Neurosurg, Baise, Guangxi, Peoples R China.
   [Ju, Yuanyuan; Zhou, Yamei] Nantong Univ, Med Coll, Nantong, Jiangsu, Peoples R China.
C3 Nantong University; Nantong University; Soochow University - China;
   Nantong University; Nantong University
RP Zhu, MH (通讯作者)，Soochow Univ, Lixiang Eye Hosp, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.; Sang, AM (通讯作者)，Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong, Jiangsu, Peoples R China.
EM sangam@ntu.edu.cn; zhumanhuieye@126.com
RI 涂, 园园/AGE-3991-2022; Liu, Wangrui/AAS-9052-2021; Liu,
   WangRui/AAS-9057-2021
OI Liu, WangRui/0000-0002-0459-4446; Zhu, Manhui/0000-0002-3396-0222
FU major project of Nantong city [MS22018009]; Suzhou Commission of Health
   and Family Planning [KJXW2018076]; Natural Science Foundation of Yinzhou
   District [[2019]63]; Project of Suzhou Lixiang Eye Hospital
   [SLKY2020117]; Suzhou Science and Technology Bureau [SYS2018005]
FX The study was partially supported by the major project (No. MS22018009)
   of Nantong city, Suzhou Science and Technology Bureau (No. SYS2018005),
   the Suzhou Commission of Health and Family Planning (No. KJXW2018076),
   Natural Science Foundation of Yinzhou District (No. [2019]63), and
   Project of Suzhou Lixiang Eye Hospital (No. SLKY2020117).
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Basavarajappa HD, 2017, EMBO MOL MED, V9, P786, DOI 10.15252/emmm.201606561
   Burki TK, 2018, LANCET ONCOL, V19, pE388, DOI 10.1016/S1470-2045(18)30503-5
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chen ZG, 2019, EXPERT REV CLIN PHAR, V12, P713, DOI 10.1080/17512433.2019.1630272
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   Franceschini A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052394
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   Guo JX, 2017, J OCUL PHARMACOL TH, V33, P50, DOI 10.1089/jop.2016.0153
   Kelly A, 2018, METHODS MOL BIOL, V1784, P1, DOI 10.1007/978-1-4939-7837-3_1
   Kim KL, 2017, INVEST OPHTH VIS SCI, V58, P3592, DOI 10.1167/iovs.17-21416
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Li CH, 2011, CANCER BIOL THER, V12, P872, DOI 10.4161/cbt.12.10.17672
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Long D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120231
   Lu S, 2018, J CLIN ONCOL, V36, P1207, DOI 10.1200/JCO.2017.76.7145
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   Nio Y, 2012, DIABETOLOGIA, V55, P3350, DOI 10.1007/s00125-012-2710-2
   Omar HA, 2013, TOXICOL APPL PHARM, V272, P616, DOI 10.1016/j.taap.2013.07.014
   Phagura RS, 2020, CLIN EXP OPHTHALMOL, V48, P520, DOI 10.1111/ceo.13712
   Shah RS, 2016, INVEST OPHTH VIS SCI, V57, pOCT86, DOI 10.1167/iovs.15-18891
   Shirley M, 2018, DRUGS, V78, P1757, DOI 10.1007/s40265-018-0998-z
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Tomida D, 2011, INVEST OPHTH VIS SCI, V52, P3193, DOI 10.1167/iovs.10-6737
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Wang N, 2011, ATHEROSCLEROSIS, V218, P543, DOI 10.1016/j.atherosclerosis.2011.08.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu Y, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12660
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zambarakji HJ, 2006, INVEST OPHTH VIS SCI, V47, P2623, DOI 10.1167/iovs.05-0855
   Zhang HM, 2015, CYTOKINE, V76, P549, DOI 10.1016/j.cyto.2015.06.019
   Zhao T, 2015, J OCUL PHARMACOL TH, V31, P611, DOI 10.1089/jop.2014.0148
   Zhou SF, 2017, CANCER CHEMOTH PHARM, V80, P563, DOI 10.1007/s00280-017-3394-6
   Zhou YD, 2017, MOL MED REP, V15, P3949, DOI 10.3892/mmr.2017.6491
   Zhu YJ, 2016, IMMUNOLOGY, V147, P414, DOI 10.1111/imm.12571
NR 41
TC 6
Z9 7
U1 4
U2 11
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV 27
PY 2020
VL 11
IS 11
AR 1016
DI 10.1038/s41419-020-03222-1
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OX9QL
UT WOS:000593890400001
PM 33247124
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tisi, A
   Parete, G
   Flati, V
   Maccarone, R
AF Tisi, A.
   Parete, G.
   Flati, V
   Maccarone, R.
TI Up-regulation of pro-angiogenic pathways and induction of
   neovascularization by an acute retinal light damage
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EXPOSURE; NEUROPROTECTION; MECHANISMS;
   EXPRESSION; HYPOXIA; SAFFRON; ABSENCE
AB The light damage (LD) model was mainly used to study some of the main aspects of age related macular degeneration (AMD), such as oxidative stress and photoreceptor death. Several protocols of light-induced retinal degeneration exist. Acute light damage is characterized by a brief exposure (24hours) to high intensity light (1000 lux) and leads to focal degeneration of the retina which progresses over time. To date there are not experimental data that relate this model to neovascular events. Therefore, the purpose of this study was to characterize the retina after an acute light damage to assess whether the vascularization was affected. Functional, molecular and morphological investigations were carried out. The electroretinographic response was assessed at all recovery times (7, 60, 120 days after LD). Starting from 7 days after light damage there was a significant decrease in the functional response, which remained low up to 120 days of recovery. At 7 days after light exposure, neo-vessels invaded the photoreceptor layer and retinal neovascularization occurred. Remarkably, neoangiogenesis was associated to the up-regulation of VEGF, bFGF and their respective receptors (VEGFR2 and FGFR1) with the progression of degeneration. These important results indicate that a brief exposure to bright light induces the up-regulation of pro-angiogenic pathways with subsequent neovascularization.
C1 [Tisi, A.; Parete, G.; Flati, V; Maccarone, R.] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
C3 University of L'Aquila
RP Maccarone, R (通讯作者)，Univ Aquila, Dept Biotechnol & Appl Clin Sci, Via Vetoio,Coppito 2, I-67100 Laquila, Italy.
EM rita.maccarone@univaq.it
RI ; FLATI, VINCENZO/R-6231-2018
OI MACCARONE, Rita/0000-0003-0648-3771; FLATI, VINCENZO/0000-0003-1014-297X
CR Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395
   Alizadeh E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123846
   Anand-Apte B, 2010, ENCY EYE, P9
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bisti S, 2014, VISUAL NEUROSCI, V31, P355, DOI 10.1017/S0952523814000108
   Boscia F, 2013, J NEUROCHEM, V126, P428, DOI 10.1111/jnc.12209
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Cabral Thiago, 2017, Int J Retina Vitreous, V3, P31, DOI 10.1186/s40942-017-0084-9
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Coorey NJ, 2012, CLIN EXP OPTOM, V95, P266, DOI 10.1111/j.1444-0938.2012.00741.x
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Ding X, 2018, BMC OPHTHALMOL, V18, P1, DOI [10.1186/s12886-017-0645-6, DOI 10.1186/S12886-017-0645-6]
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fiorani L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140387
   Flynn E, 2014, INVEST OPHTH VIS SCI, V55, P5643, DOI 10.1167/iovs.14-14136
   Gargini C, 1999, INVEST OPHTH VIS SCI, V40, P2088
   Gutsaeva DR, 2017, ONCOTARGET, V8, P103568, DOI 10.18632/oncotarget.21592
   Heckenlively J. R., 2006, PRINCIPLES PRACTICE, V2nd
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Maccarone R, 2020, J OCUL PHARMACOL TH, V36, P376, DOI 10.1089/jop.2019.0105
   Manley G, 2013, NIH PUBLIC ACCESS, V71, P233
   Murakami M, 2011, J CLIN INVEST, V121, P2668, DOI 10.1172/JCI44762
   Natoli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072135
   Neurol L., 2006, FORUM INFECT CAUSES
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Petricca S, 2019, TOXICOL SCI, V169, P209, DOI 10.1093/toxsci/kfz031
   Pisani F, 2018, J CELL MOL MED, V22, P613, DOI 10.1111/jcmm.13348
   Randi AM, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-109556
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   Semeraro F, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/582060
   Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127
   Stankovic ND, 2016, ACTA NEUROPATHOL, V131, P347, DOI 10.1007/s00401-015-1524-y
   Sun Y., 2018, CHEMOKINE
   Tisi A, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107797
   Tisi A, 2019, EXP EYE RES, V182, P30, DOI 10.1016/j.exer.2019.03.003
   Wachtmeister L, 1998, PROG RETIN EYE RES, V17, P485, DOI 10.1016/S1350-9462(98)00006-8
   Waller R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210888
   Williams JAE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068616
   Wu WK, 2010, IMMUNOBIOLOGY, V215, P796, DOI 10.1016/j.imbio.2010.05.025
   Yin J, 2017, J CELL MOL MED, V21, P3467, DOI 10.1111/jcmm.13256
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
NR 50
TC 8
Z9 8
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 14
PY 2020
VL 10
IS 1
AR 6376
DI 10.1038/s41598-020-63449-y
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ND8OT
UT WOS:000562162800054
PM 32286488
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Donato, L
   D'Angelo, R
   Alibrandi, S
   Rinaldi, C
   Sidoti, A
   Scimone, C
AF Donato, Luigi
   D'Angelo, Rosalia
   Alibrandi, Simona
   Rinaldi, Carmela
   Sidoti, Antonina
   Scimone, Concetta
TI Effects of A2E-Induced Oxidative Stress on Retinal Epithelial Cells: New
   Insights on Differential Gene Response and Retinal Dystrophies
SO ANTIOXIDANTS
LA English
DT Article
DE RNA-Seq; RPE; Retinitis pigmentosa; A2E
ID PIGMENT EPITHELIUM; MACULAR DEGENERATION; RPE; INFLAMMATION; DEATH; A2E;
   MECHANISM; ESTROGEN; VEGF; MAP
AB Oxidative stress represents one of the principal inductors of lifestyle-related and genetic diseases. Among them, inherited retinal dystrophies, such as age-related macular degeneration and retinitis pigmentosa, are well known to be susceptible to oxidative stress. To better understand how high reactive oxygen species levels may be involved in retinal dystrophies onset and progression, we performed a whole RNA-Seq experiment. It consisted of a comparison of transcriptomes' profiles among human retinal pigment epithelium cells exposed to the oxidant agent N-retinylidene-N-retinylethanolamine (A2E), considering two time points (3h and 6h) after the basal one. The treatment with A2E determined relevant differences in gene expression and splicing events, involving several new pathways probably related to retinal degeneration. We found 10 different clusters of pathways involving differentially expressed and differentially alternative spliced genes and highlighted the sub- pathways which could depict a more detailed scenario determined by the oxidative-stress-induced condition. In particular, regulation and/or alterations of angiogenesis, extracellular matrix integrity, isoprenoid-mediated reactions, physiological or pathological autophagy, cell-death induction and retinal cell rescue represented the most dysregulated pathways. Our results could represent an important step towards discovery of unclear molecular mechanisms linking oxidative stress and etiopathogenesis of retinal dystrophies.
C1 [Donato, Luigi; D'Angelo, Rosalia; Alibrandi, Simona; Rinaldi, Carmela; Sidoti, Antonina; Scimone, Concetta] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Div Med Biotechnol & Prevent Med, I-98125 Messina, Italy.
   [Donato, Luigi; D'Angelo, Rosalia; Sidoti, Antonina; Scimone, Concetta] IEMEST, Dept Biomol Strategies Genet & Avant Garde Therap, I-90139 Palermo, Italy.
   [Alibrandi, Simona] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, I-98125 Messina, Italy.
C3 University of Messina; University of Messina
RP Donato, L; Sidoti, A (通讯作者)，Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Div Med Biotechnol & Prevent Med, I-98125 Messina, Italy.; Donato, L; Sidoti, A (通讯作者)，IEMEST, Dept Biomol Strategies Genet & Avant Garde Therap, I-90139 Palermo, Italy.
EM ldonato@unime.it; rdangelo@unime.it; simona.alibrandi@live.it;
   crinaldi@unime.it; asidoti@unime.it; cscimone@unime.it
RI Scimone, Concetta/P-4366-2015; D'Angelo, Rosalia/K-5482-2016; Donato,
   Luigi/I-1765-2018
OI Donato, Luigi/0000-0002-5292-426X
CR Agbaga MP, 2018, J LIPID RES, V59, P1586, DOI 10.1194/jlr.M082495
   Akanuma S, 2013, INVEST OPHTH VIS SCI, V54, P1469, DOI 10.1167/iovs.12-10905
   Alaimo A, 2020, ARCH TOXICOL, V94, P553, DOI 10.1007/s00204-019-02637-w
   Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Audo I, 2018, HUM MUTAT, V39, P887, DOI 10.1002/humu.23431
   Birtel J, 2019, CLIN EXP OPHTHALMOL, V47, P779, DOI 10.1111/ceo.13516
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Cornish E, 2004, MOL VIS, V10, P1
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   D'Angelo R, 2017, INT J MOL MED, V39, P1011, DOI 10.3892/ijmm.2017.2917
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Dhingra A, 2018, ADV EXP MED BIOL, V1074, P609, DOI 10.1007/978-3-319-75402-4_74
   Donato L, 2019, CELL CYCLE, V18, P84, DOI 10.1080/15384101.2018.1558873
   Donato L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35086-z
   Donato L, 2018, INVEST OPHTH VIS SCI, V59, P843, DOI 10.1167/iovs.17-22962
   Donato L, 2018, FEBS OPEN BIO, V8, P219, DOI 10.1002/2211-5463.12360
   Dontsov Alexander, 2016, World J Exp Med, V6, P63
   dos Santos-Rodrigues A, 2015, VITAM HORM, V98, P487, DOI 10.1016/bs.vh.2014.12.014
   Fahim A, 2018, CURR OPIN PEDIATR, V30, P725, DOI 10.1097/MOP.0000000000000690
   Fliesler SJ, 1997, INT J BIOCHEM CELL B, V29, P877, DOI 10.1016/S1357-2725(97)00018-6
   Frost LS, 2015, MOL NEUROBIOL, V52, P1135, DOI 10.1007/s12035-014-8920-5
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Ge YC, 2008, STAT SINICA, V18, P881
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Joyal JS, 2018, PROG RETIN EYE RES, V64, P131, DOI 10.1016/j.preteyeres.2017.11.002
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kivinen Niko, 2017, Duodecim, V133, P641
   Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marchesi N., 2018, OXID MED CELL LONGEV, V2018, P1, DOI DOI 10.1155/2018/4956080
   McCann KL, 2015, GENE DEV, V29, P862, DOI 10.1101/gad.256370.114
   McGrew DA, 2012, ADV EXP MED BIOL, V723, P539, DOI 10.1007/978-1-4614-0631-0_68
   Moiseyev G, 2010, P NATL ACAD SCI USA, V107, P17551, DOI 10.1073/pnas.1008769107
   Natarajan S, 2013, INDIAN J OPHTHALMOL, V61, P91, DOI 10.4103/0301-4738.109372
   Nivison-Smith L, 2014, OPTOMETRY VISION SCI, V91, P832, DOI 10.1097/OPX.0000000000000281
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Okabe K, 2014, CELL, V159, P584, DOI 10.1016/j.cell.2014.09.025
   Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566
   Olejniczak M, 2018, CELL MOL LIFE SCI, V75, P177, DOI 10.1007/s00018-017-2591-0
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Pereira MB, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4637-6
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Preising Markus, 2004, Ophthalmic Genet, V25, P101, DOI 10.1080/13816810490514333
   Randolph SA, 2014, WORKPLACE HEALTH SAF, V62, P352, DOI 10.3928/21650799-20140708-06
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Roysommuti S, 2013, ADV EXP MED BIOL, V776, P67, DOI 10.1007/978-1-4614-6093-0_8
   Scimone C, 2017, HUM GENOMICS, V11, DOI 10.1186/s40246-017-0114-6
   Sies H, 2015, REDOX BIOL, V4, P180, DOI 10.1016/j.redox.2015.01.002
   Soneson C, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-015-0862-3
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stephen, 2019, 3D RNA SEQ POWERFUL, DOI [10.1101/656686, DOI 10.1101/656686]
   Subrizi A, 2015, PHARM RES-DORDR, V32, P211, DOI 10.1007/s11095-014-1456-6
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Vancura P, 2018, INVEST OPHTH VIS SCI, V59, P3789, DOI 10.1167/iovs.18-24558
   Verbakel SK, 2018, PROG RETIN EYE RES, V66, P157, DOI 10.1016/j.preteyeres.2018.03.005
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   Wiktor A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36322-2
   Xu B, 2019, ADV EXP MED BIOL, V1185, P469, DOI 10.1007/978-3-030-27378-1_77
NR 65
TC 39
Z9 40
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD APR
PY 2020
VL 9
IS 4
AR 307
DI 10.3390/antiox9040307
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA LT3HG
UT WOS:000536961200080
PM 32290199
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wei, Y
   Liu, Y
   Sun, T
   Chen, W
   Ding, Y
AF Wei, Yue
   Liu, Yi
   Sun, Tao
   Chen, Wei
   Ding, Ying
TI Gene-based association analysis for bivariate time-to-event data through
   functional regression with copula models
SO BIOMETRICS
LA English
DT Article
DE AMD progression; bivariate time-to-event; copula; functional regression;
   gene-based association analysis
ID MACULAR DEGENERATION; SEQUENCING DATA; LINEAR-MODELS; PROGRESSION;
   DISEASE; RARE; SUSCEPTIBILITY; VARIANTS; TRAITS
AB Several gene-based association tests for time-to-event traits have been proposed recently to detect whether a gene region (containing multiple variants), as a set, is associated with the survival outcome. However, for bivariate survival outcomes, to the best of our knowledge, there is no statistical method that can be directly applied for gene-based association analysis. Motivated by a genetic study to discover the gene regions associated with the progression of a bilateral eye disease, age-related macular degeneration (AMD), we implement a novel functional regression (FR) method under the copula framework. Specifically, the effects of variants within a gene region are modeled through a functional linear model, which then contributes to the marginal survival functions within the copula. Generalized score test statistics are derived to test for the association between bivariate survival traits and the genetic region. Extensive simulation studies are conducted to evaluate the type I error control and power performance of the proposed approach, with comparisons to several existing methods for a single survival trait, as well as the marginal Cox FR model using the robust sandwich estimator for bivariate survival traits. Finally, we apply our method to a large AMD study, the Age-related Eye Disease Study, and to identify the gene regions that are associated with AMD progression.
C1 [Wei, Yue; Sun, Tao; Ding, Ying] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
   [Liu, Yi] Boehringer Ingelheim GmbH & Co KG, Dept Biostat & Data Sci, Ridgefield, CT USA.
   [Chen, Wei] Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Boehringer Ingelheim; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Ding, Y (通讯作者)，Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
EM yingding@pitt.edu
RI Chen, Wei/AAX-5994-2020
OI Chen, Wei/0000-0001-7196-8703; Sun, Tao/0000-0003-4447-3005; Wei,
   Yue/0000-0002-9922-3479
FU National Eye Institute [EY024226]; NATIONAL EYE INSTITUTE [R01EY024226]
   Funding Source: NIH RePORTER
FX National Eye Institute, Grant/Award Number: EY024226
CR Abe Sklar., 1959, FONCTIONS REPARTITIO, V8, P229
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Chen H, 2014, GENET EPIDEMIOL, V38, P191, DOI 10.1002/gepi.21791
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chien LC, 2017, GENET EPIDEMIOL, V41, P511, DOI 10.1002/gepi.22054
   CLAYTON DG, 1978, BIOMETRIKA, V65, P141, DOI 10.2307/2335289
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Boor C., 2011, APPL MATH SCI
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Fan RZ, 2016, GENET EPIDEMIOL, V40, P133, DOI 10.1002/gepi.21947
   Fan RZ, 2014, GENET EPIDEMIOL, V38, P622, DOI 10.1002/gepi.21840
   Fan RZ, 2013, GENET EPIDEMIOL, V37, P726, DOI 10.1002/gepi.21757
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   GUMBEL EJ, 1960, J AM STAT ASSOC, V55, P698, DOI 10.2307/2281591
   Han F, 2010, HUM HERED, V70, P42, DOI 10.1159/000288704
   Hougaard P., 2012, ANAL MULTIVARIATE SU
   Joe H., 1997, MULTIVARIATE MODELS
   Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024
   Luo L, 2013, EUR J HUM GENET, V21, P217, DOI 10.1038/ejhg.2012.141
   Luo L, 2012, J MED GENET, V49, P513, DOI 10.1136/jmedgenet-2012-100798
   Luo L, 2011, GENOME RES, V21, P1099, DOI 10.1101/gr.115998.110
   OAKES D, 1982, J ROY STAT SOC B MET, V44, P414
   Ramsay JO, 2009, USE R, P1, DOI 10.1007/978-0-387-98185-7_1
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Schaffner SF, 2005, GENOME RES, V15, P1576, DOI 10.1101/gr.3709305
   Sun T, 2019, LIFETIME DATA ANAL, V25, P546, DOI 10.1007/s10985-018-09459-5
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Voorman A., 2016, METAANALYSIS REGION
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Wu XW, 2018, ANN APPL STAT, V12, P1558, DOI 10.1214/17-AOAS1121
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
NR 34
TC 3
Z9 3
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-341X
EI 1541-0420
J9 BIOMETRICS
JI Biometrics
PD JUN
PY 2020
VL 76
IS 2
BP 619
EP 629
DI 10.1111/biom.13165
EA NOV 2019
PG 11
WC Biology; Mathematical & Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology; Mathematics
GA PI2KL
UT WOS:000496510600001
PM 31625595
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Hughes, CP
   O'Flynn, NMJ
   Gatherer, M
   McClements, ME
   Scott, JA
   MacLaren, RE
   Goverdhan, S
   Glennie, MJ
   Lotery, AJ
AF Hughes, Chris P.
   O'Flynn, Neil M. J.
   Gatherer, Maureen
   McClements, Michelle E.
   Scott, Jennifer A.
   MacLaren, Robert E.
   Goverdhan, Srinivas
   Glennie, Martin J.
   Lotery, Andrew J.
TI AAV2/8 Anti-angiogenic Gene Therapy Using Single-Chain Antibodies
   Inhibits Murine Choroidal Neovascularization
SO MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; OCULAR
   NEOVASCULARIZATION; MONOCLONAL-ANTIBODY; EXPRESSION; MOUSE; VEGF; MICE;
   SEROTYPES; VECTORS
AB While anti-angiogenic therapies for wet age-related macular degeneration (AMD) are effective for many patients, they require multiple injections and are expensive and prone to complications. Gene therapy could be an elegant solution for this problem by providing a long-term source of anti-angiogenic proteins after a single administration. Another potential issue with current therapeutic proteins containing a fragment crystallizable (Fc) domain (such as whole antibodies like bevacizumab) is the induction of an unwanted immune response. In wet AMD, a low level of inflammation is already present, so to avoid exacerbation of disease by the therapeutic protein, we propose single-chain fragment variable (scFv) antibodies, which lack the Fc domain, as a safer alternative. To investigate the feasibility of this, anti-vascular endothelial growth factor (VEGF)-blocking antibodies in two formats were produced and tested in vitro and in vivo. The scFv transgene was then cloned into an adeno-associated virus (AAV) vector. A therapeutic effect in a mouse model of choroidal neovascularization (CNV) was demonstrated with antibodies in both scFv and immunoglobulin G1 (IgG1) formats (p < 0.04). Importantly, the scFv anti-VEGF antibody expressed from an AAV vector also had a significant beneficial effect (p = 0.02), providing valuable preclinical data for future translation to the clinic.
C1 [Hughes, Chris P.; O'Flynn, Neil M. J.; Gatherer, Maureen; Scott, Jennifer A.; Goverdhan, Srinivas; Lotery, Andrew J.] Univ Southampton, Fac Med, Clin Neurosci, Southampton, Hants, England.
   [McClements, Michelle E.; MacLaren, Robert E.] Univ Oxford, Oxford Eye Hosp, Oxford, England.
   [McClements, Michelle E.; MacLaren, Robert E.] Univ Oxford, Nuffield Lab Ophthalmol, Oxford, England.
   [Glennie, Martin J.] Univ Southampton, Fac Med, Canc Sci, Southampton, Hants, England.
C3 University of Southampton; University of Oxford; University of Oxford;
   University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Southampton Gen Hosp, Fac Med, Clin Neurosci, South Lab & Path Block,MP 806,Level D,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
OI MacLaren, Robert/0000-0002-3096-4682; Lotery, Andrew/0000-0001-5541-4305
FU Gift of Sight charity; MRC DPFS [MR/K007629/1]; Oxford University
   Hospitals NHS Foundation Trust NIHR Biomedical Research Centre
FX This work was supported by the Gift of Sight charity. Gift of Sight is
   managed by the University of Southampton Exempt Charity (Inland Revenue
   reference number X19140). M.E.M. is funded by an MRC DPFS grant awarded
   to R.E.M. (MR/K007629/1) to develop AAV8 retinal gene therapy, and the
   vector facilities are funded by the Oxford University Hospitals NHS
   Foundation Trust NIHR Biomedical Research Centre. We would like to thank
   Claude Chan for providing help and advice with producing the antibodies
   and Savannah Lynn for working on the graphs (both University of
   Southampton).
CR Allocca M, 2007, J VIROL, V81, P11372, DOI 10.1128/JVI.01327-07
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Cesana D, 2014, MOL THER, V22, P774, DOI 10.1038/mt.2014.3
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Donello JE, 1996, J VIROL, V70, P4345, DOI 10.1128/JVI.70.7.4345-4351.1996
   Hansel TT, 2010, NAT REV DRUG DISCOV, V9, P325, DOI 10.1038/nrd3003
   HARFST E, 1992, MOL CELL ENDOCRINOL, V83, P117, DOI 10.1016/0303-7207(92)90152-V
   Hasegawa E, 2012, J LEUKOCYTE BIOL, V91, P267, DOI 10.1189/jlb.1110603
   Hutton D, 2014, HEALTH AFFAIR, V33, P931, DOI 10.1377/hlthaff.2013.0832
   Kim SJ, 2013, BRIT J OPHTHALMOL, V97, P367, DOI 10.1136/bjophthalmol-2012-302307
   Kovaleva M, 2014, EXPERT OPIN BIOL TH, V14, P1527, DOI 10.1517/14712598.2014.937701
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   MacLaren RE, 2014, LANCET, V383, P1129, DOI 10.1016/S0140-6736(13)62117-0
   Mao YX, 2011, HUM GENE THER, V22, P1525, DOI 10.1089/hum.2011.090
   MIYAZAKI J, 1989, GENE, V79, P269
   Mordenti J, 1999, TOXICOL SCI, V52, P101, DOI 10.1093/toxsci/52.1.101
   Murinello S, 2014, INVEST OPHTH VIS SCI, V55, P247, DOI 10.1167/iovs.13-11821
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Stieger K, 2006, MOL THER, V13, P967, DOI 10.1016/j.ymthe.2005.12.001
   Tiller KE, 2015, ANNU REV BIOMED ENG, V17, P191, DOI 10.1146/annurev-bioeng-071114-040733
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Wakusawa R, 2011, INVEST OPHTH VIS SCI, V52, P3272, DOI 10.1167/iovs.10-6295
   Wigg JP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128418
NR 35
TC 5
Z9 6
U1 1
U2 10
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2329-0501
J9 MOL THER-METH CLIN D
JI Mol.Ther.-Methods Clin. Dev.
PD JUN 14
PY 2019
VL 13
BP 86
EP 98
DI 10.1016/j.omtm.2018.11.005
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IC9EK
UT WOS:000471284200009
PM 30719487
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Gavini, E
   Bonferoni, MC
   Rassu, G
   Obinu, A
   Ferrari, F
   Giunchedi, P
AF Gavini, Elisabetta
   Bonferoni, Maria C.
   Rassu, Giovanna
   Obinu, Antonella
   Ferrari, Franca
   Giunchedi, Paolo
TI Biodegradable Microspheres as Intravitreal Delivery Systems for
   Prolonged Drug Release. What is their Eminence in the Nanoparticle Era?
SO CURRENT DRUG DELIVERY
LA English
DT Review
DE Posterior segment; intravitreal injections; repeated administrations;
   prolonged release; microspheres; nanoparticles; biodegradable polymers
ID IN-VITRO; PLGA MICROSPHERES; ENGINEERED MICROPARTICLES; TRIAMCINOLONE
   ACETONIDE; SUSTAINED DELIVERY; ACID MICROSPHERES; OCULAR DELIVERY;
   CELL-DEATH; CHITOSAN; INJECTION
AB Drug administration to the posterior segment of the eye has many challenges due to the natural barriers and consequent problems of low and unpredictable bioavailability. There is an increasing need for managing severe posterior eye diseases, such as age-related macular degeneration, diabetic retinopathy, etc. Most of these diseases, if left untreated, lead to blindness. Traditional ocular formulations and topical administrations are almost inefficient and the drug delivery to the back of the eye requires direct administrations through intravitreal injections of innovative drug delivery systems. These systems must be easily injectable, able to release the drug for a prolonged period of time (to overcome the problem of repeated administrations) and made of biodegradable/biocompatible polymers. Among these delivery systems, microspheres still have an important role. This overview wants to highlight the use of microspheres as intravitreal systems to overcome the challenges of back of the eye diseases. Studies have shown that microspheres are able to enhance the intravitreal half-life and thus bioavailability of many drugs, protecting them from degradation. Furthermore, personalized therapies can be made by changing the amount of administered microspheres. This review focuses on the materials (polymers) used for the preparation of the microparticulate systems and comparative remarks are made with respect to the use of nanoparticles.
C1 [Gavini, Elisabetta; Giunchedi, Paolo] Univ Sassari, Dept Chem & Pharm, Sassari, Italy.
   [Bonferoni, Maria C.; Rassu, Giovanna; Ferrari, Franca] Univ Pavia, Dept Drug Sci, Viale Taramelli 12, I-27100 Pavia, Italy.
   [Obinu, Antonella] Univ Pavia, Dept Clin Surg Diagnost & Paediat Sci, Expt Med, Pavia, Italy.
C3 University of Sassari; University of Pavia; University of Pavia
RP Bonferoni, MC (通讯作者)，Univ Pavia, Dept Drug Sci, Viale Taramelli 12, I-27100 Pavia, Italy.
EM cbonferoni@unipv.it
RI Rassu, Giovanna/I-5495-2015; Gavini, Elisabetta/AAU-5392-2020; Rassu,
   Giovanna/O-1215-2019
OI Rassu, Giovanna/0000-0001-6268-8179; Gavini,
   Elisabetta/0000-0002-0499-9419; Rassu, Giovanna/0000-0001-6268-8179;
   Bonferoni, Maria Cristina/0000-0002-1194-9372
CR Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Andres-Guerrero V, 2015, J CONTROL RELEASE, V211, P105, DOI 10.1016/j.jconrel.2015.05.279
   ARAIZ JJ, 1993, INVEST OPHTH VIS SCI, V34, P522
   Barcia E, 2009, EXP EYE RES, V89, P238, DOI 10.1016/j.exer.2009.03.012
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Bonferoni MC, 2016, J BIOMED NANOTECHNOL, V12, P231, DOI 10.1166/jbn.2016.2140
   Bonferoni MC, 2008, EUR J PHARM SCI, V33, P166, DOI 10.1016/j.ejps.2007.11.004
   Bonferoni MC, 2017, COLLOID SURFACE B, V152, P385, DOI 10.1016/j.colsurfb.2017.01.043
   Bonferoni MC, 2009, EXPERT OPIN DRUG DEL, V6, P923, DOI 10.1517/17425240903114142
   Bonferoni MC, 2004, EUR J PHARM BIOPHARM, V57, P465, DOI 10.1016/j.ejpb.2003.12.002
   Cardillo J A, 2006, Arch Soc Esp Oftalmol, V81, P675
   Checa-Casalengua P, 2011, J CONTROL RELEASE, V156, P92, DOI 10.1016/j.jconrel.2011.06.023
   Chen J.X., 2002, ACAD J PLA POSTGRAD, V6, P139
   Cheng L, 2008, BRIT J OPHTHALMOL, V92, P705, DOI 10.1136/bjo.2007.133587
   Chhablani J, 2013, INVEST OPHTH VIS SCI, V54, P1268, DOI 10.1167/iovs.12-11172
   Cho YW, 2014, INT J OPHTHALMOL-CHI, V7, P952, DOI 10.3980/j.issn.2222-3959.2014.06.07
   Chowdhury DK, 2000, PHARM DEV TECHNOL, V5, P279, DOI 10.1081/PDT-100100542
   Comyn O, 2013, CURR OPIN OPHTHALMOL, V24, P248, DOI 10.1097/ICU.0b013e32835fab27
   Conti B, 1997, EUR J PHARM SCI, V5, P287, DOI 10.1016/S0928-0987(97)00023-7
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Engin KN, 2009, MOL VIS, V15, P855
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferrari F, 1997, FARMACO, V52, P493
   Freier T, 2002, BIOMATERIALS, V23, P2649, DOI 10.1016/S0142-9612(01)00405-7
   Garcia-Caballero C, 2017, EUR J PHARM SCI, V103, P19, DOI 10.1016/j.ejps.2017.02.037
   Gavini E, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060117
   Gavini E, 2004, EUR J PHARM BIOPHARM, V57, P207, DOI 10.1016/j.ejpb.2003.10.018
   Gavini E, 2016, DRUG DEV IND PHARM, V42, P554, DOI 10.3109/03639045.2015.1100201
   Giunchedi P, 1998, J CONTROL RELEASE, V56, P53, DOI 10.1016/S0168-3659(98)00068-6
   Herrero-Vanrell R, 2014, PROG RETIN EYE RES, V42, P27, DOI 10.1016/j.preteyeres.2014.04.002
   Hu T, 2007, J PHARMACEUT BIOMED, V43, P263, DOI 10.1016/j.jpba.2006.06.032
   Inoue M, 2004, AM J OPHTHALMOL, V138, P1046, DOI 10.1016/j.ajo.2004.05.028
   Isiegas C, 2016, INVEST OPHTH VIS SCI, V57, P3610, DOI 10.1167/iovs.16-19300
   Janoria KG, 2007, EXPERT OPIN DRUG DEL, V4, P371, DOI 10.1517/17425247.4.4.371
   Jiang C, 2007, MOL VIS, V13, P1783
   Joseph M, 2017, EXPERT OPIN DRUG DEL, V14, P631, DOI 10.1080/17425247.2016.1227783
   Kaur IP, 2014, J CONTROL RELEASE, V193, P100, DOI 10.1016/j.jconrel.2014.05.031
   KHOOBEHI B, 1991, OPHTHALMIC SURG LAS, V22, P175
   Kim MM, 2006, FEBS LETT, V580, P2661, DOI 10.1016/j.febslet.2006.04.015
   Klausner EA, 2010, BIOMATERIALS, V31, P1814, DOI 10.1016/j.biomaterials.2009.10.031
   Kropp M, 2014, POLYMERS-BASEL, V6, P243, DOI 10.3390/polym6010243
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lens A., 2008, OCULAR ANATOMY PHYSL
   Li WC, 2014, INT OPHTHALMOL, V34, P465, DOI 10.1007/s10792-013-9829-0
   Lu F., 1993, J INJ OCCUP DIS EYE, V15, P254
   Martinez-Sancho C, 2006, INT J PHARMACEUT, V326, P100, DOI 10.1016/j.ijpharm.2006.07.010
   Martinez-Sancho C, 2004, J CONTROL RELEASE, V99, P41, DOI 10.1016/j.jconrel.2004.06.004
   Martinez-Sancho C, 2004, INT J PHARMACEUT, V273, P45, DOI 10.1016/j.ijpharm.2003.12.006
   Martinez-Sancho C, 2003, J MICROENCAPSUL, V20, P799, DOI 10.1080/02652040310001600532
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   McGhee CNJ, 2002, DRUG SAFETY, V25, P33, DOI 10.2165/00002018-200225010-00004
   MORITERA T, 1992, INVEST OPHTH VIS SCI, V33, P3125
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel SR, 2012, INVEST OPHTH VIS SCI, V53, P4433, DOI 10.1167/iovs.12-9872
   Patel SP, 2015, AAPS PHARMSCITECH, V16, P327, DOI 10.1208/s12249-014-0196-6
   Puras G, 2013, EUR J PHARM BIOPHARM, V83, P131, DOI 10.1016/j.ejpb.2012.09.010
   Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002
   Rafat M, 2010, BIOMATERIALS, V31, P3414, DOI 10.1016/j.biomaterials.2010.01.031
   Rassu G, 2016, J DRUG DELIV SCI TEC, V32, P77, DOI 10.1016/j.jddst.2015.05.002
   Rassu G, 2015, J CONTROL RELEASE, V201, P68, DOI 10.1016/j.jconrel.2015.01.025
   Rassu G, 2009, J PHARM SCI-US, V98, P4852, DOI 10.1002/jps.21751
   Robinson R, 2011, ACS NANO, V5, P4392, DOI 10.1021/nn103146p
   Robinson R, 2010, J MICROENCAPSUL, V27, P263, DOI 10.3109/02652040903131285
   Villanueva JR, 2016, EUR J PHARM SCI, V92, P287, DOI 10.1016/j.ejps.2016.03.012
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Sandri G, 2011, J PHARM PHARMACOL, V63, P189, DOI 10.1111/j.2042-7158.2010.01208.x
   Sarao V, 2014, SCI WORLD J, DOI 10.1155/2014/989501
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   Sherif Z, 2002, OPHTHALMOLOGICA, V216, P305, DOI 10.1159/000066189
   Shmueli RB, 2013, BIOMATERIALS, V34, P7544, DOI 10.1016/j.biomaterials.2013.06.044
   Sigurdsson HH, 2007, ACTA OPHTHALMOL SCAN, V85, P598, DOI 10.1111/j.1600-0420.2007.00885.x
   Stewart MP, 2000, ADV MATER, V12, P859, DOI 10.1002/1521-4095(200006)12:12<859::AID-ADMA859>3.0.CO;2-0
   Tanetsugu Y, 2017, BIOL PHARM BULL, V40, P145, DOI 10.1248/bpb.b16-00437
   Thakur SS, 2014, EXPERT OPIN DRUG DEL, V11, P1575, DOI 10.1517/17425247.2014.927864
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Tolentino F.I., 1989, OPHTHALMOL ANN, V96, P337
   Velez G, 1999, BRIT J OPHTHALMOL, V83, P1225, DOI 10.1136/bjo.83.11.1225
   Wang CY, 2014, EXP EYE RES, V129, P74, DOI 10.1016/j.exer.2014.11.002
   Wassmer S, 2013, ACTA BIOMATER, V9, P7855, DOI 10.1016/j.actbio.2013.04.025
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yang H, 2008, GRAEF ARCH CLIN EXP, V246, P1097, DOI 10.1007/s00417-008-0813-8
NR 86
TC 12
Z9 12
U1 4
U2 33
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2018
EI 1875-5704
J9 CURR DRUG DELIV
JI Curr. Drug Deliv.
PY 2018
VL 15
IS 7
BP 930
EP 940
DI 10.2174/1567201815666180226121020
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GQ5WF
UT WOS:000441763900002
PM 29484995
DA 2022-11-30
ER

PT J
AU Joseph, RR
   Tan, DWN
   Ramon, MRM
   Natarajan, JV
   Agrawal, R
   Wong, TT
   Venkatraman, SS
AF Joseph, Rini Rachel
   Tan, Dulcia Wei Ni
   Ramon, Moreno Raja Miguel
   Natarajan, Jayaganesh V.
   Agrawal, Rupesh
   Wong, Tina T.
   Venkatraman, Subbu S.
TI Characterization of liposomal carriers for the trans-scleral transport
   of Ranibizumab
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DRUG-DELIVERY SYSTEMS; RETINAL DISEASES; NANOPARTICLES; RELEASE;
   PHARMACOKINETICS; BEVACIZUMAB; CHOLESTEROL; STABILITY; SIZE
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the modern world. The standard treatment regimen for neovascular AMD is the monthly/bimonthly intravitreal injection of anti-VEGF agents such as ranibizumab or aflibercept. However, these repeated invasive injections can lead to sight-threatening complications. Sustained delivery by encapsulation of the drug in carriers is a way to reduce the frequency of these injections. Liposomes are biocompatible, non-toxic vesicular nanocarriers, which can be used to encapsulate therapeutic agents to provide sustained release. The protein encapsulation was performed by a modified dehydration-rehydration (DRV) method. The liposomes formed were characterized for size, zeta potential, encapsulation efficiency, stability, in vitro release, and ex vivo release profiles. In addition, the localization of the liposomes themselves was studied ex vivo. Entrapment-efficiency of ranibizumab into 100-nm liposomes varied from 14.7 to 57.0%. Negatively-charged liposomes prepared from DPPC-DPPG were found to have the slowest release with a low initial burst release compared to the rest of liposomal formulations. The ex vivo protein release was found to slower than the in vitro protein release for all samples. In conclusion, the DPPC-DPPG liposomes significantly improved the encapsulation and release profile of ranibizumab.
C1 [Joseph, Rini Rachel; Tan, Dulcia Wei Ni; Ramon, Moreno Raja Miguel; Natarajan, Jayaganesh V.; Wong, Tina T.; Venkatraman, Subbu S.] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore, Singapore.
   [Wong, Tina T.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Wong, Tina T.] Singapore Eye Res Inst, Ocular Drug Delivery Grp, Singapore, Singapore.
   [Agrawal, Rupesh] Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore, Singapore.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Singapore National Eye
   Center; National University of Singapore; Singapore National Eye Center;
   Tan Tock Seng Hospital
RP Wong, TT; Venkatraman, SS (通讯作者)，Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore, Singapore.; Wong, TT (通讯作者)，Singapore Natl Eye Ctr, Singapore, Singapore.; Wong, TT (通讯作者)，Singapore Eye Res Inst, Ocular Drug Delivery Grp, Singapore, Singapore.
EM tina.wong.t.l@singhealth.com.sg; assubbu@ntu.edu.sg
RI Venkatraman, Subramanian/A-2228-2011
OI Venkatraman, Subramanian/0000-0002-8693-1070; Agrawal,
   Rupesh/0000-0002-6662-5850; Moreno Raja, Miguel/0000-0002-6758-3998
FU NMRC TCR
FX The authors would like to acknowledge the financial support provided by
   the NMRC TCR grant, as well as the use of microscopy and histology
   facilities at SERI.
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Ambati J, 2000, INVEST OPHTHALMOL VI, V41
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   BARZA M, 1987, INVEST OPHTH VIS SCI, V28, P893
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Booth BA, 2007, DRUG AGING, V24, P581, DOI 10.2165/00002512-200724070-00006
   Briuglia ML, 2015, DRUG DELIV TRANSL RE, V5, P231, DOI 10.1007/s13346-015-0220-8
   Cardillo J.A., 2006, Arch Soc Esp Oftalmol, V81, P679
   Carrasquillo K. G., 2003, INVEST OPHTHALMOL VI, V44
   Cheruvu N. P. S., 2006, INVEST OPHTHALMOL VI, V46
   Cruysberg L. P. J, 2005, INVEST OPHTHALMOL VI, V46
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Geroski H. D., 2000, INVEST OPHTHALMOL VI, V41
   Goda Y, 2016, AAPS PHARMSCITECH, P1
   Honda M, 2011, ARCH OPHTHALMOL, V129
   Kadam RS, 2010, J PHARMACOL EXP THER, V332, P1107, DOI 10.1124/jpet.109.161570
   Kim E. S, 2009, PHARM RES, V26
   Kim S, 2007, 2007 IEEE NINTH WORKSHOP ON MULTIMEDIA SIGNAL PROCESSING, P48, DOI 10.1109/MMSP.2007.4412815
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   Lee SS, 2009, OPHTHALMIC RES, V41, P124, DOI 10.1159/000209665
   Lesar T, 1986, INVEST OPHTHALMOL VI, V27
   Li SK, 2011, J PHARMACEUT BIOMED, V55, P603, DOI 10.1016/j.jpba.2010.12.027
   MCMULLEN TPW, 1993, BIOCHEMISTRY-US, V32, P516, DOI 10.1021/bi00053a016
   Miao H., 2012, ACTA OPHTHALMOL COPE
   Moreno MR, 2016, EUR J PHARM BIOPHARM, V108, P156, DOI 10.1016/j.ejpb.2016.09.003
   Natarajan JV, 2014, ACS NANO, V8, P419, DOI 10.1021/nn4046024
   Natarajan JV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024513
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   Szoka F. J, 1984, INVEST OPHTHALMOL VI
   Thakur A, 2011, DRUG METAB DISPOS, V39, P771, DOI 10.1124/dmd.110.037408
   Wen H, 2010, PHARM RES-DORDR, V27, P2446, DOI 10.1007/s11095-010-0237-0
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Zhang LH, 2009, INT J NANOMED, V4, P175
NR 35
TC 15
Z9 15
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 1
PY 2017
VL 7
AR 16803
DI 10.1038/s41598-017-16791-7
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FO5YO
UT WOS:000416938200111
PM 29196745
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, K
   Zhu, X
   Zhang, K
   Yao, Y
   Zhuang, M
   Tan, CY
   Zhou, FF
   Zhu, L
AF Wang, Ke
   Zhu, Xue
   Zhang, Kai
   Yao, Yong
   Zhuang, Miao
   Tan, Chengye
   Zhou, Fanfan
   Zhu, Ling
TI Puerarin inhibits amyloid beta-induced NLRP3 inflammasome activation in
   retinal pigment epithelial cells via suppressing ROS-dependent oxidative
   and endoplasmic reticulum stresses
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Puerarin; Amyloid beta(1-40); NLRP3 inflammasome; Retinal pigment
   epithelial; Reactive oxygen species
ID NF-KAPPA-B; MACULAR DEGENERATION; DRUSEN; INDUCTION; APOPTOSIS;
   DISEASES; PATHWAY; INJURY; NRF2; EYE
AB Amyloid beta (A beta) is a critical stimulator that promotes the progression of age-related macular degeneration (AMD). NLRP3 inflammasome activation induced by A beta is estimated to be responsible for retinal pigment epithelium (RPE) dysfunction in such disease. Puerarin, one of the major active constituents of Kudzu root, has been widely used in the clinical treatment of AMD in China for decades; however, the detailed molecular mechanism remains far from clear. In this study, we investigated the protective effect and underlying mechanism of puerarin against AN to-induced NLRP3 inflammasome activation in LPS-primed ARPE-19 cells. The results showed that A beta(1-40) induced NLRP3 inflammasome activation mainly via triggering ROS-dependent oxidative stress, particularly lipid peroxidation, and endoplasmic reticulum stress in LPS-primed ARPE-19 cells; however, such effect could be significantly reversed by puerarin in a dose-dependent manner. Furthermore, the effect of puerarin was potentially mediated through activating Nrf2/HO-1 antioxidant signaling pathway and inhibiting A beta(1-40)-induced phosphorylation of IRE1 and PERK as well as nuclear expression of ATF6 alpha. Therefore, the significance of the current study is to reveal the novel mechanism of puerarin in the prevention of AMD.
C1 [Wang, Ke; Zhu, Xue; Zhang, Kai] Wuxi Jiangsu Prov, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Key Lab Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
   [Yao, Yong; Zhuang, Miao; Tan, Chengye] Nanjing Med Univ, Wuxi Peoples Hosp, Dept Ophthalmol, Wuxi 214023, Jiangsu, Peoples R China.
   [Zhou, Fanfan] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia.
   [Zhu, Ling] Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia.
C3 Jiangnan University; Nanjing Medical University; University of Sydney;
   University of Sydney
RP Wang, K (通讯作者)，20 Qianrong Rd, Wuxi 214063, Jiangsu, Peoples R China.; Yao, Y (通讯作者)，299 Qingyang Rd, Wuxi 214023, Jiangsu, Peoples R China.
EM wangke@jsinm.org; wxry_yaoyong@outlook.com
RI Zhou, Fanfan/M-4404-2013; Zhu, Xue/AAR-9416-2020; Zhang,
   Kai/AGI-6985-2022; Zhou, Fanfan/J-2327-2019; Zhu, Ling/M-3887-2013
OI Zhou, Fanfan/0000-0002-1982-1541; Zhou, Fanfan/0000-0002-1982-1541; Zhu,
   Ling/0000-0003-0776-1630; Zhang, Kai/0000-0002-7021-5395
FU National Natural Science Foundation [81300787]; Natural Science
   Foundation of Jiangsu Province [BK20141103]; Major Project of Wuxi
   Municipal Health Bureau [ZS201401, Z201508]; Project of Wuxi Municipal
   Science and Technology Bureau [CSE31N1520, CSE31N1621]
FX This work was supported by grants from the National Natural Science
   Foundation (81300787), the Natural Science Foundation of Jiangsu
   Province (BK20141103), the Major Project of Wuxi Municipal Health Bureau
   (ZS201401, Z201508), and the Project of Wuxi Municipal Science and
   Technology Bureau (CSE31N1520, CSE31N1621).
CR Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994
   Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   AITKEN RJ, 1989, BIOL REPROD, V41, P183, DOI 10.1095/biolreprod41.1.183
   Aprioku Jonah Sydney, 2013, J Reprod Infertil, V14, P158
   Barros GP, 2012, INT J GEOPHYS, V2012, DOI [10.1155/2012/459497, 10.5402/2012/137289]
   Boussabbeh M, 2015, TOXICOL SCI, V144, P328, DOI 10.1093/toxsci/kfu319
   Bronner DN, 2015, IMMUNITY, V43, P451, DOI 10.1016/j.immuni.2015.08.008
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Ding W, 2016, ONCOTARGET, V7, P17479, DOI 10.18632/oncotarget.8243
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Freigang S, 2011, EUR J IMMUNOL, V41, P2040, DOI 10.1002/eji.201041316
   Garai K, 2013, P NATL ACAD SCI USA, V110, P3321, DOI 10.1073/pnas.1222478110
   Howcroft TK, 2013, AGING-US, V5, P84, DOI 10.18632/aging.100531
   Jin SE, 2012, ARCH PHARM RES, V35, P823, DOI 10.1007/s12272-012-0508-x
   Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kim SR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.460
   Kim S, 2014, INNATE IMMUN-LONDON, V20, P799, DOI 10.1177/1753425913508593
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Menu P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.132
   Min A., 2014, J BIOCH MOL TOXICOL
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Salminen A, 2012, CELL MOL LIFE SCI, V69, P2999, DOI 10.1007/s00018-012-0962-0
   Singh AK, 2013, J MED FOOD, V16, P899, DOI 10.1089/jmf.2012.0049
   Tao ZW, 2016, AM J TRANSL RES, V8, P4425
   Wang K., 2016, INT J MOL SCI, V17
   Wang K, 2016, J BIOCH MOL TOXICOL
   Xuan B, 1999, J OCUL PHARMACOL TH, V15, P207, DOI 10.1089/jop.1999.15.207
   Zhao CC, 2014, J BIOL CHEM, V289, P17020, DOI 10.1074/jbc.M114.563114
   Zheng QX, 2015, EXP EYE RES, V134, P133, DOI 10.1016/j.exer.2015.02.013
   Zhu X, 2016, J BIOCHEM MOL TOXIC, V30, P22, DOI 10.1002/jbt.21736
   Zhu X, 2014, MOL VIS, V20, P1815
NR 43
TC 45
Z9 47
U1 0
U2 28
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD AUG 15
PY 2017
VL 357
IS 2
BP 335
EP 340
DI 10.1016/j.yexcr.2017.05.030
PG 6
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FC6XT
UT WOS:000406985700021
PM 28583762
DA 2022-11-30
ER

PT J
AU Keir, LS
   Firth, R
   Aponik, L
   Feitelberg, D
   Sakimoto, S
   Aguilar, E
   Welsh, GI
   Richards, A
   Usui, Y
   Satchell, SC
   Kuzmuk, V
   Coward, RJ
   Goult, J
   Bull, KR
   Sharma, R
   Bharti, K
   Westenskow, PD
   Michael, IP
   Saleem, MA
   Friedlander, M
AF Keir, Lindsay S.
   Firth, Rachel
   Aponik, Lyndsey
   Feitelberg, Daniel
   Sakimoto, Susumu
   Aguilar, Edith
   Welsh, Gavin I.
   Richards, Anna
   Usui, Yoshihiko
   Satchell, Simon C.
   Kuzmuk, Valeryia
   Coward, Richard J.
   Goult, Jonathan
   Bull, Katherine R.
   Sharma, Ruchi
   Bharti, Kapil
   Westenskow, Peter D.
   Michael, Iacovos P.
   Saleem, Moin A.
   Friedlander, Martin
TI VEGF regulates local inhibitory complement proteins in the eye and
   kidney
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS;
   MEMBRANE-ATTACK-COMPLEX; FACTOR-H; MACULAR DEGENERATION; GEOGRAPHIC
   ATROPHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; INTRAVITREAL
   INJECTION; OXIDATIVE STRESS; MEDIATED INJURY
AB Outer retinal and renal glomerular functions rely on specialized vasculature maintained by VEGF that is produced by neighboring epithelial cells, the retinal pigment epithelium (RPE) and podocytes, respectively. Dysregulation of RPE- and podocyte-derived VEGF is associated with neovascularization in wet age-related macular degeneration (ARMD), choriocapillaris degeneration, and glomerular thrombotic microangiopathy (TMA). Since complement activation and genetic variants in inhibitory complement factor H (CFH) are also features of both ARMD and TMA, we hypothesized that VEGF and CFH interact. Here, we demonstrated that VEGF inhibition decreases local CFH and other complement regulators in the eye and kidney through reduced VEGFR2/PKC-alpha/CREB signaling. Patient podocytes and RPE cells carrying disease-associated CFH genetic variants had more alternative complement pathway deposits than controls. These deposits were increased by VEGF antagonism, a common wet ARMD treatment, suggesting that VEGF inhibition could reduce cellular complement regulatory capacity. VEGF antagonism also increased markers of endothelial cell activation, which was partially reduced by genetic complement inhibition. Together, these results suggest that VEGF protects the retinal and glomerular microvasculature, not only through VEGFR2-mediated vasculotrophism, but also through modulation of local complement proteins that could protect against complement-mediated damage. Though further study is warranted, these findings could be relevant for patients receiving VEGF antagonists.
C1 [Keir, Lindsay S.; Aponik, Lyndsey; Feitelberg, Daniel; Sakimoto, Susumu; Aguilar, Edith; Usui, Yoshihiko; Westenskow, Peter D.; Friedlander, Martin] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
   [Keir, Lindsay S.; Firth, Rachel; Welsh, Gavin I.; Satchell, Simon C.; Kuzmuk, Valeryia; Coward, Richard J.; Saleem, Moin A.] Univ Bristol, Sch Clin Sci, Acad Renal Unit, Bristol, Avon, England.
   [Richards, Anna] Univ Edinburgh, Queens Med Res Inst, Edinburgh, Midlothian, Scotland.
   [Usui, Yoshihiko] Tokyo Med Univ Hosp, Tokyo, Japan.
   [Goult, Jonathan; Bull, Katherine R.] Univ Oxford, Ctr Cellular & Mol Physiol, Oxford OX1 2JD, England.
   [Sharma, Ruchi; Bharti, Kapil] NEI, NIH, Bethesda, MD 20892 USA.
   [Westenskow, Peter D.] Lowy Med Res Inst, La Jolla, CA USA.
   [Michael, Iacovos P.] Ecole Polytech Fed Lausanne, Lausanne, Switzerland.
C3 Scripps Research Institute; University of Bristol; University of
   Edinburgh; Tokyo Medical University; University of Oxford; National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI);
   Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne
RP Friedlander, M (通讯作者)，Scripps Res Inst, MB 28,10550 North Torrey Pines Rd, La Jolla, CA 92037 USA.; Saleem, MA (通讯作者)，Univ Bristol, Acad Renal Unit, 3rd Floor,Dorothy Hodgkin Bldg, Bristol BS1 3NY, Avon, England.
EM m.saleem@bristol.ac.uk; friedlan@scripps.edu
RI Bull, Katherine/AAC-2411-2019; /AAD-1824-2020; Michael, Iacovos
   P/C-8695-2016
OI Bull, Katherine/0000-0003-0656-0917; Michael, Iacovos
   P/0000-0001-7674-1233; Coward, Richard/0000-0001-6183-2546; Goult,
   Jonathan/0000-0001-8513-7054; Westenskow, Peter/0000-0001-9841-6220;
   Saleem, Moin/0000-0002-9808-4518; Welsh, Gavin Iain/0000-0002-2148-6658
FU medical research council clinical research training fellowship
   [G0901987]; University of Bristol MRC Centenary award; NIHR clinical
   lecturer post; Wellcome Trust intermediate clinical training fellowship
   [WT085226]; National Eye Institute of the NIH [EY011254]; Lowy Medical
   Research Institute; MRC [G0901987, G0800571, MR/K010492/1, MR/L002418/1]
   Funding Source: UKRI; Academy of Medical Sciences (AMS)
   [AMS-SGCL13-Bull] Funding Source: researchfish; Kidney Research UK
   [RP45/2008, RP22/2012] Funding Source: researchfish; Medical Research
   Council [MR/K010492/1, G0800571, MR/L002418/1] Funding Source:
   researchfish; NATIONAL EYE INSTITUTE [ZIAEY000532, R01EY011254,
   ZIAEY000539] Funding Source: NIH RePORTER
FX We would like to thank all collaborators who provided samples and
   reagents as listed in the manuscript; the Wolfson biomedical imaging
   facility at the University of Bristol; the flow cytometry facility at
   the Scripps Research Institute; Lea Scheppke, Salome Murinello, and Alys
   Belcher for review of the manuscript; and Stacey Moreno, Carli
   Wittgrove, Mauricio Rosenfeld, and Lan Ni for excellent technical
   assistance. LSK was funded by a medical research council clinical
   research training fellowship (G0901987), a University of Bristol MRC
   Centenary award, and an NIHR clinical lecturer post. AR was funded by a
   Wellcome Trust intermediate clinical training fellowship (WT085226;
   2009-2014). This work was also funded by grants to MF from the National
   Eye Institute of the NIH (EY011254) and the Lowy Medical Research
   Institute.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Barilla-LaBarca ML, 2002, J IMMUNOL, V168, P6298, DOI 10.4049/jimmunol.168.12.6298
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brar VS, 2009, J OCUL PHARMACOL TH, V25, P507, DOI 10.1089/jop.2009.0028
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Campa C, 2013, EUR J OPHTHALMOL, V23, P690, DOI 10.5301/ejo.5000248
   Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726
   Chen CL, 2012, ACTA OPHTHALMOL, V90, pe389, DOI 10.1111/j.1755-3768.2012.02426.x
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Cheungpasitporn W, 2015, TRANSPLANTATION, V99, P2382, DOI 10.1097/TP.0000000000000750
   CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Clegg LW, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004158
   Domingues I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025668
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Foster RR, 2013, AM J PATHOL, V183, P604, DOI 10.1016/j.ajpath.2013.04.019
   Georgalas I, 2014, CURR DRUG SAF, V9, P156, DOI 10.2174/1574886309666140211113635
   George M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017838
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamdulay SS, 2014, J IMMUNOL, V192, P4316, DOI 10.4049/jimmunol.1301702
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Izzedine H, 2014, INT J NEPHROL, V2014, DOI 10.1155/2014/143426
   Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Keir L, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3838
   Keir L, 2011, PEDIATR NEPHROL, V26, P523, DOI 10.1007/s00467-010-1637-4
   Kemper C, 2001, CLIN EXP IMMUNOL, V124, P180, DOI 10.1046/j.1365-2249.2001.01458.x
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li ZJ, 2013, P NATL ACAD SCI USA, V110, P5004, DOI 10.1073/pnas.1218620110
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   Lynch AM, 2011, OBSTET GYNECOL, V117, P75, DOI 10.1097/AOG.0b013e3181fc3afa
   Mason JC, 2004, J BIOL CHEM, V279, P41611, DOI 10.1074/jbc.M407981200
   Miura Y, 2010, INVEST OPHTH VIS SCI, V51, P4848, DOI 10.1167/iovs.09-4699
   MOHAN S, 1995, J CLIN ENDOCR METAB, V80, P637, DOI 10.1210/jc.80.2.637
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Noris M, 2009, NEW ENGL J MED, V361, P1676, DOI 10.1056/NEJMra0902814
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Penning M, 2015, HYPERTENSION, V66, P117, DOI 10.1161/HYPERTENSIONAHA.115.05484
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Pickering MC, 2007, J EXP MED, V204, P1249, DOI 10.1084/jem.20070301
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Rask-Madsen C, 2008, ARTERIOSCL THROM VAS, V28, P919, DOI 10.1161/ATVBAHA.108.162842
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rose KL, 2008, J CLIN INVEST, V118, P608, DOI 10.1172/JCI32525
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saleem MA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133630
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Satchell SC, 2006, KIDNEY INT, V69, P1633, DOI 10.1038/sj.ki.5000277
   Schraermeyer U, 2013, EXPERT OPIN BIOL TH, V13, P157, DOI 10.1517/14712598.2012.748741
   Shah AR, 2016, AM J OPHTHALMOL, V163, P154, DOI 10.1016/j.ajo.2015.11.033
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tan WH, 2013, CELL SIGNAL, V25, P2496, DOI 10.1016/j.cellsig.2013.08.015
   Tolentino MJ, 2015, EXPERT OPIN INV DRUG, V24, P183, DOI 10.1517/13543784.2015.961601
   Tschulakow A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113701
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Usui Y, 2012, INVEST OPHTH VIS SCI, V53, P5395, DOI 10.1167/iovs.11-8719
   van der Giet M, 2015, CURR PHARM DESIGN, V21, P3548, DOI 10.2174/1381612821666150225120314
   Veron D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040589
   Ward HM, 1997, IMMUNOL CELL BIOL, V75, P508, DOI 10.1038/icb.1997.79
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong RK, 2015, RETINA-J RET VIT DIS, V35, P675, DOI 10.1097/IAE.0000000000000578
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiong Y, 2009, J BIOL CHEM, V284, P23217, DOI 10.1074/jbc.M109.019679
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhang J, 2010, TOXICOL PATHOL, V38, P856, DOI 10.1177/0192623310378866
NR 92
TC 88
Z9 96
U1 0
U2 9
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JAN 3
PY 2017
VL 127
IS 1
BP 199
EP 214
DI 10.1172/JCI86418
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EI1UK
UT WOS:000392271300022
PM 27918307
OA hybrid, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Song, MJ
   Bharti, K
AF Song, Min Jae
   Bharti, Kapil
TI Looking into the future: Using induced pluripotent stem cells to build
   two and three dimensional ocular tissue for cell therapy and disease
   modeling
SO BRAIN RESEARCH
LA English
DT Review
DE Retinal degeneration; Age related macular degeneration; Transplantation;
   Retinal pigment epithelium; Induced pluripotent stem cells; Tissue
   engineering; Microfluidics; 3D disease models
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS DYSTROPHY MUTATIONS; HUMAN IPS CELLS;
   MACULAR DEGENERATION; GENE-EXPRESSION; DIRECTED DIFFERENTIATION;
   SUBRETINAL IMPLANTATION; MOLECULAR SIGNATURE; FUNCTIONAL-ANALYSIS;
   NEURAL RETINA
AB Retinal degenerative diseases are the leading cause of irreversible vision loss in developed countries. In many cases the diseases originate in the homeostatic unit in the back of the eye that contains the retina, retinal pigment epithelium (RPE) and the choriocapillaris. RPE is a central and a critical component of this homeostatic unit, maintaining photoreceptor function and survival on the apical side and choriocapillaris health on the basal side. In diseases like age-related macular degeneration (AMD), it is thought that RPE dysfunctions cause disease-initiating events and as the RPE degenerates photoreceptors begin to die and patients start loosing vision. Patient-specific induced pluripotent stem (iPS) cell-derived RPE provides direct access to a patient's genetics and allow the possibility of identifying the initiating events of RPE-associated degenerative diseases. Furthermore, iPS cell-derived RPE cells are being tested as a potential cell replacement in disease stages. with RPE atrophy. In this article we summarize the recent progress in the field of iPS cell-derived RPE "disease modeling" and cell therapies and also discuss the possibilities of developing a model of the entire homeostatic unit to aid in studying disease processes in the future. This article is part of a Special Issue entitled SI: PSC and the brain. Published by Elsevier B.V.
C1 [Song, Min Jae; Bharti, Kapil] NEI, Unit Ocular & Stem Cell Translat Res, 10 Ctr Dr,Room 10B10, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Bharti, K (通讯作者)，NEI, Unit Ocular & Stem Cell Translat Res, 10 Ctr Dr,Room 10B10, Bethesda, MD 20892 USA.
EM kapilbharti@nei.nih.gov
FU NATIONAL EYE INSTITUTE [ZIAEY000532, ZIAEY000542, ZIAEY000559] Funding
   Source: NIH RePORTER; Intramural NIH HHS [ZIA EY000531-02] Funding
   Source: Medline
CR Adams WJ, 2013, STEM CELL REP, V1, P105, DOI 10.1016/j.stemcr.2013.06.007
   Adijanto J, 2009, J GEN PHYSIOL, V133, P603, DOI 10.1085/jgp.200810169
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bakall B, 2007, EXP EYE RES, V85, P34, DOI 10.1016/j.exer.2007.02.018
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Bharti K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002757
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   BLODI CF, 1990, OPHTHALMIC PAED GEN, V11, P49
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Burnight E. R., 2015, COLD SPRING HARB PER, V5
   Cai H, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00008
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Cereso N, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.11
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Chou BK, 2015, STEM CELL TRANSL MED, V4, P320, DOI 10.5966/sctm.2014-0214
   Croze RH, 2014, STEM CELL TRANSL MED, V3, P1066, DOI 10.5966/sctm.2014-0079
   Dahl M, 2015, HUM IMMUNOL, V76, P260, DOI 10.1016/j.humimm.2015.01.015
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Esch EW, 2015, NAT REV DRUG DISCOV, V14, P248, DOI 10.1038/nrd4539
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Goh PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081622
   Goldberg AC, 2015, EINSTEIN-SAO PAULO, V13, P153, DOI 10.1590/S1679-45082015RB3122
   Gourraud PA, 2012, STEM CELLS, V30, P180, DOI 10.1002/stem.772
   Grosberg A, 2011, LAB CHIP, V11, P4165, DOI 10.1039/c1lc20557a
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huh D, 2011, TRENDS CELL BIOL, V21, P745, DOI 10.1016/j.tcb.2011.09.005
   Huh D, 2010, SCIENCE, V328, P1662, DOI 10.1126/science.1188302
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Inoue H, 2014, EMBO J, V33, P409, DOI 10.1002/embj.201387098
   Jha BS, 2015, CURR STEM CELL REP, V1, P79, DOI 10.1007/s40778-015-0014-4
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Lee J, 2015, JALA-J LAB AUTOM, V20, P96, DOI 10.1177/2211068214560903
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Li R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023148
   Li R, 2009, AM J PHYSIOL-CELL PH, V297, pC1452, DOI 10.1152/ajpcell.00255.2009
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   Lu B, 2014, DEV OPHTHALMOL, V53, P155, DOI 10.1159/000357375
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   Maminishkis A., 2010, J VIS EXP
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   McUsic AC, 2012, BIOMATERIALS, V33, P1396, DOI 10.1016/j.biomaterials.2011.10.083
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   MOHLER CW, 1981, OPHTHALMOLOGY, V88, P688
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Orlova VV, 2014, NAT PROTOC, V9, P1514, DOI 10.1038/nprot.2014.102
   Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Patsch C, 2015, NAT CELL BIOL, V17, P994, DOI 10.1038/ncb3205
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Phillips MJ, 2012, INVEST OPHTH VIS SCI, V53, P2007, DOI 10.1167/iovs.11-9313
   Polinati PP, 2015, INVEST OPHTH VIS SCI, V56, P3371, DOI 10.1167/iovs.14-14007
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Qu ZQ, 2008, AM J PHYSIOL-CELL PH, V294, pC1371, DOI 10.1152/ajpcell.00398.2007
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Reardon S, 2014, NATURE, V513, P287, DOI 10.1038/513287a
   Reh TA, 2010, METHODS MOL BIOL, V636, P139, DOI 10.1007/978-1-60761-691-7_9
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Rickman CB, 2006, INVEST OPHTH VIS SCI, V47, P2305, DOI 10.1167/iovs.05-1437
   Riolobos L, 2013, MOL THER, V21, P1232, DOI 10.1038/mt.2013.59
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Rosenthal R, 2005, FASEB J, V19, P178, DOI 10.1096/fj.05-4495fje
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sparrow JR, 2003, ADV EXP MED BIOL, V533, P205
   Sridhar A, 2013, STEM CELL TRANSL MED, V2, P255, DOI 10.5966/sctm.2012-0101
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sung JH, 2014, EXP BIOL MED, V239, P1225, DOI 10.1177/1535370214529397
   Taylor CJ, 2012, CELL STEM CELL, V11, P147, DOI 10.1016/j.stem.2012.07.014
   Turner M, 2013, CELL STEM CELL, V13, P382, DOI 10.1016/j.stem.2013.08.003
   van Soest SS, 2007, MOL VIS, V13, P1608
   van Zeeburg EJT, 2011, INVEST OPHTH VIS SCI, V52, P5881, DOI 10.1167/iovs.11-7245
   Vugler A, 2007, MECH DEVELOP, V124, P807, DOI 10.1016/j.mod.2007.08.002
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wright LS, 2014, EXP EYE RES, V123, P161, DOI 10.1016/j.exer.2013.12.001
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zhong M, 2010, METHODS MOL BIOL, V652, P163, DOI 10.1007/978-1-60327-325-1_9
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   Zhou J, 2014, ARTERIOSCL THROM VAS, V34, P2191, DOI 10.1161/ATVBAHA.114.303422
   Zhou L, 2011, STEM CELLS, V29, P972, DOI 10.1002/stem.637
   Zimmermann A, 2012, STEM CELLS DEV, V21, P2364, DOI 10.1089/scd.2012.0088
NR 117
TC 41
Z9 42
U1 0
U2 48
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD MAY 1
PY 2016
VL 1638
SI SI
BP 2
EP 14
DI 10.1016/j.brainres.2015.12.011
PN A
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA DN8EH
UT WOS:000377311500002
PM 26706569
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Johnen, S
   Djalali-Talab, Y
   Kazanskaya, O
   Moller, T
   Harmening, N
   Kropp, M
   Izsvak, Z
   Walter, P
   Thumann, G
AF Johnen, Sandra
   Djalali-Talab, Yassin
   Kazanskaya, Olga
   Moeller, Theresa
   Harmening, Nina
   Kropp, Martina
   Izsvak, Zsuzsanna
   Walter, Peter
   Thumann, Gabriele
TI Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated
   PEDF-Transfected RPE Cells In Vitro and In Vivo
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; GENE-TRANSFER; INTRAVITREAL BEVACIZUMAB; IMMUNE-RESPONSE;
   VITREOUS LEVELS; FACTOR VEGF; RANIBIZUMAB; ANGIOGENESIS
AB Pigment epithelium-derived factor (PEDF) is a potent multifunctional protein that inhibits angiogenesis and has neurogenic and neuroprotective properties. Since the wet form of age-related macular degeneration is characterized by choroidal neovascularization (CNV), PEDF would be an ideal candidate to inhibit CNV and support retinal pigment epithelial (RPE) cells. However, its short half-life has precluded its clinical use. To deliver PEDF to the subretinal space, we transfected RPE cells with the PEDF gene using the Sleeping Beauty transposon system. Transfected cells expressed and secreted biologically active recombinant PEDF (rPEDF). In cultures of human umbilical vein endothelial cells, rPEDF reduced VEGF-induced cumulative sprouting by >= 47%, decreased migration by 77%, and increased rate of apoptosis at least 3.4 times. rPEDF induced neurite outgrowth in neuroblastoma cells and protected ganglion and photoreceptor cells in organotypic retinal cultures. In a rat model of CNV, subretinal transplantation of PEDF-transfected cells led to a reduction of the CNV area by 48% 14 days after transplantation and decreased clinical significant lesions by 55% and 40% after 7 and 14 days, respectively. We showed that transplantation of pigment epithelial cells overexpressing PEDF can restore a permissive subretinal environment for RPE and photoreceptor maintenance, while inhibiting choroidal blood vessel growth.
C1 [Johnen, Sandra; Djalali-Talab, Yassin; Kazanskaya, Olga; Moeller, Theresa; Walter, Peter; Thumann, Gabriele] Univ Hosp RWTH Aachen, Dept Ophthalmol, D-52074 Aachen, Germany.
   [Harmening, Nina; Kropp, Martina; Thumann, Gabriele] Univ Hosp Geneva, Dept Ophthalmol, CH-1211 Geneva 14, Switzerland.
   [Izsvak, Zsuzsanna] Max Delbruck Ctr Mol Med Helmholtz Assoc, D-13125 Berlin, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Geneva; Helmholtz Association; Max Delbruck Center for Molecular
   Medicine
RP Thumann, G (通讯作者)，Univ Hosp RWTH Aachen, Dept Ophthalmol, Pauwelsstr 30, D-52074 Aachen, Germany.
EM gabriele.thumann@hcuge.ch
RI Walter, Peter/L-5982-2018; Harmening, Nina/F-7804-2017; Johnen,
   Sandra/ABA-9955-2020; Kropp, Martina/H-9260-2018
OI Walter, Peter/0000-0001-8745-6593; Johnen, Sandra/0000-0003-0028-2557;
   Izsvak, Zsuzsanna/0000-0002-2053-2384; Kropp,
   Martina/0000-0001-6861-5851
FU Interdisciplinary Center for Clinical Research IZKF Aachen within the
   Faculty of Medicine at the RWTH Aachen University
FX This work was supported by a grant from the Interdisciplinary Center for
   Clinical Research IZKF Aachen within the Faculty of Medicine at the RWTH
   Aachen University.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Alberdi E, 1999, J BIOL CHEM, V274, P31605, DOI 10.1074/jbc.274.44.31605
   Amaral J, 2005, INVEST OPHTH VIS SCI, V46, P4383, DOI 10.1167/iovs.05-0492
   Amaral J, 2010, INVEST OPHTH VIS SCI, V51, P1318, DOI 10.1167/iovs.09-4455
   Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287
   Bai YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112448
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Farnoodian M, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12266
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Filleur S, 2005, CANCER RES, V65, P5144, DOI 10.1158/0008-5472.CAN-04-3744
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Ginn SL, 2010, MOL THER, V18, P965, DOI 10.1038/mt.2010.50
   Hartman ZC, 2007, VIROLOGY, V358, P357, DOI 10.1016/j.virol.2006.08.041
   Huber M, 2012, OPHTHALMOLOGICA, V228, P188, DOI 10.1159/000339952
   Ildefonso CJ, 2010, MOL THER, V18, P1885, DOI 10.1038/mt.2010.139
   Izsvak Z, 2010, BIOESSAYS, V32, P756, DOI 10.1002/bies.201000027
   Izsvak Z, 2009, METHODS, V49, P287, DOI 10.1016/j.ymeth.2009.07.001
   Johnen S, 2012, INVEST OPHTH VIS SCI, V53, P4787, DOI 10.1167/iovs.12-9951
   Kaempf S, 2008, J NEUROSCI METH, V173, P47, DOI 10.1016/j.jneumeth.2008.05.018
   Kaempf S, 2008, INVEST OPHTH VIS SCI, V49, P3164, DOI 10.1167/iovs.07-1265
   Kaur C, 2012, J NEUROPATH EXP NEUR, V71, P330, DOI 10.1097/NEN.0b013e31824deb21
   Kim SY, 2003, EXP EYE RES, V77, P433, DOI 10.1016/S0014-4835(03)00174-X
   Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Marneros AG, 2007, FASEB J, V21, P3809, DOI 10.1096/fj.07-8422com
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Mohan N, 2012, J DIABETES COMPLICAT, V26, P435, DOI 10.1016/j.jdiacomp.2012.05.005
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Nair V, 2008, CURR OPIN MOL THER, V10, P431
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Palejwala NV, 2014, DRUG TODAY, V50, P779, DOI 10.1358/dot.2014.50.12.2245587
   Parmeggiani F., 2010, MEDIAT INFLAMM, V2010
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   Sonmez K, 2008, OPHTHALMOLOGY, V115, P1065, DOI 10.1016/j.ophtha.2007.08.050
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Uno K, 2006, BRIT J OPHTHALMOL, V90, P48, DOI 10.1136/bjo.2005.074005
   Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Yamagishi SI, 2004, J MOL CELL CARDIOL, V37, P497, DOI 10.1016/j.yjmcc.2004.04.007
   Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
   Zhou Y., 2015, GRAEFEARCH CLIN EX
NR 60
TC 16
Z9 16
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 863845
DI 10.1155/2015/863845
PG 14
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CY6QE
UT WOS:000366533100001
PM 26697494
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Ahmad, BU
   Shah, GK
   Hardten, DR
AF Ahmad, Baseer U.
   Shah, Gaurav K.
   Hardten, David R.
TI PRESBYOPIA-CORRECTING INTRAOCULAR LENSES AND CORNEAL REFRACTIVE
   PROCEDURES A Review for Retinal Surgeons
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE premium; presbyopia; multifocal; intraocular lens; corneal inlay;
   Z-syndrome; contrast sensitivity; decentration;
   challenges/complications; vitreoretinal surgery; vitrectomy
AB Purpose: To review the specific challenges and pitfalls that vitreoretinal surgeons may face when operating on eyes with presbyopia-correcting intraocular lenses or previous corneal refractive surgery. In addition, this review aims to familiarize vitreoretinal surgeons with specifications of currently available Food and Drug Administration-approved presbyopia-correcting intraocular lenses.
   Methods: Review of current literature performed with PubMed for search terms "presbyopia," "correction," "IOL," "vitreoretinal," "challenges," and "surgical" both singly and in combination as well as closely related terms.
   Results and Conclusion: Specific intraoperative issues with presbyopia-correcting intraocular lenses that may be encountered include peripheral visualization, condensation, lens material issues particularly with silicone oil, decentration, Z-syndrome, and foveal image displacement. Every patient undergoing retinal surgery should also be asked about previous laser-assisted in situ keratomileusis/photorefractive keratectomy because those eyes require special attention to surface hydration and care to avoid epithelial removal if possible. Intracorneal ring segments and corneal inlays can cause effects similar to those of a small pupil. However, these can be managed with thorough preoperative evaluation and various intraoperative maneuvers. In addition, retinal physicians should be aware that macular disorders, such as age-related macular degeneration, may be exacerbated by potential loss of contrast sensitivity.
C1 [Ahmad, Baseer U.; Shah, Gaurav K.] Retina Consultants, Retina Inst, St Louis, MO 63144 USA.
   [Hardten, David R.] Minnesota Eye Consultants, Minneapolis, MN USA.
RP Shah, GK (通讯作者)，Retina Consultants, 1600 South Brentwood Ave,Suite 800, St Louis, MO 63144 USA.
EM gkshah1@gmail.com
OI Ahmad, Baseer/0000-0002-2216-4263
FU TRI
FX B. U. Ahmad is a fellow at The Retina Institute (TRI) in St Louis, MO.
   G. K. Shah is a fellowship codirector and an attending physician at TRI.
   D. R. Hardten is the director of Refractive Surgery at Minnesota Eye
   Consultants in Minneapolis.
CR Arthur SN, 2001, INT OPHTHALMOL CLIN, V41, P33, DOI 10.1097/00004397-200107000-00005
   Bhavsar AR, 2001, OPHTHALMOLOGY, V108, P1513, DOI 10.1016/S0161-6420(01)00663-7
   Browning DJ, 2005, AM J OPHTHALMOL, V139, P740, DOI 10.1016/j.ajo.2004.10.027
   Cillino S, 2008, OPHTHALMOLOGY, V115, P1508, DOI 10.1016/j.ophtha.2008.04.017
   de Vries NE, 2013, J CATARACT REFR SURG, V39, P268, DOI 10.1016/j.jcrs.2012.12.002
   de Vries NE, 2011, J CATARACT REFR SURG, V37, P859, DOI 10.1016/j.jcrs.2010.11.032
   Kawano K, 2013, EYE LOND
   Krueger RR, 2005, J CATARACT REFR SURG, V31, P2386, DOI 10.1016/j.jcrs.2005.05.034
   Lichtinger A, 2012, CURR OPIN OPHTHALMOL, V23, P40, DOI 10.1097/ICU.0b013e32834cd5be
   Lim JI, 2000, OPHTHALMOLOGY, V107, P1083, DOI 10.1016/S0161-6420(00)00096-8
   Negishi K, 2005, JPN J OPHTHALMOL, V49, P281, DOI 10.1007/s10384-005-0194-z
   Porter RGB, 2000, OPHTHALMOLOGY, V107, P778, DOI 10.1016/S0161-6420(99)00175-X
   Shiragami C, 2010, OPHTHALMOLOGY, V117, P86, DOI 10.1016/j.ophtha.2009.06.025
   Tewari A, 2008, RETINA-J RET VIT DIS, V28, P535, DOI 10.1097/IAE.0b013e31816697a9
   Waring George O 4th, 2013, Int Ophthalmol Clin, V53, P129, DOI 10.1097/IIO.0b013e318277442e
   Yoshikawa M, 2013, INVEST OPHTH VIS SCI, V54, P629, DOI 10.1167/iovs.12-10907
   Yuen L, 2008, J CATARACT REFR SURG, V34, P1986, DOI 10.1016/j.jcrs.2008.05.061
NR 17
TC 7
Z9 7
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2014
VL 34
IS 6
BP 1046
EP 1054
DI 10.1097/IAE.0000000000000237
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AI8GP
UT WOS:000337149000002
PM 24849701
DA 2022-11-30
ER

PT J
AU Hu, CC
   Chaw, JR
   Chen, CF
   Liu, HW
AF Hu, Chao-Chien
   Chaw, Jen-Ray
   Chen, Chin-Fu
   Liu, Hsia-Wei
TI Controlled release bevacizumab in thermoresponsive hydrogel found to
   inhibit angiogenesis
SO BIO-MEDICAL MATERIALS AND ENGINEERING
LA English
DT Article
DE Bevacizumab; thermo-responsive hydrogel; drug delivery system;
   angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; AVASTIN; BINDING
AB Age-related macular degeneration (ARMD) and intraocular neovascular diseases have been treated clinically by anti-VEGF antibody drug bevacizumab. However, the use of bevacizumab in the treatment of retinal neovascular diseases has been limited due to the short half-life and frequent injections. In this research, novel amphiphilic hydrophilic-hydrophobic block copolymers of methoxy-poly (ethylene glycol)-block-poly (lactic-co-glycolic acid) were synthesized with ring-opening polymerization, and cross-linked with 2,2-bis (2-oxazoline) (BOX). The aqueous solution of the block copolymers can reverse the sol-gel-sol phase transition. After 1 month of intravitreal injection, the histomorphology of a rabbit's retina was preserved, which indicated the mPEG-PLGA-BOX hydrogel had no cytotoxicity in vivo. Released bevacizumab from the mPEG-PLGA-BOX hydrogel inhibited the RF/6A (Maraca mulatta retina epithelial cell) and HUVEC cell growth, and anti-angiogenesis in 3-D cultures, which showed the bioactivity of the anti-VEGF agent, were maintained in the hydrogel within the release process. In conclusion, the mPEG-PLGA-BOX hydrogel had a sol-gel behavior phase transition, and its intraocular biocompatibility and the characteristics of biodegradability and bioactivity appear to be a promising intravitreal injection carrier for bevacizumab delivery.
C1 [Hu, Chao-Chien] Shin Kong Wu Ho Su Mem Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hu, Chao-Chien] Fu Jen Catholic Univ, Sch Med, New Taipei City 24205, Taiwan.
   [Chaw, Jen-Ray] Fu Jen Catholic Univ, Grad Inst Appl Sci & Engn, New Taipei City 24205, Taiwan.
   [Chen, Chin-Fu] Ind Technol Res Inst, Biomed Technol & Device Res Labs, Hsinchu, Taiwan.
   [Liu, Hsia-Wei] Fu Jen Catholic Univ, Dept Life Sci, New Taipei City 24205, Taiwan.
C3 Shin Kong Wu Ho Su Memorial Hospital; Fu Jen Catholic University; Fu Jen
   Catholic University; Industrial Technology Research Institute - Taiwan;
   Fu Jen Catholic University
RP Liu, HW (通讯作者)，Fu Jen Catholic Univ, Dept Life Sci, 510 Jhongiheng Rd, New Taipei City 24205, Taiwan.
EM 079336@mail.fju.edu.tw
FU National Science Foundation [101-2221-E-030-002]; Shin Kong Wu Ho-Su
   Memorial Hospital [SKH-8302-100-DR-13]
FX This research was financially supported by the National Science
   Foundation (101-2221-E-030-002) and Shin Kong Wu Ho-Su Memorial Hospital
   (SKH-8302-100-DR-13).
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Baushur Z.F., 2008, AM J OPHTHALMOL, V145, P249
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   *GEN INC, 2004, AV PRESCR INF
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
NR 8
TC 30
Z9 31
U1 0
U2 35
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0959-2989
EI 1878-3619
J9 BIO-MED MATER ENG
JI Bio-Med. Mater. Eng.
PY 2014
VL 24
IS 6
BP 1941
EP 1950
DI 10.3233/BME-141003
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA AQ7NW
UT WOS:000343005700006
PM 25226890
OA Bronze
DA 2022-11-30
ER

PT J
AU Kilic, R
   Sezer, H
   Comcali, SU
   Bayraktar, S
   Goktolga, G
   Cakmak, Y
   Cetin, AB
   Cumurcu, T
AF Kilic, Rasit
   Sezer, Hafize
   Comcali, Sebile U.
   Bayraktar, Serdar
   Goktolga, Gokay
   Cakmak, Yasin
   Cetin, Abdi B.
   Cumurcu, Tongabay
TI The Frequency of Exfoliation Syndrome in the Central Anatolia Region of
   Turkey
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PSEUDOEXFOLIATION SYNDROME; MACULAR DEGENERATION; PLASMA HOMOCYSTEINE;
   PREVALENCE; ASSOCIATION; GLAUCOMA; POPULATION; CATARACT
AB Aim. The aim of this study was to investigate the frequency of exfoliation syndrome in the Central Anatolia region of Turkey and to evaluate its relationship with cardiovascular and ocular diseases. Methods. Patients over the age of 45 years who presented to the clinic were included in the study. All cases underwent a comprehensive ophthalmology examination. Exfoliation syndrome was diagnosed with the presence of exfoliative material on the lens anterior capsule or iris on slit lamp examination. The patients were divided into two groups as the exfoliation syndrome group and nonexfoliation syndrome group according to the presence of exfoliative material. Results. Exfoliative material was found in one or both eyes of 212 of the 2103 patients (10.1%) evaluated within the scope of the study. A significant relationship was found between exfoliation syndrome and increasing age and male gender. A significant relationship was found between exfoliation syndrome and glaucoma, cataracts, age-related macular degeneration, and phacodonesis. While no relationship was found between exfoliation syndrome and hypertension or diabetes mellitus, a significant relationship was found with coronary artery disease. Conclusion. The unilateral or bilateral exfoliation syndrome frequency was 10.1% in this hospital-based study. A statistically significant relationship was found between exfoliation syndrome and advancing age, gender, and coronary artery disease.
C1 [Kilic, Rasit; Comcali, Sebile U.; Bayraktar, Serdar; Goktolga, Gokay; Cakmak, Yasin; Cetin, Abdi B.] Sivas Numune Hosp, Dept Ophthalmol, Sivas, Turkey.
   [Sezer, Hafize] Cumhuriyet Univ, Fac Med, Dept Biostat, Sivas, Turkey.
   [Cumurcu, Tongabay] Inonu Univ, Fac Med, Dept Ophthalmol, Malatya, Turkey.
C3 Sivas Numune Hospital; Cumhuriyet University; Inonu University
RP Kilic, R (通讯作者)，Sivas Numune Hosp, Dept Ophthalmol, Sivas, Turkey.
EM kilicrasit@gmail.com
RI Kılıç, Raşit/AAP-6844-2021
OI Kilic, Rasit/0000-0001-6671-9067; Bayraktar, Serdar/0000-0001-6521-9984
CR Al-Bdour MD, 2008, ACTA OPHTHALMOL, V86, P755, DOI 10.1111/j.1755-3768.2008.01258.x
   Anastasopoulos E, 2011, J GLAUCOMA, V20, P160, DOI 10.1097/IJG.0b013e3181d9d8bd
   Andrikopoulos GK, 2009, EYE, V23, P442, DOI 10.1038/sj.eye.6702992
   Astrom S, 2007, ACTA OPHTHALMOL SCAN, V85, P828, DOI 10.1111/j.1600-0420.2007.00992.x
   Blomquist PH, 2012, J CATARACT REFR SURG, V38, P208, DOI 10.1016/j.jcrs.2011.10.001
   Bojic L, 2005, GRAEF ARCH CLIN EXP, V243, P446, DOI 10.1007/s00417-004-1074-9
   Casson J, 2007, BRIT J OPHTHALMOL, V91, P710, DOI 10.1136/bjo.2006.107573
   Citirik M, 2007, EYE, V21, P11, DOI 10.1038/sj.eye.6702177
   Cumurcu T, 2010, EUR J OPHTHALMOL, V20, P1007, DOI 10.1177/112067211002000621
   Demir N, 2011, EYE, V25, P1177, DOI 10.1038/eye.2011.145
   Djordjevic-Jocic J, 2012, CURR EYE RES, V37, P617, DOI 10.3109/02713683.2012.665120
   Emiroglu MY, 2010, N AM J MED SCI, V2, P487, DOI [10.4297/najms.2010.2487, 10.4297/najms.2010.2306]
   FAULKNER HW, 1971, AM J OPHTHALMOL, V72, P206, DOI 10.1016/0002-9394(71)91616-3
   FORSIUS H, 1979, T OPHTHAL SOC UK, V99, P296
   Hietanen J, 2002, ACTA OPHTHALMOL SCAN, V80, P617, DOI 10.1034/j.1600-0420.2002.800611.x
   Kaljurand K, 2010, EUR J OPHTHALMOL, V20, P1012, DOI 10.1177/112067211002000622
   Kling F, 2001, J FR OPHTALMOL, V24, P7
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Kozobolis VP, 1997, ACTA OPHTHALMOL SCAN, V75, P726
   Liu XW, 2011, INT J OPHTHALMOL-CHI, V4, P508, DOI 10.3980/j.issn.2222-3959.2011.05.10
   Mitchell P, 1997, AM J OPHTHALMOL, V124, P685, DOI 10.1016/S0002-9394(14)70908-0
   Miyazaki M, 2005, J GLAUCOMA, V14, P482, DOI 10.1097/01.ijg.0000185436.15675.b3
   Paliobei VP, 2011, OTOLARYNG HEAD NECK, V145, P125, DOI 10.1177/0194599811401206
   Rao Rashad Qamar, 2006, BMC Ophthalmol, V6, P27, DOI 10.1186/1471-2415-6-27
   Ritch R, 1994, J Glaucoma, V3, P176
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   SCHLOTZERSCHREHARDT UM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1752, DOI 10.1001/archopht.1992.01080240092038
   Shazly TA, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-18
   Shrum KR, 2000, AM J OPHTHALMOL, V129, P83, DOI 10.1016/S0002-9394(99)00255-X
   Speckauskas M, 2012, ACTA OPHTHALMOL, V90, pe470, DOI 10.1111/j.1755-3768.2012.02439.x
   Stein JD, 2011, ARCH OPHTHALMOL-CHIC, V129, P1053, DOI 10.1001/archophthalmol.2011.191
   Tranchina L, 2011, GRAEF ARCH CLIN EXP, V249, P443, DOI 10.1007/s00417-010-1487-6
   Turacli ME, 2007, CAN J OPHTHALMOL, V42, P56, DOI 10.3129/canjophthalmol.06-087
   Vessani RM, 2003, AM J OPHTHALMOL, V136, P41, DOI 10.1016/S0002-9394(03)00077-1
   Viso E, 2010, OPHTHAL EPIDEMIOL, V17, P118, DOI 10.3109/09286581003624970
   YALAZ M, 1992, ACTA OPHTHALMOL, V70, P209
   You QS, 2013, OPHTHALMOLOGY, V120, P1551, DOI 10.1016/j.ophtha.2013.01.020
   Young AL, 2004, BRIT J OPHTHALMOL, V88, P193, DOI 10.1136/bjo.2003.021816
NR 38
TC 5
Z9 5
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2014
VL 2014
AR 139826
DI 10.1155/2014/139826
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN2ND
UT WOS:000340421600001
PM 25165574
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Nadri, S
   Kazemi, B
   Eeslaminejad, MB
   Yazdani, S
   Soleimani, M
AF Nadri, Samad
   Kazemi, Bahram
   Eeslaminejad, Mohamadreza Baghaban
   Yazdani, Shahin
   Soleimani, Masoud
TI High yield of cells committed to the photoreceptor-like cells from
   conjunctiva mesenchymal stem cells on nanofibrous scaffolds
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Photoreceptor cells; Aligned and random nanofibrous scaffold;
   Conjunctiva mesenchymal stem cell
ID RETINAL-PIGMENT EPITHELIUM; ADULT MAMMALIAN EYE; PROGENITOR CELLS;
   BIPOLAR CELLS; STROMAL CELLS; RODENT MODEL; BONE-MARROW;
   DIFFERENTIATION; TRANSPLANTATION; DEGENERATION
AB Transplantation of stem cells using biodegradable and biocompatible nanofibrous scaffolds is a promising therapeutic approach for treating inherited retinal degenerative diseases such as retinitis pigmentosa and age-related macular degeneration. In this study, conjunctiva mesenchymal stem cells (CJMSCs) were seeded onto poly-l-lactic acid (PLLA) nanofibrous scaffolds and were induced to differentiate toward photoreceptor cell lineages. Furthermore, the effects of orientation of scaffold on photoreceptor differentiation were examined. Scanning electron microscopy (SEM) imaging, quantitative real time RT-PCR (qPCR) and immunocytochemistry were used to analyze differentiated cells and their expression of photoreceptor-specific genes. Our observations demonstrated the differentiation of CJMSCs to photoreceptor cells on nanofibrous scaffolds and suggested their potential application in retinal regeneration. SEM imaging showed that CJMSCs were spindle shaped and well oriented on the aligned nanofiber scaffolds. The expression of rod photoreceptor-specific genes was significantly higher in CJMSCs differentiated on randomly-oriented nanofibers compared to those on aligned nanofibers. According to our results we may conclude that the nanofibrous PLLA scaffold reported herein could be used as a potential cell carrier for retinal tissue engineering and a combination of electrospun nanofiber scaffolds and MSC-derived conjunctiva stromal cells may have potential application in retinal regenerative therapy.
C1 [Nadri, Samad] Shahid Beheshti Univ Med Sci, Med Phys & Biomed Engn Dept, Tehran, Iran.
   [Nadri, Samad] Shahid Beheshti Univ Med Sci, Student Res Comm, Tehran, Iran.
   [Nadri, Samad] Stem Cell Technol Res Ctr, Stem Cell Biol Dept, Tehran, Iran.
   [Kazemi, Bahram] Shahid Beheshti Univ Med Sci, Fac Med, Dept Biotechnol, Tehran, Iran.
   [Kazemi, Bahram] Shahid Beheshti Univ Med Sci, Cellular & Mol Biol Res Ctr, Tehran, Iran.
   [Eeslaminejad, Mohamadreza Baghaban] ACECR, Royan Inst Stem Cell Biol & Technol, Cell Sci Res Ctr, Dept Stem Cell & Dev Biol, Tehran, Iran.
   [Yazdani, Shahin] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
   [Soleimani, Masoud] Tarbiat Modares Univ, Fac Med Sci, Dept Hematol, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; Shahid Beheshti University Medical Sciences; Shahid
   Beheshti University Medical Sciences; Academic Center for Education,
   Culture & Research (ACECR); Shahid Beheshti University Medical Sciences;
   Tarbiat Modares University
RP Kazemi, B (通讯作者)，Shahid Beheshti Univ Med Sci, Fac Med, Dept Biotechnol, Tehran, Iran.
EM bahram_14@yahoo.com; soleim_m@modares.ac.ir
RI Nadri, Samad/M-9349-2016; Eslaminejad, Mohamadreza Baghaban/S-3645-2017;
   Nadri, Samad/N-4548-2016; Kazemi, Bahram/GRR-9838-2022; Yazdani,
   Shahin/AAW-5387-2020; Kazemi, Bahram/F-2785-2016
OI Eslaminejad, Mohamadreza Baghaban/0000-0002-1036-0072; Nadri,
   Samad/0000-0002-2710-3128; Kazemi, Bahram/0000-0002-3072-8831; Yazdani,
   Shahin/0000-0002-9583-1434; Nadri, Samad/0000-0002-1523-3152
CR Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, P1557
   Bhang SH, 2007, J BIOMAT SCI-POLYM E, V18, P223, DOI 10.1163/156856207779116711
   Bockelmann J, 2011, TISSUE ENG PT A, V17, P475, DOI [10.1089/ten.tea.2010.0369, 10.1089/ten.TEA.2010.0369]
   Chang EJ, 2005, EXP CELL RES, V303, P197, DOI 10.1016/j.yexcr.2004.09.024
   Cong LD, 2008, INVEST OPHTH VIS SCI, V49, P4115, DOI 10.1167/iovs.08-1976
   Dosunmu OO, 2006, NANOTECHNOLOGY, V17, P1123, DOI 10.1088/0957-4484/17/4/046
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   GREFERATH U, 1990, J COMP NEUROL, V301, P433, DOI 10.1002/cne.903010308
   Gu P, 2009, MOL VIS, V15, P2111
   Hwang NS, 2008, ADV DRUG DELIVER REV, V60, P199, DOI 10.1016/j.addr.2007.08.036
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kieswetter K, 1996, J BIOMED MATER RES, V32, P55, DOI 10.1002/(SICI)1097-4636(199609)32:1<55::AID-JBM7>3.0.CO;2-O
   Klassen HJ, 2004, INVEST OPHTH VIS SCI, V45, P4167, DOI 10.1167/iovs.04-0511
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Lavik EB, 2005, BIOMATERIALS, V26, P3187, DOI 10.1016/j.biomaterials.2004.08.022
   Livesey FJ, 2004, P NATL ACAD SCI USA, V101, P1374, DOI 10.1073/pnas.0307014101
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220
   Margalit E, 2003, ARTIF ORGANS, V27, P963, DOI 10.1046/j.1525-1594.2003.07304.x
   MILAM AH, 1993, VISUAL NEUROSCI, V10, P1, DOI 10.1017/S0952523800003175
   Mohammadi Y, 2007, INT J ARTIF ORGANS, V30, P204, DOI 10.1177/039139880703000305
   Nadri S, 2008, DIFFERENTIATION, V76, P223, DOI 10.1111/j.1432-0436.2007.00216.x
   Nadri S, 2007, IN VITRO CELL DEV-AN, V43, P276, DOI 10.1007/s11626-007-9041-5
   Neeley WL, 2008, BIOMATERIALS, V29, P418, DOI 10.1016/j.biomaterials.2007.10.007
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pham QP, 2006, TISSUE ENG, V12, P1197, DOI 10.1089/ten.2006.12.1197
   Redenti S, 2009, BIOMATERIALS, V30, P3405, DOI 10.1016/j.biomaterials.2009.02.046
   Sagdullaev BT, 2003, INVEST OPHTH VIS SCI, V44, P1686, DOI 10.1167/iovs.02-0615
   Schnell E, 2007, BIOMATERIALS, V28, P3012, DOI 10.1016/j.biomaterials.2007.03.009
   SEILER MJ, 1995, CURR EYE RES, V14, P199, DOI 10.3109/02713689509033515
   Sharma RK, 2007, BRAIN RES, V1176, P11, DOI 10.1016/j.brainres.2007.07.090
   Silverman M S, 1989, Prog Clin Biol Res, V314, P687
   Soleimani M, 2010, INT J DEV BIOL, V54, P1295, DOI 10.1387/ijdb.092999ms
   Steedman MR, 2010, BIOMED MICRODEVICES, V12, P363, DOI 10.1007/s10544-009-9392-7
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tomita M, 2005, STEM CELLS, V23, P1579, DOI 10.1634/stemcells.2005-0111
   Tomita M, 2006, STEM CELLS, V24, P2270, DOI 10.1634/stemcells.2005-0507
   Tropel P, 2004, EXP CELL RES, V295, P395, DOI 10.1016/j.yexcr.2003.12.030
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Xu CY, 2004, BIOMATERIALS, V25, P877, DOI 10.1016/S0142-9612(03)00593-3
   Yang F, 2004, BIOMATERIALS, V25, P1891, DOI 10.1016/j.biomaterials.2003.08.062
   Zhang YZ, 2005, J BIOMED MATER RES B, V72B, P156, DOI 10.1002/jbm.b.30128
   Zhao SL, 1997, INT REV CYTOL, V171, P225
NR 45
TC 35
Z9 39
U1 0
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JUN
PY 2013
VL 40
IS 6
BP 3883
EP 3890
DI 10.1007/s11033-012-2360-y
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 142JR
UT WOS:000318794000002
PM 23588957
DA 2022-11-30
ER

PT J
AU Liu, JH
   Chen, MM
   Huang, JW
   Wann, H
   Ho, LK
   Pan, WHT
   Chen, YC
   Liu, CM
   Yeh, MY
   Tsai, SK
   Young, MS
   Ho, LT
   Kuo, CD
   Chuang, HY
   Chao, FP
   Chao, HM
AF Liu, Jorn-Hon
   Chen, Mi-Mi
   Huang, Jhao-Wei
   Wann, Hsiung
   Ho, Li-Kang
   Pan, Wynn H. T.
   Chen, Yei-Ching
   Liu, Chi-Ming
   Yeh, Ming-Yang
   Tsai, Shen-Kou
   Young, Mason Shing
   Ho, Low-Tone
   Kuo, Cheng-Deng
   Chuang, Hui-Yen
   Chao, Fang-Ping
   Chao, Hsiao-Ming
TI Therapeutic Effects and Mechanisms of Action of Mannitol During
   H2O2-Induced Oxidative Stress in Human Retinal Pigment Epithelium Cells
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID AGE-RELATED MACULOPATHY; CEREBRAL-ISCHEMIA; PREVALENCE; PATHOGENESIS;
   RADICALS; INJURY; ASSAY; SHOCK; ACID
AB Background: Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly. At a later stage, neovascular or exudative AMD can lead to severe central vision loss that is related to aging-associated cumulative oxidative stress of the human retinal pigment epithelium (hRPE) and choroid capillary. Early prevention with antioxidants is mandatory. The aim of this study was to determine whether and how mannitol can act as an antioxidant.
   Methods: The methods used included measurements of cell viability, oxygen free radical (OFR) levels, lipid peroxide (LP) levels, and OFR-related enzyme protein levels.
   Results: H2O2 dose-dependently reduced the cell viability of hRPE cells. This negative effect was significantly counteracted by pretreatment with mannitol (1 mM). H2O2 significantly stimulated the formation of OFR and LP. These increases were dose-dependently and significantly blunted by mannitol. Furthermore, treatment with H2O2 was associated with a reduction in the level of catalase, but not of manganese superoxide dismutase (MnSOD). In contrast, it was shown that mannitol protected hRPE cells against the H2O2-induced oxidative stress by increasing the level of catalase, but not the level of MnSOD.
   Conclusion: This study supports an antioxidative role for mannitol that acts through up-regulating the level of catalase, which is decreased by H2O2.
C1 [Liu, Jorn-Hon; Chen, Mi-Mi; Wann, Hsiung; Chen, Yei-Ching; Chuang, Hui-Yen; Chao, Fang-Ping; Chao, Hsiao-Ming] Cheng Hsin Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Liu, Jorn-Hon; Chao, Hsiao-Ming] Natl Yang Ming Univ, Dept Ophthalmol, Fac Med, Taipei 112, Taiwan.
   [Huang, Jhao-Wei; Wann, Hsiung; Ho, Li-Kang; Pan, Wynn H. T.; Chao, Hsiao-Ming] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 112, Taiwan.
   [Liu, Chi-Ming; Yeh, Ming-Yang; Tsai, Shen-Kou; Young, Mason Shing] Cheng Hsin Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan.
   [Ho, Low-Tone; Kuo, Cheng-Deng] Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan.
C3 Cheng Hsin General Hospital; National Yang Ming Chiao Tung University;
   National Yang Ming Chiao Tung University; Cheng Hsin General Hospital
RP Chao, HM (通讯作者)，Cheng Hsin Gen Hosp, Dept Ophthalmol, 45 Cheng Hsin St, Taipei, Taiwan.
EM ox_drchao@yahoo.ca
RI Kuo, Cheng-Deng/AAP-7010-2021; CHUANG, HUI-YEN/GVW-2101-2022
OI Kuo, Cheng-Deng/0000-0002-3989-1950; 
FU Cheng Hsin General Hospital (CHGH) [CHGH98-77]; Committee on Chinese
   Medicine and Pharmacy (CCMP) [CCMP97-RD-012]; Taipei Veterans General
   Hospital (TPE-VGH) [V96E2-012]; Department of Medical Research and
   Education
FX The authors would like to thank Cheng Hsin General Hospital (CHGH), the
   Committee on Chinese Medicine and Pharmacy (CCMP), and Taipei Veterans
   General Hospital (TPE-VGH) for providing 3 grants, respectively
   (CHGH98-77, CCMP97-RD-012, and V96E2-012), to carry out this study. They
   also thank the Department of Medical Research and Education both in the
   Cheng Hsin General Hospital and in the Taipei Veterans General Hospital
   for their generosity in providing the financial support and an access to
   the relevant facilities at the Core Laboratories. They would also like
   to express their sincere gratitude to Prof. Ralph Kirby at the Taipei
   National Yang-Ming University for professional revision.
CR Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   BROWN SA, 1992, J AM VET MED ASSOC, V200, P1849
   Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4
   Chao HM, 2008, HUM EXP TOXICOL, V27, P327, DOI 10.1177/0960327108092294
   Chao HM, 2008, J OCUL PHARMACOL TH, V24, P461, DOI 10.1089/jop.2008.0005
   CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   GINSBERG MD, 1988, NEUROCHEM PATHOL, V9, P171
   IKEDA Y, 1990, NEUROSURGERY, V27, P1
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEBEL CP, 1990, TOXICOL APPL PHARM, V104, P17, DOI 10.1016/0041-008X(90)90278-3
   Li PA, 1997, ACTA PHYSIOL SCAND, V161, P567, DOI 10.1046/j.1365-201X.1997.00264.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Niu KC, 2003, CLIN EXP PHARMACOL P, V30, P745, DOI 10.1046/j.1440-1681.2003.03905.x
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3
   Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WATSON BD, 1989, ANN NY ACAD SCI, V559, P269
   Yang CY, 2002, STROKE, V33, P790, DOI 10.1161/hs0102.100208
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 13
Z9 14
U1 1
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD JUN
PY 2010
VL 26
IS 3
BP 249
EP 257
DI 10.1089/jop.2009.0127
PG 9
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 614CW
UT WOS:000279033800005
PM 20565311
DA 2022-11-30
ER

PT J
AU Mousa, SA
   Mousa, AS
AF Mousa, SA
   Mousa, AS
TI Angiogenesis inhibitors: Current & future directions
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
ID ENDOTHELIAL-CELL PROLIFERATION; TISSUE FACTOR; GROWTH-FACTOR; CARCINOMA;
   CANCER; ANTICOAGULANTS; FIBRINOLYSIS; METASTASIS; ENDOSTATIN; THROMBOSIS
AB The field of angiogenesis modulation is at a major crossroad. A tremendous advancement in basic science in this field is providing an excellent support for the concept, which is in contrast to a lack of strong clinical support to date. With regard to the large gap between experimental data and clinical data, the best model of human malignancy is in human cancer patients and the best model of human ocular angiogenesis-mediated disorders such as diabetic retinopathy (DR) and age related macular degeneration (AMD) is in human RD and AMD patients. Additionally, clinical outcomes should include benefit/risk ratios, hard end points (mortality and quality of life as opposed to increased microvascular density with pro-angiogenic agents or tumor size reduction with anti-angiogenesis agents) as well as cost effectiveness.
   Experimental models should be used to provide guidance, placebo effect, comparative data, and mechanistic understanding as opposed to being used for expected clinical efficacy. We also have to understand existing strategies and how angiogenesis modulation can add further value (i.e. not to replace existing strategy but rather improve efficacy/safety).
   Recent investigation defined numerous strategies in the modulation of angiogenesis. Those strategies are driven from haemostatic, fibrinolytic, cell adhesion molecules, extracellular matrix, growth factors, and other endogenous systems involved in the modulation of angiogenesis.
C1 Albany Coll Pharm & Pharmaceut Res Inst, Albany, NY 12208 USA.
   Cornell Univ, Ithaca, NY USA.
C3 Albany College of Pharmacy & Health Sciences; Cornell University
RP Mousa, SA (通讯作者)，Albany Coll Pharm & Pharmaceut Res Inst, 106 New Scotland Ave, Albany, NY 12208 USA.
EM mousas@acp.edu
RI Mousa, Shaker A/A-7151-2017
OI Mousa, Shaker A/0000-0002-9294-015X
CR Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663
   Basser R, 2002, CURR PHARM DESIGN, V8, P369, DOI 10.2174/1381612023395989
   Bennett CL, 2002, AM J MED, V113, P603, DOI 10.1016/S0002-9343(02)01300-1
   Bilfinger TV, 2002, CURR PHARM DESIGN, V8, P505, DOI 10.2174/1381612023395763
   BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205
   CAMPOCHIARO PA, 2000, ANGIOGENESIS INHIBIT
   Chen Z, 1999, CLIN CANCER RES, V5, P1369
   Clark ER, 1939, AM J ANAT, V64, P251, DOI 10.1002/aja.1000640203
   Colman RW, 2003, J THROMB HAEMOST, V1, P164, DOI 10.1046/j.1538-7836.2003.00025.x
   Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543
   Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6
   Fernandez PM, 2002, CURR OPIN HEMATOL, V9, P401, DOI 10.1097/00062752-200209000-00003
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Gordeladze JO, 2001, CURR PHARM DESIGN, V7, P275, DOI 10.2174/1381612013398167
   Hembrough TA, 2001, J BIOL CHEM, V276, P12241, DOI 10.1074/jbc.M010395200
   Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265
   Jung Sung P., 2001, Angiogenesis, V4, P175, DOI 10.1023/A:1014089706107
   Kaushal V, 2002, J CLIN ONCOL, V20, P3042, DOI 10.1200/JCO.2002.20.13.3042
   Kerbel RS, 2001, CANCER METAST REV, V20, P1, DOI 10.1023/A:1013129128673
   Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5
   Kuenen BC, 2002, J CLIN ONCOL, V20, P1657, DOI 10.1200/JCO.20.6.1657
   LEBEAU B, 1994, CANCER, V74, P38, DOI 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E
   LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6
   Luna J, 1996, LAB INVEST, V75, P563
   McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797
   Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798
   Mousa S A, 2001, Expert Opin Investig Drugs, V10, P387, DOI 10.1517/13543784.10.2.387
   Mousa SA, 2002, CARDIOVASC DRUG REV, V20, P199
   Mousa SA, 2002, SEMIN THROMB HEMOST, V28, P45, DOI 10.1055/s-2002-20559
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mousa SA, 1999, BLOOD, V94, p22A
   MOUSA SA, 2000, MED INTELL UNIT, V20, P1
   Pavlakovic Helena, 2001, Angiogenesis, V4, P259, DOI 10.1023/A:1016045012466
   Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685
   PIRIESHEPHERD SR, 2003, FRONTIERS BIOSCIENCE, V8, P286
   Ranieri G., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P241, DOI 10.2174/1568008013341073
   Rickles FR, 2001, INT J HEMATOL, V73, P145, DOI 10.1007/BF02981930
   Shahan TA, 1999, CONNECT TISSUE RES, V40, P221, DOI 10.3109/03008209909005285
   Sorensen HT, 2000, NEW ENGL J MED, V343, P1846, DOI 10.1056/NEJM200012213432504
   Thomas JP, 2003, J CLIN ONCOL, V21, P223, DOI 10.1200/JCO.2003.12.120
   THOMPSON WD, 1991, J PATHOL, V165, P311, DOI 10.1002/path.1711650406
   THORNES RD, 1983, PROTECTIVE AGENTS CA, P43
   Tosi P, 2001, ACTA HAEMATOL-BASEL, V106, P208, DOI 10.1159/000046617
   Trousseau A., 1865, CLINIQUE MEDICULE HO, V3, P94
   Van Waes C, 2000, INT J ONCOL, V16, P1189
   WOJTUKIEWICZ MZ, 1990, ANTICANCER RES, V10, P579
   Yoon SO, 2003, J BIOCHEM MOL BIOL, V36, P128
   ZACHARSKI LR, 1993, CANCER J - FRANCE, V6, P16
   ZACHARSKI LR, 1992, SEMIN THROMB HEMOST, V18, P104, DOI 10.1055/s-2007-1002415
   ZACHARSKI LR, 1984, CANCER, V53, P2046, DOI 10.1002/1097-0142(19840515)53:10<2046::AID-CNCR2820531007>3.0.CO;2-F
NR 50
TC 25
Z9 40
U1 0
U2 2
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2004
VL 10
IS 1
BP 1
EP 9
DI 10.2174/1381612043453531
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 762RU
UT WOS:000187996600002
PM 14754401
DA 2022-11-30
ER

PT J
AU Zaitoun, IS
   Song, YS
   Zaitoun, HB
   Sorenson, CM
   Sheibani, N
AF Zaitoun, Ismail S.
   Song, Yong-Seok
   Zaitoun, Hammam B.
   Sorenson, Christine M.
   Sheibani, Nader
TI Assessment of Choroidal Vasculature and Innate Immune Cells in the Eyes
   of Albino and Pigmented Mice
SO CELLS
LA English
DT Article
DE choriocapillaris; mast cells; macrophages; smooth muscle cells; uveal
   diseases; age-related macular degeneration
ID MAST-CELLS; DEGRANULATION
AB The visualization of choroidal vasculature and innate immune cells in the eyes of pigmented mice has been challenging due to the presence of a retinal pigment epithelium (RPE) layer separating the choroid and retina. Here, we established methods for visualizing the choroidal macrophages, mast cells, and vasculature in eyes of albino and pigmented mice using cell type-specific staining. We were able to visualize the choroidal arterial and venous systems. An arterial circle around the optic nerve was found in mice similar to the Zinn-Haller arterial circle that exists in humans and primates. Three different structural patterns of choriocapillaris were observed throughout the whole choroid: honeycomb-like, maze-like, and finger-like patterns. Choroidal mast cells were relatively few but dense around the optic nerve. Mast cell distribution in the middle and periphery was different among strains. Macrophages were found in all layers of the choroid. Thus, utilizing the simple and reliable methods described herein will allow the evaluation of transgenic and preclinical mouse models of ocular diseases that affect the choroid, including age-related macular degeneration (AMD), diabetic choroidopathy, and retinopathy of prematurity. These studies will advance our understanding of the pathophysiology, and molecular and cellular mechanisms that can be targeted therapeutically, in these diseases.
C1 [Zaitoun, Ismail S.; Song, Yong-Seok; Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA.
   [Zaitoun, Ismail S.; Song, Yong-Seok; Sorenson, Christine M.; Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, McPherson Eye Res Inst, Madison, WI 53705 USA.
   [Zaitoun, Hammam B.] Yarmouk Univ Irbid, Fac Med, Irbid 21163, Jordan.
   [Sorenson, Christine M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI 53705 USA.
   [Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Cell & Regenerat Biol, Madison, WI 53705 USA.
   [Sheibani, Nader] Univ Wisconsin, Dept Biomed Engn, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Yarmouk
   University; University of Wisconsin System; University of Wisconsin
   Madison; University of Wisconsin System; University of Wisconsin
   Madison; University of Wisconsin System; University of Wisconsin Madison
RP Zaitoun, IS (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA.; Zaitoun, IS (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, McPherson Eye Res Inst, Madison, WI 53705 USA.
EM iszaitoun@wisc.edu
OI Sheibani, Nader/0000-0003-2723-9217
FU Research to Prevent Blindness; Retina Research Foundation; RRF/Daniel M.
   Albert chair; Carl Marshall Reeves & Mildred Almen Reeves Foundation;
   National Institutes of Health [P30 EY016665, EY030076, EY032543,
   HL158073]; UW Department of Pathology and Laboratory Medicine, UWCCC
   [P30 CA014520]; Office of The Director-NIH [S10 OD023526]
FX This work and/or the investigator(s) were supported by an unrestricted
   award from Research to Prevent Blindness to the Department of
   Ophthalmology and Visual Sciences, Retina Research Foundation,
   RRF/Daniel M. Albert chair, Carl Marshall Reeves & Mildred Almen Reeves
   Foundation, and by the National Institutes of Health grants P30
   EY016665, EY030076, EY032543, and HL158073. We also thank the University
   of Wisconsin Translational Research Initiatives in Pathology laboratory
   (TRIP), supported by the UW Department of Pathology and Laboratory
   Medicine, UWCCC (P30 CA014520), and the Office of The Director-NIH (S10
   OD023526) for use of its facilities and services.
CR Abdel-Majid RM, 2004, J IMMUNOL, V172, P1227, DOI 10.4049/jimmunol.172.2.1227
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bhutto IA, 2001, ANAT RECORD, V264, P63, DOI 10.1002/ar.1102
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2020, INVEST OPHTH VIS SCI, V61
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   Cherwinski HM, 2005, J IMMUNOL, V174, P1348, DOI 10.4049/jimmunol.174.3.1348
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Jiao CH, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.1.1
   Kim SY, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.1.6
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Kunder CA, 2009, J EXP MED, V206, P2455, DOI 10.1084/jem.20090805
   Lejoyeux R, 2022, PROG RETIN EYE RES, V87, DOI 10.1016/j.preteyeres.2021.100997
   Li J, 2022, TRANSL VIS SCI TECHN, V11, DOI 10.1167/tvst.11.2.37
   Liu J, 2015, SCI REP-UK, V5, DOI 10.1038/srep17569
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   McMenamin PG, 2019, PROG RETIN EYE RES, V70, P85, DOI 10.1016/j.preteyeres.2018.12.002
   McNeil BD, 2015, NATURE, V519, P237, DOI 10.1038/nature14022
   Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Ninomiya Hiroyoshi, 2006, Journal of Experimental Animal Science, V43, P149, DOI 10.1016/j.jeas.2006.05.002
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   PARVER LM, 1983, ARCH OPHTHALMOL-CHIC, V101, P1604, DOI 10.1001/archopht.1983.01040020606021
   Reekie IR, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.721953
   Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0B013E31822F5678, 10.1097/IAE.0b013e31822f5678]
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   THARP MD, 1985, J HISTOCHEM CYTOCHEM, V33, P27, DOI 10.1177/33.1.2578142
   Wang SJ, 2022, LIFE-BASEL, V12, DOI 10.3390/life12020208
   Ye YY, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.1
NR 30
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD OCT
PY 2022
VL 11
IS 20
AR 3329
DI 10.3390/cells11203329
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 5O8NN
UT WOS:000872722900001
PM 36291198
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ohno, Y
   Yako, T
   Satoh, K
   Nagase, H
   Shitara, A
   Hara, H
   Kashimata, M
AF Ohno, Yuta
   Yako, Tomohiro
   Satoh, Keitaro
   Nagase, Haruna
   Shitara, Akiko
   Hara, Hideaki
   Kashimata, Masanori
TI Retinal damage alters gene expression profile in lacrimal glands of mice
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE RNA sequencing (RNA-seq); Lacrimal gland; Retinal damage; NMDA
   injection; Excessive light exposure
ID METHYL-D-ASPARTATE; GROWTH-FACTOR; DEGENERATION; PATHOGENESIS; GLAUCOMA
AB Early detection of such retinal diseases as glaucoma and age-related macular degeneration (AMD) is important to prevent blindness. There have been reports of changes in some components in the tears of glaucoma and AMD patients, suggesting tears' potential usefulness in screening for retinal diseases. We hypothesized that retinal damage might alter gene expression in the lacrimal gland, leading to those changes in tear components. We caused retinal damage in mice by intravitreal injection of N-methyl-Daspartate (NMDA) or excessive light exposure. Hematoxylin and eosin staining showed no histological changes in the lacrimal glands of animals whose retinas had been damaged. However, RNA sequencing of lacrimal glands on the 3rd day after NMDA injection or light exposure revealed changes in the expression of 491 genes (268 up-regulated; 223 down-regulated) in the NMDA group and 531 genes (311 upregulated; 220 down-regulated) in the light group. Further gene-set enrichment analysis indicated that both types of retinal damage activated the immune system in the lacrimal glands. This is the first demonstration that retinal damage can alter gene expression in the lacrimal glands, and it might lead to a novel non-invasive screening method for early detection of retinal diseases. (C) 2022 The Authors. Production and hosting by Elsevier B.V.
C1 [Ohno, Yuta; Satoh, Keitaro; Nagase, Haruna; Shitara, Akiko; Kashimata, Masanori] Asahi Univ, Sch Dent, Dept Pharmacol, Mizuho Ku, 1851-1 Hozumi, Gifu 5010296, Japan.
   [Yako, Tomohiro; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu, Gifu 5011196, Japan.
   [Satoh, Keitaro] Meikai Univ, Sch Dent, Dept Pharmacol, 1-1 Keyakidai, Sakado, Saitama 3500283, Japan.
C3 Asahi University; Gifu Pharmaceutical University; Meikai University
RP Ohno, Y (通讯作者)，Asahi Univ, Sch Dent, Dept Pharmacol, Mizuho Ku, 1851-1 Hozumi, Gifu 5010296, Japan.
EM ohnoyuta@dent.asahi-u.ac.jp
RI Ohno, Yuta/AIE-4047-2022; Nagase, Haruna/AIF-0376-2022
OI Ohno, Yuta/0000-0002-8182-3150; Satoh, Keitaro/0000-0003-4921-6753
CR Chistyakov DV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030704
   Dreyer EB, 1998, J GLAUCOMA, V7, P62
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Ghaffariyeh A, 2009, OPTOMETRY, V80, P635, DOI 10.1016/j.optm.2008.09.014
   Hayashi I, 2015, BIOL PHARM BULL, V38, P1765, DOI 10.1248/bpb.b15-00464
   Inoue Y, 2017, J NEUROCHEM, V141, P750, DOI 10.1111/jnc.14029
   Inoue Y, 2013, INVEST OPHTH VIS SCI, V54, P3815, DOI 10.1167/iovs.12-11236
   Kuehn Markus H, 2005, Ophthalmol Clin North Am, V18, P383, DOI 10.1016/j.ohc.2005.04.002
   Lam TT, 1999, INVEST OPHTH VIS SCI, V40, P2391
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ohno Y, 2013, EXP EYE RES, V113, P19, DOI 10.1016/j.exer.2013.05.009
   Ohno Y, 2012, EUR J PHARMACOL, V690, P84, DOI 10.1016/j.ejphar.2012.06.035
   Pesaresi M, 2018, EBIOMEDICINE, V30, P38, DOI 10.1016/j.ebiom.2018.02.023
   Pieragostino D, 2013, MOL BIOSYST, V9, P1108, DOI 10.1039/c3mb25463a
   Roedl JB, 2008, OPHTHALMIC RES, V40, P249, DOI 10.1159/000127832
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shimazawa M, 2007, INVEST OPHTH VIS SCI, V48, P3729, DOI 10.1167/iovs.06-1122
   Takahashi K, 2017, INVEST OPHTH VIS SCI, V58, P6299, DOI 10.1167/iovs.17-22556
   Todd L, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1505-5
   Vohra R, 2013, SURV OPHTHALMOL, V58, P311, DOI 10.1016/j.survophthal.2012.08.010
   Wang Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050245
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/724648
   Winiarczyk M, 2018, GRAEF ARCH CLIN EXP, V256, P1127, DOI 10.1007/s00417-018-3984-y
   Wu JT, 2007, J BIOMED LAB SCI, V19, P107
   YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012
NR 28
TC 1
Z9 1
U1 0
U2 1
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD MAY
PY 2022
VL 149
IS 1
BP 20
EP 26
DI 10.1016/j.jphs.2022.02.007
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0J9DD
UT WOS:000780397800003
PM 35369901
OA gold
DA 2022-11-30
ER

PT J
AU Lee, JJ
   Chang-Chien, GP
   Lin, SF
   Hsiao, YT
   Ke, MC
   Chen, A
   Lin, TK
AF Lee, Jong-Jer
   Chang-Chien, Guo-Ping
   Lin, Sufan
   Hsiao, Yu-Ting
   Ke, Mu-Chan
   Chen, Alexander
   Lin, Tsu-Kung
TI 5-Lipoxygenase Inhibition Protects Retinal Pigment Epithelium from
   Sodium Iodate-Induced Ferroptosis and Prevents Retinal Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID OXIDATIVE STRESS; CELL-DEATH; MOUSE MODEL; DAMAGE; NEURODEGENERATION;
   HOMEOSTASIS; METABOLISM; APOPTOSIS; FORM
AB Excessive reactive oxygen species (ROS) contribute to damage of retinal cells and the development of retinal diseases including age-related macular degeneration (AMD). ROS result in increased metabolites of lipoxygenases (LOXs), which react with ROS to induce lipid peroxidation and may lead to ferroptosis. In this study, the effect of 5-LOX inhibition on alleviating ROS-induced cell death was evaluated using sodium iodate (NaIO3) in the retinal pigment epithelium (RPE) cell line ARPE-19 and a mouse model investigating oxidative stress in AMD. We demonstrated that NaIO3 induced cell death in the RPE cells through mechanisms including ferroptosis. Inhibition of 5-LOX with specific inhibitor, Zileuton, or siRNA knockdown of ALXO5 mitigated NaIO3-induced lipid peroxidation, mitochondrial damage, DNA impairment, and cell death in ARPE-19 cells. Additionally, in the mouse model, pretreatment with Zileuton reduced the NaIO3-induced lipid peroxidation of RPE cells, cell death in the photoreceptor layer of the retina, inflammatory responses, and degeneration of both the neuroretina and RPE monolayer cells. Our results suggest that 5-LOX plays a crucial role in ROS-induced cell death in the RPE and that regulating 5-LOX activity could be a useful approach to control ROS and ferroptosis-induced damage, which promote degeneration in retinal diseases.
C1 [Lee, Jong-Jer; Hsiao, Yu-Ting; Ke, Mu-Chan; Chen, Alexander; Lin, Tsu-Kung] Chang Gung Univ, Coll Med, Kaohsiung 833401, Taiwan.
   [Lee, Jong-Jer; Hsiao, Yu-Ting; Ke, Mu-Chan; Chen, Alexander] Kaohsiung Chang Gung Mem Hosp, Dept Ophthalmol, Kaohsiung 833401, Taiwan.
   [Lee, Jong-Jer; Lin, Tsu-Kung] Kaohsiung Chang Gung Mem Hosp, Ctr Mitochondrial Res & Med, Kaohsiung 833401, Taiwan.
   [Chang-Chien, Guo-Ping; Lin, Sufan] Cheng Shiu Univ, Super Micro Mass Res & Technol Ctr, Kaohsiung 833301, Taiwan.
   [Chang-Chien, Guo-Ping; Lin, Sufan] Cheng Shiu Univ, Ctr Environm Toxin & Emerging Contaminant Res, Kaohsiung 833301, Taiwan.
   [Chang-Chien, Guo-Ping; Lin, Sufan] Cheng Shiu Univ, Inst Environm Toxin & Emerging Contaminant, Kaohsiung 833301, Taiwan.
   [Lin, Tsu-Kung] Kaohsiung Chang Gung Mem Hosp, Dept Neurol, Kaohsiung 833401, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Cheng Shiu
   University; Cheng Shiu University; Cheng Shiu University; Chang Gung
   Memorial Hospital
RP Lin, TK (通讯作者)，Chang Gung Univ, Coll Med, Kaohsiung 833401, Taiwan.; Lin, TK (通讯作者)，Kaohsiung Chang Gung Mem Hosp, Ctr Mitochondrial Res & Med, Kaohsiung 833401, Taiwan.; Lin, TK (通讯作者)，Kaohsiung Chang Gung Mem Hosp, Dept Neurol, Kaohsiung 833401, Taiwan.
EM tojjlee@cgmh.org.tw; guoping@gcloud.csu.edu.tw; k6101@gcloud.csu.edu.tw;
   born2bunique1008@gmail.com; ps2000115@cgmh.org.tw; b9902055@cgmh.org.tw;
   tklin@cgmh.org.tw
OI Lee, Jong-Jer/0000-0002-9213-0288; Hsiao, Yu-Ting/0000-0001-5739-7967;
   Lin, Tsu-Kung/0000-0001-6656-1319
FU Ministry of Science and Technology Research Project Grant [MOST
   110-2314-B-182A-117]; Chang Gung Memorial Hospital [CMRPG8K1341]
FX We appreciate the Center for Shockwave Medicine and Tissue Engineering,
   Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College
   of Medicine, Kaohsiung, Taiwan, for providing the immunofluorescence
   microscope. We thank the service of real-time PCR provided by the
   Instrumentation Laboratory, Department of Medical Research, Kaohsiung
   Chang Gung Memorial Hospital. This work was supported by the Ministry of
   Science and Technology Research Project Grant (MOST 110-2314-B-182A-117)
   and Chang Gung Memorial Hospital under grant (CMRPG8K1341).
CR Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064
   Balboa MA, 2006, BBA-MOL CELL BIOL L, V1761, P385, DOI 10.1016/j.bbalip.2006.03.014
   Battaglia AM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061505
   Chaudhary K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21276-2
   Chen C, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.015779
   Chen MS, 2017, ONCOTARGET, V8, P114588, DOI 10.18632/oncotarget.23055
   Chowers G, 2017, INVEST OPHTH VIS SCI, V58, P2239, DOI 10.1167/iovs.16-21255
   Ciudin A, 2010, EXP DIABETES RES, DOI 10.1155/2010/714108
   Czapski GA, 2012, PHARMACOL REP, V64, P1179, DOI 10.1016/S1734-1140(12)70914-3
   Daruich A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau9940
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0
   Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/nchembio.2239, 10.1038/NCHEMBIO.2239]
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Higdon A, 2012, BIOCHEM J, V442, P453, DOI 10.1042/BJ20111752
   Kajarabille N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194968
   Lee JJ, 2020, BIOCHEM BIOPH RES CO, V521, P414, DOI 10.1016/j.bbrc.2019.10.138
   Leung HH, 2020, NEUROCHEM RES, V45, P1007, DOI 10.1007/s11064-020-02994-4
   Liu BH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03520-2
   Liu Y, 2015, BIOL PHARM BULL, V38, P1234, DOI 10.1248/bpb.b15-00048
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Maccarrone M, 2003, KIDNEY INT, V63, pS33, DOI 10.1046/j.1523-1755.63.s84.26.x
   Fernandez-Real JM, 2015, DIABETES CARE, V38, P2169, DOI 10.2337/dc14-3082
   Marshall J, 2015, J BIOL CHEM, V290, P22030, DOI 10.1074/jbc.M115.662791
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Murakami Y, 2014, CELL DEATH DIFFER, V21, P270, DOI 10.1038/cdd.2013.109
   Noro T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.93
   Noro T, 2015, INVEST OPHTH VIS SCI, V56, P5012, DOI 10.1167/iovs.15-17142
   Obolensky A, 2011, FREE RADICAL BIO MED, V51, P1482, DOI 10.1016/j.freeradbiomed.2011.07.014
   Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x
   Prentice H, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/964518
   Steinhilber D, 2010, FRONT PHARMACOL, V1, DOI 10.3389/fphar.2010.00143
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Subramanian P, 2016, INVEST OPHTH VIS SCI, V57, P4581, DOI 10.1167/iovs.15-19039
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Tadokoro T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.132747
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Ueda K, 2018, P NATL ACAD SCI USA, V115, P4963, DOI 10.1073/pnas.1722601115
   Wu H, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030222
   Xiong WJ, 2015, J CLIN INVEST, V125, P1433, DOI 10.1172/JCI79735
   Yu HT, 2017, J CELL MOL MED, V21, P648, DOI 10.1111/jcmm.13008
   Yuan H, 2016, BIOCHEM BIOPH RES CO, V478, P838, DOI 10.1016/j.bbrc.2016.08.034
NR 46
TC 2
Z9 2
U1 7
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD FEB 23
PY 2022
VL 2022
AR 1792894
DI 10.1155/2022/1792894
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 0P6EE
UT WOS:000784319100007
PM 35251467
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, TX
   Zhou, PZ
   Xie, XM
   Tomita, Y
   Cho, S
   Tsirukis, D
   Lam, E
   Luo, HR
   Sun, Y
AF Wang, Tianxi
   Zhou, Pingzhu
   Xie, Xuemei
   Tomita, Yohei
   Cho, Steve
   Tsirukis, Demetrios
   Lam, Enton
   Luo, Hongbo Robert
   Sun, Ye
TI Myeloid lineage contributes to pathological choroidal neovascularization
   formation via SOCS3
SO EBIOMEDICINE
LA English
DT Article
DE Choroidal neovascularization; Myeloid lineage; SOCS3; Pathological
   endothelium formation; Age-related macular degeneration
ID ENDOTHELIAL PROGENITOR CELLS; BONE-MARROW; MACROPHAGE POLARIZATION;
   STAT3 ACTIVATION; MICROGLIA; RECEPTOR; MODEL; ANGIOGENESIS; SUPPRESSOR;
   VEGF
AB Background: Pathological neovascularization in neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss in the elderly. Increasing evidence shows that cells of myeloid lineage play important roles in controlling pathological endothelium formation. Suppressor of cytokine signaling 3 (SOCS3) pathway has been linked to neovascularization.
   Methods: We utilised a laser-induced choroidal neovascularization (CNV) mouse model to investigate the neovascular aspect of human AMD. In several cell lineage reporter mice, bone marrow chimeric mice and Socs3 loss-of-function (knockout) and gain-of-function (overexpression) mice, immunohistochemistry, con-focal, and choroidal explant co-culture with bone marrow-derived macrophage medium were used to study the mechanisms underlying pathological CNV formation via myeloid SOCS3.
   Findings: SOCS3 was significantly induced in myeloid lineage cells, which were recruited into the CNV lesion area. Myeloid Socs3 overexpression inhibited laser-induced CNV, reduced myeloid lineage-derived macro-phage/microglia recruitment onsite, and attenuated pro-inflammatory factor expression. Moreover, SOCS3 in myeloid regulated vascular sprouting ex vivo in choroid explants and SOCS3 agonist reduced in vivo CNV.
   Interpretation: These findings suggest that myeloid lineage cells contributed to pathological CNV formation regulated by SOCS3. (C) 2021 The Author(s). Published by Elsevier B.V.
C1 [Wang, Tianxi; Tomita, Yohei; Cho, Steve; Tsirukis, Demetrios; Lam, Enton; Sun, Ye] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
   [Zhou, Pingzhu] Harvard Med Sch, Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
   [Xie, Xuemei; Luo, Hongbo Robert] Boston Childrens Hosp, Dept Lab Med, Div Blood Bank, Stem Cell Program, Boston, MA USA.
   [Luo, Hongbo Robert] Harvard Med Sch, Dept Pathol, Joint Program Transfus Med, Boston, MA 02115 USA.
   [Luo, Hongbo Robert] Dana Farber Harvard Canc Ctr, Boston, MA USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Boston Children's Hospital; Harvard University;
   Harvard Medical School; Harvard University; Dana-Farber Cancer Institute
RP Sun, Y (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
EM ye.sun@childrens.harvard.edu
RI Tomita, Yohei/AGR-6793-2022
OI Sun, Ye/0000-0002-7674-9056; Tomita, Yohei/0000-0003-1013-5737
FU National Institutes of Health/National Eye Institute [R01EY030140,
   R01EY029238]; BrightFocus Foundation; Children's Hospital Oph-thalmology
   Foundation; National Institutes of Health/National Heart, Lung and Blood
   Institute [U01HL098166]; American Health Assistance Foundation (AHAF)
FX We thank Dr. Lois E.H. Smith for her advice and critical review of the
   manuscript, and thank Drs. Yan Gong, Chi-Hsiu Liu and Raffael Liegl for
   their excellent technical assistance. This work was supported by the
   National Institutes of Health/National Eye Institute (R01EY030140,
   R01EY029238) , BrightFocus Foundation, American Health Assistance
   Foundation (AHAF) , and Children's Hospital Oph-thalmology Foundation
   for Ye Sun, and the National Institutes of Health/National Heart, Lung
   and Blood Institute (U01HL098166) for Pingzhu Zhou. The funding sources
   had no role in determining how the research was conducted.
CR Akhtar LN, 2010, J IMMUNOL, V185, P2393, DOI 10.4049/jimmunol.0903563
   ALROY J, 1987, HISTOCHEMISTRY, V86, P603, DOI 10.1007/BF00489554
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arnold CE, 2013, IMMUNOLOGY
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Baba T, 2020, ELIFE, V9, DOI 10.7554/eLife.54257
   Bailey AS, 2006, P NATL ACAD SCI USA, V103, P13156, DOI 10.1073/pnas.0604203103
   Bhattacharya V, 2000, BLOOD, V95, P581, DOI 10.1182/blood.V95.2.581
   Binet F, 2013, CELL METAB, V17, P353, DOI 10.1016/j.cmet.2013.02.003
   Boscia F, 2013, J NEUROCHEM, V126, P428, DOI 10.1111/jnc.12209
   Chambers SEJ, 2013, IMMUNOBIOLOGY, V218, P1370, DOI 10.1016/j.imbio.2013.06.010
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Chen M, 2016, CURR MOL MED, V16, P412, DOI 10.2174/1566524016666160324130031
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Clement M, 2014, P NATL ACAD SCI USA, V111, pE1101, DOI 10.1073/pnas.1314505111
   Crespo-Garcia S, 2015, EXP EYE RES, V139, P13, DOI 10.1016/j.exer.2015.07.012
   Croker BA, 2004, IMMUNITY, V20, P153, DOI 10.1016/S1074-7613(04)00022-6
   Dejda A, 2014, J CLIN INVEST, V124, P4807, DOI 10.1172/JCI76492
   Feng T, 2020, CIRC RES, V127, P1221, DOI 10.1161/CIRCRESAHA.120.317442
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grigsby JG, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/705783
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Holl EK, 2013, METHODS MOL BIOL, V1032, P315, DOI 10.1007/978-1-62703-496-8_24
   Hou HY, 2006, CURR EYE RES, V31, P1051, DOI 10.1080/02713680601100459
   Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198
   Kambhampati SP, 2015, INVEST OPHTH VIS SCI, V56, P4413, DOI 10.1167/iovs.14-16250
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kester L, 2018, CELL STEM CELL, V23, P166, DOI 10.1016/j.stem.2018.04.014
   Kumar A, 2014, INVEST OPHTH VIS SCI, V55, P1787, DOI 10.1167/iovs.13-13522
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   La Manna S, 2018, INT J CANCER
   La Manna S, 2018, INT J CANCER, V143, P2177, DOI 10.1002/ijc.31594
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Li QY, 2016, FITOTERAPIA, V111, P78, DOI 10.1016/j.fitote.2016.04.015
   Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071
   Liyanage SE, 2016, ARTERIOSCL THROM VAS, V36, P19, DOI 10.1161/ATVBAHA.115.306681
   Luckoff A, 2016, EMBO MOL MED, V8, P670, DOI 10.15252/emmm.201505994
   Madonna S, 2017, ONCOTARGET, V8, P24652, DOI 10.18632/oncotarget.15629
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   Merchand-Reyes G, 2019, J IMMUNOL, V203, P3216, DOI 10.4049/jimmunol.1900059
   MILLER H, 1990, INVEST OPHTH VIS SCI, V31, P899
   Park S, 2004, PLAST RECONSTR SURG, V113, P284, DOI 10.1097/01.PRS.0000091169.51035.A5
   Plein A, 2018, NATURE, V562, P223, DOI 10.1038/s41586-018-0552-x
   Qin HW, 2012, J IMMUNOL, V189, P3439, DOI 10.4049/jimmunol.1201168
   Quijano E, 2017, YALE J BIOL MED, V90, P583
   Rani N, 2016, CURR PHARM DESIGN, V22, P4341, DOI 10.2174/1381612822666160530150936
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reed AS, 2010, DIABETES, V59, P894, DOI 10.2337/db09-1024
   Ritter MR, 2006, J CLIN INVEST, V116, P3266, DOI 10.1172/JCI29683
   SADLER JE, 1991, J BIOL CHEM, V266, P22777
   Salehi B, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12010011
   Santos AM, 2008, J COMP NEUROL, V506, P224, DOI 10.1002/cne.21538
   Schmid MC, 2007, CANCER LETT, V250, P1, DOI 10.1016/j.canlet.2006.09.002
   SCHMIDT D, 1995, PATHOL RES PRACT, V191, P410, DOI 10.1016/S0344-0338(11)80727-2
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Spence S, 2013, IMMUNITY, V38, P66, DOI 10.1016/j.immuni.2012.09.013
   Stahl A, 2012, BLOOD, V120, P2925, DOI 10.1182/blood-2012-04-422527
   Stefater JA, 2011, TRENDS MOL MED, V17, P743, DOI 10.1016/j.molmed.2011.07.009
   Stefater JA, 2011, NATURE, V474, P511, DOI 10.1038/nature10085
   Sun Y, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa8695
   Sun Y, 2015, P NATL ACAD SCI USA, V112, P10401, DOI 10.1073/pnas.1504387112
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8
   Talia DM, 2016, ARTERIOSCL THROM VAS, V36, P1186, DOI 10.1161/ATVBAHA.115.307080
   Tomita M, 2004, STEM CELLS, V22, P21, DOI 10.1634/stemcells.22-1-21
   Ushiki T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162111
   Vahatupa M, 2018, EXP EYE RES, V166, P160, DOI 10.1016/j.exer.2017.10.013
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002
   Weischenfeldt Joachim, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot5080
   Wieghofer P, 2021, EMBO J, V40, DOI 10.15252/embj.2020105123
   Wieghofer P, 2015, GLIA, V63, P1, DOI 10.1002/glia.22727
   Wiejak J, 2013, BIOCHEM J, V454, P283, DOI 10.1042/BJ20130481
   Wu LH, 2016, MOL NEUROBIOL, V53, P1080, DOI 10.1007/s12035-014-9042-9
   Yan ZQ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126520
   Yang PZ, 1997, BRIT J OPHTHALMOL, V81, P396, DOI 10.1136/bjo.81.5.396
   Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938
   Zhao SK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193543
   Zhou JH, 2005, MOL VIS, V11, P414
NR 86
TC 2
Z9 2
U1 4
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD NOV
PY 2021
VL 73
AR 103632
DI 10.1016/j.ebiom.2021.103632
EA OCT 2021
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA WL8BJ
UT WOS:000710624100006
PM 34688035
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yiu, G
   Tieu, E
   Munevar, C
   Wong, B
   Cunefare, D
   Farsiu, S
   Garzel, L
   Roberts, J
   Thomasy, SM
AF Yiu, Glenn
   Tieu, Eric
   Munevar, Christian
   Wong, Brittany
   Cunefare, David
   Farsiu, Sina
   Garzel, Laura
   Roberts, Jeffrey
   Thomasy, Sara M.
TI In Vivo Multimodal Imaging of Drusenoid Lesions in Rhesus Macaques
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; AGE-RELATED MACULOPATHY; BASAL LAMINAR
   DRUSEN; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC
   ATROPHY; MACACA-MULATTA; EYE DISEASE; RETICULAR PSEUDODRUSEN;
   NATURAL-HISTORY
AB Nonhuman primates are the only mammals to possess a true macula similar to humans, and spontaneously develop drusenoid lesions which are hallmarks of age-related macular degeneration (AMD). Prior studies demonstrated similarities between human and nonhuman primate drusen based on clinical appearance and histopathology. Here, we employed fundus photography, spectral domain optical coherence tomography (SD-OCT), fundus autofluorescence (FAF), and infrared reflectance (IR) to characterize drusenoid lesions in aged rhesus macaques. Of 65 animals evaluated, we identified lesions in 20 animals (30.7%). Using the Age-Related Eye Disease Study 2 (AREDS2) grading system and multimodal imaging, we identified two distinct drusen phenotypes-1) soft drusen that are larger and appear as hyperreflective deposits between the retinal pigment epithelium (RPE) and Bruch's membrane on SD-OCT, and 2) hard, punctate lesions that are smaller and undetectable on SD-OCT. Both exhibit variable FAF intensities and are poorly visualized on IR. Eyes with drusen exhibited a slightly thicker RPE compared with control eyes (+3.4 mu m, P=0.012). Genetic polymorphisms associated with drusenoid lesions in rhesus monkeys in ARMS2 and HTRA1 were similar in frequency between the two phenotypes. These results refine our understanding of drusen development, and provide insight into the absence of advanced AMD in nonhuman primates.
C1 [Yiu, Glenn; Tieu, Eric] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Munevar, Christian; Roberts, Jeffrey; Thomasy, Sara M.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.
   [Wong, Brittany; Cunefare, David; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27706 USA.
   [Garzel, Laura; Roberts, Jeffrey] Calif Natl Primate Res Ctr, Davis, CA USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis; Duke
   University
RP Yiu, G (通讯作者)，Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
EM gyiu@ucdavis.edu
RI Yiu, Glenn/AAF-2858-2020
OI Yiu, Glenn/0000-0003-3061-3310; Wong, Brittany/0000-0002-0837-8492;
   Farsiu, Sina/0000-0003-4872-2902
FU California National Primate Research Center base grant [NIH
   P510D011107]; NIH [K08 EY026101, P30 EY005722, K08 EY021142]; E. Matilda
   Ziegler Foundation for the Blind; Alcon Research Institute; ARVO
   Foundation; Barr Foundation for Retinal Research; California National
   Primate Research Center; NATIONAL EYE INSTITUTE [K08EY026101,
   P30EY005722, K08EY021142] Funding Source: NIH RePORTER; OFFICE OF THE
   DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011107] Funding Source:
   NIH RePORTER
FX We thank Dr. Philip Kass at UC Davis School of Veterinary Medicine for
   input with statistical analyses. This study was supported by the
   California National Primate Research Center base grant NIH P510D011107.
   GY is supported by NIH K08 EY026101, the E. Matilda Ziegler Foundation
   for the Blind, Alcon Research Institute, ARVO Foundation, Barr
   Foundation for Retinal Research, and the California National Primate
   Research Center. SF is supported by NIH P30 EY005722. ST is supported by
   NIH K08 EY021142. No funding organizations had any role in the design or
   conduct of this research. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   funding agencies.
CR Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   [Anonymous], 1991, Ophthalmology, V98, P807
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Chiu SJ, 2012, BIOMED OPT EXPRESS, V3, P1127, DOI 10.1364/BOE.3.001127
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DAWSON WW, 1989, DOC OPHTHALMOL, V71, P253
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   ENGEL HM, 1988, OPHTHALMOLOGICA, V196, P143, DOI 10.1159/000309891
   Ersoy L, 2016, BRIT J OPHTHALMOL, V100, P1047, DOI 10.1136/bjophthalmol-2015-306806
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   FEENEYBURNS L, 1981, ARCH OPHTHALMOL-CHIC, V99, P664, DOI 10.1001/archopht.1981.03930010664013
   FINE BS, 1978, INVEST OPHTH VIS SCI, V17, P1059
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Frank R. N., 2000, T AM OPHTHALMOLOGICA, V98
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Heiferman MJ, 2015, RETINA-J RET VIT DIS, V35, P2593, DOI 10.1097/IAE.0000000000000666
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Jonas JB, 2000, INVEST OPHTH VIS SCI, V41, P2978
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   McGill TJ, 2016, INVEST OPHTH VIS SCI, V57, P1361, DOI 10.1167/iovs.15-18596
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neuringer M., 2016, ASS RES VIS OPHTH AN
   Nishiguchi KM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164899
   OLIN KL, 1995, P SOC EXP BIOL MED, V208, P370, DOI 10.3181/00379727-208-43864
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pahl L, 2012, EXP EYE RES, V98, P75, DOI 10.1016/j.exer.2012.03.007
   Pennesi ME, 2014, ADV EXP MED BIOL, V801, P309, DOI 10.1007/978-1-4614-3209-8_39
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Singh KK, 2005, EXP EYE RES, V81, P401, DOI 10.1016/j.exer.2005.02.011
   Singh KK, 2009, EXP EYE RES, V88, P479, DOI 10.1016/j.exer.2008.10.019
   Smith RT, 2016, INVEST OPHTH VIS SCI, V57, P6766, DOI 10.1167/iovs.16-21081
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Vuong VS, 2016, AM J OPHTHALMOL, V169, P104, DOI 10.1016/j.ajo.2016.06.023
   Writing Committee for the OPTOS PEripheral RetinA (OPERA) study (Ancillary Study of Age-Related Eye Disease Study 2), 2017, Ophthalmology, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yiu G., 2016, INVESTIGATIVE OPHTHA
   Yiu G, 2016, INVEST OPHTH VIS SCI, V57, P5764, DOI 10.1167/iovs.16-20070
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 64
TC 20
Z9 20
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 3
PY 2017
VL 7
AR 15013
DI 10.1038/s41598-017-14715-z
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FL7FM
UT WOS:000414412200001
PM 29101353
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Gupta, T
   Saini, N
   Arora, J
   Sahni, D
AF Gupta, Tulika
   Saini, Narbada
   Arora, Jasbir
   Sahni, Daisy
TI Age-Related Changes in the Chorioretinal Junction: An
   Immunohistochemical Study
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE Bruch's membrane; chorioretinal junction; lipofuscin; retinal pigment
   epithelium
ID BRUCHS MEMBRANE; LIPOFUSCIN; DRUSEN
AB The chorioretinal junction comprises the retinal pigment epithelium, Bruch's membrane (BM), and adjacent choroidal capillaries. Its significance lies in its ability to support the retina mechanically and metabolically. The aim of this cross-sectional study was to record the senescent changes affecting all the constituents of the chorioretinal junction in 40 histological specimens across the whole spectrum of the adult age range. This study included light microscopy, with hematoxylin and eosin and PAS stains, and fluorescent microscopy. Immunohistochemistry was done using antibodies against neurofilament, synaptophysin, S-100, and collagen IV. The descriptive microanatomy was corroborated by morphometry. The amount of melanin and lipofuscin granule and drusens were noted. The ratio of thickness of BM to capillary diameter reduced from 1:6 or less in the 2nd decade to 1:3 in the 10th decade. Complete hyalinization of intercapillary pillars was seen in the 10th decade. The accumulation of lipofuscin with age was documented with the diminution in the size of epithelial cells. The subepithelial accumulation of drusen was first noted in the specimen from the late 60s. We have described all senescent changes in the chorioretinal junction chronologically. Similar changes are found in a more pronounced form in age-related macular degeneration. These data might serve as a reference baseline for clinicians and pathologists.
C1 [Gupta, Tulika; Saini, Narbada; Arora, Jasbir; Sahni, Daisy] Postgrad Inst Med Educ & Res, Dept Anat, Chandigarh 160012, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh
RP Gupta, T (通讯作者)，Postgrad Inst Med Educ & Res, Dept Anat, Chandigarh 160012, India.
EM tulikag11@gmail.com
OI Saini, Narbada/0000-0002-3424-9272
CR BOK D, 1993, J CELL SCI, P189
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Cai H, 2006, CURR EYE RES, V31, P181, DOI 10.1080/02713680500514628
   COFFEY AJH, 1986, AM J OPHTHALMOL, V102, P164, DOI 10.1016/0002-9394(86)90138-8
   Cole EC, 1943, STAIN TECHNOL, V18, P125, DOI 10.3109/10520294309105804
   DESAI VN, 1995, ARCH OPHTHALMOL-CHIC, V113, P409, DOI 10.1001/archopht.1995.01100040023014
   Green WR, 1996, OPHTHALMIC PATHOLOGY, P667
   Grossniklaus HE, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12711
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661
   LISON L, 1954, STAIN TECHNOL, V29, P131, DOI 10.3109/10520295409115457
   Lutty G, 1999, MOL VIS, V5
   May CA, 2013, SCI WORLD J, DOI 10.1155/2013/378206
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Ross M. H., 2010, HISTOLOGY TEXT ATLAS
   Rymgayllo-Jankowska Beata, 2002, Klin Oczna, V104, P327
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmucker DL, 2002, ARCH GERONTOL GERIAT, V34, P249, DOI 10.1016/S0167-4943(01)00218-7
   Sun K, 2007, MOL VIS, V13, P2310
   Terman A, 2007, J PATHOL, V211, P134, DOI 10.1002/path.2094
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 27
TC 10
Z9 10
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
EI 1551-5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD OCT
PY 2017
VL 65
IS 10
BP 567
EP 577
DI 10.1369/0022155417726507
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FI2YX
UT WOS:000411821400001
PM 28813619
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Dasari, BC
   Cashman, SM
   Kumar-Singh, R
AF Dasari, Bhanu Chandar
   Cashman, Siobhan M.
   Kumar-Singh, Rajendra
TI Reducible PEG-POD/DNA Nanoparticles for Gene Transfer In Vitro and In
   Vivo: Application in a MouseModel of Age-RelatedMacular Degeneration
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID LEBERS CONGENITAL AMAUROSIS; RETINAL-PIGMENT EPITHELIUM; LASER
   PHOTOCOAGULATION; VISUAL FUNCTION; DELIVERY; THERAPY; VIRUS; AAV;
   NEOVASCULARIZATION; MECHANISMS
AB Non-viral gene delivery systems are being developed to address limitations of viral gene delivery. Many of these non-viral systems are modeled on the properties of viruses including cell surface binding, endocytosis, endosomal escape, and nuclear targeting. Most non-viral gene transfer systems exhibit little correlation between in vitro and in vivo efficiency, hampering a systematic approach to their development. Previously, we have described a 3.5 kDa peptide (peptide for ocular delivery [POD]) that targets cell surface sialic acid. When functionalized with polyethylene glycol (PEG) via a sulfhydryl group on the N-terminal cysteine of POD, PEG-POD could compact plasmid DNA, forming 120- to 180-nm homogeneous nanoparticles. PEG-POD enabled modest gene transfer and rescue of retinal degeneration in vivo. Systematic investigation of different stages of gene transfer by PEG-POD nanoparticles was hampered by their inability to deliver genes in vitro. Herein, we describe functionalization of POD with PEG using a reducible orthopyridyl disulfide bond. These reducible nanoparticles enabled gene transfer in vitro while retaining their in vivo gene transfer properties. These reducible PEG-POD nanoparticles were utilized to deliver human FLT1 to the retina in vivo, achieving a 50% reduction in choroidal neovascularization in a murine model of age-related macular degeneration.
C1 [Dasari, Bhanu Chandar; Cashman, Siobhan M.; Kumar-Singh, Rajendra] Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Dept Dev Mol & Chem Biol,Program Genet, 136 Harrison Ave, Boston, MA 02111 USA.
C3 Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Dept Dev Mol & Chem Biol,Program Genet, 136 Harrison Ave, Boston, MA 02111 USA.
EM rajendra.kumar-singh@tufts.edu
OI Kumar-Singh, Rajendra/0000-0002-7754-0713
FU National Institutes of Health/NEI [EY021805, EY013837]; Department of
   Defense/CDMRP [W81XWH-12-1-0374, W81XWH-16-1-0650]; Ellison Foundation;
   Paul and Phyllis Fireman Foundation; NATIONAL EYE INSTITUTE
   [R01EY021805, R01EY013837] Funding Source: NIH RePORTER
FX This study was supported by grants to R.K.-S. from the National
   Institutes of Health/NEI (EY021805 and EY013837), the Department of
   Defense/CDMRP (W81XWH-12-1-0374 and W81XWH-16-1-0650), The Ellison
   Foundation, and The Paul and Phyllis Fireman Foundation. We wish to
   thank Dr. Srinivas Sridhar and Dr. Rajiv Kumar (Northeastern University)
   for providing access to a Zetasizer for these studies.
CR Aguilar E, 2008, METHOD ENZYMOL, V444, P115, DOI 10.1016/S0076-6879(08)02806-1
   Ahmed A, 2000, PLACENTA, V21, pS16, DOI 10.1053/plac.1999.0524
   Alley SC, 2008, BIOCONJUGATE CHEM, V19, P759, DOI 10.1021/bc7004329
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   BAUER WR, 1980, SCI AM, V243, P118
   Binder C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082295
   Breunig M, 2007, P NATL ACAD SCI USA, V104, P14454, DOI 10.1073/pnas.0703882104
   Bryant LM, 2013, HUM GENE THER CL DEV, V24, P55, DOI 10.1089/humc.2013.087
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Chamberlain K, 2016, HUM GENE THER METHOD, V27, P1, DOI 10.1089/hgtb.2015.140
   Chancham P, 2001, J LIPOSOME RES, V11, P139, DOI 10.1081/LPR-100108458
   Chandler RJ, 2015, J CLIN INVEST, V125, P870, DOI 10.1172/JCI79213
   Dhanoya A, 2011, J BIOTECHNOL, V155, P377, DOI 10.1016/j.jbiotec.2011.07.023
   Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038
   Han JW, 2015, INVEST OPHTH VIS SCI, V56, P8314, DOI 10.1167/iovs.15-18359
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Ishida T, 2001, BBA-BIOMEMBRANES, V1515, P144, DOI 10.1016/S0005-2736(01)00409-6
   Johnson LN, 2008, MOL THER, V16, P107, DOI 10.1038/sj.mt.6300324
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lee SH, 2015, INVEST OPHTH VIS SCI, V56, P2696, DOI 10.1167/iovs.14-16112
   Lei Y, 2013, J GENE MED, V15, P291, DOI 10.1002/jgm.2726
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100
   Mingozzi F, 2011, CURR GENE THER, V11, P321, DOI 10.2174/156652311796150354
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046
   Ni R, 2016, ADV DRUG DELIVER REV, V106, P3, DOI 10.1016/j.addr.2016.07.005
   Patel VR, 2011, J ADV PHARM TECHNOL, V2, P81, DOI 10.4103/2231-4040.82950
   Read SP, 2010, MOL THER, V18, P1917, DOI 10.1038/mt.2010.167
   Read SP, 2010, J GENE MED, V12, P86, DOI 10.1002/jgm.1415
   Rettig GR, 2007, EXPERT OPIN BIOL TH, V7, P799, DOI 10.1517/14712598.7.6.799
   Romberg B, 2008, PHARM RES, V25, P55, DOI 10.1007/s11095-007-9348-7
   Samulski RJ, 2014, ANNU REV VIROL, V1, P427, DOI 10.1146/annurev-virology-031413-085355
   Schuster BS, 2015, ADV DRUG DELIVER REV, V91, P70, DOI 10.1016/j.addr.2015.03.017
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suk JS, 2016, ADV DRUG DELIVER REV, V99, P28, DOI 10.1016/j.addr.2015.09.012
   Sun WC, 2010, J CONTROL RELEASE, V146, P118, DOI 10.1016/j.jconrel.2010.04.031
   van Gaal EVB, 2011, J CONTROL RELEASE, V154, P218, DOI 10.1016/j.jconrel.2011.05.001
   Vercauteren D, 2012, J CONTROL RELEASE, V161, P566, DOI 10.1016/j.jconrel.2012.05.020
   Visentini J, 1989, Rapid Commun Mass Spectrom, V3, P390, DOI 10.1002/rcm.1290031105
   Wang LJ, 2011, METHODS MOL BIOL, V807, P361, DOI 10.1007/978-1-61779-370-7_16
   Watson WH, 2016, REDOX BIOL, V8, P305, DOI 10.1016/j.redox.2016.02.005
   Yang S, 2015, DISCOV MED, V20, P207
NR 46
TC 13
Z9 13
U1 1
U2 33
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD SEP 15
PY 2017
VL 8
BP 77
EP 89
DI 10.1016/j.omtn.2017.06.004
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EY6DS
UT WOS:000404073300004
PM 28918058
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Qi, XP
   Pay, SL
   Yan, YQ
   Thomas, J
   Lewin, AS
   Chang, LJ
   Grant, MB
   Boulton, ME
AF Qi, Xiaoping
   Pay, S. Louise
   Yan, Yuanqing
   Thomas, James, Jr.
   Lewin, Alfred S.
   Chang, Lung-Ji
   Grant, Maria B.
   Boulton, Michael E.
TI Systemic Injection of RPE65-Programmed Bone Marrow-Derived Cells
   Prevents Progression of Chronic Retinal Degeneration
SO MOLECULAR THERAPY
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; MOUSE MODEL; RPE TRANSPLANTATION; PIGMENT
   EPITHELIUM; PERIPHERAL-BLOOD; OXIDATIVE STRESS; PURKINJE NEURONS;
   IN-VIVO; FUSION; LIVER
AB Bone marrow stem and progenitor cells can differentiate into a range of non-hematopoietic cell types, including retinal pigment epithelium (RPE)-like cells. In this study, we programmed bone marrow-derived cells (BMDCs) ex vivo by inserting a stable RPE65 transgene using a lentiviral vector. We tested the efficacy of systemically administered RPE65-programmed BMDCs to prevent visual loss in the superoxide dismutase 2 knockdown (Sod2 KD) mouse model of age-related macular degeneration. Here, we present evidence that these RPE65-programmed BMDCs are recruited to the subretinal space, where they repopulate the RPE layer, preserve the photoreceptor layer, retain the thickness of the neural retina, reduce lipofuscin granule formation, and suppress microgliosis. Importantly, electroretinography and optokinetic response tests confirmed that visual function was significantly improved. Mice treated with non-modified BMDCs or BMDCs pre-programmed with LacZ did not exhibit significant improvement in visual deficit. RPE65-BMDC administration was most effective in early disease, when visual function and retinal morphology returned to near normal, and less effective in late-stage disease. This experimental paradigm offers a minimally invasive cellular therapy that can be given systemically overcoming the need for invasive ocular surgery and offering the potential to arrest progression in early AMD and other RPE-based diseases.
C1 [Qi, Xiaoping; Pay, S. Louise; Grant, Maria B.; Boulton, Michael E.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Qi, Xiaoping] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Yan, Yuanqing] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA.
   [Thomas, James, Jr.; Lewin, Alfred S.; Chang, Lung-Ji] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida
RP Boulton, ME (通讯作者)，Indiana Univ Sch Med, Dept Ophthalmol, 980 Walnut St,R3-426A, Indianapolis, IN 46202 USA.
EM mboulton@iupui.edu
OI Lewin, Alfred/0000-0002-4192-9727
FU NIH [EY023629]; BrightFocus [M2009024]; National Eye Institute [P30
   EY02172]; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [R01EY023629] Funding Source: NIH RePORTER
FX This research was supported by the NIH (EY023629), BrightFocus
   (M2009024), an unrestricted grant from Research to Prevent Blindness,
   and a National Eye Institute core grant to the University of Florida
   (P30 EY02172).
CR Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Avots A, 2002, IMMUNOL REV, V187, P9, DOI 10.1034/j.1600-065X.2002.18702.x
   Bae JS, 2005, HUM GENE THER, V16, P1006, DOI 10.1089/hum.2005.16.1006
   Bazan NG, 2008, ADV EXP MED BIOL, V613, P39
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Boulton M E., 2016, FUNDUS AUTOFLUORESCE, P3
   Boulton ME, 2004, OPHTHALMOLOGE, V101, P877
   Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chan-Ling T, 2006, AM J PATHOL, V168, P1031, DOI 10.2353/ajpath.2006.050697
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Dawn B, 2005, BASIC RES CARDIOL, V100, P494, DOI 10.1007/s00395-005-0552-5
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080
   El-Mandi MM, 2014, KOREAN J PARASITOL, V52, P151, DOI 10.3347/kjp.2014.52.2.151
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Howell JC, 2003, ANN NY ACAD SCI, V996, P158, DOI 10.1111/j.1749-6632.2003.tb03244.x
   Iskovich S, 2012, STEM CELLS DEV, V21, P86, DOI 10.1089/scd.2011.0057
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kucia M, 2004, CIRC RES, V95, P1191, DOI 10.1161/01.RES.0000150856.47324.5b
   Kucia M, 2004, BLOOD CELL MOL DIS, V32, P52, DOI 10.1016/j.bcmd.2003.09.025
   Marquez-Curtis LA, 2011, STEM CELL REV REP, V7, P590, DOI 10.1007/s12015-010-9212-8
   Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779
   Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040
   Okonogi N, 2014, J RADIAT RES, V55, P713, DOI 10.1093/jrr/rru015
   Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587
   Ratajczak MZ, 2004, LEUKEMIA, V18, P29, DOI 10.1038/sj.leu.2403184
   Rowland TJ, 2012, J CELL PHYSIOL, V227, P457, DOI 10.1002/jcp.22814
   Sengupta N, 2009, MOL THER, V17, P1594, DOI 10.1038/mt.2009.145
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124
   Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Treleaven J., 2009, HEMATOPOIETIC STEM C
   Vassilopoulos G, 2003, CURR OPIN GENET DEV, V13, P480, DOI 10.1016/S0959-437X(03)00110-2
   Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531
   Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326
NR 48
TC 15
Z9 15
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD APR 5
PY 2017
VL 25
IS 4
BP 917
EP 927
DI 10.1016/j.ymthe.2017.01.015
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA ER5YC
UT WOS:000398879500011
PM 28202390
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Goutham, G
   Manikandan, R
   Beulaja, M
   Thiagarajan, R
   Arulvasu, C
   Arumugam, M
   Setzer, WN
   Daglia, M
   Nabavi, SF
   Nabavi, SM
AF Goutham, Ganesh
   Manikandan, Ramar
   Beulaja, Manikandan
   Thiagarajan, Raman
   Arulvasu, Chinnasamy
   Arumugam, Munusamy
   Setzer, William N.
   Daglia, Maria
   Nabavi, Seyed Fazel
   Nabavi, Seyed Mohammad
TI A focus on resveratrol and ocular problems, especially cataract: From
   chemistry to medical uses and clinical relevance
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Cataracts; Resveratrol; Ocular diseases; Phytochemicals
ID INDUCED OXIDATIVE STRESS; NATURAL-PRODUCT PRESENT; LENS
   EPITHELIAL-CELLS; TRANS-RESVERATROL; CIS-RESVERATROL; HUMAN LIVER;
   POLY(ADP-RIBOSE) POLYMERASE; ANTIOXIDANT PROPERTIES; INDUCED-APOPTOSIS;
   ORTHO-TYROSINE
AB Low vision and blindness are important health problems that affect millions of people throughout the world. The most common and important pathologies are diabetic retinopathy, age-related macular degeneration, glaucoma as well as cataracts. The latter consists of an opacification of the lens of the eye which impedes the passage of light and represents one of the most important causes of vision loss. Among the risk factors for cataract development, there are life-style factors such as the use of tobacco, abuse of alcohol and unhealthy diet. In light of this, dietary components that possess anti-oxidant activity, such as polyphenols for instance, can be considered good candidates for human studies in the prevention and or treatment of such diseases. Among dietary components, the antioxidant capacity of certain polyphenols is well known, and these could be good candidates. In this review we focus our attention on the current scientific literature regarding to the effects of resveratrol on cataracts and other ocular diseases, along with its potential mechanism/s of action. A large number of preclinical studies support the involvement of resveratrol in clinical trials for the prevention and treatment of eye diseases induced by oxidative stress and inflammation, such as age-related cataract. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Goutham, Ganesh; Manikandan, Ramar; Arulvasu, Chinnasamy; Arumugam, Munusamy] Univ Madras, Dept Zool, Guindy Campus, Madras 600025, Tamil Nadu, India.
   [Beulaja, Manikandan] Annai Veilakkannis Coll Women, Dept Biochem, Madras 60015, Tamil Nadu, India.
   [Thiagarajan, Raman] SASTRA Univ, Sch Chem Sci & Biotechnol, Thanjavur, India.
   [Setzer, William N.] Univ Alabama, Dept Chem, Huntsville, AL 35899 USA.
   [Daglia, Maria] Univ Pavia, Med Chem & Pharmaceut Technol Sect, Dept Drug Sci, I-27100 Pavia, Italy.
   [Nabavi, Seyed Fazel; Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran.
C3 University of Madras; Shanmugha Arts, Science, Technology & Research
   Academy (SASTRA); University of Alabama System; University of Alabama
   Huntsville; University of Pavia; Baqiyatallah University of Medical
   Sciences (BMSU)
RP Manikandan, R (通讯作者)，Univ Madras, Dept Zool, Guindy Campus, Madras 600025, Tamil Nadu, India.; Thiagarajan, R (通讯作者)，SASTRA Univ, Sch Chem Sci & Biotechnol, Thanjavur, India.; Nabavi, SM (通讯作者)，Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran, Iran.
EM manikandanramar@yahoo.co.in; thiagi200@yahoo.co.in; Nabavi208@gmail.com
RI Raman, Thiagarajan/AAP-6638-2021; Daglia, Maria/AAC-9498-2019; nabavi,
   seyed fazel/A-2223-2010; Nabavi, Seyed Mohammad/G-5335-2010
OI Nabavi, Seyed Mohammad/0000-0001-8859-5675
FU UGC-UPE-Phase II programme; Science and Engineering Research Board
   (SERB), Government of India [SERB/F/1266/2012-13, EMR/2015/000648]
FX MA would like to thank UGC-UPE-Phase II programme for its financial
   support. TR would like to thank the Science and Engineering Research
   Board (SERB), Government of India, (SERB/F/1266/2012-13, dated 31st May
   2012 and File No. EMR/2015/000648, dated 31 May 2016) for financial
   support.
CR Abbott JA, 2010, BIOTECHNOL PROGR, V26, P1344, DOI 10.1002/btpr.454
   Adrian M, 2000, J AGR FOOD CHEM, V48, P6103, DOI 10.1021/jf0009910
   Antosova B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078279
   Aumont V, 2001, ARCH BIOCHEM BIOPHYS, V393, P281, DOI 10.1006/abbi.2001.2496
   Bao XL, 2012, MOL VIS, V18, P1983
   Bode LM, 2013, AM J CLIN NUTR, V97, P295, DOI 10.3945/ajcn.112.049379
   Bonnin N, 2014, ACTA OPHTHALMOL, V92, pE366, DOI 10.1111/aos.12365
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Bosch-Preseguee L, 2015, FEBS J, V282, P1745, DOI 10.1111/febs.13053
   Brill SS, 2006, J PHARM PHARMACOL, V58, P469, DOI 10.1211/jpp.58.4.0006
   Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637
   Burns J, 2002, J AGR FOOD CHEM, V50, P3337, DOI 10.1021/jf0112973
   Buttari B, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/574029
   Cain S, 2008, DEV BIOL, V321, P420, DOI 10.1016/j.ydbio.2008.07.002
   Camont L, 2009, ANAL CHIM ACTA, V634, P121, DOI 10.1016/j.aca.2008.12.003
   Canto C, 2013, MOL ASPECTS MED, V34, P1168, DOI 10.1016/j.mam.2013.01.004
   Canto C, 2011, AGING-US, V3, P543, DOI 10.18632/aging.100326
   Cao DF, 2015, GENE DEV, V29, P1316, DOI 10.1101/gad.265462.115
   Careri M, 2003, J AGR FOOD CHEM, V51, P5226, DOI 10.1021/jf034149g
   Chen WM, 2016, EXP THER MED, V11, P1231, DOI 10.3892/etm.2016.3077
   Chen YJ, 2008, DEV BIOL, V324, P161, DOI 10.1016/j.ydbio.2008.09.002
   Chitchumroonchokchai C, 2004, J NUTR, V134, P3225, DOI 10.1093/jn/134.12.3225
   Chong CCW, 2009, EXP EYE RES, V88, P307, DOI 10.1016/j.exer.2008.07.018
   Corduneanu O, 2006, ELECTROANAL, V18, P757, DOI 10.1002/elan.200503469
   Counet C, 2006, FOOD CHEM, V98, P649, DOI 10.1016/j.foodchem.2005.06.030
   Das Gupta P, 2004, ACTA PHARMACOL SIN, V25, P1250
   De Santi C, 2000, XENOBIOTICA, V30, P609, DOI 10.1080/004982500406435
   De Santi C, 2000, XENOBIOTICA, V30, P857, DOI 10.1080/004982500433282
   De Santi C, 2000, XENOBIOTICA, V30, P1047, DOI 10.1080/00498250010002487
   Deby-Dupont G, 2005, BIOCHEM BIOPH RES CO, V333, P21, DOI 10.1016/j.bbrc.2005.05.073
   Doganay S, 2006, CURR EYE RES, V31, P147, DOI 10.1080/02713680500514685
   Dourtoglou Vassilis G., 1999, Journal of Food Composition and Analysis, V12, P227, DOI 10.1006/jfca.1999.0821
   Ector BJ, 1996, AM J ENOL VITICULT, V47, P57
   Juan ME, 2010, J PHARMACEUT BIOMED, V51, P391, DOI 10.1016/j.jpba.2009.03.026
   Eren MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124837
   Ford CT, 2016, BRIT J NUTR, V115, P1699, DOI 10.1017/S0007114516000805
   Francioso A, 2014, J ORG CHEM, V79, P9381, DOI 10.1021/jo501405m
   Fraser Christopher M, 2011, Arabidopsis Book, V9, pe0152, DOI 10.1199/tab.0152
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Glasser A, 1998, VISION RES, V38, P209, DOI 10.1016/S0042-6989(97)00102-8
   Gulcin I, 2010, INNOV FOOD SCI EMERG, V11, P210, DOI 10.1016/j.ifset.2009.07.002
   Halls C, 2008, TRENDS BIOTECHNOL, V26, P77, DOI 10.1016/j.tibtech.2007.11.002
   Han SY, 2013, J NUTR, V143, P632, DOI 10.3945/jn.112.173302
   INGHAM JL, 1976, PHYTOCHEMISTRY, V15, P1791, DOI 10.1016/S0031-9422(00)97494-6
   Ipson BR, 2016, AGEING RES REV, V27, P93, DOI 10.1016/j.arr.2016.03.005
   Ishikawa K, 2015, SCI REP-UK, V5, DOI 10.1038/srep16386
   Ji YH, 2015, MOL CELL BIOCHEM, V401, P87, DOI 10.1007/s11010-014-2294-x
   Kokkola T, 2015, CHEMBIOCHEM, V16, P1997, DOI 10.1002/cbic.201500272
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Kubota M, 2016, FREE RADICAL BIO MED, V97, P513, DOI 10.1016/j.freeradbiomed.2016.07.016
   Kubota S, 2009, INVEST OPHTH VIS SCI, V50, P3512, DOI 10.1167/iovs.08-2666
   Kuhnle G, 2000, BIOCHEM BIOPH RES CO, V272, P212, DOI 10.1006/bbrc.2000.2750
   Kulkarni SS, 2015, BBA-MOL BASIS DIS, V1852, P1114, DOI 10.1016/j.bbadis.2014.10.005
   Lerman S., 1990, LENS EYE TOX RES, V8, P121
   Leske MC, 1998, OPHTHALMOLOGY, V105, P831, DOI 10.1016/S0161-6420(98)95021-7
   Li GR, 2011, INVEST OPHTH VIS SCI, V52, P4395, DOI 10.1167/iovs.10-6652
   Li P, 2015, J TOXICOL SCI, V40, P615, DOI 10.2131/jts.40.615
   Li X, 2016, NAT IMMUNOL, V17, P806, DOI 10.1038/ni.3464
   Luan ZG, 2010, IMMUNOBIOLOGY, V215, P956, DOI 10.1016/j.imbio.2009.11.001
   Luna C, 2009, FOOD CHEM TOXICOL, V47, P198, DOI 10.1016/j.fct.2008.10.029
   Malhotra A, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/803971
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Miksits M, 2005, XENOBIOTICA, V35, P1101, DOI 10.1080/00498250500354253
   Mikulski D, 2010, J MOL STRUC-THEOCHEM, V951, P37, DOI 10.1016/j.theochem.2010.04.005
   Mikulski D, 2010, EUR J MED CHEM, V45, P1015, DOI 10.1016/j.ejmech.2009.11.044
   Minagawa T, 2015, J PERIODONTAL RES, V50, P586, DOI 10.1111/jre.12238
   Moffat BA, 2002, OPTOMETRY VISION SCI, V79, P148, DOI 10.1097/00006324-200203000-00008
   Molnar GA, 2005, FREE RADICAL RES, V39, P1359, DOI 10.1080/10715760500307107
   Nagai N, 2014, J NUTR BIOCHEM, V25, P1218, DOI 10.1016/j.jnutbio.2014.05.015
   North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224
   Oh YC, 2009, AM J CHINESE MED, V37, P1203, DOI 10.1142/S0192415X09007600
   Orallo F, 2006, CURR MED CHEM, V13, P87, DOI 10.2174/092986706775197953
   Peng W, 2016, CHEM PHARM BULL, V64, P609, DOI 10.1248/cpb.c16-00030
   Pinto MD, 2003, J AGR FOOD CHEM, V51, P1653, DOI 10.1021/jf025818d
   Queiroz AN, 2009, EUR J MED CHEM, V44, P1644, DOI 10.1016/j.ejmech.2008.09.023
   Rajamohan SB, 2009, MOL CELL BIOL, V29, P4116, DOI 10.1128/MCB.00121-09
   Sabolovic N, 2006, BIOPHARM DRUG DISPOS, V27, P181, DOI 10.1002/bdd.498
   Sergides C, 2016, EXP THER MED, V11, P164, DOI 10.3892/etm.2015.2895
   Shen HJ, 2015, INT J CLIN EXP PATHO, V8, P12589
   Sheu SJ, 2010, J OCUL PHARMACOL TH, V26, P231, DOI 10.1089/jop.2009.0137
   Shrikanta A, 2015, J FOOD SCI TECH MYS, V52, P383, DOI 10.1007/s13197-013-0993-z
   SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49
   Soares DG, 2003, J AGR FOOD CHEM, V51, P1077, DOI 10.1021/jf020864z
   Sobolev VS, 1999, J AGR FOOD CHEM, V47, P1435, DOI 10.1021/jf9809885
   Stojanovic S, 2001, ARCH BIOCHEM BIOPHYS, V391, P79, DOI 10.1006/abbi.2001.2388
   Szewczuk LM, 2005, J NAT PROD, V68, P36, DOI 10.1021/np049702i
   Vasamsetti SB, 2016, FREE RADICAL BIO MED, V96, P392, DOI 10.1016/j.freeradbiomed.2016.05.003
   Villano D, 2007, TALANTA, V71, P230, DOI 10.1016/j.talanta.2006.03.050
   Vitaglione P, 2005, MOL NUTR FOOD RES, V49, P495, DOI 10.1002/mnfr.200500002
   Vogt T, 2010, MOL PLANT, V3, P2, DOI 10.1093/mp/ssp106
   Walle T, 2004, DRUG METAB DISPOS, V32, P1377, DOI 10.1124/dmd.104.000885
   Wang DG, 2005, J CHROMATOGR B, V829, P97, DOI 10.1016/j.jchromb.2005.09.040
   Wang Xiaoyi, 2015, MATH PROBL ENG, V2015, P1, DOI DOI 10.1016/J.CMET.2015.09.010
   Wang Y, 2002, J AGR FOOD CHEM, V50, P431, DOI 10.1021/jf010812u
   Wang Y, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0229-y
   Wenzel E, 2005, MOL NUTR FOOD RES, V49, P472, DOI 10.1002/mnfr.200500010
   Willenberg I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139147
   Xu W, 2015, CLIN EXP PHARMACOL P, V42, P1075, DOI 10.1111/1440-1681.12459
   Yu CW, 2002, PHARM RES-DORDR, V19, P1907, DOI 10.1023/A:1021414129280
   Zeng WJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16013
   Zhang YL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7589813
   Zhang ZM, 2013, J FOOD AGRIC ENVIRON, V11, P278
   Zheng TY, 2016, CURR EYE RES, V41, P1068, DOI 10.3109/02713683.2015.1093641
   Zheng Y, 2010, MOL VIS, V16, P1467
NR 105
TC 21
Z9 22
U1 0
U2 21
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2017
VL 86
BP 232
EP 241
DI 10.1016/j.biopha.2016.11.141
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EM7WU
UT WOS:000395523800031
PM 28006748
DA 2022-11-30
ER

PT J
AU Wang, T
   Ji, ZX
   Sun, QS
   Chen, Q
   Yu, SC
   Fan, W
   Yuan, ST
   Liu, QH
AF Wang, Tao
   Ji, Zexuan
   Sun, Quansen
   Chen, Qiang
   Yu, Shengchen
   Fan, Wen
   Yuan, Songtao
   Liu, Qinghuai
TI Label propagation and higher-order constraint-based segmentation of
   fluid-associated regions in retinal SD-OCT images
SO INFORMATION SCIENCES
LA English
DT Article
DE Spectral domain optical coherence tomography; Retina segmentation; Graph
   cuts; Higher-order information; Motion estimation; Label propagation
ID OPTICAL COHERENCE TOMOGRAPHY; ENERGY MINIMIZATION; SUBRETINAL FLUID;
   ALGORITHM; SUPERPIXELS
AB The segmentation of the fluid-associated region in the retina plays an important role in the treatment of retinal diseases, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). The existing methods for the detection of the fluid region generally suffer from the limitation of the segmentation accuracy and the expensive time costs. To overcome these problems, in this paper, we propose an interactive segmentation method for the fluid-associated region in three-dimensional (3-D) spectral domain optical coherence tomography (SD-OCT) retinal imaging, in which only a few seeds in one SD-OCT slice are needed, after which the algorithm finishes the segmentation automatically. To improve the segmentation accuracy, the higher-order constraint is introduced into the conventional Markov random field (MRF) framework to impose the superpixel consistency. To maintain temporal coherence of the 3-D SD-OCT slices, the labeling information is propagated slice by slice via a proposed motion-estimation-based algorithm. The proposed higher-order based energy function can be efficiently solved by the max flow algorithm on a specified graph with several auxiliary nodes. Experiments on 28 SD-OCT cubes demonstrate the competitiveness of the proposed method compared with the state-of-the-art methods. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Wang, Tao; Ji, Zexuan; Sun, Quansen; Chen, Qiang; Yu, Shengchen] Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, Nanjing, Jiangsu, Peoples R China.
   [Fan, Wen; Yuan, Songtao; Liu, Qinghuai] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing University of Science & Technology; Nanjing Medical University
RP Sun, QS; Chen, Q (通讯作者)，Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, Nanjing, Jiangsu, Peoples R China.
EM 670101389@qq.com; sunquansen@njust.edu.cn; chen2qiang@163.com
RI chen, qiang/GWZ-7308-2022
FU Graduate Innovation Project of Jiangsu Province [KYZZ15_0125]; six
   talent peaks project in Jiangsu Province [2014-SWXY-024]; fundamental
   Research Funds for the Central Universities [30920140111004]; National
   Science Foundation of China [61401209, 61273251]; Natural Science
   Foundation of Jiangsu Province, China [BK20140790]; China Postdoctoral
   Science Foundation [2014T70525, 2013M531364]
FX This work was supported in part by the Graduate Innovation Project of
   Jiangsu Province under Grants KYZZ15_0125, in part by the six talent
   peaks project in Jiangsu Province under Grant 2014-SWXY-024, in part by
   the fundamental Research Funds for the Central Universities under Grant
   30920140111004, in part by the National Science Foundation of China
   under Grants 61401209 and 61273251, in part by the Natural Science
   Foundation of Jiangsu Province, China under Grant BK20140790, and in
   part by China Postdoctoral Science Foundation under Grants 2014T70525 &
   2013M531364.
CR Arbelaez P, 2008, PROC CVPR IEEE, P1158
   Arya S, 1998, J ACM, V45, P891, DOI 10.1145/293347.293348
   Bai XF, 2007, IEEE IC COMP COM NET, P1
   Blake A, 2004, LECT NOTES COMPUT SC, V3021, P428
   Bogunovic H., 2014, MICCAI WORKSH OPHTH, P129, DOI DOI 10.17077/OMIA.1018
   Boykov Y, 2001, IEEE T PATTERN ANAL, V23, P1222, DOI 10.1109/34.969114
   Boykov Y, 2004, IEEE T PATTERN ANAL, V26, P1124, DOI 10.1109/TPAMI.2004.60
   Boykov Y, 2006, INT J COMPUT VISION, V70, P109, DOI 10.1007/s11263-006-7934-5
   Boykov YY, 2001, EIGHTH IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION, VOL I, PROCEEDINGS, P105, DOI 10.1109/ICCV.2001.937505
   Bruhn A, 2005, INT J COMPUT VISION, V61, P211
   Buades A, 2005, PROC CVPR IEEE, P60, DOI 10.1109/cvpr.2005.38
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chung CY, 2010, IEEE T CIRC SYST VID, V20, P149, DOI 10.1109/TCSVT.2009.2026823
   Comaniciu D, 2002, IEEE T PATTERN ANAL, V24, P603, DOI 10.1109/34.1000236
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Du B, 2014, IEEE T GEOSCI REMOTE, V52, P6844, DOI 10.1109/TGRS.2014.2303895
   Fabijanska A, 2015, IEEE T IMAGE PROCESS, V24, DOI 10.1109/TIP.2014.2383323
   Fang LY, 2012, BIOMED OPT EXPRESS, V3, P927, DOI 10.1364/BOE.3.000927
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Fujimoto JG, 2000, NEOPLASIA, V2, P9, DOI 10.1038/sj.neo.7900071
   Gargesha M, 2008, OPT EXPRESS, V16, P12313, DOI 10.1364/OE.16.012313
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gong MG, 2015, INFORM SCIENCES, V293, P351, DOI 10.1016/j.ins.2014.09.023
   Grady L, 2006, IEEE T PATTERN ANAL, V28, P1768, DOI 10.1109/TPAMI.2006.233
   Han SD, 2009, IEEE T IMAGE PROCESS, V18, P2289, DOI 10.1109/TIP.2009.2025560
   He P, 2014, PATTERN RECOGN, V47, P820, DOI 10.1016/j.patcog.2013.07.023
   He XM, 2006, LECT NOTES COMPUT SC, V3951, P338
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang QH, 2015, INFORM SCIENCES, V314, P293, DOI 10.1016/j.ins.2014.08.021
   Ji ZX, 2015, INFORM SCIENCES, V301, P285, DOI 10.1016/j.ins.2015.01.006
   Ji ZX, 2014, PATTERN RECOGN, V47, P2454, DOI 10.1016/j.patcog.2014.01.017
   Ju W, 2015, IEEE T IMAGE PROCESS, V24, DOI 10.1109/TIP.2015.2488902
   Kim TH, 2013, IEEE T PATTERN ANAL, V35, P1690, DOI 10.1109/TPAMI.2012.237
   Kim TH, 2010, PROC CVPR IEEE, P3201, DOI 10.1109/CVPR.2010.5540078
   Kohli P., 2007, P IEEE C COMP VIS PA, P1
   Kohli P, 2009, INT J COMPUT VISION, V82, P302, DOI 10.1007/s11263-008-0202-0
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee K.M., 2009, THESIS U IOWA
   Li J., 2014, ARTIF INTELL RES, V3
   Li Y, 2004, ACM T GRAPHIC, V23, P303, DOI 10.1145/1015706.1015719
   Li ZG, 2012, PROC CVPR IEEE, P789, DOI [10.1109/ISRA.2012.6219309, 10.1109/CVPR.2012.6247750]
   Liu C, 2008, LECT NOTES COMPUT SC, V5304, P28, DOI 10.1007/978-3-540-88690-7_3
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Pathak D, 2015, IEEE I CONF COMP VIS, P1796, DOI 10.1109/ICCV.2015.209
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rabinovich A., 2006, P IEEE C COMP VIS PA, P1130
   Rogowska J, 2000, IEEE T MED IMAGING, V19, P1261, DOI 10.1109/42.897820
   Rother C, 2004, ACM T GRAPHIC, V23, P309, DOI 10.1145/1015706.1015720
   Shen JB, 2014, IEEE T IMAGE PROCESS, V23, P1451, DOI 10.1109/TIP.2014.2302892
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Tao WB, 2014, INFORM SCIENCES, V281, P373, DOI 10.1016/j.ins.2014.05.032
   Thomas D, 2004, EYE, V18, P561, DOI 10.1038/sj.eye.6700729
   Wang T, 2016, PATTERN RECOGN, V55, P28, DOI 10.1016/j.patcog.2016.01.018
   Wang T, 2015, J VIS COMMUN IMAGE R, V33, P10, DOI 10.1016/j.jvcir.2015.08.013
   Wang T, 2015, NEUROCOMPUTING, V158, P13, DOI 10.1016/j.neucom.2015.02.010
   Wang TH, 2012, IEEE T MULTIMEDIA, V14, P389, DOI 10.1109/TMM.2011.2177078
   Wang TH, 2010, IEEE IMAGE PROC, P3005, DOI 10.1109/ICIP.2010.5649291
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wu JJ, 2014, PROC CVPR IEEE, P256, DOI 10.1109/CVPR.2014.40
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yang SY, 2014, INFORM SCIENCES, V269, P48, DOI 10.1016/j.ins.2014.01.023
   Yang WX, 2010, IEEE T IMAGE PROCESS, V19, P2470, DOI 10.1109/TIP.2010.2048611
   Yu J, 2014, INFORM SCIENCES, V281, P674, DOI 10.1016/j.ins.2014.01.025
   Yu J, 2014, IEEE T CYBERNETICS, V44, P2431, DOI 10.1109/TCYB.2014.2307862
   Yu J, 2012, IEEE T IMAGE PROCESS, V21, P3262, DOI 10.1109/TIP.2012.2190083
   Zhang LF, 2015, PATTERN RECOGN, V48, P3102, DOI 10.1016/j.patcog.2014.12.016
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
   Zhou HL, 2013, PATTERN RECOGN, V46, P1719, DOI 10.1016/j.patcog.2012.12.005
NR 71
TC 33
Z9 35
U1 2
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0020-0255
EI 1872-6291
J9 INFORM SCIENCES
JI Inf. Sci.
PD SEP 1
PY 2016
VL 358
BP 92
EP 111
DI 10.1016/j.ins.2016.04.017
PG 20
WC Computer Science, Information Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA DN8IN
UT WOS:000377322500007
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhu, Y
   Zhao, KK
   Tong, Y
   Zhou, YL
   Wang, YX
   Zhao, PQ
   Wang, ZY
AF Zhu, Ying
   Zhao, Ke-ke
   Tong, Yao
   Zhou, Ya-li
   Wang, Yi-xiao
   Zhao, Pei-quan
   Wang, Zhao-yang
TI Exogenous NAD(+) decreases oxidative stress and protects H2O2-treated
   RPE cells against necrotic death through the up-regulation of autophagy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; LIGHT-INDUCED PHOTORECEPTOR; MACULAR
   DEGENERATION; HYDROGEN-PEROXIDE; DNA-DAMAGE; ACTIVATION; PREVALENCE;
   MECHANISM; APOPTOSIS; MITOCHONDRIA
AB Increased oxidative stress, which can lead to the retinal pigment epithelium (RPE) cell death by inducing ATP depletion and DNA repair, is believed to be a prominent pathology in age-related macular degeneration (AMD). In the present study, we showed that and 0.1 mM nicotinamide adenine dinucleotide (NAD(+)) administration significantly blocked RPE cell death induced by 300 mu M H2O2. Further investigation showed that H2O2 resulted in increased intracellular ROS level, activation of PARP-1 and subsequently necrotic death of RPE cells. Exogenous NAD+ administration significantly decreased intracellular and intranuclear ROS levels in H2O2-treated RPE cells. In addition, NAD(+) administration to H2O2-treated RPE cells inhibited the activation of PARP-1 and protected the RPE cells against necrotic death. Moreover, exogenous NAD(+) administration up-regulated autophagy in the H2O2-treated RPE cells. Inhibition of autophagy by LY294002 blocked the decrease of intracellular and intranuclear ROS level. Besides, inhibition of autophagy by LY294002 abolished the protection of exogenous NAD(+) against H2O2-induced cell necrotic death. Taken together, our findings indicate that that exogenous NAD(+) administration suppresses H2O2-induced oxidative stress and protects RPE cells against PARP-1 mediated necrotic death through the up-regulation of autophagy. The results suggest that exogenous NAD(+) administration might be potential value for the treatment of AMD.
C1 [Zhu, Ying; Tong, Yao; Zhou, Ya-li; Wang, Yi-xiao; Zhao, Pei-quan; Wang, Zhao-yang] Shanghai Jiao Tong Univ, Scool Med, Xinhua Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
   [Zhao, Ke-ke] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Ophthalmol, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zhao, PQ; Wang, ZY (通讯作者)，Shanghai Jiao Tong Univ, Scool Med, Xinhua Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China.
EM zhaopeiquan@126.com; zhaokekewzy@hotmail.com
FU National Natural Science Funds of China [81371040]; Shanghai Pujiang
   Program [15PJD028]
FX This study was supported by the Project of the National Natural Science
   Funds of China (No. 81371040), and the Shanghai Pujiang Program (No.
   15PJD028).
CR Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Bai S, 2013, EXP EYE RES, V108, P76, DOI 10.1016/j.exer.2012.12.007
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Belenky P, 2007, TRENDS BIOCHEM SCI, V32, P12, DOI 10.1016/j.tibs.2006.11.006
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Ding DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079817
   Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200
   Dutta D, 2013, AUTOPHAGY, V9, P328, DOI 10.4161/auto.22971
   Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199
   Guarente L, 2014, CELL METAB, V20, P706, DOI 10.1016/j.cmet.2014.10.015
   Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978
   Hanus J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.478
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kaushik S., 2006, Molecular Aspects of Medicine, V27, P444, DOI 10.1016/j.mam.2006.08.007
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Li SY, 2012, APOPTOSIS, V17, P113, DOI 10.1007/s10495-011-0671-4
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lim L.L., 2008, GARNER KLINTWORTHS P, Vthird, P371, DOI [10.1177/1755738014566436, DOI 10.1177/1755738014566436]
   Liu LL, 2014, J CHEM RES, P180, DOI 10.3184/174751914X13922969308054
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ou X, 2014, STEM CELLS, V32, P1183, DOI 10.1002/stem.1641
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271
   Randolph SA, 2014, WORKPLACE HEALTH SAF, V62, P352, DOI 10.3928/21650799-20140708-06
   Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Sheline CT, 2010, MOL VIS, V16, P2639
   Shen HM, 2012, EXP CELL RES, V318, P1304, DOI 10.1016/j.yexcr.2012.02.006
   Wang J, 2005, J CELL BIOL, V170, P349, DOI 10.1083/jcb.200504028
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Won SJ, 2012, J NEUROTRAUM, V29, P1401, DOI 10.1089/neu.2011.2228
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MF, 2014, FREE RADICAL RES, V48, P794, DOI 10.3109/10715762.2014.907889
   Xu Y, 2006, J BIOL CHEM, V281, P8788, DOI 10.1074/jbc.M508135200
   Yan TQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0154-3
   Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
NR 45
TC 39
Z9 40
U1 0
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 31
PY 2016
VL 6
AR 26322
DI 10.1038/srep26322
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DN2CU
UT WOS:000376872500001
PM 27240523
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Goo, YS
   Park, DJ
   Ahn, JR
   Senok, SS
AF Goo, Yong Sook
   Park, Dae Jin
   Ahn, Jung Ryul
   Senok, Solomon S.
TI Spontaneous Oscillatory Rhythms in the Degenerating Mouse Retina
   Modulate Retinal Ganglion Cell Responses to Electrical Stimulation
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Review
DE retinal degeneration; rdl mice; rd10 mice; retinal ganglion cell;
   oscillatory local field potential
ID RD10 MOUSE; PRIMATE RETINA; BIPOLAR CELLS; MICE; PIGMENTOSA; NETWORK;
   LIGHT; MODEL; PRESERVATION; ACTIVATION
AB Characterization of the electrical activity of the retina in the animal models of retinal degeneration has been carried out in part to understand the progression of retinal degenerative diseases like age-related macular degeneration (AMD) and retinitis pigmentosa (RP), but also to determine optimum stimulus paradigms for use with retinal prosthetic devices. The models most studied in this regard have been the two lines of mice deficient in the beta-subunit of phosphodiesterase (rdl and rd10 mice), where the degenerating retinas exhibit characteristic spontaneous hyperactivity and oscillatory local field potentials (LFPs). Additionally, there is a robust similar to 10 Hz rhythmic burst of retinal ganglion cell (RGC) spikes on the trough of the oscillatory LFP. In rd1 mice, the rhythmic burst of RGC spikes is always phase-locked with the oscillatory LFP and this phase-locking property is preserved regardless of postnatal ages. However, in rd10 mice, the frequency of the oscillatory rhythm changes according to postnatal age, suggesting that this rhythm might be a marker of the stage of degeneration. Furthermore when a biphasic current stimulus is applied to rd10 mice degenerate retina, distinct RGC response patterns that correlate with the stage of degeneration emerge. This review also considers the significance of these response properties.
C1 [Goo, Yong Sook; Park, Dae Jin; Ahn, Jung Ryul] Chungbuk Natl Univ, Sch Med, Dept Physiol, Cheongju, South Korea.
   [Goo, Yong Sook; Park, Dae Jin; Ahn, Jung Ryul] Seoul Natl Univ Hosp, Nano Artificial Vis Res Ctr, Seoul 110744, South Korea.
   [Senok, Solomon S.] Alfaisal Univ, Coll Med, Div Neurosci, Riyadh, Saudi Arabia.
C3 Chungbuk National University; Seoul National University (SNU); Seoul
   National University Hospital; Alfaisal University
RP Goo, YS (通讯作者)，Chungbuk Natl Univ, Sch Med, Dept Physiol, Cheongju, South Korea.
EM ysgoo@chungbuk.ac.kr
OI Senok, Solomon/0000-0002-9041-5845
FU MEST in Republic of Korea [NU-2010-0020852, NRE-2013R1A1A3009574]
FX Rights were obtained for the use of Figure 1 from Ye et al. (2008;
   license number 3722331159370). For Figures 2B-D copyright belongs to
   Park a al. (2015). We acknowledge the following funding sources: grants
   of the MEST (NU-2010-0020852, NRE-2013R1A1A3009574) in Republic of Korea
   to YSG.
CR Barhoum R, 2008, NEUROSCIENCE, V155, P698, DOI 10.1016/j.neuroscience.2008.06.042
   Biswas S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099075
   Borowska J, 2011, J NEUROSCI, V31, P5000, DOI 10.1523/JNEUROSCI.5800-10.2011
   Choi H, 2014, J NEUROPHYSIOL, V112, P1491, DOI 10.1152/jn.00437.2014
   Chua J, 2009, J COMP NEUROL, V514, P473, DOI 10.1002/cne.22029
   Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144
   Goo YS, 2011, KOREAN J PHYSIOL PHA, V15, P415, DOI 10.4196/kjpp.2011.15.6.415
   Goo YS, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/035003
   Im M, 2015, J PHYSIOL-LONDON, V593, P3577, DOI 10.1113/JP270606
   Ivanova E, 2016, EXP EYE RES, V150, P81, DOI 10.1016/j.exer.2015.05.013
   Jensen RJ, 2008, VISION RES, V48, P1562, DOI 10.1016/j.visres.2008.04.016
   Jepson LH, 2013, J NEUROSCI, V33, P7194, DOI 10.1523/JNEUROSCI.4967-12.2013
   Jones BW, 2012, JPN J OPHTHALMOL, V56, P289, DOI 10.1007/s10384-012-0147-2
   Lee SW, 2013, J NEUROPHYSIOL, V109, P1954, DOI 10.1152/jn.00293.2012
   Lin YH, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-7
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Margolis DJ, 2008, J NEUROSCI, V28, P6526, DOI 10.1523/JNEUROSCI.1533-08.2008
   Margolis DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086253
   Menzler J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106047
   Menzler J, 2011, J NEUROSCI, V31, P2280, DOI 10.1523/JNEUROSCI.4238-10.2011
   Park D. J., 2015, C P IEEE ENG MED BIO, P3351
   Phillips MJ, 2010, J COMP NEUROL, V518, P2071, DOI 10.1002/cne.22322
   Pu ML, 2006, INVEST OPHTH VIS SCI, V47, P3579, DOI 10.1167/iovs.05-1450
   Puthussery T, 2009, EUR J NEUROSCI, V29, P1533, DOI 10.1111/j.1460-9568.2009.06728.x
   Ryu SB, 2010, INVEST OPHTH VIS SCI, V51, P6762, DOI 10.1167/iovs.10-5577
   Sekirnjak C, 2008, J NEUROSCI, V28, P4446, DOI 10.1523/JNEUROSCI.5138-07.2008
   Sekirnjak C, 2011, J NEUROPHYSIOL, V105, P2560, DOI 10.1152/jn.01061.2010
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   Stasheff SF, 2011, J NEUROPHYSIOL, V105, P3002, DOI 10.1152/jn.00704.2010
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Strettoi E, 2003, VISION RES, V43, P867, DOI 10.1016/S0042-6989(02)00594-1
   Toychiev AH, 2013, J NEUROSCI, V33, P13972, DOI 10.1523/JNEUROSCI.2399-13.2013
   Trenholm S, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00277
   Trenholm S, 2012, J PHYSIOL-LONDON, V590, P2501, DOI 10.1113/jphysiol.2011.225060
   Varela C, 2003, VISION RES, V43, P879, DOI 10.1016/S0042-6989(02)00493-5
   Ye JH, 2007, PHYSIOL MEAS, V28, P1079, DOI 10.1088/0967-3334/28/9/009
   Ye JH, 2008, IEEE ENG MED BIO, P2465, DOI 10.1109/IEMBS.2008.4649699
   Yee CW, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00008
NR 39
TC 21
Z9 21
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD JAN 12
PY 2016
VL 9
AR 512
DI 10.3389/fncel.2015.00512
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA DA8EN
UT WOS:000368038000001
PM 26793063
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pikuleva, IA
   Curcio, CA
AF Pikuleva, Irina A.
   Curcio, Christine A.
TI Cholesterol in the retina: The best is yet to come
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Cholesterol; Lipoproteins; Retina; Age-related macular degeneration;
   Drusen; Choroid
ID SUBRETINAL DRUSENOID DEPOSITS; AGE-RELATED MACULOPATHY;
   APOLIPOPROTEIN-A-I; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT-EPITHELIUM
   DEPOSITS; LIPOPROTEIN-LIKE PARTICLES; TO-RETENTION HYPOTHESIS;
   LIPID-RICH CORE; MACULAR DEGENERATION; BRUCHS MEMBRANE
AB Historically understudied, cholesterol in the retina is receiving more attention now because of genetic studies showing that several cholesterol-related genes are risk factors for age-related macular degeneration (AMD) and because of eye pathology studies showing high cholesterol content of drusen, aging Bruch's membrane, and newly found subretinal lesions. The challenge before us is determining how the cholesterol-AMD link is realized. Meeting this challenge will require an excellent understanding these genes' roles in retinal physiology and how chorioretinal cholesterol is maintained. In the first half of this review, we will succinctly summarize physico-chemical properties of cholesterol, its distribution in the human body, general principles of maintenance and metabolism, and differences in cholesterol handling in human and mouse that impact on experimental approaches. This information will provide a backdrop to the second part of the review focusing on unique aspects of chorioretinal cholesterol homeostasis, aging in Bruch's membrane, cholesterol in AMD lesions, a model for lesion biogenesis, a model for macular vulnerability based on vascular biology, and alignment of AMD-related genes and pathobiology using cholesterol and an atherosclerosis-like progression as unifying features. We conclude with recommendations for the most important research steps we can take towards delineating the cholesterol-AMD link. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
   [Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
C3 Case Western Reserve University; University of Alabama System;
   University of Alabama Birmingham
RP Pikuleva, IA (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
EM iap8@case.edu
OI Pikuleva, Irina/0000-0001-9742-6232
FU National Institutes of Health [EY018383, EY06109]; Jules and Doris Stein
   Professorship from the Research to Prevent Blindness; NATIONAL EYE
   INSTITUTE [R01EY006109, R01EY018383] Funding Source: NIH RePORTER
FX This research was supported in part by grants from the National
   Institutes of Health (EY018383 to IAP and EY06109 to CAC). IAP is a
   recipient of the Jules and Doris Stein Professorship from the Research
   to Prevent Blindness.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Acton JH, 2011, ACTA OPHTHALMOL, V89, pE404, DOI 10.1111/j.1755-3768.2011.02123.x
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Ahmed J, 2001, MICROVASC RES, V62, P143, DOI 10.1006/mvre.2001.2321
   Albert AD, 2005, PROG LIPID RES, V44, P99, DOI 10.1016/j.plipres.2005.02.001
   Aleman TS, 2013, DOC OPHTHALMOL, V127, P239, DOI 10.1007/s10633-013-9403-0
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628
   Anand-Apte B., 2011, IMMUNOLOGY INFLAMMAT, P186
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   ANDERSSON S, 1989, J BIOL CHEM, V264, P8222
   Anitschkow N, 1913, BEITR PATHOL ANAT AL, V56, P379
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Babiker A, 1999, J LIPID RES, V40, P1417
   Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253
   BAIRATI A, 1963, J ULTRA MOL STRUCT R, V9, P484, DOI 10.1016/S0022-5320(63)80080-5
   Barathi VA, 2014, INVEST OPHTH VIS SCI, V55, P460, DOI 10.1167/iovs.13-11636
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   Beebe D.C., 2013, OPHTHALMOL VIS SCI, P54
   Beltran WA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090390
   BERSON EL, 1973, INVEST OPHTH VISUAL, V12, P35
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b
   Bjorkhem I, 1998, J LIPID RES, V39, P1594
   Bjorkhem I., 1995, METABOLIC MOL BASES, P2073
   Bjorkhem I, 2009, J LIPID RES, V50, pS213, DOI 10.1194/jlr.R800025-JLR200
   Bobryshev YV, 2010, LAB INVEST, V90, P970, DOI 10.1038/labinvest.2010.94
   BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   Bok D., 1979, PHAGOCYTIC PROPERTIE
   BRESLOW JL, 1993, P NATL ACAD SCI USA, V90, P8314, DOI 10.1073/pnas.90.18.8314
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   BROEKHUYSE RM, 1972, BIOCHIM BIOPHYS ACTA, V280, P637, DOI 10.1016/0005-2760(72)90143-9
   Brown MS, 2009, J LIPID RES, V50, pS15, DOI 10.1194/jlr.R800054-JLR200
   Brunzell JD, 2012, BBA-MOL CELL BIOL L, V1821, P365, DOI 10.1016/j.bbalip.2011.09.008
   Burglin TR, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-11-241
   Caldes C, 2011, CHEM BIODIVERS, V8, P1318, DOI 10.1002/cbdv.201000296
   CALI JJ, 1991, J BIOL CHEM, V266, P7774
   CASTANHO MARB, 1992, J BIOL CHEM, V267, P204
   Charvet C, 2011, J BIOL CHEM, V286, P20413, DOI 10.1074/jbc.M111.232546
   Charvet CD, 2013, J BIOL CHEM, V288, P29267, DOI 10.1074/jbc.M113.498832
   Charvet CD, 2013, J LIPID RES, V54, P1421, DOI 10.1194/jlr.M035790
   Chen JL, 2009, STROKE, V40, P2532, DOI 10.1161/STROKEAHA.108.545095
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cheng JB, 2004, P NATL ACAD SCI USA, V101, P7711, DOI 10.1073/pnas.0402490101
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Choi JH, 2011, IMMUNITY, V35, P819, DOI 10.1016/j.immuni.2011.09.014
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chowers I, 2001, EYE, V15, P525, DOI 10.1038/eye.2001.167
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Claudepierre T, 2010, MOL CELL NEUROSCI, V43, P164, DOI 10.1016/j.mcn.2009.10.007
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CRUYSBERG JRM, 1995, AM J OPHTHALMOL, V120, P597, DOI 10.1016/S0002-9394(14)72206-8
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, METHODS MOL BIOL, V580, P267, DOI 10.1007/978-1-60761-325-1_15
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Turco EBR, 1999, J NEUROSCI RES, V57, P479
   DeBose-Boyd RA, 2008, CELL RES, V18, P609, DOI 10.1038/cr.2008.61
   Deeb SS, 2003, J LIPID RES, V44, P1279, DOI 10.1194/jlr.R200017-JLR200
   Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003
   Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200
   Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200
   DIETSCHY JM, 1993, J LIPID RES, V34, P1637
   Distler C, 1996, VISION RES, V36, P2381, DOI 10.1016/0042-6989(96)00005-3
   Donders FC, 1854, ARCH OPHTHALMOL-CHIC, V1, P106
   Dotti MT, 2001, J INHERIT METAB DIS, V24, P696, DOI 10.1023/A:1012981019336
   Dowhan W., 2002, NEW COMPR BIOCH, P1, DOI DOI 10.1016/50167-7306(02)36003-4
   Drasdo N, 2007, VISION RES, V47, P2901, DOI 10.1016/j.visres.2007.01.007
   DUDLEY PA, 1978, FEBS LETT, V95, P57, DOI 10.1016/0014-5793(78)80051-9
   Duncan KG, 2009, BRIT J OPHTHALMOL, V93, P1116, DOI 10.1136/bjo.2008.144006
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   Esteve-Rudd J., 2012, INVESTIG OPHTHALMOL, V53, P4756
   FEENEYBURNS L, 1988, INVEST OPHTH VIS SCI, V29, P708
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleming CP, 2013, BIOMED OPT EXPRESS, V4, P1269, DOI 10.1364/BOE.4.001269
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   FLIESLER SJ, 1995, BIOCHEM BIOPH RES CO, V210, P695, DOI 10.1006/bbrc.1995.1715
   FLIESLER SJ, 1993, FEBS LETT, V335, P234, DOI 10.1016/0014-5793(93)80736-E
   FLIESLER SJ, 1982, BIOCHIM BIOPHYS ACTA, V711, P138, DOI 10.1016/0005-2760(82)90020-0
   Fliesler SJ, 2007, PEDIATR RES, V61, P273, DOI 10.1203/pdr.0b013e318030d1cf
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fliesler SJ, 2010, ADV EXP MED BIOL, V664, P481, DOI 10.1007/978-1-4419-1399-9_55
   Fliesler SJ, 2010, J LIPID RES, V51, P1, DOI 10.1194/jlr.E003533-JLR200
   Fourgeux C, 2012, INVEST OPHTH VIS SCI, V53, P7026, DOI 10.1167/iovs.12-9652
   Fourgeux C, 2011, CHEM PHYS LIPIDS, V164, P496, DOI 10.1016/j.chemphyslip.2011.04.006
   Fourgeux C, 2009, INVEST OPHTH VIS SCI, V50, P5712, DOI 10.1167/iovs.09-3655
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman E., 1971, 21 CONCILIUM OPHTHAL, P454
   Fritsche L.G., 2014, ANN REV GEN IN PRESS, V15
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Funatsu T, 2001, ATHEROSCLEROSIS, V157, P107, DOI 10.1016/S0021-9150(00)00714-0
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Garlipp MA, 2013, EXP EYE RES, V113, P192, DOI 10.1016/j.exer.2013.02.003
   Gaynor PM, 1996, J LIPID RES, V37, P1849
   Gehlbach P, 2012, COCHRANE DB SYST REV, V3
   Genead MA, 2010, OPHTHALMIC GENET, V31, P66, DOI 10.3109/13816810903584971
   George KS, 2012, TOXICOL APPL PHARM, V259, P311, DOI 10.1016/j.taap.2012.01.007
   GIDDENS DP, 1993, J BIOMECH ENG-T ASME, V115, P588, DOI 10.1115/1.2895545
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   GUARNERI P, 1994, J NEUROCHEM, V63, P86
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   GUYTON JR, 1989, AM J PATHOL, V134, P705
   Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Heo GY, 2012, ARCH BIOCHEM BIOPHYS, V518, P119, DOI 10.1016/j.abb.2011.12.016
   Heo GY, 2011, J LIPID RES, V52, P1117, DOI 10.1194/jlr.M014217
   Hicks DA, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00189
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hu J, 2001, MOL VIS, V7, P14
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jaliffa CO, 2005, J NEUROCHEM, V94, P1666, DOI 10.1111/j.1471-4159.2005.03321.x
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kitteringham NR, 2009, J CHROMATOGR B, V877, P1229, DOI 10.1016/j.jchromb.2008.11.013
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Knupp C, 2000, J STRUCT BIOL, V129, P38, DOI 10.1006/jsbi.1999.4202
   KOOIJMAN AC, 1983, J OPT SOC AM, V73, P1544, DOI 10.1364/JOSA.73.001544
   KrisEtherton PM, 1997, AM J CLIN NUTR, V65, P1590
   Kruth HS, 2011, CURR OPIN LIPIDOL, V22, P386, DOI 10.1097/MOL.0b013e32834adadb
   Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002
   Kuhrt H, 1997, J BRAIN RES, V38, P223
   Kurumada S, 2007, INVEST OPHTH VIS SCI, V48, P1815, DOI 10.1167/iovs.06-0902
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Lemaire-Ewing S, 2012, ATHEROSCLEROSIS, V221, P303, DOI 10.1016/j.atherosclerosis.2011.10.016
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li M., 2014, HUM MOL GEN IN PRESS
   Li XL, 2010, EXPERT OPIN THER PAT, V20, P535, DOI 10.1517/13543771003621269
   Liao WL, 2011, J PROTEOME RES, V10, P241, DOI 10.1021/pr1008898
   Liao WL, 2010, ANAL CHEM, V82, P5760, DOI 10.1021/ac100811x
   Liao WL, 2009, BIOCHEMISTRY-US, V48, P4150, DOI 10.1021/bi900168m
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
   Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200
   Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Mast N, 2014, J BIOL CHEM, V289, P3529, DOI 10.1074/jbc.M113.532846
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   Meadway A, 2014, BIOMED OPT EXPRESS, V5, P713, DOI 10.1364/BOE.5.000713
   Meaney S, 2002, J LIPID RES, V43, P2130, DOI 10.1194/jlr.M200293-JLR200
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   MORGAN SJ, 1989, BRIT J OPHTHALMOL, V73, P1011, DOI 10.1136/bjo.73.12.1011
   Mossbock G, 2011, MOL VIS, V17, P616
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Mukkamala S.K., 2012, ARCH OPHTHALMOL-CHIC, V130, P1
   Muniz A, 2014, INVEST OPHTH VIS SCI, V55, P198, DOI 10.1167/iovs.13-11740
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P395, DOI 10.1001/archopht.1964.00970020395018
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Noghero A, 2012, ARTERIOSCL THROM VAS, V32, P2280, DOI 10.1161/ATVBAHA.112.250621
   Nork TM, 2006, ARCH OPHTHALMOL-CHIC, V124, P860, DOI 10.1001/archopht.124.6.860
   Norlin M, 2007, CURR MOL MED, V7, P199, DOI 10.2174/156652407780059168
   O'Byrne SM, 2013, J LIPID RES, V54, P1731, DOI 10.1194/jlr.R037648
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Oksjoki R, 2007, FRONT BIOSCI-LANDMRK, V12, P4696, DOI 10.2741/2419
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   Ostlund RE, 1999, J LIPID RES, V40, P1453
   Pannu PS, 2013, MOL CELL ENDOCRINOL, V368, P99, DOI 10.1016/j.mce.2012.07.013
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PFLIBSEN KP, 1988, J OPT SOC AM A, V5, P146, DOI 10.1364/JOSAA.5.000146
   Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7
   Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195
   Phillips SE, 2008, J NEUROSCI, V28, P6569, DOI 10.1523/JNEUROSCI.5529-07.2008
   Pike LJ, 2006, J LIPID RES, V47, P1597, DOI 10.1194/jlr.E600002-JLR200
   Pikuleva IA, 1998, J BIOL CHEM, V273, P18153, DOI 10.1074/jbc.273.29.18153
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Prosser HC, 2012, CURR OPIN LIPIDOL, V23, P182, DOI 10.1097/MOL.0b013e328352c4dd
   Provis JM, 2013, PROG RETIN EYE RES, V35, P63, DOI 10.1016/j.preteyeres.2013.01.005
   Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2009, ARCH OPHTHALMOL-CHIC, V127, P703, DOI 10.1001/archophthalmol.2009.87
   Ramirez DMO, 2008, J COMP NEUROL, V507, P1676, DOI 10.1002/cne.21605
   Reiss AB, 1997, J LIPID RES, V38, P1254
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   Rudolf M, 2010, INVEST OPHTH VIS SCI, V51
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2014, BRIT J OPHTHALMOL, V98, P698, DOI 10.1136/bjophthalmol-2013-304226
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Ruiz A, 2012, INVEST OPHTH VIS SCI, V53, P3027, DOI 10.1167/iovs.11-8476
   RUSSELL DW, 2008, J LIPID RES, pS120
   Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921
   Rye KA, 2014, J LIPID RES, V55, P168, DOI 10.1194/jlr.R039297
   Sabine J., 1977, CHOLESTEROL
   Saher G, 2011, NEUROSCIENTIST, V17, P79, DOI 10.1177/1073858410373835
   Salomon RG, 2005, ANTIOXID REDOX SIGN, V7, P185, DOI 10.1089/ars.2005.7.185
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schatz P, 2010, RETINA-J RET VIT DIS, V30, P1704, DOI 10.1097/IAE.0b013e3181dc050a
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schneeberger SA, 1997, RETINA-J RET VIT DIS, V17, P38, DOI 10.1097/00006982-199701000-00008
   Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103
   Smith E B, 1974, Adv Lipid Res, V12, P1
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soh J, 2013, NAT MED, V19, P892, DOI 10.1038/nm.3200
   Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   SPADY DK, 1985, J LIPID RES, V26, P465
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   SPARKS CE, 1981, CAN J BIOCHEM CELL B, V59, P693, DOI 10.1139/o81-096
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391
   STARY HC, 1992, VIRCHOWS ARCH A, V421, P277, DOI 10.1007/BF01660974
   Steinberg D, 2006, J LIPID RES, V47, P1, DOI 10.1194/jlr.R500014-JLR200
   Steinberg D, 2005, J LIPID RES, V46, P2037, DOI 10.1194/jlr.R500010-JLR200
   Steinberg D, 2005, J LIPID RES, V46, P179, DOI 10.1194/jlr.R400012-JLR200
   Steinberg D, 2004, J LIPID RES, V45, P1583, DOI 10.1194/jlr.R400003-JLR200
   Steinberg D, 2006, J LIPID RES, V47, P1339, DOI 10.1194/jlr.R600009-JLR200
   STREETEN BW, 1961, ARCH OPHTHALMOL-CHIC, V66, P391
   Sudhop T, 2002, CIRCULATION, V106, P1943, DOI 10.1161/01.CIR.0000034044.95911.DC
   Suzuki M, 2007, MOL VIS, V13, P772
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Thomas GS, 2013, J AM COLL CARDIOL, V62, P2178, DOI 10.1016/j.jacc.2013.07.081
   Thomas T, 2010, CURR ATHEROSCLER REP, V12, P58, DOI 10.1007/s11883-009-0078-7
   Treharne AJ, 2012, J BIOMED MATER RES A, V100A, P2358, DOI 10.1002/jbm.a.34178
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   TURLEY SD, 1995, J LIPID RES, V36, P67
   Turley SD, 2003, CURR OPIN LIPIDOL, V14, P233, DOI 10.1097/00041433-200306000-00002
   Turley SD, 1998, HEPATOLOGY, V28, P1088, DOI 10.1002/hep.510280425
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Upston JM, 2002, AM J PATHOL, V160, P701, DOI 10.1016/S0002-9440(10)64890-0
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Van Lenten BJ, 2009, CURR ATHEROSCLER REP, V11, P52, DOI 10.1007/s11883-009-0008-8
   VanderLaan PA, 2004, ARTERIOSCL THROM VAS, V24, P12, DOI 10.1161/01.ATV.0000105054.43931.f0
   VERHOEFF F. H., 1926, ARCH OPHTHALMOL, V55, P125
   Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551
   Walczak R, 2004, J BIOL CHEM, V279, P9905, DOI 10.1074/jbc.M310587200
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang MY, 2012, ANAL CHEM, V84, P5186, DOI 10.1021/ac300587v
   Wavre-Shapton ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057769
   Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538
   Wedl C, 1854, GRUNDZUGE PATHOLOGIS
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wierzbicki AS, 2009, CURR VASC PHARMACOL, V7, P277, DOI 10.2174/157016109788340703
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Wong P, 2000, MOL VIS, V6, P184
   Wu MY, 2008, INVEST OPHTH VIS SCI, V49, P2679, DOI 10.1167/iovs.07-1440
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
   Xu LB, 2012, BBA-MOL CELL BIOL L, V1821, P877, DOI 10.1016/j.bbalip.2012.03.001
   Xu LB, 2011, J LIPID RES, V52, P1810, DOI 10.1194/jlr.M018366
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zak Z, 2002, J LIPID RES, V43, P2164, DOI 10.1194/jlr.M200253-JLR200
   Zambon D, 2010, AM J MED, V123, P267, DOI 10.1016/j.amjmed.2009.08.015
   Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883
   Zhang ZH, 2009, AM J PHYSIOL-HEART C, V297, pH866, DOI 10.1152/ajpheart.01232.2008
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 335
TC 169
Z9 172
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2014
VL 41
BP 64
EP 89
DI 10.1016/j.preteyeres.2014.03.002
PG 26
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK7JH
UT WOS:000338604100004
PM 24704580
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bown, SG
AF Bown, Stephen G.
TI Photodynamic therapy for photochemists
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY A-MATHEMATICAL PHYSICAL
   AND ENGINEERING SCIENCES
LA English
DT Review
DE photodynamic therapy; minimally invasive treatment; cancer therapy;
   lasers
ID PROSTATE-CANCER; 5-AMINOLEVULINIC ACID; PHASE-III; RESECTION;
   INTERNALIZATION; PHTHALOCYANINE; EFFICACY; CELLS; HEAD
AB Photodynamic therapy (PDT) is an evolving technique for localized control of diseased tissue with light after prior administration of a photosensitizing agent and in the presence of oxygen. The biological effect is quite different from surgery, radiotherapy and chemotherapy. With no temperature change during treatment, connective tissues like collagen are largely unaffected, so maintaining the mechanical integrity of hollow organs. PDT is of particular value for pre-cancer and early cancers of the skin (not melanomas) and mouth as the cosmetic and functional results are so good. Another key indication is for small areas of cancer that are unsuitable for or have persisted or recurred after conventional management. It can be applied in areas already exposed to the maximum safe dose of radiotherapy. Outside cancer, in ophthalmology, it is established for age-related macular degeneration, and has considerable potential in arterial disease for preventing restenosis after balloon angioplasty and in the treatment of infectious diseases, where the responsible organisms are accessible to both the photosensitizer and light. New developments on the horizon include techniques for increasing the selectivity for cancers, such as coupling photosensitizers to antibodies, and for stimulating immunological responses, but many further pre-clinical and clinical studies are needed to establish PDT's role in routine clinical practice.
C1 UCL, Natl Med Laser Ctr, London, England.
C3 University of London; University College London
RP Bown, SG (通讯作者)，UCL, Natl Med Laser Ctr, London, England.
EM s.bown@ucl.ac.uk
RI Bown, Stephen/AAX-6573-2020
OI Bown, Stephen/0000-0002-5538-9303
CR Ahmed HU, 2007, NAT CLIN PRACT ONCOL, V4, P632, DOI 10.1038/ncponc0959
   BADER MJ, 2012, UROL ONCOL, DOI DOI 10.1016/J.UR0L0NC.2012.02.007)
   BARR H, 1990, GASTROENTEROLOGY, V98, P1532, DOI 10.1016/0016-5085(90)91086-L
   BARR H, 1987, PHOTOCHEM PHOTOBIOL, V46, P795, DOI 10.1111/j.1751-1097.1987.tb04850.x
   Betrouni N, 2011, PHYS MED BIOL, V56, P4771, DOI 10.1088/0031-9155/56/15/009
   Betz CS, 2007, LASER SURG MED, V39, P571, DOI 10.1002/lsm.20535
   Biel MA, 2007, PHOTOCHEM PHOTOBIOL, V83, P1063, DOI 10.1111/j.1751-1097.2007.00153.x
   Bown SG, 2002, GUT, V50, P549, DOI 10.1136/gut.50.4.549
   BOWN SG, 1990, J PHOTOCH PHOTOBIO B, V6, P1, DOI 10.1016/1011-1344(90)85069-9
   Campbell SM, 2004, BRIT J DERMATOL, V151, P1076, DOI 10.1111/j.1365-2133.2004.06197.x
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Chevalier S, 2011, J UROLOGY, V186, P302, DOI 10.1016/j.juro.2011.03.039
   del Carmen MG, 2005, JNCI-J NATL CANCER I, V97, P1516, DOI 10.1093/jnci/dji314
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Grant WE, 1997, INT J CANCER, V71, P937, DOI 10.1002/(SICI)1097-0215(19970611)71:6<937::AID-IJC4>3.0.CO;2-Z
   GRANT WE, 1994, BRIT J CANCER, V70, P72, DOI 10.1038/bjc.1994.252
   HARTY JI, 1989, J UROLOGY, V141, P1341, DOI 10.1016/S0022-5347(17)41302-4
   Hermann GG, 2011, BJU INT, V108, pE297, DOI 10.1111/j.1464-410X.2011.10090.x
   Hopper C, 2004, INT J CANCER, V111, P138, DOI 10.1002/ijc.20209
   Hopper C, 2000, Lancet Oncol, V1, P212
   Istomin YP, 2010, PHOTODIAGN PHOTODYN, V7, P144, DOI 10.1016/j.pdpdt.2010.06.005
   Jenkins MP, 1999, BRIT J SURG, V86, P1258, DOI 10.1046/j.1365-2168.1999.01247.x
   Jocham D, 2009, AKTUEL UROL, V40, P91, DOI 10.1055/s-0028-1098741
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kennedy TC, 2007, CHEST, V132, p221S, DOI 10.1378/chest.07-1377
   Kharkwal GB, 2011, LASER SURG MED, V43, P755, DOI 10.1002/lsm.21080
   Korbelik M, 2007, BRIT J CANCER, V96, P67, DOI 10.1038/sj.bjc.6603508
   Kostron H, 2010, METHODS MOL BIOL, V635, P261, DOI 10.1007/978-1-60761-697-9_17
   lbbotoson S, 2006, PHOTODERMATOSES, P125
   Li WT, 2009, CURR DRUG METAB, V10, P851, DOI 10.2174/138920009790274559
   Lou PJ, 2006, INT J CANCER, V119, P2692, DOI 10.1002/ijc.22098
   Lou PJ, 2004, BRIT J CANCER, V91, P441, DOI 10.1038/sj.bjc.6601993
   Matull WR, 2011, LIVER INT, V31, P99, DOI 10.1111/j.1478-3231.2010.02345.x
   MEYER M, 1991, BRIT J CANCER, V64, P1093, DOI 10.1038/bjc.1991.470
   Moghissi K, 2009, PHOTODIAGN PHOTODYN, V6, P159, DOI 10.1016/j.pdpdt.2009.07.026
   Morton CA, 2008, BRIT J DERMATOL, V159, P1245, DOI 10.1111/j.1365-2133.2008.08882.x
   Overholt BF, 2007, GASTROINTEST ENDOSC, V66, P460, DOI 10.1016/j.gie.2006.12.037
   Perrett CM, 2007, BRIT J DERMATOL, V156, P320, DOI 10.1111/j.1365-2133.2006.07616.x
   Selbo PK, 2006, J PHARMACOL EXP THER, V319, P604, DOI 10.1124/jpet.106.109165
   St Denis TG, 2011, PHOTOCH PHOTOBIO SCI, V10, P792, DOI 10.1039/c0pp00326c
   Stummer W, 2006, LANCET ONCOL, V7, P392, DOI 10.1016/S1470-2045(06)70665-9
   Theodossiou T, 2003, CANCER RES, V63, P1818
   Trachtenberg J, 2008, BJU INT, V102, P556, DOI 10.1111/j.1464-410X.2008.07753.x
   Trushina OI, 2008, PHOTODIAGN PHOTODYN, V5, P256, DOI 10.1016/j.pdpdt.2008.09.005
NR 45
TC 38
Z9 44
U1 0
U2 67
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1364-503X
EI 1471-2962
J9 PHILOS T R SOC A
JI Philos. Trans. R. Soc. A-Math. Phys. Eng. Sci.
PD JUL 28
PY 2013
VL 371
IS 1995
AR UNSP 20120371
DI 10.1098/rsta.2012.0371
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 164VX
UT WOS:000320440200015
PM 23776302
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhang, H
   Yang, Y
   Takeda, A
   Yoshimura, T
   Oshima, Y
   Sonoda, KH
   Ishibashi, T
AF Zhang, Han
   Yang, Yang
   Takeda, Atsunobu
   Yoshimura, Takeru
   Oshima, Yuji
   Sonoda, Koh-Hei
   Ishibashi, Tatsuro
TI A Novel Platelet-Activating Factor Receptor Antagonist Inhibits
   Choroidal Neovascularization and Subretinal Fibrosis
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; IN-VIVO ANGIOGENESIS; MACULAR DEGENERATION;
   CYTOKINE PRODUCTION; VEGF EXPRESSION; GENE-EXPRESSION; BINDING-SITES;
   FACTOR PAF; CELLS; RAT
AB Choroidal neovascularization (CNV) is a critical pathogenesis in age-related macular degeneration (AMD), the most common cause of blindness in developed countries. To date, the precise molecular and cellular mechanisms underlying CNV have not been elucidated. Platelet-activating factor (PAF) has been previously implicated in angiogenesis; however, the roles of PAF and its receptor (PAF-R) in CNV have not been addressed. The present study reveals several important findings concerning the relationship of the PAF-R signaling with CNV. PAF-R was detected in a mouse model of laser-induced CNV and was upregulated during CNV development. Experimental CNV was suppressed by administering WEB2086, a novel PAF-R antagonist. WEB2086-dependent suppression of CNV occurred via the inhibition of macrophage infiltration and the expression of proangiogenic (vascular endothelial growth factor) and proinflammatory molecules (monocyte chemotactic protein-1 and IL-6) in the retinal pigment epithelium-choroid complex. Additionally, WEB2086-induced PAF-R blockage suppresses experimentally induced subretinal fibrosis, which resembles the fibrotic subretinal scarring observed in neovascular AMD. As optimal treatment modalities for neovascular AMD would target the multiple mechanisms of AMD-associated vision loss, including neovascularization, inflammation and fibrosis, our results suggest PAF-R as an attractive molecular target in the treatment of AMD.
C1 [Zhang, Han; Yang, Yang; Takeda, Atsunobu; Yoshimura, Takeru; Oshima, Yuji; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka, Japan.
   [Zhang, Han] China Med Univ, Hosp 1, Dept Ophthalmol, Shenyang, Peoples R China.
   [Sonoda, Koh-Hei] Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, Ube, Yamaguchi 755, Japan.
C3 Kyushu University; China Medical University; Yamaguchi University
RP Zhang, H (通讯作者)，Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka, Japan.
EM zhanghan0614@139.com
OI Yoshimura, Takeru/0000-0002-5983-7193; Zhang, Han/0000-0002-9338-0051
FU Ministry of Education, Science, Sports and Culture of Japan;
   Grants-in-Aid for Scientific Research [23689071] Funding Source: KAKEN
FX This work was supported by grants C (K-H. S.) and grant-in-aid for Young
   Scientists (A) (A. T.) from the Ministry of Education, Science, Sports
   and Culture of Japan. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771
   BITO H, 1994, EUR J BIOCHEM, V221, P211, DOI 10.1111/j.1432-1033.1994.tb18731.x
   BRAQUET P, 1989, J LIPID MEDIATOR, V1, P75
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142
   CAMUSSI G, 1995, J IMMUNOL, V154, P6492
   Camussi G, 1997, J IMMUNOL, V158, P1302
   CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974
   Chen J, 1997, J PHARMACOL EXP THER, V280, P1219
   COHEN RA, 1994, CURR EYE RES, V13, P139, DOI 10.3109/02713689409042408
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Doi K, 2006, AM J PATHOL, V168, P1413, DOI 10.2353/ajpath.2006.050634
   DOMINGO MT, 1989, BIOCHEM BIOPH RES CO, V160, P250, DOI 10.1016/0006-291X(89)91648-3
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fukuda AI, 1996, HUM REPROD, V11, P2746
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   GIRI SN, 1995, EXP LUNG RES, V21, P287, DOI 10.3109/01902149509068833
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   He YG, 2009, CURR EYE RES, V34, P957, DOI 10.3109/02713680903231135
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Honda Z, 2002, J BIOCHEM, V131, P773, DOI 10.1093/oxfordjournals.jbchem.a003164
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kasperska-Zajac A, 2008, INFLAMMATION, V31, P112, DOI 10.1007/s10753-007-9056-9
   Kent D, 2003, MOL VIS, V9, P747
   Kim HA, 2011, CELL PHYSIOL BIOCHEM, V27, P55, DOI 10.1159/000325205
   Ko HM, 2002, CANCER RES, V62, P1809
   Ma X, 2004, INVEST OPHTH VIS SCI, V45, P2915, DOI 10.1167/iovs.04-0128
   Ma X, 2000, INVEST OPHTH VIS SCI, V41, P1696
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Montrucchio G, 2000, PHYSIOL REV, V80, P1669, DOI 10.1152/physrev.2000.80.4.1669
   MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377
   Montrucchio G, 2000, ARTERIOSCL THROM VAS, V20, P80, DOI 10.1161/01.ATV.20.1.80
   Montrucchio G, 1998, AM J PATHOL, V153, P1589, DOI 10.1016/S0002-9440(10)65747-1
   Mori M, 1997, INVEST OPHTH VIS SCI, V38, P2672
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nilsson G, 2000, IMMUNOLOGY, V99, P314, DOI 10.1046/j.1365-2567.2000.00972.x
   Ogata M, 2004, ANESTH ANALG, V98, P1767, DOI 10.1213/01.ANE.0000112310.93297.AF
   Proudfoot JM, 2003, J PHARMACOL EXP THER, V305, P846, DOI 10.1124/jpet.102.047795
   Robert EG, 2001, CURR PHARM DESIGN, V7, P1615, DOI 10.2174/1381612013397203
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ruiz-Ortega M, 1998, NEPHROL DIAL TRANSPL, V13, P886, DOI 10.1093/ndt/13.4.886
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732
   Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   THIERRY A, 1989, EUR J PHARMACOL, V163, P97, DOI 10.1016/0014-2999(89)90400-7
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yang HH, 1997, J IMMUNOL, V158, P2771
   Yang Y, 2004, GUT, V53, P877, DOI 10.1136/gut.2003.024893
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang H, 2009, BIOCHEM BIOPH RES CO, V381, P471, DOI 10.1016/j.bbrc.2009.01.178
NR 61
TC 22
Z9 22
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 27
PY 2013
VL 8
IS 6
AR e68173
DI 10.1371/journal.pone.0068173
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 174IX
UT WOS:000321150000129
PM 23826375
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ye, L
   Yu, T
   Li, YQ
   Chen, BN
   Zhang, JS
   Wen, ZY
   Zhang, B
   Zhou, XH
   Li, XQ
   Li, F
   Cao, W
   Huang, Z
AF Ye, Liang
   Yu, Ting
   Li, Yanqun
   Chen, Bingni
   Zhang, Jinshun
   Wen, Zhongyang
   Zhang, Bo
   Zhou, Xiaohong
   Li, Xiaoqing
   Li, Feng
   Cao, Wei
   Huang, Zhong
TI Sulforaphane Enhances the Ability of Human Retinal Pigment Epithelial
   Cell against Oxidative Stress, and Its Effect on Gene Expression Profile
   Evaluated by Microarray Analysis
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID THIOREDOXIN-INTERACTING PROTEIN; ANTIOXIDANT-RESPONSIVE ELEMENT;
   PATHOGENESIS; DAMAGE; MOUSE; MODEL; NRF2; DEGENERATION; SULFIREDOXIN;
   INFLAMMATION
AB To gain further insights into the molecular basis of Sulforaphane (SF) mediated retinal pigment epithelial (RPE) 19 cell against oxidative stress, we investigated the effects of SF on the regulation of gene expression on a global scale and tested whether SF can endow RPE cells with the ability to resist apoptosis. The data revealed that after exposure to H2O2, RPE 19 cell viability was increased in the cells pretreated with SF compared to the cell not treated with SF. Microarray analysis revealed significant changes in the expression of 69 genes in RPE 19 cells after 6 hours of SF treatment. Based on the functional relevance, eight of the SF-responsive genes, that belong to antioxidant redox system, and inflammatory responsive factors were validated. The up-regulating translation of thioredoxin-1 (Trx1) and the nuclear translocation of Nuclear factor-like2 (Nrf2) were demonstrated by immunoblot analysis in SF treated RPE cells. Our data indicate that SF increases the ability of RPE 19 cell against oxidative stress through up-regulating antioxidative enzymes and down-regulating inflammatory mediators and chemokines. The results suggest that the antioxidant, SF, may be a valuable supplement for preventing and retarding the development of Age Related Macular Degeneration.
C1 [Ye, Liang; Yu, Ting; Li, Yanqun; Chen, Bingni; Zhang, Jinshun; Wen, Zhongyang; Zhang, Bo; Li, Xiaoqing; Huang, Zhong] Shenzhen Univ, Sch Med, Inst Biotherapy, Shenzhen 518060, Guangdong, Peoples R China.
   [Zhou, Xiaohong; Li, Feng; Cao, Wei] Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Dept Ophthalmol, Oklahoma City, OK 73104 USA.
C3 Shenzhen University; University of Oklahoma System; University of
   Oklahoma Health Sciences Center
RP Huang, Z (通讯作者)，Shenzhen Univ, Sch Med, Inst Biotherapy, Nanhai Ave 3688, Shenzhen 518060, Guangdong, Peoples R China.
EM zhuang809@126.com
RI ye, liang/X-7553-2019; Ye, Liang/T-1332-2018; Ye, Liang/AAC-4651-2022
OI ye, liang/0000-0002-6735-0836; Ye, Liang/0000-0002-6735-0836; 
CR Ansari AW, 2006, INT IMMUNOL, V18, P1443, DOI 10.1093/intimm/dxl078
   Asher G, 2004, METHOD ENZYMOL, V382, P278
   Bazan NG, 2006, ADV EXP MED BIOL, V572, P531
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bell KF, 2011, P NATL ACAD SCI USA, V108, pE1, DOI 10.1073/pnas.1015229108
   Berndt C, 2007, AM J PHYSIOL-HEART C, V292, pH1227, DOI 10.1152/ajpheart.01162.2006
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   CHEN HM, 1992, EXP EYE RES, V55, P93, DOI 10.1016/0014-4835(92)90097-C
   Chen Y, 2005, J BIOL CHEM, V280, P33766, DOI 10.1074/jbc.M504604200
   Felius J, 2002, ARCH OPHTHALMOL-CHIC, V120, P55
   Findlay VJ, 2006, CANCER RES, V66, P6800, DOI 10.1158/0008-5472.CAN-06-0484
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998
   Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4
   Huang Z, 2004, MOL CELL BIOL, V24, P8951, DOI 10.1128/MCB.24.20.8951-8962.2004
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kong L, 2007, J NEUROCHEM, V101, P1041, DOI 10.1111/j.1471-4159.2007.04481.x
   Korn EL, 2007, STAT MED, V26, P4428, DOI 10.1002/sim.2865
   Kulinsky VI, 2007, BIOCHEMISTRY-MOSCOW+, V72, P595, DOI 10.1134/S0006297907060028
   MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015
   Muoio DM, 2007, CELL METAB, V5, P412, DOI 10.1016/j.cmet.2007.05.011
   Nakamura H, 2005, ANTIOXID REDOX SIGN, V7, P823, DOI 10.1089/ars.2005.7.823
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Sato A, 2006, ANTIOXID REDOX SIGN, V8, P1891, DOI 10.1089/ars.2006.8.1891
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Soriano FX, 2008, J NEUROCHEM, V107, P533, DOI 10.1111/j.1471-4159.2008.05648.x
   Soriano FX, 2009, MOL CELLS, V27, P279, DOI 10.1007/s10059-009-0050-y
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takagi Y, 1999, P NATL ACAD SCI USA, V96, P4131, DOI 10.1073/pnas.96.7.4131
   Talalay P, 2004, METHOD ENZYMOL, V382, P355
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P979, DOI 10.1167/iovs.04-1120
   Tanito M, 2002, NEUROSCI LETT, V326, P142, DOI 10.1016/S0304-3940(02)00314-2
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wang Z, 2006, ONCOGENE, V25, P1903, DOI 10.1038/sj.onc.1209218
   Warabi E, 2007, FREE RADICAL BIO MED, V42, P260, DOI 10.1016/j.freeradbiomed.2006.10.043
   Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345
   Yamawaki H, 2005, J CLIN INVEST, V115, P733, DOI 10.1172/JCI200523001
   Zhou XH, 2005, J BIOL CHEM, V280, P31240, DOI 10.1074/jbc.M502641200
NR 41
TC 16
Z9 17
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2013
VL 2013
AR 413024
DI 10.1155/2013/413024
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 229WV
UT WOS:000325299300001
PM 24187606
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Maloney, SC
   Antecka, E
   Orellana, ME
   Fernandes, BF
   Odashiro, AN
   Eghtedari, M
   Burnier, MN
AF Maloney, Shawn C.
   Antecka, Emilia
   Orellana, Maria E.
   Fernandes, Bruno F.
   Odashiro, Alexandre N.
   Eghtedari, Masoomeh
   Burnier, Miguel N., Jr.
TI Choroidal Neovascular Membranes Express Toll-Like Receptor 3
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Choroidal neovascular membrane; Toll-like receptor 3; Age-related
   macular degeneration
ID MACULAR DEGENERATION; EPITHELIAL-CELLS; TLR3; PREVALENCE; ACTIVATION;
   RESPONSES; VIRUS; RNA
AB Background: Recent evidence has suggested a role for toll-like receptor 3 (TLR3) in experimental models of age-related macular degeneration (AMD). To date, however, few data exist about TLR3 in human AMD. The purpose of this study was to investigate the expression of TLR3 in human choroidal neovascular (CNV) membranes. Methods: Immunostaining for TLR3 was performed on sections of CNV membranes from 8 AMD patients and eyes from 4 donors without CNV. Results: All CNV membranes expressed TLR3 in retinal pigment epithelial (RPE) cells. One was classified as having strong intensity, 5 as having moderate intensity and 2 as having weak intensity. All cases had >= 30% of the RPE cells staining for TLR3, ranging from 30 to 90%. No expression of TLR3 was observed in vascular endothelial cells or fibroblasts in any CNV membrane. In the donor eyes, the RPE cells near the ora serrata stained stronger than those at the posterior pole, where no staining was observed in 3 out of 4 cases. Conclusion: TLR3 was found in all CNV membranes and was expressed exclusively in RPE cells. The observed difference RPE staining for TLR3 in donor eyes and CNV membranes suggests a possible role for this receptor in human neovascular AMD. Copyright (C) 2010 S. Karger AG, Basel
C1 [Maloney, Shawn C.; Antecka, Emilia; Orellana, Maria E.; Fernandes, Bruno F.; Odashiro, Alexandre N.; Eghtedari, Masoomeh; Burnier, Miguel N., Jr.] McGill Univ, Henry C Witelson Ocular Pathol Lab, Montreal, PQ H3A 2B4, Canada.
C3 McGill University
RP Maloney, SC (通讯作者)，McGill Univ, Henry C Witelson Ocular Pathol Lab, 3775 Univ St,Room 216, Montreal, PQ H3A 2B4, Canada.
EM shawn.maloney@mail.mcgill.ca
RI Eghtedari, Masoomeh/H-4556-2011; Fernandes, Bruno F./ABA-3567-2020
OI Fernandes, Bruno F./0000-0002-5385-3571; Burnier,
   Miguel/0000-0002-2335-7470; Orellana Torres, Maria
   Eugenia/0000-0001-7412-7352; Eghtedari, Masoomeh/0000-0002-8079-1177
FU Sinclair Foundation
FX This study was generously supported by the Sinclair Foundation.
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000
   Cho WG, 2009, P NATL ACAD SCI USA, V106, P7137, DOI 10.1073/pnas.0812317106
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GERMANN T, 1993, EUR J IMMUNOL, V23, P1762, DOI 10.1002/eji.1830230805
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320
   Jorgenson RL, 2005, HUM IMMUNOL, V66, P469, DOI 10.1016/j.humimm.2004.12.003
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kong KF, 2008, J VIROL, V82, P7613, DOI 10.1128/JVI.00618-08
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lin CF, 2007, ACTA OTO-LARYNGOL, V127, P395, DOI 10.1080/00016480601089416
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450
   Schaefer TM, 2004, IMMUNOLOGY, V112, P428, DOI 10.1111/j.1365-2567.2004.01898.x
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581
   WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0
NR 20
TC 15
Z9 18
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2010
VL 44
IS 4
BP 237
EP 241
DI 10.1159/000313989
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 638XL
UT WOS:000280932000003
PM 20699627
DA 2022-11-30
ER

PT J
AU Menon, G
   Walters, G
AF Menon, G.
   Walters, G.
TI New paradigms in the treatment of wet AMD: the impact of anti-VEGF
   therapy
SO EYE
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; pegaptanib;
   commissioning; cost effectiveness; photodynamic therapy
ID MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN
AB The incidence of age-related macular degeneration (AMD) in the United Kingdom is increasing with the ageing population. The wet form of this progressive and potentially blinding disease can develop very rapidly and lead to severe loss of central vision and reduction in quality of life, sometimes in just a matter of weeks. Recent advances in the treatment of wet AMD with the licensing of anti-vascular endothelial growth factor therapies, coupled with current guidance from the Scottish Medicines Consortium and the National Institute of Health and Clinical Excellence have led to a subsequent increase in workload at AMD clinics due to the increased number of patients now eligible for treatment. In addition, the Royal College of Ophthalmologists recommend a 2-week diagnosis to treatment schedule due to the aggressive nature of the disease. The role of the retinal specialist is thus changing, and business management skills are becoming increasingly necessary to obtain the necessary resources to implement the guidance. Through prior experience and formal external evaluation of services at Frimley Park and Harrogate District Hospitals, a number of critical success factors have been developed for optimising treatment pathways in efficient wet AMD clinics. Eye (2009) 23, S1-S7; doi:10.1038/eye.2009.13
C1 [Walters, G.] Harrogate Dist Hosp, Harrogate HG2 7SX, N Yorkshire, England.
RP Walters, G (通讯作者)，Harrogate Dist Hosp, Lancaster Pk Rd, Harrogate HG2 7SX, N Yorkshire, England.
EM gavin.walters@hdft.nhs.uk
FU Novartis Pharmaceuticals Limited (UK)
FX This article was supported by Novartis Pharmaceuticals Limited (UK). The
   company has had the opportunity to comment on the medical content and
   accuracy of the article; however, final editorial content resides with
   the author and the journal. The authors thank Sue Harris from Huntsworth
   Health, who provided medical writing support on behalf of Novartis
   Pharmaceuticals.
CR [Anonymous], 2003, TA68 MACULAR DEGENER
   [Anonymous], LUCENTIS SUMMARY PRO
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   *RCOPHTH, 2007, RCOPHTH COMM CONT AM
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists, RAN CLIN GUID COMM C
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   PEGAPTANIB 0 3 MG SO
   MACUGEN SUMMARY PROD
   RANIBIZUMAB 10 MG ML
   2008, MACULAR DEGENERATION
NR 18
TC 22
Z9 22
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2009
VL 23
SU 1
BP S1
EP S7
DI 10.1038/eye.2009.13
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 418AI
UT WOS:000264119200001
PM 19287467
OA Bronze
DA 2022-11-30
ER

PT J
AU Gotting, C
   Hendig, D
   Zarbock, R
   Szliska, C
   Kleesiek, K
AF Goetting, Christian
   Hendig, Doris
   Zarbock, Ralf
   Szliska, Christiane
   Kleesiek, Knut
TI Complement factor H variant p.Y402H in pseudoxanthoma elasticum patients
SO GENETIC TESTING
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; FAMILIAL AGGREGATION; CONNECTIVE-TISSUE; ABCC6
   MUTATIONS; SAMPLE-SIZE; POLYMORPHISM; DISEASE; RISK
AB Pseudoxanthoma elasticum (PXE) is a hereditary disorder predominantly affecting the eyes, the skin, and the vascular system. The subretinal neovascularization and retinal hemorrhages leading to the loss of central vision in PXE are similar to the process observed in age-related macular degeneration (AMD). The complement factor H (CFH) variant c. 1277T> C (p.Y402H) is a recently discovered risk factor for AMD. The aim of this study was to analyze whether this CFH variant is a secondary genetic risk factor for PXE. Therefore, the genotypes of CFH c. 1277T> C (p.Y402H) were determined in 189 German PXE patients and 189 age- and sex-matched controls. The allelic frequencies of the investigated variant did not differ between patients and controls. The frequencies were 33%, 56%, and 11% for wild-type, heterozygous, and homozygous genotypes in the PXE patients and 36%, 51%, and 13% in the control cohort, respectively. Further, no significant associations were identified when allele carriers were analyzed or after adjustment for sex, age, smoking, organ involvement, hypertension, or age at disease onset. No significant genotype-phenotype correlation was detected. In conclusion, our data reliably show that the CFH variant c. 1277T> C (p.Y402H) is not a genetic risk factor for PXE.
C1 [Goetting, Christian; Hendig, Doris; Zarbock, Ralf; Kleesiek, Knut] Ruhr Univ Bochum, Univ Klin, Herz & Diabeteszentrum Nordrhein Westfalen, Inst Labs & Transfus Med, D-32545 Bad Oeynhausen, Germany.
   [Szliska, Christiane] Krankenhaus Bethesda, Dermatol Klin, Freudenberg, Germany.
C3 Ruhr University Bochum
RP Gotting, C (通讯作者)，Ruhr Univ Bochum, Univ Klin, Herz & Diabeteszentrum Nordrhein Westfalen, Inst Labs & Transfus Med, Georgstr 11, D-32545 Bad Oeynhausen, Germany.
EM cgoetting@hdz-nrw.de
RI Zarbock, Ralf/K-9031-2019; Hendig, Doris/F-1112-2013
OI Hendig, Doris/0000-0002-3660-6923
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chassaing N, 2005, J MED GENET, V42, P881, DOI 10.1136/jmg.2004.030171
   Chassaing N, 2004, J INVEST DERMATOL, V122, P608, DOI 10.1111/j.0022-202X.2004.22312.x
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Gorin MB, 1999, MOL VIS, V5, pU31
   Gotting C, 2005, J MOL MED, V83, P984, DOI 10.1007/s00109-005-0693-x
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hendig D, 2006, CLIN CHEM, V52, P227, DOI 10.1373/clinchem.2005.059253
   Hendig D, 2007, CLIN CHEM, V53, P829, DOI 10.1373/clinchem.2006.083675
   Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P537, DOI 10.1007/s00347-006-1353-4
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   LEBWOHL M, 1993, NEW ENGL J MED, V329, P1237, DOI 10.1056/NEJM199310213291705
   LEBWOHL M, 1994, J AM ACAD DERMATOL, V30, P103, DOI 10.1016/S0190-9622(08)81894-4
   Neldner K., 2002, CONNECTIVE TISSUE IT, P561, DOI DOI 10.1002/0471221929.CH11
   NELDNER KH, 1988, INT J DERMATOL, V27, P98, DOI 10.1111/j.1365-4362.1988.tb01280.x
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Oppermann M, 2006, CLIN EXP IMMUNOL, V144, P342, DOI 10.1111/j.1365-2249.2006.03071.x
   Pasquali-Ronchetti I, 2006, J PATHOL, V208, P54, DOI 10.1002/path.1867
   Passi A, 1996, CELL BIOCHEM FUNCT, V14, P111, DOI 10.1002/cbf.653
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   RENIE WA, 1984, AM J MED GENET, V19, P235, DOI 10.1002/ajmg.1320190205
   Ringpfeil F, 2005, CLIN DERMATOL, V23, P41, DOI 10.1016/j.clindermatol.2004.09.006
   Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494
   Scheffer GL, 2002, LAB INVEST, V82, P515, DOI 10.1038/labinvest.3780444
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sherer DW, 2001, J AM ACAD DERMATOL, V44, P534, DOI 10.1067/mjd.2001.112401
   Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706
   Uitto J, 2004, J INVEST DERMATOL, V122, pIX, DOI 10.1111/j.0022-202x.2004.22350.x
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zarbock R, 2007, CLIN CHEM, V53, P1734, DOI 10.1373/clinchem.2007.088211
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 44
TC 2
Z9 2
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1090-6576
J9 GENET TEST
JI Genet. Test.
PD SEP
PY 2008
VL 12
IS 3
BP 431
EP 436
DI 10.1089/gte.2008.0026
PG 6
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 348SO
UT WOS:000259230500020
PM 18627285
DA 2022-11-30
ER

PT J
AU Chichili, GR
   Nohr, D
   Frank, J
   Flaccus, A
   Fraser, PD
   Enfissi, EMA
   Biesalski, HK
AF Chichili, Gurunadh R.
   Nohr, Donatus
   Frank, Juergen
   Flaccus, Andrea
   Fraser, Paul D.
   Enfissi, Eugenia M. A.
   Biesalski, Hans K.
TI Protective effects of tomato extract with elevated beta-carotene levels
   on oxidative stress in ARPE-19 cells
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE beta-carotene; oxidative stress; retina; AMD; retinal pigment
   epithelium; tomato; carotenoids
ID DIETARY CAROTENOIDS; NITROGEN-DIOXIDE; BINDING PROTEIN; VITAMIN-A;
   OXYGEN; DEGENERATION; PURIFICATION; ANTIOXIDANTS; MECHANISMS; NITRATION
AB Epidemiological studies show that dietary products rich in carotenoids delay the progression of age-related macular degeneration. Experimental evidence from cellular studies on the antioxidant actions of carotenoids in the retinal pigment epithelium is still, however, fragmentary. The present study examined the uptake and protective potential of dietary carotenoids from tomato on the human retinal pigment epithelial cell line ARPE-19. ARPE-19 cells were incubated in medium supplemented with tomato extract containing high levels of beta-carotene, lycopene and traces of lutein. The cellular uptake of carotenoids was analysed by reverse-phase HPLC. Oxidative stress was induced by treatment with 1mM-H2O2. Nitrotyrosine was detected by immunocytochemistry, and oxidised proteins (protein carbonyls) were measured by a quantitative ELISA method. Lipid peroxidation was assessed by quantifying thiobarbituric acid reactive substances. ARPE-19 cells preferentially accumulated lutein and beta-carotene rather than lycopene. Nitrotyrosine formation was considerably reduced in cells incubated with tomato extract compared with controls after H2O2 treatment. Protein carbonyls were reduced by 30% (P=0.015), and the formation of thiobarbituric acid-reactive substances was reduced by 140% (P=0.003) in cells incubated with tomato extract. The present study provides the experimental evidence for protective effects of dietary tomatoes rich in carotenoids on oxidative stress in the retinal pigment epithelium.
C1 Univ Hohenheim, Inst Biol Chem & Nutr, D-70599 Stuttgart, Germany.
   Univ London Royal Holloway & Bedford New Coll, Sch Biol Sci, Egham TW20 0EX, Surrey, England.
C3 University Hohenheim; University of London; Royal Holloway University
   London
RP Biesalski, HK (通讯作者)，Univ Hohenheim, Inst Biol Chem & Nutr, Garbenstr 30, D-70599 Stuttgart, Germany.
EM biesal@uni-hohenheim.de
CR Abushita AA, 1997, FOOD CHEM, V60, P207, DOI 10.1016/S0308-8146(96)00321-4
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445
   Beecher GR, 1998, P SOC EXP BIOL MED, V218, P98, DOI 10.3181/00379727-218-44282a
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Chichili GR, 2005, INVEST OPHTH VIS SCI, V46, P3562, DOI 10.1167/iovs.05-0089
   Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3
   Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317
   Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gross J., 1987, PIGMENTS FRUITS
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   Hawkins BS, 1999, MOL VIS, V5
   HIRAYAMA O, 1994, LIPIDS, V29, P149, DOI 10.1007/BF02537155
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8
   Jouni ZE, 1996, J BIOL CHEM, V271, P14722, DOI 10.1074/jbc.271.25.14722
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kikugawa K, 1999, FREE RADICAL RES, V30, P37, DOI 10.1080/10715769900300051
   Kikugawa K, 1997, FEBS LETT, V404, P175, DOI 10.1016/S0014-5793(97)00124-5
   KRINSKY NI, 1982, J NATL CANCER I, V69, P205
   KRINSKY NI, 1998, FREE RADIC BIOL MED, V7, P617
   Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9
   Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686
   Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200
   NATARAJAN N, 1994, BIOTECHNIQUES, V17, P166
   Nomura AMY, 1997, CANCER EPIDEM BIOMAR, V6, P407
   Paetau I, 1999, AM J CLIN NUTR, V70, P490
   Raffo A, 2002, J AGR FOOD CHEM, V50, P6550, DOI 10.1021/jf020315t
   Rao MN, 1997, J BIOL CHEM, V272, P24455, DOI 10.1074/jbc.272.39.24455
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Romer S, 2000, NAT BIOTECHNOL, V18, P666, DOI 10.1038/76523
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   TONUCCI LH, 1995, J AGR FOOD CHEM, V43, P579, DOI 10.1021/jf00051a005
   TSO MOM, 1989, INVEST OPHTH VIS SCI, V30, P2430
   van het Hof KH, 2000, J NUTR, V130, P1189
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WAMER WG, 1993, NUTR CANCER, V19, P31, DOI 10.1080/01635589309514234
   Willcox JK, 2003, CRIT REV FOOD SCI, V43, P1, DOI 10.1080/10408690390826437
   Winkler BS, 1999, MOL VIS, V5
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 45
TC 18
Z9 21
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT
PY 2006
VL 96
IS 4
BP 643
EP 649
DI 10.1079/BJN20061843
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 089GB
UT WOS:000240867300005
PM 17010222
DA 2022-11-30
ER

PT J
AU Schweitzer, D
   Hammer, M
   Schweitzer, F
   Anders, R
   Doebbecke, T
   Schenke, S
   Gaillard, ER
   Gaillard, ER
AF Schweitzer, D
   Hammer, M
   Schweitzer, F
   Anders, R
   Doebbecke, T
   Schenke, S
   Gaillard, ER
   Gaillard, ER
TI In vivo measurement of time-resolved autofluorescence at the human
   fundus
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE time-resolved autofluorescence; fluorescence lifetime imaging; human
   fundus; time-correlated single photon counting; scanning laser
   ophthalmoscopy; lipofuscin; coenzymes
ID RETINAL-PIGMENT EPITHELIUM; FLUORESCENCE; LIPOFUSCIN; SPECTROSCOPY;
   IMAGES; TISSUE
AB An experimental setup for measurement of time-resolved autofluorescence of the human eye funclus is demonstrated. The method combines laser scanning technique and time-correlated single photon counting. The light source is a laser diode, delivering pulses of about 100 ps duration at a repetition rate of 40 MHz. The excitation wavelength is 446 nm and the cutoff wavelength of fluorescence detection is at 475 nm. The autofluorescence can be determined with a spatial resolution of 80X80 mum(2) and 25 ps time resolution. The fluorescence decay is optimally approximated by a biexponential model. The dominating lifetime lambda1 is shortest in the macula (320 to 380 ps) and reaches 1500 ps in the optic disk. The lifetime lambda2 varies between 2 ns and 5 ns, but the spatial distribution is more homogeneous. Respiration of 100% oxygen for 6 min leads to changes in the fluorescence lifetime pointing to detection of coenzymes. Diagrams of lifetime lambda2 versus -lambda1 are well suited for comparison of substances. Such lifetime clusters of a 20 deg macular field of a young healthy subject and of a patient suffering from dry age-related macular degeneration overlap only partially with lambda2-lambda1 clusters of lipofuscin. (C) 2004 Society of Photo-Optical Instrumentation Engineers.
C1 Univ Jena, Dept Expt Ophthalmol, Eye Clin, Bachstr 18, D-07740 Jena, Germany.
   No Illinois Univ, Dept Biochem & Chem, De Kalb, IL 60115 USA.
C3 Friedrich Schiller University of Jena; Northern Illinois University
RP Schweitzer, F (通讯作者)，Univ Jena, Dept Expt Ophthalmol, Eye Clin, Bachstr 18, D-07740 Jena, Germany.
EM Dietrich.Schweitzer@med.uni-jena.de; Gillard.@uni.edu
RI Gaillard, Elizabeth/M-2627-2019
CR *AM NAT STNAD SAF, 2000, 13612000 ANSI Z
   Andersson-Engels S., 1992, Lasers in the Life Sciences, V5, P1
   ANDERSSONENGELS S, 1991, PHOTOCHEM PHOTOBIOL, V53, P807, DOI 10.1111/j.1751-1097.1991.tb09895.x
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   CHANCE B, 1976, CIRC RES, V38, P31
   Cubeddu R, 1999, PHOTOCHEM PHOTOBIOL, V70, P172, DOI 10.1111/j.1751-1097.1999.tb07986.x
   DELORI FC, 1994, APPL OPTICS, V33, P7439, DOI 10.1364/AO.33.007439
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DOCCHIO F, 1991, PHOTOCHEM PHOTOBIOL, V54, P247, DOI 10.1111/j.1751-1097.1991.tb02013.x
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P563
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, V3rd
   Mycek MA, 1998, GASTROINTEST ENDOSC, V48, P390, DOI 10.1016/S0016-5107(98)70009-4
   Pogue BW, 2001, PHOTOCHEM PHOTOBIOL, V74, P817, DOI 10.1562/0031-8655(2001)074<0817:IVNFMA>2.0.CO;2
   POKORNY J, 1987, APPL OPTICS, V26, P1437, DOI 10.1364/AO.26.001437
   RichardsKortum R, 1996, ANNU REV PHYS CHEM, V47, P555, DOI 10.1146/annurev.physchem.47.1.555
   SACHS L, 1999, ANGEWANDTE STAT, P211
   Schulman S. G., 1985, MOL LUMINESCENCE SPE, P848
   Schweitzer D, 2003, PROC SPIE, V5141, P8, DOI 10.1117/12.499641
   Schweitzer D., 2001, International Ophthalmology, V23, P399, DOI 10.1023/A:1014475219117
   Schweitzer D, 2000, PROC SPIE, V4164, P79, DOI 10.1117/12.410636
   Schweitzer D, 2001, PROC SPIE, V4432, P29, DOI 10.1117/12.447153
   Schweitzer D, 2002, OPHTHALMOLOGE, V99, P774, DOI 10.1007/s00347-002-0656-3
   Schweitzer D, 2000, OPHTHALMOLOGE, V97, P84, DOI 10.1007/s003470050017
   SCHWEITZER D, 2003, ARVO M, P3615
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   STRYER L, 1991, BIOCHIMIE, P413
   VISSER AJWG, 1979, J BIOCHEM BIOPH METH, V1, P195, DOI 10.1016/0165-022X(79)90006-X
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   VOSS K, 1998, P 20 DAGM S, P439
   Wagnieres GA, 1998, PHOTOCHEM PHOTOBIOL, V68, P603
NR 34
TC 108
Z9 110
U1 0
U2 15
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD NOV-DEC
PY 2004
VL 9
IS 6
BP 1214
EP 1222
DI 10.1117/1.1806833
PG 9
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 879DU
UT WOS:000225697400014
PM 15568942
DA 2022-11-30
ER

PT J
AU Tan, WC
   Beaumont, PE
   Chang, AA
AF Tan, WC
   Beaumont, PE
   Chang, AA
TI Case series outcomes at 1 week following verteporfin photodynamic
   therapy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy
ID CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; MACULOPATHY;
   PHASE-1; EYE
AB Purpose: To examine the choroidal neovascularization (CNV) fluorescein angiographic perfusion and visual acuity 1 week after photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis AG, Switzerland) on predominantly classic, subfoveal lesions in age-related macular degeneration (AMD).
   Method: A retrospective case series study was conducted on the 1-week outcome of PDT treatment of 76 of 79 consecutive patients with the subfoveal, predominantly classic CNV form of AMD. Leakage from CNV was assessed by fluorescein angiography and best-corrected visual acuity determined on projected Snellen charts using a standardized protocol.
   Results: One week after PDT treatment, absence of fluorescein leakage from CNV was observed in 100% of the 76 patients. Visual acuity improved (at least a three-line gain) in 11 patients (15%), remained unchanged (less than a three-line gain or loss) in 64 patients (84%), and deteriorated (at least a three-line loss) in only one patient (1%).
   Conclusion: The absence of fluorescein leakage from classic CNV at 1 week in all cases was consistent with the published outcome of the clinical Phase I and 11 PDT trials. Further, vision loss 1 week after PDT for predominantly classic CNV was very uncommon. Therefore 1-week post-PDT angiography is unnecessary for predominantly classic CNV in patients with AMD.
C1 Eye & Vis Res Inst, Sydney, NSW 2000, Australia.
   Sydney Retinal Consultants, Sydney, NSW, Australia.
RP Beaumont, PE (通讯作者)，Eye & Vis Res Inst, Suite 6,6th Floor,Pk House,187 Macquarie St, Sydney, NSW 2000, Australia.
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 14
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2003
VL 23
IS 2
BP 166
EP 170
DI 10.1097/00006982-200304000-00005
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 679AK
UT WOS:000182898700005
PM 12707594
DA 2022-11-30
ER

PT J
AU Xiao, S
   Ahn, DU
AF Xiao, Shulan
   Ahn, Dong Uk
TI Enhanced lutein stability under UV-Light and high temperature by loading
   it into alginate-chitosan complex
SO LWT-FOOD SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Lutein; Sodium alginate; Chitosan; Complex; Chemical stability
ID ENCAPSULATION; DELIVERY; MICROCAPSULES; COACERVATION
AB Lutein is one of the carotenoids found in various fruits, green leafy vegetables, and egg yolk. Lutein has multiple functions, including preventing age-related macular degeneration in the human body. However, lutein is susceptible to high temperature, light, and oxygen. The objective of this study was to produce lutein-loaded polysaccharide complexes to increase the stability of lutein. The physical and chemical properties of lutein-polysaccharide complexes were characterized. The entrapment efficiency (EE%) and loading capacity (LC%) of ltuein, and the lutein's stability to high temperatures and UV light were tested. The results showed that the lutein-loaded complexes had greater than 98% entrapment efficiency and 35% loading capacity. The AL/CS complexes showed significantly higher thermal (70 degrees C, 3 h) and UV-light stabilities than the free lutein. The SEM, FTIR, and XRD results suggested that the lutein-loaded AL/CS complexes had a flake-like structure, and lutein was inserted into the AL/CS complexes as amorphous forms. The main forces that incorporated and stabilized lutein inside the AL/CS complexes were the hydrophobic environments caused by the neutralization of net charge on the alginate and chitosan and the intermolecular hydrogen bonds between lutein, alginate, and chitosan.
C1 [Xiao, Shulan; Ahn, Dong Uk] Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.
   [Xiao, Shulan] Iowa State Univ, Dept Food Sci & Human Nutr, Ames, IA 50011 USA.
C3 Iowa State University; Iowa State University
RP Ahn, DU (通讯作者)，Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.
EM duahn@iastate.edu
OI Xiao, Shulan/0000-0001-6969-5566
FU China Scholarship Council, China [201806850101]; Iowa Agriculture and
   Home Economics Experiment Station, Ames, Iowa
FX This work was supported by the China Scholarship Council, China (Grant
   No. 201806850101) and the Iowa Agriculture and Home Economics Experiment
   Station, Ames, Iowa.
CR Aizura Aren Z., GEOMICROBIOL J, V33, P303, DOI [10.1080/10357820903153707, DOI 10.1080/01490451003702933, 10.1080/10408690590957034, DOI https://doi.org/10.1080/07391102.2020.1776639]
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Arunkumar R, 2013, FOOD CHEM, V141, P327, DOI 10.1016/j.foodchem.2013.02.108
   Barry John A., 2014, J CONSUM RES, V20, P748, DOI [10.1093/ajcn.70.2.247, DOI 10.1093/ACPROF:OSO/9780195389579.001.0001, 10.1093/humupd/dmu012, DOI 10.1093/JCR/UCV038]
   Baruch L, 2006, BIOPOLYMERS, V82, P570, DOI 10.1002/bip.20509
   Calvo MM, 2005, CRIT REV FOOD SCI, V45, P671, DOI 10.1080/10408690590957034
   Costa AMM, 2020, LWT-FOOD SCI TECHNOL, V131, DOI 10.1016/j.lwt.2020.109519
   de Boer FY, 2020, FOOD CHEM X, V5, DOI 10.1016/j.fochx.2019.100071
   de Souza VB, 2018, FOOD HYDROCOLLOID, V77, P297, DOI 10.1016/j.foodhyd.2017.09.040
   Devi N, 2017, ADV COLLOID INTERFAC, V239, P136, DOI 10.1016/j.cis.2016.05.009
   Dias DR, 2017, CURR OPIN FOOD SCI, V13, P31, DOI 10.1016/j.cofs.2017.02.001
   Erdman JW, 2015, FOODS, V4, P547, DOI 10.3390/foods4040547
   Fleming C A, 2018, CHEMCATCHEM, V105, P1098, DOI [10.1002/bjs.10899, DOI 10.1002/CCTC.202001179, 10.1002/bip.20509, DOI https://doi.org/10.1002/ddr.21666]
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Hashim AF, 2019, INT J BIOL MACROMOL, V140, P682, DOI 10.1016/j.ijbiomac.2019.08.085
   Hernandez-Nava R, 2020, FOOD HYDROCOLLOID, V109, DOI 10.1016/j.foodhyd.2020.106077
   Kariuki Boniface Wainaina, BOLET N M DICO HOSP, V116, P88, DOI [10.1016/j.beproc.2017.02.005, DOI https://doi.org/10.3390/ma10070775, 10.1016/j.renene.2017.09.069, DOI 10.1016/J.BMHIMX.2017.02.005]
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kopec RE, 2017, FOOD FUNCT, V8, P1494, DOI [10.1039/c7fo00021a, 10.1039/C7FO00021A]
   Lawrie G, 2007, BIOMACROMOLECULES, V8, P2533, DOI 10.1021/bm070014y
   Leeson S, 2004, POULTRY SCI, V83, P1709, DOI 10.1093/ps/83.10.1709
   Leeson S., 2012, PEST MANAG SCI, V83, P1709, DOI [10.1093/ps/83.10.1709, DOI 10.1093/PS/83.10.1709, DOI 10.1002/PS.3412]
   Leng X, 2022, J AGR FOOD CHEM, V70, P2328, DOI 10.1021/acs.jafc.1c04615
   Lertsutthiwong P, 2009, MAT SCI ENG C-BIO S, V29, P856, DOI 10.1016/j.msec.2008.08.004
   Li SE, 2020, MOLECULES, V25, DOI 10.3390/molecules25051231
   Li XY, 2007, J AGR FOOD CHEM, V55, P2911, DOI 10.1021/jf062900q
   Ma MJ, 2020, LWT-FOOD SCI TECHNOL, V125, DOI 10.1016/j.lwt.2020.109270
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Orozco Toro Jaime Alberto, 2018, APPL PHYS EXPRESS, V16, P95, DOI [10.1021/acs.jafc.9b05175, DOI https://doi.org/10.1080/14616688.2020.1765010, 10.22395/angr.v16n32a6, DOI 10.1143/APEX.3.055002]
   Pereira PF, 2017, CARBOHYD POLYM, V165, P238, DOI 10.1016/j.carbpol.2017.02.047
   Pereira Pamela F., CARBOHYD POLYM, V165, P238, DOI [10.1016/j.carbpol.2017.02.047, DOI 10.1016/J.CARBPOL.2017.02.047, DOI 10.1016/J.JCIN.2017.02.047]
   Sankalia MG, 2007, EUR J PHARM BIOPHARM, V65, P215, DOI 10.1016/j.ejpb.2006.07.014
   Brum AAS, 2017, COLLOID SURFACE A, V522, P477, DOI 10.1016/j.colsurfa.2017.03.041
   Sato Y, 2018, EUR J PHARM BIOPHARM, V127, P171, DOI 10.1016/j.ejpb.2018.02.013
   Sjogren Lea L., ANIM BEHAV, V91, P25, DOI [10.1016/j.maturitas.2016.05.013, DOI 10.1016/J.ANBEHAV.2014.11.002, 10.1016/j.geomorph.2006.04.020, DOI 10.32674/JIS.V5I4.412]
   TAY LF, 1993, BIOTECHNOL BIOENG, V42, P449, DOI 10.1002/bit.260420407
   Teixeira-Costa BE, 2020, FOOD HYDROCOLLOID, V109, DOI 10.1016/j.foodhyd.2020.106097
   Timilsena YP, 2019, INT J BIOL MACROMOL, V121, P1276, DOI 10.1016/j.ijbiomac.2018.10.144
   Vandenberg GW, 2001, J CONTROL RELEASE, V77, P297, DOI 10.1016/S0168-3659(01)00517-X
   Xia F, 2012, FOOD HYDROCOLLOID, V26, P456, DOI 10.1016/j.foodhyd.2010.11.014
   Yuan YK, 2019, J AGR FOOD CHEM, V67, P11977, DOI 10.1021/acs.jafc.9b05175
   Zhang Yifeng, EUR J PHARMACOL, V150, P47, DOI [10.1016/j.meatsci.2018.12.008, DOI 10.1016/J.EJPHAR.2018.08.021, 10.1016/j.ijbiomac.2018.10.144, DOI 10.1016/J.JECE.2018.08.061]
   Zhao CD, 2014, FOOD CHEM, V156, P123, DOI 10.1016/j.foodchem.2014.01.086
NR 45
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0023-6438
EI 1096-1127
J9 LWT-FOOD SCI TECHNOL
JI LWT-Food Sci. Technol.
PD JUL 15
PY 2022
VL 164
AR 113663
DI 10.1016/j.lwt.2022.113663
PG 8
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 5V8DR
UT WOS:000877455100010
OA gold
DA 2022-11-30
ER

PT J
AU Kim, J
   Won, JY
AF Kim, Jongmin
   Won, Jae Yon
TI Effect of Photobiomodulation in Suppression of Oxidative Stress on
   Retinal Pigment Epithelium
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE photobiomodulation; oxidative stress; antioxidant; retinal pigment
   epithelium degeneration
ID DEGENERATION; PHAGOCYTOSIS; MODEL
AB As the world undergoes aging, the number of age-related diseases has increased. One of them is disease related to retinal pigment epithelium (RPE) degeneration, such as age-related macular degeneration, causing vision loss without physical damage in the ocular system. It is the leading cause of blindness, with no cure. Although the exact pathogenesis is still unknown, the research shows that oxidative stress is one of the risk factors. Various molecules have been reported as anti-oxidative materials; however, the disease has not yet been conquered. Here, we would like to introduce photobiomodulation (PBM). PBM is a non-invasive treatment based on red and near-infrared light and has been used to cure various diseases by regulating cellular functions. Furthermore, recent studies showed its antioxidant effect, and due to this reason, PBM is arising as a new treatment for ocular disease. In this study, we confirm the antioxidant effect of PBM in retinal pigment epithelium via an RPE model with hypoxia. The function of RPE is protected by PBM against damage from hypoxia. Furthermore, we observed the protective mechanism of PBM by its suppression effect on reactive oxygen species generation. These results indicate that PBM shows great potential to cure RPE degeneration to help patients with blindness.
C1 [Kim, Jongmin] Pohang Univ Sci & Technol POSTECH, Dept Mech Engn, Pohang 37673, South Korea.
   [Won, Jae Yon] Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 03312, South Korea.
   [Won, Jae Yon] Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul 14662, South Korea.
C3 Pohang University of Science & Technology (POSTECH); Catholic University
   of Korea; Catholic University of Korea
RP Won, JY (通讯作者)，Catholic Univ Korea, Eunpyeong St Marys Hosp, Dept Ophthalmol & Visual Sci, Seoul 03312, South Korea.; Won, JY (通讯作者)，Catholic Univ Korea, Coll Med, Catholic Inst Visual Sci, Seoul 14662, South Korea.
EM mandarinbear@postech.ac.kr; jaywon24@catholic.ac.kr
FU National Research Foundation of Korea - Korean Government (MSIP)
   [NRF-2021R1C1C1008042]; Catholic University of Korea, Eunpyeong St.
   Mary's Hospital Research Institute of Medical Science
FX This work was supported by a National Research Foundation of Korea grant
   funded by the Korean Government (MSIP) (NRF-2021R1C1C1008042) and The
   Catholic University of Korea, Eunpyeong St. Mary's Hospital Research
   Institute of Medical Science.
CR Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Barreiro E, 2010, AM J RESP CRIT CARE, V182, P477, DOI 10.1164/rccm.200908-1220OC
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   BONDY SC, 1995, P SOC EXP BIOL MED, V208, P337
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073484
   Fuma S, 2015, MOL VIS, V21, P883
   Geneva II, 2016, INT J OPHTHALMOL-CHI, V9, P145, DOI 10.18240/ijo.2016.01.24
   Glazer Liane Clamen, 2002, Ophthalmol Clin North Am, V15, P93, DOI 10.1016/S0896-1549(01)00011-6
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Hamilton RD, 2011, METHODS MOL BIOL, V686, P401, DOI 10.1007/978-1-60761-938-3_20
   Heinig N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072370
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jauregui R, 2018, OPHTHALMIC GENET, V39, P544, DOI 10.1080/13816810.2018.1484929
   Kim BS, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120776
   Kim J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212298
   Kim J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031095
   Kim J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207757
   Kong JS, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100581
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Lakshmi SVV, 2009, INDIAN J BIOCHEM BIO, V46, P421
   Lee H, 2017, BIOMACROMOLECULES, V18, P1229, DOI 10.1021/acs.biomac.6b01908
   Li K, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0084171, 10.1371/journal.pone.0067018, 10.1371/journal.pone.0058057, 10.1371/journal.pone.0063139, 10.1371/journal.pone.0068157]
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Merry G., 2012, INVESTIG OPHTHALMOL, V53, P2049
   Montoro LA, 2014, INT ENDOD J, V47, P747, DOI 10.1111/iej.12211
   Naeser M.A., 2015, TRAUMATIC BRAIN INJU
   Nguyen-Legros J, 2000, INT REV CYTOL, V196, P245
   Rinaldi C, 2021, LIFE-BASEL, V11, DOI 10.3390/life11080767
   Scimone C, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108641
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strong S, 2017, BRIT J OPHTHALMOL, V101, P31, DOI 10.1136/bjophthalmol-2016-309376
   Takemoto MM, 2019, J PHOTOCH PHOTOBIO B, V199, DOI 10.1016/j.jphotobiol.2019.111592
   Tang J, 2014, BRIT J OPHTHALMOL, V98, P1013, DOI 10.1136/bjophthalmol-2013-304477
   Winkler BS, 1999, MOL VIS, V5
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
NR 43
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2022
VL 23
IS 12
AR 6413
DI 10.3390/ijms23126413
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 2P3EN
UT WOS:000819629100001
PM 35742861
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU de Imperial-Ollero, JAM
   Gallego-Ortega, A
   Ortin-Martinez, A
   Villegas-Perez, MP
   Valiente-Soriano, FJ
   Vidal-Sanz, M
AF Miralles de Imperial-Ollero, Juan A.
   Gallego-Ortega, Alejandro
   Ortin-Martinez, Arturo
   Paz Villegas-Perez, Maria
   Valiente-Soriano, Francisco J.
   Vidal-Sanz, Manuel
TI Animal Models of LED-Induced Phototoxicity. Short- and Long-Term In Vivo
   and Ex Vivo Retinal Alterations
SO LIFE-BASEL
LA English
DT Review
DE LED induced phototoxicity; cone photoreceptor; microglia activation;
   retinal pigment epithelium; neuroprotection
ID PIGMENT EPITHELIAL-CELLS; LIGHT DAMAGE; MACULAR DEGENERATION;
   NEUROTROPHIC FACTOR; MICROGLIAL CELLS; GANGLION-CELLS; FUNDUS
   AUTOFLUORESCENCE; PHOTORECEPTOR DEGENERATION; PHOTOCHEMICAL DAMAGE;
   OCULAR HYPERTENSION
AB Phototoxicity animal models have been largely studied due to their degenerative communalities with human pathologies, e.g., age-related macular degeneration (AMD). Studies have documented not only the effects of white light exposure, but also other wavelengths using LEDs, such as blue or green light. Recently, a blue LED-induced phototoxicity (LIP) model has been developed that causes focal damage in the outer layers of the superior-temporal region of the retina in rodents. In vivo studies described a progressive reduction in retinal thickness that affected the most extensively the photoreceptor layer. Functionally, a transient reduction in a- and b-wave amplitude of the ERG response was observed. Ex vivo studies showed a progressive reduction of cones and an involvement of retinal pigment epithelium cells in the area of the lesion and, in parallel, an activation of microglial cells that perfectly circumscribe the damage in the outer retinal layer. The use of neuroprotective strategies such as intravitreal administration of trophic factors, e.g., basic fibroblast growth factor (bFGF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF) or pigment epithelium-derived factor (PEDF) and topical administration of the selective alpha-2 agonist (Brimonidine) have demonstrated to increase the survival of the cone population after LIP.
C1 [Miralles de Imperial-Ollero, Juan A.; Gallego-Ortega, Alejandro; Paz Villegas-Perez, Maria; Valiente-Soriano, Francisco J.; Vidal-Sanz, Manuel] Univ Murcia & Inst Murciano Invest Biosanitaria I, Dept Oftalmol, Campus CC Salud, Murcia 30120, Spain.
   [Ortin-Martinez, Arturo] Univ Hlth Network, Krembil Res Inst, Donald K Johnson Eye Inst, Toronto, ON M5T 2S8, Canada.
C3 Krembil Research Institute; University of Toronto; University Toronto
   Affiliates; University Health Network Toronto
RP Valiente-Soriano, FJ; Vidal-Sanz, M (通讯作者)，Univ Murcia & Inst Murciano Invest Biosanitaria I, Dept Oftalmol, Campus CC Salud, Murcia 30120, Spain.
EM juanantonio.miralles@um.es; alejandrogallego@um.es;
   Arturo.OrtinMartinez@uhnresearch.ca; mpville@um.es; fjvaliente@um.es;
   manuel.vidal@um.es
RI Miralles de Imperial-Ollero, Juan Antonio/GLT-9319-2022; Vidal-Sanz,
   Manuel/J-6989-2016
OI Miralles de Imperial-Ollero, Juan Antonio/0000-0003-4582-2297;
   Valiente-Soriano, Francisco J,/0000-0002-1837-6589; Ortin Martinez,
   Arturo/0000-0003-0492-6604; Villegas-Perez, Maria
   Paz/0000-0002-5734-482X; Gallego-Ortega, Alejandro/0000-0001-6770-7463;
   Vidal-Sanz, Manuel/0000-0002-9216-1615
FU Fundacion Seneca, Agencia de Ciencia y Tecnologia Region de Murcia -
   ERDF "A way of making Europe" [19881/GERM/15]; Instituto de Salud Carlos
   III - ERDF "A way of making Europe" [PI19/00203, RD16/0008/0026]; 
   [RED2018-102499-T];  [PID2019-106498GB-I00]; 
   [MCIN/AEI/10.13039/501100011033]
FX Fundacion Seneca, Agencia de Ciencia y Tecnologia Region de Murcia:
   19881/GERM/15 to M.V.-S.; Instituto de Salud Carlos III: PI19/00203 and
   RD16/0008/0026, both cofinanced by ERDF "A way of making Europe" to
   M.P.V.-P.; RED2018-102499-T and PID2019-106498GB-I00 funded by
   MCIN/AEI/10.13039/501100011033 to M.V.-S.
CR Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Aviles-Trigueros M, 2003, EXP NEUROL, V184, P767, DOI 10.1016/S0014-4886(03)00298-X
   Bailey JNC, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030031
   Baptiste DC, 2005, NEUROSCIENCE, V134, P575, DOI 10.1016/j.neuroscience.2005.04.011
   Becerra SP, 2006, EXP EYE RES, V82, P739, DOI 10.1016/j.exer.2005.10.016
   Becerra SP, 1997, ADV EXP MED BIOL, V425, P223
   Behar-Cohen F, 2011, PROG RETIN EYE RES, V30, P239, DOI 10.1016/j.preteyeres.2011.04.002
   Beltramo E, 2016, ACTA DIABETOL, V53, P957, DOI 10.1007/s00592-016-0895-4
   Bjorkholm C, 2016, NEUROPHARMACOLOGY, V102, P72, DOI 10.1016/j.neuropharm.2015.10.034
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Broadhead ML, 2010, GROWTH FACTORS, V28, P280, DOI 10.3109/08977191003604513
   Castanares M, 2005, BIOCHEM BIOPH RES CO, V337, P663, DOI 10.1016/j.bbrc.2005.09.101
   Cerri E, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.6.1
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang CJ, 2005, OPHTHALMIC RES, V37, P202, DOI 10.1159/000086610
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Choi JY, 2016, ENVIRON TOXICOL PHAR, V45, P140, DOI 10.1016/j.etap.2016.05.026
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Conti Federica, 2021, Front Pharmacol, V12, P705405, DOI 10.3389/fphar.2021.705405
   de Hoz R, 2018, EXP EYE RES, V171, P12, DOI 10.1016/j.exer.2018.03.006
   del Rio-Hortega P, 1939, LANCET, V1, P1023
   Denman DJ, 2017, J NEUROSCI, V37, P1102, DOI 10.1523/JNEUROSCI.1742-16.2016
   Di Carlo E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153297
   Di Pierdomenico J, 2019, NEURAL REGEN RES, V14, P1186, DOI 10.4103/1673-5374.251204
   Di Pierdomenico J, 2018, INVEST OPHTH VIS SCI, V59, P4392, DOI 10.1167/iovs.18-24621
   Di Pierdomenico J, 2016, INVEST OPHTH VIS SCI, V57, P3533, DOI 10.1167/iovs.16-19618
   Dixit S, 2020, EXP EYE RES, V198, DOI 10.1016/j.exer.2020.108121
   Downie LE, 2019, JAMA OPHTHALMOL, V137, P694, DOI 10.1001/jamaophthalmol.2019.0019
   Dulz S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092082
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Galindo-Romero C, 2013, INVEST OPHTH VIS SCI, V54, P974, DOI 10.1167/iovs.12-11207
   Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022
   Garcia-Ayuso D, 2018, INVEST OPHTH VIS SCI, V59, P1396, DOI 10.1167/iovs.17-23258
   Garcia-Ayuso D, 2017, EXP EYE RES, V161, P10, DOI 10.1016/j.exer.2017.05.010
   Garcia-Ayuso D, 2011, MOL VIS, V17, P1716
   Gauthier R, 2005, INVEST OPHTH VIS SCI, V46, P3383, DOI 10.1167/iovs.05-0362
   Gliem M, 2020, OPHTHALMOL RETINA, V4, P737, DOI 10.1016/j.oret.2020.02.009
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Grotegut P, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02012-y
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Jaadane I, 2015, J CELL MOL MED, V19, P1646, DOI 10.1111/jcmm.12539
   Jaadane I, 2015, FREE RADICAL BIO MED, V84, P373, DOI 10.1016/j.freeradbiomed.2015.03.034
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Jonas RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030763
   Ju WK, 1999, NEUROREPORT, V10, P419, DOI 10.1097/00001756-199902050-00038
   Kano T, 2002, INVEST OPHTH VIS SCI, V43, P3744
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kenealey J, 2015, J BIOL CHEM, V290, P25241, DOI 10.1074/jbc.M115.645846
   Kim GH, 2016, GRAEF ARCH CLIN EXP, V254, P705, DOI 10.1007/s00417-015-3258-x
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Krigel A, 2016, NEUROSCIENCE, V339, P296, DOI 10.1016/j.neuroscience.2016.10.015
   Kumar A, 2013, EUR J PHARMACOL, V720, P16, DOI 10.1016/j.ejphar.2013.10.057
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   Lafuente MP, 2002, EXP EYE RES, V74, P181, DOI 10.1006/exer.2001.1122
   Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074
   Lambert WS, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-4
   Levkovitch-Verbin H, 2006, ARCH OPHTHALMOL-CHIC, V124, P520, DOI 10.1001/archopht.124.4.520
   Levkovitch-Verbin H, 2014, INT J NEUROSCI, V124, P755, DOI 10.3109/00207454.2013.878340
   Levkovitch-Verbin H, 2014, GRAEF ARCH CLIN EXP, V252, P761, DOI 10.1007/s00417-014-2588-4
   Li SH, 2018, J BIOL CHEM, V293, P15256, DOI 10.1074/jbc.RA118.004008
   Li XL, 2021, MOL VIS, V27, P438
   Lin CH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071799
   Lin CH, 2017, TOXICOL SCI, V157, P196, DOI 10.1093/toxsci/kfx030
   Lusthaus JA, 2017, EXPERT OPIN DRUG SAF, V16, P1071, DOI 10.1080/14740338.2017.1346083
   Marco-Gomariz MA, 2006, J COMP NEUROL, V498, P163, DOI 10.1002/cne.21028
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Marquioni-Ramella MD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1560, DOI 10.1039/c5pp00188a
   Mathews MK, 2015, BRIT J OPHTHALMOL, V99, P133, DOI 10.1136/bjophthalmol-2014-305969
   Mayor-Torroglosa S, 2005, INVEST OPHTH VIS SCI, V46, P3825, DOI 10.1167/iovs.05-0392
   Michelis G, 2021, J NEUROCHEM, V159, P840, DOI 10.1111/jnc.15454
   de Imperial-Ollero JMA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189742
   de Imperial-Ollero JAM, 2021, EXP EYE RES, V211, DOI 10.1016/j.exer.2021.108746
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Montalban-Soler L, 2012, MOL VIS, V18, P675
   Moon J, 2017, INTEGR BIOL-UK, V9, P436, DOI 10.1039/c7ib00032d
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Nadal-Nicolas FM, 2020, ELIFE, V9, DOI 10.7554/eLife.56840
   Nadal-Nicolas FM, 2018, NEUROBIOL AGING, V61, P146, DOI 10.1016/j.neurobiolaging.2017.09.021
   Nadal-Nicolas FM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0982-7
   Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267
   Nakamura M, 2018, EXP EYE RES, V177, P1, DOI 10.1016/j.exer.2018.07.022
   Nakamura M, 2017, BIOL PHARM BULL, V40, P1219, DOI 10.1248/bpb.b16-01008
   Narimatsu T, 2015, EXP EYE RES, V132, P48, DOI 10.1016/j.exer.2015.01.003
   Navarro V, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00140
   Nir I, 2001, INVEST OPHTH VIS SCI, V42, P842
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   O'Driscoll C, 2008, J NEUROCHEM, V105, P524, DOI 10.1111/j.1471-4159.2007.05189.x
   O'Hagan JB, 2016, EYE, V30, P230, DOI 10.1038/eye.2015.261
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Ortin-Martinez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113798
   Ortin-Martinez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102392
   Ortin-Martinez A, 2010, INVEST OPHTH VIS SCI, V51, P3171, DOI 10.1167/iovs.09-4861
   Ouyang XL, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110577
   Paavo M, 2019, J NEUROSCI RES, V97, P98, DOI 10.1002/jnr.24252
   Parrilla-Reverter G, 2009, EXP EYE RES, V89, P32, DOI 10.1016/j.exer.2009.02.015
   Pichi F, 2018, ACTA OPHTHALMOL, V96, pE549, DOI 10.1111/aos.13602
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rajagopalan L, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108678
   Ramirez AI, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00214
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Rapp M, 2014, ADV EXP MED BIOL, V801, P813, DOI 10.1007/978-1-4614-3209-8_102
   Reichenbach A, 2020, GLIA, V68, P768, DOI 10.1002/glia.23727
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133
   Rovere G, 2016, INVEST OPHTH VIS SCI, V57, P6652, DOI 10.1167/iovs.16-20146
   Salinas-Navarro M, 2009, VISION RES, V49, P115, DOI 10.1016/j.visres.2008.09.029
   Salvador-Silva M, 2000, J COMP NEUROL, V417, P431, DOI 10.1002/(SICI)1096-9861(20000221)417:4<431::AID-CNE4>3.0.CO;2-G
   Sanchez-Migallon MC, 2016, INVEST OPHTH VIS SCI, V57, P81, DOI 10.1167/iovs.15-17841
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0431-4
   Sepah YJ, 2014, SAUDI J OPHTHALMOL, V28, P111, DOI 10.1016/j.sjopt.2014.03.008
   Shang YM, 2014, ENVIRON HEALTH PERSP, V122, P269, DOI 10.1289/ehp.1307294
   Shen C, 2018, OPT EXPRESS, V26, pA219, DOI 10.1364/OE.26.00A219
   Shimazawa M, 2005, BRAIN RES, V1053, P185, DOI 10.1016/j.brainres.2005.06.053
   Silverman SM, 2018, ANNU REV VIS SCI, V4, P45, DOI 10.1146/annurev-vision-091517-034425
   Sobrado-Calvo P, 2007, J COMP NEUROL, V501, P866, DOI 10.1002/cne.21279
   Song JA, 2019, FISH PHYSIOL BIOCHEM, V45, P391, DOI 10.1007/s10695-018-0571-4
   Song JA, 2016, BIOCHEM BIOPH RES CO, V476, P96, DOI 10.1016/j.bbrc.2016.05.049
   Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5
   Subramanian P, 2013, J BIOL CHEM, V288, P23928, DOI 10.1074/jbc.M113.487884
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tanito M, 2006, EXP EYE RES, V83, P1493, DOI 10.1016/j.exer.2006.08.006
   Terauchi R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0239108
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tombran-Tink J, 2003, NAT REV NEUROSCI, V4, P628, DOI 10.1038/nrn1176
   Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12
   Tsukahara N, 2014, J VET MED SCI, V76, P93, DOI 10.1292/jvms.13-0293
   Unsicker K, 2013, CELL TISSUE RES, V353, P205, DOI 10.1007/s00441-013-1585-y
   Valiente-Soriano FJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197242
   Valiente-Soriano FJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.36
   Valiente-Soriano FJ, 2015, INVEST OPHTH VIS SCI, V56, P1924, DOI 10.1167/iovs.15-16454
   van der Meer AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.21
   van Norren D, 2016, EYE, V30, P169, DOI 10.1038/eye.2015.218
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Vicente-Tejedor J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194218
   Vidal-Sanz M, 2007, EYE, V21, pS42, DOI 10.1038/sj.eye.6702888
   Vidal-Sanz M, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00235
   Vidal-Sanz M, 2015, PROG BRAIN RES, V220, P1, DOI 10.1016/bs.pbr.2015.04.008
   Walsh N, 2001, EXP EYE RES, V72, P495, DOI 10.1006/exer.2000.0984
   Wang AL, 2005, NEUROCHEM INT, V47, P152, DOI 10.1016/j.neuint.2005.04.018
   Wen R, 1998, CURR EYE RES, V17, P494, DOI 10.1076/ceyr.17.5.494.5186
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wheeler LA, 2001, EUR J OPHTHALMOL, V11, pS30
   Wheeler LA, 2001, SURV OPHTHALMOL, V45, pS290, DOI 10.1016/S0039-6257(01)00206-5
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Wohl SG, 2010, INVEST OPHTH VIS SCI, V51, P2686, DOI 10.1167/iovs.09-4537
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xia HK, 2019, SCI CHINA LIFE SCI, V62, P244, DOI 10.1007/s11427-018-9357-y
   Yokoyama Y, 2019, J GLAUCOMA, V28, P575, DOI 10.1097/IJG.0000000000001285
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344
   Zhang TZ, 2018, BIOMED PHARMACOTHER, V103, P1355, DOI 10.1016/j.biopha.2018.04.081
NR 158
TC 1
Z9 1
U1 5
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-1729
J9 LIFE-BASEL
JI Life-Basel
PD NOV
PY 2021
VL 11
IS 11
AR 1137
DI 10.3390/life11111137
PG 21
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Microbiology
GA XF9BY
UT WOS:000724360900001
PM 34833013
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Saxena, A
   Yao, XW
   Wong, D
   Chua, J
   Ang, M
   Hoang, QV
   Agrawal, R
   Girard, M
   Cheung, G
   Schmetterer, L
   Tan, BY
AF Saxena, Ashish
   Yao, Xinwen
   Wong, Damon
   Chua, Jacqueline
   Ang, Marcus
   Hoang, Quan, V
   Agrawal, Rupesh
   Girard, Michael
   Cheung, Gemmy
   Schmetterer, Leopold
   Tan, Bingyao
TI Framework for quantitative three-dimensional choroidal vasculature
   analysis using optical coherence tomography
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID VESSEL SEGMENTATION; AUTOMATED SEGMENTATION; MACULAR DEGENERATION; AXIAL
   LENGTH; THICKNESS; IMAGES; CHORIOCAPILLARIS; ENHANCEMENT; REMOVAL;
   ADULTS
AB Choroidal vasculature plays an important role in the pathogenesis of retinal diseases, such asmyopic maculopathy, age-related macular degeneration, diabetic retinopathy, central serous chorioretinopathy, and ocular inflammatory diseases. Current optical coherence tomography (OCT) technology provides three-dimensional visualization of the choroidal angioarchitecture; however, quantitative measures remain challenging. Here, we propose and validate a framework to segment and quantify the choroidal vasculature from a prototype swept-source OCT (PLEX Elite 9000, Carl Zeiss Meditec, USA) using a 3x3 mm scan protocol centered on the macula. Enface images referenced from the retinal pigment epithelium were reconstructed from the volumetric data. The boundaries of the choroidal volume were automatically identified by tracking the choroidal vessel feature structure over the depth, and a selective sliding window was applied for segmenting the vessels adaptively from attenuation-corrected enface images. We achieved a segmentation accuracy of 96% +/- 1% as compared with manual annotation, and a dice coefficient of 0.83 +/- 0.04 for repeatability. Using this framework on both control (0.00 D to -2.00 D) and highly myopic (-8.00 D to -11.00 D) eyes, we report a decrease in choroidal vessel volume (p<0.001) in eyes with high myopia. (C) 2021 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Saxena, Ashish; Yao, Xinwen; Wong, Damon; Chua, Jacqueline; Ang, Marcus; Hoang, Quan, V; Agrawal, Rupesh; Girard, Michael; Cheung, Gemmy; Schmetterer, Leopold; Tan, Bingyao] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Saxena, Ashish; Yao, Xinwen; Wong, Damon; Chua, Jacqueline; Schmetterer, Leopold; Tan, Bingyao] SERI NTU Adv Ocular Engn STANCE, Singapore, Singapore.
   [Yao, Xinwen; Wong, Damon; Cheung, Gemmy; Schmetterer, Leopold; Tan, Bingyao] NTU Inst Hlth Technol, Singapore, Singapore.
   [Chua, Jacqueline; Ang, Marcus; Hoang, Quan, V; Agrawal, Rupesh; Girard, Michael; Schmetterer, Leopold] Duke NUS Med Sch, Dept Ophthalmol, Singapore, Singapore.
   [Hoang, Quan, V] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Hoang, Quan, V] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.
   [Agrawal, Rupesh] Tan Tock Seng Hosp, Singapore, Singapore.
   [Agrawal, Rupesh] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Schmetterer, Leopold] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore, Singapore.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Girard, Michael; Schmetterer, Leopold] Inst Mol & Clin Ophthalmol, CH-4031 Basel, Switzerland.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   Columbia University; Tan Tock Seng Hospital; Nanyang Technological
   University & National Institute of Education (NIE) Singapore; Nanyang
   Technological University; Nanyang Technological University & National
   Institute of Education (NIE) Singapore; Nanyang Technological
   University; Medical University of Vienna; Medical University of Vienna
RP Tan, BY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.; Tan, BY (通讯作者)，SERI NTU Adv Ocular Engn STANCE, Singapore, Singapore.; Tan, BY (通讯作者)，NTU Inst Hlth Technol, Singapore, Singapore.
EM Bingyao.tun@ntu.edu.sg
OI Schmetterer, Leopold/0000-0002-7189-1707; Wong,
   Damon/0000-0003-4601-9121
FU National Medical Research Council [CG/C010A/2017_SERI, OFIRG/0048/2017,
   OFLCG/004c/2018, TA/MOH-000249-00/2018]; National Research Foundation
   Singapore; Agency for Science, Technology and Research [A20H4b014];
   Singapore Eye Research Institute & Nanyang Technological University
   SERI-NTU Advanced Ocular Engineering (STANCE) Program; Duke-NUS Medical
   School [Duke-NUS-KP(Coll)/2018/0009A]; SERI-Lee Foundation, Singapore
   [LF1019-1]
FX National Medical Research Council (CG/C010A/2017_SERI, OFIRG/0048/2017,
   OFLCG/004c/2018, TA/MOH-000249-00/2018); National Research Foundation
   Singapore; Agency for Science, Technology and Research (A20H4b014);
   Singapore Eye Research Institute & Nanyang Technological University
   SERI-NTU Advanced Ocular Engineering (STANCE) Program; Duke-NUS Medical
   School (Duke-NUS-KP(Coll)/2018/0009A); SERI-Lee Foundation, Singapore
   (LF1019-1).
CR Alshareef Rayan A, 2017, Int J Retina Vitreous, V3, P25, DOI 10.1186/s40942-017-0078-7
   Ang M, 2019, BRIT J OPHTHALMOL, V103, P855, DOI 10.1136/bjophthalmol-2018-312866
   [Anonymous], 2012, OCULAR BLOOD FLOW
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Azuma S, 2018, BIOMED OPT EXPRESS, V9, P2955, DOI 10.1364/BOE.9.002955
   Bradley Derek, 2007, Journal of Graphics Tools, V12, P13
   Calzetti G, 2018, BRIT J OPHTHALMOL, V102, P1679, DOI 10.1136/bjophthalmol-2017-311750
   Chang S, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.9.090901
   Cole ED, 2016, CLIN EXP OPHTHALMOL, V44, P289, DOI 10.1111/ceo.12711
   Criminisi A, 2004, IEEE T IMAGE PROCESS, V13, P1200, DOI 10.1109/TIP.2004.833105
   Dai YN, 2021, QUANT IMAG MED SURG, V11, P948, DOI 10.21037/qims-20-1011
   Devarajan K, 2020, BRIT J OPHTHALMOL, V104, P917, DOI 10.1136/bjophthalmol-2019-314769
   Duan L, 2013, OPT EXPRESS, V21, P15787, DOI 10.1364/OE.21.015787
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Girard MJA, 2011, INVEST OPHTH VIS SCI, V52, P7738, DOI 10.1167/iovs.10-6925
   Gorczynska I, 2017, PROC SPIE, V10045, DOI 10.1117/12.2251704
   Grove K., AM J OPHTHALMOL
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Isono H, 2003, ARCH OPHTHALMOL-CHIC, V121, P225
   Jung JJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.50
   Kajic V, 2013, BIOMED OPT EXPRESS, V4, P134, DOI 10.1364/BOE.4.000134
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Kuo AN, 2013, AM J OPHTHALMOL, V156, P304, DOI 10.1016/j.ajo.2013.03.012
   Le Meur O, 2013, IEEE T IMAGE PROCESS, V22, P3779, DOI 10.1109/TIP.2013.2261308
   Liu XX, 2019, BIOMED OPT EXPRESS, V10, P1601, DOI 10.1364/BOE.10.001601
   Maurer CR, 2003, IEEE T PATTERN ANAL, V25, P265, DOI 10.1109/TPAMI.2003.1177156
   Merkle CW, 2016, BIOMED OPT EXPRESS, V7, P4289, DOI 10.1364/BOE.7.004289
   Moccia S, 2018, COMPUT METH PROG BIO, V158, P71, DOI 10.1016/j.cmpb.2018.02.001
   Mori K, 2004, OPHTHALMOLOGY, V111, P507, DOI 10.1016/j.ophtha.2003.06.009
   Mukaka MM, 2012, MALAWI MED J, V24, P69
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Ohsugi H, 2013, OPTOMETRY VISION SCI, V90, P599, DOI 10.1097/OPX.0b013e3182924017
   Podoleanu AG, 2012, J MICROSC-OXFORD, V247, P209, DOI 10.1111/j.1365-2818.2012.03619.x
   Read SA, 2019, CLIN EXP OPTOM, V102, P270, DOI 10.1111/cxo.12862
   Sanchez-Cano A, 2014, AM J OPHTHALMOL, V158, P574, DOI 10.1016/j.ajo.2014.05.035
   Sang N, 2007, IMAGE VISION COMPUT, V25, P1263, DOI 10.1016/j.imavis.2006.07.026
   Sekiryu T, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.5.31
   Sezgin M, 2004, J ELECTRON IMAGING, V13, P146, DOI 10.1117/1.1631315
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Tan BY, 2019, BIOMED OPT EXPRESS, V10, P356, DOI 10.1364/BOE.10.000356
   Tan CSH, 2014, INVEST OPHTH VIS SCI, V55, P6452, DOI 10.1167/iovs.13-13771
   Thomsen J.B., 2009, ADV IMAGING BIOL MED, V66, P103
   Verma S., 2020, BIOREFINERY PRODUCTI, DOI [10.1002/9781119593065.ch1, DOI 10.1002/9781119593065.CH1]
   Wang Z, 2004, IEEE T IMAGE PROCESS, V13, P600, DOI 10.1109/TIP.2003.819861
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei X, 2018, SURV OPHTHALMOL, V63, P646, DOI 10.1016/j.survophthal.2018.03.003
   Wong CW, 2021, BRIT J OPHTHALMOL, V105, P1196, DOI 10.1136/bjophthalmol-2020-316475
   Xu Y, 2012, COMPUT MED IMAG GRAP, V36, P11, DOI 10.1016/j.compmedimag.2011.03.004
   Zhang L, 2012, INVEST OPHTH VIS SCI, V53, P7510, DOI 10.1167/iovs.12-10311
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
   Zhou H, 2018, BIOMED OPT EXPRESS, V9, P6067, DOI 10.1364/BOE.9.006067
NR 56
TC 6
Z9 6
U1 2
U2 8
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD AUG 1
PY 2021
VL 12
IS 8
BP 4982
EP 4996
DI 10.1364/BOE.426093
PG 15
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA TV1XF
UT WOS:000681519500001
PM 34513237
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Li, BY
   Tan, W
   Zou, JL
   He, Y
   Yoshida, S
   Jiang, B
   Zhou, YD
AF Li, Bing-Yan
   Tan, Wei
   Zou, Jing-Ling
   He, Yan
   Yoshida, Shigeo
   Jiang, Bing
   Zhou, Ye-Di
TI Role of interferons in diabetic retinopathy
SO WORLD JOURNAL OF DIABETES
LA English
DT Review
DE Interferons; Cytokines; Diabetic retinopathy; Interferon-alpha;
   Interferon-gamma; Inflammation
ID ENDOTHELIAL GROWTH-FACTOR; TOPICAL INTERFERON-ALPHA-2B; STIMULATED
   GENES; MACULAR EDEMA; IFN-GAMMA; COMBINATION THERAPY; SIGNALING PATHWAY;
   AQUEOUS-HUMOR; IN-VIVO; ALPHA
AB Diabetic retinopathy (DR) is one of the major causes of visual impairment and irreversible blindness in developed regions. Aside from abnormal angiogenesis, inflammation is the most specific and might be the initiating factor of DR. As a key participant in inflammation, interferon-gamma (IFN-gamma) can be detected in different parts of the eye and is responsible for the breakdown of the blood-retina barrier and activation of inflammatory cells and other cytokines, which accelerate neovascularization and neuroglial degeneration. In addition, IFN-gamma is involved in other vascular complications of diabetes mellitus and angiogenesis-dependent diseases, such as diabetic nephropathy, cerebral microbleeds, and age-related macular degeneration. Traditional treatments, such as anti-vascular endothelial growth factor agents, vitrectomy, and laser photocoagulation therapy, are more effective for angiogenesis and not tolerable for every patient. Many ongoing clinical trials are exploring effective drugs that target inflammation. For instance, IFN-alpha acts against viruses and angiogenesis and is commonly used to treat malignant tumors. Moreover, IFN-alpha has been shown to contribute to alleviating the progression of DR and other ocular diseases. In this review, we emphasize the roles that IFNs play in the pathogenesis of DR and discuss potential clinical applications of IFNs in DR, such as diagnosis, prognosis, and therapeutic treatment.
C1 [Li, Bing-Yan; Tan, Wei; Zou, Jing-Ling; He, Yan; Jiang, Bing; Zhou, Ye-Di] Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
   [Li, Bing-Yan; Tan, Wei; Zou, Jing-Ling; He, Yan; Jiang, Bing; Zhou, Ye-Di] Cent South Univ, Xiangya Hosp 2, Hunan Clin Res Ctr Ophthalm Dis, Changsha 410011, Hunan, Peoples R China.
   [Yoshida, Shigeo] Kurume Univ, Sch Med, Dept Ophthalmol, Kurume, Fukuoka 8300011, Japan.
C3 Central South University; Central South University; Kurume University
RP Zhou, YD (通讯作者)，Cent South Univ, Xiangya Hosp 2, Dept Ophthalmol, 139 Renmin Middle Rd, Changsha 410011, Hunan, Peoples R China.
EM zhouyedi@csu.edu.cn
RI li, bing/GWQ-9617-2022
FU National Natural Science Foundation of China [81800855, 82070967];
   Natural Science Foundation of Hunan Province [2018JJ3765]
FX National Natural Science Foundation of China, No. 81800855 and No.
   82070967; and Natural Science Foundation of Hunan Province, No.
   2018JJ3765.
CR AASLD-IDSA Hepatitis C Guidance, 2020, HEPATOLOGY, V71, P686, DOI 10.1002/hep.31060
   Abdel-Moneim A, 2019, DIABETES METAB SYND, V13, P1963, DOI 10.1016/j.dsx.2019.04.046
   Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   Alspach E, 2019, COLD SPRING HARB PER, V11
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Amin K, 2020, PRIM CARE DIABETES, V14, P61, DOI 10.1016/j.pcd.2019.03.008
   Anguille S, 2011, LEUKEMIA, V25, P739, DOI 10.1038/leu.2010.324
   Aouiss A, 2019, CURR RES TRANSL MED, V67, P62, DOI 10.1016/j.retram.2019.01.005
   Baker CW, 2019, JAMA-J AM MED ASSOC, V321, P1880, DOI 10.1001/jama.2019.5790
   Battle TE, 2006, CANCER RES, V66, P3649, DOI 10.1158/0008-5472.CAN-05-3612
   Blasi MA, 2012, OPHTHALMOLOGY, V119, P494, DOI 10.1016/j.ophtha.2011.09.008
   Bolek B, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019181
   Borden EC, 2019, NAT REV DRUG DISCOV, V18, P219, DOI 10.1038/s41573-018-0011-2
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brasnu E, 2005, AM J OPHTHALMOL, V140, P746, DOI 10.1016/j.ajo.2005.04.025
   Brown JN, 2010, J LEUKOCYTE BIOL, V87, P655, DOI 10.1189/jlb.0809570
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Burke JD, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.05.002
   Butler NJ, 2012, OCUL IMMUNOL INFLAMM, V20, P86, DOI 10.3109/09273948.2011.645989
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Capitao M, 2016, J CELL BIOCHEM, V117, P2443, DOI 10.1002/jcb.25575
   Carinelli S, 2018, BIOSENS BIOELECTRON, V117, P183, DOI 10.1016/j.bios.2018.05.030
   Castro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00847
   Celiker H, 2019, OCUL IMMUNOL INFLAMM, V27, P15, DOI 10.1080/09273948.2017.1332768
   Cellini M, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-63
   Chen H, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0572-6
   Cheung CMG, 2012, MOL VIS, V18, P830
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chistiakov DA, 2017, IMMUNOBIOLOGY, V223, P101, DOI 10.1016/j.imbio.2017.10.005
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Colli ML, 2018, EBIOMEDICINE, V36, P367, DOI 10.1016/j.ebiom.2018.09.040
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Couret C, 2020, OCUL IMMUNOL INFLAMM, V28, P329, DOI 10.1080/09273948.2019.1604001
   Crosse KM, 2018, J INNATE IMMUN, V10, P85, DOI 10.1159/000484258
   Cunha-Vaz J, 2014, PROG RETIN EYE RES, V41, P90, DOI 10.1016/j.preteyeres.2014.03.003
   Cvitkovic K, 2020, SEMIN OPHTHALMOL, V35, P126, DOI 10.1080/08820538.2020.1755320
   Das A, 2015, OPHTHALMOLOGY, V122, P1375, DOI 10.1016/j.ophtha.2015.03.024
   Demirtas L, 2015, INT J CLIN EXP MED, V8, P11420
   Du J, 2018, PHARMACOL REP, V70, P607, DOI 10.1016/j.pharep.2017.12.009
   Du J, 2011, PHARMACOL REP, V63, P1137
   Dulull N, 2019, DRUG DISCOV TODAY, V24, P1499, DOI 10.1016/j.drudis.2019.03.028
   ENGLER C, 1994, BRIT J OPHTHALMOL, V78, P749, DOI 10.1136/bjo.78.10.749
   Erdem U, 2007, OPHTHALMOLOGY, V114, P446, DOI 10.1016/j.ophtha.2006.09.024
   Fardeau C, 2017, AM J OPHTHALMOL, V177, P182, DOI 10.1016/j.ajo.2017.03.001
   Forrester JV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583687
   Franco MM, 2015, RGO REV GAUC ODONTOL, V63, P432, DOI DOI 10.1590/1981-863720150003000093063
   George PM, 2012, PHARMACOL THERAPEUT, V135, P44, DOI 10.1016/j.pharmthera.2012.03.006
   Gerber SA, 2008, J IMMUNOL, V181, P1052, DOI 10.4049/jimmunol.181.2.1052
   Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341
   Gross JG, 2018, JAMA OPHTHALMOL, V136, P1138, DOI 10.1001/jamaophthalmol.2018.3255
   GUYER DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P350, DOI 10.1001/archopht.1993.01090030068041
   Gysemans CA, 2005, DIABETES, V54, P2396, DOI 10.2337/diabetes.54.8.2396
   Hammes HP, 2018, DIABETOLOGIA, V61, P29, DOI 10.1007/s00125-017-4435-8
   Hasan Z, 2019, J PAK MED ASSOC, V69, P468
   Hume DA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00370
   ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048
   Iwasaki A, 2012, ANNU REV MICROBIOL, V66, P177, DOI 10.1146/annurev-micro-092611-150203
   Jakimovski D, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a032003
   Karp CL, 2010, OPHTHALMOLOGY, V117, P2241, DOI 10.1016/j.ophtha.2010.03.052
   Kastelan S, 2020, BIOCHEM MEDICA, V30, DOI 10.11613/BM.2020.030502
   Kastelan S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/436329
   Kawano Y, 2000, AM J REPROD IMMUNOL, V43, P47, DOI 10.1111/j.8755-8920.2000.430109.x
   Kiladjian JJ, 2016, LEUKEMIA, V30, P776, DOI 10.1038/leu.2015.326
   Kim SE, 2018, EYE, V32, P460, DOI 10.1038/eye.2017.196
   Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7
   Kivela T, 2003, EUR J CANCER, V39, P1115, DOI 10.1016/S0959-8049(03)00132-1
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Konrad T, 1999, EXP CLIN ENDOCR DIAB, V107, P343, DOI 10.1055/s-0029-1212124
   Krilis M, 2012, OPHTHALMOLOGY, V119, P1969, DOI 10.1016/j.ophtha.2012.03.045
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Leibovitch I, 2004, OPHTHAL SURG LAS IM, V35, P16, DOI 10.3928/1542-8877-20040101-05
   Lewczuk N, 2019, J INTERF CYTOK RES, V39, P259, DOI 10.1089/jir.2018.0125
   Li HY, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104924
   Liu BY, 2010, MOL VIS, V16, P184
   Liu JF, 2010, MOL VIS, V16, P2931
   Lombardi A, 2018, J AUTOIMMUN, V94, P7, DOI 10.1016/j.jaut.2018.08.003
   Lv WS, 2018, EUR J PHARMACOL, V820, P65, DOI 10.1016/j.ejphar.2017.12.016
   Mahmoud MH, 2015, CELL SIGNAL, V27, P2110, DOI 10.1016/j.cellsig.2015.07.005
   Maleki A, 2020, J OPHTHAL VIS RES, V15, P453, DOI 10.18502/jovr.v15i4.7785
   Marro BS, 2017, P NATL ACAD SCI USA, V114, P3708, DOI 10.1073/pnas.1700878114
   Marroqui L, 2017, DIABETOLOGIA, V60, P656, DOI 10.1007/s00125-016-4201-3
   Merida S, 2015, INT J MOL SCI, V16, P18778, DOI 10.3390/ijms160818778
   Mesquida M, 2019, SEMIN IMMUNOPATHOL, V41, P427, DOI 10.1007/s00281-019-00750-7
   MINKOVITZ JB, 1995, CORNEA, V14, P326, DOI 10.1097/00003226-199505000-00017
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moreno A, 2013, NUTR HOSP, V28, P53, DOI 10.3305/nh.2013.28.sup2.6714
   Morrison JL, 2016, CLIN EXP OPHTHALMOL, V44, P321, DOI 10.1111/ceo.12760
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Mousa N, 2013, J OCUL PHARMACOL TH, V29, P345, DOI 10.1089/jop.2012.0169
   Muhl H, 2003, INT IMMUNOPHARMACOL, V3, P1247, DOI 10.1016/S1567-5769(03)00131-0
   Othman R, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00300
   Ozay Y, 2020, ADV CLIN EXP MED, V29, P449, DOI 10.17219/acem/115004
   Pan WH, 1997, J NEUROIMMUNOL, V76, P105, DOI 10.1016/S0165-5728(97)00034-9
   Panetta JD, 2009, ALIMENT PHARM THER, V30, P597, DOI 10.1111/j.1365-2036.2009.04071.x
   Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x
   Pinto EF, 2016, CURR NEUROPHARMACOL, V14, P743, DOI 10.2174/1570159X14666160106155129
   Plskova J, 2007, AM J OPHTHALMOL, V144, P55, DOI 10.1016/j.ajo.2007.03.050
   Poothullil Antony M, 2006, Semin Ophthalmol, V21, P161, DOI 10.1080/08820530500351694
   Qian ZY, 2015, EUR J OPHTHALMOL, V25, P431, DOI 10.5301/ejo.5000591
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Reyes-Vazquez C, 2012, BRAIN RES, V1442, P76, DOI 10.1016/j.brainres.2011.09.061
   Rivera JC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3940241
   Rubsam A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040942
   Sabanayagam C, 2019, LANCET DIABETES ENDO, V7, P140, DOI 10.1016/S2213-8587(18)30128-1
   Santiago AR, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00820
   Satari M, 2019, J CELL BIOCHEM, V120, P9514, DOI 10.1002/jcb.28227
   Schoggins JW, 2019, ANNU REV VIROL, V6, P567, DOI 10.1146/annurev-virology-092818-015756
   Schoggins JW, 2014, CURR OPIN VIROL, V6, P40, DOI 10.1016/j.coviro.2014.03.006
   Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008
   Semeraro F, 2019, DIABETES METAB, V45, P517, DOI 10.1016/j.diabet.2019.04.002
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Simo R, 2018, DIABETOLOGIA, V61, P1902, DOI 10.1007/s00125-018-4692-1
   Simo R, 2015, PROG RETIN EYE RES, V48, P160, DOI 10.1016/j.preteyeres.2015.04.003
   Sinclair SH, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00843
   Skowsky WR, 1996, J DIABETES COMPLICAT, V10, P94
   Sobaci G, 2005, OCUL IMMUNOL INFLAMM, V13, P59, DOI 10.1080/09273940490518865
   Sobaci G, 2010, OPHTHALMOLOGY, V117, P1430, DOI 10.1016/j.ophtha.2009.11.022
   Stifter SA, 2015, J IMMUNOL, V194, P2455, DOI 10.4049/jimmunol.1402794
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   SUNDMACHER R, 1987, CURR EYE RES, V6, P273, DOI 10.3109/02713688709020104
   Sutter K, 2018, CYTOKINE GROWTH F R, V40, P13, DOI 10.1016/j.cytogfr.2018.02.002
   Suzuki Y, 2011, JPN J OPHTHALMOL, V55, P256, DOI 10.1007/s10384-011-0004-8
   Takeuchi M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178230
   Tan GS, 2017, LANCET DIABETES ENDO, V5, P143, DOI 10.1016/S2213-8587(16)30052-3
   Tan JCK, 2016, BRIT J OPHTHALMOL, V100, P944, DOI 10.1136/bjophthalmol-2015-307411
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Taylor S, 2018, J NEUROSCI, V38, P8707, DOI 10.1523/JNEUROSCI.0734-18.2018
   Thomas RL, 2015, BRIT J OPHTHALMOL, V99, P64, DOI 10.1136/bjophthalmol-2013-304017
   Tsai T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194603
   Tseng SH, 2009, OPHTHALMOLOGY, V116, P1013, DOI 10.1016/j.ophtha.2008.12.035
   Tu KL, 2003, BRIT J OPHTHALMOL, V87, P247, DOI 10.1136/bjo.87.2.247
   Tugues S, 2015, CELL DEATH DIFFER, V22, P237, DOI 10.1038/cdd.2014.134
   Vaziri Kamyar, 2015, Rev Diabet Stud, V12, P196, DOI 10.1900/RDS.2015.12.196
   VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581
   Vujosevic S, 2016, ACTA OPHTHALMOL, V94, P56, DOI 10.1111/aos.12812
   Vujosevic S, 2012, HEPATOLOGY, V56, P455, DOI 10.1002/hep.25654
   Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang YL, 2015, GRAEF ARCH CLIN EXP, V253, P389, DOI 10.1007/s00417-014-2832-y
   Whitehead M, 2018, EXPERT OPIN BIOL TH, V18, P1257, DOI 10.1080/14712598.2018.1545836
   Wolfs IMJ, 2011, THROMB HAEMOSTASIS, V106, P763, DOI 10.1160/TH11-05-0320
   Wong TY, 2018, OPHTHALMOLOGY, V125, P1608, DOI 10.1016/j.ophtha.2018.04.007
   Wu HL, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/9402198
   Wu MY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3420187
   Xue JH, 2014, WORLD J GASTROENTERO, V20, P7505, DOI 10.3748/wjg.v20.i23.7505
   Youngblood H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194755
   Zanjani H, 2017, CORNEA, V36, P675, DOI 10.1097/ICO.0000000000001200
   Zhang SH, 2019, CANCER IMMUNOL RES, V7, P1237, DOI 10.1158/2326-6066.CIR-18-0940
   Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]
   Zhou Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep28140
NR 151
TC 2
Z9 2
U1 1
U2 8
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
EI 1948-9358
J9 WORLD J DIABETES
JI World J. Diabetes
PD JUL 15
PY 2021
VL 12
IS 7
BP 939
EP 953
DI 10.4239/wjd.v12.i7.939
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA TQ9SH
UT WOS:000678615000003
PM 34326947
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Varinthra, P
   Huang, SP
   Chompoopong, S
   Wen, ZH
   Liu, IY
AF Varinthra, Peeraporn
   Huang, Shun-Ping
   Chompoopong, Supin
   Wen, Zhi-Hong
   Liu, Ingrid Y.
TI 4-(Phenylsulfanyl) Butan-2-One Attenuates the Inflammatory Response
   Induced by Amyloid-beta Oligomers in Retinal Pigment Epithelium Cells
SO MARINE DRUGS
LA English
DT Article
DE coral; 4-(Phenylsulfanyl) Butan-2-One; inflammatory responses;
   amyloid-&#946; retinal pigment epithelium cells
AB Age-related macular degeneration (AMD) is a progressive eye disease that causes irreversible impairment of central vision, and effective treatment is not yet available. Extracellular accumulation of amyloid-beta (A beta) in drusen that lie under the retinal pigment epithelium (RPE) has been reported as one of the early signs of AMD and was found in more than 60% of Alzheimer's disease (AD) patients. Extracellular deposition of A beta can induce the expression of inflammatory cytokines such as IL-1 beta, TNF-alpha, COX-2, and iNOS in RPE cells. Thus, finding a compound that can effectively reduce the inflammatory response may help the treatment of AMD. In this research, we investigated the anti-inflammatory effect of the coral-derived compound 4-(phenylsulfanyl) butan-2-one (4-PSB-2) on A beta(1-42) oligomer (oA beta(1-42)) added to the human adult retinal pigment epithelial cell line (ARPE-19). Our results demonstrated that 4-PSB-2 can decrease the elevated expressions of TNF-alpha, COX-2, and iNOS via NF-kappa B signaling in ARPE-19 cells treated with oA beta(1-42) without causing any cytotoxicity or notable side effects. This study suggests that 4-PSB-2 is a promising drug candidate for attenuation of AMD.
C1 [Varinthra, Peeraporn; Liu, Ingrid Y.] Tzu Chi Univ, Inst Med Sci, Hualien 970, Taiwan.
   [Huang, Shun-Ping] Tzu Chi Univ, Dept Mol Biol & Human Genet, Hualien 970, Taiwan.
   [Chompoopong, Supin] Mahidol Univ, Fac Med, Dept Anat, Siriraj Hosp, Bangkok 10700, Thailand.
   [Wen, Zhi-Hong] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 804, Taiwan.
C3 Tzu Chi University; Tzu Chi University; Mahidol University; National Sun
   Yat Sen University
RP Liu, IY (通讯作者)，Tzu Chi Univ, Inst Med Sci, Hualien 970, Taiwan.
EM vpeeraporn@gms.tcu.edu.tw; sphophdoc1688@gms.tcu.edu.tw;
   supin.cho@mahidol.ac.th; wzh@mail.nsysu.edu.tw; ycliu@gms.tcu.edu.tw
RI Varinthra, Peeraporn/ABA-8260-2021; Liu, Ingrid Y/AAN-2606-2021
OI Varinthra, Peeraporn/0000-0001-8070-5016; 
FU Buddhist Tzu Chi Medical Foundation; Tzu Chi University [TCMMP
   105-08-01, TCMF-SP 108-04]; Ministry of Science and Technology (MOST),
   Taiwan [MOST-107-2410-H320-DOI-MY3]
FX This research was supported by the Buddhist Tzu Chi Medical Foundation
   and Tzu Chi University grant "TCMMP 105-08-01", "TCMF-SP 108-04", and
   Ministry of Science and Technology (MOST), Taiwan
   (MOST-107-2410-H320-DOI-MY3).
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Chen NF, 2014, MAR DRUGS, V12, P3792, DOI 10.3390/md12073792
   Chernykh V, 2019, INT J OPHTHALMOL-CHI, V12, P25, DOI 10.18240/ijo.2019.01.04
   Chien JY, 2016, EXP EYE RES, V143, P148, DOI 10.1016/j.exer.2015.10.004
   Chin MS, 2001, INVEST OPHTH VIS SCI, V42, P2338
   Chiou GCY., 2011, TAIWAN J OPHTHALMOL, V1, P2, DOI [10.1016/j.tjo.2011.08.001, DOI 10.1016/J.TJO.2011.08.001]
   Dinet V, 2012, AGING CELL, V11, P683, DOI 10.1111/j.1474-9726.2012.00834.x
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Feng L, 2019, DISCOV MED, V27, P153
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hattenbach LO, 2002, OPHTHALMOLOGICA, V216, P209, DOI 10.1159/000059634
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kivinen N, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13753
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lee HP, 2013, MAR DRUGS, V11, P99, DOI 10.3390/md11010099
   Lee J, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/416036
   Lin YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062926
   Maloney SC, 2009, RETINA-J RET VIT DIS, V29, P176, DOI 10.1097/IAE.0b013e3181884fa6
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Masuda N, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1076-3
   Mayer AMS, 2013, MAR DRUGS, V11, P2510, DOI 10.3390/md11072510
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Sedger LM, 2014, CYTOKINE GROWTH F R, V25, P453, DOI 10.1016/j.cytogfr.2014.07.016
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Snow WM, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00118
   Song SB, 2012, J GINSENG RES, V36, P146, DOI 10.5142/jgr.2012.36.2.146
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wen ZH, 2010, EUR J MED CHEM, V45, P5998, DOI 10.1016/j.ejmech.2010.09.067
   Wu SYS, 2015, INT J MOL SCI, V16, P20240, DOI 10.3390/ijms160920240
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
NR 41
TC 5
Z9 5
U1 2
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD JAN
PY 2021
VL 19
IS 1
AR 1
DI 10.3390/md19010001
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PX0TE
UT WOS:000611077000001
PM 33374505
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Tanaka, K
   Miki, A
   Matsumoto, H
   Kawamura, A
   Mukai, R
   Akiyama, H
   Honda, S
   Mori, R
   Iijima, H
AF Sakurada, Yoichi
   Tanaka, Koji
   Miki, Akiko
   Matsumoto, Hidetaka
   Kawamura, Akiyuki
   Mukai, Ryo
   Akiyama, Hideo
   Honda, Shigeru
   Mori, Ryusaburo
   Iijima, Hiroyuki
TI Clinical characteristics of cuticular drusen in the Japanese population
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Cuticular drusen; Age-related macular degeneration; Drusenoid pigment
   epithelial detachment; Large colloid drusen
ID BASAL LAMINAR DRUSEN; MACULAR DEGENERATION; FEATURES; EYE
AB PurposeTo investigate the clinical characteristics of eyes with cuticular drusen in Japanese individuals, while paying special attention to large colloid drusen (LCD).Study designRetrospective case series.MethodsEyes with cuticular drusen, from patients of 4 medical institutes in Japan, were investigated. Multimodal imaging findings were used to diagnose cuticular drusen. LCD was defined as cuticular drusen >200 mu m.ResultsTwenty-four eyes from 12 patients (8 women, 4 men) were diagnosed with cuticular drusen. The mean age of all patients (n=12) was 60.8 years. The mean age of patients without additional macular pathology (n=5) was 55.4 years. Of the 7 patients with additional macular pathology, 6 (85.7%) exhibited age-related macular degeneration-associated macular pathology, including drusenoid pigment epithelial detachment (PED) (8 eyes from 4 patients), geographic atrophy (2 eyes from 1 patient), and occult choroidal neovascularization (1 eye). LCD were found in 6 eyes of 3 patients (25%), those with LCD were on average 53.78.7 years old and those without 69.9 +/- 14.1 years of age (P=0.064, Mann-Whitney U test).Conclusions Cuticular drusen were predominantly seen in females, and drusenoid PED was most frequently seen in eyes with additional macular pathology. LCD were seen in 25% of eyes with cuticular drusen.
C1 [Sakurada, Yoichi; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Ku, Shimokato 1110, Yamanashi 4093821, Japan.
   [Tanaka, Koji; Kawamura, Akiyuki; Mori, Ryusaburo] Nihon Univ, Sch Med, Dept Visual Sci, Div Ophthalmol, Tokyo, Japan.
   [Miki, Akiko] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo, Japan.
   [Matsumoto, Hidetaka; Mukai, Ryo; Akiyama, Hideo] Gunma Univ, Sch Med, Dept Ophthalmol, Gunma, Japan.
   [Honda, Shigeru] Osaka City Univ, Dept Ophthalmol & Visual Sci, Grad Sch Med, Osaka, Japan.
C3 University of Yamanashi; Nihon University; Kobe University; Gunma
   University; Osaka Metropolitan University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo Ku, Shimokato 1110, Yamanashi 4093821, Japan.
EM sakurada@yamanashi.ac.jp
CR Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gass JD, 1977, STEREOSCOPIC ATLAS M, P46
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Roberti NC, 2017, ARQ BRAS OFTALMOL, V80, P122, DOI 10.5935/0004-2749.20170029
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P257, DOI 10.1097/IAE.0000000000002399
   Sato A, 2015, CASE REP OPHTHALM, V6, P127, DOI 10.1159/000381616
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Terao Ryo, 2021, Retin Cases Brief Rep, V15, P581, DOI 10.1097/ICB.0000000000000856
   van de Ven JPH, 2012, MOL VIS, V18, P2271
   van de Ven JPH, 2012, AM J OPHTHALMOL, V154, P560, DOI 10.1016/j.ajo.2012.03.012
   Veronese C, 2017, RETINA-J RET VIT DIS, V37, pE132, DOI 10.1097/IAE.0000000000001868
NR 19
TC 5
Z9 5
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2019
VL 63
IS 6
BP 448
EP 456
DI 10.1007/s10384-019-00692-5
EA OCT 2019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JL0ST
UT WOS:000493335800001
PM 31664630
DA 2022-11-30
ER

PT J
AU Cense, B
   Miller, DT
   King, BJ
   Theelen, T
   Elsner, AE
AF Cense, Barry
   Miller, Donald T.
   King, Brett J.
   Theelen, Thomas
   Elsner, Ann E.
TI Measuring polarization changes in the human outer retina with
   polarization-sensitive optical coherence tomography
SO JOURNAL OF BIOPHOTONICS
LA English
DT Article
DE age-related macular degeneration; aging; optical coherence tomography;
   polarization-sensitive optical coherence tomography; retinal imaging
ID NERVE-FIBER LAYER; PHASE RETARDATION; IN-VIVO; MACULAR DEGENERATION;
   IMAGING POLARIMETRY; PIGMENT-EPITHELIUM; BIREFRINGENCE; THICKNESS;
   SYSTEM; IDENTIFICATION
AB Morphological changes in the outer retina such as drusen are established biomarkers to diagnose age-related macular degeneration. However, earlier diagnosis might be possible by taking advantage of more subtle changes that accompany tissues that bear polarization-altering properties. To test this hypothesis, we developed a method based on polarization-sensitive optical coherence tomography with which volumetric data sets of the macula were obtained from 10 young (<25 years) and 10 older (>54 years) subjects. All young subjects and 5 of the older subjects had retardance values induced by the retinal pigment epithelium and Bruch's membrane (RPE-BM) complex that were just above the noise floor measurement (5 degrees-13 degrees at 840 nm). In contrast, elevated retardance, up to 180 degrees, was observed in the other 5 older subjects. Analysis of the degree of polarization uniformity (DOPU) demonstrates that reduced DOPU (<0.4) in the RPE is associated with elevated double pass phase retardation (DPPR) below the RPE-BM complex, suggesting that the observed elevated DPPR in older subjects is the result of increased scattering or polarization scrambling. Collectively, our measurements show that the outer retina can undergo dramatic change in its polarization properties with age, and in some cases still retain its clinically normal appearance.
C1 [Cense, Barry] Utsunomiya Univ, Ctr Opt Res & Educ, Utsunomiya, Tochigi 3218585, Japan.
   [Miller, Donald T.; King, Brett J.; Elsner, Ann E.] Indiana Univ, Sch Optometry, Bloomington, IN USA.
   [Theelen, Thomas] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
C3 Utsunomiya University; Indiana University System; Indiana University
   Bloomington; Radboud University Nijmegen
RP Cense, B (通讯作者)，Utsunomiya Univ, Ctr Opt Res & Educ, Utsunomiya, Tochigi 3218585, Japan.
EM bcense@cc.utsunomiya-u.ac.jp
RI Theelen, Thomas/A-3192-2012
OI Theelen, Thomas/0000-0001-9067-1171; King, Brett/0000-0003-4790-3541;
   Cense, Barry/0000-0002-7164-8053
FU National Eye Institute [EY007624, EY019008, EY018339, EY014743];
   NATIONAL EYE INSTITUTE [R01EY018339, R01EY014743, R01EY007624] Funding
   Source: NIH RePORTER
FX National Eye Institute, Grant/Award numbers: EY007624, EY019008,
   EY018339, EY014743
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Braaf B, 2014, BIOMED OPT EXPRESS, V5, P2736, DOI 10.1364/BOE.5.002736
   Bueno JM, 2001, VISION RES, V41, P2687, DOI 10.1016/S0042-6989(01)00167-5
   Cense B, 2004, INVEST OPHTH VIS SCI, V45, P2606, DOI 10.1167/iovs.03-1160
   Cense B, 2004, J BIOMED OPT, V9, P121, DOI 10.1117/1.1627774
   Cense B, 2002, OPT LETT, V27, P1610, DOI 10.1364/OL.27.001610
   Cense B, 2007, OPT EXPRESS, V15, P2421, DOI 10.1364/OE.15.002421
   Cense B, 2013, BIOMED OPT EXPRESS, V4, P2296, DOI 10.1364/BOE.4.002296
   Cense B, 2009, OPT EXPRESS, V17, P21634, DOI 10.1364/OE.17.021634
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Dwelle J, 2012, INVEST OPHTH VIS SCI, V53, P4380, DOI 10.1167/iovs.11-9130
   Elmaanaoui B, 2011, OPT EXPRESS, V19, P10252, DOI 10.1364/OE.19.010252
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   FEENEY L, 1973, INVEST OPHTH VISUAL, V12, P635
   Gotzinger E, 2008, J BIOPHOTONICS, V1, P129, DOI 10.1002/jbio.200710009
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mujat M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2764460
   Park BH, 2005, OPT LETT, V30, P2587, DOI 10.1364/OL.30.002587
   Park BH, 2005, OPT EXPRESS, V13, P3931, DOI 10.1364/OPEX.13.003931
   Pircher M, 2004, PHYS MED BIOL, V49, P1257, DOI 10.1088/0031-9155/49/7/013
   Pircher M, 2006, INVEST OPHTH VIS SCI, V47, P5487, DOI 10.1167/iovs.05-1589
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Saxer CE, 2000, OPT LETT, V25, P1355, DOI 10.1364/OL.25.001355
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Sugita M, 2015, BIOMED OPT EXPRESS, V6, P1030, DOI 10.1364/BOE.6.001030
   Sugita M, 2014, BIOMED OPT EXPRESS, V5, P106, DOI 10.1364/BOE.5.000106
   Torzicky T, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.026008
   Twietmeyer KM, 2008, OPT EXPRESS, V16, P21339, DOI 10.1364/OE.16.021339
   VanNasdale DA, 2015, INVEST OPHTH VIS SCI, V56, P284, DOI 10.1167/iovs.14-14459
   VanNasdale DA, 2011, VISION RES, V51, P2263, DOI 10.1016/j.visres.2011.08.017
   Yamanari M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2841024
   Young R. W., 1979, METABOLISM RETINAL P, P103
   Zotter S, 2013, INVEST OPHTH VIS SCI, V54, P72, DOI 10.1167/iovs.12-10089
NR 42
TC 9
Z9 9
U1 1
U2 8
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1864-063X
EI 1864-0648
J9 J BIOPHOTONICS
JI J. Biophotonics
PD MAY
PY 2018
VL 11
IS 5
AR e201700134
DI 10.1002/jbio.201700134
PG 10
WC Biochemical Research Methods; Biophysics; Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA GF5LM
UT WOS:000432008800001
PM 29282883
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bowrey, HE
   Anderson, DM
   Pallitto, P
   Gutierrez, DB
   Fan, J
   Crouch, RK
   Schey, KL
   Ablonczy, Z
AF Bowrey, Hannah E.
   Anderson, David M.
   Pallitto, Patrick
   Gutierrez, Danielle B.
   Fan, Jie
   Crouch, Rosalie K.
   Schey, Kevin L.
   Ablonczy, Zsolt
TI Imaging mass spectrometry of the visual system: Advancing the molecular
   understanding of retina degenerations
SO PROTEOMICS CLINICAL APPLICATIONS
LA English
DT Review
DE Bisretinoid; Mass spectrometry imaging; Lipids; Retina; Vision
ID INTEGRAL MEMBRANE-PROTEINS; RETINYLIDENE-N-RETINYLETHANOLAMINE;
   HIGH-SPATIAL-RESOLUTION; FACTOR-H POLYMORPHISM; HUMAN LENS;
   ALPHA-CRYSTALLIN; ELECTROSPRAY-IONIZATION; LIPOFUSCIN FLUOROPHORE;
   MACULAR DEGENERATION; PIGMENT EPITHELIUM
AB Visual sensation is fundamental for quality of life, and loss of vision to retinal degeneration is a debilitating condition. The eye is the only part of the central nervous system that can be noninvasively observed with optical imaging. In the clinics, various spectroscopic methods provide high spatial resolution images of the fundus and the developing degenerative lesions. However, the currently utilized tools are not specific enough to establish the molecular underpinnings of retinal diseases. In contrast, mass spectrometric imaging (MSI) is a powerful tool to identify molecularly specific disease indicators and classification markers. This technique is particularly well suited to the eye, where molecular information can be correlated with clinical data collected via noninvasive diagnostic imaging modalities. Recent studies during the last few recent years have uncovered a plethora of new spatially defined molecular information on several vision-threatening diseases, including age-related macular degeneration, Stargardt disease, glaucoma, cataract, as well as lipid disorders. Even though MS inside the eye cannot be performed noninvasively, by linking diagnostic and molecular information, these studies are the first step toward the development of smart ophthalmic diagnostic and surgical tools. Here, we provide an overview of current approaches applying MSI technology to ocular pathology.
C1 [Bowrey, Hannah E.] Rutgers State Univ, Brain Hlth Inst, New Brunswick, NJ 08903 USA.
   [Anderson, David M.; Gutierrez, Danielle B.; Schey, Kevin L.] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.
   [Pallitto, Patrick] Rutgers State Univ, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA.
   [Fan, Jie; Crouch, Rosalie K.; Ablonczy, Zsolt] Med Univ S Carolina, Dept Ophthalmol, SEI 518E,167 Ashley Ave, Charleston, SC 29425 USA.
C3 Rutgers State University New Brunswick; Vanderbilt University; Rutgers
   State University New Brunswick; Rutgers State University Medical Center;
   Medical University of South Carolina
RP Ablonczy, Z (通讯作者)，Med Univ S Carolina, Dept Ophthalmol, SEI 518E,167 Ashley Ave, Charleston, SC 29425 USA.
EM ablonczy@musc.edu
OI Bowrey, Hannah/0000-0002-3774-4201
FU NIH [R21 EY020661, R01 EY004939, R01 EY019728, R01 EY019065]; Allergan;
   Department of Ophthalmology at MUSC from Research to Prevent Blindness
   (RPB, NY); Cancer Center Support [P30 CA138313]; Vanderbilt Mass
   Spectrometry Research Center as part of the NIH Imaging Mass
   Spectrometry Research Resource [P41 GM103391]; NATIONAL EYE INSTITUTE
   [R21EY020661, R01EY019065, R01EY004939] Funding Source: NIH RePORTER
FX This study was supported in part by NIH Grant Nos. R21
   EY020661(Z.A./R.K.C.), R01 EY004939 (R.K.C.), R01 EY019728 (K.S.), and
   R01 EY019065 (Z.A.); a research grant from Allergan (R.K.C./Z.A./P.P.);
   and an unrestricted grant to the Department of Ophthalmology at MUSC
   from Research to Prevent Blindness (RPB, NY); R.K.C. is an RPB Senior
   Scientific Investigator. The work has in part been conducted in the MUSC
   Mass Spectrometry Institutional Research Resource Facility, the Cell &
   Molecular Imaging Shared Resource of the Hollings Cancer Center, which
   was supported by Cancer Center Support Grant No. P30 CA138313 to the
   Hollings Cancer Center, MUSC, and in the Vanderbilt Mass Spectrometry
   Research Center as part of the NIH Imaging Mass Spectrometry Research
   Resource (P41 GM103391).
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ablonczy Z, 2001, ANAL CHEM, V73, P4774, DOI 10.1021/ac015563n
   Ablonczy Z, 2006, VISION RES, V46, P4493, DOI 10.1016/j.visres.2006.08.003
   Ablonczy Z, 2014, PROTEOMICS, V14, P936, DOI 10.1002/pmic.201300406
   Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ablonczy Z, 2012, ADV EXP MED BIOL, V723, P75, DOI 10.1007/978-1-4614-0631-0_11
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Anderson DMG, 2015, J AM SOC MASS SPECTR, V26, P940, DOI 10.1007/s13361-015-1143-9
   Anderson DMG, 2015, ANAL BIOANAL CHEM, V407, P2311, DOI 10.1007/s00216-015-8489-5
   Anderson DMG, 2014, J AM SOC MASS SPECTR, V25, P1394, DOI 10.1007/s13361-014-0883-2
   Anderson David M G, 2013, Mol Vis, V19, P581
   Ball LE, 1998, PROTEIN SCI, V7, P758
   Ball LE, 2004, BIOCHEMISTRY-US, V43, P9856, DOI 10.1021/bi0496034
   Barcelo-Coblijn G, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00003
   Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207
   BELLHORN MB, 1976, EXP EYE RES, V22, P505, DOI 10.1016/0014-4835(76)90188-3
   Berry KAZ, 2014, J LIPID RES, V55, P504, DOI 10.1194/jlr.M044990
   Beynon J. H, 1956, MIKROCHIM ACTA, V44, P437
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   BOYLE D, 1994, EXP EYE RES, V58, P9, DOI 10.1006/exer.1994.1190
   Brignole-Baudouin F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050180
   BROEKHUYSE RM, 1974, EXP EYE RES, V19, P477, DOI 10.1016/0014-4835(74)90054-2
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   CAMERON AE, 1948, REV SCI INSTRUM, V19, P605, DOI 10.1063/1.1741336
   Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i
   Cooks RG, 2006, SCIENCE, V311, P1566, DOI 10.1126/science.1119426
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324
   Curcio C.A., 2013, RETINA-J RET VIT DIS, V5th, P465
   Deeley JM, 2010, J LIPID RES, V51, P2753, DOI 10.1194/jlr.M007716
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Desbenoit N, 2013, ANAL BIOANAL CHEM, V405, P4039, DOI 10.1007/s00216-013-6811-7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315
   Finley EL, 1997, PHOTOCHEM PHOTOBIOL, V66, P635, DOI 10.1111/j.1751-1097.1997.tb03200.x
   Fournaise E, 2015, ANAL BIOANAL CHEM, V407, P2159, DOI 10.1007/s00216-014-8300-z
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fukuyama Y, 2006, J MASS SPECTROM, V41, P191, DOI 10.1002/jms.977
   FUTRELL JH, 1966, REV SCI INSTRUM, V37, P1521, DOI 10.1063/1.1720033
   GARRETT TJ, 2009, METH MOL B 1, V579, P247, DOI DOI 10.1007/978-1-60761-322-0_12
   Gobom J, 2001, ANAL CHEM, V73, P434, DOI 10.1021/ac001241s
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Grey AC, 2009, INVEST OPHTH VIS SCI, V50, P4319, DOI 10.1167/iovs.09-3522
   Grey AC, 2009, J PROTEOME RES, V8, P3278, DOI 10.1021/pr800956y
   Groseclose MR, 2007, J MASS SPECTROM, V42, P254, DOI 10.1002/jms.1177
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Han J, 2006, INVEST OPHTH VIS SCI, V47, P2990, DOI 10.1167/iovs.05-1529
   Hayasaka T, 2008, RAPID COMMUN MASS SP, V22, P3415, DOI 10.1002/rcm.3751
   Hye A, 2006, BRAIN, V129, P3042, DOI 10.1093/brain/awl279
   Jurchen JC, 2005, J AM SOC MASS SPECTR, V16, P1654, DOI 10.1016/j.jasms.2005.06.006
   KARAS M, 1985, ANAL CHEM, V57, P2935, DOI 10.1021/ac00291a042
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kolb H., 1995, GROSS ANATOMY EYE OR
   Kolb Helga, 1995, SIMPLE ANATOMY RETIN, P1
   Laskin J, 2012, ANAL CHEM, V84, P141, DOI 10.1021/ac2021322
   Le CH, 2012, ANAL CHEM, V84, P8391, DOI 10.1021/ac301901s
   LEINO M, 1984, EXP EYE RES, V38, P325, DOI 10.1016/0014-4835(84)90170-2
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lois N, 2008, BRIT J OPHTHALMOL, V92, P1304, DOI 10.1136/bjo.2008.141168
   MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   MEYERS SM, 1988, ARCH OPHTHALMOL-CHIC, V106, P651
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Nemeth-Cahalan KL, 2000, J BIOL CHEM, V275, P6777, DOI 10.1074/jbc.275.10.6777
   OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030
   Pallitto P, 2015, PHOTOCH PHOTOBIO SCI, V14, P1888, DOI 10.1039/c5pp00170f
   Palmer AD, 2012, J MASS SPECTROM, V47, P237, DOI 10.1002/jms.2049
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peng G, 2009, NAT NANOTECHNOL, V4, P669, DOI 10.1038/nnano.2009.235
   Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Ronci M, 2013, J PROTEOMICS, V82, P27, DOI 10.1016/j.jprot.2013.01.008
   Ronci M, 2011, J PROTEOME RES, V10, P3522, DOI 10.1021/pr200148k
   Roy MC, 2011, J LIPID RES, V52, P463, DOI 10.1194/jlr.M010546
   Sabatine MS, 2005, CIRCULATION, V112, P3868, DOI 10.1161/CIRCULATIONAHA.105.569137
   Shi M, 2015, MOL CELL PROTEOMICS, V14, P544, DOI 10.1074/mcp.M114.040576
   Skeie JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127567
   Snovida SI, 2006, ANAL CHEM, V78, P8561, DOI 10.1021/ac061375r
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762
   Stella DR, 2010, INVEST OPHTH VIS SCI, V51, P5153, DOI 10.1167/iovs.10-5302
   Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573
   Takats Z, 2004, SCIENCE, V306, P471, DOI 10.1126/science.1104404
   Tanaka K., 1988, RAPID COMMUN MASS SP, V2, P151, DOI [DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Thomson J. J., 1897, PHILOS MAG, V44, P293, DOI [DOI 10.1080/14786449708621070, 10.1080/14786449708621070]
   Van de Plas R, 2015, NAT METHODS, V12, P366, DOI [10.1038/nmeth.3296, 10.1038/NMETH.3296]
   Vidova V, 2010, J LIPID RES, V51, P2295, DOI 10.1194/jlr.M005488
   Wang H, 2013, EXP EYE RES, V108, P110, DOI 10.1016/j.exer.2012.11.023
   Wang XD, 2013, ANAL CHEM, V85, P7566, DOI 10.1021/ac401595a
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Zavalin A, 2015, ANAL BIOANAL CHEM, V407, P2337, DOI 10.1007/s00216-015-8532-6
   Zavalin A, 2012, J MASS SPECTROM, V47, P1473, DOI 10.1002/jms.3108
   Zhong WD, 2011, RAPID COMMUN MASS SP, V25, P3650, DOI 10.1002/rcm.5249
NR 103
TC 20
Z9 20
U1 1
U2 25
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1862-8346
EI 1862-8354
J9 PROTEOM CLIN APPL
JI Proteom. Clin. Appl.
PD APR
PY 2016
VL 10
IS 4
SI SI
BP 391
EP 402
DI 10.1002/prca.201500103
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DJ1EX
UT WOS:000373947200009
PM 26586164
DA 2022-11-30
ER

PT J
AU Westenskow, PD
   Bucher, F
   Bravo, S
   Kurihara, T
   Feitelberg, D
   Paris, LP
   Aguilar, E
   Lin, JH
   Friedlander, M
AF Westenskow, Peter D.
   Bucher, Felicitas
   Bravo, Stephen
   Kurihara, Toshihide
   Feitelberg, Daniel
   Paris, Liliana P.
   Aguilar, Edith
   Lin, Jonathan H.
   Friedlander, Martin
TI iPSC-Derived Retinal Pigment Epithelium Allografts Do Not Elicit
   Detrimental Effects in Rats: A Follow-Up Study
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID EMBRYONIC STEM-CELLS; LONG-TERM SAFETY; MACULAR DEGENERATION; RPE;
   TRANSPLANTATION; PHAGOCYTOSIS; NEOVASCULARIZATION; DIFFERENTIATION;
   GENERATION; OCT4
AB Phototransduction is accomplished in the retina by photoreceptor neurons and retinal pigment epithelium (RPE) cells. Photoreceptors rely heavily on the RPE, and death or dysfunction of RPE is characteristic of age-related macular degeneration (AMD), a very common neurodegenerative disease for which no cure exists. RPE replacement is a promising therapeutic intervention for AMD, and large numbers of RPE cells can be generated from pluripotent stem cells. However, questions persist regarding iPSC-derived RPE (iPS-RPE) viability, immunogenicity, and tumorigenesis potential. We showed previously that iPS-RPE prevent photoreceptor atrophy in dystrophic rats up until 24 weeks after implantation. In this follow-up study, we longitudinally monitored the same implanted iPS-RPE, in the same animals. We observed no gross abnormalities in the eyes, livers, spleens, brains, and blood in aging rats with iPSC-RPE grafts. iPS-RPE cells that integrated into the subretinal space outlived the photoreceptors and survived for as long as 21/2 years while nonintegrating RPE cells were ingested by host macrophages. Both populations could be distinguished using immunohistochemistry and electron microscopy. iPSC-RPE could be isolated from the grafts and maintained in culture; these cells also phagocytosed isolated photoreceptor outer segments. We conclude that iPS-RPE grafts remain viable and do not induce any obvious associated pathological changes.
C1 [Westenskow, Peter D.; Bucher, Felicitas; Bravo, Stephen; Kurihara, Toshihide; Feitelberg, Daniel; Paris, Liliana P.; Aguilar, Edith; Friedlander, Martin] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
   [Westenskow, Peter D.] Lowy Med Res Inst, La Jolla, CA 92037 USA.
   [Lin, Jonathan H.] Univ Calif San Diego, VA San Diego Healthcare Syst, Dept Pathol, La Jolla, CA 92037 USA.
C3 Scripps Research Institute; University of California System; University
   of California San Diego; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); VA San Diego Healthcare System
RP Friedlander, M (通讯作者)，Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
EM friedlan@scripps.edu
RI Kurihara, Toshihide/ABA-7058-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; Bucher,
   Felicitas/0000-0003-0081-1420; Lin, Jonathan/0000-0002-7438-6941;
   Westenskow, Peter/0000-0001-9841-6220; Paris,
   Liliana/0000-0002-9312-9924
FU California Institute of Regenerative Medicine (CIRM) [TR1-01219]; Lowy
   Medical Research Institute; National Eye Institute [EY11254, EY020846];
   National Institutes of Health under Ruth L. Kirschstein National
   Research Service Award [EY021416]; NATIONAL EYE INSTITUTE [R01EY020846,
   F32EY021416, R01EY011254, P30EY022589] Funding Source: NIH RePORTER
FX The authors wish to acknowledge assistance from Drs. Lea Scheppke and
   Alan Bird for critically evaluating the paper. They also acknowledge
   technical assistance from Dr. Malcolm R. Wood at the EM Core Facility,
   Michele Courtney in the TSRI Pathology Lab, and Dr. Shari Hamilton at
   IDEXX RADIL. This work was funded by grants from The California
   Institute of Regenerative Medicine (CIRM TR1-01219) and The Lowy Medical
   Research Institute to Martin Friedlander and from the National Eye
   Institute to Martin Friedlander (EY11254) and Jonathan H. Lin (EY020846)
   and by the National Institutes of Health under Ruth L. Kirschstein
   National Research Service Award EY021416 to Peter D. Westenskow.
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Nork TM, 2012, ARCH OPHTHALMOL-CHIC, V130, P65, DOI 10.1001/archophthalmol.2011.295
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Ross W H, 2000, Curr Opin Ophthalmol, V11, P191, DOI 10.1097/00055735-200006000-00007
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   WEBER ML, 1989, CURR EYE RES, V8, P61, DOI 10.3109/02713688909013895
   Westenskow P, 2015, JOVE-J VIS EXP, DOI 10.3791/52214
   Westenskow PD, 2015, JOVE-J VIS EXP, DOI 10.3791/52247
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015
NR 39
TC 16
Z9 17
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-966X
EI 1687-9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2016
VL 2016
AR 8470263
DI 10.1155/2016/8470263
PG 8
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DF7DN
UT WOS:000371518000001
PM 26880994
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shen, F
   Mao, L
   Zhu, W
   Lawton, MT
   Pechan, P
   Colosi, P
   Wu, Z
   Scaria, A
   Su, H
AF Shen, F.
   Mao, L.
   Zhu, W.
   Lawton, M. T.
   Pechan, P.
   Colosi, P.
   Wu, Z.
   Scaria, A.
   Su, H.
TI Inhibition of pathological brain angiogenesis through systemic delivery
   of AAV vector expressing soluble FLT1
SO GENE THERAPY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; HEREDITARY HEMORRHAGIC TELANGIECTASIA;
   ADULT-MOUSE BRAIN; ADENOASSOCIATED VIRUS; GENE-TRANSFER;
   ARTERIOVENOUS-MALFORMATION; VASCULAR MALFORMATIONS; IMMUNE-RESPONSES;
   VEGF; THERAPY
AB The soluble vascular endothelial growth factor (VEGF) receptor 1 (sFLT1) has been tested in both animals and humans for anti-angiogenic therapies, for example, age-related macular degeneration. We hypothesized that adeno-associated viral vector (AAV)mediated sFLT1 expression could be used to inhibit abnormal brain angiogenesis. We tested the anti-angiogenic effect of sFLT1 and the feasibility of using AAV serotype 9 to deliver sFLT1 through intravenous injection (IV) to the brain angiogenic region. AAVs were packaged in AAV serotypes 1 and 2 (stereotactic injection) and 9 (IV injection). Brain angiogenesis was induced in adult mice through stereotactic injection of AAV1-VEGF. AAV2-sFLT02 containing sFLT1 VEGF-binding domain (domain 2) was injected into the brain angiogenic region, and AAV9-sFLT1 was injected into the jugular vein at the time of or 4 weeks after AAV1-VEGF injection. We showed that AAV2-sFLT02 inhibited brain angiogenesis at both time points. IV injection of AAV9-sFLT1 inhibited angiogenesis only when the vector was injected 4 weeks after angiogenic induction. Neither lymphocyte infiltration nor neuron loss was observed in AAV9-sFLT1-treated mice. Our data show that systemically delivered AAV9-sFLT1 inhibits angiogenesis in the mouse brain, which could be utilized to treat brain angiogenic diseases such as brain arteriovenous malformation.
C1 [Shen, F.; Mao, L.; Zhu, W.; Su, H.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Ctr Cerebrovasc Res, San Francisco, CA 94110 USA.
   [Shen, F.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Neurol, Shanghai, Peoples R China.
   [Lawton, M. T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.
   [Pechan, P.; Scaria, A.] Sanofi Genzyme R&D Ctr, Framingham, MA USA.
   [Colosi, P.; Wu, Z.] NEI, Ocular Gene Therapy Core, NIH, Bethesda, MD 20892 USA.
C3 University of California System; University of California San Francisco;
   Shanghai Jiao Tong University; University of California System;
   University of California San Francisco; Sanofi-Aventis; Genzyme
   Corporation; National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Su, H (通讯作者)，Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, 1001 Potrero Ave Box 1368, San Francisco, CA 94110 USA.
EM hua.su@ucsf.edu
FU National Institutes of Health [R01 NS027713, R01 HL122774, R21
   NS070153]; Michael Ryan Zodda Foundation; UCSF Research Evaluation and
   Allocation Committee (REAC); National Natural Science Foundation of
   China [81471177]; NATIONAL EYE INSTITUTE [ZIAEY000443] Funding Source:
   NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL122774]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKE [R21NS070153, R01NS027713, R21NS083788] Funding
   Source: NIH RePORTER
FX We thank the members of the UCSF BAVM Study Project
   (http://avm.ucsf.edu) for their support, and Voltaire Gungab for
   assistance with manuscript preparation. This study was supported by
   grants to H. Su from the National Institutes of Health (R01 NS027713,
   R01 HL122774, and R21 NS070153) and from the Michael Ryan Zodda
   Foundation and UCSF Research Evaluation and Allocation Committee (REAC),
   and by a grant to F Shen from the National Natural Science Foundation of
   China (No 81471177).
CR Al-Maghrabi J, 2014, TUMOR BIOL, V35, P9045, DOI 10.1007/s13277-014-2124-5
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Baluk P, 2004, AM J PATHOL, V165, P1071, DOI 10.1016/S0002-9440(10)63369-X
   Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761
   Bish LT, 2008, HUM GENE THER, V19, P1359, DOI 10.1089/hum.2008.123
   Bowles DE, 2012, MOL THER, V20, P443, DOI 10.1038/mt.2011.237
   Chen WQ, 2014, TRANSL STROKE RES, V5, P316, DOI 10.1007/s12975-014-0343-0
   Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002
   Ciesielska A, 2013, MOL THER, V21, P158, DOI 10.1038/mt.2012.167
   DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x
   Dupuis-Girod S, 2012, JAMA-J AM MED ASSOC, V307, P948, DOI 10.1001/jama.2012.250
   Duque S, 2009, MOL THER, V17, P1187, DOI 10.1038/mt.2009.71
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Flieger D, 2006, ANN HEMATOL, V85, P631, DOI 10.1007/s00277-006-0147-8
   Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515
   Gong Y, 2015, MOL THER, V23, P824, DOI 10.1038/mt.2015.6
   Grimm D, 2003, BLOOD, V102, P2412, DOI 10.1182/blood-2003-02-0495
   Hajjar RJ, 2008, J CARD FAIL, V14, P355, DOI 10.1016/j.cardfail.2008.02.005
   Hao Q, 2008, ARTERIOSCL THROM VAS, V28, P2151, DOI 10.1161/ATVBAHA.108.176297
   Heist RS, 2015, P NATL ACAD SCI USA, V112, P1547, DOI 10.1073/pnas.1424024112
   Herzog RW, 2010, DISCOV MED, V9, P105
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Kay MA, 2011, NAT REV GENET, V12, P316, DOI 10.1038/nrg2971
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kim H, 2011, ACTA NEUROCHIR SUPPL, V111, P83, DOI 10.1007/978-3-7091-0693-8_14
   Limberis MP, 2006, P NATL ACAD SCI USA, V103, P12993, DOI 10.1073/pnas.0601433103
   Liu L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1140-1
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Matsushita T, 1998, GENE THER, V5, P938, DOI 10.1038/sj.gt.3300680
   Meyer S, 2005, J BIOL CHEM, V280, P37349, DOI 10.1074/jbc.M507100200
   Mingozzi F, 2013, BLOOD, V122, P23, DOI 10.1182/blood-2013-01-306647
   Mitchell A, 2008, LIVER TRANSPLANT, V14, P210, DOI 10.1002/lt.21417
   Mori S, 2004, VIROLOGY, V330, P375, DOI 10.1016/j.virol.2004.10.012
   Nathwani AC, 2011, NEW ENGL J MED, V365, P2357, DOI 10.1056/NEJMoa1108046
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Pollack A., 2012, EUROPEAN AGENCY BACK, pB1
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Ramirez M, 2011, INVEST OPHTH VIS SCI, V52, P8944, DOI 10.1167/iovs.11-8190
   Shen FX, 2006, FRONT BIOSCI-LANDMRK, V11, P3190, DOI 10.2741/2042
   Shen FX, 2013, STROKE, V44, P252, DOI 10.1161/STROKEAHA.112.662965
   Shen FX, 2011, J CEREBR BLOOD F MET, V31, P2343, DOI 10.1038/jcbfm.2011.97
   Shen FX, 2010, STROKE, V41, pE392
   Shen FX, 2006, STROKE, V37, P685
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8
   Simons M, 2012, J AM COLL CARDIOL, V60, P626, DOI 10.1016/j.jacc.2012.01.069
   Smith AJ, 2012, GENE THER, V19, P154, DOI 10.1038/gt.2011.161
   Su H, 2006, GENE THER, V13, P1495, DOI 10.1038/sj.gt.3302787
   Su H, 2000, P NATL ACAD SCI USA, V97, P13801, DOI 10.1073/pnas.250488097
   Sullivan LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012031
   Tanvetyanon T, 2009, J THORAC ONCOL, V4, P268, DOI 10.1097/JTO.0b013e318195a642
   Walker EJ, 2012, STROKE, V43, P1925, DOI 10.1161/STROKEAHA.111.647982
   Walker EJ, 2011, ANN NEUROL, V69, P954, DOI 10.1002/ana.22348
   Williams BJ, 2012, J NEUROSURG, V116, P972, DOI 10.3171/2012.1.JNS111627
   Xiao PJ, 2012, THER DELIV, V3, P835, DOI 10.4155/TDE.12.63
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
NR 60
TC 5
Z9 11
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD NOV
PY 2015
VL 22
IS 11
BP 893
EP 900
DI 10.1038/gt.2015.57
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA CV8YO
UT WOS:000364574500007
PM 26090874
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hartnett, TE
   O'Connor, AJ
   Ladewig, K
AF Hartnett, Terence E.
   O'Connor, Andrea J.
   Ladewig, Katharina
TI Cubosomes and other potential ocular drug delivery vehicles for
   macromolecular therapeutics
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE age-related macular degeneration; cubosome; ocular drug delivery;
   posterior; segment eye disease
ID LIQUID-CRYSTALLINE NANOPARTICLES; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; POSTERIOR SEGMENT; CHOROIDAL NEOVASCULARIZATION;
   SUSTAINED-RELEASE; CUBIC PHASE; OPHTHALMIC DELIVERY; INTERNAL STRUCTURE;
   CANCER-THERAPY
AB Introduction: Many macronnolecular therapeutics designed to treat posterior segment eye diseases (PSEDs) are administered through frequent ocular injection, which can further deteriorate eye health. Due to the high frequency of injection and the high cost of the therapeutics, there is a need to develop new ways in which to deliver these therapeutics: ways which are both safer and more cost effective.
   Areas covered: Using the most common PSED, age-related macular degeneration, as an example of a debilitating ocular disease, this review examines the key barriers limiting the delivery of macromolecular therapeutics to the posterior segment of the eye and defines the key requirements placed on particulate drug delivery vehicles (DDVs) to be suitable for this application. Recent developments in macromolecular drug delivery to treat this disease as well as the remaining shortcomings in its treatment are surveyed. Lastly, an emerging class of DDVs potentially suited to this application, called cubosomes, is introduced.
   Expert opinion: Based on their excellent colloidal stability and high internal surface area, cubosomes hold great potential for the sustained release of therapeutics. Novel production methods and a better understanding of the mechanisms through which drug release from these particles can be controlled are two major recent developments toward successful application.
C1 [Hartnett, Terence E.; O'Connor, Andrea J.; Ladewig, Katharina] Univ Melbourne, Dept Chem & Biomol Engn, Parkville, Vic 3010, Australia.
   [Hartnett, Terence E.; O'Connor, Andrea J.; Ladewig, Katharina] Univ Melbourne, Particulate Fluids Proc Ctr PFPC, Parkville, Vic 3010, Australia.
   [Hartnett, Terence E.] Commonwealth Sci & Ind Res Org CSIRO, Mat Sci & Engn, Clayton, Vic 3168, Australia.
C3 University of Melbourne; University of Melbourne; Commonwealth
   Scientific & Industrial Research Organisation (CSIRO)
RP Ladewig, K (通讯作者)，Univ Melbourne, Dept Chem & Biomol Engn, Parkville, Vic 3010, Australia.
EM kladewig@unimelb.edu.au
RI O'Connor, Andrea J/B-1225-2011
OI O'Connor, Andrea J/0000-0001-6925-885X
FU Australian Research Council
FX The review was funded by the Australian Research Council. The authors
   declare no relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript. This includes employment, consultancies, honoraria, stock
   ownership or options, expert testimony, grants or patents received or
   pending, or royalties.
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Albini T.A., 2014, RETIN TODAY, P70
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Angelov B, 2003, J AM CHEM SOC, V125, P7188, DOI 10.1021/ja034578v
   Angelov B, 2013, J PHYS CHEM LETT, V4, P1959, DOI 10.1021/jz400857z
   Angelov B, 2012, LANGMUIR, V28, P16647, DOI 10.1021/la302721n
   Angelov B, 2012, J PHYS CHEM B, V116, P7676, DOI 10.1021/jp303863q
   Angelov B, 2011, SOFT MATTER, V7, P9714, DOI 10.1039/c1sm06447a
   Angelova A, 2008, J DRUG DELIV SCI TEC, V18, P41, DOI 10.1016/S1773-2247(08)50005-0
   Angelova A, 2005, LANGMUIR, V21, P4138, DOI 10.1021/la047745t
   Angelova A, 2003, LANGMUIR, V19, P6928, DOI 10.1021/la0345284
   Angius R, 2006, J PHYS-CONDENS MAT, V18, pS2203, DOI 10.1088/0953-8984/18/33/S35
   ASSIL KK, 1991, INVEST OPHTH VIS SCI, V32, P2891
   Barman S, 2014, ON DRUG DELIV, P4
   BARTH RF, 1994, BIOCONJUGATE CHEM, V5, P58, DOI 10.1021/bc00025a008
   Bhadra D, 2004, J PHARM PHARM SCI, V7, P241
   Bochot A, 2012, J CONTROL RELEASE, V161, P628, DOI 10.1016/j.jconrel.2012.01.019
   Boyer DS, 2014, OCUL SURG NEWS APAO, P8
   CAVALLARO G, 1994, INT J PHARM, V111, P31, DOI 10.1016/0378-5173(94)90399-9
   Chang H. I., 2012, J NANOMED BIOTHERAPE, V1, P1
   Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766
   Chemelli A, 2012, LANGMUIR, V28, P16788, DOI 10.1021/la303373q
   Cheng YY, 2008, J PHARM SCI-US, V97, P123, DOI 10.1002/jps.21079
   Conn CE, 2013, SOFT MATTER, V9, P3449, DOI 10.1039/c3sm27743g
   Crommelin DJA, 1997, J CONTROL RELEASE, V46, P165, DOI 10.1016/S0168-3659(96)01583-0
   Dai WB, 2014, BIOMATERIALS, V35, P5347, DOI 10.1016/j.biomaterials.2014.03.036
   Davide B., 2014, SMALL, P1
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077
   De Temmerman ML, 2011, BIOMACROMOLECULES, V12, P1283, DOI 10.1021/bm101559w
   DEKOZAK Y, 1987, EUR J IMMUNOL, V17, P541, DOI 10.1002/eji.1830170417
   Deli MA, 2009, BBA-BIOMEMBRANES, V1788, P892, DOI 10.1016/j.bbamem.2008.09.016
   Driever CD, 2013, LANGMUIR, V29, P12891, DOI 10.1021/la401660h
   Eljarrat-Binstock E, 2010, PHARM RES-DORDR, V27, P530, DOI 10.1007/s11095-009-0042-9
   Engstrom S, 1996, CRS BUI NAT, P89
   ERICSSON B, 1991, ACS SYM SER, V469, P251
   Family F, 2010, PHYSCS PROC, V4, P21, DOI 10.1016/j.phpro.2010.08.006
   Fan YC, 2013, ASIAN J PHARM SCI, V8, P81, DOI 10.1016/j.ajps.2013.07.010
   Fatouros DG, 2002, J COLLOID INTERF SCI, V251, P271, DOI 10.1006/jcis.2002.8432
   Feast GC, 2014, BEILSTEIN J ORG CHEM, V10, P1578, DOI 10.3762/bjoc.10.163
   Feast GC, 2014, CHEM-EUR J, V20, P2783, DOI 10.1002/chem.201303514
   Felt O, 1999, INT J PHARM, V180, P185, DOI 10.1016/S0378-5173(99)00003-4
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FISHMAN PH, 1986, INVEST OPHTH VIS SCI, V27, P1103
   Friberg SE, 1997, COLLOID SURFACE A, V129, P167, DOI 10.1016/S0927-7757(97)00035-6
   Gaede HC, 2003, BIOPHYS J, V85, P1734, DOI 10.1016/S0006-3495(03)74603-7
   Gan L, 2010, INT J PHARMACEUT, V396, P179, DOI 10.1016/j.ijpharm.2010.06.015
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Gordon S, 2012, J LIPOSOME RES, V22, P193, DOI 10.3109/08982104.2011.637502
   GRASS GM, 1988, J PHARM SCI, V77, P15, DOI 10.1002/jps.2600770104
   Han S, 2010, ACTA PHARMACOL SIN, V31, P990, DOI 10.1038/aps.2010.98
   Hartnett TE, 2014, J PHYS CHEM B, V118, P7430, DOI 10.1021/jp502898a
   Hinton TM, 2014, TOXICOL RES-UK, V3, P11, DOI 10.1039/c3tx50075f
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Hyde S.T., 1997, LANGUAGE SHAPE ROLE
   Ip MS, 2004, DIABETES CARE, V27, P1794, DOI 10.2337/diacare.27.7.1794
   ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525
   Jain GK, 2012, DRUG DISCOV TODAY, V17, P748, DOI 10.1016/j.drudis.2012.03.006
   Kang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1043, DOI 10.1001/archophthalmol.2009.185
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kaur IP, 2004, INT J PHARMACEUT, V269, P1, DOI 10.1016/j.ijpharm.2003.09.016
   KEELEY FW, 1984, EXP EYE RES, V39, P533, DOI 10.1016/0014-4835(84)90053-8
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kim SH, 2007, OPHTHALMIC RES, V39, P244, DOI 10.1159/000108117
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001
   Kuppermann BD, 1996, J INFECT DIS, V173, P18, DOI 10.1093/infdis/173.1.18
   Lai J, 2009, AAPS PHARMSCITECH, V10, P960, DOI 10.1208/s12249-009-9292-4
   LeBourlais C, 1996, J MICROENCAPSUL, V13, P473
   Lee KWY, 2009, INT J PHARMACEUT, V365, P190, DOI 10.1016/j.ijpharm.2008.08.022
   Lee TWY, 2001, J OCUL PHARMACOL TH, V17, P565, DOI 10.1089/10807680152729257
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Liu CW, 2012, INT J NANOMED, V7, P4749, DOI 10.2147/IJN.S32830
   Liu HZ, 2013, J DRUG TARGET, V21, P846, DOI 10.3109/1061186X.2013.829075
   Liu QT, 2013, LANGMUIR, V29, P14265, DOI 10.1021/la402426y
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   MAYHEW E, 1987, EXP CELL RES, V171, P195, DOI 10.1016/0014-4827(87)90262-X
   MCCAA CS, 1982, ENVIRON HEALTH PERSP, V44, P1, DOI 10.2307/3429469
   MISHIMA S., 1966, INVEST OPHTHALMOL, V5, P264
   Mozafari MR, 2005, CELL MOL BIOL LETT, V10, P711
   Muir BW, 2012, J PHYS CHEM B, V116, P3551, DOI 10.1021/jp300239g
   Mulet X, 2013, J COLLOID INTERF SCI, V393, P1, DOI 10.1016/j.jcis.2012.10.014
   Negrini R, 2012, LANGMUIR, V28, P16455, DOI 10.1021/la303833s
   Negrini R, 2011, LANGMUIR, V27, P5296, DOI 10.1021/la200591u
   Nii T, 2005, INT J PHARMACEUT, V298, P198, DOI 10.1016/j.ijpharm.2005.04.029
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nwe K, 2012, MOL PHARMACEUT, V9, P374, DOI 10.1021/mp2003219
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Patel NR, 2011, INT J PHARMACEUT, V416, P296, DOI 10.1016/j.ijpharm.2011.05.082
   Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y
   Patri AK, 2004, BIOCONJUGATE CHEM, V15, P1174, DOI 10.1021/bc0499127
   PMLiVE, 2014, TOP 50 PHARM PROD GL
   Poelstra KA, 2002, J BIOMED MATER RES, V60, P206, DOI 10.1002/jbm.10069
   Ranta VP, 2006, ADV DRUG DELIVER REV, V58, P1164, DOI 10.1016/j.addr.2006.07.025
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Resnikoff S, 2004, B WORLD, V012831, P9
   Rizwan SB, 2013, J CONTROL RELEASE, V165, P16, DOI 10.1016/j.jconrel.2012.10.020
   Rizwan SB, 2011, EUR J PHARM BIOPHARM, V79, P15, DOI 10.1016/j.ejpb.2010.12.034
   Rojas IA, 2000, J CONTROL RELEASE, V63, P175, DOI 10.1016/S0168-3659(99)00195-9
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Schwartz SG, 2014, EXPERT OPIN DRUG DEL, V11, P61, DOI 10.1517/17425247.2013.859135
   Schwartz SG, 2009, EXPERT OPIN PHARMACO, V10, P2119, DOI 10.1517/14656560903081752
   Sevenson S, 2012, ADV DRUG DELIVER REV, V64, P102, DOI 10.1016/j.addr.2012.09.030
   Shailesh S, 2009, J PHARM RES, V2, P1163
   Slingerland M, 2012, DRUG DISCOV TODAY, V17, P160, DOI 10.1016/j.drudis.2011.09.015
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spicer PT, 2001, LANGMUIR, V17, P5748, DOI 10.1021/la010161w
   Stano P, 2011, J MATER CHEM, V21, P18887, DOI 10.1039/c1jm12298c
   Steedman MR, 2010, BIOMED MICRODEVICES, V12, P363, DOI 10.1007/s10544-009-9392-7
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Tetz M, 2012, OPHTHALMOLOGICA, V227, P183, DOI 10.1159/000336045
   Thomas TP, 2004, BIOMACROMOLECULES, V5, P2269, DOI 10.1021/bm049704h
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Vyas SP, 1998, PHARMAZIE, V53, P466
   Wadhwa S, 2009, CURR PHARM DESIGN, V15, P2724, DOI 10.2174/138161209788923886
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
   WHO, 2012, WHO PRIOR EYE DIS
   Winterton L, 2001, Single-dip process for achieving a layer-by-layer-like coating, P1, Patent No. [US0048975 A1, 0048975]
   WU CC, 1994, BIOORG MED CHEM LETT, V4, P449, DOI 10.1016/0960-894X(94)80014-6
   Yaghmur A, 2006, LANGMUIR, V22, P9919, DOI 10.1021/la061303v
   Yaghmur A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000479
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
   Yasukawa Tsutomu, 2011, Recent Pat Drug Deliv Formul, V5, P1, DOI 10.2174/187221111794109529
   Zabara A, 2014, J CONTROL RELEASE, V188, P31, DOI 10.1016/j.jconrel.2014.05.052
   Zabara A, 2013, SOFT MATTER, V9, P1010, DOI 10.1039/c2sm26988k
   Zabara A, 2012, SOFT MATTER, V8, P6535, DOI 10.1039/c2sm25249j
NR 136
TC 22
Z9 24
U1 0
U2 40
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD SEP
PY 2015
VL 12
IS 9
BP 1513
EP 1526
DI 10.1517/17425247.2015.1021680
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CP8ZV
UT WOS:000360184400009
PM 25745885
DA 2022-11-30
ER

PT J
AU McKibbin, M
   Baker, L
   Baxter, P
   Czoski-Muray, C
   Setty, R
AF McKibbin, Martin
   Baker, Lucy
   Baxter, Paul
   Czoski-Muray, Carolyn
   Setty, Roopa
TI The accuracy of home monitoring to detect disease activity during
   maintenance therapy for neovascular ARMD
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Self-monitoring; Sensitivity
ID PREFERENTIAL HYPERACUITY PERIMETRY; MACULAR DEGENERATION; VISUAL
   FUNCTION; RANIBIZUMAB; COEFFICIENT; TOOL
AB To report the reproducibility, sensitivity, specificity, and predictive value of home monitoring for disease activity in neovascular age-related macular degeneration (ARMD).
   Participants were trained to complete three separate home monitoring tasks, designed to identify subtle changes in visual function that may indicate increasing neovascular ARMD disease activity. These included measurement of near acuity and assessments of environmental distortion and overall visual function. The need for repeat intra-vitreal injection, as predicted by home monitoring, was compared to standard clinical assessment involving ETDRS distance acuity, slit lamp examination, and spectral domain ocular coherence tomography.
   Although all participants were able to complete the home monitoring tasks, the reproducibility of each of the three tasks was modest. Cohen's kappa was 0.118 (p = 0.54) for the comparison of the outcome of the home monitoring exercise with the gold standard of hospital assessment to determine disease activity. The sensitivity of the home monitoring exercise was 33.3 % (95 % CI 15.2-51.4) and the specificity was 77.8 % (95 % CI 61.8-93.8).
   This study suggests that current tests of visual function, which are readily completed at home, cannot replace traditional clinic-based assessments for neovascular ARMD disease activity. Instead, such tests are likely to remain complementary to standard assessment in clinic.
C1 [McKibbin, Martin; Baker, Lucy] St James Univ Hosp, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
   [Baxter, Paul] Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England.
   [Czoski-Muray, Carolyn] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England.
   [Setty, Roopa] Bradford Royal Infirm, Eye Clin, Bradford BD9 6RJ, W Yorkshire, England.
C3 Saint James's University Hospital; University of Leeds; University of
   Leeds; Bradford Royal Infirmary
RP McKibbin, M (通讯作者)，St James Univ Hosp, Eye Clin, Leeds LS9 7TF, W Yorkshire, England.
EM martin.mckibbin@btinternet.com
OI McKibbin, Martin/0000-0003-4388-243X; Baxter, Paul/0000-0003-2699-3103
FU Biomedical Health Research Centre Problem Solving Fund [PSF87]
FX This project was supported by an award from the Biomedical Health
   Research Centre Problem Solving Fund (PSF87).
CR BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Das R, 2009, RETINA-J RET VIT DIS, V29, P1013, DOI 10.1097/IAE.0b013e3181a91dbf
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mathew R, 2012, EYE, V26, P389, DOI 10.1038/eye.2011.326
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P7012, DOI 10.1167/iovs.11-7517
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Trevino Richard, 2008, Optometry, V79, P397, DOI 10.1016/j.optm.2007.09.017
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Weymouth AE, 2012, INVEST OPHTH VIS SCI, V53, P3226, DOI 10.1167/iovs.11-8807
NR 21
TC 3
Z9 3
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2015
VL 253
IS 9
BP 1479
EP 1483
DI 10.1007/s00417-014-2839-4
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CQ0MQ
UT WOS:000360290700008
PM 25367832
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Nowak, JZ
AF Nowak, Jerzy Z.
TI AMD - THE RETINAL DISEASE WITH AN UNPRECISED ETIOPATHOGENESIS: IN SEARCH
   OF EFFECTIVE THERAPEUTICS
SO ACTA POLONIAE PHARMACEUTICA
LA English
DT Article
DE AMD; age-related macular degeneration; pathogenesis; lipofuscin; drusen;
   oxidative stress; inflammation; retina; vision; therapeutic strategies
AB AMD (age-related macular degeneration) is a progressive vision-threatening ocular disease, affecting central region of the retina - the macula - and manifesting in the elderly. AMD is a degenerative disease, and the degeneration affects primarily the retinal pigment epithelial (RPE) cells and secondarily the photoreceptors, leading consequently to disturbances or partial loss of central vision and legal blindness. Clinically, the disease is classified as: atrophic - dry AMD (in majority of cases), and neovascular - wet AMD (with chomidal neovascularization- CNV; 10-15% of all AMD cases). Pathogenesis of AMD is complex, multifactorial and only poorly recognized. Main risk factors include: advanced age, genetic predispositions. environmental determinants. history of exposure to intensive light and smoking. At least four molecular processes contribute to the development of AMD pathology: lipofuscinogenesis, drusogenesis, inflammation and choroidal neovascularization (in wet AMD). Since vascular endothelial growth factor (VEGF) is a predominant proangiogenic factor in CNV, the wet AMD can be treated with intravitreous application of "anti-VEGF" agents (Avastin, Lucentis, Eylea). Till now, there is no approved therapy for dry AMD, although several agents/treatments are currently in clinical trials. This paper briefly describes major molecular and cellular events leading to AMD, and presents currently used and new experimental therapeutic strategies against AMD.
C1 [Nowak, Jerzy Z.] Med Univ Lodz, Interfac Chair Gen & Clin Pharmacol, Dept Pharmacol & Toxicol, Lodz, Poland.
   [Nowak, Jerzy Z.] Polish Acad Sci, Inst Pharmacol, Sci Board, Krakow, Poland.
C3 Medical University Lodz; Polish Academy of Sciences
RP Nowak, JZ (通讯作者)，Med Univ Lodz, Interfac Chair Gen & Clin Pharmacol, Dept Pharmacol & Toxicol, Lodz, Poland.
EM jznowak07@gmail.com
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P427, DOI 10.1034/j.1600-0420.2003.00157.x
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Calippe B, 2014, CR BIOL, V337, P178, DOI 10.1016/j.crvi.2013.12.003
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088201
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Evens J.R., 2012, COCHRANE DB SYST REV, V11
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1
   Gaynes B. I., 2004, EXPERT OPIN DRUG SAF, V3, P345
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Gross A.K.., 2011, ADLERS PHYSL EYE, P395
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klaska Izabela, 2007, Postepy Hig Med Dosw (Online), V61, P167
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   McConnell V, 2005, Ulster Med J, V74, P82
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Nowak J.Z., 2014, OXIDATIVE STRESS APP
   Nowak J.Z., 2013, MAG LEK OKUL, V7, P42
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   NOWAK JZ, 2005, MAG OKUL, V3, P174
   Nowak JZ, 2012, MIL PHARM MED, V4, P1
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Salminen A, 2012, AGING-US, V4, P166, DOI 10.18632/aging.100444
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schraermeyer U, 2013, EXPERT OPIN BIOL TH, V13, P157, DOI 10.1517/14712598.2012.748741
   Schutt F, 2007, GRAEF ARCH CLIN EXP, V245, P391, DOI 10.1007/s00417-006-0376-5
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Troutbeck R, 2012, CLIN EXP OPHTHALMOL, V40, P18, DOI 10.1111/j.1442-9071.2011.02581.x
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015
NR 78
TC 24
Z9 34
U1 0
U2 7
PU POLSKIE TOWARZYSTWO FARMACEUTYCZNE
PI WARSAW
PA DLUGA 16, 00-238 WARSAW, POLAND
SN 0001-6837
EI 2353-5288
J9 ACTA POL PHARM
JI ACTA POL. PHARM.
PD NOV-DEC
PY 2014
VL 71
IS 6
BP 900
EP 916
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA V46QS
UT WOS:000209899300003
PM 25745762
DA 2022-11-30
ER

PT J
AU Yu, Y
   Triebwasser, MP
   Wong, EKS
   Schramm, EC
   Thomas, B
   Reynolds, R
   Mardis, ER
   Atkinson, JP
   Daly, M
   Raychaudhuri, S
   Kavanagh, D
   Seddon, JM
AF Yu, Yi
   Triebwasser, Michael P.
   Wong, Edwin K. S.
   Schramm, Elizabeth C.
   Thomas, Brett
   Reynolds, Robyn
   Mardis, Elaine R.
   Atkinson, John P.
   Daly, Mark
   Raychaudhuri, Soumya
   Kavanagh, David
   Seddon, Johanna M.
TI Whole-exome sequencing identifies rare, functional CFHvariants in
   families with macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; HEMOLYTIC-UREMIC SYNDROME; HIGH-RISK;
   BINDING-AFFINITY; VARIANT; MUTATIONS; DISEASE; MEMBRANE; PROTEIN; C3B
AB We sequenced the whole exome of 35 cases and 7 controls from 9 age-related macular degeneration (AMD) families in whom known common genetic risk alleles could not explain their high disease burden and/or their early-onset advanced disease. Two families harbored novel rare mutations in CFH(R53C and D90G). R53C segregates perfectly with AMD in 11 cases (heterozygous) and 1 elderly control (reference allele) (LOD = 5.07, P = 6.7 x 10(-7)). In an independent cohort, 4 out of 1676 cases but none of the 745 examined controls or 4300 NHBLI Exome Sequencing Project (ESP) samples carried the R53C mutation (P = 0.0039). In another family of six siblings, D90G similarly segregated with AMD in five cases and one control (LOD = 1.22, P = 0.009). No other sample in our large cohort or the ESP had this mutation. Functional studies demonstrated that R53C decreased the ability of FH to perform decay accelerating activity. D90G exhibited a decrease in cofactor-mediated inactivation. Both of these changes would lead to a loss of regulatory activity, resulting in excessive alternative pathway activation. This study represents an initial application of the whole-exome strategy to families with early-onset AMD. It successfully identified high impact alleles leading to clearer functional insight into AMD etiopathogenesis.
C1 [Yu, Yi; Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Triebwasser, Michael P.; Schramm, Elizabeth C.; Atkinson, John P.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Wong, Edwin K. S.; Kavanagh, David] Newcastle Univ, Inst Med Genet, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Thomas, Brett; Daly, Mark] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Mardis, Elaine R.] Washington Univ, Genome Inst, St Louis, MO USA.
   [Daly, Mark; Raychaudhuri, Soumya] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Raychaudhuri, Soumya] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Med Sci, Boston, MA 02111 USA.
C3 Tufts Medical Center; Washington University (WUSTL); Newcastle
   University - UK; Harvard University; Massachusetts General Hospital;
   Washington University (WUSTL); Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; Partners Healthcare
   System; Harvard University; Brigham & Women's Hospital; Harvard
   University; Brigham & Women's Hospital; University of Manchester; Tufts
   University; Tufts University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Wong, Edwin/B-8599-2014; Mardis, Elaine/W-2202-2019; Kavanagh,
   David/E-8498-2011; Daly, Mark J/B-2453-2017
OI Kavanagh, David/0000-0003-4718-0072; Daly, Mark J/0000-0002-0949-8752;
   Raychaudhuri, Soumya/0000-0002-1901-8265; Wong,
   Edwin/0000-0003-4867-6117
FU NIH [R01-EY11309, K08AR055688, U01HG0070033, F30HL103072, R01-AI041592,
   U54HG00307910, U54 HL112303]; Edward N. & Della L.Thome Memorial
   Foundation; Doris Duke Clinical Scientist Development Award; Facility of
   the Rheumatic Diseases Core; NIH-Arthritis and Musculoskeletal and Skin
   Diseases [P30 AR48335]; Massachusetts Lions Eye Research Fund, Inc.;
   Foundation Fighting Blindness; Macular Vision Research Foundation;
   Research to Prevent Blindness Challenge Grant; American Macular
   Degeneration Foundation; Arnold and Mabel Beckman Initiative for Macular
   Research; Macular Degeneration Research Fund of the Ophthalmic
   Epidemiology and Genetics Service, New England Eye Center, Tufts Medical
   Center, Tufts University School of Medicine; Ruth L. Kirschstein
   National Research Service Award (National Heart, Lung and Blood
   Institute); MRC [MR/K023519/1] Funding Source: UKRI; Medical Research
   Council [MR/K023519/1] Funding Source: researchfish; NATIONAL EYE
   INSTITUTE [R01EY011309] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [U54HL112303, F30HL103072] Funding Source: NIH
   RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASES [R01AI041592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048335,
   K08AR055688] Funding Source: NIH RePORTER
FX This research was supported in part by NIH grants R01-EY11309 (J.M.S.),
   K08AR055688 (S.R.), U01HG0070033 (S.R.), F30HL103072 (M.T.),
   R01-AI041592 (J.P.A. and E.C.S.), U54HG00307910 (E.M.), U54 HL112303
   (J.P.A.); Edward N. & Della L.Thome Memorial Foundation (J.P.A.); the
   Doris Duke Clinical Scientist Development Award; the Facility of the
   Rheumatic Diseases Core supported by NIH-Arthritis and Musculoskeletal
   and Skin Diseases P30 AR48335 (J.P.A.), Massachusetts Lions Eye Research
   Fund, Inc. (J.M.S.); the Foundation Fighting Blindness (J.M.S.); the
   Macular Vision Research Foundation (J.M.S.); Research to Prevent
   Blindness Challenge Grant to the New England Eye Center, Department of
   Ophthalmology, Tufts University School of Medicine; American Macular
   Degeneration Foundation (J.M.S.); The Arnold and Mabel Beckman
   Initiative for Macular Research (E.M., S.R., J.M.S.) and the Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, New England Eye Center, Tufts Medical Center, Tufts University
   School of Medicine. D.K. is a Wellcome Intermediate Clinical Fellow.
   E.K.S.W. is a Medical Research Council clinical research training
   fellow. M.T. is a Ruth L. Kirschstein National Research Service Award
   recipient (National Heart, Lung and Blood Institute). The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fakhouri F, 2010, J AM SOC NEPHROL, V21, P859, DOI 10.1681/ASN.2009070706
   Fang CJ, 2008, BLOOD, V111, P624, DOI 10.1182/blood-2007-04-084533
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111
   Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623
   KRYCH M, 1994, J BIOL CHEM, V269, P13273
   LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443
   Legendre CM, 2013, NEW ENGL J MED, V368, P2169, DOI 10.1056/NEJMoa1208981
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330
   Morrison AC, 2013, NAT GENET, V45, P899, DOI 10.1038/ng.2671
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 46
TC 76
Z9 79
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 1
PY 2014
VL 23
IS 19
BP 5283
EP 5293
DI 10.1093/hmg/ddu226
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AQ9OM
UT WOS:000343185200022
PM 24847005
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jackson, GR
   Clark, ME
   Scott, IU
   Walter, LE
   Quillen, DA
   Brigell, MG
AF Jackson, Gregory R.
   Clark, Mark E.
   Scott, Ingrid U.
   Walter, Laura E.
   Quillen, David A.
   Brigell, Mitchell G.
TI Twelve-Month Natural History of Dark Adaptation in Patients with AMD
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE dark adaptation; age-related macular degeneration; longitudinal; human;
   clinical trial endpoint
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; RETINAL FUNCTION;
   VISUAL-ACUITY; FELLOW EYE; ROD; IMPAIRMENT; VISION
AB Purpose. A sensitive endpoint is required for clinical trials evaluating preventative therapies for early age-related macular degeneration (AMD). Dark adaptation (DA) is a sensitive marker of AMD and has been proposed as a potential endpoint. This study evaluated whether significant changes in DA speed could be detected in participants with early to intermediate AMD at 12 months following baseline DA measurement.
   Methods. Dark adaptation, visual acuity (VA), and fundus photography were obtained at baseline and at 6 and 12 months in 26 subjects with AMD and in 6 subjects with normal retinal health. Disease severity was assessed by the Nine-Step Age-Related Eye Disease Study AMD severity scale.
   Results. At 12 months, significant progression of DA impairment occurred in 5 of 26 (19%) participants with AMD. None of the participants with AMD exhibited a significant worsening of fundus grade or decrease of acuity related to disease progression. The normal group exhibited stable DA and VA during the observation period.
   Conclusions. Significant worsening of DA was observed in 19% of subjects with AMD in 12 months of observation, despite stable VA and fundus appearance. This study suggests that DA may be a suitable functional endpoint for early clinical studies evaluating novel treatments for early to intermediate AMD.
C1 [Jackson, Gregory R.; Scott, Ingrid U.; Walter, Laura E.; Quillen, David A.] Penn State Coll Med, Penn State Hershey Eye Ctr, Hershey, PA 17033 USA.
   [Clark, Mark E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Brigell, Mitchell G.] Novartis Inst BioMed Res, Cambridge, MA USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; University of Alabama
   System; University of Alabama Birmingham; Novartis
RP Jackson, GR (通讯作者)，Penn State Coll Med, 500 Univ Dr,HU19, Hershey, PA 17033 USA.
EM jackson@maculogix.com
RI Brigell, Mitchell/AAA-3437-2019
OI Scott, Ingrid/0000-0002-3908-7153
FU Novartis, Inc.
FX Supported by Novartis, Inc. DAQ is the George and Barbara Blankenship
   Professor. GRJ is an employee of and an investor in MacuLogix, the
   manufacturer of the AdaptDx. MGB is an employee of Novartis.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bland JM, 1996, BRIT MED J, V312, P1654, DOI 10.1136/bmj.312.7047.1654
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Holfort SK, 2011, DIABETOLOGIA, V54, P1853, DOI 10.1007/s00125-011-2149-x
   Holfort SK, 2010, EXP EYE RES, V91, P710, DOI 10.1016/j.exer.2010.08.017
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Siderov J, 1999, ACTA OPHTHALMOL SCAN, V77, P673, DOI 10.1034/j.1600-0420.1999.770613.x
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
NR 25
TC 32
Z9 32
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 925
EP 931
DI 10.1097/OPX.0000000000000247
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500016
PM 24705482
DA 2022-11-30
ER

PT J
AU Davis, BM
   Normando, EM
   Guo, L
   Turner, LA
   Nizari, S
   O'Shea, P
   Moss, SE
   Somavarapu, S
   Cordeiro, MF
AF Davis, Benjamin M.
   Normando, Eduardo M.
   Guo, Li
   Turner, Lisa A.
   Nizari, Shereen
   O'Shea, Paul
   Moss, Stephen E.
   Somavarapu, Satyanarayana
   Cordeiro, M. Francesca
TI Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo
   Using Annexin A5-associated Liposomes
SO SMALL
LA English
DT Article
DE drug delivery; medicine; nanotechnology; avastin; retina
ID CELL-LINE; PHOSPHOLIPID-MEMBRANES; DRUG-DELIVERY; FUSION DOMAIN;
   APOPTOSIS; A5; PERMEABILITY; PROTEIN; BEVACIZUMAB; VESICLES
AB Effective delivery to the retina is presently one of the most challenging areas in drug development in ophthalmology, due to anatomical barriers preventing entry of therapeutic substances. Intraocular injection is presently the only route of administration for large protein therapeutics, including the anti-Vascular Endothelial Growth Factors Lucentis (ranibizumab) and Avastin (bevacizumab). Anti-VEGFs have revolutionised the management of age-related macular degeneration and have increasing indications for use as sight-saving therapies in diabetes and retinal vascular disease. Considerable resources have been allocated to develop non-invasive ocular drug delivery systems. It has been suggested that the anionic phospholipid binding protein annexin A5, may have a role in drug delivery. In the present study we demonstrate, using a combination of in vitro and in vivo assays, that the presence of annexin A5 can significantly enhance uptake and transcytosis of liposomal drug carrier systems across corneal epithelial barriers. This system is employed to deliver physiologically significant concentrations of Avastin to the posterior of the rat eye (127 ng/g) and rabbit retina (18 ng/g) after topical application. Our observations provide evidence to suggest annexin A5 mediated endocytosis can enhance the delivery of associated lipidic drug delivery vehicles across biological barriers, which may have therapeutic implications.
C1 [Davis, Benjamin M.; Normando, Eduardo M.; Guo, Li; Turner, Lisa A.; Nizari, Shereen; Cordeiro, M. Francesca] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Normando, Eduardo M.; Turner, Lisa A.; Cordeiro, M. Francesca] Imperial Coll Healthcare NHSTrust, Western Eye Hosp, London NW1 5QH, England.
   [O'Shea, Paul] Univ Nottingham, Cell Biophys Grp, Inst Biophys Imaging & Opt Sci, Nottingham NG7 2RD, England.
   [Moss, Stephen E.] UCL, Dept Cell Biol, UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Somavarapu, Satyanarayana] UCL, Sch Pharm, London WC1N 1AX, England.
C3 University of London; University College London; University of
   Nottingham; University of London; University College London; University
   of London; University College London; University of London School of
   Pharmacy
RP Cordeiro, MF (通讯作者)，UCL, UCL Inst Ophthalmol, Bath St, London EC1V 9EL, England.
EM M.Cordeiro@ucl.ac.uk
OI Normando, Eduardo Maria/0000-0002-5774-8082; Davis,
   Benjamin/0000-0001-6121-1635; Cordeiro, Maria
   Francesca/0000-0001-8663-6525; O'Shea, paul/0000-0001-9313-8313; Guo,
   Li/0000-0002-3124-4505
FU UCLB
FX This work was supported by a proof of concept grant from UCLB. The
   authors would like to thank Mohammad H Dehabadi and Mark W Tilley for
   proofreading the manuscript. The authors would also like to thank the
   anonymous reviewers for their useful comments. Conflict of Interest: M F
   Cordeiro and S E Moss-Patent application.
CR ANDREE HAM, 1993, BIOCHEMISTRY-US, V32, P4634, DOI 10.1021/bi00068a022
   Asawakarn T, 2001, J BIOL CHEM, V276, P38457, DOI 10.1074/jbc.M103269200
   Becker U, 2007, J OCUL PHARMACOL TH, V23, P172, DOI 10.1089/jop.2006.0095
   Binder H, 2000, PHYS CHEM CHEM PHYS, V2, P4615, DOI 10.1039/b003033n
   CHARLES J, 1980, ANAL BIOCHEM, V104, P10
   Ciesielski F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038677
   Cladera J, 1999, J BIOL CHEM, V274, P29951, DOI 10.1074/jbc.274.42.29951
   Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19
   Cordeiro MF, 2011, EYE, V25, P545, DOI 10.1038/eye.2011.64
   Coxon KM, 2011, METHODS MOL BIOL, V731, P293, DOI 10.1007/978-1-61779-080-5_24
   Davis BM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013522
   Engelke H, 2011, J PHYS CHEM B, V115, P12963, DOI 10.1021/jp2048579
   Galvao J, 2013, CURR OPIN PHARMACOL, V13, P123, DOI 10.1016/j.coph.2012.08.007
   Garnier B, 2009, BIOCONJUGATE CHEM, V20, P2114, DOI 10.1021/bc9002579
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Ghate D, 2008, J GLAUCOMA, V17, P147, DOI 10.1097/IJG.0b013e31814b990d
   GIAMBANCO I, 1991, J HISTOCHEM CYTOCHEM, V39, P1189, DOI 10.1177/39.9.1833446
   Gubernator J, 1999, BBA-BIOMEMBRANES, V1418, P253, DOI 10.1016/S0005-2736(99)00026-7
   Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kenis H, 2007, CELL MOL LIFE SCI, V64, P2859, DOI 10.1007/s00018-007-7297-2
   Kenis H, 2004, J BIOL CHEM, V279, P52623, DOI 10.1074/jbc.M409009200
   KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591
   Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u
   Koide T, 2003, INVEST OPHTH VIS SCI, V44, pU329
   KONDO S, 1987, THROMB RES, V48, P449, DOI 10.1016/0049-3848(87)90402-6
   Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453
   Li XH, 2008, BIOCONJUGATE CHEM, V19, P1684, DOI 10.1021/bc800164d
   Liang MY, 1999, KIDNEY INT, V56, P2304, DOI 10.1046/j.1523-1755.1999.00787.x
   Lorberboym M, 2006, BRAIN RES, V1103, P13, DOI 10.1016/j.brainres.2006.05.073
   MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   MORTON RE, 1992, ANAL BIOCHEM, V204, P332, DOI 10.1016/0003-2697(92)90248-6
   Nielsen UB, 2002, BBA-MOL CELL RES, V1591, P109, DOI 10.1016/S0167-4889(02)00256-2
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Notara M, 2010, BRAIN RES BULL, V81, P279, DOI 10.1016/j.brainresbull.2009.08.009
   O'Shea P, 2003, BIOCHEM SOC T, V31, P990
   O'Shea P., 1990, PLANT CELL ENVIRON, P447
   Oling F, 2001, J STRUCT BIOL, V133, P55, DOI 10.1006/jsbi.2000.4337
   Reichl S, 2008, J PHARM PHARMACOL, V60, P299, DOI 10.1211/jpp.60.3.0004
   Rijmisch J., 1991, THROMB RES, V61, P93
   Seaton B. A., 1992, FEBS, V314, P159
   Tait J., 1988, BIOCHEMISTRY-US, P6268
   Ungethum L, 2011, J BIOL CHEM, V286, P1903, DOI 10.1074/jbc.M110.163527
   van S. P. M., 1994, BLOOD, V84, P1415
   VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281
   WALL J, 1995, MOL MEMBR BIOL, V12, P183, DOI 10.3109/09687689509027506
   Wang Yaning, 2004, Angiogenesis, V7, P335, DOI 10.1007/s10456-004-8272-2
NR 48
TC 88
Z9 98
U1 4
U2 62
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD APR
PY 2014
VL 10
IS 8
BP 1575
EP 1584
DI 10.1002/smll.201303433
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA AE8VH
UT WOS:000334280500018
PM 24596245
DA 2022-11-30
ER

PT J
AU Ojino, K
   Shimazawa, M
   Ohno, Y
   Otsuka, T
   Tsuruma, K
   Hara, H
AF Ojino, Kazuki
   Shimazawa, Masamitsu
   Ohno, Yuta
   Otsuka, Tomohiro
   Tsuruma, Kazuhiro
   Hara, Hideaki
TI Protective Effect of SUN N8075, a Free Radical Scavenger, against
   Excessive Light-Induced Retinal Damage in Mice
SO BIOLOGICAL & PHARMACEUTICAL BULLETIN
LA English
DT Article
DE age-related macular degeneration; light-induced retinal damage;
   oxidative stress
ID INDUCED PHOTORECEPTOR APOPTOSIS; MACULAR DEGENERATION; ANTIOXIDANT
   PROPERTIES; IN-VITRO; AMELIORATION; FLUNARIZINE; MECHANISMS; DISEASE;
   BLOCKER; AGENT
AB Although dry age-related macular degeneration (AMD) is one of the major causes of blindness, no effective therapies are developed. In this study, we investigated the effects of SUN N8075, a radical scavenger with neuroprotective properties, against light-induced retinal damage used as the model of dry AMD in mice. After dark adaption for 24h, we exposed the mice at 8000 lx for 3 h. We evaluated the retinal damage by recording the electroretinagram (ERG) and measuring the thickness of outer nuclear layer (ONL) at 5d after the light exposure. Retinal apoptotic cells were also detected by terminal deoxynucleotidyl transeferase mediated deoxyuridine triphosphate (dUTP) nick end labeling (TUNEL) staining, and the expression of 8-hydroxy-2-deoxyguanosine (8-OHdG) as an index for oxidative stress at 48 h after exposure to light. In ERG measurement, the intraperitoneal administration of SUN N8075 at 30 mg/kg improved the retinal dysfunction induced by the excess light exposure. In the histological evaluation, SUN N8075 inhibited the reduction of ONL thickness. In addition, SUN N8075 decreased in both numbers of TUNEL- and 8-OHdG-positive cells in ONL. These findings suggest that the systemic administration of SUN N8075 has protective effects on excess light-induced photoreceptor degeneration, via inhibition of oxidative stress.
C1 [Ojino, Kazuki; Shimazawa, Masamitsu; Ohno, Yuta; Otsuka, Tomohiro; Tsuruma, Kazuhiro; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
RI Ohno, Yuta/AIE-4047-2022
OI Ohno, Yuta/0000-0002-8182-3150
CR Akane M, 2011, NEUROSCI LETT, V488, P87, DOI 10.1016/j.neulet.2010.11.008
   Annoura H, 2000, J MED CHEM, V43, P3372, DOI 10.1021/jm000143w
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   EDWARD DP, 1991, ARCH OPHTHALMOL-CHIC, V109, P554, DOI 10.1001/archopht.1991.01080040122042
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Inokuchi Y, 2009, J NEUROSCI RES, V87, P906, DOI 10.1002/jnr.21906
   Kotani Y, 2007, NEUROSCIENCE, V149, P779, DOI 10.1016/j.neuroscience.2007.08.029
   LI JP, 1993, EXP EYE RES, V56, P71
   Marc RE, 2008, MOL VIS, V14, P782
   Oyagi A, 2008, BRAIN RES, V1214, P169, DOI 10.1016/j.brainres.2008.02.073
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
NR 15
TC 11
Z9 14
U1 0
U2 4
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0918-6158
J9 BIOL PHARM BULL
JI Biol. Pharm. Bull.
PD MAR
PY 2014
VL 37
IS 3
BP 424
EP 430
DI 10.1248/bpb.b13-00778
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AB8RL
UT WOS:000332057600013
PM 24583861
OA gold
DA 2022-11-30
ER

PT J
AU Gupta, P
   Zheng, YF
   Ting, TW
   Lamoureux, EL
   Cheng, CY
   Wong, TY
AF Gupta, Preeti
   Zheng, Yingfeng
   Ting, Tay Wan
   Lamoureux, Ecosse L.
   Cheng, Ching-Yu
   Wong, Tien-Yin
TI Prevalence of Cataract Surgery and Visual Outcomes in Indian Immigrants
   in Singapore: The Singapore Indian Eye Study
SO PLOS ONE
LA English
DT Article
ID RISK-FACTORS; POPULATION; BLINDNESS; BARRIERS; CHINESE; IMPAIRMENT;
   EXTRACTION; VISION; ACUITY
AB Objective: To determine the prevalence of cataract surgery and factors associated with post-surgical visual outcomes in migrant Indians living in Singapore.
   Research Design and Methods: We conducted a population-based study in 3,400 Indian immigrants residing in Singapore-the Singapore Indian Eye Study (SINDI). All participants underwent comprehensive medical eye examination and a standardized interview. Post-operative visual impairment (VI) was defined as best-corrected or presenting visual acuity (BCVA or PVA) of 20/60 or worse.
   Results: The age-and gender-standardized prevalence of cataract surgery was 9.7% (95% confidence interval [CI]: 8.9%, 10.7%) in Singapore resident Indians. Post-operative VI defined by BCVA occurred in 10.9% eyes (87/795). The main causes of post-operative VI were diabetic retinopathy (20.7%), posterior capsular opacification (18.4%), and age-related macular degeneration (12.6%). Undercorrected refractive error doubled the prevalence of post-operative VI when PVA was used.
   Conclusions: The rate of cataract surgery is about 10% in Indian residents in Singapore. Socioeconomic variables and migration had no significant impact on the prevalence of cataract surgery. Diabetic retinopathy was a major cause of postoperative VI in migrant Indians living in Singapore. Uncorrected postoperative refractive error remains an efficient way to improve vision.
C1 [Gupta, Preeti; Zheng, Yingfeng; Ting, Tay Wan; Lamoureux, Ecosse L.; Cheng, Ching-Yu; Wong, Tien-Yin] Singapore Eye Res Inst, Singapore, Singapore.
   [Gupta, Preeti; Zheng, Yingfeng; Ting, Tay Wan; Lamoureux, Ecosse L.; Cheng, Ching-Yu; Wong, Tien-Yin] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Lamoureux, Ecosse L.; Wong, Tien-Yin] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3010, Australia.
   [Cheng, Ching-Yu; Wong, Tien-Yin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Cheng, Ching-Yu] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Cheng, Ching-Yu] Duke NUS Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; National
   University of Singapore; National University of Singapore; National
   University of Singapore
RP Cheng, CY (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.
EM ching-yu_cheng@nuhs.edu.sg
RI Cheng, Ching-Yu/Y-2229-2019; Wong, Tien Yin/AAC-9724-2020; Zheng,
   Yingfeng/CAE-9225-2022; Zheng, Yingfeng/AAE-2983-2022; Lamoureux,
   Ecosse/Z-5482-2019
OI Cheng, Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264;
   Zheng, Yingfeng/0000-0002-0914-7864; 
FU Biomedical Research Council (BMRC) [08/1/35/19/550]; National Medical
   Research Council (NMRC), Singapore [StaR/0003/2008]
FX This study was funded by Biomedical Research Council (BMRC),
   08/1/35/19/550 and National Medical Research Council (NMRC),
   StaR/0003/2008, Singapore. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Baranano AE, 2008, OPHTHALMOLOGY, V115, P815, DOI 10.1016/j.ophtha.2007.05.052
   Broman AT, 2005, ARCH OPHTHALMOL-CHIC, V123, P1231, DOI 10.1001/archopht.123.9.1231
   Chiang PPC, 2011, INVEST OPHTH VIS SCI, V52, P7586, DOI 10.1167/iovs.11-7698
   Congdon NG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1546, DOI 10.1001/archopht.125.11.eeb70014
   Dandona L, 1999, AM J OPHTHALMOL, V127, P650, DOI 10.1016/S0002-9394(99)00044-6
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   Foster PJ, 2003, BRIT J OPHTHALMOL, V87, P1112, DOI 10.1136/bjo.87.9.1112
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Huang WY, 2011, INVEST OPHTH VIS SCI, V52, P16, DOI 10.1167/iovs.10-5382
   Jeganathan VSE, 2008, DIABETES CARE, V31, P1905, DOI 10.2337/dc08-0342
   Khanna RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035701
   KHOO D H C, 1990, Annals Academy of Medicine Singapore, V19, P484
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lau J, 2002, BRIT J OPHTHALMOL, V86, P12, DOI 10.1136/bjo.86.1.12
   Lavanya R, 2009, BRIT J OPHTHALMOL, V93, P299, DOI 10.1136/bjo.2008.148650
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Liu B, 2009, OPHTHALMOLOGY, V116, P1322, DOI 10.1016/j.ophtha.2009.01.030
   Murthy GVS, 2009, OPHTHAL EPIDEMIOL, V16, P400, DOI 10.3109/09286580903315809
   Nangia V, 2011, J CATARACT REFR SURG, V37, P1932, DOI 10.1016/j.jcrs.2011.08.020
   Nirmalan PK, 2002, BRIT J OPHTHALMOL, V86, P505, DOI 10.1136/bjo.86.5.505
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Singapore Department of Statistics, 2009, SING FIG 2010 ETHN D
   Tan CE, 1999, DIABETES CARE, V22, P241, DOI 10.2337/diacare.22.2.241
   United Nations Development Programme, 2009, HUM DEV REP 2009 OV
   United States Census Bureau, SEL POP PROF US POP
   Vaidyanathan K, 1999, B WORLD HEALTH ORGAN, V77, P104
   Vijaya L, 2010, INDIAN J OPHTHALMOL, V58, P223, DOI 10.4103/0301-4738.62648
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Wong TY, 2001, ARCH OPHTHALMOL-CHIC, V119, P727, DOI 10.1001/archopht.119.5.727
   World Health Organization International Agency for the Prevention of Blindness, 2002, REP WORLD VIS 2002 S
   Yin QX, 2009, INVEST OPHTH VIS SCI, V50, P1069, DOI 10.1167/iovs.08-2783
   Yorston D, 2005, EYE, V19, P1083, DOI 10.1038/sj.eye.6701966
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P2120, DOI 10.1016/j.ophtha.2010.03.005
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 35
TC 13
Z9 13
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 7
PY 2013
VL 8
IS 10
AR e75584
DI 10.1371/journal.pone.0075584
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 232NS
UT WOS:000325501300035
PM 24116058
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Haddley, K
AF Haddley, K.
TI TREBANANIB Anti-Angiopoietin Fusion Protein Oncolytic
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Fusion protein; Angiogenesis; Trebananib; AMG-386
ID AMG 386; TUMOR-GROWTH; 1/2-NEUTRALIZING PEPTIBODY; INHIBITS
   ANGIOGENESIS; PHARMACOKINETICS; CHEMOTHERAPY; BEVACIZUMAB; COMBINATION;
   SUPPRESSION; ACTIVATION
AB The maintenance of a tumor is highly dependent on the blood supply feeding it. Angiogenesis, or the formation of new blood vessels, is a major target for a number of anticancer drugs, including monoclonal antibodies and small-molecule inhibitors that effectively destroy tumor vasculature, causing tumor shrinkage. There are a number of FDA-approved drugs on the market targeting the vascular endothelial growth factor pathway, a key contributor to angiogenesis, although not all patients respond favorably to such drugs and many develop resistance. Trebananib (AMG-386) is a first-in-class peptibody that targets the angiopoietins ANG-1 and ANG-2, and the interaction with their receptor, TIE2. The angiopoietin-TIE2 axis is a major target in the regulation of angiogenesis and has become an attractive target for drug development in treating cancer and non-neoplastic diseases, such as age-related macular degeneration. Trebananib has demonstrated good pharmacokinetics and efficacy in preclinical models. It is currently being investigated as monotherapy and in combination with other therapies in targeting various cancers. The antibody is generally well tolerated and has demonstrated potential in relation to the overall response rate in patients with cancer, although any effect on progression-free survival in comparison to existing treatments has been minimal.
EM khaddley@gmail.com
CR Ahmad SA, 2001, CANCER RES, V61, P1255
   Atkins M.B, 2012, 48 ANN M AM SOC CLIN
   Cao YT, 2007, CANCER RES, V67, P3835, DOI 10.1158/0008-5472.CAN-06-4056
   Casado A, 2012, 48 ANN M AM SOC CLIN
   Coxon A., 2008, P AM ASS CANC RES AA, V49, P1113
   Coxon A, 2010, MOL CANCER THER, V9, P2641, DOI 10.1158/1535-7163.MCT-10-0213
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Dieras V, 2011, 47 ANN M AM SOC CLIN, P3
   Doi T, 2011, P AM ASS CANC RES AA, V52
   Eatock MM, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.4_suppl.66
   Elfrich I., 2009, CLIN CANCER RES, V15, P1384
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Gusani NJ, 2009, DRUGS, V69, P2533, DOI 10.2165/11530870-000000000-00000
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Hawighorst T, 2002, AM J PATHOL, V160, P1381, DOI 10.1016/S0002-9440(10)62565-5
   Herbst R., 2006, EUR J CANC S, V4
   Herbst RS, 2009, J CLIN ONCOL, V27, P3557, DOI 10.1200/JCO.2008.19.6683
   Hong D, 2008, ANN ONCOL S8, P12
   Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100
   Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894
   Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100
   Ita A, 2007, EUR J CANC S, V5, P23
   Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005
   Karlan B.Y, 2012, 48 ANN M AM SOC CLIN
   Karlan B.Y., 2010, 46 ANN M AM SOC CLIN
   Karlan BY, 2012, J CLIN ONCOL, V30, P362, DOI 10.1200/JCO.2010.34.3178
   Lu J, 2010, 46 ANN M AM SOC CLIN
   Lu J, 2010, ANN ONCOL S8, V21
   Lu JF, 2012, CANCER CHEMOTH PHARM, V69, P1135, DOI 10.1007/s00280-011-1787-5
   Machein MR, 2004, AM J PATHOL, V165, P1557, DOI 10.1016/S0002-9440(10)63413-X
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374
   Mita AC, 2010, CLIN CANCER RES, V16, P3044, DOI 10.1158/1078-0432.CCR-09-3368
   Oliner J, 2004, CANCER CELL, V6, P507, DOI 10.1016/j.ccr.2004.09.030
   Oliner JD, 2012, INVEST OPHTH VIS SCI, V53, P2170, DOI 10.1167/iovs.11-7381
   Pal SK, 2012, MOL CANCER THER, V11, P526, DOI 10.1158/1535-7163.MCT-11-0806
   Park JH, 2007, CHEST, V132, P200, DOI 10.1378/chest.06-2915
   Peeters M, 2011, ANN ONCOL S5, V22, P22
   RINI BI, 2011, J CLIN ONCOL S7, V29
   Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155
   Rosen L.S., 2007, J CLIN ONCOL S, V25
   Sallinen H, 2010, INT J GYNECOL CANCER, V20, P1498, DOI 10.1111/IGC.0b013e3181f936e3
   Teoh D, 2012, INT J GYNECOL CANCER, V22, P348, DOI 10.1097/IGC.0b013e31823c6efd
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Tian S, 2002, BRIT J CANCER, V86, P645, DOI 10.1038/sj.bjc.6600082
   Vergote I.B, 2010, ANN ONCOL S8, V21
   Wang YMC, 2011, PHARM RES-DORDR, V28, P1931, DOI 10.1007/s11095-011-0420-y
   Wenham R.M., 2010, 46 ANN M AM SOC CLIN
   Wildiers H., 2012, 48 ANN M AM SOC CLIN
   Wu B, 2012, PHARM RES-DORDR, V29, P1057, DOI 10.1007/s11095-011-0650-z
NR 50
TC 0
Z9 0
U1 0
U2 5
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD SEP
PY 2012
VL 37
IS 9
BP 651
EP 658
DI 10.1358/dof.2012.037.09.1876619
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 042QP
UT WOS:000311486400004
DA 2022-11-30
ER

PT J
AU Bartlett, HE
   Eperjesi, F
AF Bartlett, Hannah E.
   Eperjesi, Frank
TI Nutritional supplementation for type 2 diabetes: a systematic review
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Review
DE antioxidants; diabetic retinopathy; minerals; nutritional
   supplementation; Type 2 diabetes; vitamins
ID GLYCATION END-PRODUCTS; ALPHA-LIPOIC ACID; PROTEIN-KINASE-C; ORAL
   VITAMIN-C; CHROMIUM PICOLINATE SUPPLEMENTATION; ENDOTHELIUM-DEPENDENT
   VASODILATION; OPTIC-NERVE HEAD; FACTOR-KAPPA-B; OXIDATIVE STRESS;
   ASCORBIC-ACID
AB The role of nutritional supplementation is of increasing interest with regard to ocular disease. Randomised controlled trials have demonstrated the effectiveness of supplementation for age-related macular degeneration, and formulations are now being developed for use by people with diabetes and diabetic retinopathy. The aim of this review was to synthesise the evidence for use of nutritional supplementation in type 2 diabetes. MEDLINE and EMBASE databases were searched using a systematic approach. Only double-masked randomised controlled trials were selected. A total of 50 trials were identified as suitable for inclusion. The potential role of alpha-lipoic acid, chromium, folic acid, isoflavones, magnesium, Pycnogenol((R)), selenium, vitamin C, vitamin E, and zinc in the treatment of type 2 diabetes is discussed. The review of trials identifies positive effects of these nutrients on various outcome measures relating to insulin resistance and cardiovascular factors. Chromium was the most studied supplement, accounting for 16 of the 50 trials. A majority of the trials found a positive effect of chromium on fasting plasma glucose. Isoflavones were found to have a positive effect on insulin resistance and cardiovascular outcome measures, but only when combined with soy proteins. Vitamin E is reported to reduce oxidative stress at levels of 200 mg day(-1) or more.
C1 [Bartlett, Hannah E.; Eperjesi, Frank] Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Bartlett, HE (通讯作者)，Aston Univ, Sch Life & Hlth Sci, Ophthalm Res Grp, Birmingham B4 7ET, W Midlands, England.
EM H.E.Bartlett@aston.ac.uk
RI Eperjesi, Frank/A-9275-2013
OI Bartlett Eperjesi, Hannah E/0000-0002-7531-6902; Eperjesi,
   Frank/0000-0003-4358-0095
CR AHMED M, 1976, DIABETOLOGIA, V12, P61, DOI 10.1007/BF01221966
   AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
   Althuis MD, 2002, AM J CLIN NUTR, V76, P148, DOI 10.1093/ajcn/76.1.148
   ALVAREZ RA, 1987, AM J CLIN NUTR, V46, P481, DOI 10.1093/ajcn/46.3.481
   *AM DIAB ASS, 2004, ALL DIAB
   Anderson RA, 1997, DIABETES, V46, P1786, DOI 10.2337/diabetes.46.11.1786
   Anderson RA, 2001, J AM COLL NUTR, V20, P212, DOI 10.1080/07315724.2001.10719034
   [Anonymous], 1989, INT J BIOSOCIAL MED
   ASHTON N, 1974, BRIT J OPHTHALMOL, V58, P344, DOI 10.1136/bjo.58.4.344
   Bahijiri SM, 2000, SAUDI MED J, V21, P831
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Bartlett H, 2005, OPHTHAL PHYSL OPT, V25, P179, DOI 10.1111/j.1475-1313.2005.00294.x
   Bartlett H, 2003, OPHTHAL PHYSL OPT, V23, P383, DOI 10.1046/j.1475-1313.2003.00130.x
   Baynes J.W., 1996, CURR OPIN ENDOCRINOL, V3, P277, DOI DOI 10.1097/00060793-199608000-00001
   Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1
   BEARDSLEY T, 1991, SCI AM, V265, P86, DOI 10.1038/scientificamerican0891-86
   Beare-Rogers J, 2001, PURE APPL CHEM, V73, P685, DOI 10.1351/pac200173040685
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhathena SJ, 2002, AM J CLIN NUTR, V76, P1191, DOI 10.1093/ajcn/76.6.1191
   Bierhaus A, 2004, J CLIN INVEST, V114, P1741, DOI 10.1172/JCI200418058
   Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0
   Ble-Castillo JL, 2005, BIOMED PHARMACOTHER, V59, P290, DOI 10.1016/j.biopha.2005.05.002
   Boehm BO, 2004, DIABETOLOGIA, V47, P1376, DOI 10.1007/s00125-004-1455-y
   BORISH ET, 1987, CARCINOGENESIS, V8, P1517, DOI 10.1093/carcin/8.10.1517
   Boshtam M, 2005, INT J VITAM NUTR RES, V75, P341, DOI 10.1024/0300-9831.75.5.341
   Broadhurst CL, 2006, DIABETES TECHNOL THE, V8, P677, DOI 10.1089/dia.2006.8.677
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035
   Cefalu WT, 2004, DIABETES CARE, V27, P2741, DOI 10.2337/diacare.27.11.2741
   Chen H, 2006, AM J PHYSIOL-HEART C, V290, pH137, DOI 10.1152/ajpheart.00768.2005
   Cherubini A, 2005, FREE RADICAL BIO MED, V39, P841, DOI 10.1016/j.freeradbiomed.2005.06.025
   Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657
   Chidlow G, 2002, NEUROPHARMACOLOGY, V43, P1015, DOI 10.1016/S0028-3908(02)00129-6
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Clarke MW, 2006, AM J CLIN NUTR, V83, P95
   COGAN DG, 1967, ARCH OPHTHALMOL-CHIC, V78, P133
   CRAVEN PA, 1994, J CLIN INVEST, V93, P311, DOI 10.1172/JCI116961
   Craven PA, 1997, DIABETES, V46, P671, DOI 10.2337/diabetes.46.4.671
   CUNNINGHAM JJ, 1994, J AM COLL NUTR, V13, P344, DOI 10.1080/07315724.1994.10718420
   Darko D, 2002, CLIN SCI, V103, P339, DOI 10.1042/cs1030339
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0
   DILLEY RA, 1970, J MEMBRANE BIOL, V2, P317, DOI 10.1007/BF01869867
   DIPLOCK AT, 1991, AM J CLIN NUTR, V53, pS189, DOI 10.1093/ajcn/53.1.189Sb
   DREVON CA, 1991, FREE RADICAL RES COM, V14, P229, DOI 10.3109/10715769109088952
   Ebara T, 2000, J CLIN INVEST, V105, P1807, DOI 10.1172/JCI8283
   ERIKSSON J, 1995, ANN NUTR METAB, V39, P217, DOI 10.1159/000177865
   Fatini C, 2000, BLOOD COAGUL FIBRIN, V11, P657, DOI 10.1097/00001721-200010000-00010
   Faure P, 2004, EUR J CLIN INVEST, V34, P475, DOI 10.1111/j.1365-2362.2004.01362.x
   Feng JG, 2002, DIABETES, V51, pA469
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Forbes JM, 2003, FASEB J, V17, P1762, DOI 10.1096/fj.02-1102fje
   FORRESTER JV, 1993, EYE, V7, P276, DOI 10.1038/eye.1993.61
   Fosmark DS, 2006, METABOLISM, V55, P232, DOI 10.1016/j.metabol.2005.08.017
   Ganz MB, 2000, AM J PHYSIOL-ENDOC M, V278, pE146, DOI 10.1152/ajpendo.2000.278.1.E146
   Gazis A, 1999, DIABETIC MED, V16, P304, DOI 10.1046/j.1464-5491.1999.00049.x
   Ghosh D, 2002, J NUTR BIOCHEM, V13, P690, DOI 10.1016/S0955-2863(02)00220-6
   Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563
   GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296
   GIBSON BL, 1985, NEUROSCI LETT, V57, P13, DOI 10.1016/0304-3940(85)90033-3
   Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237
   Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762
   Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257
   Gong HQ, 2003, CORNEA, V22, P448, DOI 10.1097/00003226-200307000-00011
   Gong HQ, 2001, EXP EYE RES, V72, P23, DOI 10.1006/exer.2000.0928
   Gonzalez S, 2007, DIABETES CARE, V30, P1871, DOI 10.2337/dc06-1814
   Gross M, 2005, CLIN CHEM, V51, P125, DOI 10.1373/clinchem.2004.037630
   Gultekin E, 2006, PHYTOESTROGENS IN FUNCTIONAL FOODS, P3
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   HANDELMAN GJ, 1985, J NUTR, V115, P807, DOI 10.1093/jn/115.6.807
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P563, DOI 10.1016/S1350-9462(01)00004-0
   Heitzer T, 2001, FREE RADICAL BIO MED, V31, P53, DOI 10.1016/S0891-5849(01)00551-2
   Hermansen K, 2001, DIABETES CARE, V24, P228, DOI 10.2337/diacare.24.2.228
   Huebschmann AG, 2006, DIABETES CARE, V29, P1420, DOI 10.2337/dc05-2096
   HUNT DF, 1984, CURR EYE RES, V3, P1281, DOI 10.3109/02713688409007414
   Jacob S, 1999, FREE RADICAL BIO MED, V27, P309, DOI 10.1016/S0891-5849(99)00089-1
   Jayagopal V, 2002, DIABETES CARE, V25, P1709, DOI 10.2337/diacare.25.10.1709
   JHA HC, 1985, BIOCHEM PHARMACOL, V34, P1367, DOI 10.1016/0006-2952(85)90672-0
   JOHN WG, 1993, EYE, V7, P230, DOI 10.1038/eye.1993.55
   Kahler W, 1993, Z Gesamte Inn Med, V48, P223
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KAYSEN GA, 1995, KIDNEY INT, V48, P510, DOI 10.1038/ki.1995.321
   Keogh RJ, 1997, METABOLISM, V46, P41, DOI 10.1016/S0026-0495(97)90165-7
   Kleefstra N, 2006, DIABETES CARE, V29, P521, DOI 10.2337/diacare.29.03.06.dc05-1453
   Kleefstra N, 2007, DIABETES CARE, V30, P1092, DOI 10.2337/dc06-2192
   Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875
   Kowluru RA, 2001, EXPERT OPIN INV DRUG, V10, P1665, DOI 10.1517/13543784.10.9.1665
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768
   Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23
   LEE NA, 1994, DIABETES CARE, V17, P1449, DOI 10.2337/diacare.17.12.1449
   Levin G, 1997, NUTR CANCER, V27, P293, DOI 10.1080/01635589709514540
   Leydhecker W., 1986, MEDICAMENTOSEN BEHAN
   Lima MDL, 1998, DIABETES CARE, V21, P682, DOI 10.2337/diacare.21.5.682
   Liu XM, 2004, LIFE SCI, V75, P2505, DOI 10.1016/j.lfs.2003.10.043
   Lu Q, 2005, CLIN SCI, V108, P507, DOI 10.1042/CS20040291
   Machlin L. J., 1980, VITAMIN E COMPREHENS
   MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Man AMES, 2004, NETH J MED, V62, P246
   Mangoni AA, 2005, AM J HYPERTENS, V18, P220, DOI 10.1016/j.amjhyper.2004.08.036
   Martin J, 2006, DIABETES CARE, V29, P1826, DOI 10.2337/dc06-0254
   Martinelli I, 2001, THROMB HAEMOSTASIS, V86, P395
   MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482
   McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5
   Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1
   Mullan BA, 2002, HYPERTENSION, V40, P804, DOI 10.1161/01.HYP.0000039961.13718.00
   Murata T, 1997, DIABETOLOGIA, V40, P764, DOI 10.1007/s001250050747
   NAIM M, 1973, PHYTOCHEMISTRY, V12, P169, DOI 10.1016/S0031-9422(00)84641-5
   Nakamura N, 2003, DIABETES RES CLIN PR, V61, P93, DOI 10.1016/S0168-8227(03)00109-8
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Osborne NN, 2001, BRIT J OPHTHALMOL, V85, P1252, DOI 10.1136/bjo.85.10.1252
   PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R
   PAOLISSO G, 1995, J AM COLL NUTR, V14, P387
   PAOLISSO G, 1993, AM J CLIN NUTR, V57, P650, DOI 10.1093/ajcn/57.5.650
   PAOLISSO G, 1992, AM J CLIN NUTR, V55, P1161, DOI 10.1093/ajcn/55.6.1161
   PASQUARE SJ, 1993, COMP BIOCHEM PHYS B, V104, P141, DOI 10.1016/0305-0491(93)90350-E
   Pei D, 2006, METABOLISM, V55, P923, DOI 10.1016/j.metabol.2006.02.021
   Portilla D, 2000, AM J PHYSIOL-RENAL, V278, pF667, DOI 10.1152/ajprenal.2000.278.4.F667
   Rabinovitz H, 2004, INT J VITAM NUTR RES, V74, P178, DOI 10.1024/0300-9831.74.3.178
   Racek J, 2006, BIOL TRACE ELEM RES, V109, P215, DOI 10.1385/BTER:109:3:215
   Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2
   REAVEN PD, 1995, DIABETES CARE, V18, P807, DOI 10.2337/diacare.18.6.807
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   ROGHDEWALD P, 2002, INT J CLIN PHARM TH, V30, P158
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Roussel AM, 2003, J AM COLL NUTR, V22, P316, DOI 10.1080/07315724.2003.10719310
   Russell RM, 1996, JAMA-J AM MED ASSOC, V275, P1828, DOI 10.1001/jama.275.23.1828
   Salvador GA, 1998, LIPIDS, V33, P853, DOI 10.1007/s11745-998-0281-z
   SEDDON JM, 1999, BACKGROUNDER, V2, P1
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   SHERMAN L, 1968, METABOLISM, V17, P439, DOI 10.1016/0026-0495(68)90066-8
   Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885
   Sigel H, 1983, METAL IONS BIOL SYST, V15
   SINCLAIR AJ, 1992, GERONTOLOGY, V38, P268
   SINCLAIR AJ, 1991, DIABETOLOGIA, V34, P171, DOI 10.1007/BF00418271
   SINGH SV, 1984, CURR EYE RES, V3, P1273, DOI 10.3109/02713688409007413
   Spadea L, 2001, PHYTOTHER RES, V15, P219, DOI 10.1002/ptr.853
   Stitt A, 2002, DIABETES, V51, P2826, DOI 10.2337/diabetes.51.9.2826
   Stracke H, 2001, EXP CLIN ENDOCR DIAB, V109, P330, DOI 10.1055/s-2001-17399
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taddei S, 1998, CIRCULATION, V97, P2222, DOI 10.1161/01.CIR.97.22.2222
   Timimi FK, 1998, J AM COLL CARDIOL, V31, P552, DOI 10.1016/S0735-1097(97)00536-6
   Title LM, 2006, VASC MED, V11, P101, DOI 10.1191/1358863x06vm664oa
   TSAI AC, 1983, AM J CLIN NUTR, V38, P504, DOI 10.1093/ajcn/38.4.504
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   UUSITUPA MIJ, 1983, AM J CLIN NUTR, V38, P404, DOI 10.1093/ajcn/38.3.404
   van der Hagen A M, 1993, J Am Optom Assoc, V64, P871
   Virgili F, 1998, FREE RADICAL BIO MED, V24, P1120, DOI 10.1016/S0891-5849(97)00430-9
   VISNON J, 1989, DIABETES, V38, P1036
   Vrtovec M, 2005, AM HEART J, V149, P632, DOI 10.1016/j.ahj.2004.07.021
   WANG H, 1995, DIABETES RES CLIN PR, V28, P1, DOI 10.1016/0168-8227(95)01059-M
   Ward NC, 2007, J HYPERTENS, V25, P227, DOI 10.1097/01.hjh.0000254373.96111.43
   Watkins P, 2003, DIABETES ITS MANAGEM, P16
   Wei H, 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P619
   WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265
   Wei HC, 1996, CARCINOGENESIS, V17, P73, DOI 10.1093/carcin/17.1.73
   Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167
   Wei ZH, 1997, REDOX REP, V3, P219, DOI 10.1080/13510002.1997.11747113
   WHO, 2006, WHO INT DIAB FED DEF
   Wilkinson IB, 1999, J CARDIOVASC PHARM, V34, P690, DOI 10.1097/00005344-199911000-00010
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820
   Wu H P, 1992, J Formos Med Assoc, V91, P270
   Wu JHY, 2007, CLIN CHEM, V53, P511, DOI 10.1373/clinchem.2006.076992
   XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312
   YOUNG IS, 1995, FREE RADICAL BIO MED, V18, P833, DOI 10.1016/0891-5849(94)00202-U
   YUE DK, 1989, DIABETES, V38, P257, DOI 10.2337/diabetes.38.2.257
   Yuyun MF, 2005, CURR OPIN NEPHROL HY, V14, P271, DOI 10.1097/01.mnh.0000165895.90748.3b
   Ziegler D, 1999, EXP CLIN ENDOCR DIAB, V107, P421, DOI 10.1055/s-0029-1212132
NR 171
TC 66
Z9 68
U1 1
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD NOV
PY 2008
VL 28
IS 6
BP 503
EP 523
DI 10.1111/j.1475-1313.2008.00595.x
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 367CA
UT WOS:000260528900001
PM 19076553
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wu, ZH
   Rogers, B
   Kachi, S
   Hackett, SF
   Sick, A
   Campochiaro, PA
AF Wu, Zhihao
   Rogers, Brian
   Kachi, Shu
   Hackett, Sean F.
   Sick, Anna
   Campochiaro, Peter A.
TI Reduction of p66Shc suppresses oxidative damage in retinal pigmented
   epithelial cells and retina
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID NF-KAPPA-B; D-DEPENDENT ACTIVATION; SUPEROXIDE-DISMUTASE; SIGNALING
   PATHWAY; HYDROGEN-PEROXIDE; STRESS; SURVIVAL; CANCER; FAMILY; DEATH
AB The largest isoform of the Shc adapter protein, p66Shc, has been implicated in oxidative damage-induced apoptosis in vital organs, because mice deficient in p66Shc have a 30% increase in life span and are resistant to the lethal effects of systemically administered paraquat, a source of severe oxidative damage. In this study, we utilized siRNA directed against the CH2 domain of Shc, to reduce p66Shc, but not p52Shc nor p46Shc in retinal pigmented epithelial (RPE) cells. RPE cells deficient in p66Shc had reduced susceptibility to oxidative stress-induced apoptosis. Compared to control cells, those with reduced p66Shc had increased basal and oxidative stress-induced NF-kappa B transcriptional activity, increased levels of antioxidant enzymes, and less generation of reactive oxygen species when challenged with H2O2. The increase in oxidative stress-induced NF-kappa B activity was mediated by activation of ERK. Compared to eyes injected with GFP siRNA, those injected with p66Shc siRNA showed less loss of retinal function as assessed by electroretinograms from paraquat-induced oxidative stress. These data suggest that p66Shc and molecular signals involved in its regulation provide therapeutic targets for retinal degenerations in which oxidative-damage plays a major role, including age-related macular degeneration and cone cell death in retinitis pigmentosa.
C1 Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St,Maumenee 719, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
OI Sick-Samuels, Anna/0000-0002-9247-9340
FU NATIONAL EYE INSTITUTE [P30EY001765, R01EY011498, R01EY012609] Funding
   Source: NIH RePORTER; NEI NIH HHS [P30 EY 0572, EY 05951, P30 EY 1765,
   EY 12609, EY 11498] Funding Source: Medline
CR Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Ceryak S, 2004, MOL CELL BIOCHEM, V255, P139, DOI 10.1023/B:MCBI.0000007270.82431.3e
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Culmsee C, 2003, J NEUROSCI, V23, P8586
   Guo Z, 2003, J BIOL CHEM, V278, P23570, DOI 10.1074/jbc.M303431200
   Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102
   Hayashi H, 2006, J BIOL CHEM, V281, P1332, DOI 10.1074/jbc.M505905200
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Je JH, 2004, FEBS LETT, V566, P183, DOI 10.1016/j.febslet.2004.04.037
   Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kratsovnik E, 2005, J MOL NEUROSCI, V26, P27, DOI 10.1385/JMN:26:1:027
   Lee KW, 2004, ANN NY ACAD SCI, V1030, P258, DOI 10.1196/annals.1329.032
   Lee M, 2004, J CELL BIOCHEM, V93, P629, DOI 10.1002/jcb.20215
   Lee YJ, 2004, J APPL PHYSIOL, V96, P793, DOI 10.1152/japplphysiol.00797.2003
   Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706
   Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Oh YK, 2004, BIOCHEM BIOPH RES CO, V319, P41, DOI 10.1016/j.bbrc.2004.04.145
   Okoye G, 2003, J NEUROSCI, V23, P4164
   Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Pelicci G, 1996, ONCOGENE, V13, P633
   Pellegrini M, 2005, APOPTOSIS, V10, P13, DOI 10.1007/s10495-005-6057-8
   Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776
   Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004
   Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346
   Shen ZG, 2005, CHINESE J CHEM ENG, V13, P225
   Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687
   Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004
   Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513
   Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291
   Yoshida Y, 2003, FREE RADICAL RES, V37, P861, DOI 10.1080/1071576031000148736
   Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5
NR 39
TC 29
Z9 31
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2006
VL 209
IS 3
BP 996
EP 1005
DI 10.1002/jcp.20819
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 101QD
UT WOS:000241754600051
PM 16972253
DA 2022-11-30
ER

PT J
AU Nagpal, A
   Biswas, J
AF Nagpal, A
   Biswas, J
TI Pseudouveitis - Analysis of cases misdiagnosed as posterior uveitis
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE posterior uveitis; pseudouveitis
ID CENTRAL SEROUS CHORIORETINOPATHY; RETINAL-DETACHMENT; CHOROIDAL
   NEOVASCULARIZATION; MELANOMA
AB Purpose: Analysis of non-uveitic entities that were referred as posterior uveitis to a uveitis referral center. Methods: We came across and analyzed 32 cases of non-uveitic entities (1.12%) that had been misdiagnosed and referred as posterior uveitis out of 2846 outpatient cases of posterior uveitis registered from 1990 to June 2002. The final diagnosis was achieved by history, slit-lamp biomicroscopy, meticulous fundus evaluation, imaging, and ancillary studies. Results: The finally diagnosed 32 non-uveitic entities that mimicked posterior uveitis were multiple leak central serous retinopathy (n = 8; 25%), choroidal neovascular membrane (n = 6; 18.75%), typical central serous retinopathy (n = 4; 12.5%), dry form of age-related macular degeneration (n = 3; 9.3%), retinitis pigmentosa (n = 3; 9.3%), heredomacular degeneration (n = 3; 9.3%), myelinated nerve fibers (n = 2; 6.2%), malignant melanoma of the choroid (n = 1; 3.1%), old spontaneously reattached retinal detachment (n = 1; 3.1%), and subhyaloid hemorrhage (n = 1; 3.1%). Conclusion: The purpose of the study was to underline the fact that there are some non-uveitic entities that mimic posterior uveitis and that an ophthalmologist can be deceived. The study highlights the problems diagnosing posterior uveitis and presents an algorithm of diagnostic approach to avoid misdiagnosis.
C1 Sankara Nethralaya, Med & Vis Res Fdn, Madras 600006, Tamil Nadu, India.
RP Biswas, J (通讯作者)，Sankara Nethralaya, Med & Vis Res Fdn, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM mrf@sankaranethralaya.org
CR Amann T, 1997, KLIN MONATSBL AUGENH, V210, P43, DOI 10.1055/s-2008-1035012
   Biswas J, 2002, ARCH OPHTHALMOL-CHIC, V120, P522
   Brancato R, 1991, Bull Soc Belge Ophtalmol, V240, P119
   BRESSLER NM, 2001, RETINA, pCH66
   CIARDELLA AP, 2001, RETINA, pCH68
   DAS D, 1996, INT OPHTHALMOL, V20, P223
   Das Debashis, 1995, Indian Journal of Ophthalmology, V43, P117
   DEUTMAN AF, 2001, RETINA, pCH70
   GASS JDM, 1995, OPHTHALMOLOGY, V102, P737, DOI 10.1016/S0161-6420(95)30960-8
   Grant-Kels JM, 1999, J AM ACAD DERMATOL, V40, P539, DOI 10.1016/S0190-9622(99)70435-4
   HARPER SL, 2002, DIAGNOSIS TREATMENT, pCH6
   HIROSE T, 1979, ANN OPHTHALMOL, V11, P709
   Jampol LM, 1996, AM J OPHTHALMOL, V121, P643, DOI 10.1016/S0002-9394(14)70630-0
   Nguyen QD, 1998, OCUL IMMUNOL INFLAMM, V6, P253, DOI 10.1076/ocii.6.4.253.4031
   O'CONNOR P R, 1975, Annals of Ophthalmology, V7, P237
   Otsuka S, 2002, RETINA-J RET VIT DIS, V22, P25, DOI 10.1097/00006982-200202000-00005
   SALKA HW, 1979, AM J OPHTHALMOL, V87, P286
   SARKS SH, 2001, RETINA
   Sharma T, 1998, RETINA-J RET VIT DIS, V18, P23
   STEPHEN JHM, 1990, PARSONS DIS EYE
   Wakakura M, 1997, JPN J OPHTHALMOL, V41, P180, DOI 10.1016/S0021-5155(97)00027-0
   WELEBER RG, 2001, RETINA
   WOLF MD, 1991, INVEST OPHTH VIS SCI, V32, P689
NR 23
TC 1
Z9 1
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD FEB
PY 2006
VL 14
IS 1
BP 13
EP 20
DI 10.1080/09273940500545627
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 017KL
UT WOS:000235692400003
PM 16507486
DA 2022-11-30
ER

PT J
AU Chen, L
   Wu, W
   Dentchev, T
   Wong, R
   Dunaief, JL
AF Chen, L
   Wu, W
   Dentchev, T
   Wong, R
   Dunaief, JL
TI Increased metallothionein in light damaged mouse retinas
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE oxidative stress; metallothionein; apoptosis; antioxidant; AMD; light
   damage
ID PIGMENT EPITHELIAL-CELLS; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   PHOTIC INJURY; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; GENE-EXPRESSION;
   RAT RETINA; II GENES; ZINC
AB Oxidative stress plays a role in human age-related macular degeneration and in the light damage model of retinal degeneration. Metallothionein (MT), an antioxidant, has been reported to protect retinal pigment epithelial cells against apoptosis and oxidative stress. The purpose of this study was to evaluate changes in NIT expression level and retinal localization following light damage. To accomplish this, Balb/c mice were exposed to cool white fluorescent light (10 000 1x) for 7 hr. In three independent experiments, at several intervals after the light injury, retinal MTs were studied at the protein level by immunohistochemistry (IHC) and Western analysis, and at the mRNA level by quantitative PCR with isoform-specific primers. Western analysis and IHC indicated an increase in metallothionein protein following light damage. MT localized to the retinal pigment epithelium and several layers of neural retina. Quantitative PCR identified the expression of MT I-III isoforms, not the MT IV isoform in the mouse retina, and, following light damage, showed increased expression of retinal MT-I and MT-II mRNAs by 8- and 22-fold, respectively. Increased expression of the antioxidant NIT in the light damaged mouse retina suggests that upregulation of MT is an important acute retinal response to photo-oxidative stress. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Opthalmol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Univ Penn, Scheie Eye Inst, FM Kirby Ctr Mol Opthalmol, Stellar Chance Room 305,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
RI Mohammed, Imran/J-8271-2012
OI Mohammed, Imran/0000-0002-8412-0768
FU NEI NIH HHS [EY00417] Funding Source: Medline
CR Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054
   Bremner I, 1987, Experientia Suppl, V52, P81
   CAI L, 1995, CHEM-BIOL INTERACT, V96, P143, DOI 10.1016/0009-2797(94)03585-V
   Chen L, 2003, MOL VIS, V9, P151
   Chen WH, 1999, INVEST OPHTH VIS SCI, V40, P744
   Cho EY, 2001, ANN EPIDEMIOL, V11, P328, DOI 10.1016/S1047-2797(01)00217-4
   COOK B, 1995, INVEST OPHTH VIS SCI, V36, P990
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Hafezi F, 1999, CELL DEATH DIFFER, V6, P934, DOI 10.1038/sj.cdd.4400574
   Jacob ST, 1999, GENE EXPRESSION, V7, P301
   Jacobson SG, 2002, NAT GENET, V32, P215, DOI 10.1038/ng1002-215
   KAGI JHR, 1974, J BIOL CHEM, V249, P3537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Lu HS, 2002, EXP EYE RES, V74, P83, DOI 10.1006/exer.2001.1101
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   NISHIMURA H, 1991, HISTOCHEMISTRY, V95, P535, DOI 10.1007/BF00266738
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Noell W K, 1987, Prog Clin Biol Res, V247, P469
   Ohira A, 2003, INVEST OPHTH VIS SCI, V44, P1230, DOI 10.1167/iovs.02-0191
   Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426
   Palmiter R D, 1987, Experientia Suppl, V52, P63
   PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   PRZEDBORSKI S, 1992, J NEUROCHEM, V58, P1760, DOI 10.1111/j.1471-4159.1992.tb10051.x
   QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029
   Samson SLA, 1998, PROG NUCLEIC ACID RE, V59, P257, DOI 10.1016/S0079-6603(08)61034-X
   SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T
   SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221
   SEWELL AK, 1995, BIOCHEMISTRY-US, V34, P4740, DOI 10.1021/bi00014a031
   SOUMILLION A, 1992, EUR J BIOCHEM, V209, P999, DOI 10.1111/j.1432-1033.1992.tb17374.x
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P1162
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tate DJ, 2002, CURR EYE RES, V24, P12, DOI 10.1076/ceyr.24.1.12.5426
   THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6
   Trendelenburg G, 2002, J NEUROSCI, V22, P5879
   UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2
   Wood JPM, 2003, NEUROCHEM RES, V28, P1525, DOI 10.1023/A:1025622425501
   YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291
NR 43
TC 27
Z9 28
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2004
VL 79
IS 2
BP 287
EP 293
DI 10.1016/j.exer.2004.05.004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 845CG
UT WOS:000223212700015
PM 15325575
DA 2022-11-30
ER

PT J
AU Andras, V
   Peter, MD
   Ferenc, K
   Anita, C
   Mikos, R
   Zsolt, NZ
   Arnold, S
AF Andras, Vegh
   Peter, Magda Daniel
   Ferenc, Kilin
   Anita, Csorba
   Mikos, Resch
   Zsolt, Nagy Zoltan
   Arnold, Szabo
TI In vivo cellular imaging of the retina: present and future
SO ORVOSI HETILAP
LA English
DT Article
DE retina; optical coherence tomography (OCT); fluorescence lifetime
   imaging ophthalmoscopy (FLIO); adaptive optics; two-photon
   ophthalmoscopy
ID OPTICAL COHERENCE TOMOGRAPHY; GANGLION-CELLS; MARKERS; NEURONS
AB Diseases of the visual system as well as many systemic illnesses are usually associated with retinal damage. With the help of pathology, we can clearly identify the affected layer(s): while age-related macular degeneration mostly damages the photoreceptors in the outer retina at the central fovea, glaucoma promotes ganglion cell death in the ganglion cell layer and damages respective neural fibers. However, the diverse cell types of the human retina have not been fully characterized yet, thus in most cases our knowledge on cellular pathologies is not precise enough. While histopathological preparation and examination of the retinal tissue provide more detailed information about the diagnosis and the severity of the condition, unfortunately, it cannot be used in vivo in everyday clinical practice. Our understanding of the cellular changes in different diseases has revealed a need for new everyday clinical examination methods that can be used in vivo to asses cellular and subcellular changes in neural and other cells of the retina, such as blood cells flowing in healthy vessels or in vessels of neovascular origin. In addition to the currently used clinical examination methods, these imaging methods could help confirm or dismiss diagnoses, assess the severity of a condition, and monitor disease progression or remission.
C1 [Andras, Vegh; Peter, Magda Daniel; Ferenc, Kilin; Arnold, Szabo] Semmelweis Egyet, Altalanos Orvostudomanyi Kar, Anat Szovet & Fejlodestani Int, Budapest, Hungary.
   [Andras, Vegh; Anita, Csorba; Mikos, Resch; Zsolt, Nagy Zoltan] Semmelweis Egyet, Altalanos Orvostudomanyi Kar, Szemeszeti Klin, Budapest, Hungary.
C3 Semmelweis University; Semmelweis University
RP Arnold, S (通讯作者)，Tuzolto U 58, H-1094 Budapest, Hungary.
EM szabo.arnold@med.semmelweis-univ.hu
OI Vegh, Andras/0000-0001-6281-3363
CR Aboualizadeh E, 2018, TRENDS BIOCHEM SCI, V43, P650, DOI 10.1016/j.tibs.2018.04.005
   Baden T, 2016, NATURE, V529, P345, DOI 10.1038/nature16468
   Barth A, 2007, BBA-BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   Bernstein P., 2019, HIGH RESOLUTION IMAG, P213
   Berta AI, 2007, MOL VIS, V13, P881
   Billheimer J, 2019, SCREEN CLASSIC, P59
   Braaf B., 2019, HIGH RESOLUTION IMAG, P161
   Burns SA, 2019, PROG RETIN EYE RES, V68, P1, DOI 10.1016/j.preteyeres.2018.08.002
   Carroll J, 2013, CURR EYE RES, V38, P709, DOI 10.3109/02713683.2013.784792
   Chauhan BC, 2000, INVEST OPHTH VIS SCI, V41, P775
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Cuenca N, 2018, OPHTHALMOLOGY, V125, P407, DOI 10.1016/j.ophtha.2017.09.016
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Fischer J, 2019, HIGH RESOLUTION IMAG, P35
   Harmening WM, 2019, HIGH RESOLUTION IMAG, P359
   Hirano T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27536-5
   Hoon M, 2014, PROG RETIN EYE RES, V42, P44, DOI 10.1016/j.preteyeres.2014.06.003
   Jayabalan GS, 2019, HIGH RESOLUTION IMAG, P376
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Juttner J, 2019, NAT NEUROSCI, V22, P1345, DOI 10.1038/s41593-019-0431-2
   Kamali T, 2019, HIGH RESOLUTION IMAG, P195
   Kantor O, 2016, BRAIN STRUCT FUNCT, V221, P2963, DOI 10.1007/s00429-015-1082-z
   Kantor O, 2016, CELL TISSUE RES, V365, P29, DOI 10.1007/s00441-016-2376-z
   Kusnyerik Akos, 2015, Opt Express, V23, P23436, DOI 10.1364/OE.23.023436
   Li DQ, 2020, CURR OPIN OPHTHALMOL, V31, P199, DOI 10.1097/ICU.0000000000000653
   Liu ZL, 2017, P NATL ACAD SCI USA, V114, P12803, DOI 10.1073/pnas.1711734114
   Morgan JIW, 2016, OPHTHAL PHYSL OPT, V36, P218, DOI 10.1111/opo.12289
   Nelidova D, 2020, SCIENCE, V368, P1108, DOI 10.1126/science.aaz5887
   Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004
   Recsan Zs, 2018, OPTIKAI KOHERENCIA T, P53
   Rocholz R., 2019, HIGH RESOLUTION IMAG, P135
   Rossi EA, 2017, P NATL ACAD SCI USA, V114, P586, DOI 10.1073/pnas.1613445114
   Sauer L, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.9.091415
   Schneider M., 2018, OPTIKAI KOHERENCIA T, P7
   Sharma R, 2016, INVEST OPHTH VIS SCI, V57, P632, DOI 10.1167/iovs.15-17961
   Sharma R, 2013, BIOMED OPT EXPRESS, V4, P1285, DOI 10.1364/BOE.4.001285
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Szabo A, 2018, OPTIKAI KOHERENCIA T, P49
   Szabo A, 2018, INVEST OPHTH VIS SCI, V59
   Szel A., 2014, HISTOLOGY BELSO BURO, P493
   WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991
   Williams DR, 2011, VISION RES, V51, P1379, DOI 10.1016/j.visres.2011.05.002
NR 44
TC 0
Z9 0
U1 1
U2 3
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD MAY
PY 2021
VL 162
IS 22
BP 851
EP 860
DI 10.1556/650.2021.32101
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SP1OI
UT WOS:000659441100001
PM 34052799
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Zhang, QT
   Presswalla, F
   Ali, RR
   Zacks, DN
   Thompson, DA
   Miller, JML
AF Zhang, Qitao
   Presswalla, Feriel
   Ali, Robin R.
   Zacks, David N.
   Thompson, Debra A.
   Miller, Jason M. L.
TI Pharmacologic activation of autophagy without direct mTOR inhibition as
   a therapeutic strategy for treating dry macular degeneration
SO AGING-US
LA English
DT Article
DE age-related macular degeneration (AMD); drusen; lipofuscin; retinal
   pigment epithelium (RPE); autophagy
ID RETINAL-PIGMENT EPITHELIUM; LIPID DROPLETS; RPE LIPOFUSCIN; DISEASE;
   SURVIVAL; TARGET; PHAGOCYTOSIS; INDUCTION; OXIDATION; INCREASES
AB Dry age-related macular degeneration (AMD) is marked by the accumulation of extracellular and intracellular lipid-rich deposits within and around the retinal pigment epithelium (RPE). Inducing autophagy, a conserved, intracellular degradative pathway, is a potential treatment strategy to prevent disease by clearing these deposits. However, mTOR inhibition, the major mechanism for inducing autophagy, disrupts core RPE functions. Here, we screened autophagy inducers that do not directly inhibit mTOR for their potential as an AMD therapeutic in primary human RPE culture. Only two out of more than thirty autophagy inducers tested reliably increased autophagy flux in RPE, emphasizing that autophagy induction mechanistically differs across distinct tissues. In contrast to mTOR inhibitors, these compounds preserved RPE health, and one inducer, the FDA approved compound flubendazole (FLBZ), reduced the secretion of apolipoprotein that contributes to extracellular deposits termed drusen. Simultaneously, FLBZ increased production of the lipid-degradation product ?-hydroxybutyrate, which is used by photoreceptor cells as an energy source. FLBZ also reduced the accumulation of intracellular deposits, termed lipofuscin, and alleviated lipofuscin-induced cellular senescence and tight-junction disruption. FLBZ triggered compaction of lipofuscin-like granules into a potentially less toxic form. Thus, induction of RPE autophagy without direct mTOR inhibition is a promising therapeutic approach for dry AMD.
C1 [Zhang, Qitao; Presswalla, Feriel; Ali, Robin R.; Zacks, David N.; Thompson, Debra A.; Miller, Jason M. L.] Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
   [Ali, Robin R.] KCL Ctr Cell & Gene Therapy, London WC2R 2LS, England.
   [Thompson, Debra A.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Miller, JML (通讯作者)，Univ Michigan, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
EM miljason@med.umich.edu
OI Ali, Robin/0000-0003-3126-6517; Miller, Jason/0000-0002-2784-9560;
   Presswalla, Feriel/0000-0001-7190-5622
FU NEI NIH HHS [P30 EY007003] Funding Source: Medline
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Adijanto J, 2014, J BIOL CHEM, V289, P20570, DOI 10.1074/jbc.M114.565457
   BAKER BN, 1986, EXP EYE RES, V42, P547, DOI 10.1016/0014-4835(86)90045-X
   Barmada SJ, 2014, NAT CHEM BIOL, V10, P677, DOI 10.1038/nchembio.1563
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Bulloj A, 2013, EXP EYE RES, V113, P9, DOI 10.1016/j.exer.2013.05.002
   Carnero A, 2009, EXPERT OPIN INV DRUG, V18, P1265, DOI 10.1517/13543780903066798
   Chauhan S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9620
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Cheong JK, 2015, J CLIN INVEST, V125, P1401, DOI 10.1172/JCI78018
   Chiang CK, 2017, J BIOL CHEM, V292, P19826, DOI 10.1074/jbc.M117.812677
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Debnath Puja, 2015, J Oral Biol Craniofac Res, V5, P2, DOI 10.1016/j.jobcr.2014.12.004
   Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Escrevente C, 2021, FORMATION LIPOFUSCIN, V2021
   Fletcher EL, 2014, OPTOMETRY VISION SCI, V91, P878, DOI 10.1097/OPX.0000000000000322
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Getz GS, 2015, METHODS MOL BIOL, V1339, P1, DOI 10.1007/978-1-4939-2929-0_1
   Goldberg IJ, 2012, CELL METAB, V15, P805, DOI 10.1016/j.cmet.2012.04.006
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Halapin NA, 2010, NEUROCHEM RES, V35, P1944, DOI 10.1007/s11064-010-0351-8
   Hale CM, 2016, AUTOPHAGY, V12, P713, DOI 10.1080/15548627.2016.1147669
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hasegawa J, 2015, METHODS, V75, P128, DOI 10.1016/j.ymeth.2014.12.014
   Hussain RM, 2018, EXPERT OPIN PHARMACO, V19, P471, DOI 10.1080/14656566.2018.1448060
   Iorio F, 2010, AUTOPHAGY, V6, P1204, DOI [10.4161/auto.6.8.13551, 10.1073/pnas.1000138107]
   Kaizuka T, 2016, MOL CELL, V64, P835, DOI 10.1016/j.molcel.2016.09.037
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Krahmer N, 2013, EMBO MOL MED, V5, P973, DOI 10.1002/emmm.201100671
   Kuoa SY, 2015, P NATL ACAD SCI USA, V112, pE4281, DOI 10.1073/pnas.1512289112
   Kuramoto K, 2016, AUTOPHAGY, V12, P1460, DOI 10.1080/15548627.2016.1187367
   Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lee JM, 2014, NATURE, V516, P112, DOI 10.1038/nature13961
   Lee JJ, 2020, BIOCHEM BIOPH RES CO, V521, P414, DOI 10.1016/j.bbrc.2019.10.138
   Lin CW, 2015, SCI REP-UK, V5, DOI 10.1038/srep15807
   Liu FT, 2016, BRAIN RES, V1632, P9, DOI 10.1016/j.brainres.2015.12.002
   Liu L, 2015, CELL, V160, P177, DOI 10.1016/j.cell.2014.12.019
   Liu QS, 2010, J MED CHEM, V53, P7146, DOI 10.1021/jm101144f
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Lobner D, 2000, J NEUROSCI METH, V96, P147, DOI 10.1016/S0165-0270(99)00193-4
   Lorenzi PL, 2014, AUTOPHAGY, V10, P1316, DOI 10.4161/auto.28773
   Luo RC, 2020, AUTOPHAGY, V16, P52, DOI 10.1080/15548627.2019.1596488
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Malek G, 2018, EXPERT OPIN DRUG DIS, V13, P359, DOI 10.1080/17460441.2018.1430136
   Manchon JFM, 2015, SCI REP-UK, V5, DOI 10.1038/srep15213
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Melo E, 2018, EBIOMEDICINE, V27, P258, DOI 10.1016/j.ebiom.2017.12.011
   Menzies FM, 2015, CELL DEATH DIFFER, V22, P433, DOI 10.1038/cdd.2014.151
   Miller JM, 2021, GRAEFES ARCH CLIN EX
   Min H, 2014, CANCER CHEMOTH PHARM, V74, P167, DOI 10.1007/s00280-014-2451-7
   Miranda S, 2012, J CELL PHYSIOL, V227, P2352, DOI 10.1002/jcp.22970
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Muniz-Feliciano L, 2017, AUTOPHAGY, V13, P2072, DOI 10.1080/15548627.2017.1380124
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Perera ND, 2018, AUTOPHAGY, V14, P534, DOI 10.1080/15548627.2017.1385674
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Rai A, 2016, CELL, V164, P722, DOI 10.1016/j.cell.2015.12.054
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Renna M, 2010, J BIOL CHEM, V285, P11061, DOI 10.1074/jbc.R109.072181
   Reyes-Reveles J, 2017, J BIOL CHEM, V292, P8038, DOI 10.1074/jbc.M116.770784
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rudolf M, 2019, INVEST OPHTH VIS SCI, V60, P461, DOI 10.1167/iovs.18-25786
   Schwartz EL, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-850
   Shibuya Y, 2014, J NEUROSCI, V34, P14484, DOI 10.1523/JNEUROSCI.2567-14.2014
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Sun S, 2019, AGING-US, V11, P4323, DOI 10.18632/aging.102039
   Takenouchi T, 2009, J IMMUNOL, V182, P2051, DOI 10.4049/jimmunol.0802577
   Tan CC, 2014, NEUROBIOL AGING, V35, P941, DOI 10.1016/j.neurobiolaging.2013.11.019
   Tate DJ, 2006, CURR EYE RES, V31, P675, DOI 10.1080/02713680600801024
   Tian WH, 2020, NAT METHODS, V17, P232, DOI 10.1038/s41592-019-0661-y
   To KKW, 2018, EUR J PHARMACOL, V823, P19, DOI 10.1016/j.ejphar.2018.01.036
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Tsvetkov AS, 2010, P NATL ACAD SCI USA, V107, P16982, DOI 10.1073/pnas.1004498107
   Tung YT, 2012, J BIOSCIENCES, V37, P157, DOI 10.1007/s12038-011-9176-0
   Valcifahmetoglu-Norberg H, 2015, J CLIN INVEST, V125, P5, DOI 10.1172/JCI73937
   van Deursen JM, 2019, SCIENCE, V364, P636, DOI 10.1126/science.aaw1299
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Ward C, 2016, BBA-MOL CELL BIOL L, V1861, P269, DOI 10.1016/j.bbalip.2016.01.006
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Woo K I, 1995, Korean J Ophthalmol, V9, P19
   Xia D, 2017, LEUKEMIA LYMPHOMA, V58, P2208, DOI 10.1080/10428194.2017.1287358
   Yang M, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0242-1
   Yu B, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aag3315
   Yu B, 2014, INVEST OPHTH VIS SCI, V55, P8638, DOI 10.1167/iovs.14-14758
   Yu HC, 2013, J BIOL CHEM, V288, P18249, DOI 10.1074/jbc.M112.446385
   Zhan Y, 2012, FREE RADICAL BIO MED, V53, P532, DOI 10.1016/j.freeradbiomed.2012.05.018
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang JJ, 2016, CLIN SCI, V130, P625, DOI 10.1042/CS20150623
   Zhang L, 2015, MOL BIOSYST, V11, P2860, DOI 10.1039/c5mb00466g
   Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104
   Zhang Q, 2019, INVEST OPHTH VIS SCI, V60, P3468, DOI 10.1167/iovs.19-26690
   Zhang QT, 2019, EXP EYE RES, V178, P212, DOI 10.1016/j.exer.2018.10.008
   Zhang XY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053931, 10.1371/journal.pone.0060781, 10.1371/journal.pone.0061922]
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
NR 112
TC 10
Z9 10
U1 2
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD APR 30
PY 2021
VL 13
IS 8
BP 10866
EP 10890
DI 10.18632/aging.202974
PG 25
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA RW7RY
UT WOS:000646719700007
PM 33872219
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ishizuka, ET
   Kanda, A
   Shinmei, Y
   Ohguchi, T
   Tagawa, Y
   Hase, K
   Yamamoto, T
   Noda, K
   Chin, S
   Ishida, S
AF Ishizuka, Erdal Tan
   Kanda, Atsuhiro
   Shinmei, Yasuhiro
   Ohguchi, Takeshi
   Tagawa, Yoshiaki
   Hase, Keitaro
   Yamamoto, Taku
   Noda, Kousuke
   Chin, Shinki
   Ishida, Susumu
TI Receptor-Associated Prorenin System in the Trabecular Meshwork of
   Patients with Primary Open-Angle Glaucoma and Neovascular Glaucoma
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE angiogenesis; angiotensin II type 1 receptor; neovascular glaucoma;
   primary open-angle glaucoma; prorenin; (pro)renin receptor;
   receptor-associated prorenin system; renin-angiotensin system; tissue
   remodeling; trabecular meshwork
ID II TYPE-1 RECEPTOR; ENDOTHELIAL GROWTH-FACTOR; ANGIOTENSIN-II;
   AQUEOUS-HUMOR; INTRAOCULAR-PRESSURE; SIGNAL-TRANSDUCTION; VITREOUS
   FLUID; DNA-DAMAGE; SUPPRESSION; BLOCKING
AB The receptor-associated prorenin system (RAPS) is associated with several pathologic conditions, including diabetic retinopathy, age-related macular degeneration, and uveitis. Here, we show the involvement of RAPS in the trabecular meshwork (TM) from patients with primary open-angle glaucoma (POAG) and neovascular glaucoma (NVG) due to proliferative diabetic retinopathy. Anterior chamber (AC) levels of prorenin significantly increased in both POAG and NVG, as did those of angiotensin II in NVG alone, compared to cataract. In surgically excised TM tissues, (pro)renin receptor ((P)RR) and angiotensin II type 1 receptor (AT1R) co-localized with prorenin and angiotensinogen, respectively. In screening for various genes related to glaucoma, prorenin stimulation to human TM cells exclusively upregulated cell junction constituentsconnexin 43andzona occludens 1, while downregulating an extracellular matrix-degrading enzymetissue plasminogen activator, all of which were reversed by (P)RR blockade. In contrast, angiotensin II application upregulated a pro-angiogenic factorplacental growth factoralone, which was abolished by AT1R blockade. Consistently, (P)RR and AT1R co-localized with these corresponding proteins in patient TM tissues. Oxidative stress, a known etiology for glaucoma, induced the expression ofproreninandangiotensinogenin human TM cells. These data suggest the contribution of RAPS to the molecular pathogenesis of POAG and NVG through TM tissue remodeling and AC angle angiogenesis.
C1 [Ishizuka, Erdal Tan; Kanda, Atsuhiro; Shinmei, Yasuhiro; Ohguchi, Takeshi; Tagawa, Yoshiaki; Hase, Keitaro; Yamamoto, Taku; Noda, Kousuke; Chin, Shinki; Ishida, Susumu] Hokkaido Univ, Fac Med, Dept Ophthalmol, Lab Ocular Cell Biol & Visual Sci, Sapporo, Hokkaido 0608638, Japan.
   [Ishizuka, Erdal Tan; Kanda, Atsuhiro; Shinmei, Yasuhiro; Ohguchi, Takeshi; Tagawa, Yoshiaki; Hase, Keitaro; Yamamoto, Taku; Noda, Kousuke; Chin, Shinki; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan.
C3 Hokkaido University; Hokkaido University
RP Kanda, A (通讯作者)，Hokkaido Univ, Fac Med, Dept Ophthalmol, Lab Ocular Cell Biol & Visual Sci, Sapporo, Hokkaido 0608638, Japan.
EM erdaltan@gmail.com; kanda@med.hokudai.ac.jp; yshinmei@med.hokudai.ac.jp;
   tohguchi@med.hokudai.ac.jp; yocchinn0127@med.hokudai.ac.jp;
   k.hase59@med.hokudai.ac.jp; taku.yamamoto@med.hokudai.ac.jp;
   nodako@med.hokudai.ac.jp; schin@med.hokudai.ac.jp;
   ishidasu@med.hokudai.ac.jp
OI Yamamoto, Taku/0000-0001-7375-8021; Kanda, Atsuhiro/0000-0001-7192-9974
FU Bayer Japan Retina Award; Institute of Science of Blood Pressure and
   Hormone; Ministry of Education, Science and Culture of Japan [16K11279,
   19K09944, 16H05484]
FX This work was supported in part by the Bayer Japan Retina Award (to
   A.K.), the Institute of Science of Blood Pressure and Hormone (to A.K.),
   and the Ministry of Education, Science and Culture of Japan
   (grant-in-aid nos. 16K11279 and 19K09944 to A.K. and 16H05484 to S.I.).
CR Agarwal P, 2018, EXPERT OPIN THER TAR, V22, P629, DOI 10.1080/14728222.2018.1486822
   Ando R, 2014, ACTA OPHTHALMOL, V92, pE245, DOI 10.1111/aos.12251
   Carreon T, 2017, PROG RETIN EYE RES, V57, P108, DOI 10.1016/j.preteyeres.2016.12.004
   Costagliola C, 2000, EXP EYE RES, V71, P167, DOI 10.1006/exer.2000.0866
   De Groef L, 2013, INVEST OPHTH VIS SCI, V54, P7756, DOI 10.1167/iovs.13-13088
   Dong YK, 2017, SCI REP-UK, V7, DOI 10.1038/srep44266
   Ferreira SM, 2010, INVEST OPHTH VIS SCI, V51, P4635, DOI 10.1167/iovs.09-5044
   Funatsu H, 2002, BRIT J OPHTHALMOL, V86, P311, DOI 10.1136/bjo.86.3.311
   Hase K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189696
   Hashizume K, 2005, INVEST OPHTH VIS SCI, V46, P1993, DOI 10.1167/iovs.04-1100
   Holappa M, 2020, ANN MED, V52, P191, DOI 10.1080/07853890.2020.1758341
   Ichihara A, 2010, HYPERTENS RES, V33, P177, DOI 10.1038/hr.2009.214
   Ishizuka ET, 2015, INVEST OPHTH VIS SCI, V56, P74, DOI 10.1167/iovs.14-15743
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Kanda A, 2012, DIABETOLOGIA, V55, P3104, DOI 10.1007/s00125-012-2702-2
   Kanda A, 2019, J DIABETES INVEST, V10, P6, DOI 10.1111/jdi.12842
   Kanda A, 2017, MOL THER-NUCL ACIDS, V7, P116, DOI 10.1016/j.omtn.2017.01.001
   Kanda A, 2013, BRIT J OPHTHALMOL, V97, P666, DOI 10.1136/bjophthalmol-2012-302680
   Kokubun T, 2018, OCUL IMMUNOL INFLAMM, V26, P1177, DOI 10.1080/09273948.2017.1327605
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kumar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072447
   Kurihara T, 2008, DIABETES, V57, P2191, DOI 10.2337/db07-1281
   Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Maruichi M, 2004, CURR EYE RES, V29, P321, DOI 10.1080/02713680490516161
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P2925, DOI 10.1167/iovs.04-1476
   Nagai N, 2005, INVEST OPHTH VIS SCI, V46, P1078, DOI 10.1167/iovs.04-1101
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P4342, DOI 10.1167/iovs.06-1473
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Ohira S, 2015, INVEST OPHTH VIS SCI, V56, P3541, DOI 10.1167/iovs.14-15918
   Okunuki Y, 2009, INVEST OPHTH VIS SCI, V50, P2255, DOI 10.1167/iovs.08-2649
   Oshida E, 2010, CLIN OPHTHALMOL, V4, P653
   Pan PX, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-36
   PANG IH, 1994, CURR EYE RES, V13, P51, DOI 10.3109/02713689409042398
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Rodrigues Gustavo B, 2016, Int J Retina Vitreous, V2, P26
   Sacca SC, 2016, AGEING RES REV, V29, P26, DOI 10.1016/j.arr.2016.05.012
   Satofuka S, 2009, DIABETES, V58, P1625, DOI 10.2337/db08-0254
   Satofuka S, 2008, AM J PATHOL, V173, P1911, DOI 10.2353/ajpath.2008.080457
   Seftor R E, 1994, J Glaucoma, V3, P323
   Semba K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.296
   Sorkhabi R, 2011, MOL VIS, V17, P41
   Takahashi H, 2007, J AM SOC NEPHROL, V18, P2054, DOI 10.1681/ASN.2006080820
   Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330, DOI 10.1152/ajpcell.1999.277.2.C330
   Usui T, 2008, INVEST OPHTH VIS SCI, V49, P4370, DOI 10.1167/iovs.07-0964
   Vaajanen A, 2011, BASIC CLIN PHARMACOL, V109, P217, DOI 10.1111/j.1742-7843.2011.00729.x
   Vranka JA, 2015, EXP EYE RES, V133, P112, DOI 10.1016/j.exer.2014.07.014
   Wang RF, 2005, EXP EYE RES, V80, P629, DOI 10.1016/j.exer.2004.11.012
   Weinreb RN, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.67
   White AJR, 2015, J RENIN-ANGIO-ALDO S, V16, P1193, DOI 10.1177/1470320314566018
   Yaguchi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064724
   Yang JG, 2015, J GLAUCOMA, V24, P291, DOI 10.1097/IJG.0b013e31829d9b91
   Yu XB, 2007, OPHTHAL SURG LAS IM, V38, P6, DOI 10.3928/15428877-20070101-01
   Zhuo YH, 2010, MOL VIS, V16, P61
NR 54
TC 0
Z9 0
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2020
VL 9
IS 8
AR 2336
DI 10.3390/jcm9082336
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NH3SV
UT WOS:000564594300001
PM 32707887
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ayton, LN
   Barnes, N
   Dagnelie, G
   Fujikado, T
   Goetz, G
   Hornig, R
   Jones, BW
   Muqit, MMK
   Rathbun, DL
   Stingl, K
   Weiland, JD
   Petoe, MA
AF Ayton, Lauren N.
   Barnes, Nick
   Dagnelie, Gislin
   Fujikado, Takashi
   Goetz, Georges
   Hornig, Ralf
   Jones, Bryan W.
   Muqit, Mahiul M. K.
   Rathbun, Daniel L.
   Stingl, Katarina
   Weiland, James D.
   Petoe, Matthew A.
TI An update on retinal prostheses
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Review
DE Retinal prosthesis; Vision restoration; Retinal disease; Ophthalmology
ID SUPRACHOROIDAL-TRANSRETINAL STIMULATION; AFFECTING PERCEPTUAL
   THRESHOLDS; ELECTRICAL-STIMULATION; ARTIFICIAL VISION; FUNCTIONAL
   VISION; BLIND PATIENTS; ELECTRODE STIMULATION; RETINITIS-PIGMENTOSA;
   VISUAL-PERCEPTION; INNER RETINA
AB Retinal prostheses are designed to restore a basic sense of sight to people with profound vision loss. They require a relatively intact posterior visual pathway (optic nerve, lateral geniculate nucleus and visual cortex). Retinal implants are options for people with severe stages of retinal degenerative disease such as retinitis pigmentosa and age-related macular degeneration.
   There have now been three regulatory-approved retinal prostheses. Over five hundred patients have been implanted globally over the past 15 years. Devices generally provide an improved ability to localize high-contrast objects, navigate, and perform basic orientation tasks. Adverse events have included conjunctival erosion, retinal detachment, loss of light perception, and the need for revision surgery, but are rare. There are also specific device risks, including overstimulation (which could cause damage to the retina) or delamination of implanted components, but these are very unlikely.
   Current challenges include how to improve visual acuity, enlarge the field-of-view, and reduce a complex visual scene to its most salient components through image processing. This review encompasses the work of over 40 individual research groups who have built devices, developed stimulation strategies, or investigated the basic physiology underpinning retinal prostheses. Current technologies are summarized, along with future challenges that face the field.
C1 [Ayton, Lauren N.] Univ Melbourne, Dept Optometry & Vis Sci, Level 4,Alice Hoy Bldg,Monash Rd, Parkville, Vic 3010, Australia.
   [Ayton, Lauren N.] Univ Melbourne, Dept Surg Ophthalmol, Level 4,Alice Hoy Bldg,Monash Rd, Parkville, Vic 3010, Australia.
   [Barnes, Nick] CSIRO, Data61, Canberra, ACT, Australia.
   [Barnes, Nick] Australian Natl Univ, Canberra, ACT, Australia.
   [Dagnelie, Gislin] Johns Hopkins Univ, Sch Med, Lions Vis Res & Rehabil Ctr, Baltimore, MD USA.
   [Fujikado, Takashi] Osaka Univ, Dept Appl Visual Sci, Osaka, Japan.
   [Goetz, Georges] Waymo & Verily Life Sci, Mountain View, CA USA.
   [Hornig, Ralf] Pixium Vis, Paris, France.
   [Jones, Bryan W.] Univ Utah, Sch Med, Moran Eye Ctr, Salt Lake City, UT USA.
   [Muqit, Mahiul M. K.] Moorfields Eye Hosp NHS Trust, Vitreoretinal Serv, London, England.
   [Muqit, Mahiul M. K.] UCL, Inst Ophthalmol, London, England.
   [Rathbun, Daniel L.] Henry Ford Hlth Syst, Detroit Inst Ophthalmol, Detroit, MI USA.
   [Rathbun, Daniel L.; Stingl, Katarina] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany.
   [Weiland, James D.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.
   [Weiland, James D.] Univ Michigan, Dept Ophthalmol, Ann Arbor, MI USA.
   [Petoe, Matthew A.] Bion Inst, East Melbourne, Vic, Australia.
   [Petoe, Matthew A.] Univ Melbourne, Dept Med Bion, Parkville, Vic 3010, Australia.
C3 University of Melbourne; University of Melbourne; Commonwealth
   Scientific & Industrial Research Organisation (CSIRO); Australian
   National University; Johns Hopkins University; Osaka University; Utah
   System of Higher Education; University of Utah; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; Henry Ford Health
   System; Henry Ford Hospital; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; Bionics Institute; University of Melbourne
RP Ayton, LN (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Level 4,Alice Hoy Bldg,Monash Rd, Parkville, Vic 3010, Australia.; Ayton, LN (通讯作者)，Univ Melbourne, Dept Surg Ophthalmol, Level 4,Alice Hoy Bldg,Monash Rd, Parkville, Vic 3010, Australia.
EM layton@unimelb.edu.au; Nick.Barnes@data61.csiro.au;
   gislin@lions.med.jhu.edu; fujikado@ophthal.med.osaka-u.ac.jp;
   ggoetz@stanford.edu; rhornig@pixium-vision.com;
   bryan.jones@m.cc.utah.edu; mahi.muqit1@nhs.net; DRathbu2@hfhs.org;
   katarina.stingl@med.uni-tuebingen.de; weiland@umich.edu;
   MPetoe@bionicsinstitute.org
RI Petoe, Matthew/ABD-8365-2020; Barnes, Nick/Y-2744-2018; Ayton,
   Lauren/AAV-2977-2021
OI Petoe, Matthew/0000-0002-1865-3566; Barnes, Nick/0000-0002-9343-9535;
   Ayton, Lauren/0000-0001-9907-084X; Muqit, Mahiul/0000-0003-1161-3956;
   Weiland, James/0000-0003-3453-9074
FU NHMRC Next Generation Fellowship [1151055]; NHMRC [1082358]; NIH [R01
   EY015128, R01 EY028927]; Vision Core Grant [P30 EY014800]; Research to
   Prevent Blindness; National Institute for Health Research (NIHR) London
   Biomedical Research Centre (BRC) at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology; Bionic Vision
   Technologies (Australia); German Ministry for Education and Research
   [BMBF 031a308]; NATIONAL EYE INSTITUTE [R01EY015128, P30EY014800,
   R01EY028927] Funding Source: NIH RePORTER
FX LA receives licensing royalties for purchase by commercial entities for
   the IVI-VLV tool and is supported by a NHMRC Next Generation Fellowship
   (1151055) and an NHMRC Project Grant (1082358). GD is a consultant to
   Second Sight Medical Products (USA), and receives licensing royalties
   for purchase by commercial entities for the ULV-VFQ tool. JW is a
   consultant to Second Sight Medical Products (USA). BJ is supported by
   NIH grants R01 EY015128, R01 EY028927, a P30 EY014800 Vision Core Grant
   and an unrestricted grant from Research to Prevent Blindness to the
   Moran Eye Center. RH is an employee of Pixium Vision (France). MM is a
   consultant to Pixium Vision (France) and receives support from the
   National Institute for Health Research (NIHR) London Biomedical Research
   Centre (BRC) at Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology. MP and NB receive funding from Bionic Vision
   Technologies (Australia). DR is supported by the German Ministry for
   Education and Research, BMBF 031a308.
CR Abbott CJ, 2019, INVEST OPHTH VIS SCI, V60
   Abbott CJ, 2018, INVEST OPHTH VIS SCI, V59, P1410, DOI 10.1167/iovs.17-23086
   Adeyemo O, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.10
   Ahuja AK, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.4.1
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008
   Bach M, 2010, INVEST OPHTH VIS SCI, V51, P1255, DOI 10.1167/iovs.09-3512
   Baden T, 2016, NATURE, V529, P345, DOI 10.1038/nature16468
   Bajaj R, 2019, INVEST OPHTH VIS SCI, V60
   Barnes N, 2016, J NEURAL ENG, V13, DOI 10.1088/1741-2560/13/3/036013
   BARNES NM, 2015, INVEST OPHTH VIS SCI, V56
   Beyeler M, 2017, J NEURAL ENG, V14, DOI 10.1088/1741-2552/aa795e
   Boinagrov D, 2014, J NEURAL ENG, V11, DOI 10.1088/1741-2560/11/2/026008
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   Caspi A, 2017, 8 INT IEEE EMBS C NE, P9
   Caspi A, 2017, INVEST OPHTH VIS SCI, V58, P119, DOI 10.1167/iovs.16-20398
   Chader GJ, 2009, PROG BRAIN RES, V175, P317, DOI 10.1016/S0079-6123(09)17522-2
   Cheng DL, 2017, CURR EYE RES, V42, P334, DOI 10.1080/02713683.2016.1270326
   Chow AY, 2013, ASIA-PAC J OPHTHALMO, V2, P253, DOI 10.1097/APO.0b013e3182a0b4fe
   da Cruz L, 2016, OPHTHALMOLOGY, V123, P2248, DOI 10.1016/j.ophtha.2016.06.049
   da Cruz L, 2013, BRIT J OPHTHALMOL, V97, P632, DOI 10.1136/bjophthalmol-2012-301525
   Dagnelie G, 2008, ANNU REV BIOMED ENG, V10, P339, DOI 10.1146/annurev.bioeng.10.061807.160529
   Dagnelie G, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.12
   Dagnelie G, 2017, CLIN EXP OPHTHALMOL, V45, P152, DOI 10.1111/ceo.12812
   Daschner R, 2018, SENSOR MATER, V30, P179, DOI 10.18494/SAM.2018.1726
   Daschner R, 2017, BIOMED MICRODEVICES, V19, DOI 10.1007/s10544-017-0147-6
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   DOBELLE WH, 1976, NATURE, V259, P111, DOI 10.1038/259111a0
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   Edwards TL, 2018, OPHTHALMOLOGY, V125, P432, DOI 10.1016/j.ophtha.2017.09.019
   Eickenscheidt M, 2012, J NEUROPHYSIOL, V107, P2742, DOI 10.1152/jn.00909.2011
   Fine I, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0208
   Finger RP, 2016, OPTOMETRY VISION SCI, V93, P1127, DOI 10.1097/OPX.0000000000000891
   Finger RP, 2014, INVEST OPHTH VIS SCI, V55, P8458, DOI 10.1167/iovs.14-14732
   Finger RP, 2014, INVEST OPHTH VIS SCI, V55, P6150, DOI 10.1167/iovs.14-14731
   Fletcher EL, 1996, J COMP NEUROL, V376, P343
   Foerster O., 1929, J PSYCHOL NEUROL, V39, P435
   Fornos AP, 2012, INVEST OPHTH VIS SCI, V53, P2720, DOI 10.1167/iovs.11-9344
   Freeman DK, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/1/016008
   Freeman DK, 2010, J NEUROPHYSIOL, V104, P2778, DOI 10.1152/jn.00551.2010
   Fujikado T, 2016, INVEST OPHTH VIS SCI, V57, P6147, DOI 10.1167/iovs.16-20367
   Fujikado T, 2011, INVEST OPHTH VIS SCI, V52, P4726, DOI 10.1167/iovs.10-6836
   Geruschat DR, 2016, CLIN EXP OPTOM, V99, P227, DOI 10.1111/cxo.12359
   Geruschat DR, 2015, CLIN EXP OPTOM, V98, P342, DOI 10.1111/cxo.12242
   Goetz GA, 2016, REP PROG PHYS, V79, DOI 10.1088/0034-4885/79/9/096701
   Graf M, 2004, KLIN MONATSBL AUGENH, V221, P557, DOI 10.1055/s-2004-812893
   Greenwald SH, 2009, INVEST OPHTH VIS SCI, V50, P5017, DOI 10.1167/iovs.08-2897
   Hallum Luke E, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P1634
   Hayes JS, 2003, ARTIF ORGANS, V27, P1016, DOI 10.1046/j.1525-1594.2003.07309.x
   Hemami P, 2017, PIXIUM SEEKS ADDRESS
   Ho E, 2018, J NEUROPHYSIOL, V119, P389, DOI 10.1152/jn.00872.2016
   Hornig R, 2007, ARTIFICIAL SIGHT BAS, P111, DOI [10.1007/978-0-387-49331-2_6, DOI 10.1007/978-0-387-49331-2_6]
   Horsager A, 2011, INVEST OPHTH VIS SCI, V52, P549, DOI 10.1167/iovs.10-5282
   Horsager A, 2010, INVEST OPHTH VIS SCI, V51, P1223, DOI 10.1167/iovs.09-3746
   Horsager A, 2009, INVEST OPHTH VIS SCI, V50, P1483, DOI 10.1167/iovs.08-2595
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 2009, IEEE ENG MED BIO, P4566, DOI 10.1109/IEMBS.2009.5332695
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Jepson LH, 2014, NEURON, V83, P87, DOI 10.1016/j.neuron.2014.04.044
   Jeter PE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.11
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Jones BW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00103
   Kling A, 2019, ANNU REV NEUROSCI, V42, P169, DOI 10.1146/annurev-neuro-070918-050233
   Krause F, 1931, NEUE DTSCH CHIRURG
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lane FJ, 2012, EYE CHIP WORLD C ART
   LAURITZEN TZ, 2011, ARVO M, V52, P4927
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851
   Luo YHL, 2016, AM J OPHTHALMOL, V170, P100, DOI 10.1016/j.ajo.2016.07.021
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Massof RW, 2007, OPHTHAL EPIDEMIOL, V14, P198, DOI 10.1080/09286580701487883
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P954, DOI 10.1016/j.apmr.2004.09.017
   Massof RW, 2002, OPTOMETRY VISION SCI, V79, P516, DOI 10.1097/00006324-200208000-00015
   McCarthy C, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/1/016003
   Mills JO, 2017, EYE, V31, P1383, DOI 10.1038/eye.2017.65
   Muqit MMK, 2019, OPHTHALMOLOGY, V126, P637, DOI 10.1016/j.ophtha.2018.11.010
   Nanduri D, 2008 30 ANN INT C IE, V1-8
   Nanduri D, 2011, THESIS
   Nanduri D, 2012, INVEST OPHTH VIS SCI, V53, P205, DOI 10.1167/iovs.11-8401
   Opie NL, 2014, ARTIF ORGANS, V38, pE82, DOI 10.1111/aor.12287
   Rathbun DL, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aae493
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Rizzo S, 2020, RETINA-J RET VIT DIS, V40, P303, DOI 10.1097/IAE.0000000000002394
   Rizzo S, 2015, GRAEF ARCH CLIN EXP, V253, P323, DOI 10.1007/s00417-014-2822-0
   Roessler G, 2009, INVEST OPHTH VIS SCI, V50, P3003, DOI 10.1167/iovs.08-2752
   Sabbah N, 2014, INVEST OPHTH VIS SCI, V55, P8259, DOI 10.1167/iovs.14-15392
   SADEGHI R, 2019, INVEST OPHTH VIS SCI, V60
   SAHEL J, 2013, INVEST OPHTH VIS SCI, V54
   Sakaguchi H, 2011, INVEST OPHTH VIS SCI, V52, P4963
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Saunders AL, 2014, CLIN EXP OPHTHALMOL, V42, P665, DOI 10.1111/ceo.12287
   Schatz A, 2011, INVEST OPHTH VIS SCI, V52, P4485, DOI 10.1167/iovs.10-6932
   Shire DB, C P IEEE ENG MED BIO, P292
   Shivdasani MN, 2017, INVEST OPHTH VIS SCI, V58, P3962, DOI 10.1167/iovs.16-21311
   Shivdasani MN, 2014, INVEST OPHTH VIS SCI, V55, P6467, DOI 10.1167/iovs.14-14396
   Sinclair NC, 2016, INVEST OPHTH VIS SCI, V57, P4948, DOI 10.1167/iovs.15-18991
   Stanga P, 2013, INVEST OPHTH VIS SCI, V54
   Stanga PE, 2012, INVEST OPHTH VIS SCI, V53
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Stelmack JA, 2007, OPTOMETRY VISION SCI, V84, P705, DOI 10.1097/OPX.0b013e3181339f1a
   Stiles Noelle R. B., 2011, Optical Processes in Microparticles and Nanostructures. A Festschrift Dedicated to Richard Kounai Chang on His Retirement from Yale University, P385, DOI 10.1142/9789814295789_0020
   Stingl K, 2016, DOC OPHTHALMOL, V133, P81, DOI 10.1007/s10633-016-9557-7
   Stingl K, 2013, OPHTHALMIC RES, V50, P215, DOI 10.1159/000354424
   Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445
   Stingl K, 2015, VISION RES, V111, P149, DOI 10.1016/j.visres.2015.03.001
   Stingl K, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0077
   Stingl K, 2013, CLIN EXP OPTOM, V96, P4, DOI 10.1111/j.1444-0938.2012.00816.x
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   TASSICKER G E, 1956, Br J Physiol Opt, V13, P102
   Titchener SA, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.1.2
   Tran BK, 2017, KLIN MONATSBL AUGENH, V234, P538, DOI 10.1055/s-0042-121660
   Twyford P, 2016, IEEE T NEUR SYS REH, V24, P413, DOI 10.1109/TNSRE.2015.2415811
   Uhlig CE, 2001, OPHTHALMOLOGE, V98, P1089, DOI 10.1007/s003470170031
   Vanhoestenberghe A, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/1/011001
   Velikay-Parel M, 2013, ACTA OPHTHALMOL, V91, pE595, DOI 10.1111/aos.12179
   Wagner SK, 2017, BMJ OPEN OPHTHALMOL, V2, DOI 10.1136/bmjophth-2017-000096
   Weiland JD, 2016, ANNU REV VIS SCI, V2, P273, DOI 10.1146/annurev-vision-111815-114425
   Weitz AC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4877
   Wilke R., 2007, ARTIFICIAL SIGHT BIO, P91, DOI [10.1007/978- 0- 387-49331-2_5, DOI 10.1007/978-0-387-49331-2_5]
   Wilke R, 2011, INVEST OPHTH VIS SCI, V52, P5995, DOI 10.1167/iovs.10-6946
   Yue L, 2016, PROG RETIN EYE RES, V53, P21, DOI 10.1016/j.preteyeres.2016.05.002
   Yue L, 2015, OPHTHALMOLOGY, V122, P2545, DOI 10.1016/j.ophtha.2015.08.008
   Zhou CQ, 2010, ARTIF ORGANS, V34, P518, DOI 10.1111/j.1525-1594.2009.00915.x
   Zhou DM, US Patent, Patent No. 6974533
   Zrenner E., 2017, ARTIFICIAL VISION, P65, DOI DOI 10.1007/978-3-319-41876-6_6
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 129
TC 54
Z9 56
U1 8
U2 44
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUN
PY 2020
VL 131
IS 6
BP 1383
EP 1398
DI 10.1016/j.clinph.2019.11.029
PG 16
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA LL4WT
UT WOS:000531558300009
PM 31866339
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Kularatne, RN
   Bulumulla, C
   Catchpole, T
   Takacs, A
   Christie, A
   Stefan, MC
   Csaky, KG
AF Kularatne, Ruvanthi N.
   Bulumulla, Chandima
   Catchpole, Timothy
   Takacs, Alison
   Christie, Abigail
   Stefan, Mihaela C.
   Csaky, Karl G.
TI Protection of human retinal pigment epithelial cells from oxidative
   damage using cysteine prodrugs
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Oxidative stress; N-acetylcysteine
   butyl ester (NACBE); Glutathione; Mitochondria
ID MITOCHONDRIAL GLUTATHIONE TRANSPORT; MACULAR DEGENERATION; STRESS;
   SMOKING; INJURY; ROS
AB Age -related macular degeneration (AMD) is one of the major causes of vision loss in the elderly in most de- veloped countries. Among other causes, oxidative stress in the retinal pigment epithelium (RPE) has been hy- pothesized to be a major driving force of AMD pathology. Oxidative stress could be treated by antioxidant administration into the RPE cells. However, to achieve high in -vivo e fficacy of an antioxidant, it is imperative that the agent be able to penetrate the tissues and cells. Evidence suggests that lipophilicity governs cellular penetrance. Out of many antioxidant candidates, N -acetyl- L -cysteine (a prodrug of L -cysteine) (NAC) is a potent antioxidant as the bioavailability of the parent drug, L -cysteine, determines the production of glutathione; the universal antioxidant that regulates ROS. To increase the lipophilicity, four ester derivatives of N -acetylcysteine: N -acetylcysteine methyl ester, N -acetylcysteine ethyl ester, N -acetylcysteine propyl ester, and N -acetylcysteine butyl ester were synthesized. To mimic in vitro AMD conditions, hydroquinone, a component of cigarette smoke, was used as the oxidative insult. Cytosolic and mitochondrial protection against oxidative stress were tested using cytosolic and mitochondrial speci fic assays. The results provide evidence that these lipophilic cysteine prodrugs provide increased protection against oxidative stress in human RPE cells compared with NAC.
C1 [Kularatne, Ruvanthi N.; Bulumulla, Chandima; Catchpole, Timothy; Takacs, Alison; Christie, Abigail; Csaky, Karl G.] Retina Fdn Southwest, Dallas, TX 75231 USA.
   [Stefan, Mihaela C.] Univ Texas Dallas, Dept Chem & Biochem, Richardson, TX 75080 USA.
   [Stefan, Mihaela C.] Univ Texas Dallas, Dept Bioengn, Richardson, TX 75080 USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Dallas; University of Texas System; University of
   Texas Dallas
RP Csaky, KG (通讯作者)，Retina Fdn Southwest, Dallas, TX 75231 USA.
EM kcsaky@retinafoundation.org
RI Kularatne, Ruvanthi/U-7697-2019
OI Kularatne, Ruvanthi/0000-0002-6916-2011; Bulumulla,
   Chandima/0000-0003-0324-2008
FU Stillwater Foundation; Wilson Foundation
FX This study was supported by the funding received from the Stillwater
   Foundation and the Wilson Foundation.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Cao SJ, 2013, MOL VIS, V19, P718
   Carey JW, 2012, J BIOPHYS CHEM, V3, P101
   Carver KA, 2016, INVEST OPHTH VIS SCI, V57, P360, DOI 10.1167/iovs.15-17117
   Celis J.E., 2005, CELL BIOL LAB HDB
   Chaiyarit S, 2009, ANAL BIOCHEM, V394, P249, DOI 10.1016/j.ab.2009.07.026
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fisher Cody R., 2018, INVEST OPHTH VIS SCI, V59, P41, DOI DOI 10.1167/I0VS.18-24289
   Giustarini D, 2018, FREE RADICAL BIO MED, V126, P202, DOI 10.1016/j.freeradbiomed.2018.08.013
   Giustarini D, 2012, BIOCHEM PHARMACOL, V84, P1522, DOI 10.1016/j.bcp.2012.09.010
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Hsiu-Jen W., 2017, FREE RADIC ANTIOXIDA, V7
   Isik B, 2007, INHAL TOXICOL, V19, P767, DOI 10.1080/08958370701401418
   Kagan DB, 2012, CLIN OPHTHALMOL, V6, P1471, DOI 10.2147/OPTH.S35139
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lash LH, 2006, CHEM-BIOL INTERACT, V163, P54, DOI 10.1016/j.cbi.2006.03.001
   Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008
   Mannermaa E, 2006, ADV DRUG DELIVER REV, V58, P1136, DOI 10.1016/j.addr.2006.07.024
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   PIZZINO G, 2017, OXID MED CELL LONGEV, V2017, DOI DOI 10.1155/2017/8416763
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Sacca SC, 2008, PROG BRAIN RES, V173, P385, DOI 10.1016/S0079-6123(08)01127-8
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159
   Song JM, 2004, CURR EYE RES, V28, P195, DOI 10.1076/ceyr.28.3.195.26251
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wang M, 2019, INVEST OPHTH VIS SCI, V60, P500, DOI 10.1167/iovs.18-25686
   Wilkins HM, 2013, J BIOL CHEM, V288, P5091, DOI 10.1074/jbc.M112.405738
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 39
TC 8
Z9 8
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAY 20
PY 2020
VL 152
BP 386
EP 394
DI 10.1016/j.freeradbiomed.2020.03.024
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA MB9XB
UT WOS:000542949700007
PM 32229256
OA hybrid
DA 2022-11-30
ER

PT J
AU Fujii, S
   Sugita, S
   Futatsugi, Y
   Ishida, M
   Edo, A
   Makabe, K
   Kamao, H
   Iwasaki, Y
   Sakaguchi, H
   Hirami, Y
   Kurimoto, Y
   Takahashi, M
AF Fujii, Shota
   Sugita, Sunao
   Futatsugi, Yoko
   Ishida, Masaaki
   Edo, Ayaka
   Makabe, Kenichi
   Kamao, Hiroyuki
   Iwasaki, Yuko
   Sakaguchi, Hirokazu
   Hirami, Yasuhiko
   Kurimoto, Yasuo
   Takahashi, Masayo
TI A Strategy for Personalized Treatment of iPS-Retinal Immune Rejections
   Assessed in Cynomolgus Monkey Models
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE iPS cells; retinal pigment epithelial cells; immune rejection; drug;
   transplantation
ID PIGMENT EPITHELIAL-CELLS; INDUCED PLURIPOTENT; TRANSPLANTATION; RPE;
   INTRAVITREAL; ENDOPHTHALMITIS; INHIBITION; ACTIVATION; RABBIT; SAFETY
AB Recently, we successfully transplanted an autograft, or major histocompatibility complex (MHC)-matched allografts, from induced-pluripotent-stem-cell-derived retinal pigment epithelial (iPSC-RPE) cells in patients with age-related macular degeneration. However, there was an issue regarding immune rejection after transplantation. In this study, we established a preoperational in vitro "drug-lymphocytes-grafts immune reaction (Drug-LGIR)" test to determine the medication for immune rejection using host immunocompetent cells (lymphocytes) and transplant cells (target iPSC-RPE cells) together with different medications. The adequacy of the test was assessed by in vivo transplantation in monkey models together with medication based on in vitro data. In the results of Drug-LGIR tests, some drugs exhibited significant suppression of RPE cell-related allogeneic reactions, while other drugs did not, and the efficacy of each drug differed among the recipient monkeys. Based on the results of Drug-LGIR, we applied cyclosporine A or local steroid (triamcinolone) therapy to two monkeys, and successfully suppressed RPE-related immune rejections with RPE grafts, which survived without any signs of rejection under drug administration. We propose that our new preoperational in vitro Drug-LGIR test, which specifies the most efficacious medication for each recipient, is useful for controlling immune attacks with personalized treatment for each patient after retinal transplantation.
C1 [Fujii, Shota; Sugita, Sunao; Futatsugi, Yoko; Ishida, Masaaki; Edo, Ayaka; Makabe, Kenichi; Takahashi, Masayo] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
   [Kamao, Hiroyuki] Kawasaki Med Sch, Dept Ophthalmol, 577 Matsushima, Kurashiki, Okayama 7010114, Japan.
   [Iwasaki, Yuko] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.
   [Sakaguchi, Hirokazu] Osaka Univ, Med Sch, Dept Ophthalmol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Hirami, Yasuhiko; Kurimoto, Yasuo] Kobe City Eye Hosp, Dept Ophthalmol, Chuo Ku, 218 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
C3 RIKEN; Kawasaki Medical School; Tokyo Medical & Dental University
   (TMDU); Osaka University
RP Sugita, S (通讯作者)，RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.
EM shota.fujii@gmail.com; sunao.sugita@riken.jp; yoko.futatsugi@riken.jp;
   masaaki.ishida@riken.jp; ayaka.edo@riken.jp; makabe.k1@gmail.com;
   hiroyuki_retina_galileogalilei@yahoo.co.jp; sahnya96@gmail.com;
   sakaguh@ophthal.med.osaka-u.ac.jp; yhirami@kcho.jp; ykurimoto@mac.com;
   retinalab@ml.riken.jp
OI Kamao, Hiroyuki/0000-0002-2194-7063; Nakai-Futatsugi,
   Yoko/0000-0003-4187-6060
FU Research Center Network for Realization of Regenerative Medicine from
   the Japan Agency for Medical Research and Development (AMED); Ministry
   of Education, Culture, Sports, Science and Technology of Japan
   [18H02959]; RIKEN Junior Research Associate Program
FX This work was supported by the Research Center Network for Realization
   of Regenerative Medicine from the Japan Agency for Medical Research and
   Development (AMED) to M.T., by the RIKEN Junior Research Associate
   Program to S.F., and by a Scientific Research Grant (B, 18H02959) from
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan to S.S.
CR Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Araki R, 2013, NATURE, V494, P100, DOI 10.1038/nature11807
   Cao JN, 2014, PROTEIN CELL, V5, P1, DOI 10.1007/s13238-013-0003-2
   Charalampidou S, 2011, EYE, V25, P494, DOI 10.1038/eye.2010.229
   Choudhry S, 2007, CLIN EXP OPHTHALMOL, V35, P713, DOI 10.1111/j.1442-9071.2007.01578.x
   Diaz-Llopis M, 2012, OPHTHALMOLOGY, V119, P1575, DOI 10.1016/j.ophtha.2012.02.018
   GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   Jin ZB, 2019, PROG RETIN EYE RES, V69, P38, DOI 10.1016/j.preteyeres.2018.11.003
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kennelly KP, 2017, CELL TRANSPLANT, V26, P983, DOI 10.3727/096368917X694697
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Lai CC, 2000, INVEST OPHTH VIS SCI, V41, P3134
   Makabe K, 2019, INVEST OPHTH VIS SCI, V60, P1298, DOI 10.1167/iovs.18-26222
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   McGill TJ, 2018, INVEST OPHTH VIS SCI, V59, P1374, DOI 10.1167/iovs.17-22467
   Mochizuki M, 1997, Int Rev Immunol, V14, P49, DOI 10.3109/08830189709116844
   Ohno S, 2004, J RHEUMATOL, V31, P1362
   Okada AA, 2003, BRIT J OPHTHALMOL, V87, P968, DOI 10.1136/bjo.87.8.968
   Otsuka H, 2013, INVEST OPHTH VIS SCI, V54, P1758, DOI 10.1167/iovs.12-11247
   Petrus-Reurer S, 2020, STEM CELL REP, V14, P648, DOI 10.1016/j.stemcr.2020.02.006
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rezai KA, 2000, GRAEF ARCH CLIN EXP, V238, P352, DOI 10.1007/s004170050364
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P1719, DOI 10.1167/iovs.17-22703
   Sugita S, 2017, STEM CELL REP, V9, P1501, DOI 10.1016/j.stemcr.2017.10.003
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2016, STEM CELL REP, V7, P635, DOI 10.1016/j.stemcr.2016.08.010
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   VanderBeek BL, 2015, OPHTHALMOLOGY, V122, P2311, DOI 10.1016/j.ophtha.2015.07.005
   Wong CA, 2002, CAN J OPHTHALMOL, V37, P211, DOI 10.1016/S0008-4182(02)80112-0
   Xian BK, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0167-1
   Xing KL, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0103-2
NR 37
TC 13
Z9 13
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2020
VL 21
IS 9
AR 3077
DI 10.3390/ijms21093077
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LR3GK
UT WOS:000535581700048
PM 32349277
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yan, YT
   Ren, YF
   Li, XM
   Zhang, XX
   Guo, HQ
   Han, YT
   Hu, JX
AF Yan, Yitao
   Ren, Yanfan
   Li, Xinmin
   Zhang, Xinxia
   Guo, Huiqing
   Han, Yutong
   Hu, Junxi
TI A polysaccharide from green tea (Camellia sinensis L.) protects human
   retinal endothelial cells against hydrogen peroxide-induced oxidative
   injury and apoptosis
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Age-related macular degeneration (AMD); Green tea polysaccharide;
   Oxidative stress
ID WATER-SOLUBLE POLYSACCHARIDE; MACULAR DEGENERATION; PIGMENT EPITHELIUM;
   G2/M ARREST; STRESS; PURIFICATION; PATHOGENESIS; COMPONENTS; SUGARS;
   DAMAGE
AB Oxidative damage of retinal pigment epithelium (RPE) cells is involved in the pathogenesis age related macular degeneration (AMD). The purpose of this study was to evaluate the potential protective effect of a purified green tea polysaccharide (GTWP) against hydrogen peroxide (H2O2) induced oxidative stress and apoptosis in human retinal pigment epithelial cells (ARPE-19 cells). Human ARPE-19 cells were treated with 1 h of 500 M H2O2 before incubation with GTWP for 24 h. Pretreatment of GTWP decreased H2O2-induced cell death and cell apoptosis, and efficiently suppressed the intracellular ROS production and malondialdehyde (MDA) generation induced by H2O2 treatment. Moreover, a loss of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione (GSH) activities were restored to normal level in H2O2-induced ARPE-19 cells upon GTWP (100 mu g/ml) exposure. Also, the tendency of increased protein expression of Bax and cleaved-caspsae-3, as well as decrease of Bcl-2 protein in ARPE-19 cells challenged with H2O2 was changed to individual opposite way, thus inhibiting the apoptotic cell death. Our results demonstrated that GTWP protected RPE cells against oxidative injury through activation of anti-apoptotic and endogenous antioxidant enzymes signaling pathway, suggesting MVP has attractive therapeutic potential to AMD. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Yan, Yitao; Ren, Yanfan; Li, Xinmin; Zhang, Xinxia; Guo, Huiqing; Hu, Junxi] Xinxiang Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Xinxiang 453100, Henan, Peoples R China.
   [Han, Yutong] Xinxiang Med Univ, Affiliated Hosp 3, Dept Ophthalmol, Xinxiang 453000, Henan, Peoples R China.
C3 Xinxiang Medical University; Xinxiang Medical University
RP Hu, JX (通讯作者)，88 Hlth Rd, Xinxiang, Henan, Peoples R China.
EM hujx258@163.com
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chen HX, 2005, FOOD CHEM, V90, P17, DOI 10.1016/j.foodchem.2004.03.001
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Crespy V, 2004, J NUTR, V134, p3431S, DOI 10.1093/jn/134.12.3431S
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017
   FILISETTICOZZI TMCC, 1991, ANAL BIOCHEM, V197, P157, DOI 10.1016/0003-2697(91)90372-Z
   Han Q, 2011, CARBOHYD POLYM, V86, P797, DOI 10.1016/j.carbpol.2011.05.039
   Harman D, 2006, ANN NY ACAD SCI, V1067, P10, DOI 10.1196/annals.1354.003
   HONDA S, 1981, J CHROMATOGR, V226, P341, DOI 10.1016/S0378-4347(00)86068-5
   Hwang JW, 2012, EUR FOOD RES TECHNOL, V234, P431, DOI 10.1007/s00217-011-1648-9
   Jeung IC, 2016, INT J MED SCI, V13, P139, DOI 10.7150/ijms.13861
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   Monobe M, 2010, BIOSCI BIOTECH BIOCH, V74, P1306, DOI 10.1271/bbb.100087
   Nie SP, 2011, FOOD HYDROCOLLOID, V25, P144, DOI 10.1016/j.foodhyd.2010.04.010
   Qin H, 2014, TUMOR BIOL, V35, P1267, DOI 10.1007/s13277-013-1169-1
   Rattner A, 2008, J NEUROSCI, V28, P9880, DOI 10.1523/JNEUROSCI.2401-08.2008
   Sachidanandam K, 2005, CARDIOVASC DRUG REV, V23, P115
   Sampath C, 2016, PHYTOMEDICINE, V23, P200, DOI 10.1016/j.phymed.2015.12.013
   Sevag MG, 1938, J BIOL CHEM, V124, P0425
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Sun YX, 2008, BIORESOURCE TECHNOL, V99, P900, DOI 10.1016/j.biortech.2007.01.029
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Violi F, 2005, Arterioscler Thromb Vasc Biol, V25, pe37, DOI 10.1161/01.ATV.0000159889.32537.43
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Xin T, 2012, CARBOHYD POLYM, V90, P1127, DOI 10.1016/j.carbpol.2012.06.058
NR 32
TC 30
Z9 30
U1 5
U2 53
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD AUG
PY 2018
VL 115
BP 600
EP 607
DI 10.1016/j.ijbiomac.2018.04.011
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA GN0MK
UT WOS:000438662500068
PM 29627466
DA 2022-11-30
ER

PT J
AU Cao, X
   Xin, Z
   Li, SM
   Qi, Y
   Yuan, MX
   Zhu, XR
   Yang, JK
AF Cao, Xi
   Xin, Zhong
   Li, Shiming
   Qi, Yue
   Yuan, Mingxia
   Zhu, Xiaorong
   Yang, Jin-Kui
TI The Status of Maculopathy in Diabetes and Prediabetes Patients in a
   Population-Based Study Detected by Optical Coherence Tomography: The
   2011 Health Examination Survey in Beijing
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MACULAR EDEMA; RETINAL THICKNESS; RISK-FACTORS; RETINOPATHY; PREVALENCE;
   DEGENERATION; ASSOCIATION; PROGRESSION; MELLITUS; TYPE-2
AB Objective. The aim of the study was to investigate the prevalence and the risk factors of maculopathy detected by optical coherence tomography (OCT) in a Chinese population with diabetes or prediabetes. Methods. 8,155 people were randomly selected to participate in the 2011 annual Health Examination Survey in Beijing. A 75 g oral glucose tolerance test (OGTT) was tested in 3760 subjects with fasting plasma glucose (FPG) >= 5.6mmol/L. Of 3,760 subjects, 583 were also randomly selected to take OCT. Results. In this study population, 21 (3.95%) patients had maculopathy. Eight patients had diabetes macular edema (DME) and the prevalence was 6.72% in diabetes patients and 1.51% in all subjects. Eleven patients had age-related macular degeneration (AMD) and the prevalence was 3.36% in diabetes patients and 2.07% in all subjects. Logistic regression model confirmed that elevated HbA1c (p < 0.001) and systolic pressure (p < 0.05) made significant contributions to DME. Stepwise regression analysis revealed that HbA1c and blood creatinine were significantly independent influence factors for central subfield thickness (CST) (p = 0.01, p < 0.001). Conclusions. High prevalence of maculopathy was found in patients with diabetes in a Chinese population. Maculopathy poses a significant public health problem in China with rapid rising trend of diabetes.
C1 [Cao, Xi; Xin, Zhong; Yuan, Mingxia; Zhu, Xiaorong; Yang, Jin-Kui] Capital Med Univ, Beijing Tongren Hosp, Dept Endocrinol, Beijing 10730, Peoples R China.
   [Cao, Xi; Xin, Zhong; Yuan, Mingxia; Zhu, Xiaorong; Yang, Jin-Kui] Beijing Key Lab Diabet Res & Care, Beijing 100730, Peoples R China.
   [Li, Shiming; Qi, Yue] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing 100730, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Yang, JK (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Dept Endocrinol, Beijing 10730, Peoples R China.; Yang, JK (通讯作者)，Beijing Key Lab Diabet Res & Care, Beijing 100730, Peoples R China.
EM jkyang@ccmu.edu.cn
OI Yang, Jin-Kui/0000-0002-5430-2149
FU National Natural Science Foundation of China [81070644, 81561128015];
   Capital Medical Development Foundation [2009-Z-SQ03]; Expert Promotion
   Program of Beijing Health Systems [2015-3-017]
FX This work was supported by the National Natural Science Foundation of
   China (81070644, 81561128015), the Capital Medical Development
   Foundation (2009-Z-SQ03) to Jin-Kui Yang, and the Expert Promotion
   Program of Beijing Health Systems (2015-3-017) to Zhong Xin.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Asensio-Sánchez V.M., 2008, Arch Soc Esp Oftalmol, V83, P173
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown JC, 2004, ARCH OPHTHALMOL-CHIC, V122, P330, DOI 10.1001/archopht.122.3.330
   Browning DJ, 2004, OPHTHALMOLOGY, V111, P712, DOI 10.1016/j.ophtha.2003.06.028
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Fong DS, 1999, AM J OPHTHALMOL, V127, P137, DOI 10.1016/S0002-9394(98)00309-2
   Guan K, 2006, DIABETES, V55, P813, DOI 10.2337/diabetes.55.03.06.db05-0937
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   Lang GE, 2012, OPHTHALMOLOGICA, V227, P21, DOI 10.1159/000337156
   Leske MC, 1999, OPHTHALMOLOGY, V106, P1893, DOI 10.1016/S0161-6420(99)90398-6
   Maalej W. C. Afef, 2012, J CLIN EXPT OPHTHALM, VS2, P1
   Mackenzie S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014811
   Minassian DC, 2012, BRIT J OPHTHALMOL, V96, P345, DOI 10.1136/bjo.2011.204040
   Peyman M, 2012, J DIABETES COMPLICAT, V26, P210, DOI 10.1016/j.jdiacomp.2012.03.019
   Raman R, 2010, OPHTHALMOLOGY, V117, P766, DOI 10.1016/j.ophtha.2009.09.005
   Rema M, 1996, DIABETES RES CLIN PR, V34, P29, DOI 10.1016/S0168-8227(96)01327-7
   Sanchez-Tocino H, 2002, INVEST OPHTH VIS SCI, V43, P1588
   Sasaki M, 2014, INVEST OPHTH VIS SCI, V55, P1749, DOI 10.1167/iovs.13-13035
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Wang FH, 2009, OPHTHALMOLOGY, V116, P461, DOI 10.1016/j.ophtha.2008.10.003
   Wang N, 2008, OPHTHALMOLOGICA, V222, P32, DOI 10.1159/000109276
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Xin Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040610
   Yang CS, 2001, ACTA OPHTHALMOL SCAN, V79, P266, DOI 10.1034/j.1600-0420.2001.790311.x
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yuan Ming-Xia, 2012, Diabetes Care, V35, pe61, DOI 10.2337/dc12-0600
   Zander E, 2000, BRIT J OPHTHALMOL, V84, P871, DOI 10.1136/bjo.84.8.871
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 31
TC 2
Z9 1
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2017
VL 2017
AR 6513076
DI 10.1155/2017/6513076
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA FB0XR
UT WOS:000405868800001
PM 28808662
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wagner, EK
   Raychaudhuri, S
   Villalonga, MB
   Java, A
   Triebwasser, MP
   Daly, MJ
   Atkinson, JP
   Seddon, JM
AF Wagner, Erin K.
   Raychaudhuri, Soumya
   Villalonga, Mercedes B.
   Java, Anuja
   Triebwasser, Michael P.
   Daly, Mark J.
   Atkinson, John P.
   Seddon, Johanna M.
TI Mapping rare, deleterious mutations in Factor H: Association with early
   onset, drusen burden, and lower antigenic levels in familial AMD
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; AGE-RELATED MACULOPATHY;
   MACULAR DEGENERATION; HIGH-RISK; SUSCEPTIBILITY LOCI; GENETIC-VARIANTS;
   C3; POLYMORPHISM; CFH
AB The genetic architecture of age-related macular degeneration (AMD) involves numerous genetic variants, both common and rare, in the coding region of complement factor H (CFH). While these variants explain high disease burden in some families, they fail to explain the pathology in all. We selected families whose AMD was unexplained by known variants and performed whole exome sequencing to probe for other rare, highly penetrant variants. We identified four rare loss-of-function variants in CFH associated with AMD. Missense variant CFH 1: 196646753 (C192F) segregated perfectly within a family characterized by advanced AMD and drusen temporal to the macula. Two families, each comprising a pair of affected siblings with extensive extramacular drusen, carried essential splice site variant CFH 1:196648924 (IVS6+1G>A) or missense variant rs139360826 (R175P). In a fourth family, missense variant rs121913058 (R127H) was associated with AMD. Most carriers had early onset bilateral advanced AMD and extramacular drusen. Carriers tended to have low serum Factor H levels, especially carriers of the splice variant. One missense variant (R127H) has been previously shown not to be secreted. The two other missense variants were produced recombinantly: compared to wild type, one (R175P) had no functional activity and the other (C192F) had decreased secretion.
C1 [Wagner, Erin K.; Villalonga, Mercedes B.; Seddon, Johanna M.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Wagner, Erin K.; Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Raychaudhuri, Soumya; Daly, Mark J.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
   [Raychaudhuri, Soumya; Daly, Mark J.] Partners HealthCare Ctr Personalized Genet Med, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester M13 9PL, Lancs, England.
   [Java, Anuja] Washington Univ, Sch Med, Dept Med, Div Nephrol, St Louis, MO 63110 USA.
   [Triebwasser, Michael P.; Atkinson, John P.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts University; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute; Partners
   Healthcare System; Harvard University; Brigham & Women's Hospital;
   Harvard University; Brigham & Women's Hospital; University of
   Manchester; Washington University (WUSTL); Washington University
   (WUSTL); Harvard University; Massachusetts General Hospital; Tufts
   University
RP Seddon, JM (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.; Seddon, JM (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.; Seddon, JM (通讯作者)，Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017
OI Daly, Mark J/0000-0002-0949-8752
FU NIH [R01-EY11309, 1R01AR063759-01A1, 5U01GM092691-04, 1U01HG007690-01,
   F30HL103072, R01-AI041592, U54 HL112303]; Doris Duke Clinical Scientist
   Development Award; NIH-Arthritis and Musculoskeletal and Skin Diseases
   [P30 AR48335]; Massachusetts Lions Eye Research Fund, Inc.; Research to
   Prevent Blindness Challenge Grant to the New England Eye Center,
   Department of Ophthalmology, Tufts University School of Medicine;
   Macular Degeneration Research Fund of the Ophthalmic Epidemiology and
   Genetics Service, New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine; F30 Ruth L. Kirschstein National Research
   Service Award (National Heart, Lung and Blood Institute); NATIONAL EYE
   INSTITUTE [R01EY011309] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [F30HL103072, U54HL112303] Funding Source: NIH
   RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG007690] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASES [R01AI041592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048335,
   R01AR063759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [U01GM092691] Funding Source: NIH RePORTER
FX This research was supported in part by NIH grants R01-EY11309 (J.M.S.),
   1R01AR063759-01A1 (S.R.), 5U01GM092691-04 (S.R.), 1U01HG007690-01
   (S.R.), F30HL103072 (M.T.), R01-AI041592 (J.P.A.), U54 HL112303
   (J.P.A.); the Doris Duke Clinical Scientist Development Award (S.R.);
   the Rheumatic Disease Core Center supported by NIH-Arthritis and
   Musculoskeletal and Skin Diseases P30 AR48335 (J.P.A.), Massachusetts
   Lions Eye Research Fund, Inc. (J.M.S.); Research to Prevent Blindness
   Challenge Grant to the New England Eye Center, Department of
   Ophthalmology, Tufts University School of Medicine; and the Macular
   Degeneration Research Fund of the Ophthalmic Epidemiology and Genetics
   Service, New England Eye Center, Tufts Medical Center, Tufts University
   School of Medicine. M.T. is a F30 Ruth L. Kirschstein National Research
   Service Award recipient (National Heart, Lung and Blood Institute). The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Albuquerque JAT, 2012, J IMMUNOL, V189, P3242, DOI 10.4049/jimmunol.1201418
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281
   Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shihab HA, 2014, HUM GENOMICS, V8, DOI 10.1186/1479-7364-8-11
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sobrin L, 2010, EUR J HUM GENET, V18, P496, DOI 10.1038/ejhg.2009.185
   Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 49
TC 33
Z9 33
U1 1
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 30
PY 2016
VL 6
AR 31531
DI 10.1038/srep31531
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DU4BR
UT WOS:000382157300001
PM 27572114
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sinha, D
   Valapala, M
   Shang, P
   Hose, S
   Grebe, R
   Lutty, GA
   Zigler, JS
   Kaarniranta, K
   Handa, JT
AF Sinha, Debasish
   Valapala, Mallika
   Shang, Peng
   Hose, Stacey
   Grebe, Rhonda
   Lutty, Gerard A.
   Zigler, J. Samuel, Jr.
   Kaarniranta, Kai
   Handa, James T.
TI Lysosomes: Regulators of autophagy in the retinal pigmented epithelium
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE AMD; Autophagy; beta A3/A1-crystallin; Lysosome; mTORC1; Oxidative
   stress; RPE; V-ATPase
ID FACTOR-H POLYMORPHISM; OXIDATIVE STRESS; NLRP3 INFLAMMASOME; MACULAR
   DEGENERATION; NALP3 INFLAMMASOME; AMINO-ACIDS; RPE CELLS; MTOR;
   DEGRADATION; ACTIVATION
AB The retinal pigmented epithelium (RPE) is critically important to retinal homeostasis, in part due to its very active processes of phagocytosis and autophagy. Both of these processes depend upon the normal functioning of lysosomes, organelles which must fuse with (auto)phagosomes to deliver the hydrolases that effect degradation of cargo. It has become clear that signaling through mTOR complex 1 (mTORC1), is very important in the regulation of lysosomal function. This signaling pathway is becoming a target for therapeutic intervention in diseases, including age-related macular degeneration (AMD), where lysosomal function is defective. In addition, our laboratory has been studying animal models in which the gene (Cryba1) for beta A3/A1-crystallin is deficient. These animals exhibit impaired lysosomal clearance in the RPE and pathological signs that are similar to some of those seen in AMD patients. The data demonstrate that beta A3/A1-crystallin localizes to lysosomes in the RPE and that it is a binding partner of V-ATPase, the proton pump that acidifies the lysosomal lumen. This suggests that beta A3/A1-crystallin may also be a potential target for therapeutic intervention in AMD. In this review, we focus on effector molecules that impact the lysosomal autophagic pathway in RPE cells. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Sinha, Debasish; Valapala, Mallika; Shang, Peng; Hose, Stacey; Grebe, Rhonda; Lutty, Gerard A.; Zigler, J. Samuel, Jr.; Handa, James T.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21287 USA.
   [Shang, Peng] Tongji Univ, Sch Med, Dept Ophthalmol, Shanghai Hosp 10, Shanghai 200092, Peoples R China.
   [Shang, Peng] Tongji Univ, Sch Med, Tongji Eye Inst, Shanghai 200092, Peoples R China.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, Kuopio, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Kuopio Univ Hosp, Kuopio, Finland.
C3 Johns Hopkins University; Johns Hopkins Medicine; Tongji University;
   Tongji University; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland
RP Sinha, D (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21287 USA.
EM Debasish@jhmi.edu
OI /0000-0002-3780-5641; Kaarniranta, Kai/0000-0003-2600-8679
FU BrightFocus Foundation; Research to Prevent Blindness; National
   Institutes of Health [EY019037-S, EY019904, EY14005, EY01765]; IPA from
   National Eye Institute; RPB Senior Scientist Award; Thome Foundation;
   NATIONAL EYE INSTITUTE [R01EY014005, R01EY019904, P30EY001765,
   R01EY019037, R01EY016151] Funding Source: NIH RePORTER
FX We would like to thank all members of Sinha, Kaarniranta, Handa and
   Lutty laboratories. DS is a recipient of the Carolyn K. McGillvray
   Memorial Award for Macular Degeneration Research from BrightFocus
   Foundation and the Sybil B. Harrington Special Scholar Award for Macular
   Degeneration from Research to Prevent Blindness. Dr. Handa is the Robert
   Bond Welch Professor. The authors would like to acknowledge funding
   support from National Institutes of Health: EY019037-S (DS), EY019904
   (JTH) EY14005 (JTH), EY01765 (Wilmer Imaging Core); IPA from National
   Eye Institute (DS); RPB Senior Scientist Award (JTH); Thome Foundation
   (JTH); Research to Prevent Blindness (unrestricted grant to The Wilmer
   Eye Institute). We apologize to our colleagues for not being able to
   cite important contributions due to space constraints.
CR Bar-Peled L, 2014, TRENDS CELL BIOL, V24, P400, DOI 10.1016/j.tcb.2014.03.003
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Bergamini E, 2004, INT J BIOCHEM CELL B, V36, P2392, DOI 10.1016/j.biocel.2004.05.007
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Betz C, 2013, J CELL BIOL, V203, P563, DOI 10.1083/jcb.201306041
   Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   BOK D, 1993, J CELL SCI, P189
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226
   Cuervo AM, 2000, J BIOL CHEM, V275, P31505, DOI 10.1074/jbc.M002102200
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Efeyan A, 2013, NATURE, V493, P679, DOI 10.1038/nature11745
   Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Guha S, 2014, EXP EYE RES, V126, P68, DOI 10.1016/j.exer.2014.05.013
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hirotsu Y, 2012, NUCLEIC ACIDS RES, V40, P10228, DOI 10.1093/nar/gks827
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hyttinen JMT, 2014, AGEING RES REV, V18, P16, DOI 10.1016/j.arr.2014.07.002
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kapphahn RJ, 2007, EXP EYE RES, V84, P646, DOI 10.1016/j.exer.2006.12.002
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kaushik S, 2012, TRENDS CELL BIOL, V22, P407, DOI 10.1016/j.tcb.2012.05.006
   Keller JN, 2004, INT J BIOCHEM CELL B, V36, P2376, DOI 10.1016/j.biocel.2004.05.003
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kirkin V, 2009, AUTOPHAGY, V5, P732, DOI 10.4161/auto.5.5.8566
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2010, EUR J HUM GENET, V18, P634, DOI 10.1038/ejhg.2009.243
   Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Lamb LE, 2004, PHOTOCHEM PHOTOBIOL, V79, P127, DOI 10.1562/0031-8655(2004)079<0127:AACOOL>2.0.CO;2
   Lamming DW, 2013, J CLIN INVEST, V123, P980, DOI 10.1172/JCI64099
   Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Larsen KB, 2010, AUTOPHAGY, V6, P784, DOI 10.4161/auto.6.6.12510
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Puertollano Rosa, 2014, F1000Prime Rep, V6, P52, DOI 10.12703/P6-52
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   Rubinsztein DC, 2012, CURR BIOL, V22, pR29, DOI 10.1016/j.cub.2011.11.034
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saftig P., 2006, PHYSL LYSOSOME
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Shen HM, 2014, TRENDS BIOCHEM SCI, V39, P61, DOI 10.1016/j.tibs.2013.12.001
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sinha D, 2008, MOL CELL NEUROSCI, V37, P85, DOI 10.1016/j.mcn.2007.08.016
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun-Wada GH, 2003, CELL STRUCT FUNCT, V28, P455, DOI 10.1247/csf.28.455
   Taguchi K, 2012, P NATL ACAD SCI USA, V109, P13561, DOI 10.1073/pnas.1121572109
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Toei M, 2010, BIOCHEMISTRY-US, V49, P4715, DOI 10.1021/bi100397s
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Vnri J., 2013, PLOS ONE, V8
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev-physiol-021014-071649
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Yu B, 2014, INVEST OPHTH VIS SCI, V55, P8638, DOI 10.1167/iovs.14-14758
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zigler JS, 2011, J CELL SCI, V124, P523, DOI 10.1242/jcs.078790
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 97
TC 50
Z9 51
U1 1
U2 27
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2016
VL 144
SI SI
BP 46
EP 53
DI 10.1016/j.exer.2015.08.018
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG9BI
UT WOS:000372377400007
PM 26321509
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zur, D
   Loewenstein, A
   Barak, A
AF Zur, Dinah
   Loewenstein, Anat
   Barak, Adiel
TI One-Year Results From Clinical Practice of Epimacular Strontium-90
   Brachytherapy for the Treatment of Subfoveal Choroidal
   Neovascularization Secondary to AMD
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; VISUAL-ACUITY; RADIATION-THERAPY; BEAM
   IRRADIATION; 12-MONTH SAFETY; TRIAL; BEVACIZUMAB; RANIBIZUMAB;
   VITRECTOMY; PREVALENCE
AB BACKGROUND AND OBJECTIVE: To evaluate clinical feasibility, safety, and efficacy of epiretinal strontium-90 brachytherapy in subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) in eyes unresponsive to repeated anti-VEGF injections.
   PATIENTS AND METHODS: A retrospective, single-center study on patients treated with strontium-90 brachytherapy for CNV secondary to neovascular AMD. Patients underwent pars plana vitrectomy with a single 24 Gy dose brachytherapy. They were re-treated with anti-VEGF injections on an as-needed basis if subretinal or intraretinal fluid was detected on optical coherence tomography imaging.
   RESULTS: Twenty-two patients were treated, and 20 completed 12 months of follow-up. Ten patients maintained stable vision, eight gained vision, and two lost more than three Snellen lines. The mean best corrected visual acuity change from baseline was -8 +/- 5.7 letters. A mean of 5.5 +/- 4.4 anti-VEGF injections were administered throughout 12 months.
   CONCLUSION: Epimacular brachytherapy is feasible in clinical practice. While some patients benefit from the treatment and need significantly fewer as-needed injections, others appear not to react to irradiation treatment after 1 year of follow-up. Larger numbers of patients are needed to evaluate therapeutic efficacy and to determine which patients can benefit from combined radiation and anti-VEGF therapy.
C1 [Zur, Dinah; Loewenstein, Anat; Barak, Adiel] Tel Aviv Univ, Tel Aviv Med Ctr, Dept Ophthalmol, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Barak, A (通讯作者)，Tel Aviv Univ, Tel Aviv Med Ctr, Dept Ophthalmol, IL-69978 Tel Aviv, Israel.
EM adielbarak@gmail.com
RI Zur, Dinah/AAX-7620-2020
OI Zur, Dinah/0000-0003-1147-444X
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Barak A, 2005, BRIT J RADIOL, V78, P827, DOI 10.1259/bjr/17631422
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Flaxel CJ, 2000, EYE, V14, P155, DOI 10.1038/eye.2000.46
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gunduz K, 1999, ARCH OPHTHALMOL-CHIC, V117, P609
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Jackson TL, OPHTHALMOLOGY, V120, P1893
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Schramm K, 2014, ACTA OPHTHALMOL, V92, P465, DOI 10.1111/aos.12326
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
NR 23
TC 2
Z9 3
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAR
PY 2015
VL 46
IS 3
BP 338
EP 343
DI 10.3928/23258160-20150323-07
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6UH
UT WOS:000359291400008
PM 25856820
DA 2022-11-30
ER

PT J
AU Yang, H
   Afshari, NA
AF Yang, Hongseok
   Afshari, Natalie A.
TI The yellow intraocular lens and the natural ageing lens
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE blue light filtering intraocular lens; cataract; phacoemulsification;
   ultraviolet blocking intraocular lens; yellow tinted intraocular lens
ID BLUE-LIGHT; VISIBLE-LIGHT; PHACOEMULSIFICATION SURGERY; PHOTOCHEMICAL
   DAMAGE; QUALITY; SLEEP; PHOTORECEPTION; ILLUMINATION; IMPLANTS; RETINA
AB Purpose of reviewThe purpose of this study is to review and evaluate the advantages and disadvantages of blue light (400-480nm) filtering intraocular lenses (IOLs) when compared with the ultraviolet (UV)-blocking IOLs.Recent findingsTheories that blue light could be related to the pathogenesis of age-related macular degeneration (AMD) have led to the use of yellow tinted IOLs in cataract surgery to filter short wavelength light. In spite of the potential benefits, some concerns have been raised. The potential advantages of the blue light filtering IOLs are that they could better mimic the conditions of phakia and therefore be more protective for the retina in decreasing the incidence of AMD. However, the potential disadvantages are that blue light filtering could negatively affect scotopic vision and circadian rhythms in older patients.SummaryThese advantages and disadvantages of blue light filtering IOLs have not been proven clinically and thus many questions remain. Studies have shown that each type of IOL may have its own benefits and the type of IOL should be picked on the basis of patients' specific situations. In cataract surgery, considerations such as preexisting AMD, night vision problems or sleep problems may be considered with the choice of IOL.
C1 [Yang, Hongseok] Ajou Univ, Sch Med, Dept Ophthalmol, Suwon 441749, South Korea.
   [Afshari, Natalie A.] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
C3 Ajou University; University of California System; University of
   California San Diego
RP Afshari, NA (通讯作者)，Shiley Eye Ctr, 9415 Campus Point Dr 0946, La Jolla, CA 92093 USA.
EM naafshari@ucsd.edu
CR Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Brondsted AE, 2013, ACTA OPHTHALMOL, V91, P52, DOI 10.1111/j.1755-3768.2011.02291.x
   Cuthbertson FM, 2009, J CATARACT REFR SURG, V35, P1281, DOI 10.1016/j.jcrs.2009.04.017
   Espindle D, 2005, J CATARACT REFR SURG, V31, P1952, DOI 10.1016/j.jcrs.2005.03.060
   ESPIRITU RC, 1994, BIOL PSYCHIAT, V35, P403, DOI 10.1016/0006-3223(94)90007-8
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hammond BR, 2009, AM J OPHTHALMOL, V148, P272, DOI 10.1016/j.ajo.2009.03.014
   Hankins MW, 2008, TRENDS NEUROSCI, V31, P27, DOI 10.1016/j.tins.2007.11.002
   Haynes PL, 2005, CHRONOBIOL INT, V22, P279, DOI 10.1081/CBI-200053546
   Henderson BA, 2010, SURV OPHTHALMOL, V55, P284, DOI 10.1016/j.survophthal.2009.07.007
   Hood B, 2004, AGE AGEING, V33, P159, DOI 10.1093/ageing/afh051
   Hunter JJ, 2012, PROG RETIN EYE RES, V31, P28, DOI 10.1016/j.preteyeres.2011.11.001
   Landers JA, 2009, J CATARACT REFR SURG, V35, P83, DOI 10.1016/j.jcrs.2008.10.015
   Lee RMH, 2012, EYE, V26, P1400, DOI 10.1038/eye.2012.177
   Lee RMH, 2012, ACTA OPHTHALMOL, V90, pe151, DOI 10.1111/j.1755-3768.2011.02166.x
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mainster MA, 2011, OPHTHALMOLOGY, V118, P1, DOI 10.1016/j.ophtha.2010.11.016
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Mishima K, 2001, J CLIN ENDOCR METAB, V86, P129, DOI 10.1210/jc.86.1.129
   Symes RJ, 2012, EYE, V26, P1397, DOI 10.1038/eye.2012.178
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Turner PL, 2008, BRIT J OPHTHALMOL, V92, P1439, DOI 10.1136/bjo.2008.141747
   Turner PL, 2010, SLEEP MED REV, V14, P269, DOI 10.1016/j.smrv.2009.11.002
   van Norren D, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.117903
   van Norren D, 2011, PHOTOCHEM PHOTOBIOL, V87, P747, DOI 10.1111/j.1751-1097.2011.00921.x
   Van Someren EJW, 2000, EXP GERONTOL, V35, P1229, DOI 10.1016/S0531-5565(00)00191-1
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Zhu X, 2012, PLOS ONE, V7
NR 30
TC 14
Z9 16
U1 1
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD JAN
PY 2014
VL 25
IS 1
BP 40
EP 43
DI 10.1097/ICU.0000000000000020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 266BF
UT WOS:000327996600007
PM 24270599
DA 2022-11-30
ER

PT J
AU Song, D
   Dunaief, JL
AF Song, Delu
   Dunaief, Joshua L.
TI Retinal iron homeostasis in health and disease
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Review
DE iron; retina; age-related macular degeneration (AMD); chelator;
   oxidative stress; ferroportin; ceruloplasmin; hephaestin
ID GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED FORM; CHELATOR DEFERIPRONE
   PROTECTS; HANDLING PROTEINS FERRITIN; TRANSFERRIN RECEPTOR;
   PHOTORECEPTOR DEGENERATION; MACULAR DEGENERATION; INCREASED EXPRESSION;
   OXIDATIVE STRESS; PEPTIDE HEPCIDIN; AQUEOUS-HUMOR
AB Iron is essential for life, but excess iron can be toxic. As a potent free radical creator, iron generates hydroxyl radicals leading to significant oxidative stress. Since iron is not excreted from the body, it accumulates with age in tissues, including the retina, predisposing to age-related oxidative insult. Both hereditary and acquired retinal diseases are associated with increased iron levels. For example, retinal degenerations have been found in hereditary iron overload disorders, like aceruloplasminemia, Friedreich's ataxia, and pantothenate kinase-associated neurodegeneration. Similarly, mice with targeted mutation of the iron exporter ceruloplasmin and its homolog hephaestin showed age-related retinal iron accumulation and retinal degeneration with features resembling human age-related macular degeneration (AMD). Post mortem AMD eyes have increased levels of iron in retina compared to age-matched healthy donors. Iron accumulation in AMD is likely to result, in part, from inflammation, hypoxia, and oxidative stress, all of which can cause iron dysregulation. Fortunately, it has been demonstrated by in vitro and in vivo studies that iron in the retinal pigment epithelium (RPE) and retina is chelatable. Iron chelation protects photoreceptors and retinal pigment epithelial cells (RPE) in a variety of mouse models. This has therapeutic potential for diminishing iron-induced oxidative damage to prevent or treat AMD.
C1 [Song, Delu; Dunaief, Joshua L.] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Dunaief, JL (通讯作者)，Univ Penn, FM Kirby Ctr Mol Ophthalmol, Scheie Eye Inst, Perelman Sch Med,Stellar Chance Labs 305B, 422 Curie Blvd, Philadelphia, PA 19104 USA.
EM jdunaief@mail.med.upenn.edu
FU Research to Prevent Blindness; NIH [EY015240]; FM Kirby Foundation;
   Pennsylvania Lions Eye Research Foundation; NATIONAL EYE INSTITUTE
   [R01EY015240] Funding Source: NIH RePORTER
FX We would like to thank Xiaomin (Sharon) Ma at University of the Arts for
   her assistance in preparing the schematic diagram. For funding, we thank
   Research to Prevent Blindness, the NIH (EY015240), the FM Kirby
   Foundation, and the Pennsylvania Lions Eye Research Foundation.
CR Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x
   BRILL PW, 1991, AM J ROENTGENOL, V156, P561, DOI 10.2214/ajr.156.3.1899759
   Burdo JR, 2001, J NEUROSCI RES, V66, P1198, DOI 10.1002/jnr.1256
   Burdo JR, 1999, NEUROSCIENCE, V93, P1189, DOI 10.1016/S0306-4522(99)00207-9
   Cheah JH, 2006, NEURON, V51, P431, DOI 10.1016/j.neuron.2006.07.011
   Chen HJ, 2010, J NUTR, V140, P1728, DOI 10.3945/jn.109.117531
   Chen L, 2003, MOL VIS, V9, P151
   Chen Y, 2013, J NEUROSCI, V33, P3582, DOI 10.1523/JNEUROSCI.1497-12.2013
   Chowers I, 2006, INVEST OPHTH VIS SCI, V47, P2135, DOI 10.1167/iovs.05-1135
   CIBIS PA, 1959, ARCH OPHTHALMOL-CHIC, V62, P180
   DECLERCQ SS, 1977, ARCH OPHTHALMOL-CHIC, V95, P1051, DOI 10.1001/archopht.1977.04450060138014
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   DEVIRGILIIS S, 1988, J PEDIATR-US, V113, P661
   Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   DRAYER B, 1987, AM J ROENTGENOL, V149, P357, DOI 10.2214/ajr.149.2.357
   Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014
   Dunaief J. L., 2012, ROLE IRON RETINUL DI, P259
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Ebrahimi KH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040287
   Farkas RH, 2004, INVEST OPHTH VIS SCI, V45, P1410, DOI 10.1167/iovs.03-0872
   Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472
   Fonseca AM, 2003, FREE RADICAL BIO MED, V35, P1404, DOI 10.1016/j.freeradbiomed.2003.08.011
   Ganz T, 2009, SEMIN HEMATOL, V46, P387, DOI 10.1053/j.seminhematol.2009.06.001
   Gerhardinger C, 2005, INVEST OPHTH VIS SCI, V46, P349, DOI 10.1167/iovs.04-0860
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gnana-Prakasam JP, 2008, BIOCHEM J, V411, P79, DOI 10.1042/BJ20071377
   Gnana-Prakasam JP, 2012, BIOCHEM J, V441, P599, DOI 10.1042/BJ20111148
   Gnana-Prakasam JP, 2009, BIOCHEM J, V424, P243, DOI 10.1042/BJ20090424
   Gnana-Prakasam JP, 2009, BIOCHEM J, V419, P533, DOI 10.1042/BJ20082240
   Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   Haimovici R, 2002, OPHTHALMOLOGY, V109, P164, DOI 10.1016/S0161-6420(01)00947-2
   HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001
   Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812
   HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539
   HAWKINS KN, 1986, CURR EYE RES, V5, P655, DOI 10.3109/02713688609015133
   Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175
   Hunt RC, 1996, J CELL PHYSIOL, V168, P71, DOI 10.1002/(SICI)1097-4652(199607)168:1<71::AID-JCP9>3.0.CO;2-5
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Junemann AGM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056734
   Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Knave B, 1969, ACTA OPHTHALMOL    S, V100, P4
   Knutson MD, 2005, P NATL ACAD SCI USA, V102, P1324, DOI 10.1073/pnas.0409409102
   Koeppen AH, 2001, PEDIATR NEUROL, V25, P148, DOI 10.1016/S0887-8994(01)00269-7
   Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7
   Kuo YM, 2005, HUM MOL GENET, V14, P49, DOI 10.1093/hmg/ddi005
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   LAICINE EM, 1994, EXP EYE RES, V59, P441, DOI 10.1006/exer.1994.1129
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Levi S, 2001, J BIOL CHEM, V276, P24437, DOI 10.1074/jbc.C100141200
   LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325
   Levin LA, 1998, INVEST OPHTH VIS SCI, V39, P157
   LEVINE SM, 1990, J NEUROSCI RES, V26, P508, DOI 10.1002/jnr.490260415
   Li DY, 2004, EXP EYE RES, V78, P301, DOI 10.1016/j.exer.2003.10.016
   Liu ZD, 2002, MED RES REV, V22, P26, DOI 10.1002/med.1027
   LUCKENBACH MW, 1983, AM J OPHTHALMOL, V95, P369, DOI 10.1016/S0002-9394(14)78308-4
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Martin PM, 2006, INVEST OPHTH VIS SCI, V47, P4238, DOI 10.1167/iovs.06-0026
   MAXTON DG, 1986, CLIN SCI, V71, P71, DOI 10.1042/cs0710071
   MCGAHAN MC, 1986, CURR EYE RES, V5, P641, DOI 10.3109/02713688609015131
   McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6
   Miyahara T, 2003, INVEST OPHTH VIS SCI, V44, P4347, DOI 10.1167/iovs.02-1032
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Morgan E. H., 1994, IRON METABOLISM HLTH, P63
   MORRIS CM, 1992, ACTA ANAT, V144, P235
   Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   Nemeth E, 2006, ANNU REV NUTR, V26, P323, DOI 10.1146/annurev.nutr.26.061505.111303
   NEWELL FW, 1979, AM J OPHTHALMOL, V88, P467, DOI 10.1016/0002-9394(79)90648-2
   Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686
   Obolensky A, 2011, FREE RADICAL BIO MED, V51, P1482, DOI 10.1016/j.freeradbiomed.2011.07.014
   OSAKI S, 1966, J BIOL CHEM, V241, P5053
   OSAKI S, 1966, J BIOL CHEM, V241, P2746
   Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200
   Patel BN, 2000, J BIOL CHEM, V275, P4305, DOI 10.1074/jbc.275.6.4305
   Patel BN, 1997, J BIOL CHEM, V272, P20185, DOI 10.1074/jbc.272.32.20185
   Patel BN, 2002, J NEUROSCI, V22, P6578
   Picard E, 2010, MOL VIS, V16, P2612
   Pietrangelo A, 2005, SEMIN LIVER DIS, V25, P450, DOI 10.1055/s-2005-923316
   Pietrangelo A, 2004, BLOOD CELL MOL DIS, V32, P131, DOI 10.1016/j.bcmd.2003.08.003
   Pietrangelo A, 2006, BBA-MOL CELL RES, V1763, P700, DOI 10.1016/j.bbamcr.2006.05.013
   Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200
   Porter N, 2007, ARCH OPHTHALMOL-CHIC, V125, P273, DOI 10.1001/archopht.125.2.273
   Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919
   Richardson DR, 2004, ANN NY ACAD SCI, V1012, P326, DOI 10.1196/annals.1306.026
   Rodrigues MLP, 1998, CURR EYE RES, V17, P694, DOI 10.1080/02713689808951245
   Rogers BS, 2007, INVEST OPHTH VIS SCI, V48, P438, DOI 10.1167/iovs.06-0528
   Roncagliolo M, 1998, AM J CLIN NUTR, V68, P683, DOI 10.1093/ajcn/68.3.683
   ROTH AM, 1972, ARCH OPHTHALMOL-CHIC, V87, P507
   Rouault Tracey A, 2006, Semin Pediatr Neurol, V13, P142, DOI 10.1016/j.spen.2006.08.002
   Sarkar J, 2003, J BIOL CHEM, V278, P44018, DOI 10.1074/jbc.M304926200
   SHICHI H, 1969, EXP EYE RES, V8, P60, DOI 10.1016/S0014-4835(69)80081-3
   SIPE DM, 1991, J BIOL CHEM, V266, P8002
   Smith MA, 1997, P NATL ACAD SCI USA, V94, P9866, DOI 10.1073/pnas.94.18.9866
   SNEED SR, 1988, ARCH OPHTHALMOL-CHIC, V106, P997
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   TALAMO JH, 1985, OPHTHALMOLOGY, V92, P1675
   TENENBEIN M, 1992, LANCET, V339, P699, DOI 10.1016/0140-6736(92)90598-W
   TRIPATHI RC, 1990, EXP EYE RES, V50, P109, DOI 10.1016/0014-4835(90)90016-N
   Ugarte M, 2012, METALLOMICS, V4, P1245, DOI 10.1039/c2mt20157g
   Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979
   Wang D, 2010, IUBMB LIFE, V62, P629, DOI 10.1002/iub.363
   WIGGLESWORTH JM, 1988, BRAIN IRON NEUROCHEM, P25
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Yamaguchi K, 1998, OPHTHALMOLOGICA, V212, P11, DOI 10.1159/000027251
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Yefimova MG, 2000, INVEST OPHTH VIS SCI, V41, P2343
   Youssef TA, 2002, INVEST OPHTH VIS SCI, V43, pU845
   YU TC, 1988, JPN J OPHTHALMOL, V32, P268
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zheng HL, 2005, BIOORGAN MED CHEM, V13, P773, DOI 10.1016/j.bmc.2004.10.037
   Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572
NR 128
TC 76
Z9 76
U1 1
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD JUN 28
PY 2013
VL 5
AR 24
DI 10.3389/fnagi.2013.00024
PG 13
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 204PV
UT WOS:000323381000001
PM 23825457
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kur, J
   Newman, EA
   Chan-Ling, T
AF Kur, Joanna
   Newman, Eric A.
   Chan-Ling, Tailoi
TI Cellular and physiological mechanisms underlying blood flow regulation
   in the retina and choroid in health and disease
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Blood flow; Retina; Choroid; Regulation; Functional hyperemia;
   Autoregulation; Pathology; Diabetic retinopathy; Microvasculature;
   Review
ID OPTIC-NERVE HEAD; PRIMARY OPEN-ANGLE; DIFFUSE LUMINANCE FLICKER;
   LASER-DOPPLER FLOWMETRY; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR VEGF; K-ATP
   CHANNELS; RADIAL PERIPAPILLARY CAPILLARIES; VOLTAGE-DEPENDENT CALCIUM;
   NORMAL-TENSION GLAUCOMA
AB We review the cellular and physiological mechanisms responsible for the regulation of blood flow in the retina and choroid in health and disease. Due to the intrinsic light sensitivity of the retina and the direct visual accessibility of fundus blood vessels, the eye offers unique opportunities for the non-invasive investigation of mechanisms of blood flow regulation. The ability of the retinal vasculature to regulate its blood flow is contrasted with the far more restricted ability of the choroidal circulation to regulate its blood flow by virtue of the absence of glial cells, the markedly reduced pericyte ensheathment of the choroidal vasculature, and the lack of intermediate filaments in choroidal pericytes. We review the cellular and molecular components of the neurovascular unit in the retina and choroid, techniques for monitoring retinal and choroidal blood flow, responses of the retinal and choroidal circulation to light stimulation, the role of capillaries, astrocytes and pericytes in regulating blood flow, putative signaling mechanisms mediating neurovascular coupling in the retina, and changes that occur in the retinal and choroidal circulation during diabetic retinopathy, age-related macular degeneration, glaucoma, and Alzheimer's disease. We close by discussing issues that remain to be explored. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.
C1 [Kur, Joanna; Newman, Eric A.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA.
   [Chan-Ling, Tailoi] Univ Sydney, Dept Anat, Sch Med Sci, Sydney, NSW 2006, Australia.
   [Chan-Ling, Tailoi] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Sydney; University of Sydney
RP Newman, EA (通讯作者)，Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA.
EM ean@umn.edu; tailoi@anatomy.usyd.edu.au
RI Chan-Ling, Tailoi/X-2718-2019; Chan-Ling, Tailoi/A-2177-2008
OI Chan-Ling, Tailoi/0000-0002-8225-3671; Kur, Joanna/0000-0003-0664-1856
FU Fondation Leducq of France; National Institutes of Health of the United
   States [EY004077]; National Health and Medical Research Council of
   Australia [571100, 1005730]; Rebecca L. Cooper Medical Research
   Foundation; Brian M Kirby Foundation - Gift of Sight Initiative; NSW
   Optometrist Registration Board - Best Practice Grant; NATIONAL EYE
   INSTITUTE [P30EY011374, R01EY004077] Funding Source: NIH RePORTER
FX The authors thank Mr. Sam Adamson for assistance with digital imaging.
   Supported by Fondation Leducq of France, the National Institutes of
   Health of the United States (EY004077), the National Health and Medical
   Research Council of Australia (#571100, 1005730), the Rebecca L. Cooper
   Medical Research Foundation, the Brian M Kirby Foundation - Gift of
   Sight Initiative, and the NSW Optometrist Registration Board - Best
   Practice Grant.
CR Akata T, 2007, J ANESTH, V21, P232, DOI 10.1007/s00540-006-0488-4
   ALDER VA, 1990, INVEST OPHTH VIS SCI, V31, P1029
   Allende A, 2006, BRIT J OPHTHALMOL, V90, P1046, DOI 10.1136/bjo.2006.092080
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P261, DOI 10.1111/j.1748-1716.1972.tb05177.x
   ALM A, 1977, EXP EYE RES, V25, P19, DOI 10.1016/0014-4835(77)90241-X
   ALM A, 1972, ACTA PHYSIOL SCAND, V84, P306, DOI 10.1111/j.1748-1716.1972.tb05182.x
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Anand-Apte B., 2009, ENCY EYE, P9
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Archer D.B., 2007, RETINAL VASCULAR DIS, P3
   ARMALY MF, 1975, INVEST OPHTH VISUAL, V14, P584
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001
   ASHTON N, 1970, BRIT MED BULL, V26, P103, DOI 10.1093/oxfordjournals.bmb.a070758
   Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613
   Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Barber AJ, 2011, INVEST OPHTH VIS SCI, V52, P1156, DOI 10.1167/iovs.10-6293
   Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220
   Bek T, 2008, GRAEF ARCH CLIN EXP, V246, P763, DOI 10.1007/s00417-008-0766-y
   Ben-nun Joshua, 2005, International Ophthalmology, V25, P187
   Berisha F, 2007, INVEST OPHTH VIS SCI, V48, P2285, DOI 10.1167/iovs.06-1029
   BILL A, 1980, T OPHTHAL SOC UK, V100, P332
   BILL A, 1990, EYE, V4, P319, DOI 10.1038/eye.1990.43
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bizheva K, 2006, P NATL ACAD SCI USA, V103, P5066, DOI 10.1073/pnas.0506997103
   Blum M, 1999, GRAEF ARCH CLIN EXP, V237, P296, DOI 10.1007/s004170050236
   Bobbie MW, 2010, INVEST OPHTH VIS SCI, V51, P3758, DOI 10.1167/iovs.09-4489
   Bogner B, 2011, INVEST OPHTH VIS SCI, V52, P7134, DOI 10.1167/iovs.11-7791
   Bringmann A, 1999, EUR J NEUROSCI, V11, P2883, DOI 10.1046/j.1460-9568.1999.00706.x
   Bringmann A, 2002, CAN J OPHTHALMOL, V37, P221, DOI 10.1016/S0008-4182(02)80113-2
   Brouwers O, 2011, J BIOL CHEM, V286, P1374, DOI 10.1074/jbc.M110.144097
   BRUUN A, 1984, INVEST OPHTH VIS SCI, V25, P1113
   BUERK DG, 1995, INVEST OPHTH VIS SCI, V36, P2216
   Buerk DG, 1996, MICROVASC RES, V52, P13, DOI 10.1006/mvre.1996.0040
   Burnette JO, 2006, EXP EYE RES, V83, P1359, DOI 10.1016/j.exer.2006.07.011
   BURSELL SE, 1992, CURR EYE RES, V11, P287, DOI 10.3109/02713689209001782
   BUTTERY RG, 1991, VISION RES, V31, P169, DOI 10.1016/0042-6989(91)90110-Q
   Cai WJ, 2004, MOL CELL BIOCHEM, V262, P17, DOI 10.1023/B:MCBI.0000038201.43148.20
   Chakravarthy U, 1999, PROG RETIN EYE RES, V18, P511, DOI 10.1016/S1350-9462(98)00034-2
   Chan-Ling T, 2004, AM J PATHOL, V165, P1301, DOI 10.1016/S0002-9440(10)63389-5
   Chan-Ling T, 2004, INVEST OPHTH VIS SCI, V45, P2020, DOI 10.1167/iovs.03-1169
   Chan-Ling T., ENCY EYE, V2, P22
   Chan-Ling T, 2008, RETINAL AND CHOROIDAL ANGIOGENESIS, P119, DOI 10.1007/978-1-4020-6780-8_6
   Chan-Ling T, 2011, EXP EYE RES, V92, P361, DOI 10.1016/j.exer.2011.02.009
   Chan-Ling T, 2011, INVEST OPHTH VIS SCI, V52, P399, DOI 10.1167/iovs.10-5403
   Chan-Ling T, 2009, GLIA, V57, P39, DOI 10.1002/glia.20733
   Chang-Ling T, 2006, BLOOD BRAIN BARRIERS, P701
   CHANLING T, 1990, CURR EYE RES, V9, P459, DOI 10.3109/02713689008999612
   CHANLING TL, 1994, PROG RETIN EYE RES, V13, P357, DOI 10.1016/1350-9462(94)90015-9
   CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201
   Chauhan BC, 2004, INVEST OPHTH VIS SCI, V45, P144, DOI 10.1167/iovs.03-0687
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   CHEN CR, 1993, J BIOMECH ENG-T ASME, V115, P231, DOI 10.1115/1.2895480
   Chen SJ, 2001, BRIT J OPHTHALMOL, V85, P1411, DOI 10.1136/bjo.85.12.1411
   Cheng HY, 2007, OPT LETT, V32, P2188, DOI 10.1364/OL.32.002188
   Cheng HY, 2006, P NATL ACAD SCI USA, V103, P17525, DOI 10.1073/pnas.0605790103
   Cheung N, 2008, DIABETES CARE, V31, P1842, DOI 10.2337/dc08-0189
   Chiu K., 2011, AGE DORDR
   Cioffi GA, 1995, CURR EYE RES, V14, P1147, DOI 10.3109/02713689508995821
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2002, BRIT J OPHTHALMOL, V86, P209, DOI 10.1136/bjo.86.2.209
   COGAN DG, 1967, ARCH OPHTHALMOL-CHIC, V78, P133
   Curtis TM, 2009, EYE, V23, P1496, DOI 10.1038/eye.2009.108
   Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015
   Davis MJ, 1999, PHYSIOL REV, V79, P387, DOI 10.1152/physrev.1999.79.2.387
   de Hoz R, 2008, HISTOL HISTOPATHOL, V23, P1249, DOI 10.14670/HH-23.1249
   de la Torre JC, 2009, INT REV NEUROBIOL, V84, P35, DOI 10.1016/S0074-7742(09)00403-6
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Delaey C, 2000, INVEST OPHTH VIS SCI, V41, P1871
   DEOLIVEIRA F, 1966, BRIT J OPHTHALMOL, V50, P134, DOI 10.1136/bjo.50.3.134
   Dorner GT, 2003, AM J PHYSIOL-HEART C, V285, pH631, DOI 10.1152/ajpheart.00111.2003
   Dorrell M.I., 2007, RETINAL VASCULAR DIS, P24
   Dorrell MI, 2002, INVEST OPHTH VIS SCI, V43, P3500
   DREHER Z, 1988, VISUAL NEUROSCI, V1, P169, DOI 10.1017/S0952523800001449
   Dumskyj MJ, 1996, MICROVASC RES, V51, P378, DOI 10.1006/mvre.1996.0034
   Duong TQ, 2002, INVEST OPHTH VIS SCI, V43, P1176
   Eckes B, 2000, J CELL SCI, V113, P2455
   ENGERMAN RL, 1976, INVEST OPHTH VISUAL, V15, P835
   ENGERMAN RL, 1967, LAB INVEST, V17, P738
   ERNEST JT, 1972, INVEST OPHTH VISUAL, V11, P29
   FALLON TJ, 1985, OPHTHALMOLOGY, V92, P701
   FALLON TJ, 1987, OPHTHALMOLOGY, V94, P1410
   Falsini B, 2002, INVEST OPHTH VIS SCI, V43, P2309
   Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832
   Feke G T, 2006, Bull Soc Belge Ophtalmol, P171
   FEKE GT, 1983, INVEST OPHTH VIS SCI, V24, P136
   Feletou M, 2006, ARTERIOSCL THROM VAS, V26, P1215, DOI 10.1161/01.ATV.0000217611.81085.c5
   Fernandez-Klett F, 2010, P NATL ACAD SCI USA, V107, P22290, DOI 10.1073/pnas.1011321108
   Filosa JA, 2006, NAT NEUROSCI, V9, P1397, DOI 10.1038/nn1779
   Findl O, 2000, AM J OPHTHALMOL, V130, P589, DOI 10.1016/S0002-9394(00)00636-X
   Findl O, 2000, BRIT J OPHTHALMOL, V84, P493, DOI 10.1136/bjo.84.5.493
   Flammer J, 2008, CAN J OPHTHALMOL, V43, P317, DOI 10.3129/i08-056
   FLOWER RW, 1995, INVEST OPHTH VIS SCI, V36, P1247
   Formaz F, 1997, CURR EYE RES, V16, P1252, DOI 10.1076/ceyr.16.12.1252.5021
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   FRANK RN, 1987, INVEST OPHTH VIS SCI, V28, P1086
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   FRIEDMAN E, 1970, ARCH OPHTHALMOL-CHIC, V83, P95, DOI 10.1001/archopht.1970.00990030097018
   FRIEDMAN E, 1972, ARCH OPHTHALMOL-CHIC, V87, P70, DOI 10.1001/archopht.1972.01000020072015
   Friedman E, 2008, AM J OPHTHALMOL, V146, P348, DOI 10.1016/j.ajo.2008.05.017
   Fuchsjager-Mayrl G, 2001, VISION RES, V41, P2919, DOI 10.1016/S0042-6989(01)00171-7
   Galassi F, 2011, INVEST OPHTH VIS SCI, V52, P4467, DOI 10.1167/iovs.10-6710
   Gardiner TA, 2007, MICROCIRCULATION, V14, P25, DOI 10.1080/10739680601072123
   Garhofer G, 2004, BRIT J OPHTHALMOL, V88, P887, DOI 10.1136/bjo.2003.033548
   Garhofer G, 2004, VISION RES, V44, P833, DOI 10.1016/j.visres.2003.11.013
   Garhofer G, 2003, INVEST OPHTH VIS SCI, V44, P5309, DOI 10.1167/iovs.03-0587
   Garhofer G, 2002, CURR EYE RES, V24, P109, DOI 10.1076/ceyr.24.2.109.8164
   Gariano RF, 2003, PROG RETIN EYE RES, V22, P295, DOI 10.1016/S1350-9462(02)00062-9
   Gebremedhin D, 2003, J NEUROSCI, V23, P1678
   GEERAETS WJ, 1962, INVEST OPHTH VISUAL, V1, P340
   Geiser MH, 2000, CURR EYE RES, V21, P669, DOI 10.1076/0271-3683(200008)21:2;1-V;FT669
   Geitzenauer W, 2011, BRIT J OPHTHALMOL, V95, P171, DOI 10.1136/bjo.2010.182170
   Geraldes P, 2009, NAT MED, V15, P1298, DOI 10.1038/nm.2052
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Ghanem AA, 2011, OPHTHALMIC RES, V46, P98, DOI 10.1159/000323584
   GHEREZGHIHER T, 1991, EXP EYE RES, V53, P151, DOI 10.1016/0014-4835(91)90068-P
   Gidday JM, 1996, INVEST OPHTH VIS SCI, V37, P2624
   Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005
   Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525
   Gottanka J, 2005, INVEST OPHTH VIS SCI, V46, P4170, DOI 10.1167/iovs.05-0289
   Grammas P, 1999, AM J PATHOL, V154, P337, DOI 10.1016/S0002-9440(10)65280-7
   Grauslund J, 2009, DIABETOLOGIA, V52, P2213, DOI 10.1007/s00125-009-1459-8
   Grieshaber MC, 2007, J GLAUCOMA, V16, P215, DOI 10.1097/IJG.0b013e31802d045a
   GRUNWALD JE, 1988, BRIT J OPHTHALMOL, V72, P754, DOI 10.1136/bjo.72.10.754
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P2329
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   GRUNWALD JE, 1992, INVEST OPHTH VIS SCI, V33, P356
   GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1447
   GRUNWALD JE, 1987, OPHTHALMOLOGY, V94, P1614
   GRUNWALD JE, 1984, OPHTHALMOLOGY, V91, P1690
   Guo L, 2010, CURR ALZHEIMER RES, V7, P3, DOI 10.2174/156720510790274491
   Haefliger IO, 1997, GRAEF ARCH CLIN EXP, V235, P388, DOI 10.1007/BF00937289
   Haefliger IO, 1997, INVEST OPHTH VIS SCI, V38, P1563
   HAEFLIGER IO, 1994, INVEST OPHTH VIS SCI, V35, P991
   Hamilton Nicola B, 2010, Front Neuroenergetics, V2, DOI 10.3389/fnene.2010.00005
   Hammer M, 2011, INVEST OPHTH VIS SCI, V52, P274, DOI 10.1167/iovs.10-5537
   Hancock HA, 2004, INVEST OPHTH VIS SCI, V45, P1002, DOI 10.1167/iovs.03-1080
   Haribalaganesh R, 2009, ANGIOGENESIS, V12, P381, DOI 10.1007/s10456-009-9159-z
   Harris A, 1996, GRAEF ARCH CLIN EXP, V234, P440, DOI 10.1007/BF02539410
   Harris A, 1996, BRIT J OPHTHALMOL, V80, P209, DOI 10.1136/bjo.80.3.209
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hasegawa T, 2007, DEV DYNAM, V236, P2089, DOI 10.1002/dvdy.21231
   Havelius U, 1999, INVEST OPHTH VIS SCI, V40, P1850
   Hein TW, 2010, INVEST OPHTH VIS SCI, V51, P1583, DOI 10.1167/iovs.09-4391
   Hein TW, 2006, INVEST OPHTH VIS SCI, V47, P693, DOI 10.1167/iovs.05-1224
   Hein TW, 2005, INVEST OPHTH VIS SCI, V46, P2113, DOI 10.1167/iovs.04-1438
   HENKIND P, 1967, BRIT J OPHTHALMOL, V51, P115, DOI 10.1136/bjo.51.2.115
   HENKIND P, 1968, INVEST OPHTH VISUAL, V7, P584
   HERMAN IM, 1985, J CELL BIOL, V101, P43, DOI 10.1083/jcb.101.1.43
   Hessellund A, 2006, CURR EYE RES, V31, P427, DOI 10.1080/02713680600681236
   Hillman EMC, 2007, NEUROIMAGE, V35, P89, DOI 10.1016/j.neuroimage.2006.11.032
   Hirao M, 2004, EXP EYE RES, V79, P729, DOI 10.1016/j.exer.2004.08.008
   HOGAN MJ, 1963, J ULTRA MOL STRUCT R, V9, P29, DOI 10.1016/S0022-5320(63)80034-9
   HOLLANDER H, 1991, J COMP NEUROL, V313, P587, DOI 10.1002/cne.903130405
   Horiuchi T, 2002, STROKE, V33, P2692, DOI 10.1161/01.STR.0000034791.52151.6B
   Howlett D.R., 2011, EXP BRAIN RES
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Hughes S, 2004, INVEST OPHTH VIS SCI, V45, P2795, DOI 10.1167/iovs.03-1312
   Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217
   Hughes SJ, 2004, MOL VIS, V10, P996
   Hughes S, 2007, INVEST OPHTH VIS SCI, V48, P1368, DOI 10.1167/iovs.06-0850
   Hughes S, 2006, NEUROBIOL AGING, V27, P1838, DOI 10.1016/j.neurobiolaging.2005.10.021
   IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR1153, DOI 10.1152/ajpregu.1995.268.5.R1153
   Iseri PK, 2006, J NEURO-OPHTHALMOL, V26, P18, DOI 10.1097/01.wno.0000204645.56873.26
   ISHIKAWA T, 1963, INVEST OPHTH VISUAL, V2, P1
   Ishizaki E, 2009, J PHYSIOL-LONDON, V587, P2233, DOI 10.1113/jphysiol.2009.169003
   Jeppesen P, 2007, INVEST OPHTH VIS SCI, V48, P328, DOI 10.1167/iovs.06-0360
   Justino L, 2001, NEUROBIOL AGING, V22, P691, DOI 10.1016/S0197-4580(01)00234-2
   KAISER HJ, 1995, GRAEF ARCH CLIN EXP, V233, P484, DOI 10.1007/BF00183429
   Kalaria RN, 1995, BRAIN RES, V705, P349, DOI 10.1016/0006-8993(95)01250-8
   KARWOSKI CJ, 1985, J GEN PHYSIOL, V86, P189, DOI 10.1085/jgp.86.2.189
   Kawamura H, 2003, J PHYSIOL-LONDON, V551, P787, DOI 10.1113/jphsiol.2003.047977
   Kawarai M, 1998, EUR J PHARMACOL, V363, P35, DOI 10.1016/S0014-2999(98)00790-0
   Kergoat H, 2002, GERONTOLOGY, V48, P197, DOI 10.1159/000058350
   Kern TS, 2000, INVEST OPHTH VIS SCI, V41, P3972
   KERN TS, 1995, INVEST OPHTH VIS SCI, V36, P490
   Kiel JW, 1999, EXP EYE RES, V69, P413, DOI 10.1006/exer.1999.0717
   Kiss B, 2002, MICROVASC RES, V64, P75, DOI 10.1006/mvre.2002.2402
   KLEIN R, 1984, AM J EPIDEMIOL, V119, P54, DOI 10.1093/oxfordjournals.aje.a113725
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x
   Knot HJ, 1996, J PHYSIOL-LONDON, V492, P419, DOI 10.1113/jphysiol.1996.sp021318
   Knot HJ, 1998, J PHYSIOL-LONDON, V508, P211, DOI 10.1111/j.1469-7793.1998.211br.x
   Kofuji P, 2004, NEUROSCIENCE, V129, P1045, DOI 10.1016/j.neurscience.2004.06.008
   Kofuji P, 2002, GLIA, V39, P292, DOI 10.1002/glia.10112
   Kofuji P, 2000, J NEUROSCI, V20, P5733, DOI 10.1523/JNEUROSCI.20-15-05733.2000
   Kondo M, 1997, ACTA OPHTHALMOL SCAN, V75, P232
   KORNZWEIG AL, 1968, ARCH OPHTHALMOL-CHIC, V80, P696
   Kotecha N, 2005, AM J PHYSIOL-HEART C, V289, pH1326, DOI 10.1152/ajpheart.00323.2005
   Kotliar KE, 2004, GRAEF ARCH CLIN EXP, V242, P377, DOI 10.1007/s00417-003-0847-x
   Kubista KE, 2011, MOL VIS, V17, P2080
   Kuo IY, 2008, J COMP NEUROL, V511, P773, DOI 10.1002/cne.21873
   Kutcher ME, 2007, AM J PATHOL, V171, P693, DOI 10.2353/ajpath.2007.070102
   LATIES AM, 1967, ARCH OPHTHALMOL-CHIC, V77, P405, DOI 10.1001/archopht.1967.00980020407021
   Le YZ, 2010, J NEUROCHEM, V112, P1584, DOI 10.1111/j.1471-4159.2010.06573.x
   Lecleire-Collet A, 2011, INVEST OPHTH VIS SCI, V52, P2861, DOI 10.1167/iovs.10-5960
   Leske MC, 2007, OPHTHALMOLOGY, V114, P1965, DOI 10.1016/j.ophtha.2007.03.016
   Li WY, 1998, INVEST OPHTH VIS SCI, V39, P1535
   Li YX, 2008, NEUROIMAGE, V39, P1744, DOI 10.1016/j.neuroimage.2007.10.030
   Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803
   LINSENMEIER RA, 1986, J GEN PHYSIOL, V88, P521, DOI 10.1085/jgp.88.4.521
   LITTLE TL, 1995, AM J PHYSIOL-HEART C, V268, pH729, DOI 10.1152/ajpheart.1995.268.2.H729
   Longo A, 2000, INVEST OPHTH VIS SCI, V41, P2678
   Loufrani L, 2002, ARTERIOSCL THROM VAS, V22, P1579, DOI 10.1161/01.ATV.0000032652.24932.1A
   Loufrani L, 2001, FASEB J, V15, P117, DOI 10.1096/fj.01-0505fje
   Lovasik JV, 2005, AM J PHYSIOL-HEART C, V289, pH683, DOI 10.1152/ajpheart.01187.2004
   Lovasik JV, 2003, INVEST OPHTH VIS SCI, V44, P2126, DOI 10.1167/iovs.02-0825
   Lutty G, 1999, MOL VIS, V5
   Maleki N, 2011, NMR BIOMED, V24, P104, DOI 10.1002/nbm.1564
   Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765
   Mandecka A, 2007, DIABETES CARE, V30, P3048, DOI 10.2337/dc07-0927
   Mansour H, 2008, AGING CELL, V7, P526, DOI 10.1111/j.1474-9726.2008.00402.x
   Markhotina N, 2007, IET NANOBIOTECHNOL, V1, P44, DOI 10.1049/iet-nbt:20060019
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin PM, 2004, INVEST OPHTH VIS SCI, V45, P3330, DOI 10.1167/iovs.04-0247
   Matsugi T, 1997, ARCH OPHTHALMOL-CHIC, V115, P1281, DOI 10.1001/archopht.1997.01100160451011
   Matsugi T, 1997, INVEST OPHTH VIS SCI, V38, P2695
   Matsushita K, 2006, J PHYSIOL-LONDON, V573, P483, DOI 10.1113/jphysiol.2006.107102
   Matsushita K, 2010, INVEST OPHTH VIS SCI, V51, P5979, DOI 10.1167/iovs.10-5377
   Matsuura T, 1999, COMP BIOCHEM PHYS A, V124, P47, DOI 10.1016/S1095-6433(99)00086-0
   McGahon MK, 2007, CIRC RES, V100, P703, DOI 10.1161/01.RES.0000260182.36481.c9
   McGahon MK, 2007, AM J PHYSIOL-HEART C, V292, pH1001, DOI 10.1152/ajpheart.01003.2006
   McGahon MK, 2009, INVEST OPHTH VIS SCI, V50, P364, DOI 10.1167/iovs.08-2524
   Metea MR, 2007, J NEUROSCI, V27, P2468, DOI 10.1523/JNEUROSCI.3204-06.2007
   Metea MR, 2006, J NEUROSCI, V26, P2862, DOI 10.1523/JNEUROSCI.4048-05.2006
   Michelson G, 1996, J GLAUCOMA, V5, P91
   Michelson G, 1996, J GLAUCOMA, V5, P99
   Michelson G, 2007, RETINA-J RET VIT DIS, V27, P490, DOI 10.1097/01.iae.0000243032.33738.f7
   Mishra A., 2012, FRONT NEUROENERG, V3, P10, DOI DOI 10.3389/FNENE.2011.00010)
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P17827, DOI 10.1073/pnas.1110533108
   Mishra A, 2010, GLIA, V58, P1996, DOI 10.1002/glia.21068
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Motiejunaite R, 2008, EXP EYE RES, V86, P171, DOI 10.1016/j.exer.2007.10.013
   Movaffaghy A, 1998, EXP EYE RES, V67, P561, DOI 10.1006/exer.1998.0556
   Muir ER, 2011, NMR BIOMED, V24, P216, DOI 10.1002/nbm.1576
   Mulligan SJ, 2004, NATURE, V431, P195, DOI 10.1038/nature02827
   Nagahara M, 2011, INVEST OPHTH VIS SCI, V52, P87, DOI 10.1167/iovs.09-4422
   Nagel E, 2004, INVEST OPHTH VIS SCI, V45, P1486, DOI 10.1167/iovs.03-0667
   Nagel E, 2004, BRIT J OPHTHALMOL, V88, P54, DOI 10.1136/bjo.88.1.54
   NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Newman EA, 2005, J NEUROSCI, V25, P5502, DOI 10.1523/JNEUROSCI.1354-05.2005
   NEWMAN EA, 1986, ANN NY ACAD SCI, V481, P273, DOI 10.1111/j.1749-6632.1986.tb27158.x
   NEWMAN EA, 1985, NATURE, V317, P809, DOI 10.1038/317809a0
   Nguyen TT, 2008, DIABETES, V57, P536, DOI 10.2337/db07-1376
   Nguyen TT, 2009, DIABETES CARE, V32, P2075, DOI 10.2337/dc09-0075
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nilsson SFE, 1996, INVEST OPHTH VIS SCI, V37, P2110
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Niwa K, 2000, J NEUROSCI, V20, P763, DOI 10.1523/JNEUROSCI.20-02-00763.2000
   Obrosova IG, 2011, CURR PHARM BIOTECHNO, V12, P373
   Ogura, 2000, Jpn J Ophthalmol, V44, P322, DOI 10.1016/S0021-5155(00)00164-7
   OKADA S, 1994, SCANNING MICROSCOPY, V8, P415
   Okamoto K, 2010, PAIN, V149, P235, DOI 10.1016/j.pain.2010.02.004
   Oku H, 2001, INVEST OPHTH VIS SCI, V42, P1915
   Olive M, 2004, J NEUROL SCI, V219, P125, DOI 10.1016/j.jns.2004.01.007
   OZANICS V, 1978, EXP EYE RES, V26, P25, DOI 10.1016/0014-4835(78)90149-5
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pannicke T, 2006, DIABETES, V55, P633, DOI 10.2337/diabetes.55.03.06.db05-1349
   Parisi Vincenzo, 2003, Semin Ophthalmol, V18, P50
   Park SH, 2003, DIABETOLOGIA, V46, P1260, DOI 10.1007/s00125-003-1177-6
   PARVER LM, 1982, RETINA-J RET VIT DIS, V2, P117, DOI 10.1097/00006982-198200220-00008
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   PAULSON OB, 1987, SCIENCE, V237, P896, DOI 10.1126/science.3616619
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Pemp B, 2009, INVEST OPHTH VIS SCI, V50, P4029, DOI 10.1167/iovs.08-3260
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P255, DOI 10.1007/BF00920031
   Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   PETRIG BL, 1991, APPL OPTICS, V30, P2073, DOI 10.1364/AO.30.002073
   Petzold GC, 2008, NEURON, V58, P897, DOI 10.1016/j.neuron.2008.04.029
   Pfister F, 2008, DIABETES, V57, pA234, DOI 10.2337/db08-0325
   Pfister F, 2010, ACTA DIABETOL, V47, P59, DOI 10.1007/s00592-009-0099-2
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P4592, DOI 10.1167/iovs.04-0842
   Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X
   Polak K, 2000, BRIT J OPHTHALMOL, V84, P1285, DOI 10.1136/bjo.84.11.1285
   Polak K, 2002, INVEST OPHTH VIS SCI, V43, P2721
   Polska E, 2004, BRIT J OPHTHALMOL, V88, P533, DOI 10.1136/bjo.2003.028480
   Polska E, 2007, INVEST OPHTH VIS SCI, V48, P3768, DOI 10.1167/iovs.07-0307
   POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0
   Pomero F, 2003, DIABETOLOGIA, V46, P416, DOI 10.1007/s00125-003-1044-5
   Portmann N, 2011, INVEST OPHTH VIS SCI, V52, P7068, DOI 10.1167/iovs.11-7758
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Prasanna G., 2010, EXP EYE RES
   Preitner A, 2004, CURR EYE RES, V28, P233, DOI 10.1076/ceyr.28.4.233.27830
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   PRUNTE C, 1988, GRAEF ARCH CLIN EXP, V226, P55, DOI 10.1007/BF02172719
   Puro DG, 2007, MICROCIRCULATION, V14, P1, DOI 10.1080/10739680601072099
   Puro Donald G, 2002, Trans Am Ophthalmol Soc, V100, P339
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quignard JF, 2003, J CARDIOVASC PHARM, V42, P379, DOI 10.1097/00005344-200309000-00009
   Ramirez JM, 1996, VISION RES, V36, P2029, DOI 10.1016/0042-6989(95)00322-3
   Reber F, 2003, GRAEF ARCH CLIN EXP, V241, P140, DOI 10.1007/s00417-002-0560-1
   Resch H, 2009, INVEST OPHTH VIS SCI, V50, P358, DOI 10.1167/iovs.08-2460
   Riva C E, 2006, Bull Soc Belge Ophtalmol, P185
   RIVA CE, 1991, NEUROSCI LETT, V128, P291, DOI 10.1016/0304-3940(91)90282-X
   RIVA CE, 1983, INVEST OPHTH VIS SCI, V24, P737
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P1752
   Riva CE, 2005, PROG RETIN EYE RES, V24, P183, DOI 10.1016/j.preteyeres.2004.07.002
   RIVA CE, 1981, INVEST OPHTH VIS SCI, V21, P34
   RIVA CE, 1981, APPL OPTICS, V20, P117, DOI 10.1364/AO.20.000117
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P608
   Riva CE, 2001, INVEST OPHTH VIS SCI, V42, P756
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva CE, 2011, ADLERS PHYSL EYE, P243, DOI [10.1016/b978-0-323-05714-1.00010-8, DOI 10.1016/B978-0-323-05714-1.00010-8]
   Riva CE, 2008, PROG BRAIN RES, V173, P149, DOI 10.1016/S0079-6123(08)01111-4
   Robinson CJ, 2001, J CELL SCI, V114, P853
   ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722
   ROBISON WG, 1990, EXP EYE RES, V50, P355, DOI 10.1016/0014-4835(90)90136-I
   Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241
   Roy C S, 1890, J Physiol, V11, P85
   Roy S, 2010, BIOGERONTOLOGY, V11, P447, DOI 10.1007/s10522-010-9263-x
   Ruitenberg A, 2005, ANN NEUROL, V57, P789, DOI 10.1002/ana.20493
   Ruskell GL, 1997, BRIT J OPHTHALMOL, V81, P76, DOI 10.1136/bjo.81.1.76
   Saari J.C., 1987, ADLERS PHYSL EYE CLI, P356
   Sakagami K, 2001, MICROVASC RES, V62, P196, DOI 10.1006/mvre.2001.2343
   Sakagami K, 1999, J PHYSIOL-LONDON, V521, P637, DOI 10.1111/j.1469-7793.1999.00637.x
   Sandercoe TM, 1999, EXP EYE RES, V69, P511, DOI 10.1006/exer.1999.0730
   Sasongko MB, 2010, DIABETES CARE, V33, P1331, DOI 10.2337/dc10-0055
   Schmetterer L, 2000, EYE, V14, P39, DOI 10.1038/eye.2000.9
   Schmetterer L, 2000, EYE, V14, P46, DOI 10.1038/eye.2000.10
   Schmetterer L, 1998, GRAEF ARCH CLIN EXP, V236, P160, DOI 10.1007/s004170050058
   Schmetterer L, 1995, EXP EYE RES, V61, P685, DOI 10.1016/S0014-4835(05)80019-3
   Schnitzer J., 1988, Progress in Retinal Research, V7, P209, DOI 10.1016/0278-4327(88)90009-0
   Scholfield CN, 2007, MICROCIRCULATION, V14, P11, DOI 10.1080/10739680601072115
   Scholfield CN, 2000, MICROVASC RES, V59, P233, DOI 10.1006/mvre.1999.2227
   Scott A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011863
   Seeliger MW, 2005, VISION RES, V45, P3512, DOI 10.1016/j.visres.2005.08.014
   Shakoor A, 2006, INVEST OPHTH VIS SCI, V47, P4962, DOI 10.1167/iovs.06-0291
   Shih YYI, 2011, INVEST OPHTH VIS SCI, V52, P5303, DOI 10.1167/iovs.10-6438
   Shih YF, 1997, J OCUL PHARMACOL TH, V13, P213, DOI 10.1089/jop.1997.13.213
   Shimazawa M, 2008, J NEUROCHEM, V107, P279, DOI 10.1111/j.1471-4159.2008.05606.x
   Silver D M, 1994, Surv Ophthalmol, V38 Suppl, pS72, DOI 10.1016/0039-6257(94)90049-3
   Silver DM, 2000, CURR EYE RES, V20, P115, DOI 10.1076/0271-3683(200002)20:2;1-D;FT115
   Singh ASG, 2010, BIOMED OPT EXPRESS, V1, P1047, DOI 10.1364/BOE.1.001047
   SPEISER P, 1968, ARCH OPHTHALMOL-CHIC, V80, P332, DOI 10.1001/archopht.1968.00980050334007
   Srienc Anja I, 2010, Front Neuroenergetics, V2, DOI 10.3389/fnene.2010.00128
   Srinivasan VJ, 2006, OPT LETT, V31, P2308, DOI 10.1364/OL.31.002308
   Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362
   Steinle JJ, 2003, AUTON NEUROSCI-BASIC, V108, P57, DOI 10.1016/S1566-0702(03)00151-6
   Stitt AW, 2004, DIABETOLOGIA, V47, P1735, DOI 10.1007/s00125-004-1523-3
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   SUGIYAMA T, 1995, SURV OPHTHALMOL, V39, pS49, DOI 10.1016/S0039-6257(05)80073-6
   TACHIBANA H, 1982, STROKE, V13, P149, DOI 10.1161/01.STR.13.2.149
   Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623
   TILTON RG, 1985, INVEST OPHTH VIS SCI, V26, P68
   Tumelty J, 2007, CELL CALCIUM, V41, P451, DOI 10.1016/j.ceca.2006.08.005
   Udosen IT, 2003, AM J PHYSIOL-HEART C, V285, pH2054, DOI 10.1152/ajpheart.00075.2003
   Ulrich A, 1996, OPHTHALMIC SURG LAS, V27, P746
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   van Dijk HW, 2009, INVEST OPHTH VIS SCI, V50, P3404, DOI 10.1167/iovs.08-3143
   Vanzetta I, 2005, J NEUROSCI, V25, P2233, DOI 10.1523/JNEUROSCI.3032-04.2005
   Venkataraman ST, 2010, INVEST OPHTH VIS SCI, V51, P2043, DOI 10.1167/iovs.09-3630
   Venkataraman ST, 2008, EXP EYE RES, V87, P535, DOI 10.1016/j.exer.2008.08.020
   Vinters HV, 1996, BRAIN PATHOL, V6, P179, DOI 10.1111/j.1750-3639.1996.tb00799.x
   Walshe TE, 2011, CARDIOVASC RES, V89, P661, DOI 10.1093/cvr/cvq341
   Wang L, 1997, INVEST OPHTH VIS SCI, V38, P48
   Wang L, 2008, EXP EYE RES, V86, P908, DOI 10.1016/j.exer.2008.03.005
   Wang YM, 2011, BIOMED OPT EXPRESS, V2, P1852, DOI 10.1364/BOE.001852
   Wang YM, 2011, INVEST OPHTH VIS SCI, V52, P840, DOI 10.1167/iovs.10-5985
   Watanabe G, 2008, JPN J OPHTHALMOL, V52, P175, DOI 10.1007/s10384-007-0521-7
   Weidemann A, 2010, GLIA, V58, P1177, DOI 10.1002/glia.20997
   Williamson J.F., 2011, GENOMICS
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
   Wong TY, 2005, ARCH INTERN MED, V165, P1060, DOI 10.1001/archinte.165.9.1060
   Wu DM, 2003, AM J PHYSIOL-HEART C, V284, pH2083, DOI 10.1152/ajpheart.01007.2002
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamanishi S, 2006, AM J PHYSIOL-HEART C, V290, pH925, DOI 10.1152/ajpheart.01012.2005
   Yang G, 1997, AM J PHYSIOL-REG I, V272, pR1155, DOI 10.1152/ajpregu.1997.272.4.R1155
   YE XO, 1990, INVEST OPHTH VIS SCI, V31, P1731
   Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022
   Yu DY, 1999, INVEST OPHTH VIS SCI, V40, P2082
   Zeng XX, 2000, VISUAL NEUROSCI, V17, P463, DOI 10.1017/S0952523800173122
   Zhang T, 2011, J PHYSIOL-LONDON, V589, P2383, DOI 10.1113/jphysiol.2010.202937
   Zhang Y, 1999, DEV BRAIN RES, V118, P135, DOI 10.1016/S0165-3806(99)00140-6
   Zong HL, 2011, CURR DIABETES REP, V11, P244, DOI 10.1007/s11892-011-0198-7
   Zonta M, 2003, NAT NEUROSCI, V6, P43, DOI 10.1038/nn980
NR 381
TC 398
Z9 414
U1 9
U2 118
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2012
VL 31
IS 5
BP 377
EP 406
DI 10.1016/j.preteyeres.2012.04.004
PG 30
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 983AU
UT WOS:000307089400002
PM 22580107
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Bathija-Lala, B
   Bass, SJ
   Madonna, RJ
   Dayan, A
AF Bathija-Lala, Bharti
   Bass, Sherry J.
   Madonna, Richard J.
   Dayan, Alan
TI Choroidal neovascularization in a young, healthy eye after LASIK
SO OPTOMETRY-JOURNAL OF THE AMERICAN OPTOMETRIC ASSOCIATION
LA English
DT Article
DE Choroidal neovascularization; Laser-in-situ keratomileusis (LASIK);
   Myopia, macular hemorrhage
ID IN-SITU KERATOMILEUSIS; MACULAR HEMORRHAGE; LASER; PATIENT
AB BACKGROUND: Choroidal neovascularization (CNV) is associated with age-related macular degeneration (AMD), degenerative myopia, angioid streaks, presumed ocular histoplasmosis syndrome, and numerous other ocular and systemic conditions. Idiopathic CNV is also a common form of the condition. However, CNV has rarely been noted after laser-assisted in situ keratomileusis (LASIK) and a cause-and-effect relationship has not been found. A case of CNV after uneventful LASIK is reported here, along with a literature review of previously reported cases and suggested pathophysiology. A link between LASIK and CNV is sought.
   METHODS: A case report of CNV in a young, healthy eye after uneventful LASIK is presented. Review of the pertinent literature reporting a relationship between LASIK and CNV was conducted through 2007, and few studies are reported after 2005.
   CONCLUSION: To date, there is anecdotal evidence of CNV after LASIK. The incidence from prior reports ranges from 0.003% to 0.33%. However, a causal link cannot be disregarded and merits further study. Each patient undergoing LASIK warrants a thorough preoperative dilated fundus examination, including a thorough examination of the macula. This occurrence, albeit rare, should be considered for inclusion in the refractive surgery consent form. Optometry 2010:81:632-637
C1 [Bathija-Lala, Bharti; Bass, Sherry J.; Madonna, Richard J.] SUNY Coll Optometry, New York, NY 10010 USA.
   [Dayan, Alan] New York Eye & Ear Infirm, New York, NY 10003 USA.
C3 State University of New York (SUNY) System; SUNY Optometry; New York Eye
   & Ear Infirmary of Mount Sinai
RP Bathija-Lala, B (通讯作者)，11468 Mabrypk Pl, Alpharetta, GA 30022 USA.
EM bbathija@gmail.com
CR Alexander LJ, 2002, PRIMARY CARE POSTERI, V3rd
   Arevalo J Fernando, 2004, Curr Opin Ophthalmol, V15, P184, DOI 10.1097/01.icu.0000120674.27548.9c
   Arevalo JF, 2000, OPHTHALMOLOGY, V107, P258, DOI 10.1016/S0161-6420(99)00078-0
   Arevalo JF, 2004, OPHTHAL SURG LAS IM, V35, P58, DOI 10.3928/1542-8877-20040101-13
   Bailey CS, 2005, J CATARACT REFR SURG, V31, P2041, DOI 10.1016/j.jcrs.2005.12.012
   Browning DJ, 2005, OPHTHALMOLOGY, V112, P1054, DOI 10.1016/j.ophtha.2004.11.062
   Chen YC, 2001, RETINA-J RET VIT DIS, V21, P174, DOI 10.1097/00006982-200104000-00013
   Ellies P, 2000, J CATARACT REFR SURG, V26, P922, DOI 10.1016/S0886-3350(00)00313-8
   Fedorovich I, 2004, EUR J OPHTHALMOL, V14, P261, DOI 10.1177/112067210401400312
   FLAXEL CJ, 2003, OPHTHALMOLOGY, V110, P1669
   Ghanbari H, 2003, J CATARACT REFR SURG, V29, P2232, DOI 10.1016/S0886-3350(03)00355-9
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Loewenstein A, 2002, SURV OPHTHALMOL, V47, P125, DOI 10.1016/S0039-6257(01)00298-3
   Luna JD, 1999, GRAEF ARCH CLIN EXP, V237, P611, DOI 10.1007/s004170050286
   Luna JD, 2001, GRAEF ARCH CLIN EXP, V239, P416, DOI 10.1007/s004170100295
   Maturi RK, 2003, J REFRACT SURG, V19, P463
   Mostafavi R, 2002, OPHTHALMOLOGY, V109, P624
   PINTO RVB, 2005, OPHTHAL SURG LAS IM, V35, P58
   Principe AH, 2004, AM J OPHTHALMOL, V138, P657, DOI 10.1016/j.ajo.2004.04.030
   Ruiz-Moreno JM, 2003, OPHTHALMOLOGY, V110, P1669, DOI 10.1016/S0161-6420(03)00810-8
   Ruiz-Moreno JM, 2001, RETINA-J RET VIT DIS, V21, P115, DOI 10.1097/00006982-200104000-00003
   Saeed M, 2004, J CATARACT REFR SURG, V30, P2632, DOI 10.1016/j.jcrs.2004.04.065
   Singhwi A, 2004, AM J OPHTHALMOL, V138, P1069, DOI 10.1016/j.ajo.2004.06.066
   Sobha S, 2004, CLIN EXP OPHTHALMOL, V32, P443, DOI 10.1111/j.1442-9071.2004.00854.x
   Stulting RD, 1999, OPHTHALMOLOGY, V106, P13, DOI 10.1016/S0161-6420(99)90000-3
NR 25
TC 0
Z9 0
U1 0
U2 0
PU AMER OPTOMETRIC ASSN INC
PI ST LOUIS
PA 243 N LINDBERGH BLVD, ST LOUIS, MO 63141 USA
SN 1529-1839
EI 1558-1527
J9 OPTOMETRY
JI Optometry
PD DEC
PY 2010
VL 81
IS 12
BP 632
EP 637
DI 10.1016/j.optm.2010.04.093
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 778ML
UT WOS:000291708300003
PM 20728413
DA 2022-11-30
ER

PT J
AU Peyman, GA
   Lad, EM
   Moshfeghi, DM
AF Peyman, Gholam A.
   Lad, Eleonora M.
   Moshfeghi, Darius M.
TI INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE antibiotic; antiinflammatory; antineoplastic; antiviral; complication;
   endophthalmitis; intravitreal injection; pneumatic retinopexy; vascular
   endothelial growth factor inhibitors
ID CYSTOID MACULAR EDEMA; ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL
   PROLIFERATIVE VITREORETINOPATHY; RETINAL VEIN OCCLUSION;
   LIPOSOME-ENCAPSULATED GANCICLOVIR; ENDOGENOUS FUNGAL ENDOPHTHALMITIS;
   DRUG-DELIVERY SYSTEM; EXPERIMENTAL SUBRETINAL NEOVASCULARIZATION;
   COMPARING PNEUMATIC RETINOPEXY; COHERENCE TOMOGRAPHY FINDINGS
AB Background: Intravitreal injection (M) with administration of various pharmacological agents is a mainstay of treatment in ophthalmology for endopthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, vascular occlusions, and retinal detachment. The indications and therapeutic agents are reviewed in this study.
   Methods: A search of the English, German, and Spanish language MEDLINE database was conducted. A total of 654 references spanning the period through early 2008 were individually evaluated.
   Results: The advantage of the IVI technique is the ability to maximize intraocular levels of medications and to avoid the toxicities associated with systemic treatment. Intravitreal injection has been used to deliver several types of pharmacological agents into the vitreous cavity: antiinfective and anti inflammatory medications, immunomodulators, anticancer agents, gas, antivascular endothelial growth factor, and several others. The goal of this review is to provide a detailed description of the properties of numerous therapeutic agents that can be delivered through IVI, potential complications of the technique, and recommendations to avoid side effects.
   Conclusion: The IVI technique is a valuable tool that can be tailored to the disease process of interest based on the pharmacological agent selected. This review provides the reader with a comprehensive summary of the IVI technique and its multitude of uses.
C1 [Peyman, Gholam A.] Univ Arizona, Coll Med, Dept Ophthalmol & Vis Sci, Tucson, AZ USA.
   [Peyman, Gholam A.] Maricopa Hlth Syst, Phoenix, AZ USA.
   [Peyman, Gholam A.] Tulane Univ, Dept Ophthalmol, New Orleans, LA 70118 USA.
   [Peyman, Gholam A.; Lad, Eleonora M.; Moshfeghi, Darius M.] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.
C3 University of Arizona; Maricopa County General Hospital; Tulane
   University; Stanford University
RP Peyman, GA (通讯作者)，Univ Arizona, Dept Ophthalmol & Vis Sci, Coll Med, 10650 Tropicana Circle, Sun City, AZ 85351 USA.
EM gpeyman1@yahoo.com
OI Moshfeghi, Darius Mohammad/0000-0003-2254-292X
CR Agarwal M B, 2006, J Assoc Physicians India, V54, P943
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Aizman A, 2007, OPHTHALMOLOGY, V114, P307, DOI 10.1016/j.ophtha.2006.06.058
   AKULA SK, 1994, BRIT J OPHTHALMOL, V78, P677, DOI 10.1136/bjo.78.9.677
   Alfaro DV, 1996, RETINA-J RET VIT DIS, V16, P317, DOI 10.1097/00006982-199616040-00007
   Alfaro DV, 1997, RETINA-J RET VIT DIS, V17, P139, DOI 10.1097/00006982-199703000-00010
   ALGHADYAN AA, 1988, INT OPHTHALMOL, V12, P109, DOI 10.1007/BF00137135
   ALGHADYAN AA, 1988, INT OPHTHALMOL, V12, P105, DOI 10.1007/BF00137134
   Anand R, 1997, Curr Opin Ophthalmol, V8, P8, DOI 10.1097/00055735-199706000-00003
   Androudi S, 2005, OCUL IMMUNOL INFLAMM, V13, P205, DOI 10.1080/09273940590933511
   [Anonymous], 1995, Arch Ophthalmol, V113, P1479
   [Anonymous], 1992, Control Clin Trials, V13, P22
   Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   Anteby I, 1997, Eur J Ophthalmol, V7, P294
   APT L, 1984, ARCH OPHTHALMOL-CHIC, V102, P728, DOI 10.1001/archopht.1984.01040030584025
   APT L, 1982, OPHTHALMIC SURG LAS, V13, P1026
   ASSIL KK, 1987, ARCH OPHTHALMOL-CHIC, V105, P400, DOI 10.1001/archopht.1987.01060030120040
   Augustin A J, 1992, Ger J Ophthalmol, V1, P394
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Ausayakhun Somsanguan, 2005, Journal of the Medical Association of Thailand, V88, P103
   Avci R, 2006, CLIN EXP OPHTHALMOL, V34, P27, DOI 10.1111/j.1442-9071.2006.01103.x
   AVERY RL, 2006, OPHTHALMOLOGY, V113
   Avitabile T, 2005, AM J OPHTHALMOL, V140, P695, DOI 10.1016/j.ajo.2005.05.021
   Avunduk MC, 2004, EXP EYE RES, V79, P357, DOI 10.1016/j.exer.2004.06.001
   AXELROD AJ, 1973, AM J OPHTHALMOL, V76, P584, DOI 10.1016/0002-9394(73)90754-X
   AXELROD JL, 1987, AM J OPHTHALMOL, V104, P649, DOI 10.1016/0002-9394(87)90180-2
   Aydin E, 2006, RETINA-J RET VIT DIS, V26, P187, DOI 10.1097/00006982-200602000-00011
   Bains HS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1292, DOI 10.1001/archopht.125.9.1292
   Bakri SJ, 2003, OPHTHALMIC SUR LA IM, V34, P386
   BALEY JE, 1984, PEDIATRICS, V73, P144
   Baley JE, 2003, SEMIN PERINATOL, V27, P401, DOI 10.1016/S0146-0005(03)00064-8
   Banker AS, 1997, AM J OPHTHALMOL, V124, P168, DOI 10.1016/S0002-9394(14)70781-0
   BARRADA A, 1983, OPHTHALMIC SURG LAS, V14, P845
   BARRADA A, 1984, OPHTHALMIC SURG LAS, V15, P767
   BARZA M, 1985, AM J OPHTHALMOL, V100, P259, DOI 10.1016/0002-9394(85)90791-3
   BARZA M, 1984, INVEST OPHTH VIS SCI, V25, P486
   Bashshur ZF, 2004, ARCH OPHTHALMOL-CHIC, V122, P1137, DOI 10.1001/archopht.122.8.1137
   Baudouin C, 1996, OPHTHALMOLOGICA, V210, P329, DOI 10.1159/000310734
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   BEHRENSBAUMANN W, 1986, GRAEF ARCH CLIN EXP, V224, P520, DOI 10.1007/BF02154739
   Benhamou N, 2003, AM J OPHTHALMOL, V135, P246, DOI 10.1016/S0002-9394(02)01938-4
   BENSON JD, 1990, J VIROL, V64, P9, DOI 10.1128/JVI.64.1.9-15.1990
   BENSON JD, 1988, J VIROL, V62, P4797, DOI 10.1128/JVI.62.12.4797-4800.1988
   Benz MS, 2003, ARCH OPHTHALMOL-CHIC, V121, P271
   Benz MS, 2004, AM J OPHTHALMOL, V137, P38, DOI 10.1016/S0002-9394(03)00896-1
   BERMAN DH, 1989, OPHTHALMIC SURG LAS, V20, P268
   Bhavsar AR, 2007, AM J OPHTHALMOL, V144, P454, DOI 10.1016/j.ajo.2007.04.011
   Biron KK, 2006, ANTIVIR RES, V71, P154, DOI 10.1016/j.antiviral.2006.05.002
   Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   BLUMENKRANZ M, 1984, OPHTHALMOLOGY, V91, P122
   BLUMENKRANZ M, 1989, MECH ACTION DRUGS TR, P401
   BLUMENKRANZ MS, 1987, ARCH OPHTHALMOL-CHIC, V105, P396, DOI 10.1001/archopht.1987.01060030116039
   BLUMENKRANZ MS, 1982, AM J OPHTHALMOL, V94, P458, DOI 10.1016/0002-9394(82)90239-2
   BLUMENKRANZ MS, 1980, ARCH OPHTHALMOL-CHIC, V98, P1216, DOI 10.1001/archopht.1980.01020040068006
   BLUMENKRANZ MS, 1984, ARCH OPHTHALMOL-CHIC, V102, P598, DOI 10.1001/archopht.1984.01040030470029
   BODEY GP, 1992, CLIN INFECT DIS, V14, pS161, DOI 10.1093/clinids/14.Supplement_1.S161
   Boldrey E E, 1981, Retina, V1, P171
   Bonini MA, 2005, INVEST OPHTH VIS SCI, V46, P3845, DOI 10.1167/iovs.05-0297
   BORHANI H, 1994, OPHTHALMIC SURG LAS, V25, P166
   BORHANI H, 1995, INT OPHTHALMOL, V19, P43, DOI 10.1007/BF00156419
   BORHANI H, 1993, INT OPHTHALMOL, V17, P85, DOI 10.1007/BF00942780
   BRAUN G, 1922, ARCH OPHTHALMOL-CHIC, V110, P59
   Breit SM, 2005, AM J OPHTHALMOL, V139, P135, DOI 10.1016/j.ajo.2004.08.077
   Briggs MC, 1998, EYE, V12, P252, DOI 10.1038/eye.1998.59
   BRISSONNOEL A, 1988, J ANTIMICROB CHEMOTH, V22, P13, DOI 10.1093/jac/22.Supplement_B.13
   BROD RD, 1990, OPHTHALMOLOGY, V97, P666, DOI 10.1016/S0161-6420(90)32547-2
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869
   CAMPOCHIARO PA, 1986, EXP EYE RES, V43, P449, DOI 10.1016/S0014-4835(86)80080-X
   CAMPOCHIARO PA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1403
   Cannon JP, 2003, INVEST OPHTH VIS SCI, V44, P2112, DOI 10.1167/iovs.02-1020
   Cappelletty D, 2007, PHARMACOTHERAPY, V27, P369, DOI 10.1592/phco.27.3.369
   Cardillo JA, 2004, BRIT J OPHTHALMOL, V88, P1201, DOI 10.1136/bjo.2003.039917
   Cardillo JA, 2005, OPHTHALMOLOGY, V112, P1557, DOI 10.1016/j.ophtha.2005.03.023
   CARNEY M, 1988, OPHTHALMIC SURG LAS, V19, P119
   CASE JL, 1985, OPHTHALMIC SURG LAS, V16, P378
   Chambers HF, 2007, EXPERT REV ANTI-INFE, V5, P333, DOI 10.1586/14787210.5.3.333
   CHANDLER DB, 1987, GRAEF ARCH CLIN EXP, V225, P259, DOI 10.1007/BF02150144
   CHANDLER DB, 1985, AM J OPHTHALMOL, V99, P686, DOI 10.1016/S0002-9394(14)76037-4
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   ChavezdelaPaz E, 1997, OPHTHALMOLOGY, V104, P539, DOI 10.1016/S0161-6420(97)30278-4
   CHAWLA HB, 1973, BRIT J OPHTHALMOL, V57, P60, DOI 10.1136/bjo.57.1.60
   CHAWLA HB, 1973, BRIT J OPHTHALMOL, V57, P58, DOI 10.1136/bjo.57.1.58
   CHEN EP, 1992, INVEST OPHTH VIS SCI, V33, P2160
   Chen FK, 2007, CLIN EXP OPHTHALMOL, V35, P382, DOI 10.1111/j.1442-9071.2007.01493.x
   Cheng LY, 2004, INVEST OPHTH VIS SCI, V45, P4138, DOI 10.1167/iovs.04-0064
   CHENG YC, 1976, ANTIMICROB AGENTS CH, V10, P119, DOI 10.1128/AAC.10.1.119
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   CHUNG H, 1988, CURR EYE RES, V7, P1199, DOI 10.3109/02713688809033224
   Ciardella AP, 2004, BRIT J OPHTHALMOL, V88, P1131, DOI 10.1136/bjo.2004.041707
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   CLEMENTS DB, 1987, BRIT J OPHTHALMOL, V71, P433, DOI 10.1136/bjo.71.6.433
   CLINCH TE, 1989, SURV OPHTHALMOL, V34, P107, DOI 10.1016/0039-6257(89)90038-6
   COATS ML, 1992, RETINA-J RET VIT DIS, V12, P46, DOI 10.1097/00006982-199212010-00010
   COCHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348
   CODISH SD, 1979, JAMA-J AM MED ASSOC, V241, P2418, DOI 10.1001/jama.241.22.2418
   CONNOLLY SE, 1992, CURR EYE RES, V11, P1005, DOI 10.3109/02713689209033499
   Conti SM, 2006, CURR OPIN OPHTHALMOL, V17, P235, DOI 10.1097/01.icu.0000193107.00089.ee
   Conway MD, 2003, J CATARACT REFR SURG, V29, P27, DOI 10.1016/S0886-3350(02)01441-4
   COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473
   COX SN, 1988, ARCH OPHTHALMOL-CHIC, V106, P1190
   CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056
   CRUZ SA, 1992, INT OPHTHALMOL, V16, P153, DOI 10.1007/BF00916434
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   DAMJI KF, 1990, OPHTHALMIC SURG LAS, V21, P31
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DAVIDSON C, 1983, INVEST OPHTH VIS SCI, V24, P301
   Manzano RPD, 2009, ARQ BRAS OFTALMOL, V72, P18, DOI 10.1590/S0004-27492009000100004
   De Caro JJ, 2008, RETINA-J RET VIT DIS, V28, P877, DOI 10.1097/IAE.0b013e31816b3180
   De Clercq E, 1996, Verh K Acad Geneeskd Belg, V58, P19
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012
   De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009
   de Smet M D, 2001, Bull Soc Belge Ophtalmol, P91
   de Smet MD, 1999, BRIT J OPHTHALMOL, V83, P448, DOI 10.1136/bjo.83.4.448
   DECLERCQ E, 1980, J INFECT DIS, V141, P563, DOI 10.1093/infdis/141.5.563
   DECLERCQ E, 1996, VERH K ACAD GENEESKD, V58, P47
   DELPIERO E, 1985, ANN OPHTHALMOL, V17, P753
   DERICK RJ, 1987, ANN OPHTHALMOL, V19, P338
   DHARMA SK, 1986, ACTA OPHTHALMOL, V64, P298
   DIETSOUWEHAND JJAT, 1992, GRAEF ARCH CLIN EXP, V230, P488, DOI 10.1007/BF00175939
   Doft BH, 2001, ARCH OPHTHALMOL-CHIC, V119, P650, DOI 10.1001/archopht.119.5.650
   DOLNAK DR, 1992, INVEST OPHTH VIS SCI, V33, P1557
   DOMINQUEZ DA, 1985, ARCH SOC ESP OFTALMO, V48, P47
   Duker JS, 1995, OPHTHALMIC SURG LAS, V26, P442
   DUNLAP WA, 1994, OPHTHALMIC SURG LAS, V25, P303
   Dupont P, 2003, QJM-INT J MED, V96, P401, DOI 10.1093/qjmed/hcg072
   Durand ML, 2005, AM J OPHTHALMOL, V140, P552, DOI 10.1016/j.ajo.2005.03.030
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   EDWARDS JE, 1980, ANTIMICROB AGENTS CH, V17, P484, DOI 10.1128/AAC.17.3.484
   EHRLICH HP, 1972, NATURE-NEW BIOL, V238, P257, DOI 10.1038/newbio238257a0
   ELLISON AC, 1976, AM J OPHTHALMOL, V81, P157, DOI 10.1016/0002-9394(76)90727-3
   ELSCHNIG A, 1912, ARCH OPHTHALMOL-CHIC, V80, P514
   Elze K L, 1979, Adv Ophthalmol, V38, P134
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Emmerson AM, 2003, J ANTIMICROB CHEMOTH, V51, P13, DOI 10.1093/jac/dkg208
   Engelbert M, 2004, GRAEF ARCH CLIN EXP, V242, P313, DOI 10.1007/s00417-003-0767-9
   Enyedi LB, 1996, CURR EYE RES, V15, P549, DOI 10.3109/02713689609000766
   ERLICHMAN C, 1987, PHARM ANTICANCER DRU, P292
   Esfahani MR, 2006, RETINA-J RET VIT DIS, V26, P182, DOI 10.1097/00006982-200602000-00010
   Esmaeli B, 2003, RETINA-J RET VIT DIS, V23, P118, DOI 10.1097/00006982-200302000-00024
   Essman TF, 1997, OPHTHALMIC SURG LAS, V28, P185
   Eter N, 2006, BIODRUGS, V20, P167, DOI 10.2165/00063030-200620030-00004
   EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Falappone P C F, 2004, Reumatismo, V56, P185
   FERGUSON IA, 1990, J NEUROSCI, V10, P2176
   Ferrara DC, 2007, AM J OPHTHALMOL, V144, P864, DOI 10.1016/j.ajo.2007.07.038
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   FERRARA N, 2005, ONCOLOGY S3, V69, pS11
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FINE BS, 1960, ARCH OPHTHALMOL-CHIC, V64, P849
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   FISCELLA R, 1985, OPHTHALMIC SURG LAS, V16, P247
   FISCELLA R, 1991, OPHTHALMIC SURG LAS, V22, P740
   FISCELLA R, 1987, CAN J OPHTHALMOL, V22, P307
   Fishburne BC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1152, DOI 10.1001/archopht.1997.01100160322009
   FISHMAN PH, 1986, INVEST OPHTH VIS SCI, V27, P1103
   Foster CS, 2003, ARCH OPHTHALMOL-CHIC, V121, P437, DOI 10.1001/archopht.121.4.437
   Fraser TG, 2006, CLEV CLIN J MED, V73, P847, DOI 10.3949/ccjm.73.9.847
   FRAUNFELDER FT, 1985, AM J OPHTHALMOL, V100, P79, DOI 10.1016/S0002-9394(14)74987-6
   FREEMAN WR, 1984, AM J OPHTHALMOL, V98, P235, DOI 10.1016/0002-9394(87)90360-6
   Frenkel S, 2008, BRIT J OPHTHALMOL, V92, P383, DOI 10.1136/bjo.2007.127928
   Freund KB, 2006, RETINA-J RET VIT DIS, V26, P701, DOI 10.1097/00006982-200607000-00021
   FRIDLENDER B, 1978, VIROLOGY, V84, P551, DOI 10.1016/0042-6822(78)90274-X
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gao H, 2004, ARCH OPHTHALMOL-CHIC, V122, P1687, DOI 10.1001/archopht.122.11.1687
   GEIST FC, 1987, ANTIMICROB AGENTS CH, V31, P622, DOI 10.1128/AAC.31.4.622
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Glasgow BJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P873, DOI 10.1001/archopht.1996.01100140087017
   Goldberg DE, 2005, RETINA-J RET VIT DIS, V25, P633, DOI 10.1097/00006982-200507000-00015
   GOLDBERG DE, 2005, RETINA, V25, P682
   Goldblum D, 2007, GRAEF ARCH CLIN EXP, V245, P825, DOI 10.1007/s00417-006-0460-x
   Goldstein MH, 1999, OPHTHALMOLOGY, V106, P1313, DOI 10.1016/S0161-6420(99)00716-2
   Gonzales CA, 2000, OPHTHALMOLOGY, V107, P725, DOI 10.1016/S0161-6420(99)00179-7
   Gordon YJ, 2001, AM J OPHTHALMOL, V131, P371, DOI 10.1016/S0002-9394(00)00955-7
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRAHAM RO, 1975, ARCH OPHTHALMOL-CHIC, V93, P56
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   GRESSEL MG, 1987, ARCH OPHTHALMOL-CHIC, V105, P169
   GRISOLANO J, 1986, OPHTHALMIC SURG LAS, V17, P155
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128
   Gupta A, 2008, EYE, V22, P13, DOI 10.1038/sj.eye.6702463
   GUPTA P, 1976, P SOC EXP BIOL MED, V152, P455
   HAGEMAN GS, 1991, P NATL ACAD SCI USA, V88, P6706, DOI 10.1073/pnas.88.15.6706
   Han DP, 1996, AM J OPHTHALMOL, V122, P1
   Hardwig PW, 2008, RETINA-J RET VIT DIS, V28, P1082, DOI 10.1097/IAE.0b013e3181754231
   Hardwig PW, 2006, AM J OPHTHALMOL, V142, P883, DOI 10.1016/j.ajo.2006.06.002
   HARIPRASAD SM, 2008, RETIN PHYS
   Harper T, 2007, OPHTHALMOLOGY, V114, P871, DOI 10.1016/j.ophtha.2007.01.007
   HARTZER MK, 1989, EXP EYE RES, V48, P321, DOI 10.1016/S0014-4835(89)80001-6
   Hayashi K, 2005, AM J OPHTHALMOL, V139, P972, DOI 10.1016/j.ajo.2004.12.087
   HEATH TD, 1986, INVEST OPHTH VIS SCI, V27, P940
   HEATH TD, 1986, BIOCHIM BIOPHYS ACTA, V862, P72, DOI 10.1016/0005-2736(86)90470-0
   HECTOR RF, 1993, CLIN MICROBIOL REV, V6, P1
   Hegazy HM, 1999, RETINA-J RET VIT DIS, V19, P553, DOI 10.1097/00006982-199911000-00013
   HEIDELBERGER C, 1963, EXP CELL RES, V24, pS62
   HEIER JS, 2006, OPHTHALMOLOGY, V113
   HEIGLE TJ, 1990, OPHTHALMIC SURG LAS, V21, P563
   HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P1767, DOI 10.1001/archopht.1989.01070020849025
   HEINEMANN MH, 1989, ARCH OPHTHALMOL-CHIC, V107, P643, DOI 10.1001/archopht.1989.01070010661016
   HENRY K, 1987, AM J OPHTHALMOL, V103, P17, DOI 10.1016/S0002-9394(14)74163-7
   HEWITT AT, 1990, EXP EYE RES, V50, P79
   HICKS D, 1992, J NEUROSCI, V12, P2022
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   HILTON GF, 1986, OPHTHALMOLOGY, V93, P626
   Hodge WG, 1996, J INFECT DIS, V174, P393, DOI 10.1093/infdis/174.2.393
   HOMER P, 1975, ACTA OPHTHALMOL, V53, P311
   Hsu J, 2007, RETINA-J RET VIT DIS, V27, P1013, DOI 10.1097/IAE.0b013e318050ca7c
   HUANG DSS, 1988, RETINA-J RET VIT DIS, V8, P205, DOI 10.1097/00006982-198808030-00011
   HUANG K, 1979, OPHTHALMIC SURG LAS, V10, P84
   HUNTER PA, 1982, BRIT J OPHTHALMOL, V66, P292, DOI 10.1136/bjo.66.5.292
   Iaccheri B, 2008, CLIN THER, V30, P2069, DOI 10.1016/j.clinthera.2008.10.021
   *INTR INJ SURV, 2006, RETIN PHYS
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Ip MS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1131, DOI 10.1001/archopht.122.8.1131
   Ip MS, 2002, ARCH OPHTHALMOL-CHIC, V120, P1217
   ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048
   ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P268, DOI 10.1098/rspb.1957.0049
   ISENBERG S, 1983, ARCH OPHTHALMOL-CHIC, V101, P764, DOI 10.1001/archopht.1983.01040010764013
   ISENBERG S, 1983, ARCH OPHTHALMOL-CHIC, V101, P761, DOI 10.1001/archopht.1983.01040010761012
   ISENBERG SJ, 1985, ARCH OPHTHALMOL-CHIC, V103, P1340, DOI 10.1001/archopht.1985.01050090092039
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Islam MS, 2007, EYE, V21, P321, DOI 10.1038/sj.eye.6702304
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Jacob Robert A, 2002, Nutr Clin Care, V5, P66, DOI 10.1046/j.1523-5408.2002.00005.x
   JACOBSON MA, 1989, ANTIMICROB AGENTS CH, V33, P736, DOI 10.1128/AAC.33.5.736
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jain AT, 2007, ARCH OPHTHALMOL-CHIC, V125, P1286, DOI 10.1001/archopht.125.9.1286
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EUR J OPHTHALMOL, V15, P462, DOI 10.1177/112067210501500407
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P1054, DOI 10.1016/j.ajo.2004.06.041
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P158, DOI 10.1016/j.ajo.2004.02.025
   Jonas JB, 2004, AM J OPHTHALMOL, V137, P560, DOI 10.1016/j.ajo.2003.08.012
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, AM J OPHTHALMOL, V136, P384, DOI 10.1016/S0002-9394(03)00230-7
   Jonas JB, 2002, BRIT J OPHTHALMOL, V86, P1450, DOI 10.1136/bjo.86.12.1450-a
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   JONES DB, 1978, T OPHTHAL SOC UK, V98, P367
   JOSEPH JP, 1989, CURR EYE RES, V8, P203, DOI 10.3109/02713688908995193
   JULIANO RL, 1980, LIPOSOMES DRUG DELIV, P189
   Kahn P, 2006, OPHTHALMOLOGY, V113, P860, DOI 10.1016/j.ophtha.2006.01.005
   KANA JS, 1982, INVEST OPHTH VIS SCI, V22, P686
   Karacorlu M, 2004, AM J OPHTHALMOL, V138, P289, DOI 10.1016/j.ajo.2004.02.053
   Karacorlu M, 2003, ACTA OPHTHALMOL SCAN, V81, P648, DOI 10.1046/j.1395-3907.2003.0146.x
   KARACORLU MA, 1992, OPHTHALMIC SURG LAS, V23, P833
   KARACORLU S, 1992, RETINA-J RET VIT DIS, V12, P261, DOI 10.1097/00006982-199212030-00012
   KASBEER RT, 1975, A GRAEF ARCH KLIN EX, V196, P279, DOI 10.1007/BF00410039
   Kaur IP, 2008, J OCUL PHARMACOL TH, V24, P481, DOI 10.1089/jop.2008.0031
   Kazi AA, 2006, OPHTHAL SURG LAS IM, V37, P224, DOI 10.3928/15428877-20060501-07
   Kernt M, 2009, RETINA-J RET VIT DIS, V29, P362, DOI 10.1097/IAE.0b013e31818d4b9b
   KESSEL D, 1980, CANCER RES, V40, P3576
   Khairallah M, 2005, RETINA-J RET VIT DIS, V25, P835, DOI 10.1097/00006982-200510000-00003
   KHOOBEHI B, 1991, OPHTHALMIC SURG LAS, V22, P175
   KHOOBEHI B, 1988, OPHTHALMOLOGY, V95, P950
   KHOOBEHI B, 1990, LASER SURG MED, V10, P60, DOI 10.1002/lsm.1900100113
   KHOOBEHI B, 1990, OPHTHALMIC SURG LAS, V21, P840
   Kim H, 2006, EXP EYE RES, V82, P760, DOI 10.1016/j.exer.2005.09.018
   KIRSCH LS, 1995, OPHTHALMOLOGY, V102, P533, DOI 10.1016/S0161-6420(95)30985-2
   KIRSH LS, 1995, AM J OPHTHALMOL, V119, P466, DOI 10.1016/S0002-9394(14)71233-4
   Kishore K, 2001, OPHTHALMIC SURG LAS, V32, P183
   Kitzmann AS, 2007, EYE, V21, P1524, DOI 10.1038/sj.eye.6702804
   Kivilcim Muhamet, 2006, J Coll Physicians Surg Pak, V16, P351
   Kivilcim M, 2007, J OCUL PHARMACOL TH, V23, P57, DOI 10.1089/jop.2006.0083
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Klotz SA, 2000, CLIN MICROBIOL REV, V13, P662, DOI 10.1128/CMR.13.4.662-685.2000
   Kok H, 2005, OPHTHALMOLOGY, V112, P1916, DOI 10.1016/j.ophtha.2005.06.009
   KOMOTO G, 1912, KLIN MONATSBL AUGENH, V50, P265
   Konafani ZA, 2007, EXPERT REV ANTI-INFE, V5, P177, DOI 10.1586/14787210.5.2.177
   Konstantopoulos A, 2007, EYE, V21, P317, DOI 10.1038/sj.eye.6702416
   KOUTSANDREA CN, 1991, CURR EYE RES, V10, P249, DOI 10.3109/02713689109003447
   KOZIOL J, 1974, CAN J OPHTHALMOL, V9, P316
   Kreissig I, 2006, OPHTHALMOLOGE, V103, P30, DOI 10.1007/s00347-005-1235-1
   Krepler K, 2005, ACTA OPHTHALMOL SCAN, V83, P600, DOI 10.1111/j.1600-0420.2005.00490.x
   Krepler K, 2005, ACTA OPHTHALMOL SCAN, V83, P71, DOI 10.1111/j.1600-0420.2005.00400.x
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   KUCERS A, 1979, USE ANTIBIOTICS COMP
   Kukner AS, 2004, CELL BIOCHEM FUNCT, V22, P299, DOI 10.1002/cbf.1105
   Kumar A, 2002, CLIN EXP OPHTHALMOL, V30, P348, DOI 10.1046/j.1442-9071.2002.00554.x
   Kuppermann BD, 1996, J INFECT DIS, V173, P18, DOI 10.1093/infdis/173.1.18
   Kusbeci T, 2007, CURR EYE RES, V32, P57, DOI 10.1080/02713680601107157
   LAI YL, 1986, CURR EYE RES, V5, P933, DOI 10.3109/02713688608995174
   Lam DSC, 1999, EYE, V13, P113, DOI 10.1038/eye.1999.23
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Lee H, 2005, RETINA-J RET VIT DIS, V25, P551, DOI 10.1097/00006982-200507000-00001
   LEEDS NH, 1984, ARCH OPHTHALMOL-CHIC, V102, P1267
   LEEDS NH, 1982, OPHTHALMIC SURG LAS, V13, P653
   Lemley CA, 2007, RETINA-J RET VIT DIS, V27, P662, DOI 10.1097/IAE.0b013e3180323f96
   LEMOR M, 1986, ARCH OPHTHALMOL-CHIC, V104, P1226
   LEOPOLD IH, 1945, ARCH OPHTHALMOL-CHIC, V33, P211
   Liang CP, 1998, AM J OPHTHALMOL, V125, P191, DOI 10.1016/S0002-9394(99)80091-9
   Lin RC, 2008, J OCUL PHARMACOL TH, V24, P245, DOI 10.1089/jop.2007.0105
   Lin Richard C., 2007, International Ophthalmology Clinics, V47, P117, DOI 10.1097/IIO.0b013e31802bd873
   LINCOFF A, 1980, ARCH OPHTHALMOL-CHIC, V98, P1646
   LINCOFF H, 1980, ARCH OPHTHALMOL-CHIC, V98, P1610
   LINCOFF H, 1984, ARCH OPHTHALMOL-CHIC, V102, P928
   LINCOFF H, 1968, INVESTIGATION GASES
   LIU KR, 1987, OPHTHALMOLOGY, V94, P1155
   LIU KR, 1989, INVEST OPHTH VIS SCI, V30, P1527
   Liu M, 2005, CANCER RES, V65, P5325, DOI 10.1158/0008-5472.CAN-04-4589
   Lois N, 2003, SURV OPHTHALMOL, V48, P467, DOI 10.1016/S0039-6257(03)00083-3
   LOPEZBERESTEIN G, 1984, CANCER RES, V44, P375
   LOWENSTEIN A, 1912, ARCH OPHTHALMOL-CHIC, V80, P500
   Lu S, 2005, J OCUL PHARMACOL TH, V21, P205, DOI 10.1089/jop.2005.21.205
   MANDELL GL, 1970, AM J MED SCI, V259, P346, DOI 10.1097/00000441-197005000-00006
   Manzano RPA, 2008, GRAEF ARCH CLIN EXP, V246, P907, DOI 10.1007/s00417-008-0765-z
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Manzouri B, 2001, Expert Opin Pharmacother, V2, P1849, DOI 10.1517/14656566.2.11.1849
   Marangon FB, 2004, AM J OPHTHALMOL, V137, P820, DOI 10.1016/j.ajo.2003.11.078
   Markomichelakis NN, 2004, AM J OPHTHALMOL, V138, P648, DOI 10.1016/j.ajo.2004.04.066
   MARMOR MF, 1986, ARCH OPHTHALMOL-CHIC, V104, P1674
   MARMOR MF, 1982, INVEST OPHTH VIS SCI, V23, P121
   MARMOR MF, 1990, ARCH OPHTHALMOL-CHIC, V108, P1524, DOI 10.1001/archopht.1990.01070130026013
   Martidis A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1380
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mason JO, 2004, RETINA-J RET VIT DIS, V24, P900, DOI 10.1097/00006982-200412000-00009
   MAXWELL DP, 1991, OPHTHALMOLOGY, V98, P1370
   MAY DR, 1974, ARCH OPHTHALMOL-CHIC, V91, P487, DOI 10.1001/archopht.1974.03900060501015
   MCALLISTER IL, 1987, ARCH OPHTHALMOL-CHIC, V105, P913
   MCCALL JM, 1989, NEW CLASS 21 AMINO S, P69
   MCCUEN BW, 1981, AM J OPHTHALMOL, V91, P785, DOI 10.1016/0002-9394(81)90013-1
   MCDONNELL PJ, 1985, OPHTHALMOLOGY, V92, P706, DOI 10.1016/S0161-6420(85)33989-1
   MCGREGOR JA, 1986, J INFECT DIS, V154, P542, DOI 10.1093/infdis/154.3.542-a
   MCGUIGAN LJB, 1988, INVEST OPHTH VIS SCI, V29, P112
   MEISELS H I, 1976, Annals of Ophthalmology, V8, P939
   MEZEI M, 1982, J PHARM PHARMACOL, V34, P473, DOI 10.1111/j.2042-7158.1982.tb04767.x
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mineo JF, 2008, INVEST OPHTH VIS SCI, V49, P4738, DOI 10.1167/iovs.07-1494
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   MORGAN BS, 1979, OPHTHALMIC SURG LAS, V10, P74
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Moshfeghi AA, 2004, AM J OPHTHALMOL, V138, P489, DOI 10.1016/j.ajo.2004.03.025
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Moshfeghi DM, 2005, OPHTHAL SURG LAS IM, V36, P24
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   MUELLERJENSEN K, 1975, AM J OPHTHALMOL, V80, P530, DOI 10.1016/0002-9394(75)90222-6
   Murphy CC, 2004, OPHTHALMOLOGY, V111, P352, DOI 10.1016/S0161-6420(03)00721-8
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   NIKOLEIT JR, 1988, ANN OPHTHALMOL, V20, P385
   NIMNI ME, 1979, SCAND J RHEUMATOL, P71
   Nochez Y, 2008, J OCUL PHARMACOL TH, V24, P87, DOI 10.1089/jop.2007.0087
   Norton E W, 1973, Trans Am Acad Ophthalmol Otolaryngol, V77, pOP85
   NUSSENBLATT RB, 1983, AM J OPHTHALMOL, V96, P275, DOI 10.1016/S0002-9394(14)77814-6
   Ober MD, 2006, AM J OPHTHALMOL, V142, P597, DOI 10.1016/j.ajo.2006.05.041
   OH JO, 1985, INVEST OPHTH VIS SCI, V26, P494
   Ohm J, 1911, GRAEFE ARCH KLIN OPH, V79, P442, DOI [10.1007/BF01977971, DOI 10.1007/BF01977971, 10.1007/bf01977971]
   Ohno S, 2004, J RHEUMATOL, V31, P1362
   OLSEN TW, 1994, ARCH OPHTHALMOL-CHIC, V112, P1471, DOI 10.1001/archopht.1994.01090230085026
   ORGEL IK, 1989, OPHTHALMIC SURG LAS, V20, P584
   Ozdemir H, 2005, AM J OPHTHALMOL, V140, P251, DOI 10.1016/j.ajo.2005.03.004
   Ozdemir H, 2005, ACTA OPHTHALMOL SCAN, V83, P248, DOI 10.1111/j.1600-0420.2005.00395.x
   Ozkiris A, 2005, CAN J OPHTHALMOL, V40, P63, DOI 10.1016/S0008-4182(05)80119-X
   Ozkiris A, 2004, OPHTHALMIC RES, V36, P139, DOI 10.1159/000077326
   Ozkiris AO, 2006, EYE, V20, P13, DOI 10.1038/sj.eye.6701803
   Pai SA, 2007, AM J OPHTHALMOL, V143, P601, DOI 10.1016/j.ajo.2006.12.037
   PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665
   PANG MP, 1986, RETINA-J RET VIT DIS, V6, P260, DOI 10.1097/00006982-198606040-00011
   PANG MP, 1992, CAN J OPHTHALMOL, V27, P6
   PARIS CL, 1991, INT OPHTHALMOL, V15, P173, DOI 10.1007/BF00153923
   Park CH, 2003, AM J OPHTHALMOL, V136, P419, DOI 10.1016/S0002-9394(03)00228-9
   Paskowitz DM, 2007, INVEST OPHTH VIS SCI, V48, P430, DOI 10.1167/iovs.06-0690
   Passos E, 2002, OPHTHALMIC SURG LAS, V33, P140
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Patelli F, 2005, RETINA-J RET VIT DIS, V25, P840, DOI 10.1097/00006982-200510000-00004
   PERRAUT LE, 1981, ARCH OPHTHALMOL-CHIC, V99, P1565, DOI 10.1001/archopht.1981.03930020439006
   PEYMAN G, 1994, INTRAVITREAL SURG PR
   Peyman G A, 1972, Surv Ophthalmol, V17, P41
   PEYMAN GA, 1992, INT OPHTHALMOL, V16, P109, DOI 10.1007/BF00918942
   PEYMAN GA, 1971, INVEST OPHTH VISUAL, V10, P181
   PEYMAN GA, 1971, INVEST OPHTH VISUAL, V10, P489
   PEYMAN GA, 1987, RETINA-J RET VIT DIS, V7, P227, DOI 10.1097/00006982-198707040-00005
   PEYMAN GA, 1984, OPHTHALMIC SURG LAS, V15, P411
   PEYMAN GA, 1974, ARCH OPHTHALMOL-CHIC, V92, P42, DOI 10.1001/archopht.1974.01010010046011
   PEYMAN GA, 1975, DOC OPHTHALMOL, V39, P183, DOI 10.1007/BF00578762
   PEYMAN GA, 1989, RETINA-J RET VIT DIS, V9, P232, DOI 10.1097/00006982-198909030-00012
   PEYMAN GA, 1988, INT OPHTHALMOL, V12, P175, DOI 10.1007/BF00130002
   PEYMAN GA, 1984, OPHTHALMIC SURG LAS, V15, P844
   PEYMAN GA, 1985, SURV OPHTHALMOL, V29, P434, DOI 10.1016/0039-6257(85)90208-5
   PEYMAN GA, 1974, ARCH OPHTHALMOL-CHIC, V91, P416, DOI 10.1001/archopht.1974.03900060428017
   PEYMAN GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P446, DOI 10.1001/archopht.1992.01080160024002
   PEYMAN GA, 1980, OPHTHALMOLOGY, V87, P320
   Peyman GA, 2007, GRAEF ARCH CLIN EXP, V245, P1461, DOI 10.1007/s00417-007-0542-4
   PILLAT A, 1956, Trans Am Acad Ophthalmol Otolaryngol, V60, P206
   POLAK A, 1987, CHEMOTHERAPY, V33, P381, DOI 10.1159/000238524
   POLLARD RB, 1980, ANN INTERN MED, V93, P655, DOI 10.7326/0003-4819-93-5-655
   Prydal JI, 2005, BRIT J OPHTHALMOL, V89, P1418, DOI 10.1136/bjo.2005.073700
   PULIDO J, 1985, ARCH OPHTHALMOL-CHIC, V103, P840
   Pulido JS, 2007, RETINA-J RET VIT DIS, V27, P1071, DOI 10.1097/IAE.0b013e31804ac032
   PULIDO JS, 1984, OPHTHALMIC SURG LAS, V15, P666
   RADTKE ND, 1986, GRAEF ARCH CLIN EXP, V224, P230, DOI 10.1007/BF02143060
   Rahhal FM, 1996, OPHTHALMOLOGY, V103, P1078, DOI 10.1016/S0161-6420(96)30564-2
   RAHIMY MH, 1994, J OCUL PHARMACOL, V10, P561, DOI 10.1089/jop.1994.10.561
   RAHIMY MH, 1994, J DRUG TARGET, V2, P289, DOI 10.3109/10611869409015909
   Rajaraman RT, 2006, OPHTHALMOLOGY, V113, P308, DOI 10.1016/j.ophtha.2005.09.037
   RAO VS, 1989, INT OPHTHALMOL, V13, P181, DOI 10.1007/BF02028207
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reich S, 2003, MOL VIS, V9, P210
   Reiff A, 2001, ARTHRITIS RHEUM, V44, P1411, DOI 10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O
   Rensch F, 2009, ACTA OPHTHALMOL, V87, P77, DOI 10.1111/j.1755-3768.2008.01313.x
   Rezai KA, 2005, ARCH OPHTHALMOL-CHIC, V123, P702, DOI 10.1001/archopht.123.5.702
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Richards JC, 2005, CLIN EXP OPHTHALMOL, V33, P461, DOI 10.1111/j.1442-9071.2005.01062.x
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   ROSENFELD PJ, 2006, OPHTHALMOLOGY, V113
   Rosengren, 1938, ACTA OPHTHALMOL, V16, P573, DOI 10.1111/j.1755-3768.1938.tb06267.x
   ROSENGREN B, 1952, Acta Ophthalmol (Copenh), V30, P117
   Roth DB, 1997, SURV OPHTHALMOL, V41, P395, DOI 10.1016/S0039-6257(97)00005-2
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   RUTGARD JJ, 1978, ANN OPHTHALMOL, V10, P293
   Rybak MJ, 2006, CLIN MICROBIOL INFEC, V12, P24, DOI 10.1111/j.1469-0691.2006.01342.x
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P222, DOI 10.1001/archopht.1995.01100020106040
   SALISBURY JD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1640
   SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023
   SANTANA M, 1984, GRAEF ARCH CLIN EXP, V221, P210, DOI 10.1007/BF02134142
   SARKIES NJC, 1985, T OPHTHAL SOC UK, V104, P243
   Sarria JC, 2005, CLIN INFECT DIS, V40, pE46, DOI 10.1086/427753
   Saurenmann RK, 2006, RHEUMATOLOGY, V45, P982, DOI 10.1093/rheumatology/kel030
   SAVANI DV, 1987, ANTIMICROB AGENTS CH, V31, P6, DOI 10.1128/AAC.31.1.6
   SCHAEFFER HE, 1982, INVEST OPHTH VIS SCI, V22, P220
   SCHENK AG, 1974, ACTA OPHTHALMOL, V52, P707
   SCHENK AG, 1974, A GRAEF ARCH KLIN EX, V190, P281, DOI 10.1007/BF00407889
   SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0
   Schliemann C, 2009, BLOOD, V113, P2275, DOI 10.1182/blood-2008-05-160747
   Schmeling H, 2005, RHEUMATOLOGY, V44, P1008, DOI 10.1093/rheumatology/keh658
   SCHULMAN J, 1986, JPN J OPHTHALMOL, V30, P116
   SCHULMAN JA, 1987, CAN J OPHTHALMOL, V22, P304
   SCHULMAN JA, 1988, BRIT J OPHTHALMOL, V72, P171, DOI 10.1136/bjo.72.3.171
   SCHULMAN JA, 1989, INT OPHTHALMOL, V13, P201, DOI 10.1007/BF02028210
   Scott IU, 2005, ARCH OPHTHALMOL-CHIC, V123, P581, DOI 10.1001/archopht.123.4.581
   Scott IU, 2003, OPHTHALMOLOGY, V110, P1573, DOI 10.1016/S0161-6420(03)00502-5
   SEBAG J, 1987, GRAEF ARCH CLIN EXP, V225, P89, DOI 10.1007/BF02160337
   Sebastian RT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1505, DOI 10.1001/archopht.124.10.1505-a
   SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727
   Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9
   Sen P, 2006, RETINA-J RET VIT DIS, V26, P935, DOI 10.1097/01.iae.0000250011.68532.a2
   Seppala H, 2004, J CATARACT REFR SURG, V30, P307, DOI 10.1016/S0886-3350(03)00617-5
   Sfikakis PP, 2004, ANN INTERN MED, V140, P404, DOI 10.7326/0003-4819-140-5-200403020-00025
   SHAHSAVARI M, 1990, OPHTHALMIC SURG LAS, V21, P726
   Sharma MC, 2004, CORNEA, V23, P398, DOI 10.1097/00003226-200405000-00016
   SHE SC, 1988, INT OPHTHALMOL, V12, P151, DOI 10.1007/BF00137142
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Shen WY, 2000, GRAEF ARCH CLIN EXP, V238, P273, DOI 10.1007/s004170050353
   Shen YC, 2007, INVEST OPHTH VIS SCI, V48, P2238, DOI 10.1167/iovs.06-1362
   Shields CL, 2005, RETINA-J RET VIT DIS, V25, P868, DOI 10.1097/00006982-200510000-00009
   SHORT C, 1966, ARCH OPHTHALMOL-CHIC, V75, P689, DOI 10.1001/archopht.1966.00970050691021
   SIEGEL RC, 1977, J BIOL CHEM, V252, P254
   SIVALINGAM A, 1990, ARCH OPHTHALMOL-CHIC, V108, P869, DOI 10.1001/archopht.1990.01070080113046
   SKOUTELIS AT, 1988, ARCH OPHTHALMOL-CHIC, V106, P404
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   SMALL GH, 1987, CAN J OPHTHALMOL, V22, P300
   Smiddy W E, 1998, Curr Opin Ophthalmol, V9, P66, DOI 10.1097/00055735-199806000-00012
   Smith JA, 2005, ARTHRIT RHEUM-ARTHR, V53, P18, DOI 10.1002/art.20904
   Smith JR, 2002, OPHTHALMOLOGY, V109, P1709, DOI 10.1016/S0161-6420(02)01125-9
   Smith JR, 2001, ARTHRIT RHEUM-ARTHR, V45, P252, DOI 10.1002/1529-0131(200106)45:3<252::AID-ART257>3.3.CO;2-X
   SMITH TJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P255, DOI 10.1001/archopht.1992.01080140111037
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   SMOLIN G, 1981, AM J OPHTHALMOL, V91, P220, DOI 10.1016/0002-9394(81)90177-X
   SNOECK R, 1988, ANTIMICROB AGENTS CH, V32, P1839, DOI 10.1128/AAC.32.12.1839
   Soheilian M, 2007, ARCH OPHTHALMOL-CHIC, V125, P460, DOI 10.1001/archopht.125.4.460
   Soheilian Masoud, 2001, International Ophthalmology, V24, P323, DOI 10.1023/B:INTE.0000006768.66170.c1
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P298, DOI 10.1016/j.ajo.2008.08.016
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P999, DOI 10.1136/bjo.2004.062596
   SPECTOR SA, 1983, ANTIMICROB AGENTS CH, V23, P113, DOI 10.1128/AAC.23.1.113
   Stahl A, 2007, GRAEF ARCH CLIN EXP, V245, P1429, DOI 10.1007/s00417-007-0569-6
   STERN GA, 1977, ARCH OPHTHALMOL-CHIC, V95, P89, DOI 10.1001/archopht.1977.04450010089008
   STERN WH, 1985, OPHTHALMOLOGY, V92, P1701, DOI 10.1016/S0161-6420(85)34095-2
   STERN WH, 1982, AM J OPHTHALMOL, V93, P757, DOI 10.1016/0002-9394(82)90472-X
   STERN WH, 1983, AM J OPHTHALMOL, V96, P43, DOI 10.1016/0002-9394(83)90453-1
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Straus SK, 2006, BBA-BIOMEMBRANES, V1758, P1215, DOI 10.1016/j.bbamem.2006.02.009
   Suhler EB, 2005, ARCH OPHTHALMOL-CHIC, V123, P903, DOI 10.1001/archopht.123.7.903
   Ta CN, 2004, RETINA-J RET VIT DIS, V24, P699, DOI 10.1097/00006982-200410000-00003
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Tammewar AM, 2007, J OCUL PHARMACOL TH, V23, P433, DOI 10.1089/jop.2007.0018
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   *VISION CLIN TRIAL, 2006, OPHTHALMOLOGY, V113
   1983, MED LETT DRUGS THER, V25, P77
   Taskintuna I, 1997, OPHTHALMOLOGY, V104, P1049, DOI 10.1016/S0161-6420(97)30188-2
   Taskintuna I, 1997, EXP EYE RES, V64, P795, DOI 10.1006/exer.1996.0273
   Thompson JT, 2006, AM J OPHTHALMOL, V141, P629, DOI 10.1016/j.ajo.2005.11.050
   TOLENTINO FI, 1982, ARCH OPHTHALMOL-CHIC, V100, P1504, DOI 10.1001/archopht.1982.01030040482021
   TORNAMBE PE, 1989, OPHTHALMOLOGY, V96, P772
   TORNAMBE PE, 1991, OPHTHALMOLOGY, V98, P1115
   TORNAMBE PE, 1988, SURV OPHTHALMOL, V32, P270, DOI 10.1016/0039-6257(88)90175-0
   Tourville E, 2003, CAN J OPHTHALMOL, V38, P598, DOI 10.1016/S0008-4182(03)80115-1
   TREMBLAY C, 1985, INVEST OPHTH VIS SCI, V26, P711
   Unal M, 1999, RETINA-J RET VIT DIS, V19, P442, DOI 10.1097/00006982-199909000-00013
   Ung T, 2007, EYE, V21, P423, DOI 10.1038/sj.eye.6702599
   USSERY FM, 1988, OPHTHALMOLOGY, V95, P640
   VANBOCKXMEER FM, 1985, INVEST OPHTH VIS SCI, V26, P1140
   Velez G, 2002, OPHTHALMIC SURG LAS, V33, P329
   Velez G, 2001, ARCH OPHTHALMOL-CHIC, V119, P1518
   VERDOORN C, 1986, ARCH OPHTHALMOL-CHIC, V104, P1216, DOI 10.1001/archopht.1986.01050200122064
   VONSALLMANN L, 1945, ARCH OPHTHALMOL-CHIC, V33, P455
   VONSALLMANN L, 1945, ARCH OPHTHALMOL-CHIC, V34, P195, DOI 10.1001/archopht.1945.00890190195004
   VYGANTAS CM, 1973, ARCH OPHTHALMOL-CHIC, V90, P235
   WALLERST.RO, 1969, J AMER MED ASSOC, V208, P2045, DOI 10.1001/jama.208.11.2045
   Wang LC, 2005, OCUL IMMUNOL INFLAMM, V13, P295, DOI 10.1080/09273940590951007
   Watanabe M, 2003, NEUROSCIENCE, V116, P733, DOI 10.1016/S0306-4522(02)00562-6
   Weishaar PD, 1998, OPHTHALMOLOGY, V105, P57, DOI 10.1016/S0161-6420(98)71225-3
   WELLER M, 1987, GRAEF ARCH CLIN EXP, V225, P235, DOI 10.1007/BF02175455
   WHITLEY R, 1980, DRUGS, V20, P267, DOI 10.2165/00003495-198020040-00002
   Wickham L, 2007, OPHTHALMOLOGY, V114, P698, DOI 10.1016/j.ophtha.2006.08.042
   Widmer S, 2006, KLIN MONATSBL AUGENH, V223, P456, DOI 10.1055/s-2006-926635
   WIEDEMANN P, 1983, GRAEF ARCH CLIN EXP, V220, P233, DOI 10.1007/BF02308080
   WIEDEMANN P, 1985, INVEST OPHTH VIS SCI, V26, P719
   WIEDEMANN P, 1987, AM J OPHTHALMOL, V104, P10, DOI 10.1016/0002-9394(87)90286-8
   Williamson TH, 2005, AM J OPHTHALMOL, V139, P860, DOI 10.1016/j.ajo.2005.01.001
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   WOODS AC, 1950, AM J OPHTHALMOL, V33, P1325, DOI 10.1016/0002-9394(50)91827-7
   Xu JF, 2007, J OCUL PHARMACOL TH, V23, P527, DOI 10.1089/jop.2007.0002
   Yang CS, 2005, OPHTHALMOLOGICA, V219, P413, DOI 10.1159/000088388
   YANG YZ, 1972, J BIOL CHEM, V247, P4503
   YOSHIZUMI MO, 1986, ARCH OPHTHALMOL-CHIC, V104, P426
   YOSHIZUMI MO, 1985, ANN OPHTHALMOL, V17, P58
   YOSHIZUMI MO, 1988, RETINA-J RET VIT DIS, V8, P210, DOI 10.1097/00006982-198808030-00012
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
   Zarkovic Andrea, 2007, International Ophthalmology, V27, P391, DOI 10.1007/s10792-007-9095-0
   ZIRM E, 1925, KLIN MBL AUGENHEILK, V75, P730
NR 542
TC 145
Z9 156
U1 1
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2009
VL 29
IS 7
BP 875
EP 912
DI 10.1097/IAE.0b013e3181a94f01
PG 38
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 470DT
UT WOS:000267955400002
PM 19584648
DA 2022-11-30
ER

PT J
AU Hashizume, K
   Hirasawa, M
   Imamura, Y
   Noda, S
   Shimizu, T
   Shinoda, K
   Kurihara, T
   Noda, K
   Ozawa, Y
   Ishida, S
   Miyake, Y
   Shirasawa, T
   Tsubota, K
AF Hashizume, Kouhei
   Hirasawa, Manabu
   Imamura, Yutaka
   Noda, Setsuko
   Shimizu, Takahiko
   Shinoda, Kei
   Kurihara, Toshihide
   Noda, Kousuke
   Ozawa, Yoko
   Ishida, Susumu
   Miyake, Yozo
   Shirasawa, Takuji
   Tsubota, Kazuo
TI Retinal dysfunction and progressive retinal cell death in SOD1-deficient
   mice
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID MEDIATED MULTIFOCAL ELECTRORETINOGRAM; ELEVATED OXIDATIVE STRESS;
   AGE-RELATED MACULOPATHY; SUPEROXIDE-DISMUTASE; A-WAVE; CONE;
   DEGENERATION; MODEL; MUTANTS; IMPACT
AB The superoxide dismutase (SOD) family is a major antioxidant system, and deficiency of Cu,Zn-superoxide dismutase (SOD1) in Mice leads to many different phenotypes that resemble accelerated aging. The purpose of this study was to examine the morphology and physiology of the sensory retina in Sod1(-/-) mice. The amplitudes of the a- and b-waves of electroretinograms elicited by stimuli of different intensity were reduced in senescent Sod1(-/-) mice, and this reduction in amplitude was more pronounced with increasing age. Retinal morphometric analyses showed a reduced number of nuclei in both the inner nuclear cell layer and outer nuclear cell layer. Electron microscopy revealed swollen cells and degenerated mitochondria in the inner nuclear cell and outer nuclear cell layer of senescent Sod1(-/-) mice indicating necrotic cell death. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling revealed no significant differences in the number of apoptotic cells between Sod1(-/-) and wild-type mice, and activated caspase-3 could not be detected in the retina of Sod1(-/-) mice. In addition to the age-related macular degeneration-like phenotypes previously reported, Sod1(-/-) mice also present progressive retinal degeneration. Our results indicate that Sod1(-/-) mice may be a good model system in which to study the mechanism of reactive oxygen species-mediated retinal degeneration.
C1 [Hashizume, Kouhei; Hirasawa, Manabu; Imamura, Yutaka; Kurihara, Toshihide; Noda, Kousuke; Ozawa, Yoko; Ishida, Susumu; Tsubota, Kazuo] Keio Univ, Sch Med, Dept Ophthalmol, Inaida Lab,Shinjuku Ku, Tokyo 1608582, Japan.
   [Hashizume, Kouhei] Iwate Med Univ, Sch Med, Dept Ophthalmol, Morioka, Iwate 020, Japan.
   [Noda, Setsuko] Tokai Univ, Dept Hlth Sci, Sch Nursing, Kanagawa 2591100, Japan.
   [Shimizu, Takahiko; Shirasawa, Takuji] Tokyo Metropolitan Inst Gerontol, Res Team Mol Biomarkers, Tokyo, Japan.
   [Shinoda, Kei; Miyake, Yozo] Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo, Japan.
   [Shinoda, Kei] Oita Univ, Sch Med, Dept Ophthalmol, Oita 87011, Japan.
C3 Keio University; Iwate Medical University; Tokai University; Tokyo
   Metropolitan Institute of Gerontology; Oita University
RP Imamura, Y (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Inaida Lab,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM imamura@sc.itc.keio.ac.jp
RI Kurihara, Toshihide/ABA-7058-2020; Ozawa, Yoko/AAH-9888-2020; Shinoda,
   Kei/ABC-7993-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; Shinoda,
   Kei/0000-0002-1543-9345
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Behndig A, 1998, INVEST OPHTH VIS SCI, V39, P471
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dalke C, 2005, EXP EYE RES, V81, P503, DOI 10.1016/j.exer.2005.06.004
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207
   Feigl B, 2006, CURR EYE RES, V31, P635, DOI 10.1080/02713680600762739
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Goto Y, 1998, OPHTHALMIC RES, V30, P368, DOI 10.1159/000055497
   GOTO Y, 1995, INVEST OPHTH VIS SCI, V36, P62
   GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hopp R M, 1998, Mol Vis, V4, P5
   Ikegami T, 2002, BIOCHEM BIOPH RES CO, V296, P729, DOI 10.1016/S0006-291X(02)00933-6
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Iuchi Y, 2007, BIOCHEM J, V402, P219, DOI 10.1042/BJ20061386
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Katai N, 1999, INVEST OPHTH VIS SCI, V40, P1802
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Matzuk MM, 1998, ENDOCRINOLOGY, V139, P4008, DOI 10.1210/en.139.9.4008
   McFadden SL, 1999, J COMP NEUROL, V413, P101
   McFadden SL, 2001, AUDIOLOGY, V40, P313
   Mori M, 2004, AM J PATHOL, V164, P701, DOI 10.1016/S0002-9440(10)63157-4
   Muller FL, 2006, FREE RADICAL BIO MED, V40, P1993, DOI 10.1016/j.freeradbiomed.2006.01.036
   Pacione LR, 2003, ANNU REV NEUROSCI, V26, P657, DOI 10.1146/annurev.neuro.26.041002.131416
   Phelan JK, 2000, MOL VIS, V6, P116
   Sandbach JM, 2001, INVEST OPHTH VIS SCI, V42, P2173
   Sano Y, 2006, AM J PATHOL, V169, P132, DOI 10.2353/ajpath.2006.060085
   SIEVING PA, 1994, VISUAL NEUROSCI, V11, P519, DOI 10.1017/S0952523800002431
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   Uchiyama S, 2006, J BIOL CHEM, V281, P31713, DOI 10.1074/jbc.M603422200
   Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Weiss MJ, 1997, RETINA-J RET VIT DIS, V17, P105, DOI 10.1097/00006982-199703000-00004
NR 40
TC 90
Z9 92
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2008
VL 172
IS 5
BP 1325
EP 1331
DI 10.2353/ajpath.2008.070730
PG 7
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 294CP
UT WOS:000255382000016
PM 18372426
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Yu, LL
   Wu, XM
   Cheng, ZY
   Lee, CV
   LeCouter, J
   Campa, C
   Fuh, G
   Lowman, H
   Ferrara, N
AF Yu, Lanlan
   Wu, Xiumin
   Cheng, Zhiyong
   Lee, Chingwei V.
   LeCouter, Jennifer
   Campa, Claudio
   Fuh, Germaine
   Lowman, Henry
   Ferrara, Napoleone
TI Interaction between bevacizumab and murine VEGF-A: A reassessment
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; KINETIC-ANALYSIS; ANGIOGENESIS; ANTIBODY;
   TUMOR; NEOVASCULARIZATION; LYMPHANGIOGENESIS; FRAGMENT; THERAPY; CANCER
AB PURPOSE. Bevacizumab is a humanized anti-human VEGF-A monoclonal antibody (mAb) approved by the United States Food and Drug Administration for cancer therapy and used off label to treat neovascular age-related macular degeneration. Earlier studies characterized bevacizumab as species specific and lacking the ability to neutralize murine (m) VEGF-A. However, a recent study reported that bevacizumab is a potent inhibitor of hemangiogenesis and lymphangiogenesis in murine models. The authors sought to reassess the interaction between bevacizumab and mVEGF-A.
   METHODS. The authors performed Western blot analysis, plasmon resonance by BIAcore, and endothelial cell proliferation assays to characterize the interaction between bevacizumab and mVEGF-A. They also tested whether bevacizumab had any effects in two in vivo murine models, laser-induced choroidal neovascularization (CNV) and melanoma growth.
   RESULTS. Western blot detected a very weak interaction, but BIAcore detected no measurable interaction between mVEGF and bevacizumab. Bevacizumab failed to inhibit mVEGF-stimulated endothelial cell proliferation. In addition, bevacizumab was indistinguishable from the control antibody in the CNV and tumor models, whereas a cross-reactive anti-VEGF-A mAb had dramatic inhibitory effects.
   CONCLUSIONS. Bevacizumab has an extremely weak interaction with mVEGF-A, which fails to result in immunoneutralization as assessed by several bioassays.
C1 [Yu, Lanlan; Wu, Xiumin; Cheng, Zhiyong; Lee, Chingwei V.; LeCouter, Jennifer; Campa, Claudio; Fuh, Germaine; Lowman, Henry; Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ferrara, N (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM nf@gene.com
RI campa, claudio/B-3992-2013
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bock F, 2007, INVEST OPHTH VIS SCI, V48, P2545, DOI 10.1167/iovs.06-0570
   CAMPA C, IN PRESS INVEST OPHT
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Gerber HP, 2007, P NATL ACAD SCI USA, V104, P3478, DOI 10.1073/pnas.0611492104
   Halin C, 2007, BLOOD, V110, P3158, DOI 10.1182/blood-2007-01-066811
   Hirakawa S, 2005, J EXP MED, V201, P1089, DOI 10.1084/jem.20041896
   Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0
   Katsamba PS, 2006, ANAL BIOCHEM, V352, P208, DOI 10.1016/j.ab.2006.01.034
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937
   Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Presta LG, 1997, CANCER RES, V57, P4593
   Red-Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013
   Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770
   Zheng M, 2001, J VIROL, V75, P9828, DOI 10.1128/JVI.75.20.9828-9835.2001
NR 29
TC 132
Z9 352
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2008
VL 49
IS 2
BP 522
EP 527
DI 10.1167/iovs.07-1175
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 256RK
UT WOS:000252747100006
PM 18234994
DA 2022-11-30
ER

PT J
AU Yang, Y
   Yang, DL
   Schluesener, HJ
   Zhang, ZR
AF Yang, Yan
   Yang, Dongliang
   Schluesener, Hermann J.
   Zhang, Zhiren
TI Advances in SELEX and application of aptamers in the central nervous
   system
SO BIOMOLECULAR ENGINEERING
LA English
DT Review
DE SELEX; aptamers; central nervous system
ID IN-VITRO SELECTION; RNA APTAMERS; PRION-PROTEIN; AUTOMATED SELECTION;
   MOLECULAR APTAMERS; DNA APTAMERS; AFFINITY; LIGANDS; GENE; EVOLUTION
AB SELEX (Systematic Evolution of Ligands by Exponential Enrichment) is a screening technique that involves the progressive selection of highly specific ligands by repeated rounds of partition and amplification from a large combinatorial nucleic acid library. The products of the selection are called aptamers, which are short single stranded DNA or RNA molecules, binding with high affinity, attributed to their specific three-dimensional shapes, to a large variety of targets, ranging from small molecules to complex mixtures. Various improvement of the original SELEX method described in 1990 have been obtained recently, such as capillary electrophoresis SELEX, Toggle-SELEX, Tailored-SELEX, Photo-SELEX, and others. These new variants greatly shorten time of selection and improve aptamer affinity and specificity. Such aptamers have great potential as detecting and/or diagnostic reagents. Furthermore, some aptamers specifically inhibit biological functions of targeted proteins, and are considered as potent therapeutic lead structures evaluated in preclinical disease models. Recently, one aptamer has been approved by Food and Drug Administration of US for treating age-related macular degeneration. This review presents recent advances in the field of SELEX with special emphasis on applications of aptamers as analytical, diagnostic and therapeutic tools in the central nervous system. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Schluesener, Hermann J.; Zhang, Zhiren] Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany.
   [Yang, Yan; Yang, Dongliang] Huazhong Univ Sci & Technol, Tongji Med Coll, Ctr Med Expt, Wuhan 430030, Peoples R China.
C3 Eberhard Karls University of Tubingen; Huazhong University of Science &
   Technology
RP Zhang, ZR (通讯作者)，Univ Tubingen, Inst Brain Res, Calwer St 3, D-72076 Tubingen, Germany.
EM zhangzhiren@yahoo.com
RI Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014
OI Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835
CR Berezovski MV, 2006, NAT PROTOC, V1, P1359, DOI 10.1038/nprot.2006.200
   Bischoff A, 1999, TRENDS PHARMACOL SCI, V20, P104, DOI 10.1016/S0165-6147(99)01319-X
   Brockstedt U, 2004, BIOCHEM BIOPH RES CO, V313, P1004, DOI 10.1016/j.bbrc.2003.12.030
   Bunka DHJ, 2006, NAT REV MICROBIOL, V4, P588, DOI 10.1038/nrmicro1458
   Calo G, 2000, PEPTIDES, V21, P935, DOI 10.1016/S0196-9781(00)00230-8
   Calo' G, 2002, CLIN EXP PHARMACOL P, V29, P223, DOI 10.1046/j.1440-1681.2002.03633.x
   Cao ZH, 2005, CHEM-EUR J, V11, P4502, DOI 10.1002/chem.200400983
   Centi S, 2007, ANAL CHEM, V79, P1466, DOI 10.1021/ac061879p
   Cerchia L, 2005, PLOS BIOL, V3, P697, DOI 10.1371/journal.pbio.0030123
   Cerchia L, 2006, MOL CANCER RES, V4, P481, DOI 10.1158/1541-7786.MCR-06-0050
   Chaloin L, 2002, NUCLEIC ACIDS RES, V30, P4001, DOI 10.1093/nar/gkf522
   Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9
   Cox JC, 2001, BIOORGAN MED CHEM, V9, P2525, DOI 10.1016/S0968-0896(01)00028-1
   Cox JC, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf107
   Cui Y, 2004, J MEMBRANE BIOL, V202, P137, DOI 10.1007/s00232-004-0725-4
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Daniels DA, 2002, ANAL BIOCHEM, V305, P214, DOI 10.1006/abio.2002.5663
   Drabovich A, 2005, J AM CHEM SOC, V127, P11224, DOI 10.1021/ja0530016
   DRACMAN DB, 1994, NATURE, V346, P818
   ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443
   Eulberg D, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni044
   Faulhammer D, 2004, RNA, V10, P516, DOI 10.1261/rna.5186504
   German I, 1998, ANAL CHEM, V70, P4540, DOI 10.1021/ac980638h
   Golden MC, 2000, J BIOTECHNOL, V81, P167, DOI 10.1016/S0168-1656(00)00290-X
   Gopinath SCB, 2006, THROMB HAEMOSTASIS, V95, P767, DOI 10.1160/TH06-01-0047
   Heckel A, 2005, J AM CHEM SOC, V127, P822, DOI 10.1021/ja043285e
   Held DM, 2006, FRONT BIOSCI-LANDMRK, V11, P89, DOI 10.2741/1782
   Hicke BJ, 2001, J BIOL CHEM, V276, P48644, DOI 10.1074/jbc.M104651200
   Huang CC, 2004, ANAL CHEM, V76, P6973, DOI 10.1021/ac049158i
   Hussein M. F., 2004, Scientific Journal of King Faisal University (Basic and Applied Sciences), V5, P139
   Hwang J, 2006, J BIOMOL SCREEN, V11, P599, DOI 10.1177/1087057106288491
   Hybarger G, 2006, ANAL BIOANAL CHEM, V384, P191, DOI 10.1007/s00216-005-0089-3
   Jarosch F, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl463
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Koch TH, 2004, J MOL BIOL, V336, P1159, DOI 10.1016/j.jmb.2004.01.001
   Lee SW, 1997, NAT BIOTECHNOL, V15, P41, DOI 10.1038/nbt0197-41
   Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379
   Martell RE, 2002, MOL THER, V6, P30, DOI 10.1006/mthe.2002.0624
   Mayer G, 2005, CHEMBIOCHEM, V6, P1966, DOI 10.1002/cbic.200500198
   Mendonsa SD, 2004, ANAL CHEM, V76, P5387, DOI 10.1021/ac049857v
   Mendonsa SD, 2005, J AM CHEM SOC, V127, P9382, DOI 10.1021/ja052406n
   Mendonsa SD, 2004, J AM CHEM SOC, V126, P20, DOI 10.1021/ja037832s
   Mercey R, 2006, ARCH VIROL, V151, P2197, DOI 10.1007/s00705-006-0790-3
   Proske D, 2002, J BIOL CHEM, V277, P11416, DOI 10.1074/jbc.M109752200
   Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C
   Que-Gewirth NS, 2007, GENE THER, V14, P283, DOI 10.1038/sj.gt.3302900
   Rentmeister A, 2006, RNA, V12, P1650, DOI 10.1261/rna.126306
   Rhie A, 2003, J BIOL CHEM, V278, P39697, DOI 10.1074/jbc.M305297200
   Romig TS, 1999, J CHROMATOGR B, V731, P275, DOI 10.1016/S0378-4347(99)00243-1
   Sayer NM, 2004, J BIOL CHEM, V279, P13102, DOI 10.1074/jbc.M310928200
   Seiwert SD, 2000, CHEM BIOL, V7, P833, DOI 10.1016/S1074-5521(00)00032-6
   Sekiya S, 2006, J BIOCHEM, V139, P383, DOI 10.1093/jb/mvj046
   Seo HS, 2000, J MICROBIOL BIOTECHN, V10, P707
   Stojanovic MN, 2004, J AM CHEM SOC, V126, P9266, DOI 10.1021/ja032013t
   Takemura K, 2006, EXP BIOL MED, V231, P204
   Tu D, 2005, CELL, V121, P257, DOI 10.1016/j.cell.2005.02.005
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Ulrich H, 1998, P NATL ACAD SCI USA, V95, P14051, DOI 10.1073/pnas.95.24.14051
   VARGHESE JN, 1995, PROTEIN SCI, V4, P1081, DOI 10.1002/pro.5560040606
   Vater A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng130
   Vivekananda J, 2006, LAB INVEST, V86, P610, DOI 10.1038/labinvest.3700417
   Wang XL, 2004, ANAL CHEM, V76, P5605, DOI 10.1021/ac0494228
   Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997
   Wen JD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh179
   White R, 2001, MOL THER, V4, P567, DOI 10.1006/mthe.2001.0495
NR 65
TC 61
Z9 71
U1 0
U2 59
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1389-0344
J9 BIOMOL ENG
JI Biomol. Eng.
PD DEC
PY 2007
VL 24
IS 6
BP 583
EP 592
DI 10.1016/j.bioeng.2007.06.003
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 247FS
UT WOS:000252063800001
PM 17681489
DA 2022-11-30
ER

PT J
AU Rosenthal, R
   Malek, G
   Salomon, N
   Peill-Meininghaus, M
   Coeppicus, L
   Wohlleben, H
   Wimmers, S
   Rickman, CB
   Strauss, O
AF Rosenthal, R
   Malek, G
   Salomon, N
   Peill-Meininghaus, M
   Coeppicus, L
   Wohlleben, H
   Wimmers, S
   Rickman, CB
   Strauss, O
TI The fibroblast growth factor receptors, FGFR-1 and FGFR-2, mediate two
   independent signalling pathways in human retinal pigment epithelial
   cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE fibroblast growth factor receptors; L-type calcium channels;
   bFGF-induced-c-fos expression; neovascularisation; age-related macular
   degeneration; retinal pigment epithelial cells
ID EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; L-TYPE CHANNELS;
   PROTEIN-KINASE-C; MACULAR DEGENERATION; INCREASED EXPRESSION;
   CALCIUM-CHANNELS; RAT RETINA; IGFBP-3 SECRETION; TYROSINE KINASE; BRAIN
   NEURONS
AB To examine the effects and potential implications for the expression of the two basic fibroblast growth factor (bFGF) receptors, FGFR-1 and FGFR-2, in retinal pigment epithelial (RPE) cells, bFGF-dependent changes in gene expression and RPE cell function were studied. bFGF increased L-type Ca2+ channel activity of RPE cells, which in turn resulted in an increase of vascular endothelial growth factor A (VEGF-A) secretion from RPE cells. Also, both bFGF and direct stimulation of L-type Ca2+ channels by BayK8644 increased the expression of c-fos in RPE cells, to the same extent. bFGF-induced-c-fos expression was reduced by inhibition of FGFR-1, but not by L-type Ca2+ channel inhibition, demonstrating that stimulation of FGFR-1 results in a Ca2+ channel-independent change of gene expression. In contrast, stimulation of FGFR-2 results in a Ca2+ channel-dependent stimulation of VEGF secretion. Furthermore, immunohistological investigation of neovascular tissues obtained from patients with age-related macular degeneration (AMD) revealed FGFR-1 and FGFR-2 expression in the RPE of the diseased tissue. Our findings support the hypothesis that there are two different FGFR-1- and FGFR-2-dependent pathways that modulate the role of bFGF in induction of neovascularisation in AMD. (c) 2005 Elsevier Inc. All rights reserved.
C1 Charite Univ Med, Augenklin & Hochschulambulanz, Berlin, Germany.
   Charite Univ Med, Inst Klin Physiol, Berlin, Germany.
   Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   Univ Hamburg, Klinikum Eppendorf, Klin & Poliklin Augenheilkunde, Hamburg, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Duke
   University; Duke University; University of Hamburg
RP Rosenthal, R (通讯作者)，Charite Univ Med, Augenklin & Hochschulambulanz, Berlin Campus Benjamin Franklin, Berlin, Germany.
EM rita.rosenthal@charite.de
RI Cordeiro, Soenke/H-9002-2012; Cordeiro, Soenke/A-1782-2012; Rosenthal,
   Rita/M-5652-2014; Strauss, Olaf/AAA-6485-2019
OI Cordeiro, Soenke/0000-0002-1049-8303; Bowes Rickman,
   Catherine/0000-0002-8555-9596; Malek, Goldis/0000-0003-0026-2388;
   Strauss, Olaf/0000-0002-6272-8596
FU NATIONAL EYE INSTITUTE [R01EY011286] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY011286, E01 EY 11286] Funding Source: Medline
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   Barg S, 2003, PHARMACOL TOXICOL, V92, P3, DOI 10.1034/j.1600-0773.2003.920102.x
   Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blanco RE, 2000, J COMP NEUROL, V423, P646
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328
   Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521
   CONNOLLY SE, 1992, CURR EYE RES, V11, P1005, DOI 10.3109/02713689209033499
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215
   Geller SF, 2001, INVEST OPHTH VIS SCI, V42, P1363
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Guerrin M, 1997, ONCOGENE, V14, P463, DOI 10.1038/sj.onc.1200846
   Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542
   Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Matsushima M, 1996, JPN J OPHTHALMOL, V40, P329
   McLaren MJ, 1996, FEBS LETT, V387, P63, DOI 10.1016/0014-5793(96)00461-9
   Mergler S, 2002, EXP EYE RES, V74, P29, DOI 10.1006/exer.2001.1128
   Mergler S, 1998, FASEB J, V12, P1125, DOI 10.1096/fasebj.12.12.1125
   Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955
   MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A
   Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   PERRY J, 1995, CURR EYE RES, V14, P585, DOI 10.3109/02713689508998406
   Premkumar DRD, 2000, J APPL PHYSIOL, V88, P1898, DOI 10.1152/jappl.2000.88.5.1898
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Rosenthal R, 2002, ADV EXP MED BIOL, V514, P225
   Rosenthal R, 2001, FASEB J, V15, P970, DOI 10.1096/fj.00-0188com
   Sakai H, 1997, J NEUROBIOL, V32, P377, DOI 10.1002/(SICI)1097-4695(199704)32:4<377::AID-NEU2>3.0.CO;2-3
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   SOUBRANE G, 1994, CURR EYE RES, V13, P183, DOI 10.3109/02713689408995776
   STERNFELD MD, 1989, CURR EYE RES, V8, P1029, DOI 10.3109/02713688908997395
   Strauss O, 1997, FASEB J, V11, P859, DOI 10.1096/fasebj.11.11.9285484
   Strauss O, 2000, BIOCHEM BIOPH RES CO, V270, P806, DOI 10.1006/bbrc.2000.2513
   STRAUSS O, 2003, INVEST OPHTH VIS SCI, P3926
   Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   UEDA Y, 1995, INVEST OPHTH VIS SCI, V36, P373
   UEDA Y, 1993, INVEST OPHTH VIS SCI, V34, P3408
   Wada M, 2001, CURR EYE RES, V23, P226, DOI 10.1076/ceyr.23.3.226.5467
   Walsh N, 2001, EXP EYE RES, V72, P495, DOI 10.1006/exer.2000.0984
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   WEN R, 1995, J NEUROSCI, V15, P7377
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yamamoto C, 1996, JPN J OPHTHALMOL, V40, P480
NR 58
TC 43
Z9 47
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 11
PY 2005
VL 337
IS 1
BP 241
EP 247
DI 10.1016/j.bbrc.2005.09.028
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 974IE
UT WOS:000232584000036
PM 16188231
DA 2022-11-30
ER

PT J
AU Watanabe, D
   Takagi, H
   Suzuma, K
   Oh, H
   Ohashi, H
   Honda, Y
AF Watanabe, D
   Takagi, H
   Suzuma, K
   Oh, H
   Ohashi, H
   Honda, Y
TI Expression of connective tissue growth factor and its potential role in
   choroidal neovascularization
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID OCULAR HISTOPLASMOSIS SYNDROME; VASCULAR ENDOTHELIAL-CELLS; MACULAR
   DEGENERATION; MEMBRANES; PATHOGENESIS; FIBROSIS; FIBROBLASTS; VEGF
AB Background: To determine the expression of connective tissue growth factor (CTGF) in choroidal neovascularization.
   Methods: Surgically excised choroidal neovascular membranes (CNVMs) were obtained at vitrectomy from eight eyes with age-related macular degeneration, five eyes with high myopia, and two eyes with angioid streaks. Light microscopic immunohistochemical analysis was performed to detect CTGF, transforming growth factor beta 1 (TGF-beta 1), vascular endothelial growth factor (VEGF), pancytokeratin, and smooth muscle actin (SMA).
   Results: CNVMs were classified by fibrotic status as cellular CNVM, moderate fibrous CNVM, and extensive fibrous CNVM. CTGF expression was found in vascular cells, stromal cells, and retinal pigment epithelium (RPE) cells. For the stromal cells, fibroblastlike cells were most strongly positive for CTGF. CTGF immunoreactivity in the stroma was stronger in the fibrous CNVMs than in the cellular CNVMs. Immunohistochemical analysis of serial sections revealed colocalization of CTGF with TGF-beta 1 and VEGF; colocalization of CTGF with pancytokeratin and SMA was also found.
   Conclusion: Our findings suggest that transdifferentiated RPE cells and vascular cells possess remarkable CTGF expression in CNVMs. This expression of CTGF may stimulate fibroblasts to produce extracellular matrix and may promote angiogenesis in vascular cells. Colocalized TGF-beta 1 and VEGF may also contribute the upregulation of CTGF.
C1 Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Takagi, H (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoinkawara Cho, Kyoto 6068507, Japan.
EM hitoshi@kuhp.kyoto-u.ac.jp
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
   BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285
   Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   HERIOT WJ, 1984, OPHTHALMOLOGY, V91, P1603
   Hinton DR, 2002, EYE, V16, P422, DOI 10.1038/sj.eye.6700190
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637
   Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1111/j.1523-1755.1998.00820.x
   Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sato S, 2000, J RHEUMATOL, V27, P149
   Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414
   Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
NR 24
TC 39
Z9 43
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT-NOV
PY 2005
VL 25
IS 7
BP 911
EP 918
DI 10.1097/00006982-200510000-00015
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 008AP
UT WOS:000235012900015
PM 16205572
DA 2022-11-30
ER

PT J
AU Fernandez, DC
AF Fernandez, DC
TI Delineating fluid-filled region boundaries in optical coherence
   tomography images of the retina
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE active contour models; age-related macular degeneration; deformable
   models; edge detection; lesion volume; ophthalmology; optical coherence
   tomography; retina; snakes
ID GRADIENT VECTOR FLOW; ACTIVE CONTOUR MODELS; SCALE-SPACE; SNAKES;
   TRACKING
AB We evaluate the ability of a deformable model to yield accurate shape descriptions of fluid-filled regions associated with age-related macular degeneration. Calculation of retinal thickness and volume by the current optical coherence tomography (OCT) system includes fluid-filled regions or lesions along with actual retinal tissue. In order to quantify these lesions independently from the retinal tissue, they must be outlined. A deformable model was applied to OCT images of retinas demonstrating cystoids and subretinal fluid spaces. Several implementation issues were addressed in order to choose appropriate parameters. The use of a nonlinear anisotropic diffusion filter to suppress speckle noise while at the same time preserving the edges of the original image was explored. Once the contours of the lesions were outlined, quantitative analysis of the surface area and volume of the lesions was performed. The deformable model could accurately outline fluid-filled regions within the retina. The detection method tested proved effective in capturing the complexity of fluid-filled regions in OCT images. Deformable models combined with nonlinear anisotropic diffusion filtering show promise in the detection of retinal features of interest for diagnosis in clinical OCT images. Thus, fluid-filled region detection may significantly aid in analysis of treatments and diagnosis.
C1 Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Fernandez, DC (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
EM dcabrera2@med.miami.edu
OI Cabrera DeBuc, Delia/0000-0002-4726-894X
FU NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH RePORTER; NEI
   NIH HHS [P30-EY014801] Funding Source: Medline
CR BREIMAN RS, 1982, AM J ROENTGENOL, V138, P329, DOI 10.2214/ajr.138.2.329
   Brezinski ME, 1996, CIRCULATION, V93, P1206, DOI 10.1161/01.CIR.93.6.1206
   COHEN LD, 1991, CVGIP-IMAG UNDERSTAN, V53, P211, DOI 10.1016/1049-9660(91)90028-N
   COHEN LD, 1993, IEEE T PATTERN ANAL, V15, P1131, DOI 10.1109/34.244675
   COURANT R, 1953, METHODS MATH PHYSICS, V1
   DURIKOVIC R, 1995, VISUAL COMPUT, V11, P277, DOI 10.1007/s003710050021
   FERNANDEZ DC, 2003, INVEST OPHTH VIS SCI, V44, P1770
   Gagnon L, 1997, P SOC PHOTO-OPT INS, V3169, P80, DOI 10.1117/12.279681
   Hao XH, 1999, IEEE T MED IMAGING, V18, P787, DOI 10.1109/42.802756
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KASS M, 1987, INT J COMPUT VISION, V1, P321, DOI 10.1007/BF00133570
   LEYMARIE F, 1993, IEEE T PATTERN ANAL, V15, P617, DOI 10.1109/34.216733
   LU Y, 1992, IEEE T PATTERN ANAL, V14, P450, DOI 10.1109/34.126806
   McInerney T, 1996, Med Image Anal, V1, P91, DOI 10.1016/S1361-8415(96)80007-7
   MCINERNEY T, 1995, FIFTH INTERNATIONAL CONFERENCE ON COMPUTER VISION, PROCEEDINGS, P840, DOI 10.1109/ICCV.1995.466850
   PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205
   Tang JS, 2004, IEEE T BIO-MED ENG, V51, P316, DOI 10.1109/TBME.2003.820374
   TERZOPOULOS D, 1988, ARTIF INTELL, V36, P91, DOI 10.1016/0004-3702(88)90080-X
   Terzopoulos D., 1988, Visual Computer, V4, P306, DOI 10.1007/BF01908877
   Terzopoulos D., 1992, TRACKING KALMAN SNAK, P3
   WILLIAMS DJ, 1990, COMPUT VISION GRAPH, V51, P256, DOI 10.1016/0734-189X(90)90003-E
   Xu CY, 1998, IEEE T IMAGE PROCESS, V7, P359, DOI 10.1109/83.661186
   Xu CY, 1998, SIGNAL PROCESS, V71, P131, DOI 10.1016/S0165-1684(98)00140-6
   ZIOU D, 1993, PATTERN RECOGN, V26, P1305, DOI 10.1016/0031-3203(93)90137-L
   ZIOU D, 1998, INT J PATTERN RECOGN, V8
NR 25
TC 95
Z9 106
U1 0
U2 14
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD AUG
PY 2005
VL 24
IS 8
BP 929
EP 945
DI 10.1109/TMI.2005.848655
PG 17
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 950IW
UT WOS:000230851800001
PM 16092326
DA 2022-11-30
ER

PT J
AU Xie, LR
   Gu, Q
   Wu, XW
   Yin, LL
AF Xie, Lirong
   Gu, Qing
   Wu, Xingwei
   Yin, Lili
TI Activation of LXRs Reduces Oxysterol Lipotoxicity in RPE Cells by
   Promoting Mitochondrial Function
SO NUTRIENTS
LA English
DT Article
DE liver X receptors; lipid metabolism; lipotoxicity; mitochondrial
   function; age-related macular degeneration
ID LIVER X RECEPTORS; SELECTIVE AUTOPHAGY; OXIDATIVE STRESS; CHOLESTEROL;
   PATHOGENESIS; ASSOCIATION; DYSFUNCTION; IMPAIRMENT; METABOLISM;
   MITOPHAGY
AB Effective treatments for age-related macular degeneration (AMD), the most prevalent neurodegenerative form of blindness in older adults, are lacking. Genome-wide association studies have identified lipid metabolism and inflammation as AMD-associated pathogenic changes. Liver X receptors (LXRs) play a critical role in intracellular homeostases, such as lipid metabolism, glucose homeostasis, inflammation, and mitochondrial function. However, its specific role in AMD and its underlying molecular mechanisms remain unknown. In this study, we investigated the effects of lipotoxicity in human retinal pigmental epithelial (ARPE-19) cells and evaluated how LXRs reduce 7-ketocholesterol (7KCh) lipotoxicity in RPE cells using models, both in vivo and in vitro. A decrease in oxidative lipid accumulation was observed in mouse retinas following the activation of the LXRs; this result was also confirmed in cell experiments. At the same time, LXRs activation reduced RPE cell apoptosis induced by oxysterols. We found that oxysterols decreased the mitochondrial membrane potential in ARPE-19 cells, while LXR agonists counteracted these effects. In cultured ARPE-19 cells, activating LXRs reduced p62, mTOR, and LC3I/II levels, and the knockdown of LXRs elevated the expression of these proteins, indicating that activating LXRs could boost mitophagy. The findings of this study suggest LXR-active pharmaceuticals as a potential therapeutic target for dry AMD.
C1 [Xie, Lirong; Gu, Qing; Wu, Xingwei; Yin, Lili] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol,Sch Med, Shanghai 200080, Peoples R China.
   [Xie, Lirong; Gu, Qing; Wu, Xingwei; Yin, Lili] Shanghai Key Lab Fundus Dis, Shanghai 200080, Peoples R China.
   [Yin, Lili] Tongji Univ, Dept Ophthalmol, Shanghai Peoples Hosp 4, Shanghai 200434, Peoples R China.
C3 Shanghai Jiao Tong University; Tongji University
RP Yin, LL (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai Gen Hosp, Dept Ophthalmol,Sch Med, Shanghai 200080, Peoples R China.; Yin, LL (通讯作者)，Shanghai Key Lab Fundus Dis, Shanghai 200080, Peoples R China.; Yin, LL (通讯作者)，Tongji Univ, Dept Ophthalmol, Shanghai Peoples Hosp 4, Shanghai 200434, Peoples R China.
EM xielirong@alumni.sjtu.edu.cn; guqing6823@163.com; wuxingwei2010@tom.com;
   yll1444@alumni.sjtu.edu.cn
FU Science and Technology Project of Songjiang District [2020SJ292]
FX This study was supported by the Science and Technology Project of
   Songjiang District 2020SJ292.
CR A-Gonzalez N, 2009, IMMUNITY, V31, P245, DOI 10.1016/j.immuni.2009.06.018
   Alba G, 2016, EUR J NUTR, V55, P2485, DOI 10.1007/s00394-015-1142-4
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Dernie F, 2020, NEUROCHEM INT, V138, DOI 10.1016/j.neuint.2020.104756
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Graham A, 2015, FREE RADICAL BIO MED, V89, P982, DOI 10.1016/j.freeradbiomed.2015.08.010
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hong C, 2014, NAT REV DRUG DISCOV, V13, P433, DOI 10.1038/nrd4280
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Li W, 2012, FREE RADICAL BIO MED, V53, P2054, DOI 10.1016/j.freeradbiomed.2012.09.007
   Li W, 2021, THERANOSTICS, V11, P222, DOI 10.7150/thno.49860
   Liu LJ, 2003, J BIOL CHEM, V278, P42976, DOI 10.1074/jbc.M308420200
   Mani S, 2021, MITOCHONDRION, V57, P270, DOI 10.1016/j.mito.2021.01.001
   Maruyama Y, 2014, BIOCHEM BIOPH RES CO, V446, P309, DOI 10.1016/j.bbrc.2014.02.093
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nury T, 2014, BIOCHEM BIOPH RES CO, V446, P714, DOI 10.1016/j.bbrc.2013.11.081
   Parikh S, 2016, JOVE-J VIS EXP, DOI 10.3791/54808
   Pascual-Garcia M, 2012, ARCH IMMUNOL THER EX, V60, P235, DOI 10.1007/s00005-012-0179-9
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rami A, 2009, NEUROPATH APPL NEURO, V35, P449, DOI 10.1111/j.1365-2990.2009.01034.x
   Rao SR, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000979
   Riazi-Esfahani Mohammad, 2017, J Ophthalmic Vis Res, V12, P424, DOI 10.4103/jovr.jovr_182_17
   Saliba-Gustafsson P, 2019, J INTERN MED, V286, P660, DOI 10.1111/joim.12951
   Sallam T, 2016, NATURE, V534, P124, DOI 10.1038/nature17674
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Storti F, 2017, EXP EYE RES, V165, P65, DOI 10.1016/j.exer.2017.09.008
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Wei YH, 2015, BIOL REV, V90, P167, DOI 10.1111/brv.12103
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Yang C, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107849
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
NR 36
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2022
VL 14
IS 12
AR 2473
DI 10.3390/nu14122473
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 2K5DC
UT WOS:000816355300001
PM 35745203
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Haensli, C
   Sugiura, Y
   Freund, KB
   Zweifel, SA
AF Haensli, Christof
   Sugiura, Yoshimi
   Freund, K. Bailey
   Zweifel, Sandrine A.
TI CORRELATION OF OUTER RETINAL TUBULATIONS AND CHORIOCAPILLARIS FLOW
   SIGNAL DEFICITS SURROUNDING GEOGRAPHIC ATROPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; atrophy of the
   outer retina and the retinal pigment epithelium; choriocapillaris; flow
   deficits; flow signal deficits; geographic atrophy; optical coherence
   tomography angiography; outer retinal tubulations
ID MACULAR DEGENERATION
AB Purpose: To evaluate and compare paralesional and perilesional choriocapillaris vascular impairment in eyes with geographic atrophy with and without outer retinal tubulations (ORT). Methods: Using swept-source optical coherence tomography angiography, 6 x 6 mm scans of eyes with geographic atrophy with and without ORT were acquired. Choriocapillaris en-face flow and structural images were binarized, before flow signal deficit (FD) analysis in the paraatrophy zone (a 500-mu m-wide band adjacent to the geographic atrophy) and the periatrophy zone (a 500-mu m-wide band adjacent to the latter). Results: Twenty-four eyes of 19 patients with ORT and 18 eyes of 15 patients without ORT were analyzed. With and without ORT, mean percental area of FD (%FD) was greater in para- than in periatrophy zone. The difference of %FD between para- and periatrophy zone (deltaFD) was lower in eyes with ORT (mean 1.8477%, 95% confidence interval 0.8607-2.8346) than without ORT (mean 4.0018%, 95% confidence interval 2.8622-5.1414). Conclusion: In eyes with geographic atrophy caused by non-neovascular age-related macular degeneration, smaller reductions in FDs were found between the para- and periatrophy zone in eyes with ORT. In both cohorts, the paraatrophy zone had more FD than the periatrophy zone.
C1 [Haensli, Christof; Zweifel, Sandrine A.] Univ Hosp Zurich, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
   [Haensli, Christof; Zweifel, Sandrine A.] Univ Zurich, Zurich, Switzerland.
   [Sugiura, Yoshimi; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Sugiura, Yoshimi] Univ Tsukuba, Fac Med, Ibaraki, Japan.
   [Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU Grossman Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   Vitreous Retina Macula Consultants of New York; University of Tsukuba;
   Manhattan Eye Ear & Throat Hospital
RP Zweifel, SA (通讯作者)，Univ Hosp Zurich, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM sandrine.zweifel@usz.ch
RI ; Freund, K. Bailey/V-7488-2018
OI Hansli, Christof/0000-0002-2615-197X; Freund, K.
   Bailey/0000-0002-7888-9773
FU Bruppacher Stiftung; Novartis Pharma CH AG
FX Support by Bruppacher Stiftung and Novartis Pharma CH AG (unrestricted
   research grant).
CR Alagorie AR, 2020, GRAEF ARCH CLIN EXP, V258, P995, DOI 10.1007/s00417-020-04615-w
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Bretz F., 2010, MULTIPLE COMP USING
   Byon I, 2020, AM J OPHTHALMOL, V219, P21, DOI 10.1016/j.ajo.2020.05.027
   Byon I, 2019, AM J OPHTHALMOL, V208, P397, DOI 10.1016/j.ajo.2019.08.026
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Chua J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41917-4
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dirani A, 2015, RETINA-J RET VIT DIS, V35, P1166, DOI 10.1097/IAE.0000000000000439
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Goldberg NR, 2013, RETINA-J RET VIT DIS, V33, P1871, DOI 10.1097/IAE.0b013e318296b12f
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Matet A, 2019, RETINA-J RET VIT DIS, V39, P2178, DOI 10.1097/IAE.0000000000002271
   Mehta N, 2019, AM J OPHTHALMOL, V205, P54, DOI 10.1016/j.ajo.2019.03.008
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Takayama K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33580-y
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 30
TC 3
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2021
VL 41
IS 9
BP 1940
EP 1947
DI 10.1097/IAE.0000000000003135
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5QE
UT WOS:000711821200040
PM 33625113
DA 2022-11-30
ER

PT J
AU Behning, C
   Fleckenstein, M
   Pfau, M
   Adrion, C
   Goerdt, L
   Lindner, M
   Schmitz-Valckenberg, S
   Holz, FG
   Schmid, M
AF Behning, Charlotte
   Fleckenstein, Monika
   Pfau, Maximilian
   Adrion, Christine
   Goerdt, Lukas
   Lindner, Moritz
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Schmid, Matthias
TI Modeling of atrophy size trajectories: variable transformation,
   prediction and age-of-onset estimation
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE Geographic atrophy; Age-related macular degeneration; Box-Cox
   transformation; Mixed-effects models; Prediction; Age-of-onset
   estimation
ID GEOGRAPHIC ATROPHY; MACULAR DEGENERATION; NATURAL-HISTORY; RISK-FACTORS;
   SECONDARY; PROGRESSION; PREVALENCE; DISEASE
AB Background To model the progression of geographic atrophy (GA) in patients with age-related macular degeneration (AMD) by building a suitable statistical regression model for GA size measurements obtained from fundus autofluorescence imaging. Methods Based on theoretical considerations, we develop a linear mixed-effects model for GA size progression that incorporates covariable-dependent enlargement rates as well as correlations between longitudinally collected GA size measurements. To capture nonlinear progression in a flexible way, we systematically assess Box-Cox transformations with different transformation parameters lambda. Model evaluation is performed on data collected for two longitudinal, prospective multi-center cohort studies on GA size progression. Results A transformation parameter of lambda=0.45 yielded the best model fit regarding the Akaike information criterion (AIC). When hypertension and hypercholesterolemia were included as risk factors in the model, they showed an association with progression of GA size. The mean estimated age-of-onset in this model was 67.21 +/- 6.49 years. Conclusions We provide a comprehensive framework for modeling the course of uni- or bilateral GA size progression in longitudinal observational studies. Specifically, the model allows for age-of-onset estimation, identification of risk factors and prediction of future GA size. A square-root transformation of atrophy size is recommended before model fitting.
C1 [Behning, Charlotte; Schmid, Matthias] Univ Hosp Bonn, Dept Med Biometry Informat & Epidemiol, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Pfau, Maximilian] NEI, Ophthalm Genet & Visual Funct Branch, Bethesda, MD 20892 USA.
   [Adrion, Christine] Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Munich, Germany.
   [Goerdt, Lukas; Lindner, Moritz; Holz, Frank G.] Univ Hosp Bonn, Dept Ophthalmol, Bonn, Germany.
C3 University of Bonn; Utah System of Higher Education; University of Utah;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Munich; University of Bonn
RP Behning, C (通讯作者)，Univ Hosp Bonn, Dept Med Biometry Informat & Epidemiol, Venusberg Campus 1, D-53127 Bonn, Germany.
EM charlotte.behning@imbie.uni-bonn.de
OI Behning, Charlotte/0000-0002-9310-3804; Schmid,
   Matthias/0000-0002-0788-0317; Pfau, Maximilian/0000-0001-9761-9640
FU DFG (German Research Foundation) [FL658/4-1, FL658/4-2, PF950/1-1, SPP
   1088, Ho 1926/1-3]; National Institutes of Health Core Grant [EY014800];
   Research to Prevent Blindness, New York, NY
FX This work was supported by the DFG (German Research Foundation) Grant No
   FL658/4-1 and FL658/4-2 (MF); PF950/1-1 (MP) Research Priority Program
   Age-Related Macular Degeneration Grant SPP 1088, Ho 1926/1-3 (FGH);
   Grants from National Institutes of Health Core Grant (EY014800) (MF);
   and in part by an Unrestricted Grant from Research to Prevent Blindness,
   New York, NY, to the Department of Ophthalmology & Visual Sciences,
   University of Utah. The authors would like to thank Joanna Czauderna for
   her support in conducting the DSGA study.
CR Adrion C., 2010, GESUNDHEITSWESEN, V72, P207, DOI [10.1055/s-0030-1266388, DOI 10.1055/S-0030-1266388]
   AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Almohaimeed A, PACKAGE BOXCOXMIX 20
   Arslan J, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.57
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Godunova EK, 2011, ENCY MATH
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Holekamp N, 2020, OPHTHALMOLOGY, V127, P769, DOI 10.1016/j.ophtha.2019.12.009
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Muller PL, 2021, OPHTHALMOLOGICA, V244, P42, DOI 10.1159/000510727
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Shen LB, 2018, OPHTHALMOL RETINA, V2, P914, DOI 10.1016/j.oret.2018.01.019
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Verbeke G, 2009, SPRINGER SER STAT, P1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Ying GS, 2011, OPHTHALMOLOGY, V118, P332, DOI 10.1016/j.ophtha.2010.06.030
NR 37
TC 0
Z9 0
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD AUG 17
PY 2021
VL 21
IS 1
AR 170
DI 10.1186/s12874-021-01356-0
PG 12
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA UC6MT
UT WOS:000686638700002
PM 34404346
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kitano, M
   Fujita, A
   Asaoka, R
   Inoue, T
   Amari, T
   Komatsu, K
   Yamamoto, M
   Ogawa, A
   Aoki, N
   Yamanari, M
   Sugiyama, S
   Aihara, M
   Kato, S
   Azuma, K
   Maruyama-Inoue, M
   Kadonosono, K
   Obata, R
AF Kitano, Marie
   Fujita, Asahi
   Asaoka, Ryo
   Inoue, Tatsuya
   Amari, Tatsuaki
   Komatsu, Kayoko
   Yamamoto, Motoshi
   Ogawa, Asako
   Aoki, Nobuyori
   Yamanari, Masahiro
   Sugiyama, Satoshi
   Aihara, Makoto
   Kato, Satoshi
   Azuma, Keiko
   Maruyama-Inoue, Maiko
   Kadonosono, Kazuaki
   Obata, Ryo
TI Assessment of macular function in patients with non-vascularized pigment
   epithelial detachment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PHASE RETARDATION; SPECTRAL-DOMAIN;
   IDENTIFICATION; DEGENERATION; DISEASES; BLEBS; EYE; OCT
AB Non-vascularized pigment epithelial detachments (PED) are usually associated with dry age-related macular degeneration (AMD). In this study, we aimed to investigate the correlation between visual function and morphologic parameters. Seventeen eyes of eleven patients with non-vascularized AMD were enrolled. In addition to conventional optical coherence tomography (OCT), polarization-sensitive optical coherence tomography (PS-OCT) measurements were performed by evaluating the regularity of retinal pigment epithelium (RPE) entropy within the PED area. Retinal sensitivity was measured with MP-3 microperimetry, and retinal sensitivities within (RSin) and outside (RSout) the PED area were calculated. The relationship between OCT parameters and visual function was analyzed. As a result, there was a significant difference between the RSin and RSout (p < 0.001, Wilcoxon signed rank test). Moreover, RSin was significantly related to logMAR VA (p = 0.033, linear mixed model). The regularity of RPE entropy was significantly related to visual acuity and RSin (p = 0.00038, p = 0.031, linear mixed model), although neither the height nor area of PED correlated with visual function. Our results suggest that retinal sensitivity is significantly deteriorated within the PED area and RPE entropy measured with PS-OCT was closely related to visual function in eyes with non-vascularized PED.
C1 [Kitano, Marie; Fujita, Asahi; Asaoka, Ryo; Inoue, Tatsuya; Amari, Tatsuaki; Komatsu, Kayoko; Yamamoto, Motoshi; Ogawa, Asako; Aihara, Makoto; Kato, Satoshi; Azuma, Keiko; Obata, Ryo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Asaoka, Ryo] Seirei Hamamatsu Gen Hosp, Dept Ophthalmol, Shizuoka, Japan.
   [Asaoka, Ryo] Seirei Christopher Univ, Shizuoka, Japan.
   [Inoue, Tatsuya; Maruyama-Inoue, Maiko; Kadonosono, Kazuaki] Yokohama City Univ, Dept Ophthalmol & Microtechnol, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan.
   [Aoki, Nobuyori; Yamanari, Masahiro; Sugiyama, Satoshi] Forney Corp, Nagoya, Aichi, Japan.
C3 University of Tokyo; Yokohama City University
RP Inoue, T (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.; Inoue, T (通讯作者)，Yokohama City Univ, Dept Ophthalmol & Microtechnol, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan.
EM inouet-tky@umin.ac.jp
CR Asahina Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16143-5
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   de Boer JF, 2017, BIOMED OPT EXPRESS, V8, P1838, DOI 10.1364/BOE.8.001838
   Fujino R, 2020, GRAEF ARCH CLIN EXP, V258, P1949, DOI 10.1007/s00417-020-04759-9
   Fujita A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48825-7
   Fukuda S, 2016, INVEST OPHTH VIS SCI, V57, P5919, DOI 10.1167/iovs.16-19548
   Fukuda S, 2015, INVEST OPHTH VIS SCI, V56, P3196, DOI 10.1167/iovs.14-16327
   Fukuda S, 2014, INVEST OPHTH VIS SCI, V55, P5200, DOI 10.1167/iovs.14-14474
   Fukuda S, 2013, INVEST OPHTH VIS SCI, V54, P1384, DOI 10.1167/iovs.12-10979
   Gotzinger E, 2007, INVEST OPHTH VIS SCI, V48, P3551, DOI 10.1167/iovs.06-0727
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kasaragod D, 2016, INVEST OPHTH VIS SCI, V57, P2305, DOI 10.1167/iovs.15-18178
   MALLOWS CL, 1973, TECHNOMETRICS, V15, P661, DOI 10.2307/1267380
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Obata R, 2021, JPN J OPHTHALMOL, V65, P30, DOI 10.1007/s10384-020-00787-4
   Ogino K, 2014, JPN J OPHTHALMOL, V58, P155, DOI 10.1007/s10384-013-0295-z
   Ritter M, 2013, INVEST OPHTH VIS SCI, V54, P6416, DOI 10.1167/iovs.12-11550
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Schutze C, 2013, INVEST OPHTH VIS SCI, V54, P739, DOI 10.1167/iovs.11-7877
   Schutze C, 2012, RETINA-J RET VIT DIS, V32, P256, DOI 10.1097/IAE.0b013e31821edfb0
   Sugiyama S, 2015, BIOMED OPT EXPRESS, V6, P4951, DOI 10.1364/BOE.6.004951
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Tibshirani RJ, 2012, ANN STAT, V40, P1198, DOI 10.1214/12-AOS1003
   Yasuno Y, 2009, OPT EXPRESS, V17, P3980, DOI 10.1364/OE.17.003980
   Zotter S, 2012, BIOMED OPT EXPRESS, V3, P2720, DOI 10.1364/BOE.3.002720
NR 34
TC 0
Z9 0
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 16
PY 2021
VL 11
IS 1
AR 16577
DI 10.1038/s41598-021-96151-8
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UC6WE
UT WOS:000686663200038
PM 34400749
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Dao, D
   Xie, BQ
   Nadeem, U
   Xiao, JS
   Movahedan, A
   D'Souza, M
   Leone, V
   Hariprasad, SM
   Chang, EB
   Sulakhe, D
   Skondra, D
AF Dao, David
   Xie, Bingqing
   Nadeem, Urooba
   Xiao, Jason
   Movahedan, Asad
   D'Souza, Mark
   Leone, Vanessa
   Hariprasad, Seenu M.
   Chang, Eugene B.
   Sulakhe, Dinanath
   Skondra, Dimitra
TI High-Fat Diet Alters the Retinal Transcriptome in the Absence of Gut
   Microbiota
SO CELLS
LA English
DT Article
DE age-related macular degeneration; high-fat diet; gut microbiome;
   gut-retina axis; RNA sequencing; germ-free mice; complement cascade;
   angiogenesis; retinal inflammation
ID MACULAR DEGENERATION; DIABETIC-RETINOPATHY; NEUROPEPTIDE-Y; NATRIURETIC
   PEPTIDE; METABOLIC MEMORY; CELL MIGRATION; EYE DISEASE; GENE;
   ASSOCIATION; PROTEIN
AB The relationship between retinal disease, diet, and the gut microbiome has shown increasing importance over recent years. In particular, high-fat diets (HFDs) are associated with development and progression of several retinal diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. However, the complex, overlapping interactions between diet, gut microbiome, and retinal homeostasis are poorly understood. Using high-throughput RNA-sequencing (RNA-seq) of whole retinas, we compare the retinal transcriptome from germ-free (GF) mice on a regular diet (ND) and HFD to investigate transcriptomic changes without influence of gut microbiome. After correction of raw data, 53 differentially expressed genes (DEGs) were identified, of which 19 were upregulated and 34 were downregulated in GF-HFD mice. Key genes involved in retinal inflammation, angiogenesis, and RPE function were identified. Enrichment analysis revealed that the top 3 biological processes affected were regulation of blood vessel diameter, inflammatory response, and negative regulation of endopeptidase. Molecular functions altered include endopeptidase inhibitor activity, protease binding, and cysteine-type endopeptidase inhibitor activity. Human and mouse pathway analysis revealed that the complement and coagulation cascades are significantly affected by HFD. This study demonstrates novel data that diet can directly modulate the retinal transcriptome independently of the gut microbiome.
C1 [Dao, David; Xiao, Jason; Hariprasad, Seenu M.; Skondra, Dimitra] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
   [Xie, Bingqing; D'Souza, Mark] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA.
   [Xie, Bingqing; Sulakhe, Dinanath] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Nadeem, Urooba] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
   [Movahedan, Asad] Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, New Haven, CT 06437 USA.
   [Leone, Vanessa] Univ Wisconsin, Dept Anim Biol & Metab, Madison, WI 53706 USA.
   [Leone, Vanessa; Chang, Eugene B.] Univ Chicago, Knapp Ctr Biomed Discovery, Dept Med, Microbiome Med Program, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   University of Chicago; Yale University; University of Wisconsin System;
   University of Wisconsin Madison; University of Chicago
RP Skondra, D (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
EM David.Dao@uchospitals.edu; bxie@medicine.bsd.uchicago.edu;
   Urooba.Nadeem@uchospitals.edu; jason.xiao@uchospitals.edu;
   asadolah.movahedan@yale.edu; dsouza@bsd.uchicago.edu; valeone@wisc.edu;
   sharipra@bsd.uchicago.edu; echang@medicine.bsd.uchicago.edu;
   sulakhe@uchicago.edu; dskondra@bsd.uchicago.edu
OI Leone, Vanessa/0000-0003-4012-4377; Sulakhe,
   Dinanath/0000-0002-4680-1212; Xie, Bingqing/0000-0001-9246-9321
FU BrightFocus Foundation [M2018042]; NIDDK [DK42086]; University of
   Chicago Women's Board; Illinois Society for the Prevention of Blindness
   [FP067271-01-PR, FP105447]
FX This research was funded by BrightFocus Foundation "Role of high fat
   diet and gut microbiome in macular degeneration" (Dimitra Skondra,
   M2018042), NIDDK P30 (E.B.C., DK42086), The University of Chicago
   Women's Board (Dimitra Skondra), and the Illinois Society for the
   Prevention of Blindness (Dimitra Skondra, FP067271-01-PR and J.X.,
   FP105447).
CR Aaltonen V, 2014, ACTA OPHTHALMOL, V92, P740, DOI 10.1111/aos.12415
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Albouery M, 2020, EXP EYE RES, V196, DOI 10.1016/j.exer.2020.108059
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Asare-Bediako B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020464
   Banday AR, 2014, CELL CYCLE, V13, P2526, DOI 10.4161/15384101.2015.941757
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Berry KAZ, 2014, J LIPID RES, V55, P504, DOI 10.1194/jlr.M044990
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brink TC, 2008, CELLS TISSUES ORGANS, V188, P9, DOI 10.1159/000112843
   Buhr ED, 2015, P NATL ACAD SCI USA, V112, P13093, DOI 10.1073/pnas.1516259112
   Bujakowska KM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028274
   Butler JM, 2015, HUM GENET, V134, P705, DOI 10.1007/s00439-015-1552-7
   Cao JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02373-8
   Carlsson E, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.9
   Chang RCA, 2015, INVEST OPHTH VIS SCI, V56, P2367, DOI 10.1167/iovs.14-16143
   Chavali VRM, 2010, INVEST OPHTH VIS SCI, V51, P5499, DOI 10.1167/iovs.10-5543
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Chen W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00474
   Chen Yunshun, 2016, F1000Res, V5, P1438, DOI 10.12688/f1000research.8987.2
   Cheng YH, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720962052
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Choi EH, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.011996
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Clarkson-Townsend DA, 2021, EXP EYE RES, V204, DOI 10.1016/j.exer.2021.108440
   Crawford FC, 2000, NEUROLOGY, V55, P763, DOI 10.1212/WNL.55.6.763
   David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820
   Do MH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060761
   Dow C, 2018, EUR J EPIDEMIOL, V33, P141, DOI 10.1007/s10654-017-0338-8
   Dvorakova MC, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00981
   Elmasry K, 2019, BRIT J PHARMACOL, V176, P93, DOI 10.1111/bph.14507
   Fujimura KE, 2015, CELL HOST MICROBE, V17, P592, DOI 10.1016/j.chom.2015.04.007
   Fukuda S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022751118
   Gong HJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107921
   Govindarajan G, 2017, MITOCHONDRION, V36, P150, DOI 10.1016/j.mito.2017.07.007
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Horne-Badovinac S, 2017, CURR OPIN CELL BIOL, V48, P26, DOI 10.1016/j.ceb.2017.04.003
   Hudson DF, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006483
   Jaakkola U, 2006, EXP CLIN ENDOCR DIAB, V114, P147, DOI 10.1055/s-2006-924079
   Jandhyala SM, 2015, WORLD J GASTROENTERO, V21, P8787, DOI 10.3748/wjg.v21.i29.8787
   Jovancevic N, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00888
   Jovancevic N, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00003
   Kandpal RP, 2012, MOL VIS, V18, P1123
   Kang JH, 2016, JAMA OPHTHALMOL, V134, P294, DOI 10.1001/jamaophthalmol.2015.5601
   Kang JH, 2004, AM J CLIN NUTR, V79, P755
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Kennedy EA, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01534
   Kou BJ, 2008, MICROCIRCULATION, V15, P251, DOI 10.1080/10739680701651495
   Koulu M, 2004, ANN MED, V36, P232, DOI 10.1080/07853890410031236
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kurashige T, 2020, J NEUROL NEUROSUR PS, V91, P220, DOI 10.1136/jnnp-2019-321279
   Lee J, 2021, MOL CELL ENDOCRINOL, V521, DOI 10.1016/j.mce.2020.111114
   Lee JJ, 2015, INVEST OPHTH VIS SCI, V56, P3041, DOI 10.1167/iovs.15-16504
   Liu JH, 2019, J CELL PHYSIOL, V234, P21260, DOI 10.1002/jcp.28731
   Lores-Motta L, 2018, OPHTHALMOLOGY, V125, P1064, DOI 10.1016/j.ophtha.2017.12.023
   Ma JL, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101124
   Manzoni C, 2018, BRIEF BIOINFORM, V19, P286, DOI 10.1093/bib/bbw114
   Mapes J, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006654
   Martinez G, 2020, J MED GENET, V57, P708, DOI 10.1136/jmedgenet-2019-106775
   Nguyen MTT, 2019, NAT CELL BIOL, V21, P420, DOI 10.1038/s41556-019-0301-x
   Mohajeri MH, 2018, NUTR REV, V76, P481, DOI 10.1093/nutrit/nuy009
   Mohamed IN, 2014, DIABETOLOGIA, V57, P413, DOI 10.1007/s00125-013-3101-z
   Murphy EA, 2015, CURR OPIN CLIN NUTR, V18, P515, DOI 10.1097/MCO.0000000000000209
   Nadeem U., 2020, HIGH THROUGHPUT RNA, DOI [10.1101/2020.10.01.318949, DOI 10.1101/2020.10.01.318949]
   Oresic M, 2009, EXP EYE RES, V89, P604, DOI 10.1016/j.exer.2009.06.018
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Pavan B, 2018, DRUG DISCOV TODAY, V23, P1672, DOI 10.1016/j.drudis.2018.06.009
   Pavan B, 2017, DRUG DISCOV TODAY, V22, P1123, DOI 10.1016/j.drudis.2017.05.003
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rollin R, 2004, MOL VIS, V10, P15
   Rowan S, 2018, ADV EXP MED BIOL, V1074, P429, DOI 10.1007/978-3-319-75402-4_53
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Sadeqzadeh E, 2014, MED RES REV, V34, P190, DOI 10.1002/med.21286
   Santos-Carvalho A, 2015, PROG RETIN EYE RES, V47, P19, DOI 10.1016/j.preteyeres.2015.03.001
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Shinomiya K, 2016, INVEST OPHTH VIS SCI, V57
   Singh G, 2006, BRIT J PHARMACOL, V148, P1033, DOI 10.1038/sj.bjp.0706825
   Skondra D., 2007, INVESTIG OPHTHALMOL, V48, P1768
   Skondra D, 2020, J AAPOS, V24, P236, DOI 10.1016/j.jaapos.2020.03.010
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Tang WHW, 2017, CIRC RES, V120, P1183, DOI 10.1161/CIRCRESAHA.117.309715
   Theriault B, 2015, TRANSPLANT DIRECT, V1, DOI 10.1097/TXD.0000000000000539
   Unterholzner L, 2010, NAT IMMUNOL, V11, P997, DOI 10.1038/ni.1932
   Villeneuve LM, 2008, P NATL ACAD SCI USA, V105, P9047, DOI 10.1073/pnas.0803623105
   Wang YE, 2018, JAMA OPHTHALMOL, V136, P141, DOI 10.1001/jamaophthalmol.2017.5702
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Wortmann SB, 2019, J INHERIT METAB DIS, V42, P237, DOI 10.1002/jimd.12011
   Xie Zhuorui, 2021, Curr Protoc, V1, pe90, DOI 10.1002/cpz1.90
   Yamamoto S, 2021, BIOL OPEN, V10, DOI 10.1242/bio.056432
   Yoshimura T, 2018, EMBO REP, V19, DOI 10.15252/embr.201642054
   Youngblood H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194755
   Zhan WX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00295-4
   Zhong Q, 2010, J CELL BIOCHEM, V110, P1306, DOI 10.1002/jcb.22644
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
   Zysset-Burri DC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51698-5
NR 102
TC 5
Z9 5
U1 2
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD AUG
PY 2021
VL 10
IS 8
AR 2119
DI 10.3390/cells10082119
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA UF8RX
UT WOS:000688836700001
PM 34440888
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sharma, S
   Sharma, T
   Prasad, S
   Gopalakrishnan, M
   Chaturvedi, A
AF Sharma, Shashikant
   Sharma, Tanishq
   Prasad, Somdutt
   Gopalakrishnan, Mahesh
   Chaturvedi, Alok
TI Treatment Landscape of Macular Disorders in Indian Patients with the
   Advent of Razumab (TM) (World's First Biosimilar Ranibizumab): A
   Comprehensive Review
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Razumab; Biosimilar ranibizumab; Wet age-related macular degeneration;
   Diabetic macular edema; Retinal vein occlusion; Myopic choroidal
   neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL VEIN OCCLUSION; MYOPIC CHOROIDAL
   NEOVASCULARIZATION; EDEMA SECONDARY; EXTEND REGIMEN; 0.5 MG; VEGF;
   PREVALENCE; DEGENERATION; SAFETY
AB Ranibizumab is approved for the treatment of several macular disorders, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV), among others. The unaffordability of the innovator ranibizumab among patients from developing countries such as India led to the development of the world's first biosimilar ranibizumab, which is a cost-effective alternative that does not compromise efficacy and safety. Razumab (TM), developed and produced by Intas Pharmaceuticals Ltd., India, is the world's first biosimilar of ranibizumab, and is approved in India for the treatment of various macular disorders, including wet AMD, DME, RVO and mCNV. The efficacy and safety of Razumab for the treatment of these macular disorders have been evaluated in both prospective and real-world retrospective studies. Razumab has shown an efficacy similar to that of the innovator ranibizumab, achieving improved visual acuity, as measured by the best corrected visual acuity, and reduction in the central macular thickness, leading to improved patient outcomes. The safety profile of Razumab is comparable to that of the innovator ranibizumab and is well tolerated without any new safety concerns. Here, we review the clinical and real-world data of Razumab in the treatment of macular disorders.
C1 [Sharma, Shashikant; Chaturvedi, Alok] Intas Pharmaceut Ltd, Med Affairs, Ahmadabad, Gujarat, India.
   [Sharma, Tanishq] Shree Krishna Hosp, Karamsad, Gujarat, India.
   [Prasad, Somdutt] AMRI & Fortis Med Ctr, Kolkata, W Bengal, India.
   [Gopalakrishnan, Mahesh] Giridhar Eye Inst, Cochin, Kerala, India.
RP Sharma, S (通讯作者)，Intas Pharmaceut Ltd, Med Affairs, Ahmadabad, Gujarat, India.
EM shashikant_sharma@intaspharma.com
OI Sharma, Tanishq/0000-0002-7135-8160
CR Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Anantharaman G, 2021, INDIAN J OPHTHALMOL, V69, P358, DOI 10.4103/ijo.IJO_40_21
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Azad R, 2012, INDIAN J OPHTHALMOL, V60, P263, DOI 10.4103/0301-4738.98701
   Banker AS., AM SOC RET SPEC ASRS
   Boyer DS, 2013, THER ADV ENDOCRINOL, V4, P151, DOI 10.1177/2042018813512360
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Canadian Agency for Drugs and Technologies in Health, 2015, RAN LUC VIS IMP DUE
   Chakraborty D, 2021, OPHTHALMOL THER, V10, P337, DOI 10.1007/s40123-021-00345-2
   Channa R, 2014, Eye (Lond), V28, P269, DOI 10.1038/eye.2013.245
   Chaturvedi MA, 2019, J CLIN EXP OPHTHALMO, V10, P2
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Ciulla TA, 2003, DIABETES CARE, V26, P2653, DOI 10.2337/diacare.26.9.2653
   Danyliv A, 2017, ADV THER, V34, P611, DOI 10.1007/s12325-017-0484-0
   Dervenis N, 2017, ADV THER, V34, P1270, DOI 10.1007/s12325-017-0548-1
   Desideri LF, 2019, EXPERT OPIN BIOL TH, V19, P735, DOI 10.1080/14712598.2019.1627322
   Ehlken C, 2011, AM J OPHTHALMOL, V152, P298, DOI 10.1016/j.ajo.2011.01.040
   Fogli S, 2016, PHARMACOL RES, V103, P149, DOI 10.1016/j.phrs.2015.11.003
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Genentech Inc, 2018, LUC RAN PRESCR INF
   Gerding H, 2015, BRIT J OPHTHALMOL, V99, P297, DOI 10.1136/bjophthalmol-2014-305041
   Gopal S., 2020, TNOA J OPHTHALMIC SC, V58, P154, DOI [10.4103/tjosr.tjosr_41_20, DOI 10.4103/TJOSR.TJOSR_41_20]
   Grisanti S, 2015, RETINA-J RET VIT DIS, V35, P764, DOI 10.1097/IAE.0000000000000385
   Hamilton RD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227557
   Harrison L, 2017, MEDSCAPE
   Harrison L, 2016, MEDSCAPE
   Harrison L, AM AC OPHTH AAO 2018
   Honavar SG, 2021, INDIAN J OPHTHALMOL, V69, P207, DOI 10.4103/ijo.IJO_150_21
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kasza M, 2015, GRAEF ARCH CLIN EXP, V253, P1581, DOI 10.1007/s00417-015-3030-2
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kim Ramasamy, 2007, Indian Journal of Ophthalmology, V55, P413
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Leveziel N, 2014, OPHTHALMOLOGICA, V232, P53, DOI 10.1159/000360186
   Lowe J, 2003, INVEST OPHTH VIS SCI, V44, pU423
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Minami Y, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0485-4
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Neely KA, 1998, AM J PATHOL, V153, P665, DOI 10.1016/S0002-9440(10)65607-6
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Payne JF, 2017, OPHTHALMOLOGY, V124, P74, DOI 10.1016/j.ophtha.2016.09.021
   Pearce I, 2015, OPHTHALMOLOGY, V122, P1811, DOI 10.1016/j.ophtha.2015.05.038
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Prunte C, 2016, BRIT J OPHTHALMOL, V100, P787, DOI 10.1136/bjophthalmol-2015-307249
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rehak J, 2008, CURR EYE RES, V33, P111, DOI 10.1080/02713680701851902
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Sameera VV., 2016, KERALA J OPHTHALMOL, V28, P180, DOI [DOI 10.4103/KJO.KJO_18_17, 10.4103/kjo.kjo_18_17]
   Sayanagi K, 2019, GRAEF ARCH CLIN EXP, V257, P749, DOI 10.1007/s00417-018-04214-w
   Scott IU, 2020, LANCET, V396, P1927, DOI 10.1016/S0140-6736(20)31559-2
   Sengupta S, 2021, INDIAN J OPHTHALMOL, V69, P209, DOI 10.4103/ijo.IJO_72_21
   Sharma A, 2020, EYE, V34, P1008, DOI 10.1038/s41433-019-0745-z
   Sharma A, 2020, EYE, V34, P1006, DOI 10.1038/s41433-019-0722-6
   Sharma A, 2018, CLIN OPHTHALMOL, V12, P2137, DOI 10.2147/OPTH.S180393
   Sharma K, 2015, ANN NEUROSCI, V22, P232, DOI 10.5214/ans.0972.7531.220408
   Sharma S., 2018, INT J OPHTHALMOL EYE, V6, P368
   Sharma S., 2018, INT J OPHTHALMOL EYE, V6, P377
   Sharma S, 2021, INDIAN J CLIN EXP OP, V7, P246, DOI [10.18231/j.ijceo.2021.050, DOI 10.18231/J.IJCEO.2021.050]
   Sharma S, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00293-w
   Sharma S, 2020, OPHTHALMOL THER, V9, P625, DOI 10.1007/s40123-020-00277-3
   Sharma S, 2020, OPHTHALMOL THER, V9, P103, DOI 10.1007/s40123-019-00228-7
   Sharma S, 2019, OPHTHALMOLOGICA, V241, P24, DOI 10.1159/000488602
   Sheth JU, 2021, INDIAN J OPHTHALMOL, V69, P352, DOI 10.4103/ijo.IJO_2703_20
   Sheth JU, 2020, INDIAN J OPHTHALMOL, V68, P2291, DOI 10.4103/ijo.IJO_2380_20
   Sinha S., 2016, 10 C AS PAC VITR RET
   Song WT, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0017-z
   Srinivas J., AS PAC VITR RET SOC
   Suner IJ, 2013, JAMA OPHTHALMOL, V131, P851, DOI 10.1001/jamaophthalmol.2013.114
   Thapa R, 2017, CLIN OPHTHALMOL, V11, P963, DOI 10.2147/OPTH.S132338
   Topal T, 2017, TURK OFTALMOL DERG, V47, P133, DOI 10.4274/tjo.34735
   Verma L, 2021, INDIAN J OPHTHALMOL, V69, P347, DOI 10.4103/ijo.IJO_2516_20
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Willis JR, 2016, OPHTHALMOLOGY, V123, P1771, DOI 10.1016/j.ophtha.2016.04.021
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang Y, 2015, DRUG DES DEV THER, V9, P3413, DOI 10.2147/DDDT.S87920
NR 81
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD SEP
PY 2021
VL 10
IS 3
BP 431
EP 443
DI 10.1007/s40123-021-00362-1
EA JUN 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TR1YM
UT WOS:000663974300001
PM 34155608
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Uyama, H
   Mandai, M
   Takahashi, M
AF Uyama, Hirofumi
   Mandai, Michiko
   Takahashi, Masayo
TI Stem-cell-based therapies for retinal degenerative diseases: Current
   challenges in the establishment of new treatment strategies
SO DEVELOPMENT GROWTH & DIFFERENTIATION
LA English
DT Article
DE regenerative medicine; retinal organoid; retinal pigment epithelium;
   stem cell; transplantation
ID HUMAN IPS CELLS; PIGMENT-EPITHELIUM; MACULAR DEGENERATION; VISUAL
   FUNCTION; IN-VITRO; HOST PHOTORECEPTORS; SELF-FORMATION; NEURAL RETINA;
   TRANSPLANTATION; GENERATION
AB Various advances have been made in the treatment of retinal diseases, including new treatment strategies and innovations in surgical devices. However, the treatment of degenerative retinal diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), continues to pose a significant challenge. In this review, we focus on the use of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to treat retinal diseases by harnessing the ability of stem cells to differentiate into different body tissues. The retina is a tissue specialized for light sensing, and its degradation leads to vision loss. As part of the central nervous system, the retina has very low regenerative capability, and therefore, treatment options are limited once it degenerates. Nevertheless, innovations in methods to induce the generation of retinal cells and tissues from ESCs/iPSCs enable the development of novel approaches for these irreversible diseases. Here we review some historical background and current clinical trials involving the use of stem-cell-derived retinal pigment epithelial cells for AMD treatment and stem cell-derived retinal cells/tissues for RP therapy. Finally, we discuss our future vision of regenerative treatment for retinal diseases with a partial focus on our studies and introduce other interesting approaches for restoring vision.
C1 [Uyama, Hirofumi; Mandai, Michiko; Takahashi, Masayo] RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
   [Uyama, Hirofumi; Mandai, Michiko; Takahashi, Masayo] Kobe City Eye Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan.
C3 RIKEN
RP Mandai, M (通讯作者)，RIKEN Ctr Biosyst Dynam Res, Lab Retinal Regenerat, Kobe, Hyogo 6500047, Japan.
EM michiko.mandai@riken.jp
OI Uyama, Hirofumi/0000-0002-8951-1565
CR Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Aramant RB, 2002, PROG RETIN EYE RES, V21, P57, DOI 10.1016/S1350-9462(01)00020-9
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Barnea-Cramer AO, 2016, SCI REP-UK, V6, DOI 10.1038/srep29784
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben M'Barek K, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119603
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Das T, 1999, EXP NEUROL, V157, P58, DOI 10.1006/exnr.1998.6992
   Decembrini S, 2017, MOL THER, V25, P634, DOI 10.1016/j.ymthe.2016.12.015
   Deng WL, 2018, STEM CELL REP, V10, P1267, DOI 10.1016/j.stemcr.2018.02.003
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Garita-Hernandez M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12330-2
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Iraha S, 2018, STEM CELL REP, V10, P1059, DOI 10.1016/j.stemcr.2018.01.032
   Jung YH, 2018, ADV MATER, V30, DOI 10.1002/adma.201803550
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kuwahara A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55130-w
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Liu Y, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0053-y
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Morizane Y, 2019, JPN J OPHTHALMOL, V63, P26, DOI 10.1007/s10384-018-0623-4
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Ortin-Martinez A, 2017, STEM CELLS, V35, P932, DOI 10.1002/stem.2552
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Pearson RA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13029
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 1999, AM J OPHTHALMOL, V128, P384, DOI 10.1016/S0002-9394(99)00250-0
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Reichman S, 2017, STEM CELLS, V35, P1176, DOI 10.1002/stem.2586
   Reichman S, 2014, P NATL ACAD SCI USA, V111, P8518, DOI 10.1073/pnas.1324212111
   Santos-Ferreira T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13028
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shimada H, 2017, CELL REP, V20, P384, DOI 10.1016/j.celrep.2017.06.045
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13537
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Sugita S, 2006, EXP EYE RES, V83, P1459, DOI 10.1016/j.exer.2006.08.005
   Sugita S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072217
   Sung Y., 2020, BRIT J OPHTHALMOLOGY, DOI [10.1136/bjophthalmol, DOI 10.1136/BJOPHTHALMOL]
   Takagi S, 2019, OPHTHALMOL RETINA, V3, P850, DOI 10.1016/j.oret.2019.04.021
   Takagi S, 2018, JPN J OPHTHALMOL, V62, P568, DOI 10.1007/s10384-018-0611-8
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takahashi M, 2021, DEV GROWTH DIFFER, V00, P1
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Tu HY, 2018, INVEST OPHTH VIS SCI, V59
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Umekage M, 2019, INFLAMM REGEN, V39, DOI 10.1186/s41232-019-0106-0
   van Zeeburg EJT, 2012, AM J OPHTHALMOL, V153, P120, DOI 10.1016/j.ajo.2011.06.007
   Wako Rina, 2014, Nippon Ganka Gakkai Zasshi, V118, P495
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HG, 2019, CELL STEM CELL, V24, P566, DOI 10.1016/j.stem.2019.02.005
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 82
TC 14
Z9 14
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1592
EI 1440-169X
J9 DEV GROWTH DIFFER
JI Dev. Growth Diff.
PD JAN
PY 2021
VL 63
IS 1
SI SI
BP 59
EP 71
DI 10.1111/dgd.12704
EA JAN 2021
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA QS8HG
UT WOS:000609922500001
PM 33315237
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Aslam, TM
   Mahmood, S
   Balaskas, K
   Hoyle, DC
AF Aslam, Tariq M.
   Mahmood, Sajjad
   Balaskas, Konstantinos
   Hoyle, David C.
TI Statistical Modelling of the Visual Impact of Subretinal Fluid and
   Associated Features
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Image analysis; Macular degeneration; Optical coherence tomography;
   Subretinal fluid
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; MORPHOLOGY; ACUITY
AB Introduction The aim of this study was to develop a statistical model to determine the visual significance of subretinal fluid (SRF) in combination with other constructed optical coherence tomography (OCT) features in patients with wet age-related macular degeneration. Methods The project used labelled data from 1211 OCTs of patients with neovascular macular degeneration (nAMD) attending the macular treatment centre of Manchester Royal Eye Hospital to build a statistical model to determine vision for any virtual, constructed OCT. A four-dimensional plot was created to represent the visual impact of SRF in OCTs in the context of the associated OCT characteristics of atrophy and subretinal hyperreflective material (SHRM). Results The plot illustrates that at levels of SRF below 150 mu m, the impact of SRF on vision is very low. Increasing the amount of fluid to 200 mu m and beyond increases the impact on vision, but only if there is little atrophy or SHRM. Conclusions This study suggests that levels of SRF up to around 150 mu m thickness on OCT have minimal impact on vision. Greater levels of SRF have greater impact on vision, unless associated with significant amounts of atrophy or SHRM, when the additional effect of the SRF on vision remains low.
C1 [Aslam, Tariq M.; Mahmood, Sajjad; Hoyle, David C.] Univ Manchester, Fac Biol Med & Hlth, Sch Pharm & Optometry, Manchester, Lancs, England.
   [Aslam, Tariq M.; Mahmood, Sajjad] NHS Cent Manchester Univ Hosp, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Balaskas, Konstantinos] UCL Inst Ophthalmol, London, England.
C3 University of Manchester; Manchester Royal Eye Hospital; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London
RP Aslam, TM (通讯作者)，Univ Manchester, Fac Biol Med & Hlth, Sch Pharm & Optometry, Manchester, Lancs, England.
EM Tariq.aslam@cmft.nhs.uk
RI Mahmood, Sajjad/AAK-7645-2021; Balaskas, Konstantinos/ABD-5979-2020;
   Aslam, Tariq/A-8532-2016
OI Balaskas, Konstantinos/0000-0002-7690-6277; Aslam,
   Tariq/0000-0002-9739-7280; Hoyle, David/0000-0003-3483-5885
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Aslam TM, 2018, AM J OPHTHALMOL, V185, P94, DOI 10.1016/j.ajo.2017.10.015
   Balaskas K, 2017, RETINA-J RET VIT DIS, V37, P1297, DOI 10.1097/IAE.0000000000001342
   Bates DM, 1988, APPL PROBABILITY STA, P365
   Caballero S, 2009, EXP EYE RES, V88, P367, DOI 10.1016/j.exer.2008.07.012
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
NR 11
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD MAR
PY 2021
VL 10
IS 1
BP 127
EP 135
DI 10.1007/s40123-020-00327-w
EA JAN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI3UY
UT WOS:000606416000001
PM 33420953
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ilochonwu, BC
   Urtti, A
   Hennink, WE
   Vermonden, T
AF Ilochonwu, Blessing C.
   Urtti, Arto
   Hennink, Wim E.
   Vermonden, Tina
TI Intravitreal hydrogels for sustained release of therapeutic proteins
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Review
DE Therapeutic proteins; ocular diseases; retina; Anti-VEGF's; Sustained
   protein release
ID OCULAR DRUG-DELIVERY; ENDOTHELIAL GROWTH-FACTOR; CONTROLLED ANTIBODY
   RELEASE; POLY N-ISOPROPYLACRYLAMIDE; ORTHOGONAL CROSS-LINKING; REVERSE
   THERMAL GEL; IN-SITU GEL; HYALURONIC-ACID; CHITOSAN NANOPARTICLES;
   THERMORESPONSIVE HYDROGELS
AB This review highlights how hydrogel formulations can improve intravitreal protein delivery to the posterior segment of the eye in order to increase therapeutic outcome and patient compliance. Several therapeutic proteins have shown excellent clinical successes for the treatment of various intraocular diseases. However, drug delivery to the posterior segment of the eye faces significant challenges due to multiple physiological barriers preventing drugs from reaching the retina, among which intravitreal protein instability and rapid clearance from the site of injection. Hence, frequent injections are required to maintain therapeutic levels. Moreover, because the world population ages, the number of patients suffering from ocular diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR) is increasing and causing increased health care costs. Therefore, there is a growing need for suitable delivery systems able to tackle the current limitations in retinal protein delivery, which also may reduce costs. Hydrogels have shown to be promising delivery systems capable of sustaining release of therapeutic proteins and thus extending their local presence. Here, an extensive overview of preclinically developed intravitreal hydrogels is provided with attention to the rational design of clinically useful intravitreal systems. The currently used polymers, crosslinking mechanisms, in vitro/in vivo models and advancements are discussed together with the limitations and future perspective of these biomaterials.
C1 [Ilochonwu, Blessing C.; Hennink, Wim E.; Vermonden, Tina] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Univ Weg 99, NL-3584 CG Utrecht, Netherlands.
   [Urtti, Arto] Univ Helsinki, Ctr Drug Res, Div Pharmaceut Biosci, Helsinki, Finland.
   [Urtti, Arto] Univ Eastern Finland, Sch Pharm, Kuopio, Finland.
C3 Utrecht University; University of Helsinki; University of Eastern
   Finland
RP Vermonden, T (通讯作者)，Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, Univ Weg 99, NL-3584 CG Utrecht, Netherlands.
EM t.vermonden@uu.nl
RI Hennink, Wim/O-8632-2016
OI Vermonden, Tina/0000-0002-6047-5900; Urtti, Arto/0000-0001-6064-3102
FU European Union's Horizon 2020 research and innovation programme under
   the Marie Sklodowska-Curie grant [722717]
FX The authors have received funding from the European Union's Horizon 2020
   research and innovation programme under the Marie Sklodowska-Curie grant
   agreement No 722717.
CR Agrahari V, 2017, EXPERT OPIN DRUG DEL, V14, P1145, DOI 10.1080/17425247.2017.1272569
   Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Agrahari V, 2016, MOL PHARMACEUT, V13, P2912, DOI 10.1021/acs.molpharmaceut.5b00828
   Ahmed EM, 2015, J ADV RES, V6, P105, DOI 10.1016/j.jare.2013.07.006
   Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   Akhtar MF, 2016, SAUDI PHARM J, V24, P554, DOI 10.1016/j.jsps.2015.03.022
   Alconcel SNS, 2011, POLYM CHEM-UK, V2, P1442, DOI 10.1039/c1py00034a
   Alexander A, 2014, EUR J PHARM BIOPHARM, V88, P575, DOI 10.1016/j.ejpb.2014.07.005
   Alhalafi Ali Mohammed, 2017, Oman J Ophthalmol, V10, P3, DOI 10.4103/0974-620X.200692
   Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ameeduzzafar, 2016, DRUG DELIV, V23, P710, DOI 10.3109/10717544.2014.923065
   Amrite AC, 2008, MOL VIS, V14, P150
   ANDERSON JA, 1980, ARCH OPHTHALMOL-CHIC, V98, P350
   Annamalai B, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.3
   Ashraf S, 2016, MACROMOL RES, V24, P297, DOI 10.1007/s13233-016-4052-2
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Awwad S, 2015, J PHARM SCI-US, V104, P3330, DOI 10.1002/jps.24480
   Bachu RD, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010028
   Bae KH, 2013, J MATER CHEM B, V1, P5371, DOI 10.1039/c3tb20940g
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bansal P, 2016, J OCUL PHARMACOL TH, V32, P135, DOI 10.1089/jop.2015.0133
   Barar J, 2008, EXPERT OPIN DRUG DEL, V5, P567, DOI [10.1517/17425247.5.5.567, 10.1517/17425247.5.5.567 ]
   Basile AS, 2015, CLIN OPHTHALMOL, V9, P323, DOI 10.2147/OPTH.S74050
   Basuki JS, 2017, ANGEW CHEM INT EDIT, V56, P966, DOI 10.1002/anie.201610618
   Bisht R, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1473
   Boere K., 2015, THERMOGELLING CHEMOS
   Bond-Taylor M, 2017, CLIN OPHTHALMOL, V11, P1689, DOI 10.2147/OPTH.S143898
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Boyer DS, 1999, AM J OPHTHALMOL, V127, P349, DOI 10.1016/S0002-9394(98)00176-7
   Boyette J.C., 2016, POROUS STRUCTURE SUS
   Bravo-Osuna I, 2018, ADV DRUG DELIVER REV, V126, P127, DOI 10.1016/j.addr.2018.01.007
   Britta T.R.F., 2014, BIOCOMPATIBLE REVERS, V55, P469
   Burdick JA, 2011, ADV MATER, V23, pH41, DOI 10.1002/adma.201003963
   Buwalda SJ, 2019, EUR J PHARM BIOPHARM, V139, P232, DOI 10.1016/j.ejpb.2019.04.006
   Buwalda SJ, 2017, BIOMACROMOLECULES, V18, P316, DOI 10.1021/acs.biomac.6b01604
   Calo E, 2015, EUR POLYM J, V65, P252, DOI 10.1016/j.eurpolymj.2014.11.024
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cao YX, 2007, J CONTROL RELEASE, V120, P186, DOI 10.1016/j.jconrel.2007.05.009
   Carreon T, 2017, PROG RETIN EYE RES, V57, P108, DOI 10.1016/j.preteyeres.2016.12.004
   Cascone S, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118803
   Castilho M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19502-y
   Censi R, 2009, J CONTROL RELEASE, V140, P230, DOI 10.1016/j.jconrel.2009.06.003
   Censi R, 2012, J CONTROL RELEASE, V161, P680, DOI 10.1016/j.jconrel.2012.03.002
   Chan A, 2011, CLIN OPHTHALMOL, V5, P1043, DOI 10.2147/OPTH.S13775
   Chang D, 2019, DRUG DISCOV TODAY, V24, P1470, DOI 10.1016/j.drudis.2019.05.037
   Chen XW, 2012, J BIOMATER APPL, V27, P391, DOI 10.1177/0885328211406563
   Cheng YH, 2019, EXP EYE RES, V179, P179, DOI 10.1016/j.exer.2018.11.017
   Cheng YH, 2016, CARBOHYD POLYM, V144, P390, DOI 10.1016/j.carbpol.2016.02.080
   Chou PY, 2017, ACTA BIOMATER, V63, P85, DOI 10.1016/j.actbio.2017.09.010
   Christoforidis JB, 2017, INVEST OPHTH VIS SCI, V58, P5636, DOI 10.1167/iovs.17-22431
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cui ZW, 2007, BIOMACROMOLECULES, V8, P1280, DOI 10.1021/bm061045g
   Cui ZW, 2011, J BIOMED MATER RES A, V98A, P159, DOI 10.1002/jbm.a.33093
   D'souza AA, 2016, EXPERT OPIN DRUG DEL, V13, P1257, DOI 10.1080/17425247.2016.1182485
   Dang JM, 2006, ADV DRUG DELIVER REV, V58, P487, DOI 10.1016/j.addr.2006.03.001
   Darr A, 2009, J MATER SCI-MATER M, V20, P33, DOI 10.1007/s10856-008-3540-0
   Das UN, 2016, ARCH MED SCI, V12, P1142, DOI 10.5114/aoms.2016.61918
   De Gennes P-G., 1979, SCALING CONCEPTS POL
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   del Amo EM, 2015, EUR J PHARM BIOPHARM, V95, P215, DOI 10.1016/j.ejpb.2015.01.003
   del Amo EM, 2015, EXP EYE RES, V137, P111, DOI 10.1016/j.exer.2015.05.003
   Delplace V, 2019, J CONTROL RELEASE, V293, P10, DOI 10.1016/j.jconrel.2018.11.012
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   den Engelsman J, 2011, PHARM RES-DORDR, V28, P920, DOI 10.1007/s11095-010-0297-1
   Dias CS, 2000, J PHARM SCI, V89, P572, DOI 10.1002/(SICI)1520-6017(200005)89:5<572::AID-JPS2>3.0.CO;2-P
   Donnenfeld E, 2018, OPHTHALMOLOGY, V125, P799, DOI 10.1016/j.ophtha.2017.12.029
   Drapala PW, 2011, J BIOMAT SCI-POLYM E, V22, P59, DOI 10.1163/092050609X12578498952315
   Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   DUNCAN TE, 1983, AM J OPHTHALMOL, V95, P562, DOI 10.1016/0002-9394(83)90288-X
   Durairaj C, 2017, HANDB EXP PHARMACOL, V242, P31, DOI 10.1007/164_2016_32
   Egbu R, 2018, EUR J PHARM BIOPHARM, V124, P95, DOI 10.1016/j.ejpb.2017.12.019
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   El Sanharawi M, 2010, PROG RETIN EYE RES, V29, P443, DOI 10.1016/j.preteyeres.2010.04.001
   Elgundi Z, 2017, ADV DRUG DELIVER REV, V122, P2, DOI 10.1016/j.addr.2016.11.004
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Famili A, 2017, MOL PHARMACEUT, V14, P1961, DOI 10.1021/acs.molpharmaceut.7b00067
   Fathalla ZMA, 2016, DRUG DEV IND PHARM, V42, P514, DOI 10.3109/03639045.2015.1081236
   FEIL H, 1993, MACROMOLECULES, V26, P2496, DOI 10.1021/ma00062a016
   Franssen O, 1999, J CONTROL RELEASE, V60, P211, DOI 10.1016/S0168-3659(99)00074-7
   Franssen O, 1997, J CONTROL RELEASE, V44, P237, DOI 10.1016/S0168-3659(96)01527-1
   Frokjaer S, 2005, NAT REV DRUG DISCOV, V4, P298, DOI 10.1038/nrd1695
   Fu SL, 2017, CARBOHYD POLYM, V169, P332, DOI 10.1016/j.carbpol.2017.04.028
   Gan TT, 2010, J MATER CHEM, V20, P5937, DOI 10.1039/c0jm00338g
   Gharazi S, 2018, ACS APPL MATER INTER, V10, P34664, DOI 10.1021/acsami.8b14126
   Ghobril C, 2015, CHEM SOC REV, V44, P1820, DOI 10.1039/c4cs00332b
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   Giri TK, 2016, NANOARCHITECTONICS FOR SMART DELIVERY AND DRUG TARGETING, P119, DOI 10.1016/B978-0-323-47347-7.00005-7
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gregoritza M, 2017, BIOMACROMOLECULES, V18, P2410, DOI 10.1021/acs.biomac.7b00587
   Grilo AL, 2019, TRENDS BIOTECHNOL, V37, P9, DOI 10.1016/j.tibtech.2018.05.014
   Gupta MK, 2014, J AM CHEM SOC, V136, P14896, DOI 10.1021/ja507626y
   Hafner A, 2015, EUR J PHARM SCI, V75, P142, DOI 10.1016/j.ejps.2015.04.003
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Haller JA, 2009, RETINA-J RET VIT DIS, V29, P46, DOI 10.1097/IAE.0b013e318188c814
   Han CK, 1998, POLYMER, V39, P2809, DOI 10.1016/S0032-3861(97)00612-5
   Haq MA, 2017, MAT SCI ENG C-MATER, V70, P842, DOI 10.1016/j.msec.2016.09.081
   Hartman RR, 2018, J OCUL PHARMACOL TH, V34, P141, DOI 10.1089/jop.2017.0121
   Heilkkinen EM, 2019, MOL PHARMACEUT, V16, P3968, DOI 10.1021/acs.molpharmaceut.9b00585
   Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI [DOI 10.1080/10601326808051910, 10.1080/10601326808051910]
   Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027
   Hoffman AS, 2012, ADV DRUG DELIVER REV, V64, P18, DOI 10.1016/j.addr.2012.09.010
   Horvat G, 2015, EUR J PHARM SCI, V67, P1, DOI 10.1016/j.ejps.2014.10.013
   Huang JH, 2017, COLLOID SURFACE B, V159, P241, DOI 10.1016/j.colsurfb.2017.07.057
   Huang X, 2005, BIOMACROMOLECULES, V6, P2131, DOI 10.1021/bm050116t
   Hurler J, 2012, J FUNCT BIOMATER, V3, P37, DOI 10.3390/jfb3010037
   Hutton-Smith LA, 2016, MOL PHARMACEUT, V13, P2941, DOI 10.1021/acs.molpharmaceut.5b00849
   Ibrahim MA, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.4
   Imai G.P.M. Hisanori, 2015, LOWE SUBCONJUNCTIVAL, V56, P7839
   Imperiale JC, 2018, J CONTROL RELEASE, V285, P106, DOI 10.1016/j.jconrel.2018.06.031
   Inoue K, 2014, CLIN OPHTHALMOL, V8, P903, DOI 10.2147/OPTH.S44708
   Jaffe GJ, 2006, OPHTHALMOLOGY, V113, P1020, DOI 10.1016/j.ophtha.2006.02.021
   Jarrat-Binstock E, 2007, POLYM ADVAN TECHNOL, V18, P720, DOI 10.1002/pat.948
   Jay SM, 2009, J CONTROL RELEASE, V134, P26, DOI 10.1016/j.jconrel.2008.10.019
   Jiang J, 2007, INVEST OPHTH VIS SCI, V48, P4038, DOI 10.1167/iovs.07-0066
   Jiang SB, 2018, INT J OPHTHALMOL-CHI, V11, P1038, DOI 10.18240/ijo.2018.06.23
   Jiang Y, 2015, J BIOMAT SCI-POLYM E, V26, P917, DOI 10.1080/09205063.2015.1068532
   Jiskoot W, 2012, J PHARM SCI-US, V101, P946, DOI 10.1002/jps.23018
   Jonker AM, 2012, CHEM MATER, V24, P759, DOI 10.1021/cm202640w
   Jooybar E, 2019, EUR POLYM J, V115, P234, DOI 10.1016/j.eurpolymj.2019.03.032
   Kasdorf BT, 2015, BIOPHYS J, V109, P2171, DOI 10.1016/j.bpj.2015.10.002
   Kaja Simon, 2011, Human Antibodies, V20, P95, DOI 10.3233/HAB-2011-0244
   Kalam MA, 2016, INT J BIOL MACROMOL, V89, P559, DOI 10.1016/j.ijbiomac.2016.05.016
   Kalam MA, 2016, INT J BIOL MACROMOL, V89, P127, DOI 10.1016/j.ijbiomac.2016.04.070
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Kang DJJ, 2008, T AM OPHTHAL SOC, V106, P206
   Kang-Mieler JJ, 2017, EXPERT OPIN DRUG DEL, V14, P611, DOI 10.1080/17425247.2016.1227785
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kanjickal D, 2008, J BIOMED MATER RES A, V87A, P608, DOI 10.1002/jbm.a.31811
   Katiyar S, 2014, CARBOHYD POLYM, V102, P117, DOI 10.1016/j.carbpol.2013.10.079
   Kato A., 2014, TAIWAN J OPHTHALMOL, V4, P3
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Khalili H, 2016, SCI REP-UK, V6, DOI 10.1038/srep36905
   Kharkar PM, 2013, CHEM SOC REV, V42, P7335, DOI 10.1039/c3cs60040h
   Kirchhof S, 2015, EUR J PHARM BIOPHARM, V95, P227, DOI 10.1016/j.ejpb.2015.05.016
   Kirchhof S, 2015, MOL PHARMACEUT, V12, P3358, DOI 10.1021/acs.molpharmaceut.5b00375
   Klotz U, 2007, CLIN PHARMACOKINET, V46, P645, DOI 10.2165/00003088-200746080-00002
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kong XY, 2018, EXP THER MED, V15, P1442, DOI 10.3892/etm.2017.5586
   Kruh JN, 2014, OPHTHALMOLOGY, V121, P358, DOI 10.1016/j.ophtha.2013.07.019
   Kuno N, 2011, POLYMERS-BASEL, V3, P193, DOI 10.3390/polym3010193
   Kushwaha SKS, 2012, INT J PHARM INVESTIG, V2, P54, DOI 10.4103/2230-973X.100036
   Lamminsalo M, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2435-0
   Lanzalaco S, 2017, GELS-BASEL, V3, DOI 10.3390/gels3040036
   Laptos T, 2018, EXP THER MED, V15, P3161, DOI 10.3892/etm.2018.5821
   Lee F, 2009, J CONTROL RELEASE, V134, P186, DOI 10.1016/j.jconrel.2008.11.028
   Lee SS, 2010, PHARM RES-DORDR, V27, P2043, DOI 10.1007/s11095-010-0159-x
   Lele BS, 2000, J CONTROL RELEASE, V69, P237, DOI 10.1016/S0168-3659(00)00303-5
   LEUCUTA SE, 1989, INT J PHARM, V54, P71, DOI 10.1016/0378-5173(89)90167-1
   Levy-Clarke G, 2014, OPHTHALMOLOGY, V121, P785, DOI 10.1016/j.ophtha.2013.09.048
   Li C, 2018, DRUG DELIV, V25, P1258, DOI 10.1080/10717544.2018.1474972
   Li SK, 2011, J PHARMACEUT BIOMED, V55, P603, DOI 10.1016/j.jpba.2010.12.027
   Liang Wenting, 2019, Polymers (Basel), V11, DOI 10.3390/polym11010133
   Lim Lyndell L, 2005, Curr Opin Investig Drugs, V6, P1159
   Lin CC, 2006, ADV DRUG DELIVER REV, V58, P1379, DOI 10.1016/j.addr.2006.09.004
   Liu SY, 2016, MOL PHARMACEUT, V13, P2897, DOI 10.1021/acs.molpharmaceut.6b00445
   Liu VA, 2002, BIOMED MICRODEVICES, V4, P257, DOI 10.1023/A:1020932105236
   Liu WG, 2008, J MATER SCI-MATER M, V19, P3365, DOI 10.1007/s10856-008-3486-2
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Liu YX, 2019, NAT BIOMED ENG, V3, P58, DOI 10.1038/s41551-018-0335-6
   Loch C, 2012, EUR J PHARM SCI, V47, P131, DOI 10.1016/j.ejps.2012.05.007
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   Lu CH, 2014, J PHARM SCI-US, V103, P216, DOI 10.1002/jps.23777
   Lu Y, 2014, INT J OPHTHALMOL-CHI, V7, P1, DOI 10.3980/j.issn.2222-3959.2014.01.01
   Luo ZC, 2016, DRUG DELIV, V23, P63, DOI 10.3109/10717544.2014.903535
   Madl CM, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201706046
   Madl CM, 2017, BIOCONJUGATE CHEM, V28, P724, DOI 10.1021/acs.bioconjchem.6b00720
   Magnenat L, 2017, MABS-AUSTIN, V9, P127, DOI 10.1080/19420862.2016.1259046
   Mahor A, 2016, J COLLOID INTERF SCI, V483, P132, DOI 10.1016/j.jcis.2016.08.018
   Makwana S B, 2016, Results Pharma Sci, V6, P1, DOI 10.1016/j.rinphs.2015.06.001
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Mandal A, 2017, J CONTROL RELEASE, V248, P96, DOI 10.1016/j.jconrel.2017.01.012
   Manning MC, 2010, PHARM RES-DORDR, V27, P544, DOI 10.1007/s11095-009-0045-6
   Markovsky E, 2012, J CONTROL RELEASE, V161, P446, DOI 10.1016/j.jconrel.2011.12.021
   Mateescu M. A., 2015, CONTROLLED DRUG DELI, P85, DOI DOI 10.1016/B978-1-907568-45-9.00003-2
   Maurice D.M., 1984, HDB EXPT PHARM, P16
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Moradi A, 2013, WORLD J DIABETES, V4, P303, DOI 10.4239/wjd.v4.i6.303
   Moreno TA, 2016, SEMIN OPHTHALMOL, V31, P378, DOI 10.3109/08820538.2016.1154174
   Moussa EM, 2016, J PHARM SCI-US, V105, P417, DOI 10.1016/j.xphs.2015.11.002
   Nagarwal RC, 2012, EUR J PHARM SCI, V47, P678, DOI 10.1016/j.ejps.2012.08.008
   Najafi M., 2018, TEMPERATURE RESPONSI, DOI [10.1002/9781119157830.ch1, DOI 10.1002/9781119157830.CH1]
   Nasongkla N, 2009, J AM CHEM SOC, V131, P3842, DOI 10.1021/ja900062u
   Negrini NC, 2019, ACTA BIOMATER, V87, P61, DOI 10.1016/j.actbio.2019.01.018
   Neradovic D, 2001, MACROMOLECULES, V34, P7589, DOI 10.1021/ma011198q
   Neri P, 2010, MIDDLE EAST AFR J OP, V17, P290, DOI 10.4103/0974-9233.71588
   Nimmo CM, 2011, BIOCONJUGATE CHEM, V22, P2199, DOI 10.1021/bc200281k
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Otero-Espinar FJ, 2018, DRUG TARGETING AND STIMULI SENSITIVE DRUG DELIVERY SYSTEMS, P211, DOI 10.1016/B978-0-12-813689-8.00006-9
   Pahuja P, 2012, EXPERT OPIN DRUG DEL, V9, P837, DOI 10.1517/17425247.2012.690733
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Park D, 2013, MACROMOL BIOSCI, V13, P464, DOI 10.1002/mabi.201200384
   Park D, 2011, BIOMATERIALS, V32, P777, DOI 10.1016/j.biomaterials.2010.09.044
   Park MR, 2010, J CONTROL RELEASE, V147, P359, DOI 10.1016/j.jconrel.2010.07.126
   Park SH, 2018, EUR J PHARM BIOPHARM, V133, P31, DOI 10.1016/j.ejpb.2018.09.021
   Passos MF, 2016, J THERM ANAL CALORIM, V125, P361, DOI 10.1007/s10973-016-5329-6
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel SR, 2011, PHARM RES-DORDR, V28, P166, DOI 10.1007/s11095-010-0271-y
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Popa L., 2018, CHITOSAN GOOD CANDID
   Prestwich GD, 1998, J CONTROL RELEASE, V53, P93, DOI 10.1016/S0168-3659(97)00242-3
   Nguyen QD, 2020, OPHTHALMOLOGY, V127, P963, DOI 10.1016/j.ophtha.2019.12.031
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Raghava Swita, 2004, Expert Opin Drug Deliv, V1, P99, DOI 10.1517/17425247.1.1.99
   Rana A, 2016, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2016/07/026
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Ratanji KD, 2014, J IMMUNOTOXICOL, V11, P99, DOI 10.3109/1547691X.2013.821564
   RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2
   Raza F, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10010016
   Rimpela AK, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010009
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168-3659(87)90035-6
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Rodell CB, 2013, BIOMACROMOLECULES, V14, P4125, DOI 10.1021/bm401280z
   Rong XF, 2019, INT J NANOMED, V14, P45, DOI 10.2147/IJN.S184574
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   Rwei SP, 2018, MATERIALS, V11, DOI 10.3390/ma11050696
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Saher O, 2016, PHARM DEV TECHNOL, V21, P600, DOI 10.3109/10837450.2015.1035728
   Saunders L, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201800313
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R
   Schuurmans CCL, 2018, SOFT MATTER, V14, P6327, DOI 10.1039/c8sm00686e
   Schwartz DM, 1996, CURR EYE RES, V15, P1156, DOI 10.3109/02713689608995150
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Shimada N, 2013, ACS SYM SER, V1135, P235
   Shirasaki Y, 2008, J PHARM SCI-US, V97, P2462, DOI 10.1002/jps.21200
   Shire SJ, 2004, J PHARM SCI-US, V93, P1390, DOI 10.1002/jps.20079
   Singh B, 2014, COLLOID SURFACE B, V121, P230, DOI 10.1016/j.colsurfb.2014.06.020
   Singh RRT, 2017, EXPERT OPIN DRUG DEL, V14, P525, DOI 10.1080/17425247.2016.1218460
   Sobrin L, 2007, ARCH OPHTHALMOL-CHIC, V125, P895, DOI 10.1001/archopht.125.7.895
   Soga O, 2004, BIOMACROMOLECULES, V5, P818, DOI 10.1021/bm049955q
   Song HB, 2015, J CONTROL RELEASE, V209, P272, DOI 10.1016/j.jconrel.2015.04.041
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Souto EB, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11090460
   Srividya B, 2001, J CONTROL RELEASE, V73, P205, DOI 10.1016/S0168-3659(01)00279-6
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sueda J, 2007, JPN J OPHTHALMOL, V51, P89, DOI 10.1007/s10384-006-0405-2
   Sung HW, 2001, J BIOMED MATER RES, V55, P538, DOI 10.1002/1097-4636(20010615)55:4<538::AID-JBM1047>3.3.CO;2-U
   Supper S, 2014, EUR J PHARM BIOPHARM, V88, P361, DOI 10.1016/j.ejpb.2014.05.015
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Sze JH, 2016, 3 BIOTECH, V6, DOI 10.1007/s13205-016-0379-9
   Szymanska E, 2015, MAR DRUGS, V13, P1819, DOI 10.3390/md13041819
   Tabata Y, 1998, ADV DRUG DELIVER REV, V31, P287, DOI 10.1016/S0169-409X(97)00125-7
   Takahashi A, 2013, BIOMACROMOLECULES, V14, P3581, DOI 10.1021/bm4009606
   Tang S, 2017, ACS OMEGA, V2, P8723, DOI 10.1021/acsomega.7b01247
   Thakur RRS, 2014, J PHARM PHARMACOL, V66, P584, DOI 10.1111/jphp.12152
   Than A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06981-w
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Turco G, 2011, BIOMACROMOLECULES, V12, P1272, DOI 10.1021/bm101556m
   Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058
   Tyagi P, 2013, MOL PHARMACEUT, V10, P2858, DOI 10.1021/mp300716t
   U.S.F.A.D. Administration, 2015, END TEST REC SINGL U
   Upadhayay P, 2016, IRAN J PHARM RES, V15, P3
   URTTI A, 1990, INT J PHARM, V61, P241, DOI 10.1016/0378-5173(90)90215-P
   URTTI A, 1993, SURV OPHTHALMOL, V37, P435, DOI 10.1016/0039-6257(93)90141-S
   van de Manakker F, 2009, BIOMACROMOLECULES, V10, P3157, DOI 10.1021/bm901065f
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Varshosaz J., 2008, OPEN DRUG DELIV J, V2, P61, DOI DOI 10.2174/1874126600802010061
   Vermonden T, 2012, CHEM REV, V112, P2853, DOI 10.1021/cr200157d
   Vinores SA, 2006, INT J NANOMED, V1, P263
   Vlckova M, 2008, J CHROMATOGR A, V1181, P145, DOI 10.1016/j.chroma.2007.12.046
   Vo TN, 2014, BIOMACROMOLECULES, V15, P132, DOI 10.1021/bm401413c
   Vyas SP, 2011, PEPTIDE AND PROTEIN DELIVERY, P87, DOI 10.1016/B978-0-12-384935-9.10005-7
   Walsh G, 2014, NAT BIOTECHNOL, V32, P992, DOI 10.1038/nbt.3040
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang K, 2017, J CONTROL RELEASE, V268, P212, DOI 10.1016/j.jconrel.2017.10.031
   Wang W, 2007, J PHARM SCI-US, V96, P1, DOI 10.1002/jps.20727
   Wassmer S, 2013, ACTA BIOMATER, V9, P7855, DOI 10.1016/j.actbio.2013.04.025
   Watson BM, 2014, BIOMACROMOLECULES, V15, P1788, DOI 10.1021/bm500175e
   Weber LF, 2019, J OPHTHALMIC INFLAMM, V9, DOI 10.1186/s12348-019-0168-9
   Wei W, 1999, INT J PHARMACEUT, V185, P129, DOI 10.1016/S0378-5173(99)00152-0
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
   WILLIAMS S, 2014, INVEST OPHTH VIS SCI, V55
   Wong FSY, 2017, NEURAL REGEN RES, V12, P576, DOI 10.4103/1673-5374.205093
   Wu JY, 2005, J CONTROL RELEASE, V102, P361, DOI 10.1016/j.jconrel.2004.10.008
   Wu WH, 2016, MOL THER, V24, P1388, DOI 10.1038/mt.2016.107
   Xie BB, 2015, INT J PHARMACEUT, V490, P375, DOI 10.1016/j.ijpharm.2015.05.071
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Xu QG, 2013, J CONTROL RELEASE, V167, P76, DOI 10.1016/j.jconrel.2013.01.018
   Xu XD, 2008, J POLYM SCI POL CHEM, V46, P5263, DOI 10.1002/pola.22857
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yang LQ, 2010, ACTA PHARMACOL SIN, V31, P1625, DOI 10.1038/aps.2010.125
   Yang YJ, 2018, BIOMACROMOLECULES, V19, P3905, DOI 10.1021/acs.biomac.8b00556
   Yao J, 2018, ANN TIME TIME INTERV, P11
   Yasin MN, 2014, J CONTROL RELEASE, V196, P208, DOI 10.1016/j.jconrel.2014.09.030
   Yasukawa Tsutomu, 2006, Expert Opin Drug Deliv, V3, P261, DOI 10.1517/17425247.3.2.261
   Yu J, 2014, INT J PHARMACEUT, V470, P151, DOI 10.1016/j.ijpharm.2014.04.053
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Yu Y, 2015, BIOMACROMOLECULES, V16, P56, DOI 10.1021/bm501063n
   Zhang H, 2014, ACS MACRO LETT, V3, P727, DOI 10.1021/mz5002993
   Zhang J, 2013, J MATER CHEM B, V1, P4388, DOI 10.1039/c3tb20391c
   Zhang JT, 2003, COLLOID POLYM SCI, V281, P580, DOI 10.1007/s00396-002-0829-2
   Zhang XY, 2016, RSC ADV, V6, P55666, DOI 10.1039/c6ra09534h
   Zhang YB, 2019, BIOMACROMOLECULES, V20, P1478, DOI 10.1021/acs.biomac.9b00043
   Zhang Z, 2011, BIOMATERIALS, V32, P4725, DOI 10.1016/j.biomaterials.2011.03.046
   Zhao RB, 2017, AAPS PHARMSCITECH, V18, P997, DOI 10.1208/s12249-016-0669-x
NR 308
TC 32
Z9 32
U1 6
U2 54
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD OCT 10
PY 2020
VL 326
BP 419
EP 441
DI 10.1016/j.jconrel.2020.07.031
PG 23
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA NS2HA
UT WOS:000572084900005
PM 32717302
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Tomita, YH
   Shao, Z
   Cakir, B
   Kotoda, Y
   Fu, ZJ
   Smith, LEH
AF Tomita, Yohei
   Shao, Zhuo
   Cakir, Bertan
   Kotoda, Yumi
   Fu, Zhongjie
   Smith, Lois E. H.
TI An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID NEOVASCULARIZATION; PROTECTION; EXPLANT
AB Pathological choroidal angiogenesis, a salient feature of age-related macular degeneration, leads to vision impairment and blindness. Endothelial cell (EC) proliferation assays using human retinal microvascular endothelial cells (HRMECs) or isolated primary retinal ECs are widely used in vitro models to study retinal angiogenesis. However, isolating pure murine retinal endothelial cells is technically challenging and retinal ECs may have different proliferation responses than choroidal endothelial cells and different cell/cell interactions. A highly reproducible ex vivo choroidal sprouting assay as a model of choroidal microvascular proliferation was developed. This model includes the interaction between choroid vasculature (EC, macrophages, pericytes) and retinal pigment epithelium (RPE). Mouse RPE/choroid/scleralu explants are isolated and incubated in growth-factor-reduced basal membrane extract (BME) (day 0). Medium is changed every other day and choroid sprouting is quantified at day 6. The images of individual choroid explant are taken with an inverted phase microscope and the sprouting area is quantified using a semi-automated macro plug-in to the ImageJ software developed in this lab. This reproducible ex vivo choroidal sprouting assay can be used to assess compounds for potential treatment and for microvascular disease research to assess pathways involved in choroidal micro vessel proliferation using wild type and genetically modified mouse tissue.
C1 [Tomita, Yohei; Cakir, Bertan; Kotoda, Yumi; Fu, Zhongjie; Smith, Lois E. H.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
   [Shao, Zhuo] Univ Toronto, Hosp Sick Children, Dept Clin & Metab Genet, Toronto, ON, Canada.
   [Fu, Zhongjie] Harvard Med Sch, Manton Ctr Orphan Dis, Boston Childrens Hosp, Boston, MA 02115 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   University of Toronto; University Toronto Affiliates; Hospital for Sick
   Children (SickKids); Harvard University; Boston Children's Hospital;
   Harvard Medical School
RP Tomita, YH; Smith, LEH (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, Boston, MA 02115 USA.
EM yohei.tomita@childrens.harvard.edu; lois.Smith@childrens.harvard.edu
RI Tomita, Yohei/AGR-6793-2022; Tomita, Yohei/AAC-6968-2021
OI FU, ZHONGJIE/0000-0002-8182-2983; Tomita, Yohei/0000-0003-1013-5737
FU Manpei Suzuki Diabetic Foundation; Boston Children's Hospital
   OFD/BTREC/CTREC Faculty Career Development Grant; Boston Children's
   Hospital Ophthalmology Foundation; BCH Pilot Award; German Research
   Foundation (DFG) [CA1940/1-1]; NIH [R24EY024868, EY017017,
   R01EY01717-13S1, EY030904-01]; BCH IDDRC [1U54HD090255]; Massachusetts
   Lions Eye Foundation; BCH Manton Center Fellowship; Little Giraffe
   Foundation
FX The work was supported by Grants from the Manpei Suzuki Diabetic
   Foundation (YT), Boston Children's Hospital OFD/BTREC/CTREC Faculty
   Career Development Grant, Boston Children's Hospital Ophthalmology
   Foundation, BCH Pilot Award, BCH Manton Center Fellowship, and Little
   Giraffe Foundation (ZF), The German Research Foundation (DFG; to BC
   [CA1940/1-1]), NIH R24EY024868, EY017017, R01EY01717-13S1, EY030904-01,
   BCH IDDRC (1U54HD090255), Massachusetts Lions Eye Foundation (LEHS).
CR Bellacen Keren, 2009, J Vis Exp, DOI 10.3791/1564
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Browning AC, 2012, BRIT J OPHTHALMOL, V96, DOI 10.1136/bjophthalmol-2012-301800
   Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006
   Fu ZJ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910473
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Gong Y, 2016, ARTERIOSCL THROM VAS, V36, P1919, DOI 10.1161/ATVBAHA.116.307558
   Katakia YT, 2020, MICROVASC RES, V128, DOI 10.1016/j.mvr.2019.103939
   Kobayashi S, 2004, BIOL PHARM BULL, V27, P1565, DOI 10.1248/bpb.27.1565
   Kobayashi S, 2004, BIOL PHARM BULL, V27, P1382, DOI 10.1248/bpb.27.1382
   Kobayashi S, 1999, BIOL PHARM BULL, V22, P360, DOI 10.1248/bpb.22.360
   Kobayashi S, 1998, JPN J PHARMACOL, V78, P471, DOI 10.1254/jjp.78.471
   Li J, 2014, INVEST OPHTH VIS SCI, V55, P8267, DOI 10.1167/iovs.14-15623
   Liu CH, 2015, P NATL ACAD SCI USA, V112, P12163, DOI 10.1073/pnas.1508426112
   Maisto R, 2019, CELL CYCLE, V18, P413, DOI 10.1080/15384101.2019.1568745
   Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30
   Mazzoni J, 2017, NEURON, V96, P1055, DOI 10.1016/j.neuron.2017.10.025
   Murakami Y, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.100778
   Nicosia RF, 2011, INT J DEV BIOL, V55, P447, DOI 10.1387/ijdb.103222rn
   Pemp B, 2008, CAN J OPHTHALMOL, V43, P295, DOI 10.3129/i08-049
   Rezzola S, 2014, ANGIOGENESIS, V17, P429, DOI 10.1007/s10456-013-9398-x
   Rezzola S, 2013, EXP EYE RES, V112, P51, DOI 10.1016/j.exer.2013.04.014
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Tomita Y., 2020, INT J MOL SCI, V21
   Tomita Y, 2020, ANGIOGENESIS, V23, P385, DOI 10.1007/s10456-020-09717-x
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou QB, 2019, ELIFE, V8, DOI 10.7554/eLife.40470
NR 27
TC 4
Z9 4
U1 0
U2 2
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD AUG
PY 2020
IS 162
AR e61677
DI 10.3791/61677
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OM1YE
UT WOS:000585824100068
PM 32831307
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Harrison, EH
AF Harrison, Earl H.
TI Mechanisms of Transport and Delivery of Vitamin A and Carotenoids to the
   Retinal Pigment Epithelium
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Review
DE lutein; macular pigments; xanthophylls; zeaxanthin
ID RECEPTOR CLASS-B; FAT-SOLUBLE VITAMINS; BETA-CAROTENE;
   INTESTINAL-ABSORPTION; MESO-ZEAXANTHIN; BASOLATERAL SECRETION; MACULAR
   DEGENERATION; ALPHA-TOCOPHEROL; CELLULAR UPTAKE; ARPE-19 CELLS
AB Vision depends on the delivery of vitamin A (retinol) to the retina. Retinol in blood is bound to retinol-binding protein (RBP). Retinal pigment epithelia (RPE) cells express the RBP receptor, STRA6, that facilitates uptake of retinol. The retinol is then converted to retinyl esters by the enzyme lecithin:retinol acyltransferase. The esters are the substrate for RPE65, an enzyme that produces 11-cis retinol, which is converted to 11-cis retinaldehyde for transport to the photoreceptors to form rhodopsin. The dietary xanthophylls, lutein (LUT) and zeaxanthin (ZEA), accumulate in the macula of the eye, providing protection against age-related macular degeneration. To reach the macula, carotenoids cross the RPE. In blood, xanthophylls and beta-carotene mostly associate with high-density lipoprotein (HDL) and low-density lipoprotein (LDL), respectively. Studies using a human RPE cell model evaluate the kinetics of cell uptake when carotenoids are delivered in LDL or HDL. For LUT and beta-carotene, LDL delivery result in the highest rate of uptake. HDL is more effective in delivering ZEA (and meso-ZEA). This selective HDL-mediated uptake of ZEA, via a scavenger receptor and LDL-mediated uptake of LUT and beta-carotene provides a mechanism for the selective accumulation of ZEA > LUT and xanthophylls over beta-carotene in the macula.
C1 [Harrison, Earl H.] Ohio State Univ, Dept Human Sci, Program Human Nutr, Columbus, OH 43206 USA.
   [Harrison, Earl H.] Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43206 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University
RP Harrison, EH (通讯作者)，Ohio State Univ, Dept Human Sci, Program Human Nutr, Columbus, OH 43206 USA.; Harrison, EH (通讯作者)，Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43206 USA.
EM Harrison.304@osu.edu
RI Harrison, Earl H/AAN-5378-2021
FU NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045967] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [R01DK101251] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01
   HL049879, R01 HL045967] Funding Source: Medline; NIDDK NIH HHS [R01
   DK044498] Funding Source: Medline
CR Akanuma S, 2009, BIOL PHARM BULL, V32, P1131, DOI 10.1248/bpb.32.1131
   Aronow ME, 2014, CURR OPIN OPHTHALMOL, V25, P186, DOI 10.1097/ICU.0000000000000046
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Blaner W. S., 2015, RETINOIDS BIOL BIOCH
   BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326
   BLOMSTRA.R, 1967, SCAND J CLIN LAB INV, V19, P339, DOI 10.3109/00365516709090648
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Breithaupt DE, 2004, BRIT J NUTR, V91, P707, DOI 10.1079/BJN20041105
   Brevik A, 2004, EUR J CLIN NUTR, V58, P1166, DOI 10.1038/sj.ejcn.1601945
   Chen Y, 2016, SCIENCE, V353, DOI 10.1126/science.aad8266
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Chitchumroonchokcai C, 2006, J NUTR, V136, P588, DOI 10.1093/jn/136.3.588
   Chung HY, 2009, AM J CLIN NUTR, V90, P533, DOI 10.3945/ajcn.2009.27712
   dela Sena C, 2013, J BIOL CHEM, V288, P37094, DOI 10.1074/jbc.M113.507160
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   During A, 2007, J LIPID RES, V48, P2283, DOI 10.1194/jlr.M700263-JLR200
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Fleshman MK, 2012, J LIPID RES, V53, P820, DOI 10.1194/jlr.D021139
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Gorusupudi A, 2016, INVEST OPHTH VIS SCI, V57, P1853, DOI 10.1167/iovs.16-19111
   Harrison E. H., 2015, RETINOIDS BIOL BIOCH
   HARRISON EH, 1987, J LIPID RES, V28, P973
   HARRISON EH, 1995, J LIPID RES, V36, P1498
   Harrison EH, 2001, J NUTR, V131, P1405, DOI 10.1093/jn/131.5.1405
   HUANG HS, 1965, J BIOL CHEM, V240, P2839
   Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0
   Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244
   Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Kotake-Nara E, 2011, MAR DRUGS, V9, P1024, DOI 10.3390/md9061024
   KRINSKY NI, 1958, ARCH BIOCHEM BIOPHYS, V73, P233, DOI 10.1016/0003-9861(58)90259-5
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Lobo GP, 2010, FASEB J, V24, P1656, DOI 10.1096/fj.09-150995
   Ma G, 2017, FOOD CHEM, V234, P356, DOI 10.1016/j.foodchem.2017.05.015
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mares J, 2016, ANNU REV NUTR, V36, P571, DOI 10.1146/annurev-nutr-071715-051110
   Matsuura T, 1997, J NUTR, V127, P218, DOI 10.1093/jn/127.2.218
   Mercadante AZ, 2017, FOOD RES INT, V99, P830, DOI 10.1016/j.foodres.2016.12.018
   Moussa M, 2008, J NUTR, V138, P1432, DOI 10.1093/jn/138.8.1432
   O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200
   PENG YM, 1995, NUTR CANCER, V23, P233, DOI 10.1080/01635589509514378
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Reboul E, 2011, PROG LIPID RES, V50, P388, DOI 10.1016/j.plipres.2011.07.001
   ROMANCHIK JE, 1995, J NUTR, V125, P2610
   Ross A. C., 2014, HDB VITAMINS
   SCHMITZ HH, 1993, METHOD ENZYMOL, V214, P102
   Seifried R. M., 2017, NUTR PREVENTION TREA
   SHEN BW, 1977, P NATL ACAD SCI USA, V74, P837, DOI 10.1073/pnas.74.3.837
   Shen WJ, 2018, J LIPID RES, V59, P1114, DOI 10.1194/jlr.R083121
   Shirakami Y, 2012, BBA-MOL CELL BIOL L, V1821, P124, DOI 10.1016/j.bbalip.2011.06.023
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Sirwi A, 2018, J LIPID RES, V59, P1094, DOI 10.1194/jlr.R083451
   Thomas JB, 2012, ANAL BIOANAL CHEM, V402, P749, DOI 10.1007/s00216-011-5447-8
   Thomas SE, 2016, J LIPID RES, V57, P1865, DOI 10.1194/jlr.M070193
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   van Bennekum A, 2005, BIOCHEMISTRY-US, V44, P4517, DOI 10.1021/bi0484320
   vonsLintig J., 2010, ANNU REV NUTR, V126, P499
   Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu TH, 2010, J NEUROCHEM, V114, P1734, DOI 10.1111/j.1471-4159.2010.06884.x
   Yoshizako H, 2016, ACTA OPHTHALMOL, V94, pE411, DOI 10.1111/aos.13106
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 69
TC 35
Z9 36
U1 4
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD AUG
PY 2019
VL 63
IS 15
SI SI
AR 1801046
DI 10.1002/mnfr.201801046
PG 7
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA IN8DZ
UT WOS:000478912100012
PM 30698921
OA Bronze
DA 2022-11-30
ER

PT J
AU Pilling, LC
   Atkins, JL
   Duff, MO
   Beaumont, RN
   Jones, SE
   Tyrrell, J
   Kuo, CL
   Ruth, KS
   Tuke, MA
   Yaghootkar, H
   Wood, AR
   Murray, A
   Weedon, MN
   Harries, LW
   Kuchel, GA
   Ferrucci, L
   Frayling, TM
   Melzer, D
AF Pilling, Luke C.
   Atkins, Janice L.
   Duff, Michael O.
   Beaumont, Robin N.
   Jones, Samuel E.
   Tyrrell, Jessica
   Kuo, Chia-Ling
   Ruth, Katherine S.
   Tuke, Marcus A.
   Yaghootkar, Hanieh
   Wood, Andrew R.
   Murray, Anna
   Weedon, Michael N.
   Harries, Lorna W.
   Kuchel, George A.
   Ferrucci, Luigi
   Frayling, Timothy M.
   Melzer, David
TI Red blood cell distribution width: Genetic evidence for aging pathways
   in 116,666 volunteers
SO PLOS ONE
LA English
DT Article
ID TELOMERE LENGTH; ASSOCIATION; POPULATION; DISEASE; RISK
AB Introduction
   Variability in red blood cell volumes (distribution width, RDW) increases with age and is strongly predictive of mortality, incident coronary heart disease and cancer. We investigated inherited genetic variation associated with RDW in 116,666 UK Biobank human volunteers.
   Results
   A large proportion RDW is explained by genetic variants (29%), especially in the older group (60+ year olds, 33.8%, < 50 year olds, 28.4%). RDW was associated with 194 independent genetic signals; 71 are known for conditions including autoimmune disease, certain cancers, BMI, Alzheimer's disease, longevity, age at menopause, bone density, myositis, Parkinson's disease, and age-related macular degeneration. Exclusion of anemic participants did not affect the overall findings. Pathways analysis showed enrichment for telomere maintenance, ribosomal RNA, and apoptosis. The majority of RDW-associated signals were intronic (119 of 194), including SNP rs6602909 located in an intron of oncogene GAS6, an eQTL in whole blood.
   Conclusions
   Although increased RDW is predictive of cardiovascular outcomes, this was not explained by known CVD or related lipid genetic risks, and a RDW genetic score was not predictive of incident disease. The predictive value of RDW for a range of negative health outcomes may in part be due to variants influencing fundamental pathways of aging.
C1 [Pilling, Luke C.; Atkins, Janice L.; Melzer, David] Univ Exeter, Epidemiol & Publ Hlth Grp, Sch Med, Royal Devon & Exeter Hosp, RILD Level 3, Exeter EX2 5DW, Devon, England.
   [Duff, Michael O.] Univ Connecticut, Ctr Hlth, Dept Genet & Genome Sci, Inst Syst Genom, Farmington, CT USA.
   [Beaumont, Robin N.; Jones, Samuel E.; Tyrrell, Jessica; Ruth, Katherine S.; Tuke, Marcus A.; Yaghootkar, Hanieh; Wood, Andrew R.; Murray, Anna; Weedon, Michael N.; Frayling, Timothy M.] Univ Exeter, Genet Complex Traits Grp, Sch Med, Royal Devon & Exeter Hosp, RILD Level 3, Exeter EX2 5DW, Devon, England.
   [Kuo, Chia-Ling] Univ Connecticut, Ctr Hlth, Dept Community Med & Hlth Care, Connecticut Inst Clin & Translat Sci,Inst Syst Ge, Farmington, CT USA.
   [Harries, Lorna W.] Univ Exeter, Inst Biomed & Clin Sci, Sch Med, Royal Devon & Exeter Hosp, RILD Level 3, Exeter, Devon, England.
   [Kuchel, George A.; Melzer, David] Univ Connecticut, Ctr Aging, Farmington, CT USA.
   [Ferrucci, Luigi] NIA, Baltimore, MD 21224 USA.
C3 University of Exeter; University of Connecticut; University of Exeter;
   University of Connecticut; University of Exeter; University of
   Connecticut; National Institutes of Health (NIH) - USA; NIH National
   Institute on Aging (NIA)
RP Pilling, LC (通讯作者)，Univ Exeter, Epidemiol & Publ Hlth Grp, Sch Med, Royal Devon & Exeter Hosp, RILD Level 3, Exeter EX2 5DW, Devon, England.
EM L.Pilling@exeter.ac.uk
RI Jones, Samuel/AAF-3100-2019; Wood, Andrew R/AAB-3807-2019; Ruth,
   Katherine/K-2745-2019; Atkins, Janice L/R-5886-2019; Pilling,
   Luke/E-4917-2013
OI Jones, Samuel/0000-0003-0153-922X; Wood, Andrew R/0000-0003-1726-948X;
   Ruth, Katherine/0000-0003-4966-9170; Atkins, Janice
   L/0000-0003-4919-9068; Murray, Anna/0000-0002-2351-2522; Weedon,
   Michael/0000-0002-6174-6135; Pilling, Luke/0000-0002-3332-8454; ,
   Hanieh/0000-0001-9672-9477; Kuchel, George/0000-0001-8387-7040;
   Beaumont, Robin/0000-0003-0750-8248
FU UK Medical Research Council [MR/M023095/1]; Medical Research Council
   [MR/M005070/1]; Diabetes Research and Wellness Foundation Fellowship;
   Wellcome Trust; Royal Society [104150/Z/14/Z]; Wellcome Trust
   Institutional Strategic Support Award [WT097835MF]; European Research
   Council [323195:GLUCOSEGENES-FP7-IDEAS-ERC]; Intramural Research Program
   of the National Institute on Aging; U.S. National Institutes of Health;
   University of Connecticut Health Center; Medical Research Council
   [MR/M023095/1, MC_qA137853] Funding Source: researchfish; MRC
   [MR/M023095/1] Funding Source: UKRI
FX This work was supported by an award to DM, TF, AM and LH by the UK
   Medical Research Council (grant number MR/M023095/1). SEJ is funded by
   the Medical Research Council (grant: MR/M005070/1). JT is funded by a
   Diabetes Research and Wellness Foundation Fellowship. RB is funded by
   the Wellcome Trust and Royal Society grant: 104150/Z/14/Z. MAT, MNW and
   AM are supported by the Wellcome Trust Institutional Strategic Support
   Award (WT097835MF). ARW, HY, and TF are supported by the European
   Research Council grant: 323195:GLUCOSEGENES-FP7-IDEAS-ERC. LF is
   supported by the Intramural Research Program of the National Institute
   on Aging, U.S. National Institutes of Health. Input from MD, CLK and GK
   was supported by the University of Connecticut Health Center. This
   research has been conducted using the UK Biobank Resource under
   Application Number 14631. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abraham G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093766
   Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burdett T, 2016, NHGRI EBI CATALOG PU
   Chakrabarti RS, 2017, ELIFE, V6, DOI 10.7554/eLife.23355
   Cheng Calvino Ka-Wing, 2004, Lab Hematol, V10, P42, DOI 10.1532/LH96.04010
   Danese E, 2015, J THORAC DIS, V7, pE402, DOI 10.3978/j.issn.2072-1439.2015.10.04
   Fyhrquist FY, 2016, OXID STRESS APPL BAS, P67, DOI 10.1007/978-3-319-33486-8_4
   Harries LW, 2011, AGING CELL, V10, P868, DOI 10.1111/j.1474-9726.2011.00726.x
   Haycock PC, 2017, JAMA ONCOL, V3, P636, DOI 10.1001/jamaoncol.2016.5945
   Inuzuka R, 2015, CIRC J, V79, P974, DOI 10.1253/circj.CJ-15-0254
   Kato N, 2015, NAT GENET, V47, P1282, DOI 10.1038/ng.3405
   Kozlitina J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051046
   Lippi G, 2016, INT J CARDIOL, V206, P129, DOI 10.1016/j.ijcard.2016.01.122
   Lippi G, 2013, KARDIOL POL, V71, P931, DOI 10.5603/KP.2013.0228
   Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177
   Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Manolio TA, 2010, JAMA-J AM MED ASSOC, V304, P2290, DOI 10.1001/jama.2010.1686
   Megel C, 2015, INT J MOL SCI, V16, P1873, DOI 10.3390/ijms16011873
   NCBI ClinVar, CLINVAR REC RS738409
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Patel KV, 2010, J GERONTOL A-BIOL, V65, P258, DOI 10.1093/gerona/glp163
   Patel KV, 2009, ARCH INTERN MED, V169, P515, DOI 10.1001/archinternmed.2009.11
   Pilling LC, 2016, AGING-US, V8, P547, DOI 10.18632/aging.100930
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7
   Salvagno GL, 2015, CRIT REV CL LAB SCI, V52, P86, DOI 10.3109/10408363.2014.992064
   Segre AV, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001058
   Sharma R., 2015, INT CARDIOVASC FORUM, V2, P27, DOI 10.17987/icfj.v2i1.68
   Sheard S, 2016, UK BIOBANK HAEMATOLO
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Turcato G, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.35
   UK Biobank, 2015, UK BIOB IMP 150K PAR
   UK Biobank, 2014, UK BIOB GEN COLL QC
   Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164
   Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756
   *WHO, WHO DEF AN HEM CONC
   Yang J, 2011, EUR J HUM GENET, V19, P807, DOI 10.1038/ejhg.2011.39
NR 39
TC 33
Z9 33
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 28
PY 2017
VL 12
IS 9
AR e0185083
DI 10.1371/journal.pone.0185083
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FI4YC
UT WOS:000411985200028
PM 28957414
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Subramani, M
   Ponnalagu, M
   Krishna, L
   Jeyabalan, N
   Chevour, P
   Sharma, A
   Jayadev, C
   Shetty, R
   Begum, N
   Archunan, G
   Das, D
AF Subramani, Murali
   Ponnalagu, Murugeswari
   Krishna, Lekshmi
   Jeyabalan, Nallathambi
   Chevour, Priyanka
   Sharma, Anupam
   Jayadev, Chaitra
   Shetty, Rohit
   Begum, Nargis
   Archunan, Govindaraju
   Das, Debashish
TI Resveratrol reverses the adverse effects of bevacizumab on cultured
   ARPE-19 cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; DIABETIC MACULAR EDEMA; TO-MESENCHYMAL
   TRANSITION; GROWTH-FACTOR PHARMACOTHERAPY; ANTI-VEGF AGENTS; MEDIATED
   INHIBITION; OXIDATIVE STRESS; CROSS-LINKING; EXPRESSION; LIMBAL
AB Age-related macular degeneration (AMD) and proliferative diabetic retinopathy (PDR) are one of the major causes of blindness caused by neo-vascular changes in the retina. Intravitreal anti-VEGF injections are widely used in the treatment of wet-AMD and PDR. A significant percentage of treated patients have complications of repeated injections. Resveratrol (RES) is a polyphenol phytoalexin with anti-oxidative, anti-inflammatory and anti-proliferative properties. Hence, we hypothesized that if RES is used in combination with bevacizumab (BEV, anti-VEGF), it could reverse the adverse effects that precipitate fibrotic changes, drusen formation, tractional retinal detachment and so on. Human retinal pigment epithelial cells were treated with various combinations of BEV and RES. There was partial reduction in secreted VEGF levels compared to untreated controls. Epithelial-mesenchymal transition was lower in BEV + RES treated cultures compared to BEV treated cultures. The proliferation status was similar in BEV + RES as well as BEV treated cultures both groups. Phagocytosis was enhanced in the presence of BEV + RES compared to BEV. Furthermore, we observed that notch signaling was involved in reversing the adverse effects of BEV. This study paves way for a combinatorial strategy to treat as well as prevent adverse effects of therapy in patients with wet AMD and PDR.
C1 [Subramani, Murali; Ponnalagu, Murugeswari; Krishna, Lekshmi; Das, Debashish] Narayana Nethralaya Fdn, Stem Cell Lab, GROW Labs, Bangalore, Karnataka, India.
   [Jeyabalan, Nallathambi; Chevour, Priyanka; Sharma, Anupam] Narayana Nethralaya Fdn, GROW Labs, Bangalore, Karnataka, India.
   [Jayadev, Chaitra] Narayana Nethralaya Eye Hosp, Vitreoretina Serv, Bangalore, Karnataka, India.
   [Shetty, Rohit] Narayana Nethralaya Eye Hosp, Dept Cornea & Refract Surg, Bangalore, Karnataka, India.
   [Subramani, Murali; Begum, Nargis] Jamal Mohammed Coll, Postgrad Dept Biotechnol, Tiruchirappalli, Tamil Nadu, India.
   [Archunan, Govindaraju] Bharatidasan Univ, Dept Anim Sci, Tiruchirappalli, Tamil Nadu, India.
C3 Jamal Mohamed College; Bharathidasan University
RP Das, D (通讯作者)，Narayana Nethralaya Fdn, Stem Cell Lab, GROW Labs, Bangalore, Karnataka, India.
EM dasdebashish@yahoo.co.uk
RI GOVINDARAJU, ARCHUNAN/A-9072-2019; Das, Debashish/ABB-4272-2020
OI GOVINDARAJU, ARCHUNAN/0000-0002-7094-0351; Das,
   Debashish/0000-0002-9171-656X; Subramani, Murali/0000-0002-3503-9381;
   Jayadev, Chaitra/0000-0001-8392-7159; KRISHNA,
   LEKSHMI/0000-0001-8971-6723
FU Narayana Nethralaya Foundation; Department of Science and Technology and
   DBT-BioCare, Government of India
FX The authors thank Dr. P Narendra and Dr. Arkasubhra Ghosh for their
   support in administration and research activities. The authors also
   thank Dr. K Bhujang Shetty for providing the inhouse logistics for this
   study. The authors extend their gratitude to Narayana Nethralaya
   Foundation, Department of Science and Technology and DBT-BioCare,
   Government of India for partial funding.
CR Abu-Amero KK, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040200
   Alex D, 2010, J CELL BIOCHEM, V109, P339, DOI 10.1002/jcb.22405
   [Anonymous], 1998, P MOL VIS, V5, P24
   Bola C, 2014, GRAEF ARCH CLIN EXP, V252, P699, DOI 10.1007/s00417-014-2604-8
   Bureau G, 2008, J NEUROSCI RES, V86, P403, DOI 10.1002/jnr.21503
   Chen CL, 2017, DRUG DES DEV THER, V11, P163, DOI 10.2147/DDDT.S126743
   Chen CL, 2012, ACTA OPHTHALMOL, V90, pe389, DOI 10.1111/j.1755-3768.2012.02426.x
   Chifflet S, 2004, EXP EYE RES, V79, P769, DOI 10.1016/j.exer.2004.08.031
   Dabir SS, 2014, INDIAN J OPHTHALMOL, V62, P66, DOI 10.4103/0301-4738.126186
   Das D, 2010, DEV BIOL, V348, P153, DOI 10.1016/j.ydbio.2010.09.018
   Dhamodaran K, 2016, CYTOTHERAPY, V18, P546, DOI 10.1016/j.jcyt.2016.01.003
   Dhamodaran K, 2015, MOL VIS, V21, P828
   Dou GR, 2012, MOL MED, V18, P47, DOI 10.2119/molmed.2011.00256
   Enslow R, 2016, OPHTHALMOL EYE DIS, V8, P31, DOI 10.4137/OED.S38863
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Gidfar S, 2016, INVEST OPHTH VIS SCI, V57, P859, DOI 10.1167/iovs.15-18319
   Grandbarbe L, 2007, GLIA, V55, P1519, DOI 10.1002/glia.20553
   Gridley T, 2010, CURR TOP DEV BIOL, V92, P277, DOI 10.1016/S0070-2153(10)92009-7
   Hao XN, 2016, INT J OPHTHALMOL-CHI, V9, P1725, DOI 10.18240/ijo.2016.12.04
   Ho AC, 2012, OPHTHALMOLOGY, V119, P2179, DOI 10.1016/j.ophtha.2012.07.058
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Ishikawa K, 2015, SCI REP-UK, V5, DOI 10.1038/srep16386
   Joe AK, 2002, CLIN CANCER RES, V8, P893
   Kanavi MR, 2014, MOLECULES, V19, P17578, DOI 10.3390/molecules191117578
   Karmel M, 2013, EYENET MAGAZINE, P37
   Kim LA, 2012, AM J PATHOL, V181, P376, DOI 10.1016/j.ajpath.2012.06.006
   Kim Ramasamy, 2007, Indian Journal of Ophthalmology, V55, P413
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Krishna L., 2017, INT J PHARM BIOSCIEN, V8, pB316
   Kubicz A., 2016, ACTA OPHTHALMOL, V94
   Kubota S, 2009, INVEST OPHTH VIS SCI, V50, P3512, DOI 10.1167/iovs.08-2666
   Kulkarni SS, 2015, BBA-MOL BASIS DIS, V1852, P1114, DOI 10.1016/j.bbadis.2014.10.005
   Kwong TQ, 2014, BRIT J CLIN PHARMACO, V78, P699, DOI 10.1111/bcp.12371
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Lee CS, 2015, YONSEI MED J, V56, P1678, DOI 10.3349/ymj.2015.56.6.1678
   Lindsey JD, 2015, NEUROBIOL AGING, V36, P1969, DOI 10.1016/j.neurobiolaging.2014.12.021
   Liu SL, 2016, EXP THER MED, V11, P257, DOI 10.3892/etm.2015.2877
   Luna C, 2009, FOOD CHEM TOXICOL, V47, P198, DOI 10.1016/j.fct.2008.10.029
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matalia H, 2012, BRIT J OPHTHALMOL, V96, P1339, DOI 10.1136/bjophthalmol-2012-301811
   Miura Y, 2010, INVEST OPHTH VIS SCI, V51, P4848, DOI 10.1167/iovs.09-4699
   Modi YS, 2015, DRUG SAFETY, V38, P279, DOI 10.1007/s40264-015-0273-0
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Murugeswari P, 2017, CYTOKINE, V95, P126, DOI 10.1016/j.cyto.2017.02.013
   Murugeswari P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107551
   Naga SHA, 2015, EXP EYE RES, V131, P29, DOI 10.1016/j.exer.2014.12.010
   Nagineni CN, 2014, AGING DIS, V5, P88, DOI 10.14366/AD.2014.050088
   Natsumeda M, 2016, BRAIN PATHOL, V26, P713, DOI 10.1111/bpa.12343
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Pinchot SN, 2011, CANCER-AM CANCER SOC, V117, P1386, DOI 10.1002/cncr.25652
   Pintea A, 2011, J OCUL PHARMACOL TH, V27, P315, DOI 10.1089/jop.2010.0144
   Pirhan D, 2016, CURR EYE RES, V41, P59, DOI 10.3109/02713683.2015.1004719
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Rad EB, 2016, CANCER RES, V76, P1690, DOI 10.1158/0008-5472.CAN-15-1722
   Ranjbar M, 2016, CELL PHYSIOL BIOCHEM, V38, P737, DOI 10.1159/000443030
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schauwvlieghe AME, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0043-x
   Seong H, 2015, MOL MED REP, V12, P1479, DOI 10.3892/mmr.2015.3518
   Shetty R, 2015, BRIT J OPHTHALMOL, V99, P272, DOI 10.1136/bjophthalmol-2014-305495
   Sheu SJ, 2009, KAOHSIUNG J MED SCI, V25, P381, DOI 10.1016/S1607-551X(09)70531-5
   Sheu SJ, 2008, J OCUL PHARMACOL TH, V24, P551, DOI 10.1089/jop.2008.0013
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sinha R, 2009, INDIAN J OPHTHALMOL, V57, P481
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Subramani M, 2016, INVEST OPHTH VIS SCI, V57, P1140, DOI 10.1167/iovs.15-18330
   Szatmari-Toth M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.133
   Venturelli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073097
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Zhang HM, 2015, CYTOKINE, V76, P549, DOI 10.1016/j.cyto.2015.06.019
   Zhang JJ, 2015, INT J OPHTHALMOL-CHI, V8, P245, DOI 10.3980/j.issn.2222-3959.2015.02.06
   Zheng TY, 2016, CURR EYE RES, V41, P1068, DOI 10.3109/02713683.2015.1093641
NR 79
TC 21
Z9 21
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 25
PY 2017
VL 7
AR 12242
DI 10.1038/s41598-017-12496-z
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FI0VS
UT WOS:000411648500016
PM 28947815
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhao, Z
   Sun, T
   Jiang, Y
   Wu, LJ
   Cai, XZ
   Sun, XD
   Sun, XJ
AF Zhao, Zhao
   Sun, Tao
   Jiang, Yun
   Wu, Lijiang
   Cai, Xiangzhong
   Sun, Xiaodong
   Sun, Xiangjun
TI Photooxidative damage in retinal pigment epithelial cells via GRP78 and
   the protective role of grape skin polyphenols
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Grape skin polyphenols; RPE; Apoptosis; Photooxidation; ER stress
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; OXIDATIVE
   STRESS; INDUCED APOPTOSIS; ER STRESS; IN-VITRO; MITOCHONDRIAL
   DYSFUNCTION; LIPOFUSCIN FLUOROPHORE; RPE CELLS; A2E
AB Blue light induced oxidative damage and ER stress are related to the pathogenesis of age-related macular degeneration (AMD). However, the mechanism of blue light-induced damage remained obscure. The objective of this work is to assess the photooxidative damage to retinal pigment epithelial cells (RPE) and oxidation-induced changes in expression of ER stress associated apoptotic proteins, and investigate the mechanism underlying the protective effects of grape skin extracts. To mimic lipofuscin-mediated photooxidation in vivo, ARPE-19 cells that accumulated A2E, one of lipofuscin fluorophores, were used as a model system to investigate the mechanism of photooxidative damage and the protective effects of grape skin polyphenols. Exposure of A2E containing ARPE-19 cells to blue light resulted in significant apoptosis and increases in levels of GRP78, CHOP, p-JNK, Bax, cleaved caspase-9, and cleaved caspase-3, indicating that photooxidative damage to RPE cells is mediated by the ER-stress-induced intrinsic apoptotic pathway. Cells in which GRP78 had been knocked down with shRNA were more vulnerable to photooxidative damage. Pre-treatment of blue-light-exposed A2E containing ARPE-19 cells, with grape skin extracts, inhibited apoptosis, in a dose dependent manner. Knockdown GRP78 blocked the protective effect of grape skin extracts. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Zhao, Zhao; Sun, Tao; Jiang, Yun; Wu, Lijiang; Cai, Xiangzhong; Sun, Xiangjun] Shanghai Jiao Tong Univ, Coll Agr & Biol, Shanghai 200030, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol, Shanghai 200030, Peoples R China.
   [Sun, Xiaodong] Shanghai Jiao Tong Univ, Eye Res Inst, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Eye Res Inst, Shanghai 200030, Peoples R China.
EM xdsun@sjtu.edu.cn; xjsun@sjtu.edu.cn
FU National Natural Science Foundation of China [31271843]; National Basic
   Research Program of China "973 Program" [2011CB707506]
FX This study was supported by the National Natural Science Foundation of
   China (No. 31271843) and by the National Basic Research Program of China
   "973 Program" (2011CB707506).
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Apostolova N, 2013, J HEPATOL, V59, P780, DOI 10.1016/j.jhep.2013.06.005
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Cao XG, 2010, EXP EYE RES, V91, P15, DOI 10.1016/j.exer.2010.03.016
   Chang YC, 2013, TOXICOL APPL PHARM, V268, P178, DOI 10.1016/j.taap.2013.01.014
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624
   Harris G., 2013, FOOD NUTR DIS MANAGE, P3
   Hogan S, 2010, J AGR FOOD CHEM, V58, P11250, DOI 10.1021/jf102759e
   Huang LH, 2007, TOXICOLOGY, V242, P109, DOI 10.1016/j.tox.2007.09.015
   Jomova K, 2013, EUR J MED CHEM, V70, P102, DOI 10.1016/j.ejmech.2013.09.054
   Kalt W, 2010, J AGR FOOD CHEM, V58, P4001, DOI 10.1021/jf903038r
   Katalinic V, 2010, FOOD CHEM, V119, P715, DOI 10.1016/j.foodchem.2009.07.019
   Kim HJ, 2008, J NUTR BIOCHEM, V19, P459, DOI 10.1016/j.jnutbio.2007.06.001
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kurz T, 2008, BBA-GEN SUBJECTS, V1780, P1291, DOI 10.1016/j.bbagen.2008.01.009
   Laabich A, 2007, EXP EYE RES, V85, P154, DOI 10.1016/j.exer.2007.04.003
   Lee CY, 2013, J FUNCT FOODS, V5, P524, DOI 10.1016/j.jff.2012.10.018
   Liu BQ, 2010, BIOCHEM BIOPH RES CO, V391, P778, DOI 10.1016/j.bbrc.2009.11.137
   de Lerma N, 2013, J FUNCT FOODS, V5, P914, DOI 10.1016/j.jff.2013.02.001
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   National Eye Institute, 2001, AREDS 1 AG REL EYE D
   National Eye Institute, 2013, AREDS 2 AG REL EYE D
   Olmedilla-Alonso B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-52
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park HS, 2014, FOOD CHEM TOXICOL, V64, P157, DOI 10.1016/j.fct.2013.11.034
   Richer S, 2013, NUTRIENTS, V5, P1989, DOI 10.3390/nu5061989
   Richer S, 2009, OPTOMETRY, V80, P695, DOI 10.1016/j.optm.2009.03.018
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Schtitt F., 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sheu SJ, 2013, INVEST OPHTH VIS SCI, V54, P6426, DOI 10.1167/iovs.13-12024
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tagawa Y, 2008, FREE RADICAL BIO MED, V45, P50, DOI 10.1016/j.freeradbiomed.2008.03.003
   Tenore GC, 2013, FOOD CHEM, V140, P803, DOI 10.1016/j.foodchem.2012.10.023
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Xu JY, 2010, INVEST OPHTH VIS SCI, V51, P6665, DOI 10.1167/iovs.10-5698
   Yu CC, 2012, FREE RADICAL BIO MED, V52, P660, DOI 10.1016/j.freeradbiomed.2011.11.021
NR 41
TC 29
Z9 29
U1 0
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD DEC
PY 2014
VL 74
BP 216
EP 224
DI 10.1016/j.fct.2014.10.001
PG 9
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA AY0GD
UT WOS:000347274600029
PM 25447759
DA 2022-11-30
ER

PT J
AU Aronow, ME
   Chew, EY
AF Aronow, Mary E.
   Chew, Emily Y.
TI Age-related Eye Disease Study 2: perspectives, recommendations, and
   unanswered questions
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE age-related macular degeneration; antioxidant vitamins; lutein; omega-3
   fatty acids; zeaxanthin
ID FATTY-ACID INTAKE; MACULAR DEGENERATION; VISUAL IMPAIRMENT; FISH
   CONSUMPTION; BETA-CAROTENE; ASSOCIATIONS; ZINC; ANTIOXIDANTS;
   MACULOPATHY; PREVALENCE
AB Purpose of reviewThis review provides a perspective on the Age-related Eye Disease Study 2 (AREDS2) including a summary of the goals and rationale of the study, major findings, subsequent management recommendations, and questions that remain to be answered.Recent findingsThe primary goal of the AREDS2 was to evaluate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 long-chain polyunsaturated acid supplementation in reducing the risk of developing advanced age-related macular degeneration (AMD). AREDS2 also investigated the effects of omitting -carotene and reducing the concentration of zinc from the original AREDS formulation. Although primary analysis from the AREDS2 did not reveal a benefit of daily supplementation with lutein/zeaxanthin on AMD progression, secondary exploratory analyses suggested that lutein/zeaxanthin were helpful in reducing this risk. Comparison of low-dose to higher-dose zinc showed no significant benefit.SummaryThe overall evidence on the beneficial and adverse effects from AREDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than -carotene in AREDS-type supplements. Questions remain regarding the AREDS2 study results such as: whether the findings are generalizable to the population as a whole, what is the long-term safety profile of lutein/zeaxanthin supplementation, should other carotenoids be included in AREDS-type supplements, and at what optimal doses?
C1 [Aronow, Mary E.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10,CRC,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI Aronow, Mary/0000-0001-8228-9394
FU National Eye Institute/National Institutes of Health (NEI/NIH),
   Department of Health and Human Services, Bethesda, Maryland
   [HHS-N-260-2005-00007-C]; National Eye Institute/National Institutes of
   Health (NEI/NIH), Department of Health and Human Services, Bethesda,
   Maryland (ADB) [N01-EY-5-0007]; NATIONAL EYE INSTITUTE [ZIEEY000487,
   ZIAEY000485] Funding Source: NIH RePORTER
FX The authors have no commercial relationships to disclose. AREDS2 was
   supported by the intramural program funds and contracts from the
   National Eye Institute/National Institutes of Health (NEI/NIH),
   Department of Health and Human Services, Bethesda, Maryland (contract
   No. HHS-N-260-2005-00007-C and ADB contract No. N01-EY-5-0007).
CR ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2013, JAMA OPHTHALMOL 1205
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Hambidge M, 2003, J NUTR, V133, p1438S, DOI 10.1093/jn/133.5.1438S
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Meleth AD, 2011, CURR OPIN OPHTHALMOL, V22, P190, DOI 10.1097/ICU.0b013e32834594b0
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Musch DC, 2013, JAMA OPHTHALMOL 1205
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Pizzarello L, 2004, ARCH OPHTHALMOL-CHIC, V122, P615, DOI 10.1001/archopht.122.4.615
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
NR 31
TC 47
Z9 48
U1 0
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2014
VL 25
IS 3
BP 186
EP 190
DI 10.1097/ICU.0000000000000046
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF1GC
UT WOS:000334461400006
PM 24614146
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Abu-Asab, MS
   Salazar, J
   Tuo, JS
   Chan, CC
AF Abu-Asab, Mones S.
   Salazar, Jose
   Tuo, Jingsheng
   Chan, Chi-Chao
TI Systems Biology Profiling of AMD on the Basis of Gene Expression
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Genetic pathways underlying the initiation and progression of age-related macular degeneration (AMD) have not been yet sufficiently revealed, and the correlations of AMD's genotypes, phenotypes, and disease spectrum are still awaiting resolution. We are tackling both problems with systems biology phylogenetic parsimony analysis. Gene expression data (GSE29801: NCBI, Geo) of macular and extramacular specimens of the retinas and retinal pigment epithelium (RPE) choroid complexes representing dry AMD without geographic atrophy (GA), choroidal neovascularization (CNV), GA, as well as pre-AMD and subclinical pre-AMD were polarized against their respective normal specimens and then processed through the parsimony program MIX to produce phylogenetic cladograms. Gene lists from cladograms' nodes were processed in Genomatix GePS to reveal the affected signaling pathway networks. Cladograms exposed a highly heterogeneous transcriptomic profiles within all the conventional phenotypes. Moreover, clades and nodal synapomorphies did not support the classical AMD phenotypes as valid transcriptomal genotypes. Gene lists defined by cladogram nodes showed that the AMD-related deregulations occurring in the neural retina were different from those in RPE-choroidal tissue. Our analysis suggests a more complex transcriptional profile of the phenotypes than expected. Evaluation of the disease in much earlier stages is needed to elucidate the initial events of AMD.
C1 [Abu-Asab, Mones S.; Salazar, Jose; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Abu-Asab, MS (通讯作者)，NEI, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM mones@mail.nih.gov
OI Abu-Asab, Mones/0000-0002-4047-1232
CR Abu-Asab MS, 2013, CYTOGENET GENOME RES, V139, P206, DOI 10.1159/000348433
   Abu-Asab M, 2008, PROTEOM CLIN APPL, V2, P122, DOI 10.1002/prca.200780047
   Abu-Asab M, 2006, J PROTEOME RES, V5, P2236, DOI 10.1021/pr0504485
   Abu-Asab M, 2011, OBSTET GYNECOL INT, V2011, DOI 10.1155/2011/719059
   Abu-Asab MS, 2008, OMICS, V12, P183, DOI 10.1089/omi.2008.0010
   Abu-Asab Mones S., 2010, Advances in Bioinformatics, V2010, P178069, DOI 10.1155/2010/178069
   Abu-Asab MS, 2011, OMICS, V15, P105, DOI 10.1089/omi.2010.0023
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bereiter-Hahn J., 2013, PROTOPLASMA
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Esteve P, 2011, NAT NEUROSCI, V14, P562, DOI 10.1038/nn.2794
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Goudet J., 2001, CLADISTICS, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Wang SY, 2013, SCI CHINA LIFE SCI, V56, P32, DOI 10.1007/s11427-012-4424-6
   Wiley E, 2011, PHYLOGENETICS THEORY
   Zhong XT, 2007, J BIOL CHEM, V282, P20523, DOI 10.1074/jbc.M609096200
NR 20
TC 6
Z9 6
U1 1
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 453934
DI 10.1155/2013/453934
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 303GX
UT WOS:000330663600001
PM 24349763
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Kang, S
   Park, KC
   Yang, KJ
   Choi, HS
   Kim, SH
   Roh, YJ
AF Kang, Seungbum
   Park, Ki Cheol
   Yang, Keum-Jin
   Choi, Hyun-Su
   Kim, So-Hee
   Roh, Young-Jung
TI Effect of cediranib, an inhibitor of vascular endothelial growth factor
   receptor tyrosine kinase, in a mouse model of choroidal
   neovascularization
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE angiogenesis; cediranib; choroidal neovascularization; vascular
   endothelial growth factor
ID CELL LUNG-CANCER; DNA-SYNTHESIS; FACTOR VEGF; EXPRESSION;
   IDENTIFICATION; ANGIOGENESIS; RANIBIZUMAB; ACTIVATION; AZD2171; PATHWAY
AB Background: This study was conducted to evaluate the effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of laser-induced choroidal neovascularization. Methods: Choroidal neovascularization was induced in C57BL/6 mice by rupturing Bruch's membrane using laser photocoagulation. Following laser injury, the mice were divided into three groups and administered either vehicle, 1 mg/kg or 5 mg/kg of cediranib daily by oral gavage for 2 weeks. Two weeks after laser injury, the area of choroidal neovascularization lesions was measured by choroidal flat mounts using fluorescein-labelled dextran. Immunofluorescence staining with isolectin IB4 was also used to quantify the choroidal neovascularization lesions. Results: Choroidal flat mount analysis revealed that orally administered cediranib reduced the extent of choroidal neovascularization. The groups treated with 1 and 5 mg/kg/day showed 57.2 and 66.0% reduction of choroidal neovascularization lesions, respectively, compared with the control group treated with vehicle alone (P = 0.012). The size of the fluorescently labelled choroidal neovascularization complex in cediranib-treated groups was much smaller than that from vehicle-treated group (P = 0.035). Conclusions: Cediranib inhibited laser-induced choroidal neovascularization in mice and may have therapeutic potential for patients with neovascular age-related macular degeneration.
C1 [Kang, Seungbum; Roh, Young-Jung] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Coll Med, Seoul 150713, South Korea.
   [Kang, Seungbum; Park, Ki Cheol; Yang, Keum-Jin; Choi, Hyun-Su; Kim, So-Hee] Catholic Univ Korea, Daejeon St Marys Hosp, Coll Med, Clin Res Inst, Seoul 150713, South Korea.
C3 Catholic University of Korea; Catholic University of Korea
RP Roh, YJ (通讯作者)，Catholic Univ Korea, Dept Ophthalmol & Visual Sci, St Marys Hosp, Coll Med, 62 Yoido Dong, Seoul 150713, South Korea.
EM youngjungroh@hanmail.net
FU Clinical Research Institute Grant; Catholic University of Korea, Daejeon
   St. Mary's Hospital
FX This work was supported by Clinical Research Institute Grant funded by
   The Catholic University of Korea, Daejeon St. Mary's Hospital.
CR Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Batchelor TT, 2010, J CLIN ONCOL, V28, P2817, DOI 10.1200/JCO.2009.26.3988
   Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0
   Campochiaro PA, 2007, J CELL PHYSIOL, V210, P575, DOI 10.1002/jcp.20893
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2
   Diago T, 2008, MAYO CLIN PROC, V83, P231
   Drevs J, 2007, J CLIN ONCOL, V25, P3045, DOI 10.1200/JCO.2006.07.2066
   Eskens FALM, 2006, EUR J CANCER, V42, P3127, DOI 10.1016/j.ejca.2006.09.015
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fox E, 2010, J CLIN ONCOL, V28, P5174, DOI 10.1200/JCO.2010.30.9674
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7
   Hiratsuka S, 2001, CANCER RES, V61, P1207
   Hoff PM, 2010, ANN ONCOL, V21, P9
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kernt M, 2008, ACTA OPHTHALMOL, V86, P456, DOI 10.1111/j.1600-0420.2007.01014.x
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Langenberg MHG, 2009, J CLIN ONCOL, V27, P6152, DOI 10.1200/JCO.2009.22.2273
   Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321
   Medinger M, 2009, ANTICANCER RES, V29, P5065
   Nikolinakos P, 2008, J THORAC ONCOL, V3, pS131, DOI 10.1097/JTO.0b013e318174e910
   Ramalingam SS, 2010, J THORAC ONCOL, V5, P1279, DOI 10.1097/JTO.0b013e3181e2fcb0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661
   Schmoll H, 2010, ANN ONCOL, V21, P189
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   van Cruijsen H, 2010, EUR J CANCER, V46, P901, DOI 10.1016/j.ejca.2009.12.023
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
   Yu MJT, 2000, GROWTH FACTORS, V17, P301, DOI 10.3109/08977190009028973
NR 38
TC 7
Z9 10
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2013
VL 41
IS 1
BP 63
EP 72
DI 10.1111/j.1442-9071.2012.02813.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 079OV
UT WOS:000314181000011
PM 22594647
OA Bronze
DA 2022-11-30
ER

PT J
AU Jee, EH
   Kim, SR
   Jang, YP
AF Jee, Eun Hye
   Kim, So Ra
   Jang, Young Pyo
TI Rapid purification method for vitamin A-derived aging pigments A2E and
   iso-A2E using cation exchange resin
SO JOURNAL OF CHROMATOGRAPHY A
LA English
DT Article
DE Age-related macular degeneration; A2E; Aging pigment; Cation exchange
ID FLUOROPHORE; LIPOFUSCIN; WEAK
AB A2E, known to be involved in the pathogenesis of age-related macular degeneration (AMD), is one of the major compounds that accumulate as fluorescent pigments in retinal pigment epithelial (RPE) cells with age and in some retinal disorders. While the biomimetic synthesis of A2E and its cis-isomer, iso-A2E is as simple as 'one-pot' reaction, the purification of these amphiphillic compounds has been a bottleneck for the mass production of these pathophysiologically important eye pigments. In order to provide a new method of rapid purification of A2E and iso-A2E, we employed a cation exchange resin for the separation of these pigments from crude reaction mixture. The reaction mixture was loaded on a weak acid resin and was eluted with 80% methanol with sodium hydroxide (pH 12), 100% methanol, and 100% methanol with 0.1% trifluoroacetic acid (TFA) in sequence. A2E and isoA2E were eluted only with 100% methanol solution containing TFA. Most of unreacted starting materials and intermediates were removed with 80% methanol containing sodium hydroxide. The new method can be used as a relatively simple and economic way to purify A2E and iso-A2E compared to conventional HPLC technique. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Jee, Eun Hye; Jang, Young Pyo] Kyung Hee Univ, Coll Pharm, Div Pharmacognosy, Seoul 130701, South Korea.
   [Kim, So Ra] Seoul Natl Univ Sci & Technol, Dept Optometry, Seoul 139743, South Korea.
   [Jang, Young Pyo] Kyung Hee Univ, Coll Pharm, Dept Life & Nanopharmaceut Sci, Seoul 130701, South Korea.
C3 Kyung Hee University; Seoul National University of Science & Technology;
   Kyung Hee University
RP Jang, YP (通讯作者)，Kyung Hee Univ, Coll Pharm, Div Pharmacognosy, Seoul 130701, South Korea.
EM ypjang@khu.ac.kr
RI Jang, Young Pyo/AAJ-8782-2020
OI Jang, Young Pyo/0000-0001-5865-9228; Kim, So Ra/0000-0001-8786-2815
FU National Research Foundation of Korea (NRF); Korea Government (MEST)
   [2009-0077471, 2010-0015368]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by Korea Government (MEST) (2009-0077471 (YPJ) and
   2010-0015368 (SRK)).
CR Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Kim SR, 2007, BIOCHEMISTRY-US, V46, P10122, DOI 10.1021/bi7009635
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Mustafa S, 2008, J HAZARD MATER, V160, P1, DOI 10.1016/j.jhazmat.2008.02.071
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Stenholm A, 2006, J CHROMATOGR A, V1128, P73, DOI 10.1016/j.chroma.2006.06.042
NR 8
TC 9
Z9 9
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
J9 J CHROMATOGR A
JI J. Chromatogr. A
PD AUG 17
PY 2012
VL 1251
BP 232
EP 235
DI 10.1016/j.chroma.2012.06.046
PG 4
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 987PE
UT WOS:000307428800027
PM 22771064
DA 2022-11-30
ER

PT J
AU Koh, A
   Lim, TH
   Eong, KGA
   Chee, C
   Ong, SG
   Tan, N
   Yeo, I
   Wong, D
AF Koh, A.
   Lim, T. H.
   Eong, Au K. G.
   Chee, C.
   Ong, S. G.
   Tan, N.
   Yeo, I
   Wong, D.
TI Optimising the management of choroidal neovascularisation in Asian
   patients: consensus on treatment recommendations for anti-VEGF therapy
SO SINGAPORE MEDICAL JOURNAL
LA English
DT Review
DE age-related macular degeneration; choroidal neovascularisation;
   monoclonal antibody; ranibizumab
ID PIGMENT EPITHELIAL TEARS; ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL
   BEVACIZUMAB INJECTION; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION;
   PATHOLOGICAL MYOPIA; FOLLOW-UP; JAPANESE PATIENTS; CLINICAL-TRIAL;
   VASCULOPATHY
AB In Asian countries, age-related macular degeneration (AMD), specifically wet AMD or choroidal neovascularisation (CNV), is an important cause of blindness and visual handicap. Vascular endothelial growth factors (VEGF) play an integral role in the development of CNV and thus provide an important therapeutic target. Current treatment paradigms for neovascular AMD recognise the place of photodynamic therapy (PDT) in the management of this condition. However, combination therapy targeting different pathways to produce a synergistic effect may result in improved visual outcomes and reduced duration of treatment. Anti-VEGF therapy has greatly improved treatment outcomes in patients with CNV, and a growing body of evidence supports the role of these agents as monotherapy or in combination with PDT. In particular, anti-VEGF may be a first-line treatment option in certain types of subfoveal myopic CNV as well as for classic and occult juxtafoveal and subfoveal CNV. The implementation of evidence-based medicine into current clinical practice is paramount to improving patient care. The authors, who are also members of the Singapore Medical Retina Advisory Board, outline the consensus points and recommended treatment algorithms based on currently available knowledge to provide a structured management approach to the treatment of Asian patients with CNV.
C1 [Koh, A.; Ong, S. G.] Camden Med Ctr, Singapore 248649, Singapore.
   [Lim, T. H.; Tan, N.] Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Eong, Au K. G.] Mt Elizabeth Med Ctr, Singapore Int Eye Cataract Eye Retina Ctr, Singapore 228510, Singapore.
   [Chee, C.] Natl Univ Singapore Hosp, Eye Surg Ctr, Singapore 119074, Singapore.
   [Yeo, I; Wong, D.] Singapore Natl Eye Ctr, Vitreo Retinal Serv, Singapore 168751, Singapore.
C3 Mount Elizabeth Medical Centre; National University of Singapore;
   Singapore National Eye Center
RP Koh, A (通讯作者)，Camden Med Ctr, 1 Orchard Blvd, Singapore 248649, Singapore.
EM ahckoh@yahoo.com
RI Tan, Nikolle/GXH-5775-2022
OI Wong, Damon/0000-0003-4601-9121
FU Novartis; Alcon; Novartis (Singapore) Pte Ltd.
FX Koh A, Lim TH and Au Eong KG served as advisors to Novartis. Lim TH
   received travel sponsorship from Novartis. Chee C received conference
   sponsorship from Novartis. Tan N received travel and conference
   sponsorship from Novartis. Wong D received travel and conference
   sponsorship from Novartis and Alcon, and is an advisor to Alcon. Ong SG
   and Yeo I declared no relevant conflicts of interest.; Supported by an
   educational grant from Novartis (Singapore) Pte Ltd.
CR Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CAMPOCHIARO PA, 1999, J CHEM SOC, V5, P34
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chan WM, 2007, OPHTHALMOLOGY, V114, P2190, DOI 10.1016/j.ophtha.2007.03.043
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2005, CLIN EXP OPHTHALMOL, V33, P611, DOI 10.1111/j.1442-9071.2005.01105.x
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Cohen SY, 2003, AM J OPHTHALMOL, V136, P371, DOI 10.1016/S0002-9394(03)00201-0
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Eong KGA, 2006, ANN ACAD MED SINGAP, V35, P133
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hayashi K, 2008, AM J OPHTHALMOL, V145, P518, DOI 10.1016/j.ajo.2007.10.032
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hussain Nazimul, 2004, Indian Journal of Ophthalmology, V52, P227
   Krebs I, 2005, AM J OPHTHALMOL, V140, P416, DOI 10.1016/j.ajo.2005.03.050
   Krebs I, 2009, ACTA OPHTHALMOL, V87, P611, DOI 10.1111/j.1755-3768.2008.01312.x
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LEY AM, AAO 2009
   Lu Lawrence P. L., 2007, Hong Kong Medical Journal, V13, P460
   Mauget-Faysse M, 2006, EUR J OPHTHALMOL, V16, P695, DOI 10.1177/112067210601600506
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Pece A, 2007, AM J OPHTHALMOL, V143, P449, DOI 10.1016/j.ajo.2006.11.037
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   PEER J, 1995, LAB INVEST, V72, P638
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz-Moreno JM, 2008, BRIT J OPHTHALMOL, V92, P792, DOI 10.1136/bjo.2007.132795
   Sanjay S, 2009, CLIN EXP OPHTHALMOL, V37, P795, DOI 10.1111/j.1442-9071.2009.02153.x
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Silva RM, 2005, GRAEF ARCH CLIN EXP, V243, P973, DOI 10.1007/s00417-005-1139-4
   Smith BT, 2009, RETINA-J RET VIT DIS, V29, P335, DOI 10.1097/IAE.0b013e318195cad5
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   The Royal College of Ophthalmologists, 2017, NAT EL AG REL MAC DA
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Woo JH, 2009, ACTA OPHTHALMOL, V87, P262, DOI 10.1111/j.1755-3768.2008.01376.x
   Wu PC, 2009, EYE, V23, P2042, DOI 10.1038/eye.2008.404
   Yoon JU, 2010, RETINA-J RET VIT DIS, V30, P418, DOI 10.1097/IAE.0b013e3181bd2fe4
NR 52
TC 12
Z9 17
U1 0
U2 3
PU SINGAPORE MEDICAL ASSOC
PI SINGAPORE
PA 2985 JALAN BUKIT MERAH, #02-2C, SMF BUILDING, SINGAPORE, SINGAPORE
SN 0037-5675
J9 SINGAP MED J
JI Singap. Med. J.
PD APR
PY 2011
VL 52
IS 4
BP 232
EP 240
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 768RF
UT WOS:000290953800009
PM 21552782
DA 2022-11-30
ER

PT J
AU Neubauer, AS
   Liakopoulos, S
   van Meurs, JC
   Kirchhof, B
AF Neubauer, Aljoscha S.
   Liakopoulos, Sandra
   van Meurs, Jan C.
   Kirchhof, Bernd
TI Cost-effectiveness of autologous retinal pigment epithelium and choroid
   translocation in neovascular AMD
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   cost-utility analysis; macular surgery; QALY
ID MACULAR DEGENERATION; CONTRAST SENSITIVITY; RESOURCE UTILIZATION;
   VISUAL-ACUITY; RANIBIZUMAB; BURDEN; MULTICOUNTRY; VERTEPORFIN; UTILITY
AB AIM: To assess the cost-effectiveness of autologous retinal pigment epithelium and choroid translocation (PATCH) in neovascular age-related macular degeneration (AMD).
   METHODS: Visual acuity and complication rates of published patient series were used to determine the incremental utility of treatment for the patient. The utility data applied assume that the better eye was affected. Comparator was a meta-analysis of recent control groups, in which patients received best supportive care. To assess cost-effectiveness, costs per quality adjusted life years (QALYs) and costs of avoiding low vision ("legal blindness", i. e. <= 20/200) were calculated. Costs were based on a German sick fund perspective and in a scenario on US costs. Robustness of the model was investigated by univariate and probabilistic multivariate sensitivity analysis (PSA).
   RESULTS: Cost-utility analysis showed surgery to be the dominant ("cost-saving") strategy for Germany and for the US in both, cost-effectiveness and cost-utility analysis (costs per QALY). In the sensitivity analysis the intervention remained dominant or cost-effective in all scenarios investigated. Clinical outcomes and duration of modeling were the most influential factors in the sensitivity analyses.
   CONCLUSION: Therapy of neovascular AMD by PATCH is a cost-effective treatment option for selected patients, who are not well suitable for other current treatment options.
C1 [Neubauer, Aljoscha S.] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, D-80336 Munich, Germany.
   [Liakopoulos, Sandra; Kirchhof, Bernd] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Cologne, Germany.
   [van Meurs, Jan C.] Rotterdam Eye Hosp, Vitreoretinal Dept, NL-3011 BH Rotterdam, Netherlands.
   [van Meurs, Jan C.] Erasmus Univ, NL-3011 BH Rotterdam, Netherlands.
C3 University of Munich; University of Cologne; Rotterdam Eye Hospital;
   Erasmus University Rotterdam
RP Neubauer, AS (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM Aljoscha.Neubauer@med.uni-muenchen.de
CR Bansback N, 2007, EYE, V21, P1455, DOI 10.1038/sj.eye.6702636
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   EMSHAW SR, 2005, ISPOR 8 ANN EUR C FL, P563
   Heussen FMA, 2008, EYE, V22, P799, DOI 10.1038/sj.eye.6702823
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Knauer C, 2006, OPHTHALMOLOGE, V103, P735, DOI 10.1007/s00347-006-1411-y
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Neubauer AS, 2003, DIABETES CARE, V26, P2890, DOI 10.2337/diacare.26.10.2890
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   VONDERSCHULENBU.J, 2007, EUR J HEALTH ECON, V8, pS5
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 23
TC 3
Z9 3
U1 1
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 1672-5123
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2010
VL 3
IS 3
BP 228
EP 233
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BR
UT WOS:000282934400011
PM 22553560
DA 2022-11-30
ER

PT J
AU Bakri, SJ
   Larson, TA
   Edwards, AO
AF Bakri, Sophie J.
   Larson, Theresa A.
   Edwards, Albert O.
TI Intraocular inflammation following intravitreal injection of bevacizumab
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE avastin; bevacizumab; VEGF; macular degeneration; uveitis; vitritis;
   inflammation
ID MACULAR DEGENERATION; NONINFECTIOUS ENDOPHTHALMITIS; TRIAMCINOLONE;
   UVEITIS
AB Background Injection of drugs into the vitreous can lead to intraocular inflammation through infectious and non-infectious processes. Failure to recognize an eye with anterior chamber and vitreous cell as sterile inflammation can lead to unnecessary treatment for endophthalmitis.
   Methods Four cases of uveitis following intravitreal bevacizumab (Avastin) for exudative age-related macular degeneration are described followed by review of the literature.
   Results Four patients presented with uveitis. Two patients presented with pain and red eye associated with iritis and two patients with vitritis, several days following intravitreal injection of bevacizumab. No paracentesis was performed and no corneal epithelial defect was created. Both patients with iritis were presumed to have sterile intraocular inflammation since the anterior chamber cell was much greater than the vitreous cell and resolved with cycloplegic and topical corticosteroid therapy. The third patient presented only with vitreous cell which resolved without therapy. The fourth patient had anterior chamber cell and vitreous cell with clumps, which resolved with topical prednisolone acetate. The inflammation resolved in all cases within 1 to 2 weeks.
   Conclusion There are few published cases of uveitis following bevacizumab. With its rising use, it is important to be aware of its potential to be associated with intraocular inflammation.
C1 [Bakri, Sophie J.; Larson, Theresa A.; Edwards, Albert O.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM sbakri@hotmail.com
CR Ho Janie, 2007, International Ophthalmology Clinics, V47, P199, DOI 10.1097/IIO.0b013e318037795f
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Pieramici DJ, 2006, RETINA-J RET VIT DIS, V26, P841, DOI 10.1097/01.iae.0000234629.22614.cd
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Roth DB, 2003, ARCH OPHTHALMOL-CHIC, V121, P1279, DOI 10.1001/archopht.121.9.1279
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Taban M, 2007, AM J OPHTHALMOL, V144, P50, DOI 10.1016/j.ajo.2007.03.051
NR 10
TC 68
Z9 70
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2008
VL 246
IS 5
BP 779
EP 781
DI 10.1007/s00417-007-0754-7
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 285JO
UT WOS:000254773300021
PM 18204851
DA 2022-11-30
ER

PT J
AU Truong, SN
   Alam, S
   Zawadzki, RJ
   Choi, SS
   Telander, DG
   Park, SS
   Werner, JS
   Morse, LS
AF Truong, Steven N.
   Alam, Suhail
   Zawadzki, Robert J.
   Choi, Stacey S.
   Telander, David G.
   Park, Susanna S.
   Werner, John S.
   Morse, Lawrence S.
TI High resolution Fourier-domain optical coherence tomography of retinal
   angiomatous proliferation
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE chorioretinal anastomosis; exudative age-related macular degeneration;
   Fourier-domain optical coherence tomography; high resolution optical
   coherence tomography; intraretinal neovascularization; retinal
   angiomatous proliferation; staging system; three-dimensional
   reconstructions
ID OCCULT CHOROIDAL NEOVASCULARIZATION; ANASTOMOSES
AB Purpose: To study the anatomic details of retinal angiomatous proliferation (RAP) in patients with age-related macular degeneration (AMD) using high-resolution Fourier-domain optical coherence tomography (Fd-OCT) and its three-dimensional reconstructions.
   Methods: A Fd-OCT instrument was used to image five patients clinically diagnosed with RAP. A series of 100 raster-scanned B-scans centered over the macula was registered and rendered as a three-dimensional volume. These retinal structures were analyzed for anatomic details of the RAP lesions.
   Results: The RAP lesion could be identified within the retina on Fd-OCT in all five cases. Fd-OCT images of the first four cases revealed areas of intraretinal neovascularization (IRN) in the deep retina adjacent to a pigment epithelial detachment (PED). There was neovascular proliferation anteriorly and posteriorly through a break in the retinal pigment epithelium (RPE). In three of the four cases, Bruch membrane remained intact. There was no identifiable choroidal neovascularization (CNV). The fifth case had both subretinal and sub-RPE neovascular membranes without a PED.
   Conclusion: Fd-OCT provides unprecedented in vivo detail of the anatomy of RAP lesions that nearly resembles histologic specimens. This study suggests that the initial neovascular process in RAP can originate either within the retina or in the sub-RPE space.
C1 Univ Calif Davis, Davis Med Ctr, Dept Ophthalmol & Vis Sci, Davis, CA USA.
C3 University of California System; University of California Davis
RP Morse, LS (通讯作者)，4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
RI Zawadzki, Robert J./S-3236-2019; Zawadzki, Robert/E-7534-2011
OI Zawadzki, Robert J./0000-0002-9574-156X; Zawadzki,
   Robert/0000-0002-9574-156X; Morse, Lawrence/0000-0002-1758-2348
FU NEI NIH HHS [R01 EY014743, R01 EY014743-05] Funding Source: Medline; PHS
   HHS [014743] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R01EY014743] Funding Source: NIH RePORTER
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Fercher A F, 1996, J Biomed Opt, V1, P157, DOI 10.1117/12.231361
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   LEITGEB R, 2004, OPT EXPRESS, V12, P2435
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Parkes Susan M., 2004, DUANES FDN CLIN OPHT
   SHIMADA H, 2006, GRAEFES ARCH CLIN OP, P1
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   ZAWADZKI RJ, 2005, OPHTHALMIC TECHNOLOG, V15
NR 19
TC 47
Z9 47
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2007
VL 27
IS 7
BP 915
EP 925
DI 10.1097/IAE.0b013e31805468fd
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 212QT
UT WOS:000249612600017
PM 17891017
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Chung, SH
   Frick, SL
   Yiu, G
AF Chung, Sook H.
   Frick, Sonia L.
   Yiu, Glenn
TI Targeting vascular endothelial growth factor using retinal gene therapy
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Angiogenesis; vascular endothelial growth factor (VEGF); gene therapy;
   neovascular age-related macular degeneration (nAMD); neovascularization
ID DIABETIC MACULAR EDEMA; INTRAVITREAL AFLIBERCEPT INJECTION; OCULAR
   NEOVASCULARIZATION; ABICIPAR-PEGOL; IRIS NEOVASCULARIZATION;
   RANIBIZUMAB; DEGENERATION; BEVACIZUMAB; TRANSDUCTION; INHIBITION
AB Pharmacotherapies targeting vascular endothelial growth factor (VEGF) have revolutionized the management for neovascular retinal disorders including diabetic retinopathy and neovascular age-related macular degeneration. However, the burden of frequent injections, high cost, and treatment resistance in some patients remain unresolved. To overcome these challenges, newer generations of anti-angiogenic biological therapies, engineered proteins, implantable delivery systems, and biopolymers are currently being developed to enable more sustained, longer-lasting treatments. The use of gene therapies for pathologic angiogenesis has garnered renewed interests since the first FDA-approval of a gene therapy to treat inherited retinal diseases associated with biallelic RPE65 mutations. Newer generations of viral vectors and novel methods of intraocular injections helped overcome ocular barriers, improving the efficiency of transduction as well as safety profile. In addition, unlike current anti-VEGF gene therapy strategies which employ a biofactory approach to mimic existing pharmacotherapies, novel genome editing strategies that target proangiogenic factors at the DNA level offer a unique and distinct mechanistic approach that can potentially be more precise and lead to a permanent cure. Here, we review current anti-VEGF therapies and newer pharmacologic agents under development, examine technologies and progress in adapting anti-VEGF gene therapies, and explore the future application of CRISPR-Cas9 technology to suppress ocular angiogenesis.
C1 [Chung, Sook H.; Frick, Sonia L.; Yiu, Glenn] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA USA.
C3 University of California System; University of California Davis
RP Yiu, G (通讯作者)，4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM gyiu@ucdavis.edu
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   [Anonymous], REGENXBIO ANNOUNCES
   [Anonymous], REGENXBIO REPORTS CO
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Bainbridge JWB, 2015, NEW ENGL J MED, V372, P1887, DOI 10.1056/NEJMoa1414221
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Burnight ER, 2018, PROG RETIN EYE RES, V65, P28, DOI 10.1016/j.preteyeres.2018.03.003
   Callanan D, 2018, J OCUL PHARMACOL TH, V34, P700, DOI 10.1089/jop.2018.0062
   Callanan DG, 2013, OPHTHALMOLOGY, V120, P1843, DOI 10.1016/j.ophtha.2013.02.018
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chung SH, 2020, MOL THER-METH CLIN D, V17, P409, DOI 10.1016/j.omtm.2020.01.006
   Cideciyan AV, 2010, PROG RETIN EYE RES, V29, P398, DOI 10.1016/j.preteyeres.2010.04.002
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Cox DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/science.aaq0180
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   DiCarlo JE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.13
   Ding K, 2019, J CLIN INVEST, V129, P4901, DOI 10.1172/JCI129085
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.21, 10.1038/natrevmats.2016.71]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dykxhoorn DM, 2006, GENE THER, V13, P541, DOI 10.1038/sj.gt.3302703
   Emami-Naeini Parisa, 2019, Int Ophthalmol Clin, V59, P195, DOI 10.1097/IIO.0000000000000251
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Glassman AR, 2020, OPHTHALMOLOGY, V127, P1201, DOI 10.1016/j.ophtha.2020.03.021
   Grishanin R, 2019, MOL THER, V27, P118, DOI 10.1016/j.ymthe.2018.11.003
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Huang XG, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00140-3
   Ida H, 2003, INVEST OPHTH VIS SCI, V44, P5430, DOI 10.1167/iovs.03-0609
   Jacobson SG, 2015, NEW ENGL J MED, V372, P1920, DOI 10.1056/NEJMoa1412965
   Kachi S, 2009, HUM GENE THER, V20, P31, DOI 10.1089/hum.2008.046
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kazazi-Hyseni F, 2010, ONCOLOGIST, V15, P819, DOI 10.1634/theoncologist.2009-0317
   Khanani AM, 2020, INVEST OPHTH VIS SCI, V61
   Kim E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14500
   Kim K, 2017, NAT BIOTECHNOL, V35, P435, DOI 10.1038/nbt.3816
   Kim K, 2017, GENOME RES, V27, P419, DOI 10.1101/gr.219089.116
   Kim S, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.30
   Koo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04175-y
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kunimoto D, 2020, OPHTHALMOLOGY, V127, P1331, DOI 10.1016/j.ophtha.2020.03.035
   Lai CM, 2012, GENE THER, V19, P999, DOI 10.1038/gt.2011.169
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Liu YY, 2018, MOL THER, V26, P542, DOI 10.1016/j.ymthe.2017.12.002
   Lotery AJ, 2003, HUM GENE THER, V14, P1663, DOI 10.1089/104303403322542301
   de Redin IL, 2019, EXP EYE RES, V185, DOI 10.1016/j.exer.2019.107697
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martorana G., 2012, INVEST OPHTHALMOL VI, V53, P1931
   Matanovic MR, 2014, INT J PHARMACEUT, V472, P262, DOI 10.1016/j.ijpharm.2014.06.029
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Miller JW, 1997, AM J PATHOL, V151, P13
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Moisseiev E, 2016, CLIN OPHTHALMOL, V10, P173, DOI 10.2147/OPTH.S89784
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Peden MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017140
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Reich S, 2003, MOL VIS, V9, P210
   Robbins SG, 1997, GROWTH FACTORS, V14, P229, DOI 10.3109/08977199709021522
   Rodrigues GA, 2018, INVEST OPHTH VIS SCI, V59, P5836, DOI 10.1167/iovs.18-25307
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   Shoval A, 2019, SMALL, V15, DOI 10.1002/smll.201902776
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290
   Takahashi K, 2017, MOL THER, V25, P296, DOI 10.1016/j.ymthe.2016.10.008
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Utz VM, 2018, OPHTHALMIC GENET, V39, P671, DOI 10.1080/13816810.2018.1533027
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
   Willoughby AS, 2018, AM J OPHTHALMOL, V186, P144, DOI 10.1016/j.ajo.2017.11.020
   Xia XB, 2008, MOL VIS, V14, P1965
   Yanez-Munoz RJ, 2006, NAT MED, V12, P348, DOI 10.1038/nm1365
   Yeh S, 2020, OPHTHALMOLOGY, V127, P948, DOI 10.1016/j.ophtha.2020.01.006
   Yiu G, 2020, MOL THER-METH CLIN D, V16, P179, DOI 10.1016/j.omtm.2020.01.002
   Yiu G, 2018, OPHTHALMOL RETINA, V2, P1, DOI 10.1016/j.oret.2017.09.015
   Yiu G, 2016, INVEST OPHTH VIS SCI, V57, P5490, DOI 10.1167/iovs.16-20296
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
NR 104
TC 1
Z9 1
U1 2
U2 9
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD AUG
PY 2021
VL 9
IS 15
AR 1277
DI 10.21037/atm-20-4417
PG 15
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA UA6LY
UT WOS:000685272900015
PM 34532414
OA Green Published, gold
DA 2022-11-30
ER

EF